Antiarrhythmic	O	ADJ	B
efficacy	O	NOUN	I
of	O	ADP	O
azimilide	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
atrial	I-P	ADJ	B
fibrillation	I-P	NOUN	I
.	I-P	PUNCT	O


Maintenance	O	NOUN	B
of	O	ADP	O
sinus	O	NOUN	B
rhythm	O	NOUN	I
after	B-P	ADP	O
conversion	I-P	NOUN	B
to	I-P	ADP	O
sinus	I-P	NOUN	B
rhythm	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Azimilide	B-I	NOUN	B
dihydrochloride	I-I	NOUN	I
(	O	PUNCT	O
azimilide	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
investigational	O	ADJ	B
antiarrhythmic	O	ADJ	B
drug	O	NOUN	I
that	O	PRON	O
has	O	AUX	O
been	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
arrhythmias	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
atrial	I-P	ADJ	B
fibrillation	I-P	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
shown	O	VERB	O
excellent	O	ADJ	O
efficacy	O	NOUN	B
in	O	ADP	O
some	O	DET	O
previous	O	ADJ	O
trials	O	NOUN	B
and	O	CCONJ	O
minimal	O	ADJ	B
efficacy	O	NOUN	B
in	O	ADP	O
others	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
symptomatic	I-P	ADJ	B
atrial	I-P	ADJ	B
fibrillation	I-P	NOUN	I
for	I-P	ADP	O
>	I-P	SYM	O
48	I-P	NUM	O
hours	I-P	NOUN	B
but	I-P	CCONJ	O
<	I-P	X	O
6	I-P	NUM	O
months	I-P	NOUN	B
were	I-P	AUX	O
eligible	I-P	ADJ	B
for	O	ADP	O
this	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
were	I-P	AUX	O
admitted	I-P	VERB	B
to	I-P	ADP	O
a	I-P	DET	O
hospital	I-P	NOUN	B
and	O	CCONJ	O
randomly	B-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
receive	I-P	VERB	O
either	I-P	CCONJ	O
azimilide	I-I	NOUN	B
125	I-I	NUM	O
mg	I-I	NOUN	O
or	I-I	CCONJ	O
a	I-I	DET	O
matched	I-I	ADJ	O
placebo	I-I	NOUN	B
twice	I-I	ADV	O
daily	I-I	ADV	O
for	I-I	ADP	O
3	I-I	NUM	O
days	I-I	NOUN	B
and	I-I	CCONJ	O
then	I-I	ADV	O
once	I-I	ADV	O
daily	I-I	ADV	O
.	I-I	PUNCT	O


Patients	B-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
in	I-P	ADP	O
sinus	I-P	NOUN	B
rhythm	I-P	NOUN	I
spontaneously	I-P	ADV	I
or	I-P	CCONJ	O
had	I-P	AUX	O
sinus	I-P	NOUN	B
rhythm	I-P	NOUN	B
restored	I-P	VERB	B
by	I-P	ADP	O
electric	I-P	ADJ	B
cardioversion	I-P	NOUN	I
on	I-P	ADP	O
day	I-P	NOUN	B
4	I-P	NUM	O
were	I-P	AUX	O
discharged	I-P	VERB	B
from	I-P	ADP	O
the	I-P	DET	O
hospital	I-P	NOUN	B
.	I-P	PUNCT	O


Recurrence	B-OUT	NOUN	B
of	I-OUT	ADP	O
atrial	I-OUT	ADJ	B
fibrillation	I-OUT	NOUN	I
was	O	AUX	O
documented	O	VERB	B
by	O	ADP	O
electrocardiogram	B-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
efficacy	O	NOUN	I
analysis	O	NOUN	B
,	O	PUNCT	O
time	O	NOUN	O
to	O	PART	O
recurrence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	O
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
log-rank	O	ADJ	B
test	O	NOUN	I
in	O	ADP	O
the	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
structural	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Safety	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
as	O	ADP	O
deaths	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
serious	I-OUT	ADJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
446	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
;	I-P	PUNCT	O
314	I-P	NUM	O
were	I-P	AUX	O
in	I-P	ADP	O
the	I-P	DET	O
subgroup	I-P	NOUN	B
with	I-P	ADP	O
structural	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
time	I-OUT	NOUN	O
to	I-OUT	PART	O
arrhythmia	I-OUT	NOUN	B
recurrence	I-OUT	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
with	O	ADP	O
structural	O	ADJ	B
heart	O	NOUN	I
disease	O	NOUN	I
was	O	AUX	O
13	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
treatments	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.4596	O	NOUN	O
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
314	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
relative	B-OUT	ADJ	B
risk	I-OUT	NOUN	I
for	I-OUT	ADP	O
recurrence	I-OUT	NOUN	B
(	O	PUNCT	O
placebo	O	NOUN	B
:	O	PUNCT	O
azimilide	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
1.104	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.849-1.436	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
1	O	NUM	O
death	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
and	O	CCONJ	O
3	O	NUM	O
in	O	ADP	O
the	O	DET	O
azimilide	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Azimilide	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
demonstrate	O	VERB	O
clinically	O	ADV	B
important	O	ADJ	O
or	O	CCONJ	O
statistically	O	ADV	B
significant	O	ADJ	I
efficacy	O	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
for	O	ADP	O
arrhythmia	O	NOUN	B
recurrence	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
structural	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
who	I-P	PRON	O
were	I-P	AUX	O
in	I-P	ADP	O
atrial	I-P	ADJ	B
fibrillation	I-P	NOUN	I
and	I-P	CCONJ	O
converted	I-P	VERB	O
to	I-P	PART	O
sinus	I-P	NOUN	B
rhythm	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
assessment	O	NOUN	B
of	O	ADP	O
erythema	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
thickness	I-OUT	NOUN	B
on	I-OUT	ADP	O
burn	I-OUT	NOUN	B
related	I-OUT	ADJ	O
scars	I-OUT	NOUN	B
during	O	ADP	O
pressure	B-I	NOUN	B
garment	I-I	NOUN	I
therapy	I-I	NOUN	I
as	O	ADP	O
a	O	DET	O
preventive	O	ADJ	B
measure	O	NOUN	I
for	O	ADP	O
hypertrophic	O	ADJ	B
scarring	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
threefold	O	ADV	O
:	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
Assess	O	VERB	B
the	O	DET	O
pressure	O	NOUN	B
loss	O	NOUN	O
of	O	ADP	O
two	B-I	NUM	O
types	I-I	NOUN	O
of	I-I	ADP	O
pressure	I-I	NOUN	B
garments	I-I	NOUN	I
that	O	PRON	O
are	O	AUX	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
hypertrophic	B-P	ADJ	B
scars	I-P	NOUN	B
after	I-P	ADP	O
burn	I-P	NOUN	B
injury	I-P	NOUN	I
,	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
investigate	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
two	B-I	NUM	O
different	I-I	ADJ	O
levels	I-I	NOUN	B
of	I-I	ADP	O
compression	I-I	NOUN	B
on	O	ADP	O
erythema	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
thickness	I-OUT	NOUN	B
of	I-OUT	ADP	O
burn	I-OUT	NOUN	B
scars	I-OUT	NOUN	B
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
examine	O	VERB	O
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
erythema	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
thickness	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
prospective	O	ADJ	B
trial	O	NOUN	I
in	O	ADP	O
which	O	DET	O
76	B-P	NUM	O
burn	I-P	NOUN	B
scars	I-P	NOUN	B
in	I-P	ADP	O
60	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
objectively	O	ADV	B
assessed	B-I	VERB	B
with	I-I	ADP	O
the	I-I	DET	O
Minolta	I-OUT	PROPN	B
Chromameter	I-OUT	PROPN	I
CR-300	I-OUT	NOUN	I
for	I-I	ADP	O
erythema	I-I	NOUN	B
and	I-I	CCONJ	O
with	I-I	ADP	O
the	I-I	DET	O
Dermascan	I-OUT	PROPN	B
C	I-OUT	NOUN	I
for	I-OUT	ADP	O
thickness	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
scar	I-OUT	NOUN	B
over	I-I	ADP	O
a	I-I	DET	O
period	I-I	NOUN	B
of	I-I	ADP	O
3	I-I	NUM	O
months	I-I	NOUN	B
.	I-I	PUNCT	O


Each	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
"	B-I	PUNCT	O
normal	I-I	ADJ	B
"	I-I	PUNCT	O
or	I-I	CCONJ	O
"	I-I	PUNCT	O
lower	I-I	ADJ	B
"	I-I	PUNCT	O
compression	I-I	NOUN	B
class	I-I	NOUN	O
treatment	I-I	NOUN	B
,	I-I	PUNCT	O
with	I-I	ADP	O
respectively	I-I	ADV	O
mean	I-I	ADJ	O
values	I-I	NOUN	O
of	I-I	ADP	O
15	I-I	NUM	O
and	I-I	CCONJ	O
10	I-I	NUM	O
mmHg	I-I	NOUN	B
pressure	I-I	NOUN	B
after	I-I	ADP	O
wearing	I-I	VERB	B
the	I-I	DET	O
garment	I-I	NOUN	B
for	I-I	ADP	O
1	I-I	NUM	O
month	I-I	NOUN	B
.	I-I	PUNCT	O


Measurements	B-I	NOUN	B
for	I-I	ADP	O
both	I-I	DET	O
parameters	I-I	NOUN	B
were	I-I	AUX	O
taken	I-I	VERB	O
at	I-I	ADP	O
0	I-I	NUM	O
,	I-I	PUNCT	O
1	I-I	NUM	O
,	I-I	PUNCT	O
2	I-I	NUM	O
and	I-I	CCONJ	O
3	I-I	NUM	O
months	I-I	NOUN	B
of	I-I	ADP	O
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


Pressure	O	NOUN	B
garments	O	NOUN	B
with	O	ADP	O
"	O	PUNCT	O
normal	O	ADJ	B
"	O	PUNCT	O
compression	O	NOUN	B
did	O	AUX	O
lose	O	VERB	O
significantly	O	ADV	O
more	O	ADJ	O
compression	B-OUT	NOUN	B
over	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
(	O	PUNCT	O
4.82	O	NUM	O
mmHg	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
garments	O	NOUN	B
from	O	ADP	O
the	O	DET	O
low	O	ADJ	B
compression	O	NOUN	O
class	O	NOUN	O
(	O	PUNCT	O
2.57	O	NUM	O
mmHg	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Scars	B-OUT	NOUN	B
that	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
garments	O	NOUN	B
from	O	ADP	O
a	O	DET	O
"	O	PUNCT	O
normal	O	ADJ	B
"	O	PUNCT	O
compression	O	NOUN	B
class	O	NOUN	O
did	O	AUX	O
score	O	VERB	B
significantly	O	ADV	O
better	O	ADJ	O
for	O	ADP	O
thickness	B-OUT	NOUN	B
compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
low	O	ADJ	B
"	O	PUNCT	O
compression	O	NOUN	B
class	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
thickness	B-OUT	NOUN	B
was	O	AUX	O
most	O	ADV	O
evident	O	ADJ	O
at	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
.	O	PUNCT	O


Thereafter	O	ADV	O
no	O	DET	O
further	O	ADV	O
significant	O	ADJ	O
improvement	O	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
different	O	ADJ	O
treatments	O	NOUN	B
over	O	ADP	O
time	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
difference	O	NOUN	O
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
for	O	ADP	O
erythema	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Positive	O	ADJ	B
correlations	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
between	O	ADP	O
erythema	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
thickness	I-OUT	NOUN	B
values	I-OUT	NOUN	B
at	O	ADP	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
three	O	NUM	O
test	O	NOUN	O
points	O	NOUN	O
while	O	SCONJ	O
changes	O	NOUN	B
in	O	ADP	O
erythema	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
thickness	I-OUT	NOUN	B
only	O	ADV	O
correlated	O	VERB	B
significantly	O	ADV	O
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
month	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
change	O	NOUN	O
of	O	ADP	O
both	O	DET	O
parameters	O	NOUN	B
correlated	O	VERB	B
at	O	ADP	O
a	O	DET	O
high	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
significance	O	NOUN	B
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
pressure	O	NOUN	B
garments	O	NOUN	I
that	O	PRON	O
deliver	O	VERB	O
a	O	DET	O
pressure	O	NOUN	B
of	O	ADP	O
at	O	ADP	O
least	O	ADV	O
15	O	NUM	O
mmHg	O	NOUN	B
pressure	O	NOUN	B
tend	O	VERB	O
to	O	PART	O
accelerate	O	VERB	O
scar	B-OUT	ADJ	B
maturation	I-OUT	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
measurements	O	NOUN	B
of	O	ADP	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
change	O	NOUN	O
of	O	ADP	O
the	O	DET	O
erythema	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
predict	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
scar	O	ADJ	B
thickness	O	NOUN	B
and	O	CCONJ	O
vice	O	ADV	O
versa	O	ADV	O
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
vitamin	B-I	NOUN	B
K2	I-I	NOUN	I
on	O	ADP	O
the	O	DET	O
recurrence	B-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
hepatocellular	I-P	ADJ	B
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND/AIMS	O	ADJ	B
Vitamin	B-I	PROPN	B
K2	I-I	NOUN	I
(	I-I	PUNCT	O
VK2	I-I	NOUN	B
)	I-I	PUNCT	O
appears	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
potent	O	ADJ	O
inhibitory	O	ADJ	B
activity	O	NOUN	O
for	O	ADP	O
cell	O	NOUN	B
growth	O	NOUN	I
including	O	VERB	O
HCC	O	NOUN	B
cells	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
VK2	B-I	NOUN	B
could	O	AUX	O
reduce	O	VERB	O
incidence	O	NOUN	B
of	O	ADP	O
tumor	O	NOUN	B
recurrence	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
HCC	O	NOUN	B
.	O	PUNCT	O


Forty-five	B-P	NUM	B
patients	I-P	NOUN	B
with	I-P	ADP	O
cured	I-P	VERB	B
or	I-P	CCONJ	O
possibly	I-P	ADV	O
cured	I-P	VERB	B
HCC	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
selected	O	VERB	O
,	O	PUNCT	O
assigning	O	VERB	O
patients	O	NOUN	B
to	O	PART	O
treatment	O	NOUN	B
(	O	PUNCT	O
n=21	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
control	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
n=24	O	X	O
)	O	PUNCT	O
with	O	ADP	O
randomization	O	NOUN	B
list	O	NOUN	I
.	O	PUNCT	O


METHODOLOGY	O	ADJ	O
For	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
forty-five	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
Glakay	B-I	PROPN	B
was	O	AUX	O
given	O	VERB	O
orally	O	ADV	B
every	O	DET	O
day	O	NOUN	B
after	O	ADP	O
therapy	O	NOUN	B
for	O	ADP	O
HCC	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
patients	O	NOUN	B
complained	O	VERB	O
of	O	ADP	O
adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Abdominal	O	ADJ	B
ultrasonography	O	NOUN	I
and	O	CCONJ	O
dynamic	B-I	ADJ	B
CT	I-I	NOUN	I
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
3-month	O	ADJ	O
intervals	O	NOUN	B
.	O	PUNCT	O


Recurrence	B-OUT	NOUN	B
was	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
abdominal	B-I	ADJ	B
angiography	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	VERB	B
Recurrence	B-OUT	NOUN	B
of	I-OUT	ADP	O
HCC	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
7	O	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
33.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
12	O	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
50.0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
during	O	ADP	O
mean	O	ADJ	O
observation	O	NOUN	B
periods	O	NOUN	B
of	O	ADP	O
19.5	O	NUM	O
and	O	CCONJ	O
16.5	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
VK2	O	NOUN	B
was	O	AUX	O
not	O	PART	O
an	O	DET	O
independent	O	ADJ	B
variable	O	NOUN	B
for	O	ADP	O
the	O	DET	O
recurrence	B-OUT	NOUN	B
on	O	ADP	O
univariate	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


Cumulative	B-OUT	ADJ	B
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
HCC	I-OUT	NOUN	B
recurrence	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
cumulative	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
high	O	ADJ	O
in	O	ADP	O
treatment	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=0.054	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Cox	O	NOUN	B
regression	O	NOUN	I
analysis	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
serum	B-OUT	NOUN	B
albumin	I-OUT	NOUN	I
concentration	I-OUT	NOUN	B
alone	O	ADV	O
was	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
factor	O	NOUN	B
affecting	O	VERB	B
the	O	DET	O
recurrence	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
VK2	O	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
prevent	O	VERB	B
recurrence	B-OUT	NOUN	B
of	I-OUT	ADP	O
HCC	I-OUT	NOUN	B
after	O	ADP	O
curative	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
study	O	NOUN	B
is	O	AUX	O
preliminary	O	ADJ	B
and	O	CCONJ	O
large-scale	O	ADJ	B
trials	O	NOUN	I
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
VK2	O	NOUN	B
is	O	AUX	O
of	O	ADP	O
benefit	O	NOUN	O
to	O	PART	O
decrease	O	VERB	B
the	O	DET	O
recurrence	B-OUT	NOUN	B
of	I-OUT	ADP	O
HCC	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Couple-responsible	B-I	ADJ	B
therapy	I-I	NOUN	I
process	I-I	NOUN	O
:	I-I	PUNCT	O
positive	I-OUT	ADJ	B
proximal	I-OUT	ADJ	B
outcomes	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Therapist-couple	O	ADJ	B
struggle	O	NOUN	B
vs.	O	CCONJ	O
cooperation	O	NOUN	B
is	O	AUX	O
linked	O	VERB	O
to	O	PART	O
clinical	O	ADJ	B
outcome	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
research	O	NOUN	B
conceptualizes	O	VERB	B
and	O	CCONJ	O
investigates	O	VERB	B
treatment	O	NOUN	B
process	O	NOUN	I
as	O	ADP	O
it	O	PRON	O
relates	O	VERB	O
to	O	PART	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
struggle	O	NOUN	B
versus	O	ADP	O
cooperation	O	NOUN	B
.	O	PUNCT	O


Models	O	NOUN	B
of	O	ADP	O
couple-responsible	B-I	ADJ	B
and	I-I	CCONJ	O
therapist-responsible	I-I	ADJ	B
process	I-I	NOUN	O
in	O	ADP	O
couple	B-I	NOUN	B
therapy	I-I	NOUN	I
were	O	AUX	O
developed	O	VERB	O
.	O	PUNCT	O


Couple-responsible	B-I	ADJ	B
process	I-I	NOUN	I
consists	I-I	VERB	O
of	I-I	ADP	O
enactments	I-I	NOUN	B
,	I-I	PUNCT	O
accommodation	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
inductive	I-I	ADJ	B
process	I-I	NOUN	I
.	I-I	PUNCT	O


Therapist-responsible	B-I	ADJ	B
process	I-I	NOUN	I
consists	I-I	VERB	O
of	I-I	ADP	O
primary	I-I	ADJ	O
therapist-couple	I-I	ADJ	B
interaction	I-I	NOUN	B
,	I-I	PUNCT	O
therapist	I-I	NOUN	B
interpretation	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
direct	I-I	ADJ	O
instruction	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
counterbalanced	O	VERB	O
order	O	NOUN	O
,	O	PUNCT	O
25	B-P	NUM	O
couples	I-P	NOUN	B
were	O	AUX	O
exposed	O	VERB	O
to	O	PART	O
couple-responsible	B-I	ADJ	B
and	I-I	CCONJ	O
therapist-responsible	I-I	ADJ	B
episodes	I-I	NOUN	O
during	O	ADP	O
one	O	NUM	O
therapy	O	NOUN	B
session	O	NOUN	B
.	O	PUNCT	O


Couples	O	NOUN	B
reviewed	O	VERB	B
videotapes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
episodes	O	NOUN	B
and	O	CCONJ	O
completed	O	VERB	O
measures	O	NOUN	B
of	O	ADP	O
responsibility	O	NOUN	B
,	O	PUNCT	O
struggle	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cooperation	O	NOUN	B
.	O	PUNCT	O


Perceived	B-OUT	VERB	B
responsibility	I-OUT	NOUN	O
was	O	AUX	O
higher	O	ADJ	B
and	O	CCONJ	O
struggle	B-OUT	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
during	O	ADP	O
couple-responsible	B-I	ADJ	B
episodes	I-I	NOUN	I
.	I-I	PUNCT	O


No	O	DET	B
difference	O	NOUN	I
in	O	ADP	O
cooperation	B-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
contrast	O	NOUN	B
condition	O	NOUN	I
,	O	PUNCT	O
where	O	SCONJ	O
couples	O	NOUN	B
reported	O	VERB	O
on	O	ADP	O
one	O	NUM	O
therapist	B-I	NOUN	B
process	I-I	NOUN	B
after	O	ADP	O
already	O	ADV	O
experiencing	O	VERB	O
its	O	PRON	O
opposite	O	ADJ	B
,	O	PUNCT	O
led	O	VERB	O
to	O	PART	O
main	O	ADJ	O
effects	O	NOUN	B
for	O	ADP	O
responsibility	O	NOUN	B
and	O	CCONJ	O
struggle	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mediated	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	I
struggle	O	NOUN	B
and	O	CCONJ	O
cooperation	O	NOUN	B
.	O	PUNCT	O


Generally	O	ADV	O
speaking	O	VERB	B
,	O	PUNCT	O
responsibility	B-OUT	NOUN	B
was	O	AUX	O
even	O	ADV	O
higher	O	ADJ	O
during	O	ADP	O
couple-responsible	B-I	ADJ	B
episodes	I-I	NOUN	I
and	O	CCONJ	O
even	O	ADV	O
lower	O	ADJ	O
during	O	ADP	O
therapist-responsible	B-I	ADJ	B
episodes	I-I	NOUN	B
when	O	SCONJ	O
contrast	O	NOUN	O
was	O	AUX	O
present	O	ADJ	O
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
struggle	B-OUT	NOUN	O
was	O	AUX	O
even	O	ADV	O
lower	O	ADJ	O
during	O	ADP	O
couple-responsible	B-I	ADJ	B
episodes	I-I	NOUN	I
and	O	CCONJ	O
even	O	ADV	O
higher	O	ADJ	O
during	O	ADP	O
therapist-responsible	B-I	ADJ	B
episodes	I-I	NOUN	B
when	O	SCONJ	O
contrast	O	NOUN	O
was	O	AUX	O
present	O	ADJ	O
.	O	PUNCT	O


For	O	ADP	O
both	O	CCONJ	O
couple-responsible	O	ADJ	B
and	O	CCONJ	O
therapist-responsible	O	ADJ	B
episodes	O	NOUN	B
,	O	PUNCT	O
cooperation	B-OUT	NOUN	B
was	O	AUX	O
negatively	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
a	O	DET	O
shift	O	NOUN	B
from	O	ADP	O
the	O	DET	O
prior	O	ADJ	B
,	O	PUNCT	O
opposite	O	ADJ	O
therapist	O	NOUN	B
process	O	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
proportions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
variance	O	NOUN	B
in	O	ADP	O
responsibility	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
struggle	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cooperation	I-OUT	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
therapist	O	NOUN	B
process	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Retrograde	O	VERB	B
tracing	O	NOUN	O
and	O	CCONJ	O
electrophysiological	O	ADJ	B
findings	O	NOUN	I
of	O	ADP	O
collateral	O	ADJ	B
sprouting	O	NOUN	O
after	B-P	ADP	O
end-to-side	I-P	ADJ	B
neurorrhaphy	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
seek	O	VERB	O
more	O	ADV	O
potent	O	ADJ	O
evidences	O	NOUN	B
of	O	ADP	O
collateral	O	ADJ	B
sprouting	O	NOUN	B
for	O	ADP	O
both	O	CCONJ	O
motor	O	NOUN	B
and	O	CCONJ	O
sensory	O	ADJ	B
nerve	O	NOUN	I
fibres	O	NOUN	I
after	B-P	ADP	O
end-to-side	I-P	ADJ	B
neurorrhaphy	I-P	NOUN	I
using	O	VERB	O
a	O	DET	O
modified	O	VERB	O
double-labelling	O	ADJ	B
retrograde	O	NOUN	I
tracing	O	NOUN	I
method	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
regenerated	O	ADJ	B
motor	O	NOUN	B
axons	O	NOUN	B
with	O	ADP	O
electrophysiological	O	ADJ	B
evaluation	O	NOUN	I
.	O	PUNCT	O


Four	B-P	NUM	O
groups	I-P	NOUN	B
(	I-P	PUNCT	O
n=4	I-P	NUM	O
for	I-P	ADP	O
each	I-P	DET	O
group	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
used	I-P	VERB	O
:	I-P	PUNCT	O
end-to-end	I-I	NOUN	B
coaptation	I-I	NOUN	I
(	I-P	PUNCT	O
six	I-P	NUM	O
months	I-P	NOUN	B
postoperatively	I-P	ADV	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
end-to-side	I-I	ADJ	B
coaptation	I-I	NOUN	I
(	I-P	PUNCT	O
four	I-P	NUM	O
months	I-P	NOUN	B
and	I-P	CCONJ	O
six	I-P	NUM	O
months	I-P	NOUN	B
postoperatively	I-P	ADV	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
normal	I-I	ADJ	B
control	I-I	NOUN	I
.	I-I	PUNCT	O


Two	O	NUM	O
fluorescent	B-I	ADJ	B
tracers	I-I	NOUN	I
(	O	PUNCT	O
true	O	ADJ	B
blue	O	ADJ	I
and	O	CCONJ	O
diamidino	O	NOUN	B
yellow	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
applied	O	VERB	O
to	O	PART	O
the	O	DET	O
proximal	O	ADJ	B
ends	O	NOUN	B
of	O	ADP	O
tibial	O	ADJ	B
and	O	CCONJ	O
common	O	ADJ	O
peroneal	O	ADJ	B
nerves	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
after	O	ADP	O
four	O	NUM	O
or	O	CCONJ	O
six	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
nerve	O	NOUN	B
coaptation	O	NOUN	I
.	O	PUNCT	O


Five	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
only	O	ADV	O
found	O	VERB	O
single-labelled	B-OUT	ADJ	B
motor	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
sensory	I-OUT	ADJ	B
neurons	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
end-to-end	O	NOUN	B
coaptation	O	NOUN	I
groups	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
some	O	DET	O
dual-labelled	O	ADJ	B
neurons	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
end-to-side	O	ADJ	B
coaptation	O	NOUN	I
groups	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
motor	B-OUT	NOUN	B
nerve	I-OUT	NOUN	I
conduction	I-OUT	NOUN	I
velocity	I-OUT	NOUN	I
in	I-OUT	ADP	O
end-to-side	I-OUT	ADJ	B
coaptation	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
slower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
control	O	NOUN	I
.	O	PUNCT	O


But	O	CCONJ	O
no	O	DET	O
difference	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
sixth	O	ADJ	O
month	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
end-to-side	B-I	ADJ	B
neurorrhaphy	I-I	NOUN	I
can	O	AUX	O
induce	O	VERB	B
the	O	DET	O
functional	O	ADJ	B
collateral	O	ADJ	B
sprouting	O	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
motor	O	NOUN	B
and	O	CCONJ	O
sensory	O	ADJ	B
axons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
nerve	O	NOUN	I
.	O	PUNCT	O


Gemcitabine	B-I	NOUN	B
combined	I-I	VERB	B
with	I-I	ADP	O
either	I-I	CCONJ	O
pemetrexed	I-I	NOUN	B
or	I-I	CCONJ	O
paclitaxel	I-I	NOUN	B
in	I-I	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
advanced	B-P	ADJ	B
non-small	I-P	NOUN	O
cell	I-P	NOUN	O
lung	I-P	NOUN	O
cancer	I-P	NOUN	O
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
SICOG	O	PROPN	I
trial	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
estimate	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
activity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
impact	I-OUT	VERB	B
on	I-OUT	ADP	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
of	O	ADP	O
a	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
gemcitabine	I-I	NOUN	B
and	I-I	CCONJ	O
pemetrexed	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
locally	I-P	ADV	B
advanced	I-P	ADJ	I
or	I-P	CCONJ	O
metastatic	I-P	ADJ	B
non-small	I-P	NOUN	I
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
NSCLC	I-P	NOUN	B
)	I-P	PUNCT	O
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
two-stage	O	ADJ	O
phase	O	NOUN	O
II	O	NUM	O
study	O	NOUN	O
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	B-P	NOUN	B
in	I-P	ADP	O
stage	I-P	NOUN	B
IIIB	I-P	NOUN	I
or	I-P	CCONJ	O
IV	I-P	NUM	B
NSCLC	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
either	B-I	CCONJ	O
gemcitabine	I-I	NOUN	B
1250	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
and	B-I	CCONJ	O
pemetrexed	I-I	NOUN	B
(	O	PUNCT	O
Alimta	O	NOUN	B
)	O	PUNCT	O
500	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
followed	B-I	VERB	O
by	I-I	ADP	O
gemcitabine	I-I	NOUN	B
1250	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
day	O	NOUN	B
8	O	NUM	O
of	O	ADP	O
a	O	DET	O
3-weekly	O	ADJ	B
cycle	O	NOUN	I
(	B-I	PUNCT	O
GA	I-I	NOUN	B
arm	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
paclitaxel	B-I	NOUN	B
120	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
followed	B-I	VERB	O
by	I-I	ADP	O
gemcitabine	I-I	NOUN	B
1000	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
both	O	DET	O
given	O	VERB	O
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
of	O	ADP	O
a	O	DET	O
3-weekly	O	ADJ	B
cycle	O	NOUN	I
(	B-I	PUNCT	O
PG	I-I	NOUN	B
arm	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
105	B-P	NUM	O
(	I-P	PUNCT	O
GA	I-P	NOUN	B
arm	I-P	NOUN	B
,	I-P	PUNCT	O
51	I-P	NUM	O
;	I-P	PUNCT	O
PG	I-P	NOUN	B
arm	I-P	NOUN	I
,	I-P	PUNCT	O
54	I-P	NUM	O
)	I-P	PUNCT	O
eligible	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
stage	I-P	NOUN	B
IV	I-P	NUM	I
,	I-P	PUNCT	O
32	I-P	NUM	O
and	I-P	CCONJ	O
30	I-P	NUM	O
,	I-P	PUNCT	O
respectively	I-P	ADV	O
)	I-P	PUNCT	O
were	O	AUX	O
enrolled	O	VERB	O
into	O	ADP	O
this	O	DET	O
study	O	NOUN	B
;	O	PUNCT	O
thereafter	O	ADV	O
,	O	PUNCT	O
accrual	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	O
due	O	ADJ	O
to	O	PART	O
first-stage	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
20	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
10-33	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
GA	O	PROPN	B
arm	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
32	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
20-46	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
PG	O	NOUN	B
arm	O	NOUN	I
.	O	PUNCT	O


Median	B-OUT	ADJ	B
progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
5.1	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
3.7-6.5	O	NUM	O
)	O	PUNCT	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
GA	O	PROPN	B
arm	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
8.3	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
5.9-10.7	O	ADJ	O
)	O	PUNCT	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PG	O	NOUN	B
arm	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
median	B-OUT	ADJ	B
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
was	O	AUX	O
10.5	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
7.1-13.9	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
13.3	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
11.7-14.9	O	NUM	O
)	O	PUNCT	O
months	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Severe	B-OUT	ADJ	B
neutropenia	I-OUT	NOUN	B
(	O	PUNCT	O
36	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
22	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
febrile	B-OUT	ADJ	B
neutropenia	I-OUT	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
with	O	ADP	O
the	O	DET	O
GA	O	PROPN	B
regimen	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
hair	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
(	O	PUNCT	O
52	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
16	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
any	B-OUT	DET	O
grade	I-OUT	NOUN	B
peripheral	I-OUT	ADJ	I
neuropathy	I-OUT	NOUN	I
(	O	PUNCT	O
31	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
occurred	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
with	O	ADP	O
PG	B-I	NOUN	B
regimen	I-I	NOUN	B
.	I-I	PUNCT	O


Other	O	ADJ	O
severe	B-OUT	ADJ	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
of	O	ADP	O
GA	B-I	NOUN	B
regimen	I-I	NOUN	B
were	O	AUX	O
diarrhoea	B-OUT	ADJ	B
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
liver	B-OUT	NOUN	B
enzyme	I-OUT	NOUN	I
derangement	I-OUT	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
fatigue	B-OUT	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
GA	O	PROPN	B
regimen	O	NOUN	B
was	O	AUX	O
tolerated	B-OUT	VERB	B
and	I-OUT	CCONJ	O
moderately	I-OUT	ADV	B
active	I-OUT	ADJ	B
in	O	ADP	O
advanced	O	ADJ	B
or	O	CCONJ	O
metastatic	O	ADJ	B
NSCLC	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
combination	O	NOUN	B
did	O	AUX	O
not	O	PART	O
yield	O	VERB	O
any	O	DET	O
advantage	O	NOUN	O
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
PG	O	NOUN	B
regimen	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
deserve	O	VERB	O
further	O	ADJ	O
evaluation	O	NOUN	B
.	O	PUNCT	O


Deslorelin	B-I	ADJ	B
implants	I-I	NOUN	B
in	O	ADP	O
pre-pubertal	B-P	ADJ	B
female	I-P	ADJ	O
dogs	I-P	NOUN	B
:	I-P	PUNCT	O
short-	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
long-term	I-OUT	ADJ	B
effects	I-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
genital	I-OUT	ADJ	B
tract	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Deslorelin	B-I	ADJ	B
acetate	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
GnRH	O	NOUN	B
agonist	O	NOUN	B
used	O	VERB	O
for	O	ADP	O
contraception	O	NOUN	B
in	O	ADP	O
dogs	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
pre-pubertal	B-P	ADJ	B
female	I-P	ADJ	O
dogs	I-P	NOUN	B
with	I-P	ADP	O
deslorelin	I-I	NOUN	B
acetate	I-I	NOUN	I
implants	I-I	NOUN	B
,	O	PUNCT	O
to	O	PART	O
better	O	ADV	O
investigate	O	VERB	B
the	O	DET	O
primary	B-OUT	ADJ	B
stimulatory	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
long-term	B-OUT	ADJ	B
effects	I-OUT	NOUN	B
on	O	ADP	O
the	O	DET	O
genital	O	ADJ	B
tract	O	NOUN	I
,	O	PUNCT	O
throughout	O	ADP	O
repeated	O	VERB	O
treatments	O	NOUN	B
.	O	PUNCT	O


Sicilian	B-P	ADJ	B
hound	I-P	NOUN	B
female	I-P	ADJ	O
dogs	I-P	NOUN	O
(	I-P	PUNCT	O
24	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
treated	O	VERB	B
group	O	NOUN	B
,	O	PUNCT	O
control	O	NOUN	B
group	O	NOUN	I
1	O	NUM	I
and	O	CCONJ	O
control	O	NOUN	B
group	O	NOUN	I
2	O	NUM	I
.	O	PUNCT	O


First	O	ADJ	B
group	O	NOUN	I
bitches	O	NOUN	B
were	O	AUX	O
implanted	O	VERB	B
at	O	ADP	O
4.5	O	NUM	O
,	O	PUNCT	O
9.0	O	NUM	O
and	O	CCONJ	O
13.5	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
monitored	O	VERB	B
clinically	O	ADV	B
,	O	PUNCT	O
ultrasonographically	O	ADV	B
and	O	CCONJ	O
endocrinologically	O	ADV	B
,	O	PUNCT	O
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
period	O	NOUN	B
(	O	PUNCT	O
13.5	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Control	O	ADJ	B
group	O	NOUN	I
1	O	NUM	I
bitches	O	NOUN	B
were	O	AUX	O
not	B-I	PART	O
implanted	I-I	VERB	B
and	O	CCONJ	O
clinically	O	ADV	B
monitored	O	VERB	I
for	O	ADP	O
the	O	DET	O
same	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
animals	O	NOUN	B
underwent	O	VERB	O
ovariohysterectomy	B-I	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
allowing	O	VERB	O
evaluation	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
internal	I-OUT	ADJ	B
genitalia	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Control	O	ADJ	B
group	O	NOUN	I
2	O	NUM	I
bitches	O	NOUN	B
were	O	AUX	O
ovariohysterectomized	O	VERB	B
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
4.5	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
suppression	B-OUT	NOUN	B
of	I-OUT	ADP	O
oestrus	I-OUT	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
the	O	DET	O
treated	O	VERB	B
group	O	NOUN	B
despite	O	SCONJ	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
first	O	ADJ	O
implant	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
modest	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
plasmatic	B-OUT	ADJ	B
levels	I-OUT	NOUN	O
of	I-OUT	ADP	O
17-beta	I-OUT	NOUN	B
estradiol	I-OUT	NOUN	I
and	O	CCONJ	O
an	O	DET	O
evident	O	ADJ	O
cornification	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
vaginal	I-OUT	ADJ	B
mucosa	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
(	O	PUNCT	O
50-80	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Estradiol	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
progesterone	I-OUT	NOUN	B
were	O	AUX	O
at	O	ADP	O
baseline	O	NOUN	B
levels	O	NOUN	B
for	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
study	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
no	B-OUT	DET	O
other	I-OUT	ADJ	O
oestrous	I-OUT	ADJ	B
manifestations	I-OUT	NOUN	B
were	I-OUT	AUX	O
observed	I-OUT	VERB	B
.	I-OUT	PUNCT	O


The	O	DET	O
external	B-OUT	ADJ	B
genitalia	I-OUT	NOUN	B
maintained	I-OUT	VERB	B
a	I-OUT	DET	O
juvenile	I-OUT	ADJ	B
appearance	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
ovaries	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
ultrasonographically	I-OUT	ADV	B
,	I-OUT	PUNCT	O
showed	I-OUT	VERB	O
no	I-OUT	DET	O
follicular	I-OUT	ADJ	B
structures	I-OUT	NOUN	O
and	O	CCONJ	O
stayed	B-OUT	VERB	O
the	I-OUT	DET	O
same	I-OUT	ADJ	O
size	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


At	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
genital	B-OUT	ADJ	B
tract	I-OUT	NOUN	I
was	I-OUT	AUX	O
still	I-OUT	ADV	O
juvenile	I-OUT	ADJ	B
with	I-OUT	ADP	O
inactive	I-OUT	ADJ	B
small	I-OUT	ADJ	O
ovaries	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
thin	I-OUT	ADJ	O
filiform	I-OUT	NOUN	B
uterus	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Deslorelin	O	NOUN	B
suppressed	B-OUT	VERB	B
ovarian	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
in	O	ADP	O
pre-pubertal	O	ADJ	B
bitches	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
oestrous	B-OUT	ADJ	B
induction	I-OUT	NOUN	B
was	I-OUT	AUX	O
not	I-OUT	PART	O
observed	I-OUT	VERB	O
despite	O	SCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
stimulatory	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Juvenile	B-OUT	ADJ	B
genitalia	I-OUT	NOUN	I
were	O	AUX	O
an	O	DET	O
expected	O	ADJ	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


Chlorthalidone	B-I	NOUN	B
does	O	AUX	O
not	O	PART	O
increase	O	VERB	B
the	O	DET	O
hypotensive	B-OUT	ADJ	B
effect	I-OUT	NOUN	O
of	O	ADP	O
nifedipine	B-I	NOUN	B
in	O	ADP	O
essential	O	ADJ	B
hypertensives	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
crossover	B-P	NOUN	B
multicentre	I-P	NOUN	I
study	I-P	NOUN	I
.	I-P	PUNCT	O


To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
nifedipine	B-I	NOUN	B
+	I-I	CCONJ	O
chlorthalidone	I-I	NOUN	B
exerts	O	VERB	O
an	O	DET	O
additive	B-OUT	ADJ	O
antihypertensive	I-OUT	ADJ	B
effect	I-OUT	NOUN	O
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
single-drug	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
66	B-P	NUM	O
uncomplicated	I-P	ADJ	O
essential	I-P	ADJ	O
hypertensives	I-P	NOUN	O
,	I-P	PUNCT	O
with	I-P	ADP	O
diastolic	I-P	ADJ	B
blood	I-P	NOUN	I
pressure	I-P	NOUN	I
of	I-P	ADP	O
greater	I-P	ADJ	O
than	I-P	ADP	O
100	I-P	NUM	O
and	I-P	CCONJ	O
less	I-P	ADJ	O
than	I-P	ADP	O
115	I-P	NUM	O
mmHg	I-P	NOUN	B
.	I-P	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
a	O	DET	O
1-month	O	ADJ	O
washout	O	NOUN	O
placebo	B-I	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
double-blind	O	ADJ	B
crossover	O	NOUN	B
design	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
nifedipine	B-I	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
a	O	DET	O
day	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
chlorthalidone	B-I	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
two	O	NUM	O
drugs	O	NOUN	B
combined	O	VERB	B
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
doses	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
corresponding	O	ADJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
randomly	O	ADV	O
allocated	O	VERB	O
placebo	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
three	O	NUM	O
active	O	ADJ	B
treatments	O	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
without	O	ADP	O
changing	O	VERB	B
the	O	DET	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
absolute	B-OUT	ADJ	B
and	O	CCONJ	O
percentage	B-OUT	NOUN	B
decreases	I-OUT	VERB	B
in	O	ADP	O
mean	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
induced	O	VERB	B
by	O	ADP	O
nifedipine	B-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
combination	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
and	O	CCONJ	O
significantly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
those	O	DET	O
induced	O	VERB	B
by	O	ADP	O
chlorthalidone	B-I	NOUN	B
.	I-I	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
nifedipine	B-I	NOUN	B
+	I-I	CCONJ	O
chlorthalidone	I-I	NOUN	B
does	O	AUX	O
not	O	PART	O
exert	O	VERB	O
any	O	DET	O
additive	B-OUT	ADJ	O
antihypertensive	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
compared	O	VERB	O
with	O	ADP	O
nifedipine	B-I	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
a	O	DET	O
dihydropyridine	B-I	NOUN	B
calcium	I-I	NOUN	I
antagonist	I-I	NOUN	I
+	I-I	CCONJ	O
a	I-I	DET	O
thiazide	I-I	NOUN	B
diuretic	I-I	NOUN	I
is	O	AUX	O
probably	O	ADV	O
devoid	O	ADJ	O
of	O	ADP	O
any	O	DET	O
particular	O	ADJ	O
clinical	B-OUT	ADJ	B
significance	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
uncomplicated	B-P	ADJ	O
essential	I-P	ADJ	O
hypertensives	I-P	NOUN	O
.	I-P	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
augmented	B-I	ADJ	B
sensorimotor	I-I	NOUN	B
input	I-I	NOUN	B
on	O	ADP	O
learning	B-OUT	VERB	B
verbal	I-OUT	ADJ	I
and	I-OUT	CCONJ	O
nonverbal	I-OUT	ADJ	B
tasks	I-OUT	NOUN	O
among	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


Thirty-four	B-P	NUM	O
children	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
,	I-P	PUNCT	O
ages	I-P	NOUN	B
4-14	I-P	NUM	O
years	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
matched	O	VERB	B
and	O	CCONJ	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
conditions	O	NOUN	B
for	O	ADP	O
learning	B-OUT	VERB	B
a	I-OUT	DET	O
novel	I-OUT	ADJ	O
juice-making	I-OUT	ADJ	B
task	I-OUT	NOUN	I
and	O	CCONJ	O
producing	B-OUT	VERB	O
two	I-OUT	NUM	O
novel	I-OUT	ADJ	B
words	I-OUT	NOUN	B
about	I-OUT	ADP	O
the	I-OUT	DET	O
event	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Seventeen	O	NUM	O
sighted	O	ADJ	B
children	O	NOUN	B
were	O	AUX	O
manually	B-I	ADV	B
guided	I-I	VERB	I
to	O	PART	O
perform	O	VERB	O
the	O	DET	O
task	O	NOUN	B
and	O	CCONJ	O
tactually	O	ADV	B
prompted	O	VERB	O
during	O	ADP	O
imitated	O	VERB	B
productions	O	NOUN	B
of	O	ADP	O
novel	O	ADJ	B
words	O	NOUN	B
for	O	ADP	O
the	O	DET	O
event	O	NOUN	B
.	O	PUNCT	O


Their	O	PRON	O
matched	O	ADJ	B
controls	O	NOUN	I
heard	O	VERB	O
the	O	DET	O
novel	B-OUT	ADJ	B
words	I-OUT	NOUN	B
and	O	CCONJ	O
watched	O	VERB	O
the	O	DET	O
juice-making	B-OUT	ADJ	B
task	I-OUT	NOUN	B
being	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Performances	O	NOUN	B
on	O	ADP	O
four	B-OUT	NUM	O
verbal	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
two	I-OUT	NUM	O
nonverbal	I-OUT	ADJ	B
measures	I-OUT	NOUN	O
right	O	ADJ	O
after	O	ADP	O
instruction	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
24-48	O	NUM	O
h	O	NOUN	O
post-instruction	O	NOUN	B
,	O	PUNCT	O
revealed	O	VERB	O
higher	O	ADJ	O
scores	O	NOUN	B
for	O	ADP	O
the	O	DET	O
‘	O	NOUN	O
‘	O	NOUN	O
hands-on	O	ADJ	B
’	O	NOUN	I
’	O	NOUN	O
,	O	PUNCT	O
participation	O	NOUN	B
than	O	ADP	O
observation	O	NOUN	B
group	O	NOUN	I
on	O	ADP	O
both	O	CCONJ	O
verbal	O	ADJ	B
and	O	CCONJ	O
nonverbal	O	ADJ	B
tasks	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
offers	O	VERB	O
a	O	DET	O
paradigm	O	NOUN	B
for	O	ADP	O
exploring	O	VERB	O
the	O	DET	O
instructional	O	ADJ	B
advantage	B-OUT	NOUN	O
of	O	ADP	O
enhanced	B-OUT	VERB	B
participatory	I-OUT	ADJ	B
experience	I-OUT	NOUN	O
.	O	PUNCT	O


Efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
diclofenac	B-I	ADJ	B
diethylamine	I-I	NOUN	O
1.16	O	NUM	O
%	O	NOUN	O
gel	O	NOUN	B
in	O	ADP	O
acute	B-P	ADJ	B
neck	I-P	NOUN	I
pain	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Neck	O	PROPN	B
pain	O	NOUN	I
(	O	PUNCT	O
NP	O	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
musculoskeletal	O	ADJ	B
disorder	O	NOUN	I
in	O	ADP	O
primary	O	ADJ	B
care	O	NOUN	I
that	O	PRON	O
frequently	O	ADV	O
causes	O	VERB	O
discomfort	O	NOUN	B
.	O	PUNCT	O


Non-steroidal	O	ADJ	B
anti-inflammatory	O	ADJ	I
drugs	O	NOUN	I
(	O	PUNCT	O
NSAIDs	O	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
neck	O	NOUN	B
pain	O	NOUN	I
and	O	CCONJ	O
associated	O	VERB	O
inflammation	O	NOUN	B
and	O	CCONJ	O
facilitate	O	VERB	O
earlier	O	ADJ	O
recovery	O	NOUN	B
.	O	PUNCT	O


Topical	B-I	ADJ	B
diclofenac	I-I	ADJ	O
diethylamine	I-I	NOUN	O
(	I-I	PUNCT	O
DDEA	I-I	NOUN	B
)	I-I	PUNCT	O
1.16	I-I	NUM	O
%	I-I	NOUN	O
gel	I-I	NOUN	B
is	O	AUX	O
clinically	O	ADV	B
proven	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
in	O	ADP	O
acute	O	ADJ	B
and	O	CCONJ	O
chronic	O	ADJ	B
musculoskeletal	O	ADJ	O
conditions	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
until	O	ADP	O
now	O	ADV	O
no	O	DET	O
clinical	O	ADJ	B
data	O	NOUN	I
existed	O	VERB	O
for	O	ADP	O
its	O	PRON	O
use	O	NOUN	O
in	O	ADP	O
acute	O	ADJ	B
NP	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
DDEA	O	NOUN	B
1.16	O	NUM	O
%	O	NOUN	O
gel	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
placebo	B-I	ADJ	B
gel	I-I	NOUN	I
in	O	ADP	O
acute	O	ADJ	B
NP	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
NP	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
72	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
DDEA	O	NOUN	B
1.16	O	NUM	O
%	O	NOUN	O
gel	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
g	O	NOUN	O
,	O	PUNCT	O
4x/day	O	NOUN	O
,	O	PUNCT	O
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
assessments	O	NOUN	B
included	B-OUT	VERB	O
pain-on-movement	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
POM	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
pain-at-rest	I-OUT	X	B
(	I-OUT	PUNCT	O
PAR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
functional	I-OUT	ADJ	B
neck	I-OUT	NOUN	I
disability	I-OUT	NOUN	I
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
NDI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
response	I-OUT	NOUN	B
to	I-OUT	PART	I
treatment	I-OUT	NOUN	B
(	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
POM	O	NOUN	B
by	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
48	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Adverse	O	ADJ	B
events	O	NOUN	I
(	O	PUNCT	O
AEs	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
recorded	O	VERB	O
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
primary	O	ADJ	B
outcome	B-OUT	NOUN	I
,	I-OUT	PUNCT	O
POM	I-OUT	NOUN	B
at	I-OUT	ADP	O
48	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
statistically	O	ADV	O
significantly	O	ADV	O
lower	O	ADJ	O
with	O	ADP	O
DDEA	O	NOUN	B
gel	O	NOUN	I
(	O	PUNCT	O
19.5	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
56.9	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
representing	O	VERB	O
a	O	DET	O
clinically	O	ADV	B
relevant	O	ADJ	O
decrease	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
23	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	B-OUT	ADV	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


All	B-OUT	DET	O
POM	O	PROPN	B
scores	O	NOUN	B
were	O	AUX	O
significantly	B-I	ADV	O
lower	I-I	ADJ	O
with	O	ADP	O
DDEA	O	NOUN	B
gel	O	NOUN	I
vs.	O	CCONJ	O
placebo	O	NOUN	B
from	O	ADP	O
1	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
were	O	AUX	O
PAR	O	NOUN	B
and	O	CCONJ	O
NDI	O	PROPN	B
scores	O	NOUN	B
from	O	ADP	O
first	O	ADJ	O
assessment	O	NOUN	B
(	O	PUNCT	O
24	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
onwards	O	NOUN	O
(	B-OUT	PUNCT	O
all	I-OUT	DET	O
p	I-OUT	NOUN	O
<	I-OUT	X	O
0.0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Response	B-OUT	NOUN	B
to	O	PART	O
treatment	O	NOUN	B
was	O	AUX	O
significantly	B-I	ADV	O
higher	O	ADJ	O
with	O	ADP	O
DDEA	O	NOUN	B
gel	O	NOUN	I
(	O	PUNCT	O
94.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
8.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	B-OUT	PUNCT	O
p	I-OUT	NOUN	O
<	I-OUT	X	O
0.0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
AEs	O	NOUN	B
with	O	ADP	O
DDEA	O	NOUN	B
gel	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
DDEA	O	NOUN	B
1.16	O	NUM	O
%	O	NOUN	O
gel	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
available	B-OUT	ADJ	O
over-the-counter	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
was	I-OUT	AUX	O
effective	I-OUT	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	B-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
treatment	I-P	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
neck	O	NOUN	I
pain	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
tools	O	NOUN	B
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
efficacy	O	NOUN	B
suggest	O	VERB	O
that	B-OUT	SCONJ	O
it	I-OUT	PRON	O
quickly	I-OUT	ADV	O
reduced	I-OUT	VERB	B
neck	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
improved	O	VERB	B
neck	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
questions	O	NOUN	B
remain	O	VERB	O
regarding	O	VERB	O
the	O	DET	O
comparability	O	NOUN	B
and	O	CCONJ	O
validity	O	NOUN	B
of	O	ADP	O
such	O	ADJ	O
tools	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
will	O	AUX	O
help	O	VERB	O
ascertain	O	VERB	O
whether	O	SCONJ	O
DDEA	O	NOUN	B
1.16	O	NUM	O
%	O	NOUN	O
gel	O	NOUN	B
offers	O	VERB	O
an	O	DET	O
alternative	O	ADJ	B
treatment	O	NOUN	I
option	O	NOUN	O
in	O	ADP	O
this	O	DET	O
common	O	ADJ	O
,	O	PUNCT	O
often	O	ADV	O
debilitating	O	ADJ	B
condition	O	NOUN	O
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
ClinicalTrials.gov	O	NOUN	O
identifier	O	NOUN	O
:	O	PUNCT	O
NCT01335724	O	NOUN	O
.	O	PUNCT	O


Advice	O	NOUN	B
or	O	CCONJ	O
exercise	O	VERB	B
for	O	ADP	O
chronic	B-P	ADJ	B
whiplash	I-P	NOUN	I
disorders	I-P	NOUN	I
?	O	PUNCT	O
Design	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Whiplash-associated	B-P	ADJ	B
disorder	I-P	NOUN	I
(	O	PUNCT	O
or	O	CCONJ	O
"	O	PUNCT	O
whiplash	O	NOUN	B
"	O	PUNCT	O
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
condition	O	NOUN	B
incurring	O	VERB	B
considerable	O	ADJ	O
expense	O	NOUN	O
in	O	ADP	O
social	O	ADJ	B
and	O	CCONJ	O
economic	O	ADJ	B
terms	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
research	O	NOUN	B
on	O	ADP	O
effective	O	ADJ	B
therapy	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
whiplash	I-P	NOUN	I
associated	I-P	VERB	I
disorders	I-P	NOUN	I
prompted	O	VERB	O
the	O	DET	O
design	O	NOUN	B
of	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
is	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	B-OUT	NOUN	B
of	I-OUT	ADP	O
a	I-OUT	DET	O
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
program	I-OUT	NOUN	I
for	I-OUT	ADP	O
people	I-OUT	NOUN	B
with	I-OUT	ADP	O
chronic	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
symptoms	I-OUT	NOUN	B
of	I-OUT	ADP	O
>	I-OUT	X	O
3	I-OUT	NUM	O
months	I-OUT	NOUN	B
duration	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
whiplash	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
secondary	O	ADJ	B
aim	O	NOUN	O
is	O	AUX	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
pain	B-OUT	NOUN	B
severity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
disability	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fear	I-OUT	NOUN	B
of	I-OUT	ADP	O
movement/	I-OUT	X	O
(	I-OUT	PUNCT	O
re	I-OUT	ADP	O
)	I-OUT	PUNCT	O
injury	I-OUT	NOUN	B
predict	O	VERB	O
response	B-OUT	NOUN	B
to	O	PART	O
a	O	DET	O
physical	O	ADJ	B
activity	O	NOUN	I
program	O	NOUN	I
.	O	PUNCT	O


METHODS/DESIGN	O	NOUN	B
This	O	DET	O
paper	O	NOUN	O
presents	O	VERB	O
the	O	DET	O
rationale	O	NOUN	B
and	O	CCONJ	O
design	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
examining	O	VERB	O
the	O	DET	O
effects	B-OUT	NOUN	B
of	I-OUT	ADP	I
advice	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
individualized	I-OUT	ADJ	B
sub-maximal	I-OUT	ADJ	B
exercise	I-OUT	NOUN	I
programs	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
whiplash	B-P	NOUN	B
associated	I-P	VERB	O
disorders	I-P	NOUN	O
.	I-P	PUNCT	O


DISCUSSION	O	NOUN	O
This	O	DET	O
paper	O	NOUN	O
highlights	O	VERB	O
the	O	DET	O
design	O	NOUN	B
,	O	PUNCT	O
methods	O	NOUN	B
and	O	CCONJ	O
operational	O	ADJ	B
aspects	O	NOUN	I
of	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
clinical	O	ADJ	B
trial	O	NOUN	I
in	O	ADP	O
the	O	DET	O
area	O	NOUN	B
of	O	ADP	O
whiplash	B-P	NOUN	B
and	I-P	CCONJ	O
chronic	I-P	ADJ	B
pain	I-P	NOUN	I
.	I-P	PUNCT	O


[	O	PUNCT	O
Supplementary	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
Esberitox	B-I	NOUN	B
of	O	ADP	O
female	B-P	ADJ	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
curative	I-I	ADJ	B
adjuvant	I-I	ADJ	I
irradiation	I-I	NOUN	I
following	I-P	VERB	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
supposed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
a	O	DET	O
possible	O	ADJ	O
prevention	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
reduction	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
toxicity	I-OUT	NOUN	B
of	O	ADP	O
radiotherapy	B-I	NOUN	B
by	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
treatment	O	NOUN	B
with	O	ADP	O
Esberitox	B-I	PROPN	B
.	I-I	PUNCT	O


This	O	DET	O
question	O	NOUN	O
arose	O	VERB	O
when	O	SCONJ	O
performing	O	VERB	O
an	O	DET	O
investigation	O	NOUN	B
about	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
Esberitox	B-I	PROPN	B
in	O	ADP	O
a	O	DET	O
combined	O	ADJ	O
chemo-radiotherapy	O	NOUN	B
.	O	PUNCT	O


Whereas	O	SCONJ	O
the	O	DET	O
latter	O	ADJ	O
induces	O	VERB	B
above	O	ADP	O
all	O	DET	O
a	O	DET	O
systemic	O	ADJ	B
damage	O	NOUN	I
to	O	PART	O
the	O	DET	O
hemopoietic	O	ADJ	B
system	O	NOUN	I
,	O	PUNCT	O
radiotherapy	O	NOUN	B
is	O	AUX	O
a	O	DET	O
regional	O	ADJ	B
noxa	O	NOUN	B
.	O	PUNCT	O


2	O	X	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
with	O	ADP	O
50	B-P	NUM	O
patients	I-P	NOUN	B
submitted	I-P	VERB	O
to	I-P	PART	O
curative	I-I	ADJ	B
adjuvant	I-I	ADJ	I
irradiation	I-I	NOUN	I
following	I-P	VERB	O
surgery	I-P	NOUN	B
for	I-P	ADP	O
mammary	I-P	ADJ	B
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
radiotherapy	B-I	NOUN	B
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
way	O	NOUN	O
in	O	ADP	O
all	O	DET	O
patients	B-P	NOUN	B
with	I-P	ADP	O
irradiations	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
thoracic	I-P	NOUN	B
wall	I-P	NOUN	I
and	I-P	CCONJ	O
the	I-P	DET	O
regional	I-P	ADJ	B
lymph	I-P	NOUN	O
nodes	I-P	NOUN	O
.	I-P	PUNCT	O


Two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
built	O	VERB	O
by	O	ADP	O
randomization	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
an	O	DET	O
additional	O	ADJ	O
treatment	O	NOUN	B
with	O	ADP	O
Esberitox	B-I	PROPN	B
,	O	PUNCT	O
the	O	DET	O
control	B-I	NOUN	B
group	I-I	NOUN	I
did	I-I	AUX	O
not	I-I	PART	O
receive	I-I	VERB	O
an	I-I	DET	O
additional	I-I	ADJ	O
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


3	O	X	O
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
result	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
protective	O	ADJ	O
influence	O	NOUN	B
of	O	ADP	O
Esberitox	O	PROPN	B
could	O	AUX	O
be	O	AUX	O
demonstrated	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
parameters	O	NOUN	B
investigated	O	VERB	B
were	O	AUX	O
the	O	DET	O
peripheral	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
count	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
leucocytes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
granulocytes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
lymphocytes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
monocytes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
thrombocytes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hemoglobin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hematocrit	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
infections	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


4	O	X	O
.	O	PUNCT	O


This	O	DET	O
result	O	NOUN	O
diverging	O	VERB	O
from	O	ADP	O
literature	O	NOUN	B
is	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
probably	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
volume	O	NOUN	B
and	O	CCONJ	O
extension	O	NOUN	B
of	O	ADP	O
the	O	DET	O
injury	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
hematotoxic	O	ADJ	B
noxa	O	NOUN	B
and	O	CCONJ	O
furthermore	O	ADV	O
by	O	ADP	O
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
regeneration	O	NOUN	B
.	O	PUNCT	O


If	O	SCONJ	O
this	O	DET	O
ability	O	NOUN	B
is	O	AUX	O
exhausted	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
Esberitox	O	PROPN	B
can	O	AUX	O
act	O	VERB	O
no	O	ADV	O
longer	O	ADV	O
.	O	PUNCT	O


Therefore	O	ADV	O
the	O	DET	O
essential	O	ADJ	B
factor	O	NOUN	I
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
the	O	DET	O
noxa	O	NOUN	B
.	O	PUNCT	O


Esberitox	O	PROPN	B
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
short	O	ADJ	O
toxicity	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
ineffective	O	ADJ	B
in	O	ADP	O
case	O	NOUN	B
of	O	ADP	O
prolonged	O	ADJ	B
toxicity	O	NOUN	B
,	O	PUNCT	O
if	O	SCONJ	O
the	O	DET	O
treatment	O	NOUN	B
continuity	O	NOUN	O
(	O	PUNCT	O
noxa	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
broken	O	VERB	O
up	O	ADP	O
by	O	ADP	O
some	O	DET	O
regeneration	O	NOUN	B
intervals	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
radiotherapy	B-I	NOUN	B
studied	O	VERB	O
in	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
had	O	AUX	O
a	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
effect	O	NOUN	B
was	O	AUX	O
that	O	DET	O
of	O	ADP	O
a	O	DET	O
longterm	O	ADJ	B
injury	O	NOUN	I
.	O	PUNCT	O


Caffeine	B-I	NOUN	B
eliminates	O	VERB	O
psychomotor	B-OUT	NOUN	B
vigilance	I-OUT	NOUN	I
deficits	I-OUT	NOUN	I
from	O	ADP	O
sleep	O	NOUN	B
inertia	O	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVES	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
establish	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
caffeine	B-I	NOUN	B
on	O	ADP	O
sleep	B-OUT	NOUN	B
inertia	I-OUT	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
the	O	DET	O
ubiquitous	O	ADJ	O
phenomenon	O	NOUN	B
of	O	ADP	O
cognitive	O	ADJ	B
performance	O	NOUN	I
impairment	O	NOUN	I
,	O	PUNCT	O
grogginess	O	NOUN	B
and	O	CCONJ	O
tendency	O	NOUN	O
to	O	PART	O
return	O	VERB	B
to	O	ADP	I
sleep	O	VERB	I
immediately	O	ADV	O
after	O	ADP	O
awakening	O	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
28	B-P	NUM	O
normal	I-P	ADJ	B
adult	I-P	ADJ	I
volunteers	I-P	NOUN	B
were	O	AUX	O
administered	O	VERB	B
sustained	O	ADJ	O
low-dose	B-I	ADJ	B
caffeine	I-I	NOUN	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
last	O	ADJ	O
66	O	NUM	O
hours	O	NOUN	B
of	O	ADP	O
an	O	DET	O
88-hour	O	ADJ	O
period	O	NOUN	B
of	O	ADP	O
extended	O	VERB	B
wakefulness	O	NOUN	B
that	O	PRON	O
included	O	VERB	O
seven	O	NUM	O
2-hour	O	ADJ	B
naps	O	NOUN	I
during	O	ADP	O
which	O	DET	O
polysomnographical	O	ADJ	B
recordings	O	NOUN	I
were	O	AUX	O
made	O	VERB	O
.	O	PUNCT	O


Every	O	DET	O
2	O	NUM	O
hours	O	NOUN	O
of	O	ADP	O
wakefulness	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
immediately	O	ADV	O
after	O	ADP	O
abrupt	O	ADJ	B
awakening	O	NOUN	B
from	O	ADP	O
the	O	DET	O
naps	O	NOUN	B
,	O	PUNCT	O
psychomotor	B-OUT	NOUN	B
vigilance	I-OUT	NOUN	I
performance	I-OUT	NOUN	I
was	O	AUX	O
tested	O	VERB	B
.	O	PUNCT	O


SETTING	O	VERB	O
N/A	O	NOUN	B
.	O	PUNCT	O


PARTICIPANTS	O	NOUN	O
N/A	O	NOUN	B
.	O	PUNCT	O


INTERVENTIONS	O	NOUN	B
N/A	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
In	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
condition	O	NOUN	B
,	O	PUNCT	O
sleep	B-OUT	NOUN	B
inertia	I-OUT	NOUN	I
was	O	AUX	O
manifested	O	VERB	O
as	O	ADP	O
significantly	O	ADV	O
impaired	O	VERB	B
psychomotor	B-OUT	NOUN	O
vigilance	I-OUT	NOUN	B
upon	O	SCONJ	O
awakening	O	NOUN	B
from	O	ADP	O
the	O	DET	O
naps	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
impairment	O	NOUN	B
was	O	AUX	O
absent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
caffeine	O	NOUN	B
condition	O	NOUN	O
.	O	PUNCT	O


Caffeine	O	NOUN	B
had	O	AUX	O
only	O	ADV	O
modest	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
nap	B-OUT	NOUN	B
sleep	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Caffeine	B-I	NOUN	B
was	O	AUX	O
efficacious	O	ADJ	B
in	O	ADP	O
overcoming	O	VERB	O
sleep	B-OUT	NOUN	B
inertia	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
a	O	DET	O
reason	O	NOUN	O
for	O	ADP	O
the	O	DET	O
popularity	O	NOUN	B
of	O	ADP	O
caffeine-containing	O	VERB	B
beverages	O	NOUN	I
after	O	ADP	O
awakening	O	NOUN	B
.	O	PUNCT	O


Caffeine	O	NOUN	B
's	O	PART	I
main	O	ADJ	O
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
on	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
is	O	AUX	O
antagonism	O	NOUN	B
of	O	ADP	O
adenosine	O	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
increased	O	VERB	B
adenosine	O	NOUN	B
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
upon	O	SCONJ	O
awakening	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
sleep	B-OUT	NOUN	B
inertia	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	O	DET	O
placebo	O	NOUN	B
controlled	O	ADJ	O
crossover	O	NOUN	B
trial	O	NOUN	I
of	O	ADP	O
liquid	B-I	ADJ	B
fluoxetine	I-I	NOUN	I
on	O	ADP	O
repetitive	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
in	I-P	ADP	O
childhood	I-P	NOUN	B
and	I-P	CCONJ	O
adolescent	I-P	ADJ	B
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Repetitive	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
are	O	AUX	O
a	O	DET	O
core	O	NOUN	B
symptom	O	NOUN	I
domain	O	NOUN	O
in	O	ADP	O
autism	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
been	O	AUX	O
linked	O	VERB	O
to	O	PART	O
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serotonin	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
selective	O	ADJ	O
serotonin-receptive	B-I	ADJ	B
inhibitor	I-I	NOUN	O
fluvoxamine	I-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
adults	O	NOUN	B
with	O	ADP	O
autism	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
yet	O	ADV	O
no	O	DET	O
published	O	VERB	O
placebo	B-I	NOUN	B
controlled	O	ADJ	O
trials	O	NOUN	O
with	O	ADP	O
these	O	DET	O
agents	O	NOUN	B
document	O	VERB	O
safety	B-OUT	NOUN	B
and	O	CCONJ	O
efficacy	B-OUT	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examines	O	VERB	O
the	O	DET	O
selective	O	ADJ	O
serotonin	B-I	NOUN	B
reuptake	I-I	NOUN	I
inhibitor	I-I	NOUN	I
liquid	I-I	ADJ	B
fluoxetine	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
repetitive	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
in	I-P	ADP	O
childhood	I-P	NOUN	B
and	I-P	CCONJ	O
adolescent	I-P	ADJ	B
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASDs	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


In	O	ADP	O
total	O	NOUN	O
,	O	PUNCT	O
45	B-P	NUM	O
child	I-P	NOUN	B
or	I-P	CCONJ	O
adolescent	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	VERB	B
were	I-P	AUX	O
randomized	I-P	VERB	B
into	I-P	ADP	O
two	I-P	NUM	O
acute	I-P	ADJ	B
8-week	I-P	NOUN	B
phases	I-P	NOUN	B
in	I-P	ADP	O
a	I-P	DET	O
double-blind	I-P	ADJ	B
placebo-controlled	I-P	ADJ	B
crossover	I-P	NOUN	B
study	I-P	NOUN	I
of	I-P	ADP	O
liquid	I-I	ADJ	B
fluoxetine	I-I	NOUN	I
.	I-I	PUNCT	O


Study	O	NOUN	B
design	O	NOUN	O
included	O	VERB	O
two	O	NUM	O
randomized	O	ADJ	B
8-week	O	ADJ	B
fluoxetine	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
phases	O	NOUN	O
separated	O	VERB	O
by	O	ADP	O
a	O	DET	O
4-week	O	ADJ	O
washout	O	NOUN	B
phase	O	NOUN	I
.	O	PUNCT	O


Outcome	O	NOUN	B
measures	O	NOUN	I
included	O	VERB	O
measures	B-OUT	NOUN	B
of	I-OUT	ADP	O
repetitive	I-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
global	I-OUT	ADJ	B
improvement	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Low-dose	O	ADJ	B
liquid	B-I	ADJ	I
fluoxetine	I-I	NOUN	I
(	O	PUNCT	O
mean	O	VERB	O
final	O	ADJ	O
dose	O	NOUN	B
:	O	PUNCT	O
9.9+/-4.35	O	ADJ	O
mg/day	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
placebo	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
repetitive	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
by	O	ADP	O
CY-BOCS	B-OUT	NOUN	B
compulsion	I-OUT	NOUN	B
scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
effect	B-OUT	NOUN	B
size	I-OUT	NOUN	I
was	O	AUX	O
in	O	ADP	O
the	O	DET	O
moderate	O	ADJ	B
to	O	ADP	O
large	O	ADJ	O
range	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
doses	O	NOUN	B
used	O	VERB	O
were	O	AUX	O
low	O	ADJ	B
.	O	PUNCT	O


Liquid	B-I	ADJ	B
fluoxetine	I-I	NOUN	I
was	O	AUX	O
only	O	ADV	O
slightly	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
not	O	PART	O
significantly	O	ADV	O
,	O	PUNCT	O
superior	O	ADJ	O
to	O	PART	O
placebo	O	NOUN	B
on	O	ADP	O
CGI	B-OUT	NOUN	B
autism	I-OUT	NOUN	B
score	I-OUT	VERB	O
partially	O	ADV	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
phase	B-OUT	NOUN	B
order	I-OUT	NOUN	I
effect	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
fluoxetine	B-I	NOUN	B
was	O	AUX	O
marginally	O	ADV	O
superior	O	ADJ	O
to	O	PART	O
placebo	B-I	NOUN	B
on	O	ADP	O
a	O	DET	O
composite	B-OUT	ADJ	B
measure	I-OUT	NOUN	B
of	I-OUT	ADP	O
global	I-OUT	ADJ	B
effectiveness	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Liquid	O	ADJ	B
fluoxetine	O	NOUN	I
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
differ	O	VERB	O
from	O	ADP	O
placebo	B-I	NOUN	B
on	O	ADP	O
treatment	B-OUT	NOUN	B
emergent	I-OUT	ADJ	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Liquid	B-I	ADJ	B
fluoxetine	I-I	NOUN	I
in	O	ADP	O
low	O	ADJ	B
doses	O	NOUN	I
is	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
placebo	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
repetitive	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
autism	O	NOUN	I
.	O	PUNCT	O


Limitations	O	NOUN	B
include	O	VERB	O
small	O	ADJ	O
sample	O	NOUN	B
size	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
crossover	O	NOUN	B
design	O	NOUN	I
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
replication	O	NOUN	B
and	O	CCONJ	O
long-term	O	ADJ	B
maintenance	O	NOUN	B
trials	O	NOUN	I
are	O	AUX	O
needed	O	VERB	O
.	O	PUNCT	O


Helicobacter	O	NOUN	B
pylori	O	NOUN	I
and	O	CCONJ	O
gastric	O	ADJ	B
cancer	O	NOUN	I
:	O	PUNCT	O
current	O	ADJ	O
status	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Austrain	B-P	PROPN	B
Czech	I-P	PROPN	I
German	I-P	ADJ	B
gastric	I-P	ADJ	I
cancer	I-P	NOUN	I
prevention	O	NOUN	O
trial	O	NOUN	O
(	O	PUNCT	O
PRISMA	O	PROPN	B
Study	O	PROPN	I
)	O	PUNCT	O
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
Helicobacter	O	NOUN	B
pylori	O	NOUN	I
eradication	O	NOUN	B
alone	O	ADV	O
can	O	AUX	O
reduce	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
gastric	B-OUT	ADJ	B
cancer	I-OUT	NOUN	I
in	O	ADP	O
a	O	DET	O
subgroup	B-P	NOUN	B
of	I-P	ADP	O
individuals	I-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
increased	I-P	VERB	B
risk	I-P	NOUN	B
for	I-P	ADP	O
this	I-P	DET	O
fatal	I-P	ADJ	B
disease	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
It	O	PRON	O
is	O	AUX	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	B-I	ADJ	B
controlled	O	VERB	O
multinational	O	ADJ	B
multicenter	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


Men	B-P	NOUN	B
between	I-P	ADP	O
55	I-P	NUM	O
and	I-P	CCONJ	O
65	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
gastric	I-P	ADJ	B
cancer	I-P	NOUN	I
phenotype	I-P	NOUN	B
of	I-P	ADP	O
Helicobacter	I-P	NOUN	B
pylori	I-P	NOUN	I
gastritis	I-P	NOUN	I
are	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
receive	O	VERB	O
a	O	DET	O
7	O	NUM	O
day	O	NOUN	B
course	O	NOUN	B
of	O	ADP	O
omeprazole	B-I	NOUN	B
2	I-I	NUM	I
X	I-I	NOUN	I
20mg	I-I	NOUN	O
,	I-I	PUNCT	O
clarithromycin	I-I	NOUN	B
2	I-I	NUM	O
X	I-I	NOUN	O
500mg	I-I	ADJ	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
amoxicillin	I-I	NOUN	B
2	I-I	NUM	I
X	I-I	NOUN	I
1g	I-I	NOUN	I
for	I-I	ADP	O
7	I-I	NUM	O
days	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
omeprazole	I-I	NOUN	B
2	I-I	NUM	I
X	I-I	NOUN	I
20mg	I-I	NOUN	O
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Follow-up	O	X	B
endoscopy	O	NOUN	B
is	O	AUX	O
scheduled	O	VERB	O
3	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
thereafter	O	ADV	O
in	O	ADP	O
one-year	O	ADJ	B
intervals	O	NOUN	I
.	O	PUNCT	O


Predefined	O	ADJ	O
study	O	NOUN	B
endpoints	O	NOUN	B
are	O	AUX	O
gastric	B-OUT	ADJ	B
cancer	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
precancerous	I-OUT	ADJ	B
lesions	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
dysplasia	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
adenoma	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
other	I-OUT	ADJ	O
cancers	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
death	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
Since	B-P	SCONJ	O
March	I-P	PROPN	O
1998	I-P	NUM	O
,	I-P	PUNCT	O
1524	I-P	NUM	O
target	I-P	NOUN	B
patients	I-P	NOUN	B
have	I-P	AUX	O
been	I-P	AUX	O
screened	I-P	VERB	B
,	I-P	PUNCT	O
279	I-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
18.3	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
a	I-P	DET	O
corpus	I-P	NOUN	B
dominant	I-P	ADJ	B
type	I-P	NOUN	O
of	I-P	ADP	O
H.	I-P	X	B
pylori	I-P	NOUN	I
gastritis	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
167	I-P	NUM	O
of	I-P	ADP	O
those	I-P	DET	O
were	I-P	AUX	O
randomized	I-P	ADJ	B
(	O	PUNCT	O
58.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
active	O	ADJ	B
treatment	O	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
86	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
H.	O	X	B
pylori	O	NOUN	I
infection	O	NOUN	I
infection	O	NOUN	I
was	O	AUX	O
cured	B-OUT	VERB	B
in	O	ADP	O
88.9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Currently	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
cumulative	O	ADJ	B
follow-up	O	ADJ	B
time	O	NOUN	O
is	O	AUX	O
3046	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
253.38	O	NUM	O
patient	O	NOUN	B
years	O	NOUN	B
,	O	PUNCT	O
median	O	ADJ	B
follow	O	NOUN	O
up	O	ADV	O
16	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


So	O	ADV	O
far	O	ADV	O
,	O	PUNCT	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
developed	O	VERB	O
gastric	B-OUT	ADJ	B
cancer	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
any	I-OUT	DET	O
precancerous	I-OUT	ADJ	B
lesion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Three	O	NUM	O
(	O	PUNCT	O
1.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
reached	O	VERB	O
study	B-OUT	NOUN	B
endpoints	I-OUT	NOUN	B
other	I-OUT	ADJ	O
than	I-OUT	ADP	O
gastric	I-OUT	ADJ	B
cancer	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
Among	O	ADP	O
men	O	NOUN	B
between	O	ADP	O
55	O	NUM	O
and	O	CCONJ	O
65	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gastric	O	ADJ	B
cancer	O	NOUN	I
phenotype	O	NOUN	B
of	O	ADP	O
H.	O	X	B
pylori	O	NOUN	I
gastritis	O	NOUN	I
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
than	O	ADP	O
expected	O	VERB	O
.	O	PUNCT	O


Further	O	ADV	O
follow	O	VERB	O
up	O	ADP	O
and	O	CCONJ	O
continuing	O	VERB	B
recruitment	O	NOUN	I
are	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
fulfil	O	VERB	O
the	O	DET	O
main	O	ADJ	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
preoperative	O	ADJ	B
antibiotics	B-I	NOUN	B
on	O	ADP	O
success	B-OUT	NOUN	B
of	O	ADP	O
endosseous	B-I	ADJ	B
implants	I-I	NOUN	B
up	I-P	ADP	O
to	I-P	ADP	O
and	I-P	CCONJ	O
including	I-P	VERB	O
stage	I-P	NOUN	B
II	I-P	NUM	I
surgery	I-P	NOUN	I
:	I-P	PUNCT	O
a	I-P	DET	O
study	I-P	NOUN	B
of	I-P	ADP	O
2,641	I-P	NUM	O
implants	I-P	NOUN	B
.	I-P	PUNCT	O


According	O	VERB	O
to	O	ADP	O
the	O	DET	O
American	O	PROPN	B
College	O	PROPN	I
of	O	ADP	I
Surgeons	O	PROPN	I
,	O	PUNCT	O
complex	O	ADJ	B
oral	O	ADJ	O
surgical	O	ADJ	O
procedures	O	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
transoral	O	ADJ	B
placement	O	NOUN	B
of	O	ADP	O
endosseous	B-P	ADJ	B
implants	I-P	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
of	O	ADP	O
the	O	DET	O
type	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
require	O	VERB	O
prophylactic	B-I	ADJ	B
antibiotics	I-I	NOUN	I
.	I-I	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
routine	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
prophylactic	B-I	ADJ	B
antibiotics	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
field	O	NOUN	B
of	O	ADP	O
dental	O	NOUN	B
implantology	O	NOUN	I
continues	O	VERB	O
to	O	PART	O
be	O	AUX	O
controversial	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
utilization	O	NOUN	B
varies	O	VERB	O
widely	O	ADV	O
.	O	PUNCT	O


No	O	DET	O
data	O	NOUN	O
from	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
prospective	O	ADJ	O
clinical	O	ADJ	O
study	O	NOUN	O
of	O	ADP	O
the	O	DET	O
prophylactic	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
antibiotics	B-I	NOUN	B
in	O	ADP	O
implant	O	ADJ	B
surgery	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
published	O	VERB	B
.	O	PUNCT	O


As	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
comprehensive	O	ADJ	B
Dental	O	PROPN	B
Implant	O	PROPN	I
Clinical	O	PROPN	O
Research	O	PROPN	O
Group	O	PROPN	O
clinical	O	ADJ	B
implant	O	ADJ	I
study	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
preoperative	O	ADJ	B
or	O	CCONJ	O
postoperative	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
antibiotics	B-I	NOUN	B
,	O	PUNCT	O
the	O	DET	O
type	O	NOUN	B
used	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
coverage	O	NOUN	B
was	O	AUX	O
left	O	VERB	O
to	O	ADP	O
the	O	DET	O
discretion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
surgeon	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
and	O	CCONJ	O
correlated	O	VERB	B
with	O	ADP	O
failure	B-OUT	NOUN	B
of	I-OUT	ADP	O
osseointegration	I-OUT	NOUN	B
during	I-OUT	ADP	O
healing	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
stage	I-OUT	NOUN	B
I	I-OUT	NUM	I
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
at	I-OUT	ADP	O
stage	I-OUT	NOUN	B
II	I-OUT	NUM	I
surgery	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
uncovering	I-OUT	VERB	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
significantly	O	ADV	O
fewer	O	ADJ	O
failures	B-OUT	NOUN	B
occurred	O	VERB	O
when	O	SCONJ	O
preoperative	O	ADJ	B
antibiotics	B-I	NOUN	B
were	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Low	B-I	ADJ	B
protein	I-I	NOUN	B
provision	I-I	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
of	O	ADP	O
life	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
during	O	ADP	O
foetal	O	ADJ	B
life	O	NOUN	I
,	O	PUNCT	O
affects	O	VERB	O
metabolic	B-OUT	ADJ	B
traits	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
organ	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
development	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
growth	I-OUT	NOUN	B
in	O	ADP	O
male	B-P	NOUN	B
mink	I-P	NOUN	I
(	I-P	PUNCT	O
Neovison	I-P	NOUN	B
vison	I-P	NOUN	I
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Low	B-I	ADJ	B
protein	I-I	NOUN	B
provision	O	NOUN	B
in	O	ADP	O
utero	O	NOUN	B
and	O	CCONJ	O
post-partum	O	NOUN	B
may	O	AUX	O
induce	O	VERB	B
metabolic	B-OUT	ADJ	B
disorders	I-OUT	NOUN	I
in	O	ADP	B
adulthood	O	NOUN	I
.	O	PUNCT	O


Studies	O	NOUN	B
in	O	ADP	O
mink	O	NOUN	B
have	O	AUX	O
mainly	O	ADV	O
focused	O	VERB	O
on	O	ADP	O
short-term	O	ADJ	B
consequences	O	NOUN	B
of	O	ADP	O
low	B-I	ADJ	B
protein	I-I	NOUN	B
provision	I-I	NOUN	B
in	O	ADP	O
utero	O	NOUN	B
whereas	O	SCONJ	O
the	O	DET	O
long-term	O	ADJ	B
responses	O	NOUN	B
to	O	PART	O
low	B-I	ADJ	B
protein	I-I	NOUN	I
(	I-I	PUNCT	O
LP	I-I	NOUN	B
)	I-I	PUNCT	O
provision	I-I	NOUN	B
in	O	ADP	O
metabolically	O	ADV	B
programmed	O	VERB	B
mink	O	NOUN	I
are	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
low	O	ADJ	B
protein	O	NOUN	B
provision	O	NOUN	B
in	O	ADP	O
utero	O	NOUN	B
affects	O	VERB	O
the	O	DET	O
long-term	O	ADJ	B
response	O	NOUN	B
to	O	PART	O
adequate	O	ADJ	B
(	O	PUNCT	O
AP	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
LP	O	NOUN	B
provision	O	NOUN	B
after	O	ADP	O
weaning	O	VERB	B
in	O	ADP	O
male	O	NOUN	B
mink	O	NOUN	I
.	O	PUNCT	O


Eighty-six	B-P	NUM	O
male	I-P	NOUN	B
mink	I-P	NOUN	I
were	I-P	AUX	O
exposed	I-P	VERB	B
to	I-P	PART	I
low	I-P	ADJ	B
(	I-P	PUNCT	O
19	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
ME	I-P	NOUN	B
from	I-P	ADP	O
CP	I-P	NOUN	B
;	I-P	PUNCT	O
crude	I-I	ADJ	B
protein	I-I	NOUN	I
)	I-I	PUNCT	O
or	I-P	CCONJ	O
adequate	I-I	ADJ	B
(	I-I	PUNCT	O
31	I-I	NUM	O
%	I-I	NOUN	O
of	I-I	ADP	O
ME	I-I	NOUN	B
from	I-I	ADP	O
CP	I-I	NOUN	B
)	I-I	PUNCT	O
protein	I-I	NOUN	B
provision	I-P	NOUN	B
in	I-P	ADP	O
utero	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
to	I-P	PART	O
LP	I-P	NOUN	B
(	I-P	PUNCT	O
~20	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
ME	I-P	NOUN	B
from	I-P	ADP	O
CP	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
AP	I-P	NOUN	B
(	I-P	PUNCT	O
30-42	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
ME	I-P	NOUN	B
from	I-P	ADP	O
CP	I-P	NOUN	B
)	I-P	PUNCT	O
provision	I-P	NOUN	B
post-weaning	I-P	ADJ	B
.	I-P	PUNCT	O


Being	O	AUX	B
metabolically	O	ADV	B
programmed	O	VERB	I
by	O	ADP	O
low	B-I	ADJ	O
protein	I-I	NOUN	B
provision	O	NOUN	B
in	O	ADP	O
utero	O	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
post-weaning	B-OUT	ADJ	B
diets	I-OUT	NOUN	I
.	O	PUNCT	O


Dietary	B-OUT	ADJ	B
protein	I-OUT	NOUN	I
content	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
LP	O	NOUN	B
feed	O	NOUN	B
after	O	ADP	O
weaning	O	NOUN	B
was	O	AUX	O
below	O	ADP	O
requirements	O	NOUN	B
;	O	PUNCT	O
evidenced	O	VERB	O
by	O	ADP	O
lower	O	ADJ	B
nitrogen	B-OUT	NOUN	O
retention	I-OUT	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
preventing	O	VERB	O
LP	O	NOUN	B
mink	O	NOUN	I
from	O	ADP	O
attaining	O	VERB	O
their	O	PRON	O
growth	O	NOUN	B
potential	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


LP	O	NOUN	B
mink	B-P	NOUN	I
had	O	AUX	O
a	O	DET	O
lower	O	ADJ	O
liver	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
pancreas	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
kidney	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
lower	O	ADJ	O
plasma	B-OUT	NOUN	B
IGF-1	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
at	O	ADP	O
8	O	NUM	O
and	O	CCONJ	O
25	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
weeks	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
higher	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
hepatic	B-OUT	ADJ	B
lipidosis	I-OUT	NOUN	I
at	O	ADP	O
25	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
LP	O	NOUN	B
mink	O	NOUN	I
had	O	AUX	O
a	O	DET	O
higher	B-OUT	ADJ	B
body	I-OUT	NOUN	B
fat	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
lower	B-OUT	ADJ	B
body	I-OUT	NOUN	I
CP	I-OUT	NOUN	B
content	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
50	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
some	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
low	B-OUT	ADJ	B
protein	I-OUT	NOUN	B
provision	I-OUT	NOUN	B
in	I-I	ADP	O
utero	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
alleviated	O	VERB	O
by	O	ADP	O
an	O	DET	O
adequate	O	ADJ	B
nutrient	B-OUT	ADJ	B
supply	I-OUT	NOUN	O
post-partum	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
long-term	O	ADJ	B
exposure	O	NOUN	B
to	O	PART	I
low	B-I	ADJ	O
protein	I-I	NOUN	B
provision	I-I	NOUN	B
in	O	ADP	O
mink	O	NOUN	B
reduces	O	VERB	B
their	O	PRON	O
growth	B-OUT	NOUN	B
potential	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
induces	I-OUT	VERB	B
transient	I-OUT	ADJ	B
hepatic	I-OUT	ADJ	B
lipidosis	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
modified	I-OUT	ADJ	B
body	I-OUT	NOUN	B
composition	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Randomized	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
two	B-I	NUM	O
communication	I-I	NOUN	B
interventions	I-I	NOUN	B
for	O	ADP	O
preschoolers	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
group	O	NOUN	I
experiment	O	NOUN	I
compared	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
2	B-I	NUM	O
communication	I-I	NOUN	B
interventions	I-I	NOUN	B
(	I-I	PUNCT	O
Responsive	I-I	ADJ	B
Education	I-I	PROPN	I
and	I-I	CCONJ	O
Prelinguistic	I-I	PROPN	B
Milieu	I-I	PROPN	I
Teaching	I-I	PROPN	I
[	I-I	PUNCT	O
RPMT	I-I	PROPN	B
]	I-I	PUNCT	O
and	I-I	CCONJ	O
the	I-I	DET	O
Picture	I-I	PROPN	B
Exchange	I-I	PROPN	I
Communication	I-I	PROPN	I
System	I-I	PROPN	I
[	I-I	PUNCT	O
PECS	I-I	PROPN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
in	O	ADP	O
36	B-P	NUM	O
preschoolers	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


Each	O	DET	O
treatment	O	NOUN	B
was	O	AUX	O
delivered	O	VERB	O
3	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
week	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
20-min	O	ADJ	O
sessions	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
revealed	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
RPMT	B-I	NOUN	B
facilitated	O	VERB	O
the	O	DET	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
generalized	I-OUT	VERB	B
turn	I-OUT	NOUN	O
taking	I-OUT	VERB	O
and	I-OUT	CCONJ	O
generalized	I-OUT	VERB	B
initiating	I-OUT	VERB	I
joint	I-OUT	ADJ	I
attention	I-OUT	NOUN	B
more	O	ADJ	O
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
PECS	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
latter	O	ADJ	O
effect	O	NOUN	B
occurred	O	VERB	O
only	O	ADV	O
for	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
began	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
some	O	DET	O
initiating	B-OUT	VERB	O
joint	I-OUT	ADJ	B
attention	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
PECS	B-I	PROPN	B
facilitated	O	VERB	O
generalized	B-OUT	ADJ	O
requests	I-OUT	NOUN	B
more	O	ADJ	O
than	O	ADP	O
the	O	DET	O
RPMT	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
very	O	ADV	O
little	O	ADJ	O
initiating	B-OUT	VERB	O
joint	I-OUT	ADJ	B
attention	I-OUT	NOUN	B
prior	O	ADV	O
to	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
effect	B-OUT	NOUN	B
sizes	I-OUT	NOUN	I
were	O	AUX	O
large	B-OUT	ADJ	O
.	I-OUT	PUNCT	O


Intramedullary	B-I	ADJ	B
repair	I-I	NOUN	I
device	O	NOUN	I
against	O	ADP	O
volar	O	ADJ	B
plating	O	NOUN	I
in	O	ADP	O
the	O	DET	O
reconstruction	O	NOUN	B
of	O	ADP	O
extra-articular	O	ADJ	B
and	O	CCONJ	O
simple	O	ADJ	O
articular	O	NOUN	B
distal	O	ADJ	I
radius	O	NOUN	I
fractures	O	NOUN	I
;	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
pilot	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
pilot	O	NOUN	I
study	O	NOUN	I
reports	O	VERB	O
our	O	PRON	O
institutional	O	ADJ	B
experience	O	NOUN	I
and	O	CCONJ	O
early	O	ADJ	O
results	O	NOUN	O
using	O	VERB	O
Sonoma	O	PROPN	B
Wrx	O	PROPN	B
(	O	PUNCT	O
Sonoma	O	PROPN	B
Orthopedic	O	PROPN	I
Products	O	PROPN	I
,	O	PUNCT	O
Santa	O	PROPN	B
Rosa	O	PROPN	I
,	O	PUNCT	O
CA	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
extra-articular	O	ADJ	B
and	O	CCONJ	O
simple	O	ADJ	O
intra-articular	O	ADJ	B
distal	O	ADJ	O
radius	O	NOUN	O
fractures	O	NOUN	O
.	O	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
64	I-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
were	I-P	AUX	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


They	B-P	PRON	O
were	I-P	AUX	O
considered	I-P	VERB	O
eligible	I-P	ADJ	B
if	I-P	SCONJ	O
they	I-P	PRON	O
had	I-P	AUX	O
;	I-P	PUNCT	O
unstable	I-P	ADJ	O
extra-articular	I-P	ADJ	B
distal	I-P	ADJ	I
radius	I-P	NOUN	I
fractures	I-P	NOUN	I
and	I-P	CCONJ	O
simple	I-P	ADJ	O
intra-articular	I-P	ADJ	B
distal	I-P	ADJ	O
radius	I-P	NOUN	O
fractures	I-P	NOUN	O
suitable	I-P	ADJ	O
for	I-P	ADP	O
closed	I-P	ADJ	B
reduction	I-P	NOUN	I
(	I-P	PUNCT	O
AO	I-P	NOUN	B
types	I-P	NOUN	I
;	I-P	PUNCT	O
A2.2	I-P	NOUN	B
,	I-P	PUNCT	O
A2.3	I-P	PROPN	B
,	I-P	PUNCT	O
A3.1	I-P	NOUN	O
C2.1	I-P	NOUN	O
,	I-P	PUNCT	O
C2.2	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
in	I-P	ADP	O
group	I-P	NOUN	B
I	O	PRON	I
received	O	VERB	O
intramedullary	B-I	ADJ	B
fixation	I-I	NOUN	I
using	I-I	VERB	O
the	I-I	DET	O
Sonoma	I-I	PROPN	B
Wrx	I-I	PROPN	B
device	I-I	NOUN	I
and	O	CCONJ	O
patients	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
received	O	VERB	O
standard	B-I	ADJ	B
volar	I-I	ADJ	B
locking	I-I	NOUN	I
plate	I-I	NOUN	I
fixation	I-I	NOUN	I
.	I-I	PUNCT	O


Radiographic	O	ADJ	B
criteria	O	NOUN	B
of	O	ADP	O
acceptable	O	ADJ	O
healing	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
evaluation	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
.	O	PUNCT	O


Mean	B-OUT	VERB	B
time	I-OUT	NOUN	I
of	I-OUT	ADP	O
operation	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	B
in	O	ADP	O
Group	B-P	PROPN	B
1	I-P	NUM	O
vs.	O	X	O
in	O	ADP	O
group	B-P	NOUN	B
2	I-P	NUM	I
(	O	PUNCT	O
36.81	O	NUM	O
±	O	NOUN	O
7.11	O	NUM	O
vs.	O	CCONJ	O
48.97	O	NUM	O
±	O	NOUN	O
5.9	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
p	B-OUT	NOUN	O
=	I-OUT	ADJ	O
0.001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Time	B-OUT	NOUN	B
to	I-OUT	ADP	O
healing	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	O	DET	O
fracture	O	NOUN	B
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
5.45	O	NUM	O
±	O	NOUN	O
1.09	O	NUM	O
vs.	O	CCONJ	O
5.70	O	NUM	O
±	O	NOUN	O
1.04	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
Group	O	PROPN	B
1	O	NUM	O
vs.	O	CCONJ	O
2	O	NUM	O
,	O	PUNCT	O
respectively	B-OUT	ADV	O
p	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.36	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


Overall	O	ADJ	O
complications	B-P	NOUN	B
occurred	I-P	VERB	O
in	O	ADP	O
9	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
group	B-P	NOUN	B
1	I-P	NUM	I
and	I-P	CCONJ	O
in	O	ADP	O
15	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.17	O	NUM	O
)	O	PUNCT	O
.	B-P	PUNCT	O


Follow-up	B-P	NOUN	B
was	O	AUX	O
completed	O	VERB	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
median	O	ADJ	B
time	B-P	NOUN	O
of	I-P	ADP	O
12	I-P	NUM	O
months	I-P	NOUN	B
and	O	CCONJ	O
13	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
2	O	NUM	O
,	O	PUNCT	O
respectively	B-OUT	ADV	O
.	I-OUT	PUNCT	O


On	B-OUT	ADP	O
radiographic	I-OUT	ADJ	B
evaluation	I-OUT	NOUN	B
radial	I-OUT	ADJ	B
inclination	I-OUT	NOUN	I
,	O	PUNCT	O
radial	O	ADJ	B
height	O	NOUN	I
and	O	CCONJ	O
volar	O	ADJ	B
tilt	O	NOUN	I
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	B-OUT	ADP	O
two	I-OUT	NUM	O
groups	I-OUT	NOUN	B
in	I-OUT	ADP	O
regard	I-OUT	NOUN	O
to	O	PART	O
wrist	O	VERB	B
rotational	O	ADJ	I
degrees	O	NOUN	I
measured	O	VERB	B
in	O	ADP	O
last	B-I	ADJ	O
follow-up	I-I	ADJ	B
visit	I-I	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Sonoma	O	PROPN	B
Wrx	O	PROPN	B
Device	O	PROPN	I
is	O	AUX	O
reliable	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
achieving	O	VERB	O
satisfactory	O	ADJ	B
outcomes	O	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
distal	O	ADJ	B
radius	O	NOUN	I
fractures	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
may	O	AUX	O
be	O	AUX	O
reasonable	O	ADJ	O
to	O	PART	O
use	O	VERB	O
this	O	DET	O
device	O	NOUN	B
to	O	PART	O
prevent	O	VERB	B
complications	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
related	O	ADJ	O
to	O	PART	O
extensive	O	ADJ	B
soft	O	ADJ	B
tissue	O	NOUN	I
dissection	O	NOUN	I
.	O	PUNCT	O


Serotonergic	B-I	ADJ	B
psychedelics	I-I	NOUN	B
temporarily	O	ADV	O
modify	O	VERB	B
information	O	NOUN	B
transfer	O	NOUN	I
in	O	ADP	O
humans	B-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Psychedelics	B-I	NOUN	B
induce	O	VERB	O
intense	O	ADJ	O
modifications	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sensorium	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
sense	O	NOUN	O
of	O	ADP	O
"	O	PUNCT	O
self	O	NOUN	B
,	O	PUNCT	O
"	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
experience	O	NOUN	B
of	O	ADP	O
reality	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
advances	O	NOUN	O
in	O	ADP	O
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
and	O	CCONJ	O
cellular	O	ADJ	B
level	O	NOUN	O
mechanisms	O	NOUN	B
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
,	O	PUNCT	O
knowledge	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
actions	O	NOUN	B
on	O	ADP	O
global	B-OUT	ADJ	B
brain	I-OUT	NOUN	I
dynamics	I-OUT	NOUN	B
is	O	AUX	O
still	O	ADV	O
incomplete	O	ADJ	B
.	O	PUNCT	O


Recent	O	ADJ	O
imaging	O	NOUN	B
studies	O	NOUN	I
have	O	AUX	O
found	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
functional	O	ADJ	B
coupling	O	NOUN	I
between	O	ADP	O
frontal	O	ADJ	B
and	O	CCONJ	O
parietal	O	ADJ	B
brain	O	NOUN	I
structures	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
modification	O	NOUN	B
in	O	ADP	O
information	O	NOUN	B
flow	O	NOUN	I
between	O	ADP	O
brain	O	NOUN	B
regions	O	NOUN	I
during	O	ADP	O
acute	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Here	O	ADV	O
we	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
psychedelic-induced	O	ADJ	B
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
directionality	I-OUT	NOUN	B
of	I-OUT	ADP	O
information	I-OUT	NOUN	B
flow	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
psychedelic	O	NOUN	B
in	O	ADP	O
humans	B-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
measured	O	VERB	B
modifications	O	NOUN	B
in	O	ADP	O
connectivity	O	NOUN	B
of	O	ADP	O
brain	B-OUT	NOUN	B
oscillations	I-OUT	NOUN	I
using	O	VERB	O
transfer	O	NOUN	B
entropy	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
nonlinear	O	ADJ	B
measure	O	NOUN	I
of	O	ADP	O
directed	O	VERB	O
functional	O	ADJ	O
connectivity	O	NOUN	O
based	O	VERB	O
on	O	ADP	O
information	O	NOUN	B
theory	O	NOUN	I
.	O	PUNCT	O


Ten	B-P	NUM	O
healthy	I-P	ADJ	B
male	I-P	NOUN	B
volunteers	I-P	NOUN	B
with	I-P	ADP	O
prior	I-P	ADJ	O
experience	I-P	NOUN	B
with	I-P	ADP	O
psychedelics	I-I	NOUN	B
participated	O	VERB	O
in	O	ADP	O
2	O	NUM	O
experimental	O	ADJ	B
sessions	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
received	O	VERB	O
a	O	DET	O
placebo	B-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
dose	I-I	NOUN	B
of	I-I	ADP	O
ayahuasca	I-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
psychedelic	I-I	ADJ	B
preparation	I-I	NOUN	I
containing	I-I	VERB	O
the	I-I	DET	O
serotonergic	I-I	ADJ	B
5-HT2A	I-I	NOUN	I
agonist	I-I	NOUN	I
N	I-I	NOUN	O
,	I-I	PUNCT	O
N-dimethyltryptamine	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
analysis	O	NOUN	B
showed	O	VERB	O
significant	O	ADJ	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
coupling	I-OUT	NOUN	B
of	I-OUT	ADP	O
brain	I-OUT	NOUN	B
oscillations	I-OUT	NOUN	I
between	O	ADP	O
anterior	O	ADJ	B
and	O	CCONJ	O
posterior	O	ADJ	B
recording	O	NOUN	I
sites	O	NOUN	I
.	O	PUNCT	O


Transfer	O	NOUN	B
entropy	O	NOUN	I
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
frontal	O	ADJ	B
sources	O	NOUN	B
decreased	O	VERB	B
their	O	PRON	O
influence	O	NOUN	B
over	O	ADP	O
central	O	ADJ	B
,	O	PUNCT	O
parietal	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
occipital	O	ADJ	B
sites	O	NOUN	I
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
sources	O	NOUN	B
in	O	ADP	O
posterior	O	ADJ	B
locations	O	NOUN	B
increased	O	VERB	B
their	O	PRON	O
influence	O	NOUN	B
over	O	ADP	O
signals	O	NOUN	B
measured	O	VERB	B
at	O	ADP	O
anterior	O	ADJ	B
locations	O	NOUN	B
.	O	PUNCT	O


Exploratory	O	ADJ	B
correlations	O	NOUN	I
found	O	VERB	O
that	O	SCONJ	O
anterior-to-posterior	B-OUT	ADJ	B
transfer	I-OUT	NOUN	I
entropy	I-OUT	NOUN	I
decreases	O	NOUN	B
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
intensity	O	NOUN	B
of	O	ADP	O
subjective	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
imbalance	O	NOUN	B
between	O	ADP	O
anterior-to-posterior	B-OUT	ADJ	B
and	O	CCONJ	O
posterior-to-anterior	B-OUT	ADJ	B
transfer	I-OUT	NOUN	I
entropy	I-OUT	NOUN	I
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
incapacitation	O	NOUN	B
experienced	O	VERB	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
psychedelics	B-I	NOUN	B
induce	O	VERB	B
a	O	DET	O
temporary	B-OUT	ADJ	B
disruption	I-OUT	NOUN	B
of	O	ADP	O
neural	B-OUT	ADJ	B
hierarchies	I-OUT	NOUN	I
by	O	ADP	O
reducing	O	VERB	B
top-down	O	ADJ	B
control	O	NOUN	I
and	O	CCONJ	O
increasing	O	VERB	B
bottom-up	O	ADJ	B
information	O	NOUN	B
transfer	O	NOUN	I
in	O	ADP	O
the	O	DET	O
human	B-P	ADJ	B
brain	O	NOUN	B
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
safety	B-OUT	NOUN	B
of	O	ADP	O
repeated	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
ulipristal	B-I	ADJ	B
acetate	I-I	NOUN	I
in	O	ADP	O
uterine	B-P	ADJ	B
fibroids	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
safety	B-OUT	NOUN	B
of	O	ADP	O
repeated	O	VERB	O
12-week	O	NOUN	B
courses	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
or	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
of	O	ADP	O
ulipristal	B-I	ADJ	B
acetate	I-I	NOUN	I
for	O	ADP	O
intermittent	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
symptomatic	B-P	ADJ	B
uterine	I-P	NOUN	B
fibroids	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Double-blind	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
12-week	O	NOUN	B
courses	O	NOUN	B
of	O	ADP	O
ulipristal	B-I	NOUN	B
acetate	I-I	NOUN	I
.	I-I	PUNCT	O


SETTING	O	VERB	B
Gynecology	B-P	PROPN	I
centers	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENT	O	NOUN	B
(	O	PUNCT	O
S	O	NOUN	B
)	O	PUNCT	O
A	O	DET	O
total	B-P	NOUN	O
of	I-P	ADP	O
451	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
symptomatic	I-P	ADJ	B
uterine	I-P	ADJ	B
fibroid	I-P	NOUN	I
(	I-P	PUNCT	O
s	I-P	NOUN	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
heavy	I-P	ADJ	B
bleeding	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTION	O	NOUN	B
(	O	PUNCT	O
S	O	NOUN	B
)	O	PUNCT	O
Two	O	NUM	O
repeated	O	VERB	O
12-week	O	NOUN	B
treatment	O	NOUN	I
courses	O	NOUN	B
of	O	ADP	O
daily	O	ADV	B
5	B-I	NUM	O
or	I-I	CCONJ	O
10	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
ulipristal	I-I	NOUN	B
acetate	I-I	NOUN	I
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	O
MEASURE	O	NOUN	O
(	O	PUNCT	O
S	O	NOUN	O
)	O	PUNCT	O
Amenorrhea	B-OUT	NOUN	O
,	I-OUT	PUNCT	O
controlled	I-OUT	VERB	B
bleeding	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
fibroid	I-OUT	ADJ	B
volume	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
QoL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULT	O	NOUN	B
(	O	PUNCT	O
S	O	NOUN	B
)	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
5-	O	NUM	O
and	O	CCONJ	O
10-mg	O	ADJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
73	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
achieved	O	VERB	O
amenorrhea	B-OUT	NOUN	B
during	O	ADP	O
both	O	DET	O
treatment	O	NOUN	B
courses	O	NOUN	B
.	O	PUNCT	O


Proportions	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
achieving	O	VERB	O
controlled	B-OUT	VERB	B
bleeding	I-OUT	NOUN	I
during	O	ADP	O
two	O	NUM	O
treatment	O	NOUN	B
courses	O	NOUN	O
were	O	AUX	O
>	O	X	O
80	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Menstruation	B-OUT	NOUN	B
resumed	I-OUT	VERB	B
after	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
course	O	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
diminished	O	VERB	B
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
second	O	ADJ	O
treatment	O	NOUN	B
course	O	NOUN	I
,	O	PUNCT	O
median	B-OUT	ADJ	B
reductions	I-OUT	NOUN	B
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
in	I-OUT	ADP	O
fibroid	I-OUT	NOUN	B
volume	I-OUT	NOUN	B
were	O	AUX	O
54	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
58	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
receiving	O	VERB	O
5	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
ulipristal	O	NOUN	B
acetate	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
QoL	I-OUT	NOUN	B
improved	O	VERB	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Ulipristal	O	NOUN	B
acetate	O	NOUN	I
was	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
with	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
discontinuing	O	VERB	B
treatment	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
(	O	PUNCT	O
S	O	NOUN	B
)	O	PUNCT	O
Repeated	O	ADJ	B
12-week	O	NOUN	B
courses	O	NOUN	B
of	O	ADP	O
daily	O	ADJ	B
oral	O	ADJ	B
ulipristal	O	NOUN	B
acetate	O	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
effectively	O	ADV	O
control	O	VERB	O
bleeding	B-OUT	NOUN	O
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
,	O	PUNCT	O
reduce	O	VERB	B
fibroid	B-OUT	NOUN	B
volume	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
restore	O	VERB	B
QoL	B-OUT	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
symptomatic	O	ADJ	B
fibroids	O	NOUN	B
.	O	PUNCT	O


CLINICAL	O	X	B
TRIAL	O	NOUN	I
REGISTRATION	O	NOUN	I
NUMBER	O	NOUN	O
NCT01629563	O	NOUN	O
(	O	PUNCT	O
PEARL	O	NOUN	B
IV	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


Gastrointestinal	B-OUT	ADJ	B
safety	I-OUT	NOUN	I
of	O	ADP	O
NO-aspirin	B-I	NOUN	B
(	I-I	PUNCT	O
NCX-4016	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
healthy	B-P	ADJ	B
human	I-P	ADJ	B
volunteers	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
proof	O	NOUN	O
of	O	ADP	O
concept	O	NOUN	B
endoscopic	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
AIMS	O	ADJ	B
NCX-4016	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
nitric	O	ADJ	B
oxide-releasing	O	ADJ	I
derivative	O	NOUN	I
of	O	ADP	O
aspirin	O	NOUN	B
with	O	ADP	O
antiplatelet	B-OUT	NOUN	B
activity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
NCX-4016	B-I	NOUN	B
on	O	ADP	O
gastrointestinal	O	ADJ	B
mucosa	O	NOUN	I
and	O	CCONJ	O
platelet	B-OUT	NOUN	B
functions	I-OUT	NOUN	I
in	O	ADP	O
healthy	B-P	ADJ	B
human	I-P	ADJ	B
volunteers	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
parallel-group	O	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Forty	B-P	NUM	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
7	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
NCX-4016	B-I	NOUN	B
(	I-I	PUNCT	O
400	I-I	NUM	O
and	I-I	CCONJ	O
800	I-I	NUM	O
mg	I-I	NOUN	O
twice	I-I	ADV	O
daily	I-I	ADV	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
equimolar	I-I	ADJ	B
doses	I-I	NOUN	I
of	I-I	ADP	O
aspirin	I-I	NOUN	B
(	I-I	PUNCT	O
200	I-I	NUM	O
and	I-I	CCONJ	O
420	I-I	NUM	O
mg	I-I	NOUN	O
twice	I-I	ADV	O
daily	I-I	ADV	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Upper	O	ADJ	B
endoscopies	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
gastroduodenal	B-OUT	ADJ	B
lesions	I-OUT	NOUN	B
were	O	AUX	O
graded	O	VERB	O
using	O	VERB	O
a	O	DET	O
predefined	B-OUT	ADJ	O
scoring	I-OUT	NOUN	B
system	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Basal	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
posttreatment	I-OUT	NOUN	B
platelet	I-OUT	NOUN	O
aggregation	I-OUT	NOUN	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
arachidonic	O	ADJ	B
acid	O	NOUN	I
(	O	PUNCT	O
AA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
serum	O	NOUN	B
thromboxane	O	NOUN	I
(	O	PUNCT	I
TX	O	NOUN	I
)	O	PUNCT	I
B	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
AA-stimulated	O	ADJ	B
platelet	O	NOUN	I
TXB	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
production	O	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Mucosal	B-OUT	ADJ	B
endoscopic	I-OUT	ADJ	I
injury	I-OUT	NOUN	I
score	I-OUT	NOUN	B
on	O	ADP	O
day	O	NOUN	B
7	O	NUM	O
was	O	AUX	O
0.63	O	NUM	O
+/-	O	CCONJ	O
0.16	O	NUM	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
and	O	CCONJ	O
11.0	O	NUM	O
+/-	O	CCONJ	O
3.0	O	NUM	O
and	O	CCONJ	O
16.1	O	NUM	O
+/-	O	CCONJ	O
1.6	O	NUM	O
in	O	ADP	O
healthy	B-P	ADJ	B
volunteers	I-P	NOUN	I
treated	O	VERB	B
with	O	ADP	I
200	O	NUM	O
and	O	CCONJ	O
420	O	NUM	O
mg	O	NOUN	O
aspirin	O	NOUN	B
twice	O	ADV	B
daily	O	ADV	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
vs.	O	CCONJ	O
placebo	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


NCX-4016	O	NOUN	B
was	O	AUX	O
virtually	O	ADV	O
devoid	O	ADJ	O
of	O	ADP	O
gastric	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
duodenal	I-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
total	B-OUT	ADJ	O
gastric	I-OUT	ADJ	O
and	I-OUT	CCONJ	O
duodenal	I-OUT	ADJ	B
endoscopic	I-OUT	ADJ	O
score	I-OUT	NOUN	O
of	O	ADP	O
1.38	O	NUM	O
+/-	O	CCONJ	O
0.3	O	NUM	O
and	O	CCONJ	O
1.25	O	NUM	O
+/-	O	CCONJ	O
0.5	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
vs.	O	CCONJ	O
aspirin	O	NOUN	B
,	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
vs.	O	CCONJ	O
placebo	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


NCX-4016	O	NOUN	B
inhibited	O	VERB	B
AA-induced	B-OUT	ADJ	B
platelet	I-OUT	NOUN	B
aggregation	I-OUT	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
serum	B-OUT	NOUN	B
TXB	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
and	O	CCONJ	O
platelet	B-OUT	NOUN	B
TXB	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
generation	I-OUT	NOUN	B
induced	O	VERB	B
by	O	ADP	O
AA	O	NOUN	B
to	O	PART	O
the	O	DET	O
same	O	ADJ	O
extent	O	NOUN	O
as	O	ADP	O
aspirin	B-I	NOUN	B
(	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
vs.	O	CCONJ	O
aspirin	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
proven	O	VERB	O
the	O	DET	O
concept	O	NOUN	B
that	O	SCONJ	O
addition	O	NOUN	O
of	O	ADP	O
an	O	DET	O
NO-donating	O	ADJ	B
moiety	O	NOUN	I
to	O	PART	O
aspirin	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
new	O	ADJ	O
chemical	O	NOUN	B
entity	O	NOUN	I
that	O	PRON	O
maintains	O	VERB	O
cyclooxygenase-1	O	NOUN	B
and	O	CCONJ	O
platelet	O	NOUN	B
inhibitory	O	ADJ	I
activity	O	NOUN	I
while	O	SCONJ	O
nearly	O	ADV	O
avoiding	O	VERB	O
gastrointestinal	B-OUT	ADJ	B
damage	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Corticosteroid-induced	O	ADJ	B
osteopenia	B-OUT	NOUN	I
and	I-OUT	CCONJ	O
vitamin	I-OUT	NOUN	B
D	I-OUT	NOUN	I
metabolism	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
vitamin	B-I	NOUN	B
D2	I-I	NOUN	I
,	I-I	PUNCT	O
calcium	I-I	NOUN	B
phosphate	I-I	NOUN	I
and	O	CCONJ	O
sodium	B-I	NOUN	B
fluoride	I-I	NOUN	I
administration	O	NOUN	I
.	O	PUNCT	O


Thirty-one	B-P	NUM	O
patients	I-P	NOUN	B
scheduled	I-P	VERB	O
for	I-P	ADP	O
long-term	I-P	ADJ	B
(	I-P	PUNCT	O
24	I-P	NUM	O
weeks	I-P	NOUN	B
)	I-P	PUNCT	O
treatment	I-P	NOUN	B
with	I-P	ADP	O
prednisone	I-I	NOUN	B
in	I-P	ADP	O
comparatively	I-P	ADV	O
high	I-P	ADJ	O
doses	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
two	O	NUM	O
further	O	ADJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Group	B-I	PROPN	B
A	I-I	PROPN	O
received	I-I	VERB	O
prednisone	I-I	NOUN	B
plus	I-I	CCONJ	O
'triple-treatment	I-I	PUNCT	B
'	I-I	PUNCT	I
(	I-I	PUNCT	O
vitamin	I-I	NOUN	B
D2	I-I	NOUN	I
45000	I-I	NUM	O
iu	I-I	NOUN	O
twice	I-I	ADV	O
weekly	I-I	ADJ	B
,	I-I	PUNCT	O
sodium	I-I	NOUN	B
fluoride	I-I	NOUN	I
50	I-I	NUM	O
mg	I-I	NOUN	O
and	I-I	CCONJ	O
calcium	I-I	NOUN	B
phosphate	I-I	NOUN	I
4.5	I-I	NUM	O
g	I-I	NOUN	O
daily	I-I	ADV	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
group	I-I	NOUN	B
B	I-I	NOUN	I
received	I-I	VERB	O
only	I-I	ADV	O
prednisone	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
prednisone-	B-I	NOUN	B
and	O	CCONJ	O
triple-treatment	B-I	ADJ	B
upon	O	SCONJ	O
bone	B-OUT	NOUN	B
mineral	I-OUT	ADJ	I
content	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BMC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
vitamin	I-OUT	NOUN	B
D	I-OUT	NOUN	I
metabolism	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
and	O	CCONJ	O
prednisone	O	NOUN	B
dose	O	NOUN	B
.	O	PUNCT	O


BMC	B-OUT	NOUN	B
fell	O	VERB	O
rapidly	O	ADV	O
and	O	CCONJ	O
similarly	O	ADV	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
demonstrating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
triple-treatment	O	NOUN	B
has	O	AUX	O
no	O	DET	O
preventive	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
corticosteroid	O	NOUN	B
induced	O	VERB	B
osteopenia	O	NOUN	B
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
of	I-OUT	ADP	O
25OHD2	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
25OHD3	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
1,25	I-OUT	NUM	B
(	I-OUT	PUNCT	O
OH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
2D	I-OUT	NOUN	B
were	O	AUX	O
unchanged	O	ADJ	B
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
without	O	ADP	O
triple-treatment	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	O
25OHD2	B-OUT	NOUN	B
increased	O	VERB	B
enormously	O	ADV	O
,	O	PUNCT	O
25OHD3	B-OUT	NOUN	B
was	O	AUX	O
suppressed	O	VERB	B
possibly	O	ADV	O
by	O	ADP	O
substrate	O	ADJ	B
competition	O	NOUN	B
for	O	ADP	O
hydroxylation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
and	O	CCONJ	O
1,25	B-OUT	NUM	B
(	I-OUT	PUNCT	O
OH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
2D	I-OUT	NOUN	B
was	O	AUX	O
halved	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
suppression	O	NOUN	B
of	O	ADP	O
1,25	B-OUT	NUM	B
(	I-OUT	PUNCT	O
OH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
2D	I-OUT	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
raised	O	VERB	B
25OHD2	O	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
corticosteroid	O	NOUN	B
excess	O	NOUN	B
.	O	PUNCT	O


Anxiety	O	NOUN	B
disorders	O	NOUN	I
in	O	ADP	O
typically	O	ADV	O
developing	O	VERB	O
youth	O	NOUN	B
:	O	PUNCT	O
autism	O	NOUN	B
spectrum	O	NOUN	I
symptoms	O	NOUN	I
as	O	ADP	O
a	O	DET	O
predictor	O	NOUN	B
of	O	ADP	O
cognitive-behavioral	B-I	ADJ	B
treatment	I-I	NOUN	I
.	I-I	PUNCT	O


Symptoms	O	NOUN	B
of	O	ADP	O
autism	O	NOUN	B
spectrum	O	NOUN	I
disorder	O	NOUN	I
(	O	PUNCT	O
ASD	O	PROPN	B
)	O	PUNCT	O
were	O	AUX	O
assessed	O	VERB	B
(	O	PUNCT	O
Social	O	PROPN	B
Responsiveness	O	PROPN	I
Scale-Parent	O	ADJ	I
(	O	PUNCT	O
SRS-P	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
coded	O	VERB	O
in-session	O	NOUN	B
behavior	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
typically-developing	B-P	ADJ	B
,	I-P	PUNCT	O
anxiety-disordered	I-P	ADJ	B
children	I-P	NOUN	I
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
50	I-P	NUM	O
)	I-P	PUNCT	O
treated	O	VERB	B
with	B-I	ADP	I
cognitive-behavioral	I-I	ADJ	B
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
CBT	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Study	O	NOUN	B
1	B-P	NUM	O
:	I-P	PUNCT	O
children	I-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
autistic	I-P	ADJ	B
symptomology	I-P	NOUN	B
(	O	PUNCT	O
per	O	ADP	O
SRS-P	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
improve	O	VERB	B
from	B-I	ADP	O
family	I-I	NOUN	B
CBT	I-I	NOUN	B
(	I-I	PUNCT	O
FCBT	I-I	NOUN	B
)	I-I	PUNCT	O
than	I-I	ADP	O
individual	I-I	ADJ	B
CBT	I-I	NOUN	B
(	I-I	PUNCT	O
ICBT	I-I	NOUN	B
;	I-I	PUNCT	O
OR	O	CCONJ	B
=	O	ADJ	O
8.67	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Coded	O	VERB	B
behavior	O	NOUN	I
did	O	AUX	O
not	O	PART	O
predict	O	VERB	O
outcome	O	NOUN	B
.	O	PUNCT	O


Study	B-I	NOUN	B
2	I-I	NUM	I
:	I-I	PUNCT	O
CBT	O	NOUN	B
components	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
by	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
ASD	O	VERB	B
symptom	O	NOUN	B
status	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


At-home	B-OUT	ADJ	B
exposure	I-OUT	NOUN	B
completion	I-OUT	NOUN	B
was	O	AUX	O
greater	B-I	ADJ	O
in	I-I	ADP	O
FCBT	I-I	NOUN	B
and	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
an	O	DET	O
interaction	O	NOUN	B
in	O	ADP	O
child	O	NOUN	B
involvement	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
ASD	O	VERB	B
status	O	NOUN	B
.	O	PUNCT	O


Though	O	SCONJ	O
both	O	DET	O
treatments	O	NOUN	B
reduced	B-OUT	VERB	B
anxiety	I-OUT	NOUN	B
,	I-I	PUNCT	O
FCBT	I-I	PROPN	B
outperformed	I-I	VERB	O
ICBT	I-I	NOUN	B
for	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
moderate	O	ADJ	B
ASD	O	VERB	B
symptoms	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
benefit	O	NOUN	B
potentially	O	ADV	O
linked	O	VERB	O
to	O	ADP	O
more	O	ADV	O
at-home	O	ADJ	B
exposures	O	NOUN	B
and	O	CCONJ	O
greater	O	ADJ	O
child	O	NOUN	B
involvement	B-I	NOUN	B
in	I-I	ADP	O
FCBT	I-I	NOUN	B
.	O	PUNCT	O


Parents	B-P	NOUN	B
'	I-P	PART	O
state	O	NOUN	B
and	O	CCONJ	O
trait	O	NOUN	B
anxiety	O	NOUN	B
:	O	PUNCT	O
relationships	O	NOUN	B
with	O	ADP	O
anxiety	B-OUT	NOUN	B
severity	I-OUT	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
response	O	NOUN	I
in	O	ADP	O
adolescents	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


Comorbid	O	ADJ	B
anxiety	O	NOUN	I
is	O	AUX	O
common	O	ADJ	O
among	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
Autism	I-P	PROPN	B
Spectrum	I-P	PROPN	I
Disorder	I-P	PROPN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
parents	I-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	VERB	B
are	I-P	AUX	O
more	I-P	ADV	O
likely	I-P	ADJ	O
to	I-P	PART	O
have	I-P	AUX	O
anxiety	I-P	NOUN	B
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
investigated	O	VERB	B
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
parents	B-I	NOUN	B
'	I-I	PART	O
state	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
trait	I-OUT	NOUN	B
anxiety	I-OUT	NOUN	B
and	I-P	CCONJ	O
parent-reported	I-I	ADJ	B
internalizing	I-I	NOUN	B
and	I-I	CCONJ	O
externalizing	I-I	NOUN	B
symptoms	I-I	NOUN	I
among	I-I	ADP	O
adolescents	I-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
30	I-P	NUM	O
)	I-P	PUNCT	O
with	I-P	ADP	O
ASD	I-P	PROPN	B
,	I-P	PUNCT	O
as	I-P	ADV	O
well	I-P	ADV	O
as	I-P	ADP	O
the	I-P	DET	O
relationship	I-P	NOUN	B
of	I-OUT	ADP	O
parents	I-OUT	NOUN	B
'	I-OUT	PART	O
anxiety	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
adolescent	I-OUT	ADJ	B
treatment	I-OUT	NOUN	B
response	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Parental	B-OUT	ADJ	B
state	I-OUT	NOUN	I
anxiety	I-OUT	NOUN	I
correlated	O	VERB	B
with	B-OUT	ADP	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
adolescent	I-OUT	ADJ	B
anxiety	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
trait	I-OUT	NOUN	B
anxiety	I-OUT	NOUN	B
in	O	ADP	O
parents	O	NOUN	B
correlated	O	VERB	B
with	B-OUT	ADP	O
parent-reported	I-OUT	ADJ	B
adolescent	I-OUT	ADJ	B
internalizing	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
externalizing	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	I
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
parents	O	NOUN	B
of	O	ADP	O
adolescent	O	ADJ	B
treatment	O	NOUN	B
responders	O	NOUN	O
experienced	O	VERB	O
a	B-OUT	DET	O
decrease	I-OUT	NOUN	B
in	I-OUT	ADP	O
their	I-OUT	PRON	O
own	I-OUT	ADJ	O
trait	I-OUT	NOUN	B
anxiety	I-OUT	NOUN	B
.	O	PUNCT	O


Findings	O	NOUN	B
highlight	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	B-I	ADP	O
considering	I-OUT	VERB	O
parental	I-OUT	ADJ	B
anxiety	I-OUT	NOUN	B
when	O	SCONJ	O
targeting	B-OUT	VERB	B
anxiety	I-OUT	NOUN	B
among	O	ADP	O
youth	O	NOUN	B
with	O	ADP	O
ASD	O	PROPN	B
.	O	PUNCT	O


[	O	PUNCT	O
The	O	DET	O
application	O	NOUN	O
of	O	ADP	O
naphcon	B-I	ADJ	B
eye	I-I	NOUN	I
drops	I-I	NOUN	I
during	O	ADP	O
Lasik	B-I	PROPN	B
surgery	I-I	NOUN	I
]	I-I	PUNCT	O
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
Naphcon	B-I	NOUN	B
eye	I-I	NOUN	I
drops	I-I	VERB	I
for	O	ADP	O
preventing	O	VERB	B
conjunctival	B-P	NOUN	B
bleeding	I-P	NOUN	I
during	I-P	ADP	O
Lasik	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
cases	I-P	NOUN	B
(	I-P	PUNCT	O
200	I-P	NUM	O
eyes	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
treating	O	VERB	B
group	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
group	O	NOUN	I
randomly	O	ADV	O
according	O	VERB	O
to	O	ADP	O
using	O	VERB	O
and	O	CCONJ	O
not	O	PART	O
using	O	VERB	O
Naphcon	B-I	PROPN	B
eye	I-I	NOUN	I
drops	I-I	NOUN	I
before	O	ADP	O
Lasik	O	PROPN	B
surgery	O	NOUN	I
.	O	PUNCT	O


Treating	O	VERB	B
group	O	NOUN	B
patients	O	NOUN	B
received	O	VERB	O
three	O	NUM	O
times	O	NOUN	O
Naphcon	B-I	PROPN	B
eye	I-I	NOUN	I
drops	I-I	VERB	I
during	O	ADP	O
15	O	NUM	O
minutes	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
conjunctival	I-OUT	NOUN	B
bleeding	I-OUT	NOUN	I
from	O	ADP	O
treating	O	VERB	B
and	O	CCONJ	O
control	O	NOUN	B
group	O	NOUN	I
were	O	AUX	O
8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
significant	O	ADJ	O
statistical	O	ADJ	B
difference	O	NOUN	O
between	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
Naphcon	B-I	PROPN	B
eye	I-I	NOUN	I
drop	I-I	NOUN	I
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
agent	O	NOUN	B
to	O	PART	O
prevent	O	VERB	B
conjunctival	B-P	NOUN	B
bleeding	I-P	NOUN	I
.	I-P	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
hypertensive	B-P	ADJ	B
patients	I-P	NOUN	B
after	O	ADP	O
care	O	NOUN	B
provided	O	VERB	O
by	O	ADP	O
community	B-I	NOUN	B
pharmacists	I-I	NOUN	I
in	I-P	ADP	O
a	I-P	DET	O
rural	I-P	ADJ	B
setting	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
control	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
care	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
satisfaction	I-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
monitored	I-P	VERB	O
by	I-P	ADP	O
specially	I-I	ADV	B
trained	I-I	VERB	I
community	I-I	NOUN	B
pharmacists	I-I	NOUN	O
in	I-P	ADP	O
a	I-P	DET	O
group	I-P	NOUN	B
medical	I-P	ADJ	B
practice	I-P	NOUN	I
.	I-P	PUNCT	O


After	O	ADP	O
participating	O	VERB	O
in	O	ADP	O
an	O	DET	O
intensive	B-I	ADJ	B
skill	I-I	NOUN	I
development	I-I	NOUN	I
program	I-I	NOUN	B
,	O	PUNCT	O
pharmacists	O	NOUN	B
performed	O	VERB	O
in	O	ADP	O
an	O	DET	O
interdisciplinary	O	ADJ	B
team	O	NOUN	B
in	O	ADP	O
a	O	DET	O
rural	O	ADJ	B
clinic	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
objective	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
evaluating	O	VERB	B
outcome	O	NOUN	B
variables	O	NOUN	O
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
25	B-P	NUM	O
patients	I-P	NOUN	B
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
control	B-P	NOUN	B
group	I-P	NOUN	I
of	I-P	ADP	O
26	I-P	NUM	O
patients	I-P	NOUN	B
was	O	AUX	O
also	O	ADV	O
evaluated	O	VERB	B
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
outcome	O	NOUN	B
variables	O	NOUN	B
remained	O	VERB	O
constant	O	ADJ	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Systolic	B-OUT	NOUN	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
151	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
baseline	O	NOUN	B
,	O	PUNCT	O
140	O	NUM	O
mm	O	NOUN	O
Hg	O	NOUN	O
at	O	ADP	O
6	O	NUM	O
mo	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
diastolic	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
at	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
months	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Ratings	O	NOUN	B
from	O	ADP	O
a	O	DET	O
blinded	O	ADJ	B
peer	O	NOUN	B
review	O	NOUN	O
panel	O	NOUN	O
indicated	O	VERB	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
appropriateness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
pressure	O	NOUN	I
regimen	O	NOUN	I
,	O	PUNCT	O
going	O	VERB	O
from	O	ADP	O
8.7	O	NUM	O
+/-	O	CCONJ	O
4.7	O	NUM	O
to	O	PART	O
10.9	O	NUM	O
+/-	O	CCONJ	O
4.5	O	NUM	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
they	O	PRON	O
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Several	O	ADJ	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
improved	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
included	O	VERB	O
physical	B-OUT	ADJ	B
functioning	I-OUT	NOUN	I
(	O	PUNCT	O
61.6	O	NUM	O
vs	O	CCONJ	O
70.7	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
physical	B-OUT	ADJ	B
role	I-OUT	NOUN	I
limitations	I-OUT	NOUN	I
(	O	PUNCT	O
56.8	O	NUM	O
vs	O	CCONJ	O
72.8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
bodily	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
(	O	PUNCT	O
60.0	O	NUM	O
vs	O	CCONJ	O
71.7	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Patient	B-OUT	ADJ	B
satisfaction	I-OUT	NOUN	I
scores	I-OUT	NOUN	B
were	O	AUX	O
consistently	O	ADV	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
when	O	SCONJ	O
community	B-I	NOUN	B
pharmacists	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
clinic	O	NOUN	B
setting	O	NOUN	O
are	O	AUX	O
trained	O	VERB	B
and	O	CCONJ	O
included	O	VERB	O
as	O	ADP	O
members	O	NOUN	B
of	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
care	O	NOUN	I
team	O	NOUN	B
,	O	PUNCT	O
significant	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
control	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
patient	I-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
can	O	AUX	O
be	O	AUX	O
achieved	O	VERB	O
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
m-chlorophenylpiperazine	B-I	NOUN	B
on	O	ADP	O
plasma	B-OUT	NOUN	B
homovanillic	I-OUT	NOUN	B
acid	I-OUT	NOUN	I
concentrations	I-OUT	NOUN	B
in	O	ADP	O
healthy	B-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
the	O	DET	O
abundant	O	ADJ	B
anatomical	O	ADJ	B
and	O	CCONJ	O
functional	O	ADJ	B
interactions	O	NOUN	B
between	O	ADP	O
serotonin	O	NOUN	B
and	O	CCONJ	O
dopamine	O	NOUN	B
systems	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
serotonin	O	NOUN	B
agonist	O	NOUN	B
,	O	PUNCT	O
m-chlorophenylpiperazine	B-I	NOUN	B
(	I-I	PUNCT	O
mCPP	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
plasma	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
dopamine	I-OUT	NOUN	B
metabolite	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
homovanillic	I-OUT	NOUN	B
acid	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Plasma	O	NOUN	B
prolactin	O	NOUN	B
levels	O	NOUN	I
,	O	PUNCT	O
body	O	NOUN	B
temperature	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
mCPP	B-OUT	NOUN	B
blood	O	NOUN	I
level	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
measured	O	VERB	B
.	O	PUNCT	O


mCPP	B-I	NOUN	B
(	O	PUNCT	O
0.35	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
placebo	B-I	NOUN	B
were	O	AUX	O
administered	O	VERB	B
orally	O	ADV	B
to	O	PART	O
10	B-P	NUM	O
healthy	I-P	ADJ	B
men	I-P	NOUN	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
design	O	NOUN	I
.	O	PUNCT	O


Variables	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
for	O	ADP	O
210	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
capsules	O	NOUN	B
.	O	PUNCT	O


mCPP	B-OUT	NOUN	B
raised	I-OUT	VERB	O
prolactin	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
temperature	I-OUT	NOUN	B
as	I-OUT	ADP	O
compared	I-OUT	VERB	O
to	I-OUT	PART	O
placebo	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
plasma	B-OUT	NOUN	B
homovanillic	I-OUT	NOUN	B
acid	I-OUT	NOUN	I
concentrations	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
mCPP	B-OUT	NOUN	B
does	I-OUT	AUX	O
not	I-OUT	PART	O
alter	I-OUT	VERB	O
dopamine	I-OUT	NOUN	B
function	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Avatar	O	ADJ	B
assistant	O	NOUN	I
:	O	PUNCT	O
improving	O	VERB	B
social	B-OUT	ADJ	B
skills	I-OUT	NOUN	I
in	O	ADP	O
students	B-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
ASD	I-P	VERB	B
through	O	ADP	O
a	O	DET	O
computer-based	B-I	ADJ	B
intervention	I-I	NOUN	I
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
FaceSay	B-I	PROPN	B
,	I-I	PUNCT	O
a	I-I	DET	O
computer-based	I-I	ADJ	B
social	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
training	I-I	NOUN	B
program	I-I	NOUN	I
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
Autism	I-P	PROPN	B
Spectrum	I-P	PROPN	I
Disorders	I-P	PROPN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
study	B-P	NOUN	I
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
49	I-P	NUM	O
)	I-P	PUNCT	O
indicates	O	VERB	O
that	O	SCONJ	O
providing	B-P	VERB	O
children	I-P	NOUN	B
with	I-P	ADP	O
low-functioning	I-P	ADJ	B
autism	I-P	NOUN	O
(	I-P	PUNCT	O
LFA	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
high	I-P	ADJ	B
functioning	I-P	VERB	O
autism	I-P	NOUN	B
(	I-P	PUNCT	O
HFA	I-P	NOUN	B
)	I-P	PUNCT	O
opportunities	O	NOUN	B
to	O	PART	O
practice	O	VERB	B
attending	O	VERB	B
to	O	ADP	O
eye	O	NOUN	B
gaze	O	NOUN	I
,	O	PUNCT	O
discriminating	O	VERB	O
facial	O	ADJ	B
expressions	O	NOUN	O
and	O	CCONJ	O
recognizing	O	VERB	O
faces	O	NOUN	B
and	O	CCONJ	O
emotions	O	NOUN	B
in	O	ADP	O
FaceSay	O	PROPN	B
's	O	PART	I
structured	O	ADJ	B
environment	O	NOUN	I
with	O	ADP	O
interactive	O	ADJ	B
,	O	PUNCT	O
realistic	O	ADJ	O
avatar	O	NOUN	B
assistants	O	NOUN	O
improved	O	VERB	B
their	B-OUT	PRON	O
social	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
abilities	I-OUT	NOUN	B
.	O	PUNCT	O


The	O	DET	O
children	O	NOUN	B
with	O	ADP	O
LFA	O	NOUN	B
demonstrated	O	VERB	O
improvements	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
areas	O	NOUN	O
of	O	ADP	O
the	O	DET	O
intervention	B-OUT	NOUN	B
:	I-OUT	PUNCT	O
emotion	I-OUT	NOUN	B
recognition	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
social	I-OUT	ADJ	B
interactions	I-OUT	NOUN	I
.	O	PUNCT	O


The	O	DET	O
children	O	NOUN	B
with	O	ADP	O
HFA	O	NOUN	B
demonstrated	O	VERB	O
improvements	O	NOUN	B
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
areas	B-OUT	NOUN	B
:	I-OUT	PUNCT	O
facial	I-OUT	ADJ	B
recognition	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
emotion	I-OUT	NOUN	B
recognition	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
social	I-OUT	ADJ	B
interactions	I-OUT	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
the	O	DET	O
measured	O	VERB	B
improvements	O	NOUN	B
to	B-OUT	PART	O
social	I-OUT	ADJ	B
interactions	I-OUT	NOUN	I
in	O	ADP	O
a	O	DET	O
natural	O	ADJ	B
environment	O	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
encouraging	O	ADJ	O
.	O	PUNCT	O


Evaluating	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
thoracoscopy	B-I	NOUN	B
and	I-I	CCONJ	O
talc	I-I	NOUN	B
poudrage	I-I	NOUN	B
versus	I-I	CCONJ	O
pleurodesis	I-I	NOUN	B
using	I-I	VERB	O
talc	I-I	NOUN	B
slurry	I-I	NOUN	B
(	O	PUNCT	O
TAPPS	O	NOUN	B
trial	O	NOUN	I
)	O	PUNCT	O
:	O	PUNCT	O
protocol	O	NOUN	B
of	O	ADP	O
an	O	DET	O
open-label	O	ADJ	B
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


INTRODUCTION	O	VERB	O
The	O	DET	O
management	O	NOUN	B
of	O	ADP	O
recurrent	O	ADJ	B
malignant	O	ADJ	O
pleural	O	ADJ	O
effusions	O	NOUN	O
(	O	PUNCT	O
MPE	O	NOUN	B
)	O	PUNCT	O
can	O	AUX	O
be	O	AUX	O
challenging	O	ADJ	O
.	O	PUNCT	O


Various	O	ADJ	O
options	O	NOUN	B
are	O	AUX	O
available	O	ADJ	O
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
most	O	ADV	O
efficacious	O	ADJ	B
and	O	CCONJ	O
widely	O	ADV	O
used	O	VERB	O
being	O	AUX	O
talc	B-I	NOUN	B
pleurodesis	I-I	NOUN	B
.	I-I	PUNCT	O


Talc	B-I	NOUN	B
can	O	AUX	O
either	O	CCONJ	O
be	O	AUX	O
applied	O	VERB	O
via	O	ADP	O
a	O	DET	O
chest	O	ADJ	B
drain	O	NOUN	B
in	O	ADP	O
the	O	DET	O
form	O	NOUN	O
of	O	ADP	O
slurry	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
at	O	ADP	O
medical	B-I	ADJ	B
thoracoscopy	I-I	NOUN	I
using	I-I	VERB	O
poudrage	I-I	NOUN	B
.	I-I	PUNCT	O


Current	O	ADJ	O
evidence	O	NOUN	B
regarding	O	VERB	O
which	O	DET	O
method	O	NOUN	B
is	O	AUX	O
most	O	ADV	O
effective	O	ADJ	B
is	O	AUX	O
conflicting	O	VERB	O
and	O	CCONJ	O
often	O	ADV	O
methodologically	O	ADV	B
flawed	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
TAPPS	O	NOUN	B
trial	O	NOUN	I
is	O	AUX	O
a	O	DET	O
suitably	O	ADV	O
powered	O	ADJ	B
,	O	PUNCT	O
multicentre	O	NOUN	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
designed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
pleurodesis	O	NOUN	B
success	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
medical	B-I	ADJ	B
thoracoscopy	I-I	NOUN	I
and	I-I	CCONJ	O
talc	I-I	NOUN	B
poudrage	I-I	NOUN	B
with	I-I	ADP	O
chest	I-I	ADJ	B
drain	I-I	NOUN	I
insertion	I-I	NOUN	I
and	I-I	CCONJ	O
talc	I-I	NOUN	B
slurry	I-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
ANALYSIS	O	NOUN	O
330	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
confirmed	I-P	VERB	O
MPE	I-P	NOUN	B
requiring	I-P	VERB	O
intervention	I-P	NOUN	B
will	I-P	AUX	O
be	I-P	AUX	O
recruited	I-P	VERB	O
from	I-P	ADP	O
UK	I-P	PROPN	B
hospitals	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
randomised	O	VERB	B
(	O	PUNCT	O
1:1	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
undergo	O	VERB	O
either	O	CCONJ	O
small	B-I	ADJ	O
bore	I-I	NOUN	O
(	I-I	PUNCT	O
<	I-I	X	O
14	I-I	NUM	O
Fr	I-I	NOUN	O
)	I-I	PUNCT	O
Seldinger	I-I	PROPN	O
chest	I-I	ADJ	O
drain	I-I	NOUN	B
insertion	I-I	NOUN	I
followed	I-I	VERB	O
by	I-I	ADP	O
instillation	I-I	NOUN	B
of	I-I	ADP	O
sterile	I-I	ADJ	B
talc	I-I	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
or	B-I	CCONJ	O
to	I-I	PART	O
undergo	I-I	VERB	O
medical	I-I	ADJ	B
thoracoscopy	I-I	NOUN	I
and	I-I	CCONJ	O
simultaneous	I-I	ADJ	B
poudrage	I-I	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
allocated	O	VERB	O
procedure	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
performed	O	VERB	O
as	O	ADP	O
an	O	DET	O
inpatient	O	NOUN	B
within	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
randomisation	O	NOUN	B
taking	O	VERB	O
place	O	NOUN	O
.	O	PUNCT	O


Following	O	VERB	O
discharge	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
followed	O	VERB	B
up	O	ADP	I
at	O	ADP	O
regular	O	ADJ	O
intervals	O	NOUN	B
for	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	B-OUT	NOUN	I
is	I-OUT	AUX	O
pleurodesis	I-OUT	NOUN	B
failure	I-OUT	NOUN	B
rates	O	NOUN	B
at	O	ADP	O
3	B-OUT	NUM	O
months	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Pleurodesis	B-OUT	ADJ	B
failure	O	NOUN	O
is	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
further	O	ADJ	O
pleural	O	ADJ	B
intervention	O	NOUN	I
for	O	ADP	O
fluid	O	ADJ	B
management	O	NOUN	I
on	O	ADP	O
the	O	DET	O
side	O	NOUN	O
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
intervention	O	NOUN	B
.	O	PUNCT	O


ETHICS	O	NOUN	O
AND	O	CCONJ	O
DISSEMINATION	O	PROPN	B
The	O	DET	O
trial	O	NOUN	B
has	O	AUX	O
received	O	VERB	O
ethical	O	ADJ	B
approval	O	NOUN	B
from	O	ADP	O
the	O	DET	O
National	O	PROPN	B
Research	O	PROPN	I
Ethics	O	PROPN	I
Service	O	PROPN	I
Committee	O	PROPN	I
North	O	PROPN	I
West-Preston	O	PROPN	I
(	O	PUNCT	O
12/NW/0467	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
a	O	DET	O
trial	O	NOUN	B
steering	O	NOUN	O
committee	O	NOUN	O
which	O	DET	O
includes	O	VERB	O
independent	O	ADJ	O
members	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
patient	O	NOUN	B
and	O	CCONJ	O
public	O	ADJ	B
representative	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
trial	O	NOUN	B
results	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
published	O	VERB	B
in	O	ADP	O
a	O	DET	O
peer-reviewed	O	ADJ	B
journal	O	NOUN	I
and	O	CCONJ	O
presented	O	VERB	O
at	O	ADP	O
international	O	ADJ	B
conferences	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
being	O	AUX	O
disseminated	O	VERB	B
via	O	ADP	O
local	O	ADJ	B
and	O	CCONJ	O
national	O	ADJ	B
charities	O	NOUN	B
and	O	CCONJ	O
patient	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
participants	O	NOUN	B
who	O	PRON	O
wish	O	VERB	O
to	O	PART	O
know	O	VERB	O
the	O	DET	O
study	O	NOUN	B
results	O	NOUN	B
will	O	AUX	O
also	O	ADV	O
be	O	AUX	O
contacted	O	VERB	O
directly	O	ADV	O
on	O	ADP	O
their	O	PRON	O
publication	O	NOUN	B
.	O	PUNCT	O


TRIAL	O	NOUN	B
REGISTRATION	O	NOUN	O
NUMBER	O	NOUN	B
ISRCTN47845793	O	NOUN	B
.	O	PUNCT	O


Asthma	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
home	O	NOUN	B
environment	O	NOUN	I
of	O	ADP	O
low-income	B-P	ADJ	B
urban	I-P	ADJ	B
children	I-P	NOUN	B
:	I-P	PUNCT	O
preliminary	O	ADJ	B
findings	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Seattle-King	O	ADJ	B
County	O	PROPN	B
healthy	O	ADJ	I
homes	O	NOUN	B
project	O	NOUN	O
.	O	PUNCT	O


OBJECTIVES	O	VERB	B
Childhood	O	NOUN	I
asthma	O	NOUN	I
is	O	AUX	O
a	O	DET	O
growing	O	VERB	O
public	O	ADJ	B
health	O	NOUN	I
concern	O	NOUN	O
in	O	ADP	O
low-income	O	ADJ	B
urban	O	ADJ	B
communities	O	NOUN	B
.	O	PUNCT	O


Indoor	O	ADJ	B
exposure	O	NOUN	B
to	O	PART	I
asthma	O	NOUN	B
triggers	O	NOUN	B
has	O	AUX	O
emerged	O	VERB	O
as	O	ADP	O
an	O	DET	O
important	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
asthma	O	NOUN	B
exacerbations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
indoor	O	ADJ	B
environmental	O	ADJ	B
conditions	O	NOUN	I
related	O	ADJ	O
to	O	PART	O
asthma	O	NOUN	B
triggers	O	NOUN	B
among	O	ADP	O
a	O	DET	O
low-income	B-P	ADJ	B
urban	I-P	ADJ	B
population	I-P	NOUN	O
in	I-P	ADP	O
Seattle/King	I-P	PROPN	B
County	I-P	PROPN	B
,	I-P	PUNCT	O
Washington	I-P	PROPN	B
,	I-P	PUNCT	O
as	I-P	ADV	O
well	I-P	ADV	O
as	I-P	ADP	O
caregiver	I-P	NOUN	B
knowledge	I-P	NOUN	B
and	O	CCONJ	O
resources	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
control	O	NOUN	B
of	O	ADP	O
these	O	DET	O
triggers	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Data	O	NOUN	B
are	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
in-person	O	NOUN	B
,	O	PUNCT	O
structured	O	ADJ	B
,	O	PUNCT	O
closed-end	O	ADJ	B
interviews	O	NOUN	I
with	O	ADP	O
the	O	DET	O
caretakers	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
aged	I-P	ADJ	B
4-12	I-P	NUM	O
years	I-P	NOUN	B
with	I-P	ADP	O
persistent	I-P	ADJ	B
asthma	I-P	NOUN	B
living	I-P	VERB	B
in	I-P	ADP	O
households	I-P	NOUN	B
with	I-P	ADP	O
incomes	I-P	NOUN	B
less	I-P	ADJ	O
than	I-P	ADP	O
200	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
poverty	I-P	NOUN	B
.	I-P	PUNCT	O


Additional	O	ADJ	O
information	O	NOUN	B
is	O	AUX	O
collected	O	VERB	O
during	O	ADP	O
a	O	DET	O
home	O	NOUN	B
inspection	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
children	B-P	NOUN	B
and	I-P	CCONJ	O
their	I-P	PRON	O
caregivers	I-P	NOUN	B
are	I-P	AUX	O
participants	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
ongoing	I-P	ADJ	O
Seattle-King	I-P	ADJ	B
County	I-P	PROPN	B
Healthy	I-P	PROPN	I
Homes	I-P	PROPN	I
Project	I-P	PROPN	I
,	I-P	PUNCT	O
a	I-P	DET	O
randomized	I-P	ADJ	B
controlled	I-P	VERB	I
trial	I-P	NOUN	I
of	I-P	ADP	O
an	I-P	DET	O
intervention	I-I	NOUN	B
to	I-P	PART	O
empower	I-P	VERB	O
low-income	I-P	ADJ	B
families	I-P	NOUN	B
to	I-P	PART	O
reduce	I-P	VERB	B
exposure	I-P	NOUN	B
to	I-P	ADP	I
indoor	I-P	ADJ	B
asthma	I-P	NOUN	I
triggers	I-P	VERB	B
.	I-P	PUNCT	O


We	O	PRON	O
report	O	VERB	O
findings	O	NOUN	B
on	O	ADP	O
the	O	DET	O
conditions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
homes	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
this	O	DET	O
intervention	O	NOUN	B
among	O	ADP	O
the	B-P	DET	O
first	I-P	ADJ	O
112	I-P	NUM	O
enrolled	I-P	VERB	O
households	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
smoker	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
37.5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
homes	O	NOUN	B
.	O	PUNCT	O


Mold	B-OUT	NOUN	B
was	I-OUT	AUX	O
visible	I-OUT	ADJ	B
in	O	ADP	O
26.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
homes	O	NOUN	B
,	O	PUNCT	O
water	B-OUT	NOUN	B
damage	I-OUT	NOUN	I
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
18.6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
homes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
damp	B-OUT	ADJ	B
conditions	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
64.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
households	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
39.6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
caregivers	O	NOUN	B
were	O	AUX	O
aware	O	ADJ	O
that	O	SCONJ	O
excessive	O	ADJ	B
moisture	O	NOUN	B
can	O	AUX	O
increase	O	VERB	B
exposures	O	NOUN	B
to	O	ADP	O
allergens	O	NOUN	B
.	O	PUNCT	O


Dust-trapping	B-OUT	ADJ	B
reservoirs	I-OUT	NOUN	I
were	O	AUX	O
common	O	ADJ	O
;	O	PUNCT	O
76.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
children	O	NOUN	B
's	O	PART	O
bedrooms	O	NOUN	B
had	O	AUX	O
carpeting	O	NOUN	B
.	O	PUNCT	O


Cockroach	B-OUT	NOUN	B
infestation	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
past	I-OUT	ADJ	O
3	I-OUT	NUM	O
months	I-OUT	NOUN	B
was	O	AUX	O
reported	O	VERB	O
by	O	ADP	O
23.4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
caregivers	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
57.1	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
unaware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
association	B-OUT	NOUN	B
of	I-OUT	ADP	O
roaches	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
asthma	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Only	O	ADV	O
19.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
children	O	NOUN	B
had	O	AUX	O
allergy-control	B-OUT	ADJ	B
mattress	I-OUT	NOUN	B
covers	I-OUT	VERB	O
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Many	O	ADJ	O
low-income	B-P	ADJ	B
urban	I-P	ADJ	B
children	I-P	NOUN	B
with	I-P	ADP	O
asthma	I-P	NOUN	B
in	O	ADP	O
King	O	PROPN	B
County	O	PROPN	I
live	O	ADV	I
in	O	ADP	O
indoor	O	NOUN	B
environments	O	NOUN	I
that	O	PRON	O
place	O	VERB	O
them	O	PRON	O
at	O	ADP	O
substantial	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
ongoing	O	ADJ	O
exposure	O	NOUN	B
to	O	PART	I
asthma	O	NOUN	B
triggers	O	NOUN	B
.	O	PUNCT	O


Substandard	O	ADJ	B
housing	O	NOUN	B
and	O	CCONJ	O
lack	O	NOUN	B
of	O	ADP	O
resources	O	NOUN	B
often	O	ADV	O
underlie	O	VERB	O
these	O	DET	O
exposures	O	NOUN	B
.	O	PUNCT	O


Initiatives	O	NOUN	B
involving	O	VERB	O
health	O	NOUN	B
educators	O	NOUN	I
,	O	PUNCT	O
outreach	O	ADJ	B
workers	O	NOUN	I
,	O	PUNCT	O
medical	O	ADJ	B
providers	O	NOUN	I
,	O	PUNCT	O
health	O	NOUN	B
care	O	NOUN	I
insurers	O	NOUN	I
,	O	PUNCT	O
housing	O	NOUN	B
agencies	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
elected	O	VERB	O
officials	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
these	O	DET	O
exposures	O	NOUN	B
.	O	PUNCT	O


Percutaneous	B-I	ADJ	B
coronary	I-I	ADJ	I
intervention	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
previous	I-P	ADJ	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
bypass	I-P	NOUN	I
grafting	I-P	NOUN	I
(	I-P	PUNCT	O
from	I-P	ADP	O
the	I-P	DET	O
j-Cypher	I-P	PROPN	B
Registry	I-P	PROPN	I
)	I-P	PUNCT	O
.	I-P	PUNCT	O


A	O	DET	O
paucity	O	NOUN	O
of	O	ADP	O
data	O	NOUN	B
is	O	AUX	O
available	O	ADJ	O
from	O	ADP	O
large-scale	O	ADJ	B
studies	O	NOUN	I
evaluating	O	VERB	B
the	O	DET	O
long-term	O	ADJ	B
outcomes	O	NOUN	B
of	O	ADP	O
percutaneous	B-I	ADJ	B
coronary	I-I	ADJ	I
intervention	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
previously	I-P	ADV	O
undergone	I-P	VERB	O
coronary	I-I	ADJ	B
artery	I-I	NOUN	I
bypass	I-I	NOUN	I
grafting	I-I	NOUN	I
(	I-I	PUNCT	O
CABG	I-I	NOUN	B
)	I-I	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
drug-eluting	I-P	ADJ	B
stent	I-P	NOUN	I
era	I-P	NOUN	B
.	I-P	PUNCT	O


Of	O	ADP	O
12,812	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
undergone	I-P	VERB	O
sirolimus-eluting	I-P	ADJ	B
stent	I-P	NOUN	B
implantation	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
j-Cypher	I-P	PROPN	B
registry	I-P	NOUN	I
,	I-P	PUNCT	O
919	I-P	NUM	O
(	I-P	PUNCT	O
7.2	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
a	I-P	DET	O
history	I-P	NOUN	B
of	I-P	ADP	O
CABG	I-P	PROPN	B
and	I-P	CCONJ	O
had	I-P	AUX	O
significantly	I-P	ADV	O
higher	I-P	ADJ	O
crude	I-OUT	ADJ	B
5-year	I-OUT	ADJ	O
mortality	I-OUT	NOUN	B
(	I-P	PUNCT	O
19.9	I-P	NUM	O
%	I-P	NOUN	O
vs	I-P	CCONJ	O
14.0	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
p	I-P	X	O
<	I-P	X	O
0.001	I-P	NUM	O
)	I-P	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
confounders	O	NOUN	B
,	O	PUNCT	O
the	B-OUT	DET	O
excess	I-OUT	ADJ	B
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
death	I-OUT	NOUN	B
was	O	AUX	O
no	O	DET	O
longer	O	ADV	O
significant	O	ADJ	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
0.99	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
0.83	O	NUM	O
to	O	PART	O
1.18	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.90	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
adjusted	B-OUT	ADJ	O
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
target	I-OUT	NOUN	B
lesion	I-OUT	NOUN	B
revascularization	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
previous	I-P	ADJ	O
CABG	I-P	NOUN	B
than	O	ADP	O
in	O	ADP	O
those	O	DET	O
without	O	ADP	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
1.25	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.06	O	NUM	O
to	O	PART	O
1.47	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	O	ADP	O
the	B-P	DET	O
patients	I-P	NOUN	B
with	I-P	ADP	O
previous	I-P	ADJ	O
CABG	I-P	PROPN	B
,	O	PUNCT	O
those	O	DET	O
who	O	PRON	O
had	O	AUX	O
undergone	O	VERB	O
≥1	O	ADJ	O
saphenous	O	ADJ	B
vein	O	NOUN	I
graft	O	NOUN	B
intervention	O	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
higher	B-OUT	ADJ	O
adjusted	I-OUT	VERB	O
risks	I-OUT	NOUN	B
of	I-OUT	ADP	O
cardiac	I-OUT	ADJ	B
death	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
2.21	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	VERB	I
1.26	O	NUM	O
to	O	PART	O
3.76	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
myocardial	I-OUT	ADJ	B
infarction	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
2.56	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.10	O	NUM	O
to	O	PART	O
5.60	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
target	I-OUT	NOUN	B
lesion	I-OUT	NOUN	O
revascularization	I-OUT	NOUN	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
2.65	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.82	O	NUM	O
to	O	PART	O
3.81	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	B-OUT	X	O
0.001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
definite	I-OUT	ADJ	O
stent	I-OUT	NOUN	B
thrombosis	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
7.70	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.99	O	NUM	O
to	O	PART	O
29.1	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
who	O	PRON	O
underwent	B-I	VERB	O
percutaneous	I-I	ADJ	B
coronary	I-I	ADJ	I
intervention	I-I	NOUN	I
only	O	ADV	O
for	O	ADP	O
the	O	DET	O
native	O	ADJ	B
coronary	O	ADJ	B
artery	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	B-OUT	NOUN	O
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
adjusted	I-OUT	ADJ	O
mortality	I-OUT	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
previous	O	ADJ	O
CABG	O	PROPN	B
,	O	PUNCT	O
despite	O	SCONJ	O
a	O	DET	O
significantly	O	ADV	O
different	B-OUT	ADJ	O
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
target	I-OUT	NOUN	B
lesion	I-OUT	NOUN	B
revascularization	I-OUT	NOUN	B
.	O	PUNCT	O


Among	B-P	ADP	O
the	I-P	DET	O
patients	I-P	NOUN	B
with	I-P	ADP	O
previous	I-P	ADJ	O
CABG	O	PROPN	B
,	O	PUNCT	O
those	O	DET	O
with	O	ADP	O
saphenous	O	ADJ	B
vein	O	NOUN	I
graft	O	NOUN	B
intervention	O	NOUN	B
using	O	VERB	O
a	O	DET	O
first-generation	O	ADJ	B
drug-eluting	O	ADJ	I
stent	B-OUT	NOUN	I
had	I-OUT	AUX	O
worse	I-OUT	ADJ	O
clinical	I-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
than	O	ADP	O
those	O	DET	O
with	O	ADP	O
a	O	DET	O
native	O	ADJ	B
coronary	O	ADJ	B
artery	O	NOUN	I
target	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
trial	O	NOUN	B
with	O	ADP	O
3'-azido-2',3'-dideoxythymidine	B-I	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
interferon-α	B-I	NOUN	B
in	I-P	ADP	O
cats	I-P	NOUN	B
naturally	I-P	ADV	O
infected	I-P	VERB	B
with	I-P	ADP	O
feline	I-P	ADJ	B
leukaemia	I-P	NOUN	I
virus	I-P	NOUN	B
.	O	PUNCT	O


Feline	O	ADJ	B
leukaemia	O	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
FeLV	O	NOUN	B
)	O	PUNCT	O
infection	O	NOUN	B
is	O	AUX	O
still	O	ADV	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
leading	O	NOUN	O
causes	O	NOUN	O
of	O	ADP	O
infection-related	O	ADJ	B
deaths	O	NOUN	I
in	B-P	ADP	O
domestic	I-P	ADJ	B
cats	I-P	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
various	O	ADJ	O
drugs	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
attempted	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
none	O	NOUN	O
has	O	AUX	O
resulted	O	VERB	O
in	O	ADP	O
cure	O	NOUN	B
or	O	CCONJ	O
complete	O	ADJ	B
virus	O	NOUN	B
elimination	O	NOUN	B
.	B-I	PUNCT	O


Human	B-I	ADJ	B
interferon-α2a	I-I	ADJ	B
(	I-I	PUNCT	O
huIFN-α2a	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
3'-azido-2',3'-dideoxythymidine	I-I	NOUN	B
(	I-I	PUNCT	O
AZT	I-I	NOUN	B
)	I-I	PUNCT	O
have	O	AUX	O
been	O	AUX	O
proven	O	VERB	O
to	O	PART	O
decrease	O	VERB	B
antigenaemia	O	NOUN	B
in	O	ADP	O
cats	O	NOUN	B
infected	O	VERB	B
experimentally	O	ADV	B
with	O	ADP	O
FeLV	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	B-OUT	DET	O
efficacy	I-OUT	NOUN	B
of	I-I	ADP	O
huIFN-α2a	I-I	NOUN	B
,	O	PUNCT	O
AZT	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
in	O	ADP	O
cats	O	NOUN	B
infected	O	VERB	B
naturally	O	ADV	O
with	O	ADP	O
FeLV	O	NOUN	B
in	O	ADP	O
a	O	DET	O
placebo-controlled	O	ADJ	B
double-blinded	O	ADJ	O
trial	B-P	NOUN	O
.	I-P	PUNCT	O


Fourty-four	B-P	NUM	B
FeLV-infected	I-P	ADJ	B
cats	I-P	NOUN	I
in	I-P	ADP	O
which	I-P	DET	O
free	I-P	ADJ	B
FeLV	I-P	NOUN	O
p27	I-P	NOUN	O
antigen	I-P	NOUN	O
was	I-P	AUX	O
detected	I-P	VERB	B
in	I-P	ADP	O
serum	I-P	NOUN	B
by	I-P	ADP	O
enzyme-linked	I-P	ADJ	B
immunosorbent	I-P	ADJ	I
assay	I-P	NOUN	I
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	O	PUNCT	O


Cats	O	NOUN	B
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
that	O	PRON	O
received	O	VERB	O
either	O	CCONJ	O
high	O	ADJ	B
dose	B-I	NOUN	I
huIFN-α2a	I-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
IU/kg	O	NOUN	O
q24h	O	NOUN	O
;	O	PUNCT	O
12	O	NUM	O
cats	B-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
AZT	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg/kg	O	NOUN	O
q12h	O	NOUN	B
;	O	PUNCT	O
10	O	NUM	O
cats	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
these	O	DET	O
treatments	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
cats	B-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
cats	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
cats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
variables	O	NOUN	O
,	O	PUNCT	O
including	B-OUT	VERB	O
stomatitis	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
laboratory	I-OUT	ADJ	B
parameters	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
such	I-OUT	ADJ	O
as	I-OUT	ADP	O
CD4	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
CD8	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
counts	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
FeLV	I-OUT	NOUN	O
p	I-OUT	NOUN	O
27	I-OUT	NUM	O
antigen	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
recorded	O	VERB	O
throughout	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


No	B-OUT	DET	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
among	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
during	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
for	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
parameters	O	NOUN	B
.	O	PUNCT	O


Aside	O	ADV	O
from	B-OUT	ADP	O
anaemia	I-OUT	NOUN	B
in	O	ADP	O
one	O	NUM	O
cat	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
AZT	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
no	I-OUT	DET	O
adverse	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
not	O	PART	O
possible	O	ADJ	O
to	O	PART	O
demonstrate	B-OUT	VERB	O
efficacy	I-OUT	NOUN	B
of	I-I	ADP	O
huIFN-α2a	I-I	NOUN	B
or	O	CCONJ	O
AZT	O	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
together	O	ADV	O
in	O	ADP	O
cats	O	NOUN	B
infected	O	VERB	B
naturally	O	ADV	O
with	O	ADP	O
FeLV	O	NOUN	B
when	O	SCONJ	O
given	O	VERB	O
according	O	VERB	O
to	O	ADP	O
this	O	DET	O
regimen	O	NOUN	B
for	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
however	B-OUT	ADV	O
,	I-OUT	PUNCT	O
no	I-OUT	DET	O
notable	I-OUT	ADJ	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
Effects	O	NOUN	B
of	O	ADP	O
Naltrexone	B-I	NOUN	B
on	O	ADP	O
Subjective	O	ADJ	B
Response	O	NOUN	I
to	O	ADP	O
Methamphetamine	B-I	NOUN	B
in	O	ADP	O
a	O	DET	O
Clinical	B-P	PROPN	B
Sample	I-P	PROPN	I
:	I-P	PUNCT	O
a	O	DET	O
Double-Blind	O	NOUN	B
,	O	PUNCT	O
Placebo-Controlled	O	PROPN	B
Laboratory	O	PROPN	I
Study	O	PROPN	I
.	O	PUNCT	O


Methamphetamine	B-I	NOUN	B
(	I-P	PUNCT	O
MA	I-P	NOUN	B
)	I-P	PUNCT	O
use	I-P	NOUN	O
disorder	I-P	NOUN	B
is	O	AUX	O
a	O	DET	O
serious	O	ADJ	O
psychiatric	O	ADJ	B
condition	O	NOUN	I
for	O	ADP	O
which	O	DET	O
there	O	PRON	O
are	O	AUX	O
no	O	DET	O
FDA-approved	O	ADJ	B
medications	O	NOUN	B
.	O	PUNCT	O


Naltrexone	B-I	NOUN	B
(	O	PUNCT	O
NTX	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
opioid	O	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	B
with	O	ADP	O
demonstrated	O	VERB	O
efficacy	O	NOUN	B
,	O	PUNCT	O
albeit	O	SCONJ	O
moderate	O	ADJ	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
alcoholism	O	NOUN	B
and	O	CCONJ	O
opioid	O	NOUN	B
dependence	O	NOUN	B
.	O	PUNCT	O


Preclinical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
NTX	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
MA	O	NOUN	B
use	O	NOUN	O
disorder	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
inform	O	VERB	O
treatment	O	NOUN	B
development	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
human	O	ADJ	B
laboratory	O	NOUN	O
study	O	NOUN	O
of	O	ADP	O
NTX	O	NOUN	B
.	O	PUNCT	O


Non-treatment-seeking	B-P	ADJ	B
individuals	I-P	NOUN	B
meeting	I-P	VERB	O
DSM-IV	I-P	NOUN	B
criteria	I-P	NOUN	I
for	I-P	ADP	O
MA	I-P	NOUN	B
abuse	I-P	NOUN	I
or	I-P	CCONJ	O
dependence	I-P	NOUN	B
(	I-P	PUNCT	O
n=30	I-P	NOUN	O
)	I-P	PUNCT	O
completed	I-P	VERB	O
two	I-P	NUM	O
separate	I-P	ADJ	O
5-day	I-P	ADJ	O
inpatient	I-P	ADJ	B
stays	I-P	NOUN	B
.	I-P	PUNCT	O


During	O	ADP	O
each	O	DET	O
admission	O	NOUN	B
,	O	PUNCT	O
participants	O	NOUN	B
completed	O	VERB	O
testing	O	NOUN	B
sessions	O	NOUN	B
comprised	O	VERB	O
of	O	ADP	O
MA	B-I	NOUN	B
cue-reactivity	O	NOUN	B
and	O	CCONJ	O
intravenous	B-I	ADJ	B
MA	I-I	NOUN	O
administration	I-I	NOUN	O
(	I-I	PUNCT	O
30	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
after	I-I	ADP	O
receiving	I-I	VERB	O
oral	I-I	ADJ	B
NTX	I-I	NOUN	B
(	I-I	PUNCT	O
50	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
for	O	ADP	O
4	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
tested	O	VERB	B
the	O	DET	O
hypotheses	O	NOUN	B
that	O	SCONJ	O
NTX	O	NOUN	B
would	O	AUX	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
attenuate	O	VERB	B
cue-induced	O	ADJ	B
MA	O	NOUN	B
craving	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
reduce	O	VERB	B
subjective	O	ADJ	O
responses	O	NOUN	O
to	O	PART	O
MA	O	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
largely	O	ADV	O
supported	O	VERB	O
the	O	DET	O
study	O	NOUN	B
hypotheses	O	VERB	B
such	O	ADJ	O
that	O	SCONJ	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
NTX	O	NOUN	B
significantly	O	ADV	O
blunted	O	VERB	B
cue-induced	O	ADJ	B
craving	O	NOUN	I
for	O	ADP	O
MA	O	PROPN	B
and	O	CCONJ	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
attenuated	O	VERB	B
several	O	ADJ	O
of	O	ADP	O
the	O	DET	O
hedonic	O	ADJ	B
subjective	O	ADJ	O
effects	O	NOUN	O
of	O	ADP	O
MA	O	PROPN	B
,	O	PUNCT	O
including	O	VERB	O
craving	O	NOUN	B
,	O	PUNCT	O
during	O	ADP	O
controlled	O	VERB	B
MA	O	NOUN	B
administration	O	NOUN	B
and	O	CCONJ	O
as	O	ADP	O
compared	O	VERB	B
with	B-I	ADP	O
placebo	I-I	NOUN	B
.	O	PUNCT	O


NTX	O	NOUN	B
decreased	O	VERB	B
overall	B-OUT	ADJ	O
subjective	I-OUT	ADJ	O
ratings	I-OUT	NOUN	B
of	I-OUT	ADP	O
'crave	I-OUT	ADJ	B
drug	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
'	I-OUT	PUNCT	O
'stimulated	I-OUT	VERB	B
,	I-OUT	PUNCT	O
'	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
'would	I-OUT	AUX	O
like	I-OUT	ADP	O
drug	I-OUT	NOUN	B
access	I-OUT	NOUN	I
,	O	PUNCT	O
'	O	PUNCT	O
decreased	O	VERB	B
the	O	DET	O
the	O	DET	O
post-MA	O	ADJ	B
administration	O	NOUN	B
timecourse	B-OUT	NOUN	B
of	I-OUT	ADP	O
'anxious	I-OUT	ADJ	B
'	I-OUT	PUNCT	O
and	O	CCONJ	O
increased	B-OUT	VERB	B
ratings	I-OUT	NOUN	B
of	I-OUT	ADP	O
'bad	I-OUT	ADJ	O
drug	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
,	O	PUNCT	O
'	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	B-I	ADP	O
placebo	I-I	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
support	O	VERB	O
a	O	DET	O
potential	O	ADJ	B
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
by	O	ADP	O
showing	O	VERB	O
that	O	SCONJ	O
NTX	O	NOUN	B
reduced	B-OUT	VERB	B
cue-induced	I-OUT	ADJ	O
craving	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
subjective	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
to	I-OUT	PART	O
MA	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
positive	O	ADJ	B
treatment	O	NOUN	O
studies	B-I	NOUN	O
of	I-I	ADP	O
NTX	O	NOUN	B
for	B-I	ADP	O
amphetamine	I-I	NOUN	B
dependence	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
ongoing	O	ADJ	O
clinical	O	ADJ	B
trials	O	NOUN	I
for	O	ADP	O
MA	O	PROPN	B
.	O	PUNCT	O


Are	O	AUX	O
prenatal	B-I	ADJ	B
ultrasound	I-I	NOUN	I
scans	I-I	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
autism	B-OUT	NOUN	B
phenotype	I-OUT	NOUN	B
?	O	PUNCT	O
Follow-up	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
controlled	B-I	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
existing	O	VERB	O
randomised	O	ADJ	B
controlled	B-I	ADJ	I
trial	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
multiple	B-I	ADJ	B
ultrasound	I-I	NOUN	B
scans	I-I	NOUN	I
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
autism	B-OUT	NOUN	B
phenotype	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


From	B-P	ADP	O
2,834	I-P	NUM	O
single	I-P	ADJ	O
pregnancies	I-P	NOUN	B
,	I-P	PUNCT	O
1,415	I-P	NUM	O
were	I-P	AUX	O
selected	I-P	VERB	O
at	I-P	ADP	O
random	I-P	ADJ	B
to	O	PART	O
receive	O	VERB	O
ultrasound	B-I	NOUN	B
imaging	I-I	NOUN	I
and	I-I	CCONJ	O
continuous	I-I	ADJ	B
wave	I-I	NOUN	I
Doppler	I-I	NOUN	O
flow	I-I	NOUN	O
studies	I-I	NOUN	O
at	O	ADP	O
five	O	NUM	O
points	O	NOUN	O
throughout	O	ADP	O
pregnancy	O	NOUN	B
(	O	PUNCT	O
Intensive	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
1,419	O	NUM	O
to	O	PART	O
receive	O	VERB	O
a	O	DET	O
single	B-I	ADJ	O
imaging	I-I	NOUN	B
scan	I-I	NOUN	I
at	O	ADP	O
18	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
Regular	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
further	O	ADJ	O
scans	O	NOUN	B
only	O	ADV	O
as	O	ADP	O
indicated	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
grounds	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
Autism	I-OUT	PROPN	B
Spectrum	I-OUT	PROPN	I
Disorder	I-OUT	PROPN	I
between	O	ADP	O
the	O	DET	O
Regular	O	ADJ	B
(	O	PUNCT	O
9/1,125	O	NOUN	O
,	O	PUNCT	O
0.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
Intensive	O	PROPN	B
(	O	PUNCT	O
7/1,167	O	NOUN	O
,	O	PUNCT	O
0.6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
groups	O	NOUN	B
,	O	PUNCT	O
nor	O	CCONJ	O
a	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
in	O	ADP	O
the	O	DET	O
level	B-OUT	NOUN	B
of	I-OUT	ADP	O
autistic-like	I-OUT	ADJ	B
traits	I-OUT	NOUN	B
in	O	ADP	O
early	O	ADJ	B
adulthood	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
no	O	DET	O
clear	O	ADJ	O
link	O	NOUN	O
between	O	ADP	O
the	O	DET	O
frequency	B-OUT	NOUN	B
and	O	CCONJ	O
timing	B-OUT	NOUN	B
of	O	ADP	O
prenatal	B-I	ADJ	B
ultrasound	I-I	NOUN	I
scans	I-I	NOUN	I
and	O	CCONJ	O
the	O	DET	O
autism	B-OUT	NOUN	B
phenotype	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	X	B
vivo	O	X	I
assessment	B-OUT	NOUN	B
of	I-P	ADP	O
catheter-tip	I-I	ADJ	B
PO2	I-I	NOUN	B
sensor	I-I	NOUN	B
:	I-I	PUNCT	O
sampling	O	VERB	B
lumen	O	NOUN	B
fabrication	O	NOUN	B
.	O	PUNCT	O


Fabrication	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sampling	O	NOUN	B
lumen	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intra-arterial	B-I	ADJ	B
PO2	I-I	NOUN	B
sensor	I-I	NOUN	B
is	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
standard	B-P	ADJ	B
catheters	I-P	NOUN	I
mechanically	O	ADV	B
or	O	CCONJ	O
by	O	ADP	O
laser	O	NOUN	B
.	O	PUNCT	O


Clinical	B-OUT	ADJ	B
evaluation	I-OUT	NOUN	I
is	O	AUX	O
performed	O	VERB	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
catheter	B-OUT	NOUN	B
insertion	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
complications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
accuracy	I-OUT	NOUN	B
of	I-OUT	ADP	O
oxygen	I-OUT	NOUN	B
sensor	I-OUT	NOUN	I
data	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fibrin	I-OUT	NOUN	B
deposition	I-OUT	NOUN	I
on	I-OUT	ADP	O
the	I-OUT	DET	O
catheter	I-OUT	NOUN	B
surface	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
success	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
for	I-OUT	ADP	O
catheter	I-OUT	NOUN	B
insertion	I-OUT	NOUN	I
is	I-P	AUX	O
57	I-P	NUM	O
%	I-P	NOUN	O
for	I-P	ADP	O
138	I-P	NUM	O
standard	I-P	ADJ	B
and	I-P	CCONJ	O
50	I-P	NUM	O
%	I-P	NOUN	O
for	I-P	ADP	O
74	I-P	NUM	O
laser-cut	I-P	ADJ	O
catheters	I-P	NOUN	B
studied	I-P	VERB	O
.	I-P	PUNCT	O


The	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
catheter	B-OUT	NOUN	B
failures	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
blocked	I-OUT	VERB	B
or	I-OUT	CCONJ	O
non-reading	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
is	O	AUX	O
14	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
laser-cut	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
standard	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
differences	O	NOUN	B
are	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
%	O	NOUN	O
level	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
no	O	DET	O
clinically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
sensor	B-OUT	NOUN	B
accuracy	I-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
37.5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
results	O	NOUN	B
within	O	ADP	O
+/-	O	CCONJ	O
0.05	O	NUM	O
kPa	O	NOUN	B
and	O	CCONJ	O
80	O	NUM	O
%	O	NOUN	O
within	O	ADP	O
+/-	O	CCONJ	O
2.0	O	NUM	O
kPa	O	NOUN	O
of	O	ADP	O
simultaneous	O	ADJ	B
blood	O	NOUN	B
gas	O	NOUN	I
values	O	NOUN	O
.	O	PUNCT	O


Drift	B-OUT	NOUN	B
is	O	AUX	O
within	O	ADP	O
+/-	O	CCONJ	O
0.3	O	NUM	O
kPa	O	NOUN	B
h-1	O	NOUN	O
for	O	ADP	O
78	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
monitoring	O	VERB	B
time	O	NOUN	I
.	O	PUNCT	O


Significant	B-OUT	ADJ	B
errors	I-OUT	NOUN	B
of	I-OUT	ADP	O
recalibration	I-OUT	NOUN	B
occur	O	VERB	O
in	O	ADP	O
6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
calibrations	O	NOUN	B
.	O	PUNCT	O


Scanning	O	ADJ	B
electron	O	NOUN	I
micrographs	O	NOUN	I
demonstrate	O	VERB	O
a	O	DET	O
much	O	ADV	O
smaller	O	ADJ	O
sampling	B-OUT	NOUN	B
lumen	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
laser-cut	O	ADJ	O
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
fibrin	B-OUT	NOUN	B
deposition	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sampling	O	NOUN	B
hole	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
low	O	ADJ	B
success	B-OUT	NOUN	O
rate	I-OUT	NOUN	B
for	I-OUT	ADP	O
catheter	I-OUT	NOUN	B
insertion	I-OUT	NOUN	I
is	O	AUX	O
a	O	DET	O
problem	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
cost	O	NOUN	B
implications	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
accuracy	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
system	O	NOUN	B
is	O	AUX	O
usually	O	ADV	O
sufficient	O	ADJ	O
for	O	ADP	O
clinical	O	ADJ	B
purposes	O	NOUN	I
,	O	PUNCT	O
provided	O	VERB	O
the	O	DET	O
calibration	O	NOUN	B
is	O	AUX	O
checked	O	VERB	O
every	O	DET	O
4	O	NUM	O
h	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
water	B-I	NOUN	B
extract	I-I	NOUN	I
from	I-I	ADP	O
the	I-I	DET	O
bark	I-I	NOUN	B
of	I-I	ADP	O
Choerospondias	I-I	PROPN	B
axillaris	I-I	X	I
in	O	ADP	O
the	O	DET	O
treatment	B-P	NOUN	B
of	I-P	ADP	O
second	I-P	ADJ	O
degree	I-P	NOUN	B
burns	I-P	NOUN	B
.	I-P	PUNCT	O


Burns	B-P	NOUN	B
are	I-P	AUX	O
common	I-P	ADJ	O
in	I-P	ADP	O
Vietnam	I-P	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
because	O	SCONJ	O
of	O	ADP	O
economic	O	ADJ	B
constraints	O	NOUN	I
and	O	CCONJ	O
limited	O	ADJ	B
resources	O	NOUN	B
for	O	ADP	O
the	O	DET	O
import	O	NOUN	B
of	O	ADP	O
appropriate	O	ADJ	O
treatments	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
health	O	NOUN	B
authorities	O	NOUN	I
are	O	AUX	O
obliged	O	VERB	O
to	O	PART	O
rely	O	VERB	O
on	O	ADP	O
traditional	O	ADJ	O
herbal	O	ADJ	B
remedies	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
therefore	O	ADV	O
essential	O	ADJ	O
to	O	PART	O
evaluate	O	VERB	B
current	O	ADJ	B
drugs	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
which	O	DET	O
is	O	AUX	O
the	O	DET	O
water	B-I	NOUN	B
extract	I-I	NOUN	I
of	I-I	ADP	O
the	I-I	DET	O
bark	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
tree	I-I	NOUN	B
Choerospondias	I-I	PROPN	B
axillaris	I-I	X	I
.	I-I	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
for	O	ADP	O
many	O	ADJ	O
years	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Vietnam-Sweden	B-P	PROPN	B
hospital	I-P	NOUN	I
at	I-P	ADP	O
Uong	I-P	PROPN	O
Bi	I-P	PROPN	B
in	I-P	ADP	O
northern	I-P	ADJ	B
Vietnam	I-P	PROPN	I
.	I-P	PUNCT	O


We	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
remedy	O	NOUN	B
in	O	ADP	O
an	O	DET	O
open	O	ADJ	B
,	O	PUNCT	O
randomised	O	VERB	B
controlled	O	ADJ	I
clinical	O	ADJ	I
trial	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
20	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
second	I-P	ADJ	O
degree	I-P	NOUN	B
burns	I-P	NOUN	B
were	I-P	AUX	O
treated	I-P	VERB	B
with	I-P	ADP	I
the	I-P	DET	O
extract	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
Choerospondias	I-I	PROPN	B
axillaris	I-I	X	I
and	I-P	CCONJ	O
19	I-P	NUM	O
with	I-P	ADP	O
saline	I-I	NOUN	B
gauze	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	B
healing	I-OUT	NOUN	I
time	I-OUT	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	B
for	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
Choerospondias	B-I	PROPN	B
axillaris	I-I	X	I
(	O	PUNCT	O
11	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
saline	B-I	NOUN	B
gauze	I-I	NOUN	I
(	O	PUNCT	O
17	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
wound	I-OUT	NOUN	B
infections	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
Choerospondias	B-I	PROPN	B
axillaris	I-I	X	I
group	O	NOUN	B
(	O	PUNCT	O
7/20	O	NUM	O
compared	O	VERB	B
with	O	ADP	O
16/19	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
bark	B-I	X	B
extract	I-I	NOUN	I
was	O	AUX	O
easy	O	ADJ	O
to	O	PART	O
apply	O	VERB	O
and	O	CCONJ	O
additional	O	ADJ	O
wound	O	NOUN	B
care	O	NOUN	I
was	O	AUX	O
not	O	PART	O
usually	O	ADV	O
necessary	O	ADJ	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
treatment	O	NOUN	B
with	O	ADP	O
saline	B-I	NOUN	B
gauze	I-I	NOUN	I
was	O	AUX	O
laborious	O	ADJ	O
for	O	ADP	O
both	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
staff	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
much	O	ADV	O
more	O	ADV	O
expensive	B-OUT	ADJ	B
.	I-OUT	PUNCT	O


The	O	DET	O
extract	B-I	NOUN	B
from	I-I	ADP	O
Choerospondias	I-I	PROPN	B
axillaris	I-I	X	I
is	O	AUX	O
a	O	DET	O
convenient	O	ADJ	O
treatment	O	NOUN	B
for	O	ADP	O
second	B-P	ADJ	O
degree	I-P	NOUN	B
burns	I-P	NOUN	B
in	O	ADP	O
both	B-P	DET	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
adults	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
search	O	NOUN	B
for	O	ADP	O
serologic	O	ADJ	B
correlates	O	NOUN	B
of	O	ADP	O
immunity	O	NOUN	B
to	O	PART	O
Bordetella	O	NOUN	B
pertussis	O	NOUN	I
cough	O	NOUN	I
illnesses	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
pertussis	B-P	NOUN	B
vaccine	I-P	NOUN	B
efficacy	I-P	NOUN	B
trial	I-P	NOUN	B
in	I-P	ADP	O
Germany	I-P	PROPN	B
we	O	PRON	O
collected	O	VERB	O
sera	O	NOUN	B
from	O	ADP	O
vaccinees	B-I	NOUN	B
(	I-I	PUNCT	O
DTaP	I-I	NOUN	B
or	I-I	CCONJ	O
DTP	I-I	NOUN	B
)	I-I	PUNCT	O
after	O	ADP	O
the	O	DET	O
third	O	ADJ	O
and	O	CCONJ	O
fourth	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
vaccine	O	NOUN	B
or	O	CCONJ	O
at	O	ADP	O
comparable	O	ADJ	O
time	O	NOUN	B
periods	O	NOUN	O
in	O	ADP	O
DT	B-P	PROPN	B
vaccine	I-P	NOUN	B
recipients	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
sera	O	NOUN	B
were	O	AUX	O
collected	O	VERB	O
from	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
sample	O	NOUN	I
of	O	ADP	O
subjects	B-P	NOUN	B
in	I-P	ADP	O
each	I-P	DET	O
vaccine	I-P	NOUN	B
group	I-P	NOUN	B
at	I-P	ADP	O
approximately	I-P	ADV	O
3-month	I-P	ADJ	O
intervals	I-P	NOUN	B
from	O	ADP	O
which	O	DET	O
antibody	O	NOUN	B
kinetic	O	ADJ	I
curves	O	NOUN	I
were	O	AUX	O
constructed	O	VERB	O
,	O	PUNCT	O
which	O	DET	O
allowed	O	VERB	O
us	O	PRON	O
to	O	PART	O
estimate	O	VERB	B
specific	O	ADJ	O
antibody	O	NOUN	B
values	O	NOUN	O
to	O	PART	O
pertussis	B-I	NOUN	B
toxin	O	NOUN	I
(	O	PUNCT	O
PT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
filamentous	O	ADJ	B
hemagglutinin	O	NOUN	I
(	O	PUNCT	O
FHA	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
pertactin	O	NOUN	B
and	O	CCONJ	O
fimbriae-2	O	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
exposure	O	NOUN	B
in	O	ADP	O
the	O	DET	O
household	O	NOUN	B
setting	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
imputed	O	VERB	O
geometric	O	ADJ	O
mean	O	ADJ	O
antibody	O	NOUN	B
values	O	NOUN	I
to	O	PART	O
PT	O	NOUN	B
,	O	PUNCT	O
pertactin	O	NOUN	B
and	O	CCONJ	O
fimbriae-2	O	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
household	O	NOUN	B
exposure	O	NOUN	O
to	O	PART	O
Bordetella	O	NOUN	B
pertussis	O	NOUN	I
infection	O	NOUN	O
were	O	AUX	O
higher	O	ADJ	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.07	O	NUM	O
or	O	CCONJ	O
lower	O	ADJ	B
)	O	PUNCT	O
in	O	ADP	O
non-cases	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
cases	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
multivariate	O	NOUN	B
(	O	PUNCT	O
classification	O	NOUN	B
tree	O	NOUN	I
)	O	PUNCT	O
analysis	O	NOUN	B
found	O	VERB	O
that	O	SCONJ	O
only	O	ADV	O
pertactin	O	NOUN	B
and	O	CCONJ	O
PT	O	NOUN	B
were	O	AUX	O
significant	O	ADJ	O
in	O	ADP	O
protection	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
with	O	ADP	O
an	O	DET	O
imputed	O	VERB	O
pertactin	O	NOUN	B
value	O	NOUN	I
of	O	ADP	O
<	O	SYM	O
7	O	NUM	O
EU	O	PROPN	B
ml-1	O	NOUN	B
had	O	AUX	O
a	O	DET	O
67	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
18/27	O	NUM	O
)	O	PUNCT	O
chance	O	NOUN	B
of	O	ADP	O
infection	O	NOUN	B
regardless	O	ADV	O
of	O	ADP	O
the	O	DET	O
PT	O	PROPN	B
value	O	NOUN	B
.	O	PUNCT	O


If	O	SCONJ	O
the	O	DET	O
pertactin	O	NOUN	B
value	O	NOUN	O
was	O	AUX	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
7	O	NUM	O
EU	O	PROPN	B
ml-1	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
PT	O	NOUN	B
value	O	NOUN	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
66	O	NUM	O
EU	O	NOUN	B
ml-1	O	NOUN	O
all	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
non-cases	O	NOUN	B
.	O	PUNCT	O


If	O	SCONJ	O
the	O	DET	O
pertactin	O	NOUN	B
value	O	NOUN	O
was	O	AUX	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
7	O	NUM	O
and	O	CCONJ	O
the	O	DET	O
PT	O	PROPN	B
value	O	NOUN	B
was	O	AUX	O
<	O	X	O
66	O	NUM	O
EU	O	NOUN	B
ml-1	O	NOUN	O
the	O	DET	O
predicted	O	VERB	O
probability	O	NOUN	B
of	O	ADP	O
being	O	AUX	O
a	O	DET	O
case	O	NOUN	B
was	O	AUX	O
31	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
15/49	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Logistic	B-OUT	ADJ	B
regression	I-OUT	NOUN	I
analysis	I-OUT	NOUN	I
also	O	ADV	O
found	O	VERB	O
that	O	SCONJ	O
high	O	ADJ	B
versus	O	CCONJ	O
low	O	ADJ	B
pertactin	O	NOUN	B
values	O	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
illness	O	NOUN	B
prevention	O	NOUN	I
following	O	VERB	O
household	O	NOUN	B
exposure	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
antibody	O	NOUN	B
to	O	PART	O
pertactin	O	NOUN	B
,	O	PUNCT	O
PT	O	NOUN	B
and	O	CCONJ	O
fimbriae-2	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
additional	O	ADJ	O
presence	O	NOUN	B
of	O	ADP	O
antibody	O	NOUN	B
to	O	PART	O
FHA	O	PROPN	B
did	O	AUX	O
not	O	PART	O
contribute	O	VERB	O
to	O	ADP	O
protection	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
support	O	VERB	O
historical	O	ADJ	B
data	O	NOUN	B
indicating	O	VERB	O
that	O	SCONJ	O
agglutinating	O	VERB	B
antibodies	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
protection	O	NOUN	B
and	O	CCONJ	O
also	O	ADV	O
recent	O	ADJ	O
serologic	O	ADJ	B
correlates	O	VERB	O
data	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
efficacy	O	NOUN	I
data	O	NOUN	B
which	O	DET	O
indicate	O	VERB	O
that	O	SCONJ	O
multicomponent	B-I	ADJ	B
vaccines	I-I	NOUN	I
containing	I-I	VERB	O
pertactin	I-I	NOUN	B
and	I-I	CCONJ	O
fimbriae	I-I	NOUN	B
have	O	AUX	O
better	O	ADJ	O
efficacy	O	NOUN	B
than	O	ADP	O
PT	O	PROPN	B
or	O	CCONJ	O
PT/FHA	O	NOUN	B
vaccines	O	NOUN	B
.	O	PUNCT	O


Brief	O	ADJ	B
report	O	NOUN	I
:	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	I
cognitive	B-I	ADJ	B
behavioral	I-I	ADJ	I
therapy	I-I	NOUN	I
on	O	ADP	O
parent-reported	B-OUT	ADJ	B
autism	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
in	I-P	ADP	O
school-age	I-P	ADJ	B
children	I-P	NOUN	B
with	I-P	ADP	O
high-functioning	I-P	ADJ	B
autism	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
tested	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cognitive	B-I	ADJ	B
behavioral	I-I	ADJ	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
CBT	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
parent-reported	B-P	ADJ	B
autism	I-P	NOUN	B
symptoms	I-P	NOUN	B
.	I-P	PUNCT	O


Nineteen	B-P	NUM	B
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
and	I-P	CCONJ	O
an	I-P	DET	O
anxiety	I-P	NOUN	B
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
7-11	I-P	NUM	O
years	I-P	NOUN	O
old	I-P	ADJ	O
)	I-P	PUNCT	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	O	PART	O
16	O	NUM	O
sessions	O	NOUN	B
of	O	ADP	O
CBT	B-I	NOUN	B
or	O	CCONJ	O
a	O	DET	O
waitlist	B-I	ADJ	B
condition	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
CBT	B-I	PROPN	B
program	O	NOUN	B
emphasized	O	VERB	O
in	O	X	B
vivo	O	X	I
exposure	O	NOUN	B
supported	O	VERB	O
by	O	ADP	O
parent	O	NOUN	B
training	O	NOUN	B
and	O	CCONJ	O
school	O	NOUN	B
consultation	O	NOUN	I
to	O	PART	O
promote	O	VERB	B
social	O	ADJ	B
communication	O	NOUN	I
and	O	CCONJ	O
emotion	O	NOUN	B
regulation	O	NOUN	O
skills	O	NOUN	O
.	O	PUNCT	O


Parents	O	NOUN	B
completed	O	VERB	O
a	O	DET	O
standardized	B-OUT	ADJ	O
autism	I-OUT	NOUN	B
symptom	I-OUT	NOUN	O
checklist	I-OUT	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
posttreatment/postwaitlist	O	ADJ	B
and	O	CCONJ	O
3-month	O	ADJ	O
follow-up	O	ADJ	B
assessments	O	NOUN	B
.	O	PUNCT	O


CBT	B-I	NOUN	B
outperformed	O	VERB	O
the	O	DET	O
waitlist	O	ADJ	B
condition	O	NOUN	I
at	O	ADP	O
posttreatment/postwaitlist	O	ADJ	O
on	O	ADP	O
total	B-OUT	ADJ	O
parent-reported	I-OUT	ADJ	O
autism	I-OUT	NOUN	O
symptoms	I-OUT	NOUN	O
(	O	PUNCT	O
Cohen	O	PROPN	B
's	O	PART	I
d	O	NOUN	O
effect	O	NOUN	B
size	O	NOUN	I
=	O	ADJ	O
.77	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Treatment	O	NOUN	B
gains	O	NOUN	I
were	O	AUX	O
maintained	O	VERB	B
at	O	ADP	O
3-month	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
investigation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
intervention	O	NOUN	B
modality	O	NOUN	B
with	O	ADP	O
larger	O	ADJ	O
samples	O	NOUN	B
and	O	CCONJ	O
broader	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
indicated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
management	O	NOUN	B
of	O	ADP	O
dermoid	B-P	NOUN	B
cysts	I-P	NOUN	I
--	I-P	PUNCT	O
a	I-P	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
laparoscopy	B-I	NOUN	B
and	O	CCONJ	O
laparotomy	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
laparoscopy	B-I	NOUN	B
with	O	ADP	O
laparotomy	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
removal	O	NOUN	B
of	O	ADP	O
ovarian	B-P	ADJ	B
dermoid	I-P	NOUN	I
cysts	I-P	NOUN	I
.	I-P	PUNCT	O


Thirty-eight	B-P	NUM	O
women	I-P	NOUN	B
with	I-P	ADP	O
benign	I-P	ADJ	B
ovarian	I-P	ADJ	I
dermoid	I-P	NOUN	I
cyst	I-P	NOUN	I
were	O	AUX	O
allocated	O	VERB	O
for	O	ADP	O
either	O	DET	O
laparoscopy	B-I	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
laparotomy	B-I	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
for	O	ADP	O
operative	O	ADJ	B
and	O	CCONJ	O
hospitalization	O	NOUN	B
times	O	NOUN	O
and	O	CCONJ	O
postoperative	O	ADJ	B
course	O	NOUN	I
.	O	PUNCT	O


Operating	B-OUT	VERB	B
time	I-OUT	NOUN	I
was	O	AUX	O
longer	O	ADJ	B
(	O	PUNCT	O
93.6	O	NUM	O
+/-	O	CCONJ	O
23.8	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
hospitalization	B-OUT	NOUN	B
time	I-OUT	NOUN	O
significantly	O	ADV	O
shorter	O	ADJ	O
(	O	PUNCT	O
22.4	O	NUM	O
+/-	O	CCONJ	O
6.6	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
laparoscopy	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
complications	B-OUT	NOUN	O
were	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
operative	B-I	ADJ	B
laparoscopy	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
safe	B-OUT	ADJ	O
procedure	O	NOUN	B
for	O	ADP	O
the	O	DET	O
removal	O	NOUN	B
of	O	ADP	O
dermoid	B-P	ADJ	B
ovarian	I-P	ADJ	I
cysts	I-P	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
as	O	ADV	O
effective	B-OUT	ADJ	B
as	O	ADP	O
laparotomy	B-I	NOUN	B
.	I-I	PUNCT	O


Combined	O	ADJ	B
action	O	NOUN	O
of	O	ADP	O
enalapril	B-I	NOUN	B
or	O	CCONJ	O
timolol	B-I	NOUN	B
with	O	ADP	O
hydrochlorothiazide	B-I	NOUN	B
plus	I-I	CCONJ	O
amiloride	I-I	NOUN	B
in	O	ADP	O
hypertension	B-P	NOUN	B
.	I-P	PUNCT	O


59	B-P	NUM	O
mild	I-P	ADJ	B
to	I-P	PART	O
moderate	I-P	ADJ	B
hypertensives	I-P	NOUN	B
were	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
with	O	ADP	O
50	O	NUM	O
mg	O	NOUN	O
hydrochlorothiazide	B-I	NOUN	B
plus	O	CCONJ	O
5	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
amiloride	B-I	NOUN	B
,	O	PUNCT	O
then	O	ADV	O
concomitantly	O	ADV	O
with	O	ADP	O
these	O	DET	O
diuretics	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
enalapril	B-I	NOUN	B
(	O	PUNCT	O
10-20	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
timolol	B-I	NOUN	B
(	O	PUNCT	O
10-20	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
two	O	NUM	O
parallel	O	ADJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
for	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
12	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
study	O	NOUN	O
.	O	PUNCT	O


Addition	O	NOUN	B
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
lowered	O	VERB	B
the	O	DET	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
by	O	ADP	O
25	O	NUM	O
+/-	O	CCONJ	O
3/16	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
and	O	CCONJ	O
15	O	NUM	O
+/-	O	CCONJ	O
3/14	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	O
of	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
systolic	B-OUT	NOUN	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
between	O	ADP	O
enalapril	O	NOUN	B
and	O	CCONJ	O
timolol	O	NOUN	B
group	O	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
treatment	O	NOUN	I
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
serum	I-OUT	NOUN	B
potassium	I-OUT	NOUN	I
was	O	AUX	O
elevated	O	VERB	B
by	O	ADP	O
0.3	O	NUM	O
mmol/l	O	NOUN	O
after	O	ADP	O
addition	O	NOUN	O
of	O	ADP	O
enalapril	O	NOUN	B
to	O	PART	O
the	O	DET	O
diuretic	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
developed	O	VERB	O
hyperkalaemia	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


No	O	DET	B
adverse	B-OUT	ADJ	O
effects	I-OUT	NOUN	O
on	O	ADP	O
other	O	ADJ	O
routine	O	ADJ	O
laboratory	O	NOUN	B
values	O	NOUN	I
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Both	O	DET	O
drug	O	NOUN	B
combinations	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
efficient	O	ADJ	B
,	O	PUNCT	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
and	I-OUT	CCONJ	O
safe	I-OUT	ADJ	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
hypertension	O	NOUN	B
.	O	PUNCT	O


Procalcitonin	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
good	O	ADJ	O
tool	O	NOUN	O
to	O	PART	O
guide	O	VERB	O
duration	O	NOUN	B
of	O	ADP	O
antibiotic	B-I	ADJ	B
therapy	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
acute	I-P	ADJ	B
pancreatitis	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
prospective	O	ADJ	I
single-center	O	ADJ	I
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
usefulness	O	NOUN	I
of	O	ADP	O
procalcitonin	B-I	NOUN	B
(	O	PUNCT	O
PCT	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
guiding	O	VERB	O
duration	O	NOUN	B
of	O	ADP	O
antibiotic	B-I	ADJ	B
therapy	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
acute	I-P	ADJ	B
pancreatitis	I-P	NOUN	I
(	I-P	PUNCT	O
SAP	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
71	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
confirmed	I-P	VERB	O
severe	I-P	ADJ	B
acute	I-P	ADJ	B
pancreatitis	I-P	NOUN	I
from	I-P	ADP	O
March	I-P	PROPN	O
2009	I-P	NUM	O
to	I-P	ADP	O
September	I-P	PROPN	O
2011	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
Department	I-P	PROPN	B
of	I-P	ADP	I
Critical	I-P	PROPN	I
Care	I-P	PROPN	I
Medicine	I-P	PROPN	I
of	I-P	ADP	O
Huizhou	I-P	PROPN	B
Municipal	I-P	PROPN	I
Central	I-P	PROPN	I
Hospital	I-P	PROPN	I
,	I-P	PUNCT	O
Guangdong	I-P	PROPN	B
,	I-P	PUNCT	O
China	I-P	PROPN	B
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Procalcitonin	B-I	NOUN	B
was	I-I	AUX	O
measured	I-I	VERB	O
daily	I-I	ADV	B
by	I-I	ADP	O
a	I-I	DET	O
semi-quantitative	I-I	ADJ	B
immunoassay	I-I	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
study	I-I	NOUN	B
group	I-I	NOUN	I
.	I-I	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
into	O	ADP	O
2	B-I	NUM	O
groups	I-I	NOUN	B
including	I-I	VERB	O
a	I-I	DET	O
PCT-guided	I-I	ADJ	B
group	I-I	NOUN	I
(	I-I	PUNCT	O
study	I-I	NOUN	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
and	I-I	CCONJ	O
a	I-I	DET	O
prophylactic	I-I	ADJ	B
antibiotic	I-I	ADJ	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
control	I-I	NOUN	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


Antibiotic	B-I	ADJ	B
therapy	I-I	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
study	I-I	NOUN	B
group	I-I	NOUN	I
was	I-I	AUX	O
not	I-I	PART	O
applied	I-I	VERB	O
until	I-I	ADP	O
clinical	I-I	ADJ	B
signs	I-I	NOUN	I
and	I-I	CCONJ	O
symptoms	I-I	NOUN	B
of	I-I	ADP	O
infection	I-I	NOUN	B
appeared	I-I	VERB	O
(	I-I	PUNCT	O
PCT	I-I	NOUN	B
value	I-I	NOUN	O
was	I-I	AUX	O
>	I-I	DET	O
0.5ng/ml	I-I	NUM	O
)	I-I	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
discontinued	O	VERB	B
the	O	DET	O
antibiotic	O	ADJ	B
therapy	O	NOUN	I
if	O	SCONJ	O
clinical	O	ADJ	B
signs	O	NOUN	I
and	O	CCONJ	O
symptoms	O	NOUN	B
of	O	ADP	O
infection	O	NOUN	B
improved	O	VERB	B
and	O	CCONJ	O
PCT	O	NOUN	B
was	O	AUX	O
<	O	X	O
0.5ng/ml	O	NUM	O
over	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
antibiotic	O	ADJ	B
therapy	O	NOUN	I
was	O	AUX	O
administrated	O	VERB	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
antibiotic	B-I	ADJ	B
therapy	I-I	NOUN	I
was	O	AUX	O
continued	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
confirmed	O	VERB	O
infection	O	NOUN	B
until	O	ADP	O
clinical	O	ADJ	B
signs	O	NOUN	I
and	O	CCONJ	O
symptoms	O	NOUN	B
of	O	ADP	O
infection	O	NOUN	B
disappeared	O	VERB	O
over	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
35	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
antibiotic	I-OUT	ADJ	B
therapy	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
hospitalization	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	O
than	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
36	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
10.89+/-2.85	O	NUM	O
versus	O	CCONJ	O
16.06+/-2.48	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
16.66+/-4.02	O	NUM	O
days	O	NOUN	B
versus	O	CCONJ	O
23.81+/-7.56	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
without	O	ADP	O
negative	B-OUT	ADJ	B
clinical	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
and	O	CCONJ	O
the	O	DET	O
cost	B-OUT	NOUN	B
of	I-OUT	ADP	O
hospitalization	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Procalcitonin	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
helpful	O	ADJ	O
and	O	CCONJ	O
safe	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
guiding	O	VERB	O
duration	O	NOUN	B
of	O	ADP	O
antibiotic	O	ADJ	B
treatment	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
acute	I-P	ADJ	B
pancreatitis	I-P	NOUN	I
.	I-P	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
short-term	O	ADJ	B
complications	O	NOUN	B
after	O	ADP	O
laparoscopic	B-I	ADJ	B
transabdominal	I-I	ADJ	I
preperitoneal	I-I	NOUN	I
(	I-I	PUNCT	O
TAPP	I-I	NOUN	B
)	I-I	PUNCT	O
versus	I-I	CCONJ	O
Lichtenstein	I-I	PROPN	B
tension	I-I	NOUN	I
free	I-I	ADJ	I
inguinal	I-I	ADJ	I
hernia	I-I	NOUN	I
repair	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


AIM	O	VERB	B
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
short-term	O	ADJ	B
postoperative	O	ADJ	B
complications	B-P	NOUN	B
of	I-P	ADP	O
laparoscopic	I-I	ADJ	B
transabdominal	I-I	ADJ	I
preperitoneal	I-I	NOUN	I
(	I-I	PUNCT	O
TAPP	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
Lichtenstein	I-I	PROPN	B
tension	I-I	NOUN	I
free	I-I	ADJ	I
hernia	I-I	NOUN	I
repair	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	VERB	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
120	I-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
went	I-P	VERB	O
inguinal	I-I	ADJ	B
hernia	I-I	NOUN	I
repair	I-I	NOUN	I
at	I-P	ADP	O
Shahid	I-P	PROPN	B
Sadoughi	I-P	PROPN	I
university	I-P	NOUN	I
training	I-P	NOUN	I
hospital	I-P	NOUN	I
from	I-P	ADP	O
April	I-P	PROPN	O
2011	I-P	NUM	O
to	I-P	ADP	O
August	I-P	PROPN	O
2013	I-P	NUM	O
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
two	O	NUM	O
TAPP	B-I	NOUN	B
(	O	PUNCT	O
N.=60	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Lichtenstein	B-I	PROPN	B
(	O	PUNCT	I
N.=60	O	NOUN	I
)	O	PUNCT	I
repair	O	NOUN	I
group	O	NOUN	I
.	O	PUNCT	O


Follow-up	O	X	B
occurred	O	VERB	O
within	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
postoperative	O	ADJ	B
assessments	O	NOUN	O
included	O	VERB	O
pain	B-OUT	NOUN	B
score	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
hematoma/seroma	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
urinary	I-OUT	ADJ	B
retention	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
wound	I-OUT	NOUN	B
infection	I-OUT	NOUN	I
incidence	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	I
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Pain	B-OUT	NOUN	I
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
symptoms	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
TAPP	O	NOUN	B
group	O	NOUN	B
patients	O	NOUN	B
significantly	O	ADV	O
had	O	AUX	O
experienced	O	VERB	O
less	O	ADV	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
than	O	ADP	O
the	O	DET	O
Lichtenstein	B-I	PROPN	B
group	O	NOUN	I
in	O	ADP	O
all	O	DET	O
moments	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


TAPP	O	NOUN	B
group	O	NOUN	B
had	O	AUX	O
lower	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
hematoma	B-OUT	NOUN	B
(	O	PUNCT	O
TAPP	O	NOUN	B
,	O	PUNCT	O
6.6	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
Lichtenstein	B-I	PROPN	B
13.3	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.67	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
seroma	B-OUT	NOUN	B
(	O	PUNCT	O
TAPP	O	NOUN	B
10	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
Lichtenstein	B-I	PROPN	B
13.3	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=1.00	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
infection	B-OUT	NOUN	B
(	O	PUNCT	O
TAPP	O	NOUN	B
0	O	NUM	O
vs.	O	CCONJ	O
Lichtenstein	B-I	PROPN	O
1.6	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.67	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
postoperative	B-OUT	ADJ	B
complications	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
TAPP	O	NOUN	B
group	O	NOUN	B
mean	B-OUT	NOUN	O
of	I-OUT	ADP	O
hospital	I-OUT	NOUN	B
stay	I-OUT	NOUN	I
significantly	O	ADV	B
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
Lichtenstein	B-I	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
TAPP	O	NOUN	B
,	O	PUNCT	O
8.13±2.19	O	NOUN	O
vs.	O	CCONJ	O
Lichtenstein	O	PROPN	B
,	O	PUNCT	O
13.15±1.5	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
laparoscopic	O	ADJ	B
TAPP	O	NOUN	I
repair	O	NOUN	I
is	O	AUX	O
safer	O	ADJ	O
and	O	CCONJ	O
less	O	ADV	O
complicated	O	ADJ	O
approach	O	NOUN	O
to	O	ADP	O
inguinal	O	ADJ	B
hernia	O	NOUN	I
repair	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
main	O	ADJ	O
short-term	O	ADJ	B
advantages	O	NOUN	O
of	O	ADP	O
the	O	DET	O
laparoscopic	B-I	ADJ	B
TAPP	I-I	NOUN	I
repair	O	NOUN	I
with	O	ADP	O
the	O	DET	O
tension	O	NOUN	B
free	B-I	ADJ	I
Lichtenstein	I-I	PROPN	I
repair	O	NOUN	I
were	O	AUX	O
less	O	ADV	O
postoperative	O	ADJ	B
pain	O	NOUN	I
and	O	CCONJ	O
earlier	O	ADV	O
return	O	VERB	B
to	O	ADP	I
the	O	DET	I
normal	O	ADJ	B
life	O	NOUN	O
activities	B-OUT	NOUN	O
.	O	PUNCT	O


No	O	DET	B
difference	O	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
overall	O	ADJ	O
complications	O	NOUN	B
.	O	PUNCT	O


Rotigotine	B-I	NOUN	B
transdermal	I-I	ADJ	B
patch	I-I	NOUN	I
enables	O	VERB	O
rapid	O	ADJ	B
titration	O	NOUN	B
to	O	PART	O
effective	O	ADJ	B
doses	O	NOUN	B
in	O	ADP	O
advanced-stage	B-P	ADJ	B
idiopathic	I-P	ADJ	I
Parkinson	I-P	NOUN	I
disease	I-P	NOUN	I
:	I-P	PUNCT	O
subanalysis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
parallel	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
dose-escalation	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
Rotigotine	B-I	NOUN	B
(	I-I	PUNCT	O
Neupro	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
formulated	O	VERB	O
as	O	ADP	O
a	O	DET	O
transdermal	O	ADJ	B
delivery	O	NOUN	I
system	O	NOUN	I
designed	O	VERB	O
to	O	PART	O
provide	O	VERB	O
a	O	DET	O
selective	O	ADJ	O
,	O	PUNCT	O
non-ergot	O	ADJ	B
D3/D2/D1	O	NOUN	B
agonist	O	NOUN	B
to	O	PART	O
the	O	DET	O
systemic	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
over	O	ADP	O
a	O	DET	O
24-hour	O	ADJ	B
period	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
,	O	PUNCT	O
patches	B-I	NOUN	B
were	I-I	AUX	O
applied	I-I	VERB	O
once	I-I	ADV	O
daily	I-I	ADV	B
and	I-I	CCONJ	O
uptitrated	I-I	ADJ	B
to	I-I	ADP	O
the	I-I	DET	O
individual	I-I	ADJ	B
effective	I-I	ADJ	B
dose	I-I	NOUN	B
in	I-I	ADP	O
increments	I-I	NOUN	B
of	I-I	ADP	O
2	I-I	NUM	O
mg/24	I-I	NOUN	O
h	I-I	NOUN	O
every	I-I	DET	O
week	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
analysis	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
safety	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
more	O	ADV	O
rapid	O	ADJ	O
titration	O	NOUN	B
of	O	ADP	O
rotigotine	B-I	NOUN	B
by	O	ADP	O
assessing	O	VERB	O
the	O	DET	O
tolerability	B-OUT	NOUN	B
of	O	ADP	O
escalating	O	VERB	B
transdermal	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
rotigotine	B-I	NOUN	B
given	O	VERB	O
in	O	ADP	O
2	O	NUM	O
different	O	ADJ	O
titration	O	NOUN	B
schemes	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
of	O	ADP	O
rotigotine	B-I	NOUN	B
in	O	ADP	O
2	B-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
stage	I-P	NOUN	I
Parkinson	I-P	PROPN	B
Disease	I-P	PROPN	I
.	I-P	PUNCT	O


The	O	DET	O
starting	O	VERB	O
dose	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
mg/24	O	NOUN	O
h	O	NOUN	O
was	O	AUX	O
increased	O	VERB	B
every	O	DET	O
week	O	NOUN	B
by	O	ADP	O
2	O	NUM	O
mg/24	O	NOUN	O
h	O	NOUN	O
in	O	ADP	O
the	O	DET	O
slow-titration	O	ADJ	B
group	O	NOUN	I
and	O	CCONJ	O
4	O	NUM	O
mg/24	O	NOUN	O
h	O	NOUN	O
in	O	ADP	O
the	O	DET	O
fast-titration	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
focus	O	NOUN	O
of	O	ADP	O
this	O	DET	O
subanalysis	O	NOUN	B
was	O	AUX	O
the	O	DET	O
separate	O	ADJ	O
tolerability	B-OUT	NOUN	B
of	I-OUT	ADP	O
rotigotine	I-OUT	NOUN	B
in	O	ADP	O
each	O	DET	O
randomized	O	ADJ	B
treatment	O	NOUN	I
arm	O	NOUN	I
,	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
dose-escalation	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
2	O	NUM	O
titration	O	NOUN	B
schemes	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
compared	O	VERB	B
with	O	ADP	O
each	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
first	O	ADJ	O
reported	O	VERB	B
nausea	B-OUT	NOUN	B
and/or	I-OUT	CCONJ	O
vomiting	I-OUT	NOUN	B
was	O	AUX	O
8	O	NUM	O
mg/24	O	NOUN	O
h	O	NOUN	O
for	O	ADP	O
the	O	DET	O
fast-titration	O	ADJ	B
group	O	NOUN	I
and	O	CCONJ	O
4	O	NUM	O
mg/	O	NOUN	O
24	O	NUM	O
h	O	NOUN	O
for	O	ADP	O
the	O	DET	O
slow-titration	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
remarkable	O	ADJ	O
differences	O	NOUN	O
concerning	O	VERB	O
the	O	DET	O
side-effect	B-OUT	ADJ	B
profile	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
different	O	ADJ	O
titration	O	NOUN	B
schemes	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
fast-titration	O	ADJ	O
regimen	O	NOUN	B
had	O	AUX	O
a	O	DET	O
similar	O	ADJ	O
adverse	B-OUT	ADJ	B
event	I-OUT	NOUN	I
profile	I-OUT	NOUN	O
to	O	PART	O
slower	O	ADJ	O
titration	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
allowed	O	VERB	O
rotigotine	B-I	NOUN	B
to	O	PART	O
be	O	AUX	O
introduced	O	VERB	O
quickly	O	ADV	O
.	O	PUNCT	O


This	O	DET	O
subanalysis	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
rotigotine	B-I	NOUN	B
may	O	AUX	O
be	O	AUX	O
uptitrated	O	VERB	B
more	O	ADV	O
rapidly	O	ADV	O
.	O	PUNCT	O


Determinants	O	NOUN	B
of	O	ADP	O
improvement	O	NOUN	B
in	O	ADP	O
walking	B-OUT	NOUN	B
capacity	I-OUT	NOUN	I
among	O	ADP	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
stroke	I-P	NOUN	I
following	O	VERB	O
a	O	DET	O
multi-dimensional	B-I	ADJ	B
exercise	I-I	NOUN	I
program	I-I	NOUN	I
.	I-I	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
identify	O	VERB	O
the	O	DET	O
determinants	O	NOUN	B
of	O	ADP	O
improvement	O	NOUN	B
in	O	ADP	O
walking	B-OUT	NOUN	B
capacity	I-OUT	NOUN	I
following	O	VERB	O
therapeutic	B-I	ADJ	B
exercise	I-I	NOUN	I
in	O	ADP	O
chronic	B-P	ADJ	B
stroke	I-P	NOUN	I
survivors	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
secondary	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
data	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
single-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
controlled	O	VERB	I
intervention	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


SUBJECTS	O	VERB	O
Sixty-three	B-P	NUM	O
community-dwelling	I-P	ADJ	B
individuals	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
=	I-P	ADJ	O
65	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
age	I-P	NOUN	B
range	I-P	NOUN	O
=	I-P	ADJ	O
50-87	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
chronic	I-P	ADJ	B
stroke	I-P	NOUN	I
(	I-P	PUNCT	O
post-stroke	I-P	ADJ	B
duration	I-P	NOUN	I
:	I-P	PUNCT	O
mean	I-P	VERB	O
=	I-P	ADJ	O
5.5	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
range	I-P	NOUN	O
=	I-P	ADJ	O
1-28	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Subjects	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
a	O	DET	O
leg	B-I	NOUN	B
exercise	I-I	NOUN	O
group	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
32	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
an	O	DET	O
arm	B-I	NOUN	B
exercise	I-I	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
31	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Subjects	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
underwent	O	VERB	O
3	O	NUM	O
1-hour	O	ADJ	O
exercise	B-I	NOUN	B
sessions	I-I	NOUN	B
per	O	ADP	O
week	O	NOUN	B
for	O	ADP	O
19	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Walking	B-OUT	NOUN	B
capacity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
cardiorespiratory	I-OUT	ADJ	B
fitness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
isometric	I-OUT	ADJ	B
knee	I-OUT	NOUN	I
extensor	I-OUT	NOUN	I
muscle	I-OUT	NOUN	I
strength	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
balance	I-OUT	NOUN	B
ability	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
balance	I-OUT	NOUN	B
confidence	I-OUT	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
interventions	O	NOUN	B
.	O	PUNCT	O


Multiple	O	ADJ	B
regression	O	NOUN	I
analysis	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
determinants	O	NOUN	B
of	O	ADP	O
improvement	O	NOUN	B
in	O	ADP	O
walking	O	NOUN	B
capacity	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
After	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
gender	O	NOUN	B
,	O	PUNCT	O
post-stroke	O	ADJ	B
duration	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
baseline	O	NOUN	B
walking	B-OUT	NOUN	O
capacity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
gain	I-OUT	NOUN	B
in	I-OUT	ADP	O
paretic	I-OUT	ADJ	B
leg	I-OUT	NOUN	I
muscle	I-OUT	NOUN	O
strength	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
peak	I-OUT	VERB	B
oxygen	I-OUT	NOUN	I
consumption	I-OUT	NOUN	I
remained	I-OUT	VERB	O
independently	I-OUT	ADV	O
associated	O	VERB	B
with	O	ADP	I
gain	B-OUT	NOUN	B
in	I-OUT	ADP	O
walking	I-OUT	NOUN	B
capacity	I-OUT	NOUN	I
(	O	PUNCT	O
R2	O	NOUN	O
=	O	ADJ	O
0.229	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Enhancement	O	NOUN	B
of	O	ADP	O
cardiorespiratory	O	ADJ	B
fitness	O	NOUN	I
and	O	CCONJ	O
paretic	O	ADJ	B
leg	O	NOUN	I
muscle	O	NOUN	O
strength	O	NOUN	O
are	O	AUX	O
both	O	CCONJ	O
significant	O	ADJ	O
determinants	O	NOUN	B
in	O	ADP	O
improving	O	VERB	B
walking	O	NOUN	B
capacity	O	NOUN	I
among	O	ADP	O
chronic	O	ADJ	B
stroke	O	NOUN	I
survivors	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
rather	O	ADV	O
weak	O	ADJ	B
relationship	O	NOUN	B
(	O	PUNCT	O
R2	O	NOUN	O
=	O	ADJ	O
0.229	O	NUM	O
)	O	PUNCT	O
indicates	O	VERB	O
that	O	SCONJ	O
other	O	ADJ	O
factors	O	NOUN	B
not	O	PART	O
measured	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
may	O	AUX	O
also	O	ADV	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
walking	O	NOUN	B
capacity	O	NOUN	I
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mixed	B-I	ADJ	O
kinesio	I-I	NOUN	B
taping-compression	I-I	ADJ	I
technique	I-I	NOUN	I
on	O	ADP	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
and	O	CCONJ	O
clinical	B-OUT	ADJ	B
and	O	CCONJ	O
gait	B-OUT	NOUN	B
parameters	I-OUT	NOUN	B
in	O	ADP	O
postmenopausal	B-P	ADJ	B
women	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
venous	I-P	ADJ	I
insufficiency	I-P	NOUN	I
:	I-P	PUNCT	O
double-blinded	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
short-term	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mixed	O	ADJ	O
Kinesio	B-I	PROPN	B
taping	I-I	NOUN	I
(	O	PUNCT	O
KT	O	PROPN	B
)	O	PUNCT	O
model	O	NOUN	B
on	O	ADP	O
range	B-OUT	NOUN	O
of	I-OUT	ADP	O
ankle	I-OUT	NOUN	O
motion	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
ROAM	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
gait	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
perimeter	I-OUT	NOUN	B
of	I-OUT	ADP	O
lower	I-OUT	ADJ	B
limbs	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
in	O	ADP	O
postmenopausal	B-P	ADJ	B
women	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
venous	I-P	ADJ	I
insufficiency	I-P	NOUN	I
(	I-P	PUNCT	O
CVI	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
Double-blinded	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Clinical	O	ADJ	B
setting	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	VERB	B
Consecutive	B-P	ADJ	B
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
(	I-P	PUNCT	O
N=130	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
±	I-P	NOUN	O
SD	I-P	NOUN	B
,	I-P	PUNCT	O
65.44±14.7y	I-P	NUM	O
)	I-P	PUNCT	O
with	I-P	ADP	O
mild	I-P	ADJ	B
CVI	I-P	NOUN	B
.	O	PUNCT	O


No	O	DET	O
participant	O	NOUN	B
withdrew	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
adverse	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


INTERVENTION	O	NOUN	B
Participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
either	O	DET	O
(	B-I	PUNCT	O
1	I-I	X	O
)	I-I	PUNCT	O
an	I-I	DET	O
experimental	I-I	ADJ	B
group	I-I	NOUN	I
to	I-I	PART	O
receive	I-I	VERB	O
a	I-I	DET	O
mixed	I-I	ADJ	O
KT-compression	I-I	NOUN	B
treatment	I-I	NOUN	B
following	I-I	VERB	O
KT	I-I	NOUN	B
recommendations	I-I	NOUN	B
for	I-I	ADP	O
gastrocnemius	I-I	NOUN	B
muscle	I-I	NOUN	I
enhancement	I-I	NOUN	B
and	I-I	CCONJ	O
functional	I-I	ADJ	B
correction	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
ankle	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
adding	I-I	VERB	O
2	I-I	NUM	O
tapes	I-I	NOUN	B
to	I-I	PART	O
simulate	I-I	VERB	B
traditional	I-I	ADJ	O
compression	I-I	NOUN	B
bandages	I-I	NOUN	I
(	I-I	PUNCT	O
no	I-I	DET	O
KT	I-I	ADJ	B
guidelines	I-I	NOUN	B
)	I-I	PUNCT	O
;	I-I	PUNCT	O
or	I-I	CCONJ	O
(	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
a	I-I	DET	O
placebo	I-I	NOUN	B
control	I-I	NOUN	O
group	I-I	NOUN	O
for	I-I	ADP	O
sham	I-I	NOUN	B
KT	I-I	PROPN	B
.	O	PUNCT	O


Both	O	DET	O
interventions	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
3	O	NUM	O
times	O	NOUN	O
a	O	DET	O
week	O	NOUN	B
during	O	ADP	O
a	O	DET	O
4-week	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	B
MEASURES	B-OUT	X	O
ROAM	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
gait	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
perimeter	I-OUT	NOUN	B
of	I-OUT	ADP	O
right	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
left	I-OUT	VERB	O
lower	I-OUT	ADJ	O
limb	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
48	O	NUM	O
hours	O	NOUN	B
posttreatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	B-OUT	VERB	B
Quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
was	O	AUX	O
better	O	ADJ	O
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
by	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
of	O	ADP	O
8.76	O	NUM	O
points	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	PROPN	B
]	O	PUNCT	O
,	O	PUNCT	O
4.96-12.55	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
also	O	ADV	O
showed	O	VERB	O
significant	O	ADJ	B
pre-/posttreatment	O	ADJ	B
improvements	O	NOUN	B
in	O	ADP	O
both	B-OUT	CCONJ	O
lower	I-OUT	ADJ	B
limbs	I-OUT	NOUN	B
in	I-OUT	ADP	O
gait	I-OUT	ADJ	B
dorsiflexion	I-OUT	NOUN	I
ROAM	I-OUT	NOUN	I
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.02-2.49	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
cadence	I-OUT	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
3.45-1.47	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
stride	I-OUT	NOUN	B
length	I-OUT	NOUN	I
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
21.48-10.83	B-OUT	X	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
step	I-OUT	NOUN	B
length	I-OUT	NOUN	I
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.68-6.61	B-OUT	ADJ	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
stance	I-OUT	NOUN	B
phase	I-OUT	NOUN	I
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
61-107	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-OUT	CCONJ	O
foot	I-OUT	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
.56-.92	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
malleolus	I-OUT	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.15-1.63	B-OUT	NUM	O
)	I-OUT	PUNCT	O
circumference	I-OUT	NOUN	B
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
these	O	DET	O
variables	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
modified	O	VERB	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
reported	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	B-OUT	ADP	O
pain	I-OUT	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	B-OUT	NOUN	O
Ankle	I-OUT	ADJ	B
dorsiflexion	I-OUT	NOUN	I
during	O	ADP	O
gait	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
walking	I-OUT	VERB	B
parameters	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
peripheral	I-OUT	ADJ	B
edema	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
venous	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
remain	O	VERB	O
improved	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
CVI	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
after	B-I	ADP	O
mixed	I-I	ADJ	O
KT-compression	I-I	NOUN	B
therapy	I-I	NOUN	I
.	O	PUNCT	O


KT	O	PROPN	B
may	O	AUX	O
have	O	AUX	O
a	B-I	DET	O
placebo	I-I	ADJ	B
effect	O	NOUN	B
on	O	ADP	O
pain	O	NOUN	B
perception	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
pemetrexed	B-I	NOUN	B
as	O	ADP	O
first-line	O	ADJ	B
chemotherapy	O	NOUN	I
for	O	ADP	O
advanced	B-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	NOUN	O
Pemetrexed	B-I	NOUN	B
has	O	AUX	O
shown	O	VERB	O
varied	O	ADJ	O
response	O	NOUN	B
rates	O	NOUN	I
in	O	ADP	O
advanced	B-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
pemetrexed	B-I	NOUN	B
in	O	ADP	O
a	O	DET	O
homogeneous	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
secondary	O	ADJ	B
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
identify	O	VERB	O
molecular	O	ADJ	B
biomarkers	O	NOUN	I
correlating	O	VERB	B
with	O	ADP	O
response	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


EXPERIMENTAL	O	NOUN	B
DESIGN	O	VERB	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
newly	I-P	ADV	O
diagnosed	I-P	VERB	B
metastatic	I-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
or	I-P	CCONJ	O
locally	I-P	ADV	B
recurrent	I-P	ADJ	I
breast	I-P	NOUN	O
cancer	I-P	NOUN	O
received	O	VERB	O
600	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
(	B-I	PUNCT	O
P600	I-I	NOUN	B
arm	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
900	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
(	B-I	PUNCT	O
P900	I-I	NOUN	B
arm	O	NOUN	I
)	O	PUNCT	O
of	O	ADP	O
pemetrexed	B-I	NOUN	B
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
of	O	ADP	O
a	O	DET	O
21-day	O	ADJ	O
cycle	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
folic	B-I	ADJ	B
acid	I-I	NOUN	I
and	I-I	CCONJ	O
vitamin	I-I	NOUN	B
B	I-I	NOUN	I
(	I-I	PUNCT	O
12	I-I	NUM	O
)	I-I	PUNCT	O
supplementation	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	VERB	O
The	B-P	DET	O
P600	I-P	NOUN	B
(	I-P	PUNCT	O
47	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
P900	I-P	NOUN	B
(	I-P	PUNCT	O
45	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
arms	O	NOUN	O
had	O	AUX	O
response	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
of	O	ADP	O
17.0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
7.7-30.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
15.6	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
6.5-29.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
with	O	ADP	O
approximately	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
stable	O	ADJ	B
disease	O	NOUN	I
per	O	ADP	O
arm	O	NOUN	O
,	O	PUNCT	O
median	B-OUT	ADJ	O
progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
of	O	ADP	O
4.2	O	NUM	O
and	O	CCONJ	O
4.1	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
median	B-OUT	ADJ	B
times	I-OUT	NOUN	O
to	I-OUT	PART	O
tumor	I-OUT	NOUN	B
progression	I-OUT	NOUN	I
of	O	ADP	O
4.2	O	NUM	O
and	O	CCONJ	O
4.6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Both	O	DET	O
arms	O	NOUN	O
exhibited	O	VERB	O
minimal	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
(	O	PUNCT	O
grade	O	NOUN	O
3/4	O	NUM	O
neutropenia	B-OUT	NOUN	B
<	O	NOUN	O
20	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
leukopenia	B-OUT	NOUN	B
<	O	X	O
9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
other	B-OUT	ADJ	O
toxicities	I-OUT	NOUN	B
<	O	X	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Tumor	O	NOUN	B
samples	O	NOUN	O
from	O	ADP	O
49	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
pemetrexed-related	B-I	ADJ	B
genes	O	NOUN	I
.	O	PUNCT	O


Folylpolyglutamate	O	NOUN	B
synthetase	O	NOUN	I
and	O	CCONJ	O
thymidine	O	NOUN	B
phosphorylase	O	NOUN	I
correlated	O	VERB	B
with	O	ADP	O
efficacy	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Best	B-OUT	ADJ	B
response	I-OUT	NOUN	I
rates	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
median	I-OUT	ADJ	B
time	I-OUT	NOUN	O
to	I-OUT	PART	O
tumor	I-OUT	NOUN	B
progression	I-OUT	NOUN	I
for	O	ADP	O
high	O	ADJ	B
versus	O	CCONJ	O
low	O	ADJ	B
thymidine	O	NOUN	B
phosphorylase	O	NOUN	B
expression	O	NOUN	B
were	O	AUX	O
27.6	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
6.3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.023	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
5.4	O	NUM	O
versus	O	CCONJ	O
1.9	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.076	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
folylpolyglutamate	O	NOUN	B
synthetase	O	NOUN	I
were	O	AUX	O
37.5	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
10.0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.115	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
8.6	O	NUM	O
versus	O	CCONJ	O
3.0	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.019	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


gamma-Glutamyl	O	X	B
hydrolase	O	NOUN	I
expression	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
grade	B-OUT	NOUN	O
3/4	I-OUT	NUM	O
toxicities	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
78.6	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
high	O	ADJ	B
versus	O	CCONJ	O
27.3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
low	O	ADJ	O
gamma-glutamyl	O	ADJ	B
hydrolase	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.024	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
two	O	NUM	O
pemetrexed	B-I	NOUN	B
doses	O	NOUN	B
yielded	O	VERB	O
similar	O	ADJ	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
profiles	O	NOUN	I
.	O	PUNCT	O


Exploratory	O	ADJ	B
biomarker	O	NOUN	I
analysis	O	NOUN	I
identified	O	VERB	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
correlations	O	NOUN	B
and	O	CCONJ	O
warrants	O	VERB	O
further	O	ADJ	O
evaluation	O	NOUN	B
.	O	PUNCT	O


Expectant	B-I	ADJ	B
management	I-I	NOUN	I
of	O	ADP	O
functional	B-P	ADJ	B
ovarian	I-P	ADJ	I
cysts	I-P	NOUN	I
:	I-P	PUNCT	O
an	O	DET	O
alternative	O	NOUN	B
to	O	PART	O
hormonal	B-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
studied	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
oral	B-I	ADJ	B
contraceptives	I-I	NOUN	I
facilitates	O	VERB	O
the	O	DET	O
disappearance	O	NOUN	B
of	O	ADP	O
spontaneously	O	ADV	B
formed	B-P	VERB	O
functional	I-P	ADJ	B
ovarian	I-P	ADJ	O
cysts	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
Eighty	B-P	NUM	B
patients	I-P	NOUN	B
in	I-P	ADP	O
whom	I-P	PRON	O
ultrasonography	I-P	NOUN	B
revealed	I-P	VERB	O
unilateral	I-P	ADJ	B
,	I-P	PUNCT	O
mobile	I-P	ADJ	B
,	I-P	PUNCT	O
unilocular	I-P	ADJ	B
,	I-P	PUNCT	O
thin-walled	I-P	ADJ	B
ovarian	I-P	ADJ	I
cysts	I-P	NOUN	I
without	I-P	ADP	O
internal	I-P	ADJ	B
echoes	I-P	NOUN	I
and	I-P	CCONJ	O
greater	I-P	ADJ	O
than	I-P	ADP	O
30	I-P	NUM	O
mm	I-P	NOUN	O
but	I-P	CCONJ	O
not	I-P	PART	O
exceeding	I-P	VERB	O
60	I-P	NUM	O
mm	I-P	NOUN	O
in	I-P	ADP	O
diameter	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
into	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
by	O	ADP	O
stratification	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
a	O	DET	O
low-dose	B-I	ADJ	B
monophasic	I-I	ADJ	B
pill	I-I	NOUN	O
,	I-I	PUNCT	O
a	I-I	DET	O
high-dose	I-I	ADJ	B
monophasic	I-I	ADJ	B
pill	I-I	NOUN	O
,	I-I	PUNCT	O
a	I-I	DET	O
multiphasic	I-I	ADJ	B
pill	I-I	NOUN	I
or	I-I	CCONJ	O
no	I-I	DET	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
re-evaluated	O	VERB	O
after	O	ADP	O
5	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
mean	B-OUT	ADJ	O
ages	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
mean	I-OUT	ADJ	B
cyst	I-OUT	NOUN	B
diameters	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
for	O	ADP	O
each	O	DET	O
group	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
did	O	AUX	O
not	O	PART	O
find	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
contraceptive	O	ADJ	O
administration	O	NOUN	O
on	O	ADP	O
the	O	DET	O
disappearance	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
functional	I-OUT	ADJ	B
ovarian	I-OUT	ADJ	I
cysts	I-OUT	NOUN	I
over	O	ADP	O
that	O	DET	O
of	O	ADP	O
expectant	O	ADJ	B
management	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
oral	B-I	ADJ	B
contraceptive	I-I	ADJ	B
therapy	O	NOUN	I
even	O	ADV	O
with	O	ADP	O
multiphasic	O	ADJ	B
pills	O	NOUN	I
is	O	AUX	O
very	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
functional	B-OUT	ADJ	B
ovarian	I-OUT	ADJ	I
cysts	I-OUT	NOUN	I
but	O	CCONJ	O
expectant	O	ADJ	B
management	O	NOUN	I
achieves	O	VERB	O
similar	O	ADJ	O
success	O	NOUN	B
rates	O	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
good	O	ADJ	O
alternative	O	NOUN	O
to	O	PART	O
oral	B-I	ADJ	B
contraceptive	I-I	ADJ	I
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


[	O	PUNCT	O
Comparison	O	NOUN	B
of	O	ADP	O
complications	B-OUT	NOUN	B
after	O	ADP	O
intra-	B-I	ADJ	B
and	I-I	CCONJ	O
extracapsular	I-I	ADJ	B
cataract	I-I	NOUN	I
extraction	I-I	NOUN	I
with	I-I	ADP	O
lens	I-I	NOUN	B
implantation	I-I	NOUN	I
.	I-I	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
study	O	NOUN	I
]	O	PUNCT	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
postoperative	B-OUT	ADJ	B
complications	I-OUT	NOUN	B
of	O	ADP	O
ICCE	B-I	PROPN	B
with	I-I	ADP	O
ACL	I-I	NOUN	B
implantation	I-I	NOUN	I
are	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
ECCE	B-I	PROPN	B
and	I-I	CCONJ	O
PCL	I-I	PROPN	B
.	I-I	PUNCT	O


Our	O	PRON	O
clinical	O	ADJ	B
experience	O	NOUN	O
with	O	ADP	O
ICCE	B-I	PROPN	B
and	I-I	CCONJ	O
ACL	I-I	NOUN	B
implantation	I-I	NOUN	B
can	O	AUX	O
not	O	PART	O
confirm	O	VERB	O
the	O	DET	O
widespread	O	ADJ	B
rejection	O	NOUN	B
of	O	ADP	O
this	O	DET	O
method	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHOD	O	NOUN	O
A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
study	O	NOUN	I
with	O	ADP	O
participation	B-P	NOUN	B
of	I-P	ADP	O
medical	I-P	ADJ	B
statisticians	I-P	NOUN	I
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
190	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
ICCE	I-I	PROPN	B
and	I-I	CCONJ	O
ACL	I-I	NOUN	B
and	I-P	CCONJ	O
170	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
ECCE	I-I	NOUN	B
and	I-I	CCONJ	O
PCL	I-I	PROPN	B
were	I-P	AUX	O
followed	I-P	VERB	O
up	I-P	ADP	O
for	I-P	ADP	O
2	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
follow-up	O	ADJ	B
examinations	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
upon	O	SCONJ	O
dismission	O	NOUN	B
from	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
were	O	AUX	O
compiled	O	VERB	O
in	O	ADP	O
a	O	DET	O
computer	O	NOUN	B
program	O	NOUN	I
designed	O	VERB	O
for	O	ADP	O
this	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
evaluated	O	VERB	B
by	O	ADP	O
the	O	DET	O
statisticians	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
surgical	O	ADJ	B
procedures	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
surgeons	O	NOUN	B
were	O	AUX	O
defined	O	VERB	O
prior	O	ADV	O
to	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
patient	O	NOUN	B
recruitment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
ICCE	B-I	PROPN	B
with	I-I	ADP	O
ACL	I-I	NOUN	B
shows	O	VERB	O
much	O	ADV	O
less	O	ADV	O
postoperative	B-OUT	ADJ	B
complications	I-OUT	NOUN	B
as	O	ADP	O
usually	O	ADV	O
emphasized	O	VERB	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
only	O	ADV	O
2	O	NUM	O
(	O	PUNCT	O
1.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
retinal	B-OUT	ADJ	B
detachment	I-OUT	NOUN	B
and	O	CCONJ	O
no	O	DET	O
case	O	NOUN	O
of	O	ADP	O
corneal	B-OUT	NOUN	B
decompensation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Cystoid	B-OUT	NOUN	B
macular	I-OUT	NOUN	I
edema	I-OUT	NOUN	I
8	O	NUM	O
(	O	PUNCT	O
4.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
postoperative	B-OUT	ADJ	B
vitreous	I-OUT	ADJ	B
prolaps	I-OUT	NOUN	I
into	I-OUT	ADP	O
the	I-OUT	DET	O
anterior	I-OUT	ADJ	B
chamber	I-OUT	NOUN	I
4	O	NUM	I
(	O	PUNCT	O
2.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
spontaneous	B-OUT	ADJ	B
complaints	I-OUT	NOUN	O
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
16	O	NUM	O
(	O	PUNCT	O
9.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
a	O	DET	O
low	O	ADJ	B
percentage	O	NOUN	B
after	O	ADP	O
ICCE	B-I	PROPN	B
with	I-I	ADP	O
ACL	I-I	NOUN	B
.	I-I	PUNCT	O


These	O	DET	O
complications	O	NOUN	B
did	O	AUX	O
not	O	PART	O
occur	O	VERB	O
after	O	ADP	O
ECCE	B-I	PROPN	B
with	I-I	ADP	O
PCL	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
ECCE	B-I	NOUN	B
and	I-I	CCONJ	O
PCL	I-I	PROPN	B
showed	O	VERB	O
capsular	B-OUT	ADJ	B
fibrosis	I-OUT	NOUN	I
in	O	ADP	O
48	O	NUM	O
(	O	PUNCT	O
28	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
making	O	VERB	O
it	O	PRON	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
complication	O	NOUN	B
of	O	ADP	O
the	O	DET	O
whole	O	ADJ	O
study	O	NOUN	O
.	O	PUNCT	O


33	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
required	O	VERB	O
YAG-laser	B-I	NOUN	B
capsulotomy	I-I	NOUN	I
.	I-I	PUNCT	O


Since	O	SCONJ	O
retinal	O	ADJ	B
detachment	O	NOUN	B
occurs	O	VERB	O
in	O	ADP	O
2.5	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
YAG-laser	B-I	ADJ	B
capsulotomy	I-I	NOUN	I
we	O	PRON	O
can	O	AUX	O
not	O	PART	O
regard	O	VERB	O
capsular	O	ADJ	B
fibrosis	O	NOUN	I
as	O	ADP	O
a	O	DET	O
totally	O	ADV	O
harmless	O	ADJ	O
complication	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
noteworthy	O	ADJ	O
that	O	SCONJ	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
is	O	AUX	O
almost	O	ADV	O
identical	O	ADJ	B
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
in	O	ADP	O
both	O	DET	O
methods	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
ICCE	B-I	PROPN	B
with	I-I	ADP	O
ACL	I-I	NOUN	B
is	O	AUX	O
too	O	ADV	O
negative	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
elimination	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
complications	O	NOUN	B
in	O	ADP	O
this	O	DET	O
method	O	NOUN	B
is	O	AUX	O
more	O	ADV	O
difficult	O	ADJ	O
.	O	PUNCT	O


ECCE	B-I	NOUN	B
with	I-I	ADP	O
PCL	I-I	NOUN	B
is	O	AUX	O
burdened	O	VERB	O
by	O	ADP	O
frequent	B-OUT	ADJ	B
capsular	I-OUT	ADJ	B
fibrosis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Visual	O	ADJ	B
acuity	O	NOUN	I
is	O	AUX	O
almost	O	ADV	O
the	O	DET	O
same	O	ADJ	O
in	O	ADP	O
both	O	DET	O
methods	O	NOUN	B
1	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
.	O	PUNCT	O


ACL-implantation	B-I	NOUN	B
remains	O	VERB	O
our	O	PRON	O
method	O	NOUN	B
of	O	ADP	O
choice	O	NOUN	O
for	O	ADP	O
secondary	O	ADJ	B
implantation	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
intact	I-P	ADJ	B
iris	I-P	ADJ	B
diaphragm	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
radiography	B-I	NOUN	B
in	O	ADP	O
primary	B-P	ADJ	B
care	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
low	I-P	ADJ	B
back	I-P	ADJ	I
pain	I-P	NOUN	I
of	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADJ	O
6	I-P	NUM	O
weeks	I-P	NOUN	B
duration	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
(	O	PUNCT	O
unblinded	O	ADJ	B
)	O	PUNCT	O
controlled	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
test	O	VERB	O
the	O	DET	O
hypotheses	O	NOUN	B
that	O	SCONJ	O
:	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
Lumbar	O	ADJ	B
spine	O	NOUN	I
radiography	O	NOUN	I
in	O	ADP	O
primary	B-P	ADJ	B
care	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
low	I-P	ADJ	B
back	I-P	ADJ	I
pain	I-P	NOUN	I
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
improved	O	VERB	B
patient	O	NOUN	B
outcomes	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
pain	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
disability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
health	I-OUT	NOUN	B
status	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
sickness	I-OUT	NOUN	B
absence	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
reassurance	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
patient	O	NOUN	B
satisfaction	B-OUT	NOUN	I
or	O	CCONJ	O
belief	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
value	O	NOUN	O
of	O	ADP	O
radiography	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
Lumbar	B-I	ADJ	B
spine	I-I	NOUN	I
radiography	I-I	NOUN	I
in	O	ADP	O
primary	B-P	ADJ	B
care	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
low	I-P	ADJ	B
back	I-P	ADJ	I
pain	I-P	NOUN	I
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
changes	O	NOUN	B
in	O	ADP	O
patient	O	NOUN	B
management	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
medication	O	NOUN	B
use	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
primary	O	ADJ	B
and	O	CCONJ	O
secondary	O	ADJ	B
care	O	NOUN	I
services	O	NOUN	I
,	O	PUNCT	O
physical	O	ADJ	B
therapies	O	NOUN	I
and	O	CCONJ	O
complementary	O	ADJ	B
therapies	O	NOUN	I
.	O	PUNCT	O


(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
Participants	O	NOUN	B
choosing	O	VERB	O
their	O	PRON	O
treatment	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
i.e	O	ADV	O
.	O	PUNCT	O


radiography	B-I	NOUN	B
or	O	CCONJ	O
no	B-I	DET	O
radiography	I-I	NOUN	O
)	I-I	PUNCT	O
do	O	AUX	O
not	O	PART	O
have	O	AUX	O
better	O	ADJ	O
outcomes	O	NOUN	B
than	O	ADP	O
those	O	DET	O
randomised	O	VERB	B
to	O	PART	O
a	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


(	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
Lumbar	O	ADJ	B
spine	O	NOUN	I
radiography	O	NOUN	I
is	O	AUX	O
not	O	PART	O
cost-effective	O	ADJ	B
compared	O	VERB	B
with	O	ADP	O
usual	O	ADJ	B
care	O	NOUN	I
without	O	ADP	O
lumbar	O	ADJ	B
spine	O	NOUN	I
radiography	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
randomised	O	ADJ	B
unblinded	O	ADJ	O
controlled	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


SETTING	O	VERB	O
Seventy-three	B-P	NUM	O
general	I-P	ADJ	B
practices	I-P	NOUN	I
in	I-P	ADP	O
Nottingham	I-P	PROPN	B
,	I-P	PUNCT	O
North	I-P	PROPN	B
Nottinghamshire	I-P	PROPN	I
,	I-P	PUNCT	O
Southern	I-P	PROPN	B
Derbyshire	I-P	PROPN	I
,	I-P	PUNCT	O
North	I-P	PROPN	B
Lincolnshire	I-P	PROPN	I
and	I-P	CCONJ	O
North	I-P	PROPN	B
Leicestershire	I-P	PROPN	I
.	I-P	PUNCT	O


Fifty-two	B-P	NUM	O
practices	I-P	NOUN	B
recruited	I-P	VERB	O
participants	I-P	NOUN	B
to	I-P	ADP	O
the	I-P	DET	O
trial	I-P	NOUN	B
.	I-P	PUNCT	O


SUBJECTS	O	VERB	B
Randomised	O	ADJ	B
arm	O	NOUN	I
:	O	PUNCT	O
421	B-P	NUM	O
participants	I-P	NOUN	B
with	I-P	ADP	O
low	I-P	ADJ	B
back	I-P	ADJ	I
pain	I-P	NOUN	I
,	I-P	PUNCT	O
with	I-P	ADP	O
median	I-P	ADJ	B
duration	I-P	NOUN	B
of	I-P	ADP	O
10	I-P	NUM	O
weeks	I-P	NOUN	B
.	I-P	PUNCT	O


Patient	O	ADJ	B
preference	O	NOUN	O
arm	O	NOUN	O
:	O	PUNCT	O
55	B-P	NUM	O
participants	I-P	NOUN	B
with	I-P	ADP	O
low	I-P	ADJ	B
back	I-P	ADJ	I
pain	I-P	NOUN	I
,	I-P	PUNCT	O
with	I-P	ADP	O
median	I-P	ADJ	B
duration	I-P	NOUN	B
of	I-P	ADP	O
11	I-P	NUM	O
weeks	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTION	O	PROPN	B
Lumbar	B-I	ADJ	B
spine	I-I	NOUN	I
radiography	I-I	NOUN	I
and	I-I	CCONJ	O
usual	I-I	ADJ	B
care	I-I	NOUN	I
versus	I-I	CCONJ	O
usual	I-I	ADJ	B
care	I-I	NOUN	I
without	I-I	ADP	O
radiography	I-I	NOUN	B
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	O
MEASURES	O	ADJ	O
Roland	B-OUT	ADJ	B
adaptation	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
Sickness	I-OUT	PROPN	B
Impact	I-OUT	PROPN	I
Profile	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
visual	I-OUT	ADJ	B
analogue	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
health	I-OUT	NOUN	B
status	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
EuroQol	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
primary	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
secondary	I-OUT	ADJ	B
care	I-OUT	NOUN	I
services	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
physical	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
complementary	I-OUT	ADJ	O
therapies	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
sickness	I-OUT	NOUN	B
absence	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
medication	I-OUT	NOUN	B
use	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
patient	I-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
reassurance	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
belief	I-OUT	NOUN	B
in	I-OUT	ADP	B
value	I-OUT	NOUN	I
of	I-OUT	ADP	O
radiography	I-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
months	O	NOUN	B
post-randomisation	O	ADJ	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Participants	O	NOUN	B
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
an	O	DET	O
X-ray	O	NOUN	B
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
report	O	VERB	O
low	B-OUT	ADV	O
back	I-OUT	ADJ	O
pain	I-OUT	NOUN	O
at	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
)	O	PUNCT	O
=	O	ADJ	O
1.56	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
1.02	O	NUM	O
to	O	PART	O
2.40	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
a	O	DET	O
lower	O	ADJ	O
overall	O	ADJ	O
health	B-OUT	NOUN	B
status	I-OUT	NOUN	I
score	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
health	B-OUT	NOUN	B
or	O	CCONJ	O
functional	B-OUT	ADJ	B
status	I-OUT	NOUN	I
at	O	ADP	O
9	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
higher	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
participants	O	NOUN	B
consulted	B-OUT	VERB	B
the	I-OUT	DET	O
general	I-OUT	ADJ	B
practitioner	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
months	O	NOUN	B
following	O	VERB	O
an	O	DET	O
X-ray	O	NOUN	B
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
2.72	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.80	O	NUM	O
to	O	PART	O
4.10	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
any	B-OUT	DET	O
other	I-OUT	ADJ	O
services	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
medication	I-OUT	NOUN	B
use	I-OUT	NOUN	I
or	O	CCONJ	O
sickness	B-OUT	NOUN	B
absence	I-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
or	O	CCONJ	O
9	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
serious	B-OUT	ADJ	O
spinal	I-OUT	ADJ	B
pathology	I-OUT	NOUN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
commonest	O	ADJ	O
X-ray	O	NOUN	B
reports	O	NOUN	I
were	O	AUX	O
of	O	ADP	O
discovertebral	B-OUT	ADJ	B
degeneration	I-OUT	NOUN	I
and	O	CCONJ	O
normal	B-OUT	ADJ	O
findings	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Many	O	ADJ	O
patients	O	NOUN	B
did	O	AUX	O
not	O	PART	O
perceive	O	VERB	O
their	O	PRON	O
information	O	NOUN	B
needs	O	NOUN	O
were	O	AUX	O
met	O	VERB	O
within	O	ADP	O
the	O	DET	O
consultation	O	NOUN	B
.	O	PUNCT	O


Satisfaction	B-OUT	NOUN	B
with	O	ADP	O
care	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
radiography	O	NOUN	B
at	O	ADP	O
9	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Participants	O	NOUN	B
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
an	O	DET	O
X-ray	B-I	NOUN	B
were	O	AUX	O
not	O	PART	O
less	O	ADV	O
worried	B-OUT	ADJ	O
,	O	PUNCT	O
or	O	CCONJ	O
more	O	ADV	O
reassured	B-OUT	VERB	B
about	O	ADP	O
serious	O	ADJ	O
disease	O	NOUN	B
causing	O	VERB	O
their	O	PRON	O
low	O	ADJ	B
back	O	ADJ	I
pain	O	NOUN	I
.	O	PUNCT	O


Satisfaction	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
meeting	O	NOUN	O
participants	O	NOUN	B
'	O	PART	O
information	O	NOUN	B
needs	O	NOUN	O
and	O	CCONJ	O
reduced	O	VERB	B
belief	O	NOUN	B
in	O	ADP	O
the	O	DET	O
necessity	O	NOUN	O
for	O	ADP	O
investigations	O	NOUN	B
for	O	ADP	O
low	O	ADJ	B
back	O	ADJ	I
pain	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
X-rays	O	NOUN	B
and	O	CCONJ	O
blood	O	NOUN	B
tests	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
months	O	NOUN	B
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
participants	O	NOUN	B
would	O	AUX	O
choose	O	VERB	O
to	O	PART	O
have	O	AUX	O
an	O	DET	O
X-ray	O	NOUN	B
if	O	SCONJ	O
the	O	DET	O
choice	O	NOUN	B
was	O	AUX	O
available	O	ADJ	O
.	O	PUNCT	O


Participants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
preference	O	NOUN	O
group	O	NOUN	O
achieved	O	VERB	O
marginally	O	ADV	O
better	O	ADJ	O
outcomes	B-OUT	NOUN	B
than	O	ADP	O
those	O	DET	O
randomised	O	VERB	B
to	O	PART	O
a	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
clinical	O	ADJ	B
significance	O	NOUN	I
of	O	ADP	O
these	O	DET	O
differences	O	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


Lumbar	O	ADJ	B
spine	O	NOUN	I
radiography	O	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
net	O	ADJ	O
economic	B-OUT	ADJ	O
loss	I-OUT	NOUN	O
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Lumbar	O	ADJ	B
spine	O	NOUN	I
radiography	O	NOUN	I
in	O	ADP	O
primary	O	ADJ	B
care	O	NOUN	I
patients	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
back	O	ADJ	I
pain	O	NOUN	I
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
6	O	NUM	O
weeks	O	NOUN	B
duration	O	NOUN	B
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
improved	O	VERB	B
functioning	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
or	O	CCONJ	O
overall	B-OUT	ADJ	B
health	I-OUT	NOUN	B
status	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
GP	B-OUT	NOUN	B
workload	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Participants	O	NOUN	B
receiving	O	VERB	O
X-rays	O	NOUN	B
are	O	AUX	O
more	O	ADV	O
satisfied	O	ADJ	O
with	O	ADP	O
their	O	PRON	O
care	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
are	O	AUX	O
not	O	PART	O
less	O	ADV	O
worried	O	ADJ	O
or	O	CCONJ	O
more	O	ADV	O
reassured	O	VERB	B
about	O	ADP	O
serious	O	ADJ	O
disease	O	NOUN	B
causing	O	VERB	O
their	O	PRON	O
low	O	ADJ	B
back	O	ADJ	I
pain	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
-	O	PUNCT	O
RECOMMENDATIONS	O	NOUN	B
FOR	O	ADP	O
FURTHER	O	PROPN	O
RESEARCH	O	NOUN	O
:	O	PUNCT	O
Further	O	ADJ	O
work	O	NOUN	O
is	O	AUX	O
required	O	VERB	O
to	O	PART	O
develop	O	VERB	O
and	O	CCONJ	O
test	O	VERB	B
an	O	DET	O
educational	O	ADJ	B
package	O	NOUN	I
that	O	PRON	O
educates	O	VERB	B
patients	O	NOUN	B
and	O	CCONJ	O
GPs	O	NOUN	B
about	O	ADP	O
the	O	DET	O
utility	O	NOUN	O
of	O	ADP	O
radiography	O	NOUN	B
and	O	CCONJ	O
provides	O	VERB	O
strategies	O	NOUN	O
for	O	ADP	O
identifying	O	VERB	B
and	O	CCONJ	O
meeting	O	VERB	B
the	O	DET	O
information	O	NOUN	B
needs	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
needs	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
GPs	O	NOUN	B
to	O	PART	O
be	O	AUX	O
reassured	O	VERB	B
about	O	ADP	O
missing	O	VERB	O
serious	O	ADJ	O
disease	O	NOUN	O
.	O	PUNCT	O


Guidelines	O	NOUN	B
on	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
back	O	ADJ	I
pain	O	NOUN	I
in	O	ADP	O
primary	O	ADJ	B
care	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
consistent	O	ADJ	O
about	O	ADP	O
not	O	PART	O
recommending	O	VERB	O
lumbar	B-I	ADJ	B
spine	I-I	NOUN	I
radiography	I-I	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
back	O	ADJ	I
pain	O	NOUN	I
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
red	O	ADJ	B
flags	O	NOUN	I
for	O	ADP	O
serious	O	ADJ	O
spinal	O	ADJ	B
pathology	O	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
if	O	SCONJ	O
the	O	DET	O
pain	O	NOUN	B
has	O	AUX	O
persisted	O	VERB	O
for	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
gonadotropin-releasing	B-I	ADJ	B
hormone	I-I	NOUN	I
analog	I-I	NOUN	I
(	I-I	PUNCT	O
Diphereline	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
Cabergoline	B-I	NOUN	B
(	I-I	PUNCT	O
Dostinex	I-I	NOUN	B
)	I-I	PUNCT	O
treatment	O	NOUN	B
on	O	ADP	O
uterine	B-P	NOUN	B
myoma	I-P	NOUN	I
regression	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cabergoline	B-I	NOUN	B
(	I-I	PUNCT	O
Dostinex	I-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
dopamine	I-I	NOUN	B
agonist	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
the	O	DET	O
myoma	O	NOUN	B
growth	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
Diphereline	B-I	PROPN	B
(	I-I	PUNCT	O
a	I-I	DET	O
gonadotropin-releasing	I-I	ADJ	B
hormone	I-I	NOUN	I
agonist	I-I	NOUN	I
)	I-I	PUNCT	O
.	I-I	PUNCT	O


METHODS	O	NOUN	O
This	B-P	DET	O
study	I-P	NOUN	B
took	I-P	VERB	O
place	I-P	NOUN	O
in	I-P	ADP	O
the	I-P	DET	O
Department	I-P	PROPN	B
of	I-P	ADP	I
Obstetrics	I-P	PROPN	I
and	I-P	CCONJ	I
Gynecology	I-P	PROPN	I
of	I-P	ADP	I
Tabriz	I-P	PROPN	I
University	I-P	PROPN	I
of	I-P	ADP	I
Medical	I-P	PROPN	I
Sciences	I-P	PROPN	I
,	I-P	PUNCT	O
Tabriz	I-P	PROPN	B
,	I-P	PUNCT	O
Iran	I-P	PROPN	B
from	I-P	ADP	O
July	I-P	PROPN	O
2004	I-P	NUM	O
to	I-P	ADP	O
December	I-P	PROPN	O
2005	I-P	NUM	O
.	I-P	PUNCT	O


Fifty	B-P	NUM	O
women	I-P	NOUN	B
with	I-P	ADP	O
uterine	I-P	ADJ	B
myoma	I-P	NOUN	I
,	I-P	PUNCT	O
who	I-P	PRON	O
met	I-P	VERB	O
the	I-P	DET	O
criteria	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
thoroughly	I-P	ADV	O
,	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
into	O	ADP	O
2	O	NUM	O
equal	O	ADJ	O
groups	O	NOUN	B
to	O	PART	O
take	O	VERB	O
either	O	CCONJ	O
Diphereline	B-I	NOUN	B
or	O	CCONJ	O
Cabergoline	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
first	O	ADJ	O
Group	O	PROPN	B
took	O	VERB	O
3.75	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
Diphereline	B-I	NOUN	B
4	O	NUM	O
times	O	NOUN	O
every	O	DET	O
28	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
took	O	VERB	O
0.5	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
Cabergoline	B-I	PROPN	B
once	O	ADV	O
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
Cabergoline	B-I	NOUN	B
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	O	CCONJ	O
fewer	B-OUT	ADJ	O
adverse	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
tumor	B-OUT	NOUN	B
regressed	I-OUT	VERB	O
significantly	I-OUT	ADV	O
and	O	CCONJ	O
volume	B-OUT	NOUN	B
reduction	I-OUT	NOUN	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
individual	I-OUT	ADJ	B
tumor	I-OUT	NOUN	B
nodule	I-OUT	NOUN	I
varied	O	VERB	O
from	O	ADP	O
46-53	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
gonadotropin	B-I	NOUN	B
releasing	I-I	NOUN	I
hormone	I-I	NOUN	I
agonist	I-I	NOUN	B
group	O	NOUN	B
all	O	DET	O
responded	O	VERB	O
to	O	PART	O
the	O	DET	O
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
volume	B-OUT	NOUN	B
reduction	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
individual	O	ADJ	B
tumor	O	NOUN	B
nodule	O	NOUN	I
varied	O	VERB	O
from	O	ADP	O
21-97	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
tumor	B-OUT	NOUN	B
shrinkage	I-OUT	NOUN	I
was	O	AUX	O
positively	O	ADV	O
correlated	O	VERB	B
to	O	ADP	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
nodules	I-OUT	NOUN	B
(	O	PUNCT	O
p=0.881	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
and	O	CCONJ	O
0.701	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
light	O	NOUN	O
of	O	ADP	O
therapeutic	O	ADJ	B
efficacy	O	NOUN	B
and	O	CCONJ	O
few	O	ADJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
dopamine	B-I	NOUN	B
agonists	I-I	NOUN	B
may	O	AUX	O
hold	O	VERB	O
promise	O	NOUN	O
as	O	ADP	O
novel	O	ADJ	B
treatment	O	NOUN	B
modalities	O	NOUN	B
for	O	ADP	O
leiomyoma	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
warranted	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
optimal	O	ADJ	B
strategy	O	NOUN	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
leiomyoma	O	NOUN	B
through	O	ADP	O
these	O	DET	O
agents	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
feasibility	O	NOUN	B
study	O	NOUN	I
for	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
treatment	O	NOUN	B
withdrawal	O	NOUN	B
in	O	ADP	O
psoriatic	B-P	ADJ	B
arthritis	I-P	NOUN	I
(	O	PUNCT	O
REmoval	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
in	O	ADP	O
REmission	O	NOUN	B
in	O	ADP	O
psoriatic	O	ADJ	B
ArThritis	O	PROPN	I
(	O	PUNCT	O
RETREAT	O	NOUN	B
(	O	PUNCT	O
F	O	NOUN	B
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


TNF	O	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
effective	O	ADJ	B
for	O	ADP	O
all	O	DET	O
aspects	O	NOUN	O
of	O	ADP	O
psoriatic	O	ADJ	B
disease	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
these	O	DET	O
drugs	O	NOUN	B
are	O	AUX	O
costly	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
long-term	O	ADJ	B
effects	O	NOUN	B
are	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Further	O	ADV	O
,	O	PUNCT	O
methotrexate	O	NOUN	B
causes	O	VERB	O
concern	O	NOUN	O
with	O	ADP	O
long-term	O	ADJ	B
adverse	O	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
test	B-OUT	VERB	O
the	I-OUT	DET	O
feasibility	I-OUT	NOUN	B
of	O	ADP	O
drug	B-I	NOUN	B
withdrawal	I-I	NOUN	I
from	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
psoriatic	I-P	ADJ	B
arthritis	I-P	NOUN	I
,	I-P	PUNCT	O
in	I-P	ADP	O
stable	I-P	ADJ	B
low	I-P	ADJ	I
disease	I-P	NOUN	O
state	I-P	NOUN	O
.	I-P	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
availability	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
their	I-OUT	PRON	O
willingness	I-OUT	NOUN	O
to	I-OUT	PART	O
participate	I-OUT	VERB	B
,	I-OUT	PUNCT	O
study	I-OUT	NOUN	B
procedures	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
proportion	I-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
withdrawal	I-OUT	NOUN	B
arm	I-OUT	NOUN	I
who	I-OUT	PRON	O
relapsed	I-OUT	VERB	B
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Low	O	ADJ	B
disease	O	NOUN	B
state	O	NOUN	I
was	O	AUX	O
defined	O	VERB	O
by	O	ADP	O
minimal	O	ADJ	B
disease	O	NOUN	B
activity	O	NOUN	I
criteria	O	NOUN	I
(	O	PUNCT	O
MDA	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
relapse	O	NOUN	B
by	O	ADP	O
failure	O	NOUN	B
to	O	PART	O
achieve	O	VERB	O
these	O	DET	O
criteria	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
withdrawal	O	NOUN	B
group	O	NOUN	I
underwent	O	VERB	O
a	O	DET	O
phased	B-I	ADJ	O
withdrawal	I-I	NOUN	B
of	I-I	ADP	I
medication	I-I	NOUN	B
where	O	SCONJ	O
the	O	DET	O
last	O	ADJ	O
treatment	O	NOUN	B
added	O	VERB	O
was	O	AUX	O
the	O	DET	O
first	O	ADJ	O
withdrawn	B-I	VERB	B
.	I-I	PUNCT	O


Assessments	B-OUT	NOUN	B
were	O	AUX	O
monthly	O	ADJ	B
for	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
before	O	ADP	O
study	O	NOUN	B
exit	O	NOUN	B
.	O	PUNCT	O


Seventy-two	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
invited	I-P	VERB	O
to	I-P	PART	O
participate	I-P	VERB	B
,	I-P	PUNCT	O
of	I-P	ADP	O
which	I-P	DET	O
57	I-P	NUM	O
were	I-P	AUX	O
found	I-P	VERB	O
to	I-P	PART	O
be	I-P	AUX	O
eligible	I-P	ADJ	B
.	I-P	PUNCT	O


Twenty-six	O	NUM	O
(	O	PUNCT	O
36.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
subsequently	O	ADV	O
attended	O	VERB	B
the	O	DET	O
screening	O	NOUN	B
visit	O	NOUN	I
but	O	CCONJ	O
9	O	NUM	O
failed	O	VERB	O
eligibility	O	NOUN	B
criteria	O	NOUN	I
so	O	SCONJ	O
that	O	SCONJ	O
17	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
29.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
57	O	NUM	O
eligible	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
18.4	O	NUM	O
,	O	PUNCT	O
43.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
randomised	O	VERB	B
at	O	ADP	O
a	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
2:1	O	NUM	O
in	O	ADP	O
favour	O	NOUN	O
of	O	ADP	O
the	O	DET	O
withdrawal	B-I	NOUN	B
arm	I-I	NOUN	I
(	O	PUNCT	O
11	O	NUM	O
withdrawals	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
standard	O	ADJ	B
care	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Six	O	NUM	O
patients	O	NOUN	B
experienced	O	VERB	O
a	O	DET	O
flare	B-OUT	NOUN	B
,	O	PUNCT	O
all	O	DET	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
in	O	ADP	O
the	O	DET	O
withdrawal	B-I	NOUN	B
arm	I-I	NOUN	I
(	O	PUNCT	O
relapse	O	NOUN	B
rate	O	NOUN	B
54.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
23.4	O	NUM	O
,	O	PUNCT	O
83.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Four	O	NUM	O
of	O	ADP	O
the	O	DET	O
flares	O	NOUN	B
were	O	AUX	O
apparent	O	ADJ	B
from	O	ADP	O
visit	O	NOUN	B
3	O	NUM	O
(	O	PUNCT	O
8	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
starting	O	VERB	O
withdrawal	B-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
high	O	ADJ	O
relapse	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
,	O	PUNCT	O
an	O	DET	O
alternative	O	ADJ	O
trial	O	NOUN	O
design	O	NOUN	O
of	O	ADP	O
partial	O	ADJ	B
treatment	O	NOUN	B
withdrawal	O	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
including	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
preference	O	NOUN	I
arm	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
recommended	O	VERB	B
.	O	PUNCT	O


Histopathologic	B-OUT	ADJ	B
changes	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
eyelid	I-OUT	NOUN	B
skin	I-OUT	NOUN	I
following	I-P	VERB	O
trichloroacetic	I-I	ADJ	B
acid	I-I	NOUN	I
chemical	I-I	NOUN	B
peel	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
trichloroacetic	B-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
TCA	I-I	NOUN	B
)	I-I	PUNCT	O
as	O	ADP	O
a	O	DET	O
periorbital	O	ADJ	B
and	O	CCONJ	O
eyelid	O	NOUN	B
peel	O	NOUN	I
for	O	ADP	O
skin	O	NOUN	B
rejuvenation	O	NOUN	I
is	O	AUX	O
gaining	O	VERB	O
significant	O	ADJ	O
acceptance	O	NOUN	B
among	O	ADP	O
oculoplastic	O	ADJ	B
surgeons	O	NOUN	I
,	O	PUNCT	O
dermatologists	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
surgery	O	NOUN	B
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
spite	O	NOUN	O
of	O	ADP	O
the	O	DET	O
current	O	ADJ	O
enthusiasm	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
remain	O	VERB	O
potentially	O	ADV	O
serious	O	ADJ	O
complications	O	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
any	O	DET	O
periorbital	O	ADJ	B
peel	O	NOUN	I
.	O	PUNCT	O


Cases	O	NOUN	B
of	O	ADP	O
cicatricial	O	ADJ	B
ectropion	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
phenol-peeled	B-P	ADJ	B
patients	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
lower	O	ADJ	B
eyelid	O	ADJ	B
ectropion	O	NOUN	I
has	O	AUX	O
reportedly	O	ADV	O
occurred	O	VERB	O
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
deep	I-P	ADJ	B
eyelid	I-P	NOUN	I
peel	I-P	NOUN	I
in	I-P	ADP	O
conjunction	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
blepharoplasty	I-I	NOUN	B
(	O	PUNCT	O
1,2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
avoid	O	VERB	O
this	O	DET	O
complication	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
better	O	ADV	O
understand	O	VERB	O
the	O	DET	O
depth	O	NOUN	B
of	O	ADP	O
the	O	DET	O
wound	O	NOUN	B
produced	O	VERB	O
by	O	ADP	O
different	O	ADJ	O
strengths	O	NOUN	B
and	O	CCONJ	O
combinations	O	NOUN	B
of	O	ADP	O
peeling	O	NOUN	B
agents	O	NOUN	I
applied	O	VERB	O
to	O	ADP	O
living	O	VERB	B
eyelid	O	ADJ	B
tissue	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
more	O	ADV	O
important	O	ADJ	O
,	O	PUNCT	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
concentrations	O	NOUN	B
of	O	ADP	O
TCA	B-I	NOUN	B
that	O	PRON	O
are	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
lead	O	VERB	O
to	O	PART	O
cicatricial	O	ADJ	B
ectropion	O	NOUN	B
when	O	SCONJ	O
applied	O	VERB	O
in	O	ADP	O
a	O	DET	O
consistent	O	ADJ	O
fashion	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
chose	O	VERB	O
upper-eyelid	O	ADJ	B
skin	O	NOUN	I
because	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
easier	O	ADJ	O
to	O	PART	O
obtain	O	VERB	O
for	O	ADP	O
histopathologic	O	ADJ	B
study	O	NOUN	I
than	O	ADP	O
lower-eyelid	O	ADJ	B
skin	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
our	O	PRON	O
experience	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
more	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
hypertrophic	O	ADJ	B
changes	O	NOUN	B
after	O	ADP	O
chemical	O	ADJ	B
peeling	O	NOUN	I
or	O	CCONJ	O
carbon	O	NOUN	B
dioxide	O	NOUN	I
laser	O	NOUN	B
resurfacing	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
applied	O	VERB	O
TCA	B-I	NOUN	B
to	O	ADP	O
the	O	DET	O
preseptal	O	ADJ	B
skin	O	NOUN	I
of	O	ADP	O
10	B-P	NUM	O
patients	I-P	NOUN	B
48	O	NUM	O
h	O	NOUN	O
before	O	ADP	O
standard	B-P	ADJ	B
upper-eyelid	I-P	ADJ	B
blepharoplasty	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
acid	O	NOUN	B
was	O	AUX	O
applied	O	VERB	O
to	O	PART	O
produce	O	VERB	O
a	O	DET	O
"	O	PUNCT	O
frost	O	NOUN	B
,	O	PUNCT	O
"	O	PUNCT	O
using	O	VERB	O
varying	O	VERB	O
concentrations	O	NOUN	B
of	O	ADP	O
acid	O	NOUN	B
,	O	PUNCT	O
ranging	O	VERB	O
from	O	ADP	O
20	O	NUM	O
to	O	PART	O
50	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
treated	O	VERB	B
skin	O	NOUN	B
removed	O	VERB	O
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
blepharoplasty	O	NOUN	B
was	O	AUX	O
reviewed	O	VERB	B
in	O	ADP	O
a	O	DET	O
masked	O	VERB	O
fashion	O	NOUN	O
by	O	ADP	O
a	O	DET	O
dermatopathologist	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
depth	O	NOUN	B
of	O	ADP	O
necrosis	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
superficial	B-OUT	ADJ	B
peels	I-OUT	NOUN	I
with	I-OUT	ADP	O
necrosis	I-OUT	NOUN	B
involving	O	VERB	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
epidermis	O	NOUN	B
were	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
the	O	DET	O
lowest-concentration	O	ADJ	B
combination	O	NOUN	B
of	O	ADP	O
TCA	B-I	NOUN	B
applied	I-OUT	VERB	O
(	O	PUNCT	O
20	O	NUM	O
%	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


As	O	ADP	O
the	O	DET	O
strength	B-OUT	NOUN	B
increased	I-OUT	VERB	B
,	O	PUNCT	O
so	O	ADV	O
did	O	AUX	O
the	O	DET	O
depth	O	NOUN	B
of	O	ADP	O
peel	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
second	O	ADJ	O
application	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
produced	O	VERB	O
the	O	DET	O
deepest	B-OUT	ADJ	O
peel	I-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
necrosis	O	NOUN	B
into	O	ADP	O
the	O	DET	O
papillary	O	ADJ	B
dermis	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	B
would	O	AUX	O
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
chance	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
cicatricial	O	ADJ	B
ectropion	O	NOUN	B
with	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
tested	O	VERB	B
combinations	O	NOUN	B
of	O	ADP	O
TCA	B-I	NOUN	B
should	O	AUX	O
be	O	AUX	O
very	O	ADV	O
remote	O	ADJ	B
.	O	PUNCT	O


Interview	O	NOUN	B
skills	O	NOUN	I
for	O	ADP	O
adults	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
pilot	O	NOUN	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
interview	B-I	NOUN	B
skills	I-I	NOUN	I
curriculum	I-I	NOUN	I
(	I-I	PUNCT	O
ISC	I-I	PROPN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
manualized	O	VERB	B
12-week	O	NOUN	O
group-delivered	O	ADJ	B
intervention	O	NOUN	I
for	O	ADP	O
young	B-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


This	O	DET	O
intervention	O	NOUN	B
aims	O	VERB	O
to	O	PART	O
increase	O	VERB	B
social-pragmatic	O	ADJ	B
skills	O	NOUN	I
essential	O	ADJ	O
to	O	PART	O
a	O	DET	O
successful	O	ADJ	O
job	O	NOUN	B
interview	O	NOUN	B
.	O	PUNCT	O


Twenty-eight	B-P	NUM	B
adults	I-P	NOUN	I
(	I-P	PUNCT	O
18-36	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
ISC	B-I	NOUN	B
or	O	CCONJ	O
waitlist	B-I	ADJ	B
control	I-I	NOUN	I
.	I-I	PUNCT	O


Results	O	NOUN	B
revealed	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
showed	O	VERB	O
larger	O	ADJ	O
gains	O	NOUN	B
in	O	ADP	O
social-pragmatic	B-OUT	ADJ	B
skills	I-OUT	NOUN	I
observed	O	VERB	O
during	O	ADP	O
a	O	DET	O
mock	O	ADJ	B
job	O	NOUN	B
interview	O	NOUN	B
than	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
effects	O	NOUN	O
on	O	ADP	O
distal	O	ADJ	B
outcomes	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
social	B-OUT	ADJ	B
adaptive	I-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
depressive	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
were	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
respective	O	ADJ	O
effect	O	NOUN	B
sizes	O	NOUN	O
were	O	AUX	O
medium/large	O	ADJ	B
.	O	PUNCT	O


Results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
brief	O	NOUN	B
,	O	PUNCT	O
low-intensity	O	ADJ	B
treatment	O	NOUN	B
can	O	AUX	O
improve	O	VERB	O
the	O	DET	O
job-interview	B-OUT	ADJ	B
performance	I-OUT	NOUN	B
of	O	ADP	O
young	B-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
long-term	O	ADJ	B
asthma	O	NOUN	B
treatments	O	NOUN	B
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
asthma	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
asthma	O	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
asthma	I-P	NOUN	I
,	I-P	PUNCT	O
three	I-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
11	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
nedocromil	B-I	ADJ	B
sodium	I-I	NOUN	I
(	I-I	PUNCT	O
NS	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
beclomethasone	I-I	NOUN	B
dipropionate	I-I	NOUN	I
(	I-I	PUNCT	O
BDP	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
beclomethasone	I-I	NOUN	B
dipropionate	I-I	NOUN	I
plus	I-I	CCONJ	I
salmeterol	I-I	NOUN	B
(	I-I	PUNCT	O
BDP	I-I	NOUN	B
+	I-I	CCONJ	O
S	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Symptom	O	NOUN	B
score	O	NOUN	I
,	O	PUNCT	O
peak	O	VERB	B
expiratory	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
PEF	O	NOUN	B
)	O	PUNCT	O
maximal	O	ADJ	B
amplitude	O	NOUN	B
,	O	PUNCT	O
forced	O	ADJ	B
expiratory	O	ADJ	I
volume	O	NOUN	I
in	O	ADP	O
one	O	NUM	O
second	O	NOUN	O
(	O	PUNCT	O
FEV1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
methacholine	O	NOUN	B
reactivity	O	NOUN	O
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
intervals	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
up	O	ADV	O
to	O	PART	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
symptoms	O	NOUN	B
reduced	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
all	O	DET	O
treatment	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
PEF	O	NOUN	B
variability	O	NOUN	B
improved	O	VERB	B
in	O	ADP	O
BDP	O	NOUN	B
and	O	CCONJ	O
BDP	O	NOUN	B
+	O	CCONJ	O
S	O	NOUN	B
groups	O	NOUN	B
;	O	PUNCT	O
FEV1	O	NOUN	B
and	O	CCONJ	O
bronchial	O	ADJ	B
responsiveness	O	NOUN	I
to	O	PART	O
methacholine	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
baseline	O	NOUN	B
value	O	NOUN	O
in	O	ADP	O
the	O	DET	O
BDP	O	NOUN	B
+	O	CCONJ	O
S	O	NOUN	B
group	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


No	B-OUT	DET	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
was	I-OUT	AUX	O
observed	I-OUT	VERB	O
after	I-OUT	ADP	O
6	I-OUT	NUM	O
and	I-OUT	CCONJ	O
12	I-OUT	NUM	O
months	I-OUT	NOUN	B
of	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
in	I-OUT	ADP	O
PEF	I-OUT	NOUN	B
variability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
FEV1	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
bronchial	I-OUT	ADJ	B
hyperreactivity	I-OUT	NOUN	I
in	I-OUT	ADP	O
the	I-OUT	DET	O
NS	I-OUT	NOUN	B
group	I-OUT	NOUN	B
compared	I-OUT	VERB	B
with	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
values	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
while	I-OUT	SCONJ	O
a	I-OUT	DET	O
significant	I-OUT	ADJ	O
difference	I-OUT	NOUN	O
was	I-OUT	AUX	O
observed	I-OUT	VERB	O
in	I-OUT	ADP	O
symptom	I-OUT	NOUN	B
score	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


BDP	B-OUT	NOUN	B
group	I-OUT	NOUN	B
showed	I-OUT	VERB	O
a	I-OUT	DET	O
significant	I-OUT	ADJ	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
FEV1	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
bronchial	I-OUT	ADJ	B
reactivity	I-OUT	NOUN	I
to	I-OUT	PART	O
methacholine	I-OUT	NOUN	B
after	I-OUT	ADP	O
6	I-OUT	NUM	O
and	I-OUT	CCONJ	O
12	I-OUT	NUM	O
months	I-OUT	NOUN	B
of	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	B-OUT	ADP	O
the	I-OUT	DET	O
BDP	I-OUT	NOUN	B
+	I-OUT	CCONJ	O
S	I-OUT	NOUN	B
group	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pulmonary	I-OUT	ADJ	B
function	I-OUT	NOUN	I
persisted	I-OUT	VERB	O
until	I-OUT	ADP	O
the	I-OUT	DET	O
end	I-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
study	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	B-OUT	DET	O
combination	I-OUT	NOUN	B
of	I-OUT	ADP	O
beclomethasone	I-OUT	NOUN	B
dipropionate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
salmeterol	I-OUT	NOUN	B
improved	I-OUT	VERB	O
pulmonary	I-OUT	ADJ	B
function	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
bronchial	I-OUT	ADJ	B
reactivity	I-OUT	NOUN	I
earlier	I-OUT	ADV	O
than	I-OUT	ADP	O
beclomethasone	I-OUT	NOUN	B
dipropionate	I-OUT	NOUN	O
alone	I-OUT	ADV	O
,	I-OUT	PUNCT	O
while	I-OUT	SCONJ	O
nedocromil	I-OUT	NOUN	B
sodium	I-OUT	NOUN	O
improved	I-OUT	VERB	O
symptoms	I-OUT	NOUN	B
but	I-OUT	CCONJ	O
not	I-OUT	PART	O
pulmonary	I-OUT	ADJ	B
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Assuming	O	VERB	O
that	O	SCONJ	O
bronchial	B-OUT	ADJ	B
reactivity	I-OUT	NOUN	I
could	O	AUX	O
be	O	AUX	O
an	O	DET	O
indirect	O	ADJ	B
measurement	O	NOUN	B
of	O	ADP	O
airway	O	NOUN	B
inflammation	O	NOUN	B
,	O	PUNCT	O
overtreatment	B-OUT	NOUN	B
of	I-OUT	ADP	O
asthma	I-OUT	NOUN	B
in	I-OUT	ADP	O
relationship	I-OUT	NOUN	B
with	I-OUT	ADP	O
the	I-OUT	DET	O
classification	I-OUT	NOUN	B
of	I-OUT	ADP	O
asthma	I-OUT	NOUN	B
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
International	I-OUT	PROPN	B
Guidelines	I-OUT	PROPN	I
could	I-OUT	AUX	O
improve	I-OUT	VERB	O
both	I-OUT	DET	O
airway	I-OUT	NOUN	B
inflammation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
prognosis	I-OUT	NOUN	B
of	I-OUT	ADP	O
airway	I-OUT	NOUN	B
obstruction	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
chlorhexidine	B-I	NOUN	B
varnish	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
gingival	B-OUT	ADJ	B
status	I-OUT	NOUN	I
of	I-P	ADP	O
adolescents	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
blind	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
two-stage	O	ADJ	B
chlorhexidine	B-I	NOUN	I
varnish	I-I	NOUN	I
,	O	PUNCT	O
after	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
gingival	B-P	ADJ	B
status	I-P	NOUN	I
of	I-P	ADP	O
11-	I-P	NUM	O
to	I-P	PART	O
15-year-old	I-P	ADJ	O
children	I-P	NOUN	B
attending	I-P	VERB	B
a	I-P	DET	O
school	I-P	NOUN	B
in	I-P	ADP	O
Rio	I-P	PROPN	B
de	I-P	PROPN	I
Janeiro	I-P	PROPN	I
,	I-P	PUNCT	O
Brazil	I-P	PROPN	B
.	I-P	PUNCT	O


Subjects	O	NOUN	B
participating	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
control	B-P	NOUN	B
(	I-P	PUNCT	O
C	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
treatment	I-P	NOUN	B
(	I-P	PUNCT	O
T	I-P	NOUN	B
)	I-P	PUNCT	O
groups	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
53	I-P	NUM	O
and	I-P	CCONJ	O
n	I-P	NOUN	O
=	I-P	ADJ	O
57	I-P	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


All	O	DET	O
subjects	B-P	NOUN	B
were	O	AUX	O
matched	B-P	VERB	B
at	I-P	ADP	O
baseline	I-P	NOUN	B
on	I-P	ADP	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
salivary	I-P	ADJ	B
levels	I-P	NOUN	B
of	I-P	ADP	O
mutans	I-P	ADJ	B
streptococci	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
caries	I-P	NOUN	B
scores	I-P	NOUN	O
.	I-P	PUNCT	O


After	O	ADP	O
elimination	O	NOUN	B
of	O	ADP	O
carious	O	ADJ	B
lesions	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
prophylaxis	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
to	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
chlorhexidine	B-I	NOUN	B
varnish	I-I	NOUN	B
was	O	AUX	O
then	O	ADV	O
painted	O	VERB	B
on	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
dentition	O	NOUN	B
of	O	ADP	O
Group	O	PROPN	B
T	O	NOUN	O
subjects	O	NOUN	O
only	O	ADV	O
.	O	PUNCT	O


Prior	O	ADV	O
to	O	PART	O
caries	O	NOUN	B
elimination	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
again	O	ADV	O
after	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gingival	O	ADJ	B
index	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
gingival	B-OUT	ADJ	B
status	I-OUT	NOUN	I
of	O	ADP	O
study	O	NOUN	B
subjects	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
average	O	NOUN	B
of	O	ADP	O
106.6	O	NUM	O
+/-	O	CCONJ	O
8.9	O	NUM	O
and	O	CCONJ	O
107.7	O	NUM	O
+/-	O	CCONJ	O
6.2	O	NUM	O
gingival	O	ADJ	B
sites	O	NOUN	I
per	O	ADP	O
subject	O	NOUN	O
(	O	PUNCT	O
four	O	NUM	O
sites	O	NOUN	B
per	O	ADP	O
tooth	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
Groups	O	NOUN	B
C	O	NOUN	I
and	O	CCONJ	O
T	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
the	O	DET	O
same	O	ADJ	O
calibrated	O	VERB	B
examiner	O	NOUN	B
on	O	ADP	O
two	O	NUM	O
occasions	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
statistical	O	ADJ	B
purposes	O	NOUN	I
,	O	PUNCT	O
data	O	NOUN	B
were	O	AUX	O
dichotomized	O	VERB	B
[	O	PUNCT	O
(	O	PUNCT	O
0,1	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
2,3	O	NUM	O
)	O	PUNCT	O
]	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
gingival	O	ADJ	B
index	O	NOUN	I
.	O	PUNCT	O


Independent	O	ADJ	B
t-tests	O	NOUN	O
and	O	CCONJ	O
paired	O	ADJ	B
t-tests	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
analyze	O	VERB	B
the	O	DET	O
data	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
percentage	B-OUT	NOUN	B
of	I-OUT	ADP	O
sites	I-OUT	NOUN	B
per	I-OUT	ADP	O
subject	I-OUT	NOUN	O
with	I-OUT	ADP	O
scores	I-OUT	NOUN	B
of	I-OUT	ADP	O
two	I-OUT	NUM	O
or	I-OUT	CCONJ	O
three	I-OUT	NUM	O
at	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
were	O	AUX	O
balanced	O	VERB	O
between	O	ADP	O
study	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
3.7	O	NUM	O
+/-	O	CCONJ	O
7.1	O	NUM	O
for	O	ADP	O
T	O	NOUN	B
;	O	PUNCT	O
1.8	O	NUM	O
+/-	O	CCONJ	O
3.2	O	NUM	O
for	O	ADP	O
C	O	NOUN	B
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.08	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
average	O	ADJ	B
percentage	B-OUT	NOUN	B
of	I-OUT	ADP	O
sites	I-OUT	NOUN	B
with	I-OUT	ADP	O
scores	I-OUT	NOUN	B
of	I-OUT	ADP	O
two	I-OUT	NUM	O
or	I-OUT	CCONJ	O
three	I-OUT	NUM	O
was	O	AUX	O
demonstrated	O	VERB	O
in	O	ADP	O
the	O	DET	O
T	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
0.7	O	NUM	O
+/-	O	CCONJ	O
2.4	O	NUM	O
,	O	PUNCT	O
T	O	NOUN	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.0001	O	NUM	O
;	O	PUNCT	O
1.3	O	NUM	O
+/-	O	CCONJ	O
3.0	O	NUM	O
,	O	PUNCT	O
C	O	NOUN	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.25	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
application	O	NOUN	B
of	O	ADP	O
a	O	DET	O
chlorhexidine	B-I	NOUN	B
varnish	I-I	NOUN	B
significantly	O	ADV	O
improved	O	VERB	O
the	O	DET	O
gingival	B-OUT	ADJ	B
health	I-OUT	NOUN	I
of	O	ADP	O
T	O	NOUN	B
subjects	O	NOUN	I
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
three	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	B
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gingival	B-OUT	ADJ	B
health	I-OUT	NOUN	I
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
demonstrated	O	VERB	O
in	O	ADP	O
the	O	DET	O
C	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Matching	O	NOUN	B
doses	O	NOUN	I
of	O	ADP	O
distraction	O	NOUN	B
with	O	ADP	O
child	B-P	NOUN	B
risk	I-P	NOUN	I
for	I-P	ADP	O
distress	I-P	NOUN	B
during	O	ADP	O
a	O	DET	O
medical	O	ADJ	B
procedure	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Parents	O	NOUN	B
often	O	ADV	O
want	O	VERB	O
to	O	PART	O
provide	O	VERB	O
support	O	NOUN	O
to	O	ADP	O
their	O	PRON	O
children	O	NOUN	B
during	O	ADP	O
medical	O	ADJ	B
procedures	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
all	O	DET	O
parents	O	NOUN	B
are	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
providing	O	VERB	O
distraction	O	NOUN	B
after	O	ADP	O
brief	O	ADJ	B
training	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
three	O	NUM	O
doses	B-I	NOUN	B
of	I-I	ADP	O
distraction	I-I	NOUN	B
intervention	I-I	NOUN	I
for	O	ADP	O
children	B-P	NOUN	B
at	I-P	ADP	O
high	I-P	ADJ	B
and	I-P	CCONJ	O
medium	I-P	NOUN	B
risk	I-P	NOUN	B
for	I-P	ADP	O
procedure-related	I-P	ADJ	B
distress	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Children	B-P	NOUN	B
undergoing	I-P	VERB	O
scheduled	I-P	VERB	O
intravenous	I-P	ADJ	B
insertions	I-P	NOUN	I
for	I-P	ADP	O
diagnostic	I-P	ADJ	B
or	I-P	CCONJ	O
treatment	I-P	NOUN	B
purposes	I-P	NOUN	O
and	I-P	CCONJ	O
their	I-P	PRON	O
parents	I-P	NOUN	B
participated	I-P	VERB	O
.	I-P	PUNCT	O


A	O	DET	O
computerized	O	VERB	B
application	O	NOUN	B
,	O	PUNCT	O
Children	O	PROPN	B
,	O	PUNCT	O
Parents	O	NOUN	B
and	O	CCONJ	O
Distraction	O	PROPN	B
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
predict	O	VERB	O
distress	O	NOUN	B
risk	O	NOUN	I
.	O	PUNCT	O


Doses	B-I	NOUN	B
of	I-I	ADP	O
intervention	I-I	NOUN	B
were	O	AUX	O
basic	O	ADJ	O
(	B-I	PUNCT	O
parents	I-I	NOUN	B
trained	I-I	VERB	B
on	I-I	ADP	O
providing	I-I	VERB	O
distraction	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
enhanced	O	VERB	B
(	B-I	PUNCT	O
basic	I-I	ADJ	O
training	I-I	NOUN	O
plus	I-I	CCONJ	O
tailored	I-I	ADJ	O
instructions	I-I	NOUN	O
,	I-I	PUNCT	O
environmental	I-I	ADJ	B
modifications	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
support	I-I	NOUN	B
and	I-I	CCONJ	O
guidance	I-I	NOUN	B
from	I-I	ADP	O
the	I-I	DET	O
research	I-I	NOUN	B
assistant	I-I	NOUN	I
)	I-I	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
professional	O	ADJ	B
(	B-I	PUNCT	O
a	I-I	DET	O
trained	I-I	VERB	O
research	I-I	NOUN	O
assistant	I-I	NOUN	O
provided	I-I	VERB	O
distraction	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Outcome	O	NOUN	B
measures	O	NOUN	I
were	O	AUX	O
Observational	B-OUT	ADJ	B
Scale	I-OUT	NOUN	I
of	I-OUT	ADP	O
Behavioral	I-OUT	PROPN	O
Distress-Revised	I-OUT	PROPN	O
for	I-OUT	ADP	O
behavioral	I-OUT	ADJ	B
distress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
Oucher	I-OUT	PROPN	B
for	I-OUT	ADP	O
self-reported	I-OUT	ADJ	O
pain	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
parent	I-OUT	NOUN	B
report	I-OUT	NOUN	I
of	I-OUT	ADP	O
child	I-OUT	NOUN	B
distress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
salivary	I-OUT	ADJ	B
cortisol	I-OUT	NOUN	I
for	I-OUT	ADP	O
physiological	I-OUT	ADJ	B
distress	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
574	I-P	NUM	O
children	I-P	NOUN	B
,	I-P	PUNCT	O
ages	I-P	NOUN	B
4-10	I-P	NUM	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
their	I-P	PRON	O
parents	I-P	NOUN	B
participated	I-P	VERB	O
.	I-P	PUNCT	O


The	O	DET	O
Children	O	PROPN	B
,	O	PUNCT	O
Parents	O	NOUN	B
and	O	CCONJ	O
Distraction	O	PROPN	B
predicted	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
risk	B-OUT	NOUN	B
for	I-OUT	ADP	O
distress	I-OUT	NOUN	B
was	O	AUX	O
high	O	ADJ	O
for	O	ADP	O
156	O	NUM	O
children	O	NOUN	B
,	O	PUNCT	O
medium	O	NOUN	B
for	O	ADP	O
372	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
low	O	ADJ	B
for	O	ADP	O
46	O	NUM	O
.	O	PUNCT	O


Children	O	NOUN	B
predicted	O	VERB	B
to	O	PART	O
have	O	AUX	O
higher	O	ADJ	O
risk	O	NOUN	B
for	O	ADP	O
distress	O	NOUN	B
displayed	O	VERB	O
more	O	ADV	O
behavioral	B-OUT	ADJ	B
distress	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
medium-risk	O	ADJ	B
group	O	NOUN	I
who	O	PRON	O
had	O	AUX	O
the	O	DET	O
professional	O	ADJ	B
intervention	O	NOUN	I
displayed	O	VERB	O
significantly	O	ADV	O
less	O	ADV	O
behavioral	B-OUT	ADJ	B
distress	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
high-risk	O	ADJ	B
group	O	NOUN	I
tended	O	VERB	O
to	O	PART	O
have	O	AUX	O
less	O	ADV	O
behavioral	O	ADJ	B
distress	O	NOUN	I
when	O	SCONJ	O
receiving	O	VERB	O
the	O	DET	O
professional	O	ADJ	B
intervention	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.07	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
group	O	NOUN	B
differences	O	NOUN	O
for	O	ADP	O
self-report	B-OUT	NOUN	B
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
parent	I-OUT	NOUN	B
report	I-OUT	NOUN	I
of	I-OUT	ADP	O
distress	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
cortisol	I-OUT	NOUN	B
levels	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


DISCUSSION	O	NOUN	O
Some	O	DET	O
parents	O	NOUN	B
may	O	AUX	O
need	O	VERB	O
additional	O	ADJ	O
training	O	NOUN	B
in	O	ADP	O
providing	O	VERB	O
distraction	O	NOUN	B
to	O	ADP	O
their	O	PRON	O
children	O	NOUN	B
during	O	ADP	O
procedures	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
some	O	DET	O
children	B-P	NOUN	B
at	I-P	ADP	O
medium	I-P	NOUN	B
and	I-P	CCONJ	O
high	I-P	ADJ	B
risk	I-P	NOUN	I
for	I-P	ADP	O
distress	I-P	NOUN	B
may	O	AUX	O
need	O	VERB	O
professional	O	ADJ	B
support	O	NOUN	I
.	O	PUNCT	O


Parents	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
asked	O	VERB	O
about	O	ADP	O
their	O	PRON	O
preferences	O	NOUN	B
in	O	ADP	O
acting	O	VERB	O
as	O	ADP	O
the	O	DET	O
distraction	O	NOUN	B
coach	O	NOUN	O
and	O	CCONJ	O
,	O	PUNCT	O
if	O	SCONJ	O
willing	O	ADJ	O
,	O	PUNCT	O
be	O	AUX	O
provided	O	VERB	O
as	O	ADV	O
much	O	ADJ	O
training	O	NOUN	B
and	O	CCONJ	O
support	O	NOUN	O
as	O	ADP	O
possible	O	ADJ	O
in	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
situation	O	NOUN	I
.	O	PUNCT	O


Clinical	O	ADJ	B
impact	O	NOUN	I
of	O	ADP	O
leak	O	NOUN	B
compensation	O	NOUN	B
during	O	ADP	O
non-invasive	O	ADJ	B
ventilation	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
leak	O	VERB	B
compensation	O	NOUN	B
capabilities	O	NOUN	B
during	O	ADP	O
pressure-	B-I	ADJ	B
and	I-I	CCONJ	I
volume-limited	I-I	VERB	O
non-invasive	I-I	ADJ	O
positive-pressure	I-I	ADJ	O
ventilation	I-I	NOUN	O
(	I-I	PUNCT	O
NPPV	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
COPD	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Fourteen	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
stable	I-P	ADJ	B
hypercapnic	I-P	ADJ	B
COPD	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
receiving	I-P	VERB	O
long-term	I-P	ADJ	B
NPPV	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


For	O	ADP	O
both	O	DET	O
modes	O	NOUN	B
of	O	ADP	O
NPPV	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
full	B-I	ADJ	O
face	I-I	NOUN	B
mask	I-I	NOUN	I
and	I-I	CCONJ	O
an	I-I	DET	O
artificial	I-I	ADJ	B
leak	I-I	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
ventilatory	I-I	ADJ	B
circuit	I-I	NOUN	I
were	O	AUX	O
used	O	VERB	O
at	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
settings	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
applied	O	VERB	O
during	O	ADP	O
daytime	O	NOUN	B
NPPV	O	PROPN	B
,	O	PUNCT	O
either	B-I	CCONJ	O
without	I-I	ADP	O
leakage	I-I	NOUN	B
(	I-I	PUNCT	O
setting	I-I	VERB	B
I	I-I	PRON	I
)	I-I	PUNCT	O
,	I-I	PUNCT	O
with	I-I	ADP	O
leakage	I-I	NOUN	B
during	I-I	ADP	O
inspiration	I-I	NOUN	B
only	I-I	ADV	O
(	I-I	PUNCT	O
setting	I-I	VERB	B
II	I-I	NUM	I
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
with	I-I	ADP	O
leakage	I-I	NOUN	B
during	I-I	ADP	O
inspiration	I-I	NOUN	B
and	I-I	CCONJ	O
expiration	I-I	NOUN	B
(	I-I	PUNCT	O
setting	I-I	VERB	O
III	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Ventilation	B-OUT	NOUN	B
pattern	I-OUT	NOUN	O
was	O	AUX	O
pneumotachy-graphically	O	ADV	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
NPPV	O	NOUN	B
was	O	AUX	O
feasible	O	ADJ	O
with	O	ADP	O
negligible	O	ADJ	O
leak	B-OUT	NOUN	B
volumes	I-OUT	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
optimal	O	ADJ	B
mask	O	NOUN	B
fitting	O	VERB	I
during	O	ADP	O
the	O	DET	O
daytime	O	NOUN	B
(	O	PUNCT	O
setting	O	VERB	B
I	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
leakage	B-OUT	NOUN	B
(	O	PUNCT	O
settings	O	NOUN	B
II	O	NUM	I
and	O	CCONJ	I
III	O	NUM	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
attempt	O	NOUN	O
to	O	PART	O
compensate	O	VERB	B
for	O	ADP	O
leak	O	NOUN	B
was	O	AUX	O
only	O	ADV	O
evident	O	ADJ	O
during	O	ADP	O
pressure-limited	O	ADJ	B
NPPV	O	NOUN	B
,	O	PUNCT	O
since	O	SCONJ	O
inspiratory	B-OUT	ADJ	B
volumes	I-OUT	NOUN	B
delivered	I-OUT	VERB	O
by	I-OUT	ADP	O
the	I-OUT	DET	O
ventilator	I-OUT	NOUN	B
increased	O	VERB	B
from	O	ADP	O
726+/-129	O	PROPN	O
(	O	PUNCT	O
setting	O	VERB	B
I	O	PRON	I
)	O	PUNCT	O
to	O	PART	O
1104+/-164	O	NOUN	O
(	O	PUNCT	O
setting	O	VERB	B
II	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
1257+/-166	O	NOUN	O
(	O	PUNCT	O
setting	O	VERB	O
III	O	NUM	O
)	O	PUNCT	O
ml	O	NOUN	O
during	O	ADP	O
pressure-limited	O	ADJ	B
NPPV	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
all	O	DET	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
they	O	PRON	O
remained	O	VERB	O
stable	O	ADJ	B
during	O	ADP	O
volume-limited	O	ADJ	B
NPPV	O	NOUN	I
.	O	PUNCT	O


Leak	O	ADJ	B
compensation	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
leakage-induced	B-OUT	ADJ	B
dyspnea	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
83	O	NUM	O
%	O	NOUN	O
/87	O	PUNCT	O
%	O	NOUN	O
(	O	PUNCT	O
setting	O	VERB	O
II/III	O	ADJ	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
additionally-delivered	O	ADJ	B
inspiratory	O	ADJ	I
volume	O	NOUN	I
during	O	ADP	O
pressure-limited	O	ADJ	B
NPPV	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
lost	O	VERB	O
via	O	ADP	O
leakage	O	NOUN	B
.	O	PUNCT	O


Expiratory	B-OUT	ADJ	B
volume	I-OUT	NOUN	I
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
setting	O	VERB	B
II	O	NUM	I
compared	O	VERB	O
to	O	PART	O
setting	O	VERB	O
III	O	NUM	O
(	O	PUNCT	O
both	O	CCONJ	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
indicating	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
significant	O	ADJ	B
expiratory	O	ADJ	B
leakage	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
attempt	O	NOUN	B
at	O	ADP	O
leak	O	NOUN	B
compensation	O	NOUN	B
largely	O	ADV	O
feeds	O	VERB	B
the	O	DET	O
leakage	O	NOUN	B
itself	O	PRON	O
and	O	CCONJ	O
only	O	ADV	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
marginal	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
tidal	O	ADJ	B
volume	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
pressure-limited	O	ADJ	B
--	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
volume-limited	O	VERB	B
--	O	PUNCT	O
NPPV	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
clinically-important	O	ADJ	B
leak	O	NOUN	I
compensation	O	NOUN	I
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


TRIAL	O	NOUN	B
REGISTRATION	O	NOUN	I
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html	O	NOUN	O
Identifier	O	NOUN	O
:	O	PUNCT	O
UKF001272	O	PROPN	O
.	O	PUNCT	O


Low-dose	B-I	ADJ	B
prednisolone	I-I	NOUN	B
treatment	I-I	NOUN	B
of	O	ADP	O
early	B-P	ADJ	B
rheumatoid	I-P	ADJ	B
arthritis	I-P	NOUN	I
and	O	CCONJ	O
late	B-OUT	ADJ	O
cardiovascular	I-OUT	ADJ	B
outcome	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
10-year	O	ADJ	O
follow-up	O	NOUN	B
of	O	ADP	O
a	O	DET	O
2-year	O	ADJ	O
randomised	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
examine	O	VERB	O
the	O	DET	O
long-term	B-OUT	ADJ	B
effects	I-OUT	NOUN	B
of	O	ADP	O
early	O	ADJ	O
low-dose	O	ADJ	B
prednisolone	B-I	NOUN	B
use	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
rheumatoid	I-P	ADJ	B
arthritis	I-P	NOUN	I
(	I-P	PUNCT	O
RA	I-P	NOUN	B
)	I-P	PUNCT	O
on	I-P	ADP	O
cardiovascular	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
CV	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
morbidity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


DESIGN	O	NOUN	O
Retrieval	O	NOUN	B
of	O	ADP	O
data	O	NOUN	B
from	O	ADP	O
a	O	DET	O
2-year	O	ADJ	O
open	O	ADJ	B
randomised	O	ADJ	I
trial	O	NOUN	I
comparing	O	VERB	O
prednisolone	B-I	NOUN	B
7.5	O	NUM	O
mg/day	O	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
disease-modifying	B-I	ADJ	B
antirheumatic	I-I	ADJ	I
drugs	I-I	NOUN	I
(	I-I	PUNCT	O
DMARDs	I-I	NOUN	B
)	I-I	PUNCT	O
with	I-I	ADP	O
DMARD	I-I	NOUN	B
therapy	I-I	NOUN	I
alone	O	ADV	O
.	O	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
for	O	ADP	O
10	O	NUM	O
years	O	NOUN	B
since	O	SCONJ	O
inclusion	O	NOUN	B
into	O	ADP	O
the	O	DET	O
original	O	ADJ	B
prednisolone	B-I	NOUN	B
trial	O	NOUN	B
or	O	CCONJ	O
until	O	ADP	O
occurrence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
studied	O	VERB	O
outcomes	O	NOUN	B
.	O	PUNCT	O


SETTING	O	VERB	O
Secondary	O	ADJ	B
level	O	NOUN	I
of	O	ADP	I
care	O	NOUN	I
;	O	PUNCT	O
six	B-P	NUM	O
participating	I-P	VERB	O
centres	I-P	NOUN	B
from	I-P	ADP	O
southern	I-P	ADJ	B
Sweden	I-P	PROPN	I
;	I-P	PUNCT	O
both	I-P	CCONJ	O
urban	I-P	ADJ	B
and	I-P	CCONJ	O
rural	I-P	ADJ	B
populations	I-P	NOUN	I
.	I-P	PUNCT	O


PARTICIPANTS	O	NOUN	B
Overall	O	ADV	O
,	O	PUNCT	O
223	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
early	I-P	ADJ	O
RA	I-P	NOUN	B
were	O	AUX	O
included	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
participants	B-P	NOUN	B
had	I-P	AUX	O
no	I-P	DET	B
history	I-P	NOUN	I
of	I-P	ADP	O
CV	I-OUT	NOUN	B
events	I-OUT	NOUN	I
at	I-P	ADP	O
baseline	I-P	NOUN	B
and	O	CCONJ	O
incident	O	NOUN	B
cases	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
via	O	ADP	O
the	O	DET	O
Swedish	O	PROPN	B
Hospital	O	PROPN	I
Discharge	O	PROPN	I
and	O	CCONJ	O
Cause	O	PROPN	B
of	O	ADP	O
Death	O	PROPN	O
Registries	O	PROPN	B
.	O	PUNCT	O


OUTCOMES	O	VERB	O
Composite	B-OUT	ADJ	B
CV	I-OUT	NOUN	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
that	I-OUT	ADV	O
is	I-OUT	ADV	O
,	I-OUT	PUNCT	O
ischaemic	I-OUT	ADJ	B
coronary	I-OUT	ADJ	I
and	I-OUT	CCONJ	O
cerebrovascular	I-OUT	NOUN	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
components	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
composite	I-OUT	ADJ	B
CV	I-OUT	NOUN	B
outcome	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
death	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Relative	B-OUT	ADJ	O
HRs	I-OUT	NOUN	B
from	I-OUT	ADP	O
Cox	I-OUT	NOUN	B
proportional-hazards	I-OUT	X	I
regression	I-OUT	NOUN	I
models	I-OUT	NOUN	I
were	O	AUX	O
calculated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Within	O	ADP	O
2041	O	NUM	O
person-years	O	NOUN	O
,	O	PUNCT	O
17	O	NUM	O
incident	O	NOUN	B
composite	B-OUT	ADJ	B
CV	I-OUT	NOUN	B
events	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
112	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
randomised	O	VERB	B
to	O	PART	O
prednisolone	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
events	O	NOUN	B
of	O	ADP	O
111	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
who	O	PRON	O
were	O	AUX	O
assigned	O	VERB	O
not	O	PART	O
to	O	PART	O
receive	O	VERB	O
prednisolone	B-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
nine	O	NUM	O
deaths	B-OUT	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
age-adjusted	B-OUT	ADJ	O
relative	I-OUT	ADJ	O
hazards	I-OUT	NOUN	O
(	O	PUNCT	O
HRs	O	NOUN	B
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
composite	B-OUT	ADJ	B
CV	I-OUT	NOUN	B
event	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
first	I-OUT	ADJ	O
coronary	I-OUT	ADJ	B
event	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
death	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
prednisolone	B-I	NOUN	B
group	O	NOUN	B
versus	O	CCONJ	O
the	O	DET	O
group	O	NOUN	B
not	O	PART	O
treated	O	VERB	B
with	O	ADP	I
prednisolone	B-I	NOUN	B
were	O	AUX	O
1.8	O	NUM	O
(	O	PUNCT	O
0.9	O	NUM	O
to	O	PART	O
3.6	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
0.98	O	NUM	O
(	O	PUNCT	O
0.4	O	NUM	O
to	O	PART	O
2.6	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
1.6	O	NUM	O
(	O	PUNCT	O
0.6	O	NUM	O
to	O	PART	O
4.1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
risk	B-OUT	NOUN	B
for	I-OUT	ADP	O
the	I-OUT	DET	O
first	I-OUT	ADJ	O
cerebrovascular	I-OUT	ADJ	B
event	I-OUT	NOUN	O
showed	O	VERB	O
a	O	DET	O
3.7-fold	O	ADJ	O
increased	O	VERB	B
relative	O	ADJ	O
hazard	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1.2	O	NUM	O
to	O	PART	O
11.4	O	NUM	O
)	O	PUNCT	O
among	O	ADP	O
prednisolone	B-I	NOUN	B
treated	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
inception	O	NOUN	O
cohort	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
low-dose	O	ADJ	B
prednisolone	B-I	NOUN	B
use	O	NOUN	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
RA	O	NOUN	B
disease	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
ischaemic	I-OUT	ADJ	B
coronary	I-OUT	ADJ	I
artery	I-OUT	NOUN	I
events	I-OUT	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
long-term	B-OUT	ADJ	B
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
ischaemic	I-OUT	ADJ	B
cerebrovascular	I-OUT	NOUN	I
events	I-OUT	NOUN	I
was	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
prednisolone	B-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
towards	O	ADP	O
reduced	B-OUT	VERB	B
survival	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
prednisolone	B-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
NUMBER	O	X	B
ISRCTN20612367	O	NOUN	B
.	O	PUNCT	O


Spatial	B-I	ADJ	B
orientation	I-I	NOUN	B
adjustments	I-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
in	I-P	ADP	O
Hong	I-P	PROPN	O
Kong	I-P	PROPN	O
.	I-P	PUNCT	O


Abnormal	O	ADJ	B
spatial	B-OUT	ADJ	O
orientation	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
body	I-OUT	NOUN	B
postures	I-OUT	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
often	O	ADV	O
interfere	O	VERB	B
with	O	ADP	I
visual	O	ADJ	B
abilities	O	NOUN	O
to	O	PART	O
attend	O	VERB	B
tasks	O	NOUN	B
and	O	CCONJ	O
social	O	ADJ	B
interactions	O	NOUN	I
.	O	PUNCT	O


Twenty-four	B-P	NUM	O
children	I-P	NOUN	B
diagnosed	I-P	VERB	B
with	I-P	ADP	O
autism	I-P	NOUN	B
from	I-P	ADP	O
Kowloon	I-P	PROPN	B
,	I-P	PUNCT	O
Hong	I-P	PROPN	O
Kong	I-P	PROPN	O
were	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
spatial	B-OUT	ADJ	B
orientation	I-OUT	NOUN	B
and	O	CCONJ	O
spatial	B-OUT	ADJ	B
management	I-OUT	NOUN	I
abilities	O	NOUN	B
.	O	PUNCT	O


Positive	B-OUT	ADJ	B
changes	I-OUT	NOUN	B
in	O	ADP	O
spatial	B-OUT	ADJ	B
orientation	I-OUT	NOUN	I
were	O	AUX	O
evident	O	ADJ	O
when	O	SCONJ	O
the	O	DET	O
children	O	NOUN	B
wore	B-I	VERB	O
ambient	I-I	ADJ	B
prism	I-I	NOUN	O
lenses	I-I	NOUN	O
and	O	CCONJ	O
included	O	VERB	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
posture	I-OUT	NOUN	B
from	O	ADP	O
slanted	O	ADJ	O
to	O	PART	O
erect	O	VERB	B
.	O	PUNCT	O


Adjustments	O	NOUN	B
in	O	ADP	O
spatial	B-OUT	ADJ	B
management	I-OUT	NOUN	I
were	O	AUX	O
evident	O	ADJ	O
in	O	ADP	O
improved	O	VERB	B
ball	O	NOUN	B
catching	B-OUT	NOUN	O
ability	I-OUT	NOUN	B
,	O	PUNCT	O
a	O	DET	O
task	O	NOUN	B
requiring	O	VERB	O
visual	O	ADJ	B
tracking	O	NOUN	O
and	O	CCONJ	O
eye-hand	O	ADJ	B
coordination	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
alterations	B-I	NOUN	B
to	I-I	PART	O
the	I-I	DET	O
sensory	I-I	ADJ	B
systems	I-I	NOUN	I
may	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
behavioral	O	ADJ	B
change	O	NOUN	O
in	O	ADP	O
some	O	DET	O
children	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
large	O	ADJ	O
preoperative	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
erythropoietin	B-I	NOUN	B
do	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
the	O	DET	O
systemic	B-P	ADJ	B
inflammatory	I-P	ADJ	B
response	I-P	NOUN	I
to	I-P	ADP	O
cardiac	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVES	O	NOUN	O
Cardiac	O	ADJ	B
surgery	O	NOUN	I
and	O	CCONJ	O
cardiopulmonary	O	NOUN	B
bypass	O	NOUN	I
(	O	PUNCT	O
CPB	O	NOUN	B
)	O	PUNCT	O
induce	O	VERB	B
an	O	DET	O
inflammatory	O	ADJ	B
reaction	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
tissue	O	NOUN	B
injury	O	NOUN	I
.	O	PUNCT	O


Experimental	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
recombinant	B-I	ADJ	B
human	I-I	ADJ	O
erythropoietin	I-I	NOUN	O
(	I-I	PUNCT	O
EPO	I-I	NOUN	B
)	I-I	PUNCT	O
independent	O	ADJ	O
of	O	ADP	O
its	O	PRON	O
erythropoietic	O	ADJ	B
effect	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
clinically	O	ADV	B
as	O	ADP	O
an	O	DET	O
anti-inflammatory	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
2	O	NUM	O
large	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
EPO	B-I	NOUN	B
administered	O	VERB	B
shortly	O	ADV	O
before	O	ADP	O
CPB	O	NOUN	B
ameliorate	O	VERB	B
the	O	DET	O
systemic	O	ADJ	B
inflammatory	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
CPB	O	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
AND	O	CCONJ	O
SETTING	O	VERB	B
A	O	DET	I
prospective	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
and	O	CCONJ	O
randomized	O	ADJ	B
study	O	NOUN	I
at	O	ADP	O
a	O	DET	O
single	O	ADJ	O
tertiary	O	ADJ	B
care	O	NOUN	I
hospital	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	NOUN	B
Patients	B-P	NOUN	B
scheduled	I-P	VERB	O
for	I-P	ADP	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
bypass	I-P	NOUN	I
graft	I-P	NOUN	I
surgery	I-P	NOUN	I
with	I-P	ADP	O
CPB	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
EPO	B-I	NOUN	B
(	I-I	PUNCT	O
epoetin	I-I	NOUN	B
alfa	I-I	NOUN	I
,	O	PUNCT	O
500	O	NUM	O
IU/kg	O	NOUN	O
intravenously	O	ADV	B
,	O	PUNCT	O
n	B-P	NOUN	O
=	I-P	ADJ	O
22	I-P	NUM	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
21	I-P	NUM	O
)	I-P	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
12	O	NUM	O
to	O	PART	O
18	O	NUM	O
hours	O	NOUN	B
preoperatively	O	ADV	B
and	O	CCONJ	O
again	O	ADV	O
at	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
anesthesia	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
MAIN	O	NOUN	O
RESULTS	O	NOUN	O
CPB	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
greatly	O	ADV	O
increased	O	VERB	B
plasma	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
of	I-OUT	ADP	O
tumor	I-OUT	NOUN	B
necrosis	I-OUT	NOUN	I
factor	I-OUT	NOUN	I
alpha	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
TNF-alpha	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
interleukin	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
IL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
-1beta	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
IL-1beta	I-OUT	NOUN	B
receptor	I-OUT	NOUN	I
antagonist	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
IL-6	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
IL-10	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
N-terminal	I-OUT	ADJ	B
probrain	I-OUT	NOUN	I
natriuretic	I-OUT	ADJ	I
peptide	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
NT-proBNP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
,	I-I	PUNCT	O
EPO	I-I	NOUN	B
at	O	ADP	O
day	O	NOUN	B
3	O	NUM	O
after	O	ADP	O
CPB	O	NOUN	B
augmented	O	VERB	B
the	O	DET	O
TNF-alpha	B-OUT	NOUN	B
response	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
2	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
CPB	O	NOUN	B
increased	O	VERB	B
NT-proBNP	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
EPO	B-I	NOUN	B
tended	O	VERB	O
to	O	PART	O
enhance	O	VERB	B
the	O	DET	O
CPB-induced	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
IL-1beta	B-OUT	NOUN	B
receptor	I-OUT	NOUN	I
antagonist	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.057	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Otherwise	O	ADV	O
,	O	PUNCT	O
EPO	B-I	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
pro-	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
antiinflammatory	I-OUT	ADJ	B
mediators	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Two	O	NUM	O
large	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
EPO	B-I	NOUN	B
given	O	VERB	O
shortly	O	ADV	O
before	O	ADP	O
CPB	O	NOUN	B
do	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
perioperative	B-OUT	ADJ	B
release	I-OUT	NOUN	B
of	I-OUT	ADP	O
inflammatory	I-OUT	ADJ	B
cytokines	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
EPO	B-I	NOUN	B
may	O	AUX	O
augment	O	VERB	O
the	O	DET	O
TNF-alpha	O	NOUN	B
and	O	CCONJ	O
NT-proBNP	O	NOUN	B
response	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
long-term	O	ADJ	B
clinical	O	ADJ	B
impact	O	NOUN	I
remains	O	VERB	O
unknown	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
findings	O	NOUN	B
do	O	AUX	O
not	O	PART	O
support	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
EPO	B-I	NOUN	B
as	O	ADP	O
an	O	DET	O
anti-inflammatory	O	ADJ	B
drug	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
cardiac	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


Using	O	VERB	O
the	O	DET	O
virtual	B-I	ADJ	B
reality-cognitive	I-I	ADJ	I
rehabilitation	I-I	NOUN	I
approach	O	NOUN	I
to	O	PART	O
improve	O	VERB	B
contextual	B-OUT	ADJ	B
processing	I-OUT	NOUN	I
in	I-OUT	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
This	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
investigated	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	B-I	ADJ	B
virtual	I-I	ADJ	B
reality-cognitive	I-I	ADJ	I
rehabilitation	I-I	NOUN	I
(	I-I	PUNCT	O
VR-CR	I-I	NOUN	B
)	I-I	PUNCT	O
intervention	I-I	NOUN	B
to	O	PART	O
improve	O	VERB	B
contextual	B-OUT	ADJ	B
processing	I-OUT	NOUN	I
of	O	ADP	O
objects	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Previous	O	ADJ	O
research	O	NOUN	B
supports	O	VERB	O
that	O	SCONJ	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
show	O	VERB	O
deficits	O	NOUN	B
in	O	ADP	O
contextual	B-OUT	ADJ	B
processing	I-OUT	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
deficits	O	NOUN	B
in	O	ADP	O
its	O	PRON	O
elementary	O	ADJ	B
components	O	NOUN	B
:	O	PUNCT	O
abstraction	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
cognitive	I-OUT	ADJ	B
flexibility	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


METHODS	O	VERB	O
Four	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
participated	O	VERB	O
in	O	ADP	O
a	O	DET	O
multiple-baseline	O	ADJ	B
,	O	PUNCT	O
single-subject	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
children	B-P	NOUN	B
were	O	AUX	O
taught	O	VERB	O
how	O	SCONJ	O
to	O	PART	O
see	O	VERB	O
objects	O	NOUN	B
in	O	ADP	O
context	O	NOUN	B
by	O	ADP	O
reinforcing	O	VERB	O
attention	O	NOUN	O
to	O	ADP	O
pivotal	O	ADJ	O
contextual	O	ADJ	B
information	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
All	O	DET	O
children	B-P	NOUN	B
demonstrated	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
improvements	O	NOUN	B
in	O	ADP	O
contextual	B-OUT	ADJ	B
processing	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
cognitive	I-OUT	ADJ	B
flexibility	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Mixed	O	ADJ	B
results	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
on	O	ADP	O
the	O	DET	O
control	O	ADJ	B
test	O	NOUN	I
and	O	CCONJ	O
changes	O	NOUN	B
in	O	ADP	O
context-related	B-OUT	ADJ	B
behaviours	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Larger-scale	O	ADJ	B
studies	O	NOUN	I
are	O	AUX	O
warranted	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
and	O	CCONJ	O
usability	O	NOUN	B
in	O	ADP	O
comprehensive	O	ADJ	B
educational	O	ADJ	B
programs	O	NOUN	I
.	O	PUNCT	O


Multi-institutional	O	ADJ	B
randomized	O	ADJ	I
phase	O	NOUN	I
II	O	NUM	I
trial	O	NOUN	I
of	O	ADP	O
the	O	DET	O
epothilone	B-I	NOUN	B
B	I-I	NOUN	I
analog	I-I	NOUN	I
ixabepilone	I-I	NOUN	I
(	I-I	PUNCT	O
BMS-247550	I-I	NOUN	B
)	I-I	PUNCT	O
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
estramustine	I-I	NOUN	B
phosphate	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
progressive	I-P	ADJ	B
castrate	I-P	ADJ	B
metastatic	I-P	ADJ	O
prostate	I-P	NOUN	O
cancer	I-P	NOUN	O
.	I-P	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
antitumor	B-OUT	NOUN	B
activity	I-OUT	NOUN	I
and	O	CCONJ	O
safety	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
epothilone	B-I	NOUN	B
B	I-I	NOUN	I
analog	I-I	NOUN	I
,	I-I	PUNCT	O
ixabepilone	I-I	NOUN	B
,	I-I	PUNCT	O
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
estramustine	I-I	NOUN	B
phosphate	I-I	NOUN	I
(	I-I	PUNCT	O
EMP	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
chemotherapy-naive	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
progressive	I-P	ADJ	B
castrate	I-P	ADJ	B
metastatic	I-P	ADJ	O
prostate	I-P	NOUN	O
cancer	I-P	NOUN	O
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
ixabepilone	B-I	NOUN	B
(	O	PUNCT	O
35	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
by	O	ADP	O
intravenous	B-I	ADJ	B
infusion	I-I	NOUN	I
every	I-I	DET	O
3	I-I	NUM	O
weeks	I-I	NOUN	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
EMP	I-I	NOUN	B
280	I-I	NUM	O
mg	I-I	NOUN	O
orally	I-I	ADV	B
three	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
to	O	PART	O
5	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
Between	B-P	ADP	O
December	I-P	PROPN	O
2001	I-P	NUM	O
and	I-P	CCONJ	O
October	I-P	PROPN	O
2003	I-P	NUM	O
,	I-P	PUNCT	O
92	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
and	I-P	CCONJ	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	O	PART	O
treatment	B-P	NOUN	B
with	I-P	ADP	O
ixabepilone	I-I	NOUN	B
alone	I-I	ADV	O
(	I-P	PUNCT	O
45	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
in	I-P	ADP	O
combination	I-I	NOUN	B
with	I-I	ADP	O
EMP	I-I	NOUN	B
(	I-P	PUNCT	O
47	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Grades	B-OUT	NOUN	B
3	I-OUT	NUM	O
and	I-OUT	CCONJ	O
4	I-OUT	NUM	O
toxicities	I-OUT	NOUN	B
experienced	O	VERB	O
by	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
included	O	VERB	O
neutropenia	B-OUT	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
fatigue	B-OUT	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
neuropathy	B-OUT	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
ixabepilone	B-OUT	ADJ	B
arm	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
neutropenia	I-OUT	NOUN	B
(	O	PUNCT	O
29	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
febrile	B-OUT	ADJ	B
neutropenia	I-OUT	NOUN	I
(	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
fatigue	B-OUT	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
neuropathy	B-OUT	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
thrombosis	B-OUT	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
ixabepilone	O	NOUN	B
+	O	CCONJ	O
EMP	O	NOUN	B
arm	O	NOUN	B
.	O	PUNCT	O


Post-treatment	O	ADJ	B
declines	O	NOUN	B
in	O	ADP	O
prostate-specific	B-OUT	ADJ	B
antigen	I-OUT	NOUN	I
of	O	ADP	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
50	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
21	O	NUM	O
of	O	ADP	O
44	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
33	O	NUM	O
%	O	NOUN	O
to	O	PART	O
64	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
ixabepilone	O	ADJ	B
arm	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
31	O	NUM	O
of	O	ADP	O
45	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
69	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
55	O	NUM	O
%	O	NOUN	O
to	O	PART	O
82	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
ixabepilone	O	NOUN	B
+	O	CCONJ	O
EMP	O	NOUN	B
arm	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
measurable	O	ADJ	O
disease	O	NOUN	B
,	O	PUNCT	O
partial	B-OUT	ADJ	B
responses	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
eight	O	NUM	O
of	O	ADP	O
25	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
32	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
to	O	PART	O
50	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
ixabepilone	O	ADJ	B
arm	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
11	O	NUM	O
of	O	ADP	O
23	O	NUM	O
(	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
27	O	NUM	O
%	O	NOUN	O
to	O	PART	O
68	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
ixabepilone	O	NOUN	B
+	O	CCONJ	O
EMP	O	NOUN	B
arm	O	NOUN	B
.	O	PUNCT	O


Time	B-OUT	NOUN	B
to	I-OUT	PART	O
prostate-specific	I-OUT	ADJ	B
antigen	I-OUT	NOUN	I
progression	I-OUT	NOUN	B
was	O	AUX	O
4.4	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
3.1	O	NUM	O
to	O	PART	O
6.9	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
ixabepilone-alone	O	ADJ	B
arm	O	NOUN	I
and	O	CCONJ	O
5.2	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
4.5	O	NUM	O
to	O	PART	O
6.8	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
arm	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Ixabepilone	B-I	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
estramustine	B-I	NOUN	B
phosphate	I-I	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	O	CCONJ	O
has	O	AUX	O
antitumor	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
castrate	I-P	ADJ	B
metastatic	I-P	ADJ	O
prostate	I-P	NOUN	O
cancer	I-P	NOUN	O
.	I-P	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
randomized	O	ADJ	B
clinical	O	ADJ	I
evaluation	O	NOUN	I
of	O	ADP	O
enamel	B-I	NOUN	B
matrix	I-I	NOUN	I
derivative	I-I	ADJ	I
proteins	I-I	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
proximal	O	ADJ	B
class-II	O	ADJ	B
furcation	O	NOUN	I
involvements	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
clinical	B-OUT	ADJ	B
response	I-OUT	NOUN	I
of	O	ADP	O
proximal	O	ADJ	B
furcations	O	NOUN	O
treated	O	VERB	B
with	O	ADP	I
enamel	B-I	NOUN	B
matrix	I-I	NOUN	I
derivative	I-I	ADJ	I
proteins	I-I	NOUN	I
(	I-I	PUNCT	O
EMD	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Fifteen	B-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
each	I-P	DET	O
with	I-P	ADP	O
a	I-P	DET	O
pair	I-P	NOUN	B
of	I-P	ADP	O
contralateral	I-P	ADJ	B
class-II	I-P	ADJ	B
proximal	I-P	ADJ	I
furcation	I-P	NOUN	O
involvements	I-P	NOUN	B
,	I-P	PUNCT	O
presenting	I-P	VERB	O
probing	I-P	NOUN	B
depths	I-P	NOUN	I
(	I-P	PUNCT	O
PDs	I-P	NOUN	B
)	I-P	PUNCT	O
>	I-P	X	O
/=5	I-P	PROPN	O
mm	I-P	PROPN	O
and	I-P	CCONJ	O
bleeding	I-P	NOUN	B
on	I-P	ADP	O
probing	I-P	VERB	O
(	I-P	PUNCT	O
BOP	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
selected	I-P	VERB	O
.	I-P	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
:	O	PUNCT	O
control	B-I	ADJ	B
group	I-I	NOUN	I
(	O	PUNCT	O
n=15	O	ADJ	O
)	O	PUNCT	O
-	O	PUNCT	O
open	B-I	ADJ	B
flap	I-I	NOUN	I
debridement	I-I	NOUN	I
(	I-I	PUNCT	O
OFD	I-I	NOUN	B
)	I-I	PUNCT	O
+24	I-I	NUM	O
%	I-I	NOUN	O
ethylenediaminetetraacetic	I-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
EDTA	I-I	NOUN	B
)	I-I	PUNCT	O
conditioning	I-I	NOUN	O
;	I-I	PUNCT	O
test	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
n=15	O	ADJ	O
)	O	PUNCT	O
-	O	PUNCT	O
OFD+24	B-I	NUM	B
%	I-I	NOUN	O
EDTA	I-I	NOUN	B
conditioning+EMD	I-I	NOUN	O
application	I-I	NOUN	B
.	I-I	PUNCT	O


Plaque	B-OUT	NOUN	B
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
BOP	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
PD	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
gingival	I-OUT	ADJ	B
margin	I-OUT	NOUN	I
position	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GMP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
relative	I-OUT	ADJ	B
vertical	I-OUT	ADJ	I
and	I-OUT	CCONJ	O
horizontal	I-OUT	ADJ	B
clinical	I-OUT	ADJ	B
attachment	I-OUT	NOUN	I
level	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RVCAL	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
RHCAL	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
vertical	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
horizontal	I-OUT	ADJ	B
bone	I-OUT	NOUN	O
level	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
VBL	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
HBL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
furcation	I-OUT	NOUN	B
closure	I-OUT	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
immediately	O	ADV	O
before	O	ADV	O
and	O	CCONJ	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
surgeries	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
RVCAL	B-OUT	PROPN	B
gains	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
and	O	CCONJ	O
test	O	NOUN	B
group	O	NOUN	I
were	O	AUX	O
0.39	O	NUM	O
+/-	O	CCONJ	O
1.00	O	NUM	O
and	O	CCONJ	O
0.54	O	NUM	O
+/-	O	CCONJ	O
0.95	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
RHCAL	B-OUT	PROPN	B
gains	O	NOUN	B
were	O	AUX	O
1.21	O	NUM	O
+/-	O	CCONJ	O
2.28	O	NUM	O
and	O	CCONJ	O
1.36	O	NUM	O
+/-	O	CCONJ	O
1.26	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
VBL	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
HBL	I-OUT	NOUN	B
gains	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
were	O	AUX	O
1.04	O	NUM	O
+/-	O	CCONJ	O
1.12	O	NUM	O
and	O	CCONJ	O
1.00	O	NUM	O
+/-	O	CCONJ	O
1.79	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
0.82	O	NUM	O
+/-	O	CCONJ	O
1.82	O	NUM	O
and	O	CCONJ	O
1.17	O	NUM	O
+/-	O	CCONJ	O
1.38	O	NUM	O
mm	O	NOUN	O
for	O	ADP	O
the	O	DET	O
test	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
statistical	O	ADJ	B
difference	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
remaining	I-OUT	VERB	O
class-II	I-OUT	ADJ	B
furcations	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
test	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
this	O	DET	O
period	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
It	O	PRON	O
may	O	AUX	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
EMD	B-I	PROPN	B
in	O	ADP	O
proximal	O	ADJ	B
furcations	O	NOUN	I
did	O	AUX	O
not	O	PART	O
promote	O	VERB	O
a	O	DET	O
superior	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
PD	B-OUT	NOUN	B
or	O	CCONJ	O
a	O	DET	O
gain	O	NOUN	B
in	O	ADP	O
clinical	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
osseous	I-OUT	ADJ	B
attachment	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
higher	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
class-II	B-OUT	NOUN	B
to	I-OUT	PART	O
class-I	I-OUT	NOUN	B
furcation	I-OUT	NOUN	B
conversion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Whole-body	B-I	ADJ	B
CT	I-I	NOUN	B
screening	I-I	NOUN	B
:	I-I	PUNCT	O
scan	I-I	ADJ	B
delay	I-I	NOUN	I
and	I-I	CCONJ	O
contrast	I-I	NOUN	B
injection	I-I	NOUN	I
duration	O	NOUN	I
for	O	ADP	O
optimal	B-OUT	ADJ	B
enhancement	I-OUT	NOUN	B
of	I-OUT	ADP	O
abdominal	I-OUT	ADJ	B
organs	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
deep	I-OUT	ADJ	B
vessels	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
optimal	O	ADJ	B
scan	O	NOUN	B
delays	O	NOUN	B
and	O	CCONJ	O
contrast	O	NOUN	B
injection	O	NOUN	I
durations	O	NOUN	B
for	O	ADP	O
contrast-enhanced	B-I	ADJ	B
whole-body	I-I	ADJ	O
computed	I-I	ADJ	O
tomography	I-I	NOUN	O
(	I-I	PUNCT	O
CT	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
forty-two	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
protocol	B-I	NOUN	B
A-scan	I-I	ADJ	B
delay	I-I	NOUN	I
of	I-I	ADP	O
65	I-I	NUM	O
s	I-I	NOUN	O
after	I-I	ADP	O
starting	I-I	VERB	O
contrast	I-I	NOUN	O
injection	I-I	NOUN	B
over	I-I	ADP	O
30	I-I	NUM	O
s	I-I	NOUN	O
;	I-I	PUNCT	O
protocol	I-I	NOUN	B
B-105	I-I	NOUN	B
and	I-I	CCONJ	O
70	I-I	NUM	O
s	I-I	NOUN	O
;	I-I	PUNCT	O
and	I-I	CCONJ	O
protocol	I-I	NOUN	B
C-145	I-I	NOUN	B
and	I-I	CCONJ	O
110	I-I	NUM	O
s	I-I	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Contrast	B-OUT	NOUN	B
enhancement	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
diagnostic	I-OUT	ADJ	B
acceptability	I-OUT	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Qualitative	B-OUT	ADJ	B
assessment	I-OUT	NOUN	I
was	O	AUX	O
subtle	O	ADJ	O
among	O	ADP	O
the	O	DET	O
three	O	NUM	O
protocols	O	NOUN	B
.	O	PUNCT	O


Homogenous	B-OUT	ADJ	B
enhancement	I-OUT	NOUN	B
of	I-OUT	ADP	O
deep	I-OUT	ADJ	B
veins	I-OUT	NOUN	I
was	O	AUX	O
more	O	ADV	O
assuredly	O	ADV	O
achieved	O	VERB	O
with	O	ADP	O
protocol	O	NOUN	B
C.	O	X	B
CONCLUSION	O	NOUN	I
With	O	ADP	O
protocol	B-I	NOUN	B
C	I-I	NOUN	I
,	O	PUNCT	O
qualitatively	O	ADV	B
acceptable	O	ADJ	O
enhancement	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
whole-body	B-I	ADJ	B
CT	I-I	NOUN	B
.	I-I	PUNCT	O


Use	O	PROPN	O
of	O	ADP	O
a	O	DET	O
clay	B-I	NOUN	B
modeling	I-I	NOUN	O
task	I-I	NOUN	O
to	O	PART	O
reduce	O	VERB	B
chocolate	B-OUT	NOUN	B
craving	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Elaborated	O	ADJ	B
Intrusion	O	PROPN	I
theory	O	NOUN	I
(	O	PUNCT	O
EI	O	NOUN	B
theory	O	NOUN	I
;	O	PUNCT	O
Kavanagh	O	PROPN	B
,	O	PUNCT	O
Andrade	O	PROPN	O
,	O	PUNCT	O
&	O	CCONJ	O
May	O	PROPN	O
,	O	PUNCT	O
2005	O	NUM	O
)	O	PUNCT	O
posits	O	VERB	O
two	O	NUM	O
main	O	ADJ	O
cognitive	O	ADJ	B
components	O	NOUN	I
in	O	ADP	O
craving	B-OUT	NOUN	B
:	I-OUT	PUNCT	O
associative	O	NOUN	B
processes	O	NOUN	I
that	O	PRON	O
lead	O	VERB	O
to	O	ADP	O
intrusive	O	ADJ	B
thoughts	O	NOUN	B
about	O	ADP	O
the	O	DET	O
craved	O	VERB	B
substance	O	NOUN	I
or	O	CCONJ	O
activity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
elaborative	O	ADJ	B
processes	O	NOUN	B
supporting	O	VERB	O
mental	O	ADJ	B
imagery	O	NOUN	I
of	O	ADP	O
the	O	DET	O
substance	O	NOUN	B
or	O	CCONJ	O
activity	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
a	O	DET	O
novel	B-I	ADJ	O
visuospatial	I-I	ADJ	B
task	I-I	NOUN	I
to	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
visual	O	ADJ	B
imagery	O	NOUN	I
plays	O	VERB	O
a	O	DET	O
key	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
craving	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Experiment	O	NOUN	B
1	O	NUM	O
showed	O	VERB	O
that	O	SCONJ	O
spending	O	NOUN	B
10	O	NUM	O
min	O	NOUN	O
constructing	B-I	VERB	B
shapes	I-I	NOUN	B
from	I-I	ADP	O
modeling	I-I	VERB	B
clay	I-I	NOUN	I
(	I-I	PUNCT	O
plasticine	I-I	NOUN	B
)	I-I	PUNCT	O
reduced	O	VERB	B
participants	B-P	NOUN	B
'	I-P	PART	O
craving	I-OUT	NOUN	B
for	I-OUT	ADP	O
chocolate	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
spending	O	NOUN	B
10	O	NUM	O
min	O	NOUN	O
'letting	B-I	VERB	B
your	I-I	PRON	O
mind	I-I	NOUN	O
wander	I-I	NOUN	O
'	I-I	PUNCT	O
.	I-I	PUNCT	O


Increasing	O	VERB	B
the	O	DET	O
load	O	NOUN	B
on	O	ADP	O
verbal	O	ADJ	B
working	O	NOUN	I
memory	O	NOUN	I
using	O	VERB	O
a	O	DET	O
mental	O	ADJ	B
arithmetic	O	ADJ	I
task	O	NOUN	I
(	O	PUNCT	O
counting	O	VERB	O
backwards	O	NOUN	O
by	O	ADP	O
threes	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
craving	B-OUT	NOUN	B
further	O	ADV	O
.	O	PUNCT	O


Experiment	O	NOUN	B
2	O	NUM	O
compared	O	VERB	B
effects	O	NOUN	B
on	O	ADP	O
craving	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
simpler	B-I	ADJ	O
verbal	I-I	ADJ	B
task	I-I	NOUN	I
(	I-I	PUNCT	O
counting	I-I	VERB	O
by	I-I	ADP	O
ones	I-I	NOUN	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
clay	I-I	NOUN	B
modeling	I-I	NOUN	I
.	I-I	PUNCT	O


Clay	B-I	NOUN	B
modeling	I-I	NOUN	I
reduced	O	VERB	B
overall	B-OUT	ADJ	O
craving	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
and	O	CCONJ	O
strength	B-OUT	NOUN	B
of	I-OUT	ADP	O
craving	I-OUT	NOUN	B
imagery	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
the	O	DET	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
thoughts	I-OUT	NOUN	B
about	I-OUT	ADP	O
chocolate	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
EI	O	NOUN	B
theory	O	NOUN	I
,	O	PUNCT	O
showing	O	VERB	O
that	O	SCONJ	O
craving	B-OUT	NOUN	B
is	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
loading	O	VERB	B
the	O	DET	O
visuospatial	O	ADJ	B
sketchpad	O	NOUN	I
of	O	ADP	O
working	O	VERB	B
memory	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
by	O	ADP	O
loading	O	VERB	B
the	O	DET	O
phonological	O	ADJ	B
loop	O	NOUN	I
.	O	PUNCT	O


Clay	B-I	NOUN	B
modeling	I-I	NOUN	I
might	O	AUX	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
self-help	O	ADJ	B
tool	O	NOUN	I
to	O	PART	O
help	O	VERB	O
manage	O	VERB	O
craving	B-OUT	NOUN	B
for	I-P	ADP	O
chocolate	I-P	NOUN	B
,	I-P	PUNCT	O
snacks	I-P	NOUN	B
and	I-P	CCONJ	O
other	I-P	ADJ	O
foods	I-P	NOUN	B
.	I-P	PUNCT	O


Use	O	PROPN	O
of	O	ADP	O
EORTC	O	NOUN	B
target	O	NOUN	B
definition	O	NOUN	O
guidelines	O	NOUN	O
for	O	ADP	O
dose-intensified	O	ADJ	O
salvage	O	NOUN	B
radiation	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
recurrent	O	ADJ	B
prostate	O	NOUN	I
cancer	O	NOUN	I
:	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
quality	O	NOUN	B
assurance	O	NOUN	B
program	O	NOUN	I
of	O	ADP	O
the	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
SAKK	O	NOUN	I
09/10	O	NUM	O
.	O	PUNCT	O


PURPOSE	O	VERB	B
Different	O	ADJ	O
international	O	ADJ	B
target	O	NOUN	O
volume	O	NOUN	O
delineation	O	NOUN	O
guidelines	O	NOUN	O
exist	O	VERB	O
and	O	CCONJ	O
different	O	ADJ	O
treatment	O	NOUN	B
techniques	O	NOUN	O
are	O	AUX	O
available	O	ADJ	O
for	O	ADP	O
salvage	O	NOUN	B
radiation	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
RT	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
recurrent	O	ADJ	B
prostate	O	NOUN	I
cancer	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
less	O	ADV	O
is	O	AUX	O
known	O	VERB	O
regarding	O	VERB	O
their	O	PRON	O
respective	O	ADJ	O
applicability	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
MATERIALS	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
III	O	NUM	I
trial	O	NOUN	I
testing	O	VERB	O
64	B-I	NUM	O
Gy	I-I	NOUN	O
vs	I-I	CCONJ	O
70	I-I	NUM	O
Gy	I-I	NOUN	O
salvage	I-I	NOUN	B
RT	I-I	NOUN	B
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
an	O	DET	O
intense	B-I	ADJ	B
quality	I-I	NOUN	B
assurance	I-I	NOUN	B
program	I-I	NOUN	I
including	O	VERB	O
a	O	DET	O
site-specific	O	ADJ	B
and	O	CCONJ	O
study-specific	O	ADJ	O
questionnaire	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
dummy	B-I	ADJ	B
run	I-I	NOUN	I
(	I-I	PUNCT	O
DR	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Target	O	NOUN	B
volume	O	NOUN	O
delineation	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
European	O	PROPN	B
Organisation	O	PROPN	I
for	O	ADP	I
the	O	DET	I
Research	O	PROPN	I
and	O	CCONJ	I
Treatment	O	NOUN	B
of	O	ADP	O
Cancer	O	PROPN	B
guidelines	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
DR-based	O	ADJ	B
treatment	O	NOUN	I
plan	O	NOUN	I
was	O	AUX	O
established	O	VERB	O
for	O	ADP	O
70	O	NUM	O
Gy	O	NOUN	O
.	O	PUNCT	O


Major	O	ADJ	B
and	O	CCONJ	O
minor	O	ADJ	O
protocol	O	NOUN	O
deviations	O	NOUN	O
were	O	AUX	O
noted	O	VERB	O
,	O	PUNCT	O
interobserver	O	ADJ	B
agreement	O	NOUN	O
of	O	ADP	O
delineated	O	VERB	B
target	O	NOUN	B
contours	O	NOUN	O
was	O	AUX	O
assessed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
dose-volume	O	ADJ	B
histogram	O	NOUN	I
(	O	PUNCT	O
DVH	O	NOUN	B
)	O	PUNCT	O
parameters	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
treatment	O	NOUN	B
techniques	O	NOUN	O
were	O	AUX	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Thirty	B-P	NUM	O
European	I-P	ADJ	B
centers	I-P	NOUN	I
participated	I-P	VERB	O
,	I-P	PUNCT	O
43	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
which	I-P	DET	O
were	I-P	AUX	O
using	I-P	VERB	O
3-dimensional	I-I	ADJ	B
conformal	I-I	ADJ	I
RT	I-I	NOUN	I
(	I-I	PUNCT	O
3D-CRT	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-P	PUNCT	O
with	I-P	ADP	O
the	I-P	DET	O
remaining	I-P	VERB	O
centers	I-P	NOUN	B
using	I-P	VERB	O
intensity	I-I	NOUN	B
modulated	I-I	VERB	I
RT	I-I	NOUN	I
(	I-I	PUNCT	O
IMRT	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-P	CCONJ	O
volumetric	I-I	VERB	B
modulated	I-I	VERB	O
arc	I-I	NOUN	O
technique	I-I	NOUN	O
(	I-I	PUNCT	O
VMAT	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


The	O	DET	O
first	O	ADJ	O
submitted	O	VERB	O
version	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DR	O	NOUN	B
contained	O	VERB	O
major	O	ADJ	O
deviations	O	NOUN	O
in	O	ADP	O
21	O	NUM	O
of	O	ADP	O
30	O	NUM	O
(	O	PUNCT	O
70	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
centers	O	NOUN	B
,	O	PUNCT	O
mostly	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
inappropriately	O	ADV	O
defined	O	VERB	O
or	O	CCONJ	O
lack	O	NOUN	B
of	O	ADP	O
prostate	O	NOUN	B
bed	O	NOUN	I
(	O	PUNCT	O
PB	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
5	B-P	NUM	O
centers	I-P	NOUN	B
completed	I-P	VERB	B
the	I-P	DET	O
DR	I-P	NOUN	B
successfully	I-P	ADV	O
with	O	ADP	O
their	O	PRON	O
second	O	ADJ	O
submitted	O	VERB	O
version	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
interobserver	O	ADJ	B
agreement	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PB	O	NOUN	B
was	O	AUX	O
moderate	O	ADJ	B
and	O	CCONJ	O
was	O	AUX	O
improved	O	VERB	B
by	O	ADP	O
the	O	DET	O
DR	O	NOUN	B
review	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
indicated	O	VERB	O
by	O	ADP	O
an	O	DET	O
increased	O	VERB	B
κ	B-OUT	NOUN	O
value	I-OUT	NOUN	O
(	O	PUNCT	O
0.59	O	NUM	O
vs	O	CCONJ	O
0.55	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
mean	B-OUT	ADJ	B
sensitivity	I-OUT	NOUN	I
(	O	PUNCT	O
0.64	O	NUM	O
vs	O	CCONJ	O
0.58	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
volume	B-OUT	NOUN	B
of	I-OUT	ADP	O
total	I-OUT	ADJ	O
agreement	I-OUT	NOUN	O
(	O	PUNCT	O
3.9	O	NUM	O
vs	O	CCONJ	O
3.3	O	NUM	O
cm	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	B-OUT	DET	O
union	I-OUT	NOUN	B
volume	I-OUT	NOUN	B
(	O	PUNCT	O
79.3	O	NUM	O
vs	O	CCONJ	O
84.2	O	NUM	O
cm	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
.	B-OUT	PUNCT	O


Rectal	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
bladder	I-OUT	NOUN	B
wall	I-OUT	NOUN	I
DVH	I-OUT	PROPN	B
parameters	I-OUT	NOUN	B
of	I-OUT	ADP	O
IMRT	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
VMAT	I-OUT	NOUN	B
vs	I-OUT	CCONJ	O
3D-CRT	I-OUT	NOUN	B
plans	I-OUT	NOUN	I
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
interobserver	O	ADJ	B
agreement	O	NOUN	O
of	O	ADP	O
PB	O	NOUN	B
delineation	O	NOUN	B
was	O	AUX	O
moderate	O	ADJ	B
but	O	CCONJ	O
was	O	AUX	O
improved	O	VERB	O
by	O	ADP	O
the	O	DET	O
DR.	O	NOUN	O
Major	O	ADJ	O
deviations	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
identified	O	VERB	B
for	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
centers	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
DR	O	NOUN	B
has	O	AUX	O
improved	O	VERB	B
the	O	DET	O
acquaintance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
participating	O	VERB	O
centers	O	NOUN	B
with	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
protocol	O	NOUN	I
.	O	PUNCT	O


Sociopsychological	O	ADJ	B
tailoring	O	NOUN	O
to	O	PART	O
address	O	VERB	O
colorectal	O	ADJ	B
cancer	O	NOUN	I
screening	O	NOUN	B
disparities	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
Interventions	B-I	NOUN	B
tailored	I-I	VERB	O
to	I-I	ADP	O
sociopsychological	I-I	ADJ	B
factors	I-I	NOUN	I
associated	I-I	VERB	B
with	I-I	ADP	I
health	I-I	NOUN	B
behaviors	I-I	NOUN	I
have	O	AUX	O
promise	O	NOUN	O
for	O	ADP	O
reducing	O	VERB	B
colorectal	O	ADJ	B
cancer	O	NOUN	I
screening	O	NOUN	B
disparities	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
limited	O	ADJ	O
research	O	NOUN	B
has	O	AUX	O
assessed	O	VERB	B
their	O	PRON	O
impact	O	NOUN	B
in	O	ADP	O
multiethnic	O	ADJ	B
populations	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
whether	O	SCONJ	O
an	O	DET	O
interactive	B-I	ADJ	B
multimedia	I-I	NOUN	B
computer	I-I	NOUN	I
program	I-I	NOUN	I
(	I-I	PUNCT	O
IMCP	I-I	NOUN	B
)	I-I	PUNCT	O
tailored	O	VERB	O
to	O	PART	O
expanded	O	VERB	O
health	O	NOUN	B
belief	O	NOUN	I
model	O	NOUN	B
sociopsychological	O	ADJ	B
factors	O	NOUN	I
could	O	AUX	O
promote	O	VERB	O
colorectal	O	ADJ	B
cancer	O	NOUN	I
screening	O	NOUN	B
in	O	ADP	O
a	O	DET	O
multiethnic	B-P	ADJ	B
sample	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
undertook	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
,	O	PUNCT	O
comparing	O	VERB	B
an	O	DET	O
IMCP	B-I	NOUN	B
tailored	I-I	VERB	O
to	I-I	PART	O
colorectal	I-I	ADJ	B
cancer	I-I	NOUN	I
screening	I-I	NOUN	B
self-efficacy	I-I	NOUN	B
,	I-I	PUNCT	O
knowledge	I-I	NOUN	B
,	I-I	PUNCT	O
barriers	I-I	NOUN	B
,	I-I	PUNCT	O
readiness	I-I	NOUN	B
,	I-I	PUNCT	O
test	I-I	NOUN	B
preference	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
experiences	I-I	NOUN	B
with	I-I	ADP	O
a	I-I	DET	O
nontailored	I-I	ADJ	O
informational	I-I	ADJ	O
program	I-I	NOUN	O
,	O	PUNCT	O
both	O	DET	O
delivered	O	VERB	O
before	O	ADP	O
office	O	NOUN	B
visits	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
record-documented	B-OUT	ADJ	B
colorectal	I-OUT	ADJ	B
cancer	I-OUT	NOUN	I
screening	I-OUT	NOUN	B
during	I-OUT	ADP	O
a	I-OUT	DET	O
12-month	I-OUT	ADJ	O
follow-up	I-OUT	ADJ	B
period	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Secondary	O	ADJ	B
outcomes	O	NOUN	I
included	O	VERB	O
postvisit	B-OUT	ADJ	B
sociopsychological	I-OUT	ADJ	O
factor	I-OUT	NOUN	O
status	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
discussion	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
clinician	I-OUT	ADJ	B
recommendation	I-OUT	NOUN	B
of	I-OUT	ADP	O
screening	I-OUT	VERB	B
during	I-OUT	ADP	O
office	I-OUT	NOUN	B
visits	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


We	O	PRON	O
enrolled	B-P	VERB	O
1,164	I-P	NUM	O
patients	I-P	NOUN	B
stratified	I-P	VERB	B
by	I-P	ADP	O
ethnicity	I-P	NOUN	B
and	I-P	CCONJ	O
language	I-P	NOUN	B
(	I-P	PUNCT	O
49.3	I-P	NUM	O
%	I-P	NOUN	O
non-Hispanic	I-P	ADJ	B
,	I-P	PUNCT	O
27.2	I-P	NUM	O
%	I-P	NOUN	O
Hispanic/English	I-P	ADJ	B
,	I-P	PUNCT	O
23.4	I-P	NUM	O
%	I-P	NOUN	O
Hispanic/Spanish	I-P	ADJ	B
)	I-P	PUNCT	O
from	I-P	ADP	O
26	I-P	NUM	O
offices	I-P	NOUN	B
around	I-P	ADP	O
5	I-P	NUM	O
centers	I-P	NOUN	B
(	I-P	PUNCT	O
Sacramento	I-P	PROPN	B
,	I-P	PUNCT	O
California	I-P	PROPN	B
;	I-P	PUNCT	O
Rochester	I-P	PROPN	B
and	I-P	CCONJ	O
the	I-P	DET	O
Bronx	I-P	PROPN	B
,	I-P	PUNCT	O
New	I-P	PROPN	B
York	I-P	PROPN	I
;	I-P	PUNCT	O
Denver	I-P	PROPN	B
,	I-P	PUNCT	O
Colorado	I-P	PROPN	B
;	I-P	PUNCT	O
and	I-P	CCONJ	O
San	I-P	PROPN	B
Antonio	I-P	PROPN	I
,	I-P	PUNCT	O
Texas	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
Adjusting	O	VERB	O
for	O	ADP	O
ethnicity/language	O	NOUN	B
,	O	PUNCT	O
study	O	NOUN	B
center	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
previsit	O	NOUN	B
value	O	NOUN	O
of	O	ADP	O
the	O	DET	O
dependent	O	ADJ	B
variable	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
control	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
IMCP	O	NOUN	B
led	O	VERB	O
to	O	PART	O
significantly	O	ADV	O
greater	O	ADJ	O
colorectal	B-OUT	ADJ	B
cancer	I-OUT	NOUN	I
screening	I-OUT	NOUN	B
knowledge	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
self-efficacy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
readiness	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
test	I-OUT	NOUN	B
preference	I-OUT	NOUN	I
specificity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
discussion	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
recommendation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


During	O	ADP	O
the	O	DET	O
followup	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
132	O	NUM	O
(	O	PUNCT	O
23	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
IMCP	O	NOUN	B
and	O	CCONJ	O
123	O	NUM	O
(	O	PUNCT	O
22	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
control	O	NOUN	B
patients	O	NOUN	B
received	O	VERB	O
screening	B-OUT	NOUN	B
(	O	PUNCT	O
adjusted	O	VERB	O
difference	O	NOUN	O
=	O	ADJ	O
0.5	O	NUM	O
percentage	O	NOUN	O
points	O	NOUN	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-4.3	O	NUM	O
to	O	PART	O
5.3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


IMCP	B-OUT	NOUN	B
effects	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
by	O	ADP	O
ethnicity/language	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Sociopsychological	O	ADJ	B
factor	O	NOUN	I
tailoring	O	NOUN	O
was	O	AUX	O
no	O	DET	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
nontailored	O	ADJ	B
information	O	NOUN	I
in	O	ADP	O
encouraging	O	VERB	O
colorectal	O	ADJ	B
cancer	O	NOUN	I
screening	O	NOUN	B
in	O	ADP	O
a	O	DET	O
multiethnic	B-P	ADJ	B
sample	I-P	NOUN	I
,	O	PUNCT	O
despite	O	SCONJ	O
enhancing	O	VERB	O
sociopsychological	O	ADJ	B
factors	O	NOUN	I
and	O	CCONJ	O
visit	O	NOUN	B
behaviors	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
screening	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
utility	O	NOUN	O
of	O	ADP	O
sociopsychological	O	ADJ	B
tailoring	O	NOUN	O
in	O	ADP	O
addressing	O	VERB	O
screening	O	VERB	B
disparities	O	NOUN	B
remains	O	VERB	O
uncertain	O	ADJ	O
.	O	PUNCT	O


Early	B-I	ADV	B
versus	I-I	CCONJ	O
late	I-I	ADJ	B
replacement	I-I	NOUN	I
of	I-I	ADP	O
autotransfused	I-I	VERB	B
blood	I-I	NOUN	I
in	O	ADP	O
elective	B-P	ADJ	B
spinal	I-I	ADJ	B
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


A	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
autologous	B-I	ADJ	B
blood	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
well	O	ADV	O
established	O	VERB	O
and	O	CCONJ	O
extremely	O	ADV	B
popular	O	ADJ	O
technique	O	NOUN	B
to	O	PART	O
decrease	O	VERB	B
the	O	DET	O
necessity	O	NOUN	O
for	O	ADP	O
homologous	O	ADJ	B
transfusions	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
attendant	O	ADJ	O
risks	O	NOUN	B
of	O	ADP	O
hepatitis	O	NOUN	B
,	O	PUNCT	O
HIV	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
HTLV	O	NOUN	B
--	O	PUNCT	O
I/II	O	NOUN	O
infections	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
beneficial	O	ADJ	O
timing	O	NOUN	B
for	O	ADP	O
autologous	B-I	ADJ	B
reinfusion	O	NOUN	I
of	O	ADP	O
predonated	O	VERB	B
blood	O	NOUN	I
remains	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
optimal	O	ADJ	B
timing	O	NOUN	B
of	O	ADP	O
autologous	B-I	ADJ	B
blood	I-I	NOUN	I
reinfusion	I-I	NOUN	I
in	I-I	ADP	O
elective	I-I	ADJ	B
spinal	I-I	ADJ	B
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


Fifty-seven	B-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
prospectively	O	ADV	O
individually	O	ADV	O
randomly	O	ADV	O
allocated	O	VERB	O
into	O	ADP	O
early	B-I	ADJ	B
versus	I-I	CCONJ	O
delayed	I-I	VERB	B
reinfusion	I-I	NOUN	B
groups	I-I	NOUN	B
prior	O	ADV	O
to	O	ADP	O
undergoing	B-P	VERB	O
elective	I-I	ADJ	B
spinal	I-I	ADJ	B
surgery	I-I	NOUN	I
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
surgeon	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
surgical	O	ADJ	B
subgroups	O	NOUN	I
were	O	AUX	O
entered	O	VERB	O
into	O	ADP	O
the	O	DET	O
study	O	NOUN	B
:	O	PUNCT	O
anterior/posterior	B-P	ADJ	B
(	I-P	PUNCT	I
A/P	I-P	NOUN	I
)	I-P	PUNCT	I
spinal	I-P	ADJ	B
fusion	I-P	NOUN	I
patients	I-P	NOUN	B
,	I-P	PUNCT	O
posterior	I-P	ADJ	B
thoracolumbar	I-P	ADJ	I
scoliosis	I-P	NOUN	I
fusion	I-P	NOUN	I
patients	I-P	NOUN	I
(	I-P	PUNCT	O
PSF	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
degenerative	I-P	ADJ	B
posterior	I-P	ADJ	I
lumbar	I-P	NOUN	B
fusion	I-P	NOUN	I
patients	I-P	NOUN	I
(	I-P	PUNCT	O
LF	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


Randomization	O	NOUN	B
was	O	AUX	O
successful	O	ADJ	O
in	O	ADP	O
that	O	DET	O
three	O	NUM	O
was	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
male	O	NOUN	B
to	O	PART	O
female	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
preoperative	O	ADJ	B
hemoglobin	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
number	O	NOUN	O
of	O	ADP	O
units	O	NOUN	O
predonated	O	VERB	O
between	O	ADP	O
the	O	DET	O
early	B-I	ADJ	B
and	I-I	CCONJ	O
delayed	I-I	VERB	B
reinfusion	I-I	NOUN	B
groups	I-I	NOUN	B
.	I-I	PUNCT	O


Likewise	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
details	O	NOUN	O
of	O	ADP	O
the	O	DET	O
operative	O	ADJ	B
procedure	O	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
as	O	ADP	O
a	O	DET	O
group	O	NOUN	B
for	O	ADP	O
the	O	DET	O
early	O	ADV	B
versus	O	CCONJ	O
delayed	O	VERB	B
reinfusion	O	NOUN	B
groups	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
postoperative	O	ADJ	B
day	B-OUT	NOUN	B
#	I-OUT	NOUN	O
1	I-OUT	NUM	O
,	I-OUT	PUNCT	O
2	I-OUT	NUM	O
and	I-OUT	CCONJ	O
3	I-OUT	NUM	O
hemoglobin	I-OUT	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
early	B-I	ADJ	B
reinfusion	I-I	NOUN	B
group	I-I	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
postoperative	O	ADJ	B
day	O	NOUN	B
#	O	NOUN	O
7	O	NUM	O
hemoglobin	O	NOUN	B
between	O	ADP	O
the	O	DET	O
early	B-I	ADJ	B
versus	I-I	CCONJ	O
delayed	I-I	VERB	B
reinfusion	I-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
effect	O	NOUN	O
of	O	ADP	O
surgical	O	ADJ	B
grouping	O	NOUN	I
on	O	ADP	O
these	O	DET	O
significant	O	ADJ	O
comparisons	O	NOUN	B
.	O	PUNCT	O


Earlier	O	ADV	O
patient	B-OUT	NOUN	B
mobilization	I-OUT	NOUN	O
was	O	AUX	O
also	O	ADV	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
early	B-I	ADJ	B
reinfusion	I-I	NOUN	B
groups	O	NOUN	B
for	O	ADP	O
the	O	DET	O
A/P	O	NOUN	B
and	O	CCONJ	O
PSF	O	PROPN	B
groups	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
'	O	PART	O
subjective	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
satisfaction	O	NOUN	B
and	O	CCONJ	O
discomfort	O	NOUN	B
between	O	ADP	O
the	O	DET	O
early	O	ADJ	B
or	O	CCONJ	O
delayed	O	VERB	B
reinfusion	O	NOUN	B
groups	O	NOUN	B
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
blinded	O	VERB	B
interview	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
7	O	NUM	O
postoperatively	O	ADV	B
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O


Recommending	O	VERB	B
self-paced	B-I	ADJ	I
exercise	I-I	NOUN	B
among	O	ADP	O
overweight	B-P	ADJ	B
and	I-P	CCONJ	O
obese	I-P	ADJ	B
adults	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
pilot	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
National	O	ADJ	B
guidelines	O	NOUN	I
call	O	VERB	O
for	O	ADP	O
exercise	O	NOUN	B
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
moderate	O	ADJ	B
intensity	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
recommending	O	VERB	B
self-paced	B-I	ADJ	B
exercise	I-I	NOUN	B
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
better	O	ADJ	O
adherence	B-OUT	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
among	O	ADP	O
overweight	B-P	ADJ	B
and	I-P	CCONJ	O
obese	I-P	ADJ	B
adults	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
test	O	VERB	O
proof-of-concept	O	NOUN	O
for	O	ADP	O
recommending	O	VERB	B
self-paced	O	ADJ	B
exercise	O	NOUN	B
among	O	ADP	O
overweight	O	ADJ	B
adults	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Fifty-nine	B-P	NUM	O
healthy	I-P	ADJ	B
,	I-P	PUNCT	O
low-active	I-P	ADJ	B
(	I-P	PUNCT	O
exercise	I-P	NOUN	B
<	I-P	ADP	O
60	I-P	NUM	O
min/week	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
overweight	I-P	ADJ	B
(	I-P	PUNCT	O
body	I-P	NOUN	B
mass	I-P	NOUN	I
index	I-P	NOUN	I
25.0-39.9	I-P	X	O
)	I-P	PUNCT	O
adults	I-P	NOUN	B
(	I-P	PUNCT	O
18-65	I-P	NUM	B
)	I-P	PUNCT	O
received	O	VERB	O
a	B-I	DET	O
6-month	I-I	ADJ	O
print-based	I-I	ADJ	B
exercise	I-I	NOUN	I
promotion	I-I	NOUN	I
program	I-I	NOUN	I
with	I-I	ADP	O
the	I-I	DET	O
goal	I-I	NOUN	B
of	I-I	ADP	O
walking	I-I	VERB	O
30-60	I-I	NUM	O
min/day	I-I	NOUN	B
.	O	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
surreptitiously	O	ADV	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
a	B-I	DET	O
recommendation	I-I	NOUN	B
for	I-I	ADP	O
either	I-I	CCONJ	O
self-paced	I-I	ADJ	B
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
30	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
moderate	I-I	ADJ	B
(	O	PUNCT	O
64-76	O	NUM	O
%	O	NOUN	O
maximum	O	ADJ	O
heart	O	NOUN	B
rate	O	NOUN	I
;	O	PUNCT	O
n	B-I	NOUN	O
=	I-I	ADJ	O
29	I-I	NUM	O
)	I-I	PUNCT	O
intensity	I-I	NOUN	B
exercise	I-P	NOUN	I
.	I-P	PUNCT	O


All	B-P	DET	O
participants	I-P	NOUN	B
used	I-P	VERB	O
electronic	I-P	ADJ	B
diaries	I-P	NOUN	I
and	I-P	CCONJ	O
heart	I-P	NOUN	B
rate	I-P	NOUN	I
monitors	I-OUT	NOUN	O
to	I-OUT	PART	O
track	I-OUT	VERB	O
exercise	I-OUT	NOUN	B
frequency	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
intensity	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
self-paced	O	ADJ	B
condition	O	NOUN	B
reported	B-OUT	VERB	O
more	I-OUT	ADJ	O
minutes/week	I-OUT	NOUN	B
of	O	ADP	I
walking	O	VERB	I
(	O	PUNCT	O
f	O	X	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
0.17	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.045	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
trend	B-OUT	NOUN	O
toward	I-OUT	ADP	O
greater	I-OUT	ADJ	O
exercise-related	I-OUT	ADJ	B
energy	I-OUT	NOUN	I
expenditure/week	O	NOUN	I
(	O	PUNCT	O
f	O	X	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
0.12	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.243	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
corresponding	O	VERB	O
to	O	PART	O
approximately	O	ADV	O
26	O	NUM	O
additional	O	ADJ	O
minutes/week	O	NOUN	B
and	O	CCONJ	O
83	O	NUM	O
additional	O	ADJ	O
kilocalories/week	O	NOUN	O
over	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Explicit	B-I	ADJ	O
recommendation	I-I	NOUN	B
for	O	ADP	O
self-paced	B-OUT	ADJ	B
exercise	I-OUT	NOUN	B
may	I-OUT	AUX	O
improve	I-OUT	VERB	O
adherence	I-OUT	NOUN	B
to	I-P	PART	O
exercise	I-P	VERB	B
programs	I-P	NOUN	I
among	I-P	ADP	O
overweight	O	ADJ	B
and	O	CCONJ	O
obese	O	ADJ	B
adults	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	B
with	O	ADP	O
interleukin-1	B-I	NOUN	B
receptor	I-I	NOUN	I
antagonist	I-I	NOUN	I
on	O	ADP	O
the	O	DET	O
inflamed	O	ADJ	B
synovial	O	ADJ	B
membrane	O	NOUN	I
in	O	ADP	O
rheumatoid	B-P	ADJ	B
arthritis	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	B
with	O	ADP	O
interleukin-1	B-I	NOUN	B
receptor	I-I	NOUN	I
antagonist	I-I	NOUN	I
(	I-I	PUNCT	O
IL-1Ra	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
synovial	O	ADJ	B
tissue	O	NOUN	I
in	O	ADP	O
rheumatoid	O	ADJ	B
arthritis	O	NOUN	I
(	O	PUNCT	O
RA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	VERB	O
Twelve	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
RA	I-P	NOUN	B
entering	I-P	VERB	O
a	I-P	DET	O
randomized	I-P	ADJ	B
clinical	I-P	ADJ	I
trial	I-P	NOUN	I
of	I-P	ADP	O
human	I-I	ADJ	B
recombinant	I-I	ADJ	B
IL-1Ra	I-I	NOUN	B
underwent	O	VERB	O
synovial	B-I	ADJ	B
biopsies	I-I	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Cellular	B-OUT	ADJ	B
infiltration	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
adhesion	I-OUT	NOUN	B
molecule	I-OUT	NOUN	O
expression	I-OUT	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
after	O	ADP	O
immunohistochemical	O	ADJ	B
staining	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
a	O	DET	O
notable	O	ADJ	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
intimal	I-OUT	ADJ	B
layer	I-OUT	NOUN	I
macrophages	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
subintimal	I-OUT	ADJ	B
macrophages	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
lymphocytes	I-OUT	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
IL-1Ra	B-I	NOUN	B
at	O	ADP	O
150	O	NUM	O
mg/day	O	NOUN	B
(	O	PUNCT	O
n=3	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Increased	O	VERB	B
cellular	B-OUT	ADJ	B
infiltration	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
receiving	O	VERB	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n=3	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
variable	O	ADJ	B
changes	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
IL-1Ra	B-I	NOUN	B
30	O	NUM	O
mg/day	O	NOUN	B
(	O	PUNCT	O
n=6	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
limited	O	ADJ	O
study	O	NOUN	B
of	O	ADP	O
adhesion	O	NOUN	B
molecule	O	NOUN	O
expression	O	NOUN	B
,	O	PUNCT	O
down-regulation	B-OUT	NOUN	B
of	I-OUT	ADP	O
E-selectin	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
vascular	I-OUT	ADJ	B
cell	I-OUT	NOUN	I
adhesion	I-OUT	NOUN	I
molecule-1	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
IL-1Ra	B-I	NOUN	B
150	O	NUM	O
mg/day	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
after	O	ADP	O
IL-1Ra	B-I	NOUN	B
30	O	NUM	O
mg/day	O	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
apparent	O	ADJ	B
arrest	B-OUT	NOUN	B
of	I-OUT	ADP	O
progressive	I-OUT	ADJ	B
joint	I-OUT	ADJ	O
damage	I-OUT	NOUN	O
seen	O	VERB	O
in	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
IL-1Ra	B-I	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
reduced	O	VERB	B
intimal	O	ADJ	B
layer	O	NOUN	I
macrophage	O	NOUN	B
accumulation	O	NOUN	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Treatment	O	NOUN	B
of	O	ADP	O
RA	O	NOUN	B
with	O	ADP	O
IL-1Ra	B-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
reduced	O	VERB	B
mononuclear	O	ADJ	B
cell	O	NOUN	I
infiltration	O	NOUN	B
of	O	ADP	O
synovial	O	ADJ	B
membrane	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
represent	O	VERB	O
the	O	DET	O
in	O	X	B
vivo	O	X	I
inhibition	O	NOUN	B
of	O	ADP	O
biologically	O	ADV	B
relevant	O	ADJ	I
IL-1ss-mediated	O	ADJ	B
pathogenic	O	ADJ	B
effects	O	NOUN	O
.	O	PUNCT	O


Randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
Behavioral	B-I	PROPN	B
Family	I-I	PROPN	I
Systems	I-I	PROPN	I
Therapy	I-I	PROPN	I
for	O	ADP	O
Diabetes	B-P	PROPN	B
:	I-P	PUNCT	O
maintenance	O	NOUN	B
and	O	CCONJ	O
generalization	O	NOUN	B
of	O	ADP	O
effects	O	NOUN	B
on	O	ADP	O
parent-adolescent	O	ADJ	B
communication	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
revised	O	VERB	B
Behavioral	B-I	PROPN	B
Family	I-I	PROPN	I
Systems	I-I	PROPN	I
Therapy	I-I	PROPN	I
for	I-I	ADP	I
Diabetes	I-I	NOUN	I
(	I-I	PUNCT	O
BFST-D	I-I	NOUN	B
)	I-I	PUNCT	O
intervention	I-I	NOUN	B
.	O	PUNCT	O


Families	B-P	NOUN	B
of	I-P	ADP	O
104	I-P	NUM	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
diabetes	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
standard	B-I	ADJ	B
care	I-I	NOUN	I
(	I-I	PUNCT	O
SC	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
to	I-I	PART	O
6	I-I	NUM	O
months	I-I	NOUN	B
of	I-I	ADP	O
an	I-I	DET	O
educational	I-I	ADJ	B
support	I-I	NOUN	I
group	I-I	NOUN	I
(	I-I	PUNCT	O
ES	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
BFST-D.	I-I	PROPN	B
Family	I-OUT	PROPN	B
communication	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
problem-solving	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
0	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
18	O	NUM	O
months	O	NOUN	B
by	O	ADP	O
independent	O	ADJ	O
rating	O	NOUN	B
of	O	ADP	O
videotaped	O	VERB	B
family	O	NOUN	B
problem-solving	O	ADJ	I
discussions	O	NOUN	I
.	O	PUNCT	O


BFST-D	B-I	NOUN	B
improved	O	VERB	O
individual	O	ADJ	B
communication	B-OUT	NOUN	B
of	I-OUT	ADP	O
adolescents	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mothers	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
but	I-OUT	CCONJ	O
not	I-OUT	PART	O
fathers	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


BFST-D	B-I	NOUN	B
significantly	O	ADV	O
improved	O	VERB	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	O
family	I-OUT	NOUN	B
interaction	I-OUT	NOUN	I
compared	O	VERB	O
to	O	PART	O
SC	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
of	O	ADP	O
12	O	NUM	O
comparisons	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
ES	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
of	O	ADP	O
12	O	NUM	O
comparisons	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
family	O	NOUN	B
communication	O	NOUN	I
were	O	AUX	O
differentially	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
changes	O	NOUN	B
in	O	ADP	O
glycemic	B-OUT	ADJ	B
control	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
adherence	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
family	I-OUT	NOUN	B
conflict	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


BFST-D	B-I	NOUN	B
improved	O	VERB	O
family	B-OUT	NOUN	B
communication	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
problem	I-OUT	VERB	B
solving	I-OUT	NOUN	I
relative	O	ADJ	O
to	O	PART	O
SC	O	NOUN	B
and	O	CCONJ	O
modestly	O	ADV	B
relative	O	ADJ	O
to	O	PART	O
ES	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
lowering	O	VERB	B
LDL	O	NOUN	B
cholesterol	O	NOUN	I
on	O	ADP	O
vascular	O	ADJ	B
access	O	NOUN	I
patency	O	NOUN	I
:	O	PUNCT	O
post	O	NOUN	B
hoc	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Study	O	PROPN	B
of	O	ADP	I
Heart	O	PROPN	I
and	O	CCONJ	I
Renal	O	PROPN	O
Protection	O	PROPN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
OBJECTIVES	O	NOUN	O
Reducing	O	VERB	B
LDL	O	NOUN	B
cholesterol	O	NOUN	I
(	O	PUNCT	O
LDL-C	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
statin-based	B-I	ADJ	B
therapy	I-I	NOUN	I
reduces	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
major	O	ADJ	O
atherosclerotic	O	ADJ	B
events	O	NOUN	I
among	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
CKD	I-P	NOUN	B
,	I-P	PUNCT	O
including	I-P	VERB	O
dialysis	I-P	NOUN	B
patients	I-P	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
lowering	O	VERB	B
LDL-C	O	NOUN	B
on	O	ADP	O
vascular	O	ADJ	B
access	O	NOUN	I
patency	O	NOUN	I
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
PARTICIPANTS	O	NOUN	B
,	O	PUNCT	O
&	O	CCONJ	O
MEASUREMENTS	O	VERB	O
The	O	DET	O
Study	O	PROPN	B
of	O	ADP	O
Heart	O	PROPN	O
and	O	CCONJ	O
Renal	O	PROPN	O
Protection	O	PROPN	O
(	O	PUNCT	O
SHARP	O	PROPN	B
)	O	PUNCT	O
randomized	O	ADJ	B
patients	B-P	NOUN	B
with	I-P	ADP	O
CKD	I-P	NOUN	B
to	I-P	PART	O
20	I-I	NUM	O
mg	I-I	NOUN	O
simvastatin	I-I	NOUN	B
plus	I-I	CCONJ	O
10	I-I	NUM	O
mg	I-I	NOUN	O
ezetimibe	I-I	NOUN	B
daily	I-I	ADV	B
versus	I-I	CCONJ	O
matching	I-I	VERB	B
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	B
on	O	ADP	O
vascular	O	ADJ	B
access	O	NOUN	I
occlusive	O	ADJ	I
events	O	NOUN	I
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
any	B-OUT	DET	O
access	I-OUT	NOUN	O
revision	I-OUT	NOUN	B
procedure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
access	I-OUT	NOUN	B
thrombosis	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
removal	I-OUT	NOUN	B
of	I-OUT	ADP	O
an	I-OUT	DET	O
old	I-OUT	ADJ	B
dialysis	I-OUT	NOUN	I
access	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
formation	I-OUT	NOUN	B
of	I-OUT	ADP	O
new	I-OUT	ADJ	O
permanent	I-OUT	ADJ	B
dialysis	I-OUT	NOUN	O
access	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
Among	O	ADP	O
2353	B-P	NUM	O
SHARP	I-P	PROPN	B
participants	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
functioning	I-P	VERB	B
vascular	I-P	ADJ	B
access	I-P	NOUN	I
at	O	ADP	O
randomization	O	NOUN	B
,	O	PUNCT	O
allocation	O	NOUN	B
to	O	PART	O
simvastatin	O	NOUN	B
plus	O	CCONJ	O
ezetimibe	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
13	O	NUM	O
%	O	NOUN	O
proportional	O	ADJ	B
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
vascular	I-OUT	ADJ	B
access	I-OUT	NOUN	I
occlusive	I-OUT	ADJ	I
events	I-OUT	NOUN	I
(	O	PUNCT	O
355	O	NUM	O
[	O	PUNCT	O
29.7	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
for	O	ADP	O
simvastatin/ezetimibe	B-I	ADJ	B
versus	O	CCONJ	O
388	O	NUM	O
[	O	PUNCT	O
33.5	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
for	O	ADP	O
placebo	B-I	NOUN	B
;	I-I	PUNCT	O
risk	O	NOUN	B
ratio	O	NOUN	I
[	O	PUNCT	O
RR	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
0.87	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
0.75	O	NUM	O
to	O	PART	O
1.00	O	NUM	O
;	O	PUNCT	O
P=0.05	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	B
differed	O	VERB	O
for	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
separate	O	ADJ	O
components	O	NOUN	B
of	O	ADP	O
this	O	DET	O
outcome	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
raised	O	VERB	O
by	O	ADP	O
SHARP	O	PROPN	B
,	O	PUNCT	O
comparable	O	ADJ	O
analyses	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
the	O	DET	O
AURORA	O	NOUN	B
(	O	PUNCT	O
A	O	PROPN	O
Study	O	PROPN	B
to	O	PART	O
Evaluate	O	VERB	B
the	O	DET	O
Use	O	PROPN	O
of	O	ADP	O
Rosuvastatin	O	NOUN	B
in	O	ADP	O
Subjects	O	NOUN	B
on	O	ADP	O
Regular	O	ADJ	B
Hemodialysis	O	NOUN	B
:	O	PUNCT	O
An	O	DET	O
Assessment	O	NOUN	B
of	O	ADP	O
Survival	O	PROPN	B
and	O	CCONJ	O
Cardiovascular	O	PROPN	B
Events	O	PROPN	I
)	O	PUNCT	O
trial	O	NOUN	O
cohort	O	NOUN	B
.	O	PUNCT	O


AURORA	O	NOUN	B
did	O	AUX	O
not	O	PART	O
provide	O	VERB	O
independent	O	ADJ	O
confirmation	O	NOUN	B
(	O	PUNCT	O
vascular	O	ADJ	B
access	O	NOUN	I
occlusive	O	ADJ	I
events	O	NOUN	I
:	O	PUNCT	O
352	O	NUM	O
[	O	PUNCT	O
28.9	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
for	O	ADP	O
rosuvastatin	O	NOUN	B
versus	O	CCONJ	O
337	O	NUM	O
[	O	PUNCT	O
27.6	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
for	O	ADP	O
placebo	O	NOUN	B
;	O	PUNCT	O
RR	O	NOUN	B
,	O	PUNCT	O
1.06	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.91	O	NUM	O
to	O	PART	O
1.23	O	NUM	O
;	O	PUNCT	O
P=0.44	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
combining	O	VERB	O
the	O	DET	O
two	O	NUM	O
trials	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
overall	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
reducing	O	VERB	B
LDL-C	B-OUT	NOUN	B
with	O	ADP	O
a	O	DET	O
statin-based	O	ADJ	B
regimen	O	NOUN	I
on	O	ADP	O
vascular	O	ADJ	B
access	O	NOUN	I
occlusive	O	ADJ	I
events	O	NOUN	I
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
707	O	NUM	O
[	O	PUNCT	O
29.3	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
with	O	ADP	O
any	O	DET	O
LDL-C-lowering	O	NOUN	B
therapy	O	NOUN	I
versus	O	CCONJ	O
725	O	NUM	O
[	O	PUNCT	O
30.5	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
with	O	ADP	O
placebo	O	NOUN	B
;	O	PUNCT	O
RR	O	NOUN	B
,	O	PUNCT	O
0.95	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.85	O	NUM	O
to	O	PART	O
1.05	O	NUM	O
;	O	PUNCT	O
P=0.29	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Exploratory	O	ADJ	B
analyses	O	NOUN	I
from	O	ADP	O
SHARP	O	PROPN	B
suggest	O	VERB	O
that	O	SCONJ	O
lowering	O	VERB	B
LDL-C	O	NOUN	B
with	O	ADP	O
statin-based	B-I	ADJ	B
therapy	I-I	NOUN	I
may	O	AUX	O
improve	O	VERB	O
vascular	O	ADJ	B
access	O	NOUN	I
patency	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	B
of	O	ADP	O
benefit	O	NOUN	B
in	O	ADP	O
AURORA	O	NOUN	B
.	O	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
available	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
any	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
lowering	O	VERB	B
LDL-C	O	NOUN	B
on	O	ADP	O
vascular	O	ADJ	B
access	O	NOUN	I
patency	O	NOUN	I
are	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
modest	O	ADJ	O
.	O	PUNCT	O


Pilot	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
a	O	DET	O
moderate	B-I	ADJ	B
dose	I-I	NOUN	B
multivitamin/mineral	I-I	ADJ	B
supplement	I-I	NOUN	I
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
Determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
moderate	O	ADJ	B
dose	O	NOUN	B
multivitamin/mineral	B-I	ADJ	B
supplement	I-I	NOUN	I
on	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
3-month	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


SUBJECTS	O	NOUN	O
Twenty	B-P	NUM	O
(	I-P	PUNCT	O
20	I-P	NUM	O
)	I-P	PUNCT	O
children	I-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
,	I-P	PUNCT	O
ages	I-P	VERB	B
3-8	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
Global	O	PROPN	B
Impressions	O	PROPN	I
parental	O	ADJ	B
questionnaire	O	NOUN	I
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
supplement	O	NOUN	B
group	O	NOUN	B
reported	O	VERB	O
statistically	B-OUT	ADV	B
significant	I-OUT	ADJ	I
improvements	I-OUT	NOUN	B
in	O	ADP	O
sleep	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
gastrointestinal	I-OUT	ADJ	B
problems	I-OUT	NOUN	I
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
vitamin	B-OUT	NOUN	B
B	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
6	I-OUT	NUM	O
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
prior	O	ADJ	O
to	O	PART	O
the	O	DET	O
study	O	NOUN	B
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
autistic	B-P	ADJ	B
children	I-P	NOUN	B
had	O	AUX	O
substantially	B-OUT	ADV	O
elevated	I-OUT	ADJ	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
B6	I-OUT	NOUN	B
compared	O	VERB	B
to	O	PART	O
a	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
typical	O	ADJ	O
children	O	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
%	O	NOUN	O
higher	O	ADJ	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.0000001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Vitamin	B-OUT	NOUN	B
C	I-OUT	NOUN	I
levels	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
had	O	AUX	O
levels	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
significantly	B-OUT	ADV	O
below	I-OUT	ADP	O
average	I-OUT	NOUN	B
for	O	ADP	O
typical	O	ADJ	O
children	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
supplement	O	NOUN	B
group	O	NOUN	B
had	O	AUX	O
near-average	O	ADJ	B
levels	O	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	VERB	O
The	O	DET	O
finding	O	NOUN	B
of	O	ADP	O
high	B-OUT	ADJ	B
vitamin	I-OUT	NOUN	B
B	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
6	I-OUT	NUM	O
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
recent	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
pyridoxal-5-phosphate	I-OUT	NOUN	B
and	O	CCONJ	O
low	O	ADJ	B
activity	B-OUT	NOUN	B
of	I-OUT	ADP	O
pyridoxal	I-OUT	NOUN	B
kinase	I-OUT	NOUN	I
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
pyridoxal	O	NOUN	B
is	O	AUX	O
only	O	ADV	O
poorly	O	ADV	O
converted	O	VERB	O
to	O	PART	O
pyridoxal-5-phosphate	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
enzymatically	O	ADV	B
active	O	ADJ	I
form	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
may	O	AUX	O
explain	O	VERB	O
the	O	DET	O
functional	O	ADJ	B
need	O	NOUN	O
for	O	ADP	O
high-dose	O	ADJ	B
vitamin	B-I	NOUN	B
B	I-I	NOUN	I
(	I-I	PUNCT	O
6	I-I	NUM	O
)	I-I	PUNCT	O
supplementation	I-I	NOUN	B
in	O	ADP	O
many	O	ADJ	O
children	O	NOUN	B
and	O	CCONJ	O
adults	O	NOUN	B
with	O	ADP	O
autism	O	NOUN	B
.	O	PUNCT	O


Rituximab	B-I	NOUN	B
maintenance	O	NOUN	B
improves	O	VERB	B
survival	O	NOUN	B
in	O	ADP	O
male	B-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
diffuse	I-P	ADJ	B
large	I-P	ADJ	I
B-cell	I-P	NOUN	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HD2002	O	PROPN	B
prospective	O	ADJ	B
multicentre	B-P	NOUN	I
randomized	O	ADJ	I
phase	O	NOUN	I
III	O	NUM	I
trial	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
multicentre	O	NOUN	B
prospective	O	ADJ	I
randomized	O	ADJ	I
HD2002	O	NOUN	I
trial	O	NOUN	I
,	O	PUNCT	O
rituximab	B-I	NOUN	B
maintenance	I-I	NOUN	O
therapy	I-I	NOUN	O
(	O	PUNCT	O
375	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
every	O	DET	O
3	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
versus	O	CCONJ	O
observation	B-I	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
for	O	ADP	O
CD20	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
B-cell	O	NOUN	O
lymphoma	O	NOUN	O
.	O	PUNCT	O


Out	O	ADP	O
of	O	ADP	O
321	B-P	NUM	O
patients	I-P	NOUN	B
[	I-P	PUNCT	O
161	I-P	NUM	O
randomized	I-P	ADJ	B
to	I-P	PART	O
the	I-P	DET	O
treatment	I-P	NOUN	B
group	I-P	NOUN	I
(	I-P	PUNCT	O
TG	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
160	I-P	NUM	O
to	I-P	ADP	O
the	I-P	DET	O
observation	I-P	NOUN	B
group	I-P	NOUN	I
(	I-P	PUNCT	O
OG	I-P	NOUN	B
)	I-P	PUNCT	O
]	I-P	PUNCT	O
,	I-P	PUNCT	O
295	I-P	NUM	O
data	I-P	NOUN	B
sets	I-P	NOUN	I
were	O	AUX	O
evaluable	O	ADJ	O
for	O	ADP	O
statistical	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


Estimated	O	VERB	O
5-year	B-OUT	ADJ	O
relapse-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RFS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
81	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
TG	O	NOUN	B
and	O	CCONJ	O
70	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
OG	O	NOUN	B
(	O	PUNCT	O
logrank	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·047	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
diffuse	O	ADJ	B
large	O	ADJ	I
B-cell	O	NOUN	I
lymphoma	O	NOUN	I
(	B-P	PUNCT	O
DLBCL	I-P	NOUN	B
)	I-P	PUNCT	O
subgroup	I-P	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
152	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
5-year	B-OUT	ADJ	O
RFS	I-OUT	NOUN	B
was	O	AUX	O
excellent	O	ADJ	B
,	O	PUNCT	O
at	O	ADP	O
87	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
TG	O	NOUN	B
and	O	CCONJ	O
84	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
OG	O	NOUN	B
(	O	PUNCT	O
logrank	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·35	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	O	ADP	O
note	O	NOUN	O
,	O	PUNCT	O
only	O	ADV	O
in	B-P	ADP	O
male	I-P	ADJ	B
patients	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
DLBCL	I-P	NOUN	B
subgroup	I-P	NOUN	B
was	I-OUT	AUX	O
RFS	I-OUT	NOUN	B
significantly	O	ADV	O
superior	O	ADJ	O
in	O	ADP	O
the	O	DET	O
TG	O	NOUN	B
in	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
the	O	DET	O
OG	O	NOUN	B
(	O	PUNCT	O
5-year	O	ADJ	O
RFS	O	NOUN	B
:	O	PUNCT	O
88	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
74	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
logrank	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·05	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Cox	O	NOUN	B
regression	O	NOUN	I
analysis	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
interaction	O	NOUN	B
between	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
gender	O	NOUN	B
regarding	B-OUT	VERB	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·006	O	ADJ	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
RFS	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·02	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
lower	O	ADJ	O
hazard	O	NOUN	B
in	O	ADP	O
females	O	NOUN	B
than	O	ADP	O
males	O	NOUN	B
in	B-OUT	ADP	O
the	I-OUT	DET	O
OG	I-OUT	PROPN	B
[	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
hazard	I-OUT	NOUN	B
ratio	I-OUT	NOUN	I
(	O	PUNCT	O
HR	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
female	O	NOUN	B
:	O	PUNCT	O
male	O	NOUN	B
)	O	PUNCT	O
=	O	ADJ	O
0·11	B-OUT	ADV	O
;	I-OUT	PUNCT	O
95	I-OUT	NUM	O
%	I-OUT	NOUN	O
confidence	I-OUT	NOUN	B
interval	I-OUT	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
=	O	ADJ	O
0·00-1·03	B-OUT	NUM	O
;	I-OUT	PUNCT	O
RFS	O	NOUN	B
:	O	PUNCT	O
HR	O	NOUN	B
(	O	PUNCT	O
female	O	NOUN	B
:	O	PUNCT	O
male	O	NOUN	B
)	O	PUNCT	O
=	O	ADJ	O
0·27	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
0·05-0·97	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
males	O	NOUN	B
and	O	CCONJ	O
females	O	NOUN	B
in	O	ADP	O
the	O	DET	O
TG	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	B-I	VERB	O
that	I-I	SCONJ	O
Rituximab	I-I	NOUN	B
maintenance	I-I	NOUN	B
therapy	O	NOUN	I
improves	O	VERB	B
survival	B-P	NOUN	B
in	I-P	ADP	O
male	I-P	NOUN	B
patients	I-P	NOUN	B
with	O	ADP	O
DLBCL	O	NOUN	B
.	O	PUNCT	O


Double-blind	O	ADJ	B
trial	O	NOUN	I
comparing	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
homeopathic	B-I	ADJ	B
preparation	I-I	NOUN	I
Galphimia	I-I	PROPN	B
potentiation	I-I	NOUN	O
D6	I-I	NOUN	O
,	I-I	PUNCT	O
Galphimia	I-I	NOUN	B
dilution	I-I	NOUN	B
10	I-I	NUM	O
(	I-I	PUNCT	O
-6	I-I	NUM	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
on	O	ADP	O
pollinosis	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
preparation	O	NOUN	B
of	O	ADP	O
homeopathic	B-I	ADJ	B
drugs	I-I	NOUN	I
is	O	AUX	O
based	O	VERB	O
on	O	ADP	O
potentiation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
potentiation	O	NOUN	B
the	O	DET	O
primary	O	ADJ	B
substance	O	NOUN	I
is	O	AUX	O
specially	O	ADV	O
mixed	O	ADJ	O
with	O	ADP	O
a	O	DET	O
carrier	O	NOUN	B
(	O	PUNCT	O
typically	O	ADV	O
90	O	NUM	O
%	O	NOUN	O
ethanol	B-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
the	O	DET	O
ratio	O	NOUN	B
1:10	O	NUM	O
.	O	PUNCT	O


Usually	O	ADV	O
this	O	DET	O
potentiation	O	NOUN	B
is	O	AUX	O
done	O	VERB	O
repeatedly	O	ADV	B
and	O	CCONJ	O
the	O	DET	O
final	O	ADJ	O
drug	O	NOUN	B
is	O	AUX	O
labeled	O	VERB	B
,	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
"	B-I	PUNCT	O
D6	I-I	NOUN	B
"	I-I	PUNCT	O
which	O	DET	O
means	O	VERB	O
a	O	DET	O
6	O	NUM	O
times	O	NOUN	O
decimal	O	ADJ	O
potentiation	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
controlled	O	VERB	B
randomized	O	VERB	B
strictly	O	ADV	O
double-blind	O	ADJ	O
trial	O	NOUN	O
with	O	ADP	O
164	B-P	NUM	O
patients	I-P	NOUN	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
homeopathically	O	ADV	B
prepared	O	VERB	O
Galphimia	B-I	PROPN	B
D6	I-I	NOUN	I
,	I-I	PUNCT	O
a	I-I	DET	O
conventional	I-I	ADJ	O
Galphimia	I-I	PROPN	B
dilution	I-I	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
-6	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
placebo	B-I	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
for	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
of	O	ADP	O
pollinosis	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
average	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
was	O	AUX	O
about	O	ADV	O
5	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
no	O	DET	O
statistical	O	ADJ	B
significance	O	NOUN	I
was	O	AUX	O
achieved	O	VERB	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
remarkable	O	ADJ	O
that	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
clear	O	ADJ	O
trend	O	NOUN	O
for	O	ADP	O
the	O	DET	O
superiority	B-OUT	NOUN	B
of	O	ADP	O
Galphimia	B-OUT	PROPN	B
D6	I-OUT	NOUN	I
while	O	SCONJ	O
the	O	DET	O
Galphimia	B-OUT	PROPN	B
dilution	I-OUT	NOUN	B
10	I-OUT	NUM	O
(	I-OUT	PUNCT	O
-6	I-OUT	NUM	O
)	I-OUT	PUNCT	O
was	O	AUX	O
about	O	ADP	O
equally	O	ADV	O
effective	O	ADJ	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
study	O	NOUN	B
itself	O	PRON	O
demonstrates	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
possible	O	ADJ	O
to	O	PART	O
do	O	AUX	O
strictly	O	ADV	O
controlled	O	VERB	B
trials	O	NOUN	I
for	O	ADP	O
homeopathic	B-I	ADJ	B
drugs	I-I	NOUN	I
and	O	CCONJ	O
with	O	ADP	O
medical	O	ADJ	B
practitioners	O	NOUN	I
.	O	PUNCT	O


Intensive	B-I	NOUN	B
induction	I-I	NOUN	O
chemotherapy	I-I	NOUN	O
for	O	ADP	O
small	O	ADJ	B
cell	O	NOUN	I
anaplastic	O	ADJ	I
carcinoma	O	NOUN	I
of	O	ADP	O
the	O	DET	O
lung	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
intensive	B-I	ADJ	B
induction	I-I	NOUN	I
chemotherapy	I-I	NOUN	I
in	O	ADP	O
small	O	ADJ	B
cell	O	NOUN	I
cancer	O	NOUN	I
of	O	ADP	O
the	O	DET	O
lung	O	NOUN	B
remains	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


Twenty-eight	B-P	NUM	O
newly	I-P	ADV	O
diagnosed	I-P	VERB	B
patients	I-P	NOUN	B
with	I-P	ADP	O
small	I-P	ADJ	B
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
high-dose	B-I	ADJ	B
or	I-I	CCONJ	O
standard-dose	I-I	ADJ	B
cyclophosphamide	I-I	NOUN	I
,	I-I	PUNCT	O
vincristine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
semustine	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
trial	O	NOUN	B
where	O	SCONJ	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
induction	O	NOUN	B
chemotherapy	O	NOUN	I
was	O	AUX	O
the	O	DET	O
sole	O	ADJ	O
treatment	O	NOUN	B
variable	O	ADJ	B
.	O	PUNCT	O


Complete	B-OUT	ADJ	B
responses	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
CR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
57	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
high-dose	O	ADJ	B
therapy	O	NOUN	I
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
21	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
standard-dose	O	ADJ	B
therapy	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
severe	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
high-dose	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
overall	B-OUT	ADJ	O
median	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
improved	O	VERB	O
(	O	PUNCT	O
36	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
the	O	DET	O
high-dose	O	ADJ	B
group	O	NOUN	I
vs	O	CCONJ	O
43	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
the	O	DET	O
standard-dose	O	ADJ	B
group	O	NOUN	I
)	O	PUNCT	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
achieving	O	VERB	O
CR	O	NOUN	B
was	O	AUX	O
prolonged	O	ADJ	B
(	O	PUNCT	O
92	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
the	O	DET	O
high-dose	O	ADJ	B
group	O	NOUN	I
vs	O	CCONJ	O
50	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
the	O	DET	O
standard-dose	O	ADJ	B
group	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
effects	O	NOUN	B
were	O	AUX	O
most	O	ADV	O
pronounced	O	ADJ	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
extensive	I-P	ADJ	O
disease	I-P	NOUN	B
;	I-P	PUNCT	O
a	O	DET	O
CR	B-OUT	NOUN	B
after	O	ADP	O
induction	O	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
five	O	NUM	O
of	O	ADP	O
nine	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
high	O	ADJ	B
doses	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
those	O	DET	O
treated	O	VERB	B
with	O	ADP	I
standard	O	ADJ	B
doses	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
small	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
benefit	O	VERB	B
by	O	ADP	O
achieving	O	VERB	O
a	O	DET	O
long-term	O	ADJ	B
remission	O	NOUN	B
with	O	ADP	O
intensive	O	ADJ	O
induction	O	NOUN	O
chemotherapy	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
effect	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
offset	O	VERB	O
by	O	ADP	O
increased	O	VERB	B
morbidity	O	NOUN	B
.	O	PUNCT	O


Benefits	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
morbidity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
associated	O	VERB	B
with	O	ADP	I
long-term	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
oral	B-I	ADJ	B
anticoagulant	I-I	ADJ	I
therapy	I-I	NOUN	I
to	O	PART	O
patients	B-P	NOUN	B
with	I-P	ADP	O
peripheral	I-P	ADJ	B
arterial	I-P	ADJ	I
bypass	I-P	NOUN	I
procedures	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
the	O	DET	O
long-term	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
oral	B-I	ADJ	B
anticoagulant	I-I	ADJ	O
therapy	I-I	NOUN	O
remain	O	VERB	O
unclear	O	ADJ	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
lower	I-P	ADJ	B
extremity	I-P	NOUN	I
arterial	I-P	ADJ	I
bypass	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
warfarin	B-I	NOUN	B
plus	I-I	CCONJ	O
aspirin	I-I	NOUN	B
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
WASA	I-I	NOUN	B
)	I-I	PUNCT	O
versus	I-I	ADP	O
aspirin	I-I	NOUN	B
therapy	I-I	NOUN	I
alone	I-I	ADV	O
(	I-I	PUNCT	O
ASA	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
patient	B-OUT	NOUN	B
mortality	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
morbidity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
bypass	I-OUT	NOUN	B
patency	I-OUT	NOUN	I
rates	I-OUT	NOUN	I
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
nonmasked	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
,	O	PUNCT	O
831	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
underwent	I-P	VERB	O
peripheral	I-P	ADJ	B
arterial	I-P	ADJ	I
bypass	I-P	NOUN	I
surgery	I-P	NOUN	I
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
a	O	DET	O
long-term	B-P	ADJ	B
treatment	I-P	NOUN	B
program	I-P	NOUN	I
of	I-P	ADP	O
WASA	I-I	NOUN	B
(	O	PUNCT	O
target	O	NOUN	B
international	O	ADJ	B
normalized	O	VERB	O
ratio	O	NOUN	B
of	O	ADP	O
1.4	O	NUM	O
to	O	PART	O
2.8	O	NUM	O
;	O	PUNCT	O
325	O	NUM	O
mg/day	O	NOUN	O
)	O	PUNCT	O
with	O	ADP	O
ASA	B-I	NOUN	B
(	O	PUNCT	O
325	O	NUM	O
mg/day	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
bypass	B-OUT	NOUN	B
patency	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
morbidity	I-OUT	NOUN	B
were	O	AUX	O
the	O	DET	O
secondary	O	ADJ	B
endpoints	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
133	O	NUM	O
deaths	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
WASA	B-I	PROPN	B
group	O	NOUN	I
(	O	PUNCT	O
31.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
95	O	NUM	O
deaths	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
ASA	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
23.0	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
risk	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
1.41	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1.09	O	NUM	O
to	O	PART	O
1.84	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=.0001	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Major	B-OUT	ADJ	B
hemorrhagic	I-OUT	ADJ	O
events	I-OUT	NOUN	B
occurred	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
the	O	DET	O
WASA	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
WASA	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
35	O	NUM	O
;	O	PUNCT	O
ASA	B-I	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=.02	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
prosthetic	O	ADJ	B
bypass	O	NOUN	I
group	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
patency	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
8-mm	O	ADJ	O
bypass	O	NOUN	B
subgroup	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
patency	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
6-mm	O	ADJ	O
bypass	O	NOUN	B
subgroup	O	NOUN	B
(	O	PUNCT	O
femoral-popliteal	O	ADJ	B
;	O	PUNCT	O
71.4	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
WASA	B-I	PROPN	B
group	O	NOUN	I
versus	O	CCONJ	O
57.9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
ASA	B-I	NOUN	B
group	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=.02	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
vein	O	NOUN	B
bypass	O	NOUN	I
group	O	NOUN	I
,	O	PUNCT	O
patency	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
unaffected	O	ADJ	O
(	O	PUNCT	O
75.3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
WASA	B-I	PROPN	B
group	O	NOUN	I
versus	O	CCONJ	O
74.9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
ASA	O	NOUN	B
group	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
long-term	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
warfarin	B-I	NOUN	B
therapy	I-I	NOUN	I
when	O	SCONJ	O
combined	O	VERB	O
with	O	ADP	O
aspirin	O	NOUN	B
therapy	O	NOUN	I
has	O	AUX	O
only	O	ADV	O
a	O	DET	O
few	O	ADJ	O
selected	O	VERB	O
indications	O	NOUN	B
for	O	ADP	O
improvement	O	NOUN	B
of	O	ADP	O
bypass	B-OUT	NOUN	B
patency	I-OUT	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
morbidity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Bupropion	B-I	NOUN	B
SR	I-I	ADJ	B
and	I-I	CCONJ	O
counseling	I-I	NOUN	B
for	I-I	ADP	O
smoking	I-I	NOUN	B
cessation	I-P	NOUN	I
in	O	ADP	O
actual	O	ADJ	B
practice	O	NOUN	I
:	O	PUNCT	O
predictors	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
study	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
published	O	VERB	B
on	O	ADP	O
individual	O	ADJ	B
characteristics	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
outcome	O	NOUN	B
following	O	VERB	O
standard	B-I	ADJ	B
treatment	I-I	NOUN	I
with	I-I	ADP	O
bupropion	I-I	NOUN	B
SR	I-I	NOUN	B
for	O	ADP	O
smoking	O	NOUN	B
cessation	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
treatment	O	NOUN	B
outcome	O	NOUN	O
beyond	O	ADP	O
the	O	DET	O
6-week	O	ADJ	O
end-of-treatment	O	ADJ	B
point	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
examined	O	VERB	O
characteristics	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
more	O	ADV	O
clinically	O	ADV	B
relevant	O	ADJ	O
smoking	O	NOUN	B
endpoints	O	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
bupropion	B-I	NOUN	B
SR	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
health	O	NOUN	B
care	O	NOUN	I
system	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	B-P	NOUN	O
of	I-P	ADP	O
1,524	I-P	NUM	O
smokers	I-P	NOUN	B
(	I-P	PUNCT	O
649	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
875	I-P	NUM	O
women	I-P	NOUN	B
)	I-P	PUNCT	O
of	I-P	ADP	O
average	I-P	ADJ	B
age	I-P	NOUN	B
45.1	I-P	NUM	O
years	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
combinations	O	NOUN	B
of	O	ADP	O
bupropion	B-I	NOUN	B
SR	I-I	NOUN	B
(	O	PUNCT	O
150	O	NUM	O
or	O	CCONJ	O
300	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
behavioral	B-I	ADJ	B
counseling	I-I	NOUN	I
(	I-I	PUNCT	O
tailored	I-I	VERB	O
mailings	I-I	NOUN	B
or	I-I	CCONJ	O
proactive	I-I	ADJ	B
telephone	I-I	NOUN	I
counseling	I-I	NOUN	I
)	I-I	PUNCT	O
and	O	CCONJ	O
assessed	O	VERB	B
for	O	ADP	O
point-prevalent	O	ADJ	B
smoking	O	NOUN	I
status	O	NOUN	I
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Multiple	O	ADJ	B
logistic	O	ADJ	I
regression	O	NOUN	I
analyses	O	NOUN	I
of	O	ADP	O
potential	O	ADJ	B
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
12-month	O	ADJ	O
point-prevalent	O	ADJ	B
smoking	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
persistent	O	ADJ	B
smoking	O	NOUN	I
(	O	PUNCT	O
point-prevalent	O	ADJ	B
smoking	O	NOUN	I
at	O	ADP	O
both	O	DET	O
follow-ups	O	NOUN	B
)	O	PUNCT	O
following	O	VERB	O
treatment	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
for	O	ADP	O
men	O	NOUN	B
and	O	CCONJ	O
women	O	NOUN	B
combined	O	ADJ	B
and	O	CCONJ	O
separately	O	ADV	B
.	O	PUNCT	O


Risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
smoking	O	NOUN	B
at	O	ADP	O
both	O	DET	O
endpoints	O	NOUN	B
in	O	ADP	O
the	O	DET	O
combined	O	ADJ	O
sample	O	NOUN	B
included	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
tailored	O	ADJ	O
mailings	O	NOUN	B
,	O	PUNCT	O
female	O	ADJ	B
gender	O	NOUN	I
,	O	PUNCT	O
younger	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
higher	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
tobacco	O	NOUN	B
dependence	O	NOUN	I
,	O	PUNCT	O
shorter	O	ADJ	B
previous	O	ADJ	O
quit	O	NOUN	B
attempts	O	NOUN	I
,	O	PUNCT	O
previous	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
nicotine	O	NOUN	B
replacement	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
report	O	NOUN	B
of	O	ADP	O
current	O	ADJ	B
depressive	O	ADJ	B
symptoms	O	NOUN	I
or	O	CCONJ	O
lifetime	O	NOUN	B
depression	O	NOUN	B
.	O	PUNCT	O


Risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
smoking	O	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
women	O	NOUN	B
only	O	ADV	O
included	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
bupropion	B-I	NOUN	B
SR	I-I	NOUN	B
,	O	PUNCT	O
younger	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
higher	O	ADJ	B
perceived	O	VERB	B
stress	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
those	O	DET	O
that	O	PRON	O
were	O	AUX	O
unique	O	ADJ	O
to	O	PART	O
men	O	NOUN	B
included	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
lifetime	O	NOUN	B
depression	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
implications	O	NOUN	O
for	O	ADP	O
the	B-OUT	DET	O
need	I-OUT	NOUN	O
for	I-OUT	ADP	O
more	I-OUT	ADV	O
effective	I-OUT	ADJ	B
treatments	I-OUT	NOUN	B
in	O	ADP	O
general	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
individual	B-OUT	ADJ	O
differences	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
likelihood	I-OUT	NOUN	B
of	I-OUT	ADP	O
returning	I-OUT	VERB	O
to	I-OUT	ADP	O
smoking	I-OUT	NOUN	B
following	I-OUT	VERB	O
treatment	I-OUT	NOUN	B
for	I-OUT	ADP	O
quitting	O	NOUN	B
.	O	PUNCT	O


DNA	O	NOUN	B
as	O	ADP	O
a	O	DET	O
carrier	O	NOUN	B
for	O	ADP	O
anthracyclines	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	B-P	NOUN	B
of	I-P	ADP	O
acute	I-OUT	ADJ	B
myelocytic	I-OUT	ADJ	I
leukemia	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AML	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Mandibular	O	ADJ	B
overdentures	O	NOUN	I
supported	O	VERB	O
by	O	ADP	O
two	O	NUM	O
Brånemark	O	PROPN	B
,	O	PUNCT	O
IMZ	B-I	PROPN	B
or	I-I	CCONJ	O
ITI	I-I	NOUN	B
implants	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
5-year	O	ADJ	O
prospective	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
prospective	O	ADJ	O
comparative	O	ADJ	O
study	O	NOUN	O
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	B-OUT	DET	O
survival	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	O	CCONJ	O
the	B-OUT	DET	O
condition	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
peri-implant	I-OUT	ADJ	B
tissues	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
IMZ	B-I	PROPN	B
implant	I-I	NOUN	I
system	O	NOUN	I
(	O	PUNCT	O
two-stage	O	ADJ	B
cylindertype	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
the	B-I	DET	O
Brånemark	I-I	ADJ	B
implant	I-I	ADJ	O
system	O	NOUN	O
(	O	PUNCT	O
two-stage	O	ADJ	B
screwtype	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
the	B-I	DET	O
ITI	I-I	NOUN	B
implant	I-I	NOUN	B
system	O	NOUN	I
(	O	PUNCT	O
one-stage	O	ADJ	B
screwtype	O	NOUN	I
)	O	PUNCT	O
supporting	O	VERB	O
a	O	DET	O
mandibular	O	ADJ	B
overdenture	O	NOUN	I
during	O	ADP	O
a	O	DET	O
5-year	O	ADJ	O
follow-up	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	B-P	VERB	O
Three	I-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
30	I-P	NUM	O
edentulous	I-P	ADJ	B
patients	I-P	NOUN	B
were	I-P	AUX	O
treated	I-P	VERB	B
with	I-I	ADP	I
two	I-I	NUM	O
endosseous	I-I	ADJ	B
implants	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
interforaminal	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
mandible	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
radiographic	O	ADJ	B
parameters	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
immediately	O	ADV	O
after	O	ADP	O
completion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
prosthetic	O	ADJ	B
treatment	O	NOUN	I
and	O	CCONJ	O
after	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
loading	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	B-OUT	DET	O
five-year	I-OUT	ADJ	O
survival	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
is	O	AUX	O
98.3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
IMZ	O	PROPN	B
group	O	NOUN	O
,	O	PUNCT	O
98.3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
Brå	O	PROPN	B
group	O	NOUN	B
and	O	CCONJ	O
100	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
ITI	O	NOUN	B
group	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Mean	B-OUT	VERB	B
scores	I-OUT	NOUN	I
on	I-OUT	ADP	O
indices	I-OUT	NOUN	B
for	I-OUT	ADP	O
plaque	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
calculus	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
gingiva	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
bleeding	I-OUT	NOUN	B
were	O	AUX	O
very	O	ADV	O
low	O	ADJ	O
at	O	ADP	O
all	O	DET	O
evaluation	O	NOUN	B
periods	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Mean	B-OUT	VERB	O
marginal	I-OUT	ADJ	B
bone	I-OUT	NOUN	I
loss	I-OUT	NOUN	O
over	I-OUT	ADP	O
a	I-OUT	DET	O
period	I-OUT	NOUN	B
of	I-OUT	ADP	O
5	I-OUT	NUM	O
years	I-OUT	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
1.4	O	NUM	O
mm	O	NOUN	O
for	O	ADP	O
the	O	DET	O
IMZ	O	PROPN	B
group	O	NOUN	B
,	O	PUNCT	O
0.7	O	NUM	O
mm	O	NOUN	O
for	O	ADP	O
the	O	DET	O
Brå	O	PROPN	B
group	O	NOUN	B
and	O	CCONJ	O
0.9	O	NUM	O
mm	O	NOUN	O
for	O	ADP	O
the	O	DET	O
ITI	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
two	O	NUM	O
implants	O	NOUN	B
placed	O	VERB	O
in	O	ADP	O
the	O	DET	O
interforaminal	O	ADJ	B
region	O	NOUN	I
,	O	PUNCT	O
connected	O	VERB	O
with	O	ADP	O
a	O	DET	O
bar	O	NOUN	B
,	O	PUNCT	O
supply	O	VERB	O
a	O	DET	O
proper	O	ADJ	O
base	O	NOUN	B
for	O	ADP	O
the	O	DET	O
support	O	NOUN	O
of	B-P	ADP	O
a	I-P	DET	O
mandibular	I-P	ADJ	B
overdenture	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
edentulous	I-P	ADJ	B
patient	I-P	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
no	O	DET	O
clinically	O	ADV	O
relevant	O	ADJ	O
and	O	CCONJ	O
statistically	O	ADV	B
significant	O	ADJ	I
radiographic	O	ADJ	B
changes	O	NOUN	B
had	O	AUX	O
developed	O	VERB	O
between	O	ADP	O
the	O	DET	O
three	O	NUM	O
implant	O	ADJ	B
systems	O	NOUN	I
.	O	PUNCT	O


Tubeless	B-I	ADJ	B
percutaneous	I-I	ADJ	I
nephrolithotomy	I-I	NOUN	I
:	I-I	PUNCT	O
safe	O	ADJ	O
even	O	ADV	O
in	O	ADP	O
supracostal	O	ADJ	B
access	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
outcome	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
tubeless	B-I	ADJ	B
percutaneous	I-I	ADJ	I
nephrolithotomy	I-I	NOUN	I
(	I-I	PUNCT	O
PCNL	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
renal	B-P	ADJ	B
calculi	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Between	B-P	ADP	O
November	I-P	PROPN	O
2005	I-P	NUM	O
and	I-P	CCONJ	O
March	I-P	PROPN	O
2006	I-P	NUM	O
,	I-P	PUNCT	O
48	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	PART	O
either	I-P	CCONJ	O
an	I-P	DET	O
18F	I-I	NOUN	B
Re-entry	I-I	NOUN	I
nephrostomy	I-I	NOUN	I
tube	I-I	NOUN	I
(	I-P	PUNCT	O
group	I-P	NOUN	B
1	I-P	NUM	O
)	I-P	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
6F	I-I	NOUN	O
Double-J	I-I	NOUN	B
stent	I-I	NOUN	I
(	I-P	PUNCT	O
group	I-P	NOUN	B
2	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
matched	O	VERB	O
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
stone	O	NOUN	B
size	O	NOUN	B
,	O	PUNCT	O
stone	O	NOUN	B
laterality	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
number	O	NOUN	O
of	O	ADP	O
previous	O	ADJ	O
renal	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
PCNL	O	PROPN	B
procedures	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
by	O	ADP	O
the	O	DET	O
same	O	ADJ	O
surgeon	O	NOUN	B
.	O	PUNCT	O


Postoperative	B-OUT	ADJ	B
visual	I-OUT	ADJ	O
analog	I-OUT	NOUN	O
pain	I-OUT	NOUN	O
scale	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
scores	I-OUT	NOUN	B
at	O	ADP	O
8	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	B
and	O	CCONJ	O
14	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
in-hospital	B-OUT	ADJ	B
analgesic	I-OUT	NOUN	I
use	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
length	I-OUT	NOUN	B
of	I-OUT	ADP	I
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
success	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
transfusion	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
were	O	AUX	O
compared	O	VERB	B
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
mean	B-OUT	ADJ	O
hospital	I-OUT	NOUN	B
stays	I-OUT	VERB	I
in	O	ADP	O
groups	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
were	O	AUX	O
3.1	O	NUM	O
and	O	CCONJ	O
1.6	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
VAS	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
8	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
surgery	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	O
than	O	ADP	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
postoperative	B-OUT	ADJ	B
analgesic	I-OUT	NOUN	O
requirement	I-OUT	NOUN	O
(	I-I	PUNCT	O
diclofenac	I-I	ADJ	B
sodium	I-I	NOUN	I
)	I-I	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	I
(	O	PUNCT	O
263	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
(	O	PUNCT	O
120	O	NUM	O
mg	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
blood	I-OUT	NOUN	B
transfusion	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
NS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
VAS	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
on	O	ADP	O
postoperative	O	ADJ	B
day	O	NOUN	B
14	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
supracostal	I-OUT	ADJ	B
accesses	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	O
than	O	ADP	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
stone-free	B-OUT	ADJ	B
rates	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
numbers	I-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	O	ADP	O
insignificant	B-OUT	ADJ	B
residual	I-OUT	ADJ	B
fragments	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	O
urine	I-OUT	NOUN	B
leakage	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
formation	I-OUT	NOUN	B
of	I-OUT	ADP	O
urinoma	I-OUT	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Double-J	O	NOUN	B
stents	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Tubeless	B-I	PROPN	B
PCNL	I-I	PROPN	B
is	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
even	O	ADV	O
after	O	ADP	O
supracostal	O	ADJ	B
access	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
less	O	ADV	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
and	O	CCONJ	O
a	B-OUT	DET	O
shorter	I-OUT	ADJ	B
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Cardiovascular	O	ADJ	B
and	O	CCONJ	O
behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
aerobic	B-I	ADJ	B
exercise	I-I	NOUN	B
training	O	NOUN	O
in	O	ADP	O
healthy	B-P	ADJ	B
older	I-P	ADJ	B
men	I-P	NOUN	I
and	I-P	CCONJ	O
women	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
cardiovascular	O	ADJ	B
and	O	CCONJ	O
behavioral	O	ADJ	B
adaptations	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
4-month	O	ADJ	B
program	O	NOUN	I
of	O	ADP	O
aerobic	B-I	ADJ	B
exercise	I-I	NOUN	B
training	I-I	NOUN	O
were	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
101	B-P	NUM	O
older	I-P	ADJ	B
men	I-P	NOUN	I
and	I-P	CCONJ	O
women	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
=	I-P	ADJ	O
67	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
an	O	DET	O
Aerobic	B-I	PROPN	B
Exercise	I-I	PROPN	B
group	I-I	NOUN	I
,	I-I	PUNCT	O
a	I-I	DET	O
Yoga	I-I	PROPN	B
and	I-I	CCONJ	O
Flexibility	I-I	PROPN	B
control	I-I	NOUN	O
group	I-I	NOUN	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
Waiting	I-I	PROPN	B
List	I-I	PROPN	I
control	I-I	NOUN	B
group	I-I	NOUN	I
.	I-I	PUNCT	O


Prior	O	ADV	O
to	O	ADP	O
and	O	CCONJ	O
following	O	VERB	O
the	O	DET	O
4-month	O	ADJ	B
program	O	NOUN	I
,	O	PUNCT	O
subjects	O	NOUN	B
underwent	O	VERB	O
comprehensive	O	ADJ	B
physiological	O	ADJ	B
and	O	CCONJ	O
psychological	O	ADJ	B
evaluations	O	NOUN	B
.	O	PUNCT	O


Physiological	B-OUT	ADJ	B
measures	I-OUT	NOUN	I
included	I-OUT	VERB	O
measurement	I-OUT	NOUN	B
of	I-OUT	ADP	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
lipids	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
bone	I-OUT	NOUN	B
density	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cardiorespiratory	I-OUT	ADJ	B
fitness	I-OUT	NOUN	I
including	I-OUT	VERB	O
direct	I-OUT	ADJ	O
measurements	I-OUT	NOUN	B
of	I-OUT	ADP	O
peak	I-OUT	ADJ	B
oxygen	I-OUT	NOUN	I
consumption	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VO2	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anaerobic	I-OUT	ADJ	B
threshold	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Psychological	B-OUT	ADJ	B
measures	I-OUT	NOUN	B
included	I-OUT	VERB	O
measures	I-OUT	NOUN	B
of	I-OUT	ADP	O
mood	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
psychiatric	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
neuropsychological	I-OUT	ADJ	B
functioning	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
4	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
aerobic	B-I	ADJ	B
exercise	I-I	NOUN	B
training	O	NOUN	O
produced	O	VERB	O
an	O	DET	O
overall	O	ADJ	O
11.6	O	NUM	O
%	O	NOUN	O
improvement	O	NOUN	B
in	O	ADP	O
peak	O	NOUN	B
VO2	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
13	O	NUM	O
%	O	NOUN	O
increase	O	NOUN	B
in	O	ADP	O
anaerobic	O	ADJ	B
threshold	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
Yoga	B-I	PROPN	B
and	O	CCONJ	O
Waiting	B-I	PROPN	O
List	I-I	ADJ	O
control	O	NOUN	B
groups	O	NOUN	I
experienced	O	VERB	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
cardiorespiratory	O	ADJ	B
fitness	O	NOUN	I
.	O	PUNCT	O


Other	O	ADJ	O
favorable	O	ADJ	O
physiological	O	ADJ	B
changes	O	NOUN	O
observed	O	VERB	O
among	O	ADP	O
aerobic	O	ADJ	B
exercise	O	NOUN	B
participants	O	NOUN	B
included	O	VERB	O
lower	O	ADJ	B
cholesterol	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
diastolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
levels	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
subjects	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
bone	O	NOUN	B
fracture	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
bone	O	NOUN	B
mineral	O	ADJ	I
content	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
few	O	ADJ	O
significant	O	ADJ	O
psychological	O	ADJ	B
changes	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
aerobic	B-I	ADJ	B
exercise	I-I	NOUN	B
training	O	NOUN	O
,	O	PUNCT	O
participants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
active	O	ADJ	B
treatment	O	NOUN	B
groups	O	NOUN	O
perceived	O	VERB	B
themselves	O	PRON	O
as	O	ADP	O
improving	O	VERB	B
on	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
psychological	O	ADJ	B
and	O	CCONJ	O
behavioral	O	ADJ	B
dimensions	O	NOUN	B
.	O	PUNCT	O


Locomoting-to-reach	B-I	NOUN	B
:	I-I	PUNCT	O
information	O	NOUN	B
variables	O	NOUN	I
and	O	CCONJ	O
control	O	NOUN	B
strategies	O	NOUN	I
for	O	ADP	O
nested	O	ADJ	B
actions	O	NOUN	B
.	O	PUNCT	O


Locomoting-to-reach	B-I	PROPN	B
is	O	AUX	O
a	O	DET	O
basic	O	ADJ	O
perception/action	O	NOUN	B
behavior	O	NOUN	I
that	O	PRON	O
requires	O	VERB	O
visual	O	ADJ	B
information	O	NOUN	B
for	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
locomotion	O	NOUN	B
and	O	CCONJ	O
reaching	O	VERB	O
components	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
visual	O	ADJ	B
information	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
strategies	O	NOUN	I
used	O	VERB	O
to	O	PART	O
guide	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
head	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
hand	O	NOUN	B
on	O	ADP	O
approach	O	NOUN	O
to	O	PART	O
a	O	DET	O
target	O	NOUN	B
in	O	ADP	O
a	O	DET	O
locomotion-to-reach	B-I	ADJ	B
task	I-I	NOUN	I
.	I-I	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
participants	B-P	NOUN	B
were	I-P	AUX	O
required	I-P	VERB	O
to	I-P	PART	O
locomote	I-I	VERB	B
in	I-I	ADP	O
the	I-I	DET	O
dark	I-I	NOUN	B
to	I-I	ADP	O
a	I-I	DET	O
lit	I-I	ADJ	O
target	I-I	NOUN	B
in	I-I	ADP	O
three	I-I	NUM	O
different	I-I	ADJ	O
conditions	I-I	NOUN	B
:	I-I	PUNCT	O
monocular	I-I	ADJ	B
vision/target	I-I	NOUN	B
with	I-I	ADP	O
image	I-I	NOUN	B
size	I-I	NOUN	I
,	I-I	PUNCT	O
binocular	I-I	ADJ	B
vision/target	I-I	NOUN	O
with	I-I	ADP	O
image	I-I	NOUN	B
size	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
binocular	I-I	ADJ	B
vision/point-light	I-I	ADJ	B
target	I-I	NOUN	B
(	I-I	PUNCT	O
without	I-I	ADP	O
image	I-I	NOUN	B
size	I-I	NOUN	I
)	I-I	PUNCT	O
.	I-I	PUNCT	O


In	O	ADP	O
task	O	NOUN	O
one	O	NUM	O
,	O	PUNCT	O
participants	O	NOUN	B
brought	O	VERB	O
their	O	PRON	O
eyes	O	NOUN	B
to	O	ADP	O
the	O	DET	O
target	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
task	O	NOUN	O
two	O	NUM	O
,	O	PUNCT	O
participants	O	NOUN	B
brought	O	VERB	O
their	O	PRON	O
outstretched	O	NOUN	B
hand	O	NOUN	I
to	O	ADP	O
the	O	DET	O
target	O	NOUN	B
.	O	PUNCT	O


Movement	B-OUT	ADJ	B
trajectories	I-OUT	NOUN	B
for	O	ADP	O
both	O	DET	O
tasks	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


Results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
participants	B-P	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
accurate	B-OUT	ADJ	B
when	I-OUT	SCONJ	O
binocular	I-OUT	ADJ	B
information	I-OUT	NOUN	B
was	I-OUT	AUX	O
present	I-OUT	ADJ	O
.	I-OUT	PUNCT	O


In	O	ADP	O
both	O	DET	O
tasks	O	NOUN	B
,	O	PUNCT	O
participants	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
use	O	VERB	O
a	O	DET	O
proportional	B-OUT	ADJ	B
rate	I-OUT	NOUN	I
control	I-OUT	NOUN	I
strategy	I-OUT	NOUN	I
rather	I-OUT	ADV	O
than	I-OUT	ADP	O
a	I-OUT	DET	O
constant	I-OUT	ADJ	B
τ	I-OUT	NOUN	I
strategy	I-OUT	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
the	B-OUT	DET	O
walk-to-reach	I-OUT	ADJ	O
task	I-OUT	NOUN	B
,	O	PUNCT	O
they	O	PRON	O
used	B-OUT	VERB	O
monocular	I-OUT	ADJ	B
and/or	I-OUT	CCONJ	O
binocular	I-OUT	ADJ	B
τ	I-OUT	NOUN	I
information	I-OUT	NOUN	B
to	I-OUT	PART	O
guide	I-OUT	VERB	O
the	I-OUT	DET	O
head	I-OUT	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
switched	O	VERB	O
to	O	ADP	O
using	B-OUT	VERB	O
relative	I-OUT	ADJ	B
disparity	I-OUT	NOUN	I
τ	I-OUT	NOUN	I
to	I-OUT	PART	O
guide	I-OUT	VERB	O
the	I-OUT	DET	O
hand	I-OUT	NOUN	B
to	I-OUT	ADP	O
final	I-OUT	ADJ	O
target	I-OUT	NOUN	B
acquisition	I-OUT	NOUN	B
,	O	PUNCT	O
switching	O	NOUN	B
when	O	SCONJ	O
the	O	DET	O
hand	O	NOUN	B
centric	O	ADJ	I
τ	O	NOUN	I
became	O	VERB	O
less	O	ADJ	O
than	O	ADP	O
the	O	DET	O
head	O	NOUN	B
centric	O	ADJ	I
τ.	O	NOUN	O
Dynamical	O	ADJ	B
models	O	NOUN	I
of	O	ADP	O
the	O	DET	O
information	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
strategies	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
perform	B-OUT	VERB	O
simulations	I-OUT	NOUN	B
that	O	PRON	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
fit	O	VERB	O
the	O	DET	O
data	O	NOUN	B
well	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
conclusion	O	NOUN	O
is	O	AUX	O
that	B-OUT	SCONJ	O
proportional	I-OUT	ADJ	B
rate	I-OUT	NOUN	I
control	I-OUT	NOUN	I
is	O	AUX	O
used	O	VERB	O
sequentially	O	ADV	O
with	B-OUT	ADP	O
head	I-OUT	NOUN	B
centric	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
then	I-OUT	ADV	O
hand-centric	I-OUT	ADJ	B
τ-based	I-OUT	VERB	B
information	I-OUT	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
at	O	ADP	O
each	O	DET	O
moment	B-OUT	NOUN	O
the	O	DET	O
τ	O	NOUN	B
with	O	ADP	O
the	O	DET	O
smallest	O	ADJ	O
value	O	NOUN	O
.	O	PUNCT	O


0.1	O	NUM	O
%	O	NOUN	O
bupivacaine	B-I	NOUN	B
does	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
the	O	DET	O
requirement	O	NOUN	B
for	O	ADP	O
epidural	O	ADJ	B
fentanyl	O	NOUN	B
infusion	O	NOUN	B
after	B-P	ADP	O
major	I-P	ADJ	O
abdominal	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
OBJECTIVES	O	NOUN	O
Although	O	SCONJ	O
local	O	ADJ	B
anesthesia	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
potentiate	O	VERB	B
spinal	O	ADJ	B
morphine	O	NOUN	B
analgesia	O	NOUN	B
in	O	ADP	O
animal	O	NOUN	B
studies	O	NOUN	I
,	O	PUNCT	O
results	O	VERB	B
comparing	O	VERB	O
epidural	O	ADJ	B
local	O	ADJ	O
anesthesia/opioid	O	ADJ	O
mixtures	O	NOUN	O
with	O	ADP	O
opioid	O	NOUN	B
alone	O	ADV	O
are	O	AUX	O
contradictory	O	ADJ	O
in	O	ADP	O
clinical	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
hypothesis	O	NOUN	B
was	O	AUX	O
that	O	DET	O
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
concentration	O	NOUN	B
of	O	ADP	O
bupivacaine	B-I	NOUN	B
(	O	PUNCT	O
0.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
low	O	ADJ	O
to	O	PART	O
minimize	O	VERB	O
its	O	PRON	O
adverse	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
if	O	SCONJ	O
the	O	DET	O
infusion	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
a	O	DET	O
fentanyl/bupivacaine	B-I	NOUN	B
solution	O	NOUN	O
was	O	AUX	O
closely	O	ADV	O
adjusted	O	VERB	O
according	O	VERB	O
to	O	PART	O
need	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
presence	O	NOUN	B
bupivacaine	O	NOUN	B
would	O	AUX	O
reduce	O	VERB	B
the	O	DET	O
requirement	O	NOUN	B
for	O	ADP	O
epidural	O	ADJ	B
fentanyl	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Forty	B-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	B-I	VERB	O
to	I-I	PART	O
receive	I-I	VERB	O
either	I-I	CCONJ	O
fentanyl	I-I	NOUN	B
(	I-I	PUNCT	O
10	I-I	NUM	O
micrograms/mL	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
fentanyl/bupivacaine	I-I	NOUN	B
(	I-I	PUNCT	O
0.1	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
mixture	I-I	NOUN	O
epidurally	I-I	ADV	B
corresponding	I-I	VERB	O
to	I-I	PART	O
the	I-I	DET	O
dermatome	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
surgical	I-I	ADJ	B
incision	I-I	NOUN	I
in	I-I	ADP	O
a	I-I	DET	O
double-blind	I-I	ADJ	B
fashion	I-I	NOUN	I
for	I-I	ADP	O
the	I-I	DET	O
first	I-I	ADJ	O
18	I-I	NUM	O
hours	I-I	NOUN	B
after	I-I	ADP	O
major	I-I	ADJ	O
abdominal	I-I	ADJ	B
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


The	B-I	DET	O
infusion	I-I	NOUN	B
was	I-I	AUX	O
titrated	I-I	VERB	B
for	I-I	ADP	O
each	I-I	DET	O
patient	I-I	NOUN	B
to	I-I	ADP	O
the	I-I	DET	O
rate	I-I	NOUN	B
required	I-I	VERB	O
for	I-I	ADP	O
pain	I-I	NOUN	B
relief	I-I	NOUN	I
during	I-I	ADP	O
forced	I-I	VERB	B
inspiration	I-I	NOUN	B
(	I-I	PUNCT	O
pain	I-I	NOUN	B
score	I-I	NOUN	I
<	I-I	X	O
or	I-I	CCONJ	O
=	I-I	ADJ	O
2	I-I	NUM	O
,	I-I	PUNCT	O
maximum	I-I	NOUN	O
10	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Pain	O	NOUN	B
scores	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
fentanyl	O	NOUN	B
doses	O	NOUN	I
required	O	VERB	O
,	O	PUNCT	O
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
fentanyl	O	NOUN	B
at	O	ADP	O
18	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Patients	O	NOUN	B
reported	O	VERB	O
similar	O	ADJ	O
median	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
scores	I-OUT	NOUN	O
and	O	CCONJ	O
were	O	AUX	O
equally	O	ADV	O
satisfied	O	ADJ	O
with	O	ADP	O
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	NOUN	O
required	I-OUT	VERB	O
post-operative	I-OUT	ADJ	B
fentanyl	I-OUT	ADJ	B
infusion	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
(	O	PUNCT	O
57.7	O	NUM	O
+/-	O	CCONJ	O
19.5	O	NUM	O
micrograms/h	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
plasma	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
(	O	PUNCT	O
0.84	O	NUM	O
+/-	O	CCONJ	O
0.36	O	NUM	O
ng/mL	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
fentanyl	O	NOUN	B
group	O	NOUN	I
were	O	AUX	O
comparable	O	ADJ	O
to	O	PART	O
the	O	DET	O
infusion	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
(	O	PUNCT	O
54.4	O	NUM	O
+/-	O	CCONJ	O
19.2	O	NUM	O
micrograms/h	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
plasma	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
(	O	PUNCT	O
0.86	O	NUM	O
+/-	O	CCONJ	O
0.36	O	NUM	O
ng/mL	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
fentanyl/bupivacaine	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Respiratory	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
cardiovascular	I-OUT	ADJ	B
functions	I-OUT	NOUN	I
were	O	AUX	O
preserved	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
nausea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pruritus	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
periods	I-OUT	NOUN	B
of	I-OUT	ADP	O
drowsiness	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
sleep	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
low	O	ADJ	B
concentrations	O	NOUN	B
(	O	PUNCT	O
0.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
bupivacaine	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
the	O	DET	O
titrated	O	VERB	B
dose	O	NOUN	B
of	O	ADP	O
epidural	O	ADJ	B
fentanyl	O	NOUN	B
required	O	VERB	O
for	O	ADP	O
adequate	O	ADJ	B
pain	O	NOUN	B
relief	O	NOUN	I
during	O	ADP	O
forced	O	VERB	B
inspiration	O	NOUN	B
after	O	ADP	O
major	O	ADJ	O
abdominal	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
comparable	O	ADJ	O
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
low-dose	O	ADJ	B
bupivacaine	B-I	NOUN	B
infusion	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Capsaicin	B-I	NOUN	B
jelly	I-I	NOUN	B
against	O	ADP	O
migraine	B-OUT	NOUN	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


OBJECTIVE	O	ADJ	O
Recent	O	ADJ	O
studies	O	NOUN	B
support	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
extracranial	O	ADJ	B
perivascular	O	ADJ	B
afferents	O	NOUN	B
in	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
percentage	O	NOUN	O
of	O	ADP	O
migraineurs	B-P	NOUN	B
.	I-P	PUNCT	O


Perivascular	O	ADJ	B
afferent	O	NOUN	O
fibres	O	NOUN	O
of	O	ADP	O
the	O	DET	O
superficial	O	ADJ	B
temporal	O	ADJ	O
artery	O	NOUN	O
contain	O	VERB	O
peptides	O	NOUN	B
,	O	PUNCT	O
like	O	ADP	O
calcitonin	O	NOUN	B
gene-related	O	ADJ	I
peptide	O	NOUN	I
(	O	PUNCT	O
CGRP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
substance	O	NOUN	B
P	O	NOUN	I
(	O	PUNCT	O
SP	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CGRP	O	NOUN	B
and	O	CCONJ	O
SP	O	NOUN	B
are	O	AUX	O
considered	O	VERB	O
relevant	O	ADJ	B
in	O	ADP	O
the	O	DET	O
genesis	O	NOUN	B
of	O	ADP	O
migraine	O	NOUN	B
pain	O	NOUN	I
.	O	PUNCT	O


Capsaicin	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
agonist	O	NOUN	B
of	O	ADP	O
the	O	DET	O
transient	O	ADJ	B
receptor	O	NOUN	I
potential	O	ADJ	I
vanilloid	O	NOUN	I
type	O	NOUN	I
1	O	NUM	I
.	O	PUNCT	O


It	O	PRON	O
causes	O	VERB	O
membrane	O	NOUN	B
depolarisation	O	NOUN	B
of	O	ADP	O
sensory	O	ADJ	B
neurons	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
release	O	VERB	O
CGRP	O	NOUN	B
,	O	PUNCT	O
SP	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
pain	O	NOUN	B
peptides	O	NOUN	I
;	O	PUNCT	O
excitation	O	NOUN	B
is	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
refractory	O	ADJ	B
state	O	NOUN	I
,	O	PUNCT	O
causing	O	VERB	O
inactivation	O	NOUN	B
.	O	PUNCT	O


Topical	B-I	ADJ	B
capsaicin	I-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
efficacious	O	ADJ	B
in	O	ADP	O
several	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
neuropathic	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


We	O	PRON	O
attempted	O	VERB	O
to	O	PART	O
verify	O	VERB	O
whether	O	SCONJ	O
topical	B-I	ADJ	B
periarterial	I-I	ADJ	B
capsaicin	I-I	NOUN	B
could	O	AUX	O
ameliorate	O	VERB	B
pain	B-OUT	NOUN	B
in	I-OUT	ADP	O
absence	I-OUT	NOUN	B
of	I-OUT	ADP	O
and	I-OUT	CCONJ	O
during	I-OUT	ADP	O
a	I-OUT	DET	O
migraine	I-OUT	NOUN	B
attack	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
On	O	ADP	O
23	B-P	NUM	O
migraineurs	I-P	NOUN	B
showing	I-P	VERB	O
pain	I-P	NOUN	B
at	I-P	ADP	O
pressure	I-P	NOUN	B
on	I-P	ADP	O
scalp	I-P	NOUN	B
arteries	I-P	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
administered	O	VERB	B
topical	B-I	ADJ	B
capsaicin	I-I	NOUN	B
0.1	I-I	NUM	O
%	I-I	NOUN	O
or	I-I	CCONJ	O
vaseline	I-I	ADJ	B
jelly	I-I	ADV	I
on	O	ADP	O
painful	O	ADJ	B
arteries	O	NOUN	I
in	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
migraine	O	NOUN	B
attack	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
those	O	DET	O
having	O	VERB	O
pain	O	NOUN	B
reduction	O	NOUN	I
>	O	NOUN	O
50	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
made	O	VERB	O
the	O	DET	O
same	O	ADJ	O
comparison	O	NOUN	B
during	O	ADP	O
a	O	DET	O
migraine	O	NOUN	B
attack	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Topical	B-I	ADJ	B
capsaicin	I-I	NOUN	O
caused	O	VERB	O
>	O	PROPN	O
50	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
of	O	ADP	O
arterial	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
in	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
attack	O	NOUN	B
in	O	ADP	O
17/23	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
opposed	O	VERB	O
to	O	ADP	O
two	O	NUM	O
with	O	ADP	O
vaseline	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
attacks	O	NOUN	B
of	O	ADP	O
mild-	O	ADJ	O
to	O	PART	O
moderate-intensity	O	NOUN	B
,	O	PUNCT	O
>	O	X	O
50	O	NUM	O
%	O	NOUN	O
improvement	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
11/17	O	NUM	O
with	O	ADP	O
capsaicin	B-I	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
with	O	ADP	O
vaseline	B-I	NOUN	B
.	I-I	PUNCT	O


CONCLUSIONS	O	NOUN	O
Although	O	SCONJ	O
referring	O	VERB	O
to	O	ADP	O
a	O	DET	O
small	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
topical	B-I	ADJ	B
capsaicin	I-I	NOUN	B
may	O	AUX	O
relieve	O	VERB	O
arterial	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
in	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
and	O	CCONJ	O
during	O	ADP	O
a	O	DET	O
migraine	O	NOUN	B
attack	O	NOUN	B
in	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
patients	B-P	NOUN	B
experiencing	I-P	VERB	O
scalp	I-P	ADJ	B
arterial	I-P	ADJ	B
tenderness	I-P	NOUN	I
.	I-P	PUNCT	O


More	O	ADV	O
active	O	ADJ	O
capsacinoids	B-I	NOUN	B
might	O	AUX	O
be	O	AUX	O
tried	O	VERB	O
in	O	ADP	O
the	O	DET	O
future	O	NOUN	B
and	O	CCONJ	O
could	O	AUX	O
provide	O	VERB	O
a	O	DET	O
new	O	ADJ	O
method	O	NOUN	B
for	O	ADP	O
treating	O	VERB	B
migraine	O	NOUN	B
attacks	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
enzalutamide	B-I	NOUN	B
on	O	ADP	O
health-related	B-OUT	ADJ	B
quality	I-OUT	NOUN	I
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
skeletal-related	I-OUT	ADJ	B
events	I-OUT	NOUN	I
in	O	ADP	O
asymptomatic	B-P	ADJ	B
and	I-P	CCONJ	O
minimally	I-P	ADV	B
symptomatic	I-P	ADJ	I
,	I-P	PUNCT	O
chemotherapy-naive	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
castration-resistant	I-P	ADJ	I
prostate	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
PREVAIL	I-P	NOUN	B
)	I-P	PUNCT	O
:	I-P	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
3	O	NUM	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Enzalutamide	B-I	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
and	O	CCONJ	O
radiographic	B-OUT	ADJ	B
progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
PREVAIL	O	NOUN	B
trial	O	NOUN	O
of	O	ADP	O
asymptomatic	B-P	ADJ	B
and	I-P	CCONJ	O
minimally	I-P	ADV	B
symptomatic	I-P	ADJ	I
,	I-P	PUNCT	O
chemotherapy-naive	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
castration-resistant	I-P	ADJ	I
prostate	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
enzalutamide	B-I	NOUN	B
on	O	ADP	O
health-related	B-OUT	ADJ	B
quality	I-OUT	NOUN	I
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HRQoL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
skeletal-related	I-OUT	ADJ	B
events	I-OUT	NOUN	I
observed	O	VERB	O
during	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
phase	O	NOUN	B
3	O	NUM	I
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
patients	B-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
(	I-P	PUNCT	O
1:1	I-P	NUM	O
)	I-P	PUNCT	O
to	I-P	PART	O
receive	I-P	VERB	O
enzalutamide	I-I	NOUN	B
160	I-I	NUM	O
mg/day	I-I	NOUN	B
(	I-P	PUNCT	O
n=872	I-P	NOUN	O
)	I-P	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
n=845	I-P	NOUN	O
)	I-P	PUNCT	O
orally	I-P	ADV	B
.	I-P	PUNCT	O


HRQoL	B-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
during	O	ADP	O
treatment	O	NOUN	B
using	O	VERB	O
the	O	DET	O
Functional	O	ADJ	B
Assessment	O	PROPN	I
of	O	ADP	I
Cancer	O	PROPN	I
Therapy-Prostate	O	PROPN	I
(	O	PUNCT	I
FACT-P	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
EQ-5D	O	ADJ	B
questionnaires	O	NOUN	B
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
status	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
screening	O	NOUN	B
,	O	PUNCT	O
baseline	O	NOUN	B
,	O	PUNCT	O
week	O	NOUN	B
13	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
week	O	NOUN	B
25	O	NUM	O
with	O	ADP	O
the	O	DET	O
Brief	B-OUT	PROPN	B
Pain	I-OUT	PROPN	I
Inventory	I-OUT	PROPN	I
Short	I-OUT	PROPN	I
Form	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BPI-SF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	O	DET	O
primary	B-OUT	ADJ	B
analysis	I-OUT	NOUN	I
of	I-OUT	ADP	O
HRQoL	I-OUT	NOUN	B
data	I-OUT	NOUN	B
used	O	VERB	O
a	O	DET	O
mixed-effects	O	ADJ	B
model	O	NOUN	I
to	O	PART	O
test	O	VERB	O
the	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
least	O	ADJ	O
square	O	ADJ	B
means	O	VERB	O
change	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
at	O	ADP	O
week	O	NOUN	B
61	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
assessed	O	VERB	B
change	B-OUT	NOUN	O
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
percentage	I-OUT	NOUN	B
improvement	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
to	I-OUT	PART	O
deterioration	I-OUT	NOUN	B
in	I-OUT	ADP	O
HRQoL	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
,	O	PUNCT	O
the	O	DET	O
proportion	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
a	I-OUT	DET	O
skeletal-related	I-OUT	ADJ	B
event	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
time	B-OUT	NOUN	B
to	I-OUT	PART	O
first	I-OUT	ADJ	O
skeletal-related	I-OUT	ADJ	B
event	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Analysis	O	NOUN	B
was	O	AUX	O
done	O	VERB	O
on	O	ADP	O
the	O	DET	O
intention-to-treat	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
is	O	AUX	O
registered	O	VERB	O
with	O	ADP	O
ClinicalTrials.gov	O	NOUN	B
,	O	PUNCT	O
number	O	NOUN	O
NCT01212991	O	NOUN	B
.	O	PUNCT	O


FINDINGS	O	ADJ	B
Median	B-OUT	ADJ	B
treatment	I-OUT	NOUN	I
duration	I-OUT	NOUN	O
was	O	AUX	O
16·6	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
IQR	O	NOUN	B
10·1-21·1	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	B-I	DET	O
enzalutamide	I-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
4·6	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
2·8-9·7	O	NUM	O
)	O	PUNCT	O
in	B-I	ADP	O
the	I-I	DET	O
placebo	I-I	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mixed-effects	O	ADJ	B
model	O	NOUN	I
analyses	O	NOUN	I
showed	O	VERB	O
significant	B-OUT	ADJ	B
treatment	I-OUT	NOUN	B
differences	I-OUT	NOUN	O
in	O	ADP	O
change	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
week	O	NOUN	B
61	B-I	NUM	O
with	I-I	ADP	O
enzalutamide	I-I	NOUN	B
compared	I-I	VERB	O
with	I-I	ADP	O
placebo	I-I	NOUN	B
for	O	ADP	O
most	O	ADJ	O
FACT-P	O	NUM	B
endpoints	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
EQ-5D	I-OUT	ADJ	B
visual	I-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
time	I-OUT	NOUN	I
to	I-OUT	PART	O
deterioration	I-OUT	NOUN	B
in	I-OUT	ADP	O
FACT-P	I-OUT	ADJ	B
total	I-OUT	ADJ	I
score	O	NOUN	I
was	O	AUX	O
11·3	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
11·1-13·9	B-I	NUM	O
)	I-I	PUNCT	O
in	I-I	ADP	O
the	I-I	DET	O
enzalutamide	I-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
5·6	O	ADJ	O
months	O	NOUN	B
(	B-I	PUNCT	O
5·5-5·6	I-I	NUM	O
)	I-I	PUNCT	O
in	I-I	ADP	O
the	O	DET	O
placebo	O	NOUN	B
groups	O	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
[	O	PUNCT	O
HR	O	NOUN	B
]	O	PUNCT	O
0·62	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0·54-0·72	O	NUM	O
]	O	PUNCT	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0·0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
significantly	O	ADV	O
greater	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
patients	B-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
enzalutamide	O	NOUN	B
group	B-I	NOUN	B
than	I-I	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
reported	O	VERB	O
clinically	O	ADV	B
meaningful	O	ADJ	O
improvements	B-OUT	NOUN	B
in	I-OUT	ADP	O
FACT-P	I-OUT	ADJ	B
total	O	ADJ	I
score	O	NOUN	I
(	O	PUNCT	O
327	O	NUM	O
[	O	PUNCT	O
40	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
of	O	ADP	O
826	O	NUM	O
vs	O	CCONJ	O
181	O	NUM	O
[	B-OUT	PUNCT	O
23	I-OUT	NUM	O
%	I-OUT	NOUN	O
]	I-OUT	PUNCT	O
of	I-OUT	ADP	O
790	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
in	I-OUT	ADP	O
EQ-5D	I-OUT	ADJ	B
utility	O	NOUN	B
index	O	NOUN	I
(	O	PUNCT	O
224	O	NUM	O
[	O	PUNCT	O
28	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
of	O	ADP	O
812	O	NUM	O
vs	O	CCONJ	O
99	O	NUM	O
[	B-OUT	PUNCT	O
16	I-OUT	NUM	O
%	I-OUT	NOUN	O
]	I-OUT	PUNCT	O
of	I-OUT	ADP	O
623	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
visual	I-OUT	ADJ	B
analogue	O	NOUN	I
scale	O	NOUN	I
(	O	PUNCT	O
218	O	NUM	O
[	O	PUNCT	O
27	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
of	O	ADP	O
803	O	NUM	O
vs	O	CCONJ	O
106	O	NUM	O
of	O	ADP	O
[	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
603	B-OUT	NUM	O
;	I-OUT	PUNCT	O
all	I-OUT	DET	O
p	I-OUT	NOUN	O
<	I-OUT	X	O
0·0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
time	I-OUT	NOUN	I
to	I-OUT	PART	O
progression	I-OUT	NOUN	B
in	O	ADP	O
BPI-SF	O	NOUN	B
pain	O	NOUN	I
at	O	ADP	O
its	O	PRON	O
worst	O	ADJ	O
was	O	AUX	O
5·7	O	NOUN	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	B-I	NOUN	B
5·6-5·7	I-I	NUM	O
)	I-I	PUNCT	O
in	O	ADP	O
the	O	DET	O
enzalutamide	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
5·6	O	ADJ	O
months	B-I	NOUN	B
(	I-I	PUNCT	O
5·4-5·6	I-I	PROPN	O
)	I-I	PUNCT	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
HR	O	NOUN	B
0·62	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	B-OUT	NOUN	B
0·53-0·74	I-OUT	NOUN	O
]	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
p	I-OUT	X	O
<	I-OUT	X	O
0·0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


Progression	O	NOUN	B
of	O	ADP	O
pain	O	NOUN	B
at	O	ADP	O
its	O	PRON	O
worst	O	ADJ	O
was	O	AUX	O
less	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
the	O	DET	O
enzalutamide	B-I	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
at	O	ADP	O
week	O	NOUN	B
13	O	NUM	O
(	O	PUNCT	O
220	O	NUM	O
[	O	PUNCT	O
29	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
of	O	ADP	O
769	O	NUM	O
vs	O	CCONJ	O
257	O	NUM	O
[	O	PUNCT	O
42	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
of	O	ADP	O
610	O	NUM	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0·0001	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
at	O	ADP	O
week	O	NOUN	B
25	O	NUM	O
(	O	PUNCT	O
225	O	NUM	O
[	O	PUNCT	O
32	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
of	O	ADP	O
705	O	NUM	O
vs	O	CCONJ	O
135	O	NUM	O
[	O	PUNCT	O
38	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
of	O	ADP	O
360	O	NUM	O
;	O	PUNCT	O
p=0·068	O	VERB	B
)	O	PUNCT	O
.	O	PUNCT	O


278	O	NUM	O
(	B-I	PUNCT	O
32	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
of	I-I	ADP	O
872	I-I	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
enzalutamide	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
309	O	NUM	O
(	B-I	PUNCT	O
37	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
of	I-I	ADP	O
845	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	B-OUT	ADJ	B
group	I-OUT	NOUN	B
had	I-OUT	AUX	O
experienced	I-OUT	VERB	O
a	O	DET	O
skeletal-related	B-OUT	ADJ	B
event	I-OUT	NOUN	I
by	I-OUT	ADP	O
data	I-OUT	NOUN	B
cutoff	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
time	I-OUT	NOUN	I
to	I-OUT	ADP	O
first	I-OUT	ADJ	O
skeletal-related	I-I	ADJ	B
events	O	NOUN	I
in	O	ADP	O
the	O	DET	O
enzalutamide	O	NOUN	B
group	O	NOUN	B
was	O	AUX	O
31·1	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
29·5-not	O	NUM	O
reached	O	VERB	O
)	O	PUNCT	O
and	O	CCONJ	O
31·3	O	NUM	O
months	O	NOUN	B
(	B-I	PUNCT	O
95	I-I	NUM	O
%	I-I	NOUN	O
CI	I-I	NOUN	B
23·9-not	I-I	NUM	O
reached	O	VERB	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
HR	O	NOUN	B
0·72	O	NOUN	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0·61-0·84	O	NUM	O
]	O	PUNCT	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0·0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


INTERPRETATION	B-OUT	NOUN	B
In	I-OUT	ADP	O
addition	I-OUT	NOUN	O
to	O	ADP	O
improving	B-I	VERB	B
overall	I-I	ADJ	B
survival	I-I	NOUN	B
relative	O	ADJ	O
to	O	PART	O
placebo	O	NOUN	B
,	O	PUNCT	O
enzalutamide	B-OUT	NOUN	B
significantly	I-OUT	ADV	O
improves	I-OUT	VERB	B
patient-related	I-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
delays	I-OUT	NOUN	B
occurrence	I-OUT	NOUN	B
of	I-P	ADP	O
first	I-P	ADJ	O
skeletal-related	I-P	ADJ	B
event	I-P	NOUN	I
in	I-P	ADP	O
chemotherapy-naive	I-P	ADJ	B
men	I-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
castration-resistant	O	ADJ	I
prostate	O	NOUN	I
cancer	O	NOUN	I
.	O	PUNCT	O


FUNDING	O	PROPN	B
Astellas	O	PROPN	O
Pharma	O	PROPN	O
and	O	CCONJ	O
Medivation	O	PROPN	B
.	O	PUNCT	O


A	B-P	DET	O
controlled	I-P	ADJ	B
clinical	I-P	ADJ	I
trial	I-P	NOUN	I
of	I-P	ADP	O
a	I-P	DET	O
muscle	I-I	NOUN	B
relaxant	I-I	ADJ	B
analgesic	I-I	NOUN	O
combination	I-I	NOUN	O
in	I-P	ADP	O
the	I-P	DET	O
treatment	I-P	NOUN	B
of	I-P	ADP	O
acute	I-P	ADJ	B
lumbago	I-P	NOUN	I
.	I-P	PUNCT	O


[	O	PUNCT	O
The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
thoracic	B-I	ADJ	B
peridural	I-I	ADJ	I
analgesia	I-I	NOUN	I
on	O	ADP	O
the	O	DET	O
cortisol	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
glucose	I-OUT	NOUN	B
response	I-OUT	NOUN	I
in	O	ADP	O
surgery	B-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
abdominal	I-P	ADJ	B
aorta	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


UNLABELLED	O	NOUN	B
It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
stress	O	NOUN	B
response	O	NOUN	I
to	O	PART	O
lower	B-P	ADJ	O
abdominal	I-P	ADJ	B
surgery	I-P	NOUN	I
can	O	AUX	O
be	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
epidural	B-I	ADJ	B
analgesia	I-I	NOUN	I
(	I-I	PUNCT	O
EA	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


But	O	CCONJ	O
EA	O	PROPN	B
seems	O	VERB	O
to	O	PART	O
have	O	AUX	O
little	O	ADJ	O
influence	O	NOUN	B
on	O	ADP	O
the	O	DET	O
stress	O	NOUN	B
reaction	O	NOUN	I
to	O	ADP	O
major	O	ADJ	O
abdominal	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
find	O	VERB	O
out	O	ADP	O
whether	O	SCONJ	O
EA	O	NOUN	B
is	O	AUX	O
able	O	ADJ	O
to	O	PART	O
diminish	O	VERB	B
the	O	DET	O
cortisol	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
glucose	I-OUT	NOUN	B
response	I-OUT	NOUN	I
to	O	PART	O
major	B-P	ADJ	O
transabdominal	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
31	B-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
surgery	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
abdominal	I-P	ADJ	B
aorta	I-P	NOUN	I
were	O	AUX	O
subdivided	O	VERB	O
at	O	ADP	O
random	O	ADJ	B
into	O	ADP	O
3	O	NUM	O
different	O	ADJ	O
anaesthesia	O	NOUN	B
groups	O	NOUN	B
:	O	PUNCT	O
1.	O	X	O
halothane	B-I	NOUN	B
anesthesia	I-I	NOUN	O
,	O	PUNCT	O
2.	O	X	O
neuroleptanalgesia	B-I	NOUN	B
(	I-I	PUNCT	O
NLA	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
3.	O	X	O
thoracic	B-I	ADJ	B
EA	I-I	NOUN	I
with	I-I	ADP	O
bupivacaine	I-I	NOUN	B
(	I-I	PUNCT	O
0.5	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
in	O	ADP	O
combination	B-I	NOUN	B
with	I-I	ADP	O
a	I-I	DET	O
light	I-I	ADJ	O
general	I-I	ADJ	B
anesthesia	I-I	NOUN	I
.	I-I	PUNCT	O


Some	O	DET	O
patients	O	NOUN	B
of	O	ADP	O
each	O	DET	O
group	O	NOUN	B
received	O	VERB	O
an	O	DET	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
glucose	O	NOUN	B
.	O	PUNCT	O


Blood	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
drawn	O	VERB	O
before	O	ADP	B
anesthesia	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
intubation	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
times	O	NOUN	O
during	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
analysed	O	VERB	B
for	O	ADP	O
cortisol	O	NOUN	B
and	O	CCONJ	O
glucose	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
early	O	ADJ	B
postoperative	O	ADJ	B
period	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
cortisol	B-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Only	O	ADV	O
the	O	DET	O
glucose	B-OUT	NOUN	B
levels	I-OUT	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
no	O	DET	O
carbohydrate-containing	O	ADJ	B
infusion	O	NOUN	I
fluids	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
stress	O	NOUN	B
response	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
halothane	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mean	B-OUT	ADJ	O
cortisol	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
glucose	I-OUT	NOUN	B
levels	I-OUT	NOUN	I
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
intraoperative	O	ADJ	B
elevations	O	NOUN	B
of	O	ADP	O
blood	B-OUT	NOUN	B
glucose	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
cortisol	I-OUT	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
EA	O	NOUN	B
group	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
of	O	ADP	O
the	O	DET	O
NLA	O	NOUN	B
group	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
hyperglycaemia	O	NOUN	B
and	O	CCONJ	O
only	O	ADV	O
mild	O	ADJ	B
elevations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cortisol	O	NOUN	B
levels	O	NOUN	O
during	O	ADP	O
the	O	DET	O
intraoperative	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O


Treatment	B-P	NOUN	B
of	I-P	ADP	O
renal	I-OUT	ADJ	B
failure	I-OUT	NOUN	I
associated	I-P	VERB	B
with	I-P	ADP	I
multiple	I-P	ADJ	B
myeloma	I-P	NOUN	I
.	I-P	PUNCT	O


Plasmapheresis	O	NOUN	B
,	O	PUNCT	O
hemodialysis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aims	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
were	O	AUX	O
to	O	PART	O
examine	O	VERB	O
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
plasmapheresis	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	O
irreversible	B-OUT	ADJ	B
renal	I-OUT	ADJ	B
failure	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
multiple	I-P	ADJ	B
myeloma	I-P	NOUN	I
and	O	CCONJ	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
renal	O	ADJ	B
biopsy	O	NOUN	I
tissues	O	NOUN	I
from	O	ADP	O
such	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


Twenty-one	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
active	I-P	ADJ	B
myeloma	I-P	NOUN	I
and	I-P	CCONJ	O
progressive	I-P	ADJ	B
renal	I-P	ADJ	B
failure	I-P	NOUN	I
were	O	AUX	O
randomized	B-I	VERB	B
to	I-I	ADP	O
one	I-I	NUM	O
of	I-I	ADP	O
two	I-I	NUM	O
groups	I-I	NOUN	B
:	I-I	PUNCT	O
group	I-I	NOUN	B
1	I-I	NUM	I
,	I-I	PUNCT	O
forced	I-I	VERB	B
diuresis	I-I	NOUN	I
and	I-I	CCONJ	O
chemotherapy	I-I	NOUN	B
(	I-I	PUNCT	O
10	I-I	NUM	O
patients	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
group	I-I	NOUN	B
2	I-I	NUM	I
,	I-I	PUNCT	O
forced	I-I	VERB	B
diuresis	I-I	NOUN	I
,	I-I	PUNCT	O
chemotherapy	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
plasmapheresis	I-I	NOUN	B
(	I-I	PUNCT	O
11	I-I	NUM	O
patients	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Plasmapheresis	O	NOUN	B
and	O	CCONJ	O
chemotherapy	O	NOUN	B
lowered	O	VERB	B
the	O	DET	O
serum	B-OUT	NOUN	B
myeloma	I-OUT	NOUN	I
protein	I-OUT	NOUN	I
value	I-OUT	VERB	I
much	O	ADV	O
more	O	ADV	O
rapidly	O	ADV	O
than	O	ADP	O
chemotherapy	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Of	B-P	ADP	O
5	I-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
oliguric	I-P	ADJ	B
and	I-P	CCONJ	O
undergoing	I-P	VERB	O
dialysis	I-P	NOUN	B
at	I-P	ADP	O
presentation	I-P	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
3	O	NUM	O
who	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
plasmapheresis	O	NOUN	B
recovered	O	VERB	B
.	O	PUNCT	O


Of	B-P	ADP	O
16	I-P	NUM	O
polyuric	I-P	ADJ	B
patients	I-P	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
7	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
showed	O	VERB	O
improvement	O	NOUN	B
in	O	ADP	O
renal	B-OUT	ADJ	B
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
main	O	ADJ	O
factor	O	NOUN	B
that	O	PRON	O
determined	O	VERB	O
irreversibility	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
failure	O	NOUN	I
was	O	AUX	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
myeloma	O	NOUN	B
cast	O	NOUN	B
formation	O	NOUN	I
.	O	PUNCT	O


Rioprostil	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
prostaglandin	O	NOUN	B
E1	O	NOUN	I
analogue	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
once-daily	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
duodenal	B-P	ADJ	B
ulcer	I-P	NOUN	I
recurrence	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
comparison	O	NOUN	B
with	O	ADP	O
ranitidine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
Rioprostil	B-I	NOUN	B
(	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
prostaglandin	O	NOUN	B
E1	O	NOUN	I
analogue	O	NOUN	I
)	O	PUNCT	O
is	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
ranitidine	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
recurrence	O	NOUN	B
prevention	O	NOUN	B
of	O	ADP	O
duodenal	O	ADJ	B
ulcer	O	NOUN	I
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Duration	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
is	O	AUX	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Ninety-seven	B-P	NUM	O
patients	I-P	NOUN	B
received	I-P	VERB	O
rioprostil	I-I	NOUN	B
,	I-I	PUNCT	O
600	I-I	NUM	O
micrograms	I-I	NOUN	O
once-daily	I-I	ADJ	B
orally	I-I	ADV	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
110	I-I	NUM	O
patients	I-I	NOUN	B
received	I-I	VERB	O
ranitidine	I-I	NOUN	B
,	I-I	PUNCT	O
150	I-I	NUM	O
mg	I-I	NOUN	O
once-daily	I-I	ADV	B
orally	I-I	ADV	B
.	I-I	PUNCT	O


On	O	ADP	O
rioprostil	B-I	NOUN	B
,	O	PUNCT	O
14.9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
relapse	B-OUT	NOUN	B
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
10.1	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
ranitidine	B-I	NOUN	B
.	I-I	PUNCT	O


Diarrhoea	B-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
7	O	NUM	O
patients	O	NOUN	B
on	O	ADP	O
rioprostil	B-I	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
patients	O	NOUN	B
on	O	ADP	O
ranitidine	B-I	NOUN	B
.	I-I	PUNCT	O


Rioprostil	B-I	NOUN	B
given	O	VERB	O
600	O	NUM	O
micrograms	O	NOUN	B
daily	O	ADV	B
in	O	ADP	O
the	O	DET	O
evening	O	NOUN	B
is	O	AUX	O
a	O	DET	O
highly	O	ADV	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
duodenal	O	ADJ	B
ulcer	O	NOUN	I
relapse	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
not	O	PART	O
being	O	AUX	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
ranitidine	B-I	NOUN	B
150	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
TOM	B-I	PROPN	B
test	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
new	O	ADJ	O
instrument	O	NOUN	B
for	O	ADP	O
assessing	B-P	VERB	B
theory	I-P	NOUN	B
of	I-P	ADP	O
mind	I-P	NOUN	O
in	I-P	ADP	O
normal	I-P	ADJ	B
children	I-P	NOUN	I
and	I-P	CCONJ	O
children	I-P	NOUN	B
with	I-P	ADP	O
pervasive	I-P	ADJ	B
developmental	I-P	ADJ	B
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
article	O	NOUN	B
describes	O	VERB	O
a	O	DET	O
first	O	ADJ	O
attempt	O	NOUN	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
reliability	O	NOUN	B
and	O	CCONJ	O
validity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
TOM	B-OUT	PROPN	B
test	I-OUT	NOUN	I
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
instrument	O	NOUN	B
for	O	ADP	O
assessing	O	VERB	B
theory	O	NOUN	B
of	O	ADP	O
mind	O	NOUN	O
ability	O	NOUN	O
in	O	ADP	O
normal	B-P	ADJ	B
children	I-P	NOUN	I
and	I-P	CCONJ	O
children	I-P	NOUN	B
with	I-P	ADP	O
pervasive	I-P	ADJ	B
developmental	I-P	ADJ	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
PDDs	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


In	O	ADP	O
Study	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
TOM	B-I	PROPN	B
test	I-I	NOUN	I
scores	O	NOUN	B
of	O	ADP	O
normal	B-P	ADJ	B
children	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
70	I-P	NUM	O
)	I-P	PUNCT	O
correlated	O	VERB	B
positively	O	ADV	B
with	O	ADP	O
their	O	PRON	O
performance	O	NOUN	B
on	O	ADP	O
other	O	ADJ	O
theory	O	NOUN	B
of	O	ADP	O
mind	O	NOUN	B
tasks	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
young	B-P	ADJ	B
children	I-P	NOUN	B
only	O	ADV	O
succeeded	O	VERB	O
on	O	ADP	O
TOM	O	PROPN	B
items	O	NOUN	B
that	O	PRON	O
tap	O	VERB	O
the	O	DET	O
basic	O	ADJ	O
domains	O	NOUN	O
of	O	ADP	O
theory	O	NOUN	B
of	O	ADP	O
mind	O	NOUN	O
(	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
emotion	O	NOUN	B
recognition	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
older	B-P	ADJ	B
children	I-P	NOUN	I
also	O	ADV	O
passed	O	VERB	O
items	O	NOUN	B
that	O	PRON	O
measure	O	VERB	B
the	O	DET	O
more	O	ADV	O
mature	O	ADJ	B
areas	O	NOUN	B
of	O	ADP	O
theory	O	NOUN	B
of	O	ADP	O
mind	O	NOUN	O
(	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
understanding	O	NOUN	O
of	O	ADP	O
humor	O	NOUN	B
,	O	PUNCT	O
understanding	O	NOUN	O
of	O	ADP	O
second-order	O	ADJ	B
beliefs	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
findings	O	NOUN	B
of	O	ADP	O
Study	O	NOUN	B
1	O	NUM	I
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
TOM	B-OUT	PROPN	B
test	I-OUT	NOUN	I
is	O	AUX	O
a	O	DET	O
valid	O	ADJ	O
measure	O	NOUN	B
.	O	PUNCT	O


Study	O	NOUN	B
2	O	NUM	I
showed	O	VERB	O
for	O	ADP	O
a	O	DET	O
separate	O	ADJ	O
sample	O	NOUN	B
of	O	ADP	O
normal	B-P	ADJ	B
children	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
12	I-P	NUM	O
)	I-P	PUNCT	O
that	O	SCONJ	O
the	O	DET	O
TOM	B-OUT	PROPN	B
test	I-OUT	NOUN	I
possesses	O	VERB	O
sufficient	O	ADJ	O
test-retest	O	ADJ	B
stability	O	NOUN	I
.	O	PUNCT	O


Study	O	NOUN	B
3	O	NUM	O
demonstrated	O	VERB	O
for	O	ADP	O
a	O	DET	O
sample	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
PDDs	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
10	I-P	NUM	O
)	I-P	PUNCT	O
that	O	SCONJ	O
the	O	DET	O
interrater	B-OUT	ADJ	B
reliability	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
TOM	B-OUT	PROPN	B
test	I-OUT	NOUN	I
is	O	AUX	O
good	O	ADJ	O
.	O	PUNCT	O


Study	O	NOUN	B
4	O	NUM	O
found	O	VERB	O
that	O	SCONJ	O
children	B-P	NOUN	B
with	I-P	ADP	O
PDDs	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
20	I-P	NUM	O
)	I-P	PUNCT	O
had	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
TOM	B-OUT	PROPN	B
test	I-OUT	NOUN	I
scores	I-OUT	NOUN	O
than	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
other	I-P	ADJ	O
psychiatric	I-P	ADJ	B
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
e.g.	I-P	X	O
,	O	PUNCT	O
children	B-P	NOUN	B
with	I-P	ADP	O
Attention-deficit	I-P	PROPN	B
Hyperactivity	I-P	PROPN	I
Disorder	I-P	NOUN	I
;	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
32	I-P	NUM	O
)	I-P	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
finding	O	NOUN	B
that	O	PRON	O
underlines	O	VERB	O
the	O	DET	O
discriminant	O	ADJ	B
validity	O	NOUN	I
of	O	ADP	O
the	O	DET	O
TOM	B-I	PROPN	B
test	I-I	NOUN	I
.	I-I	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
Study	O	NOUN	B
4	O	NUM	O
showed	O	VERB	O
that	O	SCONJ	O
intelligence	B-OUT	NOUN	B
as	O	ADP	O
indexed	O	VERB	O
by	O	ADP	O
the	O	DET	O
Wechsler	B-OUT	PROPN	B
Intelligence	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
for	I-OUT	ADP	I
Children	I-OUT	PROPN	B
was	O	AUX	O
positively	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
TOM	B-OUT	NOUN	B
test	I-OUT	NOUN	I
scores	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
all	O	DET	O
studies	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
TOM	B-OUT	PROPN	B
test	I-OUT	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
reliable	O	ADJ	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
internal	O	ADJ	B
consistency	O	NOUN	I
.	O	PUNCT	O


Altogether	O	ADV	O
,	O	PUNCT	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
TOM	B-I	PROPN	B
test	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
reliable	O	ADJ	O
and	O	CCONJ	O
valid	O	ADJ	O
instrument	O	NOUN	B
that	O	PRON	O
can	O	AUX	O
be	O	AUX	O
employed	O	VERB	O
to	O	PART	O
measure	O	VERB	B
various	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
theory	O	NOUN	B
of	O	ADP	O
mind	O	NOUN	O
.	O	PUNCT	O


Feasibility	O	NOUN	B
of	O	ADP	O
a	O	DET	O
sensory-adapted	O	ADJ	B
dental	O	NOUN	B
environment	O	NOUN	I
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
provide	O	VERB	O
an	O	DET	O
example	O	NOUN	O
of	O	ADP	O
an	O	DET	O
occupational	O	ADJ	B
therapy	O	NOUN	I
feasibility	O	NOUN	B
study	O	NOUN	I
and	O	CCONJ	O
evaluate	O	VERB	B
the	O	DET	O
implementation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
pilot	O	NOUN	I
and	O	CCONJ	O
feasibility	O	NOUN	B
trial	O	NOUN	I
examining	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
a	O	DET	O
sensory-adapted	O	ADJ	B
dental	O	NOUN	B
environment	O	NOUN	I
(	O	PUNCT	O
SADE	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
enhance	O	VERB	O
oral	O	ADJ	B
care	O	NOUN	I
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHOD	O	NOUN	O
Twenty-two	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
and	I-P	CCONJ	O
22	I-P	NUM	O
typically	I-P	ADV	O
developing	I-P	VERB	O
children	I-P	NOUN	B
,	I-P	PUNCT	O
ages	I-P	NOUN	B
6-12	I-P	NUM	O
yr	I-P	NOUN	O
,	O	PUNCT	O
attended	O	VERB	B
a	O	DET	O
dental	O	NOUN	B
clinic	O	NOUN	I
in	O	ADP	O
an	O	DET	O
urban	O	ADJ	B
hospital	O	NOUN	I
.	O	PUNCT	O


Participants	B-P	NOUN	B
completed	O	VERB	O
two	B-I	NUM	O
dental	I-I	NOUN	B
cleanings	I-I	NOUN	I
,	I-I	PUNCT	O
3-4	I-I	NUM	O
mo	I-I	NOUN	O
apart	I-I	ADV	O
,	I-I	PUNCT	O
one	I-I	NUM	O
in	I-I	ADP	O
a	I-I	DET	O
regular	I-I	ADJ	O
environment	I-I	NOUN	B
and	I-I	CCONJ	O
one	I-I	NUM	O
in	I-I	ADP	O
a	I-I	DET	O
SADE	I-I	NOUN	B
.	I-I	PUNCT	O


Feasibility	O	NOUN	B
outcome	O	NOUN	I
measures	O	NOUN	I
were	O	AUX	O
recruitment	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
retention	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
accrual	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
dropout	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
protocol	I-OUT	NOUN	B
adherence	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Intervention	O	NOUN	B
outcome	O	NOUN	O
measures	O	NOUN	O
were	O	AUX	O
physiological	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
behavioral	I-OUT	ADJ	B
distress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cost	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
We	O	PRON	O
successfully	O	ADV	O
recruited	O	VERB	O
and	O	CCONJ	O
retained	O	VERB	O
participants	B-P	NOUN	B
.	I-P	PUNCT	O


Parents	O	NOUN	B
expressed	O	VERB	B
satisfaction	O	NOUN	O
with	O	ADP	O
research	O	NOUN	B
study	O	NOUN	I
participation	O	NOUN	B
.	O	PUNCT	O


Dentists	O	NOUN	B
stated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
intervention	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
incorporated	O	VERB	O
in	O	ADP	O
normal	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


Intervention	O	NOUN	B
outcome	O	NOUN	O
measures	O	NOUN	O
favored	O	VERB	O
the	O	DET	O
SADE	O	PROPN	B
condition	O	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	ADJ	O
Preliminary	O	ADJ	B
positive	O	ADJ	B
benefit	O	NOUN	B
of	O	ADP	O
SADE	O	NOUN	B
in	B-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
warrants	O	VERB	O
moving	O	VERB	B
forward	O	ADV	I
with	O	ADP	O
a	O	DET	O
large-scale	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
immunogenicity	I-OUT	NOUN	B
of	O	ADP	O
IMVAMUNE	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
promising	O	ADJ	O
candidate	O	NOUN	O
as	O	ADP	O
a	O	DET	O
third	O	ADJ	O
generation	O	NOUN	O
smallpox	O	NOUN	B
vaccine	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
Phase	O	NOUN	B
I	O	NUM	I
trial	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
immunogenicity	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
third	B-I	ADJ	O
generation	I-I	NOUN	O
smallpox	I-I	NOUN	B
vaccine	I-I	NOUN	O
MVA-BN	I-I	NOUN	B
(	I-I	PUNCT	O
IMVAMUNE	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
highly	O	ADV	O
attenuated	O	VERB	B
clone	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
Modified	O	PROPN	B
Vaccinia	O	PROPN	I
Virus	O	PROPN	I
Ankara	O	PROPN	B
strain	O	PROPN	I
571	O	NUM	O
,	O	PUNCT	O
in	B-P	ADP	O
naive	I-P	ADJ	B
and	I-P	CCONJ	O
pre-immunized	I-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
86	I-P	NUM	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
received	O	VERB	O
the	O	DET	O
vaccine	B-I	NOUN	B
in	O	ADP	O
five	O	NUM	O
groups	O	NOUN	B
using	O	VERB	O
different	O	ADJ	O
doses	O	NOUN	B
and	O	CCONJ	O
routes	O	NOUN	B
of	O	ADP	I
administration	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
38	O	NUM	O
subjects	O	NOUN	B
seroconverted	O	VERB	B
in	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
highest	O	ADJ	B
dose	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
(	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
TCID50	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
vaccinations	O	NOUN	B
were	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
with	O	ADP	O
mainly	O	ADV	O
mild	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
moderate	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
at	I-OUT	ADP	O
the	I-OUT	DET	O
injection	I-OUT	NOUN	B
site	I-OUT	NOUN	I
being	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
symptom	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
MVA-BN	O	NOUN	B
has	O	AUX	O
the	O	DET	O
potential	O	NOUN	B
to	O	PART	O
be	O	AUX	O
developed	O	VERB	O
as	O	ADP	O
an	O	DET	O
efficient	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
safe	I-OUT	ADJ	O
alternative	O	NOUN	B
to	O	ADP	O
the	O	DET	O
conventional	O	ADJ	O
smallpox	O	NOUN	B
vaccines	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
Lister-Elstree	B-I	ADJ	B
or	I-I	CCONJ	O
Dryvax	I-I	PROPN	B
.	I-I	PUNCT	O


Unique	O	ADJ	B
attributes	O	NOUN	B
render	O	VERB	O
it	O	PRON	O
a	O	DET	O
promising	O	ADJ	O
candidate	O	NOUN	O
for	O	ADP	O
prophylactic	O	ADJ	B
mass	O	NOUN	I
immunization	O	NOUN	I
,	O	PUNCT	O
even	O	ADV	O
in	O	ADP	O
subjects	O	NOUN	B
for	O	ADP	O
whom	O	PRON	O
conventional	O	ADJ	O
smallpox	O	NOUN	B
vaccines	O	NOUN	B
are	O	AUX	O
contraindicated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
acne	B-P	NOUN	B
vulgaris	I-P	X	I
in	O	ADP	O
general	B-P	ADJ	B
practice	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
assessment	O	NOUN	B
of	O	ADP	O
co-trimoxazole	B-I	NOUN	B
and	I-I	CCONJ	O
tetracycline	I-I	NOUN	B
.	I-I	PUNCT	O


Postoperative	O	ADJ	B
analgesia	O	NOUN	I
with	O	ADP	O
preoperative	O	ADJ	B
oral	O	ADJ	B
ibuprofen	B-I	NOUN	B
or	O	CCONJ	O
acetaminophen	B-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
undergoing	I-P	VERB	O
myringotomy	I-P	NOUN	B
.	I-P	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
over	O	ADP	O
70	B-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
children	I-P	NOUN	B
require	O	VERB	O
analgesics	B-I	NOUN	B
following	O	VERB	O
bilateral	B-P	ADJ	B
myringotomy	I-P	NOUN	I
and	I-P	CCONJ	O
tube	I-P	NOUN	B
placement	I-P	NOUN	I
(	I-P	PUNCT	O
BM	I-P	NOUN	B
&	I-P	CCONJ	I
T	I-P	NOUN	I
)	I-P	PUNCT	O
.	I-P	PUNCT	O


This	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
compared	O	VERB	O
the	O	DET	O
postoperative	O	ADJ	B
analgesic	O	NOUN	B
effects	O	NOUN	O
of	O	ADP	O
preoperatively	O	ADV	B
administered	O	VERB	B
oral	O	ADJ	B
acetaminophen	B-I	NOUN	B
or	I-I	CCONJ	O
ibuprofen	I-I	NOUN	B
.	I-I	PUNCT	O


Forty	B-P	NUM	O
three	I-P	NUM	O
ASA	I-P	NOUN	B
I	I-P	NUM	I
or	I-P	CCONJ	O
II	I-P	NUM	B
children	I-P	NOUN	B
age	I-P	NOUN	B
six	I-P	NUM	O
months	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
scheduled	I-P	VERB	I
for	I-P	ADP	O
elective	I-P	ADJ	B
BM	I-P	NOUN	B
&	I-P	CCONJ	I
T	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
acetaminophen	B-I	NOUN	B
(	I-I	PUNCT	O
paracetamol	I-I	NOUN	B
)	I-I	PUNCT	O
15	I-I	NUM	O
mg.kg-1	I-I	NOUN	B
,	I-I	PUNCT	O
ibuprofen	I-I	NOUN	B
10	I-I	NUM	O
mg.kg-1	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Postoperative	O	ADJ	B
pain	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
the	O	DET	O
Children	B-OUT	PROPN	B
's	I-OUT	PART	I
Hospital	I-OUT	PROPN	I
of	I-OUT	ADP	O
Eastern	I-OUT	PROPN	B
Ontario	I-OUT	PROPN	I
Pain	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
CHEOPS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
upon	O	SCONJ	O
arrival	O	NOUN	B
to	O	ADP	O
the	O	DET	O
PACU	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
5	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
15	O	NUM	O
,	O	PUNCT	O
30	O	NUM	O
,	O	PUNCT	O
45	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
60	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


CHEOP	O	PROPN	B
scores	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
at	O	ADP	O
any	O	DET	O
time	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
children	B-P	NOUN	B
receiving	I-P	VERB	O
rescue	I-OUT	NOUN	B
analgesia	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
benefit	O	NOUN	O
of	O	ADP	O
preoperatively	O	ADV	B
administered	O	VERB	B
oral	O	ADJ	B
ibuprofen	B-I	NOUN	B
10	O	NUM	O
mg.kg-1	O	NOUN	B
or	O	CCONJ	O
acetaminophen	B-I	NOUN	B
15	O	NUM	O
mg.kg-1	O	NOUN	B
over	O	ADP	O
placebo	O	NOUN	B
for	O	ADP	O
the	O	DET	O
relief	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
pain	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
undergoing	I-P	VERB	O
BM	I-P	PROPN	B
&	I-P	CCONJ	I
T	I-P	NOUN	I
.	I-P	PUNCT	O


Long-term	O	ADJ	B
growth	O	NOUN	B
hormone	O	NOUN	I
treatment	O	NOUN	B
in	O	ADP	O
growth	B-P	NOUN	B
hormone	I-P	NOUN	I
deficient	I-P	ADJ	B
adults	I-P	NOUN	B
.	I-P	PUNCT	O


Growth	B-I	NOUN	B
hormone	I-I	NOUN	I
treatment	I-I	NOUN	B
in	O	ADP	O
GH-deficient	B-P	ADJ	B
adults	I-P	NOUN	B
has	O	AUX	O
proved	O	VERB	O
beneficial	O	ADJ	O
in	O	ADP	O
recent	O	ADJ	O
short-term	O	ADJ	B
trials	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
long-term	O	ADJ	B
results	O	NOUN	B
have	O	AUX	O
not	O	PART	O
yet	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Thirteen	B-P	NUM	B
GH-deficient	I-P	ADJ	B
adults	I-P	NOUN	B
(	I-P	PUNCT	O
4	I-P	NUM	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
9	I-P	NUM	O
males	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	NOUN	O
(	I-P	PUNCT	O
SEM	I-P	NOUN	B
)	I-P	PUNCT	O
age	I-P	NOUN	B
26.4	I-P	NUM	O
(	I-P	PUNCT	O
1.7	I-P	NUM	O
)	I-P	PUNCT	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
completed	O	VERB	O
4	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
GH	B-I	NOUN	B
therapy	I-I	NOUN	I
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
placebo-controlled	B-I	ADJ	I
cross-over	O	ADJ	B
study	O	NOUN	I
were	O	AUX	O
followed	O	VERB	O
,	O	PUNCT	O
for	O	ADP	O
further	O	ADV	O
16.1	O	NUM	O
(	O	PUNCT	O
0.8	O	NUM	O
)	O	PUNCT	O
months	O	NOUN	B
of	O	ADP	O
uninterrupted	O	ADJ	O
GH	B-I	NOUN	B
therapy	I-I	NOUN	I
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
design	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	B
mean	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
1.3	O	NUM	O
cm	O	NOUN	O
in	O	ADP	O
linear	B-OUT	ADJ	B
height	I-OUT	NOUN	I
was	O	AUX	O
recorded	O	VERB	O
,	O	PUNCT	O
whereas	O	SCONJ	O
body	B-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
remained	O	VERB	O
unchanged	O	ADJ	B
.	O	PUNCT	O


Mean	B-OUT	VERB	B
muscle	I-OUT	NOUN	I
volume	I-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
thigh	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
estimated	I-OUT	VERB	O
by	I-OUT	ADP	O
computerised	I-OUT	ADJ	B
tomography	I-OUT	NOUN	I
,	O	PUNCT	O
increased	O	VERB	B
significantly	O	ADV	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
placebo	B-I	NOUN	B
period	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
slight	O	ADJ	O
decrease	O	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
adipose	B-OUT	NOUN	B
tissue	I-OUT	NOUN	I
volume	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
thigh	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.10	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
subscapular	B-OUT	ADJ	B
skinfold	I-OUT	ADJ	I
thickness	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.10	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Still	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
muscle	B-OUT	NOUN	B
to	I-OUT	PART	O
fat	I-OUT	NOUN	B
ratio	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
thigh	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
normal	B-P	ADJ	B
subjects	I-P	NOUN	I
(	O	PUNCT	O
72.6/27.4	O	ADV	O
vs	O	CCONJ	O
77.9/22.1	O	ADJ	O
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
isometric	I-OUT	ADJ	B
strength	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
quadriceps	I-OUT	NOUN	B
muscles	I-OUT	NOUN	I
increased	I-OUT	VERB	B
significantly	O	ADV	O
during	O	ADP	O
long-term	O	ADJ	B
GH	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
remained	O	VERB	O
lower	O	ADJ	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
normal	O	ADJ	B
subjects	O	NOUN	I
(	O	PUNCT	O
1.66	O	NUM	O
(	O	PUNCT	O
0.10	O	NUM	O
)	O	PUNCT	O
vs	O	CCONJ	O
2.13	O	NUM	O
(	O	PUNCT	O
0.11	O	NUM	O
)	O	PUNCT	O
Nm/kg	O	NOUN	B
body	O	NOUN	I
weight	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Exercise	B-OUT	NOUN	B
capacity	I-OUT	NOUN	B
performed	I-OUT	VERB	O
on	I-OUT	ADP	O
a	I-OUT	DET	O
bicycle	I-OUT	NOUN	B
ergometer	I-OUT	NOUN	I
increased	O	VERB	B
significantly	O	ADV	O
after	O	ADP	O
long-term	O	ADJ	B
therapy	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
still	O	ADV	O
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
the	O	DET	O
values	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
normal	O	ADJ	B
subjects	O	NOUN	I
(	O	PUNCT	O
22.5	O	NUM	O
(	O	PUNCT	O
3.4	O	NUM	O
)	O	PUNCT	O
vs	O	CCONJ	O
37.4	O	NUM	O
(	O	PUNCT	O
4.2	O	NUM	O
)	O	PUNCT	O
watt.min.kg-1	O	NOUN	O
.	O	PUNCT	O


No	O	DET	B
adverse	B-OUT	ADJ	I
reactions	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
during	O	ADP	O
long-term	O	ADJ	B
therapy	O	NOUN	B
and	O	CCONJ	O
hemoglobin	B-OUT	NOUN	B
A1c	I-OUT	NOUN	I
remained	O	VERB	O
unchanged	O	ADJ	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
long-term	O	ADJ	B
GH	O	NOUN	B
replacement	O	NOUN	I
therapy	O	NOUN	I
in	O	ADP	O
GH-deficient	O	ADJ	B
adults	O	NOUN	B
has	O	AUX	O
beneficial	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
several	O	ADJ	O
physiological	O	ADJ	B
features	O	NOUN	O
which	O	DET	O
are	O	AUX	O
subnormal	O	ADJ	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Brief	O	ADJ	B
Report	O	PROPN	I
:	O	PUNCT	O
Randomized	O	ADJ	B
test	O	NOUN	I
of	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
picture	B-I	NOUN	B
exchange	I-I	NOUN	I
communication	I-I	NOUN	O
system	I-I	NOUN	O
on	O	ADP	O
highly	O	ADV	O
generalized	B-OUT	VERB	O
picture	I-OUT	NOUN	O
exchanges	I-OUT	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
control	O	NOUN	I
trial	O	NOUN	I
comparing	O	VERB	O
two	O	NUM	O
social-communication	B-I	ADJ	B
interventions	I-I	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
examined	O	VERB	O
far-transfer	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
picture	I-OUT	NOUN	B
exchange	I-OUT	NOUN	I
to	I-OUT	PART	O
communicate	I-OUT	VERB	O
.	I-OUT	PUNCT	O


Thirty-six	B-P	NUM	O
children	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
treatment	O	NOUN	B
conditions	O	NOUN	O
,	O	PUNCT	O
one	B-I	NUM	O
of	I-I	ADP	O
which	I-I	DET	O
was	I-I	AUX	O
the	I-I	DET	O
Picture	I-I	PROPN	B
Exchange	I-I	PROPN	I
Communication	I-I	PROPN	I
System	I-I	PROPN	I
(	I-I	PUNCT	O
PECS	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


All	O	DET	O
children	O	NOUN	B
had	O	AUX	O
access	O	NOUN	O
to	O	PART	O
picture	B-I	VERB	B
symbols	I-I	NOUN	I
during	I-I	ADP	O
assessments	I-I	NOUN	B
.	I-I	PUNCT	O


Post-treatment	O	ADJ	B
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
picture	I-OUT	NOUN	B
exchanges	I-OUT	NOUN	B
in	I-OUT	ADP	O
a	I-OUT	DET	O
far-transfer	I-OUT	NOUN	B
,	O	PUNCT	O
assessment	O	NOUN	B
context	O	NOUN	O
favored	O	VERB	O
the	O	DET	O
PECS	B-I	NOUN	B
intervention	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
were	O	AUX	O
interpreted	O	VERB	O
as	O	ADP	O
support	O	NOUN	O
for	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
PECS	B-I	NOUN	B
curriculum	O	NOUN	B
can	O	AUX	O
successfully	O	ADV	O
teach	O	VERB	O
a	O	DET	O
generalized	O	VERB	O
means	O	NOUN	O
of	O	ADP	O
showing	O	VERB	O
coordinated	B-OUT	VERB	B
attention	I-OUT	NOUN	B
to	I-OUT	ADP	O
object	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
person	I-OUT	NOUN	B
without	I-OUT	ADP	O
requiring	I-OUT	VERB	O
eye	I-OUT	NOUN	B
contact	I-OUT	NOUN	O
to	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Prognostic	O	ADJ	B
significance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dobutamine	O	NOUN	B
echocardiography	O	NOUN	I
test	O	NOUN	I
in	O	ADP	O
idiopathic	B-OUT	ADJ	B
dilated	I-OUT	ADJ	I
cardiomyopathy	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Dobutamine	B-I	NOUN	B
stress	I-I	NOUN	O
echo	I-I	NOUN	O
provides	O	VERB	O
potentially	O	ADV	O
useful	B-OUT	ADJ	O
information	I-OUT	NOUN	B
on	O	ADP	O
idiopathic	B-I	ADJ	B
dilated	I-I	ADJ	I
cardiomyopathy	I-I	NOUN	I
(	I-P	PUNCT	O
IDC	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


From	B-P	ADP	O
February	I-P	PROPN	O
1	I-P	NUM	O
,	I-P	PUNCT	O
1997	I-P	NUM	O
,	I-P	PUNCT	O
to	I-P	ADP	O
October	I-P	PROPN	O
1	I-P	NUM	O
,	I-P	PUNCT	O
1999	I-P	NUM	O
,	I-P	PUNCT	O
186	I-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
131	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
55	I-P	NUM	O
women	I-P	NOUN	B
,	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
56	I-P	NUM	O
+/-	I-P	CCONJ	O
12	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
IDC	I-P	NOUN	B
,	I-P	PUNCT	O
ejection	I-P	NOUN	B
fraction	I-P	NOUN	I
<	I-P	X	O
35	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
angiographically	I-P	ADV	B
normal	I-P	ADJ	O
coronary	I-P	ADJ	B
arteries	I-P	NOUN	I
were	I-P	AUX	O
studied	I-P	VERB	O
by	I-P	ADP	O
high-dose	I-I	ADJ	B
(	I-P	PUNCT	O
up	I-P	ADV	O
to	I-P	PART	O
40	I-P	NUM	O
micro/kg/min	I-P	NOUN	B
)	I-P	PUNCT	O
dobutamine	I-I	NOUN	B
echo	I-I	ADJ	B
in	I-P	ADP	O
6	I-P	NUM	O
centers	I-P	NOUN	B
,	I-P	PUNCT	O
all	I-P	DET	O
quality	I-P	NOUN	B
controlled	I-P	VERB	B
for	I-P	ADP	O
stress	I-P	NOUN	B
echo	I-P	ADJ	I
reading	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
wall	O	NOUN	B
motion	O	NOUN	I
score	O	NOUN	I
index	O	NOUN	I
(	O	PUNCT	O
WMSI	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
from	O	ADP	O
1	O	NUM	O
=	O	ADJ	O
normal	O	ADJ	O
to	O	PART	O
4	O	NUM	O
=	O	ADJ	O
dyskinetic	O	ADJ	B
in	O	ADP	O
a	O	DET	O
16-	O	NUM	O
segment	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
the	O	DET	O
left	O	ADJ	B
ventricle	O	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
echo	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
peak	O	ADJ	B
dobutamine	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
eighty-four	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
followed	O	VERB	B
up	O	ADP	I
(	O	PUNCT	O
mean	O	VERB	O
15	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
cardiac	B-OUT	ADJ	B
death	I-OUT	NOUN	I
was	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
an	O	DET	O
end	O	NOUN	O
point	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
29	O	NUM	O
cardiac	O	ADJ	B
deaths	O	NOUN	I
.	O	PUNCT	O


Significant	O	ADJ	B
parameters	O	NOUN	B
for	O	ADP	O
survival	O	NOUN	B
prediction	O	NOUN	B
at	O	ADP	O
univariate	O	ADJ	B
analysis	O	NOUN	I
are	O	AUX	O
:	O	PUNCT	O
DeltaWMSI	O	NOUN	O
(	O	PUNCT	O
chi-square	O	NOUN	B
20.1	O	NUM	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.0000	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
New	O	PROPN	B
York	O	PROPN	I
Heart	O	PROPN	I
Association	O	PROPN	I
(	O	PUNCT	O
NYHA	O	NOUN	B
)	O	PUNCT	O
class	O	NOUN	O
(	O	PUNCT	O
chi-square	O	ADJ	B
17.57	O	NUM	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.0000	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
rest	O	NOUN	B
ejection	O	NOUN	I
fraction	O	NOUN	I
(	O	PUNCT	O
chi-square	O	ADJ	B
10.41	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0013	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
angiotensin-converting	O	ADJ	B
enzyme	O	NOUN	I
inhibitors	O	NOUN	I
(	O	PUNCT	O
chi-square	O	ADJ	B
8.23	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0041	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
hypertension	O	NOUN	B
(	O	PUNCT	O
chi-square	O	NOUN	B
8.08	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0045	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
multivariate	O	ADJ	B
stepwise	O	ADJ	I
analysis	O	NOUN	I
only	O	ADV	O
DeltaWMSI	O	NOUN	B
and	O	CCONJ	O
NYHA	O	PROPN	B
were	O	AUX	O
independent	O	ADJ	O
predictors	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
(	O	PUNCT	O
DeltaWMSI	O	NOUN	O
=	O	ADJ	O
hazard	O	NOUN	B
ratio	O	NOUN	I
0.02	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.0000	O	NUM	O
;	O	PUNCT	O
NYHA	O	NOUN	B
class	O	NOUN	I
=	O	ADJ	O
hazard	O	NOUN	B
ratio	O	NOUN	I
3.83	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.0000	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Kaplan-Meier	O	ADJ	B
survival	O	NOUN	I
estimates	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
better	B-OUT	ADJ	O
outcome	I-OUT	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
large	B-OUT	ADJ	O
inotropic	I-OUT	ADJ	B
response	I-OUT	NOUN	I
(	O	PUNCT	O
DeltaWMSI	O	NOUN	O
>	O	X	O
or	O	CCONJ	O
=0.44	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
cutoff	O	NOUN	B
identified	O	VERB	B
by	O	ADP	O
receiver-operating	O	ADJ	B
characteristic	O	ADJ	I
curves	O	NOUN	I
analysis	O	NOUN	I
)	O	PUNCT	O
than	O	ADP	O
for	O	ADP	O
those	O	DET	O
with	O	ADP	O
a	O	DET	O
small	O	ADJ	B
or	O	CCONJ	O
no	O	DET	O
myocardial	O	ADJ	B
inotropic	O	ADJ	O
response	O	NOUN	O
to	O	PART	O
dobutamine	O	NOUN	B
(	O	PUNCT	O
93.6	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
69.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.00033	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
IDC	I-P	NOUN	B
,	O	PUNCT	O
an	O	DET	O
extensive	O	ADJ	O
contractile	O	NOUN	B
reserve	O	NOUN	I
identified	O	VERB	B
by	O	ADP	O
high-dose	O	ADJ	B
dobutamine	O	NOUN	O
stress	O	NOUN	O
echocardiography	O	NOUN	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
better	B-OUT	ADJ	O
survival	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


[	O	PUNCT	O
The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
losartan	B-I	NOUN	B
versus	I-I	CCONJ	O
atenolol	I-I	ADV	B
on	O	ADP	O
cardiovascular	B-OUT	ADJ	B
morbidity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
diabetes	I-P	NOUN	B
mellitus	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
LIFE-study	I-P	NOUN	B
]	I-P	PUNCT	O
.	O	PUNCT	O


INTRODUCTION	O	VERB	O
The	O	DET	O
most	O	ADV	O
suitable	O	ADJ	O
antihypertensive	O	ADJ	B
drug	O	NOUN	I
to	O	PART	O
reduce	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
disease	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
hypertension	I-P	NOUN	B
and	I-P	CCONJ	O
diabetes	I-P	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
prespecified	O	ADJ	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LIFE-study	O	NOUN	B
we	O	PRON	O
compared	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
losartan	B-I	NOUN	B
and	I-I	CCONJ	O
atenolol	I-I	ADV	B
on	O	ADP	O
cardiovascular	B-OUT	ADJ	B
morbidity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
in	O	ADP	O
diabetic	B-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
1195	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
LIFE-study	I-P	NOUN	B
had	I-P	AUX	O
diabetes	I-P	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
the	O	DET	O
randomisation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
for	O	ADP	O
double-blind	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
losartan	B-I	NOUN	B
versus	I-I	CCONJ	O
atenolol	I-I	ADV	B
.	I-I	PUNCT	O


The	O	DET	O
patients	B-P	NOUN	B
had	I-P	AUX	O
ECG-verified	I-P	ADJ	B
left	I-P	ADJ	B
ventricular	I-P	ADJ	I
hypertrophy	I-P	NOUN	I
,	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
67	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
blood	I-P	NOUN	B
pressure	I-P	NOUN	I
177/96	I-P	NUM	O
mmHg	I-P	NOUN	B
after	I-P	ADP	O
two	I-P	NUM	O
weeks	I-P	NOUN	B
placebo	I-I	ADJ	B
run-in	I-P	ADJ	B
period	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
were	I-P	AUX	O
followed	I-P	VERB	O
for	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADJ	O
four	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	NOUN	O
4.7	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
composite	O	ADJ	B
endpoint	O	NOUN	B
was	O	AUX	O
cardiovascular	B-OUT	ADJ	B
death	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
stroke	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
myocardial	I-OUT	ADJ	B
infarction	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
to	O	PART	O
146/79	O	NUM	O
and	O	CCONJ	O
148/79	O	ADJ	O
in	O	ADP	O
losartan-treated	B-I	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
atenolol-treated	B-I	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
endpoint	O	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
103	O	NUM	O
patients	O	NOUN	B
assigned	O	VERB	O
losartan	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
586	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
139	O	NUM	O
assigned	O	VERB	O
atenolol	B-I	ADV	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
609	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Relative	B-OUT	ADJ	B
risk	I-OUT	NOUN	I
reduction	I-OUT	NOUN	B
24	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.031	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Cardiovascular	B-OUT	ADJ	B
mortality	I-OUT	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
37	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
favour	O	NOUN	O
of	O	ADP	O
losartan	B-I	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.028	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
cause	O	VERB	O
mortality	B-OUT	NOUN	B
by	O	ADP	O
39	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
Losartan	B-I	NOUN	B
was	O	AUX	O
very	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
reducing	O	VERB	B
cardiovascular	B-OUT	ADJ	B
morbidity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	ADP	O
atenolol	B-I	NOUN	B
.	I-I	PUNCT	O


These	O	DET	O
results	O	NOUN	B
will	O	AUX	O
have	O	AUX	O
a	O	DET	O
major	O	ADJ	O
impact	O	NOUN	B
on	O	ADP	O
the	O	DET	O
choice	O	NOUN	B
of	O	ADP	O
anti-hypertensive	O	ADJ	B
treatment	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
hypertension	I-P	NOUN	B
and	I-P	CCONJ	O
diabetes	I-P	NOUN	B
.	I-P	PUNCT	O


Prognostic	O	ADJ	B
factor	O	NOUN	I
analysis	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
prostate	I-P	NOUN	I
cancer	I-P	NOUN	I
treated	I-P	VERB	B
by	I-P	ADP	O
castration	I-I	NOUN	B
plus	I-I	CCONJ	O
anandron	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
final	O	ADJ	O
update	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	VERB	B
Different	O	ADJ	O
outcome	O	NOUN	B
results	O	NOUN	O
have	O	AUX	O
been	O	AUX	O
published	O	VERB	B
in	O	ADP	O
trials	O	NOUN	B
comparing	O	VERB	O
maximal	O	ADJ	B
androgen	O	NOUN	O
blockade	O	NOUN	O
(	O	PUNCT	O
MAB	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
chemical	B-I	NOUN	B
or	I-I	CCONJ	O
surgical	I-I	ADJ	B
castration	I-I	NOUN	I
alone	I-I	ADV	O
.	I-I	PUNCT	O


The	O	DET	O
conflicting	O	VERB	O
results	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
patients	O	NOUN	B
were	O	AUX	O
included	O	VERB	O
with	O	ADP	O
different	O	ADJ	O
prognostic	O	ADJ	B
factors	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
new	O	ADJ	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Anandron	O	PROPN	B
European	O	PROPN	B
Study	O	PROPN	I
,	O	PUNCT	O
independent	O	ADJ	O
prognostic	O	ADJ	B
factors	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
identify	O	VERB	O
those	O	DET	O
which	O	DET	O
could	O	AUX	O
influence	O	VERB	B
the	O	DET	O
study	O	NOUN	B
outcome	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
399	B-P	NUM	O
out	I-P	ADP	O
of	I-P	ADP	O
457	I-P	NUM	O
patients	I-P	NOUN	B
recruited	I-P	VERB	O
in	I-P	ADP	O
this	I-P	DET	O
study	I-P	NOUN	B
were	I-P	AUX	O
divided	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
good	I-P	ADJ	B
or	I-P	CCONJ	O
poor	I-P	ADJ	B
prognostic	I-P	ADJ	B
group	I-P	NOUN	I
depending	I-P	VERB	O
on	I-P	ADP	O
the	I-P	DET	O
presence	I-P	NOUN	B
of	I-P	ADP	O
two	I-P	NUM	O
or	I-P	CCONJ	O
more	I-P	ADV	O
poor	I-P	ADJ	O
prognostic	I-P	ADJ	B
factors	I-P	NOUN	I
,	I-P	PUNCT	O
these	I-P	DET	O
were	I-P	AUX	O
pain	I-P	NOUN	B
requiring	I-P	VERB	O
treatment	I-P	NOUN	B
,	I-P	PUNCT	O
>	I-P	X	O
5	I-P	NUM	O
bone	I-P	NOUN	B
metastases	I-P	NOUN	I
,	I-P	PUNCT	O
hydronephrosis	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
alkaline	I-P	NOUN	B
phosphatase	I-P	NOUN	I
>	I-P	NOUN	O
2	I-P	NUM	O
ULN	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
When	O	SCONJ	O
expressed	O	VERB	B
as	O	ADP	O
a	O	DET	O
percentage	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
improvement	B-OUT	NOUN	B
in	I-OUT	ADP	O
time	I-OUT	NOUN	O
to	I-OUT	PART	O
progression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
overall	I-OUT	ADV	B
and	I-OUT	CCONJ	O
cancer	I-OUT	NOUN	B
specific	I-OUT	ADJ	O
survival	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
Anandron	B-I	NOUN	B
treated	O	ADJ	B
patients	O	NOUN	B
was	O	AUX	O
identical	O	ADJ	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
absolute	O	ADJ	B
terms	O	NOUN	O
this	O	DET	O
improvement	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
good	O	ADJ	O
prognostic	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
surgical	B-I	ADJ	B
castration	I-I	NOUN	B
MAB	I-I	NOUN	B
using	I-I	VERB	O
Anandron	I-I	PROPN	B
,	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
prostate	I-P	NOUN	I
cancer	I-P	NOUN	I
improves	O	VERB	B
the	O	DET	O
time	O	NOUN	O
to	O	PART	O
objective	B-OUT	ADJ	O
progression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
overall	I-OUT	ADV	B
and	I-OUT	CCONJ	O
cancer	I-OUT	NOUN	B
specific	I-OUT	ADJ	O
survival	I-OUT	NOUN	B
,	O	PUNCT	O
irrespective	O	ADV	O
of	O	ADP	O
certain	O	ADJ	O
poor	O	ADJ	O
prognostic	O	ADJ	B
factors	O	NOUN	I
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
Orlistat	B-I	NOUN	B
in	O	ADP	O
obese	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
heart	I-P	NOUN	B
failure	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Heart	O	NOUN	B
failure	O	NOUN	I
is	O	AUX	O
the	O	DET	O
leading	O	NOUN	O
cause	O	NOUN	O
of	O	ADP	O
hospitalization	O	NOUN	B
.	O	PUNCT	O


Obesity	O	NOUN	B
is	O	AUX	O
increasingly	O	ADV	O
common	O	ADJ	O
and	O	CCONJ	O
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
public	O	ADJ	B
health	O	NOUN	I
problem	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
assess	O	VERB	B
whether	O	SCONJ	O
obese	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
heart	I-P	NOUN	B
failure	I-P	NOUN	I
can	O	AUX	O
benefit	O	VERB	B
from	O	ADP	O
losing	O	VERB	O
weight	O	NOUN	B
via	O	ADP	O
an	O	DET	O
orlistat-assisted	B-I	ADJ	B
diet	I-I	NOUN	I
.	I-I	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
included	O	VERB	O
obese	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
ejection	I-P	NOUN	B
fractions	I-P	NOUN	I
<	I-P	X	O
or	I-P	CCONJ	O
=40	I-P	NUM	O
%	I-P	NOUN	O
.	I-P	PUNCT	O


Orlistat	B-I	NOUN	B
and	I-I	CCONJ	O
diet	I-I	NOUN	B
counseling	I-I	NOUN	I
were	I-I	AUX	O
compared	I-I	VERB	B
with	I-I	ADP	O
diet	I-I	ADJ	B
counseling	I-I	NOUN	I
alone	I-I	ADV	O
.	I-I	PUNCT	O


Twenty-one	B-P	NUM	O
consecutive	I-P	ADJ	B
obese	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
heart	I-P	NOUN	B
failure	I-P	NOUN	I
were	I-P	AUX	O
recruited	I-P	VERB	O
.	I-P	PUNCT	O


Significant	O	ADJ	B
improvement	O	NOUN	B
in	O	ADP	O
6-minute	B-OUT	ADJ	B
walk	I-OUT	NOUN	I
test	I-OUT	NOUN	I
(	O	PUNCT	O
45.8	O	NUM	O
m	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
5.2-86.4	O	NUM	O
m	O	NOUN	O
;	O	PUNCT	O
p=0.031	O	ADJ	O
)	O	PUNCT	O
,	O	PUNCT	O
functional	B-OUT	ADJ	B
class	I-OUT	NOUN	I
(	O	PUNCT	O
-0.6+/-0.5	O	NOUN	O
,	O	PUNCT	O
p=0.014	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
weight	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
(	O	PUNCT	O
-8.55	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
-13.0	O	NUM	O
to	O	PART	O
-4.1	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
significant	O	ADJ	O
decreases	O	NOUN	B
in	O	ADP	O
total	B-OUT	ADJ	B
cholesterol	I-OUT	NOUN	I
(	O	PUNCT	O
p=0.017	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
low-density	B-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
(	O	PUNCT	O
p=0.03	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
triglycerides	B-OUT	NOUN	B
(	O	PUNCT	O
p=0.036	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
orlistat	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Orlistat	B-I	PROPN	B
can	O	AUX	O
promote	O	VERB	O
significant	O	ADJ	O
weight	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
symptoms	I-OUT	NOUN	B
of	I-OUT	ADP	O
relief	I-OUT	NOUN	B
in	O	ADP	O
obese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
heart	O	NOUN	B
failure	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
6-minute	O	ADJ	B
walk	O	NOUN	I
test	O	NOUN	I
and	O	CCONJ	O
functional	O	ADJ	B
capacity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
lipid	O	NOUN	B
profile	O	NOUN	I
improved	O	VERB	B
.	O	PUNCT	O


Orlistat	B-I	PROPN	B
was	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	ADJ	B
.	O	PUNCT	O


[	B-OUT	PUNCT	O
Efficacy	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
extended-release	O	ADJ	B
niacin	B-I	NOUN	B
alone	I-I	ADV	O
or	I-I	CCONJ	O
with	I-I	ADP	O
atorvastatin	I-I	NOUN	B
for	O	ADP	O
lipid	O	NOUN	B
profile	O	NOUN	I
modification	O	NOUN	B
]	O	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
extended-release	B-I	ADJ	B
niacin	I-I	NOUN	B
(	I-I	PUNCT	O
niacin	I-I	NOUN	B
ER	I-I	NOUN	I
)	I-I	PUNCT	O
either	I-I	CCONJ	O
alone	I-I	ADV	O
or	I-I	CCONJ	O
in	I-I	ADP	O
combination	I-I	NOUN	B
with	I-I	ADP	O
atorvastatin	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
lipid	O	NOUN	B
profile	O	NOUN	I
modification	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patients	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
CHD	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
its	I-P	PRON	O
equivalents	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
ten	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
CHD	I-P	NOUN	B
and	I-P	CCONJ	O
its	I-P	PRON	O
equivalents	I-P	NOUN	B
with	I-P	ADP	O
serum	I-P	NOUN	B
total	I-P	NOUN	I
cholesterol	I-P	NOUN	I
(	I-P	PUNCT	O
TC	I-P	NOUN	B
)	I-P	PUNCT	O
>	I-P	X	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
3.5	I-P	NUM	O
mmol/L	I-P	NOUN	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
into	O	ADP	O
three	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
:	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
atorvastatin	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
38	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
receiving	O	VERB	O
atorvastatin	B-I	NOUN	B
10	O	NUM	O
mg/d	O	NOUN	O
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
niacin	B-I	NOUN	B
ER	I-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
38	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
given	O	VERB	O
niacin	B-I	NOUN	B
ER	I-I	NOUN	I
500	O	NUM	O
mg/d	O	NOUN	O
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
1000	O	NUM	O
mg/d	O	NOUN	O
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
combination	B-I	NOUN	B
treatment	I-I	NOUN	O
group	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
34	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
treated	B-I	VERB	B
with	I-I	ADP	I
atorvastatin	I-I	NOUN	B
(	I-I	PUNCT	O
10	I-I	NUM	O
mg/d	I-I	NOUN	O
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
niacin	I-I	NOUN	B
ER	I-I	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
initiating	O	VERB	O
from	O	ADP	O
500	O	NUM	O
mg/d	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
increasing	O	VERB	B
to	O	ADP	O
1000	O	NUM	O
mg/d	O	NOUN	O
after	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
serums	B-OUT	NOUN	B
lipid	I-OUT	NOUN	B
profiles	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
adverse	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
all	O	DET	O
the	O	DET	O
patients	O	NOUN	B
before	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
After	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
serum	B-OUT	NOUN	B
level	I-OUT	NOUN	O
of	I-OUT	ADP	O
triglyceride	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
TG	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
high-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HDL-C	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
16	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
in	O	ADP	O
the	O	DET	O
niacin	O	NOUN	B
ER	O	NOUN	I
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
values	O	NOUN	O
(	O	PUNCT	O
both	O	DET	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
TC	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
low-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
LDL-C	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
TG	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
atorvastatin	I-OUT	NOUN	B
group	I-OUT	NOUN	B
decreased	O	VERB	B
by	O	ADP	O
19	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
26	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
17	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
values	O	NOUN	O
(	O	PUNCT	O
all	O	DET	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Combination	O	NOUN	B
treatment	O	NOUN	I
decreased	O	VERB	B
the	O	DET	O
TC	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
LDL-C	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
TG	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
by	O	ADP	O
28	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
38	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
39	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
the	O	DET	O
HDL-C	B-OUT	NOUN	B
level	I-OUT	NOUN	B
by	O	ADP	O
23	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
all	O	DET	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
TC	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
LDL-C	I-OUT	NOUN	B
achieved	O	VERB	O
by	O	ADP	O
combination	O	NOUN	B
treatment	O	NOUN	I
was	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
treatment	O	NOUN	B
of	O	ADP	O
atorvastatin	O	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
treatment	O	NOUN	B
of	O	ADP	O
niacin	O	NOUN	B
ER	O	NOUN	I
alone	O	ADV	O
(	O	PUNCT	O
all	O	DET	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
The	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
achieving	O	VERB	O
the	O	DET	O
LDL-C	B-OUT	NOUN	B
goal	O	NOUN	O
of	O	ADP	O
The	O	DET	O
National	O	PROPN	B
Cholesterol	O	PROPN	I
Education	O	PROPN	I
Program	O	PROPN	I
(	O	PUNCT	O
NCEP	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
Adult	O	PROPN	B
Treatment	O	NOUN	O
Panel	O	PROPN	O
III	O	NUM	O
(	O	PUNCT	O
ATP	O	NOUN	O
III	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
therapy	O	NOUN	I
group	O	NOUN	B
was	O	AUX	O
73.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
atorvastatin	O	NOUN	B
and	O	CCONJ	O
niacin	O	NOUN	B
groups	O	NOUN	B
(	O	PUNCT	O
47.7	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
42.1	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
,	O	PUNCT	O
both	O	CCONJ	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
Adverse	O	ADJ	B
effect	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
flushing	B-OUT	VERB	B
(	O	PUNCT	O
15.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
gastrointestinal	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
(	O	PUNCT	O
23.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
niacin	O	NOUN	B
ER	O	NOUN	I
group	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
more	O	ADV	O
adverse	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
therapy	O	NOUN	I
group	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
serious	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
Niacin	O	NOUN	B
ER	O	NOUN	I
has	O	AUX	O
a	O	DET	O
favorable	O	ADJ	O
effect	B-OUT	NOUN	O
in	I-OUT	ADP	O
modulating	I-OUT	VERB	B
the	I-OUT	DET	O
blood	I-OUT	NOUN	B
lipid	I-OUT	NOUN	I
profile	I-OUT	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
reducing	B-OUT	VERB	B
TG	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
elevating	I-OUT	VERB	B
HDL-C	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Combined	O	ADJ	B
statin	O	NOUN	B
with	O	ADP	O
niacin	O	NOUN	B
may	O	AUX	O
produce	O	VERB	O
a	O	DET	O
more	O	ADV	O
global	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
lipid	I-OUT	NOUN	B
blood	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
than	O	ADP	O
monotherapy	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
generally	O	ADV	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
well	I-OUT	ADV	O
tolerable	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
placebo-controlled	B-I	ADJ	I
prevention	O	NOUN	I
trial	O	NOUN	I
of	O	ADP	O
aspirin	B-I	NOUN	B
and/or	I-I	CCONJ	O
resistant	I-I	ADJ	B
starch	I-I	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
people	I-P	NOUN	I
with	I-P	ADP	O
familial	I-OUT	ADJ	B
adenomatous	I-OUT	ADJ	I
polyposis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Evidence	O	NOUN	B
supporting	O	VERB	O
aspirin	B-I	NOUN	B
and	I-I	CCONJ	O
resistant	I-I	ADJ	B
starch	I-I	NOUN	O
(	I-I	PUNCT	O
RS	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
colorectal	B-P	ADJ	B
cancer	I-P	NOUN	I
prevention	O	NOUN	B
comes	O	VERB	O
from	O	ADP	O
epidemiologic	O	ADJ	B
and	O	CCONJ	O
laboratory	O	NOUN	B
studies	O	NOUN	I
(	B-I	PUNCT	O
aspirin	I-I	NOUN	B
and	I-I	CCONJ	O
RS	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
clinical	O	ADJ	I
trials	O	NOUN	I
(	B-I	PUNCT	O
aspirin	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Familial	B-P	ADJ	B
adenomatous	I-P	ADJ	I
polyposis	I-P	NOUN	I
(	I-P	PUNCT	O
FAP	I-P	NOUN	B
)	I-P	PUNCT	O
strikes	O	VERB	O
young	O	ADJ	B
people	O	NOUN	O
and	O	CCONJ	O
,	O	PUNCT	O
untreated	O	ADJ	B
,	O	PUNCT	O
confers	O	VERB	O
virtually	O	ADV	O
a	O	DET	O
100	O	NUM	O
%	O	NOUN	O
risk	O	NOUN	B
of	O	ADP	O
colorectal	O	ADJ	B
cancer	O	NOUN	I
and	O	CCONJ	O
early	O	ADJ	B
death	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
an	O	DET	O
international	O	ADJ	B
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
aspirin	B-I	NOUN	B
(	O	PUNCT	O
600	O	NUM	O
mg/d	O	NOUN	O
)	O	PUNCT	O
and/or	O	CCONJ	O
RS	B-I	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
g/d	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
from	O	ADP	O
1	O	NUM	O
to	O	PART	O
12	O	NUM	O
years	O	NOUN	B
to	O	PART	O
prevent	O	VERB	B
disease	O	NOUN	B
progression	O	NOUN	I
in	O	ADP	O
FAP	B-P	NOUN	B
patients	I-P	NOUN	B
from	I-P	ADP	O
10	I-P	NUM	O
to	I-P	PART	O
21	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
2	O	NUM	O
×	O	NOUN	O
2	O	NUM	O
factorial	O	ADJ	B
design	O	NOUN	I
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
the	O	DET	O
following	O	VERB	O
four	O	NUM	O
study	O	NOUN	B
arms	B-I	NOUN	O
:	I-I	PUNCT	O
aspirin	I-I	NOUN	B
plus	I-I	CCONJ	O
RS	I-I	NOUN	B
placebo	I-I	NOUN	B
;	I-I	PUNCT	O
RS	I-I	NOUN	B
plus	I-I	CCONJ	O
aspirin	I-I	NOUN	B
placebo	I-I	NOUN	B
;	I-I	PUNCT	O
aspirin	I-I	NOUN	B
plus	I-I	CCONJ	O
RS	I-I	NOUN	B
;	I-I	PUNCT	O
RS	I-I	NOUN	B
placebo	I-I	NOUN	B
plus	I-I	CCONJ	O
aspirin	I-I	NOUN	B
placebo	I-I	NOUN	B
;	I-I	PUNCT	O
they	O	PRON	O
were	O	AUX	O
followed	O	VERB	O
with	O	ADP	O
standard	O	ADJ	O
annual	O	ADJ	B
clinical	O	ADJ	B
examinations	O	NOUN	I
including	O	VERB	O
endoscopy	O	NOUN	B
.	B-OUT	PUNCT	O


The	B-OUT	DET	O
primary	I-OUT	ADJ	B
endpoint	I-OUT	NOUN	I
was	I-OUT	AUX	O
polyp	I-OUT	NOUN	B
number	I-OUT	NOUN	I
in	I-OUT	ADP	O
the	I-OUT	DET	O
rectum	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
sigmoid	I-OUT	NOUN	B
colon	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
at	I-OUT	ADP	O
the	I-OUT	DET	O
end	I-OUT	NOUN	O
of	I-OUT	ADP	O
intervention	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
major	I-OUT	ADJ	O
secondary	I-OUT	ADJ	B
endpoint	I-OUT	NOUN	I
was	I-OUT	AUX	O
size	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
largest	I-OUT	ADJ	O
polyp	I-OUT	NOUN	B
.	O	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
206	I-P	NUM	O
randomized	I-P	ADJ	B
FAP	I-P	NOUN	B
patients	I-P	NOUN	B
commenced	I-P	VERB	O
intervention	I-P	NOUN	B
,	I-P	PUNCT	O
of	I-P	ADP	O
whom	I-P	PRON	O
133	I-P	NUM	O
had	I-P	AUX	O
at	I-P	ADP	O
least	I-P	ADV	O
one	I-P	NUM	O
follow-up	I-P	ADJ	B
endoscopy	I-P	NOUN	B
and	I-P	CCONJ	O
were	I-P	AUX	O
therefore	I-P	ADV	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
primary	I-P	ADJ	B
analysis	I-P	NOUN	I
.	O	PUNCT	O


Neither	O	DET	O
intervention	O	NOUN	B
significantly	O	ADV	O
reduced	B-OUT	VERB	B
polyp	I-OUT	NOUN	B
count	I-OUT	NOUN	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
rectum	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
sigmoid	I-OUT	NOUN	B
colon	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
aspirin	O	NOUN	B
relative	O	ADJ	B
risk	O	NOUN	I
=	O	ADJ	O
0.77	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.54-1.10	O	NUM	O
;	O	PUNCT	O
versus	O	CCONJ	O
nonaspirin	O	NOUN	B
arms	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
RS	O	NOUN	B
relative	O	ADJ	B
risk	O	NOUN	I
=	O	ADJ	O
1.05	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.73-1.49	O	NUM	O
;	O	PUNCT	O
versus	O	CCONJ	O
non-RS	O	ADJ	O
arms	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
a	O	DET	O
smaller	O	ADJ	B
size	O	NOUN	I
of	O	ADP	O
largest	O	ADJ	O
polyp	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
aspirin	O	NOUN	B
versus	O	CCONJ	O
nonaspirin	O	PROPN	B
--	O	PUNCT	O
mean	O	VERB	O
3.8	O	NUM	O
mm	O	NOUN	O
versus	O	CCONJ	O
5.5	O	NUM	O
mm	O	NOUN	O
for	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
1	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
years	O	NOUN	B
(	O	PUNCT	O
adjusted	O	VERB	O
P	O	NOUN	O
=	O	ADJ	O
0.09	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
mean	O	VERB	O
3.0	O	NUM	O
mm	O	NOUN	O
versus	O	CCONJ	O
6.0	O	NUM	O
mm	O	NOUN	O
for	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
more	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
similar	O	ADJ	O
weaker	O	ADJ	O
trends	O	NOUN	B
with	O	ADP	O
RS	O	NOUN	B
versus	O	CCONJ	O
non-RS	O	NOUN	O
.	O	PUNCT	O


Exploratory	O	ADJ	B
translational	O	ADJ	I
endpoints	O	NOUN	B
included	O	VERB	O
crypt	O	NOUN	B
length	O	NOUN	B
(	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	B
in	O	ADP	O
normal-appearing	O	ADJ	B
mucosa	O	NOUN	O
in	O	ADP	O
the	O	DET	O
RS	O	NOUN	B
group	O	NOUN	B
over	O	ADP	O
time	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
laboratory	O	ADJ	B
measures	O	NOUN	I
of	O	ADP	O
proliferation	O	NOUN	B
(	O	PUNCT	O
including	O	VERB	O
Ki67	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
is	O	AUX	O
the	O	DET	O
largest	O	ADJ	O
ever	O	ADV	O
conducted	O	VERB	O
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
FAP	O	NOUN	B
and	O	CCONJ	O
found	O	VERB	O
a	O	DET	O
trend	O	NOUN	O
of	O	ADP	O
reduced	B-OUT	VERB	B
polyp	I-OUT	NOUN	B
load	I-OUT	NOUN	B
(	O	PUNCT	O
number	O	NOUN	B
and	O	CCONJ	O
size	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
600	O	NUM	O
mg	O	NOUN	O
of	B-I	ADP	O
aspirin	I-I	NOUN	B
daily	O	ADV	B
.	O	PUNCT	O


RS	O	NOUN	B
had	O	AUX	O
no	O	DET	O
clinical	O	ADJ	B
effect	O	NOUN	I
on	B-OUT	ADP	O
adenomas	I-OUT	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
Quest	B-I	PROPN	O
to	I-I	ADP	O
Lava	I-I	PROPN	B
Mountain	I-I	PROPN	I
Computer	I-I	PROPN	I
Game	I-I	PROPN	I
on	O	ADP	O
Dietary	B-OUT	PROPN	B
and	I-OUT	CCONJ	O
Physical	I-OUT	PROPN	B
Activity	I-OUT	NOUN	I
Behaviors	I-OUT	PROPN	O
of	O	ADP	O
Elementary	B-P	PROPN	B
School	I-P	PROPN	I
Children	I-P	PROPN	O
:	I-P	PUNCT	O
A	O	DET	O
Pilot	O	PROPN	B
Group-Randomized	O	PROPN	I
Controlled	O	PROPN	I
Trial	O	PROPN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Computer-based	B-I	ADJ	B
educational	I-I	ADJ	O
games	I-I	NOUN	O
present	O	VERB	O
an	O	DET	O
opportunity	O	NOUN	O
for	O	ADP	O
health	O	NOUN	B
education	O	NOUN	I
in	O	ADP	O
school	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
their	O	PRON	O
feasibility	O	NOUN	B
in	O	ADP	O
school	O	NOUN	B
settings	O	NOUN	I
and	O	CCONJ	O
effectiveness	O	NOUN	B
in	O	ADP	O
changing	O	VERB	B
behavior	O	NOUN	I
are	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
feasibility	O	NOUN	B
,	O	PUNCT	O
acceptability	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
Quest	B-I	PROPN	B
to	I-I	ADP	O
Lava	I-I	PROPN	O
Mountain	I-I	PROPN	O
(	I-I	PUNCT	O
QTLM	I-I	PROPN	B
)	I-I	PUNCT	O
computer	I-I	NOUN	B
game	I-I	NOUN	I
on	O	ADP	O
dietary	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
behaviors	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
psychosocial	I-OUT	ADJ	B
factors	I-OUT	NOUN	I
among	O	ADP	O
ethnically	B-P	ADV	B
diverse	I-P	ADJ	O
children	I-P	NOUN	B
in	I-P	ADP	O
Texas	I-P	PROPN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Quasi-experimental	O	ADJ	B
group-randomized	O	ADJ	I
controlled	O	VERB	I
trial	O	NOUN	I
conducted	O	VERB	O
during	O	ADP	O
the	O	DET	O
2012-2013	B-P	NUM	O
school	I-P	NOUN	B
year	I-P	NOUN	I
.	I-P	PUNCT	O


PARTICIPANTS/SETTING	O	NOUN	B
A	B-P	NOUN	O
total	I-P	NOUN	O
of	I-P	ADP	O
107	I-P	NUM	O
children	I-P	NOUN	B
in	I-P	ADP	O
fourth	I-P	ADJ	O
and	I-P	CCONJ	O
fifth	I-P	ADJ	O
grade	I-P	NOUN	O
consented	I-P	VERB	B
.	I-P	PUNCT	O


There	B-P	PRON	O
was	I-P	AUX	O
an	I-P	DET	O
attrition	I-P	NOUN	B
rate	I-P	NOUN	B
of	I-P	ADP	O
8.8	I-P	NUM	O
%	I-P	NOUN	O
with	I-P	ADP	O
a	I-P	DET	O
final	I-P	ADJ	O
sample	I-P	NOUN	B
size	I-P	NOUN	I
of	I-P	ADP	O
44	I-P	NUM	O
children	I-P	NOUN	B
in	I-P	ADP	O
three	I-P	NUM	O
intervention	I-P	NOUN	B
schools	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
a	I-P	DET	O
sample	I-P	NOUN	B
of	I-P	ADP	O
50	I-P	NUM	O
children	I-P	NOUN	B
in	I-P	ADP	O
three	I-P	NUM	O
comparison	I-P	NOUN	B
schools	I-P	NOUN	B
.	I-P	PUNCT	O


Dietary	O	ADJ	B
intake	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
two	O	NUM	O
random	O	ADJ	B
24-hour	O	NOUN	B
recalls	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
child	O	NOUN	B
self-report	O	ADJ	B
surveys	O	NOUN	B
measured	O	VERB	O
diet	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
psychosocial	I-OUT	ADJ	B
factors	I-OUT	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


Process	O	NOUN	B
data	O	NOUN	B
on	O	ADP	O
QTLM	B-I	PROPN	B
usability	O	NOUN	B
and	O	CCONJ	O
back-end	O	NOUN	B
server	O	NOUN	I
data	O	NOUN	B
on	O	ADP	O
QTLM	O	PROPN	B
exposure	O	NOUN	B
and	O	CCONJ	O
progress	O	NOUN	B
achieved	O	VERB	O
were	O	AUX	O
collected	O	VERB	B
.	O	PUNCT	O


INTERVENTION	O	PROPN	B
QTLM	B-I	PROPN	B
was	O	AUX	O
implemented	O	VERB	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
in-school	B-P	NOUN	B
or	I-P	CCONJ	O
afterschool	I-P	NOUN	B
program	I-P	NOUN	I
.	I-P	PUNCT	O


Recommended	O	VERB	B
game	O	NOUN	O
exposure	O	NOUN	B
duration	O	NOUN	B
was	O	AUX	O
90	O	NUM	O
min/wk	O	NOUN	O
for	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


STATISTICAL	O	NOUN	B
ANALYSIS	O	NOUN	I
Analysis	O	NOUN	I
of	O	ADP	O
covariance	O	NOUN	B
or	O	CCONJ	O
logistic	O	ADJ	B
regression	O	NOUN	I
models	O	NOUN	I
evaluated	O	VERB	B
effects	O	NOUN	B
of	O	ADP	O
QTLM	B-I	PROPN	B
on	O	ADP	O
diet	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
psychosocial	I-OUT	ADJ	B
factors	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Post	O	NOUN	B
hoc	O	NOUN	I
exploratory	O	ADJ	I
analysis	O	NOUN	I
examined	O	VERB	O
the	O	DET	O
changes	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
in	O	ADP	O
outcome	O	NOUN	B
variables	O	NOUN	B
among	O	ADP	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Significance	O	NOUN	B
was	O	AUX	O
set	O	VERB	O
at	O	ADP	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Children	O	NOUN	B
played	O	VERB	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
274±110	O	ADJ	O
minutes	O	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
4.6	O	NUM	O
hours	O	NOUN	B
)	O	PUNCT	O
of	B-I	ADP	O
QTLM	I-I	PROPN	B
during	O	ADP	O
the	O	DET	O
6	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
51	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
recommended	O	VERB	B
dosage	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
comparison	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
reported	B-OUT	VERB	O
decreased	I-OUT	VERB	B
sugar	I-OUT	NOUN	B
consumption	I-OUT	NOUN	B
(	O	PUNCT	O
P=0.021	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
higher	I-OUT	ADJ	B
nutrition/physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
attitudes	I-OUT	NOUN	O
(	O	PUNCT	O
P=0.041	O	NOUN	O
)	O	PUNCT	O
pre-	O	ADJ	O
to	O	PART	O
postintervention	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
QTLM	O	PROPN	B
on	B-OUT	ADP	O
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
post	O	NOUN	B
hoc	O	NOUN	I
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
higher	B-I	ADJ	O
QTLM	I-I	PROPN	B
exposure	O	NOUN	B
and	O	CCONJ	O
gaming	O	NOUN	B
progress	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	B-OUT	VERB	B
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	B-I	NOUN	O
QTLM	I-I	PROPN	B
has	O	AUX	O
some	O	DET	O
promising	O	ADJ	O
acceptability	O	NOUN	B
and	O	CCONJ	O
initial	O	ADJ	B
effects	O	NOUN	B
on	B-OUT	ADP	O
diet	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
behaviors	I-OUT	NOUN	I
among	I-P	ADP	O
children	I-P	NOUN	B
in	I-P	ADP	O
elementary	I-P	ADJ	B
school	I-P	NOUN	I
.	O	PUNCT	O


Clonidine	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
noncardiac	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Marked	O	ADJ	O
activation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sympathetic	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
occurs	O	VERB	O
during	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
noncardiac	B-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


Low-dose	O	ADJ	B
clonidine	B-I	NOUN	B
,	O	PUNCT	O
which	O	DET	O
blunts	O	VERB	B
central	O	ADJ	B
sympathetic	O	ADJ	I
outflow	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
prevent	O	VERB	O
perioperative	B-OUT	ADJ	B
myocardial	I-OUT	ADJ	B
infarction	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
death	I-OUT	NOUN	B
without	O	ADP	O
inducing	O	VERB	B
hemodynamic	O	ADJ	B
instability	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
blinded	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
with	O	ADP	O
a	O	DET	O
2-by-2	O	NUM	O
factorial	O	ADJ	O
design	O	NOUN	O
to	O	PART	O
allow	O	VERB	O
separate	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
low-dose	B-I	ADJ	B
clonidine	I-I	NOUN	B
versus	I-I	CCONJ	O
placebo	I-I	NOUN	B
and	I-I	CCONJ	O
low-dose	I-I	ADJ	B
aspirin	I-I	NOUN	B
versus	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
at	I-P	ADP	O
risk	I-P	NOUN	B
for	I-P	ADP	O
,	I-P	PUNCT	O
atherosclerotic	I-P	ADJ	B
disease	I-P	NOUN	I
who	I-P	PRON	O
were	I-P	AUX	O
undergoing	I-P	VERB	O
noncardiac	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
10,010	B-P	NUM	O
patients	I-P	NOUN	B
at	I-P	ADP	O
135	I-P	NUM	O
centers	I-P	NOUN	B
in	I-P	ADP	O
23	I-P	NUM	O
countries	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


For	O	ADP	O
the	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
clonidine	B-I	NOUN	B
with	I-I	ADP	O
placebo	I-I	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
clonidine	B-I	NOUN	B
(	O	PUNCT	O
0.2	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
)	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
just	O	ADV	O
before	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
study	O	NOUN	B
drug	O	NOUN	B
continued	O	VERB	O
until	O	ADP	O
72	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
a	O	DET	O
composite	O	NOUN	B
of	O	ADP	O
death	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
nonfatal	I-OUT	ADJ	B
myocardial	I-OUT	ADJ	I
infarction	I-OUT	NOUN	I
at	O	ADP	O
30	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Clonidine	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
primary-outcome	B-OUT	ADJ	B
events	I-OUT	NOUN	I
(	O	PUNCT	O
367	O	NUM	O
and	O	CCONJ	O
339	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
with	O	ADP	O
clonidine	O	NOUN	B
,	O	PUNCT	O
1.08	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
0.93	O	NUM	O
to	O	PART	O
1.26	O	NUM	O
;	O	PUNCT	O
P=0.29	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Myocardial	B-OUT	ADJ	B
infarction	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
329	B-P	NUM	O
patients	I-P	NOUN	B
(	O	PUNCT	O
6.6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
assigned	O	VERB	O
to	O	PART	O
clonidine	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
295	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
5.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
assigned	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
1.11	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.95	O	NUM	O
to	O	PART	O
1.30	O	NUM	O
;	O	PUNCT	O
P=0.18	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Significantly	O	ADV	O
more	O	ADJ	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
clonidine	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
had	O	AUX	O
clinically	O	ADV	B
important	O	ADJ	O
hypotension	B-OUT	NOUN	B
(	O	PUNCT	O
2385	O	NUM	O
patients	O	NOUN	B
[	O	PUNCT	O
47.6	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
vs.	O	CCONJ	O
1854	O	NUM	O
patients	O	NOUN	B
[	O	PUNCT	O
37.1	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
1.32	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.24	O	NUM	O
to	O	PART	O
1.40	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Clonidine	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
rate	O	NOUN	B
of	O	ADP	O
nonfatal	B-OUT	ADJ	B
cardiac	I-OUT	ADJ	I
arrest	I-OUT	NOUN	I
(	O	PUNCT	O
0.3	O	NUM	O
%	O	NOUN	O
[	O	PUNCT	O
16	O	NUM	O
patients	O	NOUN	B
]	O	PUNCT	O
vs.	O	CCONJ	O
0.1	O	NUM	O
%	O	NOUN	O
[	O	PUNCT	O
5	O	NUM	O
patients	O	NOUN	B
]	O	PUNCT	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
,	O	PUNCT	O
3.20	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.17	O	NUM	O
to	O	PART	O
8.73	O	NUM	O
;	O	PUNCT	O
P=0.02	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Administration	O	PROPN	B
of	O	ADP	O
low-dose	O	ADJ	B
clonidine	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
noncardiac	I-P	ADJ	B
surgery	I-P	NOUN	I
did	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
the	O	DET	O
composite	O	ADJ	B
outcome	O	NOUN	B
of	O	ADP	O
death	B-OUT	NOUN	B
or	O	CCONJ	O
nonfatal	B-OUT	ADJ	B
myocardial	I-OUT	ADJ	I
infarction	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
it	O	PRON	O
did	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
clinically	B-OUT	ADV	B
important	I-OUT	ADJ	O
hypotension	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
nonfatal	I-OUT	ADJ	B
cardiac	I-OUT	ADJ	I
arrest	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


(	O	PUNCT	O
Funded	O	VERB	B
by	O	ADP	O
the	O	DET	O
Canadian	O	PROPN	B
Institutes	O	PROPN	O
of	O	ADP	O
Health	O	PROPN	O
Research	O	PROPN	O
and	O	CCONJ	O
others	O	NOUN	O
;	O	PUNCT	O
POISE-2	O	NUM	B
ClinicalTrials.gov	O	NOUN	I
number	O	NOUN	I
,	O	PUNCT	O
NCT01082874	O	NOUN	O
.	O	PUNCT	O


)	O	PUNCT	O
.	O	PUNCT	O


Application	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Itch	O	PROPN	B
Severity	O	PROPN	I
Score	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
moderate-to-severe	I-P	ADJ	O
plaque	I-P	NOUN	B
psoriasis	I-P	NOUN	B
:	I-P	PUNCT	O
Clinically	O	ADV	B
important	O	ADJ	I
difference	O	NOUN	O
and	O	CCONJ	O
responder	O	NOUN	B
analyses	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
Itch	O	NOUN	B
Severity	O	PROPN	I
Score	O	NOUN	I
(	O	PUNCT	O
ISS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
0-10	O	NUM	O
numeric	O	ADJ	B
rating	O	NOUN	I
scale	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
pruritus	O	NOUN	B
due	O	ADP	O
to	O	PART	O
psoriasis	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Phase	O	NOUN	B
2	O	NUM	I
b	O	NOUN	O
trial	O	NOUN	B
of	O	ADP	O
tofacitinib	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
oral	O	ADJ	B
Janus	O	NOUN	B
kinase	O	NOUN	I
inhibitor	B-P	NOUN	I
.	I-P	PUNCT	O


197	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
moderate-to-severe	I-P	ADJ	O
plaque	I-P	NOUN	B
psoriasis	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-I	PART	O
tofacitinib	I-I	NOUN	B
2	I-I	NUM	O
,	I-I	PUNCT	O
5	I-I	NUM	O
or	I-I	CCONJ	O
15	I-I	NUM	O
mg	I-I	NOUN	O
twice	I-I	ADV	O
daily	I-I	ADV	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ISS	O	PROPN	B
was	O	AUX	O
recorded	O	VERB	O
daily	O	ADV	O
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
week	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
at	O	ADP	O
study	O	NOUN	B
visits	O	NOUN	I
.	O	PUNCT	O


Following	O	VERB	O
good	O	ADJ	O
and	O	CCONJ	O
recommended	O	VERB	B
research	O	NOUN	B
practice	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
analyses	O	NOUN	B
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
clinically	O	ADV	B
important	O	ADJ	O
differences	O	NOUN	O
(	O	PUNCT	O
CID	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
between-group	O	ADJ	B
difference	O	NOUN	I
or	O	CCONJ	O
within-group	O	ADJ	B
difference	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
clinically	O	ADV	B
important	O	ADJ	O
responders	O	NOUN	B
(	O	PUNCT	O
CIR	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
within-patient	O	ADJ	B
change	O	NOUN	I
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
ISS	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
CID	O	PROPN	B
and	O	CCONJ	O
CIR	O	PROPN	B
were	O	AUX	O
defined	O	VERB	O
using	B-OUT	VERB	O
Patient	I-OUT	PROPN	B
Global	I-OUT	PROPN	O
Assessment	I-OUT	PROPN	O
of	I-OUT	ADP	O
psoriasis	I-OUT	NOUN	B
as	O	ADP	O
an	O	DET	O
anchor	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
estimated	O	VERB	B
with	O	ADP	O
a	O	DET	O
longitudinal	O	ADJ	B
model	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
CID	O	NOUN	B
on	O	ADP	O
the	O	DET	O
ISS	O	NOUN	B
was	O	AUX	O
1.64	O	NUM	O
and	O	CCONJ	O
,	O	PUNCT	O
by	O	ADP	O
day	O	NOUN	B
10	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
mean	O	NOUN	O
changes	O	NOUN	B
from	O	ADP	O
baseline	B-OUT	NOUN	B
in	I-OUT	ADP	O
ISS	I-OUT	NOUN	B
values	I-OUT	NOUN	B
for	O	ADP	O
the	B-I	DET	O
tofacitinib	I-I	NOUN	B
doses	O	NOUN	B
(	O	PUNCT	O
placebo-adjusted	O	ADJ	B
)	O	PUNCT	O
exceeded	O	VERB	O
CID	O	PROPN	B
.	O	PUNCT	O


A	O	DET	O
CIR	O	PROPN	B
on	O	ADP	O
the	O	DET	O
ISS	O	NOUN	B
was	O	AUX	O
a	O	DET	O
30	O	NUM	O
%	O	NOUN	O
improvement	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
at	O	ADP	O
week	O	NOUN	B
12	O	NUM	O
,	O	PUNCT	O
87.2	O	NUM	O
%	O	NOUN	O
to	O	PART	O
100	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
receiving	B-I	VERB	O
tofacitinib	I-I	NOUN	B
reached	O	VERB	O
≥30	O	NUM	O
%	O	NOUN	O
improvement	O	NOUN	B
versus	O	CCONJ	O
29.4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
receiving	B-I	VERB	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
CID	O	PROPN	B
and	O	CCONJ	O
CIR	O	NOUN	B
analyses	O	NOUN	B
play	O	VERB	O
vital	O	ADJ	O
roles	O	NOUN	O
in	O	ADP	O
the	O	DET	O
interpretation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
effects	O	NOUN	O
measured	O	VERB	B
by	O	ADP	O
ISS	O	NOUN	B
.	O	PUNCT	O


Do	O	AUX	O
heavier	B-P	ADJ	O
women	I-P	NOUN	B
benefit	O	VERB	B
from	O	ADP	O
a	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
leuprolide	B-I	NOUN	B
acetate	I-I	NOUN	B
for	O	ADP	O
suppression	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
estradiol	O	NOUN	B
?	O	PUNCT	O
OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
heavier	B-P	ADJ	O
women	I-P	NOUN	B
benefit	O	VERB	B
from	O	ADP	O
a	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gonadotropin-releasing	B-I	ADJ	B
hormone	I-I	NOUN	I
analogue	I-I	NOUN	O
leuprolide	I-I	NOUN	B
acetate	I-I	NOUN	I
(	I-I	PUNCT	O
LA	I-I	NOUN	B
)	I-I	PUNCT	O
depot	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
suppression	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
estradiol	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
retrospective	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
LA	B-I	NOUN	B
depot	I-I	NOUN	B
3.75	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
7.5	O	NUM	O
mg	O	NOUN	O
on	O	ADP	O
serum	B-I	NOUN	B
estradiol	I-I	NOUN	B
from	O	ADP	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
parallel-group	O	NOUN	B
,	O	PUNCT	O
12-week	O	ADJ	O
study	O	NOUN	B
of	O	ADP	O
women	B-P	NOUN	B
with	I-P	ADP	O
anemia	I-P	NOUN	B
due	I-P	ADP	O
to	I-P	ADP	O
bleeding	I-P	VERB	B
from	I-P	ADP	O
uterine	I-P	NOUN	B
leiomyomata	I-P	NOUN	I
.	I-P	PUNCT	O


Serum	B-OUT	NOUN	B
estradiol	I-OUT	NOUN	O
levels	I-OUT	NOUN	O
were	O	AUX	O
obtained	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
week	O	NOUN	B
12	O	NUM	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
were	I-P	AUX	O
divided	I-P	VERB	O
into	I-P	ADP	O
weight	I-P	NOUN	B
quartiles	I-P	NOUN	I
according	I-P	VERB	O
to	I-P	PART	O
their	I-P	PRON	O
baseline	I-P	NOUN	B
weight	I-P	NOUN	B
in	I-P	ADP	O
kilograms	I-P	NOUN	B
:	I-P	PUNCT	O
46-	I-P	NUM	O
<	I-P	X	O
64	I-P	NUM	O
,	I-P	PUNCT	O
64-	I-P	NUM	O
<	I-P	X	O
72	I-P	NUM	O
,	I-P	PUNCT	O
72-	I-P	NUM	O
<	I-P	X	O
89	I-P	NUM	O
,	I-P	PUNCT	O
89-159	I-P	NUM	O
(	I-P	PUNCT	O
pounds-102-	I-P	NOUN	O
<	I-P	X	O
140	I-P	NUM	O
,	I-P	PUNCT	O
140-	I-P	NUM	O
<	I-P	X	O
159	I-P	NUM	O
,	I-P	PUNCT	O
159-	I-P	NUM	O
<	I-P	X	O
196	I-P	NUM	O
,	I-P	PUNCT	O
196-350	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
baseline	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	O
statistically	I-OUT	ADV	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
in	O	ADP	O
estradiol	B-OUT	NOUN	B
level	I-OUT	NOUN	B
between	O	ADP	O
groups	O	NOUN	B
as	O	ADP	O
a	O	DET	O
whole	O	ADJ	O
or	O	CCONJ	O
within	O	ADP	O
weight	O	NOUN	B
quartiles	O	NOUN	I
.	O	PUNCT	O


Within	O	ADP	O
each	O	DET	O
group	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
weight	O	NOUN	B
and	O	CCONJ	O
baseline	O	NOUN	B
estradiol	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
week	O	NOUN	B
12	O	NUM	O
,	O	PUNCT	O
whereas	O	SCONJ	O
estradiol	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
were	O	AUX	O
significantly	B-OUT	ADV	O
greater	I-OUT	ADJ	O
in	O	ADP	O
the	O	DET	O
heavier	O	ADJ	O
patients	O	NOUN	B
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
LA	O	NOUN	B
3.75	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.044	O	NUM	O
;	O	PUNCT	O
LA	O	PROPN	B
7.5	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
in	I-OUT	ADP	O
estradiol	I-OUT	NOUN	B
between	O	ADP	O
groups	O	NOUN	B
as	O	ADP	O
a	O	DET	O
whole	O	NOUN	O
or	O	CCONJ	O
within	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
weight	O	NOUN	B
quartiles	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
at	O	ADP	O
week	O	NOUN	B
12	O	NUM	O
there	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
in	O	ADP	O
the	O	DET	O
percentage	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
estradiol	I-OUT	NOUN	B
suppressed	I-OUT	VERB	B
to	I-OUT	PART	O
the	I-OUT	DET	O
menopausal	I-OUT	ADJ	B
range	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
Heavier	B-P	ADJ	B
women	I-P	NOUN	B
do	O	AUX	O
not	O	PART	O
benefit	O	VERB	O
from	O	ADP	O
a	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
LA	B-I	NOUN	B
depot	O	NOUN	B
(	O	PUNCT	O
7.5	O	NUM	O
vs.	O	CCONJ	O
3.75	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
suppression	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
estradiol	O	NOUN	B
.	O	PUNCT	O


Endometrial	B-P	ADJ	B
cytodiagnosis	I-P	NOUN	I
using	O	VERB	O
a	O	DET	O
new	B-I	ADJ	O
softcyte	I-I	NOUN	B
versus	O	CCONJ	O
a	B-I	DET	O
conventional	I-I	ADJ	B
endocyte	I-I	NOUN	I
.	I-I	PUNCT	O


A	O	DET	O
new	O	ADJ	O
endometrial	O	ADJ	B
cytologic	O	ADJ	O
sampling	O	NOUN	O
device	O	NOUN	O
,	O	PUNCT	O
softcyte	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
cytological	B-P	ADJ	B
screening	I-P	NOUN	I
for	I-P	ADP	O
endometrial	I-P	ADJ	B
cancer	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
endocyte	B-I	NOUN	B
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
manipulability	O	NOUN	B
,	O	PUNCT	O
adverse	O	ADJ	B
effects	O	NOUN	I
(	O	PUNCT	O
including	O	VERB	O
pain	O	NOUN	B
and	O	CCONJ	O
hemorrhage	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
cellular	O	ADJ	B
findings	O	NOUN	I
(	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
quantity	O	NOUN	B
of	O	ADP	O
cells	O	NOUN	B
collected	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
success	O	NOUN	B
rate	O	NOUN	B
,	O	PUNCT	O
cell	O	NOUN	B
freshness	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cellular	O	ADJ	B
clumping	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
315	B-P	NUM	O
women	I-P	NOUN	B
(	I-P	PUNCT	O
premenopause	I-P	NOUN	B
251	I-P	NUM	O
,	I-P	PUNCT	O
postmenopause	I-P	NOUN	B
64	I-P	NUM	O
)	I-P	PUNCT	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	ADP	O
two	I-P	NUM	O
groups	I-P	NOUN	B
who	I-P	PRON	O
underwent	I-P	VERB	O
the	I-P	DET	O
endometrial	I-I	ADJ	B
cytological	I-I	ADJ	I
screening	I-I	NOUN	O
with	I-I	ADP	O
either	I-I	CCONJ	O
the	I-I	DET	O
softcyte	I-I	NOUN	B
or	I-I	CCONJ	O
the	I-I	DET	O
endocyte	I-I	NOUN	B
.	I-I	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	O	DET	O
value	O	NOUN	O
of	O	ADP	O
the	O	DET	O
softcyte	B-I	NOUN	B
we	O	PRON	O
compared	O	VERB	O
it	O	PRON	O
with	O	ADP	O
the	O	DET	O
endocyte	B-I	NOUN	B
.	I-I	PUNCT	O


Endometrial	O	ADJ	B
cytology	O	NOUN	I
using	O	VERB	O
a	O	DET	O
softcyte	B-I	NOUN	B
or	O	CCONJ	O
an	O	DET	O
endocyte	B-I	NOUN	B
achieved	O	VERB	O
high	O	ADJ	O
correct	B-OUT	ADJ	O
diagnosis	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
for	I-OUT	ADP	O
cancer	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
instruments	O	NOUN	B
are	O	AUX	O
valuable	O	ADJ	O
as	O	ADP	O
endometrial	O	ADJ	B
cytologic	O	ADJ	I
sample	O	NOUN	I
devices	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
softcyte	O	NOUN	B
causes	O	VERB	O
only	O	ADV	O
mild	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
on	I-OUT	ADP	O
introduction	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
during	I-OUT	ADP	O
collection	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
large	O	ADJ	O
quantity	B-OUT	NOUN	B
of	I-OUT	ADP	O
cells	I-OUT	NOUN	B
could	O	AUX	O
be	O	AUX	O
harvested	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
softcyte	O	NOUN	B
is	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
cytologic	O	ADJ	B
sampling	O	NOUN	I
device	O	NOUN	I
in	O	ADP	O
screening	B-P	NOUN	B
for	I-P	ADP	O
endometrial	I-P	ADJ	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
acupressure	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
extra	O	ADJ	O
1	O	NUM	O
point	O	NOUN	O
on	O	ADP	O
subjective	O	ADJ	B
and	O	CCONJ	O
autonomic	B-OUT	ADJ	B
responses	I-OUT	NOUN	I
to	O	PART	O
needle	O	VERB	B
insertion	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Premedication	B-I	NOUN	B
with	I-I	ADP	O
sedatives	I-I	NOUN	B
can	O	AUX	O
decrease	O	VERB	B
the	O	DET	O
discomfort	B-OUT	NOUN	B
associated	O	VERB	B
with	O	ADP	I
invasive	O	ADJ	B
anesthetic	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


Some	O	DET	O
researchers	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
acupressure	O	NOUN	B
on	O	ADP	O
the	O	DET	O
acupuncture	O	NOUN	B
extra	O	ADJ	O
1	O	NUM	O
point	O	NOUN	O
is	O	AUX	O
effective	O	ADJ	B
for	O	ADP	O
sedation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
acupressure	O	NOUN	B
on	O	ADP	O
the	O	DET	O
extra	O	ADJ	O
1	O	NUM	O
point	O	NOUN	O
could	O	AUX	O
alleviate	O	VERB	O
the	O	DET	O
pain	B-OUT	NOUN	B
of	O	ADP	O
needle	O	NOUN	B
insertion	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
acupressure	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
extra	O	ADJ	O
1	O	NUM	O
point	O	NOUN	O
or	O	CCONJ	O
a	O	DET	O
sham	O	NOUN	B
point	O	NOUN	O
on	O	ADP	O
needle	O	NOUN	B
insertion	O	NOUN	B
using	O	VERB	O
verbal	B-OUT	ADJ	B
rating	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VRS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
and	O	CCONJ	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
variability	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HRV	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Twenty-two	B-P	NUM	O
healthy	I-P	ADJ	B
female	I-P	ADJ	B
volunteers	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
the	O	DET	O
extra	B-I	ADJ	O
1	I-I	NUM	O
group	I-I	NOUN	B
received	O	VERB	O
acupressure	B-I	NOUN	B
at	I-I	ADP	O
the	I-I	DET	O
extra	I-I	ADJ	O
1	I-I	NUM	O
point	I-I	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
sham	B-I	NOUN	B
group	I-I	NOUN	B
received	O	VERB	O
acupressure	B-I	NOUN	B
at	I-I	ADP	O
a	I-I	DET	O
sham	I-I	NOUN	B
point	I-I	NOUN	O
.	I-I	PUNCT	O


After	O	ADP	O
starting	O	VERB	O
the	O	DET	O
electrocardiogram	B-I	NOUN	B
record	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
27-gauge	O	ADJ	B
needle	O	NOUN	I
was	O	AUX	O
inserted	O	VERB	O
into	O	ADP	O
the	O	DET	O
skin	O	NOUN	B
of	O	ADP	O
a	O	DET	O
forearm	O	NOUN	B
.	O	PUNCT	O


Thereafter	O	ADV	O
,	O	PUNCT	O
another	O	DET	O
needle	O	NOUN	B
was	O	AUX	O
inserted	O	VERB	O
into	O	ADP	O
the	O	DET	O
skin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
forearm	O	NOUN	B
during	O	ADP	O
acupressure	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Acupressure	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
extra	O	ADJ	O
1	O	NUM	O
point	O	NOUN	O
significantly	O	ADV	O
reduced	O	VERB	O
the	O	DET	O
VRS	B-OUT	PROPN	B
,	O	PUNCT	O
but	O	CCONJ	O
acupressure	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
sham	O	NOUN	B
increased	O	VERB	B
the	O	DET	O
VRS	B-OUT	PROPN	B
.	I-OUT	PUNCT	O


Acupressure	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
extra	O	ADJ	O
1	O	NUM	O
significantly	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
low	B-OUT	ADJ	B
frequency/high	I-OUT	ADJ	B
frequency	I-OUT	NOUN	I
ratio	I-OUT	NOUN	I
of	I-OUT	ADP	O
HRV	I-OUT	NOUN	B
responding	I-OUT	VERB	B
to	I-OUT	PART	O
needle	I-OUT	NOUN	B
insertion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Acupressure	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
extra	O	ADJ	O
1	O	NUM	O
point	O	NOUN	O
significantly	O	ADV	O
reduced	O	VERB	O
needle	B-OUT	NOUN	B
insertion	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
acupressure	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
sham	O	NOUN	B
point	O	NOUN	O
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
acupressure	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
extra	O	ADJ	O
1	O	NUM	O
point	O	NOUN	O
significantly	O	ADV	O
reduced	O	VERB	O
the	O	DET	O
low	B-OUT	ADJ	B
frequency/high	I-OUT	ADJ	B
frequency	I-OUT	NOUN	I
ratio	I-OUT	NOUN	I
of	I-OUT	ADP	O
HRV	I-OUT	NOUN	B
responding	O	VERB	B
to	O	PART	O
needle	O	NOUN	B
insertion	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
implies	O	VERB	O
a	O	DET	O
reduction	B-OUT	NOUN	B
in	O	ADP	O
sympathetic	B-OUT	ADJ	B
nervous	I-OUT	ADJ	I
system	I-OUT	NOUN	I
activity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Marginal	O	ADJ	B
biotin	O	NOUN	I
deficiency	O	NOUN	I
during	O	ADP	O
normal	B-P	ADJ	B
pregnancy	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Biotin	O	NOUN	B
deficiency	O	NOUN	I
is	O	AUX	O
teratogenic	O	ADJ	B
in	O	ADP	O
several	B-P	ADJ	O
mammalian	I-P	ADJ	B
species	I-P	NOUN	B
.	I-P	PUNCT	O


Approximately	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
have	O	AUX	O
an	O	DET	O
abnormally	O	ADV	B
increased	O	VERB	B
urinary	O	ADJ	B
excretion	O	NOUN	B
of	O	ADP	O
3-hydroxyisovaleric	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
3-HIA	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
probably	O	ADV	O
reflects	O	VERB	O
decreased	O	VERB	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
biotin-dependent	O	ADJ	B
enzyme	O	NOUN	I
methylcrotonyl-CoA	O	ADJ	I
carboxylase	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
increased	O	VERB	B
3-HIA	O	NOUN	O
excretion	O	NOUN	B
could	O	AUX	O
result	O	VERB	O
from	O	ADP	O
pregnancy	O	NOUN	B
per	O	X	O
se	O	X	O
(	O	PUNCT	O
eg	O	ADP	O
,	O	PUNCT	O
from	O	ADP	O
an	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
pregnancy	O	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
handling	O	NOUN	B
of	O	ADP	O
organic	O	ADJ	B
acids	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
biotin	O	NOUN	B
supplementation	O	NOUN	B
significantly	O	ADV	O
decreases	O	VERB	B
3-HIA	O	NOUN	O
excretion	O	NOUN	B
in	O	ADP	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
with	I-P	ADP	O
abnormally	I-P	ADV	B
increased	I-P	VERB	B
3-HIA	I-P	NOUN	O
excretion	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Twenty-six	B-P	NUM	O
pregnant	I-P	ADJ	B
women	I-P	NOUN	I
with	I-P	ADP	O
increased	I-P	VERB	B
3-HIA	I-P	NOUN	O
excretion	I-P	NOUN	B
were	I-P	AUX	O
studied	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
randomized	I-P	ADJ	B
,	I-P	PUNCT	O
placebo-controlled	I-I	ADJ	B
trial	I-P	NOUN	I
;	I-P	PUNCT	O
10	O	NUM	O
women	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
during	O	ADP	O
early	O	ADJ	B
pregnancy	O	NOUN	I
(	O	PUNCT	O
6-17	O	NUM	O
wk	O	NOUN	O
gestation	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
16	O	NUM	O
women	O	NOUN	B
during	O	ADP	O
late	O	ADJ	B
pregnancy	O	NOUN	I
(	O	PUNCT	O
21-37	O	NUM	O
wk	O	NOUN	O
gestation	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Urine	B-OUT	NOUN	B
samples	I-OUT	NOUN	I
were	O	AUX	O
collected	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
14	O	NUM	O
d	O	NOUN	O
of	O	ADP	O
supplementation	O	NOUN	B
with	O	ADP	O
300	B-I	NUM	O
microg	I-I	NOUN	B
(	I-I	PUNCT	O
1.2	I-I	NUM	O
micromol	I-I	NOUN	O
)	I-I	PUNCT	O
biotin/d	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
the	O	DET	O
early-pregnancy	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
3-HIA	B-OUT	NOUN	O
excretion	I-OUT	NOUN	B
decreased	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.006	O	NUM	O
)	O	PUNCT	O
by	O	ADP	O
11.7	O	NUM	O
+/-	O	CCONJ	O
3.6	O	NUM	O
mmol/mol	O	NOUN	O
creatinine	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SEM	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
women	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
biotin	O	NOUN	B
supplements	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
3-HIA	B-OUT	NOUN	O
excretion	I-OUT	NOUN	B
increased	O	VERB	B
by	O	ADP	O
1.6	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
mmol/mol	O	NOUN	O
creatinine	O	NOUN	B
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
women	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
placebo	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
late-pregnancy	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
3-HIA	B-OUT	NOUN	O
excretion	I-OUT	NOUN	B
decreased	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.002	O	NUM	O
)	O	PUNCT	O
by	O	ADP	O
7.1	O	NUM	O
+/-	O	CCONJ	O
1.2	O	NUM	O
mmol/mol	O	NOUN	O
creatinine	O	NOUN	B
in	O	ADP	O
the	O	DET	O
8	O	NUM	O
women	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
biotin	O	NOUN	B
supplements	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
3-HIA	B-OUT	NOUN	O
excretion	I-OUT	NOUN	B
increased	O	VERB	B
by	O	ADP	O
0.9	O	NUM	O
+/-	O	CCONJ	O
1.8	O	NUM	O
mmol/mol	O	NOUN	O
creatinine	O	NOUN	B
in	O	ADP	O
the	O	DET	O
8	O	NUM	O
women	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
placebo	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
increased	O	VERB	B
excretion	B-OUT	NOUN	B
of	I-OUT	ADP	O
3-HIA	I-OUT	NOUN	O
seen	O	VERB	O
frequently	O	ADV	O
in	O	ADP	O
normal	B-P	ADJ	B
pregnancy	I-P	NOUN	I
reflects	O	VERB	O
reduced	O	VERB	B
biotin	B-OUT	NOUN	B
status	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
conclusion	O	NOUN	O
that	O	SCONJ	O
marginal	O	ADJ	B
biotin	O	NOUN	B
deficiency	O	NOUN	I
occurs	O	VERB	O
frequently	O	ADV	O
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
trimester	O	NOUN	B
further	O	ADV	O
raises	O	VERB	O
concern	O	NOUN	O
about	O	ADP	O
potential	O	ADJ	B
human	O	ADJ	B
teratogenicity	O	NOUN	B
.	O	PUNCT	O


Group	B-I	NOUN	B
cognitive	I-I	ADJ	B
behavioural	I-I	ADJ	I
therapy	I-I	NOUN	I
and	I-I	CCONJ	O
group	I-I	NOUN	B
recreational	I-I	ADJ	O
activity	I-I	NOUN	O
for	O	ADP	O
adults	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
preliminary	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
adults	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
are	O	AUX	O
an	O	DET	O
increasingly	O	ADV	O
identified	O	VERB	O
patient	O	NOUN	B
population	O	NOUN	I
,	O	PUNCT	O
few	O	ADJ	O
treatment	O	NOUN	B
options	O	NOUN	I
are	O	AUX	O
available	O	ADJ	O
.	O	PUNCT	O


This	O	DET	O
preliminary	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
open	O	ADJ	I
trial	O	NOUN	I
with	O	ADP	O
a	O	DET	O
parallel	O	ADJ	O
design	O	NOUN	B
developed	O	VERB	O
two	O	NUM	O
group	O	NOUN	B
interventions	O	NOUN	B
for	O	ADP	O
adults	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
and	I-P	CCONJ	O
intelligence	I-P	NOUN	B
within	I-P	ADP	O
the	I-P	DET	O
normal	I-P	ADJ	O
range	I-P	NOUN	O
:	I-P	PUNCT	O
cognitive	I-I	ADJ	B
behavioural	I-I	ADJ	I
therapy	I-I	NOUN	I
and	I-I	CCONJ	O
recreational	I-I	ADJ	B
activity	I-I	NOUN	I
.	I-I	PUNCT	O


Both	O	DET	O
interventions	O	NOUN	B
comprised	O	VERB	O
36	O	NUM	O
weekly	O	ADJ	B
3-h	O	ADJ	O
sessions	O	NOUN	B
led	O	VERB	O
by	O	ADP	O
two	O	NUM	O
therapists	O	NOUN	B
in	O	ADP	O
groups	B-P	NOUN	B
of	I-P	ADP	O
6-8	I-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
68	B-P	NUM	O
psychiatric	I-P	ADJ	B
patients	I-P	NOUN	I
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
participated	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Outcome	O	NOUN	B
measures	O	NOUN	I
were	O	AUX	O
Quality	B-OUT	ADJ	B
of	I-OUT	ADP	I
Life	I-OUT	PROPN	I
Inventory	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
Sense	I-OUT	NOUN	B
of	I-OUT	ADP	I
Coherence	I-OUT	NOUN	I
Scale	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
Rosenberg	I-OUT	PROPN	B
Self-Esteem	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
an	I-OUT	DET	O
exploratory	I-OUT	ADJ	B
analysis	I-OUT	NOUN	I
on	I-OUT	ADP	O
measures	I-OUT	NOUN	B
of	I-OUT	ADP	O
psychiatric	I-OUT	ADJ	B
health	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Participants	O	NOUN	B
in	O	ADP	O
both	O	DET	O
treatment	O	NOUN	B
conditions	O	NOUN	O
reported	O	VERB	O
an	O	DET	O
increased	O	VERB	B
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
at	O	ADP	O
post-treatment	O	ADJ	B
(	O	PUNCT	O
d	O	NOUN	O
=	O	ADJ	O
0.39	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
interventions	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
amelioration	O	NOUN	B
of	O	ADP	O
psychiatric	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
dropout	B-OUT	ADJ	B
rate	I-OUT	NOUN	I
was	O	AUX	O
lower	O	ADJ	O
with	O	ADP	O
cognitive	B-I	ADJ	B
behavioural	I-I	ADJ	I
therapy	I-I	NOUN	I
than	O	ADP	O
with	O	ADP	O
recreational	O	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
participants	O	NOUN	B
in	O	ADP	O
cognitive	B-I	ADJ	B
behavioural	I-I	ADJ	I
therapy	I-I	NOUN	I
rated	O	VERB	B
themselves	O	PRON	O
as	O	ADP	O
more	O	ADV	O
generally	O	ADV	O
improved	O	VERB	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
more	O	ADV	O
improved	O	VERB	B
regarding	O	VERB	O
expression	O	NOUN	B
of	O	ADP	O
needs	O	NOUN	B
and	O	CCONJ	O
understanding	O	NOUN	O
of	O	ADP	O
difficulties	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
interventions	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
promising	O	ADJ	O
treatment	O	NOUN	B
options	O	NOUN	I
for	O	ADP	O
adults	O	NOUN	B
with	O	ADP	O
autism	O	NOUN	B
spectrum	O	NOUN	I
disorder	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
interventions	O	NOUN	B
'	O	PART	O
similar	O	ADJ	O
efficacy	B-OUT	NOUN	B
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
common	O	ADJ	O
elements	O	NOUN	B
,	O	PUNCT	O
structure	O	NOUN	B
and	O	CCONJ	O
group	O	NOUN	B
setting	O	NOUN	I
.	O	PUNCT	O


Cognitive	B-I	ADJ	B
behavioural	I-I	ADJ	I
therapy	I-I	NOUN	I
may	O	AUX	O
be	O	AUX	O
additionally	O	ADV	O
beneficial	O	ADJ	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
increasing	O	VERB	B
specific	O	ADJ	B
skills	O	NOUN	B
and	O	CCONJ	O
minimizing	O	VERB	O
dropout	O	NOUN	B
.	O	PUNCT	O


Dose-response	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
concentration-response	I-OUT	ADJ	B
relation	O	NOUN	O
of	O	ADP	O
rocuronium	B-I	NOUN	B
infusion	I-I	NOUN	B
during	O	ADP	O
propofol-nitrous	B-I	ADJ	B
oxide	I-I	NOUN	I
and	O	CCONJ	O
isoflurane-nitrous	B-I	ADJ	B
oxide	I-I	NOUN	I
anaesthesia	I-I	NOUN	I
.	I-I	PUNCT	O


The	B-OUT	DET	O
dose-response	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
concentration-response	I-OUT	ADJ	B
relation	I-OUT	NOUN	O
of	O	ADP	O
rocuronium	B-I	NOUN	B
infusion	I-I	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
20	B-P	NUM	O
adult	I-P	ADJ	B
surgical	I-P	ADJ	B
patients	I-P	NOUN	B
during	I-P	ADP	O
propofol-nitrous	I-I	ADJ	B
oxide	I-I	NOUN	I
and	I-I	CCONJ	O
isoflurane	I-I	NOUN	B
(	I-I	PUNCT	O
1	I-I	NUM	O
MAC	I-I	NOUN	B
)	I-I	PUNCT	O
-nitrous	I-I	ADJ	O
oxide	I-I	NOUN	B
anaesthesia	I-I	NOUN	I
.	I-I	PUNCT	O


Neuromuscular	O	ADJ	B
block	O	NOUN	I
was	O	AUX	O
kept	O	VERB	O
constant	O	ADJ	B
,	O	PUNCT	O
initially	O	ADV	B
at	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
then	O	ADV	O
at	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
a	O	DET	O
closed-loop	B-I	ADJ	B
feedback	I-I	NOUN	I
controller	I-I	NOUN	I
.	I-I	PUNCT	O


At	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
block	O	NOUN	B
the	O	DET	O
steady-state	B-OUT	ADJ	B
infusion	I-OUT	NOUN	B
of	I-I	ADP	O
rocuronium	I-I	NOUN	B
was	O	AUX	O
0.55	O	NUM	O
+/-	O	CCONJ	O
0.16	O	NUM	O
mg	O	NOUN	O
kg-1	O	NOUN	O
h-1	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
corresponding	B-I	ADJ	O
concentration	I-OUT	NOUN	B
1714	O	NUM	O
+/-	O	CCONJ	O
281	O	NUM	O
ng	O	NOUN	O
mL-1	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
propofol	B-I	NOUN	B
.	I-I	PUNCT	O


At	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
block	O	NOUN	B
the	O	DET	O
corresponding	B-OUT	ADJ	O
infusion	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
was	O	AUX	O
0.27	O	NUM	O
+/-	O	CCONJ	O
0.11	O	NUM	O
mg	O	NOUN	O
kg-1	O	NOUN	O
h-1	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
concentration	B-OUT	NOUN	B
1077	O	NUM	O
+/-	O	CCONJ	O
244	O	NUM	O
ng	O	NOUN	O
mL-1	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


At	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
block	O	NOUN	B
isoflurane	B-I	NOUN	B
reduced	O	VERB	B
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
infusion	I-OUT	NOUN	B
by	O	ADP	O
52	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
concentration	B-OUT	NOUN	B
by	O	ADP	O
59	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
at	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
block	O	NOUN	B
both	O	CCONJ	O
the	O	DET	O
mean	B-OUT	ADJ	O
infusion	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
and	O	CCONJ	O
the	O	DET	O
concentration	B-OUT	NOUN	B
of	I-OUT	ADP	O
rocuronium	I-OUT	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
35	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
rocuronium	I-OUT	NOUN	B
clearance	I-OUT	NOUN	B
at	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
block	O	NOUN	B
was	O	AUX	O
unaffected	O	ADJ	O
by	O	ADP	O
the	O	DET	O
type	O	NOUN	B
of	O	ADP	I
anaesthesia	B-I	NOUN	I
;	I-I	PUNCT	O
it	O	PRON	O
was	O	AUX	O
4.1	O	NUM	O
+/-	O	CCONJ	O
1.6	O	NUM	O
and	O	CCONJ	O
4.9	O	NUM	O
+/-	O	CCONJ	O
2.7	O	NUM	O
mL	O	NOUN	O
kg-1	O	NOUN	O
min-1	O	NOUN	O
in	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
receiving	O	VERB	O
propofol	B-I	NOUN	B
and	O	CCONJ	O
isoflurane	B-I	NOUN	B
anaesthesia	I-I	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
isoflurane	O	NOUN	B
reduces	O	VERB	B
the	O	DET	O
infusion	B-OUT	NOUN	B
requirements	I-OUT	NOUN	B
of	I-OUT	ADP	O
rocuronium	I-OUT	NOUN	B
by	O	ADP	O
changing	O	VERB	B
the	O	DET	O
pharmacodynamic	O	ADJ	B
behaviour	O	NOUN	I
.	O	PUNCT	O


Protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
1-adamantanamine	B-I	NOUN	B
hydrochloride	I-I	NOUN	I
on	O	ADP	O
influenza	B-P	NOUN	B
A2	I-P	NOUN	I
infections	I-OUT	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
family	I-P	NOUN	B
environment	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
controlled	O	VERB	B
double-blind	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


Multicyclic	B-I	ADJ	B
,	I-I	PUNCT	O
dose-intensive	I-I	ADJ	B
chemotherapy	I-I	NOUN	I
supported	O	VERB	O
by	O	ADP	O
sequential	O	ADJ	B
reinfusion	O	NOUN	B
of	O	ADP	O
hematopoietic	B-I	ADJ	B
progenitors	I-I	NOUN	I
in	O	ADP	O
whole	O	ADJ	B
blood	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
support	O	VERB	O
multicyclic	O	ADJ	B
,	O	PUNCT	O
dose-intensive	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
reinfusing	B-I	VERB	B
hematopoietic	I-I	ADJ	B
progenitors	I-I	NOUN	I
collected	O	VERB	B
at	O	ADP	O
each	O	DET	O
cycle	O	NOUN	B
in	O	ADP	O
leukapheresis	O	NOUN	B
product	O	NOUN	I
or	O	CCONJ	O
whole	O	ADJ	B
blood	O	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	VERB	O
Twenty-five	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
small-cell	I-P	ADJ	B
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
SCLC	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
six	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
ifosfamide	B-I	NOUN	B
,	I-I	PUNCT	O
carboplatin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
etoposide	I-I	NOUN	B
(	I-I	PUNCT	O
ICE	I-I	NOUN	B
)	I-I	PUNCT	O
with	I-I	ADP	O
granulocyte	I-I	NOUN	B
colony-stimulating	I-I	ADJ	I
factor	I-I	NOUN	I
(	I-I	PUNCT	O
G-CSF	I-I	NOUN	B
)	I-I	PUNCT	O
300	O	NUM	O
micrograms/d	O	NOUN	O
subcutaneously	O	ADV	O
(	O	PUNCT	O
SC	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
days	O	NOUN	B
4	O	NUM	O
to	O	PART	O
15	O	NUM	O
.	O	PUNCT	O


Hematopoietic	O	ADJ	B
progenitors	O	NOUN	I
collected	O	VERB	O
during	O	ADP	O
each	O	DET	O
cycle	O	NOUN	B
were	O	AUX	O
reinfused	O	VERB	B
on	O	ADP	O
day	O	NOUN	B
3	O	NUM	O
of	O	ADP	O
the	O	DET	O
next	O	ADJ	B
cycle	O	NOUN	I
.	O	PUNCT	O


Cohort	O	NOUN	B
1	O	NUM	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
treated	O	VERB	B
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
leukapheresis	B-I	NOUN	B
after	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
cryopreservation	B-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
leukapheresis	I-I	NOUN	B
product	I-I	NOUN	O
.	I-I	PUNCT	O


Chemotherapy	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
if	O	SCONJ	O
the	O	DET	O
WBC	O	NOUN	B
count	O	NOUN	B
was	O	AUX	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
3	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/L	O	NUM	O
and	O	CCONJ	O
platelet	O	NOUN	B
count	O	NOUN	I
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
100	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/L	O	NUM	O
.	O	PUNCT	O


Cohort	O	NOUN	B
2	O	NUM	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
treated	O	VERB	B
every	O	DET	O
2	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
leukapheresis	B-I	NOUN	B
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
of	O	ADP	O
the	O	DET	O
next	O	ADJ	B
cycle	O	NOUN	I
and	O	CCONJ	O
storage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
leukapheresis	B-I	NOUN	B
product	I-I	NOUN	O
at	O	ADP	O
4	O	NUM	O
degrees	O	NOUN	B
C.	O	PROPN	B
Cohort	O	PROPN	I
3	O	NUM	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
treated	O	VERB	B
every	O	DET	O
2	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
500	O	NUM	O
to	O	PART	O
750	O	NUM	O
mL	O	NOUN	O
of	O	ADP	O
blood	O	NOUN	B
drawn	O	VERB	O
by	O	ADP	O
venesection	O	NOUN	B
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
of	O	ADP	O
the	O	DET	O
next	O	ADJ	B
cycle	O	NOUN	I
and	O	CCONJ	O
stored	O	VERB	B
at	O	ADP	O
4	O	NUM	O
degrees	O	NOUN	B
C.	O	X	O
In	O	ADP	O
cohorts	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
chemotherapy	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
if	O	SCONJ	O
the	O	DET	O
WBC	O	NOUN	B
count	O	NOUN	B
was	O	AUX	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
3	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/L	O	NUM	O
and	O	CCONJ	O
platelet	O	NOUN	B
count	O	NOUN	I
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
30	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/L	O	NUM	O
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
leukapheresis	I-OUT	NOUN	B
products	I-OUT	NOUN	I
were	O	AUX	O
assayed	O	VERB	B
for	O	ADP	O
hematopoietic	O	ADJ	B
progenitors	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
ICE	B-I	NOUN	B
chemotherapy	I-I	NOUN	B
with	O	ADP	O
G-CSF	O	NOUN	B
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
mobilizing	B-OUT	VERB	O
blood	I-OUT	NOUN	B
progenitors	I-OUT	NOUN	I
(	O	PUNCT	O
median	O	ADJ	B
,	O	PUNCT	O
120-fold	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Long-term	O	ADJ	B
cultures	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
stem-cell	B-OUT	ADJ	B
depletion	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
cytotoxic	B-OUT	ADJ	B
dose-intensity	I-OUT	NOUN	B
of	O	ADP	O
standard	O	ADJ	B
every-4-weeks	O	PROPN	B
ICE	O	PROPN	B
is	O	AUX	O
100	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
first	O	ADJ	O
three	O	NUM	O
cycles	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
134	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
median	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
cohort	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
200	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
cohorts	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Toxicity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
supportive	I-OUT	ADJ	B
care	I-OUT	NOUN	I
requirements	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
increased	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
dose-intensity	O	NOUN	B
of	O	ADP	O
ICE	B-I	NOUN	B
chemotherapy	I-I	NOUN	B
can	O	AUX	O
be	O	AUX	O
doubled	O	VERB	O
by	O	ADP	O
reinfusing	O	VERB	B
hematopoietic	O	ADJ	B
progenitors	O	NOUN	I
collected	O	VERB	O
by	O	ADP	O
leukapheresis	O	NOUN	B
or	O	CCONJ	O
venesection	O	NOUN	B
and	O	CCONJ	O
stored	O	VERB	B
at	O	ADP	O
4	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Cardiac	O	ADJ	B
protection	O	NOUN	I
is	O	AUX	O
a	O	DET	O
clinical	O	ADJ	B
evidence	O	NOUN	I
]	O	PUNCT	O
.	O	PUNCT	O


AIM	O	PROPN	B
Anaesthetics	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
protective	O	ADJ	B
effect	O	NOUN	I
against	O	ADP	O
myocardial	O	ADJ	B
ischemia	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
if	O	SCONJ	O
sevoflurane	O	NOUN	B
administration	O	NOUN	I
could	O	AUX	O
exert	O	VERB	O
myocardial	B-OUT	ADJ	B
protection	I-OUT	NOUN	B
during	O	ADP	O
following	O	VERB	O
coronary	O	ADJ	B
occlusion	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
a	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


EXPERIMENTAL	O	NOUN	B
DESIGN	O	NOUN	I
prospective	O	ADJ	I
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


b	O	X	O
)	O	PUNCT	O
.	O	PUNCT	O


SETTING	O	NOUN	B
University	B-P	PROPN	I
Hospital	I-P	PROPN	I
,	I-P	PUNCT	O
cardiac	I-P	ADJ	B
surgical	I-P	ADJ	I
operative	I-P	ADJ	I
theatre	I-P	NOUN	I
.	I-P	PUNCT	O


c	O	X	O
)	O	PUNCT	O
.	O	PUNCT	O


PATIENTS	O	VERB	B
42	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
,	I-P	PUNCT	O
scheduled	I-P	VERB	O
to	I-P	PART	O
undergo	I-P	VERB	O
coronary	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


INCLUSION	B-P	NOUN	B
CRITERIA	I-P	VERB	I
severe	I-P	ADJ	O
coronary	I-P	ADJ	B
stenosis	I-P	NOUN	I
of	I-P	ADP	O
anterior	I-P	ADJ	B
descending	I-P	ADJ	I
coronary	I-P	ADJ	I
artery	I-P	NOUN	I
;	I-P	PUNCT	O
no	I-P	DET	O
collateral	I-P	ADJ	B
flow	I-P	NOUN	I
on	I-P	ADP	O
angiography	I-P	NOUN	B
;	I-P	PUNCT	O
at	I-P	ADP	O
least	I-P	ADJ	O
two	I-P	NUM	O
normokinetic	I-P	ADJ	B
segments	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
myocardial	I-P	ADJ	B
region	I-P	NOUN	I
supplied	I-P	VERB	O
by	I-P	ADP	O
the	I-P	DET	O
vessel	I-P	NOUN	B
being	I-P	AUX	O
bypassed	I-P	VERB	O
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	B-I	PART	O
receive	I-I	VERB	O
(	I-I	PUNCT	O
group	I-I	NOUN	B
S	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
not	I-I	PART	O
(	I-I	PUNCT	O
group	I-I	NOUN	B
C	I-I	NOUN	I
)	I-I	PUNCT	O
sevoflurane	I-I	NOUN	B
administration	O	NOUN	I
for	O	ADP	O
15	O	NUM	O
min	O	NOUN	O
just	O	ADV	O
before	O	ADP	O
coronary	O	ADJ	B
occlusion	O	NOUN	I
.	O	PUNCT	O


d	O	X	O
)	O	PUNCT	O
.	O	PUNCT	O


INTERVENTIONS	O	VERB	B
Transoesophageal	B-I	PROPN	B
Tissue	I-I	PROPN	I
Doppler	I-I	PROPN	I
echocardiographic	I-I	ADJ	O
examination	I-I	NOUN	O
of	I-I	ADP	O
myocardial	I-I	ADJ	B
systolic	I-I	NOUN	I
and	I-I	CCONJ	O
early	I-I	ADJ	B
diastolic	I-I	ADJ	B
velocities	I-I	NOUN	B
in	I-I	ADP	O
both	I-I	DET	O
groups	I-I	NOUN	B
basally	I-I	ADV	B
and	I-I	CCONJ	O
60	I-I	NUM	O
s	I-I	NOUN	O
after	I-I	ADP	O
coronary	I-I	ADJ	B
occlusion	I-I	NOUN	I
by	I-I	ADP	O
the	I-I	DET	O
surgeon	I-I	NOUN	B
.	I-I	PUNCT	O


e	O	X	O
)	O	PUNCT	O
.	O	PUNCT	O


MEASURES	O	ADJ	O
systolic	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
early	I-OUT	ADJ	B
diastolic	I-OUT	ADJ	B
velocities	I-OUT	NOUN	B
were	O	AUX	O
registered	O	VERB	O
by	O	ADP	O
Tissue	O	NOUN	B
Doppler	O	PROPN	I
from	O	ADP	O
a	O	DET	O
long-axis	O	ADJ	B
view	O	NOUN	I
of	O	ADP	O
the	O	DET	O
interventricular	O	ADJ	B
septum	O	NOUN	I
or	O	CCONJ	O
the	O	DET	O
anterior	O	ADJ	B
wall	O	NOUN	O
of	O	ADP	O
the	O	DET	O
left	O	ADJ	B
ventricle	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
group	O	NOUN	B
C	O	NOUN	I
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
systolic	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
intramyocardial	I-OUT	ADJ	B
velocities	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
during	O	ADP	O
myocardial	O	ADJ	B
ischemia	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
coronary	O	ADJ	B
occlusion	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Treatment	O	NOUN	B
with	O	ADP	O
sevoflurane	O	NOUN	B
before	O	ADP	O
coronary	O	ADJ	B
occlusion	O	NOUN	I
seem	O	VERB	O
effective	O	ADJ	B
in	O	ADP	O
reducing	O	VERB	B
functional	B-OUT	ADJ	B
myocardial	I-OUT	ADJ	O
impairment	I-OUT	NOUN	O
due	O	ADJ	O
to	O	ADP	O
ischemia	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Total	O	ADJ	B
parenteral	B-OUT	ADJ	B
nutrition	I-OUT	NOUN	I
in	O	ADP	O
colon	B-I	NOUN	B
surgery	I-I	NOUN	I
]	I-I	PUNCT	O
.	O	PUNCT	O


Pars	B-I	ADJ	B
plana	I-I	NOUN	I
vitrectomy	I-I	NOUN	I
for	O	ADP	O
diabetic	O	ADJ	B
macular	O	NOUN	I
edema	O	NOUN	I
.	O	PUNCT	O


Internal	B-I	ADJ	B
limiting	I-I	VERB	I
membrane	I-I	NOUN	I
delamination	I-I	NOUN	I
vs	O	CCONJ	O
posterior	B-I	ADJ	B
hyaloid	I-I	ADJ	I
removal	I-I	NOUN	I
.	I-I	PUNCT	O


A	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Diabetes	O	NOUN	B
mellitus	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
subsequent	O	ADJ	O
ocular	O	ADJ	B
complications	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
cystoid	O	NOUN	B
macular	O	NOUN	I
edema	O	NOUN	I
(	O	PUNCT	O
CME	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
are	O	AUX	O
of	O	ADP	O
fundametal	O	ADJ	B
socio-economic	O	ADJ	B
relevance	O	NOUN	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
internal	B-I	ADJ	B
limiting	I-I	VERB	I
membrane	I-I	NOUN	I
(	I-I	PUNCT	O
ILM	I-I	NOUN	B
)	I-I	PUNCT	O
removal	I-I	NOUN	B
on	O	ADP	O
longterm	O	ADJ	B
morphological	O	ADJ	B
and	O	CCONJ	O
functional	O	ADJ	B
outcome	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
diabetes	I-P	NOUN	B
mellitus	I-P	NOUN	I
(	I-P	PUNCT	O
DM	I-P	NOUN	B
)	I-P	PUNCT	O
type	I-P	NOUN	O
2	I-P	NUM	O
and	I-P	CCONJ	O
chronic	I-P	ADJ	B
CME	I-P	NOUN	I
without	I-P	ADP	O
evident	I-P	ADJ	O
vitreomacular	I-P	NOUN	B
traction	I-P	NOUN	I
.	I-P	PUNCT	O


METHOD	O	PROPN	O
Forty	B-P	NUM	O
eyes	I-P	NOUN	B
with	I-P	ADP	O
attached	I-P	VERB	O
posterior	I-P	ADJ	B
hyaloid	I-P	NOUN	B
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
this	O	DET	O
prospective	O	ADJ	B
trial	O	NOUN	I
and	O	CCONJ	O
randomized	O	VERB	B
intraoperatively	O	ADV	I
.	O	PUNCT	O


Prior	O	ADJ	O
focal	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
31	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
panretinal	O	NOUN	B
(	B-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
25	I-I	NUM	O
)	I-I	PUNCT	O
laser	I-I	NOUN	B
coagulation	I-I	NOUN	I
was	O	AUX	O
permitted	O	VERB	O
.	O	PUNCT	O


Group	O	PROPN	B
I	O	NUM	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
19	O	NUM	O
patients	B-I	NOUN	B
)	I-I	PUNCT	O
underwent	I-I	VERB	O
surgical	I-I	ADJ	B
induction	I-I	NOUN	I
of	I-I	ADP	O
posterior	I-I	ADJ	B
vitreous	I-I	ADJ	I
detachment	I-I	NOUN	I
(	O	PUNCT	O
PVD	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
group	O	NOUN	B
II	O	NUM	I
(	B-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
20	I-I	NUM	O
patients	I-I	NOUN	B
)	I-I	PUNCT	O
PVD	I-I	NOUN	B
and	I-I	CCONJ	O
removal	I-I	NOUN	B
of	O	ADP	O
the	O	DET	O
ILM	O	PROPN	B
.	O	PUNCT	O


Eleven	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
detached	O	VERB	B
posterior	O	ADJ	I
hyaloid	O	NOUN	I
(	O	PUNCT	O
group	O	NOUN	B
III	O	NUM	I
)	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
randomized	B-I	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
ILM	O	NOUN	B
removal	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
eye	O	NOUN	B
had	O	AUX	O
to	O	PART	O
be	O	AUX	O
excluded	O	VERB	O
from	O	ADP	O
further	O	ADJ	O
analysis	O	NOUN	B
.	O	PUNCT	O


Examinations	B-OUT	NOUN	B
included	I-OUT	VERB	O
ETDRS	I-OUT	NOUN	B
best-corrected	I-OUT	ADJ	B
visual	I-OUT	ADJ	O
acuity	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
BCVA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
fluorescein	I-OUT	NOUN	B
angiography	I-OUT	NOUN	I
(	O	PUNCT	O
FLA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
OCT	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
postoperatively	O	ADV	B
.	O	PUNCT	O


Main	O	ADJ	O
outcome	B-OUT	NOUN	O
measure	O	NOUN	O
was	O	AUX	O
BCVA	O	NOUN	B
at	O	ADP	O
6	B-OUT	NUM	O
months	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
secondary	I-OUT	ADJ	B
was	I-OUT	AUX	O
foveal	O	NOUN	B
thickness	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
Mean	O	VERB	O
BCVA	O	NOUN	B
over	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
in	O	ADP	O
85	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
decreased	O	VERB	B
in	O	ADP	O
53	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
group	O	NOUN	B
I	O	NUM	I
.	O	PUNCT	O


Results	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
different	O	ADJ	O
[	O	PUNCT	O
group	O	NOUN	B
I	O	NOUN	I
:	O	PUNCT	O
mean	O	VERB	O
decrease	O	NOUN	B
log	O	NOUN	O
MAR	O	PROPN	B
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
(	O	PUNCT	O
0.06	O	NUM	O
;	O	PUNCT	O
0.32	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
group	O	NOUN	B
II	O	NUM	I
:	O	PUNCT	O
(	O	PUNCT	O
-0.02	O	NUM	O
;	O	PUNCT	O
0.11	O	NUM	O
)	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


OCT	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
significantly	O	ADV	O
greater	B-OUT	ADJ	O
reduction	I-OUT	NOUN	B
of	I-OUT	ADP	O
foveal	O	ADJ	B
thickness	O	NOUN	I
following	O	VERB	O
PVD	O	NOUN	B
with	O	ADP	O
ILM	O	NOUN	B
removal	O	NOUN	B
[	O	PUNCT	O
group	O	NOUN	B
I	O	NOUN	I
:	O	PUNCT	O
mean	O	VERB	O
change	O	NOUN	O
:	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
(	O	PUNCT	O
-208.95	O	X	O
μm	O	NOUN	O
;	O	PUNCT	O
-78.05	O	NOUN	O
μm	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
group	O	NOUN	B
II	O	NUM	I
:	O	PUNCT	O
(	B-I	PUNCT	O
-80.90	I-I	NOUN	O
μm	I-I	ADP	O
:	I-I	PUNCT	O
+59.17	I-I	NOUN	B
μm	I-I	NOUN	I
)	I-I	PUNCT	I
]	I-I	PUNCT	O
.	I-I	PUNCT	O


CONCLUSION	B-I	NOUN	O
Vitrectomy	I-I	NOUN	B
,	I-I	PUNCT	O
PVD	I-I	NOUN	B
with	I-I	ADP	O
or	O	CCONJ	O
without	O	ADP	O
ILM	O	NOUN	B
removal	O	NOUN	B
does	B-P	AUX	O
not	I-P	PART	O
improve	I-P	VERB	O
vision	I-P	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
DM	I-P	NOUN	B
type	I-P	NOUN	I
2	I-P	NUM	I
and	I-P	CCONJ	O
cystoid	I-P	NOUN	B
diabetic	I-P	ADJ	I
macular	I-P	NOUN	I
edema	I-P	NOUN	I
without	I-P	ADP	O
evident	I-P	ADJ	O
vitreoretinal	O	ADJ	B
traction	O	NOUN	I
.	O	PUNCT	O


ILM	O	NOUN	B
delamination	O	NOUN	B
shows	O	VERB	O
improved	O	VERB	O
morphological	O	ADJ	B
results	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
appears	B-P	VERB	O
to	I-P	PART	O
be	I-P	AUX	O
beneficial	I-P	ADJ	O
in	I-P	ADP	O
eyes	O	NOUN	B
with	O	ADP	O
preexisting	O	VERB	O
PVD	O	NOUN	B
.	O	PUNCT	O


Intraperitoneal	B-I	NOUN	B
cisplatin	I-I	NOUN	B
versus	O	CCONJ	O
no	O	DET	O
further	O	ADJ	O
treatment	O	NOUN	B
:	O	PUNCT	O
8-year	O	ADJ	O
results	O	NOUN	B
of	O	ADP	O
EORTC	O	NOUN	B
55875	O	NUM	I
,	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
III	O	NUM	I
study	O	NOUN	I
in	O	ADP	O
ovarian	B-P	ADJ	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
pathologically	I-P	ADV	B
complete	I-P	ADJ	O
remission	I-P	NOUN	B
after	I-P	ADP	O
platinum-based	I-I	ADJ	B
intravenous	I-I	ADJ	I
chemotherapy	I-I	NOUN	I
.	I-I	PUNCT	O


First-line	B-I	ADJ	B
intravenous	I-I	ADJ	I
chemotherapy	I-I	NOUN	I
(	O	PUNCT	O
CT	O	NOUN	B
)	O	PUNCT	O
following	O	VERB	O
debulking	O	NOUN	B
surgery	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
prolonged	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
particular	O	ADJ	O
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
achieve	I-P	VERB	O
a	I-P	DET	O
pathological	I-P	ADJ	B
complete	I-P	ADJ	O
remission	I-P	NOUN	O
(	I-P	PUNCT	O
pCR	I-P	NOUN	B
)	I-P	PUNCT	O
at	I-P	ADP	O
second-look	I-P	ADJ	B
surgery	I-P	NOUN	I
but	I-P	CCONJ	O
in	I-P	ADP	O
whom	I-P	PRON	O
a	I-P	DET	O
high	I-P	ADJ	O
rate	I-P	NOUN	B
of	I-P	ADP	O
relapses	I-P	NOUN	B
still	I-P	ADV	O
occurs	I-P	VERB	O
.	I-P	PUNCT	O


Between	B-P	ADP	O
1988	I-P	NUM	O
and	I-P	CCONJ	O
1997	I-P	NUM	O
,	I-P	PUNCT	O
153	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
pCR	I-P	NOUN	B
following	I-P	VERB	O
platinum-based	I-I	ADJ	B
intravenous	I-I	ADJ	I
CT	I-I	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
between	O	ADP	O
four	B-I	NUM	O
courses	I-I	NOUN	B
of	I-I	ADP	O
intraperitoneal	I-I	ADJ	B
cisplatin	I-I	NOUN	B
(	I-I	PUNCT	O
P	I-I	NOUN	O
)	I-I	PUNCT	O
(	I-I	PUNCT	O
90	I-I	NUM	O
mg/m2	I-I	NOUN	O
every	I-I	DET	O
3	I-I	NUM	O
weeks	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
observation	I-I	NOUN	B
.	I-I	PUNCT	O


Overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
the	O	DET	O
primary	O	ADJ	B
endpoint	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
progression-free	O	ADJ	B
survival	O	NOUN	I
(	O	PUNCT	O
PFS	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
a	O	DET	O
secondary	O	ADJ	B
endpoint	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
intent-to-treat	O	ADJ	B
analysis	O	NOUN	I
includes	B-P	VERB	O
16	I-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
not	I-P	PART	O
eligible	I-P	ADJ	O
and	I-P	CCONJ	O
17	I-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
protocol	I-P	NOUN	B
violations	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
two	B-P	NUM	O
groups	I-P	NOUN	B
were	I-P	AUX	O
well	I-P	ADV	O
balanced	I-P	ADJ	O
in	I-P	ADP	O
terms	I-P	NOUN	O
of	I-P	ADP	O
age	I-P	NOUN	B
(	I-P	PUNCT	O
median	I-P	NOUN	B
=	I-P	ADJ	O
55	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
performance	I-P	NOUN	B
status	I-P	NOUN	I
(	I-P	PUNCT	O
78	I-P	NUM	O
%	I-P	NOUN	O
P.S	I-P	PROPN	B
.	I-P	PUNCT	O


O	B-P	INTJ	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
FIGO	I-P	NOUN	B
stage	I-P	NOUN	I
(	I-P	PUNCT	O
96	I-P	NUM	O
%	I-P	NOUN	O
stage	I-P	NOUN	B
III	I-P	NUM	I
)	I-P	PUNCT	O
,	I-P	PUNCT	O
histology	I-P	NOUN	B
(	I-P	PUNCT	O
serous	I-P	ADJ	B
in	I-P	ADP	O
66	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
grade	I-P	NOUN	B
(	I-P	PUNCT	O
2	I-P	NUM	O
or	I-P	CCONJ	O
3	I-P	NUM	O
in	I-P	ADP	O
80	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
residuum	I-P	NOUN	B
before	I-P	ADP	O
intravenous	I-P	ADJ	B
CT	I-P	NOUN	O
(	I-P	PUNCT	O
>	I-P	NOUN	O
1	I-P	NUM	O
cm	I-P	NOUN	O
in	I-P	ADP	O
40	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Intraperitoneal	B-I	PROPN	B
CT	I-I	NOUN	B
was	O	AUX	O
delivered	O	VERB	O
mainly	O	ADV	O
through	O	ADP	O
intraperitoneal	O	ADJ	B
catheters	O	NOUN	I
(	O	PUNCT	O
Port-a-Cath	O	NOUN	B
61	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
Tenckhoff	O	NOUN	B
25	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Side	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
intraperitoneal	B-I	ADJ	B
cisplatin	I-I	NOUN	B
included	O	VERB	O
vomiting	B-OUT	NOUN	B
[	O	PUNCT	O
>	O	NOUN	O
or	O	CCONJ	O
=grade	O	NOUN	B
2	O	NUM	I
(	O	PUNCT	O
82	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
]	O	PUNCT	O
,	O	PUNCT	O
rise	B-OUT	VERB	O
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
creatinine	I-OUT	NOUN	I
[	O	PUNCT	O
>	O	NOUN	O
or	O	CCONJ	O
=grade	O	NOUN	B
2	O	NUM	I
(	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
]	O	PUNCT	O
,	O	PUNCT	O
abdominal	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
[	O	PUNCT	O
grade	O	NOUN	B
1-2	O	NUM	O
(	O	PUNCT	O
38	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
]	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
neurotoxicity	B-OUT	NOUN	B
[	O	PUNCT	O
grade	O	NOUN	B
2-3	O	NUM	O
(	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow-up	O	NOUN	B
of	O	ADP	O
8	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
80	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
52	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
have	O	AUX	O
progressed	O	VERB	O
with	O	ADP	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pattern	B-OUT	NOUN	B
of	I-OUT	ADP	O
relapse	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
and	O	CCONJ	O
75	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
49	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
have	O	AUX	O
died	B-OUT	VERB	B
;	I-OUT	PUNCT	O
the	O	DET	O
respective	O	ADJ	O
hazard	O	NOUN	B
ratios	O	NOUN	I
for	O	ADP	O
PFS	O	NOUN	B
and	O	CCONJ	O
OS	O	NOUN	B
with	O	ADP	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
are	O	AUX	O
0.89	O	NUM	O
(	O	PUNCT	O
0.59-1.33	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
0.82	O	NUM	O
(	O	PUNCT	O
0.52-1.29	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
suggestive	O	ADJ	O
of	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
benefit	O	NOUN	B
but	O	CCONJ	O
do	O	AUX	O
not	O	PART	O
support	O	VERB	O
a	O	DET	O
change	O	NOUN	O
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


Other	O	ADJ	O
randomized	O	ADJ	B
clinical	O	ADJ	O
trials	O	NOUN	O
of	O	ADP	O
intraperitoneal	B-I	ADJ	B
CT	I-I	NOUN	B
are	O	AUX	O
reviewed	O	VERB	B
and	O	CCONJ	O
briefly	O	ADV	O
discussed	O	VERB	O
.	O	PUNCT	O


Dark-phase	O	ADJ	B
light	O	ADJ	I
contamination	O	NOUN	B
disrupts	O	VERB	B
circadian	O	ADJ	B
rhythms	O	NOUN	B
in	O	ADP	O
plasma	B-OUT	NOUN	B
measures	O	NOUN	B
of	O	ADP	O
endocrine	B-P	ADJ	B
physiology	I-OUT	NOUN	B
and	I-P	CCONJ	O
metabolism	I-OUT	NOUN	B
in	I-P	ADP	O
rats	I-P	NOUN	B
.	I-P	PUNCT	O


Dark-phase	B-I	ADJ	B
light	I-I	ADJ	I
contamination	I-I	NOUN	B
can	O	AUX	O
significantly	O	ADV	O
disrupt	O	VERB	O
chronobiologic	B-OUT	ADJ	B
rhythms	I-OUT	NOUN	I
,	O	PUNCT	O
thereby	O	ADV	O
potentially	O	ADV	O
altering	O	VERB	B
the	O	DET	O
endocrine	O	ADJ	B
physiology	O	NOUN	B
and	O	CCONJ	O
metabolism	O	NOUN	B
of	O	ADP	O
experimental	B-P	ADJ	B
animals	I-P	NOUN	I
and	O	CCONJ	O
influencing	O	VERB	B
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
scientific	O	ADJ	B
investigations	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
sought	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
exposure	O	NOUN	B
to	O	PART	I
low-level	O	ADJ	B
light	O	ADJ	O
contamination	O	NOUN	B
during	O	ADP	O
the	O	DET	O
dark	O	ADJ	B
phase	O	NOUN	I
influenced	O	VERB	B
the	O	DET	O
normally	O	ADV	O
entrained	O	VERB	B
circadian	O	ADJ	B
rhythms	O	NOUN	B
of	O	ADP	O
various	O	ADJ	O
substances	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
.	O	PUNCT	O


Male	B-P	ADJ	B
Sprague-Dawley	I-P	NOUN	O
rats	I-P	NOUN	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
6	I-P	NUM	O
per	I-P	ADP	O
group	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
housed	O	VERB	B
in	O	ADP	O
photobiologic	B-I	ADJ	B
light-exposure	I-I	ADJ	B
chambers	I-I	NOUN	I
configured	O	VERB	O
to	O	PART	O
create	O	VERB	O
1	O	NUM	O
)	O	PUNCT	O
a	O	DET	O
12:12-h	O	ADJ	B
light	B-I	NOUN	I
:	I-I	PUNCT	O
dark	I-I	ADJ	B
cycle	I-I	NOUN	I
without	I-I	ADP	O
dark-phase	I-I	ADJ	B
light	I-I	ADJ	I
contamination	I-I	NOUN	I
(	O	PUNCT	O
control	O	NOUN	B
condition	O	NOUN	I
;	O	PUNCT	O
123	O	NUM	O
μW/cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
lights	O	VERB	B
on	O	ADP	O
at	O	ADP	O
0600	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
experimental	O	ADJ	B
exposure	O	NOUN	B
to	O	PART	O
a	B-I	DET	O
low	I-I	ADJ	B
level	I-I	NOUN	B
of	I-I	ADP	O
light	I-I	NOUN	O
during	O	ADP	O
the	O	DET	O
12-h	O	ADJ	O
dark	O	ADJ	O
phase	O	NOUN	O
(	O	PUNCT	O
with	O	ADP	O
0.02	O	NUM	O
,	O	PUNCT	O
0.05	O	NUM	O
,	O	PUNCT	O
0.06	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
0.08	O	NUM	O
μW/cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
light	O	NOUN	O
at	O	ADP	O
night	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
3	B-I	X	O
)	I-I	PUNCT	O
constant	I-I	ADJ	O
bright	I-I	ADJ	O
light	I-I	NOUN	O
(	O	PUNCT	O
123	O	NUM	O
μW/cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Dietary	O	ADJ	B
and	O	CCONJ	O
water	O	NOUN	B
intakes	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
daily	O	ADV	B
.	O	PUNCT	O


After	O	ADP	O
2	O	NUM	O
wk	O	NOUN	O
,	O	PUNCT	O
rats	O	NOUN	B
underwent	O	VERB	O
6	O	NUM	O
low-volume	O	ADJ	B
blood	O	NOUN	I
draws	O	VERB	O
at	O	ADP	O
4-h	O	ADJ	O
intervals	O	NOUN	B
(	O	PUNCT	O
beginning	O	VERB	O
at	O	ADP	O
0400	O	NUM	O
)	O	PUNCT	O
during	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
light	O	ADJ	B
and	O	CCONJ	O
dark	O	ADJ	B
phases	B-OUT	NOUN	O
.	I-OUT	PUNCT	O


Circadian	B-OUT	ADJ	B
rhythms	I-OUT	NOUN	B
in	I-OUT	ADP	O
dietary	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
water	I-OUT	NOUN	B
intake	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
total	I-OUT	ADJ	O
fatty	I-OUT	ADJ	O
acids	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
lipid	I-OUT	NOUN	B
fractions	I-OUT	NOUN	I
remained	O	VERB	O
entrained	O	VERB	B
during	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
either	O	CCONJ	O
control	O	NOUN	B
conditions	O	NOUN	I
or	O	CCONJ	O
low-intensity	O	ADJ	B
light	O	NOUN	I
during	O	ADP	O
the	O	DET	O
dark	O	ADJ	B
phase	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
patterns	O	NOUN	B
were	O	AUX	O
disrupted	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
exposed	O	VERB	B
to	B-I	PART	I
constant	I-I	ADJ	O
bright	I-I	ADJ	O
light	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Circadian	B-OUT	ADJ	B
patterns	I-OUT	NOUN	B
of	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
melatonin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
glucose	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
lactic	I-OUT	ADJ	B
acid	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
corticosterone	I-OUT	NOUN	B
were	O	AUX	O
maintained	O	VERB	B
in	O	ADP	O
all	O	DET	O
rats	O	NOUN	B
except	O	SCONJ	O
those	O	DET	O
exposed	O	VERB	B
to	B-I	PART	I
constant	I-I	ADJ	O
bright	I-I	ADJ	O
light	I-I	NOUN	O
or	O	CCONJ	O
the	O	DET	O
highest	O	ADJ	B
level	O	NOUN	B
of	O	ADP	O
light	O	NOUN	O
during	O	ADP	O
the	O	DET	O
dark	O	ADJ	B
phase	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
even	O	ADV	O
minimal	O	ADJ	B
light	O	ADJ	O
contamination	O	NOUN	B
during	O	ADP	O
the	O	DET	O
dark	O	ADJ	B
phase	O	NOUN	I
can	O	AUX	O
disrupt	O	VERB	O
normal	B-OUT	ADJ	O
circadian	I-OUT	ADJ	B
rhythms	I-OUT	NOUN	O
of	O	ADP	O
endocrine	O	ADJ	B
metabolism	O	NOUN	I
and	O	CCONJ	O
physiology	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
alter	O	VERB	O
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
scientific	O	ADJ	B
investigations	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
aerobic	B-I	ADJ	B
exercise	I-I	NOUN	B
on	O	ADP	O
academic	O	ADJ	B
engagement	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
participation	O	NOUN	B
in	O	ADP	O
aerobic	B-I	ADJ	B
exercise	I-I	NOUN	I
before	O	ADP	O
classroom	O	NOUN	B
activities	O	NOUN	I
improves	O	VERB	B
academic	O	ADJ	B
engagement	O	NOUN	I
and	O	CCONJ	O
reduces	O	VERB	B
stereotypic	O	ADJ	B
behaviors	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
employed	O	VERB	O
a	O	DET	O
within-subjects	O	ADJ	O
crossover	O	NOUN	B
design	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
treatment	O	NOUN	B
condition	O	NOUN	I
(	B-I	PUNCT	O
aerobic	I-I	ADJ	B
exercise	I-I	NOUN	I
)	I-I	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
control	B-I	ADJ	B
condition	I-I	NOUN	I
,	O	PUNCT	O
across	O	ADP	O
4	O	NUM	O
classrooms	O	NOUN	B
.	O	PUNCT	O


The	B-I	DET	O
treatment	I-I	NOUN	B
condition	I-I	NOUN	I
included	I-I	VERB	O
15	I-I	NUM	O
minutes	I-I	NOUN	B
of	I-I	ADP	O
running/jogging	I-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
classroom	I-I	NOUN	B
task	I-I	NOUN	B
.	I-I	PUNCT	O


The	B-I	DET	O
control	I-I	ADJ	B
condition	I-I	NOUN	I
included	I-I	VERB	O
a	I-I	DET	O
classroom	I-I	NOUN	B
task	I-I	NOUN	B
not	I-I	PART	O
preceded	I-I	VERB	O
by	I-I	ADP	O
exercise	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
stereotypic	I-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
percentage	I-OUT	NOUN	B
of	I-OUT	ADP	O
on-task	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
correct/incorrect	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
were	I-I	AUX	O
measured	I-I	VERB	B
.	I-I	PUNCT	O


The	B-I	DET	O
Wilcoxon	I-OUT	PROPN	B
signed	I-OUT	VERB	I
rank	I-OUT	NOUN	I
test	I-OUT	NOUN	I
was	I-OUT	AUX	O
used	I-OUT	VERB	O
to	I-OUT	PART	O
compare	I-OUT	VERB	B
differences	I-OUT	NOUN	B
between	I-OUT	ADP	O
conditions	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Statistically	O	ADV	B
significant	O	ADJ	I
improvements	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
correct	O	ADJ	O
responding	O	VERB	B
following	O	VERB	O
exercise	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
for	O	ADP	O
on-task	B-OUT	ADJ	B
behavior	I-OUT	NOUN	I
or	O	CCONJ	O
stereotypic	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Consistent	O	ADJ	B
with	O	ADP	I
findings	O	NOUN	B
in	O	ADP	O
older	O	ADJ	B
children	O	NOUN	I
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
aerobic	B-I	ADJ	B
exercise	I-I	NOUN	B
prior	O	ADV	O
to	O	ADP	O
classroom	O	NOUN	B
activities	O	NOUN	I
may	O	AUX	O
improve	O	VERB	B
academic	O	ADJ	B
responding	O	VERB	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Assessing	O	VERB	B
the	O	DET	O
benefit	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
personalized	B-I	ADJ	B
EHR-generated	I-I	ADJ	B
informed	I-I	ADJ	O
consent	I-I	NOUN	O
in	I-P	ADP	O
a	I-P	DET	O
dental	I-P	NOUN	B
school	I-P	NOUN	I
setting	I-P	NOUN	I
.	I-P	PUNCT	O


Informed	O	ADJ	B
consents	O	NOUN	I
are	O	AUX	O
routinely	O	ADV	O
used	O	VERB	O
as	O	ADP	O
an	O	DET	O
important	O	ADJ	O
source	O	NOUN	B
of	O	ADP	O
information	O	NOUN	B
to	O	PART	O
help	O	VERB	O
patients	B-P	NOUN	B
make	O	VERB	O
appropriate	O	ADJ	O
clinical	O	ADJ	B
decisions	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
current	O	ADJ	O
standard	O	ADJ	O
consent	O	NOUN	O
forms	O	NOUN	O
may	O	AUX	O
not	O	PART	O
accomplish	O	VERB	O
their	O	PRON	O
intended	O	ADJ	O
purpose	O	NOUN	B
due	O	ADP	O
to	O	ADP	O
the	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
patient	O	NOUN	B
literacy	O	NOUN	I
and	O	CCONJ	O
experiences	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
dental	O	NOUN	B
school	O	NOUN	I
setting	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
developing	O	VERB	O
competence	O	NOUN	B
of	O	ADP	O
students	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
personalized	O	ADJ	B
informed	O	ADJ	O
consent	O	NOUN	O
generated	O	VERB	O
through	O	ADP	O
an	O	DET	O
electronic	O	ADJ	B
health	O	NOUN	I
record	O	NOUN	I
(	O	PUNCT	O
EHR	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
one	O	NUM	O
dental	O	NOUN	B
school	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
role	O	NOUN	O
in	O	ADP	O
patient	O	NOUN	B
decision	O	NOUN	B
making	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
set	O	NOUN	O
of	O	ADP	O
informed	O	ADJ	O
consents	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
SmartConsents	B-I	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
developed	O	VERB	O
for	O	ADP	O
specific	O	ADJ	O
diagnoses	O	NOUN	B
and	O	CCONJ	O
procedures	O	NOUN	B
,	O	PUNCT	O
enhanced	O	VERB	B
with	O	ADP	O
graphics	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
delivered	O	VERB	B
through	O	ADP	O
the	O	DET	O
school	O	NOUN	B
's	O	PART	I
EHR	O	PROPN	B
.	O	PUNCT	O


Fifty	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
recruited	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
school	I-P	NOUN	B
's	I-P	PART	I
Urgent	I-P	PROPN	B
Care	I-P	PROPN	I
Clinic	I-P	PROPN	I
and	O	CCONJ	O
divided	O	VERB	O
evenly	O	ADV	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
one	O	NUM	O
(	O	PUNCT	O
control	O	NOUN	B
)	O	PUNCT	O
receiving	O	VERB	O
the	O	DET	O
standard	B-I	ADJ	B
consent	I-I	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
second	O	ADJ	O
receiving	O	VERB	O
a	O	DET	O
SmartConsent	B-I	PROPN	B
.	I-I	PUNCT	O


Following	O	VERB	O
treatment	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
based	O	VERB	O
on	O	ADP	O
demographics	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
decisional	I-OUT	ADJ	B
conflict	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
satisfaction	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
health	I-OUT	NOUN	B
literacy	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
knowledge	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
main	B-OUT	ADJ	O
effects	I-OUT	NOUN	B
between	O	ADP	O
SmartConsent	O	PROPN	B
and	O	CCONJ	O
standard	O	ADJ	B
informed	O	ADJ	O
consents	O	NOUN	O
for	O	ADP	O
decisional	B-OUT	ADJ	B
conflict	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
satisfaction	I-OUT	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
significant	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
identified	O	VERB	B
during	O	ADP	O
secondary	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
satisfaction	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
gender	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
ethnicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
study	O	NOUN	B
also	O	ADV	O
demonstrated	O	VERB	O
the	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
consents	O	NOUN	B
to	O	PART	O
aid	O	VERB	O
the	O	DET	O
student	O	NOUN	B
provider	O	NOUN	B
in	O	ADP	O
better	B-OUT	ADV	O
communicating	I-OUT	VERB	B
with	I-OUT	ADP	O
patients	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


PTK2	O	NOUN	B
expression	O	NOUN	B
and	O	CCONJ	O
immunochemotherapy	O	NOUN	B
outcome	O	NOUN	B
in	O	ADP	O
chronic	B-P	ADJ	B
lymphocytic	I-P	ADJ	I
leukemia	I-P	NOUN	I
.	I-P	PUNCT	O


Addition	O	NOUN	B
of	O	ADP	O
rituximab	B-I	NOUN	B
(	I-I	PUNCT	O
R	I-I	NOUN	B
)	I-I	PUNCT	O
to	I-I	PART	O
fludarabine	I-I	NOUN	B
and	I-I	CCONJ	O
cyclophosphamide	I-I	NOUN	B
(	O	PUNCT	O
FC	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
significantly	O	ADV	O
improved	O	VERB	B
patient	B-OUT	NOUN	B
outcomes	I-OUT	NOUN	B
in	I-P	ADP	O
chronic	I-P	ADJ	B
lymphocytic	I-P	ADJ	I
leukemia	I-P	NOUN	I
(	I-P	PUNCT	O
CLL	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Whether	O	SCONJ	O
baseline	O	NOUN	B
gene	O	NOUN	B
expression	O	NOUN	I
can	O	AUX	O
identify	O	VERB	O
patients	B-P	NOUN	B
who	I-P	PRON	O
will	I-P	AUX	O
benefit	I-P	VERB	B
from	I-P	ADP	O
immunochemotherapy	I-P	NOUN	B
over	I-P	ADP	O
chemotherapy	I-P	NOUN	B
alone	I-P	ADV	O
has	I-P	AUX	O
not	I-P	PART	O
been	I-P	AUX	O
determined	I-P	VERB	O
.	I-P	PUNCT	O


We	B-P	PRON	O
assessed	I-P	VERB	B
genome-wide	I-OUT	ADJ	B
expression	I-OUT	NOUN	I
of	I-P	ADP	O
300	I-P	NUM	O
pretreatment	I-P	NOUN	B
specimens	I-P	NOUN	B
from	I-P	ADP	O
a	I-P	DET	O
subset	I-P	NOUN	O
of	I-P	ADP	O
552	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
REACH	I-P	NOUN	B
,	I-P	PUNCT	O
a	I-P	DET	O
study	I-P	NOUN	B
of	I-P	ADP	O
FC	I-I	NOUN	B
or	I-P	CCONJ	O
R-FC	I-I	NOUN	B
in	I-P	ADP	O
relapsed	I-P	ADJ	B
CLL	I-P	NOUN	B
.	I-P	PUNCT	O


An	B-P	DET	O
independent	I-P	ADJ	O
test	I-P	NOUN	O
set	I-P	NOUN	O
was	I-P	AUX	O
derived	I-P	VERB	O
from	I-P	ADP	O
282	I-P	NUM	O
pretreatment	I-P	NOUN	B
specimens	I-P	NOUN	O
from	I-P	ADP	O
CLL8	I-P	NOUN	B
,	I-P	PUNCT	O
a	I-P	DET	O
study	I-P	NOUN	B
of	I-P	ADP	O
FC	I-P	NOUN	B
or	I-P	CCONJ	O
R-FC	I-P	NOUN	B
in	I-P	ADP	O
treatment-naïve	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Genes	O	NOUN	B
specific	O	ADJ	O
for	O	ADP	O
benefit	O	NOUN	B
from	B-I	ADP	O
R-FC	I-I	NOUN	B
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
assessing	O	VERB	O
treatment-gene	O	ADJ	B
interactions	O	NOUN	B
in	O	ADP	O
Cox	O	NOUN	B
proportional	O	ADJ	I
hazards	O	NOUN	I
models	O	NOUN	I
.	O	PUNCT	O


REACH	O	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
higher	O	ADJ	O
pretreatment	O	NOUN	B
protein	O	NOUN	B
tyrosine	O	NOUN	I
kinase	O	NOUN	I
2	O	NUM	I
(	O	PUNCT	O
PTK2	O	NOUN	B
)	O	PUNCT	O
messenger	O	NOUN	O
RNA	O	NOUN	O
levels	O	NOUN	O
derived	O	VERB	O
greater	O	ADJ	O
benefit	O	NOUN	B
from	B-I	ADP	O
R-FC	I-I	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
significant	O	ADJ	O
improvements	O	NOUN	B
in	B-OUT	ADP	O
progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	O	PUNCT	O
independent	O	ADJ	O
of	O	ADP	O
known	O	VERB	O
prognostic	O	ADJ	B
factors	O	NOUN	I
in	O	ADP	O
a	O	DET	O
multivariate	O	ADJ	B
model	O	NOUN	I
.	O	PUNCT	O


Examination	O	NOUN	B
of	B-OUT	ADP	O
PTK2	I-OUT	NOUN	B
gene	I-OUT	NOUN	B
expression	I-OUT	NOUN	I
in	O	ADP	O
CLL8	O	NOUN	B
patients	O	NOUN	B
yielded	O	VERB	O
similar	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
PTK2	B-OUT	NOUN	B
inhibition	I-OUT	NOUN	B
blunted	I-OUT	VERB	O
R-dependent	I-OUT	ADJ	B
cell	I-OUT	NOUN	I
death	I-OUT	NOUN	O
in	I-OUT	X	B
vitro	I-OUT	X	I
.	O	PUNCT	O


This	O	DET	O
retrospective	O	ADJ	B
analysis	O	NOUN	I
from	O	ADP	O
2	O	NUM	O
independent	O	ADJ	B
trials	O	NOUN	B
revealed	O	VERB	O
that	O	SCONJ	O
increased	B-OUT	VERB	B
PTK2	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
improved	O	VERB	O
outcomes	O	NOUN	B
for	B-P	ADP	O
CLL	I-P	NOUN	B
patients	I-P	NOUN	B
treated	O	VERB	B
with	B-I	ADP	I
R-FC	I-I	NOUN	B
vs	I-I	CCONJ	O
FC	I-I	PROPN	B
.	O	PUNCT	O


PTK2	O	NOUN	B
expression	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
biomarker	O	NOUN	B
for	O	ADP	O
patient	O	NOUN	B
selection	O	NOUN	O
in	O	ADP	O
future	O	ADJ	O
trials	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
trials	O	NOUN	B
were	O	AUX	O
registered	O	VERB	O
at	O	ADP	O
www.clinicaltrials.gov	O	NOUN	O
as	O	ADP	O
#	O	SYM	O
NCT00090051	O	PROPN	O
(	O	PUNCT	O
REACH	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
#	O	SYM	O
NCT00281918	O	NOUN	O
(	O	PUNCT	O
CLL8	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
postural	B-OUT	ADJ	B
stability	I-OUT	NOUN	I
by	O	ADP	O
computerised	B-I	ADJ	B
posturography	I-I	NOUN	I
following	O	VERB	O
outpatient	B-P	ADJ	B
paediatric	I-I	ADJ	B
anaesthesia	I-I	NOUN	I
.	I-I	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
propofol/alfentanil/N2O	B-I	NOUN	B
anaesthesia	I-I	NOUN	B
with	I-I	ADP	O
thiopentone/halothane/N2O	I-I	NOUN	B
anaesthesia	I-I	NOUN	I
.	I-I	PUNCT	O


Simple	O	ADJ	O
clinical	O	ADJ	B
tests	O	NOUN	I
,	O	PUNCT	O
like	O	ADP	O
Romberg	O	PROPN	B
's	O	PART	I
test	O	NOUN	I
or	O	CCONJ	O
a	O	DET	O
walking	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
have	O	AUX	O
proved	O	VERB	O
to	O	PART	O
be	O	AUX	O
inadequate	O	ADJ	O
guidelines	O	NOUN	B
for	O	ADP	O
safe	B-OUT	ADJ	B
discharge	I-OUT	NOUN	I
after	O	ADP	O
outpatient	O	ADJ	B
anaesthesia	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
therefore	O	ADV	O
planned	O	VERB	B
to	O	PART	O
compare	O	VERB	B
postural	O	ADJ	B
stability	O	NOUN	I
measured	O	VERB	B
by	O	ADP	O
computerised	O	ADJ	B
posturography	O	NOUN	I
in	O	ADP	O
31	B-P	NUM	O
oral	I-I	ADJ	B
midazolam-atropine	I-I	ADJ	B
premedicated	I-P	ADJ	B
children	I-P	NOUN	B
aged	I-P	ADJ	B
6.9	I-P	NUM	O
(	I-P	PUNCT	O
s.e	I-P	NOUN	O
.	I-P	PUNCT	O


0.4	B-P	NUM	O
)	I-P	PUNCT	O
years	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
been	I-P	AUX	O
anaesthetised	I-I	VERB	B
with	I-P	ADP	O
either	I-P	CCONJ	O
propofol/alfentanil/N2O	I-I	NOUN	B
or	I-I	CCONJ	O
thiopentone/halothane/N2O	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
sway	B-OUT	NOUN	B
velocity	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
children	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
before	O	ADP	O
premedication	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
end	O	NOUN	B
of	O	ADP	I
anaesthesia	O	NOUN	I
.	O	PUNCT	O


Results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
sway	B-OUT	NOUN	B
velocity	I-OUT	NOUN	I
had	O	AUX	O
returned	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
values	O	NOUN	B
3	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
anaesthesia	O	NOUN	B
in	O	ADP	O
all	O	DET	O
children	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
received	O	VERB	O
propofol/alfentanil/N2O	B-I	PROPN	B
and	O	CCONJ	O
in	O	ADP	O
12	O	NUM	O
of	O	ADP	O
the	O	DET	O
15	O	NUM	O
children	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
received	O	VERB	O
thiopentone/halothane/N2O	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
quantified	O	VERB	B
version	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Romberg	B-OUT	PROPN	B
test	I-OUT	NOUN	I
performed	O	VERB	O
with	O	ADP	O
eyes	O	NOUN	B
open	O	ADJ	O
or	O	CCONJ	O
closed	O	VERB	B
was	O	AUX	O
not	O	PART	O
impaired	O	ADJ	B
after	O	ADP	O
anaesthesia	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
control	O	NOUN	B
values	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
children	O	NOUN	B
poor	O	ADJ	O
equilibrium	O	NOUN	B
is	O	AUX	O
not	O	PART	O
compensated	O	VERB	O
by	O	ADP	O
vision	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
recovery	O	NOUN	I
with	O	ADP	O
respect	O	NOUN	O
to	O	ADP	O
the	O	DET	O
times	O	NOUN	O
to	O	PART	O
eye	B-OUT	VERB	B
opening	I-OUT	NOUN	I
,	O	PUNCT	O
to	O	PART	O
responding	O	VERB	B
to	O	ADP	O
command	O	NOUN	B
or	O	CCONJ	O
to	O	PART	O
being	O	AUX	O
fully	O	ADV	O
awake	O	ADJ	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
anaesthesia	O	NOUN	B
methods	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
recovery	O	NOUN	B
assessed	O	VERB	B
by	O	ADP	O
postural	O	ADJ	B
stability	O	NOUN	I
,	O	PUNCT	O
propofol/alfentanil/N2O	B-I	X	B
anaesthesia	I-I	NOUN	B
was	O	AUX	O
not	O	PART	O
preferable	O	ADJ	O
to	O	PART	O
thiopentone/halothane/N2O	B-I	NOUN	B
anaesthesia	I-I	NOUN	I
after	O	ADP	O
minor	O	ADJ	O
paediatric	O	ADJ	O
otolaryngological	B-I	ADJ	B
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


Calcium	B-I	NOUN	B
chloride	I-I	NOUN	I
before	I-I	ADP	O
i.v	I-I	PROPN	O
.	I-I	PUNCT	O


diltiazem	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
management	B-OUT	NOUN	B
of	I-OUT	ADP	O
atrial	I-OUT	ADJ	B
fibrillation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Diltiazem	B-I	NOUN	B
is	O	AUX	O
commonly	O	ADV	O
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
atrial	B-P	ADJ	B
fibrillation	I-P	NOUN	I
or	I-P	CCONJ	O
flutter	I-P	NOUN	B
(	I-P	PUNCT	O
AFF	I-P	PROPN	B
)	I-P	PUNCT	O
with	O	ADP	O
rapid	O	ADJ	O
ventricular	O	ADJ	O
response	O	NOUN	O
(	O	PUNCT	O
RVR	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Although	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
very	O	ADV	O
effective	O	ADJ	B
for	O	ADP	O
rate	B-OUT	NOUN	B
control	I-OUT	NOUN	I
,	O	PUNCT	O
up	O	ADV	O
to	O	ADP	O
an	O	DET	O
18	O	NUM	O
%	O	NOUN	O
prevalence	O	NOUN	B
of	O	ADP	O
reported	O	VERB	O
diltiazem-induced	B-OUT	ADJ	B
hypotension	I-OUT	NOUN	B
[	I-OUT	PUNCT	O
defined	I-OUT	VERB	O
by	I-OUT	ADP	O
systolic	I-OUT	NOUN	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SBP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
<	I-OUT	X	O
90	I-OUT	NUM	O
mm	I-OUT	NOUN	B
Hg	I-OUT	NOUN	I
]	I-OUT	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
mean	O	NOUN	O
of	O	ADP	O
9.7	O	NUM	O
%	O	NOUN	O
hypotension	B-OUT	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
from	O	ADP	O
several	O	ADJ	O
studies	O	NOUN	B
totaling	O	VERB	O
over	B-P	ADP	O
450	I-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
hypotension	B-OUT	NOUN	B
may	O	AUX	O
complicate	O	VERB	O
therapy	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
calcium	B-I	NOUN	B
chloride	I-I	NOUN	I
(	I-I	PUNCT	O
CaCl	I-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
pre-treatment	O	NOUN	B
would	O	AUX	O
blunt	O	VERB	B
a	O	DET	O
SBP	B-OUT	NOUN	B
drop	I-OUT	NOUN	B
after	O	ADP	O
i.v	O	PROPN	O
.	O	PUNCT	O


diltiazem	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
allowing	O	VERB	O
diltiazem	B-I	NOUN	B
to	O	PART	O
maintain	O	VERB	O
its	O	PRON	O
efficacy	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


Seventy-eight	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
AFF	I-P	PROPN	B
and	I-P	CCONJ	O
a	I-P	DET	O
ventricular	I-P	ADJ	B
rate	I-P	NOUN	I
of	I-P	ADP	O
>	I-P	X	O
/=	I-P	NOUN	O
120	I-P	NUM	O
beats	I-P	NOUN	B
per	I-P	ADP	I
minute	I-P	NOUN	I
were	I-P	AUX	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


Half	O	NOUN	O
received	O	VERB	O
i.v	O	PROPN	O
.	O	PUNCT	O


CaCl	B-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
pre-treatment	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
other	O	ADJ	O
half	O	NOUN	O
received	O	VERB	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
then	O	ADV	O
received	O	VERB	O
i.v	O	PROPN	O
.	O	PUNCT	O


diltiazem	B-I	NOUN	B
in	O	ADP	O
a	O	DET	O
standard	O	ADJ	B
,	O	PUNCT	O
weight-based	O	ADJ	B
dose	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
second	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
CaCl	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
pre-treatment	O	ADJ	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
diltiazem	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
if	O	SCONJ	O
clinically	O	ADV	B
indicated	O	VERB	O
for	O	ADP	O
additional	O	ADJ	O
rate	O	NOUN	B
control	O	NOUN	O
.	O	PUNCT	O


Both	O	DET	O
CaCl	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
placebo	B-I	ADJ	B
pre-treatment	O	ADJ	B
groups	O	NOUN	B
had	O	AUX	O
equal	O	ADJ	O
lowering	O	NOUN	B
of	O	ADP	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
adverse	B-OUT	ADJ	O
events	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
calcium	O	NOUN	B
pre-treatment	O	ADJ	O
study	O	NOUN	O
arm	O	NOUN	O
.	O	PUNCT	O


One	B-P	NUM	O
patient	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
placebo	I-P	ADJ	B
group	I-P	NOUN	B
became	O	VERB	O
paradoxically	O	ADV	O
more	O	ADV	O
tachycardic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
apneic	I-OUT	ADJ	B
after	O	ADP	O
the	O	DET	O
diltiazem	O	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
i.v	O	PROPN	O
.	O	PUNCT	O


CaCl	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
equally	O	ADV	O
safe	O	ADJ	O
compared	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
as	O	ADP	O
a	O	DET	O
pre-treatment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
AFF	O	PROPN	B
with	O	ADP	O
RVR	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
find	O	VERB	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
blunting	B-OUT	NOUN	B
of	I-OUT	ADP	O
SBP	I-OUT	NOUN	B
drop	I-OUT	NOUN	B
with	O	ADP	O
CaCl	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
i.v	O	NOUN	O
.	O	PUNCT	O


pre-treatment	O	ADJ	B
.	O	PUNCT	O


Until	O	ADP	O
further	O	ADJ	O
research	O	NOUN	B
determines	O	VERB	O
a	O	DET	O
benefit	O	NOUN	B
exists	O	VERB	O
,	O	PUNCT	O
we	O	PRON	O
can	O	AUX	O
not	O	PART	O
recommend	O	VERB	O
i.v	O	PROPN	O
.	O	PUNCT	O


CaCl	B-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
pre-treatment	O	NOUN	B
before	O	ADP	O
diltiazem	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
AFF	O	NOUN	B
with	O	ADP	O
RVR	O	NOUN	B
.	O	PUNCT	O


Brain	B-OUT	NOUN	B
activity	I-OUT	NOUN	I
correlates	I-P	VERB	O
differentially	I-P	ADV	B
with	I-P	ADP	O
increasing	I-P	VERB	B
temporal	I-P	ADJ	B
complexity	I-P	NOUN	B
of	I-P	ADP	O
rhythms	I-P	NOUN	B
during	I-P	ADP	O
initialisation	I-P	NOUN	B
,	I-P	PUNCT	O
synchronisation	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
continuation	I-P	NOUN	B
phases	I-P	NOUN	I
of	I-P	ADP	O
paced	I-I	ADJ	B
finger	I-I	NOUN	I
tapping	I-I	NOUN	I
.	I-I	PUNCT	O


Activity	B-OUT	NOUN	B
in	I-OUT	ADP	O
parts	I-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
human	I-OUT	ADJ	B
motor	I-OUT	NOUN	O
system	I-OUT	NOUN	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
correlate	O	VERB	B
with	O	ADP	O
the	O	DET	O
complexity	O	NOUN	B
of	O	ADP	O
performed	O	VERB	O
motor	O	NOUN	B
sequences	O	NOUN	I
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
limbs	O	NOUN	B
moved	O	VERB	O
,	O	PUNCT	O
number	O	NOUN	O
of	O	ADP	O
movements	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
number	O	NOUN	O
of	O	ADP	O
trajectories	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
searched	O	VERB	O
for	O	ADP	O
activity	O	NOUN	B
correlating	O	VERB	B
with	O	ADP	O
temporal	O	ADJ	B
complexity	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
different	O	ADJ	O
intervals	O	NOUN	B
produced	O	VERB	O
in	O	ADP	O
the	O	DET	O
sequence	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
an	O	DET	O
overlearned	O	ADJ	B
tapping	O	NOUN	I
task	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
task	O	NOUN	B
was	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
three	O	NUM	O
phases	O	NOUN	B
:	O	PUNCT	O
movement	B-I	NOUN	B
selection	I-I	NOUN	B
and	I-I	CCONJ	O
initiation	I-I	NOUN	B
(	I-I	PUNCT	O
initiate	I-I	VERB	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
synchronisation	I-I	NOUN	B
of	I-I	ADP	O
finger	I-I	NOUN	B
tapping	I-I	VERB	O
with	I-I	ADP	O
an	I-I	DET	O
external	I-I	ADJ	B
auditory	I-I	ADJ	B
cue	I-I	NOUN	B
(	I-I	PUNCT	O
synchronise	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
continued	B-I	VERB	O
tapping	I-I	VERB	B
in	I-I	ADP	O
absence	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
auditory	I-I	ADJ	B
pacer	I-I	NOUN	I
(	O	PUNCT	O
continue	O	VERB	O
)	O	PUNCT	O
.	O	PUNCT	O


Comparisons	O	NOUN	B
between	O	ADP	O
synchronisation	O	NOUN	B
and	O	CCONJ	O
continuation	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
pattern	O	NOUN	B
in	O	ADP	O
keeping	O	VERB	O
with	O	ADP	O
prior	O	ADJ	O
neuroimaging	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
paced	O	ADJ	B
finger	O	NOUN	I
tapping	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
activation	B-OUT	NOUN	B
of	I-OUT	ADP	O
bilateral	I-OUT	ADJ	B
SMA	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
basal	I-OUT	ADJ	B
ganglia	I-OUT	NOUN	I
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
continuation	B-I	NOUN	B
tapping	O	VERB	I
than	O	ADP	O
in	O	ADP	O
synchronisation	B-I	NOUN	B
tapping	O	NOUN	I
.	O	PUNCT	O


Parametric	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
activity	B-OUT	NOUN	B
correlating	I-OUT	VERB	B
with	I-OUT	ADP	O
temporal	I-OUT	ADJ	B
complexity	I-OUT	NOUN	B
during	I-OUT	ADP	O
initiate	I-OUT	NOUN	B
in	I-OUT	ADP	O
bilateral	I-OUT	ADJ	B
supplementary	I-OUT	ADJ	O
and	I-OUT	CCONJ	O
pre-supplementary	I-OUT	ADJ	B
motor	I-OUT	NOUN	I
cortex	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SMA	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
preSMA	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
rostral	I-OUT	ADJ	B
dorsal	I-OUT	ADJ	I
premotor	I-OUT	ADJ	I
cortex	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PMC	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
basal	I-OUT	ADJ	B
ganglia	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
dorsolateral	I-OUT	ADJ	B
prefrontal	I-OUT	ADJ	I
cortex	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
DLPFC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
among	I-OUT	ADP	O
other	I-OUT	ADJ	O
areas	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


During	O	ADP	O
synchronise	O	NOUN	B
,	O	PUNCT	O
correlated	B-OUT	VERB	B
activity	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
bilateral	O	ADJ	B
SMA	O	NOUN	B
,	O	PUNCT	O
more	O	ADV	O
caudal	O	ADJ	B
dorsal	O	NOUN	B
and	O	CCONJ	O
ventral	O	ADJ	B
PMC	O	PROPN	I
,	O	PUNCT	O
right	O	ADJ	B
DLPFC	O	NOUN	I
and	O	CCONJ	O
right	O	ADJ	O
primary	O	ADJ	O
motor	O	NOUN	B
cortex	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
correlated	O	VERB	I
activity	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
during	O	ADP	O
continue	O	NOUN	O
at	O	ADP	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
(	O	PUNCT	O
corrected	O	VERB	O
,	O	PUNCT	O
cluster	O	NOUN	B
level	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
though	O	SCONJ	O
left	O	VERB	B
angular	O	ADJ	I
gyrus	O	NOUN	I
was	O	AUX	O
active	O	ADJ	B
at	O	ADP	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
preSMA	B-OUT	PROPN	B
and	I-OUT	CCONJ	O
rostral	I-OUT	ADJ	B
dorsal	I-OUT	ADJ	B
PMC	I-OUT	PROPN	B
activities	I-OUT	NOUN	B
during	O	ADP	O
initiate	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
selection	B-OUT	NOUN	B
of	I-OUT	ADP	O
timing	I-OUT	NOUN	B
parameters	I-OUT	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
activation	O	NOUN	B
in	O	ADP	O
centromedial	O	ADJ	B
prefrontal	O	ADJ	I
cortex	O	NOUN	I
during	O	ADP	O
both	O	CCONJ	O
initiate	O	VERB	B
and	O	CCONJ	O
synchronise	O	VERB	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
temporal	B-OUT	ADJ	B
error	I-OUT	NOUN	I
monitoring	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
correction	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
activity	B-OUT	NOUN	B
significantly	I-OUT	ADV	O
correlated	I-OUT	VERB	B
with	I-OUT	ADP	O
temporal	I-OUT	ADJ	B
complexity	I-OUT	NOUN	B
during	O	ADP	O
continue	O	NOUN	O
suggests	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
once	O	SCONJ	O
an	O	DET	O
overlearned	O	ADJ	B
timed	O	ADJ	O
movement	O	NOUN	B
sequence	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
selected	O	VERB	O
and	O	CCONJ	O
initiated	O	VERB	B
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
further	O	ADJ	O
adjustment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
timing	O	NOUN	B
control	O	NOUN	B
processes	O	NOUN	I
related	O	VERB	O
to	O	ADP	O
its	O	PRON	O
continued	O	ADJ	O
production	O	NOUN	B
in	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
external	O	ADJ	B
cues	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
exercise	B-I	NOUN	B
,	I-I	PUNCT	O
training	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
glycogen	B-I	NOUN	B
availability	I-I	NOUN	B
on	O	ADP	O
IL-6	O	NOUN	B
receptor	O	NOUN	I
expression	O	NOUN	B
in	O	ADP	O
human	B-P	ADJ	B
skeletal	I-P	ADJ	B
muscle	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
cytokine	O	NOUN	B
interleukin-6	O	NOUN	B
(	O	PUNCT	O
IL-6	O	NOUN	B
)	O	PUNCT	O
exerts	O	VERB	O
it	O	PRON	O
actions	O	VERB	B
via	O	ADP	O
the	O	DET	O
IL-6	O	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
IL-6R	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
the	O	DET	O
ubiquitously	O	ADV	O
expressed	O	VERB	B
gp130	O	NOUN	B
receptor	O	NOUN	I
.	O	PUNCT	O


IL-6	O	NOUN	B
is	O	AUX	O
tightly	O	ADV	O
regulated	O	VERB	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
exercise	B-I	VERB	B
,	O	PUNCT	O
being	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
factors	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
exercise	O	NOUN	B
intensity	O	NOUN	B
and	O	CCONJ	O
duration	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
energy	O	NOUN	B
availability	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
IL-6	O	NOUN	B
response	O	NOUN	B
to	O	PART	O
exercise	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
extensively	O	ADV	O
studied	O	VERB	O
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
IL-6R	O	NOUN	B
response	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
exercise	B-I	NOUN	B
,	I-I	PUNCT	O
training	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
glycogen	I-I	NOUN	B
availability	I-I	NOUN	B
,	O	PUNCT	O
factors	O	NOUN	B
known	O	VERB	O
to	O	PART	O
affect	O	VERB	O
IL-6	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
gene	O	NOUN	B
expression	O	NOUN	I
of	O	ADP	O
the	O	DET	O
IL-6R	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
skeletal	O	ADJ	B
muscle	O	NOUN	I
.	O	PUNCT	O


Human	B-P	ADJ	B
subjects	I-P	NOUN	B
performed	O	VERB	O
either	O	CCONJ	O
10	B-I	NUM	O
wk	I-I	NOUN	O
of	I-I	ADP	O
training	I-I	NOUN	B
with	I-I	ADP	O
an	I-I	DET	O
acute	I-I	ADJ	B
exercise	I-I	NOUN	B
bout	I-I	NOUN	B
before	I-I	ADP	O
and	I-I	CCONJ	O
after	I-I	ADP	O
the	I-I	DET	O
training	I-I	NOUN	B
period	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
low-glycogen	I-I	ADJ	B
vs.	I-I	CCONJ	O
normal-glycogen	I-I	ADJ	O
acute	I-I	ADJ	O
exercise	I-I	NOUN	O
trial	I-I	NOUN	O
.	I-I	PUNCT	O


The	O	DET	O
IL-6R	B-OUT	NOUN	B
mRNA	I-OUT	NOUN	B
response	I-OUT	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
both	O	DET	O
trials	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
response	O	NOUN	B
to	O	PART	O
acute	O	ADJ	B
exercise	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
IL-6R	B-OUT	NOUN	B
mRNA	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


Neither	O	DET	O
training	O	NOUN	B
nor	O	CCONJ	O
intramuscular	O	ADJ	B
glycogen	O	NOUN	B
levels	O	NOUN	O
had	O	AUX	O
an	O	DET	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
IL-6R	B-OUT	NOUN	B
mRNA	I-OUT	NOUN	B
response	I-OUT	NOUN	I
to	O	PART	O
exercise	O	VERB	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
after	O	ADP	O
10	O	NUM	O
wk	O	NOUN	O
of	O	ADP	O
training	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
expressed	O	VERB	B
a	O	DET	O
higher	O	ADJ	O
mRNA	B-OUT	NOUN	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
IL-6R	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
before	O	ADP	O
training	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
IL-6R	B-OUT	NOUN	B
gene	I-OUT	NOUN	B
expression	I-OUT	NOUN	I
levels	I-OUT	NOUN	O
in	O	ADP	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
are	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
acute	O	ADJ	B
exercise	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
response	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
very	O	ADV	O
well	O	ADV	O
conserved	O	VERB	O
,	O	PUNCT	O
being	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
neither	O	DET	O
training	B-OUT	NOUN	B
status	I-OUT	NOUN	I
nor	O	CCONJ	O
intramuscular	B-OUT	ADJ	B
glycogen	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
opposed	O	VERB	O
to	O	PART	O
IL-6	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
after	O	ADP	O
the	O	DET	O
training	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
IL-6R	B-OUT	NOUN	B
mRNA	I-OUT	NOUN	B
production	I-OUT	NOUN	B
was	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
sensitization	O	NOUN	B
of	O	ADP	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
to	O	PART	O
IL-6	O	NOUN	B
at	O	ADP	O
rest	O	NOUN	B
.	O	PUNCT	O


Exemestane	B-I	NOUN	B
for	O	ADP	O
breast-cancer	B-P	NOUN	B
prevention	I-P	NOUN	I
in	I-P	ADP	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	ADJ	O
Tamoxifen	O	NOUN	B
and	O	CCONJ	O
raloxifene	O	NOUN	B
have	O	AUX	O
limited	O	ADJ	O
patient	O	NOUN	B
acceptance	O	NOUN	B
for	O	ADP	O
primary	O	ADJ	B
prevention	O	NOUN	I
of	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
.	O	PUNCT	O


Aromatase	O	NOUN	B
inhibitors	O	NOUN	B
prevent	O	VERB	B
more	O	ADV	O
contralateral	O	ADJ	B
breast	O	NOUN	B
cancers	O	NOUN	I
and	O	CCONJ	O
cause	O	VERB	O
fewer	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
than	O	ADP	O
tamoxifen	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
early-stage	I-P	ADJ	B
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
exemestane	B-I	NOUN	B
designed	O	VERB	O
to	O	PART	O
detect	O	VERB	B
a	O	DET	O
65	O	NUM	O
%	O	NOUN	O
relative	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
invasive	O	ADJ	B
breast	O	NOUN	B
cancer	O	NOUN	I
,	O	PUNCT	O
eligible	B-P	ADJ	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
35	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
had	I-P	AUX	O
at	I-P	ADP	O
least	I-P	ADJ	O
one	I-P	NUM	O
of	I-P	ADP	O
the	I-P	DET	O
following	I-P	VERB	O
risk	I-P	NOUN	B
factors	I-P	NOUN	I
:	I-P	PUNCT	O
60	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
;	I-P	PUNCT	O
Gail	I-P	NOUN	B
5-year	I-P	ADJ	O
risk	I-P	NOUN	B
score	I-P	NOUN	I
greater	I-P	ADJ	O
than	I-P	ADP	O
1.66	I-P	NUM	O
%	I-P	NOUN	O
(	I-P	PUNCT	O
chances	I-P	NOUN	B
in	I-P	ADP	O
100	I-P	NUM	O
of	I-P	ADP	O
invasive	I-P	ADJ	B
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
developing	I-P	VERB	O
within	I-P	ADP	O
5	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
;	I-P	PUNCT	O
prior	I-P	ADV	O
atypical	I-P	ADJ	B
ductal	I-P	NOUN	B
or	I-P	CCONJ	O
lobular	I-P	ADJ	B
hyperplasia	I-P	NOUN	I
or	I-P	CCONJ	O
lobular	I-P	ADJ	B
carcinoma	I-P	NOUN	I
in	I-P	X	B
situ	I-P	X	I
;	I-P	PUNCT	O
or	I-P	CCONJ	O
ductal	I-P	ADJ	B
carcinoma	I-P	NOUN	I
in	I-P	X	B
situ	I-P	X	I
with	I-P	ADP	I
mastectomy	I-P	NOUN	B
.	I-P	PUNCT	O


Toxic	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
health-related	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
menopause-specific	I-OUT	ADJ	B
qualities	I-OUT	NOUN	O
of	I-OUT	ADP	O
life	I-OUT	NOUN	O
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
total	B-P	NOUN	O
of	I-P	ADP	O
4560	I-P	NUM	O
women	I-P	NOUN	B
for	I-P	ADP	O
whom	I-P	PRON	O
the	I-P	DET	O
median	I-P	ADJ	B
age	I-P	NOUN	B
was	I-P	AUX	O
62.5	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
the	I-P	DET	O
median	I-OUT	ADJ	B
Gail	I-OUT	NOUN	B
risk	I-OUT	NOUN	I
score	I-OUT	NOUN	I
was	I-P	AUX	O
2.3	I-P	NUM	O
%	I-P	NOUN	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
exemestane	B-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


At	O	ADP	O
a	O	DET	O
median	O	ADJ	O
follow-up	O	NOUN	B
of	O	ADP	O
35	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
11	O	NUM	O
invasive	O	ADJ	B
breast	O	NOUN	B
cancers	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
those	O	DET	O
given	O	VERB	O
exemestane	B-I	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
32	O	NUM	O
of	O	ADP	O
those	O	DET	O
given	O	VERB	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
65	O	NUM	O
%	O	NOUN	O
relative	O	ADJ	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
annual	I-OUT	ADJ	B
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
invasive	I-OUT	ADJ	B
breast	I-OUT	NOUN	O
cancer	I-OUT	NOUN	O
(	O	PUNCT	O
0.19	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
0.55	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.35	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
0.18	O	NUM	O
to	O	PART	O
0.70	O	NUM	O
;	O	PUNCT	O
P=0.002	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
annual	B-OUT	ADJ	B
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
invasive	I-OUT	ADJ	B
plus	I-OUT	CCONJ	I
noninvasive	I-OUT	ADJ	I
(	I-OUT	PUNCT	O
ductal	I-OUT	ADJ	B
carcinoma	I-OUT	NOUN	I
in	I-OUT	X	B
situ	I-OUT	X	I
)	I-OUT	PUNCT	O
breast	I-OUT	NOUN	B
cancers	I-OUT	NOUN	I
was	O	AUX	O
0.35	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
exemestane	O	NOUN	B
and	O	CCONJ	O
0.77	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.47	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.27	O	NUM	O
to	O	PART	O
0.79	O	NUM	O
;	O	PUNCT	O
P=0.004	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
88	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
exemestane	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
85	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	O
(	O	PUNCT	O
P=0.003	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
skeletal	B-OUT	ADJ	B
fractures	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
cardiovascular	I-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
other	I-OUT	ADJ	O
cancers	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
treatment-related	I-OUT	ADJ	B
deaths	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Minimal	O	ADJ	B
quality-of-life	B-OUT	ADJ	B
differences	O	NOUN	B
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Exemestane	B-I	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	O
invasive	B-P	ADJ	B
breast	I-P	NOUN	B
cancers	I-P	NOUN	I
in	I-P	ADP	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
at	I-P	ADP	O
moderately	I-P	ADV	O
increased	I-P	VERB	B
risk	I-P	NOUN	B
for	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


During	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow-up	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
exemestane	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
no	O	DET	O
serious	O	ADJ	O
toxic	O	ADJ	B
effects	O	NOUN	O
and	O	CCONJ	O
only	O	ADV	O
minimal	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
health-related	O	ADJ	B
quality	O	NOUN	I
of	O	ADP	I
life	O	NOUN	I
.	O	PUNCT	O


(	O	PUNCT	O
Funded	O	VERB	B
by	O	ADP	O
Pfizer	O	PROPN	B
and	O	CCONJ	O
others	O	NOUN	O
;	O	PUNCT	O
NCIC	O	NOUN	B
CTG	O	NOUN	I
MAP.3	O	ADJ	I
ClinicalTrials.gov	O	NOUN	I
number	O	NOUN	I
,	O	PUNCT	O
NCT00083174	O	PROPN	O
.	O	PUNCT	O


)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-masked	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
parallel	O	ADJ	O
study	O	NOUN	O
of	O	ADP	O
loteprednol	B-I	ADJ	B
etabonate	I-I	NOUN	I
0.2	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
seasonal	I-P	ADJ	B
allergic	I-P	ADJ	I
conjunctivitis	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
loteprednol	B-I	ADJ	B
etabonate	I-I	NOUN	I
(	I-I	PUNCT	O
LE	I-I	NOUN	B
)	I-I	PUNCT	O
0.2	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
signs	O	NOUN	B
and	O	CCONJ	O
symptoms	O	NOUN	B
of	O	ADP	O
seasonal	B-OUT	ADJ	B
allergic	I-OUT	ADJ	I
conjunctivitis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
,	O	PUNCT	O
double-masked	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	B
group	O	NOUN	I
multicenter	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
duration	O	NOUN	B
.	O	PUNCT	O


PARTICIPANTS	O	VERB	B
A	B-P	DET	I
total	I-P	NOUN	O
of	I-P	ADP	O
135	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
signs	I-P	NOUN	B
and	I-P	CCONJ	O
symptoms	I-P	NOUN	B
of	I-P	ADP	O
seasonal	I-P	ADJ	B
allergic	I-P	ADJ	I
conjunctivitis	I-P	NOUN	I
participated	I-P	VERB	O
.	I-P	PUNCT	O


INTERVENTION	O	VERB	B
All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
either	O	CCONJ	O
LE	B-I	NOUN	B
0.2	I-I	NUM	O
%	I-I	NOUN	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
vehicle	O	NOUN	B
)	O	PUNCT	O
four	O	NUM	O
times	O	NOUN	O
a	O	DET	O
day	O	NOUN	B
in	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
for	O	ADP	O
42	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	B
MEASURES	O	PROPN	O
Bulbar	B-OUT	ADJ	B
conjunctival	I-OUT	NOUN	I
injection	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
primary	I-OUT	ADJ	B
sign	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
itching	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
primary	I-OUT	ADJ	B
symptom	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
over	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
severity	I-OUT	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
both	O	CCONJ	O
LE	O	NOUN	B
and	O	CCONJ	O
placebo	O	ADJ	B
groups	O	NOUN	B
for	O	ADP	O
bulbar	B-OUT	ADJ	B
conjunctival	I-OUT	NOUN	I
injection	I-OUT	NOUN	I
(	O	PUNCT	O
1.5	O	NUM	O
vs.	O	CCONJ	O
1.0	O	NUM	O
units	O	NOUN	B
on	O	ADP	O
a	O	DET	O
0-3	O	NUM	O
scale	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
itching	O	NOUN	B
(	O	PUNCT	O
3.4	O	NUM	O
vs.	O	CCONJ	O
3.0	O	NUM	O
units	O	NOUN	B
on	O	ADP	O
a	O	DET	O
0-4	O	NUM	O
scale	O	NOUN	B
)	O	PUNCT	O
over	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
effect	O	NOUN	I
by	O	ADP	O
these	O	DET	O
measures	O	NOUN	B
was	O	AUX	O
-0.5	O	NUM	O
and	O	CCONJ	O
-0.4	O	NUM	O
units	O	NOUN	B
in	O	ADP	O
favor	O	NOUN	O
of	O	ADP	O
LE	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0.008	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Resolution	O	NOUN	B
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
the	O	DET	O
proportion	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
signs	I-OUT	NOUN	B
or	I-OUT	CCONJ	I
symptoms	I-OUT	NOUN	B
no	I-OUT	ADV	B
longer	I-OUT	ADV	I
present	I-OUT	ADJ	O
)	I-OUT	PUNCT	O
at	O	ADP	O
day	O	NOUN	B
14	O	NUM	O
strongly	O	ADV	O
favored	O	VERB	O
LE-treated	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
36	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
58	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
38	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
for	O	ADP	O
injection	O	NOUN	B
and	O	CCONJ	O
itching	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	DET	O
treatments	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
.	I-OUT	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
in	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
67	O	NUM	O
and	O	CCONJ	O
1	O	NUM	O
of	O	ADP	O
68	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
had	O	AUX	O
an	O	DET	O
elevation	B-OUT	NOUN	B
of	I-OUT	ADP	O
intraocular	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
of	O	ADP	O
10	O	NUM	O
mmHg	O	NOUN	B
or	O	CCONJ	O
greater	O	ADJ	O
during	O	ADP	O
the	O	DET	O
6	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Loteprednol	O	NOUN	B
etabonate	O	NOUN	I
0.2	O	NUM	O
%	O	NOUN	O
was	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
placebo	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
seasonal	O	ADJ	B
allergic	O	ADJ	I
conjunctivitis	O	NOUN	I
.	O	PUNCT	O


Loteprednol	O	NOUN	B
etabonate	O	NOUN	I
0.2	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
a	O	DET	O
safety	O	NOUN	B
profile	O	NOUN	O
comparable	O	ADJ	O
to	O	PART	O
placebo	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
Regulated	O	ADJ	O
Trial	O	PROPN	O
of	O	ADP	O
Bicuspid	O	PROPN	B
Aortic	O	PROPN	I
Valve	O	PROPN	I
Repair	O	PROPN	I
Supported	O	VERB	O
by	O	ADP	O
Geometric	B-I	PROPN	B
Ring	I-I	PROPN	I
Annuloplasty	I-I	PROPN	I
.	I-I	PUNCT	O


BACKGROUND	O	ADJ	O
Annular	O	ADJ	B
stabilization	O	NOUN	B
is	O	AUX	O
important	O	ADJ	O
during	O	ADP	O
bicuspid	O	ADJ	B
aortic	O	ADJ	I
valve	O	NOUN	I
(	O	PUNCT	I
BAV	O	NOUN	B
)	O	PUNCT	O
repair	O	NOUN	B
to	O	PART	O
obtain	O	VERB	O
the	O	DET	O
best	O	ADJ	O
long-term	O	ADJ	B
results	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
describes	O	VERB	O
the	O	DET	O
early	O	ADJ	B
outcomes	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
bicuspid	O	NOUN	B
annuloplasty	O	NOUN	I
ring	O	NOUN	I
for	O	ADP	O
this	O	DET	O
purpose	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Under	O	ADP	O
regulatory	O	ADJ	B
supervision	O	NOUN	I
(	O	PUNCT	O
NCT02071849	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
geometric	B-I	ADJ	B
bicuspid	I-I	NOUN	I
annuloplasty	I-I	NOUN	I
ring	I-I	NOUN	I
was	O	AUX	O
used	O	VERB	O
during	B-P	ADP	O
valve	I-P	NOUN	B
repair	I-P	NOUN	I
in	I-P	ADP	O
16	I-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Three	B-P	NUM	O
patients	I-P	NOUN	B
had	I-P	AUX	O
Sievers	I-P	NOUN	B
type	I-P	NOUN	I
0	I-P	NUM	I
valves	I-P	NOUN	I
,	I-P	PUNCT	O
11	I-P	NUM	O
had	I-P	AUX	O
Sievers	I-P	PROPN	B
type	I-P	NOUN	I
1	I-P	NUM	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
2	I-P	NUM	O
had	I-P	AUX	O
Sievers	I-P	PROPN	B
type	I-P	NOUN	I
2	I-P	NUM	I
.	I-P	PUNCT	O


Thirteen	B-P	NUM	O
patients	I-P	NOUN	B
had	I-P	AUX	O
left-/right-coronary	I-P	ADJ	B
cusp	I-P	NOUN	I
fusion	I-P	NOUN	I
,	I-P	PUNCT	O
1	I-P	NUM	O
had	I-P	AUX	O
right-/noncoronary	I-P	ADJ	B
cusp	I-P	NOUN	B
fusion	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
2	I-P	NUM	O
had	I-P	AUX	O
both	I-P	DET	O
.	I-P	PUNCT	O


Moderate	B-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	O
aortic	I-P	ADJ	B
insufficiency	I-P	NOUN	I
(	I-P	PUNCT	O
AI	I-P	NOUN	B
)	I-P	PUNCT	O
was	I-P	AUX	O
present	I-P	ADJ	O
in	I-P	ADP	O
13	I-P	NUM	O
of	I-P	ADP	O
16	I-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
3	I-P	NUM	O
had	I-P	AUX	O
mild	I-P	ADJ	B
AI	I-P	NOUN	B
with	I-P	ADP	O
aortic	I-P	ADJ	B
aneurysms	I-P	NOUN	I
.	I-P	PUNCT	O


Ascending	O	VERB	B
aortic	O	ADJ	I
aneurysms	O	NOUN	O
,	O	PUNCT	O
root	O	NOUN	B
aneurysms	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
were	O	AUX	O
replaced	O	VERB	O
in	O	ADP	O
7	O	NUM	O
of	O	ADP	O
16	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Dacron-covered	B-I	ADJ	B
titanium	I-I	NOUN	I
ring	I-I	NOUN	I
had	O	AUX	O
circular	O	ADJ	B
base	O	NOUN	I
geometry	O	NOUN	I
and	O	CCONJ	O
two	O	NUM	O
outwardly	O	ADV	B
flaring	O	VERB	I
subcommissural	O	ADJ	B
posts	O	NOUN	I
positioned	O	VERB	O
opposite	O	ADV	O
on	O	ADP	O
the	O	DET	O
circumference	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ring	O	NOUN	B
was	O	AUX	O
implanted	O	VERB	B
into	O	ADP	O
the	O	DET	O
annulus	O	NOUN	B
beneath	O	ADP	O
the	O	DET	O
valve	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
leaflet	O	NOUN	B
repair	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Immediate	B-OUT	ADJ	B
postrepair	I-OUT	NOUN	I
echocardiograms	I-OUT	NOUN	O
showed	I-OUT	VERB	O
grade	I-OUT	NOUN	O
0	I-OUT	NUM	O
residual	I-OUT	ADJ	B
AI	O	NOUN	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
good	O	ADJ	O
cusp	B-OUT	NOUN	B
mobility	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
height	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
satisfactory	I-OUT	ADJ	B
gradients	I-OUT	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	B-OUT	DET	O
in-hospital	I-OUT	ADJ	B
or	I-OUT	CCONJ	O
late	I-OUT	ADJ	O
mortalities	I-OUT	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
experienced	B-OUT	VERB	O
leaflet	I-OUT	NOUN	B
tears	I-OUT	NOUN	I
from	O	ADP	O
long	O	ADJ	B
annular	O	ADJ	I
suture	O	NOUN	I
tails	O	NOUN	B
,	O	PUNCT	O
requiring	B-OUT	VERB	O
late	I-OUT	ADJ	B
valve	I-OUT	NOUN	I
replacement	I-OUT	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
implementation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
lateral	O	ADJ	B
suture	O	NOUN	I
fixation	O	NOUN	I
technique	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
more	B-OUT	ADJ	O
failures	I-OUT	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


At	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
follow-up	O	ADJ	B
time	O	NOUN	O
of	O	ADP	O
9	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
remaining	O	VERB	O
14	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
in	B-OUT	ADP	O
New	I-OUT	PROPN	B
York	I-OUT	PROPN	I
Heart	I-OUT	PROPN	I
Association	I-OUT	PROPN	I
class	I-OUT	NOUN	I
I	O	NUM	I
,	O	PUNCT	O
with	O	ADP	O
predominant	B-OUT	ADJ	B
grade	I-OUT	NOUN	O
0	I-OUT	NUM	O
AI	I-OUT	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
As	O	ADP	O
a	O	DET	O
technique	O	NOUN	B
for	O	ADP	O
BAV	O	NOUN	B
repair	O	NOUN	B
,	O	PUNCT	O
internal	O	ADJ	B
ring	O	NOUN	I
annuloplasty	O	NOUN	I
produces	O	VERB	O
major	B-OUT	ADJ	O
annular	I-OUT	ADJ	B
remodeling	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
stabilization	I-OUT	NOUN	B
.	O	PUNCT	O


Annular	O	ADJ	B
reduction	O	NOUN	B
and	O	CCONJ	O
reshaping	O	VERB	B
to	O	ADP	O
a	O	DET	O
50/50	O	NUM	O
%	O	NOUN	O
symmetric	O	ADJ	O
circular	O	ADJ	O
geometry	O	NOUN	O
facilitates	B-OUT	VERB	O
leaflet	I-OUT	NOUN	B
repair	I-OUT	NOUN	I
and	O	CCONJ	O
enhances	B-OUT	VERB	B
cusp	I-OUT	NOUN	B
coaptation	I-OUT	NOUN	I
.	O	PUNCT	O


Geometric	O	ADJ	B
ring	O	NOUN	I
annuloplasty	O	NOUN	I
could	O	AUX	O
have	O	AUX	O
useful	O	ADJ	O
applications	O	NOUN	O
in	O	ADP	O
BAV	O	NOUN	B
repair	O	NOUN	B
.	O	PUNCT	O


Is	O	AUX	O
chronic	B-I	ADJ	B
sildenafil	I-I	NOUN	O
therapy	I-I	NOUN	O
safe	O	ADJ	O
and	O	CCONJ	O
clinically	O	ADV	B
beneficial	O	ADJ	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
systolic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
?	O	PUNCT	O
Sildenafil	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
selective	O	ADJ	O
phosphodiesterase-5	O	NOUN	B
inhibitor	O	NOUN	I
and	O	CCONJ	O
causes	O	VERB	O
vasodilatation	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
pulmonary	O	ADJ	B
circulation	O	NOUN	I
.	O	PUNCT	O


Since	O	SCONJ	O
left	B-P	VERB	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
pulmonary	O	ADJ	B
hypertension	O	NOUN	I
"	O	PUNCT	O
out	O	ADP	O
of	O	ADP	O
proportion	O	NOUN	B
to	O	PART	O
left	O	VERB	B
heart	O	NOUN	I
disease	O	NOUN	I
,	O	PUNCT	O
"	O	PUNCT	O
sildenafil	B-I	NOUN	B
may	O	AUX	O
have	O	AUX	O
beneficial	O	ADJ	O
effect	O	NOUN	B
in	O	ADP	O
such	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
investigation	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
as	O	ADP	O
a	O	DET	O
12-week	O	NOUN	B
,	O	PUNCT	O
single-center	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
evaluating	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
sildenafil	B-I	NOUN	B
on	O	ADP	O
mean	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
(	O	PUNCT	O
primary	O	ADJ	B
endpoint	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
left	I-P	ADJ	B
systolic	I-P	ADJ	I
heart	I-P	NOUN	I
failure	I-P	NOUN	I
.	I-P	PUNCT	O


Secondary	O	ADJ	B
endpoints	O	NOUN	I
included	O	VERB	O
exercise	B-OUT	NOUN	B
capacity	I-OUT	NOUN	O
assessed	O	VERB	B
by	O	ADP	O
6-minute	B-OUT	ADJ	B
walk	I-OUT	NOUN	I
test	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
106	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
1:1	I-P	NUM	O
to	I-P	PART	O
sildenafil	I-I	NOUN	B
(	I-P	PUNCT	O
n=53	I-P	NOUN	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
n=53	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
received	I-P	VERB	O
sildenafil	I-I	NOUN	B
25	I-P	NUM	O
mg	I-P	NOUN	O
twice	I-P	ADV	O
a	I-P	DET	O
day	I-P	NOUN	B
or	I-P	CCONJ	O
matching	I-P	VERB	O
placebo	I-I	NOUN	B
for	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
2	I-P	NUM	O
weeks	I-P	NOUN	B
and	I-P	CCONJ	O
50	I-P	NUM	O
mg	I-P	NOUN	O
3	I-P	NUM	O
times	I-P	NOUN	O
a	I-P	DET	O
week	I-P	NOUN	B
for	I-P	ADP	O
the	I-P	DET	O
remainder	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
trial	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
placebo-corrected	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
mean	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
was	O	AUX	O
1.16	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
-1.6	O	NUM	O
to	O	PART	O
5.1	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
demonstrating	O	VERB	O
that	O	SCONJ	O
sildenafil	O	NOUN	B
did	O	AUX	O
not	O	PART	O
decrease	O	VERB	B
mean	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
sildenafil	B-I	NOUN	B
increased	O	VERB	B
the	O	DET	O
6-minute	B-OUT	ADJ	B
walk	I-OUT	NOUN	I
test	I-OUT	NOUN	I
by	O	ADP	O
a	O	DET	O
nonsignificant	O	ADJ	B
treatment	O	NOUN	B
effect	O	NOUN	O
of	O	ADP	O
14	O	NUM	O
m	O	NOUN	O
(	O	PUNCT	O
P=.67	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
a	O	DET	O
comparable	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
taking	O	VERB	O
sildenafil	B-I	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
needed	O	VERB	O
to	O	PART	O
discontinue	O	VERB	B
therapy	O	NOUN	I
.	O	PUNCT	O


Sildenafil	O	NOUN	B
is	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
in	O	ADP	O
left	B-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
patients	I-P	NOUN	B
and	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
decrease	O	VERB	B
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


It	O	PRON	O
can	O	AUX	O
be	O	AUX	O
safely	O	ADV	O
added	O	VERB	O
to	O	PART	O
standard	O	ADJ	B
heart	O	NOUN	B
failure	O	NOUN	I
therapy	O	NOUN	I
.	O	PUNCT	O


Continual	B-I	ADJ	B
feeding	I-I	NOUN	B
of	O	ADP	O
two	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
microalgal	B-I	ADJ	B
biomass	I-I	NOUN	B
affected	O	VERB	O
protein	O	NOUN	B
digestion	O	NOUN	I
and	O	CCONJ	O
metabolism	O	NOUN	B
in	O	ADP	O
laying	B-P	VERB	B
hens	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
14-wk	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
nutritional	O	ADJ	B
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
ssmetabolic	I-OUT	ADJ	B
impact	I-OUT	NOUN	B
of	O	ADP	O
2	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
microalgal	B-I	ADJ	B
biomass	I-I	NOUN	B
as	O	ADP	O
alternative	O	ADJ	B
protein	O	NOUN	B
sources	O	NOUN	B
in	O	ADP	O
laying	B-P	VERB	B
hen	I-P	NOUN	B
diets	O	NOUN	B
.	O	PUNCT	O


Shaver	B-P	ADJ	B
hens	I-P	NOUN	I
(	I-P	PUNCT	O
total	I-P	NOUN	O
=	I-P	ADJ	O
150	I-P	NUM	O
and	I-P	CCONJ	O
26	I-P	NUM	O
wk	I-P	NOUN	O
old	I-P	ADJ	O
)	I-P	PUNCT	O
were	O	AUX	O
fed	O	VERB	O
1	O	NUM	O
of	O	ADP	O
5	O	NUM	O
diets	O	NOUN	B
:	O	PUNCT	O
a	B-I	DET	O
control	I-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
defatted	I-I	ADJ	B
green	I-I	ADJ	I
microalgal	I-I	NOUN	O
biomass	I-I	NOUN	B
(	I-I	PUNCT	O
DG	I-I	NOUN	B
;	I-I	PUNCT	O
Desmodesmus	I-I	NOUN	B
spp	I-I	NOUN	I
.	I-I	PUNCT	O


)	B-I	PUNCT	O
at	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
a	B-I	DET	O
full-fatted	I-I	ADJ	B
diatom	I-I	NOUN	B
biomass	I-I	NOUN	B
(	I-I	PUNCT	O
FD	I-I	PROPN	B
;	I-I	PUNCT	O
Staurosira	I-I	PROPN	B
spp	I-I	X	I
.	I-I	PUNCT	O


)	B-I	PUNCT	O
at	O	ADP	O
11.7	O	NUM	O
%	O	NOUN	O
inclusion	B-I	NOUN	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
protease	I-I	NOUN	B
.	I-I	PUNCT	O


This	O	DET	O
experiment	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
5	O	NUM	O
replicates	O	NOUN	B
per	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
each	O	DET	O
replicate	O	NOUN	B
contained	O	VERB	O
6	O	NUM	O
hens	O	NOUN	B
individually	O	ADV	O
reared	O	VERB	B
in	O	ADP	O
cages	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
hen	O	NOUN	B
for	O	ADP	O
biochemical	O	ADJ	B
data/replicate	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Despite	O	SCONJ	O
decreased	O	VERB	B
ADFI	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
hens	O	NOUN	B
fed	O	VERB	B
DG	O	NOUN	B
or	O	CCONJ	O
FD	O	PROPN	B
had	O	AUX	O
final	O	ADJ	O
BW	O	NOUN	B
,	O	PUNCT	O
overall	O	ADJ	O
hen-day	O	NOUN	B
egg	O	NOUN	O
production	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
egg	O	NOUN	B
quality	O	NOUN	I
similar	O	ADJ	O
to	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
.	O	PUNCT	O


Feeding	O	VERB	B
DG	O	NOUN	B
or	O	CCONJ	O
FD	O	PROPN	B
did	O	AUX	O
not	O	PART	O
alter	B-OUT	VERB	O
plasma	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
of	I-OUT	ADP	O
insulin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
glutamine	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
uric	I-OUT	ADJ	B
acid	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
alkaline	I-OUT	NOUN	B
phosphatase	I-OUT	NOUN	I
activity	I-OUT	NOUN	I
at	O	ADP	O
wk	O	NOUN	O
8	O	NUM	O
or	O	CCONJ	O
14	O	NUM	O
but	O	CCONJ	O
decreased	O	VERB	B
plasma	B-OUT	NOUN	B
3-methyhistine	I-OUT	NOUN	O
concentrations	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
tartrate-resistant	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
phosphatase	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
TRAP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
activities	I-OUT	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
wk	O	NOUN	O
14	O	NUM	O
and	O	CCONJ	O
improved	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
ileal	O	ADJ	B
total	O	ADJ	O
AA	O	ADJ	O
digestibility	O	NOUN	O
.	O	PUNCT	O


Although	O	SCONJ	O
DG	O	NOUN	B
or	O	CCONJ	O
FD	O	PROPN	B
exhibited	O	VERB	O
moderate	B-OUT	ADJ	B
effects	I-OUT	NOUN	B
on	O	ADP	O
intestinal	B-OUT	ADJ	B
brush	I-OUT	NOUN	I
border	I-OUT	NOUN	I
protease	I-OUT	NOUN	I
activities	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
mRNA	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
of	I-OUT	ADP	O
duodenal	I-OUT	ADJ	B
transporters	I-OUT	NOUN	I
Pept1	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
Lat1	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Cat1	I-OUT	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
substantially	O	ADV	O
enhanced	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	NOUN	O
0.05	O	NUM	O
)	O	PUNCT	O
phosphorylation	B-OUT	NOUN	B
of	I-OUT	ADP	O
hepatic	I-OUT	ADJ	B
protein	I-OUT	NOUN	I
synthesis	I-OUT	NOUN	O
key	I-OUT	NOUN	O
regulator	I-OUT	NOUN	O
S6	I-OUT	NOUN	O
ribosomal	I-OUT	ADJ	O
protein	I-OUT	NOUN	O
(	O	PUNCT	O
S6	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
phospho-S6	O	NOUN	B
to	O	PART	O
S6	O	NOUN	B
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
of	O	ADP	O
hens	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
DG	O	NOUN	B
and	O	CCONJ	O
FD	O	PROPN	B
manifested	O	VERB	O
with	O	ADP	O
different	O	ADJ	O
impacts	O	NOUN	B
on	O	ADP	O
weights	B-OUT	NOUN	B
of	I-OUT	ADP	O
egg	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
egg	I-OUT	NOUN	B
albumen	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
proteolytic	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
of	I-OUT	ADP	O
jejunal	I-OUT	ADJ	B
digesta	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
TRAP	I-OUT	NOUN	O
activity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
ileal	I-OUT	ADJ	B
total	I-OUT	ADJ	O
AA	I-OUT	ADJ	O
digestibility	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
several	I-OUT	ADJ	O
intestinal	I-OUT	ADJ	B
genes	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
hepatic	I-OUT	ADJ	B
proteins	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Supplemental	O	NOUN	B
protease	O	NOUN	I
in	O	ADP	O
the	O	DET	O
DG	O	NOUN	B
and	O	CCONJ	O
FD	O	PROPN	B
diets	O	NOUN	B
produced	O	VERB	O
mixed	B-OUT	ADJ	O
effects	I-OUT	NOUN	B
on	O	ADP	O
a	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
measures	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
our	O	PRON	O
findings	O	NOUN	B
revealed	O	VERB	O
the	O	DET	O
feasibility	O	NOUN	B
of	O	ADP	O
including	O	VERB	O
greater	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
microalgal	B-I	ADJ	B
biomass	I-I	NOUN	B
as	O	ADP	O
a	O	DET	O
source	O	NOUN	B
of	O	ADP	O
feed	O	NOUN	B
protein	O	NOUN	I
for	O	ADP	O
laying	B-P	VERB	B
hens	I-P	NOUN	B
and	O	CCONJ	O
a	O	DET	O
novel	O	ADJ	O
potential	O	NOUN	B
of	O	ADP	O
the	O	DET	O
biomass	O	NOUN	B
in	O	ADP	O
improving	O	VERB	B
dietary	O	ADJ	B
protein	O	NOUN	I
digestion	O	NOUN	B
and	O	CCONJ	O
body	O	NOUN	B
protein	O	NOUN	I
metabolism	O	NOUN	I
than	O	ADP	O
previously	O	ADV	O
perceived	O	VERB	B
.	O	PUNCT	O


High	B-P	ADJ	O
general	I-P	ADJ	B
anger	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
correlates	I-I	VERB	B
and	O	CCONJ	O
treatment	B-I	NOUN	B
.	I-I	PUNCT	O


Acute	B-I	ADJ	B
intravenous	I-I	ADJ	O
L-arginine	I-I	NOUN	B
infusion	I-I	NOUN	B
decreases	O	VERB	B
endothelin-1	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
and	O	CCONJ	O
improves	O	VERB	B
endothelial	B-OUT	ADJ	B
function	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
angina	I-P	ADJ	B
pectoris	I-P	NOUN	I
and	I-P	CCONJ	O
normal	I-P	ADJ	B
coronary	I-P	ADJ	I
arteriograms	I-P	NOUN	I
:	I-P	PUNCT	O
correlation	O	NOUN	B
with	O	ADP	O
asymmetric	O	ADJ	B
dimethylarginine	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


BACKGROUND	O	NOUN	O
We	O	PRON	O
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
asymmetric	B-OUT	ADJ	B
dimethylarginine	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
ADMA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
could	O	AUX	O
be	O	AUX	O
elevated	O	ADJ	B
and	O	CCONJ	O
influence	O	VERB	B
endothelin-1	B-OUT	NOUN	B
and	I-I	CCONJ	O
nitric	I-OUT	ADJ	B
oxide	I-OUT	NOUN	I
release	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
action	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cardiac	I-P	ADJ	B
syndrome	I-P	NOUN	I
X	I-P	NOUN	I
(	I-P	PUNCT	O
CSX	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
evaluated	O	VERB	B
whether	O	SCONJ	O
an	O	DET	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
L-arginine	B-I	NOUN	B
would	O	AUX	O
improve	O	VERB	B
endothelial	B-OUT	ADJ	B
function	I-OUT	NOUN	I
in	O	ADP	O
these	O	DET	O
subjects	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	VERB	O
Nine	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
CSX	I-P	NOUN	B
and	I-P	CCONJ	O
14	I-P	NUM	O
control	I-P	ADJ	B
subjects	I-P	NOUN	I
underwent	I-P	VERB	O
a	I-P	DET	O
continuous	I-P	ADJ	B
infusion	I-P	NOUN	B
of	I-P	ADP	O
L-arginine	I-I	NOUN	B
(	I-I	PUNCT	O
0.125	I-I	NUM	O
g/min	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
saline	I-I	NOUN	B
for	I-P	ADP	O
120	I-P	NUM	O
minutes	I-P	NOUN	B
.	I-P	PUNCT	O


Sixty	O	NUM	O
minutes	O	NOUN	O
after	O	ADP	O
L-arginine	B-I	NOUN	B
or	I-I	CCONJ	O
saline	I-I	NOUN	B
infusions	I-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
intravenous	O	ADJ	B
insulin	B-I	NOUN	O
bolus	O	NOUN	O
(	O	PUNCT	O
0.1	O	NUM	O
U/kg	O	NOUN	O
)	O	PUNCT	O
combined	O	VERB	O
with	O	ADP	O
a	O	DET	O
euglycemic	B-I	ADJ	B
clamp	I-I	NOUN	I
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Basal	B-OUT	ADJ	B
ADMA	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
endothelin-1	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
CSX	I-P	NOUN	B
than	O	ADP	O
in	O	ADP	O
controls	B-P	NOUN	B
.	I-P	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
hour	O	NOUN	O
of	O	ADP	O
infusion	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
saline	B-I	NOUN	B
,	I-I	PUNCT	O
L-arginine	I-I	NOUN	B
infusion	O	NOUN	B
increased	O	VERB	B
basal	B-OUT	ADJ	B
forearm	I-OUT	NOUN	I
blood	I-OUT	NOUN	O
flow	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
nitrite	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
nitrate	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
NOx	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
forearm	I-OUT	NOUN	B
cGMP	I-OUT	NOUN	B
release	I-OUT	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
endothelin-1	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


After	O	ADP	O
insulin	O	NOUN	B
bolus	O	NOUN	I
,	O	PUNCT	O
during	O	ADP	O
saline	O	NOUN	B
,	O	PUNCT	O
insulin-induced	B-OUT	ADJ	B
NOx	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
endothelin-1	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
forearm	I-OUT	NOUN	B
cGMP	I-OUT	NOUN	B
release	I-OUT	NOUN	B
was	O	AUX	O
almost	O	ADV	O
abolished	O	VERB	B
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
L-arginine	O	NOUN	B
restored	O	VERB	B
a	O	DET	O
physiological	O	ADJ	B
profile	O	NOUN	I
of	O	ADP	O
all	O	DET	O
endothelial	B-OUT	ADJ	B
variables	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
control	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
control	O	ADJ	B
subjects	O	NOUN	I
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
saline	B-I	NOUN	B
infusion	I-I	NOUN	I
,	I-I	PUNCT	O
L-arginine	I-I	NOUN	B
infusion	I-I	NOUN	B
did	O	AUX	O
not	O	PART	O
modify	O	VERB	B
any	O	DET	O
parameter	O	NOUN	B
.	O	PUNCT	O


ADMA	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
were	O	AUX	O
positively	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
basal	O	ADJ	B
endothelin-1	B-OUT	NOUN	I
levels	I-OUT	NOUN	B
and	O	CCONJ	O
negatively	O	ADV	B
correlated	O	VERB	B
with	O	ADP	O
insulin-induced	B-OUT	ADJ	B
incremental	I-OUT	ADJ	O
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
NOx	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
forearm	I-OUT	NOUN	B
cGMP	I-OUT	NOUN	B
release	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Plasma	B-OUT	NOUN	B
ADMA	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
are	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
CSX	I-P	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
they	O	PRON	O
are	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
increases	O	NOUN	B
in	O	ADP	O
endothelin-1	B-OUT	NOUN	B
and	O	CCONJ	O
reductions	O	NOUN	B
in	O	ADP	O
insulin-induced	O	ADJ	B
increments	O	NOUN	B
in	O	ADP	O
plasma	B-OUT	NOUN	B
NOx	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
cGMP	I-OUT	NOUN	B
,	O	PUNCT	O
effects	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
reversed	O	VERB	O
by	O	ADP	O
intravenous	O	ADJ	B
L-arginine	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
increased	O	VERB	B
ADMA	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
abnormal	O	ADJ	B
vascular	O	ADJ	B
reactivity	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
CSX	B-P	NOUN	B
.	I-P	PUNCT	O


An	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
an	O	DET	O
adaptive	B-I	ADJ	B
automation	I-I	NOUN	I
system	I-I	NOUN	I
using	O	VERB	O
a	O	DET	O
cognitive	B-I	ADJ	B
vigilance	I-I	NOUN	I
task	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
performance	O	NOUN	B
of	O	ADP	O
an	O	DET	O
adaptive	B-I	ADJ	B
automation	I-I	NOUN	I
system	I-I	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
a	O	DET	O
cognitive	O	ADJ	B
vigilance	O	NOUN	I
task	O	NOUN	I
.	O	PUNCT	O


Participants	B-P	NOUN	B
responded	O	VERB	O
to	O	PART	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
green	B-I	ADJ	B
"	I-I	PUNCT	O
K	I-I	PROPN	O
"	I-I	PUNCT	O
in	I-I	ADP	O
an	I-I	DET	O
array	I-I	NOUN	B
of	I-I	ADP	O
two	I-I	NUM	O
,	I-I	PUNCT	O
five	I-I	NUM	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
nine	I-I	NUM	O
distractor	I-I	NOUN	B
stimuli	I-I	NOUN	O
during	I-I	ADP	O
a	I-I	DET	O
40-min	I-I	ADJ	O
vigil	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
array	O	NOUN	B
with	O	ADP	O
the	O	DET	O
target	O	NOUN	B
stimulus	O	NOUN	B
was	O	AUX	O
presented	O	VERB	O
once	O	SCONJ	O
each	O	DET	O
minute	O	NOUN	B
.	O	PUNCT	O


Participants	B-P	NOUN	B
EEG	I-I	PROPN	B
was	O	AUX	O
recorded	O	VERB	O
and	O	CCONJ	O
an	O	DET	O
engagement	B-OUT	NOUN	B
index	I-OUT	NOUN	I
(	O	PUNCT	O
EI	O	NOUN	B
=	O	ADJ	O
20	O	NUM	O
x	O	NOUN	O
beta/	O	NOUN	O
(	O	PUNCT	O
alpha	O	NOUN	B
+	O	CCONJ	O
theta	O	NOUN	B
)	O	PUNCT	O
)	O	PUNCT	O
was	O	AUX	O
derived	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
negative	O	ADJ	B
feedback	O	NOUN	O
condition	O	NOUN	O
,	O	PUNCT	O
increases	O	VERB	B
in	O	ADP	O
the	O	DET	O
EI	B-OUT	PROPN	B
caused	I-OUT	VERB	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
stimuli	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
array	I-OUT	NOUN	B
to	I-OUT	PART	O
decrease	I-OUT	VERB	B
while	O	SCONJ	O
decreases	B-OUT	VERB	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
EI	I-OUT	PROPN	B
caused	I-OUT	VERB	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
stimuli	I-OUT	NOUN	B
to	I-OUT	PART	O
increase	I-OUT	VERB	B
.	I-OUT	PUNCT	O


For	O	ADP	O
the	O	DET	O
positive	O	ADJ	B
feedback	O	NOUN	O
condition	O	NOUN	O
,	O	PUNCT	O
increases	B-OUT	VERB	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
index	I-OUT	NOUN	B
caused	I-OUT	VERB	O
an	I-OUT	DET	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
array	I-OUT	NOUN	B
size	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AS	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
while	O	SCONJ	O
decreases	B-OUT	VERB	B
caused	I-OUT	VERB	O
a	I-OUT	DET	O
decrease	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
array	I-OUT	NOUN	B
size	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Each	O	DET	O
experimental	O	ADJ	B
participant	B-P	NOUN	B
had	I-P	AUX	O
a	I-P	DET	O
yoked	I-P	VERB	B
control	I-P	NOUN	O
partner	I-P	NOUN	O
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
same	O	ADJ	O
pattern	O	NOUN	B
of	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
array	O	NOUN	B
irrespective	O	ADV	O
of	O	ADP	O
their	O	PRON	O
engagement	O	NOUN	B
index	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
vigilance	O	NOUN	B
decrement	O	NOUN	I
was	O	AUX	O
seen	O	VERB	O
only	O	ADV	O
for	O	ADP	O
the	O	DET	O
positive	O	ADJ	B
feedback	O	NOUN	B
,	O	PUNCT	O
experimental	B-P	ADJ	B
group	I-P	NOUN	I
.	I-P	PUNCT	O


Lifetime	O	NOUN	B
history	O	NOUN	O
of	O	ADP	O
heroin	O	NOUN	B
use	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
greater	O	ADJ	O
drug	O	NOUN	B
severity	O	NOUN	I
among	O	ADP	O
prescription	B-P	NOUN	B
opioid	I-P	NOUN	I
abusers	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
While	O	SCONJ	O
research	O	NOUN	B
suggests	O	VERB	O
primary	O	ADJ	O
prescription	O	NOUN	O
opioid	O	NOUN	O
(	O	PUNCT	O
PO	O	NOUN	B
)	O	PUNCT	O
abusers	O	NOUN	B
may	O	AUX	O
exhibit	O	VERB	O
less	O	ADV	O
severe	O	ADJ	B
demographic	O	ADJ	B
and	O	CCONJ	O
drug	O	NOUN	B
use	O	NOUN	I
characteristics	O	NOUN	B
than	O	ADP	O
primary	O	ADJ	B
heroin	O	NOUN	B
abusers	O	NOUN	B
,	O	PUNCT	O
less	O	ADV	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
whether	O	SCONJ	O
a	O	DET	O
lifetime	O	NOUN	B
history	O	NOUN	B
of	O	ADP	O
heroin	O	NOUN	B
use	O	NOUN	O
confers	O	VERB	O
greater	O	ADJ	O
severity	O	NOUN	B
among	O	ADP	O
PO	O	NOUN	B
abusers	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
In	O	ADP	O
this	O	DET	O
secondary	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
demographic	O	ADJ	B
and	O	CCONJ	O
drug	O	NOUN	B
use	O	NOUN	I
characteristics	O	NOUN	I
as	O	ADP	O
a	O	DET	O
function	O	NOUN	B
of	O	ADP	O
lifetime	O	NOUN	B
heroin	O	NOUN	B
use	O	NOUN	B
among	O	ADP	O
89	B-P	NUM	O
PO-dependent	I-P	ADJ	B
adults	I-P	NOUN	B
screened	I-P	VERB	B
for	I-P	ADP	O
a	I-P	DET	O
trial	I-P	NOUN	B
evaluating	I-P	VERB	B
the	I-P	DET	O
relative	I-P	ADJ	O
efficacy	I-P	NOUN	B
of	I-P	ADP	O
buprenorphine	I-P	NOUN	B
taper	I-P	NOUN	B
durations	I-P	NOUN	B
.	I-P	PUNCT	O


Exploratory	O	ADJ	B
analyses	O	NOUN	I
also	O	ADV	O
examined	O	VERB	O
contribution	O	NOUN	B
of	O	ADP	O
lifetime	O	NOUN	B
heroin	O	NOUN	B
use	O	NOUN	O
to	O	PART	O
treatment	O	NOUN	B
response	O	NOUN	I
among	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
participants	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
a	O	DET	O
uniform	O	ADJ	O
set	O	NOUN	O
of	O	ADP	O
study	O	NOUN	B
procedures	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Baseline	O	NOUN	B
characteristics	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
participants	B-P	NOUN	B
reporting	I-P	VERB	O
lifetime	I-P	NOUN	B
heroin	I-P	NOUN	B
use	I-P	NOUN	O
≥5	I-P	ADJ	O
(	I-P	PUNCT	O
H	I-P	NOUN	O
(	I-P	PUNCT	O
+	I-P	CCONJ	O
)	I-P	PUNCT	O
;	I-P	PUNCT	O
n=41	I-P	ADJ	O
)	I-P	PUNCT	O
vs.	I-P	CCONJ	O
<	I-P	X	O
5	I-P	NUM	O
(	I-P	PUNCT	O
H	I-P	NOUN	B
(	I-P	PUNCT	O
-	I-P	PUNCT	O
)	I-P	PUNCT	O
;	I-P	PUNCT	O
n=48	I-P	NOUN	O
)	I-P	PUNCT	O
times	I-P	NOUN	O
.	O	PUNCT	O


Treatment	O	NOUN	B
response	O	NOUN	I
(	O	PUNCT	O
i.e.	B-I	X	O
,	O	PUNCT	O
illicit	B-I	NOUN	B
opioid	I-I	NOUN	I
abstinence	I-I	NOUN	I
and	O	CCONJ	O
treatment	O	NOUN	B
retention	O	NOUN	I
at	O	ADP	O
end	O	NOUN	O
of	O	ADP	O
study	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
the	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
H	O	NOUN	B
(	O	PUNCT	I
+	O	CCONJ	I
)	O	PUNCT	I
and	O	CCONJ	O
H	O	NOUN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
participants	O	NOUN	B
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
the	O	DET	O
4-week	O	NOUN	O
taper	O	NOUN	B
condition	O	NOUN	O
(	O	PUNCT	O
N=22	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
H	O	NOUN	I
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
participants	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
older	O	ADJ	O
and	O	CCONJ	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
male	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
reported	O	VERB	O
longer	B-OUT	ADJ	O
durations	I-OUT	NOUN	B
of	I-OUT	ADP	O
illicit	I-OUT	X	B
opioid	I-OUT	NOUN	I
use	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
greater	I-OUT	ADJ	O
alcohol-related	I-OUT	ADJ	B
problems	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
more	I-OUT	ADV	O
past-month	I-OUT	ADJ	B
cocaine	I-OUT	NOUN	B
use	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
greater	I-OUT	ADJ	O
lifetime	I-OUT	NOUN	B
IV	I-OUT	NUM	O
drug	I-OUT	NOUN	O
use	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
greater	I-OUT	ADJ	O
lifetime	I-OUT	NOUN	B
use	I-OUT	NOUN	B
of	I-OUT	ADP	I
cigarettes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
amphetamines	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
hallucinogens	I-OUT	NOUN	B
.	O	PUNCT	O


H	O	NOUN	O
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
participants	O	NOUN	B
also	O	ADV	O
had	O	AUX	O
lower	O	ADJ	B
scores	O	NOUN	B
on	O	ADP	O
the	B-OUT	DET	O
Positive	I-OUT	ADJ	B
Symptom	I-OUT	NOUN	I
Distress	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
Depression	I-OUT	NOUN	B
subscales	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
Brief	O	PROPN	B
Symptom	O	NOUN	I
Inventory	O	PROPN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
poorer	O	ADJ	B
treatment	O	NOUN	B
outcomes	O	NOUN	B
among	O	ADP	O
H	O	NOUN	B
(	O	PUNCT	I
+	O	CCONJ	I
)	O	PUNCT	I
participants	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
A	O	DET	O
lifetime	O	NOUN	B
history	O	NOUN	O
of	O	ADP	O
heroin	O	NOUN	B
use	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
elevated	O	ADJ	B
drug	O	NOUN	B
severity	O	NOUN	I
and	O	CCONJ	O
unique	O	ADJ	B
treatment	O	NOUN	B
needs	O	VERB	O
among	O	ADP	O
treatment-seeking	B-P	ADJ	B
PO	I-P	NOUN	B
abusers	I-P	NOUN	B
.	O	PUNCT	O


Optimization	O	NOUN	B
of	O	ADP	O
acid	O	NOUN	B
suppression	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
peptic	I-P	ADJ	B
ulcer	I-P	NOUN	I
bleeding	I-P	NOUN	I
:	I-P	PUNCT	O
an	O	DET	O
intragastric	O	ADJ	B
pH-metry	O	NOUN	B
study	O	NOUN	O
with	O	ADP	O
omeprazole	B-I	NOUN	B
.	I-I	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
study	O	VERB	B
whether	O	SCONJ	O
an	O	DET	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
omeprazole	B-I	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
mg	O	NOUN	O
+	O	CCONJ	O
8	O	NUM	O
mg/h	O	NOUN	O
)	O	PUNCT	O
during	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
can	O	AUX	O
be	O	AUX	O
subsequently	O	ADV	O
reduced	O	VERB	B
with	O	ADP	O
maintained	O	ADJ	B
effect	O	NOUN	B
.	O	PUNCT	O


Second	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
omeprazole	B-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
given	O	VERB	O
once	O	ADV	O
or	O	CCONJ	O
twice	O	ADV	O
daily	O	ADV	O
up	O	ADV	O
to	O	ADP	O
day	O	NOUN	B
10	O	NUM	O
,	O	PUNCT	O
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
3-day	O	ADJ	O
intravenous	O	ADJ	B
infusion	O	NOUN	O
(	O	PUNCT	O
80	O	NUM	O
mg	O	NOUN	O
+	O	CCONJ	O
8	O	NUM	O
mg/h	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


DESIGN	O	VERB	O
Prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
partly	O	ADV	O
blinded	O	VERB	B
study	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Twelve	B-P	NUM	O
Helicobacter	I-P	PROPN	B
pylori	I-P	NOUN	I
(	I-P	PUNCT	O
+	I-P	CCONJ	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
and	I-P	CCONJ	O
12	I-P	NUM	O
H.	I-P	NOUN	B
pylori	I-P	NOUN	I
(	I-P	PUNCT	O
-	I-P	PUNCT	O
)	I-P	PUNCT	O
subjects	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
.	I-P	PUNCT	O


In	O	ADP	O
part	O	NOUN	O
I	O	NUM	O
the	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
omeprazole	B-I	NOUN	B
,	O	PUNCT	O
80	O	NUM	O
mg	O	NOUN	O
+	O	CCONJ	O
8	O	NUM	O
mg/h	O	NOUN	O
,	O	PUNCT	O
during	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
8	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
or	O	CCONJ	O
2	O	NUM	O
mg/h	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
part	O	NOUN	O
II	O	NUM	O
the	O	DET	O
subjects	O	NOUN	B
received	O	VERB	O
80	O	NUM	O
mg	O	NOUN	O
+	O	CCONJ	O
8	O	NUM	O
mg/h	O	NOUN	O
during	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
20	O	NUM	O
mg	O	NOUN	O
omeprazole	B-I	NOUN	B
orally	O	ADV	B
,	O	PUNCT	O
once	O	ADV	O
or	O	CCONJ	O
twice	O	ADV	O
daily	O	ADV	O
until	O	ADP	O
day	O	NOUN	B
10	O	NUM	O
.	O	PUNCT	O


Intragastric	B-OUT	ADJ	B
pH	I-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
All	O	DET	O
H.	O	PROPN	B
pylori	O	NOUN	I
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
patients	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
rapid	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
intragastric	B-OUT	ADJ	B
pH	I-OUT	NOUN	B
with	I-OUT	ADP	O
a	I-OUT	DET	O
mean	I-OUT	ADJ	O
intragastric	I-OUT	ADJ	B
pH	I-OUT	NOUN	B
of	O	ADP	O
6.7	O	NUM	O
during	O	ADP	O
the	O	DET	O
second	O	ADJ	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
subsequent	O	ADJ	O
dose	O	NOUN	B
reduction	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mean	B-OUT	NOUN	B
pH	I-OUT	NOUN	B
decreased	O	VERB	B
to	O	PART	O
6.1-6.2	O	NUM	O
.	O	PUNCT	O


Patients	O	NOUN	B
continuing	O	VERB	B
on	O	ADP	O
8	O	NUM	O
mg/h	O	NOUN	O
showed	O	VERB	O
the	O	DET	O
best	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


Likewise	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
H.	O	PROPN	B
pylori	O	NOUN	I
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
subjects	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
rapid	O	ADJ	B
and	O	CCONJ	O
sustained	O	ADJ	B
reduction	O	NOUN	B
of	O	ADP	O
intragastric	B-OUT	ADJ	B
acidity	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
.	O	PUNCT	O


Subsequent	O	ADJ	B
dose	O	NOUN	B
reduction	O	NOUN	B
to	O	PART	O
20	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
led	O	VERB	O
to	O	PART	O
a	O	DET	O
stable	O	ADJ	B
fraction	O	NOUN	B
of	O	ADP	O
time	O	NOUN	O
with	O	ADP	O
pH	O	NOUN	B
>	O	X	O
3	O	NUM	O
of	O	ADP	O
72	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Omeprazole	B-I	NOUN	B
given	O	VERB	O
as	O	ADP	O
a	O	DET	O
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
80	O	NUM	O
mg	O	NOUN	O
+	O	CCONJ	O
8	O	NUM	O
mg/h	O	NOUN	O
for	O	ADP	O
72	O	NUM	O
h	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
omeprazole	B-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
raised	O	VERB	O
the	O	DET	O
intragastric	B-OUT	ADJ	B
pH	I-OUT	NOUN	B
to	O	PART	O
and	O	CCONJ	O
above	O	ADJ	O
levels	O	NOUN	B
alleged	O	VERB	O
to	O	PART	O
allow	O	VERB	O
haemostasis	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
peptic	B-P	ADJ	B
ulcer	I-P	NOUN	I
bleeding	I-P	NOUN	I
and	O	CCONJ	O
subsequent	O	ADJ	O
healing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ulcer	O	NOUN	B
.	O	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
surgical	B-I	ADJ	B
staging	I-I	NOUN	I
in	O	ADP	O
evaluating	O	VERB	B
the	O	DET	O
radiotherapeutic	O	ADJ	B
outcome	O	NOUN	I
in	O	ADP	O
RTOG	O	PROPN	B
#	O	NOUN	O
77-06	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
study	O	NOUN	I
for	O	ADP	O
T1BN0M0	O	NOUN	B
(	O	PUNCT	O
A2	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
T2N0M0	O	NOUN	B
(	O	PUNCT	O
B	O	NOUN	O
)	O	PUNCT	O
prostate	O	NOUN	O
carcinoma	O	NOUN	O
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
survival	O	NOUN	B
and	O	CCONJ	O
time	O	NOUN	B
to	O	PART	O
metastatic	O	ADJ	B
disease	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
treated	I-P	VERB	B
for	I-P	ADP	O
localized	I-P	ADJ	B
prostatic	I-P	ADJ	B
carcinoma	I-P	NOUN	I
in	I-P	ADP	O
a	I-P	DET	O
Phase	I-I	NOUN	B
III	I-I	NUM	I
radiotherapy	I-I	NOUN	I
(	I-P	PUNCT	O
RT	I-P	NOUN	B
)	I-P	PUNCT	O
protocol	I-P	NOUN	O
,	I-P	PUNCT	O
Radiation	I-I	PROPN	B
Therapy	I-I	PROPN	I
Oncology	I-I	PROPN	I
Group	I-I	PROPN	I
(	I-P	PUNCT	O
RTOG	I-P	PROPN	B
)	I-P	PUNCT	O
77-06	I-P	NUM	O
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
T18N0M0	I-P	NOUN	B
(	I-P	PUNCT	O
A2	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
T2N0M0	I-P	NOUN	B
(	I-P	PUNCT	O
B	I-P	NOUN	O
)	I-P	PUNCT	O
disease	I-P	NOUN	O
after	I-P	ADP	O
lymphangiogram	I-P	NOUN	B
(	I-P	PUNCT	O
LAG	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
staging	I-P	NOUN	B
laparotomy	I-P	NOUN	I
(	I-P	PUNCT	O
SL	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
randomized	I-P	VERB	B
between	I-P	ADP	O
prophylactic	I-P	ADJ	B
radiation	I-P	NOUN	I
to	I-P	ADP	O
the	I-P	DET	O
pelvic	I-P	ADJ	B
lymph	I-P	NOUN	I
nodes	I-P	NOUN	I
and	I-P	CCONJ	O
prostatic	I-P	ADJ	B
bed	I-P	NOUN	I
vs.	I-P	CCONJ	O
prostatic	I-P	ADJ	B
bed	I-P	NOUN	I
alone	I-P	ADV	O
.	I-P	PUNCT	O


The	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
arms	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LAG	O	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
to	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
SL	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
updated	O	VERB	O
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
MATERIALS	O	VERB	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
449	I-P	NUM	O
eligible	I-P	ADJ	B
males	I-P	NOUN	B
were	I-P	AUX	O
entered	I-P	VERB	O
into	I-P	ADP	O
RTOG	I-P	PROPN	B
protocol	I-P	NOUN	B
7706	I-P	NUM	O
between	I-P	ADP	O
1978	I-P	NUM	O
and	I-P	CCONJ	O
1983	I-P	NUM	O
.	I-P	PUNCT	O


Lymph	O	NOUN	B
node	O	NOUN	I
staging	O	NOUN	I
was	O	AUX	O
mandatory	O	ADJ	B
but	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
physician	O	NOUN	B
's	O	PART	O
discretion	O	NOUN	B
;	O	PUNCT	O
117	B-P	NUM	O
(	I-P	PUNCT	O
26	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
had	I-P	AUX	O
SL	I-P	PROPN	B
,	I-P	PUNCT	O
while	I-P	SCONJ	O
332	I-P	NUM	O
(	I-P	PUNCT	O
74	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
LAG	I-P	PROPN	B
.	I-P	PUNCT	O


Follow-up	O	X	B
was	O	AUX	O
a	O	DET	O
median	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
16	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
those	O	DET	O
randomized	O	ADJ	B
to	O	PART	O
receive	O	VERB	O
prophylactic	O	ADJ	B
pelvic	O	ADJ	I
lymph	O	NOUN	I
nodal	O	NOUN	I
irradiation	O	NOUN	I
,	O	PUNCT	O
45	O	NUM	O
Gy	O	NOUN	O
of	O	ADP	O
megavoltage	O	ADJ	B
RT	O	NOUN	I
was	O	AUX	O
delivered	O	VERB	O
via	O	ADP	O
multiple	O	ADJ	B
portals	O	NOUN	B
in	O	ADP	O
4.5-5	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
all	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
65	O	NUM	O
Gy	O	NOUN	O
in	O	ADP	O
6.5-8	O	NUM	O
weeks	O	NOUN	B
to	O	PART	O
the	O	DET	O
prostatic	O	ADJ	B
bed	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
survival	B-OUT	NOUN	B
whether	O	SCONJ	O
treatment	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
to	O	PART	O
the	O	DET	O
prostate	O	NOUN	B
or	O	CCONJ	O
prostate	O	NOUN	B
and	O	CCONJ	O
pelvic	O	ADJ	B
lymph	O	NOUN	I
nodes	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
SL	O	NOUN	B
group	O	NOUN	B
had	O	AUX	O
greater	O	ADJ	O
12-year	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
than	O	ADP	O
the	O	DET	O
LAG	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
38	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Disease-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
,	O	PUNCT	O
with	O	ADP	O
38	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
SL	O	NOUN	B
group	O	NOUN	B
vs.	O	CCONJ	O
26	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
LAG	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Bone	B-OUT	NOUN	B
metastasis	I-OUT	NOUN	I
was	O	AUX	O
less	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
the	O	DET	O
SL	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
the	O	DET	O
LAG	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
27	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
At	O	ADP	O
12-year	O	ADJ	O
median	O	NOUN	B
follow-up	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
still	O	ADV	O
was	O	AUX	O
no	O	DET	B
survival	O	NOUN	I
difference	O	NOUN	O
in	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
treated	O	VERB	B
prophylactically	O	ADV	B
to	O	PART	O
the	O	DET	O
pelvic	O	ADJ	B
nodes	O	NOUN	I
and	O	CCONJ	O
prostatic	O	ADJ	B
bed	O	NOUN	I
vs.	O	CCONJ	O
the	O	DET	O
prostatic	O	ADJ	B
bed	O	NOUN	I
alone	O	ADV	O
.	O	PUNCT	O


Those	O	DET	O
patients	O	NOUN	B
not	O	PART	O
surgically	O	ADV	B
staged	O	VERB	I
with	O	ADP	O
only	O	ADV	O
LAG	O	NOUN	B
for	O	ADP	O
lymph	O	NOUN	B
node	O	NOUN	I
evaluation	O	NOUN	B
were	O	AUX	O
less	O	ADV	O
accurately	O	ADV	B
staged	O	VERB	B
,	O	PUNCT	O
as	O	ADP	O
reflected	O	VERB	O
by	O	ADP	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
reduced	O	VERB	B
survival	O	NOUN	B
and	O	CCONJ	O
earlier	O	ADJ	O
metastases	O	NOUN	B
.	O	PUNCT	O


Improved	O	ADJ	B
fibrinolysis	O	NOUN	B
after	O	ADP	O
1-year	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
HMG	B-I	NOUN	B
CoA	I-I	NOUN	I
reductase	I-I	NOUN	I
inhibitors	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
statins	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
haemostatic	O	ADJ	B
variables	O	NOUN	B
reflecting	O	VERB	O
procoagulant	O	ADJ	B
and	O	CCONJ	O
fibrinolytic	O	ADJ	B
activity	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
CHD	I-P	NOUN	B
)	I-P	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
statins	B-I	NOUN	B
might	O	AUX	O
beneficially	O	ADV	B
modify	O	VERB	B
these	O	DET	O
levels	O	NOUN	B
.	O	PUNCT	O


Fifty-eight	B-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
atorvastatin	B-I	NOUN	B
(	O	PUNCT	O
n=28	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
simvastatin	B-I	NOUN	B
(	O	PUNCT	O
n=30	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
starting	O	VERB	O
dose	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
was	O	AUX	O
20	O	NUM	O
mg/day	O	NOUN	B
.	O	PUNCT	O


Fasting	B-OUT	ADJ	B
blood	I-OUT	NOUN	B
samples	I-OUT	NOUN	I
were	O	AUX	O
collected	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
12-month	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
determinations	O	NOUN	B
of	O	ADP	O
fibrinogen	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
prothrombin	I-OUT	NOUN	B
fragment	I-OUT	NOUN	I
1+2	I-OUT	NUM	I
(	I-OUT	PUNCT	O
F1+2	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
D-dimer	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
soluble	I-OUT	ADJ	B
tissue	I-OUT	NOUN	O
factor	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
tissue	I-OUT	NOUN	B
plasminogen	I-OUT	NOUN	I
activator	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
tPA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
antigen	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
tPA	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
plasminogen	I-OUT	NOUN	B
activator	I-OUT	NOUN	I
inhibitor	I-OUT	NOUN	I
type-1	I-OUT	NOUN	O
activity	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
PAI-1	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
D-dimer	I-OUT	NOUN	I
as	I-OUT	ADP	O
a	I-OUT	DET	O
global	I-OUT	ADJ	B
test	I-OUT	NOUN	I
of	I-OUT	ADP	O
fibrinolytic	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
total	O	ADJ	B
population	O	NOUN	I
,	O	PUNCT	O
improved	B-OUT	VERB	B
fibrinolytic	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
with	O	ADP	O
increased	B-OUT	VERB	B
levels	I-OUT	NOUN	B
of	O	ADP	O
serum	B-OUT	NOUN	O
D-dimer	I-OUT	NOUN	O
(	O	PUNCT	O
P=.001	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
tPA	B-OUT	NOUN	B
activity	I-OUT	NOUN	B
(	O	PUNCT	O
P=.024	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
tPA	I-OUT	NOUN	B
antigen	I-OUT	NOUN	O
(	O	PUNCT	O
P=.048	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
statistically	O	ADV	O
significant	O	ADJ	O
changes	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
measured	O	VERB	B
coagulation	O	NOUN	B
variables	O	NOUN	B
.	O	PUNCT	O


Separately	O	ADV	O
examined	O	VERB	O
,	O	PUNCT	O
an	O	DET	O
improved	O	ADJ	B
fibrinolytic	O	ADJ	B
profile	O	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
atorvastatin	B-I	NOUN	B
group	O	NOUN	B
with	O	ADP	O
a	O	DET	O
significant	B-OUT	ADJ	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
D-dimer	I-OUT	NOUN	I
(	O	PUNCT	O
P=.005	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
borderline	B-OUT	NOUN	B
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
tPA	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
(	O	PUNCT	O
P=.083	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
borderline	B-OUT	NOUN	B
reduction	I-OUT	NOUN	I
in	I-OUT	ADP	O
tPA	I-OUT	NOUN	B
antigen	I-OUT	NOUN	I
(	O	PUNCT	O
P=.069	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
simvastatin	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
prothrombin	I-OUT	NOUN	B
F1+2	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
(	O	PUNCT	O
P=.038	O	X	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
differences	O	NOUN	B
in	O	ADP	O
changes	O	NOUN	B
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
only	O	ADV	O
for	O	ADP	O
global	B-OUT	ADJ	B
fibrinolysis	I-OUT	NOUN	I
(	O	PUNCT	O
serum	O	NOUN	B
D-dimer	O	NOUN	I
,	O	PUNCT	O
P=.046	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
an	O	DET	O
improved	O	ADJ	B
fibrinolytic	B-OUT	ADJ	B
profile	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
statin	B-I	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
most	O	ADV	O
pronounced	O	ADJ	O
with	O	ADP	O
atorvastatin	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
drugs	O	NOUN	B
promote	O	VERB	B
a	O	DET	O
profibrinolytic	O	ADJ	B
profile	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
in	O	ADP	O
part	O	NOUN	O
explain	O	VERB	O
the	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
statin	B-I	NOUN	B
treatment	O	NOUN	B
rendered	O	VERB	O
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
CHD	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
home	B-I	NOUN	B
strength	I-I	NOUN	I
training	I-I	NOUN	I
and	I-I	CCONJ	O
stretching	I-I	VERB	B
versus	I-I	ADP	O
stretching	I-I	NOUN	B
alone	I-I	ADV	O
after	I-P	ADP	O
lumbar	I-P	ADJ	B
disk	I-P	NOUN	I
surgery	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
with	O	ADP	O
a	O	DET	O
1-year	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
adherence	O	NOUN	B
to	O	PART	O
and	O	CCONJ	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
12-month	O	ADJ	O
combined	B-I	ADJ	O
strength	I-I	NOUN	O
and	I-I	CCONJ	O
stretching	I-I	VERB	B
home	I-I	NOUN	B
exercise	I-I	NOUN	I
regimen	I-I	NOUN	I
versus	I-I	CCONJ	O
stretching	I-I	NOUN	B
alone	I-I	ADV	O
,	O	PUNCT	O
on	O	ADP	O
patient	B-P	NOUN	B
outcome	I-P	NOUN	I
after	I-P	ADP	O
lumbar	I-P	ADJ	B
disk	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
Departments	B-P	NOUN	I
of	I-P	ADP	O
physical	I-P	ADJ	B
medicine	I-P	NOUN	I
and	I-P	CCONJ	O
rehabilitation	I-P	NOUN	B
and	I-P	CCONJ	O
orthopedics	I-P	NOUN	B
at	I-P	ADP	O
a	I-P	DET	O
Finnish	I-P	ADJ	B
hospital	I-P	NOUN	B
.	I-P	PUNCT	O


PARTICIPANTS	O	ADJ	B
Patients	B-P	NOUN	B
(	I-P	PUNCT	O
N=126	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
randomized	I-P	VERB	B
into	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
combined	B-I	ADJ	O
strength	I-I	NOUN	O
training	I-I	NOUN	B
and	I-I	CCONJ	O
stretching	I-I	VERB	B
group	I-I	NOUN	I
(	O	PUNCT	O
STG	O	PROPN	B
,	O	PUNCT	O
n=65	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
control	B-I	NOUN	B
group	I-I	NOUN	I
(	O	PUNCT	O
CG	O	NOUN	B
,	O	PUNCT	O
n=61	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


INTERVENTION	O	VERB	B
The	O	DET	O
STG	O	PROPN	B
was	O	AUX	O
instructed	O	VERB	O
to	O	PART	O
perform	O	VERB	O
strength	B-I	NOUN	B
training	I-I	NOUN	B
and	O	CCONJ	O
both	O	CCONJ	O
the	O	DET	O
STG	O	PROPN	B
and	O	CCONJ	O
CG	O	NOUN	B
were	O	AUX	O
instructed	O	VERB	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
stretching	B-I	NOUN	B
and	I-I	CCONJ	O
stabilization	I-I	NOUN	B
exercises	I-I	NOUN	I
for	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	B
MEASURES	O	ADJ	B
Pain	O	PROPN	I
on	O	ADP	O
the	O	DET	O
visual	B-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
Oswestry	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Million	I-OUT	NUM	B
disability	I-OUT	NOUN	B
indexes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
isometric	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
dynamic	I-OUT	ADJ	B
trunk	I-OUT	NOUN	I
muscle	I-OUT	NOUN	O
strength	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
mobility	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
lumbar	I-OUT	ADJ	B
spine	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
straight-leg	I-OUT	ADJ	B
raising	I-OUT	NOUN	O
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
completed	O	VERB	O
by	O	ADP	O
71	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
77	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
from	O	ADP	O
the	O	DET	O
STG	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
CG	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	B
strength	I-OUT	NOUN	I
training	I-OUT	NOUN	O
frequency	I-OUT	NOUN	O
decreased	O	VERB	B
from	O	ADP	O
1.5	O	NUM	O
to	O	PART	O
0.6	O	NUM	O
times	O	NOUN	O
a	O	DET	O
week	O	NOUN	B
in	O	ADP	O
the	O	DET	O
STG	O	PROPN	B
during	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	B
stretching	I-OUT	NOUN	I
frequency	I-OUT	NOUN	I
decreased	O	VERB	B
from	O	ADP	O
3.7	O	NUM	O
to	O	PART	O
1.6	O	NUM	O
times	O	NOUN	O
a	O	DET	O
week	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Median	B-OUT	VERB	B
back	I-OUT	ADV	O
and	I-OUT	CCONJ	O
leg	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
varied	O	VERB	O
between	O	ADP	O
17	O	NUM	O
and	O	CCONJ	O
23	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
VAS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Million	B-OUT	NUM	B
and	I-OUT	CCONJ	O
Oswestry	I-OUT	PROPN	B
indices	I-OUT	NOUN	I
varied	O	VERB	O
between	O	ADP	O
14	O	NUM	O
and	O	CCONJ	O
23	O	NUM	O
points	O	NOUN	O
2	O	NUM	O
months	O	NOUN	B
postoperatively	O	ADV	B
.	O	PUNCT	O


No	O	DET	O
statistically	O	ADV	O
significant	O	ADJ	O
changes	O	NOUN	B
took	O	VERB	O
place	O	NOUN	O
in	O	ADP	O
these	O	DET	O
outcome	O	NOUN	B
measures	O	NOUN	I
during	O	ADP	O
the	O	DET	O
12-month	O	ADJ	O
follow-up	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
isometric	B-OUT	ADJ	B
trunk	I-OUT	NOUN	I
extension	I-OUT	NOUN	B
favored	O	VERB	O
the	O	DET	O
STG	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.016	O	NOUN	O
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
whole	O	ADJ	O
12-month	O	ADJ	O
training	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
dynamic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
isometric	I-OUT	ADJ	B
back	I-OUT	NOUN	I
extension	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
flexion	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
mobility	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
spine	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
repetitive	I-OUT	ADJ	B
squat-test	I-OUT	ADJ	I
results	I-OUT	NOUN	B
,	O	PUNCT	O
improved	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
physical	B-OUT	ADJ	B
function	I-OUT	NOUN	I
parameters	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
STG	O	NOUN	B
and	O	CCONJ	O
CG	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
At	O	ADP	O
the	O	DET	O
12-month	O	ADJ	O
follow-up	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
changes	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
physical	B-OUT	ADJ	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
measures	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
STG	O	PROPN	B
,	O	PUNCT	O
training	O	NOUN	B
adherence	O	NOUN	B
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
training	O	NOUN	B
frequency	O	NOUN	I
and	O	CCONJ	O
intensity	O	NOUN	B
remained	O	VERB	O
too	O	ADV	O
low	O	ADJ	O
to	O	PART	O
lead	O	VERB	O
to	O	PART	O
specific	O	ADJ	O
training-induced	O	ADJ	B
adaptations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
neuromuscular	O	ADJ	B
system	O	NOUN	I
.	O	PUNCT	O


Progressive	O	ADJ	B
loading	O	NOUN	B
,	O	PUNCT	O
supervision	O	NOUN	B
of	O	ADP	O
training	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
psychosocial	O	ADJ	B
support	O	NOUN	O
is	O	AUX	O
needed	O	VERB	O
in	O	ADP	O
long-term	O	ADJ	B
rehabilitation	O	NOUN	B
programs	O	NOUN	I
to	O	PART	O
maintain	O	VERB	O
patient	O	NOUN	B
motivation	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
with	O	ADP	O
computed	B-I	VERB	B
tomography	I-I	NOUN	I
of	O	ADP	O
two	O	NUM	O
ultrasound	O	NOUN	B
devices	O	NOUN	I
for	O	ADP	O
diagnosis	O	NOUN	B
of	O	ADP	O
abdominal	B-P	ADJ	B
aortic	I-P	ADJ	I
aneurysm	I-P	NOUN	I
.	I-P	PUNCT	O


Screening	O	VERB	B
for	O	ADP	O
abdominal	B-P	ADJ	B
aortic	I-P	ADJ	I
aneurysms	I-P	NOUN	I
(	I-P	PUNCT	O
AAAs	I-P	NOUN	B
)	I-P	PUNCT	O
in	I-P	ADP	O
patients	I-P	NOUN	B
at	I-P	ADP	O
risk	I-P	NOUN	B
will	O	AUX	O
become	O	VERB	O
more	O	ADV	O
cost	O	NOUN	B
effective	O	ADJ	B
if	O	SCONJ	O
a	O	DET	O
simple	O	ADJ	O
,	O	PUNCT	O
inexpensive	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
reliable	O	ADJ	O
ultrasound	O	NOUN	B
device	O	NOUN	I
is	O	AUX	O
available	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
a	O	DET	O
2-dimensional	O	ADJ	B
,	O	PUNCT	O
handheld	B-I	NOUN	B
ultrasound	I-I	NOUN	I
device	I-I	NOUN	I
and	O	CCONJ	O
a	O	DET	O
newly	O	ADV	O
developed	O	VERB	O
ultrasound	B-I	NOUN	B
volume	I-I	NOUN	I
scanner	I-I	NOUN	I
(	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
bladder	O	NOUN	B
scan	O	NOUN	I
technology	O	NOUN	I
)	O	PUNCT	O
with	O	ADP	O
computed	B-I	ADJ	B
tomography	I-I	NOUN	I
(	I-I	PUNCT	O
CT	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
diagnosing	O	VERB	B
AAA	O	PROPN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
146	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
69	I-P	NUM	O
+/-	I-P	CCONJ	O
10	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
127	I-P	NUM	O
men	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
AAAs	O	NOUN	B
(	O	PUNCT	O
diameter	O	NOUN	B
>	O	X	O
3	O	NUM	O
cm	O	NOUN	O
)	O	PUNCT	O
using	O	VERB	O
CT.	O	NOUN	B
All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
with	O	ADP	O
the	O	DET	O
handheld	O	NOUN	B
ultrasound	O	NOUN	I
device	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
volume	O	NOUN	B
scanner	O	NOUN	I
.	O	PUNCT	O


Maximal	B-OUT	ADJ	B
diameters	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
volumes	I-OUT	NOUN	B
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
analyses	O	NOUN	B
.	O	PUNCT	O


AAAs	O	NOUN	B
were	O	AUX	O
diagnosed	O	VERB	B
by	O	ADP	O
CT	B-I	NOUN	B
in	O	ADP	O
116	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
absolute	B-OUT	ADJ	B
difference	I-OUT	NOUN	O
of	I-OUT	ADP	O
aortic	I-OUT	ADJ	B
diameter	I-OUT	NOUN	B
between	O	ADP	O
ultrasound	B-I	NOUN	B
and	O	CCONJ	O
CT	B-I	NOUN	B
was	O	AUX	O
<	O	X	O
5	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
88	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Limits	O	NOUN	B
of	O	ADP	O
agreement	O	NOUN	O
between	O	ADP	O
ultrasound	O	NOUN	B
and	O	CCONJ	O
CT	B-I	NOUN	B
(	O	PUNCT	O
-6.6	O	NUM	O
to	O	PART	O
9.4	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
exceeded	O	VERB	O
the	O	DET	O
limits	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
acceptability	O	NOUN	I
(	O	PUNCT	O
+/-5	O	NUM	O
mm	O	PROPN	O
)	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
excellent	O	ADJ	B
correlation	B-OUT	NOUN	B
between	O	ADP	O
ultrasound	B-I	NOUN	B
and	O	CCONJ	O
CT	B-I	NOUN	B
was	O	AUX	O
observed	O	VERB	O
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.98	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
correlation	B-OUT	NOUN	B
coefficient	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
volume	O	NOUN	B
scanner	O	NOUN	I
and	O	CCONJ	O
CT	B-I	NOUN	B
was	O	AUX	O
0.86	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
agreement	O	NOUN	O
of	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
kappa	O	NOUN	B
value	O	NOUN	I
of	O	ADP	O
0.73	O	NUM	O
.	O	PUNCT	O


Using	O	VERB	O
an	O	DET	O
optimal	B-OUT	ADJ	B
cut-off	I-OUT	ADJ	B
value	I-OUT	NOUN	I
of	O	ADP	O
>	O	SYM	O
56	O	NUM	O
ml	O	NOUN	O
,	O	PUNCT	O
defined	O	VERB	O
by	O	ADP	O
receiver-operating	B-OUT	ADJ	B
characteristic	I-OUT	ADJ	I
curve	I-OUT	NOUN	I
analysis	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
sensitivity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
specificity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
positive	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
negative	I-OUT	ADJ	B
predictive	I-OUT	ADJ	O
values	I-OUT	NOUN	O
of	O	ADP	O
the	O	DET	O
volume	O	NOUN	B
scanner	O	NOUN	I
for	O	ADP	O
detecting	O	VERB	B
AAA	O	PROPN	B
were	O	AUX	O
90	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
97	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
71	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
2-dimensional	O	ADJ	B
,	O	PUNCT	O
handheld	O	NOUN	B
ultrasound	O	NOUN	I
device	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
newly	O	ADV	O
developed	O	VERB	O
ultrasound	O	NOUN	B
volume	O	NOUN	I
scanner	O	NOUN	I
can	O	AUX	O
effectively	O	ADV	O
identify	O	VERB	O
patients	B-P	NOUN	B
with	I-P	ADP	O
AAAs	I-P	NOUN	B
confirmed	I-P	VERB	O
by	I-P	ADP	O
CT	I-P	NOUN	B
.	I-P	PUNCT	O


Impact	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
fixed	O	ADJ	O
combination	O	NOUN	B
of	O	ADP	O
clindamycin	B-I	NOUN	B
phosphate	I-I	NOUN	B
1.2	I-I	NUM	O
%	I-I	NOUN	O
-benzoyl	I-I	NOUN	O
peroxide	I-I	NOUN	B
2.5	I-I	NUM	O
%	I-I	NOUN	O
aqueous	I-I	ADJ	B
gel	I-I	NOUN	I
on	O	ADP	O
health-related	O	ADJ	B
quality	O	NOUN	I
of	O	ADP	I
life	O	NOUN	I
in	O	ADP	O
moderate	O	ADJ	B
to	O	PART	O
severe	O	ADJ	B
acne	O	NOUN	B
vulgaris	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
acne-specific	O	ADJ	B
quality	O	NOUN	I
of	O	ADP	I
life	O	NOUN	I
(	O	PUNCT	O
Acne-QoL	O	NOUN	B
)	O	PUNCT	O
questionnaire	O	NOUN	B
was	O	AUX	O
developed	O	VERB	O
to	O	PART	O
measure	B-OUT	VERB	B
the	I-OUT	DET	O
impact	I-OUT	NOUN	B
of	I-OUT	ADP	O
facial	I-OUT	ADJ	B
acne	I-OUT	NOUN	I
across	O	ADP	O
4	O	NUM	O
domains	O	NOUN	B
(	O	PUNCT	O
acne	O	NOUN	B
symptoms	O	NOUN	I
,	O	PUNCT	O
role-emotional	O	ADJ	B
,	O	PUNCT	O
self-perception	O	NOUN	B
,	O	PUNCT	O
role-social	O	ADJ	B
)	O	PUNCT	O
of	O	ADP	O
health-related	B-OUT	ADJ	B
quality	I-OUT	NOUN	I
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HRQL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


This	O	DET	O
analysis	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
clindamycin	B-I	NOUN	B
phosphate	I-I	NOUN	B
1.2	I-I	NUM	O
%	I-I	NOUN	O
-benzoyl	I-I	NOUN	O
peroxide	I-I	NOUN	B
2.5	I-I	NUM	O
%	I-I	NOUN	O
(	I-I	PUNCT	O
clindamycin-BPO	I-I	NOUN	B
2.5	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
gel	I-I	NOUN	B
on	O	ADP	O
HRQL	O	NOUN	B
in	O	ADP	O
a	O	DET	O
combined	B-P	ADJ	O
study	I-P	NOUN	O
population	I-P	NOUN	O
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
2813	I-P	NUM	O
)	I-P	PUNCT	O
of	I-P	ADP	O
participants	I-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
acne	I-P	NOUN	B
vulgaris	I-P	NOUN	I
.	I-P	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
results	O	NOUN	B
presented	O	VERB	O
within	O	ADP	O
do	O	AUX	O
not	O	PART	O
include	O	VERB	O
factors	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
and	O	CCONJ	O
study-by-treatment	O	ADJ	B
interaction	O	NOUN	B
,	O	PUNCT	O
analyses	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
to	O	PART	O
confirm	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
results	O	NOUN	B
were	O	AUX	O
consistent	O	ADJ	O
across	O	ADP	O
the	O	DET	O
2	O	NUM	O
identical	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
studies	O	NOUN	I
and	O	CCONJ	O
within	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
across	O	ADP	O
studies	O	NOUN	B
to	O	PART	O
justify	O	VERB	O
pooling	O	VERB	B
the	O	DET	O
data	O	NOUN	B
from	O	ADP	O
both	O	DET	O
studies	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Acne-QoL	B-OUT	NOUN	B
questionnaire	I-OUT	NOUN	I
was	O	AUX	O
administered	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
week	O	NOUN	B
12	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
clindamycin-BPO	B-I	NOUN	B
2.5	O	NUM	I
%	O	NOUN	I
gel	O	NOUN	I
significantly	B-P	ADV	O
improved	I-P	VERB	O
participant-reported	I-P	ADJ	B
HRQL	I-OUT	NOUN	B
across	O	ADP	O
all	O	DET	O
4	O	NUM	O
domains	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
individual	O	ADJ	O
active	O	ADJ	B
ingredients	O	NOUN	I
and	O	CCONJ	O
vehicle	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
percentage	O	NOUN	B
improvement	O	NOUN	B
in	O	ADP	O
mean	B-OUT	ADJ	O
Acne-QoL	I-OUT	NOUN	B
domain	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
with	O	ADP	O
clindamycin-BPO	B-I	NOUN	B
2.5	O	NUM	I
%	O	NOUN	I
gel	O	NOUN	I
ranged	O	VERB	O
from	O	ADP	O
37	O	NUM	O
%	O	NOUN	O
to	O	PART	O
59	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Because	O	SCONJ	O
the	O	DET	O
negative	O	ADJ	B
impact	O	NOUN	B
of	O	ADP	O
facial	O	ADJ	B
acne	O	NOUN	I
on	O	ADP	O
HRQL	B-OUT	NOUN	B
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
motivators	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
to	O	PART	O
seek	O	VERB	O
treatment	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
analysis	O	NOUN	B
underscores	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
physicians	O	NOUN	B
incorporating	O	VERB	O
assessments	O	NOUN	B
of	O	ADP	O
HRQL	O	NOUN	B
into	O	ADP	O
their	O	PRON	O
clinical	O	ADJ	B
decision	O	NOUN	I
making	O	NOUN	I
.	O	PUNCT	O


Enhanced	O	VERB	B
inotropic	O	ADJ	B
state	O	NOUN	I
of	O	ADP	O
the	O	DET	O
failing	O	ADJ	B
left	O	VERB	B
ventricle	O	NOUN	I
by	O	ADP	O
cardiac	B-I	ADJ	B
contractility	I-I	NOUN	I
modulation	I-I	NOUN	I
electrical	I-I	ADJ	B
signals	I-I	NOUN	I
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
myocardial	B-OUT	ADJ	B
oxygen	I-OUT	NOUN	I
consumption	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


BACKGROUND	O	NOUN	O
Previous	O	ADJ	O
studies	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
and	I-P	CCONJ	O
in	I-P	ADP	O
dogs	I-P	NOUN	B
with	I-P	ADP	O
experimentally	I-P	ADV	B
induced	I-P	VERB	B
heart	I-P	NOUN	B
failure	I-P	NOUN	I
(	I-P	PUNCT	O
HF	I-P	NOUN	B
)	I-P	PUNCT	O
showed	O	VERB	O
that	O	SCONJ	O
electrical	B-I	ADJ	B
signals	I-I	NOUN	I
applied	O	VERB	O
to	O	ADP	O
the	O	DET	O
failing	O	ADJ	B
myocardium	O	NOUN	B
during	O	ADP	O
the	O	DET	O
absolute	O	ADJ	B
refractory	O	ADJ	B
period	O	NOUN	B
improved	O	VERB	O
left	B-OUT	VERB	B
ventricular	I-OUT	ADJ	I
(	I-OUT	PUNCT	I
LV	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
function	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
these	O	DET	O
same	O	ADJ	O
cardiac	B-I	ADJ	B
contractility	I-I	NOUN	I
modulating	I-I	NOUN	I
(	I-I	PUNCT	O
CCM	I-I	NOUN	B
)	I-I	PUNCT	O
electrical	I-I	ADJ	B
signals	I-I	NOUN	I
on	O	ADP	O
myocardial	B-OUT	ADJ	B
oxygen	I-OUT	NOUN	I
consumption	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
MVO	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
in	O	ADP	O
both	B-P	DET	O
patients	I-P	NOUN	B
and	I-P	CCONJ	O
dogs	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
HF	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	VERB	O
Six	B-P	NUM	O
dogs	I-P	NOUN	B
with	I-P	ADP	O
microembolizations-induced	I-I	ADJ	B
HF	I-I	NOUN	I
and	I-P	CCONJ	O
9	I-P	NUM	O
HF	I-P	NOUN	B
patients	I-P	NOUN	B
underwent	I-P	VERB	O
CCM	I-I	NOUN	B
leads	I-I	VERB	O
and	I-I	CCONJ	O
generator	I-I	NOUN	B
(	I-I	PUNCT	O
OPTIMIZER	I-I	NOUN	B
II	I-I	NUM	I
)	I-I	PUNCT	O
implantation	I-I	NOUN	B
.	I-I	PUNCT	O


After	O	ADP	O
baseline	O	NOUN	B
measurements	O	NOUN	B
,	O	PUNCT	O
CCM	B-I	NOUN	B
signals	I-I	NOUN	B
were	O	AUX	O
delivered	O	VERB	O
continuously	O	ADV	O
for	O	ADP	O
2	O	NUM	O
hours	O	NOUN	B
in	O	ADP	O
dogs	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


MVO	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
was	O	AUX	O
measured	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
CCM	B-I	NOUN	B
therapy	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
dogs	O	NOUN	B
,	O	PUNCT	O
CCM	B-I	NOUN	B
therapy	I-I	NOUN	B
increased	O	VERB	B
LV	B-OUT	NOUN	B
ejection	I-OUT	NOUN	I
fraction	I-OUT	NOUN	I
at	O	ADP	O
2	O	NUM	O
hours	O	NOUN	B
(	O	PUNCT	O
26	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
versus	O	CCONJ	O
31	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.001	O	NUM	O
)	O	PUNCT	O
without	O	ADP	O
increasing	O	VERB	B
MVO	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
(	O	PUNCT	O
257	O	NUM	O
+/-	O	CCONJ	O
41	O	NUM	O
versus	O	CCONJ	O
180	O	NUM	O
+/-	O	CCONJ	O
34	O	NUM	O
micromol/min	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
CCM	B-I	NOUN	B
therapy	I-I	NOUN	B
increased	O	VERB	B
LV	B-OUT	NOUN	B
peak	I-OUT	NOUN	O
+dP/dt	I-OUT	NOUN	O
by	O	ADP	O
10.1	O	NUM	O
+/-	O	CCONJ	O
1.5	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


As	O	ADP	O
with	O	ADP	O
dogs	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
LV	B-OUT	NOUN	B
function	I-OUT	NOUN	I
after	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	O
of	O	ADP	O
CCM	B-I	NOUN	B
therapy	I-I	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
MVO	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
(	O	PUNCT	O
13.6	O	NUM	O
+/-	O	CCONJ	O
9.7	O	NUM	O
versus	O	CCONJ	O
12.5	O	NUM	O
+/-	O	CCONJ	O
7.2	O	NUM	O
mL	O	NOUN	O
O	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/min	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
unlike	O	ADP	O
cAMP-dependent	O	ADJ	B
positive	O	ADJ	I
inotropic	O	ADJ	I
drugs	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
LV	B-OUT	NOUN	B
function	I-OUT	NOUN	I
during	O	ADP	O
CCM	B-I	NOUN	B
therapy	I-I	NOUN	B
is	O	AUX	O
elicited	O	VERB	O
without	O	ADP	O
increasing	O	VERB	B
MVO	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Clomipramine	B-I	NOUN	B
versus	I-I	CCONJ	O
haloperidol	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
autistic	B-P	ADJ	B
disorder	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Clomipramine	B-I	NOUN	B
,	I-I	PUNCT	O
haloperidol	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
autism	B-P	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
overall	B-OUT	ADJ	O
outcome	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
specific	I-OUT	ADJ	O
symptoms	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
examined	O	VERB	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
hypothesized	O	VERB	O
that	O	SCONJ	O
clomipramine	B-I	NOUN	B
would	O	AUX	O
be	O	AUX	O
better	O	ADV	O
tolerated	O	VERB	B
than	O	ADP	O
haloperidol	B-I	NOUN	B
and	O	CCONJ	O
prove	O	VERB	O
superior	O	ADJ	B
on	O	ADP	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
stereotypy	O	NOUN	B
.	O	PUNCT	O


Individuals	B-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
DSM-IV	I-P	NOUN	B
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
mean	I-P	NOUN	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
16.3	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
range	I-P	NOUN	O
,	I-P	PUNCT	O
10-36	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
,	I-P	PUNCT	O
by	I-P	ADP	O
using	I-P	VERB	O
a	I-P	DET	O
Latin	I-P	ADJ	B
square	I-P	ADJ	I
design	I-P	NOUN	B
,	I-P	PUNCT	O
to	I-P	ADP	O
the	I-P	DET	O
following	I-P	VERB	O
7-week	I-P	ADJ	B
trials	I-P	NOUN	I
:	I-P	PUNCT	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
clomipramine	I-I	NOUN	B
(	I-P	PUNCT	O
mean	I-P	VERB	O
daily	I-P	ADJ	O
dose	I-P	NOUN	O
,	I-P	PUNCT	O
128.4	I-P	NUM	O
mg	I-P	NOUN	O
;	I-P	PUNCT	O
range	I-P	NOUN	O
,	I-P	PUNCT	O
100-150	I-P	NUM	O
mg	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
haloperidol	I-I	NOUN	B
(	I-P	PUNCT	O
mean	I-P	VERB	O
daily	I-P	ADJ	O
dose	I-P	NOUN	O
,	I-P	PUNCT	O
1.3	I-P	NUM	O
mg	I-P	NOUN	O
;	I-P	PUNCT	O
range	I-P	NOUN	O
,	I-P	PUNCT	O
1-1.5	I-P	NUM	O
mg	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Data	B-P	NOUN	B
on	I-P	ADP	O
36	I-P	NUM	O
subjects	I-P	NOUN	B
were	I-P	AUX	O
analyzed	I-P	VERB	B
and	O	CCONJ	O
taken	O	VERB	O
together	O	ADV	O
;	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
favored	O	VERB	O
haloperidol	B-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
complete	O	VERB	O
a	O	DET	O
full	O	ADJ	O
therapeutic	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
clomipramine	B-I	NOUN	B
proved	O	VERB	O
comparable	O	ADJ	O
to	O	PART	O
haloperidol	B-I	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
improvement	B-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
significantly	O	ADV	O
fewer	O	ADJ	O
individuals	O	NOUN	B
receiving	O	VERB	O
clomipramine	B-I	NOUN	B
versus	O	CCONJ	O
haloperidol	B-I	NOUN	B
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
complete	O	VERB	O
the	O	DET	O
trial	O	NOUN	B
(	O	PUNCT	O
37.5	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
69.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
for	O	ADP	O
reasons	O	NOUN	O
related	O	VERB	O
to	O	PART	O
both	O	DET	O
side	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
behavior	I-OUT	NOUN	B
problems	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
intent-to-treat	O	ADJ	B
sample	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
perhaps	O	ADV	O
more	O	ADV	O
clinically	O	ADV	B
relevant	O	ADJ	O
,	O	PUNCT	O
only	O	ADV	O
haloperidol	B-I	NOUN	B
proved	O	VERB	O
superior	O	ADJ	O
to	O	PART	O
baseline	O	NOUN	B
on	O	ADP	O
a	O	DET	O
global	O	ADJ	B
measure	O	NOUN	I
of	O	ADP	O
autistic	B-OUT	ADJ	B
symptom	I-OUT	NOUN	O
severity	I-OUT	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
specific	O	ADJ	O
measures	O	NOUN	B
for	O	ADP	O
irritability	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
hyperactivity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Clomipramine	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
seem	O	VERB	O
more	O	ADV	O
effective	O	ADJ	B
on	O	ADP	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
stereotypy	O	NOUN	B
,	O	PUNCT	O
nor	O	CCONJ	O
was	O	AUX	O
it	O	PRON	O
better	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


[	O	PUNCT	O
Clinical	O	ADJ	B
trials	O	NOUN	I
with	O	ADP	O
pirprofen	B-I	NOUN	B
and	I-I	CCONJ	O
naproxen	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
gonarthrosis	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
coxarthrosis	I-OUT	NOUN	B
]	I-OUT	PUNCT	O
.	O	PUNCT	O


Topical	O	ADJ	B
adrenaline	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
intraoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	O
in	O	ADP	O
adenoidectomy	B-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
topical	O	ADJ	B
racemic	B-I	ADJ	O
adrenaline	I-I	NOUN	B
(	I-I	PUNCT	O
RA	I-I	NOUN	B
)	I-I	PUNCT	O
(	O	PUNCT	O
Micronefrin	O	PROPN	B
;	O	PUNCT	O
Bird	O	PROPN	B
Products	O	PROPN	I
,	O	PUNCT	O
Palm	O	PROPN	B
Springs	O	PROPN	I
,	O	PUNCT	O
CA	O	PROPN	B
,	O	PUNCT	O
USA	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
intraoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
prevention	I-OUT	NOUN	B
of	I-OUT	ADP	O
postoperative	I-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
laryngeal	I-OUT	ADJ	B
spasm	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
in	O	ADP	O
adenoidectomy	B-P	NOUN	B
among	I-P	ADP	O
children	I-P	NOUN	B
<	I-P	PROPN	O
6	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Prospective	O	ADJ	B
,	O	PUNCT	O
randomised	O	VERB	B
,	O	PUNCT	O
blinded	O	VERB	B
and	O	CCONJ	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	B
Kanta-Hame	B-P	PROPN	I
Central	I-P	PROPN	I
Hospital	I-P	PROPN	I
,	I-P	PUNCT	O
a	I-P	DET	O
district	I-P	NOUN	B
referral	I-P	NOUN	O
center	I-P	NOUN	O
in	I-P	ADP	O
Finland	I-P	PROPN	B
.	I-P	PUNCT	O


PATIENTS	O	VERB	B
A	O	DET	O
consecutive	O	ADJ	B
sample	O	NOUN	B
of	O	ADP	O
93	B-P	NUM	O
children	I-P	NOUN	B
undergoing	I-P	VERB	O
outpatient	I-P	ADJ	B
adenoidectomy	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTION	O	NOUN	B
Patients	O	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
topical	B-I	ADJ	B
gauze	I-I	NOUN	O
sponges	I-I	NOUN	B
soaked	I-I	VERB	B
in	I-I	ADP	O
either	I-I	CCONJ	O
1:500	I-I	NUM	B
RA	I-I	NOUN	I
or	I-I	CCONJ	O
0.9	I-I	NUM	O
%	I-I	NOUN	O
sodium	I-I	NOUN	B
chloride	I-I	NOUN	I
(	I-I	PUNCT	O
physiological	I-I	ADJ	B
saline	I-I	NOUN	I
)	I-I	PUNCT	O
for	I-I	ADP	O
3	I-I	NUM	O
min	I-I	NOUN	O
after	I-I	ADP	O
adenoidectomy	I-I	NOUN	B
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	X	B
MEASURES	O	NOUN	O
Amount	O	PROPN	B
of	O	ADP	O
intraoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
(	O	PUNCT	O
surgeons	O	NOUN	B
'	O	PART	O
subjective	O	ADJ	O
estimate	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
need	B-OUT	VERB	O
for	I-OUT	ADP	O
additional	I-OUT	ADJ	O
packings	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
need	I-OUT	VERB	O
for	I-OUT	ADP	O
electrocautery	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
laryngeal	I-OUT	ADJ	B
spasm	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
postoperative	I-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	I
procedure	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
'	I-OUT	PART	O
stay	I-OUT	VERB	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
operation	I-OUT	NOUN	B
room	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Adrenaline	B-I	NOUN	B
significantly	O	ADV	O
decreased	O	VERB	B
surgeons	O	NOUN	B
'	O	PART	O
subjective	O	ADJ	O
estimate	O	NOUN	B
of	O	ADP	O
the	O	DET	O
amount	B-OUT	NOUN	B
of	I-OUT	ADP	O
intraoperative	I-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
(	O	PUNCT	O
proportion	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
significant	O	ADJ	O
decrease	O	NOUN	B
67	O	NUM	O
versus	O	CCONJ	O
21	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
reduced	O	VERB	B
the	O	DET	O
mean	O	ADJ	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
packings	I-OUT	NOUN	B
needed	I-OUT	VERB	O
(	O	PUNCT	O
0.6	O	NUM	O
versus	O	CCONJ	O
1.2	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
use	B-OUT	NOUN	O
of	I-OUT	ADP	O
electrocautery	I-OUT	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
versus	O	CCONJ	O
45	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.015	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
shortened	O	VERB	B
the	O	DET	O
mean	O	ADJ	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
procedure	I-OUT	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
versus	O	CCONJ	O
18	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.043	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
mean	O	NOUN	O
stay	B-OUT	NOUN	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
OR	I-OUT	NOUN	B
(	O	PUNCT	O
31	O	NUM	O
versus	O	CCONJ	O
35	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.058	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
adrenaline	B-I	NOUN	B
was	O	AUX	O
even	O	ADV	O
more	O	ADV	O
pronounced	O	ADJ	O
among	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
extensive	I-P	ADJ	B
adenoids	I-OUT	NOUN	B
and/or	I-P	CCONJ	O
profuse	I-P	ADJ	B
intraoperative	I-OUT	ADJ	O
bleeding	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


A	O	DET	O
slight	O	ADJ	O
elevation	B-OUT	NOUN	B
of	I-OUT	ADP	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
more	O	ADV	O
often	O	ADV	O
in	O	ADP	O
the	O	DET	O
adrenaline	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.043	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Use	O	PROPN	O
of	O	ADP	O
topical	O	ADJ	B
adrenaline	B-I	NOUN	B
can	O	AUX	O
be	O	AUX	O
recommended	O	VERB	B
in	O	ADP	O
adenoidectomy	B-P	NOUN	B
among	I-P	ADP	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


It	O	PRON	O
helps	O	VERB	O
control	O	VERB	B
the	O	DET	O
intraoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	O
,	O	PUNCT	O
reduces	O	VERB	B
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
electrocautery	B-OUT	NOUN	B
and	O	CCONJ	O
shortens	O	VERB	B
the	O	DET	O
durations	O	NOUN	B
of	O	ADP	O
procedure	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
stay	I-OUT	VERB	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
OR	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
double-blind	O	ADJ	I
control	O	NOUN	I
study	O	NOUN	I
of	O	ADP	O
early	O	ADJ	B
intracoronary	B-I	ADJ	B
autologous	I-I	ADJ	B
bone	I-I	NOUN	I
marrow	I-I	NOUN	I
cell	I-I	NOUN	I
infusion	I-I	NOUN	B
in	O	ADP	O
acute	B-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
(	O	PUNCT	O
REGENERATE-AMI	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


INTRODUCTION	O	PROPN	O
Acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
(	O	PUNCT	O
AMI	O	NOUN	B
)	O	PUNCT	O
remains	O	VERB	O
a	O	DET	O
major	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
mortality	O	NOUN	B
and	O	CCONJ	O
morbidity	O	NOUN	B
worldwide	O	ADV	O
despite	O	SCONJ	O
the	O	DET	O
latest	O	ADJ	O
therapeutic	O	ADJ	B
advances	O	NOUN	O
designed	O	VERB	O
to	O	PART	O
decrease	O	VERB	B
myocardial	O	ADJ	B
injury	O	NOUN	I
.	O	PUNCT	O


Preclinical	O	ADJ	B
and	O	CCONJ	O
emerging	O	VERB	O
clinical	O	ADJ	B
evidence	O	NOUN	I
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
intracoronary	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
autologous	B-I	ADJ	B
bone	I-I	NOUN	I
marrow	I-I	NOUN	I
mononuclear	I-I	ADJ	I
cells	I-I	NOUN	I
(	O	PUNCT	O
BMCs	O	NOUN	B
)	O	PUNCT	O
following	O	VERB	O
AMI	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
improvement	O	NOUN	B
in	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
ejection	O	NOUN	I
function	O	NOUN	I
(	O	PUNCT	O
LVEF	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
we	O	PRON	O
will	O	AUX	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
assess	O	VERB	O
the	O	DET	O
effect	B-OUT	NOUN	B
of	O	ADP	O
early	O	ADJ	B
(	O	PUNCT	O
<	O	X	O
24	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
infusion	O	NOUN	B
of	O	ADP	O
autologous	O	ADJ	B
BMCs	O	NOUN	B
following	O	VERB	O
AMI	O	NOUN	B
on	O	ADP	O
cardiac	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
ANALYSIS	O	ADJ	B
REGENERATE-AMI	O	PROPN	B
is	O	AUX	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
,	O	PUNCT	O
multicentre	B-P	NOUN	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
early	O	ADJ	B
(	O	PUNCT	O
<	O	X	O
24	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
intracoronary	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
BMCs	O	NOUN	B
improves	O	VERB	O
LVEF	O	NOUN	B
after	O	ADP	O
AMI	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
will	O	AUX	O
enrol	B-P	VERB	B
100	I-P	NUM	O
patients	I-P	NOUN	B
presenting	I-P	VERB	O
with	I-P	ADP	O
an	I-P	DET	O
anterior	I-P	ADJ	B
AMI	I-P	PROPN	B
demonstrating	I-P	VERB	O
anterior	I-P	ADJ	B
regional	I-P	ADJ	O
wall	I-P	NOUN	O
motion	I-P	NOUN	O
abnormality	I-P	NOUN	O
.	I-P	PUNCT	O


Patients	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
intracoronary	B-I	ADJ	B
infusion	I-I	NOUN	B
of	I-I	ADP	O
BMCs	I-I	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
0.9	O	NUM	O
%	O	NOUN	O
saline	B-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Primary	O	ADJ	B
endpoint	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
change	B-OUT	NOUN	O
in	I-OUT	ADP	O
LVEF	I-OUT	NOUN	B
at	I-OUT	ADP	O
1	I-OUT	NUM	O
year	I-OUT	NOUN	B
compared	I-OUT	VERB	B
to	I-OUT	PART	O
baseline	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
measured	I-OUT	VERB	B
by	I-OUT	ADP	O
cardiac	I-OUT	ADJ	B
MRI	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Secondary	O	ADJ	B
endpoints	O	NOUN	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
include	O	VERB	O
the	O	DET	O
change	B-OUT	NOUN	O
in	I-OUT	ADP	O
global	I-OUT	ADJ	B
LVEF	I-OUT	NOUN	B
relative	I-OUT	ADJ	O
to	I-OUT	PART	O
baseline	I-OUT	NOUN	B
measured	I-OUT	VERB	B
by	I-OUT	ADP	O
quantitative	I-OUT	ADJ	B
left	I-OUT	ADJ	I
ventriculography	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
echocardiography	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
major	I-OUT	ADJ	O
adverse	I-OUT	ADJ	B
cardiac	I-OUT	ADJ	I
events	I-OUT	NOUN	I
which	O	DET	O
is	O	AUX	O
also	O	ADV	O
measured	O	VERB	B
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


ETHICS	O	NOUN	O
AND	O	CCONJ	O
DISSEMINATION	O	PROPN	B
The	O	DET	O
study	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
agreement	O	NOUN	O
with	O	ADP	O
the	O	DET	O
Declaration	O	PROPN	B
of	O	ADP	I
Helsinki	O	PROPN	I
and	O	CCONJ	O
is	O	AUX	O
approved	O	VERB	O
by	O	ADP	O
local	O	ADJ	B
ethics	O	NOUN	I
committee	O	NOUN	I
(	O	PUNCT	O
NRES	O	PROPN	O
Committee	O	PROPN	O
London	O	PROPN	O
West	O	PROPN	O
London	O	PROPN	O
:	O	PUNCT	O
07/Q0603/76	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


TRIAL	O	NOUN	B
REGISTRATION	O	NOUN	I
http	O	NOUN	I
:	O	PUNCT	O
//clincialtrials.gov	O	NOUN	O
(	O	PUNCT	O
NCT00765453	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
published	O	VERB	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
CONSORT	O	PROPN	B
statement	O	NOUN	B
and	O	CCONJ	O
will	O	AUX	O
be	O	AUX	O
presented	O	VERB	O
at	O	ADP	O
conferences	O	NOUN	B
and	O	CCONJ	O
reported	O	VERB	O
in	O	ADP	O
peer-reviewed	O	ADJ	B
journals	O	NOUN	I
.	O	PUNCT	O


Skin	B-OUT	NOUN	B
manifestations	I-OUT	NOUN	B
of	I-OUT	ADP	O
inhaled	I-OUT	ADJ	B
corticosteroids	I-OUT	NOUN	I
in	O	ADP	O
COPD	B-P	NOUN	B
patients	I-P	NOUN	B
:	I-P	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
Lung	O	PROPN	B
Health	O	PROPN	I
Study	O	PROPN	I
II	O	PROPN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
define	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
skin	B-OUT	NOUN	B
bruising	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
other	I-OUT	ADJ	O
cutaneous	I-OUT	ADJ	B
manifestations	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
and	O	CCONJ	O
inhaled	O	VERB	B
corticosteroid	B-I	NOUN	I
(	I-I	PUNCT	O
ICS	I-I	NOUN	B
)	I-I	PUNCT	O
therapy	O	NOUN	B
vs	O	CCONJ	O
placebo	O	NOUN	B
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
COPD	I-P	NOUN	B
who	O	PRON	O
were	O	AUX	O
participating	O	VERB	O
in	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
explore	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
easy	B-OUT	ADJ	O
skin	I-OUT	NOUN	B
bruising	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
other	I-OUT	ADJ	O
systemic	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
of	I-OUT	ADP	O
ICS	I-OUT	NOUN	B
therapy	I-OUT	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
adrenal	B-OUT	ADJ	B
suppression	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
loss	I-OUT	NOUN	B
of	I-OUT	ADP	O
bone	I-OUT	NOUN	B
mineral	I-OUT	ADJ	I
density	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BMD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
Double-blind	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
triamcinolone	B-I	NOUN	B
acetonide	I-I	NOUN	B
(	O	PUNCT	O
1200	O	NUM	O
microg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
vs	O	CCONJ	O
placebo	B-I	NOUN	B
in	O	ADP	O
participants	B-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
COPD	I-P	NOUN	B
.	I-P	PUNCT	O


SETTING	O	VERB	O
Lung	O	PROPN	B
Health	O	PROPN	I
Study	O	PROPN	I
II	O	PROPN	I
,	O	PUNCT	O
a	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
ICS	B-I	NOUN	B
compared	O	VERB	B
to	O	PART	O
placebo	B-I	NOUN	B
in	O	ADP	O
1,116	B-P	NUM	O
participants	I-P	NOUN	B
in	I-P	ADP	O
10	I-P	NUM	O
centers	I-P	NOUN	B
over	I-P	ADP	O
>	I-P	SYM	O
3.5	I-P	NUM	O
to	I-P	PART	O
4.5	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


PARTICIPANTS	O	VERB	B
A	B-P	DET	I
total	I-P	NOUN	O
of	I-P	ADP	O
1,116	I-P	NUM	O
smokers	I-P	NOUN	B
or	I-P	CCONJ	O
recent	I-P	ADJ	O
ex-smokers	I-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
COPD	I-P	NOUN	B
(	I-P	PUNCT	O
age	I-P	NOUN	B
range	I-P	NOUN	O
,	I-P	PUNCT	O
40	I-P	NUM	O
to	I-P	PART	O
69	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
56.3	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
37.2	I-P	NUM	O
%	I-P	NOUN	O
female	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	VERB	O
Every	O	DET	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
structured	O	ADJ	B
questionnaire	O	NOUN	I
was	O	AUX	O
administered	O	VERB	B
to	O	PART	O
elicit	O	VERB	O
reports	O	NOUN	B
of	O	ADP	O
any	O	DET	O
bruising	B-OUT	NOUN	B
and/or	I-OUT	CCONJ	O
skin	I-OUT	NOUN	B
rashes	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
slow	I-OUT	ADJ	B
healing	I-OUT	NOUN	I
of	I-OUT	ADP	O
cuts	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
sores	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
other	I-OUT	ADJ	O
skin	I-OUT	NOUN	B
changes	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Compliance	O	NOUN	B
with	O	ADP	O
inhaler	O	NOUN	B
use	O	NOUN	O
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
canister	O	NOUN	B
weighing	O	VERB	I
.	O	PUNCT	O


A	O	DET	O
significantly	O	ADV	B
higher	O	ADJ	I
proportion	O	NOUN	B
of	O	ADP	O
ICS	B-I	NOUN	B
than	O	ADP	O
placebo	B-I	NOUN	B
participants	O	NOUN	B
who	O	PRON	O
complied	O	VERB	O
with	O	ADP	O
using	O	VERB	O
their	O	PRON	O
inhaler	O	NOUN	B
reported	O	VERB	O
easy	B-OUT	ADJ	O
bruising	I-OUT	NOUN	B
(	O	PUNCT	O
11.2	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
3.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
slow	B-OUT	ADJ	B
healing	I-OUT	NOUN	I
of	I-OUT	ADP	O
skin	I-OUT	NOUN	B
cuts	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
sores	I-OUT	NOUN	B
(	O	PUNCT	O
2.4	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
0.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Older	B-P	ADJ	B
men	I-P	NOUN	I
in	O	ADP	O
the	O	DET	O
ICS	B-I	NOUN	B
group	O	NOUN	B
with	O	ADP	O
good	O	ADJ	O
inhaler	O	NOUN	B
compliance	O	NOUN	B
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
at	O	ADP	O
the	O	DET	O
greatest	O	ADJ	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
bruising	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
those	O	DET	O
participants	O	NOUN	B
undergoing	O	VERB	O
serial	O	ADJ	O
measurements	O	NOUN	B
of	O	ADP	O
adrenal	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
BMD	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
association	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
between	O	ADP	O
skin	B-OUT	NOUN	B
bruising	I-OUT	NOUN	I
and	O	CCONJ	O
either	O	CCONJ	O
the	O	DET	O
suppression	B-OUT	NOUN	B
of	I-OUT	ADP	O
adrenal	I-OUT	ADJ	B
function	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
the	I-OUT	DET	O
loss	I-OUT	NOUN	B
of	I-OUT	ADP	O
BMD	I-OUT	NOUN	B
as	O	ADP	O
systemic	O	ADJ	B
complications	O	NOUN	I
of	O	ADP	O
ICS	O	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
moderate-to-high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
ICSs	O	NOUN	B
result	O	VERB	B
in	O	ADP	O
an	O	DET	O
increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
easy	B-OUT	ADJ	O
bruising	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
impairment	I-OUT	NOUN	B
in	I-OUT	ADP	O
skin	I-OUT	NOUN	B
healing	I-OUT	NOUN	I
in	O	ADP	O
middle-aged	B-P	ADJ	B
to	I-P	PART	O
elderly	I-P	ADJ	B
persons	I-P	NOUN	I
with	I-P	ADP	O
COPD	I-P	NOUN	B
.	I-P	PUNCT	O


No	O	DET	O
association	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
between	O	ADP	O
skin	B-OUT	NOUN	B
bruising	I-OUT	NOUN	I
and	O	CCONJ	O
other	O	ADJ	O
markers	O	NOUN	B
of	O	ADP	O
systemic	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
from	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
ICSs	B-I	NOUN	B
.	O	PUNCT	O


A	O	DET	O
multicenter	O	NOUN	B
investigation	O	NOUN	B
of	O	ADP	O
lorazepam	B-I	NOUN	B
in	I-P	ADP	O
anxiety	I-OUT	NOUN	B
neurosis	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Recurrent	O	ADJ	B
ulcer	O	NOUN	I
after	O	ADP	O
successful	O	ADJ	O
treatment	O	NOUN	B
with	O	ADP	O
cimetidine	B-I	NOUN	B
or	O	CCONJ	O
antacid	B-I	NOUN	B
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
rates	O	NOUN	B
of	O	ADP	O
duodenal	O	ADJ	B
ulcer	O	NOUN	I
healing	O	NOUN	O
and	O	CCONJ	O
recurrence	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
cimetidine	B-I	NOUN	B
or	I-I	CCONJ	O
antacid	I-I	NOUN	B
.	I-I	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
endoscopically	I-P	ADV	B
documented	I-P	VERB	I
duodenal	I-P	ADJ	B
ulcer	I-P	NOUN	I
received	O	VERB	O
cimetidine	B-I	NOUN	B
,	O	PUNCT	O
1200	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
,	O	PUNCT	O
or	B-I	CCONJ	O
Mylanta	I-I	PROPN	B
II	I-I	PROPN	I
,	O	PUNCT	O
7	O	NUM	O
oz	O	NOUN	O
daily	O	ADV	B
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
69	B-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
each	I-P	DET	O
group	I-P	NOUN	B
who	O	PRON	O
completed	O	VERB	O
the	O	DET	O
healing	O	NOUN	B
phase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
,	O	PUNCT	O
endoscopic	O	ADJ	B
ulcer	O	NOUN	I
healing	O	NOUN	I
was	O	AUX	O
almost	O	ADV	O
identical	O	ADJ	B
.	O	PUNCT	O


At	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
6	O	NUM	O
wk	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
cumulative	O	ADJ	B
percent	O	NOUN	O
healed	O	VERB	B
on	O	ADP	O
antacid	B-I	NOUN	B
was	O	AUX	O
33	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
64	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
80	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
cimetidine	B-I	NOUN	B
it	O	PRON	O
was	O	AUX	O
25	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
86	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
114	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
healed	I-P	VERB	B
ulcer	I-P	NOUN	I
were	O	AUX	O
observed	O	VERB	O
on	O	ADP	O
no	O	DET	O
therapy	O	NOUN	B
and	O	CCONJ	O
underwent	O	VERB	O
additional	O	ADJ	O
endoscopy	O	NOUN	B
to	O	PART	O
detect	O	VERB	B
recurrences	O	NOUN	B
when	O	SCONJ	O
symptomatic	O	ADJ	B
or	O	CCONJ	O
at	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
mo	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
recurrences	I-OUT	NOUN	B
between	O	ADP	O
treatments	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
mo	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
cumulative	B-OUT	ADJ	B
percentages	I-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
recurrence	I-OUT	NOUN	B
were	O	AUX	O
29	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
56	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
antacid	B-I	NOUN	B
therapy	I-I	NOUN	I
and	O	CCONJ	O
36	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
55	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
cimetidine	B-I	NOUN	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


Some	O	DET	O
patient	O	NOUN	B
variables	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
delayed	B-OUT	VERB	B
ulcer	I-OUT	NOUN	B
healing	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
ulcer	I-OUT	NOUN	B
recurrence	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
included	O	VERB	O
sex	O	NOUN	B
,	O	PUNCT	O
pain	O	NOUN	B
frequency	O	NOUN	I
,	O	PUNCT	O
smoking	O	NOUN	B
,	O	PUNCT	O
disease	O	NOUN	B
duration	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
acid	O	NOUN	B
secretion	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Observation	O	NOUN	B
on	O	ADP	O
therapeutic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
electroacupuncture	B-I	NOUN	B
plus	I-I	CCONJ	O
blood-letting	I-I	ADJ	B
puncture	I-I	NOUN	I
and	I-I	CCONJ	O
cupping	I-I	NOUN	B
combined	I-I	VERB	B
with	I-I	ADP	O
diet	I-I	ADJ	B
intervention	I-I	NOUN	I
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
acute	B-P	ADJ	B
gouty	I-P	NOUN	I
arthritis	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
explore	O	VERB	O
a	O	DET	O
more	O	ADV	O
effective	O	ADJ	B
therapy	O	NOUN	B
for	O	ADP	O
acute	B-P	ADJ	B
gouty	I-P	NOUN	I
arthritis	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Sixty	B-P	NUM	O
cases	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
an	O	DET	O
observation	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
30	O	NUM	O
cases	O	NOUN	B
in	O	ADP	O
eachgroup	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
diet	B-I	ADJ	B
intervention	I-I	NOUN	I
,	O	PUNCT	O
the	O	DET	O
observation	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
electroacupuncture	B-I	NOUN	B
at	I-I	ADP	O
local	I-I	ADJ	B
points	I-I	NOUN	I
combined	I-I	VERB	O
with	I-I	ADP	O
blood-letting	I-I	ADJ	B
puncture	I-I	NOUN	I
and	I-I	CCONJ	O
cupping	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
with	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
Probenecid	B-I	NOUN	B
.	I-I	PUNCT	O


Their	O	PRON	O
therapeutic	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
ob	O	PART	B
served	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
effective	O	ADJ	B
rate	O	NOUN	B
was	O	AUX	O
96.7	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
group	O	NOUN	I
which	O	DET	O
was	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
86.7	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
blood	B-OUT	NOUN	B
uric	I-OUT	ADJ	I
acid	I-OUT	NOUN	I
decreased	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
both	O	DET	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
observed	O	VERB	O
group	O	NOUN	B
being	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
diet	B-I	ADJ	B
intervention	I-I	NOUN	I
,	I-I	PUNCT	O
electroacupuncture	I-I	NOUN	B
plus	I-I	CCONJ	I
blood-letting	I-I	ADJ	B
puncture	I-I	NOUN	I
and	I-I	CCONJ	O
cupping	I-I	NOUN	B
is	O	AUX	O
a	O	DET	O
better	O	ADJ	O
therapy	O	NOUN	B
for	O	ADP	O
acute	O	ADJ	B
gouty	O	NOUN	I
arthritis	O	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
Positive	B-I	ADJ	B
Action	I-I	PROPN	I
on	O	ADP	O
the	O	DET	O
emotional	O	ADJ	B
health	O	NOUN	I
of	O	ADP	O
urban	B-P	ADJ	B
youth	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
cluster-randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	VERB	B
We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
Positive	B-I	ADJ	B
Action	I-I	PROPN	I
(	I-I	PUNCT	O
PA	I-I	PROPN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
school-based	B-I	ADJ	B
social-emotional	I-I	ADJ	O
learning	I-I	NOUN	O
and	I-I	CCONJ	O
health	I-I	NOUN	B
promotion	I-I	NOUN	I
program	I-I	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
emotional	O	ADJ	B
health	O	NOUN	O
of	O	ADP	O
predominately	B-P	ADV	O
low-income	I-P	ADJ	B
and	I-P	CCONJ	O
ethnic	I-P	ADJ	B
minority	I-P	NOUN	I
urban	I-P	ADJ	B
youth	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
matched-pair	O	ADJ	B
,	O	PUNCT	O
cluster-randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
involving	O	VERB	O
14	B-P	NUM	O
Chicago	I-P	PROPN	B
public	I-P	ADJ	I
schools	I-P	NOUN	I
.	I-P	PUNCT	O


Outcomes	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
over	O	ADP	O
a	O	DET	O
6-year	B-P	ADJ	O
period	I-P	NOUN	B
of	I-P	ADP	O
program	I-P	NOUN	B
implementation	I-P	NOUN	B
for	I-P	ADP	O
a	I-P	DET	O
cohort	I-P	NOUN	B
of	I-P	ADP	O
youth	I-P	NOUN	B
in	I-P	ADP	O
each	I-P	DET	O
school	I-P	NOUN	B
,	I-P	PUNCT	O
followed	I-P	VERB	O
from	I-P	ADP	O
grades	I-P	NOUN	B
3	I-P	NUM	O
to	I-P	PART	O
8	I-P	NUM	O
.	I-P	PUNCT	O


Youth	O	NOUN	B
reported	O	VERB	O
on	O	ADP	O
their	O	PRON	O
emotional	O	ADJ	B
health	O	NOUN	I
(	O	PUNCT	O
positive	O	ADJ	B
affect	O	NOUN	B
,	O	PUNCT	O
life	O	NOUN	B
satisfaction	O	NOUN	I
,	O	PUNCT	O
depression	O	NOUN	B
,	O	PUNCT	O
anxiety	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
social-emotional	O	ADJ	B
and	O	CCONJ	O
character	O	NOUN	O
development	O	NOUN	B
.	O	PUNCT	O


Growth-curve	O	ADJ	B
and	O	CCONJ	O
structural-equation	O	ADJ	B
modeling	O	NOUN	I
analyses	O	NOUN	I
assessed	O	VERB	B
overall	O	ADJ	O
program	O	NOUN	B
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
emotional	O	ADJ	B
health	O	NOUN	B
outcomes	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
mediation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
effects	O	NOUN	B
via	O	ADP	O
the	O	DET	O
program	O	NOUN	B
's	O	PART	I
impact	O	NOUN	B
on	O	ADP	O
youths	O	NOUN	B
'	O	PART	O
social-emotional	O	ADJ	B
and	O	CCONJ	O
character	O	NOUN	O
development	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Students	O	NOUN	B
in	O	ADP	O
PA	B-I	NOUN	B
schools	O	NOUN	I
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
in	O	ADP	O
control	B-I	NOUN	B
schools	O	NOUN	I
,	O	PUNCT	O
had	O	AUX	O
more	O	ADV	O
favorable	O	ADJ	B
change	O	NOUN	I
over	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
in	O	ADP	O
positive	O	ADJ	B
affect	O	NOUN	B
(	O	PUNCT	O
standardized	O	VERB	B
mean	O	ADJ	I
difference	O	NOUN	I
effect	O	NOUN	I
size	O	NOUN	I
[	O	PUNCT	O
ES	O	PROPN	B
]	O	PUNCT	O
=	O	ADJ	O
.17	O	PUNCT	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
life	I-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
(	O	PUNCT	O
ES	O	NOUN	B
=	O	ADJ	O
.13	O	PUNCT	O
)	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
significantly	O	ADV	O
lower	B-OUT	ADJ	O
depression	I-OUT	NOUN	O
(	O	PUNCT	O
ES	O	NOUN	B
=	O	ADJ	O
-.14	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
anxiety	I-OUT	NOUN	B
(	O	PUNCT	O
ES	O	NOUN	B
=	O	ADJ	O
-.26	O	PUNCT	O
)	O	PUNCT	O
at	O	ADP	O
study	O	NOUN	B
end	O	NOUN	B
point	O	NOUN	I
.	O	PUNCT	O


Program	O	NOUN	B
effects	B-OUT	NOUN	B
for	I-OUT	ADP	O
positive	I-OUT	ADJ	B
affect	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
depression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anxiety	I-OUT	NOUN	B
were	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
more	O	ADV	O
favorable	O	ADJ	O
change	O	NOUN	O
over	O	ADP	O
time	O	NOUN	O
in	O	ADP	O
social-emotional	O	ADJ	B
and	O	CCONJ	O
character	O	NOUN	O
development	O	NOUN	B
for	O	ADP	O
students	O	NOUN	B
in	O	ADP	O
PA	O	NOUN	B
schools	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
universal	B-I	ADJ	B
,	I-I	PUNCT	O
school-based	I-I	ADJ	B
programs	I-I	NOUN	I
can	O	AUX	O
benefit	O	VERB	B
the	O	DET	O
emotional	O	ADJ	B
health	B-P	NOUN	I
of	I-P	ADP	O
youth	I-P	NOUN	B
in	I-P	ADP	O
low-income	I-P	ADJ	B
,	I-P	PUNCT	O
urban	I-P	ADJ	B
settings	I-P	NOUN	I
.	O	PUNCT	O


The	O	DET	O
modest	O	ADJ	O
magnitude	O	NOUN	B
of	O	ADP	O
effects	O	NOUN	B
over	O	ADP	O
an	O	DET	O
extended	O	VERB	O
period	O	NOUN	B
of	O	ADP	O
program	O	NOUN	B
implementation	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
reflects	O	VERB	O
the	O	DET	O
challenges	O	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
mounting	O	VERB	B
interventions	O	NOUN	B
and	O	CCONJ	O
offsetting	O	VERB	O
formidable	O	ADJ	O
risks	O	NOUN	B
for	O	ADP	O
mental	O	ADJ	B
health	O	NOUN	I
problems	O	NOUN	O
in	O	ADP	O
such	O	ADJ	O
environments	O	NOUN	B
.	O	PUNCT	O


Absence	B-OUT	NOUN	B
of	I-OUT	ADP	O
cervical	I-OUT	ADJ	B
radiation	I-OUT	NOUN	I
myelitis	I-OUT	NOUN	I
after	O	ADP	O
hyperfractionated	B-I	ADJ	B
radiation	I-I	NOUN	I
therapy	I-I	NOUN	I
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
concurrent	B-I	ADJ	B
chemotherapy	I-I	NOUN	B
for	O	ADP	O
locally	B-P	ADV	B
advanced	I-P	ADJ	I
,	I-P	PUNCT	O
unresectable	I-P	ADJ	B
,	I-P	PUNCT	O
nonmetastatic	I-P	ADJ	B
squamous	I-P	ADJ	B
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
head	I-P	NOUN	B
and	I-P	CCONJ	I
neck	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
developing	I-OUT	VERB	O
radiation	I-OUT	NOUN	B
myelitis	I-OUT	NOUN	I
after	O	ADP	O
a	O	DET	O
cervical	O	ADJ	B
spinal	O	ADJ	O
cord	O	NOUN	O
dose	O	NOUN	O
of	O	ADP	O
50.6	O	NUM	O
Gy	B-I	NOUN	O
given	O	VERB	O
via	O	ADP	O
1.1	O	NUM	O
Gy	O	NOUN	O
b.i.d	O	NOUN	B
.	O	PUNCT	O


fractionation	O	NOUN	B
during	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
hyperfractionated	B-I	ADJ	B
radiation	I-I	NOUN	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
HFX	I-I	NOUN	B
RT	I-I	NOUN	I
)	I-I	PUNCT	O
to	O	PART	O
a	O	DET	O
total	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
77	O	NUM	O
Gy	B-I	NOUN	O
given	O	VERB	O
in	O	ADP	O
70	O	NUM	O
fractions	O	NOUN	B
of	O	ADP	O
1.1	O	NUM	O
Gy	O	NOUN	O
b.i.d.	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
concurrent	O	ADJ	B
low-dose	O	ADJ	B
,	O	PUNCT	O
daily	O	ADJ	O
cisplatin	B-I	NOUN	B
(	I-I	PUNCT	O
CDDP	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
head	B-P	NOUN	B
and	I-P	CCONJ	I
neck	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Of	O	ADP	O
130	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
locally	I-P	ADV	B
advanced	I-P	ADJ	I
,	I-P	PUNCT	O
unresectable	I-P	ADJ	B
,	I-P	PUNCT	O
nonmetastatic	I-P	ADJ	B
squamous	I-P	ADJ	B
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
head	I-P	NOUN	B
and	I-P	CCONJ	I
neck	I-P	NOUN	I
(	I-P	PUNCT	O
SCC	I-P	NOUN	B
H	I-P	NOUN	I
&	I-P	CCONJ	I
N	I-P	NOUN	I
)	I-P	PUNCT	O
who	O	PRON	O
entered	O	VERB	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
101	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
50.6	B-I	NUM	O
Gy	I-I	NOUN	O
to	I-I	ADP	O
a	O	DET	O
portion	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
spinal	O	ADJ	B
cord	O	NOUN	I
and	O	CCONJ	O
survived	O	VERB	O
>	O	NOUN	O
1	O	NUM	O
year	O	NOUN	B
following	O	VERB	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Forty-five	O	ADJ	B
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
HFX	B-I	NOUN	B
RT	I-I	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
fifty-six	O	NUM	O
patients	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
CDDP	B-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	VERB	O
None	O	NOUN	O
of	O	ADP	O
these	O	DET	O
101	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
cervical	B-OUT	ADJ	B
radiation	I-OUT	NOUN	I
myelitis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
not	O	PART	O
possible	O	ADJ	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
potentially	B-OUT	ADV	O
contributing	I-OUT	VERB	O
factors	I-OUT	NOUN	B
on	O	ADP	O
the	O	DET	O
occurrence	B-OUT	NOUN	B
of	I-OUT	ADP	O
radiation	I-OUT	NOUN	B
myelitis	I-OUT	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
interfraction	B-OUT	NOUN	B
interval	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
cord	I-OUT	NOUN	B
length	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
administration	I-OUT	NOUN	B
of	I-OUT	ADP	O
concurrent	I-OUT	ADJ	B
CDDP	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Given	O	VERB	O
the	O	DET	O
increasing	O	VERB	B
number	O	NOUN	O
of	O	ADP	O
studies	O	NOUN	B
with	O	ADP	O
both	O	CCONJ	O
altered	O	ADJ	O
fractionated	O	VERB	B
regimens	O	NOUN	I
and	O	CCONJ	O
concurrent	O	ADJ	B
radio-chemotherapy	B-I	NOUN	B
in	O	ADP	O
SCC	O	NOUN	B
H	O	NOUN	O
&	O	CCONJ	O
N	O	NOUN	O
,	O	PUNCT	O
new	O	ADJ	O
studies	O	NOUN	B
with	O	ADP	O
more	O	ADJ	O
patients	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
gain	O	VERB	O
better	O	ADJ	O
insight	O	NOUN	O
into	O	ADP	O
the	O	DET	O
risks	B-OUT	NOUN	B
of	I-OUT	ADP	O
developing	I-OUT	VERB	O
cervical	I-OUT	ADJ	B
radiation	I-OUT	NOUN	I
myelitis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


[	O	PUNCT	O
Comparative	O	ADJ	O
study	O	NOUN	O
of	O	ADP	O
cinoxacin	B-I	NOUN	B
(	I-I	PUNCT	O
Cinobac	I-I	PROPN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
nitrofurantoin	I-I	NOUN	B
(	I-I	PUNCT	O
Furadantine	I-I	NOUN	B
MC	I-I	NOUN	I
)	I-I	PUNCT	O
and	I-I	CCONJ	O
oxolinic	I-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
Uritrate	I-I	PROPN	B
)	I-I	PUNCT	O
in	O	ADP	O
urinary	O	ADJ	B
tract	O	NOUN	I
infections	O	NOUN	I
.	O	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
random	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
three	B-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
30	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
uncomplicated	I-P	ADJ	B
urinary	I-P	ADJ	I
infections	I-P	NOUN	I
]	I-P	PUNCT	O
.	I-P	PUNCT	O


Pharmacodynamic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
intravenous	B-I	ADJ	B
recombinant	I-I	ADJ	O
urate	I-I	NOUN	B
oxidase	I-I	NOUN	I
using	O	VERB	O
an	O	DET	O
indirect	B-P	ADJ	B
pharmacological	I-P	ADJ	B
response	I-P	NOUN	I
model	I-P	NOUN	O
in	I-P	ADP	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


AIM	O	NOUN	B
Pharmacodynamic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
intravenous	B-I	ADJ	B
recombinant	I-I	ADJ	O
urate	I-I	NOUN	O
oxidase	I-I	NOUN	O
produced	O	VERB	O
by	O	ADP	O
Escherichia	O	X	B
coli	O	X	I
was	O	AUX	O
performed	O	VERB	O
in	B-P	ADP	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
using	I-P	VERB	O
a	I-P	DET	O
pharmacokinetic/pharmacodynamic	I-P	ADJ	B
(	I-P	PUNCT	O
PK/PD	I-P	NOUN	B
)	I-P	PUNCT	O
model	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
single-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	B-P	ADP	O
40	I-P	NUM	O
healthy	I-P	ADJ	B
Chinese	I-P	ADJ	O
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
4	I-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
10	I-P	NUM	O
subjects	I-P	NOUN	B
each	I-P	DET	O
,	I-P	PUNCT	O
placebo	I-P	ADJ	B
4:1	I-P	NUM	O
ratio	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
received	I-P	VERB	O
infusions	I-P	NOUN	B
of	I-P	ADP	O
uricase	I-I	NOUN	B
(	I-P	PUNCT	O
single	I-P	ADJ	B
doses	I-P	NOUN	I
of	I-P	ADP	O
0.1	I-P	NUM	O
,	I-P	PUNCT	O
0.2	I-P	NUM	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
0.3	I-P	NUM	O
mg/kg	I-P	NOUN	O
;	I-P	PUNCT	O
multiple	I-P	ADJ	B
doses	I-P	NOUN	I
of	I-P	ADP	O
0.2	I-P	NUM	O
mg·kg	I-P	NOUN	O
(	I-P	PUNCT	O
-1	I-P	NUM	O
)	I-P	PUNCT	O
·d	I-P	NOUN	O
(	I-P	PUNCT	O
-1	I-P	NUM	O
)	I-P	PUNCT	O
for	I-P	ADP	O
7	I-P	NUM	O
d	I-P	NOUN	O
)	I-P	PUNCT	O
.	O	PUNCT	O


PK	O	NOUN	B
profiles	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
through	B-OUT	ADP	O
plasma	I-OUT	NOUN	B
uricase	I-OUT	NOUN	B
activity	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
PD	O	NOUN	B
profiles	O	NOUN	B
were	O	AUX	O
established	O	VERB	O
using	B-OUT	VERB	O
uric	I-OUT	ADJ	B
acid	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
in	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
urine	I-OUT	NOUN	B
.	O	PUNCT	O


The	O	DET	O
plasma	O	NOUN	B
PD	O	NOUN	I
parameter	O	NOUN	B
was	O	AUX	O
estimated	O	VERB	O
as	O	ADP	O
changes	O	NOUN	B
in	B-OUT	ADP	O
plasma	I-OUT	NOUN	B
uric	I-OUT	ADJ	O
acid	I-OUT	NOUN	O
levels	I-OUT	NOUN	O
as	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
indirect	O	ADJ	B
response	O	NOUN	O
model	B-OUT	NOUN	O
.	I-OUT	PUNCT	O


Adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
were	O	AUX	O
also	O	ADV	O
monitored	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
two-compartment	O	ADJ	O
PK	O	NOUN	B
model	O	NOUN	B
with	O	ADP	O
constant	O	ADJ	B
iv	O	NOUN	O
input	O	NOUN	B
and	O	CCONJ	O
first-order	O	ADJ	O
output	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
describe	O	VERB	O
the	O	DET	O
kinetic	O	ADJ	B
process	O	NOUN	I
of	O	ADP	O
plasma	O	NOUN	B
uricase	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
low	O	ADJ	B
value	O	NOUN	I
(	O	PUNCT	O
2.8	O	NUM	O
U/L	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
drug	O	NOUN	B
concentration	O	NOUN	I
that	O	PRON	O
achieved	O	VERB	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
maximum	O	ADJ	B
effect	O	NOUN	O
(	O	PUNCT	O
EC50	O	NOUN	B
)	O	PUNCT	O
indicated	O	VERB	O
that	O	SCONJ	O
low	O	ADJ	O
plasma	O	NOUN	B
uricase	O	NOUN	B
concentrations	O	NOUN	B
were	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
produce	B-OUT	VERB	O
pharmacological	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
.	O	PUNCT	O


A	O	DET	O
strong	O	ADJ	O
relationship	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=0.9991	O	NOUN	O
)	O	PUNCT	O
between	O	ADP	O
the	B-OUT	DET	O
mean	I-OUT	ADJ	O
uric	I-OUT	ADJ	B
acid	I-OUT	NOUN	I
concentration	I-OUT	NOUN	B
in	I-OUT	ADP	O
blood	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
mean	I-OUT	ADJ	O
uric	I-OUT	ADJ	B
acid	I-OUT	NOUN	I
excretion	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
in	I-OUT	ADP	O
urine	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
range	O	NOUN	B
of	O	ADP	O
11	O	NUM	O
to	O	PART	O
30	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
single	O	ADJ	O
dosing	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	B-P	PUNCT	O


Infusions	B-P	NOUN	B
of	I-I	ADP	O
uricase	I-I	NOUN	B
were	I-P	AUX	O
well	I-P	ADV	O
tolerated	I-P	VERB	B
in	I-P	ADP	O
all	I-P	DET	O
subjects	I-P	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
PK/PD	O	NOUN	B
model	O	NOUN	B
predicted	O	VERB	B
the	B-P	DET	O
effective	I-P	ADJ	B
dose	I-P	NOUN	B
to	I-P	PART	O
be	I-P	AUX	O
0.1	I-P	NUM	O
mg/kg	I-P	NOUN	O
in	I-P	ADP	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
.	O	PUNCT	O


The	O	DET	O
excretion	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
uric	O	ADJ	B
acid	O	NOUN	I
in	O	ADP	O
urine	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
new	O	ADJ	O
index	O	NOUN	O
for	O	ADP	O
pharmacological	O	ADJ	B
effects	O	NOUN	O
in	O	ADP	O
further	O	ADJ	O
clinical	O	ADJ	B
trials	O	NOUN	I
.	O	PUNCT	O


Lactoferrin	B-I	NOUN	B
supplementation	I-I	NOUN	B
to	O	ADP	O
Holstein	B-P	NOUN	B
calves	I-P	NOUN	I
during	I-P	ADP	O
the	I-P	DET	O
preweaning	I-P	NOUN	B
and	I-P	CCONJ	O
postweaning	I-P	NOUN	B
phases	I-P	NOUN	I
.	I-P	PUNCT	O


Sixty	B-P	NUM	O
Holstein	I-P	NOUN	B
calves	I-P	NOUN	I
(	I-P	PUNCT	O
30	I-P	NUM	O
bulls	I-P	NOUN	B
,	I-P	PUNCT	O
30	I-P	NUM	O
heifers	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
supplemental	B-I	ADJ	B
lactoferrin	I-I	NOUN	B
on	O	ADP	O
feed	B-OUT	NOUN	B
intake	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
growth	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
health	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
preweaning	O	NOUN	B
and	O	CCONJ	O
postweaning	O	NOUN	B
periods	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
3	O	NUM	O
levels	O	NOUN	B
of	O	ADP	O
lactoferrin	B-I	NOUN	B
was	O	AUX	O
supplemented	O	VERB	O
from	O	ADP	O
3	O	NUM	O
to	O	PART	O
56	O	NUM	O
d	O	NOUN	O
in	O	ADP	O
either	O	CCONJ	O
whole	O	ADJ	B
milk	O	NOUN	I
or	O	CCONJ	O
water	O	NOUN	B
to	O	PART	O
produce	O	VERB	O
3	O	NUM	O
dietary	O	ADJ	B
treatments	O	NOUN	I
:	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
0	O	NUM	O
g/d	O	NOUN	O
,	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
0.5	O	NUM	O
g/d	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
3	O	X	O
)	O	PUNCT	O
1	O	NUM	O
g/d	O	NOUN	O
.	O	PUNCT	O


Whole	O	ADJ	B
milk	O	NOUN	I
(	O	PUNCT	O
3.8	O	NUM	O
L/d	O	NOUN	O
)	O	PUNCT	O
containing	O	VERB	O
lactoferrin	B-I	NOUN	B
supplements	I-I	NOUN	B
was	O	AUX	O
fed	O	VERB	O
from	O	ADP	O
bottles	O	NOUN	B
until	O	ADP	O
weaning	O	VERB	B
at	O	ADP	O
35	O	NUM	O
d.	O	NOUN	O
From	O	ADP	O
d	O	NOUN	O
36	O	NUM	O
to	O	PART	O
56	O	NUM	O
,	O	PUNCT	O
lactoferrin	B-I	NOUN	B
supplements	I-I	NOUN	B
were	O	AUX	O
added	O	VERB	O
to	O	PART	O
water	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
to	O	PART	O
25	O	NUM	O
mL	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
fed	O	VERB	B
from	O	ADP	O
bottles	O	NOUN	B
.	O	PUNCT	O


Lactoferrin	B-I	NOUN	B
supplementation	I-I	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
feed	B-OUT	NOUN	B
intake	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
average	I-OUT	ADJ	B
daily	I-OUT	ADJ	O
gain	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
heart	I-OUT	NOUN	B
girth	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
temperature	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
fecal	I-OUT	ADJ	B
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
respiratory	I-OUT	ADJ	B
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
haptoglobin	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Calves	B-P	NOUN	B
were	O	AUX	O
housed	O	VERB	B
in	O	ADP	O
individual	O	ADJ	B
pens	O	NOUN	B
in	O	ADP	O
either	O	CCONJ	O
an	O	DET	O
open-sided	O	ADJ	B
barn	O	NOUN	I
or	O	CCONJ	O
hutches	O	NOUN	B
.	O	PUNCT	O


Calves	B-P	NOUN	B
raised	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
barn	I-P	NOUN	B
consumed	O	VERB	O
more	O	ADJ	O
calf	O	NOUN	B
starter	O	NOUN	B
and	O	CCONJ	O
therefore	O	ADV	O
grew	O	VERB	O
better	O	ADV	O
than	O	ADP	O
calves	O	NOUN	B
raised	O	VERB	B
in	O	ADP	O
hutches	O	NOUN	B
.	O	PUNCT	O


Under	O	ADP	O
the	O	DET	O
conditions	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
lactoferrin	B-I	NOUN	B
supplementation	I-I	NOUN	B
was	O	AUX	O
not	O	PART	O
beneficial	O	ADJ	O
.	O	PUNCT	O


Further	O	ADJ	O
research	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
to	O	PART	O
fully	O	ADV	O
elucidate	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
lactoferrin	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
possible	O	ADJ	O
benefits	O	NOUN	B
during	O	ADP	O
different	O	ADJ	O
feeding	O	NOUN	B
conditions	O	NOUN	O
or	O	CCONJ	O
milk	O	NOUN	B
sources	O	NOUN	B
.	O	PUNCT	O


5-Fluorouracil	B-I	NOUN	B
,	I-I	PUNCT	O
adriamycin	I-I	NOUN	B
,	I-I	PUNCT	O
cyclophosphamide	I-I	NOUN	B
(	I-I	PUNCT	O
FAC	I-I	NOUN	B
)	I-I	PUNCT	O
vs.	O	CCONJ	O
5-fluorouracil	B-I	NOUN	B
,	I-I	PUNCT	O
epirubicin	I-I	NOUN	B
,	I-I	PUNCT	O
cyclophosphamide	I-I	NOUN	B
(	I-I	PUNCT	O
FEC	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
metastatic	B-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


94	B-P	NUM	O
evaluable	I-P	ADJ	O
patients	I-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
5-fluorouracil	B-I	NOUN	B
,	I-I	PUNCT	O
adriamycin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
cyclophosphamide	I-I	NOUN	B
(	I-I	PUNCT	O
FAC	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
5-fluorouracil	I-I	NOUN	B
,	I-I	PUNCT	O
epirubicin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
cyclophosphamide	I-I	NOUN	B
(	I-I	PUNCT	O
FEC	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
cycles	O	NOUN	B
repeated	O	VERB	O
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	B-OUT	ADJ	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
to	O	ADP	O
FAC	B-I	PROPN	B
was	O	AUX	O
46	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
44	O	NUM	O
%	O	NOUN	O
to	O	PART	O
FEC	B-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
median	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
response	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
median	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
regimens	O	NOUN	B
.	O	PUNCT	O


Toxicity	B-OUT	NOUN	B
was	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
and	O	CCONJ	O
more	O	ADV	O
pronounced	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
FAC	B-I	NOUN	B
.	I-I	PUNCT	O


Results	O	NOUN	B
indicate	O	VERB	O
therapeutic	O	ADJ	B
equivalence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
regimens	O	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
toxicity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
epirubicin	O	NOUN	B
arm	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
L-type	O	ADJ	B
calcium	O	NOUN	I
channel	O	NOUN	I
blocker	O	NOUN	I
(	B-I	PUNCT	O
amlodipine	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
myocardial	B-OUT	ADJ	B
iron	I-OUT	NOUN	B
deposition	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
thalassaemia	I-P	NOUN	B
with	I-P	ADP	O
moderate-to-severe	I-P	ADJ	O
myocardial	I-OUT	ADJ	B
iron	I-OUT	NOUN	I
deposition	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
protocol	O	NOUN	B
for	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


INTRODUCTION	O	PROPN	O
Sideroblastic	O	ADJ	B
cardiomyopathy	O	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
repeated	B-OUT	VERB	O
blood	I-OUT	NOUN	B
transfusions	I-OUT	NOUN	I
is	O	AUX	O
a	O	DET	O
feared	O	ADJ	O
complication	O	NOUN	B
in	O	ADP	O
thalassaemia	O	NOUN	B
.	O	PUNCT	O


Control	O	NOUN	B
of	O	ADP	O
myocardial	B-OUT	ADJ	B
iron	I-OUT	NOUN	I
is	O	AUX	O
thus	O	ADV	O
becoming	O	VERB	O
the	O	DET	O
cornerstone	O	NOUN	B
of	O	ADP	O
thalassaemia	O	NOUN	B
management	O	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
L-type	O	ADJ	B
Ca	O	NOUN	I
(	O	PUNCT	I
2+	O	NUM	I
)	O	PUNCT	I
channels	O	NOUN	I
in	O	ADP	O
mediating	O	VERB	O
iron	O	NOUN	B
uptake	O	NOUN	O
by	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
.	O	PUNCT	O


Blocking	O	VERB	B
the	O	DET	O
cellular	O	ADJ	B
iron	O	NOUN	I
uptake	O	NOUN	I
through	O	ADP	O
these	O	DET	O
channels	O	NOUN	B
may	O	AUX	O
add	O	VERB	O
to	O	ADP	O
the	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
to	O	PART	O
standard	O	ADJ	O
chelation	O	NOUN	B
in	O	ADP	O
reducing	O	VERB	O
myocardial	B-OUT	ADJ	B
iron	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


We	O	PRON	O
aim	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
amlodipine	B-I	NOUN	B
(	O	PUNCT	O
a	O	DET	O
calcium	O	NOUN	B
channel	O	NOUN	I
blocker	O	NOUN	I
)	O	PUNCT	O
as	O	ADP	O
an	O	DET	O
adjunct	O	NOUN	B
to	O	PART	O
standard	O	ADJ	O
aggressive	O	ADJ	B
chelation	O	NOUN	O
in	O	ADP	O
retarding	O	VERB	O
myocardial	B-OUT	ADJ	B
iron	I-OUT	NOUN	O
deposition	I-OUT	NOUN	O
in	O	ADP	O
thalassaemics	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
cardiomyopathy	O	NOUN	B
.	O	PUNCT	O


OUTCOMES	O	VERB	O
The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
is	O	AUX	O
to	O	PART	O
compare	B-OUT	VERB	B
the	I-OUT	DET	O
efficacy	I-OUT	NOUN	B
of	I-OUT	ADP	O
amlodipine+chelation	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
intervention	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
versus	I-OUT	CCONJ	O
standard	I-OUT	ADJ	B
chelation	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
control	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	I-OUT	ADP	O
retarding	I-OUT	VERB	B
myocardial	I-OUT	ADJ	B
iron	I-OUT	NOUN	B
deposition	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Secondary	O	ADJ	B
outcomes	O	NOUN	I
include	O	VERB	O
the	O	DET	O
effect	B-OUT	NOUN	B
of	I-OUT	ADP	O
amlodipine	I-OUT	NOUN	B
therapy	I-OUT	NOUN	I
on	I-OUT	ADP	O
systolic	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
strain	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
strain	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
liver	I-OUT	NOUN	B
iron	I-OUT	NOUN	I
content	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
ANALYSIS	O	NOUN	O
This	O	DET	O
is	O	AUX	O
a	O	DET	O
single-centre	O	ADJ	B
,	O	PUNCT	O
parallel-group	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
randomised	O	ADJ	I
control	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


Twenty	B-P	NUM	O
patients	I-P	NOUN	B
will	O	AUX	O
be	O	AUX	O
randomised	O	VERB	B
in	O	ADP	O
a	O	DET	O
1:1	O	NUM	O
allocation	O	NOUN	B
ratio	O	NOUN	I
into	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
arms	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
conventional	O	ADJ	B
echocardiography	O	NOUN	B
,	O	PUNCT	O
MRI	O	NOUN	B
T2*	O	NOUN	B
values	O	NOUN	O
for	O	ADP	O
assessment	O	NOUN	B
of	O	ADP	O
cardiac	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
liver	I-OUT	NOUN	B
iron	I-OUT	NOUN	I
load	I-OUT	NOUN	I
will	O	AUX	O
be	O	AUX	O
obtained	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Cardiac	O	ADJ	B
T2*	O	NOUN	O
will	O	AUX	O
be	O	AUX	O
reported	O	VERB	O
as	O	ADP	O
the	O	DET	O
geometric	O	ADJ	B
mean	O	NOUN	O
and	O	CCONJ	O
per	O	X	B
cent	O	NOUN	I
coefficient	O	NOUN	I
of	O	ADP	I
variation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
cardiac	O	ADJ	B
T2*	O	NOUN	O
values	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
an	O	DET	O
end	O	NOUN	O
point	O	NOUN	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
p	O	NOUN	O
Value	O	NOUN	O
of	O	ADP	O
<	O	X	O
0.05	O	NUM	O
will	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
significant	O	ADJ	B
.	O	PUNCT	O


STUDY	O	NOUN	B
SETTING	O	NOUN	I
Department	B-P	PROPN	I
of	I-P	ADP	O
Pediatric	I-P	PROPN	O
and	I-P	CCONJ	O
Child	I-P	PROPN	O
Health	I-P	PROPN	O
,	I-P	PUNCT	O
Aga	I-P	PROPN	O
Khan	I-P	PROPN	O
University	I-P	PROPN	O
Hospital	I-P	PROPN	O
,	I-P	PUNCT	O
Karachi	I-P	PROPN	B
,	I-P	PUNCT	O
Pakistan	I-P	PROPN	B
.	I-P	PUNCT	O


ETHICS	O	NOUN	O
AND	O	CCONJ	O
DISSEMINATION	O	PROPN	B
This	O	DET	O
study	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
approved	O	VERB	O
by	O	ADP	O
the	O	DET	O
Ethics	O	PROPN	B
Review	O	PROPN	I
Committee	O	PROPN	I
and	O	CCONJ	I
Clinical	O	PROPN	I
Trials	O	PROPN	I
Unit	O	PROPN	I
at	O	ADP	O
The	B-P	DET	O
Aga	I-P	PROPN	B
Khan	I-P	PROPN	I
University	I-P	PROPN	I
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
scientific	O	ADJ	B
content	O	NOUN	I
and	O	CCONJ	O
compliance	O	NOUN	B
with	O	ADP	O
applicable	O	ADJ	O
research	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
subjects	O	NOUN	O
regulations	O	NOUN	B
.	O	PUNCT	O


Findings	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
reported	O	VERB	O
through	O	ADP	O
scientific	O	ADJ	B
publications	O	NOUN	I
and	O	CCONJ	O
research	O	NOUN	B
conferences	O	NOUN	I
and	O	CCONJ	O
project	O	NOUN	B
summary	O	NOUN	O
papers	O	NOUN	B
for	O	ADP	O
participants	O	NOUN	B
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
NUMBER	O	NOUN	B
ClinicalTrials.Gov	O	NOUN	B
.	O	PUNCT	O


Registration	O	NOUN	B
no	O	INTJ	O
:	O	PUNCT	O
NCT02065492	O	NOUN	B
.	O	PUNCT	O


Modified	B-I	ADJ	B
constraint-induced	I-I	ADJ	I
therapy	I-I	NOUN	I
combined	O	VERB	O
with	O	ADP	O
mental	B-I	ADJ	B
practice	I-I	NOUN	I
:	I-I	PUNCT	O
thinking	O	VERB	B
through	O	ADP	O
better	O	ADJ	O
motor	O	NOUN	B
outcomes	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
PURPOSE	O	PROPN	O
Modified	B-I	ADJ	O
constraint-induced	I-I	ADJ	O
therapy	I-I	NOUN	O
(	I-I	PUNCT	O
mCIT	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
an	O	DET	O
outpatient	O	ADJ	B
therapy	O	NOUN	I
encouraging	O	VERB	O
repetitive	O	ADJ	B
,	O	PUNCT	O
task-specific	O	ADJ	B
practice	O	NOUN	I
with	O	ADP	O
the	O	DET	O
affected	O	VERB	B
arm	O	NOUN	I
.	O	PUNCT	O


mCIT	B-I	NOUN	B
has	O	AUX	O
shown	O	VERB	O
efficacy	B-OUT	NOUN	B
in	O	ADP	O
all	O	DET	O
stages	O	NOUN	B
poststroke	O	ADJ	B
.	O	PUNCT	O


Given	O	VERB	O
its	O	PRON	O
efficacy	O	NOUN	B
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
other	O	ADJ	O
therapy	O	NOUN	B
regimens	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
mental	B-I	ADJ	B
practice	I-I	NOUN	I
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
mCIT	B-I	NOUN	B
versus	O	CCONJ	O
mCIT	B-I	NOUN	B
only	I-I	ADV	O
using	O	VERB	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
methods	O	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	O
Ten	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
stroke	I-P	NOUN	I
(	I-P	PUNCT	O
7	I-P	NUM	O
males	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
61.4+/-3.02	I-P	NOUN	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
age	I-P	NOUN	B
range	I-P	NOUN	O
,	I-P	PUNCT	O
48	I-P	NUM	O
to	I-P	PART	O
79	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	ADJ	O
time	I-P	NOUN	O
since	I-P	SCONJ	O
stroke	I-P	NOUN	B
,	I-P	PUNCT	O
28.5	I-P	NUM	O
months	I-P	NOUN	B
;	I-P	PUNCT	O
range	I-P	NOUN	B
,	I-P	PUNCT	O
13	I-P	NUM	O
to	I-P	PART	O
42	I-P	NUM	O
months	I-P	NOUN	B
)	I-P	PUNCT	O
exhibiting	I-P	VERB	O
stable	I-P	ADJ	B
,	I-P	PUNCT	O
affected	I-P	VERB	B
arm	I-P	NOUN	O
motor	I-P	NOUN	O
deficits	I-P	NOUN	O
were	O	AUX	O
administered	O	VERB	B
mCIT	B-I	NOUN	B
,	O	PUNCT	O
consisting	O	VERB	O
of	O	ADP	O
:	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
structured	O	ADJ	B
therapy	O	NOUN	I
emphasizing	O	VERB	O
affected	O	ADJ	B
arm	O	NOUN	O
use	O	NOUN	O
in	O	ADP	O
functional	O	ADJ	B
activities	O	NOUN	I
3	O	NUM	O
days/week	O	NOUN	B
for	O	ADP	O
10	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
less	O	ADV	O
affected	O	VERB	B
arm	O	NOUN	O
restraint	O	NOUN	O
5	O	NUM	O
days/week	O	NOUN	B
for	O	ADP	O
5	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
of	O	ADP	O
these	O	DET	O
components	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
during	O	ADP	O
a	O	DET	O
10-week	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
the	O	DET	O
mCIT+mental	B-I	NOUN	B
practice	I-I	NOUN	I
experimental	O	ADJ	B
condition	O	NOUN	I
also	O	ADV	O
received	O	VERB	O
30-minute	O	ADJ	O
mental	O	ADJ	B
practice	O	NOUN	I
sessions	O	NOUN	B
provided	O	VERB	O
directly	O	ADV	O
after	O	ADP	O
therapy	O	NOUN	B
sessions	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
mental	B-I	ADJ	B
practice	I-I	NOUN	I
sessions	O	NOUN	B
required	O	VERB	O
daily	O	ADJ	B
cognitive	O	ADJ	B
rehearsal	O	NOUN	I
of	O	ADP	O
the	O	DET	O
activities	O	NOUN	B
of	O	ADP	O
daily	O	ADV	B
living	O	NOUN	O
practiced	O	VERB	O
during	O	ADP	O
mCIT	B-I	NOUN	B
clinical	O	ADJ	B
sessions	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
No	O	DET	O
pre-existing	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
on	O	ADP	O
any	O	DET	O
demographic	O	ADJ	B
variable	O	ADJ	I
or	O	CCONJ	O
movement	O	NOUN	B
scale	O	NOUN	O
.	O	PUNCT	O


All	O	DET	O
subjects	O	NOUN	B
exhibited	O	VERB	O
marked	O	ADJ	O
reductions	O	NOUN	B
in	O	ADP	O
affected	B-OUT	VERB	B
arm	I-OUT	NOUN	B
impairment	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
functional	I-OUT	ADJ	B
limitation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
subjects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mCIT+mental	B-I	NOUN	B
practice	I-I	NOUN	I
group	O	NOUN	I
exhibited	O	VERB	O
significantly	O	ADV	O
larger	O	ADJ	O
changes	O	NOUN	B
on	O	ADP	O
both	O	DET	O
movement	B-OUT	NOUN	B
measures	I-OUT	NOUN	B
after	O	ADP	O
intervention	O	NOUN	B
:	O	PUNCT	O
Action	O	PROPN	B
Research	O	PROPN	I
Arm	O	PROPN	I
Test	O	PROPN	I
,	O	PUNCT	O
+15.4-point	O	ADJ	O
change	O	NOUN	O
versus	O	CCONJ	O
+8.4-point	O	ADJ	O
change	O	NOUN	O
for	O	ADP	O
mCIT	B-I	NOUN	B
only	I-I	ADV	O
subjects	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
Fugl-Meyer	O	ADJ	B
,	O	PUNCT	O
+7.8-point	O	ADJ	O
change	O	NOUN	B
versus	O	CCONJ	O
+4.1-point	O	NOUN	O
change	O	NOUN	O
for	O	ADP	O
the	O	DET	O
mCIT	B-I	NOUN	B
only	I-I	ADV	O
subjects	O	NOUN	B
(	O	PUNCT	O
P=0.01	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
were	O	AUX	O
sustained	O	ADJ	B
3	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
intervention	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
mCIT	B-I	NOUN	B
remains	O	VERB	O
a	O	DET	O
promising	O	ADJ	O
motor	O	NOUN	B
intervention	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
its	O	PRON	O
efficacy	B-OUT	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
enhanced	O	VERB	B
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
mental	B-I	ADJ	B
practice	I-I	NOUN	I
provided	O	VERB	O
directly	O	ADV	O
after	O	ADP	O
mCIT	B-I	NOUN	B
clinical	O	ADJ	B
sessions	O	NOUN	I
.	O	PUNCT	O


Middle	B-OUT	ADJ	B
cerebral	I-OUT	ADJ	I
arterial	I-OUT	ADJ	I
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
velocity	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
hemodynamics	I-OUT	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
surgery	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
propofol	B-I	NOUN	B
,	I-I	PUNCT	O
isoflurane	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
sevoflurane	I-I	NOUN	B
on	O	ADP	O
middle	B-OUT	ADJ	B
cerebral	I-OUT	ADJ	I
arterial	I-OUT	ADJ	I
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
velocity	I-OUT	NOUN	I
during	O	ADP	O
open	B-P	ADJ	B
heart	I-P	NOUN	I
surgery	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
these	O	DET	O
effects	O	NOUN	B
and	O	CCONJ	O
hemodynamic	O	ADJ	B
parameters	O	NOUN	B
.	O	PUNCT	O


Fifty-two	B-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
bypass	I-P	NOUN	I
on	I-P	ADP	O
cardiopulmonary	I-P	NOUN	B
bypass	I-P	NOUN	I
were	O	AUX	O
divided	O	VERB	O
randomly	O	ADV	O
into	O	ADP	O
3	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
the	O	DET	O
first	O	ADJ	O
group	B-I	NOUN	B
received	I-I	VERB	O
100	I-I	NUM	O
microg	I-I	NOUN	B
x	I-I	NOUN	O
kg	I-I	NOUN	O
(	I-I	PUNCT	O
-1	I-I	NUM	O
)	I-I	PUNCT	O
x	I-I	NOUN	O
min	I-I	NOUN	O
(	I-I	PUNCT	O
-1	I-I	NUM	O
)	I-I	PUNCT	O
propofol	I-I	NOUN	B
,	I-I	PUNCT	O
the	I-I	DET	O
other	I-I	ADJ	O
groups	I-I	NOUN	B
received	I-I	VERB	O
one	I-I	NUM	O
minimum	I-I	ADJ	O
alveolar	I-I	ADJ	B
concentration	I-I	NOUN	O
of	I-I	ADP	O
sevoflurane	I-I	NOUN	B
or	I-I	CCONJ	O
isoflurane	I-I	NOUN	B
for	I-I	ADP	O
anesthesia	I-I	NOUN	B
maintenance	I-I	NOUN	B
.	I-I	PUNCT	O


Middle	B-OUT	ADJ	B
cerebral	I-OUT	ADJ	I
arterial	I-OUT	ADJ	I
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
velocities	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
transcranial	O	ADJ	B
Doppler	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
hemodynamics	B-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
thermodilution	O	NOUN	B
technique	O	NOUN	I
.	O	PUNCT	O


Middle	B-OUT	ADJ	B
cerebral	I-OUT	ADJ	I
arterial	I-OUT	ADJ	I
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
velocities	I-OUT	NOUN	B
decreased	O	VERB	B
significantly	O	ADV	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
isoflurane	O	NOUN	B
and	O	CCONJ	O
propofol	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
weaning	O	VERB	B
from	O	ADP	O
cardiopulmonary	O	NOUN	B
bypass	O	NOUN	I
,	O	PUNCT	O
cerebral	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
increased	I-OUT	VERB	B
and	O	CCONJ	O
came	O	VERB	O
close	O	ADV	O
to	O	ADP	O
the	O	DET	O
value	O	NOUN	O
after	O	ADP	O
induction	O	NOUN	B
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pulsatility	B-OUT	NOUN	B
index	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
resistivity	I-OUT	NOUN	B
index	I-OUT	NOUN	I
increased	O	VERB	B
significantly	O	ADV	O
only	O	ADV	O
after	O	ADP	O
the	O	DET	O
propofol	O	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
placebo	O	ADJ	B
awareness	O	NOUN	B
on	O	ADP	O
stimulant	O	ADJ	B
drug	O	NOUN	B
response	O	NOUN	I
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


RATIONALE	O	NOUN	B
Critics	O	NOUN	B
have	O	AUX	O
called	O	VERB	O
into	O	ADP	O
question	O	NOUN	O
findings	O	NOUN	B
from	O	ADP	O
double-blind	O	ADJ	B
placebo-controlled	O	ADJ	B
studies	O	NOUN	I
because	O	SCONJ	O
subjects	O	NOUN	B
are	O	AUX	O
given	O	VERB	O
drug	O	NOUN	B
administration	O	NOUN	I
instructions	O	NOUN	I
informing	O	VERB	B
them	O	PRON	O
of	O	ADP	O
a	O	DET	O
placebo	O	ADJ	B
condition	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
assertion	O	NOUN	B
that	O	SCONJ	O
these	O	DET	O
drug	O	NOUN	B
administration	O	NOUN	I
instructions	O	NOUN	I
bias	O	VERB	B
estimates	O	NOUN	B
of	O	ADP	O
effectiveness	O	NOUN	B
has	O	AUX	O
undergone	O	VERB	O
surprisingly	O	ADV	O
little	O	ADJ	O
empirical	O	ADJ	B
investigation	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
The	O	DET	O
primary	O	ADJ	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
drug	O	NOUN	B
administration	O	NOUN	I
instructions	O	NOUN	I
informing	O	VERB	O
subjects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
placebo	B-I	ADJ	B
condition	O	NOUN	B
affect	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
response	O	NOUN	I
and	O	CCONJ	O
affect	O	VERB	O
the	O	DET	O
saliva	B-OUT	NOUN	B
concentration	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
stimulant	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
assessed	O	VERB	B
caffeine	B-OUT	NOUN	B
responses	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
saliva	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
of	I-OUT	ADP	O
caffeine	I-OUT	NOUN	B
in	I-P	ADP	O
52	I-P	NUM	O
subjects	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
receive	I-P	VERB	O
one	I-P	NUM	O
of	I-P	ADP	O
two	I-P	NUM	O
drug	I-P	NOUN	B
administration	I-P	NOUN	I
instructions	I-P	NOUN	I
:	I-P	PUNCT	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
placebo-informed	B-I	ADJ	O
instructions	I-I	NOUN	O
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
individuals	B-I	NOUN	B
informed	I-I	VERB	B
of	I-I	ADP	O
the	I-I	DET	O
placebo	I-I	NOUN	B
)	I-I	PUNCT	O
analogous	O	ADJ	O
to	O	PART	O
those	O	DET	O
used	O	VERB	O
in	O	ADP	O
double-blind	O	ADJ	B
studies	O	NOUN	I
and	O	CCONJ	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
placebo-uninformed	B-I	ADJ	O
instructions	I-I	NOUN	O
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
individuals	B-I	NOUN	B
informed	I-I	VERB	B
they	I-I	PRON	O
are	I-I	AUX	O
taking	I-I	VERB	O
an	I-I	DET	O
active	I-I	ADJ	B
stimulant	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
On	O	ADP	O
most	O	ADJ	O
measures	O	NOUN	B
(	B-OUT	PUNCT	O
systolic	I-OUT	NOUN	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
hand	I-OUT	NOUN	B
steadiness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
reaction	I-OUT	NOUN	B
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
tension	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
drug	O	NOUN	B
administration	O	NOUN	I
instructions	O	NOUN	I
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
influence	O	VERB	B
caffeine	B-OUT	NOUN	B
response	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Instructions	O	NOUN	B
also	O	ADV	O
had	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
effect	O	NOUN	O
on	O	ADP	O
saliva	B-OUT	NOUN	B
concentration	I-OUT	NOUN	B
of	O	ADP	O
caffeine	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
only	O	ADV	O
individuals	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
uninformed	O	ADJ	O
of	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
condition	O	NOUN	B
showed	O	VERB	O
significant	O	ADJ	O
diastolic	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
vigor	I-OUT	NOUN	B
increases	O	NOUN	B
with	O	ADP	O
125	O	NUM	O
mg	O	NOUN	O
caffeine	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
significant	O	ADJ	B
hand	B-OUT	NOUN	B
steadiness	I-OUT	NOUN	I
impairment	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
vigor	I-OUT	NOUN	B
increases	O	NOUN	B
with	O	ADP	O
325	O	NUM	O
mg	O	NOUN	O
caffeine	B-I	NOUN	B
compared	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
overall	O	ADJ	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
limited	O	ADJ	O
bias	O	NOUN	B
is	O	AUX	O
introduced	O	VERB	O
by	O	ADP	O
drug	O	NOUN	B
administration	O	NOUN	I
instructions	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
do	O	AUX	O
not	O	PART	O
support	O	VERB	O
any	O	DET	O
suggestion	O	NOUN	O
that	O	SCONJ	O
information	O	NOUN	B
about	O	ADP	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
placebo	O	ADJ	B
condition	O	NOUN	B
dramatically	O	ADV	O
influences	O	VERB	B
conclusions	O	NOUN	B
drawn	O	VERB	O
about	O	ADP	O
drug	O	NOUN	B
responses	O	NOUN	I
in	O	ADP	O
placebo-controlled	O	ADJ	B
trials	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
parent-delivered	B-I	ADJ	B
intervention	I-I	NOUN	I
on	O	ADP	O
parents	B-P	NOUN	B
of	I-P	ADP	O
very	I-P	ADV	O
young	I-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
investigated	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
a	O	DET	O
parent-coaching	B-I	ADJ	B
intervention	I-I	NOUN	I
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
Early	B-I	PROPN	B
Start	I-I	PROPN	I
Denver	I-I	PROPN	I
Model	I-I	PROPN	I
(	I-I	PUNCT	O
P-ESDM	I-I	NOUN	O
)	I-I	PUNCT	O
on	O	ADP	O
parenting-related	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
and	O	CCONJ	O
sense	B-OUT	NOUN	B
of	I-OUT	ADP	I
competence	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


This	O	DET	O
was	O	AUX	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
multisite	B-P	ADJ	B
,	O	PUNCT	O
randomized	B-I	ADJ	B
trial	I-I	NOUN	I
comparing	O	VERB	B
P-ESDM	B-I	NOUN	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
49	I-P	NUM	O
)	I-P	PUNCT	O
with	I-I	ADP	O
community	I-I	NOUN	B
intervention	I-I	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
49	I-P	NUM	O
)	I-P	PUNCT	O
for	I-P	ADP	O
children	I-P	NOUN	B
aged	I-P	ADJ	B
12	I-P	NUM	O
and	I-P	CCONJ	O
24	I-P	NUM	O
months	I-P	NOUN	B
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
P-ESDM	I-OUT	NOUN	O
group	O	NOUN	B
reported	O	VERB	O
no	O	DET	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
parenting	I-OUT	NOUN	B
stress	I-OUT	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
Community	O	PROPN	B
group	O	NOUN	I
experienced	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
over	O	ADP	O
the	O	DET	O
same	O	ADJ	O
3-month	O	ADJ	O
period	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Parental	B-OUT	ADJ	B
sense	I-OUT	NOUN	B
of	I-OUT	ADP	I
competence	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	B-OUT	VERB	O
.	I-OUT	PUNCT	O


Number	B-OUT	NOUN	O
of	I-OUT	ADP	O
negative	I-OUT	ADJ	B
life	I-OUT	NOUN	O
events	I-OUT	NOUN	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
parenting	O	NOUN	B
stress	O	NOUN	I
and	O	CCONJ	O
sense	O	NOUN	B
of	O	ADP	I
competence	O	NOUN	B
across	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	B-I	SCONJ	O
a	I-I	DET	O
parent-coaching	I-I	ADJ	B
intervention	I-I	NOUN	I
may	O	AUX	O
help	B-OUT	VERB	O
maintain	I-OUT	VERB	O
parental	I-OUT	ADJ	B
adjustment	I-OUT	NOUN	B
directly	O	ADV	O
after	O	ADP	O
a	O	DET	O
child	O	NOUN	B
is	O	AUX	O
diagnosed	O	VERB	B
with	O	ADP	O
ASD	O	PROPN	B
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
some	O	DET	O
benefits	O	NOUN	B
for	O	ADP	O
eradicating	O	VERB	B
Helicobacter	O	NOUN	B
pylori	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
non-ulcer	I-P	ADJ	B
dyspepsia	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
Helicobacter	O	NOUN	B
pylori	O	NOUN	I
infection	O	NOUN	I
and	O	CCONJ	O
non-ulcer	O	ADJ	B
dyspepsia	O	NOUN	I
is	O	AUX	O
not	O	PART	O
established	O	VERB	O
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
eradication	O	NOUN	B
of	O	ADP	O
H.	O	PROPN	B
pylori	O	NOUN	I
might	O	AUX	O
be	O	AUX	O
of	O	ADP	O
benefit	O	NOUN	B
in	O	ADP	O
non-ulcer	B-P	ADJ	B
dyspepsia	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
randomly	O	ADV	O
assigned	O	VERB	O
129	B-P	NUM	O
H.	I-P	NOUN	B
pylori	I-P	NOUN	I
infected	I-P	VERB	B
patients	I-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
epigastric	I-P	ADJ	B
pain	I-P	NOUN	I
,	I-P	PUNCT	O
without	I-P	ADP	O
gastro-oesophageal	I-P	ADJ	B
reflux	I-P	NOUN	I
symptoms	I-P	NOUN	B
,	O	PUNCT	O
to	O	PART	O
receive	O	VERB	O
twice	O	ADV	O
daily	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
300	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
ranitidine	B-I	NOUN	B
,	O	PUNCT	O
1000	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
amoxicillin	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
500	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
clarithromycin	B-I	NOUN	B
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
124	B-P	NUM	O
such	I-P	ADJ	O
patients	I-P	NOUN	B
to	I-P	PART	O
receive	I-P	VERB	O
identical-appearing	I-P	ADJ	B
placebos	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	VERB	B
Treatment	O	NOUN	B
was	O	AUX	O
successful	O	ADJ	O
(	O	PUNCT	O
decrease	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
at	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
62	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
active-treatment	O	ADJ	B
group	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	O
(	O	PUNCT	O
N.S.	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
eradication	I-OUT	NOUN	B
of	I-OUT	ADP	O
H.	I-OUT	X	B
pylori	I-OUT	NOUN	I
was	O	AUX	O
69	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
active-treatment	O	ADJ	B
group	O	NOUN	B
and	O	CCONJ	O
18	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Complete	B-OUT	ADJ	B
relief	I-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
occurred	O	VERB	O
significantly	O	ADV	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
the	O	DET	O
active	O	ADJ	B
treatment	O	NOUN	I
(	O	PUNCT	O
43	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
placebo-treated	B-I	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
31	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P=0.048	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
active-treatment	O	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
therapeutic	B-OUT	ADJ	B
success	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
non-infected	B-P	ADJ	B
patients	I-P	NOUN	B
(	O	PUNCT	O
84	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
64	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P=0.04	O	PROPN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Although	O	SCONJ	O
eradicating	O	VERB	O
H.	O	PROPN	B
pylori	O	NOUN	I
is	O	AUX	O
not	O	PART	O
likely	O	ADJ	O
to	O	PART	O
relieve	O	VERB	O
symptoms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
non-ulcer	I-P	ADJ	B
dyspepsia	I-P	NOUN	I
,	O	PUNCT	O
a	O	DET	O
small	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
H.	B-P	X	B
pylori-infected	I-P	ADJ	I
patients	I-P	NOUN	B
may	O	AUX	O
benefit	O	VERB	O
from	O	ADP	O
eradication	O	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


Positive	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
methylphenidate	B-I	NOUN	B
on	O	ADP	O
social	B-OUT	ADJ	B
communication	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
self-regulation	I-OUT	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
pervasive	I-P	ADJ	B
developmental	I-P	ADJ	B
disorders	I-P	NOUN	I
and	I-P	CCONJ	O
hyperactivity	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
report	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
methylphenidate	B-I	NOUN	B
on	O	ADP	O
social	B-OUT	ADJ	B
communication	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
self-regulation	I-OUT	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
pervasive	I-P	ADJ	B
developmental	I-P	ADJ	B
disorders	I-P	NOUN	I
and	I-P	CCONJ	O
hyperactivity	I-P	NOUN	B
in	O	ADP	O
a	O	DET	O
secondary	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
RUPP	B-P	PROPN	B
Autism	I-P	PROPN	O
Network	I-P	PROPN	B
data	I-P	NOUN	B
.	I-P	PUNCT	O


Participants	B-P	NOUN	B
were	I-P	AUX	O
33	I-P	NUM	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
29	I-P	NUM	O
boys	I-P	NOUN	B
)	I-P	PUNCT	O
between	I-P	ADP	O
the	I-P	DET	O
ages	I-P	NOUN	B
of	I-P	ADP	O
5	I-P	NUM	O
and	I-P	CCONJ	O
13	I-P	NUM	O
years	I-P	NOUN	B
who	O	PRON	O
participated	O	VERB	O
in	O	ADP	O
a	O	DET	O
four-week	O	ADJ	B
crossover	O	NOUN	B
trial	O	NOUN	I
of	O	ADP	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
increasing	B-I	VERB	B
doses	I-I	NOUN	B
of	I-I	ADP	O
methylphenidate	I-I	NOUN	B
given	O	VERB	O
in	O	ADP	O
random	O	ADJ	B
order	O	NOUN	O
each	O	DET	O
for	O	ADP	O
one	O	NUM	O
week	O	NOUN	B
.	O	PUNCT	O


Observational	O	ADJ	B
measures	O	NOUN	B
of	O	ADP	O
certain	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
children	O	NOUN	B
's	O	PART	O
social	B-OUT	ADJ	B
communication	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
self-regulation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
affective	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
each	O	DET	O
week	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
positive	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
methylphenidate	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
on	O	ADP	O
children	O	NOUN	B
's	O	PART	I
use	O	NOUN	B
of	O	ADP	I
joint	B-OUT	ADJ	B
attention	I-OUT	NOUN	O
initiations	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
response	I-OUT	NOUN	B
to	I-OUT	PART	O
bids	I-OUT	NOUN	O
for	I-OUT	ADP	O
joint	I-OUT	ADJ	B
attention	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
self-regulation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
regulated	I-OUT	VERB	O
affective	I-OUT	ADJ	O
state	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
go	O	VERB	O
beyond	O	ADP	O
the	O	DET	O
recent	O	ADJ	O
literature	O	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
methylphenidate	B-I	NOUN	B
may	O	AUX	O
have	O	AUX	O
positive	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
social	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
PDD	I-P	NOUN	B
and	I-P	CCONJ	O
hyperactivity	I-P	NOUN	B
.	I-P	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
umbilical	B-I	ADJ	B
cord	I-I	NOUN	I
serum	I-I	NOUN	I
therapy	I-I	NOUN	I
for	O	ADP	O
persistent	B-P	ADJ	B
corneal	I-P	NOUN	B
epithelial	I-P	ADJ	O
defects	I-P	NOUN	O
.	I-P	PUNCT	O


AIMS	O	NOUN	B
To	O	PART	O
evaluate	O	VERB	B
umbilical	B-I	ADJ	B
cord	I-I	NOUN	I
serum	I-I	NOUN	I
therapy	I-I	NOUN	I
as	O	ADP	O
a	O	DET	O
means	O	NOUN	O
of	O	ADP	O
promoting	O	VERB	B
the	O	DET	O
healing	O	NOUN	B
of	O	ADP	O
persistent	B-OUT	ADJ	B
corneal	I-OUT	NOUN	B
epithelial	I-OUT	ADJ	O
defects	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
Umbilical	B-I	ADJ	B
cord	I-I	NOUN	I
serum	I-I	NOUN	I
or	I-I	CCONJ	O
autologous	I-I	ADJ	B
serum	I-I	NOUN	O
drops	I-I	NOUN	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
promote	O	VERB	B
the	O	DET	O
healing	O	NOUN	B
of	O	ADP	O
persistent	B-OUT	ADJ	B
epithelial	I-OUT	ADJ	B
defects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
study	O	NOUN	B
design	O	NOUN	B
was	O	AUX	O
a	O	DET	O
prospective	O	ADJ	B
randomised	O	ADJ	I
controlled	O	ADJ	I
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


60	B-P	NUM	O
eyes	I-P	NOUN	B
of	I-P	ADP	O
59	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
31	O	NUM	O
in	O	ADP	O
the	O	DET	O
cord	B-I	NOUN	B
serum	I-I	NOUN	O
group	O	NOUN	O
and	O	CCONJ	O
29	O	NUM	O
in	O	ADP	O
the	O	DET	O
autologous	B-I	ADJ	B
serum	I-I	NOUN	O
control	I-I	NOUN	O
group	I-I	NOUN	O
.	I-I	PUNCT	O


Epithelial	O	ADJ	B
defects	O	NOUN	O
measuring	O	VERB	B
at	O	ADP	O
least	O	ADV	O
2	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
linear	O	ADJ	B
dimension	O	NOUN	I
resistant	O	ADJ	I
to	O	PART	O
conventional	O	ADJ	B
medical	O	ADJ	B
management	O	NOUN	I
were	O	AUX	O
included	O	VERB	O
.	O	PUNCT	O


Serial	O	ADJ	O
measurements	O	NOUN	B
of	O	ADP	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
epithelial	O	ADJ	B
defects-namely	O	NOUN	O
,	O	PUNCT	O
two	O	NUM	O
maximum	O	ADJ	O
linear	O	ADJ	B
dimensions	O	NOUN	I
perpendicular	O	ADJ	O
to	O	ADP	O
each	O	DET	O
other	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
area	O	NOUN	B
and	O	CCONJ	O
perimeter	O	NOUN	B
was	O	AUX	O
done	O	VERB	O
at	O	ADP	O
start	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
and	O	CCONJ	O
follow	O	VERB	B
up	O	ADP	I
days	O	NOUN	I
3	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
21	O	NUM	O
.	O	PUNCT	O


Rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
healing	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
epithelial	I-OUT	ADJ	B
defects	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
as	O	ADP	O
percentage	O	NOUN	B
decrease	O	NOUN	B
from	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
parameter	O	NOUN	B
at	O	ADP	O
each	O	DET	O
subsequent	O	ADJ	O
follow	O	VERB	B
up	O	ADP	I
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
by	O	ADP	O
the	O	DET	O
non-parametric	O	ADJ	B
Wilcoxon	O	PROPN	I
rank	O	NOUN	I
sum	O	NOUN	I
test	O	NOUN	I
using	O	VERB	O
STATA	O	PROPN	B
7.0	O	NUM	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
median	O	ADJ	B
percentage	O	NOUN	B
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
size	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
epithelial	I-OUT	ADJ	B
defect	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
cord	B-I	NOUN	B
serum	I-I	NOUN	O
group	O	NOUN	O
at	O	ADP	O
days	O	NOUN	B
7	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
and	O	CCONJ	O
21	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
when	O	SCONJ	O
measured	O	VERB	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
area	O	NOUN	B
and	O	CCONJ	O
perimeter	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
greater	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
showed	O	VERB	O
complete	B-OUT	ADJ	B
re-epithelialisation	I-OUT	NOUN	B
with	O	ADP	O
umbilical	O	ADJ	B
cord	B-I	NOUN	I
serum	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
18	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
with	O	ADP	O
autologous	O	ADJ	B
serum	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
Pearson	O	NOUN	B
chi	O	NOUN	I
=	O	ADJ	O
0.19	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
reported	O	VERB	O
any	O	DET	O
side	O	NOUN	B
effects	O	NOUN	I
or	O	CCONJ	O
discomfort	O	NOUN	B
with	O	ADP	O
either	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Umbilical	B-I	ADJ	B
cord	I-I	NOUN	I
serum	I-I	NOUN	B
leads	O	VERB	O
to	O	PART	O
faster	B-OUT	ADJ	O
healing	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
persistent	I-OUT	ADJ	B
corneal	I-OUT	NOUN	B
epithelial	I-OUT	ADJ	O
defects	I-OUT	NOUN	O
refractory	O	ADJ	O
to	O	ADP	O
all	O	DET	O
medical	O	ADJ	B
management	O	NOUN	I
compared	O	VERB	O
to	O	PART	O
autologous	B-I	ADJ	B
serum	I-I	NOUN	B
.	I-I	PUNCT	O


Denosumab	B-I	NOUN	B
compared	O	VERB	O
with	O	ADP	O
zoledronic	B-I	ADJ	B
acid	I-I	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
bone	O	NOUN	B
metastases	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
compared	O	VERB	O
denosumab	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
fully	O	ADV	O
human	O	ADJ	B
monoclonal	O	ADJ	B
antibody	O	NOUN	I
against	O	ADP	O
receptor	O	NOUN	B
activator	O	NOUN	I
of	O	ADP	O
nuclear	O	ADJ	O
factor	O	NOUN	O
κ	O	NOUN	O
B	O	NOUN	O
(	O	PUNCT	O
RANK	O	NOUN	B
)	O	PUNCT	O
ligand	O	NOUN	B
,	O	PUNCT	O
with	B-I	ADP	O
zoledronic	I-I	ADJ	B
acid	I-I	NOUN	I
in	O	ADP	O
delaying	O	NOUN	B
or	O	CCONJ	O
preventing	O	VERB	B
skeletal-related	O	ADJ	B
events	O	NOUN	I
(	O	PUNCT	O
SREs	O	NOUN	B
)	O	PUNCT	O
in	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
with	I-P	ADP	O
bone	I-P	NOUN	B
metastases	I-P	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	B-I	VERB	O
either	I-I	CCONJ	O
subcutaneous	I-I	ADJ	B
denosumab	I-I	NOUN	B
120	I-I	NUM	O
mg	I-I	NOUN	O
and	I-I	CCONJ	O
intravenous	I-I	ADJ	B
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
1,026	I-P	NUM	O
)	I-P	PUNCT	O
or	I-I	CCONJ	O
intravenous	I-I	ADJ	B
zoledronic	I-I	ADJ	B
acid	I-I	NOUN	I
4	I-I	NUM	I
mg	I-I	NOUN	O
adjusted	I-I	VERB	O
for	I-I	ADP	O
creatinine	I-I	NOUN	B
clearance	I-I	NOUN	B
and	I-I	CCONJ	O
subcutaneous	I-I	ADJ	B
placebo	I-I	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
1,020	I-P	NUM	O
)	I-P	PUNCT	O
every	O	DET	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
strongly	O	ADV	O
recommended	O	VERB	B
to	O	PART	O
take	O	VERB	O
daily	B-I	ADJ	B
calcium	I-I	NOUN	B
and	I-I	CCONJ	O
vitamin	I-I	NOUN	B
D	I-I	NOUN	I
supplements	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
time	O	NOUN	O
to	B-OUT	PART	O
first	I-OUT	ADJ	O
on-study	I-OUT	ADJ	O
SRE	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
defined	I-OUT	VERB	O
as	I-OUT	ADP	O
pathologic	I-OUT	ADJ	B
fracture	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
radiation	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
surgery	I-OUT	NOUN	B
to	I-OUT	ADP	O
bone	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
spinal	I-OUT	ADJ	B
cord	I-OUT	NOUN	I
compression	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	O	PUNCT	O


RESULTS	B-I	NOUN	O
Denosumab	I-I	NOUN	B
was	O	AUX	O
superior	O	ADJ	O
to	B-I	PART	O
zoledronic	I-I	ADJ	B
acid	I-I	NOUN	I
in	I-OUT	ADP	O
delaying	I-OUT	VERB	B
time	I-OUT	NOUN	O
to	I-OUT	ADP	O
first	I-OUT	ADJ	O
on-study	I-OUT	ADJ	O
SRE	I-OUT	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.82	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.71	O	NUM	O
to	O	PART	O
0.95	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.01	O	NUM	O
superiority	O	NOUN	B
)	O	PUNCT	O
and	B-OUT	CCONJ	O
time	I-OUT	NOUN	B
to	I-OUT	ADP	O
first	I-OUT	ADV	O
and	I-OUT	CCONJ	O
subsequent	I-OUT	ADJ	O
(	I-OUT	PUNCT	O
multiple	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
on-study	I-OUT	ADJ	O
SREs	I-OUT	NOUN	B
(	O	PUNCT	O
rate	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.77	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.66	O	NUM	O
to	O	PART	O
0.89	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.001	O	NUM	O
)	O	PUNCT	O
.	B-OUT	PUNCT	O


Reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
bone	I-OUT	NOUN	B
turnover	I-OUT	NOUN	B
markers	I-OUT	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
with	O	ADP	O
denosumab	O	NOUN	B
.	B-OUT	PUNCT	O


Overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
disease	I-OUT	NOUN	B
progression	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
rates	I-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AEs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
serious	I-OUT	ADJ	O
AEs	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


An	B-OUT	DET	O
excess	I-OUT	NOUN	B
of	I-OUT	ADP	O
renal	I-OUT	ADJ	B
AEs	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
acute-phase	I-OUT	ADJ	B
reactions	I-OUT	NOUN	I
occurred	O	VERB	O
with	O	ADP	O
zoledronic	O	ADJ	B
acid	B-OUT	NOUN	I
;	I-OUT	PUNCT	O
hypocalcemia	I-OUT	NOUN	B
occurred	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
with	B-I	ADP	O
denosumab	I-I	NOUN	B
.	I-OUT	PUNCT	O


Osteonecrosis	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
jaw	I-OUT	NOUN	B
occurred	O	VERB	O
infrequently	O	ADV	O
(	O	PUNCT	O
2.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
denosumab	B-I	NOUN	B
;	I-I	PUNCT	O
1.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
zoledronic	B-I	ADJ	B
acid	I-I	NOUN	I
;	I-I	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.39	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	B-I	NOUN	O
Denosumab	I-I	NOUN	B
was	O	AUX	O
superior	O	ADJ	O
to	B-I	PART	O
zoledronic	I-I	ADJ	B
acid	I-I	NOUN	I
in	O	ADP	O
delaying	O	NOUN	B
or	O	CCONJ	O
preventing	O	VERB	B
SREs	O	NOUN	B
in	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
metastatic	I-P	ADJ	B
to	I-P	PART	O
bone	I-P	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
generally	O	ADV	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


With	O	ADP	O
the	O	DET	O
convenience	O	NOUN	B
of	O	ADP	O
a	O	DET	O
subcutaneous	O	ADJ	B
injection	O	NOUN	I
and	O	CCONJ	O
no	O	DET	O
requirement	O	NOUN	O
for	O	ADP	O
renal	O	ADJ	B
monitoring	O	NOUN	I
,	O	PUNCT	O
denosumab	B-I	NOUN	B
represents	O	VERB	O
a	O	DET	O
potential	O	ADJ	B
treatment	O	NOUN	B
option	O	NOUN	O
for	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
bone	I-P	NOUN	B
metastases	I-P	NOUN	I
.	O	PUNCT	O


Combination	O	NOUN	B
cyclopentolate	B-I	NOUN	I
and	O	CCONJ	O
phenylephrine	B-I	NOUN	B
for	O	ADP	O
mydriasis	O	NOUN	B
in	O	ADP	O
premature	B-P	ADJ	B
infants	I-P	NOUN	I
with	I-P	ADP	O
heavily	I-P	ADV	O
pigmented	I-P	ADJ	B
irides	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
whether	O	SCONJ	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
mydriasis	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
premature	B-P	ADJ	B
infants	I-P	NOUN	I
with	I-P	ADP	O
heavily	I-P	ADV	O
pigmented	I-P	ADJ	B
irides	I-P	NOUN	B
using	O	VERB	O
combination	O	NOUN	B
cyclopentolate	B-I	NOUN	I
0.2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
phenylephrine	B-I	NOUN	B
1	O	NUM	O
%	O	NOUN	O
eyedrops	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
combination	O	NOUN	B
cyclopentolate	B-I	NOUN	B
0.2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
phenylephrine	B-I	NOUN	B
1	O	NUM	O
%	O	NOUN	O
eye-drops	O	NOUN	B
with	O	ADP	O
triple	O	ADJ	B
instillation	O	NOUN	I
of	O	ADP	O
tropicamide	B-I	NOUN	B
0.5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
phenylephrine	B-I	NOUN	B
2.5	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Twenty-eight	B-P	NUM	O
consecutive	I-P	ADJ	B
babies	I-P	NOUN	B
with	I-P	ADP	O
dark	I-P	ADJ	B
irides	I-P	NOUN	I
and	I-P	CCONJ	O
birthweight	I-P	NOUN	B
<	I-P	NOUN	O
1600	I-P	NUM	O
g	I-P	NOUN	O
referred	I-P	VERB	O
for	I-P	ADP	O
screening	I-P	NOUN	B
for	I-P	ADP	O
retinopathy	I-P	NOUN	B
of	I-P	ADP	O
prematurity	I-P	NOUN	B
comprised	I-P	VERB	O
the	I-P	DET	O
study	I-P	NOUN	B
population	I-P	NOUN	I
.	I-P	PUNCT	O


Infants	O	NOUN	B
'	O	PART	O
eyes	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
dilated	O	ADJ	B
twice	O	ADV	B
with	O	ADP	I
both	O	DET	O
regimens	O	NOUN	B
within	O	ADP	O
a	O	DET	O
2-week	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
pupil	I-OUT	NOUN	B
size	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Good	O	ADJ	B
mydriasis	O	NOUN	I
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
differences	B-OUT	NOUN	O
in	I-OUT	ADP	O
pupil	I-OUT	NOUN	B
size	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
systolic	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
diastolic	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
mean	I-OUT	VERB	O
arterial	I-OUT	ADJ	B
pressures	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
over	O	ADP	O
starting	O	VERB	O
baseline	O	NOUN	B
values	O	NOUN	O
.	O	PUNCT	O


Pulse	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
decelerated	O	VERB	B
below	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
values	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
these	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
large	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
single	O	ADJ	O
combination	O	NOUN	B
eyedrop	O	NOUN	B
of	O	ADP	O
cyclopentolate	O	NOUN	B
0.2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
phenylephrine	O	NOUN	B
1	O	NUM	O
%	O	NOUN	O
is	O	AUX	O
as	O	ADV	O
effective	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
a	O	DET	O
mydriatic	O	ADJ	B
for	O	ADP	O
infants	O	NOUN	B
with	O	ADP	O
dark	O	ADJ	B
irides	O	NOUN	I
as	O	ADP	O
both	O	DET	O
tropicamide	O	NOUN	B
0.5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
phenylephrine	O	NOUN	B
2.5	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Tacrolimus	B-I	NOUN	B
monotherapy	O	NOUN	B
without	O	ADP	O
steroids	O	NOUN	B
after	B-P	ADP	O
liver	I-P	NOUN	B
transplantation	I-P	NOUN	I
--	I-P	PUNCT	O
a	I-P	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
double-blinded	O	ADJ	O
placebo-controlled	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


Early	O	ADJ	B
steroid	O	NOUN	B
withdrawal	O	NOUN	B
after	B-P	ADP	O
liver	I-P	NOUN	B
transplantation	I-P	NOUN	I
(	I-P	PUNCT	O
LT	I-P	NOUN	B
)	I-P	PUNCT	O
is	O	AUX	O
desirable	O	ADJ	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
reduce	O	VERB	B
steroid	O	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


Between	B-P	ADP	O
February	I-P	PROPN	O
2000	I-P	NUM	O
and	I-P	CCONJ	O
August	I-P	PROPN	O
2004	I-P	NUM	O
,	I-P	PUNCT	O
110	I-P	NUM	O
patients	I-P	NOUN	B
after	I-P	ADP	O
LT	I-P	NOUN	B
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
this	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Randomization	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
before	O	ADP	O
LT	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
tacrolimus	B-I	NOUN	B
was	I-I	AUX	O
used	I-I	VERB	O
without	I-I	ADP	O
induction	I-I	NOUN	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


All	B-P	DET	O
patients	I-P	NOUN	B
received	I-P	VERB	O
methylprednisolon	I-I	NOUN	B
for	I-P	ADP	O
14	I-P	NUM	O
days	I-P	NOUN	B
,	O	PUNCT	O
thereafter	O	ADP	O
a	O	DET	O
double-blinded	O	ADJ	B
medication	O	NOUN	B
containing	O	VERB	O
either	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
56	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
methylprednisolon	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
54	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
completely	O	ADV	O
stopped	O	VERB	O
thereafter	O	ADV	O
.	O	PUNCT	O


End	O	NOUN	O
points	O	NOUN	O
were	O	AUX	O
patient	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
graft	I-OUT	NOUN	B
survival	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
acute	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
chronic	I-OUT	ADJ	B
rejection	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
steroid	I-OUT	NOUN	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
after	B-P	ADP	O
LT	I-P	NOUN	B
.	I-P	PUNCT	O


One-year	O	ADJ	B
patient	B-OUT	NOUN	B
survival	I-OUT	NOUN	I
was	O	AUX	O
85.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
placebo	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
88.8	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
steroid	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.572	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Twenty-seven	O	NUM	O
(	O	PUNCT	O
48.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
19	O	NUM	O
(	O	PUNCT	O
35.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
experienced	O	VERB	O
acute	B-OUT	ADJ	B
rejection	I-OUT	NOUN	I
(	O	PUNCT	O
placebo	O	NOUN	B
versus	O	CCONJ	O
steroid	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.116	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	B
but	O	CCONJ	O
none	O	NOUN	O
in	O	ADP	O
the	O	DET	O
steroid	O	NOUN	B
group	O	NOUN	B
experienced	O	VERB	O
chronic	B-OUT	ADJ	B
rejection	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.257	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
(	B-I	PUNCT	O
placebo	I-I	NOUN	B
versus	O	CCONJ	O
steroid	B-I	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
:	O	PUNCT	O
CMV	B-OUT	NOUN	B
infection	I-OUT	NOUN	I
25	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
33	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.336	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
post-transplant	B-OUT	ADJ	B
diabetes	I-OUT	NOUN	I
30	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
53	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.024	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
hypertension	B-OUT	NOUN	B
39	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
52	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.248	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
hypercholesterolemia	B-OUT	NOUN	B
10	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
41	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
hypertriglyceridemia	B-OUT	NOUN	B
32	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
54	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.046	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
early	O	ADJ	O
steroid	O	NOUN	B
withdrawal	O	NOUN	B
after	B-P	ADP	O
LT	I-P	NOUN	B
is	O	AUX	O
feasible	B-OUT	ADJ	O
under	O	ADP	O
tacrolimus	B-I	NOUN	B
monotherapy	O	NOUN	B
without	O	ADP	O
increased	O	VERB	B
rejection	O	NOUN	B
rates	O	NOUN	I
and	O	CCONJ	O
with	O	ADP	O
a	O	DET	O
lower	B-OUT	ADJ	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Diet	B-I	ADJ	B
and	O	CCONJ	O
tobacco	O	NOUN	B
use	O	NOUN	I
:	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
data	O	NOUN	B
from	O	ADP	O
the	O	DET	O
diabetic	O	ADJ	B
control	O	NOUN	B
and	O	CCONJ	O
complications	O	NOUN	B
trial	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


CONTEXT	O	NOUN	B
The	O	DET	O
Diabetic	O	ADJ	B
Control	O	PROPN	I
and	O	CCONJ	I
Complications	O	PROPN	I
Trial	O	PROPN	I
(	O	PUNCT	O
DCCT	O	NOUN	B
)	O	PUNCT	O
researchers	O	NOUN	B
kept	O	VERB	O
careful	O	ADJ	O
records	O	NOUN	B
of	O	ADP	O
the	O	DET	O
food	O	NOUN	B
consumption	O	NOUN	I
and	O	CCONJ	O
tobacco	O	NOUN	B
using	O	VERB	O
habits	O	NOUN	B
of	B-P	ADP	O
type	I-P	NOUN	B
1	I-P	NUM	I
diabetic	I-P	ADJ	I
subjects	I-P	NOUN	B
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
they	O	PRON	O
did	O	AUX	O
not	O	PART	O
report	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
tobacco	B-OUT	NOUN	B
using	I-OUT	VERB	O
habits	I-OUT	NOUN	B
with	O	ADP	O
dietary	B-OUT	ADJ	B
intake	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


OBJECTIVE	O	NOUN	O
Analyze	O	VERB	O
the	O	DET	O
relationship	B-OUT	NOUN	B
between	I-OUT	ADP	O
tobacco	I-OUT	NOUN	B
smoking	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
intake	I-OUT	NOUN	B
of	I-OUT	ADP	O
macro	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
micronutrients	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
Referral	B-P	ADJ	I
clinics	I-P	NOUN	I
in	I-P	ADP	O
27	I-P	NUM	O
academic	I-P	ADJ	B
centers	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	B-P	VERB	B
Type	I-P	NOUN	I
1	I-P	NUM	I
diabetics	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTION	O	PROPN	B
Using	O	VERB	O
the	O	DET	O
data	B-I	NOUN	B
sets	I-I	NOUN	I
of	I-I	ADP	O
the	I-I	DET	O
DCCT	I-I	PROPN	B
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
analyzed	O	VERB	B
the	O	DET	O
strengths	O	NOUN	B
of	O	ADP	O
the	O	DET	O
associations	B-OUT	NOUN	B
between	I-OUT	ADP	O
smoking	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
macronutrient	I-OUT	ADJ	B
consumption	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hemoglobin	I-OUT	NOUN	B
A1c	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HbA1c	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BMI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
lipid	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
study	O	NOUN	B
baseline	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	B
MEASURES	O	NOUN	O
Statistically	B-OUT	ADV	B
significant	I-OUT	ADJ	I
correlations	I-OUT	NOUN	B
between	I-OUT	ADP	O
smoking	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
nutrient	I-OUT	ADJ	B
intake	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
HbA1c	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
lipid	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Cigarette	B-OUT	PROPN	B
,	I-OUT	PUNCT	O
cigar	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
pipe	I-OUT	NOUN	B
use	I-OUT	NOUN	I
at	O	ADP	O
each	O	DET	O
time	O	NOUN	B
interval	O	NOUN	I
correlated	O	VERB	B
with	O	ADP	O
significantly	O	ADV	O
increased	O	VERB	B
caloric	B-OUT	ADJ	B
intake	I-OUT	NOUN	I
in	O	ADP	O
males	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
males	B-P	NOUN	B
and	I-P	CCONJ	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
tobacco	I-OUT	NOUN	B
users	I-OUT	NOUN	I
consumed	I-OUT	VERB	O
more	I-OUT	ADJ	O
fat	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
cholesterol	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
alcohol	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Female	B-P	ADJ	B
smokers	I-P	NOUN	I
had	O	AUX	O
higher	O	ADJ	B
serum	B-OUT	NOUN	B
low-density	I-OUT	ADJ	I
lipoprotein	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
LDL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
/high-density	I-OUT	ADJ	O
lipoprotein	I-OUT	NOUN	B
(	I-OUT	PUNCT	I
HDL	I-OUT	NOUN	I
)	I-OUT	PUNCT	I
ratios	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
triglycerides	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Serum	B-OUT	NOUN	B
cholesterols	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
LDL/HDL	I-OUT	NOUN	B
ratios	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
LDL	I-OUT	NOUN	B
cholesterols	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
triglyceride	I-OUT	NOUN	B
determinations	I-OUT	NOUN	O
in	O	ADP	O
male	B-P	NOUN	B
tobacco	I-P	NOUN	O
users	I-P	NOUN	O
significantly	O	ADV	O
exceeded	O	VERB	O
those	O	DET	O
in	O	ADP	O
nonsmoking	O	ADJ	B
males	O	NOUN	B
.	O	PUNCT	O


HDL	B-OUT	NOUN	B
cholesterols	I-OUT	NOUN	I
were	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
both	O	CCONJ	O
female	B-P	ADJ	B
and	I-P	CCONJ	O
male	I-P	NOUN	B
tobacco	I-P	NOUN	O
users	I-P	NOUN	O
.	I-P	PUNCT	O


Nutrient	B-OUT	ADJ	B
intake	I-OUT	NOUN	B
of	O	ADP	O
former	B-P	ADJ	B
tobacco	I-P	NOUN	I
users	I-P	NOUN	I
resembled	O	VERB	O
that	O	DET	O
of	O	ADP	O
nonusers	O	NOUN	B
rather	O	ADV	O
than	O	ADP	O
current	O	ADJ	B
users	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
A	O	DET	O
significant	O	ADJ	O
association	O	NOUN	B
exists	O	VERB	O
between	O	ADP	O
smoking	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
diet	B-OUT	NOUN	B
with	I-OUT	ADP	O
higher	I-OUT	ADJ	O
risks	I-OUT	NOUN	B
of	I-OUT	ADP	O
atherosclerosis	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
cancer	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
other	I-OUT	ADJ	O
degenerative	I-OUT	ADJ	B
diseases	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
strong	O	ADJ	O
association	O	NOUN	B
of	O	ADP	O
tobacco	O	NOUN	B
with	O	ADP	I
heart	O	NOUN	B
disease	O	NOUN	I
,	O	PUNCT	O
stroke	O	NOUN	B
,	O	PUNCT	O
vasculopathies	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
various	O	ADJ	O
malignancies	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
in	O	ADP	O
part	O	NOUN	O
due	O	ADJ	O
to	O	PART	O
its	O	PRON	O
association	O	NOUN	B
with	O	ADP	O
a	O	DET	O
higher	O	ADJ	B
fat	B-OUT	ADJ	B
diet	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
higher	O	ADJ	B
fat	O	ADJ	B
diet	O	NOUN	I
of	O	ADP	O
tobacco	O	NOUN	B
users	O	NOUN	I
probably	O	ADV	O
accounts	O	VERB	O
in	O	ADP	O
part	O	NOUN	O
for	O	ADP	O
their	O	PRON	O
higher	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
and	O	CCONJ	O
hyperlipidemia	O	NOUN	B
.	O	PUNCT	O


Tobacco	O	PROPN	B
users	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
informed	O	VERB	O
about	O	ADP	O
the	O	DET	O
diet	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tobacco	I-OUT	NOUN	B
use	I-OUT	NOUN	I
association	O	NOUN	B
.	O	PUNCT	O


Blockade	O	NOUN	B
of	O	ADP	O
endogenous	O	ADJ	B
growth	O	NOUN	O
hormone-releasing	O	ADJ	B
hormone	O	NOUN	I
receptors	O	NOUN	I
dissociates	O	VERB	B
nocturnal	B-OUT	ADJ	B
growth	I-OUT	NOUN	O
hormone	I-OUT	NOUN	O
secretion	I-OUT	NOUN	B
and	O	CCONJ	O
slow-wave	B-OUT	ADJ	B
sleep	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


OBJECTIVES	O	VERB	O
A	O	DET	O
temporal	O	ADJ	B
association	O	NOUN	B
between	O	ADP	O
non-rapid	O	ADJ	B
eye	O	NOUN	I
movement	O	NOUN	I
(	O	PUNCT	O
NREM	O	NOUN	B
)	O	PUNCT	O
sleep	O	NOUN	B
stages	O	NOUN	I
3	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
and	O	CCONJ	O
nocturnal	O	ADJ	B
augmentation	O	NOUN	B
of	O	ADP	O
GH	O	NOUN	B
release	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
long	O	ADV	O
ago	O	ADV	O
,	O	PUNCT	O
yet	O	CCONJ	O
the	O	DET	O
precise	O	ADJ	O
mechanism	O	NOUN	B
for	O	ADP	O
this	O	DET	O
association	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
,	O	PUNCT	O
however	O	ADV	O
that	O	SCONJ	O
pulsatile	O	ADJ	B
GHRH	O	NOUN	B
administration	O	NOUN	B
increases	O	VERB	B
both	O	CCONJ	O
slow-wave	B-OUT	ADJ	B
sleep	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SWS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
GH	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
these	O	DET	O
data	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
GHRH	O	NOUN	B
as	O	ADP	O
an	O	DET	O
inducer	O	NOUN	B
of	O	ADP	O
SWS	O	NOUN	B
was	O	AUX	O
proposed	O	VERB	O
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
performed	O	VERB	O
the	O	DET	O
corollary	O	ADJ	O
experiment	O	NOUN	B
whereby	O	SCONJ	O
the	O	DET	O
action	O	NOUN	B
of	O	ADP	O
endogenous	O	ADJ	B
GHRH	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
antagonized	O	VERB	B
.	O	PUNCT	O


DESIGN	O	VERB	O
Healthy	B-P	ADJ	B
men	I-P	NOUN	B
(	I-P	PUNCT	O
20-33	I-P	NUM	O
years	I-P	NOUN	O
old	I-P	ADJ	O
)	I-P	PUNCT	O
had	O	AUX	O
an	O	DET	O
infusion	B-I	NOUN	B
of	I-I	ADP	O
GHRH	I-I	NOUN	B
antagonist	I-I	NOUN	B
(	I-I	PUNCT	O
(	I-I	PUNCT	O
N-Ac-Tyr	I-I	NOUN	B
(	I-I	PUNCT	O
1	I-I	NUM	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
D-Arg	I-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
GHRH-29	I-I	NOUN	B
(	I-I	PUNCT	O
NH	I-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
saline	I-I	NOUN	B
for	I-I	ADP	O
a	I-I	DET	O
12-h	I-I	ADJ	O
period	I-I	NOUN	B
,	O	PUNCT	O
between	O	ADP	O
2100	O	NUM	O
and	O	CCONJ	O
0900	O	NUM	O
h.	O	NOUN	O
An	O	DET	O
i.v	O	NOUN	O
.	O	PUNCT	O


bolus	O	NOUN	B
of	O	ADP	O
GHRH	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
at	O	ADP	O
0700	O	NUM	O
h	O	NOUN	O
and	O	CCONJ	O
GH	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
drawn	O	VERB	O
from	O	ADP	O
0700	O	NUM	O
to	O	PART	O
0900	O	NUM	O
h	O	NOUN	O
to	O	PART	O
document	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
GH	B-OUT	NOUN	B
suppression	O	NOUN	I
by	O	ADP	O
the	O	DET	O
GHRH	O	NOUN	B
antagonist	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
A	O	DET	O
limited	O	ADJ	O
montage	O	NOUN	B
sleep	O	NOUN	I
study	O	NOUN	O
was	O	AUX	O
recorded	O	VERB	O
from	O	ADP	O
2300	O	NUM	O
to	O	PART	O
0700	O	NUM	O
h	O	NOUN	O
during	O	ADP	O
each	O	DET	O
admission	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
GH	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
sensitive	O	ADJ	B
chemiluminometric	O	ADJ	B
assay	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Effectiveness	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
GHRH	O	NOUN	B
antagonist	O	NOUN	B
was	O	AUX	O
validated	O	VERB	O
in	O	ADP	O
all	O	DET	O
subjects	O	NOUN	B
by	O	ADP	O
demonstrating	O	VERB	O
93+/-1.8	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P=0.012	O	NOUN	O
)	O	PUNCT	O
suppression	B-OUT	NOUN	B
of	I-OUT	ADP	O
GH	I-OUT	NOUN	B
response	I-OUT	NOUN	I
to	O	PART	O
a	O	DET	O
GHRH	O	NOUN	B
bolus	O	NOUN	B
.	O	PUNCT	O


Polysomnography	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
SWS	B-OUT	NOUN	B
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
when	O	SCONJ	O
saline	O	NOUN	B
and	O	CCONJ	O
GHRH	O	NOUN	B
antagonist	O	NOUN	B
nights	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
(	O	PUNCT	O
P=0.607	O	ADJ	O
)	O	PUNCT	O
;	O	PUNCT	O
other	O	ADJ	O
quantifiable	O	ADJ	O
sleep	B-OUT	NOUN	B
parameters	I-OUT	NOUN	B
were	O	AUX	O
also	O	ADV	O
unchanged	O	ADJ	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
endogenous	O	ADJ	B
GHRH	O	NOUN	B
is	O	AUX	O
indispensable	O	ADJ	O
for	O	ADP	O
the	O	DET	O
nocturnal	O	ADJ	B
augmentation	O	NOUN	B
of	O	ADP	O
GH	O	NOUN	B
secretion	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
unlikely	O	ADJ	O
to	O	PART	O
participate	O	VERB	B
in	O	ADP	O
the	O	DET	O
genesis	O	NOUN	B
of	O	ADP	O
SWS	O	NOUN	B
.	O	PUNCT	O


Reducing	O	VERB	B
iodine	O	NOUN	B
load	O	NOUN	I
in	O	ADP	O
hepatic	O	ADJ	B
CT	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
liver	I-P	NOUN	I
disease	I-P	NOUN	I
with	O	ADP	O
a	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
low-tube-voltage	I-I	NOUN	B
and	I-I	CCONJ	O
adaptive	I-I	ADJ	B
statistical	I-I	ADJ	I
iterative	I-I	NOUN	I
reconstruction	I-I	NOUN	I
.	I-I	PUNCT	O


PURPOSE	O	VERB	O
To	O	PART	O
prospectively	O	ADV	O
assess	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
reduced	O	VERB	B
iodine	O	NOUN	B
load	O	NOUN	I
to	O	PART	O
contrast	O	NOUN	B
enhancement	O	NOUN	I
,	O	PUNCT	O
image	O	NOUN	B
quality	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
detectability	O	NOUN	B
of	O	ADP	O
hepatocellular	O	ADJ	B
carcinomas	O	NOUN	I
(	O	PUNCT	O
HCCs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
hepatic	O	ADJ	B
CT	O	NOUN	I
with	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
80	B-I	NUM	O
kVp	I-I	NOUN	B
tube	I-I	NOUN	I
voltage	I-I	NOUN	I
setting	I-I	NOUN	I
and	I-I	CCONJ	O
adaptive	I-I	ADJ	B
statistical	I-I	ADJ	I
iterative	I-I	NOUN	I
reconstruction	I-I	NOUN	I
(	I-I	PUNCT	O
ASIR	I-I	NOUN	B
)	I-I	PUNCT	O
technique	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
liver	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
This	O	DET	O
HIPAA-compliant	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
approved	O	VERB	O
by	O	ADP	O
our	O	PRON	O
institutional	O	ADJ	B
review	O	NOUN	I
board	O	NOUN	I
and	O	CCONJ	O
written	O	VERB	B
informed	O	ADJ	I
consent	O	NOUN	I
was	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
a	O	DET	O
recent	O	ADJ	O
9-month	O	ADJ	O
period	O	NOUN	B
,	O	PUNCT	O
170	B-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
114	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
56	I-P	NUM	O
women	I-P	NOUN	B
;	I-P	PUNCT	O
age	I-P	NOUN	B
range	I-P	NOUN	O
,	I-P	PUNCT	O
40-85	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	VERB	O
,	I-P	PUNCT	O
67.7	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
suspected	I-P	VERB	B
chronic	I-P	ADJ	B
liver	I-P	NOUN	I
diseases	I-P	NOUN	I
were	O	AUX	O
randomized	B-I	VERB	B
into	I-I	ADP	O
three	I-I	NUM	O
CT	I-I	NOUN	B
groups	I-I	NOUN	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
following	O	VERB	O
iodine-load	B-I	ADJ	B
and	I-I	CCONJ	O
tube-voltage	I-I	ADJ	B
protocols	I-I	NOUN	I
:	I-I	PUNCT	O
600	I-I	NUM	O
milligram	I-I	NOUN	O
per	I-I	ADP	O
kilogram	I-I	NOUN	O
body	I-I	NOUN	O
weight	I-I	NOUN	O
(	I-I	PUNCT	O
mg/kg	I-I	NOUN	O
)	I-I	PUNCT	O
iodine	I-I	NOUN	B
load	I-I	NOUN	I
and	I-I	CCONJ	O
120	I-I	NUM	O
peak	I-I	NOUN	B
kilovolt	I-I	NOUN	I
(	I-I	PUNCT	O
kVp	I-I	NOUN	B
)	I-I	PUNCT	O
tube	I-I	NOUN	O
voltage	I-I	NOUN	O
setting	I-I	NOUN	O
(	I-I	PUNCT	O
600-120	I-I	NUM	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
,	I-I	PUNCT	O
500	I-I	NUM	O
mg/kg	I-I	NOUN	O
and	I-I	CCONJ	O
80	I-I	NUM	O
kVp	I-I	NOUN	B
(	I-I	PUNCT	O
500-80	I-I	NUM	O
group	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
400mg/kg	I-I	ADJ	O
and	I-I	CCONJ	O
80	I-I	NUM	O
kVp	I-I	NOUN	B
(	I-I	PUNCT	O
400-80	I-I	NUM	O
group	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
variance	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
differences	O	NOUN	B
in	O	ADP	O
CT	B-OUT	NOUN	B
number	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
background	I-OUT	NOUN	B
noise	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
signal-to-noise	I-OUT	ADJ	B
ratio	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SNR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
effective	I-OUT	ADJ	B
dose	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
HCC-to-liver	I-OUT	ADJ	B
contrast-to-noise	I-OUT	ADJ	O
ratio	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
CNR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
figure	I-OUT	NOUN	O
of	I-OUT	ADP	O
merit	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
FOM	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Sensitivity	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
specificity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
area	I-OUT	NOUN	B
under	I-OUT	ADP	I
the	I-OUT	DET	I
receiver-operating-characteristic	I-OUT	ADJ	B
curve	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AUC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
detectability	O	NOUN	B
of	O	ADP	O
HCCs	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Vascular	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
hepatic	I-OUT	ADJ	B
enhancement	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
400-80	O	NUM	O
and	O	CCONJ	O
500-80	O	NUM	O
groups	O	NOUN	B
was	O	AUX	O
comparable	O	ADJ	O
to	O	PART	O
or	O	CCONJ	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
600-120	O	NUM	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Subjective	B-OUT	ADJ	B
image	I-OUT	NOUN	O
quality	I-OUT	NOUN	O
was	O	AUX	O
comparable	O	ADJ	O
among	O	ADP	O
the	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Sensitivity	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
specificity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
AUC	I-OUT	NOUN	B
for	O	ADP	O
detecting	B-OUT	VERB	B
HCCs	I-OUT	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
among	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effective	O	ADJ	B
dose	O	NOUN	B
was	O	AUX	O
kept	O	VERB	O
low	O	ADJ	B
(	O	PUNCT	O
3.3-4.1	O	NUM	O
mSv	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Iodine	O	NOUN	B
load	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
33	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
CT	O	NOUN	B
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
with	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
80	B-I	NUM	O
kVp	I-I	NOUN	B
tube	I-I	NOUN	I
voltage	I-I	NOUN	I
setting	I-I	NOUN	I
and	I-I	CCONJ	O
ASIR	I-I	NOUN	B
technique	I-I	NOUN	O
,	O	PUNCT	O
without	O	ADP	O
compromising	O	VERB	O
the	O	DET	O
contrast	B-OUT	NOUN	B
enhancement	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
image	I-OUT	NOUN	B
quality	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
detection	B-OUT	NOUN	B
of	I-OUT	ADP	O
HCCs	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Safety	O	NOUN	B
and	O	CCONJ	O
benefit	O	NOUN	B
of	O	ADP	O
discontinuing	O	VERB	B
statin	B-I	NOUN	B
therapy	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
advanced	B-P	ADJ	B
,	I-P	PUNCT	O
life-limiting	I-P	ADJ	B
illness	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


IMPORTANCE	O	NOUN	B
For	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
limited	I-P	ADJ	O
prognosis	I-P	NOUN	B
,	O	PUNCT	O
some	O	DET	O
medication	O	NOUN	B
risks	O	NOUN	B
may	O	AUX	O
outweigh	O	VERB	O
the	O	DET	O
benefits	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
when	O	SCONJ	O
benefits	O	NOUN	B
take	O	VERB	O
years	O	NOUN	B
to	O	PART	O
accrue	O	VERB	O
;	O	PUNCT	O
statins	O	NOUN	B
are	O	AUX	O
one	O	NUM	O
example	O	NOUN	O
.	O	PUNCT	O


Data	O	NOUN	B
are	O	AUX	O
lacking	O	VERB	O
regarding	O	VERB	O
the	O	DET	O
risks	O	NOUN	B
and	O	CCONJ	O
benefits	O	NOUN	B
of	O	ADP	O
discontinuing	O	VERB	B
statin	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
limited	I-P	ADJ	B
life	I-P	NOUN	O
expectancy	I-P	NOUN	O
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
,	O	PUNCT	O
clinical	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
cost	O	NOUN	B
impact	O	NOUN	B
of	O	ADP	O
discontinuing	O	VERB	B
statin	B-I	ADJ	B
medications	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
palliative	I-P	ADJ	B
care	I-P	NOUN	I
setting	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
AND	O	CCONJ	O
PARTICIPANTS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
parallel-group	O	NOUN	B
,	O	PUNCT	O
unblinded	O	ADJ	B
,	O	PUNCT	O
pragmatic	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Eligibility	B-P	NOUN	B
included	I-P	VERB	O
adults	I-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
estimated	I-P	VERB	B
life	I-P	NOUN	B
expectancy	I-P	NOUN	I
of	I-P	ADP	O
between	I-P	ADP	O
1	I-P	NUM	O
month	I-P	NOUN	B
and	I-P	CCONJ	O
1	I-P	NUM	O
year	I-P	NOUN	B
,	I-P	PUNCT	O
statin	I-P	NOUN	B
therapy	I-P	NOUN	I
for	I-P	ADP	O
3	I-P	NUM	O
months	I-P	NOUN	B
or	I-P	CCONJ	O
more	I-P	ADJ	O
for	I-P	ADP	O
primary	I-P	ADJ	B
or	I-P	CCONJ	O
secondary	I-P	ADJ	B
prevention	I-P	NOUN	I
of	I-P	ADP	O
cardiovascular	I-P	ADJ	B
disease	I-P	NOUN	I
,	I-P	PUNCT	O
recent	I-P	ADJ	O
deterioration	I-P	NOUN	B
in	I-P	ADP	O
functional	I-P	ADJ	B
status	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
no	I-P	DET	O
recent	I-P	ADJ	O
active	I-P	ADJ	O
cardiovascular	I-P	ADJ	B
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
either	O	CCONJ	O
discontinue	B-I	VERB	B
or	I-I	CCONJ	O
continue	I-I	VERB	O
statin	I-I	NOUN	B
therapy	I-I	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
monitored	O	VERB	O
monthly	O	ADV	B
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
conducted	B-P	VERB	O
from	I-P	ADP	O
June	I-P	PROPN	O
3	I-P	NUM	O
,	I-P	PUNCT	O
2011	I-P	NUM	O
,	I-P	PUNCT	O
to	I-P	ADP	O
May	I-P	PROPN	O
2	I-P	NUM	O
,	I-P	PUNCT	O
2013	I-P	NUM	O
.	I-P	PUNCT	O


All	O	DET	O
analyses	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
an	O	DET	O
intent-to-treat	O	ADJ	B
approach	O	NOUN	I
.	O	PUNCT	O


INTERVENTIONS	O	VERB	B
Statin	B-I	NOUN	B
therapy	I-I	NOUN	I
was	O	AUX	O
withdrawn	O	VERB	O
from	O	ADP	O
eligible	O	ADJ	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
randomized	O	ADJ	B
to	O	PART	O
the	O	DET	O
discontinuation	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
continuation	O	NOUN	B
group	O	NOUN	I
continued	O	VERB	O
to	O	PART	O
receive	B-I	VERB	O
statins	I-I	NOUN	B
.	I-I	PUNCT	O


MAIN	O	ADJ	O
OUTCOMES	O	NOUN	O
AND	O	CCONJ	O
MEASURES	O	PROPN	O
Outcomes	O	NOUN	B
included	O	VERB	O
death	B-OUT	NOUN	B
within	I-OUT	ADP	O
60	I-OUT	NUM	O
days	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
primary	I-OUT	ADJ	B
outcome	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
survival	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
cardiovascular	I-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
performance	I-OUT	NOUN	B
status	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
QOL	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
symptoms	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
nonstatin	I-OUT	NOUN	B
medications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cost	I-OUT	VERB	B
savings	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
381	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
;	I-P	PUNCT	O
189	O	NUM	O
of	O	ADP	O
these	O	DET	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
discontinue	O	VERB	B
statins	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
192	O	NUM	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
continue	O	VERB	O
therapy	O	NOUN	B
.	O	PUNCT	O


Mean	B-OUT	VERB	O
(	I-OUT	PUNCT	O
SD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
age	I-OUT	NOUN	B
was	I-P	AUX	O
74.1	I-P	NUM	O
(	I-P	PUNCT	O
11.6	I-P	NUM	O
)	I-P	PUNCT	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
22.0	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
participants	I-P	NOUN	B
were	I-P	AUX	O
cognitively	I-P	ADV	B
impaired	I-P	ADJ	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
48.8	I-P	NUM	O
%	I-P	NOUN	O
had	I-P	AUX	O
cancer	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
participants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
discontinuation	O	NOUN	B
vs	O	CCONJ	O
continuation	O	NOUN	B
groups	O	NOUN	I
who	O	PRON	O
died	O	VERB	B
within	O	ADP	O
60	O	NUM	O
days	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
(	O	PUNCT	O
23.8	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
20.3	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
-3.5	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
10.5	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=.36	O	ADJ	O
)	O	PUNCT	O
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
meet	O	VERB	O
the	O	DET	O
noninferiority	O	NOUN	B
end	O	NOUN	O
point	O	NOUN	O
.	O	PUNCT	O


Total	B-OUT	ADJ	O
QOL	I-OUT	PROPN	B
was	O	AUX	O
better	O	ADJ	O
for	O	ADP	O
the	O	DET	O
group	O	NOUN	B
discontinuing	O	VERB	O
statin	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
mean	O	VERB	O
McGill	O	PROPN	O
QOL	O	PROPN	O
score	O	NOUN	O
,	O	PUNCT	O
7.11	O	NUM	O
vs	O	CCONJ	O
6.85	O	NUM	O
;	O	PUNCT	O
P=.04	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


Few	O	ADJ	O
participants	O	NOUN	B
experienced	O	VERB	O
cardiovascular	B-OUT	ADJ	B
events	I-OUT	NOUN	I
(	O	PUNCT	O
13	O	NUM	O
in	O	ADP	O
the	O	DET	O
discontinuation	O	NOUN	B
group	O	NOUN	B
vs	O	CCONJ	O
11	O	NUM	O
in	O	ADP	O
the	O	DET	O
continuation	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Mean	B-OUT	VERB	O
cost	I-OUT	NOUN	O
savings	I-OUT	NOUN	O
were	O	AUX	O
$	O	SYM	O
3.37	O	NUM	O
per	O	ADP	O
day	O	NOUN	B
and	O	CCONJ	O
$	O	SYM	O
716	O	NUM	O
per	O	ADP	O
patient	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
AND	O	CCONJ	O
RELEVANCE	O	NOUN	B
This	O	DET	O
pragmatic	O	ADJ	B
trial	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
stopping	O	VERB	O
statin	O	NOUN	B
medication	O	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
benefits	O	NOUN	B
including	O	VERB	O
improved	B-OUT	VERB	B
QOL	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
fewer	I-OUT	ADJ	O
nonstatin	I-OUT	NUM	B
medications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
corresponding	I-OUT	ADJ	O
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
medication	I-OUT	NOUN	B
costs	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Thoughtful	O	ADJ	B
patient-provider	O	ADJ	B
discussions	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
uncertain	O	ADJ	O
benefit	O	NOUN	B
and	O	CCONJ	O
potential	O	ADJ	B
decrement	O	NOUN	B
in	O	ADP	O
QOL	O	PROPN	B
associated	O	VERB	B
with	O	ADP	I
statin	O	ADJ	B
continuation	O	NOUN	B
in	O	ADP	O
this	O	DET	O
setting	O	NOUN	O
are	O	AUX	O
warranted	O	VERB	O
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
clinicaltrials.gov	O	NOUN	O
Identifier	O	NOUN	O
:	O	PUNCT	O
NCT01415934	O	NOUN	O
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
long-term	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
risperidone	B-I	NOUN	B
and	I-I	CCONJ	O
haloperidol	I-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


An	O	DET	O
open	O	ADJ	O
label	O	NOUN	O
maintenance	O	NOUN	O
study	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
safety	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
efficacy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
risperidone	B-I	NOUN	B
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
haloperidol	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
long-term	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
autistic	B-P	ADJ	B
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
an	O	DET	O
open-label	O	ADJ	B
continuation	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
risperidone	B-I	NOUN	B
and	I-I	CCONJ	O
haloperidol	I-I	NOUN	B
study	O	NOUN	B
for	O	ADP	O
12	O	NUM	O
week	O	NOUN	B
in	B-P	ADP	O
autistic	I-P	ADJ	B
children	I-P	NOUN	I
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
.	I-P	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
28	I-P	NUM	O
subjects	I-P	NOUN	B
between	I-P	ADP	O
8	I-P	NUM	O
and	I-P	CCONJ	O
18	I-P	NUM	O
ages	I-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
were	O	AUX	O
enrolled	O	VERB	O
to	O	ADP	O
the	O	DET	O
open	O	ADJ	O
label	O	NOUN	O
phase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Behavioral	B-OUT	ADJ	B
rating	I-OUT	NOUN	I
scales	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
Clinical	I-OUT	ADJ	B
Global	I-OUT	PROPN	I
Impression	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
[	I-OUT	PUNCT	O
CGI-I	I-OUT	NOUN	B
]	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Ritvo-Freeman	I-OUT	ADJ	B
Real	I-OUT	ADJ	I
Life	I-OUT	PROPN	I
Rating	I-OUT	NOUN	I
Scale	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
RF-RLRS	I-OUT	NOUN	B
]	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Aberrant	I-OUT	ADJ	B
Behavior	I-OUT	PROPN	I
Checklist	I-OUT	PROPN	I
[	I-OUT	PUNCT	O
ABC	I-OUT	PROPN	B
]	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Turgay	I-OUT	PROPN	O
DSM-IV	I-OUT	PROPN	O
Pervasive	I-OUT	PROPN	O
Developmental	I-OUT	PROPN	O
Disorder	I-OUT	PROPN	O
Rating	I-OUT	NOUN	O
Scale	I-OUT	NOUN	O
[	I-OUT	PUNCT	O
TPDDRS	I-OUT	NOUN	B
]	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
assessment	I-OUT	NOUN	I
scales	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
Extrapyramidal	I-OUT	ADJ	B
Symptoms	I-OUT	NOUN	I
Rating	I-OUT	VERB	I
Scale	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
ESRS	I-OUT	PROPN	B
]	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
UKU-Side	I-OUT	PROPN	B
Effect	I-OUT	PROPN	B
Rating	I-OUT	NOUN	I
Scale	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
12	O	NUM	O
,	O	PUNCT	O
16	O	NUM	O
,	O	PUNCT	O
20	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
following	O	VERB	O
the	O	DET	O
12	O	NUM	O
week	O	NOUN	B
double-blind	O	ADJ	B
phase	O	NOUN	O
.	O	PUNCT	O


Risperidone	B-I	NOUN	B
and	I-I	CCONJ	O
haloperidol	I-I	NOUN	B
treatments	O	NOUN	B
were	O	AUX	O
applied	O	VERB	O
with	O	ADP	O
a	O	DET	O
once	O	ADV	O
daily	O	ADJ	O
dosage	O	NOUN	B
regimen	O	NOUN	I
as	O	ADP	O
0.01-0.08	O	NUM	O
mg/kg/day	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
Risperidone	O	NOUN	B
led	O	VERB	O
to	O	PART	O
a	O	DET	O
significant	O	ADJ	O
greater	O	ADJ	O
reduction	B-OUT	NOUN	B
on	O	ADP	O
CGI	B-OUT	NOUN	B
scale	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


There	O	PRON	O
was	O	AUX	O
significant	O	ADJ	O
improvement	O	NOUN	B
on	O	ADP	O
RF-RLRS	B-OUT	NOUN	B
sensory	I-OUT	ADJ	B
motor	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
language	I-OUT	NOUN	B
subscale	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
ABC	I-OUT	PROPN	B
scores	I-OUT	NOUN	I
in	O	ADP	O
risperidone	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
the	O	DET	O
haloperidol	O	NOUN	B
group	O	NOUN	B
at	O	ADP	O
week	O	NOUN	B
24	O	NUM	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
risperidone	O	NOUN	B
is	O	AUX	O
more	O	ADV	O
efficacious	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
than	O	ADP	O
haloperidol	O	NOUN	B
in	O	ADP	O
the	O	DET	O
long-term	O	ADJ	B
maintenance	O	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
autistic	O	ADJ	B
disorder	O	NOUN	I
.	O	PUNCT	O


Offering	O	VERB	B
personalized	B-I	ADJ	B
health	I-I	NOUN	B
behavior	I-I	NOUN	I
feedback	I-I	NOUN	O
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
a	O	DET	O
randomized	B-P	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


Reliance	O	NOUN	B
on	O	ADP	O
visual	B-OUT	ADJ	B
information	I-OUT	NOUN	B
after	O	ADP	O
stroke	O	NOUN	B
.	O	PUNCT	O


Part	O	PROPN	O
II	O	NUM	O
:	O	PUNCT	O
Effectiveness	O	NOUN	B
of	O	ADP	O
a	O	DET	O
balance	O	NOUN	B
rehabilitation	B-I	NOUN	I
program	I-I	NOUN	I
with	O	ADP	O
visual	B-I	ADJ	B
cue	I-I	NOUN	I
deprivation	I-I	NOUN	I
after	I-P	ADP	O
stroke	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
balance	O	NOUN	B
rehabilitation	B-I	NOUN	I
with	I-I	ADP	O
visual	I-I	ADJ	B
cue	I-I	NOUN	O
deprivation	I-I	NOUN	B
improves	O	VERB	B
balance	B-OUT	NOUN	B
more	O	ADV	O
effectively	O	ADV	O
than	O	ADP	O
rehabilitation	B-I	NOUN	B
with	I-I	ADP	O
free	I-I	ADJ	B
vision	I-I	NOUN	I
.	I-I	PUNCT	O


DESIGN	O	VERB	O
Single-blind	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Public	B-P	ADJ	B
rehabilitation	I-P	NOUN	I
center	I-P	NOUN	I
in	I-P	ADP	O
France	I-P	PROPN	B
.	I-P	PUNCT	O


PARTICIPANTS	O	VERB	B
Twenty	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
hemiplegia	I-P	NOUN	B
after	I-P	ADP	O
a	I-P	DET	O
single-hemisphere	I-P	ADJ	B
stroke	I-P	NOUN	I
that	I-P	PRON	O
occurred	I-P	VERB	O
at	I-P	ADP	O
least	I-P	ADV	O
12	I-P	NUM	O
months	I-P	NOUN	B
before	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTION	O	NOUN	B
Patients	B-I	NOUN	B
were	I-I	AUX	O
randomly	I-I	ADV	O
assigned	I-I	VERB	O
to	I-I	PART	O
1	I-I	NUM	O
of	I-I	ADP	O
2	I-I	NUM	O
balance	I-I	NOUN	B
rehabilitation	I-I	NOUN	I
programs-with	I-I	ADJ	O
and	I-I	CCONJ	O
without	I-I	ADP	O
visual	I-I	ADJ	B
cue	I-I	NOUN	O
deprivation	I-I	NOUN	B
.	I-I	PUNCT	O


In	B-I	ADP	O
all	I-I	DET	O
other	I-I	ADJ	O
respects	I-I	NOUN	O
,	I-I	PUNCT	O
the	I-I	DET	O
programs	I-I	NOUN	B
were	I-I	AUX	O
identical	I-I	ADJ	B
.	I-I	PUNCT	O


Each	O	DET	O
lasted	O	VERB	O
for	O	ADP	O
1	O	NUM	O
hour	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
implemented	O	VERB	O
5	O	NUM	O
days	O	NOUN	B
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


All	B-P	DET	O
patients	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
program	I-P	NOUN	B
.	I-P	PUNCT	O


Mean	O	VERB	O
outcome	O	NOUN	O
measures	O	VERB	O
Balance	B-OUT	NOUN	B
under	O	ADP	O
6	O	NUM	O
sensory	O	ADJ	B
conditions	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
computerized	O	VERB	B
dynamic	B-OUT	ADJ	I
posturography	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
EquiTest	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
gait	I-OUT	NOUN	B
velocity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
timed	I-OUT	VERB	B
stair	I-OUT	NOUN	O
climbing	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
self-assessment	I-OUT	ADJ	B
of	I-OUT	ADP	O
ease	I-OUT	NOUN	O
of	I-OUT	ADP	O
gait	I-OUT	NOUN	B
before	I-OUT	ADV	O
and	I-OUT	CCONJ	O
after	I-OUT	ADP	O
program	I-OUT	NOUN	B
completion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
After	O	ADP	O
completing	O	VERB	O
the	O	DET	O
program	O	NOUN	B
,	O	PUNCT	O
balance	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
gait	I-OUT	NOUN	B
velocity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
self-assessment	I-OUT	ADJ	B
of	I-OUT	ADP	O
gait	I-OUT	NOUN	B
improved	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
improvements	O	NOUN	B
in	O	ADP	O
gait	B-OUT	ADJ	B
velocity	I-OUT	NOUN	I
(	O	PUNCT	O
P=	O	NOUN	O
.03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
timed	B-OUT	ADJ	B
stair	I-OUT	NOUN	O
climbing	I-OUT	NOUN	O
(	O	PUNCT	O
P=	O	NOUN	O
.01	O	NUM	O
)	O	PUNCT	O
correlated	O	VERB	B
significantly	O	ADV	O
with	O	ADP	O
improved	O	ADJ	B
balance	O	NOUN	B
.	O	PUNCT	O


Balance	B-OUT	NOUN	B
improved	O	VERB	B
more	O	ADV	O
in	O	ADP	O
the	O	DET	O
vision-deprived	O	ADJ	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
free-vision	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Balance	B-OUT	NOUN	B
improved	O	VERB	B
more	O	ADV	O
after	O	ADP	O
rehabilitation	O	NOUN	B
with	O	ADP	O
visual	B-I	ADJ	B
deprivation	I-I	NOUN	I
than	O	ADP	O
with	O	ADP	O
free	B-I	ADJ	B
vision	I-I	NOUN	I
.	I-I	PUNCT	O


Visual	O	ADJ	B
overuse	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
compensatory	O	ADJ	B
strategy	O	NOUN	O
for	O	ADP	O
coping	O	VERB	B
with	O	ADP	O
initial	O	ADJ	O
imbalance	O	NOUN	B
exacerbated	O	VERB	B
by	O	ADP	O
traditional	O	ADJ	B
rehabilitation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
problem	O	NOUN	B
of	O	ADP	O
measurement	O	NOUN	B
error	O	NOUN	O
in	O	ADP	O
multisite	B-P	ADJ	B
clinical	I-P	ADJ	B
trials	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
implementation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
multisite	B-P	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
psychopharmacologic	O	ADJ	O
trial	O	NOUN	O
involves	O	VERB	O
a	O	DET	O
substantial	O	ADJ	O
investment	O	NOUN	B
of	O	ADP	O
time	O	NOUN	B
and	O	CCONJ	O
effort	O	NOUN	B
on	O	ADP	O
the	O	DET	O
part	O	NOUN	O
of	O	ADP	O
all	O	DET	O
participants	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
their	O	PRON	O
complexity	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
clinical	O	ADJ	B
trials	O	NOUN	I
present	O	VERB	O
unique	O	ADJ	B
methodological	O	ADJ	B
and	O	CCONJ	O
design	O	NOUN	B
challenges	O	NOUN	B
.	O	PUNCT	O


Indeed	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
uncommon	O	ADJ	O
for	O	ADP	O
such	O	ADJ	O
studies	O	NOUN	B
to	O	PART	O
conclude	O	VERB	O
with	O	ADP	O
uninterpretable	O	ADJ	O
results	O	NOUN	B
,	O	PUNCT	O
due	O	ADP	O
in	O	ADP	O
part	O	NOUN	O
to	O	ADP	O
such	O	ADJ	O
methodological	O	ADJ	B
pitfalls	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
clarification	O	NOUN	B
of	O	ADP	O
such	O	ADJ	O
methodologic	O	ADJ	B
dilemmas	O	NOUN	I
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
important	O	ADJ	O
challenges	O	NOUN	O
facing	O	VERB	O
the	O	DET	O
future	O	NOUN	O
of	O	ADP	O
industry-sponsored	O	ADJ	B
psychopharmacologic	O	ADJ	I
drug	O	NOUN	I
development	O	NOUN	I
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
many	O	ADJ	O
factors	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
problematic	O	ADJ	O
clinical	B-P	ADJ	B
trial	I-P	NOUN	I
results	I-P	NOUN	B
,	O	PUNCT	O
error	O	NOUN	B
in	O	ADP	O
measuring	O	VERB	B
the	O	DET	O
phenomena	O	NOUN	B
being	O	AUX	O
studied	O	VERB	O
is	O	AUX	O
of	O	ADP	O
particular	O	ADJ	O
concern	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
article	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
describe	O	VERB	O
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intensive	B-I	ADJ	B
series	I-I	NOUN	O
of	I-I	ADP	O
interrater	I-I	ADJ	B
reliability	I-I	NOUN	I
training	I-I	NOUN	O
sessions	I-I	NOUN	O
for	O	ADP	O
the	O	DET	O
17-item	B-I	PROPN	B
Hamilton	I-OUT	PROPN	I
Depression	I-OUT	PROPN	I
Rating	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
conducted	O	VERB	O
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
a	O	DET	O
Phase	B-P	NOUN	B
II	I-P	NUM	I
multisite	I-P	ADJ	O
clinical	I-P	ADJ	B
drug	I-P	NOUN	I
trial	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
data	O	NOUN	B
underscore	O	VERB	O
the	O	DET	O
magnitude	B-OUT	NOUN	B
of	I-OUT	ADP	O
error	I-OUT	NOUN	B
present	I-OUT	ADJ	O
in	O	ADP	O
such	O	DET	O
a	O	DET	O
test	O	NOUN	O
setting	O	NOUN	O
and	O	CCONJ	O
provide	O	VERB	O
preliminary	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
the	O	DET	O
potential	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
this	O	DET	O
problem	O	NOUN	B
on	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
change	O	NOUN	I
.	O	PUNCT	O


Participant	O	ADJ	B
characteristics	O	NOUN	B
and	O	CCONJ	O
intervention	O	NOUN	B
processes	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
reductions	O	NOUN	B
in	O	ADP	O
television	B-OUT	NOUN	B
viewing	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
High	O	ADJ	O
Five	O	NUM	O
for	O	ADP	O
Kids	B-P	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
High	B-I	ADJ	O
Five	I-I	NUM	O
for	I-I	ADP	O
Kids	I-I	PROPN	B
intervention	I-I	NOUN	I
effect	O	NOUN	I
on	O	ADP	O
television	B-OUT	NOUN	B
within	O	ADP	O
subgroups	O	NOUN	B
,	O	PUNCT	O
examine	O	VERB	O
participant	O	NOUN	B
characteristics	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
process	O	NOUN	B
measures	O	NOUN	B
and	O	CCONJ	O
assess	O	VERB	B
perceived	O	VERB	B
helpfulness	O	NOUN	B
of	O	ADP	O
television	O	NOUN	B
intervention	O	NOUN	I
components	O	NOUN	I
.	O	PUNCT	O


METHOD	O	PROPN	O
High	B-P	ADJ	O
Five	I-P	NUM	O
(	I-P	PUNCT	O
randomized	I-P	VERB	B
controlled	I-P	VERB	I
trial	I-P	NOUN	I
of	I-P	ADP	O
445	I-P	NUM	O
overweight/obese	I-P	ADJ	B
2-7	I-P	NUM	O
year-olds	I-P	NOUN	B
in	I-P	ADP	O
Massachusetts	I-P	PROPN	B
[	I-P	PUNCT	O
2006-2008	I-P	NUM	O
]	I-P	PUNCT	O
)	I-P	PUNCT	O
reduced	I-I	VERB	B
television	I-I	NOUN	B
by	I-I	ADP	O
0.36	I-I	NUM	O
h/day	I-I	NOUN	O
.	I-I	PUNCT	O


1-year	O	ADJ	B
effects	O	NOUN	O
on	O	ADP	O
television	O	NOUN	B
viewing	O	NOUN	I
,	O	PUNCT	O
stratified	O	VERB	B
by	O	ADP	O
subgroup	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
linear	O	ADJ	B
regression	O	NOUN	I
.	O	PUNCT	O


Among	B-P	ADP	O
intervention	I-P	NOUN	B
participants	I-P	NOUN	I
(	I-P	PUNCT	O
n=253	I-P	PROPN	O
)	I-P	PUNCT	O
,	O	PUNCT	O
associations	O	NOUN	B
of	O	ADP	O
intervention	B-I	NOUN	B
component	I-I	NOUN	O
helpfulness	O	NOUN	B
with	O	ADP	O
television	B-OUT	NOUN	B
reduction	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
using	O	VERB	O
linear	O	ADJ	B
regression	O	NOUN	I
and	O	CCONJ	O
associations	O	NOUN	B
of	O	ADP	O
participant	O	NOUN	B
characteristics	O	NOUN	B
with	O	ADP	O
processes	O	NOUN	B
linked	O	VERB	O
to	O	ADP	O
television	O	NOUN	B
reduction	O	NOUN	B
(	O	PUNCT	O
choosing	O	VERB	O
television	O	NOUN	B
and	O	CCONJ	O
completing	O	VERB	O
intervention	O	NOUN	B
visits	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
examined	O	VERB	O
using	O	VERB	O
logistic	O	ADJ	B
regression	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
High	O	ADJ	O
Five	O	NUM	O
reduced	O	VERB	B
television	O	NOUN	B
across	O	ADP	O
subgroups	O	NOUN	B
.	O	PUNCT	O


Parents	B-P	NOUN	B
of	I-P	ADP	O
Latino	I-P	PROPN	B
(	I-P	PUNCT	O
versus	I-P	ADP	O
white	I-P	ADJ	B
)	I-P	PUNCT	O
children	I-P	NOUN	B
had	O	AUX	O
lower	O	ADJ	O
odds	O	NOUN	B
of	O	ADP	O
completing	B-OUT	VERB	O
≥2	I-OUT	NOUN	O
study	I-OUT	NOUN	B
visits	I-OUT	NOUN	I
(	O	PUNCT	O
Odds	O	NOUN	B
Ratio	O	PROPN	I
:	O	PUNCT	O
0.39	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
Confidence	O	PROPN	B
Interval	O	NOUN	I
:	O	PUNCT	O
0.18	O	NUM	O
,	O	PUNCT	O
0.84	B-P	NUM	O
]	I-P	PUNCT	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Parents	B-P	NOUN	B
of	I-P	ADP	O
black	I-P	ADJ	O
(	I-P	PUNCT	O
versus	I-P	ADP	O
white	I-P	ADJ	B
)	I-P	PUNCT	O
children	I-P	NOUN	B
had	O	AUX	O
higher	O	ADJ	B
odds	O	NOUN	B
of	B-OUT	ADP	O
choosing	I-OUT	VERB	O
television	I-OUT	NOUN	B
(	O	PUNCT	O
Odds	O	PROPN	B
Ratio	O	PROPN	I
:	O	PUNCT	O
2.23	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
Confidence	O	PROPN	B
Interval	O	NOUN	I
:	O	PUNCT	O
1.08	O	NUM	O
,	O	PUNCT	O
4.59	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADP	O
did	B-P	AUX	O
parents	I-P	NOUN	B
of	I-P	ADP	O
obese	I-P	ADJ	B
(	I-P	PUNCT	O
versus	I-P	ADP	O
overweight	I-P	ADJ	B
)	I-P	PUNCT	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
children	I-P	NOUN	B
watching	I-P	VERB	B
≥2	I-P	NUM	O
h/day	I-P	NOUN	O
(	I-P	PUNCT	O
versus	I-P	ADP	O
<	I-P	X	O
2	I-P	NUM	O
)	I-P	PUNCT	O
at	I-P	ADP	O
baseline	I-P	NOUN	B
.	O	PUNCT	O


Greater	O	ADJ	O
perceived	B-OUT	VERB	B
helpfulness	I-OUT	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
greater	O	ADJ	O
television	O	NOUN	B
reduction	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	B-I	NOUN	O
Clinic-based	I-I	ADJ	B
motivational	I-I	ADJ	O
interviewing	I-I	NOUN	O
reduces	I-OUT	VERB	B
television	I-OUT	NOUN	B
viewing	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-I	NOUN	B
.	I-I	PUNCT	O


Low	B-I	ADJ	B
cost	I-I	NOUN	O
education	I-I	NOUN	O
approaches	I-I	NOUN	O
(	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
printed	O	VERB	B
materials	O	NOUN	I
)	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
well-received	O	VERB	B
.	O	PUNCT	O


Parents	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
at	I-P	ADP	O
higher	I-P	ADJ	B
obesity	I-P	NOUN	B
risk	I-P	NOUN	B
could	O	AUX	O
be	O	AUX	O
more	O	ADV	O
motivated	O	VERB	O
to	O	PART	O
reduce	B-OUT	VERB	B
television	I-OUT	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
comparative	O	ADJ	I
study	O	NOUN	I
of	O	ADP	O
tegafur/uracil	B-I	NOUN	B
and	I-I	CCONJ	O
oral	I-I	ADJ	B
leucovorin	I-I	NOUN	B
versus	I-I	CCONJ	O
parenteral	I-I	ADJ	B
fluorouracil	I-I	NOUN	I
and	I-I	CCONJ	O
leucovorin	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
previously	I-P	ADV	O
untreated	I-P	ADJ	B
metastatic	I-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
study	O	NOUN	I
compared	O	VERB	O
the	O	DET	O
time	B-OUT	NOUN	B
to	I-OUT	PART	O
progression	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
TTP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
of	O	ADP	O
an	O	DET	O
oral	O	ADJ	B
regimen	O	NOUN	I
of	O	ADP	O
dihydropyrimidine	B-I	NOUN	B
dehydrogenase	I-I	NOUN	I
inhibitory	I-I	ADJ	B
fluoropyrimidine	I-I	NOUN	O
composed	O	VERB	O
of	O	ADP	O
a	O	DET	O
fixed	O	ADJ	O
combination	O	NOUN	B
of	O	ADP	O
tegafur	B-I	NOUN	B
and	I-I	CCONJ	O
uracil	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
1:4	O	NUM	B
molar	O	ADJ	I
ratio	O	NOUN	I
(	O	PUNCT	O
UFT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
leucovorin	B-I	NOUN	B
(	O	PUNCT	O
LV	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
intravenous	B-I	ADJ	B
(	I-I	PUNCT	O
IV	I-I	NUM	O
)	I-I	PUNCT	O
fluorouracil	I-I	NOUN	B
(	O	PUNCT	O
5-FU	O	NOUN	B
)	O	PUNCT	O
and	B-I	CCONJ	O
LV	I-I	PROPN	B
in	O	ADP	O
previously	B-P	ADV	O
untreated	I-P	ADJ	B
metastatic	I-P	ADJ	B
colorectal	I-P	NOUN	I
carcinoma	I-P	NOUN	I
(	I-P	PUNCT	O
CRC	I-P	NOUN	B
)	I-P	PUNCT	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Secondary	O	ADJ	B
end	O	NOUN	I
points	O	NOUN	I
were	O	AUX	O
survival	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
tumor	I-OUT	NOUN	B
response	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
safety	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Between	B-P	ADP	O
May	I-P	PROPN	O
1996	I-P	NUM	O
and	I-P	CCONJ	O
July	I-P	PROPN	O
1997	I-P	NUM	O
,	I-P	PUNCT	O
380	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
UFT	B-I	NOUN	B
(	O	PUNCT	O
300	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/d	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
LV	B-I	PROPN	B
(	O	PUNCT	O
90	O	NUM	O
mg/d	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
administered	O	VERB	B
for	O	ADP	O
28	O	NUM	O
days	O	NOUN	B
every	O	DET	O
35	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
5-FU	B-I	NOUN	B
(	O	PUNCT	O
425	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/d	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
LV	B-I	PROPN	B
(	O	PUNCT	O
20	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/d	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
given	O	VERB	O
IV	O	NUM	O
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
every	O	DET	O
35	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
No	O	DET	O
statistically	O	ADV	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
TTP	B-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
treatments	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
320	B-P	NUM	O
events	I-P	NOUN	B
assessed	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
median	O	ADJ	B
TTP	B-OUT	NOUN	B
was	O	AUX	O
3.4	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
Confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
2.6	O	NUM	O
to	O	PART	O
3.8	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
UFT/LV	O	NOUN	B
and	O	CCONJ	O
3.3	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
2.5	O	NUM	O
to	O	PART	O
3.7	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
5-FU/LV	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.591	O	NOUN	B
,	O	PUNCT	O
stratified	O	VERB	B
log-rank	O	ADJ	I
test	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
survival	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
tumor	I-OUT	NOUN	B
response	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
response	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
to	I-OUT	PART	O
response	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Substantial	O	ADJ	O
safety	B-OUT	NOUN	O
benefits	I-OUT	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
UFT/LV	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
experienced	O	VERB	O
significantly	O	ADV	O
less	O	ADV	O
stomatitis/mucositis	B-OUT	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
myelosuppression	B-OUT	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
fewer	O	ADJ	O
episodes	O	NOUN	B
of	O	ADP	O
febrile	B-OUT	ADJ	B
neutropenia	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
less	O	ADV	B
documented	B-OUT	VERB	I
infection	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Concomitant	O	ADJ	B
medication	O	NOUN	B
usage	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
on	O	ADP	O
5-FU/LV	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.010	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


With	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
,	O	PUNCT	O
after	O	ADP	O
correcting	O	VERB	B
for	O	ADP	O
baseline	O	NOUN	B
imbalances	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
treatments	O	NOUN	B
for	O	ADP	O
any	O	DET	O
scale	O	NOUN	B
,	O	PUNCT	O
except	O	SCONJ	O
diarrhea	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
oral	O	ADJ	B
UFT/LV	O	NOUN	B
regimen	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
achieve	O	VERB	O
improved	O	VERB	O
TTP	B-OUT	NOUN	B
;	I-OUT	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
study	O	NOUN	B
confirms	O	VERB	O
significant	O	ADJ	O
safety	O	NOUN	B
improvements	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
bolus	O	NOUN	B
IV	O	NUM	I
5-FU/LV	O	NOUN	O
for	O	ADP	O
the	O	DET	O
first-line	O	NOUN	B
treatment	O	NOUN	I
of	O	ADP	O
metastatic	O	ADJ	B
CRC	O	NOUN	B
.	O	PUNCT	O


Direct	B-I	ADJ	B
aortic	I-I	ADJ	I
cannulation	I-I	NOUN	I
in	O	ADP	O
minimally	B-P	ADV	B
invasive	I-P	ADJ	I
mitral-valve	I-P	ADJ	B
operations	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
minimally	B-I	ADV	B
invasive	I-I	ADJ	I
Port-Access	I-I	NOUN	I
(	O	PUNCT	O
Heartport	O	PROPN	B
,	O	PUNCT	O
Redwood	O	PROPN	B
City	O	PROPN	I
,	O	PUNCT	O
CA	O	PROPN	B
)	O	PUNCT	O
approach	O	NOUN	O
in	O	ADP	O
mitral-valve	O	ADJ	B
operations	O	NOUN	I
originally	O	ADV	O
required	O	VERB	O
femoral	B-I	ADJ	B
arterial	I-I	ADJ	I
cannulation	I-I	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
considered	O	VERB	O
a	O	DET	O
disadvantage	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
peripheral	I-P	ADJ	B
vessel	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
20	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
prospectively	I-P	ADV	O
randomized	I-P	VERB	B
into	I-P	ADP	O
2	I-P	NUM	O
groups	I-P	NOUN	B
,	I-P	PUNCT	O
to	I-P	PART	O
undergo	I-P	VERB	O
either	I-P	CCONJ	O
standard	I-I	ADJ	B
femoral	I-I	ADJ	B
(	I-I	PUNCT	O
group	I-I	NOUN	B
A	I-I	NOUN	I
)	I-I	PUNCT	O
or	I-I	CCONJ	O
direct	I-I	ADJ	B
aortic	I-I	ADJ	I
cannulation	I-I	NOUN	I
(	I-P	PUNCT	O
group	I-P	NOUN	B
B	I-P	NOUN	I
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Pre-	O	ADJ	B
and	O	CCONJ	I
postoperative	O	ADJ	B
data	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
markers	O	NOUN	B
for	O	ADP	O
myocardial	O	ADJ	B
damage	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


Postoperatively	O	ADV	B
,	O	PUNCT	O
patients	O	NOUN	B
of	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
showed	O	VERB	O
lower	O	ADJ	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
damage	I-OUT	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
direct	B-I	ADJ	O
aortic	I-I	ADJ	B
cannulation	I-I	NOUN	I
might	O	AUX	O
provide	O	VERB	O
better	O	ADJ	O
myocardial	O	ADJ	B
protection	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
direct	B-I	ADJ	O
aortic	I-I	ADJ	O
cannulation	I-I	NOUN	O
technique	O	NOUN	O
may	O	AUX	O
eliminate	O	VERB	O
complications	B-OUT	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
standard	B-I	ADJ	B
femoral	I-I	ADJ	B
artery	I-I	NOUN	I
cannulation	I-I	NOUN	I
.	I-I	PUNCT	O


Anticholinergic	B-I	ADJ	B
drugs	I-I	NOUN	I
:	I-I	PUNCT	O
effects	O	NOUN	B
on	O	ADP	O
oxygen	B-OUT	NOUN	B
consumption	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
energy	I-OUT	NOUN	B
expenditure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Premedication	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
affect	O	VERB	O
both	O	CCONJ	O
oxygen	B-OUT	NOUN	B
consumption	I-OUT	NOUN	I
(	O	PUNCT	O
VO2	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
energy	B-OUT	NOUN	B
expenditure	I-OUT	NOUN	I
(	O	PUNCT	O
EE	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
metabolic	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
anticholinergic	O	ADJ	B
drugs	O	NOUN	I
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
anticholinergic	B-I	ADJ	B
drugs	I-I	NOUN	I
on	O	ADP	O
VO2	O	NOUN	B
and	O	CCONJ	O
EE	O	NOUN	B
(	O	PUNCT	O
calculated	O	VERB	B
from	O	ADP	O
the	O	DET	O
measured	O	VERB	B
rates	O	NOUN	B
of	O	ADP	O
VO2	O	NOUN	B
and	O	CCONJ	O
carbon	O	NOUN	B
dioxide	O	NOUN	I
production	O	NOUN	O
[	O	PUNCT	O
VCO2	O	NOUN	B
]	O	PUNCT	O
:	O	PUNCT	O
EE	O	PROPN	B
[	O	PUNCT	O
kcal/d	O	PROPN	O
]	O	PUNCT	O
=	O	ADJ	O
3.581	O	NUM	O
x	O	NOUN	O
VO2	O	NOUN	B
[	O	PUNCT	O
L/d	O	NOUN	O
]	O	PUNCT	O
+	O	CCONJ	O
1.448	O	NUM	O
x	O	NOUN	O
VCO2	O	NOUN	B
[	O	PUNCT	O
L/d	O	NOUN	B
]	O	PUNCT	O
-	O	PUNCT	O
32.4	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
six	B-P	NUM	O
healthy	I-P	ADJ	B
female	I-P	ADJ	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


They	O	PRON	O
were	O	AUX	O
given	O	VERB	O
intramuscular	O	ADJ	B
atropine	B-I	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
micrograms/kg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
glycopyrrolate	B-I	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
micrograms/kg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
scopolamine	B-I	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
micrograms/kg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
random	O	ADJ	B
double-blind	O	ADJ	B
cross-over	O	ADJ	B
design	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
consecutive	O	ADJ	B
sessions	O	NOUN	B
were	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
1	O	NUM	O
wk	O	NOUN	O
apart	O	ADV	O
for	O	ADP	O
each	O	DET	O
subject	O	NOUN	B
.	O	PUNCT	O


VO2	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
EE	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
an	O	DET	O
indirect	O	ADJ	B
calorimetry	O	NOUN	I
(	O	PUNCT	O
Deltatrac	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Cardiovascular	B-OUT	ADJ	B
responses	I-OUT	NOUN	O
were	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
standard	O	ADJ	B
noninvasive	O	ADJ	B
monitoring	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
drug	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
using	O	VERB	O
a	O	DET	O
sensitive	O	ADJ	B
modification	O	NOUN	B
of	O	ADP	O
radioreceptor	O	NOUN	B
assay	O	NOUN	I
.	O	PUNCT	O


Subjective	O	ADJ	B
responses	O	NOUN	I
were	O	AUX	O
measured	O	VERB	B
with	O	ADP	O
visual	B-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


Atropine	B-I	NOUN	B
and	O	CCONJ	O
glycopyrrolate	B-I	NOUN	B
induced	O	VERB	B
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
with	O	ADP	O
a	O	DET	O
simultaneous	O	ADJ	B
decrease	O	NOUN	B
in	O	ADP	O
pressure	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
quotient	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PRQ	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
while	O	SCONJ	O
scopolamine	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
with	O	ADP	O
a	O	DET	O
simultaneous	O	ADJ	B
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
PRQ	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Scopolamine	B-I	NOUN	B
significantly	O	ADV	O
decreased	O	VERB	B
both	O	CCONJ	O
VO2	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
EE	I-OUT	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
glycopyrrolate	B-I	NOUN	B
increased	O	VERB	B
VO2	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Atropine	B-I	NOUN	B
had	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
effect	O	NOUN	O
on	O	ADP	O
metabolic	B-OUT	ADJ	B
variables	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Only	O	ADV	O
scopolamine	O	NOUN	B
induced	O	VERB	B
sedation	B-OUT	NOUN	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
atropine	B-I	NOUN	B
,	I-I	PUNCT	O
glycopyrrolate	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
scopolamine	B-I	NOUN	B
differ	O	VERB	O
not	O	PART	O
only	O	ADV	O
in	O	ADP	O
their	O	PRON	O
cardiovascular	O	ADJ	B
and	O	CCONJ	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
effects	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
in	O	ADP	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
metabolism	O	NOUN	B
.	O	PUNCT	O


S-phase	B-I	NOUN	B
kinase-associated	I-I	ADJ	I
protein	I-I	NOUN	I
2	O	NUM	I
expression	O	NOUN	B
in	O	ADP	O
laryngeal	B-P	ADJ	B
squamous	I-P	ADJ	I
cell	I-P	NOUN	I
carcinomas	I-P	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
prognostic	O	ADJ	B
implications	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
F-box	O	NOUN	B
protein	O	NOUN	I
S-phase	B-I	NOUN	I
kinase-associated	I-I	ADJ	I
protein	I-I	NOUN	I
2	O	NUM	I
(	B-I	PUNCT	O
Skp2	I-I	NOUN	B
)	I-I	PUNCT	O
positively	O	ADV	O
regulates	O	VERB	B
the	O	DET	O
G1-S	O	NOUN	B
transition	O	NOUN	B
by	O	ADP	O
controlling	O	VERB	B
the	O	DET	O
stability	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
G1	O	NOUN	B
regulators	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
cycle	O	NOUN	I
inhibitor	O	NOUN	I
p27kip1	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
clinical	O	ADJ	B
significance	O	NOUN	I
of	O	ADP	O
Skp2	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
laryngeal	I-P	ADJ	B
squamous	I-P	ADJ	I
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
(	I-P	PUNCT	O
LSCC	I-P	NOUN	B
)	I-P	PUNCT	O
remains	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
potential	O	ADJ	B
distribution	O	NOUN	B
of	O	ADP	O
Skp2	B-I	NOUN	B
in	O	ADP	O
LSCC	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
clinical	O	ADJ	B
implications	O	NOUN	O
was	O	AUX	O
investigated	O	VERB	B
by	O	ADP	O
an	O	DET	O
immunohistochemical	B-I	ADJ	B
study	I-I	NOUN	I
.	I-I	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
Skp2	B-OUT	NOUN	B
overexpression	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
36.7	B-P	NUM	O
%	I-P	NOUN	O
(	I-P	PUNCT	O
37	I-P	NUM	O
of	I-P	ADP	O
102	I-P	NUM	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
lymph	O	NOUN	B
node	O	NOUN	I
metastasis	O	NOUN	I
(	O	PUNCT	O
p=0.002	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
inversely	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
p27kip1	O	NOUN	B
expression	O	NOUN	B
(	O	PUNCT	O
p=0.026	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Survival	B-OUT	NOUN	B
analysis	I-OUT	NOUN	I
using	O	VERB	O
the	O	DET	O
Kaplan-Meier	O	ADJ	B
method	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
Skp2	B-I	NOUN	B
overexpression	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
shorter	O	ADJ	B
disease-free	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
p=0.0051	O	NOUN	B
and	O	CCONJ	O
p=0.0002	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


When	O	SCONJ	O
Skp2	B-OUT	NOUN	B
expression	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
p27kip1	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
were	O	AUX	O
combined	O	VERB	O
,	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
both	O	CCONJ	O
Skp2	B-I	NOUN	B
overexpression	O	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
expression	B-OUT	NOUN	B
of	I-OUT	ADP	O
p27kip1	I-OUT	NOUN	B
revealed	O	VERB	B
poorest	B-OUT	ADJ	O
disease-free	I-OUT	ADJ	B
and	O	CCONJ	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
other	O	ADJ	O
cases	O	NOUN	B
(	O	PUNCT	O
p=0.0017	O	NOUN	O
and	O	CCONJ	O
p	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
early	O	ADJ	B
stage	O	NOUN	I
(	O	PUNCT	O
I	O	PRON	B
,	O	PUNCT	O
II	O	NUM	B
)	O	PUNCT	O
cases	O	NOUN	B
,	O	PUNCT	O
Skp2	B-I	NOUN	B
expression	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
revealed	O	VERB	O
to	O	PART	O
possess	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
prognostic	O	ADJ	B
factor	O	NOUN	I
in	O	ADP	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
p=0.0234	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
disease-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
p=0.2055	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


By	O	ADP	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
using	O	VERB	O
the	O	DET	O
Cox	B-OUT	PROPN	B
proportional	I-OUT	ADJ	I
hazards	I-OUT	NOUN	I
model	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
tumor	I-OUT	NOUN	B
grade	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
tumor	I-OUT	NOUN	B
size	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
clinical	I-OUT	ADJ	B
stage	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
Skp2	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
were	O	AUX	O
independent	O	ADJ	O
prognostic	O	ADJ	B
factors	O	NOUN	I
both	O	CCONJ	O
in	O	ADP	O
disease-free	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
Skp2	B-OUT	NOUN	B
expression	I-OUT	NOUN	B
was	O	AUX	O
closely	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
tumor	O	NOUN	B
progression	O	NOUN	I
and	O	CCONJ	O
represented	O	VERB	O
an	O	DET	O
independent	O	ADJ	O
marker	O	NOUN	B
for	O	ADP	O
prognosis	O	NOUN	B
of	O	ADP	O
LSCC	O	NOUN	B
.	O	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
beclomethasone	B-I	NOUN	B
dipropionate	I-I	NOUN	I
for	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
graft-versus-host	O	NOUN	I
disease	O	NOUN	I
.	O	PUNCT	O


Results	O	NOUN	B
from	O	ADP	O
two	O	NUM	O
randomized	O	ADJ	B
trials	O	NOUN	I
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
oral	B-I	ADJ	B
beclomethasone	I-I	NOUN	O
dipropionate	I-I	NOUN	O
(	I-I	PUNCT	O
BDP	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
effective	O	ADJ	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
gastrointestinal	O	ADJ	I
graft-versus-host	O	NOUN	I
disease	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
placebo-controlled	O	ADJ	I
phase	O	NOUN	I
II	O	NUM	I
study	O	NOUN	I
designed	O	VERB	O
to	O	PART	O
test	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
acute	O	ADJ	B
graft-versus-host	O	NOUN	I
disease	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
oral	B-I	ADJ	B
BDP	I-I	NOUN	B
,	O	PUNCT	O
beginning	O	VERB	O
before	O	ADP	O
hematopoietic	O	ADJ	B
cell	O	NOUN	I
transplantation	O	NOUN	I
and	O	CCONJ	O
continuing	O	VERB	B
until	O	ADP	O
day	O	NOUN	B
75	O	NUM	O
after	O	ADP	O
hematopoietic	O	ADJ	B
cell	O	NOUN	I
transplantation	O	NOUN	I
after	O	ADP	O
myeloablative	O	ADJ	B
conditioning	O	NOUN	I
.	O	PUNCT	O


Study	B-I	NOUN	B
drug	I-I	NOUN	I
(	I-I	PUNCT	O
BDP	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
as	O	ADP	O
1-mg	O	ADJ	O
immediate-release	O	ADJ	B
formulation	O	NOUN	B
plus	O	CCONJ	O
1-mg	O	ADJ	O
delayed-release	O	ADJ	B
formulation	O	NOUN	B
orally	O	ADV	B
four	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
.	O	PUNCT	O


According	O	VERB	O
to	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
endpoint	O	NOUN	I
,	O	PUNCT	O
systemic	B-OUT	ADJ	B
glucocorticoid	I-OUT	NOUN	B
treatment	I-OUT	NOUN	I
for	I-OUT	ADP	O
graft-versus-host	I-OUT	NOUN	B
disease	I-OUT	NOUN	I
was	O	AUX	O
given	O	VERB	O
to	B-P	ADP	O
60	I-P	NUM	O
of	I-P	ADP	O
the	I-P	DET	O
92	I-P	NUM	O
participants	I-P	NOUN	B
(	I-P	PUNCT	O
65	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
BDP	I-I	NOUN	B
arm	I-P	NOUN	B
,	I-P	PUNCT	O
versus	I-P	CCONJ	O
31	I-P	NUM	O
of	I-P	ADP	O
46	I-P	NUM	O
participants	I-P	NOUN	B
(	I-P	PUNCT	O
67	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
placebo	I-I	ADJ	B
arm	I-P	NOUN	I
.	O	PUNCT	O


The	O	DET	O
secondary	B-OUT	ADJ	O
efficacy	I-OUT	NOUN	B
endpoints	I-OUT	NOUN	B
showed	O	VERB	O
no	B-OUT	DET	O
statistically	I-OUT	ADV	B
significant	I-OUT	ADJ	I
differences	I-OUT	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
arms	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
proportion	B-OUT	NOUN	B
of	I-OUT	ADP	O
participants	I-OUT	NOUN	B
who	I-OUT	PRON	O
took	I-OUT	VERB	O
at	I-OUT	ADP	O
least	I-OUT	ADV	O
90	I-OUT	NUM	O
%	I-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
prescribed	I-OUT	VERB	B
study	I-OUT	NOUN	B
drug	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
4	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
hematopoietic	B-OUT	ADJ	B
cell	I-OUT	NOUN	I
transplantation	I-OUT	NOUN	I
was	O	AUX	O
54	O	NUM	O
%	O	NOUN	O
overall	O	ADJ	B
.	O	PUNCT	O


Lower	O	ADJ	B
severity	B-OUT	NOUN	B
of	I-OUT	ADP	O
mucositis	I-OUT	NOUN	B
strongly	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
higher	O	ADJ	O
adherence	B-OUT	NOUN	B
to	O	PART	O
the	O	DET	O
schedule	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
drug	O	NOUN	B
administration	O	NOUN	I
.	O	PUNCT	O


Inconsistent	O	ADJ	B
adherence	B-OUT	NOUN	B
related	O	ADJ	O
to	O	PART	O
mucositis	O	NOUN	B
during	O	ADP	O
recovery	O	NOUN	B
after	O	ADP	O
myeloablative	B-I	ADJ	B
conditioning	I-I	NOUN	I
may	O	AUX	O
have	O	AUX	O
obscured	O	VERB	O
a	O	DET	O
beneficial	O	ADJ	O
therapeutic	O	ADJ	B
effect	O	NOUN	I
in	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


Emerging	O	VERB	B
treatment	B-OUT	NOUN	I
of	O	ADP	O
acute	B-OUT	ADJ	B
coronary	I-OUT	ADJ	I
syndromes	I-OUT	NOUN	I
with	O	ADP	O
platelet	B-I	NOUN	B
glycoprotein	I-I	NOUN	I
IIB/IIIA	I-I	NOUN	O
inhibitors	I-I	NOUN	O
.	I-I	PUNCT	O


Physiologic	O	ADJ	B
modeling	O	NOUN	I
of	O	ADP	O
the	O	DET	O
intravenous	B-OUT	ADJ	B
glucose	I-OUT	NOUN	I
tolerance	I-OUT	NOUN	I
test	I-OUT	NOUN	I
in	O	ADP	O
type	B-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
new	O	ADJ	O
approach	O	NOUN	O
to	O	PART	O
the	O	DET	O
insulin	O	NOUN	B
compartment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
minimal	O	ADJ	B
model	O	NOUN	B
of	O	ADP	O
Bergman	O	PROPN	O
et	O	X	O
al	O	X	O
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
yield	O	VERB	O
estimates	O	NOUN	B
of	O	ADP	O
insulin	B-OUT	NOUN	B
sensitivity	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
Si	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
glucose	I-OUT	NOUN	B
effectiveness	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
Sg	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
by	O	ADP	O
incorporating	O	VERB	O
exogenous	B-I	ADJ	B
insulin	I-I	NOUN	B
protocols	I-I	NOUN	I
into	O	ADP	O
the	O	DET	O
regular	O	ADJ	O
intravenous	O	ADJ	B
glucose	O	NOUN	I
tolerance	O	NOUN	I
test	O	NOUN	I
(	O	PUNCT	O
IVGTT	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
estimates	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
are	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
to	O	PART	O
which	O	DET	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
exogenous	B-I	ADJ	B
insulin	I-I	NOUN	B
is	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
the	O	DET	O
physiologic	O	ADJ	B
response	O	NOUN	O
to	O	PART	O
a	O	DET	O
glucose	O	NOUN	B
load	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
most	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
related	O	VERB	O
to	O	PART	O
type	B-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
subjects	I-P	NOUN	I
whose	O	DET	O
diabetes	O	NOUN	B
was	O	AUX	O
relatively	O	ADV	O
mild	O	ADJ	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
therapeutic	O	ADJ	B
requirements	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
develop	O	VERB	O
a	O	DET	O
"	O	PUNCT	O
minimal	O	ADJ	B
disturbance	O	NOUN	I
"	O	PUNCT	O
approach	O	NOUN	O
in	O	ADP	O
estimating	O	VERB	B
Si	B-OUT	PROPN	B
and	I-OUT	CCONJ	O
Sg	I-OUT	NOUN	B
in	O	ADP	O
type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
used	O	VERB	O
a	O	DET	O
reduced	B-I	VERB	B
glucose	I-I	NOUN	B
load	I-I	NOUN	I
(	O	PUNCT	O
200	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
and	B-I	CCONJ	O
a	I-I	DET	O
"	I-I	PUNCT	O
physiologic	I-I	ADJ	B
"	I-I	PUNCT	O
insulin	I-I	NOUN	B
infusion	I-I	NOUN	B
throughout	O	ADP	O
the	O	DET	O
IVGTT	O	NOUN	B
in	O	ADP	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
8	B-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
5	I-P	NUM	O
of	I-P	ADP	O
whom	I-P	PRON	O
were	I-P	AUX	O
insulin-requiring	I-P	ADJ	B
.	I-P	PUNCT	O


Data	O	NOUN	B
from	O	ADP	O
this	O	DET	O
approach	O	NOUN	O
were	O	AUX	O
analyzed	O	VERB	B
using	O	VERB	O
the	O	DET	O
modelling	O	VERB	B
program	O	NOUN	I
CONSAM	O	PROPN	B
to	O	PART	O
apply	O	VERB	O
the	O	DET	O
Bergman	O	PROPN	B
model	O	NOUN	I
,	O	PUNCT	O
either	O	CCONJ	O
unmodified	O	ADJ	B
(	O	PUNCT	O
BMM	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
incorporating	O	VERB	O
an	O	DET	O
additional	O	ADJ	O
delay	O	NOUN	B
element	O	NOUN	I
between	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
and	O	CCONJ	O
"	O	PUNCT	O
remote	O	ADJ	B
"	O	PUNCT	O
insulin	O	NOUN	B
compartments	O	NOUN	I
(	O	PUNCT	O
MMD	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Application	O	NOUN	B
of	O	ADP	O
the	O	DET	O
MMD	O	NOUN	B
and	O	CCONJ	O
extension	O	NOUN	B
of	O	ADP	O
the	O	DET	O
IVGTT	O	NOUN	B
from	O	ADP	O
3	O	NUM	O
to	O	PART	O
5	O	NUM	O
hours	O	NOUN	B
improved	O	VERB	O
successful	O	ADJ	O
resolution	B-OUT	NOUN	B
of	I-OUT	ADP	O
Si	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
Sg	I-OUT	NOUN	B
from	O	ADP	O
37.5	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
BMM	O	NOUN	B
,	O	PUNCT	O
3-hour	O	ADJ	O
IVGTT	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
100	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
MMD	O	NOUN	B
,	O	PUNCT	O
5-hour	O	ADJ	B
IVGTT	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Si	B-OUT	PROPN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
these	O	DET	O
type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
patients	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
normal	O	ADJ	B
subjects	O	NOUN	I
(	O	PUNCT	O
1.86	O	NUM	O
+/-	O	CCONJ	O
0.60	O	NUM	O
v.	O	NOUN	O
8.65	O	NUM	O
+/-	O	CCONJ	O
2.27	O	NUM	O
min	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
x	O	NOUN	O
microU	O	NOUN	B
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
x	O	NOUN	O
mL	O	NOUN	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
were	O	AUX	O
validated	O	VERB	O
in	O	ADP	O
the	O	DET	O
type	B-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
group	I-P	NOUN	B
using	O	VERB	O
a	O	DET	O
2-stage	O	ADJ	O
euglycemic	O	ADJ	B
clamp	O	NOUN	I
(	O	PUNCT	O
(	O	PUNCT	O
Si	O	NOUN	B
)	O	PUNCT	O
CLAMP	O	NOUN	B
=	O	ADJ	O
2.02	O	NUM	O
+/-	O	CCONJ	O
0.42	O	NUM	O
min	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
x	O	NOUN	O
microU	O	NOUN	B
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
x	O	NOUN	O
mL	O	NOUN	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
.4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Sg	B-OUT	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
reduced	O	VERB	O
(	O	PUNCT	O
2.00	O	NUM	O
+/-	O	CCONJ	O
0.25	O	NUM	O
type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
v.	O	NOUN	O
1.55	O	NUM	O
+/-	O	CCONJ	O
0.26	O	NUM	O
normal	O	ADJ	O
min	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Data	O	NOUN	B
from	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
normal	B-P	ADJ	O
nondiabetic	I-P	ADJ	B
subjects	I-P	NOUN	B
was	O	AUX	O
then	O	ADV	O
analyzed	O	VERB	B
using	O	VERB	O
the	O	DET	O
MMD	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
approach	O	NOUN	O
did	O	AUX	O
not	O	PART	O
enhance	O	VERB	O
the	O	DET	O
fit	O	NOUN	B
of	O	ADP	O
the	O	DET	O
model	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
BMM	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
result	O	NOUN	O
indicates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
delay	O	NOUN	B
in	O	ADP	O
insulin	O	NOUN	B
action	O	NOUN	O
in	O	ADP	O
type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
represents	O	VERB	O
an	O	DET	O
abnormality	O	NOUN	B
whereby	O	SCONJ	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
insulin	O	NOUN	B
action	O	NOUN	O
can	O	AUX	O
not	O	PART	O
be	O	AUX	O
described	O	VERB	O
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
phase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
transfer	O	NOUN	B
of	O	ADP	O
insulin	O	NOUN	B
from	O	ADP	O
plasma	O	NOUN	B
to	O	ADP	O
the	O	DET	O
remote	O	ADJ	B
compartment	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
postulated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
physiologic	O	ADJ	B
basis	O	NOUN	O
for	O	ADP	O
this	O	DET	O
delayed	O	VERB	B
action	O	NOUN	I
may	O	AUX	O
relate	O	VERB	O
to	O	PART	O
transcapillary	O	ADJ	B
endothelial	O	ADJ	B
transfer	O	NOUN	I
of	O	ADP	O
insulin	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
process	O	NOUN	B
limiting	O	VERB	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
insulin	O	NOUN	B
action	O	NOUN	O
.	O	PUNCT	O


Treating	O	VERB	B
the	O	DET	O
substance-abusing	B-P	ADJ	B
suicidal	I-P	ADJ	B
patient	I-P	NOUN	B
.	I-P	PUNCT	O


Studies	O	NOUN	B
concerning	O	VERB	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
substance-abusing	B-P	ADJ	B
suicidal	I-P	ADJ	B
patients	I-P	NOUN	B
are	O	AUX	O
scarce	O	ADJ	O
despite	O	SCONJ	O
the	O	DET	O
frequent	O	ADJ	B
presence	O	NOUN	B
of	O	ADP	O
suicidal	O	ADJ	B
behavior	O	NOUN	I
among	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


Indeed	O	ADV	O
,	O	PUNCT	O
suicidality	O	NOUN	B
(	O	PUNCT	O
ideation	O	NOUN	B
or	O	CCONJ	O
behavior	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
generally	O	ADV	O
an	O	DET	O
exclusion	O	NOUN	B
criterion	O	NOUN	I
for	O	ADP	O
participation	O	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
studies	O	NOUN	I
of	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
alcohol	I-P	NOUN	B
or	I-P	CCONJ	O
drug	I-P	NOUN	B
abuse	I-P	NOUN	I
.	I-P	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
to	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
optimal	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
study	O	NOUN	B
involving	O	VERB	O
substance-abusing	B-P	ADJ	B
suicidal	I-P	ADJ	B
patients	I-P	NOUN	B
was	O	AUX	O
an	O	DET	O
open-label	O	ADJ	B
trial	O	NOUN	B
conducted	O	VERB	O
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
1990s	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
involved	O	VERB	O
12	B-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
all	I-P	DET	O
of	I-P	ADP	O
whom	I-P	PRON	O
demonstrated	I-P	VERB	O
recent	I-P	ADJ	O
suicidal	I-OUT	ADJ	B
ideations	I-OUT	NOUN	O
and	I-P	CCONJ	O
had	I-P	AUX	O
made	I-P	VERB	O
a	I-P	DET	O
lifetime	I-P	NOUN	B
suicide	I-P	NOUN	B
attempt	I-P	NOUN	O
.	I-P	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
that	O	DET	O
open-label	B-I	ADJ	B
study	I-I	NOUN	I
demonstrated	O	VERB	O
significant	O	ADJ	O
within-group	O	ADJ	B
improvement	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
including	I-OUT	VERB	O
suicidal	I-OUT	ADJ	B
ideations	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
drinking	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
substantial	O	ADJ	O
residual	O	ADJ	B
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
drinking	I-OUT	NOUN	B
persisted	O	VERB	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
because	O	SCONJ	O
no	O	DET	O
placebo	B-I	NOUN	B
control	O	NOUN	O
group	O	NOUN	O
was	O	AUX	O
utilized	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
of	O	ADP	O
that	O	DET	O
study	O	NOUN	B
could	O	AUX	O
not	O	PART	O
rule	O	VERB	O
out	O	ADP	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
apparent	O	ADJ	B
therapeutic	O	ADJ	B
effect	O	NOUN	I
from	O	ADP	O
fluoxetine	B-I	NOUN	B
was	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
of	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
alcohol	I-P	NOUN	B
or	I-P	CCONJ	O
substance	I-P	NOUN	B
abuse	I-P	NOUN	I
has	O	AUX	O
included	O	VERB	O
substantial	O	ADJ	B
numbers	O	NOUN	I
of	O	ADP	O
suicidal	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
involved	O	VERB	O
51	B-P	NUM	O
subjects	I-P	NOUN	B
,	I-P	PUNCT	O
of	I-P	ADP	O
whom	I-P	PRON	O
20	I-P	NUM	O
(	I-P	PUNCT	O
39	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
made	I-P	VERB	O
a	I-P	DET	O
suicide	I-P	NOUN	B
attempt	I-P	NOUN	O
in	I-P	ADP	O
the	I-P	DET	O
current	I-P	ADJ	B
depressive	I-P	ADJ	B
episode	I-P	NOUN	I
,	I-P	PUNCT	O
31	I-P	NUM	O
(	I-P	PUNCT	O
61	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
made	I-P	VERB	O
a	I-P	DET	O
suicide	I-P	NOUN	B
attempt	I-P	NOUN	O
in	I-P	ADP	O
their	I-P	PRON	O
lifetime	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
46	I-P	NUM	O
(	I-P	PUNCT	O
90	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
reported	I-P	VERB	O
suicidal	I-P	ADJ	B
ideations	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
week	I-P	NOUN	B
before	I-P	ADP	O
hospitalization	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
that	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
fluoxetine	B-I	NOUN	B
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
decreasing	O	VERB	B
but	O	CCONJ	O
not	O	PART	O
eliminating	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
including	I-OUT	VERB	O
suicidal	I-OUT	ADJ	B
ideations	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
alcohol	I-OUT	NOUN	B
consumption	I-OUT	NOUN	I
among	O	ADP	O
a	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
of	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
comorbid	O	ADJ	B
major	O	ADJ	I
depressive	O	ADJ	B
disorder	O	NOUN	I
and	O	CCONJ	O
alcohol	O	NOUN	B
dependence	O	NOUN	I
,	O	PUNCT	O
many	O	ADJ	O
of	O	ADP	O
whom	O	PRON	O
displayed	O	VERB	O
suicidal	O	ADJ	B
ideations	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
secondary	O	ADJ	B
data	O	NOUN	I
analysis	O	NOUN	I
from	O	ADP	O
that	O	DET	O
study	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
cigarette	B-OUT	NOUN	B
smoking	I-OUT	NOUN	I
is	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
decreased	O	VERB	B
by	O	ADP	O
fluoxetine	B-I	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
the	O	DET	O
decrease	O	NOUN	B
is	O	AUX	O
limited	O	ADJ	B
and	O	CCONJ	O
few	O	ADJ	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
totally	O	ADV	O
quit	O	VERB	O
smoking	O	NOUN	O
with	O	ADP	O
fluoxetine	O	NOUN	B
treatment	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Another	O	DET	O
secondary	O	ADJ	B
data	O	NOUN	O
analysis	O	NOUN	O
from	O	ADP	O
that	O	DET	O
study	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
marijuana	B-OUT	NOUN	B
smoking	I-OUT	NOUN	I
was	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
subjects	O	NOUN	B
who	O	PRON	O
demonstrated	O	VERB	O
cannabis	O	NOUN	B
abuse	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
this	O	DET	O
improvement	O	NOUN	B
was	O	AUX	O
robust	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
third	O	ADJ	O
secondary	O	ADJ	O
data	O	NOUN	O
analysis	O	NOUN	O
from	O	ADP	O
that	O	DET	O
study	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
cocaine	B-OUT	NOUN	B
abuse	I-OUT	NOUN	I
acts	O	VERB	O
as	O	ADP	O
a	O	DET	O
predictor	O	NOUN	B
of	O	ADP	O
poor	O	ADJ	B
outcome	O	NOUN	I
for	O	ADP	O
both	O	CCONJ	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
including	I-OUT	VERB	O
suicidality	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
alcohol	I-OUT	NOUN	B
use	I-OUT	NOUN	I
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
1-year	O	ADJ	O
naturalistic	O	ADJ	B
follow-up	O	ADJ	I
study	O	NOUN	I
involving	O	VERB	O
the	O	DET	O
patients	O	NOUN	B
from	O	ADP	O
that	O	DET	O
study	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
fluoxetine	B-I	NOUN	B
in	O	ADP	O
decreasing	O	VERB	B
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
drinking	I-OUT	NOUN	B
persist	O	NOUN	O
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
entering	O	VERB	O
the	O	DET	O
treatment	O	NOUN	B
program	O	NOUN	I
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
no	O	DET	O
other	O	ADJ	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
studies	O	NOUN	I
involving	O	VERB	O
substantial	O	ADJ	O
numbers	O	NOUN	O
of	O	ADP	O
substance-abusing	B-P	ADJ	B
suicidal	I-P	ADJ	B
patients	I-P	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
confirm	O	VERB	B
or	O	CCONJ	O
refute	O	VERB	O
these	O	DET	O
findings	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
clearly	O	ADV	O
warranted	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
various	O	ADJ	O
pharmacotherapeutic	O	ADJ	B
agents	O	NOUN	I
and	O	CCONJ	O
various	O	ADJ	O
psychotherapies	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
substance-abusing	B-P	ADJ	B
suicidal	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Sequential	B-I	ADJ	B
therapy	I-I	NOUN	O
versus	I-I	CCONJ	O
standard	I-I	ADJ	B
triple-drug	I-I	ADJ	B
therapy	I-I	NOUN	I
for	O	ADP	O
Helicobacter	O	NOUN	B
pylori	O	NOUN	I
eradication	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Antimicrobial	O	ADJ	B
resistance	O	NOUN	I
has	O	AUX	O
decreased	O	VERB	B
eradication	O	NOUN	B
rates	O	NOUN	I
for	O	ADP	O
Helicobacter	B-P	NOUN	B
pylori	I-P	NOUN	I
infection	I-P	NOUN	I
worldwide	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
sequential	O	ADJ	B
treatment	O	NOUN	B
schedule	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
studies	O	NOUN	B
published	O	VERB	O
to	O	PART	O
date	O	NOUN	O
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
Italy	O	PROPN	B
.	O	PUNCT	O


We	O	PRON	O
undertook	O	VERB	O
this	O	DET	O
study	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
these	O	DET	O
results	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
replicated	O	VERB	B
in	B-P	ADP	O
India	I-P	PROPN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
open-labeled	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
comparing	O	VERB	O
sequential	B-I	ADJ	B
vs.	I-I	CCONJ	O
standard	I-I	ADJ	B
triple-drug	I-I	ADJ	B
therapy	I-I	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
at	B-P	ADP	O
Lokmanya	I-P	PROPN	B
Tilak	I-P	PROPN	I
Municipal	I-P	PROPN	I
General	I-P	PROPN	I
Hospital	I-P	PROPN	I
,	I-P	PUNCT	O
Mumbai	I-P	PROPN	B
.	I-P	PUNCT	O


Two	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
thirty-one	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
dyspepsia	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
a	O	DET	O
10-day	B-I	ADJ	O
sequential	I-I	ADJ	B
regimen	I-I	NOUN	B
(	I-I	PUNCT	O
40	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
pantoprazole	I-I	NOUN	B
,	I-I	PUNCT	O
1	I-I	NUM	O
g	I-I	NOUN	O
of	I-I	ADP	O
amoxicillin	I-I	NOUN	B
,	I-I	PUNCT	O
each	I-I	DET	O
administered	I-I	VERB	B
twice	I-I	ADV	O
daily	I-I	ADV	B
for	I-I	ADP	O
the	I-I	DET	O
first	I-I	ADJ	O
5	I-I	NUM	O
days	I-I	NOUN	B
,	I-I	PUNCT	O
followed	I-I	VERB	O
by	I-I	ADP	O
40	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
pantoprazole	I-I	NOUN	B
,	I-I	PUNCT	O
500	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
clarithromycin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
500	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
tinidazole	I-I	NOUN	B
,	I-I	PUNCT	O
each	I-I	DET	O
administered	I-I	VERB	B
twice	I-I	ADV	O
daily	I-I	ADV	B
for	I-I	ADP	O
the	I-I	DET	O
remaining	I-I	VERB	O
5	I-I	NUM	O
days	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
to	I-I	PART	O
standard	I-I	ADJ	O
14-day	I-I	ADJ	O
therapy	I-I	NOUN	B
(	I-I	PUNCT	O
40	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
pantoprazole	I-I	NOUN	B
,	I-I	PUNCT	O
500	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
clarithromycin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
1	I-I	NUM	O
g	I-I	NOUN	O
of	I-I	ADP	O
amoxicillin	I-I	NOUN	B
,	I-I	PUNCT	O
each	I-I	DET	O
administered	I-I	VERB	B
twice	I-I	ADV	O
daily	I-I	ADV	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
eradication	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
achieved	O	VERB	O
with	O	ADP	O
the	O	DET	O
sequential	B-I	ADJ	B
regimen	I-I	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
obtained	O	VERB	O
with	O	ADP	O
the	O	DET	O
triple	B-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


Per-protocol	B-OUT	ADJ	B
eradication	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
of	O	ADP	O
sequential	B-I	ADJ	B
therapy	I-I	NOUN	B
was	O	AUX	O
92.4	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
85.8-96.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
81.8	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
73.9-87.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.027	O	NUM	O
)	O	PUNCT	O
for	B-I	ADP	O
standard	I-I	ADJ	B
drug	I-I	NOUN	B
therapy	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Intention-to-treat	B-OUT	ADJ	B
eradication	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
88.2	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
80.9-93.0	O	VERB	O
%	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
79.1	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
71.1-85.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.029	O	NUM	O
,	O	PUNCT	O
respectively	B-OUT	ADV	O
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
major	I-OUT	ADJ	O
and	I-OUT	CCONJ	O
minor	I-OUT	ADJ	B
side	I-OUT	NOUN	B
effects	O	NOUN	I
between	O	ADP	O
therapy	O	NOUN	B
groups	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
(	O	PUNCT	O
14.6	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
triple	O	ADJ	B
therapy	O	NOUN	I
group	O	NOUN	B
vs.	O	CCONJ	O
23.5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
sequential	O	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.12	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Follow	O	VERB	B
up	O	ADP	I
was	O	AUX	O
incomplete	O	ADJ	B
in	O	ADP	O
3.3	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
4.7	O	NUM	O
%	O	NOUN	O
patients	B-I	NOUN	B
in	I-I	ADP	O
standard	I-I	ADJ	B
and	I-I	CCONJ	O
sequential	I-I	ADJ	B
therapy	O	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	B-I	ADV	O
.	I-I	PUNCT	O


Sequential	B-I	ADJ	B
therapy	O	NOUN	O
includes	O	VERB	O
one	O	NUM	O
additional	O	ADJ	O
antibiotic	B-I	ADJ	B
(	O	PUNCT	O
tinidazole	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
is	O	AUX	O
not	O	PART	O
contained	B-I	VERB	O
in	I-I	ADP	O
standard	I-I	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	B-I	VERB	O
Sequential	I-I	ADJ	B
therapy	O	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
better	B-I	ADJ	O
than	I-I	ADP	O
standard	I-I	ADJ	B
therapy	I-OUT	NOUN	I
for	I-OUT	ADP	O
eradicating	I-OUT	VERB	B
H.	I-OUT	NOUN	B
pylori	I-OUT	NOUN	I
infection	O	NOUN	I
.	O	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
additional	B-I	ADJ	O
counselling	I-I	NOUN	B
sessions	I-I	NOUN	O
through	I-I	ADP	O
phone	I-I	NOUN	B
calls	I-I	NOUN	I
on	O	ADP	O
smoking	B-OUT	VERB	B
cessation	I-OUT	NOUN	B
outcomes	I-OUT	NOUN	B
among	O	ADP	O
smokers	B-P	NOUN	B
in	I-P	ADP	O
Penang	I-P	PROPN	B
State	I-P	PROPN	I
,	I-P	PUNCT	O
Malaysia	I-P	PROPN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Studies	O	NOUN	B
all	O	ADV	O
over	O	ADP	O
the	O	DET	O
world	O	NOUN	B
reported	O	VERB	O
that	O	SCONJ	O
smoking	O	NOUN	B
relapses	O	NOUN	I
occur	O	VERB	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
two	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
a	O	DET	O
quit	O	NOUN	O
date	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
the	O	DET	O
additional	B-I	ADJ	O
phone	I-I	NOUN	B
calls	I-I	NOUN	I
counselling	I-I	VERB	I
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
month	O	NOUN	B
on	O	ADP	O
the	O	DET	O
abstinence	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
quit	O	VERB	O
date	O	NOUN	O
among	B-P	ADP	O
smokers	I-P	NOUN	B
in	I-P	ADP	O
Penang	I-P	PROPN	B
,	I-P	PUNCT	O
Malaysia	I-P	PROPN	B
.	O	PUNCT	O


METHODS	B-P	NOUN	O
The	I-P	DET	O
study	I-P	NOUN	B
was	I-P	AUX	O
conducted	I-P	VERB	O
at	I-P	ADP	O
Quit	I-P	PROPN	B
Smoking	I-P	NOUN	I
Clinic	I-P	PROPN	I
of	I-P	ADP	O
two	I-P	NUM	O
major	I-P	ADJ	O
hospitals	I-P	NOUN	B
in	I-P	ADP	O
Penang	I-P	PROPN	B
,	I-P	PUNCT	O
Malaysia	I-P	PROPN	B
.	I-P	PUNCT	O


All	B-P	DET	O
the	I-P	DET	O
eligible	I-P	ADJ	B
smokers	I-P	NOUN	B
who	I-P	PRON	O
attended	I-P	VERB	B
the	I-P	DET	O
clinics	I-P	NOUN	B
between	I-P	ADP	O
February	I-P	PROPN	O
1st	I-P	NOUN	O
and	I-P	CCONJ	O
October	I-P	PROPN	O
31st	I-P	NOUN	O
2012	I-P	NUM	O
were	I-P	AUX	O
invited	I-P	VERB	B
.	O	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
by	O	ADP	O
using	O	VERB	O
urn	O	NOUN	O
design	O	NOUN	B
method	O	NOUN	B
either	O	CCONJ	O
to	B-I	PART	O
receive	I-I	VERB	O
the	I-I	DET	O
usual	I-I	ADJ	B
care	I-I	NOUN	I
that	I-I	PRON	O
followed	I-I	VERB	O
in	I-I	ADP	O
the	I-I	DET	O
clinics	I-I	NOUN	B
(	I-I	PUNCT	O
control	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
the	I-I	DET	O
usual	I-I	ADJ	B
care	I-I	NOUN	I
procedure	I-I	NOUN	I
plus	I-I	CCONJ	O
extra	I-I	ADJ	O
counselling	I-I	NOUN	O
sessions	I-I	NOUN	O
through	I-I	ADP	O
phone	I-I	NOUN	B
calls	I-I	NOUN	I
during	I-I	ADP	O
the	I-I	DET	O
first	I-I	ADJ	O
month	I-I	NOUN	B
of	I-I	ADP	O
quit	I-I	NOUN	B
attempt	I-I	NOUN	I
(	I-I	PUNCT	O
intervention	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


RESULTS	B-P	VERB	O
Participants	I-P	NOUN	B
in	I-P	ADP	O
our	I-P	PRON	O
cohort	I-P	NOUN	B
smoked	I-P	VERB	I
about	I-P	ADV	O
14	I-P	NUM	O
cigarettes	I-P	NOUN	B
per	I-P	ADP	O
day	I-P	NOUN	B
on	I-P	ADP	O
average	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	NOUN	O
=	I-P	ADJ	O
13.78	I-P	NUM	O
±	I-P	NOUN	O
7.0	I-P	NUM	O
)	I-P	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
control	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
less	B-OUT	ADV	O
likely	I-OUT	ADJ	O
to	I-OUT	PART	O
quit	I-OUT	VERB	O
smoking	O	NOUN	B
compared	O	VERB	B
to	O	ADP	O
intervention	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
36.9	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
46.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
verified	O	VERB	O
smoking	O	NOUN	B
status	O	NOUN	I
)	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
statistical	O	ADJ	B
significance	O	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
0.669	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
0.395-1.133	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.86	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
71.7	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	B-OUT	NOUN	I
were	I-OUT	AUX	O
successfully	I-OUT	ADV	O
quit	I-OUT	VERB	B
smoking	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
bio-chemically	I-OUT	NOUN	B
verified	O	VERB	O
)	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
48.6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
were	O	AUX	O
significantly	B-OUT	ADV	O
less	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
quit	O	VERB	B
smoking	O	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
0.375	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	B-I	NOUN	B
=	I-I	ADJ	O
0.217-0.645	I-I	NOUN	O
,	I-I	PUNCT	O
P	I-I	NOUN	O
<	I-I	X	O
0.001	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


CONCLUSIONS	B-I	NOUN	O
Smoking	I-I	NOUN	B
cessation	I-I	NOUN	B
intervention	I-I	NOUN	B
consisting	O	VERB	O
of	O	ADP	O
phone	O	NOUN	B
calls	O	NOUN	I
counselling	O	NOUN	O
delivered	O	VERB	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
month	O	NOUN	B
of	O	ADP	O
quit	O	NOUN	B
attempt	O	NOUN	I
revealed	O	VERB	O
significantly	O	ADV	O
higher	O	ADJ	O
abstinence	O	NOUN	B
rates	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
a	B-I	DET	O
standard	I-I	ADJ	B
care	I-I	NOUN	I
approach	I-I	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
additional	O	ADJ	O
counselling	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
few	O	ADJ	O
weeks	O	NOUN	B
after	O	ADP	O
stop	O	VERB	B
smoking	O	NOUN	I
is	O	AUX	O
a	O	DET	O
promising	O	ADJ	O
treatment	O	NOUN	B
strategy	O	NOUN	O
that	O	PRON	O
should	O	AUX	O
be	O	AUX	O
evaluated	O	VERB	B
further	O	ADV	O
.	O	PUNCT	O


TRIAL	O	NOUN	B
REGISTRATION	O	NOUN	O
TCTR20140504001	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
on	O	ADP	O
therapeutic	O	ADJ	B
effect	B-OUT	NOUN	I
of	O	ADP	O
plasma	B-I	NOUN	B
exchange	I-I	NOUN	I
and	I-I	CCONJ	O
intravenous	I-I	ADJ	B
immunoglobulin	I-I	NOUN	O
for	O	ADP	O
Guillian-Barre	B-P	ADJ	B
syndrome	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
observe	O	VERB	O
and	O	CCONJ	O
compare	O	VERB	B
the	O	DET	O
clinical	B-OUT	ADJ	B
curative	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
plasma	B-I	NOUN	B
exchange	I-I	NOUN	I
(	I-I	PUNCT	O
PE	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-P	CCONJ	O
intravenous	I-I	ADJ	B
immunoglobulin	I-I	NOUN	I
(	I-I	PUNCT	I
IVIg	I-I	NOUN	B
)	I-I	PUNCT	O
for	I-P	ADP	O
Guillian-Barre	I-P	PROPN	B
Syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
GBS	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Overall	O	ADV	O
,	O	PUNCT	O
64	B-P	NUM	O
adult	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
GBS	I-P	NOUN	B
for	I-P	ADP	O
PE	I-I	NOUN	B
and	I-P	CCONJ	O
IVIg	I-I	NOUN	B
treatment	I-P	NOUN	B
,	I-P	PUNCT	O
respectively	I-P	ADV	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
nerve	I-OUT	NOUN	B
function	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
pre-treatment	O	ADJ	B
and	O	CCONJ	O
at	O	ADP	O
1	O	NUM	O
week/2	O	ADJ	O
weeks	O	NOUN	B
after	O	ADP	O
completion	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
blood	O	NOUN	B
immunoglobulin	O	NOUN	I
,	O	PUNCT	O
complement	O	NOUN	B
,	O	PUNCT	O
fibrinogen	O	NOUN	O
(	O	PUNCT	O
Fib	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
monocyte	O	NOUN	B
percentage	O	NOUN	I
(	O	PUNCT	O
MON	O	NOUN	B
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
detected	O	VERB	B
simultaneously	O	ADV	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
After	B-I	ADP	O
PE	O	NOUN	B
treatment	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
nerve	I-OUT	NOUN	B
function	I-OUT	NOUN	I
defect	I-OUT	NOUN	I
appeared	O	VERB	O
to	O	PART	O
improve	O	VERB	O
better	O	ADJ	O
than	O	ADP	O
the	B-I	DET	O
IVIg	I-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
effect	O	NOUN	I
was	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
the	B-I	DET	O
IVIg	I-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Treatment	B-OUT	NOUN	B
effective	I-OUT	ADJ	B
rates	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
after	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
are	O	AUX	O
96	O	NUM	O
and	B-I	CCONJ	O
79	I-I	NUM	O
%	I-I	NOUN	O
.	O	PUNCT	O


PE	B-I	NOUN	B
and	I-I	CCONJ	O
IVIg	O	NOUN	B
can	O	AUX	O
significantly	O	ADV	O
reduce	B-OUT	VERB	O
the	I-OUT	DET	O
GBS	I-OUT	NOUN	B
patients	I-OUT	NOUN	B
'	I-OUT	PART	O
blood	I-OUT	NOUN	B
immunoglobulin	I-OUT	NOUN	I
IgG	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
IgA	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
IgM	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
C3	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
C4	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
these	O	DET	O
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	B-I	ADP	O
the	I-I	DET	O
PE	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	B-I	ADP	O
the	I-I	DET	O
IVIg	O	NOUN	B
group	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Fib	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
MON	O	NOUN	B
%	O	NOUN	O
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	B-I	ADP	O
the	I-I	DET	O
PE	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	B-I	ADP	O
the	I-I	DET	O
IVIg	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	B-I	NOUN	O
Both	I-I	CCONJ	O
PE	I-I	NOUN	B
and	I-I	CCONJ	O
IVIg	O	NOUN	B
have	O	AUX	O
a	O	DET	O
high	O	ADJ	B
response	O	NOUN	I
as	O	ADP	O
therapy	O	NOUN	B
and	O	CCONJ	O
are	O	AUX	O
reasonable	O	ADJ	O
therapeutic	O	ADJ	B
options	O	NOUN	I
for	O	ADP	O
GBS	O	NOUN	B
.	O	PUNCT	O


However	B-I	ADV	O
,	O	PUNCT	O
PE	O	NOUN	B
treatment	O	NOUN	B
has	O	AUX	O
a	O	DET	O
more	O	ADV	O
significantly	O	ADV	O
curative	O	ADJ	B
effect	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
it	O	PRON	O
can	O	AUX	O
effectively	O	ADV	O
improve	O	VERB	B
symptoms	O	NOUN	B
and	O	CCONJ	O
be	O	AUX	O
helpful	O	ADJ	O
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
rehabilitation	B-P	NOUN	B
of	I-P	ADP	O
patients	I-P	NOUN	B
.	O	PUNCT	O


High	O	ADJ	O
Platelet	O	PROPN	B
Reactivity	O	NOUN	I
in	O	ADP	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
Acute	I-P	ADJ	B
Coronary	I-P	PROPN	I
Syndromes	I-P	PROPN	I
Undergoing	I-P	PROPN	O
Percutaneous	I-P	PROPN	B
Coronary	I-P	PROPN	I
Intervention	I-P	PROPN	I
:	I-P	PUNCT	O
Randomised	O	PROPN	B
Controlled	O	PROPN	I
Trial	O	PROPN	I
Comparing	O	PROPN	O
Prasugrel	O	PROPN	B
and	O	CCONJ	O
Clopidogrel	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Prasugrel	O	PROPN	B
is	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
clopidogrel	O	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
platelet	O	NOUN	B
aggregation	O	NOUN	I
in	O	ADP	O
acute	B-P	ADJ	B
coronary	I-P	ADJ	I
syndromes	I-P	NOUN	I
.	I-P	PUNCT	O


Data	O	NOUN	B
available	O	ADJ	O
on	O	ADP	O
prasugrel	O	NOUN	B
reloading	O	NOUN	B
in	O	ADP	O
clopidogrel	O	NOUN	B
treated	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
high	O	ADJ	O
residual	O	ADJ	B
platelet	O	NOUN	O
reactivity	O	NOUN	O
(	O	PUNCT	O
HRPR	O	NOUN	B
)	O	PUNCT	O
i.e	O	ADV	O
.	O	PUNCT	O


poor	O	ADJ	B
responders	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
limited	O	VERB	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
prasugrel	B-I	NOUN	B
loading	O	NOUN	B
on	O	ADP	O
platelet	O	NOUN	B
function	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
on	I-P	ADP	O
clopidogrel	I-I	NOUN	B
and	I-P	CCONJ	O
high	I-P	ADJ	B
platelet	I-P	NOUN	B
reactivity	I-P	NOUN	I
undergoing	I-P	VERB	O
percutaneous	I-I	ADJ	B
coronary	I-I	ADJ	I
intervention	I-I	NOUN	I
for	I-P	ADP	O
acute	I-P	ADJ	B
coronary	I-P	ADJ	I
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
ACS	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


PATIENTS	O	VERB	B
Patients	B-P	NOUN	B
with	I-P	ADP	O
ACS	I-P	NOUN	B
on	O	ADP	O
clopidogrel	B-I	NOUN	B
who	O	PRON	O
were	O	AUX	O
scheduled	O	VERB	B
for	O	ADP	O
PCI	B-I	NOUN	B
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
platelet	O	NOUN	B
reactivity	O	NOUN	I
≥40	O	NOUN	O
AUC	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Multiplate	O	PROPN	B
Analyzer	O	PROPN	I
,	O	PUNCT	O
i.e	O	ADV	O
.	O	PUNCT	O


"	O	PUNCT	O
poor	O	ADJ	B
responders	O	NOUN	I
"	O	PUNCT	O
were	O	AUX	O
randomised	O	VERB	B
to	B-I	PART	O
prasugrel	I-I	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
loading	O	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
maintenance	O	NOUN	B
dose	O	NOUN	I
)	O	PUNCT	O
or	B-I	CCONJ	O
clopidogrel	I-I	NOUN	B
(	O	PUNCT	O
600	O	NUM	O
mg	O	NOUN	O
reloading	O	NOUN	B
and	O	CCONJ	O
150	O	NUM	O
mg	O	NOUN	O
maintenance	O	NOUN	B
dose	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
was	B-OUT	AUX	O
proportion	I-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
platelet	I-OUT	NOUN	B
reactivity	I-OUT	NOUN	I
<	I-OUT	X	O
40	I-OUT	NUM	O
AUC	O	NOUN	B
4	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
loading	O	VERB	B
with	O	ADP	O
study	O	NOUN	B
medication	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
at	O	ADP	O
one	O	NUM	O
hour	O	NOUN	B
(	O	PUNCT	O
secondary	O	ADJ	B
outcome	B-P	NOUN	I
)	I-P	PUNCT	O
.	I-P	PUNCT	O


44	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
and	O	CCONJ	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
terminated	O	VERB	O
early	O	ADV	O
as	O	ADP	O
clopidogrel	O	NOUN	B
use	O	NOUN	O
decreased	O	VERB	B
sharply	O	ADV	O
due	O	ADP	O
to	O	ADP	O
introduction	O	NOUN	B
of	O	ADP	O
newer	O	ADJ	O
P2Y12	O	NOUN	B
inhibitors	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
4	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
study	O	NOUN	B
medication	O	NOUN	B
100	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
prasugrel	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
91	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
those	O	DET	O
treated	O	VERB	B
with	O	ADP	I
clopidogrel	O	NOUN	B
had	B-OUT	AUX	O
platelet	I-OUT	NOUN	B
reactivity	I-OUT	NOUN	I
<	I-OUT	X	O
40	I-OUT	NUM	O
AUC	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.49	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
while	O	SCONJ	O
at	O	ADP	O
1	O	NUM	O
hour	O	NOUN	B
the	O	DET	O
proportions	O	NOUN	B
were	O	AUX	O
95	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
64	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Mean	B-OUT	VERB	B
platelet	I-OUT	NOUN	B
reactivity	I-OUT	NOUN	I
at	O	ADP	O
4	O	NUM	O
and	O	CCONJ	O
1	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
study	O	NOUN	B
medication	O	NOUN	B
in	O	ADP	O
prasugrel	O	NOUN	B
and	O	CCONJ	O
clopidogrel	O	NOUN	B
groups	O	NOUN	B
respectively	O	ADV	O
were	O	AUX	O
12	O	NUM	O
versus	O	CCONJ	O
22	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
19	O	NUM	O
versus	O	CCONJ	O
34	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Routine	O	ADJ	B
platelet	O	NOUN	B
function	O	NOUN	I
testing	O	NOUN	I
identifies	O	VERB	O
patients	O	NOUN	B
with	O	ADP	O
high	B-OUT	ADJ	O
residual	I-OUT	ADJ	B
platelet	I-OUT	NOUN	B
reactivity	I-OUT	NOUN	I
(	O	PUNCT	O
"	O	PUNCT	O
poor	O	ADJ	B
responders	O	NOUN	I
"	O	PUNCT	O
)	O	PUNCT	O
on	O	ADP	O
clopidogrel	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
strategy	O	NOUN	O
of	O	ADP	O
prasugrel	O	NOUN	B
rather	O	ADV	O
than	O	ADP	O
clopidogrel	O	NOUN	B
reloading	O	NOUN	B
results	O	NOUN	B
in	O	ADP	O
earlier	O	ADV	O
and	O	CCONJ	O
more	O	ADV	O
sustained	O	ADJ	B
suppression	O	NOUN	B
of	O	ADP	O
platelet	O	NOUN	B
reactivity	O	NOUN	I
.	O	PUNCT	O


Future	O	ADJ	B
trials	O	NOUN	B
need	O	VERB	O
to	O	PART	O
identify	O	VERB	O
if	O	SCONJ	O
this	O	DET	O
translates	O	VERB	O
into	O	ADP	O
clinical	O	ADJ	B
benefit	O	NOUN	I
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
ClinicalTrials.gov	O	NOUN	O
NCT01339026	O	PROPN	O
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
high	B-I	ADJ	B
and	I-I	CCONJ	O
low	I-I	ADJ	B
fat	I-I	ADJ	B
meals	I-I	NOUN	B
on	O	ADP	O
postprandial	B-P	ADJ	B
esophageal	I-P	NOUN	B
acid	I-P	NOUN	I
exposure	I-P	NOUN	B
.	I-P	PUNCT	O


Fatty	O	ADJ	B
foods	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
precipitating	O	NOUN	B
factors	O	NOUN	I
in	O	ADP	O
symptomatic	O	ADJ	B
gastroesophageal	B-P	NOUN	B
reflux	I-P	NOUN	I
(	I-P	PUNCT	O
GER	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


A	O	DET	O
fat	O	ADJ	B
meal	O	NOUN	I
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
decrease	O	VERB	B
lower	O	ADJ	O
esophageal	B-OUT	NOUN	O
sphincter	I-OUT	NOUN	O
pressure	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
LESP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
normal	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
the	O	DET	O
ambulatory	O	ADJ	B
24-h	O	ADJ	O
pH	O	NOUN	B
monitor	O	NOUN	I
to	O	PART	O
assess	O	VERB	O
esophageal	O	ADJ	B
acid	O	NOUN	I
exposure	O	NOUN	B
in	O	ADP	O
10	B-P	NUM	O
normal	I-P	ADJ	B
subjects	I-P	NOUN	I
and	I-P	CCONJ	O
10	I-P	NUM	O
GER	I-P	NOUN	B
patients	I-P	NOUN	B
following	I-P	VERB	O
low	I-I	ADJ	B
and	I-I	CCONJ	O
high	I-I	ADJ	B
fat	I-I	ADJ	B
meals	I-I	NOUN	O
eaten	I-I	VERB	B
in	I-I	ADP	O
two	I-I	NUM	O
body	I-I	NOUN	B
positions	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
meals	O	NOUN	B
had	O	AUX	O
nearly	O	ADV	O
identical	O	ADJ	O
protein	O	NOUN	B
content	O	NOUN	B
,	O	PUNCT	O
volumes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
calories	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
successive	O	ADJ	O
days	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
ingested	O	VERB	B
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
meals	B-I	NOUN	B
twice	O	ADV	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
random	O	ADJ	B
assignment	O	NOUN	B
to	O	PART	O
3	O	NUM	O
h	O	NOUN	O
upright	B-I	ADJ	B
and	I-I	CCONJ	O
3	O	NUM	O
h	O	NOUN	O
recumbent	B-I	ADJ	B
position	I-I	NOUN	I
.	I-I	PUNCT	O


Acid	B-OUT	NOUN	B
exposure	I-OUT	NOUN	I
for	I-OUT	ADP	O
each	I-OUT	DET	O
hour	I-OUT	NOUN	B
over	O	ADP	O
a	O	DET	O
3-h	O	ADJ	O
postprandial	O	ADJ	B
(	O	PUNCT	O
PP	O	NOUN	B
)	O	PUNCT	O
period	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
as	O	ADP	O
the	O	DET	O
percent	O	NOUN	O
time	O	NOUN	O
pH	O	NOUN	B
less	O	ADJ	O
than	O	ADP	O
4.0	O	NUM	O
.	O	PUNCT	O


Increased	O	VERB	B
upright	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
exposure	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
normals	O	NOUN	B
after	O	ADP	O
the	O	DET	O
high	O	ADJ	B
fat	O	NOUN	I
(	O	PUNCT	O
6.2	O	NUM	O
+/-	O	CCONJ	O
2.1	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SE	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
low	O	ADJ	B
fat	O	ADJ	O
meal	O	NOUN	O
(	O	PUNCT	O
1.5	O	NUM	O
+/-	O	CCONJ	O
0.5	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


GER	O	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
greater	O	ADJ	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
acid	B-OUT	NOUN	B
exposure	I-OUT	NOUN	I
than	O	ADP	O
normals	O	NOUN	B
in	O	ADP	O
all	O	DET	O
study	O	NOUN	B
periods	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
low	O	ADJ	B
and	O	CCONJ	O
high	O	ADJ	B
fat	O	ADJ	B
meals	O	NOUN	B
in	O	ADP	O
either	O	DET	O
study	O	NOUN	B
position	O	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
fat	O	NOUN	B
meals	O	NOUN	O
induce	O	VERB	B
upright	B-OUT	ADJ	O
GER	I-OUT	NOUN	B
in	O	ADP	O
normals	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
do	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
affect	O	VERB	O
the	O	DET	O
abnormal	O	ADJ	B
amount	O	NOUN	O
of	O	ADP	O
GER	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
progressive	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
acid	B-OUT	NOUN	B
exposure	I-OUT	NOUN	I
were	O	AUX	O
found	O	VERB	O
over	O	ADP	O
the	O	DET	O
3	O	NUM	O
postprandial	O	ADJ	B
hours	O	NOUN	B
in	O	ADP	O
GER	O	NOUN	B
patients	O	NOUN	B
in	O	ADP	O
a	O	DET	O
recumbent	O	ADJ	B
position	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
prior	O	ADJ	O
data	O	NOUN	B
showing	O	VERB	O
decreased	O	VERB	B
LESP	B-OUT	NOUN	B
with	O	ADP	O
a	O	DET	O
fat	O	ADJ	B
meal	O	NOUN	I
in	O	ADP	O
normals	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
topical	B-I	ADJ	B
and	I-I	CCONJ	O
systemic	I-I	ADJ	B
folic	I-I	ADJ	B
acid	I-I	NOUN	I
supplementation	O	NOUN	B
on	O	ADP	O
gingivitis	B-OUT	NOUN	B
in	I-OUT	ADP	O
pregnancy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
study	O	NOUN	I
evaluated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
systemic	B-I	ADJ	B
and	I-I	CCONJ	O
topical	I-I	ADJ	B
folate	I-I	NOUN	O
on	O	ADP	O
gingival	B-OUT	ADJ	B
inflammation	I-OUT	NOUN	I
during	I-OUT	ADP	O
the	I-OUT	DET	O
fourth	I-OUT	ADJ	O
and	I-OUT	CCONJ	O
eighth	I-OUT	ADJ	O
months	I-OUT	NOUN	B
of	I-OUT	ADP	O
pregnancy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Thirty	B-P	NUM	O
women	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Group	O	PROPN	B
A	O	PROPN	O
received	O	VERB	O
placebo	B-I	NOUN	B
mouthwash	I-I	NOUN	O
and	I-I	CCONJ	O
tablets	I-I	NOUN	B
;	I-I	PUNCT	O
Group	O	PROPN	B
B	O	NOUN	I
;	O	PUNCT	O
placebo	B-I	ADJ	B
mouthwash	I-I	NOUN	O
and	I-I	CCONJ	O
5	I-I	NUM	O
mg	I-I	NOUN	O
folate	I-I	NOUN	B
tablets	I-I	NOUN	I
;	I-I	PUNCT	O
Group	O	PROPN	B
C	O	NOUN	O
:	O	PUNCT	O
folate	B-I	NOUN	B
mouthwash	I-I	NOUN	I
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
tablets	I-I	NOUN	B
.	I-I	PUNCT	O


Supplementation	O	NOUN	B
lasted	O	VERB	O
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
during	O	ADP	O
months	O	NOUN	B
4	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


Subjects	O	NOUN	B
took	O	VERB	O
one	O	NUM	O
tablet	O	NOUN	B
daily	O	ADV	B
and	O	CCONJ	O
rinsed	O	VERB	B
twice	O	ADV	O
daily	O	ADV	O
for	O	ADP	O
1	O	NUM	O
min	O	NOUN	O
with	O	ADP	O
the	O	DET	O
mouthwash	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
start	O	NOUN	O
and	O	CCONJ	O
finish	O	NOUN	O
of	O	ADP	O
each	O	DET	O
14-day	O	ADJ	O
period	O	NOUN	B
,	O	PUNCT	O
fasting	B-OUT	VERB	B
serum	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
red	I-OUT	ADJ	B
cell	I-OUT	NOUN	I
folate	I-OUT	NOUN	O
levels	I-OUT	NOUN	O
were	O	AUX	O
estimated	O	VERB	B
and	O	CCONJ	O
oral	B-OUT	ADJ	B
status	I-OUT	NOUN	I
assessed	O	VERB	B
by	O	ADP	O
a	O	DET	O
plaque	B-OUT	NOUN	B
index	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
P1I	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
a	I-OUT	DET	O
gingival	I-OUT	ADJ	B
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
gingival	I-OUT	ADJ	B
exudate	I-OUT	ADJ	I
flow	I-OUT	NOUN	I
meter	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GEF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Subjects	O	NOUN	B
completed	O	VERB	O
1-week	O	ADJ	B
diet	O	ADJ	B
sheets	O	NOUN	I
which	O	DET	O
were	O	AUX	O
analysed	O	VERB	B
for	O	ADP	O
dietary	B-OUT	ADJ	B
folate	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


All	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
each	O	DET	O
parameter	O	NOUN	B
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
.	O	PUNCT	O


Correlation	O	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
between	O	ADP	O
GI	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
P1I	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
between	O	ADP	O
GI	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
GEF	I-OUT	PROPN	B
.	I-OUT	PUNCT	O


GI	B-OUT	NOUN	B
tended	O	VERB	O
to	O	PART	O
increase	O	VERB	B
throughout	O	ADP	O
pregnancy	O	NOUN	B
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
except	O	SCONJ	O
Group	O	PROPN	B
C	O	PROPN	O
,	O	PUNCT	O
when	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
eighth	O	ADJ	O
month	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
highly	O	ADV	O
significant	O	ADJ	O
improvement	O	NOUN	B
(	O	PUNCT	O
0.001	O	NUM	O
less	O	ADJ	O
than	O	ADP	O
P	O	NOUN	O
0.01	O	NUM	O
)	O	PUNCT	O
despite	O	SCONJ	O
no	O	DET	B
significant	O	ADJ	I
change	O	NOUN	O
in	O	ADP	O
P1I	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
dietary	O	ADJ	B
intake	O	NOUN	I
of	O	ADP	O
folate	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
during	O	ADP	O
the	O	DET	O
eighth	O	ADJ	O
month	O	NOUN	B
in	O	ADP	O
Group	O	PROPN	B
C	O	NOUN	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
Groups	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
B	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
0.001	O	NUM	O
less	O	ADJ	O
than	O	ADP	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
folate	O	NOUN	B
mouthwash	O	NOUN	I
produced	O	VERB	O
highly	O	ADV	O
significantly	O	ADV	O
improvement	O	NOUN	B
in	O	ADP	O
gingival	B-OUT	ADJ	B
health	I-OUT	NOUN	I
in	I-P	ADP	O
pregnancy	I-P	NOUN	B
.	I-P	PUNCT	O


Superior	O	NOUN	B
fixation	O	NOUN	B
of	O	ADP	O
pegged	B-I	ADJ	B
trabecular	I-I	NOUN	I
metal	I-I	NOUN	I
over	O	ADP	O
screw-fixed	B-I	ADJ	B
pegged	I-I	ADJ	I
porous	I-I	ADJ	I
titanium	I-I	NOUN	O
fiber	I-I	NOUN	O
mesh	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
RSA	O	NOUN	I
study	O	NOUN	B
on	O	ADP	O
cementless	O	ADJ	B
tibial	O	ADJ	B
components	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
PURPOSE	O	VERB	O
Lasting	O	NOUN	O
stability	B-OUT	NOUN	O
of	O	ADP	O
cementless	O	NOUN	B
implants	O	NOUN	B
depends	O	VERB	O
on	O	ADP	O
osseointegration	O	NOUN	B
into	O	ADP	O
the	O	DET	O
implant	O	ADJ	B
surface	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
long-term	O	ADJ	B
implant	O	ADJ	B
fixation	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
predicted	O	VERB	B
using	O	VERB	O
radiostereometric	O	ADJ	B
analysis	O	NOUN	I
(	O	PUNCT	O
RSA	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
short-term	O	ADJ	B
follow-up	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
would	O	AUX	O
be	O	AUX	O
improved	O	VERB	O
fixation	B-OUT	NOUN	B
of	O	ADP	O
high-porosity	B-I	ADJ	B
trabecular	I-I	NOUN	B
metal	I-I	NOUN	I
(	I-I	PUNCT	O
TM	I-I	NOUN	B
)	I-I	PUNCT	O
tibial	I-I	NOUN	B
components	I-I	NOUN	I
compared	O	VERB	O
to	O	PART	O
low-porosity	B-I	ADJ	B
titanium	I-I	NOUN	B
pegged	I-I	ADJ	O
porous	I-I	ADJ	B
fiber-metal	I-I	ADJ	I
(	I-I	PUNCT	O
Ti	I-I	NOUN	O
)	I-I	PUNCT	O
polyethylene	I-I	NOUN	B
metal	I-I	NOUN	B
backings	I-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
parallel-group	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
unblinded	O	ADJ	O
clinical	O	ADJ	O
trial	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
compared	O	VERB	O
cementless	B-I	ADJ	B
tibial	I-I	ADJ	B
components	I-I	NOUN	I
in	I-P	ADP	O
patients	I-P	NOUN	B
aged	I-P	ADJ	B
70	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
younger	I-P	ADJ	B
with	I-P	ADP	O
osteoarthritis	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
pre-study	O	ADJ	B
sample	O	NOUN	B
size	O	NOUN	I
calculation	O	NOUN	B
was	O	AUX	O
22	B-P	NUM	O
patients	I-P	NOUN	B
per	I-P	ADP	O
group	I-P	NOUN	B
.	I-P	PUNCT	O


25	B-I	NUM	O
TM	I-I	NOUN	B
tibial	I-I	NOUN	O
components	I-I	NOUN	B
were	I-I	AUX	O
fixed	I-I	VERB	O
press-fit	I-I	NOUN	B
by	I-I	ADP	O
2	I-I	NUM	O
hexagonal	I-I	ADJ	B
pegs	I-I	NOUN	I
(	O	PUNCT	O
TM	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
25	B-I	NUM	O
Ti	I-I	NOUN	B
tibial	I-I	NOUN	B
components	I-I	NOUN	B
were	I-I	AUX	O
fixed	I-I	VERB	O
press-fit	I-I	NOUN	B
and	I-I	CCONJ	O
by	I-I	ADP	O
4	I-I	NUM	O
supplemental	I-I	ADJ	B
screws	I-I	NOUN	I
(	O	PUNCT	O
Ti	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Stereo	O	ADJ	B
radiographs	O	NOUN	I
for	O	ADP	O
evaluation	O	NOUN	B
of	O	ADP	O
absolute	O	ADJ	B
component	O	NOUN	O
migration	O	NOUN	O
(	O	PUNCT	O
primary	O	ADJ	B
effect	O	NOUN	I
size	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
single-direction	O	ADJ	B
absolute	O	ADJ	I
component	O	NOUN	I
migration	O	NOUN	I
(	O	PUNCT	O
secondary	O	ADJ	B
effect	O	NOUN	I
size	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
obtained	O	VERB	O
within	O	ADP	O
the	O	DET	O
first	O	ADJ	O
postoperative	O	ADJ	B
week	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


American	B-OUT	PROPN	B
Knee	I-OUT	PROPN	I
Society	I-OUT	PROPN	I
score	I-OUT	NOUN	I
was	O	AUX	O
used	O	VERB	O
for	O	ADP	O
clinical	O	ADJ	B
assessment	O	NOUN	I
preoperatively	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
intraoperative	B-OUT	ADJ	B
complications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
no	I-OUT	DET	O
postoperative	I-OUT	ADJ	B
infections	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
revisions	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


All	B-P	DET	O
patients	I-P	NOUN	B
had	O	AUX	O
improved	B-OUT	VERB	B
function	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
regained	I-OUT	VERB	B
full	I-OUT	ADJ	O
extension	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


All	O	DET	O
tibial	O	ADJ	B
components	O	NOUN	I
migrated	B-OUT	VERB	O
initially	O	ADV	B
.	O	PUNCT	O


Most	O	ADJ	O
migration	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
TM	I-OUT	NOUN	B
components	I-OUT	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
24	O	NUM	O
)	O	PUNCT	O
occurred	O	VERB	O
within	O	ADP	O
the	O	DET	O
first	O	ADJ	O
3	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
whereas	O	SCONJ	O
migration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Ti	B-I	NOUN	B
components	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
22	O	NUM	O
)	O	PUNCT	O
appeared	O	VERB	O
to	O	PART	O
stabilize	O	VERB	B
first	O	ADV	O
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
TM	B-I	NOUN	B
components	I-I	NOUN	B
migrated	O	VERB	O
less	O	ADJ	O
than	O	ADP	O
the	O	DET	O
Ti	B-I	NOUN	B
components	I-I	NOUN	B
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


INTERPRETATION	O	ADJ	B
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mechanical	O	ADJ	B
fixation	O	NOUN	I
of	O	ADP	O
TM	B-I	NOUN	B
tibial	I-I	NOUN	O
components	I-I	NOUN	O
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
screw-fixed	O	ADJ	B
Ti	B-I	NOUN	I
tibial	I-I	NOUN	I
components	I-I	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
expect	O	VERB	O
long-term	B-OUT	ADJ	B
implant	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
to	O	PART	O
be	O	AUX	O
better	O	ADJ	O
with	O	ADP	O
the	O	DET	O
TM	B-I	NOUN	B
tibial	I-I	NOUN	O
component	I-I	NOUN	O
.	I-I	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
supplementation	O	NOUN	B
of	O	ADP	O
whole	O	ADJ	B
corn	O	NOUN	I
germ	O	NOUN	I
on	O	ADP	O
reproductive	B-OUT	ADJ	B
performance	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
calf	I-OUT	NOUN	B
performance	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
leptin	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
in	O	ADP	O
primiparous	B-P	ADJ	B
and	I-P	CCONJ	O
mature	I-P	ADJ	B
beef	I-P	NOUN	B
cows	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
2-yr	O	ADJ	O
study	O	NOUN	B
using	O	VERB	O
primiparous	B-P	ADJ	B
and	I-P	CCONJ	O
multiparous	I-P	ADJ	B
,	I-P	PUNCT	O
spring-calving	I-P	ADJ	B
,	I-P	PUNCT	O
crossbred	I-P	ADJ	B
beef	I-P	NOUN	O
cows	I-P	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
supplemental	B-I	ADJ	B
whole	I-I	ADJ	I
corn	I-I	NOUN	I
germ	I-I	NOUN	I
on	O	ADP	O
reproductive	B-OUT	ADJ	B
performance	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
calf	I-OUT	NOUN	B
performance	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
leptin	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Each	O	DET	O
year	O	NOUN	B
,	O	PUNCT	O
cows	B-P	NOUN	B
were	O	AUX	O
blocked	B-I	VERB	B
by	I-I	ADP	O
age	I-I	NOUN	B
and	I-I	CCONJ	O
BCS	I-I	NOUN	B
and	I-I	CCONJ	O
assigned	I-I	VERB	O
randomly	I-I	ADV	O
to	I-I	PART	O
one	I-I	NUM	O
of	I-I	ADP	O
three	I-I	NUM	O
treatments	I-I	NOUN	B
:	I-I	PUNCT	O
PRE	I-I	NOUN	B
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
115	I-I	NUM	O
)	I-I	PUNCT	O
cows	I-I	NOUN	B
received	I-I	VERB	O
1.14	I-I	NUM	O
kg/d	I-I	NOUN	O
(	I-I	PUNCT	O
DM	I-I	NOUN	B
basis	I-I	NOUN	O
)	I-I	PUNCT	O
of	I-I	ADP	O
whole	I-I	ADJ	B
corn	I-I	NOUN	I
germ	I-I	NOUN	I
for	I-I	ADP	O
approximately	I-I	ADV	B
45	I-I	NUM	O
d	I-I	NOUN	O
before	I-I	ADP	O
calving	I-I	NOUN	B
;	I-I	PUNCT	O
POST	I-I	NOUN	B
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
109	I-I	NUM	O
)	I-I	PUNCT	O
cows	I-I	NOUN	B
were	I-I	AUX	O
fed	I-I	VERB	B
1.14	I-I	NUM	O
kg/d	I-I	NOUN	O
of	I-I	ADP	O
whole	I-I	ADJ	B
corn	I-I	NOUN	I
germ	I-I	NOUN	I
for	I-I	ADP	O
approximately	I-I	ADV	B
45	I-I	NUM	O
d	I-I	NOUN	O
after	I-I	ADP	O
calving	I-I	NOUN	B
;	I-I	PUNCT	O
and	I-I	CCONJ	O
control	I-I	NOUN	B
cows	I-I	NOUN	I
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
118	I-I	NUM	O
)	I-I	PUNCT	O
were	I-I	AUX	O
fed	I-I	VERB	O
similar	I-I	ADJ	O
energy	I-I	NOUN	B
and	I-I	CCONJ	O
protein	I-I	NOUN	B
from	I-I	ADP	O
dry-rolled	I-I	ADJ	B
corn	I-I	NOUN	I
(	I-I	PUNCT	O
1.82	I-I	NUM	O
kg	I-I	NOUN	O
of	I-I	ADP	O
DM/d	I-I	NOUN	O
)	I-I	PUNCT	O
for	I-I	ADP	O
45	I-I	NUM	O
d	I-I	NOUN	O
before	I-I	ADP	B
and	I-I	CCONJ	O
after	I-I	ADP	O
calving	I-I	NOUN	B
.	I-I	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
PRE	O	NOUN	B
cows	O	NOUN	B
were	O	AUX	O
grouped	B-I	VERB	B
with	I-I	ADP	O
controls	I-I	NOUN	B
after	I-I	ADP	O
calving	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
POST	I-I	NOUN	B
cows	I-I	NOUN	B
were	I-I	AUX	O
grouped	I-I	VERB	B
with	I-I	ADP	O
control	I-I	NOUN	B
cows	I-I	NOUN	B
before	I-I	ADP	O
calving	I-I	NOUN	B
,	I-I	PUNCT	O
so	I-I	CCONJ	O
that	I-I	SCONJ	O
corn	I-I	NOUN	B
germ-supplemented	I-I	ADJ	B
cows	I-I	NOUN	B
received	I-I	VERB	O
the	I-I	DET	O
control	I-I	NOUN	B
supplement	I-I	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
alternate	I-I	ADJ	B
feeding	I-I	NOUN	B
period	I-I	NOUN	B
.	I-I	PUNCT	O


Cow	B-OUT	NOUN	B
BW	I-OUT	NOUN	B
(	O	PUNCT	O
538	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
kg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
BCS	O	NOUN	B
(	O	PUNCT	O
5.4	O	NUM	O
+/-	O	CCONJ	O
0.13	O	NUM	O
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
among	O	ADP	O
treatments	O	NOUN	B
at	O	ADP	O
any	O	DET	O
time	O	NOUN	B
during	O	ADP	O
the	O	DET	O
experiment	O	NOUN	B
.	O	PUNCT	O


Calf	B-OUT	ADJ	B
birth	I-OUT	NOUN	I
weight	I-OUT	NOUN	I
(	O	PUNCT	O
39	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
kg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
weaning	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
(	O	PUNCT	O
225	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
kg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
age-adjusted	B-OUT	ADJ	B
weaning	I-OUT	NOUN	I
weight	I-OUT	NOUN	I
(	O	PUNCT	O
234	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
kg	O	NOUN	O
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
dam	O	NOUN	B
supplementation	O	NOUN	O
regimen	O	NOUN	O
.	O	PUNCT	O


Treatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
cows	O	NOUN	B
exhibiting	O	VERB	O
ovarian	B-OUT	ADJ	B
luteal	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
before	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
the	O	DET	O
breeding	O	NOUN	B
season	O	NOUN	B
(	O	PUNCT	O
67	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
pregnancy	O	NOUN	B
rate	O	NOUN	I
(	O	PUNCT	O
91	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
interval	O	NOUN	B
from	O	ADP	O
exposure	B-OUT	NOUN	B
to	O	ADP	I
bulls	O	NOUN	B
until	O	ADP	O
subsequent	O	ADJ	O
calving	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.16	O	NUM	O
)	O	PUNCT	O
among	O	ADP	O
PRE	O	NOUN	B
(	O	PUNCT	O
298	O	NUM	O
+/-	O	CCONJ	O
2.3	O	NUM	O
d	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
POST	O	NOUN	B
(	O	PUNCT	O
303	O	NUM	O
+/-	O	CCONJ	O
2.6	O	NUM	O
d	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
control	O	NOUN	B
(	O	PUNCT	O
304	O	NUM	O
+/-	O	CCONJ	O
2.3	O	NUM	O
d	O	NOUN	O
)	O	PUNCT	O
cows	O	NOUN	B
.	O	PUNCT	O


Leptin	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
among	O	ADP	O
treatments	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
2.15	O	NUM	O
+/-	O	CCONJ	O
0.75	O	NUM	O
,	O	PUNCT	O
1.88	O	NUM	O
+/-	O	CCONJ	O
0.76	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1.91	O	NUM	O
+/-	O	CCONJ	O
0.75	O	NUM	O
ng/mL	O	NOUN	O
for	O	ADP	O
control	O	NOUN	B
,	O	PUNCT	O
POST	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
PRE	O	NOUN	B
cows	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Age	O	NOUN	B
and	O	CCONJ	O
week	O	NOUN	B
relative	O	ADJ	O
to	O	ADP	O
calving	O	NOUN	B
influenced	O	VERB	O
leptin	O	NOUN	B
concentration	O	NOUN	B
.	O	PUNCT	O


Primiparous	B-P	ADJ	B
cows	I-P	NOUN	I
had	O	AUX	O
similar	O	ADJ	O
leptin	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
to	O	PART	O
3-yr-old	O	NOUN	O
and	O	CCONJ	O
mature	O	ADJ	B
cows	B-P	NOUN	B
for	O	ADP	O
wk	O	NOUN	O
-7	O	NUM	O
and	O	CCONJ	O
-6	O	NUM	O
relative	O	ADJ	O
to	O	ADP	O
calving	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
lower	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.10	O	NUM	O
)	O	PUNCT	O
concentrations	O	NOUN	B
than	O	ADP	O
mature	O	ADJ	B
cows	O	NOUN	B
for	O	ADP	O
wk	O	NOUN	O
-5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
lower	O	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	NOUN	O
0.05	O	NUM	O
)	O	PUNCT	O
concentrations	O	NOUN	B
than	O	ADP	O
either	O	CCONJ	O
3-yr-old	O	ADJ	O
or	O	CCONJ	O
mature	O	ADJ	B
cows	O	NOUN	B
for	O	ADP	O
wk	O	NOUN	O
-4	O	NUM	O
to	O	PART	O
+7	O	NUM	O
relative	O	ADJ	O
to	O	ADP	O
calving	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
leptin	O	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
BCS	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
;	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.35	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
feeding	O	NOUN	B
period	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
BCS	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
;	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.12	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
weight	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
;	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.14	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
supplement	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
was	O	AUX	O
not	O	PART	O
correlated	O	VERB	B
with	O	ADP	O
initial	O	ADJ	O
BW	O	NOUN	B
or	O	CCONJ	O
interim	O	ADJ	B
BCS	O	NOUN	B
.	O	PUNCT	O


Calving	O	NOUN	B
interval	O	NOUN	I
was	O	AUX	O
not	O	PART	O
correlated	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.12	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
weekly	O	ADJ	B
measures	O	NOUN	B
of	O	ADP	O
serum	B-OUT	NOUN	B
leptin	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Supplementing	O	VERB	B
beef	B-P	NOUN	B
cows	I-P	NOUN	B
with	O	ADP	O
whole	O	ADJ	B
corn	O	NOUN	I
germ	O	NOUN	I
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
cow	O	NOUN	B
performance	O	NOUN	B
,	O	PUNCT	O
calf	O	NOUN	B
performance	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
serum	O	NOUN	B
leptin	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
cows	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
exposure	B-P	NOUN	O
to	I-P	PART	O
acid	I-P	NOUN	B
fog	I-P	NOUN	I
:	I-P	PUNCT	O
influence	O	NOUN	B
of	O	ADP	O
breathing	O	NOUN	B
pattern	O	NOUN	I
on	O	ADP	O
effective	B-OUT	ADJ	B
dose	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Concern	O	NOUN	B
about	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
adverse	B-OUT	ADJ	B
health	I-OUT	NOUN	I
effects	I-OUT	NOUN	O
of	O	ADP	O
acid	O	NOUN	B
fog	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
fed	O	VERB	O
by	O	ADP	O
two	O	NUM	O
observations	O	NOUN	B
:	O	PUNCT	O
air	O	NOUN	B
pollution	O	NOUN	I
disasters	O	NOUN	B
earlier	O	ADV	O
in	O	ADP	O
this	O	DET	O
century	O	NOUN	O
were	O	AUX	O
typically	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
fog	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
current	O	ADJ	O
samples	O	NOUN	B
of	O	ADP	O
fog	O	NOUN	B
water	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
strongly	O	ADV	B
acid	O	ADJ	I
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
the	O	DET	O
acute	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
acid	O	NOUN	B
fog	O	NOUN	I
on	O	ADP	O
the	O	DET	O
lung	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
generated	O	VERB	O
a	O	DET	O
monodisperse	B-I	ADJ	B
10	I-I	NUM	I
microM	I-I	NOUN	O
MMAD	I-I	NOUN	B
aerosol	I-I	NOUN	B
of	I-I	ADP	O
H2SO4	I-I	NOUN	B
with	O	ADP	O
a	O	DET	O
pH	O	NOUN	B
of	O	ADP	O
2.0	O	NUM	O
and	O	CCONJ	O
a	O	DET	O
nominal	B-I	ADJ	O
concentration	I-I	NOUN	B
of	O	ADP	O
500	O	NUM	O
micrograms/m3	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
exposed	O	VERB	O
seven	B-P	NUM	O
healthy	I-P	ADJ	B
young	I-P	ADJ	B
men	I-P	NOUN	B
on	O	ADP	O
alternate	O	ADJ	B
days	O	NOUN	I
to	O	PART	O
acid	B-I	NOUN	B
or	I-I	CCONJ	O
control	I-I	VERB	B
equiosmolar	I-I	ADJ	B
NaCl	I-I	NOUN	B
aerosol	I-I	NOUN	B
during	O	ADP	O
40	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
resting	O	VERB	B
ventilation	O	NOUN	I
and	O	CCONJ	O
20	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
exercise	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
latter	O	ADJ	O
was	O	AUX	O
sufficiently	O	ADV	O
intense	O	ADJ	O
to	O	PART	O
induce	O	VERB	B
oronasal	B-OUT	ADJ	B
breathing	I-OUT	NOUN	I
.	O	PUNCT	O


Exposure	O	NOUN	B
was	O	AUX	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
a	O	DET	O
head	O	NOUN	B
dome	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
head-only	O	ADJ	O
exposure	O	NOUN	B
device	O	NOUN	I
that	O	PRON	O
permitted	O	VERB	O
continuous	O	ADJ	B
measurement	O	NOUN	I
(	O	PUNCT	O
unfettered	O	ADJ	B
breathing	O	NOUN	I
)	O	PUNCT	O
of	O	ADP	O
Vr	O	NOUN	B
,	O	PUNCT	O
f	O	X	O
,	O	PUNCT	O
VE	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
onset	O	NOUN	B
and	O	CCONJ	O
persistence	O	NOUN	B
of	O	ADP	O
oronasal	B-OUT	ADJ	B
breathing	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
this	O	DET	O
article	O	NOUN	O
the	O	DET	O
authors	O	NOUN	B
compare	O	VERB	B
the	O	DET	O
relative	O	ADJ	O
importance	O	NOUN	O
of	O	ADP	O
parameters	O	NOUN	B
contributing	O	VERB	O
to	O	PART	O
the	O	DET	O
between-subject	O	ADJ	B
variability	O	NOUN	B
in	O	ADP	O
estimated	O	VERB	B
hydrogen	O	NOUN	B
ion	O	NOUN	I
dose	O	NOUN	I
to	O	PART	O
the	O	DET	O
lower	B-OUT	ADJ	B
airways	I-OUT	NOUN	I
(	O	PUNCT	O
H+LAW	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
variance	O	NOUN	B
.	O	PUNCT	O


Physiologic	O	ADJ	B
parameters	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
70	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
variability	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
34	O	NUM	O
%	O	NOUN	O
was	O	AUX	O
due	O	ADJ	O
to	O	PART	O
differences	O	NOUN	B
in	O	ADP	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
oronasal	I-OUT	ADJ	B
breathing	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
tON	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
36	O	NUM	O
%	O	NOUN	O
to	O	PART	O
differences	O	NOUN	B
in	O	ADP	O
ventilation	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
during	I-OUT	ADP	O
oronasal	I-OUT	ADJ	B
breathing	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VE	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
ON	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
inhaled	I-OUT	VERB	B
hydrogen	I-OUT	NOUN	I
ion	I-OUT	NOUN	I
concentration	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
H+	I-OUT	NOUN	B
]	I-OUT	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
environmental	O	ADJ	B
parameter	O	NOUN	I
,	O	PUNCT	O
contributed	O	VERB	O
only	O	ADV	O
30	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Minute	O	NOUN	B
ventilation	O	NOUN	I
at	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
transition	O	NOUN	B
from	O	ADP	O
nasal	O	ADJ	B
to	O	PART	O
oronasal	O	ADJ	B
breathing	O	NOUN	I
varied	O	VERB	O
significantly	O	ADV	O
among	O	ADP	O
subjects	O	NOUN	B
even	O	ADV	O
if	O	SCONJ	O
normalized	O	VERB	O
to	O	ADP	O
FVC	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
index	O	NOUN	O
of	O	ADP	O
lung	O	NOUN	B
size	O	NOUN	I
.	O	PUNCT	O


Determinants	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
creatinine	O	NOUN	O
trajectory	O	NOUN	O
in	O	ADP	O
acute	B-P	ADJ	B
contrast	I-P	NOUN	I
nephropathy	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
describe	O	VERB	O
the	O	DET	O
trajectory	O	NOUN	B
of	O	ADP	O
creatinine	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
Cr	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
rise	I-OUT	NOUN	O
and	O	CCONJ	O
its	O	PRON	O
determinants	O	NOUN	B
after	B-P	ADP	O
exposure	I-P	NOUN	B
to	I-P	PART	I
radiocontrast	I-P	NOUN	B
media	I-P	NOUN	I
.	I-P	PUNCT	O


Included	O	VERB	O
were	O	AUX	O
98	B-P	NUM	O
subjects	I-P	NOUN	B
who	I-P	PRON	O
underwent	I-P	VERB	O
cardiac	I-P	ADJ	B
catheterization	I-P	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
forced	O	VERB	O
diuresis	B-I	NOUN	B
with	I-I	ADP	O
i.v	I-I	NOUN	O
.	I-I	PUNCT	O


crystalloid	B-I	NOUN	B
,	I-I	PUNCT	O
furosemide	I-I	NOUN	B
,	I-I	PUNCT	O
mannitol	I-I	NOUN	B
(	I-I	PUNCT	O
if	I-I	SCONJ	O
pulmonary	I-I	ADJ	B
capillary	I-I	ADJ	I
wedge	I-I	NOUN	I
pressure	I-I	NOUN	I
was	I-I	AUX	O
<	I-I	X	O
20	I-I	NUM	O
mmHg	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
low	I-I	ADJ	B
dose	I-I	NOUN	B
dopamine	I-I	NOUN	B
versus	I-I	CCONJ	O
intravenous	I-I	ADJ	B
crystalloid	I-I	NOUN	B
and	I-I	CCONJ	O
matching	I-I	VERB	B
placebos	I-I	NOUN	B
.	I-I	PUNCT	O


Baseline	O	NOUN	B
and	O	CCONJ	O
postcatheterization	O	NOUN	B
serum	B-OUT	NOUN	O
Cr	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
in	O	ADP	O
a	O	DET	O
longitudinal	O	ADJ	B
fashion	O	NOUN	I
,	O	PUNCT	O
allowing	O	VERB	O
for	O	ADP	O
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
time	O	NOUN	B
between	O	ADP	O
blood	O	NOUN	B
draws	O	VERB	O
,	O	PUNCT	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
different	O	ADJ	O
critical	O	ADJ	B
trajectories	O	NOUN	I
of	O	ADP	O
serum	O	NOUN	B
Cr	O	NOUN	B
.	O	PUNCT	O


The	B-P	DET	O
mean	I-OUT	ADJ	O
age	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
baseline	I-OUT	NOUN	B
serum	I-OUT	NOUN	B
Cr	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Cr	I-OUT	NOUN	B
clearance	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
CrCl	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	I-P	AUX	O
69.3	I-P	NUM	O
+/-	I-P	CCONJ	O
10.8	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
2.5	I-P	NUM	O
+/-	I-P	CCONJ	O
0.9	I-P	NUM	O
mg/dL	I-P	NOUN	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
31.4	I-P	NUM	O
+/-	I-P	CCONJ	O
12.1	I-P	NUM	O
mL/min	I-P	NOUN	O
,	I-P	PUNCT	O
respectively	I-P	ADV	O
.	I-P	PUNCT	O


The	O	DET	O
clinically	B-OUT	ADV	B
driven	I-OUT	VERB	O
postprocedural	I-OUT	ADJ	B
observation	I-OUT	NOUN	I
time	I-OUT	NOUN	I
was	O	AUX	O
5.5	O	NUM	O
+/-	O	CCONJ	O
5.1	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
19	O	NUM	O
hours	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
Cr	O	NOUN	B
value	O	NOUN	O
to	O	ADP	O
25.7	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
18	O	NUM	O
values	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
maximum	I-OUT	ADJ	B
Cr	I-OUT	NOUN	B
was	O	AUX	O
3.3	O	NUM	O
+/-	O	CCONJ	O
1.4	O	NUM	O
,	O	PUNCT	O
range	O	NOUN	O
1.7-8.7	O	NUM	O
mg/dL	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Longitudinal	O	ADJ	B
models	O	NOUN	I
support	O	VERB	O
baseline	O	NOUN	B
Cr	B-OUT	NOUN	B
clearance	I-OUT	NOUN	B
predictions	O	NOUN	B
for	O	ADP	O
the	O	DET	O
change	O	NOUN	B
in	O	ADP	O
Cr	O	NOUN	B
at	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
time	O	NOUN	O
as	O	ADP	O
the	O	DET	O
determinant	O	NOUN	O
of	O	ADP	O
Cr	O	NOUN	B
trajectory	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
requisite	O	ADJ	O
monitoring	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
any	O	DET	O
given	O	VERB	O
individual	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
Cr	B-OUT	NOUN	B
of	O	ADP	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0.5	O	NUM	O
mg/dL	O	NOUN	O
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
24	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
contrast	O	NOUN	O
exposure	O	NOUN	B
predicted	O	VERB	O
a	O	DET	O
favorable	O	ADJ	O
outcome	O	NOUN	B
.	O	PUNCT	O


Baseline	B-OUT	NOUN	B
renal	I-OUT	ADJ	B
function	I-OUT	NOUN	I
is	O	AUX	O
the	O	DET	O
major	O	ADJ	O
determinant	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
rise	O	NOUN	O
,	O	PUNCT	O
height	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
Cr	O	NOUN	B
trajectory	O	NOUN	B
after	O	ADP	O
contrast	O	NOUN	O
exposure	O	NOUN	B
.	O	PUNCT	O


Length	O	NOUN	B
of	O	ADP	O
observation	O	NOUN	B
and	O	CCONJ	O
frequency	O	NOUN	B
of	O	ADP	O
laboratory	O	NOUN	B
measures	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
anticipated	O	VERB	B
from	O	ADP	O
these	O	DET	O
models	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
cuffed	B-I	VERB	B
and	I-I	CCONJ	O
uncuffed	I-I	VERB	B
endotracheal	I-I	NOUN	I
tubes	I-I	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	B
during	I-P	ADP	O
general	I-P	ADJ	B
anesthesia	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Uncuffed	B-I	NOUN	B
endotracheal	I-I	NOUN	O
tubes	I-I	NOUN	O
are	O	AUX	O
routinely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
tests	O	VERB	I
a	O	DET	O
formula	O	NOUN	B
for	O	ADP	O
selecting	O	VERB	O
appropriately	O	ADV	O
sized	O	ADJ	O
cuffed	O	VERB	B
endotracheal	O	NOUN	B
tubes	O	NOUN	I
and	O	CCONJ	O
compares	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
cuffed	B-I	VERB	B
versus	I-I	CCONJ	O
uncuffed	I-I	ADJ	B
endotracheal	I-I	NOUN	I
tubes	I-I	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
whose	O	DET	O
lungs	O	NOUN	B
are	O	AUX	O
mechanically	O	ADV	B
ventilated	O	VERB	I
during	O	ADP	O
anesthesia	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Full-term	B-P	ADJ	B
newborns	I-P	NOUN	I
and	I-P	CCONJ	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
488	I-P	NUM	O
)	I-P	PUNCT	O
through	I-P	ADP	O
8	I-P	NUM	O
yr	I-P	NOUN	O
of	I-P	ADP	O
age	I-P	NOUN	B
who	I-P	PRON	O
required	I-P	VERB	O
general	I-P	ADJ	B
anesthesia	I-P	NOUN	I
and	I-P	CCONJ	O
tracheal	I-P	ADJ	B
intubation	I-P	NOUN	I
were	O	AUX	O
assigned	O	VERB	O
randomly	O	ADV	O
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
a	O	DET	O
cuffed	B-I	VERB	B
tube	I-I	NOUN	I
sized	I-I	ADJ	B
by	I-I	ADP	O
a	I-I	DET	O
new	I-I	ADJ	O
formula	I-I	NOUN	B
[	O	PUNCT	O
size	O	NOUN	B
(	O	PUNCT	O
mm	O	NOUN	O
internal	O	ADJ	B
diameter	O	NOUN	I
)	O	PUNCT	O
=	O	ADJ	O
(	O	PUNCT	O
age/4	O	NOUN	O
)	O	PUNCT	O
+	O	CCONJ	O
3	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
an	O	DET	O
uncuffed	B-I	ADJ	B
tube	I-I	NOUN	I
sized	I-I	ADJ	B
by	I-I	ADP	O
the	I-I	DET	O
modified	I-I	VERB	O
Cole	I-I	PROPN	B
's	I-I	PART	I
formula	I-I	NOUN	I
[	O	PUNCT	O
size	O	NOUN	B
(	O	PUNCT	O
mm	O	NOUN	O
internal	O	ADJ	B
diameter	O	NOUN	I
)	O	PUNCT	O
=	O	ADJ	O
(	O	PUNCT	O
age/4	O	NOUN	O
)	O	PUNCT	O
+	O	CCONJ	O
4	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
intubations	I-OUT	NOUN	B
required	I-OUT	VERB	O
to	I-OUT	PART	O
achieve	I-OUT	VERB	O
an	I-OUT	DET	O
appropriately	I-OUT	ADV	O
sized	I-OUT	ADJ	B
tube	I-OUT	NOUN	I
,	O	PUNCT	O
the	O	DET	O
need	B-OUT	NOUN	O
to	I-OUT	PART	O
use	I-OUT	VERB	O
more	I-OUT	ADJ	O
than	I-OUT	ADP	O
21.min-1	I-OUT	NUM	O
fresh	I-OUT	ADJ	B
gas	I-OUT	NOUN	O
flow	I-OUT	NOUN	O
,	O	PUNCT	O
the	O	DET	O
concentration	B-OUT	NOUN	B
of	I-OUT	ADP	O
nitrous	I-OUT	ADJ	B
oxide	I-OUT	NOUN	I
in	I-OUT	ADP	O
the	I-OUT	DET	O
operating	I-OUT	NOUN	B
room	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
croup	I-OUT	NOUN	B
were	O	AUX	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Cuffed	B-I	PROPN	B
tubes	I-I	NOUN	I
selected	O	VERB	O
by	O	ADP	O
our	O	PRON	O
formula	O	NOUN	B
were	O	AUX	O
appropriate	B-OUT	ADJ	O
for	O	ADP	O
99	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Uncuffed	B-I	NOUN	B
tubes	I-I	NOUN	I
selected	O	VERB	O
by	O	ADP	O
Cole	O	PROPN	B
's	O	PART	I
formula	O	NOUN	I
were	O	AUX	O
appropriate	B-OUT	ADJ	O
for	O	ADP	O
77	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
lungs	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	O	ADP	O
cuffed	O	VERB	B
tubes	O	NOUN	I
were	O	AUX	O
adequately	B-OUT	ADV	O
ventilated	I-OUT	VERB	B
with	O	ADP	O
2	O	NUM	O
1.min-1	O	NUM	O
fresh	O	ADJ	B
gas	O	NOUN	B
flow	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
11	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
those	O	DET	O
with	O	ADP	O
uncuffed	O	ADJ	B
tubes	O	NOUN	I
needed	O	VERB	O
greater	O	ADJ	O
fresh	O	ADJ	B
gas	O	NOUN	B
flow	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Ambient	B-OUT	ADJ	B
nitrous	I-OUT	ADJ	B
oxide	I-OUT	NOUN	I
concentration	I-OUT	NOUN	B
exceeded	O	VERB	O
25	O	NUM	O
parts	O	NOUN	B
per	O	ADP	O
million	O	NUM	O
in	O	ADP	O
37	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
with	O	ADP	O
uncuffed	O	ADJ	B
tubes	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
0	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
with	O	ADP	O
cuffed	O	VERB	B
tubes	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
croup	B-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
(	O	PUNCT	O
1.2	O	NUM	O
%	O	NOUN	O
cuffed	O	NOUN	B
;	O	PUNCT	O
1.3	O	NUM	O
%	O	NOUN	O
uncuffed	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Our	O	PRON	O
formula	O	NOUN	B
for	O	ADP	O
cuffed	O	VERB	B
tube	O	NOUN	I
selection	O	NOUN	O
is	O	AUX	O
appropriate	B-OUT	ADJ	O
for	O	ADP	O
young	B-OUT	ADJ	B
children	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Advantages	B-OUT	NOUN	O
of	O	ADP	O
cuffed	B-I	VERB	B
endotracheal	I-I	NOUN	B
tubes	I-I	NOUN	I
include	O	VERB	O
avoidance	B-OUT	NOUN	B
of	I-OUT	ADP	O
repeated	I-OUT	ADJ	O
laryngoscopy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
low	I-OUT	ADJ	B
fresh	I-OUT	ADJ	B
gas	I-OUT	NOUN	O
flow	I-OUT	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
reduction	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
concentration	I-OUT	NOUN	B
of	I-OUT	ADP	O
anesthetics	I-OUT	NOUN	B
detectable	I-OUT	ADJ	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
operating	I-OUT	NOUN	B
room	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
cuffed	B-I	VERB	B
endotracheal	I-I	NOUN	B
tubes	I-I	NOUN	I
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
routinely	O	ADV	O
during	O	ADP	O
controlled	O	VERB	B
ventilation	O	NOUN	I
in	O	ADP	O
full-term	B-P	ADJ	B
newborns	I-P	NOUN	B
and	I-P	CCONJ	O
children	I-P	NOUN	B
during	I-P	ADP	O
anesthesia	I-P	NOUN	B
.	I-P	PUNCT	O


[	O	PUNCT	O
Clinical	O	ADJ	B
observation	O	NOUN	I
on	O	ADP	O
acupuncture	B-I	NOUN	B
combined	O	VERB	O
with	O	ADP	O
Yizhi	B-I	PROPN	B
Jiannao	I-I	PROPN	I
granules	I-I	NOUN	I
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
Alzheimer	O	NOUN	B
's	O	PART	I
disease	O	NOUN	I
]	O	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
observe	O	VERB	O
clinical	O	ADJ	B
therapeutic	B-OUT	ADJ	B
effect	I-OUT	NOUN	I
of	O	ADP	O
acupuncture	B-I	NOUN	B
combined	O	VERB	O
with	O	ADP	O
Yizhi	B-I	PROPN	B
Jiannao	I-I	PROPN	I
Granules	I-I	PROPN	I
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
Alzheimer	O	NOUN	B
's	O	PART	I
disease	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
intelligence	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
daily	I-OUT	ADJ	B
life	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
social	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
ability	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


METHODS	O	VERB	O
Eighty-four	B-P	NUM	O
cases	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
divided	I-P	VERB	O
into	I-P	ADP	O
3	I-P	NUM	O
groups	I-P	NOUN	B
,	I-P	PUNCT	O
28	I-P	NUM	O
cases	I-P	NOUN	B
in	I-P	ADP	O
each	I-P	DET	O
group	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
combined	O	ADJ	O
acupuncture	B-I	NOUN	B
and	O	CCONJ	O
medication	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
acupuncture	B-I	NOUN	B
at	O	ADP	O
Baihui	O	PROPN	B
(	O	PUNCT	O
GV	O	NOUN	B
20	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Sishencong	O	PROPN	B
(	O	PUNCT	O
EX-HN	O	NOUN	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Dazhui	O	PROPN	B
(	O	PUNCT	O
GV	O	PROPN	B
14	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Guanyuan	O	NOUN	B
(	O	PUNCT	O
CV	O	NOUN	B
4	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
etc	O	X	O
.	O	PUNCT	O


and	O	CCONJ	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
Yizhi	B-I	PROPN	B
Jiannao	I-I	PROPN	I
Granules	I-I	PROPN	I
;	I-I	PUNCT	O
the	O	DET	O
Chinese	O	ADJ	B
herb	O	NOUN	I
group	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
Yizhi	B-I	PROPN	B
Jiannao	I-I	PROPN	I
Granules	I-I	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
western	B-I	ADJ	B
medicine	I-I	NOUN	I
group	I-I	NOUN	O
with	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
Aricept	B-I	PROPN	B
.	I-I	PUNCT	O


The	O	DET	O
scores	B-OUT	NOUN	B
for	I-OUT	ADP	O
the	I-OUT	DET	O
Mini-Mental	I-OUT	PROPN	B
State	I-OUT	PROPN	I
Examination	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
MMSE	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Ability	I-OUT	NOUN	B
of	I-OUT	ADP	O
Daily	I-OUT	PROPN	O
Life	I-OUT	PROPN	O
(	I-OUT	PUNCT	O
ADL	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
therapeutic	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
and	O	CCONJ	O
compared	O	VERB	B
before	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
among	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
After	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
scores	O	NOUN	B
for	O	ADP	O
MMSE	B-OUT	PROPN	B
and	I-OUT	CCONJ	O
ADL	I-OUT	PROPN	B
were	O	AUX	O
improved	O	VERB	B
in	O	ADP	O
the	O	DET	O
combined	B-I	ADJ	B
acupuncture	I-I	NOUN	I
and	I-I	CCONJ	O
medication	I-I	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
Chinese	B-I	ADJ	B
herb	I-I	NOUN	I
group	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
western	B-I	ADJ	B
medicine	I-I	NOUN	I
group	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
better	O	ADJ	O
in	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
acupuncture	B-I	NOUN	I
and	I-I	CCONJ	O
medication	I-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
total	B-OUT	ADJ	O
effective	I-OUT	ADJ	B
rate	I-OUT	NOUN	B
of	O	ADP	O
85.7	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
combined	B-I	ADJ	B
acupuncture	I-I	NOUN	I
and	I-I	CCONJ	O
medication	I-I	NOUN	B
group	O	NOUN	I
was	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
71.4	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Chinese	O	ADJ	B
herb	O	NOUN	I
group	O	NOUN	B
and	O	CCONJ	O
67.9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
western	O	ADJ	B
medicine	O	NOUN	I
group	O	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Acupuncture	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
Yizhi	I-I	PROPN	B
Jiannao	I-I	PROPN	I
Granules	I-I	PROPN	I
has	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
therapeutic	B-OUT	ADJ	B
effect	I-OUT	NOUN	I
on	O	ADP	O
Alzheimer	O	NOUN	B
's	O	PART	I
disease	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
Yizhi	B-I	PROPN	B
Jiannao	I-I	PROPN	I
Granules	I-I	PROPN	I
or	O	CCONJ	O
Aricept	B-I	PROPN	B
.	I-I	PUNCT	O


Oral	B-I	ADJ	B
sucrose	I-I	NOUN	I
as	O	ADP	O
an	O	DET	O
analgesic	O	NOUN	B
drug	O	NOUN	I
for	O	ADP	O
procedural	O	ADJ	B
pain	O	NOUN	I
in	O	ADP	O
newborn	B-P	ADJ	B
infants	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Many	O	ADJ	O
infants	B-P	NOUN	B
admitted	I-P	VERB	B
to	I-P	ADP	I
hospital	I-P	NOUN	B
undergo	O	VERB	O
repeated	O	VERB	O
invasive	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


Oral	B-I	ADJ	B
sucrose	I-I	NOUN	I
is	O	AUX	O
frequently	O	ADV	O
given	O	VERB	O
to	O	PART	O
relieve	O	VERB	O
procedural	O	ADJ	B
pain	O	NOUN	I
in	O	ADP	O
neonates	B-P	NOUN	B
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
effect	O	NOUN	B
on	O	ADP	O
behavioural	O	ADJ	B
and	O	CCONJ	O
physiological	O	ADJ	B
pain	O	NOUN	I
scores	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
assessed	O	VERB	B
whether	O	SCONJ	O
sucrose	B-I	NOUN	B
administration	O	NOUN	I
reduces	O	VERB	B
pain-specific	B-OUT	ADJ	B
brain	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
spinal	I-OUT	ADJ	B
cord	I-OUT	NOUN	I
activity	I-OUT	NOUN	I
after	O	ADP	O
an	O	DET	O
acute	B-P	ADJ	B
noxious	I-P	ADJ	B
procedure	I-P	NOUN	I
in	O	ADP	O
newborn	B-P	ADJ	B
infants	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
,	O	PUNCT	O
59	B-P	NUM	O
newborn	I-P	ADJ	B
infants	I-P	NOUN	I
at	I-P	ADP	O
University	I-P	PROPN	B
College	I-P	PROPN	I
Hospital	I-P	PROPN	I
(	I-P	PUNCT	O
London	I-P	PROPN	B
,	I-P	PUNCT	O
UK	I-P	PROPN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
0·5	O	NOUN	O
mL	O	NOUN	O
24	B-I	NUM	O
%	I-I	NOUN	O
sucrose	I-I	NOUN	B
solution	I-I	NOUN	I
or	O	CCONJ	O
0·5	O	NOUN	O
mL	B-I	NOUN	O
sterile	I-I	ADJ	B
water	I-I	NOUN	I
2	O	NUM	I
min	O	NOUN	O
before	O	ADP	O
undergoing	O	VERB	O
a	O	DET	O
clinically	O	ADV	B
required	O	VERB	O
heel	O	NOUN	B
lance	O	NOUN	B
.	O	PUNCT	O


Randomisation	O	NOUN	B
was	O	AUX	O
by	O	ADP	O
a	O	DET	O
computer-generated	O	ADJ	O
randomisation	O	NOUN	O
code	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
researchers	O	NOUN	B
,	O	PUNCT	O
clinicians	O	NOUN	B
,	O	PUNCT	O
participants	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
parents	O	NOUN	B
were	O	AUX	O
masked	O	VERB	O
to	O	PART	O
the	O	DET	O
identity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
solutions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	B-OUT	AUX	O
pain-specific	I-OUT	ADJ	B
brain	I-OUT	NOUN	O
activity	I-OUT	NOUN	O
evoked	I-OUT	VERB	B
by	O	ADP	O
one	O	NUM	O
time-locked	O	ADJ	B
heel	O	NOUN	B
lance	B-OUT	NOUN	O
,	I-OUT	PUNCT	O
recorded	I-OUT	VERB	O
with	I-OUT	ADP	O
electroencephalography	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
identified	I-OUT	VERB	B
by	I-OUT	ADP	O
principal	I-OUT	ADJ	B
component	I-OUT	NOUN	I
analysis	I-OUT	NOUN	I
.	O	PUNCT	O


Secondary	O	ADJ	B
measures	O	NOUN	I
were	B-OUT	AUX	O
baseline	I-OUT	NOUN	B
behavioural	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
physiological	I-OUT	ADJ	B
measures	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
observational	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PIPP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
spinal	I-OUT	ADJ	B
nociceptive	I-OUT	ADJ	I
reflex	I-OUT	ADJ	I
withdrawal	I-OUT	NOUN	B
activity	I-OUT	NOUN	I
.	O	PUNCT	O


Data	O	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
per	O	ADP	O
protocol	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
is	O	AUX	O
registered	O	VERB	O
,	O	PUNCT	O
number	O	NOUN	O
ISRCTN78390996	O	NOUN	B
.	O	PUNCT	O


FINDINGS	O	NOUN	B
29	B-P	NUM	O
infants	I-P	NOUN	B
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
receive	B-I	VERB	O
sucrose	I-I	NOUN	B
and	O	CCONJ	O
30	O	NUM	O
to	B-I	PART	O
sterilised	I-I	VERB	B
water	I-I	NOUN	I
;	I-I	PUNCT	O
20	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
infants	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Nociceptive	B-OUT	ADJ	B
brain	I-OUT	NOUN	O
activity	I-OUT	NOUN	O
after	I-OUT	ADP	O
the	I-OUT	DET	O
noxious	I-OUT	ADJ	B
heel	I-OUT	NOUN	I
lance	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
infants	O	NOUN	B
who	O	PRON	O
received	B-I	VERB	O
sucrose	I-I	NOUN	B
and	O	CCONJ	O
those	O	DET	O
who	O	PRON	O
received	B-I	VERB	O
sterile	I-I	ADJ	B
water	I-I	NOUN	I
(	I-I	PUNCT	O
sucrose	I-I	NOUN	B
:	I-I	PUNCT	O
mean	O	VERB	O
0·10	O	X	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0·04-0·16	B-I	NUM	O
;	I-I	PUNCT	O
sterile	I-I	ADJ	B
water	I-I	NOUN	I
:	I-I	PUNCT	O
mean	O	VERB	O
0·08	O	NUM	O
,	O	PUNCT	O
0·04-0·12	O	NUM	O
;	O	PUNCT	O
p=0·46	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
recorded	O	VERB	O
between	B-I	ADP	O
the	I-I	DET	O
sucrose	I-I	NOUN	B
and	I-I	CCONJ	O
sterile	I-I	ADJ	B
water	O	NOUN	I
groups	O	NOUN	I
in	O	ADP	O
the	O	DET	O
magnitude	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
latency	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
spinal	I-OUT	ADJ	B
nociceptive	I-OUT	ADJ	I
reflex	I-OUT	ADJ	I
withdrawal	I-OUT	NOUN	B
recorded	O	VERB	O
from	O	ADP	O
the	O	DET	O
biceps	O	X	B
femoris	O	NOUN	I
of	O	ADP	O
the	O	DET	O
stimulated	O	VERB	B
leg	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
PIPP	I-OUT	NOUN	B
score	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
infants	B-I	NOUN	B
given	I-I	VERB	O
sucrose	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
those	B-I	DET	O
given	I-I	VERB	O
sterile	I-I	ADJ	B
water	O	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	B
5·8	O	X	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
3·7-7·8	O	NUM	O
vs	O	CCONJ	O
8·5	O	NOUN	O
,	O	PUNCT	O
7·3-9·8	O	NUM	O
;	O	PUNCT	O
p=0·02	O	X	O
)	O	PUNCT	O
and	O	CCONJ	O
significantly	B-P	ADV	O
more	O	ADJ	O
infants	O	NOUN	B
had	O	AUX	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
facial	O	ADJ	B
expression	B-I	NOUN	I
after	O	ADP	O
sucrose	O	NOUN	B
administration	O	NOUN	I
(	O	PUNCT	O
seven	O	NUM	O
of	O	ADP	O
20	O	NUM	O
[	O	PUNCT	O
35	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
vs	O	CCONJ	O
none	O	NOUN	O
of	O	ADP	O
24	O	NUM	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0·0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


INTERPRETATION	O	VERB	B
Our	O	PRON	O
data	O	NOUN	B
suggest	B-I	VERB	O
that	I-I	SCONJ	O
oral	O	ADJ	B
sucrose	O	NOUN	I
does	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
affect	B-P	VERB	O
activity	I-P	NOUN	B
in	O	ADP	O
neonatal	O	ADJ	B
brain	O	NOUN	B
or	O	CCONJ	O
spinal	O	ADJ	B
cord	O	NOUN	I
nociceptive	O	ADJ	O
circuits	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
therefore	O	ADV	O
might	O	AUX	O
not	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
analgesic	O	NOUN	B
drug	B-I	NOUN	I
.	I-I	PUNCT	O


The	B-I	DET	O
ability	I-I	NOUN	O
of	O	ADP	O
sucrose	O	NOUN	B
to	O	PART	O
reduce	O	VERB	O
clinical	O	ADJ	B
observational	O	ADJ	O
scores	O	NOUN	O
after	O	ADP	O
noxious	B-P	ADJ	B
events	I-P	NOUN	I
in	I-P	ADP	O
newborn	O	ADJ	B
infants	O	NOUN	I
should	O	AUX	O
not	O	PART	O
be	O	AUX	O
interpreted	O	VERB	O
as	O	ADP	O
pain	O	NOUN	B
relief	O	NOUN	I
.	O	PUNCT	O


FUNDING	O	PROPN	B
Medical	O	PROPN	I
Research	O	PROPN	I
Council	O	PROPN	I
.	O	PUNCT	O


Baseline	O	NOUN	B
distribution	O	NOUN	B
of	O	ADP	O
participants	B-P	NOUN	B
with	I-P	ADP	O
depression	I-P	NOUN	B
and	I-P	CCONJ	O
impaired	I-P	ADJ	B
quality	I-P	NOUN	B
of	I-P	ADP	I
life	I-P	NOUN	I
in	O	ADP	O
the	O	DET	O
Treatment	O	NOUN	B
of	O	ADP	O
Preserved	O	VERB	B
Cardiac	O	PROPN	I
Function	O	PROPN	I
Heart	O	PROPN	I
Failure	O	PROPN	I
with	O	ADP	O
an	O	DET	O
Aldosterone	O	NOUN	B
Antagonist	O	PROPN	I
Trial	O	PROPN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
demonstrated	O	VERB	O
the	O	DET	O
psychosocial	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
heart	O	NOUN	B
failure	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
reduced	I-P	VERB	B
ejection	I-P	NOUN	O
fraction	I-P	NOUN	O
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
preserved	O	ADJ	O
ejection	O	NOUN	O
fraction	O	NOUN	O
have	O	AUX	O
not	O	PART	O
yet	O	ADV	O
been	O	AUX	O
elucidated	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
of	O	ADP	O
participants	B-P	NOUN	B
with	I-P	ADP	O
heart	I-P	NOUN	B
failure	I-P	NOUN	I
with	I-P	ADP	O
preserved	I-P	VERB	O
ejection	I-P	NOUN	O
fraction	I-P	NOUN	O
as	O	ADP	O
it	O	PRON	O
relates	O	VERB	O
to	O	ADP	O
impaired	O	ADJ	B
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
(	O	PUNCT	O
QOL	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
depression	O	NOUN	B
,	O	PUNCT	O
identify	O	VERB	O
predictors	O	NOUN	B
of	O	ADP	O
poor	O	ADJ	B
QOL	O	PROPN	B
and	O	CCONJ	O
depression	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
determine	O	VERB	O
the	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
QOL	O	PROPN	B
and	O	CCONJ	O
depression	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
Among	O	ADP	O
patients	B-P	NOUN	B
enrolled	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
Treatment	I-P	NOUN	B
of	I-P	ADP	O
Preserved	I-P	VERB	B
Cardiac	I-P	PROPN	I
Function	I-P	PROPN	I
Heart	I-P	PROPN	I
Failure	I-P	PROPN	I
With	I-P	ADP	O
an	I-P	DET	O
Aldosterone	I-I	NOUN	B
Antagonist	I-I	PROPN	I
Trial	I-I	PROPN	I
(	I-I	PUNCT	O
TOPCAT	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-P	PUNCT	O
3400	I-P	NUM	O
patients	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
Kansas	I-OUT	PROPN	B
City	I-OUT	PROPN	I
Cardiomyopathy	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
,	I-P	PUNCT	O
3395	I-P	NUM	O
patients	I-P	NOUN	B
completed	I-P	VERB	O
European	I-OUT	ADJ	B
QOL	I-OUT	PROPN	B
5D	I-OUT	PROPN	I
Visual	I-OUT	PROPN	O
Analog	I-OUT	PROPN	O
Scale	I-OUT	PROPN	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
1431	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
United	I-P	PROPN	B
States	I-P	PROPN	I
and	I-P	CCONJ	O
Canada	I-P	PROPN	B
completed	I-P	VERB	O
the	I-P	DET	O
Patient	I-OUT	PROPN	B
Health	I-OUT	PROPN	I
Questionnaire-9	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
summary	O	ADJ	O
score	O	NOUN	O
on	O	ADP	O
the	O	DET	O
Kansas	B-OUT	PROPN	B
City	I-OUT	PROPN	I
Cardiomyopathy	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
was	O	AUX	O
54.8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
European	B-OUT	ADJ	B
QOL	I-OUT	PROPN	B
5D	I-OUT	PROPN	I
Visual	I-OUT	PROPN	O
Analog	I-OUT	PROPN	O
Scale	I-OUT	PROPN	O
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
60.3	O	NUM	O
;	O	PUNCT	O
27	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
had	O	AUX	O
moderate	O	ADJ	B
to	O	ADP	O
severe	O	ADJ	B
depression	O	NOUN	B
.	O	PUNCT	O


Factors	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
better	O	ADJ	O
Kansas	B-OUT	PROPN	B
City	I-OUT	PROPN	I
Cardiomyopathy	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
European	I-OUT	ADJ	B
QOL	I-OUT	PROPN	B
5D	I-OUT	PROPN	I
Visual	I-OUT	PROPN	O
Analog	I-OUT	PROPN	O
Scale	I-OUT	PROPN	O
via	O	ADP	O
multiple	O	ADJ	O
logistic	O	ADJ	O
regression	O	NOUN	O
analysis	O	NOUN	O
were	O	AUX	O
American	O	ADJ	B
region	O	NOUN	I
,	O	PUNCT	O
older	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
no	O	DET	B
history	O	NOUN	I
of	O	ADP	O
angina	O	ADJ	B
pectoris	O	NOUN	I
or	O	CCONJ	O
asthma	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
use	O	NOUN	O
of	O	ADP	O
hypoglycemic	O	ADJ	B
agent	O	NOUN	I
,	O	PUNCT	O
more	O	ADJ	O
activity	O	NOUN	B
level	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
lower	O	ADJ	B
New	O	PROPN	O
York	O	PROPN	O
Heart	O	PROPN	O
Association	O	PROPN	O
class	O	NOUN	O
.	O	PUNCT	O


Factors	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
depression	O	NOUN	B
via	O	ADP	O
multiple	O	ADJ	O
logistic	O	ADJ	O
regression	O	NOUN	O
analysis	O	NOUN	O
included	O	VERB	O
younger	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
female	O	ADJ	B
sex	O	NOUN	I
,	O	PUNCT	O
comorbid	O	ADJ	B
angina	O	ADJ	I
,	O	PUNCT	O
chronic	O	ADJ	B
obstructive	O	ADJ	I
pulmonary	O	ADJ	I
disease	O	NOUN	I
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
hypoglycemic	O	ADJ	B
agent	O	NOUN	I
,	O	PUNCT	O
lower	O	ADJ	O
activity	O	NOUN	B
level	O	NOUN	B
,	O	PUNCT	O
higher	O	ADJ	O
New	O	PROPN	B
York	O	PROPN	I
Heart	O	PROPN	I
Association	O	PROPN	I
class	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
selective	O	ADJ	O
serotonin	O	NOUN	B
reuptake	O	NOUN	I
inhibitor	O	NOUN	I
use	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
significant	O	ADJ	O
correlations	O	NOUN	B
between	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
QOL	B-OUT	PROPN	B
scores	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
depression	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	VERB	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
heart	I-P	NOUN	B
failure	I-P	NOUN	I
with	I-P	ADP	O
preserved	I-P	VERB	O
ejection	I-P	NOUN	O
fraction	I-P	NOUN	O
,	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
younger	I-P	ADJ	B
had	I-P	AUX	O
higher	I-P	ADJ	B
New	I-P	PROPN	B
York	I-P	PROPN	I
Heart	I-P	PROPN	I
Association	I-P	PROPN	I
class	I-P	NOUN	I
or	I-P	CCONJ	O
comorbid	I-P	ADJ	B
angina	I-P	ADJ	I
pectoris	I-P	NOUN	I
,	I-P	PUNCT	O
had	I-P	AUX	O
lower	I-P	ADJ	O
activity	I-P	NOUN	B
levels	I-P	NOUN	O
,	I-P	PUNCT	O
lived	I-P	VERB	B
in	I-P	ADP	O
Eastern	I-P	PROPN	B
Europe	I-P	PROPN	I
or	I-P	CCONJ	O
were	I-P	AUX	O
taking	I-P	VERB	O
hypoglycemic	I-P	ADJ	B
agents	I-P	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
impaired	B-P	VERB	B
QOL	I-P	PROPN	B
and	I-P	CCONJ	O
depression	I-P	NOUN	B
.	I-P	PUNCT	O


CLINICAL	O	X	B
TRIAL	O	NOUN	I
REGISTRATION	O	NOUN	I
URL	O	NOUN	O
:	O	PUNCT	O
http	O	NOUN	B
:	O	PUNCT	O
//www.clinicaltrials.gov	O	PUNCT	O
.	O	PUNCT	O


Unique	O	ADJ	O
identifier	O	NOUN	O
:	O	PUNCT	O
NCT00094302	O	PROPN	O
.	O	PUNCT	O


Use	O	PROPN	B
of	O	ADP	I
World	B-I	PROPN	I
Wide	I-I	ADJ	I
Web-based	I-I	ADJ	I
directories	I-I	NOUN	I
for	O	ADP	O
tracing	B-P	VERB	O
subjects	I-P	NOUN	O
in	I-P	ADP	O
epidemiologic	I-P	ADJ	B
studies	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
recent	O	ADJ	O
availability	O	NOUN	B
of	O	ADP	I
World	O	PROPN	B
Wide	O	ADJ	I
Web-based	O	ADJ	I
directories	O	NOUN	I
has	O	AUX	O
opened	O	VERB	O
up	O	ADP	O
a	O	DET	O
new	O	ADJ	O
approach	O	NOUN	O
for	O	ADP	O
tracing	B-P	VERB	O
subjects	I-P	NOUN	B
in	I-P	ADP	O
epidemiologic	I-P	ADJ	B
studies	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
completeness	O	NOUN	B
of	O	ADP	O
two	B-P	NUM	O
World	I-I	PROPN	B
Wide	I-I	PROPN	I
Web-based	I-I	ADJ	I
directories	I-I	NOUN	I
(	I-I	PUNCT	O
Canada411	I-I	NOUN	B
and	I-I	CCONJ	O
InfoSpace	I-I	PROPN	B
Canada	I-I	PROPN	I
)	I-I	PUNCT	O
for	O	ADP	O
subject	O	ADJ	B
tracing	O	NOUN	O
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
using	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
crossover	O	NOUN	O
design	O	NOUN	O
for	O	ADP	O
346	B-P	NUM	O
adults	I-P	NOUN	B
randomly	I-P	ADV	O
selected	I-P	VERB	O
from	I-P	ADP	O
respondents	I-P	NOUN	B
in	I-P	ADP	O
an	I-P	DET	O
ongoing	I-P	ADJ	O
cohort	I-P	NOUN	B
study	I-P	NOUN	I
.	I-P	PUNCT	O


About	O	ADV	O
half	O	NOUN	O
(	O	PUNCT	O
56.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
successfully	O	ADV	O
located	O	VERB	O
by	O	ADP	O
using	O	VERB	O
either	O	CCONJ	O
Canada411	B-I	NOUN	B
or	I-I	CCONJ	O
InfoSpace	I-I	PROPN	B
.	I-I	PUNCT	O


Of	O	ADP	O
the	O	DET	O
43.6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
who	O	PRON	O
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
located	O	VERB	O
using	O	VERB	O
either	O	DET	O
directory	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
majority	O	NOUN	O
(	O	PUNCT	O
73.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
female	O	ADJ	B
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
clear	O	ADJ	O
advantage	B-OUT	NOUN	O
of	O	ADP	O
one	O	NUM	O
directory	O	NOUN	B
over	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


Although	O	SCONJ	O
Canada411	O	NOUN	B
could	O	AUX	O
find	B-OUT	VERB	O
significantly	I-OUT	ADV	O
more	I-OUT	ADJ	O
subjects	I-OUT	NOUN	B
than	O	ADP	O
InfoSpace	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
potential	I-OUT	ADJ	B
matches	I-OUT	NOUN	B
returned	O	VERB	O
by	O	ADP	O
Canada411	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
higher	O	ADJ	B
,	O	PUNCT	O
which	O	DET	O
meant	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
longer	O	ADV	O
list	O	NOUN	O
of	O	ADP	O
potential	O	ADJ	B
matches	O	NOUN	B
had	O	AUX	O
to	O	PART	O
be	O	AUX	O
examined	O	VERB	B
before	O	ADP	O
a	O	DET	O
true	O	ADJ	O
match	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
strategy	O	NOUN	O
to	O	PART	O
minimize	O	VERB	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
potential	O	ADJ	B
matches	O	NOUN	B
per	O	ADP	O
true	O	ADJ	O
match	O	NOUN	B
is	O	AUX	O
to	O	PART	O
first	O	ADJ	O
search	O	NOUN	B
by	O	ADP	O
InfoSpace	O	PROPN	B
with	O	ADP	O
the	O	DET	O
last	O	ADJ	O
name	O	NOUN	O
and	O	CCONJ	O
first	O	ADJ	O
name	O	NOUN	O
,	O	PUNCT	O
then	O	ADV	O
by	O	ADP	O
Canada411	O	NOUN	B
with	O	ADP	O
the	O	DET	O
last	O	ADJ	O
name	O	NOUN	O
and	O	CCONJ	O
first	O	ADJ	O
name	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
finally	O	ADV	O
by	O	ADP	O
InfoSpace	O	PROPN	B
with	O	ADP	O
the	O	DET	O
last	O	ADJ	O
name	O	NOUN	O
and	O	CCONJ	O
first	O	ADJ	O
initial	O	ADJ	B
.	O	PUNCT	O


Internet-based	O	ADJ	B
searches	O	NOUN	I
represent	O	VERB	O
a	O	DET	O
potentially	O	ADV	O
useful	O	ADJ	O
approach	O	NOUN	O
to	O	ADP	O
tracing	O	VERB	O
subjects	B-P	NOUN	B
in	I-P	ADP	O
epidemiologic	I-P	ADJ	B
studies	I-P	NOUN	I
.	I-P	PUNCT	O


Ketorolac	B-I	NOUN	B
versus	I-I	CCONJ	O
fentanyl	I-I	NOUN	B
for	O	ADP	O
gynaecological	B-P	ADJ	B
day-case	I-P	ADJ	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
fentanyl	B-I	NOUN	B
and	O	CCONJ	O
ketorolac	B-I	NOUN	B
in	O	ADP	O
providing	O	VERB	O
analgesia	O	NOUN	B
for	O	ADP	O
day-case	B-P	ADJ	B
gynaecological	I-P	ADJ	B
procedures	I-P	NOUN	I
was	I-P	AUX	O
evaluated	I-P	VERB	B
in	I-P	ADP	O
55	I-P	NUM	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
in	I-P	ADP	O
a	I-P	DET	O
single	I-P	ADJ	O
blinded	I-P	ADJ	O
fashion	I-P	NOUN	O
.	I-P	PUNCT	O


Fentanyl	B-I	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mcg/kg	O	NOUN	O
iv	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
ketorolac	B-I	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
im	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
administered	O	VERB	B
immediately	O	ADV	O
following	O	VERB	O
induction	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	O
.	O	PUNCT	O


Anaesthesia	O	NOUN	B
was	O	AUX	O
standardized	O	VERB	O
with	O	ADP	O
propofol	B-I	NOUN	B
,	I-I	PUNCT	O
nitrous	I-I	ADJ	B
oxide	I-I	NOUN	I
and	I-I	CCONJ	O
enflurane	I-I	NOUN	B
.	I-I	PUNCT	O


Outcome	O	NOUN	B
variables	O	NOUN	I
assessed	O	VERB	B
were	O	AUX	O
pain	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
additional	I-OUT	ADJ	O
analgesic	I-OUT	NOUN	B
requirements	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
postoperative	I-OUT	ADJ	B
nausea	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
vomiting	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


All	O	DET	O
variables	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
at	O	ADP	O
15	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
hours	O	NOUN	B
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	B
postoperatively	O	ADV	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
measured	O	VERB	B
variables	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
ineffective	B-OUT	ADJ	B
as	O	ADP	O
sole	B-OUT	ADJ	O
analgesic	I-OUT	NOUN	B
agents	I-OUT	NOUN	I
in	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
respective	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
may	O	AUX	O
be	O	AUX	O
that	O	SCONJ	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
,	O	PUNCT	O
providing	O	VERB	O
a	O	DET	O
multireceptor	O	NOUN	B
approach	O	NOUN	I
to	O	PART	O
analgesia	O	NOUN	B
,	O	PUNCT	O
will	O	AUX	O
prove	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
.	O	PUNCT	O


Diazoxide	B-I	NOUN	B
and	I-I	CCONJ	O
labetalol	I-I	NOUN	B
in	O	ADP	O
acute	B-P	ADJ	B
hypertension	I-OUT	NOUN	I
during	O	ADP	O
haemodialysis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
antihypertensive	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
the	O	DET	O
peripheral	B-I	ADJ	B
vasodilator	I-I	NOUN	I
diazoxide	I-I	NOUN	B
in	O	ADP	O
13	B-P	NUM	O
patients	I-P	NOUN	B
and	I-P	CCONJ	O
the	I-P	DET	O
alpha-beta	I-I	NOUN	B
adrenoceptor	I-I	NOUN	I
blocking	I-I	NOUN	B
agent	I-I	NOUN	O
labetalol	I-I	NOUN	B
in	I-P	ADP	O
12	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
compared	I-P	VERB	B
in	I-P	ADP	O
46	I-P	NUM	O
severe	I-P	ADJ	B
acute	I-P	ADJ	B
hypertensive	I-OUT	NOUN	I
episodes	I-P	NOUN	I
during	I-P	ADP	O
haemodialysis	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
diazoxide	B-I	NOUN	B
150	I-I	NUM	O
mg	I-I	NOUN	O
or	I-I	CCONJ	O
labetalol	I-I	NOUN	B
50	I-I	NUM	O
mg	I-I	NOUN	O
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
74	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
70	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hypertensive	B-OUT	ADJ	B
episodes	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
diazoxide-treated	B-I	ADJ	B
patients	I-P	NOUN	B
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
fell	O	VERB	O
from	O	ADP	O
192	O	NUM	O
+/-	O	CCONJ	O
3/115	O	ADJ	O
+/-	O	CCONJ	O
4	O	NUM	O
mmHg	O	NOUN	B
to	O	PART	O
141	O	NUM	O
+/-	O	CCONJ	O
8/85	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
mmHg	O	NOUN	B
2	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
injection	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
7	O	NUM	O
hypertensive	B-OUT	NOUN	B
episodes	O	NOUN	B
a	O	DET	O
second	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
diazoxide	B-I	NOUN	B
150	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
given	O	VERB	O
60	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
injection	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
mean	B-OUT	ADJ	O
arterial	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
haemodialysis	O	NOUN	B
was	O	AUX	O
21.5	O	NUM	O
+/-	O	CCONJ	O
2.6	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
and	O	CCONJ	O
24.8	O	NUM	O
+/-	O	CCONJ	O
3.5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
repeated	O	VERB	O
dose	O	NOUN	B
of	O	ADP	O
diazoxide	B-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
labetalol-treated	B-I	ADJ	B
patients	I-P	NOUN	B
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
in	O	ADP	O
17	O	NUM	O
instances	O	NOUN	O
fell	O	VERB	O
from	O	ADP	O
198	O	NUM	O
+/-	O	CCONJ	O
5/104	O	NOUN	O
+/-	O	CCONJ	O
4	O	NUM	O
mmHg	O	NOUN	B
to	O	PART	O
143	O	NUM	O
+/-	O	CCONJ	O
7/89	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
mmHg	O	NOUN	B
180	O	NUM	O
min	O	NOUN	O
following	O	VERB	O
injection	O	NOUN	B
of	O	ADP	O
labetalol	B-I	NOUN	B
50	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
6	O	NUM	O
episodes	O	NOUN	B
a	O	DET	O
second	O	ADJ	O
dose	O	NOUN	B
labetalol	B-I	NOUN	B
50	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
given	O	VERB	O
41	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
injection	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
haemodialysis	O	NOUN	B
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
mean	B-OUT	ADJ	O
arterial	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
was	O	AUX	O
17.2	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
and	O	CCONJ	O
18	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
given	O	VERB	O
the	O	DET	O
repeated	O	VERB	O
dose	O	NOUN	B
of	O	ADP	O
labetalol	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
caused	O	VERB	O
by	O	ADP	O
diazoxide	B-I	NOUN	B
was	O	AUX	O
slightly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
due	O	ADP	O
to	O	PART	O
labetalol	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
haemodialysis	O	NOUN	B
the	O	DET	O
percentage	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
was	O	AUX	O
23	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
diazoxide-treated	O	ADJ	B
group	O	NOUN	B
and	O	CCONJ	O
17	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
labetalol	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O


Topical	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
diclofenac	B-I	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
miosis	B-OUT	NOUN	B
during	I-P	ADP	O
vitrectomy	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	NOUN	B
A	O	DET	I
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
usefulness	O	NOUN	B
of	O	ADP	O
preoperative	O	ADJ	B
diclofenac	B-I	ADJ	B
eye	O	NOUN	O
drops	O	NOUN	O
in	O	ADP	O
maintaining	O	VERB	O
mydriasis	B-OUT	NOUN	B
during	O	ADP	O
vitrectomy	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
reducing	O	VERB	B
postoperative	B-OUT	ADJ	B
inflammation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	VERB	O
Fifty	B-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
vitrectomy	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
diclofenac	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
24	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
control	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
26	O	NUM	O
)	O	PUNCT	O
groups	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
standard	O	ADJ	O
preoperative	O	ADJ	B
regimen	O	NOUN	B
of	O	ADP	O
cyclopentolate	B-I	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
phenylephrine	B-I	NOUN	B
hydrochloride	I-I	NOUN	I
(	O	PUNCT	O
2.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
diclofenac	B-I	ADJ	B
group	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
diclofenac	B-I	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
preoperatively	O	ADV	B
.	O	PUNCT	O


Pupillary	B-OUT	ADJ	B
diameter	I-OUT	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
at	O	ADP	O
four	O	NUM	O
time	O	NOUN	B
points	O	NOUN	I
during	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Inflammatory	B-OUT	ADJ	B
indices	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
postoperatively	O	ADV	B
using	O	VERB	O
slit-lamp	O	ADJ	B
examination	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
After	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
anesthesia	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
pupil	I-OUT	NOUN	B
size	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.112	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
for	O	ADP	O
the	O	DET	O
next	O	ADJ	O
two	O	NUM	O
stages	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
in	O	ADP	O
the	O	DET	O
diclofenac	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.012	O	NUM	O
and	O	CCONJ	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
for	O	ADP	O
anterior	B-OUT	ADJ	B
chamber	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
and	O	CCONJ	O
redness	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
eye	I-OUT	NOUN	B
postoperatively	O	ADV	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.609	O	NUM	O
and	O	CCONJ	O
P	O	NOUN	O
=	O	ADJ	O
0.123	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
anterior	B-OUT	ADJ	B
chamber	I-OUT	NOUN	I
flare	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.035	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
patients	O	NOUN	B
felt	O	VERB	O
significantly	O	ADV	O
more	O	ADV	O
pain	B-OUT	NOUN	B
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Topical	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
diclofenac	B-I	NOUN	B
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
maintaining	B-OUT	VERB	O
mydriasis	I-OUT	NOUN	B
during	O	ADP	O
vitrectomy	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
reducing	O	VERB	B
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
and	O	CCONJ	O
anterior	B-OUT	ADJ	B
chamber	I-OUT	NOUN	I
flare	I-OUT	NOUN	B
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
slit-lamp	O	ADJ	B
evaluations	O	NOUN	B
.	O	PUNCT	O


Clarithromycin	B-I	NOUN	B
reduces	O	VERB	B
the	O	DET	O
severity	B-OUT	NOUN	B
of	I-OUT	ADP	O
bronchial	I-OUT	ADJ	B
hyperresponsiveness	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
asthma	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
double-blind	O	ADJ	I
placebo-controlled	B-I	ADJ	I
study	O	NOUN	I
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
evaluate	B-OUT	VERB	B
the	I-OUT	DET	O
effects	I-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
semisynthetic	B-I	ADJ	B
macrolide	I-I	NOUN	B
antibiotic	I-I	NOUN	B
,	I-I	PUNCT	O
clarithromycin	I-I	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
bronchial	B-OUT	ADJ	B
hyperresponsiveness	I-OUT	NOUN	I
to	O	PART	O
methacholine	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
asthma	I-P	NOUN	B
.	I-P	PUNCT	O


Adult	B-P	ADJ	B
asthma	I-P	NOUN	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
treatment	I-P	NOUN	B
with	I-P	ADP	O
budesonide	I-I	NOUN	B
400	I-P	NUM	O
microg	I-P	NOUN	O
b.i.d	I-P	NOUN	B
.	I-P	PUNCT	O


and	B-P	CCONJ	O
salbutamol	I-I	NOUN	B
200	I-P	NUM	O
microg	I-P	NOUN	O
p.r.n	I-P	ADJ	B
.	I-P	PUNCT	O


less	B-P	ADJ	O
than	I-P	ADP	O
twice	I-P	ADV	O
weekly	I-P	ADJ	B
were	I-P	AUX	O
studied	I-P	VERB	O
.	I-P	PUNCT	O


Arm	B-P	NOUN	B
A	I-P	NOUN	I
(	I-P	PUNCT	O
16	I-P	NUM	O
males/six	I-P	NUM	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
aged	I-P	ADJ	B
48	I-P	NUM	O
+/-	I-P	CCONJ	O
16	I-P	NUM	O
yrs	I-P	NOUN	B
)	I-P	PUNCT	O
received	I-P	VERB	O
clarithromycin	I-I	NOUN	B
250	I-P	NUM	O
mg	I-P	NOUN	O
b.i.d	I-P	NOUN	B
.	I-P	PUNCT	O


for	B-P	ADP	O
8	I-P	NUM	O
weeks	I-P	NOUN	B
,	I-P	PUNCT	O
arm	I-P	NOUN	B
B	I-P	NOUN	I
(	I-P	PUNCT	O
eight	I-P	NUM	O
males/12	I-P	NOUN	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
aged	I-P	ADJ	B
42	I-P	NUM	O
+/-	I-P	CCONJ	O
12	I-P	NUM	O
yrs	I-P	NOUN	B
)	I-P	PUNCT	O
clarithromycin	I-I	NOUN	B
250	O	NUM	O
mg	O	NOUN	O
t.id	O	NOUN	O
.	O	PUNCT	O


and	O	CCONJ	O
arm	O	NOUN	B
C	O	NOUN	I
(	O	PUNCT	O
six	O	NUM	O
males/15	O	ADJ	B
females	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
41	O	NUM	O
+/-	O	CCONJ	O
16	O	NUM	O
yrs	O	NOUN	B
)	O	PUNCT	O
placebo	B-I	ADJ	B
dextrose	I-I	NOUN	O
tablets	O	NOUN	B
.	O	PUNCT	O


Bronchial	B-OUT	ADJ	B
hyperresponsiveness	I-OUT	NOUN	I
was	I-OUT	AUX	O
quantified	I-OUT	VERB	B
by	O	ADP	O
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
provocative	B-OUT	ADJ	B
dose	I-OUT	NOUN	B
of	I-OUT	ADP	O
methacholine	I-OUT	NOUN	B
causing	O	VERB	O
a	O	DET	O
20	B-OUT	NUM	O
%	I-OUT	NOUN	O
fall	I-OUT	NOUN	B
in	I-OUT	ADP	O
forced	I-OUT	ADJ	B
expiratory	I-OUT	ADJ	I
volume	I-OUT	NOUN	I
in	I-OUT	ADP	O
one	I-OUT	NUM	O
second	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
PD20	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
(	I-OUT	PUNCT	O
interquartile	I-OUT	NOUN	B
range	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
PD20	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
clarithromycin	B-I	NOUN	B
were	O	AUX	O
:	O	PUNCT	O
arm	O	NOUN	B
A	O	NOUN	I
:	O	PUNCT	O
0.3	O	NUM	O
(	O	PUNCT	O
0.1-1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
1.3	O	NUM	O
(	O	PUNCT	O
0.6-2	O	NUM	O
)	O	PUNCT	O
mg	O	NOUN	O
;	O	PUNCT	O
arm	O	NOUN	B
B	O	NOUN	I
:	O	PUNCT	O
0.4	O	NUM	O
(	O	PUNCT	O
0.1-0.9	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
(	O	PUNCT	O
2-2	O	NUM	O
)	O	PUNCT	O
mg	O	NOUN	O
;	O	PUNCT	O
and	O	CCONJ	O
arm	O	NOUN	B
C	O	NOUN	I
:	O	PUNCT	O
0.4	O	NUM	O
(	O	PUNCT	O
0.1-0.9	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
0.3	O	NUM	O
(	O	PUNCT	O
0.1-0.6	O	NUM	O
)	O	PUNCT	O
mg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
free	I-OUT	ADJ	I
cortisol	I-OUT	NOUN	I
levels	I-OUT	NOUN	O
were	O	AUX	O
determined	O	VERB	O
and	O	CCONJ	O
remained	O	VERB	O
unchanged	O	ADJ	B
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
the	O	DET	O
clarithromycin-treated	B-I	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
clarithromycin	B-I	NOUN	B
reduces	O	VERB	B
the	O	DET	O
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
bronchial	I-OUT	ADJ	B
hyperresponsiveness	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
asthma	I-P	NOUN	B
.	I-P	PUNCT	O


Risperidone	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
negative	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
of	O	ADP	O
schizophrenia	B-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
meta-analysis	O	NOUN	B
.	O	PUNCT	O


Risperidone	B-I	NOUN	B
has	O	AUX	O
antiserotonergic	O	ADJ	B
and	O	CCONJ	O
antidopaminergic	O	ADJ	B
properties	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
make	O	VERB	O
it	O	PRON	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
conventional	O	ADJ	B
antipsychotic	O	ADJ	B
agents	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
negative	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
of	O	ADP	O
schizophrenia	B-P	NOUN	B
.	I-P	PUNCT	O


Clinical	O	ADJ	B
trials	O	NOUN	I
in	O	ADP	O
chronic	B-P	ADJ	B
schizophrenic	I-P	ADJ	I
patients	I-P	NOUN	B
have	O	AUX	O
shown	O	VERB	O
trends	O	NOUN	B
in	O	ADP	O
favor	O	NOUN	O
of	O	ADP	O
risperidone	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
negative	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
haloperidol	B-I	NOUN	B
,	I-I	PUNCT	O
perphenazine	I-I	NOUN	B
or	I-I	CCONJ	O
zuclopenthixol	I-I	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
consistently	O	ADV	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


A	O	DET	O
meta-analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
pooled	O	ADJ	B
results	O	NOUN	B
from	O	ADP	O
six	B-P	NUM	O
double-blind	I-P	ADJ	B
trials	I-P	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
risperidone	B-I	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
ranging	O	VERB	O
from	O	ADP	O
4	O	NUM	O
to	O	PART	O
8	O	NUM	O
mg/day	O	NOUN	B
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.004	O	NUM	O
)	O	PUNCT	O
higher	O	ADJ	O
negative	B-OUT	ADJ	B
symptom	I-OUT	NOUN	B
response	I-OUT	NOUN	I
rate	I-OUT	NOUN	O
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
20	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
more	B-OUT	ADJ	O
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
scores	I-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
negative	I-OUT	ADJ	B
subscale	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
Positive	I-OUT	ADJ	B
and	I-OUT	CCONJ	I
Negative	I-OUT	ADJ	O
Syndrome	I-OUT	NOUN	O
Scale	I-OUT	NOUN	O
,	O	PUNCT	O
than	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
active	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
combined	B-P	ADJ	O
patient	I-P	NOUN	B
population	I-P	NOUN	I
treated	O	VERB	B
with	O	ADP	I
4-8	O	NUM	O
mg/day	O	NOUN	B
of	O	ADP	O
risperidone	B-I	NOUN	B
was	O	AUX	O
1.43	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
had	O	AUX	O
a	O	DET	O
clinical	B-OUT	ADJ	B
response	I-OUT	NOUN	I
on	I-OUT	ADP	O
the	I-OUT	DET	O
negative	I-OUT	ADJ	B
symptom	I-OUT	NOUN	B
subscale	I-OUT	NOUN	I
than	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
population	O	NOUN	I
treated	O	VERB	B
with	O	ADP	I
haloperidol	B-I	NOUN	B
,	I-I	PUNCT	O
perphenazine	I-I	NOUN	B
or	I-I	CCONJ	O
zuclopenthixol	I-I	NOUN	B
.	I-I	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
sodium	B-I	NOUN	B
and	I-I	CCONJ	O
potassium	I-I	NOUN	B
supplementation	I-I	NOUN	I
on	O	ADP	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
arterial	I-OUT	ADJ	B
stiffness	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
a	O	DET	O
fully	O	ADV	O
controlled	O	VERB	B
dietary	O	ADJ	B
intervention	O	NOUN	O
study	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
sodium	B-I	NOUN	B
and	I-I	CCONJ	O
potassium	I-I	NOUN	B
supplementation	I-I	NOUN	I
on	O	ADP	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
arterial	I-OUT	ADJ	B
stiffness	I-OUT	NOUN	I
in	I-P	ADP	O
untreated	I-P	ADJ	B
(	I-P	PUNCT	O
pre	I-P	ADJ	B
)	I-P	PUNCT	O
hypertensive	I-P	ADJ	B
individuals	I-P	NOUN	B
.	I-P	PUNCT	O


During	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
subjects	B-P	NOUN	B
were	I-P	AUX	O
on	I-P	ADP	O
a	I-P	DET	O
fully	I-P	ADV	O
controlled	I-P	VERB	B
diet	I-P	NOUN	I
that	I-P	PRON	O
was	I-P	AUX	O
relatively	I-P	ADV	O
low	I-P	ADJ	O
in	I-P	ADP	O
sodium	I-P	NOUN	B
and	I-P	CCONJ	O
potassium	I-P	NOUN	B
.	I-P	PUNCT	O


After	O	ADP	O
a	O	DET	O
1-week	O	ADJ	O
run-in	O	ADJ	B
period	O	NOUN	B
,	O	PUNCT	O
subjects	O	NOUN	B
received	B-I	VERB	O
capsules	I-I	NOUN	B
with	I-I	ADP	O
supplemental	I-I	ADJ	B
sodium	I-I	NOUN	I
(	I-I	PUNCT	O
3	I-I	NUM	O
g	I-I	NOUN	O
d	I-I	NOUN	O
(	I-I	PUNCT	O
-1	I-I	NUM	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
equals	I-I	VERB	O
7.6	I-I	NUM	O
g	I-I	NOUN	O
d	I-I	NOUN	O
(	I-I	PUNCT	O
-1	I-I	NUM	O
)	I-I	PUNCT	O
of	I-I	ADP	O
salt	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
supplemental	I-I	ADJ	B
potassium	I-I	NOUN	I
(	I-I	PUNCT	O
3	I-I	NUM	O
g	I-I	NOUN	O
d	I-I	NOUN	O
(	I-I	PUNCT	O
-1	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
for	I-I	ADP	O
4	I-I	NUM	O
weeks	I-I	NOUN	B
each	I-I	DET	O
,	I-I	PUNCT	O
in	I-I	ADP	O
random	I-OUT	ADJ	B
order	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Fasting	B-OUT	ADJ	B
office	I-OUT	NOUN	O
BP	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
24-h	I-OUT	ADJ	O
ambulatory	I-OUT	ADJ	B
BP	I-I	NOUN	I
and	I-I	CCONJ	O
measures	I-OUT	NOUN	B
of	I-OUT	ADP	O
arterial	I-OUT	ADJ	B
stiffness	I-I	NOUN	I
were	I-I	AUX	O
assessed	I-I	VERB	B
at	I-I	ADP	O
baseline	I-I	NOUN	B
and	I-I	CCONJ	O
every	I-I	DET	O
4	I-P	NUM	O
weeks	I-P	NOUN	B
.	I-P	PUNCT	O


Of	B-P	ADP	O
37	I-P	NUM	O
randomized	I-P	ADJ	B
subjects	I-P	NOUN	I
,	I-P	PUNCT	O
36	I-P	NUM	O
completed	I-P	VERB	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
had	O	AUX	O
a	O	DET	O
mean	O	ADJ	O
pre-treatment	B-OUT	ADJ	B
BP	O	NOUN	O
of	O	ADP	O
145/81	B-OUT	X	O
mm	I-OUT	X	B
Hg	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
69	I-OUT	NUM	O
%	I-OUT	NOUN	O
had	O	AUX	O
systolic	B-OUT	NOUN	B
BP	I-OUT	NOUN	I
⩾140	I-OUT	ADJ	O
mm	I-OUT	NOUN	O
Hg	I-OUT	NOUN	O
.	O	PUNCT	O


Sodium	O	NOUN	B
excretion	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
by	B-OUT	ADP	O
98	I-OUT	NUM	O
mmol	I-OUT	NOUN	O
per	I-OUT	ADP	O
24	I-OUT	NUM	O
h	I-OUT	NOUN	O
and	O	CCONJ	O
potassium	O	NOUN	B
excretion	O	NOUN	B
by	O	ADP	O
63	O	NUM	O
mmol	O	NOUN	O
per	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
during	O	ADP	O
active	O	ADJ	B
interventions	O	NOUN	B
,	O	PUNCT	O
compared	B-I	VERB	B
with	I-I	ADP	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


During	B-OUT	ADP	O
sodium	I-OUT	NOUN	B
supplementation	I-OUT	NOUN	I
,	O	PUNCT	O
office	O	NOUN	B
BP	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
increased	B-OUT	VERB	B
by	O	ADP	O
7.5/3.3	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
,	O	PUNCT	O
24-h	B-OUT	ADJ	O
BP	I-OUT	NOUN	B
by	I-OUT	ADP	O
7.5/2.7	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
and	O	CCONJ	O
central	B-I	ADJ	B
BP	I-I	NOUN	I
by	I-I	ADP	O
8.5/3.6	I-OUT	NUM	O
mm	I-OUT	NOUN	B
Hg	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


During	B-OUT	ADP	O
potassium	O	NOUN	B
supplementation	O	NOUN	B
,	O	PUNCT	O
24-h	O	ADJ	O
BP	O	NOUN	B
was	O	AUX	O
significantly	B-OUT	ADV	O
reduced	I-OUT	VERB	B
by	I-OUT	ADP	O
3.9/1.6	I-OUT	NUM	O
mm	I-OUT	X	B
Hg	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
central	I-OUT	ADJ	B
pulse	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
by	I-OUT	ADP	O
2.9	I-OUT	NUM	O
mm	I-OUT	X	B
Hg	I-OUT	NOUN	I
.	O	PUNCT	O


Pulse	O	NOUN	B
wave	O	NOUN	I
velocity	O	NOUN	I
and	O	CCONJ	O
augmentation	B-I	NOUN	B
index	I-I	NOUN	I
were	I-I	AUX	O
not	I-I	PART	O
significantly	I-I	ADV	O
affected	I-I	VERB	B
by	O	ADP	O
sodium	O	NOUN	B
or	O	CCONJ	O
potassium	O	NOUN	B
supplementation	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
increasing	O	VERB	B
the	O	DET	O
intake	B-OUT	NOUN	B
of	O	ADP	O
sodium	B-P	NOUN	B
caused	I-P	VERB	O
a	I-P	DET	O
substantial	I-P	ADJ	O
increase	I-OUT	NOUN	B
in	O	ADP	O
BP	O	NOUN	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
untreated	O	ADJ	O
elevated	O	ADJ	O
BP	O	NOUN	O
.	O	PUNCT	O


Increased	O	VERB	B
potassium	O	NOUN	B
intake	O	NOUN	O
,	O	PUNCT	O
on	O	ADP	O
top	O	NOUN	O
of	O	ADP	O
a	O	DET	O
relatively	B-OUT	ADV	O
low-sodium	I-OUT	ADJ	B
diet	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
had	I-OUT	AUX	O
a	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	O
on	O	ADP	O
BP	O	NOUN	B
.	O	PUNCT	O


Arterial	O	ADJ	B
stiffness	O	NOUN	I
did	O	AUX	O
not	O	PART	O
materially	O	ADV	B
change	O	VERB	I
during	O	ADP	O
4-week	O	NOUN	O
interventions	O	NOUN	B
with	O	ADP	O
sodium	O	NOUN	B
or	O	CCONJ	O
potassium	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
radiation	B-I	NOUN	B
therapy	I-I	NOUN	I
compared	O	VERB	O
to	O	PART	O
split	B-I	VERB	O
course	I-I	NOUN	B
radiation	I-I	NOUN	B
therapy	I-I	NOUN	I
combined	I-I	VERB	O
with	I-I	ADP	O
mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
and	I-I	CCONJ	O
5	I-I	NUM	O
fluorouracil	I-I	NOUN	B
as	O	ADP	O
initial	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
advanced	B-P	ADJ	B
laryngeal	I-P	ADJ	B
and	I-P	CCONJ	O
hypopharyngeal	I-P	NOUN	B
squamous	I-P	ADJ	I
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


Two	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
twelve	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
previously	I-P	ADV	O
untreated	I-P	ADJ	B
advanced	I-P	ADJ	O
squamous	I-P	ADJ	O
carcinoma	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
larynx	I-P	NOUN	B
or	I-P	CCONJ	O
hypopharynx	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
initial	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
radiotherapy	B-I	NOUN	B
,	I-I	PUNCT	O
50	I-I	NUM	O
Gy	I-I	NOUN	O
in	I-I	ADP	O
20	I-I	NUM	O
fractions	I-I	NOUN	B
in	I-I	ADP	O
28	I-I	NUM	O
days	I-I	NOUN	B
or	O	CCONJ	O
split	B-I	ADJ	B
course	I-I	NOUN	I
radiotherapy	I-I	NOUN	B
and	I-I	CCONJ	O
concurrent	I-I	ADJ	B
chemotherapy	I-I	NOUN	B
,	I-I	PUNCT	O
25	I-I	NUM	O
Gy	I-I	NOUN	O
in	I-I	ADP	O
10	I-I	NUM	O
fractions	I-I	NOUN	B
in	I-I	ADP	O
14	I-I	NUM	O
days	I-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
4	I-I	NUM	O
week	I-I	NOUN	B
rest	I-I	NOUN	B
and	I-I	CCONJ	O
a	I-I	DET	O
further	I-I	ADJ	O
25	I-I	NUM	O
Gy	I-I	NOUN	O
in	I-I	ADP	O
10	I-I	NUM	O
fractions	I-I	NOUN	B
in	I-I	ADP	O
14	I-I	NUM	O
days	I-I	NOUN	B
starting	I-I	VERB	O
on	I-I	ADP	O
day	I-I	NOUN	B
43	I-I	NUM	O
;	I-I	PUNCT	O
Mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
was	I-I	AUX	O
given	I-I	VERB	O
on	I-I	ADP	O
day	I-I	NOUN	B
1	I-I	NUM	O
and	I-I	CCONJ	O
day	I-I	NOUN	B
43	I-I	NUM	O
and	I-I	CCONJ	O
5FU	I-I	NOUN	O
continuous	I-I	ADJ	B
infusions	I-I	NOUN	B
on	I-I	ADP	O
days	I-I	NOUN	B
1	I-I	NUM	O
--	I-I	SYM	O
4	I-I	NUM	O
and	I-I	CCONJ	O
days	I-I	NOUN	B
43	I-I	NUM	O
--	I-I	PUNCT	O
46	I-I	NUM	O
.	I-I	PUNCT	O


Surgery	O	NOUN	B
was	O	AUX	O
reserved	O	ADJ	O
for	O	ADP	O
persistent	O	ADJ	B
or	O	CCONJ	O
recurrent	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


Two	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
nine	I-P	NUM	O
of	I-P	ADP	O
the	I-P	DET	O
212	I-P	NUM	O
patients	I-P	NOUN	B
randomized	I-P	VERB	B
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
analyses	I-P	NOUN	B
.	I-P	PUNCT	O


Outcome	O	NOUN	B
analyses	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow-up	O	ADJ	B
interval	O	NOUN	O
of	O	ADP	O
4.4	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
lost	O	VERB	B
to	O	PART	O
follow-up	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
arms	O	NOUN	O
for	O	ADP	O
the	O	DET	O
end	O	NOUN	O
points	O	NOUN	O
of	O	ADP	O
local	B-OUT	ADJ	B
relapse-free	I-OUT	ADJ	O
rate	I-OUT	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.91	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
regional	B-OUT	ADJ	B
relapse-free	I-OUT	ADJ	O
rate	I-OUT	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.17	O	NUM	O
,	O	PUNCT	O
adjusted	O	VERB	O
)	O	PUNCT	O
or	O	CCONJ	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.86	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Eight-eight	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
attempted	O	VERB	B
surgical	B-OUT	ADJ	B
resection	I-OUT	NOUN	I
following	I-OUT	VERB	O
radiotherapy	I-OUT	NOUN	B
failure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
salvage	O	NOUN	B
surgery	O	NOUN	I
to	O	ADP	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
was	I-OUT	AUX	O
similar	O	ADJ	O
for	O	ADP	O
both	O	DET	O
arms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
as	O	ADP	O
was	O	AUX	O
the	O	DET	O
surgical	B-OUT	ADJ	B
complication	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Serious	B-OUT	ADJ	O
late	I-OUT	ADJ	O
radiation	I-OUT	NOUN	O
toxicity	I-OUT	NOUN	B
was	O	AUX	O
minimal	O	ADJ	B
(	O	PUNCT	O
3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
RT	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
radiation	O	NOUN	B
therapy	O	NOUN	I
plus	O	CCONJ	O
chemotherapy	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
shows	O	VERB	O
no	O	DET	O
advantage	O	NOUN	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
local	O	ADJ	B
control	O	NOUN	I
or	O	CCONJ	O
survival	O	NOUN	B
for	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
treatment	O	NOUN	I
arm	O	NOUN	I
of	O	ADP	O
split	O	ADJ	O
course	O	NOUN	O
radiotherapy	B-I	NOUN	B
and	O	CCONJ	O
concurrent	B-I	ADJ	B
chemotherapy	I-I	NOUN	B
with	I-I	ADP	O
Mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
and	I-I	CCONJ	O
5	I-I	NUM	O
Fluorouracil	I-I	NOUN	B
compared	O	VERB	O
to	O	PART	O
radiotherapy	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
indicators	O	NOUN	B
for	O	ADP	O
a	O	DET	O
primary	O	ADJ	B
care	O	NOUN	I
medical	O	ADJ	B
home	O	NOUN	I
between	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
or	I-P	CCONJ	O
asthma	I-P	NOUN	B
and	I-P	CCONJ	O
other	I-P	ADJ	O
special	I-P	ADJ	O
health	I-P	NOUN	B
care	I-P	NOUN	I
needs	I-P	VERB	O
:	I-P	PUNCT	O
National	O	PROPN	B
Survey	O	PROPN	I
of	O	ADP	I
Children	O	PROPN	I
's	O	PART	I
Health	O	PROPN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
extent	O	NOUN	O
to	O	PART	O
which	O	DET	O
parents	B-I	NOUN	B
of	I-I	ADP	O
children	I-I	NOUN	B
with	I-I	ADP	O
autism	I-I	NOUN	B
compared	I-I	VERB	B
with	I-I	ADP	O
parents	I-I	NOUN	B
of	I-I	ADP	O
children	I-I	NOUN	B
with	I-I	ADP	O
asthma	I-I	NOUN	B
or	I-I	CCONJ	O
other	I-I	ADJ	O
special	I-I	ADJ	O
health	I-I	NOUN	B
care	I-I	NOUN	I
needs	I-I	NOUN	B
report	O	NOUN	I
receiving	O	VERB	O
primary	O	ADJ	B
care	O	NOUN	I
for	O	ADP	O
their	O	PRON	O
child	O	NOUN	B
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
American	O	PROPN	B
Academy	O	PROPN	I
of	O	ADP	I
Pediatrics	O	PROPN	I
medical	O	ADJ	I
home	O	NOUN	I
model	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	VERB	O
Population-based	O	ADJ	B
cross-sectional	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
National	B-I	PROPN	B
Survey	I-I	PROPN	I
for	I-I	ADP	I
Children	I-I	PROPN	B
's	I-I	PART	I
Health	I-I	PROPN	B
2003-2004	I-I	NUM	O
telephone	I-I	NOUN	O
interview	I-I	NOUN	O
.	I-I	PUNCT	O


PARTICIPANTS	O	NOUN	B
Parents	B-P	NOUN	B
of	I-P	ADP	O
495	I-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
,	I-P	PUNCT	O
parents	I-P	NOUN	B
of	I-P	ADP	O
6716	I-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
asthma	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
parents	I-P	NOUN	B
of	I-P	ADP	O
11,403	I-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
other	I-P	ADJ	O
special	I-P	ADJ	O
health	I-P	NOUN	B
care	I-P	NOUN	I
needs	I-P	VERB	O
without	I-P	ADP	O
asthma	I-P	NOUN	B
.	I-P	PUNCT	O


Main	O	PROPN	O
Exposures	O	PROPN	O
Autism	O	PROPN	O
and	O	CCONJ	O
other	O	ADJ	O
special	O	ADJ	O
health	O	NOUN	B
care	O	NOUN	I
needs	O	NOUN	O
including	O	VERB	O
asthma	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	B
MEASURES	O	ADJ	O
Medical	O	ADJ	B
home	O	NOUN	I
score	O	NOUN	I
and	O	CCONJ	O
components	O	NOUN	B
of	O	ADP	I
care	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
personal	O	ADJ	B
provider	O	NOUN	I
and	O	CCONJ	O
preventive	O	ADJ	B
;	O	PUNCT	O
family-centered	O	ADJ	B
,	O	PUNCT	O
compassionate	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
culturally	O	ADV	B
appropriate	O	ADJ	O
;	O	PUNCT	O
accessible	O	ADJ	O
;	O	PUNCT	O
comprehensive	O	ADJ	B
;	O	PUNCT	O
and	O	CCONJ	O
coordinated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
odds	B-OUT	NOUN	B
of	I-OUT	ADP	O
parents	I-OUT	NOUN	B
reporting	I-OUT	VERB	O
care	I-OUT	NOUN	B
consistent	I-OUT	ADJ	B
with	I-OUT	ADP	I
that	I-OUT	DET	O
in	I-OUT	ADP	O
a	I-OUT	DET	O
medical	I-OUT	ADJ	B
home	I-OUT	NOUN	I
were	O	AUX	O
less	B-OUT	ADV	O
likely	I-OUT	ADJ	O
for	I-OUT	ADP	O
children	I-OUT	NOUN	B
with	I-OUT	ADP	O
autism	I-OUT	NOUN	B
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.45	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.30-0.66	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
more	O	ADV	O
likely	O	ADJ	O
for	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
asthma	O	NOUN	B
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
1.17	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1.06-1.30	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
special	O	ADJ	O
health	O	NOUN	B
care	O	NOUN	I
needs	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
[	O	PUNCT	O
reference	O	NOUN	B
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
differences	O	NOUN	O
persisted	O	VERB	O
even	O	ADV	O
after	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
condition	O	NOUN	B
severity	O	NOUN	B
,	O	PUNCT	O
personal	O	ADJ	B
characteristics	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
insurance	O	NOUN	B
status	O	NOUN	I
.	O	PUNCT	O


Specific	O	ADJ	O
components	O	NOUN	B
of	O	ADP	O
a	O	DET	O
medical	O	ADJ	B
home	O	NOUN	I
less	O	ADV	O
prevalent	O	ADJ	O
among	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
autism	O	NOUN	B
than	O	ADP	O
among	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
special	O	ADJ	O
health	O	NOUN	B
care	O	NOUN	I
needs	O	NOUN	O
included	O	VERB	O
family-centered	O	ADJ	B
,	O	PUNCT	O
comprehensive	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
coordinated	O	VERB	B
care	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Although	O	SCONJ	O
we	O	PRON	O
could	O	AUX	O
not	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
reasons	O	NOUN	B
why	O	SCONJ	O
,	O	PUNCT	O
a	O	DET	O
large	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
autism	O	NOUN	B
do	O	AUX	O
not	O	PART	O
receive	O	VERB	O
primary	B-OUT	ADJ	B
care	I-OUT	NOUN	I
consistent	I-OUT	ADJ	B
with	I-OUT	ADP	I
that	I-OUT	DET	O
in	I-OUT	ADP	O
a	I-OUT	DET	O
medical	I-OUT	ADJ	B
home	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Primary	B-OUT	ADJ	B
hypothyroidism	I-OUT	NOUN	I
associated	O	VERB	B
with	O	ADP	I
interferon	B-I	NOUN	B
therapy	I-P	NOUN	I
of	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
men	B-P	NOUN	B
with	I-P	ADP	O
flat	I-P	ADJ	B
(	I-P	PUNCT	O
FC	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
acuminata	I-P	NOUN	B
(	I-P	PUNCT	O
CA	I-P	NOUN	B
)	I-P	PUNCT	O
condylomata	I-P	NOUN	B
with	I-P	ADP	O
interferon	I-I	NOUN	B
alpha-2a	I-I	NOUN	I
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
CO2	B-I	NOUN	B
laser	I-I	NOUN	B
vaporization	I-I	NOUN	I
,	I-I	PUNCT	O
5-fluorouracil	I-I	NOUN	B
5	I-I	NUM	O
%	I-I	NOUN	O
(	I-I	PUNCT	O
5-FU	I-I	NOUN	B
)	I-I	PUNCT	O
topical	I-I	ADJ	B
application	I-I	NOUN	B
and	I-I	CCONJ	O
Interferon	I-I	NOUN	B
alpha-2a	I-I	NOUN	I
(	I-I	PUNCT	O
IFA	I-I	NOUN	B
alpha-2a	I-I	NOUN	I
)	I-I	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
C.A	B-P	PROPN	B
.	I-P	PUNCT	O


or	B-P	CCONJ	O
F.C	I-P	PROPN	B
.	I-P	PUNCT	O


of	B-P	ADP	O
the	I-P	DET	O
male	I-P	ADJ	B
genital	I-P	ADJ	B
tract	I-P	NOUN	I
.	I-P	PUNCT	O


From	B-P	ADP	O
March	I-P	PROPN	O
1986	I-P	NUM	O
to	I-P	ADP	O
September	I-P	PROPN	O
1991	I-P	NUM	O
,	I-P	PUNCT	O
1372	I-P	NUM	O
men	I-P	NOUN	B
,	I-P	PUNCT	O
sexual	I-P	ADJ	B
partners	I-P	NOUN	I
of	I-P	ADP	O
women	I-P	NOUN	B
with	I-P	ADP	O
F.C	I-P	PROPN	B
.	I-P	PUNCT	O


or	B-P	CCONJ	O
C.A	I-P	PROPN	B
.	I-P	PUNCT	O


or	B-P	CCONJ	O
cervical	I-P	ADJ	B
intraepithelial	I-P	ADJ	I
neoplasia	I-P	NOUN	I
,	I-P	PUNCT	O
were	I-P	AUX	O
submitted	I-P	VERB	O
to	I-P	PART	O
peoscopy	I-I	NOUN	B
.	I-I	PUNCT	O


One	B-P	NUM	O
thousand	I-P	NUM	O
and	I-P	CCONJ	O
nineteen	I-P	NUM	O
(	I-P	PUNCT	O
74.27	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
men	I-P	NOUN	B
presented	I-P	VERB	O
with	I-P	ADP	O
various	I-P	ADJ	O
penile	I-P	ADJ	B
lesions	I-P	NOUN	B
caused	I-P	VERB	O
by	I-P	ADP	O
HPV	I-P	NOUN	B
(	I-P	PUNCT	O
histologically	I-P	ADV	B
confirmed	I-P	VERB	O
)	I-P	PUNCT	O
;	I-P	PUNCT	O
of	O	ADP	O
these	O	DET	O
505	B-P	NUM	O
were	I-P	AUX	O
treated	I-P	VERB	B
for	I-P	ADP	O
C.A	I-P	PROPN	B
.	I-P	PUNCT	O


or	B-P	CCONJ	O
F.C	I-P	PROPN	B
.	I-P	PUNCT	O


or	B-P	CCONJ	O
a	I-P	DET	O
combination	I-P	NOUN	B
of	I-P	ADP	O
F.C	I-P	PROPN	B
.	I-P	PUNCT	O


and	B-P	CCONJ	O
C.A	I-P	PROPN	B
.	I-P	PUNCT	O


The	O	DET	O
best	O	ADJ	O
treatment	O	NOUN	B
modalities	O	NOUN	B
,	O	PUNCT	O
irrespective	O	ADV	O
of	O	ADP	O
the	O	DET	O
kind	O	NOUN	O
of	O	ADP	O
lesion	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
5-FU	B-I	NOUN	B
plus	I-I	CCONJ	O
IFN	I-I	NOUN	B
alpha-2a	I-I	NOUN	I
(	O	PUNCT	O
high	O	ADJ	B
dose	O	NOUN	I
)	O	PUNCT	O
(	O	PUNCT	O
98.27	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
CO2	B-I	NOUN	B
laser	I-I	NOUN	B
vaporization	I-I	NOUN	I
plus	I-I	CCONJ	O
5-FU	I-I	NOUN	B
plus	I-I	CCONJ	O
IFN	I-I	NOUN	B
alpha-2a	I-I	NOUN	I
(	I-I	PUNCT	O
high	I-I	ADJ	B
dose	I-I	NOUN	I
)	I-I	PUNCT	O
(	I-I	PUNCT	O
93.93	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
CO2	I-I	NOUN	B
laser	I-I	NOUN	B
vaporization	I-I	NOUN	I
plus	I-I	CCONJ	O
5-FU	I-I	NOUN	B
(	O	PUNCT	O
87.23	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
we	O	PRON	O
believe	O	VERB	O
that	O	SCONJ	O
IFN	B-I	NOUN	B
alpha-2a	I-I	NOUN	I
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
with	O	ADP	O
excellent	O	ADJ	B
results	O	NOUN	O
as	O	ADP	O
first	O	ADJ	O
line	O	NOUN	O
treatment	O	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
CO2	B-I	NOUN	B
laser	I-I	NOUN	B
vaporization	I-I	NOUN	I
or/plus	I-I	ADP	O
5-FU	I-I	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
C.A	B-P	PROPN	B
.	I-P	PUNCT	O


or	B-P	CCONJ	O
F.C	I-P	PROPN	B
.	I-P	PUNCT	O


or	B-P	CCONJ	O
combined	I-P	ADJ	B
condylomata	I-P	NOUN	I
.	O	PUNCT	O


Riluzole	B-I	NOUN	B
as	O	ADP	O
an	O	DET	O
adjunctive	O	ADJ	B
therapy	O	NOUN	I
to	O	PART	O
risperidone	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
irritability	B-OUT	NOUN	B
in	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
A	O	DET	O
hyperglutamatergic	O	ADJ	B
state	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
play	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
autistic	B-P	ADJ	B
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


Riluzole	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
glutamate-modulating	O	ADJ	B
agent	O	NOUN	I
with	O	ADP	O
neuroprotective	O	ADJ	B
properties	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
have	O	AUX	O
positive	O	ADJ	B
effects	O	NOUN	B
in	O	ADP	O
many	O	ADJ	O
neuropsychiatric	B-OUT	ADJ	B
disorders	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
riluzole	B-I	NOUN	B
as	O	ADP	O
an	O	DET	O
adjunctive	O	NOUN	B
to	O	PART	O
risperidone	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
irritability	B-P	NOUN	B
in	I-P	ADP	O
autistic	I-P	ADJ	B
children	I-P	NOUN	I
who	I-P	PRON	O
were	I-P	AUX	O
not	I-P	PART	O
optimally	I-P	ADV	O
responding	I-P	VERB	B
to	O	ADP	O
previous	O	ADJ	O
medications	O	NOUN	B
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
10-week	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
parallel-group	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	NOUN	B
The	O	DET	O
study	O	NOUN	B
enrolled	O	VERB	O
male	B-P	NOUN	B
and	I-P	CCONJ	O
female	I-P	ADJ	B
outpatients	I-P	NOUN	B
aged	I-P	ADJ	B
5-12	I-P	NUM	O
years	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
based	I-P	VERB	O
on	I-P	ADP	O
the	I-P	DET	O
DSM-IV-TR	I-P	NOUN	B
criteria	I-P	NOUN	B
and	I-P	CCONJ	O
a	I-P	DET	O
score	I-P	NOUN	B
of	I-P	ADP	O
≥12	I-P	NOUN	O
on	I-P	ADP	O
the	I-P	DET	O
Aberrant	I-P	PROPN	B
Behavior	I-P	PROPN	O
Checklist-Community	I-P	PROPN	O
(	I-P	PUNCT	O
ABC-C	I-P	NOUN	B
)	I-P	PUNCT	O
irritability	I-P	NOUN	B
subscale	I-P	NOUN	O
who	I-P	PRON	O
had	I-P	AUX	O
discontinued	I-P	VERB	B
other	I-P	ADJ	O
medications	I-P	NOUN	B
because	I-P	SCONJ	O
of	I-P	ADP	O
a	I-P	DET	O
lack	I-P	NOUN	B
of	I-P	ADP	O
efficacy	I-P	NOUN	B
.	O	PUNCT	O


INTERVENTIONS	O	NOUN	B
Subjects	O	NOUN	B
received	B-I	VERB	O
riluzole	I-I	NOUN	B
(	O	PUNCT	O
titrated	O	VERB	O
to	O	ADP	O
50	O	NUM	O
or	O	CCONJ	O
100	O	NUM	O
mg/day	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
bodyweight	B-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
addition	B-I	NOUN	O
to	I-I	PART	O
risperidone	I-I	NOUN	B
(	O	PUNCT	O
titrated	O	VERB	O
up	O	ADV	O
to	O	PART	O
2	O	NUM	O
or	O	CCONJ	O
3	O	NUM	O
mg/day	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
bodyweight	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
10	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


OUTCOME	O	VERB	B
Patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
week	O	NOUN	B
5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
week	O	NOUN	B
10	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
was	O	AUX	O
the	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
change	O	NOUN	B
in	B-OUT	ADP	O
the	I-OUT	DET	O
ABC-C	I-OUT	NOUN	B
irritability	I-OUT	NOUN	O
subscale	I-OUT	NOUN	O
score	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
week	O	NOUN	B
10	O	NUM	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
compared	O	VERB	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
other	I-OUT	ADJ	O
ABC-C	I-OUT	NOUN	B
subscale	I-OUT	NOUN	O
scores	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
Clinical	I-OUT	PROPN	B
Global	I-OUT	PROPN	I
Impressions-Improvement	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
CGI-I	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
scale	I-OUT	NOUN	O
scores	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	B-P	VERB	O
Forty-nine	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
forty	I-P	NUM	O
children	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
trial	O	NOUN	B
(	O	PUNCT	O
dropouts	O	NOUN	B
:	O	PUNCT	O
placebo	O	NOUN	B
=	O	ADJ	O
4	O	NUM	O
,	O	PUNCT	O
riluzole	O	NOUN	B
=	O	ADJ	O
5	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
significantly	O	ADV	O
greater	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
primary	O	ADJ	B
outcome	B-OUT	NOUN	I
(	I-OUT	PUNCT	O
the	I-OUT	DET	O
ABC-C	I-OUT	NOUN	B
irritability	I-OUT	NOUN	I
subscale	I-OUT	NOUN	I
score	O	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
achieved	B-I	VERB	O
by	I-I	ADP	O
the	I-I	DET	O
riluzole-treated	O	ADJ	B
children	O	NOUN	B
compared	B-I	VERB	B
with	I-I	ADP	O
the	I-I	DET	O
placebo	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Patients	B-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
riluzole	O	NOUN	B
group	O	NOUN	B
also	O	ADV	O
showed	O	VERB	O
significantly	O	ADV	O
greater	O	ADJ	O
improvement	B-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
lethargy/social	I-OUT	ADJ	B
withdrawal	O	NOUN	I
(	B-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.02	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
stereotypic	I-OUT	ADJ	B
behavior	O	NOUN	I
(	B-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.03	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
hyperactivity/non-compliance	I-OUT	NOUN	B
subscales	O	NOUN	B
(	B-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.005	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
but	I-OUT	CCONJ	O
not	I-OUT	PART	O
on	I-OUT	ADP	O
the	I-OUT	DET	O
inappropriate	I-OUT	ADJ	B
speech	O	NOUN	B
subscale	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.20	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


Eleven	B-I	NUM	O
patients	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
riluzole	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
five	B-I	NUM	O
patients	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
were	O	AUX	O
classified	O	VERB	O
as	O	ADP	O
responders	B-OUT	NOUN	B
based	I-OUT	VERB	O
on	I-OUT	ADP	O
their	O	PRON	O
CGI-I	O	NOUN	B
scores	O	NOUN	I
[	O	PUNCT	O
χ	O	ADV	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
3.750	O	NUM	O
,	O	PUNCT	O
P	B-I	NOUN	O
=	I-I	ADJ	O
0.05	I-I	NUM	O
]	I-I	PUNCT	O
.	I-I	PUNCT	O


Children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
riluzole	O	NOUN	B
group	O	NOUN	B
experienced	O	VERB	O
significantly	B-OUT	ADV	O
more	I-OUT	ADJ	O
increases	I-OUT	NOUN	B
in	I-OUT	ADP	O
their	I-OUT	PRON	O
appetite	O	NOUN	B
and	O	CCONJ	O
bodyweight	B-I	NOUN	B
than	I-I	ADP	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
by	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	B-I	ADP	O
the	I-I	DET	O
study	I-I	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Riluzole	O	NOUN	B
add-on	B-OUT	ADJ	B
therapy	I-OUT	NOUN	I
shows	I-OUT	VERB	O
several	I-OUT	ADJ	O
therapeutic	O	ADJ	B
outcomes	O	NOUN	B
,	O	PUNCT	O
particularly	B-OUT	ADV	O
for	I-OUT	ADP	O
improving	O	VERB	B
irritability	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
autism	B-I	NOUN	B
.	I-I	PUNCT	O


However	B-I	ADV	O
,	I-I	PUNCT	O
its	I-I	PRON	O
add-on	O	NOUN	B
to	O	PART	O
risperidone	O	NOUN	B
also	O	ADV	O
results	O	VERB	B
in	B-OUT	ADP	O
significantly	I-OUT	ADV	O
increased	I-OUT	VERB	B
appetite	O	NOUN	O
and	O	CCONJ	O
weight	O	NOUN	B
gain	O	NOUN	I
.	O	PUNCT	O


Aspartame	B-I	NOUN	B
:	I-I	PUNCT	O
neuropsychologic	O	ADJ	B
and	O	CCONJ	O
neurophysiologic	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
and	O	CCONJ	O
chronic	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Neurobehavioral	O	ADJ	B
symptoms	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
anecdotally	O	ADV	O
with	O	ADP	O
aspartame	B-I	NOUN	B
.	I-I	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
aspartame	B-I	NOUN	B
can	O	AUX	O
disrupt	B-P	VERB	B
cognitive	I-P	ADJ	B
,	I-P	PUNCT	O
neurophysiologic	I-P	ADJ	B
,	I-P	PUNCT	O
or	I-P	CCONJ	O
behavioral	I-P	ADJ	B
functioning	I-P	NOUN	B
in	I-P	ADP	O
normal	I-P	ADJ	O
individuals	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Forty-eight	B-P	NUM	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
completed	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
month	O	NOUN	B
was	O	AUX	O
aspartame	B-I	NOUN	B
free	O	ADJ	I
.	O	PUNCT	O


Subjects	O	NOUN	B
then	O	ADV	O
consumed	O	VERB	O
sodas	B-I	NOUN	B
and	I-I	CCONJ	O
capsules	I-I	NOUN	B
with	I-I	ADP	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
aspartame	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
sucrose	I-I	NOUN	B
for	I-I	ADP	O
20	I-I	NUM	O
d	I-I	NOUN	O
each	I-I	DET	O
.	I-I	PUNCT	O


Order	O	NOUN	B
was	O	AUX	O
randomized	O	ADJ	B
and	O	CCONJ	O
subjects	O	NOUN	B
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
a	O	DET	O
high-	O	ADJ	O
(	O	PUNCT	O
45	O	NUM	O
mg	O	NOUN	O
x	O	NOUN	O
kg	O	NOUN	O
body	O	NOUN	O
wt	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
x	O	NOUN	O
d	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
or	O	CCONJ	O
low-	O	ADJ	O
(	O	PUNCT	O
15	O	NUM	O
mg	O	NOUN	O
x	O	NOUN	O
kg	O	NOUN	O
body	O	NOUN	O
wt	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
x	O	NOUN	O
d	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
dose	O	NOUN	B
aspartame	B-I	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Neuropsychologic	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
testing	O	NOUN	I
was	O	AUX	O
done	O	VERB	O
on	O	ADP	O
day	O	NOUN	B
10	O	NUM	O
of	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
possible	O	ADJ	O
acute	O	ADJ	B
effects	O	NOUN	O
and	O	CCONJ	O
on	O	ADP	O
day	O	NOUN	B
20	O	NUM	O
for	O	ADP	O
possible	O	ADJ	O
chronic	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Plasma	O	NOUN	B
phenylalanine	O	NOUN	B
concentrations	O	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
during	O	ADP	O
aspartame	O	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


Neuropsychologic	O	ADJ	B
results	O	NOUN	O
;	O	PUNCT	O
adverse	O	ADJ	B
experiences	O	NOUN	I
;	O	PUNCT	O
amino	O	NOUN	B
acid	O	NOUN	I
,	O	PUNCT	O
insulin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
glucose	O	NOUN	B
values	O	NOUN	I
;	O	PUNCT	O
and	O	CCONJ	O
electroencephalograms	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
by	O	ADP	O
sex	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
for	O	ADP	O
any	O	DET	O
dependent	O	ADJ	B
measure	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	ADJ	O
Large	O	ADJ	O
daily	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
aspartame	B-I	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
neuropsychologic	O	ADJ	B
,	O	PUNCT	O
neurophysiologic	O	ADJ	B
,	O	PUNCT	O
or	O	CCONJ	O
behavioral	O	ADJ	B
functioning	O	NOUN	B
in	O	ADP	O
healthy	B-P	ADJ	B
young	I-P	ADJ	B
adults	I-P	NOUN	I
.	I-P	PUNCT	O


How	O	SCONJ	O
can	O	AUX	O
we	O	PRON	O
help	O	VERB	O
witnesses	B-P	NOUN	B
to	O	PART	O
remember	B-OUT	VERB	O
more	I-OUT	ADV	O
?	O	PUNCT	O
It	O	PRON	O
's	O	AUX	O
an	O	DET	O
(	O	PUNCT	O
eyes	O	NOUN	B
)	O	PUNCT	O
open	O	ADJ	O
and	O	CCONJ	O
shut	O	VERB	O
case	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
experiments	O	NOUN	B
tested	O	VERB	B
the	O	DET	O
idea	O	NOUN	O
that	O	SCONJ	O
instructing	O	VERB	O
a	O	DET	O
witness	B-P	NOUN	B
to	O	PART	O
close	O	VERB	O
their	O	PRON	O
eyes	O	NOUN	B
during	O	ADP	O
retrieval	O	NOUN	B
might	O	AUX	O
increase	O	VERB	B
retrieval	B-OUT	NOUN	B
success	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
Experiment	O	NOUN	B
1	O	NUM	O
participants	B-P	NOUN	B
watched	I-I	VERB	O
a	I-I	DET	O
video	I-I	NOUN	B
,	O	PUNCT	O
before	O	ADP	O
a	O	DET	O
cued-recall	O	ADJ	B
test	O	NOUN	I
for	O	ADP	O
which	O	DET	O
they	O	PRON	O
were	O	AUX	O
either	O	ADV	O
instructed	O	VERB	O
to	O	PART	O
close	O	VERB	O
their	O	PRON	O
eyes	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
received	O	VERB	O
no-instructions	B-I	NOUN	B
.	I-I	PUNCT	O


Eye-closure	O	ADV	B
led	O	VERB	O
to	O	PART	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
correct	B-OUT	ADJ	B
cued-recall	I-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
incorrect	B-OUT	ADJ	O
responses	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Experiments	O	NOUN	B
2-5	O	NUM	O
sought	O	VERB	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
generality	O	NOUN	B
of	O	ADP	O
this	O	DET	O
effect	O	NOUN	B
over	O	ADP	O
variations	O	NOUN	B
in	O	ADP	O
study	O	NOUN	B
material	O	NOUN	I
(	B-I	PUNCT	O
video	I-I	NOUN	B
or	I-I	CCONJ	O
live	I-I	ADJ	B
interaction	I-I	NOUN	I
)	I-I	PUNCT	O
,	O	PUNCT	O
test	O	NOUN	B
format	O	NOUN	I
(	B-I	PUNCT	O
cued-	I-I	NUM	O
or	I-I	CCONJ	O
free-recall	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
information	O	NOUN	B
modality	O	NOUN	I
(	B-I	PUNCT	O
visual	I-I	ADJ	B
or	I-I	CCONJ	O
auditory	I-I	ADJ	B
details	I-I	NOUN	I
recalled	I-I	VERB	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
eye-closure	O	DET	B
increased	O	VERB	B
recall	B-OUT	NOUN	B
of	I-OUT	ADP	O
both	I-OUT	CCONJ	O
visual	I-OUT	ADJ	B
detail	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
auditory	I-OUT	ADJ	B
details	I-OUT	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
accompanying	O	VERB	O
increase	O	NOUN	B
in	O	ADP	O
recall	B-OUT	NOUN	B
of	I-OUT	ADP	O
false	I-OUT	ADJ	O
details	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Collectively	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
data	O	NOUN	B
convincingly	O	ADV	O
demonstrate	O	VERB	O
the	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
eye-closure	O	ADJ	B
as	O	ADP	O
an	O	DET	O
aid	O	NOUN	O
to	O	ADP	O
retrieval	B-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
offer	O	VERB	O
insight	O	NOUN	O
into	O	ADP	O
why	O	SCONJ	O
hypnosis	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
usually	O	ADV	O
involves	O	VERB	O
eye-closure	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
facilitate	O	VERB	O
eyewitness	B-OUT	NOUN	B
recall	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


B-type	B-I	ADJ	B
natriuretic	I-I	ADJ	I
peptide	I-I	NOUN	I
for	O	ADP	O
acute	O	ADJ	B
dyspnea	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
kidney	I-P	NOUN	B
disease	I-P	NOUN	I
:	I-P	PUNCT	O
insights	O	NOUN	O
from	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
comparison	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
B-type	B-OUT	ADJ	B
natriuretic	I-OUT	ADJ	I
peptide	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BNP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
are	O	AUX	O
reliably	O	ADV	O
elevated	O	ADJ	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
congestive	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
(	I-P	PUNCT	O
CHF	I-P	NOUN	B
)	I-P	PUNCT	O
and	O	CCONJ	O
therefore	O	ADV	O
helpful	O	ADJ	O
in	O	ADP	O
its	O	PRON	O
diagnosis	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
kidney	O	NOUN	B
disease	O	NOUN	I
results	O	VERB	B
in	O	ADP	O
elevated	O	ADJ	B
BNP	O	NOUN	B
levels	O	NOUN	B
independently	O	ADV	O
of	O	ADP	O
CHF	O	NOUN	B
.	O	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
kidney	O	NOUN	B
disease	O	NOUN	I
on	O	ADP	O
the	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
BNP	B-I	NOUN	B
testing	O	NOUN	B
needs	O	VERB	O
to	O	PART	O
be	O	AUX	O
scrutinized	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	O
patients	B-P	NOUN	B
with	I-P	ADP	O
and	I-P	CCONJ	O
without	I-P	ADP	O
kidney	I-P	NOUN	B
disease	I-P	NOUN	I
[	I-P	PUNCT	O
glomerular	I-P	ADJ	B
filtration	I-P	NOUN	I
rate	I-P	NOUN	I
(	I-P	PUNCT	O
GFR	I-P	NOUN	B
)	I-P	PUNCT	O
less	I-P	ADJ	O
than	I-P	ADP	O
60	I-P	NUM	O
mL/min/1.73	I-P	NOUN	O
m	I-P	NOUN	O
(	I-P	PUNCT	O
2	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
presenting	I-P	VERB	O
with	I-P	ADP	O
acute	I-P	ADJ	B
dyspnea	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
452	B-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
240	I-P	NUM	O
with	I-P	ADP	O
kidney	I-P	NOUN	B
disease	I-P	NOUN	I
and	I-P	CCONJ	O
212	I-P	NUM	O
without	I-P	ADP	O
kidney	I-P	NOUN	B
disease	I-P	NOUN	I
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
diagnostic	B-I	ADJ	B
strategy	I-I	NOUN	I
with	I-I	ADP	O
(	I-I	PUNCT	O
BNP	I-I	NOUN	B
group	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
without	I-I	ADP	O
(	I-I	PUNCT	O
control	I-I	ADJ	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
the	I-I	DET	O
use	I-I	NOUN	O
of	I-I	ADP	O
BNP	I-I	NOUN	B
levels	I-I	NOUN	B
provided	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
rapid	I-I	ADJ	O
bedside	I-I	NOUN	B
assay	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	VERB	B
Patients	B-P	NOUN	B
with	I-P	ADP	O
kidney	I-P	NOUN	B
disease	I-P	NOUN	I
were	I-P	AUX	O
older	I-P	ADJ	B
,	I-P	PUNCT	O
more	I-P	ADV	O
often	I-P	ADV	O
had	I-P	AUX	O
CHF	I-OUT	NOUN	B
as	I-OUT	ADP	O
the	I-OUT	DET	O
cause	I-OUT	NOUN	O
of	I-OUT	ADP	O
acute	I-OUT	ADJ	B
dyspnea	I-OUT	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
more	I-P	ADV	O
often	I-P	ADV	O
died	I-P	VERB	B
in-hospital	I-P	ADJ	B
or	I-P	CCONJ	O
within	I-P	ADP	O
30	I-P	NUM	O
days	I-P	NOUN	B
as	I-P	ADP	O
compared	I-P	VERB	O
to	I-P	PART	O
patients	I-P	NOUN	B
without	I-P	ADP	O
kidney	I-P	NOUN	B
disease	I-P	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
without	O	ADP	O
kidney	O	NOUN	B
disease	O	NOUN	I
,	O	PUNCT	O
BNP	B-I	NOUN	B
testing	I-I	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	O
median	B-OUT	ADJ	B
time	I-OUT	NOUN	O
to	I-OUT	PART	O
discharge	I-OUT	VERB	B
(	O	PUNCT	O
from	O	ADP	O
9.5	O	NUM	O
days	O	NOUN	B
to	O	ADP	O
2.5	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
P=	O	NOUN	O
0.003	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
total	B-OUT	ADJ	O
cost	I-OUT	NOUN	B
of	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
7184	O	NUM	O
dollars	O	NOUN	O
to	O	ADP	O
4151	O	NUM	O
dollars	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
P=	O	NOUN	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
kidney	O	NOUN	B
disease	O	NOUN	I
,	O	PUNCT	O
time	O	NOUN	O
to	O	PART	O
discharge	O	VERB	B
and	O	CCONJ	O
total	O	ADJ	O
cost	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
When	O	SCONJ	O
applying	O	VERB	O
BNP	B-I	PROPN	B
cut-off	O	ADJ	B
values	O	NOUN	I
without	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
kidney	O	NOUN	B
disease	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
BNP	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
does	O	AUX	O
significantly	O	ADV	O
improve	O	VERB	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
without	O	ADP	O
kidney	O	NOUN	B
disease	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
of	O	ADP	O
those	O	DET	O
with	O	ADP	O
kidney	O	NOUN	B
disease	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
Cys	B-I	NOUN	B
LT1	I-I	NOUN	I
receptor	I-I	NOUN	I
blockade	I-I	NOUN	B
on	O	ADP	O
airway	B-P	NOUN	B
responses	I-P	NOUN	B
to	I-P	PART	O
allergen	I-P	NOUN	B
.	I-P	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
potent	O	ADJ	O
experimental	O	ADJ	B
leukotriene	B-I	NOUN	B
receptor	I-I	NOUN	I
antagonist	I-I	NOUN	B
,	I-I	PUNCT	O
MK-571	I-I	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
airway	B-P	NOUN	B
responses	I-P	NOUN	B
to	I-P	PART	O
inhaled	I-P	ADJ	B
allergen	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Clinical	O	ADJ	B
research	O	NOUN	I
center	O	NOUN	I
.	O	PUNCT	O


SUBJECTS	O	VERB	O
Eight	B-P	NUM	O
male	I-P	NOUN	B
volunteers	I-P	NOUN	I
with	I-P	ADP	O
allergic	I-P	ADJ	B
asthma	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTIONS	O	VERB	B
An	O	DET	O
intravenous	O	ADJ	B
loading	O	NOUN	O
dose	O	NOUN	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
an	O	DET	O
8-hour	B-I	ADJ	O
infusion	I-I	NOUN	B
of	I-I	ADP	O
MK-571	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
7-	O	NUM	O
to	O	PART	O
14-day	O	ADJ	O
washout	O	NOUN	O
between	O	ADP	O
treatments	O	NOUN	B
.	O	PUNCT	O


Allergen	O	NOUN	B
challenge	O	NOUN	O
was	O	AUX	O
performed	O	VERB	O
after	O	ADP	O
the	O	DET	O
loading	O	NOUN	B
dose	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
histamine	B-I	NOUN	B
challenge	O	NOUN	O
was	O	AUX	O
performed	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
allergen	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
MAIN	O	NOUN	O
RESULTS	O	NOUN	O
Forced	B-OUT	ADJ	B
expiratory	I-OUT	ADJ	I
volume	I-OUT	NOUN	I
in	O	ADP	O
1	O	NUM	O
second	O	NOUN	O
was	O	AUX	O
measured	O	VERB	B
serially	O	ADV	B
.	O	PUNCT	O


MK-571	B-I	NOUN	B
provided	O	VERB	O
about	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
protection	O	NOUN	B
during	O	ADP	O
maximum	O	ADJ	B
early	O	ADV	B
and	O	CCONJ	O
late	O	ADJ	O
responses	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
p=0.005	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
airway	B-OUT	NOUN	B
obstruction	I-OUT	NOUN	I
persisted	O	VERB	O
8-24	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
allergen	O	NOUN	B
on	O	ADP	O
both	O	DET	O
treatment	O	NOUN	B
days	O	NOUN	B
.	O	PUNCT	O


Airway	B-OUT	NOUN	B
responsiveness	I-OUT	NOUN	B
to	I-OUT	PART	O
histamine	I-OUT	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
attenuated	O	VERB	B
at	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Blocking	O	VERB	B
Cys	O	NOUN	B
LT1	O	NOUN	I
receptors	O	NOUN	I
for	O	ADP	O
8	O	NUM	O
hours	O	NOUN	B
attenuated	O	VERB	B
the	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
late	O	ADJ	O
responses	O	NOUN	B
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
interrupt	O	VERB	O
the	O	DET	O
cascade	O	NOUN	O
of	O	ADP	O
events	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
subsequent	O	ADJ	O
allergen-induced	O	ADJ	B
airway	O	NOUN	I
obstruction	O	NOUN	I
and	O	CCONJ	O
hyperreactivity	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
recovery	B-OUT	NOUN	B
times	I-OUT	NOUN	O
of	O	ADP	O
desflurane	B-I	NOUN	B
and	O	CCONJ	O
isoflurane	B-I	NOUN	B
in	O	ADP	O
outpatient	B-P	ADJ	B
anesthesia	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
low	O	ADJ	B
solubility	O	NOUN	B
of	O	ADP	O
desflurane	B-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
contribute	O	VERB	O
to	O	ADP	O
faster	O	ADV	B
awakening	O	NOUN	B
from	O	ADP	O
anesthesia	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
other	O	ADJ	O
anesthetics	O	NOUN	B
in	O	ADP	O
common	O	ADJ	O
use	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
research	O	NOUN	B
has	O	AUX	O
failed	O	VERB	B
to	O	PART	O
consistently	O	ADV	O
demonstrate	O	VERB	O
faster	O	ADV	O
discharge	O	NOUN	B
times	O	NOUN	I
from	O	ADP	O
the	O	DET	O
postanesthesia	O	NOUN	B
care	O	NOUN	I
unit	O	NOUN	I
following	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
desflurane	B-I	NOUN	B
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
recovery	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
discharge	I-OUT	VERB	B
times	I-OUT	NOUN	I
of	O	ADP	O
outpatients	B-P	NOUN	B
undergoing	I-P	VERB	O
procedures	I-P	NOUN	B
greater	I-P	ADJ	O
than	I-P	ADP	O
2	I-P	NUM	O
hours	I-P	NOUN	O
in	I-P	ADP	O
length	I-P	NOUN	B
.	I-P	PUNCT	O


Thirty-three	B-P	NUM	O
patients	I-P	NOUN	B
aged	I-P	ADJ	B
18	I-P	NUM	O
to	I-P	PART	O
70	I-P	NUM	O
years	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
desflurane	B-I	NOUN	B
or	O	CCONJ	O
isoflurane	B-I	NOUN	B
following	O	VERB	O
a	O	DET	O
standard	O	ADJ	O
intravenous	O	ADJ	B
induction	O	NOUN	O
with	O	ADP	O
propofol	B-I	NOUN	B
.	I-I	PUNCT	O


Patients	B-P	NOUN	B
received	O	VERB	O
premedication	O	NOUN	B
and	O	CCONJ	O
opioids	O	NOUN	B
consistent	O	ADJ	B
with	O	ADP	I
institutional	O	ADJ	B
practice	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
inhalation	O	NOUN	B
agents	O	NOUN	I
were	O	AUX	O
titrated	O	VERB	B
to	O	PART	O
effect	O	VERB	B
during	O	ADP	O
anesthetic	O	ADJ	B
maintenance	O	NOUN	I
.	O	PUNCT	O


Following	O	VERB	O
surgery	O	NOUN	B
,	O	PUNCT	O
patients	B-P	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
for	O	ADP	O
time	B-OUT	NOUN	O
to	I-OUT	PART	O
emergence	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
to	I-OUT	ADP	O
meeting	I-OUT	VERB	O
discharge	I-OUT	NOUN	B
criteria	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
demonstrated	O	VERB	O
no	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
emergence	O	NOUN	B
or	O	CCONJ	O
discharge	O	VERB	B
times	O	NOUN	I
following	O	VERB	O
desflurane	B-I	NOUN	B
or	O	CCONJ	O
isoflurane	B-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
measured	O	VERB	B
parameters	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
intraoperative	B-OUT	ADJ	B
vital	I-OUT	ADJ	B
signs	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
emesis	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
opioid	I-OUT	NOUN	B
requirements	I-OUT	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
desflurane	B-I	NOUN	B
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
balanced	O	ADJ	O
anesthetic	O	ADJ	B
technique	O	NOUN	I
did	O	AUX	O
not	O	PART	O
speed	O	VERB	B
the	O	DET	O
emergence	O	NOUN	B
or	O	CCONJ	O
discharge	B-OUT	VERB	B
time	I-OUT	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
isoflurane	B-I	NOUN	B
.	I-I	PUNCT	O


Removing	B-I	VERB	B
bee	I-I	NOUN	I
stings	I-I	NOUN	B
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
Conventional	O	ADJ	B
advice	O	NOUN	I
on	O	ADP	O
immediate	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
honey-bee	O	ADJ	B
stings	O	NOUN	B
has	O	AUX	O
emphasised	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
sting	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
scraped	O	VERB	O
off	O	ADP	O
,	O	PUNCT	O
never	O	ADV	B
pinched	O	VERB	I
.	O	PUNCT	O


The	O	DET	O
morphology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sting	O	NOUN	B
suggested	O	VERB	O
little	O	ADJ	O
basis	O	NOUN	O
for	O	ADP	O
this	O	DET	O
advice	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
slow	O	VERB	B
down	O	ADP	I
removal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sting	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
response	O	NOUN	B
to	O	PART	O
honey-bee	B-P	ADJ	B
stings	I-P	NOUN	B
was	O	AUX	O
assayed	O	VERB	B
with	O	ADP	O
a	O	DET	O
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
resulting	O	VERB	O
weal	O	NOUN	B
.	O	PUNCT	O


Injection	O	NOUN	B
of	O	ADP	O
known	O	ADJ	O
quantities	O	NOUN	B
of	O	ADP	O
venom	B-I	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
measurement	O	NOUN	B
is	O	AUX	O
a	O	DET	O
good	O	ADJ	O
indicator	O	NOUN	B
of	O	ADP	O
envenomisation	O	NOUN	B
.	O	PUNCT	O


FINDINGS	O	ADJ	B
Weal	B-OUT	ADJ	B
size	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
thus	O	ADV	O
envenomisation	O	NOUN	B
,	O	PUNCT	O
increased	O	VERB	B
as	O	ADP	O
the	O	DET	O
time	B-OUT	NOUN	B
from	I-OUT	ADP	O
stinging	I-OUT	NOUN	B
to	I-OUT	ADP	O
removal	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
sting	I-OUT	NOUN	B
increased	O	VERB	B
,	O	PUNCT	O
even	O	ADV	O
within	O	ADP	O
a	O	DET	O
few	O	ADJ	O
seconds	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
response	O	NOUN	B
between	O	ADP	O
stings	B-OUT	NOUN	B
scraped	I-OUT	VERB	B
or	I-OUT	CCONJ	O
pinched	I-OUT	VERB	B
off	I-OUT	ADP	O
after	O	ADP	O
2	O	NUM	O
s.	O	NOUN	B
INTERPRETATION	O	ADP	I
These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
advice	O	NOUN	B
to	O	ADP	O
patients	B-P	NOUN	B
on	I-P	ADP	O
the	I-P	DET	O
immediate	I-P	ADJ	B
treatment	I-P	NOUN	B
of	I-P	ADP	O
bee	I-OUT	NOUN	B
stings	I-OUT	NOUN	I
should	O	AUX	O
emphasise	O	VERB	O
quick	B-I	ADJ	O
removal	I-I	NOUN	B
,	O	PUNCT	O
without	O	ADP	O
concern	O	NOUN	O
for	O	ADP	O
the	O	DET	O
method	O	NOUN	B
of	O	ADP	O
removal	O	NOUN	B
.	O	PUNCT	O


Atrophy	O	NOUN	B
and	O	CCONJ	O
intestinal	B-P	ADJ	B
metaplasia	I-P	NOUN	I
one	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
cure	O	NOUN	B
of	O	ADP	O
H.	B-P	X	B
pylori	I-P	NOUN	I
infection	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
&	O	CCONJ	O
AIMS	O	ADJ	O
Helicobacter	O	NOUN	O
pylori-infected	O	ADJ	O
gastric	O	ADJ	B
mucosa	O	NOUN	I
evolves	O	VERB	O
through	O	ADP	O
stages	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
gastritis	O	NOUN	I
,	O	PUNCT	O
intestinal	O	ADJ	B
metaplasia	O	NOUN	I
(	O	PUNCT	O
IM	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
glandular	O	ADJ	B
atrophy	O	NOUN	I
(	O	PUNCT	O
GA	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
dysplasia	O	NOUN	B
before	O	ADP	O
carcinoma	O	NOUN	B
develops	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
if	O	SCONJ	O
H.	O	PROPN	B
pylori	O	NOUN	I
eradication	O	NOUN	B
would	O	AUX	O
alter	O	VERB	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
premalignant	O	ADJ	B
histologic	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
stomach	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Volunteers	B-P	NOUN	B
from	I-P	ADP	O
the	I-P	DET	O
Yantai	I-P	PROPN	B
County	I-P	PROPN	I
in	I-P	ADP	O
China	I-P	PROPN	B
underwent	I-P	VERB	O
upper	I-I	ADJ	B
endoscopy	I-I	NOUN	I
with	I-I	ADP	O
biopsy	I-I	NOUN	B
specimens	I-P	NOUN	I
obtained	I-P	VERB	O
from	I-P	ADP	O
the	I-P	DET	O
antrum	I-P	NOUN	B
and	I-P	CCONJ	O
corpus	I-P	NOUN	B
.	I-P	PUNCT	O


H.	B-P	NOUN	B
pylori-infected	I-P	ADJ	I
subjects	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
a	O	DET	O
1-week	B-I	ADJ	O
course	I-I	NOUN	O
of	I-I	ADP	O
omeprazole	I-I	NOUN	B
,	I-I	PUNCT	O
amoxicillin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
clarithromycin	I-I	NOUN	B
(	I-I	PUNCT	O
OAC	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


At	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
endoscopies	O	NOUN	B
with	O	ADP	O
biopsies	O	NOUN	B
were	O	AUX	O
repeated	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
total	B-P	NOUN	O
of	I-P	ADP	O
587	I-P	NUM	O
H.	I-P	NOUN	O
pylori-infected	I-P	ADJ	B
subjects	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	ADP	O
OAC	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
295	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
292	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
H.	O	PROPN	B
pylori	O	NOUN	I
was	O	AUX	O
eradicated	O	VERB	B
in	O	ADP	O
226	O	NUM	O
subjects	O	NOUN	B
assigned	O	VERB	O
to	O	ADP	O
OAC	B-I	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
245	B-P	NUM	O
patients	I-P	NOUN	B
remained	I-P	VERB	O
H.	I-P	NOUN	B
pylori	I-P	NOUN	I
infected	I-P	VERB	B
.	I-P	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
paired	O	ADJ	B
samples	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
patients	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
acute	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
chronic	I-OUT	ADJ	B
gastritis	I-OUT	NOUN	I
decreased	O	VERB	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
antrum	O	NOUN	B
and	O	CCONJ	O
corpus	O	NOUN	B
after	O	ADP	O
H.	O	X	B
pylori	O	NOUN	I
eradication	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
activity	B-OUT	NOUN	B
of	I-OUT	ADP	O
IM	I-OUT	NOUN	B
decreased	O	VERB	B
in	O	ADP	O
antrum	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.014	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
H.	O	NOUN	B
pylori-infected	O	ADJ	I
group	O	NOUN	B
,	O	PUNCT	O
antral	O	ADJ	B
biopsy	O	NOUN	I
specimens	O	NOUN	I
had	O	AUX	O
more	O	ADV	O
pronounced	O	ADJ	O
acute	B-OUT	ADJ	B
gastritis	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
corpus	O	NOUN	B
specimens	O	NOUN	I
showed	O	VERB	O
increased	O	VERB	B
acute	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
chronic	I-OUT	ADJ	B
gastritis	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
marginal	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
GA	B-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.052	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


When	O	SCONJ	O
histologic	O	ADJ	B
changes	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
acute	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
chronic	I-OUT	ADJ	B
gastritis	I-OUT	NOUN	I
was	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
after	O	ADP	O
H.	O	X	B
pylori	O	NOUN	I
eradication	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
changes	O	NOUN	B
in	O	ADP	O
IM	B-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
H.	O	NOUN	B
pylori-infected	O	ADJ	I
group	O	NOUN	B
,	O	PUNCT	O
increase	O	NOUN	B
in	O	ADP	O
GA	B-OUT	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
corpus	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
At	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
H.	O	X	B
pylori	O	NOUN	I
eradication	O	NOUN	B
is	O	AUX	O
beneficial	O	ADJ	O
in	O	ADP	O
preventing	O	VERB	B
progression	O	NOUN	B
of	O	ADP	O
pathologic	B-OUT	ADJ	B
changes	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
gastric	O	ADJ	B
mucosa	O	NOUN	I
.	O	PUNCT	O


Metronidazole	B-I	NOUN	B
in	O	ADP	O
periodontitis	B-I	NOUN	B
(	O	PUNCT	O
IV	O	NUM	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
patient	O	NOUN	B
compliance	O	NOUN	B
on	O	ADP	O
treatment	O	NOUN	B
parameters	O	NOUN	B
.	O	PUNCT	O


Patient	O	ADJ	B
compliance	O	NOUN	B
with	O	ADP	O
the	O	DET	O
unsupervised	O	ADJ	B
usage	O	NOUN	I
of	O	ADP	O
prescription	O	NOUN	B
medication	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
poor	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
periodontal	B-P	ADJ	B
infections	I-P	NOUN	I
with	I-P	ADP	O
systemic	I-P	ADJ	B
antimicrobial	I-P	ADJ	B
agents	I-P	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
situations	O	NOUN	B
where	O	SCONJ	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
antimicrobial	O	ADJ	B
agent	O	NOUN	I
is	O	AUX	O
being	O	AUX	O
evaluated	O	VERB	B
,	O	PUNCT	O
non-compliance	O	NOUN	B
could	O	AUX	O
underestimate	O	VERB	O
the	O	DET	O
true	O	ADJ	O
efficacy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
agent	O	NOUN	B
.	O	PUNCT	O


Metronidazole	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
agent	O	NOUN	B
with	O	ADP	O
reported	O	VERB	O
success	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
anaerobic	O	ADJ	B
periodontal	O	ADJ	B
infections	O	NOUN	I
.	O	PUNCT	O


Metronidazole	B-I	NOUN	B
is	O	AUX	O
particularly	O	ADV	O
effective	O	ADJ	B
in	O	X	B
vitro	O	X	I
against	O	ADP	O
spirochetes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
efficacy	O	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
as	O	ADP	O
a	O	DET	O
means	O	NOUN	O
of	O	ADP	O
measuring	O	VERB	B
patient	O	NOUN	B
compliance	O	NOUN	B
with	O	ADP	O
metronidazole	B-I	NOUN	B
usage	O	NOUN	B
.	O	PUNCT	O


Patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
high	I-P	ADJ	O
proportions	I-P	NOUN	B
of	I-P	ADP	O
spirochetes	I-P	NOUN	B
,	I-P	PUNCT	O
i.e.	I-P	X	O
,	O	PUNCT	O
>	B-P	X	O
20	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
in	I-P	ADP	O
plaques	I-P	NOUN	B
removed	I-P	VERB	B
from	I-P	ADP	O
diseased	I-P	ADJ	B
periodontal	I-P	ADJ	B
sites	I-P	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
given	O	VERB	O
metronidazole	B-I	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
bid	O	NOUN	B
)	O	PUNCT	O
under	O	ADP	O
supervision	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
individuals	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
metronidazole	B-I	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
rapid	I-OUT	ADJ	O
decline	I-OUT	NOUN	B
and/or	I-OUT	CCONJ	O
disappearance	I-OUT	NOUN	B
of	I-OUT	ADP	O
spirochetes	I-OUT	NOUN	B
from	I-OUT	ADP	O
the	I-OUT	DET	O
plaque	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
time	O	NOUN	B
interval	O	NOUN	I
that	O	PRON	O
metronidazole	B-I	NOUN	B
was	O	AUX	O
detectable	O	ADJ	B
in	O	ADP	O
the	O	DET	O
saliva	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observed	O	VERB	O
decline	O	NOUN	B
in	O	ADP	O
spirochetes	O	NOUN	B
was	O	AUX	O
then	O	ADV	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
which	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
compliant	O	ADJ	B
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
involving	O	VERB	O
the	O	DET	O
unsupervised	O	ADJ	B
usage	O	NOUN	I
of	O	ADP	O
metronidazole	B-I	NOUN	B
.	I-I	PUNCT	O


Only	O	ADV	O
10	O	NUM	O
of	O	ADP	O
18	B-P	NUM	O
patients	I-P	NOUN	B
(	O	PUNCT	O
56	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
considered	O	VERB	O
compliant	O	ADJ	B
in	O	ADP	O
their	O	PRON	O
usage	O	NOUN	B
of	O	ADP	O
metronidazole	B-I	NOUN	B
.	I-I	PUNCT	O


These	O	DET	O
10	O	NUM	O
patients	O	NOUN	B
experienced	O	VERB	O
a	O	DET	O
significantly	B-OUT	ADV	O
greater	I-OUT	ADJ	O
benefit	I-OUT	NOUN	B
from	I-OUT	ADP	O
the	I-OUT	DET	O
metronidazole	I-OUT	NOUN	B
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
8	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
considered	O	VERB	O
noncompliant	O	ADJ	B
,	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
a	O	DET	O
reduction	B-OUT	NOUN	B
of	I-OUT	ADP	O
surgical	I-OUT	ADJ	B
needs	I-OUT	NOUN	O
of	O	ADP	O
8.3	O	NUM	O
teeth	O	NOUN	B
per	O	ADP	O
compliant	O	ADJ	B
patient	O	NOUN	B
versus	O	CCONJ	O
3.6	O	NUM	O
teeth	O	NOUN	B
per	O	ADP	O
non-compliant	O	ADJ	B
patient	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
test	O	NOUN	O
for	O	ADP	O
the	O	DET	O
hydrolysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
synthetic	O	ADJ	B
peptide	O	NOUN	I
(	O	PUNCT	O
BANA	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
also	O	ADV	O
able	O	ADJ	O
to	O	PART	O
identify	O	VERB	O
most	O	ADV	O
non-compliant	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
trials	O	NOUN	I
involving	O	VERB	O
the	O	DET	O
unsupervised	O	ADJ	B
usage	O	NOUN	I
of	O	ADP	O
systemic	O	ADJ	B
medication	O	NOUN	I
need	O	VERB	O
to	O	PART	O
take	O	VERB	O
into	O	ADP	O
account	O	NOUN	O
patient	O	NOUN	B
non-compliance	O	NOUN	B
.	O	PUNCT	O


Chromium	B-I	NOUN	B
Supplementation	I-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
Effects	O	NOUN	B
on	O	ADP	O
Metabolic	B-OUT	PROPN	B
Status	I-OUT	PROPN	I
in	O	ADP	O
Women	B-P	PROPN	B
with	I-P	ADP	O
Polycystic	I-P	ADJ	B
Ovary	I-P	NOUN	I
Syndrome	I-P	NOUN	I
:	I-P	PUNCT	O
A	O	DET	O
Randomized	O	ADJ	B
,	O	PUNCT	O
Double-Blind	O	ADJ	B
,	O	PUNCT	O
Placebo-Controlled	O	PROPN	B
Trial	O	PROPN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
beneficial	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
chromium	B-I	NOUN	B
intake	O	NOUN	B
on	O	ADP	O
markers	O	NOUN	B
of	O	ADP	O
insulin	B-OUT	NOUN	B
metabolism	I-OUT	NOUN	I
and	O	CCONJ	O
lipid	B-OUT	NOUN	B
profiles	I-OUT	NOUN	I
in	O	ADP	O
women	B-P	NOUN	B
with	I-P	ADP	O
polycystic	I-P	ADJ	B
ovary	I-P	ADJ	I
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
PCOS	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
64	B-P	NUM	O
women	I-P	NOUN	B
with	I-P	ADP	O
PCOS	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
receive	O	VERB	O
200	B-I	NUM	O
µg	I-I	NOUN	O
chromium	I-I	NOUN	B
picolinate	I-I	NOUN	I
supplements	I-I	NOUN	I
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
32	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
32	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Fasting	B-OUT	ADJ	B
blood	I-OUT	NOUN	B
samples	I-OUT	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
8	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
to	O	PART	O
quantify	O	VERB	B
markers	O	NOUN	B
of	O	ADP	O
insulin	O	NOUN	B
metabolism	O	NOUN	I
and	O	CCONJ	O
lipid	O	NOUN	B
concentrations	O	NOUN	I
.	O	PUNCT	O


RESULTS	B-I	VERB	B
Chromium	I-I	NOUN	B
supplementation	O	NOUN	B
in	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
PCOS	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
significant	O	ADJ	O
decreases	O	NOUN	B
in	B-OUT	ADP	O
serum	I-OUT	NOUN	B
insulin	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
(	O	PUNCT	O
-3.6	O	NUM	O
±	O	NOUN	O
7.4	O	NUM	O
vs.	O	CCONJ	O
+3.6	O	NUM	O
±	O	NOUN	O
6.2	O	NUM	O
µIU/ml	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
homeostasis	I-OUT	NOUN	B
model	I-OUT	NOUN	B
of	I-OUT	ADP	O
assessment-insulin	I-OUT	ADJ	B
resistance	I-OUT	NOUN	I
(	O	PUNCT	O
HOMA-IR	O	NOUN	B
;	O	PUNCT	O
-0.8	O	NUM	O
±	O	NOUN	O
1.6	O	NUM	O
vs.	O	X	O
+0.9	O	NOUN	O
±	O	NOUN	O
1.5	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
homeostatic	I-OUT	ADJ	B
model	I-OUT	NOUN	I
assessment-beta	I-OUT	NOUN	B
cell	I-OUT	NOUN	I
function	I-OUT	NOUN	I
(	O	PUNCT	O
HOMA-B	O	NOUN	B
;	O	PUNCT	O
-15.5	O	NUM	O
±	O	NOUN	O
32.3	O	NUM	O
vs.	O	CCONJ	O
+13.6	O	NUM	O
±	O	NOUN	O
23.1	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
quantitative	I-OUT	ADJ	B
insulin	I-OUT	NOUN	B
sensitivity	I-OUT	NOUN	I
check	I-OUT	VERB	I
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
QUICKI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
score	O	NOUN	O
(	O	PUNCT	O
+0.02	O	NUM	O
±	O	NOUN	O
0.03	O	NUM	O
vs.	O	CCONJ	O
-0.008	O	NUM	O
±	O	NOUN	O
0.02	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
compared	B-I	VERB	B
with	I-I	ADP	O
the	I-I	DET	O
placebo	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
effect	B-I	NOUN	B
of	I-I	ADP	O
chromium	O	NOUN	B
supplementation	O	NOUN	B
on	O	ADP	O
decreasing	B-OUT	VERB	B
serum	I-OUT	NOUN	B
triglycerides	I-OUT	NOUN	O
(	O	PUNCT	O
-12.4	O	NUM	O
±	O	NOUN	O
74.4	O	NUM	O
vs.	O	CCONJ	O
+15.2	O	NUM	O
±	O	NOUN	O
32.4	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.05	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
very	I-OUT	ADV	O
low-density	I-OUT	ADJ	B
lipoprotein-cholesterol	I-OUT	NOUN	I
(	O	PUNCT	I
-2.5	O	NUM	O
±	O	NOUN	O
14.9	O	NUM	O
vs.	O	CCONJ	O
+3.0	O	NUM	O
±	O	NOUN	O
6.5	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
p	B-OUT	NOUN	O
=	I-OUT	ADJ	O
0.05	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cholesterol	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	O
(	O	PUNCT	O
-8.6	O	NUM	O
±	O	NOUN	O
21.9	O	NUM	O
vs.	O	CCONJ	O
+0.7	O	NOUN	O
±	O	NOUN	O
22.4	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.09	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
seen	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	B-I	NOUN	O
Eight	I-I	NUM	O
weeks	I-I	NOUN	B
of	O	ADP	O
chromium	O	NOUN	B
supplementation	B-P	NOUN	B
among	I-P	ADP	O
PCOS	O	NOUN	B
women	O	NOUN	B
had	O	AUX	O
favorable	B-OUT	ADJ	B
effects	I-OUT	NOUN	B
on	I-OUT	ADP	O
markers	I-OUT	NOUN	B
of	I-OUT	ADP	O
insulin	I-OUT	NOUN	B
metabolism	O	NOUN	I
.	O	PUNCT	O


Delayed	B-P	VERB	B
perceptual	I-P	ADJ	B
awareness	I-P	NOUN	B
in	O	ADP	O
rapid	B-P	ADJ	B
perceptual	I-P	ADJ	B
decisions	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
flourishing	O	NOUN	B
of	O	ADP	O
studies	O	NOUN	B
on	O	ADP	O
the	O	DET	O
neural	O	ADJ	B
correlates	O	NOUN	B
of	O	ADP	O
decision-making	O	ADJ	B
calls	O	NOUN	I
for	O	ADP	O
an	O	DET	O
appraisal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
relation	O	NOUN	O
between	O	ADP	O
perceptual	O	ADJ	B
decisions	O	NOUN	B
and	O	CCONJ	O
conscious	O	ADJ	B
perception	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
exploiting	O	VERB	O
the	O	DET	O
long	B-I	ADJ	B
integration	I-I	NOUN	I
time	I-I	NOUN	I
of	I-I	ADP	O
noisy	I-I	ADJ	B
motion	I-I	NOUN	I
stimuli	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
by	I-I	ADP	O
forcing	I-I	VERB	O
human	I-I	ADJ	B
observers	I-I	NOUN	B
to	I-I	PART	O
make	I-I	VERB	O
difficult	I-I	ADJ	O
speeded	I-I	ADJ	O
decisions	I-I	NOUN	B
--	I-I	PUNCT	O
sometimes	I-I	ADV	O
a	I-I	DET	O
blind	I-I	ADJ	B
guess	I-I	NOUN	B
--	I-I	PUNCT	O
about	I-I	ADP	O
stimulus	I-I	NOUN	B
direction	I-I	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
traced	O	VERB	O
the	O	DET	O
temporal	O	ADJ	B
buildup	O	NOUN	B
of	O	ADP	O
motion	O	NOUN	B
discrimination	O	NOUN	I
capability	O	NOUN	B
and	O	CCONJ	O
perceptual	O	ADJ	B
awareness	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
assessed	O	VERB	B
trial	O	NOUN	B
by	O	ADP	O
trial	O	NOUN	B
through	O	ADP	O
direct	O	ADJ	O
rating	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
increased	O	VERB	B
gradually	O	ADV	B
with	O	ADP	O
motion	B-OUT	NOUN	B
coherence	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
viewing	I-OUT	VERB	B
time	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
discrimination	B-OUT	NOUN	B
was	I-OUT	AUX	O
systematically	I-OUT	ADV	B
leading	I-OUT	VERB	O
awareness	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
reaching	I-OUT	VERB	O
a	I-OUT	DET	O
plateau	I-OUT	NOUN	B
much	I-OUT	ADV	O
earlier	I-OUT	ADV	O
.	I-OUT	PUNCT	O


Sensitivity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
criterion	I-OUT	NOUN	B
changes	I-OUT	NOUN	B
contributed	O	VERB	O
jointly	O	ADV	O
to	O	ADP	O
the	O	DET	O
slow	B-OUT	ADJ	B
buildup	I-OUT	NOUN	B
of	I-OUT	ADP	O
perceptual	I-OUT	ADJ	B
awareness	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


It	O	PRON	O
made	O	VERB	O
no	B-OUT	DET	O
difference	I-OUT	NOUN	O
whether	O	SCONJ	O
motion	B-OUT	NOUN	B
discrimination	I-OUT	NOUN	I
was	O	AUX	O
accomplished	O	VERB	O
by	O	ADP	O
saccades	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
verbal	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
perceptual	B-OUT	ADJ	B
awareness	I-OUT	NOUN	B
emerges	I-OUT	VERB	O
on	I-OUT	ADP	O
the	I-OUT	DET	O
top	I-OUT	NOUN	O
of	I-OUT	ADP	O
a	I-OUT	DET	O
developing	I-OUT	NOUN	O
or	I-OUT	CCONJ	O
even	I-OUT	ADV	O
mature	I-OUT	ADJ	B
perceptual	I-OUT	ADJ	B
decision	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


We	O	PRON	O
argue	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
middle	O	ADJ	B
temporal	O	ADJ	I
(	O	PUNCT	O
MT	O	NOUN	B
)	O	PUNCT	O
cortical	O	ADJ	B
region	O	NOUN	I
does	O	AUX	O
not	O	PART	O
confer	O	VERB	O
us	O	PRON	O
the	O	DET	O
full	B-OUT	ADJ	O
phenomenic	I-OUT	ADJ	B
depth	I-OUT	NOUN	I
of	I-OUT	ADP	O
motion	I-OUT	NOUN	B
perception	I-OUT	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
represent	O	VERB	O
a	O	DET	O
precursor	B-OUT	NOUN	B
stage	I-OUT	NOUN	I
in	I-OUT	ADP	O
building	I-OUT	VERB	O
our	I-OUT	PRON	O
subjective	I-OUT	ADJ	O
sense	I-OUT	NOUN	B
of	I-OUT	ADP	I
visual	I-OUT	ADJ	B
motion	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
multicenter	O	ADJ	B
trial	O	NOUN	I
comparing	O	VERB	B
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
arzoxifene	B-I	NOUN	B
(	I-I	PUNCT	O
LY353381	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
hormone-sensitive	B-P	ADJ	B
advanced	I-P	ADJ	B
or	I-P	CCONJ	O
metastatic	I-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
This	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	I
assessed	O	VERB	B
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
the	O	DET	O
selective	B-I	ADJ	B
estrogen	I-I	NOUN	I
receptor	I-I	NOUN	I
modulator	I-I	NOUN	I
arzoxifene	I-I	NOUN	B
in	O	ADP	O
women	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
to	O	PART	O
choose	O	VERB	O
the	O	DET	O
best	O	ADJ	O
of	O	ADP	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
arzoxifene	B-I	NOUN	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
the	I-OUT	DET	O
clinical	I-OUT	ADJ	B
benefit	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CBR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Pharmacokinetics	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
toxicities	I-OUT	NOUN	B
were	O	AUX	O
also	O	ADV	O
assessed	O	VERB	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Ninety-two	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
received	I-I	VERB	O
arzoxifene	I-I	NOUN	B
20	I-I	NUM	O
or	I-I	CCONJ	O
50	I-I	NUM	O
mg/day	I-I	NOUN	B
.	I-I	PUNCT	O


Tumor	B-OUT	NOUN	B
response	I-OUT	NOUN	I
was	I-I	AUX	O
assessed	I-I	VERB	B
using	I-I	VERB	O
World	I-I	PROPN	B
Health	I-I	PROPN	I
Organization	I-I	PROPN	I
criteria	I-I	NOUN	I
.	I-I	PUNCT	O


Toxicities	B-OUT	NOUN	B
were	I-I	AUX	O
graded	I-I	VERB	B
according	I-I	VERB	O
to	I-I	ADP	O
the	I-I	DET	O
National	I-I	PROPN	B
Cancer	I-I	PROPN	I
Institute	I-I	PROPN	I
Common	I-I	PROPN	O
Toxicity	I-I	PROPN	O
Criteria	I-I	PROPN	O
(	I-I	PUNCT	O
NCI-CTC	I-I	NOUN	O
)	I-I	PUNCT	O
system	I-I	NOUN	O
.	I-I	PUNCT	O


Pharmacokinetic	B-OUT	ADJ	B
data	I-OUT	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
using	O	VERB	O
the	O	DET	O
NONMEM	O	PROPN	B
software	O	NOUN	I
program	O	NOUN	I
(	O	PUNCT	O
GloboMax	O	PROPN	B
,	O	PUNCT	O
Hanover	O	PROPN	B
,	O	PUNCT	O
MD	O	PROPN	B
,	O	PUNCT	O
USA	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Response	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
20	O	NUM	O
mg	O	NOUN	O
arm	O	NOUN	B
were	O	AUX	O
numerically	O	ADV	B
higher	O	ADJ	I
than	O	ADP	O
the	O	DET	O
50-mg	O	ADJ	O
arm	O	NOUN	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
investigator	O	NOUN	B
(	O	PUNCT	O
40.5	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
36.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
independent	O	ADJ	O
review	O	NOUN	B
panel	O	NOUN	I
(	O	PUNCT	O
42.9	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
27.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CBR	B-OUT	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
20	O	NUM	O
mg	O	NOUN	O
arm	O	NOUN	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
investigator	O	NOUN	B
(	O	PUNCT	O
64.3	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
61.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
independent	O	ADJ	O
review	O	NOUN	B
panel	O	NOUN	I
(	O	PUNCT	O
59.5	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
47.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Arzoxifene	B-I	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
study	O	NOUN	O
drug-related	B-OUT	ADJ	B
deaths	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Mean	O	VERB	O
observed	O	VERB	O
steady-state	B-OUT	ADJ	B
plasma	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
of	O	ADP	O
arzoxifene	B-I	NOUN	B
were	O	AUX	O
3.62	O	NUM	O
and	O	CCONJ	O
7.48	O	NUM	O
ng/ml	O	NOUN	O
for	O	ADP	O
the	O	DET	O
20	O	NUM	O
and	O	CCONJ	O
50	O	NUM	O
mg	O	NOUN	O
doses	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
efficacy	B-OUT	NOUN	B
or	O	CCONJ	O
safety	B-OUT	NOUN	B
between	O	ADP	O
20	O	NUM	O
and	O	CCONJ	O
50	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
arzoxifene	B-I	NOUN	B
.	I-I	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
arzoxifene	B-I	NOUN	B
20	O	NUM	O
mg/day	O	NOUN	B
was	O	AUX	O
selected	O	VERB	O
for	O	ADP	O
further	O	ADJ	O
study	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
.	O	PUNCT	O


Institutional	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
accrual	O	NOUN	B
volume	O	NOUN	I
and	O	CCONJ	O
survival	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
head	I-P	NOUN	B
and	I-P	CCONJ	I
neck	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	PROPN	O
National	O	PROPN	O
Comprehensive	O	PROPN	O
Cancer	O	PROPN	O
Network	O	PROPN	O
guidelines	O	NOUN	O
recommend	O	VERB	O
patients	B-P	NOUN	B
with	I-P	ADP	O
head	I-P	NOUN	B
and	I-P	CCONJ	I
neck	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
HNC	I-P	NOUN	B
)	I-P	PUNCT	O
receive	O	VERB	O
treatment	O	NOUN	B
at	O	ADP	O
centers	O	NOUN	B
with	O	ADP	O
expertise	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
whether	O	SCONJ	O
provider	O	NOUN	B
experience	O	NOUN	B
affects	O	VERB	O
survival	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
institutional	O	ADJ	B
experience	O	NOUN	B
on	O	ADP	O
overall	O	ADJ	B
survival	O	NOUN	I
(	O	PUNCT	O
OS	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
stage	I-P	NOUN	B
III	I-P	NUM	I
or	I-P	CCONJ	O
IV	I-P	NUM	B
HNC	I-P	PROPN	I
was	O	AUX	O
investigated	O	VERB	B
within	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Radiation	O	PROPN	B
Therapy	O	PROPN	I
Oncology	O	PROPN	I
Group	O	PROPN	I
(	O	PUNCT	O
RTOG	O	PROPN	O
0129	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
compared	O	VERB	O
cisplatin	B-I	NOUN	B
concurrent	I-I	ADJ	B
with	I-I	ADP	O
standard	I-I	ADJ	B
versus	I-I	CCONJ	O
accelerated	I-I	VERB	B
fractionation	I-I	NOUN	B
radiotherapy	I-I	NOUN	I
.	I-I	PUNCT	O


As	O	ADP	O
a	O	DET	O
surrogate	O	NOUN	B
for	O	ADP	O
experience	O	NOUN	B
,	O	PUNCT	O
institutions	O	NOUN	B
were	O	AUX	O
classified	O	VERB	O
as	O	ADP	O
historically	O	ADV	O
low-	O	ADJ	O
(	O	PUNCT	O
HLACs	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
high-accruing	O	ADJ	B
centers	O	NOUN	I
(	O	PUNCT	O
HHACs	O	NOUN	B
)	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
accrual	O	NOUN	B
to	O	ADP	O
21	B-P	NUM	O
RTOG	I-P	PROPN	B
HNC	I-P	PROPN	B
trials	I-P	NOUN	B
(	I-P	PUNCT	O
1997	I-P	NUM	O
to	I-P	PART	O
2002	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
accrual	O	ADJ	B
volume	O	NOUN	I
on	O	ADP	O
OS	O	NOUN	B
was	O	AUX	O
estimated	O	VERB	O
by	O	ADP	O
Cox	O	NOUN	B
proportional	O	ADJ	I
hazards	O	NOUN	I
models	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Median	B-OUT	ADJ	B
RTOG	I-OUT	PROPN	B
accrual	I-OUT	NOUN	B
(	O	PUNCT	O
1997	O	NUM	O
to	O	PART	O
2002	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
HLACs	O	NOUN	B
was	O	AUX	O
four	O	NUM	O
versus	O	CCONJ	O
65	O	NUM	O
patients	O	NOUN	B
at	O	ADP	O
HHACs	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
included	O	VERB	O
471	B-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
RTOG	I-P	PROPN	B
0129	I-P	NUM	I
(	I-P	PUNCT	O
2002	I-P	NUM	O
to	I-P	PART	O
2005	I-P	NUM	O
)	I-P	PUNCT	O
with	I-P	ADP	O
known	I-P	VERB	O
human	I-P	ADJ	B
papillomavirus	I-P	NOUN	O
and	I-P	CCONJ	O
smoking	I-P	NOUN	B
status	I-P	NOUN	I
.	I-P	PUNCT	O


Patients	O	NOUN	B
at	O	ADP	O
HLACs	O	NOUN	B
versus	O	CCONJ	O
HHACs	O	PROPN	B
had	O	AUX	O
better	O	ADJ	O
performance	O	NOUN	B
status	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
:	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
52	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.04	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
lower	O	ADJ	B
T	O	NOUN	O
stage	O	NOUN	O
(	O	PUNCT	O
T4	O	NOUN	B
:	O	PUNCT	O
26.5	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
35.3	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.002	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
were	O	AUX	O
otherwise	O	ADV	O
similar	O	ADJ	O
.	O	PUNCT	O


Radiotherapy	B-OUT	NOUN	B
protocol	I-OUT	NOUN	I
deviations	I-OUT	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
at	O	ADP	O
HLACs	O	NOUN	B
versus	O	CCONJ	O
HHACs	O	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
6	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


When	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
HHACs	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
at	O	ADP	O
HLACs	O	NOUN	B
had	O	AUX	O
worse	O	ADJ	O
OS	B-OUT	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
years	O	NOUN	B
:	O	PUNCT	O
51.0	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
69.1	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Treatment	O	NOUN	B
at	O	ADP	O
HLACs	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
death	B-OUT	NOUN	B
risk	I-OUT	NOUN	I
of	O	ADP	O
91	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
[	O	PUNCT	O
HR	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
1.91	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.37	O	NUM	O
to	O	PART	O
2.65	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
prognostic	O	ADJ	B
factors	O	NOUN	I
and	O	CCONJ	O
72	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
1.72	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.23	O	NUM	O
to	O	PART	O
2.40	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
radiotherapy	O	NOUN	B
compliance	O	NOUN	B
adjustment	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
OS	O	NOUN	B
is	O	AUX	O
worse	O	ADJ	O
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
HNC	O	NOUN	B
treated	O	VERB	B
at	O	ADP	O
HLACs	O	NOUN	B
versus	O	CCONJ	O
HHACs	O	NOUN	B
to	O	PART	O
cooperative	O	ADJ	B
group	O	NOUN	I
trials	O	NOUN	O
after	O	ADP	O
accounting	O	VERB	O
for	O	ADP	O
radiotherapy	O	NOUN	B
protocol	O	NOUN	I
deviations	O	NOUN	B
.	O	PUNCT	O


Institutional	O	ADJ	B
experience	O	NOUN	B
substantially	O	ADV	O
influences	O	VERB	B
survival	O	NOUN	B
in	O	ADP	O
locally	O	ADV	B
advanced	O	ADJ	I
HNC	O	NOUN	I
.	O	PUNCT	O


Multidose	O	NOUN	B
,	O	PUNCT	O
live	O	ADV	B
attenuated	O	VERB	B
,	O	PUNCT	O
cold-recombinant	O	ADJ	B
,	O	PUNCT	O
trivalent	O	ADJ	O
influenza	B-I	NOUN	O
vaccine	I-I	NOUN	O
in	O	ADP	O
infants	B-P	NOUN	B
and	I-P	CCONJ	O
young	I-P	ADJ	B
children	I-P	NOUN	B
.	I-P	PUNCT	O


Twenty-two	B-P	NUM	O
healthy	I-P	ADJ	B
infants	I-P	NOUN	I
and	I-P	CCONJ	O
children	I-P	NOUN	B
received	O	VERB	O
either	O	CCONJ	O
cold-recombinant	B-I	ADJ	B
,	I-I	PUNCT	O
trivalent	I-I	ADJ	O
influenza	I-I	NOUN	O
vaccine	I-I	NOUN	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
in	O	ADP	O
a	O	DET	O
three-dose	O	ADJ	B
vaccine	O	NOUN	O
trial	O	NOUN	O
.	O	PUNCT	O


Most	O	ADV	O
(	O	PUNCT	O
82	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
who	O	PRON	O
received	O	VERB	O
vaccine	O	NOUN	B
were	O	AUX	O
seronegative	O	ADJ	B
to	O	ADP	O
all	O	DET	O
three	B-I	NUM	O
vaccine	I-I	NOUN	B
strains	I-I	NOUN	B
(	I-I	PUNCT	O
10	I-I	NUM	O
(	I-I	PUNCT	O
6	I-I	NUM	O
)	I-I	PUNCT	O
TCID50/dose	I-I	NOUN	O
each	I-I	DET	O
)	I-I	PUNCT	O
:	I-I	PUNCT	O
A/Kawasaki/9/86	I-I	NOUN	B
(	I-I	PUNCT	O
H1N1	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
A/Los	I-I	NOUN	B
Angeles/2/87	I-I	NOUN	I
(	I-I	PUNCT	O
H3N2	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
B/Yamagata/16/88	I-I	NOUN	B
.	I-I	PUNCT	O


Vaccine	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
intranasally	O	ADV	B
at	O	ADP	O
time	O	NOUN	O
0	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
vaccine	O	NOUN	B
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	I-OUT	CCONJ	O
immunogenic	I-OUT	ADJ	B
when	O	SCONJ	O
administered	O	VERB	B
in	O	ADP	O
a	O	DET	O
multidose	O	ADJ	B
regimen	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
dose	O	NOUN	B
stimulated	O	ADJ	B
antibody	O	NOUN	B
to	O	PART	O
H1	O	NOUN	B
,	O	PUNCT	O
H3	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
B	O	NOUN	B
in	O	ADP	O
59	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
94	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
35	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
vaccinees	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
by	O	ADP	O
hemagglutination	O	NOUN	B
inhibition	O	NOUN	B
(	O	PUNCT	O
HAI	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
ELISA	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
vaccine	O	NOUN	B
,	O	PUNCT	O
93	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
93	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
80	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
antibody	O	NOUN	B
by	O	ADP	O
HAI	O	NOUN	B
or	O	CCONJ	O
ELISA	O	NOUN	B
to	O	PART	O
H1	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
H3	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
B	I-OUT	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Most	O	ADJ	O
vaccinees	O	NOUN	B
(	O	PUNCT	O
67	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
responded	O	VERB	O
to	O	ADP	O
all	O	DET	O
three	O	NUM	O
viruses	O	NOUN	B
after	O	ADP	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
vaccine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
third	O	ADJ	B
dose	O	NOUN	I
contributed	O	VERB	O
little	O	ADJ	O
to	O	ADP	O
the	O	DET	O
vaccine	B-OUT	NOUN	B
's	I-OUT	PART	O
immunogenicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Multidose	O	ADJ	B
trivalent	O	ADJ	I
influenza	O	NOUN	B
vaccine	O	NOUN	I
is	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
induces	O	VERB	B
an	O	DET	O
immune	B-OUT	ADJ	B
response	I-OUT	NOUN	I
in	O	ADP	O
most	O	ADJ	O
vaccinees	O	NOUN	B
after	O	ADP	O
two	O	NUM	O
doses	O	NOUN	B
.	O	PUNCT	O


ApoA-I	B-I	NOUN	B
induction	O	NOUN	B
as	O	ADP	O
a	O	DET	O
potential	O	ADJ	O
cardioprotective	O	ADJ	B
strategy	O	NOUN	O
:	O	PUNCT	O
rationale	O	VERB	O
for	O	ADP	O
the	O	DET	O
SUSTAIN	O	NOUN	B
and	O	CCONJ	O
ASSURE	O	NOUN	B
studies	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Considerable	O	ADJ	O
interest	O	NOUN	O
has	O	AUX	O
focused	O	VERB	O
on	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
therapies	O	NOUN	B
that	O	PRON	O
target	O	VERB	B
the	O	DET	O
functionality	O	NOUN	B
of	O	ADP	O
high-density	O	ADJ	B
lipoproteins	O	NOUN	I
(	O	PUNCT	O
HDL	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Upregulation	O	NOUN	B
of	O	ADP	O
endogenous	O	ADJ	B
synthesis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
protein	O	NOUN	B
on	O	ADP	O
HDL	O	NOUN	B
particles	O	NOUN	I
,	O	PUNCT	O
apolipoprotein	B-I	NOUN	B
A-I	I-I	NOUN	I
(	O	PUNCT	O
apoA-I	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
represents	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
approach	O	NOUN	O
to	O	PART	O
generation	O	NOUN	O
of	O	ADP	O
new	O	ADJ	O
HDL	O	NOUN	B
particles	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Study	O	NOUN	B
of	O	ADP	O
Quantitative	O	PROPN	B
Serial	O	ADJ	B
Trends	O	PROPN	I
in	O	ADP	O
Lipids	O	NOUN	B
with	O	ADP	O
Apolipoprotein	B-I	NOUN	B
A-I	I-I	NOUN	I
Stimulation	I-I	NOUN	I
(	O	PUNCT	O
SUSTAIN	O	NOUN	B
,	O	PUNCT	O
NCT01423188	O	ADJ	O
)	O	PUNCT	O
study	O	NOUN	B
aims	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
lipid	B-OUT	NOUN	B
efficacy	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
safety	I-OUT	NOUN	B
and	O	CCONJ	O
tolerability	B-OUT	NOUN	B
of	O	ADP	O
an	O	DET	O
apoA-I	B-I	NOUN	B
inducer	I-I	NOUN	B
(	I-I	PUNCT	O
RVX-208	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
ApoA-I	O	NOUN	B
Synthesis	O	NOUN	I
Stimulation	O	NOUN	B
and	O	CCONJ	O
Intravascular	B-I	PROPN	B
Ultrasound	I-I	PROPN	I
for	O	ADP	O
Coronary	O	PROPN	B
Atheroma	O	PROPN	I
Regression	O	PROPN	I
Evaluation	O	NOUN	I
(	O	PUNCT	O
ASSURE	O	NOUN	B
,	O	PUNCT	O
NCT01067820	O	NOUN	O
)	O	PUNCT	O
study	O	NOUN	B
aims	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
RVX-208	O	NOUN	B
on	O	ADP	O
plaque	O	NOUN	B
burden	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	B-P	ADP	O
SUSTAIN	I-P	NOUN	B
,	I-P	PUNCT	O
172	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
low	I-P	ADJ	B
levels	I-P	NOUN	B
of	I-P	ADP	O
HDL-C	I-P	NOUN	B
will	I-P	AUX	O
be	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
receive	O	VERB	O
RVX-208	B-I	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
bid	O	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
for	O	ADP	O
24	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
parameter	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
the	O	DET	O
percentage	B-OUT	NOUN	O
change	I-OUT	NOUN	O
in	I-OUT	ADP	O
HDL-C	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	B-P	ADP	O
ASSURE	I-P	PROPN	B
,	I-P	PUNCT	O
310	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
angiographic	I-P	ADJ	B
coronary	I-P	ADJ	I
artery	I-P	NOUN	I
disease	I-P	NOUN	I
and	I-P	CCONJ	O
low	I-P	ADJ	B
HDL-C	I-P	NOUN	B
levels	I-P	NOUN	B
will	I-P	AUX	O
be	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
receive	O	VERB	O
RVX-208	B-I	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
bid	O	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
for	O	ADP	O
26	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
parameter	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
the	O	DET	O
nominal	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
percent	B-OUT	ADJ	O
atheroma	I-OUT	NOUN	B
volume	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
PAV	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
determined	O	VERB	O
by	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
intravascular	O	ADJ	B
ultrasound	O	NOUN	I
(	O	PUNCT	I
IVUS	O	NOUN	B
)	O	PUNCT	O
images	O	NOUN	B
of	O	ADP	O
matched	O	VERB	O
coronary	O	ADJ	B
artery	O	NOUN	I
segments	O	NOUN	O
acquired	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
26-week	O	NOUN	B
follow-up	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
RVX-208	B-I	NOUN	B
on	O	ADP	O
other	O	ADJ	O
lipid	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
inflammatory	I-OUT	ADJ	B
markers	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
safety	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
will	O	AUX	O
also	O	ADV	O
be	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
both	O	DET	O
studies	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
ApoA-I	B-I	NOUN	B
induction	O	NOUN	B
represents	O	VERB	O
a	O	DET	O
potential	O	ADJ	B
novel	O	ADJ	O
strategy	O	NOUN	O
to	O	PART	O
reduce	O	VERB	B
cardiovascular	B-OUT	ADJ	B
risk	I-OUT	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
generating	O	VERB	O
nascent	O	ADJ	B
HDL	O	NOUN	O
particles	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
will	O	AUX	O
provide	O	VERB	O
early	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
RVX-208	B-I	NOUN	B
on	O	ADP	O
lipids	O	NOUN	B
and	O	CCONJ	O
atherosclerotic	O	ADJ	B
plaque	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
peroxisome	O	NOUN	B
proliferator-activated	O	ADJ	I
receptor-gamma	O	NOUN	I
agonist	O	NOUN	I
pioglitazone	B-I	NOUN	B
increases	O	VERB	B
number	B-OUT	NOUN	O
and	I-OUT	CCONJ	O
function	I-OUT	NOUN	B
of	I-OUT	ADP	O
endothelial	I-OUT	ADJ	B
progenitor	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
and	I-P	CCONJ	O
normal	I-P	ADJ	B
glucose	I-P	NOUN	I
tolerance	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	B
Peroxisome	O	NOUN	B
proliferator-activated	O	ADJ	I
receptor-gamma	O	NOUN	I
(	O	PUNCT	O
PPAR	O	NOUN	B
gamma	O	NOUN	I
)	O	PUNCT	I
agonists	O	NOUN	I
(	B-I	PUNCT	O
thiazolidinediones	I-I	NOUN	B
[	I-I	PUNCT	O
TZDs	I-I	NOUN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
are	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
diabetes	O	NOUN	B
.	O	PUNCT	O


Bone	O	NOUN	B
marrow-derived	O	ADJ	B
endothelial	O	ADJ	B
progenitor	O	NOUN	I
cells	O	NOUN	I
(	O	PUNCT	O
EPCs	O	NOUN	B
)	O	PUNCT	O
improve	O	VERB	O
vascular	B-OUT	ADJ	B
function	I-OUT	NOUN	I
and	O	CCONJ	O
predict	O	VERB	O
cardiovascular	B-OUT	ADJ	B
risk	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
pioglitazone	B-I	NOUN	B
therapy	O	NOUN	B
on	O	ADP	O
EPCs	O	NOUN	B
was	O	AUX	O
examined	O	VERB	O
.	O	PUNCT	O


RESEARCH	O	NOUN	B
DESIGN	O	NOUN	I
AND	O	CCONJ	O
METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
study	O	NOUN	I
on	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
documented	I-P	VERB	B
stable	I-P	ADJ	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
and	I-P	CCONJ	O
normal	I-P	ADJ	B
glucose	I-P	NOUN	I
tolerance	I-P	NOUN	I
.	I-P	PUNCT	O


Of	O	ADP	O
54	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
normal	I-P	ADJ	B
fasting	I-P	NOUN	I
glucose	I-P	NOUN	O
levels	I-P	NOUN	O
,	I-P	PUNCT	O
18	I-P	NUM	O
showed	I-P	VERB	O
impaired	I-P	ADJ	B
glucose	I-P	NOUN	B
tolerance	I-P	NOUN	I
and	I-P	CCONJ	O
36	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
normal	I-P	ADJ	B
glucose	I-P	NOUN	I
tolerance	I-P	NOUN	I
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
30-day	O	ADJ	O
treatment	O	NOUN	B
with	O	ADP	O
pioglitazone	B-I	NOUN	B
(	O	PUNCT	O
45	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
in	I-I	ADP	O
addition	I-I	NOUN	O
to	I-I	PART	O
optimal	I-I	ADJ	B
medical	I-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
TZD	B-I	NOUN	B
group	O	NOUN	B
showed	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
adiponectin	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
as	O	ADP	O
an	O	DET	O
indicator	O	NOUN	B
of	O	ADP	O
compliance	O	NOUN	B
(	O	PUNCT	O
11.4	O	NUM	O
+/-	O	CCONJ	O
1.1	O	NUM	O
to	O	PART	O
36.8	O	NUM	O
+/-	O	CCONJ	O
2.1	O	NUM	O
microg/ml	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


TZD	B-I	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
decreased	O	VERB	B
mean	B-OUT	ADJ	O
high-sensitivity	I-OUT	ADJ	B
C-reactive	I-OUT	ADJ	I
protein	I-OUT	NOUN	I
to	O	PART	O
43	O	NUM	O
+/-	O	CCONJ	O
19	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Pioglitazone	O	NOUN	B
increased	O	VERB	B
CD34	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
/kinase	I-OUT	NOUN	O
insert	I-OUT	NOUN	O
domain	I-OUT	NOUN	O
receptor	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
EPCs	I-OUT	NOUN	B
to	O	PART	O
142	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
cultured	B-OUT	VERB	B
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	I-OUT	ADJ	O
acetylated	I-OUT	VERB	O
LDL	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
/lectin	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
EPCs	I-OUT	NOUN	B
to	O	PART	O
180	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


EPC	B-OUT	NOUN	B
numbers	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
changed	O	VERB	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


TZD	O	NOUN	B
increased	O	VERB	B
the	O	DET	O
SDF-1-induced	B-OUT	ADJ	B
migratory	I-OUT	NOUN	B
capacity	I-OUT	NOUN	B
to	O	PART	O
146	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
%	O	NOUN	O
per	O	ADP	O
EPC	O	NOUN	B
number	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
upregulated	O	VERB	B
the	O	DET	O
clonogenic	B-OUT	ADJ	B
potential	I-OUT	NOUN	B
of	I-OUT	ADP	O
EPCs	I-OUT	NOUN	B
,	O	PUNCT	O
increasing	O	VERB	B
the	B-OUT	DET	O
colony-forming	I-OUT	ADJ	B
units	I-OUT	NOUN	I
to	O	PART	O
172	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
cultured	O	VERB	B
human	O	ADJ	B
EPCs	O	NOUN	B
,	O	PUNCT	O
TZD	B-I	NOUN	B
increased	O	VERB	B
EPC	B-OUT	NOUN	B
numbers	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
migration	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
reduced	I-OUT	VERB	B
NADPH-oxidase	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
TZD	B-I	NOUN	B
effect	O	NOUN	B
was	O	AUX	O
reversed	O	VERB	O
by	O	ADP	O
the	O	DET	O
PPAR	O	NOUN	B
gamma	O	NOUN	O
antagonist	O	NOUN	B
GW9662	O	NOUN	B
and	O	CCONJ	O
mimicked	O	VERB	B
by	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
adiponectin	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
PPAR	O	NOUN	B
gamma	O	NOUN	O
agonist	O	NOUN	O
pioglitazone	B-I	NOUN	B
increases	O	VERB	B
the	O	DET	O
number	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
function	I-OUT	NOUN	B
of	I-OUT	ADP	O
EPCs	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
represents	O	VERB	O
a	O	DET	O
potential	O	ADJ	O
regenerative	O	ADJ	B
mechanism	O	NOUN	B
in	O	ADP	O
atherosclerosis	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
normoglycemic	B-P	ADJ	B
individuals	I-P	NOUN	B
with	I-P	ADP	O
stable	I-P	ADJ	B
coronary	I-P	ADJ	I
artery	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Long-term	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
Viozan	B-I	NOUN	B
(	I-I	PUNCT	O
sibenadet	I-I	NOUN	B
HCl	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
1-year	O	ADJ	O
study	O	NOUN	O
.	O	PUNCT	O


Viozan	B-I	NOUN	B
(	I-I	PUNCT	O
sibenadet	I-I	NOUN	B
HCl	I-I	NOUN	B
,	I-I	PUNCT	O
AR-C68397AA	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
dual	O	ADJ	B
D2	O	NOUN	I
dopamine	O	NOUN	I
receptor	O	NOUN	I
,	O	PUNCT	O
beta2-adrenoceptor	O	NOUN	B
agonist	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
been	O	AUX	O
investigated	O	VERB	B
for	O	ADP	O
efficacy	O	NOUN	B
in	O	ADP	O
alleviating	O	VERB	O
the	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
obstructive	O	ADJ	I
pulmonary	O	ADJ	I
disease	O	NOUN	I
(	O	PUNCT	O
COPD	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
slowly	O	ADV	O
progressive	O	ADJ	B
nature	O	NOUN	B
of	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
means	O	VERB	O
that	O	SCONJ	O
patients	O	NOUN	B
will	O	AUX	O
require	O	VERB	O
ongoing	O	ADJ	O
therapeutic	O	ADJ	B
management	O	NOUN	I
for	O	ADP	O
many	O	ADJ	O
years	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
even	O	ADV	O
decades	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
such	O	ADJ	O
long-term	O	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
safety	O	NOUN	B
profile	O	NOUN	O
of	O	ADP	O
new	O	ADJ	O
agents	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
of	O	ADP	O
paramount	O	ADJ	O
importance	O	NOUN	O
.	O	PUNCT	O


As	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
large-scale	O	ADJ	B
assessment	O	NOUN	I
of	O	ADP	O
sibenadet	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
12-month	O	ADJ	O
safety	O	NOUN	B
study	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


Following	O	VERB	O
completion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
2-week	O	ADJ	O
baseline	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
435	B-P	NUM	O
adults	I-P	NOUN	B
with	I-P	ADP	O
stable	I-P	ADJ	B
,	I-P	PUNCT	O
symptomatic	I-P	ADJ	B
,	I-P	PUNCT	O
smoking-related	I-P	ADJ	O
COPD	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
500	B-I	NUM	O
microg	I-I	NOUN	B
sibenadet	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
delivered	O	VERB	O
via	O	ADP	O
pressurized	O	ADJ	B
metered	O	ADJ	I
dose	O	NOUN	I
inhaler	O	NOUN	I
(	O	PUNCT	O
pMDI	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
three	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
for	O	ADP	O
52	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Sibenadet	B-I	NOUN	B
therapy	I-I	NOUN	I
was	O	AUX	O
generally	O	ADV	O
well	B-OUT	ADV	O
tolerated	I-OUT	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
only	O	ADV	O
notable	B-OUT	ADJ	O
differences	I-OUT	NOUN	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
tremor	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
taste	I-OUT	NOUN	B
of	I-OUT	ADP	I
treatment	I-OUT	NOUN	B
(	O	PUNCT	O
16.9	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
4.1	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
14.5	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
4.1	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
sibenadet	O	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
groups	O	NOUN	B
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
79	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
serious	I-OUT	ADJ	B
adverse	I-OUT	ADJ	I
events	I-OUT	NOUN	I
(	I-P	PUNCT	O
SAEs	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
43	I-P	NUM	O
(	I-P	PUNCT	O
14.8	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
sibenadet	I-P	NOUN	B
pMDI	I-P	NOUN	B
group	I-P	NOUN	B
and	I-P	CCONJ	O
36	I-P	NUM	O
(	I-P	PUNCT	O
24.8	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
placebo	I-I	ADJ	B
group	I-I	NOUN	B
.	I-I	PUNCT	O


No	O	DET	O
clinically	B-OUT	ADV	B
significant	I-OUT	ADJ	I
abnormal	I-OUT	ADJ	B
laboratory	I-OUT	NOUN	B
values	I-OUT	NOUN	I
or	O	CCONJ	O
overall	B-OUT	ADJ	O
differences	I-OUT	NOUN	O
between	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
were	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	B-OUT	DET	O
clinically	I-OUT	ADV	B
significant	I-OUT	ADJ	I
differences	I-OUT	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
for	O	ADP	O
cardiac	B-OUT	ADJ	B
variables	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
in	I-OUT	ADP	O
vital	I-OUT	ADJ	B
signs	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
secondary	B-OUT	ADJ	B
variables	I-OUT	NOUN	O
showed	O	VERB	O
no	B-OUT	DET	O
notable	I-OUT	ADJ	O
differences	I-OUT	NOUN	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
lung	B-OUT	NOUN	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
exacerbations	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
health-related	I-OUT	ADJ	B
quality	I-OUT	NOUN	I
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Due	O	ADP	O
to	O	ADP	O
the	O	DET	O
effective	O	ADJ	B
beta2-agonist	O	NOUN	B
properties	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sibenadet	O	NOUN	B
group	O	NOUN	B
did	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
report	O	VERB	B
reduced	B-OUT	VERB	O
rescue	I-OUT	NOUN	O
medication	I-OUT	NOUN	B
usage	I-OUT	NOUN	B
at	I-OUT	ADP	O
all	I-OUT	DET	O
timepoints	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
overall	O	ADJ	B
,	O	PUNCT	O
sibenadet	O	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
,	O	PUNCT	O
the	O	DET	O
lack	B-OUT	NOUN	B
of	I-OUT	ADP	O
sustained	I-OUT	ADJ	B
benefit	I-OUT	NOUN	B
reported	O	VERB	O
in	O	ADP	O
large-scale	B-OUT	ADJ	B
clinical	I-OUT	ADJ	I
efficacy	I-OUT	NOUN	I
studies	I-OUT	NOUN	B
means	O	VERB	O
that	O	SCONJ	O
sibenadet	O	NOUN	B
development	O	NOUN	B
will	O	AUX	O
not	O	PART	O
be	O	AUX	O
continued	O	VERB	O
.	O	PUNCT	O


Maternal	B-I	ADJ	B
dietary	I-I	ADJ	B
counseling	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
of	O	ADP	O
life	O	NOUN	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
higher	O	ADV	O
healthy	B-OUT	ADJ	B
eating	I-OUT	NOUN	O
index	I-OUT	NOUN	O
in	O	ADP	O
childhood	B-P	NOUN	B
.	I-P	PUNCT	O


Food	O	NOUN	B
preferences	O	NOUN	I
are	O	AUX	O
established	O	VERB	O
in	O	ADP	O
early	O	ADJ	B
childhood	O	NOUN	I
and	O	CCONJ	O
track	O	NOUN	O
later	O	ADV	O
in	O	ADP	O
life	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
promote	O	VERB	B
healthy	O	ADJ	B
feeding	O	NOUN	B
practices	O	NOUN	I
as	O	ADV	O
early	O	ADV	O
as	O	ADP	O
possible	O	ADJ	O
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
field	O	NOUN	I
trial	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
with	O	ADP	O
500	B-P	NUM	O
mother-child	I-P	ADJ	B
pairs	I-P	NOUN	I
from	I-P	ADP	O
a	I-P	DET	O
low-income	I-P	ADJ	B
area	I-P	NOUN	O
of	I-P	ADP	O
São	I-P	PROPN	B
Leopoldo	I-P	PROPN	I
,	I-P	PUNCT	O
State	I-P	PROPN	B
of	I-P	ADP	O
Rio	I-P	PROPN	B
Grande	I-P	PROPN	I
do	I-P	AUX	O
Sul	I-P	PROPN	B
,	I-P	PUNCT	O
Brazil	I-P	PROPN	B
,	I-P	PUNCT	O
to	I-P	PART	O
evaluate	I-P	VERB	B
the	I-P	DET	O
impact	I-P	NOUN	B
of	I-P	ADP	O
a	I-I	DET	O
nutritional	I-I	ADJ	B
intervention	I-I	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
year	I-P	NOUN	B
of	I-P	ADP	O
life	I-P	NOUN	O
on	I-P	ADP	O
the	I-P	DET	O
dietary	I-P	ADJ	B
quality	I-P	NOUN	I
of	I-P	ADP	O
3-	I-P	NUM	O
to	I-P	PART	O
4-y-old	I-P	NUM	O
children	I-P	NOUN	B
.	O	PUNCT	O


Mother-child	O	ADJ	B
pairs	O	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
either	O	CCONJ	O
to	B-I	PART	O
intervention	I-I	NOUN	B
and	I-I	CCONJ	O
control	I-I	NOUN	B
groups	O	NOUN	I
and	B-I	CCONJ	O
dietary	I-I	ADJ	B
counseling	I-I	NOUN	I
was	O	AUX	O
provided	O	VERB	O
for	O	ADP	O
mothers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
during	O	ADP	O
10	O	NUM	O
home	O	NOUN	B
visits	O	NOUN	I
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	O
of	O	ADP	O
life	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
visits	O	NOUN	B
were	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
by	O	ADP	O
fieldworkers	O	NOUN	B
who	B-I	PRON	O
counseled	I-I	VERB	B
the	O	DET	O
mothers	O	NOUN	B
about	O	ADP	O
the	O	DET	O
Ten	O	NUM	O
Steps	O	NOUN	O
for	O	ADP	O
Healthy	O	PROPN	B
Feeding	O	PROPN	B
from	O	ADP	O
Birth	O	PROPN	B
to	O	ADP	O
Two	O	NUM	O
Years	O	NOUN	B
of	O	ADP	O
Age	O	PROPN	B
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
WHO	O	PRON	B
guidelines	O	NOUN	B
.	B-OUT	PUNCT	O


Dietary	B-OUT	ADJ	B
intake	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
3-4	O	NUM	O
y	O	NOUN	O
of	O	ADP	O
age	O	NOUN	B
for	B-P	ADP	O
345	I-P	NUM	O
children	I-P	NOUN	B
using	O	VERB	O
two	O	NUM	O
24-h	O	ADJ	O
food	O	NOUN	B
recalls	O	VERB	I
.	B-OUT	PUNCT	O


Overall	B-OUT	ADJ	O
diet	I-OUT	ADJ	B
quality	I-OUT	NOUN	I
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
the	O	DET	O
Healthy	O	PROPN	B
Eating	O	PROPN	I
Index	O	PROPN	I
.	O	PUNCT	O


The	B-OUT	DET	O
prevalence	I-OUT	NOUN	B
of	I-OUT	ADP	O
poor	I-OUT	ADJ	B
diet	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
lower	O	ADJ	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
[	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
)	O	PUNCT	O
=	O	ADJ	O
0.30	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
0.13-0.71	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
achieved	O	VERB	O
the	B-OUT	DET	O
75th	I-OUT	ADJ	O
percentile	I-OUT	NOUN	B
for	I-OUT	ADP	O
the	I-OUT	DET	O
vegetable	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fruit	I-OUT	NOUN	B
component	I-OUT	NOUN	O
score	I-OUT	NOUN	O
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
=	O	ADJ	O
1.95	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
1.31-2.89	O	NUM	O
and	O	CCONJ	O
RR	O	NOUN	B
=	O	ADJ	O
1.49	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
1.07-2.07	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Such	O	ADJ	O
data	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
that	B-I	SCONJ	O
dietary	I-I	ADJ	B
counseling	I-I	NOUN	I
for	O	ADP	O
mothers	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
of	O	ADP	O
life	O	NOUN	O
improves	O	VERB	B
the	B-OUT	DET	O
overall	I-OUT	ADJ	B
dietary	I-OUT	ADJ	B
quality	I-OUT	NOUN	I
of	I-P	ADP	O
children	I-P	NOUN	B
in	I-P	ADP	O
a	I-P	DET	O
low-income	I-P	ADJ	B
population	I-P	NOUN	I
.	O	PUNCT	O


Use	O	NOUN	B
of	O	ADP	I
transdermal	B-I	ADJ	B
glyceryl	I-I	NOUN	I
trinitrate	I-I	NOUN	I
to	O	PART	O
reduce	O	VERB	O
failure	B-OUT	NOUN	B
of	I-OUT	ADP	O
intravenous	I-OUT	ADJ	B
infusion	I-OUT	NOUN	I
due	I-P	ADJ	O
to	I-P	PART	O
phlebitis	I-P	NOUN	B
and	I-P	CCONJ	O
extravasation	I-P	NOUN	B
.	I-P	PUNCT	O


Self-adhesive	O	ADJ	B
patches	O	NOUN	I
which	O	DET	O
release	O	VERB	O
glyceryl	B-I	NOUN	B
trinitrate	I-I	NOUN	I
at	O	ADP	O
a	O	DET	O
slow	O	ADJ	B
continuous	O	ADJ	I
rate	O	NOUN	I
or	O	CCONJ	O
placebo	B-I	NOUN	B
patches	I-I	NOUN	I
were	O	AUX	O
applied	O	VERB	O
to	O	ADP	O
the	O	DET	O
skin	B-P	NOUN	B
of	I-P	ADP	O
patients	I-P	NOUN	B
distal	O	ADJ	B
to	O	PART	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
sites	O	NOUN	O
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
infusion	I-OUT	NOUN	B
failure	I-OUT	NOUN	B
was	O	AUX	O
three	O	NUM	O
times	O	NOUN	O
lower	O	ADJ	B
with	O	ADP	O
the	O	DET	O
glyceryl	B-I	NOUN	B
trinitrate	I-I	NOUN	I
than	O	ADP	O
with	O	ADP	O
placebo	B-I	NOUN	B
patches	I-I	NOUN	O
.	I-I	PUNCT	O


The	O	DET	O
decrease	O	NOUN	B
was	O	AUX	O
of	O	ADP	O
similar	O	ADJ	O
magnitude	O	NOUN	B
whether	O	SCONJ	O
failure	O	NOUN	B
was	O	AUX	O
due	O	ADJ	O
to	O	PART	O
extravasation	O	NOUN	B
or	O	CCONJ	O
phlebitis	O	NOUN	B
.	O	PUNCT	O


Headaches	B-OUT	NOUN	B
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
active	I-P	ADJ	B
patches	I-P	NOUN	I
but	O	CCONJ	O
were	O	AUX	O
relieved	O	VERB	O
by	O	ADP	O
simple	O	ADJ	O
analgesics	B-I	NOUN	B
.	I-I	PUNCT	O


Several	O	ADJ	O
indicators	B-OUT	NOUN	B
of	I-OUT	ADP	O
oxidative	I-OUT	ADJ	B
stress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
immunity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
illness	I-OUT	NOUN	B
improved	O	VERB	B
in	O	ADP	O
trained	B-P	VERB	B
men	I-P	NOUN	B
consuming	O	VERB	O
an	O	DET	O
encapsulated	B-I	ADJ	B
juice	I-I	NOUN	B
powder	I-I	NOUN	I
concentrate	I-I	NOUN	B
for	O	ADP	O
28	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Phytonutrients	B-I	NOUN	B
from	I-I	ADP	O
plant	I-I	NOUN	B
foods	I-I	NOUN	I
provide	O	VERB	O
numerous	O	ADJ	O
antioxidants	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
supplementation	O	NOUN	B
for	O	ADP	O
28	O	NUM	O
wk	O	NOUN	O
with	O	ADP	O
a	O	DET	O
commercially	B-I	ADV	O
available	I-I	ADJ	O
encapsulated	I-I	ADJ	B
juice	I-I	NOUN	B
powder	I-I	NOUN	I
concentrate	I-I	NOUN	B
(	I-I	PUNCT	O
JPC	I-I	NOUN	B
)	I-I	PUNCT	O
could	O	AUX	O
influence	O	VERB	B
indicators	B-OUT	NOUN	B
of	I-OUT	ADP	O
oxidative	I-OUT	ADJ	B
stress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
immunity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
illness	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Trained	B-P	VERB	B
men	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
41	I-P	NUM	O
;	I-P	PUNCT	O
34	I-P	NUM	O
+/-	I-P	CCONJ	O
5	I-P	NUM	O
y	I-P	NOUN	O
;	I-P	PUNCT	O
maximum	I-P	ADJ	B
oxygen	I-P	NOUN	B
uptake	I-P	NOUN	I
=	I-P	ADJ	O
55	I-P	NUM	O
+/-	I-P	CCONJ	O
7	I-P	NUM	O
mL	I-P	NOUN	O
x	I-P	NOUN	O
kg	I-P	NOUN	O
(	I-P	PUNCT	O
-1	I-P	NUM	O
)	I-P	PUNCT	O
x	I-P	NOUN	O
min	I-P	NOUN	O
(	I-P	PUNCT	O
-1	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
from	I-P	ADP	O
a	I-P	DET	O
homogenous	I-P	ADJ	B
police	I-P	NOUN	B
Special	I-P	PROPN	B
Forces	I-P	PROPN	I
unit	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
in	O	ADP	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	B
manner	O	NOUN	O
to	O	PART	O
either	O	CCONJ	O
JPC	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
21	O	NUM	O
)	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
multiple	O	ADJ	B
7-d	B-OUT	ADJ	O
food	I-OUT	NOUN	B
records	I-OUT	NOUN	I
to	O	PART	O
assess	O	VERB	B
dietary	O	ADJ	B
intake	O	NOUN	I
and	O	CCONJ	O
found	O	VERB	O
inadequate	B-P	ADJ	B
mean	I-P	NOUN	O
daily	I-P	ADJ	O
fruit	I-P	NOUN	O
and	I-P	CCONJ	O
vegetable	I-P	NOUN	B
consumption	I-P	NOUN	I
(	I-P	PUNCT	O
3.2	I-P	NUM	O
+/-	I-P	CCONJ	O
1.2	I-P	NUM	O
servings	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
group	O	NOUN	B
physician	O	NOUN	I
documented	O	VERB	B
all	O	DET	O
duty	O	NOUN	B
days	O	NOUN	I
lost	O	VERB	B
due	O	ADP	O
to	O	ADP	O
illness	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


We	B-I	PRON	O
collected	I-I	VERB	O
plasma	I-I	NOUN	B
at	I-I	ADP	O
baseline	I-I	NOUN	B
and	I-I	CCONJ	O
study	I-I	NOUN	B
wk	I-I	NOUN	O
4	I-I	NUM	O
,	I-I	PUNCT	O
8	I-I	NUM	O
,	I-I	PUNCT	O
16	I-I	NUM	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
28	I-I	NUM	O
for	I-I	ADP	O
analysis	I-I	NOUN	B
of	I-I	ADP	O
carbonyl	I-OUT	NOUN	B
groups	I-OUT	NOUN	I
on	I-OUT	ADP	O
protein	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
CP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
TNFalpha	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Over	O	ADP	O
the	O	DET	O
28-wk	O	ADJ	O
investigation	O	NOUN	B
,	O	PUNCT	O
CP	B-OUT	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
JPC	B-I	PROPN	B
group	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
both	O	CCONJ	O
a	O	DET	O
treatment	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
time	O	NOUN	O
x	O	NOUN	O
treatment	O	NOUN	B
interaction	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Concentrations	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
CP	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
TNFalpha	I-OUT	NOUN	B
at	O	ADP	O
16	O	NUM	O
and	O	CCONJ	O
28	O	NUM	O
wk	O	NOUN	O
were	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
JPC	B-I	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


TNFalpha	B-OUT	NOUN	B
increased	O	VERB	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
8	O	NUM	O
wk	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
for	O	ADP	O
the	O	DET	O
following	O	VERB	O
20	O	NUM	O
wk	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Over	O	ADP	O
the	O	DET	O
final	O	ADJ	O
20	O	NUM	O
wk	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
have	O	AUX	O
more	O	ADJ	O
days	O	NOUN	B
of	O	ADP	O
illness	B-OUT	NOUN	B
than	O	ADP	O
the	O	DET	O
JPC	B-I	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.068	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
beneficial	O	ADJ	O
JPC	B-I	NOUN	B
effects	O	NOUN	B
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
reduction	O	NOUN	B
of	O	ADP	O
duty	O	NOUN	B
days	O	NOUN	I
lost	O	VERB	B
due	O	ADP	O
to	O	ADP	O
illness	B-OUT	NOUN	B
and	O	CCONJ	O
reduction	O	NOUN	B
of	O	ADP	O
CP	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
TNFalpha	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
in	O	ADP	O
this	O	DET	O
group	B-P	NOUN	B
of	I-P	ADP	O
trained	I-P	VERB	B
men	I-P	NOUN	B
over	I-P	ADP	O
28	I-P	NUM	O
wk	I-P	NOUN	O
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
prophylactic	B-I	ADJ	B
fentanyl	I-I	NOUN	I
on	O	ADP	O
shivering	B-OUT	NOUN	B
in	I-OUT	ADP	O
elective	I-OUT	ADJ	B
caesarean	I-OUT	ADJ	I
section	I-OUT	NOUN	I
under	I-P	ADP	O
epidural	I-P	ADJ	B
analgesia	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
aims	O	NOUN	O
of	O	ADP	O
this	O	DET	O
randomised	O	ADJ	B
double-blind	O	ADJ	I
study	O	NOUN	I
were	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
25	O	NUM	O
micrograms	O	NOUN	O
of	O	ADP	O
fentanyl	B-I	NOUN	B
administered	O	VERB	B
prophylactically	O	ADV	B
by	O	ADP	O
the	O	DET	O
epidural	O	ADJ	B
route	O	NOUN	B
would	O	AUX	O
influence	O	VERB	B
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
shivering	I-OUT	NOUN	B
in	O	ADP	O
parturients	B-P	NOUN	B
who	I-P	PRON	O
underwent	I-P	VERB	O
elective	I-P	ADJ	B
Caesarean	I-P	ADJ	B
section	I-P	NOUN	I
under	I-P	ADP	O
epidural	I-P	ADJ	B
analgesia	I-P	NOUN	I
and	O	CCONJ	O
whether	O	SCONJ	O
it	O	PRON	O
would	O	AUX	O
affect	O	VERB	O
the	O	DET	O
axillary	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
calf	I-OUT	NOUN	B
temperatures	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
50	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
overall	O	ADJ	B
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
shivering	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
who	O	PRON	O
received	O	VERB	O
fentanyl	B-I	NOUN	B
and	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
some	O	DET	O
evidence	O	NOUN	B
to	O	PART	O
suggest	O	VERB	O
that	O	SCONJ	O
low-dose	O	ADJ	B
epidural	O	ADJ	B
fentanyl	O	NOUN	B
might	O	AUX	O
reduce	O	VERB	B
shivering	B-OUT	NOUN	B
by	O	ADP	O
an	O	DET	O
influence	O	NOUN	B
on	O	ADP	O
thermoregulation	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Serum	B-OUT	NOUN	B
C-peptide	I-OUT	NOUN	B
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
on	O	ADP	O
glibenclamide	B-I	NOUN	B
remains	O	VERB	O
higher	O	ADJ	O
than	O	ADP	O
during	O	ADP	O
insulin	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
C-peptide	I-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	O
fasting	O	NOUN	B
and	O	CCONJ	O
6	B-I	NUM	O
minutes	I-I	NOUN	B
after	I-I	ADP	O
glucagon	I-I	NOUN	B
(	I-I	PUNCT	O
1	I-I	NUM	O
mg	I-I	NOUN	O
given	I-I	VERB	O
intravenously	I-I	ADV	B
)	I-I	PUNCT	O
in	O	ADP	O
49	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
non-insulin-dependent	I-P	ADJ	B
diabetes	I-P	NOUN	I
mellitus	I-P	NOUN	I
,	O	PUNCT	O
after	B-I	ADP	O
4	I-I	NUM	O
and	I-I	CCONJ	O
6	I-I	NUM	O
months	I-I	NOUN	B
of	I-I	ADP	O
successive	I-I	ADJ	O
periods	I-I	NOUN	B
of	I-I	ADP	O
treatment	I-I	NOUN	B
with	I-I	ADP	O
insulin	I-I	NOUN	B
and	I-I	CCONJ	O
oral	I-I	ADJ	B
hypoglycaemics	I-I	NOUN	I
(	I-I	PUNCT	O
glibenclamide	I-I	NOUN	B
and	I-I	CCONJ	O
metformin	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
given	O	VERB	O
in	O	ADP	O
random	O	ADJ	B
order	O	NOUN	O
.	O	PUNCT	O


Glycaemic	B-OUT	ADJ	B
control	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
on	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatments	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
C-peptide	B-OUT	NOUN	B
was	O	AUX	O
much	O	ADV	O
higher	O	ADJ	B
while	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
on	O	ADP	O
glibenclamide	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
glibenclamide	B-I	NOUN	B
stimulates	O	VERB	B
pancreatic	O	ADJ	B
insulin	O	NOUN	O
production	O	NOUN	O
even	O	ADV	O
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Therapist	B-P	PROPN	B
Empathy	O	PROPN	I
Scale	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Few	O	ADJ	O
measures	O	NOUN	B
exist	O	VERB	O
to	O	PART	O
examine	O	VERB	O
therapist	B-P	NOUN	B
empathy	O	NOUN	B
as	O	ADP	O
it	O	PRON	O
occurs	O	VERB	O
in	O	ADP	O
session	O	NOUN	B
.	O	PUNCT	O


AIMS	O	PROPN	B
A	O	DET	I
9-item	O	ADJ	O
observer	O	NOUN	O
rating	O	NOUN	O
scale	O	NOUN	O
,	O	PUNCT	O
called	O	VERB	O
the	O	DET	O
Therapist	B-I	PROPN	B
Empathy	I-I	PROPN	I
Scale	I-I	NOUN	I
(	O	PUNCT	O
TES	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
developed	O	VERB	O
based	O	VERB	O
on	O	ADP	O
Watson	O	PROPN	B
's	O	PART	I
(	O	PUNCT	O
1999	O	NUM	O
)	O	PUNCT	O
work	O	NOUN	O
to	O	PART	O
assess	O	VERB	B
affective	O	ADJ	B
,	O	PUNCT	O
cognitive	O	ADJ	B
,	O	PUNCT	O
attitudinal	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
attunement	O	NOUN	B
aspects	O	NOUN	I
of	O	ADP	O
therapist	O	NOUN	B
empathy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
inter-rater	O	ADJ	B
reliability	O	NOUN	I
,	O	PUNCT	O
internal	O	ADJ	B
consistency	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
construct	O	NOUN	B
and	O	CCONJ	O
criterion	O	NOUN	B
validity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
TES	O	NOUN	B
.	O	PUNCT	O


METHOD	O	PROPN	O
Raters	O	NOUN	B
evaluated	O	VERB	B
therapist	B-P	NOUN	B
empathy	O	NOUN	B
in	O	ADP	O
315	B-P	NUM	O
client	I-I	NOUN	B
sessions	I-I	NOUN	B
conducted	I-P	VERB	O
by	I-P	ADP	O
91	I-P	NUM	O
therapists	I-P	NOUN	B
,	I-P	PUNCT	O
using	I-P	VERB	O
data	I-P	NOUN	B
from	I-P	ADP	O
a	I-P	DET	O
multi-site	I-P	ADJ	B
therapist	I-P	NOUN	B
training	I-P	NOUN	O
trial	I-P	NOUN	O
(	I-P	PUNCT	O
Martino	I-P	PROPN	O
et	I-P	X	O
al.	I-P	X	O
,	O	PUNCT	O
2010	B-P	NUM	O
)	I-P	PUNCT	O
in	I-P	ADP	O
Motivational	I-I	PROPN	B
Interviewing	I-I	NOUN	I
(	I-I	PUNCT	O
MI	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


RESULTS	O	VERB	O
Inter-rater	B-OUT	NOUN	B
reliability	I-OUT	NOUN	I
(	O	PUNCT	O
ICC	O	NOUN	B
=	O	ADJ	O
.87	O	X	O
to	O	PART	O
.91	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
internal	B-OUT	ADJ	B
consistency	I-OUT	NOUN	I
(	O	PUNCT	O
Cronbach	O	NOUN	B
's	O	PART	I
alpha	O	NOUN	I
=	O	ADJ	O
.94	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
high	O	ADJ	O
.	O	PUNCT	O


Confirmatory	O	ADJ	B
factor	B-OUT	NOUN	I
analyses	I-OUT	NOUN	I
indicated	O	VERB	O
some	O	DET	O
support	O	NOUN	O
for	O	ADP	O
single-factor	O	ADJ	B
fit	O	NOUN	I
.	O	PUNCT	O


Convergent	B-OUT	ADJ	B
validity	I-OUT	NOUN	I
was	O	AUX	O
supported	O	VERB	O
by	O	ADP	O
correlations	O	NOUN	B
between	O	ADP	O
TES	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
MI	I-OUT	NOUN	B
fundamental	I-OUT	ADJ	B
adherence	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
range	O	NOUN	O
.50	O	X	O
to	O	PART	O
.67	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
competence	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
range	O	NOUN	B
.56	O	NUM	O
to	O	PART	O
.69	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Discriminant	B-OUT	ADJ	B
validity	I-OUT	NOUN	I
was	O	AUX	O
indicated	O	VERB	O
by	O	ADP	O
negative	O	ADJ	B
or	O	CCONJ	O
nonsignificant	O	ADJ	O
correlations	O	NOUN	B
between	O	ADP	O
TES	O	NOUN	B
and	O	CCONJ	O
MI-inconsistent	O	ADJ	B
behavior	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
range	O	NOUN	O
.05	O	NUM	O
to	O	PART	O
-.33	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
TES	O	PROPN	B
demonstrates	O	VERB	O
excellent	O	ADJ	O
inter-rater	O	ADJ	B
reliability	O	NOUN	I
and	O	CCONJ	O
internal	O	ADJ	B
consistency	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
indicate	O	VERB	O
some	O	DET	O
support	O	NOUN	O
for	O	ADP	O
a	O	DET	O
single-factor	O	ADJ	B
solution	O	NOUN	I
and	O	CCONJ	O
convergent	O	ADJ	B
and	O	CCONJ	O
discriminant	O	ADJ	O
validity	O	NOUN	O
.	O	PUNCT	O


Future	O	ADJ	O
studies	O	NOUN	B
should	O	AUX	O
examine	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
TES	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
therapist	B-P	NOUN	B
empathy	O	NOUN	B
in	O	ADP	O
different	O	ADJ	O
psychotherapy	O	NOUN	B
approaches	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
therapist	O	NOUN	B
empathy	O	NOUN	B
on	O	ADP	O
client	O	NOUN	B
outcome	O	NOUN	B
.	O	PUNCT	O


Conduit	O	NOUN	B
artery	O	NOUN	I
structure	O	NOUN	O
and	O	CCONJ	O
function	O	NOUN	B
in	O	ADP	O
lowlanders	B-P	NOUN	B
and	I-P	CCONJ	O
native	I-P	ADJ	B
highlanders	I-P	NOUN	B
:	I-P	PUNCT	O
relationships	O	NOUN	B
with	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
and	O	CCONJ	O
role	O	NOUN	O
of	O	ADP	O
sympathoexcitation	O	NOUN	B
.	O	PUNCT	O


Research	O	NOUN	B
detailing	O	VERB	O
the	O	DET	O
normal	O	ADJ	O
vascular	O	ADJ	B
adaptions	O	NOUN	B
to	O	PART	O
high	O	ADJ	B
altitude	O	NOUN	I
is	O	AUX	O
minimal	O	ADJ	B
and	O	CCONJ	O
often	O	ADV	O
confounded	O	VERB	O
by	O	ADP	O
pathology	O	NOUN	B
(	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
chronic	O	ADJ	B
mountain	O	NOUN	I
sickness	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
methodological	O	ADJ	B
issues	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
vascular	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
structure	O	NOUN	B
in	O	ADP	O
:	O	PUNCT	O
(	B-P	PUNCT	O
1	I-P	X	O
)	I-P	PUNCT	O
healthy	I-P	ADJ	B
lowlanders	I-P	NOUN	B
during	I-P	ADP	O
acute	I-P	ADJ	B
hypoxia	I-P	NOUN	B
and	I-P	CCONJ	O
prolonged	I-P	ADJ	B
(	I-P	PUNCT	O
∼2	I-P	ADJ	O
weeks	I-I	NOUN	B
)	I-I	PUNCT	O
exposure	I-I	NOUN	B
to	I-I	PART	I
high	I-I	ADJ	B
altitude	I-I	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
(	I-P	PUNCT	O
2	I-P	X	O
)	I-P	PUNCT	O
high-altitude	I-P	ADJ	B
natives	I-P	NOUN	I
at	I-P	ADP	O
5050	I-P	NUM	O
m	I-P	NOUN	O
(	I-P	PUNCT	O
highlanders	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


In	B-P	ADP	O
12	I-P	NUM	O
healthy	I-P	ADJ	B
lowlanders	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
32	I-P	NUM	O
±	I-P	NOUN	O
7	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
12	I-P	NUM	O
highlanders	I-P	NOUN	B
(	I-P	PUNCT	O
Sherpa	I-P	PROPN	B
;	I-P	PUNCT	O
33	I-P	NUM	O
±	I-P	NOUN	O
14	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
we	I-P	PRON	O
assessed	I-OUT	VERB	B
brachial	I-OUT	ADJ	B
endothelium-dependent	I-OUT	ADJ	I
flow-mediated	I-OUT	ADJ	I
dilatation	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
FMD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
endothelium-independent	I-OUT	ADJ	B
dilatation	I-OUT	NOUN	I
(	I-I	PUNCT	O
via	I-I	ADP	O
glyceryl	I-I	NOUN	B
trinitrate	I-I	NOUN	I
;	I-I	PUNCT	O
GTN	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
common	I-OUT	ADJ	O
carotid	I-OUT	NOUN	B
intima-media	I-OUT	NOUN	I
thickness	I-OUT	NOUN	I
(	I-P	PUNCT	O
CIMT	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
diameter	I-P	NOUN	B
(	I-P	PUNCT	O
ultrasound	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-OUT	CCONJ	O
arterial	I-OUT	ADJ	B
stiffness	I-OUT	NOUN	I
via	I-OUT	ADP	O
pulse	I-OUT	NOUN	B
wave	I-OUT	NOUN	I
velocity	I-OUT	NOUN	I
(	I-I	PUNCT	O
PWV	I-I	NOUN	B
;	I-I	PUNCT	O
applanation	I-I	NOUN	B
tonometry	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


Cephalic	O	ADJ	B
venous	O	ADJ	B
biomarkers	O	NOUN	I
of	O	ADP	O
free	O	ADJ	B
radical-mediated	O	ADJ	O
lipid	O	NOUN	O
peroxidation	O	NOUN	O
(	O	PUNCT	O
lipid	O	NOUN	B
hydroperoxides	O	NOUN	I
,	O	PUNCT	O
LOOH	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
nitrite	O	NOUN	B
(	O	PUNCT	O
NO2-	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
lipid	O	NOUN	B
soluble	O	ADJ	O
antioxidants	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
obtained	O	VERB	O
at	O	ADP	O
rest	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
lowlanders	O	NOUN	B
,	O	PUNCT	O
measurements	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
sea	O	NOUN	B
level	O	NOUN	B
(	O	PUNCT	O
334	O	NUM	O
m	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
between	O	ADP	O
days	O	NOUN	B
3-4	O	NUM	O
(	O	PUNCT	O
acute	O	ADJ	B
high	O	ADJ	I
altitude	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
12-14	O	NUM	O
(	O	PUNCT	O
chronic	O	ADJ	B
high	O	ADJ	I
altitude	O	NOUN	I
)	O	PUNCT	O
following	O	VERB	O
arrival	O	NOUN	B
to	O	ADP	O
5050	O	NUM	O
m.	O	NOUN	B
Highlanders	O	PROPN	I
were	O	AUX	O
assessed	O	VERB	B
once	O	ADV	O
at	O	ADP	O
5050	O	NUM	O
m.	O	NOUN	O
Compared	O	VERB	B
with	O	ADP	O
sea	O	NOUN	B
level	O	NOUN	B
,	O	PUNCT	O
acute	O	ADJ	B
high	O	ADJ	I
altitude	O	NOUN	I
reduced	B-OUT	VERB	O
lowlanders	I-OUT	NOUN	B
'	I-OUT	PART	O
FMD	O	NOUN	B
(	O	PUNCT	O
7.9	O	NUM	O
±	O	NOUN	O
0.4	O	NUM	O
vs.	O	CCONJ	O
6.8	O	NUM	O
±	O	NOUN	O
0.4	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.004	B-OUT	NUM	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
GTN-induced	I-OUT	ADJ	B
dilatation	I-OUT	NOUN	O
(	O	PUNCT	O
16.6	O	NUM	O
±	O	NOUN	O
0.9	O	NUM	O
vs.	O	CCONJ	O
14.5	O	NUM	O
±	O	NOUN	O
0.8	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.006	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-OUT	CCONJ	O
raised	I-OUT	VERB	B
central	I-OUT	ADJ	I
PWV	O	NOUN	O
(	O	PUNCT	O
6.0	O	NUM	O
±	O	NOUN	O
0.2	O	NUM	O
vs.	O	CCONJ	O
6.6	O	NUM	O
±	O	NOUN	O
0.3	O	NUM	O
m	O	NOUN	O
s	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
persisted	O	VERB	O
at	O	ADP	O
days	O	NOUN	B
12-14	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
allometrically	O	ADV	B
scaling	O	VERB	O
FMD	O	NOUN	B
to	O	PART	O
adjust	O	VERB	O
for	O	ADP	O
altered	O	ADJ	O
baseline	O	NOUN	B
diameter	O	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	O
to	O	ADP	O
lowlanders	O	NOUN	B
at	O	ADP	O
sea	O	NOUN	B
level	O	NOUN	B
and	O	CCONJ	O
high	O	ADJ	B
altitude	O	NOUN	I
,	O	PUNCT	O
highlanders	O	NOUN	B
had	B-OUT	AUX	O
a	I-OUT	DET	O
lower	I-OUT	ADJ	O
carotid	I-OUT	NOUN	B
wall	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
lumen	I-OUT	NOUN	B
ratio	O	NOUN	B
(	O	PUNCT	O
∼19	O	ADJ	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
≤	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
attributable	O	ADJ	O
to	O	PART	O
a	O	DET	O
narrower	O	ADJ	O
CIMT	O	NOUN	B
and	O	CCONJ	O
wider	O	ADJ	O
lumen	O	NOUN	B
.	O	PUNCT	O


Although	B-OUT	SCONJ	O
both	I-OUT	CCONJ	O
LOOH	O	NOUN	B
and	O	CCONJ	O
NO2-	O	NOUN	B
increased	O	VERB	B
with	O	ADP	O
high	O	ADJ	B
altitude	O	NOUN	B
in	O	ADP	O
lowlanders	B-OUT	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
LOOH	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
the	B-OUT	DET	O
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
GTN-induced	I-OUT	ADJ	B
dilatation	O	NOUN	B
evident	O	ADJ	O
during	O	ADP	O
acute	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
,	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-0.53	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
chronic	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
,	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-0.69	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
≤	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
exposure	O	NOUN	B
to	O	PART	I
5050	O	NUM	O
m.	O	NOUN	O
In	B-I	ADP	O
a	I-I	DET	O
follow-up	I-I	NOUN	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
experiment	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
healthy	O	ADJ	B
lowlanders	B-I	NOUN	B
)	I-I	PUNCT	O
conducted	I-I	VERB	O
in	I-I	ADP	O
a	I-I	DET	O
normobaric	I-I	ADJ	B
hypoxic	O	ADJ	I
chamber	O	NOUN	I
(	O	PUNCT	O
inspired	O	VERB	O
O2	O	NOUN	O
fraction	O	NOUN	O
(	O	PUNCT	O
F	O	NOUN	B
IO	O	NOUN	I
2	O	NUM	I
)	O	PUNCT	O
=	O	ADJ	O
0.11	O	NUM	O
;	O	PUNCT	O
6	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
sustained	B-OUT	ADJ	O
reduction	I-OUT	NOUN	B
in	O	ADP	O
FMD	O	NOUN	B
was	O	AUX	O
evident	O	ADJ	O
within	O	ADP	O
1	O	NUM	O
h	O	NOUN	O
of	O	ADP	O
hypoxic	O	ADJ	B
exposure	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
normoxic	O	ADJ	B
baseline	O	NOUN	B
(	O	PUNCT	O
5.7	O	NUM	O
±	O	NOUN	O
1.6	O	NUM	O
vs.	O	CCONJ	O
8.0	O	NUM	O
±1.3	O	NOUN	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	B-OUT	NUM	O
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
this	I-OUT	DET	O
decline	O	NOUN	B
in	O	ADP	O
FMD	O	NOUN	B
was	O	AUX	O
largely	O	ADV	O
reversed	O	VERB	O
following	O	VERB	O
α1-adrenoreceptor	O	NOUN	B
blockade	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
high-altitude	O	ADJ	B
exposure	O	NOUN	B
in	B-OUT	ADP	O
lowlanders	I-OUT	NOUN	B
caused	I-OUT	VERB	O
persistent	I-OUT	ADJ	B
impairment	I-OUT	NOUN	I
in	I-OUT	ADP	O
vascular	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
mediated	O	VERB	O
partially	O	ADV	O
via	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
and	O	CCONJ	O
sympathoexcitation	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
a	O	DET	O
lifetime	O	NOUN	B
of	O	ADP	O
high-altitude	O	ADJ	B
exposure	O	NOUN	B
neither	O	CCONJ	O
intensifies	O	VERB	O
nor	O	CCONJ	O
attenuates	O	VERB	B
the	O	DET	O
impairments	O	NOUN	B
seen	O	VERB	O
with	O	ADP	O
short-term	B-I	ADJ	B
exposure	I-I	NOUN	B
,	I-I	PUNCT	O
chronic	I-I	ADJ	B
high-altitude	O	ADJ	I
exposure	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
arterial	O	ADJ	B
remodelling	O	NOUN	I
.	O	PUNCT	O


Prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
diclofenac	B-I	NOUN	B
and	O	CCONJ	O
ketorolac	O	NOUN	B
after	O	ADP	O
refractive	B-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
diclofenac	B-I	NOUN	B
and	I-I	CCONJ	O
ketorolac	I-I	NOUN	B
in	O	ADP	O
relieving	B-OUT	VERB	O
corneal	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
after	I-P	ADP	O
refractive	I-P	ADJ	B
surgery	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
determine	O	VERB	O
if	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
stinging	O	NOUN	B
on	O	ADP	O
instillation	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Thirty	B-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
prospectively	O	ADV	O
to	O	PART	O
postoperative	B-I	ADJ	B
diclofenac	I-I	NOUN	B
in	I-I	ADP	O
one	I-I	NUM	O
eye	I-I	NOUN	B
and	I-I	CCONJ	O
ketorolac	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
other	I-I	ADJ	O
.	I-I	PUNCT	O


Patients	O	NOUN	B
and	O	CCONJ	O
surgeon	O	NOUN	B
did	O	AUX	O
not	O	PART	O
know	O	VERB	O
which	O	DET	O
medications	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Ocular	B-OUT	ADJ	B
postoperative	I-OUT	ADJ	O
pain	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
discomfort	I-OUT	NOUN	B
on	I-OUT	ADP	O
instillation	I-OUT	NOUN	B
of	I-OUT	ADP	O
medication	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	O
after	O	ADP	O
radial	O	ADJ	B
keratotomy	O	NOUN	I
with	O	ADP	O
a	O	DET	O
visual	B-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
questionnaire	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
Both	O	DET	O
medications	O	NOUN	B
were	O	AUX	O
highly	O	ADV	O
effective	B-OUT	ADJ	B
in	I-OUT	ADP	O
relieving	I-OUT	VERB	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
stinging	B-OUT	NOUN	B
on	I-OUT	ADP	O
instillation	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.29	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistical	O	ADJ	B
difference	O	NOUN	I
in	O	ADP	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
medications	O	NOUN	B
on	O	ADP	O
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
in	O	ADP	O
stinging	B-OUT	NOUN	B
on	I-OUT	ADP	O
instillation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Nurse-led	O	VERB	B
cardiac	O	ADJ	I
clinics	O	NOUN	I
for	O	ADP	O
adults	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
information	O	NOUN	B
on	O	ADP	O
best	O	ADJ	O
practice	O	NOUN	B
is	O	AUX	O
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
systematic	B-I	ADJ	B
review	I-I	NOUN	I
of	I-I	ADP	O
research	I-I	NOUN	B
,	O	PUNCT	O
published	O	VERB	B
by	O	ADP	O
Blackwell	O	PROPN	B
Publishing	O	PROPN	I
Asia	O	PROPN	I
and	O	CCONJ	O
conducted	O	VERB	O
by	O	ADP	O
the	O	DET	O
Centre	O	PROPN	B
for	O	ADP	I
Evidence-based	O	ADJ	I
Nursing	O	PROPN	I
South	O	PROPN	I
Australia	O	PROPN	I
,	O	PUNCT	O
a	O	DET	O
collaborating	O	VERB	O
centre	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Joanna	O	PROPN	B
Briggs	O	PROPN	I
Institute	O	PROPN	I
(	O	PUNCT	O
JBI	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
references	O	NOUN	I
on	O	ADP	O
which	O	DET	O
this	O	DET	O
information	O	NOUN	B
is	O	AUX	O
based	O	VERB	O
are	O	AUX	O
provided	O	VERB	O
in	O	ADP	O
the	O	DET	O
systematic	O	ADJ	B
review	O	NOUN	I
report	O	NOUN	O
available	O	ADJ	O
online	O	ADV	O
via	O	ADP	O
Blackwell	O	PROPN	B
Synergy	O	PROPN	I
www.blackwell-synergy.com	O	NOUN	I
and	O	CCONJ	O
to	O	ADP	O
members	O	NOUN	B
of	O	ADP	O
the	O	DET	O
institute	O	NOUN	B
via	O	ADP	O
the	O	DET	O
web	O	NOUN	B
site	O	NOUN	I
:	O	PUNCT	O
www.joannabriggs.edu.au	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
information	O	NOUN	B
sheet	O	NOUN	I
covers	O	VERB	O
the	O	DET	O
following	O	NOUN	O
:	O	PUNCT	O
Nurse-led	O	VERB	B
education	O	NOUN	I
and	O	CCONJ	O
self-help	O	NOUN	B
.	O	PUNCT	O


Education	O	PROPN	B
and	O	CCONJ	O
motivational	O	ADJ	B
interview	O	NOUN	I
.	O	PUNCT	O


Audit	O	ADJ	B
and	O	CCONJ	O
recall	O	VERB	B
.	O	PUNCT	O


Secondary	O	ADJ	B
prevention	O	NOUN	I
.	O	PUNCT	O


Mediastinal	O	ADJ	B
lymphadenectomy	B-I	NOUN	I
in	O	ADP	O
non-small	B-P	ADJ	B
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
effectiveness	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
or	I-P	CCONJ	O
without	I-P	ADP	O
nodal	I-P	ADJ	B
micrometastases	I-P	NOUN	B
-	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
preliminary	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
So	O	ADV	O
far	O	ADV	O
it	O	PRON	O
has	O	AUX	O
not	O	PART	O
clearly	O	ADV	O
been	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
systematic	O	ADJ	B
mediastinal	O	ADJ	I
lymphadenectomy	B-I	NOUN	I
improves	O	VERB	B
survival	B-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
non-small	I-P	ADJ	B
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


One	O	NUM	O
explanation	O	NOUN	B
might	O	AUX	O
be	O	AUX	O
that	O	SCONJ	O
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
an	O	DET	O
early	O	ADJ	O
spread	O	NOUN	B
of	O	ADP	O
tumor	O	NOUN	B
cells	O	NOUN	I
has	O	AUX	O
occurred	O	VERB	O
which	O	DET	O
might	O	AUX	O
not	O	PART	O
be	O	AUX	O
curable	O	ADJ	B
by	O	ADP	O
surgical	O	ADJ	B
means	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
lymph	O	NOUN	B
nodes	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
which	O	DET	O
were	O	AUX	O
treated	O	VERB	B
either	O	CCONJ	O
by	O	ADP	O
lymph	B-I	NOUN	B
node	I-I	NOUN	I
sampling	I-I	NOUN	I
or	O	CCONJ	O
systematic	B-I	ADJ	B
lymphadenectomy	I-I	NOUN	I
were	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
micrometastatic	O	ADJ	B
spread	O	NOUN	I
of	O	ADP	O
tumor	O	NOUN	B
cells	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
nodal	O	ADJ	B
micrometastases	O	NOUN	I
on	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
lymphadenectomy	B-I	NOUN	B
was	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Lymph	B-P	NOUN	B
nodes	I-P	NOUN	I
from	I-P	ADP	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
n=94	I-P	NOUN	O
)	I-P	PUNCT	O
which	O	DET	O
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
lymph	B-I	NOUN	B
node	I-I	NOUN	I
sampling	I-I	NOUN	I
(	I-I	PUNCT	O
LS	I-I	NOUN	B
,	O	PUNCT	O
n=41	O	ADJ	O
)	O	PUNCT	O
versus	O	CCONJ	O
radical	B-I	ADJ	B
systematic	I-I	ADJ	I
lymphadenectomy	I-I	NOUN	I
(	I-I	PUNCT	O
LA	I-I	PROPN	B
,	O	PUNCT	O
n=53	O	ADJ	O
)	O	PUNCT	O
were	O	AUX	O
screened	O	VERB	B
by	O	ADP	O
immunohistochemistry	O	NOUN	B
for	O	ADP	O
disseminated	O	ADJ	B
tumor	O	NOUN	B
cells	O	NOUN	I
using	O	VERB	O
the	O	DET	O
antibody	O	NOUN	B
Ber-Ep4	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
observation	I-OUT	NOUN	O
time	I-OUT	NOUN	O
was	O	AUX	O
longer	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
follow-up	O	ADJ	B
data	O	NOUN	B
were	O	AUX	O
available	O	ADJ	O
from	O	ADP	O
all	O	DET	O
94	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Kaplan-Meier	B-OUT	ADJ	B
curves	I-OUT	NOUN	I
were	O	AUX	O
calculated	O	VERB	B
and	O	CCONJ	O
tested	O	VERB	B
for	O	ADP	O
statistical	O	ADJ	B
significance	O	NOUN	I
using	O	VERB	O
the	O	DET	O
log-rank	O	ADJ	B
test	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
Standard	O	ADJ	O
histopathological	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
no	B-OUT	DET	O
lymph	I-OUT	NOUN	B
node	I-OUT	NOUN	I
involvement	I-OUT	NOUN	B
(	O	PUNCT	O
pN0	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
61	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
pN1	O	NOUN	B
disease	O	NOUN	I
in	O	ADP	O
13	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
pN2	O	NOUN	B
disease	O	NOUN	I
in	O	ADP	O
20	O	NUM	O
patients	O	NOUN	B
without	O	ADP	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
LA	O	NOUN	B
and	O	CCONJ	O
LS	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
T-stage	O	NOUN	B
,	O	PUNCT	O
N-stage	O	NOUN	B
or	O	CCONJ	O
age	O	NOUN	B
and	O	CCONJ	O
sex	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
immunohistochemistry	O	NOUN	B
a	O	DET	O
minimal	O	ADJ	B
nodal	B-OUT	ADJ	B
spread	I-OUT	NOUN	B
of	I-OUT	ADP	O
tumor	I-OUT	NOUN	B
cells	I-OUT	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
21	O	NUM	O
out	O	ADP	O
of	O	ADP	O
94	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
LS	O	NOUN	B
,	O	PUNCT	O
n=10	O	NOUN	O
(	O	PUNCT	O
24	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
LA	O	PROPN	B
,	O	PUNCT	O
n=11	O	ADJ	O
(	O	PUNCT	O
21	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Similar	O	ADJ	O
to	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
also	O	ADV	O
in	O	ADP	O
the	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
nodal	O	ADJ	B
micrometastases	O	NOUN	I
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
lymphadenectomy	O	NOUN	B
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
influence	O	VERB	B
the	O	DET	O
long-term	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
(	O	PUNCT	O
P=0.27	O	NOUN	O
and	O	CCONJ	O
P=0.39	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
negative	O	ADJ	B
immunohistochemical	O	ADJ	B
analysis	O	NOUN	I
systematic	O	ADJ	B
lymphadenectomy	B-I	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
improved	B-OUT	ADJ	B
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
P=0.044	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Our	O	PRON	O
data	O	NOUN	B
provide	O	VERB	O
some	O	DET	O
evidence	O	NOUN	B
that	O	SCONJ	O
systematic	B-I	ADJ	B
lymphadenectomy	I-I	NOUN	I
improves	O	VERB	B
survival	B-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
without	I-P	ADP	O
an	I-P	DET	O
early	I-P	ADJ	B
locoregional	I-OUT	ADJ	B
spread	I-OUT	NOUN	B
of	I-OUT	ADP	O
cancer	I-OUT	NOUN	B
cells	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


As	O	ADV	O
long	O	ADV	O
as	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
can	O	AUX	O
not	O	PART	O
be	O	AUX	O
identified	O	VERB	B
preoperatively	O	ADV	B
all	O	DET	O
patients	O	NOUN	B
should	O	AUX	O
undergo	O	VERB	O
a	O	DET	O
systematic	O	ADJ	B
mediastinal	O	ADJ	I
lymphadenectomy	B-I	NOUN	I
.	I-I	PUNCT	O


Safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
pharmacokinetics	I-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
glycoPEGylated	B-I	ADJ	B
recombinant	I-I	ADJ	I
activated	I-I	VERB	I
factor	I-I	NOUN	I
VII	I-I	NOUN	I
derivative	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
first	O	ADJ	O
human	O	ADJ	B
dose	O	NOUN	O
trial	O	NOUN	O
in	B-P	ADP	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Extensive	O	ADJ	O
research	O	NOUN	B
is	O	AUX	O
currently	O	ADV	O
ongoing	O	ADJ	O
to	O	PART	O
prolong	O	VERB	O
the	O	DET	O
half-life	O	NOUN	B
of	O	ADP	O
coagulation	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
these	O	DET	O
techniques	O	NOUN	B
is	B-I	AUX	O
glycoPEGylation	I-I	NOUN	B
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
applied	O	VERB	O
to	O	PART	O
recombinant	O	ADJ	B
activated	O	VERB	I
factor	O	NOUN	I
VII	O	NOUN	I
(	O	PUNCT	O
rFVIIa	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	B-I	DET	O
rFVIIa	I-I	NOUN	B
derivative	I-I	NOUN	B
(	I-I	PUNCT	O
N7-GP	I-I	NOUN	B
)	I-I	PUNCT	O
with	O	ADP	O
a	O	DET	O
prolonged	O	ADJ	B
terminal	O	ADJ	O
half-life	O	NOUN	O
(	O	PUNCT	O
t	O	NOUN	O
(	O	PUNCT	O
1/2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
clinical	O	ADJ	B
purpose	O	NOUN	O
of	B-I	ADP	O
N7-GP	I-I	NOUN	B
is	O	AUX	O
to	O	PART	O
provide	O	VERB	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
prophylaxis	O	NOUN	B
to	B-P	PART	O
patients	I-P	NOUN	B
with	I-P	ADP	O
hemophilia	I-P	NOUN	B
and	I-P	CCONJ	O
inhibitors	I-P	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prolonged	O	ADJ	B
t	O	NOUN	O
(	O	PUNCT	O
1/2	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
N7-GP	O	NOUN	B
can	O	AUX	O
potentially	O	ADV	O
reduce	O	VERB	O
the	O	DET	O
dosing	O	ADJ	B
frequency	O	NOUN	B
and	O	CCONJ	O
thereby	O	ADV	O
facilitate	O	VERB	O
convenience	O	NOUN	B
and	O	CCONJ	O
compliance	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
two	O	NUM	O
significant	O	ADJ	B
barriers	O	NOUN	B
to	O	PART	O
effective	O	ADJ	B
prophylaxis	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	B-OUT	DET	O
safety	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pharmacokinetics	I-OUT	NOUN	B
of	O	ADP	O
single	O	ADJ	B
doses	O	NOUN	I
of	B-P	ADP	O
N7-GP	I-P	NOUN	B
in	I-P	ADP	O
healthy	I-P	ADJ	B
men	I-P	NOUN	B
.	O	PUNCT	O


METHODS	B-P	VERB	O
A	I-P	DET	O
randomized	I-P	ADJ	B
,	I-P	PUNCT	O
placebo-controlled	I-P	ADJ	B
,	I-P	PUNCT	O
dose-escalation	I-P	ADJ	B
trial	I-P	NOUN	I
with	I-P	ADP	O
five	I-P	NUM	O
cohorts	I-P	NOUN	B
(	I-P	PUNCT	O
N7-GP	I-P	ADJ	B
dose	I-P	NOUN	B
of	I-P	ADP	O
12.5-100	I-P	NUM	B
μg	I-P	NOUN	O
kg	I-P	NOUN	O
(	I-P	PUNCT	O
-1	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
was	I-P	AUX	O
performed	I-P	VERB	O
.	I-P	PUNCT	O


In	B-P	ADP	O
each	I-P	DET	O
cohort	I-P	NOUN	B
,	I-P	PUNCT	O
eight	I-P	NUM	O
subjects	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
receive	O	VERB	O
N7-GP	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
)	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	B-OUT	DET	O
mean	I-OUT	ADJ	O
FVIIa	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
was	O	AUX	O
measurable	O	ADJ	O
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
at	O	ADV	O
least	O	ADJ	O
72	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
dosing	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
overall	O	ADJ	O
mean	O	ADJ	O
t	O	NOUN	O
(	O	PUNCT	O
1/2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
FVIIa	O	NOUN	B
activity	O	NOUN	B
was	O	AUX	O
15	O	NUM	O
h.	O	NOUN	O
The	B-OUT	DET	O
pharmacokinetics	I-OUT	NOUN	B
of	I-OUT	ADP	O
N7-GP	I-OUT	NOUN	B
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
dose-proportional	O	ADJ	B
in	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
range	O	NOUN	O
investigated	B-OUT	VERB	B
.	I-OUT	PUNCT	O


No	B-OUT	DET	O
serious	I-OUT	ADJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
including	I-OUT	VERB	O
thromboembolic	I-OUT	ADJ	B
events	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
were	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


The	B-OUT	DET	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
placebo	O	NOUN	B
and	O	CCONJ	O
N7-GP	O	ADJ	B
groups	O	NOUN	B
.	O	PUNCT	O


No	B-OUT	DET	O
neutralizing	I-OUT	VERB	O
antibodies	I-OUT	NOUN	O
against	I-OUT	ADP	O
N7-GP	I-OUT	NOUN	B
were	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


A	B-OUT	DET	O
pharmacologic	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
was	O	AUX	O
apparent	O	ADJ	B
from	O	ADP	O
a	O	DET	O
dose-dependent	O	ADJ	B
statistically	O	ADV	B
significant	O	ADJ	I
decrease	O	NOUN	B
in	O	ADP	O
the	B-OUT	DET	O
mean	I-OUT	ADJ	B
prothrombin	I-OUT	NOUN	I
time	I-OUT	NOUN	I
in	O	ADP	O
all	O	DET	O
N7-GP	O	ADJ	B
groups	O	NOUN	B
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
N7-GP	O	NOUN	B
had	O	AUX	O
a	O	DET	O
plasma	O	NOUN	B
half-life	O	NOUN	B
of	O	ADP	O
15	O	NUM	O
h	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
profile	O	NOUN	B
that	O	PRON	O
makes	O	VERB	O
it	O	PRON	O
a	O	DET	O
potential	O	ADJ	O
candidate	O	NOUN	O
for	O	ADP	O
prophylaxis	O	NOUN	B
in	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
hemophilia	I-P	NOUN	B
and	I-P	CCONJ	O
inhibitors	I-P	NOUN	B
.	O	PUNCT	O


[	B-I	PUNCT	O
Radiotherapy	I-I	NOUN	B
for	O	ADP	O
choroidal	O	ADJ	B
neovascularization	O	NOUN	I
in	O	ADP	O
age-related	O	ADJ	B
macular	O	NOUN	I
degeneration	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
using	O	VERB	O
low-	B-I	ADJ	O
versus	I-I	CCONJ	O
high-dose	I-I	ADJ	B
photon	I-I	ADJ	O
bean	I-I	NOUN	O
radiation	I-I	NOUN	B
]	I-I	PUNCT	O
.	O	PUNCT	O


PURPOSE	O	VERB	O
Several	O	ADJ	O
pilot	O	NOUN	B
studies	O	NOUN	I
have	O	AUX	O
indicated	O	VERB	O
that	O	SCONJ	O
low-dose	B-I	ADJ	B
radiation	I-I	NOUN	B
therapy	I-I	NOUN	I
might	O	AUX	O
have	O	AUX	O
a	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
choroidal	O	ADJ	B
neovascularization	O	NOUN	I
(	O	PUNCT	O
CNV	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
age-related	B-P	ADJ	B
macular	I-P	NOUN	I
degeneration	I-P	NOUN	I
(	I-P	PUNCT	O
AMD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
ascertain	O	VERB	O
whether	O	SCONJ	O
such	O	ADJ	O
treatment	O	NOUN	B
might	O	AUX	O
halt	O	VERB	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
neovascular	O	ADJ	B
AMD	O	NOUN	B
and	O	CCONJ	O
whether	O	SCONJ	O
a	O	DET	O
low	O	ADJ	B
or	O	CCONJ	O
a	O	DET	O
high	O	ADJ	B
radiation	O	NOUN	B
dose	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
applied	O	VERB	O
.	O	PUNCT	O


PATIENTS	O	VERB	O
The	O	DET	O
patients	B-P	NOUN	B
comprised	I-P	VERB	O
some	I-P	DET	O
randomized	I-P	ADJ	B
to	I-P	PART	O
0	I-I	NUM	O
vs	I-I	CCONJ	O
10	I-I	NUM	O
vs	I-I	CCONJ	O
36	I-I	NUM	O
Gy	I-I	NOUN	O
of	I-I	ADP	O
radiation	I-I	NOUN	B
and	I-P	CCONJ	O
(	I-P	PUNCT	O
after	I-P	ADP	O
a	I-P	DET	O
change	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
protocol	I-P	NOUN	I
became	I-P	VERB	O
necessary	I-P	ADJ	O
)	I-P	PUNCT	O
others	I-P	NOUN	O
who	I-P	PRON	O
participated	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
prospective	I-P	ADJ	B
,	I-P	PUNCT	O
controlled	I-P	VERB	B
non-randomized	I-P	ADJ	B
pilot	I-P	NOUN	O
study	I-P	NOUN	O
.	I-P	PUNCT	O


Enclosed	O	PROPN	O
were	O	AUX	O
eyes	B-P	NOUN	B
with	I-P	ADP	O
visual	I-P	ADJ	B
acuity	I-P	NOUN	I
of	I-P	ADP	O
>	I-P	X	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
0.1	I-P	NUM	O
and	I-P	CCONJ	O
<	I-P	X	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
0.6	I-P	NUM	O
revealing	I-P	VERB	O
a	I-P	DET	O
juxta-subfoveal	I-P	ADJ	B
CNV	I-P	NOUN	I
either	I-P	DET	O
of	I-P	ADP	O
the	I-P	DET	O
occult	I-P	NOUN	B
type	I-P	NOUN	O
(	I-P	PUNCT	O
type	I-P	NOUN	O
1	I-P	NUM	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
the	I-P	DET	O
classic	I-P	ADJ	B
type	I-P	NOUN	O
(	I-P	PUNCT	O
isolated	I-P	VERB	B
or	I-P	CCONJ	O
as	I-P	ADP	O
part	I-P	NOUN	O
of	I-P	ADP	O
a	I-P	DET	O
predominantly	I-P	ADV	O
occult	I-P	ADJ	B
lesion	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


RESULTS	O	VERB	O
Eyes	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
10	B-I	NUM	O
Gy	I-I	NOUN	O
for	O	ADP	O
occult	O	ADJ	B
CNV	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
subject	O	ADJ	O
to	O	ADP	O
severe	B-OUT	ADJ	B
visual	I-OUT	ADJ	B
loss	I-OUT	NOUN	I
in	O	ADP	O
41.6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
38.5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
13	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
eyes	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
10	B-I	NUM	O
Gy	I-I	NOUN	O
because	O	SCONJ	O
of	O	ADP	O
classic	O	ADJ	B
CNV	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
corresponding	O	ADJ	O
figures	O	NOUN	B
were	O	AUX	O
33	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
18	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
57	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
14	O	NUM	O
)	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


At	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
percentages	O	NOUN	B
were	O	AUX	O
63	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
75	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


Fluorescein	B-OUT	NOUN	B
angiographic	I-OUT	ADJ	I
growth	I-OUT	NOUN	I
of	I-OUT	ADP	O
classic	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
occult	I-OUT	ADJ	B
CNV	I-OUT	NOUN	B
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
halted	O	VERB	B
by	O	ADP	O
10	O	NUM	O
Gy	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
a	O	DET	O
temporary	B-OUT	ADJ	B
growth	I-OUT	NOUN	B
retardation	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
cases	O	NOUN	B
irradiated	O	VERB	B
with	O	ADP	O
36	B-I	NUM	O
Gy	I-I	NOUN	B
.	I-I	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
the	O	DET	O
study	O	NOUN	B
presented	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
natural	O	ADJ	B
course	O	NOUN	I
of	O	ADP	O
occult	O	ADJ	B
CNV	O	NOUN	B
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
improved	O	VERB	B
by	O	ADP	O
irradiation	O	NOUN	B
with	O	ADP	O
10	B-I	NUM	O
or	I-I	CCONJ	O
36	I-I	NUM	O
Gy	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
classic	O	ADJ	B
CNV	O	NOUN	B
,	O	PUNCT	O
low-dose	O	ADJ	B
irradiation	O	NOUN	I
with	O	ADP	O
10	B-I	NUM	O
Gy	I-I	NOUN	O
postponed	O	VERB	O
severe	B-OUT	ADJ	B
visual	I-OUT	ADJ	B
loss	I-OUT	NOUN	I
by	O	ADP	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
positive	O	ADJ	B
treatment	O	NOUN	B
effect	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
in	O	ADP	O
cases	O	NOUN	B
irradiated	O	VERB	B
with	O	ADP	O
36	B-I	NUM	O
Gy	I-I	NOUN	B
;	I-I	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
25	O	NUM	O
%	O	NOUN	O
incidence	O	NOUN	B
of	O	ADP	O
radiation	O	NOUN	B
retinopathy	O	NOUN	I
seems	O	VERB	O
unacceptable	O	ADJ	B
.	O	PUNCT	O


Monitoring	O	NOUN	B
tumour	O	NOUN	O
cells	O	NOUN	O
in	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
blood	O	NOUN	I
of	O	ADP	O
small	B-P	ADJ	B
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Flow	B-I	NOUN	B
cytometry	I-I	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
enumerate	O	VERB	O
tumour	O	NOUN	B
cells	O	NOUN	I
in	O	ADP	O
longitudinal	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
from	O	ADP	O
small	B-P	ADJ	B
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
SCLC	I-P	NOUN	B
)	I-P	PUNCT	O
patients	I-P	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
magnetic	O	ADJ	B
bead	O	NOUN	I
selection	O	NOUN	O
to	O	PART	O
isolate	O	VERB	B
and	O	CCONJ	O
identify	O	VERB	O
these	O	DET	O
cells	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
trial	O	NOUN	B
,	O	PUNCT	O
11	B-P	NUM	O
patients	I-P	NOUN	B
received	I-P	VERB	O
either	I-P	DET	O
standard	I-P	ADJ	B
(	I-P	PUNCT	O
four	I-P	NUM	O
weekly	I-P	ADJ	B
)	I-P	PUNCT	O
chemotherapy	I-I	NOUN	B
with	I-I	ADP	O
ifosfamide	I-I	NOUN	B
,	I-I	PUNCT	O
carboplatin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
etoposide	I-I	NOUN	B
(	I-I	PUNCT	O
ICE	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
accelerated	I-I	VERB	B
(	I-I	PUNCT	O
two	I-I	NUM	O
weekly	I-I	ADJ	B
)	I-I	PUNCT	O
ICE	I-I	NOUN	B
with	I-I	ADP	O
filgrastim	I-I	NOUN	B
(	I-I	PUNCT	O
granulocyte	I-I	NOUN	B
colony-stimulating	I-I	ADJ	I
factor	I-I	NOUN	I
[	I-I	PUNCT	O
G-CSF	I-I	NOUN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
autologous	I-I	ADJ	B
stem	I-I	NOUN	I
cell	I-I	NOUN	I
support	I-I	NOUN	O
.	I-I	PUNCT	O


METHODS	O	VERB	O
Fresh	O	ADJ	B
venous	O	ADJ	B
blood	O	NOUN	I
was	O	AUX	O
taken	O	VERB	O
throughout	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Aliquots	O	NOUN	B
were	O	AUX	O
stained	O	VERB	B
with	O	ADP	O
a	O	DET	O
"	O	PUNCT	O
tumour-specific	O	ADJ	B
"	O	PUNCT	O
antibody	O	NOUN	B
against	O	ADP	O
epithelial	O	ADJ	B
tissue	O	NOUN	I
(	O	PUNCT	O
Ber	O	NOUN	B
EP4	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
verified	O	VERB	O
as	O	ADP	O
a	O	DET	O
good	O	ADJ	O
marker	O	NOUN	B
of	O	ADP	O
SCLC	O	NOUN	B
cells	O	NOUN	O
by	O	ADP	O
immunohistochemistry	O	NOUN	B
.	O	PUNCT	O


Matched	O	ADJ	B
samples	O	NOUN	I
labelled	O	VERB	O
with	O	ADP	O
Ber	O	NOUN	B
EP4	O	NOUN	B
were	O	AUX	O
separated	O	VERB	O
magnetically	O	ADV	B
by	O	ADP	O
adding	O	VERB	O
a	O	DET	O
secondary	O	ADJ	B
bead-antibody	O	ADJ	B
conjugate	O	NOUN	O
for	O	ADP	O
confirmation	O	NOUN	O
of	O	ADP	O
tumour	O	NOUN	B
cell	O	NOUN	I
identity	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Circulating	B-OUT	VERB	B
tumour	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
were	O	AUX	O
detected	O	VERB	B
and	O	CCONJ	O
monitored	O	VERB	B
throughout	O	ADP	O
treatment	O	NOUN	B
periods	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
initial	B-OUT	ADJ	O
rise	I-OUT	NOUN	O
in	I-OUT	ADP	O
circulating	I-OUT	VERB	B
cells	I-OUT	NOUN	I
after	I-OUT	ADP	O
the	I-OUT	DET	O
first	I-OUT	ADJ	O
cycle	I-OUT	NOUN	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
fall	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
arms	O	NOUN	O
to	O	PART	O
baseline	O	NOUN	B
levels	O	NOUN	B
set	O	VERB	O
by	O	ADP	O
normal	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
achieved	O	VERB	O
by	O	ADP	O
week	O	NOUN	B
12	O	NUM	O
in	O	ADP	O
the	O	DET	O
accelerated	O	VERB	B
treatment	O	NOUN	B
arm	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
week	O	NOUN	B
24	O	NUM	O
in	O	ADP	O
the	O	DET	O
standard	O	ADJ	B
arm	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Flow	O	NOUN	B
cytometry	O	NOUN	I
and	O	CCONJ	O
magnetic	O	ADJ	B
bead	O	NOUN	I
isolation	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
identify	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
numbers	O	NOUN	O
of	O	ADP	O
circulating	O	VERB	B
tumour	O	NOUN	I
cells	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
chemotherapy	B-I	NOUN	B
for	O	ADP	O
SCLC	O	NOUN	B
and	O	CCONJ	O
thereafter	O	ADV	O
during	O	ADP	O
follow-up	O	ADJ	B
periods	O	NOUN	B
.	O	PUNCT	O


Absence	O	NOUN	B
of	O	ADP	O
tumour	O	NOUN	B
cells	O	NOUN	I
may	O	AUX	O
indicate	O	VERB	O
a	O	DET	O
more	O	ADV	O
favourable	O	ADJ	O
patient	O	NOUN	B
group	O	NOUN	I
who	O	PRON	O
would	O	AUX	O
benefit	O	VERB	B
from	O	ADP	O
a	O	DET	O
more	O	ADV	O
intense	O	ADJ	O
course	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Individual	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
short	B-I	ADJ	B
theory	I-I	NOUN	I
of	I-I	ADP	O
mind	I-I	NOUN	O
intervention	I-I	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Having	O	VERB	O
a	O	DET	O
'theory	O	NOUN	B
of	O	ADP	O
mind	O	NOUN	B
'	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
having	O	VERB	O
the	O	DET	O
ability	O	NOUN	O
to	O	PART	O
attribute	O	VERB	O
mental	O	ADJ	B
states	O	NOUN	I
to	O	ADP	O
oneself	O	PRON	B
or	O	CCONJ	O
others	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
considered	O	VERB	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
central	O	ADJ	B
domains	O	NOUN	I
of	O	ADP	O
impairment	O	NOUN	B
among	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Many	O	ADJ	O
interventions	O	NOUN	B
focus	O	VERB	O
on	O	ADP	O
improving	O	VERB	B
theory	B-I	NOUN	B
of	I-I	ADP	O
mind	I-I	NOUN	B
skills	I-I	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Nonetheless	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
empirical	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
these	O	DET	O
interventions	O	NOUN	B
is	O	AUX	O
limited	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
goal	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
a	O	DET	O
short	B-I	ADJ	B
theory	I-I	NOUN	I
of	I-I	ADP	O
mind	I-I	NOUN	O
intervention	I-I	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


A	O	DET	O
second	O	ADJ	O
objective	O	NOUN	B
is	O	AUX	O
to	O	PART	O
determine	O	VERB	O
which	O	DET	O
subgroups	O	NOUN	B
within	O	ADP	O
the	O	DET	O
autism	O	NOUN	B
spectrum	O	NOUN	O
profit	O	NOUN	O
most	O	ADJ	O
from	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
is	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
,	I-P	PUNCT	O
aged	I-P	ADJ	B
7	I-P	NUM	O
to	I-P	PART	O
12	I-P	NUM	O
years	I-P	NOUN	B
will	I-P	AUX	O
be	I-P	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
an	O	DET	O
intervention	B-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
waiting	I-I	NOUN	B
list	I-I	NOUN	I
control	I-I	NOUN	I
group	I-I	NOUN	I
.	I-I	PUNCT	O


Outcome	O	NOUN	B
measures	O	NOUN	I
include	O	VERB	O
the	O	DET	O
completion	B-OUT	NOUN	B
of	I-OUT	ADP	O
theory	I-OUT	NOUN	B
of	I-OUT	ADP	O
mind	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
emotion	I-OUT	NOUN	B
understanding	I-OUT	NOUN	O
tasks	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
parent	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
teacher	I-OUT	NOUN	B
questionnaires	I-OUT	NOUN	B
on	I-OUT	ADP	O
children	I-OUT	NOUN	B
's	I-OUT	PART	I
social	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Follow-up	O	NUM	B
data	O	NOUN	B
for	O	ADP	O
the	O	DET	O
intervention	B-I	NOUN	B
group	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
collected	O	VERB	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
interventions	O	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
evaluates	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
theory	O	NOUN	B
of	O	ADP	O
mind	B-I	NOUN	O
intervention	I-I	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Hypotheses	B-OUT	PROPN	B
,	I-OUT	PUNCT	O
strengths	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
limitations	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


TRIAL	O	PROPN	B
REGISTRATION	O	NOUN	I
Netherlands	O	PROPN	I
Trial	O	PROPN	I
Register	O	PROPN	O
NTR2327	O	NOUN	O
.	O	PUNCT	O


NSAID	B-I	NOUN	B
Pretreatment	O	NOUN	B
Inhibits	O	VERB	B
Prostaglandin	B-OUT	NOUN	B
Release	I-OUT	PROPN	I
in	O	ADP	O
Femtosecond	B-I	PROPN	B
Laser-Assisted	I-I	ADJ	I
Cataract	I-I	PROPN	I
Surgery	I-I	PROPN	I
.	I-I	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
short-term	O	ADJ	B
nonsteroidal	B-I	ADJ	B
anti-inflammatory	I-I	ADJ	I
drug	I-I	NOUN	I
(	I-I	PUNCT	O
NSAID	I-I	NOUN	B
)	I-I	PUNCT	O
pretreatment	O	NOUN	B
on	O	ADP	O
the	O	DET	O
day	O	NOUN	B
of	O	ADP	O
surgery	O	NOUN	B
inhibits	O	VERB	B
prostaglandin	B-OUT	NOUN	B
release	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
detected	O	VERB	O
elevated	O	ADJ	B
prostaglandin	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
after	O	ADP	O
femtosecond	B-I	ADJ	B
laser	I-I	NOUN	I
treatment	I-I	NOUN	B
and	O	CCONJ	O
identified	O	VERB	B
them	O	PRON	O
as	O	ADP	O
a	O	DET	O
potential	O	ADJ	O
mediator	O	NOUN	O
for	O	ADP	O
laser-induced	O	ADJ	B
miosis	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
underwent	I-P	VERB	O
either	I-P	CCONJ	O
image-guided	I-I	ADJ	B
femtosecond	I-I	ADJ	I
laser	I-I	NOUN	I
cataract	I-I	NOUN	I
surgery	I-I	NOUN	I
or	I-I	CCONJ	O
conventional	I-I	ADJ	B
cataract	I-I	NOUN	B
surgery	I-I	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
75	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
eyes	O	NOUN	B
per	O	ADP	O
group	O	NOUN	B
received	O	VERB	O
topical	B-I	ADJ	B
NSAID	I-I	NOUN	B
treatment	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
day	O	NOUN	B
of	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Aqueous	O	ADJ	B
humor	O	NOUN	B
was	O	AUX	O
collected	O	VERB	O
from	O	ADP	O
all	B-P	DET	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


ELISA	O	NOUN	B
measurements	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
to	O	PART	O
detect	O	VERB	B
aqueous	B-OUT	ADJ	B
humor	I-OUT	NOUN	B
prostaglandin	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Femtosecond	B-I	ADJ	B
laser	I-I	NOUN	I
cataract	I-I	NOUN	I
surgery	I-I	NOUN	I
led	O	VERB	O
to	O	PART	O
higher	O	ADJ	O
prostaglandin	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
than	O	ADP	O
conventional	B-I	ADJ	B
cataract	I-I	NOUN	B
surgery	I-I	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.007	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
NSAID	B-I	NOUN	B
pretreatment	I-I	NOUN	B
led	O	VERB	O
to	O	PART	O
reduced	O	VERB	B
prostaglandin	B-OUT	NOUN	B
release	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
femtosecond	B-P	ADJ	B
laser	I-P	NOUN	I
group	I-P	NOUN	I
,	I-P	PUNCT	O
patients	I-P	NOUN	B
pretreated	I-I	VERB	B
with	I-I	ADP	O
NSAIDs	I-I	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
prostaglandin	B-OUT	NOUN	B
values	I-OUT	NOUN	I
(	O	PUNCT	O
65.3	O	NUM	O
±	O	NOUN	O
13.2	O	NUM	O
pg/mL	O	NOUN	O
)	O	PUNCT	O
than	B-P	ADP	O
patients	I-I	NOUN	B
not	I-I	PART	O
pretreated	I-I	VERB	B
with	I-I	ADP	O
NSAIDs	I-I	NOUN	B
(	O	PUNCT	O
294.4	O	NUM	O
±	O	NOUN	O
66.5	O	NUM	O
pg/mL	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.0009	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
short-term	B-I	ADJ	B
NSAID	I-I	NOUN	B
treatment	I-I	NOUN	B
prevented	I-OUT	VERB	B
prostaglandin	I-OUT	NOUN	B
release	I-OUT	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-I	ADP	I
image-guided	I-I	ADJ	B
femtosecond	I-I	ADJ	I
laser	I-I	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
potential	O	ADJ	B
to	O	PART	O
limit	O	VERB	O
intraoperative	O	ADJ	B
laser-induced	O	ADJ	B
miosis	O	NOUN	I
.	O	PUNCT	O


Limited	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
micronutrient	B-I	ADJ	B
supplementation	I-I	NOUN	B
on	O	ADP	O
strength	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
physical	I-OUT	ADJ	B
function	I-OUT	NOUN	I
after	O	ADP	O
abdominal	B-OUT	ADJ	B
aortic	I-P	ADJ	I
aneurysmectomy	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Tissue	O	NOUN	B
injury	O	NOUN	I
following	O	VERB	O
ischemia-reperfusion	O	NOUN	B
is	O	AUX	O
mediated	O	VERB	O
in	O	ADP	O
part	O	NOUN	O
by	O	ADP	O
free	O	ADJ	B
oxygen	O	NOUN	I
radicals	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
perioperative	O	ADJ	B
micronutrient	B-I	ADJ	B
supplementation	I-I	NOUN	B
would	O	AUX	O
augment	B-OUT	VERB	O
antioxidant	I-OUT	ADJ	B
defenses	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
minimize	I-OUT	VERB	O
muscle	I-OUT	NOUN	B
injury	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
minimize	I-OUT	VERB	O
postoperative	I-OUT	ADJ	B
decreases	I-OUT	NOUN	B
in	I-OUT	ADP	O
muscle	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
physical	I-OUT	ADJ	B
function	I-OUT	NOUN	I
following	O	VERB	O
abdominal	O	ADJ	B
aortic	O	ADJ	I
aneurysmectomy	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	B
A	O	DET	I
university-affiliated	B-P	ADJ	B
hospital	I-P	NOUN	I
and	I-P	CCONJ	O
regional	I-P	ADJ	B
referral	I-P	NOUN	I
center	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
supplementation	B-I	NOUN	B
with	I-I	ADP	O
beta-carotene	I-I	NOUN	B
,	I-I	PUNCT	O
vitamins	I-I	NOUN	B
C	I-I	NOUN	I
and	I-I	CCONJ	O
E	I-I	NOUN	B
,	I-I	PUNCT	O
zinc	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
selenium	I-I	NOUN	B
for	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
2-3	O	NUM	O
weeks	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
week	O	NOUN	B
thereafter	O	ADV	O
.	O	PUNCT	O


STUDY	O	ADJ	O
POPULATION	O	NOUN	B
Patients	B-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
abdominal	I-I	ADJ	I
aortic	I-I	ADJ	I
aneurysmectomy	I-I	NOUN	I
(	I-P	PUNCT	O
n=18	I-P	ADV	O
per	I-P	ADP	O
group	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


PRINCIPAL	O	NOUN	B
MEASUREMENTS	O	NOUN	O
Handgrip	B-OUT	PROPN	O
and	I-OUT	CCONJ	O
other	I-OUT	ADJ	O
measures	I-OUT	NOUN	B
of	I-OUT	ADP	O
strength	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
physical	I-OUT	ADJ	B
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Handgrip	B-OUT	PROPN	I
and	I-OUT	CCONJ	O
quadriceps	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
decreased	O	VERB	B
following	O	VERB	O
surgery	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
to	O	PART	O
a	O	DET	O
significantly	O	ADV	O
different	O	ADJ	O
extent	O	NOUN	O
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
and	O	CCONJ	O
supplemented	O	VERB	B
groups	O	NOUN	I
.	O	PUNCT	O


Self-rated	B-OUT	ADJ	B
physical	I-OUT	ADJ	B
function	I-OUT	NOUN	I
decreased	O	VERB	B
following	O	VERB	O
surgery	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	O
and	O	CCONJ	O
was	O	AUX	O
preserved	O	VERB	O
in	O	ADP	O
the	O	DET	O
supplemented	O	VERB	B
group	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Perioperative	B-I	ADJ	B
supplementation	I-I	NOUN	B
with	I-I	ADP	O
micronutrients	I-I	NOUN	B
with	O	ADP	O
antioxidant	O	ADJ	B
properties	O	NOUN	O
has	O	AUX	O
limited	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
strength	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
physical	I-OUT	ADJ	B
function	I-OUT	NOUN	I
following	O	VERB	O
major	O	ADJ	O
elective	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


Lung	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
respiratory	O	ADJ	B
symptoms	O	NOUN	I
in	O	ADP	O
a	O	DET	O
1-year	O	ADJ	O
randomized	O	ADJ	B
smoking	O	NOUN	I
cessation	O	NOUN	I
trial	O	NOUN	I
of	O	ADP	O
varenicline	B-I	NOUN	B
in	O	ADP	O
COPD	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


UNLABELLED	O	NOUN	B
There	O	PRON	O
are	O	AUX	O
few	O	ADJ	O
data	O	NOUN	B
concerning	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
lung	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
respiratory	O	ADJ	B
symptoms	O	NOUN	I
in	O	ADP	O
smokers	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
COPD	I-P	NOUN	B
)	I-P	PUNCT	O
weeks	I-P	NOUN	B
to	I-P	PART	O
months	I-P	NOUN	B
after	I-P	ADP	O
quitting	I-P	VERB	B
smoking	I-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
serial	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
spirometry	O	NOUN	B
and	O	CCONJ	O
Clinical	O	ADJ	B
COPD	O	PROPN	I
Questionnaire	O	PROPN	I
(	O	PUNCT	O
CCQ	O	PROPN	B
)	O	PUNCT	O
scores	O	NOUN	O
(	O	PUNCT	O
measuring	O	VERB	B
respiratory	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
health-related	O	ADJ	B
quality	O	NOUN	I
of	O	ADP	I
life	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
COPD	B-P	NOUN	B
participants	I-P	NOUN	B
by	I-P	ADP	O
smoking	I-P	VERB	B
status	I-P	NOUN	I
during	O	ADP	O
a	O	DET	O
smoking	O	NOUN	B
cessation	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
smokers	B-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
COPD	I-P	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
varenicline	B-I	NOUN	B
1	I-I	NUM	I
mg	I-I	NOUN	O
b.i.d	I-I	NOUN	B
.	I-I	PUNCT	O


or	B-I	CCONJ	O
placebo	I-I	NOUN	B
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
followed	O	VERB	O
to	O	ADP	O
Week	O	PROPN	B
52	O	NUM	O
.	O	PUNCT	O


Primary	O	ADJ	B
endpoints	O	NOUN	B
of	O	ADP	O
abstinence	B-OUT	NOUN	B
were	O	AUX	O
previously	O	ADV	O
reported	O	VERB	O
.	O	PUNCT	O


Secondary	O	ADJ	B
endpoints	O	NOUN	I
were	O	AUX	O
mean	B-OUT	VERB	O
changes	I-OUT	NOUN	B
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
in	O	ADP	O
post-bronchodilator	B-OUT	ADJ	B
forced	I-OUT	ADJ	B
expired	I-OUT	ADJ	I
volume	I-OUT	NOUN	I
in	I-OUT	ADP	O
1	I-OUT	NUM	O
s	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
FEV	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
CCQ	I-OUT	PROPN	B
scores	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Change	B-OUT	NOUN	B
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
in	O	ADP	O
post-bronchodilator	O	ADJ	B
FEV	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
continuous	O	ADJ	B
abstainers	O	NOUN	I
(	O	PUNCT	O
121.8	O	NUM	O
mL	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
continuous	O	ADJ	B
smokers	O	NOUN	I
(	O	PUNCT	O
37.9	O	NUM	O
mL	O	NOUN	O
)	O	PUNCT	O
at	O	ADP	O
Week	O	NOUN	B
12	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0069	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
at	O	ADP	O
Weeks	O	PROPN	B
24	O	NUM	O
or	O	CCONJ	O
52	O	NUM	O
.	O	PUNCT	O


Mean	B-OUT	VERB	B
change	I-OUT	NOUN	I
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
at	I-OUT	ADP	O
Week	I-OUT	PROPN	B
12	I-OUT	NUM	O
in	I-OUT	ADP	O
CCQ	I-OUT	PROPN	B
Total	I-OUT	PROPN	B
Score	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
better	O	ADJ	O
in	O	ADP	O
continuous	O	ADJ	B
abstainers	O	NOUN	I
(	O	PUNCT	O
-1.04	O	NUM	O
)	O	PUNCT	O
vs.	O	CCONJ	O
continuous	O	ADJ	B
smokers	O	NOUN	I
(	O	PUNCT	O
-0.53	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
:	O	PUNCT	O
this	O	DET	O
improvement	O	NOUN	B
was	O	AUX	O
sustained	O	ADJ	B
at	O	ADP	O
Weeks	O	PROPN	B
24	O	NUM	O
and	O	CCONJ	O
52	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
1-year	O	ADJ	O
cessation	O	NOUN	O
trial	O	NOUN	O
of	O	ADP	O
smokers	B-P	NOUN	B
with	I-P	ADP	O
COPD	I-P	NOUN	B
,	O	PUNCT	O
continuous	B-OUT	ADJ	B
abstinence	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
continuous	O	ADJ	B
smoking	O	NOUN	B
significantly	O	ADV	O
improved	O	VERB	O
post-bronchodilator	B-OUT	ADJ	B
FEV	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
Week	O	PROPN	B
12	O	NUM	O
(	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
difference	O	NOUN	O
narrowed	O	VERB	O
subsequently	O	ADV	O
)	O	PUNCT	O
and	O	CCONJ	O
CCQ	B-OUT	PROPN	B
Total	I-OUT	PROPN	O
Scores	I-OUT	PROPN	O
at	O	ADP	O
Week	O	PROPN	B
12	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
sustained	O	ADJ	B
improvement	O	NOUN	B
thereafter	O	ADV	O
.	O	PUNCT	O


(	O	PUNCT	O
TRIAL	O	NOUN	B
REGISTRY	O	ADJ	I
http	O	NOUN	I
:	O	PUNCT	O
//www.clinicaltrials.gov	O	PUNCT	O
;	O	PUNCT	O
trial	O	NOUN	B
identifier	O	NOUN	O
:	O	PUNCT	O
NCT00285012	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
Thai	O	ADJ	B
traditional	O	ADJ	B
massage	O	NOUN	B
on	O	ADP	O
autistic	B-P	ADJ	B
children	I-P	NOUN	I
's	I-P	PART	I
behavior	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVES	O	NOUN	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
access	O	VERB	O
whether	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
any	O	DET	O
therapeutic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
Thai	B-I	PROPN	B
Traditional	I-I	PROPN	O
Massage	I-I	PROPN	O
(	I-I	PUNCT	O
TTM	I-I	PROPN	B
)	I-I	PUNCT	O
on	O	ADP	O
major	O	ADJ	O
behavioral	B-P	ADJ	B
and	I-P	CCONJ	O
emotional	I-P	ADJ	B
disturbances	I-P	NOUN	I
in	I-P	ADP	O
Thai	I-P	ADJ	B
autistic	I-P	ADJ	B
children	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


SETTINGS/LOCATION	O	NOUN	B
The	B-P	DET	O
study	I-P	NOUN	B
was	I-P	AUX	O
conducted	I-P	VERB	O
at	I-P	ADP	O
the	I-P	DET	O
Rehabilitation	I-P	PROPN	B
Centre	I-P	PROPN	I
of	I-P	ADP	I
the	I-P	DET	O
Thai	I-P	PROPN	B
Red	I-P	PROPN	I
Cross	I-P	PROPN	I
Society	I-P	PROPN	I
.	I-P	PUNCT	O


SUBJECTS	O	VERB	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
60	I-P	NUM	O
autistic	I-P	ADJ	B
children	I-P	NOUN	O
between	I-P	ADP	O
the	I-P	DET	O
ages	I-P	NOUN	B
of	I-P	ADP	O
3	I-P	NUM	O
and	I-P	CCONJ	O
10	I-P	NUM	O
completed	I-P	VERB	O
this	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
Standard	B-I	ADJ	B
sensory	I-I	ADJ	B
integration	I-I	NOUN	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
SI	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
SI	O	PROPN	B
with	O	ADP	O
TTM	B-I	NOUN	B
treatments	O	NOUN	B
.	O	PUNCT	O


OUTCOME	O	VERB	B
MEASURES	O	NOUN	O
Parents	O	NOUN	B
and	O	CCONJ	O
teachers	O	NOUN	B
assessed	O	VERB	B
major	B-OUT	ADJ	O
behavior	I-OUT	NOUN	O
disturbances	I-OUT	NOUN	B
using	O	VERB	O
the	O	DET	O
Conners	B-OUT	PROPN	B
'	I-OUT	PART	I
Rating	I-OUT	PROPN	I
Scales	I-OUT	PROPN	I
at	O	ADP	O
0	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Sleep	B-OUT	PROPN	B
Diary	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
recorded	O	VERB	O
by	O	ADP	O
the	O	DET	O
parents	O	NOUN	B
,	O	PUNCT	O
assessed	O	VERB	B
the	O	DET	O
patient	O	NOUN	B
's	O	PART	I
sleeping	O	VERB	B
patterns	O	NOUN	I
every	O	DET	O
week	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Sixty	B-P	NUM	O
(	I-P	PUNCT	O
60	I-P	NUM	O
)	I-P	PUNCT	O
autistic	I-P	ADJ	B
children	I-P	NOUN	I
,	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
4.67	I-P	NUM	O
+/-	I-P	CCONJ	O
1.82	I-P	NUM	O
,	I-P	PUNCT	O
were	I-P	AUX	O
recruited	I-P	VERB	O
.	I-P	PUNCT	O


No	O	DET	O
statistical	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
demographic	O	ADJ	B
and	O	CCONJ	O
baseline	O	NOUN	B
data	O	NOUN	B
among	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
Conners	B-OUT	PROPN	B
'	I-OUT	PART	I
Teacher	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
SD	I-OUT	NOUN	B
,	O	PUNCT	O
statistical	O	ADJ	B
improvement	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
for	O	ADP	O
conduct	B-OUT	NOUN	B
problem	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
hyperactivity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
inattention-passivity	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
hyperactivity	I-OUT	NOUN	B
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
sleeping	I-OUT	VERB	B
behavior	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Conners	B-OUT	PROPN	B
'	I-OUT	PART	I
Parent	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
revealed	O	VERB	O
an	O	DET	O
improvement	O	NOUN	B
only	O	ADV	O
for	O	ADP	O
anxiety	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
massage	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
when	O	SCONJ	O
both	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
conduct	B-OUT	NOUN	B
problem	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
anxiety	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Results	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
TTM	O	PROPN	B
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
positive	O	ADJ	B
effect	O	NOUN	B
in	O	ADP	O
improving	O	VERB	B
stereotypical	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
in	O	ADP	O
autistic	O	ADJ	B
children	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Over	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
findings	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
TTM	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
complementary	O	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
autistic	O	ADJ	B
children	O	NOUN	I
in	O	ADP	O
Thailand	B-P	PROPN	B
.	I-P	PUNCT	O


Gum	B-I	ADJ	O
elastic	I-I	ADJ	B
bougie-guided	I-I	ADJ	O
insertion	I-I	NOUN	B
of	O	ADP	O
the	O	DET	O
ProSeal	O	PROPN	B
Laryngeal	O	PROPN	B
Mask	O	PROPN	O
Airway	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	DET	O
gum	B-I	NOUN	B
elastic-bougie-guided	I-I	ADJ	O
insertion	I-I	NOUN	B
of	O	ADP	O
the	O	DET	O
ProSeal	O	PROPN	B
Laryngeal	O	PROPN	B
Mask	O	PROPN	O
Airway	O	PROPN	B
is	O	AUX	O
more	O	ADV	O
frequently	O	ADV	O
successful	O	ADJ	O
than	O	ADP	O
introducer	O	NOUN	B
tool	O	NOUN	I
guided	O	VERB	O
insertion	O	NOUN	B
after	O	ADP	O
failed	O	VERB	B
digital	O	ADJ	B
insertion	O	NOUN	I
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
anaesthetized	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
ASA	I-P	NOUN	B
1-2	I-P	NUM	O
,	I-P	PUNCT	O
aged	I-P	ADJ	B
18	I-P	NUM	O
to	I-P	PART	O
80	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
for	O	ADP	O
the	O	DET	O
second	B-I	ADJ	O
insertion	I-I	NOUN	B
attempt	I-I	NOUN	B
using	I-I	VERB	O
either	I-I	CCONJ	O
the	I-I	DET	O
gum	I-I	NOUN	B
elastic	I-I	ADJ	I
bougie-guided	I-I	ADJ	O
or	I-I	CCONJ	O
introducer	I-I	NOUN	B
tool	I-I	NOUN	I
techniques	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
bougie-guided	B-I	ADJ	B
technique	I-I	NOUN	I
involved	O	VERB	O
priming	O	VERB	B
the	O	DET	O
drain	O	NOUN	B
tube	O	NOUN	I
with	O	ADP	O
the	O	DET	O
bougie	O	NOUN	B
,	O	PUNCT	O
placing	O	VERB	O
the	O	DET	O
bougie	O	NOUN	B
in	O	ADP	O
the	O	DET	O
oesophagus	O	NOUN	B
using	O	VERB	O
laryngoscope	O	NOUN	B
guidance	O	NOUN	I
,	O	PUNCT	O
digital	O	ADJ	B
insertion	O	NOUN	I
along	O	ADP	O
the	O	DET	O
palato-pharyngeal	O	ADJ	B
curve	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
bougie	O	VERB	B
removal	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
introducer	B-I	NOUN	B
tool	I-I	NOUN	I
technique	I-I	NOUN	I
involved	O	VERB	O
attaching	O	VERB	O
the	O	DET	O
introducer	O	NOUN	B
tool	O	NOUN	I
,	O	PUNCT	O
single-handed	O	ADJ	B
rotation	O	NOUN	I
along	O	ADP	O
the	O	DET	O
palatopharyngeal	O	NOUN	B
curve	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
introducer	O	NOUN	B
tool	O	NOUN	I
removal	O	NOUN	B
.	O	PUNCT	O


Failed	O	ADJ	B
insertion	O	NOUN	B
was	O	AUX	O
classified	O	VERB	O
as	O	ADP	O
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
failed	O	VERB	B
passage	O	NOUN	B
into	O	ADP	O
the	O	DET	O
pharynx	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
malposition	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
(	O	PUNCT	O
iii	O	X	O
)	O	PUNCT	O
ineffective	O	ADJ	B
ventilation	O	NOUN	B
.	O	PUNCT	O


Any	O	DET	O
blood	B-OUT	NOUN	B
staining	I-OUT	NOUN	I
was	O	AUX	O
documented	O	VERB	B
.	O	PUNCT	O


Insertion	B-OUT	NOUN	B
was	O	AUX	O
more	O	ADV	O
frequently	B-OUT	ADV	O
successful	I-OUT	ADJ	O
(	O	PUNCT	O
50/50	O	NUM	O
vs	O	CCONJ	O
15/50	O	NUM	O
,	O	PUNCT	O
P=0.0002	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
faster	B-OUT	ADV	B
(	O	PUNCT	O
35+/-17	O	NUM	O
s	O	NOUN	O
vs	O	CCONJ	O
54+/-45	O	NUM	O
s	O	NOUN	O
,	O	PUNCT	O
mean+/-SD	O	NOUN	O
,	O	PUNCT	O
P=0.006	O	NOUN	O
)	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
bougie-guided	O	ADJ	B
technique	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
failed	B-OUT	VERB	B
insertions	I-OUT	NOUN	B
with	O	ADP	O
the	O	DET	O
introducer	O	NOUN	B
tool	O	NOUN	I
technique	O	NOUN	I
were	O	AUX	O
successful	O	ADJ	O
with	O	ADP	O
the	O	DET	O
bougie-guided	O	ADJ	B
technique	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aetiology	B-OUT	NOUN	B
of	I-OUT	ADP	O
failed	I-OUT	VERB	B
insertion	I-OUT	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
for	O	ADP	O
the	O	DET	O
digital	O	ADJ	B
and	O	CCONJ	O
introducer	O	NOUN	B
tool	O	NOUN	I
techniques	O	NOUN	I
in	O	ADP	O
94	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
33/35	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
blood	B-OUT	NOUN	B
staining	I-OUT	NOUN	I
on	O	ADP	O
the	O	DET	O
bougie	O	NOUN	B
,	O	PUNCT	O
laryngoscope	O	NOUN	B
or	O	CCONJ	O
introducer	O	NOUN	B
tool	O	NOUN	I
at	O	ADP	O
removal	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
blood	B-OUT	NOUN	B
staining	I-OUT	NOUN	I
was	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
on	O	ADP	O
the	O	DET	O
ProSeal	O	PROPN	B
Laryngeal	O	PROPN	B
Mask	O	PROPN	O
Airway	O	NOUN	B
with	O	ADP	O
the	O	DET	O
introducer	O	NOUN	B
tool	O	NOUN	I
technique	O	NOUN	I
(	O	PUNCT	O
9/50	O	NUM	O
vs	O	CCONJ	O
2/50	O	NUM	O
,	O	PUNCT	O
P=0.03	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
gum	B-I	NOUN	B
elastic	I-I	ADJ	B
bougie-guided	I-I	ADJ	B
insertion	I-I	NOUN	I
has	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
success	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
and	O	CCONJ	O
causes	O	VERB	O
less	O	ADJ	O
trauma	B-OUT	NOUN	B
than	O	ADP	O
the	O	DET	O
insertion	O	NOUN	B
tool	B-I	NOUN	O
insertion	I-I	NOUN	B
technique	I-I	NOUN	I
after	O	ADP	O
failed	O	VERB	B
digital	O	ADJ	B
insertion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
ProSeal	O	PROPN	B
Laryngeal	O	PROPN	B
Mask	O	PROPN	O
Airway	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
cigarette	O	NOUN	B
smoking	O	NOUN	I
on	O	ADP	O
gastric	O	ADJ	B
emptying	O	NOUN	I
of	O	ADP	O
solids	O	NOUN	B
in	O	ADP	O
Japanese	B-P	ADJ	B
smokers	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
crossover	O	NOUN	B
study	O	NOUN	I
using	O	VERB	O
the	O	DET	O
13C-octanoic	O	ADJ	B
acid	O	NOUN	I
breath	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Cigarette	O	PROPN	B
smoking	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
peptic	O	ADJ	B
ulcer	O	NOUN	I
and	O	CCONJ	O
gastroesophageal	O	ADJ	B
reflux	O	NOUN	I
disease	O	NOUN	I
.	O	PUNCT	O


Gastric	O	ADJ	B
emptying	O	NOUN	I
disorders	O	NOUN	I
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
these	O	DET	O
upper	O	ADJ	B
gastrointestinal	O	ADJ	I
diseases	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
studies	O	NOUN	B
examining	O	VERB	O
a	O	DET	O
link	O	NOUN	O
between	O	ADP	O
smoking	O	NOUN	B
and	O	CCONJ	O
gastric	O	ADJ	B
emptying	O	NOUN	I
disorders	O	NOUN	I
have	O	AUX	O
clinical	O	ADJ	B
relevance	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	B-OUT	NOUN	B
of	I-OUT	ADP	O
smoking	I-OUT	NOUN	B
on	O	ADP	O
gastric	O	ADJ	B
emptying	O	NOUN	I
of	O	ADP	O
solids	O	NOUN	B
in	O	ADP	O
Japanese	B-P	ADJ	B
smokers	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
(	B-I	PUNCT	O
13	I-I	NUM	O
)	I-I	PUNCT	O
C-octanoic	I-I	ADJ	B
acid	I-OUT	NOUN	I
breath	I-OUT	NOUN	I
test	I-OUT	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
eight	B-P	NUM	O
male	I-P	NOUN	B
habitual	I-P	ADJ	B
smokers	I-P	NOUN	I
on	O	ADP	O
two	O	NUM	O
randomized	O	ADJ	B
occasions	O	NOUN	I
(	O	PUNCT	O
either	O	CCONJ	O
sham	O	NOUN	B
smoking	O	NOUN	B
or	O	CCONJ	O
actively	O	ADV	O
smoking	O	VERB	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
time	O	NOUN	B
vs	O	CCONJ	O
(	O	PUNCT	O
13	O	NUM	O
)	O	PUNCT	O
CO	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
excretion	B-OUT	NOUN	B
rate	I-OUT	NOUN	O
curve	I-OUT	NOUN	O
was	O	AUX	O
mathematically	O	ADV	O
fitted	O	VERB	O
to	O	PART	O
a	O	DET	O
conventional	O	ADJ	B
formula	O	NOUN	B
of	O	ADP	O
y	O	NOUN	O
(	O	PUNCT	O
t	O	NOUN	O
)	O	PUNCT	O
=	O	ADJ	O
m*k*beta*e	O	NUM	B
(	O	PUNCT	O
-k*t	O	NOUN	B
)	O	PUNCT	O
*	O	PUNCT	O
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
e	O	X	B
(	O	PUNCT	O
-k*t	O	NOUN	B
)	O	PUNCT	O
)	O	PUNCT	O
(	O	PUNCT	O
beta-1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
parameters	B-OUT	NOUN	B
of	I-OUT	ADP	O
k	I-OUT	X	O
and	I-OUT	CCONJ	O
beta	I-OUT	NOUN	B
were	O	AUX	O
determined	O	VERB	O
:	O	PUNCT	O
under	O	ADP	O
the	O	DET	O
crossover	O	NOUN	B
protocol	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
larger	O	ADJ	O
(	O	PUNCT	O
smaller	O	ADJ	O
)	O	PUNCT	O
beta	O	NOUN	B
indicates	O	VERB	O
slower	B-OUT	ADJ	O
(	I-OUT	PUNCT	O
faster	I-OUT	ADV	B
)	I-OUT	PUNCT	O
emptying	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
phase	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
larger	O	ADJ	B
(	O	PUNCT	O
smaller	O	ADJ	B
)	O	PUNCT	O
k	O	X	O
indicates	O	VERB	O
faster	B-OUT	ADV	O
(	I-OUT	PUNCT	O
slower	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
emptying	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	O	DET	O
later	O	ADJ	O
phase	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
half	B-OUT	NOUN	O
(	I-OUT	PUNCT	O
13	I-OUT	NUM	O
)	I-OUT	PUNCT	O
CO	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
excretion	I-OUT	NOUN	B
time	I-OUT	NOUN	O
(	O	PUNCT	O
t	O	NOUN	O
(	O	PUNCT	O
1/2b	O	X	O
)	O	PUNCT	O
=	O	ADJ	O
-	O	PUNCT	O
[	O	PUNCT	O
ln	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
2	O	NUM	O
(	O	PUNCT	O
-1/beta	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
]	O	PUNCT	O
/k	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
time	B-OUT	NOUN	B
of	I-OUT	ADP	O
maximal	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
13	I-OUT	NUM	O
)	I-OUT	PUNCT	O
CO	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
excretion	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
t	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
max	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
=	O	ADJ	O
[	O	PUNCT	O
lnbeta	O	NOUN	B
]	O	PUNCT	O
/k	O	PUNCT	O
)	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
calculated	O	VERB	B
.	O	PUNCT	O


Between	O	ADP	O
the	O	DET	O
two	O	NUM	O
occasions	O	NOUN	B
,	O	PUNCT	O
k	O	X	O
,	O	PUNCT	O
beta	O	NOUN	B
,	O	PUNCT	O
t	O	X	O
(	O	PUNCT	O
1/2b	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
t	O	NOUN	O
(	O	PUNCT	O
max	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
by	O	ADP	O
the	O	DET	O
Wilcoxon	O	PROPN	B
signed-rank	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
After	O	ADP	O
smoking	O	NOUN	B
,	O	PUNCT	O
k	B-OUT	X	O
was	I-OUT	AUX	O
significantly	I-OUT	ADV	O
increased	I-OUT	VERB	B
.	I-OUT	PUNCT	O


No	B-OUT	DET	B
significant	I-OUT	ADJ	I
differences	I-OUT	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
beta	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
t	I-OUT	X	O
(	I-OUT	PUNCT	O
1/2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
t	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
max	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
occasions	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
k	I-OUT	NOUN	O
suggests	O	VERB	O
the	O	DET	O
acceleration	O	NOUN	B
of	O	ADP	O
gastric	O	ADJ	B
emptying	O	NOUN	I
in	O	ADP	O
the	O	DET	O
later	O	ADJ	O
phase	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
has	O	AUX	O
revealed	O	VERB	O
that	O	SCONJ	O
acute	O	ADJ	B
smoking	O	NOUN	O
speeds	O	NOUN	B
the	O	DET	O
gastric	O	ADJ	B
emptying	O	NOUN	I
of	O	ADP	O
solids	O	NOUN	B
in	O	ADP	O
Japanese	B-P	ADJ	B
habitual	I-P	ADJ	B
smokers	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
adrenocorticotrophic	B-I	ADJ	B
hormone	I-I	NOUN	I
(	I-I	PUNCT	O
4-9	I-I	NUM	O
)	I-I	PUNCT	O
analog	I-I	NOUN	O
ORG	I-I	NOUN	B
2766	I-I	NUM	O
benefits	O	VERB	B
autistic	B-P	ADJ	B
children	I-P	NOUN	B
:	I-P	PUNCT	O
report	O	VERB	B
on	O	ADP	O
a	O	DET	O
second	O	ADV	O
controlled	O	VERB	B
clinical	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
second	O	ADV	O
controlled	O	VERB	B
crossover	O	NOUN	B
trial	O	NOUN	I
,	O	PUNCT	O
20	B-P	NUM	O
autistic	I-P	ADJ	B
children	I-P	NOUN	B
received	I-P	VERB	O
40	I-I	NUM	O
mg/day	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
neuropeptide	I-I	NOUN	B
ORG	I-I	NOUN	I
2766	I-I	NUM	I
,	I-I	PUNCT	O
a	I-I	DET	O
synthetic	I-I	ADJ	B
analog	I-I	NOUN	I
of	I-I	ADP	O
ACTH	I-I	NOUN	B
(	I-I	PUNCT	O
4-9	I-I	NUM	O
)	I-I	PUNCT	O
,	I-P	PUNCT	O
for	I-P	ADP	O
8	I-P	NUM	O
weeks	I-P	NOUN	B
.	I-P	PUNCT	O


Parents	B-OUT	NOUN	B
'	I-OUT	PART	O
checklist	I-OUT	NOUN	B
ratings	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
ABC	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
clinicians	B-OUT	NOUN	B
'	I-OUT	PART	O
ratings	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
CGI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
pointed	O	VERB	O
to	O	PART	O
significant	O	ADJ	O
improvements	O	NOUN	B
after	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
;	O	PUNCT	O
improvements	O	NOUN	B
were	O	AUX	O
clearest	O	ADJ	O
on	O	ADP	O
the	O	DET	O
ABC	B-OUT	PROPN	B
social	I-OUT	ADJ	B
withdrawal	I-OUT	NOUN	I
subscale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
individual	O	ADJ	B
target	O	NOUN	B
symptoms	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
parents	O	NOUN	B
'	O	PART	O
treatment	O	NOUN	B
preferences	O	NOUN	O
substantiated	O	VERB	O
the	O	DET	O
beneficial	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
ORG	B-I	NOUN	B
2766	I-I	NUM	O
.	I-I	PUNCT	O


In	O	ADP	O
an	O	DET	O
ethologically	O	ADV	B
analyzed	O	VERB	O
playroom	O	NOUN	B
session	O	NOUN	B
,	O	PUNCT	O
ORG	O	NOUN	B
2766	O	NUM	O
treatment	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
children	B-OUT	NOUN	B
's	I-OUT	PART	I
play	I-OUT	NOUN	B
behavior	I-OUT	NOUN	I
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
social	B-OUT	ADJ	B
interaction	I-OUT	NOUN	I
between	I-OUT	ADP	O
child	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
experimenter	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Gaze	B-OUT	NOUN	B
coordination	I-OUT	NOUN	B
between	O	ADP	O
child	O	NOUN	B
and	O	CCONJ	O
experimenter	O	NOUN	B
also	O	ADV	O
was	O	AUX	O
improved	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
SNRI	B-I	NOUN	B
venlafaxine	I-I	NOUN	B
improves	O	VERB	O
emotional	B-OUT	ADJ	B
unawareness	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
post-stroke	I-P	ADJ	B
depression	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
stroke	I-P	NOUN	B
have	O	AUX	O
a	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
depression	O	NOUN	B
and	O	CCONJ	O
unawareness	O	NOUN	B
of	O	ADP	O
emotions	O	NOUN	B
or	O	CCONJ	O
alexithymia	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
serotoninergic	B-I	ADJ	B
and	I-I	CCONJ	O
noradrenergic	I-I	ADJ	B
reuptake	I-I	NOUN	I
inhibitor	I-I	NOUN	I
(	I-I	PUNCT	O
SNRI	I-I	NOUN	B
)	I-I	PUNCT	O
venlafaxine	I-I	NOUN	B
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
SSRI	B-I	NOUN	B
fluoxetine	I-I	NOUN	B
on	O	ADP	O
alexithymia	B-OUT	NOUN	B
severity	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
DSM-IV	I-P	NOUN	B
post-stroke	I-P	ADJ	B
major	I-P	ADJ	O
depressive-like	I-P	ADJ	B
episode	I-P	NOUN	I
(	I-P	PUNCT	O
PSD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fifty	B-P	NUM	O
inpatients	I-P	NOUN	B
with	I-P	ADP	O
first-ever	I-P	ADJ	B
stroke	I-P	NOUN	B
and	I-P	CCONJ	O
PSD	I-P	NOUN	B
were	I-P	AUX	O
consecutively	I-P	ADV	O
enrolled	I-P	VERB	O
in	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
open-label	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


Twenty-five	O	NUM	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
SNRI	B-I	NOUN	B
venlafaxine	I-I	NOUN	B
SR	O	NOUN	B
(	O	PUNCT	O
75-150	O	NUM	O
mg/die	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
25	O	NUM	O
with	O	ADP	O
the	O	DET	O
SSRI	B-I	NOUN	B
fluoxetine	I-I	NOUN	B
(	O	PUNCT	O
20-40	O	NUM	O
mg/die	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
the	O	DET	O
Mini-Mental	B-OUT	PROPN	B
State	I-OUT	PROPN	I
Examination	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
Hamilton	I-OUT	PROPN	B
Depression	I-OUT	PROPN	I
Rating	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Toronto	I-OUT	PROPN	B
Alexithymia	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
(	O	PUNCT	O
TAS-20	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
fluoxetine	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
treated	O	VERB	B
with	O	ADP	I
venlafaxine	O	NOUN	B
showed	O	VERB	O
similar	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
venlafaxine	O	NOUN	B
had	O	AUX	O
a	O	DET	O
greater	O	ADJ	O
improvement	O	NOUN	B
on	O	ADP	O
alexithymia	B-OUT	NOUN	B
severity	I-OUT	NOUN	B
than	O	ADP	O
those	O	DET	O
treated	O	VERB	B
with	O	ADP	I
fluoxetine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
venlafaxine	O	NOUN	B
on	O	ADP	O
unawareness	B-OUT	NOUN	B
of	I-OUT	ADP	O
emotions	I-OUT	NOUN	B
was	O	AUX	O
evident	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
alexithymia	O	NOUN	B
(	O	PUNCT	O
TAS-20	O	X	B
>	O	X	O
or=	O	ADJ	O
61	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
those	O	DET	O
without	O	ADP	O
alexithymia	O	NOUN	B
(	O	PUNCT	O
TAS-20	O	X	B
<	O	X	O
61	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Antidepressants	O	NOUN	B
acting	O	VERB	O
on	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
serotoninergic	O	ADJ	B
and	O	CCONJ	O
noradrenergic	O	ADJ	B
systems	O	NOUN	I
might	O	AUX	O
represent	O	VERB	O
a	O	DET	O
valid	O	ADJ	O
resource	O	NOUN	B
not	O	PART	O
only	O	ADV	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
depression	O	NOUN	B
but	O	CCONJ	O
also	O	ADV	O
for	O	ADP	O
improving	O	VERB	B
emotional	B-OUT	ADJ	B
unawareness	I-OUT	NOUN	I
in	O	ADP	O
stroke	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Effect	B-OUT	NOUN	B
of	O	ADP	O
motivational	B-I	ADJ	B
music	I-I	NOUN	I
on	O	ADP	O
lactate	B-OUT	NOUN	B
levels	I-OUT	NOUN	I
during	O	ADP	O
recovery	O	NOUN	B
from	O	ADP	O
intense	O	ADJ	B
exercise	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
music	O	NOUN	B
played	O	VERB	O
during	O	ADP	O
an	O	DET	O
exercise	O	NOUN	B
task	O	NOUN	B
on	O	ADP	O
athletic	O	ADJ	B
performance	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
studied	O	VERB	O
.	O	PUNCT	O


Yet	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
are	O	AUX	O
not	O	PART	O
applicable	O	ADJ	O
for	O	ADP	O
competitive	B-P	ADJ	B
athletes	I-P	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
can	O	AUX	O
use	O	VERB	O
music	O	NOUN	B
only	O	ADV	O
during	O	ADP	O
warm-up	O	NOUN	B
or	O	CCONJ	O
recovery	O	NOUN	B
from	O	ADP	O
exercise	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
motivational	B-I	ADJ	B
music	I-I	NOUN	I
(	I-I	PUNCT	O
music	I-I	NOUN	B
that	I-I	PRON	O
stimulates	I-I	VERB	B
or	I-I	CCONJ	O
inspires	I-I	VERB	O
physical	I-I	ADJ	B
activity	I-I	NOUN	I
)	I-I	PUNCT	O
during	O	ADP	O
recovery	B-OUT	NOUN	B
from	I-OUT	ADP	O
intense	I-OUT	ADJ	B
exercise	I-OUT	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
activity	B-OUT	NOUN	B
pattern	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
perceived	I-OUT	VERB	B
exertion	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RPE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
lactate	I-OUT	NOUN	I
concentration	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Twenty	B-P	NUM	B
young	I-P	ADJ	B
,	I-P	PUNCT	O
active	I-P	ADJ	B
men	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
26.2	I-P	NUM	O
±	I-P	NOUN	O
2.1	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
performed	O	VERB	O
a	B-I	DET	O
6-minute	I-I	ADJ	O
run	I-I	NOUN	O
at	I-I	ADP	O
peak	I-I	NOUN	B
oxygen	I-I	NOUN	I
consumption	I-I	NOUN	I
speed	I-I	NOUN	I
(	O	PUNCT	O
predetermined	O	VERB	O
from	O	ADP	O
the	O	DET	O
VO	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
max	O	NOUN	O
test	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
mean	I-OUT	ADJ	B
heart	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
RPE	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
steps	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
determined	I-OUT	VERB	O
by	I-OUT	ADP	O
step	I-OUT	NOUN	O
counter	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
lactate	I-OUT	NOUN	I
concentrations	I-OUT	NOUN	I
were	O	AUX	O
determined	O	VERB	O
at	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
minutes	O	NOUN	B
during	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
from	O	ADP	O
the	O	DET	O
exercise	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
motivational	O	ADJ	B
music	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
separate	O	ADJ	O
sessions	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
random	O	ADJ	B
order	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	B-OUT	DET	O
mean	I-OUT	ADJ	O
HR	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
with	O	ADP	O
and	B-I	CCONJ	O
without	I-I	ADP	O
music	I-I	NOUN	B
.	O	PUNCT	O


Listening	O	VERB	B
to	O	ADP	O
motivational	O	ADJ	B
music	O	NOUN	I
during	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	B-OUT	VERB	B
voluntary	I-OUT	ADJ	B
activity	I-OUT	NOUN	O
of	O	ADP	O
the	O	DET	O
participants	O	NOUN	B
,	O	PUNCT	O
determined	O	VERB	O
by	O	ADP	O
increased	B-OUT	VERB	B
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
steps	I-OUT	NOUN	B
(	O	PUNCT	O
499.4	O	NUM	O
±	O	PROPN	O
220.1	O	NUM	O
vs.	O	CCONJ	O
413.2	O	NUM	O
±	O	NOUN	O
150.6	O	NUM	O
steps	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
music	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
p	O	NOUN	O
≤	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
increased	O	VERB	B
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
steps	I-OUT	NOUN	O
during	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
a	O	DET	O
significantly	O	ADV	O
greater	O	ADJ	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
blood	I-OUT	NOUN	B
lactate	I-OUT	NOUN	I
concentration	I-OUT	NOUN	I
percentage	O	NOUN	I
(	O	PUNCT	O
28.1	O	NUM	O
±	O	NOUN	O
12.2	O	NUM	O
vs.	O	CCONJ	O
22.8	O	NUM	O
±	O	NOUN	O
10.9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
music	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
p	O	NOUN	O
≤	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
greater	O	ADJ	O
decrease	B-OUT	NOUN	B
in	O	ADP	O
RPE	O	NOUN	B
(	O	PUNCT	O
77.7	O	NUM	O
±	O	NOUN	O
14.4	O	NUM	O
vs.	O	CCONJ	O
73.1	O	NUM	O
±	O	NOUN	O
14.7	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
music	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
p	O	NOUN	O
≤	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
listening	O	VERB	B
to	O	ADP	O
motivational	O	ADJ	B
music	O	NOUN	I
during	O	ADP	O
nonstructured	O	ADJ	O
recovery	O	NOUN	B
from	O	ADP	O
intense	O	ADJ	B
exercise	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
increased	O	VERB	B
activity	O	NOUN	B
,	O	PUNCT	O
faster	O	ADJ	O
lactate	O	NOUN	B
clearance	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
RPE	O	NOUN	B
and	O	CCONJ	O
therefore	O	ADV	O
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
by	O	ADP	O
athletes	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
effort	O	NOUN	O
to	O	PART	O
enhance	O	VERB	B
recovery	O	NOUN	B
.	O	PUNCT	O


Fludarabine	B-I	NOUN	B
in	O	ADP	O
chronic	B-P	ADJ	B
leukaemia	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
antiarrhythmic-drug	B-I	ADJ	B
therapy	I-I	NOUN	I
with	I-I	ADP	O
implantable	I-I	ADJ	B
defibrillators	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
resuscitated	I-P	VERB	B
from	I-P	ADP	O
near-fatal	I-P	ADJ	B
ventricular	I-P	ADJ	I
arrhythmias	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
Antiarrhythmics	B-I	PROPN	B
versus	O	CCONJ	I
Implantable	B-I	PROPN	I
Defibrillators	I-I	PROPN	I
(	O	PUNCT	O
AVID	O	PROPN	B
)	O	PUNCT	O
Investigators	O	PROPN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Patients	O	NOUN	B
who	O	PRON	O
survive	O	VERB	B
life-threatening	O	ADJ	B
ventricular	O	ADJ	B
arrhythmias	O	NOUN	I
are	O	AUX	O
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
recurrent	O	ADJ	B
arrhythmias	O	NOUN	I
.	O	PUNCT	O


They	O	PRON	O
can	O	AUX	O
be	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
either	O	CCONJ	O
an	O	DET	O
implantable	B-I	ADJ	B
cardioverter-defibrillator	I-I	ADJ	I
or	O	CCONJ	O
antiarrhythmic	B-I	ADJ	B
drugs	I-I	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
relative	O	ADJ	O
efficacy	O	NOUN	B
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
strategies	O	NOUN	O
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


METHODS	O	NOUN	O
To	O	PART	O
address	O	VERB	O
this	O	DET	O
issue	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
strategies	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
been	I-P	AUX	O
resuscitated	I-P	VERB	B
from	I-P	ADP	O
near-fatal	I-P	ADJ	B
ventricular	I-P	ADJ	I
fibrillation	I-P	NOUN	I
or	I-P	CCONJ	O
who	I-P	PRON	O
had	I-P	AUX	O
undergone	I-P	VERB	O
cardioversion	I-P	NOUN	B
from	I-P	ADP	O
sustained	I-P	ADJ	B
ventricular	I-P	ADJ	B
tachycardia	I-P	NOUN	I
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
ventricular	I-P	ADJ	B
tachycardia	I-P	NOUN	I
also	I-P	ADV	O
had	I-P	AUX	O
either	I-P	DET	O
syncope	I-P	NOUN	B
or	I-P	CCONJ	O
other	I-P	ADJ	O
serious	I-P	ADJ	O
cardiac	I-P	ADJ	B
symptoms	I-P	NOUN	I
,	I-P	PUNCT	O
along	I-P	ADP	O
with	I-P	ADP	O
a	I-P	DET	O
left	I-P	ADJ	B
ventricular	I-P	ADJ	I
ejection	I-P	NOUN	I
fraction	I-P	NOUN	I
of	I-P	ADP	O
0.40	I-P	NUM	O
or	I-P	CCONJ	O
less	I-P	ADJ	O
.	I-P	PUNCT	O


One	O	NUM	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
implantation	B-I	NOUN	B
of	I-I	ADP	O
a	I-I	DET	O
cardioverter-defibrillator	I-I	NOUN	B
;	I-I	PUNCT	O
the	O	DET	O
other	O	ADJ	O
received	O	VERB	O
class	B-I	NOUN	B
III	I-I	NUM	I
antiarrhythmic	I-I	ADJ	I
drugs	I-I	NOUN	I
,	I-I	PUNCT	O
primarily	I-I	ADV	O
amiodarone	I-I	NOUN	B
at	O	ADP	O
empirically	O	ADV	O
determined	O	VERB	O
doses	O	NOUN	B
.	O	PUNCT	O


Fifty-six	O	NUM	O
clinical	O	ADJ	B
centers	O	NOUN	I
screened	O	VERB	B
all	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
presented	O	VERB	O
with	O	ADP	O
ventricular	O	ADJ	B
tachycardia	O	NOUN	I
or	O	CCONJ	O
ventricular	O	ADJ	B
fibrillation	O	NOUN	I
during	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
nearly	O	ADV	O
four	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Of	B-P	ADP	O
1016	I-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
45	I-P	NUM	O
percent	I-P	NOUN	O
of	I-P	ADP	O
whom	I-P	PRON	O
had	I-P	AUX	O
ventricular	I-P	ADJ	B
fibrillation	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
55	I-P	NUM	O
percent	I-P	NOUN	O
ventricular	I-P	ADJ	B
tachycardia	I-P	NOUN	I
)	I-P	PUNCT	O
,	I-P	PUNCT	O
507	I-P	NUM	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
treatment	I-P	NOUN	B
with	I-P	ADP	O
implantable	I-I	ADJ	B
cardioverter-defibrillators	I-I	NOUN	I
and	I-P	CCONJ	O
509	I-P	NUM	O
to	I-P	PART	O
antiarrhythmic-drug	I-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
overall	B-OUT	ADJ	O
mortality	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
Follow-up	O	NOUN	I
was	O	AUX	O
complete	O	ADJ	O
for	O	ADP	O
1013	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
99.7	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Overall	O	ADJ	B
survival	B-OUT	NOUN	I
was	O	AUX	O
greater	O	ADJ	O
with	O	ADP	O
the	O	DET	O
implantable	B-I	ADJ	B
defibrillator	I-I	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
unadjusted	O	ADJ	O
estimates	O	NOUN	B
of	O	ADP	O
89.3	O	NUM	O
percent	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
82.3	O	NUM	O
percent	O	NOUN	O
in	O	ADP	O
the	O	DET	O
antiarrhythmic-drug	B-I	ADJ	B
group	O	NOUN	I
at	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
81.6	O	NUM	O
percent	O	NOUN	O
versus	O	ADP	O
74.7	O	NUM	O
percent	O	NOUN	O
at	O	ADP	O
two	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
75.4	O	NUM	O
percent	O	NOUN	O
versus	O	ADP	O
64.1	O	NUM	O
percent	O	NOUN	O
at	O	ADP	O
three	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
corresponding	O	ADJ	O
reductions	O	NOUN	B
in	O	ADP	O
mortality	B-OUT	NOUN	B
(	O	PUNCT	O
with	O	ADP	O
95	O	NUM	O
percent	O	NOUN	B
confidence	O	NOUN	I
limits	O	NOUN	I
)	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
implantable	B-I	ADJ	B
defibrillator	I-I	NOUN	I
were	O	AUX	O
39+/-20	O	NUM	O
percent	O	NOUN	O
,	O	PUNCT	O
27+/-21	O	NUM	O
percent	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
31+/-21	O	NUM	O
percent	O	NOUN	O
CONCLUSIONS	O	NOUN	O
Among	O	ADP	O
survivors	B-P	NOUN	B
of	I-P	ADP	O
ventricular	I-P	ADJ	B
fibrillation	I-P	NOUN	I
or	I-P	CCONJ	O
sustained	I-P	ADJ	B
ventricular	I-P	ADJ	B
tachycardia	I-P	NOUN	I
causing	I-P	VERB	O
severe	I-P	ADJ	B
symptoms	I-P	NOUN	B
,	O	PUNCT	O
the	O	DET	O
implantable	B-I	ADJ	B
cardioverter-defibrillator	I-I	NOUN	I
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
antiarrhythmic	B-I	ADJ	B
drugs	I-I	NOUN	I
for	O	ADP	O
increasing	O	VERB	B
overall	O	ADJ	B
survival	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
nonlinear	B-I	ADJ	B
frequency	I-I	NOUN	I
compression	I-I	NOUN	I
versus	I-I	CCONJ	O
conventional	I-I	ADJ	B
processing	I-I	NOUN	O
in	I-I	ADP	O
hearing	I-I	NOUN	B
aids	I-I	NOUN	I
:	I-I	PUNCT	O
speech	O	NOUN	B
and	O	CCONJ	O
language	O	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
at	I-P	ADP	O
three	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
nonlinear	B-I	ADJ	B
frequency	I-I	NOUN	I
compression	I-I	NOUN	I
(	I-I	PUNCT	O
NLFC	I-I	PROPN	B
)	I-I	PUNCT	O
on	O	ADP	O
children	B-P	NOUN	B
's	I-P	PART	I
development	I-P	NOUN	B
of	I-P	ADP	O
speech	I-P	NOUN	B
and	I-P	CCONJ	O
language	I-P	NOUN	B
at	I-P	ADP	O
three	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
population-based	B-P	ADJ	B
longitudinal	O	ADJ	I
study	O	NOUN	I
on	O	ADP	O
outcomes	O	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
hearing	I-P	VERB	B
impairment	I-P	NOUN	I
(	I-P	PUNCT	O
LOCHI	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
fitting	O	VERB	B
with	O	ADP	O
NLFC	B-I	PROPN	B
(	I-I	PUNCT	O
Phonak	I-I	PROPN	B
Naida	I-I	PROPN	I
V	I-I	NOUN	I
SP	I-I	PROPN	I
or	I-I	CCONJ	O
UP	I-I	NOUN	B
)	I-I	PUNCT	O
or	O	CCONJ	O
with	O	ADP	O
conventional	B-I	ADJ	B
processing	I-I	NOUN	O
in	I-I	ADP	O
hearing	I-I	NOUN	B
aids	I-I	NOUN	I
,	O	PUNCT	O
prescribed	O	VERB	B
by	O	ADP	O
using	O	VERB	O
either	O	CCONJ	O
the	O	DET	O
NAL	B-I	NOUN	B
or	O	CCONJ	O
the	O	DET	O
DSL	B-I	NOUN	B
formula	O	NOUN	I
.	O	PUNCT	O


Standardized	O	ADJ	B
tests	O	NOUN	I
of	O	ADP	O
speech	B-OUT	NOUN	B
production	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
receptive	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
expressive	I-OUT	ADJ	B
language	I-OUT	NOUN	O
were	O	AUX	O
administered	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
parent	O	NOUN	B
ratings	O	NOUN	B
were	O	AUX	O
collected	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
assessments	O	NOUN	B
were	O	AUX	O
double-blinded	O	ADJ	B
.	O	PUNCT	O


STUDY	O	NOUN	O
SAMPLE	O	NOUN	B
Participants	B-P	NOUN	B
were	I-P	AUX	O
44	I-P	NUM	O
of	I-P	ADP	O
the	I-P	DET	O
450	I-P	NUM	O
children	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
LOCHI	I-P	PROPN	B
cohort	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
Compared	O	VERB	O
to	O	ADP	O
children	B-P	NOUN	B
using	O	VERB	O
conventional	B-I	ADJ	B
processing	I-I	NOUN	I
,	O	PUNCT	O
receptive	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
expressive	I-OUT	ADJ	B
language	I-OUT	NOUN	O
was	O	AUX	O
higher	O	ADJ	B
but	O	CCONJ	O
receptive	B-OUT	ADJ	B
vocabulary	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
consonant	I-OUT	ADJ	B
articulation	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
were	O	AUX	O
lower	O	ADJ	O
for	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
use	O	VERB	O
NLFC	B-I	PROPN	B
.	I-I	PUNCT	O


There	O	PRON	O
was	O	AUX	O
increased	O	VERB	B
substitution	B-OUT	NOUN	B
of	I-OUT	ADP	O
affricates	I-OUT	NOUN	B
by	I-OUT	ADP	O
fricatives	I-OUT	NOUN	B
for	O	ADP	O
children	O	NOUN	B
using	O	VERB	O
NLFC	B-I	PROPN	B
,	O	PUNCT	O
compared	O	VERB	O
to	O	ADP	O
children	O	NOUN	B
using	O	VERB	O
conventional	B-I	ADJ	B
amplification	I-I	NOUN	I
.	I-I	PUNCT	O


After	O	ADP	O
allowing	O	VERB	O
for	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
multiple	O	ADJ	B
demographic	O	ADJ	B
variables	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
global	B-OUT	ADJ	B
language	I-OUT	NOUN	O
scores	I-OUT	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
(	O	PUNCT	O
effect	O	NOUN	B
:	O	PUNCT	O
0.8	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
:	O	PUNCT	O
-	O	PUNCT	O
6.7	O	NUM	O
,	O	PUNCT	O
8.3	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
There	O	PRON	O
is	O	AUX	O
insufficient	O	ADJ	O
evidence	O	NOUN	B
to	O	PART	O
indicate	O	VERB	O
a	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
language	B-OUT	NOUN	B
ability	I-OUT	NOUN	B
between	O	ADP	O
children	B-P	NOUN	B
using	I-P	VERB	O
NLFC	I-I	PROPN	B
and	I-P	CCONJ	O
those	I-P	DET	O
using	I-P	VERB	O
conventional	I-I	ADJ	B
amplification	I-I	NOUN	I
.	I-I	PUNCT	O


Mechanisms	O	NOUN	B
underlying	O	VERB	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
effect	O	NOUN	B
of	O	ADP	O
implantable	B-I	ADJ	B
cardioverter-defibrillator	I-I	ADJ	I
therapy	I-I	NOUN	I
on	O	ADP	O
mortality	B-OUT	NOUN	B
in	O	ADP	O
high-risk	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
recent	I-P	ADJ	O
myocardial	I-P	ADJ	B
infarction	I-P	NOUN	I
:	I-P	PUNCT	O
insights	O	NOUN	O
from	O	ADP	O
the	O	DET	O
Defibrillation	O	PROPN	B
in	O	ADP	O
Acute	O	PROPN	B
Myocardial	O	PROPN	I
Infarction	O	PROPN	I
Trial	O	PROPN	I
(	O	PUNCT	O
DINAMIT	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
although	O	SCONJ	O
implantable	B-I	ADJ	B
cardioverter-defibrillators	I-I	NOUN	I
(	O	PUNCT	O
ICDs	O	NOUN	B
)	O	PUNCT	O
lower	O	ADJ	O
mortality	O	NOUN	B
in	O	ADP	O
stable	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
low	I-P	ADJ	B
ejection	I-P	NOUN	I
fraction	I-P	NOUN	I
late	I-P	ADJ	I
after	I-P	ADP	O
myocardial	I-P	ADJ	B
infarction	I-P	NOUN	I
,	O	PUNCT	O
randomized	O	ADJ	B
trials	O	NOUN	I
of	O	ADP	O
ICD	B-I	PROPN	B
versus	O	CCONJ	O
control	O	NOUN	B
subjects	O	NOUN	I
implanted	O	VERB	B
early	O	ADV	O
after	O	ADP	O
myocardial	O	ADJ	B
infarction	O	NOUN	I
do	O	AUX	O
not	O	PART	O
show	O	VERB	O
mortality	O	NOUN	B
benefit	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
possible	O	ADJ	O
mechanisms	O	NOUN	B
underlying	O	VERB	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
mortality	B-OUT	NOUN	B
benefit	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Defibrillation	O	PROPN	B
in	O	ADP	O
Acute	O	PROPN	B
Myocardial	O	PROPN	I
Infarction	O	PROPN	I
Trial	O	PROPN	I
(	O	PUNCT	O
DINAMIT	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
this	O	DET	O
is	O	AUX	O
a	O	DET	O
secondary	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Outpatients	B-P	NOUN	B
with	I-P	ADP	O
recent	I-P	ADJ	O
(	I-P	PUNCT	O
6	I-P	NUM	O
to	I-P	PART	O
40	I-P	NUM	O
days	I-P	NOUN	B
)	I-P	PUNCT	O
acute	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
,	I-P	PUNCT	O
left	I-P	VERB	B
ventricular	I-P	ADJ	I
dysfunction	I-P	NOUN	I
(	I-P	PUNCT	O
ejection	I-P	NOUN	B
fraction	I-P	NOUN	I
<	I-P	X	O
35	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
low	I-P	ADJ	B
heart	I-P	NOUN	O
rate	I-P	NOUN	O
variability	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
ICD	B-I	PROPN	B
(	O	PUNCT	O
n=311	O	PROPN	O
)	O	PUNCT	O
or	O	CCONJ	O
to	O	PART	O
standard	B-I	ADJ	B
medical	I-I	ADJ	B
therapy	I-I	NOUN	I
(	O	PUNCT	O
n=342	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
competing-risks	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
those	O	DET	O
factors	O	NOUN	B
that	O	PRON	O
increased	O	VERB	B
the	O	DET	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
arrhythmic	I-OUT	ADJ	B
death	I-OUT	NOUN	I
also	O	ADV	O
increased	O	VERB	B
the	O	DET	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
nonarrhythmic	I-OUT	ADJ	B
deaths	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


After	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
these	O	DET	O
factors	O	NOUN	B
,	O	PUNCT	O
receiving	O	VERB	O
an	O	DET	O
ICD	O	PROPN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
decreased	O	VERB	B
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
arrhythmic	I-OUT	ADJ	B
death	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.33	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.15	O	NUM	O
to	O	PART	O
0.71	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
nonarrhythmic	B-OUT	ADJ	B
death	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
1.70	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1.00	O	NUM	O
to	O	PART	O
2.80	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
adjusted	O	ADJ	O
time-dependent	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
patients	O	NOUN	B
receiving	O	VERB	O
an	O	DET	O
ICD	O	PROPN	B
and	O	CCONJ	O
having	O	VERB	O
appropriate	O	ADJ	O
ICD	O	PROPN	B
therapy	O	NOUN	B
had	O	AUX	O
a	O	DET	O
15.1	O	NUM	O
%	O	NOUN	O
yearly	B-OUT	ADJ	B
hazard	I-OUT	NOUN	B
of	I-OUT	ADP	O
mortality	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
5.2	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
ICD	B-P	NOUN	B
patients	I-P	NOUN	B
with	O	ADP	O
no	O	DET	O
appropriate	O	ADJ	O
therapy	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
sudden	B-OUT	ADJ	B
death	I-OUT	NOUN	I
in	O	ADP	O
ICD	B-P	NOUN	B
patients	I-P	NOUN	B
was	O	AUX	O
completely	O	ADV	O
offset	O	VERB	O
by	O	ADP	O
increased	O	VERB	B
nonarrhythmic	B-OUT	ADJ	B
deaths	I-OUT	NOUN	I
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
greatest	O	ADJ	O
in	O	ADP	O
patients	B-P	NOUN	B
receiving	O	VERB	O
ICD	O	NOUN	B
shock	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
6.0	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
2.8	O	NUM	O
to	O	PART	O
12.7	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
receiving	I-P	VERB	O
ICDs	I-P	NOUN	B
early	I-P	ADV	B
after	I-P	ADP	O
myocardial	I-P	ADJ	B
infarction	I-P	NOUN	I
,	O	PUNCT	O
those	O	DET	O
factors	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
arrhythmia	O	NOUN	B
requiring	O	VERB	O
ICD	O	NOUN	B
therapy	O	NOUN	B
are	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
high	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
nonsudden	B-OUT	ADJ	B
death	I-OUT	NOUN	I
,	O	PUNCT	O
negating	O	VERB	O
the	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
ICDs	O	PROPN	B
in	O	ADP	O
this	O	DET	O
setting	O	NOUN	O
.	O	PUNCT	O


Controlled	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
IV	O	NUM	O
cyclophosphamide	B-I	NOUN	O
versus	O	CCONJ	O
IV	O	NUM	B
methylprednisolone	B-I	NOUN	B
in	O	ADP	O
severe	B-P	ADJ	O
neurological	I-P	ADJ	B
manifestations	I-P	NOUN	I
in	I-P	ADP	O
systemic	I-P	ADJ	B
lupus	I-P	NOUN	I
erythematosus	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Severe	B-P	ADJ	B
neurological	I-P	ADJ	B
involvement	I-P	NOUN	B
in	I-P	ADP	O
systemic	I-P	ADJ	B
lupus	I-P	NOUN	I
erythematosus	I-P	NOUN	I
(	I-P	PUNCT	O
NPSLE	I-P	NOUN	B
)	I-P	PUNCT	O
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
dreadful	O	ADJ	O
complications	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
identify	O	VERB	O
the	O	DET	O
best	O	ADJ	O
drug	O	NOUN	B
,	O	PUNCT	O
dose	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
treatment	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
controlled	O	VERB	B
clinical	O	ADJ	I
trial	O	NOUN	I
at	O	ADP	O
two	B-P	NUM	O
tertiary	I-P	ADJ	B
care	I-P	NOUN	I
centres	I-P	NOUN	I
of	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
SLE	I-P	NOUN	B
according	I-P	VERB	O
to	I-P	ADP	O
the	I-P	DET	O
ACR	I-P	NOUN	B
criteria	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
incident	I-P	NOUN	B
(	I-P	PUNCT	O
no	I-P	ADV	O
more	I-P	ADJ	O
than	I-P	ADP	O
15	I-P	NUM	O
days	I-P	NOUN	B
)	I-P	PUNCT	O
onset	I-P	NOUN	O
of	I-P	ADP	O
severe	I-P	ADJ	B
NP	I-P	NOUN	B
manifestations	I-P	NOUN	B
such	I-P	ADJ	O
as	I-P	ADP	O
seizures	I-P	NOUN	B
,	I-P	PUNCT	O
optic	I-P	ADJ	B
neuritis	I-P	NOUN	I
,	I-P	PUNCT	O
peripheral	I-P	ADJ	B
or	I-P	CCONJ	O
cranial	I-P	ADJ	B
neuropathy	I-P	NOUN	I
,	I-P	PUNCT	O
coma	I-P	NOUN	B
,	I-P	PUNCT	O
brainstem	I-P	NOUN	B
disease	I-P	NOUN	I
,	I-P	PUNCT	O
or	I-P	CCONJ	O
transverse	I-P	ADJ	B
myelitis	I-P	NOUN	I
.	I-P	PUNCT	O


Induction	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
3	O	NUM	O
g	O	NOUN	O
of	O	ADP	O
IV	O	NUM	O
methylprednisolone	B-I	NOUN	O
(	O	PUNCT	O
MP	O	NOUN	B
)	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
either	O	CCONJ	O
IV	O	NUM	B
monthly	O	ADJ	I
cyclophosphamide	B-I	NOUN	I
(	O	PUNCT	O
Cy	O	NOUN	B
)	O	PUNCT	O
versus	O	CCONJ	O
IV	B-I	NUM	B
MP	I-I	NOUN	I
bimonthly	I-I	ADV	B
every	O	DET	O
4	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
IV	O	NUM	B
Cy	O	PROPN	O
or	O	CCONJ	O
IV	O	NUM	B
MP	O	NOUN	I
every	O	DET	O
3	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
another	O	DET	O
year	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
response	B-OUT	NOUN	B
to	I-OUT	PART	O
treatment	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
at	O	ADP	O
least	O	ADV	O
20	B-OUT	NUM	O
%	I-OUT	NOUN	O
improvement	I-OUT	NOUN	B
from	I-OUT	ADP	O
basal	I-OUT	ADJ	B
conditions	I-OUT	NOUN	I
on	O	ADP	O
clinical	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
laboratory	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
specific	I-OUT	ADJ	O
neurological	I-OUT	ADJ	B
testing	I-OUT	NOUN	I
variables	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Overall	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
of	O	ADP	O
75	O	NUM	O
%	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
32	B-P	NUM	O
patients	I-P	NOUN	B
studied	I-P	VERB	B
,	O	PUNCT	O
18/19	O	NUM	O
receiving	O	VERB	O
Cy	O	PROPN	B
and	O	CCONJ	O
7/13	O	NUM	O
receiving	O	VERB	O
MP	O	NOUN	B
responded	O	VERB	O
to	O	PART	O
treatment	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Cy	O	PROPN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
effective	B-OUT	ADJ	B
than	O	ADP	O
MP	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
,	O	PUNCT	O
severe	O	ADJ	B
NPSLE	O	NOUN	B
.	O	PUNCT	O


Learning	O	NOUN	B
curve	O	NOUN	I
in	O	ADP	O
multidetector	B-I	NOUN	B
CT	I-I	NOUN	I
coronary	I-I	ADJ	I
angiography	I-I	NOUN	I
(	O	PUNCT	O
MDCT-CA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


PURPOSE	O	ADJ	O
Coronary	B-I	ADJ	B
angiography	I-I	NOUN	I
using	I-I	VERB	O
multidetector	I-I	NOUN	B
computed	I-I	ADJ	I
tomography	I-I	NOUN	I
(	I-I	PUNCT	O
MDCT-CA	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
a	O	DET	O
recent	O	ADJ	O
technique	O	NOUN	B
for	O	ADP	O
the	O	DET	O
nonivasive	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
coronary	O	ADJ	B
arteries	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
diagnostic	B-OUT	ADJ	B
accuracy	I-OUT	NOUN	I
of	I-OUT	ADP	O
coronary	I-OUT	ADJ	B
artery	I-OUT	NOUN	I
stenosis	I-OUT	NOUN	I
evaluation	I-OUT	NOUN	B
obtained	O	VERB	O
by	O	ADP	O
three	B-P	NUM	O
readers	I-P	NOUN	B
at	I-P	ADP	O
different	I-P	ADJ	O
levels	I-P	NOUN	B
of	I-P	ADP	O
training	I-P	NOUN	B
or	I-P	CCONJ	O
at	I-P	ADP	O
different	I-P	ADJ	O
points	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
learning	I-P	NOUN	B
curve	I-P	NOUN	I
proposed	I-P	VERB	O
by	I-P	ADP	O
the	I-P	DET	O
international	I-P	ADJ	B
guidelines	I-P	NOUN	I
.	I-P	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
Three	B-P	NUM	O
radiologists	I-P	NOUN	B
in	I-P	ADP	O
training	I-P	NOUN	B
with	I-P	ADP	O
different	I-P	ADJ	O
levels	I-P	NOUN	B
of	I-P	ADP	O
experience	I-P	NOUN	B
in	I-P	ADP	O
MDCT-CA	I-P	NOUN	B
scored	O	VERB	B
50	O	NUM	O
cases	O	NOUN	B
at	O	ADP	O
various	O	ADJ	O
time	O	NOUN	B
points	O	NOUN	I
of	O	ADP	O
the	O	DET	O
learning	O	NOUN	B
curve	O	NOUN	I
:	O	PUNCT	O
baseline	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
8	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	B-P	DET	O
trainee	I-P	NOUN	B
radiologists	I-P	NOUN	I
evaluated	O	VERB	B
the	O	DET	O
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
stenosis	I-OUT	NOUN	B
on	I-OUT	ADP	O
each	I-OUT	DET	O
coronary	I-OUT	ADJ	B
segment	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
overall	B-OUT	ADJ	O
accuracy	I-OUT	NOUN	B
was	O	AUX	O
calculated	O	VERB	B
on	O	ADP	O
a	O	DET	O
per-segment	O	ADJ	B
,	O	PUNCT	O
pervessel	O	NOUN	B
and	O	CCONJ	O
per-patient	O	ADJ	B
basis	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	O
All	O	DET	O
readers	O	NOUN	B
improved	B-OUT	VERB	O
analysis	I-OUT	NOUN	B
accuracy	I-OUT	NOUN	B
per	I-OUT	ADP	O
segment	I-OUT	NOUN	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
73-90	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
sensitivity	B-OUT	NOUN	B
reached	O	VERB	O
45	O	NUM	O
%	O	NOUN	O
per	O	ADP	O
segment	O	NOUN	B
,	O	PUNCT	O
84	O	NUM	O
%	O	NOUN	O
per	O	ADP	B
vessel	O	NOUN	I
and	O	CCONJ	O
93	O	NUM	O
%	O	NOUN	O
per	O	ADP	O
patient	O	NOUN	B
;	O	PUNCT	O
specificity	B-OUT	NOUN	B
was	O	AUX	O
99	O	NUM	O
%	O	NOUN	O
per	O	ADP	O
segment	O	NOUN	B
and	O	CCONJ	O
vessel	O	NOUN	B
and	O	CCONJ	O
98	O	NUM	O
%	O	NOUN	O
per	O	ADP	O
patient	O	NOUN	B
.	O	PUNCT	O


Positive	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
negative	I-OUT	ADJ	B
predictive	I-OUT	ADJ	O
values	I-OUT	NOUN	O
increased	I-OUT	VERB	B
to	O	ADP	O
94	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
92	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Although	O	SCONJ	O
all	O	DET	O
readers	O	NOUN	B
improved	O	VERB	B
in	O	ADP	O
diagnostic	B-OUT	ADJ	B
performance	I-OUT	NOUN	I
with	O	ADP	O
growing	O	VERB	O
experience	O	NOUN	O
with	O	ADP	O
MDCT-CA	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
longer	B-I	ADJ	O
training	I-I	NOUN	B
period	I-I	NOUN	B
may	O	AUX	O
be	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
achieve	O	VERB	O
adequate	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
expertise	O	NOUN	B
in	O	ADP	O
MDCT-CA	O	NOUN	B
to	O	PART	O
be	O	AUX	O
able	O	ADJ	O
to	O	PART	O
perform	O	VERB	O
as	O	ADP	O
independent	O	ADJ	B
readers	O	NOUN	B
.	O	PUNCT	O


Benefit	O	NOUN	B
of	O	ADP	O
adjuvant	B-I	ADJ	B
interferon	I-I	NOUN	I
alfa-2b	I-I	NOUN	I
(	I-I	PUNCT	O
IFN-α	I-I	NOUN	B
)	I-I	PUNCT	O
therapy	I-I	NOUN	B
in	I-P	ADP	O
melanoma	I-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
high	I-P	ADJ	O
serum	I-P	NOUN	B
MMP-8	I-P	NOUN	B
levels	I-P	NOUN	B
.	O	PUNCT	O


Matrix	O	NOUN	B
metalloproteinases	O	NOUN	I
(	O	PUNCT	O
MMPs	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
important	O	ADJ	O
enzymes	O	NOUN	B
in	O	ADP	O
tissue	O	NOUN	B
turnover	O	NOUN	B
and	O	CCONJ	O
various	O	ADJ	O
inflammatory	O	ADJ	B
processes	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
evaluated	O	VERB	B
whether	O	SCONJ	O
serum	O	NOUN	B
MMP-8	O	NOUN	B
can	O	AUX	O
predict	O	VERB	O
the	O	DET	O
response	O	NOUN	B
to	B-I	PART	O
adjuvant	I-I	ADJ	B
interferon	I-I	NOUN	I
alfa-2b	I-I	NOUN	I
(	I-I	PUNCT	O
IFN-α	I-I	NOUN	B
)	I-I	PUNCT	O
therapy	I-I	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
operated	O	VERB	B
high-risk	O	ADJ	B
cutaneous	O	ADJ	O
melanoma	B-P	NOUN	O
.	O	PUNCT	O


Pre-treatment	O	ADJ	B
sera	O	NOUN	B
from	B-P	ADP	O
460	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
stage	I-P	NOUN	B
IIB-IIIC	I-P	NOUN	I
melanoma	I-P	NOUN	I
were	I-P	AUX	O
analyzed	I-P	VERB	B
for	I-P	ADP	O
MMP-8	I-P	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
after	B-I	ADP	O
surgery	I-I	NOUN	B
to	I-I	PART	O
adjuvant	I-I	VERB	B
IFN-α	I-I	NOUN	B
for	O	ADP	O
12	O	NUM	O
or	O	CCONJ	O
24	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
313	O	NUM	O
)	O	PUNCT	O
or	B-I	CCONJ	O
observation	I-I	NOUN	B
only	I-I	ADV	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
147	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
median	I-OUT	ADJ	B
serum	I-OUT	NOUN	B
MMP-8	I-OUT	NOUN	B
level	I-OUT	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
classify	O	VERB	O
the	O	DET	O
patients	O	NOUN	B
into	O	ADP	O
a	O	DET	O
low	O	ADJ	B
MMP-8	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
232	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
high	O	ADJ	O
MMP-8	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
228	O	NUM	O
)	O	PUNCT	O
group	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
high	O	ADJ	O
MMP-8	O	NOUN	B
subgroup	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
IFN-α	I-OUT	NOUN	B
therapy	I-OUT	NOUN	B
significantly	O	ADV	O
improved	B-OUT	VERB	O
relapse-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RFS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


RFS	O	NOUN	B
was	O	AUX	O
36.8	O	NUM	O
months	B-P	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
high	I-OUT	ADJ	O
MMP-8	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
receiving	I-I	VERB	O
IFN-α	I-I	NOUN	B
therapy	I-I	NOUN	B
,	O	PUNCT	O
whereas	B-OUT	SCONJ	O
RFS	O	NOUN	B
for	O	ADP	O
those	O	DET	O
with	O	ADP	O
high	B-OUT	ADJ	O
MMP-8	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
with	O	ADP	O
observation	O	NOUN	B
only	O	ADV	O
was	O	AUX	O
10.6	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.027	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
overall	I-OUT	ADJ	O
survival	I-OUT	NOUN	B
for	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
high	I-OUT	ADJ	O
MMP-8	I-OUT	NOUN	B
and	O	CCONJ	O
observation	O	NOUN	B
only	O	ADV	O
was	O	AUX	O
36.7	O	NUM	O
versus	O	CCONJ	O
71.7	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
those	O	DET	O
receiving	O	VERB	O
IFN-α	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.13	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
multivariate	O	ADJ	B
model	B-OUT	NOUN	I
,	I-OUT	PUNCT	O
IFN-α	I-OUT	NOUN	B
therapy	I-OUT	NOUN	I
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
favorable	B-OUT	ADJ	O
RFS	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
0.74	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.55-0.99	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.048	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
after	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
pre-treatment	O	ADJ	B
MMP-8	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
1.17	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.88-1.55	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.28	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
gender	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
1.16	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.86-1.56	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.32	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
age	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
1.00	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1.00-1.02	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.12	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
ulceration	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
1.09	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.81-1.46	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.58	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
node	O	NOUN	B
metastases	O	NOUN	I
(	O	PUNCT	O
HR	O	NOUN	B
1.36	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1.17-1.58	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
patients	O	NOUN	B
with	B-OUT	ADP	O
high	I-OUT	ADJ	O
serum	I-OUT	NOUN	B
MMP-8	I-OUT	NOUN	B
levels	O	NOUN	B
may	O	AUX	O
benefit	B-I	VERB	O
from	I-I	ADP	O
adjuvant	I-I	ADJ	B
IFN-α	I-I	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
observation	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
further	O	ADV	O
investigated	O	VERB	B
.	O	PUNCT	O


Improved	B-OUT	ADJ	O
responsiveness	I-OUT	NOUN	B
of	O	ADP	O
PCOS	B-P	NOUN	B
patients	I-P	NOUN	B
to	O	PART	O
clomiphene	B-I	NOUN	B
after	I-P	ADP	O
CYP17a	I-I	NOUN	B
inhibitor	I-I	NOUN	B
.	I-I	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
study	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
CYP17a	B-I	NOUN	B
inhibitor	I-I	NOUN	B
,	I-I	PUNCT	O
"	I-I	PUNCT	O
ketoconazole	I-I	NOUN	B
,	I-I	PUNCT	O
"	I-I	PUNCT	O
on	O	ADP	O
clomiphene	O	NOUN	B
responsiveness	O	NOUN	B
in	O	ADP	O
PCOS	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Prospective	O	ADJ	B
analysis	O	NOUN	I
was	O	AUX	O
employed	O	VERB	O
with	O	ADP	O
the	O	DET	O
setup	O	NOUN	B
at	O	ADP	O
Alexandria	B-P	PROPN	B
IVF/ICSI	I-P	NOUN	B
center	I-P	NOUN	I
.	I-P	PUNCT	O


Ninety-seven	B-P	NUM	O
insulin-resistant	I-P	ADJ	B
PCOS	I-P	NOUN	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
ovulation	I-P	NOUN	B
induction	I-P	NOUN	B
using	I-P	VERB	O
clomiphene	I-I	NOUN	B
citrate	I-I	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
,	O	PUNCT	O
by	O	ADP	O
random	O	ADJ	B
number	O	NOUN	I
table	O	NOUN	I
,	O	PUNCT	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
group	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
49	O	NUM	O
)	O	PUNCT	O
received	O	VERB	O
ketoconazole	B-I	NOUN	B
(	O	PUNCT	O
400	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
till	O	SCONJ	O
correction	O	NOUN	B
of	O	ADP	O
metabolic	O	ADJ	B
syndrome	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
clomiphene	B-I	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg/day	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
the	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
48	O	NUM	O
)	O	PUNCT	O
receiving	O	VERB	O
clomiphene	B-I	NOUN	B
without	I-I	ADP	O
ketoconazole	I-I	NOUN	B
pretreatment	I-I	NOUN	B
.	I-I	PUNCT	O


Main	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	O
were	O	AUX	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
clomiphene	I-OUT	NOUN	B
resistance	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
monofollicular	I-OUT	NOUN	B
response	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
fasting	I-OUT	VERB	B
insulin/glucose	I-OUT	NOUN	B
ratio	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
serum	I-OUT	NOUN	B
testosterone	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
pregnancy	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
ketoconazole	B-I	NOUN	B
group	O	NOUN	B
showed	O	VERB	O
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
higher	O	ADJ	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
monofollicular	I-OUT	ADJ	B
response	I-OUT	NOUN	B
(	O	PUNCT	O
38	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
higher	B-OUT	ADJ	B
pregnancy	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
significantly	B-OUT	ADV	O
less	I-OUT	ADV	O
marked	I-OUT	ADJ	O
antiestrogenic	I-OUT	ADJ	B
manifestations	I-OUT	NOUN	B
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


They	O	PRON	O
also	O	ADV	O
had	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
clomiphene	I-OUT	NOUN	B
resistance	I-OUT	NOUN	B
(	O	PUNCT	O
11.6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
lower	B-OUT	ADJ	O
serum	I-OUT	NOUN	B
testosterone	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
,	O	PUNCT	O
less	O	ADJ	O
hyperinsulinaemia	B-OUT	NOUN	B
,	O	PUNCT	O
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Ketoconazole	B-I	NOUN	B
improved	O	VERB	O
clomiphene	B-OUT	NOUN	B
responsivenss	I-OUT	NOUN	B
in	I-OUT	ADP	O
PCOS	I-OUT	NOUN	B
patients	I-OUT	NOUN	B
and	O	CCONJ	O
attenuated	O	VERB	B
its	O	PRON	O
untoward	B-OUT	ADJ	O
biological	I-OUT	ADJ	B
effects	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Efficacy	O	NOUN	B
of	O	ADP	O
colchicine	B-I	NOUN	B
versus	O	CCONJ	O
placebo	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
pericardial	B-P	ADJ	B
effusion	I-P	NOUN	I
after	I-P	ADP	O
open-heart	I-P	ADJ	B
surgery	I-P	NOUN	I
:	I-P	PUNCT	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Pericardial	B-OUT	ADJ	B
effusion	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
complication	O	NOUN	B
after	O	ADP	O
open-heart	O	ADJ	B
surgery	O	NOUN	I
,	O	PUNCT	O
accounts	O	VERB	O
for	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
to	O	PART	O
85	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
reversible	O	ADJ	O
in	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
could	O	AUX	O
be	O	AUX	O
life	O	NOUN	B
threatening	O	VERB	I
in	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
tamponade	O	NOUN	B
in	O	ADP	O
large	O	ADJ	O
effusions	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
therapeutic	O	ADJ	B
efficacy	O	NOUN	I
of	O	ADP	O
colchicine	O	NOUN	B
on	O	ADP	O
PE	B-OUT	NOUN	B
after	I-P	ADP	O
open-heart	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
is	O	AUX	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
triple-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
single-center	I-P	ADJ	I
trial	I-P	NOUN	I
at	I-P	ADP	O
Tehran	I-P	PROPN	B
Heart	I-P	PROPN	I
Center	I-P	PROPN	I
.	I-P	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
149	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
mild	I-P	ADJ	B
or	I-P	CCONJ	O
moderate	I-P	ADJ	B
PE	I-P	NOUN	B
in	I-P	ADP	O
transthoracic	I-P	NOUN	B
echocardiography	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	B-I	VERB	O
1	I-I	NUM	O
mg/d	I-I	NOUN	O
colchicine	I-I	NOUN	B
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
74	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
1	I-I	NUM	O
tablet	I-I	NOUN	B
of	I-I	ADP	O
placebo	I-I	NOUN	B
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
75	I-I	NUM	O
)	I-I	PUNCT	O
for	I-I	ADP	O
2	I-I	NUM	O
weeks	I-I	NOUN	B
and	I-I	CCONJ	O
then	I-I	ADV	O
underwent	I-I	VERB	O
follow-up	I-I	ADJ	B
echocardiography	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	VERB	O
Baseline	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
characteristics	O	NOUN	I
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
study	O	NOUN	B
groups	O	NOUN	B
except	O	SCONJ	O
for	O	ADP	O
age	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.02	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
graft	O	NOUN	B
numbers	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
pretreatment	O	NOUN	B
and	O	CCONJ	O
posttreatment	O	NOUN	B
PE	B-OUT	NOUN	B
sizes	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
study	O	NOUN	B
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.440	O	NUM	O
and	O	CCONJ	O
.844	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Median	O	ADJ	B
(	O	PUNCT	O
25th-75th	O	ADJ	O
percentiles	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
effusion	B-OUT	NOUN	B
changes	I-OUT	NOUN	B
was	O	AUX	O
5	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
1-7.6	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
colchicine	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
5	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
1-6.6	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.932	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Intervention	O	NOUN	B
had	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
impact	O	NOUN	B
on	O	ADP	O
pretreatment	O	NOUN	B
and	O	CCONJ	O
posttreatment	B-OUT	NOUN	B
effusion	I-OUT	NOUN	B
values	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
changes	I-OUT	NOUN	B
in	O	ADP	O
isolated	B-OUT	VERB	B
coronary	I-OUT	ADJ	O
artery	I-OUT	NOUN	O
bypass	I-OUT	NOUN	O
graft	I-OUT	NOUN	B
surgery	I-OUT	NOUN	I
patients	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.607	O	NUM	O
,	O	PUNCT	O
.539	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
.628	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
possible	O	ADJ	O
confounders	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
still	O	ADV	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
postoperative	O	ADJ	B
PE	B-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
study	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
t	O	NOUN	O
=	O	ADJ	O
-0.285	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.776	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
We	O	PRON	O
concluded	O	VERB	O
that	O	SCONJ	O
prescription	O	NOUN	B
of	O	ADP	O
colchicine	B-I	NOUN	B
does	O	AUX	O
not	O	PART	O
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
asymptomatic	B-OUT	ADJ	B
postoperative	I-OUT	ADJ	B
PE	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
could	O	AUX	O
be	O	AUX	O
justified	O	VERB	O
in	O	ADP	O
case	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
etiology	O	NOUN	B
of	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
PEs	B-P	NOUN	B
might	O	AUX	O
be	O	AUX	O
contribution	O	NOUN	B
of	O	ADP	O
noninflammatory	O	ADJ	B
factors	O	NOUN	O
which	O	DET	O
are	O	AUX	O
better	O	ADJ	O
to	O	PART	O
be	O	AUX	O
dealt	O	VERB	O
with	O	ADP	O
observational	O	ADJ	B
approaches	O	NOUN	I
.	O	PUNCT	O


Intravenous	O	ADJ	B
pretreatment	O	NOUN	B
of	O	ADP	O
hypertonic	B-I	ADJ	B
saline	I-I	NOUN	I
can	O	AUX	O
prevent	O	VERB	B
systemic	B-OUT	ADJ	B
hypotension	I-OUT	NOUN	I
induced	O	VERB	B
by	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Hypertonic	O	ADJ	B
saline	O	NOUN	I
improves	O	VERB	B
organ	B-OUT	NOUN	B
perfusion	I-OUT	NOUN	I
and	O	CCONJ	O
patient	B-OUT	NOUN	B
survival	I-OUT	NOUN	I
during	O	ADP	O
hemorrhagic	O	ADJ	B
shock	O	NOUN	I
because	O	SCONJ	O
it	O	PRON	O
expands	O	VERB	O
plasma	O	NOUN	B
volume	O	NOUN	I
and	O	CCONJ	O
increases	O	VERB	B
tissue	O	NOUN	B
oxygenation	O	NOUN	I
.	O	PUNCT	O


Its	O	PRON	O
beneficial	O	ADJ	O
results	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
hypotension	O	NOUN	B
during	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
between	O	ADP	O
prehydration	O	NOUN	B
with	O	ADP	O
3	O	NUM	O
%	O	NOUN	O
hypertonic	B-I	ADJ	B
saline	I-I	NOUN	I
and	I-I	CCONJ	O
with	I-I	ADP	O
isotonic	I-I	ADJ	B
lactated	I-I	ADJ	I
Ringer	I-I	NOUN	I
's	I-I	PART	I
solution	I-I	NOUN	I
on	O	ADP	O
the	O	DET	O
hemodynamic	O	ADJ	B
changes	O	NOUN	B
and	O	CCONJ	O
serum	O	NOUN	B
electrolyte	O	NOUN	O
concentrations	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
spinal	I-P	ADJ	B
anesthesia	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Sixty	B-P	NUM	B
ASA	I-P	NOUN	B
class	I-P	NOUN	B
I	I-P	NUM	I
patients	I-P	NOUN	B
scheduled	I-P	VERB	O
for	I-P	ADP	O
herniorrhapy	I-I	NOUN	B
under	I-P	ADP	O
spinal	I-P	ADJ	B
anesthesia	I-P	NOUN	I
were	O	AUX	O
assigned	O	VERB	O
randomly	O	ADV	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Group	B-P	NOUN	B
1	I-P	NUM	O
=	I-P	ADJ	O
patients	I-P	NOUN	B
were	O	AUX	O
prehydrated	B-I	VERB	B
with	I-I	ADP	O
isotonic	I-I	ADJ	B
lactated	I-I	ADJ	I
Ringer	I-I	NOUN	I
's	I-I	PART	I
solution	I-I	NOUN	I
at	I-I	ADP	O
7	I-I	NUM	O
mg/kg	I-I	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
30	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
Group	B-P	PROPN	B
2	I-P	NUM	O
=	I-P	ADJ	O
patients	I-P	NOUN	B
were	O	AUX	O
given	O	VERB	O
prehydration	B-I	NOUN	B
with	I-I	ADP	O
3	I-I	NUM	O
%	I-I	NOUN	O
hypertonic	I-I	ADJ	B
saline	I-I	NOUN	I
at	I-I	ADP	O
7	I-I	NUM	O
ml/kg	I-I	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
30	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Following	O	VERB	O
prehydration	O	NOUN	B
,	O	PUNCT	O
arterial	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
and	O	CCONJ	O
serum	B-OUT	NOUN	B
electrolyte	I-OUT	NOUN	O
concentrations	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
hypotension	I-OUT	NOUN	B
was	O	AUX	O
17/30	O	NUM	O
(	O	PUNCT	O
57	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
isotonic	O	ADJ	B
lactated	O	ADJ	I
Ringer	O	NOUN	I
's	O	PART	I
solution	O	NOUN	I
group	O	NOUN	B
as	O	ADP	O
against	O	ADP	O
7/30	O	NUM	O
(	O	PUNCT	O
23	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
hypertonic	O	ADJ	B
saline	O	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	B-OUT	ADJ	I
difference	I-OUT	NOUN	O
between	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
the	O	DET	O
level	B-OUT	NOUN	B
of	I-OUT	ADP	O
anesthesia	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
maximal	I-OUT	ADJ	B
heart	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
electrolyte	I-OUT	NOUN	B
imbalance	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
occur	O	VERB	O
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Prior	O	ADV	O
to	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
,	O	PUNCT	O
hydration	O	NOUN	B
with	O	ADP	O
small	O	ADJ	O
amount	O	NOUN	B
of	O	ADP	O
hypertonic	B-I	ADJ	B
saline	I-I	NOUN	I
is	O	AUX	O
effective	O	ADJ	B
to	O	PART	O
minimize	O	VERB	O
hypotension	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
spinal	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


If	O	SCONJ	O
so	O	ADV	O
administered	O	VERB	B
it	O	PRON	O
would	O	AUX	O
not	O	PART	O
increase	O	VERB	B
bodily	O	ADJ	B
sodium	O	NOUN	I
load	O	NOUN	O
and	O	CCONJ	O
unlike	O	ADP	O
isotonic	O	ADJ	B
crystalloid	O	ADJ	I
solution	O	NOUN	I
it	O	PRON	O
dose	O	NOUN	B
not	O	PART	O
cause	O	VERB	O
accumulation	O	NOUN	B
of	O	ADP	O
water	O	NOUN	B
in	O	ADP	O
the	O	DET	O
body	O	NOUN	B
on	O	ADP	O
equipollent	O	ADJ	O
basis	O	NOUN	O
.	O	PUNCT	O


Dairy	B-I	NOUN	B
products	I-I	NOUN	I
do	O	AUX	O
not	O	PART	O
lead	O	VERB	O
to	O	PART	O
alterations	O	NOUN	B
in	O	ADP	O
body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
fat	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
in	I-OUT	ADP	O
young	I-OUT	ADJ	B
women	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
1-y	O	ADJ	O
intervention	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Previous	O	ADJ	O
results	O	NOUN	O
suggested	O	VERB	O
that	O	SCONJ	O
increased	O	VERB	B
intake	O	NOUN	B
of	O	ADP	O
dairy	B-I	ADJ	B
calcium	I-I	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
reduced	B-OUT	VERB	B
weight	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
fat	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
long-term	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
consumption	O	NOUN	B
of	O	ADP	O
dairy	B-I	ADJ	B
calcium	I-I	NOUN	I
alter	O	VERB	O
body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
fat	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
in	I-OUT	ADP	O
young	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
healthy	I-OUT	ADJ	B
women	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
We	O	PRON	O
used	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
1-y	O	ADJ	O
intervention	O	NOUN	B
for	O	ADP	O
dairy	O	ADJ	B
calcium	O	NOUN	I
.	O	PUNCT	O


Subjects	B-P	NOUN	B
were	I-P	AUX	O
155	I-P	NUM	O
young	I-P	ADJ	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
18-30	I-P	NUM	O
y	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
healthy	I-P	ADJ	B
,	I-P	PUNCT	O
normal-weight	I-P	ADJ	B
women	I-P	NOUN	B
with	I-P	ADP	O
intake	I-P	NOUN	B
of	I-P	ADP	O
dietary	I-I	ADJ	B
calcium	I-I	NOUN	I
<	I-P	NOUN	O
800	I-P	NUM	O
mg/d	I-P	NOUN	O
and	I-P	CCONJ	O
energy	I-P	NOUN	B
intake	I-P	NOUN	I
<	I-P	X	O
/=	I-P	NOUN	O
2200	I-P	NUM	O
kcal/d	I-P	NOUN	O
.	I-P	PUNCT	O


Women	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
1	O	NUM	O
of	O	ADP	O
3	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
control	B-I	NOUN	B
:	I-I	PUNCT	O
continue	I-I	VERB	O
established	I-I	VERB	B
dietary	I-I	ADJ	B
intake	I-I	NOUN	I
;	I-I	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
medium	B-I	NOUN	B
dairy	I-I	NOUN	B
:	I-I	PUNCT	O
substitute	I-I	VERB	B
dairy	I-I	NOUN	I
products	I-I	NOUN	I
to	I-I	PART	O
achieve	I-I	VERB	O
intake	I-I	NOUN	B
of	I-I	ADP	O
calcium	I-I	NOUN	B
of	I-I	ADP	O
approximately	I-I	ADV	B
1000-1100	I-I	NUM	O
mg/d	I-I	NOUN	O
and	I-I	CCONJ	O
maintain	I-I	VERB	O
isocaloric	I-I	ADJ	B
intake	I-I	NOUN	B
;	I-I	PUNCT	O
3	O	X	O
)	O	PUNCT	O
high	B-I	ADJ	O
dairy	I-I	NOUN	B
:	I-I	PUNCT	O
substitute	I-I	VERB	B
dairy	I-I	NOUN	I
products	I-I	NOUN	I
to	I-I	PART	O
achieve	I-I	VERB	O
intake	I-I	NOUN	B
of	I-I	ADP	O
calcium	I-I	NOUN	B
of	I-I	ADP	O
1300-1400	I-I	NUM	O
mg/d	I-I	NOUN	O
and	I-I	CCONJ	O
maintain	I-I	VERB	O
isocaloric	I-I	ADJ	B
intake	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
main	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	O
were	O	AUX	O
1-y	B-OUT	ADJ	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
in	I-OUT	ADP	O
kg	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
fat	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
in	I-OUT	ADP	O
kg	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
thirty-five	I-P	ADJ	O
women	I-P	NOUN	B
completed	I-P	VERB	B
the	I-P	DET	O
trial	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	O
Mean	O	VERB	O
intakes	B-OUT	NOUN	B
of	I-OUT	ADP	O
calcium	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
were	O	AUX	O
742.4	O	NUM	O
+/-	O	CCONJ	O
321.5	O	NUM	O
,	O	PUNCT	O
1026.4	O	NUM	O
+/-	O	CCONJ	O
311.3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1131.29	O	NUM	O
+/-	O	CCONJ	O
337.2	O	NUM	O
mg/d	O	NOUN	O
for	O	ADP	O
the	O	DET	O
control	O	NOUN	B
,	O	PUNCT	O
medium-dairy	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
high-dairy	O	ADJ	B
groups	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
mean	B-OUT	ADJ	O
1-y	I-OUT	ADJ	O
change	I-OUT	NOUN	B
in	I-OUT	ADP	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
control	O	NOUN	B
,	O	PUNCT	O
medium-dairy	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
high-dairy	O	ADJ	B
groups	O	NOUN	I
(	O	PUNCT	O
0.8	O	NUM	O
+/-	O	CCONJ	O
2.8	O	NUM	O
,	O	PUNCT	O
0.7	O	NUM	O
+/-	O	CCONJ	O
3.0	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1.5	O	NUM	O
+/-	O	CCONJ	O
4.1	O	NUM	O
kg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.45	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
mean	B-OUT	ADJ	O
1-y	I-OUT	ADJ	O
change	I-OUT	NOUN	O
in	I-OUT	ADP	O
fat	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
control	O	NOUN	B
,	O	PUNCT	O
medium-dairy	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
high-dairy	O	ADJ	B
groups	O	NOUN	I
(	O	PUNCT	O
-0.5	O	NUM	O
+/-	O	CCONJ	O
2.5	O	NUM	O
,	O	PUNCT	O
0.3	O	NUM	O
+/-	O	CCONJ	O
2.7	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
0.5	O	NUM	O
+/-	O	CCONJ	O
3.5	O	NUM	O
kg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.26	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Increased	O	VERB	B
intake	O	NOUN	B
of	O	ADP	O
dairy	B-I	NOUN	B
products	I-I	NOUN	I
does	O	AUX	O
not	O	PART	O
alter	O	VERB	O
body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
fat	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
in	I-OUT	ADP	O
young	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
healthy	I-OUT	ADJ	B
women	I-OUT	NOUN	B
over	I-OUT	ADP	O
1	I-OUT	NUM	O
y	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


A	O	DET	O
Randomized	O	ADJ	B
Clinical	O	PROPN	I
Trial	O	PROPN	I
Comparison	O	NOUN	B
Between	O	ADP	O
Pivotal	B-I	PROPN	B
Response	I-I	NOUN	I
Treatment	I-I	NOUN	O
(	I-I	PUNCT	O
PRT	I-I	PROPN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
Adult-Driven	I-I	ADJ	B
Applied	I-I	PROPN	I
Behavior	I-I	PROPN	I
Analysis	I-I	PROPN	I
(	I-I	PUNCT	O
ABA	I-I	NOUN	B
)	I-I	PUNCT	O
Intervention	I-I	NOUN	B
on	O	ADP	O
Disruptive	B-OUT	ADJ	B
Behaviors	I-OUT	PROPN	I
in	I-P	ADP	O
Public	I-P	PROPN	B
School	I-P	PROPN	I
Children	I-P	PROPN	B
with	I-P	ADP	O
Autism	I-P	PROPN	B
.	I-P	PUNCT	O


Children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
often	O	ADV	O
demonstrate	O	VERB	O
disruptive	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
during	O	ADP	O
demanding	O	VERB	O
teaching	O	NOUN	B
tasks	O	NOUN	I
.	O	PUNCT	O


Language	O	NOUN	B
intervention	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
particularly	O	ADV	O
difficult	O	ADJ	O
as	O	ADP	O
it	O	PRON	O
involves	O	VERB	O
social	O	ADJ	B
and	O	CCONJ	O
communicative	O	ADJ	B
areas	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
challenging	O	VERB	O
for	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
two	O	NUM	O
intervention	O	NOUN	B
conditions	O	NOUN	O
,	O	PUNCT	O
a	B-I	DET	O
naturalistic	I-I	ADJ	B
approach	I-I	NOUN	I
,	I-I	PUNCT	O
Pivotal	I-I	ADJ	B
Response	I-I	NOUN	I
Treatment	I-I	NOUN	I
(	I-I	PUNCT	O
PRT	I-I	PROPN	B
)	I-I	PUNCT	O
with	I-I	ADP	O
an	I-I	DET	O
adult-directed	I-I	ADJ	B
ABA	I-I	NOUN	B
approach	I-I	NOUN	O
on	I-I	ADP	O
disruptive	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
during	I-I	ADP	O
language	I-I	NOUN	B
intervention	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
public	O	ADJ	B
schools	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
design	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
with	O	ADP	O
two	B-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
,	I-P	PUNCT	O
matched	I-P	VERB	B
according	I-P	VERB	O
to	I-P	ADP	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
sex	I-P	NOUN	B
and	I-P	CCONJ	O
mean	I-P	VERB	O
length	I-P	NOUN	B
of	I-P	ADP	I
utterance	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
data	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
children	O	NOUN	B
demonstrated	O	VERB	O
significantly	O	ADV	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
disruptive	B-OUT	ADJ	B
behavior	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
PRT	O	PROPN	B
condition	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
antecedent	O	ADJ	O
manipulations	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
helpful	O	ADJ	O
in	O	ADP	O
reducing	O	VERB	B
disruptive	B-OUT	ADJ	B
behavior	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Removal	O	NOUN	B
of	O	ADP	O
humoral	O	ADJ	B
mediators	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
survival	O	NOUN	B
of	O	ADP	O
septic	B-P	ADJ	B
patients	I-P	NOUN	B
by	O	ADP	O
hemoperfusion	B-I	NOUN	B
with	O	ADP	O
neutral	O	ADJ	O
microporous	O	ADJ	B
resin	O	NOUN	I
column	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
neutral	B-I	ADJ	B
microporous	I-I	ADJ	B
resin	I-I	NOUN	I
hemoperfusion	I-I	NOUN	I
on	O	ADP	O
hemodynamic	O	ADJ	B
improvement	O	NOUN	B
,	O	PUNCT	O
removal	O	NOUN	B
of	O	ADP	O
inflammatory	O	ADJ	B
cytokines	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
mortality	O	NOUN	B
in	O	ADP	O
critical	B-P	ADJ	B
care	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
sepsis	I-P	NOUN	B
.	I-P	PUNCT	O


Forty-four	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
sepsis	I-P	NOUN	B
or	I-P	CCONJ	O
septic	I-P	ADJ	B
shock	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
HA	B-I	NOUN	B
type	I-I	NOUN	I
hemoperfusion	I-I	NOUN	B
treatment	I-I	NOUN	B
(	O	PUNCT	O
N=24	O	NOUN	O
)	O	PUNCT	O
or	B-I	CCONJ	O
standard	I-I	ADJ	B
therapy	I-I	NOUN	I
(	O	PUNCT	O
N=20	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Those	O	DET	O
undergoing	O	VERB	O
hemoperfusion	O	NOUN	B
treatment	O	NOUN	B
received	O	VERB	O
HA330	B-I	NOUN	B
hemoperfusion	I-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
measured	O	VERB	B
the	O	DET	O
plasma	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
of	I-OUT	ADP	O
IL-6	I-OUT	NOUN	B
and	O	CCONJ	O
IL-8	B-OUT	NOUN	B
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
every	O	DET	O
hemoperfusion	O	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
following	O	VERB	O
parameters	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
between	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
hemoperfusion	B-I	NOUN	B
group	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
3	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
14	O	NUM	O
:	O	PUNCT	O
hemodynamics	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
cardiac	I-OUT	ADJ	B
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
systemic	I-OUT	ADJ	B
vascular	I-OUT	ADJ	B
resistance	I-OUT	NOUN	I
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
mean	I-OUT	VERB	O
arterial	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
change	I-OUT	NOUN	O
of	I-OUT	ADP	O
hematology	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
coagulation	I-OUT	NOUN	B
function	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
organ	I-OUT	ADJ	B
function	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
sequential	B-OUT	ADJ	B
organ	I-OUT	NOUN	B
failure	I-OUT	NOUN	I
assessment	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
SOFA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
score	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Hospital	B-OUT	PROPN	B
,	I-OUT	PUNCT	O
28-day	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
ICU	I-OUT	NOUN	B
mortality	I-OUT	NOUN	B
were	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
.	O	PUNCT	O


Patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
HA	B-I	NOUN	B
hemoperfusion	I-I	NOUN	I
showed	O	VERB	O
a	O	DET	O
significant	B-OUT	ADJ	O
removal	I-OUT	NOUN	B
of	O	ADP	O
plasma	B-OUT	NOUN	B
IL-6	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
IL-8	I-OUT	NOUN	B
over	O	ADP	O
time	O	NOUN	B
while	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HA	O	NOUN	B
group	O	NOUN	O
also	O	ADV	O
demonstrated	O	VERB	O
significant	B-OUT	ADJ	O
increases	I-OUT	NOUN	B
in	O	ADP	O
cardiac	B-OUT	ADJ	B
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
systemic	I-OUT	ADJ	B
vascular	I-OUT	ADJ	B
resistant	I-OUT	ADJ	I
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
fast	I-OUT	ADJ	B
withdrawal	I-OUT	NOUN	I
of	I-OUT	ADP	O
vasoactive	I-OUT	ADJ	B
agents	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
decreases	I-OUT	VERB	B
in	I-OUT	ADP	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
at	O	ADP	O
days	O	NOUN	B
3	O	NUM	O
and	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


Although	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	B-OUT	ADJ	I
difference	I-OUT	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
organ	B-OUT	NOUN	B
dysfunction	I-OUT	NOUN	I
as	O	ADP	O
assessed	O	VERB	B
by	O	ADP	O
SOFA	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
from	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
(	O	PUNCT	O
baseline	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
day	O	NOUN	B
7	O	NUM	O
,	O	PUNCT	O
significant	O	ADJ	B
improvement	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
demonstrated	O	VERB	O
in	O	ADP	O
the	O	DET	O
hemoperfusion	O	NOUN	B
group	O	NOUN	B
at	O	ADP	O
day	O	NOUN	B
14	O	NUM	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	B-OUT	ADJ	I
difference	I-OUT	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
28-day	B-OUT	ADJ	O
mortality	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hospital	I-OUT	NOUN	B
mortality	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
length	I-OUT	NOUN	B
of	I-OUT	ADP	I
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
but	I-OUT	CCONJ	O
ICU	I-OUT	NOUN	B
mortality	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
length	I-OUT	NOUN	B
of	I-OUT	ADP	I
ICU	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
HA	O	NOUN	B
group	O	NOUN	O
were	O	AUX	O
markedly	O	ADV	O
reduced	B-OUT	VERB	B
.	I-OUT	PUNCT	O


Hemoperfusion	O	NOUN	B
treatment	O	NOUN	B
using	O	VERB	O
the	O	DET	O
HA	O	NOUN	B
type	O	NOUN	I
cartridge	O	NOUN	I
in	O	ADP	O
sepsis	O	NOUN	B
is	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
it	O	PRON	O
may	O	AUX	O
improve	O	VERB	O
organ	B-OUT	NOUN	B
dysfunction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
ICU	I-OUT	NOUN	B
mortality	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
shorten	I-OUT	VERB	O
the	I-OUT	DET	O
length	I-OUT	NOUN	B
of	I-OUT	ADP	I
ICU	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Clinical	O	ADJ	B
significant	O	ADJ	I
removal	O	NOUN	B
of	O	ADP	O
inflammatory	O	ADJ	B
cytokines	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
IL-6	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
IL-8	I-OUT	NOUN	B
from	O	ADP	O
circulation	O	NOUN	B
by	O	ADP	O
hemoperfusion	B-I	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	ADP	O
improving	O	VERB	B
a	O	DET	O
patient	O	NOUN	B
's	O	PART	I
outcome	O	NOUN	B
in	O	ADP	O
an	O	DET	O
ICU	O	NOUN	B
.	O	PUNCT	O


Pharmacokinetics	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerance	I-OUT	NOUN	B
of	O	ADP	O
single-	O	ADJ	O
and	O	CCONJ	O
multiple-dose	O	ADJ	B
oral	O	ADJ	I
or	O	CCONJ	O
intravenous	O	ADJ	B
linezolid	B-I	ADJ	B
,	O	PUNCT	O
an	O	DET	O
oxazolidinone	O	NOUN	B
antibiotic	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
healthy	B-P	ADJ	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


AIMS	O	NOUN	B
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
pharmacokinetics	O	NOUN	B
and	O	CCONJ	O
tolerance	B-OUT	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
and	O	CCONJ	O
intravenous	O	ADJ	B
linezolid	B-I	ADJ	B
,	O	PUNCT	O
an	O	DET	O
oxazolidinone	O	NOUN	B
antibiotic	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
healthy	B-P	ADJ	B
volunteers	I-P	NOUN	I
following	O	VERB	O
single-	O	ADJ	O
and	O	CCONJ	O
multiple-dose	O	ADJ	B
administration	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
two	O	NUM	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
dose-escalating	O	ADJ	B
trials	O	NOUN	I
,	O	PUNCT	O
subjects	B-P	NOUN	B
were	O	AUX	O
exposed	O	VERB	B
either	O	CCONJ	O
to	O	PART	O
oral	O	ADJ	B
(	O	PUNCT	O
375	O	NUM	O
,	O	PUNCT	O
500	O	NUM	O
or	O	CCONJ	O
625	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
intravenous	O	ADJ	B
(	O	PUNCT	O
500	O	NUM	O
or	O	CCONJ	O
625	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
linezolid	B-I	ADJ	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
twice	O	ADV	O
daily	O	ADV	O
.	O	PUNCT	O


Serial	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
urine	I-OUT	NOUN	B
samples	I-OUT	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
after	O	ADP	O
the	O	DET	O
first-	O	ADJ	B
and	O	CCONJ	O
multiple-dose	O	ADJ	B
administrations	O	NOUN	I
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
18	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Non-compartmental	O	ADJ	B
pharmacokinetic	B-OUT	ADJ	B
analyses	I-OUT	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
describe	O	VERB	O
the	O	DET	O
disposition	O	NOUN	B
of	O	ADP	O
linezolid	B-I	ADJ	B
.	I-I	PUNCT	O


RESULTS	O	VERB	O
Plasma	B-OUT	NOUN	B
linezolid	I-OUT	ADJ	B
concentrations	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
area	I-OUT	NOUN	B
under	I-OUT	ADP	O
the	I-OUT	DET	O
concentration-time	I-OUT	NOUN	B
curves	I-OUT	NOUN	I
increased	O	VERB	B
proportionally	O	ADV	B
with	O	ADP	I
dose	O	NOUN	B
irrespective	O	ADV	O
of	O	ADP	O
the	O	DET	O
route	O	NOUN	B
of	O	ADP	I
administration	O	NOUN	I
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
linezolid	I-OUT	ADJ	B
concentrations	I-OUT	NOUN	B
remained	O	VERB	O
above	O	ADP	O
the	O	DET	O
MIC90	O	NOUN	B
for	O	ADP	O
susceptible	O	ADJ	B
target	O	NOUN	B
pathogens	O	NOUN	B
(	O	PUNCT	O
4.0	O	NUM	O
mg/L	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
the	O	DET	O
12	O	NUM	O
h	O	NOUN	O
dosing	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O


Mean	B-OUT	VERB	B
clearance	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
half-life	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
volume	I-OUT	NOUN	B
of	I-OUT	ADP	O
distribution	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
irrespective	O	ADJ	O
of	O	ADP	O
dose	O	NOUN	B
for	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
oral	O	ADJ	B
and	O	CCONJ	O
intravenous	O	ADJ	B
routes	O	NOUN	I
.	O	PUNCT	O


Linezolid	B-I	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
and	O	CCONJ	O
the	O	DET	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
drug-related	I-OUT	ADJ	B
adverse	I-OUT	ADJ	I
events	I-OUT	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
the	O	DET	O
linezolid	B-I	ADJ	B
and	O	CCONJ	O
placebo	O	ADJ	B
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Oral	O	ADJ	B
and	O	CCONJ	O
intravenous	O	ADJ	B
linezolid	B-I	ADJ	B
exhibit	O	VERB	O
linear	B-OUT	ADJ	O
pharmacokinetics	I-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
concentrations	O	NOUN	B
remaining	O	VERB	O
above	O	ADP	O
the	O	DET	O
target	B-OUT	NOUN	B
MIC90	I-OUT	NOUN	B
for	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
dosing	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
support	O	VERB	O
a	O	DET	O
twice-daily	O	ADJ	O
schedule	O	NOUN	O
for	O	ADP	O
linezolid	O	ADJ	B
and	O	CCONJ	O
demonstrate	O	VERB	O
the	O	DET	O
feasibility	O	NOUN	B
of	O	ADP	O
converting	O	VERB	O
from	O	ADP	O
intravenous	O	ADJ	B
to	O	PART	O
oral	O	ADJ	B
dosing	O	NOUN	B
without	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
adjustment	O	NOUN	B
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
safety	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
fixed	O	ADJ	O
low-dose	O	ADJ	B
perindopril/indapamide	B-I	NOUN	B
combination	I-I	NOUN	B
in	O	ADP	O
essential	B-P	ADJ	B
hypertension	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
parallel-group	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
the	O	DET	O
safety	B-OUT	NOUN	B
of	O	ADP	O
fixed	O	VERB	B
low	B-I	ADJ	I
dose	I-I	NOUN	I
combination	I-I	NOUN	O
perindopril	I-I	NOUN	B
2	I-I	NUM	O
mg/indapamide	I-I	NOUN	O
0.625	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
Per/Ind	O	NOUN	B
)	O	PUNCT	O
versus	O	CCONJ	O
atenolol	B-I	ADV	B
50	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
Ate	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
4-week	O	ADJ	O
placebo	O	NOUN	B
run-in	O	NOUN	B
,	O	PUNCT	O
446	B-P	NUM	O
hypertensive	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
:	I-P	PUNCT	O
55.8	I-P	NUM	O
+/-	I-P	CCONJ	O
11.0	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
Per/Ind	B-I	NOUN	B
or	I-I	CCONJ	O
Ate	I-I	NOUN	B
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
outcome	O	NOUN	O
measures	O	NOUN	O
were	O	AUX	O
the	O	DET	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
trough	I-OUT	NOUN	O
supine	I-OUT	ADJ	B
systolic	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
sSBP	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
sDBP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
between	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
last	O	ADJ	O
observation	O	NOUN	B
.	O	PUNCT	O


Equivalence	B-OUT	NOUN	B
was	O	AUX	O
assessed	B-OUT	VERB	B
in	O	ADP	O
an	O	DET	O
intention-to-treat	O	ADJ	B
analysis	O	NOUN	I
using	O	VERB	O
a	O	DET	O
two	O	NUM	O
one-sided	O	ADJ	B
tests	O	NOUN	I
procedure	O	NOUN	I
.	O	PUNCT	O


Per/Ind	O	NOUN	B
and	O	CCONJ	O
Ate	O	NOUN	B
decreased	B-OUT	VERB	B
sSBP	I-OUT	NOUN	B
by	O	ADP	O
-20.5	O	NUM	O
mmHg	O	NOUN	B
and	O	CCONJ	O
-20.1	O	NUM	O
mmHg	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
the	O	DET	O
90	O	NUM	O
%	O	NOUN	O
confidence	B-OUT	NOUN	B
interval	I-OUT	NOUN	I
[	O	PUNCT	O
-2.3	O	NUM	O
;	O	PUNCT	O
1.5	O	NUM	O
]	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
intertreatment	O	ADJ	B
difference	O	NOUN	I
(	O	PUNCT	O
-0.4	O	NUM	O
mmHg	O	NOUN	B
)	O	PUNCT	O
fell	O	VERB	O
within	O	ADP	O
the	O	DET	O
predefined	B-OUT	ADJ	O
equivalence	I-OUT	NOUN	B
interval	I-OUT	NOUN	I
[	O	PUNCT	O
-8	O	NUM	B
;	O	PUNCT	O
+8	O	ADJ	O
mmHg	O	NOUN	B
]	O	PUNCT	O
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
sDBP	B-OUT	NOUN	B
decreased	I-OUT	VERB	B
by	O	ADP	O
-15.1	O	NUM	O
mmHg	O	NOUN	B
(	O	PUNCT	O
Per/Ind	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
-16.2	O	NUM	O
mmHg	O	NOUN	B
(	O	PUNCT	O
Ate	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
intertreatment	O	ADJ	B
difference	O	NOUN	O
of	O	ADP	O
1.1	O	NUM	O
mmHg	O	NOUN	B
whose	O	DET	O
90	O	NUM	O
%	O	NOUN	O
confidence	B-OUT	NOUN	B
interval	I-OUT	NOUN	I
[	O	PUNCT	O
-0.1	O	NUM	O
;	O	PUNCT	O
2.2	O	NUM	O
mmHg	O	NOUN	B
]	O	PUNCT	O
fell	O	VERB	O
within	O	ADP	O
the	O	DET	O
predefined	O	ADJ	O
equivalence	B-OUT	NOUN	B
interval	I-OUT	NOUN	I
[	O	PUNCT	O
-4	O	NUM	O
;	O	PUNCT	O
+4	O	ADJ	O
mmHg	O	NOUN	B
]	O	PUNCT	O
;	O	PUNCT	O
thus	O	ADV	O
antihypertensive	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	B
of	O	ADP	O
Per/Ind	O	NOUN	B
and	O	CCONJ	O
Ate	O	NOUN	B
were	O	AUX	O
equivalent	B-OUT	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
older	O	ADJ	B
than	O	ADP	O
65	O	NUM	O
,	O	PUNCT	O
Per/Ind	O	NOUN	B
induces	O	VERB	O
a	O	DET	O
statistically	O	ADV	B
greater	O	ADJ	I
decrease	O	NOUN	B
in	O	ADP	O
sSBP	B-OUT	NOUN	B
than	O	ADP	O
Ate	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Per/Ind	O	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
.	I-OUT	PUNCT	O


Further	O	ADV	O
controlled	O	VERB	B
studies	O	NOUN	I
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
confirm	O	VERB	O
these	O	DET	O
results	O	NOUN	B
on	O	ADP	O
a	O	DET	O
long-term	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
systemic	O	ADJ	B
nitric	B-I	ADJ	I
oxide	I-I	NOUN	I
synthase	I-I	NOUN	I
inhibition	O	NOUN	B
on	O	ADP	O
postexercise	B-P	NOUN	B
hypotension	I-P	NOUN	I
in	I-P	ADP	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


An	O	DET	O
acute	O	ADJ	B
bout	O	NOUN	B
of	O	ADP	O
aerobic	O	ADJ	B
exercise	O	NOUN	B
results	O	NOUN	O
in	O	ADP	O
a	O	DET	O
reduced	O	VERB	B
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
that	O	PRON	O
lasts	O	VERB	O
several	O	ADJ	O
hours	O	NOUN	B
.	O	PUNCT	O


Animal	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
this	O	DET	O
response	O	NOUN	B
is	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
increased	O	VERB	B
production	O	NOUN	B
of	O	ADP	O
nitric	O	ADJ	B
oxide	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
tested	O	VERB	B
the	O	DET	O
extent	O	NOUN	O
to	O	PART	O
which	O	DET	O
systemic	O	ADJ	B
nitric	O	ADJ	B
oxide	O	NOUN	I
synthase	O	NOUN	I
inhibition	O	NOUN	I
[	O	PUNCT	O
N	O	NOUN	O
(	O	PUNCT	O
G	O	NOUN	O
)	O	PUNCT	O
-monomethyl-L-arginine	O	NOUN	O
(	O	PUNCT	O
L-NMMA	O	NOUN	B
)	O	PUNCT	O
]	O	PUNCT	O
can	O	AUX	O
reverse	O	VERB	O
the	O	DET	O
drop	O	NOUN	B
in	O	ADP	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
that	I-P	PRON	O
occurs	I-P	VERB	O
after	I-P	ADP	O
exercise	I-P	NOUN	B
in	I-P	ADP	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


Eight	B-P	NUM	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
underwent	O	VERB	O
parallel	O	ADJ	O
experiments	O	NOUN	B
on	O	ADP	O
2	O	NUM	O
separate	O	ADJ	B
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
order	O	NOUN	O
of	O	ADP	O
the	O	DET	O
experiments	O	NOUN	B
was	O	AUX	O
randomized	O	VERB	B
between	O	ADP	O
sham	O	NOUN	B
(	B-I	PUNCT	O
60	I-I	NUM	O
min	I-I	NOUN	O
of	I-I	ADP	O
seated	I-I	VERB	B
upright	I-I	ADJ	O
rest	I-I	NOUN	O
)	I-I	PUNCT	O
and	O	CCONJ	O
exercise	O	VERB	B
(	B-I	PUNCT	O
60	I-I	NUM	O
min	I-I	NOUN	O
of	I-I	ADP	O
upright	I-I	ADJ	B
cycling	I-I	NOUN	I
at	I-I	ADP	O
60	I-I	NUM	O
%	I-I	NOUN	O
peak	I-I	NOUN	B
aerobic	I-I	ADJ	I
capacity	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
both	O	CCONJ	O
sham	O	NOUN	B
and	O	CCONJ	O
exercise	O	NOUN	B
,	O	PUNCT	O
subjects	O	NOUN	B
received	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
sequence	O	NOUN	B
,	O	PUNCT	O
systemic	O	ADJ	B
alpha-adrenergic	O	ADJ	O
blockade	O	NOUN	O
(	O	PUNCT	O
phentolamine	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
L-NMMA	O	NOUN	B
.	O	PUNCT	O


Phentolamine	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
first	O	ADJ	O
to	O	PART	O
isolate	O	VERB	B
the	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
nitric	O	ADJ	B
oxide	O	NOUN	I
to	O	PART	O
postexercise	O	VERB	B
hypotension	O	NOUN	B
by	O	ADP	O
preventing	O	VERB	B
reflex	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
sympathetic	O	ADJ	B
tone	O	NOUN	I
that	O	PRON	O
result	O	VERB	O
from	O	ADP	O
systemic	O	ADJ	B
nitric	O	ADJ	B
oxide	O	NOUN	I
synthase	O	NOUN	I
inhibition	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
control	O	VERB	B
for	O	ADP	O
alterations	O	NOUN	B
in	O	ADP	O
resting	O	VERB	B
sympathetic	O	ADJ	I
activity	O	NOUN	I
after	O	ADP	O
exercise	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
each	O	DET	O
condition	O	NOUN	B
,	O	PUNCT	O
systemic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
regional	I-OUT	ADJ	B
hemodynamics	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


Throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
arterial	B-OUT	ADJ	B
pressure	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
vascular	I-OUT	ADJ	B
resistances	I-OUT	NOUN	I
remained	O	VERB	O
lower	O	ADJ	O
postexercise	O	NOUN	B
vs.	O	CCONJ	O
postsham	O	NOUN	B
despite	O	SCONJ	O
nitric	B-OUT	ADJ	B
oxide	I-OUT	NOUN	I
synthase	I-OUT	NOUN	I
inhibition	O	NOUN	O
(	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
mean	B-OUT	VERB	O
arterial	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
after	I-OUT	ADP	O
L-NMMA	I-OUT	NOUN	B
was	O	AUX	O
108.0+/-2.4	O	NUM	O
mmHg	O	NOUN	B
postsham	O	NOUN	B
vs.	O	CCONJ	O
102.1+/-3.3	O	NOUN	O
mmHg	O	NOUN	B
postexercise	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Thus	O	ADV	O
it	O	PRON	O
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
that	O	SCONJ	O
postexercise	B-OUT	NOUN	B
hypotension	I-OUT	NOUN	B
is	O	AUX	O
dependent	O	ADJ	O
on	O	ADP	O
increased	O	VERB	B
production	B-OUT	NOUN	B
of	I-OUT	ADP	O
nitric	I-OUT	ADJ	B
oxide	I-OUT	NOUN	I
in	O	ADP	O
humans	B-P	NOUN	B
.	I-P	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
protein	B-I	NOUN	B
ingestion	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
glucose	B-OUT	NOUN	B
appearance	I-OUT	NOUN	O
rate	I-OUT	NOUN	B
in	O	ADP	O
people	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


Amino	O	NOUN	B
acids	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
ingested	O	VERB	B
protein	O	NOUN	B
are	O	AUX	O
potential	O	ADJ	B
substrates	O	NOUN	B
for	O	ADP	O
gluconeogenesis	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
several	O	ADJ	O
laboratories	O	NOUN	B
have	O	AUX	O
reported	O	VERB	O
that	O	SCONJ	O
protein	O	NOUN	B
ingestion	O	NOUN	B
does	O	AUX	O
not	O	PART	O
result	O	VERB	O
in	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
circulating	B-OUT	VERB	B
glucose	I-OUT	NOUN	O
concentration	I-OUT	NOUN	O
in	O	ADP	O
people	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
type	B-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
reason	O	NOUN	O
for	O	ADP	O
this	O	DET	O
has	O	AUX	O
remained	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
people	O	NOUN	B
without	O	ADP	O
diabetes	O	NOUN	B
it	O	PRON	O
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
less	O	ADJ	O
glucose	O	NOUN	B
being	O	AUX	O
produced	O	VERB	O
and	O	CCONJ	O
entering	O	VERB	O
the	O	DET	O
circulation	O	NOUN	B
than	O	ADP	O
the	O	DET	O
calculated	O	VERB	B
theoretical	O	ADJ	B
amount	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
interested	O	ADJ	O
in	O	ADP	O
determining	O	VERB	O
whether	O	SCONJ	O
this	O	DET	O
also	O	ADV	O
was	O	AUX	O
the	O	DET	O
case	O	NOUN	B
in	O	ADP	O
people	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


Ten	B-P	NUM	O
male	I-P	ADJ	B
subjects	I-P	NOUN	B
with	I-P	ADP	O
untreated	I-P	ADJ	B
type	I-P	NOUN	O
2	I-P	NUM	O
diabetes	I-P	NOUN	O
were	O	AUX	O
given	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
random	O	ADJ	B
sequence	O	NOUN	I
,	O	PUNCT	O
50	B-I	NUM	O
g	I-I	NOUN	O
protein	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
form	I-I	NOUN	O
of	I-I	ADP	O
very	I-I	ADV	O
lean	I-I	ADJ	B
beef	I-I	NOUN	I
or	I-I	CCONJ	O
only	I-I	ADV	O
water	I-I	NOUN	B
at	I-I	ADP	O
0800	I-I	NUM	O
h	I-I	NOUN	O
and	I-I	CCONJ	O
studied	I-I	VERB	O
over	I-I	ADP	O
the	I-I	DET	O
subsequent	I-I	ADJ	O
8	I-I	NUM	O
h.	I-I	NOUN	O
Protein	I-I	NOUN	B
ingestion	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
circulating	B-OUT	VERB	B
insulin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
C-peptide	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
glucagon	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
alpha	I-OUT	NOUN	B
amino	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
urea	I-OUT	NOUN	B
nitrogen	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
triglycerides	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
a	I-OUT	DET	O
decrease	I-OUT	NOUN	B
in	I-OUT	ADP	O
nonesterified	I-OUT	ADJ	B
fatty	I-OUT	ADJ	I
acids	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
modest	I-OUT	ADJ	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
respiratory	I-OUT	ADJ	B
quotient	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
total	O	ADJ	O
amount	O	NOUN	B
of	O	ADP	O
protein	B-OUT	NOUN	B
deaminated	I-OUT	VERB	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
amino	I-OUT	NOUN	B
groups	I-OUT	NOUN	I
incorporated	I-OUT	VERB	O
into	I-OUT	ADP	O
urea	I-OUT	NOUN	B
was	O	AUX	O
calculated	O	VERB	B
to	O	PART	O
be	O	AUX	O
approximately	O	ADV	O
20-23	O	NUM	O
g.	O	X	O
The	O	DET	O
net	O	ADJ	O
amount	O	NOUN	O
of	O	ADP	O
glucose	B-OUT	NOUN	B
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
produced	O	VERB	O
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
quantity	B-OUT	NOUN	B
of	I-OUT	ADP	O
amino	I-OUT	NOUN	B
acids	I-OUT	NOUN	I
deaminated	I-OUT	VERB	B
,	O	PUNCT	O
was	O	AUX	O
approximately	O	ADV	O
11-13	O	NUM	O
g.	O	X	O
However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
amount	B-OUT	NOUN	B
of	I-OUT	ADP	O
glucose	I-OUT	NOUN	B
appearing	I-OUT	VERB	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
circulation	I-OUT	NOUN	B
was	O	AUX	O
only	O	ADV	O
approximately	O	ADV	O
2	O	NUM	O
g.	O	NOUN	O
The	O	DET	O
peripheral	B-OUT	ADJ	B
plasma	I-OUT	NOUN	I
glucose	I-OUT	NOUN	I
concentration	I-OUT	NOUN	I
decreased	O	VERB	B
by	O	ADP	O
approximately	O	ADV	O
1	O	NUM	O
mM	O	NOUN	O
after	O	ADP	O
ingestion	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
protein	O	NOUN	B
or	O	CCONJ	O
water	O	NOUN	B
,	O	PUNCT	O
confirming	O	VERB	O
that	O	SCONJ	O
ingested	O	VERB	B
protein	O	NOUN	B
does	O	AUX	O
not	O	PART	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
net	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
glucose	B-OUT	NOUN	B
concentration	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
results	O	VERB	B
in	O	ADP	O
only	O	ADV	O
a	O	DET	O
modest	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
glucose	I-OUT	NOUN	B
disappearance	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Recombinant	B-I	ADJ	B
human	I-I	ADJ	B
thrombopoietin	I-I	NOUN	B
augments	O	VERB	O
mobilization	O	NOUN	B
of	O	ADP	O
peripheral	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
progenitor	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
for	O	ADP	O
autologous	B-P	ADJ	B
transplantation	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
various	O	ADJ	O
schedules	O	NOUN	B
of	O	ADP	O
recombinant	B-I	ADJ	B
human	I-I	ADJ	O
thrombopoietin	I-I	NOUN	O
(	I-I	PUNCT	O
rhTPO	I-I	NOUN	B
)	I-I	PUNCT	O
to	O	PART	O
enhance	O	VERB	B
mobilization	O	NOUN	B
of	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
progenitor	O	NOUN	I
cells	O	NOUN	I
(	O	PUNCT	O
PBPCs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
134	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
cancer	I-P	NOUN	B
undergoing	I-P	VERB	O
high-dose	I-P	ADJ	B
chemotherapy	I-P	NOUN	I
and	I-P	CCONJ	O
autologous	I-P	ADJ	B
PBPC	I-P	NOUN	O
transplantation	I-P	NOUN	O
.	I-P	PUNCT	O


Patients	O	NOUN	B
received	O	VERB	O
the	O	DET	O
study	O	NOUN	B
drug	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
before	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
granulocyte	O	NOUN	B
colony-stimulating	O	ADJ	I
factor	O	NOUN	I
(	O	PUNCT	O
G-CSF	O	NOUN	B
)	O	PUNCT	O
10	O	NUM	O
microg/kg/day	O	NOUN	B
on	O	ADP	O
day	O	NOUN	B
5	O	NUM	O
and	O	CCONJ	O
pheresis	O	NOUN	B
starting	O	VERB	O
on	O	ADP	O
day	O	NOUN	B
9	O	NUM	O
.	O	PUNCT	O


Randomly	O	ADV	B
assigned	O	VERB	O
treatments	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
were	O	AUX	O
:	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
(	O	PUNCT	O
n=27	O	ADJ	O
)	O	PUNCT	O
placebo	B-I	NOUN	B
,	I-I	PUNCT	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
rhTPO	I-I	NOUN	B
1.5	O	NUM	O
microg/kg	O	NOUN	B
;	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	I
(	O	PUNCT	O
n=27	O	ADJ	O
)	O	PUNCT	O
rhTPO	O	NOUN	B
1.5	O	NUM	O
microg/kg	O	NOUN	B
,	O	PUNCT	O
placebo	O	NOUN	B
,	O	PUNCT	O
placebo	O	NOUN	B
;	O	PUNCT	O
groups	O	NOUN	B
3	O	NUM	O
(	O	PUNCT	O
n=28	O	ADJ	O
)	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
(	O	PUNCT	O
n=22	O	ADJ	O
)	O	PUNCT	O
rhTPO	O	NOUN	B
0.5	O	NUM	O
microg/kg	O	NOUN	O
on	O	ADP	O
all	O	DET	O
3	O	NUM	O
treatment	O	NOUN	B
days	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
group	O	NOUN	B
5	O	NUM	O
(	O	PUNCT	O
n=30	O	NOUN	O
)	O	PUNCT	O
placebo	O	NOUN	B
on	O	ADP	O
all	O	DET	O
3	O	NUM	O
treatment	O	NOUN	B
days	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
high-dose	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
and	I-I	CCONJ	O
PBPC	I-I	NOUN	B
transplantation	I-I	NOUN	I
,	O	PUNCT	O
groups	O	NOUN	B
1	O	NUM	O
through	O	ADP	O
4	O	NUM	O
received	O	VERB	O
rhTPO	O	NOUN	B
1.5	O	NUM	O
microg/kg	O	NOUN	O
days	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
+2	O	NUM	B
,	O	PUNCT	O
+4	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
+6	O	DET	O
with	O	ADP	O
either	O	CCONJ	O
G-CSF	O	NOUN	B
5	O	NUM	O
microg/kg/day	O	NOUN	B
(	O	PUNCT	O
groups	O	NOUN	B
1-3	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
granulocyte-macrophage	O	ADJ	B
colony-stimulating	O	ADJ	I
factor	O	NOUN	I
250	O	NUM	O
microg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/day	O	NOUN	O
(	O	PUNCT	O
group	O	NOUN	B
4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Group	O	NOUN	B
5	O	NUM	O
received	O	VERB	O
placebo	B-I	NOUN	B
plus	O	CCONJ	O
G-CSF	O	NOUN	B
5	O	NUM	O
microg/kg/day	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
rhTPO	B-I	NOUN	B
to	O	PART	O
G-CSF	O	NOUN	B
increased	O	VERB	B
median	B-OUT	ADJ	B
CD34+	I-OUT	ADJ	B
cell	I-OUT	NOUN	I
yield/pheresis	I-OUT	NOUN	B
in	O	ADP	O
cohorts	O	NOUN	B
in	O	ADP	O
which	O	DET	O
rhTPO	B-I	NOUN	B
was	O	AUX	O
started	O	VERB	O
before	O	ADP	O
day	O	NOUN	B
5	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
higher	O	ADJ	O
yields	O	NOUN	O
in	O	ADP	O
groups	O	NOUN	B
2	O	NUM	O
(	O	PUNCT	O
2.67	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
/kg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
groups	O	NOUN	B
3	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
(	O	PUNCT	O
3.10	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
/kg	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
(	O	PUNCT	O
1.86	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
/kg	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
group	O	NOUN	B
5	O	NUM	I
(	O	PUNCT	O
1.65	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
/kg	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
P=.006	O	NOUN	O
across	O	ADP	O
groups	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Comparing	O	VERB	O
rhTPO	B-I	NOUN	B
to	O	PART	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
higher	O	ADJ	O
percentages	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
achieved	O	VERB	O
the	O	DET	O
minimum	B-OUT	ADJ	O
yield	I-OUT	NOUN	B
of	I-OUT	ADP	O
CD34+	I-OUT	ADJ	B
>	O	NOUN	O
or	O	CCONJ	O
=2	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
/kg	O	NOUN	O
(	O	PUNCT	O
92	O	NUM	O
%	O	NOUN	O
v	O	CCONJ	O
75	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=.050	O	NOUN	O
)	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
target	O	NOUN	B
yield	O	NOUN	B
of	O	ADP	O
CD34+	O	ADJ	B
>	O	X	O
or	O	CCONJ	O
=5	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
/kg	O	NOUN	O
(	O	PUNCT	O
73	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
46	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=	O	X	O
.041	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


rhTPO-treated	B-I	ADJ	B
patients	O	NOUN	B
required	O	VERB	O
fewer	O	ADJ	O
phereses	O	NOUN	B
to	O	PART	O
achieve	O	VERB	O
minimum	O	NOUN	O
(	O	PUNCT	O
P=	O	NOUN	O
.011	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
target	O	NOUN	B
(	O	PUNCT	O
P=	O	NOUN	O
.015	O	NUM	O
)	O	PUNCT	O
CD34+	B-OUT	ADJ	B
cell	I-OUT	NOUN	I
values	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


rhTPO	B-I	NOUN	B
given	O	VERB	O
after	O	ADP	O
transplantation	O	NOUN	B
did	O	AUX	O
not	O	PART	O
speed	O	VERB	B
platelet	B-OUT	NOUN	B
recovery	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


No	O	DET	O
neutralizing	O	VERB	O
antibodies	O	NOUN	O
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
rhTPO	B-I	NOUN	B
can	O	AUX	O
safely	O	ADV	O
enhance	O	VERB	B
mobilization	O	NOUN	B
of	O	ADP	O
PBPC	B-OUT	NOUN	B
,	O	PUNCT	O
reduce	O	VERB	B
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
leukapheresis	B-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
allow	O	VERB	O
more	O	ADJ	O
patients	O	NOUN	B
to	O	PART	O
meet	O	VERB	O
minimal	O	ADJ	B
cell	O	NOUN	B
yield	O	NOUN	I
requirements	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
high-dose	O	ADJ	B
chemotherapy	B-I	NOUN	I
with	O	ADP	O
PBPC	B-I	NOUN	B
transplantation	I-I	NOUN	I
.	I-I	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
antioxidants	B-I	NOUN	B
,	I-I	PUNCT	O
zinc	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
copper	I-I	NOUN	B
on	O	ADP	O
cognition	B-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
elderly	I-P	ADJ	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


Participants	B-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
Age-Related	I-P	PROPN	B
Eye	I-P	PROPN	I
Disease	I-P	PROPN	I
Study	I-P	PROPN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
daily	O	ADJ	B
antioxidants	B-I	NOUN	O
(	I-I	PUNCT	O
vitamin	I-I	NOUN	B
C	I-I	NOUN	I
,	I-I	PUNCT	O
500	I-I	NUM	O
mg	I-I	NOUN	O
;	I-I	PUNCT	O
vitamin	I-I	NOUN	B
E	I-I	NOUN	I
,	I-I	PUNCT	O
400	I-I	NUM	O
IU	I-I	NOUN	B
;	I-I	PUNCT	O
beta	I-I	NOUN	B
carotene	I-I	NOUN	I
,	I-I	PUNCT	O
15	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
zinc	I-I	NOUN	B
and	I-I	CCONJ	O
copper	I-I	NOUN	B
(	I-I	PUNCT	O
zinc	I-I	NOUN	B
,	I-I	PUNCT	O
80	I-I	NUM	O
mg	I-I	NOUN	O
;	I-I	PUNCT	O
cupric	I-I	ADJ	B
oxide	I-I	NOUN	I
,	I-I	PUNCT	O
2	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
antioxidants	I-I	NOUN	B
plus	I-I	CCONJ	O
zinc	I-I	NOUN	B
and	I-I	CCONJ	O
copper	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


A	O	DET	O
cognitive	O	ADJ	B
battery	O	NOUN	I
was	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
2,166	B-P	NUM	O
elderly	I-P	ADJ	B
persons	I-P	NOUN	I
after	I-P	ADP	O
a	I-P	DET	O
median	I-P	NOUN	B
of	I-P	ADP	O
6.9	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
treatment	I-P	NOUN	B
.	I-P	PUNCT	O


Treatment	O	NOUN	B
groups	O	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
on	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
six	B-OUT	NUM	O
cognitive	I-OUT	ADJ	B
tests	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
for	O	ADP	O
all	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
do	O	AUX	O
not	O	PART	O
support	O	VERB	O
a	O	DET	O
beneficial	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
harmful	I-OUT	ADJ	O
effect	I-OUT	NOUN	O
of	I-OUT	ADP	O
antioxidants	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
zinc	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
copper	I-OUT	NOUN	B
on	O	ADP	O
cognition	B-OUT	NOUN	B
in	O	ADP	O
older	O	ADJ	B
adults	O	NOUN	I
.	O	PUNCT	O


Randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
patient	O	NOUN	B
triggered	B-I	VERB	B
and	I-I	CCONJ	O
conventional	I-I	ADJ	B
fast	I-I	ADJ	O
rate	I-I	NOUN	O
ventilation	I-I	NOUN	O
in	O	ADP	O
neonatal	B-P	ADJ	B
respiratory	I-P	ADJ	B
distress	I-P	NOUN	I
syndrome	I-P	NOUN	I
.	I-P	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
compare	O	VERB	B
patient	O	NOUN	B
triggered	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
conventional	O	ADJ	O
fast	O	ADJ	O
rate	O	NOUN	O
,	O	PUNCT	O
ventilation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
using	O	VERB	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
chronic	I-OUT	ADJ	B
lung	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
as	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Three	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
eighty	I-P	NUM	O
six	I-P	NUM	O
preterm	I-P	NOUN	B
infants	I-P	NOUN	I
with	I-P	ADP	O
birthweights	I-P	NOUN	B
from	I-P	ADP	O
1000	I-P	NUM	O
to	I-P	PART	O
2000	I-P	NUM	O
g	I-P	NOUN	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
requiring	I-P	VERB	O
ventilation	I-P	NOUN	B
for	I-P	ADP	O
respiratory	I-P	ADJ	B
distress	I-P	NOUN	I
syndrome	I-P	NOUN	I
within	I-P	ADP	O
24	I-P	NUM	O
hours	I-P	NOUN	O
of	I-P	ADP	O
birth	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
conventional	B-I	ADJ	B
or	I-I	CCONJ	O
trigger	I-I	VERB	B
ventilation	I-I	NOUN	B
with	I-I	ADP	O
the	I-I	DET	O
SLE	I-I	NOUN	B
2000	I-I	NUM	O
ventilator	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
chronic	I-OUT	ADJ	B
lung	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
(	O	PUNCT	O
28	O	NUM	O
day	O	NOUN	B
and	O	CCONJ	O
36	O	NUM	O
week	O	NOUN	B
definitions	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
death	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
pneumothorax	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
intraventricular	I-OUT	ADJ	B
haemorrhage	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
ventilator	I-OUT	NOUN	B
days	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
length	I-OUT	NOUN	B
of	I-OUT	ADP	I
oxygen	I-OUT	NOUN	I
dependency	I-OUT	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Patient	O	NOUN	B
triggered	O	VERB	O
ventilation	O	NOUN	O
in	O	ADP	O
preterm	B-P	NOUN	B
infants	I-P	NOUN	I
with	I-P	ADP	O
respiratory	I-P	ADJ	B
distress	I-P	NOUN	I
syndrome	I-P	NOUN	I
is	O	AUX	O
feasible	O	ADJ	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
,	O	PUNCT	O
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
conventional	O	ADJ	B
fast	O	ADJ	O
rate	O	NOUN	O
ventilation	O	NOUN	O
in	O	ADP	O
important	O	ADJ	O
medium	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
longer	I-OUT	ADJ	O
term	I-OUT	NOUN	O
outcome	I-OUT	NOUN	B
measures	I-OUT	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
evident	O	ADJ	O
.	O	PUNCT	O


Pacifier	B-I	NOUN	B
as	I-P	ADP	O
a	I-P	DET	O
risk	I-P	NOUN	B
factor	I-P	NOUN	I
for	I-P	ADP	O
acute	I-P	ADJ	B
otitis	I-P	NOUN	I
media	I-P	NOUN	I
.	I-P	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
metastases	O	NOUN	I
of	O	ADP	O
small-cell	O	ADJ	B
lung	O	NOUN	I
cancer	O	NOUN	I
:	O	PUNCT	O
comparing	O	VERB	B
teniposide	B-I	NOUN	B
and	O	CCONJ	O
teniposide	B-I	NOUN	B
with	I-I	ADP	O
whole-brain	I-I	ADJ	B
radiotherapy	I-I	NOUN	I
--	I-I	PUNCT	O
a	I-I	DET	O
phase	O	NOUN	B
III	O	NUM	I
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
European	O	PROPN	B
Organization	O	PROPN	I
for	O	ADP	I
the	O	DET	I
Research	O	PROPN	B
and	O	CCONJ	O
Treatment	O	NOUN	B
of	O	ADP	O
Cancer	O	PROPN	B
Lung	O	PROPN	I
Cancer	O	PROPN	I
Cooperative	O	PROPN	I
Group	O	PROPN	I
.	O	PUNCT	O


PURPOSE	O	VERB	O
Approximately	O	ADV	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
small-cell	I-P	ADJ	B
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
SCLC	I-P	NOUN	B
)	I-P	PUNCT	O
develop	O	VERB	O
brain	O	NOUN	B
metastases	O	NOUN	I
.	O	PUNCT	O


Whole-brain	B-I	NOUN	B
radiotherapy	I-I	NOUN	I
(	I-I	PUNCT	O
WBRT	I-I	NOUN	B
)	I-I	PUNCT	O
gives	O	VERB	O
symptomatic	O	ADJ	B
improvement	O	NOUN	B
in	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
brain	O	NOUN	B
metastases	O	NOUN	I
are	O	AUX	O
a	O	DET	O
sign	O	NOUN	O
of	O	ADP	O
systemic	O	ADJ	B
progression	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
chemotherapy	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
as	O	ADV	O
well	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
becomes	O	VERB	O
questionable	O	ADJ	O
whether	O	SCONJ	O
WBRT	B-I	NOUN	B
is	O	AUX	O
the	O	DET	O
only	O	ADV	O
appropriate	O	ADJ	O
therapy	O	NOUN	B
in	O	ADP	O
this	O	DET	O
situation	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
study	O	NOUN	I
,	O	PUNCT	O
SCLC	B-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
brain	I-P	NOUN	B
metastases	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
teniposide	B-I	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
WBRT	B-I	NOUN	B
.	I-I	PUNCT	O


Teniposide	B-I	NOUN	B
120	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
intravenously	O	ADV	B
three	O	NUM	O
times	O	NOUN	O
a	O	DET	O
week	O	NOUN	B
,	O	PUNCT	O
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


WBRT	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
fractions	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
Gy	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
to	O	PART	O
start	O	VERB	O
within	O	ADP	O
3	O	NUM	O
weeks	O	NOUN	B
from	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
chemotherapy	B-I	NOUN	B
.	I-I	PUNCT	O


Response	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
clinically	B-OUT	ADV	B
and	O	CCONJ	O
by	O	ADP	O
computed	B-OUT	VERB	B
tomography	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
brain	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
twenty	I-P	NUM	O
eligible	I-P	ADJ	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
57	O	NUM	O
%	O	NOUN	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
combined-modality	O	ADJ	B
arm	O	NOUN	I
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
43	O	NUM	O
%	O	NOUN	O
to	O	PART	O
69	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
22	O	NUM	O
%	O	NOUN	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
teniposide-alone	B-I	ADJ	B
arm	O	NOUN	I
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
%	O	NOUN	O
to	O	PART	O
34	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Time	B-OUT	NOUN	B
to	I-OUT	PART	O
progression	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
brain	I-OUT	NOUN	B
was	O	AUX	O
longer	B-OUT	ADJ	O
in	O	ADP	O
the	O	DET	O
combined-modality	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P=.005	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Clinical	B-OUT	ADJ	B
response	I-OUT	NOUN	I
and	O	CCONJ	O
response	B-OUT	NOUN	B
outside	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
time	I-OUT	NOUN	I
was	O	AUX	O
3.5	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
combined-modality	O	ADJ	B
arm	O	NOUN	I
and	O	CCONJ	O
3.2	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
teniposide-alone	B-I	ADJ	B
arm	O	NOUN	I
.	O	PUNCT	O


Overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
(	O	PUNCT	O
P=.087	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Adding	O	VERB	O
WBRT	B-I	NOUN	B
to	O	PART	O
teniposide	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
much	O	ADV	O
higher	O	ADJ	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
of	O	ADP	O
brain	O	NOUN	B
metastases	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
longer	O	ADJ	O
time	O	NOUN	O
to	O	PART	O
progression	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
metastases	O	NOUN	I
than	O	ADP	O
teniposide	B-I	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Survival	B-OUT	NOUN	B
was	O	AUX	O
poor	O	ADJ	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
and	O	CCONJ	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


Non-pharmacological	O	ADJ	B
care	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
generalized	I-OUT	VERB	B
osteoarthritis	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
design	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Non-pharmacological	B-I	ADJ	B
treatment	I-I	NOUN	I
(	I-I	PUNCT	O
NPT	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
treatment	O	NOUN	B
option	O	NOUN	O
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
hip	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
knee	I-OUT	NOUN	B
osteoarthritis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
however	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
studies	O	NOUN	O
have	O	AUX	O
investigated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
NPT	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
generalized	I-P	VERB	B
osteoarthritis	I-P	NOUN	I
(	I-P	PUNCT	O
GOA	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
currently	O	ADV	O
existing	O	VERB	O
health	O	NOUN	B
care	O	NOUN	I
programs	O	NOUN	I
with	O	ADP	O
different	O	ADJ	O
intensity	O	NOUN	B
and	O	CCONJ	O
mode	O	NOUN	B
of	O	ADP	O
delivery	O	NOUN	B
on	O	ADP	O
daily	O	ADJ	B
functioning	O	VERB	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
GOA	I-P	PROPN	B
.	I-P	PUNCT	O


The	O	DET	O
secondary	O	ADJ	O
objective	O	NOUN	B
is	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
cost-effectiveness	O	NOUN	B
of	O	ADP	O
both	O	DET	O
interventions	O	NOUN	B
.	O	PUNCT	O


METHODS/DESIGN	O	NOUN	B
In	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
single	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
trial	O	NOUN	I
with	O	ADP	O
active	O	ADJ	B
controls	O	NOUN	I
,	O	PUNCT	O
we	B-P	PRON	O
aim	I-P	VERB	O
to	I-P	PART	O
include	I-P	VERB	O
170	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
GOA	I-P	PROPN	B
.	I-P	PUNCT	O


The	O	DET	O
experimental	O	ADJ	B
intervention	O	NOUN	I
consist	O	NOUN	O
of	O	ADP	O
six	B-I	NUM	O
self-management	I-I	ADJ	B
group	I-I	NOUN	I
sessions	I-I	NOUN	B
provided	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
multi-disciplinary	I-I	ADJ	B
team	I-I	NOUN	I
(	O	PUNCT	O
occupational	O	ADJ	B
therapist	O	NOUN	I
,	O	PUNCT	O
physiotherapist	O	NOUN	B
,	O	PUNCT	O
dietician	O	ADJ	B
and	O	CCONJ	O
specialized	O	ADJ	B
nurse	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
active	O	ADJ	B
control	O	NOUN	I
group	O	NOUN	I
consists	O	VERB	O
of	O	ADP	O
two	B-I	NUM	O
group	I-I	NOUN	B
sessions	I-I	NOUN	B
and	I-I	CCONJ	O
four	I-I	NUM	O
sessions	I-I	NOUN	B
by	I-I	ADP	O
telephone	I-I	NOUN	B
,	O	PUNCT	O
provided	O	VERB	O
by	O	ADP	O
a	O	DET	O
specialized	O	ADJ	B
nurse	O	NOUN	B
and	O	CCONJ	O
physiotherapist	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
therapies	O	NOUN	B
last	O	ADJ	O
six	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Main	O	ADJ	O
study	O	NOUN	B
outcome	O	NOUN	B
is	O	AUX	O
daily	B-OUT	ADV	B
functioning	I-OUT	VERB	B
during	I-OUT	ADP	O
the	I-OUT	DET	O
first	I-OUT	ADJ	O
year	I-OUT	NOUN	B
after	I-OUT	ADP	O
the	I-OUT	DET	O
treatment	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
assessed	I-OUT	VERB	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
Health	I-OUT	PROPN	B
Assessment	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


Secondary	O	ADJ	B
outcomes	O	NOUN	I
are	O	AUX	O
health	B-OUT	NOUN	B
related	I-OUT	ADJ	O
quality	I-OUT	NOUN	O
of	I-OUT	ADP	O
life	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
specific	I-OUT	ADJ	O
complaints	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
costs	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Illness	B-OUT	ADJ	B
cognitions	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
global	I-OUT	ADJ	B
perceived	I-OUT	VERB	O
effect	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
self-efficacy	I-OUT	NOUN	B
,	O	PUNCT	O
will	O	AUX	O
also	O	ADV	O
be	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
a	O	DET	O
responder	O	NOUN	B
analysis	O	NOUN	O
.	O	PUNCT	O


Outcome	O	NOUN	B
assessments	O	NOUN	I
are	O	AUX	O
performed	O	VERB	O
directly	O	ADV	O
after	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
26	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
52	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
This	O	DET	O
article	O	NOUN	B
describes	O	VERB	O
the	O	DET	O
design	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
single	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
trial	O	NOUN	I
with	O	ADP	O
a	O	DET	O
one	O	NUM	O
year	O	NOUN	B
follow	O	VERB	B
up	O	ADP	I
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
costs	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
effectiveness	I-OUT	NOUN	B
of	O	ADP	O
two	O	NUM	O
non-pharmacological	B-I	ADJ	B
interventions	I-I	NOUN	I
with	O	ADP	O
different	O	ADJ	O
modes	O	NOUN	B
of	O	ADP	O
delivery	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
GOA	I-P	PROPN	B
.	I-P	PUNCT	O


TRIAL	O	NOUN	B
REGISTRATION	O	NOUN	I
Dutch	O	ADJ	I
Trial	O	PROPN	I
Register	O	PROPN	I
NTR2137	O	NUM	O
.	O	PUNCT	O


Acute	O	ADJ	B
and	O	CCONJ	O
subchronic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
levocetirizine	B-I	NOUN	B
and	I-I	CCONJ	O
diphenhydramine	I-I	NOUN	B
on	O	ADP	O
memory	B-OUT	NOUN	B
functioning	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
psychomotor	I-OUT	NOUN	B
performance	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
mood	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


BACKGROUND	O	NOUN	O
Central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
adverse	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
sedation	B-OUT	NOUN	B
,	O	PUNCT	O
often	O	ADV	O
accompany	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
first-generation	O	ADJ	B
antihistamines	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
effects	O	NOUN	B
might	O	AUX	O
interfere	O	VERB	B
with	O	ADP	I
memory	O	NOUN	B
functioning	O	NOUN	I
and	O	CCONJ	O
psychomotor	O	NOUN	B
performance	O	NOUN	I
.	O	PUNCT	O


Levocetirizine	B-I	NOUN	B
was	O	AUX	O
recently	O	ADV	O
introduced	O	VERB	O
as	O	ADP	O
a	O	DET	O
new	O	ADJ	O
antihistamine	O	NOUN	B
said	O	VERB	O
to	O	PART	O
be	O	AUX	O
free	O	ADJ	B
from	O	ADP	O
sedative	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
sought	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
levocetirizine	B-I	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
diphenhydramine	B-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-I	CCONJ	O
placebo	I-I	NOUN	B
on	O	ADP	O
memory	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
psychomotor	I-OUT	NOUN	B
performance	I-OUT	NOUN	I
after	O	ADP	O
acute	O	ADJ	B
(	O	PUNCT	O
day	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
subchronic	O	ADJ	B
(	O	PUNCT	O
day	O	NOUN	B
4	O	NUM	O
)	O	PUNCT	O
daily	O	ADJ	B
administration	O	NOUN	B
in	O	ADP	O
48	B-P	NUM	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
(	I-P	PUNCT	O
24	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
24	I-P	NUM	O
women	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Treatments	O	NOUN	B
were	O	AUX	O
administrated	O	VERB	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
hours	O	NOUN	B
before	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
the	O	DET	O
laboratory	O	ADJ	B
test	O	NOUN	I
battery	O	NOUN	I
(	O	PUNCT	O
performed	O	VERB	O
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
comprising	O	VERB	O
a	O	DET	O
word-learning	O	ADJ	B
test	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
Sternberg	O	PROPN	B
Memory	O	PROPN	I
Scanning	O	PROPN	I
Test	O	PROPN	I
,	O	PUNCT	O
a	O	DET	O
tracking	O	NOUN	B
test	O	NOUN	I
(	O	PUNCT	O
easy	O	ADJ	O
and	O	CCONJ	O
hard	O	ADJ	B
version	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
divided	O	ADJ	O
attention	O	NOUN	O
test	O	NOUN	O
(	O	PUNCT	O
tracking	O	NOUN	B
and	O	CCONJ	O
memory	O	NOUN	B
scanning	O	NOUN	I
simultaneously	O	ADV	I
)	O	PUNCT	O
.	O	PUNCT	O


Statistical	O	ADJ	B
analyses	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
separately	O	ADV	O
for	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
by	O	ADP	O
using	O	VERB	O
analysis	O	NOUN	B
of	O	ADP	O
variance	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
On	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
diphenhydramine	B-I	NOUN	B
significantly	O	ADV	O
impaired	O	VERB	B
tracking	B-OUT	NOUN	B
performance	I-OUT	NOUN	I
(	O	PUNCT	O
easy	O	ADJ	O
:	O	PUNCT	O
F	O	NOUN	B
(	O	PUNCT	O
1,90	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
25.9	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.0001	O	NUM	O
;	O	PUNCT	O
hard	O	ADV	O
:	O	PUNCT	O
F	O	NOUN	B
(	O	PUNCT	O
1,90	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
20.5	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.0001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
divided	B-OUT	VERB	B
attention	I-OUT	NOUN	B
(	O	PUNCT	O
tracking	O	NOUN	B
:	O	PUNCT	O
F	O	NOUN	B
(	O	PUNCT	O
1,90	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
23.8	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.0001	O	NUM	O
;	O	PUNCT	O
memory	B-OUT	NOUN	B
scanning	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
F	O	NOUN	B
(	O	PUNCT	O
1,90	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
22.0	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Results	O	NOUN	B
on	O	ADP	O
word-learning	B-OUT	ADJ	B
tests	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
Sternberg	I-OUT	PROPN	B
Memory	I-OUT	PROPN	I
Scanning	I-OUT	PROPN	I
Tests	I-OUT	PROPN	I
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
impaired	O	ADJ	B
.	O	PUNCT	O


On	O	ADP	O
day	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
diphenhydramine	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
significance	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
on	O	ADP	O
both	O	DET	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
,	O	PUNCT	O
levocetirizine	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
impair	O	VERB	B
laboratory	B-OUT	ADJ	B
test	I-OUT	NOUN	I
performance	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
The	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
memory	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
attention	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
tracking	I-OUT	VERB	B
performance	I-OUT	NOUN	I
are	O	AUX	O
unaffected	O	ADJ	O
after	O	ADP	O
acute	O	ADJ	B
and	O	CCONJ	O
subchronic	O	ADJ	B
administration	O	NOUN	O
of	O	ADP	O
levocetirizine	B-I	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
diphenhydramine	B-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
significantly	O	ADV	O
affected	O	VERB	B
divided	B-OUT	ADJ	O
attention	I-OUT	NOUN	B
and	O	CCONJ	O
tracking	B-OUT	NOUN	B
after	O	ADP	O
acute	O	ADJ	B
administration	O	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
nifedipine	B-I	NOUN	B
on	O	ADP	O
gastric	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
secretion	I-OUT	NOUN	I
and	I-P	CCONJ	O
gastrin	I-OUT	NOUN	B
release	I-OUT	NOUN	B
in	I-P	ADP	O
man	I-P	NOUN	B
.	I-P	PUNCT	O


As	O	ADP	O
calcium	O	NOUN	B
is	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
gastric	O	ADJ	B
acid	O	NOUN	I
secretion	O	NOUN	I
and	O	CCONJ	O
gastrin	O	NOUN	B
release	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
calcium	O	NOUN	B
antagonist	O	NOUN	I
nifedipine	B-I	NOUN	B
on	O	ADP	O
these	O	DET	O
processes	O	NOUN	B
in	O	ADP	O
man	B-P	NOUN	B
.	I-P	PUNCT	O


Nifedipine	B-I	NOUN	B
30	O	NUM	O
mg	O	NOUN	O
orally	O	ADV	B
inhibited	O	VERB	B
basal	O	ADJ	B
acid	O	NOUN	I
output	O	NOUN	B
by	O	ADP	O
37	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.025	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
that	O	DET	O
stimulated	O	VERB	B
by	O	ADP	O
low	O	ADJ	B
infusion	O	NOUN	B
rates	O	NOUN	B
of	O	ADP	O
pentagastrin	B-I	NOUN	B
--	I-I	PUNCT	O
that	I-I	ADV	O
is	O	ADV	O
,	O	PUNCT	O
0.031	O	NUM	O
and	O	CCONJ	O
0.062	O	NUM	O
microgram/kg/h	O	NOUN	O
by	O	ADP	O
44	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
39	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.02	O	NUM	O
)	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


On	O	ADP	O
increasing	O	VERB	B
the	O	DET	O
pentagastrin	B-I	NOUN	B
infusion	O	NOUN	B
rate	O	NOUN	B
the	O	DET	O
inhibition	O	NOUN	B
was	O	AUX	O
surmounted	O	VERB	O
suggesting	O	VERB	O
it	O	PRON	O
was	O	AUX	O
competitive	O	ADJ	B
in	O	ADP	O
type	O	NOUN	B
.	O	PUNCT	O


Nifedipine	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
basal	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
Oxo	I-OUT	NOUN	B
meal	I-OUT	NOUN	I
stimulated	I-OUT	VERB	O
gastrin	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
in	O	ADP	O
normal	B-P	ADJ	B
volunteers	I-P	NOUN	I
nor	O	CCONJ	O
did	O	AUX	O
it	O	PRON	O
affect	O	VERB	O
resting	B-OUT	VERB	B
serum	I-OUT	NOUN	I
gastrin	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
calcium	I-OUT	NOUN	B
stimulated	I-OUT	VERB	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
gastrin	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
single	B-P	ADJ	O
patient	I-P	NOUN	B
with	I-P	ADP	O
Zollinger-Ellison	I-P	NOUN	B
syndrome	I-P	NOUN	I
.	I-P	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
transmembrane	O	ADJ	B
flux	O	NOUN	I
of	O	ADP	O
calcium	O	NOUN	B
ions	O	NOUN	I
being	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
basal	O	ADJ	B
and	O	CCONJ	O
pentagastrin	B-P	NOUN	B
stimulated	I-P	VERB	O
acid	I-P	NOUN	B
secretion	I-P	NOUN	I
in	I-P	ADP	O
man	I-P	NOUN	B
.	I-P	PUNCT	O


Prospective	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
intraoperative	B-I	ADJ	B
mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
primary	B-P	ADJ	B
pterygium	I-P	NOUN	I
.	I-P	PUNCT	O


AIMS	O	ADJ	B
A	O	DET	I
prospective	O	ADJ	B
,	O	PUNCT	O
randomised	O	VERB	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	B-I	NOUN	B
controlled	O	ADJ	O
study	O	NOUN	O
of	O	ADP	O
intraoperative	B-I	ADJ	B
mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
as	O	ADP	O
adjunctive	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
primary	B-P	ADJ	B
pterygium	I-P	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


METHODS	O	VERB	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
66	I-P	NUM	O
eyes	I-P	NOUN	B
of	I-P	ADP	O
54	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
primary	I-P	ADJ	B
pterygium	I-P	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
excision	B-I	NOUN	B
,	I-I	PUNCT	O
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
a	I-I	DET	O
single	I-I	ADJ	O
intraoperative	I-I	ADJ	B
application	I-I	NOUN	B
of	I-I	ADP	O
mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
(	O	PUNCT	O
0.1	O	NUM	O
mg/ml	O	NOUN	O
for	O	ADP	O
5	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
of	O	ADP	O
this	O	DET	O
adjunctive	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
follow	O	VERB	B
up	O	ADP	I
was	O	AUX	O
14.1	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
12-23	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
Of	O	ADP	O
the	O	DET	O
36	O	NUM	O
eyes	O	NOUN	B
that	O	PRON	O
underwent	O	VERB	O
simple	O	ADJ	O
excision	O	NOUN	O
,	O	PUNCT	O
14	O	NUM	O
(	O	PUNCT	O
38.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
exhibited	O	VERB	O
recurrences	B-OUT	NOUN	B
whereas	O	SCONJ	O
only	O	ADV	O
one	O	NUM	O
of	O	ADP	O
30	O	NUM	O
eyes	O	NOUN	B
(	O	PUNCT	O
3.33	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	I
excision	O	NOUN	B
and	O	CCONJ	O
intraoperative	O	ADJ	B
application	O	NOUN	B
of	O	ADP	O
mitomycin	B-I	NOUN	B
C	I-I	NOUN	O
had	O	AUX	O
recurrence	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0006	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Neither	O	CCONJ	O
serious	O	ADJ	O
ocular	B-OUT	ADJ	B
complications	I-OUT	NOUN	O
nor	I-OUT	CCONJ	O
systemic	I-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
were	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
mitomycin	B-I	NOUN	B
C	I-I	NOUN	I
treated	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
Intraoperative	O	ADJ	B
mitomycin	B-I	NOUN	B
C	I-I	NOUN	I
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
adjunctive	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
primary	B-P	ADJ	B
pterygium	I-P	NOUN	I
.	I-P	PUNCT	O


Randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
balance-based	O	ADJ	B
torso	B-I	NOUN	I
weighting	I-I	VERB	O
for	O	ADP	O
improving	O	VERB	B
upright	B-OUT	ADJ	B
mobility	I-OUT	NOUN	I
in	O	ADP	O
people	B-P	NOUN	B
with	I-P	ADP	O
multiple	I-P	ADJ	B
sclerosis	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Torso	O	PROPN	B
weighting	O	NOUN	B
has	O	AUX	O
sometimes	O	ADV	O
been	O	AUX	O
effective	O	ADJ	B
for	O	ADP	O
improving	O	VERB	B
upright	B-OUT	ADJ	B
mobility	I-OUT	NOUN	I
in	O	ADP	O
people	B-P	NOUN	B
with	I-P	ADP	O
multiple	I-P	ADJ	B
sclerosis	I-P	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
parameters	B-OUT	NOUN	B
for	I-OUT	ADP	O
weighting	I-OUT	NOUN	B
have	O	AUX	O
been	O	AUX	O
inconsistent	O	ADJ	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
balance-based	B-I	ADJ	B
torso	I-I	NOUN	I
weighting	I-I	NOUN	O
(	I-I	PUNCT	O
BBTW	I-I	NOUN	B
)	I-I	PUNCT	O
has	O	AUX	O
immediate	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
upright	O	ADJ	B
mobility	O	NOUN	I
in	O	ADP	O
people	O	NOUN	B
with	O	ADP	O
multiple	B-P	ADJ	B
sclerosis	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
2-phase	O	ADJ	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


In	B-P	ADP	O
phase	I-P	NOUN	B
1	I-P	NUM	I
,	I-P	PUNCT	O
36	I-P	NUM	O
participants	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
experimental	I-P	ADJ	B
and	I-P	CCONJ	O
control	I-P	NOUN	B
groups	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
phase	B-P	NOUN	B
2	I-P	NUM	I
,	I-P	PUNCT	O
the	I-P	DET	O
control	I-P	NOUN	B
group	I-P	NOUN	I
was	O	AUX	O
subsequently	O	ADV	O
randomized	O	VERB	B
into	O	ADP	O
2	O	NUM	O
groups	O	NOUN	B
with	O	ADP	O
alternate	O	ADJ	O
weight-placement	O	ADJ	B
.	O	PUNCT	O


Tests	O	NOUN	B
of	O	ADP	O
upright	B-OUT	ADJ	B
mobility	I-OUT	NOUN	B
included	O	VERB	O
:	O	PUNCT	O
timed	B-OUT	VERB	B
up	I-OUT	ADP	I
and	I-OUT	CCONJ	O
go	I-OUT	VERB	O
(	I-OUT	PUNCT	O
TUG	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
sharpened	I-OUT	VERB	B
Romberg	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
360-degree	I-OUT	ADJ	O
turns	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
25-foot	I-OUT	ADJ	B
walk	I-OUT	VERB	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
computerized	I-OUT	VERB	B
platform	I-OUT	NOUN	I
posturography	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
again	O	ADV	O
with	O	ADP	O
weights	O	NOUN	B
placed	O	VERB	O
according	O	VERB	O
to	O	ADP	O
group	O	NOUN	B
membership	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
phases	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
physical	O	ADJ	B
therapist	O	NOUN	I
assessed	O	VERB	B
balance	O	NOUN	B
for	O	ADP	O
the	O	DET	O
BBTW	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
placed	O	VERB	O
weights	O	NOUN	B
to	O	PART	O
decrease	O	VERB	B
balance	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
phase	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
had	O	AUX	O
no	O	DET	O
weights	O	NOUN	B
placed	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
phase	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
the	O	DET	O
alternate	O	ADJ	B
treatment	O	NOUN	I
group	O	NOUN	I
received	O	VERB	O
standard	O	ADJ	O
weight	O	NOUN	B
placement	O	NOUN	I
of	O	ADP	O
1.5	O	NUM	O
%	O	NOUN	O
body	O	NOUN	B
weight	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
People	O	NOUN	B
with	O	ADP	O
BBTW	B-I	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
25-foot	B-OUT	ADJ	B
walk	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.01	O	NUM	O
)	O	PUNCT	O
over	O	ADP	O
those	O	DET	O
with	O	ADP	O
no	O	DET	B
weight	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
TUG	B-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.01	O	NUM	O
)	O	PUNCT	O
over	O	ADP	O
those	O	DET	O
with	O	ADP	O
standard	O	ADJ	B
weight	O	NOUN	I
placement	O	NOUN	I
.	O	PUNCT	O


BBTW	O	NOUN	B
participants	O	NOUN	B
received	O	VERB	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
0.5	O	NUM	O
kg	B-OUT	NOUN	O
,	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
1.5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
any	O	DET	O
participant	O	NOUN	B
's	O	PART	O
body	O	NOUN	B
weight	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
BBTW	B-I	NOUN	B
can	O	AUX	O
have	O	AUX	O
immediate	O	ADJ	O
advantages	O	NOUN	O
over	O	ADP	O
a	O	DET	O
nonweighted	O	ADJ	B
condition	O	NOUN	B
for	O	ADP	O
gait	B-OUT	ADJ	B
velocity	I-OUT	NOUN	I
and	O	CCONJ	O
over	O	ADP	O
a	O	DET	O
standardized	O	ADJ	B
weighted	O	VERB	I
condition	O	NOUN	I
for	O	ADP	O
a	O	DET	O
functional	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
in	O	ADP	O
people	B-P	NOUN	B
with	I-P	ADP	O
multiple	I-P	ADJ	B
sclerosis	I-P	NOUN	I
(	I-P	PUNCT	O
MS	I-P	NOUN	B
)	I-P	PUNCT	O
who	O	PRON	O
are	O	AUX	O
ambulatory	O	ADJ	B
but	O	CCONJ	O
have	O	AUX	O
balance	O	NOUN	B
and	O	CCONJ	O
mobility	O	NOUN	B
abnormalities	O	NOUN	I
.	O	PUNCT	O


Adequacy	O	NOUN	B
of	O	ADP	O
vitamin	B-I	NOUN	B
B6	I-I	NOUN	I
supplementation	I-I	NOUN	B
during	O	ADP	O
pregnancy	B-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
assesses	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
2.5	B-I	NUM	O
,	I-I	PUNCT	O
4	I-I	NUM	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
10	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
pyridoxine	I-I	NOUN	B
supplementation	I-I	NOUN	B
during	I-I	ADP	O
pregnancy	I-I	NOUN	B
on	I-I	ADP	O
maternal	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
fetal	I-OUT	ADJ	B
plasma	I-OUT	NOUN	O
levels	I-OUT	NOUN	O
of	I-OUT	ADP	O
pyridoxal	I-OUT	NOUN	B
5'-phosphate	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PLP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
coenzyme	I-OUT	ADJ	B
saturation	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
activation	I-OUT	NOUN	B
factor	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
of	I-OUT	ADP	O
aspartate	I-OUT	NOUN	B
aminotransferase	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
alanine	I-OUT	NOUN	B
aminotransferase	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
alphaEGOT	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
alphaEGPT	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
in	I-OUT	ADP	O
maternal	I-OUT	ADJ	B
erythrocytes	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


More	O	ADJ	O
than	O	ADP	O
4	B-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
pyridoxine	I-I	NOUN	B
supplementation	I-I	NOUN	B
daily	I-I	ADV	B
was	O	AUX	O
required	O	VERB	O
for	O	ADP	O
most	O	ADJ	O
pregnancies	O	NOUN	B
to	O	PART	O
maintain	O	VERB	O
maternal	B-OUT	ADJ	B
plasma	I-OUT	NOUN	B
PLP	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
within	O	ADP	O
the	O	DET	O
range	O	NOUN	B
observed	O	VERB	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
trimester	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
nonpregnant	O	ADJ	B
state	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
plasma	B-OUT	NOUN	B
PLP	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
in	I-OUT	ADP	O
maternal	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
cord	I-OUT	NOUN	B
blood	I-OUT	NOUN	I
were	O	AUX	O
highly	O	ADV	O
correlated	O	VERB	B
and	O	CCONJ	O
indicated	O	VERB	O
a	O	DET	O
dependence	O	NOUN	B
of	O	ADP	O
fetal	O	ADJ	B
vitamin	O	NOUN	B
B6	O	NOUN	I
nutrition	O	NOUN	B
on	O	ADP	O
maternal	O	ADJ	B
circulating	O	VERB	O
PLP	O	NOUN	B
.	O	PUNCT	O


Measurements	B-OUT	NOUN	B
of	I-OUT	ADP	O
alphaEGOT	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
alphaEGPT	I-OUT	ADJ	B
were	O	AUX	O
not	O	PART	O
as	O	ADV	O
reproducible	O	ADJ	O
as	O	ADP	O
plasma	B-OUT	NOUN	B
PLP	I-OUT	NOUN	B
assays	I-OUT	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
less	O	ADV	O
sensitive	O	ADJ	B
and	O	CCONJ	O
quantitative	O	ADJ	B
indicators	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
subjects	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
alphaEGOT	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
alphaEGPT	I-OUT	ADV	B
with	O	ADP	O
time	O	NOUN	B
correlated	O	VERB	O
poorly	O	ADV	B
with	O	ADP	O
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
plasma	B-OUT	NOUN	B
PLP	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
data	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
without	O	ADP	O
regard	O	NOUN	O
for	O	ADP	O
their	O	PRON	O
dependence	O	NOUN	B
on	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
they	O	PRON	O
demonstrated	O	VERB	O
a	O	DET	O
negative	O	ADJ	B
,	O	PUNCT	O
linear	O	ADJ	B
correlation	O	NOUN	I
between	O	ADP	O
alphaEGOT	B-OUT	ADJ	B
and	O	CCONJ	O
log	O	NOUN	B
plasma	B-OUT	NOUN	I
PLP	I-OUT	NOUN	I
and	O	CCONJ	O
between	O	ADP	O
alphaEGPT	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
log	I-OUT	NOUN	B
plasma	I-OUT	NOUN	I
PLP	I-OUT	NOUN	I
for	O	ADP	O
the	O	DET	O
group	O	NOUN	B
on	O	ADP	O
2.5	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
pyridoxine	B-I	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
all	O	DET	O
the	O	DET	O
subjects	O	NOUN	B
combined	O	VERB	O
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
dietary	O	ADJ	B
records	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
consumed	O	VERB	O
less	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
vitamin	B-I	NOUN	B
B6	I-I	NOUN	I
daily	O	ADV	B
from	O	ADP	O
their	O	PRON	O
food	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
current	O	ADJ	O
Recommended	O	VERB	B
Dietary	O	ADJ	B
Allowance	O	PROPN	I
for	O	ADP	O
vitamin	B-I	NOUN	B
B6	I-I	NOUN	I
during	O	ADP	O
pregnancy	O	NOUN	B
(	O	PUNCT	O
2.5	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
is	O	AUX	O
too	O	ADV	O
low	O	ADJ	B
and	O	CCONJ	O
that	O	SCONJ	O
supplementation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
vitamin	O	NOUN	B
in	O	ADP	O
an	O	DET	O
amount	O	NOUN	B
more	O	ADJ	O
than	O	ADP	O
4	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
is	O	AUX	O
recommended	O	VERB	B
.	O	PUNCT	O


Intensive	B-I	NOUN	B
insulin	I-I	NOUN	I
therapy	I-I	NOUN	I
improves	O	VERB	O
endothelial	B-OUT	ADJ	B
function	I-OUT	NOUN	I
and	O	CCONJ	O
microvascular	O	ADJ	B
reactivity	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
people	I-P	NOUN	I
with	I-P	ADP	O
type	I-P	NOUN	B
1	I-P	NUM	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


AIMS/HYPOTHESIS	O	ADJ	B
Macrovascular	O	ADJ	B
disease	O	NOUN	I
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
the	O	DET	O
increased	O	VERB	B
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
rates	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
type	O	NOUN	B
1	O	NUM	I
diabetes	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
vascular	O	ADJ	B
impairment	O	NOUN	I
begins	O	VERB	O
in	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
introducing	O	VERB	O
intensive	B-I	ADJ	B
diabetes	I-I	NOUN	I
management	I-I	NOUN	I
[	I-I	PUNCT	O
intensive	I-I	ADJ	B
insulin	O	NOUN	I
therapy	O	NOUN	I
(	O	PUNCT	O
IIT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
'Sweet	B-I	PUNCT	B
Talk	I-I	PROPN	B
'	I-I	PUNCT	I
text-messaging	I-I	ADJ	O
support	I-I	NOUN	O
]	I-I	PUNCT	O
produces	O	VERB	O
measurable	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
endothelial	B-OUT	ADJ	B
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
twenty-six	I-P	NUM	O
patients	I-P	NOUN	B
fulfilled	I-P	VERB	O
the	I-P	DET	O
eligibility	I-P	NOUN	B
criteria	I-P	NOUN	I
(	I-P	PUNCT	O
type	I-P	NOUN	B
1	I-P	NUM	I
diabetes	I-P	NOUN	I
for	I-P	ADP	O
>	I-P	NOUN	O
1	I-P	NUM	O
year	I-P	NOUN	B
;	I-P	PUNCT	O
on	I-P	ADP	O
conventional	I-I	ADJ	B
insulin	I-I	NOUN	B
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
CIT	I-I	NOUN	B
)	I-I	PUNCT	O
;	I-I	PUNCT	O
aged	I-P	ADJ	B
between	I-P	ADP	O
8	I-P	NUM	O
and	I-P	CCONJ	O
18	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
of	I-P	ADP	O
whom	I-P	PRON	O
92	I-P	NUM	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
group	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
CIT	B-I	NOUN	B
only	I-I	ADV	O
(	I-I	PUNCT	O
n=28	I-I	ADJ	O
)	I-I	PUNCT	O
;	I-I	PUNCT	O
group	I-I	NOUN	B
2	I-I	NUM	I
,	I-I	PUNCT	O
CIT	I-I	NOUN	B
and	I-I	CCONJ	O
Sweet	I-I	PROPN	B
Talk	I-I	PROPN	I
(	I-I	PUNCT	O
n=33	I-I	NOUN	O
)	I-I	PUNCT	O
;	I-I	PUNCT	O
or	I-I	CCONJ	O
group	I-I	NOUN	B
3	I-I	NUM	I
,	I-I	PUNCT	O
IIT	I-I	PROPN	B
and	I-I	CCONJ	O
Sweet	I-I	PROPN	B
Talk	I-I	PROPN	I
(	I-I	PUNCT	O
n=31	I-I	ADJ	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Vascular	B-OUT	ADJ	B
assessments	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
including	I-OUT	VERB	O
measures	I-OUT	NOUN	B
of	I-OUT	ADP	O
endothelial	I-OUT	ADJ	B
damage	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
activation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
dysfunction	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
oxidative	I-OUT	ADJ	B
stress	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
HbA1c	I-OUT	NOUN	B
were	I-I	AUX	O
performed	I-I	VERB	O
at	I-I	ADP	O
baseline	I-I	NOUN	B
and	I-I	CCONJ	O
repeated	I-I	VERB	O
after	I-I	ADP	O
12	I-I	NUM	O
months	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
study	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	VERB	B
Glycaemic	B-OUT	ADJ	B
control	I-OUT	NOUN	I
deteriorated	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
CIT	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
improved	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
allocated	O	VERB	O
to	O	PART	O
IIT	O	NOUN	B
(	O	PUNCT	O
p=0.007	O	VERB	O
)	O	PUNCT	O
.	O	PUNCT	O


IIT	O	PROPN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
significantly	O	ADV	O
greater	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
E-selectin	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
CIT	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
p=0.026	O	NOUN	O
and	O	CCONJ	O
group	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
p=0.053	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Vascular	B-OUT	ADJ	B
responses	I-OUT	NOUN	I
to	O	PART	O
acetylcholine	O	NOUN	B
improved	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
IIT	O	NOUN	B
(	O	PUNCT	O
p=0.017	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
CIT	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
were	O	AUX	O
all	O	DET	O
independent	O	ADJ	B
of	O	ADP	O
HbA1c	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS/INTERPRETATION	O	PROPN	B
IIT	O	PROPN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
improvements	O	NOUN	B
in	O	ADP	O
vascular	B-OUT	ADJ	B
markers	I-OUT	NOUN	I
,	O	PUNCT	O
independently	O	ADV	O
of	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
HbA1c	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
IIT	O	PROPN	B
may	O	AUX	O
confer	O	VERB	O
vascular	O	ADJ	B
protection	O	NOUN	I
in	O	ADP	O
addition	O	NOUN	O
to	O	ADP	O
improving	O	VERB	B
glycaemic	B-OUT	ADJ	B
control	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Angiotensin-converting	B-I	ADJ	B
enzyme	I-I	NOUN	O
inhibition	I-I	NOUN	B
does	O	AUX	O
not	O	PART	O
suppress	O	VERB	B
plasma	O	NOUN	B
angiotensin	O	NOUN	B
II	O	NUM	I
increase	O	NOUN	B
during	O	ADP	O
exercise	B-P	NOUN	B
in	I-P	ADP	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


Physical	O	ADJ	B
effort	O	NOUN	I
stimulates	O	VERB	B
the	O	DET	O
reninangiotensin	O	NOUN	B
system	O	NOUN	I
(	O	PUNCT	O
RAS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
an	O	DET	O
angiotensin-converting	B-I	ADJ	B
enzyme	I-I	NOUN	I
inhibitor	I-I	NOUN	I
(	I-I	PUNCT	O
ACE	I-I	NOUN	B
inhibitor	I-I	NOUN	I
)	I-I	PUNCT	O
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
placebo-controlled	O	ADJ	I
study	O	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
eight	B-P	NUM	O
volunteers	I-P	NOUN	B
undergoing	I-P	VERB	O
physical	I-P	ADJ	B
stress	I-P	NOUN	I
on	I-P	ADP	O
an	I-P	DET	O
ergometric	I-P	ADJ	B
bicycle	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
captopril	B-I	NOUN	B
(	O	PUNCT	O
C	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
three	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
arterial	B-OUT	ADJ	B
pressure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
O2	I-OUT	NOUN	B
consumption	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VO2	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
variations	I-OUT	NOUN	B
in	I-OUT	ADP	O
auricular	I-OUT	ADJ	B
natriuretic	I-OUT	ADJ	I
factor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ANF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
renin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
angiotensin	I-OUT	NOUN	B
II	I-OUT	NUM	I
(	I-OUT	PUNCT	O
AII	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
glomerular	I-OUT	ADJ	B
filtration	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GFR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
microalbuminuria	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
MA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
different	O	ADJ	O
parameters	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
by	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
variance	O	NOUN	O
(	O	PUNCT	O
ANOVA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
pressure	O	NOUN	B
profile	O	NOUN	I
and	O	CCONJ	O
VO2	O	NOUN	B
were	O	AUX	O
not	O	PART	O
modified	O	VERB	O
by	O	ADP	O
ACE	B-I	NOUN	B
inhibitor	I-I	NOUN	I
.	I-I	PUNCT	O


Exercise	O	NOUN	B
stimulates	O	VERB	B
release	O	NOUN	B
of	O	ADP	O
renin	O	NOUN	B
;	O	PUNCT	O
this	O	DET	O
action	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
with	O	ADP	O
captopril	B-I	NOUN	B
administration	O	NOUN	B
(	O	PUNCT	O
treatment	O	NOUN	B
effect	O	NOUN	I
:	O	PUNCT	O
p	O	X	O
<	O	X	O
10	O	NUM	O
(	O	PUNCT	O
-4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
indicating	O	VERB	O
blockade	O	NOUN	B
of	O	ADP	O
the	O	DET	O
RAS	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
inhibition	O	NOUN	B
was	O	AUX	O
incomplete	O	ADJ	B
because	O	SCONJ	O
AII	O	NOUN	B
levels	O	NOUN	B
increased	O	VERB	B
markedly	O	ADV	O
when	O	SCONJ	O
captopril	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
(	O	PUNCT	O
no	O	DET	O
treatment	O	NOUN	O
effect	O	NOUN	O
:	O	PUNCT	O
p	O	X	O
<	O	X	O
0.37	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
ACE	B-I	NOUN	B
inhibitor	I-I	NOUN	O
resulted	O	VERB	O
in	O	ADP	O
decreased	O	VERB	B
GFR	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
115	O	NUM	O
+/-	O	CCONJ	O
5.8	O	NUM	O
ml/mn-1	O	NOUN	B
,	O	PUNCT	O
C	O	NOUN	O
=	O	ADJ	O
91.1	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
exercise	O	NOUN	B
without	O	ADP	O
modification	O	NOUN	B
of	O	ADP	O
MA	O	PROPN	B
.	O	PUNCT	O


ACE	B-I	NOUN	B
inhibitor	I-I	NOUN	B
administration	I-I	NOUN	B
does	O	AUX	O
not	O	PART	O
modify	O	VERB	O
the	O	DET	O
physical	O	ADJ	B
performance	O	NOUN	I
of	O	ADP	O
nonathletic	O	ADJ	B
subjects	O	NOUN	I
;	O	PUNCT	O
AII	O	NOUN	B
is	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
with	O	ADP	O
exercise	O	NOUN	B
despite	O	SCONJ	O
captopril	O	NOUN	B
treatment	O	NOUN	B
;	O	PUNCT	O
ACE	B-I	NOUN	B
inhibitor	I-I	NOUN	B
decreases	O	VERB	B
GFR	B-OUT	NOUN	B
significantly	O	ADV	B
but	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
influence	O	VERB	B
MA	O	PROPN	B
with	O	ADP	O
prolonged	O	ADJ	B
physical	O	ADJ	B
effort	O	NOUN	I
.	O	PUNCT	O


Heart	O	NOUN	B
rate	O	NOUN	I
variability	O	NOUN	B
characteristics	O	NOUN	B
in	B-P	ADP	O
sedentary	I-P	ADJ	B
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
following	O	VERB	O
six	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
exercise	B-I	NOUN	B
training	I-I	NOUN	B
:	I-I	PUNCT	O
the	O	DET	O
DREW	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Decreased	O	VERB	B
heart	O	NOUN	O
rate	O	NOUN	O
variability	O	NOUN	O
(	O	PUNCT	O
HRV	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
higher	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
mortality	O	NOUN	B
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
postmenopausal	B-P	ADJ	B
women	I-P	NOUN	B
have	O	AUX	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
HRV	O	NOUN	B
than	O	ADP	O
premenopausal	O	ADJ	B
women	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
additionally	O	ADV	O
complicated	O	ADJ	O
by	O	ADP	O
lifestyle	O	NOUN	B
related	O	ADJ	O
behaviors	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
physical	O	ADJ	B
inactivity	O	NOUN	I
and	O	CCONJ	O
obesity	O	NOUN	B
.	O	PUNCT	O


Though	O	SCONJ	O
cardiorespiratory	B-I	ADJ	B
exercise	I-I	NOUN	I
training	I-I	NOUN	I
increases	O	VERB	B
HRV	O	NOUN	B
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
regarding	O	VERB	O
the	O	DET	O
exercise	O	NOUN	B
dose	O	NOUN	B
necessary	O	ADJ	O
to	O	PART	O
promote	O	VERB	B
this	O	DET	O
improvement	O	NOUN	B
.	O	PUNCT	O


METHODOLOGY/PRINCIPAL	O	NOUN	B
FINDINGS	O	VERB	O
Our	O	PRON	O
primary	O	ADJ	O
aim	O	NOUN	B
was	O	AUX	O
to	O	PART	O
measure	O	VERB	B
HRV	O	NOUN	B
in	O	ADP	O
post-menopausal	B-P	ADJ	B
women	I-P	NOUN	B
following	O	VERB	O
6-months	O	NOUN	B
of	O	ADP	O
exercise	B-I	NOUN	B
training	I-I	NOUN	O
.	I-I	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
supine	B-P	ADJ	B
resting	I-P	VERB	O
HRV	I-P	NOUN	B
in	I-P	ADP	O
373	I-P	NUM	O
post-menopausal	I-P	ADJ	B
women	I-P	NOUN	B
(	I-P	PUNCT	O
45-75	I-P	NUM	O
y	I-P	NOUN	O
)	I-P	PUNCT	O
after	I-P	ADP	O
6-months	I-P	NOUN	B
of	I-P	ADP	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
and	O	CCONJ	O
double-blinded	O	ADJ	B
administered	O	VERB	B
exercise	B-I	NOUN	B
training	I-I	NOUN	O
exercise	I-I	NOUN	O
training	I-I	NOUN	O
at	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
100	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
150	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
NIH	O	PROPN	B
Consensus	O	PROPN	B
Development	O	PROPN	I
Panel	O	PROPN	I
's	O	PART	I
recommended	O	VERB	B
minimal	O	ADJ	B
physical	O	ADJ	B
activity	O	NOUN	I
level	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
corresponded	O	VERB	O
to	O	PART	O
4	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
12	O	NUM	O
kcal/kg	O	NOUN	O
per	O	ADP	O
week	O	NOUN	B
(	O	PUNCT	O
KKW	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
energy	O	NOUN	B
expenditure	O	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
HRV	B-OUT	NOUN	B
or	O	CCONJ	O
hormone	B-OUT	NOUN	B
replacement	O	NOUN	O
use	O	NOUN	O
between	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
did	O	AUX	O
observe	O	VERB	O
that	O	SCONJ	O
Caucasian	O	ADJ	B
women	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
taking	O	VERB	O
antidepressant	O	ADJ	B
medications	O	NOUN	B
had	O	AUX	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
baseline	B-OUT	NOUN	B
HRV	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


After	O	ADP	O
6-months	O	NOUN	B
of	O	ADP	O
exercise	B-I	NOUN	B
intervention	I-I	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
dependent	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
all	O	DET	O
parasympathetically	O	ADV	B
derived	O	VERB	O
time	B-OUT	NOUN	O
and	I-OUT	CCONJ	O
frequency	I-OUT	NOUN	B
domain	I-OUT	NOUN	I
measurements	I-OUT	NOUN	I
across	O	ADP	O
exercise	O	NOUN	B
groups	O	NOUN	I
after	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
ethnicity	O	NOUN	B
,	O	PUNCT	O
antidepressants	B-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
baseline	O	NOUN	B
rMSSD	O	NOUN	B
(	O	PUNCT	O
all	O	DET	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
example	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
parasympathetic	B-OUT	ADJ	B
index	I-OUT	NOUN	I
rMSSD	I-OUT	PROPN	B
was	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
control	O	NOUN	B
(	O	PUNCT	O
23.19+/-1.0	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
4-KKW	O	NOUN	O
(	O	PUNCT	O
25.98+/-0.8	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.14	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
8-KKW	O	NOUN	O
(	O	PUNCT	O
27.66+/-1.0	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
12-KKW	O	NUM	O
(	O	PUNCT	O
27.40+/-0.0	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
groups	O	NOUN	B
at	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS/SIGNIFICANCE	O	NOUN	B
Moderate	B-I	ADJ	B
intensity	I-I	NOUN	O
exercise	I-I	NOUN	O
training	I-I	NOUN	O
exercise	I-I	NOUN	O
is	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
improve	O	VERB	B
HRV	O	NOUN	B
in	O	ADP	O
previously	O	ADV	O
sedentary	B-P	ADJ	B
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
in	O	ADP	O
a	O	DET	O
dose-dependent	O	ADJ	B
manner	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
4-KKW	O	NOUN	O
is	O	AUX	O
insufficient	O	ADJ	B
to	O	PART	O
improve	O	VERB	B
parasympathetic	O	ADJ	B
indices	O	NOUN	I
of	O	ADP	O
HRV	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
12-KKW	O	NUM	O
conferred	O	VERB	O
no	O	DET	O
greater	O	ADJ	O
improvement	O	NOUN	B
than	O	ADP	O
8-KKW	O	NOUN	O
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
Clinicaltrials.gov	O	NOUN	O
NCT	O	NOUN	B
00011193	O	NUM	O
.	O	PUNCT	O


Tetracaine	B-I	NOUN	B
(	I-I	PUNCT	O
ametop	I-I	NOUN	B
)	I-I	PUNCT	O
compared	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
for	O	ADP	O
reducing	O	VERB	B
pain	B-P	NOUN	I
associated	I-P	VERB	B
with	I-P	ADP	I
intramuscular	I-P	ADJ	B
injection	I-P	NOUN	B
of	I-P	ADP	O
palivizumab	I-P	NOUN	B
(	I-P	PUNCT	O
synagis	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Infants	B-P	NOUN	B
receive	I-P	VERB	O
many	I-P	ADJ	O
painful	I-P	ADJ	B
immunizations	I-P	NOUN	B
before	I-P	ADP	O
they	I-P	PRON	O
are	I-P	AUX	O
2	I-P	NUM	O
years	I-P	NOUN	B
old	I-P	ADJ	O
.	I-P	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
if	O	SCONJ	O
topical	B-I	ADJ	B
tetracaine	I-I	NOUN	I
reduces	O	VERB	B
the	O	DET	O
pain	B-P	NOUN	B
of	I-P	ADP	O
intramuscular	I-P	ADJ	B
palivizumab	I-I	NOUN	B
compared	O	VERB	B
to	O	PART	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
two	O	NUM	O
study	O	NOUN	B
injections	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
with	O	ADP	O
tetracaine	B-I	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
with	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Pain	B-OUT	NOUN	B
was	O	AUX	O
scored	O	VERB	B
by	O	ADP	O
their	O	PRON	O
parents	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
pediatric	O	ADJ	B
nurse	O	NOUN	B
.	O	PUNCT	O


Topical	O	ADJ	B
tetracaine	B-I	NOUN	I
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
score	I-OUT	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
it	O	PRON	O
did	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
faster	O	ADJ	O
recovery	B-OUT	NOUN	B
times	O	NOUN	O
.	O	PUNCT	O


Additional	O	ADJ	O
pain-reduction	O	NOUN	B
strategies	O	NOUN	O
are	O	AUX	O
required	O	VERB	O
.	O	PUNCT	O


Intravenous	B-I	ADJ	B
hyperimmune	I-I	ADJ	O
globulin	I-I	NOUN	O
prophylaxis	I-I	NOUN	O
against	O	ADP	O
cytomegalovirus	O	NOUN	B
interstitial	O	ADJ	I
pneumonitis	O	NOUN	I
after	O	ADP	O
allogenic	B-I	ADJ	B
bone	I-I	NOUN	I
marrow	I-I	NOUN	I
transplantation	I-I	NOUN	I
.	I-I	PUNCT	O


In	O	ADP	O
an	O	DET	O
attempt	O	NOUN	O
to	O	PART	O
reduce	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
lethal	O	ADJ	B
cytomegalovirus	B-OUT	NOUN	I
(	I-OUT	PUNCT	O
CMV	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
interstitial	I-OUT	ADJ	B
pneumonitis	I-OUT	NOUN	I
after	I-P	ADP	O
allogenic	I-I	ADJ	B
bone	I-I	NOUN	I
marrow	I-I	NOUN	I
transplantation	I-I	NOUN	I
49	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
in	I-P	ADP	O
a	I-P	DET	O
multicenter	I-P	NOUN	B
controlled	I-P	VERB	I
study	I-P	NOUN	I
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
CMV-hyperimmune	B-I	ADJ	B
globulin	I-I	NOUN	I
or	O	CCONJ	O
a	O	DET	O
control	B-I	ADJ	B
immune	I-I	ADJ	B
globulin	I-I	NOUN	I
with	I-I	ADP	O
low	I-I	ADJ	B
anticytomegalovirus	I-I	NOUN	B
titer	I-I	NOUN	B
.	I-I	PUNCT	O


Immune	B-I	ADJ	B
globulin	I-I	NOUN	I
was	O	AUX	O
administered	O	VERB	B
intravenously	O	ADV	B
6	O	NUM	O
times	O	NOUN	O
with	O	ADP	O
20	O	NUM	O
days	O	NOUN	B
interval	O	NOUN	B
,	O	PUNCT	O
starting	O	VERB	O
on	O	ADP	O
day	O	NOUN	B
7	O	NUM	O
before	O	ADP	O
transplantation	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
receiving	O	VERB	O
CMV	B-I	NOUN	B
hyperimmune	I-I	ADJ	B
globulin	I-I	NOUN	I
or	O	CCONJ	O
control	B-I	ADJ	B
immune	I-I	ADJ	I
globulin	I-I	NOUN	I
were	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
age	O	NOUN	B
,	O	PUNCT	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
pretransplant	O	ADJ	B
anti-CMV	O	ADJ	I
titer	O	NOUN	I
,	O	PUNCT	O
incidence	O	NOUN	B
of	O	ADP	O
graft-versus-host	O	NOUN	B
disease	O	NOUN	I
and	O	CCONJ	O
transfusions	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
each	O	DET	O
group	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
histologically	I-OUT	ADV	B
proven	I-OUT	VERB	O
CMV	I-OUT	NOUN	B
interstitial	I-OUT	ADJ	B
pneumonitis	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
110	O	NUM	O
days	O	NOUN	B
post	O	NOUN	B
BMT	O	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


Six	B-P	NUM	O
of	I-P	ADP	O
23	I-P	NUM	O
patients	I-P	NOUN	B
in	O	ADP	O
the	O	DET	O
control	B-I	ADJ	B
group	O	NOUN	I
versus	O	CCONJ	O
1	O	NUM	O
of	O	ADP	O
26	O	NUM	O
in	O	ADP	O
the	O	DET	O
CMV	B-I	NOUN	B
hyperimmune	I-I	ADJ	O
globulin	I-I	NOUN	B
group	O	NOUN	I
died	B-OUT	VERB	B
of	I-OUT	ADP	O
CMV	I-OUT	NOUN	B
interstitial	I-OUT	ADJ	O
pneumonitis	I-OUT	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
effect	B-OUT	NOUN	O
on	I-OUT	ADP	O
idiopathic	I-OUT	ADJ	B
pneumonitis	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
supraglotttic	B-I	ADJ	B
devices	I-I	NOUN	I
used	O	VERB	O
by	O	ADP	O
paramedics	O	NOUN	B
during	O	ADP	O
simulated	O	ADJ	B
CPR	O	PROPN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
crossover	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Ensuring	O	VERB	O
an	O	DET	O
open	O	ADJ	B
airway	O	NOUN	I
during	O	ADP	O
cardiopulmonary	O	NOUN	B
resuscitation	O	NOUN	I
is	O	AUX	O
fundamental	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
success	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
blind	O	ADJ	B
intubation	O	NOUN	B
during	O	ADP	O
simulated	O	ADJ	B
cardiopulmonary	O	NOUN	B
resuscitation	O	NOUN	I
by	O	ADP	O
untrained	B-P	ADJ	B
personnel	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Four	B-P	NUM	O
devices	I-P	NOUN	B
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
a	O	DET	O
simulated	O	ADJ	B
resuscitation	O	NOUN	B
scenario	O	NOUN	O
:	O	PUNCT	O
ILMA	B-I	NOUN	B
(	O	PUNCT	O
Intavent	O	PROPN	B
Direct	O	PROPN	I
Ltd	O	PROPN	I
,	O	PUNCT	O
Buckinghamshire	O	PROPN	B
,	O	PUNCT	O
United	O	PROPN	B
Kingdom	O	PROPN	I
)	O	PUNCT	O
,	O	PUNCT	O
Cobra	B-I	PROPN	B
PLA	I-I	PROPN	I
(	O	PUNCT	O
Engineered	O	VERB	B
Medical	O	PROPN	I
Systems	O	PROPN	I
Inc	O	PROPN	I
,	O	PUNCT	O
Indianapolis	O	PROPN	B
,	O	PUNCT	O
IN	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
Supraglottic	B-I	PROPN	B
Airway	I-I	PROPN	I
Laryngopharyngeal	I-I	PROPN	I
Tube	I-I	PROPN	I
(	I-I	PUNCT	O
SALT	I-I	NOUN	B
)	I-I	PUNCT	O
(	O	PUNCT	O
ECOLAB	O	NOUN	B
,	O	PUNCT	O
St.	O	PROPN	B
Paul	O	PROPN	I
,	O	PUNCT	O
MN	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Air-Q	B-I	NOUN	B
(	O	PUNCT	O
Mercury	O	PROPN	B
Medical	O	PROPN	I
,	O	PUNCT	O
Clearwater	O	PROPN	B
,	O	PUNCT	O
FL	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
group	B-P	NOUN	B
of	I-P	ADP	O
210	I-P	NUM	O
paramedics	I-P	NOUN	B
intubated	O	VERB	B
a	O	DET	O
manikin	O	NOUN	B
with	O	ADP	O
continuous	O	ADJ	B
chest	O	ADJ	I
compressions	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
mean	O	ADJ	O
times	O	NOUN	O
to	O	PART	O
intubation	O	NOUN	B
were	O	AUX	O
40.46	O	NUM	O
±	O	PROPN	O
4.64	O	NUM	O
,	O	PUNCT	O
33.96	O	NUM	O
±	O	PROPN	O
6.23	O	NUM	O
,	O	PUNCT	O
17.2	O	NUM	O
±	O	NOUN	O
4.63	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
49.23	O	NUM	O
±	O	NOUN	O
13.19	O	NUM	O
seconds	O	NOUN	O
(	O	PUNCT	O
SALT	O	NOUN	B
vs	O	CCONJ	O
ILMA	O	NOUN	B
,	O	PUNCT	O
Cobra	O	PROPN	B
PLA	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
Air-Q	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
success	I-OUT	NOUN	B
ratios	I-OUT	NOUN	B
of	I-OUT	ADP	O
blind	I-OUT	ADJ	B
intubation	I-OUT	NOUN	B
for	O	ADP	O
the	O	DET	O
devices	O	NOUN	B
were	O	AUX	O
86.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
85.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
100	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
71.4	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
SALT	O	NOUN	B
vs	O	CCONJ	O
ILMA	O	NOUN	B
,	O	PUNCT	O
Cobra	O	PROPN	B
PLA	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
Air-Q	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
most	O	ADV	O
efficient	O	ADJ	B
device	O	NOUN	B
with	O	ADP	O
the	O	DET	O
shortest	O	ADJ	O
blind	O	ADJ	B
intubation	O	NOUN	B
time	O	NOUN	I
was	O	AUX	O
the	B-I	DET	O
SALT	I-I	NOUN	B
device	I-I	NOUN	I
.	O	PUNCT	O


Three-Arm	O	VERB	B
Randomized	O	ADJ	I
Phase	O	NOUN	I
III	O	NUM	I
Trial	O	PROPN	I
:	O	PUNCT	O
Quality	O	PROPN	B
Aloe	B-I	PROPN	I
and	I-I	CCONJ	O
Placebo	I-I	PROPN	B
Cream	O	PROPN	I
Versus	O	PROPN	O
Powder	B-I	PROPN	B
as	O	ADP	O
Skin	O	PROPN	B
Treatment	O	NOUN	I
During	O	ADP	O
Breast	B-P	PROPN	B
Cancer	I-P	PROPN	I
Radiation	I-P	PROPN	I
Therapy	I-P	PROPN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
aloe	B-I	NOUN	B
extract	I-I	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
radiation-induced	B-OUT	ADJ	B
skin	I-OUT	NOUN	I
injury	I-OUT	NOUN	I
is	O	AUX	O
controversial	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
3-arm	O	ADJ	O
randomized	O	ADJ	B
trial	O	NOUN	I
was	O	AUX	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
quality-tested	O	ADJ	B
aloe	O	NOUN	I
extract	O	NOUN	I
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
radiation-induced	O	ADJ	B
skin	O	NOUN	I
injury	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
secondarily	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
moist	B-I	ADJ	B
cream	I-I	NOUN	I
versus	O	ADP	O
a	O	DET	O
dry	B-I	ADJ	B
powder	I-I	NOUN	I
skin	I-I	NOUN	B
care	I-I	NOUN	I
regimen	I-I	NOUN	B
.	I-I	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
248	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
powder	B-I	NOUN	B
,	I-I	PUNCT	O
aloe	I-I	NOUN	B
cream	I-I	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	ADJ	B
cream	I-I	NOUN	I
.	I-I	PUNCT	O


Acute	B-OUT	ADJ	B
skin	I-OUT	NOUN	O
toxicity	I-OUT	NOUN	B
was	O	AUX	O
scored	O	VERB	B
weekly	O	ADJ	B
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
at	O	ADP	O
weeks	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
using	O	VERB	O
a	O	DET	O
modified	O	VERB	B
10-point	O	ADJ	O
Catterall	O	PROPN	O
scale	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
scored	O	VERB	B
their	O	PRON	O
symptom	O	NOUN	B
severity	O	NOUN	B
using	O	VERB	O
a	O	DET	O
6-point	O	ADJ	B
Likert	O	NOUN	I
scale	O	NOUN	I
and	O	CCONJ	O
kept	O	VERB	O
an	O	DET	O
acute	O	ADJ	B
phase	O	NOUN	I
diary	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
aloe	O	NOUN	B
formulation	O	NOUN	B
did	O	AUX	O
not	O	PART	O
reduce	B-OUT	VERB	O
acute	I-OUT	ADJ	B
skin	I-OUT	NOUN	O
toxicity	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
symptom	I-OUT	NOUN	B
severity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Patients	B-P	NOUN	B
with	O	ADP	O
a	O	DET	O
greater	O	ADJ	O
body	O	NOUN	B
mass	O	NOUN	I
index	O	NOUN	I
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
develop	B-OUT	VERB	O
acute	I-OUT	ADJ	B
skin	I-OUT	NOUN	O
toxicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
similar	O	ADJ	O
pattern	O	NOUN	B
of	O	ADP	O
increased	O	VERB	B
skin	B-OUT	NOUN	B
reaction	I-OUT	NOUN	O
toxicity	I-OUT	NOUN	B
occurred	O	VERB	O
with	O	ADP	O
both	O	DET	O
study	O	NOUN	B
creams	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
dry	O	ADJ	B
powder	O	NOUN	I
regimen	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
No	O	DET	B
evidence	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
support	O	VERB	O
prophylactic	O	ADJ	B
application	O	NOUN	B
of	O	ADP	O
quality	O	NOUN	B
aloe	B-I	NOUN	B
extract	I-I	NOUN	I
or	O	CCONJ	O
cream	O	NOUN	B
to	O	PART	O
improve	O	VERB	B
the	O	DET	O
symptoms	O	NOUN	B
or	O	CCONJ	O
reduce	O	VERB	B
the	O	DET	O
skin	B-OUT	NOUN	B
reaction	I-OUT	NOUN	I
severity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
support	O	VERB	O
a	O	DET	O
dry	O	ADJ	B
skin	O	NOUN	I
care	O	NOUN	I
regimen	O	NOUN	B
of	O	ADP	O
powder	O	NOUN	B
during	O	ADP	O
radiation	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Timing	O	NOUN	B
of	O	ADP	O
antibiotic	B-I	ADJ	B
administration	I-I	NOUN	I
in	O	ADP	O
knee	B-P	NOUN	B
replacement	I-P	NOUN	I
under	I-P	ADP	O
tourniquet	I-P	NOUN	B
.	I-P	PUNCT	O


Cephamandole	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
drain	I-OUT	NOUN	B
fluid	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
32	B-P	NUM	O
knee	I-P	NOUN	B
replacement	I-P	NOUN	I
operations	I-P	NOUN	I
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intravenous	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
antibiotic	O	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
tourniquet	O	NOUN	B
deflation	O	NOUN	B
.	O	PUNCT	O


Concentrations	O	NOUN	B
of	O	ADP	O
cephamandole	B-OUT	NOUN	B
in	I-OUT	ADP	O
drain	I-OUT	NOUN	B
fluid	I-OUT	NOUN	I
were	O	AUX	O
directly	O	ADV	O
proportional	O	ADJ	O
to	O	PART	O
the	O	DET	O
serum	O	NOUN	B
concentration	O	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
tourniquet	O	NOUN	B
release	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
'tourniquet-release	B-I	NUM	B
'	I-I	PART	O
dose	I-I	NOUN	B
of	I-I	ADP	O
antibiotic	I-I	ADJ	B
increased	O	VERB	B
drain	B-OUT	NOUN	B
fluid	I-OUT	ADJ	I
concentration	I-OUT	NOUN	B
threefold	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
chiropractic	B-I	ADJ	B
and	I-I	CCONJ	O
medical	I-I	ADJ	B
care	I-I	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
low	I-OUT	ADJ	B
back	I-OUT	ADJ	I
pain	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
eighteen-month	O	ADJ	B
follow-up	O	ADJ	B
outcomes	O	NOUN	B
from	O	ADP	O
the	O	DET	O
UCLA	O	PROPN	B
low	O	ADJ	O
back	O	ADV	O
pain	O	NOUN	O
study	O	NOUN	O
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
Randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
long-term	O	ADJ	B
effectiveness	O	NOUN	B
of	O	ADP	O
medical	B-I	ADJ	B
and	I-I	CCONJ	O
chiropractic	I-I	ADJ	B
care	I-I	NOUN	I
for	I-I	ADP	O
low	I-I	ADJ	B
back	I-I	ADJ	I
pain	I-I	NOUN	I
in	I-P	ADP	O
managed	I-P	VERB	O
care	I-P	NOUN	B
and	O	CCONJ	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
physical	B-I	ADJ	B
therapy	I-I	NOUN	I
and	O	CCONJ	O
modalities	O	NOUN	B
among	O	ADP	O
patients	B-P	NOUN	B
receiving	I-P	VERB	O
medical	I-I	ADJ	B
or	I-I	CCONJ	O
chiropractic	I-I	ADJ	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


SUMMARY	O	NOUN	B
OF	O	ADP	O
BACKGROUND	O	NOUN	O
DATA	O	PROPN	B
Evidence	O	NOUN	O
comparing	O	VERB	O
the	O	DET	O
long-term	O	ADJ	B
relative	O	ADJ	O
effectiveness	O	NOUN	B
of	O	ADP	O
common	O	ADJ	O
treatment	O	NOUN	B
strategies	O	NOUN	O
offered	O	VERB	O
to	O	PART	O
low	B-P	ADV	B
back	I-P	ADV	I
pain	I-P	NOUN	I
patients	I-P	NOUN	B
in	O	ADP	O
managed	O	ADJ	B
care	O	NOUN	I
is	O	AUX	O
lacking	O	VERB	B
.	O	PUNCT	O


METHODS	O	VERB	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
681	I-P	NUM	O
low	I-P	ADJ	B
back	I-P	ADV	I
pain	I-P	NOUN	I
patients	I-P	NOUN	B
presenting	I-P	VERB	O
to	I-P	PART	O
a	I-P	DET	O
managed-care	I-P	ADJ	B
facility	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
chiropractic	B-I	ADJ	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
physical	I-I	ADJ	B
modalities	I-I	NOUN	I
,	I-I	PUNCT	O
or	I-I	CCONJ	O
medical	I-I	ADJ	B
care	I-I	NOUN	I
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
physical	I-I	ADJ	B
therapy	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
followed	O	VERB	O
for	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
outcome	O	NOUN	B
variables	O	NOUN	O
are	O	AUX	O
low	B-OUT	ADJ	B
back	I-OUT	ADV	I
pain	I-OUT	NOUN	I
intensity	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
disability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
complete	I-OUT	ADJ	O
remission	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
secondary	O	ADJ	B
outcome	O	NOUN	I
is	O	AUX	O
participants	B-OUT	NOUN	B
'	I-OUT	PART	O
perception	I-OUT	NOUN	B
of	I-OUT	ADP	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
low	I-OUT	ADJ	B
back	I-OUT	NOUN	I
symptoms	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
Of	O	ADP	O
the	O	DET	O
681	B-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
610	I-P	NUM	O
(	I-P	PUNCT	O
89.6	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
were	I-P	AUX	O
followed	I-P	VERB	O
through	I-P	ADP	O
18	I-P	NUM	O
months	I-P	NOUN	B
.	I-P	PUNCT	O


Among	O	ADP	O
participants	O	NOUN	B
not	O	PART	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
physical	O	ADJ	B
therapy	O	NOUN	I
or	O	CCONJ	O
modalities	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
estimated	O	VERB	O
improvements	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
and	O	CCONJ	O
18-month	O	ADJ	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
complete	I-OUT	ADJ	B
remission	I-OUT	NOUN	B
were	O	AUX	O
a	O	DET	O
little	O	ADJ	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
chiropractic	O	ADJ	B
group	O	NOUN	I
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
medical	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
adjusted	O	VERB	O
RR	O	NOUN	B
of	O	ADP	O
remission	O	NOUN	B
=	O	ADJ	O
1.29	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
0.80-2.07	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Among	O	ADP	O
participants	O	NOUN	B
assigned	O	VERB	B
to	O	ADP	O
medical	O	ADJ	B
care	O	NOUN	I
,	O	PUNCT	O
mean	B-OUT	VERB	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
pain	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
remission	I-OUT	NOUN	B
were	O	AUX	O
larger	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
physical	B-I	ADJ	B
therapy	I-I	NOUN	I
(	O	PUNCT	O
adjusted	O	VERB	O
RR	O	NOUN	B
=	O	ADJ	O
1.69	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
1.08-2.66	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Among	O	ADP	O
those	O	DET	O
assigned	O	VERB	O
to	O	PART	O
chiropractic	B-I	ADJ	B
care	I-I	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
assignment	O	NOUN	B
to	O	ADP	O
methods	O	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
improvement	O	NOUN	B
or	O	CCONJ	O
remission	O	NOUN	B
(	O	PUNCT	O
adjusted	O	VERB	O
RR	O	NOUN	B
=	O	ADJ	O
0.98	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
0.62-1.55	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
medical	O	ADJ	B
care	O	NOUN	I
only	O	ADV	O
patients	O	NOUN	B
,	O	PUNCT	O
chiropractic	B-I	ADJ	B
and	O	CCONJ	O
physical	O	ADJ	B
therapy	O	NOUN	I
patients	O	NOUN	B
were	O	AUX	O
much	O	ADV	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
perceive	O	VERB	O
improvement	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
low	O	ADJ	B
back	O	NOUN	I
symptoms	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
pain-free	B-OUT	ADJ	B
at	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Differences	O	NOUN	B
in	O	ADP	O
outcomes	O	NOUN	B
between	O	ADP	O
medical	B-I	ADJ	B
and	I-I	CCONJ	O
chiropractic	I-I	ADJ	B
care	I-I	NOUN	I
without	O	ADP	O
physical	O	ADJ	B
therapy	O	NOUN	I
or	O	CCONJ	O
modalities	O	NOUN	B
are	O	AUX	O
not	O	PART	O
clinically	O	ADV	O
meaningful	O	ADJ	O
,	O	PUNCT	O
although	O	SCONJ	O
chiropractic	O	NOUN	B
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
greater	O	ADJ	O
likelihood	O	NOUN	B
of	O	ADP	O
perceived	O	VERB	B
improvement	O	NOUN	B
,	O	PUNCT	O
perhaps	O	ADV	O
reflecting	O	VERB	O
satisfaction	O	NOUN	B
or	O	CCONJ	O
lack	O	NOUN	B
of	O	ADP	O
blinding	O	NOUN	B
.	O	PUNCT	O


Physical	B-I	ADJ	B
therapy	I-I	NOUN	I
may	O	AUX	O
be	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
medical	O	ADJ	B
care	O	NOUN	I
alone	O	ADV	O
for	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
physical	O	ADJ	B
modalities	O	NOUN	I
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
no	O	DET	O
benefit	O	NOUN	O
in	O	ADP	O
chiropractic	O	ADJ	B
care	O	NOUN	I
.	O	PUNCT	O


Safety	O	NOUN	B
and	O	CCONJ	O
pharmacology	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
intravenous	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
ponezumab	B-I	NOUN	B
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
Alzheimer	I-P	NOUN	O
disease	I-P	NOUN	O
:	I-P	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
I	O	NUM	I
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
dose-escalation	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
Ponezumab	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
humanized	O	ADJ	B
antiamyloid	O	ADJ	B
beta	O	NOUN	I
(	O	PUNCT	O
Aβ	O	NOUN	B
)	O	PUNCT	O
monoclonal	O	ADJ	B
antibody	O	NOUN	I
designed	O	VERB	O
to	O	PART	O
treat	O	VERB	B
Alzheimer	O	NOUN	B
disease	O	NOUN	I
(	O	PUNCT	O
AD	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
single-dose-escalation	O	ADJ	B
study	O	NOUN	I
evaluated	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
,	O	PUNCT	O
pharmacokinetics	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
pharmacodynamics	O	NOUN	B
of	O	ADP	O
0.1	O	NUM	O
,	O	PUNCT	O
0.3	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
10	O	NUM	O
mg/kg	B-I	NOUN	O
ponezumab	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
versus	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
a	O	DET	O
2-hour	O	ADJ	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
in	B-P	ADP	O
subjects	I-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
AD	I-P	NOUN	B
.	O	PUNCT	O


Cerebrospinal	O	ADJ	B
fluid	O	NOUN	I
(	O	PUNCT	O
CSF	O	NOUN	B
)	O	PUNCT	O
samples	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
1-	O	NUM	O
and	O	CCONJ	O
10-mg/kg	O	NOUN	O
groups	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
day	O	NOUN	B
29	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
for	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
All	O	DET	O
subjects	O	NOUN	B
completed	O	VERB	O
the	O	DET	O
trial	O	NOUN	B
.	B-I	PUNCT	O


Ponezumab	B-I	NOUN	B
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
with	O	ADP	O
no	O	DET	O
drug-attributed	B-OUT	ADJ	O
serious	I-OUT	ADJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
were	B-OUT	AUX	O
upper	I-OUT	ADJ	B
respiratory	I-OUT	ADJ	I
tract	I-OUT	NOUN	I
infection	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
headache	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
back	I-OUT	ADV	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
all	I-OUT	DET	O
mild	I-OUT	ADJ	B
to	I-OUT	PART	O
moderate	I-OUT	ADJ	B
.	O	PUNCT	O


One	O	NUM	O
subject	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
experienced	O	VERB	O
a	B-OUT	DET	O
mild	I-OUT	ADJ	B
hypersensitivity	I-OUT	NOUN	I
reaction	I-OUT	NOUN	O
.	O	PUNCT	O


Another	O	DET	O
subject	O	NOUN	B
(	O	PUNCT	O
0.1	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
demonstrated	B-OUT	VERB	O
slight	I-OUT	ADJ	O
enlargement	I-OUT	NOUN	B
of	I-OUT	ADP	O
a	I-OUT	DET	O
preexisting	I-OUT	VERB	O
midbrain	I-OUT	ADJ	B
lesion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Electrocardiography	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
laboratory	I-OUT	NOUN	B
values	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
including	I-OUT	VERB	O
CSF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
unremarkable	O	ADJ	B
.	O	PUNCT	O


No	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
new	B-OUT	ADJ	O
microhemorrhage	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
vasogenic	I-OUT	ADJ	B
edema	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
meningoencephalitis	I-OUT	NOUN	B
was	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


Plasma	O	NOUN	B
maximum	O	NOUN	B
observed	O	VERB	O
concentration	O	NOUN	B
increased	O	VERB	B
approximately	O	ADV	B
dose	O	NOUN	B
proportionally	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
the	B-OUT	DET	O
area	I-OUT	NOUN	B
under	I-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
concentration-time	I-OUT	ADJ	O
profile	I-OUT	NOUN	O
from	O	ADP	O
time	O	NOUN	B
zero	O	NUM	I
extrapolated	O	VERB	O
to	O	PART	O
infinite	O	ADJ	O
time	O	NOUN	O
(	O	PUNCT	O
AUC	O	NOUN	B
(	O	PUNCT	O
inf	O	NOUN	B
)	O	PUNCT	O
)	O	PUNCT	O
increased	O	VERB	B
slightly	O	ADV	O
more	O	ADJ	O
than	O	ADP	O
dose	O	NOUN	B
proportionally	O	ADV	B
.	B-OUT	PUNCT	O


Mean	B-OUT	VERB	O
terminal	I-OUT	ADJ	B
half-life	I-OUT	NOUN	B
was	O	AUX	O
approximately	O	ADV	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
subjects	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
measurable	B-OUT	ADJ	O
CSF	I-OUT	NOUN	B
ponezumab	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
(	O	PUNCT	O
~0.5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
plasma	O	NOUN	B
values	O	NOUN	O
)	O	PUNCT	O
at	O	ADP	O
day	O	NOUN	B
29	O	NUM	O
.	O	PUNCT	O


Plasma	O	NOUN	B
Aβ	O	PROPN	B
(	O	PUNCT	O
1-x	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
Aβ	O	PROPN	B
(	O	PUNCT	O
1-40	O	NUM	O
)	O	PUNCT	O
increased	O	VERB	B
dose	O	NOUN	B
dependently	O	ADV	B
,	O	PUNCT	O
and	B-OUT	CCONJ	O
mean	I-OUT	VERB	O
CSF	I-OUT	PROPN	B
Aβ	O	PROPN	B
(	O	PUNCT	O
1-x	O	NOUN	O
)	O	PUNCT	O
increased	O	VERB	B
38	O	NUM	O
%	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
with	O	ADP	O
10	O	NUM	O
mg/kg	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	B-I	NUM	O
vs	I-I	CCONJ	O
placebo	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
A	O	DET	O
2-hour	O	ADJ	O
infusion	O	NOUN	B
of	O	ADP	O
0.1	O	NUM	O
to	O	PART	O
10	O	NUM	O
mg/kg	B-I	NOUN	O
ponezumab	I-I	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
mild-to-moderate	O	ADJ	B
AD	O	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
pharmacokinetic	O	ADJ	B
profile	O	NOUN	I
was	O	AUX	O
approximately	O	ADV	O
linear	O	ADJ	O
.	O	PUNCT	O


Plasma	O	NOUN	B
Aβ	O	PROPN	B
increased	O	VERB	B
with	O	ADP	O
dose	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
CSF	O	PROPN	B
Aβ	O	PROPN	B
increased	O	VERB	B
at	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
dose	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
intravenous	B-I	ADJ	B
ponezumab	I-I	NOUN	B
alters	O	VERB	O
central	O	ADJ	O
Aβ	O	PROPN	B
levels	O	NOUN	B
.	O	PUNCT	O


Prostaglandin	B-P	NOUN	B
E1	I-P	NOUN	I
as	I-P	ADP	O
a	I-P	DET	O
hypotensive	I-P	ADJ	B
drug	I-P	NOUN	I
during	I-P	ADP	O
general	I-P	ADJ	B
anaesthesia	I-P	NOUN	I
.	I-P	PUNCT	O


Hypotension	B-OUT	NOUN	B
induced	O	VERB	B
by	O	ADP	O
prostaglandin	B-I	NOUN	B
E1	I-I	NOUN	I
(	I-I	PUNCT	O
PGE1	I-I	NOUN	B
)	I-I	PUNCT	O
infusion	I-I	NOUN	B
(	O	PUNCT	O
100-150	O	NUM	O
ng/kg/minute	O	NOUN	O
)	O	PUNCT	O
during	O	ADP	O
halothane	B-I	NOUN	B
anaesthesia	I-I	NOUN	O
to	O	PART	O
reduce	O	VERB	B
operative	O	ADJ	B
blood	O	NOUN	I
loss	O	NOUN	I
during	B-P	ADP	O
mastectomy	I-P	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


PGE1	O	NOUN	B
decreased	O	VERB	B
systolic	B-OUT	NOUN	B
arterial	I-OUT	ADJ	O
pressure	I-OUT	NOUN	O
approximately	O	ADV	O
34	O	NUM	O
%	O	NOUN	O
from	O	ADP	O
pre-administration	O	NOUN	B
values	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
induced	B-P	VERB	B
hypotension	I-P	NOUN	B
was	O	AUX	O
about	O	ADV	O
75	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
infusion	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
,	O	PUNCT	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
returned	O	VERB	O
to	O	ADP	O
within	O	ADP	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
with	O	ADP	O
15	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Heart	B-OUT	PROPN	B
rate	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	O
during	O	ADP	O
PGE1	O	NOUN	B
infusion	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
pre-ejection	B-OUT	ADJ	B
period	I-OUT	NOUN	B
and	O	CCONJ	O
left	B-OUT	VERB	B
ventricular	I-OUT	ADJ	I
ejection	I-OUT	NOUN	I
period	O	NOUN	I
were	O	AUX	O
shortened	O	VERB	B
.	O	PUNCT	O


Renal	B-OUT	ADJ	B
function	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
hypotensive	O	ADJ	B
period	O	NOUN	B
was	O	AUX	O
well	O	ADV	O
maintained	O	ADJ	B
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
during	O	ADP	O
surgery	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
PGE1	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
safely	O	ADV	O
to	O	PART	O
control	O	VERB	O
arterial	B-OUT	ADJ	B
pressure	I-OUT	NOUN	I
during	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Report	O	NOUN	B
on	O	ADP	O
the	O	DET	O
second	O	ADJ	O
myelomatosis	O	NOUN	B
trial	O	NOUN	B
after	O	ADP	O
five	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Medical	O	PROPN	B
Research	O	PROPN	I
Council	O	PROPN	I
's	O	PART	I
Working	O	PROPN	O
Party	O	PROPN	O
on	O	ADP	O
Leukaemia	B-P	PROPN	B
in	I-P	ADP	O
Adults	I-P	NOUN	B
.	I-P	PUNCT	O


Three	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
seventy-two	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
between	O	ADP	O
3	B-I	NUM	O
regimens	I-I	NOUN	B
of	I-I	ADP	O
chemotherapy	I-I	NOUN	B
:	I-I	PUNCT	O
cyclophosphamide	I-I	NOUN	B
,	I-I	PUNCT	O
intermittent	I-I	ADJ	B
melphalan	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
melphalan	I-I	NOUN	B
with	I-I	ADP	O
prednisone	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
were	I-I	AUX	O
followed	I-I	VERB	B
up	I-I	ADP	I
to	I-I	ADP	O
death	I-I	NOUN	B
or	I-I	CCONJ	O
for	I-I	ADP	O
at	I-I	ADP	O
least	I-I	ADV	O
5	I-I	NUM	O
years	I-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
survival	B-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
treatments	O	NOUN	B
,	O	PUNCT	O
either	O	CCONJ	O
overall	O	ADJ	B
or	O	CCONJ	O
in	O	ADP	O
any	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
choice	O	NOUN	O
among	O	ADP	O
these	O	DET	O
3	O	NUM	O
treatments	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
guided	O	VERB	O
by	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
's	O	PART	I
comfort	O	NOUN	B
and	O	CCONJ	O
convenience	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
important	O	ADJ	O
prognostic	O	ADJ	B
feature	O	NOUN	O
at	O	ADP	O
presentation	O	NOUN	B
was	O	AUX	O
the	O	DET	O
quality	O	NOUN	B
of	O	ADP	O
renal	B-OUT	ADJ	B
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


It	O	PRON	O
was	O	AUX	O
possible	O	ADJ	O
to	O	PART	O
define	O	VERB	O
good	B-P	ADJ	O
,	I-P	PUNCT	O
intermediate	I-P	ADJ	B
and	I-P	CCONJ	O
poor	I-P	ADJ	B
renal-function	I-P	ADJ	B
groups	I-P	NOUN	O
which	O	DET	O
were	O	AUX	O
highly	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
prognosis	O	NOUN	B
(	O	PUNCT	O
X2	O	NOUN	O
for	O	ADP	O
trend	O	NOUN	O
=	O	ADJ	O
62.6	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
haemoglobin	B-OUT	NOUN	B
level	I-OUT	NOUN	B
at	O	ADP	O
presentation	O	NOUN	B
was	O	AUX	O
strongly	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
prognosis	O	NOUN	B
among	O	ADP	O
patients	B-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
good	I-P	ADJ	O
renal-function	I-P	ADJ	B
group	I-P	NOUN	I
.	I-P	PUNCT	O


Among	O	ADP	O
107	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
presented	I-P	VERB	O
with	I-P	ADP	O
good	I-P	ADJ	O
renal	I-P	ADJ	B
function	I-P	NOUN	I
and	I-P	CCONJ	O
with	I-P	ADP	O
haemoglobin	I-P	NOUN	B
above	I-P	ADP	O
100	I-P	NUM	O
g/l	I-P	NOUN	O
,	O	PUNCT	O
the	O	DET	O
5-year	O	ADJ	O
survival	B-OUT	NOUN	B
was	O	AUX	O
43	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Other	O	ADJ	O
prognostic	O	ADJ	B
features	O	NOUN	I
were	O	AUX	O
much	O	ADV	O
less	O	ADV	O
important	O	ADJ	O
when	O	SCONJ	O
account	O	NOUN	O
was	O	AUX	O
taken	O	VERB	O
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
haemoglobin	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	O
comparison	O	NOUN	B
of	O	ADP	O
halothane	B-I	NOUN	B
,	I-I	PUNCT	O
isoflurane	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
enflurane	I-I	NOUN	B
on	O	ADP	O
baroreflex	B-P	NOUN	B
control	I-OUT	NOUN	B
of	I-OUT	ADP	I
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
in	I-OUT	ADP	O
humans	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Prenatal	O	ADJ	B
depression	O	NOUN	I
predicts	O	VERB	O
postpartum	O	NOUN	B
maternal	O	ADJ	B
attachment	O	NOUN	B
in	O	ADP	O
low-income	B-P	ADJ	B
Latina	I-P	ADJ	B
mothers	I-P	NOUN	O
with	I-P	ADP	O
infants	I-P	NOUN	B
.	I-P	PUNCT	O


Although	O	SCONJ	O
maternal	O	ADJ	B
attachment	O	NOUN	B
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
infant	O	ADJ	B
attachment	O	NOUN	B
security	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
developmental	O	ADJ	B
outcomes	O	NOUN	B
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
maternal	O	ADJ	B
attachment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
few	O	ADJ	O
months	O	NOUN	B
of	O	ADP	O
the	O	DET	O
infant	O	NOUN	B
's	O	PART	I
life	O	NOUN	O
,	O	PUNCT	O
particularly	O	ADV	O
among	O	ADP	O
ethnic	O	ADJ	B
minority	O	NOUN	I
mothers	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
predictors	O	NOUN	B
of	O	ADP	O
postpartum	O	NOUN	B
maternal	O	ADJ	B
attachment	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
217	B-P	NUM	O
Latina	I-P	ADJ	B
women	I-P	NOUN	B
enrolled	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
perinatal	I-P	ADJ	B
depression	I-P	NOUN	I
prevention	I-P	NOUN	I
trial	I-P	NOUN	O
.	I-P	PUNCT	O


Mothers	O	NOUN	B
'	O	PART	O
attachment	B-I	NOUN	B
to	O	ADP	O
their	O	PRON	O
infants	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
6-8	B-I	NUM	O
weeks	I-I	NOUN	B
postpartum	I-I	NOUN	B
using	I-I	VERB	O
the	I-I	DET	O
Maternal	I-OUT	ADJ	B
Postnatal	I-OUT	PROPN	I
Attachment	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
predictors	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
attachment	O	NOUN	B
were	O	AUX	O
explored	O	VERB	O
including	O	VERB	O
:	O	PUNCT	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
during	I-OUT	ADP	O
pregnancy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pregnancy	I-OUT	NOUN	B
intention	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
feelings	I-OUT	NOUN	B
about	I-OUT	ADP	O
the	I-OUT	DET	O
pregnancy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
partner	I-OUT	NOUN	O
relationship	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
strongest	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
lower	B-OUT	ADJ	B
maternal	I-OUT	ADJ	B
attachment	I-OUT	NOUN	B
was	O	AUX	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
late	O	ADV	O
in	O	ADP	O
pregnancy	O	NOUN	B
;	O	PUNCT	O
pregnancy	O	NOUN	B
intention	O	NOUN	B
was	O	AUX	O
marginally	O	ADV	O
predictive	O	ADJ	B
of	O	ADP	O
attachment	B-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
lower	O	ADJ	O
scores	O	NOUN	B
being	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
unwanted	O	ADJ	O
pregnancies	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
fills	O	VERB	O
a	O	DET	O
critical	O	ADJ	O
gap	O	NOUN	B
in	O	ADP	O
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
depressive	O	ADJ	B
symptoms	O	NOUN	I
during	O	ADP	O
pregnancy	O	NOUN	B
in	O	ADP	O
shaping	O	VERB	O
mothers	O	NOUN	B
'	O	PART	O
early	O	ADJ	B
attachment	O	NOUN	B
to	O	ADP	O
their	O	PRON	O
infants	O	NOUN	B
.	O	PUNCT	O


D-dimer	O	NOUN	B
predicts	O	VERB	O
outcome	O	NOUN	B
after	O	ADP	O
aneurysmal	O	ADJ	B
subarachnoid	B-P	ADJ	B
hemorrhage	I-P	NOUN	B
:	I-P	PUNCT	O
no	O	DET	B
effect	O	NOUN	I
of	O	ADP	O
thromboprophylaxis	O	NOUN	B
on	O	ADP	O
coagulation	B-OUT	NOUN	B
activity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


OBJECTIVE	O	NOUN	O
Approximately	O	ADV	O
one-third	O	NUM	O
of	O	ADP	O
all	O	DET	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
nontraumatic	I-P	ADJ	O
subarachnoid	I-P	ADJ	O
hemorrhage	I-P	NOUN	O
(	I-P	PUNCT	O
SAH	I-P	NOUN	B
)	I-P	PUNCT	O
experience	O	NOUN	O
complications	O	NOUN	B
owing	O	VERB	O
to	O	PART	O
delayed	O	VERB	B
ischemic	O	ADJ	B
deficit	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
reported	O	VERB	O
recently	O	ADV	O
that	O	SCONJ	O
enoxaparin	B-I	NOUN	B
40	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
seems	O	VERB	O
safe	O	ADJ	O
and	O	CCONJ	O
demonstrates	O	VERB	O
thromboprophylactic	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
failed	O	VERB	O
to	O	PART	O
improve	O	VERB	B
outcome	O	NOUN	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
SAH	O	NOUN	B
trial	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
assessed	O	VERB	B
hemostatic	B-OUT	ADJ	B
variables	I-OUT	NOUN	I
associated	O	VERB	B
with	O	ADP	I
clinical	O	ADJ	B
status	O	NOUN	I
and	O	CCONJ	O
outcome	O	NOUN	B
of	O	ADP	O
SAH	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
monitored	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
enoxaparin	B-I	NOUN	B
on	O	ADP	O
activation	B-OUT	NOUN	B
of	I-OUT	ADP	O
coagulation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fibrinolysis	I-OUT	NOUN	B
after	O	ADP	O
closure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ruptured	O	ADJ	B
aneurysm	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Blood	B-OUT	NOUN	B
samples	I-OUT	NOUN	I
to	O	PART	O
measure	O	VERB	B
activation	B-OUT	NOUN	B
of	I-OUT	ADP	O
coagulation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fibrinolysis	I-OUT	NOUN	B
were	O	AUX	O
collected	O	VERB	O
from	O	ADP	O
42	B-P	NUM	O
patients	I-P	NOUN	B
participating	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
enoxaparin	I-I	NOUN	B
trial	I-P	NOUN	B
for	I-P	ADP	O
acute	I-P	ADJ	B
aneurysmal	I-P	ADJ	I
SAH	I-P	NOUN	B
at	I-P	ADP	O
four	I-P	NUM	O
time	I-P	NOUN	B
points	I-P	NOUN	I
:	I-P	PUNCT	O
1	I-P	X	O
)	I-P	PUNCT	O
at	I-P	ADP	O
hospital	I-P	NOUN	B
admission	I-P	NOUN	I
;	I-P	PUNCT	O
2	I-P	X	O
)	I-P	PUNCT	O
12	I-P	NUM	O
to	I-P	PART	O
24	I-P	NUM	O
hours	I-P	NOUN	O
after	I-P	ADP	O
aneurysm	I-P	NOUN	B
surgery	I-P	NOUN	I
but	I-P	CCONJ	O
before	I-P	ADP	O
initiation	I-P	NOUN	B
of	I-P	ADP	O
enoxaparin	I-I	NOUN	B
therapy	I-P	NOUN	B
;	I-P	PUNCT	O
3	I-P	X	O
)	I-P	PUNCT	O
3	I-P	NUM	O
hours	I-P	NOUN	B
after	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
dose	I-P	NOUN	B
;	I-P	PUNCT	O
and	I-P	CCONJ	O
4	I-P	X	O
)	I-P	PUNCT	O
at	I-P	ADP	O
the	I-P	DET	O
conclusion	I-P	NOUN	O
of	I-P	ADP	O
treatment	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
several	O	ADJ	O
variables	B-OUT	NOUN	B
of	I-OUT	ADP	O
coagulation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fibrinolysis	I-OUT	NOUN	B
were	O	AUX	O
elevated	O	VERB	B
and	O	CCONJ	O
correlated	O	VERB	B
well	O	ADV	O
with	O	ADP	O
clinical	O	ADJ	B
status	O	NOUN	I
.	O	PUNCT	O


Specifically	O	ADV	O
,	O	PUNCT	O
D-dimer	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
at	O	ADP	O
all	O	DET	O
four	O	NUM	O
time	O	NOUN	B
points	O	NOUN	I
correlated	O	VERB	B
with	O	ADP	O
patients	O	NOUN	B
'	O	PART	O
long-term	O	ADJ	B
outcomes	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
enoxaparin	B-I	NOUN	B
suppressed	O	VERB	B
early	B-OUT	ADJ	O
coagulation	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
thrombin	B-OUT	NOUN	B
generation	I-OUT	NOUN	B
was	O	AUX	O
not	B-OUT	PART	O
inhibited	I-OUT	VERB	B
during	O	ADP	O
thromboprophylaxis	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
PAI-1	B-OUT	NOUN	B
activity	I-OUT	NOUN	B
was	O	AUX	O
suppressed	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
D-dimer	O	NOUN	B
offers	O	VERB	O
a	O	DET	O
useful	O	ADJ	O
laboratory	O	NOUN	B
tool	O	NOUN	I
for	O	ADP	O
assessing	O	VERB	O
early	O	ADV	B
and	O	CCONJ	O
late	O	ADJ	O
clinical	O	ADJ	B
severity	B-OUT	NOUN	I
of	I-OUT	ADP	O
SAH	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
thromboprophylactic	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
enoxaparin	B-I	NOUN	B
inhibited	O	VERB	B
PAI-1	B-OUT	NOUN	B
activity	I-OUT	NOUN	B
but	O	CCONJ	O
failed	O	VERB	O
to	O	PART	O
down-regulate	O	VERB	B
coagulation	B-OUT	NOUN	O
activity	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
D-dimer	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
of	O	ADP	O
enoxaparin	B-I	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
ischemic	O	ADJ	B
deficit	O	NOUN	I
after	O	ADP	O
SAH	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
emotional	B-I	ADJ	B
distress	I-I	NOUN	I
on	O	ADP	O
HIV	B-OUT	NOUN	B
risk	I-OUT	NOUN	B
reduction	I-OUT	NOUN	B
among	I-P	ADP	O
women	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	B
whether	O	SCONJ	O
333	B-P	NUM	O
seronegative	I-P	ADJ	B
African	I-P	ADJ	B
American	I-P	ADJ	I
female	I-P	ADJ	B
drug	I-P	NOUN	O
users	I-P	NOUN	O
(	I-P	PUNCT	O
aged	I-P	ADJ	O
18-59	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
participating	I-P	VERB	O
in	I-P	ADP	O
an	I-P	DET	O
HIV	I-I	NOUN	B
intervention	I-I	NOUN	B
and	I-P	CCONJ	O
with	I-P	ADP	O
higher	I-P	ADJ	O
levels	I-P	NOUN	B
of	I-P	ADP	O
emotional	I-P	ADJ	B
distress	I-P	NOUN	I
,	I-P	PUNCT	O
specifically	I-P	ADV	O
symptoms	I-P	NOUN	B
of	I-P	ADP	O
depression	I-P	NOUN	B
and	I-P	CCONJ	O
anxiety	I-P	NOUN	B
,	O	PUNCT	O
reduced	O	VERB	B
HIV	O	NOUN	B
risk	O	NOUN	O
behaviors	O	NOUN	O
to	O	PART	O
a	O	DET	O
lesser	O	ADJ	B
extent	O	NOUN	B
than	O	ADP	O
those	O	DET	O
with	O	ADP	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
emotional	O	ADJ	B
distress	O	NOUN	I
.	O	PUNCT	O


Participants	B-P	NOUN	B
were	O	AUX	O
recruited	B-P	VERB	O
between	I-P	ADP	O
June	I-P	PROPN	O
1998	I-P	NUM	O
and	I-P	CCONJ	O
January	I-P	PROPN	O
2001	I-P	NUM	O
from	I-P	ADP	O
inner-city	I-P	ADJ	B
Atlanta	I-P	PROPN	I
(	I-P	PUNCT	O
Georgia	I-P	PROPN	B
,	I-P	PUNCT	O
U.S.	I-P	PROPN	B
)	I-P	PUNCT	O
neighborhoods	I-P	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
randomly	B-P	ADV	O
assigned	I-P	VERB	O
to	I-P	ADP	O
one	I-P	NUM	O
of	I-P	ADP	O
two	I-P	NUM	O
enhanced	I-I	VERB	B
gender-specific	I-I	ADJ	B
and	I-I	CCONJ	O
culturally	I-I	ADV	B
specific	I-I	ADJ	O
HIV	I-I	NOUN	B
intervention	I-I	NOUN	B
conditions	I-P	NOUN	I
or	O	CCONJ	O
to	O	ADP	O
the	O	DET	O
NIDA	O	NOUN	B
standard	O	ADJ	B
condition	O	NOUN	I
.	O	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
interviewed	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
post-intervention	O	ADJ	B
and	O	CCONJ	O
at	O	ADP	O
6-month	O	ADJ	O
follow-up	O	NOUN	B
with	O	ADP	O
a	O	DET	O
structured	B-I	ADJ	B
questionnaire	I-I	NOUN	I
including	O	VERB	O
information	O	NOUN	B
on	O	ADP	O
sociodemographics	O	NOUN	B
,	O	PUNCT	O
sexual	O	ADJ	B
and	O	CCONJ	O
drug-using	O	ADJ	B
behavior	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
psychosocial	O	ADJ	B
characteristics	O	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
a	O	DET	O
significant	O	ADJ	O
decline	O	NOUN	B
in	O	ADP	O
symptoms	O	NOUN	B
of	O	ADP	O
emotional	O	ADJ	B
distress	O	NOUN	I
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
women	O	NOUN	B
in	O	ADP	O
this	O	DET	O
sample	O	NOUN	B
reported	O	VERB	O
high	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
depressive	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
anxiety	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
6-month	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Higher	B-OUT	ADJ	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
emotional	I-OUT	ADJ	B
distress	I-OUT	NOUN	I
were	O	AUX	O
positively	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
post-intervention	B-OUT	ADJ	B
sexual	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
drug-taking	I-OUT	ADJ	B
risk	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Women	O	NOUN	B
in	O	ADP	O
both	O	DET	O
enhanced	B-I	VERB	B
intervention	I-I	NOUN	B
conditions	I-I	NOUN	O
reduced	O	VERB	B
their	O	PRON	O
sexual	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
drug-taking	I-OUT	ADJ	B
risks	I-OUT	NOUN	B
more	O	ADJ	O
than	O	ADP	O
women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
standard	B-I	ADJ	B
intervention	I-I	NOUN	I
.	I-I	PUNCT	O


Those	O	DET	O
in	O	ADP	O
the	O	DET	O
motivation	B-I	NOUN	B
intervention	I-I	NOUN	B
arm	O	NOUN	I
experienced	O	VERB	O
a	O	DET	O
greater	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
,	O	PUNCT	O
accompanied	O	VERB	O
by	O	ADP	O
a	O	DET	O
greater	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
sexual	B-OUT	ADJ	B
risk	I-OUT	NOUN	I
behavior	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Findings	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
effective	O	ADJ	B
interventions	O	NOUN	B
and	O	CCONJ	O
mental	O	ADJ	B
health	O	NOUN	I
resources	O	NOUN	B
among	O	ADP	O
subgroups	O	NOUN	B
of	O	ADP	O
high-risk	B-P	ADJ	B
women	I-P	NOUN	B
who	I-P	PRON	O
may	I-P	AUX	O
be	I-P	AUX	O
most	I-P	ADV	O
resistant	I-P	ADJ	B
to	I-P	PART	O
behavioral	I-P	ADJ	B
change	I-P	NOUN	I
.	I-P	PUNCT	O


Primary	B-I	ADJ	B
capsulectomy	I-I	NOUN	I
,	I-I	PUNCT	O
anterior	I-I	ADJ	B
vitrectomy	I-I	NOUN	B
,	I-I	PUNCT	O
lensectomy	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
posterior	I-I	ADJ	B
chamber	I-I	NOUN	I
lens	I-I	NOUN	I
implantation	I-I	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
:	I-P	PUNCT	O
limbal	O	ADJ	B
versus	O	CCONJ	O
pars	O	ADJ	B
plana	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
limbal	B-I	ADJ	B
versus	O	CCONJ	O
a	O	DET	O
pars	B-I	ADJ	B
plana	I-I	NOUN	I
approach	I-I	NOUN	O
for	O	ADP	O
primary	B-I	ADJ	B
posterior	I-I	ADJ	B
capsulectomy	I-I	NOUN	I
and	I-I	CCONJ	O
anterior	I-I	ADJ	B
vitrectomy	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
childhood	B-OUT	ADJ	B
cataract	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


SETTING	O	VERB	B
Department	O	PROPN	I
of	O	ADP	I
Ophthalmology	O	PROPN	I
,	O	PUNCT	O
Labbafinejad	O	PROPN	B
Medical	O	PROPN	I
Center	O	PROPN	I
,	O	PUNCT	O
Tehran	O	PROPN	B
,	O	PUNCT	O
Iran	O	PROPN	B
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
double-masked	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
45	B-P	NUM	O
eyes	I-P	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


After	O	ADP	O
being	O	AUX	O
matched	O	VERB	B
,	O	PUNCT	O
38	B-P	NUM	O
eyes	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
2	O	NUM	O
equal	O	ADJ	O
groups	O	NOUN	B
for	O	ADP	O
data	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


All	B-P	DET	O
eyes	I-P	NOUN	B
had	I-P	AUX	O
lensectomy	I-I	NOUN	B
and	I-I	CCONJ	O
posterior	I-I	ADJ	B
chamber	I-I	NOUN	I
intraocular	I-I	NOUN	I
lens	I-I	NOUN	I
(	I-I	PUNCT	O
PC	I-I	NOUN	B
IOL	I-I	NOUN	I
)	I-I	PUNCT	O
implantation	I-I	NOUN	B
.	I-I	PUNCT	O


Primary	B-I	ADJ	B
posterior	I-I	ADJ	I
capsulectomy	I-I	NOUN	I
and	I-I	CCONJ	O
anterior	I-I	ADJ	B
vitrectomy	I-I	NOUN	B
were	O	AUX	O
performed	O	VERB	O
through	O	ADP	O
the	O	DET	O
limbus	O	NOUN	B
in	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
eyes	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
pars	O	ADJ	B
plana	O	NOUN	I
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
half	O	NOUN	O
.	O	PUNCT	O


Main	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	O
included	O	VERB	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
estimated	I-OUT	VERB	B
red	I-OUT	ADJ	I
reflex	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
postsurgical	I-OUT	ADJ	B
inflammatory	I-OUT	ADJ	B
reaction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
corneal	I-OUT	NOUN	B
clarity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
posterior	I-OUT	ADJ	B
synechias	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
iris	I-OUT	ADJ	B
capture	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
IOL	I-OUT	PROPN	B
position	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
capsulectomy	I-OUT	NOUN	B
size	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
glaucoma	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
cystoid	I-OUT	NOUN	B
macular	I-OUT	NOUN	I
edema	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
retinal	I-OUT	ADJ	B
tear	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
refraction	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
No	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
approaches	O	NOUN	B
in	O	ADP	O
the	O	DET	O
outcome	O	NOUN	B
measures	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
anatomic	O	ADJ	B
and	O	CCONJ	O
visual	O	ADJ	B
results	O	NOUN	O
were	O	AUX	O
encouraging	O	ADJ	O
when	O	SCONJ	O
posterior	B-I	ADJ	B
capsulectomy	I-I	NOUN	B
and	I-I	CCONJ	O
anterior	I-I	ADJ	B
vitrectomy	I-I	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
limbal	O	ADJ	B
or	O	CCONJ	O
pars	O	ADJ	B
plana	O	NOUN	I
approach	O	NOUN	O
,	O	PUNCT	O
were	O	AUX	O
combined	O	VERB	O
with	O	ADP	O
lensectomy	B-I	NOUN	B
and	I-I	CCONJ	O
PC	I-I	NOUN	B
IOL	I-I	PROPN	O
implantation	I-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
application	O	NOUN	B
of	O	ADP	O
these	O	DET	O
techniques	O	NOUN	B
depends	O	VERB	O
on	O	ADP	O
surgeon	O	NOUN	B
experience	O	NOUN	B
and	O	CCONJ	O
skill	O	NOUN	B
.	O	PUNCT	O


Treatment	B-P	NOUN	B
of	I-P	ADP	O
bladder	I-P	NOUN	B
cancer	I-P	NOUN	I
with	I-P	ADP	O
intravesical	I-P	ADJ	B
instillation	I-P	NOUN	I
of	I-P	ADP	O
adriamycin	I-I	NOUN	B
.	I-I	PUNCT	O


Intravesical	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
adriamycin	B-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
extensively	O	ADV	O
employed	O	VERB	O
in	O	ADP	O
the	O	DET	O
last	O	ADJ	O
decade	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
carcinoma	O	NOUN	B
in	O	X	B
situ	O	X	I
complete	O	ADJ	I
responses	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
about	O	ADV	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
.	O	PUNCT	O


Its	O	PRON	O
efficacy	B-OUT	NOUN	B
is	O	AUX	O
probably	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
of	O	ADP	O
multiple	O	ADJ	B
or	O	CCONJ	O
diffuse	O	ADJ	O
low	O	ADJ	O
stage	O	NOUN	O
transitional	O	ADJ	O
cell	O	NOUN	O
carcinoma	O	NOUN	O
that	O	PRON	O
is	O	AUX	O
too	O	ADV	O
extensive	O	ADJ	O
to	O	PART	O
be	O	AUX	O
completely	O	ADV	O
resected	O	VERB	B
by	O	ADP	O
conventional	O	ADJ	B
transurethral	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
such	O	ADJ	O
circumstances	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
cancer	O	NOUN	B
in	O	X	B
situ	O	X	I
,	O	PUNCT	O
adriamycin	B-I	NOUN	B
compares	O	VERB	O
favorably	O	ADV	O
with	O	ADP	O
other	O	ADJ	O
local	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prophylactic	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
intravesical	O	ADJ	B
instillation	O	NOUN	I
of	O	ADP	O
Adriamycin	B-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
studied	O	VERB	O
more	O	ADV	O
extensively	O	ADV	B
.	O	PUNCT	O


Preliminary	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
controlled	O	VERB	O
randomized	O	ADJ	B
trials	O	NOUN	I
implemented	O	VERB	O
from	O	ADP	O
the	O	DET	O
EORTC	O	PROPN	B
Urological	O	PROPN	I
Group	O	PROPN	I
show	O	VERB	O
that	O	SCONJ	O
adriamycin	B-I	NOUN	B
instillations	O	NOUN	B
significantly	O	ADV	O
reduce	O	VERB	O
recurrence	B-OUT	NOUN	B
rate	I-OUT	NOUN	O
after	I-OUT	ADP	O
TUR	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
is	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
.	I-OUT	PUNCT	O


Systemic	B-OUT	ADJ	B
absorption	I-OUT	NOUN	I
is	O	AUX	O
virtually	O	ADV	O
absent	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
no	B-OUT	DET	O
severe	I-OUT	ADJ	O
drug-related	I-OUT	ADJ	B
side	I-OUT	NOUN	I
effects	I-OUT	NOUN	I
have	O	AUX	O
ever	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Chemical	B-OUT	NOUN	B
cystitis	I-OUT	NOUN	I
is	O	AUX	O
occasionally	O	ADV	O
observed	O	VERB	B
,	O	PUNCT	O
especially	O	ADV	O
if	O	SCONJ	O
multiple	O	ADJ	B
instillations	O	NOUN	B
are	O	AUX	O
started	O	VERB	O
immediately	O	ADV	O
after	O	ADP	O
TUR	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
additional	O	ADJ	O
inflammatory	O	ADJ	B
conditions	O	NOUN	O
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
previous	O	ADJ	O
irradiation	O	NOUN	B
or	O	CCONJ	O
bacterial	O	ADJ	B
cystitis	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
an	O	DET	O
interim	O	ADJ	B
methadone	B-I	NOUN	B
maintenance	I-P	NOUN	O
clinic	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Interim	O	ADJ	B
methadone	B-I	NOUN	B
maintenance	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
as	O	ADP	O
a	O	DET	O
method	O	NOUN	B
of	O	ADP	O
providing	O	VERB	O
clinically	B-OUT	ADV	B
effective	I-OUT	ADJ	B
services	O	NOUN	B
to	O	PART	O
heroin	B-P	NOUN	B
addicts	I-P	NOUN	B
waiting	I-P	VERB	B
for	I-P	ADP	O
treatment	I-P	NOUN	B
in	I-P	ADP	O
standard	I-P	ADJ	O
comprehensive	I-P	ADJ	B
methadone	I-P	NOUN	B
maintenance	I-P	NOUN	O
programs	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
clinic	O	NOUN	B
that	O	PRON	O
provided	O	VERB	O
initial	O	ADJ	O
medical	O	ADJ	B
evaluation	O	NOUN	I
,	O	PUNCT	O
methadone	O	NOUN	B
medication	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
AIDS	O	NOUN	B
education	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
include	O	VERB	O
formal	O	ADJ	O
drug	O	NOUN	B
abuse	O	NOUN	I
counseling	O	NOUN	O
or	O	CCONJ	O
other	O	ADJ	O
social	O	ADJ	B
support	O	NOUN	I
services	O	NOUN	I
was	O	AUX	O
established	O	VERB	O
in	O	ADP	O
New	B-P	PROPN	B
York	I-P	PROPN	I
City	I-P	PROPN	I
.	I-P	PUNCT	O


A	B-P	DET	O
sample	I-P	NOUN	B
of	I-P	ADP	O
301	I-P	NUM	O
volunteer	I-P	NOUN	B
subjects	I-P	NOUN	B
recruited	I-P	VERB	O
from	I-P	ADP	O
the	I-P	DET	O
waiting	I-P	NOUN	B
list	I-P	NOUN	I
for	I-P	ADP	O
treatment	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
Beth	I-P	PROPN	B
Israel	I-P	PROPN	I
methadone	I-I	NOUN	I
program	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
immediate	O	ADJ	B
entry	O	NOUN	B
into	O	ADP	O
the	O	DET	O
interim	B-I	ADJ	B
clinic	I-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
control	I-I	NOUN	B
group	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
initial	O	ADJ	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
illicit	I-OUT	NOUN	B
drug	I-OUT	NOUN	I
use	I-OUT	NOUN	I
across	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


One-month	O	ADJ	B
urinalysis	O	NOUN	B
follow-up	O	X	B
data	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
heroin	I-OUT	NOUN	B
use	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
from	O	ADP	O
63	O	NUM	O
%	O	NOUN	O
positive	O	ADJ	B
at	O	ADP	O
intake	O	NOUN	B
to	O	PART	O
29	O	NUM	O
%	O	NOUN	O
positive	O	ADJ	B
)	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
to	O	PART	O
60	O	NUM	O
%	O	NOUN	O
positive	O	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
change	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
cocaine	B-OUT	NOUN	B
urinalyses	I-OUT	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
70	O	NUM	O
%	O	NOUN	O
positive	O	ADJ	B
for	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
at	O	ADP	O
intake	O	NOUN	B
and	O	CCONJ	O
follow-up	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
higher	O	ADJ	B
percentage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
were	O	AUX	O
in	O	ADP	O
treatment	O	NOUN	B
at	O	ADP	O
16-month	O	ADJ	O
follow-up	O	NOUN	B
(	O	PUNCT	O
72	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
56	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Limited	O	ADJ	B
services	O	NOUN	I
interim	O	ADJ	B
methadone	O	NOUN	B
maintenance	O	NOUN	B
can	O	AUX	O
reduce	O	VERB	O
heroin	B-OUT	NOUN	B
use	I-OUT	NOUN	B
among	O	ADP	O
persons	B-P	NOUN	B
awaiting	I-P	VERB	O
entry	I-P	NOUN	B
into	I-P	ADP	O
comprehensive	I-P	ADJ	B
treatment	I-P	NOUN	B
and	O	CCONJ	O
increase	O	VERB	B
the	O	DET	O
percentage	O	NOUN	B
entering	O	NOUN	O
treatment	O	NOUN	B
.	O	PUNCT	O


Short-term	B-I	ADJ	B
amiodarone	I-I	NOUN	B
therapy	I-I	NOUN	I
after	O	ADP	O
reversion	O	NOUN	B
of	O	ADP	O
persistent	B-P	ADJ	B
atrial	I-P	ADJ	O
fibrillation	I-P	NOUN	O
reduces	O	VERB	O
recurrences	B-OUT	NOUN	B
at	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
outcome	B-OUT	NOUN	B
of	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
vs.	O	CCONJ	O
18	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
amiodarone	B-I	NOUN	B
treatment	O	NOUN	B
after	O	ADP	O
atrial	O	ADJ	B
fibrillation	O	NOUN	I
(	O	PUNCT	O
AF	O	NOUN	B
)	O	PUNCT	O
conversion	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
the	O	DET	O
first	O	ADJ	O
episode	O	NOUN	B
of	O	ADP	O
persistent	O	ADJ	B
AF	O	PROPN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
included	O	VERB	O
51	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
experienced	I-P	VERB	O
the	I-P	DET	O
first	I-P	ADJ	O
episode	I-P	NOUN	B
of	I-P	ADP	O
persistent	I-P	ADJ	B
AF	I-P	NOUN	I
receiving	I-P	VERB	O
amiodarone	I-I	NOUN	B
(	I-P	PUNCT	O
600	I-P	NUM	O
mg	I-P	NOUN	O
)	I-P	PUNCT	O
daily	I-P	ADV	B
for	I-P	ADP	O
4-6	I-P	NUM	O
weeks	I-P	NOUN	B
.	I-P	PUNCT	O


If	O	SCONJ	O
AF	O	NOUN	B
persisted	O	VERB	O
,	O	PUNCT	O
electrical	B-I	ADJ	B
cardioversion	I-I	NOUN	I
(	I-I	PUNCT	O
ECV	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
amiodarone	B-I	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
for	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
amiodarone	B-I	NOUN	B
(	O	PUNCT	O
Group	O	PROPN	B
I	O	NUM	I
)	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
Group	O	PROPN	B
II	O	NUM	I
)	O	PUNCT	O
and	O	CCONJ	O
followed	O	VERB	O
for	O	ADP	O
15	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
control	B-P	ADJ	B
group	I-P	NOUN	I
comprised	O	VERB	O
9	O	NUM	O
untreated	O	ADJ	B
patients	B-P	NOUN	B
undergoing	O	VERB	O
ECV	B-I	PROPN	B
.	I-I	PUNCT	O


Treatment	O	NOUN	B
effectiveness	B-OUT	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
a	O	DET	O
Bayesian	O	ADJ	B
model	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
Eighteen	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
AF	O	NOUN	B
reversion	O	NOUN	B
,	O	PUNCT	O
22	O	NUM	O
(	O	PUNCT	O
81.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
in	O	ADP	O
Group	O	PROPN	B
I	O	PROPN	I
,	O	PUNCT	O
13	O	NUM	O
(	O	PUNCT	O
54.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
in	O	ADP	O
Group	O	PROPN	B
II	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
(	O	PUNCT	O
11.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patient	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
remained	B-OUT	VERB	O
in	I-OUT	ADP	O
sinus	I-OUT	NOUN	B
rhythm	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


No	O	DET	B
differences	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
Group	O	PROPN	B
I	O	NUM	I
patients	O	NOUN	B
who	O	PRON	O
required	O	VERB	O
ECV	B-I	PROPN	B
and	O	CCONJ	O
Group	O	PROPN	B
II	O	NUM	I
patients	O	NOUN	B
.	O	PUNCT	O


Sinus	B-OUT	NOUN	B
rhythm	I-OUT	NOUN	I
was	O	AUX	O
preserved	O	VERB	O
in	O	ADP	O
all	O	DET	O
Group	O	PROPN	B
I	O	NUM	I
patients	O	NOUN	B
when	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
achieved	O	VERB	O
during	O	ADP	O
amiodarone	O	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Limiting	B-OUT	VERB	B
adverse	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
3	O	NUM	O
(	O	PUNCT	O
11.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
in	O	ADP	O
Group	O	PROPN	B
I	O	PRON	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
patients	O	NOUN	B
regaining	O	VERB	O
sinus	O	NOUN	B
rhythm	O	NOUN	I
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
episode	O	NOUN	B
of	O	ADP	O
persistent	O	ADJ	B
AF	O	PROPN	I
,	O	PUNCT	O
a	O	DET	O
3-month	O	ADJ	O
amiodarone	B-I	NOUN	B
treatment	O	NOUN	B
after	O	ADP	O
reversion	O	NOUN	B
is	O	AUX	O
a	O	DET	O
reasonable	O	ADJ	O
option	O	NOUN	O
for	O	ADP	O
rhythm	O	NOUN	B
control	O	NOUN	O
.	O	PUNCT	O


Pilot	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
Panax	B-I	PROPN	B
quinquefolius	I-I	NOUN	I
(	I-I	PUNCT	O
American	I-I	ADJ	B
ginseng	I-I	NOUN	I
)	I-I	PUNCT	O
to	O	PART	O
improve	O	VERB	O
cancer-related	B-P	ADJ	B
fatigue	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
dose-finding	O	ADJ	B
evaluation	O	NOUN	B
:	O	PUNCT	O
NCCTG	O	NOUN	B
trial	O	NOUN	I
N03CA	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
pilot	O	NOUN	B
trial	O	NOUN	I
sought	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
any	O	DET	O
of	O	ADP	O
three	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
American	B-I	ADJ	B
ginseng	I-I	NOUN	I
(	I-I	PUNCT	O
Panax	I-I	NOUN	B
quinquefolius	I-I	NOUN	I
)	I-I	PUNCT	O
might	O	AUX	O
help	O	VERB	O
cancer-related	B-P	ADJ	B
fatigue	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
secondary	O	ADJ	B
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
toxicity	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Eligible	B-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
cancer	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
manner	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
receive	O	VERB	O
American	B-I	ADJ	B
ginseng	I-I	NOUN	I
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
750	O	NUM	O
,	O	PUNCT	O
1,000	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
2,000	O	NUM	O
mg/day	O	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
given	O	VERB	O
in	O	ADP	O
twice	O	ADV	O
daily	O	ADJ	B
dosing	O	NOUN	B
over	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Outcome	O	NOUN	B
measures	O	NOUN	I
included	O	VERB	O
the	O	DET	O
Brief	B-OUT	PROPN	B
Fatigue	I-OUT	PROPN	I
Inventory	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
vitality	I-OUT	NOUN	B
subscale	I-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
Medical	I-OUT	PROPN	B
Outcome	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
Short	I-OUT	PROPN	I
Form-36	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SF-36	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Global	I-OUT	PROPN	B
Impression	I-OUT	PROPN	I
of	I-OUT	ADP	I
Benefit	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
at	O	ADP	O
4	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Two	B-P	NUM	O
hundred	I-P	NUM	O
ninety	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
accrued	I-P	VERB	O
to	I-P	PART	O
this	I-P	DET	O
trial	I-P	NOUN	B
.	I-P	PUNCT	O


Nonsignificant	O	ADJ	B
trends	O	NOUN	B
for	O	ADP	O
all	O	DET	O
outcomes	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
favor	O	NOUN	O
of	O	ADP	O
the	O	DET	O
1,000-	O	NOUN	O
and	O	CCONJ	O
2,000-mg/day	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
American	B-I	ADJ	B
ginseng	I-I	NOUN	I
.	I-I	PUNCT	O


Area	O	NOUN	B
under	O	ADP	O
the	O	DET	O
curve	O	NOUN	O
analysis	O	NOUN	B
of	O	ADP	O
activity	B-OUT	NOUN	B
interference	I-OUT	NOUN	B
from	I-OUT	ADP	O
the	I-OUT	DET	O
Brief	I-OUT	PROPN	B
Fatigue	I-OUT	PROPN	I
Inventory	I-OUT	PROPN	I
was	O	AUX	O
460-467	O	NUM	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	O
and	O	CCONJ	O
750	O	NUM	O
mg/day	O	ADJ	O
group	O	NOUN	B
versus	O	CCONJ	O
480-551	O	NUM	B
in	O	ADP	O
the	O	DET	O
1,000-	O	NOUN	O
and	O	CCONJ	O
2,000-mg/day	O	NUM	O
arms	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Change	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
the	O	DET	O
vitality	B-OUT	NOUN	B
subscale	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
SF-36	O	NOUN	B
was	O	AUX	O
7.3-7.8	O	NUM	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
750-mg/day	O	NOUN	O
arm	O	NOUN	B
,	O	PUNCT	O
versus	O	X	O
10.5-14.6	O	NUM	O
in	O	ADP	O
the	O	DET	O
1,000-	O	NOUN	O
and	O	CCONJ	O
2,000-mg/day	O	NUM	O
arms	O	NOUN	O
.	O	PUNCT	O


Over	O	ADV	O
twice	O	ADV	O
as	O	ADV	O
many	O	ADJ	O
patients	O	NOUN	B
on	O	ADP	O
ginseng	B-I	NOUN	B
perceived	O	VERB	B
a	O	DET	O
benefit	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
satisfied	B-OUT	ADJ	O
with	O	ADP	O
treatment	O	NOUN	B
over	O	ADP	O
those	O	DET	O
on	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
any	O	DET	O
measured	O	VERB	B
toxicities	B-OUT	NOUN	B
between	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
arms	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
There	O	PRON	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
some	O	DET	O
activity	O	NOUN	B
and	O	CCONJ	O
tolerable	O	ADJ	B
toxicity	O	NOUN	B
at	O	ADP	O
1,000-2,000	O	NUM	O
mg/day	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
American	B-I	ADJ	B
ginseng	I-I	NOUN	I
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
cancer-related	B-P	ADJ	B
fatigue	I-P	NOUN	I
.	I-P	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
further	O	ADJ	O
study	O	NOUN	B
of	O	ADP	O
American	B-I	ADJ	B
ginseng	I-I	NOUN	I
is	O	AUX	O
warranted	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
coenzyme	B-I	ADJ	B
Q10	I-I	NOUN	I
on	O	ADP	O
microcirculatory	B-OUT	ADJ	B
endothelial	I-OUT	ADJ	I
function	I-OUT	NOUN	I
of	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
mellitus	I-P	NOUN	I
.	I-P	PUNCT	O


Mortality	B-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
small	I-P	ADJ	B
choroidal	I-P	ADJ	I
melanoma	I-P	NOUN	I
.	I-P	PUNCT	O


COMS	O	NOUN	B
report	O	VERB	B
no	O	INTJ	O
.	O	PUNCT	O


4	O	X	O
.	O	PUNCT	O


The	O	DET	O
Collaborative	O	ADJ	B
Ocular	O	PROPN	I
Melanoma	O	PROPN	I
Study	O	PROPN	I
Group	O	PROPN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
describe	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
characteristics	O	NOUN	I
and	O	CCONJ	O
survival	O	NOUN	B
experience	O	NOUN	B
of	O	ADP	O
a	O	DET	O
prospectively	O	ADV	O
followed	O	VERB	B
up	O	ADP	I
group	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
small	I-P	ADJ	B
choroidal	I-P	ADJ	I
melanoma	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
Collaborative	O	ADJ	B
Ocular	O	PROPN	I
Melanoma	O	PROPN	I
Study	O	PROPN	I
(	O	PUNCT	O
COMS	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
set	O	NOUN	O
of	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
designed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
radiotherapy	B-I	NOUN	B
and	O	CCONJ	O
enucleation	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
medium	O	NOUN	B
and	O	CCONJ	O
large-size	O	ADJ	O
choroidal	O	ADJ	B
melanoma	O	NOUN	I
.	O	PUNCT	O


From	B-P	ADP	O
December	I-P	PROPN	O
1986	I-P	NUM	O
to	I-P	ADP	O
August	I-P	PROPN	O
1989	I-P	NUM	O
,	I-P	PUNCT	O
patients	I-P	NOUN	B
with	I-P	ADP	O
small	I-P	ADJ	B
choroidal	I-P	ADJ	I
melanoma	I-P	NOUN	I
,	I-P	PUNCT	O
not	I-P	PART	O
large	I-P	ADJ	O
enough	I-P	ADV	O
to	I-P	PART	O
be	I-P	AUX	O
eligible	I-P	ADJ	B
for	I-P	ADP	O
the	I-P	DET	O
COMS	I-P	NOUN	B
clinical	I-P	ADJ	B
trials	I-P	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
offered	O	VERB	O
participation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
nonrandomized	O	ADJ	B
prospective	O	ADJ	B
follow-up	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


Small	O	ADJ	B
choroidal	O	ADJ	I
melanomas	O	NOUN	I
were	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
1.0	O	NUM	O
to	O	PART	O
3.0	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
apical	O	ADJ	B
height	O	NOUN	I
and	O	CCONJ	O
at	O	ADP	O
least	O	ADJ	O
5.0	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
basal	O	ADJ	B
diameter	O	NOUN	I
.	O	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
204	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
up	O	ADP	O
annually	O	ADV	B
through	O	ADP	O
August	O	PROPN	O
1989	O	NUM	O
.	O	PUNCT	O


Two	O	NUM	O
additional	O	ADJ	O
assessments	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
status	O	NOUN	I
and	O	CCONJ	O
mortality	B-OUT	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
1993-1994	O	NUM	O
and	O	CCONJ	O
1995-1996	O	NUM	B
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
length	I-OUT	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
was	O	AUX	O
92	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
study	O	NOUN	B
enrollment	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
additional	O	ADJ	O
33	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
treated	O	VERB	B
during	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Twenty-seven	O	NUM	O
patients	O	NOUN	B
have	O	AUX	O
died	B-OUT	VERB	B
;	I-OUT	PUNCT	O
6	O	NUM	O
deaths	B-OUT	NOUN	B
were	O	AUX	O
reported	O	VERB	O
by	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
center	O	NOUN	I
as	O	ADP	O
due	O	ADJ	O
to	O	PART	O
metastatic	B-OUT	ADJ	B
melanoma	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
Kaplan-Meier	O	ADJ	B
estimate	O	NOUN	I
of	O	ADP	O
5-year	O	ADJ	O
all-cause	O	ADJ	B
mortality	B-OUT	NOUN	B
was	O	AUX	O
6.0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
2.7	O	NUM	O
%	O	NOUN	O
-9.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
8-year	O	ADJ	O
all-cause	O	ADJ	O
mortality	B-OUT	NOUN	B
was	O	AUX	O
14.9	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
9.6	O	NUM	O
%	O	NOUN	O
-20.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Otherwise	B-P	ADV	O
healthy	I-P	ADJ	B
patients	I-P	NOUN	B
,	I-P	PUNCT	O
average	I-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
60	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
without	I-P	ADP	O
a	I-P	DET	O
previous	I-P	ADJ	O
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
malignant	I-P	ADJ	B
disease	I-P	NOUN	I
who	I-P	PRON	O
have	I-P	AUX	O
small	I-P	ADJ	O
choroidal	I-OUT	ADJ	B
lesions	I-OUT	NOUN	B
judged	I-P	VERB	O
to	I-P	PART	O
be	I-P	AUX	O
melanoma	I-P	NOUN	B
have	O	AUX	O
a	O	DET	O
low	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
dying	O	VERB	B
within	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
ofloxacin	B-I	NOUN	B
and	O	CCONJ	O
cefixime	B-I	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
typhoid	B-P	ADJ	B
fever	I-P	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
Dong	B-P	PROPN	O
Nai	I-P	PROPN	B
Pediatric	I-P	PROPN	I
Center	I-P	PROPN	I
Typhoid	O	PROPN	O
Study	O	PROPN	O
Group	O	PROPN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Despite	O	SCONJ	O
concerns	O	NOUN	B
about	O	ADP	O
safety	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
,	O	PUNCT	O
fluoroquinolone	B-I	ADJ	B
antibiotics	I-I	NOUN	I
have	O	AUX	O
become	O	VERB	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
choice	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
multidrug-resistant	I-P	ADJ	B
typhoid	I-P	NOUN	I
fever	I-P	NOUN	I
in	I-P	ADP	O
Vietnam	I-P	PROPN	B
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
quinolone-resistant	O	ADJ	B
strains	O	NOUN	I
of	O	ADP	O
Salmonella	O	X	B
typhi	O	X	I
have	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
from	O	ADP	O
Vietnam	O	PROPN	B
;	O	PUNCT	O
and	O	CCONJ	O
if	O	SCONJ	O
quinolone	O	ADJ	B
resistance	O	NOUN	B
becomes	O	VERB	O
established	O	VERB	O
,	O	PUNCT	O
alternative	O	ADJ	B
oral	O	ADJ	B
treatment	O	NOUN	I
options	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
needed	O	VERB	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
Cefixime	B-I	PROPN	B
,	O	PUNCT	O
an	O	DET	O
orally	O	ADV	B
administered	O	VERB	I
third	O	ADJ	O
generation	O	NOUN	O
cephalosporin	B-I	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
compared	O	VERB	O
with	O	ADP	O
ofloxacin	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
uncomplicated	O	ADJ	B
typhoid	O	NOUN	B
fever	O	NOUN	I
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	B-P	ADP	O
an	I-P	DET	O
open	I-P	ADJ	O
trial	I-P	NOUN	O
children	I-P	NOUN	B
with	I-P	ADP	O
suspected	I-P	VERB	B
typhoid	I-P	NOUN	B
fever	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
ofloxacin	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg/kg/day	O	NOUN	O
in	O	ADP	O
two	O	NUM	O
divided	O	ADJ	O
doses	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
or	O	CCONJ	O
cefixime	B-I	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg/kg/day	O	NOUN	O
in	O	ADP	O
two	O	NUM	O
divided	O	ADJ	O
doses	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
S.	O	X	B
typhi	O	NOUN	I
was	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
82	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
44	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
cefixime	I-I	NOUN	B
group	I-P	NOUN	B
,	I-P	PUNCT	O
38	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
ofloxacin	I-I	NOUN	B
group	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
70	I-P	NUM	O
(	I-P	PUNCT	O
85	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
of	I-P	ADP	O
the	I-P	DET	O
isolates	I-P	NOUN	B
were	I-P	AUX	O
multidrug-resistant	I-P	ADJ	B
.	I-P	PUNCT	O


Median	O	ADJ	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
range	O	NOUN	B
)	O	PUNCT	O
fever	B-OUT	NOUN	B
clearance	I-OUT	NOUN	B
times	I-OUT	NOUN	I
were	O	AUX	O
4.4	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
to	O	PART	O
5.2	O	NUM	O
,	O	PUNCT	O
0.2	O	NUM	O
to	O	PART	O
9.9	O	NUM	O
)	O	PUNCT	O
days	O	NOUN	B
for	O	ADP	O
ofloxacin	B-I	NOUN	B
recipients	O	NOUN	B
and	O	CCONJ	O
8.5	O	NUM	O
(	O	PUNCT	O
4.2	O	NUM	O
to	O	PART	O
9	O	NUM	O
,	O	PUNCT	O
1.8	O	NUM	O
to	O	PART	O
15.2	O	NUM	O
)	O	PUNCT	O
days	O	NOUN	B
for	O	ADP	O
cefixime-treated	B-I	ADJ	B
patients	I-P	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
11	O	NUM	O
treatment	B-OUT	NOUN	B
failures	I-OUT	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
acute	O	ADJ	B
and	O	CCONJ	O
one	O	NUM	O
relapse	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
cefixime	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
acute	B-OUT	ADJ	B
treatment	I-OUT	NOUN	I
failure	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
ofloxacin	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	O
difference	O	NOUN	O
,	O	PUNCT	O
22	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
9	O	NUM	O
to	O	PART	O
36	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Short	O	ADJ	B
course	O	NOUN	I
treatment	O	NOUN	B
with	O	ADP	O
cefixime	B-I	NOUN	B
may	O	AUX	O
provide	O	VERB	O
a	O	DET	O
useful	O	ADJ	O
alternative	O	ADJ	B
treatment	O	NOUN	I
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
uncomplicated	B-P	ADJ	O
typhoid	I-P	NOUN	B
fever	I-P	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
less	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
short	O	ADJ	B
course	O	NOUN	I
treatment	O	NOUN	B
with	O	ADP	O
ofloxacin	B-I	NOUN	B
.	I-I	PUNCT	O


Is	O	AUX	O
successful	O	ADJ	O
rehabilitation	O	NOUN	B
of	O	ADP	O
complex	B-P	ADJ	B
regional	I-P	ADJ	I
pain	I-P	NOUN	I
syndrome	I-P	NOUN	I
due	O	ADJ	O
to	O	PART	O
sustained	O	ADJ	B
attention	O	NOUN	B
to	O	ADP	O
the	O	DET	O
affected	O	VERB	B
limb	O	NOUN	B
?	O	PUNCT	O
A	O	DET	O
randomised	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
complex	O	ADJ	B
regional	O	ADJ	I
pain	O	NOUN	I
syndrome	O	NOUN	I
(	O	PUNCT	O
CRPS1	O	NOUN	B
)	O	PUNCT	O
initiated	O	VERB	O
by	O	ADP	O
wrist	O	ADJ	B
fracture	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
motor	B-I	NOUN	B
imagery	I-I	NOUN	I
program	I-I	NOUN	I
(	O	PUNCT	O
MIP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
consisting	O	VERB	O
of	O	ADP	O
hand	O	NOUN	B
laterality	O	NOUN	I
recognition	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
imagined	B-I	VERB	B
movements	I-I	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
mirror	B-I	NOUN	B
movements	I-I	NOUN	B
,	O	PUNCT	O
reduces	O	VERB	B
pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
effect	O	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


Possibilities	O	NOUN	B
include	O	VERB	O
sustained	O	ADJ	B
attention	O	NOUN	B
to	O	ADP	O
the	O	DET	O
affected	O	VERB	B
limb	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
case	O	VERB	B
the	O	DET	O
order	O	NOUN	O
of	O	ADP	O
MIP	O	NOUN	B
components	O	NOUN	B
would	O	AUX	O
not	O	PART	O
alter	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
sequential	O	ADJ	B
activation	O	NOUN	B
of	O	ADP	O
cortical	O	ADJ	B
motor	O	NOUN	I
networks	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
case	O	NOUN	B
it	O	PRON	O
would	O	AUX	O
.	O	PUNCT	O


Twenty	B-P	NUM	O
subjects	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
CRPS1	I-P	NOUN	B
initiated	I-P	VERB	O
by	I-P	ADP	O
wrist	I-P	ADJ	B
fracture	I-P	NOUN	I
and	I-P	CCONJ	O
who	I-P	PRON	O
satisfied	I-P	VERB	O
stringent	I-P	ADJ	O
inclusion	I-P	NOUN	B
criteria	I-P	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
hand	B-I	NOUN	B
laterality	I-I	NOUN	I
recognition	I-I	NOUN	I
,	I-I	PUNCT	O
imagined	I-I	VERB	B
movements	I-I	NOUN	B
,	I-I	PUNCT	O
mirror	I-I	NOUN	B
movements	I-I	NOUN	I
(	I-I	PUNCT	O
RecImMir	I-I	NOUN	B
,	I-I	PUNCT	O
MIP	I-I	PROPN	B
)	I-I	PUNCT	O
;	I-I	PUNCT	O
imagined	I-I	VERB	B
movements	I-I	NOUN	B
,	I-I	PUNCT	O
recognition	I-I	NOUN	B
,	I-I	PUNCT	O
imagined	I-I	VERB	B
movements	I-I	NOUN	B
(	I-I	PUNCT	O
ImRecIm	I-I	NOUN	B
)	I-I	PUNCT	O
;	I-I	PUNCT	O
recognition	I-I	NOUN	B
,	I-I	PUNCT	O
mirror	I-I	NOUN	B
movements	I-I	NOUN	B
,	I-I	PUNCT	O
recognition	I-I	NOUN	B
(	I-I	PUNCT	O
RecMirRec	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


At	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
18	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
reduced	O	VERB	B
pain	B-OUT	NOUN	I
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
were	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
the	O	DET	O
RecImMir	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
for	O	ADP	O
the	O	DET	O
other	O	ADJ	O
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Hand	O	NOUN	B
laterality	O	NOUN	I
recognition	O	NOUN	B
imparted	O	VERB	O
a	O	DET	O
consistent	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
across	O	ADP	O
groups	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
limited	O	VERB	O
in	O	ADP	O
magnitude	O	NOUN	B
.	O	PUNCT	O


Imagined	O	ADJ	B
movements	O	NOUN	B
imparted	O	VERB	B
a	O	DET	O
further	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
if	O	SCONJ	O
they	O	PRON	O
followed	O	VERB	O
hand	O	NOUN	B
laterality	O	NOUN	I
recognition	O	NOUN	B
.	O	PUNCT	O


Mirror	O	NOUN	B
movements	O	NOUN	B
also	O	ADV	O
imparted	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
when	O	SCONJ	O
they	O	PRON	O
followed	O	VERB	O
imagined	O	VERB	O
movements	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
MIP	O	PROPN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
order	O	NOUN	O
of	O	ADP	O
components	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
due	O	ADJ	O
to	O	PART	O
sustained	O	ADJ	B
attention	O	NOUN	B
to	O	ADP	O
the	O	DET	O
affected	O	VERB	B
limb	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
sequential	O	ADJ	O
activation	O	NOUN	B
of	O	ADP	O
cortical	O	ADJ	B
motor	O	NOUN	I
networks	O	NOUN	I
.	O	PUNCT	O


Confidential	B-I	ADJ	B
registration	I-I	NOUN	I
in	O	ADP	O
health	O	NOUN	B
services	O	NOUN	I
:	O	PUNCT	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Human	O	ADJ	B
rights	O	NOUN	O
legislation	O	NOUN	B
safeguards	O	NOUN	B
the	O	DET	O
privacy	O	NOUN	B
and	O	CCONJ	O
dignity	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
patient	O	NOUN	B
assessed	O	VERB	B
privacy	O	NOUN	B
of	O	ADP	O
confidential	B-I	ADJ	B
registration	I-I	NOUN	I
.	I-I	PUNCT	O


DESIGN	O	VERB	O
Randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	B
Emergency	B-P	PROPN	I
Department	I-P	PROPN	I
,	I-P	PUNCT	O
University	I-P	PROPN	B
Hospital	I-P	PROPN	I
of	I-P	ADP	I
Wales	I-P	PROPN	I
.	I-P	PUNCT	O


PARTICIPANTS	O	VERB	B
A	B-P	DET	I
total	I-P	NOUN	O
of	I-P	ADP	O
302	I-P	NUM	O
patients	I-P	NOUN	B
aged	I-P	ADJ	B
over	I-P	ADP	O
15	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	B
MEASURES	O	PROPN	O
Binary	B-I	ADJ	B
choices	I-I	NOUN	O
and	O	CCONJ	O
ordinal	B-I	ADJ	B
visual	I-I	ADJ	I
analogue	I-I	NOUN	I
scores	O	NOUN	I
from	O	ADP	O
a	O	DET	O
validated	B-I	VERB	O
questionnaire	I-I	NOUN	B
on	I-I	ADP	O
self	I-I	NOUN	O
reported	I-I	VERB	O
measures	I-I	NOUN	B
:	I-I	PUNCT	O
patient	I-OUT	ADJ	B
ability	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
preference	I-OUT	NOUN	B
to	I-OUT	PART	O
speak	I-OUT	VERB	O
to	I-OUT	ADP	O
receptionists	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
disclose	I-OUT	VERB	O
confidential	I-OUT	ADJ	B
information	I-OUT	NOUN	B
without	I-OUT	ADP	O
being	I-OUT	AUX	O
overhead	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
concern	I-OUT	NOUN	O
about	I-OUT	ADP	O
disclosure	I-OUT	NOUN	B
of	I-OUT	ADP	O
items	I-OUT	NOUN	B
of	I-OUT	ADP	O
confidential	I-OUT	ADJ	B
personal	I-OUT	ADJ	O
information	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Patients	O	NOUN	B
who	O	PRON	O
registered	O	VERB	O
in	O	ADP	O
a	O	DET	O
screened	B-I	VERB	B
area	I-I	NOUN	O
felt	O	VERB	O
significantly	O	ADV	O
more	O	ADV	O
able	O	ADJ	O
to	O	PART	O
tell	B-OUT	VERB	O
receptionists	I-OUT	NOUN	B
things	I-OUT	NOUN	O
they	I-OUT	PRON	O
did	I-OUT	AUX	O
not	I-OUT	PART	O
want	I-OUT	VERB	O
others	I-OUT	NOUN	O
to	I-OUT	PART	O
hear	I-OUT	VERB	O
.	I-OUT	PUNCT	O


Control	O	ADJ	B
patients	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
concerned	O	ADJ	O
than	O	ADP	O
intervention	O	NOUN	B
patients	O	NOUN	B
that	O	PRON	O
others	B-OUT	NOUN	O
heard	I-OUT	VERB	O
their	I-OUT	PRON	O
name	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
address	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
date	I-OUT	NOUN	O
of	I-OUT	ADP	O
birth	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
reason	I-OUT	NOUN	O
for	I-OUT	ADP	O
emergency	I-OUT	NOUN	B
department	I-OUT	NOUN	I
attendance	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
telephone	I-OUT	NOUN	B
number	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
but	I-OUT	CCONJ	O
not	I-OUT	PART	O
their	I-OUT	PRON	O
marital	I-OUT	ADJ	B
status	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
intervention	O	NOUN	B
patients	O	NOUN	B
were	O	AUX	O
less	O	ADV	O
concerned	O	ADJ	O
about	O	ADP	O
disclosure	B-OUT	NOUN	B
of	I-OUT	ADP	O
information	I-OUT	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
they	O	PRON	O
had	O	AUX	O
been	O	AUX	O
overheard	O	VERB	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Patients	O	NOUN	B
value	O	VERB	O
privacy	O	NOUN	B
when	O	SCONJ	O
they	O	PRON	O
register	O	VERB	B
and	O	CCONJ	O
are	O	AUX	O
concerned	O	ADJ	O
if	O	SCONJ	O
others	O	NOUN	O
can	O	AUX	O
hear	O	VERB	O
them	O	PRON	O
tell	O	VERB	O
receptionists	O	NOUN	B
who	O	PRON	O
they	O	PRON	O
are	O	AUX	O
,	O	PUNCT	O
how	O	SCONJ	O
to	O	PART	O
contact	O	VERB	B
them	O	PRON	O
,	O	PUNCT	O
and	O	CCONJ	O
why	O	SCONJ	O
they	O	PRON	O
are	O	AUX	O
there	O	ADV	O
.	O	PUNCT	O


Confidential	B-I	ADJ	B
registration	I-I	NOUN	I
should	O	AUX	O
be	O	AUX	O
instituted	O	VERB	B
in	O	ADP	O
health	O	NOUN	B
services	O	NOUN	I
.	O	PUNCT	O


Confidential	B-I	ADJ	B
registration	I-I	NOUN	I
increased	O	VERB	B
patient	O	NOUN	B
privacy	O	NOUN	O
and	O	CCONJ	O
should	O	AUX	O
be	O	AUX	O
instituted	O	VERB	B
in	O	ADP	O
health	O	NOUN	B
services	O	NOUN	I
.	O	PUNCT	O


Early	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
continuous	O	ADJ	B
low-dosage	O	ADJ	B
all-norgestrel	B-I	NOUN	O
administered	O	VERB	B
alone	O	ADV	O
or	O	CCONJ	O
with	O	ADP	O
estrogen	O	NOUN	B
.	O	PUNCT	O


Twenty-six	B-P	NUM	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
participated	O	VERB	O
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
trial	O	NOUN	I
involving	O	VERB	O
treatment	O	NOUN	B
according	O	VERB	O
to	O	ADP	O
a	O	DET	O
Latin	O	ADJ	B
square	O	ADJ	I
design	O	NOUN	B
with	O	ADP	O
either	O	DET	O
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
dl-norgestrel	B-I	NOUN	B
alone	I-I	ADV	O
(	O	PUNCT	O
0.075	O	NUM	O
mg/day	O	NOUN	O
)	O	PUNCT	O
continuously	O	ADV	O
for	O	ADP	O
two	O	NUM	O
cycles	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
estradiol-17	B-I	NOUN	B
beta	I-I	NOUN	I
alone	I-I	ADV	O
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
on	O	ADP	O
25	O	NUM	O
of	O	ADP	O
28	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
two	O	NUM	O
cycles	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
(	O	PUNCT	O
iii	O	X	O
)	O	PUNCT	O
the	O	DET	O
combined	B-I	ADJ	B
hormones	I-I	NOUN	B
for	O	ADP	O
six	O	NUM	O
cycles	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
placebo	B-I	NOUN	B
control	I-I	NOUN	O
cycle	O	NOUN	O
followed	O	VERB	O
each	O	DET	O
hormonal	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
triglycerides	I-OUT	NOUN	B
decreased	I-OUT	VERB	B
by	O	ADP	O
an	O	DET	O
average	O	ADJ	B
22	O	NUM	O
%	O	NOUN	O
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
dl-norgestrel	B-I	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
123	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
vs.	O	CCONJ	O
160	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
combination	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
126	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
vs.	O	CCONJ	O
162	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
control	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
total	I-OUT	ADJ	B
cholesterol	I-OUT	NOUN	I
fell	O	VERB	O
by	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
during	O	ADP	O
two	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
dl-norgestrel	B-I	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
229	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
vs.	O	CCONJ	O
242	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.02	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
combination	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
233	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
vs.	O	CCONJ	O
246	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
versus	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
fifth	O	ADJ	O
and	O	CCONJ	O
sixth	O	ADJ	O
cycles	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
therapy	O	NOUN	I
94	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cycles	O	NOUN	B
were	O	AUX	O
free	B-OUT	ADJ	B
of	I-OUT	ADP	I
flushing	I-OUT	VERB	B
(	O	PUNCT	O
vs.	O	CCONJ	O
31	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
control	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
64	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cycles	O	NOUN	B
were	O	AUX	O
free	B-OUT	ADJ	B
of	I-OUT	ADP	O
spotting	I-OUT	VERB	O
not	I-OUT	PART	O
requiring	I-OUT	VERB	O
protection	I-OUT	NOUN	B
(	O	PUNCT	O
control	O	NOUN	B
75	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
96	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cycles	O	NOUN	B
were	O	AUX	O
free	B-OUT	ADJ	B
of	I-OUT	ADP	O
vaginal	I-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
(	O	PUNCT	O
control	O	NOUN	B
100	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
endometrial	O	ADJ	B
biopsy	O	NOUN	I
showed	O	VERB	O
inactive	B-OUT	ADJ	B
endometrium	I-OUT	NOUN	B
in	O	ADP	O
nine	O	NUM	O
of	O	ADP	O
the	O	DET	O
10	O	NUM	O
subjects	O	NOUN	B
re-biopsied	O	VERB	B
,	O	PUNCT	O
fasting	B-OUT	ADJ	B
blood	I-OUT	NOUN	B
pyruvate	I-OUT	NOUN	I
decreased	I-OUT	VERB	B
by	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
diastolic	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
fell	I-OUT	VERB	O
by	O	ADP	O
4	O	NUM	O
%	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
control	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
glucose	B-OUT	NOUN	B
tolerance	I-OUT	NOUN	I
was	I-OUT	AUX	O
unchanged	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
vasomotor	B-OUT	NOUN	B
flushing	I-OUT	NOUN	I
beginning	O	NOUN	O
with	O	ADP	O
the	O	DET	O
third	O	ADJ	O
to	O	ADP	O
fourth	O	ADJ	O
cycles	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Rational-emotive	B-I	ADJ	B
therapy	I-I	NOUN	I
and	O	CCONJ	O
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
interpersonal	B-OUT	ADJ	B
anxiety	I-OUT	NOUN	I
in	O	ADP	O
junior	B-P	ADJ	B
high	I-P	ADJ	I
school	I-P	NOUN	I
students	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
rational-emotive	B-I	ADJ	B
therapy	I-I	NOUN	I
and	I-I	CCONJ	O
rational-emotive	I-I	ADJ	B
imagery	I-I	NOUN	I
.	I-I	PUNCT	O


Fifty-nine	B-P	NUM	B
junior	I-P	ADJ	B
high	I-P	ADJ	I
school	I-P	NOUN	I
students	I-P	NOUN	I
who	I-P	PRON	O
volunteered	I-P	VERB	B
to	I-P	PART	O
participate	I-P	VERB	B
in	I-P	ADP	O
treatment	I-P	NOUN	B
for	I-P	ADP	O
interpersonal	I-OUT	ADJ	B
anxiety	I-OUT	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
rational-emotive	B-I	ADJ	B
therapy	I-I	NOUN	I
without	I-I	ADP	O
imagery	I-I	NOUN	B
(	I-I	PUNCT	O
RET	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
rational-emotive	I-I	ADJ	B
therapy	I-I	NOUN	I
with	I-I	ADP	O
imagery	I-I	NOUN	B
(	I-I	PUNCT	O
REI	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
relationship-oriented	I-I	ADJ	B
counseling	I-I	NOUN	I
(	I-I	PUNCT	O
ROC	I-I	PROPN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
waiting-list	I-I	ADJ	B
control	I-I	NOUN	I
(	I-I	PUNCT	O
WLC	I-I	NOUN	B
)	I-I	PUNCT	O
groups	I-I	NOUN	B
.	I-I	PUNCT	O


Groups	O	NOUN	B
met	O	VERB	O
for	O	ADP	O
seven	O	NUM	O
50-minute	O	ADJ	O
treatment	O	NOUN	B
sessions	O	NOUN	O
during	O	ADP	O
a	O	DET	O
three-week	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


Assessments	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
at	O	ADP	O
pretreatment	O	NOUN	B
,	O	PUNCT	O
posttreatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
three-week	O	ADJ	B
follow-up	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
self-report	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
sociometric	I-OUT	ADJ	B
measures	I-OUT	NOUN	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
treatment	O	NOUN	B
outcome	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
postassessment	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
the	O	DET	O
RET	O	NOUN	B
and	O	CCONJ	O
REI	O	NOUN	B
groups	O	NOUN	B
were	O	AUX	O
rated	O	VERB	O
on	O	ADP	O
sociometric	B-OUT	ADJ	B
measures	I-OUT	NOUN	B
as	O	ADP	O
significantly	B-OUT	ADV	O
less	I-OUT	ADV	O
interpersonally	I-OUT	ADV	B
anxious	I-OUT	ADJ	B
than	O	ADP	O
the	O	DET	O
WLC	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Mean	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
favored	O	VERB	O
the	O	DET	O
RET	O	NOUN	B
and	O	CCONJ	O
REI	O	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
these	O	DET	O
groups	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
ROC	O	PROPN	B
group	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
self-report	B-OUT	ADJ	B
measure	I-OUT	NOUN	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
differentiate	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
REI	O	NOUN	B
group	O	NOUN	B
demonstrated	O	VERB	O
significant	O	ADJ	O
pre-	O	ADJ	B
to	O	PART	O
follow-up	O	ADJ	B
changes	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
RET	O	NOUN	B
and	O	CCONJ	O
REI	O	NOUN	B
groups	O	NOUN	B
yielded	O	VERB	O
greater	O	ADJ	O
reductions	B-OUT	NOUN	B
in	I-OUT	ADP	O
irrational	I-OUT	ADJ	B
thinking	I-OUT	NOUN	B
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
ROC	O	PROPN	B
and	O	CCONJ	O
WLC	O	PROPN	B
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
the	O	DET	O
results	O	NOUN	B
supported	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
rational-emotive	B-I	ADJ	B
imagery	I-I	NOUN	I
as	O	ADP	O
a	O	DET	O
component	O	NOUN	B
of	O	ADP	O
rational-emotive	B-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
practical	O	ADJ	O
implications	O	NOUN	O
of	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


Cost-effectiveness	O	NOUN	B
of	O	ADP	O
clopidogrel	B-I	NOUN	B
in	O	ADP	O
acute	B-P	ADJ	B
coronary	I-P	ADJ	I
syndromes	I-P	NOUN	I
in	I-P	ADP	O
Canada	I-P	PROPN	B
:	I-P	PUNCT	O
a	O	DET	O
long-term	O	ADJ	B
analysis	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
CURE	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Cardiovascular	O	ADJ	B
diseases	O	NOUN	I
account	O	VERB	O
for	O	ADP	O
nearly	O	ADV	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
hospitalizations	O	NOUN	B
in	O	ADP	O
Canada	O	PROPN	B
and	O	CCONJ	O
consume	O	VERB	O
12	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
total	O	ADJ	O
cost	O	NOUN	B
of	O	ADP	O
all	O	DET	O
illnesses	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
increasing	O	VERB	B
trends	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
disease	O	NOUN	I
and	O	CCONJ	O
increasing	O	VERB	B
costs	O	NOUN	B
of	O	ADP	O
care	O	NOUN	B
,	O	PUNCT	O
development	O	NOUN	B
of	O	ADP	O
cost-effective	O	ADJ	B
strategies	O	NOUN	B
is	O	AUX	O
vital	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
Clopidogrel	B-I	NOUN	B
in	O	ADP	O
Unstable	O	ADJ	B
angina	O	NOUN	I
to	O	PART	O
prevent	O	VERB	O
Recurrent	O	ADJ	B
Events	O	NOUN	I
(	O	PUNCT	O
CURE	O	NOUN	B
)	O	PUNCT	O
trial	O	NOUN	B
demonstrated	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
clopidogrel	B-I	NOUN	B
plus	I-I	CCONJ	O
acetylsalicylic	I-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
ASA	I-I	NOUN	B
)	I-I	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
ASA	B-I	NOUN	B
alone	I-I	ADV	O
in	O	ADP	O
reducing	O	VERB	B
cardiovascular	O	ADJ	B
events	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
coronary	I-P	ADJ	I
syndromes	I-P	NOUN	I
and	I-P	CCONJ	O
,	I-P	PUNCT	O
in	I-P	ADP	O
addition	I-P	NOUN	O
,	I-P	PUNCT	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
percutaneous	I-P	ADJ	B
coronary	I-P	ADJ	I
intervention	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
Percutaneous	I-P	PROPN	B
Coronary	I-P	PROPN	I
Intervention	I-P	PROPN	I
in	I-P	ADP	O
CURE	I-P	PROPN	B
(	I-P	PUNCT	O
PCI-CURE	I-P	NOUN	B
)	I-P	PUNCT	O
trial	I-P	NOUN	O
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
cost-effectiveness	O	NOUN	B
of	O	ADP	O
clopidogrel	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
Canadian	B-P	ADJ	B
health	I-P	NOUN	B
care	I-P	NOUN	I
system	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Estimates	O	NOUN	B
of	O	ADP	O
hospitalization	O	NOUN	B
costs	O	NOUN	B
were	O	AUX	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
2003	O	NUM	O
cost	O	NOUN	B
schedules	O	NOUN	B
released	O	VERB	B
by	O	ADP	O
the	O	DET	O
Health	O	PROPN	B
Funding	O	PROPN	I
and	O	CCONJ	I
Costing	O	PROPN	I
Branch	O	PROPN	I
of	O	ADP	I
the	O	DET	I
Alberta	O	PROPN	I
Health	O	PROPN	I
and	O	CCONJ	O
Wellness	O	PROPN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
on	O	ADP	O
the	O	DET	O
Case	O	NOUN	B
Mix	O	PROPN	I
Group	O	PROPN	B
classification	O	NOUN	O
system	O	NOUN	O
.	O	PUNCT	O


Life	O	NOUN	B
expectancy	O	NOUN	I
beyond	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
estimated	O	VERB	O
from	O	ADP	O
the	O	DET	O
Saskatchewan	O	PROPN	B
Health	O	PROPN	I
Database	O	PROPN	I
.	O	PUNCT	O


Cost-effectiveness	O	NOUN	B
was	O	AUX	O
expressed	O	VERB	B
as	O	ADP	O
the	O	DET	O
incremental	O	ADJ	B
cost-effectiveness	O	ADJ	O
ratio	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
bootstrap	O	NOUN	B
methods	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
joint	O	ADJ	B
distribution	O	NOUN	B
of	O	ADP	O
costs	O	NOUN	B
and	O	CCONJ	O
effectiveness	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Clopidogrel	B-I	NOUN	B
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
cost-effective	B-OUT	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
incremental	O	ADJ	B
cost-effectiveness	B-OUT	ADJ	B
ratios	I-OUT	NOUN	O
less	O	ADJ	O
than	O	ADP	O
$	O	SYM	O
10,000	O	NUM	O
per	O	ADP	O
event	O	NOUN	B
prevented	B-OUT	VERB	B
and	O	CCONJ	O
less	O	ADJ	O
than	O	ADP	O
$	O	SYM	O
4,000	O	NUM	O
per	O	ADP	O
life-year	O	NOUN	O
gained	B-OUT	VERB	B
.	I-OUT	PUNCT	O


The	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
clopidogrel	B-I	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
cost	B-OUT	NOUN	B
per	I-OUT	ADP	O
life-year	I-OUT	NOUN	O
gained	I-OUT	VERB	O
of	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
$	O	SYM	O
20,000	O	NUM	O
was	O	AUX	O
0.975	O	NUM	O
for	O	ADP	O
CURE	B-P	NOUN	B
patients	I-P	NOUN	B
and	O	CCONJ	O
0.904	O	NUM	O
for	O	ADP	O
PCI-CURE	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
economic	O	ADJ	B
analysis	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
clopidogrel	B-I	NOUN	B
combination	I-I	NOUN	B
therapy	I-I	NOUN	I
is	O	AUX	O
not	O	PART	O
only	O	ADV	O
cost-effective	O	ADJ	B
as	O	ADP	O
antiplatelet	O	NOUN	B
therapy	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
ASA	B-I	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
also	O	ADV	O
cost-effective	O	ADJ	B
compared	O	VERB	B
with	O	ADP	O
other	O	ADJ	O
commonly	O	ADV	O
used	O	VERB	O
and	O	CCONJ	O
openly	O	ADV	O
reimbursed	O	VERB	B
cardiovascular	O	ADJ	B
therapies	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Canadian	O	ADJ	B
health	O	NOUN	B
care	O	NOUN	I
system	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
bromazepam	B-I	NOUN	B
over	I-P	ADP	O
the	I-P	DET	O
central	I-P	ADJ	B
and	I-P	CCONJ	O
frontal	I-P	ADJ	B
areas	I-P	NOUN	I
during	I-P	ADP	O
a	I-P	DET	O
motor	I-P	NOUN	B
task	I-P	NOUN	I
:	I-P	PUNCT	O
an	O	DET	O
EEG	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
investigates	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
bromazepam	B-I	NOUN	B
while	I-P	SCONJ	O
executing	I-P	VERB	O
a	I-P	DET	O
motor	I-P	NOUN	B
task	I-P	NOUN	I
.	I-P	PUNCT	O


Specifically	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
intend	O	VERB	O
to	O	PART	O
analyze	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
alpha	B-OUT	NOUN	B
absolute	I-OUT	ADJ	I
power	I-OUT	NOUN	O
under	O	ADP	O
two	O	NUM	O
experimental	O	ADJ	B
conditions	O	NOUN	I
,	O	PUNCT	O
bromazepam	B-I	NOUN	B
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
also	O	ADV	O
included	O	VERB	O
analyses	O	NOUN	B
of	O	ADP	O
theta	O	NOUN	B
and	O	CCONJ	O
beta	O	NOUN	B
frequencies	O	NOUN	I
.	O	PUNCT	O


We	B-P	PRON	O
collected	I-P	VERB	O
electroencephalographic	I-I	ADJ	B
data	I-I	NOUN	O
before	I-I	ADP	O
,	I-I	PUNCT	O
during	I-I	ADP	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
after	I-I	ADP	O
motor	I-I	NOUN	B
task	I-I	NOUN	I
execution	I-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
used	O	VERB	O
a	O	DET	O
Two	B-I	NUM	O
Way	I-I	NOUN	B
ANOVA	I-I	NOUN	I
to	I-I	PART	O
investigate	I-I	VERB	B
the	I-I	DET	O
condition	I-I	NOUN	B
(	I-I	PUNCT	O
PL	I-I	NOUN	B
×	I-I	NOUN	O
Br6	I-I	NOUN	B
mg	I-I	NOUN	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
moment	I-I	NOUN	B
(	I-I	PUNCT	O
pre	I-I	NOUN	B
and	I-I	CCONJ	O
post	I-I	NOUN	B
)	I-I	PUNCT	O
variables	I-I	NOUN	B
for	I-I	ADP	O
the	I-I	DET	O
following	I-I	VERB	O
electrodes	I-I	NOUN	B
:	I-I	PUNCT	O
Fp1	I-I	NOUN	B
,	I-I	PUNCT	O
Fp2	I-I	NOUN	B
,	I-I	PUNCT	O
F7	I-I	NOUN	B
,	I-I	PUNCT	O
F3	I-I	NOUN	O
,	I-I	PUNCT	O
Fz	I-I	NOUN	B
,	I-I	PUNCT	O
F4	I-I	PROPN	B
,	I-I	PUNCT	O
F8	I-I	NOUN	O
,	I-I	PUNCT	O
C3	I-I	NOUN	B
,	I-I	PUNCT	O
CZ	I-I	NOUN	B
and	I-I	CCONJ	O
C4	I-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
found	O	VERB	O
a	O	DET	O
main	O	ADJ	O
effect	O	NOUN	B
for	O	ADP	O
condition	O	NOUN	B
on	O	ADP	O
the	O	DET	O
electrodes	O	NOUN	B
FP1	O	NOUN	B
,	O	PUNCT	O
F7	O	NOUN	B
,	O	PUNCT	O
F3	O	NOUN	O
,	O	PUNCT	O
Fz	O	NOUN	B
,	O	PUNCT	O
F4	O	PROPN	B
,	O	PUNCT	O
C3	O	NOUN	B
and	O	CCONJ	O
CZ	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
alpha	O	NOUN	B
and	O	CCONJ	O
beta	O	NOUN	B
bands	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
beta	O	NOUN	B
band	O	NOUN	I
we	O	PRON	O
also	O	ADV	O
found	O	VERB	O
a	O	DET	O
main	O	ADJ	O
effect	O	NOUN	B
for	O	ADP	O
condition	O	NOUN	B
on	O	ADP	O
the	O	DET	O
electrodes	O	NOUN	B
Fp2	O	NOUN	O
,	O	PUNCT	O
F8	O	NOUN	B
and	O	CCONJ	O
C4	O	NOUN	B
;	O	PUNCT	O
for	O	ADP	O
theta	O	NOUN	B
band	O	NOUN	I
we	O	PRON	O
identified	O	VERB	B
a	O	DET	O
main	O	ADJ	O
effect	O	NOUN	B
for	O	ADP	O
condition	O	NOUN	B
on	O	ADP	O
C3	O	NOUN	B
,	O	PUNCT	O
Cz	O	NOUN	B
and	O	CCONJ	O
C4	O	NOUN	B
electrodes	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
motor	O	NOUN	B
task	O	NOUN	I
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
any	O	DET	O
influence	O	NOUN	B
on	O	ADP	O
the	B-OUT	DET	O
electrocortical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
in	O	ADP	O
alpha	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
existing	O	VERB	O
modifications	O	NOUN	B
were	O	AUX	O
a	O	DET	O
consequence	O	NOUN	O
due	O	ADJ	O
merely	O	ADV	O
to	O	PART	O
the	O	DET	O
drug	O	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
its	O	PRON	O
anxiolytic	O	ADJ	B
and	O	CCONJ	O
sedative	O	ADJ	B
action	O	NOUN	I
,	O	PUNCT	O
bromazepam	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
any	O	DET	O
significant	O	ADJ	O
changes	O	NOUN	B
when	B-P	SCONJ	O
the	I-P	DET	O
individuals	I-P	NOUN	B
executed	I-P	VERB	O
a	I-P	DET	O
finger	I-P	NOUN	B
extension	I-P	NOUN	O
motor	I-P	NOUN	O
task	I-P	NOUN	O
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
amantadine	B-I	NOUN	B
and	I-I	CCONJ	O
desipramine	I-I	NOUN	B
combined	O	VERB	B
with	O	ADP	O
psychotherapy	B-I	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
cocaine	B-P	NOUN	B
dependence	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
single-blind	O	ADJ	B
,	O	PUNCT	O
random	O	ADJ	B
assignment	O	NOUN	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
12-week	O	NOUN	O
comparison	O	NOUN	B
of	O	ADP	O
desipramine	B-I	NOUN	B
hydrochloride	I-I	NOUN	B
and	I-I	CCONJ	O
amantadine	I-I	NOUN	B
hydrochloride	I-I	NOUN	I
as	O	ADP	O
adjunctive	O	ADJ	B
treatments	O	NOUN	I
to	O	PART	O
counseling	O	VERB	B
for	O	ADP	O
cocaine	O	NOUN	B
dependence	O	NOUN	I
.	O	PUNCT	O


Subjects	B-P	NOUN	B
were	I-P	AUX	O
54	I-P	NUM	O
outpatients	I-P	NOUN	B
who	I-P	PRON	O
met	I-P	VERB	O
DSM	I-P	PROPN	B
III-R	I-P	NOUN	I
criteria	I-P	NOUN	I
for	I-P	ADP	O
active	I-P	ADJ	B
cocaine	I-P	NOUN	B
dependence	I-P	NOUN	I
and	I-P	CCONJ	O
who	I-P	PRON	O
completed	I-P	VERB	O
a	I-P	DET	O
minimum	I-P	NOUN	O
of	I-P	ADP	O
2	I-P	NUM	O
weeks	I-P	NOUN	B
of	I-P	ADP	O
treatment	I-P	NOUN	B
.	I-P	PUNCT	O


Subjects	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
fixed	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
200	O	NUM	O
mg/day	O	ADJ	O
desipramine	B-I	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
17	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
400	O	NUM	O
mg/day	O	NOUN	O
amantadine-placebo	B-I	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
16	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
21	O	NUM	O
)	O	PUNCT	O
did	B-P	AUX	O
not	I-P	PART	O
differ	I-P	VERB	O
for	I-P	ADP	O
lifetime	I-P	NOUN	B
cocaine	I-P	NOUN	B
use	I-P	NOUN	O
,	I-P	PUNCT	O
lifetime	I-P	NOUN	B
histories	I-P	NOUN	B
of	I-P	ADP	O
psychopathology	I-P	NOUN	B
,	I-P	PUNCT	O
admission	I-P	NOUN	B
scores	I-P	NOUN	I
on	I-P	ADP	O
psychometric	I-P	ADJ	B
assessments	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
sociodemographics	I-P	NOUN	B
.	I-P	PUNCT	O


All	O	DET	O
treatment	O	NOUN	B
groups	O	NOUN	I
demonstrated	O	VERB	O
dramatic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
persistent	I-OUT	ADJ	B
decreases	I-OUT	NOUN	B
in	O	ADP	O
cocaine	B-OUT	NOUN	B
use	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
craving	I-OUT	NOUN	B
for	I-OUT	ADP	O
cocaine	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
psychiatric	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
consequent	O	ADJ	B
to	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
for	O	ADP	O
more	O	ADJ	O
dropouts	B-OUT	NOUN	B
by	O	ADP	O
subjects	O	NOUN	B
taking	O	VERB	O
desipramine	B-I	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
among	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
regarding	O	VERB	O
retention	B-OUT	NOUN	B
in	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
craving	I-OUT	NOUN	B
for	I-OUT	ADP	O
cocaine	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
decreased	I-OUT	VERB	B
cocaine	I-OUT	NOUN	B
use	I-OUT	NOUN	O
confirmed	O	VERB	O
by	O	ADP	O
urine	B-OUT	NOUN	B
toxicology	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
for	O	ADP	O
subjects	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
desipramine	B-I	NOUN	B
to	O	PART	O
maintain	O	VERB	O
longer	O	ADJ	B
periods	O	NOUN	B
of	O	ADP	O
cocaine	B-OUT	NOUN	B
abstinence	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Mean	B-OUT	VERB	O
plasma	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
of	I-OUT	ADP	O
desipramine	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
subsample	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
subjects	O	NOUN	B
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
that	O	DET	O
recommended	O	VERB	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
depression	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
the	O	DET	O
dosage	O	NOUN	B
of	O	ADP	O
desipramine	B-I	NOUN	B
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
subtherapeutic	O	ADJ	B
.	O	PUNCT	O


Endocrine	B-OUT	ADJ	B
response	I-OUT	NOUN	I
to	O	PART	O
cataract	B-I	NOUN	B
surgery	I-I	NOUN	I
under	I-I	ADP	O
total	I-I	ADJ	B
intravenous	I-I	ADJ	I
anaesthesia	I-I	NOUN	I
,	I-I	PUNCT	O
local	I-I	ADJ	B
anaesthesia	I-I	NOUN	I
under	I-I	ADP	O
sedation	I-I	NOUN	B
or	I-I	CCONJ	O
local	I-I	ADJ	B
anaesthesia	I-I	NOUN	I
alone	I-I	ADV	O
:	I-I	PUNCT	O
a	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Predictive	O	ADJ	B
validity	O	NOUN	I
of	O	ADP	O
a	O	DET	O
medication	O	NOUN	B
adherence	O	NOUN	I
measure	O	NOUN	I
in	O	ADP	O
an	O	DET	O
outpatient	B-P	ADJ	B
setting	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examines	O	VERB	O
the	O	DET	O
psychometric	O	ADJ	B
properties	O	NOUN	B
and	O	CCONJ	O
tests	O	VERB	B
the	O	DET	O
concurrent	O	ADJ	B
and	O	CCONJ	O
predictive	O	ADJ	B
validity	O	NOUN	O
of	O	ADP	O
a	O	DET	O
structured	B-I	ADJ	B
,	I-I	PUNCT	O
self-reported	I-I	ADJ	O
medication	I-I	NOUN	B
adherence	I-I	NOUN	O
measure	I-I	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
hypertension	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
also	O	ADV	O
assessed	O	VERB	B
various	O	ADJ	O
psychosocial	B-OUT	ADJ	B
determinants	I-OUT	NOUN	O
of	I-OUT	ADP	O
adherence	I-OUT	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
knowledge	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
social	I-OUT	ADJ	B
support	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
satisfaction	I-OUT	NOUN	B
with	I-OUT	ADP	O
care	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
complexity	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
medical	I-OUT	ADJ	B
regimen	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
1367	I-P	NUM	O
patients	I-P	NOUN	B
participated	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
was	I-P	AUX	O
52.5	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
40.8	I-P	NUM	O
%	I-P	NOUN	O
were	I-P	AUX	O
male	I-P	NOUN	B
,	I-P	PUNCT	O
76.5	I-P	NUM	O
%	I-P	NOUN	O
were	I-P	AUX	O
black	I-P	ADJ	B
,	I-P	PUNCT	O
50.8	I-P	NUM	O
%	I-P	NOUN	O
graduated	I-P	VERB	O
from	I-P	ADP	O
high	I-P	ADJ	B
school	I-P	NOUN	I
,	I-P	PUNCT	O
26	I-P	NUM	O
%	I-P	NOUN	O
were	I-P	AUX	O
married	I-P	VERB	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
54.1	I-P	NUM	O
%	I-P	NOUN	O
had	I-P	AUX	O
income	I-P	NOUN	B
<	I-P	X	O
$	I-P	SYM	O
5,000	I-P	NUM	O
.	I-P	PUNCT	O


The	O	DET	O
8-item	O	NOUN	B
medication	B-I	NOUN	B
adherence	I-I	NOUN	I
scale	O	NOUN	I
was	O	AUX	O
reliable	O	ADJ	O
(	O	PUNCT	O
alpha=.83	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
control	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
cutpoint	O	NOUN	B
of	O	ADP	O
<	O	NOUN	O
6	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
measure	O	NOUN	B
to	O	PART	O
identify	O	VERB	O
patients	O	NOUN	B
with	O	ADP	O
poor	O	ADJ	B
blood	B-OUT	NOUN	I
pressure	I-OUT	NOUN	I
control	I-OUT	NOUN	I
was	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
93	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
specificity	O	NOUN	B
was	O	AUX	O
53	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
medication	O	NOUN	B
adherence	O	NOUN	I
measure	O	NOUN	I
proved	O	VERB	O
to	O	PART	O
be	O	AUX	O
reliable	O	ADJ	O
,	O	PUNCT	O
with	O	ADP	O
good	O	ADJ	O
concurrent	O	ADJ	B
and	O	CCONJ	O
predictive	O	ADJ	B
validity	O	NOUN	I
in	O	ADP	O
primarily	B-P	ADV	O
low-income	I-P	ADJ	B
,	I-P	PUNCT	O
minority	I-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
hypertension	I-P	NOUN	B
and	O	CCONJ	O
might	O	AUX	O
function	O	VERB	B
as	O	ADP	O
a	O	DET	O
screening	O	VERB	B
tool	O	NOUN	I
in	O	ADP	O
outpatient	B-P	ADJ	B
settings	I-P	NOUN	I
with	O	ADP	O
other	O	ADJ	O
patient	B-P	NOUN	B
groups	I-P	NOUN	I
.	I-P	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
preinduced	B-P	ADJ	B
quadriceps	I-P	NOUN	B
fatigue	I-P	NOUN	I
on	O	ADP	O
exercise	O	NOUN	B
response	O	NOUN	I
in	O	ADP	O
chronic	B-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
and	I-P	CCONJ	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


Exercise	O	NOUN	B
intolerance	O	NOUN	B
in	O	ADP	O
chronic	B-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
COPD	I-P	NOUN	B
)	I-P	PUNCT	O
results	O	VERB	B
from	O	ADP	O
a	O	DET	O
complex	O	ADJ	B
interaction	O	NOUN	B
between	O	ADP	O
central	O	ADJ	B
(	O	PUNCT	O
ventilatory	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
peripheral	O	ADJ	B
(	O	PUNCT	O
limb	O	NOUN	B
muscles	O	NOUN	I
)	O	PUNCT	O
components	O	NOUN	B
of	O	ADP	O
exercise	O	NOUN	B
limitation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
quadriceps	O	ADJ	B
muscle	O	NOUN	I
fatigue	O	NOUN	B
on	O	ADP	O
exercise	O	NOUN	B
tolerance	O	NOUN	I
and	O	CCONJ	O
ventilatory	O	ADJ	B
response	O	NOUN	I
during	O	ADP	O
constant-workrate	B-I	ADJ	B
cycling	I-I	NOUN	O
exercise	I-I	NOUN	O
testing	I-I	NOUN	O
(	I-I	PUNCT	O
CWT	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
COPD	I-P	NOUN	B
and	I-P	CCONJ	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


Fifteen	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
COPD	I-P	NOUN	B
and	I-P	CCONJ	O
nine	I-P	NUM	O
age-matched	I-P	ADJ	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
performed	O	VERB	O
,	O	PUNCT	O
7	O	NUM	O
days	O	NOUN	B
apart	O	ADV	O
,	O	PUNCT	O
two	O	NUM	O
CWTs	B-I	NOUN	B
up	O	ADV	O
to	O	PART	O
exhaustion	O	VERB	B
at	O	ADP	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
predetermined	O	ADJ	O
maximal	O	ADJ	B
work	O	NOUN	O
capacity	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
order	O	NOUN	O
,	O	PUNCT	O
one	O	NUM	O
test	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
with	O	ADP	O
preinduced	O	ADJ	B
quadriceps	O	NOUN	I
fatigue	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
in	O	ADP	O
a	O	DET	O
fresh	O	ADJ	B
state	O	NOUN	O
.	O	PUNCT	O


Quadriceps	O	PROPN	B
fatigue	O	NOUN	B
was	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
electrostimulation-induced	O	ADJ	B
contractions	O	NOUN	B
and	O	CCONJ	O
quantified	O	VERB	B
by	O	ADP	O
maximal	B-OUT	ADJ	B
voluntary	I-OUT	ADJ	B
contraction	I-OUT	NOUN	O
and	O	CCONJ	O
potentiated	B-OUT	VERB	B
twitch	I-OUT	NOUN	O
force	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
TwQ	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
pot	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


Endurance	B-OUT	NOUN	B
time	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
ventilatory	I-OUT	ADJ	B
response	I-OUT	NOUN	I
during	O	ADP	O
CWT	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
fatigued	O	VERB	B
and	O	CCONJ	O
fresh	O	ADJ	B
state	O	NOUN	O
.	O	PUNCT	O


Endurance	B-OUT	NOUN	B
time	I-OUT	NOUN	O
significantly	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
fatigued	O	VERB	B
state	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
fresh	O	ADJ	B
condition	O	NOUN	B
in	O	ADP	O
COPD	O	NOUN	B
(	O	PUNCT	O
356	O	NUM	O
+/-	O	CCONJ	O
69	O	NUM	O
s	O	NOUN	O
vs.	O	CCONJ	O
294	O	NUM	O
+/-	O	CCONJ	O
45	O	NUM	O
s	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
controls	O	NOUN	B
(	O	PUNCT	O
450	O	NUM	O
+/-	O	CCONJ	O
74	O	NUM	O
s	O	NOUN	O
vs.	O	CCONJ	O
340	O	NUM	O
+/-	O	CCONJ	O
45	O	NUM	O
s	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Controls	O	NOUN	B
showed	O	VERB	O
significantly	O	ADV	O
higher	O	ADJ	O
ventilation	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
end-exercise	I-OUT	ADJ	B
dyspnea	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
fatigued	O	VERB	B
condition	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
COPD	O	NOUN	B
,	O	PUNCT	O
fatigue	O	NOUN	B
did	O	AUX	O
not	O	PART	O
influence	O	VERB	B
ventilation	O	NOUN	B
or	O	CCONJ	O
dyspnea	O	NOUN	B
during	O	ADP	O
exercise	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
ventilatory	B-OUT	ADJ	B
limitation	I-OUT	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
expressed	O	VERB	B
by	O	ADP	O
the	O	DET	O
Ve/maximum	B-OUT	NOUN	B
voluntary	I-OUT	ADJ	O
ventilation	I-OUT	NOUN	O
ratio	I-OUT	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
conditions	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
COPD	I-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
possible	O	ADJ	O
to	O	PART	O
induce	O	VERB	B
quadriceps	O	NOUN	B
fatigue	O	NOUN	I
by	O	ADP	O
local	O	ADJ	B
electrostimulation-induced	O	ADJ	B
contractions	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
peripheral	B-P	ADJ	B
muscle	I-P	NOUN	I
fatigue	I-P	NOUN	B
is	O	AUX	O
an	O	DET	O
additional	O	ADJ	O
important	O	ADJ	O
factor	O	NOUN	B
,	O	PUNCT	O
besides	O	SCONJ	O
intense	O	ADJ	B
dyspnea	O	NOUN	B
,	O	PUNCT	O
that	O	PRON	O
limits	O	VERB	B
exercise	O	NOUN	B
tolerance	O	NOUN	O
in	O	ADP	O
COPD	O	NOUN	B
.	O	PUNCT	O


Folic	B-I	NOUN	B
acid-based	I-I	ADJ	O
intervention	I-I	NOUN	O
in	O	ADP	O
non-ST	B-P	ADJ	B
elevation	I-P	NOUN	I
acute	I-P	ADJ	I
coronary	I-P	ADJ	I
syndromes	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Homocysteinemia	O	NOUN	B
is	O	AUX	O
a	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
cardiovascular	O	ADJ	B
diseases	O	NOUN	I
.	O	PUNCT	O


Folic	B-I	NOUN	B
acid	I-I	NOUN	I
combined	I-I	VERB	O
with	I-I	ADP	O
vitamins	I-I	NOUN	B
B	I-I	NOUN	I
(	I-I	PUNCT	O
6	I-I	NUM	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
B	I-I	NOUN	B
(	I-I	PUNCT	O
12	I-I	NUM	O
)	I-I	PUNCT	O
is	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
lowering	O	VERB	B
homocysteine	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
placebo-controlled	B-I	ADJ	I
study	O	NOUN	I
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
folic	B-I	ADJ	B
acid-based	I-I	ADJ	B
supplement	I-I	NOUN	I
on	O	ADP	O
secondary	O	ADJ	B
prevention	O	NOUN	I
of	O	ADP	O
clinical	O	ADJ	B
events	O	NOUN	I
in	O	ADP	O
non-ST-segment	B-P	ADJ	B
elevation	I-P	NOUN	I
acute	I-P	ADJ	I
coronary	I-P	ADJ	I
syndromes	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
study	O	NOUN	B
comprised	O	VERB	O
240	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
either	I-P	CCONJ	O
unstable	I-P	ADJ	B
angina	I-P	ADJ	I
or	I-P	CCONJ	O
non-ST-elevation	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
previous	I-P	ADJ	O
2	I-P	NUM	O
weeks	I-P	NOUN	B
who	O	PRON	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
a	O	DET	O
folate	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=116	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
placebo	B-I	ADJ	B
group	I-I	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=124	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
folate	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
1	O	NUM	O
mg	O	NOUN	O
folic	B-I	ADJ	B
acid	I-I	NOUN	I
,	O	PUNCT	O
400	O	NUM	O
microg	O	NOUN	B
vitamin	B-I	NOUN	B
B	I-I	NOUN	I
(	I-I	PUNCT	O
12	I-I	NUM	O
)	I-I	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
vitamin	B-I	NOUN	B
B	I-I	NOUN	I
(	I-I	PUNCT	O
6	I-I	NUM	O
)	I-I	PUNCT	O
daily	O	ADV	B
.	O	PUNCT	O


Clinical	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
within	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
composite	O	ADJ	B
endpoint	B-OUT	NOUN	B
of	O	ADP	O
death	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
nonfatal	I-OUT	ADJ	B
acute	I-OUT	ADJ	I
coronary	I-OUT	ADJ	I
syndrome	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
serious	I-OUT	ADJ	O
re-hospitalization	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
folate	O	NOUN	B
group	O	NOUN	I
;	O	PUNCT	O
serious	O	ADJ	O
re-hospitalization	O	NOUN	B
alone	O	ADV	O
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


Advanced	B-OUT	ADJ	B
age	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
diabetes	I-OUT	NOUN	B
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
the	O	DET	O
composite	O	ADJ	B
outcome	O	NOUN	B
.	O	PUNCT	O


Folic	B-I	NOUN	B
acid-based	I-I	ADJ	O
supplementation	I-I	NOUN	B
is	O	AUX	O
not	B-OUT	PART	O
beneficial	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
may	I-OUT	AUX	O
even	I-OUT	ADV	O
be	I-OUT	AUX	O
harmful	I-OUT	ADJ	O
in	O	ADP	O
the	O	DET	O
secondary	O	ADJ	B
prevention	B-OUT	NOUN	I
of	I-OUT	ADP	O
cardiovascular	I-OUT	ADJ	B
events	I-OUT	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
unstable	O	ADJ	B
angina	O	ADJ	I
and	O	CCONJ	O
non-ST-elevation	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
on	O	ADP	O
the	O	DET	O
safety	O	NOUN	B
of	O	ADP	O
such	O	ADJ	O
supplements	O	NOUN	B
are	O	AUX	O
suggested	O	VERB	O
.	O	PUNCT	O


Controlled	O	PROPN	B
Clinical	O	PROPN	I
Trials	O	PROPN	I
Registry	O	PROPN	I
no	O	DET	O
.	O	PUNCT	O


ISRCTN30249553	O	NOUN	B
.	O	PUNCT	O


Successful	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
depressed	B-P	ADJ	B
,	I-P	PUNCT	O
distensible	I-P	ADJ	B
acne	I-P	NOUN	I
scars	I-P	NOUN	I
using	O	VERB	O
autologous	B-I	ADJ	B
fibroblasts	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
multi-site	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
A	O	DET	O
previous	O	ADJ	O
clinical	O	ADJ	B
trial	O	NOUN	I
evaluating	O	VERB	O
autologous	B-I	ADJ	B
fibroblasts	I-I	NOUN	B
(	I-I	PUNCT	O
human	I-I	ADJ	B
dermal	I-I	ADJ	O
)	I-I	PUNCT	O
injections	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
facial	O	ADJ	B
contour	O	NOUN	I
deformities	O	NOUN	I
found	O	VERB	O
significantly	O	ADV	O
greater	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
wrinkle	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
acne	I-OUT	NOUN	B
scar	I-OUT	ADJ	I
appearance	I-OUT	NOUN	B
than	O	ADP	O
with	O	ADP	O
placebo	B-I	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
autologous	B-I	ADJ	B
fibroblast	I-I	NOUN	O
treatment	O	NOUN	B
of	O	ADP	O
moderate	B-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
,	I-P	PUNCT	O
depressed	I-P	ADJ	B
,	I-P	PUNCT	O
distensible	I-P	ADJ	B
facial	I-P	ADJ	I
acne	I-P	NOUN	I
scars	I-P	NOUN	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
vehicle	O	NOUN	B
control	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
multicenter	O	NOUN	I
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
bilateral	I-P	ADJ	B
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
acne	I-P	NOUN	B
scarring	I-P	NOUN	I
;	I-P	PUNCT	O
subjects	O	NOUN	B
served	O	VERB	O
as	O	ADP	O
their	O	PRON	O
own	O	ADJ	O
controls	O	NOUN	B
.	O	PUNCT	O


Skin	O	NOUN	B
biopsies	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
randomized	O	ADJ	B
subjects	B-P	NOUN	I
for	O	ADP	O
fibroblast	O	NOUN	B
production	O	NOUN	I
.	O	PUNCT	O


Subjects	B-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
99	I-P	NUM	O
)	I-P	PUNCT	O
underwent	O	VERB	O
three	O	NUM	O
intradermal	O	ADJ	B
injection	O	NOUN	O
sessions	O	NOUN	B
with	O	ADP	O
2	B-I	NUM	O
mL	I-I	NOUN	O
of	I-I	ADP	O
autologous	I-I	ADJ	B
fibroblast	I-I	NOUN	O
suspension	I-I	NOUN	O
(	O	PUNCT	O
10-20	O	NUM	O
million	O	NUM	O
cells/mL	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
one	O	NUM	O
cheek	O	NOUN	B
and	O	CCONJ	O
vehicle	B-I	NOUN	O
control	I-I	NOUN	O
(	O	PUNCT	O
cell	O	NOUN	B
culture	O	NOUN	I
medium	O	NOUN	I
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
other	O	ADJ	O
at	O	ADP	O
14-day	O	ADJ	O
intervals	O	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
was	O	AUX	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
blinded	O	VERB	B
subject	B-OUT	NOUN	I
's	I-OUT	PART	I
,	I-OUT	PUNCT	O
evaluator	I-OUT	NOUN	B
's	I-OUT	PART	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
independent	I-OUT	ADJ	O
photographic	I-OUT	ADJ	B
viewer	I-OUT	NOUN	O
's	I-OUT	PART	O
(	I-OUT	PUNCT	O
IPR	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
assessment	I-OUT	NOUN	B
of	I-OUT	ADP	O
acne	I-OUT	NOUN	B
scarring	I-OUT	NOUN	I
1	O	NUM	I
to	O	PART	O
4	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
last	O	ADJ	O
treatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Autologous	B-I	ADJ	B
fibroblast	I-I	NOUN	O
treatment	I-I	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
significantly	O	ADV	O
greater	O	ADJ	O
treatment	O	NOUN	B
success	O	NOUN	O
than	O	ADP	O
vehicle	O	NOUN	B
control	O	NOUN	I
for	O	ADP	O
the	O	DET	O
subject	O	NOUN	B
(	O	PUNCT	O
43	O	NUM	O
%	O	NOUN	O
vs.18	O	NOUN	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
evaluator	O	NOUN	B
(	O	PUNCT	O
59	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
IPR	O	PROPN	B
assessments	O	NOUN	B
.	O	PUNCT	O


Autologous	B-I	ADJ	B
fibroblast	I-I	NOUN	O
injections	I-I	NOUN	O
were	O	AUX	O
well	O	ADV	O
tolerated	O	ADJ	B
,	O	PUNCT	O
without	O	ADP	O
permanent	O	ADJ	B
adverse	O	ADJ	O
effects	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Autologous	B-I	ADJ	B
fibroblast	I-I	NOUN	O
injections	I-I	NOUN	O
safely	O	ADV	O
and	O	CCONJ	O
effectively	O	ADV	O
improved	O	VERB	B
the	O	DET	O
appearance	B-OUT	NOUN	B
of	I-OUT	ADP	O
depressed	I-OUT	ADJ	B
distensible	I-OUT	ADJ	I
acne	I-OUT	NOUN	I
scars	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
antisecretory	B-I	ADJ	B
treatment	I-I	NOUN	B
on	O	ADP	O
respiratory	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
of	I-OUT	ADP	O
gastroesophageal	I-OUT	ADJ	B
reflux	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
effect	B-OUT	NOUN	B
of	O	ADP	O
antisecretory	B-I	ADJ	B
treatment	I-I	NOUN	B
on	O	ADP	O
extraesophageal	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
of	I-OUT	ADP	O
gastroesophageal	I-OUT	ADJ	B
reflux	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


Seventy-eight	B-P	NUM	O
children	I-P	NOUN	B
presenting	I-P	VERB	O
with	I-P	ADP	O
typical	I-P	ADJ	B
and	I-P	CCONJ	O
extraesophageal	I-P	ADJ	B
symptoms	I-P	NOUN	I
of	I-P	ADP	O
gastroesophageal	I-P	ADJ	B
reflux	I-P	NOUN	I
disease	I-P	NOUN	I
underwent	I-P	VERB	O
a	I-P	DET	O
multichannel	I-P	ADJ	B
intraluminal	I-P	ADJ	I
impedance	I-P	NOUN	I
and	I-P	CCONJ	O
pH	I-P	NOUN	B
monitoring	I-P	NOUN	I
(	I-P	PUNCT	O
MII/pH	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Children	O	NOUN	B
with	O	ADP	O
a	O	DET	O
positive	O	ADJ	B
MII/pH	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
proton	B-I	NOUN	B
pump	I-I	NOUN	I
inhibitors	I-I	NOUN	I
(	I-I	PUNCT	O
PPIs	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
histamine	I-I	NOUN	B
H	I-I	NOUN	I
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
-receptor	I-I	NOUN	O
antagonists	I-I	NOUN	B
(	I-I	PUNCT	O
H	I-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
RAs	I-I	NOUN	B
)	I-I	PUNCT	O
during	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
recalled	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
second	O	ADJ	O
treatment	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
to	O	PART	O
those	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
not	O	PART	O
symptom-free	O	ADJ	O
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Thirty-five	O	NUM	O
of	O	ADP	O
the	O	DET	O
forty-one	O	NUM	O
(	O	PUNCT	O
85.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
children	O	NOUN	B
with	O	ADP	O
a	O	DET	O
pathologic	O	ADJ	B
MII/pH	O	NOUN	I
presented	O	VERB	O
with	O	ADP	O
extraesophageal	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
PPIs	B-I	NOUN	B
(	I-I	PUNCT	O
omeprazole	I-I	NOUN	B
;	I-I	PUNCT	O
n:19	O	ADJ	O
)	O	PUNCT	O
or	O	CCONJ	O
H	B-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
RAs	I-I	NOUN	B
(	I-I	PUNCT	O
ranitidine	I-I	NOUN	B
;	I-I	PUNCT	O
n:16	O	ADV	O
)	O	PUNCT	O
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
11/19	O	NUM	O
(	O	PUNCT	O
57.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
PPI-treated	B-I	ADJ	B
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
complete	O	ADJ	O
resolution	B-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
6/8	O	NUM	O
nonresponders	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
PPI	B-I	NOUN	B
for	O	ADP	O
another	O	DET	O
3	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
became	O	VERB	O
all	O	DET	O
symptom-free	B-OUT	ADJ	B
.	I-OUT	PUNCT	O


The	O	DET	O
other	O	ADJ	O
two	O	NUM	O
underwent	O	VERB	O
a	O	DET	O
Nissen	O	PROPN	B
fundoplication	O	NOUN	I
.	O	PUNCT	O


Only	O	ADV	O
5/16	O	NUM	O
(	O	PUNCT	O
31.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
H	B-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
RAs	I-I	NOUN	B
had	O	AUX	O
a	O	DET	O
complete	B-OUT	ADJ	O
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
;	O	PUNCT	O
1/11	O	NUM	O
was	O	AUX	O
treated	O	VERB	B
again	O	ADV	O
with	O	ADP	O
H	B-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
RAs	I-I	NOUN	B
during	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
10/11	O	NUM	O
were	O	AUX	O
changed	O	VERB	O
to	O	ADP	O
PPIs	B-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
3/10	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
partial	B-OUT	ADJ	B
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
,	O	PUNCT	O
while	O	SCONJ	O
in	O	ADP	O
7/10	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
complete	B-OUT	ADJ	O
remission	I-OUT	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Antisecretory	B-I	ADJ	B
reflux	I-I	NOUN	I
treatment	I-I	NOUN	B
improves	O	VERB	O
extraesophageal	B-OUT	ADJ	B
reflux	I-OUT	NOUN	I
symptoms	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
PPIs	B-I	NOUN	B
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
H	B-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
RAs	I-I	NOUN	B
in	O	ADP	O
these	O	DET	O
children	O	NOUN	B
.	O	PUNCT	O


Endovascular	O	ADJ	B
aneurysm	O	NOUN	I
repair	O	NOUN	I
and	O	CCONJ	O
outcome	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
unfit	I-P	ADJ	O
for	I-P	ADP	O
open	I-P	ADJ	B
repair	I-P	NOUN	I
of	I-P	ADP	O
abdominal	I-P	ADJ	B
aortic	I-P	ADJ	I
aneurysm	I-P	NOUN	I
(	I-P	PUNCT	O
EVAR	I-P	NOUN	B
trial	I-P	NOUN	I
2	I-P	NUM	I
)	I-P	PUNCT	O
:	I-P	PUNCT	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Endovascular	B-I	ADJ	B
aneurysm	I-I	NOUN	I
repair	I-I	NOUN	I
(	I-I	PUNCT	O
EVAR	I-I	NOUN	B
)	I-I	PUNCT	O
to	O	PART	O
exclude	O	VERB	O
abdominal	O	ADJ	B
aortic	O	ADJ	I
aneurysm	O	NOUN	I
(	O	PUNCT	I
AAA	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
introduced	O	VERB	O
for	O	ADP	O
patients	B-P	NOUN	B
of	I-P	ADP	O
poor	I-P	ADJ	B
health	I-P	NOUN	B
status	I-P	NOUN	I
considered	I-P	VERB	O
unfit	I-P	ADJ	O
for	I-P	ADP	O
major	I-P	ADJ	O
surgery	I-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
instigated	O	VERB	O
EVAR	O	NOUN	B
trial	O	NOUN	O
2	O	NUM	O
to	O	PART	O
identify	O	VERB	O
whether	O	SCONJ	O
EVAR	O	NOUN	B
improves	O	VERB	B
survival	B-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
no	O	DET	O
intervention	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
unfit	I-P	ADJ	O
for	I-P	ADP	O
open	I-P	ADJ	B
repair	I-P	NOUN	I
of	I-P	ADP	O
aortic	I-P	ADJ	O
aneurysm	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
did	O	AUX	O
a	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
338	B-P	NUM	O
patients	I-P	NOUN	B
aged	I-P	ADJ	B
60	I-P	NUM	O
years	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
who	I-P	PRON	O
had	I-P	AUX	O
aneurysms	I-P	NOUN	B
of	I-P	ADP	O
at	I-P	ADV	O
least	I-P	ADJ	O
5.5	I-P	NUM	O
cm	I-P	NOUN	O
in	I-P	ADP	O
diameter	I-P	NOUN	B
and	I-P	CCONJ	O
who	I-P	PRON	O
had	I-P	AUX	O
been	I-P	AUX	O
referred	I-P	VERB	O
to	I-P	ADP	O
one	I-P	NUM	O
of	I-P	ADP	O
31	I-P	NUM	O
hospitals	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
UK	I-P	PROPN	B
.	I-P	PUNCT	O


We	O	PRON	O
assigned	O	VERB	O
patients	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
either	O	DET	O
EVAR	B-I	NOUN	B
(	O	PUNCT	O
n=166	O	PROPN	O
)	O	PUNCT	O
or	B-I	CCONJ	O
no	I-I	DET	B
intervention	I-I	NOUN	I
(	O	PUNCT	O
n=172	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Our	O	PRON	O
primary	O	ADJ	B
endpoint	O	NOUN	I
was	O	AUX	O
all-cause	B-OUT	ADJ	O
mortality	I-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
secondary	O	ADJ	O
endpoints	O	NOUN	B
of	O	ADP	O
aneurysm-related	B-OUT	ADJ	B
mortality	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
health-related	I-OUT	ADJ	B
quality	I-OUT	NOUN	I
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HRQL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
postoperative	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
hospital	I-OUT	NOUN	B
costs	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Analyses	O	NOUN	B
were	O	AUX	O
by	O	ADP	O
intention	O	NOUN	B
to	O	PART	O
treat	O	VERB	B
.	O	PUNCT	O


FINDINGS	O	NOUN	B
197	B-P	NUM	O
patients	I-P	NOUN	B
underwent	O	VERB	O
aneurysm	B-I	NOUN	B
repair	I-I	NOUN	I
(	O	PUNCT	O
47	O	NUM	O
assigned	O	VERB	O
no	O	DET	O
intervention	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
adhered	O	VERB	O
to	O	ADP	O
protocol	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
30-day	B-OUT	ADJ	O
operative	I-OUT	ADJ	B
mortality	I-OUT	NOUN	I
in	I-OUT	ADP	O
the	I-OUT	DET	O
EVAR	I-OUT	NOUN	B
group	I-OUT	NOUN	B
was	O	AUX	O
9	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
13	O	NUM	O
of	O	ADP	O
150	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
5-15	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
no	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
had	O	AUX	O
a	O	DET	O
rupture	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
9.0	O	NUM	O
per	O	ADP	O
100	O	NUM	O
person	O	NOUN	B
years	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
6.0-13.5	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


By	O	ADP	O
end	O	NOUN	O
of	O	ADP	O
follow	O	NOUN	B
up	O	ADP	I
142	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
died	B-OUT	VERB	B
,	O	PUNCT	O
42	O	NUM	O
of	O	ADP	O
aneurysm-related	O	ADJ	B
factors	O	NOUN	I
;	O	PUNCT	O
overall	B-OUT	ADJ	B
mortality	I-OUT	NOUN	B
after	O	ADP	O
4	O	NUM	O
years	O	NOUN	B
was	O	AUX	O
64	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
EVAR	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
no	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
for	O	ADP	O
all-cause	B-OUT	ADJ	O
mortality	I-OUT	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
1.21	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.87-1.69	O	NUM	O
,	O	PUNCT	O
p=0.25	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
aneurysm-related	B-OUT	ADJ	B
mortality	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
hospital	I-OUT	NOUN	B
costs	I-OUT	NOUN	I
per	I-OUT	ADP	O
patient	I-OUT	NOUN	B
over	I-OUT	ADP	O
4	I-OUT	NUM	O
years	I-OUT	NOUN	B
were	O	AUX	O
UK	O	PROPN	B
pound	O	NOUN	O
sterling	O	NOUN	O
13,632	O	NUM	O
in	O	ADP	O
the	O	DET	O
EVAR	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
pound	O	NOUN	O
sterling	O	NOUN	O
4983	O	NUM	O
in	O	ADP	O
the	O	DET	O
no	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	B
difference	O	NOUN	I
pound	O	NOUN	I
sterling	O	NOUN	I
8649	O	NUM	I
,	O	PUNCT	O
SE	O	NOUN	O
1248	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
HRQL	O	NOUN	B
scores	O	NOUN	B
.	O	PUNCT	O


INTERPRETATION	O	ADJ	B
EVAR	O	NOUN	B
had	O	AUX	O
a	O	DET	O
considerable	O	ADJ	O
30-day	B-OUT	ADJ	O
operative	I-OUT	ADJ	B
mortality	I-OUT	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
already	O	ADV	O
unfit	O	ADJ	O
for	O	ADP	O
open	O	ADJ	O
repair	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
aneurysm	O	NOUN	B
.	O	PUNCT	O


EVAR	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
improve	O	VERB	B
survival	O	NOUN	B
over	O	ADP	O
no	O	DET	O
intervention	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
need	O	NOUN	O
for	O	ADP	O
continued	O	VERB	O
surveillance	O	NOUN	B
and	O	CCONJ	O
reinterventions	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
substantially	O	ADV	O
increased	O	VERB	B
cost	O	NOUN	B
.	O	PUNCT	O


Ongoing	O	ADJ	B
follow-up	O	NOUN	B
and	O	CCONJ	O
improved	O	VERB	B
fitness	O	NOUN	B
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
is	O	AUX	O
a	O	DET	O
priority	O	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
3,4-dihydroxyphenylethyleneglycol	O	NOUN	B
and	O	CCONJ	O
3-methoxy-4-hydroxyphenylethyleneglycol	O	NOUN	B
as	O	ADP	O
indicators	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
noradrenergic	O	ADJ	I
activity	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
on	O	ADP	O
control	B-P	ADJ	B
subjects	I-P	NOUN	I
and	I-P	CCONJ	O
depressed	I-P	ADJ	B
patients	I-P	NOUN	I
.	I-P	PUNCT	O


Animal	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
suggested	O	VERB	O
interspecies	O	NOUN	B
differences	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
norepinephrine	O	NOUN	I
(	O	PUNCT	O
NE	O	NOUN	B
)	O	PUNCT	O
metabolism	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
the	O	DET	O
relative	O	ADJ	O
proportions	O	NOUN	B
of	O	ADP	O
3,4-dihydroxyphenylethyleneglycol	O	NOUN	B
(	O	PUNCT	O
DOPEG	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
3-methoxy-4-hydroxyphenylethyleneglycol	O	NOUN	B
(	O	PUNCT	O
MOPEG	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
question	O	VERB	O
the	O	DET	O
value	O	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
glycol	O	NOUN	B
metabolites	O	NOUN	B
as	O	ADP	O
peripheral	O	ADJ	B
indices	O	NOUN	I
of	O	ADP	O
central	B-OUT	ADJ	B
noradrenergic	I-OUT	ADJ	I
activity	I-OUT	NOUN	I
,	O	PUNCT	O
a	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
plasma	O	NOUN	B
DOPEG	O	NOUN	B
and	O	CCONJ	O
MOPEG	O	NOUN	B
(	O	PUNCT	O
measured	O	VERB	B
by	O	ADP	O
HPLC	O	NOUN	B
)	O	PUNCT	O
related	O	ADJ	O
to	O	ADP	O
depression	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
age	O	NOUN	B
and	O	CCONJ	O
diagnostic	O	ADJ	B
categories	O	NOUN	I
(	O	PUNCT	O
DSM-III	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
on	O	ADP	O
depressed	B-P	ADJ	B
and	I-P	CCONJ	O
control	I-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
two	B-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
8	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
submitted	O	VERB	O
to	O	PART	O
a	O	DET	O
desipramine	B-I	NOUN	B
150	I-I	NUM	O
mg/day	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
metapramine	I-I	NOUN	B
450	I-I	NUM	O
mg/day	I-I	ADJ	O
antidepressant	I-I	ADJ	B
treatment	I-I	NOUN	B
influencing	O	VERB	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
DOPEG	O	NOUN	B
and	O	CCONJ	O
MOPEG	O	NOUN	B
in	O	ADP	O
a	O	DET	O
different	O	ADJ	O
way	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
did	O	AUX	O
not	O	PART	O
demonstrate	O	VERB	O
any	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
DOPEG	O	NOUN	B
and	O	CCONJ	O
MOPEG	O	NOUN	B
for	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
factors	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
also	O	ADV	O
a	O	DET	O
significant	O	ADJ	O
positive	B-OUT	ADJ	B
correlation	I-OUT	NOUN	B
between	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
DOPEG	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
MOPEG	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
idea	O	NOUN	O
that	O	SCONJ	O
each	O	DET	O
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
biological	O	ADJ	B
indices	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
assessment	O	NOUN	B
of	O	ADP	O
central	B-OUT	ADJ	B
noradrenergic	I-OUT	ADJ	I
activity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Argatroban	B-I	PROPN	B
for	O	ADP	O
elective	O	ADJ	B
percutaneous	O	ADJ	B
coronary	O	ADJ	I
intervention	O	NOUN	I
:	O	PUNCT	O
the	O	DET	O
ARG-E04	O	NOUN	B
multi-center	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


UNLABELLED	O	VERB	B
The	O	DET	O
synthetic	O	ADJ	B
arginine-derived	O	ADJ	O
direct	O	ADJ	O
thrombin	O	NOUN	B
inhibitor	O	NOUN	I
argatroban	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
attractive	O	ADJ	O
anticoagulant	O	NOUN	B
for	O	ADP	O
percutaneous	B-I	ADJ	B
coronary	I-I	ADJ	I
intervention	I-I	NOUN	I
(	I-I	PUNCT	O
PCI	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
its	O	PRON	O
rapid	O	ADJ	O
onset	O	NOUN	O
and	O	CCONJ	O
offset	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
hepatic	O	ADJ	B
elimination	O	NOUN	B
.	O	PUNCT	O


Argatroban	B-I	PROPN	B
was	O	AUX	O
approved	O	VERB	O
for	O	ADP	O
PCI	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
heparin-induced	I-P	ADJ	B
thrombocytopenia	I-P	NOUN	I
(	I-P	PUNCT	O
HIT	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
limited	O	ADJ	O
data	O	NOUN	B
about	O	ADP	O
argatroban	B-I	NOUN	B
in	O	ADP	O
non-HIT	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
open-label	O	ADJ	B
,	O	PUNCT	O
multiple-dose	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	O	ADP	O
argatroban	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
PCI	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
Of	O	ADP	O
140	B-P	NUM	O
patients	I-P	NOUN	B
randomized	O	VERB	B
to	O	PART	O
three	O	NUM	O
argatroban	B-I	ADJ	B
dose	O	NOUN	B
groups	O	NOUN	I
(	B-I	PUNCT	O
ARG250	I-I	NOUN	B
,	I-I	PUNCT	O
ARG300	I-I	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
ARG350	B-I	ADP	B
with	O	ADP	O
250	O	NUM	O
,	O	PUNCT	O
300	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
350	O	NUM	O
μg/kg	O	NOUN	O
bolus	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
15	O	NUM	O
,	O	PUNCT	O
20	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
25	O	NUM	O
μg/kg/min	O	ADJ	O
infusion	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
one	B-I	NUM	O
unfractionated	I-I	ADJ	B
heparin	I-I	NOUN	I
(	I-I	PUNCT	O
UFH	I-I	NOUN	B
)	I-I	PUNCT	O
group	O	NOUN	B
(	O	PUNCT	O
70-100	O	NUM	O
IU/kg	O	NOUN	O
bolus	B-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
138	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
analyzed	I-I	VERB	B
.	I-I	PUNCT	O


Argatroban	B-I	NOUN	B
dose-dependently	O	ADV	O
prolonged	B-OUT	VERB	B
activated	I-OUT	VERB	B
clotting	I-OUT	NOUN	I
time	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ACT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
with	O	ADP	O
more	O	ADJ	O
patients	O	NOUN	B
reaching	O	VERB	O
the	O	DET	O
minimum	O	ADJ	B
target	B-OUT	NOUN	B
ACT	I-OUT	NOUN	B
after	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
bolus	O	NOUN	B
injection	B-I	NOUN	I
(	I-I	PUNCT	O
ARG250	I-I	ADJ	B
:	I-I	PUNCT	O
86.1	I-I	NUM	O
%	I-I	NOUN	O
,	I-I	PUNCT	O
ARG300	I-I	PROPN	B
:	I-I	PUNCT	O
89.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	B-I	CCONJ	O
ARG350	I-I	PROPN	B
:	I-I	PUNCT	O
96.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
45.5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
UFH	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
patient	I-OUT	NOUN	B
proportion	I-OUT	NOUN	B
who	I-OUT	PRON	O
did	I-OUT	AUX	O
not	I-OUT	PART	O
require	I-OUT	VERB	O
additional	I-OUT	ADJ	O
bolus	I-OUT	NOUN	B
injections	I-OUT	NOUN	I
to	O	PART	O
start	O	VERB	O
PCI	O	PROPN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	B-I	ADP	O
argatroban	I-I	NOUN	B
than	O	ADP	O
in	B-I	ADP	O
UFH	I-I	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
≤	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Consequently	B-OUT	ADV	O
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
time	I-OUT	NOUN	O
to	I-OUT	PART	O
start	I-OUT	VERB	O
of	I-OUT	ADP	O
PCI	O	NOUN	B
was	O	AUX	O
shortened	B-I	VERB	O
in	I-I	ADP	O
argatroban	I-I	ADJ	B
groups	O	NOUN	B
.	O	PUNCT	O


Composite	B-OUT	ADJ	B
incidences	I-OUT	NOUN	B
of	I-OUT	ADP	O
death	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
myocardial	I-OUT	ADJ	B
infarction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
urgent	I-OUT	ADJ	O
revascularization	I-OUT	NOUN	B
until	O	ADP	O
day	O	NOUN	B
30	O	NUM	O
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
groups	B-I	NOUN	B
(	I-I	PUNCT	O
ARG250	I-I	ADJ	B
:	I-I	PUNCT	O
2.8	I-I	NUM	O
%	I-I	NOUN	O
,	I-I	PUNCT	O
ARG300	I-I	PROPN	B
:	I-I	PUNCT	O
0.0	I-I	NUM	O
%	I-I	NOUN	O
,	I-I	PUNCT	O
ARG350	I-I	X	B
:	I-I	PUNCT	O
3.2	O	NUM	O
%	O	NOUN	O
vs.	B-I	CCONJ	O
UFH	O	PROPN	B
:	O	PUNCT	O
3.0	B-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Major	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
only	B-I	ADV	O
in	I-I	ADP	O
UFH	O	NOUN	B
(	O	PUNCT	O
3.0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
while	B-OUT	SCONJ	O
minor	I-OUT	ADJ	O
bleeding	I-OUT	NOUN	B
occurred	I-I	VERB	O
in	I-I	ADP	O
ARG350	I-I	PROPN	B
(	O	PUNCT	O
3.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	B-I	CCONJ	O
UFH	O	PROPN	B
(	O	PUNCT	O
6.1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
n.s.	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	B-I	NOUN	O
Argatroban	I-I	NOUN	B
dose-dependently	O	ADV	O
increases	B-OUT	VERB	B
coagulation	I-OUT	NOUN	B
parameters	I-OUT	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
compared	B-I	VERB	O
to	I-I	ADP	O
UFH	O	NOUN	B
,	O	PUNCT	O
demonstrates	O	VERB	O
a	O	DET	O
superior	O	ADJ	O
predictable	B-OUT	ADJ	O
anticoagulant	I-OUT	ADJ	B
effect	I-OUT	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
undergoing	I-I	VERB	O
elective	I-I	ADJ	B
PCI	I-P	NOUN	B
.	O	PUNCT	O


Timing	O	VERB	B
for	O	ADP	O
delivering	O	VERB	B
individualized	B-I	ADJ	B
patient	I-I	NOUN	B
education	I-I	NOUN	O
intervention	I-I	NOUN	B
to	O	ADP	O
Coronary	B-P	PROPN	B
Artery	I-P	PROPN	I
Bypass	I-P	PROPN	I
Graft	I-P	PROPN	B
patients	I-P	NOUN	B
:	I-P	PUNCT	O
An	O	DET	O
RCT	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
primary	O	ADJ	B
focus	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
on	O	ADP	O
the	O	DET	O
timing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
delivery	O	NOUN	B
of	O	ADP	O
education	O	NOUN	B
to	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
CABG	I-I	PROPN	B
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
an	O	DET	O
individualized	B-I	ADJ	B
telephone	I-I	NOUN	B
patient	I-I	NOUN	B
education	I-I	NOUN	O
intervention	I-I	NOUN	B
,	O	PUNCT	O
delivered	O	VERB	O
at	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
points	O	NOUN	O
in	O	ADP	O
time	O	NOUN	B
(	O	PUNCT	O
1-2	O	NUM	O
days	O	NOUN	B
pre-discharge	O	ADJ	B
versus	O	ADP	O
1-2	O	NUM	O
days	O	NOUN	B
post-discharge	O	ADJ	B
)	O	PUNCT	O
in	O	ADP	O
enhancing	O	VERB	B
the	O	DET	O
CABG	B-P	NOUN	B
patient	I-P	NOUN	B
's	I-P	PART	I
knowledge	O	NOUN	B
of	O	ADP	O
self-care	O	ADJ	B
behaviours	O	NOUN	I
,	O	PUNCT	O
performance	O	NOUN	B
of	O	ADP	O
self-care	O	ADJ	B
behaviours	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
symptom	O	NOUN	B
frequency	O	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
A	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
that	O	PRON	O
included	O	VERB	O
a	O	DET	O
convenience	B-P	NOUN	B
sample	I-P	NOUN	B
of	I-P	ADP	O
first	I-P	ADJ	O
time	I-P	NOUN	O
CABG	I-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Individuals	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
education	B-I	NOUN	B
pre-discharge	I-I	NOUN	I
were	O	AUX	O
compared	O	VERB	O
to	O	ADP	O
individuals	B-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
education	I-P	NOUN	B
post-discharge	I-P	ADJ	B
on	I-P	ADP	O
the	I-P	DET	O
outcomes	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
Results	O	NOUN	I
indicated	O	VERB	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
outcomes	B-OUT	NOUN	B
between	I-OUT	ADP	O
the	I-OUT	DET	O
two	I-OUT	NUM	O
time	I-OUT	NOUN	B
points	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


As	O	ADV	O
well	O	ADV	O
,	O	PUNCT	O
anxiety	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
pre-discharge	O	ADJ	B
group	O	NOUN	I
than	O	ADP	O
the	O	DET	O
post-discharge	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
individualized	O	ADJ	B
nature	O	NOUN	B
of	O	ADP	O
the	O	DET	O
educational	B-I	ADJ	B
intervention	I-I	NOUN	I
may	O	AUX	O
have	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
non-significant	O	ADJ	B
findings	O	NOUN	B
reported	O	VERB	O
in	O	ADP	O
outcomes	O	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
time	O	NOUN	B
points	O	NOUN	I
.	O	PUNCT	O


PRACTICE	O	NOUN	B
IMPLICATIONS	O	NOUN	B
Nurses	O	NOUN	I
may	O	AUX	O
consider	O	VERB	O
assessing	O	VERB	O
anxiety	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
prior	O	ADJ	O
to	O	ADP	O
delivery	O	NOUN	B
of	O	ADP	O
educational	O	ADJ	B
interventions	O	NOUN	I
,	O	PUNCT	O
implement	O	VERB	B
interventions	O	NOUN	B
aimed	O	VERB	O
at	O	ADP	O
reducing	O	VERB	B
anxiety	O	NOUN	B
levels	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
provide	O	VERB	O
individualized	O	ADJ	B
teaching	O	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
of	O	ADP	O
TeachTown	O	PROPN	B
:	O	PUNCT	O
Basics	B-I	NOUN	B
computer-assisted	I-I	ADJ	O
intervention	I-I	NOUN	O
for	O	ADP	O
the	O	DET	O
Intensive	O	PROPN	B
Comprehensive	O	PROPN	I
Autism	O	PROPN	I
Program	O	PROPN	I
in	O	ADP	O
Los	O	PROPN	B
Angeles	O	PROPN	I
Unified	O	PROPN	O
School	O	PROPN	O
District	O	PROPN	O
.	O	PUNCT	O


Computer	B-I	PROPN	B
Assisted	I-I	PROPN	I
Instruction	I-I	PROPN	I
(	I-I	PUNCT	O
CAI	I-I	NOUN	B
)	I-I	PUNCT	O
has	O	AUX	O
shown	O	VERB	O
increased	O	VERB	B
popularity	O	NOUN	O
recently	O	ADV	O
and	O	CCONJ	O
there	O	PRON	O
are	O	AUX	O
many	O	ADJ	O
studies	O	NOUN	B
showing	O	VERB	O
promise	O	NOUN	O
for	O	ADP	O
this	O	DET	O
approach	O	NOUN	O
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
Autism	I-P	PROPN	B
Spectrum	I-P	PROPN	I
Disorders	I-P	PROPN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
no	O	DET	O
between-subject	O	ADJ	B
studies	O	NOUN	I
to	O	ADP	O
date	O	NOUN	O
assessing	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
CAI	B-I	NOUN	B
with	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
47	B-P	NUM	O
preschool	I-P	NOUN	B
and	I-P	CCONJ	O
K-1	I-P	NOUN	B
students	I-P	NOUN	I
in	I-P	ADP	O
ASD	I-P	PROPN	B
classrooms	I-P	NOUN	B
participated	I-P	VERB	O
from	I-P	ADP	O
Los	I-P	PROPN	B
Angeles	I-P	PROPN	I
Unified	I-P	PROPN	O
School	I-P	PROPN	O
District	I-P	PROPN	O
.	I-P	PUNCT	O


TeachTown	B-I	PROPN	B
:	I-I	PUNCT	O
Basics	I-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
CAI	I-I	NOUN	B
program	I-I	NOUN	O
which	I-I	DET	O
also	I-I	ADV	O
includes	I-I	VERB	O
supplementary	I-I	ADJ	O
off-computer	I-I	ADJ	B
activities	I-I	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
implemented	O	VERB	O
over	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
approximately	O	ADV	O
20	O	NUM	O
minutes	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
on	O	ADP	O
the	O	DET	O
computer	B-I	NOUN	B
and	O	CCONJ	O
20	B-I	NUM	O
minutes	I-I	NOUN	B
per	I-I	ADP	O
day	I-I	NOUN	B
in	I-I	ADP	O
supplementary	I-I	ADJ	O
TeachTown	I-I	PROPN	B
:	I-I	PUNCT	O
Basics	I-I	NOUN	B
activities	I-I	NOUN	I
.	I-I	PUNCT	O


Compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
students	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
TeachTown	O	PROPN	B
:	O	PUNCT	O
Basics	O	NOUN	B
students	O	NOUN	I
showed	O	VERB	O
more	O	ADJ	O
improvement	O	NOUN	B
overall	B-OUT	ADV	B
on	I-OUT	ADP	O
language	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
cognitive	I-OUT	ADJ	B
outcome	I-OUT	NOUN	I
measures	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
students	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
TeachTown	O	PROPN	B
:	O	PUNCT	O
Basics	O	NOUN	B
demonstrated	O	VERB	O
significant	O	ADJ	O
progress	B-OUT	NOUN	B
overall	I-OUT	ADV	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
software	I-OUT	NOUN	B
and	O	CCONJ	O
those	O	DET	O
students	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
the	O	DET	O
program	O	NOUN	B
for	O	ADP	O
more	O	ADJ	O
time	O	NOUN	O
demonstrated	B-OUT	VERB	O
larger	I-OUT	ADJ	O
gains	I-OUT	NOUN	B
within	I-OUT	ADP	O
the	I-OUT	DET	O
software	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
in	I-OUT	ADP	O
outcome	I-OUT	NOUN	B
measures	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Although	O	SCONJ	O
not	O	PART	O
conclusive	O	ADJ	B
,	O	PUNCT	O
these	O	DET	O
findings	O	NOUN	B
offer	O	VERB	O
possibilities	O	NOUN	B
for	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
CAI	B-I	NOUN	B
for	O	ADP	O
remediating	O	VERB	B
many	O	ADJ	O
deficits	O	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
and	I-P	CCONJ	O
other	I-P	ADJ	O
special	I-P	ADJ	O
needs	I-P	NOUN	O
.	I-P	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
CAI	B-I	NOUN	B
may	O	AUX	O
offer	O	VERB	O
solutions	O	NOUN	B
to	O	ADP	O
schools	O	NOUN	B
and	O	CCONJ	O
parents	O	NOUN	B
with	O	ADP	O
insufficient	O	ADJ	B
funds	O	NOUN	B
for	O	ADP	O
more	O	ADV	O
expensive	O	ADJ	B
treatments	O	NOUN	B
.	O	PUNCT	O


Equivalence	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
a	O	DET	O
topical	B-I	ADJ	B
diclofenac	I-I	ADJ	O
solution	I-I	NOUN	O
(	I-I	PUNCT	O
pennsaid	I-I	NOUN	B
)	I-I	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
oral	B-I	ADJ	B
diclofenac	I-I	NOUN	I
in	O	ADP	O
symptomatic	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
osteoarthritis	B-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
knee	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
compare	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
topical	B-I	ADJ	B
diclofenac	I-I	ADJ	O
solution	I-I	NOUN	O
versus	O	CCONJ	O
oral	B-I	ADJ	B
diclofenac	I-I	NOUN	B
in	O	ADP	O
relieving	O	VERB	O
the	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
primary	B-P	ADJ	B
osteoarthritis	I-P	NOUN	I
(	I-P	PUNCT	O
OA	I-P	NOUN	B
)	I-P	PUNCT	O
of	I-P	ADP	O
the	I-P	DET	O
knee	I-P	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
double-dummy	O	ADJ	B
equivalence	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
total	B-P	NOUN	O
of	I-P	ADP	O
622	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
women	I-P	NOUN	B
with	I-P	ADP	O
radiological	I-P	ADJ	B
evidence	I-P	NOUN	B
of	I-P	ADP	O
primary	I-P	ADJ	B
knee	I-P	NOUN	B
OA	I-P	NOUN	I
and	I-P	CCONJ	O
mild	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
symptoms	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
a	O	DET	O
topical	B-I	ADJ	B
diclofenac	I-I	ADJ	B
solution	I-I	NOUN	I
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
oral	I-I	ADJ	B
capsules	I-I	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	ADJ	B
topical	I-I	ADJ	O
solution	I-I	NOUN	O
plus	I-I	CCONJ	O
oral	I-I	ADJ	B
diclofenac	I-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
capsules	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
applied	O	VERB	O
50	O	NUM	O
drops	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
solution	O	NOUN	O
and	O	CCONJ	O
took	O	VERB	O
1	O	NUM	O
study	O	NOUN	B
capsule	O	NOUN	B
3	O	NUM	I
times	O	NOUN	O
daily	O	ADV	B
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
variables	O	NOUN	B
were	O	AUX	O
pain	O	NOUN	B
and	O	CCONJ	O
physical	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
Western	O	PROPN	B
Ontario	O	PROPN	I
and	O	CCONJ	I
McMaster	O	PROPN	I
Universities	O	PROPN	I
(	O	PUNCT	O
WOMAC	O	NOUN	B
)	O	PUNCT	O
VA	O	PROPN	O
3.1	O	NUM	O
OA	O	PROPN	O
Index	O	PROPN	O
,	O	PUNCT	O
and	O	CCONJ	O
patient	O	NOUN	B
global	O	ADJ	O
assessment	O	NOUN	O
(	O	PUNCT	O
PGA	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


Equivalence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
per-protocol	O	ADJ	B
group	O	NOUN	B
was	O	AUX	O
based	O	VERB	O
on	O	ADP	O
previously	O	ADV	O
defined	O	VERB	O
ranges	O	NOUN	B
of	O	ADP	O
clinically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	I
.	O	PUNCT	O


Safety	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
evaluation	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
,	O	PUNCT	O
vital	O	ADJ	B
signs	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
laboratory	O	ADJ	B
data	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
mean	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
)	O	PUNCT	O
change	O	NOUN	O
scores	O	NOUN	O
(	O	PUNCT	O
final	O	ADJ	O
minus	O	NOUN	O
baseline	O	NOUN	B
)	O	PUNCT	O
between	O	ADP	O
treatments	O	NOUN	B
was	O	AUX	O
13.3	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
-8.6	O	NUM	O
to	O	PART	O
35.2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
pain	O	NOUN	B
(	O	PUNCT	O
total	O	ADJ	O
scale	O	NOUN	O
500	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
71.0	O	NUM	O
mm	O	PROPN	O
(	O	PUNCT	O
-2.4	O	NUM	O
to	O	PART	O
144.5	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
physical	O	ADJ	B
function	O	NOUN	I
(	O	PUNCT	O
total	O	ADJ	O
scale	O	NOUN	O
1700	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
4.3	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
-1.2	O	NUM	O
to	O	PART	O
9.8	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
PGA	O	PROPN	B
(	O	PUNCT	O
total	O	ADJ	O
scale	O	NOUN	O
100	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
CI	O	NOUN	B
for	O	ADP	O
each	O	DET	O
efficacy	O	NOUN	B
variable	O	ADJ	B
fell	O	VERB	O
within	O	ADP	O
the	O	DET	O
predefined	O	ADJ	O
equivalence	O	NOUN	B
ranges	O	NOUN	I
(	O	PUNCT	O
pain	O	NOUN	B
,	O	PUNCT	O
+/-	O	CCONJ	O
75	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
physical	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
+/-	O	CCONJ	O
255	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
PGA	O	PROPN	B
,	O	PUNCT	O
+/-	O	CCONJ	O
20	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
no	O	DET	O
clinically	O	ADV	B
relevant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
treatment	O	NOUN	B
arms	O	NOUN	I
.	O	PUNCT	O


Safety	B-OUT	NOUN	B
analyses	I-OUT	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
applying	O	VERB	O
topical	O	ADJ	B
diclofenac	B-I	ADJ	B
solution	I-I	NOUN	I
revealed	O	VERB	B
some	O	DET	O
minor	B-OUT	ADJ	B
skin	I-OUT	NOUN	B
irritation	I-OUT	NOUN	O
at	I-OUT	ADP	O
the	I-OUT	DET	O
application	I-OUT	NOUN	B
site	I-OUT	NOUN	I
--	I-OUT	PUNCT	O
mostly	I-OUT	ADV	O
skin	O	NOUN	B
dryness	O	NOUN	I
in	O	ADP	O
83/311	O	NOUN	O
(	O	PUNCT	O
27	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
--	O	PUNCT	O
but	O	CCONJ	O
a	O	DET	O
significantly	O	ADV	O
reduced	O	VERB	B
incidence	O	NOUN	B
,	O	PUNCT	O
relative	O	ADJ	O
to	O	PART	O
oral	O	ADJ	B
diclofenac	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
total	B-OUT	NOUN	O
and	I-OUT	CCONJ	O
severe	I-OUT	ADJ	B
gastrointestinal	I-OUT	ADJ	O
(	I-OUT	PUNCT	O
GI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
including	I-OUT	VERB	O
dyspepsia	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
abdominal	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
diarrhea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
nausea	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
developing	O	VERB	O
abnormal	O	ADJ	B
liver	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	I
(	O	PUNCT	O
including	O	VERB	O
clinically	O	ADV	B
significant	O	ADJ	I
elevation	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
hemoglobin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
creatinine	O	NOUN	B
clearance	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
oral	B-I	ADJ	B
diclofenac	I-I	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Application	O	NOUN	B
of	O	ADP	O
this	O	DET	O
topical	B-I	ADJ	B
diclofenac	I-I	ADJ	B
solution	I-I	NOUN	I
to	O	ADP	O
the	O	DET	O
knee	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
OA	I-P	NOUN	B
produced	O	VERB	O
relief	B-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
equivalent	O	ADJ	O
to	O	PART	O
oral	B-I	ADJ	B
diclofenac	I-I	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
minor	O	ADJ	O
local	O	ADJ	O
skin	O	NOUN	O
irritation	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
significantly	O	ADV	O
reduced	O	VERB	B
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
diclofenac-related	I-OUT	ADJ	B
GI	I-OUT	NOUN	B
complaints	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
abnormal	I-OUT	ADJ	B
laboratory	I-OUT	NOUN	B
values	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Wavefront-guided	B-I	ADJ	B
versus	I-I	CCONJ	O
standard	I-I	ADJ	B
LASIK	I-I	NOUN	B
enhancement	I-I	NOUN	B
for	O	ADP	O
residual	O	ADJ	B
refractive	O	ADJ	B
errors	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
efficacy	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
safety	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
predictability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
stability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
higher-order	I-OUT	ADJ	B
aberrations	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HOAs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
contrast	B-OUT	NOUN	B
sensitivity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
after	O	ADP	O
wavefront-guided	B-I	ADJ	B
and	I-I	CCONJ	O
standard	I-I	ADJ	B
LASIK	I-I	NOUN	B
enhancement	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
correction	O	NOUN	B
of	O	ADP	O
residual	O	ADJ	B
refractive	O	ADJ	B
errors	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	VERB	O
Prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
comparative	O	ADJ	B
clinical	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	VERB	B
Twenty	B-P	NUM	O
eyes	I-P	NOUN	B
of	I-P	ADP	O
20	I-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
spherical	I-P	ADJ	B
equivalent	I-P	NOUN	O
[	I-P	PUNCT	O
SE	I-P	NOUN	B
]	I-P	PUNCT	O
,	I-P	PUNCT	O
-2.01+/-1.36	I-P	NOUN	O
diopters	I-P	NOUN	B
[	I-P	PUNCT	O
D	I-P	NOUN	B
]	I-P	PUNCT	O
)	I-P	PUNCT	O
treated	I-P	VERB	B
with	I-P	ADP	I
wavefront-guided	I-I	ADJ	B
Zyoptix	I-I	PROPN	O
Ablation	I-I	PROPN	O
Refinement	I-I	PROPN	O
software	I-I	NOUN	O
(	I-I	PUNCT	O
ZAR	I-I	PROPN	B
)	I-I	PUNCT	O
LASIK	I-I	PROPN	B
and	I-P	CCONJ	O
20	I-P	NUM	O
eyes	I-P	NOUN	B
of	I-P	ADP	O
20	I-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
SE	I-P	NOUN	B
,	I-P	PUNCT	O
-1.81+/-1.21	I-P	NOUN	B
D	I-P	NOUN	I
)	I-P	PUNCT	O
treated	I-P	VERB	B
with	I-P	ADP	I
standard	I-I	ADJ	O
Planoscan	I-I	ADJ	B
LASIK	I-I	NOUN	I
,	I-P	PUNCT	O
both	I-P	CCONJ	O
for	I-P	ADP	O
residual	I-P	ADJ	B
refractive	I-P	ADJ	B
error	I-P	NOUN	I
enhancement	I-P	NOUN	B
.	I-P	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	B
MEASURES	O	NOUN	O
Efficacy	B-OUT	PROPN	B
,	I-OUT	PUNCT	O
safety	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
predictability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
stability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
HOAs	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
CS	I-OUT	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
enhancement	O	NOUN	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
'	O	PART	O
follow-up	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Uncorrected	B-OUT	ADJ	B
visual	I-OUT	ADJ	I
acuity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
UCVA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
best-corrected	I-OUT	ADJ	B
visual	I-OUT	ADJ	I
acuity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BCVA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
manifest	I-OUT	VERB	B
refraction	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
CS	I-OUT	NOUN	B
by	I-OUT	ADP	O
means	I-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
Functional	I-OUT	PROPN	B
Acuity	I-OUT	PROPN	I
Contrast	I-OUT	PROPN	I
Test	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
HOAs	I-OUT	NOUN	B
by	I-OUT	ADP	O
means	I-OUT	NOUN	O
of	I-OUT	ADP	O
Zywave	I-OUT	PROPN	B
aberrometry	I-OUT	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
preoperatively	O	ADV	B
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
retreatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
postoperatively	O	ADV	B
,	O	PUNCT	O
UCVA	B-OUT	NOUN	B
was	O	AUX	O
20/25	O	NUM	O
or	O	CCONJ	O
better	O	ADJ	O
in	O	ADP	O
100	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
eyes	O	NOUN	B
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
indexes	I-OUT	NOUN	B
were	O	AUX	O
1.09	O	NUM	O
for	O	ADP	O
ZAR	B-I	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
0.95	O	NUM	O
for	O	ADP	O
Planoscan	B-I	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


No	B-OUT	DET	B
eyes	I-OUT	NOUN	I
lost	I-OUT	VERB	B
>	O	NOUN	O
or	O	CCONJ	O
=1	O	NUM	B
line	O	NOUN	I
of	O	ADP	O
BCVA	B-OUT	NOUN	B
;	I-OUT	PUNCT	O
in	O	ADP	O
the	O	DET	O
ZAR	B-I	PROPN	B
group	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
eyes	O	NOUN	B
gained	B-OUT	VERB	O
1	O	NUM	O
line	O	NOUN	O
and	O	CCONJ	O
6	O	NUM	O
eyes	O	NOUN	B
gained	B-OUT	VERB	O
>	O	NOUN	O
or	O	CCONJ	O
=2	O	NUM	B
lines	O	NOUN	I
;	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
Planoscan	B-I	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
eyes	O	NOUN	B
gained	O	VERB	O
1	O	NUM	O
line	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
ZAR	B-I	PROPN	B
group	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
eyes	O	NOUN	B
(	O	PUNCT	O
94.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
within	O	ADP	O
the	O	DET	O
0.5-D	O	NUM	O
range	O	NOUN	O
in	O	ADP	O
SE	O	NOUN	B
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
shown	O	VERB	O
by	O	ADP	O
the	O	DET	O
Planoscan	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
88.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
HOA	B-OUT	NOUN	B
root	I-OUT	NOUN	B
mean	I-OUT	VERB	I
square	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RMS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
increased	O	VERB	B
on	O	ADP	O
average	O	NOUN	B
by	O	ADP	O
a	O	DET	O
factor	O	NOUN	B
of	O	ADP	O
1.44	O	NUM	O
for	O	ADP	O
the	O	DET	O
Planoscan	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
change	O	NOUN	I
or	O	CCONJ	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
HOA	I-OUT	NOUN	B
RMS	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
ZAR	B-I	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
factor	O	NOUN	B
of	O	ADP	O
0.96	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Contrast	B-OUT	NOUN	B
sensitivity	I-OUT	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
Planoscan	B-I	ADJ	B
group	O	NOUN	B
only	O	ADV	O
at	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
spatial	O	ADJ	B
frequency	O	NOUN	I
(	O	PUNCT	O
18	O	NUM	O
cycles	O	NOUN	B
per	O	ADP	O
degree	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
reduction	B-OUT	NOUN	B
of	I-OUT	ADP	O
CS	I-OUT	NOUN	B
as	I-OUT	ADP	O
a	I-OUT	DET	O
function	I-OUT	NOUN	B
of	I-OUT	ADP	O
HOA	I-OUT	NOUN	B
increase	I-OUT	NOUN	B
for	O	ADP	O
the	O	DET	O
Planoscan	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
changes	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
the	O	DET	O
ZAR	B-I	PROPN	B
group	O	NOUN	B
at	O	ADP	O
any	O	DET	O
spatial	B-OUT	ADJ	B
frequency	I-OUT	NOUN	I
(	O	PUNCT	O
1.5-18	O	NUM	O
cycles	O	NOUN	B
per	O	ADP	O
degree	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Wavefront-guided	B-I	VERB	B
LASIK	I-I	NOUN	I
using	O	VERB	O
the	O	DET	O
ZAR	O	PROPN	B
algorithm	O	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
procedure	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
residual	O	ADJ	B
refractive	O	ADJ	B
errors	O	NOUN	I
.	O	PUNCT	O


Wavefront-guided	B-I	ADJ	B
LASIK	I-I	NOUN	I
does	O	AUX	O
not	O	PART	O
increase	O	VERB	B
HOAs	O	NOUN	B
and	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
modify	O	VERB	B
CS	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
preoperative	O	ADJ	B
values	O	NOUN	B
.	O	PUNCT	O


Wavefront-guided	B-I	ADJ	B
LASIK	I-I	NOUN	I
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
standard	O	ADJ	B
LASIK	B-I	NOUN	B
for	O	ADP	O
retreatments	O	NOUN	B
.	O	PUNCT	O


Elevation	O	NOUN	B
of	O	ADP	O
HDL-C	B-OUT	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
statin	B-I	NOUN	B
treatment	O	NOUN	B
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
regression	B-P	NOUN	B
of	I-P	ADP	O
carotid	I-P	NOUN	B
atherosclerosis	I-P	NOUN	I
.	I-P	PUNCT	O


AIM	O	PROPN	B
Atherosclerosis	O	NOUN	B
is	O	AUX	O
strongly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
mortality	O	NOUN	B
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
diabetes	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
carotid	B-OUT	NOUN	B
intima-media	I-OUT	NOUN	I
thickness	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
IMT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
is	O	AUX	O
commonly	O	ADV	O
measured	O	VERB	B
as	O	ADP	O
a	O	DET	O
surrogate	O	ADJ	B
marker	O	NOUN	B
for	O	ADP	O
cardiovascular	O	ADJ	B
risk	O	NOUN	I
.	O	PUNCT	O


Statins	O	NOUN	B
are	O	AUX	O
well-established	O	ADJ	O
protective	O	ADJ	B
agents	O	NOUN	I
against	O	ADP	O
atherosclerosis	O	NOUN	B
and	O	CCONJ	O
reportedly	O	ADV	B
suppress	O	VERB	B
IMT	O	NOUN	B
progression	O	NOUN	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
diabetes	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
clarify	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
statins	O	NOUN	B
on	O	ADP	O
subclinical	O	ADJ	B
atherosclerosis	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
herein	O	ADV	O
investigated	O	VERB	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
carotid	O	NOUN	B
IMT	O	NOUN	I
and	O	CCONJ	O
lipid	O	NOUN	B
profiles	O	NOUN	I
in	O	ADP	O
a	O	DET	O
multi-center	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Hypercholesterolemic	B-P	ADJ	B
subjects	I-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
open-label	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
pravastatin	B-I	NOUN	B
or	I-I	CCONJ	O
pitavastatin	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
endpoint	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
the	O	DET	O
IMT	B-OUT	NOUN	B
change	I-OUT	NOUN	B
after	O	ADP	O
36	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
statin	B-I	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
97	I-P	NUM	O
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
51	I-P	NUM	O
pitavastatin	I-I	NOUN	B
;	I-I	PUNCT	O
46	I-P	NUM	O
pravastatin	I-I	NOUN	B
)	I-I	PUNCT	O
completed	I-P	VERB	O
this	I-P	DET	O
36-month	I-P	ADJ	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
LDL-C	B-OUT	NOUN	B
decreased	O	VERB	B
significantly	O	ADV	O
from	O	ADP	O
163.4	O	NUM	O
±	O	NOUN	O
27.9	O	NUM	O
mg/dl	O	NOUN	O
at	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
100.4	O	NUM	O
±	O	NOUN	O
19.6	O	NUM	O
mg/dl	O	NOUN	O
at	O	ADP	O
36	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
pitavastatin	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
from	O	ADP	O
159.7	O	NUM	O
±	O	NOUN	O
25.6	O	NUM	O
mg/dl	O	NOUN	O
to	O	PART	O
118.5	O	NUM	O
±	O	NOUN	O
22.1	O	NUM	O
mg/dl	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pravastatin	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	B-OUT	DET	O
mean	I-OUT	ADJ	O
IMT	O	NOUN	B
showed	O	VERB	O
moderate	O	ADJ	B
regression	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	B-I	DET	O
pitavastatin	I-I	NOUN	B
(	O	PUNCT	O
-0.070	O	PUNCT	O
±	O	X	O
0.215	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	B-I	CCONJ	O
the	I-I	DET	O
pravastatin	I-I	NOUN	B
(	O	PUNCT	O
-0.067	O	PUNCT	O
±	O	NOUN	O
0.260	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
group	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	B-OUT	ADP	O
the	I-OUT	DET	O
IMT	I-OUT	NOUN	B
change	I-OUT	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
combined	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
36-month	O	ADJ	O
change	O	NOUN	O
in	B-OUT	ADP	O
the	I-OUT	DET	O
mean	I-OUT	NOUN	O
IMT	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
associated	B-OUT	VERB	B
with	I-OUT	ADP	I
HDL-C	I-OUT	NOUN	B
change	I-OUT	NOUN	O
(	O	PUNCT	O
r=-0.24	O	NOUN	O
,	O	PUNCT	O
P=	O	NOUN	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Multiple	O	ADJ	B
linear	O	ADJ	I
regression	O	NOUN	I
analysis	O	NOUN	I
revealed	O	VERB	O
the	O	DET	O
change	B-OUT	NOUN	B
in	I-OUT	ADP	O
HDL-C	O	NOUN	B
to	O	PART	O
be	O	AUX	O
an	O	DET	O
independent	O	ADJ	B
variable	O	ADJ	B
showing	O	VERB	O
a	O	DET	O
positive	O	ADJ	B
correlation	O	NOUN	B
with	O	ADP	O
the	O	DET	O
carotid	O	NOUN	B
IMT	O	NOUN	I
reduction	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
statins	O	NOUN	B
for	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
to	O	PART	O
subjects	O	NOUN	B
with	O	ADP	O
type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
regression	O	NOUN	B
of	B-OUT	ADP	O
the	I-OUT	DET	O
carotid	I-OUT	NOUN	B
IMT	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
elevation	O	NOUN	B
of	B-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
HDL-C	I-I	NOUN	B
with	I-I	ADP	O
statin	I-I	NOUN	B
treatment	O	NOUN	B
was	O	AUX	O
closely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
regression	O	NOUN	B
of	O	ADP	O
atherosclerosis	O	NOUN	B
.	O	PUNCT	O


Prospective	O	ADJ	B
controlled	O	VERB	I
study	O	NOUN	I
of	O	ADP	O
androgen	B-I	NOUN	B
therapy	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
anemia	B-OUT	NOUN	B
of	I-P	ADP	O
chronic	I-P	ADJ	B
renal	I-P	ADJ	I
disease	I-P	NOUN	I
:	I-P	PUNCT	O
effects	O	NOUN	B
on	O	ADP	O
iron	O	NOUN	B
kinetics	O	NOUN	B
.	O	PUNCT	O


Ferrokinetic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
RBC	I-OUT	NOUN	B
mass	I-OUT	NOUN	B
determinations	I-OUT	NOUN	I
were	O	AUX	O
made	O	VERB	O
at	O	ADP	O
3-month	O	ADJ	O
intervals	O	NOUN	B
in	O	ADP	O
iron-replete	B-P	ADJ	B
hemodialysis	I-P	NOUN	I
patients	I-P	NOUN	B
randomized	O	VERB	B
to	O	PART	O
a	O	DET	O
control	B-I	ADJ	B
group	I-I	NOUN	I
or	I-I	CCONJ	O
to	I-I	PART	O
nandrolone	I-I	NOUN	B
decanoate	I-I	NOUN	I
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


After	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
increased	O	VERB	B
in	O	ADP	O
two	O	NUM	O
of	O	ADP	O
4	O	NUM	O
androgen-treated	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Erythron	B-OUT	NOUN	B
iron	I-OUT	NOUN	B
turnover	I-OUT	NOUN	I
,	O	PUNCT	O
an	O	DET	O
index	O	NOUN	O
of	O	ADP	O
RBC	O	NOUN	B
production	O	NOUN	B
,	O	PUNCT	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
one	O	NUM	O
responder	O	NOUN	B
studied	O	VERB	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
nonresponders	O	NOUN	B
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
fifth	O	ADJ	O
subject	O	NOUN	O
,	O	PUNCT	O
who	O	PRON	O
was	O	AUX	O
not	O	PART	O
restudied	O	VERB	O
until	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
androgen	B-I	NOUN	B
therapy	I-I	NOUN	I
were	O	AUX	O
completed	O	VERB	B
,	O	PUNCT	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
erythron	O	NOUN	B
iron	O	NOUN	B
turnover	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
between	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
increased	O	VERB	B
in	O	ADP	O
all	O	DET	O
4	B-P	NUM	O
androgen-treated	I-I	ADJ	O
patients	I-P	NOUN	B
studied	O	VERB	O
even	O	ADV	O
though	O	SCONJ	O
erythron	O	NOUN	B
iron	O	NOUN	B
turnovers	O	NOUN	I
remained	O	VERB	O
unchanged	O	ADJ	B
and	O	CCONJ	O
dialysis-associated	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
losses	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
decrease	O	VERB	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
two	O	NUM	O
androgen-treated	B-I	ADJ	B
patients	O	NOUN	B
had	O	AUX	O
increases	O	NOUN	B
in	O	ADP	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
without	O	ADP	O
ever	O	ADV	O
increasing	O	VERB	B
their	O	PRON	O
erythron	B-OUT	NOUN	B
iron	I-OUT	NOUN	B
turnover	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
three	O	NUM	O
control	O	ADJ	B
subjects	O	NOUN	I
also	O	ADV	O
had	O	AUX	O
increased	O	VERB	B
erythron	B-OUT	NOUN	B
iron	I-OUT	NOUN	O
turnovers	I-OUT	NOUN	O
,	O	PUNCT	O
which	O	DET	O
in	O	ADP	O
one	O	NUM	O
case	O	NOUN	B
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
increased	O	VERB	B
dialysis-associated	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
losses	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
consistently	O	ADV	O
paralleled	O	VERB	O
by	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
Hb	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
increases	O	NOUN	B
in	O	ADP	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
during	O	ADP	O
nandrolone	O	NOUN	B
decanoate	O	NOUN	I
therapy	O	NOUN	I
result	O	VERB	O
from	O	ADP	O
two	O	NUM	O
mechanisms	O	NOUN	B
:	O	PUNCT	O
increased	O	VERB	B
erythropoiesis	O	NOUN	B
(	O	PUNCT	O
shown	O	VERB	O
by	O	ADP	O
simultaneous	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
and	O	CCONJ	O
erythron	B-OUT	NOUN	B
iron	I-OUT	NOUN	O
turnover	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
RBC	B-OUT	NOUN	B
survival	I-OUT	NOUN	B
(	O	PUNCT	O
indirectly	O	ADV	O
shown	O	VERB	O
by	O	ADP	O
increases	O	NOUN	B
in	O	ADP	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
without	O	ADP	O
increases	O	NOUN	B
in	O	ADP	O
erythron	B-OUT	NOUN	B
iron	I-OUT	NOUN	B
turnover	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
control	O	ADJ	B
groups	O	NOUN	I
,	O	PUNCT	O
RBC	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
determinations	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
monitoring	O	NOUN	B
of	O	ADP	O
dialysis-associated	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
losses	I-OUT	NOUN	I
in	O	ADP	O
studying	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
androgens	O	NOUN	B
on	O	ADP	O
erythropoiesis	O	NOUN	B
in	O	ADP	O
chronic	B-P	ADJ	B
hemodialysis	I-P	NOUN	I
patients	I-P	NOUN	B
is	O	AUX	O
also	O	ADV	O
demonstrated	O	VERB	O
.	O	PUNCT	O


Design	O	NOUN	B
of	O	ADP	O
a	O	DET	O
cost-effectiveness	O	ADJ	B
study	O	NOUN	I
within	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
:	O	PUNCT	O
the	O	DET	O
LIPID	O	NOUN	B
Trial	O	PROPN	I
for	O	ADP	O
Secondary	O	PROPN	B
Prevention	O	PROPN	I
of	O	ADP	O
IHD	B-P	NOUN	B
.	I-P	PUNCT	O


Long-term	O	ADJ	B
Intervention	O	NOUN	B
with	O	ADP	O
Pravastatin	B-I	NOUN	B
in	O	ADP	O
Ischemic	B-P	ADJ	B
Heart	I-P	PROPN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
Long-term	O	ADJ	B
Intervention	O	NOUN	B
with	O	ADP	O
Pravastatin	B-I	NOUN	B
in	O	ADP	O
Ischemic	B-P	PROPN	B
Heart	I-P	PROPN	I
Disease	I-P	PROPN	I
(	O	PUNCT	O
LIPID	O	NOUN	B
)	O	PUNCT	O
trial	O	NOUN	O
is	O	AUX	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
evaluating	O	VERB	B
the	O	DET	O
long-term	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
pravastatin	B-I	NOUN	B
on	O	ADP	O
coronary	O	ADJ	B
mortality	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
previous	I-P	ADJ	O
myocardial	I-P	ADJ	B
infarction	I-P	NOUN	I
or	I-P	CCONJ	O
unstable	I-P	ADJ	O
angina-ischemic	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
IHD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


It	O	PRON	O
is	O	AUX	O
planned	O	VERB	B
to	O	PART	O
run	O	VERB	O
for	O	ADP	O
at	O	ADV	O
least	O	ADJ	O
five	O	NUM	O
years	O	NOUN	B
with	O	ADP	O
9014	B-P	NUM	O
patients	I-P	NOUN	B
from	I-P	ADP	O
85	I-P	NUM	O
centers	I-P	NOUN	B
in	I-P	ADP	O
Australia	I-P	PROPN	B
and	I-P	CCONJ	O
New	I-P	PROPN	B
Zealand	I-P	PROPN	I
.	I-P	PUNCT	O


The	O	DET	O
trial	O	NOUN	B
will	O	AUX	O
monitor	O	VERB	O
cause-specific	O	ADJ	B
mortality	O	NOUN	I
and	O	CCONJ	O
major	O	ADJ	O
clinical	O	ADJ	B
events	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
each	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


Running	O	VERB	B
in	O	ADP	O
parallel	O	NOUN	O
with	O	ADP	O
the	O	DET	O
main	O	ADJ	O
study	O	NOUN	B
is	O	AUX	O
a	O	DET	O
prospective	O	ADJ	O
economic	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
objectives	O	NOUN	O
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
pravastatin	B-I	NOUN	B
compared	O	VERB	O
with	O	ADP	O
placebo	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
survival	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
QOL	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
quality-adjusted	I-OUT	ADJ	B
life-years	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
QALY	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
resource	O	NOUN	B
usage	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
pravastatin	B-I	NOUN	B
compared	O	VERB	O
with	O	ADP	O
placebo-in	B-I	ADJ	B
particular	O	ADJ	O
,	O	PUNCT	O
to	O	PART	O
study	O	VERB	B
whether	O	SCONJ	O
it	O	PRON	O
alters	O	VERB	O
resource	O	NOUN	B
usage	O	NOUN	B
through	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
to	O	PART	O
use	O	VERB	O
this	O	DET	O
information	O	NOUN	B
for	O	ADP	O
a	O	DET	O
cost-utility	O	ADJ	B
analysis	O	NOUN	I
with	O	ADP	O
cost	O	NOUN	B
per	O	ADP	O
quality-adjusted	O	ADJ	O
life-year	O	NOUN	O
as	O	ADP	O
the	O	DET	O
unit	O	NOUN	O
of	O	ADP	O
analysis	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
novel	O	ADJ	B
aspect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
design	O	NOUN	B
is	O	AUX	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
preliminary	O	ADJ	B
cost-effectiveness	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
"	O	PUNCT	O
best-guess	O	ADJ	B
"	O	PUNCT	O
values	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
sensitivity	O	NOUN	B
analysis	O	NOUN	I
over	O	ADP	O
plausible	O	ADJ	O
ranges	O	NOUN	B
to	O	PART	O
guide	O	VERB	O
the	O	DET	O
choice	O	NOUN	B
of	O	ADP	O
subsample	O	NOUN	B
size	O	NOUN	I
.	O	PUNCT	O


Some	O	DET	O
data	O	NOUN	B
,	O	PUNCT	O
such	O	DET	O
a	O	DET	O
mortality	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
days	I-OUT	NOUN	B
spent	I-OUT	VERB	O
in	I-OUT	ADP	O
hospital	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
major	I-OUT	ADJ	O
clinical	I-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
drug	I-OUT	NOUN	B
use	I-OUT	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
being	O	AUX	O
collected	O	VERB	B
within	O	ADP	O
the	O	DET	O
main	O	ADJ	O
LIPID	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
additional	O	ADJ	O
subsamples	O	NOUN	B
for	O	ADP	O
the	O	DET	O
cost-effectiveness	B-OUT	ADJ	B
study	O	NOUN	I
will	O	AUX	O
include	O	VERB	O
information	O	NOUN	B
on	O	ADP	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
time	I-OUT	NOUN	B
off	I-OUT	ADP	I
work	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
resources	I-OUT	NOUN	B
used	I-OUT	VERB	O
,	I-OUT	PUNCT	O
such	I-OUT	ADJ	O
as	I-OUT	ADP	O
time	I-OUT	NOUN	O
in	I-OUT	ADP	O
hospital	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
procedures	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
medications	I-OUT	NOUN	B
taken	I-OUT	VERB	O
.	I-OUT	PUNCT	O


The	O	DET	O
methods	O	NOUN	B
and	O	CCONJ	O
sample	O	NOUN	B
sizes	O	NOUN	I
for	O	ADP	O
these	O	DET	O
substudies	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
a	O	DET	O
crucial	O	ADJ	O
issue	O	NOUN	B
in	O	ADP	O
validity	O	NOUN	B
and	O	CCONJ	O
feasibility	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
localized	B-P	ADJ	B
non-Hodgkin	I-P	ADJ	I
's	I-P	PART	I
lymphoma	I-P	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
report	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
's	O	PART	I
Cancer	O	PROPN	I
Study	O	PROPN	I
Group	O	PROPN	I
.	O	PUNCT	O


Investigators	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
's	O	PART	I
Cancer	O	PROPN	I
Study	O	PROPN	I
Group	O	PROPN	B
entered	O	VERB	O
73	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
previously	I-P	ADV	O
untreated	I-P	ADJ	B
localized	I-P	ADJ	I
non-Hodgkin	I-P	ADJ	I
's	I-P	PART	I
lymphoma	I-P	NOUN	I
on	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
trial	O	NOUN	O
of	O	ADP	O
systemic	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
four-drug	O	ADJ	B
program	O	NOUN	I
(	B-I	PUNCT	O
cyclophosphamide	I-I	NOUN	B
,	I-I	PUNCT	O
vincristine	I-I	NOUN	B
,	I-I	PUNCT	O
methotrexate	I-I	NOUN	B
,	I-I	PUNCT	O
prednisone	I-I	NOUN	B
[	I-I	PUNCT	O
COMP	I-I	NOUN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
10-drug	B-I	NOUN	B
(	I-I	PUNCT	O
LSA2-L2	I-I	NOUN	B
modified	I-I	VERB	O
)	I-I	PUNCT	O
program	O	NOUN	O
of	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
duration	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
central	B-I	ADJ	B
nervous	I-I	ADJ	I
system	I-I	NOUN	I
prophylaxis	I-I	NOUN	B
with	I-I	ADP	O
intrathecal	I-I	ADJ	B
methotrexate	I-I	NOUN	I
and	O	CCONJ	O
most	O	ADV	O
received	O	VERB	O
local	B-I	ADJ	B
or	I-I	CCONJ	O
regional	I-I	ADJ	B
radiation	I-I	NOUN	B
treatment	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
three-year	B-OUT	ADJ	O
relapse-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
for	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
73	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
84	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
for	O	ADP	O
COMP	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
42	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
85	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
LSA2-L2	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
31	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
84	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
12	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
suffered	O	VERB	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
eight	O	NUM	O
relapsed	B-OUT	ADJ	B
and	O	CCONJ	O
four	O	NUM	O
died	B-OUT	VERB	B
of	I-OUT	ADP	O
toxicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Histopathology	O	NOUN	B
was	O	AUX	O
reviewed	O	VERB	B
centrally	O	ADV	B
.	O	PUNCT	O


Of	O	ADP	O
32	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
nonlymphoblastic	O	ADJ	B
disease	O	NOUN	I
treated	O	VERB	B
with	O	ADP	I
COMP	B-I	NOUN	B
only	O	ADV	O
one	O	NUM	O
relapsed	B-OUT	VERB	B
.	I-OUT	PUNCT	O


Of	O	ADP	O
26	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
LSA2-L2	B-I	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
relapsed	B-OUT	ADJ	B
.	I-OUT	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
localized	B-OUT	ADJ	B
lymphoblastic	I-OUT	ADJ	I
disease	I-OUT	NOUN	I
were	O	AUX	O
uncommon	O	ADJ	O
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
three	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
LSA2-L2	B-I	NOUN	B
relapsed	O	VERB	B
compared	O	VERB	B
with	O	ADP	O
three	O	NUM	O
of	O	ADP	O
nine	O	NUM	O
treated	O	VERB	B
with	O	ADP	I
COMP	O	NOUN	B
.	O	PUNCT	O


COMP	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
excellent	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
localized	O	ADJ	B
disease	O	NOUN	I
of	O	ADP	O
nonlymphoblastic	O	ADJ	B
type	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
relative	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
regimens	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
localized	O	ADJ	B
lymphoblastic	O	ADJ	I
disease	O	NOUN	I
is	O	AUX	O
uncertain	O	ADJ	O
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
vitamin	B-I	NOUN	B
A	I-I	NOUN	I
or	I-I	CCONJ	O
beta	I-I	NOUN	B
carotene	I-I	NOUN	I
supplementation	I-I	NOUN	B
on	O	ADP	O
pregnancy-related	B-OUT	ADJ	B
mortality	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
infant	I-OUT	NOUN	B
mortality	I-OUT	NOUN	B
in	I-P	ADP	O
rural	I-P	ADJ	B
Bangladesh	I-P	PROPN	I
:	I-P	PUNCT	O
a	O	DET	O
cluster	O	NOUN	B
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


CONTEXT	O	ADJ	B
Maternal	O	ADJ	B
vitamin	O	NOUN	B
A	O	NOUN	I
deficiency	O	NOUN	I
is	O	AUX	O
a	O	DET	O
public	O	ADJ	B
health	O	NOUN	I
concern	O	NOUN	O
in	O	ADP	O
the	O	DET	O
developing	O	VERB	B
world	O	NOUN	I
.	O	PUNCT	O


Its	O	PRON	O
prevention	O	NOUN	B
may	O	AUX	O
improve	O	VERB	B
maternal	O	ADJ	B
and	O	CCONJ	O
infant	O	NOUN	B
survival	O	NOUN	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
efficacy	O	NOUN	B
of	O	ADP	O
maternal	O	ADJ	B
vitamin	B-I	NOUN	B
A	I-I	NOUN	I
or	O	CCONJ	O
beta	B-I	NOUN	B
carotene	I-I	NOUN	I
supplementation	O	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
pregnancy-related	B-P	ADJ	B
and	I-P	CCONJ	O
infant	I-P	NOUN	B
mortality	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
AND	O	CCONJ	O
PARTICIPANTS	O	NOUN	B
Cluster	O	NOUN	I
randomized	O	ADJ	B
,	O	PUNCT	O
double-masked	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
among	O	ADP	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
13	I-P	NUM	O
to	I-P	PART	O
45	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
and	I-P	CCONJ	O
their	I-P	PRON	O
live-born	I-P	ADJ	B
infants	I-P	NOUN	I
to	I-P	PART	O
12	I-P	NUM	O
weeks	I-P	NOUN	B
(	I-P	PUNCT	O
84	I-P	NUM	O
days	I-P	NOUN	B
)	I-P	PUNCT	O
postpartum	I-P	NOUN	B
in	I-P	ADP	O
rural	I-P	ADJ	B
northern	I-P	ADJ	I
Bangladesh	I-P	PROPN	I
between	I-P	ADP	O
2001	I-P	NUM	O
and	I-P	CCONJ	O
2007	I-P	NUM	O
.	I-P	PUNCT	O


Interventions	O	NOUN	B
Five	B-P	NUM	O
hundred	I-P	NUM	O
ninety-six	I-P	NUM	O
community	I-P	NOUN	B
clusters	I-P	NOUN	I
(	I-P	PUNCT	O
study	I-P	NOUN	B
sectors	I-P	NOUN	I
)	I-P	PUNCT	O
were	I-P	AUX	O
randomized	I-P	VERB	B
for	I-P	ADP	O
pregnant	I-P	ADJ	B
women	I-P	NOUN	I
to	O	PART	O
receive	O	VERB	O
weekly	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
first	O	ADJ	O
trimester	O	NOUN	B
through	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
postpartum	O	NOUN	B
,	O	PUNCT	O
7000	B-I	NUM	O
μg	I-I	NOUN	O
of	I-I	ADP	O
retinol	I-I	NOUN	B
equivalents	I-I	NOUN	B
as	I-I	ADP	O
retinyl	I-I	NOUN	B
palmitate	I-I	NOUN	I
,	I-I	PUNCT	O
42	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
all-trans	I-I	ADJ	B
beta	I-I	NOUN	I
carotene	I-I	NOUN	I
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-P	PUNCT	O


Married	B-P	ADJ	B
women	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
125,257	I-P	NUM	O
)	I-P	PUNCT	O
underwent	O	VERB	O
5-week	O	ADJ	B
surveillance	O	NOUN	B
for	O	ADP	O
pregnancy	O	NOUN	B
,	O	PUNCT	O
ascertained	O	VERB	O
by	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	I
amenorrhea	O	NOUN	B
and	O	CCONJ	O
confirmed	O	VERB	O
by	O	ADP	O
urine	O	NOUN	B
test	O	NOUN	I
.	B-P	PUNCT	O


Blood	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
participants	O	NOUN	B
in	O	ADP	O
32	O	NUM	O
sectors	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
biochemical	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	O
MEASURES	B-OUT	NOUN	O
All-cause	I-OUT	ADJ	B
mortality	I-OUT	NOUN	B
of	I-OUT	ADP	O
women	I-OUT	NOUN	B
related	I-OUT	ADJ	O
to	I-OUT	PART	O
pregnancy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
stillbirth	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
infant	I-OUT	NOUN	B
mortality	I-OUT	NOUN	B
to	O	PART	O
12	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
84	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
following	O	VERB	O
pregnancy	O	NOUN	B
outcome	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
Groups	O	NOUN	I
were	O	AUX	O
comparable	O	ADJ	O
across	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
the	B-OUT	DET	O
mortality	I-OUT	NOUN	B
outcomes	I-OUT	NOUN	B
,	O	PUNCT	O
neither	O	DET	O
of	O	ADP	O
the	O	DET	O
supplement	O	NOUN	B
group	O	NOUN	B
outcomes	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
outcomes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
numbers	O	NOUN	O
of	B-OUT	ADP	O
deaths	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
all-cause	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pregnancy-related	I-OUT	ADJ	B
mortality	I-OUT	NOUN	O
rates	I-OUT	NOUN	O
(	O	PUNCT	O
per	O	ADP	O
100,000	O	NUM	O
pregnancies	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
41	O	NUM	O
and	O	CCONJ	O
206	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
140-273	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	B-I	DET	O
placebo	I-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
47	O	NUM	O
and	O	CCONJ	O
237	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
166-309	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
vitamin	O	NOUN	B
A	O	NOUN	I
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
50	O	NUM	O
and	O	CCONJ	O
250	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
177-323	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
carotene	O	NOUN	I
group	O	NOUN	O
.	O	PUNCT	O


Relative	O	ADJ	O
risks	O	NOUN	B
for	B-OUT	ADP	O
mortality	I-OUT	NOUN	B
in	O	ADP	O
the	B-I	DET	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
and	I-I	CCONJ	O
beta	I-I	NOUN	B
carotene	I-I	NOUN	I
groups	O	NOUN	B
were	O	AUX	O
1.15	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.75-1.76	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
1.21	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.81-1.81	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
the	B-I	DET	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
beta	I-I	NOUN	B
carotene	I-I	NOUN	I
groups	O	NOUN	B
the	O	DET	O
rates	O	NOUN	B
of	B-OUT	ADP	O
stillbirth	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
infant	I-OUT	NOUN	B
mortality	I-OUT	NOUN	B
were	O	AUX	O
47.9	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
44.3-51.5	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
45.6	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
42.1-49.2	O	ADJ	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
51.8	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
48.0-55.6	O	X	O
)	O	PUNCT	O
per	O	ADP	O
1000	O	NUM	O
births	O	NOUN	B
and	O	CCONJ	O
68.1	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
63.7-72.5	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
65.0	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
60.7-69.4	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
69.8	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
65.4-72.3	O	NUM	O
)	O	PUNCT	O
per	O	ADP	O
1000	O	NUM	O
live	O	ADJ	B
births	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Vitamin	O	NOUN	B
A	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
either	O	CCONJ	O
placebo	O	NOUN	B
or	O	CCONJ	O
beta	O	NOUN	B
carotene	O	NOUN	I
supplementation	O	NOUN	B
increased	B-OUT	VERB	B
plasma	I-OUT	NOUN	B
retinol	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
by	O	ADP	O
end	O	NOUN	O
of	O	ADP	O
study	O	NOUN	B
(	O	PUNCT	O
1.46	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.42-1.50	O	NUM	O
]	O	PUNCT	O
μmol/L	O	NOUN	O
vs	O	CCONJ	O
1.13	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.09-1.17	O	ADJ	O
]	O	PUNCT	O
μmol/L	O	NOUN	O
and	O	CCONJ	O
1.18	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.14-1.22	O	NUM	O
]	O	PUNCT	O
μmol/L	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
eliminate	B-OUT	VERB	O
,	I-OUT	PUNCT	O
gestational	I-OUT	ADJ	B
night	I-OUT	NOUN	I
blindness	I-OUT	NOUN	I
(	O	PUNCT	O
7.1	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
vitamin	O	NOUN	B
A	O	NOUN	I
vs	O	CCONJ	O
9.2	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
placebo	O	NOUN	B
and	O	CCONJ	O
8.9	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
beta	O	NOUN	B
carotene	O	NOUN	I
[	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
for	O	ADP	O
both	O	DET	O
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Use	O	PROPN	O
of	O	ADP	O
weekly	B-I	ADJ	B
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
or	I-I	CCONJ	O
beta	I-I	NOUN	B
carotene	I-I	NOUN	I
in	I-P	ADP	O
pregnant	I-P	ADJ	B
women	I-P	NOUN	I
in	I-P	ADP	O
Bangladesh	I-P	PROPN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
reduce	B-OUT	VERB	O
all-cause	I-OUT	ADJ	O
maternal	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
fetal	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
infant	I-OUT	NOUN	B
mortality	I-OUT	NOUN	B
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
clinicaltrials.gov	O	NOUN	O
Identifier	O	NOUN	O
:	O	PUNCT	O
NCT00198822	O	NOUN	O
.	O	PUNCT	O


Targeting	O	VERB	B
alpha-7	B-I	NOUN	B
nicotinic	I-I	ADJ	I
neurotransmission	I-I	NOUN	B
in	O	ADP	O
schizophrenia	B-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
agonist	O	NOUN	B
strategy	O	NOUN	O
.	O	PUNCT	O


Alpha7	B-I	NOUN	B
nicotinic	I-I	ADJ	B
acetylcholine	I-I	NOUN	I
receptor	I-I	NOUN	I
(	I-I	PUNCT	O
α7	I-I	NOUN	B
nAChR	I-I	NOUN	I
)	I-I	PUNCT	O
agonists	I-I	NOUN	B
may	O	AUX	O
be	O	AUX	O
valuable	O	ADJ	O
treatments	O	NOUN	B
for	O	ADP	O
negative	O	ADJ	B
symptoms	O	NOUN	B
and	O	CCONJ	O
cognitive	O	ADJ	B
impairment	O	NOUN	I
in	B-P	ADP	O
schizophrenia	I-P	NOUN	B
.	O	PUNCT	O


Unfortunately	O	ADV	O
,	O	PUNCT	O
chronic	O	ADJ	B
exposure	O	NOUN	I
to	O	PART	O
an	O	DET	O
agonist	O	NOUN	B
may	O	AUX	O
reduce	O	VERB	O
the	O	DET	O
receptor	O	NOUN	B
's	O	PART	I
sensitivity	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
combined	B-I	VERB	O
CDP-choline	I-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
dietary	O	ADJ	B
source	O	NOUN	O
of	O	ADP	O
the	O	DET	O
direct	O	ADJ	O
agonist	O	NOUN	B
choline	O	NOUN	B
,	O	PUNCT	O
with	B-I	ADP	O
galantamine	I-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
positive	I-I	ADJ	B
allosteric	I-I	ADJ	O
modulator	I-I	NOUN	O
(	I-I	PUNCT	O
PAM	I-I	NOUN	B
)	I-I	PUNCT	O
of	I-I	ADP	O
nicotinic	I-I	ADJ	B
acetylcholine	I-I	NOUN	I
receptors	I-I	NOUN	I
,	O	PUNCT	O
to	O	PART	O
improve	O	VERB	B
the	O	DET	O
efficiency	O	NOUN	B
of	O	ADP	O
transducing	O	VERB	B
the	O	DET	O
choline	O	NOUN	B
signal	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
possibly	O	ADV	O
,	O	PUNCT	O
preserve	O	VERB	O
the	O	DET	O
receptor	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sensitive	O	ADJ	B
state	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
single-site	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
comparing	B-I	VERB	O
galantamine/CDP-choline	I-I	NOUN	B
to	I-I	ADP	O
placebos	I-I	NOUN	B
in	I-P	ADP	O
schizophrenia	I-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
negative	I-P	ADJ	B
symptoms	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
receiving	I-P	VERB	O
second	I-P	ADJ	O
generation	I-P	NOUN	O
antipsychotics	I-P	NOUN	B
.	I-P	PUNCT	O


Forty-three	B-P	NUM	O
subjects	I-P	NOUN	B
received	I-I	VERB	O
galantamine	I-I	NOUN	B
and	I-I	CCONJ	O
CDP-choline	I-I	NOUN	B
or	O	CCONJ	O
matching	B-I	VERB	O
placebos	I-I	NOUN	B
for	O	ADP	O
16weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
was	O	AUX	O
the	B-OUT	DET	O
5-item	I-OUT	ADJ	B
Marder	I-OUT	PROPN	I
negative-symptoms	I-OUT	ADJ	I
factor	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
Positive	I-OUT	ADJ	B
and	I-OUT	CCONJ	I
Negative	I-OUT	ADJ	O
Syndrome	I-OUT	NOUN	O
Scale	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
PANSS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Cognition	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
functioning	I-OUT	NOUN	B
were	O	AUX	O
also	O	ADV	O
assessed	O	VERB	B
.	O	PUNCT	O


Trial	O	ADJ	B
completion	O	NOUN	B
was	O	AUX	O
high	O	ADJ	O
;	O	PUNCT	O
79	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
treatment	O	NOUN	B
effect	O	NOUN	I
on	B-OUT	ADP	O
negative	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
other	I-OUT	ADJ	O
PANSS	I-OUT	ADJ	B
symptom	I-OUT	NOUN	B
factors	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
the	I-OUT	DET	O
MATRICS	I-OUT	PROPN	B
Cognitive	I-OUT	PROPN	I
Consensus	I-OUT	PROPN	I
Battery	I-OUT	PROPN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
significant	O	ADJ	B
treatment	O	NOUN	B
effects	O	NOUN	O
in	B-OUT	ADP	O
overall	I-OUT	ADJ	O
functioning	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
test	I-OUT	NOUN	B
of	I-OUT	ADP	O
free	I-OUT	ADJ	B
verbal	I-OUT	ADJ	B
recall	I-OUT	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
subjects	O	NOUN	B
discontinued	O	VERB	B
treatment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
active	O	ADJ	B
treatment	O	NOUN	I
group	O	NOUN	I
for	O	ADP	O
gastro-intestinal	O	ADJ	B
adverse	O	ADJ	I
events	O	NOUN	I
(	O	PUNCT	O
AE	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
AE	O	NOUN	B
for	B-I	ADP	O
galantamine/CDP-choline	I-I	NOUN	B
was	I-OUT	AUX	O
abdominal	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
for	I-I	ADP	O
placebo	I-I	NOUN	B
it	O	PRON	O
was	B-OUT	AUX	O
headache	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
sweating	I-OUT	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
treatment	O	NOUN	B
effect	O	NOUN	I
on	O	ADP	O
negative	O	ADJ	B
symptoms	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
direction	O	NOUN	B
of	O	ADP	O
effect	O	NOUN	B
mirrored	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
a	O	DET	O
cognitive	O	ADJ	B
measure	O	NOUN	I
and	O	CCONJ	O
overall	O	ADJ	B
functioning	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
study	O	NOUN	B
of	B-I	ADP	O
α7	I-I	NOUN	B
nAChR	I-I	NOUN	I
agonist/PAMs	I-I	NOUN	B
is	O	AUX	O
warranted	O	VERB	O
in	O	ADP	O
larger	O	ADJ	O
studies	O	NOUN	B
that	O	PRON	O
will	O	AUX	O
have	O	AUX	O
greater	O	ADJ	O
power	O	NOUN	B
.	O	PUNCT	O


Omega-3	B-I	VERB	B
fatty	I-I	ADJ	B
acids	I-I	NOUN	I
supplementation	I-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
double-blind	O	ADJ	B
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
pilot	O	NOUN	O
study	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
There	O	PRON	O
is	O	AUX	O
increasing	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
fatty	O	ADJ	B
acid	O	NOUN	I
deficiencies	O	NOUN	I
or	O	CCONJ	O
imbalances	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
childhood	B-P	ADJ	B
neurodevelopmental	I-P	ADJ	B
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
6-week	O	ADJ	O
pilot	O	NOUN	O
trial	O	NOUN	O
investigating	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
1.5	B-I	NUM	O
g/d	I-I	NOUN	O
of	I-I	ADP	O
omega-3	I-I	ADJ	B
fatty	I-I	ADJ	I
acids	I-I	NOUN	I
(	I-I	PUNCT	O
.84	I-I	NUM	O
g/d	I-I	NOUN	O
eicosapentaenoic	I-I	ADJ	B
acid	I-I	NOUN	I
,	I-I	PUNCT	O
.7	I-I	NOUN	O
g/d	I-I	NOUN	O
docosahexaenoic	I-I	ADJ	B
acid	I-I	NOUN	I
)	I-I	PUNCT	O
supplementation	I-I	NOUN	B
in	O	ADP	O
13	B-P	NUM	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
5	I-P	NUM	O
to	I-P	PART	O
17	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
autistic	I-P	ADJ	B
disorders	I-P	NOUN	I
accompanied	I-P	VERB	O
by	I-P	ADP	O
severe	I-P	ADJ	B
tantrums	I-P	NOUN	B
,	I-P	PUNCT	O
aggression	I-P	NOUN	B
,	I-P	PUNCT	O
or	I-P	CCONJ	O
self-injurious	I-P	ADJ	B
behavior	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
outcome	O	NOUN	B
measure	O	NOUN	I
was	O	AUX	O
the	O	DET	O
Aberrant	B-OUT	ADJ	B
Behavior	I-OUT	PROPN	I
Checklist	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
ABC	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
at	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
We	O	PRON	O
observed	O	VERB	O
an	O	DET	O
advantage	O	NOUN	O
of	O	ADP	O
omega-3	B-I	ADJ	B
fatty	I-I	ADJ	I
acids	I-I	NOUN	I
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
for	O	ADP	O
hyperactivity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
stereotypy	I-OUT	NOUN	B
,	O	PUNCT	O
each	O	DET	O
with	O	ADP	O
a	O	DET	O
large	O	ADJ	O
effect	O	NOUN	B
size	O	NOUN	I
.	O	PUNCT	O


Repeated-measures	O	NOUN	B
ANOVA	O	NOUN	I
indicated	O	VERB	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
superiority	O	NOUN	B
of	O	ADP	O
omega-3	B-I	ADJ	B
fatty	I-I	ADJ	I
acids	I-I	NOUN	I
over	O	ADP	O
placebo	O	NOUN	B
for	O	ADP	O
hyperactivity	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


No	O	DET	O
clinically	O	ADV	O
relevant	O	ADJ	O
adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
elicited	O	VERB	O
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
provide	O	VERB	O
preliminary	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
omega-3	B-I	ADJ	B
fatty	I-I	ADJ	B
acids	I-I	NOUN	I
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Radiotherapy	B-I	NOUN	B
and	O	CCONJ	O
CCNU	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
high-grade	O	ADJ	B
supratentorial	O	ADJ	O
astrocytomas	O	NOUN	O
.	O	PUNCT	O


Forty-one	B-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
supratentorial	I-P	ADJ	B
primary	I-P	ADJ	O
brain	I-P	NOUN	O
tumors	I-P	NOUN	O
(	I-P	PUNCT	O
38	I-P	NUM	O
Grade	I-P	PROPN	B
III	I-P	NUM	I
and	I-P	CCONJ	I
IV	I-P	NUM	I
astrocytomas	I-P	NOUN	I
,	I-P	PUNCT	O
one	I-P	NUM	O
giant-cell	I-P	ADJ	B
astrocytoma	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
two	I-P	NUM	O
cases	I-P	NOUN	B
with	I-P	ADP	O
insufficient	I-P	ADJ	B
tissue	I-P	NOUN	B
for	I-P	ADP	O
diagnosis	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
within	B-P	ADP	O
2	I-P	NUM	O
weeks	I-P	NOUN	B
of	I-P	ADP	O
surgery	I-P	NOUN	B
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
therapeutic	O	ADJ	B
groups	O	NOUN	I
.	O	PUNCT	O


Group	O	NOUN	B
1	O	NUM	O
(	O	PUNCT	O
15	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
radiation	B-I	NOUN	B
therapy	I-I	NOUN	I
totaling	O	VERB	O
4000	O	NUM	O
to	O	PART	O
4500	O	NUM	O
rads	O	NOUN	O
in	O	ADP	O
4	O	NUM	O
to	O	PART	O
5	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Group	O	NOUN	B
2	O	NUM	O
(	O	PUNCT	O
13	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
1-	B-I	NUM	O
(	I-I	PUNCT	O
2-chloroethyl	I-I	ADJ	B
)	I-I	PUNCT	O
-3-cyclohexyl-1-nitrosourea	I-I	NOUN	O
CCNU	I-I	NOUN	B
)	I-I	PUNCT	O
130	O	NUM	O
mg/sq	O	NOUN	O
m	O	NOUN	O
orally	O	ADV	B
every	O	DET	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Group	O	NOUN	B
3	O	NUM	O
(	O	PUNCT	O
13	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
radiation	B-I	NOUN	B
therapy	I-I	NOUN	I
plus	I-I	CCONJ	O
CCNU	I-I	NOUN	B
as	O	ADP	O
for	O	ADP	O
Groups	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
disease	O	NOUN	B
progressed	O	VERB	O
,	O	PUNCT	O
patients	O	NOUN	B
in	O	ADP	O
Groups	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
2	O	NUM	O
were	O	AUX	O
crossed	O	VERB	O
over	O	ADP	O
to	O	PART	O
receive	O	VERB	O
CCNU	B-I	NOUN	B
and	O	CCONJ	O
irradiation	O	NOUN	B
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
time	I-OUT	NOUN	I
in	O	ADP	O
these	O	DET	O
groups	O	NOUN	B
was	O	AUX	O
188	O	NUM	O
,	O	PUNCT	O
259	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
252	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
mean	O	ADJ	B
survival	B-OUT	NOUN	I
263	O	NUM	O
,	O	PUNCT	O
262	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
329	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
time	I-OUT	NOUN	O
from	I-OUT	ADP	O
diagnosis	I-OUT	NOUN	B
to	I-OUT	PART	O
crossover	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
Groups	I-OUT	NOUN	B
1	I-OUT	NUM	O
and	I-OUT	CCONJ	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
to	I-OUT	PART	O
progression	I-OUT	NOUN	B
(	O	PUNCT	O
Group	O	NOUN	B
3	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
163	O	NUM	O
,	O	PUNCT	O
99	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
220	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
mean	O	ADJ	O
time	O	NOUN	O
was	O	AUX	O
172	O	NUM	O
,	O	PUNCT	O
108	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
231	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
means	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
medians	I-OUT	NOUN	B
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
these	O	DET	O
situations	O	NOUN	B
.	O	PUNCT	O


Controlled-release	O	ADJ	B
melatonin	B-I	NOUN	B
,	I-I	PUNCT	O
singly	I-I	ADV	B
and	I-I	CCONJ	O
combined	I-I	VERB	B
with	I-I	ADP	O
cognitive	I-I	ADJ	B
behavioural	I-I	ADJ	I
therapy	I-I	NOUN	I
,	O	PUNCT	O
for	O	ADP	O
persistent	B-P	ADJ	B
insomnia	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
placebo-controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
melatonin	B-I	NOUN	B
and	I-I	CCONJ	O
cognitive-behavioural	I-I	ADJ	B
therapy	I-I	NOUN	I
have	O	AUX	O
shown	O	VERB	O
efficacy	O	NOUN	B
in	O	ADP	O
treating	O	VERB	B
sleep	B-P	NOUN	B
disorders	I-P	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
their	O	PRON	O
relative	O	ADJ	O
or	O	CCONJ	O
combined	O	ADJ	O
efficacy	O	NOUN	B
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
sixty	I-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
,	I-P	PUNCT	O
aged	I-P	ADJ	B
4-10	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
suffering	I-P	VERB	B
from	I-P	ADP	O
sleep	I-P	NOUN	B
onset	I-P	NOUN	I
insomnia	I-P	NOUN	I
and	I-P	CCONJ	O
impaired	I-P	ADJ	B
sleep	I-P	NOUN	O
maintenance	I-P	NOUN	O
,	O	PUNCT	O
were	O	AUX	O
assigned	O	VERB	O
randomly	O	ADV	O
to	O	PART	O
either	O	CCONJ	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
combination	B-I	NOUN	B
of	I-I	ADP	O
controlled-release	I-I	ADJ	B
melatonin	I-I	NOUN	B
and	I-I	CCONJ	O
cognitive-behavioural	I-I	ADJ	B
therapy	I-I	NOUN	I
;	I-I	PUNCT	O
(	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
controlled-release	I-I	ADJ	B
melatonin	I-I	NOUN	B
;	I-I	PUNCT	O
(	I-I	PUNCT	O
3	I-I	X	O
)	I-I	PUNCT	O
four	I-I	NUM	O
sessions	I-I	NOUN	B
of	I-I	ADP	O
cognitive-behavioural	I-I	ADJ	B
therapy	I-I	NOUN	I
;	I-I	PUNCT	O
or	I-I	CCONJ	O
(	I-I	PUNCT	O
4	I-I	NUM	O
)	I-I	PUNCT	O
placebo	I-I	NOUN	B
drug	I-I	NOUN	B
treatment	I-I	NOUN	I
condition	I-I	NOUN	O
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
a	O	DET	O
1	O	NUM	O
:	O	PUNCT	O
1	O	NUM	O
:	O	PUNCT	O
1	O	NUM	O
:	O	PUNCT	O
1	O	NUM	O
ratio	O	NOUN	B
.	O	PUNCT	O


Children	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
response	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
with	O	ADP	O
1-week	O	ADJ	O
actigraphic	O	ADJ	B
monitoring	O	NOUN	B
,	O	PUNCT	O
sleep	O	ADJ	B
diary	O	NOUN	I
and	O	CCONJ	O
sleep	O	NOUN	B
questionnaire	O	NOUN	I
.	O	PUNCT	O


Main	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	B
,	O	PUNCT	O
derived	O	VERB	O
actigraphically	O	ADV	B
,	O	PUNCT	O
were	O	AUX	O
sleep	B-OUT	NOUN	B
latency	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
total	I-OUT	ADJ	B
sleep	I-OUT	NOUN	I
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
wake	I-OUT	VERB	O
after	I-OUT	ADP	O
sleep	I-OUT	NOUN	B
onset	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
awakenings	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
active	O	ADJ	B
treatment	O	NOUN	O
groups	O	NOUN	O
all	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
improvements	O	NOUN	B
across	O	ADP	O
all	O	DET	O
outcome	O	NOUN	B
measures	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
moderate-to-large	O	ADJ	B
effect	O	NOUN	I
sizes	O	NOUN	I
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
a	O	DET	O
12-week	O	NOUN	B
assessment	O	NOUN	I
.	O	PUNCT	O


Melatonin	B-I	NOUN	B
treatment	O	NOUN	B
was	O	AUX	O
mainly	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
reducing	O	VERB	B
insomnia	B-OUT	NOUN	B
symptoms	I-OUT	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
cognitive-behavioural	B-I	ADJ	B
therapy	I-I	NOUN	I
had	O	AUX	O
a	O	DET	O
light	O	ADJ	O
positive	O	ADJ	B
impact	O	NOUN	B
mainly	O	ADV	O
on	O	ADP	O
sleep	B-OUT	NOUN	B
latency	I-OUT	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
some	O	DET	O
behavioural	O	ADJ	B
aspects	O	NOUN	I
might	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
determining	O	VERB	O
initial	B-OUT	ADJ	O
insomnia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
combination	O	NOUN	B
treatment	O	NOUN	B
group	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
trend	O	NOUN	O
to	O	PART	O
outperform	O	VERB	O
other	O	ADJ	O
active	O	ADJ	B
treatment	O	NOUN	B
groups	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
fewer	O	ADJ	O
dropouts	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
greater	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
responders	O	NOUN	B
achieving	O	VERB	O
clinically	O	ADV	B
significant	O	ADJ	I
changes	O	NOUN	B
(	O	PUNCT	O
63.38	O	NUM	O
%	O	NOUN	O
normative	O	ADJ	B
sleep	O	NOUN	I
efficiency	O	NOUN	B
criterion	O	NOUN	B
of	O	ADP	O
>	O	X	O
85	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
84.62	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
sleep	O	NOUN	B
onset	O	NOUN	I
latency	O	NOUN	I
<	O	X	O
30	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
adding	O	VERB	O
behavioural	B-I	ADJ	B
intervention	I-I	NOUN	I
to	O	PART	O
melatonin	B-I	NOUN	B
treatment	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
better	O	ADJ	O
treatment	O	NOUN	B
response	O	NOUN	I
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
in	O	ADP	O
the	O	DET	O
short	O	ADJ	B
term	O	NOUN	I
.	O	PUNCT	O


Metabolic	O	ADJ	B
and	O	CCONJ	O
hormonal	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
induced	B-I	VERB	B
hypotension	I-I	NOUN	B
for	O	ADP	O
middle	B-P	ADJ	B
ear	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
have	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
30	B-P	NUM	O
patients	I-P	NOUN	B
the	O	DET	O
metabolic	O	ADJ	B
and	O	CCONJ	O
hormonal	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
middle	B-P	ADJ	B
ear	I-P	NOUN	I
surgery	I-P	NOUN	I
using	I-P	VERB	O
induced	I-I	VERB	B
hypotension	I-I	NOUN	B
to	I-P	PART	O
a	I-P	DET	O
mean	I-P	ADJ	O
arterial	I-P	ADJ	B
pressure	I-P	NOUN	I
of	I-P	ADP	O
55	I-P	NUM	O
mm	I-P	NOUN	B
Hg	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
standardized	O	ADJ	B
anaesthetic	O	ADJ	B
technique	O	NOUN	I
of	O	ADP	O
propranolol	B-I	NOUN	B
,	I-I	PUNCT	O
thiopentone-vecuronium-isoflurane	I-I	NOUN	B
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
hypotension	B-I	NOUN	B
induced	I-I	VERB	B
with	I-I	ADP	O
sodium	I-I	NOUN	B
nitroprusside	I-I	NOUN	I
,	I-I	PUNCT	O
trimetaphan	I-I	NOUN	B
camsylate	I-I	NOUN	I
or	I-I	CCONJ	O
additional	I-I	ADJ	O
isoflurane	I-I	NOUN	B
.	I-I	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
classic	B-OUT	ADJ	O
stress	I-OUT	NOUN	B
response	I-OUT	NOUN	I
with	I-OUT	ADP	O
an	I-OUT	DET	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
circulating	I-OUT	VERB	B
blood	I-OUT	NOUN	I
glucose	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
cortisol	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
growth	I-OUT	NOUN	B
hormone	I-OUT	NOUN	I
concentrations	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Blood	B-OUT	NOUN	B
lactate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
plasma	I-OUT	NOUN	B
uric	I-OUT	ADJ	O
acid	I-OUT	NOUN	O
concentrations	I-OUT	NOUN	B
changed	O	VERB	O
little	O	ADV	O
during	O	ADP	O
operation	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
tissue	O	NOUN	B
oxygenation	O	NOUN	I
was	O	AUX	O
adequate	O	ADJ	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
former	O	NOUN	O
declined	O	VERB	B
after	O	ADP	O
operation	O	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
concomitant	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
propranolol	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
three	O	NUM	O
hypotensive	O	ADJ	B
techniques	O	NOUN	I
in	O	ADP	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
hormonal	O	ADJ	B
and	O	CCONJ	O
metabolic	O	ADJ	B
response	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
blood	B-OUT	NOUN	B
glucose	I-OUT	NOUN	I
concentration	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
trimetaphan	O	NOUN	B
group	O	NOUN	B
was	O	AUX	O
obtunded	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
induced	O	VERB	B
hypotension	O	NOUN	B
for	O	ADP	O
middle	B-P	ADJ	B
ear	I-P	NOUN	I
surgery	I-P	NOUN	I
induced	O	VERB	B
an	O	DET	O
endocrine	O	ADJ	B
and	O	CCONJ	O
metabolic	O	ADJ	B
response	O	NOUN	I
of	O	ADP	O
small	O	ADJ	O
magnitude	O	NOUN	B
and	O	CCONJ	O
short	O	ADJ	B
duration	O	NOUN	I
.	O	PUNCT	O


Influence	B-OUT	NOUN	B
of	O	ADP	O
bony	B-P	NOUN	B
defects	I-P	NOUN	B
on	O	ADP	O
implant	O	ADJ	B
stability	O	NOUN	I
.	O	PUNCT	O


INTRODUCTION	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
analyze	O	VERB	B
the	O	DET	O
evolution	O	NOUN	B
of	O	ADP	O
implant	O	ADJ	B
mechanical	O	ADJ	B
stability	O	NOUN	I
in	O	ADP	O
different	O	ADJ	O
types/sizes	O	NOUN	B
of	O	ADP	O
bony	B-P	NOUN	B
defects	I-P	NOUN	O
using	O	VERB	O
both	O	CCONJ	O
Periotest	B-I	NOUN	B
and	O	CCONJ	O
Osstell	B-I	NOUN	B
devices	O	NOUN	I
as	O	ADP	O
"	O	PUNCT	O
objective	O	ADJ	O
tools	O	NOUN	B
.	O	PUNCT	O


"	O	PUNCT	O
MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
Thirty-two	B-P	NUM	O
implants	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
allocated	I-P	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
four	B-P	NUM	O
types	I-P	NOUN	O
of	I-P	ADP	O
bone	I-P	NOUN	B
defects	I-P	NOUN	B
:	I-P	PUNCT	O
marginal	I-P	ADJ	B
bone	I-P	NOUN	I
loss	I-P	NOUN	I
,	I-P	PUNCT	O
peri-apical	I-P	ADJ	B
bone	I-P	NOUN	I
defect	I-P	NOUN	I
,	I-P	PUNCT	O
constant	I-P	ADJ	B
width	I-P	NOUN	O
dehiscence	I-P	NOUN	O
and	I-P	CCONJ	O
constant	I-P	ADJ	B
length	I-P	NOUN	O
dehiscences	I-P	NOUN	B
.	I-P	PUNCT	O


Periotest/Osstell	B-OUT	ADJ	B
measurements	I-OUT	NOUN	B
were	O	AUX	O
completed	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
during	O	ADP	O
staged	O	VERB	B
bone	O	NOUN	I
removal	O	NOUN	I
(	O	PUNCT	O
to	O	PART	O
enlarge	O	VERB	O
defect	O	NOUN	B
size	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Significant	O	ADJ	O
differences	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
initial	O	ADJ	B
values	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
after	O	ADP	O
a	O	DET	O
2	O	NUM	O
mm	O	NOUN	O
marginal	O	ADJ	B
bone	O	NOUN	O
removal	O	NOUN	O
(	O	PUNCT	O
Osstell/Periotest	O	PROPN	B
)	O	PUNCT	O
;	O	PUNCT	O
for	O	ADP	O
a	O	DET	O
peri-apical	B-OUT	ADJ	B
bone	I-OUT	NOUN	O
lesion	I-OUT	NOUN	O
,	O	PUNCT	O
after	O	ADP	O
removal	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
mm	O	NOUN	O
(	B-I	PUNCT	O
Osstell	I-I	NOUN	B
)	I-I	PUNCT	O
or	O	CCONJ	O
8	O	NUM	O
mm	O	NOUN	O
(	B-I	PUNCT	O
Periotest	I-I	NOUN	B
)	I-I	PUNCT	O
;	I-I	PUNCT	O
for	O	ADP	O
a	O	DET	O
6-mm-long	O	NUM	B
dehiscence	O	NOUN	I
,	O	PUNCT	O
after	O	ADP	O
removal	O	NOUN	B
up	O	ADP	O
to	O	PART	O
180	O	NUM	O
degrees	O	NOUN	B
of	O	ADP	O
the	O	DET	O
implant	O	ADJ	B
perimeter	O	NOUN	I
(	O	PUNCT	O
Osstell/Periotest	O	PROPN	B
)	O	PUNCT	O
;	O	PUNCT	O
for	O	ADP	O
a	O	DET	O
3-mm-wide	O	NUM	B
dehiscence	O	NOUN	I
,	O	PUNCT	O
after	O	ADP	O
removal	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
Osstell	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
6	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
Periotest	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Periotest	B-OUT	PROPN	B
and	O	CCONJ	O
Osstell	B-OUT	PROPN	B
are	O	AUX	O
in	O	ADP	O
general	O	ADJ	O
not	O	PART	O
very	O	ADV	O
sensitive	O	ADJ	B
in	O	ADP	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
peri-implant	O	ADJ	B
bone	O	NOUN	I
destruction	O	NOUN	B
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
marginal	O	ADJ	B
bone	O	NOUN	I
loss	O	NOUN	O
.	O	PUNCT	O


Comparing	O	VERB	B
microvascular	B-OUT	ADJ	B
alterations	I-OUT	NOUN	B
during	O	ADP	O
minimal	O	ADJ	B
extracorporeal	B-I	ADJ	B
circulation	I-I	NOUN	I
and	O	CCONJ	O
conventional	O	ADJ	B
cardiopulmonary	B-I	NOUN	B
bypass	I-I	NOUN	I
in	O	ADP	O
coronary	B-I	ADJ	B
artery	I-I	NOUN	I
bypass	I-I	NOUN	I
graft	I-I	NOUN	I
surgery	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
Minimal	B-I	ADJ	B
extracorporeal	I-I	ADJ	O
circulation	I-I	NOUN	O
(	I-I	PUNCT	O
MECC	I-I	NOUN	B
)	I-I	PUNCT	O
has	O	AUX	O
been	O	AUX	O
introduced	O	VERB	O
in	O	ADP	O
coronary	B-I	ADJ	B
artery	I-I	NOUN	I
bypass	I-I	NOUN	I
graft	I-I	NOUN	I
(	I-I	PUNCT	O
CABG	I-I	NOUN	B
)	I-I	PUNCT	O
surgery	I-I	NOUN	O
,	O	PUNCT	O
offering	O	VERB	O
clinical	O	ADJ	B
benefits	O	NOUN	I
owing	O	VERB	O
to	O	PART	O
reduced	O	VERB	B
hemodilution	O	NOUN	B
and	O	CCONJ	O
no	O	DET	O
blood-air	O	ADJ	B
interface	O	NOUN	O
.	O	PUNCT	O


Yet	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
MECC	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
intraoperative	O	ADJ	B
microvascular	O	ADJ	B
perfusion	O	NOUN	I
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
conventional	B-I	ADJ	B
extracorporeal	I-I	ADJ	B
circulation	I-I	NOUN	I
(	I-I	PUNCT	O
CECC	I-I	NOUN	B
)	I-I	PUNCT	O
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
studied	O	VERB	O
so	O	ADV	O
far	O	ADV	O
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
analyze	O	VERB	O
alterations	B-OUT	NOUN	B
in	I-OUT	ADP	O
microvascular	I-OUT	ADJ	B
perfusion	I-OUT	NOUN	I
at	O	ADP	O
4	O	NUM	O
predefined	O	ADJ	O
time	O	NOUN	O
points	O	NOUN	O
(	O	PUNCT	O
T1-T4	O	X	B
)	O	PUNCT	O
during	O	ADP	O
on-pump	O	ADJ	B
CABG	O	PROPN	B
using	O	VERB	O
orthogonal	O	ADJ	B
polarization	O	NOUN	I
spectral	O	ADJ	I
imaging	O	NOUN	I
.	O	PUNCT	O


Forty	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
for	O	ADP	O
being	O	AUX	O
operated	O	VERB	O
on	O	ADP	O
with	O	ADP	O
either	O	CCONJ	O
MECC	B-I	NOUN	B
or	I-I	CCONJ	O
CECC	I-I	PROPN	B
.	I-I	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
functional	B-OUT	ADJ	B
capillary	I-OUT	ADJ	I
density	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
FCD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
flow	I-OUT	NOUN	I
velocity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
vessel	I-OUT	NOUN	B
diameter	I-OUT	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
a	O	DET	O
blinded	O	ADJ	B
investigator	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
After	O	ADP	O
start	O	NOUN	O
of	O	ADP	O
extracorporeal	O	ADJ	B
circulation	O	NOUN	I
(	O	PUNCT	O
ECC	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
aortic	O	ADJ	B
crossclamping	O	NOUN	I
(	O	PUNCT	O
T2	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
both	O	DET	O
groups	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
drop	O	NOUN	B
of	O	ADP	O
FCD	B-OUT	PROPN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
FCD	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
MECC	O	NOUN	B
group	O	NOUN	O
(	O	PUNCT	O
206.8	O	NUM	O
±	O	NOUN	O
33.6	O	NUM	O
cm/cm²	O	NOUN	O
in	O	ADP	O
CECC	O	NOUN	B
group	O	NOUN	O
versus	O	CCONJ	O
217.8	O	NUM	O
±	O	NOUN	O
35.3	O	NUM	O
cm/cm²	O	NOUN	O
in	O	ADP	O
MECC	O	NOUN	B
group	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.034	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
late	O	ADJ	B
phase	O	NOUN	I
of	O	ADP	O
the	O	DET	O
ECC	O	PROPN	B
(	B-OUT	PUNCT	O
T3	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
FCD	O	NOUN	B
in	O	ADP	O
the	O	DET	O
MECC	O	NOUN	B
group	O	NOUN	B
was	O	AUX	O
already	O	ADV	O
recovered	O	VERB	B
,	O	PUNCT	O
whereas	B-OUT	SCONJ	O
FCD	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CECC	O	PROPN	B
group	O	NOUN	B
was	O	AUX	O
still	O	ADV	O
significantly	O	ADV	B
depressed	O	ADJ	I
(	O	PUNCT	O
223.1	O	NUM	O
±	O	NOUN	O
35.6	O	NUM	O
cm/cm²	O	NOUN	O
in	O	ADP	O
MECC	O	NOUN	B
group	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.100	O	NUM	O
vs	O	CCONJ	O
T1	O	NOUN	B
;	O	PUNCT	O
211.1	O	NUM	O
±	O	NOUN	O
36.9	O	NUM	O
cm/cm²	O	NOUN	O
in	O	ADP	O
CECC	O	PROPN	B
group	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.017	O	NUM	O
vs	O	CCONJ	O
T1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
termination	O	NOUN	B
of	O	ADP	O
ECC	B-OUT	PROPN	B
(	I-OUT	PUNCT	O
T4	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
FCD	O	NOUN	B
recovered	O	VERB	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
to	O	PART	O
baseline	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Blood	B-OUT	NOUN	B
flow	I-OUT	NOUN	I
velocity	I-OUT	NOUN	B
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
MECC	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
significant	O	ADJ	B
intergroup	O	NOUN	B
difference	O	NOUN	O
after	O	ADP	O
aortic	O	ADJ	B
crossclamping	O	NOUN	I
(	O	PUNCT	O
T2	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Orthogonal	O	ADJ	B
polarization	O	NOUN	I
spectral	O	ADJ	I
imaging	O	NOUN	I
data	O	NOUN	B
reveal	O	VERB	O
an	O	DET	O
impairment	B-OUT	NOUN	B
of	I-OUT	ADP	O
microvascular	I-OUT	ADJ	B
perfusion	I-OUT	NOUN	I
during	O	ADP	O
on-pump	O	ADJ	B
CABG	O	PROPN	B
.	O	PUNCT	O


Changes	B-OUT	NOUN	B
in	O	ADP	O
FCD	O	PROPN	B
indicate	O	VERB	O
a	O	DET	O
faster	O	ADJ	O
recovery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
microvascular	O	ADJ	B
perfusion	O	NOUN	O
in	O	ADP	O
MECC	O	NOUN	B
during	O	ADP	O
the	O	DET	O
reperfusion	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Beneficial	O	ADJ	B
recovery	O	NOUN	B
of	O	ADP	O
microvascular	O	ADJ	B
organ	O	NOUN	I
perfusion	O	NOUN	I
could	O	AUX	O
partly	O	ADV	O
explain	O	VERB	O
the	O	DET	O
perioperative	O	ADJ	B
advantages	O	NOUN	O
reported	O	VERB	O
for	O	ADP	O
MECC	O	NOUN	B
.	O	PUNCT	O


Study	O	NOUN	B
design	O	NOUN	B
and	O	CCONJ	O
rationale	O	NOUN	B
of	O	ADP	O
a	O	DET	O
dose-ranging	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
LX4211	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
dual	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
SGLT1	O	NOUN	B
and	O	CCONJ	O
SGLT2	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
type	B-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
inadequately	I-P	ADV	B
controlled	I-P	VERB	B
on	I-P	ADP	O
metformin	I-P	NOUN	B
monotherapy	I-P	NOUN	B
.	I-P	PUNCT	O


Sodium-glucose	O	ADJ	B
cotransporters	O	NOUN	I
1	O	NUM	I
(	O	PUNCT	O
SGLT1	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
(	O	PUNCT	O
SGLT2	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
the	O	DET	O
major	O	ADJ	O
cellular	O	ADJ	B
transporters	O	NOUN	I
responsible	O	ADJ	O
for	O	ADP	O
gastrointestinal	O	ADJ	B
(	O	PUNCT	I
GI	O	NOUN	O
)	O	PUNCT	O
glucose	O	NOUN	O
absorption	O	NOUN	O
and	O	CCONJ	O
renal	O	ADJ	B
glucose	O	NOUN	I
reabsorption	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


LX4211	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
dual	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
SGLT1	O	NOUN	B
and	O	CCONJ	O
SGLT2	O	NOUN	B
,	O	PUNCT	O
reduces	O	VERB	B
glucose	O	NOUN	B
absorption	O	NOUN	I
from	O	ADP	O
the	O	DET	O
GI	O	NOUN	B
tract	O	NOUN	I
and	O	CCONJ	O
enhances	O	VERB	B
urinary	O	ADJ	B
glucose	O	NOUN	I
excretion	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
several	O	ADJ	O
SGLT2-selective	O	ADJ	B
inhibitors	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
large	O	ADJ	O
phase	O	NOUN	B
2	O	NUM	I
studies	O	NOUN	I
,	O	PUNCT	O
dual	O	ADJ	O
inhibition	O	NOUN	B
of	O	ADP	O
SGLT1	O	NOUN	B
and	O	CCONJ	O
SGLT2	O	NOUN	B
is	O	AUX	O
novel	O	ADJ	O
at	O	ADP	O
this	O	DET	O
stage	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
development	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
has	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
clinical-trial	O	ADJ	B
design	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
article	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
describe	O	VERB	O
the	O	DET	O
design	O	NOUN	B
and	O	CCONJ	O
rationale	O	NOUN	B
of	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	B
group	O	NOUN	I
study	O	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	I-OUT	ADP	O
LX4211	I-OUT	NOUN	B
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
mellitus	I-P	NOUN	I
who	I-P	PRON	O
have	I-P	AUX	O
inadequate	I-P	ADJ	B
glycemic	I-OUT	ADJ	B
control	I-OUT	NOUN	I
on	I-P	ADP	O
metformin	I-P	NOUN	B
monotherapy	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
endpoint	O	NOUN	I
is	O	AUX	O
the	O	DET	O
change	O	NOUN	O
in	O	ADP	O
glycated	B-OUT	ADJ	B
hemoglobin	I-OUT	NOUN	I
A1c	I-OUT	NOUN	I
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
week	O	NOUN	B
12	O	NUM	O
.	O	PUNCT	O


Secondary	O	ADJ	B
endpoints	O	NOUN	I
include	O	VERB	O
the	O	DET	O
proportion	B-OUT	NOUN	B
of	I-OUT	ADP	O
subjects	I-OUT	NOUN	B
achieving	I-OUT	VERB	O
a	I-OUT	DET	O
glycated	I-OUT	ADJ	B
hemoglobin	I-OUT	NOUN	I
A1c	I-OUT	NOUN	I
value	I-OUT	NOUN	I
of	I-OUT	ADP	O
<	I-OUT	CCONJ	O
7	I-OUT	NUM	O
%	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
change	I-OUT	NOUN	O
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
in	I-OUT	ADP	O
fasting	I-OUT	VERB	B
plasma	I-OUT	NOUN	B
glucose	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
postprandial	I-OUT	ADJ	B
glucose	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
as	I-OUT	ADP	O
part	I-OUT	NOUN	O
of	I-OUT	ADP	O
an	I-OUT	DET	O
oral	I-OUT	ADJ	B
glucose	I-OUT	NOUN	I
tolerance	I-OUT	NOUN	I
test	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Safety	B-OUT	NOUN	B
is	O	AUX	O
evaluated	O	VERB	B
with	O	ADP	O
particular	O	ADJ	O
focus	O	NOUN	O
on	O	ADP	O
hypoglycemia	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
GI	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
genitourinary	I-OUT	ADJ	B
tract	I-OUT	NOUN	I
infections	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Approval	O	PROPN	B
summary	O	NOUN	O
:	O	PUNCT	O
imatinib	B-I	NOUN	B
mesylate	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
metastatic	B-P	ADJ	B
and/or	I-P	CCONJ	O
unresectable	I-P	ADJ	B
malignant	I-P	ADJ	B
gastrointestinal	I-OUT	ADJ	O
stromal	I-OUT	ADJ	O
tumors	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
application	O	NOUN	B
was	O	AUX	O
to	O	PART	O
fulfill	O	VERB	O
a	O	DET	O
postmarketing	O	NOUN	B
commitment	O	NOUN	B
to	O	PART	O
provide	O	VERB	O
long-term	O	ADJ	B
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
data	O	NOUN	B
on	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
imatinib	B-OUT	NOUN	B
mesylate	I-OUT	NOUN	B
(	O	PUNCT	O
Gleevec	O	NOUN	B
;	O	PUNCT	O
Novartis	O	PROPN	B
Pharmaceuticals	O	PROPN	B
,	O	PUNCT	O
East	O	PROPN	B
Hanover	O	PROPN	I
,	O	PUNCT	O
NJ	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
CD117	I-P	NOUN	B
(	I-P	PUNCT	O
+	I-P	CCONJ	O
)	I-P	PUNCT	O
unresectable	I-P	ADJ	B
and/or	I-P	CCONJ	O
metastatic	I-P	ADJ	B
malignant	I-P	ADJ	I
gastrointestinal	I-P	ADJ	B
stromal	I-P	ADJ	I
tumors	I-P	NOUN	I
(	I-P	PUNCT	O
GISTs	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
application	O	NOUN	B
also	O	ADV	O
provides	O	VERB	O
evidence	O	NOUN	B
to	O	PART	O
support	O	VERB	O
a	O	DET	O
change	O	NOUN	B
in	O	ADP	O
the	O	DET	O
label	O	NOUN	B
to	O	PART	O
allow	O	VERB	O
for	O	ADP	O
an	O	DET	O
escalation	O	NOUN	B
of	O	ADP	O
imatinib	B-OUT	NOUN	B
dosing	O	VERB	B
to	O	PART	O
800	O	NUM	O
mg/day	O	NOUN	O
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
progressive	I-P	ADJ	B
disease	I-P	NOUN	O
on	I-P	ADP	O
a	I-P	DET	O
lower	I-P	ADJ	B
dose	I-P	NOUN	I
.	I-P	PUNCT	O


Two	O	NUM	O
open-label	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
intergroup	O	NOUN	B
,	O	PUNCT	O
international	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
phase	O	NOUN	I
III	O	NUM	I
studies	O	NOUN	I
were	O	AUX	O
submitted	O	VERB	B
--	O	PUNCT	O
one	O	NUM	O
conducted	O	VERB	O
by	O	ADP	O
the	O	DET	O
European	B-P	PROPN	B
Organization	I-P	PROPN	I
for	I-P	ADP	I
Research	I-P	PROPN	I
and	I-P	CCONJ	I
Treatment	I-P	NOUN	B
of	I-P	ADP	O
Cancer	I-OUT	NOUN	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
946	I-P	NUM	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
the	I-P	DET	O
other	I-P	ADJ	O
by	I-P	ADP	O
the	I-P	DET	O
Southwest	I-P	PROPN	B
Oncology	I-OUT	PROPN	I
Group	I-P	PROPN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
746	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
compared	O	VERB	O
400	O	NUM	O
mg/day	O	NOUN	O
of	O	ADP	O
imatinib	B-OUT	NOUN	B
with	O	ADP	O
800	O	NUM	O
mg/day	O	NOUN	O
of	O	ADP	O
imatinib	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
combined	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
studies	O	NOUN	B
was	O	AUX	O
prospectively	O	ADV	O
defined	O	VERB	O
and	O	CCONJ	O
agreed	O	VERB	O
to	O	ADP	O
by	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
protocols	O	NOUN	B
allowed	O	VERB	O
patients	O	NOUN	B
randomized	O	ADJ	B
to	O	PART	O
the	O	DET	O
400-mg/day	O	NOUN	O
imatinib	B-I	NOUN	B
arm	O	NOUN	O
to	O	PART	O
cross	O	VERB	O
over	O	ADV	O
to	O	PART	O
800	O	NUM	O
mg/day	O	ADJ	O
imatinib	B-OUT	NOUN	B
at	O	ADP	O
progression	O	NOUN	B
.	O	PUNCT	O


Objective	O	ADJ	O
responses	O	NOUN	B
were	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
>	O	X	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
either	O	CCONJ	O
imatinib	B-OUT	NOUN	B
dose	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	O	ADJ	O
progression-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
time	I-OUT	NOUN	I
was	O	AUX	O
approximately	O	ADV	O
20	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
median	O	ADJ	B
overall	O	ADJ	O
survival	O	NOUN	O
(	O	PUNCT	O
OS	O	NOUN	B
)	O	PUNCT	O
time	O	NOUN	O
was	O	AUX	O
approximately	O	ADV	O
49	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
347	O	NUM	O
patients	O	NOUN	B
crossed	O	VERB	B
over	O	ADP	O
to	O	PART	O
800	O	NUM	O
mg/day	O	ADJ	O
imatinib	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
progression	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
OS	I-OUT	NOUN	B
time	O	NOUN	O
after	O	ADP	O
crossover	O	NOUN	B
was	O	AUX	O
14.3	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AEs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
fluid	O	ADJ	B
retention	O	NOUN	I
,	O	PUNCT	O
nausea	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
skin	I-OUT	NOUN	B
rash	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
gastrointestinal	I-OUT	ADJ	B
complaints	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
myalgia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
laboratory	O	ADJ	B
abnormality	B-OUT	NOUN	I
was	I-OUT	AUX	O
anemia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Most	O	ADV	O
often	O	ADV	O
the	O	DET	O
AEs	B-OUT	NOUN	B
were	O	AUX	O
of	O	ADP	O
mild-to-moderate	O	ADJ	B
severity	O	NOUN	B
.	O	PUNCT	O


Fluid	O	ADJ	B
retention	O	NOUN	I
events	O	NOUN	I
and	O	CCONJ	O
skin	O	NOUN	B
rash	O	NOUN	I
were	O	AUX	O
numerically	O	ADV	B
reported	O	VERB	O
more	O	ADV	O
often	O	ADV	O
in	O	ADP	O
the	O	DET	O
800-mg/day	O	NOUN	B
treatment	O	NOUN	B
cohort	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
bumetanide	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
autism	B-P	NOUN	B
in	I-P	ADP	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


Gamma	O	NOUN	B
aminobutyric	O	ADJ	I
acid	O	NOUN	I
(	O	PUNCT	O
GABA	O	NOUN	B
)	O	PUNCT	O
-mediated	O	ADJ	O
synapses	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
oscillations	O	NOUN	B
they	O	PRON	O
orchestrate	O	VERB	B
are	O	AUX	O
altered	O	VERB	O
in	O	ADP	O
autism	O	NOUN	B
.	O	PUNCT	O


GABA-acting	O	ADJ	B
benzodiazepines	B-I	NOUN	I
exert	O	VERB	O
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
autism	O	NOUN	B
paradoxical	O	ADJ	B
effects	B-OUT	NOUN	O
,	O	PUNCT	O
raising	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
like	O	ADP	O
in	O	ADP	O
epilepsies	O	NOUN	B
,	O	PUNCT	O
GABA	O	NOUN	B
excites	O	VERB	O
neurons	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
elevated	O	ADJ	B
intracellular	O	ADJ	B
concentrations	O	NOUN	B
of	O	ADP	O
chloride	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
a	O	DET	O
successful	O	ADJ	O
pilot	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
now	O	ADV	O
performed	O	VERB	O
a	O	DET	O
double-blind	O	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
using	O	VERB	O
the	O	DET	O
diuretic	O	ADJ	B
,	O	PUNCT	O
chloride-importer	O	CCONJ	O
antagonist	O	NOUN	B
bumetanide	B-I	NOUN	B
that	O	PRON	O
reduces	O	VERB	O
intracellular	O	ADJ	B
chloride	O	NOUN	B
reinforcing	O	VERB	O
GABAergic	O	ADJ	B
inhibition	O	NOUN	I
.	O	PUNCT	O


Sixty	B-P	NUM	B
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
or	I-P	CCONJ	O
Asperger	I-P	NOUN	B
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
3-11	I-P	NUM	O
years	I-P	NOUN	O
old	I-P	ADJ	O
)	I-P	PUNCT	O
received	O	VERB	O
for	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
placebo	B-I	NOUN	B
or	O	CCONJ	O
bumetanide	B-I	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
1-month	O	ADJ	O
wash	O	NOUN	O
out	O	ADP	O
.	O	PUNCT	O


Determination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
autism	O	NOUN	B
was	O	AUX	O
made	O	VERB	O
with	O	ADP	O
video	O	NOUN	B
films	O	NOUN	B
at	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
(	O	PUNCT	O
D0	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
D90	O	NOUN	B
by	O	ADP	O
blind	O	ADJ	B
,	O	PUNCT	O
independent	O	ADJ	O
evaluators	O	NOUN	B
.	O	PUNCT	O


Bumetanide	B-I	NOUN	B
reduced	O	VERB	B
significantly	O	ADV	O
the	O	DET	O
Childhood	B-OUT	PROPN	B
Autism	I-OUT	PROPN	I
Rating	I-OUT	NOUN	I
Scale	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
CARS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
(	O	PUNCT	O
D90-D0	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.004	O	NUM	O
treated	O	VERB	B
vs	O	CCONJ	O
placebo	B-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
Clinical	B-OUT	PROPN	B
Global	I-OUT	PROPN	I
Impressions	I-OUT	PROPN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.017	O	NUM	O
treated	O	VERB	B
vs	O	CCONJ	O
placebo	B-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
Autism	B-OUT	PROPN	B
Diagnostic	I-OUT	PROPN	I
Observation	I-OUT	PROPN	I
Schedule	I-OUT	PROPN	I
values	I-OUT	NOUN	I
when	O	SCONJ	O
the	O	DET	O
most	O	ADV	O
severe	O	ADJ	B
cases	O	NOUN	B
(	O	PUNCT	O
CARS	O	NOUN	B
values	O	NOUN	I
above	O	ADP	O
the	O	DET	O
mean	O	NOUN	O
±	O	PROPN	O
s.d	O	ADV	O
.	O	PUNCT	O


;	O	PUNCT	O
n=9	O	X	O
)	O	PUNCT	O
were	O	AUX	O
removed	O	VERB	O
(	O	PUNCT	O
Wilcoxon	O	PROPN	B
test	O	NOUN	I
:	O	PUNCT	O
P-value=0.031	O	NOUN	B
;	O	PUNCT	O
Student	O	NOUN	B
's	O	PART	I
t-test	O	NOUN	I
:	O	PUNCT	O
P-value=0.017	O	NOUN	B
)	O	PUNCT	O
.	B-OUT	PUNCT	O


Side	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
an	O	DET	O
occasional	B-OUT	ADJ	O
mild	I-OUT	ADJ	O
hypokalaemia	I-OUT	NOUN	B
(	O	PUNCT	O
3.0-3.5	O	NUM	O
mM	O	NOUN	O
l	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
K	O	NOUN	O
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
)	O	PUNCT	O
that	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
supplemental	O	ADJ	O
potassium	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
companion	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
chronic	O	ADJ	B
bumetanide	O	NOUN	B
treatment	O	NOUN	B
significantly	O	ADV	O
improved	B-OUT	VERB	O
accuracy	I-OUT	NOUN	B
in	I-OUT	ADP	O
facial	I-OUT	ADJ	B
emotional	I-OUT	ADJ	I
labelling	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
increased	I-OUT	VERB	B
brain	I-OUT	NOUN	B
activation	I-OUT	NOUN	I
in	I-OUT	ADP	O
areas	I-OUT	NOUN	O
involved	I-OUT	VERB	O
in	I-OUT	ADP	O
social	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
emotional	I-OUT	ADJ	B
perception	I-OUT	NOUN	I
(	O	PUNCT	O
Hadjikhani	O	PROPN	O
et	O	X	O
al.	O	X	O
,	O	PUNCT	O
submitted	O	VERB	O
)	O	PUNCT	O
.	O	PUNCT	O


Therefore	B-I	ADV	O
,	I-I	PUNCT	O
bumetanide	I-I	NOUN	B
is	O	AUX	O
a	O	DET	O
promising	O	ADJ	O
novel	O	ADJ	O
therapeutic	O	ADJ	B
agent	O	NOUN	I
to	O	PART	O
treat	O	VERB	B
autism	O	NOUN	B
.	O	PUNCT	O


Larger	O	ADJ	O
trials	O	NOUN	B
are	O	AUX	O
warranted	O	VERB	O
to	O	PART	O
better	O	ADV	O
determine	O	VERB	O
the	O	DET	O
population	O	NOUN	B
best	O	ADV	O
suited	O	VERB	O
for	O	ADP	O
this	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
fluoxetine	B-I	NOUN	B
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
obesity	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Our	O	PRON	O
study	O	NOUN	B
aims	O	VERB	O
at	O	ADP	O
assessing	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
fluoxetine	B-I	NOUN	B
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
obesity	B-P	NOUN	B
using	O	VERB	O
a	O	DET	O
double-blind	O	ADJ	B
crossover	O	NOUN	B
design	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
42	B-P	NUM	O
obese	I-P	ADJ	B
women	I-P	NOUN	B
(	I-P	PUNCT	O
body	I-P	NOUN	B
mass	I-P	NOUN	I
index	I-P	NOUN	I
35.9	I-P	NUM	O
+/-	I-P	CCONJ	O
5.3	I-P	NUM	O
kg/m2	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
obese	B-P	ADJ	B
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
start	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
fluoxetine	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
for	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
period	O	NOUN	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
1-month	O	ADJ	O
washout	O	NOUN	O
period	O	NOUN	B
,	O	PUNCT	O
treatment	O	NOUN	B
was	O	AUX	O
crossed	O	VERB	O
for	O	ADP	O
the	O	DET	O
following	O	VERB	O
3	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
period	O	NOUN	O
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
weight	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
when	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
fluoxetine	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	O
period	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
group	O	NOUN	B
B	O	NOUN	O
period	O	NOUN	O
2	O	NUM	O
)	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
placebo	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
period	O	NOUN	O
1	O	NUM	O
and	O	CCONJ	O
group	O	NOUN	B
A	O	PROPN	O
period	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
monthly	B-OUT	ADJ	B
weight	I-OUT	NOUN	B
reduction	I-OUT	NOUN	I
during	O	ADP	O
both	O	DET	O
treatments	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
demonstrated	O	VERB	O
that	O	SCONJ	O
serotoninergic	B-I	ADJ	B
drugs	I-I	NOUN	I
such	O	ADJ	O
as	O	ADP	O
fluoxetine	B-I	NOUN	B
need	O	VERB	O
further	O	ADJ	O
investigation	O	NOUN	B
before	O	ADP	O
being	O	AUX	O
used	O	VERB	O
indiscriminately	O	ADV	O
in	O	ADP	O
obese	B-P	ADJ	B
subjects	I-P	NOUN	B
.	I-P	PUNCT	O


Six-month	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
on-demand	O	ADJ	B
rabeprazole	B-I	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
maintains	O	VERB	B
symptom	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
non-erosive	I-P	ADJ	B
reflux	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


BACKGROUND	O	NOUN	O
Compliance	O	NOUN	B
studies	O	NOUN	I
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
patients	B-P	NOUN	B
with	I-P	ADP	O
reflux	I-P	NOUN	B
symptoms	I-P	NOUN	B
generally	O	ADV	O
take	O	VERB	O
their	O	PRON	O
medication	O	NOUN	B
only	O	ADV	O
when	O	SCONJ	O
experiencing	O	VERB	O
these	O	DET	O
symptoms	O	NOUN	B
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
on-demand	O	ADJ	B
rabeprazole	B-I	NOUN	B
maintenance	O	NOUN	O
therapy	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
non-erosive	I-P	ADJ	B
reflux	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
This	O	DET	O
multicentre	B-P	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
withdrawal	O	NOUN	B
study	O	NOUN	I
compared	O	VERB	B
6	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
on-demand	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
rabeprazole	B-I	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
vs.	O	CCONJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Adults	B-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
history	I-P	NOUN	B
of	I-P	ADP	O
reflux	I-P	NOUN	B
symptoms	I-P	NOUN	B
,	I-P	PUNCT	O
a	I-P	DET	O
negative	I-P	ADJ	B
endoscopy	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
>	I-P	X	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
3	I-P	NUM	O
days	I-P	NOUN	B
of	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
very	I-P	ADV	O
severe	I-P	ADJ	B
heartburn	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
7	I-P	NUM	O
days	I-P	NOUN	B
before	I-P	ADP	O
enrollment	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
535	I-P	NUM	O
)	I-P	PUNCT	O
entered	O	VERB	O
4	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
open-label	O	ADJ	B
,	O	PUNCT	O
acute	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
rabeprazole	B-I	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
complete	I-P	ADJ	B
symptom	I-OUT	NOUN	B
relief	I-OUT	NOUN	I
then	I-P	ADV	O
entered	I-P	VERB	O
the	I-P	DET	O
on-demand	I-P	ADJ	B
phase	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end-point	O	NOUN	B
was	O	AUX	O
discontinuation	B-OUT	NOUN	B
due	I-OUT	ADJ	O
to	I-OUT	PART	O
lack	I-OUT	NOUN	O
of	I-OUT	ADP	O
heartburn	I-OUT	NOUN	B
control	I-OUT	NOUN	B
during	I-OUT	ADP	O
the	I-OUT	DET	O
on-demand	I-OUT	ADJ	B
phase	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Eighty-three	O	ADJ	O
percent	O	NOUN	O
(	O	PUNCT	O
432	O	NUM	O
of	O	ADP	O
523	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
patients	O	NOUN	B
reported	O	VERB	O
complete	O	ADJ	B
symptom	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
phase	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
on-demand	O	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
discontinuation	I-OUT	NOUN	B
because	I-OUT	SCONJ	O
of	I-OUT	ADP	O
inadequate	I-OUT	ADJ	B
heartburn	I-OUT	NOUN	B
control	I-OUT	NOUN	B
were	O	AUX	O
20	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
28	O	NUM	O
of	O	ADP	O
139	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
placebo	B-I	NOUN	B
vs.	O	CCONJ	O
6	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
16	O	NUM	O
of	O	ADP	O
279	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
rabeprazole	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.00001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Antacid	B-OUT	PROPN	B
use	I-OUT	NOUN	O
was	O	AUX	O
twofold	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	O
vs.	O	CCONJ	O
the	O	DET	O
rabeprazole	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0009	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Rabeprazole	B-I	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
is	O	AUX	O
highly	O	ADV	O
effective	B-OUT	ADJ	B
in	O	ADP	O
acute	B-OUT	ADJ	B
symptom	I-OUT	NOUN	I
relief	I-OUT	NOUN	I
and	O	CCONJ	O
as	O	ADP	O
on-demand	O	ADJ	B
long-term	O	ADJ	B
maintenance	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
non-erosive	B-P	ADJ	B
reflux	I-P	NOUN	I
disease	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Methylprednisolone	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cancer	I-P	NOUN	B
using	I-P	VERB	O
opioids	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
angiotensin-converting	B-I	ADJ	B
enzyme	I-I	NOUN	I
inhibitor	I-I	NOUN	I
imidapril	I-I	NOUN	B
on	O	ADP	O
plasma	O	NOUN	B
plasminogen	O	NOUN	B
activator	O	NOUN	I
inhibitor	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
early	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
angiotensin-converting	B-I	ADJ	B
enzyme	I-I	NOUN	I
(	I-I	PUNCT	O
ACE	I-I	NOUN	B
)	I-I	PUNCT	O
inhibitors	I-I	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
(	O	PUNCT	O
AMI	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
fibrinolytic	B-OUT	ADJ	B
function	I-OUT	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
left	B-OUT	VERB	B
ventricular	I-OUT	ADJ	I
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
plasma	B-OUT	NOUN	B
plasminogen	I-OUT	NOUN	B
activator	I-OUT	NOUN	I
inhibitor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PAI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
activity	I-OUT	NOUN	B
and	O	CCONJ	O
serum	B-OUT	NOUN	B
ACE	I-OUT	NOUN	O
activity	I-OUT	NOUN	O
during	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
40	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
AMI	I-P	NOUN	B
within	I-P	ADP	O
12	I-P	NUM	O
hours	I-P	NOUN	B
after	I-P	ADP	O
the	I-P	DET	O
onset	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
symptom	I-P	NOUN	B
and	I-P	CCONJ	O
who	I-P	PRON	O
randomly	I-P	ADV	O
received	I-P	VERB	O
early	I-P	ADJ	B
treatment	I-P	NOUN	B
with	I-P	ADP	O
either	I-P	CCONJ	O
the	I-P	DET	O
ACE	I-I	NOUN	B
inhibitor	I-I	NOUN	O
imidapril	I-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
20	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
imidapril	I-P	NOUN	B
group	I-P	NOUN	O
and	I-P	CCONJ	O
20	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
placebo	I-P	NOUN	B
group	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
serum	I-OUT	NOUN	B
ACE	I-OUT	NOUN	B
activity	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
imidapril	B-I	NOUN	B
group	O	NOUN	B
decreased	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
8	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
imidapril	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
levels	O	NOUN	B
24	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
administration	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
3.6	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
IU/L	O	NOUN	O
vs	O	CCONJ	O
7.4	O	NUM	O
+/-	O	CCONJ	O
0.8	O	NUM	O
IU/L	O	NOUN	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
plasma	B-OUT	NOUN	B
PAI	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
increased	O	VERB	B
gradually	O	ADV	O
to	O	PART	O
peak	O	VERB	O
levels	O	NOUN	O
16	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
imidapril	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
decreased	O	VERB	B
gradually	O	ADV	B
but	O	CCONJ	O
remained	O	VERB	O
high	O	ADJ	O
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
PAI	I-OUT	NOUN	B
activity	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
imidapril	B-I	NOUN	B
group	O	NOUN	B
decreased	O	VERB	B
rapidly	O	ADV	O
and	O	CCONJ	O
those	O	DET	O
48	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
7.9	O	NUM	O
+/-	O	CCONJ	O
1.9	O	NUM	O
IU/ml	O	NOUN	O
vs	O	CCONJ	O
18.4	O	NUM	O
+/-	O	CCONJ	O
3.5	O	NUM	O
IU/ml	O	NOUN	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
left	I-OUT	VERB	B
ventricular	I-OUT	ADJ	I
ejection	I-OUT	NOUN	I
fraction	I-OUT	NOUN	I
about	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
admission	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
imidapril	O	NOUN	B
group	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
65.9	O	NUM	O
%	O	NOUN	O
+/-	O	CCONJ	O
2.5	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
49.1	O	NUM	O
%	O	NOUN	O
+/-	O	CCONJ	O
4.4	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
imidapril	B-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
ACE	O	NOUN	B
inhibitor	O	NOUN	I
,	O	PUNCT	O
might	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
fibrinolytic	B-OUT	ADJ	B
function	I-OUT	NOUN	I
and	O	CCONJ	O
left	B-OUT	VERB	B
ventricular	I-OUT	ADJ	I
function	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
phase	O	NOUN	I
of	O	ADP	O
myocardial	O	ADJ	B
infarction	O	NOUN	I
.	O	PUNCT	O


Transthoracic	B-I	NOUN	B
versus	I-I	CCONJ	O
transesophageal	I-I	NOUN	B
cardioversion	I-I	NOUN	I
of	I-I	ADP	O
atrial	I-I	ADJ	B
fibrillation	I-I	NOUN	I
under	I-I	ADP	O
light	I-I	ADJ	O
sedation	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Electrical	B-P	ADJ	B
cardioversion	I-P	NOUN	I
(	I-P	PUNCT	O
ECV	I-P	NOUN	B
)	I-P	PUNCT	O
of	I-P	ADP	O
atrial	I-P	ADJ	B
fibrillation	I-P	NOUN	I
(	I-P	PUNCT	O
AF	I-P	NOUN	B
)	I-P	PUNCT	O
is	O	AUX	O
limited	O	VERB	O
by	O	ADP	O
a	O	DET	O
5-10	O	NUM	O
%	O	NOUN	O
failure	O	NOUN	B
rate	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
the	O	DET	O
expense	O	NOUN	O
arising	O	VERB	O
from	O	ADP	O
a	O	DET	O
perceived	O	VERB	B
need	O	NOUN	O
for	O	ADP	O
general	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
transesophageal	O	NOUN	B
approach	O	NOUN	I
using	O	VERB	O
light	O	ADJ	B
sedation	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
as	O	ADP	O
a	O	DET	O
means	O	NOUN	O
of	O	ADP	O
augmenting	O	VERB	B
the	O	DET	O
success	O	NOUN	B
rate	O	NOUN	B
and	O	CCONJ	O
avoiding	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
general	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
high	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
success	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
lower	O	ADJ	B
energy	O	NOUN	I
requirement	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
biphasic	O	ADJ	B
cardioversion	O	NOUN	I
might	O	AUX	O
eliminate	O	VERB	O
any	O	DET	O
advantage	O	NOUN	O
of	O	ADP	O
the	O	DET	O
transesophageal	O	NOUN	B
approach	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
randomly	O	ADV	O
assigned	O	VERB	O
60	B-P	NUM	O
patients	I-P	NOUN	B
attending	I-P	VERB	B
for	I-P	ADP	O
ECV	I-I	NOUN	B
of	I-I	ADP	O
persistent	I-I	ADJ	B
AF	I-I	NOUN	I
to	I-I	ADP	O
a	I-I	DET	O
transesophageal	I-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
transthoracic	I-I	NOUN	B
approach	I-I	NOUN	I
.	I-I	PUNCT	O


Sedation	O	NOUN	B
of	O	ADP	O
moderate	O	ADJ	B
depth	O	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
with	O	ADP	O
intravenous	B-I	ADJ	B
midazolam	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
midazolam	O	NOUN	B
was	O	AUX	O
titrated	O	VERB	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
manner	O	NOUN	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Sinus	B-OUT	NOUN	B
rhythm	I-OUT	NOUN	I
was	O	AUX	O
restored	O	VERB	B
in	O	ADP	O
29/30	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
97	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
using	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
shocks	O	NOUN	B
for	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
1.3	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
transesophageal	O	NOUN	B
vs	O	CCONJ	O
1.4	O	NUM	O
+/-	O	CCONJ	O
0.7	O	NUM	O
transthoracic	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
NS	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
procedure	O	NOUN	B
duration	O	NOUN	B
(	O	PUNCT	O
14.1	O	NUM	O
+/-	O	CCONJ	O
8.2	O	NUM	O
minutes	O	NOUN	O
vs	O	CCONJ	O
13.8	O	NUM	O
+/-	O	CCONJ	O
7.5	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
NS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
received	O	VERB	O
similar	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
midazolam	O	NOUN	B
(	O	PUNCT	O
4.2	O	NUM	O
+/-	O	CCONJ	O
2.7	O	NUM	O
mg	O	NOUN	O
vs	O	CCONJ	O
4.4	O	NUM	O
+/-	O	CCONJ	O
2.8	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
NS	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
reported	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
discomfort	B-OUT	NOUN	B
score	I-OUT	NOUN	I
in	O	ADP	O
(	O	PUNCT	O
0.9	O	NUM	O
+/-	O	CCONJ	O
1.3	O	NUM	O
vs	O	CCONJ	O
1.1	O	NUM	O
+/-	O	CCONJ	O
1.8	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
NS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
complication	B-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
AF	O	PROPN	I
may	O	AUX	O
be	O	AUX	O
cardioverted	O	VERB	B
safely	B-OUT	ADV	O
and	I-OUT	CCONJ	O
effectively	I-OUT	ADV	O
by	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
transthoracic	O	NOUN	B
or	O	CCONJ	O
a	O	DET	O
transesophageal	O	NOUN	B
approach	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
sedation	O	NOUN	B
of	O	ADP	O
moderate	O	ADJ	B
depth	O	NOUN	B
renders	O	VERB	O
cardioversion	O	NOUN	B
by	O	ADP	O
either	O	DET	O
approach	O	NOUN	O
acceptable	O	ADJ	B
.	O	PUNCT	O


As	O	ADP	O
transesophageal	O	NOUN	B
ECV	O	PROPN	I
shows	O	VERB	O
no	O	DET	O
clear	O	ADJ	O
advantage	O	NOUN	O
,	O	PUNCT	O
transthoracic	O	NOUN	B
cardioversion	O	NOUN	I
should	O	AUX	O
remain	O	VERB	O
the	O	DET	O
approach	O	NOUN	O
of	O	ADP	O
first	O	ADJ	O
choice	O	NOUN	O
.	O	PUNCT	O


Assessment	O	NOUN	B
from	O	ADP	O
Functional	O	ADJ	B
Perspectives	O	PROPN	O
:	O	PUNCT	O
Using	O	VERB	O
Sensorimotor	B-I	NOUN	B
Control	I-I	PROPN	I
in	I-I	ADP	O
the	I-I	DET	O
Hand	I-I	NOUN	O
as	O	ADP	O
an	O	DET	O
Outcome	O	PROPN	B
Indicator	O	NOUN	I
in	O	ADP	O
the	O	DET	O
Surgical	O	PROPN	B
Treatment	O	NOUN	I
of	O	ADP	O
Carpal	B-P	PROPN	B
Tunnel	I-P	PROPN	I
Syndrome	I-P	PROPN	I
.	I-P	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
sensorimotor	B-OUT	NOUN	B
control	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
hand	I-OUT	NOUN	B
could	O	AUX	O
be	O	AUX	O
an	O	DET	O
outcome	B-OUT	NOUN	B
indicator	I-OUT	NOUN	I
after	O	ADP	O
carpal	O	ADJ	B
tunnel	O	NOUN	I
release	O	NOUN	B
(	O	PUNCT	O
CTR	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
this	O	DET	O
work	O	NOUN	O
examined	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
'	O	PART	O
manual	B-I	ADJ	B
tactile	I-I	NOUN	I
test	I-I	NOUN	I
(	O	PUNCT	O
MTT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
pinch-holding-up	B-I	VERB	B
activity	I-I	NOUN	I
(	O	PUNCT	O
PHUA	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
two-point	B-I	ADJ	B
discrimination	I-I	NOUN	I
(	O	PUNCT	O
2PD	O	X	O
)	O	PUNCT	O
and	O	CCONJ	O
Semmes-Weinstein	B-I	NOUN	B
monofilament	I-I	NOUN	I
(	O	PUNCT	O
SWM	O	NOUN	B
)	O	PUNCT	O
tests	O	NOUN	B
.	O	PUNCT	O


Participants	O	NOUN	B
included	O	VERB	O
30	B-P	NUM	O
predominantly	I-P	ADV	O
sensory	I-P	ADJ	B
neuropathy	I-P	NOUN	I
CTS	I-P	NOUN	B
patients	I-P	NOUN	B
,	I-P	PUNCT	O
as	I-P	ADP	O
confirmed	I-P	VERB	O
by	I-P	ADP	O
a	I-P	DET	O
nerve	I-P	NOUN	B
conduction	I-P	NOUN	I
study	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
MTT	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
precision	I-OUT	NOUN	B
pinch	I-OUT	NOUN	O
performance	I-OUT	NOUN	B
in	I-OUT	ADP	O
PHUA	I-OUT	PROPN	B
and	I-I	CCONJ	O
traditional	I-OUT	ADJ	B
sensibility	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2PD	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
SWM	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
tests	I-OUT	NOUN	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
examine	O	VERB	O
different	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
sensory	B-OUT	ADJ	B
status	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
time-points	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
weeks	O	NOUN	B
before	O	ADP	O
operation	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
month	O	NOUN	B
post-operation	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
single-blind	O	ADJ	B
design	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
significant	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sensory	B-OUT	ADJ	B
function	I-OUT	NOUN	I
as	O	ADP	O
detected	O	VERB	B
by	O	ADP	O
the	O	DET	O
2PD	B-I	NOUN	O
and	O	CCONJ	O
SWM	B-I	NOUN	B
tests	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
sensorimotor	B-OUT	NOUN	B
function	I-OUT	NOUN	I
as	O	ADP	O
detected	O	VERB	B
by	O	ADP	O
the	O	DET	O
MTT	B-I	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
PHUA	B-I	NOUN	B
test	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
CTR	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
responsiveness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
SWM	B-I	NOUN	B
,	I-I	PUNCT	O
MTT	I-I	NOUN	B
and	I-I	CCONJ	O
PHUA	I-I	NOUN	B
tests	I-I	NOUN	I
(	O	PUNCT	O
effect	O	X	B
size	O	X	I
>	O	X	O
0.5	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
are	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
two-point	O	ADJ	B
discrimination	O	NOUN	I
test	O	NOUN	I
(	O	PUNCT	O
effect	O	NOUN	B
size	O	NOUN	I
<	O	X	O
0.5	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
pinch	B-OUT	NOUN	B
strength	I-OUT	NOUN	I
saw	O	VERB	O
a	O	DET	O
decline	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
baseline	O	NOUN	B
with	O	ADP	O
a	O	DET	O
moderate	O	ADJ	B
effect	O	NOUN	O
sizes	O	NOUN	O
(	O	PUNCT	O
effect	O	NOUN	B
size	O	NOUN	I
=	O	ADJ	O
0.7	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
cohort	O	NOUN	B
study	O	NOUN	I
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
MTT	B-I	NOUN	B
and	O	CCONJ	O
PHUA	B-I	PROPN	B
test	O	NOUN	I
can	O	AUX	O
both	O	DET	O
meet	O	VERB	O
all	O	DET	O
the	O	DET	O
statistical	O	ADJ	B
criteria	O	NOUN	I
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
assessing	O	VERB	B
treatment	O	NOUN	B
outcomes	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
CTS	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
work	O	NOUN	O
provide	O	VERB	O
clinicians	O	NOUN	B
with	O	ADP	O
the	O	DET	O
information	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
sensorimotor	B-OUT	NOUN	B
functions	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
hands	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
assessed	O	VERB	B
by	O	ADP	O
MTT	B-I	NOUN	B
and	I-I	CCONJ	O
PHUA	I-I	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
responsive	O	ADJ	B
to	O	PART	O
clinical	O	ADJ	B
changes	O	NOUN	I
due	O	ADP	O
to	O	ADP	O
CTR	O	NOUN	B
.	O	PUNCT	O


Value	O	NOUN	B
of	O	ADP	O
an	O	DET	O
anal	B-I	ADJ	B
dilator	I-I	NOUN	I
after	O	ADP	O
anal	O	ADJ	B
stretch	O	NOUN	B
for	O	ADP	O
haemorrhoids	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
trial	O	NOUN	O
compared	O	VERB	O
anal	B-I	ADJ	B
stretch	I-I	NOUN	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
continued	I-I	VERB	O
dilatation	I-I	NOUN	B
for	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
89	B-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
haemorrhoids	I-P	NOUN	B
.	I-P	PUNCT	O


Complications	B-OUT	NOUN	B
of	I-OUT	ADP	O
therapy	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
only	O	ADV	O
4	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
had	O	AUX	O
transient	O	ADJ	B
incontinence	B-OUT	NOUN	B
of	O	ADP	O
flatus	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
patients	O	NOUN	B
were	O	AUX	O
reviewed	O	VERB	B
four	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
4	O	NUM	O
of	O	ADP	O
44	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
who	O	PRON	O
used	O	VERB	O
a	O	DET	O
dilator	O	NOUN	B
had	O	AUX	O
not	O	PART	O
been	O	AUX	O
improved	O	VERB	B
and	O	CCONJ	O
required	O	VERB	O
additional	O	ADJ	O
therapy	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
15	O	NUM	O
of	O	ADP	O
42	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
36	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
anal	B-I	ADJ	B
stretch	I-I	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
an	O	DET	O
anal	O	ADJ	B
dilator	O	NOUN	I
improves	O	VERB	B
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
anal	B-OUT	ADJ	B
stretch	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Plasma	O	NOUN	B
pH	O	NOUN	B
does	O	AUX	O
not	O	PART	O
influence	O	VERB	B
the	O	DET	O
cerebral	B-P	ADJ	B
metabolic	I-P	ADJ	O
ratio	I-P	NOUN	O
during	I-P	ADP	O
maximal	I-P	ADJ	B
whole	I-P	ADJ	B
body	I-P	NOUN	I
exercise	I-P	NOUN	I
.	I-P	PUNCT	O


Exercise	O	NOUN	B
lowers	O	VERB	O
the	O	DET	O
cerebral	O	ADJ	B
metabolic	O	ADJ	O
ratio	O	NOUN	O
of	O	ADP	O
O2	O	NOUN	B
to	O	PART	O
carbohydrate	O	NOUN	B
(	O	PUNCT	O
glucose+1/2	O	X	B
lactate	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
metabolic	O	ADJ	B
acidosis	O	NOUN	I
appears	O	VERB	O
to	O	PART	O
promote	B-OUT	VERB	B
cerebral	I-OUT	ADJ	B
lactate	I-OUT	NOUN	I
uptake	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
pH	O	NOUN	B
on	O	ADP	O
cerebral	O	ADJ	B
lactate	O	NOUN	I
uptake	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
turn	O	NOUN	O
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
cerebral	O	ADJ	B
metabolic	O	ADJ	O
ratio	O	NOUN	O
during	O	ADP	O
exercise	O	NOUN	B
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
.	O	PUNCT	O


Sodium	B-I	NOUN	B
bicarbonate	I-I	NOUN	I
(	I-I	PUNCT	O
Bicarb	I-I	NOUN	B
,	I-I	PUNCT	O
1	I-I	NUM	O
M	I-I	NOUN	B
;	I-I	PUNCT	O
350-500	I-I	NUM	O
ml	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
an	I-I	DET	O
equal	I-I	ADJ	O
volume	I-I	NOUN	B
of	I-I	ADP	O
normal	I-I	ADJ	B
saline	I-I	NOUN	I
(	I-I	PUNCT	O
Sal	I-I	NOUN	B
)	I-I	PUNCT	O
was	I-I	AUX	O
infused	I-I	VERB	B
intravenously	I-I	ADV	B
at	I-I	ADP	O
a	I-I	DET	O
constant	I-I	ADJ	B
rate	I-I	NOUN	B
during	I-I	ADP	O
a	I-I	DET	O
'2000	I-I	ADJ	B
m	I-I	NOUN	I
'	I-I	PART	O
maximal	I-I	ADJ	B
ergometer	I-I	NOUN	I
row	I-I	NOUN	I
in	O	ADP	O
six	B-P	NUM	O
male	I-P	NOUN	B
oarsmen	I-P	NOUN	B
(	I-P	PUNCT	O
23±2	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
mean±S.D.	I-P	NOUN	O
)	I-P	PUNCT	O
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
Sal	O	PROPN	B
trial	B-OUT	NOUN	I
,	I-OUT	PUNCT	O
pH	I-OUT	NOUN	B
decreased	O	VERB	B
from	O	ADP	O
7.41±0.01	O	ADJ	O
at	O	ADP	O
rest	O	NOUN	O
to	O	ADP	O
7.02±0.02	O	NOUN	O
but	O	CCONJ	O
only	O	ADV	O
to	O	PART	O
7.36±0.02	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
Bicarb	O	NOUN	B
trial	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Arterial	B-OUT	ADJ	B
lactate	I-OUT	NOUN	I
increased	O	VERB	B
to	O	PART	O
21.4±0.8	O	NUM	O
and	O	CCONJ	O
32.7±2.3	O	NUM	O
mM	O	NOUN	O
during	O	ADP	O
the	O	DET	O
Sal	O	NOUN	B
and	O	CCONJ	O
Bicarb	O	NOUN	B
trials	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Also	B-OUT	ADV	O
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
arterial-jugular	I-OUT	ADJ	B
venous	I-OUT	ADJ	B
lactate	I-OUT	NOUN	I
difference	O	NOUN	I
increased	O	VERB	B
from-0.03±0.01	O	NUM	O
mM	O	NOUN	O
at	O	ADP	O
rest	O	NOUN	O
to	O	ADP	O
3.2±0.9	O	NUM	O
mM	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
3.4±1.4	O	NOUN	O
mM	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
following	O	VERB	O
the	O	DET	O
Sal	O	PROPN	B
and	O	CCONJ	O
Bicarb	O	NOUN	B
trials	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Accordingly	B-OUT	ADV	O
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
cerebral	I-OUT	ADJ	B
metabolic	I-OUT	ADJ	O
ratio	I-OUT	NOUN	O
decreased	O	VERB	B
equally	O	ADV	O
during	O	ADP	O
the	O	DET	O
Sal	O	PROPN	B
and	O	CCONJ	O
Bicarb	O	NOUN	B
trials	O	NOUN	I
:	O	PUNCT	O
from	O	ADP	O
5.8±0.6	O	NOUN	O
at	O	ADP	O
rest	O	NOUN	O
to	O	ADP	O
1.7±0.1	O	NUM	O
and	O	CCONJ	O
1.8±0.2	O	NOUN	O
,	O	PUNCT	O
respectively	B-OUT	ADV	O
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
enlarged	I-OUT	ADJ	B
blood-buffering	I-OUT	ADJ	B
capacity	O	NOUN	O
after	B-I	ADP	O
infusion	I-I	NOUN	B
of	O	ADP	O
Bicarb	B-OUT	NOUN	B
eliminated	I-OUT	VERB	O
metabolic	I-OUT	ADJ	B
acidosis	O	NOUN	I
during	O	ADP	O
maximal	O	ADJ	B
exercise	O	NOUN	B
but	O	CCONJ	O
that	O	DET	O
did	O	AUX	O
not	B-OUT	PART	O
affect	I-OUT	VERB	O
the	I-OUT	DET	O
cerebral	I-OUT	ADJ	B
lactate	I-OUT	NOUN	I
uptake	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
cerebral	I-OUT	ADJ	B
metabolic	I-OUT	ADJ	O
ratio	O	NOUN	O
.	O	PUNCT	O


[	O	PUNCT	O
Efficacy	O	NOUN	B
observation	O	NOUN	B
on	O	ADP	O
chronic	B-OUT	ADJ	B
tension-type	I-OUT	ADJ	I
headache	I-OUT	NOUN	I
treated	O	VERB	B
with	O	ADP	I
acupuncture	O	NOUN	B
at	O	ADP	O
galea	O	NOUN	B
tendon-muscle	O	NOUN	I
node	O	NOUN	I
]	O	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
explore	O	VERB	O
the	O	DET	O
better	O	ADJ	O
therapy	O	NOUN	B
for	O	ADP	O
chronic	B-OUT	ADJ	B
tension-type	I-OUT	ADJ	I
headache	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CTTH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
Two	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
eighty-eight	I-P	NUM	O
cases	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
a	O	DET	O
sticking	B-I	NOUN	O
needling	I-I	NOUN	B
group	I-I	NOUN	B
(	I-I	PUNCT	O
150	I-I	NUM	O
cases	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
an	I-I	DET	O
acupuncture	I-I	NOUN	B
group	I-I	NOUN	I
(	O	PUNCT	O
138	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
sticking	B-I	VERB	O
needling	I-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
the	B-I	DET	O
manual	I-I	ADJ	B
sticking	I-I	NOUN	O
needling	I-I	NOUN	B
technique	I-I	NOUN	I
was	O	AUX	O
adopted	O	VERB	O
to	O	PART	O
stimulate	O	VERB	B
the	O	DET	O
galea	O	NOUN	B
tendon-muscle	O	NOUN	I
node	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
acupuncture	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
conventional	B-I	ADJ	O
acupuncture	I-I	NOUN	B
therapy	I-I	NOUN	I
was	I-I	AUX	O
applied	I-I	VERB	O
to	O	ADP	O
Baihui	O	PROPN	B
(	O	PUNCT	I
GV	O	NOUN	I
20	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
Sishencong	O	PROPN	B
(	O	PUNCT	O
EX-HN	O	NOUN	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Fengchi	O	PROPN	B
(	O	PUNCT	O
GB	O	PROPN	O
20	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Taiyang	O	PROPN	B
(	O	PUNCT	O
EX-HN	O	NOUN	B
5	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Touwei	O	PROPN	B
(	O	PUNCT	O
ST	O	PROPN	B
18	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Hegu	O	NOUN	B
(	O	PUNCT	O
LI	O	NOUN	B
4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
etc	O	X	O
.	O	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
30	O	NUM	O
days	O	NOUN	B
made	O	VERB	O
one	O	NUM	O
session	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
two	O	NUM	O
sessions	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
follow-up	O	ADJ	B
,	O	PUNCT	O
CTTH	B-OUT	NOUN	B
score	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
including	I-OUT	VERB	O
the	I-OUT	DET	O
score	I-OUT	NOUN	B
of	I-OUT	ADP	O
headache	I-OUT	NOUN	B
attack	I-OUT	NOUN	B
frequency	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
score	I-OUT	NOUN	B
of	I-OUT	ADP	O
headache	I-OUT	NOUN	B
severity	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
observed	O	VERB	B
and	O	CCONJ	O
compared	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
separately	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
efficacy	B-OUT	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	ADJ	O
CTTH	B-OUT	NOUN	B
score	I-OUT	NOUN	B
was	O	AUX	O
all	O	DET	O
reduced	O	VERB	B
after	O	ADP	O
treatment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
both	O	DET	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
score	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
sticking	I-OUT	VERB	B
needling	I-OUT	NOUN	I
group	I-OUT	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
acupuncture	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
2.38	O	NUM	O
+/-	O	CCONJ	O
1.22	O	NUM	O
vs	O	CCONJ	O
4.16	O	NUM	O
+/-	O	CCONJ	O
2.54	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
effective	B-OUT	ADJ	B
rate	I-OUT	NOUN	B
was	O	AUX	O
97.3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
146/150	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
sticking	O	VERB	B
needling	O	NOUN	I
group	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
88.4	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
122/138	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
acupuncture	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
manual	B-I	ADJ	B
sticking	I-I	NOUN	O
needling	I-I	NOUN	B
technique	I-I	NOUN	I
at	O	ADP	O
galea	O	NOUN	B
tendon-muscle	O	NOUN	I
node	O	NOUN	I
achieves	O	VERB	O
the	O	DET	O
superior	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
reducing	B-OUT	VERB	B
the	I-OUT	DET	O
pain	I-OUT	NOUN	B
attack	I-OUT	NOUN	I
frequency	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
CTTH	I-OUT	NOUN	B
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
acupuncture	O	NOUN	B
therapy	O	NOUN	I
of	O	ADP	O
the	O	DET	O
routine	O	ADJ	B
acupoint	O	NOUN	B
selection	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
acceptance-	O	NOUN	O
and	O	CCONJ	O
control-based	O	ADJ	B
strategies	O	NOUN	I
for	O	ADP	O
coping	O	VERB	B
with	O	ADP	O
food	O	NOUN	B
cravings	O	NOUN	I
:	O	PUNCT	O
an	O	DET	O
analog	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
utilized	O	VERB	O
an	O	DET	O
analog	B-OUT	ADJ	B
paradigm	I-OUT	NOUN	B
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
two	O	NUM	O
strategies	O	NOUN	B
for	O	ADP	O
coping	O	VERB	B
with	O	ADP	O
food	O	NOUN	B
cravings	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
theorized	O	VERB	O
to	O	PART	O
be	O	AUX	O
critical	O	ADJ	O
to	O	PART	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
weight	O	NOUN	B
loss	O	NOUN	I
.	O	PUNCT	O


Ninety-eight	B-P	NUM	O
undergraduate	I-P	NOUN	B
students	I-P	NOUN	I
were	I-P	AUX	O
given	I-I	VERB	O
transparent	I-I	ADJ	B
boxes	I-I	NOUN	I
of	I-I	ADP	I
chocolate	I-I	NOUN	I
Hershey	I-I	PROPN	I
's	I-I	PART	I
Kisses	I-I	PROPN	I
and	I-I	CCONJ	O
instructed	I-I	VERB	B
to	I-I	PART	O
keep	I-I	VERB	O
the	I-I	DET	O
chocolates	I-I	NOUN	B
with	I-I	ADP	O
them	I-I	PRON	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
to	O	PART	O
eat	O	VERB	O
them	O	PRON	O
,	O	PUNCT	O
for	O	ADP	O
48	O	NUM	O
h.	O	NOUN	O
Before	O	ADP	O
receiving	O	VERB	O
the	O	DET	O
Kisses	O	PROPN	B
,	O	PUNCT	O
participants	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	B-I	DET	O
(	I-I	PUNCT	O
a	I-I	X	O
)	I-I	PUNCT	O
no	I-I	DET	O
intervention	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
b	I-I	X	O
)	I-I	PUNCT	O
instruction	I-I	NOUN	B
in	I-I	ADP	O
control-based	I-I	ADJ	B
coping	I-I	NOUN	I
strategies	I-I	NOUN	O
such	I-I	ADJ	O
as	I-I	ADP	O
distraction	I-I	NOUN	B
and	I-I	CCONJ	O
cognitive	I-I	ADJ	B
restructuring	I-I	NOUN	I
,	I-I	PUNCT	O
or	I-I	CCONJ	O
(	I-I	PUNCT	O
c	I-I	X	O
)	I-I	PUNCT	O
instruction	I-I	NOUN	B
in	I-I	ADP	O
acceptance-based	I-I	ADJ	B
strategies	I-I	NOUN	I
such	I-I	ADJ	O
as	I-I	ADP	O
experiential	I-I	ADJ	B
acceptance	I-I	NOUN	B
and	I-I	CCONJ	O
defusion	I-I	NOUN	B
techniques	I-I	NOUN	I
.	I-I	PUNCT	O


Measures	O	NOUN	B
included	O	VERB	O
the	O	DET	O
Power	B-OUT	PROPN	B
of	I-OUT	ADP	I
Food	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
PFS	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
a	I-OUT	DET	O
measure	I-OUT	NOUN	B
of	I-OUT	ADP	O
psychological	I-OUT	ADJ	B
sensitivity	I-OUT	NOUN	I
to	I-OUT	ADP	O
the	I-OUT	DET	O
food	I-OUT	NOUN	B
environment	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
self-report	I-OUT	ADJ	B
ratings	I-OUT	NOUN	B
of	I-OUT	ADP	O
chocolate	I-OUT	NOUN	B
cravings	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
surreptitiously	I-OUT	ADV	O
recorded	I-OUT	VERB	O
chocolate	I-OUT	NOUN	B
consumption	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Results	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
effect	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
depended	O	VERB	O
on	O	ADP	O
baseline	B-OUT	NOUN	B
PFS	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
that	O	DET	O
acceptance-based	O	ADJ	B
strategies	O	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
better	O	ADJ	O
outcomes	O	NOUN	B
(	B-OUT	PUNCT	O
cravings	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
consumption	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
among	O	ADP	O
those	O	DET	O
reporting	O	VERB	O
the	O	DET	O
highest	O	ADJ	B
susceptibility	O	NOUN	B
to	O	PART	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
food	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
greater	O	ADJ	O
cravings	O	NOUN	B
among	O	ADP	O
those	O	DET	O
who	O	PRON	O
scored	O	VERB	B
lowest	O	ADJ	B
on	O	ADP	O
the	O	DET	O
PFS	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
observed	O	VERB	O
that	O	SCONJ	O
craving	B-OUT	NOUN	B
self-report	I-OUT	ADJ	B
measures	I-OUT	NOUN	B
predicted	O	VERB	O
chocolate	B-OUT	NOUN	B
consumption	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
baseline	O	NOUN	B
PFS	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
predicted	O	VERB	O
both	O	CCONJ	O
cravings	O	NOUN	B
and	O	CCONJ	O
consumption	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
implications	O	NOUN	O
for	O	ADP	O
weight	O	NOUN	B
loss	O	NOUN	I
maintenance	O	NOUN	I
strategies	O	NOUN	O
.	O	PUNCT	O


Prolonged	O	ADJ	B
sirolimus	B-I	NOUN	B
administration	O	NOUN	B
after	B-P	ADP	O
allogeneic	I-P	ADJ	B
hematopoietic	I-P	ADJ	B
cell	I-P	NOUN	I
transplantation	I-P	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
decreased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
moderate-severe	O	ADJ	O
chronic	B-OUT	ADJ	B
graft-versus-host	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Effective	O	ADJ	B
pharmacological	O	ADJ	B
strategies	O	NOUN	O
employed	O	VERB	O
in	O	ADP	O
allogeneic	B-P	ADJ	B
hematopoietic	I-P	ADJ	B
cell	I-P	NOUN	I
transplantation	I-P	NOUN	O
should	O	AUX	O
prevent	O	VERB	O
serious	O	ADJ	O
chronic	O	ADJ	B
graft-versus-host	O	NOUN	I
disease	O	NOUN	I
and	O	CCONJ	O
facilitate	O	VERB	O
donor-recipient	O	ADJ	B
immune	O	ADJ	B
tolerance	O	NOUN	I
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
demonstrated	O	VERB	O
pro-tolerogenic	O	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
sirolimus	B-I	NOUN	B
(	I-I	PUNCT	O
rapamycin	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
an	O	DET	O
agent	O	NOUN	B
with	O	ADP	O
promise	O	NOUN	O
to	O	PART	O
achieve	O	VERB	O
these	O	DET	O
goals	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
long-term	O	ADJ	B
follow-up	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
trial	O	NOUN	I
comparing	O	VERB	O
sirolimus/tacrolimus	B-I	NOUN	B
versus	I-I	CCONJ	O
methotrexate/tacrolimus	I-I	NOUN	B
for	O	ADP	O
graft-versus-host	O	NOUN	B
disease	O	NOUN	I
prevention	O	NOUN	B
in	O	ADP	O
matched	B-P	VERB	O
sibling	I-P	NOUN	B
or	I-P	CCONJ	O
unrelated	I-P	ADJ	O
donor	I-P	NOUN	B
transplant	I-P	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
prolonged	B-P	ADJ	B
sirolimus	I-I	NOUN	B
administration	I-P	NOUN	O
(	I-P	PUNCT	O
≥	I-P	NOUN	O
1	I-P	NUM	O
year	I-P	NOUN	B
post-transplant	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
follow-up	I-OUT	X	B
time	I-OUT	NOUN	O
for	I-OUT	ADP	O
surviving	I-OUT	VERB	B
patients	I-OUT	NOUN	B
at	I-P	ADP	O
time	I-P	NOUN	O
of	I-P	ADP	O
this	I-P	DET	O
analysis	I-P	NOUN	B
was	I-P	AUX	O
41	I-P	NUM	O
months	I-P	NOUN	B
(	I-P	PUNCT	O
range	I-P	NOUN	O
27-60	I-P	NUM	O
)	I-P	PUNCT	O
for	I-I	ADP	O
sirolimus/tacrolimus	I-I	NOUN	B
and	I-P	CCONJ	O
49	I-P	NUM	O
months	I-P	NOUN	B
(	I-P	PUNCT	O
range	I-P	NOUN	O
29-63	I-P	NUM	O
)	I-P	PUNCT	O
for	I-I	ADP	O
methotrexate/tacrolimus	I-I	NOUN	B
.	I-I	PUNCT	O


Sirolimus/tacrolimus	B-I	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
lower	B-OUT	ADJ	O
National	I-OUT	PROPN	B
Institutes	I-OUT	PROPN	I
of	I-OUT	ADP	I
Health	I-OUT	PROPN	I
Consensus	I-OUT	PROPN	I
moderate-severe	I-OUT	ADJ	I
chronic	I-OUT	ADJ	I
graft-versus-host	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
(	O	PUNCT	O
34	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
65	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.004	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
late	I-OUT	ADJ	B
acute	I-OUT	ADJ	I
graft-versus-host	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
(	O	PUNCT	O
20	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
43	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.04	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


While	B-I	SCONJ	O
sirolimus/tacrolimus	I-I	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
lower	B-OUT	ADJ	B
prednisone	I-OUT	NOUN	B
exposure	I-OUT	NOUN	B
and	O	CCONJ	O
earlier	B-OUT	ADJ	O
discontinuation	I-OUT	NOUN	B
of	I-OUT	ADP	O
tacrolimus	I-OUT	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
time	O	NOUN	O
to	O	PART	O
tacrolimus	O	NOUN	B
discontinuation	O	NOUN	B
368	O	NUM	O
days	O	NOUN	B
vs.	O	CCONJ	O
821	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
P=0.002	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	B-OUT	ADP	O
complete	I-OUT	ADJ	O
immune	I-OUT	ADJ	B
suppression	I-OUT	NOUN	I
discontinuation	I-OUT	NOUN	B
(	O	PUNCT	O
60-month	O	ADJ	O
estimate	O	NOUN	B
:	O	PUNCT	O
43	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
31	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.78	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Prolonged	B-I	ADJ	B
sirolimus	I-I	NOUN	B
administration	O	NOUN	B
represents	O	VERB	O
a	O	DET	O
viable	O	ADJ	O
approach	O	NOUN	O
to	O	PART	O
mitigate	O	VERB	B
risk	O	NOUN	I
for	O	ADP	O
moderate-severe	O	ADJ	B
chronic	O	ADJ	I
and	O	CCONJ	O
late	O	ADJ	B
acute	O	ADJ	I
graft-versus-host	O	NOUN	I
disease	O	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
study	O	NOUN	B
of	O	ADP	O
determinants	O	NOUN	B
of	O	ADP	O
successful	O	ADJ	O
immune	O	ADJ	B
suppression	O	NOUN	I
discontinuation	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
recombinant	B-I	ADJ	B
adenovirus-p53	I-I	NOUN	I
combined	I-I	VERB	O
with	I-I	ADP	O
radiotherapy	I-I	NOUN	B
on	O	ADP	O
long-term	B-OUT	ADJ	B
prognosis	I-OUT	NOUN	B
of	I-OUT	ADP	O
advanced	I-OUT	ADJ	B
nasopharyngeal	I-OUT	ADJ	I
carcinoma	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


PURPOSE	O	VERB	O
To	O	PART	O
centrally	O	ADV	O
assess	O	VERB	O
the	O	DET	O
safety	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
efficacy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
6-year	I-OUT	ADJ	O
follow-up	I-OUT	NOUN	B
of	O	ADP	O
recombinant	B-I	ADJ	B
adenovirus-p53	I-I	NOUN	I
(	I-I	PUNCT	O
rAd-p53	I-I	NOUN	B
)	I-I	PUNCT	O
combined	I-I	VERB	O
with	I-I	ADP	O
radiotherapy	I-I	NOUN	B
(	I-I	PUNCT	O
RT	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
nasopharyngeal	I-P	ADJ	B
carcinoma	I-P	NOUN	I
(	I-P	PUNCT	O
NPC	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
A	O	DET	O
randomized	O	ADJ	B
controlled	O	ADJ	I
clinical	O	ADJ	I
study	O	NOUN	I
on	O	ADP	O
rAd-p53	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
RT	I-I	NOUN	B
in	O	ADP	O
42	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
NPC	I-P	NOUN	B
was	I-P	AUX	O
compared	I-P	VERB	B
with	I-P	ADP	O
a	I-P	DET	O
control	I-P	ADJ	B
group	I-P	NOUN	I
of	I-P	ADP	O
40	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
NPC	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
RT	I-I	NOUN	B
alone	I-I	ADV	O
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
rAd-p53	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
RT	I-I	NOUN	B
,	I-I	PUNCT	O
rAd-p53	I-I	NOUN	B
was	O	AUX	O
intratumorally	O	ADV	B
injected	O	VERB	I
once	O	ADV	O
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Concurrent	O	ADJ	B
RT	O	NOUN	B
(	O	PUNCT	O
70	O	NUM	O
Gy	O	NOUN	O
in	O	ADP	O
35	O	NUM	O
fractions	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
to	O	PART	O
the	O	DET	O
nasopharyngeal	O	ADJ	B
tumor	O	NOUN	I
and	O	CCONJ	O
neck	O	NOUN	B
lymph	O	NOUN	I
node	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
and	O	CCONJ	O
tumors	O	NOUN	B
were	O	AUX	O
monitored	O	VERB	B
for	O	ADP	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
responses	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
rAd-p53-specific	B-OUT	ADJ	O
p53	I-OUT	NOUN	B
mRNA	I-OUT	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
postinjection	O	NOUN	B
of	O	ADP	O
rAd-p53	O	NOUN	B
biopsies	O	NOUN	B
from	O	ADP	O
16	O	NUM	O
(	O	PUNCT	O
94.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
17	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Upregulation	O	NOUN	B
of	O	ADP	O
p21/WAF1	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
Bax	I-OUT	NOUN	B
and	O	CCONJ	O
downregulation	O	NOUN	B
of	O	ADP	O
vascular	B-OUT	ADJ	B
endothelial	I-OUT	ADJ	I
growth	I-OUT	NOUN	I
factor	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
postinjection	O	NOUN	B
tumor	O	NOUN	B
biopsy	O	NOUN	I
.	O	PUNCT	O


Complete	B-OUT	ADJ	B
response	I-OUT	NOUN	O
rate	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
rAd-p53	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
RT	I-I	NOUN	B
was	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
2.73	O	NUM	O
times	O	NOUN	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
RT	B-I	NOUN	B
alone	I-I	ADV	O
(	O	PUNCT	O
66.7	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
24.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Six-year	O	ADJ	B
follow-up	O	ADJ	B
data	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
rAd-p53	B-I	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
5-year	B-OUT	ADJ	O
locoregional	I-OUT	ADJ	B
tumor	I-OUT	NOUN	O
control	I-OUT	NOUN	O
rate	I-OUT	NOUN	O
by	O	ADP	O
25.3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
NPC	I-P	NOUN	B
treated	O	VERB	B
with	O	ADP	I
irradiation	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
5-year	B-OUT	ADJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
5-year	I-OUT	ADJ	O
disease-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
rate	I-OUT	NOUN	O
of	O	ADP	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
rAd-p53	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
RT	I-I	NOUN	B
were	O	AUX	O
7.5	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.34	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
11.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.21	O	NUM	O
)	O	PUNCT	O
higher	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
RT	B-I	NOUN	B
alone	I-I	ADV	O
.	I-I	PUNCT	O


No	O	DET	O
dose-limiting	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
appeared	O	VERB	O
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
transient	B-OUT	ADJ	B
fever	I-OUT	NOUN	I
after	O	ADP	O
rAd-p53	B-I	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
NPC	I-P	NOUN	B
,	O	PUNCT	O
rAd-p53	B-I	NOUN	B
was	O	AUX	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
biologically	I-OUT	ADV	B
active	I-OUT	ADJ	I
.	I-OUT	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
rAd-p53	B-I	NOUN	B
improves	O	VERB	O
radiotherapeutic	B-OUT	ADJ	B
tumor	I-OUT	NOUN	I
control	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
NPC	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
intravenous	O	ADJ	B
streptokinase	B-I	NOUN	B
and	O	CCONJ	O
angioplasty	B-I	NOUN	B
versus	I-I	CCONJ	O
lone	I-I	ADJ	O
angioplasty	I-I	NOUN	B
therapy	I-I	NOUN	I
of	O	ADP	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
value	O	NOUN	O
of	O	ADP	O
routine	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
thrombolytic	B-I	ADJ	B
agents	I-I	NOUN	I
during	O	ADP	O
percutaneous	B-I	ADJ	B
transluminal	I-I	ADJ	I
coronary	I-I	ADJ	I
angioplasty	I-I	NOUN	I
(	I-I	PUNCT	O
PTCA	I-I	NOUN	B
)	I-I	PUNCT	O
therapy	I-I	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
(	O	PUNCT	O
MI	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
prospectively	O	ADV	O
randomized	O	VERB	B
122	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
evolving	I-P	VERB	O
MI	I-P	PROPN	B
to	I-P	ADP	O
PTCA	I-I	NOUN	B
therapy	I-I	NOUN	I
with	I-P	ADP	O
or	I-P	CCONJ	O
without	I-P	ADP	O
adjunctive	I-P	ADJ	B
intravenous	I-I	ADJ	B
streptokinase	I-I	NOUN	O
therapy	I-I	NOUN	O
.	I-I	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	VERB	B
Patients	B-P	NOUN	B
with	I-P	ADP	O
ECG	I-P	PROPN	B
ST	I-P	NOUN	B
segment	I-P	NOUN	B
elevation	I-P	NOUN	B
who	I-P	PRON	O
presented	I-P	VERB	O
within	I-P	ADP	O
4	I-P	NUM	O
hours	I-P	NOUN	O
of	I-P	ADP	O
symptom	I-P	NOUN	B
onset	I-P	NOUN	I
,	I-P	PUNCT	O
had	I-P	AUX	O
no	I-P	DET	O
contraindication	I-P	NOUN	O
to	I-P	PART	O
thrombolytic	I-I	ADJ	B
therapy	I-I	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
were	I-P	AUX	O
not	I-P	PART	O
in	I-P	ADP	O
cardiogenic	I-P	ADJ	B
shock	I-P	NOUN	I
were	I-P	AUX	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


They	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
immediately	O	ADV	O
with	O	ADP	O
intravenous	B-I	ADJ	B
heparin	I-I	NOUN	I
(	O	PUNCT	O
10,000	O	NUM	O
units	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
oral	B-I	ADJ	B
aspirin	I-I	NOUN	B
(	O	PUNCT	O
325	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
randomized	O	VERB	B
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
placebo	B-I	NOUN	B
or	I-I	CCONJ	O
streptokinase	I-I	NOUN	B
(	O	PUNCT	O
1.5	O	NUM	O
M	O	NOUN	O
units	O	NOUN	O
)	O	PUNCT	O
administered	O	VERB	B
intravenously	O	ADV	B
over	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
then	O	ADV	O
were	O	AUX	O
taken	O	VERB	O
immediately	O	ADV	O
to	O	ADP	O
the	O	DET	O
catheterization	O	NOUN	B
laboratory	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
suitable	O	ADJ	O
coronary	O	ADJ	B
anatomy	O	NOUN	B
underwent	O	VERB	O
immediate	O	ADJ	O
PTCA	B-I	PROPN	B
.	I-I	PUNCT	O


Subsequent	O	ADJ	O
clinical	O	ADJ	B
course	O	NOUN	I
,	O	PUNCT	O
serial	O	ADJ	O
radionuclide	O	NOUN	B
ventriculography	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
6-month	O	ADJ	O
repeat	O	NOUN	O
angiography	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
106	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
treated	I-P	VERB	B
with	I-P	ADP	I
PTCA	I-I	NOUN	B
.	I-I	PUNCT	O


Use	O	PROPN	O
of	O	ADP	O
PTCA	B-I	PROPN	B
was	O	AUX	O
similar	O	ADJ	O
for	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
92	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
streptokinase	B-I	NOUN	B
(	O	PUNCT	O
83	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
groups	O	NOUN	B
.	O	PUNCT	O


Angioplasty	B-I	PROPN	B
was	O	AUX	O
successful	O	ADJ	O
in	O	ADP	O
95	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
93	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
streptokinase	B-I	NOUN	B
(	O	PUNCT	O
98	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
groups	O	NOUN	B
.	O	PUNCT	O


Serial	O	ADJ	B
radionuclide	O	NOUN	B
ventriculography	O	NOUN	I
demonstrated	O	VERB	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
24-hour	O	NOUN	B
(	O	PUNCT	O
52	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
50	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
6-week	O	ADJ	B
(	O	PUNCT	O
51	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
51	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
ejection	B-OUT	NOUN	B
fraction	I-OUT	NOUN	I
values	I-OUT	NOUN	I
for	O	ADP	O
placebo	B-I	NOUN	B
and	I-I	CCONJ	O
streptokinase	I-I	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Contrast	B-OUT	NOUN	B
ventriculography	I-OUT	NOUN	I
demonstrated	O	VERB	O
improvement	O	NOUN	B
in	O	ADP	O
immediate	O	ADJ	B
(	O	PUNCT	O
54	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
versus	O	CCONJ	O
6-month	O	ADJ	B
(	O	PUNCT	O
60	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
values	O	NOUN	B
for	O	ADP	O
the	O	DET	O
overall	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
6-month	B-OUT	ADJ	B
values	I-OUT	NOUN	B
were	O	AUX	O
present	O	ADJ	O
(	O	PUNCT	O
58	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
62	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
NS	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
placebo	B-I	NOUN	B
and	I-I	CCONJ	O
streptokinase	I-I	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Coronary	B-OUT	ADJ	B
angiography	I-OUT	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
75	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
90	O	NUM	O
patients	O	NOUN	B
eligible	O	ADJ	B
for	O	ADP	O
restudy	O	NOUN	B
.	O	PUNCT	O


Arterial	B-OUT	ADJ	B
patency	I-OUT	NOUN	I
was	O	AUX	O
87	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
coronary	B-OUT	ADJ	B
restenosis	I-OUT	NOUN	I
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
38	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
chronic	B-OUT	ADJ	B
patency	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
restenosis	I-OUT	NOUN	B
were	O	AUX	O
detected	O	VERB	B
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
adjunctive	O	ADJ	B
intravenous	O	ADJ	B
streptokinase	B-I	NOUN	O
therapy	O	NOUN	O
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
outcome	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
did	O	AUX	O
complicate	O	VERB	O
the	O	DET	O
hospital	O	NOUN	B
course	O	NOUN	I
.	O	PUNCT	O


Hospitalization	B-OUT	NOUN	B
was	O	AUX	O
longer	O	ADJ	O
(	O	PUNCT	O
9.3	O	NUM	O
+/-	O	CCONJ	O
5.0	O	NUM	O
versus	O	CCONJ	O
7.7	O	NUM	O
+/-	O	CCONJ	O
4.4	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.046	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
more	O	ADV	O
costly	B-OUT	ADJ	O
(	O	PUNCT	O
$	O	SYM	O
25,191	O	NUM	O
+/-	O	CCONJ	O
15,368	O	NUM	O
versus	O	CCONJ	O
$	O	SYM	O
19,643	O	NUM	O
+/-	O	CCONJ	O
7,250	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Transfusion	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
was	O	AUX	O
higher	O	ADJ	B
(	O	PUNCT	O
39	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
8	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
need	O	VERB	O
for	O	ADP	O
emergency	O	NOUN	B
coronary	O	ADJ	B
bypass	O	NOUN	I
surgery	O	NOUN	I
was	O	AUX	O
greater	O	ADJ	O
(	O	PUNCT	O
10.3	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
1.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
streptokinase-treated	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Adjunctive	O	ADJ	B
intravenous	O	ADJ	O
streptokinase	B-I	NOUN	O
therapy	I-I	NOUN	O
does	O	AUX	O
not	O	PART	O
enhance	O	VERB	O
early	O	ADJ	O
preservation	O	NOUN	B
of	O	ADP	O
ventricular	B-OUT	ADJ	B
function	I-OUT	NOUN	I
,	O	PUNCT	O
improve	O	VERB	O
arterial	B-OUT	ADJ	B
patency	I-OUT	NOUN	O
rates	I-OUT	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
lower	O	ADJ	O
restenosis	B-OUT	NOUN	B
rates	I-OUT	NOUN	B
after	O	ADP	O
PTCA	B-I	NOUN	B
therapy	I-I	NOUN	I
of	O	ADP	O
acute	O	ADJ	B
MI	O	PROPN	B
.	O	PUNCT	O


Hospital	O	PROPN	B
course	O	NOUN	I
is	O	AUX	O
longer	O	ADJ	O
,	O	PUNCT	O
more	O	ADV	O
expensive	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
more	O	ADV	O
complicated	O	ADJ	B
.	O	PUNCT	O


For	O	ADP	O
these	O	DET	O
reasons	O	NOUN	B
,	O	PUNCT	O
PTCA	B-I	NOUN	B
therapy	I-I	NOUN	I
of	O	ADP	O
acute	O	ADJ	B
MI	O	PROPN	B
should	O	AUX	O
not	O	PART	O
be	O	AUX	O
routinely	O	ADV	O
performed	O	VERB	O
with	O	ADP	O
adjunctive	O	ADJ	B
intravenous	O	ADJ	O
streptokinase	B-I	NOUN	O
therapy	I-I	NOUN	O
.	I-I	PUNCT	O


Intranasal	O	ADJ	B
oxytocin	B-I	NOUN	I
improves	O	VERB	B
emotion	B-OUT	NOUN	B
recognition	I-OUT	NOUN	I
for	O	ADP	O
youth	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
A	O	DET	O
diagnostic	O	ADJ	B
hallmark	O	NOUN	O
of	O	ADP	O
autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
is	O	AUX	O
a	O	DET	O
qualitative	O	ADJ	B
impairment	O	NOUN	I
in	O	ADP	O
social	O	ADJ	B
communication	O	NOUN	I
and	O	CCONJ	O
interaction	O	NOUN	B
.	O	PUNCT	O


Deficits	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ability	O	NOUN	O
to	O	PART	O
recognize	O	VERB	O
the	O	DET	O
emotions	O	NOUN	B
of	O	ADP	O
others	O	NOUN	O
are	O	AUX	O
believed	O	VERB	O
to	O	PART	O
contribute	O	VERB	O
to	O	ADP	O
this	O	DET	O
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
currently	O	ADV	O
no	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
these	O	DET	O
problems	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
design	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
administered	O	VERB	B
oxytocin	B-I	NOUN	B
nasal	I-I	ADJ	B
spray	I-I	NOUN	I
(	O	PUNCT	O
18	O	NUM	O
or	O	CCONJ	O
24	O	NUM	O
IU	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
placebo	B-I	NOUN	B
to	O	PART	O
16	B-P	NUM	O
male	I-P	ADJ	B
youth	I-P	NOUN	B
aged	I-P	ADJ	B
12	I-P	NUM	O
to	I-P	PART	O
19	I-P	NUM	O
who	I-P	PRON	O
were	I-P	AUX	O
diagnosed	I-P	VERB	B
with	I-P	ADP	O
Autistic	I-P	ADJ	B
or	I-P	CCONJ	O
Asperger	I-P	PROPN	B
's	I-P	PART	I
Disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Participants	B-P	NOUN	B
then	O	ADV	O
completed	O	VERB	B
the	O	DET	O
Reading	B-OUT	VERB	B
the	I-OUT	DET	O
Mind	I-OUT	PROPN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
Eyes	I-OUT	PROPN	B
Task	I-OUT	PROPN	I
,	O	PUNCT	O
a	O	DET	O
widely	O	ADV	O
used	O	VERB	O
and	O	CCONJ	O
reliable	O	ADJ	O
test	O	NOUN	B
of	O	ADP	O
emotion	B-OUT	NOUN	B
recognition	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
placebo	B-I	NOUN	B
,	I-I	PUNCT	O
oxytocin	I-I	NOUN	B
administration	O	NOUN	B
improved	O	VERB	B
performance	B-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
Reading	I-OUT	PROPN	B
the	I-OUT	DET	O
Mind	I-OUT	PROPN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
Eyes	I-OUT	PROPN	B
Task	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
shown	O	VERB	O
when	O	SCONJ	O
analysis	O	NOUN	B
was	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
the	O	DET	O
younger	B-P	ADJ	B
participants	I-P	NOUN	I
aged	I-P	ADJ	B
12	I-P	NUM	O
to	I-P	PART	O
15	I-P	NUM	O
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
lower	O	ADJ	B
dose	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
the	O	DET	O
first	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
oxytocin	O	NOUN	B
nasal	O	ADJ	B
spray	O	NOUN	I
improves	O	VERB	B
emotion	B-OUT	NOUN	B
recognition	I-OUT	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
people	I-P	NOUN	O
diagnosed	I-P	VERB	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


Findings	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
earlier	O	ADJ	O
intervention	O	NOUN	B
and	O	CCONJ	O
further	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
oxytocin	B-I	NOUN	B
nasal	O	ADJ	B
spray	O	NOUN	I
as	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
to	O	PART	O
improve	O	VERB	B
social	O	ADJ	B
communication	O	NOUN	I
and	O	CCONJ	O
interaction	O	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
people	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


Longitudinal	O	ADJ	B
follow-up	O	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
receiving	I-P	VERB	O
targeted	I-P	VERB	B
interventions	I-P	NOUN	B
on	I-P	ADP	O
joint	I-I	ADJ	B
attention	I-I	NOUN	B
and	I-I	CCONJ	O
play	I-I	VERB	O
.	I-I	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
examines	O	VERB	O
the	O	DET	O
cognitive	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
language	I-OUT	NOUN	B
outcomes	I-OUT	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
over	I-P	ADP	O
a	I-P	DET	O
5-year	I-P	ADJ	O
period	I-P	NOUN	B
after	I-P	ADP	O
receiving	I-P	VERB	O
targeted	I-I	VERB	B
early	I-I	ADJ	O
interventions	I-I	NOUN	B
that	I-I	PRON	O
focused	I-I	VERB	O
on	I-I	ADP	O
joint	I-I	ADJ	B
attention	I-I	NOUN	B
and	I-I	CCONJ	O
play	I-I	VERB	B
skills	I-I	NOUN	I
.	I-I	PUNCT	O


METHOD	O	NOUN	O
Forty	B-P	NUM	O
children	I-P	NOUN	B
from	I-P	ADP	O
the	I-P	DET	O
original	I-P	ADJ	B
study	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
58	I-P	NUM	O
)	I-P	PUNCT	O
had	I-P	AUX	O
complete	I-P	ADJ	B
data	I-P	NOUN	B
at	I-P	ADP	O
the	I-P	DET	O
5-year	I-P	ADJ	O
follow-up	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
all	O	DET	O
,	O	PUNCT	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
children	O	NOUN	B
had	O	AUX	O
achieved	O	VERB	O
functional	B-OUT	ADJ	B
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
spoken	I-OUT	VERB	B
language	I-OUT	NOUN	B
with	O	ADP	O
baseline	O	NOUN	B
play	O	NOUN	O
level	O	NOUN	B
predicting	O	NOUN	B
spoken	O	VERB	B
language	O	NOUN	B
at	O	ADP	O
the	O	DET	O
5-year	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
using	O	VERB	O
spoken	O	VERB	B
language	O	NOUN	B
at	O	ADP	O
age	O	NOUN	B
8	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
several	O	ADJ	O
baseline	O	NOUN	B
behaviors	O	NOUN	B
predicted	O	VERB	B
their	O	PRON	O
later	O	ADJ	O
ability	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
earlier	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
entry	O	NOUN	B
into	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
initiating	O	VERB	O
joint	B-OUT	ADJ	B
attention	I-OUT	NOUN	O
skill	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
play	I-OUT	VERB	O
level	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
assignment	O	NOUN	B
to	O	PART	O
either	O	CCONJ	O
the	O	DET	O
joint	B-I	ADJ	B
attention	I-I	NOUN	B
or	I-I	CCONJ	O
symbolic	I-I	ADJ	B
play	I-I	NOUN	O
intervention	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Only	O	ADV	O
baseline	O	NOUN	B
play	O	NOUN	O
diversity	O	NOUN	B
predicted	O	VERB	O
cognitive	O	ADJ	B
scores	O	NOUN	I
at	O	ADP	O
age	O	NOUN	B
8	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
only	O	ADJ	O
long-term	O	ADJ	B
follow-up	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
children	B-P	NOUN	B
who	I-P	PRON	O
participated	I-P	VERB	O
in	I-P	ADP	O
preschool	I-P	NOUN	B
early	I-P	ADJ	O
interventions	I-P	NOUN	B
aimed	I-P	VERB	O
at	I-P	ADP	O
targeting	I-P	VERB	B
core	I-P	NOUN	B
developmental	I-P	ADJ	I
difficulties	I-P	NOUN	O
.	I-P	PUNCT	O


The	O	DET	O
study	O	NOUN	B
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
focusing	O	VERB	O
on	O	ADP	O
joint	O	ADJ	B
attention	O	NOUN	B
and	O	CCONJ	O
play	O	VERB	O
skills	O	NOUN	B
in	O	ADP	O
comprehensive	O	ADJ	B
treatment	O	NOUN	B
models	O	NOUN	I
is	O	AUX	O
important	O	ADJ	O
for	O	ADP	O
long-term	B-OUT	ADJ	B
spoken	I-OUT	VERB	B
language	I-OUT	NOUN	B
outcomes	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Corticosteroids	B-I	NOUN	B
plus	I-I	CCONJ	O
pulse	I-I	NOUN	B
cyclophosphamide	I-I	NOUN	I
and	I-I	CCONJ	O
plasma	I-I	NOUN	B
exchanges	I-I	NOUN	B
versus	O	CCONJ	O
corticosteroids	B-I	NOUN	B
plus	I-I	CCONJ	O
pulse	I-I	NOUN	B
cyclophosphamide	I-I	NOUN	I
alone	I-I	ADV	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
polyarteritis	B-P	NOUN	B
nodosa	I-P	NOUN	I
and	I-P	CCONJ	O
Churg-Strauss	I-P	ADJ	B
syndrome	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
factors	I-P	NOUN	B
predicting	I-P	VERB	O
poor	I-P	ADJ	B
prognosis	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
in	O	ADP	O
sixty-two	B-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
define	O	VERB	O
the	O	DET	O
most	O	ADV	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
severe	B-P	ADJ	B
polyarteritis	I-P	NOUN	B
nodosa	I-P	NOUN	I
(	I-P	PUNCT	O
PAN	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
Churg-Strauss	I-P	ADJ	B
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
CSS	I-P	NOUN	B
)	I-P	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
indication	O	NOUN	B
for	O	ADP	O
plasma	O	NOUN	B
exchange	O	NOUN	O
treatment	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
multicenter	O	ADJ	B
trial	O	NOUN	I
in	O	ADP	O
which	O	DET	O
62	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
receive	I-P	VERB	O
either	I-P	CCONJ	O
prednisone	I-I	NOUN	B
plus	I-I	CCONJ	O
cyclophosphamide	I-I	NOUN	B
(	I-I	PUNCT	O
intravenous	I-I	ADJ	B
bolus	I-I	NOUN	I
)	I-I	PUNCT	O
(	I-I	PUNCT	O
group	I-I	NOUN	B
A	I-I	NOUN	I
;	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
28	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
prednisone	I-I	NOUN	B
plus	I-I	CCONJ	O
cyclophosphamide	I-I	NOUN	B
(	I-I	PUNCT	O
intravenous	I-I	ADJ	B
bolus	I-I	NOUN	I
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
plasma	I-I	NOUN	B
exchanges	I-I	NOUN	O
(	I-P	PUNCT	O
group	I-P	NOUN	B
B	I-P	NOUN	I
;	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
34	I-P	NUM	O
)	I-P	PUNCT	O
as	I-P	ADP	O
first-line	I-P	ADJ	B
treatment	I-P	NOUN	I
for	I-P	ADP	O
severe	I-P	ADJ	B
PAN	I-P	NOUN	B
or	I-P	CCONJ	O
CSS	I-P	NOUN	B
.	I-P	PUNCT	O


Factors	O	NOUN	B
predicting	O	VERB	B
poor	O	ADJ	B
prognosis	O	NOUN	I
were	O	AUX	O
renal	O	ADJ	B
symptoms	O	NOUN	I
,	O	PUNCT	O
gastrointestinal	O	ADJ	B
tract	O	NOUN	I
involvement	O	NOUN	B
,	O	PUNCT	O
cardiomyopathy	O	NOUN	B
,	O	PUNCT	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
involvement	O	NOUN	B
,	O	PUNCT	O
weight	O	NOUN	B
loss	O	NOUN	I
>	O	NOUN	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
age	O	NOUN	B
>	O	PROPN	O
50	O	NUM	O
years	O	NOUN	B
old	O	ADJ	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
hepatitis	O	NOUN	B
B	O	NOUN	I
virus-related	O	ADJ	I
PAN	O	NOUN	I
were	O	AUX	O
not	O	PART	O
included	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
end	O	NOUN	O
point	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
control	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
(	O	PUNCT	O
recovery	O	NOUN	B
or	O	CCONJ	O
remission	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
death	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Clinical	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
laboratory	O	NOUN	B
findings	O	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Initial	O	ADJ	O
control	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Relapse	B-OUT	NOUN	B
after	O	ADP	O
initial	O	ADJ	O
control	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
7	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
3	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	NOUN	O
+/-	I-OUT	CCONJ	O
SD	I-OUT	NOUN	B
followup	I-OUT	NOUN	B
period	O	NOUN	B
was	O	AUX	O
31.1	O	NUM	O
+/-	O	CCONJ	O
20	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
35.9	O	NUM	O
+/-	O	CCONJ	O
16.8	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
followup	O	NOUN	B
,	O	PUNCT	O
38	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
61.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
cured	B-OUT	VERB	B
(	O	PUNCT	O
16	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
22	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
(	O	PUNCT	O
8.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
in	O	ADP	O
remission	O	NOUN	B
without	O	ADP	O
treatment	O	NOUN	B
but	O	CCONJ	O
had	O	AUX	O
not	O	PART	O
yet	O	ADV	O
completed	O	VERB	O
the	O	DET	O
cure-defining	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
2	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Eight	O	NUM	O
(	O	PUNCT	O
12.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
2	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
2	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
considered	O	VERB	O
to	O	PART	O
be	O	AUX	O
in	O	ADP	O
clinical	B-OUT	ADJ	B
remission	I-OUT	NOUN	I
and	O	CCONJ	O
required	O	VERB	O
a	O	DET	O
maintenance	B-OUT	NOUN	O
regimen	I-OUT	NOUN	B
of	I-OUT	ADP	O
low-dose	I-OUT	ADJ	B
corticosteroids	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Eleven	O	NUM	O
patients	O	NOUN	B
died	B-OUT	VERB	B
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
period	O	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
[	O	PUNCT	O
25	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
,	O	PUNCT	O
4	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
[	O	PUNCT	O
11.8	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Uncontrolled	O	ADJ	B
vasculitis	O	NOUN	B
was	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
4	O	NUM	O
deaths	B-OUT	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
treatment	B-OUT	NOUN	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
caused	O	VERB	O
the	O	DET	O
death	B-OUT	NOUN	B
of	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
5-year	B-OUT	ADJ	O
cumulative	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
88	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Based	O	VERB	O
on	O	ADP	O
our	O	PRON	O
data	O	NOUN	B
,	O	PUNCT	O
combined	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
prednisone	B-I	NOUN	B
,	I-I	PUNCT	O
cyclophosphamide	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
plasma	B-I	NOUN	B
exchanges	I-I	NOUN	B
is	O	AUX	O
not	O	PART	O
superior	O	ADJ	O
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
prednisone	B-I	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-I	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
plasma	O	NOUN	B
exchanges	O	NOUN	B
should	O	AUX	O
not	O	PART	O
be	O	AUX	O
systematically	O	ADV	B
proposed	O	VERB	O
for	O	ADP	O
initial	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
PAN	O	NOUN	B
or	O	CCONJ	O
CSS	O	NOUN	B
.	O	PUNCT	O


Association	O	NOUN	B
of	O	ADP	O
race	B-I	NOUN	B
with	O	ADP	O
complications	O	NOUN	B
and	O	CCONJ	O
prognosis	O	NOUN	B
following	B-P	VERB	O
acute	I-P	ADJ	B
coronary	I-P	ADJ	I
syndromes	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
baseline	O	NOUN	B
characteristics	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
complications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
of	O	ADP	O
489	B-P	NUM	O
black	I-P	ADJ	B
and	I-P	CCONJ	O
6,890	I-P	NUM	O
non-black	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
coronary	I-P	ADJ	I
syndromes	I-P	NOUN	I
were	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


Important	O	ADJ	B
racial	B-OUT	ADJ	B
differences	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
demographic	B-OUT	ADJ	B
features	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
atherosclerosis	I-OUT	NOUN	B
risk	I-OUT	NOUN	B
factors	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
treatment	I-OUT	NOUN	B
strategies	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
despite	O	SCONJ	O
these	O	DET	O
differences	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
independent	O	ADJ	O
difference	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
according	O	VERB	O
to	O	ADP	O
race	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
1-year	O	ADJ	O
mortality	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
2.9	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
black	B-P	ADJ	B
patients	I-P	NOUN	B
and	O	CCONJ	O
2.5	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
non-black	B-P	ADJ	B
patients	I-P	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.93	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Effectiveness	O	NOUN	B
of	O	ADP	O
sensory	B-I	ADJ	B
integration	I-I	NOUN	I
interventions	I-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
establish	O	VERB	O
a	O	DET	O
model	O	NOUN	B
for	O	ADP	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
research	O	NOUN	B
,	O	PUNCT	O
identify	O	VERB	O
appropriate	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
address	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
sensory	B-I	ADJ	B
integration	I-I	NOUN	I
(	I-I	PUNCT	O
SI	I-I	NOUN	B
)	I-I	PUNCT	O
interventions	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Children	B-P	NOUN	B
ages	I-P	VERB	B
6-12	I-P	NUM	O
with	I-P	ADP	O
ASD	I-P	VERB	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
a	O	DET	O
fine	B-I	ADJ	O
motor	I-I	NOUN	B
or	O	CCONJ	O
SI	B-I	NOUN	B
treatment	I-I	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Pretests	O	NOUN	B
and	O	CCONJ	O
posttests	O	NOUN	B
measured	O	VERB	B
social	B-OUT	ADJ	B
responsiveness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
sensory	I-OUT	ADJ	B
processing	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
functional	I-OUT	ADJ	B
motor	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
social-emotional	I-OUT	ADJ	B
factors	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Results	O	NOUN	B
identified	O	VERB	O
significant	O	ADJ	O
positive	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
Goal	B-OUT	PROPN	B
Attainment	I-OUT	PROPN	I
Scaling	I-OUT	PROPN	O
scores	I-OUT	NOUN	O
for	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
;	O	PUNCT	O
more	O	ADV	O
significant	O	ADJ	B
changes	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
SI	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
autistic	B-OUT	ADJ	B
mannerisms	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
SI	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
results	O	NOUN	B
were	O	AUX	O
significant	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
discusses	O	VERB	O
considerations	O	NOUN	B
for	O	ADP	O
designing	O	VERB	B
future	O	ADJ	O
outcome	O	NOUN	B
studies	O	NOUN	I
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Object	B-OUT	NOUN	B
interest	I-OUT	NOUN	O
in	O	ADP	O
autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
treatment	O	NOUN	B
comparison	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
control	O	NOUN	I
trial	O	NOUN	I
comparing	O	VERB	B
two	O	NUM	O
social	B-I	ADJ	B
communication	I-I	NOUN	I
treatments	I-I	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
on	O	ADP	O
object	O	NOUN	B
interest	O	NOUN	O
.	O	PUNCT	O


Thirty-two	B-P	NUM	O
children	I-P	NOUN	B
,	I-P	PUNCT	O
18-60	I-P	NUM	O
months	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
the	O	DET	O
Picture	B-I	PROPN	B
Exchange	I-I	PROPN	I
Communication	I-I	PROPN	I
System	I-I	PROPN	I
(	I-I	PUNCT	O
PECS	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
Responsive	I-I	ADJ	B
Education	I-I	PROPN	I
and	I-I	CCONJ	O
Prelinguistic	I-I	PROPN	B
Milieu	I-I	PROPN	I
Teaching	I-I	PROPN	I
(	I-I	PUNCT	O
RPMT	I-I	NOUN	B
)	I-I	PUNCT	O
condition	I-I	NOUN	B
.	I-I	PUNCT	O


Assessment	O	NOUN	B
of	O	ADP	O
object	B-OUT	NOUN	B
interest	I-OUT	NOUN	O
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
an	O	DET	O
unstructured	O	ADJ	O
play	O	NOUN	O
session	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
toys	O	NOUN	B
,	O	PUNCT	O
activities	O	NOUN	B
,	O	PUNCT	O
adult	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
location	O	NOUN	B
than	O	ADP	O
experienced	O	VERB	O
in	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
indicated	O	VERB	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
RPMT	B-I	NOUN	B
condition	O	NOUN	B
showed	O	VERB	O
greater	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
object	B-OUT	NOUN	B
interest	I-OUT	NOUN	O
as	O	ADP	O
compared	O	VERB	O
to	O	ADP	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PECS	B-I	NOUN	B
condition	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
child	O	NOUN	B
characteristics	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
interest	O	NOUN	O
in	O	ADP	O
objects	O	NOUN	B
may	O	AUX	O
influence	O	VERB	B
response	O	NOUN	B
to	O	ADP	O
interventions	O	NOUN	B
using	O	VERB	O
object	O	NOUN	B
play	O	NOUN	O
as	O	ADP	O
contexts	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
improve	O	VERB	B
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
whether	O	SCONJ	O
intervention	O	NOUN	B
can	O	AUX	O
affect	O	VERB	O
object	O	NOUN	B
interest	O	NOUN	O
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
epidural	B-I	ADJ	B
tramadol-ropivacaine	I-I	NOUN	B
and	I-I	CCONJ	O
fentanyl-ropivacaine	I-I	NOUN	B
for	O	ADP	O
labor	B-P	NOUN	B
analgesia	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
To	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
5	O	NUM	O
mg/mL	O	NOUN	O
tramadol	B-I	NOUN	B
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
3	O	NUM	O
?	O	PUNCT	O
g/mL	O	NOUN	O
fentanyl	B-I	NOUN	B
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
0.125	O	NUM	O
%	O	NOUN	O
ropivacaine	B-I	NOUN	B
in	O	ADP	O
parturients	B-P	NOUN	B
undergoing	I-P	VERB	O
labor	I-P	NOUN	B
during	I-P	ADP	O
epidural	I-P	ADJ	B
analgesia	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Sixty-one	B-P	NUM	O
parturients	I-P	NOUN	B
undergoing	I-P	VERB	O
labor	I-P	NOUN	B
selected	I-P	VERB	O
for	I-P	ADP	O
delivery	I-P	NOUN	B
with	I-P	ADP	O
epidural	I-P	ADJ	B
analgesia	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
Group	O	NOUN	B
tramadol	B-I	NOUN	B
(	I-I	PUNCT	O
0.125	I-I	NUM	O
%	I-I	NOUN	O
ropivacaine	I-I	NOUN	B
plus	I-I	CCONJ	O
tramadol	I-I	NOUN	B
5	I-I	NUM	O
mg/mL	I-I	NOUN	O
)	I-I	PUNCT	O
and	O	CCONJ	O
Group	O	NOUN	B
fentanyl	B-I	NOUN	B
(	I-I	PUNCT	O
0.125	I-I	NUM	O
%	I-I	NOUN	O
ropivacaine	I-I	NOUN	B
plus	I-I	CCONJ	O
fentanyl	I-I	NOUN	B
3	I-I	NUM	I
ug/mL	I-I	NOUN	O
)	I-I	PUNCT	O
.	O	PUNCT	O


Hemodynamics	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
cesarean	I-OUT	NOUN	B
delivery	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
sensory	I-OUT	ADJ	B
block	I-OUT	NOUN	I
level	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
Bromage	I-OUT	NOUN	B
motor	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
instrument-assisted	I-OUT	ADJ	B
delivery	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
oxytocin	I-OUT	NOUN	B
use	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
visual	I-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
scores	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
Apgar	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
umbilical	I-OUT	ADJ	B
cord	I-OUT	NOUN	I
artery	I-OUT	NOUN	I
gas	O	NOUN	I
analysis	B-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
maternal	I-OUT	ADJ	B
side-effects	I-OUT	NOUN	O
including	I-OUT	VERB	O
nausea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
vomiting	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pruritus	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
urinary	I-OUT	ADJ	B
retention	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
shivering	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hypotension	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
respiratory	I-OUT	ADJ	B
depression	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
had	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
maternal	B-OUT	ADJ	B
hemodynamics	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
neonatal	I-OUT	ADJ	B
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
VAS	I-OUT	PROPN	B
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
cesarean	I-OUT	NOUN	B
delivery	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
sensory	I-OUT	ADJ	B
block	I-OUT	NOUN	I
level	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
Bromage	I-OUT	NOUN	B
motor	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
instrument-assisted	I-OUT	ADJ	B
delivery	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
oxytocin	I-OUT	NOUN	B
use	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hypotension	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
vomiting	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
respiratory	I-OUT	ADJ	B
depression	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
pruritus	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
shivering	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
urinary	I-OUT	ADJ	B
retention	I-OUT	NOUN	I
were	O	AUX	O
more	O	ADV	O
commonly	O	ADV	O
observed	O	VERB	B
in	O	ADP	O
Group	O	NOUN	B
fentanyl	O	NOUN	B
despite	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Umbilical	B-OUT	ADJ	B
artery	I-OUT	NOUN	I
pH	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
while	O	SCONJ	O
PCO	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
Group	O	PROPN	B
fentanyl	B-I	NOUN	B
than	O	ADP	O
Group	O	NOUN	B
tramadol	B-I	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0.026	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Birth-weight	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
umbilical	I-OUT	ADJ	B
artery	I-OUT	NOUN	I
PO	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
base	I-OUT	NOUN	B
deficit	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Apgar	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
at	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
min	O	NOUN	O
were	O	AUX	O
comparable	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Our	O	PRON	O
observations	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
tramadol	B-I	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
alternative	O	NOUN	O
to	O	PART	O
fentanyl	B-I	NOUN	B
for	O	ADP	O
labor	O	NOUN	B
analgesia	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
its	O	PRON	O
similar	O	ADJ	O
analgesic	O	NOUN	B
efficacy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
double	O	ADJ	B
blind	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
terfenadine	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
in	O	ADP	O
hay	O	NOUN	B
fever	O	NOUN	I
using	O	VERB	O
a	O	DET	O
substitution	O	NOUN	B
technique	O	NOUN	I
for	O	ADP	O
non-responders	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
terfenadine	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
in	O	ADP	O
110	B-P	NUM	O
patients	I-P	NOUN	B
suffering	I-P	VERB	B
from	I-P	ADP	O
hay	I-P	NOUN	B
fever	I-P	NOUN	I
(	I-P	PUNCT	O
confirmed	I-P	VERB	O
by	I-P	ADP	O
skin	I-P	NOUN	B
tests	I-P	NOUN	I
)	I-P	PUNCT	O
was	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
novel	O	ADJ	O
technique	O	NOUN	B
was	O	AUX	O
applied	O	VERB	O
using	O	VERB	O
an	O	DET	O
escape	O	NOUN	B
envelope	O	NOUN	I
containing	O	VERB	O
a	O	DET	O
reference	B-I	NOUN	O
drug	I-I	NOUN	B
which	O	DET	O
could	O	AUX	O
be	O	AUX	O
taken	O	VERB	O
under	O	ADP	O
controlled	O	VERB	B
conditions	O	NOUN	I
if	O	SCONJ	O
,	O	PUNCT	O
after	O	ADP	O
48	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
experienced	O	VERB	O
no	O	DET	O
relief	B-OUT	NOUN	O
.	I-OUT	PUNCT	O


Significantly	O	ADV	O
more	O	ADJ	O
patients	O	NOUN	B
on	O	ADP	O
placebo	B-I	NOUN	B
opened	I-OUT	VERB	O
the	I-OUT	DET	O
envelope	I-OUT	NOUN	B
than	O	ADP	O
patients	O	NOUN	B
taking	O	VERB	O
the	O	DET	O
active	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


Terfenadine	B-I	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	B-OUT	ADJ	B
drug	I-OUT	NOUN	B
in	O	ADP	O
hay	O	NOUN	B
fever	O	NOUN	I
and	O	CCONJ	O
produced	O	VERB	O
no	O	DET	O
more	O	ADV	O
drowsiness	B-OUT	ADJ	B
than	O	ADP	O
placebo	O	NOUN	B
.	O	PUNCT	O


Components	O	NOUN	B
of	O	ADP	O
working	O	VERB	B
memory	O	NOUN	I
and	O	CCONJ	O
visual	O	ADJ	B
selective	O	ADJ	O
attention	O	NOUN	O
.	O	PUNCT	O


Load	O	NOUN	B
theory	O	NOUN	I
(	O	PUNCT	O
Lavie	O	PROPN	B
,	O	PUNCT	O
N.	O	PROPN	O
,	O	PUNCT	O
Hirst	O	PROPN	B
,	O	PUNCT	O
A.	O	PROPN	B
,	O	PUNCT	O
De	O	PROPN	O
Fockert	O	PROPN	O
,	O	PUNCT	O
J.	O	PROPN	O
W.	O	PROPN	O
,	O	PUNCT	O
&	O	CCONJ	O
Viding	O	PROPN	O
,	O	PUNCT	O
E.	O	PROPN	B
[	O	PUNCT	O
2004	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


Load	O	NOUN	B
theory	O	NOUN	I
of	O	ADP	O
selective	O	ADJ	O
attention	O	NOUN	B
and	O	CCONJ	O
cognitive	O	ADJ	B
control	O	NOUN	I
.	O	PUNCT	O


Journal	O	PROPN	B
of	O	ADP	I
Experimental	O	PROPN	I
Psychology	O	PROPN	I
:	O	PUNCT	O
General	O	PROPN	B
,	O	PUNCT	O
133	O	NUM	O
,	O	PUNCT	O
339-354	O	NUM	O
.	O	PUNCT	O


)	O	PUNCT	O
proposes	O	VERB	O
that	O	SCONJ	O
control	B-OUT	NOUN	B
of	I-OUT	ADP	O
attention	I-OUT	NOUN	B
depends	O	VERB	O
on	O	ADP	O
the	O	DET	O
amount	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
type	I-OUT	NOUN	B
of	I-OUT	ADP	O
load	I-OUT	NOUN	B
that	O	PRON	O
is	O	AUX	O
imposed	O	VERB	O
by	O	ADP	O
current	O	ADJ	O
processing	O	NOUN	B
.	O	PUNCT	O


Specifically	O	ADV	O
,	O	PUNCT	O
perceptual	O	ADJ	B
load	O	NOUN	B
should	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
efficient	O	ADJ	B
distractor	O	NOUN	B
rejection	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
working	O	VERB	B
memory	O	NOUN	I
load	O	NOUN	I
(	O	PUNCT	O
dual-task	O	ADJ	B
coordination	O	NOUN	I
)	O	PUNCT	O
should	O	AUX	O
hinder	O	VERB	O
distractor	B-OUT	NOUN	B
rejection	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Studies	O	NOUN	B
support	O	VERB	O
load	O	NOUN	O
theory	O	NOUN	O
's	O	PART	O
prediction	O	NOUN	B
that	O	SCONJ	O
working	O	VERB	B
memory	O	NOUN	I
load	O	NOUN	B
will	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
larger	O	ADJ	B
distractor	B-OUT	NOUN	B
effects	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
studies	O	NOUN	B
used	O	VERB	O
secondary	O	ADJ	B
tasks	O	NOUN	O
that	O	PRON	O
required	O	VERB	O
only	O	ADV	O
verbal	O	ADJ	B
working	O	NOUN	I
memory	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
central	O	ADJ	B
executive	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
examined	O	VERB	B
which	O	DET	O
other	O	ADJ	O
working	O	VERB	B
memory	O	NOUN	I
components	O	NOUN	I
(	O	PUNCT	O
visual	O	ADJ	B
,	O	PUNCT	O
spatial	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
phonological	O	ADJ	B
)	O	PUNCT	O
influence	O	VERB	B
visual	B-OUT	ADJ	B
selective	I-OUT	ADJ	O
attention	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Subjects	B-P	NOUN	B
completed	I-P	VERB	O
an	I-P	DET	O
attentional	I-OUT	ADJ	B
capture	I-OUT	NOUN	I
task	I-OUT	NOUN	I
alone	I-I	ADV	O
(	I-I	PUNCT	O
single-task	I-I	ADJ	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
while	I-I	SCONJ	O
engaged	I-I	VERB	O
in	I-I	ADP	O
a	I-I	DET	O
working	I-I	VERB	B
memory	I-I	NOUN	I
task	I-I	NOUN	I
(	I-I	PUNCT	O
dual-task	I-I	ADJ	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
along	O	ADP	O
with	O	ADP	O
the	O	DET	O
central	O	ADJ	B
executive	O	NOUN	I
,	O	PUNCT	O
visual	O	ADJ	B
and	O	CCONJ	O
spatial	O	ADJ	B
working	O	NOUN	O
memory	O	NOUN	O
influenced	O	VERB	B
selective	B-OUT	ADJ	O
attention	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
phonological	O	ADJ	B
working	O	NOUN	B
memory	O	NOUN	I
did	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


Specifically	O	ADV	O
,	O	PUNCT	O
attentional	B-OUT	ADJ	B
capture	I-OUT	NOUN	I
was	O	AUX	O
larger	O	ADJ	O
when	O	SCONJ	O
visual	O	ADJ	B
or	O	CCONJ	O
spatial	O	ADJ	B
working	O	NOUN	I
memory	O	NOUN	I
was	O	AUX	O
loaded	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
phonological	O	ADJ	B
working	O	NOUN	O
memory	O	NOUN	O
load	O	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
attentional	B-OUT	ADJ	B
capture	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
load	O	NOUN	B
theory	O	NOUN	O
and	O	CCONJ	O
suggest	O	VERB	O
specific	O	ADJ	O
components	O	NOUN	B
of	O	ADP	O
working	O	VERB	B
memory	O	NOUN	I
influence	O	VERB	B
visual	B-OUT	ADJ	B
selective	I-OUT	ADJ	O
attention	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Local	O	ADJ	B
anaesthetic	O	ADJ	O
use	O	NOUN	O
for	O	ADP	O
the	O	DET	O
iliac	O	ADJ	B
crest-donor	O	ADJ	B
site	O	NOUN	I
:	O	PUNCT	O
pharmacokinetic	O	ADJ	B
and	O	CCONJ	O
pharmacodynamic	O	ADJ	B
evaluations	O	NOUN	B
.	O	PUNCT	O


During	B-P	ADP	O
orthopaedic	I-I	ADJ	B
surgery	I-I	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
limb	I-P	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	NOUN	O
controlled	O	ADJ	O
study	O	NOUN	O
on	O	ADP	O
three	B-P	NUM	O
parallel	I-P	ADJ	O
groups	I-P	NOUN	B
in	I-P	ADP	O
30	I-P	NUM	O
patients	I-P	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
pharmacokinetic	O	ADJ	B
and	O	CCONJ	O
pharmacodynamic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
infiltration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
iliac	O	ADJ	B
crest	O	NOUN	I
bone	O	NOUN	B
graft	O	NOUN	I
harvest	O	NOUN	O
site	O	NOUN	B
with	O	ADP	O
20	B-I	NUM	O
ml	I-I	NOUN	O
of	I-I	ADP	O
bupivacaine	I-I	NOUN	B
(	I-I	PUNCT	O
100	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
ropivacaine	I-I	NOUN	B
(	I-I	PUNCT	O
150	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
saline	I-I	NOUN	B
as	I-I	ADP	O
control	I-I	ADJ	B
group	I-I	NOUN	I
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
10	I-I	NUM	O
in	I-I	ADP	O
each	I-I	DET	O
group	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Then	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
sheep	O	NOUN	B
model	O	NOUN	I
of	O	ADP	O
iliac	O	ADJ	B
crest	O	NOUN	I
infiltration	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
compared	O	VERB	O
the	O	DET	O
pharmacokinetics	O	NOUN	B
of	O	ADP	O
single	B-I	ADJ	O
administration	I-I	NOUN	B
of	I-I	ADP	O
plain	I-I	ADJ	B
bupivacaine	I-I	NOUN	I
(	I-I	PUNCT	O
100	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
bupivacaine	I-I	NOUN	B
(	I-I	PUNCT	O
500	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
-loaded	I-I	ADJ	O
microspheres	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
control	O	NOUN	I
group	O	NOUN	I
,	O	PUNCT	O
pain	O	NOUN	B
from	O	ADP	O
the	O	DET	O
iliac	O	ADJ	B
crest	O	NOUN	I
was	O	AUX	O
worse	O	ADJ	O
than	O	ADP	O
pain	O	NOUN	B
from	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
surgical	O	ADJ	B
site	O	NOUN	I
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
from	I-OUT	ADP	O
the	I-OUT	DET	O
iliac	I-OUT	ADJ	B
crest	I-OUT	NOUN	I
was	O	AUX	O
significantly	B-OUT	ADV	O
reduced	I-OUT	VERB	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
12	O	NUM	O
postoperative	O	ADJ	B
hours	O	NOUN	O
in	O	ADP	O
local	O	ADJ	B
anaesthetic	O	ADJ	B
groups	O	NOUN	I
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
during	O	ADP	O
this	O	DET	O
period	O	NOUN	B
,	O	PUNCT	O
pain	B-OUT	NOUN	B
from	I-OUT	ADP	O
the	I-OUT	DET	O
primary	I-OUT	ADJ	B
surgical	I-OUT	ADJ	B
site	I-OUT	NOUN	I
was	I-OUT	AUX	O
increased	I-OUT	VERB	B
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	O
difference	I-OUT	NOUN	O
between	O	ADP	O
the	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
in	O	ADP	O
the	O	DET	O
average	O	ADJ	B
intake	O	NOUN	B
of	O	ADP	O
PCA	O	NOUN	B
morphine	B-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	O
significant	I-OUT	ADJ	O
pharmacokinetic	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
pharmacodynamic	I-OUT	ADJ	B
difference	I-OUT	NOUN	O
between	O	ADP	O
plain	O	ADJ	B
bupivacaine	B-I	NOUN	I
and	O	CCONJ	O
ropivacaine	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
maximal	B-OUT	ADJ	B
plasma	I-OUT	NOUN	B
concentration	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
Cmax	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
of	O	ADP	O
ropivacaine	B-I	NOUN	B
and	O	CCONJ	O
bupivacaine	B-I	NOUN	B
were	O	AUX	O
964	O	NUM	O
(	O	PUNCT	O
282	O	NUM	O
)	O	PUNCT	O
ng	O	NOUN	O
ml	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
638	O	NUM	O
(	O	PUNCT	O
366	O	NUM	O
)	O	PUNCT	O
ng	O	NOUN	O
ml	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
sheep	O	NOUN	B
model	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
clearly	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
release	O	NOUN	B
of	O	ADP	O
bupivacaine	B-I	NOUN	B
from	O	ADP	O
microspheres	O	NOUN	B
was	O	AUX	O
controlled	O	VERB	B
and	O	CCONJ	O
prolonged	O	VERB	B
despite	O	SCONJ	O
the	O	DET	O
largest	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
bupivacaine	B-I	NOUN	B
used	O	VERB	O
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Wound	O	NOUN	B
infiltration	O	NOUN	I
of	O	ADP	O
iliac	O	ADJ	B
crest	O	NOUN	I
harvest	O	NOUN	B
site	O	NOUN	O
with	O	ADP	O
local	O	ADJ	B
anaesthetic	O	NOUN	B
is	O	AUX	O
an	O	DET	O
easy	O	ADJ	O
technique	O	NOUN	B
for	O	ADP	O
postoperative	O	ADJ	B
analgesia	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
effect	O	NOUN	B
lasts	O	VERB	O
only	O	ADV	O
12	O	NUM	O
hours	O	NOUN	B
without	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
morphine	B-OUT	NOUN	B
consumption	I-OUT	NOUN	B
due	O	ADP	O
to	O	PART	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
pain	O	NOUN	B
from	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
surgical	O	ADJ	B
site	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
local	O	ADJ	B
anaesthetic	O	ADJ	B
infiltration	O	NOUN	I
produced	O	VERB	O
a	O	DET	O
significant	B-OUT	ADJ	O
peak	I-OUT	NOUN	O
of	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
level	I-OUT	NOUN	B
,	O	PUNCT	O
which	O	DET	O
could	O	AUX	O
be	O	AUX	O
dangerous	O	ADJ	O
if	O	SCONJ	O
another	O	DET	O
infiltration	O	NOUN	B
or	O	CCONJ	O
regional	O	ADJ	B
anaesthetic	O	ADJ	B
technique	O	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
it	O	PRON	O
.	O	PUNCT	O


Experimentally	O	ADV	B
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
drug	O	NOUN	B
delivery	O	NOUN	I
system	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
local	O	ADJ	B
anaesthetic-loaded	B-I	ADJ	O
microspheres	I-I	NOUN	O
could	O	AUX	O
be	O	AUX	O
an	O	DET	O
interesting	O	ADJ	O
alternative	O	NOUN	B
.	O	PUNCT	O


Do	O	AUX	O
cervical	O	ADJ	B
cancer	O	NOUN	I
screening	O	NOUN	B
rates	O	NOUN	I
increase	O	VERB	B
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
an	O	DET	O
intervention	O	NOUN	B
designed	O	VERB	O
to	O	PART	O
increase	O	VERB	B
mammography	O	NOUN	B
usage	O	NOUN	B
?	O	PUNCT	O
OBJECTIVES	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
cervical	B-OUT	ADJ	B
cancer	I-OUT	NOUN	I
screening	I-OUT	NOUN	B
behaviors	I-OUT	NOUN	I
among	O	ADP	O
underserved	B-P	ADJ	O
women	I-P	NOUN	B
participating	I-P	VERB	B
in	I-P	ADP	O
an	I-P	DET	O
intervention	I-P	NOUN	B
designed	I-P	VERB	O
to	I-P	PART	O
increase	I-P	VERB	B
mammography	I-P	NOUN	B
use	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
897	B-P	NUM	O
women	I-P	NOUN	B
from	I-P	ADP	O
three	I-P	NUM	O
racial	I-P	ADJ	B
groups	I-P	NOUN	I
(	I-P	PUNCT	O
white	I-P	ADJ	B
,	I-P	PUNCT	O
African	I-P	ADJ	B
American	I-P	PROPN	I
,	I-P	PUNCT	O
Native	I-P	ADJ	B
American	I-P	PROPN	I
)	I-P	PUNCT	O
living	I-P	NOUN	O
in	I-P	ADP	O
a	I-P	DET	O
rural	I-P	ADJ	B
county	I-P	NOUN	I
in	I-P	ADP	O
North	I-P	PROPN	B
Carolina	I-P	PROPN	I
.	I-P	PUNCT	O


Baseline	O	NOUN	B
and	O	CCONJ	O
followup	O	NOUN	B
surveys	O	NOUN	B
were	O	AUX	O
completed	O	VERB	O
by	O	ADP	O
815	B-P	NUM	O
women	I-P	NOUN	B
;	I-P	PUNCT	O
775	I-P	NUM	O
women	I-P	NOUN	B
provided	I-P	VERB	O
data	I-P	NOUN	B
to	O	PART	O
be	O	AUX	O
included	O	VERB	O
in	O	ADP	O
these	O	DET	O
analyses	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
an	O	DET	O
educational	B-I	ADJ	B
program	I-I	NOUN	I
focused	I-I	VERB	O
on	I-I	ADP	O
mammography	I-I	NOUN	B
delivered	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
lay	I-I	ADJ	B
health	I-I	NOUN	I
advisor	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
a	O	DET	O
physician	B-I	NOUN	B
letter/brochure	I-I	ADV	B
focusing	I-I	VERB	O
on	I-I	ADP	O
Pap	I-I	NOUN	B
tests	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	VERB	O
Women	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
intervention	O	NOUN	B
(	O	PUNCT	O
OR	O	CCONJ	B
1.70	O	NUM	O
;	O	PUNCT	O
1.31	O	NUM	O
,	O	PUNCT	O
2.21	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
OR	O	CCONJ	B
1.38	O	NUM	O
;	O	PUNCT	O
1.04	O	NUM	O
,	O	PUNCT	O
1.82	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.025	O	NUM	O
)	O	PUNCT	O
significantly	O	ADV	O
increased	O	VERB	B
cervical	B-OUT	ADJ	B
cancer	I-OUT	NOUN	I
screening	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
within	O	ADP	O
risk	O	NOUN	B
appropriate	O	ADJ	O
guidelines	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
differences	O	NOUN	O
by	O	ADP	O
racial	O	ADJ	B
group	O	NOUN	I
were	O	AUX	O
documented	O	VERB	B
.	O	PUNCT	O


Women	O	NOUN	B
categorized	O	VERB	B
in	O	ADP	O
the	O	DET	O
high-risk	O	ADJ	B
group	O	NOUN	I
for	O	ADP	O
developing	O	VERB	O
cervical	O	ADJ	B
cancer	O	NOUN	I
(	O	PUNCT	O
>	O	NOUN	O
2	O	NUM	O
sexual	O	ADJ	B
partners	O	NOUN	I
,	O	PUNCT	O
age	O	NOUN	B
<	O	X	O
18	O	NUM	O
years	O	NOUN	B
at	O	ADP	O
first	O	ADJ	O
sexual	O	ADJ	B
intercourse	O	NOUN	I
,	O	PUNCT	O
smoker	O	NOUN	B
;	O	PUNCT	O
treated	O	VERB	B
for	O	ADP	O
sexually	O	ADV	B
transmitted	O	VERB	I
disease	O	NOUN	I
[	O	PUNCT	O
STD	O	NOUN	B
]	O	PUNCT	O
or	O	CCONJ	O
partner	O	NOUN	O
with	O	ADP	O
treated	O	VERB	B
STD	O	NOUN	B
)	O	PUNCT	O
significantly	O	ADV	O
(	O	PUNCT	O
OR	O	CCONJ	B
1.88	O	NUM	O
;	O	PUNCT	O
1.54	O	NUM	O
,	O	PUNCT	O
2.28	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
increased	B-OUT	VERB	B
Pap	I-OUT	NOUN	B
test	I-OUT	NOUN	I
completion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
nonsignificant	B-OUT	ADJ	O
increase	I-OUT	NOUN	B
(	O	PUNCT	O
OR	O	CCONJ	B
1.25	O	NUM	O
;	O	PUNCT	O
0.87	O	NUM	O
,	O	PUNCT	O
1.79	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.221	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
Pap	B-OUT	NOUN	B
test	I-OUT	NOUN	I
completion	I-OUT	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
in	O	ADP	O
women	O	NOUN	B
categorized	O	VERB	B
as	O	ADP	O
low	O	ADJ	B
risk	O	NOUN	I
for	O	ADP	O
cervical	O	ADJ	B
cancer	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
women	O	NOUN	B
in	O	ADP	O
an	O	DET	O
intensive	B-I	ADJ	B
behavioral	I-I	ADJ	B
intervention	I-I	NOUN	B
designed	I-I	VERB	O
to	I-I	PART	O
increase	I-I	VERB	B
mammography	I-I	NOUN	B
use	I-I	NOUN	B
may	O	AUX	O
also	O	ADV	O
increase	O	VERB	B
Pap	B-OUT	NOUN	B
test	I-OUT	NOUN	I
completion	I-OUT	NOUN	B
,	O	PUNCT	O
similar	O	ADJ	O
to	O	PART	O
a	O	DET	O
minimal	O	ADJ	B
intervention	O	NOUN	B
focused	O	VERB	O
only	O	ADV	O
on	O	ADP	O
increasing	O	VERB	B
Pap	B-OUT	NOUN	B
test	I-OUT	NOUN	I
completion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
results	O	NOUN	B
have	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
the	O	DET	O
design	O	NOUN	B
and	O	CCONJ	O
evaluation	O	NOUN	B
of	O	ADP	O
behavioral	O	ADJ	B
intervention	O	NOUN	O
studies	O	NOUN	O
.	O	PUNCT	O


[	B-OUT	PUNCT	O
Hepatoprotective	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
of	O	ADP	O
remaxol	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatic	I-P	ADJ	I
disorders	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
milticentre	O	NOUN	O
randomized	O	VERB	B
clinical	O	ADJ	I
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
efficiency	B-OUT	NOUN	B
of	O	ADP	O
remaxol	B-I	ADJ	B
infusion	I-I	NOUN	O
solution	I-I	NOUN	O
(	O	PUNCT	O
hepatoprotective	O	ADJ	B
medicine	O	NOUN	I
for	O	ADP	O
chronic	O	ADJ	B
liver	O	NOUN	I
dysfunction	O	NOUN	I
)	O	PUNCT	O
included	O	VERB	O
494	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
B	I-P	NOUN	I
and	I-P	CCONJ	O
C.	I-P	NOUN	B
294	O	NUM	I
of	O	ADP	O
them	O	PRON	O
staying	B-P	VERB	O
in	I-P	ADP	O
7	I-P	NUM	O
clinics	I-P	NOUN	B
were	O	AUX	O
given	O	VERB	O
remaxol	B-I	ADJ	B
and	O	CCONJ	O
200	O	NUM	O
ones	O	NOUN	O
received	O	VERB	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Randomization	O	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
by	O	ADP	O
the	O	DET	O
envelope	O	NOUN	B
method	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
detailed	O	ADJ	O
description	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
characteristics	O	NOUN	I
of	O	ADP	O
the	O	DET	O
diseases	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
remaxol	B-I	ADJ	B
vs	I-I	ADP	O
placebo	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
functional	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
of	O	ADP	O
affected	O	VERB	B
liver	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
laboratory	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
analysis	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
mechanism	O	NOUN	B
of	O	ADP	O
remaxol	B-I	ADJ	B
action	O	NOUN	O
is	O	AUX	O
based	O	VERB	O
on	O	ADP	O
hepatoprotective	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
antioxidative	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anticholestatic	I-OUT	ADJ	B
activities	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Zoledronic	B-I	ADJ	B
acid	I-I	NOUN	I
combined	I-I	VERB	O
with	I-I	ADP	O
adjuvant	I-I	ADJ	B
endocrine	I-I	ADJ	I
therapy	I-I	NOUN	I
of	I-I	ADP	O
tamoxifen	I-I	NOUN	B
versus	O	CCONJ	O
anastrozol	B-I	ADJ	B
plus	I-I	CCONJ	O
ovarian	I-I	ADJ	B
function	I-I	NOUN	I
suppression	I-I	NOUN	B
in	O	ADP	O
premenopausal	B-P	ADJ	B
early	I-P	ADJ	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
final	O	ADJ	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Austrian	B-P	PROPN	B
Breast	I-P	PROPN	O
and	I-P	CCONJ	O
Colorectal	I-P	PROPN	O
Cancer	I-P	PROPN	O
Study	I-P	PROPN	O
Group	I-P	PROPN	O
Trial	I-P	PROPN	O
12	I-P	NUM	O
.	I-P	PUNCT	O


BACKGROUND	O	ADJ	O
Zoledronic	B-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
ZOL	I-I	NOUN	B
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
adjuvant	I-I	ADJ	B
endocrine	I-I	ADJ	I
therapy	I-I	NOUN	I
significantly	O	ADV	O
improved	O	VERB	O
disease-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
DFS	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
48-	O	NUM	O
and	O	CCONJ	O
62-month	O	ADJ	O
follow-up	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ABCSG-12	O	NOUN	B
trial	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
efficacy	O	NOUN	B
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
final	O	ADJ	O
additional	O	ADJ	O
analysis	O	NOUN	B
after	O	ADP	O
94.4	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	B-P	NOUN	B
were	I-P	AUX	O
premenopausal	I-P	ADJ	B
women	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
undergone	I-P	VERB	O
primary	I-P	ADJ	B
surgery	I-P	NOUN	I
for	I-P	ADP	O
stage	I-P	NOUN	B
I/II	I-P	NOUN	I
estrogen-receptor-positive	I-P	ADJ	B
and/or	I-P	CCONJ	O
progesterone-receptor-positive	I-P	ADJ	B
breast	I-P	NOUN	I
cancer	I-P	NOUN	I
with	I-P	ADP	O
<	I-P	NOUN	O
10	I-P	NUM	O
positive	I-P	ADJ	B
lymph	I-P	NOUN	B
nodes	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
were	I-P	AUX	O
scheduled	I-P	VERB	B
for	I-P	ADP	O
standard	I-P	ADJ	B
goserelin	I-P	NOUN	B
therapy	I-P	NOUN	I
.	I-P	PUNCT	O


All	O	DET	O
1803	B-P	NUM	O
patients	I-P	NOUN	B
received	I-P	VERB	O
goserelin	I-I	NOUN	B
(	I-I	PUNCT	O
3.6	I-I	NUM	O
mg	I-I	NOUN	O
every	I-I	DET	O
28	I-I	NUM	O
days	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
were	I-I	AUX	O
randomized	I-I	VERB	B
to	I-I	PART	O
tamoxifen	I-I	NOUN	B
(	I-I	PUNCT	O
20	I-I	NUM	O
mg/days	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
anastrozole	I-I	NOUN	B
(	I-I	PUNCT	O
1	I-I	NUM	O
mg/days	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
both	I-I	CCONJ	O
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
ZOL	I-I	NOUN	B
(	I-I	PUNCT	O
4	I-I	NUM	O
mg	I-I	NOUN	O
every	I-I	DET	O
6	I-I	NUM	O
months	I-I	NOUN	B
)	I-I	PUNCT	O
for	I-I	ADP	O
3	I-I	NUM	O
years	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
DFS	B-OUT	NOUN	B
;	I-OUT	PUNCT	O
recurrence-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
secondary	O	ADJ	B
end	O	NOUN	I
points	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
After	O	ADP	O
94.4-month	O	NOUN	O
median	O	NOUN	B
follow-up	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
0-114	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
relative	B-OUT	ADJ	O
risks	I-OUT	NOUN	B
of	I-OUT	ADP	O
disease	I-OUT	NOUN	B
progression	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
hazard	I-OUT	NOUN	B
ratio	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
=	O	ADJ	O
0.77	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	B-OUT	NOUN	B
interval	I-OUT	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
0.60-0.99	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.042	O	NUM	O
]	O	PUNCT	O
and	O	CCONJ	O
of	O	ADP	O
death	B-OUT	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
=	O	ADJ	O
0.66	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	PROPN	B
0.43-1.02	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.064	O	NUM	O
)	O	PUNCT	O
are	O	AUX	O
still	O	ADV	O
reduced	O	VERB	B
by	O	ADP	O
ZOL	O	NOUN	B
although	O	SCONJ	O
no	O	DET	O
longer	O	ADV	O
significant	O	ADJ	B
at	O	ADP	O
the	O	DET	O
predefined	O	ADJ	O
significance	O	NOUN	B
level	O	NOUN	I
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
251	O	NUM	O
DFS	B-OUT	NOUN	B
events	I-OUT	NOUN	O
and	O	CCONJ	O
86	O	NUM	O
deaths	B-OUT	NOUN	B
were	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Absolute	B-OUT	ADJ	B
risk	I-OUT	NOUN	O
reductions	I-OUT	NOUN	B
with	O	ADP	O
ZOL	O	NOUN	B
were	O	AUX	O
3.4	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
DFS	O	NOUN	B
and	O	CCONJ	O
2.2	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
OS	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
DFS	B-OUT	NOUN	B
difference	I-OUT	NOUN	O
between	O	ADP	O
tamoxifen	O	NOUN	B
alone	O	ADV	O
versus	O	CCONJ	O
anastrozole	O	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
pronounced	O	ADJ	O
higher	B-OUT	ADJ	B
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
death	I-OUT	NOUN	B
for	O	ADP	O
anastrozole-treated	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
=	O	ADJ	O
1.63	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1.05-1.45	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.030	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Treatments	O	NOUN	B
were	O	AUX	O
generally	O	ADV	O
well	O	ADV	O
tolerated	B-OUT	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
no	B-OUT	DET	O
reports	I-OUT	NOUN	O
of	I-OUT	ADP	O
renal	I-OUT	ADJ	B
failure	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
osteonecrosis	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
jaw	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
final	O	ADJ	O
results	O	NOUN	B
from	O	ADP	O
ABCSG	O	NOUN	B
12	O	NUM	O
suggest	O	VERB	O
that	O	SCONJ	O
twice-yearly	O	ADJ	B
ZOL	B-I	NOUN	B
enhances	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
adjuvant	O	ADJ	B
endocrine	O	ADJ	I
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
benefit	O	NOUN	B
is	O	AUX	O
maintained	O	VERB	O
long-term	O	ADJ	B
.	O	PUNCT	O


CLINICALTRIALSGOV	O	PROPN	B
NCT00295646	O	PROPN	O
(	O	PUNCT	O
http	O	NOUN	B
:	O	PUNCT	O
//www.clinicaltrials.gov/ct2/results	O	X	B
?	O	PUNCT	O
term=00295646	O	DET	B
)	O	PUNCT	O
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
choice	B-I	NOUN	O
assessment	I-I	NOUN	B
to	O	PART	O
predict	O	VERB	O
reinforcer	O	NOUN	B
effectiveness	O	NOUN	I
.	O	PUNCT	O


A	B-I	DET	O
choice	I-I	NOUN	B
assessment	I-I	NOUN	I
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
more	O	ADV	O
accurate	O	ADJ	B
method	O	NOUN	B
of	O	ADP	O
identifying	O	VERB	B
preferences	O	NOUN	B
than	O	ADP	O
is	O	AUX	O
single-item	O	ADJ	B
presentation	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
clear	O	ADJ	O
whether	O	SCONJ	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
reinforcement	O	NOUN	B
varies	O	VERB	O
positively	O	ADV	B
with	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
preference	O	NOUN	B
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
whether	O	SCONJ	O
the	O	DET	O
relative	O	ADJ	O
preference	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
choice	O	NOUN	O
assessment	O	NOUN	B
predicts	O	VERB	O
relative	O	ADJ	O
reinforcer	O	NOUN	B
effectiveness	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
attempted	O	VERB	O
to	O	PART	O
address	O	VERB	O
this	O	DET	O
question	O	NOUN	O
by	O	ADP	O
categorizing	O	VERB	B
stimuli	O	NOUN	B
as	O	ADP	O
high	O	ADJ	B
,	O	PUNCT	O
middle	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
low	O	ADJ	B
preference	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
choice	B-I	NOUN	O
assessment	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
comparing	O	VERB	B
the	O	DET	O
reinforcing	O	ADJ	O
effectiveness	O	NOUN	B
of	O	ADP	O
these	O	DET	O
stimuli	O	NOUN	B
using	O	VERB	O
a	O	DET	O
concurrent	B-I	ADJ	B
operants	I-I	NOUN	B
paradigm	I-I	NOUN	B
.	I-I	PUNCT	O


High-preference	O	ADJ	B
stimuli	O	NOUN	I
consistently	O	ADV	O
functioned	O	VERB	O
as	O	ADP	O
reinforcers	O	NOUN	B
for	O	ADP	O
all	O	DET	O
4	B-P	NUM	O
clients	I-P	NOUN	B
.	I-P	PUNCT	O


Middle-preference	O	ADJ	B
stimuli	O	NOUN	B
functioned	O	VERB	O
as	O	ADP	O
reinforcers	O	NOUN	B
for	O	ADP	O
2	B-P	NUM	O
clients	I-P	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
low-preference	O	ADJ	B
stimuli	O	NOUN	B
.	O	PUNCT	O


Low-preference	O	ADJ	B
stimuli	O	NOUN	B
did	O	AUX	O
not	O	PART	O
function	O	VERB	O
as	O	ADP	O
reinforcers	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
high-	O	ADJ	O
and	O	CCONJ	O
middle-preference	O	ADJ	B
stimuli	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
choice	B-I	NOUN	O
assessment	I-I	NOUN	O
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
predict	O	VERB	O
the	O	DET	O
relative	O	ADJ	O
reinforcing	O	VERB	B
value	O	NOUN	I
of	O	ADP	O
various	O	ADJ	O
stimuli	B-OUT	NOUN	B
,	O	PUNCT	O
which	O	DET	O
,	O	PUNCT	O
in	O	ADP	O
turn	O	NOUN	O
,	O	PUNCT	O
may	O	AUX	O
help	O	VERB	O
to	O	PART	O
improve	O	VERB	B
programs	O	NOUN	B
for	O	ADP	O
clients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
to	I-P	ADP	O
profound	I-P	ADJ	O
disabilities	I-P	NOUN	B
.	I-P	PUNCT	O


Cost-effectiveness	B-OUT	NOUN	B
of	O	ADP	O
ablation	B-I	NOUN	B
surgery	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
atrial	I-P	ADJ	B
fibrillation	I-P	NOUN	I
undergoing	I-P	VERB	O
cardiac	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
cost-effectiveness	O	NOUN	B
of	O	ADP	O
concomitant	O	ADJ	B
ablation	B-I	NOUN	B
surgery	I-I	NOUN	I
(	I-I	PUNCT	O
AS	I-I	NOUN	B
)	I-I	PUNCT	O
compared	O	VERB	O
to	O	PART	O
regular	O	ADJ	B
cardiac	B-I	ADJ	B
surgery	I-I	NOUN	I
in	O	ADP	O
atrial	B-P	ADJ	B
fibrillation	I-P	NOUN	I
(	I-P	PUNCT	O
AF	I-P	NOUN	B
)	I-P	PUNCT	O
patients	I-P	NOUN	B
over	O	ADP	O
a	O	DET	O
one-year	O	ADJ	B
follow-up	O	NOUN	B
.	O	PUNCT	O


Cost	B-OUT	NOUN	B
analysis	I-OUT	NOUN	I
was	O	AUX	O
performed	O	VERB	O
from	O	ADP	O
a	O	DET	O
societal	O	ADJ	B
perspective	O	NOUN	I
alongside	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
,	O	PUNCT	O
double-blinded	O	ADJ	B
,	O	PUNCT	O
multicentre	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
fifty	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
documented	I-P	VERB	B
AF	I-P	PROPN	B
were	O	AUX	O
randomly	B-I	ADV	O
assigned	I-I	VERB	O
to	I-I	PART	O
undergo	I-I	VERB	O
cardiac	I-I	ADJ	B
surgery	I-I	NOUN	I
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
AS	I-I	NOUN	B
.	I-I	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
thirty-two	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
cost-effectiveness	I-I	ADJ	B
study	I-P	NOUN	I
.	I-P	PUNCT	O


All	B-OUT	DET	O
costs	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
medical	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
non-medical	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
were	O	AUX	O
measured	O	VERB	B
during	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Costs	B-OUT	NOUN	B
data	I-OUT	NOUN	B
were	O	AUX	O
combined	O	VERB	O
with	O	ADP	O
quality	B-OUT	NOUN	B
adjusted	I-OUT	ADJ	O
life	I-OUT	NOUN	O
years	I-OUT	NOUN	O
(	O	PUNCT	O
QALYs	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
obtain	O	VERB	O
the	O	DET	O
incremental	O	ADJ	B
costs	O	NOUN	B
per	O	ADP	O
QALY	O	PROPN	B
.	O	PUNCT	O


Total	B-OUT	ADJ	O
costs	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
AS	B-I	ADJ	B
group	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
regular	O	ADJ	B
cardiac	O	ADJ	B
surgery	O	NOUN	I
group	O	NOUN	B
[	O	PUNCT	O
cost	O	NOUN	B
difference	O	NOUN	I
bootstrap	O	NOUN	B
:	O	PUNCT	O
€4,724	O	ADV	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
uncertainty	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
UI	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
€2,770-€6,678	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
bootstrapped	O	ADJ	B
difference	B-OUT	NOUN	I
in	I-OUT	ADP	O
QALYs	O	NOUN	B
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
0.06	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
UI	O	NOUN	B
:	O	PUNCT	O
-0.024	O	NUM	O
to	O	PART	O
0.14	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
incremental	O	ADJ	B
cost-effectiveness	O	ADJ	O
ratio	O	NOUN	O
is	O	AUX	O
€73,359	B-OUT	NOUN	O
per	I-OUT	ADP	O
QALY	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
acceptability	O	NOUN	B
curve	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
even	O	ADV	O
in	O	ADP	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
maximum	O	ADJ	B
threshold	O	NOUN	O
value	O	NOUN	O
of	O	ADP	O
€80,000	B-OUT	NOUN	O
per	O	ADP	O
QALY	O	PROPN	B
gained	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
probability	B-I	NOUN	B
of	O	ADP	O
AS	O	NOUN	B
being	O	AUX	O
more	O	ADV	O
cost-effective	O	ADJ	B
than	O	ADP	O
regular	O	ADJ	B
cardiac	O	ADJ	B
surgery	O	NOUN	I
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
beyond	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Concluding	O	VERB	B
that	O	SCONJ	O
concomitant	B-I	ADJ	B
AS	O	NOUN	B
in	O	ADP	O
AF	O	NOUN	B
is	O	AUX	O
not	O	PART	O
cost-effective	O	ADJ	B
after	O	ADP	O
a	O	DET	O
one-year	O	ADJ	B
follow-up	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
regular	O	ADJ	B
cardiac	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


Exploratory	O	ADJ	B
Subset	O	NOUN	I
Analysis	O	NOUN	I
of	O	ADP	O
African	B-P	ADJ	B
Americans	I-P	PROPN	I
From	I-P	ADP	O
the	I-P	DET	O
PointBreak	I-P	PROPN	B
Study	I-P	PROPN	I
:	I-P	PUNCT	O
Pemetrexed-Carboplatin-Bevacizumab	I-I	PROPN	B
Followed	I-I	VERB	B
by	I-I	ADP	O
Maintenance	I-I	PROPN	O
Pemetrexed-Bevacizumab	I-I	PROPN	B
Versus	O	PROPN	O
Paclitaxel-Carboplatin-Bevacizumab	B-I	PROPN	B
Followed	I-I	VERB	B
by	I-I	ADP	O
Maintenance	I-I	PROPN	B
Bevacizumab	I-I	NOUN	B
in	I-P	ADP	O
Patients	I-P	NOUN	B
With	I-P	ADP	O
Stage	I-P	NOUN	B
IIIB/IV	I-P	NOUN	I
Nonsquamous	I-P	ADJ	B
Non-Small-Cell	I-P	PROPN	I
Lung	I-P	PROPN	B
Cancer	I-P	PROPN	I
.	O	PUNCT	O


INTRODUCTION	B-P	ADJ	O
African	I-P	ADJ	B
Americans	I-P	PROPN	I
have	I-P	AUX	O
a	I-P	DET	O
greater	I-P	ADJ	O
incidence	I-P	NOUN	B
of	I-P	ADP	O
lung	I-P	NOUN	B
cancer	I-P	NOUN	I
than	I-P	ADP	O
whites	I-P	NOUN	B
and	O	CCONJ	O
have	O	AUX	O
been	O	AUX	O
underrepresented	O	ADJ	O
in	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
PointBreak	O	PROPN	B
trial	O	NOUN	I
(	B-I	PUNCT	O
pemetrexed-carboplatin-bevacizumab	I-I	NOUN	B
and	I-I	CCONJ	O
maintenance	I-I	NOUN	B
pemetrexed-bevacizumab	I-I	NOUN	B
[	I-I	PUNCT	O
PemCBev	I-I	NOUN	B
]	I-I	PUNCT	O
vs.	I-I	NOUN	O
paclitaxel-carboplatin-bevacizumab	I-I	NOUN	B
and	I-I	CCONJ	O
maintenance	I-I	NOUN	B
bevacizumab	I-I	NOUN	B
[	I-I	PUNCT	O
PacCBev	I-I	NOUN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
,	O	PUNCT	O
10	B-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
patients	I-P	NOUN	B
were	I-P	AUX	O
African	I-P	ADJ	B
American	I-P	ADJ	I
.	O	PUNCT	O


PointBreak	O	PROPN	B
had	O	AUX	O
negative	O	ADJ	B
findings	O	NOUN	B
;	O	PUNCT	O
PemCBev	O	NOUN	O
did	O	AUX	O
not	O	PART	O
demonstrate	B-OUT	VERB	O
superior	I-OUT	ADJ	B
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
PointBreak	O	PROPN	B
subgroup	B-OUT	NOUN	O
efficacy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
data	O	NOUN	B
were	O	AUX	O
retrospectively	O	ADV	B
analyzed	B-P	VERB	I
:	I-P	PUNCT	O
African	I-P	ADJ	B
Americans	I-P	PROPN	I
versus	I-P	CCONJ	O
whites	I-P	NOUN	B
for	I-I	ADP	O
PemCBev	I-I	NOUN	B
;	I-I	PUNCT	O
PemCBev	I-P	NOUN	B
versus	I-I	CCONJ	O
PacCBev	I-I	PROPN	B
in	I-P	ADP	O
African	I-P	ADJ	B
Americans	I-P	PROPN	I
;	I-P	PUNCT	O
and	I-P	CCONJ	O
academic	I-P	ADJ	B
versus	I-P	ADP	O
community	I-P	NOUN	B
settings	I-P	NOUN	I
for	I-P	ADP	O
African	I-P	ADJ	B
Americans	I-P	PROPN	I
.	I-OUT	PUNCT	O


Hazard	B-OUT	NOUN	B
ratios	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HRs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
P	I-OUT	NOUN	O
values	I-OUT	NOUN	O
were	O	AUX	O
derived	O	VERB	O
from	O	ADP	O
a	B-OUT	DET	O
multivariate	I-OUT	ADJ	B
Cox	I-OUT	NOUN	I
proportional	O	ADJ	I
hazards	O	NOUN	I
model	O	NOUN	I
after	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
covariates	O	NOUN	B
.	O	PUNCT	O


RESULTS	B-P	NOUN	O
Of	I-P	ADP	O
939	I-P	NUM	O
intent-to-treat	I-P	ADJ	B
(	I-P	PUNCT	O
ITT	I-P	NOUN	B
)	I-P	PUNCT	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
94	I-P	NUM	O
were	I-P	AUX	O
African	I-P	ADJ	B
American	I-P	ADJ	I
and	I-P	CCONJ	O
805	I-P	NUM	O
were	I-P	AUX	O
white	I-P	ADJ	B
.	I-P	PUNCT	O


African-American	B-P	ADJ	B
enrollment	O	NOUN	B
was	O	AUX	O
uniform	O	ADJ	B
across	O	ADP	O
the	O	DET	O
study	O	NOUN	B
sites	O	NOUN	I
(	O	PUNCT	O
median	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
African	O	ADJ	B
American	O	ADJ	I
per	O	ADP	O
site	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
PemCBev	O	NOUN	B
arm	O	NOUN	I
,	O	PUNCT	O
OS	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
1.125	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.525	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PFS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
1.229	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.251	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
response	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.607	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
profiles	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
African	O	ADJ	B
Americans	O	PROPN	I
versus	O	CCONJ	O
whites	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
African	O	ADJ	B
Americans	B-OUT	PROPN	I
,	O	PUNCT	O
OS	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
1.375	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.209	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	O	PUNCT	O
PFS	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
0.902	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.670	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
response	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
1.000	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
profiles	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
PemCBev	O	NOUN	B
versus	O	CCONJ	I
PacCBev	O	NOUN	I
arm	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
African	O	ADJ	B
Americans	O	PROPN	I
,	O	PUNCT	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
seen	B-OUT	VERB	O
in	O	ADP	O
OS	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
0.661	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.191	B-OUT	NUM	O
)	I-OUT	PUNCT	O
or	O	CCONJ	O
PFS	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
0.969	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.915	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
academic	O	ADJ	B
versus	O	ADP	O
community	O	NOUN	B
practice	O	NOUN	I
settings	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
the	O	DET	O
PemCBev	O	NOUN	B
arm	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
exploratory	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
differences	B-P	NOUN	O
between	I-P	ADP	O
African	I-P	ADJ	B
Americans	I-P	PROPN	I
and	I-P	CCONJ	O
whites	I-OUT	NOUN	B
for	I-OUT	ADP	O
the	I-OUT	DET	O
efficacy	I-OUT	NOUN	B
outcomes	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
profiles	O	NOUN	B
.	O	PUNCT	O


Consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
ITT	O	NOUN	B
population	O	NOUN	O
negative	O	ADJ	O
trial	O	NOUN	O
result	B-P	VERB	O
,	I-P	PUNCT	O
for	I-P	ADP	O
African	I-P	ADJ	B
Americans	I-P	PROPN	I
,	O	PUNCT	O
the	O	DET	O
median	O	ADJ	B
OS	O	NOUN	B
was	O	AUX	O
not	O	PART	O
superior	O	ADJ	O
for	O	ADP	O
either	O	DET	O
arm	B-P	NOUN	B
.	I-P	PUNCT	O


For	B-P	ADP	O
African	I-P	ADJ	B
Americans	I-P	PROPN	I
,	O	PUNCT	O
PFS	O	PROPN	B
and	O	CCONJ	O
OS	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
academic	O	ADJ	B
and	O	CCONJ	O
community	O	NOUN	B
settings	O	NOUN	I
.	O	PUNCT	O


Additional	O	ADJ	O
outcomes	B-P	NOUN	B
data	I-P	NOUN	B
for	I-P	ADP	O
African	I-P	ADJ	B
Americans	O	PROPN	I
should	O	AUX	O
be	O	AUX	O
collected	O	VERB	O
in	O	ADP	O
lung	O	NOUN	B
cancer	O	NOUN	I
studies	O	NOUN	O
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
direct	B-I	ADJ	O
current	I-I	ADJ	O
pulse	I-I	NOUN	B
stimulating	I-I	NOUN	I
acupoints	I-I	NOUN	I
of	I-I	ADP	O
JiaJi	I-I	NOUN	B
(	O	PUNCT	O
T10-13	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Ciliao	O	NOUN	B
(	O	PUNCT	O
BL	O	NOUN	B
32	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
Han	B-I	PROPN	B
's	I-I	PART	I
Acupoint	I-I	PROPN	B
Nerve	I-I	PROPN	I
Stimulator	I-I	PROPN	I
on	O	ADP	O
labour	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
in	I-P	ADP	O
women	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
clinical	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
effect	O	NOUN	I
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
direct	B-I	ADJ	B
current	I-I	ADJ	I
(	I-I	PUNCT	O
DC	I-I	NOUN	B
)	I-I	PUNCT	O
pulse	I-I	NOUN	B
produced	I-I	VERB	O
by	I-I	ADP	O
Han	I-I	PROPN	B
's	I-I	PART	I
Acupoint	I-I	PROPN	B
Nerve	I-I	PROPN	I
Stimulator	I-I	PROPN	I
in	O	ADP	O
reduction	O	NOUN	B
(	O	PUNCT	O
HANS	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
labor	B-OUT	NOUN	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


METHODS	O	VERB	O
Totally	O	ADV	O
120	B-P	NUM	O
participants	I-P	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
this	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
4	O	NUM	O
groups	O	NOUN	B
including	O	VERB	O
:	O	PUNCT	O
HANS	B-I	NOUN	B
group	I-I	NOUN	B
,	I-I	PUNCT	O
patient	I-I	NOUN	B
controlled	I-I	VERB	O
intravenous	I-I	ADJ	B
analgesia	I-I	NOUN	I
(	I-I	PUNCT	O
PCIA	I-I	NOUN	B
)	I-I	PUNCT	O
group	I-I	NOUN	B
,	I-I	PUNCT	O
patient-controlled	I-I	ADJ	B
epidural	I-I	ADJ	I
analgesia	I-I	NOUN	I
(	I-I	PUNCT	O
PCEA	I-I	NOUN	B
)	I-I	PUNCT	O
group	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
HANS	B-I	PROPN	B
group	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
stimulating	O	VERB	B
the	O	DET	O
acupoints	B-I	NOUN	B
of	I-I	ADP	O
JiaJi	I-I	NOUN	B
(	O	PUNCT	O
T10-L3	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Ciliao	B-I	NOUN	B
(	O	PUNCT	O
BL	O	NOUN	B
32	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
DC	B-I	NOUN	B
pulse	I-I	NOUN	B
of	O	ADP	O
100	O	NUM	O
Hz	O	NOUN	O
and	O	CCONJ	O
15-30	O	NUM	O
mA	O	NOUN	O
produced	O	VERB	O
by	O	ADP	O
a	O	DET	O
portable	B-I	ADJ	B
battery-powered	I-I	ADJ	I
Han	I-I	PROPN	I
's	I-I	PART	I
Acupoint	I-I	PROPN	B
Nerve	I-I	PROPN	I
Stimulator	I-I	PROPN	I
for	O	ADP	O
30	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
PCIA	B-I	PROPN	B
group	O	NOUN	B
was	O	AUX	O
intravenously	O	ADV	B
infused	O	VERB	B
Ondansetron	B-I	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
5	O	NUM	O
min	O	NOUN	B
,	O	PUNCT	O
then	O	ADV	O
tramadol	B-I	NOUN	B
injection	I-I	NOUN	B
(	O	PUNCT	O
1.5	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
slowly	O	ADV	O
dripped	O	VERB	B
by	O	ADP	O
using	O	VERB	O
BaxterAP	O	PROPN	B
II	O	NUM	I
electronic	O	ADJ	I
pump	O	NOUN	I
with	O	ADP	O
50	O	NUM	O
mL	O	NOUN	O
tramadol	B-I	NOUN	B
(	O	PUNCT	O
0.70	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
+	O	CCONJ	O
ondansetron	B-I	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
background	O	NOUN	B
infusion	O	NOUN	B
2	O	NUM	O
mL/h	O	NOUN	O
,	O	PUNCT	O
PCA	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
mL	O	NOUN	O
,	O	PUNCT	O
lockout	O	ADJ	B
interval	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
PCEA	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
women	O	NOUN	B
received	O	VERB	O
intrathecal	O	ADJ	B
injection	B-I	NOUN	I
ropivacaine	I-I	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
L2-3	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
epidural	O	ADJ	B
catheter	O	NOUN	I
was	O	AUX	O
connected	O	VERB	O
to	O	ADP	O
BaxterAP	O	NOUN	B
II	O	NUM	I
electronic	O	ADJ	I
pump	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
100	O	NUM	O
mL	O	NOUN	O
Ropivacaine	B-I	NOUN	B
(	O	PUNCT	O
0.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
Sufentanil	B-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
ug	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
background	O	NOUN	B
infusion	O	NOUN	B
5	O	NUM	O
mL	O	NOUN	O
,	O	PUNCT	O
Patient	B-I	NOUN	B
controlled	I-I	VERB	I
analgesia	I-I	NOUN	I
(	I-I	PUNCT	O
PCA	I-I	NOUN	B
)	I-I	PUNCT	O
dose	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
mL	O	NOUN	O
,	O	PUNCT	O
lockout	O	ADJ	B
interval	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
was	O	AUX	O
not	O	PART	O
received	O	VERB	O
analgesia	O	NOUN	B
.	O	PUNCT	O


The	B-OUT	DET	O
visual	I-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
stage	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
manner	I-OUT	NOUN	O
of	I-OUT	ADP	O
labor	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
Apgar	I-OUT	NOUN	B
score	I-OUT	NOUN	I
of	I-OUT	ADP	O
newborn	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
neonatal	I-OUT	ADJ	B
weights	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
oxytocin	I-OUT	NOUN	B
dosage	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
postpartum	I-OUT	NOUN	B
hemorrhage	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
monitored	O	VERB	B
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
vital	O	ADJ	B
signs	O	NOUN	I
were	O	AUX	O
all	O	ADV	O
stable	O	ADJ	B
in	O	ADP	O
the	O	DET	O
four	O	NUM	O
analgesic	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
analgesia	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
statistical	O	ADJ	B
difference	O	NOUN	I
in	O	ADP	O
VAS	B-OUT	NOUN	B
score	I-OUT	NOUN	I
between	O	ADP	O
HANS	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
control	B-I	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
between	O	ADP	O
PCEA	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
control	B-I	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
between	O	ADP	O
PCIA	B-I	PROPN	B
group	O	NOUN	B
and	O	CCONJ	O
control	B-I	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
analgesic	B-OUT	ADJ	B
effect	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
PCEA	B-I	NOUN	B
group	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
better	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
other	O	ADJ	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
stage	O	NOUN	B
of	O	ADP	O
labor	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PCEA	B-I	NOUN	B
group	O	NOUN	B
was	O	AUX	O
longer	O	ADJ	O
than	O	ADP	O
the	O	DET	O
other	O	ADJ	O
three	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
showing	O	VERB	O
significant	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


The	O	DET	O
Apgar	O	NOUN	B
score	O	NOUN	I
of	O	ADP	O
newborn	O	ADJ	B
1	O	NUM	I
min	O	NOUN	O
after	O	ADP	O
birth	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PCIA	B-I	PROPN	B
group	O	NOUN	B
was	O	AUX	O
slightly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
two	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
showing	O	VERB	O
significant	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


The	O	DET	O
neonatal	B-OUT	ADJ	B
weights	I-OUT	NOUN	B
between	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
cesarean	I-OUT	NOUN	B
section	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
labor	O	NOUN	B
analgesia	O	NOUN	I
group	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
statistically	O	ADJ	B
difference	O	NOUN	I
in	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
PCIA	B-I	PROPN	B
group	O	NOUN	B
that	O	PRON	O
used	B-OUT	VERB	O
oxytocin	I-OUT	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
other	O	ADJ	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
postpartum	B-OUT	NOUN	B
hemorrhage	I-OUT	NOUN	I
between	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
the	O	DET	O
PCEA	B-I	NOUN	B
group	O	NOUN	O
were	O	AUX	O
itching	B-OUT	VERB	B
,	I-OUT	PUNCT	O
uroschesis	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
neonatal	I-OUT	ADJ	B
asphyxia	I-OUT	NOUN	B
and	O	CCONJ	O
PCIA	B-I	NOUN	B
group	O	NOUN	B
were	O	AUX	O
nausea	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
vomiting	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
neonatal	I-OUT	ADJ	B
asphyxia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
fewer	O	ADJ	O
side-effects	B-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
HANS	B-I	PROPN	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
DC	O	NOUN	B
pulse	O	NOUN	B
produced	O	VERB	O
by	O	ADP	O
HANS	B-I	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
non-pharmacological	O	ADJ	B
alternative	O	NOUN	O
to	O	ADP	O
labor	O	NOUN	B
pain	O	NOUN	I
with	O	ADP	O
fewer	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


The	B-I	DET	O
Autism	I-I	PROPN	B
MEAL	I-I	PROPN	O
Plan	I-I	PROPN	O
:	I-I	PUNCT	O
a	O	DET	O
parent-training	O	ADJ	B
curriculum	O	NOUN	B
to	O	PART	O
manage	O	VERB	O
eating	O	NOUN	B
aversions	O	NOUN	B
and	O	CCONJ	O
low	O	ADJ	B
intake	O	NOUN	I
among	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Feeding	O	NOUN	B
problems	O	NOUN	I
represent	O	VERB	O
a	O	DET	O
frequent	O	ADJ	B
concern	O	NOUN	O
reported	O	VERB	O
by	O	ADP	O
caregivers	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
growing	O	VERB	O
evidence	O	NOUN	B
suggests	O	VERB	O
atypical	O	ADJ	B
patterns	O	NOUN	B
of	O	ADP	O
intake	O	NOUN	B
may	O	AUX	O
place	O	VERB	O
this	O	DET	O
population	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
of	O	ADP	O
nutritional	O	ADJ	B
and/or	O	CCONJ	O
related	O	ADJ	O
medical	O	ADJ	B
issues	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
chronic	O	ADJ	B
vitamin	O	NOUN	B
and	O	CCONJ	O
mineral	O	ADJ	B
deficiencies	O	NOUN	I
,	O	PUNCT	O
poor	O	ADJ	B
bone	O	NOUN	I
growth	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
obesity	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
factors	O	NOUN	B
emphasizes	O	VERB	O
a	O	DET	O
clear	O	ADJ	O
need	O	NOUN	O
to	O	PART	O
identify	O	VERB	O
and	O	CCONJ	O
disseminate	O	VERB	B
evidence-based	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
feeding	O	NOUN	B
problems	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
.	O	PUNCT	O


Behavioral	O	ADJ	B
intervention	O	NOUN	B
represents	O	VERB	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
chronic	O	ADJ	B
feeding	O	NOUN	B
concerns	O	NOUN	O
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
evidence	O	NOUN	B
has	O	AUX	O
largely	O	ADV	O
been	O	AUX	O
established	O	VERB	O
with	O	ADP	O
trained	O	VERB	B
therapists	O	NOUN	B
working	O	VERB	O
in	O	ADP	O
highly	O	ADV	O
structured	O	ADJ	B
settings	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
seeks	O	VERB	O
to	O	PART	O
fill	O	VERB	O
this	O	DET	O
gap	O	NOUN	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
by	O	ADP	O
describing	O	VERB	O
and	O	CCONJ	O
evaluating	O	VERB	B
the	O	DET	O
Autism	B-I	PROPN	B
MEAL	I-I	PROPN	I
Plan	I-I	PROPN	I
,	O	PUNCT	O
a	O	DET	O
behaviorally	O	ADV	B
based	O	VERB	O
parent-training	O	ADJ	B
curriculum	O	NOUN	B
to	O	PART	O
address	O	VERB	O
feeding	O	NOUN	B
problems	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
feasibility	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
program	O	NOUN	B
content	O	NOUN	B
and	O	CCONJ	O
study	O	NOUN	B
protocol	O	NOUN	I
(	O	PUNCT	O
e.g	O	INTJ	O
.	O	PUNCT	O


recruitment	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
retention	I-OUT	NOUN	B
of	I-OUT	ADP	O
participants	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
assessment	I-OUT	NOUN	B
procedures	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
efficacy	B-OUT	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
feeding	O	NOUN	B
behaviors	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
10	B-P	NUM	O
families	I-P	NOUN	B
participated	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
treatment	I-P	NOUN	B
condition	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
program	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
a	O	DET	O
waitlist	B-I	ADJ	B
control	I-I	NOUN	I
design	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
representing	O	VERB	O
the	O	DET	O
first	O	ADJ	O
randomized-control	O	ADJ	O
study	O	NOUN	B
of	O	ADP	O
a	O	DET	O
feeding	O	NOUN	B
intervention	O	NOUN	B
in	O	ADP	O
autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
.	O	PUNCT	O


Results	O	NOUN	B
provide	O	VERB	O
provisional	O	ADJ	O
support	O	NOUN	O
regarding	O	VERB	O
the	O	DET	O
utility	B-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
program	I-OUT	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
high	B-OUT	ADJ	B
social	I-OUT	ADJ	B
validity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
parent	I-OUT	NOUN	B
perception	I-OUT	NOUN	B
of	I-OUT	ADP	O
effectiveness	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
reduced	I-OUT	VERB	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
caregiver	I-OUT	NOUN	B
stress	I-OUT	NOUN	I
following	I-OUT	VERB	O
intervention	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Implications	O	NOUN	B
,	O	PUNCT	O
limitations	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
future	O	ADJ	O
directions	O	NOUN	B
for	O	ADP	O
this	O	DET	O
line	O	NOUN	O
of	O	ADP	O
research	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


That	O	DET	O
looks	O	VERB	O
familiar	O	ADJ	O
:	O	PUNCT	O
attention	O	NOUN	B
allocation	O	NOUN	I
to	O	ADP	O
familiar	O	ADJ	B
and	O	CCONJ	O
unfamiliar	O	ADJ	O
faces	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


INTRODUCTION	O	PROPN	O
Existing	O	VERB	O
eye-tracking	B-I	ADJ	B
literature	O	NOUN	B
has	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
adults	B-P	NOUN	B
and	I-P	CCONJ	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
show	O	VERB	O
fewer	O	ADJ	O
and	O	CCONJ	O
slower	O	ADJ	B
fixations	O	NOUN	B
on	O	ADP	O
faces	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
this	O	DET	O
reduced	O	VERB	B
saliency	O	NOUN	B
and	O	CCONJ	O
processing	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
faces	O	NOUN	B
,	O	PUNCT	O
recognition	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
own	O	ADJ	O
face	O	NOUN	B
is	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADJ	O
"	O	PUNCT	O
typical	O	ADJ	O
"	O	PUNCT	O
in	O	ADP	O
nature	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
uses	O	VERB	O
eye-tracking	B-I	ADJ	B
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
typicality	O	NOUN	B
of	O	ADP	O
gaze	O	NOUN	B
patterns	O	NOUN	B
when	O	SCONJ	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
attend	O	VERB	B
their	O	PRON	O
own	O	ADJ	O
faces	O	NOUN	B
compared	O	VERB	B
to	O	ADP	O
other	O	ADJ	O
familiar	O	ADJ	B
and	O	CCONJ	O
unfamiliar	O	ADJ	B
faces	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Eye-tracking	B-I	ADJ	B
methodology	I-I	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
explore	O	VERB	O
fixation	B-OUT	NOUN	B
duration	I-OUT	NOUN	B
and	O	CCONJ	O
time	B-OUT	NOUN	B
taken	I-OUT	VERB	O
to	I-OUT	PART	O
fixate	I-OUT	VERB	O
on	I-OUT	ADP	O
the	I-OUT	DET	O
Eye	I-OUT	PROPN	B
and	I-OUT	CCONJ	I
Mouth	I-OUT	PROPN	O
regions	I-OUT	NOUN	B
of	I-OUT	ADP	O
familiar	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
unfamiliar	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
Self	I-OUT	PROPN	B
Faces	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


Twenty-one	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
(	I-P	PUNCT	O
9-16	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
compared	I-P	VERB	B
to	I-P	PART	O
typically	I-P	ADV	O
developing	I-P	VERB	O
matched	I-P	VERB	O
groups	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	VERB	B
and	O	CCONJ	O
typically	B-P	ADV	O
matched	I-P	VERB	O
groups	I-P	NOUN	B
for	O	ADP	O
fixation	B-OUT	NOUN	B
patterns	I-OUT	NOUN	B
to	I-OUT	ADP	O
the	I-OUT	DET	O
Eye	I-OUT	PROPN	B
and	I-OUT	CCONJ	I
Mouth	I-OUT	PROPN	O
areas	I-OUT	NOUN	B
of	O	ADP	O
all	O	DET	O
face	O	NOUN	B
types	O	NOUN	I
(	O	PUNCT	O
familiar	O	ADJ	B
,	O	PUNCT	O
unfamiliar	O	ADJ	B
and	O	CCONJ	O
self	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Correlational	O	ADJ	B
analyses	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
attention	O	NOUN	O
to	O	ADP	O
the	O	DET	O
Eye	O	ADJ	B
area	O	NOUN	I
of	O	ADP	I
unfamiliar	O	ADJ	I
and	O	CCONJ	O
Self	O	PROPN	B
Faces	O	PROPN	I
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
socio-communicative	O	ADJ	B
ability	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


CONCLUSIONS	O	NOUN	O
Levels	O	NOUN	B
of	O	ADP	O
socio-communicative	O	ADJ	B
ability	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
were	O	AUX	O
related	O	ADJ	O
to	O	PART	O
gaze	B-OUT	NOUN	B
patterns	I-OUT	NOUN	B
on	I-OUT	ADP	O
unfamiliar	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
Self	I-OUT	PROPN	B
Faces	I-OUT	PROPN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
familiar	O	ADJ	O
faces	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
lack	O	NOUN	O
of	O	ADP	O
relationship	O	NOUN	B
between	O	ADP	O
ability	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
attention	I-OUT	NOUN	B
to	O	ADP	O
familiar	O	ADJ	O
faces	O	NOUN	B
may	O	AUX	O
indicate	O	VERB	O
that	O	SCONJ	O
children	O	NOUN	B
across	O	ADP	O
the	O	DET	O
autism	O	NOUN	B
spectrum	O	NOUN	B
are	O	AUX	O
able	O	ADJ	O
to	O	PART	O
fixate	O	VERB	B
these	O	DET	O
faces	O	NOUN	B
in	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
way	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
implications	O	NOUN	O
for	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


Microbiologic	O	NOUN	B
yields	O	NOUN	O
and	O	CCONJ	O
complication	O	NOUN	B
rates	O	NOUN	B
of	O	ADP	O
vitreous	B-I	ADJ	B
needle	I-I	NOUN	I
aspiration	I-I	NOUN	I
versus	O	CCONJ	O
mechanized	B-I	ADJ	B
vitreous	I-I	ADJ	I
biopsy	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
Endophthalmitis	O	NOUN	B
Vitrectomy	O	PROPN	B
Study	O	PROPN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
microbiologic	O	ADJ	B
yields	O	NOUN	O
and	O	CCONJ	O
complication	O	NOUN	B
rates	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
vitreous	B-I	ADJ	B
needle	I-I	NOUN	I
tap	I-I	NOUN	B
and	O	CCONJ	O
vitreous	B-I	ADJ	B
biopsy	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
Endophthalmitis	B-P	NOUN	B
Vitrectomy	I-P	PROPN	I
Study	I-P	PROPN	I
(	I-P	PUNCT	O
EVS	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Of	O	ADP	O
420	B-P	NUM	O
EVS	I-P	PROPN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
postoperative	I-P	ADJ	B
endophthalmitis	I-P	NOUN	I
,	I-P	PUNCT	O
201	I-P	NUM	O
received	I-P	VERB	O
immediate	I-P	ADJ	O
vitreous	I-I	ADJ	B
tap	I-I	NOUN	I
or	I-I	CCONJ	O
biopsy	I-I	NOUN	B
(	I-I	PUNCT	O
without	I-I	ADP	O
pars	I-I	ADJ	B
plana	I-I	NOUN	I
vitrectomy	I-I	NOUN	B
)	I-I	PUNCT	O
by	O	ADP	O
random	O	ADJ	B
assignment	O	NOUN	B
and	O	CCONJ	O
193	B-P	NUM	O
completed	O	VERB	O
9-12	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Vitreous	O	ADJ	B
specimens	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
by	O	ADP	O
biopsy	O	NOUN	B
with	O	ADP	O
a	O	DET	O
20-gauge	B-I	ADJ	B
vitrectomy	I-I	NOUN	I
cutting	O	NOUN	I
instrument	O	NOUN	I
or	O	CCONJ	O
by	O	ADP	O
needle	O	NOUN	B
tap	O	NOUN	O
with	O	ADP	O
a	O	DET	O
22-27-gauge	O	ADJ	B
needle	O	NOUN	I
.	O	PUNCT	O


If	O	SCONJ	O
resistance	O	NOUN	B
to	O	PART	O
aspiration	O	NOUN	B
by	O	ADP	O
needle	O	NOUN	B
tap	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
,	O	PUNCT	O
a	O	DET	O
vitreous	O	ADJ	B
biopsy	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
Of	O	ADP	O
201	B-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
tap	I-P	NOUN	B
or	I-P	CCONJ	O
biopsy	I-P	NOUN	B
,	I-P	PUNCT	O
70	I-P	NUM	O
(	I-P	PUNCT	O
35	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
needle	I-P	NOUN	B
tap	I-P	NOUN	B
,	I-P	PUNCT	O
127	I-P	NUM	O
(	I-P	PUNCT	O
63	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
mechanized	I-P	ADJ	B
biopsy	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
4	I-P	NUM	O
(	I-P	PUNCT	O
2	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
initial	I-P	ADJ	O
needle	I-P	NOUN	B
tap	I-P	NOUN	B
that	O	PRON	O
was	O	AUX	O
aborted	O	VERB	B
to	O	PART	O
mechanized	O	ADJ	B
biopsy	O	NOUN	I
(	O	PUNCT	O
"	O	PUNCT	O
abort	O	VERB	B
"	O	PUNCT	O
eyes	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Intraoperative	B-OUT	ADJ	B
hyphema	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
2	O	NUM	O
tap	O	NOUN	B
eyes	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
3	O	NUM	O
biopsy	O	NOUN	B
eyes	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
abort	O	VERB	O
eyes	O	NOUN	B
.	O	PUNCT	O


Postoperative	B-OUT	ADJ	B
retinal	I-OUT	ADJ	O
detachment	I-OUT	NOUN	O
developed	O	VERB	O
in	O	ADP	O
8	O	NUM	O
(	O	PUNCT	O
11	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
tap	O	NOUN	B
eyes	O	NOUN	I
,	O	PUNCT	O
10	O	NUM	O
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
biopsy	O	NOUN	B
eyes	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
abort	O	VERB	B
eyes	O	NOUN	B
(	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Respective	B-OUT	ADJ	O
rates	I-OUT	NOUN	B
of	I-OUT	ADP	O
culture	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
gram	I-OUT	NOUN	B
stain	I-OUT	NOUN	I
positivity	I-OUT	NOUN	I
were	O	AUX	O
69	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
42	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
tap	O	NOUN	B
eyes	O	NOUN	I
and	O	CCONJ	O
66	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
41	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
biopsy	O	NOUN	B
eyes	O	NOUN	I
(	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
severe	I-OUT	ADJ	B
visual	I-OUT	ADJ	B
loss	I-OUT	NOUN	I
(	O	PUNCT	O
final	O	ADJ	O
acuity	O	NOUN	O
<	O	X	O
5/200	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
tap	O	NOUN	B
eyes	O	NOUN	I
(	O	PUNCT	O
16	O	NUM	O
eyes	O	NOUN	B
,	O	PUNCT	O
24	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
biopsy	O	NOUN	B
eyes	O	NOUN	I
(	O	PUNCT	O
13	O	NUM	O
eyes	O	NOUN	B
,	O	PUNCT	O
11	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
abort	O	VERB	B
eyes	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
eyes	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.043	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	B
was	O	AUX	O
largely	O	ADV	O
explained	O	VERB	O
by	O	ADP	O
the	O	DET	O
greater	O	ADJ	O
proportion	B-OUT	NOUN	B
of	I-OUT	ADP	O
virulent	I-OUT	ADJ	B
organisms	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
tap	I-OUT	NOUN	B
eyes	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
biopsy	O	NOUN	B
eyes	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
outcome	I-OUT	NOUN	B
was	O	AUX	O
defined	O	VERB	O
by	O	ADP	O
other	O	ADJ	O
thresholds	O	NOUN	B
(	O	PUNCT	O
20/40	O	NUM	O
and	O	CCONJ	O
20/100	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
difference	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
mechanized	O	ADJ	B
vitreous	O	ADJ	B
biopsy	O	NOUN	I
and	O	CCONJ	O
needle	O	VERB	B
tap	O	NOUN	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
microbiologic	O	ADJ	B
yield	O	NOUN	I
,	O	PUNCT	O
operative	O	ADJ	B
complications	O	NOUN	I
,	O	PUNCT	O
short-term	O	ADJ	B
(	O	PUNCT	O
9-12	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
retinal	O	ADJ	B
detachment	O	NOUN	O
risk	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
visual	O	ADJ	B
outcome	O	NOUN	I
.	O	PUNCT	O


Choice	O	NOUN	B
of	O	ADP	O
vitreous	O	ADJ	B
sampling	O	NOUN	I
procedure	O	NOUN	I
must	O	AUX	O
depend	O	VERB	O
on	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
judgment	O	NOUN	I
of	O	ADP	O
the	O	DET	O
surgeon	O	NOUN	B
.	O	PUNCT	O


Gastric	B-P	ADJ	B
carcinoma	I-P	NOUN	I
:	I-P	PUNCT	O
expression	I-OUT	NOUN	B
of	I-OUT	ADP	O
c-erbB-2/neu	I-OUT	NOUN	B
oncoprotein	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
epidermal	I-OUT	ADJ	B
growth	I-OUT	NOUN	I
factor	I-OUT	NOUN	I
receptor	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
cathepsin	I-OUT	NOUN	B
D	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
progesterone	I-OUT	NOUN	B
receptor	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
tumor	I-OUT	NOUN	B
associated	I-OUT	VERB	O
glycoprotein-72	I-OUT	NOUN	B
in	O	ADP	O
different	O	ADJ	O
histological	O	ADJ	B
types	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	ADJ	O
Gastric	B-P	ADJ	B
carcinoma	I-P	NOUN	I
can	O	AUX	O
be	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
main	O	ADJ	O
histological	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
types	O	NOUN	I
:	O	PUNCT	O
diffuse	B-P	ADJ	B
and	I-P	CCONJ	O
intestinal	I-P	ADJ	B
.	I-P	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
expression	B-OUT	NOUN	B
of	I-OUT	ADP	O
neu/c-erbB-2	I-OUT	NOUN	B
oncoprotein	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
epidermal	I-OUT	ADJ	B
growth	I-OUT	NOUN	I
factor	I-OUT	NOUN	I
receptor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
EGFR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
cathepsin	I-OUT	NOUN	B
D	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
catD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
progesterone	I-OUT	NOUN	B
receptor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
tumor-associated	I-OUT	ADJ	B
glycoprotein-72	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
TAG-72	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
gastric	O	ADJ	B
carcinoma	O	NOUN	I
of	O	ADP	O
these	O	DET	O
histological	O	ADJ	B
types	O	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	O
In	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
study	O	NOUN	I
we	O	PRON	O
analyzed	O	VERB	B
85	B-P	NUM	O
biopsy	I-I	NOUN	B
samples	I-I	NOUN	I
from	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
gastric	I-P	ADJ	B
adenocarcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
control	B-P	ADJ	B
group	I-P	NOUN	I
consisted	I-P	VERB	O
of	I-P	ADP	O
40	I-P	NUM	O
specimens	I-P	NOUN	B
from	I-P	ADP	O
normal	I-I	ADJ	B
gastric	I-I	ADJ	I
mucosa	I-I	NOUN	I
.	I-I	PUNCT	O


Neu	B-OUT	NOUN	B
oncoprotein	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
PR	I-OUT	NOUN	B
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
ELISA	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


CatD	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
TAG-72	I-OUT	NOUN	B
were	O	AUX	O
quantified	O	VERB	B
with	O	ADP	O
immunoradiometric	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
IRMA	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
methods	I-OUT	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
EGFR	B-OUT	NOUN	B
were	I-OUT	AUX	O
studied	I-OUT	VERB	O
by	I-OUT	ADP	O
radioimmunoassay	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
RIA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Neu	B-OUT	NOUN	I
,	I-OUT	PUNCT	O
EGFR	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
catD	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
TAG-72	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
tumoral	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.00001	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0.007	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
diffuse	O	ADJ	B
adenocarcinomas	O	NOUN	I
,	O	PUNCT	O
catD	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
PR	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
was	O	AUX	O
increased	O	VERB	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
respectively	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
TAG-72	B-OUT	NOUN	B
concentration	I-OUT	NOUN	B
,	O	PUNCT	O
which	O	DET	O
correlated	O	VERB	B
with	O	ADP	O
neu	B-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.57	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
intestinal	O	ADJ	B
type	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
EGFR	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
neu	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
were	O	AUX	O
seen	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
histological	O	ADJ	B
types	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
higher	O	ADJ	O
PR	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
catD	I-OUT	ADJ	B
concentrations	I-OUT	NOUN	B
in	O	ADP	O
diffuse	O	ADJ	B
adenocarcinomas	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
overexpression	O	NOUN	B
of	O	ADP	O
TAG-72	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
intestinal	O	ADJ	B
type	O	NOUN	I
,	O	PUNCT	O
support	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
modes	O	NOUN	B
of	O	ADP	O
gastric	O	ADJ	B
carcinogenesis	O	NOUN	I
.	O	PUNCT	O


Supplemental	B-I	NOUN	B
perioperative	I-I	ADJ	B
oxygen	I-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
surgical	B-OUT	ADJ	B
wound	I-OUT	NOUN	B
infection	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


CONTEXT	O	PROPN	B
Supplemental	B-I	NOUN	I
perioperative	I-I	ADJ	B
oxygen	I-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
variously	O	ADV	O
reported	O	VERB	O
to	O	PART	O
halve	O	VERB	B
or	O	CCONJ	O
double	O	ADJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
surgical	B-OUT	ADJ	B
wound	I-OUT	NOUN	B
infection	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
supplemental	B-I	NOUN	B
oxygen	I-I	NOUN	I
reduces	O	VERB	O
infection	O	NOUN	B
risk	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
following	I-P	VERB	O
colorectal	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
AND	O	CCONJ	O
PATIENTS	O	VERB	O
A	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
of	O	ADP	O
300	B-P	NUM	O
patients	I-P	NOUN	B
aged	I-P	ADJ	B
18	I-P	NUM	O
to	I-P	PART	O
80	I-P	NUM	O
years	I-P	NOUN	B
who	I-P	PRON	O
underwent	I-P	VERB	O
elective	I-P	ADJ	B
colorectal	I-P	ADJ	B
surgery	I-P	NOUN	I
in	I-P	ADP	O
14	I-P	NUM	O
Spanish	I-P	ADJ	B
hospitals	I-P	NOUN	B
from	I-P	ADP	O
March	I-P	PROPN	O
1	I-P	NUM	O
,	I-P	PUNCT	O
2003	I-P	NUM	O
,	I-P	PUNCT	O
to	I-P	ADP	O
October	I-P	PROPN	O
31	I-P	NUM	O
,	I-P	PUNCT	O
2004	I-P	NUM	O
.	I-P	PUNCT	O


Wound	O	NOUN	B
infections	O	NOUN	I
were	O	AUX	O
diagnosed	O	VERB	B
by	O	ADP	O
blinded	O	VERB	B
investigators	O	NOUN	I
using	O	VERB	O
Centers	O	NOUN	B
for	O	ADP	I
Disease	O	PROPN	I
Control	O	PROPN	I
and	O	CCONJ	I
Prevention	O	PROPN	I
criteria	O	NOUN	I
.	O	PUNCT	O


Baseline	O	NOUN	B
patient	O	NOUN	B
characteristics	O	NOUN	B
,	O	PUNCT	O
anesthetic	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
potential	O	ADJ	O
confounding	O	NOUN	B
factors	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


INTERVENTIONS	O	NOUN	B
Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
30	B-I	NUM	O
%	I-I	NOUN	O
or	I-I	CCONJ	O
80	I-I	NUM	O
%	I-I	NOUN	O
fraction	I-I	NOUN	B
of	I-I	ADP	O
inspired	I-I	VERB	B
oxygen	I-I	NOUN	I
(	O	PUNCT	O
FIO2	O	NOUN	B
)	O	PUNCT	O
intraoperatively	O	ADV	B
and	O	CCONJ	O
for	O	ADP	O
6	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Anesthetic	O	ADJ	B
treatment	O	NOUN	I
and	O	CCONJ	O
antibiotic	O	ADJ	B
administration	O	NOUN	I
were	O	AUX	O
standardized	O	VERB	B
.	O	PUNCT	O


MAIN	O	PROPN	O
OUTCOME	O	NOUN	B
MEASURES	O	NOUN	O
Any	B-OUT	DET	O
surgical	I-OUT	ADJ	B
site	I-OUT	NOUN	I
infection	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SSI	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
secondary	O	ADJ	B
outcomes	O	NOUN	I
included	O	VERB	O
return	B-OUT	NOUN	B
of	I-OUT	ADP	I
bowel	I-OUT	NOUN	I
function	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
ability	I-OUT	NOUN	O
to	I-OUT	PART	O
tolerate	I-OUT	VERB	O
solid	I-OUT	ADJ	B
food	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
ambulation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
suture	I-OUT	NOUN	B
removal	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
hospitalization	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
143	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
30	B-I	NUM	O
%	I-I	NOUN	O
perioperative	I-I	ADJ	B
oxygen	I-I	NOUN	B
and	O	CCONJ	O
148	O	NUM	O
received	O	VERB	O
80	B-I	NUM	O
%	I-I	NOUN	O
perioperative	I-I	ADJ	B
oxygen	I-I	NOUN	B
.	I-I	PUNCT	O


Surgical	B-OUT	ADJ	B
site	I-OUT	NOUN	I
infection	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
35	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
24.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
administered	O	VERB	B
30	O	NUM	O
%	O	NOUN	O
FIO2	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
22	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
14.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
administered	O	VERB	B
80	O	NUM	O
%	O	NOUN	O
FIO2	O	NOUN	B
(	O	PUNCT	O
P=.04	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
SSI	I-OUT	PROPN	B
was	O	AUX	O
39	O	NUM	O
%	O	NOUN	O
lower	O	ADJ	B
in	O	ADP	O
the	O	DET	O
80	B-I	NUM	O
%	I-I	NOUN	O
FIO2	I-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
[	O	PUNCT	O
RR	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
0.61	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
0.38-0.98	O	NUM	O
)	O	PUNCT	O
vs	O	CCONJ	O
the	O	DET	O
30	B-I	NUM	O
%	I-I	NOUN	O
FIO2	I-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
important	O	ADJ	O
covariates	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
RR	O	NOUN	B
of	O	ADP	O
infection	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
administered	O	VERB	B
supplemental	O	ADJ	B
oxygen	O	NOUN	I
was	O	AUX	O
0.46	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.22-0.95	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
the	O	DET	O
secondary	O	ADJ	B
outcomes	O	NOUN	I
varied	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Patients	O	NOUN	B
receiving	O	VERB	O
supplemental	B-I	ADJ	O
inspired	I-I	ADJ	B
oxygen	I-I	NOUN	I
had	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
wound	I-OUT	NOUN	B
infection	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Supplemental	B-I	NOUN	B
oxygen	I-I	NOUN	I
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
intervention	O	NOUN	B
to	O	PART	O
reduce	O	VERB	B
SSI	B-OUT	PROPN	B
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
colon	I-P	NOUN	B
or	I-P	CCONJ	O
rectal	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


Trial	O	PROPN	B
Registration	O	PROPN	I
ClinicalTrials.gov	O	PROPN	I
Identifier	O	NOUN	I
:	O	PUNCT	O
NCT00235456	O	NOUN	O
.	O	PUNCT	O


Longitudinal	O	ADJ	B
quality	B-OUT	NOUN	I
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
study	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
gastric	I-P	ADJ	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Analysis	O	NOUN	B
modalities	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
applicability	O	NOUN	O
of	O	ADP	O
QoL	B-OUT	NOUN	B
in	O	ADP	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
trial	O	NOUN	I
in	O	ADP	O
a	O	DET	O
digestive	O	ADJ	B
oncology	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
longitudinal	B-OUT	ADJ	B
quality	I-OUT	NOUN	I
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
QoL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
between	O	ADP	O
LV5FU2-irinotecan	B-I	NOUN	B
and	I-I	CCONJ	O
LV5FU2	I-I	NOUN	B
alone	I-I	ADV	O
or	I-I	CCONJ	O
LV5FU2-cisplatin	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
Phase	O	NOUN	I
II	O	NUM	I
trial	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
gastric	I-P	ADJ	I
adenocarcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Among	O	ADP	O
134	B-P	NUM	O
eligible	I-P	ADJ	O
patients	I-P	NOUN	B
,	O	PUNCT	O
QLQ-C30	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
were	O	AUX	O
collected	O	VERB	B
and	O	CCONJ	O
described	O	VERB	O
at	O	ADP	O
each	O	DET	O
2	O	NUM	O
monthly	O	ADJ	B
follow-up	O	ADJ	B
visit	O	NOUN	O
during	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
frequencies	B-OUT	NOUN	B
of	I-OUT	ADP	O
QLQ-C30	I-OUT	NOUN	B
score	I-OUT	NOUN	I
improvement	I-OUT	NOUN	B
were	O	AUX	O
calculated	O	VERB	B
and	O	CCONJ	O
mixed	O	ADJ	B
models	O	NOUN	I
for	O	ADP	O
repeated	O	VERB	O
measurements	O	NOUN	B
were	O	AUX	O
applied	O	VERB	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
extreme	O	ADJ	O
poorest	O	ADJ	O
imputation	O	NOUN	B
for	O	ADP	O
missing	O	VERB	O
scores	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
"	B-OUT	PUNCT	O
survival	I-OUT	NOUN	B
"	I-OUT	PUNCT	O
until	I-OUT	ADP	O
definitive	I-OUT	ADJ	O
global	I-OUT	ADJ	B
health	I-OUT	NOUN	I
score	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GHS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
deterioration	I-OUT	NOUN	B
was	O	AUX	O
estimated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
the	O	DET	O
3rd	O	ADJ	O
follow-up	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
stable	O	ADJ	B
or	O	CCONJ	O
improved	O	VERB	O
global	B-OUT	ADJ	B
health	I-OUT	NOUN	I
ranged	O	VERB	O
from	O	ADP	O
11	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
LV5FU2-cisplatin	B-I	NOUN	B
arm	O	NOUN	I
to	O	ADP	O
18	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
LV5FU2-irinotecan	B-I	ADJ	B
arm	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
irinotecan-based-therapy	O	NOUN	B
presented	O	VERB	O
14	O	NUM	O
to	O	PART	O
15	O	NUM	O
scores	O	NOUN	B
with	O	ADP	O
a	O	DET	O
better	O	ADJ	O
QoL	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
time	B-OUT	NOUN	B
until	I-OUT	ADP	O
definitive	I-OUT	ADJ	B
GHS	I-OUT	PROPN	B
deterioration	I-OUT	NOUN	B
was	O	AUX	O
globally	O	ADV	O
similar	O	ADJ	O
between	O	ADP	O
treatment	O	NOUN	B
arms	O	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
This	O	DET	O
study	O	NOUN	B
highlights	O	VERB	O
a	O	DET	O
better	O	ADJ	O
impact	O	NOUN	B
of	O	ADP	O
LV5FU2-irinotecan	B-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
interest	O	NOUN	O
of	O	ADP	O
QoL	B-OUT	NOUN	B
assessment	I-OUT	NOUN	B
in	O	ADP	O
phase	O	NOUN	B
II	O	NUM	I
trials	O	NOUN	I
to	O	PART	O
complement	O	VERB	O
the	O	DET	O
risk-benefit	O	ADJ	B
judgement	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
fluoride	B-I	NOUN	B
and	I-I	CCONJ	O
chlorhexidine	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
microflora	B-OUT	NOUN	B
of	I-OUT	ADP	O
dental	I-OUT	ADJ	B
root	I-OUT	NOUN	I
surfaces	I-OUT	NOUN	B
and	O	CCONJ	O
progression	O	NOUN	B
of	O	ADP	O
root-surface	O	ADJ	B
caries	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
fluoride	B-I	NOUN	B
and	I-I	CCONJ	O
chlorhexidine	I-I	NOUN	B
varnishes	O	NOUN	B
on	O	ADP	O
the	O	DET	O
microflora	O	NOUN	B
of	O	ADP	O
dental	O	ADJ	B
root	O	NOUN	I
surfaces	O	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
root-surface	O	ADJ	B
caries	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


Forty-four	B-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
surgically	I-P	ADV	B
treated	I-P	VERB	B
for	I-P	ADP	O
advanced	I-P	ADJ	B
periodontal	I-P	ADJ	B
disease	I-P	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
distributed	O	VERB	B
at	O	ADP	O
random	O	ADJ	B
among	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
standardized	O	ADJ	O
preventive	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
dentition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
experimental	O	ADJ	B
groups	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
,	O	PUNCT	O
at	O	ADP	O
three-month	O	ADJ	B
intervals	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
chlorhexidine	B-I	NOUN	B
and	I-I	CCONJ	O
fluoride	I-I	NOUN	B
varnish	I-I	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	B-I	NOUN	B
group	I-I	NOUN	I
received	O	VERB	O
no	O	DET	O
additional	O	ADJ	O
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
groups	O	NOUN	I
,	O	PUNCT	O
plaque	O	NOUN	B
samples	O	NOUN	B
were	O	AUX	O
collected	O	VERB	O
from	O	ADP	O
selected	O	VERB	O
sound	O	ADJ	B
and	O	CCONJ	O
carious	O	ADJ	B
root	O	NOUN	B
surfaces	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
three	O	NUM	O
,	O	PUNCT	O
six	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
nine	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
root-surface	O	ADJ	B
caries	O	NOUN	I
was	O	AUX	O
scored	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
texture	O	NOUN	B
,	O	PUNCT	O
depth	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
color	O	NOUN	B
of	O	ADP	O
the	O	DET	O
root-surface	O	ADJ	B
lesions	O	NOUN	I
were	O	AUX	O
monitored	O	VERB	B
.	O	PUNCT	O


Mutans	B-OUT	ADJ	B
streptococci	I-OUT	NOUN	I
on	I-OUT	ADP	O
root	I-OUT	NOUN	B
surfaces	I-OUT	NOUN	B
were	I-OUT	AUX	O
suppressed	I-OUT	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
whole	O	ADJ	O
experimental	O	ADJ	B
period	O	NOUN	B
in	O	ADP	O
the	O	DET	O
chlorhexidine	B-I	NOUN	B
varnish	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
fluoride	B-I	NOUN	B
varnish	O	NOUN	I
group	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
non-significant	O	ADJ	B
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
Actinomyces	I-OUT	NOUN	B
viscosus/naeslundii	I-OUT	NOUN	I
was	O	AUX	O
noted	O	VERB	O
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
chlorhexidine	B-I	NOUN	B
and	O	CCONJ	O
fluoride	B-I	NOUN	B
varnish	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
decayed	I-OUT	VERB	B
and	I-OUT	CCONJ	O
filled	I-OUT	VERB	B
root	I-OUT	NOUN	B
surfaces	I-OUT	NOUN	B
after	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
groups	O	NOUN	I
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
chlorhexidine	B-I	NOUN	B
varnish	O	NOUN	B
,	O	PUNCT	O
significantly	O	ADV	O
more	O	ADV	O
initial	B-OUT	ADJ	O
root-surface	I-OUT	ADJ	B
lesions	I-OUT	NOUN	I
had	I-OUT	AUX	O
hardened	I-OUT	VERB	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
phenytoin	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
absorption	O	NOUN	B
of	O	ADP	O
synthetic	O	ADJ	B
folic	O	ADJ	O
acid	O	NOUN	O
polyglutamate	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
absorption	O	NOUN	B
of	O	ADP	O
synthetic	O	ADJ	B
pteroyltriglutamate	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
nine	B-P	NUM	O
normal	I-P	ADJ	B
students	I-P	NOUN	I
with	I-P	ADP	O
and	I-P	CCONJ	O
without	I-P	ADP	O
the	I-P	DET	O
anticonvulsant	I-P	ADJ	B
drug	I-P	NOUN	I
phenytoin	I-I	NOUN	B
.	I-I	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
phenytoin	B-I	NOUN	B
has	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
absorption	O	NOUN	B
of	O	ADP	O
this	O	DET	O
folate	B-OUT	NOUN	B
polyglutamate	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
reasons	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
for	O	ADP	O
the	O	DET	O
disparity	O	NOUN	B
between	O	ADP	O
this	O	DET	O
result	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
reported	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
when	O	SCONJ	O
folate	O	NOUN	B
polyglutamates	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
yeast	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Pegfilgrastim	B-I	NOUN	B
for	O	ADP	O
peripheral	O	ADJ	B
CD34+	O	ADJ	B
mobilization	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
solid	I-OUT	ADJ	B
tumours	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
pegfilgrastim+/-chemotherapy	B-I	NOUN	B
for	O	ADP	O
mobilizing	O	VERB	O
stem	O	NOUN	B
cells	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
solid	I-OUT	ADJ	B
tumours	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
cycle	O	NOUN	O
0	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
14-day	O	ADJ	O
prechemotherapy	O	NOUN	B
cycle	O	NOUN	I
,	O	PUNCT	O
patients	B-P	NOUN	B
(	I-P	PUNCT	O
N=61	I-P	NOUN	O
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
open-label	O	ADJ	I
to	O	PART	O
single	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
pegfilgrastim	B-I	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
or	O	CCONJ	O
18	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
daily	O	ADJ	O
filgrastim	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
microg/kg	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
<	O	X	O
or	O	CCONJ	O
=7	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Mean	B-OUT	VERB	B
peak	I-OUT	ADJ	I
peripheral	I-OUT	ADJ	I
CD34+	I-OUT	ADJ	I
cell	I-OUT	NOUN	I
counts	I-OUT	NOUN	O
increased	I-OUT	VERB	B
with	O	ADP	O
pegfilgrastim	B-I	ADJ	B
dose	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
were	O	AUX	O
significantly	B-OUT	ADV	O
higher	I-OUT	ADJ	O
than	O	ADP	O
filgrastim	B-I	NOUN	B
only	O	ADV	O
at	O	ADP	O
the	O	DET	O
18	O	NUM	O
mg	O	NOUN	O
dose	O	NOUN	B
(	O	PUNCT	O
10.17	O	NUM	O
vs	O	CCONJ	O
4.96	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
/ml	O	NOUN	O
;	O	PUNCT	O
P=0.014	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
clinically	O	ADV	B
relevant	O	ADJ	I
period	O	NOUN	B
of	O	ADP	O
days	O	NOUN	B
3-7	O	NUM	O
,	O	PUNCT	O
both	O	CCONJ	O
12	O	NUM	O
and	O	CCONJ	O
18	O	NUM	O
mg	O	NOUN	O
pegfilgrastim	B-I	ADJ	B
doses	O	NOUN	B
produced	O	VERB	O
significantly	B-OUT	ADV	O
higher	I-OUT	ADJ	O
peak	I-OUT	NOUN	B
CD34+	I-OUT	ADJ	I
counts	I-OUT	NOUN	I
(	O	PUNCT	O
8.18	O	NUM	O
and	O	CCONJ	O
9.96	O	NUM	O
vs	O	CCONJ	O
4.51	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
/ml	O	NOUN	O
for	O	ADP	O
filgrastim	B-I	NOUN	B
;	I-I	PUNCT	O
P=0.034	O	NOUN	O
and	O	CCONJ	O
0.006	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
cycle	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
patients	O	NOUN	B
received	O	VERB	O
carboplatin/paclitaxel	B-I	NOUN	B
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
followed	O	VERB	O
from	O	ADP	O
day	O	NOUN	B
2	O	NUM	O
by	O	ADP	O
pegfilgrastim	B-I	NOUN	B
6-18	O	NUM	O
mg	O	NOUN	O
or	O	CCONJ	O
daily	O	ADV	O
filgrastim	B-I	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
microg/kg/day	O	NOUN	B
for	O	ADP	O
<	O	X	O
or	O	CCONJ	O
=14	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
per	O	ADP	O
randomization	O	NOUN	B
in	O	ADP	O
cycle	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	B-OUT	DET	O
significant	I-OUT	ADJ	O
differences	I-OUT	NOUN	O
in	O	ADP	O
mean	B-OUT	NOUN	O
peak	I-OUT	NOUN	O
CD34+	I-OUT	ADJ	O
count	I-OUT	NOUN	O
between	O	ADP	O
pegfilgrastim	B-I	NOUN	B
and	O	CCONJ	O
filgrastim	B-I	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
an	O	DET	O
advantage	O	NOUN	O
for	O	ADP	O
pegfilgrastim	B-I	NOUN	B
18	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
the	O	DET	O
relevant	O	ADJ	O
period	O	NOUN	B
of	O	ADP	O
days	O	NOUN	B
7-12	O	NUM	O
(	O	PUNCT	O
3.14	O	NUM	O
vs	O	CCONJ	O
1.19	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
/ml	O	NOUN	O
;	O	PUNCT	O
P=0.043	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
pegfilgrastim	B-I	ADJ	B
dose	O	NOUN	B
(	O	PUNCT	O
>	O	NOUN	O
or	O	CCONJ	O
=6	O	ADJ	O
mg	O	NOUN	O
)	O	PUNCT	O
could	O	AUX	O
be	O	AUX	O
substituted	O	VERB	B
for	O	ADP	O
daily	O	ADJ	B
filgrastim	B-I	NOUN	B
in	O	ADP	O
cytokine-only	B-OUT	ADJ	O
peripheral	I-OUT	ADJ	B
CD34+	I-OUT	ADJ	O
cell	I-OUT	NOUN	O
mobilization	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Analgesic	O	ADJ	B
efficacy	O	NOUN	B
of	O	ADP	O
low-dose	O	ADJ	B
diclofenac	B-I	NOUN	B
versus	I-I	CCONJ	O
paracetamol	I-I	NOUN	B
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
postoperative	B-P	ADJ	B
dental	I-P	ADJ	B
pain	I-P	NOUN	I
.	I-P	PUNCT	O


AIMS	O	NOUN	B
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
diclofenac-K	B-I	ADJ	B
(	O	PUNCT	O
12.5	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
vs	O	CCONJ	O
paracetamol	B-I	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
placebo	B-I	NOUN	B
given	O	VERB	O
in	O	ADP	O
a	O	DET	O
flexible	O	ADJ	B
dosage	O	NOUN	B
regimen	O	NOUN	O
to	O	PART	O
treat	O	VERB	B
pain	B-P	NOUN	B
resulting	I-P	VERB	O
from	I-P	ADP	O
extraction	I-P	NOUN	B
of	I-P	ADP	O
impacted	I-P	VERB	B
third	I-P	ADJ	I
molar	I-P	ADJ	I
teeth	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
2-day	O	ADJ	O
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
double-dummy	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
parallel-group	O	NOUN	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
of	O	ADP	O
diclofenac-K	B-I	ADJ	B
(	I-I	PUNCT	O
12.5	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
tablets	I-I	NOUN	B
vs	I-I	CCONJ	O
paracetamol	I-I	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
tablets	O	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
or	I-P	CCONJ	O
severe	I-P	ADJ	B
pain	I-P	NOUN	B
within	I-P	ADP	O
8	I-P	NUM	O
hours	I-P	NOUN	O
of	I-P	ADP	O
extraction	I-P	NOUN	B
of	I-P	ADP	O
impacted	I-P	VERB	B
third	I-P	ADJ	I
molars	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
After	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2-tablet	O	ADJ	B
dose	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
took	O	VERB	O
on	O	ADP	O
average	O	ADJ	B
2.5	O	NUM	O
additional	O	ADJ	O
tablets	O	NOUN	B
of	O	ADP	O
diclofenac-K	B-I	ADJ	B
or	O	CCONJ	O
2.4	O	NUM	O
tablets	O	NOUN	B
of	O	ADP	O
paracetamol	B-I	NOUN	B
,	O	PUNCT	O
almost	O	ADV	O
all	O	ADV	O
as	O	ADP	O
1-tablet	O	ADJ	B
doses	O	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
placebo	B-I	NOUN	B
patients	O	NOUN	B
discontinued	O	VERB	B
by	O	ADP	O
taking	O	VERB	O
rescue	B-OUT	NOUN	B
medication	I-OUT	NOUN	I
(	O	PUNCT	O
ibuprofen	O	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
after	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
diclofenac-K	B-I	ADJ	B
(	O	PUNCT	O
2	O	NUM	O
x	O	CCONJ	O
12.5	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.01	O	NUM	O
for	O	ADP	O
all	O	DET	O
efficacy	O	NOUN	B
outcomes	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
comparable	O	ADJ	O
to	O	PART	O
paracetamol	B-I	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
x	O	CCONJ	O
500	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


About	O	ADV	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
each	O	DET	O
active	O	ADJ	B
treatment	O	NOUN	B
group	O	NOUN	I
took	O	VERB	O
rescue	B-OUT	NOUN	O
medication	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
78	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


About	O	ADV	O
70	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
each	O	DET	O
active	O	ADJ	B
treatment	O	NOUN	B
group	O	NOUN	I
considered	O	VERB	O
the	O	DET	O
overall	B-OUT	ADJ	B
pain	I-OUT	NOUN	B
relief	I-OUT	NOUN	I
to	O	PART	O
be	O	AUX	O
"	O	PUNCT	O
some	O	DET	O
,	O	PUNCT	O
"	O	PUNCT	O
"	O	PUNCT	O
a	O	DET	O
lot	O	NOUN	B
,	O	PUNCT	O
"	O	PUNCT	O
or	O	CCONJ	O
"	O	PUNCT	O
complete	O	ADJ	B
"	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
only	O	ADV	O
15	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
in	O	ADP	O
each	O	DET	O
active	O	ADJ	B
treatment	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
low	O	ADJ	B
and	O	CCONJ	O
comparable	O	ADJ	O
between	O	ADP	O
the	O	DET	O
treatments	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
An	O	DET	O
initial	O	ADJ	B
double-dose	O	NOUN	B
of	O	ADP	O
diclofenac-K	B-I	ADJ	B
(	O	PUNCT	O
2	O	NUM	O
x	O	CCONJ	O
12.5	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
paracetamol	B-I	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
x	O	CCONJ	O
500	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
adequately	O	ADV	O
relieved	O	VERB	O
the	O	DET	O
most	O	ADV	O
intense	O	ADJ	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
flexible	O	ADJ	B
multiple	O	ADJ	B
dose	O	NOUN	I
regimen	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
or	O	CCONJ	O
2	O	NUM	O
tablets	O	NOUN	B
)	O	PUNCT	O
maintained	O	VERB	O
adequate	O	ADJ	B
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
thereafter	O	ADV	O
.	O	PUNCT	O


Most	O	ADJ	O
patients	O	NOUN	B
needed	O	VERB	O
only	O	ADV	O
1-tablet	O	ADJ	O
doses	O	NOUN	B
following	O	VERB	O
the	O	DET	O
initial	O	ADJ	O
2-tablet	O	ADJ	B
dose	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
entacapone	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
peripherally	O	ADV	B
acting	O	VERB	O
catechol-O-methyltransferase	O	NOUN	B
inhibitor	O	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
motor	B-OUT	NOUN	B
response	I-OUT	NOUN	I
to	I-OUT	PART	O
acute	I-OUT	ADJ	B
treatment	I-OUT	NOUN	B
with	I-OUT	ADP	O
levodopa	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
Parkinson	I-P	NOUN	B
's	I-P	PART	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Catechol-O-methyltransferase	O	NOUN	B
(	O	PUNCT	O
COMT	O	NOUN	B
)	O	PUNCT	O
inhibitors	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
Parkinson	O	NOUN	B
's	O	PART	I
disease	O	NOUN	I
by	O	ADP	O
improving	O	VERB	B
the	O	DET	O
bioavailability	B-OUT	NOUN	B
of	O	ADP	O
levodopa	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
prolonging	O	VERB	B
its	O	PRON	O
effects	O	NOUN	B
.	O	PUNCT	O


Entacapone	B-I	NOUN	B
(	I-I	PUNCT	O
OR-611	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
a	I-I	DET	O
novel	I-I	ADJ	O
COMT	I-I	NOUN	B
inhibitor	I-I	NOUN	B
,	O	PUNCT	O
which	O	DET	O
does	O	AUX	O
not	O	PART	O
cross	O	VERB	O
the	O	DET	O
blood	O	NOUN	B
brain	O	NOUN	I
barrier	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
12	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
Parkinson	I-P	NOUN	B
's	I-P	PART	I
disease	I-P	NOUN	I
and	I-P	CCONJ	O
motor	I-P	NOUN	B
fluctuations	I-P	NOUN	I
in	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
cross-over	O	ADJ	B
,	O	PUNCT	O
single	O	ADJ	B
dose	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
magnitude	O	NOUN	B
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
therapeutic	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
a	O	DET	O
single	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
levodopa/50	B-I	NOUN	O
mg	O	NOUN	O
carbidopa	B-I	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
after	O	ADP	O
concomitant	O	ADJ	B
placebo	B-I	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
200	O	NUM	O
or	O	CCONJ	O
800	O	NUM	O
mg	O	NOUN	O
entacapone	B-I	NOUN	B
.	I-I	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
motor	I-OUT	NOUN	B
response	I-OUT	NOUN	I
to	I-OUT	PART	O
levodopa	I-OUT	NOUN	B
was	O	AUX	O
seen	O	VERB	O
when	O	SCONJ	O
200	O	NUM	O
mg	O	NOUN	O
entacapone	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
with	O	ADP	O
levodopa/carbidopa	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
levodopa	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
were	O	AUX	O
increased	O	VERB	B
with	O	ADP	O
both	O	DET	O
doses	O	NOUN	B
of	O	ADP	O
the	O	DET	O
COMT	O	NOUN	B
inhibitor	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
latency	B-OUT	NOUN	B
to	I-OUT	PART	O
onset	I-OUT	NOUN	O
of	I-OUT	ADP	O
motor	I-OUT	NOUN	B
response	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
active	O	ADJ	B
drug	O	NOUN	I
and	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Entacapone	O	NOUN	B
may	O	AUX	O
prove	O	VERB	O
useful	O	ADJ	O
in	O	ADP	O
prolonging	B-OUT	VERB	B
the	I-OUT	DET	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
benefit	I-OUT	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
individual	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
levodopa	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
propranolol	B-I	NOUN	B
on	O	ADP	O
word	O	NOUN	B
fluency	O	NOUN	I
in	O	ADP	O
autism	B-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
AND	O	CCONJ	O
BACKGROUND	O	NOUN	O
Autism	O	NOUN	B
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
repetitive	O	ADJ	B
behaviors	O	NOUN	I
and	O	CCONJ	O
impaired	O	ADJ	B
socialization	O	NOUN	B
and	O	CCONJ	O
communication	O	NOUN	B
.	O	PUNCT	O


Preliminary	O	ADJ	B
evidence	O	NOUN	B
showed	O	VERB	O
possible	O	ADJ	O
language	O	NOUN	B
benefits	O	NOUN	B
in	O	ADP	O
autism	O	NOUN	B
from	O	ADP	O
the	O	DET	O
β-adrenergic	B-I	ADJ	B
antagonist	I-I	NOUN	I
propranolol	I-I	NOUN	B
.	O	PUNCT	O


Earlier	O	ADJ	O
studies	O	NOUN	B
in	O	ADP	O
other	O	ADJ	O
populations	O	NOUN	B
suggested	B-I	VERB	O
propranolol	I-I	NOUN	B
might	O	AUX	O
benefit	O	VERB	B
performance	O	NOUN	B
on	O	ADP	O
tasks	O	NOUN	B
involving	O	VERB	O
a	O	DET	O
search	O	NOUN	B
of	O	ADP	O
semantic	O	ADJ	B
and	O	CCONJ	O
associative	O	ADJ	B
networks	O	NOUN	B
under	O	ADP	O
certain	O	ADJ	O
conditions	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
wished	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
this	O	DET	O
benefit	O	NOUN	B
of	B-I	ADP	O
propranolol	I-I	NOUN	B
includes	O	VERB	O
an	O	DET	O
effect	O	NOUN	B
on	O	ADP	O
semantic	O	ADJ	B
fluency	O	NOUN	I
in	O	ADP	O
autism	O	NOUN	B
.	O	PUNCT	O


METHODS	B-P	VERB	O
A	I-P	DET	O
sample	I-P	NOUN	B
of	I-P	ADP	O
14	I-P	NUM	O
high-functioning	I-P	ADJ	B
adolescent	I-P	ADJ	B
and	I-P	CCONJ	O
adult	I-P	ADJ	B
participants	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
and	I-P	CCONJ	O
14	I-P	NUM	O
matched	I-P	VERB	B
controls	I-P	NOUN	I
were	O	AUX	O
given	O	VERB	O
letter	O	NOUN	B
and	O	CCONJ	O
category	O	NOUN	B
word	O	NOUN	B
fluency	O	NOUN	I
tasks	O	NOUN	B
on	O	ADP	O
2	O	NUM	O
separate	O	ADJ	O
testing	O	NOUN	B
sessions	O	NOUN	B
;	O	PUNCT	O
1	O	NUM	O
test	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
60	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
40	O	NUM	O
mg	B-I	NOUN	O
propranolol	I-I	NOUN	B
orally	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
test	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
after	B-I	ADP	O
placebo	I-I	NOUN	B
,	O	PUNCT	O
administered	O	VERB	B
in	O	ADP	O
a	O	DET	O
double-blinded	O	ADJ	B
,	O	PUNCT	O
counterbalanced	O	VERB	B
manner	O	NOUN	O
.	O	PUNCT	O


RESULTS	B-P	VERB	O
Participants	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
impaired	O	ADJ	B
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
on	O	ADP	O
both	B-OUT	DET	O
fluency	I-OUT	NOUN	B
tasks	I-OUT	NOUN	B
.	I-I	PUNCT	O


Propranolol	B-I	NOUN	B
significantly	O	ADV	O
improved	B-OUT	VERB	B
performance	I-OUT	NOUN	B
on	I-OUT	ADP	O
category	I-OUT	NOUN	B
fluency	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	B-OUT	PART	O
letter	I-OUT	NOUN	B
fluency	I-OUT	NOUN	I
among	O	ADP	O
autism	B-P	NOUN	B
participants	I-P	NOUN	B
.	O	PUNCT	O


No	B-OUT	DET	O
drug	I-OUT	NOUN	B
effect	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
among	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Expected	O	VERB	B
drug	O	NOUN	B
effects	O	NOUN	I
on	B-OUT	ADP	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
selective	O	ADJ	O
beneficial	O	ADJ	O
effect	O	NOUN	O
of	B-I	ADP	O
propranolol	I-I	NOUN	B
on	O	ADP	O
flexibility	O	NOUN	B
of	O	ADP	O
access	O	NOUN	O
to	O	ADP	O
semantic	O	ADJ	B
and	O	CCONJ	O
associative	O	ADJ	B
networks	O	NOUN	B
in	O	ADP	O
autism	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
observed	O	VERB	O
effect	O	NOUN	B
on	O	ADP	O
phonological	O	ADJ	B
networks	O	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
study	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
understand	O	VERB	O
potential	O	ADJ	B
clinical	O	ADJ	B
implications	O	NOUN	O
of	O	ADP	O
this	O	DET	O
finding	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
comparative	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
liver	O	NOUN	B
biopsy	B-I	NOUN	I
needles	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
sheathed	B-I	ADJ	B
needle	I-I	NOUN	I
(	O	PUNCT	O
Tru-Cut	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
a	O	DET	O
suction	B-I	NOUN	B
biopsy	I-I	NOUN	I
needle	I-I	NOUN	I
(	I-I	PUNCT	O
Menghini	I-I	PROPN	B
)	I-I	PUNCT	O
in	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
prospective	O	ADJ	I
trial	O	NOUN	I
over	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
former	O	ADJ	O
offered	O	VERB	O
any	O	DET	O
special	O	ADJ	O
advantages	O	NOUN	O
in	O	ADP	O
routine	B-I	ADJ	O
percutaneous	I-I	ADJ	B
liver	I-I	NOUN	I
biopsy	I-I	NOUN	I
.	I-I	PUNCT	O


Seventy-seven	B-P	NUM	O
consecutive	I-P	ADJ	B
biopsies	I-I	NOUN	B
were	O	AUX	O
performed	O	VERB	O
by	O	ADP	O
a	B-P	DET	O
single	I-P	ADJ	O
operator	I-P	NOUN	B
.	I-P	PUNCT	O


Although	O	SCONJ	O
biopsy	O	NOUN	B
fragmentation	O	NOUN	I
was	O	AUX	O
commoner	O	ADJ	O
with	O	ADP	O
the	O	DET	O
suction	B-I	NOUN	B
needle	I-I	NOUN	I
,	O	PUNCT	O
the	O	DET	O
length	O	NOUN	B
and	O	CCONJ	O
volume	O	NOUN	B
of	O	ADP	O
the	O	DET	O
largest	O	ADJ	O
core	O	NOUN	B
obtained	O	VERB	O
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
results	O	NOUN	B
with	O	ADP	O
the	O	DET	O
sheathed	B-I	ADJ	B
needle	I-I	NOUN	I
.	I-I	PUNCT	O


Cytology	O	NOUN	B
provided	O	VERB	O
useful	O	ADJ	O
additional	O	ADJ	O
information	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Menghini	B-I	PROPN	B
technique	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
suction	B-I	NOUN	B
needle	I-I	NOUN	I
was	O	AUX	O
repeatedly	B-OUT	ADV	O
reusable	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
considerably	I-OUT	ADV	O
cheaper	I-OUT	ADJ	O
than	O	ADP	O
the	O	DET	O
sheathed	B-I	ADJ	B
needle	I-I	NOUN	I
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
once	O	ADV	O
only	O	ADV	O
.	O	PUNCT	O


Sham	O	NOUN	B
device	O	NOUN	I
v	O	ADP	O
inert	O	ADJ	B
pill	O	NOUN	I
:	O	PUNCT	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
placebo	O	NOUN	B
treatments	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
a	O	DET	O
sham	O	NOUN	B
device	O	NOUN	B
(	O	PUNCT	O
a	O	DET	O
validated	O	VERB	O
sham	O	NOUN	B
acupuncture	O	NOUN	B
needle	O	NOUN	I
)	O	PUNCT	O
has	O	AUX	O
a	O	DET	O
greater	O	ADJ	O
placebo	O	NOUN	B
effect	O	NOUN	B
than	O	ADP	O
an	O	DET	O
inert	O	ADJ	B
pill	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
persistent	I-P	ADJ	B
arm	I-P	NOUN	I
pain	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
single	O	ADJ	O
blind	O	ADJ	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
created	O	VERB	O
from	O	ADP	O
the	O	DET	O
two	O	NUM	O
week	O	NOUN	B
placebo	O	ADJ	B
run-in	O	ADJ	B
periods	O	NOUN	B
for	O	ADP	O
two	O	NUM	O
nested	O	ADJ	B
trials	O	NOUN	I
that	O	PRON	O
compared	O	VERB	B
acupuncture	O	NOUN	B
and	O	CCONJ	O
amitriptyline	O	NOUN	B
with	O	ADP	O
their	O	PRON	O
respective	O	ADJ	O
placebo	B-P	NOUN	B
controls	I-P	NOUN	O
.	I-P	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
participants	O	NOUN	B
who	O	PRON	O
remained	O	VERB	O
on	O	ADP	O
placebo	O	NOUN	B
continued	O	VERB	O
beyond	O	ADP	O
the	O	DET	O
run-in	O	ADJ	B
period	O	NOUN	B
to	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


SETTING	O	VERB	O
Academic	O	ADJ	B
medical	O	ADJ	I
centre	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	VERB	O
270	B-P	NUM	O
adults	I-P	NOUN	B
with	I-P	ADP	O
arm	I-P	NOUN	B
pain	I-P	NOUN	I
due	I-P	ADJ	O
to	I-P	PART	O
repetitive	I-P	ADJ	O
use	I-P	NOUN	O
that	I-P	PRON	O
had	I-P	AUX	O
lasted	I-P	VERB	O
at	I-P	ADP	O
least	I-P	ADJ	O
three	I-P	NUM	O
months	I-P	NOUN	B
despite	I-P	SCONJ	O
treatment	I-P	NOUN	B
and	I-P	CCONJ	O
who	I-P	PRON	O
scored	I-P	VERB	B
>	I-P	NOUN	O
or	I-P	CCONJ	O
=3	I-P	NUM	O
on	I-P	ADP	O
a	I-P	DET	O
10	I-P	NUM	O
point	I-P	NOUN	B
pain	I-P	NOUN	I
scale	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
Acupuncture	B-I	NOUN	I
with	I-I	ADP	O
sham	I-I	NOUN	B
device	I-I	NOUN	O
twice	I-I	ADV	O
a	I-I	DET	O
week	I-I	NOUN	B
for	I-I	ADP	O
six	I-I	NUM	O
weeks	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
pill	I-I	NOUN	O
once	I-I	SCONJ	O
a	I-I	DET	O
day	I-I	NOUN	B
for	I-I	ADP	O
eight	I-I	NUM	O
weeks	I-I	NOUN	B
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	B
MEASURES	O	ADJ	O
Arm	B-OUT	NOUN	B
pain	I-OUT	NOUN	I
measured	O	VERB	B
on	O	ADP	O
a	O	DET	O
10	B-OUT	NUM	O
point	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Secondary	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
were	I-OUT	AUX	O
symptoms	I-OUT	NOUN	B
measured	I-OUT	VERB	B
by	I-OUT	ADP	O
the	I-OUT	DET	O
Levine	I-OUT	PROPN	B
symptom	I-OUT	NOUN	O
severity	I-OUT	NOUN	O
scale	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
function	I-OUT	NOUN	B
measured	I-OUT	VERB	B
by	I-OUT	ADP	O
Pransky	I-OUT	PROPN	B
's	I-OUT	PART	I
upper	I-OUT	ADJ	B
extremity	I-OUT	NOUN	I
function	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
grip	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Pain	B-OUT	NOUN	I
decreased	O	VERB	B
during	O	ADP	O
the	O	DET	O
two	O	NUM	O
week	O	NOUN	B
placebo	O	ADJ	B
run-in	O	ADJ	B
period	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
sham	O	NOUN	B
device	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
pill	O	NOUN	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
changes	O	NOUN	B
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
-0.14	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
-0.52	O	NOUN	O
to	O	PART	O
0.25	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.49	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
severity	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
for	I-OUT	ADP	O
arm	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
grip	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
arm	O	NOUN	B
function	O	NOUN	I
improved	O	VERB	B
more	O	ADV	O
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
pill	O	NOUN	O
group	O	NOUN	O
(	O	PUNCT	O
2.0	O	NUM	O
,	O	PUNCT	O
0.06	O	NUM	O
to	O	PART	O
3.92	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Longitudinal	O	ADJ	B
regression	O	NOUN	I
analyses	O	NOUN	I
that	O	PRON	O
followed	O	VERB	O
participants	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
showed	O	VERB	O
significantly	O	ADV	O
greater	O	ADJ	O
downward	O	ADJ	B
slopes	O	NOUN	B
per	O	ADP	O
week	O	NOUN	B
on	O	ADP	O
the	O	DET	O
10	B-OUT	NUM	O
point	I-OUT	NOUN	B
arm	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
sham	O	NOUN	B
device	O	NOUN	B
group	O	NOUN	I
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
pill	O	NOUN	O
group	O	NOUN	O
(	O	PUNCT	O
-0.33	O	NUM	O
(	O	PUNCT	O
-0.40	O	NUM	O
to	O	PART	O
-0.26	O	NUM	O
)	O	PUNCT	O
v	O	ADP	O
-0.15	O	NUM	O
(	O	PUNCT	O
-0.21	O	PRON	O
to	O	PART	O
-0.09	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
symptom	O	NOUN	B
severity	O	NOUN	I
scale	O	NOUN	I
(	O	PUNCT	O
-0.07	O	NUM	O
(	O	PUNCT	O
-0.09	O	NUM	O
to	O	PART	O
-0.05	O	NUM	O
)	O	PUNCT	O
v	O	NOUN	O
-0.05	O	NUM	O
(	O	PUNCT	O
-0.06	O	NUM	O
to	O	ADP	O
-0.03	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
function	O	NOUN	B
scale	O	NOUN	I
or	O	CCONJ	O
for	O	ADP	O
grip	O	NOUN	B
strength	O	NOUN	I
.	O	PUNCT	O


Reported	O	ADJ	B
adverse	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
different	O	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
sham	O	NOUN	B
device	O	NOUN	B
had	O	AUX	O
greater	O	ADJ	O
effects	O	NOUN	B
than	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
pill	O	NOUN	B
on	O	ADP	O
self	O	NOUN	O
reported	O	VERB	O
pain	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
over	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
course	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
during	O	ADP	O
the	O	DET	O
two	O	NUM	O
week	O	NOUN	B
placebo	O	NOUN	B
run	O	NOUN	O
in	O	ADP	O
.	O	PUNCT	O


Placebo	O	NOUN	B
effects	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
malleable	O	ADJ	B
and	O	CCONJ	O
depend	O	VERB	O
on	O	ADP	O
the	O	DET	O
behaviours	O	NOUN	B
embedded	O	ADJ	B
in	O	ADP	O
medical	O	ADJ	B
rituals	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
angiotensin	B-I	NOUN	B
II	I-I	NUM	I
receptor	I-I	NOUN	I
blockade	I-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
DASH	B-I	NOUN	B
diet	I-I	NOUN	I
on	O	ADP	O
markers	B-OUT	NOUN	B
of	O	ADP	O
endogenous	B-P	ADJ	B
fibrinolysis	I-P	NOUN	B
.	I-P	PUNCT	O


Hypertension	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
impaired	O	ADJ	B
fibrinolysis	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
angiotensin	B-I	NOUN	B
receptor	I-I	NOUN	I
blockers	I-I	NOUN	I
(	I-I	PUNCT	O
ARB	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
DASH	B-I	NOUN	B
(	I-I	PUNCT	O
Dietary	I-I	ADJ	B
Approaches	I-I	PROPN	I
to	I-I	PART	O
Stop	I-I	VERB	B
Hypertension	I-I	NOUN	I
)	I-I	PUNCT	O
diet	I-I	NOUN	B
effectively	O	ADV	O
lower	O	ADJ	B
blood	B-OUT	NOUN	I
pressure	I-OUT	NOUN	I
in	O	ADP	O
hypertensive	B-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Some	O	DET	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
ARBs	O	NOUN	B
could	O	AUX	O
increase	O	VERB	B
fibrinolysis	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
data	O	NOUN	B
is	O	AUX	O
conflicting	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DASH	O	NOUN	B
diet	O	NOUN	I
on	O	ADP	O
fibrinolytic	B-OUT	ADJ	B
parameters	I-OUT	NOUN	B
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
.	O	PUNCT	O


Fifty-five	B-P	NUM	B
hypertensive	I-P	ADJ	O
participants	I-P	NOUN	B
(	I-P	PUNCT	O
35	I-P	NUM	O
African-American	I-P	ADJ	B
,	I-P	PUNCT	O
20	I-P	NUM	O
white	I-P	ADJ	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
control	B-I	ADJ	B
diet	I-I	NOUN	I
or	O	CCONJ	O
the	O	DET	O
DASH	B-I	NOUN	B
diet	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
diets	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
in	O	ADP	O
sodium	O	NOUN	B
content	O	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
3	O	NUM	O
g/day	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Within	O	ADP	O
each	O	DET	O
diet	O	NOUN	B
,	O	PUNCT	O
individuals	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
losartan	B-I	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
double-blind	O	ADJ	B
,	O	PUNCT	O
cross-over	O	ADJ	B
fashion	O	NOUN	I
.	O	PUNCT	O


Tissue	B-OUT	NOUN	B
plasminogen	I-OUT	NOUN	I
activator	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
t-PA	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
antigen	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
t-PA	I-OUT	NOUN	B
activity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
plasminogen	I-OUT	NOUN	B
activator	I-OUT	NOUN	I
inhibitor-1	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PAI-1	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
activity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
plasma	I-OUT	NOUN	B
renin	I-OUT	NOUN	O
activity	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
PRA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
a	O	DET	O
2-week	O	ADJ	O
run-in	O	ADJ	B
period	O	NOUN	B
on	O	ADP	O
the	O	DET	O
control	O	ADJ	B
diet	B-I	NOUN	I
and	O	CCONJ	O
after	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
DASH	O	NOUN	B
diet	O	NOUN	I
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
markers	O	NOUN	B
of	O	ADP	O
fibrinolysis	O	NOUN	B
.	O	PUNCT	O


Losartan	O	NOUN	B
significantly	O	ADV	O
lowered	O	VERB	B
t-PA	B-OUT	NOUN	B
antigen	I-OUT	NOUN	I
levels	I-OUT	NOUN	B
(	O	PUNCT	O
-1.8	O	NUM	O
ng/mL	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.045	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
t-PA	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
PAI-1	I-OUT	NOUN	B
activities	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
more	O	ADV	O
pronounced	O	ADJ	O
in	O	ADP	O
whites	B-P	NOUN	B
(	O	PUNCT	O
-4.1	O	NUM	O
ng/mL	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
African-Americans	B-P	NOUN	B
(	O	PUNCT	O
-0.3	O	NUM	O
ng/mL	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.7	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
P-interaction	O	NOUN	B
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Results	O	NOUN	B
were	O	AUX	O
not	O	PART	O
materially	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
basline	O	NOUN	B
values	O	NOUN	I
or	O	CCONJ	O
changes	O	NOUN	B
in	O	ADP	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
losartan	O	NOUN	B
reduces	O	VERB	B
t-PA	B-OUT	NOUN	B
antigen	I-OUT	NOUN	I
levels	I-OUT	NOUN	B
in	O	ADP	O
white	B-P	ADJ	B
,	I-P	PUNCT	O
but	I-P	CCONJ	O
not	I-P	PART	O
African-American	I-P	ADJ	B
hypertensive	I-P	ADJ	B
individuals	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
DASH	O	NOUN	B
diet	O	NOUN	I
had	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
effect	O	NOUN	O
on	O	ADP	O
markers	B-OUT	NOUN	B
of	I-OUT	ADP	O
fibrinolysis	I-OUT	NOUN	B
in	O	ADP	O
whites	B-P	NOUN	B
or	I-P	CCONJ	O
African-Americans	I-P	NOUN	B
.	I-P	PUNCT	O


Anxiety	B-P	NOUN	B
sensitivity	I-P	NOUN	B
as	O	ADP	O
an	O	DET	O
incremental	O	ADJ	B
predictor	O	NOUN	B
of	O	ADP	O
later	B-P	ADJ	O
anxiety	I-P	NOUN	B
symptoms	I-P	NOUN	O
and	I-P	CCONJ	O
syndromes	I-P	NOUN	B
.	I-P	PUNCT	O


Although	O	SCONJ	O
anxiety	B-P	NOUN	B
sensitivity	I-P	NOUN	B
(	I-P	PUNCT	O
AS	I-P	NOUN	B
)	I-P	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
predict	O	VERB	O
anxiety	B-P	NOUN	B
symptoms	I-P	NOUN	O
and	I-P	CCONJ	O
panic	I-P	NOUN	B
,	O	PUNCT	O
this	O	DET	O
literature	O	NOUN	B
is	O	AUX	O
limited	O	ADJ	O
in	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
evaluating	O	VERB	B
AS	O	ADJ	B
as	O	ADP	O
an	O	DET	O
incremental	O	ADJ	B
predictor	O	NOUN	B
of	O	ADP	O
anxiety	B-I	NOUN	B
psychopathology	I-I	NOUN	B
relative	O	ADJ	O
to	O	PART	O
other	O	ADJ	O
established	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
including	O	VERB	O
sex	O	NOUN	B
and	O	CCONJ	O
negative	O	ADJ	B
affect	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
report	O	NOUN	B
prospectively	O	ADV	O
evaluated	O	VERB	B
whether	O	SCONJ	O
AS	O	NOUN	B
was	O	AUX	O
predictive	O	ADJ	B
of	O	ADP	O
later	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
anxiety	B-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
after	O	ADP	O
controlling	B-I	VERB	B
for	I-I	ADP	O
potential	I-I	ADJ	B
confounding	I-I	NOUN	B
factors	I-I	NOUN	I
.	I-I	PUNCT	O


Consistent	O	ADJ	B
with	O	ADP	I
hypothesis	O	NOUN	B
,	O	PUNCT	O
AS	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
significant	O	ADJ	B
,	O	PUNCT	O
incremental	O	ADJ	B
predictor	O	NOUN	B
of	O	ADP	O
anxiety	B-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
after	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
sex	O	NOUN	B
and	O	CCONJ	O
negative	O	ADJ	B
affectivity	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
provide	O	VERB	O
novel	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
the	O	DET	O
unique	O	ADJ	B
association	O	NOUN	B
between	O	ADP	O
AS	O	NOUN	B
of	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
anxiety	B-P	NOUN	B
symptoms	I-P	NOUN	B
.	I-P	PUNCT	O


Controlled	O	PROPN	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
evaluation	O	NOUN	I
of	O	ADP	O
partial	B-I	ADJ	B
ceramic	I-I	ADJ	B
crowns	I-I	NOUN	B
inserted	O	VERB	O
with	O	ADP	O
RelyX	B-I	NOUN	B
Unicem	I-I	PROPN	I
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
selective	I-I	ADJ	O
enamel	I-I	NOUN	B
etching	I-I	NOUN	I
.	I-I	PUNCT	O


1-year	O	ADJ	O
results	O	NOUN	O
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
performance	O	NOUN	B
of	O	ADP	O
partial	B-OUT	ADJ	B
ceramic	I-OUT	ADJ	B
crowns	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
PCCs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
inserted	I-I	VERB	O
with	I-I	ADP	O
RelyX	I-I	NOUN	B
Unicem	I-I	PROPN	I
(	I-I	PUNCT	O
RXU	I-I	PROPN	B
)	I-I	PUNCT	O
either	I-I	CCONJ	O
with	I-I	ADP	O
(	I-I	PUNCT	O
RXU+E	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
without	I-I	ADP	O
(	I-I	PUNCT	O
RXU	I-I	NOUN	B
)	I-I	PUNCT	O
selective	I-I	ADJ	O
enamel	I-I	NOUN	B
etching	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	NOUN	O
34	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
15	I-P	NUM	O
male	I-P	NOUN	B
,	I-P	PUNCT	O
19	I-P	NUM	O
female	I-P	NOUN	B
)	I-P	PUNCT	O
participated	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
investigation	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
68	I-P	NUM	O
PCC	I-P	NOUN	B
restorations	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
PCC	B-I	NOUN	B
was	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
insertion	O	NOUN	B
with	O	ADP	O
RXU	B-I	PROPN	B
,	O	PUNCT	O
the	O	DET	O
second	O	ADJ	O
PCC	B-I	NOUN	B
was	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
insertion	O	NOUN	B
with	O	ADP	O
RXU+E	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
PCCs	O	NOUN	B
were	O	AUX	O
CAD/CAM	O	PROPN	B
fabricated	O	VERB	I
using	O	VERB	O
the	O	DET	O
Cerec	B-I	PROPN	B
3	I-I	NUM	I
system	I-I	NOUN	I
.	I-I	PUNCT	O


RXU	B-I	NOUN	B
:	I-I	PUNCT	O
25	O	NUM	O
PCCs	O	NOUN	B
were	O	AUX	O
placed	O	VERB	O
in	O	ADP	O
molars	O	NOUN	B
,	O	PUNCT	O
nine	O	NUM	O
in	O	ADP	O
premolars	O	NOUN	B
.	O	PUNCT	O


RXU+E	B-I	NOUN	B
:	I-I	PUNCT	O
26	O	NUM	O
PCCs	O	NOUN	B
were	O	AUX	O
placed	O	VERB	O
in	O	ADP	O
molars	O	NOUN	B
,	O	PUNCT	O
eight	O	NUM	O
in	O	ADP	O
premolars	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
restorations	O	NOUN	B
were	O	AUX	O
clinically	O	ADV	B
rated	O	VERB	O
using	O	VERB	O
modified	O	VERB	B
United	O	PROPN	B
States	O	PROPN	I
Public	O	PROPN	I
Health	O	PROPN	I
Service	O	PROPN	I
(	O	PUNCT	O
USPHS	O	PROPN	B
)	O	PUNCT	O
criteria	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
placement	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	B-P	ADJ	B
patient	I-P	NOUN	B
age	I-P	NOUN	O
was	I-P	AUX	O
41	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
24-59	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
median	O	NOUN	B
(	O	PUNCT	O
25-75	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
PBI	O	PROPN	B
was	O	AUX	O
6	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
3-9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
All	B-P	DET	O
patients	I-P	NOUN	B
were	I-P	AUX	O
available	I-P	ADJ	O
for	I-P	ADP	O
the	I-P	DET	O
three	I-P	NUM	O
recall	I-P	NOUN	B
appointments	I-P	NOUN	B
.	I-P	PUNCT	O


One	O	NUM	O
PCC	O	NOUN	B
(	B-I	PUNCT	O
RXU	I-I	PROPN	B
)	I-I	PUNCT	O
debonded	I-OUT	VERB	O
after	O	ADP	O
11	O	NUM	O
months	O	NOUN	B
in	O	X	B
situ	O	X	I
,	O	PUNCT	O
one	O	NUM	O
PCC	O	NOUN	B
(	B-I	PUNCT	O
RXU+E	I-I	NOUN	B
)	I-I	PUNCT	O
fractured	I-OUT	ADJ	B
after	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
in	O	X	B
situ	O	X	I
.	O	PUNCT	O


Both	O	DET	O
restorations	B-OUT	NOUN	B
had	O	AUX	O
to	O	PART	O
be	O	AUX	O
replaced	B-OUT	VERB	O
.	I-OUT	PUNCT	O


At	O	ADP	O
the	O	DET	O
12	O	NUM	O
months	O	NOUN	B
recall	O	NOUN	B
,	O	PUNCT	O
66	O	NUM	O
of	O	ADP	O
68	O	NUM	O
controlled	O	VERB	B
restorations	O	NOUN	I
were	O	AUX	O
functional	B-OUT	ADJ	B
without	O	ADP	O
need	O	NOUN	O
of	O	ADP	O
replacement	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
evaluation	O	NOUN	B
using	O	VERB	O
USHPS	O	NOUN	B
criteria	O	NOUN	I
revealed	O	VERB	B
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
of	O	ADP	O
alfa	B-OUT	ADJ	B
ratings	I-OUT	NOUN	B
over	I-OUT	ADP	O
time	I-OUT	NOUN	O
with	I-OUT	ADP	O
respect	I-OUT	NOUN	O
to	I-OUT	PART	O
criteria	I-OUT	NOUN	B
marginal	I-OUT	ADJ	B
adaptation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
marginal	I-OUT	ADJ	B
discoloration	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


No	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
luting	O	NOUN	B
techniques	O	NOUN	I
,	O	PUNCT	O
RXU	B-I	PROPN	B
and	I-I	CCONJ	O
RXU+E	I-I	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
reobserved	O	VERB	B
during	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
limitations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
adhesive	O	ADJ	B
luting	O	NOUN	I
with	O	ADP	O
RXU	B-I	PROPN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
selective	O	ADJ	O
enamel	O	NOUN	B
etching	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
recommended	O	VERB	B
.	O	PUNCT	O


Inclusion	O	NOUN	B
of	O	ADP	O
anti-phospholipase	B-I	ADJ	B
A2	I-I	NOUN	I
antibody	I-I	NOUN	I
to	O	ADP	O
backgrounding	O	VERB	B
diets	O	NOUN	B
on	O	ADP	O
performance	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
feed	I-OUT	NOUN	B
efficiency	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
in	I-OUT	X	B
vitro	I-OUT	X	I
fermentation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
acute-phase	I-OUT	ADJ	B
response	I-OUT	NOUN	I
of	I-OUT	ADP	O
growing	I-OUT	VERB	O
beef	I-OUT	NOUN	B
calves	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
Exp	O	NOUN	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
individual	O	ADJ	B
performance	O	NOUN	B
and	O	CCONJ	O
daily	O	ADJ	B
DMI	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
on	O	ADP	O
70	B-P	NUM	O
crossbred	I-P	ADJ	B
weaned	I-P	VERB	B
calves	I-P	NOUN	B
during	I-P	ADP	O
a	I-P	DET	O
70-d	I-P	ADJ	O
period	I-P	NOUN	B
using	I-P	VERB	O
a	I-P	DET	O
GrowSafe	I-P	PROPN	B
system	I-P	NOUN	I
(	I-P	PUNCT	O
GrowSafe	I-P	PROPN	B
Systems	I-P	PROPN	I
Ltd.	I-P	PROPN	I
,	O	PUNCT	O
Airdrie	B-P	PROPN	B
,	I-P	PUNCT	O
AB	I-P	PROPN	B
,	I-P	PUNCT	O
Canada	I-P	PROPN	B
)	I-P	PUNCT	O
at	I-P	ADP	O
the	I-P	DET	O
University	I-P	PROPN	B
of	I-P	ADP	I
Florida	I-P	PROPN	I
North	I-P	PROPN	I
Florida	I-P	PROPN	I
Research	I-P	PROPN	I
and	I-P	CCONJ	I
Education	I-P	PROPN	I
Center	I-P	PROPN	I
Feed	I-P	PROPN	I
Efficiency	I-P	PROPN	I
Facility	I-P	PROPN	I
(	I-P	PUNCT	O
FEF	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Calves	B-P	NOUN	B
were	O	AUX	O
fed	O	VERB	O
a	O	DET	O
low-concentrate	B-I	NOUN	B
(	I-I	PUNCT	O
LC	I-I	NOUN	B
)	I-I	PUNCT	O
growing	I-I	VERB	B
diet	I-I	NOUN	I
,	O	PUNCT	O
blocked	O	VERB	B
by	O	ADP	O
weight	O	NOUN	B
and	O	CCONJ	O
sex	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
pens	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
either	B-I	CCONJ	O
no	I-I	DET	O
additional	I-I	ADJ	O
supplement	I-I	NOUN	B
(	O	PUNCT	O
CON	O	NOUN	B
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
35	O	NUM	O
)	O	PUNCT	O
or	B-I	CCONJ	O
receive	I-I	VERB	O
a	I-I	DET	O
supplement	I-I	NOUN	B
of	I-I	ADP	O
anti-phospholipase	I-I	ADJ	B
A2	I-I	NOUN	I
antibody	I-I	NOUN	I
(	I-I	PUNCT	O
aPLA2	I-I	NOUN	B
)	I-I	PUNCT	O
at	O	ADP	O
an	O	DET	O
inclusion	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
0.6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
diet	O	NOUN	B
DM	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
35	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
70-d	O	ADJ	O
feed	O	NOUN	B
efficiency	O	NOUN	B
(	O	PUNCT	O
FE	O	NOUN	B
)	O	PUNCT	O
trial	O	NOUN	O
(	O	PUNCT	O
Phase	O	NOUN	B
1	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
calves	O	NOUN	B
were	O	AUX	O
loaded	O	VERB	O
into	O	ADP	O
a	O	DET	O
commercial	O	ADJ	B
livestock	O	NOUN	B
trailer	O	NOUN	O
and	O	CCONJ	O
were	O	AUX	O
driven	O	VERB	O
for	O	ADP	O
approximately	O	ADV	B
1,600	O	NUM	O
km	O	NOUN	O
during	O	ADP	O
24	O	NUM	O
h.	O	NOUN	O
Upon	O	SCONJ	O
return	O	NOUN	B
to	O	ADP	I
the	O	DET	I
FEF	O	NOUN	B
(	O	PUNCT	O
Phase	O	NOUN	B
2	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
calves	O	NOUN	B
were	O	AUX	O
relocated	O	VERB	O
to	O	PART	O
the	O	DET	O
same	O	ADJ	O
pens	O	NOUN	B
and	O	CCONJ	O
groups	O	NOUN	B
and	O	CCONJ	O
received	O	VERB	O
the	O	DET	O
same	O	ADJ	O
diets	O	NOUN	B
and	O	CCONJ	O
treatments	O	NOUN	B
for	O	ADP	O
28	O	NUM	O
d.	O	NOUN	O
Blood	O	NOUN	B
samples	O	NOUN	I
from	O	ADP	O
each	O	DET	O
calf	O	NOUN	B
were	O	AUX	O
collected	O	VERB	O
on	O	ADP	O
d	O	NOUN	O
0	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
21	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
28	O	NUM	O
relative	O	ADJ	O
to	O	PART	O
initiation	O	NOUN	B
of	O	ADP	O
transportation	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
determination	O	NOUN	B
of	O	ADP	O
concentrations	B-OUT	NOUN	B
of	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
ceruloplasmin	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
haptoglobin	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
Phase	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
initial	O	ADJ	O
BW	B-OUT	NOUN	B
(	O	PUNCT	O
242.0	O	NUM	O
±	O	NOUN	O
3.7	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.92	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
BW	B-OUT	NOUN	B
at	O	ADP	O
d	O	NOUN	O
70	O	NUM	O
(	O	PUNCT	O
313.0	O	NUM	O
±	O	PROPN	O
4.1	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.79	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-OUT	CCONJ	O
ADG	I-OUT	NOUN	B
(	O	PUNCT	O
1.01	O	NUM	O
±	O	NOUN	O
0.02	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.95	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
treatments	O	NOUN	B
.	O	PUNCT	O


However	B-OUT	ADV	O
,	I-OUT	PUNCT	O
daily	I-OUT	ADJ	B
DMI	I-OUT	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
CON	O	NOUN	B
(	O	PUNCT	O
9.18	O	NUM	O
±	O	NOUN	O
0.15	O	NUM	O
kg	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
aPLA2	O	NOUN	B
(	O	PUNCT	O
8.53	O	NUM	O
±	O	NOUN	O
0.15	O	NUM	O
kg	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	B-OUT	NOUN	O
,	I-OUT	PUNCT	O
residual	I-OUT	ADJ	B
feed	I-OUT	NOUN	B
intake	I-OUT	NOUN	I
was	O	AUX	O
greater	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
CON	O	NOUN	B
(	O	PUNCT	O
0.389	O	NUM	O
±	O	X	O
0.110	O	NUM	O
kg/d	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
aPLA2	O	NOUN	B
calves	O	NOUN	B
(	O	PUNCT	O
-0.272	O	X	O
±	O	X	O
0.110	O	NUM	O
kg/d	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
Phase	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
after	O	ADP	O
transportation	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
treatments	B-OUT	NOUN	B
on	I-OUT	ADP	O
BW	I-OUT	NOUN	B
loss	I-OUT	NOUN	B
due	I-OUT	ADP	O
to	I-OUT	ADP	O
transportation	I-OUT	NOUN	B
shrink	O	NOUN	O
(	O	PUNCT	O
26.0	O	NUM	O
±	O	NOUN	O
0.6	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.86	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
BW	O	NOUN	B
at	O	ADP	O
d	O	NOUN	O
28	O	NUM	O
(	O	PUNCT	O
339.0	O	NUM	O
±	O	PROPN	O
4.1	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.72	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
ADG	O	NOUN	B
(	O	PUNCT	O
1.28	O	NUM	O
±	O	NOUN	O
0.03	O	NUM	O
kg/d	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.72	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
G	O	NOUN	B
:	O	PUNCT	O
F	O	NOUN	B
(	O	PUNCT	O
0.164	O	NUM	O
±	O	NOUN	O
0.004	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.83	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
concentrations	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
haptoglobin	O	NOUN	B
(	O	PUNCT	O
0.08	O	NUM	O
±	O	NOUN	O
0.02	O	NUM	O
mg/mL	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.41	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


However	B-OUT	ADV	O
,	I-OUT	PUNCT	O
concentrations	I-OUT	NOUN	B
of	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
ceruloplasmin	I-OUT	NOUN	B
were	O	AUX	O
greater	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
CON	O	NOUN	B
calves	O	NOUN	B
(	O	PUNCT	O
14.3	O	NUM	O
±	O	NOUN	O
0.3	O	NUM	O
mg/dL	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
aPLA2	O	NOUN	B
calves	O	NOUN	I
(	O	PUNCT	O
13.0	O	NUM	O
±	O	NOUN	O
0.3	O	NUM	O
mg/dL	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
Exp	O	NOUN	O
.	O	PUNCT	O


2	O	X	O
,	O	PUNCT	O
the	B-OUT	DET	O
effects	I-OUT	NOUN	B
of	I-OUT	ADP	O
aPLA2	I-OUT	NOUN	B
inclusion	I-OUT	NOUN	B
on	I-OUT	ADP	O
LC	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
high-concentrate	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
HC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
substrates	I-OUT	NOUN	B
on	I-OUT	ADP	O
in	I-OUT	X	B
vitro	I-OUT	X	I
fermentation	I-OUT	NOUN	B
parameters	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


Addition	O	NOUN	B
of	O	ADP	O
aPLA2	O	NOUN	B
had	O	AUX	O
no	B-OUT	DET	B
effects	I-OUT	NOUN	I
on	I-OUT	ADP	O
in	I-OUT	X	B
vitro	I-OUT	X	I
fermentation	I-OUT	NOUN	B
parameters	I-OUT	NOUN	B
of	I-OUT	ADP	O
LC	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
HC	O	NOUN	B
substrates	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
supplementation	B-I	NOUN	B
of	O	ADP	O
aPLA2	B-OUT	NOUN	B
improved	O	VERB	B
FE	O	NOUN	B
of	O	ADP	O
growing	O	VERB	O
beef	O	NOUN	B
calves	O	NOUN	B
when	O	SCONJ	O
fed	O	VERB	B
LC	O	NOUN	B
diets	O	NOUN	B
in	O	ADP	O
Phase	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
addition	O	NOUN	O
of	O	ADP	O
aPLA2	O	NOUN	B
had	B-OUT	AUX	O
no	I-OUT	DET	B
effect	I-OUT	NOUN	I
on	I-OUT	ADP	O
fermentation	I-OUT	NOUN	B
parameters	I-OUT	NOUN	B
of	I-OUT	ADP	O
LC	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
HC	O	NOUN	B
substrates	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
calves	O	NOUN	B
supplemented	O	VERB	B
with	O	ADP	O
aPLA2	B-OUT	NOUN	B
had	I-OUT	AUX	O
reduced	I-OUT	VERB	B
concentrations	I-OUT	NOUN	B
of	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
ceruloplasmin	O	NOUN	B
after	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
of	O	ADP	O
transportation	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
brief	B-I	ADJ	O
Early	I-I	PROPN	B
Start	I-I	PROPN	I
Denver	I-I	PROPN	I
model	I-I	NOUN	I
(	I-I	PUNCT	O
ESDM	I-I	NOUN	B
)	I-I	PUNCT	O
-based	I-I	ADJ	O
parent	I-I	NOUN	B
intervention	I-I	NOUN	B
on	I-I	ADP	O
toddlers	I-I	NOUN	B
at	I-P	ADP	O
risk	I-P	NOUN	B
for	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
12-week	O	NOUN	B
,	O	PUNCT	O
low-intensity	B-I	NOUN	B
(	I-I	PUNCT	O
1-hour/wk	I-I	NUM	O
of	I-I	ADP	O
therapist	I-I	NOUN	B
contact	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
parent-delivered	I-I	ADJ	B
intervention	I-I	NOUN	I
for	I-I	ADP	O
toddlers	I-I	NOUN	B
at	I-P	ADP	O
risk	I-P	NOUN	B
for	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
aged	I-P	ADJ	B
14	I-P	NUM	O
to	I-P	PART	O
24	I-P	NUM	O
months	I-P	NOUN	B
and	I-P	CCONJ	O
their	I-P	PRON	O
families	I-P	NOUN	B
.	I-P	PUNCT	O


METHOD	O	NOUN	B
A	O	DET	I
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
involving	O	VERB	O
98	B-P	NUM	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
families	I-P	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
sites	O	NOUN	B
investigating	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
parent	O	NOUN	B
delivery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Early	B-I	PROPN	B
Start	I-I	PROPN	I
Denver	I-I	PROPN	I
model	I-I	NOUN	I
(	I-I	PUNCT	O
P-ESDM	I-I	NOUN	O
)	I-I	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
fosters	O	VERB	O
parental	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
child-centered	O	ADJ	B
responsive	O	ADJ	I
interaction	O	NOUN	B
style	O	NOUN	B
that	O	PRON	O
embeds	O	VERB	O
many	O	ADJ	O
teaching	O	NOUN	B
opportunities	O	NOUN	B
into	O	ADP	O
play	O	NOUN	O
,	O	PUNCT	O
compared	B-I	VERB	O
to	I-I	PART	O
community	I-I	NOUN	B
treatment	I-I	NOUN	I
as	I-I	ADP	O
usual	I-I	ADJ	O
.	I-I	PUNCT	O


Assessments	O	NOUN	B
were	O	AUX	O
completed	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
12	O	NUM	O
weeks	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
immediately	O	ADV	O
after	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
parent	O	NOUN	B
coaching	O	NOUN	B
sessions	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	O
effect	I-OUT	NOUN	O
of	O	ADP	O
group	O	NOUN	B
assignment	O	NOUN	B
on	O	ADP	O
parent-child	O	ADJ	B
interaction	O	NOUN	B
characteristics	O	NOUN	B
or	O	CCONJ	O
on	O	ADP	O
any	O	DET	O
child	O	NOUN	B
outcomes	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
of	O	ADP	O
parents	O	NOUN	B
improved	O	VERB	O
interaction	B-OUT	NOUN	B
skills	I-OUT	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
groups	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
demonstrated	B-OUT	VERB	O
progress	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Parents	B-I	NOUN	B
receiving	I-I	VERB	B
P-ESDM	I-I	NOUN	O
demonstrated	O	VERB	O
significantly	O	ADV	O
stronger	B-OUT	ADJ	B
working	I-OUT	NOUN	B
alliances	I-OUT	NOUN	O
with	O	ADP	O
their	O	PRON	O
therapists	B-OUT	NOUN	B
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
community	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
community	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
significantly	O	ADV	O
more	O	ADJ	O
intervention	B-OUT	NOUN	B
hours	I-OUT	NOUN	O
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
P-ESDM	B-I	NOUN	O
group	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
group	O	NOUN	B
as	O	ADP	O
a	O	DET	O
whole	O	NOUN	O
,	O	PUNCT	O
both	O	CCONJ	O
younger	O	ADJ	B
child	O	NOUN	I
age	O	NOUN	B
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
intervention	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
greater	O	ADJ	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
intervention	I-OUT	NOUN	B
hours	I-OUT	NOUN	I
were	O	AUX	O
positively	O	ADV	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
improvement	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
's	O	PART	I
behavior	O	NOUN	B
for	O	ADP	O
most	O	ADJ	O
variables	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Parent-implemented	B-I	ADJ	B
intervention	I-I	NOUN	I
studies	I-I	NOUN	I
for	O	ADP	O
early	O	ADV	O
ASD	O	PROPN	B
thus	O	ADV	O
far	O	ADV	O
have	O	AUX	O
not	O	PART	O
demonstrated	O	VERB	O
the	O	DET	O
large	O	ADJ	O
effects	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
intensive-treatment	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


Evidence	O	NOUN	B
that	O	SCONJ	O
both	O	CCONJ	O
younger	O	ADJ	B
age	O	NOUN	I
and	O	CCONJ	O
more	O	ADJ	O
intervention	O	NOUN	B
hours	O	NOUN	O
positively	O	ADV	O
affect	O	VERB	O
developmental	O	ADJ	B
rates	O	NOUN	I
has	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
,	O	PUNCT	O
service	O	NOUN	B
delivery	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
public	O	ADJ	B
policy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gastric	B-OUT	ADJ	B
emptying	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
small	I-OUT	ADJ	B
intestinal	I-OUT	ADJ	I
transit	I-OUT	NOUN	I
after	O	ADP	O
highly	B-P	ADV	O
selective	I-P	ADJ	O
vagotomy	I-P	NOUN	B
without	I-P	ADP	O
drainage	I-P	NOUN	B
and	I-P	CCONJ	O
selective	I-P	ADJ	O
vagotomy	I-P	NOUN	B
with	I-P	ADP	O
pyloroplasty	I-P	NOUN	B
.	I-P	PUNCT	O


[	O	PUNCT	O
Assessment	O	NOUN	B
of	O	ADP	O
natriuretic	B-I	ADJ	B
peptide	I-I	NOUN	I
indices	O	NOUN	I
and	O	CCONJ	O
oxidative	B-I	ADJ	B
stress	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
have	O	AUX	O
studied	O	VERB	O
indices	O	NOUN	B
of	O	ADP	O
natriuretic	B-I	ADJ	B
peptide	I-I	NOUN	I
and	O	CCONJ	O
oxidative	B-I	ADJ	B
stress	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
(	I-P	PUNCT	O
CHF	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


52	B-I	NUM	O
male	I-I	NOUN	B
patients	I-I	NOUN	B
with	I-I	ADP	O
postinfarction	I-I	NOUN	B
cardiosclerosis	I-I	NOUN	I
(	I-I	PUNCT	O
PICS	I-I	NOUN	B
)	I-I	PUNCT	O
who	I-I	PRON	O
have	I-I	AUX	O
developed	I-I	VERB	O
CHF	I-I	NOUN	B
have	I-I	AUX	O
been	I-I	AUX	O
observed	I-I	VERB	B
.	I-I	PUNCT	O


The	B-P	DET	O
age	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
patients	I-P	NOUN	B
varied	I-P	VERB	O
from	I-P	ADP	O
38	I-P	NUM	O
till	I-P	SCONJ	O
60	I-P	NUM	O
.	I-P	PUNCT	O


It	O	PRON	O
was	O	AUX	O
established	O	VERB	O
that	O	SCONJ	O
CHF	O	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
progression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
had	O	AUX	O
worsening	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
clinical	B-OUT	ADJ	B
condition	I-OUT	NOUN	I
together	O	ADV	O
with	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
which	O	DET	O
was	O	AUX	O
characterized	O	VERB	B
through	O	ADP	O
decrease	O	NOUN	B
of	O	ADP	O
NO	B-OUT	NOUN	B
metabolites	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
NADPH	I-OUT	NOUN	B
--	I-OUT	PUNCT	O
diaphorase	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
eNOS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
increase	O	NOUN	B
of	O	ADP	O
nitrite	B-OUT	NOUN	B
reductase	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
iNOS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
peroxinitrite	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
ONOO	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
correlative	O	ADJ	O
increase	O	VERB	B
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
brain	B-OUT	NOUN	B
natriuretic	I-OUT	ADJ	I
peptide	I-OUT	NOUN	I
in	I-OUT	ADP	O
blood	I-OUT	NOUN	B
plazma	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Reliable	O	ADJ	O
connection	O	NOUN	B
between	O	ADP	O
considerable	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
and	O	CCONJ	O
the	O	DET	O
level	B-OUT	NOUN	B
of	I-OUT	ADP	O
NT-pro	I-OUT	NOUN	B
BNP	I-OUT	NOUN	B
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
CHF	B-P	NOUN	B
patients	I-P	NOUN	B
,	O	PUNCT	O
which	O	DET	O
demands	O	VERB	O
necessity	O	NOUN	O
of	O	ADP	O
correction	O	NOUN	B
of	O	ADP	O
observed	O	VERB	O
disorders	O	NOUN	B
.	O	PUNCT	O


Anti-angiogenic	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
of	O	ADP	O
epigallocatechin-3-gallate	B-I	NOUN	B
in	O	ADP	O
human	O	ADJ	B
skin	O	NOUN	B
.	O	PUNCT	O


Epigallocatechin-3-gallate	B-I	NOUN	B
(	I-I	PUNCT	O
EGCG	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
the	O	DET	O
main	O	ADJ	O
polyphenol	O	NOUN	B
component	O	NOUN	O
of	O	ADP	O
green	O	ADJ	B
tea	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
compound	O	NOUN	B
exhibits	O	VERB	O
antioxidant	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
immunomodulatory	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
photoprotective	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
anti-angiogenic	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anti-inflammatory	I-OUT	ADJ	B
properties	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
small	O	ADJ	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	NOUN	B
,	O	PUNCT	O
split	O	ADJ	B
face	O	NOUN	I
trial	O	NOUN	I
using	O	VERB	O
a	O	DET	O
cream	B-I	NOUN	B
containing	I-I	VERB	O
2.5	I-I	NUM	O
%	I-I	NOUN	O
w/w	I-I	NOUN	O
of	I-I	ADP	O
EGCG	I-I	NOUN	B
.	I-I	PUNCT	O


Four	B-P	NUM	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
with	I-P	ADP	O
significant	I-P	ADJ	B
erythema	I-P	NOUN	B
and	I-P	CCONJ	O
telangiectasia	I-P	NOUN	B
on	I-P	ADP	O
the	I-P	DET	O
face	I-P	NOUN	O
applied	O	VERB	O
EGCG	B-I	NOUN	B
cream	I-I	NOUN	B
to	O	ADP	O
one	O	NUM	O
side	O	NOUN	O
of	O	ADP	O
the	O	DET	O
face	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
vehicle	B-I	NOUN	B
control	I-I	NOUN	B
cream	I-I	NOUN	I
to	O	ADP	O
the	O	DET	O
other	O	ADJ	O
,	O	PUNCT	O
twice	O	ADV	O
daily	O	ADV	O
for	O	ADP	O
six	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
six	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
biopsies	B-OUT	NOUN	B
were	O	AUX	O
taken	O	VERB	O
from	O	ADP	O
EGCG	B-I	NOUN	B
and	O	CCONJ	O
vehicle	B-I	NOUN	B
treated	I-I	ADJ	B
sites	O	NOUN	O
.	O	PUNCT	O


Immunohistochemistry	B-OUT	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
measure	O	VERB	B
VEGF	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
HIF-1	I-OUT	NOUN	B
α.	I-OUT	NOUN	O
HIF-1	I-OUT	NOUN	B
α	I-OUT	NOUN	O
expression	I-OUT	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
in	B-I	ADP	O
EGCG	I-I	NOUN	B
treated	O	ADJ	B
sites	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
that	O	DET	O
28.4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
epidermis	O	NOUN	B
showed	B-OUT	VERB	O
positive	I-OUT	ADJ	B
staining	I-OUT	NOUN	O
in	O	ADP	O
vehicle	O	NOUN	B
treated	O	VERB	B
vs.	O	CCONJ	O
13.8	O	NUM	O
%	O	NOUN	O
in	B-I	ADP	O
EGCG	I-I	NOUN	B
treated	O	ADJ	B
sites	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
similar	O	ADJ	O
decrease	O	NOUN	B
in	B-OUT	ADP	O
VEGF	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
(	O	PUNCT	O
6.7	O	NUM	O
%	O	NOUN	O
in	B-I	ADP	O
EGCG	I-I	NOUN	B
vs.	O	CCONJ	O
11.0	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
in	B-I	ADP	O
vehicle-treated	I-I	ADJ	B
skin	O	NOUN	O
(	B-I	PUNCT	O
p	I-I	NOUN	O
<	I-I	X	O
0.005	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


EGCG	B-I	NOUN	B
topical	O	ADJ	B
treatments	O	NOUN	O
influence	B-OUT	VERB	B
HIF-1	I-OUT	NOUN	B
α	I-OUT	DET	O
induction	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
VEGF	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
potential	O	ADJ	O
agent	O	NOUN	B
in	O	ADP	O
the	B-OUT	DET	O
prevention	I-OUT	NOUN	B
of	I-OUT	ADP	O
telangiectasias	I-OUT	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
on	O	ADP	O
leptin	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
leptin	I-OUT	NOUN	B
receptor	I-OUT	NOUN	I
gene	I-OUT	NOUN	B
expression	I-OUT	NOUN	I
in	O	ADP	O
myometrium	B-P	NOUN	B
and	I-P	CCONJ	O
uterine	I-P	ADJ	B
myomas	I-P	NOUN	I
of	I-P	ADP	O
gnRH	I-I	NOUN	B
analogue-treated	I-I	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
test	O	VERB	O
if	O	SCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
GnRH	B-I	NOUN	B
analogue	I-I	NOUN	B
,	O	PUNCT	O
which	O	DET	O
leads	O	VERB	O
to	O	PART	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
myoma	B-OUT	NOUN	B
volume	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
changes	I-OUT	VERB	B
expression	I-OUT	NOUN	B
of	I-OUT	ADP	O
leptin	I-OUT	NOUN	B
genes	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
gene	I-OUT	NOUN	B
coding	I-OUT	NOUN	I
leptin	I-OUT	NOUN	I
receptor	I-OUT	NOUN	I
isoforms	I-OUT	NOUN	B
in	O	ADP	O
uterine	O	NOUN	B
myomas	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
surrounding	O	VERB	O
unaltered	O	ADJ	B
myometrium	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Using	O	VERB	O
RT-PCR	O	NOUN	B
,	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
leptin	O	NOUN	B
genes	O	NOUN	I
and	O	CCONJ	O
leptin	O	NOUN	B
receptor	O	NOUN	I
genes	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
myomas	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
surrounding	O	VERB	B
myometrium	O	NOUN	B
in	O	ADP	O
women	B-P	NOUN	B
with	I-P	ADP	O
uterine	I-P	NOUN	B
myomas	I-P	NOUN	I
,	I-P	PUNCT	O
untreated	I-P	ADJ	B
or	I-P	CCONJ	O
treated	I-P	VERB	B
with	I-P	ADP	I
GnRH	I-I	NOUN	B
analogue	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
randomly	O	ADV	O
selected	O	VERB	O
cases	O	NOUN	B
presence	O	NOUN	B
of	O	ADP	O
leptin	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
of	O	ADP	O
leptin	O	NOUN	B
receptor	O	NOUN	I
proteins	O	NOUN	I
was	O	AUX	O
examined	O	VERB	O
also	O	ADV	O
by	O	ADP	O
Western	O	NOUN	B
blotting	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
Expression	B-OUT	NOUN	B
of	I-OUT	ADP	O
leptin	I-OUT	NOUN	B
genes	I-OUT	NOUN	I
was	O	AUX	O
demonstrated	O	VERB	O
both	O	CCONJ	O
in	O	ADP	O
myomas	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
surrounding	O	VERB	B
myometrium	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
similar	O	ADJ	O
pattern	O	NOUN	B
of	O	ADP	O
expression	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
leptin	O	NOUN	B
receptor	O	NOUN	I
isoforms	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
RT-PCR	O	NOUN	B
were	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
Western	O	NOUN	B
blotting	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
documented	O	VERB	B
the	O	DET	O
identical	O	ADJ	B
distribution	O	NOUN	B
of	O	ADP	O
leptin	B-OUT	NOUN	B
proteins	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
leptin	I-OUT	NOUN	B
receptor	I-OUT	NOUN	I
proteins	I-OUT	NOUN	I
in	O	ADP	O
studied	O	VERB	O
tissues	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
GnRH	B-I	NOUN	B
analogue	I-I	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	B-OUT	NOUN	I
on	O	ADP	O
the	O	DET	O
expression	B-OUT	NOUN	B
pattern	I-OUT	NOUN	O
of	O	ADP	O
studied	O	VERB	B
genes	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
on	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
GnRH	B-I	NOUN	B
analogue	I-I	NOUN	B
to	O	PART	O
females	B-P	NOUN	B
with	I-P	ADP	O
myomas	I-P	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
no	O	DET	O
direct	O	ADJ	O
or	O	CCONJ	O
immediate	O	ADJ	B
inter-relationship	O	NOUN	B
exists	O	VERB	O
between	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
leptin	B-OUT	NOUN	B
genes	I-OUT	NOUN	I
in	O	ADP	O
uterine	O	NOUN	B
myomas	O	NOUN	I
on	O	ADP	O
one	O	NUM	O
hand	O	NOUN	B
and	O	CCONJ	O
estrogen	O	NOUN	B
,	O	PUNCT	O
progesterone	O	NOUN	B
and	O	CCONJ	O
leptin	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
on	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


Expression	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
a	O	DET	O
more	O	ADV	O
durable	O	ADJ	O
nature	O	NOUN	B
but	O	CCONJ	O
factors	O	NOUN	B
that	O	PRON	O
induce	O	VERB	B
such	O	ADJ	O
expression	O	NOUN	B
remain	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


Four-year	O	ADJ	B
outcomes	O	NOUN	B
from	O	ADP	O
adolescent	B-I	ADJ	B
alcohol	I-I	NOUN	B
and	I-I	CCONJ	O
drug	I-I	NOUN	B
treatment	I-I	NOUN	I
.	I-I	PUNCT	O


OBJECTIVE	O	NOUN	O
Knowledge	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
response	O	NOUN	I
for	O	ADP	O
alcohol	O	NOUN	B
and	O	CCONJ	O
drug	O	NOUN	B
problems	O	NOUN	I
among	O	ADP	O
adults	O	NOUN	B
is	O	AUX	O
mounting	O	VERB	B
;	O	PUNCT	O
less	O	ADV	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
long-term	O	ADJ	B
outcome	O	NOUN	B
for	O	ADP	O
adolescents	B-P	NOUN	B
who	I-P	PRON	O
receive	I-P	VERB	B
treatment	I-I	NOUN	B
for	I-I	ADP	O
alcohol	I-I	NOUN	B
and	I-I	CCONJ	O
drug	I-I	NOUN	B
problems	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
examined	O	VERB	O
youth	O	NOUN	B
substance	O	NOUN	B
involvement	O	NOUN	B
over	O	ADP	O
4	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
using	O	VERB	O
five	O	NUM	O
waves	O	NOUN	O
of	O	ADP	O
data	O	NOUN	B
collection	O	NOUN	I
)	O	PUNCT	O
following	O	VERB	O
treatment	B-I	NOUN	B
for	I-I	ADP	O
alcohol	I-I	NOUN	B
and	I-I	CCONJ	O
drug	I-I	NOUN	B
abuse	I-I	NOUN	I
.	I-I	PUNCT	O


METHOD	O	NOUN	B
A	B-P	DET	O
cohort	I-P	NOUN	B
of	I-P	ADP	O
youth	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
162	I-P	NUM	O
,	I-P	PUNCT	O
60	I-P	NUM	O
%	I-P	NOUN	O
male	I-P	NOUN	B
)	I-P	PUNCT	O
treated	I-P	VERB	B
during	I-P	ADP	O
adolescence	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
=	I-P	ADJ	O
16	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
was	I-P	AUX	O
followed	I-P	VERB	O
into	I-P	ADP	O
young	I-P	ADJ	B
adulthood	I-P	NOUN	I
,	O	PUNCT	O
a	O	DET	O
period	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
stabilization	O	NOUN	B
of	O	ADP	O
alcohol	O	NOUN	B
use	O	NOUN	I
patterns	O	NOUN	I
and	O	CCONJ	O
elevated	O	ADJ	B
risk	O	NOUN	I
for	O	ADP	O
life	O	NOUN	B
problems	O	NOUN	I
secondary	O	ADJ	O
to	O	PART	O
both	O	CCONJ	O
alcohol	O	NOUN	B
and	O	CCONJ	O
drug	O	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


Participants	B-P	NOUN	B
(	I-P	PUNCT	O
14-18	I-P	NUM	O
years	I-P	NOUN	B
old	I-P	ADJ	I
)	I-P	PUNCT	O
were	I-P	AUX	O
consecutive	I-P	ADJ	B
admissions	I-P	NOUN	B
to	I-P	ADP	O
inpatient	I-P	ADJ	B
adolescent	I-P	ADJ	B
alcohol	I-P	NOUN	B
and	I-P	CCONJ	O
drug	I-P	NOUN	B
treatment	I-P	NOUN	I
centers	I-P	NOUN	I
in	I-P	ADP	O
San	I-P	PROPN	B
Diego	I-P	PROPN	I
that	I-P	PRON	O
were	I-P	AUX	O
abstinence	I-P	NOUN	B
focused	I-P	VERB	O
and	I-P	CCONJ	O
based	I-P	VERB	O
on	I-P	ADP	O
the	I-P	DET	O
12-step	I-P	ADJ	B
approach	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	VERB	B
Alcohol	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
other	I-OUT	ADJ	O
drug	I-OUT	NOUN	B
use	I-OUT	NOUN	I
were	O	AUX	O
reduced	O	VERB	B
during	O	ADP	O
the	O	DET	O
4	O	NUM	O
years	O	NOUN	B
posttreatment	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
exception	O	NOUN	O
of	O	ADP	O
nicotine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
greatest	O	ADJ	O
prevalence	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
occurred	O	VERB	O
for	O	ADP	O
stimulants	O	NOUN	B
;	O	PUNCT	O
modest	O	ADJ	O
changes	O	NOUN	B
were	O	AUX	O
evident	O	ADJ	O
in	O	ADP	O
alcohol	O	NOUN	B
and	O	CCONJ	O
marijuana	O	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


Nicotine	O	NOUN	B
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
commonly	O	ADV	O
used	O	VERB	O
substance	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
4	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Several	O	ADJ	O
distinct	O	ADJ	O
substance	O	NOUN	B
involvement	O	NOUN	B
trajectories	O	NOUN	B
were	O	AUX	O
evident	O	ADJ	O
during	O	ADP	O
the	O	DET	O
4	O	NUM	O
years	O	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Alcohol	O	PROPN	B
and	O	CCONJ	O
drug	O	NOUN	B
use	O	NOUN	I
patterns	O	NOUN	I
during	O	ADP	O
the	O	DET	O
4	O	NUM	O
years	O	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
highlight	O	VERB	O
both	O	CCONJ	O
changes	O	NOUN	B
and	O	CCONJ	O
diversity	O	NOUN	B
in	O	ADP	O
substance	O	NOUN	B
involvement	O	NOUN	B
as	O	ADP	O
youth	O	NOUN	B
make	O	VERB	O
the	O	DET	O
transitions	O	NOUN	B
from	O	ADP	O
middle	O	NOUN	O
to	O	PART	O
late	O	ADJ	B
adolescence	O	NOUN	I
and	O	CCONJ	O
into	O	ADP	O
young	O	ADJ	B
adulthood	O	NOUN	I
.	O	PUNCT	O


Findings	O	NOUN	B
demonstrate	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
identifying	O	VERB	B
transitional	O	ADJ	B
periods	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
alternative	O	ADJ	B
intervention	O	NOUN	B
strategies	O	NOUN	O
that	O	PRON	O
may	O	AUX	O
help	O	VERB	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
this	O	DET	O
population	O	NOUN	B
into	O	ADP	O
young	O	ADJ	B
adulthood	O	NOUN	I
.	O	PUNCT	O


POG	O	PROPN	B
8625	O	NUM	O
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
comparing	O	VERB	O
chemotherapy	B-I	NOUN	B
with	O	ADP	O
chemoradiotherapy	B-I	NOUN	B
for	I-P	ADP	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
Stages	I-P	NOUN	B
I	I-P	NUM	I
,	I-P	PUNCT	O
IIA	I-P	NOUN	B
,	I-P	PUNCT	O
IIIA1	I-P	NOUN	B
Hodgkin	I-P	NOUN	I
Disease	I-P	PROPN	I
:	I-P	PUNCT	O
a	O	DET	O
report	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
's	O	PART	I
Oncology	O	PROPN	B
Group	O	PROPN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
6	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
chemotherapy	B-I	NOUN	B
alone	O	ADV	O
could	O	AUX	O
achieve	O	VERB	O
the	O	DET	O
same	O	ADJ	O
or	O	CCONJ	O
better	O	ADJ	O
outcome	O	NOUN	B
than	O	ADP	O
4	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
chemotherapy	B-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
radiation	I-I	NOUN	B
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
chemoradiotherapy	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
pediatric	B-P	ADJ	B
and	I-P	CCONJ	O
adolescent	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
Hodgkin	I-P	NOUN	B
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Children	B-P	NOUN	B
<	I-P	PROPN	O
or	I-P	CCONJ	O
=21	I-P	NUM	O
years	I-P	NOUN	O
old	I-P	ADJ	O
with	I-P	ADP	O
biopsy-proven	I-P	ADJ	B
,	I-P	PUNCT	O
pathologically	I-P	ADV	B
staged	I-P	VERB	B
I	I-P	PRON	I
,	I-P	PUNCT	O
IIA	I-P	NOUN	B
,	I-P	PUNCT	O
or	I-P	CCONJ	O
IIIA1	I-P	NOUN	B
Hodgkin	I-P	NOUN	I
disease	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
6	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
alternating	B-I	VERB	B
nitrogen	I-I	NOUN	B
mustard	I-I	NOUN	I
,	I-I	PUNCT	O
oncovin	I-I	NOUN	B
,	I-I	PUNCT	O
prednisone	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
procarbazine/doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
bleomycin	I-I	NOUN	B
,	I-I	PUNCT	O
vinblastine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
dacarbazine	I-I	NOUN	B
(	I-I	PUNCT	O
treatment	I-I	NOUN	B
1	I-I	NUM	O
)	I-I	PUNCT	O
or	O	CCONJ	O
4	B-I	NUM	O
courses	I-I	NOUN	B
of	I-I	ADP	O
alternating	I-I	VERB	B
nitrogen	I-I	NOUN	B
mustard	I-I	NOUN	I
,	I-I	PUNCT	O
oncovin	I-I	NOUN	B
,	I-I	PUNCT	O
prednisone	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
procarbazine/doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
bleomycin	I-I	NOUN	B
,	I-I	PUNCT	O
vinblastine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
dacarbazine	I-I	NOUN	B
+2550	I-I	ADJ	O
cGy	I-I	NOUN	B
involved-field	I-I	ADJ	I
radiotherapy	I-I	NOUN	I
(	I-I	PUNCT	O
treatment	I-I	NOUN	B
2	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


The	O	DET	O
complete	O	ADJ	B
response	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
89	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
response	O	NOUN	B
and	O	CCONJ	O
partial	O	ADJ	B
response	O	NOUN	O
rate	O	NOUN	O
of	O	ADP	O
99.4	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
event-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
EFS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
between	O	ADP	O
arms	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
EFS	B-OUT	NOUN	B
for	O	ADP	O
those	O	DET	O
who	O	PRON	O
achieved	O	VERB	O
an	O	DET	O
early	O	ADJ	O
complete	B-OUT	ADJ	O
response	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
for	O	ADP	O
those	O	DET	O
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


For	O	ADP	O
pediatric	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
asymptomatic	I-P	ADJ	B
low-stage	I-P	ADJ	B
and	I-P	CCONJ	O
intermediate-stage	I-P	ADJ	B
Hodgkin	I-P	NOUN	I
disease	I-P	NOUN	I
,	O	PUNCT	O
chemotherapy	B-I	NOUN	B
and	O	CCONJ	O
chemoradiotherapy	B-I	NOUN	B
both	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
3-year	B-OUT	ADJ	O
EFS	I-OUT	NOUN	B
of	O	ADP	O
approximately	O	ADV	B
90	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
statistically	O	ADV	O
indistinguishable	O	ADJ	O
8-year	B-OUT	ADJ	O
EFS	I-OUT	NOUN	B
and	O	CCONJ	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	O	PUNCT	O
without	O	ADP	O
significant	O	ADJ	O
long-term	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Early	O	ADJ	B
response	B-OUT	NOUN	I
to	I-OUT	PART	O
therapy	I-OUT	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
higher	O	ADJ	O
EFS	B-OUT	NOUN	B
,	O	PUNCT	O
a	O	DET	O
concept	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
led	O	VERB	O
to	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
's	O	PART	I
Oncology	O	PROPN	B
Group	O	PROPN	I
paradigm	O	NOUN	B
of	O	ADP	O
response-based	O	ADJ	O
risk-adapted	O	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
pediatric	O	ADJ	B
Hodgkin	O	NOUN	B
disease	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Effects	O	NOUN	B
of	O	ADP	O
parecoxib	B-I	NOUN	B
on	O	ADP	O
morphine	B-I	NOUN	B
dosage	O	NOUN	B
in	O	ADP	O
postoperative	B-P	ADJ	B
patient-controlled	I-I	ADJ	B
analgesia	I-I	NOUN	I
following	O	VERB	O
thoracoscope-assisted	B-I	ADJ	B
thoracotomy	I-I	NOUN	I
]	I-I	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
observe	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
parecoxib	B-I	NOUN	B
on	O	ADP	O
morphine	O	NOUN	B
dosage	O	NOUN	B
in	O	ADP	O
patient-controlled	B-I	ADJ	B
analgesia	I-I	NOUN	I
(	I-I	PUNCT	O
PCA	I-I	NOUN	B
)	I-I	PUNCT	O
following	O	VERB	O
thoracoscope-assisted	B-I	ADJ	B
thoracotomy	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	VERB	O
A	B-P	DET	O
consecutive	I-P	ADJ	B
series	I-P	NOUN	B
of	I-P	ADP	O
100	I-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
thoracoscope-assisted	I-I	ADJ	B
thoracotomy	I-I	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
5	O	NUM	O
groups	O	NOUN	B
and	O	CCONJ	O
received	O	VERB	O
PCA	B-I	NOUN	B
with	I-I	ADP	O
morphine	I-I	NOUN	B
doses	O	NOUN	B
at	O	ADP	O
0	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
15	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
20	O	NUM	O
mg	O	NOUN	O
given	O	VERB	O
in	O	ADP	O
200	O	NUM	O
ml	O	NOUN	O
saline	B-I	NOUN	B
(	O	PUNCT	O
groups	O	NOUN	B
P	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
P	O	NOUN	O
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Parecoxib	B-I	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
in	O	ADP	O
all	O	DET	O
the	O	DET	O
patients	O	NOUN	B
immediately	O	ADV	O
before	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
mixture	O	NOUN	B
(	B-I	PUNCT	O
4-5	I-I	NUM	O
ml	I-I	NOUN	O
)	I-I	PUNCT	O
of	I-I	ADP	O
lidocaine	I-I	NOUN	B
and	I-I	CCONJ	O
ropivacaine	I-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
into	O	ADP	O
the	O	DET	O
3	O	NUM	O
intercostal	O	ADJ	B
spaces	O	NOUN	O
upper	O	ADJ	O
and	O	CCONJ	O
lower	O	ADJ	O
to	O	ADP	O
the	O	DET	O
incision	O	NOUN	B
before	O	ADP	O
chest	O	ADJ	B
closure	O	NOUN	I
.	O	PUNCT	O


PCA	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
for	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
visual	B-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
at	I-OUT	ADP	O
rest	I-OUT	NOUN	B
and	O	CCONJ	O
coughing	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
respiratory	I-OUT	ADJ	B
functional	I-OUT	ADJ	I
parameters	I-OUT	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
at	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
24	O	NUM	O
,	O	PUNCT	O
36	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
48	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
PCA	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
actual	O	ADJ	B
and	O	CCONJ	O
effective	O	ADJ	B
button-pressing	O	ADJ	B
times	O	NOUN	I
(	O	PUNCT	O
D	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
/D	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
in	O	ADP	O
PCA	B-I	NOUN	B
were	O	AUX	O
also	O	ADV	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
No	O	DET	O
patients	O	NOUN	B
showed	O	VERB	O
signs	B-OUT	NOUN	O
of	I-OUT	ADP	O
respiratory	I-OUT	ADJ	B
inhibition	I-OUT	NOUN	I
within	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
resting	B-OUT	VERB	B
VAS	I-OUT	NOUN	B
was	O	AUX	O
comparable	O	ADJ	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
within	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
6	O	NUM	O
postoperative	O	ADJ	B
hours	O	NOUN	O
.	O	PUNCT	O


At	O	ADP	O
8	O	NUM	O
to	O	PART	O
24	O	NUM	O
h	O	NOUN	O
postoperatively	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
VAS	B-OUT	PROPN	B
scores	I-OUT	NOUN	I
at	O	ADP	O
rest	O	NOUN	B
and	O	CCONJ	O
coughing	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
P	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
at	O	ADP	O
36	O	NUM	O
to	O	PART	O
48	O	NUM	O
h.	O	NOUN	O
D	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
/D	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
groups	O	NOUN	B
P	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
P	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
3	O	NUM	O
groups	O	NOUN	B
at	O	ADP	O
4-24	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
such	O	ADJ	O
difference	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
P	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
P	O	NOUN	O
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
application	O	NOUN	B
of	O	ADP	O
parecoxib	B-I	NOUN	B
may	O	AUX	O
reduce	O	VERB	O
the	O	DET	O
dosage	O	NOUN	B
of	O	ADP	O
morphine	B-I	NOUN	B
in	O	ADP	O
PCA	B-I	NOUN	B
following	O	VERB	O
thoracoscope-assisted	O	ADJ	B
thoracotomy	O	NOUN	I
and	O	CCONJ	O
results	O	VERB	B
in	O	ADP	O
good	O	ADJ	O
analgesic	O	NOUN	B
effect	O	NOUN	I
without	O	ADP	O
affecting	O	VERB	B
the	O	DET	O
patients	O	NOUN	B
respiratory	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
sputum	O	NOUN	B
elimination	O	NOUN	I
.	O	PUNCT	O


Adjuvant	O	ADJ	B
cyclophosphamide	B-I	NOUN	I
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
vincristine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
prednisone	I-I	NOUN	B
chemotherapy	I-I	NOUN	B
after	O	ADP	O
radiation	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
stage	B-P	NOUN	B
I	I-P	NUM	I
low-grade	I-P	ADJ	B
and	I-P	CCONJ	O
intermediate-grade	I-P	ADJ	B
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
In	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
manner	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
adjuvant	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
(	I-I	PUNCT	O
cyclophosphamide	I-I	NOUN	B
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
vincristine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
prednisone	I-I	NOUN	B
;	I-I	PUNCT	O
CHOP	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
Stage	I-P	NOUN	B
I	I-P	NUM	I
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
(	I-P	PUNCT	O
NHL	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
have	I-P	AUX	O
achieved	I-P	VERB	O
a	I-P	DET	O
complete	I-P	ADJ	O
response	I-P	NOUN	O
(	I-P	PUNCT	O
CR	I-P	NOUN	B
)	I-P	PUNCT	O
after	I-P	ADP	O
radiation	I-P	NOUN	B
therapy	I-P	NOUN	I
(	I-P	PUNCT	O
RT	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
Forty-four	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
clinical	I-P	ADJ	B
or	I-P	CCONJ	O
pathologic	I-P	ADJ	B
Stage	I-P	NOUN	I
I	I-P	NUM	I
intermediate-grade	I-P	ADJ	B
or	I-P	CCONJ	O
low-grade	I-P	ADJ	B
NHL	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	B-I	VERB	O
regional	I-I	ADJ	B
RT	I-I	NOUN	O
alone	I-I	ADV	O
(	I-I	PUNCT	O
median	I-I	ADJ	B
dose	I-I	NOUN	I
,	I-I	PUNCT	O
40	I-I	NUM	O
Gy	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
regional	I-I	ADJ	B
RT	I-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
six	I-I	NUM	O
cycles	I-I	NOUN	B
of	I-I	ADP	O
CHOP	I-I	NOUN	B
chemotherapy	I-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
pathologic	O	ADJ	B
characteristics	B-OUT	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
median	B-OUT	ADJ	B
follow-up	I-OUT	NOUN	B
was	O	AUX	O
7	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
2-10	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
actuarial	B-OUT	ADJ	O
relapse-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RFS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
rate	I-OUT	NOUN	B
for	O	ADP	O
the	O	DET	O
RT	O	NOUN	B
plus	O	CCONJ	O
CHOP	O	NOUN	B
group	O	NOUN	B
at	O	ADP	O
7	O	NUM	O
years	O	NOUN	B
was	O	AUX	O
83	O	NUM	O
%	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
47	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.03	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
RT-alone	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
was	O	AUX	O
88	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
66	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
intermediate-grade	O	ADJ	B
NHL	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
7-year	B-OUT	ADJ	O
actuarial	I-OUT	ADJ	B
RFS	I-OUT	NOUN	B
for	O	ADP	O
RT	O	NOUN	B
and	O	CCONJ	O
CHOP	O	NOUN	B
was	O	AUX	O
86	O	NUM	O
%	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
RT	O	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
corresponding	B-OUT	ADJ	O
actuarial	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
92	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
47	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.08	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
low-grade	O	ADJ	B
histologic	O	ADJ	B
findings	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
adjuvant	O	ADJ	B
CHOP	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
RFS	B-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.6	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
OS	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
relapses	O	NOUN	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
were	O	AUX	O
at	O	ADP	O
sites	O	NOUN	B
remote	O	ADJ	B
from	O	ADP	O
the	O	DET	O
initially	O	ADV	B
involved	O	VERB	O
areas	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
5	O	NUM	O
of	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
45	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
recurrences	O	NOUN	B
5	O	NUM	O
years	O	NOUN	B
or	O	CCONJ	O
longer	O	ADV	B
after	O	ADP	O
initial	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
adjuvant	O	ADJ	B
CHOP	B-I	NOUN	B
chemotherapy	I-I	NOUN	B
significantly	O	ADV	O
improves	O	VERB	O
RFS	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Stage	O	NOUN	B
I	O	NUM	I
intermediate-grade	O	ADJ	I
NHL	O	NOUN	I
who	O	PRON	O
achieve	O	VERB	O
a	O	DET	O
CR	O	NOUN	B
after	O	ADP	O
regional-field	O	ADJ	B
RT	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
chemotherapeutic	O	ADJ	B
regimen	O	NOUN	I
favorably	O	ADV	O
affected	O	VERB	B
their	O	PRON	O
probability	B-OUT	NOUN	B
of	O	ADP	O
survival	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Fadrozole	B-I	NOUN	B
HCL	I-I	NOUN	B
(	I-I	PUNCT	O
CGS-16949A	I-I	NOUN	B
)	I-I	PUNCT	O
versus	O	CCONJ	O
megestrol	B-I	NOUN	B
acetate	I-I	NOUN	B
treatment	O	NOUN	I
of	O	ADP	O
postmenopausal	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
breast	I-P	NOUN	I
carcinoma	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
randomized	O	ADJ	B
double	O	ADJ	O
blind	O	ADJ	O
controlled	O	VERB	O
multiinstitutional	O	ADJ	O
trials	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Breast	B-P	NOUN	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
prior	I-P	ADJ	O
response	I-P	NOUN	B
to	I-P	PART	O
endocrine	I-P	ADJ	B
therapy	I-P	NOUN	I
achieve	O	VERB	O
subsequent	O	ADJ	O
benefit	O	NOUN	B
from	O	ADP	O
additional	O	ADJ	O
endocrine	O	ADJ	B
therapies	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
an	O	DET	O
aromatase	O	NOUN	B
inhibitor	O	NOUN	I
,	O	PUNCT	O
fadrozole	B-I	NOUN	B
HCL	I-I	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
compared	O	VERB	O
with	O	ADP	O
megestrol	O	NOUN	B
acetate	O	NOUN	B
in	O	ADP	O
post	B-P	NOUN	B
menopausal	I-P	ADJ	B
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
disease	I-P	NOUN	B
progression	I-P	NOUN	I
after	I-P	ADP	O
receiving	I-P	VERB	O
antiestrogen	I-P	NOUN	B
therapy	I-P	NOUN	I
either	I-P	CCONJ	O
for	I-P	ADP	O
metastatic	I-P	ADJ	B
disease	I-P	NOUN	I
or	I-P	CCONJ	O
as	I-P	ADP	O
adjuvant	I-P	ADJ	B
therapy	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
In	B-P	ADP	O
2	I-P	NUM	O
multiinstitutional	I-P	ADJ	B
prospective	I-P	ADJ	I
trials	I-P	NOUN	I
,	I-P	PUNCT	O
683	I-P	NUM	O
postmenopausal	I-P	ADJ	B
patients	I-P	NOUN	B
were	O	AUX	O
randomized	B-I	VERB	B
to	I-I	PART	O
receive	I-I	VERB	O
either	I-I	CCONJ	O
fadrozole	I-I	NOUN	B
HCL	I-I	NOUN	B
,	I-I	PUNCT	O
1	I-I	NUM	O
mg	I-I	NOUN	O
twice	I-I	ADV	O
daily	I-I	ADV	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
megestrol	I-I	NOUN	B
acetate	I-I	NOUN	B
,	I-I	PUNCT	O
40	I-I	NUM	O
mg	I-I	NOUN	O
4	I-I	NUM	O
times	I-I	NOUN	O
daily	I-I	ADV	B
,	I-I	PUNCT	O
in	I-I	ADP	O
a	I-I	DET	O
double	I-I	ADJ	O
blind	I-I	ADJ	O
fashion	I-I	NOUN	O
after	I-I	ADP	O
progression	I-I	NOUN	B
on	I-I	ADP	O
first-line	I-I	ADJ	B
hormonal	I-I	ADJ	I
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


Objective	B-OUT	ADJ	B
response	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
time	I-OUT	NOUN	O
to	I-OUT	PART	O
progression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
survival	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
regimens	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Results	O	NOUN	O
of	O	ADP	O
intent-to-treat	O	ADJ	B
analyses	O	NOUN	I
are	O	AUX	O
presented	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
detected	O	VERB	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
in	O	ADP	O
time	B-OUT	NOUN	O
to	I-OUT	PART	O
progression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
objective	I-OUT	ADJ	O
response	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	I
response	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
in	O	ADP	O
either	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
clinically	O	ADV	O
meaningful	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
groups	O	NOUN	I
in	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
adverse	B-OUT	ADJ	B
experiences	I-OUT	NOUN	I
,	O	PUNCT	O
except	O	SCONJ	O
that	O	SCONJ	O
weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
fluid	I-OUT	ADJ	B
retention	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
dyspnea	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
more	O	ADJ	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
megestrol	O	NOUN	B
acetate	O	NOUN	B
group	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
receiving	O	VERB	O
fadrozole	O	NOUN	B
HCL	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
nausea	B-OUT	NOUN	B
and	I-OUT	CCONJ	I
vomiting	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
more	O	ADJ	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
fadrozole	O	NOUN	B
HCL	O	NOUN	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
receiving	O	VERB	O
megestrol	O	NOUN	B
acetate	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Fadrozole	B-I	NOUN	B
HCL	I-I	NOUN	B
was	O	AUX	O
as	O	ADV	O
efficacious	B-OUT	ADJ	B
as	O	ADP	O
megestrol	O	NOUN	B
acetate	O	NOUN	B
in	O	ADP	O
postmenopausal	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
breast	I-P	NOUN	I
carcinoma	I-P	NOUN	I
after	O	ADP	O
one	O	NUM	O
hormonal	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Adverse	O	ADJ	B
experiences	O	NOUN	B
were	O	AUX	O
mild	O	ADJ	B
with	O	ADP	O
both	O	DET	O
therapies	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
megestrol	O	NOUN	B
acetate	O	NOUN	B
was	O	AUX	O
associated	O	VERB	O
wiht	O	ADJ	B
a	O	DET	O
higher	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
fluid	I-OUT	ADJ	B
retention	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
dyspnea	I-OUT	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
fadrozole	B-I	NOUN	B
HCL	I-I	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
higher	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
nausea	B-OUT	NOUN	B
and	I-OUT	CCONJ	I
vomiting	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Immunologic	O	ADJ	B
and	O	CCONJ	O
hemodynamic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
"	B-I	PUNCT	O
low-dose	I-I	ADJ	B
"	I-I	PUNCT	O
hydrocortisone	I-I	NOUN	B
in	O	ADP	O
septic	B-P	ADJ	B
shock	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
last	O	ADJ	O
few	O	ADJ	O
years	O	NOUN	B
,	O	PUNCT	O
increasing	O	VERB	B
evidence	O	NOUN	B
of	O	ADP	O
relative	O	ADJ	B
adrenal	B-P	ADJ	I
insufficiency	I-P	NOUN	I
in	I-P	ADP	O
septic	I-P	ADJ	B
shock	I-P	NOUN	I
evoked	O	VERB	O
a	O	DET	O
reassessment	O	NOUN	B
of	O	ADP	O
hydrocortisone	B-I	NOUN	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
hydrocortisone	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
balance	O	NOUN	B
between	O	ADP	O
proinflammatory	O	ADJ	B
and	O	CCONJ	O
antiinflammation	O	NOUN	B
,	O	PUNCT	O
40	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
septic	I-P	ADJ	B
shock	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
crossover	O	NOUN	B
study	O	NOUN	I
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
the	O	DET	O
first	O	ADJ	O
100	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
hydrocortisone	B-I	NOUN	B
as	O	ADP	O
a	O	DET	O
loading	O	NOUN	B
dose	O	NOUN	I
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
hour	O	NOUN	O
until	O	ADP	O
Day	O	PROPN	B
3	O	NUM	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
the	O	DET	O
opposite	O	ADJ	O
medication	O	NOUN	B
until	O	ADP	O
Day	O	NOUN	B
6	O	NUM	O
.	O	PUNCT	O


Hydrocortisone	B-I	NOUN	B
infusion	O	NOUN	B
induced	O	VERB	B
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
mean	B-OUT	ADJ	O
arterial	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
systemic	I-OUT	ADJ	B
vascular	I-OUT	ADJ	B
resistance	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
decline	O	NOUN	B
of	O	ADP	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
cardiac	I-OUT	ADJ	B
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
norepinephrine	I-OUT	NOUN	B
requirement	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
plasma	B-OUT	NOUN	B
nitrite/nitrate	I-OUT	NOUN	B
indicated	O	VERB	O
inhibition	O	NOUN	B
of	O	ADP	O
nitric	B-OUT	ADJ	B
oxide	I-OUT	NOUN	I
formation	I-OUT	NOUN	B
and	O	CCONJ	O
correlated	O	VERB	B
with	O	ADP	O
a	O	DET	O
reduction	B-OUT	NOUN	B
of	I-OUT	ADP	O
vasopressor	I-OUT	ADJ	B
support	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
inflammatory	B-OUT	ADJ	B
response	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
interleukin-6	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
interleukin-8	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
endothelial	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
soluble	I-OUT	ADJ	B
E-selectin	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
neutrophil	I-OUT	NOUN	B
activation	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
expression	I-OUT	NOUN	B
of	I-OUT	ADP	O
CD11b	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
CD64	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
antiinflammatory	I-OUT	ADJ	B
response	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
soluble	I-OUT	ADJ	B
tumor	I-OUT	NOUN	B
necrosis	I-OUT	NOUN	I
factor	I-OUT	NOUN	I
receptors	I-OUT	NOUN	I
I	I-OUT	NUM	I
and	I-OUT	CCONJ	O
II	I-OUT	NUM	B
and	I-OUT	CCONJ	O
interleukin-10	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
attenuated	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
monocytes	O	NOUN	I
,	O	PUNCT	O
human	B-OUT	ADJ	B
leukocyte	I-OUT	NOUN	B
antigen-DR	I-OUT	ADJ	B
expression	I-OUT	NOUN	B
was	O	AUX	O
only	O	ADV	O
slightly	O	ADV	O
depressed	O	ADJ	B
,	O	PUNCT	O
whereas	O	SCONJ	O
in	B-OUT	X	B
vitro	I-OUT	X	I
phagocytosis	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
monocyte-activating	I-OUT	ADJ	B
cytokine	I-OUT	NOUN	B
interleukin-12	I-OUT	NOUN	I
increased	O	VERB	B
.	O	PUNCT	O


Hydrocortisone	B-I	NOUN	B
withdrawal	O	NOUN	B
induced	O	VERB	B
hemodynamic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
immunologic	I-OUT	ADJ	B
rebound	I-OUT	NOUN	O
effects	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
hydrocortisone	B-I	NOUN	B
therapy	I-I	NOUN	I
restored	O	VERB	B
hemodynamic	B-OUT	ADJ	B
stability	I-OUT	NOUN	I
and	O	CCONJ	O
differentially	O	ADV	B
modulated	O	VERB	B
the	O	DET	O
immunologic	B-OUT	ADJ	B
response	I-OUT	NOUN	I
to	I-OUT	PART	O
stress	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
way	O	NOUN	O
of	O	ADP	O
antiinflammation	O	NOUN	B
rather	O	ADV	O
than	O	ADP	O
immunosuppression	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Effect	O	NOUN	B
of	O	ADP	O
Selaginella	B-I	NOUN	B
combined	O	VERB	B
with	O	ADP	O
radiotherapy	B-I	NOUN	B
on	O	ADP	O
nasopharyngeal	B-P	ADJ	B
carcinoma	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
observe	O	VERB	O
the	O	DET	O
Chinese	O	ADJ	B
herbal	O	ADJ	I
medicine	O	NOUN	I
Selaginella-induced	O	ADJ	B
radiosensitization	O	NOUN	B
of	O	ADP	O
terminal	B-P	ADJ	B
nasopharyngeal	I-P	ADJ	O
carcinoma	I-P	NOUN	O
(	I-P	PUNCT	O
NPC	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
Totally	O	ADV	O
180	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
NPC	I-P	NOUN	B
were	O	AUX	O
divided	O	VERB	O
equally	O	ADV	O
into	O	ADP	O
3	O	NUM	O
groups	O	NOUN	B
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
radiotherapeutic	O	ADJ	B
protocols	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
group	B-I	NOUN	B
A	I-I	NOUN	O
received	I-I	VERB	O
radiotherapy	I-I	NOUN	B
alone	I-I	ADV	O
,	I-I	PUNCT	O
those	I-I	DET	O
in	I-I	ADP	O
group	I-I	NOUN	B
B	I-I	NOUN	I
were	I-I	AUX	O
given	I-I	VERB	O
daily	I-I	ADJ	O
Selaginella	I-I	NOUN	B
(	I-I	PUNCT	O
30	I-I	NUM	O
g	I-I	NOUN	O
)	I-I	PUNCT	O
prepared	I-I	VERB	O
into	I-I	ADP	O
50	I-I	NUM	O
ml	I-I	NOUN	O
decoction	I-I	NOUN	B
during	I-I	ADP	O
the	I-I	DET	O
entire	I-I	ADJ	O
course	I-I	NOUN	B
of	I-I	ADP	O
radiotherapy	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
those	O	DET	O
in	O	ADP	O
group	B-I	NOUN	B
C	I-I	NOUN	I
had	I-I	AUX	O
Selaginella	I-I	NOUN	B
30	I-I	NUM	O
g	I-I	NOUN	O
daily	I-I	ADV	B
in	I-I	ADP	O
the	I-I	DET	O
late	I-I	ADJ	O
course	I-I	NOUN	O
of	I-I	ADP	O
radiotherapy	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
complete	B-OUT	ADJ	O
remission	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
nasopharyngeal	I-OUT	ADJ	B
primary	I-OUT	ADJ	O
lesions	I-OUT	NOUN	O
in	O	ADP	O
groups	O	NOUN	B
B	O	NOUN	I
and	O	CCONJ	O
C	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
also	O	ADV	O
significantly	O	ADV	O
higher	O	ADJ	O
complete	O	ADJ	O
remission	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
cervical	I-OUT	ADJ	B
lymph	I-OUT	NOUN	I
nodes	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
acute	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
skin	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mucous	I-OUT	ADJ	B
membrane	I-OUT	NOUN	I
was	O	AUX	O
milder	O	ADJ	B
in	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
two	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Selaginella	B-I	PROPN	B
may	O	AUX	O
induce	O	VERB	B
radiosensitization	O	NOUN	B
for	O	ADP	O
terminal	B-P	ADJ	B
NPC	I-P	NOUN	B
and	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
increase	O	VERB	B
the	O	DET	O
acute	O	ADJ	B
toxicity	O	NOUN	B
of	O	ADP	O
radiotherapy	O	NOUN	B
.	O	PUNCT	O


Relationship	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
gammaglobulin	B-I	NOUN	I
to	O	PART	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
infections	O	NOUN	B
in	O	ADP	O
adults	B-P	NOUN	B
with	I-P	ADP	O
common	I-P	ADJ	O
variable	I-P	ADJ	B
immunodeficiency	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	O
clinical	O	ADJ	B
efficacy	O	NOUN	I
of	O	ADP	O
3	O	NUM	O
dosages	O	NOUN	B
of	O	ADP	O
intravenous	B-I	ADJ	B
gammaglobulins	I-I	NOUN	O
to	O	PART	O
prevent	O	VERB	O
infectious	O	ADJ	B
episodes	O	NOUN	I
in	O	ADP	O
adult	O	ADJ	B
common	O	ADJ	O
variable	O	ADJ	B
immunodeficiency	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
designed	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	NOUN	B
,	O	PUNCT	O
dose-assessing	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


The	B-P	DET	O
setting	I-P	NOUN	O
was	I-P	AUX	O
at	I-P	ADP	O
University	I-P	PROPN	B
Hospital	I-P	PROPN	I
,	I-P	PUNCT	O
Out-patient	I-P	ADJ	B
Clinic	I-P	PROPN	I
.	I-P	PUNCT	O


Our	O	PRON	O
patients	B-P	NOUN	B
were	I-P	AUX	O
twenty-one	I-P	NUM	O
adult	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
common	I-P	ADJ	O
variable	I-P	ADJ	B
immunodeficiency	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
measurements	O	NOUN	B
were	O	AUX	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
number	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
infections	I-OUT	NOUN	B
using	O	VERB	O
3	O	NUM	O
various	O	ADJ	O
dosages	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
gammaglobulins	B-I	NOUN	O
,	O	PUNCT	O
each	O	DET	O
given	O	VERB	O
monthly	O	NOUN	B
for	O	ADP	O
M	O	NOUN	B
least	O	ADJ	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
indicated	O	VERB	O
four	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
eighty-four	O	NUM	O
infectious	B-OUT	ADJ	B
episodes	I-OUT	NOUN	I
occurred	O	VERB	O
while	O	SCONJ	O
giving	O	VERB	O
305	B-I	NUM	O
infusions	I-I	NOUN	B
of	I-I	ADP	O
IVIG	I-I	NOUN	B
200	I-I	NUM	O
mg/kg	I-I	NOUN	O
;	I-I	PUNCT	O
205	O	NUM	O
infectious	O	ADJ	B
episodes	O	NOUN	I
while	O	SCONJ	O
giving	O	VERB	O
170	B-I	NUM	O
infusions	I-I	NOUN	B
of	I-I	ADP	O
400	I-I	NUM	O
mg/kg	I-I	NOUN	O
and	O	CCONJ	O
436	O	NUM	O
infectious	O	ADJ	B
episodes	O	NOUN	I
while	O	SCONJ	O
giving	O	VERB	O
247	B-I	NUM	O
infusions	I-I	NOUN	B
of	I-I	ADP	O
600	I-I	NUM	O
mg/kg	I-I	NOUN	O
.	I-I	PUNCT	O


The	O	DET	O
morbidity	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
infection/infusion	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
1.59	O	NUM	O
,	O	PUNCT	O
1.21	O	NUM	O
and	O	CCONJ	O
1.77	O	NUM	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	B
-	O	PUNCT	O
N/S	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
severity	B-OUT	NOUN	B
of	I-OUT	ADP	O
infections	I-OUT	NOUN	B
on	O	ADP	O
the	O	DET	O
above	O	ADJ	O
3	O	NUM	O
dosages	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
infection-free	I-OUT	ADJ	B
intervals	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
conclusions	O	NOUN	O
resulted	O	VERB	O
in	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
morbidity	B-OUT	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
common	O	ADJ	O
variable	O	ADJ	B
immunodeficiency	O	NOUN	I
treated	O	VERB	B
in	O	ADP	O
cross-over	O	ADJ	B
pattern	O	NOUN	I
with	O	ADP	O
IVIG	O	NOUN	B
200	O	NUM	O
mg/kg	O	NOUN	O
,	O	PUNCT	O
400	O	NUM	O
mg/kg	O	NOUN	O
and	O	CCONJ	O
600	O	NUM	O
mg/kg	O	NOUN	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
high	O	ADJ	O
dosages	O	NOUN	B
of	O	ADP	O
IVIG	O	NOUN	B
are	O	AUX	O
not	O	PART	O
conferring	O	VERB	O
better	O	ADJ	O
protection	O	NOUN	B
against	O	ADP	O
infections	O	NOUN	B
in	O	ADP	O
such	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


Low-dose	O	ADJ	B
versus	O	CCONJ	O
standard-dose	O	ADJ	B
gemcitabine	B-I	NOUN	B
infusion	I-I	NOUN	B
and	O	CCONJ	O
cisplatin	B-I	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
bladder	I-P	NOUN	I
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
trial-an	O	ADJ	O
update	O	NOUN	B
.	O	PUNCT	O


Prolonged	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
low-dose	O	ADJ	B
gemcitabine	B-I	NOUN	O
and	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
(	I-I	PUNCT	O
GC	I-I	NOUN	B
)	I-I	PUNCT	O
proved	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
bladder	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
twenty	I-P	NUM	O
untreated	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
stage	I-P	NOUN	B
III/IV	I-P	NUM	I
bladder	I-P	NOUN	I
cancer	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
gemcitabine	B-I	NOUN	B
(	O	PUNCT	O
250	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
6-h	O	ADJ	O
infusion	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
,	O	PUNCT	O
and	B-I	CCONJ	O
cisplatin	I-I	NOUN	B
(	O	PUNCT	O
70	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
on	O	ADP	O
day	O	NOUN	B
2	O	NUM	O
every	O	DET	O
21-day	O	ADJ	O
cycle	O	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	O
1	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
gemcitabine	B-I	NOUN	B
(	O	PUNCT	O
1,250	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
30-min	O	ADJ	O
infusion	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
cisplatin	B-I	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	B
2	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
92	B-P	NUM	O
males	I-P	NOUN	B
and	I-P	CCONJ	O
28	I-P	NUM	O
females	I-P	NOUN	B
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
had	I-P	AUX	O
a	I-P	DET	O
median	I-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
62	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
range	I-P	NOUN	O
40-85	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Among	O	ADP	O
the	O	DET	O
120	O	NUM	O
patient	O	NOUN	B
,	O	PUNCT	O
complete	O	ADJ	B
response	O	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
11.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
7/60	O	NUM	O
patients	O	NOUN	B
of	O	ADP	O
arm	O	NOUN	B
1	O	NUM	I
)	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
3/60	O	NUM	O
patients	O	NOUN	B
of	O	ADP	O
arm	O	NOUN	B
2	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


Eighteen	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
arm	O	NOUN	B
1	O	NUM	I
(	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
17	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
28.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
arm	O	NOUN	B
2	O	NUM	I
had	O	AUX	O
partial	O	ADJ	B
response	O	NOUN	O
on	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
overall	B-OUT	ADJ	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
arm	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
arm	O	NOUN	B
2	O	NUM	I
was	O	AUX	O
41.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
25/60	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
33.3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
20/60	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.37	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
median	B-OUT	ADJ	B
time	I-OUT	NOUN	O
to	I-OUT	PART	O
disease	I-OUT	NOUN	B
progression	I-OUT	NOUN	I
(	O	PUNCT	O
26	O	NUM	O
vs.	O	CCONJ	O
24	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
12	O	NUM	O
vs.	O	CCONJ	O
16	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
1-year	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
49.9	O	NUM	O
vs.	O	CCONJ	O
54.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.8	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
detected	O	VERB	B
between	O	ADP	O
arms	O	NOUN	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Main	B-OUT	ADJ	O
toxicities	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
arms	O	NOUN	O
with	O	ADP	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	B
.	O	PUNCT	O


Low-dose	O	NOUN	B
,	O	PUNCT	O
prolonged	O	ADJ	B
infusion	O	NOUN	B
gemcitabine	B-I	NOUN	B
in	I-I	ADP	O
combination	I-I	NOUN	B
with	I-I	ADP	O
cisplatin	I-I	NOUN	B
is	O	AUX	O
not	O	PART	O
inferior	O	ADJ	O
to	O	PART	O
the	O	DET	O
standard	B-I	ADJ	B
GC	I-I	NOUN	B
regimen	I-I	NOUN	B
with	O	ADP	O
favorable	O	ADJ	O
toxicity	B-OUT	NOUN	B
profile	I-OUT	NOUN	O
and	O	CCONJ	O
less	O	ADJ	O
financial	B-OUT	ADJ	B
costs	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Inhibition	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
seasonal	I-OUT	ADJ	B
IgE	I-OUT	NOUN	I
increase	I-P	NOUN	B
to	I-P	PART	O
Dactylis	I-P	PROPN	B
glomerata	I-P	NOUN	I
by	O	ADP	O
daily	B-I	ADJ	O
sodium	I-I	NOUN	B
chloride	I-I	NOUN	I
nasal-sinus	I-I	NOUN	B
irrigation	I-I	NOUN	B
during	O	ADP	O
the	O	DET	O
grass	O	NOUN	B
pollen	O	NOUN	B
season	O	NOUN	B
.	O	PUNCT	O


Recommendations	O	NOUN	B
for	O	ADP	O
implementing	O	VERB	B
stereotactic	B-I	ADJ	B
radiotherapy	I-I	NOUN	I
in	O	ADP	O
peripheral	B-P	ADJ	B
stage	I-P	NOUN	I
IA	I-P	NOUN	B
non-small	I-P	NOUN	I
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
report	O	VERB	B
from	O	ADP	O
the	O	DET	O
Quality	O	PROPN	B
Assurance	O	PROPN	I
Working	O	PROPN	I
Party	O	PROPN	I
of	O	ADP	I
the	O	DET	I
randomised	O	ADJ	B
phase	O	NOUN	I
III	O	NUM	I
ROSEL	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
A	O	NOUN	O
phase	O	NOUN	O
III	O	NUM	O
multi-centre	O	ADJ	O
randomised	O	ADJ	O
trial	O	NOUN	O
(	O	PUNCT	O
ROSEL	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
initiated	O	VERB	O
to	O	PART	O
establish	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
stereotactic	B-I	ADJ	B
radiotherapy	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
operable	I-P	ADJ	B
stage	I-P	NOUN	I
IA	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Due	O	ADP	O
to	O	PART	O
rapid	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
radiotherapy	O	NOUN	B
technology	O	NOUN	I
and	O	CCONJ	O
evolving	O	ADJ	B
techniques	O	NOUN	B
for	O	ADP	O
image-guided	O	ADJ	B
delivery	O	NOUN	I
,	O	PUNCT	O
guidelines	O	NOUN	B
had	O	AUX	O
to	O	PART	O
be	O	AUX	O
developed	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
ensure	O	VERB	O
uniformity	O	NOUN	B
in	O	ADP	O
implementation	O	NOUN	B
of	O	ADP	O
stereotactic	B-I	ADJ	B
radiotherapy	I-I	NOUN	I
in	O	ADP	O
this	O	DET	O
multi-centre	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


METHODS/DESIGN	O	NOUN	B
A	O	PROPN	O
Quality	O	PROPN	O
Assurance	O	PROPN	O
Working	O	PROPN	O
Party	O	PROPN	O
was	O	AUX	O
formed	O	VERB	O
by	O	ADP	O
radiation	O	NOUN	B
oncologists	O	NOUN	I
and	O	CCONJ	O
clinical	O	ADJ	B
physicists	O	NOUN	I
from	O	ADP	O
both	O	CCONJ	O
academic	O	ADJ	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
non-academic	O	ADJ	B
hospitals	O	NOUN	I
that	O	PRON	O
had	O	AUX	O
already	O	ADV	O
implemented	O	VERB	O
stereotactic	B-I	ADJ	B
radiotherapy	I-I	NOUN	I
for	O	ADP	O
lung	O	NOUN	B
cancer	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
literature	B-I	NOUN	B
survey	I-I	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
and	O	CCONJ	O
consensus	O	NOUN	B
meetings	O	NOUN	I
were	O	AUX	O
held	O	VERB	O
in	O	ADP	O
which	O	DET	O
both	O	CCONJ	O
the	O	DET	O
knowledge	O	NOUN	B
from	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
experience	O	NOUN	O
were	O	AUX	O
pooled	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
a	B-P	DET	O
planning	I-P	NOUN	B
study	I-P	NOUN	I
was	I-P	AUX	O
performed	I-P	VERB	O
in	I-P	ADP	O
26	I-P	NUM	O
stage	I-P	NOUN	B
I	I-P	NUM	I
patients	I-P	NOUN	B
,	I-P	PUNCT	O
of	I-P	ADP	O
which	I-P	DET	O
22	I-P	NUM	O
were	I-P	AUX	O
stage	I-P	NOUN	B
1A	I-P	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
develop	O	VERB	O
and	O	CCONJ	O
evaluate	O	VERB	B
the	O	DET	O
planning	O	NOUN	B
guidelines	O	NOUN	I
.	O	PUNCT	O


Plans	O	NOUN	B
were	O	AUX	O
optimised	O	VERB	O
according	O	VERB	O
to	O	ADP	O
parameters	O	NOUN	B
adopted	O	VERB	O
from	O	ADP	O
RTOG	O	PROPN	B
trials	O	NOUN	B
using	O	VERB	O
both	O	CCONJ	O
an	O	DET	O
algorithm	O	NOUN	B
with	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
homogeneity	O	NOUN	O
correction	O	NOUN	O
(	O	PUNCT	O
Type	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
more	O	ADV	O
advanced	B-I	ADJ	B
algorithm	I-I	NOUN	I
(	O	PUNCT	O
Type	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Dose	O	NOUN	B
conformity	O	NOUN	O
requirements	O	NOUN	B
were	O	AUX	O
then	O	ADV	O
formulated	O	VERB	O
based	O	VERB	O
on	O	ADP	O
these	O	DET	O
results	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Based	O	VERB	O
on	O	ADP	O
current	O	ADJ	O
literature	O	NOUN	B
and	O	CCONJ	O
expert	O	ADJ	B
experience	O	NOUN	B
,	O	PUNCT	O
guidelines	B-OUT	NOUN	B
were	I-OUT	AUX	O
formulated	I-OUT	VERB	O
for	I-OUT	ADP	O
this	I-OUT	DET	O
phase	I-OUT	NOUN	B
III	I-OUT	NUM	I
study	I-OUT	NOUN	I
of	I-OUT	ADP	O
stereotactic	I-OUT	ADJ	B
radiotherapy	I-OUT	NOUN	I
versus	I-OUT	CCONJ	O
surgery	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
guidelines	O	NOUN	B
can	O	AUX	O
serve	O	VERB	O
to	O	PART	O
facilitate	O	VERB	O
the	O	DET	O
design	O	NOUN	B
of	O	ADP	O
future	O	ADJ	O
multi-centre	O	ADJ	B
clinical	O	ADJ	I
trials	O	NOUN	I
of	O	ADP	O
stereotactic	B-I	ADJ	B
radiotherapy	I-I	NOUN	I
in	O	ADP	O
other	O	ADJ	O
patient	O	NOUN	B
groups	O	NOUN	I
and	O	CCONJ	O
aid	O	VERB	O
a	O	DET	O
more	O	ADV	O
uniform	O	ADJ	B
implementation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
technique	O	NOUN	B
outside	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
bexarotene	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
psoralen-ultraviolet	I-I	ADJ	B
A	I-I	NOUN	I
(	I-I	PUNCT	O
PUVA	I-I	NOUN	B
)	I-I	PUNCT	O
compared	I-I	VERB	B
with	I-I	ADP	O
PUVA	I-I	NOUN	B
treatment	I-I	NOUN	B
alone	I-I	ADV	O
in	O	ADP	O
stage	O	NOUN	B
IB-IIA	O	NOUN	I
mycosis	O	NOUN	I
fungoides	O	NOUN	I
:	O	PUNCT	O
final	O	ADJ	O
results	O	NOUN	B
from	O	ADP	O
the	O	DET	O
EORTC	O	PROPN	B
Cutaneous	B-P	PROPN	I
Lymphoma	I-P	NOUN	I
Task	I-P	PROPN	I
Force	I-P	PROPN	I
phase	I-P	NOUN	I
III	I-P	NUM	I
randomized	I-P	ADJ	O
clinical	I-P	ADJ	O
trial	I-P	NOUN	O
(	O	PUNCT	O
NCT00056056	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Psoralen	B-I	NOUN	B
plus	I-I	CCONJ	I
ultraviolet	I-I	NOUN	B
A	I-I	NOUN	I
(	I-I	PUNCT	O
PUVA	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
the	O	DET	O
standard	O	ADJ	B
treatment	O	NOUN	I
for	O	ADP	O
early	B-P	ADJ	B
stages	I-P	NOUN	I
of	I-P	ADP	O
mycosis	I-P	NOUN	B
fungoides	I-P	NOUN	I
.	I-P	PUNCT	O


There	O	PRON	O
have	O	AUX	O
been	O	AUX	O
no	O	DET	O
adequate	O	ADJ	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trials	O	NOUN	I
with	O	ADP	O
sufficient	O	ADJ	O
power	O	NOUN	O
comparing	O	VERB	B
this	O	DET	O
modality	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
therapies	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
disease	B-OUT	NOUN	B
response	I-OUT	NOUN	I
and	O	CCONJ	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
response	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
PUVA	I-I	NOUN	B
alone	I-I	ADV	O
or	I-P	CCONJ	O
PUVA	I-I	NOUN	B
and	I-I	CCONJ	O
bexarotene	I-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	PROPN	O
EORTC	O	NOUN	O
21011	O	NUM	O
(	O	PUNCT	O
NCT	O	NOUN	B
00056056	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
III	O	NUM	I
study	O	NOUN	I
comparing	O	VERB	O
combined	B-I	ADJ	O
bexarotene	I-I	NOUN	B
(	I-I	PUNCT	O
Targretin	I-I	NOUN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
PUVA	I-I	NOUN	B
vs.	I-I	CCONJ	O
PUVA	I-I	NOUN	B
alone	I-I	ADV	O
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
stage	I-P	NOUN	B
IB	I-P	NOUN	I
and	I-P	CCONJ	O
IIA	I-P	NOUN	B
mycosis	I-P	NOUN	I
fungoides	I-P	NOUN	I
(	I-P	PUNCT	O
MF	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
endpoint	O	NOUN	I
was	O	AUX	O
the	B-OUT	DET	O
overall	I-OUT	ADJ	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
complete	I-OUT	ADJ	O
clinical	I-OUT	ADJ	B
response	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CCR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
plus	I-OUT	CCONJ	O
partial	I-OUT	ADJ	B
response	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
]	I-OUT	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
prematurely	O	ADV	B
closed	O	VERB	B
due	O	ADP	O
to	O	PART	O
low	O	ADJ	B
accrual	O	NOUN	B
after	B-P	ADP	O
93	I-P	NUM	O
of	I-P	ADP	O
145	I-P	NUM	O
required	I-P	VERB	O
patients	I-P	NOUN	B
(	O	PUNCT	O
65	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
.	O	PUNCT	O


Of	O	ADP	O
the	B-P	DET	O
93	I-P	NUM	O
randomized	I-P	ADJ	B
patients	I-P	NOUN	B
,	I-P	PUNCT	O
87	I-P	NUM	O
started	I-P	VERB	B
treatment	I-P	NOUN	B
,	I-P	PUNCT	O
41	I-P	NUM	O
received	I-I	VERB	O
PUVA	I-I	NOUN	B
and	I-P	CCONJ	O
46	I-P	NUM	O
received	I-I	VERB	O
PUVA	I-I	NOUN	B
+	I-I	CCONJ	O
bexarotene	I-I	NOUN	B
.	I-OUT	PUNCT	O


Total	B-OUT	ADJ	B
UVA	I-OUT	NOUN	B
doses	I-OUT	NOUN	B
received	O	VERB	O
were	O	AUX	O
107	O	NUM	O
J	O	NOUN	O
cm	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
range	O	NOUN	O
1·4-489·9	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	B-I	DET	O
PUVA	I-I	NOUN	B
arm	O	NOUN	I
vs.	O	CCONJ	O
101·7	O	ADJ	O
J	O	NOUN	O
cm	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
0·2-529·9	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
arm	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
safety	I-OUT	NOUN	B
profile	I-OUT	NOUN	I
was	O	AUX	O
acceptable	O	ADJ	O
with	B-OUT	ADP	O
few	I-OUT	ADJ	O
grade	I-OUT	NOUN	O
3-4	I-OUT	NUM	O
toxicities	I-OUT	NOUN	B
observed	O	VERB	B
in	O	ADP	O
either	O	DET	O
arm	O	NOUN	B
.	B-OUT	PUNCT	O


More	B-OUT	ADV	O
drop-outs	I-OUT	NOUN	B
due	I-OUT	ADJ	O
to	I-OUT	PART	O
toxicity	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
arm	O	NOUN	I
compared	O	VERB	B
with	B-I	ADP	O
the	I-I	DET	O
PUVA-alone	I-I	ADJ	B
arm	O	NOUN	I
.	O	PUNCT	O


The	B-OUT	DET	O
best	I-OUT	ADJ	O
overall	I-OUT	ADJ	B
response	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CCR	I-OUT	NOUN	B
+	I-OUT	CCONJ	O
PR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
rate	O	NOUN	B
was	O	AUX	O
71	B-I	NUM	O
%	I-I	NOUN	O
for	I-I	ADP	O
PUVA	I-I	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
77	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·57	B-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
median	I-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
response	I-OUT	NOUN	B
was	O	AUX	O
9·7	O	NUM	O
months	B-I	NOUN	B
for	I-I	ADP	O
PUVA	O	NOUN	B
vs.	O	CCONJ	O
5·8	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	B-OUT	ADJ	O
0·33	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


CCR	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
25	O	NUM	O
patients	O	NOUN	B
of	O	ADP	O
whom	O	PRON	O
10	B-I	NUM	O
received	I-I	VERB	O
PUVA	I-OUT	NOUN	B
alone	I-OUT	ADV	O
(	O	PUNCT	O
CCR	O	NOUN	B
22	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
15	B-I	NUM	O
received	I-I	VERB	O
combination	I-OUT	NOUN	B
therapy	I-OUT	NOUN	I
(	O	PUNCT	O
CCR	O	NOUN	B
31	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	B-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0·45	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


CCR	O	NOUN	B
was	O	AUX	O
sustained	O	ADJ	B
in	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
regardless	O	ADV	O
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
towards	B-I	ADP	O
fewer	I-OUT	ADJ	O
PUVA	I-OUT	NOUN	B
sessions	I-OUT	NOUN	B
needed	I-OUT	VERB	O
to	I-OUT	PART	O
achieve	I-OUT	VERB	O
CCR	O	NOUN	B
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
median	O	NOUN	B
22	O	NUM	O
)	O	PUNCT	O
compared	B-I	VERB	B
with	I-I	ADP	O
the	O	DET	O
PUVA	O	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
median	O	ADJ	B
27·5	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·11	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
trend	O	NOUN	O
towards	B-I	ADP	O
lower	I-OUT	ADJ	O
UVA	I-OUT	NOUN	B
dose	I-OUT	NOUN	B
required	I-OUT	VERB	O
to	I-OUT	PART	O
achieve	O	VERB	O
CCR	O	NOUN	B
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
median	O	ADJ	B
55·8	O	NOUN	O
J	O	NOUN	O
cm	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
compared	B-I	VERB	B
with	O	ADP	O
the	O	DET	O
PUVA	O	NOUN	B
arm	O	NOUN	O
alone	O	ADV	O
(	O	PUNCT	O
median	O	NOUN	B
117·5	O	ADJ	O
J	O	NOUN	O
cm	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·5	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
No	O	DET	B
significant	B-OUT	ADJ	I
difference	I-OUT	NOUN	O
in	I-OUT	ADP	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
response	I-OUT	NOUN	B
duration	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	B-OUT	NOUN	O
towards	I-OUT	ADP	O
fewer	I-OUT	ADJ	O
PUVA	I-OUT	NOUN	B
sessions	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
lower	I-OUT	ADJ	O
UVA	I-OUT	NOUN	B
dose	I-OUT	NOUN	B
required	I-OUT	VERB	O
to	O	PART	O
achieve	O	VERB	O
CCR	O	NOUN	B
in	O	ADP	O
the	O	DET	O
combination	B-I	NOUN	B
arm	I-I	NOUN	I
(	I-I	PUNCT	O
PUVA	I-I	NOUN	B
+	O	CCONJ	O
bexarotene	O	NOUN	B
)	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
did	O	AUX	O
not	O	PART	O
achieve	O	VERB	O
statistical	O	ADJ	B
significance	O	NOUN	I
due	O	ADJ	O
to	O	ADP	O
insufficient	O	ADJ	B
power	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
ezetimibe/simvastatin	B-I	NOUN	B
versus	I-I	CCONJ	O
simvastatin	I-I	NOUN	B
monotherapy	I-I	NOUN	B
on	O	ADP	O
platelet	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
inflammatory	I-OUT	ADJ	B
biomarkers	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metabolic	I-P	ADJ	B
syndrome	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
15	B-P	NUM	O
aspirin-naive	I-I	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
48.8	I-P	NUM	O
±	I-P	NOUN	O
10.2	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
the	I-P	DET	O
metabolic	I-P	ADJ	B
syndrome	I-P	NOUN	I
,	O	PUNCT	O
statin	B-I	ADJ	B
monotherapy	I-I	NOUN	B
(	I-I	PUNCT	O
simvastatin	I-I	NOUN	B
40	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
was	O	AUX	O
compared	O	VERB	O
to	B-I	PART	O
combination	I-I	NOUN	B
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
simvastatin	I-I	NOUN	B
40	O	NUM	O
mg	B-I	NOUN	O
and	I-I	CCONJ	O
ezetimibe	I-I	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
on	O	ADP	O
biomarkers	O	NOUN	B
of	B-OUT	ADP	O
inflammation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
platelet	I-OUT	NOUN	B
activity	I-OUT	NOUN	I
.	O	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	B-I	ADP	O
ezetimibe	I-I	NOUN	B
to	I-I	PART	O
simvastatin	I-I	NOUN	B
over	O	ADP	O
a	O	DET	O
4-week	O	ADJ	O
period	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
reduced	B-OUT	VERB	B
expression	I-OUT	NOUN	B
of	I-OUT	ADP	O
CD141	I-OUT	NOUN	B
(	O	PUNCT	O
thrombomodulin	O	NOUN	B
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
platelet	B-OUT	NOUN	B
endothelial	I-OUT	ADJ	I
cell	I-OUT	NOUN	I
adhesion	I-OUT	NOUN	I
molecule	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
CD51/61	I-OUT	NOUN	B
(	O	PUNCT	O
vitronectin	O	NOUN	B
receptor	O	NOUN	I
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.048	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	O
to	B-I	PART	O
statin	I-I	ADJ	B
monotherapy	I-I	NOUN	B
.	I-I	PUNCT	O


Ezetimibe	B-I	NOUN	B
added	O	VERB	O
to	O	PART	O
simvastatin	O	NOUN	B
improves	B-OUT	VERB	B
several	I-OUT	ADJ	O
indices	I-OUT	NOUN	B
of	I-OUT	ADP	O
platelet	I-OUT	NOUN	B
reactivity	I-OUT	NOUN	I
beyond	I-I	ADP	O
statin	I-I	ADJ	B
monotherapy	I-I	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
clinical	O	ADJ	B
relevance	O	NOUN	B
of	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
await	O	VERB	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
IMPROVE-IT	O	NOUN	B
trial	O	NOUN	B
(	O	PUNCT	O
Improved	O	VERB	O
Reduction	O	NOUN	B
of	O	ADP	O
Outcomes	O	PROPN	B
:	O	PUNCT	O
Vytorin	O	PROPN	B
Efficacy	O	PROPN	I
International	O	PROPN	I
Trial	O	PROPN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
fasting	B-I	NOUN	B
on	O	ADP	O
total	B-OUT	ADJ	O
serum	I-OUT	NOUN	B
bilirubin	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Thirty-seven	B-P	NUM	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
,	I-P	PUNCT	O
19	I-P	NUM	O
of	I-P	ADP	O
whom	I-P	PRON	O
had	I-P	AUX	O
consistently	I-P	ADV	O
elevated	I-P	ADJ	B
total	I-OUT	ADJ	O
serum	I-OUT	NOUN	O
bilirubin	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
TSB	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
concentrations	I-OUT	NOUN	B
,	I-P	PUNCT	O
took	I-P	VERB	O
part	I-P	NOUN	O
in	O	ADP	O
an	O	DET	O
open	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
cross-over	O	ADJ	I
study	O	NOUN	I
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
fasting	B-I	NOUN	B
on	O	ADP	O
TSB	O	NOUN	B
concentrations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
comprised	O	VERB	O
of	O	ADP	O
two	O	NUM	O
treatments	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
one	O	NUM	O
treatment	O	NOUN	B
period	O	NOUN	B
volunteers	B-P	NOUN	I
ate	I-I	VERB	O
a	I-I	DET	O
standard	I-I	ADJ	B
supper	I-I	NOUN	I
but	I-I	CCONJ	O
fasted	I-I	VERB	B
for	I-I	ADP	O
24	I-I	NUM	O
h	I-I	NOUN	O
thereafter	I-I	ADV	O
.	I-I	PUNCT	O


During	O	ADP	O
the	O	DET	O
other	O	ADJ	O
treatment	O	NOUN	B
period	O	NOUN	O
volunteers	B-P	NOUN	B
ate	O	VERB	O
a	O	DET	O
standard	B-I	ADJ	B
supper	I-I	NOUN	I
,	I-I	PUNCT	O
snacks	I-I	NOUN	B
,	I-I	PUNCT	O
breakfast	I-I	NOUN	B
and	I-I	CCONJ	O
lunch	I-I	NOUN	B
.	I-I	PUNCT	O


TSB	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
regular	O	ADJ	O
intervals	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
high	O	ADJ	O
bilirubin	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
minimum	B-OUT	ADJ	O
TSB	I-OUT	NOUN	B
values	I-OUT	NOUN	O
were	O	AUX	O
recorded	O	VERB	O
4	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
supper	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
24	O	NUM	O
h	O	NOUN	O
fast	O	ADV	O
more	B-OUT	ADV	O
than	I-OUT	ADP	O
doubled	I-OUT	VERB	B
TSB	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
values	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
high	O	ADJ	O
bilirubin	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
clinically	O	ADV	B
relevant	O	ADJ	O
rise	B-OUT	NOUN	O
in	I-OUT	ADP	O
TSB	I-OUT	NOUN	B
took	O	VERB	O
place	O	NOUN	O
after	O	ADP	O
12	O	NUM	O
h	O	NOUN	O
into	O	ADP	O
the	O	DET	O
fasting	O	NOUN	B
period	O	NOUN	B
(	O	PUNCT	O
TSB	O	NOUN	B
of	O	ADP	O
17.3	O	NUM	O
mumol	O	NOUN	O
l-1	O	NOUN	O
in	O	ADP	O
the	O	DET	O
fasted	O	ADJ	B
group	O	NOUN	I
vs	O	CCONJ	O
14.0	O	NUM	O
mumol	O	NOUN	O
l-1	O	NOUN	O
in	O	ADP	O
the	O	DET	O
non-fasted	O	ADJ	B
group	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


When	O	SCONJ	O
designing	O	VERB	B
a	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
selecting	O	VERB	O
volunteers	B-P	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
judging	O	VERB	B
the	O	DET	O
tolerance	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
drug	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
TSB	B-OUT	NOUN	B
caused	O	VERB	O
by	O	ADP	O
fasting	O	NOUN	B
must	O	AUX	O
therefore	O	ADV	O
be	O	AUX	O
taken	O	VERB	O
into	O	ADP	O
account	O	NOUN	O
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
trials	O	NOUN	B
where	O	SCONJ	O
volunteers	B-P	NOUN	B
or	O	CCONJ	O
patients	O	NOUN	B
fast	O	ADV	B
before	O	ADP	O
entering	O	VERB	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Intrathecal	O	NOUN	B
lentivirus-mediated	O	ADJ	O
transfer	O	NOUN	O
of	O	ADP	O
interleukin-10	B-I	NOUN	B
attenuates	O	VERB	B
chronic	B-OUT	ADJ	B
constriction	I-OUT	NOUN	I
injury-induced	I-OUT	ADJ	B
neuropathic	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
through	O	ADP	O
modulation	O	NOUN	B
of	O	ADP	O
spinal	O	ADJ	B
high-mobility	O	ADJ	I
group	O	NOUN	I
box	O	NOUN	O
1	O	NUM	O
in	O	ADP	O
rats	B-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Neuropathic	O	ADJ	B
pain	O	NOUN	I
is	O	AUX	O
a	O	DET	O
complex	O	ADJ	B
state	O	NOUN	O
of	O	ADP	O
chronic	O	ADJ	B
pain	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
usually	O	ADV	O
accompanied	O	VERB	O
by	O	ADP	O
peripheral	O	ADJ	B
and	O	CCONJ	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
damage	O	NOUN	I
or	O	CCONJ	O
dysfunction	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
indicated	O	VERB	O
that	O	SCONJ	O
neuroinflammation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
spinal	O	ADJ	B
cord	O	NOUN	I
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
contributor	O	NOUN	O
to	O	ADP	O
neuropathological	O	ADJ	B
and	O	CCONJ	O
behavioral	O	ADJ	B
abnormalities	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
series	O	NOUN	B
of	O	ADP	O
early	O	ADJ	O
inflammatory	O	ADJ	B
markers	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
IL-1	O	NOUN	B
,	O	PUNCT	O
TNF-α	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
IFN-γ	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
advanced	O	ADJ	B
inflammatory	O	ADJ	B
markers	O	NOUN	O
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
high-mobility	O	ADJ	B
group	O	NOUN	I
box	O	NOUN	I
1	O	NUM	I
(	O	PUNCT	O
HMGB1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
neuroinflammation	O	NOUN	B
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
controlled	B-P	VERB	B
animal	I-P	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
a	B-I	DET	O
lentivirus	I-I	NOUN	B
delivering	I-I	VERB	O
human	I-I	ADJ	B
IL-10	I-I	NOUN	B
(	I-I	PUNCT	O
LV/hIL-10	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
intrathecally	O	ADV	B
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
IL-10	O	NOUN	B
on	B-OUT	ADP	O
allodynia	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
hyperalgesia	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
chronic	O	ADJ	B
constriction	O	NOUN	I
injury-induced	O	ADJ	B
(	B-P	PUNCT	O
CCI	I-P	NOUN	B
)	I-P	PUNCT	O
rat	I-P	NOUN	B
model	I-P	NOUN	B
of	O	ADP	O
neuropathic	O	ADJ	B
pain	O	NOUN	I
.	O	PUNCT	O


METHODS	B-P	VERB	O
Sprague-Dawley	I-P	ADJ	B
rats	I-P	NOUN	I
weighting	I-P	VERB	O
260	I-P	NUM	O
-	I-P	SYM	O
320	I-P	NUM	O
g	O	NOUN	O
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
4	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Group	O	PROPN	B
Sham	O	PROPN	O
(	O	PUNCT	O
Sham	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
Group	B-I	NOUN	B
CCI±Normal	I-I	ADJ	O
Saline	I-I	NOUN	B
(	I-I	PUNCT	I
NS	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
Group	I-I	PROPN	B
CCI±LV/hIL-10	I-I	PROPN	O
(	I-I	PUNCT	O
LV/hIL-10	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Group	B-I	PROPN	B
CCI±LV/control	I-I	NOUN	O
(	I-I	PUNCT	O
vector	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-P	PUNCT	O


Rats	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
were	O	AUX	O
intrathecally	O	ADV	B
delivered	O	VERB	O
with	B-I	ADP	O
NS	I-I	NOUN	B
,	I-I	PUNCT	O
LV/control	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
recombinant	I-I	ADJ	B
vector	I-I	NOUN	I
LV/hIL-10	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
total	O	ADJ	O
volume	O	NOUN	B
of	O	ADP	O
10	B-OUT	NUM	O
μl	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Paw	B-OUT	NOUN	B
withdrawal	I-OUT	NOUN	O
mechanical	I-OUT	ADJ	B
thresholds	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PWMT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
paw	I-OUT	NOUN	B
withdrawal	I-OUT	NOUN	O
thermal	I-OUT	ADJ	O
latency	I-OUT	NOUN	O
PWTL	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
one	O	NUM	O
day	O	NOUN	B
before	O	ADP	O
CCI	O	NOUN	B
(	O	PUNCT	O
baseline	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
28	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
intrathecal	O	ADJ	B
administration	O	NOUN	I
.	O	PUNCT	O


Cerebrospinal	O	ADJ	B
fluid	O	NOUN	I
(	O	PUNCT	O
CSF	O	NOUN	B
)	O	PUNCT	O
samples	O	NOUN	B
were	O	AUX	O
collected	O	VERB	O
during	O	ADP	O
surgical	O	ADJ	B
plane	O	NOUN	I
anesthesia	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
collected	O	VERB	B
CSF	O	NOUN	B
samples	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
assay	O	VERB	B
for	O	ADP	O
human	O	ADJ	B
IL-10	O	NOUN	B
,	O	PUNCT	O
rat	O	NOUN	B
IL-1β	O	PROPN	B
,	O	PUNCT	O
rat	O	NOUN	B
IL-6	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
rat	O	NOUN	B
TNF-α	O	NOUN	B
by	O	ADP	O
enzyme-linked	O	ADJ	B
immunosorbent	O	ADJ	I
assay	O	NOUN	I
(	B-P	PUNCT	O
ELISA	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Animals	B-P	NOUN	B
were	I-P	AUX	O
sacrificed	I-P	VERB	B
and	I-P	CCONJ	O
the	I-P	DET	O
L4-5	I-P	NOUN	B
lumbar	I-P	ADJ	I
segment	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
spinal	I-P	ADJ	B
cord	I-P	NOUN	I
was	I-P	AUX	O
removed	I-P	VERB	O
for	I-P	ADP	O
determination	I-P	NOUN	B
of	I-P	ADP	O
green	I-P	ADJ	B
fluorescent	I-P	ADJ	I
protein	I-P	NOUN	I
(	I-P	PUNCT	O
GFP	I-P	NOUN	B
)	I-P	PUNCT	O
expression	I-P	NOUN	B
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
analysis	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
anti	O	ADJ	B
HMGB1	O	NOUN	I
antibodies	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
HMGB1	O	NOUN	B
protein	O	NOUN	B
in	O	ADP	O
the	O	DET	O
spinal	O	ADJ	B
cord	O	NOUN	I
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
western	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
after	O	ADP	O
intrathecal	O	ADJ	B
delivery	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
each	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
results	O	NOUN	B
show	B-I	VERB	O
that	I-I	SCONJ	O
intrathecal	I-I	ADJ	B
LV/hIL-10	I-I	NOUN	B
reverses	I-OUT	VERB	B
enhanced	I-OUT	VERB	B
pain	I-OUT	NOUN	B
states	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
increased	B-OUT	VERB	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
HMGB1	O	NOUN	B
exhibited	B-OUT	VERB	O
in	I-OUT	ADP	O
a	I-OUT	DET	O
late	I-OUT	ADJ	B
stage	I-OUT	NOUN	I
of	O	ADP	O
CCI	O	NOUN	B
was	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
exogenous	O	ADJ	B
overexpression	O	NOUN	B
of	O	ADP	O
hIL-10	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CCI	B-OUT	NOUN	B
model	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Expression	B-OUT	NOUN	B
of	I-OUT	ADP	O
HMGB1	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
RAGE	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
pAkt	O	NOUN	B
were	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
CCI-induced	O	ADJ	B
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	O
LV/hIL-10	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
those	O	DET	O
treated	O	VERB	B
with	O	ADP	I
LV/control	O	NOUN	B
(	O	PUNCT	I
vector	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
saline	O	NOUN	B
(	O	PUNCT	O
NS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
showed	B-OUT	VERB	O
that	I-OUT	SCONJ	O
IL-10	O	NOUN	B
inhibits	B-OUT	VERB	B
activation	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
inflammatory	I-OUT	ADJ	B
HMGB1-RAGE	I-OUT	ADJ	B
pathway	O	NOUN	I
in	O	ADP	O
the	O	DET	O
CCI	O	NOUN	B
rat	O	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


LIMITATIONS	O	VERB	B
Further	O	ADV	O
experimental	O	ADJ	B
investigations	O	NOUN	I
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
clarify	O	VERB	O
the	O	DET	O
specific	O	ADJ	O
biological	O	ADJ	B
roles	O	NOUN	O
played	O	VERB	O
by	O	ADP	O
HMGB1	O	NOUN	B
in	O	ADP	O
IL-10-mediated	O	ADJ	B
regulation	B-OUT	NOUN	I
of	I-OUT	ADP	O
neuropathic	I-OUT	ADJ	B
pain	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	VERB	O
Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
intrathecal	O	ADJ	B
lentiviral-mediated	O	ADJ	B
transfer	B-I	NOUN	I
of	I-I	ADP	O
IL-10	O	NOUN	B
attenuates	B-OUT	VERB	B
CCI-induced	I-OUT	ADJ	B
neuropathic	I-OUT	ADJ	B
pain	I-P	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
anti-thermal	O	ADJ	B
hyperalgesia	O	NOUN	O
and	O	CCONJ	O
anti-mechanical	O	ADJ	B
allodynia	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
partly	O	ADV	O
attributable	O	ADJ	O
to	O	PART	O
the	O	DET	O
decreased	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
HMGB1	O	NOUN	B
and	O	CCONJ	O
inhibition	O	NOUN	B
of	O	ADP	O
HMGB1-RAGE	O	ADJ	B
pathway	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
A	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
intravenous	O	ADJ	B
diltiazem	B-I	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
unstable	B-P	ADJ	B
angina	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
efficacy	O	NOUN	I
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
diltiazem	B-I	NOUN	B
compared	O	VERB	O
with	O	ADP	O
nitroglycerin	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
patients	B-P	NOUN	B
with	I-P	ADP	O
unstable	I-P	ADJ	B
angina	I-P	ADJ	I
pectoris	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	B
group	O	NOUN	I
trial	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
total	B-P	NOUN	O
of	I-P	ADP	O
213	I-P	NUM	O
eligible	I-P	ADJ	O
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


They	O	PRON	O
were	O	AUX	O
randomized	O	VERB	B
either	O	CCONJ	O
to	O	PART	O
diltiazem	B-I	NOUN	B
or	I-I	CCONJ	O
nitroglycerin	I-I	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
diltiazem	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
from	O	ADP	O
100	O	NUM	O
microg/min	O	NOUN	O
at	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
largest	O	ADJ	O
dosage	O	NOUN	B
was	O	AUX	O
200	O	NUM	O
-	O	PUNCT	O
300	O	NUM	O
microg/min	O	NOUN	O
;	O	PUNCT	O
the	O	DET	O
nitroglycerin	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
from	O	ADP	O
20	O	NUM	O
microg/min	O	NOUN	O
at	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
largest	O	ADJ	O
dosage	O	NOUN	B
was	O	AUX	O
80	O	NUM	O
-	O	PUNCT	O
100	O	NUM	O
microg/min	O	NOUN	O
.	O	PUNCT	O


Intravenous	O	ADJ	B
infusion	O	NOUN	B
was	O	AUX	O
kept	O	VERB	O
over	O	ADP	O
48	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
endpoints	O	NOUN	B
included	O	VERB	O
refractory	B-OUT	ADJ	B
angina	I-OUT	ADJ	I
pectoris	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
acute	I-OUT	ADJ	B
myocardial	I-OUT	ADJ	I
infarction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
death	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
emergency	I-OUT	NOUN	B
PTCA	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
CABG	I-OUT	PROPN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
Intravenous	O	ADJ	B
diltiazem	O	NOUN	B
was	O	AUX	O
effective	O	ADJ	B
on	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
symptom	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
electrocardiogram	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
effects	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
intravenous	O	ADJ	B
nitroglycerin	O	NOUN	I
.	O	PUNCT	O


(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
Compared	O	VERB	B
with	O	ADP	O
nitroglycerin	B-I	NOUN	B
,	O	PUNCT	O
intravenous	O	ADJ	B
diltiazem	B-I	NOUN	B
lowered	I-OUT	ADJ	B
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
myocardial	I-OUT	ADJ	B
oxygen	I-OUT	NOUN	I
consumption	I-OUT	NOUN	I
index	I-OUT	NOUN	I
(	O	PUNCT	O
systolic	O	NOUN	B
pressure	O	NOUN	I
x	O	NOUN	O
heart	O	NOUN	B
rate	O	NOUN	I
)	O	PUNCT	O
to	O	PART	O
more	O	ADJ	O
extent	O	NOUN	O
significantly	O	ADV	O
.	O	PUNCT	O


(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
After	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
onsets	B-OUT	NOUN	B
of	I-OUT	ADP	O
refractory	I-OUT	ADJ	B
angina	I-OUT	ADJ	I
pectoris	I-OUT	NOUN	I
were	O	AUX	O
reduced	B-OUT	VERB	B
more	I-OUT	ADV	O
significantly	I-OUT	ADV	O
in	O	ADP	O
the	O	DET	O
diltiazem	B-I	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
nitroglycerin	O	NOUN	B
group	O	NOUN	B
[	O	PUNCT	O
4	O	NUM	O
(	O	PUNCT	O
3.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs	O	CCONJ	O
13	O	NUM	O
(	O	PUNCT	O
11.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
RR	O	NOUN	B
0.32	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.11	O	NUM	O
-	O	PUNCT	O
0.96	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


(	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
The	O	DET	O
patients	O	NOUN	B
whose	O	DET	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
were	O	AUX	O
reduced	B-OUT	VERB	B
significantly	I-OUT	ADV	O
(	O	PUNCT	O
<	O	X	O
or=	O	ADJ	O
50	O	NUM	O
beats	O	NOUN	B
per	O	ADP	I
minute	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
diltiazem	O	NOUN	B
group	O	NOUN	B
were	O	AUX	O
more	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
nitroglycerin	O	NOUN	B
group	O	NOUN	B
[	O	PUNCT	O
8	O	NUM	O
(	O	PUNCT	O
7.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs	O	CCONJ	O
0	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


But	O	CCONJ	O
these	O	DET	O
patients	O	NOUN	B
could	O	AUX	O
tolerate	O	VERB	O
the	O	DET	O
lower	O	ADJ	B
heart	B-OUT	NOUN	O
rate	I-OUT	NOUN	O
very	O	ADV	O
well	O	ADV	O
in	O	ADP	O
the	O	DET	O
diltiazem	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
The	O	DET	O
needs	O	NOUN	O
of	O	ADP	O
beta	O	NOUN	B
receptor	O	NOUN	I
blocker	O	NOUN	I
or	O	CCONJ	O
calcium	O	NOUN	B
antagonists	O	NOUN	I
were	O	AUX	O
reduced	O	VERB	B
more	O	ADV	O
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
diltiazem	B-I	NOUN	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
nitroglycerin	O	NOUN	B
group	O	NOUN	B
[	O	PUNCT	O
2	O	NUM	O
(	O	PUNCT	O
1.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs	O	CCONJ	O
13	O	NUM	O
(	O	PUNCT	O
11.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
Intravenous	O	ADJ	B
diltiazem	B-I	NOUN	I
therapy	O	NOUN	I
is	O	AUX	O
effective	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
unstable	I-P	ADJ	B
angina	I-P	ADJ	I
pectoris	I-P	NOUN	I
.	I-P	PUNCT	O


It	O	PRON	O
may	O	AUX	O
significantly	O	ADV	O
lower	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
refractory	O	ADJ	B
angina	O	ADJ	I
pectoris	O	NOUN	I
compared	O	VERB	O
with	O	ADP	O
intravenous	O	ADJ	B
nitroglycerin	O	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
ranolazine	B-I	NOUN	B
on	O	ADP	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
among	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
diabetes	I-P	NOUN	B
mellitus	I-P	NOUN	I
and	I-P	CCONJ	O
stable	I-P	ADJ	B
angina	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
reinforcement	B-I	NOUN	B
or	I-I	CCONJ	O
stimulus	I-I	NOUN	B
control	I-I	NOUN	O
to	O	PART	O
reduce	O	VERB	B
sedentary	B-OUT	ADJ	B
behavior	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
pediatric	B-P	ADJ	B
obesity	I-P	NOUN	B
.	I-P	PUNCT	O


Obese	B-P	ADJ	B
children	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
family-based	B-I	ADJ	B
behavioral	I-I	ADJ	I
treatment	I-I	NOUN	I
that	I-I	PRON	O
included	I-I	VERB	O
either	I-I	DET	O
stimulus	I-I	NOUN	B
control	I-I	NOUN	I
or	I-I	CCONJ	O
reinforcement	I-I	NOUN	B
to	O	PART	O
reduce	O	VERB	B
sedentary	O	ADJ	B
behaviors	O	NOUN	I
.	O	PUNCT	O


Significant	O	ADJ	B
and	O	CCONJ	O
equivalent	O	ADJ	O
decreases	O	NOUN	B
in	O	ADP	O
sedentary	B-OUT	ADJ	B
behavior	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
high	I-OUT	ADJ	B
energy	I-OUT	NOUN	B
density	I-OUT	NOUN	I
foods	I-OUT	NOUN	I
,	O	PUNCT	O
increases	O	VERB	B
in	O	ADP	O
physical	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
fruits	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
vegetables	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
decreases	O	VERB	B
in	O	ADP	O
standardized	O	ADJ	B
body	B-OUT	NOUN	I
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
z-BMI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Children	O	NOUN	B
who	O	PRON	O
substituted	O	VERB	B
active	O	ADJ	I
for	O	ADP	O
sedentary	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
had	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
z-BMI	B-OUT	NOUN	B
changes	I-OUT	NOUN	B
at	O	ADP	O
6	O	NUM	O
(	O	PUNCT	O
-1.21	O	NUM	O
vs.	O	CCONJ	O
-0.76	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
(	O	PUNCT	O
-1.05	O	NUM	O
vs.	O	CCONJ	O
-0.51	O	NUM	O
)	O	PUNCT	O
months	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Substitution	O	NOUN	B
of	O	ADP	O
physically	O	ADV	B
active	O	ADJ	I
for	O	ADP	O
sedentary	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
and	O	CCONJ	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
activity	I-OUT	NOUN	B
level	I-OUT	NOUN	I
predicted	O	VERB	B
6-	O	NUM	O
and	O	CCONJ	O
12-month	O	ADJ	B
z-BMI	B-OUT	NOUN	B
changes	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Results	O	NOUN	B
suggest	O	VERB	O
stimulus	B-I	NOUN	B
control	I-I	NOUN	I
and	I-I	CCONJ	O
reinforcing	I-I	VERB	O
reduced	O	VERB	B
sedentary	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
are	O	AUX	O
equivalent	O	ADJ	O
ways	O	NOUN	O
to	O	PART	O
decrease	O	VERB	B
sedentary	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
behavioral	B-OUT	ADJ	B
economic	I-OUT	ADJ	B
relationships	I-OUT	NOUN	I
in	I-OUT	ADP	O
eating	I-OUT	VERB	B
and	I-OUT	CCONJ	O
activity	I-OUT	NOUN	B
may	O	AUX	O
mediate	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
ginseng	B-I	NOUN	B
extract	I-I	VERB	I
supplementation	I-I	NOUN	B
on	O	ADP	O
testicular	B-OUT	NOUN	B
functions	I-OUT	NOUN	B
in	O	ADP	O
diabetic	B-P	ADJ	B
rats	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
It	O	PRON	O
was	O	AUX	O
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
standardized	O	ADJ	B
ginseng	B-I	NOUN	I
extract	I-I	NOUN	I
on	O	ADP	O
fertility	B-OUT	NOUN	B
parameters	I-OUT	NOUN	B
in	O	ADP	O
diabetic	B-P	ADJ	B
rats	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Thirty	B-P	NUM	O
male	I-P	NOUN	B
rats	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
into	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
rats	O	NOUN	B
each	O	DET	O
:	O	PUNCT	O
1.	O	X	O
controls	O	NOUN	B
,	O	PUNCT	O
2.	O	X	O
diabetes	O	NOUN	B
(	O	PUNCT	O
D	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
3.	O	X	O
diabetes	O	NOUN	B
+	O	CCONJ	O
ginseng	O	NOUN	B
(	O	PUNCT	O
DG	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
latter	O	ADJ	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
rendered	O	VERB	O
diabetic	O	ADJ	B
by	O	ADP	O
i.p	O	NOUN	B
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
streptozotocin	B-I	NOUN	B
(	O	PUNCT	O
STZ	O	NOUN	B
;	O	PUNCT	O
50	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Standardized	B-I	ADJ	B
ginseng	I-I	NOUN	I
extract	I-I	NOUN	I
(	O	PUNCT	O
Dansk	O	PROPN	B
Droge	O	PROPN	I
A/S	O	PROPN	I
,	O	PUNCT	O
Copenhagen	O	PROPN	B
,	O	PUNCT	O
Denmark	O	PROPN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
per	O	ADP	O
os	O	X	O
(	O	PUNCT	O
100	O	NUM	O
mg/kg	O	NOUN	O
BW	O	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
stomach	O	NOUN	B
tube	O	NOUN	I
daily	O	ADV	B
for	O	ADP	O
90	O	NUM	O
days	O	NOUN	B
starting	O	VERB	O
one	O	NUM	O
week	O	NOUN	B
after	O	ADP	O
STZ	O	NOUN	B
.	O	PUNCT	O


Ninety	O	NUM	B
days	O	NOUN	I
post	O	NOUN	B
STZ	O	NOUN	B
the	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
sacrificed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
testis	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
epididymis	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
prostate	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
seminal	I-OUT	ADJ	B
vesicles	I-OUT	NOUN	I
were	I-OUT	AUX	O
weighed	I-OUT	VERB	B
and	I-OUT	CCONJ	O
subjected	I-OUT	VERB	O
to	I-OUT	PART	O
histological	I-OUT	ADJ	B
examination	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
spermiogram	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
testicular	I-OUT	ADJ	B
enzyme	I-OUT	NOUN	B
markers	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
intratesticular	I-OUT	ADJ	B
steroid	I-OUT	NOUN	O
hormonal	I-OUT	ADJ	O
profile	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
testicular	I-OUT	ADJ	B
antioxidant	I-OUT	ADJ	B
status	I-OUT	NOUN	I
were	O	AUX	O
estimated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
ginseng	B-I	NOUN	B
extract	I-I	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
of	O	ADP	O
fertility	B-OUT	NOUN	B
parameters	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
testicular	I-OUT	NOUN	B
antioxidants	I-OUT	NOUN	I
together	I-OUT	ADV	O
with	O	ADP	O
a	O	DET	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
malondialdehyde	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
testicular	I-OUT	NOUN	B
pathological	I-OUT	ADJ	B
signs	I-OUT	NOUN	O
including	I-OUT	VERB	O
degenerative	I-OUT	ADJ	B
changes	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
seminiferous	I-OUT	ADJ	B
tubules	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
Ginseng	B-I	PROPN	B
extract	I-I	NOUN	I
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
beneficial	O	ADJ	O
adjuvant	O	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
diabetics	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
infertility	B-OUT	NOUN	B
as	O	ADP	O
a	O	DET	O
complication	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
multivendor	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
myocardial	O	ADJ	B
perfusion	O	NOUN	I
imaging	O	NOUN	I
with	O	ADP	O
regadenoson	B-I	ADJ	B
CT	I-I	NOUN	I
perfusion	I-I	NOUN	I
vs	O	CCONJ	O
single	B-I	ADJ	O
photon	I-I	ADJ	O
emission	I-I	NOUN	O
CT.	I-I	NOUN	O
BACKGROUND	O	NOUN	O
Myocardial	O	ADJ	B
CT	O	NOUN	I
perfusion	O	NOUN	I
(	O	PUNCT	O
CTP	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
promising	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
myocardial	B-P	ADJ	B
ischemia	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
regadenoson	O	NOUN	B
CTP	O	PROPN	B
is	O	AUX	O
noninferior	O	ADJ	B
to	O	PART	O
regadenoson	O	VERB	B
single	O	ADJ	I
photon	O	ADJ	I
emission	O	NOUN	I
CT	O	NOUN	I
(	O	PUNCT	O
SPECT	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
detecting	O	VERB	B
or	O	CCONJ	O
excluding	O	VERB	O
myocardial	B-P	ADJ	B
ischemia	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
(	I-P	PUNCT	O
men	I-P	NOUN	B
≥	I-P	NOUN	O
45	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
women	I-P	NOUN	B
≥	I-P	VERB	O
50	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
known	I-P	VERB	O
or	I-P	CCONJ	O
suspected	I-P	VERB	B
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
124	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
1	O	NUM	O
of	O	ADP	O
2	O	NUM	O
diagnostic	O	ADJ	B
sequences	B-I	NOUN	I
:	I-I	PUNCT	O
rest	I-I	VERB	B
and	I-I	CCONJ	O
regadenoson	I-I	NOUN	B
SPECT	I-I	PROPN	B
on	I-I	ADP	O
day	I-I	NOUN	B
1	I-I	NUM	O
,	I-I	PUNCT	O
then	I-I	ADV	O
regadenoson	I-I	ADJ	B
CTP	I-I	PROPN	B
and	I-I	CCONJ	O
rest	I-I	NOUN	B
CTP	I-I	PROPN	B
(	I-I	PUNCT	O
and	I-I	CCONJ	O
coronary	I-I	ADJ	B
CT	I-I	NOUN	I
angiography	I-I	NOUN	I
[	I-I	PUNCT	O
CTA	I-I	PROPN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
(	I-I	PUNCT	O
CTA	I-I	NOUN	B
;	I-I	PUNCT	O
same	I-I	ADJ	O
acquisition	I-I	NOUN	B
)	I-I	PUNCT	O
on	I-I	ADP	O
day	I-I	NOUN	B
2	I-I	NUM	O
or	I-I	CCONJ	O
regadenoson	I-I	NOUN	B
CTP	I-I	PROPN	B
and	I-I	CCONJ	O
rest	I-I	NOUN	B
CTP	I-I	PROPN	B
(	I-I	PUNCT	O
and	I-I	CCONJ	O
CTA	I-I	PROPN	B
)	I-I	PUNCT	O
on	I-I	ADP	O
Day	I-I	PROPN	B
1	I-I	NUM	I
,	I-I	PUNCT	O
then	I-I	ADV	O
rest	I-I	VERB	B
and	I-I	CCONJ	O
regadenoson	I-I	NOUN	B
SPECT	I-I	PROPN	B
on	I-I	ADP	O
day	I-I	NOUN	B
2	O	NUM	O
.	O	PUNCT	O


Scanning	O	ADJ	B
platforms	O	NOUN	I
included	O	VERB	O
64-	O	NUM	O
,	O	PUNCT	O
128-	O	NOUN	O
,	O	PUNCT	O
256-	O	PROPN	O
,	O	PUNCT	O
and	O	CCONJ	O
320-slice	O	ADJ	B
systems	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
analysis	O	NOUN	I
examined	O	VERB	O
the	B-OUT	DET	O
agreement	I-OUT	NOUN	O
rate	I-OUT	NOUN	B
between	I-OUT	ADP	O
CTP	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
SPECT	I-OUT	PROPN	B
for	I-OUT	ADP	O
detecting	I-OUT	VERB	B
or	I-OUT	CCONJ	O
excluding	I-OUT	VERB	O
reversible	I-OUT	ADJ	B
ischemia	I-OUT	NOUN	B
in	O	ADP	O
≥	O	NOUN	O
2	O	NUM	O
myocardial	O	ADJ	B
segments	O	NOUN	B
as	O	ADP	O
assessed	O	VERB	B
by	O	ADP	O
independent	O	ADJ	B
,	O	PUNCT	O
blinded	O	VERB	B
readers	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Complete	O	ADJ	B
and	O	CCONJ	O
interpretable	O	ADJ	O
CTP	O	PROPN	B
and	O	CCONJ	O
SPECT	O	NOUN	B
scans	O	NOUN	O
were	O	AUX	O
obtained	B-P	VERB	O
for	I-P	ADP	O
110	I-P	NUM	O
patients	I-I	NOUN	B
.	I-I	PUNCT	O


Regadenoson	B-I	NOUN	B
CTP	O	PROPN	B
was	O	AUX	O
noninferior	O	ADJ	B
to	O	PART	O
SPECT	B-OUT	PROPN	B
for	I-OUT	ADP	O
detecting	I-OUT	VERB	B
or	I-OUT	CCONJ	O
excluding	I-OUT	VERB	O
reversible	I-OUT	ADJ	B
ischemia	I-OUT	NOUN	B
with	O	ADP	O
an	O	DET	O
agreement	O	NOUN	O
rate	O	NOUN	B
of	O	ADP	O
0.87	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	PROPN	B
]	O	PUNCT	O
,	O	PUNCT	O
0.77-0.97	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
sensitivity	O	NOUN	B
and	O	CCONJ	O
specificity	O	NOUN	B
of	O	ADP	O
0.90	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.71-1.00	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
0.84	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.77-0.91	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	B-OUT	ADV	O
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
agreement	I-OUT	NOUN	O
rate	O	NOUN	B
for	O	ADP	O
detecting	O	VERB	B
or	O	CCONJ	O
excluding	B-OUT	VERB	O
≥	I-OUT	NOUN	O
1	I-OUT	NUM	O
fixed	I-OUT	ADJ	O
defects	O	NOUN	B
by	O	ADP	O
regadenoson	O	NOUN	B
CTP	O	PROPN	B
and	O	CCONJ	O
SPECT	O	PROPN	B
was	O	AUX	O
0.86	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.74-0.98	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


With	O	ADP	O
SPECT	O	PROPN	B
as	O	ADP	O
the	O	DET	O
reference	O	NOUN	B
standard	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
diagnostic	O	ADJ	B
accuracies	O	NOUN	B
for	O	ADP	O
detecting	O	VERB	B
or	O	CCONJ	O
excluding	O	VERB	O
ischemia	O	NOUN	B
by	O	ADP	O
regadenoson	O	ADJ	B
CTP	O	PROPN	B
and	O	CCONJ	O
CTA	O	NOUN	B
alone	O	ADV	O
were	O	AUX	O
0.85	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.78-0.91	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
0.69	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.60-0.77	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
establishes	O	VERB	O
the	O	DET	O
noninferiority	B-I	NOUN	B
of	I-I	ADP	O
regadenoson	I-I	ADJ	B
CTP	I-I	PROPN	B
to	I-I	PART	O
SPECT	O	PROPN	B
for	O	ADP	O
detecting	O	VERB	B
or	O	CCONJ	O
excluding	B-P	VERB	O
myocardial	I-P	ADJ	B
ischemia	I-P	NOUN	I
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
oral	B-I	ADJ	B
conivaptan	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
V1A/V2	B-I	NOUN	B
vasopressin	I-I	NOUN	I
receptor	I-I	NOUN	I
antagonist	I-I	NOUN	B
,	O	PUNCT	O
assessed	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
euvolemic	I-P	ADJ	B
or	I-P	CCONJ	O
hypervolemic	I-P	ADJ	B
hyponatremia	I-P	NOUN	I
.	I-P	PUNCT	O


CONTEXT	O	ADJ	B
Hyponatremia	O	NOUN	I
[	O	PUNCT	O
serum	O	NOUN	B
sodium	O	NOUN	I
concentration	O	NOUN	I
(	O	PUNCT	O
[	O	PUNCT	O
Na	O	PROPN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
]	O	PUNCT	O
)	O	PUNCT	O
,	O	PUNCT	O
<	O	X	O
135	O	NUM	O
mEq/liter	O	NOUN	O
]	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
fluid	O	NOUN	B
and	O	CCONJ	O
electrolyte	O	NOUN	B
abnormality	B-P	NOUN	I
among	I-P	ADP	O
hospitalized	I-P	VERB	B
patients	I-P	NOUN	I
.	I-P	PUNCT	O


It	O	PRON	O
is	O	AUX	O
frequently	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
inappropriate	O	ADJ	O
release	O	NOUN	B
of	O	ADP	O
arginine	O	NOUN	B
vasopressin	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
oral	B-I	ADJ	B
conivaptan	I-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
vasopressin	I-I	NOUN	B
V	I-I	NOUN	I
(	I-I	PUNCT	O
1A	I-I	NOUN	B
)	I-I	PUNCT	O
/V	I-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
receptor	I-I	NOUN	O
antagonist	I-I	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
euvolemic	I-P	ADJ	B
or	I-P	CCONJ	O
hypervolemic	I-P	ADJ	B
hyponatremia	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
The	O	DET	O
study	O	NOUN	B
design	O	NOUN	B
was	O	AUX	O
a	O	DET	O
5-d	O	ADJ	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
at	B-P	ADP	O
a	I-P	DET	O
hospital	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTION	O	PROPN	B
Oral	B-I	ADJ	B
conivaptan	I-I	NOUN	I
(	O	PUNCT	O
40	O	NUM	O
or	O	CCONJ	O
80	O	NUM	O
mg/d	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
in	O	ADP	O
two	O	NUM	O
divided	O	ADJ	O
doses	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	VERB	B
Seventy-four	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
average	I-P	ADJ	O
baseline	I-P	NOUN	B
serum	I-P	NOUN	O
[	I-P	PUNCT	O
Na	I-P	NOUN	B
(	I-P	PUNCT	O
+	I-P	CCONJ	O
)	I-P	PUNCT	O
]	I-P	PUNCT	O
,	I-P	PUNCT	O
115	I-P	NUM	O
to	I-P	PART	O
<	I-P	X	O
130	I-P	NUM	O
mEq/liter	I-P	NOUN	O
)	I-P	PUNCT	O
were	I-P	AUX	O
studied	I-P	VERB	O
.	I-P	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	X	O
MEASURE	O	NOUN	O
The	O	DET	O
main	O	ADJ	O
outcome	O	NOUN	B
measure	O	NOUN	I
was	B-OUT	AUX	O
the	I-OUT	DET	O
change	I-OUT	NOUN	O
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
[	I-OUT	PUNCT	O
Na	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
]	I-OUT	PUNCT	O
area	I-OUT	NOUN	B
under	I-OUT	ADP	I
the	I-OUT	DET	I
curve	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
least-squares	O	NOUN	B
mean	B-OUT	ADJ	I
change	O	NOUN	I
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
[	O	PUNCT	O
Na	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
]	O	PUNCT	O
area	O	NOUN	B
under	O	ADP	I
the	O	DET	I
curve	O	NOUN	I
with	O	ADP	O
conivaptan	B-I	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
and	O	CCONJ	O
80	O	NUM	O
mg/d	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
2.0-fold	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
2.5-fold	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
greater	O	ADJ	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
than	O	ADP	O
that	O	DET	O
with	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
median	O	ADJ	B
time	O	NOUN	O
to	O	PART	O
achieve	O	VERB	O
a	O	DET	O
confirmed	O	VERB	O
increase	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
[	O	PUNCT	O
Na	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
]	O	PUNCT	O
of	O	ADP	O
4	O	NUM	O
mEq/liter	O	NOUN	O
or	O	CCONJ	O
more	O	ADJ	O
from	O	ADP	O
baseline	O	NOUN	B
was	O	AUX	O
71.7	O	NUM	O
h	O	NOUN	O
for	O	ADP	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
27.5	O	NUM	O
h	O	NOUN	O
for	O	ADP	O
40	O	NUM	O
mg/d	O	NOUN	O
conivaptan	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.044	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
12.1	O	NUM	O
h	O	NOUN	O
for	O	ADP	O
80	O	NUM	O
mg/d	O	NOUN	O
conivaptan	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
total	O	ADJ	O
times	O	NOUN	O
during	O	ADP	O
which	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
serum	B-OUT	NOUN	B
[	I-OUT	PUNCT	O
Na	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
]	I-OUT	PUNCT	O
level	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
mEq/liter	O	NOUN	O
or	O	CCONJ	O
more	O	ADV	O
above	O	ADJ	O
baseline	O	NOUN	B
were	O	AUX	O
46.5	O	NUM	O
,	O	PUNCT	O
69.8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
88.8	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
least-squares	O	NOUN	B
mean	B-OUT	ADJ	I
change	I-OUT	NOUN	I
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
[	I-OUT	PUNCT	O
Na	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
]	I-OUT	PUNCT	O
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
was	O	AUX	O
3.4	O	NUM	O
mEq/liter	O	NOUN	O
for	O	ADP	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
6.4	O	NUM	O
mEq/liter	O	NOUN	O
for	O	ADP	O
40	O	NUM	O
mg/d	O	NOUN	O
conivaptan	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
8.2	O	NUM	O
mEq/liter	O	NOUN	O
for	O	ADP	O
80	O	NUM	O
mg/d	O	NOUN	O
conivaptan	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
confirmed	O	VERB	O
normal	B-OUT	ADJ	O
serum	I-OUT	NOUN	O
[	I-OUT	PUNCT	O
Na	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
+	I-OUT	CCONJ	O
)	I-OUT	PUNCT	O
]	I-OUT	PUNCT	O
(	O	PUNCT	O
>	O	X	O
/=135	O	PUNCT	O
mEq/liter	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
increase	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
mEq/liter	O	NOUN	B
or	O	CCONJ	O
more	O	ADJ	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
48	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
given	O	VERB	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
71	O	NUM	O
%	O	NOUN	O
given	O	VERB	O
40	O	NUM	O
mg/d	O	NOUN	O
conivaptan	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
82	O	NUM	O
%	O	NOUN	O
given	O	VERB	O
80	O	NUM	O
mg/d	O	NOUN	O
conivaptan	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.014	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Headache	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
hypotension	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
constipation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
postural	I-OUT	ADJ	B
hypotension	I-OUT	NOUN	I
were	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Oral	B-I	ADJ	B
conivaptan	I-I	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
and	O	CCONJ	O
80	O	NUM	O
mg/d	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
and	O	CCONJ	O
efficacious	O	ADJ	B
in	O	ADP	O
correcting	O	VERB	B
serum	O	NOUN	O
[	O	PUNCT	O
Na	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
]	O	PUNCT	O
in	O	ADP	O
hyponatremia	O	NOUN	B
.	O	PUNCT	O


Prevalence	B-OUT	NOUN	B
of	I-OUT	ADP	O
metabolic	I-OUT	ADJ	B
syndrome	I-OUT	NOUN	I
in	O	ADP	O
rural	B-P	ADJ	B
and	I-P	CCONJ	O
urban	I-P	ADJ	B
Chinese	I-P	ADJ	B
population	I-P	NOUN	I
in	I-P	ADP	O
Qingdao	I-P	PROPN	B
.	I-P	PUNCT	O


AIMS	O	NOUN	B
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
prevalence	B-OUT	NOUN	B
of	I-OUT	ADP	O
metabolic	I-OUT	ADJ	B
syndrome	I-OUT	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
components	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
rural	B-P	ADJ	B
and	I-P	CCONJ	O
urban	I-P	ADJ	B
Chinese	I-P	ADJ	B
population	I-P	NOUN	I
.	I-P	PUNCT	O


SUBJECTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
A	O	DET	O
population-based	B-I	ADJ	B
crosssectional	I-I	ADJ	O
survey	I-I	NOUN	O
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
Qingdao	B-P	PROPN	B
,	I-P	PUNCT	O
China	I-P	PROPN	B
in	I-P	ADP	O
2006	I-P	NUM	O
with	I-P	ADP	O
6100	I-P	NUM	O
Chinese	I-P	ADJ	B
aged	I-P	ADJ	B
35-74	I-P	NUM	O
yr	I-P	NOUN	O
invited	I-P	VERB	B
and	I-P	CCONJ	O
5355	I-P	NUM	O
who	I-P	PRON	O
attended	I-P	VERB	B
;	I-P	PUNCT	O
3357	I-P	NUM	O
subjects	I-P	NOUN	B
,	I-P	PUNCT	O
1562	I-P	NUM	O
urban	I-P	ADJ	B
(	I-P	PUNCT	O
46.5	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
1795	I-P	NUM	O
rural	I-P	ADJ	B
residents	I-P	NOUN	I
(	I-P	PUNCT	O
53.5	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
met	I-P	VERB	O
the	I-P	DET	O
inclusion	I-P	NOUN	B
criteria	I-P	NOUN	I
for	I-P	ADP	O
the	I-P	DET	O
current	I-P	ADJ	O
data	I-P	NOUN	B
analysis	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
metabolic	O	ADJ	B
syndrome	O	NOUN	I
definitions	O	NOUN	B
of	O	ADP	O
National	O	PROPN	B
Cholesterol	O	PROPN	I
Education	O	PROPN	I
Program	O	PROPN	I
Adult	O	PROPN	I
Treatment	O	PROPN	I
Expert	O	PROPN	I
Panel	O	PROPN	I
III	O	NUM	I
(	O	PUNCT	O
NCEPATPIII	O	PROPN	B
)	O	PUNCT	O
2004	O	NUM	O
,	O	PUNCT	O
NCEP	O	PROPN	B
2005	O	NUM	O
and	O	CCONJ	O
International	O	PROPN	B
Diabetes	O	PROPN	I
Federation	O	PROPN	I
(	O	PUNCT	O
IDF	O	PROPN	B
)	O	PUNCT	O
were	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
age-standardized	B-OUT	ADJ	B
prevalences	I-OUT	NOUN	B
of	I-OUT	ADP	O
metabolic	I-OUT	ADJ	B
syndrome	I-OUT	NOUN	I
were	O	AUX	O
16.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
32.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
28.3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
men	O	NOUN	B
and	O	CCONJ	O
26.8	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
37.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
34.6	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
women	O	NOUN	B
,	O	PUNCT	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
definitions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
NCEP	O	PROPN	B
2004	O	NUM	O
,	O	PUNCT	O
NCEP	O	PROPN	B
2005	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
IDF	O	PROPN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Urban	O	ADJ	B
men	O	NOUN	B
have	O	AUX	O
more	O	ADJ	O
risk	B-OUT	NOUN	B
factors	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
higher	I-OUT	ADJ	B
prevalence	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
metabolic	I-OUT	ADJ	B
syndrome	I-OUT	NOUN	I
than	O	ADP	O
rural	O	ADJ	B
men	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
differences	O	NOUN	B
in	O	ADP	O
women	O	NOUN	B
were	O	AUX	O
not	O	PART	O
that	O	ADV	O
striking	O	ADJ	B
.	O	PUNCT	O


Elevated	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
(	O	PUNCT	O
62.6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
,	O	PUNCT	O
among	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
,	O	PUNCT	O
most	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
population	O	NOUN	I
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
central	B-OUT	ADJ	B
obesity	I-OUT	NOUN	I
(	O	PUNCT	O
53.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
hyperglycemia	B-OUT	NOUN	B
(	O	PUNCT	O
52.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
defined	O	VERB	O
using	O	VERB	O
the	O	DET	O
NCEP	O	PROPN	B
2005	O	NUM	O
criteria	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Metabolic	O	ADJ	B
disorders	O	NOUN	I
were	O	AUX	O
common	O	ADJ	O
among	O	ADP	O
adult	B-P	ADJ	B
Chinese	I-P	PROPN	B
in	I-P	ADP	O
both	I-P	CCONJ	O
rural	I-P	ADJ	B
and	I-P	CCONJ	O
urban	I-P	ADJ	B
areas	I-P	NOUN	I
in	I-P	ADP	O
Qingdao	I-P	PROPN	B
.	I-P	PUNCT	O


A	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
FemCap	B-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
new	I-I	ADJ	O
vaginal	I-I	ADJ	B
barrier	I-I	NOUN	I
contraceptive	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Ortho	B-I	PROPN	B
All-Flex	I-I	ADJ	I
diaphragm	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
FemCap	O	PROPN	B
Investigators	O	PROPN	I
'	O	PART	O
Group	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
FemCap	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
new	O	ADJ	O
silicone	O	NOUN	B
rubber	O	NOUN	B
barrier	O	NOUN	I
contraceptive	O	NOUN	B
shaped	O	VERB	O
like	O	ADP	O
a	O	DET	O
sailor	O	NOUN	B
's	O	PART	I
hat	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
dome	O	NOUN	B
that	O	PRON	O
covers	O	VERB	O
the	O	DET	O
cervix	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
rim	O	NOUN	B
that	O	PRON	O
fits	O	VERB	O
into	O	ADP	O
the	O	DET	O
fornices	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
brim	O	NOUN	B
that	O	PRON	O
conforms	O	VERB	O
to	O	ADP	O
the	O	DET	O
vaginal	O	ADJ	B
walls	O	NOUN	I
around	O	ADP	O
the	O	DET	O
cervix	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
fewer	O	ADJ	O
dislodgments	O	NOUN	B
and	O	CCONJ	O
less	O	ADJ	O
pressure	O	NOUN	B
on	O	ADP	O
the	O	DET	O
urethra	O	NOUN	B
than	O	ADP	O
the	O	DET	O
cervical	O	ADJ	B
cap	O	NOUN	I
and	O	CCONJ	O
diaphragm	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
require	O	VERB	O
less	O	ADJ	O
clinician	O	ADJ	B
time	O	NOUN	O
for	O	ADP	O
fitting	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
a	O	DET	O
phase	O	NOUN	B
II/III	O	ADJ	I
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	B
group	O	NOUN	I
study	O	NOUN	I
of	O	ADP	O
841	B-P	NUM	O
women	I-P	NOUN	B
at	I-P	ADP	O
risk	I-P	NOUN	B
for	I-P	ADP	O
pregnancy	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
subset	B-P	NOUN	O
of	I-P	ADP	O
42	I-P	NUM	O
women	I-P	NOUN	B
at	I-P	ADP	O
one	I-P	NUM	O
site	I-P	NOUN	B
underwent	I-P	VERB	O
colposcopy	I-P	NOUN	B
.	I-P	PUNCT	O


Women	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
use	O	VERB	O
the	O	DET	O
FemCap	B-I	NOUN	B
or	I-I	CCONJ	O
Ortho	I-I	ADJ	B
All-Flex	I-I	ADJ	I
contraceptive	I-I	ADJ	I
diaphragm	I-I	NOUN	I
,	I-I	PUNCT	O
both	I-I	CCONJ	O
with	I-I	ADP	O
2	I-I	NUM	O
%	I-I	NOUN	O
nonoxynol-9	I-I	NOUN	B
spermicide	I-I	NOUN	I
,	O	PUNCT	O
for	O	ADP	O
28	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objectives	O	NOUN	B
were	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
two	O	NUM	O
devices	O	NOUN	B
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
their	O	PRON	O
safety	O	NOUN	B
and	O	CCONJ	O
acceptability	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
probability	B-OUT	NOUN	B
of	I-OUT	ADP	O
pregnancy	I-OUT	NOUN	B
among	O	ADP	O
FemCap	B-I	NOUN	B
users	O	NOUN	B
was	O	AUX	O
no	O	ADV	O
worse	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
diaphragm	B-I	NOUN	B
(	O	PUNCT	O
meaning	O	VERB	O
not	O	PART	O
more	O	ADJ	O
than	O	ADP	O
6	O	NUM	O
percentage	O	NOUN	O
points	O	NOUN	O
higher	O	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
6-month	B-OUT	ADJ	O
Kaplan-Meier	I-OUT	ADJ	B
cumulative	I-OUT	ADJ	I
unadjusted	O	ADJ	B
typical	O	ADJ	O
use	O	NOUN	O
pregnancy	O	NOUN	B
probabilities	O	NOUN	I
were	O	AUX	O
13.5	O	NUM	O
%	O	NOUN	O
among	O	ADP	O
FemCap	B-I	NOUN	B
users	O	NOUN	I
and	O	CCONJ	O
7.9	O	NUM	O
%	O	NOUN	O
among	O	ADP	O
diaphragm	B-I	NOUN	B
users	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
adjusted	B-OUT	ADJ	O
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
pregnancy	I-OUT	NOUN	B
among	O	ADP	O
FemCap	B-I	NOUN	B
users	O	NOUN	B
was	O	AUX	O
1.96	O	NUM	O
times	O	NOUN	O
that	O	SCONJ	O
among	O	ADP	O
diaphragm	B-I	NOUN	B
users	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
upper	O	ADJ	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
limit	O	NOUN	I
of	O	ADP	O
3.01	O	NUM	O
.	O	PUNCT	O


Clinical	B-OUT	ADJ	B
equivalence	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
noninferiority	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
of	O	ADP	O
the	O	DET	O
FemCap	B-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
diaphragm	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
defined	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
would	O	AUX	O
mean	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
true	B-OUT	ADJ	O
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
pregnancy	I-OUT	NOUN	B
among	O	ADP	O
FemCap	B-I	NOUN	B
users	O	NOUN	B
was	O	AUX	O
no	O	DET	O
more	O	ADJ	O
than	O	ADP	O
1.73	O	NUM	O
times	O	NOUN	O
the	O	DET	O
pregnancy	B-OUT	NOUN	B
risk	I-OUT	NOUN	I
of	O	ADP	O
diaphragm	B-I	NOUN	B
users	O	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
the	O	DET	O
observed	O	VERB	B
upper	O	ADJ	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
limit	O	NOUN	I
(	O	PUNCT	O
and	O	CCONJ	O
even	O	ADV	O
the	O	DET	O
point	O	NOUN	O
estimate	O	NOUN	O
)	O	PUNCT	O
exceeded	O	VERB	O
1.73	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
probability	B-OUT	NOUN	B
of	I-OUT	ADP	O
pregnancy	I-OUT	NOUN	B
among	I-OUT	ADP	O
FemCap	I-OUT	NOUN	B
users	O	NOUN	I
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
among	O	ADP	O
diaphragm	B-I	NOUN	B
users	O	NOUN	I
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
meet	O	VERB	O
the	O	DET	O
definition	O	NOUN	B
of	O	ADP	O
clinical	B-OUT	ADJ	B
equivalence	I-OUT	NOUN	B
used	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
FemCap	B-I	NOUN	B
was	O	AUX	O
believed	O	VERB	O
to	O	PART	O
be	O	AUX	O
safe	B-OUT	ADJ	O
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
significantly	O	ADV	O
fewer	O	ADJ	O
urinary	B-OUT	ADJ	B
tract	I-OUT	NOUN	I
infections	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


More	O	ADJ	O
women	B-P	NOUN	B
reported	O	VERB	B
problems	O	NOUN	B
with	O	ADP	O
the	O	DET	O
FemCap	B-I	NOUN	B
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
insertion	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
dislodgement	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
especially	I-OUT	ADV	O
removal	I-OUT	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
their	O	PRON	O
general	O	ADJ	O
assessments	O	NOUN	B
were	O	AUX	O
positive	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
devices	O	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
acceptability	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
a	O	DET	O
6-point	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
true	O	ADJ	O
6-month	B-OUT	ADJ	O
pregnancy	I-OUT	NOUN	B
probabilities	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
devices	O	NOUN	B
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
ruled	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
design	O	NOUN	B
modifications	O	NOUN	B
can	O	AUX	O
simplify	O	VERB	O
insertion	O	NOUN	B
and	O	CCONJ	O
removal	O	NOUN	B
.	O	PUNCT	O


Double-blind	O	ADJ	B
efficacy	O	NOUN	B
study	B-P	NOUN	B
of	I-P	ADP	O
selenium	I-I	NOUN	B
sulfide	I-I	NOUN	B
in	I-P	ADP	O
tinea	I-P	NOUN	B
versicolor	I-P	NOUN	I
.	I-P	PUNCT	O


Selenium	B-I	NOUN	B
sulfide	I-I	NOUN	B
(	I-I	PUNCT	O
2.5	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
lotion	I-I	NOUN	B
applied	O	VERB	O
daily	O	ADV	O
for	O	ADP	O
10	O	NUM	O
minutes	O	NOUN	B
for	O	ADP	O
7	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
therapeutic	O	ADJ	B
agent	O	NOUN	I
,	O	PUNCT	O
significantly	O	ADV	O
superior	O	ADJ	O
to	O	PART	O
the	O	DET	O
vehicle	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
tinea	B-P	NOUN	B
versicolor	I-P	NOUN	I
.	I-P	PUNCT	O


Mild	B-OUT	ADJ	B
transitory	I-OUT	ADJ	I
contact	I-OUT	NOUN	I
dermatitis	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
irritant	O	ADJ	B
type	O	NOUN	O
occurred	O	VERB	O
in	O	ADP	O
all	O	DET	O
the	O	DET	O
treatment	B-P	NOUN	B
groups	I-P	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
apparently	O	ADV	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
detergent	O	NOUN	B
base	O	NOUN	I
.	O	PUNCT	O


Peripheral	O	ADJ	B
arterial	O	ADJ	I
disease	O	NOUN	I
:	O	PUNCT	O
therapeutic	O	ADJ	B
confidence	O	NOUN	I
of	O	ADP	O
CT	B-I	NOUN	B
versus	I-I	CCONJ	O
digital	I-I	ADJ	B
subtraction	I-I	NOUN	I
angiography	I-I	NOUN	I
and	O	CCONJ	O
effects	O	NOUN	B
on	O	ADP	O
additional	O	ADJ	O
imaging	O	NOUN	B
recommendations	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
compare	O	VERB	O
multi-detector	B-I	ADJ	B
row	I-I	NOUN	I
computed	I-I	ADJ	I
tomographic	I-I	NOUN	I
(	I-I	PUNCT	O
CT	I-I	NOUN	B
)	I-I	PUNCT	O
angiography	I-I	NOUN	B
and	I-I	CCONJ	O
digital	I-I	ADJ	B
subtraction	I-I	NOUN	I
angiography	I-I	NOUN	I
(	I-I	PUNCT	O
DSA	I-I	NOUN	B
)	I-I	PUNCT	O
prior	O	ADJ	O
to	O	PART	O
revascularization	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
symptomatic	I-P	ADJ	B
peripheral	I-P	ADJ	B
arterial	I-P	ADJ	I
disease	I-P	NOUN	I
for	O	ADP	O
the	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
assessing	O	VERB	O
recommendations	O	NOUN	B
for	O	ADP	O
additional	O	ADJ	O
imaging	O	NOUN	B
and	O	CCONJ	O
physician	O	NOUN	B
confidence	O	NOUN	B
ratings	O	NOUN	I
for	O	ADP	O
chosen	O	VERB	O
therapy	O	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
,	O	PUNCT	O
73	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
assigned	I-P	VERB	O
to	I-P	PART	O
CT	I-I	NOUN	B
angiography	I-I	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
72	I-P	NUM	O
were	I-P	AUX	O
assigned	I-P	VERB	O
to	I-P	PART	O
DSA	I-I	NOUN	B
.	I-I	PUNCT	O


Physician	B-OUT	ADJ	B
confidence	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
treatment	I-OUT	NOUN	B
decision	I-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	B
as	O	ADP	O
a	O	DET	O
continuous	O	ADJ	B
outcome	O	NOUN	B
on	O	ADP	O
a	O	DET	O
scale	O	NOUN	O
of	O	ADP	O
0-10	O	NUM	O
(	O	PUNCT	O
uncertain	O	ADJ	O
to	O	PART	O
certain	O	ADJ	O
)	O	PUNCT	O
and	O	CCONJ	O
as	O	ADP	O
a	O	DET	O
dichotomous	B-OUT	ADJ	B
outcome	I-OUT	NOUN	I
(	O	PUNCT	O
further	O	ADV	O
imaging	O	NOUN	B
recommended	O	VERB	B
,	O	PUNCT	O
yes	O	INTJ	O
or	O	CCONJ	O
no	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


Mean	B-OUT	VERB	B
confidence	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
and	O	CCONJ	O
additional	B-OUT	ADJ	O
imaging	I-OUT	NOUN	B
recommendations	I-OUT	NOUN	B
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
CT	B-I	NOUN	B
and	I-I	CCONJ	O
DSA	I-I	NOUN	B
groups	O	NOUN	B
in	O	ADP	O
an	O	DET	O
intention-to-diagnose-and-treat	O	NOUN	O
analysis	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
detect	O	VERB	B
trends	O	NOUN	B
in	O	ADP	O
confidence	O	NOUN	B
,	O	PUNCT	O
confidence	O	NOUN	B
scores	O	NOUN	I
were	O	AUX	O
plotted	O	VERB	O
over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
multiple	O	ADJ	B
linear	O	ADJ	I
regression	O	NOUN	I
analysis	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


To	O	PART	O
detect	O	VERB	B
trends	O	NOUN	B
in	O	ADP	O
additional	B-OUT	ADJ	O
imaging	I-OUT	NOUN	B
recommendations	I-OUT	NOUN	B
,	O	PUNCT	O
logistic	O	ADJ	B
regression	O	NOUN	I
analysis	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Data	O	NOUN	B
from	O	ADP	O
eligible	O	ADJ	O
nonrandomized	O	ADJ	B
patients	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
separately	O	ADV	O
.	O	PUNCT	O


RESULTS	O	VERB	O
No	B-OUT	DET	O
statistically	I-OUT	ADV	O
significant	I-OUT	ADJ	O
difference	I-OUT	NOUN	O
in	O	ADP	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
between	O	ADP	O
randomized	O	ADJ	B
groups	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


CT	B-I	NOUN	B
had	O	AUX	O
a	O	DET	O
lower	B-OUT	ADJ	B
confidence	I-OUT	NOUN	B
score	I-OUT	NOUN	I
than	O	ADP	O
did	O	AUX	O
DSA	B-I	PROPN	B
(	O	PUNCT	O
7.2	O	NUM	O
vs	O	CCONJ	O
8.2	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Further	O	ADV	O
imaging	O	NOUN	B
was	O	AUX	O
recommended	O	VERB	O
more	O	ADV	O
often	O	ADV	O
after	O	ADP	O
CT	B-I	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
of	O	ADP	O
71	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
35	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
after	O	ADP	O
DSA	B-I	NOUN	B
(	O	PUNCT	O
nine	O	NUM	O
of	O	ADP	O
66	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
trends	O	NOUN	B
demonstrated	O	VERB	O
increasing	O	VERB	B
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
)	O	PUNCT	O
confidence	B-OUT	NOUN	B
in	O	ADP	O
CT	B-I	NOUN	B
and	O	CCONJ	O
stable	O	ADJ	B
confidence	B-OUT	NOUN	I
in	O	ADP	O
DSA	B-I	NOUN	B
.	I-I	PUNCT	O


No	B-OUT	DET	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
between	O	ADP	O
randomized	O	ADJ	B
and	O	CCONJ	O
nonrandomized	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
nonrandomized	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
mean	B-OUT	ADJ	B
confidence	I-OUT	NOUN	I
score	I-OUT	NOUN	I
(	O	PUNCT	O
8.2	O	NUM	O
vs	O	CCONJ	O
8.3	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.26	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
CT	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
24	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
DSA	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
26	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
With	O	ADP	O
CT	B-I	NOUN	B
angiography	I-I	NOUN	I
,	O	PUNCT	O
physician	O	NOUN	B
confidence	O	NOUN	B
decreases	O	VERB	B
with	O	ADP	O
an	O	DET	O
associated	O	VERB	O
increase	O	NOUN	B
in	O	ADP	O
additional	O	ADJ	O
imaging	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
revascularization	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
symptomatic	I-P	ADJ	B
peripheral	I-P	ADJ	B
arterial	I-P	ADJ	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Given	O	VERB	O
that	O	SCONJ	O
CT	B-I	NOUN	B
is	O	AUX	O
less	O	ADV	O
invasive	O	ADJ	B
than	O	ADP	O
DSA	B-I	NOUN	B
,	O	PUNCT	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
CT	B-I	NOUN	B
may	O	AUX	O
replace	O	VERB	O
DSA	B-I	NOUN	B
in	O	ADP	O
selected	O	VERB	O
cases	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
oral	B-I	ADJ	B
human	I-I	ADJ	B
immunoglobulin	I-I	NOUN	B
for	O	ADP	O
gastrointestinal	B-P	ADJ	B
dysfunction	I-P	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Controversy	O	NOUN	B
exists	O	VERB	O
regarding	O	VERB	O
the	O	DET	O
extent	O	NOUN	B
and	O	CCONJ	O
possible	O	ADJ	O
causal	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
gastrointestinal	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
autism	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	O
groups	O	NOUN	B
,	O	PUNCT	O
dose-ranging	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
oral	B-I	ADJ	B
,	I-I	PUNCT	O
human	I-I	ADJ	B
immunoglobulin	I-I	NOUN	I
(	I-I	PUNCT	O
IGOH	I-I	PROPN	B
140	O	NUM	O
,	O	PUNCT	O
420	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
840	O	NUM	O
mg/day	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
utilized	O	VERB	O
with	O	ADP	O
125	B-P	NUM	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
ages	I-P	NOUN	B
2-17	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
autism	I-P	NOUN	B
and	I-P	CCONJ	O
persistent	I-P	ADJ	B
GI	I-P	NOUN	B
symptoms	I-P	NOUN	B
.	I-P	PUNCT	O


Endpoint	O	NOUN	B
analysis	O	NOUN	I
revealed	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
across	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
on	O	ADP	O
a	O	DET	O
modified	O	ADJ	O
global	B-OUT	ADJ	B
improvement	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	O	PUNCT	O
validated	O	VERB	O
in	O	ADP	O
irritable	B-OUT	ADJ	B
bowel	I-OUT	NOUN	I
syndrome	I-OUT	NOUN	I
studies	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
daily	I-OUT	ADJ	B
bowel	I-OUT	NOUN	O
movements	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
days	I-OUT	NOUN	B
of	I-OUT	ADP	O
constipation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
problem	I-OUT	NOUN	B
behaviors	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


IGOH	B-I	PROPN	B
was	O	AUX	O
well-tolerated	B-OUT	ADJ	O
;	I-OUT	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
serious	B-OUT	ADJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
demonstrates	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
conducting	O	VERB	O
rigorous	O	ADJ	O
trials	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
and	O	CCONJ	O
casts	O	NOUN	B
doubt	O	VERB	O
on	O	ADP	O
one	O	NUM	O
GI	O	NOUN	B
mechanism	O	NOUN	B
presumed	O	VERB	O
to	O	PART	O
exert	O	VERB	O
etiological	O	ADJ	B
and/or	O	CCONJ	O
symptomatic	O	ADJ	B
effects	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


Irrigation	B-P	NOUN	B
with	I-P	ADP	O
bupivacaine	I-I	NOUN	B
at	I-P	ADP	O
the	I-P	DET	O
surgical	I-P	ADJ	B
bed	I-P	NOUN	I
for	I-P	ADP	O
postoperative	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
relief	I-OUT	NOUN	O
after	I-P	ADP	O
laparoscopic	I-P	ADJ	B
cholecystectomy	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	B-OUT	NOUN	B
of	O	ADP	O
bupivacaine	B-I	NOUN	B
irrigated	O	VERB	B
at	O	ADP	O
the	O	DET	O
surgical	O	ADJ	B
bed	O	NOUN	I
on	O	ADP	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
relief	I-OUT	NOUN	O
in	O	ADP	O
laparoscopic	B-P	ADJ	B
cholecystectomy	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
included	O	VERB	O
60	B-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
laparoscopic	I-P	ADJ	I
cholecystectomy	I-P	NOUN	I
who	I-P	PRON	O
were	I-P	AUX	O
prospectively	I-P	ADV	O
randomized	I-P	VERB	B
into	I-P	ADP	O
2	I-P	NUM	O
groups	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
n=30	O	NOUN	O
)	O	PUNCT	O
received	O	VERB	O
20cc	B-I	ADJ	O
saline	I-I	NOUN	B
without	I-I	ADP	O
bupivacaine	I-I	NOUN	B
,	O	PUNCT	O
installed	O	VERB	O
into	O	ADP	O
the	O	DET	O
gallbladder	O	NOUN	B
bed	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
bupivacaine	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
n=30	O	NOUN	O
)	O	PUNCT	O
received	O	VERB	O
20cc	O	NOUN	O
of	O	ADP	O
0.5	B-I	NUM	O
%	I-I	NOUN	O
bupivacaine	I-I	NOUN	B
in	O	ADP	O
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
surgical	O	ADJ	B
site	O	NOUN	I
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
0	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	O
by	O	ADP	O
using	O	VERB	O
a	O	DET	O
visual	O	ADJ	B
analog	O	NOUN	I
scale	O	NOUN	I
(	O	PUNCT	O
VAS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
(	O	PUNCT	O
P=.018	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
pain	B-OUT	NOUN	B
levels	I-OUT	NOUN	I
between	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
at	O	ADP	O
6	O	NUM	O
hours	O	NOUN	B
postoperatively	O	ADV	B
.	O	PUNCT	O


The	O	DET	O
average	B-OUT	ADJ	B
analgesic	I-OUT	NOUN	B
requirement	I-OUT	NOUN	O
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
bupivacaine	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
statistical	O	ADJ	B
significance	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
bupivacaine	B-I	NOUN	B
irrigated	O	VERB	B
over	O	ADP	O
the	O	DET	O
surgical	O	ADJ	B
bed	O	NOUN	I
was	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
method	O	NOUN	B
for	O	ADP	O
reducing	O	VERB	B
pain	B-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
postoperative	O	ADJ	B
hours	O	NOUN	I
after	O	ADP	O
laparoscopic	O	ADJ	B
cholecystectomy	O	NOUN	I
.	O	PUNCT	O


Safety	O	NOUN	B
and	O	CCONJ	O
immunogenicity	O	NOUN	B
of	O	ADP	O
an	O	DET	O
oral	B-I	ADJ	B
,	I-I	PUNCT	O
inactivated	I-I	VERB	B
,	I-I	PUNCT	O
whole-cell	I-I	ADJ	B
vaccine	I-I	NOUN	I
for	I-I	ADP	O
Shigella	I-I	NOUN	B
sonnei	I-I	NOUN	I
:	I-I	PUNCT	O
preclinical	O	ADJ	B
studies	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
Phase	O	NOUN	B
I	O	NUM	I
trial	O	NOUN	I
.	O	PUNCT	O


Orally	O	ADV	B
delivered	O	VERB	O
,	O	PUNCT	O
inactivated	O	VERB	B
whole-cell	O	ADJ	O
vaccines	B-I	NOUN	B
are	O	AUX	O
safe	O	ADJ	O
methods	O	NOUN	B
of	O	ADP	O
inducing	O	VERB	B
local	O	ADJ	B
and	O	CCONJ	O
systemic	O	ADJ	B
immunity	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
increase	O	VERB	B
surface	B-OUT	NOUN	B
proteins	I-OUT	NOUN	I
associated	O	VERB	B
with	O	ADP	I
adherence	O	NOUN	B
and	O	CCONJ	O
invasion	O	NOUN	B
,	O	PUNCT	O
Shigella	O	NOUN	B
sonnei	O	NOUN	I
were	O	AUX	O
grown	O	VERB	O
in	O	ADP	O
BHI	O	NOUN	B
broth	O	NOUN	I
containing	O	VERB	O
deoxycholate	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
whole-cell	B-I	ADJ	B
vaccine	I-I	NOUN	I
(	I-I	PUNCT	O
SsWC	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
then	O	ADV	O
produced	O	VERB	O
by	O	ADP	O
formalin	O	NOUN	B
inactivation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
pre-clinical	O	ADJ	B
studies	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
SsWC	B-I	PROPN	B
vaccine	I-I	NOUN	B
was	O	AUX	O
immunogenic	O	ADJ	B
and	O	CCONJ	O
protected	O	VERB	O
against	O	ADP	O
S.	O	X	B
sonnei-induced	O	ADJ	I
keratoconjunctivitis	O	NOUN	I
in	O	ADP	O
the	O	DET	O
guinea	B-P	NOUN	B
pig	I-P	NOUN	I
model	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
Phase	B-P	NOUN	B
I	I-P	NUM	I
study	I-P	VERB	I
,	I-P	PUNCT	O
10	I-P	NUM	O
evaluable	I-P	ADJ	O
subjects	I-P	NOUN	B
received	O	VERB	O
either	O	CCONJ	O
three	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
SsWC	B-I	NOUN	B
on	O	ADP	O
Days	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
28	O	NUM	O
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
five	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
SsWC	B-I	NOUN	B
on	O	ADP	O
Days	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
28	O	NUM	O
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Each	O	DET	O
dose	O	NOUN	B
contained	O	VERB	O
2.0	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
inactivated	O	VERB	B
cells	O	NOUN	I
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
fecal	I-OUT	ADJ	B
antibodies	I-OUT	NOUN	I
against	I-OUT	ADP	O
SsWC	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
LPS	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
IpaC	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	O
by	O	ADP	O
ELISA	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
4-fold	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
titer	O	NOUN	B
was	O	AUX	O
considered	O	VERB	O
significant	O	ADJ	B
.	O	PUNCT	O


Both	O	DET	O
SsWC	B-I	NOUN	B
dosing	O	NOUN	B
regimens	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
.	I-OUT	PUNCT	O


No	O	DET	O
fever	B-OUT	NOUN	O
or	I-OUT	CCONJ	O
severe	I-OUT	ADJ	B
gastrointestinal	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
were	O	AUX	O
noted	O	VERB	O
by	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
vaccinated	O	VERB	B
subjects	O	NOUN	B
.	O	PUNCT	O


Antibody	B-OUT	NOUN	B
responses	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
dosing	O	VERB	B
groups	O	NOUN	B
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
IgG	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
IgA	I-OUT	NOUN	B
responses	I-OUT	NOUN	B
to	O	PART	O
SsWC	B-I	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
six	O	NUM	O
of	O	ADP	O
seven	O	NUM	O
vaccinees	O	NOUN	B
(	O	PUNCT	O
86	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
to	O	PART	O
LPS	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
of	O	ADP	O
seven	O	NUM	O
(	O	PUNCT	O
57	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
IpaC	O	NOUN	B
in	O	ADP	O
five	O	NUM	O
of	O	ADP	O
seven	O	NUM	O
(	O	PUNCT	O
61	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Fecal	B-OUT	ADJ	B
IgA	I-OUT	NOUN	O
responses	I-OUT	NOUN	B
to	O	PART	O
these	O	DET	O
three	O	NUM	O
antigens	O	NOUN	B
developed	O	VERB	O
in	O	ADP	O
five	O	NUM	O
of	O	ADP	O
five	O	NUM	O
,	O	PUNCT	O
three	O	NUM	O
of	O	ADP	O
five	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
of	O	ADP	O
five	O	NUM	O
subjects	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
seven	O	NUM	O
vaccinees	O	NOUN	B
,	O	PUNCT	O
geometric	O	ADJ	B
mean	O	NOUN	O
rises	O	VERB	O
in	O	ADP	O
serum	B-OUT	NOUN	B
IgA	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
to	O	ADP	O
all	O	DET	O
three	O	NUM	O
immunogens	O	NOUN	B
were	O	AUX	O
significant	O	ADJ	B
;	O	PUNCT	O
IgG	B-OUT	NOUN	B
increases	I-OUT	NOUN	B
trended	O	VERB	O
toward	O	ADP	O
significance	O	NOUN	B
(	O	PUNCT	O
paired	O	VERB	B
one-tailed	O	ADJ	I
t-test	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
SsWC	B-I	NOUN	B
was	O	AUX	O
immunogenic	B-OUT	ADJ	B
and	O	CCONJ	O
protective	B-OUT	ADJ	B
in	O	ADP	O
animal	O	NOUN	B
studies	O	NOUN	I
and	O	CCONJ	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
and	O	CCONJ	O
immunogenic	B-OUT	ADJ	B
in	O	ADP	O
a	O	DET	O
Phase	O	NOUN	B
I	O	NUM	I
trial	O	NOUN	I
.	O	PUNCT	O


Salmeterol	B-I	NOUN	B
versus	O	CCONJ	O
slow-release	O	ADJ	B
theophylline	B-I	NOUN	B
combined	O	VERB	O
with	O	ADP	O
ketotifen	B-I	NOUN	B
in	O	ADP	O
nocturnal	B-P	ADJ	B
asthma	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
multicentre	B-P	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


French	B-P	PROPN	B
Multicentre	I-P	PROPN	I
Study	I-P	PROPN	I
Group	I-P	PROPN	I
.	I-P	PUNCT	O


We	O	PRON	O
wished	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
inhaled	O	ADJ	B
salmeterol	B-I	NOUN	I
(	O	PUNCT	O
SML	O	NOUN	B
;	O	PUNCT	O
50	O	NUM	O
micrograms	O	NOUN	O
b.i.d	O	NOUN	B
.	O	PUNCT	O


)	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
slow-release	O	ADJ	B
theophylline	B-I	NOUN	B
and	I-I	CCONJ	O
ketotifen	I-I	NOUN	B
p.o	O	PROPN	O
.	O	PUNCT	O


(	O	PUNCT	O
TK	O	NOUN	B
;	O	PUNCT	O
T	O	NOUN	O
300	O	NUM	O
mg+K	O	NOUN	O
1	O	NUM	O
mg	O	NOUN	O
b.i.d	O	NOUN	B
.	O	PUNCT	O


)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
nocturnal	O	ADJ	B
asthma	O	NOUN	I
.	O	PUNCT	O


Ninety	B-P	NUM	O
six	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
nocturnal	I-P	ADJ	B
asthma	I-P	NOUN	I
,	I-P	PUNCT	O
(	I-P	PUNCT	O
forced	I-P	VERB	B
expiratory	I-P	ADJ	I
volume	I-P	NOUN	I
in	I-P	ADP	O
one	I-P	NUM	O
second	I-P	NOUN	O
(	I-P	PUNCT	O
FEV1	I-P	NOUN	B
)	I-P	PUNCT	O
60-90	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
predicted	I-P	VERB	B
value	I-P	NOUN	I
,	I-P	PUNCT	O
reversibility	I-P	NOUN	B
>	I-P	NOUN	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
15	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
at	I-P	ADP	O
least	I-P	ADJ	O
two	I-P	NUM	O
nocturnal	I-P	ADJ	B
awakenings	I-P	NOUN	B
per	I-P	ADP	O
week	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
eligible	O	ADJ	B
for	O	ADP	O
a	O	DET	O
multicentre	B-P	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
double-dummy	O	ADJ	B
cross-over	O	ADJ	I
study	O	NOUN	I
(	O	PUNCT	O
14-day	O	ADJ	O
run-in	O	ADJ	B
,	O	PUNCT	O
two	O	NUM	O
successive	O	ADJ	O
28-day	O	ADJ	O
treatment	O	NOUN	B
periods	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
was	I-OUT	AUX	O
assessed	I-OUT	VERB	B
as	I-OUT	ADP	O
success/failure	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
success	I-OUT	NOUN	B
being	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
the	O	DET	O
complete	O	ADJ	O
disappearance	O	NOUN	B
of	O	ADP	O
nocturnal	O	ADJ	B
symptoms/awakening	O	NOUN	B
during	O	ADP	O
the	O	DET	O
last	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
statistically	B-OUT	ADV	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
between	O	ADP	O
SML	O	NOUN	B
and	O	CCONJ	O
TK	O	NOUN	B
for	O	ADP	O
this	O	DET	O
criterion	O	NOUN	B
:	O	PUNCT	O
46	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
39	O	NUM	O
%	O	NOUN	O
success	O	NOUN	B
with	O	ADP	O
SML	O	NOUN	B
during	O	ADP	O
periods	O	NOUN	B
I	O	NOUN	I
(	O	PUNCT	O
first	O	ADJ	O
28-day	O	ADJ	O
period	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
II	O	NUM	B
(	O	PUNCT	O
following	O	VERB	O
the	O	DET	O
cross-over	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
only	O	ADV	O
15	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
26	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
TK	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


SML	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
better	O	ADJ	O
for	O	ADP	O
the	O	DET	O
other	B-OUT	ADJ	O
criteria	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
lung	I-OUT	NOUN	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
rescue	I-OUT	NOUN	B
salbutamol	I-OUT	NOUN	B
intake	I-OUT	NOUN	B
during	I-OUT	ADP	O
day	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
night	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Side-effects	B-OUT	NOUN	B
were	O	AUX	O
five	O	NUM	O
times	O	NOUN	O
less	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
SML-treated	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerance	I-OUT	NOUN	B
of	O	ADP	O
SML	O	NOUN	B
were	O	AUX	O
obviously	O	ADV	O
far	O	ADV	O
better	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
TK	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
nocturnal	I-P	ADJ	B
asthma	I-P	NOUN	I
.	I-P	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
angiotensin-converting	O	ADJ	B
enzyme	O	NOUN	I
gene	O	NOUN	I
polymorphism	O	NOUN	B
on	O	ADP	O
neurohormonal	B-OUT	ADJ	B
responses	I-OUT	NOUN	I
to	O	PART	O
high-	O	NOUN	O
versus	O	CCONJ	O
low-dose	O	ADJ	B
enalapril	O	NOUN	B
in	O	ADP	O
advanced	B-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
angiotensin-converting	O	ADJ	B
enzyme	O	NOUN	I
(	O	PUNCT	O
ACE	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
polymorphism	O	NOUN	I
on	O	ADP	O
neurohormonal	O	ADJ	B
dose	O	NOUN	O
response	O	NOUN	O
to	O	PART	O
ACE	B-I	NOUN	B
inhibitor	O	NOUN	I
therapy	O	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


METHODS	O	NOUN	O
ACE	O	NOUN	B
Insertion	O	PROPN	B
(	O	PUNCT	O
I	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
Deletion	O	NOUN	B
(	O	PUNCT	O
D	O	NOUN	B
)	O	PUNCT	O
genotype	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
74	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
who	O	PRON	O
were	O	AUX	O
randomly	B-I	ADV	O
assigned	I-I	VERB	O
to	I-I	PART	O
receive	I-I	VERB	O
either	I-I	CCONJ	O
high-dose	I-I	ADJ	B
or	I-I	CCONJ	O
low-dose	I-I	ADJ	B
enalapril	I-I	NOUN	B
over	I-I	ADP	O
a	I-I	DET	O
period	I-I	NOUN	B
of	I-I	ADP	O
6	I-I	NUM	O
months	I-I	NOUN	B
.	I-I	PUNCT	O


Monthly	B-I	ADJ	B
pre-enalapril	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
post-enalapril	I-OUT	ADJ	B
neurohormone	I-OUT	NOUN	O
levels	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
serum	I-OUT	NOUN	B
ACE	I-OUT	NOUN	I
activity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
sACE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
angiotensin	I-OUT	NOUN	I
II	I-OUT	NUM	I
(	I-OUT	PUNCT	O
A-II	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
renin	I-OUT	NOUN	O
activity	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
PRA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
aldosterone	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ALDO	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
genotype	O	NOUN	B
subgroups	O	NOUN	B
and	O	CCONJ	O
between	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
high-	O	NOUN	O
or	O	CCONJ	O
low-dose	O	ADJ	B
enalapril	B-I	NOUN	B
within	O	ADP	O
each	O	DET	O
genotype	O	NOUN	B
subgroup	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
predose/postdose	B-OUT	NOUN	B
sACE	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
postdose	I-OUT	NOUN	B
PRA	I-OUT	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
DD	B-P	NOUN	B
genotype	I-P	NOUN	B
.	I-P	PUNCT	O


At	O	ADP	O
6-month	O	ADJ	O
follow-up	O	NOUN	B
,	O	PUNCT	O
postdose	B-OUT	NOUN	B
sACE	I-OUT	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
a	O	DET	O
dose-dependent	O	ADJ	B
fashion	O	NOUN	O
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
genotypes	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
predose	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
postdose	I-OUT	NOUN	B
ALDO	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
A-II	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
each	O	DET	O
genotype	O	NOUN	B
subgroup	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
or	O	CCONJ	O
by	O	ADP	O
enalapril	O	ADJ	B
dose	O	NOUN	I
within	O	ADP	O
each	O	DET	O
genotype	O	NOUN	B
subgroup	O	NOUN	B
.	O	PUNCT	O


ALDO	B-OUT	NOUN	B
escape	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
A-II	I-OUT	NOUN	B
reactivation	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
affected	O	VERB	O
by	O	ADP	O
ACE	B-P	NOUN	B
genotype	I-P	NOUN	B
or	O	CCONJ	O
enalapril	O	ADJ	B
dosage	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Predose	B-OUT	NOUN	B
sACE	I-OUT	NOUN	B
were	O	AUX	O
consistently	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
DD	O	NOUN	B
genotype	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
ID	B-P	PROPN	B
or	I-P	CCONJ	O
II	I-P	NUM	B
subgroups	I-P	NOUN	B
.	I-P	PUNCT	O


Despite	O	SCONJ	O
a	O	DET	O
dose-dependent	O	ADJ	B
suppression	B-OUT	NOUN	B
of	I-OUT	ADP	O
sACE	I-OUT	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
observed	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
ALDO	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
A-II	I-OUT	NOUN	B
suppression	I-OUT	NOUN	B
or	O	CCONJ	O
escape	O	VERB	O
with	O	ADP	O
escalating	O	VERB	B
doses	O	NOUN	I
of	O	ADP	O
enalapril	O	NOUN	B
within	O	ADP	O
each	O	DET	O
subgroup	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Psychoexperimental	O	ADJ	B
studies	O	NOUN	I
on	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
valepotriate	B-I	ADJ	B
combination	I-I	NOUN	B
as	I-P	ADV	O
well	I-P	ADV	O
as	I-P	ADP	O
the	I-P	DET	O
combined	I-P	ADJ	O
effects	I-P	NOUN	B
of	I-P	ADP	O
valtratum	I-I	NOUN	B
and	I-I	CCONJ	O
alcohol	I-I	NOUN	B
]	I-I	PUNCT	O
.	O	PUNCT	O


Comorbidity	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
age	I-OUT	NOUN	B
and	O	CCONJ	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
in	O	ADP	O
cetuximab-treated	B-I	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
colorectal	I-P	ADJ	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
ACRC	I-P	NOUN	B
)	I-P	PUNCT	O
--	I-P	PUNCT	O
results	I-P	NOUN	B
from	O	ADP	O
NCIC	O	NOUN	B
CTG	O	NOUN	I
CO.17	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
trial	O	NOUN	I
of	O	ADP	O
cetuximab	B-I	NOUN	B
versus	O	CCONJ	O
best	B-I	ADJ	O
supportive	I-I	ADJ	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
the	O	DET	O
interplay	O	NOUN	O
between	O	ADP	O
comorbidity	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
age	I-OUT	NOUN	B
and	O	CCONJ	O
performance	B-OUT	NOUN	B
status	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
as	O	ADP	O
predictors	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
in	O	ADP	O
advanced	O	ADJ	B
colorectal	O	ADJ	I
cancer	O	NOUN	I
(	O	PUNCT	O
ACRC	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
these	O	DET	O
factors	O	NOUN	B
as	O	ADP	O
predictors	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
toxicity	B-OUT	NOUN	B
and	O	CCONJ	O
outcome	O	NOUN	B
in	O	ADP	O
cetuximab-treated	B-I	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
ACRC	I-P	NOUN	B
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
comorbidity	O	NOUN	B
was	O	AUX	O
independently	O	ADV	O
evaluated	O	VERB	B
using	O	VERB	O
the	O	DET	O
Charlson	B-OUT	PROPN	B
Comorbidity	I-OUT	PROPN	I
Index	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
CCI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
validated	O	VERB	O
measure	O	NOUN	B
of	O	ADP	O
comorbidity	B-OUT	NOUN	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
medical	O	ADJ	B
conditions	O	NOUN	I
weighted	O	VERB	O
according	O	VERB	O
to	O	ADP	O
their	O	PRON	O
effect	O	NOUN	B
on	O	ADP	O
mortality	O	NOUN	B
.	O	PUNCT	O


CCI	B-OUT	NOUN	B
score	I-OUT	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
outcome	O	NOUN	B
data	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
five	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
seventy-two	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
;	I-P	PUNCT	O
41	I-P	NUM	O
%	I-P	NOUN	O
were	I-P	AUX	O
≥	I-P	ADV	O
65	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
25	I-P	NUM	O
%	I-P	NOUN	O
had	I-P	AUX	O
comorbidities	I-P	NOUN	B
at	I-P	ADP	O
randomization	I-P	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
(	O	PUNCT	O
MVA	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
all	O	DET	O
covariates	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
older	O	ADJ	B
age	O	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
greater	O	ADJ	O
comorbidity	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.008	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
better	O	ADJ	O
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
greater	O	ADJ	O
comorbidity	O	NOUN	B
in	O	ADP	O
univariate	O	NOUN	B
analysis	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.047	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
better	B-OUT	ADJ	O
PS	I-OUT	PROPN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
better	B-OUT	ADJ	O
OS	I-OUT	NOUN	B
in	O	ADP	O
MVA	O	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
1.92	O	NUM	O
for	O	ADP	O
PS	O	NOUN	B
=	O	ADJ	O
2	O	NUM	O
versus	O	CCONJ	O
PS	O	PROPN	B
=	O	ADJ	O
0	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Age	O	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	B-OUT	ADP	I
OS	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.13	B-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Elderly	B-P	ADJ	B
patients	I-P	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
less	B-OUT	ADJ	O
grade	I-OUT	NOUN	O
≥	I-OUT	NOUN	O
3	I-OUT	NUM	O
vomiting	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.034	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
more	B-OUT	ADV	O
dyspnea	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.005	B-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
greater	I-P	ADJ	O
comorbidity	I-P	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
less	B-OUT	ADJ	O
grade	I-OUT	NOUN	O
≥	I-OUT	NOUN	O
3	I-OUT	NUM	O
vomiting	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
but	B-OUT	CCONJ	O
more	I-OUT	ADV	O
non-neutropenic	I-OUT	ADJ	B
fever	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	B-OUT	NOUN	O
better	I-OUT	ADJ	O
PS	O	PROPN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
improved	B-OUT	VERB	O
OS	I-P	NOUN	B
.	I-P	PUNCT	O


For	B-P	ADP	O
patients	I-P	NOUN	B
with	I-OUT	ADP	O
good	O	ADJ	O
PS	O	PROPN	B
,	O	PUNCT	O
restricting	B-I	VERB	O
cetuximab	I-I	NOUN	B
use	O	NOUN	O
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
significant	O	ADJ	B
comorbidity	O	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
justified	O	VERB	O
.	O	PUNCT	O


Levosulpiride	B-I	NOUN	B
in	O	ADP	O
functional	B-P	ADJ	B
dyspepsia	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
multicentric	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


Abnormalities	O	NOUN	B
in	O	ADP	O
gastrointestinal	O	ADJ	B
motility	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
functional	I-P	ADJ	B
dyspepsia	I-P	NOUN	I
,	I-P	PUNCT	O
supporting	I-P	VERB	O
the	I-P	DET	O
use	I-P	NOUN	O
of	I-P	ADP	O
prokinetic	I-I	ADJ	B
drugs	I-I	NOUN	I
for	I-P	ADP	O
treatment	I-P	NOUN	B
of	I-P	ADP	O
dyspeptic	I-P	ADJ	B
symptoms	I-P	NOUN	B
.	I-P	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
levosulpiride	B-I	NOUN	B
in	O	ADP	O
short-term	O	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
1298	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
double-blind	I-P	ADJ	B
multicentric	I-P	ADJ	B
study	I-P	NOUN	I
carried	I-P	VERB	O
out	I-P	ADP	O
in	I-P	ADP	O
45	I-P	NUM	O
Italian	I-P	ADJ	B
Gastroenterology	I-P	PROPN	I
Departments	I-P	PROPN	I
.	I-P	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
levosulpiride	B-I	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
tid	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
domperidone	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
tid	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
metoclopramide	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
tid	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
tablet	O	NOUN	B
tid	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Patients	B-P	NOUN	B
were	I-P	AUX	O
selected	I-P	VERB	O
on	I-P	ADP	O
the	I-P	DET	O
basis	I-P	NOUN	O
of	I-P	ADP	O
:	I-P	PUNCT	O
a	I-P	X	O
)	I-P	PUNCT	O
occurrence	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
last	I-P	ADJ	O
4	I-P	NUM	O
weeks	I-P	NOUN	B
of	I-P	ADP	O
at	I-P	ADV	O
least	I-P	ADV	O
5/10	I-P	NUM	O
selected	I-P	VERB	O
symptoms	I-P	NOUN	B
(	I-OUT	PUNCT	O
anorexia	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
vomiting	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
upper	I-OUT	ADJ	B
abdominal	I-OUT	ADJ	I
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
postprandial	I-OUT	ADJ	B
bloating	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
abdominal	I-OUT	ADJ	B
fullness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
early	I-OUT	ADJ	B
satiety	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
belching	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
heartburn	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
regurgitation	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-P	PUNCT	O
severity	I-P	NOUN	B
of	I-P	ADP	O
which	I-P	DET	O
should	I-P	AUX	O
reach/exceed	I-P	VERB	O
a	I-P	DET	O
total	I-P	ADJ	O
score	I-P	NOUN	O
of	I-P	ADP	O
8	I-P	NUM	O
,	I-P	PUNCT	O
as	I-P	ADP	O
assessed	I-P	VERB	B
by	I-P	ADP	O
a	I-P	DET	O
specific	I-P	ADJ	O
scale	I-P	NOUN	B
ranging	I-P	VERB	O
from	I-P	ADP	O
0	I-P	NUM	O
(	I-P	PUNCT	O
absent	I-P	ADJ	B
)	I-P	PUNCT	O
to	I-P	PART	O
3	I-P	NUM	O
(	I-P	PUNCT	O
severe	I-P	ADJ	B
)	I-P	PUNCT	O
;	I-P	PUNCT	O
b	I-P	X	O
)	I-P	PUNCT	O
normal	I-P	ADJ	O
results	I-P	NOUN	O
of	I-P	ADP	O
routine	I-P	ADJ	B
biochemical	I-P	ADJ	B
,	I-P	PUNCT	O
ultrasound	I-P	NOUN	B
and	I-P	CCONJ	O
endoscopic	I-P	ADJ	B
examinations	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
each	O	DET	O
patient	O	NOUN	B
subjectively	O	ADV	O
evaluated	O	VERB	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
by	O	ADP	O
a	O	DET	O
visual	O	ADJ	B
analogue	O	NOUN	I
scale	O	NOUN	I
.	O	PUNCT	O


Significant	O	ADJ	B
improvement	O	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
all	O	DET	O
symptoms	O	NOUN	B
at	O	ADP	O
days	O	NOUN	B
10	O	NUM	O
and	O	CCONJ	O
28	O	NUM	O
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
levosulpiride	B-I	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
superior	O	ADJ	O
to	O	PART	O
domperidone	B-I	NOUN	B
,	I-I	PUNCT	O
metoclopramide	I-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
both	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
overall	O	ADJ	O
clinical	O	ADJ	B
improvement	O	NOUN	I
scale	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
(	B-OUT	PUNCT	O
postprandial	I-OUT	ADJ	B
bloating	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
epigastric	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
heartburn	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


Active	B-I	ADJ	B
treatments	I-I	NOUN	I
and	O	CCONJ	O
placebo	B-I	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
as	O	ADV	O
far	O	ADV	O
as	O	ADP	O
concerns	O	NOUN	B
occurrence	O	NOUN	B
of	O	ADP	O
side-effects	O	NOUN	B
(	O	PUNCT	O
12-20	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
including	O	VERB	O
galactorrhoea	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
breast	I-OUT	NOUN	B
tenderness	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
menstrual	I-OUT	ADJ	B
changes	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Isoniazid	B-I	NOUN	B
prophylaxis	O	NOUN	B
for	O	ADP	O
tuberculosis	B-P	NOUN	B
in	I-P	ADP	O
HIV	I-P	NOUN	B
infection	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
meta-analysis	O	NOUN	B
of	O	ADP	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trials	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
isoniazid	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
tuberculosis	O	NOUN	B
in	O	ADP	O
tuberculin	B-P	NOUN	B
skin	I-P	NOUN	I
test-positive	I-P	ADJ	B
and	I-P	CCONJ	O
negative	I-P	ADJ	B
individuals	I-P	NOUN	B
with	I-P	ADP	O
HIV	I-P	NOUN	B
infection	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Meta-analysis	O	NOUN	B
of	O	ADP	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trials	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Seven	B-P	NUM	O
trials	I-P	NOUN	B
from	I-P	ADP	O
Mexico	I-P	PROPN	B
,	I-P	PUNCT	O
Haiti	I-P	PROPN	B
,	I-P	PUNCT	O
the	I-P	DET	O
United	I-P	PROPN	B
States	I-P	PROPN	I
,	I-P	PUNCT	O
Zambia	I-P	PROPN	B
,	I-P	PUNCT	O
Uganda	I-P	PROPN	B
and	I-P	CCONJ	O
Kenya	I-P	PROPN	B
.	I-P	PUNCT	O


PATIENTS	O	VERB	B
Individuals	B-P	NOUN	B
free	I-P	ADJ	B
from	I-P	ADP	O
tuberculosis	I-P	NOUN	B
,	I-P	PUNCT	O
2367	I-P	NUM	O
persons	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
intervention	I-P	NOUN	B
and	I-P	CCONJ	O
2162	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
control	I-P	NOUN	B
groups	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTION	O	NOUN	B
Comparison	B-OUT	NOUN	B
of	I-OUT	ADP	O
isoniazid	I-OUT	NOUN	B
with	I-OUT	ADP	O
placebo	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
no	I-OUT	DET	O
prophylaxis	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
systematic	O	ADJ	B
search	O	NOUN	O
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
from	O	ADP	O
1985	O	NUM	O
to	O	ADP	O
October	O	PROPN	O
1997	O	NUM	O
for	O	ADP	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trials	O	NOUN	I
of	O	ADP	O
isoniazid	B-I	NOUN	B
prophylaxis	I-P	NOUN	B
in	I-P	ADP	O
HIV-infected	I-P	ADJ	B
persons	I-P	NOUN	B
.	I-P	PUNCT	O


Two	O	NUM	O
reviewers	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
relevance	O	NOUN	B
of	O	ADP	O
each	O	DET	O
candidate	O	NOUN	O
study	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
validity	O	NOUN	B
of	O	ADP	O
eligible	O	ADJ	B
trials	O	NOUN	I
.	O	PUNCT	O


Studies	O	NOUN	B
were	O	AUX	O
pooled	O	VERB	B
using	O	VERB	O
a	O	DET	O
random	O	ADJ	B
effect	O	NOUN	O
model	O	NOUN	O
,	O	PUNCT	O
conducting	O	VERB	O
secondary	O	ADJ	B
analyses	O	NOUN	I
for	O	ADP	O
tuberculin	O	NOUN	B
skin	O	NOUN	I
test-positive	O	ADJ	B
and	O	CCONJ	O
negative	O	ADJ	B
persons	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Mean	O	VERB	O
follow-up	O	NOUN	B
in	O	ADP	O
trials	O	NOUN	B
varied	O	VERB	O
between	O	ADP	O
0.4	O	NUM	O
and	O	CCONJ	O
3.2	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Pooling	O	VERB	B
all	O	DET	O
seven	O	NUM	O
trials	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
risk	B-OUT	NOUN	B
ratio	I-OUT	NOUN	I
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
persons	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
isoniazid	B-I	NOUN	B
for	O	ADP	O
developing	O	VERB	O
tuberculosis	O	NOUN	B
of	O	ADP	O
0.58	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
0.43-0.80	O	ADJ	O
]	O	PUNCT	O
and	O	CCONJ	O
0.94	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.83-1.07	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
death	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
groups	O	NOUN	B
of	O	ADP	O
tuberculin	O	NOUN	B
skin	O	NOUN	I
test-positive	O	ADJ	B
and	O	CCONJ	O
negative	O	ADJ	B
persons	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
risk	B-OUT	NOUN	B
ratio	I-OUT	NOUN	I
of	I-OUT	ADP	O
tuberculosis	I-OUT	NOUN	B
was	O	AUX	O
0.40	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.24-0.65	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
0.84	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.54-1.30	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
difference	B-OUT	NOUN	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
effectiveness	I-OUT	NOUN	B
of	O	ADP	O
isoniazid	B-I	NOUN	B
versus	O	CCONJ	O
placebo	B-I	NOUN	B
between	O	ADP	O
these	O	DET	O
groups	O	NOUN	B
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
difference	O	NOUN	O
of	O	ADP	O
summary	O	ADJ	O
estimates	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Consistency	O	NOUN	B
of	O	ADP	O
results	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
across	O	ADP	O
trials	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.10	O	NUM	O
,	O	PUNCT	O
heterogeneity	O	NOUN	B
value	O	NOUN	I
)	O	PUNCT	O
for	O	ADP	O
all	O	DET	O
comparisons	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Prophylaxis	O	NOUN	B
with	O	ADP	O
isoniazid	B-I	NOUN	B
reduces	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
tuberculosis	O	NOUN	B
in	O	ADP	O
persons	B-P	NOUN	B
with	I-P	ADP	O
HIV	I-P	NOUN	B
infection	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
is	O	AUX	O
restricted	B-P	ADJ	O
to	I-P	PART	O
tuberculin	I-P	VERB	B
skin	I-P	NOUN	I
test-positive	I-P	ADJ	B
persons	I-P	NOUN	B
.	I-P	PUNCT	O


[	O	PUNCT	O
Dose-effect	O	ADJ	B
relationship	O	NOUN	B
of	O	ADP	O
isosorbide	B-I	NOUN	B
dinitrate	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
angina	O	ADJ	B
pectoris	O	NOUN	I
(	O	PUNCT	O
author	O	NOUN	B
's	O	PART	I
transl	O	NUM	I
)	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


Fifteen	B-P	NUM	O
males	I-P	NOUN	B
with	I-P	ADP	O
angiographic	I-P	ADJ	B
evidence	I-P	NOUN	B
of	I-P	ADP	O
coronary	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
and	I-P	CCONJ	O
stable	I-P	ADJ	B
,	I-P	PUNCT	O
exercise-induced	I-P	ADJ	B
angina	I-P	ADJ	I
pectoris	I-P	NOUN	I
were	O	AUX	O
given	O	VERB	O
placebo	B-I	NOUN	B
or	I-I	CCONJ	O
isosorbide	I-I	NOUN	B
dinitrate	I-I	NOUN	O
(	I-I	PUNCT	O
ISDN	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
a	O	DET	O
dialy	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
120	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
240	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
480	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
single-blind	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
daily	O	ADJ	B
doses	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
oral	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
40	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
80	O	NUM	O
mg	O	NOUN	O
tablets	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
dose	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
for	O	ADP	O
seven	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
seventh	O	ADJ	O
day	O	NOUN	B
an	O	DET	O
exercise	B-OUT	NOUN	B
ECG	I-OUT	PROPN	B
of	O	ADP	O
standardized	O	ADJ	B
level	O	NOUN	I
and	O	CCONJ	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
exercise	I-OUT	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
ischaemia	B-OUT	NOUN	B
response	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ECG	O	PROPN	B
revealed	O	VERB	B
a	O	DET	O
dose-dependent	O	ADJ	B
reduction	B-OUT	NOUN	B
by	O	ADP	O
28	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
ISDN	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
43	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
60	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
40	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
73	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
80	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
anginal	I-OUT	ADJ	B
attacks	I-OUT	NOUN	B
similarly	O	ADV	O
fell	O	VERB	O
parallel	O	ADJ	O
to	O	PART	O
dose	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
ISDN	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
mononitrates	I-OUT	NOUN	B
,	O	PUNCT	O
measured	O	VERB	B
one	O	NUM	O
and	O	CCONJ	O
four	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
drug	O	NOUN	B
intake	O	NOUN	I
,	O	PUNCT	O
rose	O	VERB	O
almost	O	ADV	O
linearly	O	ADV	O
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
dose	O	NOUN	B
.	O	PUNCT	O


Oral	O	ADJ	B
ISDN	O	PROPN	B
thus	O	ADV	O
has	O	AUX	O
a	O	DET	O
dose-dependent	O	ADJ	B
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
angina	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
ischaemia	I-OUT	NOUN	B
parameters	I-OUT	NOUN	B
during	O	ADP	O
ergometric	O	ADJ	B
exercise	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
protracted	O	ADJ	O
anti-anginal	B-OUT	ADJ	B
effect	I-OUT	NOUN	O
of	O	ADP	O
ISDN	O	NOUN	B
is	O	AUX	O
largely	O	ADV	O
due	O	ADJ	O
to	O	PART	O
its	O	PRON	O
metabolites	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
there	O	PRON	O
is	O	AUX	O
presumably	O	ADV	O
an	O	DET	O
added	O	VERB	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
high	O	ADJ	B
blood	O	NOUN	I
level	O	NOUN	O
of	O	ADP	O
the	O	DET	O
basic	O	ADJ	O
substance.U	O	NOUN	B


Relief	O	NOUN	B
of	O	ADP	O
periorbital	O	ADJ	B
pain	O	NOUN	I
after	O	ADP	O
acute	O	ADJ	B
angle	O	NOUN	I
closure	O	NOUN	I
glaucoma	O	NOUN	B
attack	O	NOUN	I
by	O	ADP	O
botulinum	B-I	NOUN	B
toxin	I-I	NOUN	I
type	I-I	NOUN	I
A	I-I	NOUN	I
.	I-I	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
botulinum	B-I	NOUN	B
toxin	I-I	NOUN	I
type	I-I	NOUN	I
A	I-I	NOUN	I
(	I-I	PUNCT	O
BoNT-A	I-I	NOUN	B
)	I-I	PUNCT	O
injection	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
suffering	I-P	VERB	B
from	I-P	ADP	O
intractable	I-P	ADJ	B
periorbital	I-P	ADJ	B
pain	I-P	NOUN	I
after	I-P	ADP	O
acute	I-P	ADJ	B
angle	I-P	NOUN	I
closure	I-P	NOUN	I
glaucoma	I-P	NOUN	I
(	I-P	PUNCT	O
AACG	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
intervention	O	NOUN	I
study	O	NOUN	I
,	O	PUNCT	O
19	B-P	NUM	O
patients	I-P	NOUN	B
suffering	I-P	VERB	B
from	I-P	ADP	O
periorbital	I-P	ADJ	B
pain	I-P	NOUN	I
after	I-P	ADP	O
an	I-P	DET	O
AACG	I-P	ADJ	B
attack	I-P	NOUN	B
were	O	AUX	O
injected	B-I	VERB	B
with	I-I	ADP	O
BoNT-A	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
for	O	ADP	O
pain	O	NOUN	B
relief	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
30	O	NUM	O
,	O	PUNCT	O
60	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
90	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
outcomes	O	NOUN	B
were	O	AUX	O
mean	O	ADJ	O
change	O	NOUN	O
of	O	ADP	O
visual	O	ADJ	B
analog	O	NOUN	I
rating	O	NOUN	I
scale	O	NOUN	I
(	O	PUNCT	O
VARS	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
index	O	NOUN	B
scores	O	NOUN	I
measured	O	VERB	B
through	O	ADP	O
a	O	DET	O
quality-of-life	O	ADJ	B
questionnaire	O	NOUN	I
(	O	PUNCT	O
EQ-5D	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
visual	B-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	O	PUNCT	O
VAS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
all	O	DET	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
each	O	DET	O
visit	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
secondary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
the	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
nature	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
withdrew	O	VERB	O
from	O	ADP	O
the	O	DET	O
study	O	NOUN	B
as	O	ADP	O
a	O	DET	O
result	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
n=10	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
mean	B-OUT	ADJ	B
index	I-OUT	NOUN	I
score	I-OUT	NOUN	I
of	I-OUT	ADP	O
EQ-5D	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
VAS	I-OUT	PROPN	B
changed	O	VERB	O
significantly	O	ADV	O
from	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
by	O	ADP	O
0.299	O	NUM	O
and	O	CCONJ	O
2.61	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
from	O	ADP	O
day	O	NOUN	B
2	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
VARS	B-OUT	PROPN	B
of	I-OUT	ADP	O
EQ-5D	I-OUT	NOUN	B
also	O	ADV	O
disclosed	O	VERB	O
significant	O	ADJ	B
changes	O	NOUN	B
from	O	ADP	O
day	O	NOUN	B
2	O	NUM	O
(	O	PUNCT	O
17	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
efficacy	B-OUT	NOUN	B
was	O	AUX	O
maintained	O	VERB	B
mainly	O	ADV	O
between	O	ADP	O
days	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
60	O	NUM	O
but	O	CCONJ	O
declined	O	VERB	B
slightly	O	ADV	O
by	O	ADP	O
day	O	NOUN	B
90	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
reported	O	VERB	O
treatment-related	O	ADJ	B
adverse	O	ADJ	B
events	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
groups	O	NOUN	B
were	O	AUX	O
local	B-OUT	ADJ	B
tenderness	I-OUT	NOUN	I
(	O	PUNCT	O
21	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
subcutaneous	B-OUT	ADJ	B
hemorrhage	I-OUT	NOUN	I
(	O	PUNCT	O
10.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
conjunctivitis	B-OUT	NOUN	B
(	O	PUNCT	O
10.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
severe	B-OUT	ADJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
were	O	AUX	O
reported	O	VERB	O
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
or	O	CCONJ	O
follow-up	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
BoNT-A	B-I	NOUN	B
is	O	AUX	O
effective	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
periorbital	O	ADJ	B
pain	O	NOUN	I
after	O	ADP	O
an	O	DET	O
AACG	O	ADJ	B
attack	O	NOUN	B
.	O	PUNCT	O


Its	O	PRON	O
effects	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
maintained	O	VERB	B
for	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Relaxing	B-I	VERB	B
retinotomy	I-I	NOUN	I
with	I-I	ADP	O
silicone	I-I	NOUN	B
oil	I-I	NOUN	I
or	I-I	CCONJ	O
long-acting	I-I	ADJ	B
gas	I-I	NOUN	O
in	O	ADP	O
eyes	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
proliferative	I-P	ADJ	B
vitreoretinopathy	I-P	NOUN	I
.	I-P	PUNCT	O


Silicone	O	NOUN	B
Study	O	PROPN	I
Report	O	PROPN	O
5	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
Silicone	O	NOUN	B
Study	O	PROPN	I
Group	O	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
Silicone	O	NOUN	B
Study	O	PROPN	I
,	O	PUNCT	O
117	B-P	NUM	O
of	I-P	ADP	O
404	I-P	NUM	O
eyes	I-P	NOUN	B
(	I-P	PUNCT	O
29	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
with	I-P	ADP	O
severe	I-P	ADJ	B
proliferative	I-P	ADJ	B
vitreoretinopathy	I-P	NOUN	I
(	I-P	PUNCT	O
>	I-P	NOUN	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
C-3	I-P	NOUN	B
,	I-P	PUNCT	O
full-thickness	I-P	ADJ	B
retinal	I-P	ADJ	B
folds	I-P	NOUN	B
in	I-P	ADP	O
three	I-P	NUM	O
or	I-P	CCONJ	O
more	I-P	ADJ	O
quadrants	I-P	NOUN	B
)	I-P	PUNCT	O
enrolled	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
vitrectomy	B-I	NOUN	B
,	O	PUNCT	O
underwent	O	VERB	O
a	O	DET	O
relaxing	B-I	NOUN	B
retinotomy	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
treatment	B-I	NOUN	B
with	I-I	ADP	O
long-acting	I-I	ADJ	B
gas	I-I	NOUN	I
or	I-I	CCONJ	O
silicone	I-I	NOUN	B
oil	I-I	NOUN	I
.	I-I	PUNCT	O


Forty-six	B-P	NUM	O
eyes	I-P	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
undergone	O	VERB	O
no	O	DET	O
previous	O	ADJ	O
vitrectomy	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
71	O	NUM	O
eyes	O	NOUN	B
(	O	PUNCT	O
42	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
undergone	O	VERB	O
previous	O	ADJ	O
vitrectomy	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
intraocular	O	ADJ	B
gas	O	NOUN	I
tamponade	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Group	O	NOUN	B
1	O	NUM	O
eyes	O	NOUN	B
not	O	PART	O
undergoing	O	VERB	O
retinotomy	O	NOUN	B
had	O	AUX	O
better	B-OUT	ADV	O
anatomic	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
six	I-OUT	NUM	O
months	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
visual	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
six	I-OUT	NUM	O
and	I-OUT	CCONJ	O
24	I-OUT	NUM	O
months	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
outcomes	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
less	I-OUT	ADJ	O
hypotony	I-OUT	NOUN	B
(	O	PUNCT	O
six	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
eyes	O	NOUN	B
that	O	PRON	O
did	O	AUX	O
regardless	O	ADV	O
of	O	ADP	O
tamponade	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
eyes	O	NOUN	B
undergoing	O	VERB	O
retinotomy	O	NOUN	B
,	O	PUNCT	O
silicone	O	NOUN	B
oil	O	NOUN	I
decreased	B-OUT	VERB	B
the	I-OUT	DET	O
likelihood	I-OUT	NOUN	B
of	I-OUT	ADP	O
hypotony	I-OUT	NOUN	B
(	O	PUNCT	O
six	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	O
eyes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
eyes	O	NOUN	B
undergoing	O	VERB	O
a	O	DET	O
vitreous	O	ADJ	B
operation	O	NOUN	I
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
proliferative	B-OUT	ADJ	B
vitreoretinopathy	I-OUT	NOUN	I
can	O	AUX	O
in	O	ADP	O
most	O	ADJ	O
instances	O	NOUN	O
be	O	AUX	O
successfully	O	ADV	O
treated	O	VERB	B
by	O	ADP	O
conventional	O	ADJ	B
techniques	O	NOUN	B
without	O	ADP	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
relaxing	O	VERB	B
retinotomy	O	NOUN	I
.	O	PUNCT	O


Retinotomy	O	PROPN	B
may	O	AUX	O
be	O	AUX	O
required	O	VERB	O
more	O	ADV	O
often	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
repeat	O	ADJ	O
vitreous	O	ADJ	B
surgery	O	NOUN	I
for	O	ADP	O
proliferative	O	ADJ	B
vitreoretinopathy	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
case	O	NOUN	O
both	O	CCONJ	O
silicone	O	NOUN	B
oil	O	NOUN	I
and	O	CCONJ	O
long-acting	O	ADJ	B
perflouropropane	B-I	NOUN	I
gas	O	NOUN	I
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
equally	B-OUT	ADV	O
effective	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


Predictors	O	NOUN	B
of	O	ADP	O
smoking	B-P	NOUN	B
cessation	I-P	NOUN	I
among	I-P	ADP	O
cancer	I-P	NOUN	B
patients	I-P	NOUN	B
enrolled	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
smoking	I-I	NOUN	B
cessation	I-I	NOUN	I
program	I-P	NOUN	I
.	I-P	PUNCT	O


UNLABELLED	O	VERB	B
Many	O	ADJ	O
cancer	B-P	NOUN	B
patients	I-P	NOUN	B
continue	O	VERB	O
to	O	PART	O
smoke	O	VERB	B
postdiagnosis	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
poorer	O	ADJ	B
clinical	O	ADJ	B
outcomes	O	NOUN	I
.	O	PUNCT	O


Identifying	O	VERB	O
prospective	O	ADJ	O
predictors	O	NOUN	B
of	O	ADP	O
smoking	O	NOUN	B
cessation	O	NOUN	I
among	O	ADP	O
patients	O	NOUN	B
currently	O	ADV	O
receiving	O	VERB	O
smoking	B-I	NOUN	B
cessation	I-I	NOUN	B
treatment	O	NOUN	B
can	O	AUX	O
help	O	VERB	O
guide	O	VERB	O
the	O	DET	O
development	O	NOUN	B
and	O	CCONJ	O
implementation	O	NOUN	B
of	O	ADP	O
smoking	B-I	NOUN	B
cessation	I-I	NOUN	I
programs	I-I	NOUN	I
with	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Data	B-P	PROPN	B
from	I-P	ADP	O
246	I-P	NUM	O
cancer	I-P	NOUN	B
patients	I-P	NOUN	B
participating	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
randomized	I-P	ADJ	B
placebo-controlled	I-I	ADJ	I
smoking	I-P	NOUN	I
cessation	I-P	NOUN	B
clinical	I-P	ADJ	B
trial	I-P	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
examine	O	VERB	O
baseline	O	NOUN	B
predictors	O	NOUN	B
of	O	ADP	O
end-of-treatment	O	ADJ	B
and	O	CCONJ	O
six-month	O	ADJ	B
postbaseline	O	NOUN	B
smoking	B-I	NOUN	B
cessation	I-I	NOUN	B
outcomes	O	NOUN	B
.	O	PUNCT	O


Baseline	O	NOUN	B
demographic	O	ADJ	B
,	O	PUNCT	O
smoking-related	O	ADJ	B
,	O	PUNCT	O
disease-related	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
psychological	O	ADJ	B
variables	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
as	O	ADP	O
predictors	O	NOUN	B
of	O	ADP	O
biochemically-confirmed	O	ADJ	B
point-prevalence	O	ADJ	B
abstinence	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
Multivariate	B-OUT	ADJ	B
analysis	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
for	O	ADP	O
end-of-treatment	B-OUT	ADJ	B
abstinence	I-OUT	NOUN	I
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
quit	B-OUT	VERB	B
smoking	I-OUT	NOUN	I
if	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
older	O	ADJ	B
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
1.06	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
1.03-1.10	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
diagnosed	O	VERB	B
with	O	ADP	O
a	O	DET	O
non-tobacco	O	ADJ	B
related	O	ADJ	I
cancer	O	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
2.54	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
1.24-5.20	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Likewise	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
six-month	B-OUT	ADJ	B
abstinence	I-OUT	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
quit	B-OUT	VERB	B
smoking	I-OUT	NOUN	I
if	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
older	O	ADJ	B
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
1.04	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
1.01-1.08	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
significantly	O	ADV	O
less	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
quit	O	VERB	B
smoking	O	NOUN	I
if	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
female	O	ADJ	B
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
0.47	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
0.22-0.97	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
tobacco-related	I-P	ADJ	B
cancers	I-P	NOUN	I
and	I-P	CCONJ	O
female	I-P	ADJ	B
patients	I-P	NOUN	B
reported	O	VERB	O
significantly	O	ADV	O
higher	O	ADJ	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
depression	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
proved	O	VERB	O
predictive	B-OUT	ADJ	B
of	I-OUT	ADP	O
smoking	I-OUT	NOUN	B
relapse	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	VERB	O
Patient	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
gender	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cancer-type	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
factors	O	NOUN	B
to	O	PART	O
consider	O	VERB	O
when	O	SCONJ	O
developing	O	VERB	O
and	O	CCONJ	O
implementing	O	VERB	B
smoking	B-I	NOUN	B
cessation	I-I	NOUN	B
interventions	I-I	NOUN	B
for	O	ADP	O
cancer	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Efficacy	B-OUT	NOUN	B
of	O	ADP	O
amantadine	B-I	NOUN	B
on	O	ADP	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
C	I-P	NOUN	I
treated	I-P	VERB	B
with	I-P	ADP	I
interferon-alpha	I-I	NOUN	B
and	I-I	CCONJ	O
ribavirin	I-I	NOUN	B
:	I-I	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


AIM	O	VERB	B
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
amantadine	O	NOUN	B
reduces	O	VERB	B
deterioration	B-OUT	NOUN	B
of	I-OUT	ADP	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
C	I-P	NOUN	I
during	I-P	ADP	O
and	I-P	CCONJ	O
after	I-P	ADP	O
treatment	I-P	NOUN	B
with	I-P	ADP	O
interferon-alpha	I-P	NOUN	B
(	I-P	PUNCT	O
IFN-alpha	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
ribavirin	I-P	NOUN	B
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
multicenter	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
previously	B-P	ADV	O
untreated	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
C	I-P	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
IFN-alpha	B-I	NOUN	B
plus	I-I	CCONJ	O
ribavirin	I-I	NOUN	B
[	I-I	PUNCT	O
17	I-I	NUM	O
]	I-I	PUNCT	O
and	O	CCONJ	O
randomized	O	ADJ	B
for	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
amantadine	B-I	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
mg/day	O	NOUN	B
,	O	PUNCT	O
orally	O	ADV	B
,	O	PUNCT	O
n=136	O	NOUN	O
)	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n=131	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
with	O	ADP	O
the	O	DET	O
'Profile	B-OUT	NOUN	B
of	I-OUT	ADP	O
Mood	I-OUT	PROPN	B
States	I-OUT	PROPN	I
'	I-OUT	PART	I
scale	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
'Everyday	I-OUT	NOUN	B
Life	I-OUT	NOUN	I
'	I-OUT	PART	I
questionnaire	I-OUT	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
treatment	O	NOUN	B
week	O	NOUN	I
(	O	PUNCT	O
TW	O	NOUN	B
)	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
TW24	O	NOUN	B
,	O	PUNCT	O
TW48	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Early	O	ADV	B
during	O	ADP	O
treatment	O	NOUN	B
at	O	ADP	O
TW8	O	NOUN	B
,	O	PUNCT	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
patients	B-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
control	I-P	NOUN	B
and	I-P	CCONJ	O
the	I-P	DET	O
amantadine	I-P	NOUN	B
group	I-P	NOUN	O
.	I-P	PUNCT	O


At	O	ADP	O
TW24	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
amantadine	B-I	NOUN	B
group	O	NOUN	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
showed	O	VERB	O
significant	O	ADJ	O
deterioration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
modalities	B-OUT	NOUN	B
depression	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
vigor	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Especially	O	ADV	O
,	O	PUNCT	O
nonresponders	O	NOUN	B
in	O	ADP	O
the	O	DET	O
amantadine	O	NOUN	B
group	O	NOUN	O
showed	O	VERB	O
significantly	O	ADV	O
lower	B-OUT	ADJ	O
deterioration	I-OUT	NOUN	B
of	I-OUT	ADP	O
depression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
anger	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
mind	I-OUT	NOUN	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
everyday	I-OUT	ADJ	B
life	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
zest	I-OUT	ADJ	B
for	I-OUT	ADP	I
life	I-OUT	NOUN	I
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
beneficial	B-OUT	ADJ	O
effects	I-OUT	NOUN	B
of	O	ADP	O
amantadine	O	NOUN	B
disappeared	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
amantadine	B-I	NOUN	B
to	O	PART	O
IFN-alpha	B-I	NOUN	B
plus	I-I	CCONJ	O
ribavirin	I-I	NOUN	B
combination	O	NOUN	O
therapy	O	NOUN	O
may	O	AUX	O
reduce	O	VERB	O
deterioration	B-OUT	NOUN	B
of	I-OUT	ADP	O
depression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
vigor	I-OUT	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
but	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Metabolic	O	ADJ	B
and	O	CCONJ	O
ventilatory	O	ADJ	B
responses	O	NOUN	I
during	O	ADP	O
very	B-I	ADV	O
low	I-I	ADJ	B
level	I-I	NOUN	O
exercise	I-I	NOUN	B
.	I-I	PUNCT	O


1	O	X	O
.	O	PUNCT	O


Nine	B-P	NUM	O
male	I-P	NOUN	B
and	I-P	CCONJ	O
six	I-P	NUM	O
female	I-P	ADJ	B
healthy	I-P	ADJ	B
subjects	I-P	NOUN	O
were	I-P	AUX	O
studied	I-P	VERB	O
during	I-P	ADP	O
supine	I-I	ADJ	B
bicycle	I-I	NOUN	O
exercise	I-I	NOUN	B
at	I-P	ADP	O
workloads	I-P	NOUN	B
of	I-P	ADP	O
12	I-P	NUM	O
and	I-P	CCONJ	O
37	I-P	NUM	O
W	I-P	NOUN	O
;	I-P	PUNCT	O
pedalling	I-P	NOUN	B
rates	I-P	NOUN	O
varied	I-P	VERB	O
between	I-P	ADP	O
30	I-P	NUM	O
and	I-P	CCONJ	O
50	I-P	NUM	O
cycles/min	I-P	NOUN	B
at	I-P	ADP	O
each	I-P	DET	O
workload	I-P	NOUN	B
.	I-P	PUNCT	O


Measurements	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
of	O	ADP	O
oxygen	B-OUT	NOUN	B
consumption	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VO2	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
carbon	I-OUT	NOUN	B
dioxide	I-OUT	NOUN	I
production	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VCO2	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
minute	I-OUT	NOUN	B
ventilation	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
tidal	I-OUT	ADJ	B
volume	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
respiratory	I-OUT	ADJ	B
frequency	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
fR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
inspiratory	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
expiratory	I-OUT	ADJ	B
time	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
TI	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
TE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
mean	I-OUT	VERB	B
inspiratory	I-OUT	ADJ	I
flow	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VT/TI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
using	O	VERB	O
a	O	DET	O
non-invasive	O	ADJ	B
canopy-computer-spirometer	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


2	O	X	O
.	O	PUNCT	O


At	O	ADP	O
rest	O	NOUN	B
,	O	PUNCT	O
males	O	NOUN	B
had	O	AUX	O
greater	O	ADJ	O
values	O	NOUN	B
of	O	ADP	O
VE	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
VT	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
TI	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
inspiratory	I-OUT	ADJ	B
duty	I-OUT	NOUN	I
cycle	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
TI/TTOT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
VCO2	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
VO2	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
lower	I-OUT	ADJ	B
fR	I-OUT	NOUN	B
,	O	PUNCT	O
than	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
workload	O	NOUN	B
,	O	PUNCT	O
VO2	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
VCO2	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
VE	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
VT	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
VT/TI	I-OUT	NOUN	B
increased	O	VERB	B
linearly	O	ADV	O
with	O	ADP	O
increasing	O	VERB	B
pedalling	O	NOUN	B
rate	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
at	O	ADP	O
the	O	DET	O
higher	O	ADJ	B
workload	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
VO2	B-OUT	NOUN	B
and	O	CCONJ	O
little	O	ADJ	O
or	O	CCONJ	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
ventilatory	B-OUT	ADJ	B
parameters	I-OUT	NOUN	B
from	O	ADP	O
30	O	NUM	O
to	O	PART	O
50	O	NUM	O
cycles/min	O	NOUN	B
except	O	SCONJ	O
for	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
fR	B-OUT	NOUN	B
in	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


4	O	X	O
.	O	PUNCT	O


While	O	SCONJ	O
performing	O	VERB	O
supine	B-I	ADJ	B
exercise	I-I	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
an	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
pedalling	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
on	I-OUT	ADP	O
ventilatory	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
metabolic	I-OUT	ADJ	B
parameters	I-OUT	NOUN	B
at	O	ADP	O
the	O	DET	O
low	O	ADJ	B
workload	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
W	O	NOUN	O
)	O	PUNCT	O
which	O	DET	O
diminished	O	VERB	B
at	O	ADP	O
the	O	DET	O
higher	O	ADJ	B
workload	O	NOUN	B
(	O	PUNCT	O
37	O	NUM	O
W	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
pedalling	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
appears	O	VERB	O
to	O	PART	O
enhance	O	VERB	B
efficiency	O	NOUN	B
at	O	ADP	O
these	O	DET	O
low	O	ADJ	B
workloads	O	NOUN	I
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


Differences	O	NOUN	B
between	O	ADP	O
the	O	DET	O
sexes	O	NOUN	B
during	O	ADP	O
exercise	O	NOUN	B
generally	O	ADV	O
include	O	VERB	O
:	O	PUNCT	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
a	O	DET	O
higher	B-OUT	ADJ	B
breathing	I-OUT	NOUN	B
frequency	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
b	I-OUT	X	O
)	I-OUT	PUNCT	O
a	I-OUT	DET	O
greater	I-OUT	ADJ	O
mechanical	I-OUT	ADJ	B
efficiency	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
(	I-OUT	PUNCT	O
c	I-OUT	X	O
)	I-OUT	PUNCT	O
lower	I-OUT	ADJ	O
ventilatory	I-OUT	ADJ	B
equivalents	I-OUT	NOUN	I
of	I-OUT	ADP	O
O2	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
CO2	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
VE/VO2	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
VE/VCO2	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
during	O	ADP	O
the	O	DET	O
higher	O	ADJ	B
workload	O	NOUN	B
in	O	ADP	O
females	O	NOUN	B
than	O	ADP	O
males	O	NOUN	B
.	O	PUNCT	O


Osteoporosis	B-I	NOUN	B
and	O	CCONJ	O
gait	O	NOUN	B
and	O	CCONJ	O
balance	O	NOUN	B
disturbances	O	NOUN	I
in	O	ADP	O
older	B-P	ADJ	B
sarcopenic	I-P	ADJ	B
obese	I-P	ADJ	B
New	I-P	ADJ	B
Zealanders	I-P	PROPN	I
.	I-P	PUNCT	O


UNLABELLED	O	NOUN	B
Bone	O	PROPN	B
,	O	PUNCT	O
muscle	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
fat	O	NOUN	B
may	O	AUX	O
affect	O	VERB	O
gait	O	NOUN	B
and	O	CCONJ	O
balance	O	NOUN	B
in	O	ADP	O
older	B-P	ADJ	B
adults	I-P	NOUN	I
.	I-P	PUNCT	O


Osteoporosis	B-P	NOUN	B
was	I-P	AUX	O
prevalent	I-P	ADJ	O
in	I-P	ADP	O
low	I-P	ADJ	B
muscle	I-P	NOUN	B
mass	I-P	NOUN	I
participants	I-P	NOUN	I
and	I-P	CCONJ	O
related	I-P	ADJ	O
to	I-P	PART	O
gait	I-P	NOUN	B
and	I-P	CCONJ	O
balance	I-P	NOUN	B
deficits	I-P	NOUN	I
.	I-P	PUNCT	O


Low	O	ADJ	B
muscle	O	NOUN	B
combined	O	VERB	O
with	O	ADP	O
high	O	ADJ	B
fat	O	ADJ	B
mass	O	NOUN	I
had	O	AUX	O
more	O	ADV	O
functional	O	ADJ	B
deficits	O	NOUN	I
and	O	CCONJ	O
poorer	O	ADJ	B
bone	O	NOUN	B
health	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
falls	O	NOUN	B
risk	O	NOUN	I
and	O	CCONJ	O
fractures	O	NOUN	B
.	O	PUNCT	O


INTRODUCTION	O	VERB	O
Decreasing	O	VERB	B
bone	O	NOUN	B
density	O	NOUN	I
and	O	CCONJ	O
muscle	O	NOUN	B
mass	O	NOUN	I
and	O	CCONJ	O
increasing	O	VERB	B
fat	O	ADJ	B
mass	O	NOUN	I
may	O	AUX	O
act	O	VERB	O
synergistically	O	ADV	B
to	O	PART	O
affect	O	VERB	O
gait	O	NOUN	B
and	O	CCONJ	O
balance	O	NOUN	B
in	O	ADP	O
older	O	ADJ	B
adults	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
eighty-three	I-P	NUM	O
older	I-P	ADJ	B
adults	I-P	NOUN	I
(	I-P	PUNCT	O
age	I-P	NOUN	B
72.7	I-P	NUM	O
+/-	I-P	CCONJ	O
6	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
range	I-P	NOUN	O
56-93	I-P	NUM	O
;	I-P	PUNCT	O
body	I-P	NOUN	B
mass	I-P	NOUN	I
index	I-P	NOUN	I
28.2	I-P	NUM	O
+/-	I-P	CCONJ	O
4.9	I-P	NUM	O
,	I-P	PUNCT	O
range	I-P	NOUN	O
16.6-46.0	I-P	X	O
)	I-P	PUNCT	O
were	I-P	AUX	O
recruited	I-P	VERB	O
from	I-P	ADP	O
a	I-P	DET	O
New	I-P	PROPN	B
Zealand	I-P	PROPN	I
falls	I-P	VERB	O
prevention	I-P	NOUN	O
intervention	I-P	NOUN	O
trial	I-P	NOUN	O
.	I-P	PUNCT	O


Total	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
appendicular	I-OUT	ADJ	B
skeletal	I-OUT	ADJ	O
muscle	I-OUT	NOUN	O
mass	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
ASM	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
percent	I-OUT	ADJ	B
fat	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
bone	I-OUT	NOUN	B
mineralization	I-OUT	NOUN	B
were	I-P	AUX	O
assessed	I-P	VERB	B
by	I-P	ADP	O
dual	I-I	ADJ	B
energy	I-I	NOUN	I
X-ray	I-I	NOUN	I
absorptiometry	I-I	NOUN	I
and	I-P	CCONJ	O
used	I-P	VERB	O
to	I-P	PART	O
characterize	I-P	VERB	O
normal	I-P	ADJ	B
lean	I-P	NOUN	I
(	I-P	PUNCT	O
NL	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
51	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
sarcopenic	I-P	ADJ	B
(	I-P	PUNCT	O
SS	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
18	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
sarcopenic	I-P	ADJ	B
obese	I-P	ADJ	I
(	I-P	PUNCT	O
SO	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
29	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
obese	I-P	ADJ	B
(	I-P	PUNCT	O
OO	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
85	I-P	NUM	O
)	I-P	PUNCT	O
phenotypes	I-P	NOUN	B
.	I-P	PUNCT	O


Functional	O	ADJ	B
performance	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
timed	B-I	VERB	B
up	I-I	ADP	O
and	I-I	CCONJ	O
go	I-I	VERB	O
,	I-I	PUNCT	O
chair	I-I	NOUN	B
stand	I-I	NOUN	O
,	I-I	PUNCT	O
single	I-I	ADJ	B
leg	I-I	NOUN	I
stand	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
step	B-I	NOUN	B
test	I-I	NOUN	I
.	I-I	PUNCT	O


Regression	O	NOUN	B
models	O	NOUN	I
were	O	AUX	O
adjusted	O	VERB	O
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
medications	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
physical	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Femoral	B-OUT	ADJ	B
neck	I-OUT	NOUN	I
osteoporosis	I-OUT	NOUN	I
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
22	O	NUM	O
%	O	NOUN	O
SS	O	NOUN	B
,	O	PUNCT	O
17	O	NUM	O
%	O	NOUN	O
SO	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
%	O	NOUN	O
NL	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
7	O	NUM	O
%	O	NOUN	O
OO	O	NOUN	B
.	O	PUNCT	O


Femoral	O	ADJ	B
neck	O	NOUN	O
osteoporosis	O	NOUN	O
with	O	ADP	O
low	O	ADJ	B
ASM	B-OUT	NOUN	B
predicted	O	VERB	O
poor	O	ADJ	B
chair	B-OUT	NOUN	I
stand	I-OUT	VERB	I
performance	I-OUT	NOUN	B
(	O	PUNCT	O
beta	O	NOUN	B
-3.3	O	NUM	O
,	O	PUNCT	O
standard	O	ADJ	B
error	O	NOUN	I
1.6	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


SO	O	ADV	B
scored	O	VERB	B
lowest	O	ADJ	O
on	O	ADP	O
the	O	DET	O
chair	O	NOUN	B
stand	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
step	O	NOUN	B
test	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Higher	B-OUT	ADJ	B
ASM	I-OUT	NOUN	B
predicted	O	VERB	O
faster	O	ADV	O
timed	O	VERB	B
up	O	ADP	O
and	O	CCONJ	O
go	O	VERB	O
performance	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Osteoporosis	O	NOUN	B
was	O	AUX	O
prevalent	O	ADJ	O
in	O	ADP	O
low	B-P	ADJ	B
ASM	I-P	NOUN	B
groups	I-P	NOUN	B
(	O	PUNCT	O
SS	O	NOUN	B
and	O	CCONJ	O
SO	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
related	O	ADJ	O
to	O	PART	O
gait	O	NOUN	B
and	O	CCONJ	O
balance	O	NOUN	B
deficits	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
the	O	DET	O
SO	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
has	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
falls	O	NOUN	B
risk	O	NOUN	I
,	O	PUNCT	O
fractures	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
interventions	O	NOUN	B
.	O	PUNCT	O


Pegylated	B-I	ADJ	B
feline	I-I	ADJ	O
granulocyte	I-I	NOUN	O
colony-stimulating	I-I	ADJ	O
factor	I-I	NOUN	O
increases	O	VERB	O
neutrophil	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
cats	B-P	NOUN	B
.	I-P	PUNCT	O


Neutropenia	O	NOUN	B
can	O	AUX	O
often	O	ADV	O
be	O	AUX	O
corrected	O	VERB	O
by	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
granulocyte-colony	B-I	ADJ	B
stimulating	I-I	NOUN	I
factor	I-I	NOUN	I
(	I-I	PUNCT	O
G-CSF	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
off-label	B-I	ADJ	B
use	I-I	NOUN	O
of	I-I	ADP	O
commercial	I-I	ADJ	B
human	I-I	ADJ	B
G-CSF	I-I	NOUN	B
(	I-I	PUNCT	O
HuG-CSF	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
a	O	DET	O
commonly	O	ADV	O
used	O	VERB	O
treatment	O	NOUN	B
for	O	ADP	O
neutropenic	B-P	ADJ	B
animals	I-P	NOUN	I
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
long-term	O	ADJ	B
HuG-CSF	B-I	NOUN	B
treatment	I-I	NOUN	B
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
neutropenia	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
feline	O	NOUN	B
(	O	PUNCT	O
Fe	O	NOUN	B
)	O	PUNCT	O
G-CSF	O	NOUN	B
was	O	AUX	O
produced	O	VERB	O
in	O	ADP	O
Pichia	O	X	B
pastoris	O	X	I
,	O	PUNCT	O
pegylated	O	ADJ	B
(	O	PUNCT	O
Peg	O	NOUN	B
)	O	PUNCT	O
FeG-CSF	O	NOUN	B
and	O	CCONJ	O
tested	O	VERB	B
in	O	ADP	O
cats	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
controlled	O	ADJ	I
clinical	O	ADJ	I
trial	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
PegFeG-CSF	B-I	NOUN	B
compared	O	VERB	O
to	O	PART	O
FeG-CSF	B-I	NOUN	B
or	I-I	CCONJ	O
HuG-CSF	I-I	NOUN	B
in	O	ADP	O
FIV-infected	B-P	ADJ	B
(	I-P	PUNCT	O
n=14	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
FIV-uninfected	I-P	ADJ	B
healthy	I-P	ADJ	B
cats	I-P	NOUN	B
(	I-P	PUNCT	O
n=19	I-P	ADJ	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
in	I-P	ADP	O
HuG-CSF-induced	I-P	ADJ	B
neutropenic	I-P	ADJ	B
cats	I-P	NOUN	I
(	I-P	PUNCT	O
n=4	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Daily	O	ADJ	O
FeG-CSF	B-I	NOUN	B
doses	O	NOUN	O
induced	O	VERB	B
higher	B-OUT	ADJ	O
neutrophil	I-OUT	NOUN	B
production	I-OUT	NOUN	B
than	O	ADP	O
HuG-CSF	B-I	NOUN	B
after	O	ADP	O
the	O	DET	O
second	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
⩽	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Weekly	O	ADJ	B
doses	O	NOUN	B
of	B-I	ADP	O
PegFeG-CSF	I-OUT	NOUN	B
induced	I-OUT	VERB	B
higher	I-OUT	ADJ	O
neutrophil	I-OUT	NOUN	B
counts	I-OUT	NOUN	O
and	O	CCONJ	O
showed	B-OUT	VERB	O
greater	I-OUT	ADJ	O
sustained	I-OUT	ADJ	B
activity	I-OUT	NOUN	B
than	O	ADP	O
weekly	O	ADJ	B
doses	O	NOUN	B
of	B-I	ADP	O
FeG-CSF	I-I	NOUN	B
.	I-I	PUNCT	O


PegFeG-CSF	B-I	NOUN	B
provided	O	VERB	O
the	O	DET	O
most	O	ADV	O
therapeutic	O	ADJ	B
and	O	CCONJ	O
sustainable	B-OUT	ADJ	O
neutrophil	I-OUT	NOUN	B
production	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
both	B-P	CCONJ	O
FIV-uninfected	I-P	ADJ	B
and	I-P	CCONJ	O
FIV-infected	I-P	ADJ	B
cats	I-P	NOUN	B
,	O	PUNCT	O
without	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	B-OUT	ADP	O
neutralizing	I-OUT	VERB	B
antibodies	I-OUT	NOUN	I
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
all	B-I	DET	O
HuG-CSF-treated	I-I	ADJ	B
cats	I-P	NOUN	B
developed	I-OUT	VERB	O
neutralizing	I-OUT	VERB	B
antibodies	I-OUT	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
cross-reactive	O	ADJ	B
antibodies	O	NOUN	B
to	O	PART	O
endogenous	O	ADJ	B
G-CSF	O	NOUN	B
in	O	ADP	O
a	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
neutropenia	O	NOUN	B
.	O	PUNCT	O


Strikingly	O	ADV	B
,	O	PUNCT	O
when	B-I	SCONJ	O
PegFeG-CSF	I-I	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
rescue	O	VERB	B
cats	O	NOUN	B
with	B-I	ADP	O
HuG-CSF-induced	I-OUT	ADJ	B
neutropenia	I-OUT	NOUN	I
,	O	PUNCT	O
clinically	O	ADV	B
normal	B-OUT	ADJ	I
neutrophil	I-OUT	NOUN	B
numbers	I-OUT	NOUN	B
returned	O	VERB	O
.	O	PUNCT	O


Thus	B-I	ADV	O
,	I-I	PUNCT	O
PegFeG-CSF	I-I	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
superior	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
neutropenia	O	NOUN	B
in	B-P	ADP	O
feline	I-P	ADJ	B
patients	I-P	NOUN	B
.	O	PUNCT	O


Protein	B-I	NOUN	B
ingestion	I-I	NOUN	B
further	O	ADV	O
augments	O	VERB	O
S6K1	O	NOUN	B
phosphorylation	O	NOUN	B
in	O	ADP	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
following	O	VERB	O
resistance	B-P	NOUN	B
type	I-P	NOUN	O
exercise	I-P	NOUN	B
in	I-P	ADP	O
males	I-P	NOUN	B
.	I-P	PUNCT	O


Our	O	PRON	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
carbohydrate	B-I	NOUN	B
and/or	I-I	CCONJ	O
protein	I-I	NOUN	B
ingestion	I-I	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
exercise	B-I	NOUN	B
on	O	ADP	O
ribosomal	O	ADJ	B
protein	O	NOUN	I
S6	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
S6K1	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
S6	O	NOUN	B
phosphorylation	O	NOUN	B
status	O	NOUN	O
in	O	ADP	O
human	B-P	ADJ	B
skeletal	O	ADJ	B
muscle	O	NOUN	I
tissue	O	NOUN	O
.	O	PUNCT	O


Seven	B-P	NUM	O
healthy	I-P	ADJ	B
,	I-P	PUNCT	O
untrained	I-P	ADJ	B
men	I-P	NOUN	B
(	I-P	PUNCT	O
22.5	I-P	NUM	O
+/-	I-P	CCONJ	O
0.9	I-P	NUM	O
y	I-P	NOUN	O
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
2	O	NUM	O
cross-over	O	ADJ	B
experiments	O	NOUN	I
.	O	PUNCT	O


Before	O	ADV	O
,	O	PUNCT	O
immediately	O	ADV	O
after	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
a	O	DET	O
single	O	ADJ	O
bout	O	NOUN	B
of	O	ADP	O
resistance	B-I	NOUN	B
exercise	I-I	NOUN	B
,	O	PUNCT	O
subjects	O	NOUN	B
consumed	O	VERB	O
0.3	O	NUM	O
g	O	NOUN	O
x	O	NOUN	O
kg	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
carbohydrate	B-I	NOUN	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
0.3	I-I	NUM	O
g	I-I	NOUN	O
x	I-I	NOUN	O
kg	I-I	NOUN	O
(	I-I	PUNCT	O
-1	I-I	NUM	O
)	I-I	PUNCT	O
protein	I-I	NOUN	O
hydrolysate	I-I	NOUN	O
(	I-I	PUNCT	O
CHO+PRO	I-I	NOUN	B
and	I-I	CCONJ	O
CHO	I-I	NOUN	B
,	I-I	PUNCT	O
respectively	I-I	ADV	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Muscle	B-I	NOUN	B
biopsies	I-I	NOUN	I
were	O	AUX	O
taken	O	VERB	O
before	O	ADV	O
and	O	CCONJ	O
immediately	O	ADV	O
after	O	ADP	O
exercise	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
h	O	NOUN	O
of	O	ADP	O
postexercise	O	NOUN	B
recovery	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
4E-BP1	O	NOUN	B
,	O	PUNCT	O
S6K1	O	NOUN	B
(	O	PUNCT	O
both	O	DET	O
T	O	NOUN	B
(	O	PUNCT	O
421	O	NUM	O
)	O	PUNCT	O
/S	O	NOUN	O
(	O	PUNCT	O
424	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
T	O	NOUN	B
(	O	PUNCT	O
389	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
S6	O	NOUN	B
phosphorylation	O	NOUN	B
status	O	NOUN	O
.	O	PUNCT	O


Following	B-OUT	VERB	O
resistance	I-OUT	NOUN	B
exercise	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
4E-BP1	I-OUT	NOUN	B
phosphorylation	I-OUT	NOUN	B
was	I-OUT	AUX	O
reduced	I-OUT	VERB	B
to	I-OUT	PART	O
a	I-OUT	DET	O
greater	I-OUT	ADJ	O
extent	I-OUT	NOUN	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
CHO	I-OUT	NOUN	B
treatment	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
-48	I-OUT	NUM	O
+/-	I-OUT	CCONJ	O
7	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
than	I-OUT	ADP	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
CHO+PRO	I-OUT	NOUN	B
treatment	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
-15	I-OUT	NUM	O
+/-	I-OUT	CCONJ	O
14	I-OUT	NUM	O
%	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


During	B-OUT	ADP	O
recovery	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
4E-BP1	I-OUT	NOUN	B
phosphorylation	I-OUT	NOUN	B
increased	I-OUT	VERB	B
in	I-OUT	ADP	O
both	I-OUT	DET	O
experiments	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
tended	I-OUT	VERB	O
to	I-OUT	PART	O
be	I-OUT	AUX	O
higher	I-OUT	ADJ	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
CHO+PRO	I-OUT	NOUN	B
test	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.08	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


S6K1	B-OUT	NOUN	B
phosphorylation	I-OUT	NOUN	B
at	I-OUT	ADP	O
T	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
421	I-OUT	NUM	O
)	I-OUT	PUNCT	O
/S	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
424	I-OUT	NUM	O
)	I-OUT	PUNCT	O
substantially	I-OUT	ADV	O
increased	I-OUT	VERB	B
following	I-OUT	VERB	O
exercise	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
remained	I-OUT	VERB	O
elevated	I-OUT	ADJ	B
during	I-OUT	ADP	O
recovery	I-OUT	NOUN	B
with	I-OUT	ADP	O
no	I-OUT	DET	O
differences	I-OUT	NOUN	O
between	I-OUT	ADP	O
treatments	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	B-OUT	ADP	O
contrast	I-OUT	NOUN	O
to	I-OUT	PART	O
the	I-OUT	DET	O
CHO	I-OUT	NOUN	B
treatment	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
-4	I-OUT	NUM	O
+/-	I-OUT	CCONJ	O
2	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
S6K1	I-OUT	NOUN	B
phosphorylation	I-OUT	NOUN	B
at	I-OUT	ADP	O
T	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
389	I-OUT	NUM	O
)	I-OUT	PUNCT	O
was	I-OUT	AUX	O
higher	I-OUT	ADJ	O
following	I-OUT	VERB	O
exercise	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
CHO+PRO	I-OUT	NOUN	B
treatment	I-OUT	NOUN	B
only	I-OUT	ADV	O
(	I-OUT	PUNCT	O
+78	I-OUT	NUM	O
+/-	I-OUT	CCONJ	O
2	I-OUT	NUM	O
%	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


During	B-OUT	ADP	O
recovery	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
S6K1	I-OUT	NOUN	B
phosphorylation	I-OUT	NOUN	B
at	I-OUT	ADP	O
T	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
389	I-OUT	NUM	O
)	I-OUT	PUNCT	O
remained	I-OUT	VERB	O
higher	I-OUT	ADJ	O
in	I-OUT	ADP	O
CHO+PRO	I-OUT	NOUN	B
than	I-OUT	ADP	O
in	I-OUT	ADP	O
CHO	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
0.05	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


S6	B-OUT	NOUN	B
phosphorylation	I-OUT	NOUN	B
was	I-OUT	AUX	O
substantially	I-OUT	ADV	O
higher	I-OUT	ADJ	O
following	I-OUT	VERB	O
exercise	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
CHO+PRO	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
1.69	I-OUT	NUM	O
+/-	I-OUT	CCONJ	O
0.35	I-OUT	NUM	O
)	I-OUT	PUNCT	O
than	I-OUT	ADP	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
CHO	I-OUT	NOUN	B
experiment	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
0.45	I-OUT	NUM	O
+/-	I-OUT	CCONJ	O
0.07	I-OUT	NUM	O
,	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
remained	I-OUT	VERB	O
elevated	I-OUT	ADJ	B
during	I-OUT	ADP	O
recovery	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
0.05	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
availability	O	NOUN	B
of	O	ADP	I
dietary	O	ADJ	B
protein	O	NOUN	I
further	O	ADV	O
enhances	O	VERB	O
phosphorylation	O	NOUN	B
of	O	ADP	O
S6K1	O	NOUN	B
during	O	ADP	O
recovery	O	NOUN	B
from	O	ADP	O
resistance	O	NOUN	B
type	O	NOUN	O
exercise	O	NOUN	B
.	O	PUNCT	O


Albumin-glutaraldehyde	B-I	ADJ	B
bioadhesive	I-I	NOUN	I
(	I-I	PUNCT	O
"	I-I	PUNCT	O
Bioglue	I-I	ADJ	B
"	I-I	PUNCT	O
)	I-I	PUNCT	O
for	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
postoperative	B-OUT	ADJ	B
complications	I-OUT	NOUN	B
after	O	ADP	O
stapled	O	ADJ	B
hemorrhoidopexy	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Hemorrhoidopexy	O	PROPN	B
using	O	VERB	O
the	O	DET	O
circumferential	O	ADJ	B
stapler	O	NOUN	I
is	O	AUX	O
an	O	DET	O
established	O	ADJ	O
method	O	NOUN	B
for	O	ADP	O
surgical	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
prolapsing	I-P	NOUN	B
hemorrhoids	I-P	NOUN	I
.	I-P	PUNCT	O


Despite	O	SCONJ	O
its	O	PRON	O
advantages	O	NOUN	O
,	O	PUNCT	O
complications	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
anal	O	ADJ	B
canal	O	NOUN	I
stenosis	O	NOUN	I
,	O	PUNCT	O
hemorrhage	O	NOUN	B
and	O	CCONJ	O
anastomosis	O	NOUN	B
leak	O	NOUN	B
with	O	ADP	O
eventual	O	ADJ	O
intrapelvic	O	ADJ	B
sepsis	O	NOUN	I
can	O	AUX	O
cause	O	VERB	O
serious	O	ADJ	O
postoperative	O	ADJ	B
problems	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
utility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
surgical	O	ADJ	B
adhesive	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
biological	B-I	ADJ	B
albumin-glutaraldehyde	I-I	ADJ	B
glue	I-I	NOUN	I
"	I-I	PUNCT	O
Bioglue	I-I	PROPN	B
"	I-I	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
reduction	O	NOUN	B
of	O	ADP	O
these	O	DET	O
postoperative	O	ADJ	B
complications	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Between	B-P	ADP	O
January	I-P	PROPN	O
2002	I-P	NUM	O
and	I-P	CCONJ	O
November	I-P	PROPN	O
2004	I-P	NUM	O
,	I-P	PUNCT	O
200	I-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
stapled	I-I	ADJ	B
hemorrhoidopexy	I-I	NOUN	I
were	I-P	AUX	O
enrolled	I-P	VERB	O
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
the	I-P	DET	O
control	I-I	NOUN	B
group	I-I	NOUN	I
;	I-I	PUNCT	O
the	I-P	DET	O
study	I-P	NOUN	B
group	I-P	NOUN	I
consisted	I-P	VERB	O
of	I-P	ADP	O
100	I-P	NUM	O
patients	I-P	NOUN	B
who	O	PRON	O
received	O	VERB	O
Bioglue	B-I	ADJ	B
in	I-I	ADP	O
the	I-I	DET	O
mucosa	I-I	NOUN	B
anastomosis	I-I	NOUN	I
area	I-I	NOUN	B
.	I-I	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
standardized	B-I	ADJ	O
postoperative	I-I	ADJ	B
analgesic	I-I	NOUN	I
,	I-I	PUNCT	O
laxative	I-I	ADJ	B
and	I-I	CCONJ	O
antibiotic	I-I	ADJ	B
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
then	O	ADV	O
evaluated	O	VERB	B
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
for	O	ADP	O
postoperative	B-OUT	ADJ	B
complications	I-OUT	NOUN	B
(	O	PUNCT	O
after	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
postoperatively	O	ADV	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
From	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
no	O	DET	O
Bioglue	O	ADJ	B
application	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
anal	B-OUT	ADJ	B
stenosis	I-OUT	NOUN	I
,	O	PUNCT	O
two	O	NUM	O
with	O	ADP	O
hemorrhage	B-OUT	NOUN	B
,	O	PUNCT	O
three	O	NUM	O
had	O	AUX	O
anastomosis	B-OUT	NOUN	B
leak	I-OUT	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
had	O	AUX	O
thrombosis	B-OUT	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Bioglue	O	ADJ	B
group	O	NOUN	B
had	O	AUX	O
any	O	DET	O
of	O	ADP	O
these	O	DET	O
complications	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
had	O	AUX	O
patients	O	NOUN	B
with	O	ADP	O
severe	B-OUT	ADJ	B
postoperative	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
each	O	DET	O
)	O	PUNCT	O
and	O	CCONJ	O
fecal	B-OUT	ADJ	B
incontinence	I-OUT	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
patient	O	NOUN	B
each	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
overall	B-OUT	ADJ	O
difference	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
complications	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
this	O	DET	O
first	O	ADJ	O
study	O	NOUN	B
using	O	VERB	O
Bioglue	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
circumferential	O	ADJ	B
stapled	O	ADJ	I
hemorrhoidopexy	O	NOUN	I
we	O	PRON	O
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
application	O	NOUN	B
of	O	ADP	O
the	O	DET	O
glue	O	NOUN	B
is	O	AUX	O
effective	B-OUT	ADJ	B
in	O	ADP	O
reducing	B-OUT	VERB	B
postoperative	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
5-year	O	ADJ	O
randomized	O	ADJ	B
trial	O	NOUN	I
to	O	PART	O
compare	O	VERB	B
1	O	NUM	O
or	O	CCONJ	O
2	O	NUM	O
implants	B-I	NOUN	B
for	O	ADP	O
implant	B-P	ADJ	B
overdentures	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
hypothesis	O	NOUN	B
of	O	ADP	O
this	O	DET	O
5-y	O	ADJ	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
was	O	AUX	O
that	O	SCONJ	O
there	O	PRON	O
would	O	AUX	O
be	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
satisfaction	B-OUT	NOUN	B
of	O	ADP	O
edentulous	B-P	ADJ	B
participants	I-P	NOUN	I
with	I-P	ADP	O
removable	I-P	ADJ	B
complete	I-P	ADJ	I
overdentures	I-P	NOUN	I
attached	I-P	VERB	O
to	I-P	ADP	O
1	I-P	NUM	O
or	I-P	CCONJ	O
2	I-P	NUM	O
mandibular	I-I	ADJ	B
implants	I-I	NOUN	B
.	I-I	PUNCT	O


Secondary	O	ADJ	B
aims	O	NOUN	O
were	O	AUX	O
to	O	PART	O
test	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
satisfaction	B-OUT	NOUN	B
between	O	ADP	O
and	O	CCONJ	O
within	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
5	O	NUM	O
y	O	NOUN	O
and	O	CCONJ	O
differences	O	NOUN	B
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
implant	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
and	O	CCONJ	O
prosthodontic	O	ADJ	B
maintenance	O	NOUN	I
over	O	ADP	O
5	O	NUM	O
y	O	NOUN	O
.	O	PUNCT	O


Each	O	DET	O
of	O	ADP	O
the	O	DET	O
86	B-P	NUM	O
participants	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	NOUN	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
67	I-P	NUM	O
y	I-P	NOUN	O
)	I-P	PUNCT	O
was	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
1	B-I	NUM	O
implant	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
midline	I-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
2	B-I	NUM	O
implants	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
canine	I-I	NOUN	B
areas	I-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
attached	O	VERB	O
to	O	ADP	O
a	O	DET	O
mandibular	O	ADJ	B
overdenture	O	NOUN	I
opposing	O	VERB	O
a	O	DET	O
maxillary	O	ADJ	B
complete	O	ADJ	I
denture	O	NOUN	I
.	O	PUNCT	O


Satisfaction	B-OUT	NOUN	B
was	I-OUT	AUX	O
self-assessed	I-OUT	ADJ	B
by	O	ADP	O
participants	O	NOUN	B
on	O	ADP	O
a	O	DET	O
visual	B-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
implants	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
at	O	ADP	O
2	O	NUM	O
mo	O	NOUN	O
and	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
y	O	NOUN	O
with	O	ADP	O
implant	O	ADJ	B
overdentures	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
implant	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
prosthodontic	I-OUT	ADJ	B
maintenance	I-OUT	NOUN	I
were	O	AUX	O
assessed	B-OUT	VERB	B
by	I-OUT	ADP	O
clinical	I-OUT	ADJ	B
examination	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


After	O	ADP	O
5	O	NUM	O
y	O	NOUN	O
,	O	PUNCT	O
29	O	NUM	O
participants	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
33	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
were	O	AUX	O
available	O	ADJ	O
,	O	PUNCT	O
with	O	ADP	O
most	O	ADJ	O
dropouts	O	NOUN	B
due	O	ADP	O
to	O	ADP	O
death	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Satisfaction	B-OUT	NOUN	B
with	O	ADP	O
the	O	DET	O
implant	O	ADJ	B
denture	O	NOUN	I
after	O	ADP	O
5	O	NUM	O
y	O	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
higher	O	ADJ	O
than	O	ADP	O
at	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
and	O	CCONJ	O
remained	O	VERB	O
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.32	O	NUM	O
)	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
implants	O	NOUN	B
failed	B-OUT	VERB	B
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
but	O	CCONJ	O
5	O	NUM	O
failed	O	VERB	B
before	O	ADP	O
loading	O	VERB	B
in	O	ADP	O
4	O	NUM	O
participants	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
.	O	PUNCT	O


Most	O	ADJ	O
participants	O	NOUN	B
required	O	VERB	O
maintenance	B-OUT	NOUN	B
or	O	CCONJ	O
occasionally	O	ADV	O
denture	B-OUT	NOUN	B
replacement	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
although	O	SCONJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
,	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
experienced	O	VERB	O
almost	O	ADV	O
twice	O	ADV	O
as	O	ADV	O
many	O	ADJ	O
fractured	B-OUT	ADJ	B
dentures	I-OUT	NOUN	I
usually	O	ADV	O
adjacent	O	ADJ	B
to	O	ADP	O
the	O	DET	O
implant	O	ADJ	B
attachment	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
after	O	ADP	O
5	O	NUM	O
y	O	NOUN	O
in	O	ADP	O
satisfaction	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
of	I-OUT	ADP	O
implants	I-OUT	NOUN	B
with	O	ADP	O
mandibular	O	ADJ	B
overdentures	O	NOUN	I
retained	O	VERB	O
by	O	ADP	O
1	O	NUM	O
implant	O	NOUN	B
or	O	CCONJ	O
2	O	NUM	O
implants	O	NOUN	B
.	O	PUNCT	O


Additional	O	ADJ	O
research	O	NOUN	B
is	O	AUX	O
required	O	VERB	O
to	O	PART	O
confirm	O	VERB	O
long-term	O	ADJ	B
treatment	O	NOUN	B
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
single-implant	O	ADJ	B
dentures	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
implications	O	NOUN	O
of	O	ADP	O
prosthetic	O	ADJ	B
maintenance	O	NOUN	B
with	O	ADP	O
implant	O	ADJ	B
overdentures	O	NOUN	I
(	O	PUNCT	O
ClinicalTrials.gov	O	NOUN	B
:	O	PUNCT	O
NCT02117856	O	PROPN	O
)	O	PUNCT	O
.	O	PUNCT	O


Anti-inflammatory	B-OUT	ADJ	B
effects	I-OUT	NOUN	B
of	O	ADP	O
inhaled	B-I	VERB	B
carbon	I-I	NOUN	I
monoxide	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
COPD	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
studies	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
carbon	B-I	NOUN	B
monoxide	I-I	NOUN	I
(	O	PUNCT	O
CO	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
both	O	CCONJ	O
anti-inflammatory	O	ADJ	B
and	O	CCONJ	O
anti-oxidant	O	ADJ	B
capacities	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
chronic	O	ADJ	B
obstructive	O	ADJ	I
pulmonary	O	ADJ	I
disease	O	NOUN	I
(	O	PUNCT	O
COPD	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
characterised	O	VERB	O
by	O	ADP	O
inflammation	O	NOUN	B
and	O	CCONJ	O
oxidative	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
low-dose	B-I	ADJ	B
CO	I-I	NOUN	B
could	O	AUX	O
be	O	AUX	O
of	O	ADP	O
therapeutic	O	ADJ	B
use	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
feasibility	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
anti-inflammatory	I-OUT	ADJ	B
effects	I-OUT	NOUN	O
of	O	ADP	O
100-125	O	NUM	O
ppm	O	NOUN	O
CO	B-I	NOUN	B
inhalation	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
stable	I-P	ADJ	B
COPD	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
total	O	NOUN	O
,	O	PUNCT	O
20	B-P	NUM	O
ex-smoking	I-P	VERB	B
COPD	I-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
post-bronchodilator	I-P	ADJ	B
forced	I-P	ADJ	O
expiratory	I-P	ADJ	O
volume	I-P	NOUN	O
in	I-P	ADP	O
one	I-P	NUM	O
second	I-P	NOUN	O
(	I-P	PUNCT	O
FEV	I-P	NOUN	B
(	I-P	PUNCT	O
1	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
>	I-P	X	O
1.20	I-P	NUM	O
L	I-P	NOUN	B
and	I-P	CCONJ	O
FEV	I-P	PROPN	B
(	I-P	PUNCT	O
1	I-P	NUM	O
)	I-P	PUNCT	O
/forced	I-P	ADJ	O
vital	I-P	ADJ	B
capacity	I-P	NOUN	I
<	I-P	X	O
70	I-P	NUM	O
%	I-P	NOUN	O
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Effects	B-OUT	NOUN	B
on	I-OUT	ADP	O
inflammation	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
induced	B-OUT	VERB	B
sputum	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CO	B-OUT	NOUN	B
inhalation	I-OUT	NOUN	B
was	O	AUX	O
feasible	B-OUT	ADJ	O
and	O	CCONJ	O
patients	B-OUT	NOUN	B
'	I-OUT	PART	O
vital	I-OUT	ADJ	B
signs	I-OUT	NOUN	I
were	O	AUX	O
unaffected	O	ADJ	B
;	O	PUNCT	O
2	O	NUM	O
h.day	O	NOUN	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
inhalation	O	NOUN	B
of	O	ADP	O
low-dose	O	ADJ	B
CO	O	NOUN	B
on	O	ADP	O
4	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
led	O	VERB	O
to	O	PART	O
a	O	DET	O
maximal	O	ADJ	B
individual	O	ADJ	B
carboxyhaemoglobin	B-OUT	NOUN	B
level	I-OUT	NOUN	O
of	O	ADP	O
4.5	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Two	O	NUM	O
exacerbations	B-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
CO	O	PROPN	B
period	O	NOUN	B
.	O	PUNCT	O


CO	O	NOUN	B
inhalation	O	NOUN	B
led	O	VERB	O
to	O	ADP	O
trends	O	NOUN	B
in	O	ADP	O
reduced	B-OUT	VERB	B
sputum	I-OUT	NOUN	I
eosinophils	I-OUT	NOUN	I
(	O	PUNCT	O
median	O	ADJ	B
reduction	O	NOUN	B
0.25	O	NUM	O
%	O	NOUN	O
point	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
improved	B-OUT	VERB	B
responsiveness	I-OUT	NOUN	B
to	I-OUT	PART	O
methacholine	I-OUT	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
provocative	O	ADJ	B
concentration	O	NOUN	B
causing	O	VERB	O
a	O	DET	O
20	O	NUM	O
%	O	NOUN	O
fall	O	NOUN	B
in	O	ADP	O
FEV	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
0.85	O	NUM	O
versus	O	CCONJ	O
0.63	O	NUM	O
mg.mL	O	NUM	O
(	O	PUNCT	O
-1	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Inhalation	O	NOUN	B
of	O	ADP	O
100-125	O	NUM	O
ppm	O	NOUN	O
carbon	B-I	NOUN	O
monoxide	I-I	NOUN	O
by	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
in	I-P	ADP	O
a	I-P	DET	O
stable	I-P	ADJ	B
phase	I-P	NOUN	O
was	O	AUX	O
feasible	O	ADJ	O
and	O	CCONJ	O
led	O	VERB	O
to	O	ADP	O
trends	O	NOUN	B
in	O	ADP	O
reduction	O	NOUN	B
of	O	ADP	O
sputum	O	NOUN	B
eosinophils	O	NOUN	I
and	O	CCONJ	O
improvement	B-OUT	NOUN	B
of	I-OUT	ADP	O
responsiveness	I-OUT	NOUN	B
to	I-OUT	PART	O
methacholine	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
need	O	VERB	O
to	O	PART	O
confirm	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
in	O	ADP	O
inflammatory	B-P	ADJ	B
lung	I-P	NOUN	O
diseases	I-P	NOUN	O
.	I-P	PUNCT	O


Statistical	O	ADJ	B
aspects	O	NOUN	I
of	O	ADP	O
early	O	ADJ	B
termination	O	NOUN	I
in	O	ADP	O
the	O	DET	O
beta-blocker	O	NOUN	B
heart	O	NOUN	I
attack	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Beta-Blocker	O	PROPN	B
Heart	O	PROPN	I
Attack	O	PROPN	I
Trial	O	PROPN	I
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
double	O	ADJ	O
blind	O	ADJ	O
controlled	O	VERB	O
trial	O	NOUN	O
comparing	O	VERB	O
propranolol	B-I	NOUN	B
with	I-I	ADP	O
placebo	I-I	NOUN	B
in	O	ADP	O
3837	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
recent	I-P	ADJ	O
myocardial	I-P	ADJ	B
infarction	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
terminated	O	VERB	O
on	O	ADP	O
recommendation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Policy	O	PROPN	B
and	O	CCONJ	O
Data	O	PROPN	B
Monitoring	O	PROPN	O
Board	O	PROPN	O
9	O	NUM	O
months	O	NOUN	B
before	O	ADP	O
the	O	DET	O
scheduled	O	VERB	B
closing	O	NOUN	B
date	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
propranolol	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
the	O	DET	O
decision	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
26	O	NUM	O
%	O	NOUN	O
lower	O	ADJ	O
mortality	B-OUT	NOUN	B
(	O	PUNCT	O
z	O	NOUN	O
=	O	ADJ	O
2.82	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Many	O	ADJ	O
issues	O	NOUN	B
were	O	AUX	O
considered	O	VERB	O
in	O	ADP	O
this	O	DET	O
decision	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
included	O	VERB	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
the	O	DET	O
overall	O	ADJ	O
results	O	NOUN	B
;	O	PUNCT	O
consistency	O	NOUN	B
of	O	ADP	O
results	O	NOUN	B
across	O	ADP	O
subgroups	O	NOUN	B
,	O	PUNCT	O
clinical	O	ADJ	B
centers	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cause	O	NOUN	B
of	O	ADP	I
death	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
completeness	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
basic	O	ADJ	O
statistical	O	ADJ	B
methods	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
in	O	ADP	O
declaring	O	VERB	O
the	O	DET	O
overall	B-OUT	ADJ	B
mortality	I-OUT	NOUN	B
results	O	VERB	O
significant	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
method	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
current	O	ADJ	B
survival	B-OUT	NOUN	B
data	I-OUT	NOUN	O
taking	O	VERB	O
into	O	ADP	O
account	O	NOUN	O
the	O	DET	O
issue	O	NOUN	B
of	O	ADP	O
repeated	O	VERB	O
significance	O	NOUN	B
testing	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
method	O	NOUN	B
evaluated	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
observed	O	VERB	O
trend	O	NOUN	O
was	O	AUX	O
so	O	ADV	O
impressive	O	ADJ	B
that	O	SCONJ	O
the	O	DET	O
conclusion	O	NOUN	O
was	O	AUX	O
unlikely	O	ADJ	O
to	O	PART	O
change	O	VERB	B
even	O	ADV	O
if	O	SCONJ	O
the	O	DET	O
trial	O	NOUN	B
should	O	AUX	O
continue	O	VERB	O
to	O	ADP	O
the	O	DET	O
scheduled	O	VERB	B
end	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
two	O	NUM	O
methods	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
other	O	ADJ	O
considerations	O	NOUN	B
led	O	VERB	O
to	O	PART	O
the	O	DET	O
recommendation	O	NOUN	B
to	O	PART	O
discontinue	O	VERB	B
the	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


Effectiveness	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Levitan	B-I	PROPN	B
FPS	I-I	PROPN	I
Scope™	I-I	NOUN	B
for	I-P	ADP	O
tracheal	I-P	ADJ	B
intubation	I-P	NOUN	I
under	I-P	ADP	O
general	I-P	ADJ	B
anesthesia	I-P	NOUN	I
with	O	ADP	O
a	B-P	DET	O
simulated	I-P	ADJ	B
difficult	I-P	ADJ	O
airway	I-P	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
Studies	O	NOUN	I
show	O	VERB	O
that	O	SCONJ	O
the	B-I	DET	O
Levitan	I-I	PROPN	B
FPS	I-I	PROPN	I
(	I-I	PUNCT	O
first	I-I	ADJ	O
pass	I-I	NOUN	O
success	I-I	NOUN	B
)	I-I	PUNCT	O
Scope™	I-I	NOUN	B
(	I-I	PUNCT	O
LFS	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
analogous	O	ADJ	O
to	O	PART	O
a	O	DET	O
bougie	O	NOUN	B
in	O	ADP	O
simulated	O	ADJ	B
difficult	O	ADJ	O
airways	O	NOUN	B
with	O	ADP	O
comparable	O	ADJ	O
tracheal	O	ADJ	B
intubation	O	NOUN	B
success	O	NOUN	O
rates	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
tracheal	O	ADJ	B
intubation	O	NOUN	I
with	O	ADP	O
the	O	DET	O
LFS	O	NOUN	B
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
Macintosh	O	PROPN	B
laryngoscope	O	NOUN	I
utilizing	O	VERB	O
manual	O	ADJ	B
in-line	O	NOUN	O
stabilization	O	NOUN	O
(	O	PUNCT	O
MILS	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
simulate	O	VERB	B
difficult	O	ADJ	B
airways	O	NOUN	B
.	O	PUNCT	O


METHODS	B-P	VERB	O
Ninety-four	I-P	NUM	B
subjects	I-P	NOUN	I
successfully	I-P	ADV	O
completed	I-P	VERB	O
the	I-P	DET	O
trial	I-P	NOUN	B
.	O	PUNCT	O


Manual	O	ADJ	B
in-line	O	NOUN	O
stabilization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cervical	O	ADJ	B
spine	O	NOUN	I
was	O	AUX	O
applied	O	VERB	O
and	O	CCONJ	O
the	B-I	DET	O
initial	I-I	ADJ	B
laryngoscopy	I-I	NOUN	B
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
either	O	CCONJ	O
the	B-I	DET	O
Macintosh	I-I	PROPN	B
or	I-I	CCONJ	O
the	I-I	DET	O
LFS	I-I	NOUN	B
in	I-I	ADP	O
conjunction	I-I	NOUN	B
with	I-I	ADP	O
the	I-I	DET	O
Macintosh	I-I	PROPN	B
.	O	PUNCT	O


Following	O	VERB	O
the	O	DET	O
initial	O	ADJ	O
grading	B-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
second	I-I	ADJ	O
laryngoscopy	I-I	NOUN	B
was	O	AUX	O
repeated	O	VERB	O
using	O	VERB	O
the	O	DET	O
second	O	ADJ	O
randomized	O	ADJ	B
technique	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Cormack-Lehane	B-OUT	NOUN	B
grades	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
percentage	I-OUT	NOUN	B
of	I-OUT	ADP	O
glottic	I-OUT	ADJ	B
opening	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
POGO	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
scores	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
time	I-OUT	NOUN	O
to	I-OUT	PART	O
intubate	I-OUT	VERB	B
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
intubation	I-OUT	NOUN	B
attempts	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
alternate	I-OUT	ADJ	B
techniques	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
anesthesiologist	O	NOUN	B
rated	O	VERB	B
the	O	DET	O
subjective	O	ADJ	O
difficulty	O	NOUN	B
in	O	ADP	O
using	O	VERB	O
each	O	DET	O
technique	O	NOUN	B
with	B-OUT	ADP	O
a	I-OUT	DET	O
numeric	I-OUT	ADJ	B
rating	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
visual	I-OUT	ADJ	B
rating	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	B-OUT	AUX	O
no	I-OUT	DET	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
in	O	ADP	O
the	B-OUT	DET	O
primary	I-OUT	ADJ	B
outcome	I-OUT	NOUN	I
"	I-OUT	PUNCT	O
good	I-OUT	ADJ	O
laryngoscopic	I-OUT	ADJ	B
views	I-OUT	NOUN	B
"	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
Cormack-Lehane	I-OUT	NOUN	B
grade	I-OUT	NOUN	I
1	I-OUT	NUM	I
and	I-OUT	CCONJ	O
2	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	B-OUT	ADP	O
"	I-OUT	PUNCT	O
poor	I-OUT	ADJ	B
laryngoscopic	I-OUT	ADJ	B
views	I-OUT	NOUN	B
"	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
Cormack-Lehane	I-OUT	NOUN	B
grade	I-OUT	NOUN	I
3	I-OUT	NUM	I
and	I-OUT	CCONJ	O
4	O	NUM	O
)	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
LFS	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
Macintosh	O	PROPN	B
.	O	PUNCT	O


There	O	PRON	O
were	B-OUT	AUX	O
higher	I-OUT	ADJ	O
POGO	I-OUT	PROPN	B
scores	I-OUT	NOUN	O
with	O	ADP	O
the	O	DET	O
LFS	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
Macintosh	O	PROPN	B
(	O	PUNCT	O
80	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
20	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
did	O	AUX	O
not	O	PART	O
translate	O	VERB	O
to	O	ADP	O
easier	O	ADJ	O
intubations	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
documented	O	VERB	B
by	O	ADP	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
an	O	DET	O
alternate	O	ADJ	B
intubation	O	NOUN	I
technique	O	NOUN	I
or	O	CCONJ	O
time	O	NOUN	O
to	O	PART	O
intubate	O	VERB	B
(	O	PUNCT	O
<	O	X	O
30	O	NUM	O
and	O	CCONJ	O
<	O	X	O
60	O	NUM	O
sec	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
mucosal	I-OUT	ADJ	B
trauma	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
sore	I-OUT	ADJ	B
throat	I-OUT	ADV	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
hemodynamic	I-OUT	ADJ	B
responses	I-OUT	NOUN	B
did	I-OUT	AUX	O
not	I-OUT	PART	O
differ	I-OUT	VERB	O
significantly	O	ADV	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
techniques	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
LFS	O	NOUN	B
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
the	B-I	DET	O
Macintosh	I-I	PROPN	B
laryngoscope	I-I	NOUN	I
does	O	AUX	O
not	O	PART	O
improve	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
or	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
tracheal	O	ADJ	B
intubation	O	NOUN	I
in	B-P	ADP	O
a	I-P	DET	O
simulated	I-P	ADJ	B
difficult	I-P	ADJ	O
airway	I-P	NOUN	B
.	O	PUNCT	O


Divalproex	B-I	NOUN	B
sodium	I-I	NOUN	I
vs.	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
repetitive	B-OUT	ADJ	B
behaviours	I-OUT	NOUN	I
in	O	ADP	O
autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Autism	O	NOUN	B
is	O	AUX	O
a	O	DET	O
neurodevelopmental	O	ADJ	B
disorder	O	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
impairment	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
core	O	NOUN	B
symptom	O	NOUN	I
domains	O	NOUN	O
:	O	PUNCT	O
socialization	O	NOUN	B
,	O	PUNCT	O
communication	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
repetitive/stereotyped	O	ADJ	B
behaviours	O	NOUN	I
.	O	PUNCT	O


Other	O	ADJ	O
associated	O	VERB	O
symptom	O	NOUN	B
domains	O	NOUN	I
are	O	AUX	O
also	O	ADV	O
affected	O	VERB	B
including	O	VERB	O
impulsivity/aggression	O	NOUN	B
,	O	PUNCT	O
self-injury	O	NOUN	B
,	O	PUNCT	O
anxiety	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mood	O	NOUN	B
lability	O	NOUN	I
.	O	PUNCT	O


Divalproex	B-I	PROPN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
have	O	AUX	O
efficacy	O	NOUN	B
in	O	ADP	O
treating	O	VERB	B
epilepsy	O	NOUN	B
,	O	PUNCT	O
bipolar	O	ADJ	B
disorder	O	NOUN	I
,	O	PUNCT	O
mood	O	NOUN	B
lability	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
impulsive	O	ADJ	B
aggression	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
divalproex	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
repetitive	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
compulsive-like	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
of	I-OUT	ADP	O
autism	I-OUT	NOUN	B
spectrum	I-OUT	NOUN	I
disorder	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ASD	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Thirteen	B-P	NUM	O
individuals	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
participated	O	VERB	O
in	O	ADP	O
an	O	DET	O
8-wk	O	ADJ	O
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
divalproex	B-I	ADJ	B
sodium	I-I	NOUN	I
vs.	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
group	O	NOUN	B
difference	O	NOUN	O
on	O	ADP	O
improvement	O	NOUN	B
in	O	ADP	O
repetitive	B-OUT	ADJ	B
behaviours	I-OUT	NOUN	I
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
Children	B-OUT	PROPN	B
's	I-OUT	PART	I
Yale-Brown	I-OUT	PROPN	B
Obsessive	I-OUT	PROPN	I
Compulsive	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
C-YBOCS	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
(	O	PUNCT	O
p=0.037	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
large	O	ADJ	O
effect	O	NOUN	B
size	O	NOUN	I
(	O	PUNCT	O
d=1.616	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
preliminary	O	ADJ	B
support	O	NOUN	O
for	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
divalproex	B-I	NOUN	B
in	O	ADP	O
treating	O	VERB	B
repetitive	B-OUT	ADJ	B
behaviours	I-OUT	NOUN	I
in	O	ADP	O
ASD	B-P	PROPN	B
.	I-P	PUNCT	O


Further	O	ADJ	O
research	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
specificity	O	NOUN	B
and	O	CCONJ	O
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
of	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
.	O	PUNCT	O


Prospective	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
timing	O	NOUN	B
of	O	ADP	O
bacillus	B-I	X	B
Calmette-Guérin	I-I	PROPN	B
vaccination	I-I	NOUN	B
in	I-P	ADP	O
Canadian	I-P	ADJ	B
Cree	I-P	ADJ	B
infants	I-P	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
studied	B-P	VERB	O
184	I-P	NUM	O
Cree	I-P	ADJ	B
Indian	I-P	ADJ	B
infants	I-P	NOUN	B
in	O	ADP	O
randomized	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
fashion	O	NOUN	I
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
on	B-OUT	ADP	O
lymphocyte	I-OUT	NOUN	B
sensitization	I-OUT	NOUN	I
to	O	PART	O
purified	O	VERB	B
protein	O	NOUN	I
derivative	O	NOUN	I
(	O	PUNCT	O
PPD	O	NOUN	B
)	O	PUNCT	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
and	O	CCONJ	O
without	B-I	ADP	O
bacillus	I-I	X	B
Calmette-Guérin	I-I	X	B
(	I-I	PUNCT	O
BCG	I-I	NOUN	B
)	I-I	PUNCT	O
vaccination	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Lymphocyte	B-OUT	NOUN	B
responses	I-OUT	NOUN	I
to	O	PART	O
PPD	O	NOUN	B
,	O	PUNCT	O
Candida	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
streptokinase	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
birth	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
intervals	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
response	O	NOUN	B
of	O	ADP	O
paired	O	ADJ	B
values	O	NOUN	I
from	B-P	ADP	O
26	I-P	NUM	O
infants	I-P	NOUN	B
without	I-P	ADP	O
BCG	I-P	NOUN	B
vaccination	I-P	NOUN	B
rose	I-P	VERB	B
for	O	ADP	O
the	O	DET	O
PPD	O	NOUN	B
stimulation	O	NOUN	I
index	O	NOUN	I
(	O	PUNCT	O
SI	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
2.7	O	NUM	O
at	O	ADP	O
birth	O	NOUN	B
to	O	ADP	O
3.9	O	NUM	O
before	O	ADP	O
2	O	NUM	O
yr	O	NOUN	O
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
SI	O	PROPN	B
for	O	ADP	O
both	O	CCONJ	O
Candida	O	NOUN	B
and	O	CCONJ	O
streptokinase	O	NOUN	B
for	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
infants	O	NOUN	B
rose	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
yr	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	B-P	ADP	O
66	I-P	NUM	O
infants	I-P	NOUN	B
who	I-P	PRON	O
received	I-I	VERB	O
BCG	I-I	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
7	I-P	NUM	O
days	I-P	NOUN	B
of	I-P	ADP	O
life	I-P	NOUN	B
,	O	PUNCT	O
the	B-OUT	DET	O
PPD-SI	I-OUT	NOUN	B
rose	O	VERB	O
from	O	ADP	O
3.1	O	NUM	O
to	O	PART	O
35.3	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
17	O	NUM	O
infants	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
vaccine	O	NOUN	B
later	O	ADV	O
but	O	CCONJ	O
before	O	ADP	O
9	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
rose	O	VERB	O
from	O	ADP	O
3.1	O	NUM	O
at	O	ADP	O
birth	O	NOUN	B
to	O	ADP	O
24.9	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
14	O	NUM	O
who	O	PRON	O
received	O	VERB	O
it	O	PRON	O
between	O	ADP	O
9	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
yr	O	NOUN	O
,	O	PUNCT	O
it	O	PRON	O
rose	O	VERB	O
from	O	ADP	O
2.2	O	NUM	O
to	O	PART	O
52.9	O	NUM	O
.	O	PUNCT	O


The	B-OUT	DET	O
lymphocyte	I-OUT	NOUN	B
responses	I-OUT	NOUN	B
to	O	PART	O
PPD	O	NOUN	B
after	B-I	ADP	O
BCG	I-I	NOUN	B
in	O	ADP	O
these	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
different	O	ADJ	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
older	O	ADJ	B
infants	O	NOUN	I
that	O	SCONJ	O
a	O	DET	O
raised	B-OUT	VERB	O
PPD-SI	I-OUT	NOUN	B
before	O	ADP	O
BCG	O	NOUN	B
vaccination	O	NOUN	B
affected	B-OUT	VERB	O
lymphocyte	I-OUT	NOUN	B
sensitization	I-OUT	NOUN	I
by	O	ADP	O
the	O	DET	O
vaccine	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
increasing	O	VERB	B
the	O	DET	O
age	O	NOUN	B
at	O	ADP	O
vaccination	O	NOUN	B
with	B-I	ADP	O
BCG	I-I	NOUN	B
from	O	ADP	O
birth	O	NOUN	B
to	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
9	O	NUM	O
months	O	NOUN	B
enhances	B-OUT	VERB	O
immunologic	I-OUT	ADJ	B
sensitization	I-OUT	NOUN	I
to	O	PART	O
PPD	O	NOUN	B
significantly	O	ADV	O
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
infusion	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
ketamine	B-I	NOUN	B
improves	O	VERB	B
pain	O	NOUN	B
relief	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
critical	I-P	ADJ	B
limb	I-P	NOUN	I
ischaemia	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
first	O	ADJ	O
double	O	ADJ	O
blind	O	ADJ	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
regular	O	ADJ	O
opioids	B-I	NOUN	B
and	O	CCONJ	O
an	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
0.6	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
intravenous	O	ADJ	B
ketamine	B-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
opioids	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
allodynia	I-P	NOUN	B
,	I-P	PUNCT	O
hyperalgesia	I-P	NOUN	B
and	I-P	CCONJ	O
hyperpathia	I-P	NOUN	B
secondary	I-P	ADJ	B
to	I-P	PART	I
critical	I-P	ADJ	B
limb	I-P	NOUN	I
ischaemia	I-P	NOUN	O
.	I-P	PUNCT	O


Thirty-five	B-P	ADJ	O
patients	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
study	I-P	NOUN	B
,	I-P	PUNCT	O
18	I-P	NUM	O
received	O	VERB	O
regular	O	ADJ	O
opioids	B-I	NOUN	B
plus	I-I	CCONJ	O
ketamine	I-I	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
17	B-P	NUM	O
received	O	VERB	O
regular	B-I	ADJ	O
opioids	I-I	NOUN	B
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Using	O	VERB	O
the	O	DET	O
Brief	B-OUT	PROPN	B
Pain	I-OUT	PROPN	I
Inventory	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
%	I-OUT	NOUN	O
pain	I-OUT	NOUN	B
relief	I-OUT	NOUN	I
that	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ketamine	O	NOUN	B
group	O	NOUN	B
attributed	O	VERB	O
to	O	ADP	O
their	O	PRON	O
medication	O	NOUN	B
improved	O	VERB	B
significantly	O	ADV	O
from	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
immediately	O	ADV	O
pre-infusion	O	VERB	B
to	O	PART	O
65	O	NUM	O
%	O	NOUN	O
24	O	NUM	O
h	O	NOUN	O
post-infusion	O	NOUN	B
and	O	CCONJ	O
69	O	NUM	O
%	O	NOUN	O
5	O	NUM	O
days	O	NOUN	B
post	O	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


Over	O	ADP	O
the	O	DET	O
same	O	ADJ	O
period	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
achieved	I-OUT	VERB	O
by	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
rose	O	VERB	O
from	O	ADP	O
58	O	NUM	O
%	O	NOUN	O
pre-infusion	O	NOUN	B
to	O	PART	O
56	O	NUM	O
%	O	NOUN	O
24	O	NUM	O
h	O	NOUN	O
post	O	NOUN	B
infusion	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
relief	O	NOUN	B
5	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
statistically	B-OUT	ADV	B
significant	I-OUT	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
using	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
t-test	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Wilcoxon	I-OUT	PROPN	B
Rank	I-OUT	PROPN	I
Sum	I-OUT	PROPN	I
test	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
ketamine	O	NOUN	B
group	O	NOUN	B
also	O	ADV	O
showed	O	VERB	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
24	O	NUM	O
h	O	NOUN	O
post	O	NOUN	B
infusion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
pain	B-OUT	NOUN	B
on	O	ADP	O
their	O	PRON	O
general	O	ADJ	B
activity	O	NOUN	I
(	O	PUNCT	O
P=0.03	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
their	O	PRON	O
enjoyment	O	NOUN	B
of	O	ADP	O
life	O	NOUN	O
(	O	PUNCT	O
P=0.004	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
combining	O	VERB	O
a	O	DET	O
single	O	ADJ	O
infusion	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
dose	O	NOUN	I
ketamine	O	NOUN	B
with	O	ADP	O
regular	O	ADJ	O
opioid	B-I	NOUN	B
analgesia	I-I	NOUN	I
can	O	AUX	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
for	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
orthotic	B-I	ADJ	B
heel	I-I	NOUN	I
lifts	I-I	VERB	I
on	O	ADP	O
Achilles	B-OUT	PROPN	B
tendon	I-OUT	NOUN	I
force	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
strain	I-OUT	NOUN	B
during	O	ADP	O
running	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
orthotic	B-I	ADJ	B
heel	I-I	NOUN	I
lifts	I-I	VERB	I
on	O	ADP	O
Achilles	B-OUT	PROPN	B
tendon	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
force	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
strain	I-OUT	NOUN	B
during	O	ADP	O
running	O	NOUN	B
.	O	PUNCT	O


Ten	B-P	NUM	O
females	I-P	NOUN	B
ran	I-P	VERB	O
barefoot	I-P	ADV	B
over	I-P	ADP	O
a	I-P	DET	O
force	I-P	NOUN	B
plate	I-P	NOUN	O
in	I-P	ADP	O
three	I-P	NUM	O
conditions	I-P	NOUN	B
:	I-P	PUNCT	O
no	I-I	DET	O
heel	I-I	NOUN	B
lifts	I-I	VERB	I
(	I-P	PUNCT	O
NHL	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
with	I-P	ADP	O
12	I-I	NUM	O
mm	I-I	PROPN	O
heel	I-I	NOUN	O
lifts	I-I	VERB	O
(	I-P	PUNCT	O
12HL	I-P	ADJ	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
with	I-P	ADP	O
18	I-I	NUM	O
mm	I-I	PROPN	O
heel	I-I	NOUN	O
lifts	I-I	VERB	O
(	I-P	PUNCT	O
18HL	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Kinematics	B-OUT	NOUN	B
for	I-OUT	ADP	O
the	I-OUT	DET	O
right	I-OUT	ADV	O
lower	I-OUT	ADJ	O
limb	I-OUT	NOUN	O
were	O	AUX	O
collected	O	VERB	O
(	O	PUNCT	O
200	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


AT	B-OUT	ADP	B
force	I-OUT	NOUN	I
was	O	AUX	O
calculated	O	VERB	O
from	O	ADP	O
inverse	O	ADJ	B
dynamics	O	NOUN	B
.	O	PUNCT	O


AT	B-OUT	ADP	B
strain	I-OUT	NOUN	I
was	O	AUX	O
determined	O	VERB	O
from	O	ADP	O
kinematics	O	NOUN	B
and	O	CCONJ	O
ultrasound	O	NOUN	B
images	O	NOUN	I
of	O	ADP	O
medial	O	ADJ	B
gastrocnemius	O	NOUN	I
(	O	PUNCT	O
50	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Peak	B-OUT	ADJ	B
AT	I-OUT	ADP	I
strain	I-OUT	NOUN	I
was	O	AUX	O
less	O	ADJ	O
for	O	ADP	O
18HL	O	NOUN	O
(	O	PUNCT	O
5.5	O	NUM	O
±	O	NOUN	O
4.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
for	O	ADP	O
NHL	O	NOUN	B
(	O	PUNCT	O
7.4	O	NUM	O
±	O	NOUN	O
4.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.029	O	NUM	O
,	O	PUNCT	O
effect	O	NOUN	B
size	O	NOUN	I
[	O	PUNCT	O
ES	O	PROPN	B
]	O	PUNCT	O
=	O	ADJ	O
0.44	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
12HL	O	NOUN	O
(	O	PUNCT	O
5.8	O	NUM	O
±	O	NOUN	O
4.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
versus	O	CCONJ	O
NHL	O	NOUN	B
(	O	PUNCT	O
ES	O	NOUN	B
=	O	ADJ	O
0.35	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Peak	B-OUT	ADJ	B
AT	I-OUT	ADP	I
force	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.024	O	NUM	O
,	O	PUNCT	O
ES	O	NOUN	B
=	O	ADJ	O
0.42	O	NUM	O
)	O	PUNCT	O
less	O	ADJ	O
for	O	ADP	O
18HL	O	NOUN	O
(	O	PUNCT	O
2382	O	NUM	O
±	O	NOUN	O
717	O	NUM	O
N	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
for	O	ADP	O
NHL	O	NOUN	B
(	O	PUNCT	O
2710	O	NUM	O
±	O	NOUN	O
830	O	NUM	O
N	O	NOUN	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
12HL	O	NOUN	O
(	O	PUNCT	O
2538	O	NUM	O
±	O	NOUN	O
823	O	NUM	O
N	O	NOUN	O
,	O	PUNCT	O
ES	O	NOUN	B
=	O	ADJ	O
0.21	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
18HL	O	NOUN	O
reduced	B-OUT	VERB	B
ankle	I-OUT	NOUN	B
dorsiflexion	I-OUT	NOUN	O
but	I-OUT	CCONJ	O
not	I-OUT	PART	O
flexion-extension	I-OUT	ADJ	B
ankle	I-OUT	NOUN	O
moments	I-OUT	NOUN	B
and	O	CCONJ	O
increased	B-OUT	VERB	B
the	I-OUT	DET	O
AT	I-OUT	ADP	B
moment	I-OUT	NOUN	I
arm	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
NHL	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
18HL	O	NOUN	O
reduced	B-OUT	VERB	B
force	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
strain	I-OUT	NOUN	B
on	O	ADP	O
the	O	DET	O
AT	O	NOUN	B
during	O	ADP	O
running	O	VERB	B
via	O	ADP	O
a	O	DET	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
dorsiflexion	I-OUT	NOUN	B
,	O	PUNCT	O
which	O	DET	O
lengthened	B-OUT	VERB	B
the	I-OUT	DET	O
AT	I-OUT	ADP	B
moment	I-OUT	NOUN	I
arm	O	NOUN	I
.	O	PUNCT	O


Therefore	B-I	ADV	O
,	I-I	PUNCT	O
heel	I-I	NOUN	B
lifts	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
reduce	B-OUT	VERB	B
AT	I-OUT	ADP	B
loading	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
strain	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
rehabilitation	O	NOUN	B
of	O	ADP	O
AT	O	ADP	B
injuries	O	NOUN	I
.	O	PUNCT	O


Oscillatory	B-P	ADJ	B
potentials	I-P	NOUN	I
,	I-P	PUNCT	O
retinopathy	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
long-term	I-P	ADJ	B
glucose	I-P	NOUN	B
control	I-P	NOUN	I
in	I-P	ADP	O
insulin-dependent	I-P	ADJ	B
diabetes	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
main	O	ADJ	O
objective	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
effects	O	NOUN	B
of	O	ADP	I
long-term	B-I	ADJ	B
lowering	I-I	NOUN	B
of	I-I	ADP	O
glucosylated	I-OUT	VERB	B
hemoglobin	I-OUT	NOUN	I
(	I-I	PUNCT	O
HbA1	I-I	NOUN	B
%	I-I	NOUN	O
)	I-I	PUNCT	O
on	O	ADP	O
neurosensory	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
insulin-dependent	B-P	ADJ	B
diabetes	I-P	NOUN	B
.	I-P	PUNCT	O


Individual	B-I	ADJ	B
(	I-I	PUNCT	O
OP-1	I-I	NOUN	B
,	I-I	PUNCT	O
OP-2	I-I	NOUN	B
,	I-I	PUNCT	O
OP-3	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
summed	I-I	VERB	O
(	I-I	PUNCT	O
OP-sum	I-I	X	B
)	I-I	PUNCT	O
amplitudes	I-I	NOUN	B
of	I-I	ADP	O
oscillatory	I-I	ADJ	B
potentials	I-I	NOUN	I
(	I-I	PUNCT	O
OPs	I-I	NOUN	B
)	I-I	PUNCT	O
of	I-I	ADP	O
electroretinography	I-I	NOUN	B
were	I-I	AUX	O
recorded	I-I	VERB	O
at	O	ADP	O
study	O	NOUN	B
start	O	NOUN	O
and	O	CCONJ	O
7-years	O	VERB	O
later	O	ADV	O
in	O	ADP	O
45	B-P	NUM	O
patients	I-P	NOUN	B
(	O	PUNCT	O
the	O	DET	O
Oslo	B-P	PROPN	B
study	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


As	O	ADP	O
an	O	DET	O
overall	O	ADJ	O
7-year	O	ADJ	O
change	O	NOUN	B
,	O	PUNCT	O
amplitudes	B-OUT	NOUN	B
of	I-OUT	ADP	O
OP-2	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
OP-3	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
OP-sum	I-OUT	NOUN	B
were	I-OUT	AUX	O
reduced	I-OUT	VERB	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0001-0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
retinopathy	B-OUT	NOUN	B
worsened	I-OUT	VERB	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
intraocular	B-OUT	ADJ	B
pressure	I-OUT	NOUN	I
decreased	I-OUT	VERB	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
systolic	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
increased	I-OUT	VERB	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0002	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
glycemic	B-OUT	ADJ	B
control	I-OUT	NOUN	I
improved	O	VERB	O
from	O	ADP	O
HbA1	O	NOUN	B
of	O	ADP	O
11.2	O	NUM	O
+/-	O	CCONJ	O
2.2	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
study	O	NOUN	B
start	O	VERB	O
to	O	ADP	O
a	O	DET	O
7-year	O	ADJ	O
cumulative	O	ADJ	B
mean	O	NOUN	O
of	O	ADP	O
9.5	O	NUM	O
+/-	O	CCONJ	O
1.5	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Multiple	O	ADJ	B
regression	O	NOUN	I
analysis	O	NOUN	I
did	O	AUX	O
not	O	PART	O
identify	O	VERB	O
any	O	DET	O
independent	O	ADJ	B
relations	O	NOUN	B
between	O	ADP	O
change	O	NOUN	O
in	O	ADP	O
OP-1	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
OP-2	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
OP-3	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
OP-sum	I-OUT	NUM	B
and	O	CCONJ	O
change	B-OUT	NOUN	B
in	I-OUT	ADP	O
glycemic	I-OUT	ADJ	B
control	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
background	I-OUT	NOUN	B
variables	I-OUT	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
change	O	NOUN	O
in	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
diabetes	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
cross-sectional	O	ADJ	B
observations	O	NOUN	I
at	O	ADP	O
7	O	NUM	O
years	O	NOUN	B
showed	O	VERB	O
negative	O	ADJ	B
correlations	O	NOUN	B
between	O	ADP	O
all	O	DET	O
OPs	B-OUT	NOUN	B
and	O	CCONJ	O
age	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0001-0.003	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
between	O	ADP	O
OP-3	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
counts	B-OUT	NOUN	B
of	I-OUT	ADP	O
microaneurysms	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
various	O	ADJ	O
clinical	O	ADJ	B
background	O	NOUN	I
variables	O	NOUN	B
may	O	AUX	O
influence	O	VERB	B
individual	O	ADJ	B
and	O	CCONJ	O
summed	O	VERB	O
amplitudes	O	NOUN	B
of	O	ADP	O
OPs	O	NOUN	B
differently	O	ADV	O
.	O	PUNCT	O


Reduced	B-OUT	VERB	B
neurosensory	I-OUT	ADJ	B
retinal	I-OUT	ADJ	I
function	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OPs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
seemed	O	VERB	O
to	O	PART	O
appear	O	VERB	O
after	O	ADP	O
7-years	O	ADJ	B
,	O	PUNCT	O
independently	O	ADV	O
of	O	ADP	O
vascular	B-OUT	ADJ	B
defects	I-OUT	NOUN	I
of	I-OUT	ADP	O
retinopathy	I-OUT	NOUN	B
and	O	CCONJ	O
long-term	B-OUT	ADJ	B
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
glucose	I-OUT	NOUN	B
control	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Reduced	O	VERB	B
albuminuria	O	NOUN	B
with	O	ADP	O
sarpogrelate	B-I	NOUN	B
is	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
monocyte	O	NOUN	B
chemoattractant	O	NOUN	I
protein-1	O	NOUN	I
levels	O	NOUN	O
in	O	ADP	O
type	B-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
OBJECTIVES	O	NOUN	O
Sarpogrelate	B-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
albuminuria	O	NOUN	B
in	O	ADP	O
diabetic	O	ADJ	B
nephropathy	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
examination	O	NOUN	B
of	O	ADP	O
whether	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
same	O	ADJ	O
mechanisms	O	NOUN	B
as	O	ADP	O
angiotensin	O	NOUN	B
II	O	NUM	I
receptor	O	NOUN	I
blockers	O	NOUN	I
or	O	CCONJ	O
thiazolidinedione	B-I	NOUN	B
,	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	O
sarpogrelate	B-I	NOUN	B
on	O	ADP	O
atherosclerotic	O	ADJ	B
inflammatory	O	ADJ	O
molecules	O	NOUN	O
and	O	CCONJ	O
their	O	PRON	O
relations	O	NOUN	B
to	O	ADP	O
albuminuria	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
diabetes	I-P	NOUN	B
and	I-P	CCONJ	O
had	I-P	AUX	O
already	I-P	ADV	O
been	I-P	AUX	O
treated	I-P	VERB	B
with	I-P	ADP	I
angiotensin	I-I	NOUN	B
II	I-I	NUM	I
receptor	I-I	NOUN	I
blockers	I-I	NOUN	I
and	I-P	CCONJ	O
with	I-P	ADP	O
or	I-P	CCONJ	O
without	I-P	ADP	O
thiazolidinedione	I-I	NOUN	B
were	O	AUX	O
examined	O	VERB	B
.	O	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
PARTICIPANTS	O	NOUN	B
,	O	PUNCT	O
&	O	CCONJ	O
MEASUREMENTS	O	VERB	O
Forty	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
diabetes	I-P	NOUN	B
with	I-P	ADP	O
nephropathy	I-P	NOUN	B
and	I-P	CCONJ	O
arteriosclerosis	I-P	NOUN	B
obliterans	I-P	NOUN	I
and	I-P	CCONJ	O
had	I-P	AUX	O
already	I-P	ADV	O
been	I-P	AUX	O
treated	I-P	VERB	B
with	I-P	ADP	I
angiotensin	I-I	NOUN	B
II	I-I	NUM	I
receptor	I-I	NOUN	I
blocker	I-I	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
40	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
sarpogrelate	B-I	NOUN	B
(	O	PUNCT	O
300	O	NUM	O
mg/d	O	NOUN	O
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
aspirin	B-I	NOUN	B
group	I-I	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg/d	O	NOUN	O
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
monocyte	I-OUT	NOUN	B
chemoattractant	I-OUT	NOUN	I
protein-1	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
urinary	I-OUT	ADJ	B
albumin-to-creatinine	I-OUT	ADJ	O
ratio	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
monocyte	I-OUT	NOUN	B
chemoattractant	I-OUT	NOUN	I
protein-1	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
16	O	NUM	O
wk	O	NOUN	O
after	O	ADP	O
administration	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Only	O	ADV	O
the	O	DET	O
sarpogrelate	B-I	ADJ	B
group	O	NOUN	O
showed	O	VERB	O
increases	O	NOUN	B
in	O	ADP	O
plasma	B-OUT	NOUN	B
adiponectin	I-OUT	NOUN	B
and	O	CCONJ	O
decreases	O	VERB	B
in	O	ADP	O
both	O	CCONJ	O
plasma	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
urinary	I-OUT	ADJ	B
monocyte	I-OUT	NOUN	I
chemoattractant	I-OUT	NOUN	I
protein-1	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
albumin-to-creatinine	I-OUT	ADJ	B
ratio	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
percentage	B-OUT	NOUN	O
change	I-OUT	NOUN	O
of	I-OUT	ADP	O
monocyte	I-OUT	NOUN	B
chemoattractant	I-OUT	NOUN	I
protein-1	I-OUT	NOUN	I
level	I-OUT	NOUN	B
correlated	O	VERB	B
positively	O	ADV	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
albumin-to-creatinine	O	ADJ	B
ratio	O	NOUN	I
.	O	PUNCT	O


Even	O	ADV	O
when	O	SCONJ	O
the	O	DET	O
sarpogrelate	B-I	ADJ	B
group	O	NOUN	B
was	O	AUX	O
further	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
with	O	ADP	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
without	O	ADP	O
thiazolidinedione	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
changes	O	NOUN	B
in	O	ADP	O
monocyte	B-OUT	NOUN	B
chemoattractant	I-OUT	NOUN	I
protein-1	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
albumin-to-creatinine	I-OUT	ADJ	B
ratio	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Sarpogrelate	B-I	PROPN	B
can	O	AUX	O
reduce	O	VERB	B
albuminuria	O	NOUN	B
and	O	CCONJ	O
plasma	O	NOUN	B
and	O	CCONJ	O
urinary	O	ADJ	B
monocyte	O	NOUN	I
chemoattractant	O	NOUN	I
protein-1	O	NOUN	I
levels	O	NOUN	B
while	O	SCONJ	O
increasing	O	VERB	B
plasma	O	NOUN	B
adiponectin	O	NOUN	B
in	O	ADP	O
diabetic	O	ADJ	B
nephropathy	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
effects	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
mediated	O	VERB	O
via	O	ADP	O
mechanisms	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
of	O	ADP	O
angiotensin	B-I	NOUN	B
II	I-I	NUM	I
receptor	I-I	NOUN	I
blocker	I-I	NOUN	I
or	O	CCONJ	O
thiazolidinedione	B-I	NOUN	B
.	I-I	PUNCT	O


Peritonsillar	O	ADJ	B
infiltration	O	NOUN	I
with	O	ADP	O
bupivacaine	B-I	NOUN	B
for	O	ADP	O
paediatric	B-P	ADJ	B
tonsillectomy	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
study	O	NOUN	I
forty-two	B-P	NUM	O
children	I-P	NOUN	B
scheduled	I-P	VERB	O
for	I-P	ADP	O
elective	I-P	ADJ	B
adenotonsillectomy	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
peritonsillar	O	ADJ	B
infiltration	B-I	NOUN	B
,	O	PUNCT	O
following	O	VERB	O
induction	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
either	O	CCONJ	O
0.25	B-I	NUM	O
%	I-I	NOUN	O
plain	I-I	ADJ	B
bupivacaine	I-I	NOUN	I
or	I-I	CCONJ	O
0.9	I-I	NUM	O
%	I-I	NOUN	O
saline	I-I	NOUN	B
,	O	PUNCT	O
0.5	O	NUM	O
ml/kg	O	NOUN	O
to	O	ADP	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
ml	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
children	B-P	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
on	O	ADP	O
awakening	B-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
10	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
hour	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
hours	O	NOUN	B
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	O
later	O	ADV	O
.	O	PUNCT	O


On	O	ADP	O
each	O	DET	O
occasion	O	NOUN	O
the	O	DET	O
observer	O	NOUN	B
gave	O	VERB	O
the	O	DET	O
child	O	NOUN	B
a	O	DET	O
pain	B-OUT	NOUN	B
score	I-OUT	NOUN	I
from	O	ADP	O
1	O	NUM	O
(	O	PUNCT	O
no	O	DET	B
pain	O	NOUN	I
)	O	PUNCT	O
to	O	PART	O
5	O	NUM	O
(	O	PUNCT	O
severe	O	ADJ	B
pain	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
scores	B-OUT	NOUN	B
on	I-OUT	ADP	O
awakening	I-OUT	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
10	O	NUM	O
minutes	O	NOUN	B
were	O	AUX	O
significantly	B-OUT	ADV	O
lower	I-OUT	ADJ	O
in	O	ADP	O
the	O	DET	O
bupivacaine	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
,	O	PUNCT	O
Mann-Whitney	O	NOUN	B
U	O	NOUN	I
test	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Thereafter	O	ADV	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
conclude	O	VERB	O
that	O	SCONJ	O
peritonsillar	O	ADJ	B
infiltration	O	NOUN	B
with	O	ADP	O
bupivacaine	B-I	NOUN	B
is	O	AUX	O
only	O	ADV	O
moderately	O	ADV	O
useful	O	ADJ	O
as	O	ADP	O
analgesia	O	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
having	I-P	VERB	O
tonsillectomy	I-P	NOUN	B
.	I-P	PUNCT	O


Reactivation	B-OUT	NOUN	B
of	I-OUT	ADP	O
unstable	I-OUT	ADJ	B
angina	I-OUT	NOUN	I
after	O	ADP	O
the	O	DET	O
discontinuation	O	NOUN	B
of	O	ADP	O
heparin	B-I	NOUN	B
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
Heparin	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
,	O	PUNCT	O
widely	O	ADV	O
used	O	VERB	O
treatment	O	NOUN	B
for	O	ADP	O
unstable	B-P	ADJ	B
angina	I-P	NOUN	I
.	I-P	PUNCT	O


Among	O	ADP	O
patients	B-P	NOUN	B
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	I-I	NOUN	I
comparing	O	VERB	O
intravenous	B-I	ADJ	B
heparin	I-I	NOUN	B
,	I-I	PUNCT	O
aspirin	I-I	NOUN	B
,	I-I	PUNCT	O
both	I-I	DET	O
treatments	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
neither	I-I	DET	O
during	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
phase	O	NOUN	O
of	O	ADP	O
unstable	O	ADJ	B
angina	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
encountered	O	VERB	O
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
unstable	O	ADJ	O
angina	O	ADJ	B
was	O	AUX	O
reactivated	O	VERB	B
after	O	ADP	O
heparin	B-I	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
The	B-P	DET	O
study	I-P	NOUN	B
population	I-P	NOUN	I
included	I-P	VERB	O
403	I-P	NUM	O
of	I-P	ADP	O
the	I-P	DET	O
original	I-P	ADJ	B
479	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
trial	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
completed	I-P	VERB	O
six	I-P	NUM	O
days	I-P	NOUN	B
of	I-P	ADP	O
blinded	I-P	VERB	B
therapy	I-P	NOUN	I
without	I-P	ADP	O
refractory	I-P	ADJ	B
angina	I-P	ADJ	I
or	I-P	CCONJ	O
myocardial	I-P	ADJ	B
infarction	I-P	NOUN	I
.	I-P	PUNCT	O


After	O	ADP	O
the	O	DET	O
discontinuation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
clinical	B-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
including	I-OUT	VERB	O
reactivation	I-OUT	NOUN	B
of	I-OUT	ADP	O
unstable	I-OUT	ADJ	B
angina	I-OUT	ADJ	I
and	I-OUT	CCONJ	O
myocardial	I-OUT	ADJ	B
infarction	I-OUT	NOUN	I
occurring	I-OUT	VERB	O
within	I-OUT	ADP	O
96	I-OUT	NUM	O
hours	I-OUT	NOUN	B
after	I-OUT	ADP	O
hospitalization	I-OUT	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
closely	O	ADV	O
monitored	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Early	B-OUT	ADJ	B
reactivation	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
14	O	NUM	O
of	O	ADP	O
the	O	DET	O
107	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
heparin	B-I	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
only	O	ADV	O
5	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
three	O	NUM	O
study	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
reactivations	B-OUT	NOUN	B
required	O	VERB	O
urgent	O	ADJ	O
intervention	O	NOUN	B
(	O	PUNCT	O
thrombolysis	O	NOUN	B
,	O	PUNCT	O
angioplasty	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
coronary-bypass	O	ADJ	B
surgery	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
heparin	B-I	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
only	O	ADV	O
2	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
groups	O	NOUN	B
combined	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Four	O	NUM	O
of	O	ADP	O
the	O	DET	O
six	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
a	O	DET	O
myocardial	B-OUT	ADJ	B
infarction	I-OUT	NOUN	I
during	O	ADP	O
a	O	DET	O
reactivation	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
disease	O	NOUN	B
were	O	AUX	O
in	O	ADP	O
the	O	DET	O
heparin	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Reactivations	B-OUT	NOUN	B
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
a	O	DET	O
cluster	O	NOUN	B
a	O	DET	O
mean	O	NOUN	O
(	O	PUNCT	O
+/-	O	CCONJ	O
SD	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
9.5	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
the	O	DET	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
drug	O	NOUN	O
but	O	CCONJ	O
were	O	AUX	O
randomly	O	ADV	O
distributed	O	VERB	B
over	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
96	O	NUM	O
hours	O	NOUN	B
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Although	O	SCONJ	O
heparin	B-I	NOUN	B
is	O	AUX	O
beneficial	O	ADJ	O
in	O	ADP	O
treating	O	VERB	B
unstable	O	ADJ	B
angina	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
disease	O	NOUN	B
process	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
reactivated	B-OUT	VERB	B
within	O	ADP	O
hours	O	NOUN	O
of	O	ADP	O
the	O	DET	O
discontinuation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Concomitant	O	ADJ	B
therapy	O	NOUN	O
with	O	ADP	O
aspirin	O	NOUN	B
may	O	AUX	O
prevent	O	VERB	B
this	O	DET	O
withdrawal	O	NOUN	B
phenomenon	O	NOUN	B
.	O	PUNCT	O


In-hospital	B-OUT	ADJ	B
costs	I-OUT	NOUN	I
of	O	ADP	O
self-expanding	B-I	ADJ	B
nitinol	I-I	ADJ	I
stent	I-I	NOUN	I
implantation	I-I	NOUN	B
versus	O	CCONJ	O
balloon	B-I	NOUN	B
angioplasty	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
femoropopliteal	O	ADJ	B
artery	O	NOUN	I
(	O	PUNCT	O
the	O	DET	O
VascuCoil	O	PROPN	B
Trial	O	PROPN	I
)	O	PUNCT	O
.	O	PUNCT	O


PURPOSE	O	NOUN	B
Although	O	SCONJ	O
several	O	ADJ	O
prospective	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
examined	O	VERB	O
the	O	DET	O
safety	B-OUT	NOUN	B
and	O	CCONJ	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
stent	B-I	ADJ	B
placement	I-I	NOUN	B
for	O	ADP	O
femoropopliteal	B-P	ADJ	B
arterial	I-P	ADJ	I
disease	I-P	NOUN	I
,	O	PUNCT	O
the	O	DET	O
current	O	ADJ	O
cost	O	NOUN	B
of	O	ADP	O
these	O	DET	O
procedures	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


To	O	PART	O
estimate	O	VERB	B
and	O	CCONJ	O
compare	O	VERB	B
hospital	B-OUT	NOUN	B
costs	I-OUT	NOUN	I
associated	O	VERB	B
with	O	ADP	I
conventional	B-I	ADJ	B
balloon	I-I	NOUN	B
angioplasty	I-I	NOUN	I
(	I-I	PUNCT	O
percutaneous	I-I	ADJ	B
transluminal	I-I	ADJ	I
angioplasty	I-I	NOUN	I
[	I-I	PUNCT	O
PTA	I-I	PROPN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
stent	I-I	ADJ	B
placement	I-I	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
symptomatic	O	ADJ	B
peripheral	O	ADJ	B
arterial	O	ADJ	I
disease	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
performed	O	VERB	O
a	O	DET	O
prospective	O	ADJ	O
economic	O	ADJ	B
evaluation	O	NOUN	I
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Intracoil	O	PROPN	B
Femoropopliteal	O	PROPN	O
Stent	O	PROPN	O
Trial	O	PROPN	O
(	O	PUNCT	O
VascuCoil	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
Between	O	ADP	O
May	O	PROPN	O
1997	O	NUM	O
and	O	CCONJ	O
December	O	PROPN	O
1999	O	NUM	O
,	O	PUNCT	O
266	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
stenotic	I-P	ADJ	B
or	I-P	CCONJ	O
occluded	I-P	VERB	B
superficial	I-P	ADJ	B
femoral	I-P	ADJ	B
or	I-P	CCONJ	O
popliteal	I-P	NOUN	B
arteries	I-P	NOUN	I
were	O	AUX	O
prospectively	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
IntraCoil	B-I	PROPN	B
stent	I-I	NOUN	I
or	O	CCONJ	O
PTA	B-I	PROPN	B
.	I-I	PUNCT	O


Detailed	O	ADJ	O
resource	B-OUT	NOUN	B
use	I-OUT	NOUN	O
and	O	CCONJ	O
cost	B-OUT	VERB	B
data	I-OUT	NOUN	B
for	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
's	O	PART	I
initial	O	ADJ	O
revascularization	O	NOUN	B
procedure	O	NOUN	O
and	O	CCONJ	O
ensuing	O	VERB	O
hospitalization	O	NOUN	B
were	O	AUX	O
collected	O	VERB	B
and	O	CCONJ	O
analyzed	O	VERB	B
on	O	ADP	O
an	O	DET	O
intention-to-treat	O	ADJ	B
basis	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
Compared	O	VERB	O
with	O	ADP	O
conventional	B-I	ADJ	B
balloon	I-I	NOUN	B
angioplasty	I-I	NOUN	I
,	I-I	PUNCT	O
stent	I-I	ADJ	B
placement	I-I	NOUN	B
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
clinical	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
but	O	CCONJ	O
increased	O	VERB	B
procedure	B-OUT	NOUN	B
duration	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
equipment	I-OUT	NOUN	B
costs	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
physician	I-OUT	NOUN	B
services	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


As	O	ADP	O
a	O	DET	O
result	O	NOUN	B
,	O	PUNCT	O
initial	B-OUT	ADJ	O
hospital	I-OUT	NOUN	B
costs	I-OUT	NOUN	I
were	O	AUX	O
approximately	O	ADV	O
3,500	O	NUM	O
dollars	O	NOUN	O
higher	O	ADJ	O
for	O	ADP	O
patients	O	NOUN	B
randomized	O	VERB	B
to	O	ADP	O
the	O	DET	O
IntraCoil	B-I	PROPN	B
stent	I-I	NOUN	I
,	O	PUNCT	O
compared	O	VERB	O
with	O	ADP	O
PTA	B-I	PROPN	B
(	O	PUNCT	O
8,435	O	NUM	O
dollars	O	NOUN	O
vs	O	CCONJ	O
4,980	O	NUM	O
dollars	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
As	O	ADP	O
performed	O	VERB	O
in	O	ADP	O
the	O	DET	O
VascuCoil	O	PROPN	B
trial	O	NOUN	I
,	O	PUNCT	O
primary	O	ADJ	O
stent	O	NOUN	B
placement	O	NOUN	B
for	O	ADP	O
femoropopliteal	O	ADJ	B
disease	O	NOUN	I
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
clinical	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
but	O	CCONJ	O
increased	O	VERB	B
initial	B-OUT	ADJ	O
treatment	I-OUT	NOUN	B
costs	I-OUT	NOUN	O
by	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
3,000	O	NUM	O
dollars	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
substantial	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
subsequent	O	ADJ	O
clinical	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatments	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
unlikely	O	ADJ	O
that	O	SCONJ	O
these	O	DET	O
increased	O	VERB	B
initial	B-OUT	ADJ	B
costs	I-OUT	NOUN	B
would	O	AUX	O
be	O	AUX	O
offset	O	VERB	O
by	O	ADP	O
savings	O	NOUN	B
in	O	ADP	O
follow-up	B-OUT	ADJ	B
costs	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
strategy	O	NOUN	O
of	O	ADP	O
routine	O	ADJ	B
stent	B-I	NOUN	B
implantation	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
femoropopliteal	I-P	ADJ	B
PTA	I-I	PROPN	B
is	O	AUX	O
not	O	PART	O
optimal	O	ADJ	O
on	O	ADP	O
economic	O	ADJ	B
grounds	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
PTA	B-I	PROPN	B
with	O	ADP	O
provisional	B-I	ADJ	O
stent	I-I	NOUN	B
implantation	I-I	NOUN	B
is	O	AUX	O
preferred	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
dipeptidyl	B-I	ADJ	B
peptidase-4	I-I	NOUN	I
inhibitor	I-I	NOUN	I
PHX1149	I-I	NOUN	B
improves	O	VERB	B
blood	B-OUT	NOUN	B
glucose	I-OUT	NOUN	I
control	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
mellitus	I-P	NOUN	I
.	I-P	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
PHX1149	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
dipeptidyl	O	ADJ	B
peptidase-4	O	NOUN	I
(	O	PUNCT	O
DPP4	O	NOUN	B
)	O	PUNCT	O
inhibitor	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
is	O	AUX	O
a	O	DET	O
multicentre	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
4-week	O	NUM	O
study	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
with	I-P	ADP	O
suboptimal	I-P	ADJ	B
metabolic	I-P	ADJ	B
control	I-P	NOUN	I
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
baseline	I-P	NOUN	B
haemoglobin	I-P	NOUN	O
A	I-P	NOUN	O
(	I-P	PUNCT	O
1c	I-P	NOUN	O
)	I-P	PUNCT	O
(	I-P	PUNCT	O
HbA	I-P	NOUN	B
(	I-P	PUNCT	O
1c	I-P	NOUN	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
of	I-P	ADP	O
7.3	I-P	NUM	O
to	I-P	PART	O
11.0	I-P	NUM	O
%	I-P	NOUN	O
were	O	AUX	O
randomized	O	VERB	B
1	O	NUM	O
:	O	PUNCT	O
1	O	NUM	O
:	O	PUNCT	O
1	O	NUM	O
:	O	PUNCT	O
1	O	NUM	O
to	O	PART	O
receive	O	VERB	O
once-daily	O	ADJ	B
oral	O	ADJ	O
therapy	O	NOUN	O
with	O	ADP	O
either	O	CCONJ	O
PHX1149	B-I	NOUN	B
(	I-I	PUNCT	O
100	I-I	NUM	O
,	I-I	PUNCT	O
200	I-I	NUM	O
or	I-I	CCONJ	O
400	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
;	I-I	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
on	O	ADP	O
a	O	DET	O
constant	O	ADJ	B
background	O	NOUN	O
therapy	O	NOUN	O
of	O	ADP	O
either	O	CCONJ	O
metformin	O	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
metformin	O	NOUN	B
plus	O	CCONJ	O
a	O	DET	O
glitazone	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Treatment	O	NOUN	B
with	O	ADP	O
100	O	NUM	O
,	O	PUNCT	O
200	O	NUM	O
or	O	CCONJ	O
400	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
PHX1149	O	NOUN	B
significantly	O	ADV	O
decreased	O	VERB	B
postprandial	B-OUT	ADJ	B
glucose	I-OUT	NOUN	B
area	I-OUT	NOUN	I
under	I-OUT	ADP	O
the	I-OUT	DET	O
curve	I-OUT	NOUN	O
AUC	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
0-2	I-OUT	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
by	O	ADP	O
approximately	O	ADV	O
20	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
+0.11	O	NUM	O
+/-	O	CCONJ	O
0.50	O	NUM	O
,	O	PUNCT	O
-2.08	O	NUM	O
+/-	O	CCONJ	O
0.51	O	NUM	O
,	O	PUNCT	O
-1.73	O	NUM	O
+/-	O	CCONJ	O
0.49	O	NUM	O
and	O	CCONJ	O
-1.88	O	NUM	O
+/-	O	CCONJ	O
0.48	O	NUM	O
mmol/l	O	X	O
x	O	NOUN	O
h	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
placebo	O	NOUN	B
and	O	CCONJ	O
100	O	NUM	O
,	O	PUNCT	O
200	O	NUM	O
and	O	CCONJ	O
400	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
,	O	PUNCT	O
0.008	O	NUM	O
and	O	CCONJ	O
0.004	O	NUM	O
vs.	O	CCONJ	O
placebo	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Postprandial	B-OUT	ADJ	B
AUC	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
0-2	I-OUT	NUM	O
h	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
of	I-OUT	ADP	O
intact	I-OUT	ADJ	B
glucagon-like	I-OUT	ADJ	B
peptide-1	I-OUT	NOUN	I
,	O	PUNCT	O
the	O	DET	O
principal	O	ADJ	B
mediator	O	NOUN	I
of	O	ADP	O
the	O	DET	O
biological	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
DPP4	O	NOUN	B
inhibitors	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
increased	O	VERB	B
by	O	ADP	O
3.90	O	NUM	O
+/-	O	CCONJ	O
2.83	O	NUM	O
,	O	PUNCT	O
11.63	O	NUM	O
+/-	O	CCONJ	O
2.86	O	NUM	O
,	O	PUNCT	O
16.42	O	NUM	O
+/-	O	CCONJ	O
2.72	O	NUM	O
and	O	CCONJ	O
15.75	O	NUM	O
+/-	O	CCONJ	O
2.71	O	NUM	O
pmol/l	O	NOUN	O
x	O	NOUN	O
h	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
placebo	O	NOUN	B
and	O	CCONJ	O
100	O	NUM	O
,	O	PUNCT	O
200	O	NUM	O
and	O	CCONJ	O
400	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.053	O	NUM	O
,	O	PUNCT	O
0.001	O	NUM	O
and	O	CCONJ	O
0.002	O	NUM	O
vs.	O	CCONJ	O
placebo	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Mean	B-OUT	VERB	B
HbA	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
1c	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
all	O	DET	O
dose	O	NOUN	B
groups	O	NOUN	I
;	O	PUNCT	O
the	O	DET	O
placebo-corrected	O	ADJ	B
change	O	NOUN	I
in	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
receiving	O	VERB	B
400	O	NUM	O
mg	O	NOUN	O
PHX1149	O	NOUN	B
was	O	AUX	O
-0.28	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


DPP4	B-OUT	NOUN	B
inhibition	I-OUT	NOUN	B
on	O	ADP	O
day	O	NOUN	B
28	O	NUM	O
was	O	AUX	O
53	O	NUM	O
,	O	PUNCT	O
73	O	NUM	O
and	O	CCONJ	O
78	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
postdose	O	NOUN	B
in	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
receiving	O	VERB	O
100	O	NUM	O
,	O	PUNCT	O
200	O	NUM	O
and	O	CCONJ	O
400	O	NUM	O
mg	O	NOUN	O
PHX1149	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
between	O	ADP	O
PHX1149-treated	O	VERB	B
and	O	CCONJ	O
placebo	O	ADJ	B
subjects	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Addition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DPP4	O	NOUN	B
inhibitor	O	NOUN	B
PHX1149	O	NOUN	B
to	O	PART	O
a	O	DET	O
stable	O	ADJ	O
regimen	O	NOUN	B
of	O	ADP	O
metformin	O	NOUN	B
or	O	CCONJ	O
metformin	O	NOUN	B
plus	O	CCONJ	O
a	O	DET	O
glitazone	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	O	CCONJ	O
improved	B-OUT	VERB	B
blood	I-OUT	NOUN	B
glucose	I-OUT	NOUN	I
control	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Therapist	B-OUT	ADJ	B
success	I-OUT	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
determinants	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
relatively	O	ADV	O
unexplored	O	ADJ	O
contribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
therapist	B-OUT	NOUN	B
's	I-OUT	PART	O
performance	I-OUT	NOUN	B
in	O	ADP	O
determining	O	VERB	O
outcomes	B-OUT	NOUN	B
of	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Nine	B-P	NUM	O
therapists	I-P	NOUN	B
were	I-P	AUX	O
studied	I-I	VERB	O
:	I-I	PUNCT	O
three	I-I	NUM	O
performed	I-I	VERB	O
supportive-expressive	I-I	ADJ	B
psychotherapy	I-I	NOUN	I
;	I-I	PUNCT	O
three	I-I	NUM	O
,	I-I	PUNCT	O
cognitive-behavioral	I-I	ADJ	B
psychotherapy	I-I	NOUN	I
;	I-I	PUNCT	O
and	I-I	CCONJ	O
three	I-I	NUM	O
,	I-I	PUNCT	O
drug	I-I	NOUN	B
counseling	I-I	NOUN	I
.	I-I	PUNCT	O


Profound	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
discovered	O	VERB	O
in	O	ADP	O
the	O	DET	O
therapists	O	NOUN	B
'	O	PART	O
success	O	NOUN	B
with	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
case	O	NOUN	B
loads	O	NOUN	I
.	O	PUNCT	O


Four	O	NUM	O
potential	O	ADJ	B
determinants	O	NOUN	B
of	O	ADP	O
these	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
explored	O	VERB	O
:	O	PUNCT	O
patient	B-OUT	NOUN	B
factors	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
therapist	I-OUT	NOUN	B
factors	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
patient-therapist	I-OUT	ADJ	B
relationship	I-OUT	NOUN	B
factors	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
and	O	CCONJ	O
therapy	B-OUT	NOUN	B
factors	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
patient	O	NOUN	B
characteristics	O	NOUN	B
within	O	ADP	O
each	O	DET	O
case	O	NOUN	B
load	O	NOUN	I
(	O	PUNCT	O
after	O	ADP	O
random	O	ADJ	B
assignments	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
similar	O	ADJ	O
and	O	CCONJ	O
disclosed	O	VERB	O
no	O	DET	O
differences	O	NOUN	O
that	O	PRON	O
would	O	AUX	O
have	O	AUX	O
explained	O	VERB	O
the	O	DET	O
differences	O	NOUN	B
in	O	ADP	O
success	O	NOUN	B
;	O	PUNCT	O
therapist	B-OUT	NOUN	B
's	I-OUT	PART	O
personal	I-OUT	ADJ	B
qualities	I-OUT	NOUN	I
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
outcomes	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
significantly	O	ADV	O
(	O	PUNCT	O
mean	O	VERB	O
r	O	NOUN	O
=	O	ADJ	O
.32	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
an	O	DET	O
early-in-treatment	O	ADJ	O
measure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient-therapist	B-OUT	ADJ	B
relationship	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
Helping	I-OUT	PROPN	B
Alliance	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
,	O	PUNCT	O
yielded	O	VERB	O
significant	O	ADJ	O
correlations	O	NOUN	B
with	O	ADP	O
outcomes	O	NOUN	B
(	O	PUNCT	O
mean	O	VERB	O
r	O	NOUN	O
=	O	ADJ	O
.65	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
among	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
techniques	O	NOUN	B
,	O	PUNCT	O
"	B-OUT	PUNCT	O
purity	I-OUT	NOUN	B
"	I-OUT	PUNCT	O
provided	O	VERB	O
significant	O	ADJ	O
correlations	O	NOUN	B
with	O	ADP	O
outcomes	O	NOUN	B
(	O	PUNCT	O
mean	O	VERB	O
r	O	NOUN	O
=	O	ADJ	O
.44	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
both	O	CCONJ	O
across	O	ADP	O
therapists	O	NOUN	B
and	O	CCONJ	O
within	O	ADP	O
each	O	DET	O
therapist	O	NOUN	B
's	O	PART	O
case	O	NOUN	B
load	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
three	O	NUM	O
therapist-related	O	ADJ	B
factors	O	NOUN	I
were	O	AUX	O
moderately	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
each	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


Pharmacokinetics	O	NOUN	B
and	O	CCONJ	O
pharmacodynamics	O	NOUN	B
of	O	ADP	O
six	O	NUM	O
epoetin	B-I	ADJ	B
alfa	I-I	ADJ	I
dosing	O	NOUN	B
regimens	O	NOUN	B
in	O	ADP	O
anemic	B-P	ADJ	B
critically	I-P	ADV	B
ill	I-P	ADJ	I
patients	I-P	NOUN	B
without	I-P	ADP	O
acute	I-P	ADJ	B
blood	I-P	NOUN	I
loss	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
describe	O	VERB	O
the	O	DET	O
pharmacokinetic	O	ADJ	B
profiles	O	NOUN	I
of	O	ADP	O
six	O	NUM	O
different	O	ADJ	O
dosing	O	NOUN	B
regimens	O	NOUN	B
for	O	ADP	O
epoetin	B-I	NOUN	B
alfa	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
whether	O	SCONJ	O
more	O	ADV	O
rapid	O	ADJ	B
and	O	CCONJ	O
robust	O	ADJ	B
reticulocytosis	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
elicited	O	VERB	B
with	O	ADP	I
more	O	ADV	O
frequent	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
epoetin	B-I	NOUN	B
alfa	I-I	NOUN	I
in	O	ADP	O
anemic	B-P	ADJ	B
critically	I-P	ADV	B
ill	I-P	ADJ	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
28-day	O	ADJ	O
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Ten	B-P	NUM	O
centers	I-P	NOUN	O
in	I-P	ADP	O
the	I-P	DET	O
United	I-P	PROPN	B
States	I-P	PROPN	I
.	I-P	PUNCT	O


PATIENTS	O	VERB	B
Adult	B-P	ADJ	I
(	I-P	PUNCT	O
age	I-P	NOUN	B
>	I-P	X	O
or=18	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
critically	I-P	ADV	B
ill	I-P	ADJ	I
patients	I-P	NOUN	B
with	I-P	ADP	O
hemoglobin	I-P	NOUN	B
<	I-P	X	O
or=12	I-P	ADJ	O
g/dL	I-P	NOUN	O
,	I-P	PUNCT	O
expected	I-P	VERB	O
hospitalization	I-P	NOUN	B
of	I-P	ADP	O
>	I-P	X	O
or=7	I-P	VERB	B
days	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
no	I-P	DET	O
ongoing	I-P	ADJ	O
acute	I-P	ADJ	B
blood	I-P	NOUN	I
loss	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
One	O	NUM	O
of	O	ADP	O
six	B-I	NUM	O
dosing	I-I	VERB	B
epoetin	I-I	ADJ	B
alfa	I-I	ADJ	O
regimens	I-I	NOUN	O
for	O	ADP	O
15	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
40,000	B-I	NUM	O
IU	I-I	NOUN	B
once	I-I	ADV	O
weekly	I-I	ADJ	B
,	O	PUNCT	O
subcutaneously	O	ADV	B
(	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
intravenously	O	ADV	B
(	O	PUNCT	O
IV	O	NUM	B
)	O	PUNCT	O
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
;	O	PUNCT	O
15,000	B-I	NUM	O
IU	I-I	NOUN	B
every	I-I	DET	O
other	I-I	ADJ	O
day	I-I	NOUN	B
,	I-I	PUNCT	O
subcutaneously	I-I	ADV	B
(	O	PUNCT	O
group	O	NOUN	B
C	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
IV	O	NUM	B
(	O	PUNCT	O
group	O	NOUN	B
D	O	NOUN	I
)	O	PUNCT	O
;	O	PUNCT	O
or	O	CCONJ	O
40,000	B-I	NUM	O
IU	I-I	NOUN	B
day	I-I	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
subcutaneously	B-I	ADV	B
(	O	PUNCT	O
group	O	NOUN	B
E	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
IV	O	NUM	B
(	O	PUNCT	O
group	O	NOUN	B
F	O	PROPN	I
)	O	PUNCT	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
15,000	O	NUM	O
IU	O	NOUN	B
once	O	ADV	O
every	O	DET	O
other	O	ADJ	O
day	O	NOUN	B
on	O	ADP	O
[	O	PUNCT	O
corrected	O	VERB	O
]	O	PUNCT	O
days	O	NOUN	B
5-15	O	NUM	O
[	O	PUNCT	O
corrected	O	VERB	O
]	O	PUNCT	O
MEASUREMENTS	O	VERB	O
Serum	B-OUT	NOUN	B
erythropoietin	I-OUT	NOUN	O
concentration	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
absolute	I-OUT	ADJ	B
reticulocyte	I-OUT	NOUN	B
count	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


MAIN	O	ADJ	O
RESULTS	O	NOUN	O
Of	O	ADP	O
the	O	DET	O
60	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
enrolled	O	VERB	O
(	O	PUNCT	O
60	O	NUM	O
%	O	NOUN	O
men	O	NOUN	B
,	O	PUNCT	O
mean	O	VERB	O
age	O	NOUN	B
53	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
mean	O	VERB	O
Acute	O	PROPN	B
Physiology	O	PROPN	I
and	O	CCONJ	O
Chronic	O	PROPN	B
Health	O	PROPN	I
Evaluation	O	PROPN	I
II	O	NUM	I
score	O	NOUN	I
,	O	PUNCT	O
19.5	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
30	O	NUM	O
were	O	AUX	O
evaluable	O	ADJ	O
for	O	ADP	O
both	O	CCONJ	O
pharmacokinetics	O	NOUN	B
and	O	CCONJ	O
pharmacodynamics	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Erythropoietin	B-OUT	NOUN	B
exposure	I-OUT	NOUN	B
was	O	AUX	O
approximately	O	ADV	O
ten	O	NUM	O
times	O	NOUN	O
greater	O	ADJ	O
for	O	ADP	O
IV	O	NUM	B
dosing	O	NOUN	B
than	O	ADP	O
for	O	ADP	O
subcutaneous	B-I	ADJ	B
dosing	I-I	NOUN	B
.	I-I	PUNCT	O


Mean	B-OUT	VERB	O
absolute	I-OUT	ADJ	O
reticulocyte	I-OUT	NOUN	B
count	I-OUT	NOUN	O
peaked	O	VERB	O
at	O	ADP	O
day	O	NOUN	B
11	O	NUM	O
or	O	CCONJ	O
15	O	NUM	O
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
and	O	CCONJ	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
subcutaneous	O	ADJ	B
dosing	B-I	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
peak	O	ADJ	B
response	O	NOUN	I
149-169	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/L	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
IV	O	NUM	B
dosing	B-I	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
peak	O	ADJ	B
response	O	NOUN	I
138-147	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/L	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
most	O	ADJ	O
visits	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
reported	O	VERB	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
were	O	AUX	O
pyrexia	B-OUT	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
hypokalemia	B-OUT	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
hypophosphatemia	B-OUT	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
of	O	ADP	O
anemic	O	ADJ	B
critically	O	ADV	B
ill	O	ADJ	I
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
epoetin	B-I	NOUN	B
alfa	I-I	NOUN	I
,	O	PUNCT	O
all	O	DET	O
dosing	O	VERB	B
regimens	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
and	O	CCONJ	O
appeared	O	VERB	O
to	O	PART	O
effect	O	VERB	B
reticulocytosis	B-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
peak	O	NOUN	O
at	O	ADP	O
day	O	NOUN	B
11	O	NUM	O
or	O	CCONJ	O
15	O	NUM	O
in	O	ADP	O
most	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pharmacokinetics	O	NOUN	B
of	O	ADP	O
epoetin	B-I	NOUN	B
alfa	I-I	NOUN	I
did	O	AUX	O
not	O	PART	O
predict	O	VERB	O
pharmacodynamic	B-OUT	ADJ	B
response	I-OUT	NOUN	I
in	O	ADP	O
anemic	O	ADJ	B
critically	O	ADV	B
ill	O	ADJ	I
patients	O	NOUN	B
.	O	PUNCT	O


Evolution	O	NOUN	B
of	O	ADP	O
neuropathy	O	NOUN	B
and	O	CCONJ	O
myopathy	O	NOUN	B
during	O	ADP	O
intensive	O	ADJ	B
vincristine/corticosteroid	B-I	NOUN	I
chemotherapy	I-I	NOUN	I
for	O	ADP	O
non-Hodgkin	O	ADJ	B
's	O	PART	I
lymphoma	O	NOUN	I
.	O	PUNCT	O


Neuropathy	O	NOUN	B
and	O	CCONJ	O
myopathy	O	NOUN	B
are	O	AUX	O
common	O	ADJ	O
sequelae	O	NOUN	B
of	O	ADP	O
intensive	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
protocols	I-I	NOUN	O
that	I-I	PRON	O
contain	I-I	VERB	O
vincristine	I-I	NOUN	B
and	I-I	CCONJ	O
corticosteroids	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
prospectively	O	ADV	O
monitored	O	VERB	B
the	O	DET	O
evolution	O	NOUN	B
of	O	ADP	O
neuropathy	O	NOUN	B
and	O	CCONJ	O
myopathy	O	NOUN	B
during	O	ADP	O
an	O	DET	O
intensive	O	ADJ	B
12-week	O	NOUN	B
chemotherapy	B-I	NOUN	I
program	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
intermediate	I-P	NOUN	B
and	I-P	CCONJ	O
high-grade	I-P	ADJ	B
non-Hodgkin	I-P	ADJ	I
's	I-P	PART	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
vincristine	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
by	O	ADP	O
bolus	B-I	NOUN	B
injection	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
3-day	O	ADJ	O
continuous	O	ADJ	B
intravenous	O	ADJ	I
(	O	PUNCT	O
IV	O	NUM	B
)	O	PUNCT	O
infusion	O	NOUN	B
(	O	PUNCT	O
total	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
2.0	O	NUM	O
mg/m2	O	NOUN	O
every	O	DET	O
other	O	ADJ	O
week	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
the	O	DET	O
maximum	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
vincristine	B-I	NOUN	B
was	O	AUX	O
not	O	PART	O
arbitrarily	O	ADV	O
limited	O	ADJ	O
.	O	PUNCT	O


Cronassial	B-I	ADJ	B
,	I-I	PUNCT	O
a	I-I	DET	O
mixture	I-I	NOUN	O
of	I-I	ADP	O
four	I-I	NUM	O
naturally	I-I	ADV	O
occurring	I-I	VERB	O
gangliosides	I-I	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
test	O	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
whether	O	SCONJ	O
this	O	DET	O
agent	O	NOUN	B
could	O	AUX	O
prevent	O	VERB	O
vincristine-induced	B-I	ADJ	B
neuropathy	O	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
dexamethasone	B-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg/d	O	NOUN	O
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
weekly	O	ADJ	B
or	O	CCONJ	O
every	O	DET	O
other	O	ADJ	O
week	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
prescribed	O	VERB	B
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
monitored	O	VERB	O
every	O	DET	O
4	O	NUM	O
weeks	O	NOUN	B
with	O	ADP	O
comprehensive	O	ADJ	B
physical	O	ADJ	B
and	O	CCONJ	O
neurologic	O	ADJ	B
examinations	O	NOUN	I
and	O	CCONJ	O
electrophysiologic	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
peripheral	O	ADJ	B
nerve	O	NOUN	I
function	O	NOUN	I
.	O	PUNCT	O


Twenty-seven	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
fully	I-P	ADV	O
evaluable	I-P	ADJ	O
.	I-P	PUNCT	O


Weakness	B-OUT	PROPN	B
was	O	AUX	O
a	O	DET	O
prominent	O	ADJ	O
adverse	O	ADJ	B
reaction	O	NOUN	I
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
moderate	B-OUT	ADJ	B
to	I-OUT	PART	O
severe	I-OUT	ADJ	B
signs	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
symptoms	I-OUT	NOUN	B
of	I-OUT	ADP	O
neuropathy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
myopathy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Cronassial	B-I	ADJ	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
administered	O	VERB	B
by	O	ADP	O
intramuscular	O	ADJ	B
(	O	PUNCT	O
IM	O	NOUN	B
)	O	PUNCT	O
injection	O	NOUN	B
daily	O	ADV	O
provided	O	VERB	O
no	O	DET	O
protection	O	NOUN	B
against	O	ADP	O
the	O	DET	O
development	B-OUT	NOUN	B
of	I-OUT	ADP	O
neuropathic	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Vincristine	B-I	NOUN	B
typically	O	ADV	O
impaired	O	VERB	B
fine-motor	B-OUT	ADJ	B
coordination	I-OUT	NOUN	I
initially	O	ADV	B
,	O	PUNCT	O
whereas	O	SCONJ	O
corticosteroids	B-I	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
delayed	O	VERB	B
development	B-OUT	NOUN	I
of	I-OUT	ADP	O
proximal	I-OUT	ADJ	B
muscle	I-OUT	NOUN	I
weakness	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
electrodiagnostic	O	ADJ	B
studies	O	NOUN	I
did	O	AUX	O
not	O	PART	O
add	O	VERB	O
to	O	PART	O
the	O	DET	O
clinical	O	ADJ	B
examination	O	NOUN	I
results	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
conclude	O	VERB	O
that	O	SCONJ	O
symptomatic	B-OUT	ADJ	B
weakness	I-OUT	NOUN	B
due	O	ADJ	O
to	O	PART	O
neuropathy	O	NOUN	B
or	O	CCONJ	O
myopathy	O	NOUN	B
appears	O	VERB	O
in	O	ADP	O
a	O	DET	O
predictable	O	ADJ	B
manner	O	NOUN	O
during	O	ADP	O
intensive	O	ADJ	O
vincristine/corticosteroid-based	B-I	ADJ	B
treatment	I-I	NOUN	O
protocols	O	NOUN	O
.	O	PUNCT	O


Simple	O	ADJ	O
clinical	O	ADJ	B
tests	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
rapidly	O	ADV	O
distinguish	O	VERB	O
between	O	ADP	O
toxic	O	ADJ	B
effects	O	NOUN	O
due	O	ADJ	O
either	O	CCONJ	O
to	O	PART	O
vincristine	B-I	NOUN	B
or	I-I	CCONJ	O
corticosteroids	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
routine	O	ADJ	B
implementation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
tests	O	NOUN	B
can	O	AUX	O
prevent	O	VERB	O
inappropriate	O	ADJ	O
dose	O	NOUN	B
attenuation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
agents	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
glucose-insulin-potassium	B-I	NOUN	B
infusion	I-I	NOUN	B
on	O	ADP	O
ST-elevation	B-OUT	ADJ	B
myocardial	I-OUT	ADJ	I
infarction	I-OUT	NOUN	I
in	I-P	ADP	O
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
thrombolytic	I-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
glucose-insulin-potassium	B-I	NOUN	B
(	I-I	PUNCT	O
GIK	I-I	NOUN	B
)	I-I	PUNCT	O
infusion	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
acute	B-OUT	ADJ	B
myocardial	I-OUT	ADJ	I
infarction	I-OUT	NOUN	I
is	O	AUX	O
not	O	PART	O
well	O	ADV	O
established	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
comprised	O	VERB	O
120	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
ST-elevation	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
that	I-P	PRON	O
was	I-P	AUX	O
treated	I-P	VERB	B
within	I-P	ADP	O
12	I-P	NUM	O
hours	I-P	NOUN	O
from	I-P	ADP	O
symptom	I-P	NOUN	B
onset	I-P	NOUN	I
with	O	ADP	O
a	O	DET	O
high	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
GIK	B-I	NOUN	B
(	I-I	PUNCT	O
25	I-I	NUM	O
%	I-I	NOUN	O
glucose	I-I	NOUN	B
,	I-I	PUNCT	O
50	I-I	NUM	O
IU	I-I	NOUN	B
of	I-I	ADP	O
soluble	I-I	ADJ	B
insulin	I-I	NOUN	O
per	I-I	ADP	O
liter	I-I	NOUN	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
80	I-I	NUM	O
mmol	I-I	NOUN	O
of	I-I	ADP	O
potassium	I-I	NOUN	B
chloride	I-I	NOUN	I
per	I-I	ADP	O
liter	I-I	NOUN	O
at	I-I	ADP	O
1	I-I	NUM	O
ml/kg/hour	I-I	NOUN	O
over	I-I	ADP	O
24	I-I	NUM	O
hours	I-I	NOUN	B
)	I-I	PUNCT	O
as	I-I	ADP	O
adjunct	I-I	NOUN	B
to	I-I	PART	O
thrombolytic	I-I	ADJ	B
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
1.5	I-I	NUM	O
MU	I-I	NOUN	B
of	I-I	ADP	O
streptokinase/30	I-I	NOUN	O
to	I-I	PART	O
60	I-I	NUM	O
minutes	I-I	NOUN	B
;	I-I	PUNCT	O
GIK	I-I	NOUN	B
group	I-I	NOUN	B
)	I-I	PUNCT	O
or	O	CCONJ	O
thrombolytic	B-I	ADJ	B
therapy	I-I	NOUN	I
alone	I-I	ADV	O
(	I-I	PUNCT	O
control	I-I	ADJ	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
major	I-OUT	ADJ	O
adverse	I-OUT	ADJ	B
cardiac	I-OUT	ADJ	I
events	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
MACEs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
at	I-OUT	ADP	O
1	I-OUT	NUM	O
month	I-OUT	NOUN	B
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
a	B-OUT	DET	O
composite	I-OUT	NOUN	B
of	I-OUT	ADP	O
cardiac	I-OUT	ADJ	B
death	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
reinfarction	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
serious	I-OUT	ADJ	B
arrhythmias	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ventricular	I-OUT	ADJ	B
fibrillation	I-OUT	NOUN	I
and/or	I-OUT	CCONJ	O
tachycardia	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
severe	I-OUT	ADJ	B
heart	I-OUT	NOUN	B
failure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
secondary	O	ADJ	B
end	O	NOUN	I
points	O	NOUN	I
were	O	AUX	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
MACEs	I-OUT	NOUN	B
at	I-OUT	ADP	O
1	I-OUT	NUM	O
year	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
left	I-OUT	ADJ	B
ventricular	I-OUT	ADJ	I
systolic	I-OUT	NOUN	I
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
MACEs	I-OUT	NOUN	B
at	I-OUT	ADP	O
1	I-OUT	NUM	O
month	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
GIK	B-I	NOUN	B
group	I-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
32.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
0.24	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
0.09	O	NUM	O
to	O	PART	O
0.63	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0043	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
GIK	B-I	NOUN	B
group	O	NOUN	B
had	O	AUX	O
significant	O	ADJ	O
decreases	O	NOUN	B
in	O	ADP	O
ventricular	B-OUT	ADJ	B
tachycardia	I-OUT	NOUN	I
and/or	I-OUT	CCONJ	O
fibrillation	I-OUT	NOUN	B
(	O	PUNCT	O
1.3	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
15.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
severe	O	ADJ	B
heart	B-OUT	NOUN	B
failure	I-OUT	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
12.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.031	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
MACEs	I-OUT	NOUN	B
at	I-OUT	ADP	O
1	I-OUT	NUM	O
year	I-OUT	NOUN	B
was	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
GIK	B-I	NOUN	B
group	I-I	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
40.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
0.22	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
0.09	O	NUM	O
to	O	PART	O
0.55	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0012	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
left	B-OUT	ADJ	B
ventricular	I-OUT	ADJ	I
ejection	I-OUT	NOUN	I
fraction	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
GIK	B-I	NOUN	B
group	I-I	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
48	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
%	O	NOUN	O
to	O	PART	O
51	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
control	B-I	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
high-dose	O	ADJ	B
GIK	B-I	NOUN	B
,	O	PUNCT	O
used	O	VERB	O
as	O	ADP	O
an	O	DET	O
adjunct	O	NOUN	B
to	O	PART	O
thrombolytic	B-I	ADJ	B
therapy	I-I	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
safe	B-OUT	ADJ	O
and	O	CCONJ	O
improved	O	VERB	O
clinical	B-OUT	ADJ	B
outcome	I-OUT	NOUN	I
at	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
GIK	B-I	NOUN	B
infusion	O	NOUN	B
was	O	AUX	O
maintained	O	VERB	B
up	O	ADV	O
to	O	PART	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Behavioral	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
physiological	I-OUT	ADJ	B
effects	I-OUT	NOUN	O
of	O	ADP	O
remifentanil	B-I	NOUN	B
and	I-I	CCONJ	O
alfentanil	I-I	NOUN	B
in	O	ADP	O
healthy	B-P	ADJ	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	B-OUT	DET	O
subjective	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
psychomotor	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
of	O	ADP	O
remifentanil	B-I	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
used	O	VERB	O
mood	O	NOUN	B
inventories	O	NOUN	I
and	O	CCONJ	O
psychomotor	O	NOUN	B
tests	O	NOUN	I
to	O	PART	O
characterize	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
remifentanil	B-I	NOUN	B
in	O	ADP	O
healthy	B-P	ADJ	B
,	I-P	PUNCT	O
non-drug-abusing	I-P	ADJ	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


Alfentanil	O	PROPN	B
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
comparator	O	NOUN	B
drug	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Ten	B-P	NUM	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blinded	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
trial	O	NOUN	I
in	O	ADP	O
which	O	DET	O
they	O	PRON	O
received	O	VERB	O
an	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
saline	B-I	NOUN	B
,	I-I	PUNCT	O
remifentanil	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
alfentanil	I-I	NOUN	B
for	I-I	ADP	O
120	I-I	NUM	O
min	I-I	NOUN	O
.	I-I	PUNCT	O


The	O	DET	O
age-	B-I	NOUN	O
and	I-I	CCONJ	O
weight-adjusted	I-I	ADJ	O
infusions	I-I	NOUN	B
(	I-I	PUNCT	O
determined	I-I	VERB	O
with	I-I	ADP	O
STANPUMP	I-I	PROPN	B
,	I-I	PUNCT	O
a	I-I	DET	O
computer	I-I	NOUN	B
modeling	I-I	NOUN	I
software	I-I	NOUN	I
package	I-I	NOUN	I
)	I-I	PUNCT	O
were	O	AUX	O
given	O	VERB	O
to	O	PART	O
achieve	O	VERB	O
three	O	NUM	O
predicted	O	VERB	B
constant	O	ADJ	B
plasma	O	NOUN	B
levels	O	NOUN	B
for	O	ADP	O
40	B-I	NUM	O
min	I-I	NOUN	O
each	I-I	DET	O
of	I-I	ADP	O
remifentanil	I-I	NOUN	B
(	I-I	PUNCT	O
0.75	I-I	NUM	O
,	I-I	PUNCT	O
1.5	I-I	NUM	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
3	I-I	NUM	O
ng/ml	I-I	NOUN	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
alfentanil	I-I	NOUN	B
(	I-I	PUNCT	O
16	I-I	NUM	O
,	I-I	PUNCT	O
32	I-I	NUM	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
64	I-I	NUM	O
ng/ml	I-I	NOUN	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Mood	O	NOUN	B
forms	O	NOUN	I
and	O	CCONJ	O
psychomotor	O	NOUN	B
tests	O	NOUN	I
were	O	AUX	O
completed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
miosis	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
,	O	PUNCT	O
during	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
infusions	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
analgesia	O	NOUN	B
was	O	AUX	O
tested	O	VERB	B
at	O	ADP	O
each	O	DET	O
dose	O	NOUN	B
level	O	NOUN	B
using	O	VERB	O
a	O	DET	O
cold-pressor	O	NOUN	B
test	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
Remifentanil	B-I	NOUN	B
had	O	AUX	O
prototypic	B-OUT	ADJ	B
micro-like	I-OUT	ADJ	B
opioid	I-OUT	NOUN	I
subjective	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
impaired	I-OUT	ADJ	B
psychomotor	I-OUT	NOUN	O
performance	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
produced	I-OUT	VERB	O
analgesia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Alfentanil	O	NOUN	B
at	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
range	O	NOUN	O
tested	O	VERB	B
had	O	AUX	O
more	O	ADV	O
mild	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
these	O	DET	O
measures	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
analgesia	B-OUT	NOUN	B
data	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
40:1	O	NUM	O
potency	O	NOUN	B
ratio	O	NOUN	B
,	O	PUNCT	O
rather	O	ADV	O
than	O	ADP	O
the	O	DET	O
20:1	O	NUM	O
ratio	O	NOUN	B
we	O	PRON	O
used	O	VERB	O
,	O	PUNCT	O
may	O	AUX	O
exist	O	VERB	O
between	O	ADP	O
remifentanil	O	NOUN	B
and	O	CCONJ	O
alfentanil	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
psychomotor	O	NOUN	B
test	O	NOUN	I
administered	O	VERB	B
60	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
remifentanil	O	NOUN	B
infusion	O	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
volunteers	O	NOUN	B
were	O	AUX	O
still	O	ADV	O
impaired	O	ADJ	B
,	O	PUNCT	O
although	O	SCONJ	O
they	O	PRON	O
reported	O	VERB	B
feeling	O	VERB	O
no	O	DET	O
drug	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
notion	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
pharmacodynamic	B-OUT	ADJ	B
effects	I-OUT	NOUN	O
of	O	ADP	O
remifentanil	B-I	NOUN	B
are	O	AUX	O
extremely	O	ADV	O
short-lived	O	ADJ	O
after	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
is	O	AUX	O
no	O	ADV	O
longer	O	ADV	O
administered	O	VERB	B
must	O	AUX	O
be	O	AUX	O
questioned	O	VERB	O
given	O	VERB	O
our	O	PRON	O
findings	O	NOUN	B
that	O	SCONJ	O
psychomotor	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
still	O	ADV	O
apparent	O	ADJ	B
1	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


Risperidone	B-I	NOUN	B
versus	I-I	CCONJ	O
haloperidol	I-I	NOUN	B
in	I-P	ADP	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
AD	I-P	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
safety	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
efficacy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
risperidone	B-I	NOUN	B
with	I-I	ADP	O
haloperidol	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
Autistic	B-P	ADJ	B
Disorder	I-P	NOUN	I
(	I-P	PUNCT	O
AD	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


METHOD	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
as	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
for	O	ADP	O
a	O	DET	O
12-week	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
30	I-P	NUM	O
subjects	I-P	NOUN	B
,	I-P	PUNCT	O
between	I-P	ADP	O
the	I-P	DET	O
ages	I-P	NOUN	B
of	I-P	ADP	O
8	I-P	NUM	O
and	I-P	CCONJ	O
18	I-P	NUM	O
with	I-P	ADP	O
AD	I-P	NOUN	B
based	I-P	VERB	O
on	I-P	ADP	O
DSM	I-P	NOUN	B
IV	I-P	NUM	I
criteria	I-P	NOUN	I
,	I-P	PUNCT	O
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Behavioral	B-OUT	ADJ	B
Rating	I-OUT	PROPN	I
Scales	I-OUT	PROPN	I
were	O	AUX	O
performed	O	VERB	O
by	O	ADP	O
the	O	DET	O
investigators	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
parents	O	NOUN	B
.	O	PUNCT	O


Safety	B-OUT	NOUN	B
assessment	I-OUT	NOUN	B
included	O	VERB	O
vital	B-OUT	ADJ	B
signs	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
electrocardiogram	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
electroencephalogram	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
laboratory	I-OUT	ADJ	B
tests	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
extrapyramidal	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Both	O	DET	O
treatments	O	NOUN	B
were	O	AUX	O
applied	O	VERB	O
in	O	ADP	O
a	O	DET	O
once	O	ADV	O
daily	O	ADJ	O
dosage	O	NOUN	B
regimen	O	NOUN	I
of	O	ADP	O
0.01-0.08	O	NUM	O
mg/kg/day	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
reduction	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
Ritvo-Freeman	B-OUT	ADJ	B
Real	I-OUT	ADJ	I
Life	I-OUT	PROPN	I
Rating	I-OUT	NOUN	I
Scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RF-RLRS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
sensory	I-OUT	ADJ	B
motor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
subscale	I-OUT	NOUN	O
I	I-OUT	NUM	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
language	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
subscale	I-OUT	NOUN	O
V	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
scores	I-OUT	NOUN	O
were	O	AUX	O
significant	O	ADJ	O
in	O	ADP	O
risperidone	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Compared	O	VERB	O
to	O	PART	O
haloperidol	O	NOUN	B
,	O	PUNCT	O
risperidone	O	NOUN	B
led	O	VERB	O
to	O	PART	O
a	O	DET	O
significantly	O	ADV	O
greater	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Aberrant	B-OUT	PROPN	B
Behavior	I-OUT	PROPN	I
Checklist	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
ABC	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Turgay	I-OUT	PROPN	B
DSM-IV	I-OUT	PROPN	I
Pervasive	I-OUT	PROPN	I
Developmental	I-OUT	PROPN	I
Disorder	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
PDD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
scale	I-OUT	NOUN	O
scores	I-OUT	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
and	O	CCONJ	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
greater	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
prolactin	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
risperidone	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
alanine	B-OUT	NOUN	B
amino	I-OUT	NOUN	I
transferase	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ALT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
had	O	AUX	O
further	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
haloperidol	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Sensory	B-OUT	ADJ	B
motor	I-OUT	NOUN	I
behaviors	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
subscale	I-OUT	NOUN	B
I	I-OUT	NUM	I
)	I-OUT	PUNCT	O
and	O	CCONJ	O
language	B-OUT	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
12th	O	NOUN	O
week	O	NOUN	B
,	O	PUNCT	O
RF-RLRS	B-OUT	NOUN	B
sensory	I-OUT	ADJ	B
motor	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
language	I-OUT	NOUN	B
subscale	I-OUT	NOUN	O
scores	I-OUT	NOUN	B
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
risperidone	O	NOUN	B
group	O	NOUN	B
further	O	ADV	O
than	O	ADP	O
the	O	DET	O
other	O	ADJ	O
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Risperidone	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
haloperidol	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
behavioral	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
impulsivity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
language	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
impaired	B-OUT	ADJ	B
social	I-OUT	ADJ	B
relations	I-OUT	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
AD	I-P	NOUN	B
.	I-P	PUNCT	O


These	O	DET	O
results	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
AD	O	NOUN	B
.	O	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
electrofunctional	O	ADJ	B
data	O	NOUN	B
following	O	VERB	O
argon-laser	B-I	ADJ	B
trabeculoplasty	I-I	NOUN	I
in	O	ADP	O
primary	O	ADJ	B
open-angle	O	ADJ	I
glaucoma	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
establish	O	VERB	O
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
glaucomatous	B-OUT	ADJ	B
damage	I-OUT	NOUN	O
is	O	AUX	O
reversible	O	ADJ	B
,	O	PUNCT	O
we	O	PRON	O
obtained	O	VERB	O
pattern-reversal	B-OUT	ADJ	B
electroretinograms	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PERGs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
visual	I-OUT	ADJ	B
evoked	I-OUT	ADJ	O
potentials	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
VEPs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
25	B-P	NUM	O
eyes	I-P	NOUN	B
of	I-P	ADP	O
25	I-P	NUM	O
patients	I-P	NOUN	B
suffering	I-P	VERB	B
from	I-P	ADP	O
bilateral	I-P	ADJ	B
primary	I-P	ADJ	B
open-angle	I-P	ADJ	I
glaucoma	I-P	NOUN	I
(	I-P	PUNCT	O
POAG	I-P	NOUN	B
)	I-P	PUNCT	O
before	I-P	ADP	O
and	I-P	CCONJ	O
after	I-P	ADP	O
argon-laser	I-I	ADJ	B
trabeculoplasty	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
laser	O	NOUN	B
treatment	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
only	O	ADV	O
one	O	NUM	O
eye	O	NOUN	B
chosen	O	VERB	O
at	O	ADP	O
random	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
fellow	O	NOUN	B
eye	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
control	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
intended	O	VERB	O
to	O	PART	O
verify	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
using	O	VERB	O
electrofunctional	O	ADJ	B
techniques	O	NOUN	I
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
two	O	NUM	O
distinct	O	ADJ	O
and	O	CCONJ	O
,	O	PUNCT	O
probably	O	ADV	O
,	O	PUNCT	O
consecutive	O	ADJ	B
glaucomatous	B-OUT	ADJ	B
alterations	I-OUT	NOUN	B
occurring	I-OUT	VERB	O
in	I-OUT	ADP	O
ganglion	I-OUT	NOUN	B
cells	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
functional	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
reversible	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anatomical	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
irreversible	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
obtained	O	VERB	O
indicate	O	VERB	O
that	O	SCONJ	O
glaucomatous	B-OUT	ADJ	B
damage	I-OUT	NOUN	O
is	O	AUX	O
irreversible	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
such	O	ADJ	O
alterations	O	NOUN	B
differ	O	VERB	O
very	O	ADV	O
slightly	O	ADV	O
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
current	O	ADJ	O
electrofunctional	O	ADJ	B
techniques	O	NOUN	O
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
sufficiently	O	ADV	O
sophisticated	O	ADJ	O
to	O	PART	O
distinguish	O	VERB	O
between	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


A	O	DET	O
comparative	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
fixed	O	ADJ	B
ratio	O	NOUN	I
beta-adrenoceptor	B-I	NOUN	B
blocker	I-I	NOUN	I
and	I-I	CCONJ	O
diuretic	I-I	ADJ	B
combination	I-I	NOUN	I
products	I-I	NOUN	I
in	O	ADP	O
moderate	B-P	ADJ	B
hypertension	I-P	NOUN	B
.	I-P	PUNCT	O


Two	O	NUM	O
fixed	O	ADJ	B
ratio	O	NOUN	I
combination	O	NOUN	O
tablets	O	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
pindolol	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
5	I-I	NUM	O
mg	I-I	NOUN	O
clopamide	I-I	NOUN	B
and	O	CCONJ	O
100	O	NUM	O
mg	O	NOUN	O
metoprolol	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
12.5	I-I	NUM	O
mg	I-I	NOUN	O
hydrochlorothiazide	I-I	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
at	O	ADP	O
two	O	NUM	O
dose	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
crossover	O	NOUN	B
trial	O	NOUN	I
in	O	ADP	O
10	B-P	NUM	O
previously	I-P	ADV	O
untreated	I-I	ADJ	B
hypertensive	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
resting	B-OUT	VERB	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
on	O	ADP	O
the	O	DET	O
two	O	NUM	O
combinations	O	NOUN	B
at	O	ADP	O
either	O	CCONJ	O
dose	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


Exercise	B-OUT	VERB	B
systolic	I-OUT	NOUN	O
pressure	I-OUT	NOUN	O
was	O	AUX	O
lower	O	ADJ	O
after	O	ADP	O
the	O	DET	O
pindolol/clopamide	B-I	NOUN	B
combination	O	NOUN	B
at	O	ADP	O
low	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
side-effects	I-OUT	NOUN	B
in	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
high	O	ADJ	O
but	O	CCONJ	O
proper	O	ADJ	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
products	O	NOUN	B
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
made	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
small	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
combination	B-I	NOUN	B
products	I-I	NOUN	I
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
only	O	ADV	O
after	O	ADP	O
patients	O	NOUN	B
have	O	AUX	O
failed	O	VERB	B
to	O	PART	O
respond	O	VERB	O
adequately	O	ADV	O
to	O	PART	O
a	O	DET	O
single	O	ADJ	O
agent	O	NOUN	O
.	O	PUNCT	O


Randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
evaluating	O	VERB	B
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
plantar	B-P	NOUN	B
fasciitis	I-P	NOUN	I
with	O	ADP	O
an	O	DET	O
extracoporeal	B-I	ADJ	B
shockwave	I-I	NOUN	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
ESWT	I-I	NOUN	B
)	I-I	PUNCT	O
device	I-I	NOUN	O
:	I-I	PUNCT	O
a	O	DET	O
North	B-P	ADJ	B
American	I-P	ADJ	I
confirmatory	I-P	ADJ	B
study	I-P	NOUN	I
.	I-P	PUNCT	O


Despite	O	SCONJ	O
numerous	O	ADJ	O
publications	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
trials	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
recalcitrant	B-P	ADJ	B
chronic	I-P	ADJ	B
plantar	I-P	NOUN	I
fasciitis	I-P	NOUN	I
with	O	ADP	O
extracorporeal	B-I	ADJ	B
shockwave	I-I	NOUN	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
ESWT	I-I	NOUN	B
)	I-I	PUNCT	O
still	O	ADV	O
remain	O	VERB	O
equivocal	O	ADJ	B
as	O	ADP	O
to	O	ADP	O
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
this	O	DET	O
treatment	O	NOUN	B
provides	O	VERB	O
relief	B-OUT	NOUN	B
from	O	ADP	O
the	B-OUT	DET	O
pain	I-OUT	NOUN	B
associated	O	VERB	B
with	O	ADP	I
this	O	DET	O
condition	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
extracorporeal	O	ADJ	B
shock	O	NOUN	I
wave	O	NOUN	I
therapy	O	NOUN	I
can	O	AUX	O
safely	B-OUT	ADV	O
and	I-OUT	CCONJ	O
effectively	I-OUT	ADV	O
relieve	I-OUT	VERB	O
the	I-OUT	DET	O
pain	I-OUT	NOUN	B
associated	O	VERB	B
with	O	ADP	I
chronic	O	ADJ	B
plantar	O	NOUN	I
fasciitis	O	NOUN	I
compared	O	VERB	O
to	O	PART	O
placebo	O	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
demonstrated	O	VERB	O
by	O	ADP	O
pain	O	NOUN	B
with	O	ADP	O
walking	O	VERB	B
in	O	ADP	O
the	O	DET	O
morning	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
set	O	VERB	O
in	O	ADP	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
confirmatory	O	ADJ	B
clinical	O	ADJ	I
study	O	NOUN	I
undertaken	O	VERB	O
in	O	ADP	O
four	B-P	NUM	O
outpatient	I-P	ADJ	B
orthopedic	I-P	ADJ	B
clinics	I-P	NOUN	I
.	I-P	PUNCT	O


The	B-P	DET	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
114	I-P	NUM	O
adult	I-P	ADJ	B
subjects	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
plantar	I-P	NOUN	I
fasciitis	I-P	NOUN	I
,	I-P	PUNCT	O
recalcitrant	I-P	ADJ	B
to	I-P	PART	O
conservative	I-P	ADJ	O
therapies	I-P	NOUN	B
for	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADJ	O
6	I-P	NUM	O
months	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
approximately	O	ADV	O
3,800	B-I	NUM	O
total	I-I	ADJ	B
shock	I-I	NOUN	I
waves	I-I	NOUN	I
(	O	PUNCT	O
+/-10	O	NUM	O
)	O	PUNCT	O
reaching	O	VERB	O
an	O	DET	O
approximated	O	ADJ	O
total	O	ADJ	B
energy	O	NOUN	I
delivery	O	NOUN	I
of	O	ADP	O
1,300	O	NUM	O
mJ/mm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
ED+	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
session	O	NOUN	B
versus	O	CCONJ	O
placebo	B-I	NOUN	B
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
demonstrated	O	VERB	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
in	O	ADP	O
the	O	DET	O
change	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
3	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
outcome	O	NOUN	B
of	O	ADP	O
pain	B-OUT	NOUN	B
during	O	ADP	O
the	B-OUT	DET	O
first	I-OUT	ADJ	O
few	I-OUT	ADJ	O
minutes	I-OUT	NOUN	O
of	I-OUT	ADP	O
walking	I-OUT	NOUN	B
measured	O	VERB	B
by	O	ADP	O
a	O	DET	O
visual	B-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


There	O	PRON	O
was	O	AUX	O
also	O	ADV	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
treatments	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
participants	O	NOUN	B
whose	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
Visual	B-OUT	PROPN	B
Analog	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
scores	I-OUT	NOUN	I
met	O	VERB	O
the	O	DET	O
study	O	NOUN	B
definition	O	NOUN	B
of	O	ADP	O
success	O	NOUN	B
at	O	ADP	O
both	O	CCONJ	O
6	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
months	O	NOUN	B
posttreatment	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
between	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	O
in	O	ADP	O
the	O	DET	O
change	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
3	O	NUM	O
months	O	NOUN	B
posttreatment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Roles	B-OUT	PROPN	B
and	I-OUT	CCONJ	O
Maudsley	I-OUT	PROPN	B
Score	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
confirm	O	VERB	O
that	O	SCONJ	O
ESWT	B-I	NOUN	B
administered	O	VERB	B
with	O	ADP	O
the	O	DET	O
Dornier	O	PROPN	B
Epos	O	PROPN	I
Ultra	O	PROPN	I
is	O	AUX	O
a	O	DET	O
safe	B-OUT	ADJ	O
and	O	CCONJ	O
effective	B-OUT	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
recalcitrant	O	ADJ	B
plantar	O	NOUN	B
fasciitis	O	NOUN	I
.	O	PUNCT	O


Intestinal	O	ADJ	B
absorption	O	NOUN	B
of	O	ADP	O
dietary	O	ADJ	B
fat	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
multiple	I-P	ADJ	B
sclerosis	I-P	NOUN	I
.	I-P	PUNCT	O


Fat	B-OUT	ADJ	B
absorption	I-OUT	NOUN	I
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
24	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
clinically	I-P	ADV	B
definite	I-P	ADJ	I
multiple	I-P	ADJ	B
sclerosis	I-P	NOUN	I
and	I-P	CCONJ	O
in	I-P	ADP	O
36	I-P	NUM	O
healthy	I-P	ADJ	B
control	I-I	NOUN	O
subjects	I-P	NOUN	O
.	I-P	PUNCT	O


Beta-carotene	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
vitamin	I-OUT	NOUN	B
A	I-OUT	NOUN	I
in	I-OUT	ADP	O
their	I-OUT	PRON	O
plasma	I-OUT	NOUN	B
were	I-I	AUX	O
also	I-I	ADV	O
measured	I-I	VERB	B
.	I-I	PUNCT	O


This	O	DET	O
double-blind	O	ADJ	B
and	O	CCONJ	O
randomized	O	ADJ	B
study	O	NOUN	I
showed	O	VERB	O
no	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
these	O	DET	O
two	O	NUM	O
populations	O	NOUN	B
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
the	O	DET	O
three	O	NUM	O
parameters	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
did	O	AUX	O
not	O	PART	O
find	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
fat	O	ADJ	B
malabsorption	O	NOUN	I
in	O	ADP	O
multiple	O	ADJ	B
sclerosis	O	NOUN	I
.	O	PUNCT	O


Memory	B-OUT	NOUN	B
monitoring	O	VERB	B
by	O	ADP	O
animals	B-P	NOUN	B
and	I-P	CCONJ	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
asked	O	VERB	O
whether	O	SCONJ	O
animals	B-P	NOUN	B
and	I-P	CCONJ	O
humans	I-P	NOUN	B
would	O	AUX	O
use	O	VERB	O
similarly	O	ADV	O
an	O	DET	O
uncertain	O	ADJ	O
response	B-OUT	NOUN	B
to	O	PART	O
escape	O	VERB	O
indeterminate	O	ADJ	B
memories	O	NOUN	B
.	O	PUNCT	O


Monkeys	B-P	NOUN	B
and	I-P	CCONJ	O
humans	I-P	NOUN	B
performed	I-P	VERB	O
serial	I-I	ADJ	B
probe	I-I	NOUN	I
recognition	I-I	NOUN	O
tasks	I-I	NOUN	O
that	O	PRON	O
produced	O	VERB	O
differential	O	ADJ	B
memory	O	NOUN	I
difficulty	O	NOUN	B
across	O	ADP	O
serial	O	ADJ	O
positions	O	NOUN	O
(	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
primacy	O	NOUN	B
and	O	CCONJ	O
recency	O	NOUN	B
effects	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Participants	B-P	NOUN	B
were	O	AUX	O
given	O	VERB	O
an	O	DET	O
escape	O	NOUN	O
option	O	NOUN	O
that	O	PRON	O
let	O	VERB	O
them	O	PRON	O
avoid	O	VERB	O
any	O	DET	O
trials	O	NOUN	B
they	O	PRON	O
wished	O	VERB	O
and	O	CCONJ	O
receive	O	VERB	O
a	O	DET	O
hint	O	NOUN	O
to	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
's	O	PART	I
answer	O	NOUN	O
.	O	PUNCT	O


Across	O	ADP	O
species	O	NOUN	B
,	O	PUNCT	O
across	O	ADP	O
tasks	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
even	O	ADV	O
across	O	ADP	O
conspecifics	O	NOUN	B
with	O	ADP	O
sharper	O	ADJ	O
or	O	CCONJ	O
duller	O	ADJ	B
memories	O	NOUN	I
,	O	PUNCT	O
monkeys	B-P	NOUN	B
and	I-P	CCONJ	O
humans	I-P	NOUN	B
used	I-OUT	VERB	O
the	I-OUT	DET	O
escape	I-OUT	NOUN	O
option	I-OUT	NOUN	O
selectively	O	ADV	O
when	O	SCONJ	O
more	O	ADV	O
indeterminate	O	ADJ	B
memory	O	NOUN	B
traces	O	NOUN	I
were	O	AUX	O
probed	O	VERB	O
.	O	PUNCT	O


Their	O	PRON	O
pattern	O	NOUN	B
of	O	ADP	O
escaping	O	NOUN	O
always	O	ADV	O
mirrored	O	VERB	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
primary	O	ADJ	B
memory	O	NOUN	I
performance	O	NOUN	B
across	O	ADP	O
serial	O	ADJ	O
positions	O	NOUN	B
.	O	PUNCT	O


Signal-detection	B-OUT	NOUN	B
analyses	I-OUT	NOUN	I
confirm	O	VERB	O
the	O	DET	O
similarity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
'	O	PART	O
and	O	CCONJ	O
humans	O	NOUN	B
'	O	PART	O
performances	O	NOUN	B
.	O	PUNCT	O


Optimality	B-OUT	NOUN	B
analyses	I-OUT	NOUN	I
assess	O	VERB	O
their	O	PRON	O
efficiency	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Several	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
monkeys	O	NOUN	B
'	O	PART	O
performance	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
cognitive	O	ADJ	B
sophistication	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
decisions	O	NOUN	B
to	O	PART	O
escape	O	VERB	B
.	O	PUNCT	O


Use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
electrothermal	B-I	ADJ	B
bipolar	I-I	ADJ	I
vessel	I-I	NOUN	I
system	I-I	NOUN	I
(	I-I	PUNCT	O
EBVS	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
laparoscopic	O	ADJ	B
adrenalectomy	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Since	O	SCONJ	O
laparoscopic	B-P	ADJ	B
adrenalectomy	I-P	NOUN	I
(	I-P	PUNCT	O
LA	I-P	NOUN	B
)	I-P	PUNCT	O
has	O	AUX	O
been	O	AUX	O
adopted	O	VERB	O
as	O	ADP	O
the	O	DET	O
gold	O	NOUN	B
standard	O	NOUN	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
adrenal	O	ADJ	B
diseases	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
technology	O	NOUN	B
for	O	ADP	O
vascular	O	ADJ	B
control	O	NOUN	I
and	O	CCONJ	O
dissection	O	NOUN	B
manoeuvres	O	NOUN	B
,	O	PUNCT	O
amongst	O	ADP	O
other	O	ADJ	O
things	O	NOUN	O
,	O	PUNCT	O
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
pivotal	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
its	O	PRON	O
further	O	ADJ	O
improvement	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
our	O	PRON	O
experience	O	NOUN	O
with	O	ADP	O
the	O	DET	O
electrothermal	B-I	ADJ	B
bipolar	I-I	ADJ	I
vessel	I-I	NOUN	I
sealing	I-I	NOUN	I
(	I-I	PUNCT	O
EBVS	I-I	NOUN	B
)	I-I	PUNCT	O
device	O	NOUN	O
for	O	ADP	O
LA	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
From	B-P	ADP	O
January	I-P	PROPN	O
2004	I-P	NUM	O
to	I-P	ADP	O
January	I-P	PROPN	O
2006	I-P	NUM	O
,	I-P	PUNCT	O
50	I-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
pts	I-P	NOUN	B
)	I-P	PUNCT	O
undergoing	I-P	VERB	O
LA	I-P	PROPN	B
were	O	AUX	O
selected	O	VERB	O
and	O	CCONJ	O
randomized	O	VERB	B
for	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
EBVS	B-I	PROPN	B
(	I-I	PUNCT	O
25	I-I	NUM	O
pts	I-I	NOUN	B
,	I-I	PUNCT	O
group	I-I	NOUN	B
A	I-I	NOUN	I
)	I-I	PUNCT	O
versus	I-I	ADP	O
the	I-I	DET	O
UltraSonic	I-I	PROPN	B
Shears	I-I	PROPN	I
(	I-I	PUNCT	O
USS	I-I	PROPN	O
)	I-I	PUNCT	O
device	I-I	NOUN	O
(	O	PUNCT	O
25	O	NUM	O
pts	O	NOUN	B
,	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
body	O	NOUN	B
mass	O	NOUN	I
index	O	NOUN	I
(	O	PUNCT	O
BMI	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
previous	O	ADJ	O
surgery	O	NOUN	B
and	O	CCONJ	O
associated	O	VERB	O
diseases	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
surgical	O	ADJ	B
parameters	O	NOUN	B
collected	O	VERB	O
for	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
(	O	PUNCT	O
pt	O	NOUN	O
)	O	PUNCT	O
concerned	O	ADJ	O
operative	O	ADJ	B
time	O	NOUN	I
,	O	PUNCT	O
major	O	ADJ	O
and	O	CCONJ	O
minor	O	ADJ	B
complications	O	NOUN	B
,	O	PUNCT	O
conversion	O	NOUN	B
rate	O	NOUN	B
,	O	PUNCT	O
blood	O	NOUN	B
loss	O	NOUN	I
,	O	PUNCT	O
hospital	O	NOUN	B
stay	O	NOUN	I
and	O	CCONJ	O
histology	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	O
mortality	I-OUT	NOUN	B
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
right	O	ADJ	B
adrenalectomy	O	NOUN	I
mean	B-OUT	NOUN	O
operative	I-OUT	ADJ	O
time	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
OpT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
51.8	O	NUM	O
mins	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	O
40-90	O	NUM	O
mins	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
68.6	O	NUM	O
mins	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
50-130	O	ADJ	O
mins	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
B	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
left	B-OUT	ADJ	B
adrenalectomy	I-OUT	NOUN	I
mean	I-OUT	NOUN	B
OpT	I-OUT	NOUN	I
was	O	AUX	O
72.2	O	NUM	O
mins	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	O
55-100	O	NUM	O
mins	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
94	O	NUM	O
mins	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
65-140	O	NUM	O
mins	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
B	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
was	O	AUX	O
83	O	NUM	O
ml	O	NOUN	O
(	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
210	O	NUM	O
ml	O	NOUN	O
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Complications	O	NOUN	B
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	B
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
was	O	AUX	O
2.9	O	NUM	O
and	O	CCONJ	O
3.1	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
B	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
EBVS	O	NOUN	B
in	O	ADP	O
LA	O	PROPN	B
may	O	AUX	O
provide	O	VERB	O
a	O	DET	O
significantly	O	ADV	O
short	B-OUT	ADJ	O
operating	I-OUT	NOUN	O
time	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
loss	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Glibenclamide	B-I	NOUN	B
vs	I-I	CCONJ	O
gliclazide	I-I	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
of	I-P	ADP	O
noninsulin	I-P	NOUN	B
dependent	I-P	ADJ	O
diabetes	I-P	NOUN	B
mellitus	I-P	NOUN	I
--	I-P	PUNCT	O
a	I-P	DET	O
double	O	ADJ	O
blind	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
Parameters	O	NOUN	B
of	O	ADP	O
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
were	O	AUX	O
quantitated	O	VERB	B
in	O	ADP	O
50	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
mellitus	I-P	NOUN	I
in	I-P	ADP	O
uncontrolled	I-P	ADJ	B
state	I-P	NOUN	O
and	O	CCONJ	O
after	O	ADP	O
control	O	NOUN	B
using	O	VERB	O
oral	O	ADJ	B
glibenclamide	B-I	NOUN	I
or	I-I	CCONJ	O
gliclazide	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
estimates	O	NOUN	B
were	O	AUX	O
further	O	ADV	O
compared	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
irrespective	O	ADV	O
of	O	ADP	O
drug	O	NOUN	B
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
difference	O	NOUN	B
,	O	PUNCT	O
if	O	SCONJ	O
any	O	DET	O
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
uncontrolled	O	ADJ	B
,	O	PUNCT	O
noncrossover	O	ADJ	B
and	O	CCONJ	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Fifty	B-P	NUM	O
patients	I-P	NOUN	B
of	I-P	ADP	O
uncontrolled	I-P	ADJ	B
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
were	O	AUX	O
divided	O	VERB	O
in	O	ADP	O
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Group	O	PROPN	B
I	O	NUM	I
(	O	PUNCT	O
25	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
capsule	B-I	NOUN	B
A	I-I	NOUN	I
(	I-I	PUNCT	O
glibenclamide	I-I	NOUN	B
)	I-I	PUNCT	O
while	O	SCONJ	O
Group	O	PROPN	B
II	O	NUM	I
(	O	PUNCT	O
25	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
capsule	B-I	NOUN	B
B	I-I	NOUN	I
(	I-I	PUNCT	O
gliclazide	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


The	O	DET	O
parameters	O	NOUN	B
studied	O	VERB	O
were	O	AUX	O
Superoxide	B-OUT	NOUN	B
dismutase	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SOD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
malonyl-dialdehyde	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
MDA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
reduced	I-OUT	VERB	B
glutathione	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GSH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


They	O	PRON	O
were	O	AUX	O
done	O	VERB	O
at	O	ADP	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
uncontrolled	O	ADJ	O
stage	O	NOUN	O
(	O	PUNCT	O
FBS	O	NOUN	B
--	O	PUNCT	O
165	O	NUM	O
+/-	O	CCONJ	O
16.7	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
PP	O	NOUN	B
--	O	PUNCT	O
240	O	NUM	O
+/-	O	CCONJ	O
30.1	O	NUM	O
mg/dl	O	NOUN	O
and	O	CCONJ	O
HbA1	O	NOUN	B
--	O	PUNCT	O
10.5	O	NUM	O
+/-	O	CCONJ	O
0.9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
FBS	O	NOUN	B
--	O	PUNCT	O
150	O	NUM	O
+/-	O	CCONJ	O
15.8	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
PP	O	NOUN	B
--	O	PUNCT	O
246	O	NUM	O
+/-	O	CCONJ	O
29.1	O	NUM	O
mg/dl	O	NOUN	O
HbA1	O	NOUN	B
10.6	O	NUM	O
+/-	O	CCONJ	O
0.8	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
)	O	PUNCT	O
and	O	CCONJ	O
during	O	ADP	O
controlled	O	VERB	B
stage	O	NOUN	I
at	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
FBS	O	NOUN	B
--	O	PUNCT	O
120	O	NUM	O
+/-	O	CCONJ	O
18.5	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
PP	O	NOUN	B
--	O	PUNCT	O
180	O	NUM	O
+/-	O	CCONJ	O
19.1	O	NUM	O
mg/dl	O	NOUN	O
and	O	CCONJ	O
HbA1	O	NOUN	B
--	O	PUNCT	O
8.4	O	NUM	O
+/-	O	CCONJ	O
0.29	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
FBS	O	NOUN	B
--	O	PUNCT	O
118	O	NUM	O
+/-	O	CCONJ	O
17.6	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
PP	O	NOUN	B
--	O	PUNCT	O
176	O	NUM	O
+/-	O	CCONJ	O
20.1	O	NUM	O
mg/dl	O	NOUN	O
and	O	CCONJ	O
HbA1	O	NOUN	B
--	O	PUNCT	O
8.5	O	NUM	O
+/-	O	CCONJ	O
0.39	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
significantly	O	ADV	O
raised	O	VERB	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
MDA	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
SOD	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
decreased	O	VERB	B
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
reduced	I-OUT	VERB	B
glutathione	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
GSH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
during	O	ADP	O
uncontrolled	O	ADJ	B
stage	O	NOUN	B
of	O	ADP	O
diabetes	O	NOUN	B
indicated	O	VERB	O
free	O	ADJ	B
radical	O	ADJ	I
stress	O	NOUN	I
induced	O	VERB	B
lipid	O	NOUN	B
peroxidation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
significant	O	ADJ	O
fall	B-OUT	NOUN	B
of	I-OUT	ADP	O
MDA	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
SOD	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
increased	I-OUT	VERB	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
GSH	I-OUT	NOUN	B
in	I-OUT	ADP	O
blood	I-OUT	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
after	O	ADP	O
control	O	NOUN	B
revealed	O	VERB	O
beneficial	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
glycemic	O	ADJ	B
control	O	NOUN	I
on	O	ADP	O
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
levels	O	NOUN	B
were	O	AUX	O
not	O	PART	O
normalized	O	VERB	B
and	O	CCONJ	O
stayed	O	VERB	O
higher	O	ADJ	O
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
intergroup	O	NOUN	B
comparison	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	I
diabetes	O	NOUN	B
with	O	ADP	O
gliclazide	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
II	O	NUM	I
)	O	PUNCT	O
showed	O	VERB	O
improvement	O	NOUN	B
in	O	ADP	O
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
MDA	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
GSH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
better	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
glibenclamide	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
I	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
in	O	ADP	O
uncontrolled	O	ADJ	B
diabetes	O	NOUN	B
is	O	AUX	O
decreased	O	VERB	B
with	O	ADP	O
glycemic	O	ADJ	B
control	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
control	O	NOUN	B
of	O	ADP	I
diabetes	O	NOUN	B
with	O	ADP	O
gliclazide	B-I	NOUN	B
reduced	O	VERB	B
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
more	O	ADJ	O
than	O	ADP	O
glibenclamide	B-I	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
higher	O	ADJ	O
antioxidant	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
gliclazide	O	NOUN	B
.	O	PUNCT	O


Normalization	O	NOUN	B
of	O	ADP	O
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
achieved	O	VERB	O
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
required	O	VERB	O
to	O	PART	O
see	O	VERB	O
long-term	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
combating	O	VERB	O
oxidative	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
after	O	ADP	O
achieving	O	VERB	O
acceptable	O	ADJ	O
control	O	NOUN	B
of	O	ADP	O
diabetes	O	NOUN	B
.	O	PUNCT	O


Expectancies	O	NOUN	B
,	O	PUNCT	O
not	O	PART	O
aroma	O	NOUN	B
,	O	PUNCT	O
explain	O	VERB	O
impact	O	NOUN	B
of	O	ADP	O
lavender	B-I	ADJ	B
aromatherapy	I-I	NOUN	I
on	O	ADP	O
psychophysiological	O	ADJ	B
indices	O	NOUN	I
of	O	ADP	O
relaxation	O	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
healthy	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVES	O	NOUN	O
In	O	ADP	O
aromatherapy	B-I	NOUN	B
,	I-I	PUNCT	O
lavender	I-I	ADJ	B
aroma	I-I	NOUN	B
is	O	AUX	O
reputed	O	ADJ	O
to	O	PART	O
assist	O	VERB	O
with	O	ADP	O
relaxation	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
much	O	ADV	O
anecdotal	O	ADJ	B
evidence	O	NOUN	B
to	O	PART	O
that	O	DET	O
effect	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
empirical	O	ADJ	B
literature	O	NOUN	I
is	O	AUX	O
very	O	ADV	O
inconsistent	O	ADJ	B
.	O	PUNCT	O


Failure	O	NOUN	B
to	O	PART	O
employ	O	VERB	O
adequate	O	ADJ	B
placebos	B-I	NOUN	B
,	O	PUNCT	O
proper	O	ADJ	O
blinding	O	NOUN	B
,	O	PUNCT	O
objective	O	ADJ	O
measures	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
screening	O	NOUN	B
of	O	ADP	O
prior	O	ADJ	B
beliefs	O	NOUN	I
about	O	ADP	O
aromatherapy	O	NOUN	B
means	O	VERB	O
that	O	SCONJ	O
many	O	ADJ	O
previous	O	ADJ	O
findings	O	NOUN	B
could	O	AUX	O
have	O	AUX	O
been	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
expectancy	O	NOUN	B
biases	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
establish	O	VERB	O
whether	O	SCONJ	O
lavender	B-I	ADJ	B
aroma	I-I	NOUN	B
and/or	O	CCONJ	O
expectancies	O	NOUN	B
affect	O	VERB	O
post-stress	O	ADJ	B
relaxation	O	NOUN	B
.	O	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
3	O	NUM	O
(	O	PUNCT	O
aroma	O	NOUN	B
)	O	PUNCT	O
x	O	NOUN	O
3	O	NUM	O
(	O	PUNCT	O
instruction	O	NOUN	B
)	O	PUNCT	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
time	O	NOUN	O
in	O	ADP	O
minutes	O	NOUN	B
)	O	PUNCT	O
mixed-factorial	B-I	ADJ	O
placebo-controlled	I-I	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


METHOD	O	NOUN	O
In	O	ADP	O
a	O	DET	O
laboratory	O	NOUN	B
,	O	PUNCT	O
96	B-P	NUM	O
healthy	I-P	ADJ	B
undergraduate	I-P	NOUN	B
women	I-P	NOUN	B
were	O	AUX	O
exposed	B-I	VERB	O
to	I-I	ADP	O
lavender	I-I	ADJ	B
,	I-I	PUNCT	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
no	I-I	DET	O
aroma	I-I	NOUN	B
during	O	ADP	O
physiologically	O	ADV	B
assessed	O	VERB	B
relaxation	O	NOUN	B
after	O	ADP	O
an	O	DET	O
arousing	O	ADJ	O
cognitive	B-I	ADJ	B
task	I-I	NOUN	I
.	I-I	PUNCT	O


Where	O	SCONJ	O
an	O	DET	O
aroma	O	NOUN	B
was	O	AUX	O
presented	O	VERB	O
,	O	PUNCT	O
an	O	DET	O
instructional	O	ADJ	B
priming	O	NOUN	B
procedure	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
manipulate	O	VERB	O
participants	O	NOUN	B
'	O	PART	O
expectancies	O	NOUN	B
about	O	ADP	O
the	O	DET	O
aroma	O	NOUN	B
's	O	PART	O
likely	O	ADJ	O
impact	O	VERB	B
on	O	ADP	O
their	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
relax	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
Results	O	NOUN	I
showed	O	VERB	O
no	O	DET	O
effect	O	NOUN	O
of	O	ADP	O
aroma	B-OUT	NOUN	B
on	I-OUT	ADP	O
galvanic	I-OUT	ADJ	B
skin	I-OUT	NOUN	I
response	I-OUT	NOUN	I
during	O	ADP	O
relaxation	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
nature	O	NOUN	O
of	O	ADP	O
instructional	O	ADJ	B
prime	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
relaxation	B-OUT	NOUN	B
patterns	I-OUT	NOUN	O
:	I-OUT	PUNCT	O
when	O	SCONJ	O
expecting	O	VERB	O
the	O	DET	O
aroma	O	NOUN	B
to	O	PART	O
inhibit	O	VERB	B
them	O	PRON	O
,	O	PUNCT	O
participants	O	NOUN	B
relaxed	B-OUT	VERB	O
more	O	ADV	O
;	O	PUNCT	O
when	O	SCONJ	O
expecting	O	VERB	O
facilitation	O	NOUN	B
,	O	PUNCT	O
participants	O	NOUN	B
relaxed	B-OUT	VERB	B
less	O	ADV	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
not	O	PART	O
seen	O	VERB	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
self-reported	B-OUT	ADJ	B
relaxation	I-OUT	NOUN	B
(	O	PUNCT	O
as	O	ADP	O
represented	O	VERB	O
by	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
state	O	NOUN	B
anxiety	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
independent	O	ADJ	B
of	O	ADP	O
ratings	O	NOUN	B
of	O	ADP	O
attitudes	B-OUT	NOUN	B
towards	O	ADP	O
aromatherapy	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
findings	O	NOUN	B
imply	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
previous	O	ADJ	O
associations	O	NOUN	B
of	O	ADP	O
lavender	B-I	ADJ	B
aroma	I-I	NOUN	B
with	O	ADP	O
assisted	O	ADJ	B
relaxation	O	NOUN	O
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
expectancy	O	NOUN	B
biases	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
relevant	O	ADJ	B
expectancies	O	NOUN	B
are	O	AUX	O
easily	O	ADV	O
manipulable	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
fenbendazole	B-I	NOUN	B
oral	O	ADJ	B
drench	O	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
an	O	DET	O
ivermectin	B-I	NOUN	B
pour-on	O	NOUN	B
reduces	B-OUT	VERB	B
parasite	I-OUT	ADJ	B
burden	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
improves	I-OUT	VERB	B
feedlot	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
carcass	I-OUT	NOUN	B
performance	I-OUT	NOUN	B
of	O	ADP	O
finishing	B-P	VERB	B
heifers	I-P	NOUN	B
compared	O	VERB	B
with	O	ADP	O
endectocides	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Two	O	NUM	O
studies	O	NOUN	B
utilizing	O	VERB	O
1,862	B-P	NUM	O
yearling	I-P	VERB	B
heifers	I-P	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
fenbendazole	B-I	NOUN	B
oral	I-I	ADJ	B
drench	I-I	NOUN	B
in	I-I	ADP	O
addition	I-I	NOUN	O
to	I-I	PART	O
an	I-I	DET	O
ivermectin	I-I	NOUN	B
pour-on	I-I	NOUN	B
(	I-I	PUNCT	O
SG+IVPO	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
an	O	DET	O
ivermectin	B-I	NOUN	B
pour-on	I-I	NOUN	B
(	I-I	PUNCT	O
IVPO	I-I	NOUN	B
)	I-I	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
doramectin	B-I	NOUN	B
injectable	I-I	ADJ	O
(	I-I	PUNCT	O
DMX	I-I	NOUN	B
)	I-I	PUNCT	O
alone	I-I	ADV	O
,	O	PUNCT	O
on	O	ADP	O
parasite	B-OUT	ADJ	B
burden	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
feedlot	I-OUT	NOUN	B
performance	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
carcass	B-OUT	NOUN	B
merit	I-OUT	NOUN	O
of	I-OUT	ADP	O
feedlot	I-OUT	NOUN	B
cattle	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
first	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
heifers	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
SG+IVPO	O	NOUN	B
had	O	AUX	O
fewer	B-OUT	ADJ	O
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.02	I-OUT	NUM	O
)	I-OUT	PUNCT	O
cattle	I-OUT	NOUN	B
retreated	I-OUT	VERB	O
for	I-OUT	ADP	O
disease	I-OUT	NOUN	B
and	O	CCONJ	O
73	O	NUM	O
%	O	NOUN	O
fewer	B-OUT	ADJ	O
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.06	I-OUT	NUM	O
)	I-OUT	PUNCT	O
worm	I-OUT	NOUN	B
eggs	I-OUT	NOUN	B
per	I-OUT	ADP	O
fecal	I-OUT	ADJ	B
sample	I-OUT	NOUN	O
98	O	NUM	O
d	O	NOUN	O
after	O	ADP	O
treatment	O	NOUN	B
than	O	ADP	O
heifers	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
IVPO	O	NOUN	B
.	O	PUNCT	O


Heifers	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
SG+IVPO	O	NOUN	B
consumed	O	VERB	O
more	B-OUT	ADJ	O
DM	I-OUT	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
greater	B-OUT	ADJ	O
ADG	I-OUT	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
heavier	B-OUT	ADJ	B
at	I-OUT	ADP	O
slaughter	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
heavier	B-OUT	ADJ	O
carcasses	I-OUT	NOUN	B
than	O	ADP	O
IVPO-treated	O	ADJ	B
heifers	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Heifers	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
SG+IVPO	O	NOUN	B
also	O	ADV	O
had	O	AUX	O
more	B-OUT	ADJ	O
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.07	I-OUT	NUM	O
)	I-OUT	PUNCT	O
carcasses	I-OUT	NOUN	B
grading	O	VERB	O
USDA	B-OUT	PROPN	O
Prime	I-OUT	PROPN	O
or	I-OUT	CCONJ	O
Choice	I-OUT	NOUN	B
than	O	ADP	O
IVPO-treated	O	ADJ	B
heifers	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
second	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
heifers	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
SG+IVPO	O	NOUN	B
had	O	AUX	O
fewer	B-OUT	ADJ	O
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	PART	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
worm	I-OUT	NOUN	B
eggs	I-OUT	NOUN	B
per	I-OUT	ADP	O
fecal	I-OUT	ADJ	B
sample	I-OUT	NOUN	O
35	O	NUM	O
d	O	NOUN	O
after	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
fewer	O	ADJ	O
numbers	B-OUT	NOUN	O
of	I-OUT	ADP	O
adult	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
larval	I-OUT	NOUN	B
Cooperia	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
Trichostrongylus	I-OUT	NOUN	B
spp	I-OUT	X	I
.	I-OUT	PUNCT	O


in	B-OUT	ADP	O
the	I-OUT	DET	O
small	I-OUT	ADJ	B
intestine	I-OUT	NOUN	I
at	O	ADP	O
slaughter	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.10	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
heifers	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
DMX	O	NOUN	B
.	O	PUNCT	O


Heifers	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
SG+IVPO	O	NOUN	B
consumed	O	VERB	O
more	O	ADJ	O
DM	B-OUT	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
heavier	O	ADJ	B
at	O	ADP	O
slaughter	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
heavier	O	ADJ	O
carcasses	O	NOUN	B
than	O	ADP	O
DMX-treated	O	ADJ	B
heifers	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
SG+IVPO-treated	B-I	ADJ	B
heifers	O	NOUN	B
also	O	ADV	O
had	O	AUX	O
greater	B-OUT	ADJ	O
ADG	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.10	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
broad-spectrum	O	ADJ	B
effectiveness	O	NOUN	I
of	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
a	O	DET	O
fenbendazole	O	NOUN	B
oral	O	ADJ	B
drench	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
ivermectin	O	NOUN	B
pour-on	O	NOUN	B
reduced	O	VERB	B
parasite	B-OUT	ADJ	B
burden	I-OUT	NOUN	B
and	O	CCONJ	O
increased	B-OUT	VERB	B
feed	I-OUT	NOUN	B
intake	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
ADG	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
carcass	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
in	O	ADP	O
feedlot	B-P	NOUN	B
heifers	I-P	NOUN	I
compared	O	VERB	B
with	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
an	O	DET	O
endectocide	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Pilot	O	NOUN	B
comparison	O	NOUN	O
between	O	ADP	O
potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
laser	I-I	NOUN	I
and	I-I	CCONJ	O
bipolar	I-I	ADJ	B
radiofrequency	I-I	NOUN	I
in	O	ADP	O
paediatric	B-P	ADJ	B
tonsillectomy	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
advantages	O	NOUN	O
and	O	CCONJ	O
disadvantages	O	NOUN	B
of	O	ADP	O
potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
laser	I-I	NOUN	I
with	I-I	ADP	O
those	I-I	DET	O
of	I-I	ADP	O
bipolar	I-I	ADJ	B
radiofrequency	I-I	NOUN	I
techniques	I-I	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
paediatric	B-OUT	ADJ	B
tonsillectomy	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


STUDY	O	NOUN	B
DESIGN	O	VERB	I
Prospective	O	ADJ	I
,	O	PUNCT	O
randomised	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
From	B-P	ADP	O
July	I-P	PROPN	O
2004	I-P	NUM	O
to	I-P	ADP	O
April	I-P	PROPN	O
2006	I-P	NUM	O
,	I-P	PUNCT	O
80	I-P	NUM	O
patients	I-P	NOUN	B
aged	I-P	ADJ	B
between	I-P	ADP	O
10	I-P	NUM	O
and	I-P	CCONJ	O
15	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
tonsillectomy	I-I	NOUN	B
planned	I-P	VERB	B
for	I-P	ADP	O
chronic	I-P	ADJ	B
tonsillitis	I-P	NOUN	I
,	I-P	PUNCT	O
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Children	O	NOUN	B
were	O	AUX	O
prospectively	O	ADV	O
randomised	O	VERB	B
into	O	ADP	O
two	O	NUM	O
equal	O	ADJ	O
groups	O	NOUN	B
:	O	PUNCT	O
potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
laser	I-I	NOUN	I
tonsillectomy	I-I	NOUN	I
and	I-I	CCONJ	O
bipolar	I-I	ADJ	B
radiofrequency	I-I	NOUN	I
tonsillectomy	I-I	NOUN	I
.	I-I	PUNCT	O


Operative	O	ADJ	B
time	O	NOUN	I
and	O	CCONJ	O
intra-operative	O	ADJ	B
blood	O	NOUN	I
loss	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
scheduled	O	VERB	O
for	O	ADP	O
follow	O	VERB	B
up	O	ADP	I
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
,	O	PUNCT	O
second	O	ADJ	O
and	O	CCONJ	O
fourth	O	ADJ	O
post-operative	O	ADJ	B
weeks	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
asked	O	VERB	O
to	O	PART	O
record	O	VERB	B
their	O	PRON	O
pain	O	NOUN	B
and	O	CCONJ	O
discomfort	O	NOUN	B
on	O	ADP	O
a	O	DET	O
standardised	O	ADJ	B
visual	O	ADJ	O
analogue	O	NOUN	O
scale	O	NOUN	O
,	O	PUNCT	O
from	O	ADP	O
zero	O	NUM	O
(	O	PUNCT	O
no	O	DET	B
pain	O	NOUN	I
)	O	PUNCT	O
to	O	PART	O
10	O	NUM	O
(	O	PUNCT	O
severe	O	ADJ	B
pain	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Post-operative	O	ADJ	B
complications	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
recorded	O	VERB	O
and	O	CCONJ	O
managed	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
laser	I-I	NOUN	I
group	I-I	NOUN	O
showed	O	VERB	O
a	O	DET	O
slightly	O	ADV	O
longer	B-OUT	ADV	O
operative	I-OUT	ADJ	B
time	I-OUT	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
12	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
the	O	DET	O
bipolar	O	ADJ	B
radiofrequency	O	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
10	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Intra-operative	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
in	O	ADP	O
the	O	DET	O
potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
laser	I-I	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
21	O	NUM	O
cm3	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
bipolar	B-I	ADJ	B
radiofrequency	I-I	NOUN	I
group	I-I	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
30	O	NUM	O
cm3	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
first	O	ADJ	O
week	O	NOUN	B
,	O	PUNCT	O
post-operative	B-OUT	ADJ	B
pain	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
were	O	AUX	O
less	O	ADJ	O
in	O	ADP	O
the	O	DET	O
potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
laser	I-I	NOUN	I
group	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
bipolar	O	ADJ	B
radiofrequency	O	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
means	O	VERB	O
7.5	O	NUM	O
and	O	CCONJ	O
8.5	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
week	O	NOUN	B
pain	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
increased	O	VERB	B
more	O	ADV	O
in	O	ADP	O
the	O	DET	O
potassium	O	NOUN	B
titanyl	O	NOUN	I
phosphate	O	NOUN	I
laser	O	NOUN	I
group	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
bipolar	O	ADJ	B
radiofrequency	O	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
means	O	VERB	O
8.5	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
fourth	O	ADJ	O
week	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
groups	O	NOUN	B
showed	O	VERB	O
equal	O	ADJ	O
and	O	CCONJ	O
nearly	O	ADV	O
normal	O	ADJ	B
pain	B-OUT	NOUN	I
scores	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


No	O	DET	O
case	O	NOUN	O
of	O	ADP	O
reactionary	B-OUT	ADJ	B
post-tonsillectomy	I-OUT	ADJ	I
haemorrhage	I-OUT	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


Only	O	ADV	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
secondary	B-OUT	ADJ	B
post-tonsillectomy	I-OUT	ADJ	B
haemorrhage	I-OUT	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
potassium	O	NOUN	B
titanyl	O	NOUN	I
phosphate	O	NOUN	I
laser	O	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
2.5	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
managed	O	VERB	O
conservatively	O	ADV	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Both	O	CCONJ	O
the	O	DET	O
potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
and	I-I	CCONJ	O
the	I-I	DET	O
bipolar	I-I	ADJ	B
radiofrequency	I-I	NOUN	I
techniques	I-I	NOUN	I
were	O	AUX	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
easy	I-OUT	ADJ	O
to	I-OUT	PART	O
use	I-OUT	VERB	O
for	O	ADP	O
tonsillectomy	B-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
reduced	O	VERB	B
operative	B-OUT	ADJ	B
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
loss	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
complication	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
and	O	CCONJ	O
better	O	ADV	O
post-operative	O	ADJ	B
general	O	ADJ	B
patient	O	NOUN	I
condition	O	NOUN	I
.	O	PUNCT	O


Potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
laser	I-I	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
reduced	O	VERB	B
operative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
immediate	I-OUT	ADJ	O
post-operative	I-OUT	ADJ	B
pain	I-OUT	NOUN	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
bipolar	O	ADJ	B
radiofrequency	O	NOUN	I
technique	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
potassium	B-I	NOUN	B
titanyl	I-I	NOUN	I
phosphate	I-I	NOUN	I
laser	I-I	NOUN	I
required	O	VERB	O
slightly	O	ADV	O
more	O	ADV	O
operative	B-OUT	ADJ	B
time	I-OUT	NOUN	I
and	O	CCONJ	O
caused	O	VERB	O
more	O	ADV	O
late	B-OUT	ADJ	O
post-operative	I-OUT	ADJ	B
pain	I-OUT	NOUN	O
than	O	ADP	O
the	O	DET	O
bipolar	O	ADJ	B
radiofrequency	O	NOUN	I
technique	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
low	O	ADJ	B
rate	O	NOUN	B
of	O	ADP	O
recorded	O	VERB	O
complications	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
techniques	O	NOUN	B
cause	O	VERB	O
little	O	ADJ	O
damage	O	NOUN	B
to	O	ADP	O
the	O	DET	O
tonsillar	O	ADJ	B
bed	O	NOUN	I
during	O	ADP	O
dissection	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
minimising	O	VERB	O
complications	O	NOUN	B
.	O	PUNCT	O


Improving	O	VERB	B
maternal	B-OUT	ADJ	B
mental	I-OUT	ADJ	B
health	I-OUT	NOUN	I
after	I-P	ADP	O
a	I-P	DET	O
child	I-P	NOUN	B
's	I-P	PART	I
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


IMPORTANCE	O	VERB	O
The	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
psychological	O	ADJ	B
distress	O	NOUN	I
among	O	ADP	O
mothers	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
suggests	O	VERB	O
a	O	DET	O
need	O	NOUN	O
for	O	ADP	O
interventions	O	NOUN	B
that	O	PRON	O
address	O	VERB	O
parental	B-OUT	ADJ	B
mental	I-OUT	ADJ	B
health	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
critical	O	ADJ	O
period	O	NOUN	B
after	O	ADP	O
the	O	DET	O
child	O	NOUN	B
's	O	PART	I
autism	O	NOUN	B
diagnosis	O	NOUN	B
when	O	SCONJ	O
parents	O	NOUN	B
are	O	AUX	O
learning	O	VERB	B
to	O	PART	O
navigate	O	VERB	O
the	O	DET	O
complex	O	ADJ	B
system	O	NOUN	B
of	O	ADP	O
autism	O	NOUN	B
services	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
a	O	DET	O
brief	O	ADJ	O
cognitive	O	ADJ	B
behavioral	O	ADJ	O
intervention	O	NOUN	B
,	O	PUNCT	O
problem-solving	B-I	ADJ	B
education	I-I	NOUN	I
(	I-I	PUNCT	O
PSE	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
decreases	O	VERB	B
parenting	B-OUT	NOUN	B
stress	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
maternal	I-OUT	ADJ	B
depressive	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
period	O	NOUN	B
immediately	O	ADV	O
following	O	VERB	O
a	O	DET	O
child	O	NOUN	B
's	O	PART	I
diagnosis	O	NOUN	B
of	O	ADP	O
ASD	O	PROPN	B
.	O	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
AND	O	CCONJ	O
PARTICIPANTS	O	NOUN	B
A	O	DET	I
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
compared	O	VERB	O
6	O	NUM	O
sessions	O	NOUN	B
of	O	ADP	O
PSE	B-I	NOUN	B
with	O	ADP	O
usual	B-I	ADJ	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


Settings	O	NOUN	O
included	O	VERB	O
an	O	DET	O
autism	B-P	NOUN	B
clinic	I-P	NOUN	I
and	I-P	CCONJ	O
6	I-P	NUM	O
community-based	I-P	ADJ	B
early	I-P	ADJ	O
intervention	I-P	NOUN	O
programs	I-P	NOUN	O
that	I-P	PRON	O
primarily	I-P	ADV	O
serve	I-P	VERB	O
low-income	I-P	ADJ	B
families	I-P	NOUN	B
.	I-P	PUNCT	O


Participants	B-P	NOUN	B
were	I-P	AUX	O
mothers	I-P	NOUN	B
of	I-P	ADP	O
122	I-P	NUM	O
young	I-P	ADJ	B
children	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	NOUN	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
34	I-P	NUM	O
months	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
recently	I-P	ADV	O
received	I-P	VERB	O
a	I-P	DET	O
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Among	O	ADP	O
mothers	O	NOUN	B
assessed	O	VERB	B
for	O	ADP	O
eligibility	O	NOUN	B
,	O	PUNCT	O
17.0	O	NUM	O
%	O	NOUN	O
declined	O	VERB	B
participation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	B
outcomes	O	NOUN	B
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
(	O	PUNCT	O
immediate	O	ADJ	O
postdiagnosis	O	NOUN	B
period	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


INTERVENTIONS	O	NOUN	B
Problem-solving	B-I	VERB	B
education	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
brief	O	ADJ	O
,	O	PUNCT	O
cognitive	O	ADJ	B
intervention	O	NOUN	I
delivered	O	VERB	O
in	O	ADP	O
six	O	NUM	O
30-minute	B-I	ADJ	O
individualized	I-I	ADJ	B
sessions	I-I	NOUN	B
by	I-I	ADP	O
existing	I-I	VERB	O
staff	I-I	NOUN	B
(	O	PUNCT	O
early	O	ADJ	O
intervention	O	NOUN	O
programs	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
research	B-I	NOUN	B
staff	I-I	NOUN	I
without	I-I	ADP	O
formal	I-I	ADJ	O
mental	I-I	ADJ	B
health	I-I	NOUN	I
training	I-I	NOUN	I
(	O	PUNCT	O
autism	O	NOUN	B
clinic	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


MAIN	O	ADJ	O
OUTCOMES	O	NOUN	O
AND	O	CCONJ	O
MEASURES	O	ADJ	O
Primary	O	ADJ	B
outcomes	O	NOUN	I
were	O	AUX	O
parental	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
maternal	I-OUT	ADJ	B
depressive	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Fifty-nine	B-P	NUM	B
mothers	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
PSE	B-I	NOUN	B
and	O	CCONJ	O
63	O	NUM	O
to	O	PART	O
receive	O	VERB	O
usual	B-I	ADJ	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
follow-up	O	ADJ	B
rate	O	NOUN	B
was	O	AUX	O
91.0	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Most	O	ADJ	O
intervention	O	NOUN	B
mothers	O	NOUN	O
(	O	PUNCT	O
78.0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
received	O	VERB	O
the	O	DET	O
full	O	ADJ	O
PSE	B-I	NOUN	B
course	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
3-month	O	ADJ	O
follow-up	O	ADJ	B
assessment	O	NOUN	B
,	O	PUNCT	O
PSE	B-I	NOUN	B
mothers	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
less	O	ADV	O
likely	O	ADJ	O
than	O	ADP	O
those	O	DET	O
serving	O	VERB	O
as	O	ADP	O
controls	O	NOUN	B
to	O	PART	O
have	O	AUX	O
clinically	O	ADV	B
significant	O	ADJ	I
parental	B-OUT	ADJ	B
stress	I-OUT	NOUN	I
(	O	PUNCT	O
3.8	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
29.3	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
adjusted	O	VERB	O
relative	O	ADJ	B
risk	O	NOUN	I
[	O	PUNCT	O
aRR	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
0.17	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.04	O	NUM	O
to	O	PART	O
0.65	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
,	O	PUNCT	O
the	O	DET	O
risk	O	NOUN	B
reduction	O	NOUN	I
in	O	ADP	O
clinically	O	ADV	B
significant	O	ADJ	I
symptoms	O	NOUN	B
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
statistical	O	ADJ	B
significance	O	NOUN	I
(	O	PUNCT	O
5.7	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
22.4	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
aRR	O	NOUN	B
,	O	PUNCT	O
0.33	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.10	O	NUM	O
to	O	PART	O
1.08	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
mean	O	ADJ	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
Quick	O	PROPN	B
Inventory	O	PROPN	I
of	O	ADP	I
Depressive	O	ADJ	I
Symptomatology	O	NOUN	I
score	O	NOUN	I
,	O	PUNCT	O
4.6	O	NUM	O
with	O	ADP	O
PSE	O	NOUN	B
vs	O	CCONJ	O
6.9	O	NUM	O
with	O	ADP	O
usual	O	ADJ	B
care	O	NOUN	I
;	O	PUNCT	O
adjusted	O	VERB	O
mean	O	NOUN	O
difference	O	NOUN	O
,	O	PUNCT	O
-1.67	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
-3.17	O	NUM	O
to	O	PART	O
-0.18	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
AND	O	CCONJ	O
RELEVANCE	O	NOUN	B
The	O	DET	O
positive	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
PSE	B-I	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
parenting	B-OUT	NOUN	B
stress	I-OUT	NOUN	I
and	O	CCONJ	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
critical	O	ADJ	B
postdiagnosis	O	NOUN	I
period	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
parents	O	NOUN	B
are	O	AUX	O
asked	O	VERB	O
to	O	PART	O
navigate	O	VERB	O
a	O	DET	O
complex	O	ADJ	B
service	O	NOUN	O
delivery	O	NOUN	O
system	O	NOUN	O
,	O	PUNCT	O
suggest	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
place	O	NOUN	O
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
work	O	NOUN	O
will	O	AUX	O
monitor	O	VERB	O
these	O	DET	O
families	O	NOUN	B
for	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
9	O	NUM	O
months	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
trajectory	O	NOUN	B
of	O	ADP	O
outcomes	O	NOUN	B
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
clinicaltrials.gov	O	NOUN	O
Identifier	O	NOUN	O
:	O	PUNCT	O
NCT01021384	O	NOUN	O
.	O	PUNCT	O


Continuous	B-I	ADJ	B
thoracic	I-I	ADJ	I
epidural	I-I	ADJ	I
analgesia	I-I	NOUN	I
for	O	ADP	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
relief	I-OUT	NOUN	O
following	I-P	VERB	O
thoracotomy	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
prospective	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


Optimum	O	ADJ	B
frequency	O	NOUN	I
of	O	ADP	O
exercise	B-I	NOUN	B
for	O	ADP	O
bone	B-OUT	NOUN	B
health	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
randomised	O	VERB	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
high-impact	B-P	ADJ	B
unilateral	I-P	ADJ	I
intervention	I-P	NOUN	B
.	I-P	PUNCT	O


INTRODUCTION	O	PROPN	O
Exercise	B-I	NOUN	B
can	O	AUX	O
increase	O	VERB	B
bone	B-OUT	NOUN	B
strength	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
reducing	O	VERB	B
fracture	B-OUT	NOUN	B
risk	I-OUT	NOUN	I
,	O	PUNCT	O
exercise	B-I	NOUN	B
must	O	AUX	O
be	O	AUX	O
feasible	O	ADJ	O
enough	O	ADJ	O
to	O	PART	O
be	O	AUX	O
adopted	O	VERB	O
into	O	ADP	O
daily	O	ADJ	B
life	O	NOUN	O
and	O	CCONJ	O
influence	O	VERB	B
potentially	O	ADV	O
vulnerable	O	ADJ	B
skeletal	O	ADJ	B
sites	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
the	O	DET	O
superolateral	O	ADJ	B
cortex	O	NOUN	I
of	O	ADP	O
the	O	DET	O
femoral	O	ADJ	B
neck	O	NOUN	I
,	O	PUNCT	O
where	O	SCONJ	O
thinning	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
fracture	B-OUT	NOUN	B
risk	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Brief	B-I	NOUN	B
,	I-I	PUNCT	O
high-impact	I-I	ADJ	B
exercise	I-I	NOUN	I
increases	O	VERB	B
femoral	B-OUT	ADJ	B
neck	I-OUT	NOUN	I
bone	I-OUT	NOUN	O
density	I-OUT	NOUN	O
but	O	CCONJ	O
the	O	DET	O
optimal	O	ADJ	B
frequency	O	NOUN	B
of	O	ADP	O
such	O	ADJ	O
exercise	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
bone	O	NOUN	B
accrual	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
thus	O	ADV	O
examined	O	VERB	B
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
weekly	O	ADJ	B
frequencies	O	NOUN	B
of	O	ADP	O
exercise	O	NOUN	B
on	O	ADP	O
femoral	B-OUT	ADJ	B
neck	I-OUT	NOUN	I
BMD	I-OUT	NOUN	I
and	O	CCONJ	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
whether	B-OUT	SCONJ	O
BMD	I-OUT	NOUN	B
change	I-OUT	NOUN	B
differed	I-OUT	VERB	O
between	I-OUT	ADP	O
hip	I-OUT	NOUN	B
sites	I-OUT	NOUN	I
using	O	VERB	O
a	O	DET	O
high-impact	O	ADJ	B
,	O	PUNCT	O
unilateral	O	ADJ	B
intervention	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Healthy	B-P	ADJ	B
premenopausal	I-P	ADJ	B
women	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
exercise	B-I	VERB	B
0	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
7	O	NUM	O
days/week	O	NOUN	B
for	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
exercise	B-I	NOUN	B
intervention	I-I	NOUN	B
incorporated	O	VERB	O
50	O	NUM	O
multidirectional	O	ADJ	B
hops	O	NOUN	I
on	O	ADP	O
one	O	NUM	O
randomly	O	ADV	O
selected	O	VERB	O
leg	O	NOUN	B
.	O	PUNCT	O


BMD	B-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	O
by	O	ADP	O
DXA	O	PROPN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
exercise	O	NOUN	B
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
exercise	O	NOUN	B
leg	O	NOUN	I
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
using	O	VERB	O
ANCOVA	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
change	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
leg	O	NOUN	I
and	O	CCONJ	O
baseline	O	NOUN	B
BMD	O	NOUN	B
as	O	ADP	O
covariates	O	NOUN	B
.	O	PUNCT	O


RM-MANOVA	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
bone	B-OUT	NOUN	B
changes	I-OUT	NOUN	B
from	O	ADP	O
exercise	B-I	NOUN	B
differed	O	VERB	O
between	O	ADP	O
hip	O	NOUN	B
sites	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
61	B-P	NUM	O
women	I-P	NOUN	B
(	I-P	PUNCT	O
age	I-P	NOUN	B
33.6+/-11.1	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
completed	I-P	VERB	O
the	I-P	DET	O
intervention	I-P	NOUN	B
.	I-P	PUNCT	O


Compliance	O	NOUN	B
amongst	O	ADP	O
exercisers	O	NOUN	B
was	O	AUX	O
86.7+/-10.6	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Peak	B-OUT	ADJ	B
ground	I-OUT	NOUN	I
reaction	I-OUT	NOUN	I
forces	I-OUT	NOUN	I
during	O	ADP	O
exercise	O	NOUN	B
increased	O	VERB	B
from	O	ADP	O
2.5	O	NUM	O
to	O	PART	O
2.8	O	NUM	O
times	O	NOUN	O
body	O	NOUN	B
weight	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
change	B-OUT	NOUN	O
in	I-OUT	ADP	O
femoral	I-OUT	ADJ	B
neck	I-OUT	NOUN	I
BMD	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
exercise	B-I	NOUN	B
limb	O	NOUN	I
(	O	PUNCT	O
adjusted	O	VERB	O
for	O	ADP	O
change	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	ADJ	B
limb	O	NOUN	I
and	O	CCONJ	O
baseline	O	NOUN	B
BMD	O	NOUN	B
)	O	PUNCT	O
differed	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
(	O	PUNCT	O
p=0.015	O	PROPN	O
)	O	PUNCT	O
,	O	PUNCT	O
being	O	AUX	O
-0.3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
-1.2	O	NUM	O
to	O	PART	O
0.6	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
0.0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
-1.0	O	NUM	O
to	O	PART	O
1.0	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
0.9	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
-0.1	O	NUM	O
to	O	PART	O
2.0	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
1.8	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
0.8	O	NUM	O
to	O	PART	O
2.8	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
those	O	DET	O
exercising	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
and	O	CCONJ	O
7	O	NUM	O
days	O	NOUN	B
per	O	ADP	O
week	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


When	O	SCONJ	O
BMD	B-OUT	NOUN	B
changes	I-OUT	VERB	B
at	I-OUT	ADP	O
upper	I-OUT	ADJ	B
neck	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
lower	I-OUT	ADJ	B
neck	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
trochanter	I-OUT	NOUN	B
were	O	AUX	O
compared	O	VERB	O
using	O	VERB	O
RM-MANOVA	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
exercise	O	NOUN	B
effect	O	NOUN	O
was	O	AUX	O
observed	O	VERB	B
(	O	PUNCT	O
p=0.048	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
sites	O	NOUN	B
(	O	PUNCT	O
p=0.439	O	ADJ	O
)	O	PUNCT	O
despite	O	SCONJ	O
greatest	O	ADJ	O
mean	O	NOUN	O
increases	O	NOUN	B
at	O	ADP	O
the	O	DET	O
upper	O	ADJ	B
femoral	O	ADJ	I
neck	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Brief	O	NOUN	B
,	O	PUNCT	O
daily	O	ADV	B
hopping	O	NOUN	I
exercises	B-I	NOUN	I
increased	O	VERB	B
femoral	B-OUT	ADJ	B
neck	I-OUT	NOUN	I
BMD	I-OUT	NOUN	O
in	O	ADP	O
premenopausal	B-P	ADJ	B
women	I-P	NOUN	B
but	O	CCONJ	O
less	O	ADV	O
frequent	O	ADJ	B
exercise	O	NOUN	B
was	O	AUX	O
not	O	PART	O
effective	O	ADJ	B
.	O	PUNCT	O


Brief	B-I	ADJ	O
high-impact	I-I	ADJ	O
exercise	I-I	NOUN	O
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
reducing	O	VERB	B
hip	B-OUT	NOUN	B
fragility	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
may	O	AUX	O
need	O	VERB	O
to	O	PART	O
be	O	AUX	O
performed	O	VERB	O
frequently	O	ADV	O
for	O	ADP	O
optimal	O	ADJ	B
response	O	NOUN	B
.	O	PUNCT	O


Basal	B-P	ADJ	B
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
face	I-P	NOUN	B
:	I-P	PUNCT	O
surgery	I-I	NOUN	B
or	I-I	CCONJ	O
radiotherapy	I-I	NOUN	B
?	O	PUNCT	O
Results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Time	O	NOUN	B
intervals	O	NOUN	I
production	O	NOUN	B
in	O	ADP	O
tapping	B-P	NOUN	B
and	O	CCONJ	O
oscillatory	B-P	ADJ	B
motion	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
applied	O	VERB	O
spectral	B-I	ADJ	B
analysis	I-I	NOUN	I
on	O	ADP	O
series	O	NOUN	O
of	O	ADP	O
time	O	NOUN	B
intervals	O	NOUN	I
produced	O	VERB	O
in	O	ADP	O
a	O	DET	O
synchronization-continuation	O	ADJ	B
experiment	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
first	O	ADJ	O
condition	O	NOUN	B
intervals	O	NOUN	B
were	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
finger	B-P	NOUN	B
tapping	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
second	O	NOUN	O
by	O	ADP	O
an	O	DET	O
oscillatory	B-P	ADJ	B
motion	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
hand	I-P	NOUN	B
.	I-P	PUNCT	O


Results	O	NOUN	B
obtained	O	VERB	O
in	O	ADP	O
tapping	B-P	NOUN	B
were	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
discrete	O	ADJ	B
,	O	PUNCT	O
event-based	O	ADJ	B
timing	O	NOUN	I
model	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
oscillatory	B-P	ADJ	B
condition	I-P	NOUN	I
,	O	PUNCT	O
the	O	DET	O
spectra	O	NOUN	B
suggested	O	VERB	O
a	O	DET	O
continuous	O	ADJ	B
,	O	PUNCT	O
dynamic	O	ADJ	B
timing	O	NOUN	O
mechanism	O	NOUN	B
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
effector	O	NOUN	B
stiffness	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
oscillatory	B-P	ADJ	B
character	I-P	NOUN	I
of	O	ADP	O
movement	O	NOUN	B
can	O	AUX	O
offer	O	VERB	O
an	O	DET	O
important	O	ADJ	O
resource	O	NOUN	B
for	O	ADP	O
timing	O	NOUN	O
control	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
an	O	DET	O
event-based	O	ADJ	B
timing	O	NOUN	I
control	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
postulated	O	VERB	O
in	O	ADP	O
the	O	DET	O
Wing-Kristoffersson	O	NOUN	B
model	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
a	O	DET	O
quite	O	ADV	O
limited	O	ADJ	O
class	O	NOUN	O
of	O	ADP	O
rhythmic	O	ADJ	B
tasks	O	NOUN	I
,	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
concatenation	O	NOUN	B
of	O	ADP	O
discrete	O	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


Instant	B-I	PROPN	B
Recess®	I-I	PROPN	I
:	I-I	PUNCT	O
a	O	DET	O
practical	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
increasing	B-OUT	VERB	B
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
school	O	NOUN	B
day	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
An	O	DET	O
increased	O	VERB	B
prevalence	O	NOUN	B
of	B-P	ADP	O
overweight/obesity	I-P	NOUN	B
among	I-P	ADP	O
children	I-P	NOUN	B
has	O	AUX	O
led	O	VERB	O
to	O	ADP	O
school	O	NOUN	B
district	O	NOUN	I
level	O	NOUN	B
policies	O	NOUN	B
to	O	PART	O
increase	B-OUT	VERB	B
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
among	I-P	ADP	O
elementary	I-P	ADJ	B
school	I-P	NOUN	O
students	I-P	NOUN	O
.	O	PUNCT	O


Interventions	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
that	O	SCONJ	O
increase	O	NOUN	B
activity	O	NOUN	B
levels	O	NOUN	O
without	O	ADP	O
sacrificing	O	VERB	B
time	O	NOUN	B
spent	O	VERB	O
in	O	ADP	O
academics	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
We	O	PRON	O
evaluated	O	VERB	B
a	B-I	DET	O
policy	I-I	NOUN	B
implementation	I-I	NOUN	B
intervention	I-I	NOUN	B
for	O	ADP	O
to	O	PART	O
increase	O	VERB	B
in-school	B-I	NOUN	B
PA	I-I	PROPN	I
in	I-P	ADP	O
elementary	I-P	ADJ	B
schools	I-P	NOUN	I
in	I-P	ADP	O
Forsyth	I-P	PROPN	B
County	I-P	PROPN	I
,	I-P	PUNCT	O
North	I-P	PROPN	B
Carolina	I-P	PROPN	I
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
with	O	ADP	O
a	O	DET	O
delayed	O	VERB	B
intervention	O	NOUN	O
control	O	NOUN	O
group	O	NOUN	O
.	O	PUNCT	O


METHODS	B-P	NOUN	O
The	I-P	DET	O
study	I-P	NOUN	B
included	I-P	VERB	O
third-	I-P	ADJ	O
through	I-P	ADP	B
fifth-grade	I-P	ADJ	B
classrooms	I-P	NOUN	O
in	I-P	ADP	O
eight	I-P	NUM	O
elementary	I-P	ADJ	B
schools	I-P	NOUN	I
.	I-I	PUNCT	O


Instant	B-I	PROPN	B
Recess®	I-I	PROPN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
introduce	O	VERB	O
10-minute	B-I	ADJ	O
PA	I-I	NOUN	B
breaks	I-I	NOUN	I
in	O	ADP	O
classrooms	O	NOUN	B
on	O	ADP	O
schedules	O	NOUN	B
determined	O	VERB	O
by	O	ADP	O
teachers	O	NOUN	B
.	O	PUNCT	O


Direct	O	ADJ	O
observation	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
measure	B-OUT	VERB	B
activity	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
other	I-OUT	ADJ	O
student	I-OUT	NOUN	B
behaviors	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
teacher	I-OUT	NOUN	B
behaviors	I-OUT	NOUN	I
related	O	VERB	O
to	O	PART	O
PA	O	PROPN	B
in	O	ADP	O
the	O	DET	O
classrooms	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Twenty-eight	O	NUM	B
visits	O	NOUN	I
to	O	ADP	O
schools	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
during	O	ADP	O
the	O	DET	O
spring	O	NOUN	B
and	O	CCONJ	O
fall	O	VERB	B
semesters	O	NOUN	B
of	O	ADP	O
2009	O	NUM	O
.	O	PUNCT	O


At	O	ADP	O
baseline	O	NOUN	B
11	O	NUM	O
%	O	NOUN	O
to	O	PART	O
44	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
intervention	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
schools	O	NOUN	I
were	O	AUX	O
engaged	O	VERB	O
in	O	ADP	O
classroom-based	B-I	ADJ	B
PA.	I-OUT	X	B
PA	I-OUT	PROPN	I
increased	O	VERB	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
spring	O	NOUN	B
follow-up	O	NOUN	B
in	O	ADP	O
intervention	O	NOUN	B
schools	O	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
maintained	O	VERB	B
the	O	DET	O
following	O	VERB	O
fall	O	NOUN	B
.	O	PUNCT	O


Control	O	ADJ	B
schools	O	NOUN	I
decreased	B-OUT	VERB	B
PA	I-OUT	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
spring	O	NOUN	B
and	O	CCONJ	O
increased	B-OUT	VERB	B
PA	I-OUT	PROPN	B
once	O	SCONJ	O
they	O	PRON	O
began	O	VERB	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


Students	O	NOUN	B
in	O	ADP	O
classrooms	O	NOUN	B
engaged	O	VERB	O
in	O	ADP	O
Instant	O	PROPN	B
Recess	O	PROPN	I
exhibited	B-OUT	VERB	O
statistically	I-OUT	ADV	B
significant	I-OUT	ADJ	I
increases	I-OUT	NOUN	B
in	I-OUT	ADP	O
light	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
51	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
moderate-intensity	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
16	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
PA	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
increases	I-OUT	VERB	B
in	I-OUT	ADP	O
time	I-OUT	NOUN	B
spent	I-OUT	VERB	O
in	I-OUT	ADP	O
on-task	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
(	O	PUNCT	O
11	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Control	O	ADJ	B
schools	O	NOUN	I
experienced	O	VERB	O
similar	O	ADJ	O
benefits	O	NOUN	B
after	O	ADP	O
they	O	PRON	O
began	O	VERB	O
implementing	O	VERB	B
Instant	O	PROPN	B
Recess	O	PROPN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Instant	O	PROPN	B
Recess	O	PROPN	I
is	O	AUX	O
useful	O	ADJ	O
for	B-OUT	ADP	O
increasing	I-OUT	VERB	B
PA	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
improving	I-OUT	VERB	B
behavior	I-OUT	NOUN	B
among	I-P	ADP	O
elementary	I-P	ADJ	B
school	I-P	NOUN	O
children	I-P	NOUN	O
.	O	PUNCT	O


Additional	O	ADJ	O
research	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
needed	O	VERB	O
to	O	PART	O
understand	O	VERB	O
how	O	SCONJ	O
to	O	PART	O
create	O	VERB	O
policies	O	NOUN	B
supporting	O	VERB	O
classroom	O	NOUN	B
activity	O	NOUN	I
breaks	O	NOUN	O
and	O	CCONJ	O
how	O	SCONJ	O
to	O	PART	O
assess	O	VERB	B
policy	O	NOUN	B
adherence	O	NOUN	B
.	O	PUNCT	O


Recombinant	B-I	ADJ	B
human	I-I	ADJ	B
thyrotropin-stimulated	I-I	ADJ	B
radioiodine	I-I	NOUN	I
therapy	I-I	NOUN	I
of	O	ADP	O
nodular	O	ADJ	B
goiter	O	NOUN	I
allows	O	VERB	O
major	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
radiation	B-OUT	NOUN	B
burden	I-OUT	NOUN	B
with	O	ADP	O
retained	O	VERB	O
efficacy	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONTEXT	O	NOUN	B
AND	O	CCONJ	O
OBJECTIVE	O	NOUN	O
Stimulation	O	NOUN	B
with	O	ADP	O
recombinant	B-I	ADJ	B
human	I-I	ADJ	I
TSH	I-I	NOUN	I
(	I-I	PUNCT	O
rhTSH	I-I	NOUN	B
)	I-I	PUNCT	O
before	O	ADP	O
radioiodine	B-I	NOUN	B
(	I-I	PUNCT	O
131I	I-I	NOUN	B
)	I-I	PUNCT	O
therapy	I-I	NOUN	O
augments	O	VERB	O
goiter	B-OUT	NOUN	B
volume	I-OUT	NOUN	I
reduction	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GVR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Observations	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
rhTSH	B-I	NOUN	B
has	O	AUX	O
a	O	DET	O
preconditioning	O	NOUN	B
effect	O	NOUN	B
beyond	O	ADP	O
increasing	O	VERB	B
thyroid	O	NOUN	B
(	O	PUNCT	O
131	O	NUM	O
)	O	PUNCT	O
I	O	NOUN	O
uptake	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
an	O	DET	O
equivalent	O	ADJ	B
GVR	O	NOUN	B
might	O	AUX	O
be	O	AUX	O
obtained	O	VERB	O
by	O	ADP	O
an	O	DET	O
absorbed	O	VERB	B
thyroid	O	NOUN	I
dose	O	NOUN	B
well	O	ADV	O
below	O	ADP	O
what	O	PRON	O
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
DESIGN	O	NOUN	O
In	O	ADP	O
a	O	DET	O
double-blinded	O	ADJ	B
setup	O	NOUN	I
,	O	PUNCT	O
90	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
78	I-P	NUM	O
women	I-P	NOUN	B
;	I-P	PUNCT	O
median	I-P	ADJ	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
52	I-P	NUM	O
yr	I-P	NOUN	O
;	I-P	PUNCT	O
range	I-P	NOUN	O
,	I-P	PUNCT	O
22-83	I-P	NUM	O
)	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
nontoxic	I-P	ADJ	B
nodular	I-P	ADJ	I
goiter	I-P	NOUN	I
(	I-P	PUNCT	O
median	I-P	ADJ	B
size	I-P	NOUN	I
,	I-P	PUNCT	O
63	I-P	NUM	O
ml	I-P	NOUN	O
;	I-P	PUNCT	O
range	I-P	NOUN	O
,	I-P	PUNCT	O
25-379	I-P	NUM	O
ml	I-P	NOUN	O
)	I-P	PUNCT	O
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
either	O	CCONJ	O
0.1	B-I	NUM	O
mg	I-I	NOUN	O
rhTSH	I-I	NOUN	B
(	O	PUNCT	O
n=60	O	NOUN	O
)	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
thyroid	B-I	NOUN	B
dose	I-I	NOUN	O
of	I-I	ADP	O
50	I-I	NUM	O
Gy	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
followed	O	VERB	O
by	O	ADP	O
100	O	NUM	O
Gy	O	NOUN	O
(	O	PUNCT	O
n=30	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mean	O	ADJ	O
relative	B-OUT	ADJ	O
GVR	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
rhTSH	B-I	NOUN	B
group	O	NOUN	B
was	O	AUX	O
identical	O	ADJ	B
(	O	PUNCT	O
35+/-3	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.81	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
median	O	NOUN	B
administered	O	VERB	B
131I-activity	B-OUT	NUM	O
was	O	AUX	O
170	O	NUM	O
MBq	O	NOUN	B
(	O	PUNCT	O
45-1269	O	NUM	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
rhTSH	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
559	O	NUM	O
MBq	O	NOUN	B
(	O	PUNCT	O
245-3530	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
70	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


According	O	VERB	O
to	O	ADP	O
the	O	DET	O
official	O	ADJ	B
radiation	O	NOUN	B
regulation	O	NOUN	I
,	O	PUNCT	O
hospitalization	B-OUT	NOUN	B
was	O	AUX	O
required	O	VERB	O
in	O	ADP	O
14	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	O
vs.	O	CCONJ	O
one	O	NUM	O
patient	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rhTSH	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
goiter-related	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
were	O	AUX	O
effectively	O	ADV	O
relieved	O	VERB	O
in	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
myxedema	B-OUT	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
among	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
study	O	NOUN	B
to	O	PART	O
demonstrate	O	VERB	O
that	O	SCONJ	O
rhTSH	B-I	NOUN	B
not	O	PART	O
only	O	ADV	O
increases	O	VERB	B
the	O	DET	O
thyroid	B-OUT	NOUN	B
131I	I-OUT	NOUN	I
uptake	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
per	O	X	O
se	O	X	O
potentiates	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
131I-therapy	B-I	NOUN	B
,	O	PUNCT	O
allowing	O	VERB	O
a	O	DET	O
major	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
131I-activity	B-OUT	NUM	O
without	O	ADP	O
compromising	O	VERB	O
efficacy	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


This	O	DET	O
approach	O	NOUN	O
is	O	AUX	O
attractive	O	ADJ	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
minimizing	O	VERB	O
posttherapeutic	B-OUT	ADJ	B
restrictions	I-OUT	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
potential	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
radiation-induced	B-OUT	ADJ	B
malignancy	I-OUT	NOUN	I
.	O	PUNCT	O


Double-blind	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
liquid	B-I	ADJ	B
antacid	I-I	NOUN	I
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
symptomatic	B-P	ADJ	B
reflux	I-P	NOUN	B
esophagitis	I-P	NOUN	I
.	I-P	PUNCT	O


Although	O	SCONJ	O
antacids	B-I	NOUN	B
have	O	AUX	O
been	O	AUX	O
the	O	DET	O
mainstay	O	ADJ	O
of	O	ADP	O
pharmacologic	O	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
reflux	O	NOUN	B
esophagitis	O	NOUN	I
,	O	PUNCT	O
their	O	PRON	O
effectiveness	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
a	O	DET	O
placebo-controlled	B-I	ADJ	B
double-blind	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
double-blind	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
liquid	B-I	ADJ	B
antacid	I-I	NOUN	I
vs	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
reflux	O	NOUN	B
esophagitis	O	NOUN	I
in	O	ADP	O
32	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
heartburn	I-P	NOUN	I
.	I-P	PUNCT	O


Entry	B-P	NOUN	B
criteria	I-P	NOUN	I
included	I-P	VERB	O
the	I-P	DET	O
presence	I-P	NOUN	B
of	I-P	ADP	O
symptomatic	I-P	ADJ	B
gastroesophageal	I-P	NOUN	B
reflux	I-P	NOUN	I
confirmed	I-P	VERB	O
by	I-P	ADP	O
both	I-P	CCONJ	O
an	I-P	DET	O
acid	I-P	NOUN	B
perfusion	I-P	NOUN	I
(	I-P	PUNCT	O
Bernstein	I-P	NOUN	O
)	I-P	PUNCT	O
test	I-P	NOUN	O
and	I-P	CCONJ	O
by	I-P	ADP	O
intraesophageal	I-P	NOUN	B
pH	I-P	NOUN	B
probe	I-P	NOUN	I
.	I-P	PUNCT	O


Drug	O	NOUN	B
treatment	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
15	O	NUM	O
ml	O	NOUN	O
(	O	PUNCT	O
80	O	NUM	O
mEq	O	NOUN	O
)	O	PUNCT	O
doses	O	NOUN	B
of	O	ADP	O
antacid	B-I	NOUN	B
(	I-I	PUNCT	O
Maalox	I-I	PROPN	B
Therapeutic	I-I	ADJ	B
Concentration	I-I	NOUN	I
,	O	PUNCT	O
William	O	PROPN	B
H.	O	PROPN	I
Rorer	O	PROPN	I
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
taken	O	VERB	O
7	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
,	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
meals	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
bedtime	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
showed	O	VERB	O
significant	O	ADJ	O
improvement	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
both	O	CCONJ	O
frequency	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
heartburn	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
time	B-OUT	NOUN	O
to	I-OUT	PART	O
reproduce	I-OUT	VERB	O
heartburn	I-OUT	NOUN	B
with	O	ADP	O
the	O	DET	O
timed	O	ADJ	B
Bernstein	O	PROPN	O
test	O	NOUN	O
was	O	AUX	O
increased	O	VERB	B
with	O	ADP	O
both	O	CCONJ	O
active	B-I	ADJ	B
drug	I-I	NOUN	I
and	O	CCONJ	O
placebo	B-I	NOUN	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
increase	O	NOUN	B
was	O	AUX	O
402	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
41	O	NUM	O
+/-	O	CCONJ	O
20	O	NUM	O
sec	O	NOUN	O
to	O	ADP	O
169	O	NUM	O
+/-	O	CCONJ	O
66	O	NUM	O
sec	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
and	O	CCONJ	O
286	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
42	O	NUM	O
+/-	O	CCONJ	O
16	O	NUM	O
to	O	PART	O
120	O	NUM	O
+/-	O	CCONJ	O
57	O	NUM	O
sec	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
antacid	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
antacid	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
groups	O	NOUN	O
showed	O	VERB	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
esophagitis	I-OUT	NOUN	B
as	O	ADP	O
assessed	O	VERB	B
endoscopically	O	ADV	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
asked	O	VERB	O
:	O	PUNCT	O
does	O	AUX	O
regular	O	ADJ	O
antacid	O	NOUN	B
therapy	O	NOUN	I
have	O	AUX	O
a	O	DET	O
favorable	O	ADJ	O
influence	O	NOUN	B
on	O	ADP	O
the	O	DET	O
natural	O	ADJ	B
history	O	NOUN	I
of	O	ADP	O
symptomatic	B-OUT	ADJ	B
reflux	I-OUT	NOUN	B
esophagitis	I-OUT	NOUN	I
,	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
does	O	AUX	O
therapy	O	NOUN	B
heal	O	VERB	B
or	O	CCONJ	O
otherwise	O	ADV	O
change	O	VERB	O
esophagitis	O	NOUN	B
so	O	SCONJ	O
that	O	SCONJ	O
painful	O	ADJ	B
episodes	O	NOUN	B
are	O	AUX	O
either	O	ADV	O
less	O	ADV	O
frequent	O	ADJ	B
,	O	PUNCT	O
less	O	ADV	O
severe	O	ADJ	B
,	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
?	O	PUNCT	O
We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
natural	B-OUT	ADJ	B
history	I-OUT	NOUN	I
of	I-OUT	ADP	O
symptomatic	I-OUT	ADJ	B
reflux	I-OUT	NOUN	B
esophagitis	I-OUT	NOUN	I
was	O	AUX	O
to	O	PART	O
improve	O	VERB	B
with	O	ADP	O
either	O	CCONJ	O
antacid	B-I	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
antacid	B-I	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
(	O	PUNCT	O
short-term	O	ADJ	B
)	O	PUNCT	O
natural	B-OUT	ADJ	B
history	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
disease	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Variance	O	NOUN	B
in	O	ADP	O
albumin	B-I	NOUN	B
loading	O	NOUN	B
in	O	ADP	O
exchange	B-P	NOUN	B
transfusions	I-P	NOUN	I
.	I-P	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	O	DET	O
rationale	O	NOUN	B
of	O	ADP	O
albumin	O	NOUN	B
priming	O	NOUN	B
prior	O	ADV	O
to	O	PART	O
exchange	O	NOUN	B
transfusions	O	NOUN	I
,	O	PUNCT	O
42	B-P	NUM	O
hyperbilirubinemic	I-P	ADJ	B
infants	I-P	NOUN	I
who	I-P	PRON	O
required	I-P	VERB	O
exchange	I-P	NOUN	B
transfusions	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Group	O	PROPN	B
I	O	PRON	I
consisted	O	VERB	O
of	O	ADP	O
15	B-P	NUM	O
infants	I-P	NOUN	B
who	O	PRON	O
were	O	AUX	O
given	O	VERB	O
intravenously	B-I	ADV	B
1	I-I	NUM	O
gm/kg	I-I	NOUN	O
of	I-I	ADP	O
salt-poor	I-I	ADJ	O
human	I-I	ADJ	O
serum	I-I	NOUN	O
albumin	I-I	NOUN	O
one	O	NUM	O
hour	O	NOUN	B
before	O	ADP	O
the	O	DET	O
exchanges	O	NOUN	B
.	O	PUNCT	O


Group	O	PROPN	B
II	O	PROPN	I
,	O	PUNCT	O
which	O	DET	O
consisted	O	VERB	O
of	O	ADP	O
27	O	NUM	O
infants	O	NOUN	B
,	O	PUNCT	O
received	O	VERB	O
simple	O	ADJ	O
exchanges	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
statistical	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
variations	B-OUT	NOUN	B
in	I-OUT	ADP	O
reserve	I-OUT	NOUN	B
albumin-binding	I-OUT	ADJ	B
capacity	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
bilirubin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
albumin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
red	I-OUT	ADJ	B
cell	I-OUT	NOUN	I
bilirubin	I-OUT	NOUN	B
at	I-OUT	ADP	O
pre	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
one-hour	I-OUT	ADJ	B
post	I-OUT	NOUN	O
albumin	I-OUT	NOUN	O
infusion	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
primed	O	VERB	B
infants	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
amount	B-OUT	NOUN	B
of	I-OUT	ADP	O
bilirubin	I-OUT	NOUN	B
removed	I-OUT	VERB	B
per	I-OUT	ADP	O
kilogram	I-OUT	NOUN	O
is	O	AUX	O
directly	O	ADV	O
correlated	O	VERB	B
to	O	PART	O
plasma	B-OUT	NOUN	B
bilirubin	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
(	O	PUNCT	O
r=0.87	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
efficiency	B-OUT	NOUN	B
on	I-OUT	ADP	O
bilirubin	I-OUT	NOUN	B
removal	I-OUT	NOUN	B
was	O	AUX	O
seen	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Beneficial	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
albumin	O	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
apparent	O	ADJ	B
only	O	ADV	O
in	O	ADP	O
those	O	DET	O
infants	B-P	NOUN	B
with	I-P	ADP	O
low	I-P	ADJ	B
RABC	I-P	PROPN	B
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
the	O	DET	O
sephadex	O	NOUN	B
gel	O	NOUN	I
filtration	O	NOUN	I
technique	O	NOUN	I
.	O	PUNCT	O


Bevacizumab	B-I	NOUN	B
plus	I-I	CCONJ	O
irinotecan	I-I	NOUN	B
,	I-I	PUNCT	O
fluorouracil	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
leucovorin	I-I	NOUN	B
for	O	ADP	O
metastatic	B-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Bevacizumab	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
monoclonal	O	ADJ	B
antibody	O	NOUN	I
against	O	ADP	O
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
shown	O	VERB	O
promising	O	ADJ	O
preclinical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
activity	O	NOUN	I
against	O	ADP	O
metastatic	B-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Of	O	ADP	O
813	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
previously	I-P	ADV	O
untreated	I-P	ADJ	B
metastatic	I-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
randomly	O	ADV	O
assigned	O	VERB	B
402	O	NUM	O
to	O	PART	O
receive	O	VERB	O
irinotecan	B-I	NOUN	B
,	I-I	PUNCT	O
bolus	I-I	NOUN	B
fluorouracil	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
leucovorin	I-I	NOUN	B
(	I-I	PUNCT	O
IFL	I-I	NOUN	B
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
bevacizumab	I-I	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
kilogram	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
every	O	DET	O
two	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
411	O	NUM	O
to	O	PART	O
receive	O	VERB	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Secondary	O	ADJ	B
end	O	NOUN	I
points	O	NOUN	I
were	O	AUX	O
progression-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
response	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
safety	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
median	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
survival	I-OUT	NOUN	B
was	O	AUX	O
20.3	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
bevacizumab	I-I	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
15.6	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
,	O	PUNCT	O
corresponding	O	VERB	O
to	O	PART	O
a	O	DET	O
hazard	O	ADJ	B
ratio	O	NOUN	I
for	O	ADP	O
death	O	NOUN	B
of	O	ADP	O
0.66	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
10.6	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
bevacizumab	I-I	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
6.2	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
for	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
,	O	PUNCT	O
0.54	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
the	O	DET	O
corresponding	O	ADJ	O
rates	O	NOUN	B
of	O	ADP	O
response	O	NOUN	B
were	O	AUX	O
44.8	O	NUM	O
percent	O	NOUN	O
and	O	CCONJ	O
34.8	O	NUM	O
percent	O	NOUN	O
(	O	PUNCT	O
P=0.004	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
response	I-OUT	NOUN	B
was	O	AUX	O
10.4	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
bevacizumab	I-I	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
7.1	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
for	O	ADP	O
progression	O	NOUN	B
,	O	PUNCT	O
0.62	O	NUM	O
;	O	PUNCT	O
P=0.001	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Grade	B-OUT	NOUN	B
3	I-OUT	NUM	I
hypertension	I-OUT	NOUN	B
was	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
bevacizumab	I-I	NOUN	B
than	O	ADP	O
with	O	ADP	O
IFL	B-I	NOUN	B
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
11.0	O	NUM	O
percent	O	NOUN	O
vs.	O	CCONJ	O
2.3	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
easily	O	ADV	O
managed	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
bevacizumab	B-I	NOUN	B
to	O	PART	O
fluorouracil-based	B-I	ADJ	B
combination	I-I	NOUN	I
chemotherapy	I-I	NOUN	I
results	O	VERB	B
in	O	ADP	O
statistically	O	ADV	B
significant	O	ADJ	I
and	O	CCONJ	O
clinically	O	ADV	B
meaningful	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
survival	B-OUT	NOUN	B
among	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Short-	O	ADJ	B
and	O	CCONJ	O
long-term	O	ADJ	B
results	O	NOUN	B
after	O	ADP	O
thrombolytic	B-I	ADJ	B
treatment	I-I	NOUN	I
of	O	ADP	O
deep	O	ADJ	B
venous	O	ADJ	I
thrombosis	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
The	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
short-	O	NOUN	B
and	O	CCONJ	O
long-term	O	ADJ	B
efficacy	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
thrombolytic	B-I	ADJ	B
therapy	I-I	NOUN	I
regimens	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
leg	I-P	NOUN	B
or	I-P	CCONJ	O
pelvic	I-P	ADJ	B
deep	I-P	ADJ	B
venous	I-P	ADJ	I
thrombosis	I-P	NOUN	I
(	I-P	PUNCT	O
DVT	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
It	O	PRON	O
is	O	AUX	O
unclear	O	ADJ	B
whether	O	SCONJ	O
locoregional	O	NOUN	B
or	O	CCONJ	O
systemic	O	ADJ	B
thrombolysis	O	NOUN	I
is	O	AUX	O
superior	O	ADJ	O
in	O	ADP	O
treating	O	VERB	B
acute	O	ADJ	B
leg	O	NOUN	I
DVT	O	NOUN	B
or	O	CCONJ	O
even	O	ADV	O
whether	O	SCONJ	O
lysis	O	NOUN	B
is	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
anticoagulation	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
preventing	O	VERB	B
postthrombotic	O	ADJ	B
syndrome	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
250	B-P	NUM	O
patients	I-P	NOUN	B
averaging	I-P	VERB	O
40	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
DVT	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
five	O	NUM	O
groups	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
full	B-I	ADJ	O
heparinization	I-I	NOUN	B
(	I-I	PUNCT	O
1,000	I-I	NUM	O
IU/h	I-I	ADV	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
compression	I-I	NOUN	B
treatment	I-I	NOUN	I
,	I-I	PUNCT	O
with	I-I	ADP	O
four	I-I	NUM	O
groups	I-I	NOUN	B
also	I-I	ADV	O
administered	I-I	VERB	B
locoregional	I-I	ADJ	B
tissue	I-I	NOUN	O
plasminogen	I-I	NOUN	O
activator	I-I	NOUN	O
(	I-I	PUNCT	O
20	I-I	NUM	O
mg/day	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
urokinase	I-I	NOUN	B
(	I-I	PUNCT	O
100,000	I-I	NUM	O
IU/day	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
systemic	I-I	ADJ	B
streptokinase	I-I	NOUN	I
(	I-I	PUNCT	O
3,000,000	I-I	NUM	O
IU	I-I	NOUN	B
daily	I-I	ADV	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
urokinase	I-I	NOUN	B
(	I-I	PUNCT	O
5,000,000	I-I	NUM	O
IU	I-I	NOUN	B
daily	I-I	ADV	B
)	I-I	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
groups	O	NOUN	B
then	O	ADV	O
received	O	VERB	O
anticoagulation	B-I	NOUN	B
and	I-I	CCONJ	O
compression	I-I	NOUN	B
treatment	I-I	NOUN	I
for	I-I	ADP	O
one	I-I	NUM	O
year	I-I	NOUN	B
.	I-I	PUNCT	O


Primary	O	ADJ	B
efficacy	O	NOUN	I
criteria	O	NOUN	B
included	O	VERB	O
the	O	DET	O
change	O	NOUN	B
after	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
closed	B-OUT	ADJ	O
vein	I-OUT	NOUN	O
segments	I-OUT	NOUN	B
and	O	CCONJ	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
postthrombotic	O	ADJ	B
syndrome	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
Systemic	B-I	ADJ	B
thrombolytic	I-I	ADJ	B
therapy	I-I	NOUN	I
significantly	O	ADV	O
reduced	O	VERB	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
closed	B-OUT	ADJ	B
vein	I-OUT	NOUN	I
segments	I-OUT	NOUN	B
after	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
DVT	I-P	NOUN	B
compared	O	VERB	O
with	O	ADP	O
conventional	O	ADJ	B
treatment	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Postthrombotic	B-OUT	ADJ	B
syndrome	I-OUT	NOUN	I
also	O	ADV	O
occurred	O	VERB	O
with	O	ADP	O
less	O	ADJ	O
frequency	O	NOUN	B
in	O	ADP	O
systemically	O	ADV	B
treated	O	VERB	B
patients	O	NOUN	B
versus	O	CCONJ	O
controls	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


High-dose	O	ADJ	B
thrombolysis	O	NOUN	I
led	O	VERB	O
to	O	PART	O
better	O	ADJ	O
rates	O	NOUN	B
of	O	ADP	O
complete	B-OUT	ADJ	B
recanalization	I-OUT	NOUN	B
after	O	ADP	O
seven	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
locoregional	O	ADJ	B
lysis	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
12	B-P	NUM	O
patients	I-P	NOUN	B
receiving	I-P	VERB	O
thrombolysis	I-P	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
systemic	O	ADJ	B
,	O	PUNCT	O
3	O	NUM	O
local	O	ADJ	B
)	O	PUNCT	O
suffered	O	VERB	O
major	B-OUT	ADJ	O
bleeding	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
9	I-P	NUM	O
patients	I-P	NOUN	B
on	I-P	ADP	O
systemic	I-P	ADJ	B
treatment	I-P	NOUN	I
developed	O	VERB	O
pulmonary	B-OUT	ADJ	B
emboli	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Systemic	B-I	ADJ	B
thrombolytic	I-I	ADJ	B
treatment	I-I	NOUN	I
for	O	ADP	O
acute	O	ADJ	B
DVT	O	NOUN	B
achieved	O	VERB	O
a	O	DET	O
significantly	O	ADV	O
better	O	ADV	O
short-	O	ADJ	B
and	O	CCONJ	O
long-term	O	ADJ	B
clinical	O	ADJ	B
outcome	O	NOUN	I
than	O	ADP	O
conventional	O	ADJ	B
heparin/anticoagulation	O	NOUN	B
therapy	O	NOUN	I
but	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
expense	O	NOUN	B
of	O	ADP	O
a	O	DET	O
serious	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
major	O	ADJ	O
bleeding	O	NOUN	B
and	O	CCONJ	O
pulmonary	O	ADJ	B
emboli	O	NOUN	I
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
inherent	O	ADJ	O
risks	O	NOUN	B
for	O	ADP	O
such	O	ADJ	O
serious	O	ADJ	O
complications	O	NOUN	B
,	O	PUNCT	O
systemic	O	ADJ	B
thrombolysis	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
effective	O	ADJ	B
,	O	PUNCT	O
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
selectively	O	ADV	O
in	O	ADP	O
limb-threatening	O	ADJ	B
thrombotic	O	ADJ	B
situations	O	NOUN	O
.	O	PUNCT	O


Transdermal	B-I	ADJ	B
scopolamine	I-I	NOUN	B
patch	I-I	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
ondansetron	B-I	NOUN	B
for	O	ADP	O
postoperative	O	ADJ	B
nausea	O	NOUN	B
and	O	CCONJ	O
vomiting	O	NOUN	O
prophylaxis	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
ambulatory	I-P	ADJ	B
cosmetic	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
transdermal	B-I	ADJ	B
scopolamine	I-I	NOUN	I
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
ondansetron	B-I	NOUN	B
in	O	ADP	O
decreasing	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
postoperative	B-OUT	ADJ	B
nausea	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
vomiting	I-OUT	NOUN	O
(	I-P	PUNCT	O
PONV	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Academic	B-P	ADJ	B
hospital	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	O	VERB	O
126	B-P	NUM	O
ASA	I-P	NOUN	B
physical	I-P	ADJ	B
status	I-P	NOUN	I
I	I-P	NUM	I
and	I-P	CCONJ	O
II	I-P	NUM	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
outpatient	I-P	ADJ	B
plastic	I-P	ADJ	B
surgery	I-P	NOUN	I
with	I-P	ADP	O
three	I-P	NUM	O
or	I-P	CCONJ	O
more	I-P	ADJ	O
risk	I-P	NOUN	B
factors	I-P	NOUN	I
for	I-P	ADP	O
PONV	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
(	O	PUNCT	O
Group	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
a	O	DET	O
transdermal	B-I	ADJ	B
scopolamine	I-I	NOUN	I
(	I-I	PUNCT	O
TDS	I-I	NOUN	B
)	I-I	PUNCT	O
patch	I-I	NOUN	B
or	O	CCONJ	O
(	O	PUNCT	O
Group	O	PROPN	B
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
a	B-I	DET	O
placebo	I-I	NOUN	B
patch	I-I	NOUN	B
two	O	NUM	O
hours	O	NOUN	O
before	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	VERB	B
Occurrence	B-OUT	NOUN	B
of	I-OUT	ADP	O
vomiting	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
nausea	I-OUT	NOUN	B
using	I-OUT	VERB	O
a	I-OUT	DET	O
visual	I-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
rescue	I-OUT	NOUN	B
medication	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
intensity	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
medications	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
every	O	DET	O
hour	O	NOUN	B
until	O	ADP	O
discharge	O	NOUN	B
from	O	ADP	O
hospital	O	NOUN	B
,	O	PUNCT	O
then	O	ADV	O
every	O	DET	O
4	O	NUM	O
hours	O	NOUN	B
thereafter	O	ADV	O
for	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
RESULTS	O	NOUN	O
A	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
reduction	O	NOUN	B
in	O	ADP	O
postoperative	B-OUT	ADJ	B
nausea	I-OUT	NOUN	B
between	O	ADP	O
8	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
TDS	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Transdermal	O	ADJ	B
scopolamine	B-I	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
ondansetron	O	NOUN	B
benefits	O	VERB	B
patients	B-P	NOUN	B
at	I-P	ADP	O
high	I-P	ADJ	B
risk	I-P	NOUN	I
for	I-P	ADP	O
PONV	I-P	NOUN	B
undergoing	I-P	VERB	O
outpatient	I-P	ADJ	B
plastic	I-P	NOUN	B
surgery	I-P	NOUN	I
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
20	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
possible	O	ADJ	O
link	O	NOUN	O
between	O	ADP	O
early	O	ADJ	O
probiotic	B-I	ADJ	B
intervention	I-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
neuropsychiatric	I-OUT	ADJ	B
disorders	I-OUT	NOUN	I
later	I-P	ADV	O
in	I-P	ADP	O
childhood	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Recent	O	ADJ	O
experimental	O	ADJ	B
evidence	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
gut	O	NOUN	B
microbiota	O	NOUN	I
may	O	AUX	O
alter	O	VERB	O
function	O	NOUN	B
within	O	ADP	O
the	O	DET	O
nervous	O	ADJ	B
system	O	NOUN	I
providing	O	VERB	O
new	O	ADJ	O
insight	O	NOUN	O
on	O	ADP	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
neuropsychiatric	O	ADJ	B
disorders	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Seventy-five	B-P	NUM	B
infants	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	PART	O
receive	I-P	VERB	O
Lactobacillus	I-I	X	B
rhamnosus	I-I	NOUN	I
GG	I-I	NOUN	I
(	I-I	PUNCT	O
ATCC	I-I	NOUN	O
53103	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
during	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
6	I-P	NUM	O
mo	I-P	NOUN	O
of	I-P	ADP	O
life	I-P	NOUN	B
were	I-P	AUX	O
followed-up	I-P	VERB	B
for	I-P	ADP	O
13	I-P	NUM	O
y	I-P	NOUN	O
.	I-P	PUNCT	O


Gut	B-OUT	NOUN	B
microbiota	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
wk	O	NOUN	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
18	O	NUM	O
,	O	PUNCT	O
24	O	NUM	O
mo	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
13	O	NUM	O
y	O	NOUN	O
using	B-I	VERB	O
fluorescein	I-I	NOUN	B
in	I-I	X	I
situ	I-I	X	I
hybridization	I-I	NOUN	I
(	O	PUNCT	O
FISH	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
qPCR	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
indirectly	O	ADV	O
by	O	ADP	O
determining	O	VERB	O
the	B-OUT	DET	O
blood	I-OUT	NOUN	B
group	I-OUT	NOUN	I
secretor	I-OUT	NOUN	B
type	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
13	O	NUM	O
y	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
diagnoses	O	NOUN	B
of	B-OUT	ADP	O
attention	I-OUT	NOUN	B
deficit	I-OUT	NOUN	I
hyperactivity	I-OUT	NOUN	I
disorder	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ADHD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Asperger	I-OUT	NOUN	B
syndrome	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
by	O	ADP	O
a	O	DET	O
child	O	NOUN	B
neurologist	O	NOUN	I
or	O	CCONJ	O
psychiatrist	O	NOUN	B
were	O	AUX	O
based	O	VERB	O
on	O	ADP	O
ICD-10	O	NOUN	O
diagnostic	O	ADJ	B
criteria	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
13	O	NUM	O
y	B-OUT	NOUN	O
,	I-OUT	PUNCT	O
ADHD	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
AS	I-OUT	NOUN	B
was	O	AUX	O
diagnosed	O	VERB	B
in	O	ADP	O
6/35	O	NUM	O
(	O	PUNCT	O
17.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
and	O	CCONJ	O
none	O	NOUN	O
in	O	ADP	O
the	O	DET	O
probiotic	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.008	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
mean	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
SD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
numbers	I-OUT	NOUN	O
of	I-OUT	ADP	O
Bifidobacterium	I-OUT	NOUN	B
species	I-OUT	NOUN	I
bacteria	I-OUT	NOUN	I
in	I-OUT	ADP	O
feces	I-OUT	NOUN	B
during	I-OUT	ADP	O
the	I-OUT	DET	O
first	I-OUT	ADJ	O
6	I-OUT	NUM	O
mo	I-OUT	NOUN	O
of	I-OUT	ADP	O
life	I-OUT	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
affected	O	VERB	B
children	O	NOUN	B
8.26	O	NUM	O
(	O	PUNCT	O
1.24	O	NUM	O
)	O	PUNCT	O
log	O	NOUN	O
cells/g	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
healthy	O	ADJ	B
children	O	NOUN	B
9.12	O	NUM	O
(	O	PUNCT	O
0.64	O	NUM	O
)	O	PUNCT	O
log	O	NOUN	O
cells/g	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
.	O	PUNCT	O


CONCLUSION	B-I	VERB	O
Probiotic	I-I	ADJ	B
supplementation	I-I	NOUN	B
early	O	ADV	B
in	O	ADP	O
life	O	NOUN	B
may	O	AUX	O
reduce	O	VERB	B
the	B-OUT	DET	O
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
neuropsychiatric	I-OUT	ADJ	B
disorder	I-OUT	NOUN	I
development	I-OUT	NOUN	B
later	I-P	ADV	O
in	I-P	ADP	O
childhood	I-P	NOUN	B
possible	O	ADJ	O
by	O	ADP	O
mechanisms	O	NOUN	B
not	O	PART	O
limited	O	VERB	O
to	O	PART	O
gut	O	NOUN	B
microbiota	O	NOUN	I
composition	O	NOUN	B
.	O	PUNCT	O


Outcome	B-OUT	NOUN	B
assessment	I-OUT	NOUN	I
for	I-P	ADP	O
clinical	I-P	ADJ	B
trials	I-P	NOUN	I
:	I-P	PUNCT	O
how	O	SCONJ	O
many	O	ADJ	O
adjudicators	B-P	NOUN	B
do	O	AUX	O
we	O	PRON	O
need	O	VERB	O
?	O	PUNCT	O
Canadian	O	ADJ	B
Lung	O	PROPN	B
Oncology	O	PROPN	I
Group	O	PROPN	I
.	O	PUNCT	O


Considerable	O	ADJ	O
effort	O	NOUN	O
is	O	AUX	O
often	O	ADV	O
expended	O	VERB	O
to	O	PART	O
adjudicate	O	VERB	B
outcomes	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
little	O	ADJ	O
has	O	AUX	O
been	O	AUX	O
written	O	VERB	B
on	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adjudication	O	NOUN	B
process	O	NOUN	O
and	O	CCONJ	O
its	O	PRON	O
possible	O	ADJ	O
impact	O	NOUN	B
on	O	ADP	O
study	O	NOUN	B
results	O	NOUN	O
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
case	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
describe	O	VERB	O
the	O	DET	O
function	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
performance	I-OUT	NOUN	B
of	I-OUT	ADP	O
an	I-OUT	DET	O
adjudication	I-OUT	NOUN	B
committee	I-OUT	NOUN	B
in	I-P	ADP	O
a	I-P	DET	O
large	I-P	ADJ	O
randomized	I-P	ADJ	B
trial	I-P	NOUN	I
of	O	ADP	O
two	O	NUM	O
diagnostic	O	ADJ	B
approaches	O	NOUN	I
to	O	PART	O
potentially	B-P	ADV	O
operable	I-P	ADJ	B
lung	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Up	B-P	ADP	O
to	I-P	PART	O
five	I-P	NUM	O
independent	I-P	ADJ	O
adjudicators	I-P	NOUN	B
independently	O	ADV	O
determined	O	VERB	O
two	O	NUM	O
primary	O	ADJ	B
outcomes	O	NOUN	B
:	O	PUNCT	O
tumor	B-OUT	NOUN	B
status	I-OUT	NOUN	I
at	I-OUT	ADP	O
death	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
at	I-OUT	ADP	O
final	I-OUT	ADJ	O
follow-up	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
cause	I-OUT	NOUN	B
of	I-OUT	ADP	I
death	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Patients	B-P	NOUN	B
for	O	ADP	O
whom	O	PRON	O
there	O	PRON	O
was	O	AUX	O
any	O	DET	O
disagreement	O	NOUN	B
were	O	AUX	O
discussed	O	VERB	O
in	O	ADP	O
committee	O	NOUN	B
until	O	ADP	O
a	O	DET	O
consensus	O	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
agreement	O	NOUN	B
among	O	ADP	O
the	O	DET	O
adjudicators	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
final	O	ADJ	O
consensus	O	NOUN	B
result	O	NOUN	O
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
model	O	VERB	B
the	O	DET	O
adjudication	O	NOUN	B
process	O	NOUN	O
and	O	CCONJ	O
predict	O	VERB	O
the	O	DET	O
results	O	NOUN	B
if	O	SCONJ	O
a	O	DET	O
smaller	O	ADJ	O
committee	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
reducing	O	VERB	B
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
adjudicators	I-OUT	NOUN	B
from	O	ADP	O
five	O	NUM	O
to	O	PART	O
two	O	NUM	O
or	O	CCONJ	O
three	O	NUM	O
would	O	AUX	O
probably	O	ADV	O
have	O	AUX	O
changed	O	VERB	O
the	O	DET	O
consensus	O	NOUN	B
outcome	O	NOUN	B
in	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
.	O	PUNCT	O


Correspondingly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
final	O	ADJ	O
study	O	NOUN	B
results	O	NOUN	O
(	O	PUNCT	O
comparing	O	VERB	O
primary	O	ADJ	B
outcomes	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
randomized	O	ADJ	B
arms	O	NOUN	I
)	O	PUNCT	O
would	O	AUX	O
have	O	AUX	O
been	O	AUX	O
altered	O	VERB	O
very	O	ADV	O
little	O	ADJ	O
.	O	PUNCT	O


Even	O	ADV	O
using	O	VERB	O
a	O	DET	O
single	O	ADJ	O
adjudicator	O	NOUN	B
would	O	AUX	O
not	O	PART	O
have	O	AUX	O
affected	O	VERB	B
the	O	DET	O
results	O	NOUN	B
substantially	O	ADV	O
.	O	PUNCT	O


About	O	ADV	O
90	O	NUM	O
minutes	O	NOUN	O
of	O	ADP	O
person-time	O	NOUN	B
per	O	ADP	O
patient	B-P	NOUN	B
was	O	AUX	O
required	O	VERB	O
for	O	ADP	O
activities	O	NOUN	B
directly	O	ADV	O
related	O	VERB	O
to	O	ADP	O
the	O	DET	O
adjudication	B-I	NOUN	B
process	I-I	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
approximately	O	ADV	O
6	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
full	O	ADJ	B
time	O	NOUN	I
work	O	NOUN	I
for	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
level	O	NOUN	B
of	O	ADP	O
effort	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
substantially	O	ADV	O
reduced	O	VERB	B
by	O	ADP	O
using	O	VERB	O
fewer	O	ADJ	O
adjudicators	O	NOUN	B
with	O	ADP	O
little	O	ADJ	O
impact	O	NOUN	B
on	O	ADP	O
the	O	DET	O
results	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
when	O	SCONJ	O
high	O	ADJ	B
observer	O	NOUN	B
agreement	O	NOUN	O
is	O	AUX	O
demonstrated	O	VERB	O
or	O	CCONJ	O
anticipated	O	VERB	B
,	O	PUNCT	O
adjudication	O	NOUN	B
committees	O	NOUN	I
should	O	AUX	O
consist	O	VERB	O
of	O	ADP	O
no	O	DET	O
more	O	ADJ	O
than	O	ADP	O
three	O	NUM	O
members	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
work	O	NOUN	O
is	O	AUX	O
needed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
if	O	SCONJ	O
smaller	O	ADJ	O
committees	O	NOUN	B
are	O	AUX	O
adequate	O	ADJ	B
to	O	PART	O
detect	O	VERB	B
small	O	ADJ	B
but	O	CCONJ	O
important	O	ADJ	O
treatment	O	NOUN	B
effects	O	NOUN	I
or	O	CCONJ	O
if	O	SCONJ	O
they	O	PRON	O
compromise	O	VERB	O
validity	O	NOUN	O
when	O	SCONJ	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
adjudicator	O	NOUN	B
agreement	O	NOUN	B
is	O	AUX	O
lower	O	ADJ	O
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
Chinese	O	ADJ	B
medical	O	ADJ	B
herbs	O	NOUN	I
complex	O	NOUN	B
on	O	ADP	O
cellular	O	ADJ	B
immunity	O	NOUN	I
and	O	CCONJ	O
toxicity-related	O	ADJ	B
conditions	O	NOUN	I
of	O	ADP	O
breast	B-P	NOUN	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Rose	B-I	PROPN	B
geranium	I-I	NOUN	I
(	O	PUNCT	O
Pelargonium	O	NOUN	B
graveolens	O	X	I
,	O	PUNCT	O
Geraniaceae	O	PROPN	B
)	O	PUNCT	O
has	O	AUX	O
anti-cancer	O	ADJ	B
and	O	CCONJ	O
anti-inflammatory	O	ADJ	B
properties	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
promotes	O	VERB	B
wound	O	NOUN	B
healing	O	NOUN	I
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
Ganoderma	B-I	PROPN	B
tsugae	I-I	NOUN	I
(	O	PUNCT	O
Ganodermataceae	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
Codonopsis	B-I	NOUN	B
pilosula	I-I	X	I
(	O	PUNCT	O
Campanulaceae	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
Angelica	B-I	PROPN	B
sinensis	I-I	NOUN	I
(	O	PUNCT	O
Apiaceae	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
traditional	O	ADJ	O
Chinese	O	ADJ	B
herbs	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
immunomodulatory	O	ADJ	B
functions	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
examine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
Chinese	B-I	ADJ	B
medicinal	I-I	ADJ	I
herb	I-I	NOUN	I
complex	I-I	NOUN	I
,	I-I	PUNCT	O
RG-CMH	I-I	NOUN	B
,	O	PUNCT	O
which	O	DET	O
represents	O	VERB	O
a	O	DET	O
mixture	B-I	NOUN	O
of	I-I	ADP	O
rose	I-I	VERB	O
geranium	I-I	NOUN	B
and	I-I	CCONJ	O
extracts	I-I	NOUN	B
of	I-I	ADP	O
G.	I-I	X	B
tsugae	I-I	X	I
,	I-I	PUNCT	O
C.	I-I	X	B
pilosula	I-I	X	I
and	I-I	CCONJ	O
A.	I-I	NOUN	B
sinensis	I-I	NOUN	I
,	O	PUNCT	O
can	O	AUX	O
improve	O	VERB	O
the	O	DET	O
immune	O	ADJ	B
cell	O	NOUN	I
count	O	NOUN	O
of	O	ADP	O
cancer	B-P	NOUN	B
patients	I-P	NOUN	B
receiving	I-P	VERB	O
chemotherapy	I-P	NOUN	B
and/or	I-P	CCONJ	O
radiotherapy	I-P	NOUN	B
to	O	PART	O
prevent	O	VERB	B
leucopenia	O	NOUN	B
and	O	CCONJ	O
immune	O	ADJ	B
impairment	O	NOUN	I
that	O	PRON	O
usually	O	ADV	O
occurs	O	VERB	O
during	O	ADP	O
cancer	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
fifty-eight	B-P	NUM	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
chemotherapy	I-I	NOUN	B
or	I-P	CCONJ	O
radiotherapy	I-I	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


Immune	B-OUT	ADJ	B
cell	I-OUT	NOUN	I
levels	I-OUT	NOUN	B
in	I-OUT	ADP	O
patient	I-OUT	NOUN	B
serum	I-OUT	NOUN	B
were	O	AUX	O
determined	O	VERB	O
before	O	ADP	O
,	O	PUNCT	O
and	O	CCONJ	O
following	O	VERB	O
,	O	PUNCT	O
6	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
cancer	O	NOUN	B
treatment	O	NOUN	I
for	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
either	O	CCONJ	O
an	O	DET	O
RG-CMH	B-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
RG-CMH	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
leucocytes	I-OUT	NOUN	B
from	O	ADP	O
31·5	O	PROPN	O
%	O	NOUN	O
for	O	ADP	O
the	B-I	DET	O
placebo	I-I	ADJ	B
group	O	NOUN	B
to	O	ADP	O
13·4	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
RG-CMH	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Similarly	B-OUT	ADV	O
,	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
neutrophils	I-OUT	NOUN	B
significantly	O	ADV	O
decreased	O	VERB	B
from	O	ADP	O
35·6	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
to	O	ADP	O
11·0	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
RG-CMH	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


RG-CMH	O	NOUN	B
intervention	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
T	I-OUT	NOUN	B
cells	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
helper	I-OUT	NOUN	B
T	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
cytotoxic	I-OUT	ADJ	B
T	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
natural	I-OUT	ADJ	B
killer	I-OUT	NOUN	I
cells	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
RG-CMH	O	NOUN	B
to	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
chemotherapy/radiotherapy	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
the	O	DET	O
capacity	O	NOUN	B
to	O	PART	O
delay	O	VERB	B
,	O	PUNCT	O
or	O	CCONJ	O
ease	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
levels	O	NOUN	B
of	O	ADP	O
leucocytes	O	NOUN	B
and	O	CCONJ	O
neutrophils	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
experienced	O	VERB	O
by	O	ADP	O
patients	O	NOUN	B
during	O	ADP	O
cancer	O	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
risperidone	B-I	NOUN	B
and	I-I	CCONJ	O
parent	I-I	NOUN	B
training	I-I	NOUN	B
on	O	ADP	O
adaptive	O	ADJ	B
functioning	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
pervasive	I-P	ADJ	B
developmental	I-P	ADJ	B
disorders	I-P	NOUN	I
and	I-P	CCONJ	O
serious	I-P	ADJ	O
behavioral	I-P	ADJ	B
problems	I-P	NOUN	O
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	B
Children	B-P	NOUN	B
with	I-P	ADP	O
Pervasive	I-P	ADJ	B
Developmental	I-P	PROPN	I
Disorders	I-P	PROPN	I
(	I-P	PUNCT	O
PDDs	I-P	NOUN	B
)	I-P	PUNCT	O
have	O	AUX	O
social	O	ADJ	B
interaction	O	NOUN	I
deficits	O	NOUN	I
,	O	PUNCT	O
delayed	O	VERB	B
communication	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
repetitive	O	ADJ	B
behaviors	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
impairments	O	NOUN	B
in	O	ADP	O
adaptive	O	ADJ	B
functioning	O	NOUN	I
.	O	PUNCT	O


Many	O	ADJ	O
children	O	NOUN	B
actually	O	ADV	O
show	O	VERB	O
a	O	DET	O
decline	O	NOUN	B
in	O	ADP	O
adaptive	O	ADJ	B
skills	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
age	O	NOUN	B
mates	O	NOUN	B
over	O	ADP	O
time	O	NOUN	B
.	O	PUNCT	O


METHOD	O	NOUN	O
This	O	DET	O
24-week	O	NOUN	O
,	O	PUNCT	O
three-site	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
clinical	O	ADJ	I
trial	O	NOUN	I
randomized	O	VERB	B
124	B-P	NUM	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
4	I-P	NUM	O
through	I-P	ADP	O
13	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
PDDs	I-P	NOUN	B
and	I-P	CCONJ	O
serious	I-P	ADJ	O
behavioral	I-P	ADJ	B
problems	I-P	NOUN	O
to	I-P	PART	O
medication	I-I	VERB	B
alone	I-I	ADV	O
(	I-P	PUNCT	O
MED	I-P	PROPN	B
;	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
49	I-P	NUM	O
;	I-P	PUNCT	O
risperidone	I-I	NOUN	B
0.5	I-P	NUM	O
to	I-P	PART	O
3.5	I-P	NUM	O
mg/day	I-P	NOUN	B
;	I-P	PUNCT	O
if	O	SCONJ	O
ineffective	O	ADJ	B
,	O	PUNCT	O
switch	O	NOUN	B
to	O	PART	O
aripiprazole	B-I	NOUN	B
was	O	AUX	O
permitted	O	VERB	O
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
medication	I-I	NOUN	B
plus	I-I	CCONJ	I
parent	I-I	NOUN	O
training	I-I	NOUN	O
(	I-I	PUNCT	O
PT	I-I	NOUN	B
)	I-I	PUNCT	O
(	O	PUNCT	O
COMB	O	NOUN	B
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
75	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Parents	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
in	I-P	ADP	O
COMB	I-P	PROPN	B
received	I-P	VERB	O
an	I-P	DET	O
average	I-P	NOUN	B
of	I-P	ADP	O
11.4	I-P	NUM	O
PT	I-I	PROPN	B
sessions	I-I	NOUN	B
.	I-I	PUNCT	O


Standard	O	ADJ	B
scores	O	NOUN	I
and	O	CCONJ	O
Age-Equivalent	O	PROPN	B
scores	O	NOUN	I
on	O	ADP	O
Vineland	O	PROPN	B
Adaptive	O	PROPN	I
Behavior	O	PROPN	I
Scales	O	PROPN	I
were	O	AUX	O
the	O	DET	O
outcome	O	NOUN	B
measures	O	NOUN	B
of	O	ADP	O
primary	O	ADJ	B
interest	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Seventeen	B-P	NUM	O
subjects	I-P	NOUN	B
did	I-P	AUX	O
not	I-P	PART	O
have	I-P	AUX	O
a	I-P	DET	O
post-randomization	I-P	ADJ	B
Vineland	I-P	PROPN	O
assessment	I-P	NOUN	O
.	I-P	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
used	O	VERB	O
a	O	DET	O
mixed	O	ADJ	O
model	O	NOUN	B
with	O	ADP	O
outcome	O	NOUN	B
conditioned	O	VERB	I
on	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
Vineland	O	PROPN	B
scores	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
showed	O	VERB	O
improvement	O	NOUN	B
over	O	ADP	O
the	O	DET	O
24-week	O	ADJ	O
trial	O	NOUN	O
on	O	ADP	O
all	O	DET	O
Vineland	O	PROPN	B
domains	O	NOUN	I
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
MED	O	PROPN	B
,	O	PUNCT	O
Vineland	B-OUT	PROPN	B
Socialization	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
Adaptive	I-OUT	PROPN	B
Composite	I-OUT	PROPN	I
Standard	I-OUT	PROPN	I
scores	I-OUT	NOUN	I
showed	O	VERB	O
greater	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
COMB	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.01	O	NUM	O
and	O	CCONJ	O
.05	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
effect	O	NOUN	B
sizes	O	NOUN	B
=	O	ADJ	O
0.35	O	NUM	O
and	O	CCONJ	O
0.22	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


On	O	ADP	O
Age	O	PROPN	B
Equivalent	O	PROPN	O
scores	O	NOUN	O
,	O	PUNCT	O
Socialization	B-OUT	PROPN	B
and	I-OUT	CCONJ	O
Communication	I-OUT	NOUN	B
domains	I-OUT	NOUN	I
showed	O	VERB	O
greater	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
COMB	O	PROPN	B
versus	O	CCONJ	O
MED	O	PROPN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
and	O	CCONJ	O
0.05	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
effect	O	NOUN	B
sizes	O	NOUN	B
=	O	ADJ	O
0.33	O	NUM	O
and	O	CCONJ	O
0.14	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Using	O	VERB	O
logistic	O	ADJ	B
regression	O	NOUN	I
,	O	PUNCT	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
COMB	O	ADJ	B
group	O	NOUN	B
were	O	AUX	O
twice	O	ADV	O
as	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
make	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
6	O	NUM	O
months	O	NOUN	B
'	O	PART	O
gain	O	NOUN	B
(	O	PUNCT	O
equal	O	ADJ	O
to	O	ADP	O
the	O	DET	O
passage	O	NOUN	B
of	O	ADP	O
time	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
Vineland	B-OUT	PROPN	B
Communication	I-OUT	PROPN	I
Age	I-OUT	PROPN	I
Equivalent	I-OUT	ADJ	B
score	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
MED	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
IQ	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
difference	O	NOUN	O
was	O	AUX	O
no	O	DET	O
longer	O	ADV	O
significant	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Reduction	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
maladaptive	O	ADJ	B
behavior	O	NOUN	I
promotes	O	VERB	B
improvement	O	NOUN	B
in	O	ADP	O
adaptive	O	ADJ	B
behavior	O	NOUN	I
.	O	PUNCT	O


Medication	B-I	NOUN	B
plus	I-I	CCONJ	I
PT	I-I	PROPN	B
shows	O	VERB	O
modest	O	ADJ	O
additional	O	ADJ	O
benefit	O	NOUN	B
over	O	ADP	O
medication	B-I	NOUN	B
alone	I-I	ADV	O
.	I-I	PUNCT	O


Clinical	O	ADJ	B
trial	O	NOUN	I
registration	O	NOUN	O
information-RUPP	O	NOUN	B
PI	O	NOUN	B
PDD	O	NOUN	B
:	O	PUNCT	O
Drug	O	NOUN	B
and	O	CCONJ	O
Behavioral	O	PROPN	O
Therapy	O	PROPN	O
for	O	ADP	O
Children	B-P	PROPN	B
With	I-P	ADP	O
Pervasive	I-P	ADJ	B
Developmental	I-P	PROPN	I
Disorders	I-P	PROPN	I
;	I-P	PUNCT	O
http	O	NOUN	B
:	O	PUNCT	O
//www.clinicaltrials.gov	O	PUNCT	O
;	O	PUNCT	O
NCT00080145	O	NOUN	O
.	O	PUNCT	O


Most	O	ADV	O
functional	O	ADJ	B
outcomes	O	NOUN	B
are	O	AUX	O
similar	O	ADJ	O
for	O	ADP	O
men	B-P	NOUN	B
and	I-P	CCONJ	O
women	I-P	NOUN	B
after	I-P	ADP	O
hip	I-P	NOUN	B
fracture	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
secondary	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
enhancing	O	VERB	B
mobility	O	NOUN	B
after	O	ADP	O
hip	O	NOUN	B
fracture	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
gender	O	NOUN	B
on	O	ADP	O
functional	O	ADJ	B
outcomes	O	NOUN	I
after	O	ADP	O
hip	O	NOUN	B
fracture	O	NOUN	I
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
extent	O	NOUN	O
to	O	PART	O
which	O	DET	O
gender	O	NOUN	B
influenced	O	VERB	O
functional	B-OUT	ADJ	B
outcome	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
response	I-OUT	NOUN	B
to	I-OUT	PART	O
exercise	I-OUT	VERB	B
in	O	ADP	O
older	B-P	ADJ	B
people	I-P	NOUN	I
after	I-P	ADP	O
hip	I-P	NOUN	B
fracture	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
any	O	DET	O
differences	O	NOUN	O
persisted	O	VERB	O
after	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
cognition	O	NOUN	B
,	O	PUNCT	O
weight	O	NOUN	B
and	O	CCONJ	O
age	O	NOUN	B
.	O	PUNCT	O


METHOD	O	NOUN	O
Secondary	B-P	ADJ	B
analysis	I-I	NOUN	I
of	I-I	ADP	O
data	I-I	NOUN	B
from	I-I	ADP	O
the	I-I	DET	O
Enhancing	I-I	VERB	B
Mobility	I-I	NOUN	B
After	I-I	ADP	O
Hip	I-I	PROPN	B
Fracture	I-I	PROPN	I
trial	I-I	NOUN	I
in	I-P	ADP	O
which	I-P	DET	O
older	I-P	ADJ	B
people	I-P	NOUN	I
after	I-P	ADP	O
hip	I-P	NOUN	B
fracture	I-P	NOUN	I
received	O	VERB	O
either	O	CCONJ	O
a	O	DET	O
lower	B-I	ADJ	B
or	I-I	CCONJ	O
higher	I-I	ADJ	B
intensity	I-I	NOUN	B
exercise	I-I	NOUN	I
program	I-I	NOUN	I
.	I-I	PUNCT	O


Functional	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
included	O	VERB	O
physical	B-OUT	ADJ	B
performance	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
self-reported	I-OUT	ADJ	B
measures	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Regression	O	NOUN	B
models	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
compare	O	VERB	B
genders	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
week	O	NOUN	B
4	O	NUM	O
and	O	CCONJ	O
week	O	NOUN	B
16	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
baseline	O	NOUN	B
values	O	NOUN	O
,	O	PUNCT	O
cognition	O	NOUN	B
,	O	PUNCT	O
weight	O	NOUN	B
and	O	CCONJ	O
age	O	NOUN	B
.	O	PUNCT	O


Interaction	O	NOUN	B
terms	O	NOUN	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
a	O	DET	O
differential	O	ADJ	O
impact	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
by	O	ADP	O
gender	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Outcome	O	NOUN	B
data	O	NOUN	I
were	O	AUX	O
available	O	ADJ	O
for	O	ADP	O
160	B-P	NUM	O
participants	I-P	NOUN	B
,	I-P	PUNCT	O
30	I-P	NUM	O
men	I-P	NOUN	B
(	I-P	PUNCT	O
19	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
130	I-P	NUM	O
women	I-P	NOUN	B
(	I-P	PUNCT	O
81	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
withdrawal	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
men	O	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
6	O	NUM	O
women	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
at	O	ADP	O
week	O	NOUN	B
16	O	NUM	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	B-OUT	DET	O
gender	I-OUT	NOUN	B
differences	I-OUT	NOUN	O
for	O	ADP	O
any	O	DET	O
baseline	B-OUT	NOUN	B
measures	I-OUT	NOUN	B
or	O	CCONJ	O
for	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
19	O	NUM	O
functional	B-OUT	ADJ	B
outcome	I-OUT	NOUN	O
measures	I-OUT	NOUN	O
at	O	ADP	O
weeks	O	NOUN	B
4	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
.	O	PUNCT	O


At	O	ADP	O
week	O	NOUN	B
4	O	NUM	O
men	O	NOUN	B
performed	O	VERB	O
better	O	ADV	O
in	O	ADP	O
knee	B-OUT	NOUN	B
extensor	I-OUT	NOUN	I
strength	I-OUT	NOUN	I
(	O	PUNCT	O
2.1	O	NUM	O
kg	O	NOUN	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.6	O	NUM	O
to	O	PART	O
3.7	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
difference	B-OUT	NOUN	O
did	I-OUT	AUX	O
not	I-OUT	PART	O
persist	I-OUT	VERB	O
after	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
persisted	O	VERB	O
after	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
baseline	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
cognition	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
age	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.038	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
week	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
men	O	NOUN	B
performed	O	VERB	O
better	O	ADV	O
in	O	ADP	O
coordinated	B-OUT	VERB	B
stability	I-OUT	NOUN	B
(	O	PUNCT	O
-10.0	O	NUM	O
error	O	NOUN	B
score	O	NOUN	I
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-17.6	O	NUM	O
to	O	PART	O
-2.4	O	NUM	O
,	O	PUNCT	O
p=0.010	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
persisted	B-OUT	VERB	O
after	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
baseline	B-OUT	NOUN	B
values	I-OUT	NOUN	B
only	O	ADV	O
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
cognition	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
age	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.073	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
week	O	NOUN	B
16	O	NUM	O
,	O	PUNCT	O
men	O	NOUN	B
performed	O	VERB	O
better	O	ADV	O
in	O	ADP	O
coordinated	B-OUT	VERB	B
stability	I-OUT	NOUN	B
(	O	PUNCT	O
-10.2	O	NUM	O
error	O	NOUN	B
score	O	NOUN	I
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-18.4	O	NUM	O
to	O	PART	O
-1.9	O	NUM	O
,	O	PUNCT	O
p=0.016	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
persisted	B-OUT	VERB	O
after	O	ADP	O
adjusting	O	VERB	O
only	O	ADV	O
for	O	ADP	O
cognitive	B-OUT	ADJ	B
impairment	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.029	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
age	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
baseline	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.135	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
indication	O	NOUN	B
of	O	ADP	O
a	O	DET	O
differential	B-OUT	ADJ	O
impact	I-OUT	NOUN	B
of	I-OUT	ADP	O
intervention	I-OUT	NOUN	B
type	I-OUT	NOUN	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
gender	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
A	O	DET	O
few	O	ADJ	O
between	O	ADP	O
gender	O	NOUN	B
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
strength	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
balance	I-OUT	NOUN	B
,	O	PUNCT	O
however	O	SCONJ	O
these	O	DET	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
confounded	O	VERB	O
by	O	ADP	O
body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
age	I-OUT	NOUN	B
and/or	I-OUT	CCONJ	O
cognition	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Effect	B-OUT	NOUN	B
of	O	ADP	O
hydrochlorothiazide	B-I	NOUN	B
therapy	I-I	NOUN	B
on	O	ADP	O
cardiac	B-OUT	ADJ	B
arrhythmias	I-OUT	NOUN	I
in	I-P	ADP	O
African-American	I-P	ADJ	B
men	I-P	NOUN	B
with	I-P	ADP	O
systemic	I-P	ADJ	B
hypertension	I-P	NOUN	I
and	I-P	CCONJ	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
left	I-P	ADJ	B
ventricular	I-P	ADJ	I
hypertrophy	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
hydrochlorothiazide	B-I	NOUN	B
therapy	I-I	NOUN	B
on	O	ADP	O
ventricular	B-OUT	ADJ	B
arrhythmias	I-OUT	NOUN	I
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
45	B-P	NUM	O
hypertensive	I-P	ADJ	B
African-American	I-P	ADJ	B
men	I-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
left	I-P	ADJ	B
ventricular	I-P	ADJ	I
(	I-P	PUNCT	I
LV	I-P	NOUN	O
)	I-P	PUNCT	O
hypertrophy	I-P	NOUN	O
.	I-P	PUNCT	O


After	O	ADP	O
medication	O	NOUN	B
washout	O	NOUN	B
,	O	PUNCT	O
patients	B-I	NOUN	B
were	I-I	AUX	O
treated	I-I	VERB	B
with	I-I	ADP	I
placebo	I-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
hydrochlorothiazide	I-I	NOUN	B
.	I-I	PUNCT	O


Clinical	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
biochemical	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
48-hour	I-OUT	ADJ	O
ambulatory	I-OUT	ADJ	B
electrocardiographic	I-OUT	ADJ	O
data	I-OUT	NOUN	B
was	O	AUX	O
collected	O	VERB	O
after	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
phase	O	NOUN	O
.	O	PUNCT	O


Signal-averaged	B-OUT	ADJ	B
electrocardiograms	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
a	O	DET	O
subgroup	B-P	NOUN	B
of	I-P	ADP	O
24	I-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Average	B-OUT	ADJ	B
LV	I-OUT	PROPN	B
posterior	I-OUT	ADJ	I
wall	I-OUT	NOUN	I
thickness	I-OUT	NOUN	B
was	O	AUX	O
15	O	NUM	O
+/-	O	CCONJ	O
1.1	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
septum	O	NOUN	B
16	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
LV	O	PROPN	B
mass	O	NOUN	I
420	O	NUM	O
+/-	O	CCONJ	O
90	O	NUM	O
g	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
LV	O	PROPN	B
mass	O	NOUN	I
index	O	NOUN	I
212	O	NUM	O
=	O	ADJ	O
51	O	NUM	O
g/m2	O	NOUN	B
.	O	PUNCT	O


Systolic	B-OUT	NOUN	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
168	O	NUM	O
+/-	O	CCONJ	O
18	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
after	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
phase	O	NOUN	O
and	O	CCONJ	O
146	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
after	O	ADP	O
hydrochlorothiazide	O	NOUN	B
;	O	PUNCT	O
diastolic	O	ADJ	B
BP	O	NOUN	I
was	O	AUX	O
103	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
and	O	CCONJ	O
89	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
potassium	I-OUT	NOUN	I
decreased	O	VERB	B
significantly	O	ADV	O
from	O	ADP	O
4.2	O	NUM	O
+/-	O	CCONJ	O
0.4	O	NUM	O
mmol/L	O	NOUN	O
to	O	PART	O
3.7	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
mmol/L	O	NOUN	O
after	O	ADP	O
hydrochlorothiazide	B-I	NOUN	B
therapy	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
average	O	ADJ	B
hourly	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
ventricular	B-OUT	ADJ	B
premature	I-OUT	ADJ	I
contractions	I-OUT	NOUN	I
was	O	AUX	O
22	O	NUM	O
with	O	ADP	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
25	O	NUM	O
with	O	ADP	O
hydrochlorothiazide	B-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
3	O	NUM	O
and	O	CCONJ	O
1	O	NUM	O
couplets	O	NOUN	B
and	O	CCONJ	O
0.2	O	NUM	O
and	O	CCONJ	O
0.2	O	NUM	O
runs	O	NOUN	O
of	O	ADP	O
ventricular	B-OUT	ADJ	B
tachycardia	I-OUT	NOUN	I
per	O	ADP	I
patient	O	NOUN	B
per	O	ADP	O
hour	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Variables	O	NOUN	B
of	O	ADP	O
signal-averaged	B-OUT	ADJ	B
electrocardiography	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
treatments	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
hypertensive	B-P	ADJ	B
African-American	I-P	ADJ	B
men	I-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
LV	I-P	NOUN	B
hypertrophy	I-P	NOUN	I
,	O	PUNCT	O
hydrochlorothiazide	B-I	NOUN	B
does	O	AUX	O
not	O	PART	O
worsen	O	VERB	O
ventricular	B-OUT	ADJ	B
arrhythmias	I-OUT	NOUN	I
or	O	CCONJ	O
signal-averaged	B-OUT	ADJ	B
electrocardiographic	I-OUT	ADJ	I
variables	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


MSLT	B-I	NOUN	B
in	O	ADP	O
primary	O	ADJ	B
insomnia	B-OUT	NOUN	I
:	I-OUT	PUNCT	O
stability	O	NOUN	B
and	O	CCONJ	O
relation	O	NOUN	O
to	O	ADP	O
nocturnal	B-OUT	ADJ	B
sleep	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVES	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
stability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
multiple	B-I	ADJ	B
sleep	I-I	NOUN	I
latency	I-I	NOUN	I
test	I-I	NOUN	I
(	I-I	PUNCT	O
MSLT	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
primary	B-OUT	ADJ	B
insomnia	I-OUT	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
relation	O	NOUN	O
to	O	ADP	O
total	B-OUT	ADJ	O
sleep	I-OUT	NOUN	O
time	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
controlled	O	ADJ	O
,	O	PUNCT	O
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	B
Outpatient	O	PROPN	I
with	O	ADP	I
sleep	O	NOUN	B
laboratory	O	NOUN	I
assessments	O	NOUN	O
in	O	ADP	O
months	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


PARTICIPANTS	O	VERB	B
Ninety-five	B-P	ADJ	O
primary	I-P	ADJ	B
insomniacs	I-P	NOUN	I
,	I-P	PUNCT	O
32-64	I-P	NUM	O
years	I-P	NOUN	O
old	I-P	ADJ	O
and	I-P	CCONJ	O
55	I-P	NUM	O
age-	I-P	NOUN	O
and	I-P	CCONJ	O
sex-matched	I-P	ADJ	B
general	I-P	ADJ	O
population-based	I-P	ADJ	B
,	I-P	PUNCT	O
representative	I-P	ADJ	O
controls	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
After	O	ADP	O
a	O	DET	O
screening	O	VERB	B
nocturnal	B-I	ADJ	B
polysomnograms	I-I	NOUN	O
(	I-I	PUNCT	O
NPSG	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
MSLT	B-I	VERB	B
the	O	DET	O
following	O	ADJ	O
day	O	NOUN	B
,	O	PUNCT	O
participants	B-P	NOUN	B
with	I-P	ADP	O
primary	I-P	ADJ	B
insomnia	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
take	O	VERB	O
zolpidem	B-I	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
50	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
45	O	NUM	O
)	O	PUNCT	O
nightly	O	ADV	B
for	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
months	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
,	O	PUNCT	O
while	O	SCONJ	O
taking	O	VERB	O
their	O	PRON	O
prescribed	O	VERB	B
treatments	O	NOUN	B
,	O	PUNCT	O
NPSGs	O	NOUN	B
and	O	CCONJ	O
MSLTs	B-I	VERB	B
the	O	DET	O
following	O	VERB	O
day	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
population-based	O	ADJ	B
sample	O	NOUN	I
served	O	VERB	O
as	O	ADP	O
controls	O	NOUN	B
and	O	CCONJ	O
received	O	VERB	O
a	O	DET	O
single	O	ADJ	O
NPSG	O	PROPN	B
followed	O	VERB	O
by	O	ADP	O
MSLT	B-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	NOUN	B
Mean	B-OUT	VERB	O
daily	I-OUT	ADV	O
sleep	I-OUT	NOUN	O
latency	I-OUT	NOUN	O
on	I-OUT	ADP	O
the	I-OUT	DET	O
screening	I-OUT	VERB	B
MSLT	I-OUT	NOUN	B
of	I-OUT	ADP	O
insomniacs	I-OUT	NOUN	B
was	O	AUX	O
normally	O	ADV	O
distributed	O	VERB	B
across	O	ADP	O
the	O	DET	O
full	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
MSLT	B-I	NOUN	B
scores	O	NOUN	I
and	O	CCONJ	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
a	O	DET	O
population-based	O	ADJ	B
representative	O	ADJ	O
control	O	NOUN	O
sample	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.006	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
insomniacs	O	NOUN	B
with	O	ADP	O
the	O	DET	O
highest	O	ADJ	O
screening	B-OUT	NOUN	B
MSLTs	I-OUT	VERB	B
had	O	AUX	O
the	O	DET	O
shortest	O	ADJ	B
screening	B-OUT	NOUN	O
total	I-OUT	ADJ	O
sleep	I-OUT	NOUN	O
times	I-OUT	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
MSLTs	B-I	PROPN	B
of	O	ADP	O
insomniacs	O	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
in	O	ADP	O
study	O	NOUN	B
month	O	NOUN	B
1	O	NUM	O
were	O	AUX	O
correlated	O	VERB	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.44	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
their	O	PRON	O
month	O	NOUN	B
8	O	NUM	O
MSLT	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
MSLT	I-OUT	NOUN	B
score	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
zolpidem	O	ADJ	B
group	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
from	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
stability	O	NOUN	B
within	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
also	O	ADV	O
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
some	O	DET	O
insomniacs	B-P	NOUN	B
show	O	VERB	O
a	O	DET	O
reliable	O	ADJ	O
disorder	O	NOUN	B
of	O	ADP	O
hyperarousal	B-OUT	NOUN	B
with	O	ADP	O
increased	O	VERB	B
wake	B-OUT	NOUN	O
drive	I-OUT	VERB	O
both	O	CCONJ	O
at	O	ADP	O
night	O	NOUN	B
and	O	CCONJ	O
during	O	ADP	O
the	O	DET	O
day	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
of	O	ADP	O
Pivotal	B-I	ADJ	B
Response	I-I	NOUN	I
Treatment	I-I	PROPN	B
Group	I-I	PROPN	I
for	O	ADP	O
parents	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
With	O	ADP	O
rates	O	NOUN	B
of	O	ADP	O
autism	O	NOUN	B
diagnosis	O	NOUN	B
continuing	O	VERB	B
to	O	PART	O
rise	O	VERB	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
an	O	DET	O
urgent	O	ADJ	O
need	O	NOUN	O
for	O	ADP	O
effective	O	ADJ	B
and	O	CCONJ	O
efficient	O	ADJ	B
service	O	NOUN	B
delivery	O	NOUN	O
models	O	NOUN	O
.	O	PUNCT	O


Pivotal	B-I	ADJ	B
Response	I-I	NOUN	I
Treatment	I-I	NOUN	O
(	I-I	PUNCT	O
PRT	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
considered	O	VERB	O
an	O	DET	O
established	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
autism	O	NOUN	B
spectrum	O	NOUN	I
disorder	O	NOUN	I
(	O	PUNCT	O
ASD	O	PROPN	B
)	O	PUNCT	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
have	O	AUX	O
been	O	AUX	O
few	O	ADJ	O
well-controlled	O	ADJ	O
studies	O	NOUN	B
with	O	ADP	O
adequate	O	ADJ	B
sample	O	NOUN	B
size	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
conduct	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
PRT	B-I	PROPN	B
parent	I-I	NOUN	B
training	I-I	NOUN	B
group	I-I	NOUN	I
(	I-I	PUNCT	O
PRTG	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
targeting	O	VERB	B
language	O	NOUN	B
deficits	O	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fifty-three	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
and	I-P	CCONJ	O
significant	I-P	ADJ	B
language	I-P	NOUN	B
delay	I-P	NOUN	B
between	I-P	ADP	O
2	I-P	NUM	O
and	I-P	CCONJ	O
6	I-P	NUM	O
years	I-P	NOUN	B
old	I-P	ADJ	O
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-I	PART	O
PRTG	I-I	NOUN	B
(	I-I	PUNCT	O
N	I-I	NOUN	O
=	I-I	ADJ	O
27	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
psychoeducation	I-I	NOUN	B
group	I-I	NOUN	I
(	I-P	PUNCT	O
PEG	I-P	NOUN	B
;	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
26	I-P	NUM	O
)	I-P	PUNCT	O
for	I-P	ADP	O
12	I-P	NUM	O
weeks	I-P	NOUN	B
.	O	PUNCT	O


The	O	DET	O
PRTG	O	NOUN	B
taught	O	VERB	O
parents	O	NOUN	B
behavioral	O	ADJ	B
techniques	O	NOUN	O
to	O	PART	O
facilitate	O	VERB	O
language	O	NOUN	B
development	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
PEG	O	NOUN	B
taught	O	VERB	O
general	O	ADJ	O
information	O	NOUN	B
about	O	ADP	O
ASD	O	VERB	B
(	O	PUNCT	O
clinical	O	ADJ	B
trial	O	NOUN	I
NCT01881750	O	NOUN	O
;	O	PUNCT	O
http	O	NOUN	B
:	O	PUNCT	O
//www.clinicaltrials.gov	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Analysis	B-OUT	NOUN	I
of	I-OUT	ADP	O
child	I-OUT	NOUN	B
utterances	I-OUT	NOUN	B
during	I-OUT	ADP	O
the	I-OUT	DET	O
structured	I-OUT	ADJ	B
laboratory	I-OUT	NOUN	I
observation	I-OUT	NOUN	I
(	O	PUNCT	O
primary	O	ADJ	B
outcome	O	NOUN	I
)	O	PUNCT	O
indicated	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PEG	O	NOUN	B
,	O	PUNCT	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PRTG	O	NOUN	B
demonstrated	B-OUT	VERB	O
greater	I-OUT	ADJ	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
utterances	I-OUT	NOUN	B
(	O	PUNCT	O
F	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
43	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
3.53	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.038	O	NUM	O
,	O	PUNCT	O
d	O	NOUN	O
=	O	ADJ	O
0.42	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Results	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
parents	O	NOUN	B
were	O	AUX	O
able	B-I	ADJ	O
to	I-I	PART	O
learn	O	VERB	B
PRT	O	PROPN	B
in	O	ADP	O
a	O	DET	O
group	O	NOUN	B
format	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
parents	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PRTG	O	NOUN	B
(	O	PUNCT	O
84	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
met	O	VERB	O
fidelity	O	NOUN	B
of	O	ADP	O
implementation	O	NOUN	B
criteria	O	NOUN	I
after	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Children	O	NOUN	B
also	O	ADV	O
demonstrated	B-OUT	VERB	O
greater	I-OUT	ADJ	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
adaptive	I-OUT	ADJ	B
communication	I-OUT	NOUN	I
skills	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
Vineland-II	I-OUT	X	B
)	I-OUT	PUNCT	O
following	O	VERB	O
PRTG	O	NOUN	B
and	O	CCONJ	O
baseline	O	NOUN	B
Mullen	O	ADJ	B
visual	O	ADJ	B
reception	O	NOUN	I
scores	O	NOUN	O
predicted	O	VERB	O
treatment	O	NOUN	B
response	O	NOUN	I
to	O	PART	O
PRTG	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
of	O	ADP	O
group-delivered	O	ADJ	B
PRT	O	PROPN	B
and	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
largest	O	ADJ	O
experimental	O	ADJ	B
investigations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PRT	O	PROPN	B
model	O	NOUN	B
to	O	ADP	O
date	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
specific	O	ADJ	O
instruction	B-I	NOUN	B
in	O	ADP	O
PRT	B-OUT	PROPN	B
results	I-OUT	NOUN	B
in	I-OUT	ADP	O
greater	I-OUT	ADJ	O
skill	I-OUT	NOUN	B
acquisition	I-OUT	NOUN	B
for	I-OUT	ADP	O
both	I-OUT	DET	O
parents	I-OUT	NOUN	B
and	O	CCONJ	O
children	O	NOUN	B
,	O	PUNCT	O
especially	B-OUT	ADV	O
in	I-OUT	ADP	O
functional	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
adaptive	I-OUT	ADJ	B
communication	I-OUT	NOUN	I
skills	O	NOUN	I
.	O	PUNCT	O


Further	B-I	ADJ	O
research	I-I	NOUN	B
in	O	ADP	O
PRT	O	PROPN	B
is	O	AUX	O
warranted	O	VERB	O
to	O	PART	O
replicate	O	VERB	B
the	O	DET	O
observed	O	VERB	O
results	O	NOUN	B
and	O	CCONJ	O
address	O	VERB	O
other	O	ADJ	O
core	O	NOUN	O
ASD	O	VERB	B
symptoms	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Are	O	AUX	O
there	O	PRON	O
indications	O	NOUN	B
for	O	ADP	O
adjuvant	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
after	I-I	ADP	O
excision	I-P	NOUN	B
of	I-P	ADP	O
colorectal	I-P	ADJ	B
cancer	I-P	NOUN	I
?	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


Pre-bent	B-I	ADJ	B
instruments	I-I	NOUN	I
used	O	VERB	O
in	O	ADP	O
single-port	B-I	ADJ	B
laparoscopic	I-I	ADJ	I
surgery	I-I	NOUN	I
versus	I-I	CCONJ	O
conventional	I-I	ADJ	B
laparoscopic	I-I	ADJ	B
surgery	I-I	NOUN	I
:	I-I	PUNCT	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
performance	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dry	O	ADJ	B
lab	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	B
Different	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
single-incision	B-I	ADJ	B
laparoscopic	I-I	ADJ	I
surgery	I-I	NOUN	I
(	I-I	PUNCT	O
SILS	I-I	NOUN	B
)	I-I	PUNCT	O
have	O	AUX	O
become	O	VERB	O
increasingly	O	ADV	O
popular	O	ADJ	O
.	O	PUNCT	O


Although	O	SCONJ	O
SILS	O	NOUN	B
is	O	AUX	O
technically	O	ADV	O
even	O	ADV	O
more	O	ADV	O
challenging	O	ADJ	O
than	O	ADP	O
conventional	O	ADJ	B
laparoscopy	O	NOUN	B
,	O	PUNCT	O
published	O	VERB	B
data	O	NOUN	I
of	O	ADP	O
first	O	ADJ	O
clinical	O	ADJ	B
series	O	NOUN	I
seem	O	VERB	O
to	O	PART	O
demonstrate	O	VERB	O
the	O	DET	O
feasibility	O	NOUN	B
of	O	ADP	O
these	O	DET	O
approaches	O	NOUN	B
.	O	PUNCT	O


Various	O	ADJ	O
attempts	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
made	O	VERB	O
to	O	PART	O
overcome	O	VERB	B
restrictions	O	NOUN	B
due	O	ADP	O
to	O	PART	O
loss	O	NOUN	B
of	O	ADP	O
triangulation	O	NOUN	B
in	O	ADP	O
SILS	O	NOUN	B
by	O	ADP	O
specially	O	ADV	O
designed	O	VERB	O
SILS-specific	O	ADJ	B
instruments	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
involving	O	VERB	O
novices	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dry	O	ADJ	B
lab	O	NOUN	I
compared	O	VERB	O
task	B-OUT	NOUN	B
performances	I-OUT	NOUN	B
between	O	ADP	O
conventional	B-I	ADJ	B
laparoscopic	I-I	ADJ	B
surgery	I-I	NOUN	I
(	I-I	PUNCT	O
CLS	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
single-port	B-I	ADJ	B
laparoscopic	I-I	ADJ	I
surgery	I-I	NOUN	I
(	O	PUNCT	O
SPLS	O	NOUN	B
)	O	PUNCT	O
using	O	VERB	O
newly	O	ADV	O
designed	O	VERB	O
pre-bent	O	ADJ	B
instruments	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
90	B-P	NUM	O
medical	I-P	ADJ	B
students	I-P	NOUN	I
without	I-P	ADP	O
previous	I-P	ADJ	O
experience	I-P	NOUN	O
in	I-P	ADP	O
laparoscopic	I-P	ADJ	B
techniques	I-P	NOUN	I
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
undergo	I-P	VERB	O
one	I-P	NUM	O
of	I-P	ADP	O
three	I-P	NUM	O
procedures	I-P	NOUN	B
:	I-P	PUNCT	O
CLS	I-P	NOUN	B
,	I-P	PUNCT	O
SPLS	I-P	PROPN	B
using	I-P	VERB	O
two	I-P	NUM	O
pre-bent	I-P	ADJ	B
instruments	I-P	NOUN	I
(	I-P	PUNCT	O
SPLS-pp	I-P	PROPN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
SPLS	I-I	PROPN	B
using	I-P	VERB	O
one	I-P	NUM	O
pre-bent	I-P	ADJ	B
and	I-P	CCONJ	O
one	I-P	NUM	O
straight	I-P	ADJ	O
laparoscopic	I-P	ADJ	O
instrument	I-P	NOUN	O
(	I-P	PUNCT	O
SPLS-ps	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


In	O	ADP	O
the	O	DET	O
dry	O	ADJ	B
lab	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
participants	O	NOUN	B
performed	O	VERB	O
four	O	NUM	O
typical	O	ADJ	O
laparoscopic	O	ADJ	B
tasks	O	NOUN	I
of	O	ADP	O
increasing	O	VERB	B
difficulty	O	NOUN	B
.	O	PUNCT	O


Evaluation	O	NOUN	B
included	O	VERB	O
performance	B-OUT	NOUN	B
times	I-OUT	NOUN	O
or	I-OUT	CCONJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
completed	I-OUT	VERB	B
tasks	I-OUT	NOUN	B
within	I-OUT	ADP	O
a	I-OUT	DET	O
given	I-OUT	VERB	O
time	I-OUT	NOUN	B
frame	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


All	O	DET	O
performances	B-OUT	NOUN	B
were	O	AUX	O
videotaped	O	VERB	B
and	O	CCONJ	O
evaluated	O	VERB	B
for	O	ADP	O
unsuccessful	B-OUT	ADJ	O
attempts	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
unwanted	I-OUT	ADJ	O
interactions	I-OUT	NOUN	B
of	I-OUT	ADP	O
instruments	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Using	O	VERB	O
subjective	B-OUT	ADJ	B
questionnaires	I-OUT	NOUN	I
,	O	PUNCT	O
the	O	DET	O
participants	O	NOUN	B
rated	B-OUT	VERB	O
difficulties	I-OUT	NOUN	B
with	I-OUT	ADP	O
two-dimensional	I-OUT	ADJ	B
vision	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
coordination	I-OUT	NOUN	B
of	I-OUT	ADP	O
instruments	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Task	B-OUT	NOUN	B
performances	I-OUT	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
better	O	ADJ	O
in	O	ADP	O
the	O	DET	O
CLS	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
either	O	CCONJ	O
SPLS	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
SPLS-ps	O	ADJ	B
group	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
tendency	O	NOUN	O
toward	O	ADP	O
better	O	ADJ	O
performances	B-OUT	NOUN	B
than	O	ADP	O
the	O	DET	O
SPLS-pp	O	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
difference	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
.	O	PUNCT	O


Video	O	NOUN	B
sequences	O	NOUN	I
and	O	CCONJ	O
participants`	O	NOUN	O
questionnaires	O	NOUN	B
showed	O	VERB	O
instrument	B-OUT	NOUN	B
interaction	I-OUT	NOUN	B
as	O	ADP	O
the	O	DET	O
major	B-OUT	ADJ	O
problem	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
single-incision	O	ADJ	B
surgery	O	NOUN	I
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Although	O	SCONJ	O
SILS	O	NOUN	B
is	O	AUX	O
feasible	O	ADJ	O
,	O	PUNCT	O
as	O	ADP	O
shown	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
series	O	NOUN	I
published	O	VERB	B
by	O	ADP	O
laparoscopically	O	ADV	B
experienced	O	ADJ	O
experts	O	NOUN	B
,	O	PUNCT	O
SILS	O	NOUN	B
techniques	O	NOUN	I
are	O	AUX	O
demanding	O	VERB	O
due	O	ADP	O
to	O	ADP	O
restrictions	O	NOUN	O
that	O	PRON	O
come	O	VERB	O
with	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
triangulation	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
can	O	AUX	O
be	O	AUX	O
compensated	O	VERB	B
only	O	ADV	O
partially	O	ADV	O
by	O	ADP	O
currently	O	ADV	O
available	O	ADJ	O
SILS-designed	O	ADJ	B
instruments	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
future	O	NOUN	O
of	O	ADP	O
SILS	O	PROPN	B
depends	O	VERB	O
on	O	ADP	O
further	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
the	O	DET	O
available	O	ADJ	O
equipment	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
approaches	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
needlescopically	O	ADV	B
assisted	O	VERB	I
or	O	CCONJ	O
robotically	O	ADV	B
assisted	O	ADJ	I
procedures	O	NOUN	I
.	O	PUNCT	O


Gefitinib	B-I	NOUN	B
versus	O	CCONJ	O
placebo	B-I	NOUN	B
in	O	ADP	O
completely	B-P	ADV	O
resected	I-P	VERB	B
non-small-cell	I-P	ADJ	B
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
NCIC	O	NOUN	B
CTG	O	NOUN	B
BR19	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
Survival	O	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
completely	I-P	ADV	O
resected	I-P	VERB	B
non-small-cell	I-P	ADJ	B
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
NSCLC	I-P	NOUN	B
)	I-P	PUNCT	O
is	O	AUX	O
unsatisfactory	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
2002	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
adjuvant	O	ADJ	B
chemotherapy	O	NOUN	I
was	O	AUX	O
not	O	PART	O
established	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
study	O	NOUN	I
assessed	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
adjuvant	O	ADJ	B
gefitinib	B-I	NOUN	B
on	O	ADP	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
completely	I-P	ADV	O
resected	I-P	VERB	B
(	I-P	PUNCT	O
stage	I-P	NOUN	B
IB	I-P	NOUN	I
,	I-P	PUNCT	O
II	I-P	NUM	B
,	I-P	PUNCT	O
or	I-P	CCONJ	O
IIIA	I-P	NOUN	B
)	I-P	PUNCT	O
NSCLC	I-P	NOUN	B
stratified	I-P	VERB	B
by	I-P	ADP	O
stage	I-P	NOUN	B
,	I-P	PUNCT	O
histology	I-P	NOUN	B
,	I-P	PUNCT	O
sex	I-P	NOUN	B
,	I-P	PUNCT	O
postoperative	I-P	ADJ	B
radiotherapy	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
chemotherapy	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
(	O	PUNCT	O
1:1	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
receive	O	VERB	O
gefitinib	B-I	NOUN	B
250	I-I	NUM	O
mg	I-I	NOUN	O
per	I-I	ADP	O
day	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
for	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Study	O	NOUN	B
end	O	NOUN	O
points	O	NOUN	O
were	O	AUX	O
OS	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
disease-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
DFS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
As	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
early	O	ADJ	B
closure	O	NOUN	I
,	O	PUNCT	O
503	B-P	NUM	O
of	I-P	ADP	O
1,242	I-P	NUM	O
planned	I-P	VERB	B
patients	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
(	O	PUNCT	O
251	O	NUM	O
to	O	PART	O
gefitinib	B-I	NOUN	B
and	O	CCONJ	O
252	O	NUM	O
to	O	PART	O
placebo	B-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Baseline	O	NOUN	B
factors	O	NOUN	O
were	O	AUX	O
balanced	O	VERB	O
between	O	ADP	O
the	O	DET	O
arms	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
a	O	DET	O
median	O	NOUN	B
of	O	ADP	O
4.7	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
0.1	O	NUM	O
to	O	PART	O
6.3	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
OS	B-OUT	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
[	O	PUNCT	O
HR	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
1.24	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.94	O	NUM	O
to	O	PART	O
1.64	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.14	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
DFS	B-OUT	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
1.22	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.93	O	NUM	O
to	O	PART	O
1.61	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.15	O	NUM	O
)	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
arms	O	NOUN	B
.	O	PUNCT	O


Exploratory	O	ADJ	B
analyses	O	NOUN	I
demonstrated	O	VERB	O
no	O	DET	O
DFS	B-OUT	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
1.28	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.92	O	NUM	O
to	O	PART	O
1.76	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.14	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
OS	B-OUT	NOUN	B
benefit	I-OUT	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
1.24	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.90	O	NUM	O
to	O	PART	O
1.71	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.18	O	NUM	O
)	O	PUNCT	O
from	O	ADP	O
gefitinib	B-I	NOUN	B
for	O	ADP	O
344	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
epidermal	I-P	ADJ	B
growth	I-P	NOUN	I
factor	I-P	NOUN	I
receptor	I-P	NOUN	I
(	I-P	PUNCT	O
EGFR	I-P	NOUN	B
)	I-P	PUNCT	O
wild-type	O	ADJ	B
tumors	O	NOUN	I
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
DFS	B-OUT	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
1.84	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.44	O	NUM	O
to	O	PART	O
7.73	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.395	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
OS	B-OUT	NOUN	B
benefit	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
,	O	PUNCT	O
3.16	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.61	O	NUM	O
to	O	PART	O
16.45	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.15	O	NUM	O
)	O	PUNCT	O
from	O	ADP	O
gefitinib	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
15	O	NUM	O
patients	B-P	NOUN	B
with	O	ADP	O
EGFR	O	NOUN	B
mutation-positive	O	ADJ	B
tumors	O	NOUN	I
.	O	PUNCT	O


Adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
were	O	AUX	O
those	O	DET	O
expected	O	VERB	O
with	O	ADP	O
an	O	DET	O
EGFR	O	NOUN	B
inhibitor	O	NOUN	I
.	O	PUNCT	O


Serious	B-OUT	ADJ	B
adverse	I-OUT	ADJ	I
events	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
≤	O	ADJ	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
except	B-OUT	SCONJ	O
infection	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
in	O	ADP	O
each	O	DET	O
arm	O	NOUN	B
had	B-OUT	AUX	O
fatal	I-OUT	ADJ	B
pneumonitis	I-OUT	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Although	O	SCONJ	O
the	O	DET	O
trial	O	NOUN	B
closed	O	VERB	O
prematurely	O	ADV	O
and	O	CCONJ	O
definitive	O	ADJ	B
statements	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
adjuvant	B-I	ADJ	B
gefitinib	I-I	NOUN	B
can	O	AUX	O
not	O	PART	O
be	O	AUX	O
made	O	VERB	O
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
unlikely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
benefit	O	NOUN	B
.	O	PUNCT	O


Abnormal	O	ADJ	B
cardiac	O	ADJ	B
contractility	O	NOUN	I
in	O	ADP	O
long-term	B-I	ADJ	B
exogenous	I-I	ADJ	B
subclinical	I-I	ADJ	O
hyperthyroid	I-I	ADJ	B
patients	I-P	NOUN	B
as	O	ADP	O
demonstrated	O	VERB	O
by	O	ADP	O
two-dimensional	O	ADJ	B
echocardiography	O	NOUN	I
speckle	O	NOUN	I
tracking	O	NOUN	I
imaging	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Subclinical	O	ADJ	B
hyperthyroidism	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
cardiovascular	B-OUT	ADJ	B
morbidity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Recent	O	ADJ	O
advances	O	NOUN	O
in	O	ADP	O
echocardiography	O	NOUN	B
imaging	O	NOUN	I
have	O	AUX	O
allowed	O	VERB	O
sophisticated	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
myocardial	B-OUT	ADJ	B
tissue	O	NOUN	I
properties	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
myocardial	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
long-term	O	ADJ	B
exogenous	B-I	ADJ	B
subclinical	I-I	ADJ	O
hyperthyroidism	I-I	NOUN	O
using	O	VERB	O
two-dimensional	B-I	ADJ	B
speckle	I-I	NOUN	I
tracking	I-I	NOUN	I
echocardiography	I-I	NOUN	I
imaging	I-I	NOUN	I
(	I-I	PUNCT	O
2D-STE	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


DESIGN	O	VERB	O
Prospective	O	ADJ	B
,	O	PUNCT	O
single-blinded	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
duration	O	NOUN	B
with	O	ADP	O
two	O	NUM	O
parallel	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Totally	B-P	ADV	O
25	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
history	I-P	NOUN	B
of	I-P	ADP	O
differentiated	I-P	VERB	O
thyroid	I-P	NOUN	B
carcinoma	I-P	NOUN	I
on	I-P	ADP	O
long-term	I-P	ADJ	B
TSH-suppressive	I-P	ADJ	B
levothyroxine	I-P	NOUN	I
(	I-P	PUNCT	O
l-T	I-P	NOUN	B
(	I-P	PUNCT	O
4	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
substitution	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
persistent	O	ADJ	B
TSH-suppressive	B-I	ADJ	B
l-T	I-I	NOUN	B
(	I-I	PUNCT	O
4	I-I	NUM	O
)	I-I	PUNCT	O
substitution	I-I	NOUN	B
(	O	PUNCT	O
low-TSH	O	ADJ	B
group	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
restoration	B-I	NOUN	B
of	I-I	ADP	O
euthyroidism	I-I	NOUN	B
.	I-I	PUNCT	O


Additionally	B-P	ADV	O
40	I-P	NUM	O
euthyroid	I-P	ADJ	B
controls	I-P	NOUN	I
were	I-P	AUX	O
studied	I-P	VERB	O
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
(	O	PUNCT	O
PROPOSAL	O	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
At	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
showed	O	VERB	O
normal	B-OUT	ADJ	B
left	I-OUT	ADJ	I
ventricular	I-OUT	ADJ	I
(	I-OUT	PUNCT	I
LV	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
systolic	I-OUT	NOUN	B
function	I-OUT	NOUN	I
but	O	CCONJ	O
impaired	B-OUT	ADJ	B
diastolic	I-OUT	ADJ	O
function	I-OUT	NOUN	O
as	O	ADP	O
assessed	O	VERB	B
with	O	ADP	O
conventional	O	ADJ	O
echocardiographic	O	ADJ	B
parameters	O	NOUN	B
.	O	PUNCT	O


Importantly	O	ADV	O
,	O	PUNCT	O
2D-STE	O	NOUN	B
analysis	O	NOUN	I
demonstrated	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
subclinical	B-OUT	ADJ	B
LV	I-OUT	NOUN	O
systolic	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
with	O	ADP	O
impaired	B-OUT	ADJ	B
circumferential	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
longitudinal	I-OUT	ADJ	B
strain	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
strain	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
isovolumic	O	ADJ	B
relaxation	O	NOUN	I
time	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
restoration	O	NOUN	B
of	O	ADP	O
euthyroidism	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
improvement	B-OUT	NOUN	B
in	I-OUT	ADP	O
LV	I-OUT	PROPN	B
systolic	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
function	I-OUT	NOUN	I
as	O	ADP	O
assessed	O	VERB	B
with	O	ADP	O
2D-STE	O	NOUN	B
strain	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Prolonged	B-I	ADJ	B
subclinical	I-I	ADJ	B
hyperthyroidism	I-I	NOUN	I
leads	O	VERB	O
to	O	PART	O
systolic	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
reversible	O	ADJ	O
after	O	ADP	O
restoration	O	NOUN	B
of	O	ADP	O
euthyroidism	O	NOUN	B
.	O	PUNCT	O


2D-STE	O	NOUN	B
is	O	AUX	O
a	O	DET	O
more	O	ADV	O
sensitive	O	ADJ	B
technique	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	O
subtle	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
LV	O	PROPN	B
performance	O	NOUN	B
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Quadratus	O	PROPN	B
lumborum	B-I	NOUN	I
block	I-I	NOUN	I
for	O	ADP	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
after	I-P	ADP	O
caesarean	I-I	ADJ	B
section	I-I	NOUN	I
:	I-I	PUNCT	O
A	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Effective	O	ADJ	B
postoperative	O	ADJ	B
analgesia	O	NOUN	I
after	O	ADP	O
caesarean	B-I	ADJ	B
section	O	NOUN	I
is	O	AUX	O
important	O	ADJ	O
because	O	SCONJ	O
it	O	PRON	O
enables	O	VERB	O
early	O	ADJ	B
ambulation	O	NOUN	B
and	O	CCONJ	O
facilitates	O	VERB	O
breast-feeding	O	NOUN	B
.	O	PUNCT	O


Several	O	ADJ	O
case	O	NOUN	B
reports	O	NOUN	I
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
local	B-I	ADJ	B
anaesthetic	I-I	ADJ	B
injection	I-I	NOUN	I
around	O	ADP	O
the	O	DET	O
quadratus	O	X	B
lumborum	O	NOUN	I
muscle	O	NOUN	I
is	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
providing	O	VERB	O
pain	O	NOUN	B
relief	O	NOUN	I
after	O	ADP	O
various	O	ADJ	O
abdominal	O	ADJ	B
operations	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
pain	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
quadratus	B-I	NOUN	B
lumborum	I-I	NOUN	I
block	I-I	NOUN	I
(	O	PUNCT	O
QLB	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
close	O	ADJ	O
proximity	O	NOUN	B
to	O	PART	O
the	O	DET	O
surface	O	NOUN	B
and	O	CCONJ	O
uses	O	VERB	O
a	O	DET	O
fascial	O	ADJ	B
compartment	O	NOUN	I
path	O	NOUN	I
to	O	PART	O
extend	O	VERB	O
the	O	DET	O
distribution	O	NOUN	B
of	O	ADP	O
local	O	ADJ	B
anaesthesia	O	NOUN	I
into	O	ADP	O
the	O	DET	O
posterior	O	ADJ	B
abdominal	O	ADJ	I
wall	O	NOUN	I
and	O	CCONJ	O
paravertebral	O	ADJ	B
space	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
central	O	ADJ	B
effect	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
of	O	ADP	O
vital	O	ADJ	O
importance	O	NOUN	O
when	O	SCONJ	O
managing	O	VERB	B
the	O	DET	O
visceral	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
after	I-P	ADP	O
caesarean	I-P	ADJ	B
section	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
hypothesised	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
QLB	O	PROPN	B
after	O	ADP	O
caesarean	B-P	ADJ	B
section	I-P	NOUN	I
can	O	AUX	O
provide	O	VERB	O
adequate	O	ADJ	B
pain	O	NOUN	B
relief	O	NOUN	I
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
multimodal	O	ADJ	B
approach	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	VERB	O
Double-blind	O	NOUN	B
,	O	PUNCT	O
randomised	O	VERB	B
and	O	CCONJ	O
controlled	O	VERB	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
A	B-P	DET	O
single	I-P	ADJ	O
centre	I-P	NOUN	O
between	I-P	ADP	O
June	I-P	PROPN	O
2014	I-P	NUM	O
and	I-P	CCONJ	O
December	I-P	PROPN	O
2014	I-P	NUM	O
.	I-P	PUNCT	O


PATIENTS	O	VERB	O
Fifty	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
American	I-P	PROPN	B
Society	I-P	PROPN	I
of	I-P	ADP	I
Anesthesiologists	I-P	PROPN	I
physical	I-P	ADJ	O
status	I-P	NOUN	O
1	I-P	NUM	O
or	I-P	CCONJ	O
2	I-P	NUM	O
,	I-P	PUNCT	O
with	I-P	ADP	O
normal	I-P	ADJ	O
singleton	I-P	NOUN	O
pregnancies	I-P	NOUN	O
with	I-P	ADP	O
a	I-P	DET	O
gestation	I-P	NOUN	B
of	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADJ	O
37	I-P	NUM	O
weeks	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
scheduled	I-P	VERB	B
for	I-P	ADP	O
elective	I-P	ADJ	B
caesarean	I-P	ADJ	B
section	I-P	NOUN	I
under	I-P	ADP	O
spinal	I-P	ADJ	B
anaesthesia	I-P	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
enrolled	O	VERB	O
into	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
a	O	DET	O
QLB	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
0.125	B-I	NUM	O
%	I-I	NOUN	O
bupivacaine	I-I	NOUN	B
0.2	O	NUM	O
ml	O	NOUN	O
kg⁻¹	O	NOUN	O
(	B-I	PUNCT	O
Group	I-I	PROPN	B
1	I-I	NUM	O
)	I-I	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
QLB	O	NOUN	B
(	B-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
25	I-I	NUM	O
)	I-I	PUNCT	O
with	I-I	ADP	O
0.9	I-I	NUM	O
%	I-I	NOUN	O
Normal	O	ADJ	B
saline	O	NOUN	I
0.2	O	NUM	O
ml	O	NOUN	O
kg⁻¹	O	NOUN	O
(	O	PUNCT	O
Group	O	PROPN	B
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


MAIN	O	PROPN	O
OUTCOME	O	NOUN	B
MEASURES	O	NOUN	O
The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
for	B-OUT	ADP	O
the	I-OUT	DET	O
study	I-OUT	NOUN	B
was	I-OUT	AUX	O
the	I-OUT	DET	O
morphine	I-OUT	NOUN	B
demands	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
doses	I-OUT	NOUN	B
delivered	I-OUT	VERB	O
by	I-OUT	ADP	O
a	I-OUT	DET	O
patient-controlled	I-OUT	ADJ	B
analgesia	O	NOUN	I
system	O	NOUN	I
at	O	ADP	O
predetermined	O	VERB	O
intervals	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
24	O	NUM	O
and	O	CCONJ	O
48	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
secondary	B-OUT	ADJ	O
endpoints	I-OUT	NOUN	B
were	I-OUT	AUX	O
visual	I-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
for	I-OUT	ADP	O
pain	I-OUT	NOUN	B
at	I-OUT	ADP	O
rest	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
on	I-OUT	ADP	O
movement	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
dynamic	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pruritus	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
itching	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
,	O	PUNCT	O
vomiting	O	NOUN	B
and	O	CCONJ	O
sedation	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
local	O	ADJ	B
anaesthetic	O	ADJ	B
used	B-OUT	VERB	O
significantly	I-OUT	ADV	O
less	O	ADJ	O
morphine	O	NOUN	B
than	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
at	O	ADP	O
24	O	NUM	O
and	O	CCONJ	O
48	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
caesarean	O	ADJ	B
section	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
local	O	ADJ	B
anaesthetic	B-OUT	ADJ	B
group	I-OUT	NOUN	I
had	I-OUT	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
morphine	O	NOUN	B
demand	O	NOUN	B
than	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
24	O	NUM	O
and	O	CCONJ	O
48	B-OUT	NUM	O
h	I-OUT	NOUN	O
after	O	ADP	O
caesarean	O	ADJ	B
section	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
VAS	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
local	O	ADJ	B
anaesthetic	O	ADJ	B
group	O	NOUN	I
than	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
VAS	O	NOUN	B
for	O	ADP	O
pain	O	NOUN	B
at	O	ADP	O
rest	O	NOUN	B
at	O	ADP	O
all	O	DET	O
times	O	NOUN	O
except	O	SCONJ	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
caesarean	O	NOUN	B
section	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
VAS	O	NOUN	B
for	O	ADP	O
pain	O	NOUN	B
on	O	ADP	O
movement	O	NOUN	B
(	O	PUNCT	O
dynamic	O	ADJ	B
)	O	PUNCT	O
at	B-P	ADP	O
all	I-P	DET	O
times	I-P	NOUN	O
.	I-P	PUNCT	O


CONCLUSION	B-P	NOUN	O
The	O	DET	O
QLB	O	PROPN	B
after	O	ADP	O
caesarean	O	ADJ	B
section	O	NOUN	I
was	O	AUX	O
effective	O	ADJ	B
and	O	CCONJ	O
provided	O	VERB	O
satisfactory	O	ADJ	B
analgesia	O	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
a	O	DET	O
typical	O	ADJ	O
postoperative	O	ADJ	B
analgesic	O	NOUN	B
regimen	O	NOUN	I
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
ClinicalTrials.gov	O	NOUN	O
identifier	O	NOUN	O
:	O	PUNCT	O
NCT02328378	O	NOUN	O
.	O	PUNCT	O


Short-term	O	ADJ	B
studies	O	NOUN	B
on	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
glycerol	B-I	NOUN	B
as	O	ADP	O
an	O	DET	O
osmotic	O	ADJ	B
agent	O	NOUN	I
in	O	ADP	O
continuous	B-P	ADJ	B
ambulatory	I-P	ADJ	O
peritoneal	I-P	ADJ	O
dialysis	I-P	NOUN	O
(	I-P	PUNCT	O
CAPD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
glycerol	B-I	NOUN	B
as	O	ADP	O
an	O	DET	O
osmotic	O	ADJ	B
agent	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
concentrations	O	NOUN	B
(	O	PUNCT	O
92	O	NUM	O
mmol/l	O	NOUN	O
and	O	CCONJ	O
272	O	NUM	O
mmol/l	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
peritoneal	O	ADJ	B
dialysis	O	NOUN	B
fluid	O	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
over	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
in	B-P	ADP	O
six	I-P	NUM	O
patients	I-P	NOUN	B
on	I-P	ADP	O
continuous	I-P	ADJ	B
ambulatory	I-P	ADJ	B
peritoneal	I-P	ADJ	O
dialysis	I-P	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
with	O	ADP	O
two	O	NUM	O
concentrations	O	NOUN	B
of	O	ADP	O
glucose	B-I	NOUN	B
(	O	PUNCT	O
76	O	NUM	O
mmol/l	O	NOUN	O
and	O	CCONJ	O
215	O	NUM	O
mmol/l	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
calorific	B-OUT	ADJ	B
value	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
absorbed	O	VERB	B
osmotic	O	ADJ	I
agent	O	NOUN	I
was	O	AUX	O
lower	O	ADJ	O
,	O	PUNCT	O
by	O	ADP	O
19	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
isotonic	O	ADJ	B
and	O	CCONJ	O
22	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
hypertonic	O	ADJ	B
solutions	O	NOUN	I
,	O	PUNCT	O
when	O	SCONJ	O
glycerol	B-I	NOUN	B
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
place	O	NOUN	O
of	O	ADP	O
glucose	B-I	NOUN	B
.	I-I	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
glycerol	O	NOUN	B
provided	O	VERB	O
significantly	O	ADV	O
lower	O	ADJ	O
total	B-OUT	ADJ	O
ultrafiltration	I-OUT	NOUN	O
than	O	ADP	O
glucose	O	NOUN	B
at	O	ADP	O
each	O	DET	O
concentration	O	NOUN	B
,	O	PUNCT	O
despite	O	SCONJ	O
a	O	DET	O
higher	O	ADJ	O
initial	O	ADJ	O
osmotic	O	ADJ	B
pressure	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glycerol-based	O	ADJ	B
solutions	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
higher	O	ADJ	B
concentration	O	NOUN	B
of	O	ADP	O
glycerol	O	NOUN	B
required	O	VERB	O
to	O	PART	O
provide	O	VERB	O
equal	B-OUT	ADJ	O
ultrafiltration	I-OUT	NOUN	B
may	O	AUX	O
offset	O	VERB	O
any	O	DET	O
calorific	O	ADJ	B
advantage	O	NOUN	O
.	O	PUNCT	O


Equilibration	B-OUT	NOUN	B
of	I-OUT	ADP	O
creatinine	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
urea	I-OUT	NOUN	B
was	O	AUX	O
slower	O	ADJ	B
and	O	CCONJ	O
creatinine	B-OUT	NOUN	B
clearance	I-OUT	NOUN	B
lower	O	ADJ	O
with	O	ADP	O
glycerol	B-I	NOUN	B
.	I-I	PUNCT	O


Solutions	O	NOUN	B
containing	O	VERB	O
glycerol	B-I	NOUN	B
were	O	AUX	O
initially	O	ADV	O
less	O	ADJ	O
acid	O	NOUN	O
(	O	PUNCT	O
pH	O	NOUN	B
6.5	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
those	O	DET	O
containing	O	VERB	O
glucose	O	NOUN	B
(	O	PUNCT	O
pH	O	NOUN	B
5.1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
glycerol	I-OUT	NOUN	I
levels	I-OUT	NOUN	B
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
in	O	ADP	O
the	O	DET	O
physiological	O	ADJ	B
range	O	NOUN	O
with	O	ADP	O
glucose	O	NOUN	B
as	O	ADP	O
the	O	DET	O
osmotic	O	ADJ	B
agent	O	NOUN	I
,	O	PUNCT	O
reached	O	VERB	O
a	O	DET	O
peak	O	NOUN	O
80-fold	O	ADV	O
greater	O	ADJ	O
at	O	ADP	O
4.3	O	NUM	O
+/-	O	CCONJ	O
0.8	O	NUM	O
mmol/l	O	NOUN	O
during	O	ADP	O
dialysis	O	NOUN	B
with	O	ADP	O
fluid	O	NOUN	B
containing	O	VERB	O
glycerol	B-I	NOUN	B
at	O	ADP	O
272	O	NUM	O
mmol/l	O	NOUN	O
and	O	CCONJ	O
eightfold	O	ADV	O
higher	O	ADJ	O
at	O	ADP	O
0.42	O	NUM	O
+/-	O	CCONJ	O
0.09	O	NUM	O
mmol/l	O	NOUN	O
with	O	ADP	O
glycerol	B-I	NOUN	B
at	O	ADP	O
92	O	NUM	O
mmol/l	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
haemolysis	B-OUT	NOUN	B
or	O	CCONJ	O
other	O	ADJ	O
toxic	B-OUT	ADJ	B
effect	I-OUT	NOUN	I
despite	O	SCONJ	O
these	O	DET	O
levels	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
blood	B-OUT	NOUN	B
glucose	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
insulin	I-OUT	NOUN	B
noted	O	VERB	O
during	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
glucose-based	O	ADJ	B
solutions	O	NOUN	I
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
with	O	ADP	O
glycerol	B-I	NOUN	B
.	I-I	PUNCT	O


Circulating	B-OUT	VERB	B
levels	I-OUT	NOUN	O
of	I-OUT	ADP	O
lactate	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pyruvate	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
alanine	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
non-esterified	I-OUT	ADJ	B
fatty	I-OUT	ADJ	I
acids	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
ketone	I-OUT	NOUN	B
bodies	I-OUT	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
with	O	ADP	O
the	O	DET	O
two	O	NUM	O
agents	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
these	O	DET	O
short-term	O	ADJ	B
studies	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
no	O	DET	O
conclusive	O	ADJ	O
advantage	O	NOUN	O
of	O	ADP	O
glycerol	B-I	NOUN	B
over	O	ADP	O
glucose	B-I	NOUN	B
,	O	PUNCT	O
long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
glycerol	B-I	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
on	O	ADP	O
circulating	B-OUT	VERB	B
lipid	I-OUT	NOUN	O
levels	I-OUT	NOUN	O
,	O	PUNCT	O
will	O	AUX	O
determine	O	VERB	O
its	O	PRON	O
future	O	ADJ	O
role	O	NOUN	O
as	O	ADP	O
an	O	DET	O
osmotic	O	ADJ	B
agent	O	NOUN	I
in	O	ADP	O
continuous	O	ADJ	B
ambulatory	B-P	ADJ	B
peritoneal	I-P	ADJ	O
dialysis	I-P	NOUN	B
.	I-P	PUNCT	O


Final	B-OUT	ADJ	B
height	I-OUT	NOUN	B
in	I-OUT	ADP	O
girls	I-OUT	NOUN	B
with	I-P	ADP	O
turner	I-P	NOUN	B
syndrome	I-P	NOUN	I
after	O	ADP	O
long-term	O	ADJ	B
growth	B-I	NOUN	B
hormone	I-I	NOUN	I
treatment	I-I	NOUN	B
in	O	ADP	O
three	O	NUM	O
dosages	O	NOUN	B
and	O	CCONJ	O
low	O	ADJ	B
dose	O	NOUN	O
estrogens	B-I	NOUN	B
.	I-I	PUNCT	O


Although	O	SCONJ	O
GH	B-I	NOUN	B
treatment	I-I	NOUN	I
for	O	ADP	O
short	O	ADJ	B
stature	O	NOUN	I
in	O	ADP	O
Turner	O	NOUN	B
syndrome	O	NOUN	I
is	O	AUX	O
an	O	DET	O
accepted	O	VERB	B
treatment	O	NOUN	B
in	O	ADP	O
many	O	ADJ	O
countries	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
GH	O	NOUN	B
dosage	O	NOUN	I
to	O	PART	O
use	O	VERB	O
and	O	CCONJ	O
which	O	DET	O
age	O	NOUN	B
to	O	PART	O
start	O	VERB	O
puberty	O	NOUN	B
induction	O	NOUN	B
are	O	AUX	O
issues	O	NOUN	B
of	O	ADP	O
debate	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
shows	O	VERB	O
final	B-OUT	ADJ	O
height	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
FH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
60	B-P	NUM	O
girls	I-P	NOUN	B
with	I-P	ADP	O
Turner	I-P	NOUN	B
syndrome	I-P	NOUN	I
treated	I-P	VERB	B
in	I-P	ADP	O
a	I-P	DET	O
randomized	I-P	ADJ	B
dose-response	I-P	ADJ	I
trial	I-P	NOUN	I
,	O	PUNCT	O
combining	B-I	VERB	O
GH	I-I	NOUN	B
treatment	I-I	NOUN	I
with	I-I	ADP	O
low	I-I	ADJ	B
dose	I-I	NOUN	I
estrogens	I-I	NOUN	B
at	O	ADP	O
a	O	DET	O
relatively	O	ADV	O
young	O	ADJ	B
age	O	NOUN	O
.	O	PUNCT	O


Girls	B-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
group	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
IU/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.d	O	NOUN	O
;	O	PUNCT	O
approximately	O	ADV	O
0.045	O	NUM	O
mg/kg/d	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
first	O	ADJ	O
year	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
IU/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.d	O	NOUN	O
;	O	PUNCT	O
thereafter	O	ADV	O
6	O	NUM	O
IU/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.d	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
group	O	NOUN	B
C	O	NOUN	I
(	O	PUNCT	O
first	O	ADJ	O
year	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
IU/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.d	O	NOUN	O
;	O	PUNCT	O
second	O	ADJ	O
year	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
IU/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.d	O	NOUN	O
;	O	PUNCT	O
thereafter	O	ADV	O
,	O	PUNCT	O
8	O	NUM	O
IU/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.d	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
minimum	O	NOUN	O
of	O	ADP	O
4	O	NUM	O
yr	O	NOUN	O
of	O	ADP	O
GH	B-I	NOUN	B
treatment	I-I	NOUN	I
,	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
12.7	O	NUM	O
+/-	O	CCONJ	O
0.7	O	NUM	O
yr	O	NOUN	O
,	O	PUNCT	O
low	O	ADJ	B
dose	O	NOUN	I
micronized	B-I	ADJ	B
17beta-estradiol	I-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
orally	O	ADV	B
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
GH	I-OUT	NOUN	B
treatment	I-OUT	NOUN	I
of	O	ADP	O
8.6	O	NUM	O
+/-	O	CCONJ	O
1.9	O	NUM	O
yr	O	NOUN	O
,	O	PUNCT	O
FH	O	NOUN	B
was	O	AUX	O
reached	O	VERB	O
at	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
15.8	O	NUM	O
+/-	O	CCONJ	O
0.9	O	NUM	O
yr.	O	NOUN	B
FH	B-OUT	NOUN	B
,	O	PUNCT	O
expressed	O	VERB	B
in	O	ADP	O
centimeters	O	NOUN	B
or	O	CCONJ	O
SD	O	NOUN	B
score	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
157.6	O	NUM	O
+/-	O	CCONJ	O
6.5	O	NUM	O
or	O	CCONJ	O
-1.6	O	NUM	O
+/-	O	CCONJ	O
1.0	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
162.9	O	NUM	O
+/-	O	CCONJ	O
6.1	O	NUM	O
or	O	CCONJ	O
-0.7	O	NUM	O
+/-	O	CCONJ	O
1.0	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
163.6	O	NUM	O
+/-	O	CCONJ	O
6.0	O	NUM	O
or	O	CCONJ	O
-0.6	O	NUM	O
+/-	O	CCONJ	O
1.0	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
C.	O	NOUN	O
The	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
FH	B-OUT	NOUN	B
in	I-OUT	ADP	O
centimeters	I-OUT	NOUN	B
,	O	PUNCT	O
corrected	O	VERB	O
for	O	ADP	O
height	O	NOUN	B
SD	O	NOUN	I
score	O	NOUN	I
and	O	CCONJ	O
age	O	NOUN	B
at	O	ADP	O
start	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
significant	O	ADJ	O
between	O	ADP	O
groups	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
B	O	NOUN	B
[	O	PUNCT	O
regression	O	NOUN	O
coefficient	O	NOUN	O
,	O	PUNCT	O
4.1	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
1.4	O	NUM	O
,	O	PUNCT	O
6.9	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
groups	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
C	O	NOUN	O
(	O	PUNCT	O
coefficient	O	NOUN	B
,	O	PUNCT	O
5.0	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
2.3	O	NUM	O
,	O	PUNCT	O
7.7	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
between	O	ADP	O
groups	O	NOUN	B
B	O	NOUN	O
and	O	CCONJ	O
C	O	NOUN	O
(	O	PUNCT	O
coefficient	O	NOUN	B
,	O	PUNCT	O
0.9	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
-1.8	O	NUM	O
,	O	PUNCT	O
3.6	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Fifty	B-P	NUM	O
of	I-P	ADP	O
the	I-P	DET	O
60	I-P	NUM	O
girls	I-P	NOUN	B
(	I-P	PUNCT	O
83	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
had	I-P	AUX	O
reached	I-P	VERB	O
a	I-P	DET	O
normal	I-OUT	ADJ	O
FH	I-OUT	NOUN	B
(	I-P	PUNCT	O
FH	I-P	NOUN	B
SD	I-P	NOUN	O
score	I-P	NOUN	B
,	I-P	PUNCT	O
more	I-P	ADJ	O
than	I-P	ADP	O
-2	I-P	NUM	O
)	I-P	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
starting	O	VERB	O
estrogen	B-I	NOUN	B
treatment	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
height	I-OUT	NOUN	B
velocity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HV	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
changed	I-OUT	VERB	O
significantly	I-OUT	ADV	O
to	I-OUT	PART	O
a	I-OUT	DET	O
stable	I-OUT	ADJ	B
HV	I-OUT	NOUN	B
,	O	PUNCT	O
without	O	ADP	O
affecting	O	VERB	B
bone	B-OUT	NOUN	B
maturation	I-OUT	NOUN	B
(	O	PUNCT	O
change	O	NOUN	O
in	O	ADP	O
bone	O	NOUN	B
age/change	O	NOUN	O
in	O	ADP	O
chronological	O	ADJ	B
age	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
following	O	VERB	O
variables	O	NOUN	B
contributed	O	VERB	O
significantly	O	ADV	O
to	O	PART	O
predicting	O	VERB	O
FH	B-OUT	NOUN	B
SD	I-OUT	NOUN	B
score	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
GH	I-OUT	NOUN	B
dose	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
height	I-OUT	NOUN	B
SD	I-OUT	NOUN	I
score	I-OUT	NOUN	I
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O


normal	O	ADJ	O
girls	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
chronological	B-OUT	ADJ	B
age	I-OUT	NOUN	I
at	I-OUT	ADP	O
start	I-OUT	NOUN	O
of	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
HV	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
of	O	ADP	O
GH	O	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


GH	B-I	NOUN	B
treatment	O	NOUN	I
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
.	I-OUT	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
GH	B-I	NOUN	B
treatment	O	NOUN	I
leads	O	VERB	O
to	O	PART	O
a	O	DET	O
normalization	O	NOUN	B
of	O	ADP	O
FH	B-OUT	NOUN	B
in	O	ADP	O
most	O	ADJ	O
girls	O	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
when	O	SCONJ	O
puberty	O	NOUN	B
is	O	AUX	O
induced	O	VERB	B
at	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
pubertal	O	ADJ	B
age	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
optimal	O	ADJ	B
GH	B-I	NOUN	B
dosage	O	NOUN	I
depends	O	VERB	O
on	O	ADP	O
height	O	NOUN	B
and	O	CCONJ	O
age	O	NOUN	B
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
first	O	ADJ	O
year	O	NOUN	B
HV	O	PROPN	B
.	O	PUNCT	O


Simvastatin	B-I	NOUN	B
and	O	CCONJ	O
preparation	O	NOUN	B
of	O	ADP	O
polyunsaturated	B-I	ADJ	B
phospholipids	I-I	NOUN	I
produce	O	VERB	O
similar	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
phospholipid	O	ADJ	B
composition	O	NOUN	B
of	O	ADP	O
high-density	O	ADJ	B
lipoproteins	O	NOUN	I
during	O	ADP	O
hypercholesterolemia	B-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
phospholipid	O	ADJ	B
composition	O	NOUN	B
of	O	ADP	O
high-density	O	ADJ	B
lipoproteins	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
and	I-P	CCONJ	O
hypercholesterolemia	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
simvastatin	I-I	NOUN	B
(	I-I	PUNCT	O
Zocor	I-I	PROPN	B
,	I-P	PUNCT	O
inhibitor	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
key	I-P	ADJ	O
enzyme	I-P	NOUN	B
of	I-P	ADP	O
cholesterol	I-P	NOUN	B
synthesis	I-P	NOUN	I
)	I-P	PUNCT	O
and	I-P	CCONJ	O
preparation	I-P	NOUN	B
of	I-P	ADP	O
polyunsaturated	I-P	ADJ	B
phospholipids	I-I	NOUN	I
(	I-I	PUNCT	O
lipostabil	I-I	ADJ	B
forte	I-I	NOUN	I
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Simvastatin	B-I	NOUN	B
produced	O	VERB	O
a	O	DET	O
hypolipidemic	B-OUT	ADJ	B
effect	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
modulates	I-OUT	VERB	B
the	I-OUT	DET	O
phospholipid	I-OUT	ADJ	B
composition	I-OUT	NOUN	B
of	I-OUT	ADP	O
high-density	I-OUT	ADJ	B
lipoproteins	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
similarly	I-OUT	ADV	O
to	I-OUT	PART	O
lipostabil	I-OUT	ADJ	B
forte	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
contribute	O	VERB	O
to	O	PART	O
functional	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
of	O	ADP	O
high-density	B-OUT	ADJ	B
lipoproteins	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
reverse	O	ADJ	B
cholesterol	O	NOUN	I
transport	O	NOUN	I
.	O	PUNCT	O


Interferon	B-I	NOUN	B
alfa	I-I	NOUN	I
in	O	ADP	O
acute	B-P	ADJ	B
posttransfusion	I-P	NOUN	O
hepatitis	I-P	NOUN	O
C	I-P	NOUN	O
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


Is	O	AUX	O
altered	O	ADJ	O
central	O	ADJ	B
pain	O	NOUN	I
processing	O	NOUN	I
related	O	ADJ	O
to	O	PART	O
disease	O	NOUN	B
stage	O	NOUN	I
in	O	ADP	O
chronic	B-P	ADJ	B
pancreatitis	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
pain	I-P	NOUN	B
?	O	PUNCT	O
An	O	DET	O
exploratory	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
most	O	ADV	O
dominant	O	ADJ	B
feature	O	NOUN	O
in	O	ADP	O
chronic	O	ADJ	B
pancreatitis	O	NOUN	I
is	O	AUX	O
intense	O	ADJ	O
abdominal	O	ADJ	B
pain	O	NOUN	I
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
spinal	O	ADJ	B
and/or	O	CCONJ	O
supraspinal	O	ADJ	B
central	O	ADJ	I
nervous	O	ADJ	I
system	O	NOUN	I
pain	O	NOUN	B
processing	O	NOUN	I
due	O	ADP	O
to	O	PART	O
visceral	O	ADJ	B
nociceptive	O	ADJ	B
input	O	NOUN	B
play	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
this	O	DET	O
pain	O	NOUN	B
.	O	PUNCT	O


How	O	SCONJ	O
altered	B-I	VERB	O
pain	I-I	NOUN	B
processing	I-I	NOUN	I
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
disease	O	NOUN	B
stage	O	NOUN	I
still	O	ADV	O
needs	O	VERB	B
study	O	NOUN	I
.	O	PUNCT	O


METHODOLOGY/PRINCIPAL	O	ADJ	B
FINDINGS	O	NOUN	O
Sixty	B-P	NUM	O
chronic	I-P	ADJ	B
pancreatitis	I-P	NOUN	I
patients	I-P	NOUN	B
were	I-P	AUX	O
compared	I-P	VERB	O
to	I-P	PART	O
15	I-P	NUM	O
healthy	I-P	ADJ	B
controls	I-P	NOUN	I
.	I-P	PUNCT	O


Two	O	NUM	O
subgroups	O	NOUN	B
of	O	ADP	O
pancreatitis	O	NOUN	B
patients	O	NOUN	B
were	O	AUX	O
defined	O	VERB	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
M-ANNHEIM	O	NOUN	B
severity	O	NOUN	I
index	O	NOUN	I
of	O	ADP	O
chronic	O	ADJ	B
pancreatitis	O	NOUN	I
;	O	PUNCT	O
i.e	O	ADV	O
.	O	PUNCT	O


moderate	O	ADJ	B
and	O	CCONJ	O
severe	O	ADJ	B
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
detection	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
tolerance	I-OUT	NOUN	B
thresholds	I-OUT	NOUN	I
for	I-OUT	ADP	O
pressure	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
electric	I-OUT	ADJ	B
stimuli	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
six	O	NUM	O
selected	O	VERB	O
dermatomes	O	NOUN	B
(	O	PUNCT	O
C5	O	NOUN	B
,	O	PUNCT	O
T4	O	NOUN	B
,	O	PUNCT	O
T10	O	NOUN	B
,	O	PUNCT	O
L1	O	NOUN	B
,	O	PUNCT	O
L4	O	PROPN	B
and	O	CCONJ	O
T10BACK	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
conditioned	O	ADJ	B
pain	B-I	NOUN	I
modulation	I-I	NOUN	I
response	I-I	NOUN	I
to	O	ADP	O
cold	B-I	ADJ	B
pressor	I-I	NOUN	I
task	I-I	NOUN	B
was	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


These	O	DET	O
measures	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
between	O	ADP	O
the	O	DET	O
healthy	O	ADJ	B
controls	O	NOUN	I
and	O	CCONJ	O
chronic	O	ADJ	B
pancreatitis	O	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


Severe	O	ADJ	B
pancreatitis	O	NOUN	B
patients	O	NOUN	B
showed	O	VERB	O
lower	O	ADJ	B
pain	B-OUT	NOUN	I
thresholds	I-OUT	NOUN	O
than	O	ADP	O
moderate	O	ADJ	B
pancreatitis	O	NOUN	B
patients	B-P	NOUN	B
or	O	CCONJ	O
healthy	O	ADJ	B
volunteers	O	NOUN	I
.	O	PUNCT	O


Healthy	O	ADJ	B
controls	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
significantly	O	ADV	O
larger	O	ADJ	O
conditioned	O	VERB	B
pain	B-OUT	NOUN	I
modulation	I-OUT	NOUN	O
response	O	NOUN	O
compared	O	VERB	O
to	O	PART	O
all	O	DET	O
chronic	O	ADJ	B
pancreatitis	O	NOUN	I
patients	B-P	NOUN	B
taken	O	VERB	O
together	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS/SIGNIFICANCE	O	NOUN	B
The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
confirms	O	VERB	O
that	O	SCONJ	O
chronic	O	ADJ	B
pancreatitis	O	NOUN	I
patients	O	NOUN	B
show	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
altered	B-I	ADJ	O
central	I-I	ADJ	B
processing	I-I	NOUN	I
of	O	ADP	O
nociception	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
healthy	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
further	O	ADV	O
suggests	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
changes	O	NOUN	B
,	O	PUNCT	O
i.e	O	ADV	O
.	O	PUNCT	O


central	O	ADJ	B
sensitization	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
disease	O	NOUN	B
stage	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
underline	O	VERB	O
the	O	DET	O
need	O	NOUN	O
to	O	PART	O
take	O	VERB	O
altered	O	ADJ	O
central	O	ADJ	B
pain	O	NOUN	I
processing	O	NOUN	O
into	O	ADP	O
account	O	NOUN	O
when	O	SCONJ	O
managing	O	VERB	B
the	O	DET	O
pain	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
pancreatitis	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
controlled	O	ADJ	B
study	O	NOUN	I
comparing	O	VERB	O
patients	B-P	NOUN	B
with	I-P	ADP	O
and	I-P	CCONJ	O
without	I-P	ADP	O
polycystic	I-P	ADJ	B
ovaries	I-P	NOUN	I
undergoing	I-P	VERB	O
in-vitro	I-OUT	ADJ	B
fertilization	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
in-vitro	B-I	X	B
fertilization	I-I	NOUN	B
and	I-I	CCONJ	O
embryo	I-I	NOUN	B
transfer	I-I	NOUN	I
(	I-I	PUNCT	O
IVF-ET	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
76	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
polycystic	I-P	ADJ	B
ovaries	I-P	NOUN	I
(	I-P	PUNCT	O
PCO	I-P	NOUN	B
)	I-P	PUNCT	O
diagnosed	I-P	VERB	B
on	I-P	ADP	O
pre-treatment	I-P	ADJ	B
ultrasound	I-P	NOUN	B
scan	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
76	I-P	NUM	O
control	I-P	NOUN	B
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
normal	I-P	ADJ	O
ovaries	I-P	NOUN	B
and	I-P	CCONJ	O
were	I-P	AUX	O
matched	I-P	VERB	B
for	I-P	ADP	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
cause	I-P	NOUN	O
of	I-P	ADP	O
infertility	I-P	NOUN	B
and	I-P	CCONJ	O
stimulation	I-P	NOUN	B
regimen	I-P	NOUN	B
.	I-P	PUNCT	O


Despite	O	SCONJ	O
receiving	O	VERB	O
significantly	O	ADV	O
less	O	ADV	O
human	B-I	ADJ	B
menopausal	I-I	ADJ	B
gonadotrophin	I-I	NOUN	I
(	I-I	PUNCT	O
HMG	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
patients	B-P	NOUN	B
with	I-P	ADP	O
PCO	I-P	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
serum	B-OUT	NOUN	B
oestradiol	I-OUT	NOUN	B
levels	I-OUT	NOUN	I
on	O	ADP	O
the	O	DET	O
day	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
chorionic	B-I	ADJ	B
gonadotrophin	I-I	NOUN	I
administration	O	NOUN	B
(	O	PUNCT	O
5940	O	NUM	O
+/-	O	CCONJ	O
255	O	NUM	O
versus	O	CCONJ	O
4370	O	NUM	O
+/-	O	CCONJ	O
240	O	NUM	O
pmol/l	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
developed	O	VERB	O
more	O	ADJ	O
follicles	B-OUT	NOUN	B
(	O	PUNCT	O
14.9	O	NUM	O
+/-	O	CCONJ	O
0.7	O	NUM	O
versus	O	CCONJ	O
9.8	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
produced	O	VERB	O
more	O	ADJ	O
oocytes	B-OUT	NOUN	B
(	O	PUNCT	O
9.3	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
versus	O	CCONJ	O
6.8	O	NUM	O
+/-	O	CCONJ	O
0.5	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
fertilization	B-OUT	NOUN	B
rates	I-OUT	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
PCO	O	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
52.8	O	NUM	O
+/-	O	CCONJ	O
3.4	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
66.1	O	NUM	O
+/-	O	CCONJ	O
3.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.007	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
cleavage	B-OUT	NOUN	B
rates	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
pregnancy	B-OUT	NOUN	B
rate/embryo	I-OUT	ADJ	O
transfer	I-OUT	NOUN	O
was	O	AUX	O
25.4	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
PCO	B-P	NOUN	B
group	I-P	NOUN	B
and	O	CCONJ	O
23.0	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
group	B-P	NOUN	B
with	I-P	ADP	O
normal	I-P	ADJ	B
ovaries	I-P	NOUN	I
.	I-P	PUNCT	O


There	O	PRON	O
were	O	AUX	O
three	O	NUM	O
high	O	ADJ	O
order	O	NOUN	O
multiple	O	ADJ	B
pregnancies	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PCO	O	NOUN	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
none	O	NOUN	O
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	B
ovaries	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
PCO	O	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
10.5	O	NUM	O
%	O	NOUN	O
developed	O	VERB	O
moderate/severe	O	ADJ	B
ovarian	B-OUT	ADJ	I
hyperstimulation	I-OUT	NOUN	I
syndrome	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OHSS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.006	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
and	I-P	CCONJ	O
without	I-P	ADP	O
PCO	I-P	NOUN	B
undergoing	I-P	VERB	O
IVF	I-P	NOUN	B
have	O	AUX	O
comparable	O	ADJ	O
pregnancy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
livebirth	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
diagnose	O	VERB	B
PCO	O	NOUN	B
before	O	ADP	O
ovarian	O	ADJ	B
stimulation	O	NOUN	I
is	O	AUX	O
initiated	O	VERB	O
as	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
develop	O	VERB	O
moderate	O	ADJ	B
or	O	CCONJ	O
severe	O	ADJ	B
OHSS	O	NOUN	B
following	O	VERB	O
IVF-ET	O	NOUN	B
.	O	PUNCT	O


Nimodipine	B-I	NOUN	B
pharmacotherapeutic	O	ADJ	B
adjuvant	O	ADJ	I
therapy	O	NOUN	I
for	O	ADP	O
inpatient	B-P	ADJ	B
treatment	I-P	NOUN	B
of	I-P	ADP	O
cocaine	I-P	NOUN	B
dependence	I-P	NOUN	I
.	I-P	PUNCT	O


Recent	O	ADJ	O
preclinical	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
utility	O	NOUN	O
for	O	ADP	O
voltage-sensitive	O	ADJ	B
calcium	O	NOUN	I
channel	O	NOUN	I
blockers	O	NOUN	I
(	O	PUNCT	O
VSCCBs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
cocaine	B-P	NOUN	B
addiction	I-P	NOUN	O
.	I-P	PUNCT	O


The	O	DET	O
following	O	VERB	O
double-blind	O	ADJ	B
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
examined	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
VSCCB	O	NOUN	B
nimodipine	B-I	NOUN	B
in	O	ADP	O
attenuating	O	VERB	B
cocaine	O	NOUN	B
craving	O	NOUN	O
in	O	ADP	O
66	B-P	NUM	O
recently	I-P	ADV	O
abstinent	I-P	VERB	B
cocaine-dependent	I-P	ADJ	B
patients	I-P	NOUN	B
on	I-P	ADP	O
an	I-P	DET	O
inpatient	I-P	ADJ	B
substance	I-P	NOUN	B
abuse	I-P	NOUN	I
treatment	I-P	NOUN	O
unit	I-P	NOUN	O
utilizing	I-P	VERB	O
an	I-P	DET	O
intensive	I-P	ADJ	B
12-step	I-P	ADJ	O
milieu-oriented	I-P	ADJ	B
psychosocial	I-P	ADJ	O
therapy	I-P	NOUN	O
.	I-P	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
medication	O	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
nimodipine	B-I	NOUN	B
used	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
(	O	PUNCT	O
90	O	NUM	O
mg	O	NOUN	O
q.d	O	NOUN	O
.	O	PUNCT	O


)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
superior	O	ADJ	O
to	O	PART	O
placebo	B-I	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
background	O	NOUN	B
or	O	CCONJ	O
cue-induced	O	ADJ	B
cocaine	O	NOUN	B
craving	O	NOUN	O
over	O	ADP	O
the	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
the	O	DET	O
suggestion	O	NOUN	O
that	O	SCONJ	O
nimodipine	B-I	NOUN	B
might	O	AUX	O
attenuate	O	VERB	B
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
some	O	DET	O
cocaine-induced	O	ADJ	B
brain	O	NOUN	B
deficits	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
detected	O	VERB	B
by	O	ADP	O
evaluation	O	NOUN	B
of	O	ADP	O
smooth	B-OUT	ADJ	B
pursuit	I-OUT	NOUN	I
eye	I-OUT	NOUN	I
movement	I-OUT	NOUN	I
function	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
rationale	O	NOUN	O
for	O	ADP	O
evaluating	O	VERB	B
higher	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
nimodipine	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
cocaine	O	NOUN	B
addiction	O	NOUN	O
is	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


As	O	ADP	O
nimodipine	B-I	NOUN	B
might	O	AUX	O
have	O	AUX	O
anticraving	O	VERB	B
and	O	CCONJ	O
mood-stabilizing	O	ADJ	B
properties	O	NOUN	B
and	O	CCONJ	O
cardio-	O	ADJ	B
and	O	CCONJ	O
neuroprotective	O	ADJ	B
properties	O	NOUN	I
in	O	ADP	O
the	O	DET	O
face	O	NOUN	B
of	O	ADP	O
cocaine	O	NOUN	B
intoxication	O	NOUN	B
and	O	CCONJ	O
might	O	AUX	O
possibly	O	ADV	O
even	O	ADV	O
reverse	O	VERB	B
some	O	DET	O
cocaine-induced	O	ADJ	B
brain	O	NOUN	B
deficits	O	NOUN	I
,	O	PUNCT	O
further	O	ADJ	O
investigation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
nimodipine	B-I	NOUN	B
(	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
VSCCBs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
cocaine	O	NOUN	B
addiction	O	NOUN	B
appears	O	VERB	O
an	O	DET	O
attractive	O	ADJ	O
avenue	O	NOUN	O
of	O	ADP	O
future	O	ADJ	O
medication	O	NOUN	B
development	O	NOUN	I
.	O	PUNCT	O


Comparison	O	NOUN	B
between	O	ADP	O
intermittent	B-I	ADJ	B
mandatory	I-I	ADJ	O
ventilation	I-I	NOUN	O
and	O	CCONJ	O
synchronized	B-I	VERB	B
intermittent	I-I	ADJ	B
mandatory	I-I	ADJ	O
ventilation	I-I	NOUN	O
with	O	ADP	O
pressure	B-I	NOUN	B
support	I-I	NOUN	O
in	I-P	ADP	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
intermittent	B-I	ADJ	B
mandatory	I-I	ADJ	O
ventilation	I-I	NOUN	O
(	I-I	PUNCT	O
IMV	I-I	NOUN	B
)	I-I	PUNCT	O
with	O	ADP	O
synchronized	B-I	VERB	B
intermittent	I-I	ADJ	B
mandatory	I-I	ADJ	O
ventilation	I-I	NOUN	O
plus	I-I	CCONJ	O
pressure	I-I	NOUN	O
support	I-I	NOUN	O
(	I-I	PUNCT	O
SIMV+PS	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
time	B-OUT	NOUN	B
on	I-OUT	ADP	O
mechanical	I-OUT	ADJ	B
ventilation	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
weaning	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
length	I-OUT	NOUN	B
of	I-OUT	ADP	I
stay	I-OUT	NOUN	I
in	I-OUT	ADP	O
a	I-OUT	DET	O
pediatric	I-OUT	ADJ	B
intensive	I-OUT	ADJ	B
care	I-OUT	NOUN	I
unit	I-OUT	NOUN	I
(	I-P	PUNCT	O
PICU	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
that	O	PRON	O
enrolled	B-P	VERB	O
children	I-P	NOUN	B
aged	I-P	ADJ	B
28	I-P	NUM	O
days	I-P	NOUN	B
to	I-P	PART	O
4	I-P	NUM	O
years	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
admitted	I-P	VERB	B
to	I-P	ADP	O
a	I-P	DET	O
PICU	I-P	NOUN	B
between	I-P	ADP	O
October	I-P	PROPN	O
of	I-P	ADP	O
2005	I-P	NUM	O
and	I-P	CCONJ	O
June	I-P	PROPN	O
of	I-P	ADP	O
2007	I-P	NUM	O
and	I-P	CCONJ	O
put	I-P	VERB	O
on	I-P	ADP	O
mechanical	I-I	ADJ	B
ventilation	I-I	NOUN	I
(	I-I	PUNCT	O
MV	I-I	NOUN	B
)	I-I	PUNCT	O
for	I-P	ADP	O
more	I-P	ADJ	O
than	I-P	ADP	O
48	I-P	NUM	O
hours	I-P	NOUN	B
.	I-P	PUNCT	O


These	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
allocated	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
by	O	ADP	O
drawing	O	VERB	O
lots	O	NOUN	B
:	O	PUNCT	O
IMV	B-I	NOUN	B
group	O	NOUN	B
(	B-I	PUNCT	O
IMVG	I-I	PROPN	B
;	I-I	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
35	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
SIMV+PS	B-I	NOUN	B
group	O	NOUN	I
(	B-I	PUNCT	O
SIMVG	I-I	NOUN	B
;	I-I	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
35	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Children	B-P	NOUN	B
were	I-P	AUX	O
excluded	I-P	VERB	O
if	I-P	SCONJ	O
they	I-P	PRON	O
had	I-P	AUX	O
undergone	I-P	VERB	O
tracheotomy	I-P	NOUN	B
or	I-P	CCONJ	O
had	I-P	AUX	O
chronic	I-P	ADJ	B
respiratory	I-P	ADJ	I
diseases	I-P	NOUN	I
.	I-P	PUNCT	O


Data	O	NOUN	B
on	O	ADP	O
oxygenation	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
ventilation	I-OUT	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
at	O	ADP	O
admission	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
weaning	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
statistical	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
age	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
sex	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
indication	I-OUT	NOUN	B
for	I-OUT	ADP	O
MV	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
PRISM	I-OUT	ADJ	B
score	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
Comfort	I-OUT	PROPN	B
scale	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
sedatives	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
ventilation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
oxygenation	I-OUT	NOUN	B
parameters	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
time	I-OUT	NOUN	O
on	I-OUT	ADP	O
MV	I-OUT	PROPN	B
was	O	AUX	O
5	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.120	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
also	O	ADV	O
no	O	DET	O
statistical	O	ADJ	B
differences	O	NOUN	I
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
for	O	ADP	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	I
weaning	I-OUT	NOUN	B
[	I-I	PUNCT	O
IMVG	I-I	PROPN	B
:	I-I	PUNCT	O
1	O	NUM	O
day	O	NOUN	B
(	O	PUNCT	O
1-6	O	NUM	O
)	O	PUNCT	O
vs.	O	CCONJ	O
SIMVG	B-I	NOUN	B
:	I-I	PUNCT	O
1	O	NUM	O
day	O	NOUN	B
(	O	PUNCT	O
1-6	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.262	O	NUM	O
]	O	PUNCT	O
or	O	CCONJ	O
length	B-OUT	NOUN	B
of	I-OUT	ADP	I
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
[	I-I	PUNCT	O
IMVG	I-I	PROPN	B
:	I-I	PUNCT	O
8	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
2-22	O	NUM	O
)	O	PUNCT	O
vs.	O	CCONJ	O
SIMVG	B-I	NOUN	B
:	I-I	PUNCT	O
6	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
3-20	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.113	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Among	O	ADP	O
the	O	DET	O
children	B-P	NOUN	B
studied	I-P	VERB	O
here	I-P	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
IMV	B-I	NOUN	B
and	O	CCONJ	O
SIMV+PS	B-I	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
time	O	NOUN	B
on	O	ADP	O
MV	B-OUT	PROPN	B
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	I
weaning	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
spent	I-OUT	VERB	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
PICU	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


ClinicalTrials.govID	O	NOUN	B
:	O	PUNCT	O
NCT00549809	O	PROPN	O
.	O	PUNCT	O


Body	O	NOUN	B
Mass	O	PROPN	I
Index	O	PROPN	I
and	O	CCONJ	O
Adverse	O	PROPN	B
Outcomes	O	PROPN	I
in	O	ADP	O
Elderly	B-P	PROPN	B
Patients	I-P	NOUN	B
With	I-P	ADP	O
Atrial	I-P	PROPN	B
Fibrillation	I-P	PROPN	I
:	I-P	PUNCT	O
The	O	DET	O
AMADEUS	O	PROPN	B
Trial	O	PROPN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
PURPOSE	O	PROPN	B
Obesity	O	PROPN	I
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
cardiovascular	O	ADJ	B
risk	O	NOUN	I
in	O	ADP	O
atrial	O	ADJ	B
fibrillation	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
in	O	ADP	O
elderly	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
atrial	I-P	ADJ	B
fibrillation	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Post	O	PROPN	B
hoc	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
data	O	NOUN	B
from	O	ADP	O
the	O	DET	O
AMADEUS	O	PROPN	B
(	O	PUNCT	O
Evaluating	O	VERB	B
the	O	DET	O
Use	O	PROPN	O
of	O	ADP	O
SR34006	O	NOUN	B
Compared	O	VERB	O
to	O	ADP	O
Warfarin	B-I	PROPN	B
or	I-I	CCONJ	O
Acenocoumarol	I-I	PROPN	B
in	O	ADP	O
Patients	B-P	NOUN	B
With	I-P	ADP	O
Atrial	I-P	PROPN	B
Fibrillation	I-P	PROPN	I
)	I-P	PUNCT	O
trial	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	B
We	O	PRON	O
studied	O	VERB	O
1588	B-P	NUM	O
elderly	I-P	ADJ	B
patients	I-P	NOUN	B
,	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
categorized	I-P	VERB	O
as	I-P	ADP	O
normal	I-P	ADJ	B
body	I-P	NOUN	I
mass	I-P	NOUN	I
index	I-P	NOUN	I
(	I-P	PUNCT	O
BMI	I-P	PROPN	B
,	I-P	PUNCT	O
18.5-25	I-P	NUM	O
kg/m	I-P	NOUN	O
(	I-P	PUNCT	O
2	I-P	NUM	O
)	I-P	PUNCT	O
;	I-P	PUNCT	O
n=515	I-P	PROPN	O
[	I-P	PUNCT	O
32.4	I-P	NUM	O
%	I-P	NOUN	O
]	I-P	PUNCT	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
overweight	I-P	ADJ	B
(	I-P	PUNCT	O
BMI	I-P	NOUN	B
,	I-P	PUNCT	O
25-30	I-P	NUM	O
kg/m	I-P	NOUN	O
(	I-P	PUNCT	O
2	I-P	NUM	O
)	I-P	PUNCT	O
;	I-P	PUNCT	O
n=711	I-P	PROPN	O
[	I-P	PUNCT	O
44.8	I-P	NUM	O
%	I-P	NOUN	O
]	I-P	PUNCT	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
obese	I-P	ADJ	B
(	I-P	PUNCT	O
BMI≥30	I-P	ADJ	B
kg/m	I-P	NOUN	O
(	I-P	PUNCT	O
2	I-P	NUM	O
)	I-P	PUNCT	O
;	I-P	PUNCT	O
n=362	I-P	PROPN	O
[	I-P	PUNCT	O
22.8	I-P	NUM	O
%	I-P	NOUN	O
]	I-P	PUNCT	O
)	I-P	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
composite	O	ADJ	B
outcome	O	NOUN	B
of	B-OUT	ADP	O
cardiovascular	I-OUT	ADJ	B
death	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
stroke/systemic	I-OUT	ADJ	B
embolism	I-OUT	NOUN	I
with	O	ADP	O
increasing	O	VERB	B
BMI	O	NOUN	B
category	O	NOUN	B
,	O	PUNCT	O
being	O	AUX	O
5.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
3.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
1.5	O	NUM	O
%	O	NOUN	O
per	O	ADP	O
100	O	NUM	O
patient-years	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
for	O	ADP	O
trend=0.01	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Cox	O	NOUN	B
proportional	O	ADJ	I
hazards	O	NOUN	I
analysis	O	NOUN	I
found	O	VERB	O
obesity	O	NOUN	B
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
lower	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
composite	O	ADJ	O
outcome	O	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.29	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.11-0.77	O	ADJ	O
;	O	PUNCT	O
P=0.01	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	B-I	DET	O
warfarin	I-I	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
n=814	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
multivariate	O	ADJ	B
logistic	O	ADJ	I
regression	O	NOUN	I
analysis	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
obesity	O	NOUN	B
was	O	AUX	O
independently	O	ADV	O
related	O	ADJ	O
to	O	PART	O
higher	O	ADJ	O
odds	O	NOUN	B
of	O	ADP	O
time	O	NOUN	O
in	O	ADP	O
therapeutic	O	ADJ	B
range	O	NOUN	I
≥60	O	ADJ	O
%	O	NOUN	O
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
1.84	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1.21-2.80	O	NOUN	O
;	O	PUNCT	O
P=0.004	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	PROPN	O
Obesity	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	B-OUT	ADP	I
a	I-OUT	DET	O
lower	I-OUT	ADJ	O
stroke	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
in	I-P	ADP	O
elderly	I-P	ADJ	B
anticoagulated	I-P	VERB	B
atrial	I-P	ADJ	I
fibrillation	I-P	NOUN	I
patients	I-P	NOUN	B
.	O	PUNCT	O


Obesity	O	NOUN	B
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
good	O	ADJ	O
quality	O	NOUN	B
anticoagulation	O	NOUN	B
control	O	NOUN	I
.	O	PUNCT	O


Study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
therapeutic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
a	O	DET	O
hippotherapy	B-I	NOUN	B
simulator	I-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
cerebral	I-P	ADJ	B
palsy	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
stratified	O	VERB	B
single-blind	O	ADJ	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
hippotherapy	B-I	NOUN	B
(	I-I	PUNCT	O
when	I-I	SCONJ	O
applied	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
simulator	I-I	NOUN	B
)	I-I	PUNCT	O
improves	O	VERB	B
postural	O	ADJ	B
control	O	NOUN	I
and	O	CCONJ	O
balance	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
cerebral	I-P	ADJ	B
palsy	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
Stratified	O	ADJ	B
single-blind	O	ADJ	I
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
with	O	ADP	O
an	O	DET	O
independent	O	ADJ	O
assessor	O	NOUN	B
.	O	PUNCT	O


Stratification	O	NOUN	B
was	O	AUX	O
made	O	VERB	O
by	O	ADP	O
gross	O	ADJ	B
motor	O	NOUN	I
function	O	NOUN	I
classification	O	NOUN	I
system	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
allocation	O	NOUN	B
was	O	AUX	O
concealed	O	VERB	B
.	O	PUNCT	O


SUBJECTS	O	VERB	B
Children	B-P	NOUN	B
between	I-P	ADP	O
4	I-P	NUM	O
and	I-P	CCONJ	O
18	I-P	NUM	O
years	I-P	NOUN	B
old	I-P	ADJ	O
with	I-P	ADP	O
cerebral	I-P	ADJ	B
palsy	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
Participants	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
an	O	DET	O
intervention	B-I	NOUN	B
(	I-I	PUNCT	O
simulator	I-I	NOUN	B
ON	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
control	I-I	NOUN	B
(	I-I	PUNCT	O
simulator	I-I	NOUN	B
OFF	I-I	NOUN	B
)	I-I	PUNCT	O
group	O	NOUN	B
after	O	ADP	O
getting	O	VERB	O
informed	O	VERB	O
consent	O	NOUN	O
.	O	PUNCT	O


Treatment	O	NOUN	B
was	O	AUX	O
provided	O	VERB	O
once	O	ADV	O
a	O	DET	O
week	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
10	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


MAIN	O	PROPN	B
MEASURES	O	PROPN	O
Gross	B-OUT	PROPN	B
Motor	I-OUT	PROPN	I
Function	I-OUT	PROPN	I
Measure	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
dimension	I-OUT	NOUN	O
B	I-OUT	NOUN	O
for	I-OUT	ADP	O
balance	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Total	I-OUT	PROPN	B
Score	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Sitting	I-OUT	VERB	B
Assessment	I-OUT	NOUN	I
Scale	I-OUT	NOUN	I
were	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
at	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
prior	O	ADJ	O
to	O	PART	O
randomization	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
end	O	NOUN	O
of	O	ADP	O
intervention	O	NOUN	B
and	O	CCONJ	O
12	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
completing	O	VERB	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Thirty-eight	B-P	NUM	O
children	I-P	NOUN	B
participated	I-P	VERB	O
.	I-P	PUNCT	O


The	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
balanced	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Sitting	B-OUT	NOUN	B
balance	I-OUT	NOUN	B
(	O	PUNCT	O
measured	O	VERB	B
by	O	ADP	O
dimension	O	NOUN	O
B	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Gross	O	PROPN	B
Motor	O	PROPN	I
Function	O	PROPN	I
Measure	O	PROPN	I
)	O	PUNCT	O
improved	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
effect	O	NOUN	B
size	O	NOUN	I
=	O	ADJ	O
0.36	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.01-0.71	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
effect	B-OUT	NOUN	B
size	I-OUT	NOUN	I
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
severely	O	ADV	B
disabled	O	ADJ	I
group	O	NOUN	O
(	O	PUNCT	O
effect	O	NOUN	B
size	O	NOUN	I
=	O	ADJ	O
0.80	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.13-1.47	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
improvements	B-OUT	NOUN	B
in	I-OUT	ADP	O
sitting	I-OUT	NOUN	B
balance	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
maintained	O	VERB	O
over	O	ADP	O
the	O	DET	O
follow-up	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
total	B-OUT	ADJ	O
score	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
Gross	I-OUT	PROPN	B
Motor	I-OUT	PROPN	I
Function	I-OUT	PROPN	I
Measure	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Sitting	I-OUT	NOUN	B
Assessment	I-OUT	NOUN	I
Scale	I-OUT	NOUN	I
were	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Hippotherapy	B-I	NOUN	B
with	O	ADP	O
a	O	DET	O
simulator	O	NOUN	B
can	O	AUX	O
improve	O	VERB	B
sitting	B-OUT	NOUN	B
balance	I-OUT	NOUN	B
in	O	ADP	O
cerebral	B-P	ADJ	B
palsy	I-P	NOUN	I
children	I-P	NOUN	B
who	O	PRON	O
have	O	AUX	O
higher	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
disability	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
did	O	AUX	O
not	O	PART	O
lead	O	VERB	O
to	O	PART	O
a	O	DET	O
change	O	NOUN	B
in	O	ADP	O
the	O	DET	O
overall	O	ADJ	O
function	O	NOUN	B
of	O	ADP	O
these	O	DET	O
children	O	NOUN	B
(	O	PUNCT	O
Gross	O	PROPN	B
Motor	O	PROPN	I
Function	O	PROPN	I
Classification	O	PROPN	I
System	O	PROPN	I
level	O	NOUN	I
V	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
an	O	DET	O
Asha	B-I	PROPN	B
intervention	I-I	NOUN	B
on	O	ADP	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
among	O	ADP	O
rural	B-P	ADJ	B
women	I-P	NOUN	B
living	I-P	VERB	B
with	I-P	ADP	O
AIDS	I-P	NOUN	B
in	I-P	ADP	O
India	I-P	PROPN	B
:	I-P	PUNCT	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Asha-Life	B-I	NOUN	B
and	I-I	CCONJ	O
Usual	I-I	ADJ	B
Care	I-I	PROPN	I
program	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
pilot	O	NOUN	I
study	O	NOUN	I
is	O	AUX	O
to	O	PART	O
conduct	O	VERB	O
an	O	DET	O
intervention	O	NOUN	B
with	O	ADP	O
68	B-P	NUM	O
rural	I-P	ADJ	B
women	I-P	NOUN	B
living	I-P	VERB	B
with	I-P	ADP	O
AIDS	I-P	NOUN	B
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
programs	O	NOUN	B
on	O	ADP	O
depressive	O	ADJ	B
symptoms	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Asha-Life	B-I	ADJ	B
intervention	I-I	NOUN	B
engaging	O	VERB	B
with	O	ADP	O
an	O	DET	O
HIV-trained	O	ADJ	B
village	O	NOUN	B
woman	O	NOUN	B
,	O	PUNCT	O
Asha	B-I	PROPN	B
(	I-I	PUNCT	O
Accredited	I-I	PROPN	B
Social	I-I	PROPN	I
Health	I-I	PROPN	I
Activist	I-I	PROPN	I
)	I-I	PUNCT	O
,	O	PUNCT	O
to	O	PART	O
participate	O	VERB	B
in	O	ADP	O
the	O	DET	O
care	O	NOUN	B
of	O	ADP	O
women	O	NOUN	B
living	O	VERB	B
with	O	ADP	O
AIDS	O	NOUN	B
(	O	PUNCT	O
WLA	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
other	O	ADJ	O
health	O	NOUN	B
care	O	NOUN	I
providers	O	NOUN	I
compared	O	VERB	O
to	O	ADP	O
a	O	DET	O
Usual	B-I	ADJ	B
Care	I-I	PROPN	I
group	I-I	NOUN	I
.	I-I	PUNCT	O


Two	B-P	NUM	O
high	I-P	ADJ	O
prevalence	I-P	NOUN	B
HIV/AIDS	I-P	NOUN	B
villages	I-P	NOUN	B
in	I-P	ADP	O
rural	I-P	ADJ	B
Andhra	I-P	PROPN	I
Pradesh	I-P	PROPN	I
,	I-P	PUNCT	O
which	I-P	DET	O
were	I-P	AUX	O
demographically	I-P	ADV	B
alike	I-P	ADV	O
and	I-P	CCONJ	O
served	I-P	VERB	O
by	I-P	ADP	O
distinct	I-P	ADJ	O
Public	I-P	PROPN	B
Health	I-P	PROPN	I
Centers	I-P	PROPN	I
,	I-P	PUNCT	O
were	I-P	AUX	O
selected	I-P	VERB	O
randomly	I-P	ADV	O
from	I-P	ADP	O
a	I-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
16	I-P	NUM	O
villages	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Asha-Life	B-I	NOUN	B
participants	O	NOUN	B
significantly	B-OUT	ADV	O
reduced	I-OUT	VERB	B
their	O	PRON	O
depressive	B-OUT	ADJ	B
symptom	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
compared	O	VERB	O
to	O	ADP	O
the	O	DET	O
Usual	O	PROPN	B
Care	O	PROPN	I
participants	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
women	B-P	NOUN	B
living	I-P	VERB	B
with	I-P	ADP	O
AIDS	I-P	NOUN	B
who	O	PRON	O
demonstrated	O	VERB	O
higher	O	ADJ	O
depressive	B-OUT	ADJ	B
symptom	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
had	O	AUX	O
greater	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
than	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
lower	O	ADJ	O
scores	O	NOUN	B
.	O	PUNCT	O


Metoprolol	B-I	NOUN	B
CR/XL	I-I	NOUN	B
improves	O	VERB	B
systolic	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
left	I-OUT	ADJ	I
ventricular	I-OUT	ADJ	I
function	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
.	I-P	PUNCT	O


AIMS	O	NOUN	B
To	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
metoprolol	B-I	NOUN	B
controlled	I-I	ADJ	O
release/extended	I-I	ADJ	B
release	I-I	NOUN	I
(	I-I	PUNCT	O
CR/XL	I-I	NOUN	B
)	I-I	PUNCT	O
once	O	SCONJ	O
daily	O	ADV	O
would	O	AUX	O
improve	O	VERB	B
diastolic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
systolic	I-OUT	NOUN	B
left	I-OUT	ADJ	I
ventricular	I-OUT	ADJ	I
function	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
and	I-P	CCONJ	O
decreased	I-P	VERB	B
ejection	I-P	NOUN	O
fraction	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
an	O	DET	O
echocardiographic	O	ADJ	B
substudy	O	NOUN	B
to	O	ADP	O
the	O	DET	O
Metoprolol	B-I	PROPN	B
CR/XL	I-I	NOUN	B
Randomized	O	PROPN	B
Intervention	O	PROPN	I
Trial	O	PROPN	I
in	O	ADP	O
Heart	O	PROPN	B
Failure	O	PROPN	I
(	O	PUNCT	O
MERIT-HF	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
66	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
examined	I-P	VERB	O
three	O	NUM	O
times	O	NOUN	O
during	O	ADP	O
a	O	DET	O
12-month	O	ADJ	O
period	O	NOUN	B
blinded	O	VERB	B
to	O	PART	O
treatment	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
assessing	O	VERB	O
left	B-OUT	ADJ	B
ventricular	I-OUT	ADJ	I
dimensions	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
ejection	I-OUT	NOUN	B
fraction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Doppler	I-OUT	NOUN	B
mitral	I-OUT	ADJ	I
inflow	I-OUT	NOUN	I
parameters	I-OUT	NOUN	B
,	O	PUNCT	O
all	O	DET	O
measured	O	VERB	B
in	O	ADP	O
a	O	DET	O
core	O	NOUN	B
laboratory	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
the	O	DET	O
metoprolol	B-I	NOUN	B
CR/XL	I-I	NOUN	B
group	O	NOUN	I
left	B-OUT	VERB	I
ventricular	I-OUT	ADJ	I
ejection	I-OUT	NOUN	I
fraction	I-OUT	NOUN	I
increased	O	VERB	B
from	O	ADP	O
0.26	O	NUM	O
to	O	PART	O
0.31	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.009	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
observation	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
10.6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
deceleration	O	NOUN	B
time	B-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
early	I-OUT	ADJ	B
mitral	I-OUT	ADJ	B
filling	I-OUT	NOUN	I
wave	I-OUT	NOUN	I
(	O	PUNCT	O
E	O	NOUN	B
)	O	PUNCT	O
increased	O	VERB	B
from	O	ADP	O
189	O	NUM	O
to	O	PART	O
246	O	NUM	O
ms	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0012	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
time	B-OUT	NOUN	B
velocity	I-OUT	NOUN	I
integral	I-OUT	ADJ	O
of	I-OUT	ADP	O
E-wave	I-OUT	NOUN	B
increased	O	VERB	B
from	O	ADP	O
8.7	O	NUM	O
to	O	PART	O
11.2	O	NUM	O
cm	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.018	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
late	I-OUT	ADJ	B
mitral	I-OUT	ADJ	I
filling	I-OUT	NOUN	I
wave	I-OUT	NOUN	I
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
increased	O	VERB	B
from	O	ADP	O
122	O	NUM	O
to	O	PART	O
145	O	NUM	O
ms	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.014	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
changes	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
regarding	O	VERB	O
any	O	DET	O
of	O	ADP	O
these	O	DET	O
variables	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Metoprolol	B-I	PROPN	B
CR/XL	I-I	NOUN	B
once	O	ADV	O
daily	O	ADV	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
standard	O	ADJ	B
therapy	O	NOUN	I
improved	O	VERB	B
both	O	CCONJ	O
diastolic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
systolic	I-OUT	ADJ	B
function	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
and	I-P	CCONJ	O
decreased	I-P	VERB	B
ejection	I-P	NOUN	O
fraction	I-P	NOUN	O
.	I-P	PUNCT	O


Increasing	O	VERB	B
verbal	O	ADJ	B
responsiveness	O	NOUN	I
in	O	ADP	O
parents	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
:	I-P	PUNCT	O
a	I-P	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Correlational	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
revealed	O	VERB	O
a	O	DET	O
positive	O	ADJ	B
relationship	O	NOUN	B
between	O	ADP	O
parent	B-P	NOUN	B
verbal	O	ADJ	B
responsiveness	O	NOUN	I
and	O	CCONJ	O
language	O	NOUN	B
outcomes	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
parents	B-P	NOUN	B
of	I-P	ADP	O
young	I-P	ADJ	B
children	I-P	NOUN	O
on	I-P	ADP	O
the	I-P	DET	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	B
could	O	AUX	O
learn	O	VERB	B
and	O	CCONJ	O
implement	O	VERB	B
the	O	DET	O
specific	O	ADJ	B
categories	O	NOUN	B
of	O	ADP	O
verbal	O	ADJ	B
responsiveness	O	NOUN	I
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
facilitate	O	VERB	O
language	O	NOUN	B
development	O	NOUN	B
.	O	PUNCT	O


Parents	B-P	NOUN	B
were	O	AUX	O
taught	O	VERB	O
to	O	PART	O
increase	B-I	VERB	B
their	I-I	PRON	O
verbal	I-I	ADJ	B
responsiveness	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
a	O	DET	O
short-term	B-I	ADJ	B
language	I-I	NOUN	B
intervention	I-I	NOUN	B
that	O	PRON	O
included	O	VERB	O
group	B-I	NOUN	B
parent	I-I	NOUN	B
education	I-I	NOUN	O
sessions	I-I	NOUN	O
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
individual	B-I	ADJ	B
and	I-I	CCONJ	O
small-group	I-I	ADJ	B
coaching	I-I	NOUN	B
sessions	I-I	NOUN	B
of	I-I	ADP	O
parent-child	I-I	ADJ	B
play	I-I	NOUN	O
interactions	I-I	NOUN	B
.	I-I	PUNCT	O


Parents	B-P	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
increased	O	VERB	B
their	O	PRON	O
use	O	NOUN	O
of	O	ADP	O
comments	O	NOUN	B
that	O	SCONJ	O
:	O	PUNCT	O
described	O	VERB	O
their	O	PRON	O
child	B-OUT	NOUN	B
's	I-OUT	PART	I
focus	I-OUT	NOUN	O
of	I-OUT	ADP	O
attention	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
interpreted	O	VERB	B
or	O	CCONJ	O
expanded	O	VERB	O
child	B-OUT	NOUN	B
communication	I-OUT	NOUN	B
acts	I-OUT	VERB	O
;	I-OUT	PUNCT	O
and	O	CCONJ	O
prompted	O	VERB	O
child	B-OUT	NOUN	B
communication	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Preliminary	O	ADJ	B
treatment	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
noted	O	VERB	O
in	O	ADP	O
children	B-OUT	NOUN	B
's	I-OUT	PART	I
prompted	I-OUT	VERB	O
and	I-OUT	CCONJ	O
spontaneous	I-OUT	ADJ	B
communication	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
parent-mediated	B-I	ADJ	B
interventions	I-I	NOUN	I
targeting	O	VERB	O
verbal	B-OUT	ADJ	B
responsiveness	I-OUT	NOUN	I
to	O	PART	O
facilitate	O	VERB	O
language	B-OUT	NOUN	B
development	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
communication	I-OUT	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Midazolam	B-I	NOUN	B
as	O	ADP	O
a	O	DET	O
main	O	ADJ	O
anesthesia	O	NOUN	B
induction	O	NOUN	B
agent	O	NOUN	I
--	O	PUNCT	O
a	O	DET	O
comparison	O	NOUN	B
with	O	ADP	O
thiopental	B-I	NOUN	B
and	I-I	CCONJ	O
diazepam	I-I	NOUN	B
.	I-I	PUNCT	O


A	O	DET	O
clinical	O	ADJ	B
randomized	O	ADJ	O
investigation	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
value	B-OUT	NOUN	O
of	O	ADP	O
midazolam	B-I	NOUN	B
as	O	ADP	O
a	O	DET	O
narcotic	O	ADJ	B
adjuvant	O	NOUN	I
for	O	ADP	O
anesthetic	O	ADJ	B
induction	O	NOUN	I
.	O	PUNCT	O


Thirty	B-P	NUM	O
ASA	I-P	NOUN	B
I-II	I-P	NUM	I
adult	I-P	ADJ	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
selective	I-P	ADJ	B
surgery	I-P	NOUN	I
were	O	AUX	O
allocated	O	VERB	O
randomly	O	ADV	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
following	O	VERB	O
agents	O	NOUN	B
:	O	PUNCT	O
midazolam	B-I	NOUN	B
0.3	I-I	NUM	O
mg/kg	I-I	NOUN	O
,	I-I	PUNCT	O
thiopental	I-I	NOUN	B
5	I-I	NUM	O
mg/kg	I-I	NOUN	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
diazepam	I-I	NOUN	B
0.4	I-I	NUM	O
mg/kg	I-I	NOUN	O
.	I-I	PUNCT	O


The	O	DET	O
induction	B-OUT	NOUN	B
time	I-OUT	NOUN	O
as	I-OUT	ADP	O
measured	I-OUT	VERB	B
from	I-OUT	ADP	O
the	I-OUT	DET	O
onset	I-OUT	NOUN	B
of	I-OUT	ADP	I
injection	I-OUT	NOUN	B
to	I-OUT	PART	O
loss	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
eyelash	I-OUT	ADJ	B
reflex	I-OUT	NOUN	I
was	O	AUX	O
shortest	O	ADJ	O
in	O	ADP	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
thiopental	O	NOUN	B
;	O	PUNCT	O
while	O	SCONJ	O
a	O	DET	O
lower	B-OUT	ADJ	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
apnea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
lesser	I-OUT	ADJ	B
suppression	I-OUT	NOUN	I
of	I-OUT	ADP	O
circulation	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
lack	B-OUT	NOUN	B
of	I-OUT	ADP	O
venous	I-OUT	ADJ	B
irritation	I-OUT	NOUN	I
were	O	AUX	O
points	O	NOUN	O
favoring	O	VERB	O
midazolam	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
further	O	ADJ	O
study	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
to	O	PART	O
clarify	O	VERB	O
the	O	DET	O
moderate	B-OUT	ADJ	B
cardiovascular	I-OUT	ADJ	B
response	I-OUT	NOUN	I
seen	O	VERB	O
during	O	ADP	O
intubation	O	NOUN	B
in	O	ADP	O
some	O	DET	O
cases	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
to	O	PART	O
elucidate	O	VERB	O
any	O	DET	O
patient	O	NOUN	B
population	O	NOUN	I
differences	O	NOUN	B
.	O	PUNCT	O


Ceftriaxone	B-I	NOUN	B
versus	I-I	CCONJ	O
ampicillin	I-I	NOUN	B
and	I-I	CCONJ	O
chloramphenicol	I-I	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
bacterial	B-OUT	ADJ	B
meningitis	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


78	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
bacterial	I-P	ADJ	B
meningitis	I-P	NOUN	I
were	I-P	AUX	O
evaluated	I-P	VERB	B
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
study	O	NOUN	I
comparing	O	VERB	O
twice-daily	O	ADJ	B
ceftriaxone	B-I	NOUN	I
as	O	ADP	O
single-drug	O	ADJ	B
therapy	O	NOUN	I
with	O	ADP	O
ampicillin	B-I	NOUN	B
and	I-I	CCONJ	O
chloramphenicol	I-I	NOUN	B
given	O	VERB	O
every	O	DET	O
6	O	NUM	O
h.	O	NOUN	O
The	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
in	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
days	O	NOUN	B
of	O	ADP	O
illness	O	NOUN	B
before	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bacterial	O	ADJ	B
colony	O	NOUN	B
counts	O	NOUN	I
in	O	ADP	O
cerebrospinal	O	ADJ	B
fluid	O	NOUN	I
(	O	PUNCT	O
CSF	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
pathogens	O	NOUN	B
were	O	AUX	O
Haemophilus	O	NOUN	B
influenzae	O	NOUN	I
type	O	NOUN	I
b	O	NOUN	I
(	O	PUNCT	O
54	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
streptococci	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
meningococci	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
unknown	O	ADJ	O
(	O	PUNCT	O
6	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
40	O	NUM	O
CSF	O	NOUN	B
specimens	O	NOUN	B
obtained	O	VERB	O
4-12	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
cultures	B-OUT	NOUN	B
were	I-OUT	AUX	O
negative	I-OUT	ADJ	B
in	O	ADP	O
57	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ceftriaxone	O	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
42	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
others	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	NOUN	O
falls	I-OUT	VERB	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
CSF	I-OUT	NOUN	B
bacterial	I-OUT	ADJ	B
colony	I-OUT	NOUN	B
counts	I-OUT	NOUN	I
were	O	AUX	O
4.7	O	NUM	O
and	O	CCONJ	O
5.0	O	NUM	O
log10	O	NOUN	O
colony-forming	O	ADJ	B
units/ml	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Mean	B-OUT	VERB	O
bactericidal	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
in	I-OUT	ADP	O
CSF	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
ceftriaxone	B-I	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
conventional	O	ADJ	B
treatment	O	NOUN	B
group	O	NOUN	I
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	B
and	O	CCONJ	O
end	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
clinical	B-OUT	ADJ	B
responses	I-OUT	NOUN	I
or	O	CCONJ	O
in	O	ADP	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
complications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
except	I-OUT	SCONJ	O
for	I-OUT	ADP	O
mild	I-OUT	ADJ	B
diarrhoea	I-OUT	NOUN	I
,	O	PUNCT	O
which	O	DET	O
occurred	O	VERB	O
in	O	ADP	O
16	O	NUM	O
ceftriaxone	B-I	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
8	O	NUM	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Once-daily	O	ADJ	B
topical	B-I	ADJ	B
brimonidine	I-I	NOUN	I
tartrate	I-I	NOUN	B
gel	I-I	NOUN	I
0·5	O	NOUN	O
%	O	NOUN	O
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	B
treatment	O	NOUN	B
for	B-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-OUT	ADJ	B
facial	I-OUT	ADJ	B
erythema	I-OUT	NOUN	I
of	I-OUT	ADP	O
rosacea	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
multicentre	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
and	O	CCONJ	O
vehicle-controlled	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	B-P	NOUN	O
Erythema	I-P	NOUN	B
of	I-P	ADP	O
rosacea	I-P	NOUN	B
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
result	O	VERB	O
from	O	ADP	O
abnormal	O	ADJ	B
cutaneous	O	ADJ	O
vasomotor	O	NOUN	O
activity	O	NOUN	O
.	B-I	PUNCT	O


Brimonidine	B-I	NOUN	B
tartrate	I-I	NOUN	B
(	I-I	PUNCT	O
BT	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
a	O	DET	O
highly	O	ADV	O
selective	O	ADJ	O
α	O	DET	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
-adrenergic	O	ADJ	O
receptor	O	NOUN	O
agonist	O	NOUN	B
with	O	ADP	O
vasoconstrictive	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
optimal	O	ADJ	B
concentration	O	NOUN	B
and	O	CCONJ	O
dose	O	NOUN	B
regimen	O	NOUN	B
of	B-I	ADP	O
topical	I-I	ADJ	B
BT	I-I	NOUN	B
gel	I-I	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	B-OUT	ADP	O
erythema	I-OUT	NOUN	B
of	I-OUT	ADP	O
rosacea	I-OUT	NOUN	B
and	O	CCONJ	O
to	O	PART	O
evaluate	O	VERB	B
its	B-OUT	PRON	O
efficacy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	B-P	ADP	O
study	I-P	NOUN	B
A	I-P	NOUN	O
,	I-P	PUNCT	O
122	I-P	NUM	O
subjects	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	PART	O
receive	I-P	VERB	O
a	I-P	DET	O
single	I-P	ADJ	O
application	I-P	NOUN	B
of	I-I	ADP	O
BT	I-I	NOUN	B
0·07	I-P	ADJ	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
0·18	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
0·5	I-I	NUM	O
%	I-I	NOUN	O
or	I-I	CCONJ	O
vehicle	I-I	NOUN	B
.	I-P	PUNCT	O


In	B-P	ADP	O
study	I-P	NOUN	B
B	I-P	NOUN	I
(	I-P	PUNCT	O
4-week	I-P	NOUN	B
treatment	I-P	NOUN	I
and	I-P	CCONJ	O
4-week	I-P	NOUN	O
follow-up	I-P	X	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
269	I-P	NUM	O
subjects	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	B-I	VERB	O
BT	O	NOUN	B
0·5	O	NOUN	O
%	O	NOUN	O
once	O	ADV	O
daily	B-I	ADV	O
,	O	PUNCT	O
BT	O	NOUN	B
0·18	O	NUM	O
%	O	NOUN	O
once	O	ADV	O
daily	B-I	ADV	O
,	I-I	PUNCT	O
vehicle	I-I	NOUN	B
once	O	ADV	B
daily	B-I	ADV	I
,	O	PUNCT	O
BT	O	NOUN	B
0·18	O	NUM	O
%	O	NOUN	O
twice	O	ADV	O
daily	B-I	ADV	B
or	I-I	CCONJ	O
vehicle	O	NOUN	B
twice	O	ADV	O
daily	O	ADV	B
.	O	PUNCT	O


Evaluations	O	NOUN	B
included	B-OUT	VERB	O
Clinician	I-OUT	PROPN	B
's	I-OUT	PART	I
Erythema	I-OUT	PROPN	I
Assessment	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CEA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Patient	I-OUT	NOUN	B
's	I-OUT	PART	I
Self-Assessment	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
PSA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Chroma	I-OUT	PROPN	B
Meter	I-OUT	PROPN	I
measurements	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
adverse	I-OUT	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
study	O	NOUN	B
A	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
single	O	ADJ	O
application	O	NOUN	B
of	O	ADP	O
topical	B-OUT	ADJ	B
BT	I-OUT	NOUN	B
gel	I-OUT	NOUN	I
reduced	I-OUT	VERB	O
facial	I-OUT	ADJ	B
erythema	I-OUT	NOUN	I
in	O	ADP	O
a	O	DET	O
dose-dependent	O	ADJ	B
fashion	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
BT	O	NOUN	B
0·5	O	NOUN	O
%	O	NOUN	O
and	O	CCONJ	O
vehicle	B-OUT	NOUN	B
in	I-OUT	ADP	O
Chroma	I-OUT	PROPN	B
Meter	I-OUT	PROPN	I
redness	I-OUT	NOUN	I
value	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
from	O	ADP	O
30min	O	NOUN	O
to	O	PART	O
12h	O	NOUN	O
after	O	ADP	O
application	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
study	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
BT	O	NOUN	B
0·5	O	NOUN	O
%	O	NOUN	O
once	O	SCONJ	B
daily	O	ADV	I
had	O	AUX	O
a	O	DET	O
statistically	B-OUT	ADV	O
superior	I-OUT	ADJ	O
success	I-OUT	NOUN	O
profile	O	NOUN	O
(	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
two-grade	B-OUT	ADJ	B
improvement	I-OUT	NOUN	B
on	I-OUT	ADP	O
both	I-OUT	CCONJ	O
CEA	I-OUT	NOUN	B
and	O	CCONJ	O
PSA	O	NOUN	B
over	O	ADP	O
12h	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
vehicle	O	NOUN	B
once	O	ADV	B
daily	O	ADV	I
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
15	O	NUM	O
and	O	CCONJ	O
29	O	NUM	O
(	O	PUNCT	O
all	O	DET	O
P	B-OUT	NOUN	O
<	I-OUT	X	O
0·001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


No	B-OUT	DET	O
tachyphylaxis	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
rebound	I-OUT	NOUN	B
of	I-OUT	ADP	O
erythema	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
aggravation	I-OUT	NOUN	B
of	I-OUT	ADP	O
other	I-OUT	ADJ	O
disease	I-OUT	NOUN	B
signs	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
telangiectasia	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
inflammatory	I-OUT	ADJ	B
lesions	O	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


All	O	DET	O
regimens	B-OUT	NOUN	B
were	I-OUT	AUX	O
safe	I-OUT	ADJ	O
and	I-OUT	CCONJ	O
well	I-OUT	ADV	O
tolerated	O	VERB	B
with	O	ADP	O
similarly	O	ADV	O
low	O	ADJ	B
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Once-daily	O	ADJ	B
BT	O	NOUN	B
gel	O	NOUN	I
0·5	O	NOUN	O
%	O	NOUN	O
is	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
and	O	CCONJ	O
provides	O	VERB	O
significantly	B-OUT	ADV	O
greater	I-OUT	ADJ	O
efficacy	O	NOUN	B
than	O	ADP	O
vehicle	O	NOUN	B
gel	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	B-P	NOUN	B
of	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
erythema	I-P	NOUN	B
of	O	ADP	O
rosacea	O	NOUN	B
.	O	PUNCT	O


Does	O	AUX	O
surface	O	NOUN	B
preparation	O	NOUN	O
alter	O	VERB	O
ALA	B-OUT	NOUN	B
uptake	I-OUT	NOUN	B
in	O	ADP	O
superficial	O	ADJ	B
non-melanoma	B-P	ADJ	B
skin	I-P	NOUN	O
cancer	I-P	NOUN	O
in	O	X	B
vivo	O	X	I
?	O	PUNCT	O
BACKGROUND/PURPOSE	O	NOUN	B
Photodynamic	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
PDT	O	NOUN	B
)	O	PUNCT	O
using	O	VERB	O
aminolaevulinic	B-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
ALA	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
widely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
non-melanoma	B-P	ADJ	B
skin	I-P	NOUN	O
cancer	I-P	NOUN	O
.	I-P	PUNCT	O


Surface	B-I	NOUN	B
preparation	I-I	NOUN	B
of	O	ADP	O
the	O	DET	O
lesion	O	NOUN	B
is	O	AUX	O
commonly	O	ADV	O
performed	O	VERB	O
before	O	ADP	O
application	O	NOUN	B
of	O	ADP	O
ALA	O	PROPN	B
but	O	CCONJ	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
preparation	O	NOUN	B
varies	O	VERB	O
from	O	ADP	O
centre	O	NOUN	O
to	O	ADP	O
centre	O	NOUN	B
and	O	CCONJ	O
there	O	PRON	O
has	O	AUX	O
been	O	AUX	O
no	O	DET	O
study	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
effects	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
surface	B-I	NOUN	B
preparation	I-I	NOUN	O
on	O	ADP	O
the	O	DET	O
local	O	ADJ	B
uptake	B-OUT	NOUN	B
of	I-OUT	ADP	O
ALA	I-OUT	PROPN	B
by	O	ADP	O
recording	O	VERB	O
fluorescence	O	NOUN	B
from	O	ADP	O
accumulated	O	VERB	O
protoporphyrin	O	NOUN	B
IX	O	NUM	I
(	O	PUNCT	O
PPIX	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
16	B-P	NUM	O
lesions	I-P	NOUN	B
,	I-P	PUNCT	O
either	I-P	CCONJ	O
superficial	I-P	ADJ	B
basal	I-P	ADJ	B
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
(	I-P	PUNCT	O
BCC	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
Bowen	I-P	PROPN	B
's	I-P	PART	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
BD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Each	O	DET	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
lesion	O	NOUN	B
was	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
(	B-I	PUNCT	O
a	I-I	X	O
)	I-I	PUNCT	O
no	I-I	DET	O
surface	I-I	NOUN	O
preparation	I-I	NOUN	O
or	I-I	CCONJ	O
(	I-I	PUNCT	O
b	I-I	X	O
)	I-I	PUNCT	O
surface	I-I	NOUN	O
preparation	I-I	NOUN	O
(	I-I	PUNCT	O
randomly	I-I	ADV	O
allocated	I-I	VERB	O
to	I-I	PART	O
gentle	I-I	VERB	O
curettage	I-I	NOUN	B
or	I-I	CCONJ	O
abrasion	I-I	NOUN	B
with	I-I	ADP	O
a	I-I	DET	O
spatula	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


ALA	O	PROPN	B
was	O	AUX	O
left	O	VERB	O
for	O	ADP	O
4	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
BCC	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
6	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
BD	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


PPIX	B-OUT	NOUN	B
fluorescence	I-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
an	O	DET	O
excitation	O	NOUN	B
wavelength	O	NOUN	I
of	O	ADP	O
405+/-5	O	NUM	O
nm	O	NOUN	O
and	O	CCONJ	O
emission	O	NOUN	B
spectrum	O	NOUN	I
recorded	O	VERB	O
using	O	VERB	O
a	O	DET	O
photodiode	B-I	NOUN	B
array	I-I	NOUN	I
.	I-I	PUNCT	O


Spectra	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
before	O	ADP	O
and	O	CCONJ	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
after	O	ADP	O
surface	O	NOUN	B
preparation	O	NOUN	O
,	O	PUNCT	O
(	O	PUNCT	O
c	O	X	O
)	O	PUNCT	O
immediately	O	ADV	O
before	O	ADV	B
and	O	CCONJ	O
(	O	PUNCT	O
d	O	X	O
)	O	PUNCT	O
after	O	ADP	O
laser	B-I	NOUN	B
irradiation	I-I	NOUN	I
at	O	ADP	O
630	O	NUM	O
nm	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
ratio	B-OUT	NOUN	B
of	I-OUT	ADP	O
fluorescence	I-OUT	NOUN	B
after	I-OUT	ADP	O
incubation	I-OUT	NOUN	B
to	O	PART	O
that	O	DET	O
before	O	ADP	O
incubation	O	NOUN	B
was	O	AUX	O
6.1+/-1.2	O	NUM	O
in	O	ADP	O
the	O	DET	O
non-prepared	O	ADJ	B
section	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
increased	O	VERB	B
slightly	O	ADV	O
but	O	CCONJ	O
not	O	PART	O
significantly	O	ADV	O
to	O	PART	O
6.8	O	NUM	O
+/-1.8	O	NOUN	O
in	O	ADP	O
the	O	DET	O
prepared	O	VERB	B
section	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
curettage	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
abrasion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


There	O	PRON	O
was	O	AUX	O
also	O	ADV	O
no	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
outcome	B-OUT	NOUN	B
after	O	ADP	O
PDT	O	PROPN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
clinical	O	ADJ	B
assessment	O	NOUN	I
agrees	O	VERB	O
with	O	ADP	O
the	O	DET	O
fluorescence	O	NOUN	B
data	O	NOUN	B
as	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	I
was	O	AUX	O
seen	O	VERB	O
between	O	ADP	O
prepared	O	VERB	B
and	O	CCONJ	O
unprepared	O	ADJ	B
halves	O	NOUN	O
of	O	ADP	O
the	O	DET	O
lesion	O	NOUN	B
12	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
PDT	O	PROPN	B
.	O	PUNCT	O


Overall	O	ADV	O
our	O	PRON	O
data	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
suggest	O	VERB	O
that	O	SCONJ	O
for	O	ADP	O
most	O	ADJ	O
BCC	O	NOUN	B
and	O	CCONJ	O
BD	O	NOUN	B
lesions	O	NOUN	B
,	O	PUNCT	O
surface	O	NOUN	B
preparation	O	NOUN	I
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
ALA	B-OUT	NOUN	B
uptake	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Long-term	O	ADJ	B
follow-up	O	NOUN	B
of	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
I/II	O	NOUN	I
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
palifermin	B-I	NOUN	B
to	O	PART	O
prevent	O	VERB	B
graft-versus-host	B-P	NOUN	B
disease	I-P	NOUN	I
(	I-P	PUNCT	O
GVHD	I-P	NOUN	B
)	I-P	PUNCT	O
after	I-P	ADP	O
related	I-P	ADJ	O
donor	I-P	NOUN	B
allogeneic	I-P	ADJ	B
hematopoietic	I-P	ADJ	B
cell	I-P	NOUN	I
transplantation	I-P	NOUN	I
(	I-P	PUNCT	O
HCT	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


We	O	PRON	O
previously	O	ADV	O
conducted	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	I-P	NOUN	I
conducted	I-P	VERB	O
from	I-P	ADP	O
2000	I-P	NUM	O
to	I-P	PART	O
2003	I-P	NUM	O
of	I-P	ADP	O
palifermin	I-I	NOUN	B
,	I-P	PUNCT	O
a	I-P	DET	O
recombinant	I-P	ADJ	B
human	I-P	ADJ	B
keratinocyte	I-P	NOUN	O
growth	I-P	NOUN	O
factor	I-P	NOUN	O
,	I-P	PUNCT	O
dosed	I-P	VERB	B
from	I-P	ADP	O
240	I-P	NUM	O
microg/kg	I-P	NOUN	O
to	I-P	PART	O
720	I-P	NUM	O
microg/kg	I-P	NOUN	B
,	I-P	PUNCT	O
in	I-P	ADP	O
100	I-P	NUM	O
allogeneic	I-P	ADJ	B
hematopoietic	I-P	ADJ	B
stem	I-P	NOUN	I
cell	I-P	NOUN	I
transplantation	I-P	NOUN	I
(	I-P	PUNCT	O
HCT	I-P	NOUN	B
)	I-P	PUNCT	O
recipients	I-P	NOUN	B
.	I-P	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
palifermin	B-I	NOUN	B
showed	O	VERB	O
beneficial	O	ADJ	O
effects	B-OUT	NOUN	B
on	O	ADP	O
mucositis	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
but	I-OUT	CCONJ	O
no	I-OUT	DET	O
significant	I-OUT	ADJ	O
effect	I-OUT	NOUN	O
on	I-OUT	ADP	O
engraftment	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
acute	I-OUT	ADJ	B
graft-versus-host	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GVHD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
early	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
palifermin	B-I	NOUN	B
on	O	ADP	O
mucosa	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
other	I-OUT	ADJ	O
pleotrophic	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
including	I-OUT	VERB	O
more	I-OUT	ADV	O
rapid	I-OUT	ADJ	O
immune	I-OUT	ADJ	B
reconstitution	I-OUT	NOUN	I
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
experimental	O	ADJ	B
transplant	O	NOUN	I
models	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
with	O	ADP	O
longer	O	X	O
follow-up	O	ADJ	B
we	O	PRON	O
could	O	AUX	O
detect	O	VERB	B
additional	B-OUT	ADJ	O
differences	I-OUT	NOUN	O
between	O	ADP	O
the	O	DET	O
palifermin-treated	B-I	ADJ	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
cohorts	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
CMV	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
invasive	I-OUT	ADJ	B
fungal	I-OUT	ADJ	B
infections	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
chronic	I-OUT	ADJ	B
GVHD	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
long-term	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
between	O	ADP	O
cohorts	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
palifermin	B-I	NOUN	B
appear	O	VERB	O
primarily	O	ADV	O
to	O	PART	O
be	O	AUX	O
limited	O	VERB	O
to	O	ADP	O
ameliorating	O	VERB	B
mucotoxicity	B-OUT	NOUN	B
when	O	SCONJ	O
given	O	VERB	O
to	O	PART	O
allogeneic	B-P	ADJ	B
HCT	I-P	NOUN	B
recipients	I-P	NOUN	B
.	I-P	PUNCT	O


Phosphate	B-I	NOUN	B
binder	I-I	NOUN	I
impact	O	NOUN	B
on	O	ADP	O
bone	B-OUT	NOUN	B
remodeling	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
coronary	I-OUT	ADJ	B
calcification	I-OUT	NOUN	I
--	I-OUT	PUNCT	O
results	I-OUT	NOUN	B
from	O	ADP	O
the	O	DET	O
BRiC	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
AIMS	O	NOUN	B
Calcium-containing	B-I	ADJ	B
phosphate	I-I	NOUN	I
binders	I-I	NOUN	I
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
increase	O	VERB	B
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
vascular	B-OUT	ADJ	B
calcification	I-OUT	NOUN	I
in	O	ADP	O
hemodialysis	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
is	O	AUX	O
a	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
that	O	PRON	O
compares	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
calcium	B-I	NOUN	B
acetate	I-I	NOUN	I
and	I-I	CCONJ	O
sevelamer	I-I	NOUN	B
on	O	ADP	O
coronary	B-OUT	ADJ	B
calcification	I-OUT	NOUN	I
(	O	PUNCT	O
CAC	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
bone	B-OUT	NOUN	B
histology	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
101	B-P	NUM	O
hemodialysis	I-P	NOUN	B
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
for	O	ADP	O
each	O	DET	O
phosphate	B-I	NOUN	B
binder	I-I	NOUN	I
and	O	CCONJ	O
submitted	O	VERB	O
to	O	ADP	O
multislice	B-I	ADJ	B
coronary	I-I	ADJ	I
tomographies	I-I	NOUN	I
and	I-I	CCONJ	O
bone	I-I	NOUN	B
biopsies	I-I	NOUN	I
at	O	ADP	O
entry	O	NOUN	B
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	B-P	DET	O
71	I-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
concluded	I-P	VERB	O
the	I-P	DET	O
study	I-P	NOUN	B
had	I-P	AUX	O
similar	I-P	ADJ	O
baseline	I-P	NOUN	B
characteristics	I-P	NOUN	B
.	I-P	PUNCT	O


On	O	ADP	O
follow-up	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
sevelamer	O	NOUN	B
group	O	NOUN	B
had	O	AUX	O
higher	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
intact	B-OUT	ADJ	B
parathyroid	I-OUT	ADJ	B
hormone	I-OUT	NOUN	I
(	O	PUNCT	O
498	O	NUM	O
+/-	O	CCONJ	O
352	O	NUM	O
vs.	O	CCONJ	O
326	O	NUM	O
+/-	O	CCONJ	O
236	O	NUM	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.017	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
bone	B-OUT	NOUN	B
alkaline	I-OUT	NOUN	I
phosphatase	I-OUT	NOUN	I
(	O	PUNCT	O
38	O	NUM	O
+/-	O	CCONJ	O
24	O	NUM	O
vs.	O	CCONJ	O
28	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
U/l	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
deoxypyridinoline	B-OUT	NOUN	B
(	O	PUNCT	O
135	O	NUM	O
+/-	O	CCONJ	O
107	O	NUM	O
vs.	O	CCONJ	O
89	O	NUM	O
+/-	O	CCONJ	O
71	O	NUM	O
nmol/l	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
lower	B-OUT	ADJ	O
LDL	I-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
(	O	PUNCT	O
74	O	NUM	O
+/-	O	CCONJ	O
21	O	NUM	O
vs.	O	CCONJ	O
91	O	NUM	O
+/-	O	CCONJ	O
28	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.015	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Phosphorus	B-OUT	NOUN	B
(	O	PUNCT	O
5.8	O	NUM	O
+/-	O	CCONJ	O
1.0	O	NUM	O
vs.	O	CCONJ	O
6	O	NUM	O
+/-	O	CCONJ	O
1.0	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.47	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
calcium	B-OUT	NOUN	B
(	O	PUNCT	O
1.27	O	NUM	O
+/-	O	CCONJ	O
0.07	O	NUM	O
vs.	O	CCONJ	O
1.23	O	NUM	O
+/-	O	CCONJ	O
0.08	O	NUM	O
mmol/l	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.68	O	NUM	O
)	O	PUNCT	O
levels	B-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


CAC	B-OUT	NOUN	B
progression	I-OUT	NOUN	B
(	O	PUNCT	O
35	O	NUM	O
vs.	O	CCONJ	O
24	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.94	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
bone	B-OUT	NOUN	B
histological	I-OUT	ADJ	O
diagnosis	I-OUT	NOUN	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sevelamer	O	NOUN	B
group	O	NOUN	B
with	O	ADP	O
a	O	DET	O
high	O	ADJ	O
turnover	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
had	O	AUX	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
bone	B-OUT	NOUN	B
resorption	I-OUT	NOUN	I
(	O	PUNCT	O
eroded	O	VERB	B
surface	O	NOUN	I
,	O	PUNCT	O
ES/BS	O	NOUN	O
=	O	ADJ	O
9.0	O	NUM	O
+/-	O	CCONJ	O
5.9	O	NUM	O
vs.	O	CCONJ	O
13.1	O	NUM	O
+/-	O	CCONJ	O
9.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
patients	O	NOUN	B
of	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
turnover	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
had	O	AUX	O
an	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
bone	B-OUT	NOUN	B
formation	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
(	O	PUNCT	O
BFR/BS	O	NOUN	O
=	O	ADJ	O
0.015	O	NUM	O
+/-	O	CCONJ	O
0.016	O	NUM	O
vs.	O	CCONJ	O
0.062	O	NUM	O
+/-	O	CCONJ	O
0.078	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
for	O	ADP	O
calcium	O	NOUN	B
and	O	CCONJ	O
0.017	O	NUM	O
+/-	O	CCONJ	O
0.016	O	NUM	O
vs.	O	CCONJ	O
0.071	O	NUM	O
+/-	O	CCONJ	O
0.084	O	NUM	O
microm	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
/microm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/day	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.010	O	NUM	O
for	O	ADP	O
sevelamer	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
CAC	B-OUT	NOUN	B
progression	I-OUT	NOUN	B
or	O	CCONJ	O
changes	O	NOUN	B
in	O	ADP	O
bone	B-OUT	NOUN	B
remodeling	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
calcium	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
sevelamer	O	NOUN	B
groups	O	NOUN	B
.	O	PUNCT	O


Predictors	O	NOUN	B
of	O	ADP	O
incident	B-OUT	NOUN	B
depression	I-OUT	NOUN	B
after	I-P	ADP	O
hip	I-P	NOUN	B
fracture	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	B
Depression	O	NOUN	B
after	O	ADP	O
hip	B-I	NOUN	B
fracture	I-I	NOUN	I
surgery	I-I	NOUN	O
is	O	AUX	O
prevalent	O	ADJ	B
and	O	CCONJ	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
mortality	O	NOUN	B
rates	O	NOUN	I
and	O	CCONJ	O
impaired	O	VERB	B
functional	O	ADJ	B
recovery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
new-onset	O	ADJ	B
depressive	O	ADJ	B
symptoms	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
initially	O	ADV	O
not	O	PART	B
depressed	O	ADJ	I
after	O	ADP	O
hip	B-I	NOUN	B
fracture	I-I	NOUN	I
surgery	I-I	NOUN	O
and	O	CCONJ	O
their	O	PRON	O
relationship	O	NOUN	B
with	O	ADP	O
functional	O	ADJ	B
recovery	O	NOUN	I
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
cohort	O	NOUN	B
of	O	ADP	O
139	B-P	NUM	O
nondepressed	I-P	ADJ	B
elderly	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
>	I-P	NOUN	O
60	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
hospitalized	I-P	VERB	B
for	I-P	ADP	O
hip	I-I	NOUN	B
fracture	I-I	NOUN	I
surgery	I-I	NOUN	O
were	O	AUX	O
followed	O	VERB	O
up	O	ADP	O
for	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Clinically	O	ADV	B
significant	O	ADJ	I
depressive	O	ADJ	B
symptoms	O	NOUN	I
were	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
score	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
on	O	ADP	O
the	O	DET	O
15-item	B-OUT	ADJ	B
Geriatric	I-OUT	PROPN	I
Depression	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
authors	O	NOUN	B
found	O	VERB	O
a	O	DET	O
cumulative	B-OUT	ADJ	B
incidence	I-OUT	NOUN	B
rate	I-OUT	NOUN	O
of	O	ADP	O
20.5	O	NUM	O
%	O	NOUN	O
adjusted	O	VERB	O
for	O	ADP	O
dropouts	O	NOUN	B
.	O	PUNCT	O


Multiple	O	ADJ	B
Cox-regression	O	NOUN	B
analyses	O	NOUN	I
yielded	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
subthreshold	O	ADJ	B
symptoms	O	NOUN	B
of	O	ADP	O
depression	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
anxiety	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cognitive	I-OUT	ADJ	B
impairment	I-OUT	NOUN	I
at	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
premorbid	I-OUT	ADJ	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
mobility	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
history	I-OUT	NOUN	B
of	I-OUT	ADP	O
(	I-OUT	PUNCT	O
treated	I-OUT	VERB	B
)	I-OUT	PUNCT	O
depression	I-OUT	NOUN	O
as	I-OUT	ADP	O
risk	I-OUT	NOUN	B
factors	I-OUT	NOUN	I
for	I-OUT	ADP	O
incident	I-OUT	NOUN	B
depression	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
forward	O	NOUN	O
,	O	PUNCT	O
conditional	O	ADJ	B
procedure	O	NOUN	I
identified	O	VERB	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
[	O	PUNCT	O
HR	O	NOUN	B
]	O	PUNCT	O
=	O	ADJ	O
1.32	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
:	O	PUNCT	O
1.14-1.53	O	NOUN	O
,	O	PUNCT	O
Wald	O	PROPN	B
chi	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
13.57	O	NUM	O
,	O	PUNCT	O
df	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
baseline	B-OUT	NOUN	B
anxiety	I-OUT	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
=	O	ADJ	O
1.25	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
1.08-1.44	O	NUM	O
,	O	PUNCT	O
Wald	O	PROPN	B
chi	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
8.86	O	NUM	O
,	O	PUNCT	O
df	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
as	O	ADP	O
the	O	DET	O
strongest	O	ADJ	O
independent	O	ADJ	B
risk	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


Incident	B-OUT	ADJ	B
depression	I-OUT	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
less	O	ADV	O
favorable	O	ADJ	O
outcome	O	NOUN	B
at	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
follow-up	O	ADJ	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
This	O	DET	O
exploratory	O	ADJ	B
study	O	NOUN	I
identified	O	VERB	B
two	O	NUM	O
treatable	O	ADJ	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
that	O	PRON	O
predicted	O	VERB	B
incident	B-OUT	NOUN	B
depression	I-OUT	NOUN	B
in	O	ADP	O
nondepressed	B-P	ADJ	B
patients	I-P	NOUN	B
after	I-P	ADP	O
hip-fracture	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
neuropeptide	B-I	NOUN	B
oxytocin	I-I	NOUN	I
modulates	O	VERB	B
consumer	O	NOUN	B
brand	O	NOUN	B
relationships	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
year	O	NOUN	B
,	O	PUNCT	O
companies	O	NOUN	B
invest	O	VERB	O
billions	O	NOUN	O
of	O	ADP	O
dollars	O	NOUN	O
into	O	ADP	O
marketing	O	NOUN	B
activities	O	NOUN	I
to	O	ADP	O
embellish	O	ADJ	O
brands	O	NOUN	B
as	O	ADP	O
valuable	O	ADJ	O
relationship	O	NOUN	B
partners	O	NOUN	B
assuming	O	VERB	O
that	O	SCONJ	O
consumer	O	NOUN	B
brand	O	NOUN	O
relationships	O	NOUN	O
(	O	PUNCT	O
CBRs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
interpersonal	O	ADJ	B
relationships	O	NOUN	B
rest	O	VERB	O
upon	O	SCONJ	O
the	O	DET	O
same	O	ADJ	O
neurobiological	O	ADJ	B
underpinnings	O	NOUN	O
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
crucial	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
neuropeptide	B-I	NOUN	B
oxytocin	I-I	NOUN	I
(	I-I	PUNCT	O
OXT	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
social	O	ADJ	B
bonding	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
tests	O	VERB	I
whether	O	SCONJ	O
OXT-based	O	ADJ	B
mechanisms	O	NOUN	B
also	O	ADV	O
determine	O	VERB	O
the	O	DET	O
bond	O	NOUN	B
between	O	ADP	O
consumers	B-P	NOUN	B
and	O	CCONJ	O
brands	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
involving	O	VERB	O
101	B-P	NUM	O
subjects	I-P	NOUN	B
and	O	CCONJ	O
analyzed	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
intranasal	B-I	ADJ	B
OXT	I-I	PROPN	B
on	O	ADP	O
consumers	B-OUT	NOUN	B
'	I-OUT	PART	O
attribution	I-OUT	NOUN	B
of	I-OUT	ADP	O
relationship	I-OUT	NOUN	B
qualities	I-OUT	NOUN	B
to	I-OUT	ADP	O
brands	I-OUT	NOUN	B
,	O	PUNCT	O
brands	O	NOUN	B
paired	O	VERB	O
with	O	ADP	O
human	O	ADJ	B
celebrity	O	NOUN	B
endorsers	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
familiar	O	ADJ	O
persons	O	NOUN	B
.	O	PUNCT	O


OXT	B-OUT	PROPN	B
indeed	O	ADV	O
promoted	O	VERB	B
the	O	DET	O
attribution	B-OUT	NOUN	B
of	I-OUT	ADP	O
relationship	I-OUT	NOUN	B
qualities	I-OUT	NOUN	B
not	O	PART	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
social	O	ADJ	B
and	O	CCONJ	O
semi-social	O	ADJ	B
stimuli	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
brands	O	NOUN	B
.	O	PUNCT	O


Intriguingly	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
subjects	B-P	NOUN	B
scoring	I-P	VERB	B
high	I-P	ADV	O
on	I-P	ADP	O
autistic-like	I-P	ADJ	B
traits	I-P	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
OXT	B-I	NOUN	B
was	O	AUX	O
completely	O	ADV	O
reversed	O	VERB	B
,	O	PUNCT	O
evident	O	ADJ	O
in	O	ADP	O
even	O	ADV	O
lower	O	ADJ	O
relationship	B-OUT	NOUN	B
qualities	I-OUT	NOUN	B
across	O	ADP	O
all	O	DET	O
stimulus	O	NOUN	B
categories	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
OXT	B-I	NOUN	B
in	O	ADP	O
a	O	DET	O
CBR	O	NOUN	B
context	O	NOUN	B
is	O	AUX	O
further	O	ADV	O
corroborated	O	VERB	O
by	O	ADP	O
a	O	DET	O
three-fold	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
endogenous	B-OUT	ADJ	B
release	I-OUT	NOUN	B
of	I-OUT	ADP	O
OXT	I-OUT	NOUN	B
following	O	VERB	O
exposure	O	NOUN	B
to	O	ADP	I
one	O	NUM	O
's	O	PART	O
favorite	O	ADJ	O
brand	O	NOUN	B
and	O	CCONJ	O
positive	O	ADJ	B
associations	O	NOUN	B
between	O	ADP	O
baseline	O	NOUN	B
peripheral	O	ADJ	B
OXT	B-I	NOUN	B
concentrations	O	NOUN	B
and	O	CCONJ	O
brand	O	NOUN	B
relationship	O	NOUN	B
qualities	O	NOUN	B
.	O	PUNCT	O


Collectively	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
OXT	B-I	NOUN	B
not	O	PART	O
only	O	ADV	O
plays	O	VERB	O
a	O	DET	O
fundamental	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
developing	O	VERB	O
interpersonal	B-OUT	ADJ	B
relationships	I-OUT	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
enables	O	VERB	O
relationship	O	NOUN	B
formation	O	NOUN	B
with	O	ADP	O
objects	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
brands	O	NOUN	B
.	O	PUNCT	O


Tramadol	B-I	NOUN	B
suppository	I-I	NOUN	B
versus	O	CCONJ	O
placebo	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
relief	O	NOUN	B
of	O	ADP	O
perineal	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
after	I-P	ADP	O
perineorrhaphy	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
in	O	ADP	O
Thailand	B-P	PROPN	B
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
randomized	O	ADJ	B
double-blinded	O	ADJ	O
control	O	NOUN	O
trial	O	NOUN	O
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
tramodol	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	ADJ	B
rectal	O	ADJ	O
suppository	O	NOUN	B
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
postpartum	B-OUT	NOUN	B
perineal	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
after	I-P	ADP	O
perineorrhaphy	I-P	NOUN	B
.	I-P	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHOD	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
women	I-P	NOUN	B
who	I-P	PRON	O
gave	I-P	VERB	O
birth	I-P	NOUN	B
vaginally	I-P	ADV	I
with	I-P	ADP	O
episiotomy	I-P	NOUN	B
and	I-P	CCONJ	O
a	I-P	DET	O
second-	I-P	ADJ	O
or	I-P	CCONJ	O
third-degree	I-P	ADJ	B
tear	I-P	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assign	O	VERB	O
to	O	PART	O
receive	O	VERB	O
two	O	NUM	O
tablets	O	NOUN	B
oftramadol	B-I	NOUN	B
50	I-I	NUM	O
mg	I-I	NOUN	O
or	I-I	CCONJ	O
two	I-I	NUM	O
tablets	I-I	NOUN	B
ofplacebo	I-I	NOUN	B
,	O	PUNCT	O
the	O	DET	O
pill	O	NOUN	B
were	O	AUX	O
physically	O	ADV	B
similar	O	ADJ	O
to	O	ADP	O
the	O	DET	O
real	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
ratings	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
immediately	O	ADV	O
after	O	ADP	O
perineorrhaphy	O	NOUN	B
,	O	PUNCT	O
30	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
first	O	ADJ	O
dose	O	NOUN	B
on	O	ADP	O
a	O	DET	O
10-cm	O	ADJ	O
visual	B-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Side	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	O
opinion	I-OUT	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Tramadol	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
had	O	AUX	O
no	O	DET	O
statistical	O	ADJ	B
significances	O	NOUN	I
in	O	ADP	O
analgesic	B-OUT	NOUN	B
properties	I-OUT	NOUN	I
,	O	PUNCT	O
assessed	O	VERB	B
by	O	ADP	O
the	O	DET	O
means	O	NOUN	O
of	O	ADP	O
pain	B-OUT	NOUN	B
rating	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
different	O	ADJ	O
time	O	NOUN	B
intervals	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	B-OUT	DET	O
serious	I-OUT	ADJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
reported	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
No	O	DET	B
differences	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
between	O	ADP	O
Tramadol	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
in	O	ADP	O
relief	O	NOUN	B
perineal	O	NOUN	I
pain	O	NOUN	I
after	O	ADP	O
perineorrhaphy	O	NOUN	B


The	O	DET	O
logMAR	B-I	PROPN	O
Kay	I-I	PROPN	B
picture	I-I	NOUN	I
test	I-I	NOUN	I
and	O	CCONJ	O
the	O	DET	O
logMAR	B-I	ADJ	B
acuity	I-I	NOUN	I
test	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
with	O	ADP	O
crowded	B-I	ADJ	B
and	I-I	CCONJ	O
uncrowded	I-I	ADJ	O
versions	I-I	NOUN	O
of	O	ADP	O
the	O	DET	O
logMAR	B-I	ADJ	B
acuity	I-I	NOUN	I
test	I-I	NOUN	I
and	O	CCONJ	O
the	O	DET	O
Kay	B-I	PROPN	B
picture	I-I	NOUN	I
test	I-I	NOUN	I
in	O	ADP	O
amblyopia	B-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
on	O	ADP	O
51	B-P	NUM	O
participants	I-P	NOUN	B
with	I-P	ADP	O
amblyopia	I-P	NOUN	B
(	I-P	PUNCT	O
strabismic	I-P	ADJ	B
n=17	I-P	ADJ	O
;	I-P	PUNCT	O
anisometropic	I-P	ADJ	B
n=10	I-P	NOUN	O
;	I-P	PUNCT	O
combined	I-P	ADJ	O
n=24	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
10	I-P	NUM	O
years	I-P	NOUN	B
8	I-P	NUM	O
months	I-P	NOUN	B
.	I-P	PUNCT	O


The	B-P	DET	O
amblyopia	I-P	NOUN	B
was	I-P	AUX	O
defined	I-P	VERB	O
as	I-P	ADP	O
severe/moderate	I-P	NOUN	B
(	I-P	PUNCT	O
<	I-P	X	O
0.250	I-P	NUM	O
logMAR	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
n=41	I-P	NUM	O
or	I-P	CCONJ	O
mild	I-P	ADJ	B
(	I-P	PUNCT	O
>	I-P	NOUN	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
0.250	I-P	NUM	O
logMAR	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
n=10	I-P	NOUN	O
.	I-P	PUNCT	O


Visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
was	I-OUT	AUX	O
assessed	I-OUT	VERB	B
uniocularly	O	ADV	B
using	O	VERB	O
the	O	DET	O
crowded	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
uncrowded	I-OUT	ADJ	O
logMAR	I-OUT	ADJ	O
acuity	I-OUT	NOUN	O
tests	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
logMAR	I-OUT	NOUN	B
crowded	I-OUT	ADJ	I
and	I-OUT	CCONJ	O
uncrowded	I-OUT	ADJ	B
Kay	I-OUT	PROPN	B
picture	I-OUT	NOUN	I
tests	I-OUT	NOUN	I
in	O	ADP	O
random	O	ADJ	B
orders	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
mean	B-OUT	ADJ	O
visual	I-OUT	ADJ	B
acuity	I-OUT	NOUN	I
outcome	I-OUT	NOUN	B
using	O	VERB	O
the	O	DET	O
logMAR	B-I	ADJ	B
crowded	I-I	ADJ	I
Kay	I-I	PROPN	B
picture	I-I	NOUN	I
test	I-I	NOUN	I
(	O	PUNCT	O
0.343+/-0.150	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
comparable	O	ADJ	O
(	O	PUNCT	O
P=0.084	O	NOUN	O
)	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
mean	O	ADJ	O
outcome	O	NOUN	B
using	O	VERB	O
the	O	DET	O
crowded	B-I	ADJ	B
logMAR	I-I	ADJ	I
acuity	I-I	NOUN	I
test	I-I	NOUN	I
(	O	PUNCT	O
0.402+/-0.188	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
mean	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
difference	I-OUT	NOUN	O
between	O	ADP	O
these	O	DET	O
two	O	NUM	O
tests	O	NOUN	B
in	O	ADP	O
the	O	DET	O
subgroup	B-P	NOUN	B
with	I-P	ADP	O
severe/moderate	I-P	ADJ	B
amblyopia	I-P	NOUN	I
(	I-P	PUNCT	O
0.074+/-0.036	I-P	NOUN	B
)	I-P	PUNCT	O
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P=0.0382	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
uncrowded	B-I	ADJ	O
logMAR	I-OUT	ADJ	O
acuity	I-OUT	NOUN	O
test	I-I	NOUN	O
significantly	O	ADV	O
overestimated	O	VERB	B
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
logMAR	B-OUT	ADJ	O
crowded	I-OUT	ADJ	B
Kay	I-OUT	PROPN	B
picture	I-OUT	NOUN	I
test	I-I	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
by	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
of	O	ADP	O
0.088+/-0.008	O	NUM	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	B-I	DET	O
logMAR	I-I	ADJ	O
crowded	I-I	ADJ	O
Kay	I-I	PROPN	B
picture	I-I	NOUN	I
test	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
tool	O	NOUN	O
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
test	O	NOUN	B
design	O	NOUN	B
takes	O	VERB	O
the	O	DET	O
crowding	O	NOUN	B
phenomenon	O	NOUN	B
into	O	ADP	O
account	O	NOUN	O
.	O	PUNCT	O


It	O	PRON	O
provides	O	VERB	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
measures	O	NOUN	B
more	O	ADV	O
comparable	O	ADJ	O
with	O	ADP	O
the	O	DET	O
gold	O	NOUN	B
standard	O	ADJ	O
crowded	B-I	VERB	O
logMAR	I-I	ADJ	O
acuity	I-I	NOUN	O
test	I-I	NOUN	O
than	O	ADP	O
the	O	DET	O
uncrowded	O	ADJ	B
logMAR	O	ADJ	I
acuity	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
outcomes	O	NOUN	B
in	O	ADP	O
poorer	O	ADJ	B
acuities	O	NOUN	I
should	O	AUX	O
still	O	ADV	O
be	O	AUX	O
viewed	O	VERB	O
with	O	ADP	O
caution	O	NOUN	O
.	O	PUNCT	O


Safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
dalcetrapib	B-I	NOUN	B
on	O	ADP	O
atherosclerotic	O	ADJ	B
disease	O	NOUN	I
using	O	VERB	O
novel	B-I	ADJ	O
non-invasive	I-I	ADJ	B
multimodality	I-I	NOUN	O
imaging	I-I	NOUN	O
(	I-I	PUNCT	O
dal-PLAQUE	I-I	NOUN	O
)	I-I	PUNCT	O
:	I-I	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Dalcetrapib	B-I	NOUN	B
modulates	O	VERB	B
cholesteryl	O	NOUN	B
ester	O	NOUN	I
transfer	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
CETP	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
to	O	PART	O
raise	O	VERB	O
high-density	O	ADJ	B
lipoprotein	O	NOUN	I
cholesterol	O	NOUN	I
(	O	PUNCT	O
HDL-C	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
failure	O	NOUN	B
of	O	ADP	O
torcetrapib	O	NOUN	B
it	O	PRON	O
was	O	AUX	O
unknown	O	ADJ	O
if	O	SCONJ	O
HDL	O	NOUN	B
produced	O	VERB	O
by	O	ADP	O
interaction	O	NOUN	B
with	O	ADP	O
CETP	O	NOUN	B
had	O	AUX	O
pro-atherogenic	O	ADJ	B
or	O	CCONJ	O
pro-inflammatory	O	ADJ	B
properties	O	NOUN	B
.	O	PUNCT	O


dal-PLAQUE	O	NOUN	B
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
multicentre	O	NOUN	B
study	O	NOUN	I
using	O	VERB	O
novel	O	ADJ	O
non-invasive	O	ADJ	B
multimodality	O	NOUN	B
imaging	O	NOUN	I
to	O	PART	O
assess	O	VERB	B
structural	O	ADJ	B
and	O	CCONJ	O
inflammatory	O	ADJ	B
indices	O	NOUN	I
of	O	ADP	O
atherosclerosis	O	NOUN	B
as	O	ADP	O
primary	O	ADJ	O
endpoints	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
phase	O	NOUN	B
2b	O	NOUN	I
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
multicentre	O	NOUN	B
trial	O	NOUN	I
,	O	PUNCT	O
patients	B-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	O
18-75	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
with	I-P	ADP	O
high	I-P	ADJ	B
risk	I-P	NOUN	I
of	I-P	ADP	O
,	I-P	PUNCT	O
coronary	I-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
(	O	PUNCT	O
1:1	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
dalcetrapib	B-I	ADJ	B
600	I-I	NUM	O
mg/day	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
for	I-I	ADP	O
24	I-I	NUM	O
months	I-I	NOUN	B
.	I-I	PUNCT	O


Randomisation	O	NOUN	B
was	O	AUX	O
done	O	VERB	O
with	O	ADP	O
a	O	DET	O
computer-generated	O	ADJ	O
randomisation	O	NOUN	O
code	O	NOUN	O
and	O	CCONJ	O
was	O	AUX	O
stratified	O	VERB	B
by	O	ADP	O
centre	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
and	O	CCONJ	O
investigators	O	NOUN	B
were	O	AUX	O
masked	O	VERB	O
to	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


Coprimary	O	ADJ	B
endpoints	O	NOUN	I
were	O	AUX	O
MRI-assessed	B-OUT	ADJ	B
indices	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
total	I-OUT	ADJ	B
vessel	I-OUT	NOUN	I
area	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
wall	I-OUT	NOUN	B
area	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
wall	I-OUT	NOUN	B
thickness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
normalised	I-OUT	VERB	B
wall	I-OUT	NOUN	I
index	I-OUT	NOUN	I
[	O	PUNCT	O
average	O	ADJ	B
carotid	O	NOUN	O
]	O	PUNCT	O
)	O	PUNCT	O
after	O	ADP	O
24	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
(	O	PUNCT	O
18	O	NUM	O
)	O	PUNCT	O
F-fluorodeoxyglucose	O	PROPN	O
(	O	PUNCT	O
(	O	PUNCT	O
18	O	X	O
)	O	PUNCT	O
F-FDG	O	NOUN	B
)	O	PUNCT	O
PET/CT	O	NOUN	B
assessment	O	NOUN	B
of	O	ADP	O
arterial	O	ADJ	B
inflammation	O	NOUN	B
within	O	ADP	O
an	O	DET	O
index	O	NOUN	B
vessel	O	NOUN	I
(	O	PUNCT	O
right	O	ADJ	B
carotid	O	NOUN	I
,	O	PUNCT	O
left	O	VERB	B
carotid	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
ascending	O	VERB	B
thoracic	O	ADJ	B
aorta	O	NOUN	I
)	O	PUNCT	O
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no-harm	O	ADJ	O
boundaries	O	NOUN	B
established	O	VERB	O
before	O	ADP	O
unblinding	O	NOUN	B
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
was	O	AUX	O
by	O	ADP	O
intention	O	NOUN	B
to	O	PART	O
treat	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
trial	O	NOUN	B
is	O	AUX	O
registered	O	VERB	O
at	O	ADP	O
ClinicalTrials.gov	O	NOUN	B
,	O	PUNCT	O
NCT00655473	O	NUM	O
.	O	PUNCT	O


FINDINGS	O	NOUN	B
189	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
screened	I-P	VERB	B
and	I-P	CCONJ	O
130	I-P	NUM	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
66	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
dalcetrapib	I-I	NOUN	B
(	I-P	PUNCT	O
64	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


For	O	ADP	O
the	O	DET	O
coprimary	O	ADJ	B
MRI	O	NOUN	I
and	O	CCONJ	O
PET/CT	O	NOUN	B
endpoints	O	NOUN	B
,	O	PUNCT	O
CIs	O	NOUN	B
were	O	AUX	O
below	O	ADP	O
the	O	DET	O
no-harm	O	ADJ	B
boundary	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
adverse	O	ADJ	B
change	O	NOUN	I
was	O	AUX	O
numerically	O	ADV	B
lower	O	ADJ	I
in	O	ADP	O
the	O	DET	O
dalcetrapib	B-I	ADJ	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


MRI-derived	B-OUT	ADJ	B
change	I-OUT	NOUN	I
in	I-OUT	ADP	O
total	I-OUT	ADJ	B
vessel	I-OUT	NOUN	I
area	I-OUT	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
given	O	VERB	O
dalcetrapib	B-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
given	O	VERB	O
placebo	O	NOUN	B
after	O	ADP	O
24	O	NUM	O
months	O	NOUN	B
;	O	PUNCT	O
absolute	O	ADJ	B
change	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
relative	O	ADJ	O
to	O	PART	O
placebo	B-I	NOUN	B
was	O	AUX	O
-4·01	O	PART	O
mm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-7·23	O	NUM	O
to	O	PART	O
-0·80	O	X	O
;	O	PUNCT	O
nominal	O	ADJ	O
p=0·04	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
PET/CT	I-OUT	NOUN	B
measure	I-OUT	NOUN	O
of	I-OUT	ADP	O
index	I-OUT	NOUN	O
vessel	I-OUT	NOUN	O
most-diseased-segment	I-OUT	ADJ	O
target-to-background	I-OUT	ADJ	O
ratio	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
TBR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
carotid	O	NOUN	B
artery	O	NOUN	I
analysis	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
7	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
most-diseased-segment	O	ADJ	B
TBR	O	NOUN	B
in	O	ADP	O
the	B-I	DET	O
dalcetrapib	I-I	ADJ	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	B-I	DET	O
placebo	I-I	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
-7·3	O	NOUN	O
[	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-13·5	O	PUNCT	O
to	O	PART	O
-0·8	O	NOUN	O
]	O	PUNCT	O
;	O	PUNCT	O
nominal	O	ADJ	O
p=0·07	B-I	ADJ	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Dalcetrapib	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
increase	B-OUT	VERB	B
office	I-OUT	NOUN	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


INTERPRETATION	B-I	ADJ	B
Dalcetrapib	I-I	PROPN	B
showed	O	VERB	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
pathological	O	ADJ	B
effect	O	NOUN	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
arterial	O	ADJ	B
wall	O	NOUN	I
over	O	ADP	O
24	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
trial	O	NOUN	B
suggests	O	VERB	O
possible	O	ADJ	O
beneficial	O	ADJ	O
vascular	O	ADJ	B
effects	B-I	NOUN	I
of	I-I	ADP	O
dalcetrapib	I-I	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
total	O	ADJ	B
vessel	O	NOUN	I
enlargement	O	NOUN	B
over	O	ADP	O
24	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
long-term	O	ADJ	B
safety	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
efficacy	O	NOUN	B
of	O	ADP	O
dalcetrapib	O	ADJ	B
need	O	NOUN	O
to	O	PART	O
be	O	AUX	O
analysed	O	VERB	B
.	O	PUNCT	O


FUNDING	O	PROPN	B
F	O	PROPN	I
Hoffmann-La	O	PROPN	I
Roche	O	PROPN	I
Ltd	O	PROPN	I
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
pilot	O	NOUN	I
study	O	NOUN	I
with	O	ADP	O
daily	B-I	ADJ	B
walking	I-I	VERB	I
during	O	ADP	O
adjuvant	O	ADJ	B
chemotherapy	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
breast	I-P	NOUN	B
and	I-P	CCONJ	O
colorectal	I-P	ADJ	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Physical	B-I	ADJ	B
activity	I-I	NOUN	I
during	O	ADP	O
chemotherapy	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
in	O	ADP	O
several	O	ADJ	O
studies	O	NOUN	B
to	O	PART	O
reduce	O	VERB	B
fatigue	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
improve	I-OUT	VERB	B
symptoms	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
impact	I-OUT	VERB	B
positively	I-OUT	ADV	B
on	I-OUT	ADP	O
health-related	I-OUT	ADJ	B
quality	I-OUT	NOUN	I
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HRQoL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Challenges	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
intervention	O	NOUN	B
studies	O	NOUN	I
on	O	ADP	O
physical	B-I	ADJ	B
activity	I-I	NOUN	I
during	O	ADP	O
cancer	O	NOUN	B
treatment	O	NOUN	I
relate	O	VERB	O
to	O	PART	O
consistent	O	ADJ	O
adherence	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
study	O	VERB	B
feasibility	O	NOUN	B
and	O	CCONJ	O
adherence	O	NOUN	B
of	O	ADP	O
physical	B-I	ADJ	B
activity	I-I	NOUN	I
intervention	I-I	NOUN	B
among	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cancer	I-P	NOUN	B
during	I-P	ADP	O
adjuvant	I-P	ADJ	B
chemotherapy	I-P	NOUN	I
treatment	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
secondary	O	ADJ	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
physical	B-I	ADJ	B
activity	I-I	NOUN	I
on	O	ADP	O
health	B-OUT	NOUN	B
aspects	I-OUT	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
HRQoL	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
symptoms	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
surrogate	I-OUT	NOUN	B
markers	I-OUT	NOUN	B
for	I-OUT	ADP	O
cardiovascular	I-OUT	ADJ	B
disease	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
This	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
included	O	VERB	O
patients	B-P	NOUN	B
with	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
BRCA	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
colorectal	I-P	ADJ	B
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
CRC	I-P	NOUN	B
)	I-P	PUNCT	O
during	I-P	ADP	O
adjuvant	I-I	ADJ	B
chemotherapy	I-I	NOUN	I
.	I-I	PUNCT	O


The	B-I	DET	O
intervention	I-I	NOUN	B
continued	I-I	VERB	O
for	I-I	ADP	O
10	I-I	NUM	O
weeks	I-I	NOUN	B
and	I-I	CCONJ	O
included	I-I	VERB	O
daily	I-I	ADJ	B
walks	I-I	NOUN	B
of	I-I	ADP	O
10	I-I	NUM	O
000	I-I	NUM	O
steps	I-I	NOUN	B
and	I-I	CCONJ	O
a	I-I	DET	O
weekly	I-I	ADJ	B
supervised	I-I	VERB	B
group	I-I	NOUN	B
walk	I-I	NOUN	I
.	I-I	PUNCT	O


Adherence	B-OUT	NOUN	B
was	I-I	AUX	O
assessed	I-I	VERB	B
by	I-I	ADP	O
a	I-I	DET	O
pedometer	I-I	NOUN	B
and	I-I	CCONJ	O
the	I-I	DET	O
number	I-I	NOUN	O
of	I-I	ADP	O
participants	I-I	NOUN	B
who	I-I	PRON	O
reported	I-I	VERB	O
step	I-I	NOUN	O
counts	I-I	NOUN	O
every	I-I	DET	O
week	I-I	NOUN	B
and	I-I	CCONJ	O
percentage	I-I	NOUN	B
of	I-I	ADP	O
participants	I-I	NOUN	B
who	I-I	PRON	O
achieved	I-I	VERB	O
the	I-I	DET	O
target	I-I	NOUN	B
steps	I-I	NOUN	B
every	I-I	DET	O
week	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	VERB	B
Adherence	B-OUT	NOUN	B
average	O	NOUN	B
reached	O	VERB	O
91	O	NUM	O
%	O	NOUN	O
during	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
period	O	NOUN	B
;	O	PUNCT	O
in	O	ADP	O
total	O	NOUN	O
74	O	NUM	O
%	O	NOUN	O
completed	O	VERB	B
the	O	DET	O
exercise	B-I	NOUN	B
intervention	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
the	O	DET	O
participants	B-P	NOUN	B
achieved	O	VERB	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
83	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
target	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
000	O	NUM	O
steps	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
10	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
daily	B-OUT	ADJ	B
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.016	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
intervention	B-P	NOUN	B
group	I-P	NOUN	I
.	I-P	PUNCT	O


Significant	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
found	O	VERB	O
for	O	ADP	O
some	O	DET	O
breast	O	NOUN	B
cancer-specific	O	ADJ	O
symptoms	O	NOUN	O
[	B-OUT	PUNCT	O
swelling	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
mobility	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.045	O	NUM	O
)	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
relatively	O	ADV	O
small	B-OUT	ADJ	O
weight	I-OUT	NOUN	O
gain	I-OUT	VERB	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
0.9	O	NUM	O
kg	O	NOUN	O
in	O	ADP	O
the	O	DET	O
intervention	B-P	NOUN	B
group	I-P	NOUN	I
and	O	CCONJ	O
1.3	O	NUM	O
kg	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	B-I	NOUN	B
group	I-I	NOUN	I
.	I-I	PUNCT	O


CONCLUSION	O	NOUN	O
Physical	B-I	ADJ	B
activity	I-I	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
form	I-I	NOUN	O
of	I-I	ADP	O
walking	I-I	VERB	B
is	O	AUX	O
feasible	O	ADJ	O
during	O	ADP	O
adjuvant	O	ADJ	B
chemotherapy	O	NOUN	I
treatment	O	NOUN	B
despite	O	SCONJ	O
increasing	O	VERB	B
symptoms	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
physical	B-I	ADJ	B
activity	I-I	NOUN	I
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
intervention	B-P	NOUN	B
group	I-P	NOUN	I
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
time	O	NOUN	O
and	O	CCONJ	O
had	O	AUX	O
a	O	DET	O
positive	O	ADJ	B
impact	O	NOUN	B
on	O	ADP	O
breast	B-OUT	NOUN	B
symptoms	I-OUT	NOUN	I
and	O	CCONJ	O
the	O	DET	O
weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
previous	O	ADJ	O
studies	O	NOUN	B
.	O	PUNCT	O


Bitewing	B-P	VERB	B
film	I-P	NOUN	B
quality	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
clinical	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
loop	B-I	NOUN	B
vs.	I-I	CCONJ	O
holder	I-I	NOUN	B
techniques	I-I	NOUN	I
.	I-I	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
in	O	X	B
vivo	O	X	I
bitewing	O	ADJ	B
film	O	NOUN	B
quality	O	NOUN	B
using	O	VERB	O
the	O	DET	O
holder	B-I	NOUN	B
versus	I-I	ADP	O
the	I-I	DET	O
paper	I-I	NOUN	B
loop	I-I	NOUN	I
technique	I-I	NOUN	I
.	I-I	PUNCT	O


METHOD	O	NOUN	O
AND	O	CCONJ	O
MATERIALS	O	VERB	O
Four	B-P	NUM	O
bitewing	I-P	ADJ	B
films	I-P	NOUN	B
were	O	AUX	O
taken	O	VERB	O
from	O	ADP	O
the	O	DET	O
right	B-P	ADJ	B
and	I-P	CCONJ	O
left	I-P	ADJ	B
premolar	I-P	NOUN	I
and	I-P	CCONJ	O
molar	I-P	ADJ	B
regions	I-P	NOUN	I
of	I-P	ADP	O
45	I-P	NUM	O
dental	I-P	NOUN	B
students	I-P	NOUN	I
using	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
bitewing	B-I	ADJ	B
holder	I-I	NOUN	I
and	I-I	CCONJ	O
paper	I-I	NOUN	B
loop	I-I	NOUN	I
techniques	I-I	NOUN	I
.	I-I	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
360	B-P	NUM	O
films	I-P	NOUN	B
were	O	AUX	O
taken	O	VERB	O
and	O	CCONJ	O
assessed	O	VERB	B
by	O	ADP	O
an	O	DET	O
experienced	O	ADJ	O
practitioner	O	NOUN	B
not	O	PART	O
apprised	O	VERB	O
of	O	ADP	O
the	O	DET	O
bitewing	B-I	ADJ	B
technique	I-I	NOUN	I
used	O	VERB	O
.	O	PUNCT	O


Of	O	ADP	O
interest	O	NOUN	O
were	O	AUX	O
:	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
overlaps	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
teeth	O	NOUN	B
showing	O	VERB	O
the	O	DET	O
alveolar	O	ADJ	B
crest	O	NOUN	I
;	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
proper	O	ADJ	O
film	O	NOUN	B
positioning	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
cone	O	NOUN	B
cutting	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
Poisson	O	PROPN	B
regression	O	NOUN	I
using	O	VERB	O
generalized	O	VERB	B
estimating	O	NOUN	I
equations	O	NOUN	I
(	O	PUNCT	O
GEEs	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
overlap	O	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
techniques	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
proper	O	ADJ	O
positioning	O	NOUN	B
and	O	CCONJ	O
cone	O	NOUN	B
cutting	O	NOUN	I
,	O	PUNCT	O
logistic	O	ADJ	B
regressions	O	NOUN	I
using	O	VERB	O
GEEs	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
average	B-OUT	ADJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
horizontal	I-OUT	ADJ	B
overlaps	I-OUT	NOUN	B
for	I-OUT	ADP	O
the	I-OUT	DET	O
loop	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
holder	I-OUT	NOUN	O
techniques	I-OUT	NOUN	O
at	O	ADP	O
the	O	DET	O
right	O	ADJ	B
premolar	O	NOUN	I
,	O	PUNCT	O
right	O	ADJ	B
molar	O	NOUN	I
,	O	PUNCT	O
left	O	VERB	B
premolar	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
left	O	VERB	B
molar	O	NOUN	I
were	O	AUX	O
1.64	O	NUM	O
,	O	PUNCT	O
2.11	O	NUM	O
,	O	PUNCT	O
2.16	O	NUM	O
,	O	PUNCT	O
2.78	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1.64	O	NUM	O
,	O	PUNCT	O
2.00	O	NUM	O
,	O	PUNCT	O
2.00	O	NUM	O
,	O	PUNCT	O
2.18	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
loop	B-I	NOUN	B
technique	I-I	NOUN	I
was	O	AUX	O
1.11	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
cause	O	VERB	O
overlapping	B-OUT	VERB	O
than	O	ADP	O
the	O	DET	O
holder	B-I	NOUN	B
technique	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
highest	B-OUT	ADJ	B
percentage	I-OUT	NOUN	B
of	I-OUT	ADP	O
teeth	I-OUT	NOUN	B
showing	I-OUT	VERB	O
the	I-OUT	DET	O
alveolar	I-OUT	ADJ	B
crest	I-OUT	NOUN	I
by	I-OUT	ADP	O
the	I-OUT	DET	O
loop	I-OUT	NOUN	B
technique	I-OUT	NOUN	I
was	O	AUX	O
97.8	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
mandibular	O	ADJ	B
second	O	ADJ	O
premolar	O	NOUN	O
and	O	CCONJ	O
first	O	ADJ	B
molar	O	NOUN	I
.	O	PUNCT	O


With	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
film	O	NOUN	B
positioning	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
loop	B-I	NOUN	B
technique	I-I	NOUN	I
was	O	AUX	O
1.12	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
cause	O	VERB	O
improper	B-OUT	ADJ	B
positioning	I-OUT	NOUN	I
than	O	ADP	O
the	O	DET	O
holder	B-I	NOUN	B
technique	I-I	NOUN	I
.	I-I	PUNCT	O


Both	O	DET	O
techniques	O	NOUN	B
demonstrated	O	VERB	O
minimal	B-OUT	ADJ	B
cone	I-OUT	NOUN	O
cutting	I-OUT	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
in	O	ADP	O
the	O	DET	O
loop	O	NOUN	B
versus	O	CCONJ	O
0	O	NUM	O
in	O	ADP	O
the	O	DET	O
holder	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
quality	O	NOUN	B
of	O	ADP	O
bitewing	O	ADJ	B
films	O	NOUN	B
taken	O	VERB	O
by	O	ADP	O
the	O	DET	O
loop	B-I	NOUN	B
and	I-I	CCONJ	O
holder	I-I	NOUN	O
techniques	I-I	NOUN	O
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
cognitive	B-I	ADJ	B
behavioral	I-I	ADJ	I
therapy	I-I	NOUN	I
on	O	ADP	O
daily	B-OUT	ADJ	O
living	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
high-functioning	I-P	ADJ	B
autism	I-P	NOUN	O
and	I-P	CCONJ	O
concurrent	I-P	ADJ	B
anxiety	I-P	NOUN	B
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


CBT	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
promising	O	ADJ	O
treatment	O	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
and	O	CCONJ	O
focuses	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
on	O	ADP	O
children	O	NOUN	B
's	O	PART	I
independence	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
self-help	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
a	O	DET	O
trial	O	NOUN	B
of	O	ADP	O
CBT	B-I	NOUN	B
for	O	ADP	O
anxiety	O	NOUN	B
in	O	ADP	O
ASD	O	PROPN	B
(	O	PUNCT	O
Wood	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O


in	O	ADP	O
J	O	PROPN	B
Child	O	PROPN	I
Psychol	O	PROPN	I
Psychiatry	O	PROPN	I
50:224-234	O	PROPN	I
,	O	PUNCT	O
2009	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
children	O	NOUN	B
's	O	PART	I
daily	O	ADV	B
living	O	NOUN	B
skills	O	NOUN	I
and	O	CCONJ	O
related	O	ADJ	O
parental	B-OUT	ADJ	B
intrusiveness	I-OUT	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


Forty	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
(	I-P	PUNCT	O
7-11	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
their	I-P	PRON	O
primary	I-P	ADJ	B
caregiver	I-P	NOUN	B
were	O	AUX	O
randomly	B-I	ADV	O
assigned	I-I	VERB	O
to	I-I	PART	O
an	I-I	DET	O
immediate	I-I	ADJ	B
treatment	I-I	NOUN	B
(	I-I	PUNCT	O
IT	I-I	NOUN	B
;	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
17	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
3-month	I-I	ADJ	O
waitlist	I-I	NOUN	B
(	I-I	PUNCT	O
WL	I-I	PROPN	B
;	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
23	I-I	NUM	O
)	I-I	PUNCT	O
condition	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
comparison	O	NOUN	B
to	O	ADP	O
WL	O	PROPN	B
,	O	PUNCT	O
IT	O	PROPN	B
parents	O	NOUN	B
reported	O	VERB	O
increases	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
's	O	PART	I
total	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
personal	I-OUT	ADJ	B
daily	I-OUT	ADV	O
living	I-OUT	NOUN	O
skills	I-OUT	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
involvement	B-OUT	NOUN	B
in	I-OUT	ADP	O
their	I-OUT	PRON	O
children	I-OUT	NOUN	B
's	I-OUT	PART	O
private	I-OUT	ADJ	B
daily	I-OUT	ADJ	I
routines	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Reductions	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
reduced	O	VERB	B
anxiety	O	NOUN	B
severity	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
preliminary	O	ADJ	B
evidence	O	NOUN	B
that	O	SCONJ	O
CBT	O	NOUN	B
may	O	AUX	O
yield	O	VERB	O
increased	O	VERB	B
independence	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
daily	I-OUT	ADV	B
living	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
among	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Total	O	VERB	B
intravenous	O	ADJ	I
anesthesia	O	NOUN	I
using	O	VERB	O
remifentanil	B-I	NOUN	B
in	O	ADP	O
extracorporeal	B-I	ADJ	B
shock	I-I	NOUN	I
wave	I-I	NOUN	I
lithotripsy	I-I	NOUN	I
(	I-I	PUNCT	O
ESWL	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
dosages	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Extracorporeal	B-I	PROPN	B
Shock	I-I	NOUN	I
Wave	I-I	PROPN	I
Lithotripsy	I-I	PROPN	B
is	O	AUX	O
usually	O	ADV	O
performed	O	VERB	O
in	O	ADP	O
day	O	NOUN	B
surgery	O	NOUN	B
setting	O	NOUN	O
,	O	PUNCT	O
consequently	O	ADV	O
people	O	NOUN	B
who	O	PRON	O
undergo	O	VERB	O
to	O	PART	O
this	O	DET	O
procedure	O	NOUN	B
need	O	VERB	O
a	O	DET	O
safe	O	ADJ	O
and	O	CCONJ	O
fast	O	ADJ	B
recovery	O	NOUN	I
.	O	PUNCT	O


Conscious	O	ADJ	B
sedation	O	NOUN	I
with	O	ADP	O
remifentanil	B-I	NOUN	B
can	O	AUX	O
relieve	O	VERB	O
from	O	ADP	O
pain	O	NOUN	B
and	O	CCONJ	O
keep	O	VERB	O
patients	O	NOUN	B
in	O	ADP	O
touch	O	NOUN	B
with	O	ADP	O
anaesthesiologists	O	NOUN	B
.	O	PUNCT	O


Few	O	ADJ	O
publications	O	NOUN	B
tell	O	VERB	O
about	O	ADP	O
infusion	O	NOUN	B
rates	O	NOUN	B
administered	O	VERB	B
to	O	PART	O
perform	O	VERB	O
this	O	DET	O
procedure7	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
assess	O	VERB	B
which	O	DET	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
appropriate	O	ADJ	O
infusion	O	NOUN	B
rate	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	ADP	O
two	I-P	NUM	O
groups	I-P	NOUN	B
.	I-P	PUNCT	O


Two	O	NUM	O
different	O	ADJ	O
infusion	O	NOUN	B
rates	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
:	O	PUNCT	O
0,05	O	NUM	O
mcg/kg/min	O	NOUN	B
,	O	PUNCT	O
GROUP	O	PROPN	B
A	O	PROPN	I
(	O	PUNCT	O
N.=114	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
vs.	O	CCONJ	O
0.1	O	NUM	O
µg/kg/min	O	NOUN	O
,	O	PUNCT	O
GROUP	O	PROPN	B
B	O	NOUN	I
(	O	PUNCT	O
N.=114	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Patients	B-OUT	NOUN	B
'	I-OUT	PART	O
vital	I-OUT	ADJ	B
signs	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
additional	I-OUT	ADJ	O
analgesic	I-OUT	NOUN	B
requests	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
PONV	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
postoperative	I-OUT	ADJ	B
nausea	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
vomiting	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
registered	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
deepness	O	NOUN	B
of	O	ADP	O
sedation	O	NOUN	B
and	O	CCONJ	O
patient	O	NOUN	B
's	O	PART	I
satisfaction	O	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
referring	O	VERB	O
to	B-OUT	ADP	O
Obsever	I-OUT	PROPN	B
's	I-OUT	PART	I
Assessment	I-OUT	NOUN	B
of	I-OUT	ADP	O
Alertness	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
Sedation	I-OUT	ADJ	O
scale	I-OUT	NOUN	O
(	O	PUNCT	O
O/ASS	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
using	O	VERB	O
a	O	DET	O
Likert	O	NOUN	B
's	O	PART	I
scale	O	NOUN	I
respectively	O	ADV	O
.	B-OUT	PUNCT	O


Pain	B-OUT	NOUN	B
intensity	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
with	O	ADP	O
a	O	DET	O
11-points	O	NOUN	B
VAS	O	NOUN	I
(	O	PUNCT	O
visual	O	ADJ	B
analogue	O	NOUN	I
scale	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Differences	O	NOUN	B
between	O	ADP	O
groups	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
using	O	VERB	O
Student	O	NOUN	B
t	O	NOUN	I
test	O	NOUN	I
for	O	ADP	O
independent	O	ADJ	B
variables	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
χ2	O	ADJ	B
test	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
analyze	O	VERB	O
categorical	O	ADJ	B
variables	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
study	O	NOUN	B
enrolled	B-P	VERB	O
228	I-P	NUM	O
patients	I-P	NOUN	B
and	O	CCONJ	O
assigned	O	VERB	B
them	O	PRON	O
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
N.=114	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
regarding	B-OUT	VERB	O
Likert	I-OUT	NOUN	B
's	I-OUT	PART	I
scale	I-OUT	NOUN	I
values	I-OUT	NOUN	I
(	O	PUNCT	O
P=0.20	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
additional	O	ADJ	O
analgesic	O	NOUN	B
request	O	NOUN	I
(	O	PUNCT	O
P=0.30	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
mean	B-OUT	VERB	O
VAS	I-OUT	NOUN	O
values	I-OUT	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
about	B-OUT	ADP	O
PONV	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hypotension	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
oxygen	I-OUT	NOUN	B
desaturation	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
respiratory	I-OUT	ADJ	B
depression	I-OUT	NOUN	I
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
matter	O	NOUN	O
of	O	ADP	O
fact	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	O
these	O	DET	O
side	O	NOUN	B
effects	O	NOUN	I
occurred	O	VERB	O
less	O	ADV	O
frequently	O	ADV	O
.	O	PUNCT	O


The	B-OUT	DET	O
fifth	I-OUT	ADJ	O
degree	I-OUT	NOUN	B
of	I-OUT	ADP	O
O/ASS	I-OUT	PROPN	B
was	O	AUX	O
estimated	O	VERB	B
in	O	ADP	O
about	O	ADP	O
1.61±0.19	O	NOUN	O
min	O	NOUN	O
and	O	CCONJ	O
2.987±0.20	O	NUM	O
min	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
According	O	VERB	O
with	O	ADP	O
previous	O	ADJ	O
results	O	NOUN	B
remifentanil	O	NOUN	B
at	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
0.05	O	NUM	O
µg/kg/min	O	NOUN	O
provides	O	VERB	O
an	O	DET	O
effective	O	ADJ	B
analgesia	O	NOUN	B
,	O	PUNCT	O
causing	O	VERB	O
a	O	DET	O
lower	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
side	O	NOUN	B
effect	O	NOUN	I
than	O	ADP	O
0.1	O	NUM	O
µg/kg/min	O	NOUN	O
,	O	PUNCT	O
granting	O	VERB	O
a	O	DET	O
fast	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
recovery	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Effect	O	NOUN	B
of	O	ADP	O
valociclovir	B-I	NOUN	B
hydrochloride	I-I	NOUN	I
on	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
herpes	I-OUT	NOUN	B
zoster	I-OUT	NOUN	I
]	I-OUT	PUNCT	O
.	I-P	PUNCT	O


[	O	PUNCT	O
Effects	O	NOUN	B
of	O	ADP	I
betamethasone	B-I	NOUN	B
on	O	ADP	O
neuromuscular	B-OUT	ADJ	B
blockade	I-OUT	NOUN	I
induced	O	VERB	B
by	O	ADP	O
vecuronium	B-I	NOUN	B
in	O	ADP	O
continuous	O	ADJ	B
infusion	O	NOUN	B
]	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
interaction	O	NOUN	B
between	O	ADP	O
a	O	DET	O
corticosteroid	B-I	NOUN	B
(	I-I	PUNCT	O
betamethasone	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
vecuronium	I-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
nondepolarizing	B-I	NOUN	B
muscle	I-I	NOUN	I
relaxant	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
studied	O	VERB	O
20	B-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
ASA	I-P	NOUN	B
I-II	I-P	NUM	I
,	I-P	PUNCT	O
aged	I-P	ADJ	B
20-54	I-P	NUM	O
,	I-P	PUNCT	O
both	I-P	DET	O
sexes	I-P	NOUN	B
,	I-P	PUNCT	O
scheduled	I-P	VERB	B
for	I-P	ADP	O
abdominal	I-I	ADJ	B
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


Mechanomyographic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
clinical	I-OUT	ADJ	B
evaluation	I-OUT	NOUN	I
by	I-OUT	ADP	O
single	I-OUT	ADJ	O
twitch	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
TOF	I-OUT	NOUN	B
stimulation	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
ulnar	I-OUT	ADJ	B
nerve	I-OUT	NOUN	I
at	I-OUT	ADP	O
the	I-OUT	DET	O
wrist	I-OUT	NOUN	B
and	O	CCONJ	O
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
concomitant	B-OUT	ADJ	B
abductor	I-OUT	NOUN	B
pollicis	I-OUT	NOUN	I
muscle	I-OUT	NOUN	I
was	O	AUX	O
applied	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
onset	B-OUT	NOUN	O
time	I-OUT	NOUN	O
of	O	ADP	O
vecuronium	B-I	NOUN	B
after	O	ADP	O
a	O	DET	O
single	O	ADJ	O
bolus	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
0.08	O	NUM	O
mg/kg	O	NOUN	O
,	O	PUNCT	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	I
action	I-OUT	NOUN	I
to	O	PART	O
10	O	NUM	O
%	O	NOUN	O
single	B-OUT	ADJ	O
twitch	I-OUT	NOUN	B
recovery	I-OUT	NOUN	B
,	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
0.4-0.5	O	NUM	O
micrograms/kg/min	O	NOUN	B
of	O	ADP	O
vecuronium	B-I	NOUN	B
started	O	VERB	B
at	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
single	B-OUT	ADJ	O
twitch	I-OUT	NOUN	B
recovery	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
0.1	O	NUM	O
mg/kg	O	NOUN	O
betamethasone	B-I	NOUN	B
administration	O	NOUN	B
10	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
continuous	O	ADJ	B
infusion	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
recovery	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
vecuronium	I-OUT	NOUN	B
after	O	ADP	O
stopping	O	VERB	B
infusion	O	NOUN	B
at	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
recovery	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
evaluated	O	VERB	B
.	O	PUNCT	O


Corticosteroids	B-I	NOUN	B
may	O	AUX	O
interact	O	VERB	B
with	O	ADP	O
non-depolarizing	B-I	ADJ	B
muscle	I-I	NOUN	I
relaxants	I-I	NOUN	I
both	O	CCONJ	O
in	O	ADP	O
prejunctional	O	ADJ	B
and	O	CCONJ	O
postjunctional	O	ADJ	B
acetylcholine	O	NOUN	B
receptors	O	NOUN	I
by	O	ADP	O
several	O	ADJ	O
mechanisms	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
.	O	PUNCT	O


Ten-year	O	ADJ	B
results	O	NOUN	I
of	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
trial	O	NOUN	I
comparing	O	VERB	O
cisplatin	B-I	NOUN	B
with	I-I	ADP	O
cisplatin	I-I	NOUN	B
and	I-I	CCONJ	O
cyclophosphamide	I-I	NOUN	B
in	O	ADP	O
advanced	B-P	ADJ	B
,	I-P	PUNCT	O
suboptimally	I-P	ADV	B
debulked	I-P	VERB	B
ovarian	I-P	ADJ	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


176	B-P	NUM	O
eligible	I-P	ADJ	O
patients	I-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
suboptimally	I-P	ADV	B
operated	I-P	VERB	O
ovarian	I-P	ADJ	O
carcinoma	I-P	NOUN	O
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
cisplatin	B-I	NOUN	B
75	I-I	NUM	O
mg/m2	I-I	NOUN	B
or	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
50	I-I	NUM	O
mg/m2	I-I	NOUN	B
and	I-I	CCONJ	O
cyclophosphamide	I-I	NOUN	B
500	I-I	NUM	O
mg/m2	I-I	NOUN	O
(	O	PUNCT	O
CP	O	NOUN	B
)	O	PUNCT	O
every	O	DET	O
28	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
six	O	NUM	O
courses	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
overall	B-OUT	ADJ	O
clinical	I-OUT	ADJ	B
response	I-OUT	NOUN	I
rates	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
complete	I-OUT	ADJ	O
response	O	NOUN	B
plus	O	CCONJ	I
partial	O	ADJ	O
response	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
52	O	NUM	O
and	O	CCONJ	O
63	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
CP	B-I	NOUN	B
and	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
non-significant	O	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


Including	O	VERB	O
results	O	NOUN	B
obtained	O	VERB	O
by	O	ADP	O
second-look	O	ADJ	B
laparotomy	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
did	O	AUX	O
not	O	PART	O
observe	O	VERB	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
response	O	NOUN	B
rates	O	NOUN	I
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Median	B-OUT	ADJ	B
progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
10	O	NUM	O
and	O	CCONJ	O
11.9	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
CP	B-I	NOUN	B
and	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
non-significant	O	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
median	O	NOUN	B
of	O	ADP	O
19.4	O	NUM	O
and	O	CCONJ	O
21.5	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
CP	B-I	NOUN	B
and	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Thirty-seven	B-P	NUM	O
platinum-resistant	I-P	ADJ	B
and	I-P	CCONJ	O
27	I-P	NUM	O
platinum-sensitive	I-P	ADJ	B
tumours	I-P	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
carboplatin	B-I	NOUN	B
or	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
as	O	ADP	O
second-line	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Response	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
to	O	PART	O
platinum	O	NOUN	B
second-line	O	NOUN	B
therapy	O	NOUN	I
were	O	AUX	O
6	O	NUM	O
and	O	CCONJ	O
50	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
resistant	O	ADJ	B
and	O	CCONJ	O
sensitive	O	ADJ	B
tumours	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
also	O	ADV	O
confirmed	O	VERB	O
by	O	ADP	O
survival	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
platinum-sensitive	I-P	ADJ	B
tumours	I-P	NOUN	I
survived	O	VERB	O
longer	O	ADV	O
when	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
platinum-containing	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
22.8	O	NUM	O
and	O	CCONJ	O
8.5	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
second-line	O	ADJ	B
treatment	O	NOUN	I
for	O	ADP	O
the	O	DET	O
platinum-containing	B-I	ADJ	B
and	O	CCONJ	O
platinum-free	B-I	ADJ	B
regimens	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
in	O	ADP	O
suboptimally	B-P	ADV	B
operated	I-P	VERB	B
ovarian	I-P	ADJ	B
carcinoma	I-P	NOUN	I
patients	I-P	NOUN	B
similar	O	ADJ	O
response	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
progression-free	I-OUT	ADJ	B
interval	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
for	O	ADP	O
equitoxic	O	ADJ	B
cisplatin	B-I	NOUN	B
and	I-I	CCONJ	O
CP	I-I	NOUN	B
.	I-I	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
doses	O	NOUN	B
of	O	ADP	O
cisplatin	B-I	NOUN	B
and	I-I	CCONJ	O
cyclophosphamide	I-I	NOUN	B
chosen	O	VERB	B
were	O	AUX	O
substantially	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
current	O	ADJ	O
standard	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
CP	B-I	NOUN	B
.	I-I	PUNCT	O


Our	O	PRON	O
study	O	NOUN	B
demonstrates	O	VERB	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
that	O	SCONJ	O
a	O	DET	O
suboptimal	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
CP	B-I	NOUN	B
is	O	AUX	O
as	O	ADV	O
effective	O	ADJ	B
as	O	ADP	O
optimal	O	ADJ	B
dose	O	NOUN	B
monotherapy	O	NOUN	B
cisplatin	B-I	NOUN	B
.	I-I	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
recurrences	I-P	NOUN	B
considered	I-P	VERB	O
as	I-P	ADP	O
platinum-sensitive	I-P	ADJ	B
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	O	CCONJ	O
improved	O	VERB	B
survival	B-OUT	NOUN	B
when	O	SCONJ	O
retreated	O	VERB	B
with	O	ADP	O
platinum-containing	B-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	O
amlodipine	B-I	NOUN	B
and	I-I	CCONJ	O
enalapril	I-I	NOUN	B
on	O	ADP	O
platelet	B-OUT	NOUN	B
function	I-OUT	NOUN	I
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
mild	I-P	ADJ	B
to	I-P	PART	O
moderate	I-P	ADJ	B
hypertension	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
amlodipine	B-I	NOUN	B
and	I-I	CCONJ	O
enalapril	I-I	NOUN	B
on	O	ADP	O
platelet	B-OUT	NOUN	B
aggregation	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
platelet	I-OUT	NOUN	B
production	I-OUT	NOUN	I
of	I-OUT	ADP	O
malondialdehyde	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
mild	I-P	ADJ	B
to	I-P	PART	O
moderate	I-P	ADJ	B
arterial	I-P	ADJ	B
hypertension	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
A	O	DET	O
parallel	O	NOUN	O
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
24	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
2	I-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
12	I-P	NUM	O
patients	I-P	NOUN	B
each	I-P	DET	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Initially	O	ADV	O
all	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
placebo	B-I	NOUN	B
for	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
then	O	ADV	O
amlodipine	B-I	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
or	B-I	CCONJ	O
enalapril	I-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
taken	O	VERB	O
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
at	O	ADP	O
7	O	NUM	O
am	O	NOUN	O
.	O	PUNCT	O


Dosage	O	NOUN	B
was	O	AUX	O
doubled	O	VERB	O
after	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
when	O	SCONJ	O
diastolic	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
was	O	AUX	O
>	O	X	O
90	O	NUM	O
mmHg	O	NOUN	B
in	O	ADP	O
sitting	O	NOUN	B
position	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
treatment	O	NOUN	B
was	O	AUX	O
continued	O	VERB	O
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
active	O	ADJ	B
phases	O	NOUN	I
a	O	DET	O
platelet	O	NOUN	B
aggregation	O	NOUN	I
test	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
adenosine	O	NOUN	B
diphosphate	O	NOUN	I
,	O	PUNCT	O
collagen	O	NOUN	B
and	O	CCONJ	O
adrenaline	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
platelet	O	NOUN	B
malondialdehyde	O	NOUN	I
production	O	NOUN	I
test	O	NOUN	I
,	O	PUNCT	O
either	O	CCONJ	O
in	O	ADP	O
basal	O	ADJ	B
conditions	O	NOUN	I
(	O	PUNCT	O
MDA-basal	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
stimulation	O	NOUN	B
of	O	ADP	O
arachidonic	O	ADJ	B
acid	O	NOUN	I
pathway	O	NOUN	I
by	O	ADP	O
adding	O	VERB	O
ethylmaleimide	O	NOUN	B
(	O	PUNCT	O
MDA-activated	O	ADJ	B
)	O	PUNCT	O
were	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
both	O	DET	O
agents	O	NOUN	B
,	O	PUNCT	O
enalapril	B-I	NOUN	B
and	I-I	CCONJ	O
amlodipine	I-I	NOUN	B
.	I-I	PUNCT	O


Enalapril	B-I	NOUN	B
controlled	O	VERB	I
58.3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
hypertensive	B-P	ADJ	B
patients	I-P	NOUN	B
with	O	ADP	O
an	O	DET	O
average	O	ADJ	B
dosage	O	NOUN	B
of	O	ADP	O
31.7	O	NUM	O
mg/daily	O	NOUN	B
.	O	PUNCT	O


Amlodipine	B-I	NOUN	B
controlled	O	VERB	O
75	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
dosage	O	NOUN	B
of	O	ADP	O
7.1	O	NUM	O
mg/daily	O	NOUN	B
.	O	PUNCT	O


Platelet	B-OUT	NOUN	B
aggregation	I-OUT	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
amlodipine	B-I	NOUN	B
in	O	ADP	O
15.9	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
ADP	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
microM	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
17.4	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
collagen	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
microg/ml	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
19.9	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
adrenaline	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
microM	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.025	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Meanwhile	O	ADV	O
enalapril	B-I	NOUN	B
slightly	O	ADV	O
increased	O	VERB	B
platelet	B-OUT	NOUN	B
aggregation	I-OUT	NOUN	I
by	O	ADP	O
6.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
1.3	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
5.6	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
three	O	NUM	O
agents	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
,	O	PUNCT	O
ns	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Malondialdehyde	B-OUT	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
amlodipine	B-I	NOUN	B
in	O	ADP	O
45.33	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
MDA-basal	B-OUT	NOUN	B
;	I-OUT	PUNCT	O
3.76	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
MDA-activated	B-OUT	ADJ	B
;	I-OUT	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
ratio	O	NOUN	B
MDA-basal	O	NOUN	B
:	O	PUNCT	O
MDA-activated	O	VERB	B
in	O	ADP	O
36.79	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Meanwhile	O	ADV	O
enalapril	B-I	NOUN	B
increased	O	VERB	B
MDA-basal	B-OUT	ADJ	B
in	O	ADP	O
2.89	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
MDA-activated	B-OUT	VERB	B
in	O	ADP	O
3.58	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
reduced	O	VERB	B
the	O	DET	O
ratio	B-OUT	NOUN	B
MDA-basal	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
MDA-activated	I-OUT	ADJ	B
,	O	PUNCT	O
in	O	ADP	O
10.34	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Both	O	DET	O
agents	O	NOUN	B
,	O	PUNCT	O
enalapril	B-I	NOUN	B
and	O	CCONJ	O
amlodipine	B-I	NOUN	B
,	O	PUNCT	O
reduced	O	VERB	B
blood	B-OUT	NOUN	I
pressure	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
amlodipine	B-I	NOUN	B
reduced	O	VERB	B
platelet	B-OUT	NOUN	B
aggregation	I-OUT	NOUN	I
and	O	CCONJ	O
platelet	B-OUT	NOUN	B
production	I-OUT	NOUN	I
of	I-OUT	ADP	O
malondialdehyde	I-OUT	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
its	O	PRON	O
action	O	NOUN	B
on	O	ADP	O
the	O	DET	O
arachidonic	O	ADJ	B
acid	O	NOUN	I
metabolic	O	ADJ	B
pathway	O	NOUN	I
.	O	PUNCT	O


Tolerance	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	O	ADP	O
combined	B-I	ADJ	B
diethylcarbamazine	I-I	NOUN	B
and	I-I	CCONJ	O
albendazole	I-I	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
Wuchereria	B-P	PROPN	B
bancrofti	I-P	NOUN	I
and	I-P	CCONJ	O
intestinal	I-P	ADJ	B
helminth	I-P	ADJ	B
infections	I-P	NOUN	I
in	I-P	ADP	O
Haitian	I-P	ADJ	B
children	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
investigated	O	VERB	B
the	O	DET	O
tolerance	O	NOUN	B
,	O	PUNCT	O
efficacy	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
nutritional	O	ADJ	B
benefit	O	NOUN	B
of	O	ADP	O
combining	O	VERB	O
chemotherapeutic	B-I	ADJ	B
treatment	I-I	NOUN	I
of	O	ADP	O
intestinal	O	ADJ	B
helminths	O	NOUN	B
and	O	CCONJ	O
lymphatic	O	ADJ	B
filariasis	O	NOUN	I
.	O	PUNCT	O


Children	B-P	NOUN	B
were	I-P	AUX	O
infected	I-P	VERB	B
with	I-P	ADP	O
Ascaris	I-P	PROPN	B
(	I-P	PUNCT	O
30.7	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
Trichuris	I-P	PROPN	B
(	I-P	PUNCT	O
53.4	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
hookworm	I-P	NOUN	B
(	I-P	PUNCT	O
9.7	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
with	I-P	ADP	O
69.9	I-P	NUM	O
%	I-P	NOUN	O
having	I-P	VERB	O
more	I-P	ADJ	O
than	I-P	ADP	O
one	I-P	NUM	O
of	I-P	ADP	O
these	I-P	DET	O
parasites	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
15.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
children	B-P	NOUN	B
had	I-P	AUX	O
Wuchereria	I-P	PROPN	B
bancrofti	I-P	X	I
microfilariae	I-P	NOUN	I
.	I-P	PUNCT	O


Children	B-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
placebo	B-I	NOUN	B
,	I-I	PUNCT	O
albendazole	I-I	NOUN	B
(	I-I	PUNCT	O
ALB	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
diethylcarbamazine	I-I	NOUN	B
(	I-I	PUNCT	O
DEC	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
combined	I-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


The	B-OUT	DET	O
combination	I-OUT	NOUN	B
of	I-OUT	ADP	O
DEC/ALB	I-OUT	NOUN	B
reduced	I-OUT	VERB	B
microfilarial	I-OUT	ADJ	B
density	I-OUT	NOUN	O
compared	I-OUT	VERB	B
with	I-OUT	ADP	O
placebo	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
ALB	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
DEC	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
or	I-OUT	CCONJ	O
=	I-OUT	ADJ	O
0.03	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Albendazole	B-OUT	PROPN	B
and	I-OUT	CCONJ	O
DEC/ALB	I-OUT	PROPN	B
reduced	I-OUT	VERB	B
the	I-OUT	DET	O
prevalence	I-OUT	NOUN	B
of	I-OUT	ADP	O
Ascaris	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
Trichuris	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
hookworm	I-OUT	NOUN	B
more	I-OUT	ADJ	O
than	I-OUT	ADP	O
placebo	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
DEC	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
or	I-OUT	CCONJ	O
=	I-OUT	ADJ	O
0.03	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Among	B-OUT	ADP	O
Trichuris-infected	I-OUT	ADJ	B
children	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
those	I-OUT	DET	O
receiving	I-OUT	VERB	O
ALB	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
DEC/ALB	I-OUT	NOUN	B
demonstrated	I-OUT	VERB	O
greater	I-OUT	ADJ	O
gains	I-OUT	NOUN	B
in	I-OUT	ADP	O
weight	I-OUT	NOUN	B
compared	I-OUT	VERB	B
with	I-OUT	ADP	O
placebo	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
or	I-OUT	CCONJ	O
=	I-OUT	ADJ	O
0.05	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Albendazole	B-OUT	PROPN	B
and	I-OUT	CCONJ	O
DEC/ALB	I-OUT	PROPN	B
were	I-OUT	AUX	O
equally	I-OUT	ADV	O
efficacious	I-OUT	ADJ	B
in	I-OUT	ADP	O
treating	I-OUT	VERB	B
intestinal	I-OUT	ADJ	B
helminths	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
for	I-OUT	ADP	O
children	I-OUT	NOUN	B
with	I-OUT	ADP	O
W.	I-OUT	X	B
bancrofti	I-OUT	X	I
microfilaremia	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
DEC/ALB	I-OUT	NOUN	B
was	I-OUT	AUX	O
more	I-OUT	ADV	O
effective	I-OUT	ADJ	B
than	I-OUT	ADP	O
DEC	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
with	I-OUT	ADP	O
no	I-OUT	DET	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
reactions	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Mastication	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
late	I-OUT	ADJ	B
mandibular	I-OUT	ADJ	I
fracture	I-OUT	NOUN	I
after	O	ADP	O
surgery	B-I	NOUN	B
of	O	ADP	O
impacted	B-P	VERB	B
third	I-P	ADJ	I
molars	I-P	NOUN	I
associated	I-P	VERB	B
with	I-P	ADP	I
no	I-P	DET	O
gross	I-P	ADJ	O
pathology	I-P	NOUN	O
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
with	O	ADP	O
the	O	DET	O
null	O	ADJ	B
hypothesis	O	NOUN	I
that	O	SCONJ	O
in	O	ADP	O
patients	B-P	NOUN	B
,	I-P	PUNCT	O
fully	I-P	ADV	O
denate	I-P	NOUN	B
or	I-P	CCONJ	O
with	I-P	ADP	O
1	I-P	NUM	O
or	I-P	CCONJ	O
2	I-P	NUM	O
teeth	I-P	NOUN	B
missing	I-P	VERB	B
and	I-P	CCONJ	O
older	I-P	ADJ	B
than	I-P	ADP	O
25	I-P	NUM	O
years	I-P	NOUN	B
,	O	PUNCT	O
mastication	O	NOUN	B
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
late	O	ADJ	B
mandibular	B-OUT	ADJ	I
fracture	I-OUT	NOUN	I
after	I-P	ADP	O
surgical	I-I	ADJ	B
removal	I-I	NOUN	I
of	I-P	ADP	O
impacted	I-P	VERB	B
third	I-P	ADJ	I
molars	I-P	NOUN	I
(	I-P	PUNCT	O
M3s	I-P	NOUN	B
)	I-P	PUNCT	O
associated	I-P	VERB	B
with	I-P	ADP	I
no	I-P	DET	O
gross	I-P	ADJ	B
pathology	I-P	NOUN	I
.	I-P	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
Five	B-P	NUM	O
hundred	I-P	NUM	O
sixty	I-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
fully	I-P	ADV	O
dentate	I-P	ADJ	B
or	I-P	CCONJ	O
with	I-P	ADP	O
1	I-P	NUM	O
or	I-P	CCONJ	O
2	I-P	NUM	O
teeth	I-P	NOUN	B
missing	I-P	VERB	B
and	I-P	CCONJ	O
older	I-P	ADJ	B
than	I-P	ADP	O
25	I-P	NUM	O
years	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
no	I-P	DET	O
gross	I-P	ADJ	B
pathology	I-P	NOUN	I
associated	I-P	VERB	B
with	I-P	ADP	I
their	I-P	PRON	O
impacted	I-P	ADJ	O
lower	I-P	ADJ	O
M3s	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
recruited	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
operated	B-I	VERB	O
on	I-I	ADP	O
under	O	ADP	O
local	B-I	ADJ	B
anesthesia	I-I	NOUN	I
using	O	VERB	O
a	O	DET	O
standard	O	ADJ	B
technique	O	NOUN	I
and	O	CCONJ	O
randomly	O	ADV	O
assigned	O	VERB	O
into	O	ADP	O
2	O	NUM	O
groups	O	NOUN	B
for	O	ADP	O
nonroutine	O	NOUN	B
(	O	PUNCT	O
NR	O	NOUN	B
group	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
routine	O	NOUN	B
(	O	PUNCT	O
R	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
postoperative	O	ADJ	B
instructions	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
NR	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
postoperatively	O	ADV	B
educated	O	VERB	O
in	O	ADP	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
mandibular	B-OUT	ADJ	B
fracture	I-OUT	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
given	O	VERB	O
an	O	DET	O
emphasis	O	NOUN	O
on	O	ADP	O
the	O	DET	O
necessity	O	NOUN	O
of	O	ADP	O
limiting	B-OUT	VERB	B
mastication	I-OUT	NOUN	B
to	O	ADP	O
a	O	DET	O
soft	O	ADJ	B
diet	O	NOUN	I
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
R	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
no	O	DET	O
such	O	ADJ	O
education	O	NOUN	B
or	O	CCONJ	O
emphasis	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
up	O	ADP	O
for	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
data	B-OUT	NOUN	B
concerning	I-OUT	VERB	O
patients	I-OUT	NOUN	B
'	I-OUT	PART	O
age	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
gender	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
tooth	I-OUT	NOUN	B
position	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
angulation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
depth	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
date	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
site	I-OUT	NOUN	B
of	I-OUT	ADP	O
surgery	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
occurrence	I-OUT	NOUN	B
of	I-OUT	ADP	O
late	I-OUT	ADJ	B
mandibular	I-OUT	ADJ	I
fracture	I-OUT	NOUN	I
were	I-OUT	AUX	O
recorded	I-OUT	VERB	O
and	O	CCONJ	O
statistically	O	ADV	B
analyzed	O	VERB	I
.	O	PUNCT	O


A	O	DET	O
value	O	NOUN	O
of	O	ADP	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.05	O	NUM	O
was	O	AUX	O
considered	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
no	O	DET	O
patient	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
there	O	PRON	O
a	O	DET	O
late	B-OUT	ADJ	B
mandibular	I-OUT	ADJ	I
fracture	I-OUT	NOUN	I
recorded	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
completed	O	VERB	O
the	O	DET	O
follow-up	O	ADJ	B
period	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
R	O	NOUN	B
group	O	NOUN	I
patients	O	NOUN	B
had	O	AUX	O
normal	O	ADJ	B
eating	O	NOUN	B
habits	O	NOUN	I
10	O	NUM	O
to	O	PART	O
14	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
no	O	DET	O
patient	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
there	O	PRON	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
gender	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.735	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
site	O	NOUN	B
of	O	ADP	I
surgery	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.552	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
class	O	NOUN	B
horizontal	O	ADJ	B
space	O	NOUN	O
available	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.427	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
class	O	NOUN	B
highest	O	ADJ	I
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
M3	O	NOUN	B
crown	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.424	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
angulations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
teeth	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.925	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
severity	B-OUT	NOUN	B
of	I-OUT	ADP	O
impaction	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.445	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
patients	B-P	NOUN	B
,	I-P	PUNCT	O
fully	I-P	ADV	O
dentate	I-P	ADJ	B
or	I-P	CCONJ	O
with	I-P	ADP	O
1	I-P	NUM	O
or	I-P	CCONJ	O
2	I-P	NUM	O
teeth	I-P	NOUN	B
missing	I-P	VERB	B
and	I-P	CCONJ	O
older	I-P	ADJ	B
than	I-P	ADP	O
25	I-P	NUM	O
years	I-P	NOUN	B
who	I-P	PRON	O
have	I-P	AUX	O
no	I-P	DET	O
jawbone	I-P	ADJ	B
atrophy	I-P	NOUN	I
and	I-P	CCONJ	O
no	I-P	DET	O
systemic	I-P	ADJ	B
problems	I-P	NOUN	I
that	I-P	PRON	O
may	I-P	AUX	O
impair	I-OUT	VERB	B
bone	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
,	O	PUNCT	O
mastication	O	NOUN	B
seems	O	VERB	O
not	O	PART	O
to	O	PART	O
affect	O	VERB	O
late	B-OUT	ADJ	B
mandibular	I-OUT	ADJ	I
fracture	I-OUT	NOUN	I
after	O	ADP	O
surgical	O	ADJ	B
removal	O	NOUN	I
of	O	ADP	O
impacted	O	VERB	B
M3s	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
no	O	DET	O
gross	O	ADJ	O
pathology	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
remote	O	ADJ	B
possible	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
the	O	DET	O
late	B-OUT	ADJ	B
fracture	I-OUT	NOUN	I
shown	O	VERB	O
in	O	ADP	O
our	O	PRON	O
patients	O	NOUN	B
indicates	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
no	O	DET	O
special	O	ADJ	O
precautions	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	O
comparison	O	NOUN	B
of	O	ADP	O
transthoracic	B-I	NOUN	B
and	I-I	CCONJ	O
transhiatal	I-I	ADJ	B
resection	I-I	NOUN	I
for	O	ADP	O
esophageal	B-P	NOUN	B
carcinoma	I-P	NOUN	I
in	I-P	ADP	O
Asians	I-P	PROPN	B
.	I-P	PUNCT	O


BACKGROUND/AIMS	O	ADJ	B
Transthoracic	B-I	PROPN	B
and	I-I	CCONJ	O
transhiatal	I-I	ADJ	B
esophagectomy	I-I	NOUN	I
are	O	AUX	O
two	O	NUM	O
common	O	ADJ	O
procedures	O	NOUN	B
for	O	ADP	O
esophageal	O	ADJ	B
cancer	O	NOUN	I
resection	O	NOUN	B
.	O	PUNCT	O


Prospective	O	ADJ	B
studies	O	NOUN	I
comparing	O	VERB	B
the	O	DET	O
two	O	NUM	O
methods	O	NOUN	B
in	B-P	ADP	O
Asian	I-P	ADJ	B
people	I-P	NOUN	B
are	O	AUX	O
few	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
data	O	NOUN	B
comparing	O	VERB	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
are	O	AUX	O
lacking	O	VERB	B
.	O	PUNCT	O


METHODOLOGY	O	ADJ	B
A	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
from	O	ADP	O
January	O	PROPN	O
2003	O	NUM	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
of	I-P	ADP	O
resectable	I-P	ADJ	B
esophageal	I-P	NOUN	I
cancer	I-P	NOUN	I
of	I-P	ADP	O
comparable	I-P	ADJ	O
stage	I-P	NOUN	B
were	O	AUX	O
allocated	O	VERB	O
to	O	PART	O
undergo	O	VERB	O
the	O	DET	O
transthoracic	B-I	NOUN	B
or	I-I	CCONJ	O
transhiatal	I-I	ADJ	B
procedure	I-I	NOUN	I
in	O	ADP	O
turn	O	NOUN	O
.	O	PUNCT	O


They	B-I	PRON	O
were	I-I	AUX	O
all	I-I	ADV	O
reconstructed	I-I	VERB	B
with	I-I	ADP	O
stomach	I-I	NOUN	B
interposition	I-I	NOUN	I
through	I-I	ADP	O
the	I-I	DET	O
retrosternal	I-I	ADJ	B
route	I-I	NOUN	O
.	I-I	PUNCT	O


Discharged	B-I	ADJ	B
patients	I-I	NOUN	B
were	I-I	AUX	O
followed-up	I-I	VERB	B
in	I-I	ADP	O
the	I-I	DET	O
outpatient	I-I	ADJ	B
clinic	I-I	NOUN	I
.	I-I	PUNCT	O


They	B-I	PRON	O
were	I-I	AUX	O
questioned	I-I	VERB	O
on	I-I	ADP	O
the	I-I	DET	O
topics	I-I	NOUN	B
of	I-I	ADP	O
(	I-OUT	PUNCT	O
i	I-OUT	X	O
)	I-OUT	PUNCT	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
ii	I-OUT	X	O
)	I-OUT	PUNCT	O
ease	I-OUT	NOUN	O
of	I-OUT	ADP	O
swallowing	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
iii	I-OUT	X	O
)	I-OUT	PUNCT	O
satisfaction	I-OUT	NOUN	B
of	I-OUT	ADP	O
daily	I-OUT	ADJ	B
activities	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
iv	I-OUT	X	O
)	I-OUT	PUNCT	O
dependence	I-OUT	NOUN	O
on	I-OUT	ADP	O
medications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
v	I-OUT	X	O
)	I-OUT	PUNCT	O
working	I-OUT	NOUN	B
ability	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
vi	I-OUT	X	O
)	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
vii	I-OUT	X	O
)	I-OUT	PUNCT	O
appetite	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
viii	I-OUT	X	B
)	I-OUT	PUNCT	O
sociality	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
ix	I-OUT	X	O
)	I-OUT	PUNCT	O
happiness	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
(	I-OUT	PUNCT	O
x	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
self	I-OUT	NOUN	O
respect	I-OUT	NOUN	O
,	I-I	PUNCT	O
in	I-I	ADP	O
the	I-I	DET	O
third	I-I	ADJ	O
,	I-I	PUNCT	O
sixth	I-I	ADJ	O
and	I-I	CCONJ	O
twelfth	I-I	ADJ	O
month	I-I	NOUN	B
.	I-I	PUNCT	O


Also	O	ADV	O
the	O	DET	O
demographic	B-OUT	ADJ	B
data	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
operative	I-OUT	ADJ	B
results	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Up	B-P	ADP	O
to	I-P	ADP	O
December	I-P	PROPN	O
2006	I-P	NUM	O
,	I-P	PUNCT	O
eighty-seven	I-P	ADJ	O
patients	I-P	NOUN	B
of	I-P	ADP	O
stage	I-P	NOUN	B
II	I-P	NUM	I
and	I-P	CCONJ	O
III	I-P	NUM	B
,	I-P	PUNCT	O
including	I-P	VERB	O
71	I-P	NUM	O
patients	I-P	NOUN	B
of	I-P	ADP	O
middle	I-P	ADJ	B
third	I-P	ADJ	I
lesions	I-P	NOUN	I
and	I-P	CCONJ	O
16	I-P	NUM	O
lower	I-P	ADJ	O
third	I-P	ADJ	O
lesions	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


The	O	DET	O
operation	B-OUT	NOUN	B
time	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
longer	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
leakage	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
was	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
transthoracic	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
Student	O	NOUN	B
's	O	PART	I
t-test	O	NOUN	I
and	O	CCONJ	O
Fischer	O	PROPN	B
's	O	PART	I
exact	O	ADJ	I
test	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
intraoperative	B-OUT	ADJ	B
blood	I-OUT	NOUN	O
loss	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
hospital	I-OUT	NOUN	O
stay	I-OUT	NOUN	O
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
(	O	PUNCT	O
Student	O	NOUN	B
t-test	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
Kaplan-Meier	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
curves	I-OUT	NOUN	I
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
by	O	ADP	O
log-rank	O	ADJ	B
test	O	NOUN	I
(	O	PUNCT	O
p=0.286	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
score	O	NOUN	B
on	O	ADP	O
the	O	DET	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
of	O	ADP	O
transhiatal	O	ADJ	B
patients	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
transthoracic	O	NOUN	B
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
third	O	ADJ	O
,	O	PUNCT	O
sixth	O	ADJ	O
and	O	CCONJ	O
twelfth	O	ADJ	O
month	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Transhiatal	B-I	PROPN	B
esophagectomy	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
and	O	CCONJ	O
fast	O	ADJ	B
procedure	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
survival	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
transthoracic	O	NOUN	B
approach	O	NOUN	I
.	O	PUNCT	O


Its	O	PRON	O
leakage	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
was	O	AUX	O
lower	O	ADJ	B
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
was	O	AUX	O
better	O	ADJ	O
.	O	PUNCT	O


Budesonide	B-I	NOUN	B
and	I-I	CCONJ	O
beclomethasone	I-I	NOUN	B
dipropionate	I-I	NOUN	I
in	O	ADP	O
hay	B-P	NOUN	B
fever	I-P	NOUN	I
-	O	PUNCT	O
a	O	DET	O
single	O	ADJ	O
blind	O	ADJ	B
comparison	O	NOUN	B
.	O	PUNCT	O


93	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
seasonal	I-P	ADJ	B
allergic	I-P	ADJ	I
rhinitis	I-P	NOUN	I
took	O	VERB	O
part	O	NOUN	O
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
blind	O	ADJ	B
randomized	O	ADJ	B
clinical	O	ADJ	I
comparison	O	NOUN	I
of	O	ADP	O
budesonide	B-I	NOUN	B
and	I-I	CCONJ	O
beclomethasone	I-I	NOUN	B
dipropionate	I-I	NOUN	I
(	I-I	PUNCT	O
Becotide	I-I	NOUN	B
Nasal	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


All	B-P	DET	O
patients	I-P	NOUN	B
were	I-P	AUX	O
sensitive	I-P	ADJ	B
to	I-P	PART	O
either	I-P	CCONJ	O
birch	I-P	NOUN	B
or	I-P	CCONJ	O
grass	I-P	NOUN	B
pollen	I-P	NOUN	I
,	I-P	PUNCT	O
their	I-P	PRON	O
sensitivity	I-P	NOUN	B
being	I-P	AUX	O
confirmed	I-P	VERB	O
by	I-P	ADP	O
a	I-P	DET	O
skin	I-P	NOUN	B
prick	I-P	NOUN	I
test	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
total	O	ADJ	O
daily	O	ADJ	O
dose	O	NOUN	O
was	O	AUX	O
400	O	NUM	O
micrograms	O	NOUN	O
for	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
.	O	PUNCT	O


Budesonide	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
twice	O	DET	O
a	O	DET	O
day	O	NOUN	B
and	O	CCONJ	O
Becotide	B-I	PROPN	B
Nasal	I-I	PROPN	B
four	O	NUM	O
times	O	NOUN	O
a	O	DET	O
day	O	NOUN	B
.	O	PUNCT	O


Symptoms	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
over	O	ADP	O
a	O	DET	O
four-week	O	ADJ	B
period	O	NOUN	O
starting	O	VERB	O
with	O	ADP	O
a	O	DET	O
run-in	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
week	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
placebo	O	ADJ	B
control	O	NOUN	O
group	O	NOUN	O
.	O	PUNCT	O


Daily	B-OUT	ADJ	B
pollen	I-OUT	NOUN	B
counts	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
'	O	PART	O
diary	O	NOUN	B
cards	O	NOUN	I
revealed	O	VERB	B
that	O	SCONJ	O
both	O	DET	O
drugs	O	NOUN	B
had	O	AUX	O
a	O	DET	O
beneficial	O	ADJ	O
therapeutic	O	ADJ	B
effect	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
budesonide	B-I	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
active	O	ADJ	B
than	O	ADP	O
Becotide	B-I	PROPN	B
Nasal	I-I	PROPN	B
.	I-I	PUNCT	O


The	O	DET	O
side	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
of	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
few	O	ADJ	O
and	O	CCONJ	O
transient	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
Randomized	O	ADJ	B
Double	O	ADJ	I
Blind	O	PROPN	I
Clinical	O	PROPN	I
Trial	O	PROPN	I
on	O	ADP	O
a	O	DET	O
Sabgh	B-I	PROPN	B
Formulation	I-I	PROPN	I
for	O	ADP	O
Patients	B-P	NOUN	B
With	I-P	ADP	O
Vitiligo	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
cosmetic	O	ADJ	B
problem	O	NOUN	I
that	O	SCONJ	O
vitiligo	B-I	NOUN	B
produces	O	VERB	O
affects	B-P	VERB	O
patients	I-P	NOUN	B
psychologically	I-P	ADV	B
.	I-P	PUNCT	O


Many	O	ADJ	O
patients	B-P	NOUN	B
with	I-P	ADP	O
vitiligo	I-P	NOUN	B
are	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
cover	O	VERB	O
their	O	PRON	O
white	O	ADJ	B
skin	O	NOUN	I
patches	O	NOUN	I
with	O	ADP	O
cosmetic	O	ADJ	B
products	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
formulations	O	NOUN	B
in	O	ADP	O
traditional	O	ADJ	O
Iranian	O	ADJ	B
pharmacy	O	NOUN	B
to	O	PART	O
color	O	VERB	B
these	O	DET	O
white	O	ADJ	B
skin	O	NOUN	I
patches	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
formulations	B-I	NOUN	B
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
a	O	DET	O
cosmetic	B-I	ADJ	B
formulation	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	VERB	O
Two	B-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
patients	I-P	NOUN	B
were	I-P	AUX	O
selected	I-P	VERB	O
.	I-P	PUNCT	O


One	O	NUM	O
group	O	NOUN	B
used	O	VERB	O
a	O	DET	O
marketed	B-I	VERB	B
formulation	I-I	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
group	O	NOUN	B
used	O	VERB	O
a	O	DET	O
traditional	B-I	ADJ	O
Iranian	I-I	ADJ	B
Pharmacy	I-I	PROPN	B
formulation	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
compared	O	VERB	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
Dermatology	O	PROPN	B
Life	O	PROPN	I
Quality	O	PROPN	I
Index	O	PROPN	I
Questionnaire	O	PROPN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
Both	O	DET	O
interventions	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
statistically	O	ADV	B
improved	O	VERB	I
Dermatology	B-OUT	PROPN	B
Life	I-OUT	PROPN	I
Quality	I-OUT	PROPN	I
Index	I-OUT	PROPN	I
scores	I-OUT	NOUN	O
over	O	ADP	O
the	O	DET	O
8-week	O	ADJ	B
intervention	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.436	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	PROPN	O
Traditional	B-I	ADJ	B
Iranian	I-I	ADJ	I
Pharmacy	I-I	PROPN	B
formulation	O	NOUN	B
is	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
increasing	O	VERB	B
the	O	DET	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
in	O	ADP	O
vitiligo	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Blind	B-I	ADJ	B
versus	I-I	CCONJ	O
open	I-I	ADJ	O
approach	I-I	NOUN	O
to	I-I	ADP	O
laparoscopic	I-I	ADJ	B
cholecystectomy	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Intraabdominal	O	ADJ	B
structures	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
damaged	O	VERB	B
during	O	ADP	O
blind	O	ADJ	B
introduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
trocar	O	NOUN	B
for	O	ADP	O
laparoscopic	B-I	ADJ	B
operations	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
150	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
gallbladder	I-P	NOUN	B
lithiasis	I-P	NOUN	I
who	I-P	PRON	O
underwent	I-P	VERB	O
laparoscopy	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
blind	O	NOUN	B
(	O	PUNCT	O
V	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
an	O	DET	O
open	O	ADJ	O
(	O	PUNCT	O
H	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
results	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
complications	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


No	O	DET	O
mortality	B-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Major	B-OUT	ADJ	O
complications	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
3/75	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
of	O	ADP	O
the	O	DET	O
V	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
1/75	O	NUM	O
(	O	PUNCT	O
1.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patient	O	NOUN	B
of	O	ADP	O
the	O	DET	O
H	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Minor	B-OUT	ADJ	B
complications	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
5/75	O	NOUN	O
(	O	PUNCT	O
6.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
of	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
achievement	B-OUT	NOUN	B
of	I-OUT	ADP	O
pneumoperitoneum	I-OUT	NOUN	B
required	O	VERB	O
4.5+/-0.4	O	NUM	O
min	O	NOUN	O
in	O	ADP	O
the	O	DET	O
V	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
3.2+/-0.2	O	NUM	O
min	O	NOUN	O
in	O	ADP	O
the	O	DET	O
H	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
open	B-I	ADJ	B
laparoscopic	I-I	ADJ	I
technique	I-I	NOUN	I
is	O	AUX	O
safer	O	ADJ	O
and	O	CCONJ	O
faster	O	ADJ	B
than	O	ADP	O
the	O	DET	O
blind	B-I	ADJ	B
approach	I-I	NOUN	O
;	I-I	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
proposed	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
approach	O	NOUN	O
be	O	AUX	O
routinely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
all	O	DET	O
laparoscopic	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


Lofexidine	B-I	NOUN	B
in	O	ADP	O
hyperactive	B-P	ADJ	B
and	I-P	CCONJ	O
impulsive	I-P	ADJ	B
children	I-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
active-learning	B-I	ADJ	B
strategies	I-I	NOUN	I
for	O	ADP	O
motivational	B-OUT	ADJ	B
interviewing	I-OUT	NOUN	I
skills	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
knowledge	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
confidence	I-OUT	NOUN	B
in	O	ADP	O
first-year	B-P	ADJ	B
pharmacy	I-P	NOUN	B
students	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
3	O	NUM	O
strategies	O	NOUN	B
for	O	ADP	O
pharmacy	B-P	NOUN	B
student	I-P	NOUN	B
learning	O	NOUN	B
of	O	ADP	O
motivational	O	ADJ	B
interviewing	O	NOUN	I
skills	B-OUT	NOUN	I
,	I-OUT	PUNCT	O
knowledge	I-OUT	NOUN	B
of	O	ADP	O
motivational	O	ADJ	B
interviewing	O	NOUN	I
principles	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
confidence	B-OUT	NOUN	B
in	O	ADP	O
and	O	CCONJ	O
attitudes	B-OUT	NOUN	B
toward	O	ADP	O
their	O	PRON	O
application	O	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
Following	O	VERB	O
a	O	DET	O
motivational	B-I	ADJ	B
interviewing	I-I	NOUN	I
lecture	I-I	NOUN	I
,	O	PUNCT	O
first-year	B-P	ADJ	B
students	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
perform	O	VERB	O
practice	B-I	NOUN	B
activities	I-I	NOUN	I
(	I-I	PUNCT	O
written	I-I	VERB	B
dialogue	I-I	NOUN	O
,	I-I	PUNCT	O
peer	I-I	NOUN	B
role-play	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
mock-patient	I-I	ADJ	B
counseling	I-I	NOUN	I
activities	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


Motivational	B-OUT	ADJ	B
interviewing	I-OUT	NOUN	I
skills	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
knowledge	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
confidence	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
attitudes	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


ASSESSMENT	O	ADJ	O
All	O	DET	O
students	O	NOUN	B
demonstrated	O	VERB	O
improvement	O	NOUN	B
in	O	ADP	O
skills	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
knowledge	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
confidence	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Students	B-P	NOUN	B
in	O	ADP	O
the	O	DET	O
mock-patient	B-I	ADJ	B
counseling	I-I	NOUN	I
group	O	NOUN	I
demonstrated	O	VERB	O
significantly	O	ADV	O
better	O	ADJ	O
motivational	O	ADJ	B
interviewing	O	NOUN	I
skills	B-OUT	NOUN	O
during	O	ADP	O
practice	O	NOUN	B
and	O	CCONJ	O
trended	O	VERB	O
toward	O	ADP	O
higher	O	ADJ	B
scores	O	NOUN	B
on	O	ADP	O
the	O	DET	O
summative	O	ADJ	B
evaluation	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
also	O	ADV	O
demonstrated	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
knowledge	B-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
written	O	VERB	B
dialogue	O	NOUN	B
group	O	NOUN	I
during	O	ADP	O
practice	O	NOUN	B
.	O	PUNCT	O


Feedback	O	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
was	O	AUX	O
generally	O	ADV	O
positive	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
students	B-P	NOUN	B
expressing	O	VERB	B
recognition	B-OUT	NOUN	B
for	I-OUT	ADP	O
the	I-OUT	DET	O
value	I-OUT	NOUN	O
of	I-OUT	ADP	O
motivational	I-OUT	ADJ	B
interviewing	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Students	O	NOUN	B
demonstrated	O	VERB	O
their	O	PRON	O
best	O	ADJ	O
performance	O	NOUN	B
of	O	ADP	O
motivational	B-OUT	ADJ	B
interviewing	I-OUT	NOUN	I
during	O	ADP	O
assessments	O	NOUN	B
using	O	VERB	O
interactions	O	NOUN	B
with	O	ADP	O
mock	O	NOUN	B
or	O	CCONJ	O
standardized	O	ADJ	B
patients	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
fenfluramine	B-I	NOUN	B
in	O	ADP	O
autistic	B-P	ADJ	B
children	I-P	NOUN	I
:	I-P	PUNCT	O
preliminary	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
neuropsychological	B-I	ADJ	B
rehabilitation	I-I	NOUN	I
program	I-I	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
Multiple	I-P	ADJ	B
Sclerosis	I-P	PROPN	I
based	I-P	VERB	O
on	I-P	ADP	O
the	I-P	DET	O
model	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
ICF	I-P	PROPN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Forty	O	NUM	O
to	O	PART	O
sixty	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
MS	O	NOUN	B
patients	O	NOUN	B
suffer	O	VERB	O
from	O	ADP	O
cognitive	B-OUT	ADJ	B
impairments	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Cognitive	B-OUT	ADJ	B
deficits	I-OUT	NOUN	I
are	O	AUX	O
a	O	DET	O
great	O	ADJ	O
burden	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
affected	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
they	O	PRON	O
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
a	O	DET	O
reduced	O	VERB	B
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
loss	I-OUT	NOUN	B
of	I-OUT	ADP	I
work	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
problems	I-OUT	NOUN	B
with	I-OUT	ADP	O
the	I-OUT	DET	O
social	I-OUT	ADJ	B
environment	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
a	O	DET	O
specific	B-I	ADJ	O
neuropsychological	I-I	ADJ	B
rehabilitation	I-I	NOUN	I
program	I-I	NOUN	I
for	O	ADP	O
MS	B-P	NOUN	B
patients	I-P	NOUN	B
according	I-P	VERB	O
to	I-P	ADP	O
the	I-P	DET	O
ICF	I-P	PROPN	B
to	O	PART	O
be	O	AUX	O
able	O	ADJ	O
to	O	PART	O
meet	O	VERB	O
more	O	ADV	O
properly	O	ADV	O
individual	O	ADJ	O
requirements	O	NOUN	B
on	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
function	B-OUT	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
of	O	ADP	O
activities	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
participation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
Forty	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
MS	I-P	NOUN	B
were	I-P	AUX	O
randomised	I-P	VERB	B
in	I-P	ADP	O
an	I-P	DET	O
intervention	I-I	NOUN	B
(	I-I	PUNCT	O
IG	I-I	NOUN	B
)	I-I	PUNCT	O
-	I-I	PUNCT	O
and	I-I	CCONJ	O
a	I-I	DET	O
control	I-I	ADJ	B
group	I-I	NOUN	I
(	I-I	PUNCT	O
CG	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
outcome	B-OUT	NOUN	B
measure	I-OUT	NOUN	O
of	O	ADP	O
the	O	DET	O
IG	O	PROPN	B
,	O	PUNCT	O
who	O	PRON	O
started	O	VERB	O
an	O	DET	O
intensive	B-I	ADJ	B
computer	I-I	NOUN	I
based	I-I	VERB	O
home	I-I	NOUN	B
training	I-I	NOUN	I
of	I-I	ADP	O
attention	I-I	NOUN	B
and	O	CCONJ	O
attended	O	VERB	B
psychological	B-I	ADJ	B
counselling	I-I	NOUN	I
was	O	AUX	O
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
untrained	B-I	ADJ	B
CG	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
specific	O	ADJ	O
domains	O	NOUN	B
of	O	ADP	O
attention	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
simple	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
cued	I-OUT	VERB	B
alertness	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
divided	I-OUT	ADJ	O
attention	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
significant	O	ADJ	B
group	O	NOUN	B
differences	O	NOUN	O
between	O	ADP	O
CG	O	NOUN	B
and	O	CCONJ	O
IG	O	PROPN	B
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
IG	B-I	PROPN	B
reported	O	VERB	O
an	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
mental	B-OUT	ADJ	B
fatigue	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
retardation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
findings	O	NOUN	B
support	O	VERB	O
the	O	DET	O
idea	O	NOUN	O
that	O	SCONJ	O
a	O	DET	O
neuropsychological	O	ADJ	B
rehabilitation	O	NOUN	I
program	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
model	O	NOUN	B
of	O	ADP	O
ICF	O	PROPN	B
,	O	PUNCT	O
could	O	AUX	O
improve	O	VERB	O
cognitive	B-OUT	ADJ	B
impairment	I-OUT	NOUN	I
and	O	CCONJ	O
could	O	AUX	O
also	O	ADV	O
have	O	AUX	O
a	O	DET	O
positive	O	ADJ	B
influence	O	NOUN	B
of	O	ADP	O
activities	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
participation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Intervention	B-I	NOUN	B
targeting	O	NOUN	B
development	O	NOUN	B
of	O	ADP	O
socially	O	ADV	B
synchronous	O	ADJ	I
engagement	O	NOUN	I
in	O	ADP	O
toddlers	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Social	O	PROPN	B
and	O	CCONJ	O
communication	O	NOUN	B
impairments	O	NOUN	O
are	O	AUX	O
core	O	NOUN	B
deficits	O	NOUN	I
and	O	CCONJ	O
prognostic	O	ADJ	B
indicators	O	NOUN	I
of	O	ADP	O
autism	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
supplementing	O	VERB	B
a	O	DET	O
comprehensive	B-I	ADJ	B
intervention	I-I	NOUN	B
with	O	ADP	O
a	O	DET	O
curriculum	O	NOUN	B
targeting	O	VERB	B
socially	O	ADV	O
synchronous	O	ADJ	B
behavior	O	NOUN	I
on	O	ADP	O
social	O	ADJ	B
outcomes	O	NOUN	I
of	O	ADP	O
toddlers	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fifty	B-P	NUM	O
toddlers	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
,	I-P	PUNCT	O
ages	I-P	VERB	B
21	I-P	NUM	O
to	I-P	PART	O
33	I-P	NUM	O
months	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
six-month	O	ADJ	B
interventions	O	NOUN	B
:	O	PUNCT	O
Interpersonal	B-I	ADJ	B
Synchrony	I-I	PROPN	B
or	O	CCONJ	O
Non-Interpersonal	B-I	PROPN	B
Synchrony	I-I	PROPN	B
.	I-I	PUNCT	O


The	O	DET	O
interventions	O	NOUN	B
provided	O	VERB	O
identical	O	ADJ	B
intensity	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
hours	O	NOUN	O
per	O	ADP	O
week	O	NOUN	B
in	O	ADP	O
classroom	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
student-to-teacher	O	ADJ	B
ratio	O	NOUN	I
,	O	PUNCT	O
schedule	O	NOUN	B
,	O	PUNCT	O
home-based	O	ADJ	B
parent	O	NOUN	I
training	O	NOUN	I
(	O	PUNCT	O
1.5	O	NUM	O
hours	O	NOUN	O
per	O	ADP	O
month	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
parent	O	NOUN	B
education	O	NOUN	I
(	O	PUNCT	O
38	O	NUM	O
hours	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
instructional	O	ADJ	B
strategies	O	NOUN	O
,	O	PUNCT	O
except	O	SCONJ	O
the	O	DET	O
Interpersonal	O	PROPN	B
Synchrony	O	PROPN	B
condition	O	NOUN	B
provided	O	VERB	O
a	O	DET	O
supplementary	O	ADJ	O
curriculum	O	NOUN	B
targeting	O	VERB	B
socially	O	ADV	B
engaged	O	VERB	O
imitation	O	NOUN	B
,	O	PUNCT	O
joint	O	ADJ	B
attention	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
affect	O	VERB	O
sharing	O	NOUN	O
;	O	PUNCT	O
measures	O	NOUN	B
of	O	ADP	O
these	O	DET	O
were	O	AUX	O
primary	O	ADJ	B
outcomes	O	NOUN	I
.	O	PUNCT	O


Assessments	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
pre-intervention	O	NOUN	B
,	O	PUNCT	O
immediately	O	ADV	O
post-intervention	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
to	O	PART	O
assess	O	VERB	B
maintenance	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
six-month	O	ADJ	B
follow-up	O	NOUN	B
.	O	PUNCT	O


Random	O	ADJ	B
effects	O	NOUN	B
models	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
examine	O	VERB	O
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
over	O	ADP	O
time	O	NOUN	B
.	O	PUNCT	O


Secondary	O	ADJ	B
analyses	O	NOUN	I
examined	O	VERB	O
gains	B-OUT	NOUN	B
in	I-OUT	ADP	O
expressive	I-OUT	ADJ	B
language	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
nonverbal	I-OUT	ADJ	B
cognition	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
time	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
and	O	CCONJ	O
follow-up	O	ADJ	B
periods	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
significant	O	ADJ	B
treatment	O	NOUN	B
effect	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
socially	O	ADV	B
engaged	O	VERB	O
imitation	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.02	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
doubling	O	VERB	B
(	O	PUNCT	O
17	O	NUM	O
%	O	NOUN	O
to	O	PART	O
42	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
imitated	O	ADJ	B
acts	O	NOUN	O
paired	O	VERB	O
with	O	ADP	O
eye	O	NOUN	B
contact	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Interpersonal	O	PROPN	B
Synchrony	O	PROPN	B
group	O	NOUN	O
after	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
skill	O	NOUN	B
was	O	AUX	O
generalized	O	VERB	O
to	O	ADP	O
unfamiliar	O	ADJ	O
contexts	O	NOUN	B
and	O	CCONJ	O
maintained	O	VERB	B
through	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Similar	O	ADJ	O
gains	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
joint	B-OUT	ADJ	B
attention	I-OUT	NOUN	B
and	O	CCONJ	O
shared	O	VERB	O
positive	O	ADJ	B
affect	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
between-group	O	ADJ	B
differences	O	NOUN	I
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
statistical	O	ADJ	B
significance	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	B
time	O	NOUN	B
effect	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
all	O	DET	O
outcomes	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
greatest	O	ADJ	O
change	O	NOUN	O
occurred	O	VERB	O
during	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
the	O	DET	O
Interpersonal	O	PROPN	B
Synchrony	O	PROPN	B
group	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
ASD	O	VERB	B
randomized	O	ADJ	B
trial	O	NOUN	I
involving	O	VERB	O
toddlers	B-P	NOUN	B
to	O	PART	O
identify	O	VERB	O
an	O	DET	O
active	O	ADJ	B
ingredient	O	NOUN	I
for	O	ADP	O
enhancing	O	NOUN	B
socially	O	ADV	B
engaged	O	VERB	O
imitation	O	NOUN	B
.	O	PUNCT	O


Adding	O	VERB	O
social	O	ADJ	B
engagement	O	NOUN	I
targets	O	VERB	B
to	O	ADP	O
intervention	O	NOUN	B
improves	O	VERB	O
short-term	O	ADJ	B
outcome	O	NOUN	B
at	O	ADP	O
no	O	DET	O
additional	O	ADJ	O
cost	O	NOUN	B
to	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
social	O	ADJ	B
,	O	PUNCT	O
language	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cognitive	O	ADJ	B
gains	O	NOUN	I
in	O	ADP	O
our	O	PRON	O
participants	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
plasticity	O	NOUN	B
of	O	ADP	O
these	O	DET	O
developmental	O	ADJ	B
systems	O	NOUN	I
in	O	ADP	O
toddlers	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


http	O	NOUN	B
:	O	PUNCT	O
//www.clinicaltrials.gov/ct2/show/NCT00106210	O	ADJ	O
?	O	PUNCT	O
term	O	NOUN	O
=	O	ADJ	O
landa	O	NOUN	B
&	O	CCONJ	O
rank	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
multiplane	B-I	NOUN	B
probe	I-I	NOUN	I
with	O	ADP	O
the	O	DET	O
biplane	B-I	NOUN	B
probe	I-I	NOUN	I
in	O	ADP	O
structure	B-OUT	NOUN	B
visualization	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
Doppler	I-OUT	NOUN	B
examination	I-OUT	NOUN	I
during	I-P	ADP	O
transesophageal	I-P	NOUN	B
echocardiography	I-P	NOUN	I
.	I-P	PUNCT	O


To	O	PART	O
compare	O	VERB	B
the	O	DET	O
imaging	B-OUT	NOUN	B
capability	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
multiplane	B-I	NOUN	B
probe	I-I	NOUN	I
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
biplane	B-I	NOUN	B
probe	I-I	NOUN	I
,	O	PUNCT	O
317	B-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
undergo	O	VERB	O
transesophageal	B-I	NOUN	B
echocardiography	I-I	NOUN	I
with	I-I	ADP	O
either	I-I	DET	O
probe	I-I	NOUN	B
.	I-I	PUNCT	O


Images	O	NOUN	B
of	O	ADP	O
24	O	NUM	O
cardiac	O	ADJ	B
structures	O	NOUN	I
and	O	CCONJ	O
nine	B-OUT	NUM	O
Doppler	I-OUT	NOUN	B
signals	I-OUT	NOUN	I
were	O	AUX	O
graded	O	VERB	O
prospectively	O	ADV	O
on	O	ADP	O
a	O	DET	O
three-grade	O	ADJ	B
system	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
multiplane	B-I	NOUN	B
and	I-I	CCONJ	O
biplane	I-I	NOUN	B
probes	I-I	NOUN	B
provided	O	VERB	O
excellent	B-OUT	ADJ	O
visualization	I-OUT	NOUN	B
of	I-OUT	ADP	O
cardiac	I-OUT	ADJ	B
structures	I-OUT	NOUN	I
and	O	CCONJ	O
Doppler	B-OUT	NOUN	B
signals	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
multiplane	B-I	NOUN	B
probe	I-I	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
superior	O	ADJ	O
to	O	ADP	O
the	O	DET	O
biplane	O	NOUN	B
probe	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
attempts	I-OUT	NOUN	B
at	I-OUT	ADP	O
esophageal	I-OUT	ADJ	B
intubation	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
amount	I-OUT	NOUN	B
of	I-OUT	ADP	O
sedation	I-OUT	NOUN	B
used	I-OUT	VERB	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
examination	I-OUT	NOUN	B
time	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
complications	I-OUT	NOUN	B
was	I-OUT	AUX	O
similar	I-OUT	ADJ	O
,	O	PUNCT	O
although	O	SCONJ	O
all	O	DET	O
failed	B-OUT	VERB	B
intubations	I-OUT	NOUN	B
occurred	O	VERB	O
with	O	ADP	O
the	O	DET	O
multiplane	B-I	NOUN	B
probe	I-I	NOUN	I
.	I-I	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
nicorandil	B-I	NOUN	B
before	O	ADP	O
reperfusion	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
ST-segment-elevation	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Intravenous	O	ADJ	B
nicorandil	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
hybrid	O	ADJ	B
compound	O	NOUN	I
of	O	ADP	O
ATP-sensitive	O	ADJ	B
potassium	O	NOUN	I
channel	O	NOUN	I
opener	O	NOUN	I
and	O	CCONJ	O
nitric	O	ADJ	B
oxide	O	NOUN	I
donor	O	NOUN	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
ameliorate	O	VERB	B
early	O	ADJ	O
functional	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
problems	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
its	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
late	O	ADJ	B
phase	O	NOUN	I
remain	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
This	O	DET	O
follow-up	O	ADJ	B
study	O	NOUN	I
to	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blinded	O	ADJ	B
trial	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
among	O	ADP	O
368	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
first	I-P	ADJ	O
ST-segment-elevation	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
undergoing	I-P	VERB	O
percutaneous	I-P	ADJ	B
coronary	I-P	ADJ	I
intervention	I-P	NOUN	I
(	I-P	PUNCT	O
PCI	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


They	O	PRON	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
12	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
nicorandil	B-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
placebo	I-I	NOUN	B
intravenously	O	ADV	B
just	O	ADV	O
before	O	ADP	O
reperfusion	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
cardiovascular	B-OUT	ADJ	B
death	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
rehospitalization	I-OUT	NOUN	B
for	O	ADP	O
congestive	B-OUT	ADJ	B
heart	I-OUT	NOUN	I
failure	I-OUT	NOUN	I
after	O	ADP	O
PCI	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
various	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
epicardial	O	ADJ	B
flow	O	NOUN	I
and	O	CCONJ	O
microvascular	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


Mean	O	VERB	B
follow-up	O	NOUN	I
was	O	AUX	O
2.4	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
SD	O	NOUN	B
,	O	PUNCT	O
1.4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
12	O	NUM	O
(	O	PUNCT	O
6.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
receiving	O	VERB	O
nicorandil	B-I	NOUN	B
and	O	CCONJ	O
30	O	NUM	O
(	O	PUNCT	O
16.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
receiving	O	VERB	O
placebo	B-I	NOUN	B
had	O	AUX	O
cardiovascular	B-OUT	ADJ	B
death	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
hospital	I-OUT	NOUN	B
admission	I-OUT	NOUN	I
for	I-OUT	ADP	O
congestive	I-OUT	ADJ	B
heart	I-OUT	NOUN	I
failure	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.39	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.20	O	NUM	O
to	O	PART	O
0.76	O	NUM	O
;	O	PUNCT	O
P=0.0058	O	X	O
)	O	PUNCT	O
.	O	PUNCT	O


Postprocedural	B-OUT	ADJ	B
TIMI	I-OUT	NOUN	O
3	I-OUT	NUM	O
flow	I-OUT	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
89.7	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
nicorandil	B-I	ADJ	B
group	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
81.4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
1.99	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.09	O	NUM	O
to	O	PART	O
3.65	O	NUM	O
;	O	PUNCT	O
P=0.025	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Corrected	B-OUT	ADJ	O
TIMI	I-OUT	NOUN	O
frame	I-OUT	NOUN	O
count	I-OUT	NOUN	O
was	O	AUX	O
furthermore	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
nicorandil	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
21.0+/-9.1	O	NUM	O
versus	O	CCONJ	O
25.1+/-14.1	O	NUM	O
;	O	PUNCT	O
P=0.0009	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


ST-segment	B-OUT	ADJ	B
resolution	I-OUT	NOUN	B
>	I-OUT	PROPN	O
50	I-OUT	NUM	O
%	I-OUT	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
79.5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
61.2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
nicorandil	B-I	ADJ	B
and	O	CCONJ	O
placebo	B-I	ADJ	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
2.45	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.54	O	NUM	O
to	O	PART	O
3.90	O	NUM	O
;	O	PUNCT	O
P=0.0002	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
intravenous	O	ADJ	B
nicorandil	B-I	NOUN	B
to	O	PART	O
PCI	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
beneficial	O	ADJ	O
clinical	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
and	O	CCONJ	O
prevents	O	VERB	B
cardiovascular	B-OUT	ADJ	B
events	I-OUT	NOUN	O
of	I-OUT	ADP	O
long	I-OUT	ADJ	B
duration	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
death	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
ST-segment-elevation	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
gluten-free	B-I	ADJ	B
,	I-I	PUNCT	O
casein-free	I-I	ADJ	B
diet	I-I	NOUN	I
in	O	ADP	O
autism	B-P	NOUN	B
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
preliminary	O	ADJ	B
double	O	ADJ	B
blind	O	ADJ	I
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
tested	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
gluten-free	B-I	ADJ	B
and	I-I	CCONJ	O
casein-free	I-I	ADJ	B
(	I-I	PUNCT	I
GFCF	I-I	NOUN	B
)	I-I	PUNCT	O
diet	I-I	NOUN	B
in	O	ADP	O
treating	O	VERB	B
autism	B-P	NOUN	B
using	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
repeated	O	VERB	O
measures	O	NOUN	B
crossover	O	NOUN	B
design	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
sample	O	NOUN	B
included	O	VERB	O
15	B-P	NUM	O
children	I-P	NOUN	B
aged	I-P	ADJ	O
2-16	I-P	NUM	O
years	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Data	O	NOUN	B
on	O	ADP	O
autistic	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
urinary	I-OUT	ADJ	B
peptide	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
were	O	AUX	O
collected	O	VERB	O
in	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
'	O	PART	O
homes	O	NOUN	B
over	O	ADP	O
the	O	DET	O
12	O	NUM	O
weeks	O	NOUN	B
that	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
on	O	ADP	O
the	O	DET	O
diet	O	NOUN	B
.	O	PUNCT	O


Group	O	NOUN	B
data	O	NOUN	B
indicated	O	VERB	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
findings	O	NOUN	B
even	O	ADV	O
though	O	SCONJ	O
several	O	ADJ	O
parents	O	NOUN	B
reported	O	VERB	O
improvement	B-OUT	NOUN	B
in	O	ADP	O
their	O	PRON	O
children	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
preliminary	O	ADJ	B
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
demonstrates	O	VERB	O
how	O	SCONJ	O
a	O	DET	O
controlled	O	VERB	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
the	O	DET	O
GFCF	B-I	NOUN	B
diet	I-I	NOUN	B
can	O	AUX	O
be	O	AUX	O
conducted	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
suggests	O	VERB	O
directions	O	NOUN	B
for	O	ADP	O
future	O	ADJ	O
research	O	NOUN	B
.	O	PUNCT	O


Ethanol-induced	O	ADJ	B
alterations	O	NOUN	B
in	O	ADP	O
electroencephalographic	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
in	O	ADP	O
adult	B-P	ADJ	B
males	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
present	O	ADJ	O
investigation	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
placebo	B-I	NOUN	B
(	I-I	PUNCT	O
P	I-I	NOUN	O
)	I-I	PUNCT	O
,	O	PUNCT	O
low-dose	O	ADJ	B
(	O	PUNCT	O
LD	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
high-dose	O	ADJ	B
(	O	PUNCT	O
HD	O	NOUN	B
)	O	PUNCT	O
ethanol	B-I	NOUN	B
on	O	ADP	O
electroencephalographic	B-OUT	ADJ	B
(	I-OUT	PUNCT	O
EEG	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
activity	I-P	NOUN	B
in	I-P	ADP	O
21	I-P	NUM	O
healthy	I-P	ADJ	B
,	I-P	PUNCT	O
adult	I-P	ADJ	B
males	I-P	NOUN	B
(	I-P	PUNCT	O
X	I-P	NOUN	O
=	I-P	ADJ	O
22.7	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Only	O	ADV	O
one	O	NUM	O
condition	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
,	O	PUNCT	O
LD	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
HD	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
presented	O	VERB	O
per	O	ADP	O
day	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
condition	O	NOUN	B
order	O	NOUN	O
was	O	AUX	O
randomized	O	VERB	B
.	O	PUNCT	O


For	O	ADP	O
each	O	DET	O
subject	O	NOUN	B
,	O	PUNCT	O
blood-alcohol	O	NOUN	B
levels	O	NOUN	O
measured	O	VERB	B
via	O	ADP	O
breathalyzer	O	NOUN	B
and	O	CCONJ	O
EEG	B-OUT	NOUN	B
activity	I-OUT	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
10/20	O	NUM	O
International	O	PROPN	B
System	O	PROPN	I
,	O	PUNCT	O
were	O	AUX	O
recorded	O	VERB	O
both	O	CCONJ	O
prior	O	ADJ	O
to	O	PART	O
and	O	CCONJ	O
at	O	ADP	O
intervals	O	NOUN	B
of	O	ADP	O
35	O	NUM	O
,	O	PUNCT	O
70	O	NUM	O
,	O	PUNCT	O
105	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
140	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
P	O	NOUN	O
,	O	PUNCT	O
LD	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
HD	O	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Fast	O	PROPN	B
Fourier	O	PROPN	I
Transform	O	PROPN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
calculate	O	VERB	B
power	O	NOUN	O
spectral	O	ADJ	O
densities	O	NOUN	B
for	O	ADP	O
each	O	DET	O
EEG	O	PROPN	B
recording	O	NOUN	B
.	O	PUNCT	O


Measures	O	NOUN	B
of	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
areas	O	NOUN	O
under	O	ADP	O
the	O	DET	O
power	O	NOUN	B
spectral	O	ADJ	I
curve	O	NOUN	I
were	O	AUX	O
made	O	VERB	O
for	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
following	O	VERB	O
frequency	O	NOUN	B
bands	O	NOUN	I
:	O	PUNCT	O
slow	O	ADJ	B
alpha	O	NOUN	I
(	O	PUNCT	O
7.5	O	NUM	O
to	O	PART	O
10	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
fast	O	ADJ	B
alpha	O	NOUN	I
(	O	PUNCT	O
10.5	O	NUM	O
to	O	PART	O
13.0	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
slow	O	ADJ	B
beta	O	NOUN	I
(	O	PUNCT	O
13.5	O	NUM	O
to	O	PART	O
19.5	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
and	O	CCONJ	O
fast	O	ADJ	B
beta	O	NOUN	I
(	O	PUNCT	O
20	O	NUM	O
to	O	PART	O
26	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
at	O	ADP	O
electrodes	O	NOUN	B
F3	O	PROPN	I
,	O	PUNCT	O
F4	O	PROPN	B
,	O	PUNCT	O
C3	O	NOUN	B
,	O	PUNCT	O
C4	O	NOUN	B
,	O	PUNCT	O
P3	O	NOUN	B
,	O	PUNCT	O
P4	O	NOUN	B
,	O	PUNCT	O
O1	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
O2	O	NOUN	B
.	O	PUNCT	O


Repeated-measures	O	VERB	B
multivariate	O	ADJ	I
analysis	O	NOUN	I
of	O	ADP	O
variance	O	NOUN	B
performed	O	VERB	O
on	O	ADP	O
normalized	O	VERB	O
relative	O	ADJ	O
area	O	NOUN	O
values	O	NOUN	O
revealed	O	VERB	B
that	O	SCONJ	O
ethanol	O	NOUN	B
had	O	AUX	O
significant	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
EEG	B-OUT	NOUN	B
activity	I-OUT	NOUN	B
at	I-OUT	ADP	O
anterior	I-OUT	ADJ	B
sites	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
frontal	O	ADJ	B
(	O	PUNCT	O
F3	O	NOUN	O
,	O	PUNCT	O
F4	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
central	O	ADJ	B
(	O	PUNCT	O
C3	O	NOUN	B
,	O	PUNCT	O
C4	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
presented	O	VERB	O
as	O	ADP	O
increased	O	VERB	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
slow	O	ADJ	B
alpha	O	NOUN	I
frequency	O	NOUN	I
band	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
differential	O	ADJ	O
responsivity	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
cortical	B-OUT	ADJ	B
region	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
EEG	I-OUT	NOUN	B
frequency	I-OUT	NOUN	B
band	I-OUT	NOUN	I
to	O	PART	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
ethanol	O	NOUN	B
ingestion	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Effects	O	NOUN	B
of	O	ADP	I
computer-assisted	B-I	ADJ	B
practice	I-I	NOUN	I
on	O	ADP	O
reading	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
spelling	I-OUT	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
learning	I-P	NOUN	B
disabilities	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
analyze	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
computer-assisted	B-I	ADJ	B
practice	I-I	NOUN	I
on	I-I	ADP	O
reading	I-I	NOUN	B
and	I-I	CCONJ	O
spelling	I-I	NOUN	B
in	I-I	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
learning	I-P	NOUN	B
disabilities	I-P	NOUN	I
(	I-P	PUNCT	O
LD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


We	O	PRON	O
compared	O	VERB	B
three	O	NUM	O
practice	O	NOUN	B
conditions	O	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
with	O	ADP	O
reading	B-I	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
with	O	ADP	O
spelling	B-I	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
test	O	VERB	B
whether	O	SCONJ	O
computer-based	B-I	ADJ	B
reading	I-I	NOUN	I
and	I-I	CCONJ	O
spelling	I-I	NOUN	B
practice	I-I	NOUN	I
has	O	AUX	O
an	O	DET	O
influence	O	NOUN	B
on	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
reading	O	NOUN	B
and	O	CCONJ	O
spelling	O	NOUN	B
ability	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
LD	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
sample	O	NOUN	B
was	O	AUX	O
selected	O	VERB	O
of	O	ADP	O
85	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
LD	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
age	I-P	NOUN	B
range	I-P	NOUN	O
between	I-P	ADP	O
8	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
10	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
M=111.02	I-P	PROPN	B
,	I-P	PUNCT	O
SD=9.6	I-P	PROPN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
whose	I-P	DET	O
spelling	I-P	NOUN	B
performance	I-P	NOUN	I
was	I-P	AUX	O
two	I-P	NUM	O
years	I-P	NOUN	B
below	I-P	ADP	O
grade	I-P	NOUN	O
level	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
1	B-I	X	O
)	I-I	PUNCT	O
Copy	I-I	VERB	B
the	I-I	DET	I
target	I-I	NOUN	B
word	I-I	NOUN	B
from	I-I	ADP	O
the	I-I	DET	O
computer	I-I	NOUN	B
screen	I-I	NOUN	I
(	I-I	PUNCT	O
n=22	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
Memorize	I-I	VERB	B
the	I-I	DET	O
target	I-I	NOUN	B
word	I-I	NOUN	B
and	I-I	CCONJ	O
write	I-I	VERB	O
it	I-I	PRON	O
from	I-I	ADP	O
memory	I-I	NOUN	B
(	I-I	PUNCT	O
n=21	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
3	I-I	X	O
)	I-I	PUNCT	O
Word	I-I	NOUN	B
reading	I-I	VERB	I
(	I-I	PUNCT	O
n=21	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
4	I-I	X	O
)	I-I	PUNCT	O
the	I-I	DET	O
untrained	I-I	ADJ	B
control	I-I	NOUN	I
group	I-I	NOUN	I
(	O	PUNCT	O
n=21	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
administered	O	VERB	B
measures	O	NOUN	B
of	O	ADP	O
pseudoword	B-OUT	NOUN	B
reading	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
phonological	I-OUT	ADJ	B
awareness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
phonological	I-OUT	ADJ	B
word	I-OUT	NOUN	O
decoding	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
orthographical	I-OUT	ADJ	B
word	I-OUT	NOUN	O
decoding	I-OUT	NOUN	O
tasks	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
learning	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
transfer	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
on	I-OUT	ADP	O
words	I-OUT	NOUN	B
classified	I-OUT	VERB	O
as	I-OUT	ADP	O
a	I-OUT	DET	O
function	I-OUT	NOUN	B
of	I-OUT	ADP	O
length	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
consistency	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
complexity	I-OUT	NOUN	B
of	I-OUT	ADP	O
syllable	I-OUT	ADJ	B
structure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
reading	O	NOUN	B
training	O	NOUN	I
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
spelling	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
children	O	NOUN	B
who	O	PRON	O
participated	O	VERB	O
in	O	ADP	O
the	O	DET	O
copy	O	NOUN	B
training	O	NOUN	I
condition	O	NOUN	I
improved	O	VERB	B
their	O	PRON	O
spelling	O	NOUN	B
skills	O	NOUN	I
.	O	PUNCT	O


Developing	O	VERB	O
the	O	DET	O
Ho'ouna	B-I	PROPN	B
Pono	I-I	PROPN	B
substance	I-I	NOUN	I
use	I-I	VERB	I
prevention	I-I	NOUN	B
curriculum	I-I	NOUN	B
:	I-I	PUNCT	O
collaborating	O	VERB	O
with	O	ADP	O
Hawaiian	B-P	ADJ	B
youth	I-P	NOUN	B
and	I-P	CCONJ	O
communities	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
article	O	NOUN	O
briefly	O	ADV	O
outlines	O	VERB	O
a	O	DET	O
collaboration	O	NOUN	B
among	O	ADP	O
communities	B-P	NOUN	B
on	I-P	ADP	O
Hawai'i	I-P	PROPN	B
Island	I-P	PROPN	I
and	O	CCONJ	O
a	O	DET	O
university-based	B-P	ADJ	B
research	I-P	NOUN	B
team	I-P	NOUN	O
to	O	PART	O
develop	B-OUT	VERB	O
,	I-OUT	PUNCT	O
implement	I-OUT	VERB	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
evaluate	I-OUT	VERB	B
a	I-OUT	DET	O
school-based	I-OUT	ADJ	B
substance	I-OUT	NOUN	I
use	I-OUT	VERB	O
prevention	I-OUT	NOUN	B
curriculum	I-OUT	NOUN	B
called	I-I	VERB	O
Ho'ouna	I-I	PROPN	B
Pono	I-I	PROPN	I
.	I-I	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	ADP	O
providing	O	VERB	O
a	O	DET	O
rationale	O	NOUN	B
for	O	ADP	O
the	O	DET	O
project	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
this	O	DET	O
paper	O	NOUN	O
is	O	AUX	O
fourfold	O	ADJ	O
.	O	PUNCT	O


First	O	ADV	O
,	O	PUNCT	O
an	O	DET	O
overview	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Ho'ouna	B-I	PROPN	B
Pono	I-I	PROPN	I
research	O	NOUN	I
results	O	VERB	O
to	O	ADP	O
date	O	NOUN	O
(	O	PUNCT	O
2007-2013	O	NUM	O
)	O	PUNCT	O
is	O	AUX	O
provided	O	VERB	O
.	O	PUNCT	O


Second	O	ADV	O
,	O	PUNCT	O
within	O	ADP	O
this	O	DET	O
overview	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
ways	O	NOUN	O
in	O	ADP	O
which	O	DET	O
selected	O	VERB	O
results	O	NOUN	B
informed	O	VERB	O
program	O	NOUN	B
development	O	NOUN	B
are	O	AUX	O
highlighted	O	VERB	O
.	O	PUNCT	O


Third	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
curriculum	O	NOUN	B
is	O	AUX	O
briefly	O	ADV	O
described	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
finally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
students	B-P	NOUN	B
and	I-P	CCONJ	O
community	I-P	NOUN	B
in	O	ADP	O
the	O	DET	O
video	O	NOUN	B
production	O	NOUN	O
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
protective	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
angiotensin	O	NOUN	B
II	O	NUM	I
blockade	O	NOUN	I
with	O	ADP	O
olmesartan	B-I	ADJ	B
medoxomil	I-I	NOUN	B
on	O	ADP	O
resistance	O	NOUN	B
vessel	O	NOUN	I
remodeling	O	NOUN	I
(	O	PUNCT	O
The	O	DET	O
VIOS	O	NOUN	B
study	O	NOUN	I
)	O	PUNCT	O
:	O	PUNCT	O
rationale	O	NOUN	B
and	O	CCONJ	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
VIOS	O	NOUN	B
(	O	PUNCT	O
Vascular	O	PROPN	B
Improvement	O	PROPN	I
with	O	ADP	O
Olmesartan	B-I	NOUN	B
medoxomil	I-I	NOUN	I
Study	O	NOUN	I
)	O	PUNCT	O
study	O	NOUN	B
is	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	O
study	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
relative	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
suppressing	O	VERB	B
the	O	DET	O
renin-angiotensin	O	ADJ	B
system	O	NOUN	I
(	O	PUNCT	O
RAS	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
angiotensin	O	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	B
olmesartan	B-I	NOUN	B
medoxomil	I-I	NOUN	B
versus	O	CCONJ	O
suppressing	O	VERB	B
sympathetic	O	ADJ	B
drive	O	NOUN	O
with	O	ADP	O
the	O	DET	O
beta-adrenoceptor	O	NOUN	B
antagonist	O	NOUN	I
atenolol	B-I	ADV	B
on	O	ADP	O
remodeling	O	NOUN	B
of	O	ADP	O
the	O	DET	O
subcutaneous	O	ADJ	B
small	O	ADJ	I
resistance	O	NOUN	I
vessel	O	NOUN	I
.	O	PUNCT	O


Remodeling	O	NOUN	B
of	O	ADP	O
small	O	ADJ	B
resistance	O	NOUN	I
vessels	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
earliest	O	ADJ	O
pathologic	O	ADJ	B
finding	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
hypertension	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
may	O	AUX	O
predate	O	VERB	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
clinically	O	ADV	B
apparent	O	ADJ	I
hypertension	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
100	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
stage	I-P	NOUN	B
I	I-P	NUM	I
hypertension	I-P	NOUN	I
are	I-P	AUX	O
characterized	I-P	VERB	B
at	I-P	ADP	O
baseline	I-P	NOUN	B
before	I-P	ADP	O
being	I-P	AUX	O
treated	I-P	VERB	B
for	I-P	ADP	O
1	I-P	NUM	O
year	I-P	NOUN	B
to	I-P	PART	O
obtain	I-P	VERB	O
a	I-P	DET	O
goal	I-P	NOUN	B
BP	I-P	NOUN	I
of	I-P	ADP	O
less	I-P	ADJ	O
than	I-P	ADP	O
140/90	I-P	NUM	O
mm	I-P	NOUN	B
Hg	I-P	NOUN	I
as	O	ADP	O
defined	O	VERB	O
by	O	ADP	O
Joint	O	PROPN	B
National	O	PROPN	I
Committee	O	PROPN	I
(	O	PUNCT	I
JNC	O	PROPN	B
)	O	PUNCT	O
-7	O	NUM	O
.	O	PUNCT	O


Resistance	O	NOUN	B
vessel	O	NOUN	I
remodeling	O	NOUN	B
is	O	AUX	O
determined	O	VERB	O
using	O	VERB	O
the	O	DET	O
gluteal	B-I	ADJ	B
fat	I-I	NOUN	I
biopsy	I-I	NOUN	I
technique	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
hypertensive	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
normotensive	O	ADJ	B
healthy	O	ADJ	B
volunteers	O	NOUN	I
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
efforts	O	NOUN	O
will	O	AUX	O
be	O	AUX	O
made	O	VERB	O
to	O	PART	O
define	O	VERB	O
whether	O	SCONJ	O
noninvasive	B-OUT	ADJ	B
hemodynamic	I-OUT	ADJ	B
parameters	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
retinal	I-OUT	ADJ	B
vessel	I-OUT	NOUN	O
measurement	I-OUT	NOUN	B
changes	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
biologic	B-OUT	ADJ	B
markers	I-OUT	NOUN	B
may	O	AUX	O
predict	O	VERB	O
and	O	CCONJ	O
track	O	VERB	O
the	O	DET	O
underlying	O	ADJ	O
vascular	B-OUT	ADJ	B
morphologic	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
physiologic	I-OUT	ADJ	B
changes	I-OUT	NOUN	B
induced	O	VERB	B
by	O	ADP	O
either	O	DET	O
regimen	O	NOUN	B
during	O	ADP	O
the	O	DET	O
12-month	O	ADJ	B
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
primary	O	ADJ	B
endpoint	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
the	O	DET	O
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
vascular	I-OUT	ADJ	B
remodeling	I-OUT	NOUN	I
as	I-OUT	ADP	O
obtained	I-OUT	VERB	O
from	I-OUT	ADP	O
percutaneous	I-OUT	ADJ	B
biopsy	I-OUT	NOUN	I
of	I-OUT	ADP	O
gluteal	I-OUT	ADJ	B
subcutaneous	I-OUT	ADJ	I
resistance	I-OUT	NOUN	I
vessels	I-OUT	NOUN	I
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
two	O	NUM	O
treatment	O	NOUN	B
arms	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
volunteers	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
design	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
pertinent	O	ADJ	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
uncomplicated	O	ADJ	O
essential	O	ADJ	O
hypertension	O	NOUN	B
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
suppression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
RAS	O	NOUN	B
by	O	ADP	O
the	O	DET	O
blockade	O	NOUN	B
of	O	ADP	O
angiotensin	O	NOUN	B
II	O	NUM	I
type	O	NOUN	I
1	O	NUM	I
(	O	PUNCT	O
AT	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
receptors	O	NOUN	O
may	O	AUX	O
demonstrate	O	VERB	O
remodeling	O	NOUN	B
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
ubiquitous	O	ADJ	O
small	O	ADJ	O
resistance	O	NOUN	O
vessels	O	NOUN	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
myocardium	O	NOUN	B
and	O	CCONJ	O
renal	O	ADJ	B
glomeruli	O	NOUN	I
,	O	PUNCT	O
thus	O	ADV	O
affording	O	VERB	O
more	O	ADV	O
complete	O	ADJ	O
end-organ	O	ADJ	B
protection	O	NOUN	B
.	O	PUNCT	O


In	O	X	B
vivo	O	X	I
effect	O	NOUN	B
of	O	ADP	O
clarithromycin	B-I	NOUN	B
on	O	ADP	O
multiple	B-P	ADJ	B
cytochrome	I-P	NOUN	B
P450s	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
in	O	X	B
vivo	O	X	I
effects	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
clarithromycin	B-I	NOUN	B
administration	O	NOUN	B
on	O	ADP	O
the	O	DET	O
in	O	X	B
vivo	O	X	I
activity	O	NOUN	B
of	O	ADP	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
1A2	O	NOUN	I
,	O	PUNCT	O
2C9	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
2D6	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
probes	O	NOUN	I
caffeine	B-I	NOUN	B
(	O	PUNCT	O
CYP1A2	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
tolbutamide	B-I	NOUN	B
(	O	PUNCT	O
CYP2C9	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
dextromethorphan	B-I	NOUN	B
(	O	PUNCT	O
CYP2D6	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
administered	O	VERB	B
as	O	ADP	O
an	O	DET	O
oral	O	ADJ	B
cocktail	O	NOUN	I
prior	O	ADJ	O
to	O	PART	O
and	O	CCONJ	O
7	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
oral	O	ADJ	B
clarithromycin	B-I	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	O
)	O	PUNCT	O
administration	O	NOUN	B
to	O	PART	O
12	B-P	NUM	O
healthy	I-P	ADJ	B
male	I-P	ADJ	B
subjects	I-P	NOUN	O
.	I-P	PUNCT	O


Blood	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
urine	I-OUT	NOUN	B
samples	I-OUT	NOUN	I
were	O	AUX	O
collected	O	VERB	B
and	O	CCONJ	O
assayed	O	VERB	B
for	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
compounds	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
metabolites	O	NOUN	B
using	O	VERB	O
high-performance	O	ADJ	B
liquid	O	ADJ	I
chromatography	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
CYP1A2	B-OUT	NOUN	B
indices	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
oral	I-OUT	ADJ	B
caffeine	I-OUT	NOUN	I
clearance	I-OUT	NOUN	I
(	O	PUNCT	O
6.2	O	NUM	O
+/-	O	CCONJ	O
3.3	O	NUM	O
l/h	O	NOUN	O
before	O	ADP	O
and	O	CCONJ	O
5.7	O	NUM	O
+/-	O	CCONJ	O
4.2	O	NUM	O
l/h	O	NOUN	O
after	O	ADV	O
,	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
6-h	B-OUT	ADJ	O
paraxanthine	I-OUT	NOUN	B
to	I-OUT	PART	O
caffeine	I-OUT	NOUN	B
serum	I-OUT	NOUN	O
concentration	I-OUT	NOUN	O
ratio	I-OUT	NOUN	O
(	O	PUNCT	O
0.49	O	NUM	O
+/-	O	CCONJ	O
0.3	O	NUM	O
before	O	ADP	O
and	O	CCONJ	O
0.44	O	NUM	O
+/-	O	CCONJ	O
0.3	O	NUM	O
after	O	ADV	O
,	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
were	O	AUX	O
unchanged	B-OUT	ADJ	B
following	O	VERB	O
clarithromycin	O	NOUN	B
dosing	O	NOUN	B
.	O	PUNCT	O


Neither	O	CCONJ	O
the	O	DET	O
tolbutamide	B-OUT	NOUN	B
oral	I-OUT	ADJ	O
clearance	I-OUT	NOUN	B
(	O	PUNCT	O
0.77	O	NUM	O
+/-	O	CCONJ	O
0.28	O	NUM	O
l/h	O	NOUN	O
before	O	ADP	O
and	O	CCONJ	O
0.72	O	NUM	O
+/-0.24	O	NOUN	O
l/h	O	NOUN	O
after	O	ADV	O
,	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
nor	O	CCONJ	O
the	O	DET	O
tolbutamide	B-OUT	NOUN	B
urinary	I-OUT	ADJ	B
metabolic	I-OUT	ADJ	O
ratio	I-OUT	NOUN	O
(	O	PUNCT	O
779	O	NUM	O
+/-	O	CCONJ	O
294	O	NUM	O
before	O	ADV	O
and	O	CCONJ	O
681	O	NUM	O
+/-	O	CCONJ	O
416	O	NUM	O
after	O	ADV	O
,	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
indices	O	NOUN	B
of	O	ADP	O
CYP2C9	O	NOUN	B
were	O	AUX	O
altered	O	VERB	O
by	O	ADP	O
clarithromycin	B-I	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
CYP2D6	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
dextromethorphan	B-OUT	NOUN	B
to	I-OUT	PART	O
dextrorphan	I-OUT	NOUN	B
urinary	I-OUT	ADJ	O
ratio	I-OUT	NOUN	O
was	O	AUX	O
not	O	PART	O
significantly	B-OUT	ADV	O
different	I-OUT	ADJ	O
before	O	ADP	O
(	O	PUNCT	O
0.021	O	NUM	O
+/-	O	CCONJ	O
0.04	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
(	O	PUNCT	O
0.024	O	NUM	O
+/-	O	CCONJ	O
0.06	O	NUM	O
)	O	PUNCT	O
clarithromycin	B-I	NOUN	B
dosing	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
clarithromycin	B-I	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
alter	O	VERB	O
the	O	DET	O
in	O	X	B
vivo	B-OUT	X	I
catalytic	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
of	O	ADP	O
CYP1A2	O	NOUN	B
,	O	PUNCT	O
CYP2C9	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
CYP2D6	O	NOUN	B
in	O	ADP	O
healthy	O	ADJ	B
individuals	O	NOUN	B
as	O	ADP	O
assessed	O	VERB	B
by	O	ADP	O
caffeine	O	NOUN	B
,	O	PUNCT	O
tolbutamide	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
dextromethorphan	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Influence	O	NOUN	B
of	O	ADP	O
infusion	B-P	NOUN	B
time	I-P	NOUN	B
on	O	ADP	O
the	O	DET	O
acute	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
of	I-OUT	ADP	O
amphotericin	I-OUT	NOUN	B
B	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
lunar	B-I	ADJ	B
stent	I-I	NOUN	B
characteristics	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
results	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
frequent	O	ADJ	B
long-term	O	ADJ	B
complications	O	NOUN	B
after	O	ADP	O
stent	B-I	ADJ	B
implantation	I-I	NOUN	B
is	O	AUX	O
restenosis	O	NOUN	B
due	O	ADJ	O
to	O	ADP	O
the	O	DET	O
building	O	NOUN	B
up	O	ADP	I
of	O	ADP	O
a	O	DET	O
neointima	O	NOUN	B
within	O	ADP	O
the	O	DET	O
artery	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
endovascular	O	ADJ	B
hyperplasia	O	NOUN	I
(	O	PUNCT	O
tissue	O	NOUN	B
growth	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
interesting	O	ADJ	O
feature	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Lunar	B-I	PROPN	B
stent	I-I	NOUN	I
from	I-I	ADP	O
Inflow	I-I	PROPN	B
Dynamics	I-I	PROPN	I
is	O	AUX	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
coated	O	VERB	B
with	O	ADP	O
a	O	DET	O
layer	O	NOUN	B
of	O	ADP	O
iridium	O	NOUN	B
oxide	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
iridium	B-I	NOUN	B
oxide	I-I	NOUN	I
coating	O	NOUN	B
is	O	AUX	O
believed	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
restenosis	B-OUT	NOUN	B
by	O	ADP	O
decreasing	O	VERB	B
the	O	DET	O
inflammatory	B-OUT	ADJ	B
response	I-OUT	NOUN	I
to	O	PART	O
the	O	DET	O
stent	O	NOUN	B
via	O	ADP	O
its	O	PRON	O
antioxidant	O	ADJ	B
action	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
MOONLIGHT	B-P	PROPN	B
(	I-P	PUNCT	O
Multicenter	I-P	PROPN	B
Objective	I-P	ADJ	O
ObservatioNal	I-P	PROPN	O
Lunar	I-I	PROPN	O
Iridiumoxide	I-I	PROPN	O
intimal	I-P	ADJ	O
GrowtH	I-P	PROPN	O
Trial	I-P	NOUN	O
)	I-P	PUNCT	O
study	I-P	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
immediate	O	ADJ	B
outcome	O	NOUN	B
and	O	CCONJ	O
long-term	O	ADJ	B
angiographic	O	ADJ	B
success	O	NOUN	I
after	O	ADP	O
implantation	B-I	NOUN	B
of	I-I	ADP	O
Lunar	I-I	PROPN	B
stents	I-I	NOUN	I
.	I-I	PUNCT	O


Between	B-P	ADP	O
March	I-P	PROPN	O
2001	I-P	NUM	O
and	I-P	CCONJ	O
November	I-P	PROPN	O
2001	I-P	NUM	O
,	I-P	PUNCT	O
87	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
99	I-P	NUM	O
lesions	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
this	I-P	DET	O
study	I-P	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
12	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
mm	O	NOUN	O
long	O	ADJ	O
iridium-oxide	B-I	ADJ	B
coated	I-I	VERB	I
Lunar	I-I	PROPN	B
stents	I-I	NOUN	I
.	I-I	PUNCT	O


Delivery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Lunar	B-I	PROPN	B
stent	I-I	NOUN	I
was	O	AUX	O
successful	O	ADJ	O
in	O	ADP	O
most	O	ADJ	O
lesions	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
optimal	O	ADJ	B
radiopacity	O	NOUN	B
facilitated	O	VERB	O
optimal	O	ADJ	B
stent	B-OUT	NOUN	B
positioning	I-OUT	VERB	B
with	O	ADP	O
optimal	O	ADJ	B
immediate	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
angiographic	O	ADJ	B
results	O	NOUN	B
is	O	AUX	O
an	O	DET	O
unselected	O	ADJ	O
patient	O	NOUN	B
and	O	CCONJ	O
lesion	O	NOUN	B
population	O	NOUN	I
.	O	PUNCT	O


Preliminary	O	ADJ	B
clinical	O	ADJ	B
and	O	CCONJ	O
angiographic	O	ADJ	B
follow-up	O	NOUN	B
show	O	VERB	O
a	O	DET	O
low	O	ADJ	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
cardiac	I-OUT	ADJ	B
events	I-OUT	NOUN	I
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
16.1	O	NUM	O
%	O	NOUN	O
MACE	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
moderate	O	ADJ	B
hyperplastic	B-OUT	ADJ	B
response	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Intravesical	B-I	ADJ	B
seeding	I-I	NOUN	I
of	I-I	ADP	O
upper	I-I	ADJ	B
urinary	I-I	ADJ	I
tract	I-I	NOUN	I
urothelial	I-I	ADJ	I
carcinoma	I-I	NOUN	I
cells	I-I	NOUN	O
during	O	ADP	O
nephroureterectomy	B-I	NOUN	B
:	I-I	PUNCT	O
an	O	DET	O
exploratory	O	ADJ	B
analysis	O	NOUN	I
from	O	ADP	O
the	O	DET	O
THPMG	O	NOUN	B
trial	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
Pirarubicin	O	NOUN	B
Monotherapy	O	PROPN	I
Study	O	PROPN	O
Group	O	PROPN	B
trial	O	NOUN	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
Phase	O	NOUN	I
II	O	NUM	I
study	O	NOUN	B
that	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
intravesical	O	ADJ	B
instillation	O	NOUN	I
of	O	ADP	O
pirarubicin	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
bladder	O	ADJ	B
recurrence	O	NOUN	B
after	O	ADP	O
nephroureterectomy	B-P	NOUN	B
for	I-P	ADP	O
upper	I-P	ADJ	B
urinary	I-P	ADJ	I
tract	I-P	NOUN	I
urothelial	I-P	ADJ	I
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
conducted	O	VERB	O
further	O	ADJ	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Pirarubicin	O	PROPN	B
Monotherapy	O	PROPN	I
Study	O	PROPN	O
Group	O	PROPN	B
cohort	O	NOUN	B
,	O	PUNCT	O
focusing	O	VERB	O
on	O	ADP	O
intravesical	B-I	ADJ	B
seeding	I-I	NOUN	I
of	I-I	ADP	O
cancer	I-I	NOUN	B
cells	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	NOUN	O
Using	O	VERB	O
the	O	DET	O
data	B-P	NOUN	B
from	I-P	ADP	O
the	I-P	DET	O
Pirarubicin	I-P	PROPN	B
Monotherapy	I-P	PROPN	I
Study	I-P	PROPN	O
Group	I-P	PROPN	B
trial	I-P	NOUN	I
,	O	PUNCT	O
bladder	B-OUT	NOUN	B
recurrence-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
factors	I-OUT	NOUN	B
associated	I-OUT	VERB	B
with	I-OUT	ADP	I
bladder	I-OUT	NOUN	B
recurrence	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Of	O	ADP	O
36	B-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
control	I-I	NOUN	B
group	I-P	NOUN	I
,	I-P	PUNCT	O
14	I-P	NUM	O
with	I-P	ADP	O
positive	I-OUT	ADJ	B
urine	I-OUT	NOUN	B
cytology	I-OUT	NOUN	I
had	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
recurrence	B-OUT	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
22	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
negative	I-P	ADJ	B
cytology	I-P	NOUN	I
(	I-P	PUNCT	O
P	I-P	NOUN	O
=	I-P	ADJ	O
0.004	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
the	O	DET	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
voided	O	VERB	B
urine	O	NOUN	B
cytology	O	NOUN	I
was	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
predictive	O	ADJ	B
factor	O	NOUN	I
of	O	ADP	O
bladder	O	NOUN	B
recurrence	O	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
5.54	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.12-27.5	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.036	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	O	ADP	O
72	B-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
Pirarubicin	I-P	NOUN	B
Monotherapy	I-P	PROPN	I
Study	I-P	PROPN	O
Group	I-P	PROPN	B
trial	I-P	NOUN	I
,	O	PUNCT	O
31	O	NUM	O
had	O	AUX	O
positive	O	ADJ	B
urine	B-OUT	NOUN	B
cytology	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Among	B-P	ADP	O
the	I-P	DET	O
31	I-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
17	I-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
pirarubicin	I-I	NOUN	B
instillation	I-I	NOUN	B
had	O	AUX	O
fewer	O	ADJ	O
recurrences	B-OUT	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
14	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
control	I-I	ADJ	B
treatment	I-P	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


On	O	ADP	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
pirarubicin	B-I	NOUN	B
instillation	I-I	NOUN	B
was	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
better	O	ADJ	O
recurrence-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	O
rates	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
positive	O	ADJ	B
urine	O	NOUN	O
cytology	O	NOUN	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.02	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.00-0.53	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.018	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	O	ADP	O
21	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
bladder	O	NOUN	B
recurrence	O	NOUN	B
,	O	PUNCT	O
17	O	NUM	O
had	O	AUX	O
recurrent	B-OUT	ADJ	B
tumor	I-OUT	NOUN	I
around	I-OUT	ADP	O
cystotomy	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
bladder	I-OUT	NOUN	B
neck	I-OUT	NOUN	B
compromised	O	VERB	O
by	O	ADP	O
the	O	DET	O
urethral	O	ADJ	B
catheter	O	NOUN	I
,	O	PUNCT	O
supporting	O	VERB	O
the	O	DET	O
notion	O	NOUN	O
that	O	SCONJ	O
tumor	O	NOUN	B
cells	O	NOUN	I
seeded	O	VERB	B
in	O	ADP	O
the	O	DET	O
injured	O	VERB	B
urothelium	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Intravesical	B-I	ADJ	B
instillation	I-I	NOUN	I
of	I-I	ADP	O
pirarubicin	I-I	NOUN	B
immediately	O	ADV	O
after	O	ADP	O
nephroureterectomy	B-I	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	O
the	O	DET	O
bladder	B-OUT	NOUN	B
recurrence	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
positive	O	ADJ	B
voided	O	ADJ	B
urine	O	NOUN	O
cytology	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
intravesical	O	ADJ	B
seeding	O	NOUN	I
of	O	ADP	O
upper	O	ADJ	B
urinary	O	ADJ	I
tract	O	NOUN	I
urothelial	O	ADJ	I
carcinoma	O	NOUN	I
occurs	O	VERB	O
during	O	ADP	O
nephroureterectomy	O	NOUN	B
.	O	PUNCT	O


Dexamethasone	B-I	NOUN	B
versus	I-I	CCONJ	O
prednisone	I-I	NOUN	B
and	O	CCONJ	O
daily	O	ADV	B
oral	O	ADJ	B
versus	O	CCONJ	O
weekly	O	ADJ	B
intravenous	B-I	ADJ	B
mercaptopurine	I-I	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
standard-risk	I-P	ADJ	B
acute	I-P	ADJ	B
lymphoblastic	I-P	ADJ	I
leukemia	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
report	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
's	O	PART	I
Cancer	O	PROPN	I
Group	O	PROPN	I
.	O	PUNCT	O


Conventional	B-I	ADJ	B
therapy	I-I	NOUN	I
for	O	ADP	O
childhood	B-P	NOUN	B
acute	I-P	ADJ	I
lymphoblastic	I-P	ADJ	I
leukemia	I-P	NOUN	I
(	I-P	PUNCT	O
ALL	I-P	NOUN	B
)	I-P	PUNCT	O
includes	O	VERB	O
prednisone	B-I	NOUN	B
and	I-I	CCONJ	O
oral	I-I	ADJ	B
6-mercaptopurine	I-I	NOUN	I
.	I-I	PUNCT	O


Prior	O	ADJ	O
observations	O	NOUN	B
suggested	O	VERB	O
potential	O	ADJ	O
advantages	O	NOUN	O
for	O	ADP	O
dexamethasone	B-I	NOUN	B
over	I-I	ADP	O
prednisone	I-I	NOUN	B
and	I-I	CCONJ	O
for	I-I	ADP	O
intravenous	I-I	ADJ	B
(	I-I	PUNCT	O
IV	I-I	NUM	B
)	I-I	PUNCT	O
over	I-I	ADP	O
oral	I-I	ADJ	B
6-mercaptopurine	I-I	NOUN	I
,	O	PUNCT	O
which	O	DET	O
remain	O	VERB	O
to	O	PART	O
be	O	AUX	O
validated	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
more	B-P	ADJ	O
than	I-P	ADP	O
1000	I-P	NUM	O
subjects	I-P	NOUN	B
that	O	PRON	O
examined	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
dexamethasone	B-I	NOUN	B
and	I-I	CCONJ	O
IV	I-I	NUM	B
6-mercaptopurine	I-I	NOUN	I
.	I-I	PUNCT	O


Children	B-P	NOUN	B
with	I-P	ADP	O
National	I-P	PROPN	B
Cancer	I-P	PROPN	I
Institute	I-P	PROPN	I
standard-risk	I-P	ADJ	O
ALL	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
in	O	ADP	O
a	O	DET	O
2	O	NUM	O
x	O	NOUN	O
2	O	NUM	O
factorial	O	ADJ	O
design	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
dexamethasone	B-I	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/d	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
28	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
induction	O	NOUN	B
,	O	PUNCT	O
plus	B-I	CCONJ	O
taper	I-I	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
prednisone	B-I	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/d	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
randomized	O	ADJ	B
assignment	O	NOUN	B
was	O	AUX	O
for	O	ADP	O
daily	O	ADJ	B
oral	O	ADJ	B
or	O	CCONJ	O
weekly	O	ADJ	B
IV	B-I	NUM	B
6-mercaptopurine	I-I	NOUN	I
during	O	ADP	O
consolidation	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
maintenance	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
the	O	DET	O
randomized	O	ADJ	B
steroid	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
monthly	O	ADV	B
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
dose	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
daily	O	ADV	B
oral	B-I	ADJ	B
6-mercaptopurine	I-I	NOUN	I
.	I-I	PUNCT	O


During	O	ADP	O
delayed	O	VERB	B
intensification	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
dexamethasone	B-I	NOUN	B
dosage	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/d	O	NOUN	O
for	O	ADP	O
21	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
with	B-I	ADP	O
taper	I-I	NOUN	B
.	I-I	PUNCT	O


Intrathecal	B-I	NOUN	B
(	I-I	PUNCT	O
IT	I-I	NOUN	B
)	I-I	PUNCT	O
methotrexate	I-I	NOUN	B
was	O	AUX	O
the	O	DET	O
sole	O	ADJ	O
central	O	ADJ	B
nervous	O	ADJ	I
system-directed	O	ADJ	I
therapy	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
dexamethasone	B-I	NOUN	B
had	O	AUX	O
a	O	DET	O
6-year	B-OUT	ADJ	O
isolated	I-OUT	VERB	B
central	I-OUT	ADJ	B
nervous	I-OUT	ADJ	I
system-relapse	I-OUT	ADJ	I
rate	I-OUT	NOUN	B
of	O	ADP	O
3.7	O	NUM	O
%	O	NOUN	O
+/-	O	CCONJ	O
0.8	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
7.1	O	NUM	O
%	O	NOUN	O
+/-	O	CCONJ	O
1.1	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
prednisone	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.01	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
also	O	ADV	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
fewer	O	ADJ	O
isolated	B-OUT	VERB	B
bone	I-OUT	NOUN	B
marrow	I-OUT	NOUN	I
relapses	I-OUT	NOUN	B
with	O	ADP	O
dexamethasone	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
6-year	B-OUT	ADJ	O
event-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
EFS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
85	O	NUM	O
%	O	NOUN	O
+/-	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
dexamethasone	B-I	NOUN	B
and	O	CCONJ	O
77	O	NUM	O
%	O	NOUN	O
+/-	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
prednisone	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.002	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


EFS	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
with	O	ADP	O
oral	B-I	ADJ	B
or	I-I	CCONJ	O
IV	I-I	NUM	B
6-mercaptopurine	I-I	NOUN	I
;	I-I	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
assigned	O	VERB	O
to	O	PART	O
IV	B-I	NUM	B
6-mercaptopurine	I-I	NOUN	I
had	O	AUX	O
decreased	O	VERB	B
survival	B-OUT	NOUN	B
after	I-OUT	ADP	O
relapse	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Psychological	B-I	ADJ	B
adjustment	I-I	NOUN	B
and	I-I	CCONJ	O
levels	I-I	NOUN	B
of	I-I	ADP	O
self	I-I	NOUN	B
esteem	I-I	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
visual-motor	I-P	ADJ	B
integration	I-P	NOUN	I
difficulties	I-P	NOUN	I
influences	O	VERB	B
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
intervention	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
evaluates	O	VERB	O
how	O	SCONJ	O
much	O	ADJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
intervention	O	NOUN	B
programs	O	NOUN	I
are	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
pre-existing	B-P	ADJ	B
psychological	I-P	ADJ	B
adjustment	I-P	NOUN	O
and	I-P	CCONJ	O
self-esteem	I-P	ADJ	B
levels	I-P	NOUN	I
in	I-P	ADP	O
kindergarten	I-P	NOUN	B
and	I-P	CCONJ	O
first	I-P	ADJ	O
grade	I-P	NOUN	O
children	I-P	NOUN	B
with	I-P	ADP	O
poor	I-P	ADJ	O
visual-motor	I-P	ADJ	O
integration	I-P	NOUN	O
skills	I-P	NOUN	O
,	I-P	PUNCT	O
from	I-P	ADP	O
low	I-P	ADJ	B
socioeconomic	I-P	ADJ	B
backgrounds	I-P	NOUN	I
.	I-P	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
sixteen	I-P	NUM	O
mainstream	I-P	ADJ	B
kindergarten	I-P	NOUN	I
and	I-P	CCONJ	O
first-grade	I-P	ADJ	B
children	I-P	NOUN	I
,	I-P	PUNCT	O
from	I-P	ADP	O
low	I-P	ADJ	B
socioeconomic	I-P	ADJ	B
backgrounds	I-P	NOUN	I
,	I-P	PUNCT	O
scoring	I-P	VERB	B
below	I-P	ADP	O
the	I-P	DET	O
25th	I-P	ADJ	O
percentile	I-P	NOUN	B
on	I-P	ADP	O
a	I-P	DET	O
measure	I-P	NOUN	B
of	I-P	ADP	O
visual-motor	I-P	ADJ	B
integration	I-P	NOUN	I
(	I-P	PUNCT	O
VMI	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
recruited	I-P	VERB	O
and	O	CCONJ	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
parallel	O	ADJ	O
intervention	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
intervention	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
directive	B-I	ADJ	B
visual-motor	I-I	ADJ	I
intervention	I-I	NOUN	I
(	I-I	PUNCT	O
DVMI	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
second	O	ADJ	O
intervention	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
a	O	DET	O
non-directive	B-I	ADJ	B
supportive	I-I	ADJ	O
intervention	I-I	NOUN	O
(	I-I	PUNCT	O
NDSI	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Tests	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
to	O	PART	O
evaluate	O	VERB	B
visual-motor	O	ADJ	B
integration	O	NOUN	O
skills	O	NOUN	O
outcome	O	NOUN	O
.	O	PUNCT	O


Children	O	NOUN	B
with	O	ADP	O
higher	O	ADJ	O
baseline	O	NOUN	B
measures	O	NOUN	B
of	O	ADP	O
psychological	O	ADJ	B
adjustment	O	NOUN	B
and	O	CCONJ	O
self-esteem	O	ADJ	B
responded	O	VERB	O
better	O	ADV	O
in	O	ADP	O
NDSI	B-I	PROPN	B
while	O	SCONJ	O
children	O	NOUN	B
with	O	ADP	O
lower	O	ADJ	O
baseline	O	NOUN	B
performance	O	NOUN	B
on	O	ADP	O
psychological	O	ADJ	B
adjustment	O	NOUN	B
and	O	CCONJ	O
self-esteem	O	ADJ	B
responded	O	VERB	O
better	O	ADV	O
in	O	ADP	O
DVMI	B-I	PROPN	B
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
children	O	NOUN	B
from	O	ADP	O
low	O	ADJ	B
socioeconomic	O	ADJ	B
backgrounds	O	NOUN	I
with	O	ADP	O
low	O	ADJ	B
VMI	O	PROPN	B
performance	O	NOUN	O
scores	O	NOUN	O
will	O	AUX	O
benefit	O	VERB	B
more	O	ADV	O
from	O	ADP	O
intervention	O	NOUN	B
programs	O	NOUN	I
if	O	SCONJ	O
clinicians	O	NOUN	B
choose	O	VERB	O
the	O	DET	O
type	O	NOUN	B
of	O	ADP	O
intervention	O	NOUN	B
according	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
psychological	O	ADJ	B
adjustment	O	NOUN	B
and	O	CCONJ	O
self-esteem	O	ADJ	B
measures	O	NOUN	I
.	O	PUNCT	O


Absolute	O	ADJ	B
bioavailability	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
high	O	ADJ	B
dose	O	NOUN	I
methylprednisolone	B-I	ADJ	B
tablet	O	NOUN	B
formulation	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
a	O	DET	O
single-blind	O	ADJ	B
,	O	PUNCT	O
single-dose	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
crossover	O	NOUN	I
study	O	NOUN	I
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
absolute	B-OUT	ADJ	B
bioavailability	I-OUT	NOUN	B
of	O	ADP	O
Medrol	B-I	PROPN	B
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
high	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
methylprednisolone	B-I	ADJ	B
tablet	O	NOUN	O
product	O	NOUN	O
,	O	PUNCT	O
by	O	ADP	O
comparing	O	VERB	B
it	O	PRON	O
with	O	ADP	O
100	O	NUM	O
mg	O	NOUN	O
methylprednisolone	B-I	NOUN	B
from	O	ADP	O
an	O	DET	O
intravenous	O	ADJ	B
formulation	O	NOUN	I
,	O	PUNCT	O
Solu-Medrol	B-I	NOUN	B
.	I-I	PUNCT	O


Fourteen	B-P	NUM	O
healthy	I-P	ADJ	B
,	I-P	PUNCT	O
non-smoking	I-P	ADJ	B
,	I-P	PUNCT	O
Caucasian	I-P	ADJ	B
male	I-P	NOUN	B
volunteers	I-P	NOUN	B
took	O	VERB	O
part	O	NOUN	O
.	O	PUNCT	O


On	O	ADP	O
treatment	O	NOUN	B
days	O	NOUN	O
volunteers	O	NOUN	B
remained	O	VERB	O
recumbent	O	ADJ	B
for	O	ADP	O
4	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
drug	O	NOUN	B
administration	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
food	O	NOUN	B
and	O	CCONJ	O
fluid	O	ADJ	B
intake	O	NOUN	O
standardized	O	VERB	B
over	O	ADP	O
this	O	DET	O
period	O	NOUN	B
.	O	PUNCT	O


Serial	O	ADJ	B
blood	O	NOUN	I
samples	O	NOUN	I
were	O	AUX	O
drawn	O	VERB	O
over	O	ADP	O
a	O	DET	O
14-hour	O	ADJ	O
period	O	NOUN	B
after	O	ADP	O
drug	O	NOUN	B
administration	O	NOUN	I
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
methylprednisolone	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
high	O	ADJ	B
performance	O	NOUN	I
liquid	O	ADJ	I
chromatography	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
geometric	O	ADJ	B
means	O	NOUN	O
of	O	ADP	O
AUCi.v	B-OUT	PROPN	B
.	I-OUT	PUNCT	O


and	B-OUT	CCONJ	O
AUCtablet	I-OUT	PROPN	B
were	O	AUX	O
4,049	O	NUM	O
and	O	CCONJ	O
3,334	O	NUM	O
ng.h/ml	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
absolute	B-OUT	ADJ	B
bioavailability	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
tablet	O	NOUN	B
product	O	NOUN	B
was	O	AUX	O
82	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
in	O	ADP	O
agreement	O	NOUN	O
with	O	ADP	O
published	O	VERB	B
data	O	NOUN	I
for	O	ADP	O
other	O	ADJ	O
oral	O	ADJ	B
dosage	O	NOUN	I
forms	O	NOUN	O
of	O	ADP	O
methylprednisolone	B-I	NOUN	B
.	I-I	PUNCT	O


Volunteers	O	NOUN	B
displayed	O	VERB	O
the	O	DET	O
expected	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
peripheral	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
neutrophil	I-OUT	NOUN	O
count	I-OUT	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
other	O	ADJ	O
clinically	B-OUT	ADV	B
relevant	I-OUT	ADJ	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
hematology	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
clinical	I-OUT	ADJ	B
chemistry	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


No	O	DET	B
adverse	B-OUT	ADJ	I
drug	I-OUT	NOUN	O
reactions	I-OUT	NOUN	O
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
tablet	O	NOUN	B
product	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
substitute	O	NOUN	O
for	O	ADP	O
parenteral	O	ADJ	B
methylprednisolone	B-I	NOUN	I
in	O	ADP	O
situations	O	NOUN	O
requiring	O	VERB	O
high-dose	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Oxytocin	B-I	NOUN	B
increases	O	VERB	B
eye	B-OUT	NOUN	B
contact	I-OUT	NOUN	O
during	O	ADP	O
a	O	DET	O
real-time	O	ADJ	B
,	O	PUNCT	O
naturalistic	O	ADJ	B
social	O	ADJ	B
interaction	O	NOUN	I
in	O	ADP	O
males	B-P	NOUN	B
with	I-P	ADP	O
and	I-P	CCONJ	O
without	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
conditions	I-P	NOUN	I
(	I-P	PUNCT	O
autism	I-P	NOUN	B
)	I-P	PUNCT	O
affect	O	VERB	O
~1	O	NOUN	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
population	O	NOUN	B
and	O	CCONJ	O
are	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
deficits	O	NOUN	B
in	O	ADP	O
social	O	ADJ	B
communication	O	NOUN	I
.	O	PUNCT	O


Oxytocin	B-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
widely	O	ADV	O
reported	O	VERB	O
to	O	PART	O
affect	O	VERB	O
social-communicative	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
neural	O	ADJ	B
underpinnings	O	NOUN	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
first	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
intranasal	B-I	ADJ	B
oxytocin	I-I	NOUN	B
administration	O	NOUN	B
improves	O	VERB	B
a	O	DET	O
core	O	NOUN	B
problem	O	NOUN	I
that	O	SCONJ	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
have	O	AUX	O
in	O	ADP	O
using	B-OUT	VERB	O
eye	I-OUT	NOUN	B
contact	I-OUT	NOUN	I
appropriately	O	ADV	O
in	O	ADP	O
real-world	O	ADJ	B
social	O	ADJ	B
settings	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
within-subjects	O	ADJ	O
design	O	NOUN	B
is	O	AUX	O
used	O	VERB	O
to	O	PART	O
examine	O	VERB	O
how	O	SCONJ	O
intranasal	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
24	B-I	NUM	O
IU	I-I	NOUN	B
of	I-I	ADP	O
oxytocin	I-I	NOUN	B
affects	I-OUT	VERB	O
gaze	I-OUT	NOUN	B
behavior	I-OUT	NOUN	B
for	I-P	ADP	O
32	I-P	NUM	O
adult	I-P	ADJ	B
males	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
and	I-P	CCONJ	O
34	I-P	NUM	O
controls	I-P	NOUN	B
in	I-P	ADP	O
a	I-P	DET	O
real-time	I-P	ADJ	B
interaction	I-P	NOUN	B
with	O	ADP	O
a	O	DET	O
researcher	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
interactive	O	ADJ	B
paradigm	O	NOUN	B
bypasses	O	VERB	O
many	O	ADJ	O
of	O	ADP	O
the	O	DET	O
limitations	O	NOUN	B
encountered	O	VERB	O
with	O	ADP	O
conventional	O	ADJ	B
static	O	ADJ	B
or	O	CCONJ	O
computer-based	O	ADJ	B
stimuli	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Eye	B-OUT	ADJ	B
movements	I-OUT	NOUN	B
are	O	AUX	O
recorded	O	VERB	O
using	O	VERB	O
eye	O	NOUN	B
tracking	O	NOUN	I
,	O	PUNCT	O
providing	O	VERB	O
an	O	DET	O
objective	O	ADJ	O
measurement	O	NOUN	B
of	O	ADP	O
looking	O	VERB	O
patterns	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
measure	O	NOUN	B
is	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
sensitive	O	ADJ	B
to	O	PART	O
the	O	DET	O
reduced	B-OUT	VERB	B
eye	I-OUT	NOUN	B
contact	I-OUT	NOUN	O
commonly	O	ADV	O
reported	O	VERB	O
in	O	ADP	O
autism	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
autism	O	NOUN	B
group	O	NOUN	B
spending	O	NOUN	O
less	O	ADJ	O
time	O	NOUN	O
looking	O	VERB	O
to	O	ADP	O
the	O	DET	O
eye	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
face	O	NOUN	B
than	O	ADP	O
controls	B-I	NOUN	B
.	I-I	PUNCT	O


Oxytocin	B-I	NOUN	B
administration	O	NOUN	B
selectively	O	ADV	O
enhanced	B-OUT	VERB	B
gaze	I-OUT	NOUN	B
to	I-OUT	ADP	O
the	I-OUT	DET	O
eyes	I-OUT	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
autism	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
transformed	O	VERB	O
mean	B-OUT	ADJ	O
eye-fixation	I-OUT	NOUN	O
difference	I-OUT	NOUN	O
per	I-OUT	ADP	O
second=0.082	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI:0.025-0.14	O	PROPN	B
,	O	PUNCT	O
P=0.006	O	PROPN	O
)	O	PUNCT	O
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
autism	O	NOUN	B
group	O	NOUN	O
,	O	PUNCT	O
oxytocin	O	NOUN	B
has	O	AUX	O
the	O	DET	O
most	O	ADJ	O
effect	O	NOUN	B
on	B-OUT	ADP	O
fixation	I-OUT	NOUN	B
duration	I-OUT	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
impaired	O	ADJ	B
levels	O	NOUN	B
of	B-OUT	ADP	O
eye	I-OUT	NOUN	B
contact	I-OUT	NOUN	O
at	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
Cohen	O	PROPN	B
's	O	PART	I
d=0.86	O	PROPN	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
potential	O	ADJ	B
benefits	O	NOUN	B
of	O	ADP	O
oxytocin	O	NOUN	B
in	O	ADP	O
autism	O	NOUN	B
extend	O	VERB	O
to	O	PART	O
a	O	DET	O
real-time	O	ADJ	B
interaction	O	NOUN	I
,	O	PUNCT	O
providing	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
therapeutic	O	ADJ	B
effect	O	NOUN	I
in	O	ADP	O
a	O	DET	O
key	O	ADJ	O
aspect	O	NOUN	O
of	O	ADP	O
social	O	ADJ	B
communication	O	NOUN	I
.	O	PUNCT	O


Brain	O	NOUN	B
mechanisms	O	NOUN	B
of	O	ADP	O
expectation	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
insula	B-P	NOUN	B
and	I-P	CCONJ	O
amygdala	I-P	NOUN	B
response	O	NOUN	I
to	O	PART	O
aversive	O	ADJ	B
taste	O	NOUN	I
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
experience	O	NOUN	B
of	O	ADP	O
aversion	O	NOUN	B
is	O	AUX	O
shaped	O	VERB	O
by	O	ADP	O
multiple	O	ADJ	B
physiological	O	ADJ	B
and	O	CCONJ	O
psychological	O	ADJ	B
factors	O	NOUN	I
including	O	VERB	O
one	O	NUM	O
's	O	PART	O
expectations	O	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
work	O	NOUN	O
has	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
expectancy	O	NOUN	B
manipulation	O	NOUN	B
can	O	AUX	O
alter	O	VERB	O
perceptions	O	NOUN	B
of	O	ADP	O
aversive	O	ADJ	B
events	O	NOUN	I
and	O	CCONJ	O
concomitant	O	ADJ	B
brain	O	NOUN	B
activation	O	NOUN	I
.	O	PUNCT	O


Accruing	O	NOUN	B
evidence	O	NOUN	B
indicates	O	VERB	O
a	O	DET	O
primary	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
altered	O	ADJ	O
expectancies	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
probed	O	VERB	O
the	O	DET	O
mechanism	O	NOUN	B
by	O	ADP	O
which	O	DET	O
expectation	O	NOUN	O
attenuates	O	VERB	B
sensory	O	ADJ	B
taste	O	NOUN	I
transmission	O	NOUN	O
by	O	ADP	O
examining	O	VERB	O
how	O	SCONJ	O
brain	B-P	NOUN	B
areas	I-P	NOUN	I
activated	I-P	VERB	B
by	I-P	ADP	O
misleading	I-I	VERB	O
information	I-I	NOUN	B
during	I-P	ADP	O
an	I-P	DET	O
expectancy	I-P	NOUN	B
period	I-P	NOUN	B
modulate	O	VERB	B
insula	O	NOUN	B
and	O	CCONJ	O
amygdala	O	NOUN	B
activation	O	NOUN	I
to	O	PART	O
a	O	DET	O
highly	B-I	ADV	O
aversive	I-I	ADJ	B
bitter	I-I	ADJ	B
taste	I-I	NOUN	I
.	I-I	PUNCT	O


In	O	ADP	O
a	O	DET	O
rapid	O	ADJ	O
event-related	O	ADJ	B
fMRI	B-I	NOUN	B
design	I-I	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
showed	O	VERB	O
that	O	SCONJ	O
activations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rostral	B-P	ADJ	B
anterior	I-P	ADJ	I
cingulate	I-P	NOUN	I
cortex	I-P	NOUN	I
(	I-P	PUNCT	O
rACC	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
orbitofrontal	I-P	ADJ	B
cortex	I-P	NOUN	I
(	I-P	PUNCT	O
OFC	I-P	PROPN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
dorsolateral	I-P	ADJ	B
prefrontal	I-P	ADJ	B
cortex	I-P	NOUN	I
to	O	ADP	O
a	O	DET	O
misleading	O	ADJ	O
cue	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
taste	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
mildly	O	ADV	B
aversive	O	ADJ	B
predicted	O	VERB	O
decreases	O	VERB	B
in	O	ADP	O
insula	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
amygdala	I-OUT	NOUN	B
activation	I-OUT	NOUN	I
to	O	PART	O
the	O	DET	O
highly	O	ADV	O
aversive	O	ADJ	B
taste	O	NOUN	I
.	O	PUNCT	O


OFC	O	NOUN	B
and	O	CCONJ	O
rACC	O	NOUN	B
activation	O	NOUN	B
to	O	ADP	O
the	O	DET	O
misleading	B-I	ADJ	O
cue	I-I	NOUN	B
were	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
less	O	ADV	O
aversive	B-OUT	ADJ	B
ratings	I-OUT	NOUN	I
of	I-OUT	ADP	O
that	I-OUT	DET	O
taste	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Additional	O	ADJ	O
analyses	O	NOUN	B
revealed	O	VERB	O
consistent	O	ADJ	O
results	O	NOUN	O
demonstrating	O	VERB	O
functional	O	ADJ	B
connectivity	O	NOUN	O
among	O	ADP	O
the	O	DET	O
OFC	O	PROPN	B
,	O	PUNCT	O
rACC	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
insula	O	NOUN	B
.	O	PUNCT	O


Altering	O	VERB	B
expectancies	O	NOUN	O
of	O	ADP	O
upcoming	O	VERB	O
aversive	O	ADJ	B
events	O	NOUN	I
are	O	AUX	O
shown	O	VERB	O
here	O	ADV	O
to	O	PART	O
depend	O	VERB	O
on	O	ADP	O
robust	O	ADJ	B
functional	O	ADJ	B
associations	O	NOUN	B
among	O	ADP	O
brain	O	NOUN	B
regions	O	NOUN	I
implicated	O	VERB	O
in	O	ADP	O
prior	O	ADJ	O
work	O	NOUN	O
on	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
mid-term	O	ADJ	B
results	O	NOUN	O
of	O	ADP	O
stapled	B-I	VERB	B
versus	I-I	CCONJ	O
open	I-I	ADJ	O
hemorrhoidectomy	I-I	NOUN	O
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
new	O	ADJ	O
technique	O	NOUN	B
of	O	ADP	O
circular	O	ADJ	B
stapler	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
hemorrhoids	B-P	NOUN	B
has	O	AUX	O
shown	O	VERB	O
early	O	ADJ	O
promise	O	NOUN	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
minimal	O	ADJ	B
or	O	CCONJ	O
no	O	DET	O
postoperative	O	ADJ	B
pain	O	NOUN	I
,	O	PUNCT	O
early	O	ADJ	B
discharge	O	NOUN	I
from	O	ADP	O
hospital	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
quick	O	ADJ	O
return	O	NOUN	B
to	O	ADP	I
work	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
stapled	B-I	ADJ	B
technique	I-I	NOUN	I
with	I-I	ADP	O
the	I-I	DET	O
well-accepted	I-I	ADJ	O
conventional	I-I	ADJ	O
Milligan	I-I	PROPN	B
Morgan	I-I	PROPN	I
hemorrhoidectomy	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	NOUN	O
After	O	ADP	O
fulfilling	O	VERB	O
the	O	DET	O
selection	O	NOUN	B
criteria	O	NOUN	I
,	O	PUNCT	O
84	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
allocated	I-P	VERB	O
to	I-P	ADP	O
the	I-P	DET	O
stapled	I-I	ADJ	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
42	I-P	NUM	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
open	I-I	ADJ	B
group	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
42	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


All	B-P	DET	O
patients	I-P	NOUN	B
were	I-P	AUX	O
operated	I-P	VERB	O
on	I-P	ADP	O
under	I-P	ADP	O
spinal	I-I	ADJ	B
anesthesia	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
2	O	NUM	O
techniques	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
operative	B-OUT	ADJ	B
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
complications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
day	I-OUT	NOUN	B
of	I-OUT	ADP	O
discharge	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
return	I-OUT	VERB	B
to	I-OUT	ADP	I
work	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
satisfaction	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
mean	B-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
patients	I-P	NOUN	B
was	I-P	AUX	O
46.02	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
SD	I-P	NOUN	B
,	I-P	PUNCT	O
12.33	I-P	NUM	O
)	I-P	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
stapled	I-P	ADJ	B
group	I-P	NOUN	I
and	I-P	CCONJ	O
48.64	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
14.57	I-P	NUM	O
)	I-P	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
open	I-P	ADJ	B
group	I-P	NOUN	I
.	I-P	PUNCT	O


Grade	B-OUT	NOUN	B
III	I-OUT	NUM	I
or	I-OUT	CCONJ	I
IV	I-OUT	NUM	I
hemorrhoids	I-OUT	NOUN	I
were	I-P	AUX	O
more	I-P	ADV	O
common	I-P	ADJ	O
in	I-P	ADP	O
men	I-P	NOUN	B
(	I-P	PUNCT	O
ie	I-P	X	O
,	I-P	PUNCT	O
80.9	I-P	NUM	O
%	I-P	NOUN	O
and	I-P	CCONJ	O
85.7	I-P	NUM	O
%	I-P	NOUN	O
in	I-P	ADP	O
the	I-P	DET	O
stapled	I-P	ADJ	B
and	I-P	CCONJ	O
open	I-P	ADJ	O
group	I-P	NOUN	O
,	I-P	PUNCT	O
respectively	I-P	ADV	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
operative	I-OUT	ADJ	B
time	I-OUT	NOUN	I
was	O	AUX	O
shorter	O	ADJ	B
in	O	ADP	O
the	O	DET	O
stapled	O	ADJ	B
group	O	NOUN	I
24.28	O	NUM	O
minutes	O	NOUN	B
(	O	PUNCT	O
4.25	O	NUM	O
)	O	PUNCT	O
versus	O	CCONJ	O
45.21	O	NUM	O
minutes	O	NOUN	B
(	O	PUNCT	O
5.36	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
Milligan-Morgan	O	PROPN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
blood	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
requirement	I-OUT	NOUN	B
of	I-OUT	ADP	O
analgesics	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
in	O	ADP	O
the	O	DET	O
stapled	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


Mean	B-OUT	VERB	B
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
was	O	AUX	O
1.24	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
0.62	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
2.76	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
1.01	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
stapled	O	ADJ	B
and	O	CCONJ	O
open	O	ADJ	O
group	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
stapled	O	ADJ	B
group	O	NOUN	I
returned	B-OUT	VERB	O
to	I-OUT	ADP	O
work	I-OUT	NOUN	O
or	I-OUT	CCONJ	O
routine	I-OUT	ADJ	O
activities	I-OUT	NOUN	B
earlier	O	ADV	O
(	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
within	O	ADP	O
8.12	O	NUM	O
days	O	NOUN	B
[	O	PUNCT	O
2.48	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
17.62	O	NUM	O
(	O	PUNCT	O
5.59	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
open	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


Only	O	ADV	O
88.1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
were	O	AUX	O
satisfied	B-OUT	ADJ	O
by	O	ADP	O
the	O	DET	O
open	O	ADJ	B
method	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
97.6	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
the	O	DET	O
stapled	O	ADJ	B
technique	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
median	O	ADJ	B
follow-up	O	X	B
period	O	NOUN	B
was	O	AUX	O
11	O	NUM	O
months	O	NOUN	B
with	O	ADP	O
a	O	DET	O
maximum	O	NOUN	O
follow-up	O	NOUN	B
of	O	ADP	O
19	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
2-19	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Stapled	B-I	PROPN	B
hemorrhoidectomy	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
day-care	O	ADJ	B
procedure	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
grade	B-P	NOUN	B
III	I-P	NUM	I
and	I-P	CCONJ	O
grade	I-P	NOUN	B
IV	I-P	NUM	I
hemorrhoids	I-P	NOUN	I
.	I-P	PUNCT	O


It	O	PRON	O
ensures	O	VERB	O
lesser	O	ADJ	B
postoperative	B-OUT	ADJ	I
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
early	I-OUT	ADJ	B
discharge	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
less	I-OUT	ADJ	O
time	I-OUT	NOUN	O
off	I-OUT	ADP	O
work	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
complications	I-OUT	NOUN	B
similar	O	ADJ	O
to	O	ADP	O
the	O	DET	O
open	O	ADJ	B
technique	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
end	O	NOUN	O
a	O	DET	O
more	O	ADV	O
satisfied	B-OUT	ADJ	B
patient	I-OUT	NOUN	B
with	O	ADP	O
no	O	DET	B
perianal	O	ADJ	I
wound	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
more	O	ADV	O
such	O	ADJ	O
randomized	O	ADJ	B
trials	O	NOUN	I
are	O	AUX	O
essential	O	ADJ	O
to	O	PART	O
deny	O	VERB	O
any	O	DET	O
long-term	O	ADJ	B
complication	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Clinical	O	ADJ	B
study	O	NOUN	I
on	O	ADP	O
dan	B-I	ADJ	B
shao	I-I	ADJ	I
tang	I-I	NOUN	I
in	O	ADP	O
treating	O	VERB	B
IgA	O	NOUN	B
nephropathy	O	NOUN	I
of	O	ADP	O
deficiency	O	NOUN	B
of	O	ADP	O
yin	O	NOUN	B
with	O	ADP	I
damp-heat	O	ADJ	B
symptom	O	NOUN	O
]	O	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
explore	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
Dan	B-I	PROPN	O
Shao	I-I	PROPN	O
Tang	I-I	PROPN	O
(	I-I	PUNCT	O
DST	I-I	PROPN	B
)	I-I	PUNCT	O
in	O	ADP	O
treating	O	VERB	B
IgA	O	NOUN	B
nephropathy	O	NOUN	I
(	O	PUNCT	O
IgAN	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
deficiency	O	NOUN	B
of	O	ADP	O
Yin	O	PROPN	B
with	O	ADP	I
damp-heat	O	ADJ	B
symptom	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
90	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
IgAN	I-P	NOUN	B
of	I-P	ADP	O
deficiency	I-P	NOUN	B
of	I-P	ADP	O
Yin	I-P	PROPN	B
with	I-P	ADP	I
damp-heat	I-P	ADJ	B
symptom	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


50	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
group	O	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
DST	B-I	NOUN	B
and	I-I	CCONJ	O
western	I-I	ADJ	B
medicine	I-I	NOUN	I
and	O	CCONJ	O
40	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
were	O	AUX	O
treated	O	VERB	B
only	B-I	ADV	O
with	I-I	ADP	O
western	I-I	ADJ	B
medicine	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
and	O	CCONJ	O
changes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
indexes	O	NOUN	B
including	O	VERB	O
renal	B-OUT	ADJ	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
hematuria	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
proteinuria	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
IgA	I-OUT	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
After	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
general	B-OUT	ADJ	O
effective	I-OUT	ADJ	B
rate	I-OUT	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
70.00	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
markedly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
37.50	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Treatment	O	NOUN	B
group	O	NOUN	I
is	O	AUX	O
obviously	O	ADV	O
better	O	ADJ	O
than	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
on	O	ADP	O
decreasing	B-OUT	VERB	B
hematuria	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
proteinuria	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
IgA	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
improving	I-OUT	VERB	B
renal	I-OUT	ADJ	B
function	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
DST	B-I	NOUN	B
is	O	AUX	O
effective	O	ADJ	B
on	O	ADP	O
IgAN	O	NOUN	B
of	O	ADP	O
deficiency	O	NOUN	B
of	O	ADP	O
Yin	O	PROPN	B
with	O	ADP	I
damp-heat	O	ADJ	B
symptom	O	NOUN	B
.	O	PUNCT	O


Multicenter	O	NOUN	B
randomized	O	ADJ	O
phase	O	NOUN	O
2	O	NUM	O
clinical	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
recombinant	B-I	ADJ	B
human	I-I	ADJ	O
endostatin	I-I	NOUN	O
adenovirus	I-I	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
head	I-P	NOUN	I
and	I-P	CCONJ	O
neck	I-P	NOUN	O
carcinoma	I-P	NOUN	O
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
multicenter	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
a	O	DET	O
recombinant	B-I	ADJ	B
human	I-I	ADJ	O
endostatin	I-I	NOUN	O
adenovirus	I-I	NOUN	O
(	I-I	PUNCT	O
E10A	I-I	NOUN	B
)	I-I	PUNCT	O
to	I-I	PART	O
cisplatin	I-I	NOUN	B
and	I-I	CCONJ	O
paclitaxel	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
head	I-P	NOUN	I
and	I-P	CCONJ	I
neck	I-P	NOUN	I
squamous	I-P	ADJ	I
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
or	I-P	CCONJ	O
nasopharyngeal	I-P	ADJ	B
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
locally	I-P	ADV	B
advanced	I-P	ADJ	I
or	I-P	CCONJ	O
metastatic	I-P	ADJ	B
head	I-P	NOUN	I
and	I-P	CCONJ	I
neck	I-P	NOUN	I
squamous	I-P	ADJ	I
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
or	I-P	CCONJ	O
nasopharyngeal	I-P	ADJ	B
carcinoma	I-P	NOUN	I
not	I-P	PART	O
suitable	I-P	ADJ	O
for	I-P	ADP	O
operation	I-P	NOUN	B
or	I-P	CCONJ	O
radiotherapy	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
E10A	B-I	NOUN	B
plus	I-I	CCONJ	I
chemotherapy	I-I	NOUN	B
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
six	O	NUM	O
cycles	O	NOUN	B
or	O	CCONJ	O
to	O	PART	O
receive	O	VERB	O
chemotherapy	B-I	NOUN	B
only	I-I	ADV	O
.	I-I	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
thirty-six	I-P	NUM	O
eligible	I-P	ADJ	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
.	I-P	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
E10A	O	NOUN	B
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
improve	O	VERB	O
the	O	DET	O
objective	B-OUT	ADJ	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
(	O	PUNCT	O
29.9	O	NUM	O
versus	O	CCONJ	O
39.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.154	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
endostatin	O	NOUN	B
had	O	AUX	O
longer	O	ADV	O
progression-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
7.03	O	NUM	O
versus	O	CCONJ	O
3.60	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.006	O	NUM	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
:	O	PUNCT	O
0.55	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
E10A	O	NOUN	B
with	O	ADP	O
chemotherapy	O	NOUN	B
benefited	O	VERB	O
prior	O	ADJ	O
chemotherapy-treated	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
who	O	PRON	O
received	O	VERB	O
three	O	NUM	O
to	O	PART	O
four	O	NUM	O
treatment	O	NOUN	B
cycles	O	NOUN	I
(	O	PUNCT	O
6.50	O	NUM	O
versus	O	CCONJ	O
3.43	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
;	O	PUNCT	O
8.27	O	NUM	O
versus	O	CCONJ	O
4.27	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.018	O	NUM	O
;	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
overall	B-OUT	ADJ	O
disease	I-OUT	NOUN	B
control	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
significantly	O	ADV	O
increased	O	VERB	B
from	O	ADP	O
80.6	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
to	O	ADP	O
92.6	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
test	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.034	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Except	O	SCONJ	O
for	O	ADP	O
fever	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
no	I-OUT	DET	B
adverse	I-OUT	ADJ	I
events	I-OUT	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
E10A	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
E10A	O	NOUN	B
plus	O	CCONJ	I
chemotherapy	O	NOUN	I
is	O	AUX	O
a	O	DET	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
therapeutic	I-OUT	ADJ	B
approach	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
head	I-P	NOUN	I
and	I-P	CCONJ	I
neck	I-P	NOUN	I
squamous	I-P	ADJ	I
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
or	I-P	CCONJ	O
nasopharyngeal	I-P	ADJ	B
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


Correlation	O	NOUN	B
of	O	ADP	O
quantitative	O	ADJ	B
measures	O	NOUN	B
with	O	ADP	O
the	O	DET	O
modified	B-I	VERB	B
Ashworth	I-I	ADJ	I
scale	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
assessment	O	NOUN	B
of	O	ADP	O
plantar	B-P	NOUN	B
flexor	I-P	NOUN	I
spasticity	I-P	NOUN	I
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
traumatic	I-P	ADJ	B
brain	I-P	NOUN	I
injury	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
of	O	ADP	O
plantar	O	NOUN	B
flexor	O	NOUN	I
spasticity	O	NOUN	I
describes	O	VERB	O
relationships	O	NOUN	B
among	O	ADP	O
a	O	DET	O
traditional	O	ADJ	O
qualitative	O	ADJ	B
spasticity	O	NOUN	O
scale	O	NOUN	O
,	O	PUNCT	O
three	O	NUM	O
potential	O	ADJ	O
quantitative	O	ADJ	B
spasticity	O	NOUN	B
measures	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
voluntary	O	ADJ	B
ankle	O	NOUN	O
muscle	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O


Thirty-four	B-P	NUM	O
volunteer	I-P	NOUN	B
adult	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
traumatic	I-P	ADJ	B
brain	I-P	NOUN	I
injuries	I-P	NOUN	I
participated	I-P	VERB	O
.	I-P	PUNCT	O


There	B-P	PRON	O
were	I-P	AUX	O
28	I-P	NUM	O
males	I-P	NOUN	B
and	I-P	CCONJ	O
6	I-P	NUM	O
females	I-P	NOUN	B
;	I-P	PUNCT	O
the	I-P	DET	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
was	I-P	AUX	O
30.3	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
battery	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
randomly	B-I	ADV	O
sequenced	I-I	VERB	B
tests	I-I	NOUN	I
was	O	AUX	O
performed	O	VERB	O
for	O	ADP	O
each	O	DET	O
subject	O	NOUN	B
on	O	ADP	O
one	O	NUM	O
ankle	O	NOUN	B
.	O	PUNCT	O


Tests	O	NOUN	B
were	O	AUX	O
:	O	PUNCT	O
modified	B-OUT	VERB	B
Ashworth	I-OUT	ADJ	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
MAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
scoring	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
H-reflex	I-OUT	ADJ	B
testing	I-OUT	NOUN	I
with	I-OUT	ADP	O
and	I-OUT	CCONJ	O
without	I-OUT	ADP	O
Achilles	I-OUT	PROPN	B
tendon	I-OUT	NOUN	I
vibration	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
H-reflex	I-OUT	ADJ	B
testing	I-OUT	NOUN	I
with	I-OUT	ADP	O
and	I-OUT	CCONJ	O
without	I-OUT	ADP	O
dorsiflexor	I-OUT	NOUN	B
contraction	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
reflex	I-OUT	ADJ	B
threshold	I-OUT	NOUN	I
angle	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
timed	I-OUT	VERB	O
toe	I-OUT	NOUN	O
tapping	I-OUT	VERB	O
(	I-OUT	PUNCT	O
TTT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Twenty-six	B-P	NUM	O
subjects	I-P	NOUN	B
returned	I-P	VERB	O
to	I-P	PART	O
have	I-P	AUX	O
the	I-P	DET	O
second	I-P	ADJ	O
ankle	I-P	NOUN	B
tested	I-P	VERB	B
,	I-P	PUNCT	O
resulting	I-P	VERB	O
in	I-P	ADP	O
60	I-P	NUM	O
ankles	I-P	NOUN	B
for	O	ADP	O
the	O	DET	O
analyses	O	NOUN	B
.	O	PUNCT	O


Spearman	O	PROPN	B
's	O	PART	I
coefficients	O	NOUN	I
for	O	ADP	O
correlation	O	NOUN	B
of	O	ADP	O
quantitative	O	ADJ	B
spasticity	O	NOUN	B
measures	O	NOUN	B
with	O	ADP	O
MAS	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
0.39	O	NUM	O
to	O	PART	O
0.49	O	NUM	O
with	O	ADP	O
associated	O	VERB	O
probabilities	O	NOUN	B
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0.002	O	NUM	O
.	O	PUNCT	O


Pearson	O	ADJ	B
coefficients	O	NOUN	I
for	O	ADP	O
correlation	O	NOUN	B
of	O	ADP	O
quantitative	O	ADJ	B
spasticity	O	NOUN	B
measures	O	NOUN	B
with	O	ADP	O
TTT	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
were	O	AUX	O
lower	O	ADJ	O
but	O	CCONJ	O
also	O	ADV	O
significant	O	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0.07	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Multiple	O	ADJ	B
correlation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
set	O	NOUN	O
of	O	ADP	O
quantitative	O	ADJ	B
measures	O	NOUN	B
yielded	O	VERB	O
R	O	NOUN	B
=	O	ADJ	O
0.614	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
MAS	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
and	O	CCONJ	O
R	O	NOUN	B
=	O	ADJ	O
0.365	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.045	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
TTT	O	NOUN	B
scores	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
reveal	O	VERB	O
statistically	O	ADV	B
significant	B-OUT	ADJ	I
relationships	I-OUT	NOUN	B
of	O	ADP	O
low	O	ADJ	O
to	O	PART	O
moderate	O	ADJ	B
strength	O	NOUN	B
among	O	ADP	O
potential	B-OUT	ADJ	O
quantitative	I-OUT	ADJ	B
spasticity	I-OUT	NOUN	B
measures	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
traditional	B-OUT	ADJ	O
qualitative	I-OUT	ADJ	B
spasticity	I-OUT	NOUN	O
scale	I-OUT	NOUN	O
and	O	CCONJ	O
a	O	DET	O
simple	B-OUT	ADJ	O
measure	I-OUT	NOUN	B
of	I-OUT	ADP	O
voluntary	I-OUT	ADJ	B
ankle	I-OUT	NOUN	O
muscle	I-OUT	NOUN	B
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Understanding	O	VERB	O
these	O	DET	O
relationships	O	NOUN	B
is	O	AUX	O
an	O	DET	O
essential	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ongoing	O	ADJ	O
search	O	NOUN	O
for	O	ADP	O
quantitative	O	ADJ	B
spasticity	O	NOUN	B
measures	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
short-	O	ADJ	B
and	O	CCONJ	O
long-term	O	ADJ	B
risperidone	B-I	NOUN	B
treatment	I-P	NOUN	B
on	I-P	ADP	O
prolactin	I-OUT	NOUN	B
levels	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
short-	O	ADJ	B
and	O	CCONJ	O
long-term	O	ADJ	B
risperidone	B-I	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
serum	O	NOUN	B
prolactin	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
children	B-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
101	I-P	NUM	O
,	I-P	PUNCT	O
5-17	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
an	O	DET	O
8-week	O	ADJ	O
trial	O	NOUN	B
of	O	ADP	O
risperidone	B-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
and	O	CCONJ	O
63	B-P	NUM	O
then	I-P	ADV	O
took	I-P	VERB	O
part	I-P	NOUN	O
in	I-P	ADP	O
a	I-P	DET	O
4-month	I-P	ADJ	O
open-label	I-P	ADJ	B
follow-up	I-P	ADJ	B
phase	I-P	NOUN	O
.	I-P	PUNCT	O


Serum	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
at	O	ADP	O
Baseline	O	NOUN	B
and	O	CCONJ	O
Week-8	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
78	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
6-month	O	ADJ	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
43	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
22-month	O	ADJ	O
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
30	O	NUM	O
)	O	PUNCT	O
follow-up	O	ADJ	B
.	O	PUNCT	O


Serum	O	NOUN	B
prolactin	O	NOUN	I
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
immunoradiometric	O	ADJ	B
assay	O	NOUN	I
;	O	PUNCT	O
dopamine	B-OUT	NOUN	B
type-2	I-OUT	ADJ	I
receptor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
DRD2	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
polymorphisms	I-OUT	NOUN	B
were	I-OUT	AUX	O
genotyped	I-OUT	VERB	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Baseline	B-OUT	NOUN	B
prolactin	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
risperidone	B-I	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
42	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
36	O	NUM	O
)	O	PUNCT	O
groups	O	NOUN	B
(	O	PUNCT	O
9.3	O	NUM	O
+/-	O	CCONJ	O
7.5	O	NUM	O
and	O	CCONJ	O
9.3	O	NUM	O
+/-	O	CCONJ	O
7.6	O	NUM	O
ng/ml	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
risperidone	B-I	NOUN	B
,	O	PUNCT	O
prolactin	B-OUT	NOUN	B
increased	O	VERB	B
to	O	ADP	O
39.0	O	NUM	O
+/-	O	CCONJ	O
19.2	O	NUM	O
ng/ml	O	NOUN	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
10.1	O	NUM	O
+/-	O	CCONJ	O
8.8	O	NUM	O
ng/ml	O	NOUN	O
for	O	ADP	O
placebo	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Prolactin	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
were	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
increased	O	VERB	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
32.4	O	NUM	O
+/-	O	CCONJ	O
17.8	O	NUM	O
ng/ml	O	NOUN	O
;	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
43	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
.0001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
22	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
30	O	NUM	O
,	O	PUNCT	O
25.3	O	NUM	O
+/-	O	CCONJ	O
15.6	O	NUM	O
ng/ml	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Prolactin	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
were	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
adverse	O	ADJ	B
effects	O	NOUN	I
and	O	CCONJ	O
DRD2	O	NOUN	B
alleles	O	NOUN	I
(	O	PUNCT	O
Taq1A	O	NOUN	B
,	O	PUNCT	O
-141C	O	ADJ	O
Ins/Del	O	NOUN	B
,	O	PUNCT	O
C957T	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
influence	O	VERB	B
baseline	O	NOUN	B
levels	O	NOUN	B
or	O	CCONJ	O
risperidone-induced	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
prolactin	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Risperidone	B-I	NOUN	B
treatment	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
two-	O	NUM	O
to	O	PART	O
four-fold	O	ADV	O
mean	O	NOUN	O
increases	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
prolactin	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Although	O	SCONJ	O
risperidone-induced	O	ADJ	B
increases	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
diminish	O	VERB	B
with	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
further	O	ADJ	O
research	O	NOUN	B
on	O	ADP	O
the	O	DET	O
consequences	O	NOUN	B
of	O	ADP	I
long-term	O	ADJ	B
prolactin	O	NOUN	B
elevations	O	NOUN	O
in	O	ADP	O
children	B-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
is	O	AUX	O
needed	O	VERB	O
.	O	PUNCT	O


Armodafinil	B-I	NOUN	B
and	I-I	CCONJ	O
modafinil	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
excessive	I-P	ADJ	B
sleepiness	I-P	NOUN	B
associated	I-P	VERB	B
with	I-P	ADP	I
shift	I-P	NOUN	O
work	I-P	NOUN	O
disorder	I-P	NOUN	O
:	I-P	PUNCT	O
a	O	DET	O
pharmacokinetic/pharmacodynamic	B-OUT	ADJ	B
model	O	NOUN	I
for	O	ADP	O
predicting	O	VERB	B
and	O	CCONJ	O
comparing	O	VERB	B
their	O	PRON	O
concentration-effect	O	ADJ	B
relationships	O	NOUN	I
.	O	PUNCT	O


Armodafinil	B-I	NOUN	B
,	O	PUNCT	O
the	O	DET	O
longer	O	ADV	O
lasting	O	VERB	O
R-isomer	O	NOUN	B
of	O	ADP	O
racemic	O	ADJ	B
modafinil	O	NOUN	B
,	O	PUNCT	O
improves	O	VERB	B
wakefulness	B-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
excessive	I-OUT	ADJ	B
sleepiness	I-OUT	NOUN	B
associated	I-P	VERB	B
with	I-P	ADP	I
shift	I-OUT	NOUN	O
work	I-OUT	NOUN	O
disorder	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
SWD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-P	PUNCT	O


Pharmacokinetic	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
armodafinil	B-I	NOUN	B
achieves	O	VERB	O
higher	O	ADJ	O
plasma	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
than	O	ADP	O
modafinil	O	NOUN	B
late	O	ADV	O
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
interval	O	NOUN	I
following	O	VERB	O
equal	O	ADJ	O
oral	O	ADJ	B
doses	O	NOUN	I
.	O	PUNCT	O


Pooled	B-OUT	VERB	B
Multiple	I-OUT	ADJ	B
Sleep	I-OUT	PROPN	I
Latency	I-OUT	NOUN	I
Test	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
MSLT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
data	O	NOUN	B
from	O	ADP	O
2	O	NUM	O
randomized	B-P	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trials	O	NOUN	I
in	O	ADP	O
463	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
SWD	I-P	NOUN	B
,	I-P	PUNCT	O
1	I-P	NUM	O
with	I-P	ADP	O
armodafinil	I-I	ADJ	B
150	I-I	NUM	O
mg/d	I-I	NOUN	O
and	I-P	CCONJ	O
1	I-I	NUM	O
with	I-I	ADP	O
modafinil	I-I	NOUN	B
200	I-I	NUM	O
mg/d	I-I	NOUN	O
(	I-P	PUNCT	O
both	I-P	DET	O
administered	I-P	VERB	B
around	I-P	ADV	O
2200	I-P	NUM	O
h	I-P	NOUN	O
before	I-P	ADP	O
night	I-P	NOUN	B
shifts	I-P	NOUN	O
)	I-P	PUNCT	O
,	O	PUNCT	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
build	O	VERB	O
a	O	DET	O
pharmacokinetic/pharmacodynamic	B-OUT	ADJ	B
model	O	NOUN	I
.	O	PUNCT	O


Predicted	O	VERB	B
plasma	B-OUT	NOUN	B
drug	I-OUT	NOUN	O
concentrations	I-OUT	NOUN	O
were	O	AUX	O
obtained	O	VERB	O
by	O	ADP	O
developing	O	VERB	O
and	O	CCONJ	O
applying	O	VERB	O
a	O	DET	O
population	O	NOUN	B
pharmacokinetic	B-OUT	ADJ	B
model	I-OUT	NOUN	I
using	O	VERB	O
nonlinear	B-OUT	ADJ	B
mixed-effects	I-OUT	ADJ	I
modeling	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Armodafinil	O	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
produced	O	VERB	O
a	O	DET	O
plasma	B-OUT	NOUN	B
concentration	I-OUT	NOUN	B
above	O	ADP	O
the	O	DET	O
EC	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
4.6	O	NUM	O
µg/mL	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
9	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
modafinil	O	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
did	O	AUX	O
not	O	PART	O
exceed	O	VERB	O
the	O	DET	O
EC	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
armodafinil	B-OUT	ADJ	B
produced	O	VERB	O
greater	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
predicted	O	VERB	B
placebo-subtracted	B-OUT	ADJ	B
MSLT	I-OUT	NOUN	B
times	I-OUT	NOUN	O
of	O	ADP	O
0.5-1	O	NUM	O
minute	O	NOUN	B
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
10	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
dosing	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
modafinil	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
a	O	DET	O
milligram-to-milligram	O	ADJ	B
basis	O	NOUN	O
,	O	PUNCT	O
armodafinil	O	ADJ	B
200	O	NUM	O
mg	O	NOUN	O
consistently	B-OUT	ADV	O
increased	I-OUT	VERB	B
wakefulness	I-OUT	NOUN	B
more	O	ADJ	O
than	O	ADP	O
modafinil	O	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
times	O	NOUN	O
late	O	ADV	O
in	O	ADP	O
the	O	DET	O
8-hour	O	ADJ	O
shift	O	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
on	O	ADP	O
section	B-OUT	NOUN	B
2D1	I-OUT	NOUN	O
monoclonal	I-OUT	ADJ	B
antibodies	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Monoclonal	O	ADJ	B
antibodies	O	NOUN	I
in	O	ADP	O
"	O	PUNCT	O
Other	O	ADJ	O
Blood	O	PROPN	B
Groups	O	NOUN	I
"	O	PUNCT	O
were	O	AUX	O
tested	O	VERB	B
with	O	ADP	O
random	B-I	ADJ	B
blood	I-I	NOUN	I
samples	I-I	NOUN	I
collected	O	VERB	O
from	O	ADP	O
the	O	DET	O
various	B-P	ADJ	O
ethnic	I-P	ADJ	B
groups	I-P	NOUN	I
in	I-P	ADP	O
KwaZulu-Natal	I-P	NOUN	B
,	I-P	PUNCT	O
South	I-P	PROPN	B
Africa	I-P	PROPN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
with	I-P	ADP	O
samples	I-P	NOUN	B
of	I-P	ADP	O
selected	I-P	VERB	O
red	I-P	ADJ	B
cell	I-P	NOUN	I
phenotypes	I-P	NOUN	B
.	I-P	PUNCT	O


Standard	B-I	ADJ	B
red	I-I	ADJ	B
cell	I-I	NOUN	I
serological	I-I	ADJ	O
techniques	I-I	NOUN	O
were	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Do	O	AUX	O
catheter	B-I	NOUN	B
washouts	I-I	NOUN	B
extend	O	VERB	O
patency	B-OUT	NOUN	B
time	I-OUT	NOUN	I
in	O	ADP	O
long-term	B-OUT	ADJ	B
indwelling	I-OUT	NOUN	B
urethral	O	ADJ	I
catheters	O	NOUN	I
?	O	PUNCT	O
A	O	DET	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
acidic	B-I	ADJ	B
washout	I-I	NOUN	O
solution	I-I	NOUN	O
,	I-I	PUNCT	O
normal	I-I	ADJ	B
saline	I-I	NOUN	I
washout	I-I	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
standard	B-I	ADJ	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


PURPOSE	O	NOUN	O
Blockage	O	NOUN	B
of	O	ADP	O
long-term	O	ADJ	B
indwelling	O	NOUN	B
catheters	O	NOUN	I
with	O	ADP	O
mineral	O	ADJ	B
deposit	O	NOUN	O
is	O	AUX	O
an	O	DET	O
ongoing	O	ADJ	B
management	O	NOUN	B
issue	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
evidence	O	NOUN	B
on	O	ADP	O
optimal	O	ADJ	B
management	O	NOUN	B
is	O	AUX	O
lacking	O	VERB	B
.	O	PUNCT	O


Our	O	PRON	O
purpose	O	NOUN	O
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
whether	O	SCONJ	O
catheter	B-I	NOUN	B
washouts	I-I	NOUN	I
prevent	O	VERB	B
or	O	CCONJ	O
reduce	O	VERB	B
catheter	B-OUT	NOUN	B
blockage	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
multisite	O	ADJ	B
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


SUBJECTS	O	NOUN	B
AND	O	CCONJ	O
SETTING	O	VERB	B
Adults	B-P	NOUN	I
with	I-P	ADP	O
long-term	I-P	ADJ	B
indwelling	I-P	NOUN	B
catheters	I-P	NOUN	I
that	I-P	PRON	O
required	I-P	VERB	O
changing	I-P	VERB	B
every	I-P	DET	O
3	I-P	NUM	O
weeks	I-P	NOUN	B
or	I-P	CCONJ	O
less	I-P	ADJ	O
,	I-P	PUNCT	O
living	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
community	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
requiring	I-P	VERB	O
supportive	I-P	ADJ	B
or	I-P	CCONJ	O
continuing	I-P	VERB	B
care	I-P	NOUN	I
were	I-P	AUX	O
recruited	I-P	VERB	O
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
1	O	NUM	O
of	O	ADP	O
3	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
control	B-I	NOUN	B
(	I-I	PUNCT	O
usual	I-I	ADJ	B
care	I-I	NOUN	I
,	I-I	PUNCT	O
no	I-I	DET	O
washout	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
saline	I-I	NOUN	B
washout	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
commercially	I-I	ADV	O
available	I-I	ADJ	O
acidic	I-I	ADJ	B
washout	I-I	NOUN	O
solution	I-I	NOUN	O
(	I-I	PUNCT	O
Contisol	I-I	PROPN	B
Maelor	O	PROPN	I
Pharmaceuticals	O	PROPN	I
Ltd	O	PROPN	I
,	O	PUNCT	O
Wrexham	O	PROPN	B
,	O	PUNCT	O
UK	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
At	O	ADP	O
baseline	O	NOUN	B
visit	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
catheter	O	NOUN	B
was	O	AUX	O
changed	O	VERB	B
and	O	CCONJ	O
participants	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
weekly	O	ADJ	O
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
checks	B-OUT	NOUN	B
for	I-OUT	ADP	O
catheter	I-OUT	NOUN	B
patency	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
urine	I-OUT	NOUN	B
pH	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Participants	O	NOUN	B
randomized	O	VERB	B
to	O	PART	O
saline	B-I	NOUN	B
or	I-I	CCONJ	O
commercial	I-I	ADJ	B
solution	I-I	NOUN	B
had	O	AUX	O
a	O	DET	O
weekly	O	ADJ	B
washout	B-I	NOUN	B
with	O	ADP	I
the	O	DET	O
appropriate	O	ADJ	O
solution	O	NOUN	B
.	O	PUNCT	O


Endpoints	O	NOUN	B
were	O	AUX	O
8	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
completion	O	NOUN	B
data	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
3	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
catheter	O	NOUN	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
8-week	O	ADJ	B
period	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
symptomatic	B-OUT	ADJ	B
urinary	I-OUT	ADJ	B
tract	I-OUT	NOUN	I
infection	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
UTI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
requiring	O	VERB	O
antibiotics	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
hypothesis	O	NOUN	B
was	O	AUX	O
that	O	SCONJ	O
catheter	O	NOUN	B
life	O	NOUN	I
would	O	AUX	O
be	O	AUX	O
extended	O	VERB	O
by	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
commercial	B-I	ADJ	B
solution	I-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
not	O	PART	O
possible	O	ADJ	O
to	O	PART	O
blind	O	VERB	B
participants	O	NOUN	B
or	O	CCONJ	O
research	O	NOUN	B
nurses	O	NOUN	I
to	O	PART	O
washout	B-I	VERB	B
versus	I-I	CCONJ	O
no	I-I	DET	O
intervention	I-I	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
participants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
saline	B-I	NOUN	B
and	I-I	CCONJ	O
washout	I-I	NOUN	B
solution	I-I	NOUN	I
groups	O	NOUN	B
were	O	AUX	O
blinded	O	VERB	O
to	O	PART	O
solution	O	NOUN	B
type	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
twelve	I-P	NUM	O
potential	I-P	ADJ	O
participants	I-P	NOUN	B
were	I-P	AUX	O
screened	I-P	VERB	B
;	I-P	PUNCT	O
73	I-P	NUM	O
were	I-P	AUX	O
enrolled	I-P	VERB	O
,	I-P	PUNCT	O
randomized	I-P	ADJ	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
included	I-P	VERB	O
in	O	ADP	O
the	O	DET	O
final	O	ADJ	O
analysis	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
53	B-P	NUM	O
completed	I-P	VERB	O
the	O	DET	O
full	O	ADJ	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
data	O	NOUN	B
collection	O	NOUN	I
;	O	PUNCT	O
16	B-P	NUM	O
terminated	I-P	VERB	O
early	I-P	ADV	B
because	O	SCONJ	O
of	O	ADP	O
3	O	NUM	O
catheter	O	NOUN	B
changes	O	NOUN	I
or	O	CCONJ	O
self-reported	O	ADJ	B
'UTI	O	NOUN	O
'	O	PUNCT	O
.	O	PUNCT	O


Other	O	ADJ	O
reasons	O	NOUN	O
for	O	ADP	O
termination	B-OUT	NOUN	B
were	O	AUX	O
hematuria	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
latex	I-OUT	NOUN	B
sensitivity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
deceased/severe	I-OUT	ADJ	B
illness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
personal	I-OUT	ADJ	B
choice	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
variance	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
analyze	O	VERB	B
mean	O	VERB	O
differences	O	NOUN	O
on	O	ADP	O
demographic	O	ADJ	B
variables	O	NOUN	I
and	O	CCONJ	O
mean	O	VERB	O
number	O	NOUN	O
of	O	ADP	O
weeks	O	NOUN	B
in	O	ADP	O
study	O	NOUN	B
.	O	PUNCT	O


Kaplan-Meier	O	ADJ	B
survival	O	NOUN	I
curve	O	NOUN	I
analysis	O	NOUN	I
showed	O	VERB	O
no	O	DET	O
statistical	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
time	B-OUT	NOUN	O
to	I-OUT	ADP	O
first	I-OUT	ADJ	O
catheter	I-OUT	NOUN	B
change	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
At	O	ADP	O
this	O	DET	O
time	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
evidence	O	NOUN	B
is	O	AUX	O
insufficient	O	ADJ	B
to	O	PART	O
state	O	NOUN	B
whether	O	SCONJ	O
catheter	B-I	NOUN	B
washout	I-I	NOUN	B
with	I-I	ADP	I
saline	I-I	NOUN	B
or	I-I	CCONJ	O
Contisol	I-I	PROPN	B
is	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
usual	B-I	ADJ	B
care	I-I	NOUN	I
with	I-I	ADP	O
no	I-I	DET	O
washout	I-I	NOUN	O
in	O	ADP	O
preventing	O	VERB	B
blocking	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
increased	O	VERB	B
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
UTI	I-OUT	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
washout	B-I	NOUN	B
regimes	I-I	NOUN	I
.	I-I	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
gabapentin	B-I	NOUN	B
on	O	ADP	O
experimental	O	ADJ	B
somatic	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
temporal	I-OUT	ADJ	B
summation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
OBJECTIVES	O	NOUN	O
Gabapentin	B-I	NOUN	B
is	O	AUX	O
used	O	VERB	O
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
neuropathic	O	ADJ	B
pain	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
its	O	PRON	O
effect	O	NOUN	B
on	O	ADP	O
different	O	ADJ	O
somatic	O	ADJ	B
pain	O	NOUN	I
modalities	O	NOUN	B
and	O	CCONJ	O
integrative	O	ADJ	B
mechanisms	O	NOUN	B
are	O	AUX	O
not	O	PART	O
completely	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
experimental	O	ADJ	O
pain	O	NOUN	O
study	O	NOUN	O
,	O	PUNCT	O
conducted	O	VERB	O
on	O	ADP	O
20	B-P	NUM	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
1200	O	NUM	O
mg	O	NOUN	O
gabapentin	O	NOUN	B
on	O	ADP	O
multi-modal	O	ADJ	B
experimental	O	ADJ	I
cutaneous	O	ADJ	I
and	O	CCONJ	O
muscle	O	NOUN	B
pain	O	NOUN	I
models	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
following	O	VERB	O
pain	O	NOUN	B
models	O	NOUN	I
were	O	AUX	O
applied	O	VERB	O
:	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
pain	O	NOUN	B
thresholds	O	NOUN	I
to	O	PART	O
single	B-I	ADJ	O
and	I-I	CCONJ	O
repeated	I-I	VERB	O
cutaneous	I-I	ADJ	B
and	I-I	CCONJ	O
intramuscular	I-I	ADJ	B
electrical	I-I	ADJ	O
stimulation	I-I	NOUN	O
(	I-I	PUNCT	O
temporal	I-I	ADJ	B
summation	I-I	NOUN	I
to	I-I	ADP	O
5	I-I	NUM	O
stimuli	I-I	NOUN	B
delivered	I-I	VERB	O
at	I-I	ADP	O
2	I-I	NUM	O
Hz	I-I	NOUN	O
)	I-I	PUNCT	O
;	I-I	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
stimulus-response	B-I	ADJ	B
function	I-I	NOUN	I
relating	I-I	VERB	O
pain	I-OUT	NOUN	B
intensity	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
visual	I-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
to	I-I	PART	O
increasing	I-I	VERB	B
current	I-I	ADJ	O
intensities	I-I	NOUN	B
for	I-I	ADP	O
electrical	I-I	ADJ	B
skin	I-I	NOUN	I
and	I-I	CCONJ	O
muscle	I-I	NOUN	B
stimuli	I-I	NOUN	I
(	I-I	PUNCT	O
single	I-I	ADJ	O
and	I-I	CCONJ	O
repeated	I-I	VERB	B
,	I-I	PUNCT	O
determined	I-I	VERB	O
at	I-I	ADP	O
baseline	I-I	NOUN	B
)	I-I	PUNCT	O
;	I-I	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
the	O	DET	O
pain	B-OUT	NOUN	B
intensity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
areas	I-OUT	NOUN	I
after	I-OUT	ADP	O
intramuscular	I-OUT	ADJ	B
injection	I-OUT	NOUN	B
of	I-I	ADP	O
hypertonic	I-I	ADJ	B
saline	I-I	NOUN	I
.	I-I	PUNCT	O


Pain	B-OUT	NOUN	B
assessments	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
prior	O	ADJ	O
to	O	PART	O
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
4	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
medication	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
When	O	SCONJ	O
responses	O	NOUN	B
were	O	AUX	O
averaged	O	VERB	O
across	O	ADP	O
the	O	DET	O
post-dose	O	ADJ	B
times	O	NOUN	I
,	O	PUNCT	O
gabapentin	B-I	NOUN	B
:	I-I	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
temporal	B-OUT	ADJ	B
summation	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
threshold	I-OUT	NOUN	O
in	O	ADP	O
skin	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
significantly	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
area	B-OUT	NOUN	B
under	I-OUT	ADP	O
the	I-OUT	DET	O
pain	I-OUT	NOUN	B
intensity	I-OUT	NOUN	I
curve	I-OUT	NOUN	I
to	I-OUT	PART	O
hypertonic	I-OUT	ADJ	B
saline	I-OUT	NOUN	I
injections	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
muscle	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.02	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
significantly	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
area	B-OUT	NOUN	B
of	I-OUT	ADP	I
pain	I-OUT	NOUN	B
evoked	I-OUT	VERB	B
by	I-OUT	ADP	O
hypertonic	I-OUT	ADJ	B
saline	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Gabapentin	B-I	NOUN	B
reduces	O	VERB	O
temporal	B-OUT	ADJ	B
summation	I-OUT	NOUN	I
of	I-OUT	ADP	O
skin	I-OUT	NOUN	B
stimuli	I-OUT	NOUN	I
at	I-OUT	ADP	O
pain	I-OUT	NOUN	B
threshold	I-OUT	NOUN	I
intensities	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
this	O	DET	O
may	O	AUX	O
have	O	AUX	O
potential	O	ADJ	B
as	O	ADP	O
a	O	DET	O
biomarker	O	NOUN	B
for	O	ADP	O
drugs	O	NOUN	B
with	O	ADP	O
efficacy	O	NOUN	B
on	O	ADP	O
neurogenic	O	ADJ	B
pain	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
also	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
tonic	B-OUT	ADJ	B
muscle	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
is	O	AUX	O
responsive	O	ADJ	O
to	O	PART	O
gabapentin	O	NOUN	B
treatment	O	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
further	O	ADJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Effects	O	NOUN	B
of	O	ADP	I
transcutaneous	B-I	ADJ	B
electrical	I-I	ADJ	I
stimulation	I-I	NOUN	I
of	I-I	ADP	O
auricular	I-I	ADJ	B
Shenmen	I-I	PROPN	I
point	I-I	NOUN	I
on	O	ADP	O
postoperative	O	ADJ	B
nausea	O	NOUN	B
and	O	CCONJ	O
vomiting	O	NOUN	B
and	O	CCONJ	O
patient-controlled	O	ADJ	B
epidural	O	ADJ	O
analgesia	O	NOUN	O
in	O	ADP	O
cesarean	B-P	NOUN	B
section	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
transcutaneous	O	ADJ	B
electrical	O	ADJ	I
stimulation	O	NOUN	I
of	O	ADP	O
auricular	O	ADJ	B
Shenmen	O	PROPN	I
point	O	NOUN	I
on	O	ADP	O
postoperative	O	ADJ	B
nausea	O	NOUN	B
and	O	CCONJ	O
vomiting	O	NOUN	B
and	O	CCONJ	O
patient-controlled	O	ADJ	B
epidural	O	ADJ	O
analgesia	O	NOUN	O
in	O	ADP	O
cesarean	O	NOUN	B
section	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
After	O	ADP	O
IRB	O	PROPN	B
approval	O	NOUN	B
and	O	CCONJ	O
informed	O	VERB	O
consent	O	NOUN	O
,	O	PUNCT	O
one	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
eighty	I-P	NUM	O
singleton	I-P	ADJ	B
primiparas	I-P	NOUN	I
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
cesarean	I-P	NOUN	I
section	I-P	NOUN	I
,	I-P	PUNCT	O
in	I-P	ADP	O
Qingdao	I-P	PROPN	B
Municipal	I-P	PROPN	I
Hospital	I-P	PROPN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
Qingdao	I-P	PROPN	B
Hiser	I-P	PROPN	I
Medical	I-P	PROPN	I
Center	I-P	PROPN	I
,	I-P	PUNCT	O
from	I-P	ADP	O
November	I-P	PROPN	O
2011	I-P	NUM	O
to	I-P	ADP	O
March	I-P	PROPN	O
2012	I-P	NUM	O
,	I-P	PUNCT	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
transcutaneous	B-I	ADJ	B
electrical	I-I	ADJ	I
stimulation	I-I	NOUN	I
of	I-I	ADP	O
auricular	I-I	ADJ	B
Shenmen	I-I	PROPN	I
point	I-I	NOUN	I
group	I-I	NOUN	I
(	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
60	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
transcutaneous	B-I	ADJ	B
electrical	I-I	ADJ	I
stimulation	I-I	NOUN	I
of	I-I	ADP	O
auricular	I-I	ADJ	B
Eye	I-I	ADJ	I
point	I-I	NOUN	I
group	I-I	NOUN	I
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
60	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
control	B-I	NOUN	B
group	I-I	NOUN	I
(	O	PUNCT	O
group	O	NOUN	B
C	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
60	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Women	O	NOUN	B
of	O	ADP	O
group	O	NOUN	B
A	O	NOUN	O
received	O	VERB	O
transcutaneous	B-I	ADJ	B
electrical	I-I	ADJ	I
stimulation	I-I	NOUN	I
of	O	ADP	O
auricular	O	ADJ	B
Shenmen	O	PROPN	I
point	O	NOUN	I
(	O	PUNCT	O
frequency	O	NOUN	B
1.5	O	NUM	O
HZ	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
preoperation	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
22	O	NUM	O
hours	O	NOUN	O
of	O	ADP	O
postoperation	O	NOUN	B
for	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
strength	O	NOUN	B
was	O	AUX	O
controlled	O	VERB	B
by	O	ADP	O
themselves	O	PRON	O
.	O	PUNCT	O


Women	O	NOUN	B
of	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
received	O	VERB	O
stimulation	O	NOUN	B
of	O	ADP	O
auricular	O	ADJ	B
Eye	O	ADJ	I
point	O	NOUN	I
as	O	ADP	O
group	O	NOUN	B
A	O	NOUN	O
.	O	PUNCT	O


Women	O	NOUN	B
of	O	ADP	O
group	O	NOUN	B
C	O	NOUN	I
received	O	VERB	O
pressurization	B-I	NOUN	B
and	I-I	CCONJ	O
connected	I-I	VERB	B
line	I-I	NOUN	I
were	I-I	AUX	O
the	I-I	DET	O
same	I-I	ADJ	O
with	I-I	ADP	O
group	I-I	NOUN	B
A	I-I	NOUN	I
,	I-I	PUNCT	O
but	I-I	CCONJ	O
without	I-I	ADP	O
electrical	I-I	ADJ	B
stimulation	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
following	O	VERB	O
indexes	O	NOUN	B
was	O	AUX	O
observed	O	VERB	B
:	O	PUNCT	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
nausea	O	NOUN	O
and	O	CCONJ	O
vomiting	O	NOUN	O
(	O	PUNCT	O
PONV	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
48	O	NUM	O
hours	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
metoclopramide	O	NOUN	B
;	O	PUNCT	O
the	B-OUT	DET	O
visual	I-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
score	I-OUT	NOUN	B
of	I-OUT	ADP	O
rest	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
uterine	I-OUT	ADJ	B
contration	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
dynamic	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
at	I-OUT	ADP	O
the	I-OUT	DET	O
time	I-OUT	NOUN	O
of	I-OUT	ADP	O
postoperation	I-OUT	NOUN	B
for	I-OUT	ADP	O
6	I-OUT	NUM	O
,	I-OUT	PUNCT	O
12	I-OUT	NUM	O
,	I-OUT	PUNCT	O
24	I-OUT	NUM	O
and	I-OUT	CCONJ	O
48	I-OUT	NUM	O
hours	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
T	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
-T	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
4	I-OUT	NUM	O
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
the	I-OUT	DET	O
total	I-OUT	ADJ	O
number	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
compressions	I-OUT	NOUN	B
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
patient-controlled	I-OUT	ADJ	B
epidural	I-OUT	ADJ	I
analgesia	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PCEA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
the	I-OUT	DET	O
dose	I-OUT	NOUN	B
of	I-OUT	ADP	O
analgesia	I-OUT	NOUN	B
mixture	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
the	I-OUT	DET	O
anal	I-OUT	ADJ	B
exhaust	I-OUT	NOUN	B
time	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
the	I-OUT	DET	O
volume	I-OUT	NOUN	B
of	I-OUT	ADP	O
postoperative	I-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
for	I-OUT	ADP	O
6	I-OUT	NUM	O
hours	I-OUT	NOUN	B
of	I-OUT	ADP	O
postoperation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
other	I-OUT	ADJ	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
Compared	O	VERB	B
with	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
and	O	CCONJ	O
group	O	NOUN	B
C	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
PONV	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
metoclopramide	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
VAS	I-OUT	NOUN	B
score	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
T	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
-T	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
total	B-OUT	ADJ	O
number	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
compressions	I-OUT	NOUN	B
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
PCEA	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
ratio	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
total	I-OUT	ADJ	O
number	I-OUT	NOUN	O
with	I-OUT	ADP	O
effective	I-OUT	ADJ	B
compressions	I-OUT	NOUN	B
number	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
dose	I-OUT	NOUN	B
of	I-OUT	ADP	O
analgesia	I-OUT	NOUN	B
mixture	I-OUT	NOUN	O
were	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
difference	O	NOUN	O
compared	O	VERB	O
group	O	NOUN	B
B	O	NOUN	I
with	O	ADP	O
group	O	NOUN	B
C	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
anal	B-OUT	ADJ	B
exhaust	I-OUT	NOUN	B
time	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
volume	I-OUT	NOUN	B
of	I-OUT	ADP	O
postoperative	I-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
for	O	ADP	O
6	O	NUM	O
hours	O	NOUN	B
of	O	ADP	O
postoperation	O	NOUN	B
were	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
side	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Transcutaneous	O	ADJ	B
electrical	O	ADJ	I
stimulation	O	NOUN	I
of	O	ADP	O
auricular	O	ADJ	B
Shenmen	O	PROPN	I
point	O	NOUN	I
can	O	AUX	O
reduce	O	VERB	B
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
PONV	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
improves	I-OUT	VERB	B
analgesia	I-OUT	NOUN	B
effect	I-OUT	NOUN	B
of	I-OUT	ADP	O
PCEA	I-OUT	NOUN	B
in	I-OUT	ADP	O
postoperation	I-OUT	NOUN	B
of	I-OUT	ADP	O
cesarean	I-OUT	NOUN	B
section	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Dipyrone	B-I	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
post-operative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
etoposide	O	NOUN	B
and	O	CCONJ	O
G-CSF	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
rituximab	B-I	NOUN	B
for	O	ADP	O
PBSC	O	NOUN	B
mobilization	O	NOUN	B
in	O	ADP	O
B-cell	B-P	NOUN	B
non-Hodgkin	I-P	ADJ	I
's	I-P	PART	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


Some	O	DET	O
reports	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
rituximab	O	NOUN	B
administration	O	NOUN	B
before	O	ADP	O
PBSC	O	NOUN	B
mobilization	O	NOUN	B
may	O	AUX	O
adversely	O	ADV	O
affect	O	VERB	O
PBSC	O	NOUN	B
yield	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
trial	O	NOUN	O
of	O	ADP	O
PBSC	O	NOUN	B
mobilization	O	NOUN	B
using	O	VERB	O
etoposide	B-I	NOUN	B
and	I-I	CCONJ	O
G-CSF	I-I	NOUN	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
rituximab	I-I	NOUN	B
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
its	O	PRON	O
addition	O	NOUN	O
would	O	AUX	O
adversely	O	ADV	O
affect	O	VERB	O
CD34+	B-OUT	ADJ	B
cell	I-OUT	NOUN	I
yield	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
non-Hodgkin	I-P	ADJ	B
's	I-P	PART	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


Twenty	B-P	NUM	O
seven	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
mobilized	I-P	VERB	B
with	O	ADP	O
etoposide	B-I	NOUN	B
and	O	CCONJ	O
G-CSF	O	NOUN	B
and	O	CCONJ	O
28	O	NUM	O
with	O	ADP	O
etoposide	B-I	NOUN	B
,	I-I	PUNCT	O
G-CSF	I-I	NOUN	B
and	I-I	CCONJ	O
rituximab	I-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
adverse	O	ADJ	O
consequences	O	NOUN	B
of	O	ADP	I
rituximab	O	NOUN	B
on	O	ADP	O
CD34+	B-OUT	ADJ	B
cell	I-OUT	NOUN	I
yield	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
hematopoietic	I-OUT	ADJ	B
recovery	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
immunoglobulin	I-OUT	NOUN	B
levels	I-OUT	NOUN	I
after	O	ADP	O
transplantation	O	NOUN	B
.	O	PUNCT	O


Glycerol	B-I	NOUN	B
lidocaine	I-I	NOUN	B
eardrops	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
acute	B-OUT	ADJ	B
abacterial	I-OUT	ADJ	O
otitis	I-OUT	NOUN	O
externa	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Inflammations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
external	O	ADJ	B
auditory	O	ADJ	B
canal	O	NOUN	I
number	O	NOUN	O
among	O	ADP	O
the	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
occurring	O	VERB	O
ear-nose-throat	O	ADJ	B
diseases	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
local	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
substances	O	NOUN	B
from	O	ADP	O
various	O	ADJ	O
groups	O	NOUN	B
of	O	ADP	O
active	O	ADJ	B
ingredients	O	NOUN	I
are	O	AUX	O
used	O	VERB	O
as	O	ADP	O
combinations	O	NOUN	B
and	O	CCONJ	O
as	O	ADP	O
single-agent	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
e.g	O	X	O
.	O	PUNCT	O


antibiotics	B-I	NOUN	B
,	I-I	PUNCT	O
glucocorticoids	I-I	NOUN	B
or	O	CCONJ	O
analgesics	B-I	NOUN	B
[	O	PUNCT	O
1	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
otitis	O	NOUN	I
externa	O	NOUN	I
,	O	PUNCT	O
treatment	O	NOUN	B
measures	O	NOUN	I
focus	O	VERB	O
on	O	ADP	O
the	O	DET	O
reduction	B-OUT	NOUN	B
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
swelling	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
study	O	NOUN	B
described	O	VERB	O
here	O	ADV	O
investigates	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
glycerol	B-I	NOUN	B
lidocaine	I-I	NOUN	B
eardrops	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
acute	B-OUT	ADJ	B
abacterial	I-OUT	ADJ	O
otitis	I-OUT	NOUN	O
externa	I-OUT	NOUN	O
(	O	PUNCT	O
CAS	O	PROPN	B
No	O	INTJ	O
.	O	PUNCT	O


for	O	ADP	O
glycerol	B-I	NOUN	B
:	I-I	PUNCT	O
56-81-5	O	NOUN	O
,	O	PUNCT	O
lidocaine-HCl	B-I	NOUN	B
:	I-I	PUNCT	O
73-78-9	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
three-arm	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
105	B-P	NUM	O
patients	I-P	NOUN	B
diagnosed	I-P	VERB	B
with	I-P	ADP	O
acute	I-P	ADJ	B
abacterial	I-P	ADJ	O
otitis	I-P	NOUN	O
externa	I-P	NOUN	O
were	I-P	AUX	O
included	I-P	VERB	O
and	I-P	CCONJ	O
randomized	I-P	ADJ	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
glycerol	B-I	NOUN	B
eardrops	I-I	NOUN	B
,	I-I	PUNCT	O
glycerol	I-I	NOUN	B
eardrops	I-I	NOUN	B
with	I-I	ADP	O
0.5	I-I	NUM	O
%	I-I	NOUN	O
lidocaine	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
glycerol	I-I	NOUN	B
eardrops	I-I	NOUN	B
with	I-I	ADP	O
2	I-I	NUM	O
%	I-I	NOUN	O
lidocaine	I-I	NOUN	B
for	O	ADP	O
seven	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
parameter	O	NOUN	O
was	O	AUX	O
the	O	DET	O
change	O	NOUN	B
of	O	ADP	O
the	O	DET	O
five	O	NUM	O
typical	O	ADJ	O
clinical	O	ADJ	B
symptoms	O	NOUN	I
,	O	PUNCT	O
earache	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
itching	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
otorrhea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hearing	I-OUT	VERB	B
impairment	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
"	I-OUT	PUNCT	O
clogged	I-OUT	ADJ	B
ear	I-OUT	NOUN	I
"	I-OUT	PUNCT	O
at	O	ADP	O
Visit	O	NOUN	B
2	O	NUM	I
(	O	PUNCT	O
Day	O	NOUN	O
7	O	NUM	O
)	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
examination	O	NOUN	B
on	O	ADP	O
Day	O	PROPN	B
0	O	NUM	O
.	O	PUNCT	O


Both	O	CCONJ	O
therapy	O	NOUN	B
groups	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
glycerol	B-I	NOUN	B
and	I-I	CCONJ	O
lidocaine	I-I	NOUN	B
exhibited	O	VERB	O
definite	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
overall	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
after	O	ADP	O
seven	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
improvement	O	NOUN	B
differed	O	VERB	O
from	O	ADP	O
the	O	DET	O
mild	B-OUT	ADJ	B
reduction	I-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
under	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
glycerol	O	NOUN	B
eardrops	O	NOUN	I
alone	O	ADV	O
.	O	PUNCT	O


Overall	O	ADJ	O
improvement	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
,	O	PUNCT	O
expressed	O	VERB	B
by	O	ADP	O
the	O	DET	O
area	O	NOUN	B
under	O	ADP	I
the	O	DET	I
curve	O	NOUN	I
of	O	ADP	O
the	O	DET	O
baseline-adjusted	B-OUT	ADJ	B
symptom	I-OUT	NOUN	I
sum	I-OUT	NOUN	I
score	I-OUT	NOUN	I
,	O	PUNCT	O
yielded	O	VERB	O
a	O	DET	O
mean	O	ADJ	O
value	O	NOUN	O
of	O	ADP	O
10.95	O	NUM	O
(	O	PUNCT	O
standard	O	ADJ	B
deviation	O	NOUN	I
27.4	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
morning	O	NOUN	B
survey	O	NOUN	B
of	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
receiving	O	VERB	O
eardrops	O	NOUN	B
containing	O	VERB	O
only	O	ADV	O
glycerol	O	NOUN	B
;	O	PUNCT	O
in	O	ADP	O
comparison	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
eardrops	O	NOUN	B
containing	O	VERB	O
glycerol	B-I	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
lidocaine	B-I	NOUN	B
it	O	PRON	O
was	O	AUX	O
15.71	O	NUM	O
(	O	PUNCT	O
+/-	O	CCONJ	O
23.6	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
glycerol	B-I	NOUN	B
with	O	ADP	O
0.5	O	NUM	O
%	O	NOUN	O
lidocaine	B-I	NOUN	B
,	O	PUNCT	O
23.16	O	NUM	O
(	O	PUNCT	O
+/-	O	CCONJ	O
19.4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	B-OUT	DET	O
severe	I-OUT	ADJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
occurred	O	VERB	O
.	O	PUNCT	O


Five	O	NUM	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
were	O	AUX	O
documented	O	VERB	B
during	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
investigation	O	NOUN	B
,	O	PUNCT	O
none	O	NOUN	O
of	O	ADP	O
which	O	DET	O
was	O	AUX	O
considered	O	VERB	O
by	O	ADP	O
the	O	DET	O
investigators	O	NOUN	B
to	O	PART	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
study	O	NOUN	B
medication	O	NOUN	I
.	O	PUNCT	O


Local	O	ADJ	B
therapy	B-I	NOUN	I
with	I-I	ADP	O
glycerol	I-I	NOUN	B
lidocaine	I-I	NOUN	I
eardrops	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
safe	B-OUT	ADJ	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cost-effective	I-OUT	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
widely	O	ADV	O
spread	O	VERB	B
clinical	O	ADJ	B
picture	O	NOUN	I
of	O	ADP	O
acute	O	ADJ	B
abacterial	O	ADJ	O
otitis	O	NOUN	O
externa	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
advantage	O	NOUN	O
regarding	O	VERB	O
efficacy	O	NOUN	B
of	O	ADP	O
this	O	DET	O
combination	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
glycerol	B-I	NOUN	B
eardrops	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
demonstrated	O	VERB	O
in	O	ADP	O
an	O	DET	O
adequately	O	ADV	O
powered	O	ADJ	O
clinical	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


Impacts	O	NOUN	B
of	O	ADP	O
a	O	DET	O
disease	B-I	NOUN	B
management	I-I	NOUN	I
program	I-I	NOUN	I
for	O	ADP	O
dually	B-P	ADV	B
eligible	I-P	ADJ	B
beneficiaries	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
LifeMasters	B-I	PROPN	O
Supported	I-I	PROPN	B
SelfCare	I-I	PROPN	I
demonstration	I-I	NOUN	I
program	I-I	NOUN	I
provides	O	VERB	O
disease	B-I	NOUN	B
management	I-I	NOUN	I
(	I-I	PUNCT	O
DM	I-I	NOUN	B
)	I-I	PUNCT	O
services	I-I	NOUN	B
to	O	ADP	O
Florida	B-P	PROPN	B
Medicare	I-P	PROPN	I
beneficiaries	I-P	NOUN	B
who	I-P	PRON	O
are	I-P	AUX	O
also	I-P	ADV	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
Medicaid	I-P	PROPN	B
and	I-P	CCONJ	O
have	I-P	AUX	O
congestive	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
(	I-P	PUNCT	O
CHF	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
diabetes	I-P	NOUN	B
,	I-P	PUNCT	O
or	I-P	CCONJ	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
CAD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
population-based	O	ADJ	B
program	O	NOUN	I
provides	O	VERB	O
primarily	B-I	ADV	O
telephonic	I-I	ADJ	B
patient	I-I	NOUN	I
education	I-I	NOUN	I
and	I-I	CCONJ	O
monitoring	I-I	NOUN	B
services	I-I	NOUN	I
.	I-I	PUNCT	O


Findings	O	NOUN	B
from	O	ADP	O
the	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
intent-to-treat	O	ADJ	B
design	O	NOUN	I
over	O	ADP	O
the	O	DET	O
first	O	ADJ	O
18	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
operations	O	NOUN	B
show	O	VERB	O
virtually	O	ADV	O
no	O	DET	O
overall	O	ADJ	O
impacts	B-OUT	NOUN	B
on	I-OUT	ADP	O
hospital	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
emergency	I-OUT	NOUN	B
room	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ER	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
Medicare	I-OUT	PROPN	B
expenditures	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
care	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
prescription	I-OUT	NOUN	B
drug	I-OUT	NOUN	I
use	I-OUT	NOUN	I
for	O	ADP	O
the	O	DET	O
33,000	B-P	NUM	O
enrollees	I-P	NOUN	B
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
beneficiaries	B-P	NOUN	B
with	I-P	ADP	O
CHF	I-P	NOUN	B
who	I-P	PRON	O
resided	I-P	VERB	O
in	I-P	ADP	O
high-cost	I-P	ADJ	B
South	I-P	PROPN	I
Florida	I-P	PROPN	I
counties	I-P	NOUN	I
,	O	PUNCT	O
the	O	DET	O
program	O	NOUN	B
reduced	O	VERB	B
Medicare	B-OUT	PROPN	B
expenditures	I-OUT	NOUN	I
by	O	ADP	O
9.6	O	NUM	O
percent	O	NOUN	O
.	O	PUNCT	O


Comparison	B-P	NOUN	B
of	I-P	ADP	O
synemol	I-I	NOUN	B
cream	I-I	NOUN	B
and	I-P	CCONJ	O
other	I-I	ADJ	O
topical	I-I	ADJ	B
corticosteroid	I-I	NOUN	I
creams	I-I	NOUN	I
using	I-P	VERB	O
the	I-P	DET	O
vasoconstrictor	I-P	NOUN	B
bioassay	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
human	B-P	ADJ	B
vasoconstrictor	I-P	NOUN	B
bioassay	I-P	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
potency	O	NOUN	B
of	O	ADP	O
open	B-P	ADJ	O
applications	I-P	NOUN	B
of	I-P	ADP	O
Synemol	I-I	PROPN	B
cream	I-I	NOUN	I
(	I-P	PUNCT	O
0.025	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
Diprosone	I-I	NOUN	B
cream	I-I	NOUN	I
(	I-I	PUNCT	O
0.05	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
Aristocort-A	I-I	PROPN	B
cream	I-I	NOUN	I
(	I-P	PUNCT	O
0.5	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
Valisone	I-I	NOUN	B
cream	I-I	NOUN	I
(	I-I	PUNCT	O
0.1	I-I	NUM	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
.	I-P	PUNCT	O


Intensity	O	NOUN	B
of	O	ADP	O
vasoconstriction	B-P	NOUN	B
was	O	AUX	O
determined	O	VERB	O
eight	O	NUM	O
,	O	PUNCT	O
twenty-four	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
thirty-two	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
application	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
average	O	ADJ	B
intensity	B-OUT	NOUN	O
scores	I-OUT	NOUN	O
of	O	ADP	O
the	O	DET	O
three	O	NUM	O
determinations	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
Synemol	B-I	PROPN	B
cream	I-I	NOUN	I
(	O	PUNCT	O
0.025	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
is	O	AUX	O
actually	O	ADV	O
a	O	DET	O
more	O	ADV	O
active	O	ADJ	B
compound	O	NOUN	O
than	O	ADP	O
are	O	AUX	O
Diprosone	B-I	NOUN	B
cream	I-I	NOUN	I
(	O	PUNCT	O
0.05	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
Aristocort-A	B-I	PROPN	B
cream	I-I	NOUN	I
(	O	PUNCT	O
0.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Valisone	B-I	NOUN	B
cream	I-I	NOUN	I
(	O	PUNCT	O
0.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
its	O	PRON	O
activity	O	NOUN	B
is	O	AUX	O
longer	O	ADV	O
acting	O	VERB	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
imiquimod	B-I	ADJ	B
cream	O	NOUN	I
and	O	CCONJ	O
reflectance-mode	B-I	ADJ	B
confocal	I-I	ADJ	I
microscopy	I-I	NOUN	I
as	O	ADP	O
adjunct	O	ADJ	B
modalities	O	NOUN	B
to	O	ADP	O
Mohs	B-I	ADJ	B
micrographic	I-I	ADJ	I
surgery	I-I	NOUN	I
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
basal	B-P	ADJ	B
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Imiquimod	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
immune	O	ADJ	B
response	O	NOUN	I
modifier	O	NOUN	I
that	O	PRON	O
up-regulates	O	VERB	B
cytokines	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
studies	O	NOUN	I
to	O	PART	O
reduce	O	VERB	B
or	O	CCONJ	O
clear	O	ADJ	O
basal	B-P	ADJ	B
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
tumors	O	NOUN	B
when	O	SCONJ	O
applied	O	VERB	O
topically	O	ADV	B
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
objectives	O	NOUN	B
were	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
imiquimod	B-I	ADJ	B
cream	O	NOUN	I
in	O	ADP	O
treating	O	VERB	B
basal	O	ADJ	B
cell	O	NOUN	I
carcinoma	O	NOUN	I
preceding	O	VERB	O
excision	O	NOUN	B
by	O	ADP	O
Mohs	O	ADJ	B
micrographic	O	ADJ	I
surgery	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
reflectance-mode	B-I	ADJ	B
confocal	I-I	ADJ	I
microscopy	I-I	NOUN	I
is	O	AUX	O
useful	O	ADJ	O
to	O	PART	O
establish	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
surgical	O	ADJ	B
intervention	O	NOUN	I
after	O	ADP	O
imiquimod	B-I	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


METHODS	O	PROPN	O
Subjects	B-P	NOUN	B
applied	I-P	VERB	O
study	I-P	NOUN	B
cream	I-P	NOUN	B
to	I-P	PART	O
one	I-P	NUM	O
biopsy-confirmed	I-P	ADJ	B
basal	I-P	ADJ	B
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
tumor	I-P	NOUN	O
5	O	NUM	O
x/week	O	NOUN	O
for	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
6	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
this	O	DET	O
vehicle-controlled	B-P	ADJ	B
,	I-P	PUNCT	O
double-blind	I-P	ADJ	B
study	I-P	NOUN	I
.	I-P	PUNCT	O


Confocal	B-I	ADJ	B
microscopy	I-I	NOUN	I
was	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
6-week	O	ADJ	B
treatment	O	NOUN	B
group	O	NOUN	I
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
target	O	NOUN	B
tumor	O	NOUN	O
area	O	NOUN	O
at	O	ADP	O
each	O	DET	O
interval	O	NOUN	B
visit	O	NOUN	I
and	O	CCONJ	O
immediately	O	ADV	O
before	O	ADP	O
Mohs	B-I	ADJ	B
micrographic	I-I	ADJ	I
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


After	O	ADP	O
the	O	DET	O
Mohs	B-I	ADJ	B
micrographic	I-I	ADJ	I
surgery	I-I	NOUN	I
excision	I-I	NOUN	I
,	O	PUNCT	O
the	O	DET	O
tissue	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
histologically	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
excision	O	NOUN	B
area	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


Confocal	B-I	ADJ	B
microscopy	I-I	NOUN	I
readings	O	NOUN	B
were	O	AUX	O
correlated	O	VERB	B
to	O	PART	O
the	O	DET	O
histologic	O	ADJ	B
diagnosis	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
Tumors	B-OUT	NOUN	I
cleared	I-OUT	VERB	B
or	I-OUT	CCONJ	O
the	I-OUT	DET	O
target	I-OUT	NOUN	B
tumor	I-OUT	NOUN	O
area	I-OUT	NOUN	O
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
subjects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
4-	O	NUM	O
and	O	CCONJ	O
6-week	O	ADJ	B
dosing	O	NOUN	B
regimens	O	NOUN	B
.	O	PUNCT	O


Confocal	B-OUT	ADJ	B
microscopy	I-OUT	NOUN	I
assessments	I-OUT	NOUN	B
correlated	O	VERB	B
well	O	ADV	O
with	O	ADP	O
the	O	DET	O
histologic	O	ADJ	B
diagnosis	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Imiquimod	B-I	NOUN	B
improved	O	VERB	O
excision	B-OUT	NOUN	B
results	I-OUT	NOUN	I
relative	O	ADJ	O
to	O	PART	O
vehicle	O	NOUN	B
when	O	SCONJ	O
used	O	VERB	O
for	O	ADP	O
treating	O	VERB	B
basal	B-P	ADJ	B
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
before	I-P	ADP	O
Mohs	I-I	ADJ	B
micrographic	I-I	ADJ	I
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


Confocal	O	ADJ	B
microscopy	O	NOUN	I
assessments	O	NOUN	B
correlated	O	VERB	B
well	O	ADV	O
with	O	ADP	O
tumor	O	NOUN	B
response	O	NOUN	I
to	O	PART	O
therapy	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
confocal	O	ADJ	B
microscopy	O	NOUN	I
may	O	AUX	O
help	O	VERB	O
determine	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Alpha	B-I	NOUN	B
interferon	I-I	NOUN	I
clinical	O	ADJ	I
trial	O	NOUN	I
for	O	ADP	O
multiple	B-P	ADJ	B
sclerosis	I-P	NOUN	I
:	I-P	PUNCT	O
design	O	NOUN	B
considerations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
design	O	NOUN	B
and	O	CCONJ	O
course	O	NOUN	B
of	O	ADP	O
a	O	DET	O
placebo-controlled	B-I	ADJ	B
alpha-2	I-I	NOUN	I
interferon	I-I	NOUN	I
trial	O	NOUN	I
in	O	ADP	O
MS	B-P	NOUN	B
patients	I-P	NOUN	B
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


No	B-OUT	DET	O
beneficial	I-OUT	ADJ	O
effect	I-OUT	NOUN	O
of	O	ADP	O
the	O	DET	O
interferon	B-OUT	NOUN	B
on	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
MS	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
shown	O	VERB	O
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
5-aminosalicylic	B-I	ADJ	B
acid	I-I	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
prednisolone	B-I	NOUN	B
phosphate	I-I	NOUN	B
sodium	I-I	NOUN	I
enemas	O	NOUN	I
(	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
distal	B-OUT	ADJ	B
ulcerative	I-OUT	ADJ	I
colitis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Twenty-nine	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
attacks	I-P	NOUN	B
of	I-P	ADP	O
distal	I-P	ADJ	B
ulcerative	I-P	ADJ	I
colitis	I-P	NOUN	I
were	O	AUX	O
treated	O	VERB	B
randomly	O	ADV	B
with	O	ADP	I
3	O	NUM	O
g	O	NOUN	O
5-aminosalicylic	B-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
5-ASA	I-I	NOUN	B
)	I-I	PUNCT	O
or	O	CCONJ	O
30	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
prednisolone	B-I	NOUN	B
phosphate	I-I	NOUN	O
sodium	I-I	NOUN	O
(	I-I	PUNCT	O
PP	I-I	NOUN	B
)	I-I	PUNCT	O
enemas	O	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
ml	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Endoscopic	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
clinical	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
histologic	I-OUT	ADJ	B
improvement	I-OUT	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
study	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
topical	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
5-ASA	B-I	NOUN	B
is	O	AUX	O
as	O	ADV	O
efficacious	O	ADJ	B
as	O	ADP	O
PP	B-I	NOUN	B
in	O	ADP	O
improving	O	VERB	B
distal	B-OUT	ADJ	B
ulcerative	I-OUT	ADJ	I
colitis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Scales	O	NOUN	B
for	O	ADP	O
the	O	DET	O
assessment	O	NOUN	B
of	O	ADP	O
neuroleptic	B-OUT	ADJ	B
response	I-OUT	NOUN	I
in	O	ADP	O
schizophrenic	B-P	ADJ	B
children	I-P	NOUN	I
:	I-P	PUNCT	O
specific	O	ADJ	O
measures	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
CPRS	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
article	O	NOUN	O
reports	O	VERB	B
the	O	DET	O
psychometric	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
scales	O	NOUN	B
for	O	ADP	O
rating	O	VERB	B
positive	O	ADJ	I
and	O	CCONJ	O
negative	O	ADJ	B
schizophrenic	O	ADJ	B
signs	O	NOUN	O
and	O	CCONJ	O
symptoms	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
Positive	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
Negative	I-OUT	ADJ	O
Syndrome	I-OUT	PROPN	O
Scales	I-OUT	PROPN	O
consist	O	VERB	O
of	O	ADP	O
items	O	NOUN	B
selected	O	VERB	O
from	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
's	O	PART	I
Psychiatric	O	PROPN	B
Rating	O	PROPN	I
Scale	O	NOUN	I
(	O	PUNCT	O
CPRS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
contains	O	VERB	O
items	O	NOUN	B
covering	O	VERB	O
a	O	DET	O
wide	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
childhood	O	NOUN	B
psychopathology	O	NOUN	B
.	O	PUNCT	O


CPRS	O	NOUN	B
rating	O	NOUN	O
data	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
19	B-P	NUM	O
schizophrenic	I-P	ADJ	B
children	I-P	NOUN	B
,	I-P	PUNCT	O
16	I-P	NUM	O
males	I-P	NOUN	B
and	I-P	CCONJ	O
3	I-P	NUM	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
8.9	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
range	I-P	NOUN	O
5.5-11.7	I-P	NUM	O
)	I-P	PUNCT	O
,	O	PUNCT	O
evaluated	O	VERB	B
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
crossover	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
haloperidol	B-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
item	O	NOUN	B
composition	O	NOUN	B
and	O	CCONJ	O
coherence	O	NOUN	B
of	O	ADP	O
each	O	DET	O
scale	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
interrater	O	NOUN	B
reliabilities	O	NOUN	B
of	O	ADP	O
clinicians	O	NOUN	B
using	O	VERB	O
the	O	DET	O
scales	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
scales	O	NOUN	B
for	O	ADP	O
resolving	O	VERB	B
treatment	O	NOUN	I
response	O	NOUN	I
.	O	PUNCT	O


Schizophrenic	B-P	ADJ	B
children	I-P	NOUN	O
showed	O	VERB	O
both	O	CCONJ	O
positive	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
negative	I-OUT	ADJ	B
signs	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
symptoms	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
improved	O	VERB	B
with	O	ADP	O
neuroleptic	B-OUT	ADJ	B
treatment	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
creatine	B-I	NOUN	B
supplementation	I-I	NOUN	B
on	O	ADP	O
repetitive	O	ADJ	B
sprint	O	NOUN	I
performance	O	NOUN	B
and	O	CCONJ	O
body	O	NOUN	B
composition	O	NOUN	I
in	O	ADP	O
competitive	B-P	ADJ	B
swimmers	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
and	O	CCONJ	O
randomized	O	ADJ	B
manner	O	NOUN	O
,	O	PUNCT	O
18	B-P	NUM	O
male	I-P	NOUN	B
and	I-P	CCONJ	O
female	I-P	ADJ	B
junior	I-P	ADJ	O
competitive	I-P	ADJ	B
swimmers	I-P	NOUN	B
supplemented	O	VERB	B
their	O	PRON	O
diets	O	NOUN	B
with	O	ADP	O
21	O	NUM	O
g.day-1	O	NOUN	O
of	O	ADP	O
creatine	B-I	NOUN	B
monohydrate	I-I	NOUN	I
(	I-I	PUNCT	O
Cr	I-I	NOUN	B
)	I-I	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
maltodextrin	B-I	NOUN	B
placebo	I-I	NOUN	B
(	I-I	PUNCT	O
P	I-I	NOUN	O
)	I-I	PUNCT	O
for	O	ADP	O
9	B-P	NUM	O
days	I-P	NOUN	B
during	I-P	ADP	O
training	I-P	NOUN	B
.	I-P	PUNCT	O


Prior	O	ADV	O
to	O	ADP	O
and	O	CCONJ	O
following	O	VERB	O
supplementation	O	NOUN	B
,	O	PUNCT	O
subjects	O	NOUN	B
performed	O	VERB	O
three	O	NUM	O
100-m	O	ADJ	O
freestyle	O	NOUN	B
sprint	O	NOUN	B
swims	O	VERB	I
(	O	PUNCT	O
long	O	ADJ	B
course	O	NOUN	I
)	O	PUNCT	O
with	O	ADP	O
60	O	NUM	O
s	O	NOUN	O
rest/recovery	O	NOUN	B
between	O	ADP	O
heats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
subjects	O	NOUN	B
performed	O	VERB	O
three	O	NUM	O
20-s	O	ADJ	O
arm	O	NOUN	O
ergometer	O	NOUN	O
maximal-effort	O	ADJ	O
sprint	O	NOUN	O
tests	O	NOUN	O
in	O	ADP	O
the	O	DET	O
prone	O	ADJ	B
position	O	NOUN	I
with	O	ADP	O
60	O	NUM	O
s	O	NOUN	O
rest/recovery	O	NOUN	B
between	O	ADP	O
sprint	O	NOUN	B
tests	O	NOUN	I
.	O	PUNCT	O


Significant	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
among	O	ADP	O
swim	B-OUT	NOUN	B
times	I-OUT	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
Cr	O	NOUN	B
subjects	O	NOUN	B
swimming	O	VERB	B
significantly	O	ADV	B
faster	O	ADV	I
than	O	ADP	O
P	O	NOUN	O
subjects	O	NOUN	B
following	O	VERB	O
supplementation	O	NOUN	B
in	O	ADP	O
Heat	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
significantly	O	ADV	O
decreasing	O	VERB	B
swim	B-OUT	NOUN	B
time	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
100-m	O	ADJ	O
sprint	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
also	O	ADV	O
some	O	DET	O
evidence	O	NOUN	B
that	O	SCONJ	O
cumulative	B-OUT	ADJ	B
time	I-OUT	NOUN	O
to	I-OUT	PART	O
perform	I-OUT	VERB	O
the	I-OUT	DET	O
three	I-OUT	NUM	O
100-m	I-OUT	ADJ	O
swims	I-OUT	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
Cr	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
9	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
Cr	B-I	NOUN	B
supplementation	O	NOUN	B
during	O	ADP	O
swim	O	NOUN	B
training	O	NOUN	I
may	O	AUX	O
provide	O	VERB	O
some	O	DET	O
ergogenic	O	ADJ	B
value	O	NOUN	I
to	O	PART	O
competitive	O	ADJ	B
junior	O	ADJ	B
swimmers	O	NOUN	B
during	O	ADP	O
repetitive	O	ADJ	B
sprint	O	NOUN	I
performance	O	NOUN	B
.	O	PUNCT	O


Total	O	ADJ	O
anthelmintic	O	ADJ	B
failure	O	NOUN	I
to	O	PART	O
control	O	VERB	B
nematode	B-P	NOUN	I
parasites	I-P	NOUN	B
of	I-P	ADP	O
small	I-P	ADJ	B
ruminants	I-P	NOUN	I
on	I-P	ADP	O
government	I-P	NOUN	B
breeding	I-P	NOUN	B
farms	I-P	NOUN	B
in	I-P	ADP	O
Sabah	I-P	PROPN	B
,	I-P	PUNCT	O
East	I-P	PROPN	B
Malaysia	I-P	PROPN	I
.	I-P	PUNCT	O


Government-owned	B-P	ADJ	B
small-ruminant	I-P	ADJ	B
breeding	I-P	NOUN	B
farms	I-P	NOUN	B
in	O	ADP	O
Malaysia	O	PROPN	B
provide	O	VERB	O
the	O	DET	O
source	O	NOUN	B
of	O	ADP	O
sheep	O	NOUN	B
and	O	CCONJ	O
goats	O	NOUN	B
to	O	ADP	O
smallholder	O	NOUN	B
farmers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
country	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
eastern	B-P	ADJ	B
Malaysian	I-P	ADJ	I
state	I-P	NOUN	I
of	I-P	ADP	O
Sabah	I-P	PROPN	B
,	O	PUNCT	O
high-level	O	ADJ	O
stock	O	NOUN	O
losses	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
recorded	O	VERB	O
on	O	ADP	O
these	O	DET	O
farms	O	NOUN	B
for	O	ADP	O
several	O	ADJ	O
years	O	NOUN	B
,	O	PUNCT	O
frequently	O	ADV	O
accompanied	O	VERB	O
by	O	ADP	O
clinical	O	ADJ	B
signs	O	NOUN	I
indicating	O	VERB	O
pathogenic	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
infections	O	NOUN	B
with	O	ADP	O
the	O	DET	O
nematode	B-P	NOUN	B
parasite	I-P	NOUN	B
Haemonchus	I-P	PROPN	B
contortus	I-P	X	I
.	I-P	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
their	O	PRON	O
dependence	O	NOUN	O
on	O	ADP	O
chemotherapy	B-I	NOUN	B
to	O	PART	O
control	O	VERB	O
parasite	O	NOUN	B
infections	O	NOUN	B
had	O	AUX	O
failed	O	VERB	B
.	O	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
tests	O	NOUN	B
for	O	ADP	O
anthelmintic	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	B
using	O	VERB	O
the	O	DET	O
faecal	B-OUT	ADJ	B
egg	I-OUT	NOUN	O
count	I-OUT	NOUN	O
reduction	I-OUT	NOUN	O
test	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
FECRT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
on	O	ADP	O
the	O	DET	O
range	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
used	O	VERB	O
to	O	PART	O
control	O	VERB	B
nematode	O	NOUN	I
parasites	O	NOUN	B
were	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
on	O	ADP	O
the	O	DET	O
five	O	NUM	O
government	O	NOUN	B
small-ruminant	O	ADJ	B
breeding	O	NOUN	B
farms	O	NOUN	B
in	O	ADP	O
Sabah	O	PROPN	B
.	O	PUNCT	O


These	O	DET	O
tests	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
total	O	ADJ	O
failure	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
benzimidazole	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
imidothiazole	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
macrocyclic	I-OUT	ADJ	B
lactone	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
salicylanilide	I-OUT	NOUN	B
groups	I-OUT	NOUN	I
of	I-OUT	ADP	O
anthelmintics	I-OUT	NOUN	B
to	O	PART	O
control	B-OUT	VERB	O
H.	I-OUT	X	B
contortus	I-OUT	X	I
infections	I-OUT	NOUN	B
of	O	ADP	O
sheep	B-P	NOUN	B
and	I-P	CCONJ	O
goats	I-P	NOUN	B
on	I-P	ADP	O
all	I-P	DET	O
farms	I-P	NOUN	B
.	I-P	PUNCT	O


Drastic	O	ADJ	B
changes	O	NOUN	O
in	O	ADP	O
animal	O	NOUN	B
management	O	NOUN	I
need	O	NOUN	O
to	O	PART	O
be	O	AUX	O
made	O	VERB	O
in	O	ADP	O
an	O	DET	O
attempt	O	NOUN	B
to	O	PART	O
deal	O	VERB	O
with	O	ADP	O
this	O	DET	O
situation	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
which	O	DET	O
suggestions	O	NOUN	B
are	O	AUX	O
made	O	VERB	O
.	O	PUNCT	O


Clinical	O	ADJ	B
pathway	O	NOUN	I
for	O	ADP	O
fractured	B-P	ADJ	B
neck	I-P	NOUN	O
of	I-P	ADP	O
femur	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
outcomes	O	NOUN	B
of	O	ADP	O
using	O	VERB	O
a	O	DET	O
clinical	O	ADJ	B
pathway	O	NOUN	I
for	O	ADP	O
managing	O	VERB	O
patients	B-P	NOUN	B
with	I-P	ADP	O
fractured	I-P	ADJ	B
neck	I-P	NOUN	O
of	I-P	ADP	O
femur	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Prospective	O	ADJ	B
,	O	PUNCT	O
pseudorandomised	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
St	B-P	PROPN	O
Vincent	I-P	PROPN	O
's	I-P	PART	O
Hospital	I-P	PROPN	O
,	I-P	PUNCT	O
Melbourne	I-P	PROPN	B
,	I-P	PUNCT	O
Victoria	I-P	PROPN	B
(	I-P	PUNCT	O
a	I-P	DET	O
tertiary	I-P	ADJ	B
referral	I-P	NOUN	I
,	I-P	PUNCT	O
university	I-P	NOUN	B
teaching	I-P	NOUN	I
hospital	I-P	NOUN	I
)	I-P	PUNCT	O
,	I-P	PUNCT	O
1	I-P	NUM	O
October	I-P	PROPN	O
1997	I-P	NUM	O
to	I-P	ADP	O
30	I-P	NUM	O
November	I-P	PROPN	O
1998	I-P	NUM	O
.	I-P	PUNCT	O


PARTICIPANTS	O	VERB	B
111	B-P	NUM	I
patients	I-P	NOUN	B
(	I-P	PUNCT	O
80	I-P	NUM	O
women	I-P	NOUN	B
and	I-P	CCONJ	O
31	I-P	NUM	O
men	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
81	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
admitted	I-P	VERB	B
via	I-P	ADP	O
the	I-P	DET	O
emergency	I-P	NOUN	B
department	I-P	NOUN	I
with	I-P	ADP	O
a	I-P	DET	O
primary	I-P	ADJ	B
diagnosis	I-P	NOUN	I
of	I-P	ADP	O
fractured	I-P	ADJ	B
neck	I-P	NOUN	O
of	I-P	ADP	O
femur	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
Management	B-I	PROPN	B
guided	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
clinical	I-I	ADJ	B
pathway	I-I	NOUN	I
(	I-I	PUNCT	O
55	I-I	NUM	O
patients	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
established	I-I	VERB	O
standard	I-I	NOUN	B
of	I-I	ADP	I
care	I-I	NOUN	I
(	O	PUNCT	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
56	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	X	B
MEASURES	O	NOUN	O
Timing	B-OUT	NOUN	B
of	I-OUT	ADP	O
referrals	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
discharge	I-OUT	VERB	B
planning	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
total	I-OUT	ADJ	O
length	I-OUT	NOUN	O
of	I-OUT	ADP	O
stay	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
complication	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
readmission	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
within	I-OUT	ADP	O
28	I-OUT	NUM	O
days	I-OUT	NOUN	B
of	I-OUT	ADP	O
discharge	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Patients	O	NOUN	B
managed	O	VERB	O
according	O	VERB	O
to	O	PART	O
the	O	DET	O
clinical	O	ADJ	B
pathway	O	NOUN	I
had	O	AUX	O
a	O	DET	O
shorter	O	ADJ	B
total	B-OUT	ADJ	O
stay	I-OUT	NOUN	O
(	O	PUNCT	O
6.6	O	NUM	O
versus	O	CCONJ	O
8.0	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
even	O	ADV	O
if	O	SCONJ	O
assessment	O	NOUN	B
for	O	ADP	O
placement	O	NOUN	B
by	O	ADP	O
the	O	DET	O
Aged	O	PROPN	B
Care	O	PROPN	I
Assessment	O	PROPN	I
Service	O	PROPN	I
was	O	AUX	O
required	O	VERB	O
(	O	PUNCT	O
9.5	O	NUM	O
versus	O	CCONJ	O
13.6	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
complication	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
readmission	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
between	O	ADP	O
pathway	O	NOUN	B
and	O	CCONJ	O
control	B-P	NOUN	B
patients	I-P	NOUN	I
(	O	PUNCT	O
complication	O	NOUN	B
rates	O	NOUN	B
,	O	PUNCT	O
24	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
36	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.40	O	NUM	O
;	O	PUNCT	O
readmission	O	NOUN	B
rates	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
11	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.28	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Coordinated	O	ADJ	B
multidisciplinary	O	ADJ	B
care	O	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
fractured	I-P	ADJ	B
neck	I-P	NOUN	O
of	I-P	ADP	O
femur	I-P	NOUN	B
reduces	O	VERB	B
length	B-OUT	NOUN	B
of	I-OUT	ADP	I
stay	I-OUT	NOUN	I
without	O	ADP	O
increasing	O	VERB	B
complications	O	NOUN	B
.	O	PUNCT	O


Therapy	O	NOUN	B
for	O	ADP	O
progressive	B-P	ADJ	B
supranuclear	I-P	ADJ	B
palsy	I-P	NOUN	I
:	I-P	PUNCT	O
past	O	NOUN	O
and	O	CCONJ	O
future	O	NOUN	B
.	O	PUNCT	O


Dysfunction	O	NOUN	B
of	O	ADP	O
multiple	O	ADJ	O
brain	O	NOUN	B
systems	O	NOUN	I
in	O	ADP	O
progressive	B-P	ADJ	B
supranuclear	I-P	ADJ	B
palsy	I-P	NOUN	I
(	I-P	PUNCT	O
PSP	I-P	NOUN	B
)	I-P	PUNCT	O
has	O	AUX	O
complicated	O	VERB	B
attempts	O	NOUN	O
to	O	PART	O
treat	O	VERB	B
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


Neurotransmitter	B-I	NOUN	B
replacement	I-I	NOUN	O
strategies	I-I	NOUN	O
targeting	O	VERB	B
the	O	DET	O
dopaminergic	O	ADJ	B
,	O	PUNCT	O
cholinergic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
serotonergic	O	ADJ	B
systems	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
unsuccessful	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
bypass	O	VERB	B
the	O	DET	O
degenerated	O	VERB	B
cortico-striato-pallidal	O	ADJ	O
loop	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
administered	O	VERB	B
the	O	DET	O
adrenergic	B-I	ADJ	B
agonist	I-I	NOUN	I
idazoxan	I-I	NOUN	I
(	I-I	PUNCT	O
IDA	I-I	NOUN	B
)	I-I	PUNCT	O
to	O	PART	O
treat	O	VERB	B
PSP	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
,	O	PUNCT	O
placebo	B-I	NOUN	B
controlled	O	VERB	O
,	O	PUNCT	O
crossover	O	NOUN	B
studies	O	NOUN	I
.	O	PUNCT	O


Approximately	O	ADV	O
one	O	NUM	O
half	O	NOUN	O
of	O	ADP	O
patients	B-P	NOUN	B
enrolled	I-P	VERB	O
in	I-P	ADP	O
these	I-P	DET	O
studies	I-P	NOUN	B
showed	O	VERB	O
statistically	B-OUT	ADV	B
significant	I-OUT	ADJ	I
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
balance	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
manual	I-OUT	ADJ	B
dexterity	I-OUT	NOUN	O
while	O	SCONJ	O
taking	O	VERB	O
IDA	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
new	O	ADJ	O
therapies	B-I	NOUN	B
that	O	PRON	O
target	O	VERB	B
structures	O	NOUN	O
outside	O	ADP	O
of	O	ADP	O
the	O	DET	O
basal	O	ADJ	B
ganglia	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
symptomatic	B-OUT	ADJ	B
treatment	I-OUT	NOUN	B
of	I-OUT	ADP	O
PSP	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Applying	O	VERB	O
this	O	DET	O
strategy	O	NOUN	O
and	O	CCONJ	O
developing	O	VERB	O
treatments	O	NOUN	B
that	O	PRON	O
arrest	O	NOUN	B
or	O	CCONJ	O
reverse	O	ADJ	O
clinical	O	ADJ	O
deterioration	O	NOUN	O
in	O	ADP	O
PSP	O	NOUN	B
will	O	AUX	O
require	O	VERB	O
improved	O	VERB	B
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
process	O	NOUN	B
underlying	O	VERB	O
the	O	DET	O
illness	O	NOUN	B
.	O	PUNCT	O


Efficiency	B-OUT	NOUN	B
of	I-I	ADP	O
adjuvant	I-I	ADJ	B
immunochemotherapy	I-I	NOUN	B
following	O	VERB	O
curative	O	ADJ	B
resection	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
locally	I-P	ADV	B
advanced	I-P	ADJ	I
gastric	I-P	ADJ	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
Despite	O	SCONJ	O
curative	O	ADJ	B
resection	O	NOUN	I
,	O	PUNCT	O
50	O	NUM	O
%	O	NOUN	O
-90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
gastric	B-P	ADJ	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
die	O	VERB	B
of	O	ADP	O
disease	B-OUT	NOUN	B
relapse	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Although	O	SCONJ	O
some	O	DET	O
clinical	O	ADJ	B
trials	O	NOUN	I
have	O	AUX	O
indicated	O	VERB	O
that	O	SCONJ	O
chemotherapy	O	NOUN	B
and	O	CCONJ	O
immunochemotherapy	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
modalities	O	NOUN	B
,	O	PUNCT	O
more	O	ADV	O
recent	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
able	O	ADJ	O
to	O	PART	O
define	O	VERB	O
the	O	DET	O
standard	O	ADJ	B
treatment	O	NOUN	I
for	O	ADP	O
advanced	B-P	ADJ	B
gastric	I-P	ADJ	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
adjuvant	B-I	ADJ	B
immunochemotherapy	I-I	NOUN	O
with	I-I	ADP	O
the	I-I	DET	O
use	I-I	NOUN	O
of	I-I	ADP	O
BCG	I-I	NOUN	B
(	I-I	PUNCT	O
bacille	I-I	X	B
Calmette-Guerin	I-I	X	I
)	I-I	PUNCT	O
and	I-I	CCONJ	O
FAM	I-I	NOUN	B
(	I-I	PUNCT	O
5-fluorouracil	I-I	NOUN	B
,	I-I	PUNCT	O
adriamycin	I-I	NOUN	B
,	I-I	PUNCT	O
mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
)	I-I	PUNCT	O
chemotherapy	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
survival	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-P	ADP	O
locally	I-P	ADV	B
advanced	I-P	ADJ	I
resectable	I-P	ADJ	I
gastric	I-P	ADJ	O
cancer	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
156	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
stage	I-P	NOUN	B
III	I-P	NUM	I
or	I-P	CCONJ	I
IV	I-P	NUM	B
gastric	I-P	ADJ	I
cancer	I-P	NOUN	I
who	I-P	PRON	O
had	I-P	AUX	O
undergone	I-P	VERB	O
curative	I-P	ADJ	B
resection	I-P	NOUN	I
were	O	AUX	O
randomly	B-I	ADV	O
assigned	I-I	VERB	O
to	I-I	PART	O
three	I-I	NUM	O
treatment	I-I	NOUN	B
groups	I-I	NOUN	I
:	I-I	PUNCT	O
BCG	I-I	NOUN	B
+	I-I	CCONJ	O
FAM	I-I	NOUN	B
(	I-I	PUNCT	O
immunochemotherapy	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
FAM	I-I	NOUN	B
(	I-I	PUNCT	O
chemotherapy	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
control	I-I	NOUN	B
(	I-I	PUNCT	O
surgery	I-I	NOUN	B
only	I-I	ADV	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Treatment	B-I	NOUN	B
was	I-I	AUX	O
continued	I-I	VERB	O
for	I-I	ADP	O
2	I-I	NUM	O
years	I-I	NOUN	B
or	I-I	CCONJ	O
until	I-I	ADP	O
death	I-I	NOUN	B
.	I-I	PUNCT	O


Further	B-I	ADV	O
postsurgical	I-I	ADJ	B
follow	I-I	NOUN	B
up	I-I	ADP	I
was	I-I	AUX	O
carried	I-I	VERB	O
on	I-I	ADP	O
for	I-I	ADP	O
up	I-I	ADV	O
to	I-I	PART	O
10	I-I	NUM	O
years	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	VERB	O
Overall	O	ADJ	O
10-year	B-OUT	ADJ	O
survival	I-OUT	NOUN	B
was	O	AUX	O
47.1	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
immunochemotherapy	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.037	O	NUM	O
vs	O	CCONJ	O
FAM	B-I	NOUN	B
and	O	CCONJ	O
P	O	NOUN	O
<	O	X	O
0.0006	O	NUM	O
vs	O	CCONJ	O
control	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
chemotherapy	B-I	NOUN	B
group	O	NOUN	O
(	O	PUNCT	O
vs	O	CCONJ	O
control	O	NOUN	B
,	O	PUNCT	O
NS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
15.2	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
pT2/T3	I-P	ADJ	B
primary	I-P	ADJ	B
tumors	I-P	NOUN	I
,	O	PUNCT	O
10-year	B-OUT	ADJ	O
survival	I-OUT	NOUN	B
was	O	AUX	O
55.3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
BCG	B-I	NOUN	B
+	I-I	CCONJ	O
FAM	I-I	NOUN	B
vs	O	CCONJ	O
28.2	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
FAM	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
14.6	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.00018	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


BCG	B-I	NOUN	B
+	I-I	CCONJ	O
FAM	I-I	PROPN	B
significantly	O	ADV	O
improved	O	VERB	B
the	O	DET	O
survival	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-P	ADP	O
intestinal-type	I-P	ADJ	B
but	I-P	CCONJ	O
not	I-P	PART	O
diffuse-type	I-P	ADJ	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Immunochemotherapy	B-I	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
This	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
limited	B-P	ADJ	O
number	I-P	NOUN	O
of	I-P	ADP	O
patients	I-P	NOUN	B
,	O	PUNCT	O
indicates	O	VERB	O
that	O	SCONJ	O
adjuvant	O	ADJ	B
immunochemotherapy	O	NOUN	I
(	O	PUNCT	O
BCG	O	NOUN	B
+	O	CCONJ	O
FAM	O	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
prolong	O	VERB	O
the	O	DET	O
survival	B-OUT	NOUN	B
of	O	ADP	O
gastric	B-P	ADJ	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
after	I-P	ADP	O
curative	I-P	ADJ	B
gastrectomy	I-P	NOUN	I
;	I-P	PUNCT	O
in	I-P	ADP	O
particular	I-P	ADJ	O
,	I-P	PUNCT	O
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
pT2/T3	I-P	NOUN	B
tumors	I-P	NOUN	B
and	I-P	CCONJ	O
intestinal-type	I-P	ADJ	B
primary	I-P	ADJ	I
tumors	I-P	NOUN	I
.	I-P	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
survival	B-OUT	NOUN	B
benefit	I-OUT	NOUN	B
from	O	ADP	O
FAM	B-I	NOUN	B
adjuvant	I-I	ADJ	O
chemotherapy	I-I	NOUN	O
.	I-I	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
Chinese	B-I	ADJ	B
herbal	I-I	ADJ	I
medicine	I-I	NOUN	I
on	O	ADP	O
vascular	B-OUT	ADJ	B
functions	I-OUT	NOUN	I
during	O	ADP	O
60-day	O	ADJ	B
head-down	O	ADJ	B
bed	O	NOUN	I
rest	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	ADJ	B
Chinese	B-I	ADJ	I
herbal	I-I	ADJ	I
medicine	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
promising	O	ADJ	O
countermeasure	O	NOUN	B
against	O	ADP	O
cardiovascular	B-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
associated	I-P	VERB	B
with	I-P	ADP	I
a	I-P	DET	O
sedentary	I-P	ADJ	B
lifestyle	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Chinese	B-I	ADJ	B
herb	I-I	NOUN	I
,	I-I	PUNCT	O
Taikong	I-I	PROPN	B
Yangxin	I-I	PROPN	I
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
micro-	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
macrovascular	I-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
60-day	B-P	ADJ	O
bed	I-P	NOUN	B
rest	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fourteen	B-P	NUM	O
healthy	I-P	ADJ	B
men	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
those	O	DET	O
given	O	VERB	O
herbal	B-I	ADJ	B
supplement	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
;	O	PUNCT	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
underwent	O	VERB	O
a	O	DET	O
60-day	B-I	ADJ	O
bed	I-I	NOUN	B
rest	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
macrovasculature	B-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
sonography	O	NOUN	B
.	O	PUNCT	O


Skin	B-OUT	NOUN	B
microvascular	I-OUT	NOUN	B
functions	I-OUT	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
with	O	ADP	O
laser	O	NOUN	B
Doppler	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
plasma	B-OUT	NOUN	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
endothelial	I-OUT	ADJ	B
microparticles	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
EMPs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
markers	O	NOUN	B
of	O	ADP	O
endothelial	B-OUT	ADJ	B
injury	I-OUT	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Bed	O	NOUN	B
rest	O	NOUN	I
induced	O	VERB	B
a	O	DET	O
33	O	NUM	O
%	O	NOUN	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
femoral	B-OUT	ADJ	B
artery	I-OUT	NOUN	I
diameter	I-OUT	NOUN	B
and	O	CCONJ	O
compliance	B-OUT	NOUN	B
whereas	O	SCONJ	O
carotid	B-OUT	NOUN	B
wall	I-OUT	NOUN	I
thickness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
diameter	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
compliance	I-OUT	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
early	B-OUT	ADJ	B
phase	I-OUT	NOUN	B
of	I-OUT	ADP	O
endothelium-dependent	I-OUT	ADJ	B
vasodilation	I-OUT	NOUN	I
to	I-OUT	PART	O
ACh	I-OUT	NOUN	B
was	O	AUX	O
unmodified	O	VERB	O
by	O	ADP	O
bed	O	NOUN	B
rest	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
late	B-OUT	ADJ	B
phase	I-OUT	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
along	O	ADP	O
with	O	ADP	O
a	O	DET	O
twofold	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
EMPs	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
those	O	DET	O
given	O	VERB	O
Taikong	B-I	PROPN	B
Yangxin	I-I	PROPN	I
,	O	PUNCT	O
the	O	DET	O
early	B-OUT	ADJ	B
phase	I-OUT	NOUN	I
was	O	AUX	O
amplified	O	VERB	B
by	O	ADP	O
2.5-fold	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
effects	B-OUT	NOUN	B
of	I-OUT	ADP	I
bed	I-OUT	NOUN	B
rest	I-OUT	NOUN	I
on	O	ADP	O
the	O	DET	O
late	B-OUT	ADJ	B
phase	I-OUT	NOUN	I
were	O	AUX	O
prevented	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
Taikong	O	PROPN	B
Yangxin	O	PROPN	I
ameliorates	O	VERB	O
endothelium-dependent	B-OUT	ADJ	B
vasodilation	I-OUT	NOUN	I
,	O	PUNCT	O
likely	O	ADV	O
by	O	ADP	O
improving	O	VERB	B
the	O	DET	O
NO	O	NOUN	B
pathway	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
suggests	O	VERB	O
Taikong	O	PROPN	B
Yangxin	O	PROPN	I
as	O	ADP	O
a	O	DET	O
new	O	ADJ	O
countermeasure	O	NOUN	B
to	O	PART	O
prevent	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
microvascular	B-OUT	ADJ	B
function	I-OUT	NOUN	I
induced	O	VERB	B
by	O	ADP	O
physical	O	ADJ	B
inactivity	O	NOUN	I
.	O	PUNCT	O


New	B-I	ADJ	B
introducer	I-I	NOUN	I
PEG	I-I	NOUN	B
gastropexy	I-I	NOUN	I
does	O	AUX	O
not	O	PART	O
require	O	VERB	O
prophylactic	O	ADJ	B
antibiotics	O	NOUN	I
:	O	PUNCT	O
multicenter	O	ADJ	B
prospective	O	ADJ	I
randomized	O	ADJ	I
double-blind	O	ADJ	I
placebo-controlled	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Peristomal	O	ADJ	B
infections	O	NOUN	I
are	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
complications	O	NOUN	B
of	O	ADP	O
PEG	O	NOUN	B
,	O	PUNCT	O
despite	O	SCONJ	O
prophylactic	O	ADJ	B
antibiotics	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
"	O	PUNCT	O
introducer	O	NOUN	B
"	O	PUNCT	O
PEG-placement	O	ADJ	B
technique	O	NOUN	O
avoids	O	VERB	O
the	O	DET	O
sojourn	O	NOUN	B
of	O	ADP	O
a	O	DET	O
PEG	O	NOUN	B
catheter	O	NOUN	I
through	O	ADP	O
the	O	DET	O
oropharynx	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hence	O	ADV	O
minimizes	O	VERB	B
the	O	DET	O
chances	O	NOUN	B
of	O	ADP	O
infectious	O	ADJ	B
complications	O	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
obvious	O	ADJ	O
potential	O	ADJ	B
advantage	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
technique	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
gain	O	VERB	O
popularity	O	NOUN	B
,	O	PUNCT	O
mainly	O	ADV	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
other	O	ADJ	O
associated	O	VERB	O
risks	O	NOUN	B
and	O	CCONJ	O
complications	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
modified	O	VERB	B
introducer	O	NOUN	B
endoscopic	O	ADJ	I
PEG-gastropexy	O	ADJ	I
technique	O	NOUN	I
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
quite	O	ADV	O
safe	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
study	O	NOUN	B
that	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
need	O	NOUN	O
of	O	ADP	O
prophylactic	O	ADJ	B
antibiotics	O	NOUN	I
for	O	ADP	O
"	O	PUNCT	O
introducer	O	NOUN	B
"	O	PUNCT	O
PEG	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
peristomal	O	ADJ	B
wound	O	NOUN	B
infections	O	NOUN	I
during	O	ADP	O
the	O	DET	O
immediate	O	ADJ	O
7-day	O	ADJ	O
postprocedure	O	NOUN	B
follow-up	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	VERB	O
Prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


SETTINGS	O	NOUN	B
Multicenter	B-P	PROPN	I
;	I-P	PUNCT	O
a	I-P	DET	O
university	I-P	NOUN	B
tertiary-care	I-P	ADJ	I
hospital	I-P	NOUN	I
and	I-P	CCONJ	O
a	I-P	DET	O
private	I-P	ADJ	B
practice	I-P	NOUN	I
endoscopy	I-P	NOUN	I
clinic	I-P	NOUN	B
.	I-P	PUNCT	O


PATIENTS	O	VERB	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
633	I-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
PEG	I-P	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
inclusion	O	NOUN	B
.	O	PUNCT	O


Ninety-seven	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
malignant	I-P	ADJ	B
stenotic	I-P	ADJ	B
oropharyngeal	I-P	ADJ	I
stricture	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
:	O	PUNCT	O
group	O	NOUN	B
I	O	NOUN	I
(	O	PUNCT	O
49	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
prophylactic	B-I	ADJ	B
ceftriaxone	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
group	I-I	NOUN	B
II	I-I	NUM	I
(	I-I	PUNCT	O
48	I-I	NUM	O
patients	I-I	NOUN	B
)	I-I	PUNCT	O
received	I-I	VERB	O
a	I-I	DET	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
patient	O	NOUN	B
characteristics	O	NOUN	B
.	O	PUNCT	O


INTERVENTIONS	O	NOUN	B
Introducer	O	PROPN	B
PEG	B-I	NOUN	I
was	O	AUX	O
performed	O	VERB	O
by	O	ADP	O
using	O	VERB	O
the	O	DET	O
Freka	O	PROPN	B
Pexact-15	O	PROPN	B
CH/FR	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
gastric	O	ADJ	B
wall	O	NOUN	I
nonsurgically	O	ADV	B
sutured	O	VERB	I
to	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
abdominal	O	ADJ	I
wall	O	NOUN	I
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
an	O	DET	O
endoscope	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	O
MEASUREMENTS	O	NOUN	O
The	B-OUT	DET	O
peristomal	I-OUT	ADJ	B
area	I-OUT	NOUN	I
was	I-OUT	AUX	O
assessed	I-OUT	VERB	B
daily	I-OUT	ADV	B
for	I-OUT	ADP	O
7	I-OUT	NUM	O
days	I-OUT	NOUN	B
by	I-OUT	ADP	O
using	I-OUT	VERB	O
2	I-OUT	NUM	O
different	I-OUT	ADJ	O
types	I-OUT	NOUN	O
of	I-OUT	ADP	O
infection	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Clinically	B-OUT	ADV	B
significant	I-OUT	ADJ	I
wound	I-OUT	NOUN	B
reaction	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


Wound	B-OUT	NOUN	B
infection	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
were	O	AUX	O
marginally	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
values	B-OUT	NOUN	B
of	I-OUT	ADP	O
infection	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
between	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
during	O	ADP	O
the	O	DET	O
7-day	O	ADJ	O
post-PEG	O	NOUN	B
follow-up	O	NOUN	I
.	O	PUNCT	O


LIMITATIONS	O	VERB	B
The	O	DET	O
introducer	O	NOUN	B
gastropexy	O	NOUN	I
kit	O	NOUN	I
is	O	AUX	O
5	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
expensive	O	ADJ	B
than	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
pull	O	VERB	O
"	O	PUNCT	O
PEG	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	B-I	DET	O
new	I-I	ADJ	O
introducer	I-I	NOUN	B
PEG-gastropexy	I-I	ADJ	I
technique	I-I	NOUN	I
can	O	AUX	O
be	O	AUX	O
performed	O	VERB	O
safely	O	ADV	O
,	O	PUNCT	O
without	O	ADP	O
prophylactic	O	ADJ	B
antibiotics	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
potentially	I-P	ADV	O
at	I-P	ADP	O
high	I-P	ADJ	B
risk	I-P	NOUN	I
of	I-P	ADP	O
peristomal	I-P	ADJ	B
infectious	I-P	ADJ	I
complications	I-P	NOUN	O
(	I-P	PUNCT	O
those	I-P	DET	O
with	I-P	ADP	O
advanced	I-P	ADJ	B
oropharyngeal	I-P	ADJ	O
malignancy	I-P	NOUN	O
)	I-P	PUNCT	O
(	O	PUNCT	O
ClinicalTrials.gov	O	NOUN	B
identifier	O	NOUN	I
NCT00375414	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


Modelling	B-P	NOUN	B
broilers	I-P	NOUN	B
'	I-P	PART	O
abdominal	I-P	ADJ	B
fat	I-P	NOUN	I
in	O	ADP	O
response	O	NOUN	B
to	O	ADP	O
dietary	O	ADJ	B
treatments	O	NOUN	I
.	O	PUNCT	O


Neural	O	ADJ	B
networks	O	NOUN	I
are	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
modelling	O	VERB	B
any	O	DET	O
complex	O	ADJ	B
function	O	NOUN	B
and	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
in	O	ADP	O
poultry	B-P	NOUN	B
production	I-P	NOUN	B
.	I-P	PUNCT	O


Dietary	B-I	ADJ	B
crude	I-I	ADJ	I
fibre	I-I	NOUN	I
(	I-I	PUNCT	O
CF	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
exogenous	B-I	ADJ	B
enzymes	I-I	NOUN	O
(	I-I	PUNCT	O
exEn	I-I	NOUN	B
)	I-I	PUNCT	O
extensively	O	ADV	O
affected	O	VERB	O
abdominal	O	ADJ	B
fat	O	NOUN	I
(	O	PUNCT	O
AF	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
broilers	O	NOUN	B
.	O	PUNCT	O


Current	O	ADJ	B
methods	O	NOUN	B
to	O	PART	O
study	O	VERB	B
AF	O	PROPN	I
and	O	CCONJ	O
its	O	PRON	O
correlation	O	NOUN	B
with	O	ADP	O
dietary	O	ADJ	B
CF	O	NOUN	B
levels	O	NOUN	B
and	O	CCONJ	O
exEn	O	ADJ	B
supplements	O	NOUN	B
are	O	AUX	O
costly	O	ADJ	O
,	O	PUNCT	O
laborious	O	ADJ	O
and	O	CCONJ	O
time-consuming	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
develop	O	VERB	O
an	O	DET	O
artificial	O	ADJ	B
neural	O	ADJ	O
network-genetic	O	ADJ	O
algorithm	O	NOUN	O
(	O	PUNCT	O
ANN-GA	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
model	O	VERB	B
data	O	NOUN	B
on	O	ADP	O
the	O	DET	O
response	B-OUT	NOUN	B
of	I-OUT	ADP	O
broiler	I-OUT	NOUN	B
chickens	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AF	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
to	I-P	PART	O
CF	I-I	NOUN	B
and	I-P	CCONJ	O
exEn	I-I	NOUN	B
from	I-P	ADP	O
0	I-P	NUM	O
to	I-P	PART	O
42	I-P	NUM	O
days	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
.	O	PUNCT	O


A	O	DET	O
data	O	NOUN	B
set	O	VERB	I
containing	O	VERB	O
eight	O	NUM	O
treatments	O	NOUN	B
was	O	AUX	O
divided	O	VERB	O
to	O	ADP	O
the	O	DET	O
train	O	NOUN	B
,	O	PUNCT	O
validation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
test	O	VERB	B
data	O	NOUN	I
set	O	VERB	I
of	O	ADP	O
the	O	DET	O
ANN	O	PROPN	B
models	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
information	O	NOUN	B
about	O	ADP	O
feeding	O	VERB	B
eight	O	NUM	O
diets	O	NOUN	B
at	O	ADP	O
two	O	NUM	O
periods	O	NOUN	B
[	O	PUNCT	O
starter	O	NOUN	B
(	O	PUNCT	O
0-21	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
grower	O	NOUN	B
(	O	PUNCT	O
22-42	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
)	O	PUNCT	O
]	O	PUNCT	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
AF	O	PROPN	B
of	B-P	ADP	O
broilers	I-P	NOUN	B
by	O	ADP	O
ANN-GA.	O	NOUN	B
A	O	NOUN	O
multilayer	O	NOUN	B
feed-forward	O	ADJ	O
neural	O	ADJ	B
network	O	NOUN	O
with	O	ADP	O
different	O	ADJ	O
structures	O	NOUN	B
was	O	AUX	O
developed	O	VERB	O
using	O	VERB	O
matlab	O	NOUN	B
software	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
optimal	O	ADJ	B
values	O	NOUN	O
for	O	ADP	O
the	O	DET	O
ANN	O	PROPN	B
weights	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
using	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
algorithm	O	NOUN	I
(	B-OUT	PUNCT	O
GA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Crude	B-OUT	ADJ	B
fibre	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
exEn	I-OUT	NOUN	B
were	O	AUX	O
used	O	VERB	O
as	O	ADP	O
input	O	NOUN	B
variables	O	NOUN	B
and	O	CCONJ	O
AF	O	NOUN	B
of	O	ADP	O
broilers	O	NOUN	B
was	O	AUX	O
output	O	NOUN	B
variable	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
best	O	ADJ	O
model	O	NOUN	B
of	O	ADP	O
ANN-GA	O	PROPN	B
was	O	AUX	O
determined	O	VERB	O
based	O	VERB	O
on	O	ADP	O
the	B-OUT	DET	O
train	I-OUT	NOUN	B
root	I-OUT	NOUN	B
mean	I-OUT	VERB	I
square	I-OUT	ADJ	I
error	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RMSE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
best	O	ADV	O
selected	O	VERB	O
ANN-GA	O	PROPN	B
showed	O	VERB	O
desirable	O	ADJ	O
results	O	NOUN	B
,	O	PUNCT	O
RMSE	O	NOUN	B
,	O	PUNCT	O
0.1286	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
R	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
coefficient	O	NOUN	B
,	O	PUNCT	O
0.876	O	NUM	O
for	O	ADP	O
test	O	NOUN	B
data	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
laryngeal	B-I	ADJ	B
tube	I-I	NOUN	I
suction-device	I-I	NOUN	O
(	I-I	PUNCT	O
LTS-D	I-I	NOUN	B
)	I-I	PUNCT	O
reduces	O	VERB	B
the	O	DET	O
"	B-OUT	PUNCT	O
no	I-OUT	DET	O
flow	I-OUT	NOUN	O
time	I-OUT	NOUN	O
"	I-OUT	PUNCT	O
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
rescuer	O	NOUN	O
manikin	O	NOUN	O
study	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
In	O	ADP	O
2005	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
European	O	PROPN	B
Resuscitation	O	PROPN	I
Council	O	PROPN	I
and	O	CCONJ	O
the	O	DET	O
American	O	PROPN	B
Heart	O	PROPN	I
Association	O	PROPN	I
published	O	VERB	O
new	O	ADJ	O
guidelines	O	NOUN	B
for	O	ADP	O
Advanced	O	ADJ	B
Life	O	PROPN	I
Support	O	PROPN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
points	O	NOUN	B
was	O	AUX	O
to	O	PART	O
reduce	O	VERB	B
the	O	DET	O
time	B-OUT	NOUN	B
without	I-OUT	ADP	O
chest	I-OUT	ADJ	B
compressions	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
phase	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
arrest	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
evaluated	O	VERB	B
in	O	ADP	O
a	O	DET	O
manikin	O	NOUN	B
model	O	NOUN	I
whether	O	SCONJ	O
using	O	VERB	O
the	O	DET	O
single-use	B-I	NOUN	B
laryngeal	I-I	ADJ	I
tube	I-I	NOUN	I
with	I-I	ADP	O
suction	I-I	NOUN	B
option	I-I	NOUN	O
(	I-I	PUNCT	O
LTS-D	I-I	NOUN	B
)	I-I	PUNCT	O
instead	I-I	ADV	O
of	O	ADP	O
endotracheal	B-I	NOUN	B
intubation	I-I	NOUN	I
(	I-I	PUNCT	O
ET	I-I	PROPN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
bag-mask-valve	I-I	VERB	B
ventilation	I-I	NOUN	I
(	I-I	PUNCT	O
BMV	I-I	NOUN	B
)	I-I	PUNCT	O
for	I-I	ADP	O
emergency	I-I	NOUN	B
airway	I-I	NOUN	B
management	I-I	NOUN	O
could	I-I	AUX	O
reduce	O	VERB	B
the	O	DET	O
"	B-OUT	PUNCT	O
no-flow	I-OUT	ADJ	B
time	I-OUT	NOUN	I
"	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
NFT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
NFT	O	NOUN	B
is	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
the	O	DET	O
time	O	NOUN	B
during	O	ADP	O
resuscitation	O	NOUN	B
when	O	SCONJ	O
no	O	DET	O
chest	O	ADJ	B
compressions	O	NOUN	I
take	O	VERB	O
place	O	NOUN	O
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
randomized	B-P	ADJ	B
,	I-P	PUNCT	O
prospective	I-P	ADJ	B
study	I-P	NOUN	I
was	I-P	AUX	O
undertaken	I-P	VERB	O
with	I-P	ADP	O
150	I-P	NUM	O
volunteers	I-P	NOUN	B
who	I-P	PRON	O
performed	I-P	VERB	O
management	I-P	NOUN	B
of	I-P	ADP	O
a	I-P	DET	O
standardized	I-P	ADJ	B
simulated	I-P	ADJ	I
cardiac	I-P	ADJ	I
arrest	I-P	NOUN	I
in	I-P	ADP	O
a	I-P	DET	O
manikin	I-P	NOUN	B
.	I-P	PUNCT	O


Every	O	DET	O
participant	O	NOUN	B
was	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
airway	O	NOUN	B
management	O	NOUN	O
groups	O	NOUN	O
(	O	PUNCT	O
LTS-D	O	NOUN	B
vs	O	ADV	O
.	O	PUNCT	O


ET	O	PROPN	B
vs.	O	CCONJ	O
BMV	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
LTS-D	B-I	NOUN	B
was	O	AUX	O
inserted	O	VERB	B
significantly	O	ADV	O
faster	O	ADV	O
than	O	ADP	O
the	O	DET	O
ET	O	PROPN	B
tube	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
s	O	NOUN	O
vs.	O	CCONJ	O
44	O	NUM	O
s	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
cardiac	O	ADJ	B
arrest	O	NOUN	I
simulation	O	NOUN	B
,	O	PUNCT	O
establishing	B-OUT	VERB	O
and	I-OUT	CCONJ	O
performing	I-OUT	VERB	O
ventilation	I-OUT	NOUN	B
took	O	VERB	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
57	O	NUM	O
s	O	NOUN	O
with	O	ADP	O
the	O	DET	O
LTS-D	B-I	NOUN	B
compared	O	VERB	O
to	O	PART	O
116	O	NUM	O
s	O	NOUN	O
with	O	ADP	O
ET	B-I	PROPN	B
and	O	CCONJ	O
111	O	NUM	O
s	O	NOUN	O
with	O	ADP	O
the	O	DET	O
BMV	B-I	NOUN	B
.	I-I	PUNCT	O


Using	O	VERB	O
the	O	DET	O
LTS-D	B-I	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	B
NFT	B-OUT	NOUN	B
compared	O	VERB	O
to	O	PART	O
ET	B-I	PROPN	B
and	O	CCONJ	O
the	O	DET	O
BMV	B-I	NOUN	B
(	O	PUNCT	O
125	O	NUM	O
s	O	NOUN	O
vs.	O	CCONJ	O
207	O	NUM	O
s	O	NOUN	O
vs.	O	CCONJ	O
160	O	NUM	O
s	O	NOUN	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
our	O	PRON	O
manikin	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
NFT	B-OUT	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
significantly	O	ADV	O
when	O	SCONJ	O
the	O	DET	O
LTS-D	B-I	NOUN	B
was	O	AUX	O
used	O	VERB	O
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
ET	B-I	PROPN	B
and	I-I	CCONJ	O
BMV	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
manikin	O	NOUN	B
study	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
for	O	ADP	O
personnel	O	NOUN	B
not	O	PART	O
experienced	O	VERB	O
in	O	ADP	O
tracheal	O	ADJ	B
intubation	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
LTS-D	B-I	NOUN	B
offers	O	VERB	O
a	O	DET	O
good	O	ADJ	O
alternative	O	NOUN	O
to	O	ADP	O
ET	B-I	PROPN	B
and	O	CCONJ	O
BMV	B-I	NOUN	B
to	O	PART	O
manage	O	VERB	O
the	O	DET	O
airway	O	NOUN	B
during	O	ADP	O
resuscitation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
avoid	O	VERB	O
the	O	DET	O
failure	O	NOUN	B
to	O	PART	O
achieve	O	VERB	O
tracheal	O	ADJ	B
intubation	O	NOUN	I
with	O	ADP	O
the	O	DET	O
ET	B-I	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
failure	O	NOUN	B
to	O	PART	O
achieve	O	VERB	O
adequate	O	ADJ	B
ventilation	O	NOUN	B
with	O	ADP	O
the	O	DET	O
BMV	B-I	NOUN	B
.	I-I	PUNCT	O


Incidence	O	NOUN	B
and	O	CCONJ	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
cardiovascular	B-OUT	ADJ	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
during	O	ADP	O
spinal	B-I	ADJ	B
anesthesia	I-I	NOUN	I
after	I-P	ADP	O
prophylactic	I-P	ADJ	B
administration	I-P	NOUN	I
of	I-P	ADP	O
intravenous	I-I	ADJ	B
fluids	I-I	NOUN	I
or	I-I	CCONJ	O
vasoconstrictors	I-I	NOUN	B
.	I-I	PUNCT	O


UNLABELLED	O	NOUN	B
We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
arterial	O	ADJ	B
hypotension	O	NOUN	I
and/or	O	CCONJ	O
bradycardia	O	NOUN	B
requiring	O	VERB	O
treatment	O	NOUN	B
during	O	ADP	O
spinal	B-P	ADJ	B
anesthesia	I-P	NOUN	I
and	O	CCONJ	O
compared	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
i.v	B-I	PROPN	O
.	I-I	PUNCT	O


fluid	B-I	ADJ	B
or	I-I	CCONJ	O
vasoconstrictor	I-I	NOUN	B
administration	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
these	O	DET	O
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
1066	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
a	O	DET	O
volume	B-I	NOUN	B
group	I-I	NOUN	I
(	I-I	PUNCT	O
lactated	I-I	VERB	B
Ringer	I-I	PROPN	I
's	I-I	PART	I
solution	I-I	NOUN	I
15	O	NUM	O
mL/kg	O	NOUN	O
within	O	ADP	O
15	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
dihydroergotamine	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
microg/kg	O	NOUN	O
i.m	O	NOUN	O
.	O	PUNCT	O


15	O	NUM	O
min	O	NOUN	O
before	O	ADP	B
anesthesia	B-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
placebo	I-I	ADJ	B
group	I-I	NOUN	O
.	I-I	PUNCT	O


All	B-P	DET	O
patients	I-P	NOUN	B
breathed	I-P	VERB	O
O2-enriched	I-P	ADJ	B
air	I-P	NOUN	I
during	I-P	ADP	O
spinal	I-I	ADJ	B
anesthesia	I-I	NOUN	I
(	I-P	PUNCT	O
4	I-P	NUM	O
mL	I-P	NOUN	O
of	I-P	ADP	O
plain	I-P	ADJ	B
0.5	I-P	NUM	O
%	I-P	NOUN	O
bupivacaine	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-P	PUNCT	O


With	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
side	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
incidence	O	NOUN	B
22.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
45	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
anesthesia	O	NOUN	B
.	O	PUNCT	O


Dihydroergotamine	B-I	NOUN	B
reduced	O	VERB	B
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
,	O	PUNCT	O
preferentially	O	ADV	O
the	O	DET	O
late	O	ADJ	O
ones	O	NOUN	O
,	O	PUNCT	O
more	O	ADJ	O
(	O	PUNCT	O
mean	O	ADJ	O
incidence	O	NOUN	B
11.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
fluid	O	ADJ	B
administration	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
incidence	O	NOUN	B
16.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
effective	O	ADJ	B
only	O	ADV	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
15	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
anesthesia	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
arterial	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
decreased	I-OUT	VERB	B
within	O	ADP	O
15	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
the	O	DET	O
manifestation	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
greatly	O	ADV	O
reduced	O	VERB	B
by	O	ADP	O
the	O	DET	O
intraoperative	O	ADJ	B
application	O	NOUN	B
of	O	ADP	O
both	O	DET	O
sedatives	O	NOUN	B
and	O	CCONJ	O
opioids	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
cardiovascular	B-OUT	ADJ	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
may	O	AUX	O
occur	O	VERB	O
at	O	ADP	O
any	O	DET	O
time	O	NOUN	B
during	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


Fluid	O	ADJ	B
administration	O	NOUN	B
reduced	O	VERB	B
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
early	I-OUT	ADJ	B
events	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
dihydroergotamine	O	VERB	B
the	O	DET	O
late	B-OUT	ADJ	O
events	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


IMPLICATIONS	O	NOUN	B
Cardiovascular	B-OUT	ADJ	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
requiring	O	VERB	O
treatment	O	NOUN	B
occurred	O	VERB	O
at	O	ADP	O
any	O	DET	O
time	O	NOUN	B
during	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
in	O	ADP	O
our	O	PRON	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
the	O	DET	O
prophylactic	O	ADJ	B
regimen	O	NOUN	I
(	B-I	PUNCT	O
fluid	I-I	ADJ	B
infusions	I-I	NOUN	B
versus	O	CCONJ	O
dihydroergotamine	B-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Oxytocin	B-I	NOUN	B
reduces	O	VERB	B
caloric	O	ADJ	B
intake	O	NOUN	I
in	O	ADP	O
men	B-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
Preclinical	O	ADJ	B
studies	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
oxytocin	B-I	NOUN	B
is	O	AUX	O
anorexigenic	O	ADJ	B
and	O	CCONJ	O
has	O	AUX	O
beneficial	O	ADJ	O
metabolic	O	ADJ	B
effects	O	NOUN	O
.	O	PUNCT	O


Oxytocin	B-I	NOUN	B
effects	O	NOUN	B
on	O	ADP	O
nutrition	O	NOUN	B
and	O	CCONJ	O
metabolism	O	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
are	O	AUX	O
not	O	PART	O
well	O	ADV	O
defined	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
hypothesized	O	VERB	O
that	O	SCONJ	O
oxytocin	B-I	NOUN	B
would	O	AUX	O
reduce	O	VERB	B
caloric	O	ADJ	B
intake	O	NOUN	I
and	O	CCONJ	O
appetite	O	NOUN	B
and	O	CCONJ	O
alter	O	VERB	O
levels	O	NOUN	B
of	O	ADP	O
appetite-regulating	O	ADJ	B
hormones	O	NOUN	I
.	O	PUNCT	O


Metabolic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
oxytocin	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
explored	O	VERB	O
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
crossover	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
single-dose	B-I	ADJ	B
intranasal	I-I	ADJ	B
oxytocin	I-I	NOUN	I
(	I-I	PUNCT	O
24	I-I	NUM	O
IU	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
25	B-P	NUM	O
fasting	I-P	VERB	B
healthy	I-P	ADJ	B
men	I-P	NOUN	B
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


After	O	ADP	O
oxytocin/placebo	B-I	NOUN	B
,	O	PUNCT	O
subjects	O	NOUN	B
selected	B-I	VERB	O
breakfast	I-I	NOUN	B
from	I-I	ADP	O
a	I-I	DET	O
menu	I-I	NOUN	B
and	I-I	CCONJ	O
were	I-I	AUX	O
given	I-I	VERB	O
double	I-I	ADJ	O
portions	I-I	NOUN	B
.	I-I	PUNCT	O


Caloric	B-I	ADJ	B
content	I-I	NOUN	B
of	I-I	ADP	O
food	I-I	NOUN	B
consumed	I-I	VERB	I
was	I-I	AUX	O
measured	I-I	VERB	B
.	I-I	PUNCT	O


Visual	B-I	ADJ	B
analog	I-I	NOUN	I
scales	I-I	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
appetite	B-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
blood	B-I	NOUN	B
was	I-I	AUX	O
drawn	I-I	VERB	O
for	I-I	ADP	O
appetite-regulating	I-I	ADJ	B
hormones	I-I	NOUN	I
,	I-I	PUNCT	O
insulin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
glucose	I-I	NOUN	B
before	I-I	ADP	O
and	I-I	CCONJ	O
after	I-I	ADP	O
oxytocin/placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Indirect	B-I	ADJ	B
calorimetry	I-I	NOUN	I
assessed	I-I	VERB	B
resting	I-I	VERB	B
energy	I-I	NOUN	I
expenditure	I-I	NOUN	I
(	I-I	PUNCT	O
REE	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
substrate	I-I	ADJ	B
utilization	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	VERB	B
Oxytocin	B-I	NOUN	B
reduced	I-OUT	VERB	B
caloric	I-OUT	ADJ	B
intake	I-OUT	NOUN	I
with	O	ADP	O
a	O	DET	O
preferential	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
fat	B-OUT	ADJ	B
intake	I-OUT	NOUN	I
and	O	CCONJ	O
increased	B-OUT	VERB	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
anorexigenic	I-OUT	ADJ	B
hormone	I-OUT	NOUN	I
cholecystokinin	I-OUT	NOUN	B
without	O	ADP	O
affecting	O	VERB	B
appetite	O	NOUN	B
or	O	CCONJ	O
other	O	ADJ	O
appetite-regulating	O	ADJ	B
hormones	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
effect	O	NOUN	O
of	O	ADP	O
oxytocin	O	NOUN	B
on	O	ADP	O
REE	B-OUT	PROPN	B
.	I-OUT	PUNCT	O


Oxytocin	B-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
shift	O	NOUN	B
from	O	ADP	O
carbohydrate	O	NOUN	B
to	O	PART	O
fat	O	ADJ	B
utilization	O	NOUN	I
and	O	CCONJ	O
improved	O	VERB	B
insulin	O	NOUN	B
sensitivity	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Intranasal	O	ADJ	B
oxytocin	B-I	NOUN	I
reduces	O	VERB	B
caloric	O	ADJ	B
intake	O	NOUN	I
and	O	CCONJ	O
has	O	AUX	O
beneficial	O	ADJ	O
metabolic	O	ADJ	B
effects	O	NOUN	O
in	O	ADP	O
men	B-P	NOUN	B
without	O	ADP	O
concerning	O	VERB	O
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
sustained	O	ADJ	B
oxytocin	B-I	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
obesity	O	NOUN	B
warrants	O	VERB	O
investigation	O	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
interferon-	B-I	NOUN	B
and	O	CCONJ	O
ribavirin-free	B-I	ADJ	B
ombitasvir/paritaprevir/ritonavir	I-I	NOUN	O
in	O	ADP	O
treatment-experienced	B-P	ADJ	B
hepatitis	I-P	NOUN	I
C	I-P	NOUN	I
virus-infected	I-P	ADJ	I
patients	I-P	NOUN	I
.	I-P	PUNCT	O


UNLABELLED	O	VERB	B
Approximately	O	ADV	O
2	O	NUM	O
million	O	NUM	O
Japanese	B-P	ADJ	B
individuals	I-P	NOUN	B
are	O	AUX	O
infected	O	VERB	B
with	O	ADP	O
hepatitis	O	NOUN	B
C	O	NOUN	I
virus	O	NOUN	I
and	O	CCONJ	O
are	O	AUX	O
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
cirrhosis	O	NOUN	B
,	O	PUNCT	O
end-stage	O	ADJ	B
liver	O	NOUN	I
disease	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hepatocellular	O	NOUN	B
carcinoma	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
interferon	B-I	NOUN	B
(	I-I	PUNCT	O
IFN	I-I	NOUN	B
)	I-I	PUNCT	O
/ribavirin	I-I	NOUN	B
(	I-I	PUNCT	O
RBV	I-I	NOUN	B
)	I-I	PUNCT	O
therapy	I-I	NOUN	B
has	O	AUX	O
failed	O	VERB	B
remain	O	VERB	O
at	O	ADP	O
risk	O	NOUN	B
as	O	ADP	O
effective	O	ADJ	B
therapeutic	O	ADJ	B
options	O	NOUN	I
are	O	AUX	O
limited	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
phase	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
study	O	NOUN	I
evaluated	O	VERB	B
an	O	DET	O
IFN-	B-I	NOUN	B
and	I-I	CCONJ	O
RBV-free	I-I	ADJ	B
regimen	O	NOUN	B
of	O	ADP	O
once-daily	O	ADJ	B
ombitasvir	B-I	NOUN	I
(	I-I	PUNCT	O
ABT-267	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
NS5A	B-I	NOUN	B
inhibitor	I-I	NOUN	B
,	I-I	PUNCT	O
plus	I-I	CCONJ	O
paritaprevir	I-I	NOUN	B
(	I-I	PUNCT	O
ABT-450	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
NS3/4A	B-I	NOUN	B
protease	I-I	NOUN	I
inhibitor	I-I	NOUN	I
dosed	I-I	VERB	B
with	I-I	ADP	O
ritonavir	I-I	NOUN	B
(	I-I	PUNCT	O
paritaprevir/ritonavir	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
pegylated	B-P	ADJ	B
IFN/RBV	I-I	NOUN	I
treatment-experienced	I-P	ADJ	O
Japanese	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
hepatitis	I-P	NOUN	B
C	I-P	NOUN	I
virus	I-P	NOUN	I
subtype	I-P	NOUN	I
1b	I-P	NOUN	I
or	I-P	CCONJ	O
genotype	I-P	NOUN	B
2	I-P	NUM	I
infection	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
without	I-P	ADP	O
cirrhosis	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	O
18-75	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
subtype	I-P	NOUN	B
1b	I-P	NOUN	I
infection	I-P	NOUN	B
received	O	VERB	O
ombitasvir	B-I	NOUN	B
25	I-I	NUM	O
mg	I-I	NOUN	O
plus	I-I	CCONJ	O
paritaprevir/ritonavir	I-I	NOUN	O
100/100	O	NUM	O
mg	O	NOUN	O
or	O	CCONJ	O
150/100	O	NUM	O
mg	O	NOUN	O
for	O	ADP	O
12	O	NUM	O
or	O	CCONJ	O
24	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
patients	B-P	NOUN	B
with	I-P	ADP	O
genotype	I-P	NOUN	B
2	I-P	NUM	I
infection	I-P	NOUN	B
received	O	VERB	O
ombitasvir	B-I	NOUN	B
25	I-I	NUM	O
mg	I-I	NOUN	O
plus	I-I	CCONJ	O
paritaprevir/ritonavir	I-I	NOUN	O
100/100	I-I	NUM	O
mg	I-I	NOUN	O
or	I-I	CCONJ	O
150/100	I-I	NUM	O
mg	I-I	NOUN	O
for	I-I	ADP	O
12	I-I	NUM	O
weeks	I-I	NOUN	B
.	I-I	PUNCT	O


Sustained	B-OUT	ADJ	B
virologic	I-OUT	ADJ	B
response	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SVR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
at	O	ADP	O
posttreatment	O	NOUN	B
week	O	NOUN	B
24	O	NUM	O
(	O	PUNCT	O
SVR24	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
the	O	DET	O
primary	O	ADJ	B
endpoint	O	NOUN	I
.	O	PUNCT	O


Adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
ten	I-P	NUM	O
patients	I-P	NOUN	B
received	O	VERB	O
≥1	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
medication	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
subtype	O	NOUN	B
1b	O	NOUN	I
cohort	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
SVR24	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
were	O	AUX	O
high	O	ADJ	O
(	O	PUNCT	O
88.9	O	NUM	O
%	O	NOUN	O
-100	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
paritaprevir	O	NOUN	B
dose	O	NOUN	I
or	O	CCONJ	O
treatment	O	NOUN	B
duration	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
genotype	O	NOUN	B
2	O	NUM	O
cohort	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
SVR24	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
were	O	AUX	O
57.9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
72.2	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
100	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
150	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
paritaprevir	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	B-OUT	DET	O
SVR24	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
subtype	O	NOUN	B
2a	O	NOUN	I
(	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
2b	O	NOUN	B
(	O	PUNCT	O
27	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Concordance	O	NOUN	B
between	B-OUT	ADP	O
SVR12	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
SVR24	I-OUT	NOUN	B
was	O	AUX	O
100	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
overall	O	ADV	B
were	B-OUT	AUX	O
nasopharyngitis	I-OUT	ADJ	B
(	O	PUNCT	O
29	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
headache	I-OUT	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
this	B-P	DET	O
difficult-to-treat	I-P	ADJ	B
population	I-P	NOUN	I
of	I-P	ADP	O
patients	I-P	NOUN	B
in	I-P	ADP	O
whom	I-P	PRON	O
prior	I-P	ADJ	O
pegylated	I-P	ADJ	B
IFN/RBV	I-P	NOUN	B
had	I-P	AUX	O
failed	I-I	VERB	B
,	I-I	PUNCT	O
ombitasvir/paritaprevir/ritonavir	I-I	PROPN	O
demonstrated	O	VERB	O
potent	O	ADJ	O
antiviral	O	ADJ	B
activity	O	NOUN	I
with	O	ADP	O
a	O	DET	O
favorable	O	ADJ	O
safety	O	NOUN	B
profile	O	NOUN	O
among	B-P	ADP	O
Japanese	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
hepatitis	I-P	NOUN	B
C	I-P	NOUN	I
virus	I-P	NOUN	I
genotype	I-P	NOUN	O
1b	I-P	NOUN	O
or	I-P	CCONJ	O
2a	I-P	NOUN	B
infection	I-P	NOUN	I
.	O	PUNCT	O


Failure	O	NOUN	B
of	O	ADP	O
naltrexone	B-I	NOUN	B
hydrochloride	I-I	NOUN	B
to	O	PART	O
reduce	O	VERB	B
self-injurious	B-P	ADJ	B
and	I-P	CCONJ	O
autistic	I-P	ADJ	B
behavior	I-P	NOUN	I
in	I-P	ADP	O
mentally	I-P	ADV	B
retarded	I-P	VERB	B
adults	I-P	NOUN	B
.	I-P	PUNCT	O


Double-blind	O	ADJ	B
placebo-controlled	B-I	ADJ	I
studies	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
It	O	PRON	O
is	O	AUX	O
hypothesized	O	VERB	O
that	O	SCONJ	O
self-injurious	O	ADJ	B
behavior	O	NOUN	I
(	O	PUNCT	O
SIB	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
symptoms	O	NOUN	B
of	O	ADP	O
autism	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
overactivity	O	NOUN	B
in	O	ADP	O
some	O	DET	O
opioid	O	NOUN	B
systems	O	NOUN	I
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
naltrexone	B-I	NOUN	B
hydrochloride	I-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
opioid	O	NOUN	B
antagonist	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
SIB	B-P	NOUN	B
and	I-P	CCONJ	O
autism	I-P	NOUN	B
in	I-P	ADP	O
mentally	I-P	ADV	B
retarded	I-P	VERB	B
adults	I-P	NOUN	B
.	I-P	PUNCT	O


METHOD	O	NOUN	B
Thirty-three	B-P	NUM	O
mentally	I-P	ADV	B
retarded	I-P	VERB	B
adults	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
and/or	I-P	CCONJ	O
SIB	I-P	NOUN	B
participated	I-P	VERB	O
in	I-P	ADP	O
double-blind	I-P	ADJ	B
,	I-P	PUNCT	O
placebo-controlled	I-I	ADJ	B
crossover	I-P	NOUN	B
studies	I-P	NOUN	I
.	I-P	PUNCT	O


Active	O	ADJ	B
treatment	O	NOUN	I
was	O	AUX	O
first	O	ADJ	O
a	O	DET	O
single	O	ADJ	O
100-mg	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
naltrexone	B-I	NOUN	B
hydrochloride	I-I	NOUN	B
.	I-I	PUNCT	O


Subsequently	O	ADV	O
,	O	PUNCT	O
19	O	NUM	O
subjects	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
50	O	NUM	O
mg/d	O	NOUN	O
and	O	CCONJ	O
14	O	NUM	O
with	O	ADP	O
150	O	NUM	O
mg/d	O	NOUN	O
of	O	ADP	O
naltrexone	B-I	NOUN	B
hydrochloride	I-I	NOUN	B
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
outcome	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
direct	O	ADJ	O
observations	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
scores	O	NOUN	B
on	O	ADP	O
a	O	DET	O
list	B-OUT	NOUN	O
of	I-OUT	ADP	O
target	I-OUT	NOUN	B
behaviors	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
Aberrant	I-OUT	PROPN	B
Behavior	I-OUT	PROPN	I
Checklist	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Clinical	I-OUT	PROPN	B
Global	I-OUT	PROPN	I
Impression	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Thirty-two	O	NUM	O
subjects	O	NOUN	B
(	O	PUNCT	O
seven	O	NUM	O
with	O	ADP	O
autism	O	NOUN	B
,	O	PUNCT	O
16	O	NUM	O
with	O	ADP	O
autism	O	NOUN	B
and	O	CCONJ	O
SIB	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
nine	O	NUM	O
with	O	ADP	O
SIB	O	NOUN	B
)	O	PUNCT	O
completed	O	VERB	O
the	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


Naltrexone	B-I	NOUN	B
treatment	O	NOUN	B
failed	B-OUT	VERB	B
to	O	PART	O
have	O	AUX	O
therapeutic	O	ADJ	B
effects	O	NOUN	I
on	O	ADP	O
SIB	O	NOUN	B
and	O	CCONJ	O
autism	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
contrary	O	NOUN	O
,	O	PUNCT	O
naltrexone	B-I	NOUN	B
increased	I-OUT	VERB	B
the	I-OUT	DET	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
stereotypic	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
on	I-OUT	ADP	O
the	I-OUT	DET	O
Aberrant	I-OUT	PROPN	B
Behavior	I-OUT	PROPN	I
Checklist	I-OUT	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
care	O	NOUN	B
staff	O	NOUN	I
evaluated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
50-mg/d	O	ADJ	B
treatment	O	NOUN	B
as	O	ADP	O
being	O	AUX	O
significantly	B-OUT	ADV	O
worse	I-OUT	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
treatment	O	NOUN	B
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
Clinical	B-OUT	PROPN	B
Global	I-OUT	PROPN	I
Impression	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSION	O	VERB	O
Our	O	PRON	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
naltrexone	O	NOUN	B
has	O	AUX	O
no	O	DET	O
clinical	O	ADJ	B
value	O	NOUN	I
for	O	ADP	O
a	O	DET	O
broad	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
mentally	O	ADV	B
retarded	O	VERB	O
subjects	O	NOUN	B
with	O	ADP	O
SIB	O	NOUN	B
and/or	O	CCONJ	O
autism	O	NOUN	B
.	O	PUNCT	O


Low-frequency	B-I	ADJ	B
repetitive	I-I	ADJ	I
transcranial	I-I	ADJ	I
magnetic	I-I	ADJ	I
stimulation	I-I	NOUN	I
(	I-I	PUNCT	O
rTMS	I-I	NOUN	B
)	I-I	PUNCT	O
affects	O	VERB	O
event-related	O	ADJ	B
potential	O	ADJ	O
measures	O	NOUN	B
of	O	ADP	O
novelty	O	NOUN	B
processing	O	NOUN	O
in	O	ADP	O
autism	B-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
our	O	PRON	O
previous	O	ADJ	O
study	O	NOUN	B
on	O	ADP	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	VERB	B
)	I-P	PUNCT	O
(	O	PUNCT	O
Sokhadze	O	NOUN	O
et	O	X	O
al.	O	X	O
,	O	PUNCT	O
Appl	O	PROPN	B
Psychophysiol	O	PROPN	I
Biofeedback	O	PROPN	B
34:37-51	O	NOUN	O
,	O	PUNCT	O
2009a	O	NUM	O
)	O	PUNCT	O
we	O	PRON	O
reported	O	VERB	O
abnormalities	O	NOUN	B
in	O	ADP	O
the	O	DET	O
attention-orienting	O	ADJ	B
frontal	O	ADJ	O
event-related	O	ADJ	O
potentials	O	NOUN	O
(	O	PUNCT	O
ERP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
sustained-attention	O	ADJ	B
centro-parietal	O	ADJ	B
ERPs	O	NOUN	B
in	O	ADP	O
a	O	DET	O
visual	O	ADJ	B
oddball	O	ADJ	O
experiment	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
over-process	O	ADJ	B
information	O	NOUN	B
needed	O	VERB	O
for	O	ADP	O
the	O	DET	O
successful	O	ADJ	O
differentiation	O	NOUN	B
of	O	ADP	O
target	O	NOUN	B
and	O	CCONJ	O
novel	O	ADJ	B
stimuli	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
examine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
low-frequency	B-I	ADJ	B
,	I-I	PUNCT	O
repetitive	I-I	ADJ	B
Transcranial	I-I	ADJ	I
Magnetic	I-I	ADJ	I
Stimulation	I-I	NOUN	I
(	I-I	PUNCT	O
rTMS	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
novelty	O	NOUN	B
processing	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
behavior	O	NOUN	B
and	O	CCONJ	O
social	O	ADJ	B
functioning	O	NOUN	I
in	O	ADP	O
13	B-P	NUM	O
individuals	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Our	O	PRON	O
hypothesis	O	NOUN	B
was	O	AUX	O
that	O	SCONJ	O
low-frequency	B-I	ADJ	B
rTMS	I-I	NOUN	B
application	O	NOUN	B
to	O	PART	O
dorsolateral	O	ADJ	B
prefrontal	O	ADJ	I
cortex	O	NOUN	I
(	O	PUNCT	O
DLFPC	O	NOUN	B
)	O	PUNCT	O
would	O	AUX	O
result	O	VERB	O
in	O	ADP	O
an	O	DET	O
alteration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cortical	O	ADJ	B
excitatory/inhibitory	O	ADJ	B
balance	O	NOUN	B
through	O	ADP	O
the	O	DET	O
activation	O	NOUN	B
of	O	ADP	O
inhibitory	O	ADJ	B
GABAergic	O	ADJ	B
double	O	ADJ	O
bouquet	O	NOUN	O
interneurons	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
expected	O	VERB	O
to	O	PART	O
find	O	VERB	O
post-TMS	O	NOUN	B
differences	O	NOUN	B
in	O	ADP	O
amplitude	O	NOUN	B
and	O	CCONJ	O
latency	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
and	O	CCONJ	O
late	O	ADJ	O
ERP	O	NOUN	B
components	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
current	O	ADJ	O
study	O	NOUN	B
validate	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
low-frequency	O	ADJ	B
rTMS	O	NOUN	B
as	O	ADP	O
a	O	DET	O
modulatory	O	ADJ	B
tool	O	NOUN	I
that	O	PRON	O
altered	O	VERB	O
the	O	DET	O
disrupted	O	VERB	B
ratio	O	NOUN	B
of	O	ADP	O
cortical	O	ADJ	B
excitation	O	NOUN	I
to	O	PART	O
inhibition	O	NOUN	B
in	O	ADP	O
autism	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
rTMS	O	NOUN	B
the	O	DET	O
parieto-occipital	B-OUT	ADJ	B
P50	I-OUT	NOUN	B
amplitude	I-OUT	NOUN	I
decreased	I-OUT	VERB	B
to	I-OUT	PART	O
novel	I-OUT	ADJ	B
distracters	I-OUT	NOUN	B
but	I-OUT	CCONJ	O
not	I-OUT	PART	O
to	I-OUT	PART	O
targets	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
also	O	ADV	O
the	O	DET	O
amplitude	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
latency	I-OUT	NOUN	B
to	I-OUT	PART	O
targets	I-OUT	NOUN	B
increased	I-OUT	VERB	B
for	I-OUT	ADP	O
the	I-OUT	DET	O
frontal	I-OUT	ADJ	B
P50	I-OUT	NOUN	O
while	I-OUT	SCONJ	O
decreasing	I-OUT	VERB	B
to	I-OUT	PART	O
non-target	I-OUT	ADJ	B
stimuli	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Low-frequency	O	ADJ	B
rTMS	O	NOUN	I
minimized	B-OUT	VERB	O
early	I-OUT	ADJ	O
cortical	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
to	I-OUT	PART	O
irrelevant	I-OUT	ADJ	B
stimuli	I-OUT	NOUN	B
and	O	CCONJ	O
increased	B-OUT	VERB	B
responses	I-OUT	NOUN	B
to	I-OUT	PART	O
relevant	I-OUT	ADJ	B
stimuli	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Improved	O	ADJ	O
selectivity	O	NOUN	B
in	O	ADP	O
early	O	ADJ	B
cortical	O	ADJ	B
responses	O	NOUN	I
lead	O	VERB	O
to	O	PART	O
better	B-OUT	ADJ	O
stimulus	I-OUT	NOUN	B
differentiation	I-OUT	NOUN	O
at	I-OUT	ADP	O
later-stage	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
as	O	ADP	O
was	O	AUX	O
made	O	VERB	O
evident	O	ADJ	O
by	O	ADP	O
our	O	PRON	O
P3b	O	NOUN	B
and	O	CCONJ	O
P3a	O	NOUN	B
component	O	NOUN	O
findings	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
a	O	DET	O
significant	B-OUT	ADJ	O
change	I-OUT	NOUN	O
in	I-OUT	ADP	O
early	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
middle-latency	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
late	I-OUT	ADJ	O
ERP	I-OUT	NOUN	B
components	I-OUT	NOUN	B
at	I-OUT	ADP	O
the	I-OUT	DET	O
frontal	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
centro-parietal	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
parieto-occipital	I-OUT	ADJ	B
regions	I-OUT	NOUN	I
of	I-OUT	ADP	O
interest	I-OUT	NOUN	O
in	I-OUT	ADP	O
response	I-OUT	NOUN	B
to	I-OUT	PART	O
target	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
distracter	I-OUT	NOUN	B
stimuli	I-OUT	NOUN	I
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
rTMS	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
preliminary	O	ADJ	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
rTMS	O	NOUN	B
may	O	AUX	O
prove	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
important	O	ADJ	O
research	O	NOUN	B
tool	O	NOUN	I
or	O	CCONJ	O
treatment	O	NOUN	B
modality	O	NOUN	O
in	O	ADP	O
addressing	O	VERB	O
the	O	DET	O
stimulus	O	NOUN	B
hypersensitivity	O	NOUN	I
characteristic	O	ADJ	B
of	O	ADP	O
autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
.	O	PUNCT	O


Low-dose	B-I	ADJ	B
growth	I-I	NOUN	I
hormone	I-I	NOUN	I
treatment	I-I	NOUN	B
with	I-I	ADP	O
diet	I-I	NOUN	B
restriction	I-I	NOUN	I
accelerates	I-OUT	VERB	O
body	I-OUT	NOUN	B
fat	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
exerts	I-OUT	VERB	O
anabolic	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
improves	I-OUT	VERB	B
growth	I-OUT	NOUN	B
hormone	I-OUT	NOUN	I
secretory	I-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
in	O	ADP	O
obese	B-P	ADJ	B
adults	I-P	NOUN	B
.	I-P	PUNCT	O


Growth	B-I	NOUN	B
hormone	I-I	NOUN	I
(	O	PUNCT	O
GH	O	NOUN	B
)	O	PUNCT	O
can	O	AUX	O
induce	O	VERB	B
an	O	DET	O
accelerated	B-OUT	VERB	B
lipolysis	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Impaired	O	ADJ	B
secretion	O	NOUN	B
of	O	ADP	O
GH	O	NOUN	B
in	O	ADP	O
obesity	O	NOUN	B
results	O	NOUN	B
in	O	ADP	O
the	O	DET	O
consequent	O	ADJ	B
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lipolytic	B-OUT	ADJ	B
effect	I-OUT	NOUN	O
of	I-OUT	ADP	O
GH	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Dietary	O	ADJ	B
restriction	O	NOUN	I
as	O	ADP	O
a	O	DET	O
basic	O	ADJ	O
treatment	O	NOUN	B
for	O	ADP	O
obesity	O	NOUN	B
is	O	AUX	O
complicated	O	ADJ	O
by	O	ADP	O
poor	O	ADJ	B
compliance	O	NOUN	I
,	O	PUNCT	O
protein	O	NOUN	B
catabolism	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
slow	O	ADJ	B
rates	O	NOUN	I
or	O	CCONJ	O
weight	O	NOUN	B
loss	O	NOUN	I
.	O	PUNCT	O


GH	O	NOUN	B
has	O	AUX	O
an	O	DET	O
anabolic	O	ADJ	B
effect	O	NOUN	I
by	O	ADP	O
increasing	B-OUT	VERB	B
insulin-like	I-OUT	ADJ	B
growth	I-OUT	NOUN	I
factor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
IGF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
-I	I-OUT	ADJ	O
.	I-OUT	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
GH	O	NOUN	B
treatment	O	NOUN	I
and	O	CCONJ	O
dietary	O	ADJ	B
restriction	O	NOUN	I
on	O	ADP	O
lipolytic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
anabolic	I-OUT	ADJ	B
actions	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
the	I-OUT	DET	O
consequent	I-OUT	ADJ	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
insulin	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
GH	I-OUT	NOUN	B
secretion	I-OUT	NOUN	I
in	I-OUT	ADP	O
obesity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


24	B-P	NUM	O
obese	I-P	ADJ	B
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
22	I-P	NUM	O
women	I-P	NOUN	B
and	I-P	CCONJ	O
2	I-P	NUM	O
men	I-P	NOUN	B
;	I-P	PUNCT	O
22-46	I-P	NUM	O
years	I-P	NOUN	B
old	I-P	ADJ	I
)	I-P	PUNCT	O
were	O	AUX	O
fed	O	VERB	B
a	O	DET	O
diet	B-I	NOUN	B
of	O	ADP	O
25	O	NUM	O
kcal/kg	O	NOUN	O
ideal	O	ADJ	B
body	O	NOUN	I
weight	O	NOUN	I
(	O	PUNCT	O
IBW	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
1.2	O	NUM	O
g	O	NOUN	O
protein/kg	O	NOUN	O
IBW	O	PROPN	B
daily	O	ADV	B
and	O	CCONJ	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
recombinant	B-I	ADJ	B
human	I-I	ADJ	O
GH	I-I	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
,	O	PUNCT	O
0.18	O	NUM	O
U/kg	O	NOUN	O
IBW/week	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
,	O	PUNCT	O
vehicle	O	NOUN	B
injection	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
12-week	O	NOUN	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
and	O	CCONJ	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


GH	B-I	NOUN	B
treatment	O	NOUN	I
caused	O	VERB	O
a	O	DET	O
1.6-fold	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
fraction	B-OUT	NOUN	B
of	I-OUT	ADP	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
lost	I-OUT	VERB	B
as	I-OUT	ADP	O
fat	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
greater	I-OUT	ADJ	O
loss	I-OUT	NOUN	B
of	I-OUT	ADP	O
visceral	I-OUT	ADJ	B
fat	I-OUT	NOUN	I
area	I-OUT	NOUN	I
than	O	ADP	O
placebo	O	ADJ	B
treatment	O	NOUN	B
(	O	PUNCT	O
35.3	O	NUM	O
vs.	O	CCONJ	O
28.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
loss	O	NOUN	B
in	O	ADP	O
lean	B-OUT	ADJ	B
body	I-OUT	NOUN	I
mass	I-OUT	NOUN	I
(	O	PUNCT	O
-2.62	O	NUM	O
+/-	O	CCONJ	O
1.51	O	NUM	O
kg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
negative	B-OUT	ADJ	B
nitrogen	I-OUT	NOUN	O
balance	I-OUT	NOUN	O
(	O	PUNCT	O
-4.52	O	NUM	O
+/-	O	CCONJ	O
3.51	O	NUM	O
g/day	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


By	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
GH	B-I	NOUN	B
group	O	NOUN	I
increased	O	VERB	B
in	O	ADP	O
lean	B-OUT	ADJ	B
body	I-OUT	NOUN	I
mass	I-OUT	NOUN	I
(	O	PUNCT	O
1.13	O	NUM	O
+/-	O	CCONJ	O
1.04	O	NUM	O
kg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
a	O	DET	O
positive	B-OUT	ADJ	B
nitrogen	I-OUT	NOUN	O
balance	I-OUT	NOUN	O
(	O	PUNCT	O
1.81	O	NUM	O
+/-	O	CCONJ	O
2.06	O	NUM	O
g/day	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


GH	B-I	NOUN	B
injections	I-I	NOUN	I
caused	O	VERB	O
a	O	DET	O
1.6-fold	O	ADJ	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
IGF-I	I-OUT	NOUN	B
,	O	PUNCT	O
despite	O	SCONJ	O
caloric	O	ADJ	B
restriction	O	NOUN	I
.	O	PUNCT	O


GH	B-OUT	NOUN	B
response	I-OUT	NOUN	I
to	I-OUT	PART	O
L-dopa	I-OUT	ADJ	B
stimulation	I-OUT	NOUN	B
was	O	AUX	O
blunted	B-OUT	VERB	B
in	O	ADP	O
all	O	DET	O
subjects	O	NOUN	B
and	O	CCONJ	O
it	O	PRON	O
was	O	AUX	O
increased	O	VERB	B
after	O	ADP	O
treatment	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


GH	B-I	NOUN	B
treatment	O	NOUN	I
did	O	AUX	O
not	O	PART	O
induce	O	VERB	B
a	O	DET	O
further	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
insulin	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
during	O	ADP	O
an	O	DET	O
oral	O	ADJ	B
glucose	O	NOUN	I
tolerance	O	NOUN	I
test	O	NOUN	I
(	O	PUNCT	O
OGTT	O	NOUN	B
)	O	PUNCT	O
but	O	CCONJ	O
significantly	O	ADV	O
decreased	O	VERB	B
free	B-OUT	ADJ	O
fatty	I-OUT	ADJ	O
acid	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
FFA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
during	O	ADP	O
OGTT	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
FFA	B-OUT	NOUN	B
area	I-OUT	NOUN	B
under	O	ADP	I
the	O	DET	I
curve	O	NOUN	I
during	O	ADP	O
OGTT	O	NOUN	B
was	O	AUX	O
positively	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
visceral	B-OUT	ADJ	B
fat	I-OUT	ADJ	I
loss	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
obese	B-P	ADJ	B
subjects	I-P	NOUN	B
given	O	VERB	O
a	O	DET	O
hypocaloric	O	ADJ	B
diet	O	NOUN	I
,	O	PUNCT	O
GH	O	NOUN	B
accelerates	O	VERB	O
body	B-OUT	NOUN	B
fat	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
exerts	I-OUT	VERB	O
anabolic	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
improves	I-OUT	VERB	B
GH	I-OUT	NOUN	B
secretion	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
therapeutic	O	ADJ	B
role	O	NOUN	O
of	O	ADP	O
low-dose	O	ADJ	B
GH	B-I	NOUN	B
with	O	ADP	O
caloric	O	ADJ	B
restriction	O	NOUN	I
for	O	ADP	O
obesity	O	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
clinical	O	ADJ	I
study	O	NOUN	I
comparing	O	VERB	O
Compeed	B-I	ADJ	B
cold	I-I	ADJ	I
sore	I-I	ADJ	I
patch	I-I	NOUN	B
to	O	ADP	O
acyclovir	B-I	NOUN	B
cream	I-I	NOUN	I
5	I-I	NUM	O
%	I-I	NOUN	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
herpes	B-P	NOUN	B
simplex	I-P	NOUN	I
labialis	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Hydrocolloid	O	PROPN	B
technology	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
proven	O	VERB	O
effective	O	ADJ	B
in	O	ADP	O
treating	O	VERB	B
dermal	O	ADJ	B
wounds	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
previous	O	ADJ	O
study	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
newly	O	ADV	O
developed	O	VERB	O
thin	B-I	ADJ	O
hydrocolloid	I-I	NOUN	B
patch	I-I	NOUN	I
[	I-I	PUNCT	O
Compeed	I-I	PROPN	B
cold	I-I	ADJ	I
sore	I-I	ADJ	I
patch	I-I	NOUN	I
(	I-I	PUNCT	O
CSP	I-I	NOUN	B
)	I-I	PUNCT	O
]	I-I	PUNCT	O
provided	O	VERB	O
multiple	O	ADJ	B
wound-healing	O	ADJ	B
benefits	O	NOUN	B
across	O	ADP	O
all	O	DET	O
stages	O	NOUN	B
of	O	ADP	O
a	O	DET	O
herpes	B-P	NOUN	B
simplex	I-P	NOUN	I
labialis	I-P	NOUN	I
(	I-P	PUNCT	O
HSL	I-P	NOUN	B
)	I-P	PUNCT	O
outbreak	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
An	O	DET	O
assessment	O	NOUN	B
of	O	ADP	O
CSP	O	NOUN	B
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
an	O	DET	O
international	B-P	ADJ	B
,	I-P	PUNCT	O
multicentre	I-P	NOUN	B
,	O	PUNCT	O
assessor-blinded	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
enrolled	B-P	VERB	O
728	I-P	NUM	O
subjects	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
history	I-P	NOUN	B
of	I-P	ADP	O
recurrent	I-P	ADJ	B
HSL	I-P	NOUN	B
.	I-P	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
351	B-P	NUM	O
experienced	O	VERB	O
an	O	DET	O
HSL	O	NOUN	B
outbreak	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
use	O	VERB	O
CSP	O	PROPN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
179	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
acyclovir	B-I	NOUN	B
cream	I-I	NOUN	I
5	I-I	NUM	O
%	I-I	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
172	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
symptoms	O	NOUN	B
until	O	ADP	O
the	O	DET	O
lesion	O	NOUN	B
healed	O	VERB	B
,	O	PUNCT	O
for	O	ADP	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
the	O	DET	O
subject	B-OUT	NOUN	B
's	I-OUT	PART	I
global	I-OUT	ADJ	B
assessment	I-OUT	NOUN	I
of	I-OUT	ADP	O
therapy	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
SGAT	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
0-10	I-OUT	NUM	O
scale	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
0	I-OUT	NUM	O
=	I-OUT	ADJ	O
no	I-OUT	DET	B
response	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
10	I-OUT	NUM	O
=	I-OUT	ADJ	O
excellent	I-OUT	ADJ	B
response	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Multiple	O	ADJ	B
secondary	O	ADJ	O
end	O	NOUN	O
points	O	NOUN	O
included	O	VERB	O
clinician-assessed	B-OUT	ADJ	B
healing	I-OUT	NOUN	I
time	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
subject	I-OUT	ADJ	B
assessment	I-OUT	NOUN	B
of	I-OUT	ADP	O
lesion	I-OUT	NOUN	B
protection	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
noticeability	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
social	I-OUT	ADJ	B
embarrassment	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
CSP	B-I	NOUN	B
and	I-I	CCONJ	O
acyclovir	I-I	NOUN	B
were	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
(	O	PUNCT	O
mean	O	ADJ	O
SGAT	O	NOUN	B
=	O	ADJ	O
7.89	O	NUM	O
and	O	CCONJ	O
8.00	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	I
observed	O	VERB	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.65	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
healing	B-OUT	NOUN	B
times	I-OUT	NOUN	O
between	I-OUT	ADP	O
products	I-OUT	NOUN	B
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
(	O	PUNCT	O
median	O	NOUN	B
,	O	PUNCT	O
7.57	O	NUM	O
days	O	NOUN	B
with	O	ADP	O
CSP	O	PROPN	B
vs.	O	CCONJ	O
7.03	O	NUM	O
days	O	NOUN	B
with	O	ADP	O
acyclovir	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.37	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	DET	O
treatments	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
CSP	B-I	PROPN	B
using	I-I	VERB	O
hydrocolloid	I-I	NOUN	B
technology	I-I	NOUN	I
provides	O	VERB	O
an	O	DET	O
efficacious	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
safe	I-OUT	ADJ	O
alternative	O	NOUN	O
to	O	PART	O
topical	O	ADJ	B
antivirals	O	NOUN	O
in	O	ADP	O
treating	O	VERB	B
HSL	O	NOUN	B
as	O	ADP	O
a	O	DET	O
wound	O	NOUN	B
while	O	SCONJ	O
affording	O	VERB	O
additional	O	ADJ	O
immediate	O	ADJ	B
benefits	O	NOUN	B
of	O	ADP	O
wound	O	NOUN	B
protection	O	NOUN	I
,	O	PUNCT	O
discretion	O	NOUN	B
and	O	CCONJ	O
relief	O	NOUN	B
of	O	ADP	O
social	O	ADJ	B
embarrassment	O	NOUN	I
.	O	PUNCT	O


Preliminary	O	ADJ	B
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
final	O	ADJ	O
multicenter	O	NOUN	B
investigation	O	NOUN	B
of	O	ADP	O
rheopheresis	B-I	NOUN	B
for	O	ADP	O
age	B-P	NOUN	B
related	I-P	ADJ	O
macular	I-P	NOUN	B
degeneration	I-P	NOUN	I
(	I-P	PUNCT	O
AMD	I-P	NOUN	B
)	I-P	PUNCT	O
trial	O	NOUN	O
(	O	PUNCT	O
MIRA-1	O	NOUN	B
)	O	PUNCT	O
results	O	VERB	B
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
present	O	VERB	O
an	O	DET	O
initial	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
final	O	ADJ	O
data	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Multicenter	O	PROPN	B
Investigation	O	PROPN	B
of	O	ADP	O
Rheopheresis	B-I	NOUN	B
for	O	ADP	O
age-related	O	ADJ	B
macular	O	NOUN	I
degeneration	O	NOUN	I
(	O	PUNCT	O
AMD	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
MIRA-1	O	NOUN	B
)	O	PUNCT	O
trial	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
a	O	DET	O
12-month	O	ADJ	O
randomized	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
double-masked	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
Food	O	PROPN	B
and	O	CCONJ	I
Drug	O	PROPN	I
Administration	O	PROPN	I
approved	O	VERB	O
clinical	O	ADJ	O
trial	O	NOUN	O
designed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
rheopheresis	B-I	NOUN	B
treatment	I-I	NOUN	B
with	O	ADP	O
placebo-control	B-I	ADJ	B
treatment	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
that	I-P	PRON	O
had	I-P	AUX	O
nonexudative	I-P	ADJ	B
age-related	I-P	ADJ	B
macular	I-P	NOUN	I
degeneration	I-P	NOUN	I
(	I-P	PUNCT	O
AMD	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
certain	I-P	ADJ	O
hemorheologic	I-P	ADJ	B
abnormalities	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
either	O	CCONJ	O
rheopheresis	B-I	NOUN	B
or	I-I	CCONJ	O
sham	I-I	NOUN	B
treatment	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
2:1	O	NUM	O
fashion	O	NOUN	B
.	O	PUNCT	O


Best-corrected	O	ADJ	B
visual	O	ADJ	B
acuity	O	NOUN	I
was	O	AUX	O
determined	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
at	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
.	O	PUNCT	O


Adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
216	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
18	O	NUM	O
were	O	AUX	O
not	O	PART	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
vision	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
evaluation	O	NOUN	B
because	O	SCONJ	O
they	O	PRON	O
did	O	AUX	O
not	O	PART	O
complete	O	VERB	O
one	O	NUM	O
treatment	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
decreased	O	VERB	B
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
evaluated	O	VERB	B
for	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
to	O	PART	O
198	B-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
this	O	DET	O
group	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
27	O	NUM	O
serious	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
1.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
treatments	O	NOUN	B
were	O	AUX	O
suspended	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
104	O	NUM	O
treated	O	VERB	B
patients	O	NOUN	B
and	O	CCONJ	O
63	O	NUM	O
placebo	B-I	NOUN	B
patients	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
follow-up	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
treated	O	VERB	B
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
logMAR	B-OUT	ADJ	O
vision	I-OUT	NOUN	B
improvement	I-OUT	NOUN	B
of	O	ADP	O
0.02	O	NUM	O
+/-	O	CCONJ	O
0.213	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
placebo	B-I	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
vision	B-OUT	NOUN	B
improvement	I-OUT	NOUN	B
of	O	ADP	O
0.02	O	NUM	O
+/-	O	CCONJ	O
0.20	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.977	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
repeated	O	VERB	O
measure	O	NOUN	B
P	O	NOUN	O
value	O	NOUN	O
for	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
time	O	NOUN	B
interval	O	NOUN	I
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.69	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
patients	O	NOUN	B
entered	O	VERB	O
into	O	ADP	O
the	O	DET	O
study	O	NOUN	B
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
meet	O	VERB	O
inclusion	O	NOUN	B
criteria	O	NOUN	I
.	O	PUNCT	O


Excluding	O	VERB	O
37	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treated	O	VERB	B
patients	O	NOUN	B
and	O	CCONJ	O
29	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
data	O	NOUN	B
from	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treated	O	VERB	B
patients	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
control	O	ADJ	B
patients	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
with	O	ADP	O
a	O	DET	O
P	O	NOUN	O
value	O	NOUN	O
of	O	ADP	O
.001	O	NUM	O
(	O	PUNCT	O
repeated	O	VERB	O
measures	O	NOUN	B
P	O	NOUN	O
value	O	NOUN	O
=	O	ADJ	O
.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
At	O	ADP	O
best	O	ADV	O
this	O	DET	O
was	O	AUX	O
a	O	DET	O
flawed	O	ADJ	O
study	O	NOUN	B
in	O	ADP	O
that	O	DET	O
37	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treated	O	VERB	B
cases	O	NOUN	B
did	O	AUX	O
not	O	PART	O
meet	O	VERB	O
inclusion	O	NOUN	B
criteria	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
worst	O	ADV	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
effect	O	NOUN	B
.	O	PUNCT	O


Even	O	ADV	O
though	O	SCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
serious	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
is	O	AUX	O
small	O	ADJ	B
,	O	PUNCT	O
because	O	SCONJ	O
this	O	DET	O
study	O	NOUN	B
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
an	O	DET	O
effect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intent-to-treat	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
rheopheresis	B-I	NOUN	B
should	O	AUX	O
not	O	PART	O
be	O	AUX	O
performed	O	VERB	O
for	O	ADP	O
AMD	O	NOUN	B
outside	O	ADP	O
of	O	ADP	O
an	O	DET	O
approved	O	VERB	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
entecavir	B-I	NOUN	B
prophylaxis	I-I	NOUN	B
for	O	ADP	O
rituximab-associated	O	ADJ	B
hepatitis	O	NOUN	I
B	O	NOUN	I
virus	O	NOUN	I
reactivation	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
lymphoma	I-P	NOUN	B
and	I-P	CCONJ	O
resolved	I-P	VERB	B
hepatitis	I-P	NOUN	B
B	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
antiviral	B-I	ADJ	B
prophylaxis	I-I	NOUN	I
in	O	ADP	O
preventing	O	VERB	B
hepatitis	O	NOUN	B
B	O	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
HBV	O	NOUN	B
)	O	PUNCT	O
reactivation	O	NOUN	B
before	O	ADP	O
rituximab-based	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
lymphoma	I-P	NOUN	B
and	I-P	CCONJ	O
resolved	I-P	VERB	B
hepatitis	I-P	NOUN	B
B	I-P	NOUN	I
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	VERB	O
Eighty	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
CD20	I-P	NOUN	B
(	I-P	PUNCT	O
+	I-P	CCONJ	O
)	I-P	PUNCT	O
lymphoma	I-P	NOUN	O
and	I-P	CCONJ	O
resolved	I-P	VERB	B
hepatitis	I-P	NOUN	B
B	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
prophylactic	B-I	ADJ	B
entecavir	I-I	NOUN	I
(	I-I	PUNCT	O
ETV	I-I	NOUN	B
)	I-I	PUNCT	O
before	I-I	ADP	O
chemotherapy	I-I	NOUN	B
to	I-I	PART	O
3	I-I	NUM	O
months	I-I	NOUN	B
after	I-I	ADP	O
completing	I-I	VERB	O
chemotherapy	I-I	NOUN	B
(	I-I	PUNCT	O
ETV	I-I	NOUN	B
prophylactic	I-I	ADJ	B
group	I-I	NOUN	I
,	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
41	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
to	I-I	PART	O
receive	I-I	VERB	O
therapeutic	I-I	ADJ	B
ETV	I-I	NOUN	O
at	I-I	ADP	O
the	I-I	DET	O
time	I-I	NOUN	B
of	I-I	ADP	O
HBV	I-I	NOUN	B
reactivation	I-I	NOUN	B
and	I-I	CCONJ	O
hepatitis	I-I	NOUN	B
B	I-I	NOUN	I
surface	I-I	NOUN	I
antigen	I-I	NOUN	I
(	I-I	PUNCT	O
HBsAg	I-I	NOUN	B
)	I-I	PUNCT	O
reverse	I-I	VERB	O
seroconversion	I-I	NOUN	B
since	I-I	SCONJ	O
chemotherapy	I-I	NOUN	B
(	I-I	PUNCT	O
control	I-I	NOUN	B
group	I-I	NOUN	I
,	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
39	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


RESULTS	O	VERB	O
Fifty-eight	B-P	NUM	O
patients	I-P	NOUN	B
(	O	PUNCT	O
72.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
positive	O	ADJ	B
for	O	ADP	O
hepatitis	O	NOUN	B
B	O	NOUN	I
surface	O	NOUN	I
antibody	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
HBV	O	NOUN	B
DNA	O	NOUN	B
was	O	AUX	O
undetectable	O	ADJ	B
in	O	ADP	O
50	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
62.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


During	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
18-month	O	ADJ	O
follow-up	O	ADJ	B
period	O	NOUN	B
,	O	PUNCT	O
one	B-P	NUM	O
patient	I-P	NOUN	B
(	O	PUNCT	O
2.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
ETV	B-I	NOUN	B
prophylactic	O	ADJ	B
group	O	NOUN	I
and	O	CCONJ	O
seven	B-P	NUM	O
patients	I-P	NOUN	B
(	O	PUNCT	O
17.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
developed	O	VERB	O
HBV	O	NOUN	B
reactivation	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.027	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
cumulative	B-OUT	ADJ	B
HBV	I-OUT	NOUN	B
reactivation	I-OUT	NOUN	O
rates	I-OUT	NOUN	B
at	O	ADP	O
months	O	NOUN	B
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
18	O	NUM	O
after	O	ADP	O
chemotherapy	O	NOUN	B
were	O	AUX	O
8	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
11.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
25.9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
control	B-P	NOUN	B
group	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
4.3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
ETV	O	NOUN	B
prophylactic	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.019	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Four	B-P	NUM	O
patients	I-P	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
had	O	AUX	O
HBsAg	B-OUT	NOUN	B
reverse	I-OUT	ADJ	B
seroconversion	I-OUT	NOUN	I
after	O	ADP	O
HBV	O	NOUN	B
reactivation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cumulative	B-OUT	ADJ	B
HBsAg	I-OUT	NOUN	B
reverse	I-OUT	ADJ	O
seroconversion	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
at	O	ADP	O
months	O	NOUN	B
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
18	O	NUM	O
since	O	SCONJ	O
chemotherapy	O	NOUN	B
were	O	AUX	O
0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
6.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
16.3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	B-P	NOUN	B
group	I-P	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
ETV	O	NOUN	B
prophylactic	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.032	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
detectable	O	ADJ	B
or	O	CCONJ	O
undetectable	O	ADJ	B
viral	O	ADJ	B
load	O	NOUN	I
could	O	AUX	O
develop	O	VERB	O
HBV	B-OUT	NOUN	B
reactivation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
HBsAg	I-OUT	NOUN	B
reverse	I-OUT	ADJ	O
seroconversion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
Undetectable	O	NOUN	B
HBV	O	NOUN	B
viral	O	ADJ	B
load	O	NOUN	I
before	O	ADP	O
chemotherapy	O	NOUN	B
did	O	AUX	O
not	O	PART	O
confer	O	VERB	O
reactivation-free	O	ADJ	B
status	O	NOUN	I
.	O	PUNCT	O


Antiviral	B-I	ADJ	B
prophylaxis	I-I	NOUN	I
can	O	AUX	O
potentially	O	ADV	O
prevent	O	VERB	O
rituximab-associated	O	ADJ	B
HBV	O	NOUN	O
reactivation	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
lymphoma	I-P	NOUN	B
and	I-P	CCONJ	O
resolved	I-P	VERB	B
hepatitis	I-P	NOUN	B
B	I-P	NOUN	I
.	I-P	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
levosimendan	B-I	NOUN	B
versus	O	CCONJ	O
dobutamine	B-I	NOUN	B
on	O	ADP	O
inflammatory	O	ADJ	B
and	O	CCONJ	O
apoptotic	O	ADJ	B
pathways	O	NOUN	I
in	O	ADP	O
acutely	B-P	ADV	O
decompensated	I-P	ADJ	B
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
single	O	ADJ	O
levosimendan	B-I	NOUN	B
administration	O	NOUN	B
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
hemodynamic	O	ADJ	B
improvement	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
decompensated	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
(	I-P	PUNCT	O
HF	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
but	I-P	CCONJ	O
without	I-P	ADP	O
survival	I-P	NOUN	B
benefits	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
levosimendan	B-I	NOUN	B
and	O	CCONJ	O
dobutamine	B-I	NOUN	B
on	O	ADP	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
proinflammatory	O	ADJ	B
and	O	CCONJ	O
proapoptotic	O	ADJ	B
mediators	O	NOUN	I
in	O	ADP	O
decompensated	O	ADJ	B
HF	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
and	O	CCONJ	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
concomitant	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
cardiac	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
prognosis	O	NOUN	B
.	O	PUNCT	O


Sixty-nine	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
received	O	VERB	O
24-hour	O	ADJ	O
intravenous	O	ADJ	B
infusions	O	NOUN	B
of	O	ADP	O
levosimendan	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
23	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
dobutamine	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
23	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
23	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Echocardiographic	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
hemodynamic	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
biochemical	I-OUT	ADJ	B
assessments	I-OUT	NOUN	B
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
immediately	O	ADV	O
after	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
48	O	NUM	O
hours	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
subsequently	O	ADV	O
followed	O	VERB	O
for	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
.	O	PUNCT	O


End-systolic	B-OUT	ADJ	B
wall	I-OUT	NOUN	I
stress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
left	I-OUT	ADJ	B
ventricular	I-OUT	ADJ	I
ejection	I-OUT	NOUN	I
fraction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pulmonary	I-OUT	ADJ	B
capillary	I-OUT	ADJ	I
wedge	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cardiac	I-OUT	ADJ	B
index	I-OUT	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
the	O	DET	O
levosimendan	O	NOUN	B
group	O	NOUN	B
but	O	CCONJ	O
remained	O	VERB	O
practically	O	ADV	O
unaffected	O	ADJ	B
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
N-terminal-pro-B-type	I-OUT	NOUN	B
natriuretic	I-OUT	ADJ	I
peptide	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
tumor	I-OUT	NOUN	B
necrosis	I-OUT	NOUN	I
factor-alpha	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
soluble	I-OUT	ADJ	B
Fas	I-OUT	NOUN	B
ligand	I-OUT	NOUN	O
levels	I-OUT	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
levosimendan	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
1,900	O	NUM	O
+/-	O	CCONJ	O
223	O	NUM	O
to	O	PART	O
1,378	O	NUM	O
+/-	O	CCONJ	O
170	O	NUM	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
13.4	O	NUM	O
+/-	O	CCONJ	O
1.0	O	NUM	O
to	O	PART	O
12.3	O	NUM	O
+/-	O	CCONJ	O
1.2	O	NUM	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
68.2	O	NUM	O
+/-	O	CCONJ	O
3.7	O	NUM	O
to	O	PART	O
59.8	O	NUM	O
+/-	O	CCONJ	O
3.6	O	NUM	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
for	O	ADP	O
all	O	DET	O
)	O	PUNCT	O
;	O	PUNCT	O
interleukin-6	B-OUT	NOUN	B
was	O	AUX	O
also	O	ADV	O
borderline	O	NOUN	B
reduced	O	VERB	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.051	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Levosimendan-induced	B-OUT	ADJ	B
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
end-systolic	I-OUT	ADJ	B
wall	I-OUT	NOUN	I
stress	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
respective	O	ADJ	O
decreases	O	NOUN	B
in	O	ADP	O
N-terminal-pro-B-type	B-OUT	ADJ	B
natriuretic	I-OUT	ADJ	I
peptide	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.671	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
tumor	B-OUT	NOUN	B
necrosis	I-OUT	NOUN	I
factor-alpha	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.586	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
soluble	B-OUT	ADJ	B
Fas	I-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.441	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
soluble	B-OUT	ADJ	B
Fas	I-OUT	NOUN	B
ligand	I-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.614	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Event-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
longer	O	ADV	O
in	O	ADP	O
the	O	DET	O
levosimendan	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
superiority	O	NOUN	B
of	O	ADP	O
levosimendan	B-I	NOUN	B
over	O	ADP	O
dobutamine	B-I	NOUN	B
in	O	ADP	O
improving	O	VERB	B
central	B-OUT	ADJ	B
hemodynamics	I-OUT	NOUN	I
and	O	CCONJ	O
left	B-OUT	VERB	B
ventricular	I-OUT	ADJ	I
performance	I-OUT	NOUN	I
in	O	ADP	O
decompensated	B-P	ADJ	B
HF	I-P	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
its	O	PRON	O
anti-inflammatory	O	ADJ	B
and	O	CCONJ	O
antiapoptotic	O	ADJ	B
effects	O	NOUN	B
.	O	PUNCT	O


Nurse	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
patient	I-OUT	ADJ	B
communication	I-OUT	NOUN	O
profiles	I-OUT	NOUN	O
in	O	ADP	O
a	O	DET	O
home-based	B-P	ADJ	B
telehealth	I-P	NOUN	B
intervention	I-P	NOUN	O
for	O	ADP	O
heart	O	NOUN	B
failure	O	NOUN	I
management	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
compared	O	VERB	O
differences	O	NOUN	O
in	O	ADP	O
nurse	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
patient	I-OUT	ADJ	B
communication	I-OUT	NOUN	O
profiles	I-OUT	NOUN	O
between	O	ADP	O
two	O	NUM	O
telehealth	O	NOUN	B
modes	O	NOUN	I
:	O	PUNCT	O
telephone	B-I	NOUN	B
and	O	CCONJ	O
videophone	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
evaluated	O	VERB	B
longitudinal	B-OUT	ADJ	B
changes	I-OUT	NOUN	I
in	I-OUT	ADP	O
communication	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nurse	I-OUT	ADJ	B
perceptions	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
patient	I-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
Subjects	B-P	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	B-P	ADJ	B
controlled	I-P	VERB	I
clinical	I-P	ADJ	I
trial	I-P	NOUN	I
evaluating	O	VERB	B
a	O	DET	O
90-day	O	ADJ	O
home-based	O	ADJ	B
intervention	O	NOUN	I
for	O	ADP	O
heart	O	NOUN	B
failure	O	NOUN	I
.	O	PUNCT	O


Telephone	B-I	NOUN	B
(	I-P	PUNCT	O
n=14	I-P	NOUN	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
videophone	I-I	NOUN	B
(	I-P	PUNCT	O
n=14	I-P	NOUN	O
)	I-P	PUNCT	O
interactions	I-P	NOUN	B
were	O	AUX	O
audio	O	ADJ	B
taped	O	VERB	I
and	O	CCONJ	O
analyzed	O	VERB	B
using	O	VERB	O
the	O	DET	O
Roter	B-OUT	PROPN	B
Interaction	I-OUT	PROPN	I
Analysis	I-OUT	PROPN	I
System	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Nurses	B-P	NOUN	I
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
use	B-OUT	VERB	O
open-ended	I-OUT	ADJ	B
questions	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
back-channel	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
friendly	I-OUT	ADJ	O
jokes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
checks	I-OUT	VERB	B
for	I-OUT	ADP	O
understanding	I-OUT	NOUN	O
on	O	ADP	O
the	O	DET	O
telephone	B-I	NOUN	B
compared	O	VERB	B
to	O	ADP	O
videophone	B-I	NOUN	B
.	I-I	PUNCT	O


Compliments	B-OUT	NOUN	B
given	I-OUT	VERB	O
and	I-OUT	CCONJ	O
partnership	I-OUT	NOUN	B
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
on	O	ADP	O
the	O	DET	O
videophone	O	NOUN	B
.	O	PUNCT	O


Patients	B-P	NOUN	B
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
give	B-OUT	VERB	O
lifestyle	I-OUT	NOUN	B
information	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
approval	I-OUT	NOUN	B
comments	I-OUT	NOUN	B
on	O	ADP	O
the	O	DET	O
telephone	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
used	O	VERB	O
more	O	ADV	O
closed-ended	B-OUT	ADJ	B
questions	I-OUT	NOUN	I
on	O	ADP	O
the	O	DET	O
videophone	B-I	NOUN	B
.	I-I	PUNCT	O


Nurses	B-OUT	NOUN	B
perceptions	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
interactions	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
telephone	O	NOUN	B
and	O	CCONJ	O
videophone	B-I	NOUN	B
,	O	PUNCT	O
nor	O	CCONJ	O
did	O	AUX	O
their	O	PRON	O
perceptions	B-OUT	NOUN	B
change	O	VERB	O
significantly	O	ADV	O
over	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
patient	B-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
telephone	O	NOUN	B
and	O	CCONJ	O
videophone	B-I	NOUN	B
.	I-I	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
did	O	AUX	O
not	O	PART	O
support	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
videophone	B-I	NOUN	B
over	O	ADP	O
the	O	DET	O
telephone	B-I	NOUN	B
.	I-I	PUNCT	O


PRACTICE	O	NOUN	B
IMPLICATIONS	O	NOUN	O
It	O	PRON	O
is	O	AUX	O
critical	O	ADJ	O
to	O	PART	O
match	O	VERB	B
technologies	O	NOUN	B
to	O	PART	O
patient	O	NOUN	B
needs	O	NOUN	B
and	O	CCONJ	O
use	O	VERB	O
the	O	DET	O
least	O	ADJ	O
complex	O	ADJ	B
technology	O	NOUN	B
possible	O	ADJ	O
.	O	PUNCT	O


When	O	SCONJ	O
considering	O	VERB	O
use	O	VERB	O
a	O	DET	O
videophone	B-I	NOUN	B
,	O	PUNCT	O
health	O	NOUN	B
care	O	NOUN	I
providers	O	NOUN	I
should	O	AUX	O
critically	O	ADV	O
examine	O	VERB	O
the	O	DET	O
trade-offs	O	NOUN	B
between	O	ADP	O
additional	O	ADJ	O
complexities	O	NOUN	B
with	O	ADP	O
the	O	DET	O
added	O	VERB	O
value	O	NOUN	O
of	O	ADP	O
the	O	DET	O
visual	O	ADJ	B
interaction	O	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
oral	O	ADJ	B
phytonadione	B-I	NOUN	I
for	O	ADP	O
excessive	B-OUT	ADJ	B
anticoagulation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
managing	O	VERB	O
excessive	O	ADJ	B
anticoagulation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
bleeding	O	NOUN	B
by	O	ADP	O
either	O	CCONJ	O
omitting	O	VERB	O
warfarin	O	NOUN	B
therapy	O	NOUN	I
alone	O	ADV	O
or	O	CCONJ	O
administering	O	VERB	B
oral	O	ADJ	B
phytonadione	B-I	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	ADP	O
omitting	O	VERB	O
warfarin	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Clinical	O	ADJ	B
pharmacy	O	NOUN	I
anticoagulation	O	NOUN	B
service	O	NOUN	I
in	O	ADP	O
a	O	DET	O
group	O	NOUN	B
model	O	NOUN	B
health	O	NOUN	B
maintenance	O	NOUN	I
organization	O	NOUN	I
.	O	PUNCT	O


SUBJECTS	O	VERB	O
Thirty	B-P	NUM	O
nonbleeding	I-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
international	I-P	ADJ	B
normalized	I-P	VERB	O
ratios	I-P	NOUN	O
(	I-P	PUNCT	O
INRs	I-P	NOUN	B
)	I-P	PUNCT	O
ranging	I-P	VERB	O
from	I-P	ADP	O
6.0-10.0	I-P	NUM	B
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
Patients	B-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	PART	O
receive	I-P	VERB	O
either	I-P	CCONJ	O
a	I-P	DET	O
single	I-I	ADJ	O
oral	I-I	ADJ	B
dose	I-I	NOUN	I
of	I-I	ADP	O
phytonadione	I-I	NOUN	B
2.5	I-I	NUM	I
mg	I-I	NOUN	I
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
omitted	B-I	VERB	O
warfarin	I-I	NOUN	B
doses	I-I	NOUN	I
until	I-I	ADP	O
the	I-I	DET	O
INR	I-I	PROPN	B
became	I-I	VERB	O
less	I-I	ADJ	O
than	I-I	ADP	O
or	I-I	CCONJ	O
equal	I-I	ADJ	O
to	I-I	PART	O
4.0	I-I	NUM	O
.	I-I	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
The	O	DET	O
mean	B-OUT	ADJ	O
calculated	I-OUT	VERB	O
time	I-OUT	NOUN	O
to	I-OUT	PART	O
reach	I-OUT	VERB	O
an	I-OUT	DET	O
INR	I-OUT	PROPN	B
of	I-OUT	ADP	O
4.0	I-OUT	NUM	O
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
than	O	ADP	O
the	O	DET	O
phytonadione	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
2.6	O	NUM	O
vs	O	CCONJ	O
1.4	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
p=0.006	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Overcorrection	B-OUT	NOUN	B
of	I-OUT	ADP	O
anticoagulation	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
phytonadione	O	NOUN	B
.	O	PUNCT	O


Overt	B-OUT	ADJ	B
warfarin	I-OUT	NOUN	B
resistance	I-OUT	NOUN	O
was	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
after	O	ADP	O
reinitiating	O	VERB	B
warfarin	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
major	B-OUT	ADJ	I
bleeding	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
thromboembolic	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
occurred	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
minor	O	ADJ	B
bleeding	B-OUT	NOUN	I
episodes	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
oral	O	ADJ	B
phytonadione	O	NOUN	I
2.5	O	NUM	I
mg	O	NOUN	O
reduced	O	VERB	B
the	O	DET	O
time	O	NOUN	O
to	O	PART	O
achieve	O	VERB	O
an	O	DET	O
INR	O	PROPN	B
of	O	ADP	O
4.0	O	NUM	O
by	O	ADP	O
approximately	O	ADV	O
1	O	NUM	O
day	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
omitting	O	VERB	O
warfarin	O	NOUN	B
therapy	O	NOUN	I
alone	O	ADV	O
.	O	PUNCT	O


Adverse	O	ADJ	B
events	O	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
strategies	O	NOUN	B
were	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
managing	O	VERB	O
asymptomatic	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
INRs	I-P	NOUN	B
of	I-P	ADP	O
6.0-10.0	I-P	NUM	B
.	I-P	PUNCT	O


Oral	O	ADJ	B
phytonadione	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
most	O	ADV	O
appropriate	O	ADJ	O
for	O	ADP	O
patients	B-P	NOUN	B
at	I-P	ADP	O
high	I-P	ADJ	B
risk	I-P	NOUN	I
for	I-P	ADP	O
bleeding	I-P	NOUN	B
in	I-P	ADP	O
whom	I-P	PRON	O
the	I-P	DET	O
benefit	I-P	NOUN	B
of	I-P	ADP	O
prompt	I-P	ADJ	O
INR	I-OUT	PROPN	B
reduction	I-OUT	NOUN	B
would	I-P	AUX	O
outweigh	I-P	VERB	O
the	I-P	DET	O
thromboembolic	I-P	ADJ	B
risk	I-P	NOUN	B
associated	I-P	VERB	B
with	I-P	ADP	I
INR	I-OUT	NOUN	B
overcorrection	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
ventricular	O	ADJ	B
fibrillation	O	NOUN	I
duration	O	NOUN	B
on	O	ADP	O
defibrillation	B-OUT	NOUN	B
efficacy	I-OUT	NOUN	B
using	O	VERB	O
biphasic	O	ADJ	B
waveforms	O	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
prospectively	O	ADV	O
investigate	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
ventricular	O	ADJ	B
fibrillation	O	NOUN	I
(	O	PUNCT	O
VF	O	PROPN	B
)	O	PUNCT	O
durations	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
s	O	NOUN	O
on	O	ADP	O
the	O	DET	O
defibrillation	B-OUT	NOUN	B
threshold	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
DFT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
during	O	ADP	O
implantable	O	ADJ	B
cardioverter-defibrillator	O	NOUN	I
(	O	PUNCT	O
ICD	O	PROPN	B
)	O	PUNCT	O
implantation	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Although	O	SCONJ	O
the	O	DET	O
DFT	B-OUT	NOUN	B
using	I-OUT	VERB	O
monophasic	I-OUT	ADJ	B
waveforms	I-OUT	NOUN	I
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
increase	O	VERB	B
with	O	ADP	O
VF	O	NOUN	B
duration	O	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
VF	O	NOUN	B
duration	O	NOUN	B
on	O	ADP	O
defibrillation	O	NOUN	B
efficacy	O	NOUN	B
using	O	VERB	O
biphasic	O	ADJ	B
waveforms	O	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Thirty	B-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
primary	I-P	ADJ	O
ICD	I-P	PROPN	B
implantation	I-P	NOUN	B
or	I-P	CCONJ	O
pulse	I-P	NOUN	B
generator	I-P	NOUN	I
replacement	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
have	O	AUX	O
the	O	DET	O
DFT	B-I	PROPN	B
determined	I-I	VERB	O
using	I-I	VERB	O
biphasic	I-I	ADJ	B
shocks	I-I	NOUN	I
at	O	ADP	O
two	O	NUM	O
durations	O	NOUN	B
of	O	ADP	O
VF	B-I	PROPN	B
each	O	DET	O
(	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
s	O	NOUN	O
,	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
s	O	NOUN	O
or	O	CCONJ	O
5	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
s	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
mean	B-OUT	ADJ	B
DFT	I-OUT	NOUN	B
comparing	O	VERB	O
VF	O	ADJ	B
durations	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
s	O	NOUN	O
(	O	PUNCT	O
9.5+/-6.0	O	NOUN	O
J	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
10	O	NUM	O
s	O	NOUN	O
(	O	PUNCT	O
10.8+/-7.0	O	NUM	O
J	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
p=0.4	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
DFT	I-OUT	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
from	O	ADP	O
10.9+/-6.1	O	NUM	O
J	O	NOUN	O
at	O	ADP	O
10	O	NUM	O
s	O	NOUN	O
of	O	ADP	O
VF	O	PROPN	B
to	O	ADP	O
12.6+/-5.6	O	NUM	O
J	O	NOUN	O
(	O	PUNCT	O
p=0.03	O	NOUN	O
)	O	PUNCT	O
at	O	ADP	O
20	O	NUM	O
s	O	NOUN	O
of	O	ADP	O
VF	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
from	O	ADP	O
7.0+/-3.5	O	NUM	O
J	O	NOUN	O
at	O	ADP	O
5	O	NUM	O
s	O	NOUN	O
of	O	ADP	O
VF	O	PROPN	B
to	O	PART	O
10.5+/-6.3	O	NUM	O
J	O	NOUN	O
(	O	PUNCT	O
p=0.04	O	NOUN	O
)	O	PUNCT	O
at	O	ADP	O
20	O	NUM	O
s	O	NOUN	O
of	O	ADP	O
VF	O	PROPN	B
.	O	PUNCT	O


An	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DFT	B-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
14	B-P	NUM	O
patients	I-P	NOUN	B
as	O	ADP	O
VF	O	ADJ	B
duration	O	NOUN	B
increased	O	VERB	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
clinical	O	ADJ	B
characteristics	O	NOUN	I
that	O	PRON	O
differentiated	O	VERB	O
patients	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DFT	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Defibrillation	B-OUT	PROPN	B
efficacy	I-OUT	NOUN	B
decreases	O	VERB	B
with	O	ADP	O
increasing	O	VERB	B
VF	O	ADJ	B
duration	O	NOUN	B
using	O	VERB	O
biphasic	O	ADJ	B
waveforms	O	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


Ventricular	O	ADJ	B
fibrillation	O	NOUN	I
durations	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
10	O	NUM	O
s	O	NOUN	O
may	O	AUX	O
negatively	O	ADV	O
affect	O	VERB	O
the	O	DET	O
effectiveness	B-OUT	NOUN	B
of	I-OUT	ADP	O
ICD	I-OUT	NOUN	B
therapy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
risperidone	B-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
placebo	B-I	ADJ	B
discontinuation	O	NOUN	B
study	O	NOUN	O
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
short-term	O	ADJ	B
benefit	O	NOUN	B
of	O	ADP	O
risperidone	B-I	NOUN	B
in	O	ADP	O
ameliorating	O	VERB	B
severe	B-OUT	ADJ	B
disruptive	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
in	O	ADP	O
pediatric	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
is	O	AUX	O
well	O	ADV	O
established	O	VERB	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
long-term	O	ADJ	B
study	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
is	O	AUX	O
available	O	ADJ	O
.	O	PUNCT	O


METHOD	O	NOUN	O
Thirty-six	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
5-17	I-P	NUM	O
years	I-P	NOUN	O
old	I-P	ADJ	O
)	I-P	PUNCT	O
accompanied	I-P	VERB	O
by	I-P	ADP	O
severe	I-P	ADJ	B
tantrums	I-P	NOUN	B
,	I-P	PUNCT	O
aggression	I-P	NOUN	B
,	I-P	PUNCT	O
or	I-P	CCONJ	O
self-injurious	I-P	ADJ	B
behavior	I-P	NOUN	I
,	O	PUNCT	O
started	O	VERB	O
8-week	O	ADJ	B
open-label	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
risperidone	B-I	NOUN	B
.	I-I	PUNCT	O


Responders	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
26	O	NUM	O
)	O	PUNCT	O
continued	O	VERB	O
treatment	O	NOUN	B
for	O	ADP	O
another	O	DET	O
16	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
discontinuation	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
24	O	NUM	O
;	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
discontinued	O	VERB	B
treatment	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
weight	O	NOUN	B
gain	O	NOUN	I
)	O	PUNCT	O
consisting	O	VERB	O
of	O	ADP	O
either	O	CCONJ	O
3	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
taper	O	NOUN	B
and	O	CCONJ	O
5	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
placebo	B-I	NOUN	B
only	O	ADV	O
or	O	CCONJ	O
continuing	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
risperidone	B-I	NOUN	B
.	I-I	PUNCT	O


Relapse	O	NOUN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
deterioration	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
judgment	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
parent	O	NOUN	B
questionnaire	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
Risperidone	B-I	NOUN	B
was	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
placebo	B-I	NOUN	B
in	O	ADP	O
preventing	O	VERB	O
relapse	B-OUT	NOUN	B
:	I-OUT	PUNCT	O
this	O	DET	O
occurred	O	VERB	O
in	O	ADP	O
3	O	NUM	O
of	O	ADP	O
12	O	NUM	O
patients	O	NOUN	B
continuing	O	VERB	B
on	O	ADP	O
risperidone	O	NOUN	B
versus	O	CCONJ	O
8	O	NUM	O
of	O	ADP	O
12	O	NUM	O
who	O	PRON	O
switched	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.049	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
increased	I-OUT	VERB	B
appetite	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
anxiety	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
fatigue	I-OUT	NOUN	B
were	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
reported	O	VERB	O
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
indicates	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
risperidone	O	NOUN	B
during	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
months	O	NOUN	B
,	O	PUNCT	O
reducing	O	VERB	B
disruptive	B-OUT	ADJ	B
behavior	I-OUT	NOUN	I
in	O	ADP	O
about	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
a	O	DET	O
rationale	O	NOUN	O
for	O	ADP	O
the	O	DET	O
continuing	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
risperidone	B-I	NOUN	B
beyond	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
considerable	O	ADJ	O
weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
can	O	AUX	O
limit	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
this	O	DET	O
agent	O	NOUN	B
.	O	PUNCT	O


Exercise	B-OUT	NOUN	B
capacity	I-OUT	NOUN	B
in	O	ADP	O
atrial	B-P	ADJ	B
fibrillation	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
substudy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Sotalol-Amiodarone	O	ADJ	B
Atrial	O	PROPN	I
Fibrillation	O	PROPN	I
Efficacy	O	PROPN	I
Trial	O	PROPN	I
(	O	PUNCT	O
SAFE-T	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Therapy	O	NOUN	B
for	O	ADP	O
chronic	B-P	ADJ	B
atrial	I-P	ADJ	I
fibrillation	I-P	NOUN	I
(	I-P	PUNCT	O
AF	I-P	NOUN	B
)	I-P	PUNCT	O
focuses	O	VERB	O
on	O	ADP	O
rate	O	NOUN	B
versus	O	CCONJ	O
rhythm	O	NOUN	B
control	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
common	O	ADJ	O
therapeutic	O	ADJ	B
interventions	O	NOUN	O
on	O	ADP	O
exercise	O	NOUN	B
tolerance	O	NOUN	I
in	O	ADP	O
AF	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Six	B-P	NUM	O
hundred	I-P	NUM	O
fifty-five	I-P	ADJ	O
patients	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
AF	I-P	NOUN	I
underwent	I-P	VERB	O
maximal	I-I	ADJ	B
exercise	I-I	NOUN	I
testing	I-I	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
randomization	O	NOUN	B
to	O	PART	O
sotalol	B-I	NOUN	B
,	I-I	PUNCT	O
amiodarone	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
therapy	O	NOUN	I
and	O	CCONJ	O
attempted	B-I	VERB	O
direct	I-I	ADJ	B
current	I-I	ADJ	I
cardioversion	I-I	NOUN	B
.	I-I	PUNCT	O


Analyses	O	NOUN	B
of	O	ADP	O
baseline	O	NOUN	B
determinants	O	NOUN	B
of	O	ADP	O
exercise	O	NOUN	B
capacity	O	NOUN	B
,	O	PUNCT	O
predictors	O	NOUN	B
of	O	ADP	O
change	O	NOUN	O
in	O	ADP	O
exercise	O	NOUN	B
capacity	O	NOUN	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
short-	O	ADJ	B
and	O	CCONJ	O
long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
cardioversion	O	NOUN	B
on	O	ADP	O
exercise	O	NOUN	B
capacity	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Age	O	PROPN	I
,	O	PUNCT	O
obesity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
presence	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
accompanying	O	VERB	O
AF	O	PROPN	B
were	O	AUX	O
inversely	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
baseline	O	NOUN	B
exercise	O	NOUN	B
capacity	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
these	O	DET	O
factors	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
only	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
variance	O	NOUN	B
in	O	ADP	O
exercise	O	NOUN	B
capacity	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
most	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
benefit	O	VERB	B
from	O	ADP	O
cardioversion	O	NOUN	B
were	O	AUX	O
those	O	DET	O
most	O	ADV	O
limited	O	VERB	O
initially	O	ADV	B
,	O	PUNCT	O
younger	O	ADJ	B
,	O	PUNCT	O
not	O	PART	O
obese	O	ADJ	B
or	O	CCONJ	O
hypertensive	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
with	O	ADP	O
an	O	DET	O
uncontrolled	O	ADJ	B
ventricular	O	ADJ	B
rate	O	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Conversion	O	NOUN	B
to	O	ADP	O
sinus	O	NOUN	B
rhythm	O	NOUN	I
(	O	PUNCT	O
SR	O	NOUN	B
)	O	PUNCT	O
resulted	O	VERB	O
in	O	ADP	O
significant	O	ADJ	O
reductions	O	NOUN	B
in	O	ADP	O
resting	B-OUT	VERB	B
(	O	PUNCT	O
approximately	O	ADV	O
25	O	NUM	O
beat/min	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
peak	B-OUT	VERB	B
exercise	I-OUT	NOUN	I
(	O	PUNCT	O
approximately	O	ADV	O
40	O	NUM	O
beat/min	O	NOUN	B
)	O	PUNCT	O
heart	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
year	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Successful	O	ADJ	O
cardioversion	B-I	NOUN	B
improved	O	VERB	O
exercise	B-OUT	NOUN	B
capacity	I-OUT	NOUN	B
by	O	ADP	O
15	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
these	O	DET	O
improvements	O	NOUN	B
were	O	AUX	O
maintained	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
year	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
improvement	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
both	O	CCONJ	O
among	O	ADP	O
those	O	DET	O
who	O	PRON	O
maintained	O	VERB	B
SR	O	ADJ	B
and	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
intermittent	O	ADJ	B
AF	O	PROPN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Cardioversion	B-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
sustained	O	ADJ	B
improvement	O	NOUN	B
in	O	ADP	O
exercise	O	NOUN	B
capacity	O	NOUN	O
over	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
improvement	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
those	O	DET	O
in	O	ADP	O
SR	O	ADJ	B
and	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
SR	O	ADJ	B
and	O	CCONJ	O
recurrent	O	ADJ	B
AF	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
most	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
improve	O	VERB	B
with	O	ADP	O
treatment	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
younger	O	ADJ	B
and	O	CCONJ	O
nonobese	O	ADJ	B
and	O	CCONJ	O
have	O	AUX	O
the	O	DET	O
greatest	O	ADJ	O
limitations	O	NOUN	B
initially	O	ADV	B
.	O	PUNCT	O


Neuromuscular	O	ADJ	B
excitability	O	NOUN	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
vastus	O	NOUN	B
medialis	O	NOUN	I
following	O	VERB	O
anterior	B-I	ADJ	B
cruciate	I-I	NOUN	I
ligament	I-I	NOUN	I
reconstruction	I-I	NOUN	I
.	I-I	PUNCT	O


PURPOSE	O	VERB	B
Quadriceps	O	PROPN	I
weakness	O	NOUN	I
following	O	VERB	O
anterior	B-P	ADJ	B
cruciate	I-I	NOUN	I
ligament	I-I	NOUN	I
reconstruction	I-I	NOUN	I
(	I-I	PUNCT	O
ACLR	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
prevalent	O	ADJ	O
despite	O	SCONJ	O
intensive	O	ADJ	B
rehabilitation	O	NOUN	I
.	O	PUNCT	O


Diminished	O	VERB	B
neuromuscular	O	ADJ	B
excitability	O	NOUN	B
is	O	AUX	O
one	O	NUM	O
potential	O	ADJ	O
factor	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
limit	O	VERB	O
muscular	O	ADJ	B
recovery	O	NOUN	B
following	O	VERB	O
injury	O	NOUN	B
or	O	CCONJ	O
surgery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
H-reflex	B-OUT	NOUN	B
provides	O	VERB	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
alpha	O	NOUN	B
motorneuron	O	NOUN	I
(	O	PUNCT	O
neuromuscular	O	ADJ	B
)	O	PUNCT	O
excitability	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sensory-motor	O	NOUN	B
pathway	O	NOUN	I
of	O	ADP	O
the	O	DET	O
respective	O	ADJ	O
muscle	O	NOUN	B
and	O	CCONJ	O
nerve	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
date	O	VERB	O
the	O	DET	O
vastus	O	NOUN	B
medialis	O	NOUN	I
(	O	PUNCT	O
VM	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
soleus	O	NOUN	B
(	O	PUNCT	O
SOL	O	NOUN	B
)	O	PUNCT	O
H-reflexes	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
examined	O	VERB	O
primarily	O	ADV	O
in	O	ADP	O
control	O	ADJ	B
subjects	B-P	NOUN	I
with	I-P	ADP	O
induced	I-P	VERB	B
knee	I-P	NOUN	B
joint	I-P	ADJ	I
effusion	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
evaluated	O	VERB	B
the	O	DET	O
affect	O	NOUN	O
of	O	ADP	O
ACLR	B-I	NOUN	B
,	O	PUNCT	O
utilizing	O	VERB	O
hamsting	B-OUT	VERB	B
(	I-OUT	PUNCT	O
HS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
bone-patellar	I-OUT	ADJ	B
tendon-bone	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BTB	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
autograft	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
on	I-OUT	ADP	O
VM	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
SOL	I-OUT	NOUN	B
H-reflex	I-OUT	ADJ	B
latency	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
amplitude	I-OUT	NOUN	B
in	O	ADP	O
twenty	B-P	NUM	O
subjects	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
Preoperatively	O	ADV	B
bilateral	O	ADJ	B
VM	O	NOUN	B
and	O	CCONJ	O
SOL	O	NOUN	B
H-reflex	O	ADJ	B
tests	O	NOUN	I
were	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


VM	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
SOL	I-OUT	NOUN	B
H-reflexes	I-OUT	NOUN	B
were	O	AUX	O
subsequently	O	ADV	O
conducted	O	VERB	O
on	O	ADP	O
the	O	DET	O
involved	O	VERB	O
lower	O	ADJ	B
extremity	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
months	O	NOUN	B
post	O	NOUN	B
surgery	O	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
each	O	DET	O
test	O	NOUN	B
session	O	NOUN	B
subjects	B-P	NOUN	B
completed	O	VERB	O
visual	B-OUT	ADJ	B
analog	I-OUT	NOUN	I
scales	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
knee	I-OUT	NOUN	B
girth	I-OUT	NOUN	I
was	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
VM	B-OUT	NOUN	B
H-reflex	I-OUT	ADJ	B
amplitude	I-OUT	NOUN	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
HS	O	NOUN	B
group	O	NOUN	B
at	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
1-month	O	ADJ	O
post	O	NOUN	B
surgery	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Significant	O	ADJ	O
changes	O	NOUN	B
over	O	ADP	O
time	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
visual	B-OUT	ADJ	B
analog	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
functional	I-OUT	ADJ	B
scales	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
mid-patella	I-OUT	ADJ	B
girth	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
increased	O	VERB	B
VM	B-OUT	NOUN	B
H-reflex	I-OUT	ADJ	B
amplitude	I-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
following	O	VERB	O
HS	O	NOUN	B
autograft	O	NOUN	I
ACLR	B-I	NOUN	B
demonstrates	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
VM	B-OUT	NOUN	B
neuromuscular	I-OUT	NOUN	B
excitability	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Increased	O	VERB	B
VM	B-OUT	NOUN	B
neuromuscular	I-OUT	ADJ	B
excitability	I-OUT	NOUN	B
was	O	AUX	O
not	O	PART	O
evident	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
following	O	VERB	O
BTB	O	NOUN	B
reconstruction	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
increased	O	VERB	B
neuromuscular	B-OUT	ADJ	B
excitability	I-OUT	NOUN	B
,	O	PUNCT	O
observed	O	VERB	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
HS	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
warrants	O	VERB	O
consideration	O	NOUN	O
when	O	SCONJ	O
selecting	O	VERB	O
graft	O	NOUN	B
type	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
extensive	I-P	ADJ	O
preoperative	I-P	ADJ	B
quadriceps	I-P	NOUN	B
dysfunction	I-P	NOUN	I
.	I-P	PUNCT	O


GPs	O	NOUN	B
'	O	PART	O
experiences	O	NOUN	B
with	O	ADP	O
brief	B-I	ADJ	O
intervention	I-I	NOUN	B
for	O	ADP	O
medication-overuse	O	ADJ	B
headache	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
qualitative	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
general	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Medication-overuse	O	ADJ	B
headache	O	NOUN	I
(	O	PUNCT	O
MOH	O	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
common	O	ADJ	O
in	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
most	O	ADJ	O
patients	O	NOUN	B
are	O	AUX	O
managed	O	VERB	O
in	O	ADP	O
primary	O	ADJ	B
health	O	NOUN	B
care	O	NOUN	I
.	O	PUNCT	O


Brief	B-I	PROPN	B
Intervention	I-I	PROPN	I
(	I-I	PUNCT	O
BI	I-I	PROPN	B
)	I-I	PUNCT	O
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
motivational	O	ADJ	B
technique	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
drug	I-P	NOUN	B
and	I-P	CCONJ	O
alcohol	I-P	NOUN	B
overuse	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
a	O	DET	O
have	O	AUX	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
MOH	O	PROPN	B
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
explore	O	VERB	O
GPs	B-I	NOUN	B
'	I-I	PART	O
experiences	I-I	NOUN	B
using	I-I	VERB	O
BI	I-I	NOUN	B
in	I-I	ADP	O
the	O	DET	O
management	B-P	NOUN	B
of	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
MOH	I-P	PROPN	B
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
AND	O	CCONJ	O
SETTING	O	VERB	O
Qualitative	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
Norwegian	B-P	ADJ	B
general	I-P	ADJ	B
practice	I-P	NOUN	I
.	I-P	PUNCT	O


METHOD	O	PROPN	B
Data	O	PROPN	I
were	O	AUX	O
collected	O	VERB	B
through	O	ADP	O
four	B-P	NUM	O
focus	I-P	NOUN	B
group	I-P	NOUN	I
interviews	I-P	NOUN	I
with	I-P	ADP	O
22	I-P	NUM	O
GPs	I-P	NOUN	B
who	I-P	PRON	O
participated	I-P	VERB	O
in	I-P	ADP	O
an	I-P	DET	O
intervention	I-P	NOUN	B
study	I-P	NOUN	I
on	I-P	ADP	O
BI	I-I	PROPN	B
for	I-P	ADP	O
MOH	I-P	PROPN	B
.	I-P	PUNCT	O


Systematic	O	ADJ	B
text	O	NOUN	I
condensation	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
analyse	O	VERB	O
transcripts	O	NOUN	B
from	O	ADP	O
the	O	DET	O
focus	B-P	NOUN	B
group	I-P	NOUN	I
interviews	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
GPs	B-I	NOUN	B
experienced	I-I	VERB	O
challenges	O	NOUN	O
when	O	SCONJ	O
trying	O	VERB	O
to	O	PART	O
convince	O	VERB	O
patients	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
medication	O	NOUN	B
they	O	PRON	O
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
and	O	CCONJ	O
prevent	O	VERB	B
headache	O	NOUN	B
could	O	AUX	O
cause	O	VERB	O
headache	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
labelling	O	VERB	B
MOH	O	PROPN	B
as	O	ADP	O
a	O	DET	O
diagnosis	O	NOUN	B
opened	O	VERB	O
up	O	ADP	O
a	O	DET	O
space	O	NOUN	B
for	O	ADP	O
change	O	NOUN	B
.	O	PUNCT	O


GPs	O	NOUN	B
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
use	O	VERB	O
BI	B-I	PROPN	B
within	O	ADP	O
the	O	DET	O
scope	O	NOUN	O
of	O	ADP	O
a	O	DET	O
regular	O	ADJ	O
consultation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
they	O	PRON	O
thought	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
structured	O	ADJ	B
approach	O	NOUN	I
had	O	AUX	O
a	O	DET	O
potential	O	NOUN	B
to	O	PART	O
change	O	VERB	O
patients	O	NOUN	B
'	O	PART	O
views	O	NOUN	B
about	O	ADP	O
their	O	PRON	O
condition	O	NOUN	B
and	O	CCONJ	O
medication	O	NOUN	B
use	O	NOUN	O
.	O	PUNCT	O


Being	O	AUX	B
diagnosed	O	VERB	B
with	O	ADP	O
medication	O	NOUN	B
overuse	O	NOUN	I
could	O	AUX	O
bring	O	VERB	O
about	O	ADP	O
feelings	O	NOUN	B
of	O	ADP	O
guilt	B-OUT	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
GPs	O	NOUN	B
emphasised	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
good	O	ADJ	O
alliance	O	NOUN	B
with	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
successful	O	ADJ	O
change	O	NOUN	O
using	O	VERB	O
BI	O	PROPN	B
to	O	PART	O
manage	O	VERB	O
MOH	O	PROPN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
GPs	B-I	NOUN	B
experience	I-I	NOUN	O
BI	I-I	PROPN	B
as	O	ADP	O
a	O	DET	O
feasible	O	ADJ	O
strategy	O	NOUN	O
to	O	PART	O
treat	O	VERB	B
MOH	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
technique	O	NOUN	B
relies	O	VERB	O
on	O	ADP	O
a	O	DET	O
good	O	ADJ	O
alliance	O	NOUN	B
between	O	ADP	O
the	O	DET	O
doctor	O	NOUN	B
and	O	CCONJ	O
patient	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
using	O	VERB	O
BI	B-I	PROPN	B
,	O	PUNCT	O
GPs	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
prepared	O	VERB	O
to	O	PART	O
counter	O	VERB	O
patients	O	NOUN	B
'	O	PART	O
misconceptions	O	NOUN	B
about	O	ADP	O
medication	O	NOUN	B
used	O	VERB	O
for	O	ADP	O
headache	O	NOUN	B
.	O	PUNCT	O


Surgery	O	NOUN	B
of	O	ADP	O
aphakic	B-P	NOUN	B
retinal	I-P	ADJ	I
detachment	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
84	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
aphakic	I-P	NOUN	B
retinal	I-P	ADJ	I
detachment	I-P	NOUN	I
were	I-P	AUX	O
treated	I-P	VERB	B
either	I-P	CCONJ	O
by	I-P	ADP	O
local	I-I	ADJ	B
scleral	I-I	ADJ	B
buckling	I-I	NOUN	I
alone	I-I	ADV	O
or	I-I	CCONJ	O
combined	I-I	VERB	B
with	I-I	ADP	O
an	I-I	DET	O
encirclement	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
surgical	I-OUT	ADJ	B
reattachment	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
retina	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
similar	O	ADJ	O
with	O	ADP	O
either	O	DET	O
technique	O	NOUN	B
over	O	ADP	O
a	O	DET	O
minimum	O	ADJ	O
follow-up	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Simplicity	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
low	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
complications	O	NOUN	B
of	O	ADP	O
the	O	DET	O
local	O	ADJ	B
procedure	O	NOUN	I
merit	O	VERB	O
its	O	PRON	O
application	O	NOUN	O
as	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
method	O	NOUN	B
of	O	ADP	O
repairing	O	VERB	B
aphakic	O	NOUN	I
detachments	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Treatment	O	NOUN	B
of	O	ADP	O
irresectable	B-P	ADJ	B
hepatocellular	I-P	NOUN	B
carcinoma	I-P	NOUN	I
with	O	ADP	O
repeated	B-I	VERB	O
transient	I-I	ADJ	O
dearterialization	I-I	NOUN	O
]	I-I	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
joint	O	ADJ	O
clinical	O	ADJ	O
prospective	O	ADJ	O
study	O	NOUN	O
between	O	ADP	O
SUMS	B-P	PROPN	B
and	I-P	CCONJ	O
Lund	I-P	PROPN	B
university	I-P	NOUN	I
was	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


40	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
the	I-P	DET	O
irresectable	I-P	ADJ	B
hepatocellular	I-P	NOUN	B
carcinoma	I-P	NOUN	I
(	I-P	PUNCT	O
HCC	I-P	NOUN	B
)	I-P	PUNCT	O
admitted	I-P	VERB	B
to	I-P	ADP	O
the	I-P	DET	O
department	I-P	NOUN	B
of	I-P	ADP	O
HPB	I-P	PROPN	B
surgery	I-P	NOUN	O
in	I-P	ADP	O
the	I-P	DET	O
First	I-P	PROPN	B
Affiliated	I-P	PROPN	I
Hospital	I-P	PROPN	I
of	I-P	ADP	O
SUMS	I-P	PROPN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
into	I-P	ADP	O
two	I-P	NUM	O
groups	I-P	NOUN	B
:	I-P	PUNCT	O
(	I-P	PUNCT	O
20	I-P	NUM	O
each	I-P	DET	O
)	I-P	PUNCT	O
from	I-P	ADP	O
Feb.	I-P	PROPN	O
1994	I-P	NUM	O
to	I-P	ADP	O
April	I-P	PROPN	O
,	I-P	PUNCT	O
1995	I-P	NUM	O
.	I-P	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
hepatic	B-I	ADJ	B
artery	I-I	NOUN	I
ligation	I-I	NOUN	I
(	I-I	PUNCT	O
HAL	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
repeated	I-I	VERB	O
transient	I-I	ADJ	O
dearterialization	I-I	NOUN	O
(	I-I	PUNCT	O
RTD	I-I	NOUN	B
)	I-I	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Postoperative	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
treatment	O	NOUN	B
,	O	PUNCT	O
liver	B-OUT	NOUN	B
function	I-OUT	NOUN	I
change	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ALT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
AFP	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
imaging	I-OUT	NOUN	B
examination	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
tumor	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
patient	I-OUT	NOUN	B
's	I-OUT	PART	I
survival	I-OUT	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
RTD	B-I	NOUN	B
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
HAL	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
objective	O	ADJ	B
response	O	NOUN	B
to	O	PART	O
the	O	DET	O
therapy	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
reduction	I-OUT	NOUN	B
of	I-OUT	ADP	O
tumor	I-OUT	NOUN	B
size	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
patient	I-OUT	NOUN	B
's	I-OUT	PART	I
symptom	I-OUT	NOUN	B
relief	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
liver	I-OUT	NOUN	B
function	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
AFP	I-OUT	NOUN	B
changes	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
patient	I-OUT	NOUN	B
's	I-OUT	PART	I
survival	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
RTD	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effective	B-OUT	ADJ	B
rate	I-OUT	NOUN	B
was	O	AUX	O
70	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
mean	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
time	I-OUT	NOUN	I
was	O	AUX	O
8.2	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
6-month	O	ADJ	B
survival	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
79.7	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
HAL	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effective	B-OUT	ADJ	B
rate	I-OUT	NOUN	B
was	O	AUX	O
only	O	ADV	O
5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
mean	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
time	I-OUT	NOUN	I
was	O	AUX	O
5.1	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
months	O	NOUN	B
survival	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
35.8	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
postulated	O	VERB	O
that	O	SCONJ	O
RTD	B-I	NOUN	B
may	O	AUX	O
prevent	O	VERB	B
the	O	DET	O
rapid	O	ADJ	O
development	O	NOUN	B
of	O	ADP	O
collateral	O	ADJ	B
circulation	O	NOUN	B
and	O	CCONJ	O
increase	O	VERB	B
the	O	DET	O
production	B-OUT	NOUN	B
of	I-OUT	ADP	O
oxygen-derived	I-OUT	ADJ	B
free	I-OUT	ADJ	I
radicals	I-OUT	NOUN	I
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
responsible	O	ADJ	O
factors	O	NOUN	B
for	O	ADP	O
the	O	DET	O
ischemic	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
hepatic	O	ADJ	B
tumours	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
consider	O	VERB	O
that	O	SCONJ	O
RTD	B-I	NOUN	B
would	O	AUX	O
be	O	AUX	O
a	O	DET	O
promising	O	ADJ	O
polliative	O	ADJ	B
method	O	NOUN	I
for	O	ADP	O
HCC	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
prophylactic	B-I	ADJ	B
palifermin	I-I	NOUN	B
on	O	ADP	O
gastrointestinal	O	ADJ	B
toxicity	O	NOUN	B
after	O	ADP	O
intensive	O	ADJ	B
induction	O	NOUN	I
therapy	O	NOUN	I
for	O	ADP	O
acute	B-P	ADJ	B
myeloid	I-P	ADJ	I
leukaemia	I-P	NOUN	I
.	I-P	PUNCT	O


Gastrointestinal	O	ADJ	B
toxicity	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
oral	O	ADJ	B
mucositis	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
frequent	O	ADJ	O
complication	O	NOUN	B
of	O	ADP	O
intensive	O	ADJ	B
combination	O	NOUN	I
chemotherapy	O	NOUN	I
for	O	ADP	O
acute	O	ADJ	B
myeloid	O	ADJ	I
leukaemia	O	NOUN	I
(	O	PUNCT	O
AML	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
contributes	O	VERB	O
substantially	O	ADV	O
to	O	PART	O
treatment-related	O	ADJ	B
mortality	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
placebo-controlled	O	ADJ	B
randomized	O	ADJ	B
trial	O	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
palifermin	B-I	NOUN	B
(	O	PUNCT	O
keratinocyte	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
given	O	VERB	O
at	O	ADP	O
60	O	NUM	O
μg/kg	O	NOUN	O
per	O	ADP	O
daily	O	ADV	O
IV	O	NUM	O
for	O	ADP	O
3	O	NUM	O
d	O	NOUN	O
before	O	ADP	B
and	O	CCONJ	O
after	O	ADP	O
chemotherapy	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
mucosal	O	ADJ	B
protection	O	NOUN	B
in	B-P	ADP	O
adult	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
previously	I-P	ADV	O
untreated	I-P	ADJ	B
AML	I-P	NOUN	B
receiving	I-P	VERB	O
induction	I-P	NOUN	B
therapy	I-P	NOUN	I
with	I-P	ADP	O
idarubicin	I-P	NOUN	B
,	I-P	PUNCT	O
high-dose	I-P	ADJ	B
cytarabine	I-P	NOUN	I
and	I-P	CCONJ	O
etoposide	I-P	NOUN	B
.	O	PUNCT	O


Among	B-P	ADP	O
155	I-P	NUM	O
randomized	I-P	ADJ	B
patients	I-P	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	B-OUT	DET	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
grade	I-OUT	NOUN	B
3	I-OUT	NUM	I
and	I-OUT	CCONJ	O
4	I-OUT	NUM	O
oral	I-OUT	ADJ	B
mucositis	I-OUT	NOUN	I
(	O	PUNCT	O
primary	O	ADJ	B
study	O	NOUN	I
endpoint	O	NOUN	I
)	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
arms	O	NOUN	I
(	O	PUNCT	O
three	O	NUM	O
in	B-I	ADP	O
palifermin	I-I	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
8	O	NUM	O
in	B-I	ADP	O
placebo	I-I	ADJ	B
arm	O	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·21	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
considering	B-OUT	VERB	O
the	I-OUT	DET	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
oral	I-OUT	ADJ	B
mucositis	I-OUT	NOUN	I
(	O	PUNCT	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
grade	O	NOUN	I
0-4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
reduced	B-OUT	VERB	B
rates	I-OUT	NOUN	B
of	I-OUT	ADP	O
higher	I-OUT	ADJ	B
grades	I-OUT	NOUN	B
of	I-OUT	ADP	O
oral	I-OUT	ADJ	B
mucositis	I-OUT	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
palifermin	I-I	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·0007	O	NOUN	O
,	O	PUNCT	O
test	O	NOUN	B
for	O	ADP	O
trend	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
statistically	O	ADV	O
significantly	O	ADV	O
lower	B-OUT	ADJ	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
grades	I-OUT	NOUN	B
3	I-OUT	NUM	O
and	I-OUT	CCONJ	O
4	I-OUT	NUM	O
gastrointestinal	I-OUT	ADJ	B
adverse	I-OUT	ADJ	I
events	I-I	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
palifermin	I-I	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
21	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
44	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
placebo	O	ADJ	B
arm	O	NOUN	I
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0·003	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
mainly	O	ADV	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
severe	I-OUT	ADJ	B
diarrhoea	O	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
palifermin	B-I	NOUN	B
,	O	PUNCT	O
26	O	NUM	O
%	O	NOUN	O
placebo	B-I	NOUN	B
;	I-I	PUNCT	O
P	I-I	NOUN	O
=	I-I	ADJ	O
0·01	I-I	NUM	O
)	I-I	PUNCT	O
.	O	PUNCT	O


Palifermin	O	NOUN	B
has	O	AUX	O
activity	O	NOUN	B
as	O	ADP	O
a	O	DET	O
mucosal	O	ADJ	B
protectant	O	NOUN	I
in	O	ADP	O
AML	O	NOUN	B
patients	O	NOUN	B
receiving	O	VERB	O
intensive	O	ADJ	B
chemotherapy	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
trial	O	NOUN	B
is	O	AUX	O
registered	O	VERB	O
at	O	ADP	O
ACTRN012605000095662	O	NOUN	B
.	O	PUNCT	O


Double-blind	O	ADJ	B
study	O	NOUN	I
on	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
plafibride	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
type	B-P	NOUN	B
IV	I-P	NUM	I
hyperlipoproteinemia	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
drug	O	NOUN	B
,	O	PUNCT	O
N-2-	B-I	NOUN	B
(	I-I	PUNCT	O
p-chlorophenoxy	I-I	ADJ	B
)	I-I	PUNCT	O
-isobutyryl-N'-morpholinomethylurea	I-I	NOUN	O
(	I-I	PUNCT	O
plafibride	I-I	NOUN	B
,	I-I	PUNCT	O
ITA	I-I	NOUN	B
104	I-I	NUM	O
)	I-I	PUNCT	O
,	O	PUNCT	O
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	O
study	O	NOUN	O
lasting	O	VERB	O
four	O	NUM	O
months	O	NOUN	B
on	O	ADP	O
a	O	DET	O
group	B-P	NOUN	B
of	I-P	ADP	O
30	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
type	I-P	NOUN	B
IV	I-P	NUM	I
hyperlipoproteinemia	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
active	O	ADJ	B
drug	O	NOUN	I
significant	O	ADJ	I
reductions	O	NOUN	B
in	O	ADP	O
blood	B-OUT	NOUN	B
triglycerides	I-OUT	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
trend	O	NOUN	O
to	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


Reduction	O	NOUN	B
in	O	ADP	O
blood	B-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
was	O	AUX	O
inconsistent	O	ADJ	B
and	O	CCONJ	O
not	O	PART	O
significant	O	ADJ	O
.	O	PUNCT	O


As	O	ADP	O
for	O	ADP	O
the	O	DET	O
lipoproteinogram	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
tendency	O	NOUN	O
towards	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
pre-beta-lipoprotein	B-OUT	NOUN	B
fraction	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	B
and	O	CCONJ	O
so	O	ADV	O
was	O	AUX	O
a	O	DET	O
non-significant	O	ADJ	B
tendency	O	NOUN	O
towards	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
alpha-	O	NOUN	B
and	O	CCONJ	O
beta-lipoprotein	O	ADJ	B
fractions	O	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
on	O	ADP	O
the	O	DET	O
platelet	O	NOUN	B
functioning	O	NOUN	I
showed	O	VERB	O
an	O	DET	O
obvious	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
platelet	B-OUT	NOUN	B
aggregation	I-OUT	NOUN	I
in	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
active	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
very	O	ADV	O
evident	O	ADJ	O
for	O	ADP	O
the	O	DET	O
ADP	O	NOUN	B
and	O	CCONJ	O
adrenaline	O	NOUN	B
inductors	O	NOUN	I
and	O	CCONJ	O
rather	O	ADV	O
less	O	ADV	O
significant	O	ADJ	O
for	O	ADP	O
collagen	O	NOUN	B
.	O	PUNCT	O


Neither	O	CCONJ	B
platelet	B-OUT	NOUN	B
adhesiveness	I-OUT	NOUN	I
nor	I-OUT	CCONJ	O
aggregation	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
changed	O	VERB	B
.	O	PUNCT	O


Tolerance	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
generally	O	ADV	O
excellent	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
some	O	DET	O
palpebral	B-OUT	ADJ	B
xanthelasmas	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
two	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
active	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
only	O	ADV	O
one	O	NUM	O
case	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
heartburn	B-OUT	NOUN	B
and	O	CCONJ	O
this	O	DET	O
was	O	AUX	O
corrected	O	VERB	B
with	O	ADP	I
alkalines	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
other	O	ADJ	O
case	O	NOUN	O
an	O	DET	O
urticarial	B-OUT	ADJ	B
rash	I-OUT	NOUN	I
appeared	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
disappeared	O	VERB	O
spontaneously	O	ADV	B
when	O	SCONJ	O
the	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
temporarily	O	ADV	O
stopped	O	VERB	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
reappear	O	VERB	O
when	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
administered	O	VERB	B
again	O	ADV	O
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
no	O	DET	B
evidence	O	NOUN	I
of	O	ADP	O
renal	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
hepatic	I-OUT	ADJ	B
or	I-OUT	CCONJ	O
hematological	I-OUT	ADJ	B
malfunctions	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
slight	O	ADJ	O
tendency	O	NOUN	O
towards	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
GOT	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
GPT	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
LDH	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


The	O	DET	O
drug	O	NOUN	B
tested	O	VERB	I
may	O	AUX	O
be	O	AUX	O
very	O	ADV	O
useful	O	ADJ	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
type	B-OUT	NOUN	B
IV	I-OUT	NUM	I
hyperlipoproteinemia	I-OUT	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
those	O	DET	O
forms	O	NOUN	O
in	O	ADP	O
which	O	DET	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
thromboembolic	B-OUT	ADJ	B
risk	I-OUT	NOUN	O
is	O	AUX	O
suspected	O	VERB	B
,	O	PUNCT	O
either	O	CCONJ	O
associated	O	VERB	B
with	O	ADP	I
,	O	PUNCT	O
or	O	CCONJ	O
secondary	O	ADJ	B
to	O	PART	I
,	O	PUNCT	O
the	O	DET	O
actual	O	ADJ	B
atherosclerotic	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


Oestrogen	B-OUT	NOUN	B
replacement	I-OUT	NOUN	O
after	I-P	ADP	O
oophorectomy	I-P	NOUN	B
:	I-P	PUNCT	O
comparison	O	NOUN	B
of	O	ADP	O
patches	B-I	NOUN	B
and	O	CCONJ	O
implants	B-I	NOUN	B
.	I-I	PUNCT	O


Efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
safety	B-OUT	NOUN	B
of	O	ADP	O
zidovudine	B-I	NOUN	B
and	I-I	CCONJ	O
zalcitabine	I-I	NOUN	B
combined	O	VERB	O
with	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
herbs	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
HIV-infected	B-P	ADJ	B
Thai	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
double	O	ADJ	O
blind	O	ADJ	O
placebo	B-I	NOUN	O
controlled	O	ADJ	O
trial	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
safety	B-OUT	NOUN	B
of	O	ADP	O
combined-herbs	O	NOUN	B
(	O	PUNCT	O
SH	O	NOUN	B
)	O	PUNCT	O
given	O	VERB	O
with	O	ADP	O
zidovudine	B-I	NOUN	B
(	O	PUNCT	O
ZDV	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
zalcitabine	B-I	NOUN	B
(	O	PUNCT	O
ddC	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
HIV	B-P	NOUN	B
infection	I-P	NOUN	I
in	I-P	ADP	O
Thai	I-P	ADJ	B
adults	I-P	NOUN	B
was	I-P	AUX	O
conducted	I-P	VERB	O
in	I-P	ADP	O
3	I-P	NUM	O
hospitals	I-P	NOUN	B
in	I-P	ADP	O
northern	I-P	ADJ	B
Thailand	I-P	PROPN	I
during	I-P	ADP	O
2002	I-P	NUM	O
to	I-P	PART	O
2003	I-P	NUM	O
.	I-P	PUNCT	O


The	O	DET	O
eligible	O	ADJ	O
subjects	O	NOUN	B
were	O	AUX	O
HIV-infected	B-P	ADJ	B
Thai	I-P	ADJ	B
adults	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
never	I-P	ADV	O
received	I-P	VERB	O
anti-retrovirals	I-I	NOUN	B
,	I-P	PUNCT	O
had	I-P	AUX	O
a	I-P	DET	O
Karnofski	I-P	PROPN	B
Performance	I-P	PROPN	I
Score	I-P	NOUN	I
(	I-P	PUNCT	O
KPS	I-P	NOUN	B
)	I-P	PUNCT	O
of	I-P	ADP	O
>	I-P	X	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
70	I-P	NUM	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
had	I-P	AUX	O
no	I-P	DET	O
opportunistic	I-P	ADJ	B
infections	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
ZDV	B-I	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
three	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
,	O	PUNCT	O
ddC	B-I	NOUN	B
0.75	O	NUM	O
mg	O	NOUN	O
three	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
SH	B-I	NOUN	B
2.5	O	NUM	O
g	O	NOUN	O
three	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
or	O	CCONJ	O
a	B-I	DET	O
combination	I-I	NOUN	B
of	I-I	ADP	O
ZDV	I-I	NOUN	B
200	I-I	NUM	O
mg	I-I	NOUN	O
three	I-I	NUM	O
times	I-I	NOUN	O
per	I-I	ADP	O
day	I-I	NOUN	B
,	I-I	PUNCT	O
ddC	I-I	NOUN	B
0.75	I-I	NUM	O
mg	I-I	NOUN	O
three	I-I	NUM	O
times	I-I	NOUN	O
per	I-I	ADP	O
day	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
2.5	O	NUM	O
g	O	NOUN	O
three	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
24	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	O
were	O	AUX	O
HIV-RNA	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
CD4	I-OUT	NOUN	B
cells	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
chemistry	I-OUT	NOUN	I
profiles	I-OUT	NOUN	I
prior	O	ADJ	O
to	O	PART	O
the	O	DET	O
treatment	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
every	O	DET	O
4	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
24	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
of	O	ADP	O
60	B-P	NUM	O
evaluable	I-P	ADJ	O
subjects	I-P	NOUN	B
,	I-P	PUNCT	O
40	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
SH	I-I	NOUN	B
group	I-P	NOUN	B
and	I-P	CCONJ	O
20	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
placebo	I-I	NOUN	B
group	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


HIV	B-OUT	NOUN	B
RNA	I-OUT	NOUN	O
at	O	ADP	O
week	O	NOUN	B
4	O	NUM	O
and	O	CCONJ	O
thereafter	O	ADV	O
was	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
from	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
value	O	NOUN	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
decline	O	NOUN	B
in	O	ADP	O
HIV	B-OUT	NOUN	B
RNA	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
SH	B-I	NOUN	B
group	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
more	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
CD4	B-OUT	NOUN	B
cells	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
SH	O	NOUN	B
group	O	NOUN	B
at	O	ADP	O
week	O	NOUN	B
12	O	NUM	O
and	O	CCONJ	O
thereafter	O	ADV	O
were	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
from	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
value	O	NOUN	I
.	O	PUNCT	O


Serious	B-OUT	ADJ	B
adverse	I-OUT	ADJ	I
events	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
not	O	PART	O
observed	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
an	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
SH	O	NOUN	B
herbs	O	NOUN	I
to	O	PART	O
two	O	NUM	O
nucleoside	O	NOUN	B
reverse	O	ADJ	I
transcriptase	O	NOUN	I
inhibitors	O	NOUN	I
has	O	AUX	O
greater	O	ADJ	O
antiviral	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
than	O	ADP	O
antiretrovirals	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
SH	B-I	NOUN	B
herbs	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
alternative	O	NOUN	B
for	O	ADP	O
the	O	DET	O
third	O	ADJ	O
anti-retroviral	O	ADJ	B
agent	O	NOUN	I
in	O	ADP	O
the	O	DET	O
triple	O	ADJ	B
drug	O	NOUN	I
regimen	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
HIV	O	NOUN	B
infected	O	ADJ	B
patients	O	NOUN	B
in	O	ADP	O
countries	O	NOUN	B
with	O	ADP	O
limited	O	ADJ	O
resources	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
D-cycloserine	B-I	NOUN	B
added	O	VERB	O
to	O	PART	O
conventional	O	ADJ	B
neuroleptics	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
schizophrenia	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
In	O	ADP	O
a	O	DET	O
preliminary	O	ADJ	B
dose-finding	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
D-cycloserine	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
partial	O	ADJ	O
agonist	O	NOUN	B
at	O	ADP	O
the	O	DET	O
glycine	O	NOUN	B
modulatory	O	ADJ	B
site	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glutamatergic	O	ADJ	B
N-methyl-D-aspartate	O	NOUN	I
(	O	PUNCT	O
NMDA	O	NOUN	O
)	O	PUNCT	O
receptor	O	NOUN	O
,	O	PUNCT	O
improved	O	VERB	O
negative	O	ADJ	B
symptoms	O	NOUN	B
and	O	CCONJ	O
cognitive	O	ADJ	B
function	O	NOUN	I
when	O	SCONJ	O
added	O	VERB	O
to	O	PART	O
conventional	O	ADJ	B
neuroleptics	O	NOUN	B
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
mg/d	O	NOUN	O
.	O	PUNCT	O


METHODS	O	VERB	O
Forty-seven	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
schizophrenia	I-P	NOUN	B
meeting	I-P	NOUN	O
criteria	I-P	NOUN	B
for	I-P	ADP	O
deficit	I-P	NOUN	B
syndrome	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
D-cycloserine	B-I	NOUN	B
,	O	PUNCT	O
50	O	NUM	O
mg/d	O	NOUN	O
(	O	PUNCT	O
n=23	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n=24	O	X	O
)	O	PUNCT	O
added	O	VERB	O
to	O	PART	O
their	O	PRON	O
conventional	O	ADJ	O
neuroleptic	O	NOUN	B
for	O	ADP	O
an	O	DET	O
8-week	O	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Clinical	O	ADJ	B
assessments	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
weeks	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
of	I-OUT	ADP	O
D-cycloserine	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
relevant	I-OUT	ADJ	O
amino	I-OUT	NOUN	B
acids	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
homovanillic	I-OUT	NOUN	B
acid	I-OUT	NOUN	I
were	O	AUX	O
assayed	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
weeks	O	NOUN	B
4	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


A	O	DET	O
cognitive	B-OUT	ADJ	B
battery	I-OUT	NOUN	I
was	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
week	O	NOUN	B
8	O	NUM	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Thirty-nine	B-P	NUM	O
patients	I-P	NOUN	B
completed	O	VERB	O
the	O	DET	O
8-week	O	ADJ	O
trial	O	NOUN	B
.	O	PUNCT	O


Seven	O	NUM	O
dropouts	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
D-cycloserine	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
negative	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
with	O	ADP	O
D-cycloserine	B-I	NOUN	B
(	O	PUNCT	O
23	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
with	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
as	O	ADP	O
calculated	O	VERB	B
by	O	ADP	O
slopes	O	NOUN	B
representing	O	VERB	O
Scale	O	NOUN	O
for	O	ADP	O
the	O	DET	O
Assessment	O	NOUN	B
of	O	ADP	O
Negative	O	ADJ	B
Symptoms	O	NOUN	O
(	O	PUNCT	O
SANS	O	NOUN	B
)	O	PUNCT	O
total	O	NOUN	O
scores	O	NOUN	O
.	O	PUNCT	O


Improvement	O	NOUN	B
of	O	ADP	O
negative	O	ADJ	B
symptoms	O	NOUN	B
was	O	AUX	O
predicted	O	VERB	B
by	O	ADP	O
low	O	ADJ	O
neuroleptic	O	ADJ	B
dose	O	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
baseline	O	NOUN	B
SANS	O	NOUN	B
total	O	NOUN	O
score	O	NOUN	O
.	O	PUNCT	O


No	O	DET	B
differences	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
performance	B-OUT	NOUN	B
on	I-OUT	ADP	O
any	I-OUT	DET	O
cognitive	I-OUT	ADJ	B
test	I-OUT	NOUN	I
between	O	ADP	O
groups	O	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
any	O	DET	O
other	O	ADJ	O
clinical	O	ADJ	B
measure	O	NOUN	I
.	O	PUNCT	O


Clinical	O	ADJ	B
response	O	NOUN	I
did	O	AUX	O
not	O	PART	O
correlate	O	VERB	O
significantly	O	ADV	B
with	O	ADP	I
serum	O	NOUN	B
amino	O	NOUN	B
acid	O	NOUN	I
concentrations	O	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
or	O	CCONJ	O
with	O	ADP	O
concentrations	O	NOUN	B
of	O	ADP	O
D-cycloserine	B-I	NOUN	B
at	O	ADP	O
weeks	O	NOUN	B
4	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
agents	O	NOUN	B
acting	O	VERB	O
at	O	ADP	O
the	O	DET	O
glycine	O	NOUN	B
modulatory	O	ADJ	B
site	O	NOUN	I
of	O	ADP	O
the	O	DET	O
NMDA	O	NOUN	B
receptor	O	NOUN	I
improve	O	VERB	O
primary	O	ADJ	O
negative	O	ADJ	B
symptoms	O	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
octreotide	B-I	NOUN	B
vs	O	CCONJ	O
prochlorperazine	B-I	NOUN	B
for	O	ADP	O
ED	O	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
migraine	B-OUT	NOUN	B
headache	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


UNLABELLED	O	NOUN	B
Patients	B-P	NOUN	B
with	I-P	ADP	O
headaches	I-P	NOUN	B
account	O	VERB	O
for	O	ADP	O
approximately	O	ADV	O
2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
ED	O	PROPN	B
visits	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
migraines	O	NOUN	B
being	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
defined	O	VERB	O
primary	O	ADJ	B
headache	O	NOUN	I
syndrome	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
goals	O	NOUN	B
were	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
octreotide	B-I	NOUN	I
(	I-I	PUNCT	I
OC	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
migraines	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
compared	O	VERB	O
to	O	PART	O
standard	O	ADJ	B
therapy	O	NOUN	I
with	O	ADP	O
prochlorperazine	B-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
as	O	ADP	O
a	O	DET	O
double-blinded	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


Each	O	DET	O
subject	O	NOUN	B
received	O	VERB	O
either	O	CCONJ	O
100	B-I	NUM	O
microg	I-I	NOUN	B
of	I-I	ADP	O
octreotide	I-I	NOUN	B
or	I-I	CCONJ	O
10	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
prochlorperazine	I-I	NOUN	B
intravenously	I-I	ADV	B
for	O	ADP	O
a	O	DET	O
2-minute	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
change	O	NOUN	B
in	O	ADP	O
median	B-OUT	ADJ	B
visual	I-OUT	ADJ	O
analog	I-OUT	NOUN	O
scale	I-OUT	NOUN	O
scores	I-OUT	NOUN	O
for	O	ADP	O
60	O	NUM	O
minutes	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
octreotide	B-I	NOUN	B
was	O	AUX	O
less	O	ADV	O
effective	O	ADJ	B
at	O	ADP	O
reducing	O	VERB	B
pain	B-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
producing	O	VERB	O
clinical	O	ADJ	B
success	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Restlessness	B-OUT	PART	B
consistent	I-OUT	ADJ	B
with	I-OUT	ADP	I
akathisia	I-OUT	NOUN	B
was	O	AUX	O
noted	O	VERB	O
by	O	ADP	O
35	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PC	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
OC	O	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
60	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
rescue	B-OUT	NOUN	B
medication	I-OUT	NOUN	I
was	O	AUX	O
required	O	VERB	O
by	O	ADP	O
48	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
OC	O	PROPN	B
group	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PC	O	NOUN	B
group	O	NOUN	B
required	O	VERB	O
such	O	ADJ	O
therapy	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


All	B-P	DET	O
44	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
contacted	O	VERB	O
for	O	ADP	O
follow-up	O	NOUN	B
at	O	ADP	O
48	O	NUM	O
to	O	PART	O
72	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
enrollment	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
that	O	DET	O
time	O	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
prochlorperazine	B-I	NOUN	B
and	O	CCONJ	O
25	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
octreotide	B-I	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
experienced	O	VERB	O
some	O	DET	O
headache	B-OUT	NOUN	B
recurrence	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Prochlorperazine	O	NOUN	B
was	O	AUX	O
statistically	O	ADV	O
superior	O	ADJ	O
to	O	PART	O
octreotide	O	NOUN	B
in	O	ADP	O
clinical	B-OUT	ADJ	B
success	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
and	O	CCONJ	O
decrease	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
in	O	ADP	O
migraine	B-P	NOUN	B
patients	I-P	NOUN	B
but	O	CCONJ	O
caused	O	VERB	O
more	O	ADJ	O
restlessness	B-OUT	NOUN	B
and	O	CCONJ	O
sedation	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
additional	O	ADJ	O
amine	B-I	ADJ	B
fluoride/stannous	I-I	ADJ	I
fluoride-containing	I-I	ADJ	I
mouthrinse	I-I	NOUN	I
during	O	ADP	O
supportive	O	ADJ	B
therapy	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
generalized	I-P	VERB	B
aggressive	I-P	ADJ	I
periodontitis	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mouthrinse	B-I	NOUN	B
containing	I-I	VERB	O
a	I-I	DET	O
combination	I-I	NOUN	B
of	I-I	ADP	O
AmF/SnF2	I-I	NOUN	B
in	O	ADP	O
controlling	O	VERB	B
supragingival	O	NOUN	B
plaque	O	NOUN	B
accumulation	O	NOUN	B
and	O	CCONJ	O
gingival	O	ADJ	B
inflammation	O	NOUN	I
during	O	ADP	O
a	O	DET	O
12-week	O	ADJ	O
period	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
affected	I-P	VERB	B
by	I-P	ADP	O
generalized	I-P	VERB	B
aggressive	I-P	ADJ	I
periodontitis	I-P	NOUN	I
(	I-P	PUNCT	O
GAP	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
Eighteen	B-P	NUM	O
subjects	I-P	NOUN	B
,	I-P	PUNCT	O
six	I-P	NUM	O
males	I-P	NOUN	B
and	I-P	CCONJ	O
12	I-P	NUM	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
:	I-P	PUNCT	O
32.2	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
were	I-P	AUX	O
evaluated	I-P	VERB	B
.	I-P	PUNCT	O


One-half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
either	O	CCONJ	O
prescribed	O	VERB	B
an	O	DET	O
AmF/SnF2-containing	B-I	NOUN	B
mouthrinse	I-I	NOUN	I
(	O	PUNCT	O
test	O	NOUN	B
mouthrinse	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
control	B-I	ADJ	B
mouthrinse	I-I	NOUN	I
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
mechanical	B-I	ADJ	B
plaque	I-I	NOUN	I
control	I-I	NOUN	B
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
2-week	O	ADJ	O
wash-out	O	ADJ	O
period	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
the	O	DET	O
alternative	O	ADJ	B
mouthrinse	B-I	NOUN	I
.	I-I	PUNCT	O


Before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
plaque	B-OUT	NOUN	I
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PlI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
gingival	I-OUT	ADJ	B
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
angulated	I-OUT	ADJ	B
bleeding	I-OUT	ADJ	I
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AngBI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
tooth	I-OUT	NOUN	B
stain	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GMSI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
tongue	I-OUT	NOUN	B
stain	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
Test	B-I	NOUN	O
mouthrinse	I-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
decrease	O	NOUN	B
in	O	ADP	O
PlI	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.029	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
GI	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.017	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
PlI	B-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
test	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
control	O	ADJ	B
mouthrinse	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.027	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


GMSI	B-OUT	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
post-treatment	O	ADJ	B
for	O	ADP	O
both	O	DET	O
mouthrinse	B-I	NOUN	B
regimens	I-I	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
score	O	NOUN	B
being	O	AUX	O
observed	O	VERB	B
for	O	ADP	O
the	O	DET	O
test	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
control	B-I	ADJ	B
mouthrinse	I-I	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
12-week	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
AmF/SnF2-containing	B-I	NOUN	B
mouthrinse	I-I	NOUN	I
as	O	ADP	O
an	O	DET	O
adjunct	O	NOUN	B
to	O	PART	O
conventional	O	ADJ	B
mechanical	O	ADJ	B
oral	O	ADJ	I
hygiene	O	NOUN	I
procedures	O	NOUN	I
in	O	ADP	O
GAP	B-P	NOUN	B
patients	I-P	NOUN	B
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
controlling	O	VERB	B
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
supragingival	O	NOUN	B
plaque	O	NOUN	B
deposits	O	NOUN	B
.	O	PUNCT	O


Combined	B-I	ADJ	B
delivery	I-I	NOUN	I
approach	I-I	NOUN	I
of	O	ADP	O
bone	B-I	NOUN	B
marrow	I-I	NOUN	I
mononuclear	I-I	ADJ	I
stem	I-I	NOUN	I
cells	I-I	NOUN	I
early	I-I	ADV	B
and	O	CCONJ	O
late	O	ADJ	O
after	O	ADP	O
myocardial	B-P	ADJ	B
infarction	I-P	NOUN	I
:	I-P	PUNCT	O
the	O	DET	O
MYSTAR	O	ADJ	B
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Combined	O	ADJ	B
intracoronary	O	NOUN	I
and	O	CCONJ	O
intramyocardial	O	ADJ	B
administration	O	NOUN	B
might	O	AUX	O
improve	O	VERB	B
outcomes	O	NOUN	B
for	O	ADP	O
bone-marrow-derived	B-I	ADJ	B
stem	I-I	NOUN	I
cell	I-I	NOUN	I
therapy	I-I	NOUN	I
for	O	ADP	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
(	O	PUNCT	O
AMI	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
feasibility	I-OUT	NOUN	B
of	O	ADP	O
early	O	ADJ	B
and	O	CCONJ	O
late	O	ADJ	B
delivery	O	NOUN	I
of	O	ADP	O
stem	B-I	NOUN	B
cells	I-I	NOUN	I
with	O	ADP	O
combined	O	ADJ	O
therapy	O	NOUN	B
approaches	O	NOUN	O
.	O	PUNCT	O


METHODS	O	VERB	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
left	I-P	ADJ	B
ventricular	I-P	ADJ	I
ejection	I-P	NOUN	I
fraction	I-P	NOUN	I
less	I-P	ADJ	O
than	I-P	ADP	O
45	I-P	NUM	O
%	I-P	NOUN	O
after	I-P	ADP	O
AMI	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
stem	I-I	NOUN	B
cell	I-I	NOUN	I
delivery	I-I	NOUN	B
via	I-I	ADP	O
intramyocardial	I-I	ADJ	B
injection	I-I	NOUN	B
and	I-I	CCONJ	O
intracoronary	I-I	ADJ	B
infusion	I-I	NOUN	B
3-6	I-I	NUM	O
weeks	I-I	NOUN	B
or	I-I	CCONJ	O
3-4	I-I	NUM	O
months	I-I	NOUN	B
after	I-I	ADP	O
AMI	I-I	PROPN	B
.	I-I	PUNCT	O


Primary	O	ADJ	B
end	O	NOUN	I
points	O	NOUN	I
were	O	AUX	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
infarct	I-OUT	NOUN	B
size	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
left	I-OUT	VERB	B
ventricular	I-OUT	ADJ	I
ejection	I-OUT	NOUN	I
fraction	I-OUT	NOUN	I
3	I-OUT	NUM	I
months	I-OUT	NOUN	B
after	I-OUT	ADP	O
therapy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
60	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
treated	I-P	VERB	B
.	I-P	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
infarct	I-OUT	NOUN	B
size	I-OUT	NOUN	I
at	I-OUT	ADP	O
3	I-OUT	NUM	O
months	I-OUT	NOUN	B
were	O	AUX	O
-3.5	O	NUM	O
+/-	O	CCONJ	O
5.1	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-5.5	O	NUM	O
%	O	NOUN	O
to	O	PART	O
-1.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
group	O	NOUN	I
and	O	CCONJ	O
-3.9	O	NUM	O
+/-	O	CCONJ	O
5.6	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-6.1	O	NUM	O
%	O	NOUN	O
to	O	PART	O
-1.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
late	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
ejection	I-OUT	NOUN	B
fraction	I-OUT	NOUN	I
were	O	AUX	O
3.5	O	NUM	O
+/-	O	CCONJ	O
5.6	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1.3-5.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
3.4	O	NUM	O
+/-	O	CCONJ	O
7.0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	ADV	B
0.7-6.1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.017	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


At	O	ADP	O
9-12	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
AMI	O	NOUN	B
,	O	PUNCT	O
ejection	B-OUT	NOUN	B
fraction	I-OUT	NOUN	I
remained	O	VERB	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
at	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
late	O	ADJ	B
groups	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
mean	O	NOUN	O
of	O	ADP	O
200.3	O	NUM	O
+/-	O	CCONJ	O
68.7	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
194.8	O	NUM	O
+/-	O	CCONJ	O
60.4	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
stem	B-OUT	NOUN	B
cells	I-OUT	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
delivered	O	VERB	O
to	O	PART	O
the	O	DET	O
myocardium	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
1.30	O	NUM	O
+/-	O	CCONJ	O
0.68	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
1.29	O	NUM	O
+/-	O	CCONJ	O
0.41	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
cells	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
delivered	O	VERB	O
into	O	ADP	O
the	O	DET	O
artery	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
high	O	ADJ	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
cells	I-OUT	NOUN	B
was	O	AUX	O
required	O	VERB	O
for	O	ADP	O
significant	O	ADJ	B
improvements	O	NOUN	B
in	O	ADP	O
the	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
points	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Combined	O	ADJ	B
cardiac	B-I	ADJ	O
stem	I-I	NOUN	O
cell	I-I	NOUN	O
delivery	I-I	NOUN	O
induces	O	VERB	O
a	O	DET	O
moderate	O	ADJ	B
but	O	CCONJ	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
myocardial	B-OUT	ADJ	B
infarct	I-OUT	NOUN	I
size	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
left	I-OUT	VERB	B
ventricular	I-OUT	ADJ	I
function	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
sequential	O	ADJ	B
annual	O	ADJ	B
vaccination	B-I	NOUN	B
and	I-I	CCONJ	O
of	I-I	ADP	O
DHEA	I-I	NOUN	B
administration	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
immune	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
influenza	B-P	NOUN	B
vaccine	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
elderly	I-P	ADJ	B
.	I-P	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
repeated	O	VERB	O
vaccination	B-I	NOUN	B
and	O	CCONJ	O
of	O	ADP	O
dehydroepiandrosterone	B-I	NOUN	B
(	I-I	PUNCT	O
DHEA	I-I	NOUN	B
)	I-I	PUNCT	O
treatment	O	NOUN	B
on	O	ADP	O
the	O	DET	O
immune	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
influenza	B-I	NOUN	B
vaccine	I-I	NOUN	I
in	I-P	ADP	O
elderly	I-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


Seventy-one	B-P	NUM	O
elderly	I-P	ADJ	B
volunteers	I-P	NOUN	I
,	I-P	PUNCT	O
aged	I-P	ADJ	B
61-89	I-P	NUM	O
years	I-P	NOUN	B
,	O	PUNCT	O
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
study	O	NOUN	I
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
DHEA	B-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
qd	O	NOUN	B
p.o	O	PROPN	O
.	O	PUNCT	O


for	O	ADP	O
4	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
starting	O	VERB	O
2	O	NUM	O
days	O	NOUN	B
before	O	ADP	O
immunization	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Antibody	O	NOUN	B
response	O	NOUN	I
against	O	ADP	O
the	O	DET	O
three	O	NUM	O
strains	O	NOUN	B
of	O	ADP	O
vaccine	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
28	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
vaccination	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
compared	O	VERB	B
between	O	ADP	O
previously	O	ADV	O
vaccinated	O	VERB	B
and	O	CCONJ	O
non-vaccinated	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


DHEA	B-I	NOUN	B
treatment	I-I	NOUN	B
did	O	AUX	O
not	O	PART	O
enhance	O	VERB	O
established	B-OUT	VERB	O
immunity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
attainment	O	NOUN	B
of	O	ADP	O
protective	B-OUT	ADJ	B
antibody	I-OUT	NOUN	I
titer	I-OUT	NOUN	B
(	O	PUNCT	O
titer	O	NOUN	B
of	O	ADP	O
1:40	O	NUM	O
or	O	CCONJ	O
greater	O	ADJ	B
)	O	PUNCT	O
against	O	ADP	O
A/Texas	O	NOUN	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
non-protective	O	ADJ	B
baseline	O	NOUN	B
antibody	O	NOUN	B
titer	O	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
following	O	VERB	O
DHEA	B-I	NOUN	B
treatment	I-I	NOUN	B
compared	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
(	O	PUNCT	O
52	O	NUM	O
vs.	O	CCONJ	O
84	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Post-immunization	B-OUT	ADJ	B
titers	I-OUT	NOUN	B
against	O	ADP	O
influenza	O	NOUN	B
A	O	NOUN	I
strains	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
those	O	DET	O
subjects	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
never	O	ADV	O
immunized	O	VERB	B
before	O	ADV	O
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
post-vaccination	B-OUT	ADJ	B
protective	I-OUT	ADJ	O
titers	I-OUT	NOUN	O
against	O	ADP	O
the	O	DET	O
A/Johannesburg	O	ADJ	B
strain	O	NOUN	I
were	O	AUX	O
more	O	ADV	O
prevalent	O	ADJ	B
in	O	ADP	O
those	O	DET	O
subjects	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
never	O	ADV	O
vaccinated	O	VERB	B
before	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
were	O	AUX	O
not	O	PART	O
the	O	DET	O
same	O	ADJ	O
for	O	ADP	O
anti-B/Harbin	O	NOUN	B
antibodies-repeated	O	ADJ	O
vaccination	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
non-significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
HI	O	NOUN	B
titer	O	NOUN	B
in	O	ADP	O
previously	O	ADV	O
vaccinated	O	VERB	B
subjects	O	NOUN	B
.	O	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
a	O	DET	O
controlled	B-I	ADJ	B
heated	I-I	ADJ	O
breathing	I-I	NOUN	B
tube	I-I	NOUN	I
humidifier	I-I	NOUN	I
on	O	ADP	O
sleep	B-OUT	NOUN	B
quality	I-OUT	NOUN	I
during	O	ADP	O
CPAP	B-I	NOUN	B
therapy	I-I	NOUN	I
in	I-P	ADP	O
a	I-P	DET	O
cool	I-P	ADJ	B
sleeping	I-P	NOUN	B
environment	I-P	NOUN	I
.	I-P	PUNCT	O


There	O	PRON	O
are	O	AUX	O
conflicting	O	VERB	O
data	O	NOUN	B
on	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
adding	O	VERB	O
a	O	DET	O
heated	B-I	ADJ	B
humidifier	I-I	NOUN	I
to	O	ADP	O
nasal	O	ADJ	B
continuous	B-I	ADJ	I
positive	I-I	ADJ	I
airway	I-I	NOUN	I
pressure	I-I	NOUN	I
(	I-I	PUNCT	O
CPAP	I-I	NOUN	B
)	I-I	PUNCT	O
therapy	I-I	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
obstructive	I-P	ADJ	B
sleep	I-P	NOUN	I
apnoea	I-P	NOUN	I
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
OSAS	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
heated	O	ADJ	B
humidification	O	NOUN	I
on	O	ADP	O
sleep	B-OUT	NOUN	B
quality	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
treatment	I-OUT	NOUN	B
side-effects	I-OUT	NOUN	I
for	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
prefer	O	VERB	O
a	O	DET	O
cold	O	ADJ	B
bedroom	O	NOUN	I
environment	O	NOUN	I
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
crossover	O	NOUN	I
trial	O	NOUN	I
involving	O	VERB	O
19	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
first-ever	I-P	ADJ	B
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
OSAS	I-P	NOUN	B
measured	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
conventional	B-I	ADJ	B
heated	I-I	VERB	B
humidification	I-I	NOUN	I
added	I-I	VERB	O
to	I-I	PART	O
CPAP	I-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
a	O	DET	O
controlled	B-I	ADJ	B
heated	I-I	ADJ	O
breathing	I-I	NOUN	B
tube	I-I	NOUN	I
humidifier	I-I	NOUN	I
(	I-I	PUNCT	O
ThermoSmart	I-I	PROPN	B
(	I-I	PUNCT	O
R	I-I	NOUN	B
)	I-I	PUNCT	O
;	I-I	PUNCT	O
Fisher	O	PROPN	B
and	O	CCONJ	O
Paykel	O	PROPN	B
Healthcare	O	PROPN	I
,	O	PUNCT	O
Auckland	O	PROPN	B
,	O	PUNCT	O
New	O	PROPN	B
Zealand	O	PROPN	I
)	O	PUNCT	O
on	O	ADP	O
sleep	B-OUT	NOUN	B
quality	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


During	O	ADP	O
the	O	DET	O
night	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sleep	O	NOUN	B
laboratory	O	NOUN	I
at	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
room	O	NOUN	B
temperature	O	NOUN	B
of	O	ADP	O
14	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
,	O	PUNCT	O
less	O	ADJ	O
condensation	B-OUT	NOUN	B
formed	O	VERB	O
with	O	ADP	O
the	O	DET	O
controlled	B-I	VERB	B
heated	I-I	ADJ	O
breathing	I-I	NOUN	B
tube	I-I	NOUN	I
humidifier	I-I	NOUN	I
(	O	PUNCT	O
1.9	O	NUM	O
mL	O	NOUN	O
versus	O	CCONJ	O
35.3	O	NUM	O
mL	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
delivery	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
total	B-OUT	ADJ	B
sleep	I-OUT	NOUN	I
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
time	I-OUT	NOUN	B
spent	I-OUT	VERB	O
in	I-OUT	ADP	O
sleep	I-OUT	NOUN	B
stages	I-OUT	NOUN	I
3	I-OUT	NUM	O
and	I-OUT	CCONJ	O
4	I-OUT	NUM	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
rapid	I-OUT	ADJ	O
eye	I-OUT	NOUN	O
movement	I-OUT	NOUN	B
sleep	I-OUT	NOUN	B
phases	I-OUT	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
longer	O	ADV	O
and	O	CCONJ	O
the	O	DET	O
overall	B-OUT	ADJ	O
side-effect	I-OUT	ADJ	B
score	I-OUT	NOUN	I
was	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
with	O	ADP	O
conventional	O	ADJ	B
heated	O	VERB	B
humidification	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
on	O	ADP	O
nasal	O	ADJ	B
continuous	O	ADJ	I
positive	O	ADJ	I
airway	O	NOUN	B
pressure	O	NOUN	I
desiring	O	VERB	O
a	O	DET	O
cool	O	ADJ	B
bedroom	O	NOUN	B
temperature	O	NOUN	B
could	O	AUX	O
benefit	O	VERB	B
from	O	ADP	O
controlled	B-I	VERB	B
heated	I-I	ADJ	O
breathing	I-I	NOUN	B
tube	I-I	NOUN	I
humidification	I-I	NOUN	I
technology	I-I	NOUN	I
(	O	PUNCT	O
with	O	ADP	O
inputs	O	NOUN	B
from	O	ADP	O
ambient	O	ADJ	B
temperature	O	NOUN	B
,	O	PUNCT	O
set	O	VERB	O
pressure	O	NOUN	B
and	O	CCONJ	O
flow	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Carboplatin	B-I	NOUN	B
and	I-I	CCONJ	O
pegylated	I-I	ADJ	B
liposomal	I-I	ADJ	B
doxorubicin	I-I	NOUN	I
versus	O	CCONJ	O
carboplatin	B-I	NOUN	B
and	I-I	CCONJ	O
paclitaxel	I-I	NOUN	B
in	O	ADP	O
very	B-P	ADV	O
platinum-sensitive	I-P	ADJ	B
ovarian	I-P	ADJ	O
cancer	I-P	NOUN	O
patients	I-P	NOUN	B
:	I-P	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
a	O	DET	O
subset	B-P	NOUN	O
analysis	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
CALYPSO	I-P	NOUN	B
phase	I-P	NOUN	I
III	I-P	NUM	I
trial	I-P	NOUN	I
.	I-P	PUNCT	O


AIM	O	PROPN	B
To	O	PART	O
perform	O	VERB	O
a	O	DET	O
subset	O	NOUN	O
analysis	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
very	I-P	ADV	O
platinum-sensitive	I-P	ADJ	B
recurrent	I-P	ADJ	O
ovarian	I-P	ADJ	O
cancer	I-P	NOUN	O
(	I-P	PUNCT	O
ROC	I-P	PROPN	B
)	I-P	PUNCT	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
phase	I-P	NOUN	B
III	I-P	NUM	I
CALYPSO	I-P	NOUN	I
trial	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
The	B-P	DET	O
international	I-P	ADJ	B
non-inferiority	I-P	ADJ	B
trial	I-P	NOUN	I
enrolled	I-P	VERB	O
women	I-P	NOUN	B
with	I-P	ADP	O
ROC	I-P	PROPN	B
that	I-P	PRON	O
relapsed	I-P	VERB	B
>	I-P	NOUN	O
6	I-P	NUM	O
months	I-P	NOUN	B
following	I-P	VERB	O
first-	I-P	ADJ	O
or	I-P	CCONJ	O
second-line	I-P	ADJ	B
platinum-	I-I	NOUN	O
and	I-I	CCONJ	O
paclitaxel-based	I-I	ADJ	B
therapies	I-I	NOUN	I
.	I-I	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
to	O	ADP	O
CD	B-I	NOUN	B
[	I-I	PUNCT	O
carboplatin-pegylated	I-I	ADJ	O
liposomal	I-I	ADJ	O
doxorubicin	I-I	NOUN	O
(	I-I	PUNCT	O
PLD	I-I	NOUN	B
)	I-I	PUNCT	O
]	I-I	PUNCT	O
or	I-I	CCONJ	O
CP	I-I	NOUN	B
(	I-I	PUNCT	O
carboplatin-paclitaxel	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
stratified	O	VERB	B
by	O	ADP	O
treatment-free	O	ADJ	B
interval	O	NOUN	I
(	O	PUNCT	O
TFI	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
analysis	O	NOUN	B
,	O	PUNCT	O
patients	B-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
TFI	I-P	NOUN	B
>	I-P	X	O
24	I-P	NUM	O
months	I-P	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
separately	O	ADV	O
for	O	ADP	O
progression	O	NOUN	B
free	O	ADJ	O
survival	O	NOUN	O
(	O	PUNCT	O
PFS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
primary	O	ADJ	O
endpoint	O	NOUN	B
of	O	ADP	O
CALYPSO	O	NOUN	B
,	O	PUNCT	O
overall	O	ADJ	B
survival	O	NOUN	I
(	O	PUNCT	O
OS	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
safety	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
259	I-P	NUM	O
very	I-P	ADV	O
platinum-sensitive	I-P	ADJ	B
patients	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
(	I-P	PUNCT	O
n=131	I-P	PROPN	O
,	I-P	PUNCT	O
CD	I-P	PROPN	B
;	I-P	PUNCT	O
n=128	I-P	PROPN	O
,	I-P	PUNCT	O
CP	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Median	B-OUT	ADJ	B
PFS	I-OUT	PROPN	B
was	O	AUX	O
12.0	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
the	O	DET	O
CD	B-I	NOUN	B
arm	O	NOUN	I
and	O	CCONJ	O
12.3	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
CP	B-I	NOUN	B
[	O	PUNCT	O
HR=1.05	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.79-1.40	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
P=0.73	O	NOUN	O
for	O	ADP	O
superiority	O	NOUN	B
]	O	PUNCT	O
and	O	CCONJ	O
median	B-OUT	ADJ	B
OS	I-OUT	NOUN	B
was	O	AUX	O
40.2	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
CD	O	PROPN	B
and	O	CCONJ	O
43.9	O	NUM	O
for	O	ADP	O
CP	O	NOUN	B
[	O	PUNCT	O
HR=1.18	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.85-1.63	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
P=0.33	O	NOUN	O
for	O	ADP	O
superiority	O	NOUN	B
]	O	PUNCT	O
.	O	PUNCT	O


Overall	O	ADJ	O
response	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
42	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
38	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P=0.46	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Toxicities	B-OUT	NOUN	B
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
with	O	ADP	O
CP	B-I	NOUN	B
versus	O	CCONJ	O
CD	B-I	PROPN	B
,	O	PUNCT	O
including	O	VERB	O
grade	B-OUT	NOUN	B
3/4	I-OUT	NUM	I
neutropenia	I-OUT	NOUN	B
(	O	PUNCT	O
40.8	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
27.5	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.025	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
nausea	B-OUT	NOUN	B
(	O	PUNCT	O
4.8	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
3.1	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.47	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
allergic	B-OUT	ADJ	B
reaction	I-OUT	NOUN	I
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
3.1	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.082	O	NOUN	O
)	O	PUNCT	O
sensory	B-OUT	ADJ	B
neuropathy	I-OUT	NOUN	I
(	O	PUNCT	O
4.8	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
2.3	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.27	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
grade	B-OUT	NOUN	B
2	I-OUT	NUM	I
alopecia	I-OUT	NOUN	I
(	O	PUNCT	O
88	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
9.2	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Grade	B-OUT	NOUN	B
3/4	I-OUT	NUM	I
thrombocytopenia	I-OUT	NOUN	I
(	O	PUNCT	O
12.2	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
3.2	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.007	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
mucositis	B-OUT	NOUN	B
(	O	PUNCT	O
2.3	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
0	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.089	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
with	O	ADP	O
CD	B-I	NOUN	B
.	I-I	PUNCT	O


Grade	B-OUT	NOUN	B
3/4	I-OUT	NUM	I
hand-foot	I-OUT	ADJ	I
syndrome	I-OUT	NOUN	I
occurred	O	VERB	O
rarely	O	ADV	O
with	O	ADP	O
CD	B-I	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
patients	O	NOUN	B
versus	O	CCONJ	O
0	O	NUM	O
in	O	ADP	O
CP	O	NOUN	B
arm	O	NOUN	B
;	O	PUNCT	O
P=0.089	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
CP	O	NOUN	B
and	O	CCONJ	O
CD	O	NOUN	B
were	O	AUX	O
equally	O	ADV	O
effective	O	ADJ	B
treatment	O	NOUN	B
regimens	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
very	I-P	ADV	O
platinum-sensitive	I-P	ADJ	B
ROC	I-P	PROPN	B
.	I-P	PUNCT	O


The	O	DET	O
favourable	O	ADJ	O
risk-benefit	O	ADJ	B
profile	O	NOUN	I
suggests	O	VERB	O
carboplatin-PLD	B-I	NOUN	B
as	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
choice	O	NOUN	O
for	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Assessing	O	VERB	B
drug	O	NOUN	B
use	O	NOUN	I
prevalence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
workplace	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
self-report	O	ADJ	B
methods	O	NOUN	O
and	O	CCONJ	O
urinalysis	O	NOUN	B
.	O	PUNCT	O


A	B-P	DET	O
random	I-P	ADJ	B
sample	I-P	NOUN	B
of	I-P	ADP	O
800	I-P	NUM	O
employees	I-P	NOUN	B
of	I-P	ADP	O
a	I-P	DET	O
steel	I-P	NOUN	B
manufacturing	I-P	NOUN	I
company	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
self-report	B-I	ADJ	B
methods	I-I	NOUN	O
of	O	ADP	O
assessing	O	VERB	O
illicit	B-I	NOUN	B
drug	I-I	NOUN	I
use	I-I	NOUN	I
:	I-I	PUNCT	O
1	I-I	X	O
)	I-I	PUNCT	O
Individual	I-I	ADJ	O
interview	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
workplace	I-I	NOUN	B
,	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
group-administered	I-I	ADJ	B
questionnaire	I-I	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
workplace	I-I	NOUN	B
,	I-I	PUNCT	O
3	I-I	X	O
)	I-I	PUNCT	O
telephone	I-I	NOUN	B
interview	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
4	I-I	X	O
)	I-I	PUNCT	O
individual	I-I	ADJ	O
interview	I-I	NOUN	B
off	I-I	ADP	O
the	I-I	DET	O
worksite	I-I	NOUN	B
.	I-I	PUNCT	O


All	B-P	DET	O
621	I-P	NUM	O
subjects	I-P	NOUN	B
participating	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
research	I-P	NOUN	B
were	I-P	AUX	O
also	I-P	ADV	O
tested	I-P	VERB	B
by	I-P	ADP	O
urinalysis	I-P	NOUN	B
.	I-P	PUNCT	O


Rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
drug	I-OUT	NOUN	B
use	I-OUT	NOUN	I
self-report	I-OUT	ADJ	I
were	O	AUX	O
highest	O	ADJ	O
in	O	ADP	O
the	O	DET	O
workplace	O	NOUN	B
interview	O	NOUN	I
condition	O	NOUN	B
and	O	CCONJ	O
lowest	O	ADJ	B
in	O	ADP	O
the	O	DET	O
overall	O	ADJ	B
group	O	NOUN	I
questionnaire	O	NOUN	O
condition	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
overall	B-OUT	ADJ	B
prevalence	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
produced	O	VERB	O
by	O	ADP	O
self-reports	O	NOUN	B
and	O	CCONJ	O
urinalysis	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
little	O	ADJ	O
concordance	O	NOUN	B
between	O	ADP	O
urinalysis	B-OUT	NOUN	B
positives	I-OUT	NOUN	I
and	O	CCONJ	O
self-report	B-OUT	ADJ	B
positives	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
self-reports	O	NOUN	B
and	O	CCONJ	O
urinalysis	O	NOUN	B
are	O	AUX	O
complementary	O	ADJ	O
methods	O	NOUN	O
of	O	ADP	O
drug	B-OUT	NOUN	B
use	I-OUT	NOUN	I
assessment	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
are	O	AUX	O
best	O	ADV	O
used	O	VERB	O
in	O	ADP	O
combination	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
clinician	B-I	ADJ	B
feedback	I-I	NOUN	O
to	O	PART	O
improve	O	VERB	B
quality	O	NOUN	B
of	O	ADP	I
care	O	NOUN	I
for	O	ADP	O
inner-city	B-P	ADJ	B
children	I-P	NOUN	I
with	I-P	ADP	O
asthma	I-P	NOUN	B
.	I-P	PUNCT	O


CONTEXT	O	PROPN	B
Barriers	O	NOUN	B
impede	O	VERB	O
translating	O	VERB	O
recommendations	O	NOUN	B
for	O	ADP	O
asthma	O	NOUN	B
treatment	O	NOUN	B
into	O	ADP	O
practice	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
inner	O	ADJ	B
cities	O	NOUN	I
where	O	SCONJ	O
asthma	O	NOUN	B
morbidity	O	NOUN	B
is	O	AUX	O
highest	O	ADJ	B
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
timely	O	ADV	O
patient	B-I	ADJ	B
feedback	I-I	NOUN	O
in	O	ADP	O
the	O	DET	O
form	O	NOUN	O
of	O	ADP	O
a	B-I	DET	O
letter	I-I	NOUN	B
providing	O	VERB	O
recent	O	ADJ	O
patient-specific	O	ADJ	B
symptoms	O	NOUN	I
,	O	PUNCT	O
medication	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
health	O	NOUN	B
service	O	NOUN	I
use	O	NOUN	O
combined	O	VERB	O
with	O	ADP	O
guideline-based	O	ADJ	B
recommendations	O	NOUN	I
for	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
therapy	O	NOUN	B
on	O	ADP	O
improving	O	VERB	B
the	O	DET	O
quality	O	NOUN	B
of	O	ADP	O
asthma	O	NOUN	B
care	O	NOUN	I
by	O	ADP	O
inner-city	O	ADJ	B
primary	O	ADJ	B
care	O	NOUN	I
providers	O	NOUN	I
and	O	CCONJ	O
on	O	ADP	O
resultant	O	ADJ	O
asthma	O	NOUN	B
morbidity	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
clinical	O	ADJ	I
trial	O	NOUN	I
in	O	ADP	O
5-	B-P	NUM	O
to	I-P	PART	O
11-year-old	I-P	ADJ	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
937	I-P	NUM	O
)	I-P	PUNCT	O
with	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
asthma	I-P	NOUN	B
receiving	I-P	VERB	O
health	I-P	NOUN	B
care	I-P	NOUN	I
in	I-P	ADP	O
hospital-	I-P	ADJ	B
and	I-P	CCONJ	O
community-based	I-P	ADJ	B
clinics	I-P	NOUN	I
and	I-P	CCONJ	O
private	I-P	ADJ	B
practices	I-P	NOUN	I
in	I-P	ADP	O
7	I-P	NUM	O
inner-city	I-P	ADJ	B
urban	I-P	ADJ	B
areas	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
caretaker	B-P	NOUN	B
of	I-P	ADP	O
each	I-P	DET	O
child	I-P	NOUN	B
received	O	VERB	O
a	O	DET	O
bimonthly	B-I	ADJ	B
telephone	I-I	NOUN	I
call	I-I	NOUN	O
to	I-I	PART	O
collect	I-I	VERB	O
clinical	I-I	ADJ	B
information	I-I	NOUN	O
about	I-I	ADP	O
the	I-I	DET	O
child	I-I	NOUN	B
's	I-I	PART	I
asthma	I-I	NOUN	B
.	I-I	PUNCT	O


For	O	ADP	O
a	O	DET	O
full	O	ADJ	O
year	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
providers	O	NOUN	B
of	O	ADP	O
intervention	O	NOUN	B
group	O	NOUN	I
children	O	NOUN	B
received	O	VERB	O
bimonthly	B-I	ADV	B
computer-generated	I-I	ADJ	O
letters	I-I	NOUN	O
based	O	VERB	O
on	O	ADP	O
these	O	DET	O
calls	O	NOUN	O
summarizing	O	VERB	O
the	O	DET	O
child	O	NOUN	B
's	O	PART	I
asthma	O	NOUN	B
symptoms	O	NOUN	B
,	O	PUNCT	O
health	O	NOUN	B
service	O	NOUN	I
use	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
medication	O	NOUN	B
use	O	NOUN	O
with	O	ADP	O
a	O	DET	O
corresponding	O	ADJ	O
recommendation	O	NOUN	B
to	O	PART	O
step	O	VERB	O
up	O	ADP	O
or	O	CCONJ	O
step	O	VERB	O
down	O	ADP	O
medications	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
measured	O	VERB	B
the	O	DET	O
number	O	NOUN	B
and	O	CCONJ	O
proportion	O	NOUN	B
of	O	ADP	O
scheduled	O	VERB	B
visits	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
stepping	O	NOUN	B
up	O	ADP	O
of	O	ADP	O
medications	O	NOUN	B
,	O	PUNCT	O
asthma	O	NOUN	B
symptoms	O	NOUN	I
(	O	PUNCT	O
2-week	O	ADJ	B
recall	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
health	O	NOUN	B
care	O	NOUN	I
use	O	NOUN	I
(	O	PUNCT	O
2-month	O	ADJ	O
recall	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
this	O	DET	O
population	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
a	O	DET	O
modest	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
whose	O	DET	O
symptoms	O	NOUN	B
warranted	O	VERB	O
a	O	DET	O
medication	O	NOUN	B
increase	O	NOUN	B
actually	O	ADV	O
had	O	AUX	O
a	O	DET	O
scheduled	B-OUT	VERB	O
visit	I-OUT	NOUN	B
to	O	PART	O
reevaluate	O	VERB	O
their	O	PRON	O
asthma	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
2-month	O	ADJ	B
interval	O	NOUN	I
after	O	ADP	O
receipt	O	NOUN	B
of	O	ADP	O
a	O	DET	O
step-up	O	ADJ	B
letter	O	NOUN	I
,	O	PUNCT	O
17.1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
letters	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
scheduled	O	VERB	B
visits	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
scheduled	O	ADJ	B
visits	O	NOUN	B
12.3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
time	O	NOUN	B
by	O	ADP	O
the	O	DET	O
control	O	NOUN	B
children	O	NOUN	I
with	O	ADP	O
comparable	O	ADJ	O
clinical	O	ADJ	B
symptoms	O	NOUN	I
.	O	PUNCT	O


Asthma	B-I	ADJ	B
medications	I-I	NOUN	B
were	O	AUX	O
stepped	O	VERB	O
up	O	ADP	O
when	O	SCONJ	O
indicated	O	VERB	O
after	O	ADP	O
46.0	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
these	O	DET	O
visits	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
35.6	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	B-I	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
when	O	SCONJ	O
asthma	O	NOUN	B
symptoms	O	NOUN	B
warranted	O	VERB	O
a	O	DET	O
step	O	NOUN	O
up	O	ADV	O
in	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
medication	O	NOUN	B
changes	O	NOUN	I
occurred	O	VERB	O
earlier	O	ADV	O
among	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
children	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
children	O	NOUN	B
whose	O	DET	O
medications	O	NOUN	B
were	O	AUX	O
stepped	O	VERB	O
up	O	ADP	O
at	O	ADP	O
any	O	DET	O
time	O	NOUN	O
during	O	ADP	O
the	O	DET	O
12-month	O	ADJ	O
study	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
experienced	O	VERB	O
22.1	O	NUM	O
%	O	NOUN	O
fewer	O	ADJ	O
symptom	O	NOUN	B
days	O	NOUN	I
and	O	CCONJ	O
37.9	O	NUM	O
%	O	NOUN	O
fewer	O	ADJ	O
school	O	NOUN	B
days	O	NOUN	I
missed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
intention-to-treat	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
no	O	DET	B
difference	O	NOUN	I
over	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
year	O	NOUN	O
in	O	ADP	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
symptom	I-OUT	NOUN	B
days	I-OUT	NOUN	I
,	O	PUNCT	O
yet	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
fewer	O	ADJ	O
days	O	NOUN	B
of	O	ADP	O
limited	O	ADJ	O
activity	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
emergency	B-OUT	NOUN	B
department	I-OUT	NOUN	I
visits	I-OUT	NOUN	I
by	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
24	O	NUM	O
%	O	NOUN	O
drop	O	NOUN	B
in	O	ADP	O
emergency	B-OUT	NOUN	B
department	I-OUT	NOUN	I
visits	I-OUT	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
intervention	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
cost	O	VERB	B
saving	O	NOUN	O
in	O	ADP	O
its	O	PRON	O
first	O	ADJ	O
year	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Patient-specific	B-I	ADJ	B
feedback	I-I	NOUN	I
to	O	ADP	O
inner-city	O	NOUN	B
providers	O	NOUN	I
increased	O	VERB	B
scheduled	O	VERB	O
asthma	O	NOUN	B
visits	O	NOUN	I
,	O	PUNCT	O
increased	O	VERB	B
asthma	O	NOUN	B
visits	O	NOUN	O
in	O	ADP	O
which	O	DET	O
medications	O	NOUN	B
were	O	AUX	O
stepped	O	VERB	O
up	O	ADP	O
when	O	SCONJ	O
clinically	O	ADV	B
indicated	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
emergency	O	NOUN	B
department	O	NOUN	I
visits	O	NOUN	I
.	O	PUNCT	O


Effect	B-OUT	NOUN	B
of	O	ADP	O
antacids	B-I	NOUN	B
on	I-P	ADP	O
intragastric	I-OUT	ADJ	B
pH	I-OUT	NOUN	B
in	I-P	ADP	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
and	I-P	CCONJ	O
duodenal	I-P	ADJ	B
ulcer	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Influence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
antacid	B-I	NOUN	B
dose	I-I	NOUN	I
and	O	CCONJ	O
of	O	ADP	O
anticholinergics	B-I	NOUN	B
.	I-I	PUNCT	O


Different	B-I	ADJ	O
doses	I-I	NOUN	B
of	I-I	ADP	O
two	I-I	NUM	O
liquid	I-I	ADJ	B
antacids	I-I	NOUN	I
,	I-I	PUNCT	O
alone	I-I	ADV	O
and	I-I	CCONJ	O
combined	I-I	VERB	B
with	I-I	ADP	O
an	I-I	DET	O
anticholinergic	I-I	ADJ	B
agent	I-I	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
studied	O	VERB	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
antacid	I-OUT	NOUN	B
action	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
studies	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
in	B-P	ADP	O
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
with	I-P	ADP	O
MAO	I-P	NOUN	B
less	I-P	ADJ	O
than	I-P	ADP	O
30	I-P	NUM	O
mmol/h	I-P	NOUN	O
and	I-P	CCONJ	O
in	I-P	ADP	O
duodenal	I-P	ADJ	B
ulcer	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
MAO	I-P	NOUN	B
greater	I-P	ADJ	O
than	I-P	ADP	O
35	I-P	NUM	O
mmol/h	I-P	NOUN	O
.	I-P	PUNCT	O


Gastric	B-OUT	ADJ	B
pH	I-OUT	NOUN	B
was	I-OUT	AUX	O
recorded	I-OUT	VERB	O
using	I-OUT	VERB	O
radiotelemetric	I-OUT	ADJ	B
technique	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
Heidelberg	I-OUT	PROPN	B
capsule	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
healthy	B-P	ADJ	B
subjects	I-P	NOUN	I
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
action	I-OUT	NOUN	B
with	O	ADP	O
the	O	DET	O
different	O	ADJ	O
doses	O	NOUN	B
but	O	CCONJ	O
in	O	ADP	O
duodenal	B-P	ADJ	B
ulcer	I-P	NOUN	I
patients	I-P	NOUN	B
a	O	DET	O
tenfold	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
antacid	B-I	NOUN	B
dose	O	NOUN	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
doubling	O	NOUN	B
of	O	ADP	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	I
action	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Combined	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
an	O	DET	O
anticholinergic	B-I	ADJ	B
and	O	CCONJ	O
antacids	B-I	NOUN	B
enhanced	O	VERB	B
the	O	DET	O
antacid	B-OUT	NOUN	B
effects	I-OUT	NOUN	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
an	O	DET	O
antacid	O	NOUN	B
dose	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
so	O	ADV	O
great	O	ADJ	O
that	O	SCONJ	O
it	O	PRON	O
binds	O	VERB	B
secreted	O	VERB	B
acid	O	NOUN	O
before	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
leaves	O	VERB	B
the	O	DET	O
stomach	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
will	O	AUX	O
not	O	PART	O
increase	O	VERB	B
the	O	DET	O
duration	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Concomitant	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
an	O	DET	O
anticholinergic	B-I	ADJ	B
agent	I-I	NOUN	I
increases	O	VERB	B
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
antacid	I-OUT	NOUN	B
action	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Trachoma	O	NOUN	B
prevalence	O	NOUN	B
and	O	CCONJ	O
associated	O	VERB	O
risk	O	NOUN	B
factors	O	NOUN	I
in	O	ADP	O
the	B-P	DET	O
gambia	I-P	PROPN	B
and	I-P	CCONJ	O
Tanzania	I-P	PROPN	B
:	I-P	PUNCT	O
baseline	O	NOUN	B
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
cluster	O	NOUN	B
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Blinding	O	NOUN	B
trachoma	O	NOUN	B
,	O	PUNCT	O
caused	O	VERB	O
by	O	ADP	O
ocular	O	ADJ	B
infection	O	NOUN	I
with	O	ADP	O
Chlamydia	O	NOUN	B
trachomatis	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
targeted	O	VERB	B
for	O	ADP	O
global	O	ADJ	B
elimination	O	NOUN	B
by	O	ADP	O
2020	O	NUM	O
.	O	PUNCT	O


Knowledge	O	NOUN	B
of	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
can	O	AUX	O
help	O	VERB	O
target	O	VERB	B
control	O	NOUN	O
interventions	O	NOUN	B
.	O	PUNCT	O


METHODOLOGY/PRINCIPAL	O	ADJ	B
FINDINGS	O	NOUN	O
As	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
cluster	O	NOUN	B
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
assessed	B-OUT	VERB	B
the	I-OUT	DET	O
baseline	I-OUT	NOUN	B
prevalence	I-OUT	NOUN	B
of	I-OUT	ADP	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
risk	I-OUT	NOUN	B
factors	I-OUT	NOUN	I
for	I-OUT	ADP	O
,	O	PUNCT	O
active	O	ADJ	B
trachoma	B-OUT	NOUN	I
and	O	CCONJ	O
ocular	B-OUT	ADJ	B
C.	I-OUT	X	B
trachomatis	I-OUT	NOUN	I
infection	I-OUT	NOUN	O
in	O	ADP	O
randomly	B-P	ADV	O
selected	I-P	VERB	O
children	I-P	NOUN	B
aged	I-P	ADJ	B
0-5	I-P	NUM	O
years	I-P	NOUN	B
from	I-P	ADP	O
48	I-P	NUM	O
Gambian	I-P	ADJ	B
and	I-P	CCONJ	O
36	I-P	NUM	O
Tanzanian	I-P	ADJ	B
communities	I-P	NOUN	B
.	I-P	PUNCT	O


Both	B-I	DET	O
children	I-I	NOUN	B
's	I-I	PART	I
eyes	I-I	NOUN	B
were	I-I	AUX	O
examined	I-I	VERB	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
World	B-OUT	PROPN	B
Health	I-OUT	PROPN	I
Organization	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
WHO	I-OUT	PRON	B
)	I-OUT	PUNCT	O
simplified	I-OUT	VERB	O
grading	I-OUT	NOUN	B
system	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
an	B-I	DET	O
ocular	I-OUT	ADJ	B
swab	I-OUT	NOUN	I
was	I-I	AUX	O
taken	I-I	VERB	O
from	I-I	ADP	O
each	I-I	DET	O
child	I-I	NOUN	B
's	I-I	PART	I
right	I-I	ADJ	B
eye	I-I	NOUN	I
and	I-I	CCONJ	O
processed	I-I	VERB	O
by	I-I	ADP	O
Amplicor	I-OUT	NOUN	B
polymerase	I-OUT	NOUN	I
chain	I-OUT	NOUN	I
reaction	I-OUT	NOUN	I
to	I-I	PART	O
test	I-I	VERB	O
for	I-I	ADP	O
the	I-I	DET	O
presence	I-I	NOUN	B
of	I-I	ADP	O
C.	I-I	X	B
trachomatis	I-I	NOUN	I
DNA	I-I	NOUN	B
.	I-I	PUNCT	O


Prevalence	O	NOUN	B
of	O	ADP	O
active	O	ADJ	B
trachoma	O	NOUN	I
was	O	AUX	O
6.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
335/5033	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
The	B-P	DET	O
Gambia	I-P	PROPN	B
and	O	CCONJ	O
32.3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
1008/3122	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
Tanzania	B-P	PROPN	B
.	I-P	PUNCT	O


The	O	DET	O
countries	O	NOUN	B
'	O	PART	O
corresponding	O	ADJ	O
Amplicor	B-OUT	NOUN	B
positive	I-OUT	ADJ	I
prevalences	I-OUT	NOUN	B
were	O	AUX	O
0.8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
21.9	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


After	O	ADP	O
adjustment	O	NOUN	B
,	O	PUNCT	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
follicular	O	ADJ	B
trachoma	O	NOUN	B
(	O	PUNCT	O
TF	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
both	O	DET	O
countries	O	NOUN	B
were	O	AUX	O
ocular	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
nasal	I-OUT	ADJ	B
discharge	I-OUT	NOUN	I
,	O	PUNCT	O
a	O	DET	O
low	B-OUT	ADJ	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
household	I-OUT	NOUN	B
head	I-OUT	NOUN	O
education	I-OUT	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
being	O	AUX	O
aged	B-OUT	ADJ	B
≥	I-OUT	NOUN	O
1	I-OUT	NUM	O
year	I-OUT	NOUN	B
.	O	PUNCT	O


Additional	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
in	B-P	ADP	O
Tanzania	I-P	PROPN	B
were	I-OUT	AUX	O
flies	I-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
child	I-OUT	NOUN	B
's	I-OUT	PART	I
face	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
being	I-OUT	AUX	O
Amplicor	I-OUT	NOUN	B
positive	I-OUT	ADJ	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
crowding	I-OUT	NOUN	B
(	O	PUNCT	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
children	O	NOUN	B
per	O	ADP	O
household	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
being	B-OUT	AUX	O
Amplicor	I-OUT	NOUN	B
positive	I-OUT	ADJ	I
in	I-P	ADP	O
Tanzania	I-P	PROPN	B
were	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
for	O	ADP	O
TF	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
exclusion	O	NOUN	B
of	O	ADP	O
flies	O	NOUN	B
and	O	CCONJ	O
crowding	O	NOUN	B
.	O	PUNCT	O


In	B-P	ADP	O
The	I-P	DET	O
Gambia	I-P	PROPN	B
,	O	PUNCT	O
only	B-OUT	ADV	O
ocular	I-OUT	ADJ	B
discharge	I-OUT	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
being	B-OUT	AUX	O
Amplicor	I-OUT	NOUN	B
positive	I-OUT	ADJ	I
.	O	PUNCT	O


CONCLUSIONS/SIGNIFICANCE	O	NOUN	B
These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
although	O	SCONJ	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
active	O	ADJ	B
trachoma	O	NOUN	I
and	B-OUT	CCONJ	O
Amplicor	I-OUT	NOUN	B
positives	I-OUT	NOUN	I
were	O	AUX	O
very	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
countries	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
active	O	ADJ	B
trachoma	O	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
but	O	CCONJ	O
those	O	DET	O
for	O	ADP	O
being	B-OUT	AUX	O
Amplicor	I-OUT	NOUN	B
positive	I-OUT	ADJ	I
were	O	AUX	O
different	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
an	O	DET	O
association	O	NOUN	B
between	O	ADP	O
being	O	AUX	O
Amplicor	O	NOUN	B
positive	O	ADJ	I
and	O	CCONJ	O
TF	O	NOUN	B
in	B-P	ADP	O
The	I-P	DET	O
Gambia	I-P	PROPN	B
highlights	O	VERB	O
the	O	DET	O
poor	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	B-OUT	ADP	O
trachoma	I-OUT	NOUN	B
clinical	I-OUT	ADJ	B
signs	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
evidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
C.	I-OUT	X	B
trachomatis	I-OUT	NOUN	I
infection	I-OUT	NOUN	O
in	O	ADP	O
this	O	DET	O
setting	O	NOUN	O
.	O	PUNCT	O


Only	B-OUT	ADV	O
ocular	I-OUT	ADJ	B
discharge	I-OUT	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
evidence	O	NOUN	B
of	O	ADP	O
C.	O	X	B
trachomatis	O	NOUN	I
DNA	O	NOUN	B
in	B-P	ADP	O
The	I-P	DET	O
Gambia	I-P	PROPN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
at	O	ADP	O
this	O	DET	O
low	O	ADJ	B
endemicity	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
most	O	ADV	O
important	O	ADJ	O
risk	O	NOUN	B
factor	O	NOUN	I
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
ClinicalTrials.gov	O	NOUN	O
NCT00792922	O	SYM	O
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
prethrombolytic	B-I	ADJ	B
cyclosporine-A	I-I	ADJ	B
injection	I-I	NOUN	B
on	O	ADP	O
clinical	O	ADJ	B
outcome	O	NOUN	I
of	O	ADP	O
acute	B-P	ADJ	B
anterior	I-P	ADJ	I
ST-elevation	I-P	ADJ	I
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
.	I-P	PUNCT	O


INTRODUCTION	O	PROPN	O
Reperfusion	O	NOUN	B
injury	O	NOUN	I
reduces	O	VERB	B
the	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
early	O	ADJ	O
reperfusion	O	NOUN	B
therapies	O	NOUN	O
after	O	ADP	O
acute	O	ADJ	B
ST-elevation	O	ADJ	I
myocardial	O	ADJ	I
infarction	O	NOUN	I
(	O	PUNCT	O
STEMI	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Cyclosporine-A	B-I	NOUN	B
(	I-I	PUNCT	O
CsA	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
a	O	DET	O
potent	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
opening	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mitochondrial	O	ADJ	B
permeability	O	NOUN	O
transition	O	NOUN	O
pore	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
play	O	VERB	O
a	O	DET	O
key	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
myocardial	O	ADJ	B
reperfusion	O	NOUN	O
injury	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
this	O	DET	O
treatment	O	NOUN	B
on	O	ADP	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
of	O	ADP	O
acute	O	ADJ	B
STEMI	O	NOUN	B
remains	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


Our	O	PRON	O
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
of	O	ADP	O
using	O	VERB	O
this	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
anterior	I-P	ADJ	I
STEMI	I-P	NOUN	I
receiving	I-P	VERB	O
thrombolytic	I-P	ADJ	B
treatment	I-P	NOUN	I
(	I-P	PUNCT	O
TLT	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
double-blinded	O	ADJ	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
,	O	PUNCT	O
101	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
anterior	I-P	ADJ	I
STEMI	I-P	NOUN	I
who	I-P	PRON	O
were	I-P	AUX	O
candidate	I-P	NOUN	O
for	I-P	ADP	O
TLT	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
enrolled	O	VERB	O
and	O	CCONJ	O
randomly	O	ADV	O
assigned	O	VERB	O
into	O	ADP	O
treatment	O	NOUN	B
or	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Patients	B-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
treatment	I-I	NOUN	B
group	I-I	NOUN	I
received	I-I	VERB	O
an	I-I	DET	O
intravenous	I-I	ADJ	B
bolus	I-I	NOUN	I
injection	I-I	NOUN	I
of	I-I	ADP	O
2.5	I-I	NUM	O
mg/kg	I-I	NOUN	O
of	I-I	ADP	O
CsA	I-I	NOUN	B
immediately	I-I	ADV	O
before	I-I	ADP	O
TLT	I-I	PROPN	B
.	I-I	PUNCT	O


The	B-I	DET	O
patients	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
control	I-I	NOUN	B
group	I-I	NOUN	I
received	I-I	VERB	O
an	I-I	DET	O
equivalent	I-I	ADJ	B
volume	I-I	NOUN	B
of	I-I	ADP	O
normal	I-I	ADJ	B
saline	I-I	NOUN	I
.	I-I	PUNCT	O


Infarct	B-OUT	NOUN	B
size	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
occurrence	I-OUT	NOUN	B
of	I-OUT	ADP	O
major	I-OUT	ADJ	O
arrhythmias	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
heart	I-OUT	NOUN	B
failure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
left	I-OUT	VERB	B
ventricular	I-OUT	ADJ	I
ejection	I-OUT	NOUN	I
fraction	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
LVEF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
TLT-related	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
in-hospital	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
6-month	I-OUT	ADJ	O
mortality	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
among	O	ADP	O
the	O	DET	O
demographics	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
myocardial	I-OUT	ADJ	B
enzyme	I-OUT	NOUN	O
release	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
occurrence	I-OUT	NOUN	B
of	I-OUT	ADP	O
major	I-OUT	ADJ	B
arrhythmias	I-OUT	NOUN	I
[	O	PUNCT	O
9	O	NUM	O
(	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
12	O	NUM	O
(	O	PUNCT	O
23.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.80	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
heart	B-OUT	NOUN	B
failure	I-OUT	NOUN	I
[	O	PUNCT	O
18	O	NUM	O
(	O	PUNCT	O
36	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
19	O	NUM	O
(	O	PUNCT	O
38.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.83	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
LVEF	B-OUT	NOUN	B
at	I-OUT	ADP	O
first	I-OUT	ADJ	O
day	I-OUT	NOUN	B
[	O	PUNCT	O
34.7	O	NUM	O
±	O	NOUN	O
9.9	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
33.5	O	NUM	O
±	O	NOUN	O
8.1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.50	O	NUM	O
]	O	PUNCT	O
or	O	CCONJ	O
at	B-OUT	ADP	O
discharge	I-OUT	NOUN	B
[	O	PUNCT	O
37.7	O	NUM	O
±	O	NOUN	O
10	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
36.1	O	NUM	O
±	O	NOUN	O
8.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.43	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
and	B-OUT	CCONJ	O
in-hospital	I-OUT	ADJ	B
[	O	PUNCT	O
4	O	NUM	O
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
6	O	NUM	O
(	O	PUNCT	O
11.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.74	B-OUT	NUM	O
]	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
6-month	I-OUT	ADJ	O
mortality	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
[	O	PUNCT	O
9	O	NUM	O
(	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
vs.	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
19.6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.99	O	NUM	O
]	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
CsA	O	NOUN	B
vs.	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
prethrombolytic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
CsA	O	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	B-OUT	DET	O
infarct	I-OUT	NOUN	B
size	I-OUT	NOUN	I
or	O	CCONJ	O
any	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
dried	B-I	VERB	B
purple	I-I	ADJ	I
carrot	I-I	NOUN	I
on	O	ADP	O
body	O	NOUN	B
mass	O	NOUN	I
,	O	PUNCT	O
lipids	O	NOUN	B
,	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
body	O	NOUN	B
composition	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
inflammatory	O	ADJ	B
markers	O	NOUN	B
in	O	ADP	O
overweight	B-P	ADJ	B
and	I-P	CCONJ	O
obese	I-P	ADJ	B
adults	I-P	NOUN	B
:	I-P	PUNCT	O
the	O	DET	O
QUENCH	O	PROPN	B
trial	O	NOUN	B
.	O	PUNCT	O


Obesity	O	NOUN	B
is	O	AUX	O
a	O	DET	O
significant	O	ADJ	B
health	O	NOUN	B
issue	O	NOUN	I
worldwide	O	ADV	O
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
chronic	O	ADJ	B
,	O	PUNCT	O
low-grade	O	ADJ	B
inflammation	O	NOUN	B
predisposing	O	VERB	B
the	O	DET	O
individual	O	NOUN	B
to	O	PART	O
cardiovascular	O	ADJ	B
disease	O	NOUN	I
and	O	CCONJ	O
impaired	O	ADJ	B
blood	O	NOUN	I
glucose	O	NOUN	I
homeostasis	O	NOUN	I
.	O	PUNCT	O


Anthocyanins	B-I	NOUN	B
and	I-I	CCONJ	O
phenolic	I-I	ADJ	B
acids	I-I	NOUN	I
from	I-I	ADP	O
purple	I-I	ADJ	B
carrots	I-I	NOUN	I
are	O	AUX	O
effective	O	ADJ	B
at	O	ADP	O
reversing	O	VERB	B
inflammation	O	NOUN	B
and	O	CCONJ	O
metabolic	O	ADJ	B
alterations	O	NOUN	B
in	O	ADP	O
animal	O	NOUN	B
models	O	NOUN	I
,	O	PUNCT	O
potentially	O	ADV	O
through	O	ADP	O
inhibition	O	NOUN	B
of	O	ADP	O
inflammatory	O	ADJ	B
pathways	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
dried	B-I	VERB	B
purple	I-I	ADJ	I
carrot	I-I	NOUN	B
on	O	ADP	O
body	B-OUT	NOUN	B
mass	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
composition	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
lipids	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
inflammatory	I-OUT	ADJ	B
markers	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
liver	I-OUT	NOUN	B
function	I-OUT	NOUN	I
tests	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
appetite	I-OUT	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
16	B-P	NUM	O
males	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
53.1	I-P	NUM	O
±	I-P	NOUN	O
7.6	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
with	I-P	ADP	O
a	I-P	DET	O
mean	I-P	ADJ	O
BMI	I-P	NOUN	B
of	I-P	ADP	O
32.8	I-P	NUM	O
±	I-P	NOUN	O
4.6	I-P	NUM	O
kg/m	I-P	NOUN	O
(	I-P	PUNCT	O
2	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
with	I-P	ADP	O
normal	I-P	ADJ	B
lipid	I-P	NOUN	I
and	I-P	CCONJ	O
inflammatory	I-P	ADJ	B
markers	I-P	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
that	O	SCONJ	O
118.5	O	NUM	O
mg/day	O	NOUN	B
of	B-I	ADP	O
anthocyanins	I-I	NOUN	B
and	O	CCONJ	O
259.2	O	NUM	O
mg/day	O	NOUN	B
of	B-I	ADP	O
phenolic	I-I	ADJ	B
acids	I-I	NOUN	I
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
statistically	O	ADV	B
significant	O	ADJ	I
changes	O	NOUN	B
in	B-OUT	ADP	O
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
composition	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
appetite	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
dietary	I-OUT	ADJ	B
intake	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
low	I-OUT	ADJ	B
density	I-OUT	NOUN	I
lipoprotein	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
total	I-OUT	ADJ	B
cholesterol	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
C-reactive	I-OUT	ADJ	B
protein	I-OUT	NOUN	I
in	O	ADP	O
these	O	DET	O
obese	O	ADJ	B
participants	O	NOUN	B
at	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
and	O	CCONJ	O
length	O	NOUN	B
of	O	ADP	I
intervention	O	NOUN	B
used	O	VERB	O
in	O	ADP	O
this	O	DET	O
trial	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


High	B-OUT	ADJ	B
density	I-OUT	NOUN	I
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Aspartate	B-OUT	NOUN	B
amino	I-OUT	NOUN	I
transferase	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
alanine	I-OUT	NOUN	B
amino	I-OUT	NOUN	I
transferase	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
intervention	O	NOUN	B
was	O	AUX	O
safe	O	ADJ	O
.	O	PUNCT	O


More	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
required	O	VERB	O
to	O	PART	O
establish	O	VERB	O
the	B-OUT	DET	O
bioavailability	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pharmacokinetic	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
of	I-I	ADP	O
purple	I-I	ADJ	B
carrot	I-I	NOUN	B
anthocyanins	I-I	NOUN	B
and	I-I	CCONJ	O
phenolic	I-I	ADJ	B
acids	I-I	NOUN	I
prior	O	ADV	O
to	O	PART	O
further	O	ADJ	O
trials	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	B-OUT	PART	O
treating	I-OUT	VERB	B
inflammation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
metabolic	I-OUT	ADJ	B
alterations	I-OUT	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
peptic	B-OUT	ADJ	B
ulcer	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
with	O	ADP	O
furazolidone	B-I	NOUN	B
.	I-I	PUNCT	O


Furazolidone	B-I	NOUN	B
(	O	PUNCT	O
FZ	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
in	O	ADP	O
China	O	PROPN	B
as	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
peptic	B-OUT	ADJ	B
ulcer	I-P	NOUN	I
disease	I-P	NOUN	I
for	O	ADP	O
about	O	ADV	O
20	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
experimental	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
has	O	AUX	O
good	O	ADJ	O
short-term	O	ADJ	B
and	O	CCONJ	O
long-term	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
both	O	CCONJ	O
human	B-P	ADJ	B
and	I-P	CCONJ	O
animal	I-OUT	ADJ	B
ulcers	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
ulcer	B-OUT	NOUN	B
healing	I-OUT	NOUN	I
rate	O	NOUN	B
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
dosage	O	NOUN	B
and	O	CCONJ	O
course	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
healing	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
a	O	DET	O
high	O	ADJ	B
dose	O	NOUN	I
,	O	PUNCT	O
2	O	NUM	O
week	O	NOUN	B
course	O	NOUN	B
is	O	AUX	O
about	O	ADV	O
70-75	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
relapse	O	NOUN	B
rate	O	NOUN	B
after	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
is	O	AUX	O
9.5	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
adverse	O	ADJ	B
reactions	O	NOUN	I
to	O	ADP	O
FZ	O	NOUN	B
are	O	AUX	O
not	O	PART	O
severe	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
are	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
in	O	ADP	O
most	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


However	O	SCONJ	O
the	O	DET	O
mutagenic	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
several	O	ADJ	O
biological	O	ADJ	B
systems	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
has	O	AUX	O
a	O	DET	O
mutagenic	B-OUT	ADJ	B
effect	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
mutagenic	O	ADJ	B
and	O	CCONJ	O
carcinogenic	B-OUT	ADJ	B
effects	O	NOUN	I
on	O	ADP	O
humans	O	NOUN	B
and	O	CCONJ	O
animals	O	NOUN	B
remain	O	VERB	O
questionable	O	ADJ	O
,	O	PUNCT	O
because	O	SCONJ	O
FZ	O	PROPN	B
has	O	AUX	O
been	O	AUX	O
biotransformed	O	VERB	B
into	O	ADP	O
other	O	ADJ	O
metabolites	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
FZ	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
peptic	B-P	ADJ	B
ulcer	I-P	NOUN	I
disease	I-P	NOUN	I
are	O	AUX	O
not	O	PART	O
fully	O	ADV	O
understood	O	VERB	O
,	O	PUNCT	O
perhaps	O	ADV	O
partly	O	ADV	O
due	O	ADP	O
to	O	PART	O
the	O	DET	O
monoamine	B-OUT	NOUN	B
oxidase	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
MAO	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
inhibitory	I-OUT	ADJ	B
reaction	I-OUT	NOUN	O
and	O	CCONJ	O
partly	O	ADV	O
to	O	PART	O
the	O	DET	O
antibacterial	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
to	I-OUT	PART	O
Helicobacter	I-OUT	NOUN	B
pylori	I-OUT	NOUN	I
(	O	PUNCT	O
HP	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
FZ	O	NOUN	B
are	O	AUX	O
still	O	ADV	O
not	O	PART	O
clear	O	ADJ	O
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	B
,	I-I	PUNCT	O
cardiopulmonary	I-I	ADJ	B
bypass	I-I	NOUN	I
and	I-I	CCONJ	O
myocardial	I-I	ADJ	B
ischaemic/reperfusion	I-I	NOUN	I
on	O	ADP	O
free	B-OUT	ADJ	B
radical	I-OUT	ADJ	I
generation	I-OUT	NOUN	I
in	O	ADP	O
CABG	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
free	O	ADJ	B
radicals	O	NOUN	I
(	O	PUNCT	O
FR	O	NOUN	B
)	O	PUNCT	O
generation	O	NOUN	O
after	O	ADP	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	O
and	O	CCONJ	O
cardiopulmonary	B-I	NOUN	B
bypass	I-I	NOUN	I
and	O	CCONJ	O
during	O	ADP	O
reperfusion	O	NOUN	B
in	O	ADP	O
CABG	B-P	NOUN	B
patients	I-P	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	VERB	O
Forty-three	B-P	NUM	O
CABG	I-P	NOUN	B
patients	I-P	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
into	O	ADP	O
an	O	DET	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	O
and	O	CCONJ	O
a	O	DET	O
control	B-I	NOUN	B
group	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
protocol	O	NOUN	B
for	O	ADP	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	B
was	O	AUX	O
two	B-I	NUM	O
cycles	I-I	NOUN	B
of	I-I	ADP	O
2-min	I-I	ADJ	O
ischaemia	I-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
3-min	I-I	ADJ	O
reperfusion	I-I	NOUN	B
.	I-I	PUNCT	O


Free	B-OUT	ADJ	B
radicals	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
electron	O	NOUN	B
spin	O	NOUN	I
resonance	O	NOUN	I
spectroscopy	O	NOUN	I
.	O	PUNCT	O


Global	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
right	I-OUT	ADJ	B
heart	I-OUT	NOUN	I
functions	I-OUT	NOUN	I
were	O	AUX	O
collected	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
free	B-OUT	ADJ	B
radicals	I-OUT	NOUN	O
generation	I-OUT	NOUN	O
in	I-OUT	ADP	O
coronary	I-OUT	ADJ	B
sinus	I-OUT	NOUN	I
blood	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	O
group	O	NOUN	B
was	O	AUX	O
9.7	O	NUM	O
and	O	CCONJ	O
16.6	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
the	O	DET	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	O
protocol	O	NOUN	O
and	O	CCONJ	O
10	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
declamping	O	NOUN	B
,	O	PUNCT	O
6.8	O	NUM	O
and	O	CCONJ	O
13.3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
free	B-OUT	ADJ	B
radicals	I-OUT	NOUN	B
in	I-OUT	ADP	O
arterial	I-OUT	ADJ	B
samples	I-OUT	NOUN	I
were	O	AUX	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
21	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
10	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
reperfusion	O	NOUN	B
.	O	PUNCT	O


Cardiac	B-OUT	ADJ	B
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
right	I-OUT	ADV	B
ventricular	I-OUT	ADJ	I
ejection	I-OUT	NOUN	I
fraction	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RVEF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
improved	O	VERB	O
by	O	ADP	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	B
.	I-I	PUNCT	O


CONCLUSION	O	NOUN	O
Both	O	CCONJ	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	B
and	O	CCONJ	O
cardiopulmonary	B-I	ADJ	B
bypass	I-I	NOUN	I
induced	O	VERB	B
free	B-OUT	ADJ	B
radicals	I-OUT	NOUN	O
generation	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Although	O	SCONJ	O
ischaemic	B-I	ADJ	B
preconditioning	I-I	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
free	B-OUT	ADJ	B
radicals	I-OUT	NOUN	O
generation	I-OUT	NOUN	O
after	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
protected	O	VERB	O
against	O	ADP	O
postoperative	O	ADJ	B
stunning	O	NOUN	B
.	O	PUNCT	O


Osteosarcoma	O	NOUN	B
:	O	PUNCT	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
muramyl	B-I	X	B
tripeptide	I-I	NOUN	I
to	O	PART	O
chemotherapy	O	NOUN	B
improves	O	VERB	B
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
--	I-OUT	PUNCT	O
a	I-OUT	DET	O
report	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Children	B-P	PROPN	B
's	I-P	PART	I
Oncology	I-P	PROPN	B
Group	I-P	PROPN	I
.	I-P	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
compare	O	VERB	O
three-drug	O	ADJ	B
chemotherapy	O	NOUN	I
with	O	ADP	O
cisplatin	B-I	NOUN	B
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
methotrexate	I-I	NOUN	B
with	O	ADP	O
four-drug	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
with	I-I	ADP	O
cisplatin	I-I	NOUN	B
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
methotrexate	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
ifosfamide	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
osteosarcoma	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
muramyl	B-I	X	B
tripeptide	I-I	NOUN	I
(	I-I	PUNCT	O
MTP	I-I	NOUN	B
)	I-I	PUNCT	O
to	O	PART	O
chemotherapy	O	NOUN	B
enhances	O	VERB	O
event-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
EFS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
in	O	ADP	O
newly	O	ADV	B
diagnosed	O	VERB	I
patients	O	NOUN	B
with	O	ADP	O
osteosarcoma	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Six	B-P	NUM	O
hundred	I-P	NUM	O
sixty-two	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
osteosarcoma	I-P	NOUN	B
without	I-P	ADP	O
clinically	I-P	ADV	B
detectable	I-P	ADJ	B
metastatic	I-P	ADJ	B
disease	I-P	NOUN	I
and	I-P	CCONJ	O
whose	I-P	DET	O
disease	I-P	NOUN	B
was	I-P	AUX	O
considered	I-P	VERB	O
resectable	I-P	ADJ	B
received	I-P	VERB	O
one	I-P	NUM	O
of	I-P	ADP	O
four	I-P	NUM	O
prospectively	I-P	ADV	O
randomized	I-P	ADJ	B
treatments	I-P	NOUN	I
.	I-P	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
identical	O	ADJ	B
cumulative	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
cisplatin	B-I	NOUN	B
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
methotrexate	I-I	NOUN	B
and	O	CCONJ	O
underwent	O	VERB	O
definitive	O	ADJ	B
surgical	O	ADJ	B
resection	O	NOUN	I
of	O	ADP	O
primary	O	ADJ	B
tumor	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	B
or	O	CCONJ	O
not	O	PART	O
to	O	PART	O
receive	B-I	VERB	O
ifosfamide	I-I	NOUN	B
and/or	I-I	CCONJ	O
MTP	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
2	O	NUM	O
x	O	NOUN	O
2	O	NUM	O
factorial	O	ADJ	O
design	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
points	O	NOUN	O
for	O	ADP	O
analysis	O	NOUN	B
were	O	AUX	O
EFS	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
analysis	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
interaction	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
examine	O	VERB	O
each	O	DET	O
intervention	O	NOUN	B
separately	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
chemotherapy	O	NOUN	B
regimens	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
similar	O	ADJ	O
EFS	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
better	O	ADJ	O
EFS	B-OUT	NOUN	B
with	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
MTP	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.08	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
MTP	O	NOUN	B
to	O	PART	O
chemotherapy	O	NOUN	B
improved	O	VERB	O
6-year	B-OUT	ADJ	B
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
from	O	ADP	O
70	O	NUM	O
%	O	NOUN	O
to	O	PART	O
78	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
hazard	B-OUT	ADJ	B
ratio	I-OUT	NOUN	I
for	I-OUT	ADP	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
with	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
MTP	O	NOUN	B
was	O	AUX	O
0.71	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.52	O	NUM	O
to	O	PART	O
0.96	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
ifosfamide	O	NOUN	B
to	O	PART	O
cisplatin	O	NOUN	B
,	O	PUNCT	O
doxorubicin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
methotrexate	O	NOUN	B
did	O	AUX	O
not	O	PART	O
enhance	O	VERB	O
EFS	B-OUT	NOUN	B
or	O	CCONJ	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
osteosarcoma	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
MTP	O	NOUN	B
to	O	PART	O
chemotherapy	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
improvement	O	NOUN	B
in	O	ADP	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
and	O	CCONJ	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
better	O	ADJ	O
EFS	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


[	O	PUNCT	O
Effect	O	NOUN	B
of	O	ADP	O
alanyl-glutamine	B-I	NOUN	B
in	O	ADP	O
postoperative	O	ADJ	B
total	O	ADJ	O
parenteral	O	ADJ	O
nutrition	O	NOUN	O
on	O	ADP	O
postoperative	O	ADJ	B
immunosuppression	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
morbidity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Preliminary	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
study	O	NOUN	O
]	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
glutamine	B-I	NOUN	B
substitution	I-I	NOUN	B
on	O	ADP	O
postoperative	O	ADJ	B
immunosuppression	O	NOUN	B
and	O	CCONJ	O
morbidity	O	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
surgical	I-P	ADJ	B
interventions	I-P	NOUN	I
and	I-P	CCONJ	O
total	I-P	ADJ	O
parenteral	I-P	ADJ	B
nutrition	I-P	NOUN	I
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
analyze	O	VERB	O
immune	O	ADJ	B
competence	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
CD3	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
CD4	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
CD8	I-OUT	NOUN	B
on	I-OUT	ADP	O
lymphocytes	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
of	I-OUT	ADP	O
HLA-DR	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
CD14	I-OUT	NOUN	B
on	I-OUT	ADP	O
monocytes	I-OUT	NOUN	B
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
IL-6	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
IL-10	I-OUT	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
before	O	ADP	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
7	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
34	B-P	NUM	O
patients	I-P	NOUN	B
have	I-P	AUX	O
been	I-P	AUX	O
included	I-P	VERB	O
(	I-I	PUNCT	O
with	I-I	ADP	O
glutamine	I-I	NOUN	B
:	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
18	I-I	NUM	O
;	I-I	PUNCT	O
without	I-I	ADP	O
glutamine	I-I	NOUN	B
:	I-I	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
16	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
glutamine	I-I	NOUN	B
substitution	I-I	NOUN	B
showed	O	VERB	O
decreased	B-OUT	VERB	B
systemic	I-OUT	ADJ	B
inflammation	I-OUT	NOUN	I
,	O	PUNCT	O
significant	O	ADJ	B
faster	O	ADJ	O
compensation	B-OUT	NOUN	B
for	I-OUT	ADP	O
postoperative	I-OUT	ADJ	B
immunosuppression	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
lower	I-OUT	ADJ	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
postoperative	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Patients	O	NOUN	B
without	O	ADP	O
postoperative	O	ADJ	B
complications	O	NOUN	B
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
postoperative	O	ADJ	B
immunosuppression	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Association	O	NOUN	B
between	O	ADP	O
frequency	O	NOUN	B
of	O	ADP	O
ready-to-eat	O	ADJ	B
cereal	O	NOUN	I
consumption	O	NOUN	B
,	O	PUNCT	O
nutrient	O	ADJ	B
intakes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
body	B-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
in	O	ADP	O
fourth-	B-P	NOUN	O
to	I-P	ADP	O
sixth-grade	I-P	ADJ	B
low-income	I-P	ADJ	B
minority	I-P	NOUN	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
consumption	O	NOUN	B
of	O	ADP	O
non-ready-to-eat	O	NOUN	B
cereal	O	NOUN	B
and	O	CCONJ	O
ready-to-eat	B-I	ADJ	B
cereal	I-I	NOUN	I
(	I-I	PUNCT	O
RTEC	I-I	NOUN	B
)	I-I	PUNCT	O
breakfasts	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
nutrient	B-OUT	ADJ	B
intakes	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
lower	I-OUT	ADJ	B
body	I-OUT	NOUN	I
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BMI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


These	O	DET	O
relationships	O	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
low-income	B-P	ADJ	B
minority	I-P	NOUN	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
,	O	PUNCT	O
in	O	ADP	O
low-income	B-P	ADJ	B
minority	I-P	NOUN	O
children	I-P	NOUN	B
,	O	PUNCT	O
whether	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
relationship	O	NOUN	B
among	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
RTEC	B-I	NOUN	B
consumption	O	NOUN	B
and	O	CCONJ	O
nutrient	O	ADJ	B
intakes	O	NOUN	O
measured	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
whether	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
RTEC	B-I	NOUN	B
and	O	CCONJ	O
BMI	B-OUT	NOUN	B
controlling	O	VERB	B
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
ethnicity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
energy	O	NOUN	B
intake	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
longitudinal	O	ADJ	B
study	O	NOUN	I
design	O	NOUN	O
where	O	SCONJ	O
a	O	DET	O
cohort	O	NOUN	B
was	O	AUX	O
followed	O	VERB	O
for	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


SUBJECTS/SETTING	O	NOUN	B
Participants	B-P	NOUN	B
were	I-P	AUX	O
625	I-P	NUM	O
fourth-	I-P	VERB	O
through	I-P	ADP	O
sixth-grade	I-P	ADJ	B
,	I-P	PUNCT	O
low-income	I-P	ADJ	B
children	I-P	NOUN	B
living	I-P	VERB	O
in	I-P	ADP	O
San	I-P	PROPN	B
Antonio	I-P	PROPN	I
,	I-P	PUNCT	O
Texas	I-P	PROPN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
control	I-P	ADJ	B
arm	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
Bienestar	I-P	PROPN	B
Diabetes	I-P	PROPN	I
Prevention	I-P	PROPN	I
Program	I-P	PROPN	I
's	I-P	PART	I
cluster	I-P	NOUN	I
randomized	I-P	ADJ	B
trial	I-P	NOUN	I
.	I-P	PUNCT	O


Three	O	NUM	O
multiple-pass	O	ADJ	B
24-hour	O	ADJ	I
dietary	O	ADJ	O
recalls	O	NOUN	O
were	O	AUX	O
collected	O	VERB	B
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
fourth-grade	O	ADJ	O
year	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
fifth-	O	NOUN	O
and	O	CCONJ	O
sixth-grade	O	ADJ	O
years	O	NOUN	B
.	O	PUNCT	O


Children	B-P	NOUN	B
's	I-P	PART	I
age	I-P	NOUN	B
,	I-P	PUNCT	O
sex	I-P	NOUN	B
,	I-P	PUNCT	O
ethnicity	I-P	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
height	O	NOUN	B
and	O	CCONJ	O
weight	O	NOUN	B
(	O	PUNCT	O
used	O	VERB	O
to	O	PART	O
calculate	O	VERB	B
BMI	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
collected	O	VERB	O
between	O	ADP	O
August	O	PROPN	O
2001	O	NUM	O
and	O	CCONJ	O
May	O	PROPN	O
2004	O	NUM	O
.	O	PUNCT	O


STATISTICAL	O	NOUN	B
ANALYSES	O	NOUN	I
PERFORMED	O	VERB	O
Descriptive	O	ADJ	O
and	O	CCONJ	O
inferential	O	ADJ	B
statistical	O	ADJ	O
analyses	O	NOUN	O
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
breakfast	O	NOUN	B
consumption	O	NOUN	I
was	O	AUX	O
examined	O	VERB	O
using	O	VERB	O
a	O	DET	O
6×4	O	NUM	O
cross-tabulation	O	ADJ	B
table	O	NOUN	O
with	O	ADP	O
χ	O	DET	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
test	O	NOUN	O
to	O	PART	O
establish	O	VERB	O
categorical	O	ADJ	B
differences	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
association	O	NOUN	B
between	B-OUT	ADP	O
BMI	I-OUT	NOUN	B
percentile	O	NOUN	B
and	O	CCONJ	O
frequency	O	NOUN	B
of	B-I	ADP	O
RTEC	I-I	NOUN	B
consumption	O	NOUN	B
adjusted	O	VERB	O
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
ethnicity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
nutrition-related	O	ADJ	B
parameters	O	NOUN	I
were	O	AUX	O
calculated	O	VERB	B
using	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
correlation	O	NOUN	O
multivariate	O	ADJ	O
linear	O	ADJ	O
model	O	NOUN	O
analysis	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
positive	O	ADJ	B
relationship	O	NOUN	B
between	O	ADP	O
the	B-OUT	DET	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
RTEC	I-OUT	NOUN	B
consumption	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
nutrient	I-OUT	ADJ	B
intakes	I-OUT	NOUN	O
measured	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
also	O	ADV	O
a	O	DET	O
significant	O	ADJ	O
inverse	O	ADJ	B
relationship	O	NOUN	B
between	B-OUT	ADP	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
RTEC	I-OUT	NOUN	B
consumption	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
BMI	I-OUT	NOUN	B
percentile	I-OUT	NOUN	B
over	O	ADP	O
the	O	DET	O
cumulative	O	ADJ	B
3-year	O	ADJ	B
period	O	NOUN	B
controlling	O	VERB	B
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
ethnicity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
energy	O	NOUN	B
intake	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	B-P	NOUN	O
Children	I-P	NOUN	B
who	O	PRON	O
frequently	O	ADV	O
consumed	B-I	VERB	O
RTEC	I-I	NOUN	B
had	O	AUX	O
greater	O	ADJ	O
intakes	O	NOUN	B
of	B-OUT	ADP	O
essential	I-OUT	ADJ	B
nutrients	I-OUT	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
significantly	O	ADV	O
lower	B-OUT	ADJ	O
BMI	I-OUT	NOUN	B
over	O	ADP	O
a	O	DET	O
3-year	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinician	O	NOUN	B
's	O	PART	O
decision	O	NOUN	B
of	O	ADP	O
whether	O	SCONJ	O
CHOP	B-I	NOUN	B
chemotherapy	I-I	NOUN	B
should	O	AUX	O
be	O	AUX	O
standard	O	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
treatment	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
diffuse	I-OUT	ADJ	B
histiocytic	I-OUT	ADJ	I
lymphoma	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Icosapent	B-I	NOUN	B
Ethyl	I-I	NOUN	I
(	I-I	PUNCT	O
Eicosapentaenoic	I-I	PROPN	B
Acid	I-I	PROPN	I
Ethyl	I-I	PROPN	I
Ester	I-I	NOUN	I
)	I-I	PUNCT	O
:	I-I	PUNCT	O
Effects	O	NOUN	B
Upon	O	SCONJ	I
High-Sensitivity	O	NOUN	B
C-Reactive	O	NOUN	I
Protein	O	NOUN	I
and	O	CCONJ	O
Lipid	O	NOUN	B
Parameters	O	PROPN	B
in	O	ADP	O
Patients	B-P	NOUN	B
With	I-P	ADP	O
Metabolic	I-P	PROPN	B
Syndrome	I-P	PROPN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
analysis	O	NOUN	B
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
icosapent	B-I	NOUN	B
ethyl	I-I	NOUN	I
(	I-I	PUNCT	O
eicosapentaenoic	I-I	ADJ	B
acid	I-I	NOUN	I
ethyl	I-I	NOUN	I
ester	I-I	NOUN	I
,	I-I	PUNCT	O
IPE	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
high-sensitivity	O	ADJ	B
C-reactive	O	ADJ	I
protein	O	NOUN	I
(	O	PUNCT	O
hsCRP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
lipid	O	NOUN	B
parameters	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metabolic	I-P	ADJ	B
syndrome	I-P	NOUN	I
,	I-P	PUNCT	O
with	I-P	ADP	O
and	I-P	CCONJ	O
without	I-P	ADP	O
stable	I-P	ADJ	B
statin	I-P	NOUN	B
therapy	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
post	O	NOUN	B
hoc	O	NOUN	I
exploratory	O	ADJ	I
analysis	O	NOUN	I
evaluated	O	VERB	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metabolic	I-P	ADJ	B
syndrome	I-P	NOUN	I
treated	I-P	VERB	B
with	I-P	ADP	I
IPE	I-I	NOUN	B
4	I-P	NUM	O
grams/day	I-P	NOUN	B
,	I-P	PUNCT	O
IPE	I-P	NOUN	B
2	I-P	NUM	O
grams/day	I-P	NOUN	B
,	I-P	PUNCT	O
or	I-P	CCONJ	O
placebo	I-I	NOUN	B
in	I-P	ADP	O
phase	I-P	NOUN	B
3	I-P	NUM	I
,	I-P	PUNCT	O
randomized	I-P	ADJ	B
,	I-P	PUNCT	O
placebo-controlled	I-P	ADJ	B
studies	I-P	NOUN	I
entitled	I-P	VERB	O
:	I-P	PUNCT	O
MARINE	I-P	NOUN	B
[	I-P	PUNCT	O
triglyceride	I-P	NOUN	O
(	I-P	PUNCT	O
TG	I-P	NOUN	B
)	I-P	PUNCT	O
levels	I-P	NOUN	B
≥500	I-P	NUM	O
and	I-P	CCONJ	O
≤2000	I-P	ADJ	O
mg/dL	I-P	NOUN	O
]	I-P	PUNCT	O
and	I-P	CCONJ	O
ANCHOR	I-P	PROPN	B
[	I-P	PUNCT	O
TG	I-P	NOUN	B
levels	I-P	NOUN	B
≥200	I-P	VERB	O
and	I-P	CCONJ	O
<	I-P	X	O
500	I-P	NUM	O
mg/dL	I-P	NOUN	O
,	I-P	PUNCT	O
despite	I-P	SCONJ	O
low-density	I-P	ADJ	B
lipoprotein	I-P	NOUN	I
cholesterol	I-P	NOUN	I
(	I-P	PUNCT	O
LDL-C	I-P	NOUN	B
)	I-P	PUNCT	O
control	I-P	NOUN	O
with	I-P	ADP	O
stable	I-P	ADJ	O
statin	I-P	NOUN	O
therapy	O	NOUN	O
]	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
Compared	B-I	VERB	O
with	I-I	ADP	O
placebo	I-P	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
metabolic	I-P	ADJ	B
syndrome	I-P	NOUN	I
in	I-P	ADP	O
MARINE	I-P	NOUN	B
(	I-P	PUNCT	O
n=204	I-P	PROPN	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
ANCHOR	I-P	PROPN	B
(	O	PUNCT	O
n=645	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
approved	O	VERB	B
dose	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
grams/day	O	NOUN	B
,	O	PUNCT	O
IPE	O	NOUN	B
significantly	B-OUT	ADV	O
lowered	I-OUT	VERB	B
hsCRP	I-OUT	NOUN	B
levels	O	NOUN	B
40.0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P=0.0007	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
MARINE	O	NOUN	B
and	O	CCONJ	O
23.0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P=0.0003	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
ANCHOR	O	PROPN	B
.	O	PUNCT	O


Compared	B-I	VERB	B
with	I-I	ADP	O
placebo	O	NOUN	B
in	O	ADP	O
MARINE	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
included	O	VERB	O
patients	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
statin	B-I	NOUN	B
therapy	I-I	NOUN	I
,	O	PUNCT	O
IPE	O	NOUN	B
4	O	NUM	O
grams/day	O	NOUN	B
significantly	B-OUT	ADV	O
reduced	I-OUT	VERB	B
hsCRP	I-OUT	NOUN	B
levels	O	NOUN	B
78.0	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
statin-treated	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
P=0.0035	O	NOUN	O
,	O	PUNCT	O
n=16	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Compared	B-I	VERB	B
with	I-I	ADP	O
placebo	O	NOUN	B
in	O	ADP	O
MARINE	O	NOUN	B
,	O	PUNCT	O
IPE	O	NOUN	B
4	O	NUM	O
grams/day	O	NOUN	B
significantly	B-OUT	ADV	O
reduced	I-OUT	VERB	O
TG	O	NOUN	B
levels	O	NOUN	B
(	O	PUNCT	O
35.0	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	B-OUT	NOUN	O
<	I-OUT	X	O
0.0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
non-high-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
non-HDL-C	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
19.9	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	B-OUT	NOUN	O
<	I-OUT	X	O
0.0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
apolipoprotein	I-OUT	NOUN	B
B	O	NOUN	I
levels	O	NOUN	I
(	O	PUNCT	O
ApoB	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
9.1	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.0015	O	NOUN	O
)	O	PUNCT	O
without	B-OUT	ADP	O
raising	I-OUT	VERB	O
LDL-C	I-OUT	NOUN	B
levels	O	NOUN	O
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
in	B-I	ADP	O
ANCHOR	I-I	NOUN	B
,	O	PUNCT	O
IPE	O	NOUN	B
4	O	NUM	O
grams/day	O	NOUN	B
significantly	B-OUT	ADV	O
reduced	I-OUT	VERB	B
TG	O	NOUN	B
(	O	PUNCT	O
21.7	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	B-OUT	NOUN	O
<	I-OUT	X	O
0.0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	O	PUNCT	O
non-HDL-C	O	NOUN	B
(	O	PUNCT	O
13.5	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	B-OUT	NOUN	O
<	I-OUT	X	O
0.0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	O	PUNCT	O
ApoB	O	NOUN	B
(	O	PUNCT	O
8.8	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	B-OUT	NOUN	O
<	I-OUT	X	O
0.0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	O	PUNCT	O
LDL-C	O	NOUN	B
(	O	PUNCT	O
5.2	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.0236	B-OUT	X	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
HDL-C	I-OUT	NOUN	B
levels	O	NOUN	B
(	O	PUNCT	O
4.0	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P=0.0053	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
IPE	O	NOUN	B
4	O	NUM	O
grams/day	O	NOUN	B
significantly	O	ADV	O
lowered	O	VERB	B
hsCRP	O	NOUN	B
levels	O	NOUN	B
and	O	CCONJ	O
improved	O	VERB	B
lipids	O	NOUN	B
without	O	ADP	O
raising	O	VERB	O
LDL-C	O	NOUN	B
levels	B-P	NOUN	O
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
metabolic	I-P	ADJ	B
syndrome	I-P	NOUN	I
and	I-P	CCONJ	O
high	I-P	ADJ	B
(	I-P	PUNCT	O
≥200	I-P	NOUN	O
and	I-P	CCONJ	O
<	I-P	X	O
500	I-P	NUM	O
mg/dL	I-P	NOUN	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
very	I-P	ADV	B
high	I-P	ADJ	I
(	I-P	PUNCT	O
≥500	I-P	NUM	O
and	I-P	CCONJ	O
≤2000	I-P	ADJ	O
mg/dL	I-P	NOUN	O
)	I-P	PUNCT	O
TG	I-P	NOUN	B
levels	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
or	I-P	CCONJ	O
without	I-P	ADP	O
stable	I-P	ADJ	B
statin	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Does	O	AUX	O
temporary	B-I	ADJ	B
clamping	I-I	NOUN	B
of	I-I	ADP	O
drains	I-I	NOUN	B
following	O	VERB	O
knee	O	NOUN	B
arthroplasty	O	NOUN	I
reduce	O	VERB	B
blood	O	NOUN	B
loss	O	NOUN	I
?	O	PUNCT	O
A	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
blinded	O	VERB	B
study	O	NOUN	I
76	B-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
primary	I-P	ADJ	O
total	I-P	ADJ	O
knee	I-P	NOUN	O
arthroplasty	I-P	NOUN	O
were	I-P	AUX	O
assigned	I-P	VERB	O
to	O	PART	O
either	O	CCONJ	O
immediate	B-I	ADJ	B
drain	I-I	NOUN	B
opening	I-I	NOUN	I
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
45	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
drains	I-I	NOUN	B
opened	I-I	VERB	B
at	I-I	ADP	O
2	I-I	NUM	O
h	I-I	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
31	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
for	O	ADP	O
the	O	DET	O
volume	B-OUT	NOUN	B
of	I-OUT	ADP	O
drained	I-OUT	VERB	B
blood	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
transfusion	I-OUT	NOUN	B
requirements	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
knee	I-OUT	NOUN	B
motion	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
wound	I-OUT	NOUN	B
status	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
practice	O	NOUN	B
of	O	ADP	O
clamping	B-I	NOUN	B
drains	I-I	NOUN	B
has	O	AUX	O
no	O	DET	O
benefit	O	NOUN	O
in	O	ADP	O
routine	O	ADJ	B
knee	O	NOUN	B
arthroplasty	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
faced	O	VERB	O
with	O	ADP	O
immediate	O	ADJ	B
brisk	O	ADJ	B
blood	B-OUT	NOUN	I
loss	I-OUT	NOUN	I
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
drains	B-I	NOUN	B
can	O	AUX	O
be	O	AUX	O
clamped	O	VERB	B
without	O	ADP	O
any	O	DET	O
excess	O	ADJ	B
morbidity	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
temafloxacin	B-I	NOUN	B
and	O	CCONJ	O
ciprofloxacin	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
pharmacokinetics	O	NOUN	B
of	O	ADP	O
caffeine	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
number	O	NOUN	O
of	O	ADP	O
quinolone	O	ADJ	B
antibacterial	O	ADJ	B
agents	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
enoxacin	O	NOUN	B
,	O	PUNCT	O
pefloxacin	O	NOUN	B
,	O	PUNCT	O
pipemidic	O	ADJ	B
acid	O	NOUN	I
and	O	CCONJ	O
ciprofloxacin	B-I	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
decrease	O	VERB	B
the	O	DET	O
clearance	O	NOUN	B
of	O	ADP	O
methylxanthines	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
temafloxacin	B-I	NOUN	B
and	I-I	CCONJ	O
ciprofloxacin	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
pharmacokinetics	O	NOUN	B
of	O	ADP	O
caffeine	O	NOUN	B
were	O	AUX	O
therefore	O	ADV	O
compared	O	VERB	B
in	O	ADP	O
a	O	DET	O
3-way	O	ADJ	O
crossover	O	NOUN	B
study	O	NOUN	I
in	O	ADP	O
12	B-P	NUM	O
healthy	I-P	ADJ	B
young	I-P	ADJ	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


Each	O	DET	O
volunteer	O	NOUN	B
received	O	VERB	O
183mg	B-I	ADJ	O
once-daily	I-I	ADJ	B
doses	I-I	NOUN	I
of	I-I	ADP	O
caffeine	I-I	NOUN	B
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
twice-daily	O	ADJ	B
placebo	B-I	NOUN	B
,	I-I	PUNCT	O
temafloxacin	I-I	NOUN	B
600mg	I-I	ADJ	O
and	I-I	CCONJ	O
ciprofloxacin	I-I	NOUN	B
750mg	I-I	ADJ	O
in	O	ADP	O
3	O	NUM	O
separate	O	ADJ	O
phases	O	NOUN	B
according	O	VERB	O
to	O	PART	O
a	O	DET	O
randomised	O	ADJ	B
sequence	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
doubling	O	NOUN	B
of	O	ADP	O
the	O	DET	O
area	B-OUT	NOUN	B
under	I-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
concentration-time	I-OUT	NOUN	O
curve	I-OUT	NOUN	O
(	O	PUNCT	O
77.8	O	NUM	O
vs	O	CCONJ	O
31.8	O	NUM	O
mg/L.h	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
terminal-phase	B-OUT	NOUN	B
half-life	I-OUT	NOUN	B
(	O	PUNCT	O
9.7	O	NUM	O
vs	O	CCONJ	O
4.5h	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
caffeine	B-I	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
ciprofloxacin	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
magnitude	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
intrinsic	I-OUT	ADJ	B
clearance	I-OUT	NOUN	I
of	I-OUT	ADP	O
caffeine	I-OUT	NOUN	B
produced	O	VERB	O
by	O	ADP	O
ciprofloxacin	B-I	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
described	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
for	O	ADP	O
ciprofloxacin	B-I	NOUN	B
and	I-I	CCONJ	O
theophylline	I-I	NOUN	B
.	I-I	PUNCT	O


This	O	DET	O
may	O	AUX	O
partly	O	ADV	O
be	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
intertrial	O	ADJ	B
differences	O	NOUN	O
in	O	ADP	O
dosage	O	NOUN	B
and	O	CCONJ	O
study	O	NOUN	B
design	O	NOUN	I
.	O	PUNCT	O


Coadministration	O	NOUN	B
of	O	ADP	O
temafloxacin	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
any	O	DET	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
pharmacokinetics	B-OUT	NOUN	B
of	I-OUT	ADP	O
caffeine	I-OUT	NOUN	B
,	O	PUNCT	O
confirming	O	VERB	O
results	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
studies	O	NOUN	B
suggesting	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
agent	O	NOUN	B
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
methylxanthine	B-OUT	NOUN	B
clearance	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
appears	O	VERB	O
that	O	SCONJ	O
restriction	O	NOUN	B
of	O	ADP	O
caffeine	O	NOUN	B
intake	O	NOUN	O
during	O	ADP	O
temafloxacin	B-I	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
not	O	PART	O
necessary	O	ADJ	O
.	O	PUNCT	O


Combination	B-I	NOUN	B
chemotherapy	I-I	NOUN	I
and	O	CCONJ	O
ALVAC-CEA/B7.1	B-I	NOUN	B
vaccine	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
vaccines	B-I	NOUN	B
and	O	CCONJ	O
chemotherapy	B-I	NOUN	B
holds	O	VERB	O
promise	O	NOUN	O
for	O	ADP	O
cancer	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cytotoxic	O	ADJ	B
chemotherapy	O	NOUN	I
on	O	ADP	O
vaccine-induced	O	ADJ	B
antitumor	O	NOUN	B
immunity	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
systemic	O	ADJ	B
chemotherapy	O	NOUN	I
on	O	ADP	O
ALVAC-CEA/B7.1-induced	O	ADJ	O
T-cell	O	NOUN	B
immunity	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


EXPERIMENTAL	O	NOUN	B
DESIGN	O	VERB	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
fluorouracil	B-I	NOUN	B
,	I-I	PUNCT	O
leucovorin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
irinotecan	I-I	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
also	O	ADV	O
given	O	VERB	O
ALVAC-CEA/B7.1	B-I	NOUN	B
vaccine	I-I	NOUN	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
tetanus	I-I	NOUN	B
toxoid	I-I	NOUN	B
adjuvant	I-I	NOUN	B
.	I-I	PUNCT	O


Eligible	O	ADJ	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
ALVAC	B-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
chemotherapy	I-I	NOUN	B
and	I-I	CCONJ	O
booster	I-I	NOUN	B
vaccination	I-I	NOUN	B
(	I-I	PUNCT	O
group	I-I	NOUN	B
1	I-I	NUM	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
ALVAC	I-I	NOUN	B
and	I-I	CCONJ	O
tetanus	I-I	NOUN	B
toxoid	I-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
chemotherapy	I-I	NOUN	B
(	I-I	PUNCT	O
group	I-I	NOUN	B
2	I-I	NUM	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
chemotherapy	I-I	NOUN	B
alone	I-I	ADV	O
followed	I-I	VERB	O
by	I-I	ADP	O
ALVAC	I-I	NOUN	B
in	I-I	ADP	O
patients	I-I	NOUN	B
without	I-I	ADP	O
disease	I-I	NOUN	B
progression	I-I	NOUN	I
(	I-I	PUNCT	O
group	I-I	NOUN	B
3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Humoral	O	ADJ	B
immune	O	ADJ	I
responses	O	NOUN	I
were	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
standard	O	ADJ	O
ELISA	B-I	NOUN	B
assay	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
carcinoembryonic	O	ADJ	B
antigen	O	NOUN	I
(	O	PUNCT	O
CEA	O	NOUN	B
)	O	PUNCT	O
-specific	O	ADJ	O
T-cell	O	NOUN	B
responses	O	NOUN	B
were	O	AUX	O
measured	O	VERB	O
by	O	ADP	O
IFN-gamma	B-I	NOUN	B
enzyme-linked	I-I	ADJ	O
immunospot	I-I	NOUN	B
assay	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
eighteen	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	DET	O
ALVAC	B-I	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
concomitantly	O	ADV	O
with	O	ADP	O
chemotherapy	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
39	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
ALVAC	B-I	NOUN	B
with	O	ADP	O
tetanus	B-I	NOUN	B
adjuvant	I-I	NOUN	O
before	O	ADP	O
and	O	CCONJ	O
concomitantly	O	ADV	O
with	O	ADP	O
chemotherapy	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
40	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
chemotherapy	B-I	NOUN	B
followed	O	VERB	O
by	O	ADP	O
ALVAC	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
39	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Serious	B-OUT	ADJ	B
adverse	I-OUT	ADJ	I
events	I-OUT	NOUN	I
were	O	AUX	O
largely	O	ADV	O
gastrointestinal	B-OUT	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
30	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
hematologic	B-OUT	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
24	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
42	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
40.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
showed	O	VERB	O
objective	O	ADJ	O
clinical	O	ADJ	B
responses	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
developed	O	VERB	O
antibody	B-OUT	NOUN	B
responses	I-OUT	NOUN	I
against	I-OUT	ADP	O
ALVAC	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
increased	O	VERB	B
anti-CEA	B-OUT	ADJ	B
antibody	I-OUT	NOUN	I
titers	I-OUT	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
only	O	ADV	O
three	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Increases	O	NOUN	B
in	O	ADP	O
CEA-specific	B-OUT	ADJ	B
T	I-OUT	NOUN	O
cells	I-OUT	NOUN	O
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
37	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
groups	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
clinical	O	ADJ	B
or	O	CCONJ	O
immune	O	ADJ	B
responses	O	NOUN	I
between	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
ALVAC-CEA/B7.1	B-I	NOUN	B
vaccine	I-I	NOUN	B
and	O	CCONJ	O
systemic	O	ADJ	B
chemotherapy	B-I	NOUN	I
has	O	AUX	O
an	O	DET	O
acceptable	O	ADJ	O
safety	O	NOUN	B
profile	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Systemic	O	ADJ	B
chemotherapy	O	NOUN	I
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
generation	O	NOUN	B
of	O	ADP	O
CEA-specific	B-OUT	ADJ	B
T-cell	I-OUT	NOUN	I
responses	I-OUT	NOUN	B
following	O	VERB	O
vaccination	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
evening	B-I	NOUN	B
primrose	I-I	NOUN	I
oil	I-I	NOUN	I
(	I-I	PUNCT	O
gamma	I-I	NOUN	B
linolenic	I-I	ADJ	I
acid	I-I	NOUN	I
)	I-I	PUNCT	O
and	I-I	CCONJ	O
fish	I-I	NOUN	B
oil	I-I	NOUN	I
(	I-I	PUNCT	O
eicosapentaenoic	I-I	ADJ	B
+	I-I	CCONJ	O
docahexaenoic	I-I	ADJ	B
acid	I-I	NOUN	I
)	I-I	PUNCT	O
versus	I-I	CCONJ	O
magnesium	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
versus	I-I	ADP	O
placebo	I-I	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
pre-eclampsia	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
a	O	DET	O
placebo	B-I	NOUN	B
controlled	O	VERB	O
,	O	PUNCT	O
partially	O	ADV	O
double-blinded	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
evening	I-I	NOUN	B
primrose	I-I	NOUN	B
oil	I-I	NOUN	I
and	I-I	CCONJ	O
fish	I-I	NOUN	B
oil	I-I	NOUN	I
was	I-I	AUX	O
compared	I-I	VERB	O
to	I-I	PART	O
Magnesium	I-I	NOUN	B
Oxide	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
to	I-I	PART	O
a	I-I	DET	O
Placebo	I-I	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
Pre-Eclampsia	B-OUT	NOUN	B
of	I-OUT	ADP	O
Pregnancy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


All	O	DET	O
were	O	AUX	O
given	O	VERB	O
as	O	ADP	O
nutritional	O	ADJ	B
supplements	O	NOUN	I
for	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
to	O	ADP	O
a	O	DET	O
group	B-P	NOUN	B
of	I-P	ADP	O
primiparous	I-P	ADJ	B
and	I-P	CCONJ	O
multiparous	I-P	ADJ	B
pregnant	I-P	ADJ	O
women	I-P	NOUN	B
.	I-P	PUNCT	O


Some	B-P	DET	O
of	I-P	ADP	O
these	I-P	DET	O
women	I-P	NOUN	B
had	I-P	AUX	O
personal	I-P	ADJ	B
or	I-P	CCONJ	O
family	I-P	NOUN	B
histories	I-P	NOUN	I
of	I-P	ADP	O
hypertension	I-P	NOUN	B
(	I-P	PUNCT	O
21	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Only	B-P	ADV	O
those	I-P	DET	O
patients	I-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
prenatal	I-P	ADJ	B
care	I-P	NOUN	I
at	I-P	ADP	O
the	I-P	DET	O
Central	I-P	PROPN	B
Maternity	I-P	PROPN	I
Hospital	I-P	PROPN	I
for	I-P	ADP	O
Luanda	I-P	PROPN	B
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
Placebo	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
29	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
mixture	O	NOUN	O
of	O	ADP	O
evening	B-I	NOUN	O
primrose	I-I	NOUN	B
oil	I-I	NOUN	I
and	O	CCONJ	O
fish	B-I	NOUN	B
oil	I-I	NOUN	I
containing	O	VERB	O
Gamma-linolenic	B-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
GLA	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
Eicosapentaenoic	I-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
EPA	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Docosahexaenoic	B-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
DHA	I-I	NOUN	B
)	I-I	PUNCT	O
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
lower	O	ADJ	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
edema	I-OUT	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
Magnesium	B-I	NOUN	B
Oxide	I-I	NOUN	I
had	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
fewer	O	ADJ	O
subjects	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
hypertension	B-OUT	NOUN	B
of	I-OUT	ADP	O
pregnancy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


There	O	PRON	O
were	O	AUX	O
3	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
eclampsia	B-OUT	NOUN	B
,	O	PUNCT	O
all	O	DET	O
in	O	ADP	O
the	O	DET	O
Placebo	B-I	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Does	O	AUX	O
tetanus	B-I	NOUN	B
immune	I-I	ADJ	B
globulin	I-I	NOUN	I
interfere	O	VERB	B
with	O	ADP	I
the	O	DET	O
immune	B-OUT	ADJ	B
response	I-OUT	NOUN	I
to	O	PART	O
simultaneous	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
tetanus-diphtheria	B-I	ADJ	B
vaccine	I-I	NOUN	B
?	O	PUNCT	O
A	O	DET	O
comparative	O	ADJ	B
clinical	O	ADJ	I
trial	B-P	NOUN	I
in	I-P	ADP	O
adults	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
wounds	O	NOUN	B
,	O	PUNCT	O
sometimes	O	ADV	O
it	O	PRON	O
is	O	AUX	O
recommended	O	VERB	O
to	O	PART	O
give	O	VERB	O
an	O	DET	O
adult-type	O	ADJ	B
tetanus-diphtheria	B-I	NOUN	B
(	I-I	PUNCT	O
Td	I-I	NOUN	B
)	I-I	PUNCT	O
vaccine	I-I	NOUN	B
dose	O	NOUN	B
plus	O	CCONJ	O
tetanus	B-I	NOUN	B
immune	I-I	ADJ	O
globulin	I-I	NOUN	O
(	I-I	PUNCT	O
TIG	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Sixty	B-P	NUM	B
and	I-P	CCONJ	O
59	I-P	NUM	O
healthy	I-P	ADJ	B
young	I-P	ADJ	B
adults	I-P	NOUN	I
previously	I-P	ADV	O
immunized	I-P	VERB	B
against	I-P	ADP	O
tetanus	I-P	NOUN	B
(	I-P	PUNCT	O
T	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
diphtheria	I-P	NOUN	B
(	I-P	PUNCT	O
D	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	PART	O
receive	I-I	VERB	O
intramuscularly	I-I	ADV	B
either	I-I	CCONJ	O
Td	I-I	ADJ	B
vaccine	I-I	NOUN	B
alone	I-I	ADV	O
(	I-I	PUNCT	O
group	I-I	NOUN	B
1	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
Td	I-I	NOUN	B
vaccine	I-I	NOUN	B
plus	I-I	CCONJ	O
500	I-I	NUM	O
IU	I-I	NOUN	B
of	I-I	ADP	O
TIG	I-I	NOUN	B
(	I-I	PUNCT	O
group	I-I	NOUN	B
2	I-I	NUM	O
)	I-I	PUNCT	O
simultaneously	I-I	ADV	B
.	I-I	PUNCT	O


Antitoxin	B-OUT	NOUN	B
response	I-OUT	NOUN	O
was	I-I	AUX	O
assessed	I-I	VERB	B
after	I-I	ADP	O
4	I-I	NUM	O
weeks	I-I	NOUN	B
and	I-I	CCONJ	O
4	I-I	NUM	O
months	I-I	NOUN	B
.	I-I	PUNCT	O


Circulating	B-OUT	VERB	B
antibodies	I-OUT	NOUN	I
were	I-OUT	AUX	O
measured	I-OUT	VERB	B
by	I-OUT	ADP	O
enzyme-linked	I-OUT	ADJ	B
immunosorbent	I-OUT	ADJ	I
assay	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ELISA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	O	DET	O
cutoff	O	NOUN	B
of	O	ADP	O
these	O	DET	O
tests	O	NOUN	B
was	O	AUX	O
0.1	O	NUM	O
IU/mL	O	NOUN	O
.	O	PUNCT	O


Titers	O	NOUN	B
of	O	ADP	O
0.1	O	NUM	O
IU/mL	O	NOUN	O
or	O	CCONJ	O
greater	O	ADJ	O
were	O	AUX	O
considered	O	VERB	O
protective	O	ADJ	B
.	O	PUNCT	O


For	O	ADP	O
geometric	O	ADJ	B
mean	O	NOUN	I
titers	O	NOUN	I
(	O	PUNCT	O
GMT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
antibody	B-OUT	NOUN	B
titers	I-OUT	NOUN	B
below	O	ADP	O
the	O	DET	O
cutoff	O	NOUN	B
of	O	ADP	O
the	O	DET	O
assay	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
,	O	PUNCT	O
arbitrarily	O	ADV	O
,	O	PUNCT	O
0.05	O	NUM	O
IU/mL	O	NOUN	O
.	O	PUNCT	O


At	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
98	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
more	O	ADJ	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
had	O	AUX	O
circulating	B-OUT	VERB	B
T	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
D	I-OUT	NOUN	O
antitoxin	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	O	ADP	O
0.1	O	NUM	O
IU/mL	O	NOUN	O
or	O	CCONJ	O
higher	O	ADJ	B
;	O	PUNCT	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
had	O	AUX	O
titers	O	NOUN	B
above	O	ADP	O
this	O	DET	O
limit	O	NOUN	O
for	O	ADP	O
T	O	NOUN	B
and	O	CCONJ	O
D	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


At	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
percentages	O	NOUN	B
were	O	AUX	O
98	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
95	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
T	B-OUT	NOUN	B
antitoxin	I-OUT	NOUN	I
levels	I-OUT	NOUN	B
in	O	ADP	O
groups	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
whereas	O	SCONJ	O
96	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
88	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
in	O	ADP	O
groups	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
had	O	AUX	O
D	B-OUT	NOUN	B
antitoxin	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	O	ADP	O
0.1	O	NUM	O
IU/mL	O	NOUN	O
or	O	CCONJ	O
higher	O	ADJ	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
higher	O	ADJ	O
GMTs	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
at	O	ADP	O
the	O	DET	O
4-week	O	NOUN	B
assessment	O	NOUN	I
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
at	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
in	O	ADP	O
both	O	CCONJ	O
T	O	NOUN	B
and	O	CCONJ	O
D	O	NOUN	O
antitoxin	O	NOUN	O
levels	O	NOUN	O
(	O	PUNCT	O
9.91	O	NUM	O
IU/mL	O	NOUN	O
versus	O	CCONJ	O
5.60	O	NUM	O
IU/mL	O	NOUN	O
for	O	ADP	O
T	O	NOUN	B
antitoxin	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
2.86	O	NUM	O
IU/mL	O	NOUN	O
versus	O	CCONJ	O
1.45	O	NUM	O
IU/mL	O	NOUN	O
for	O	ADP	O
D	O	NOUN	B
antitoxin	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	O
resulted	O	VERB	O
from	O	ADP	O
those	O	DET	O
participants	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
(	O	PUNCT	O
<	O	X	O
0.1	O	NUM	O
IU/mL	O	NOUN	O
)	O	PUNCT	O
prevaccination	O	NOUN	B
antibody	O	NOUN	I
titers	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O


Children	B-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


II	O	NUM	O
:	O	PUNCT	O
parents	B-P	NOUN	B
are	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
distinguish	O	VERB	O
secretin	O	NOUN	B
from	O	ADP	O
placebo	O	NOUN	B
under	O	ADP	O
double-blind	O	ADJ	B
conditions	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Standardised	B-OUT	ADJ	B
measures	I-OUT	NOUN	I
of	I-OUT	ADP	O
behaviour	I-OUT	NOUN	B
have	O	AUX	O
failed	O	VERB	B
to	O	PART	O
detect	O	VERB	B
short	B-OUT	ADJ	B
term	I-OUT	NOUN	I
improvement	I-OUT	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
secretin	B-I	NOUN	B
.	I-I	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
possible	O	ADJ	O
that	O	SCONJ	O
standardised	O	VERB	B
measures	O	NOUN	I
are	O	AUX	O
insensitive	O	ADJ	O
to	O	PART	O
dimensions	O	NOUN	B
of	O	ADP	O
child	O	NOUN	B
behaviour	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
nonetheless	O	ADV	O
detectable	O	ADJ	B
by	O	ADP	O
parents	O	NOUN	B
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
ability	B-OUT	NOUN	B
of	I-OUT	ADP	O
parents	I-OUT	NOUN	B
of	I-OUT	ADP	O
children	I-OUT	NOUN	B
with	I-OUT	ADP	O
autism	I-OUT	NOUN	B
to	O	PART	O
guess	O	VERB	B
,	O	PUNCT	O
under	O	ADP	O
double	O	ADJ	O
blind	O	ADJ	B
conditions	O	NOUN	B
,	O	PUNCT	O
whether	O	SCONJ	O
their	O	PRON	O
child	O	NOUN	B
had	O	AUX	O
received	O	VERB	O
secretin	B-I	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	NOUN	O
2x2	O	NOUN	O
crossover	O	NOUN	B
randomised	O	ADJ	I
blinded	O	ADJ	I
study	O	NOUN	I
,	O	PUNCT	O
comparing	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
synthetic	B-I	ADJ	B
human	I-I	ADJ	O
secretin	I-I	NOUN	O
2	O	NUM	O
U/kg	O	NOUN	O
to	O	PART	O
placebo	B-I	NOUN	B
(	I-I	PUNCT	O
saline	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Sixty	B-P	NUM	O
two	I-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
43-103	I-P	NUM	O
months	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
received	O	VERB	O
placebo	B-I	NOUN	B
,	I-I	PUNCT	O
followed	I-I	VERB	O
six	I-I	NUM	O
weeks	I-I	NOUN	B
later	I-I	ADV	O
by	I-I	ADP	O
secretin	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
group	O	NOUN	B
2	O	NUM	O
received	O	VERB	O
secretin	B-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


At	O	ADP	O
the	O	DET	O
conclusion	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
parents	B-P	NOUN	B
were	O	AUX	O
asked	O	VERB	O
to	O	PART	O
guess	O	VERB	O
their	O	PRON	O
child	O	NOUN	B
's	O	PART	O
group	O	NOUN	B
assignment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Twenty	B-P	NUM	O
seven	I-P	NUM	O
families	I-P	NOUN	B
guessed	O	VERB	B
their	O	PRON	O
child	O	NOUN	B
's	O	PART	O
group	O	NOUN	B
assignment	O	NOUN	B
correctly	O	ADV	O
and	O	CCONJ	O
27	B-P	NUM	O
guessed	I-P	VERB	O
incorrectly	I-P	ADV	O
.	I-P	PUNCT	O


In	O	ADP	O
48	O	NUM	O
instances	O	NOUN	O
,	O	PUNCT	O
parents	O	NOUN	B
based	O	VERB	O
their	O	PRON	O
guess	O	NOUN	O
on	O	ADP	O
perceived	O	VERB	B
improvement	B-OUT	NOUN	I
;	I-OUT	PUNCT	O
in	O	ADP	O
six	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
parents	O	NOUN	B
based	O	VERB	O
their	O	PRON	O
guess	O	NOUN	O
on	O	ADP	O
perceived	O	VERB	B
deterioration	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Six	B-P	NUM	O
families	I-P	NOUN	B
saw	O	VERB	O
no	O	DET	B
difference	O	NOUN	I
after	O	ADP	O
either	O	DET	O
infusion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
offered	O	VERB	O
no	O	DET	B
guess	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
family	O	NOUN	B
dropped	O	VERB	O
out	O	ADP	O
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
infusion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
family	O	NOUN	B
was	O	AUX	O
lost	O	VERB	O
to	O	PART	O
follow	O	VERB	B
up	O	ADP	I
after	O	ADP	O
the	O	DET	O
second	O	ADJ	O
infusion	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
a	O	DET	O
controlled	O	VERB	B
setting	O	NOUN	I
,	O	PUNCT	O
parents	B-P	NOUN	B
of	I-P	ADP	O
young	I-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
are	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
distinguish	O	VERB	O
the	O	DET	O
short	B-OUT	ADJ	B
term	I-OUT	NOUN	I
behavioural	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
of	O	ADP	O
secretin	B-I	NOUN	B
from	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Acute	B-OUT	ADJ	B
rejection	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
heart	I-OUT	NOUN	B
infection	I-OUT	NOUN	I
rates	I-OUT	NOUN	I
in	O	ADP	O
FK	B-I	NOUN	B
506-	I-I	NOUN	O
versus	I-P	CCONJ	O
cyclosporine	I-I	NOUN	B
A-treated	I-I	ADJ	B
heart	I-P	NOUN	I
transplant	I-P	NOUN	I
recipients	I-P	NOUN	B
:	I-P	PUNCT	O
an	O	DET	O
endomyocardial	O	ADJ	B
biopsy	O	NOUN	I
pathologic	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
step-by-step	O	ADJ	O
introduction	O	NOUN	O
to	O	ADP	O
vegetables	B-I	NOUN	B
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
complementary	O	ADJ	B
feeding	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
early	O	ADJ	B
and	O	CCONJ	O
repeated	O	VERB	O
exposure	O	NOUN	B
.	O	PUNCT	O


Breastfeeding	B-P	NOUN	B
(	I-P	PUNCT	O
BF	I-P	NOUN	B
)	I-P	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
willingness	O	NOUN	O
to	O	PART	O
accept	O	VERB	O
vegetables	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
flavours	O	NOUN	B
delivered	O	VERB	O
via	O	ADP	O
breast	O	NOUN	B
milk	O	NOUN	I
.	O	PUNCT	O


Some	O	DET	O
mothers	B-P	NOUN	B
add	O	VERB	O
vegetables	O	NOUN	B
to	O	ADP	O
milk	O	NOUN	B
during	O	ADP	O
complementary	O	ADJ	O
feeding	O	NOUN	B
(	O	PUNCT	O
CF	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
enhance	O	VERB	B
acceptance	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
tested	O	VERB	B
a	O	DET	O
step-by-step	O	ADJ	O
exposure	O	NOUN	B
to	O	ADP	I
vegetables	B-I	NOUN	B
in	I-I	ADP	O
milk	I-I	NOUN	B
then	I-I	ADV	O
rice	I-I	NOUN	B
during	O	ADP	O
CF	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
intake	O	NOUN	B
and	O	CCONJ	O
liking	O	NOUN	B
of	O	ADP	O
vegetables	O	NOUN	B
.	O	PUNCT	O


Just	O	ADV	O
before	O	ADP	O
CF	O	NOUN	B
,	O	PUNCT	O
enrolled	B-P	VERB	O
mothers	I-P	NOUN	B
were	I-P	AUX	O
randomised	I-P	VERB	B
to	I-P	ADP	O
an	I-P	DET	O
intervention	I-P	NOUN	B
(	I-P	PUNCT	O
IG	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
18	I-P	NUM	O
;	I-P	PUNCT	O
6	I-P	NUM	O
BF	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
control	I-P	NOUN	B
group	I-P	NOUN	I
(	I-P	PUNCT	O
CG	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
18	I-P	NUM	O
;	I-P	PUNCT	O
6	I-P	NUM	O
BF	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


IG	B-P	NOUN	B
infants	O	NOUN	B
received	O	VERB	O
12	O	NUM	O
daily	O	ADJ	B
exposures	B-I	NOUN	B
to	I-I	PART	O
vegetable	I-I	ADJ	B
puree	I-I	NOUN	I
added	I-I	VERB	O
to	O	ADP	O
milk	O	NOUN	B
(	O	PUNCT	O
days	O	NOUN	B
1-12	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
then	O	ADV	O
12	O	NUM	O
×	O	NOUN	O
2	O	NUM	O
daily	O	ADJ	B
exposures	B-I	NOUN	B
to	I-I	PART	O
vegetable	I-I	ADJ	B
puree	I-I	NOUN	I
added	I-I	VERB	O
to	I-I	ADP	O
rice	O	NOUN	B
at	O	ADP	O
home	O	NOUN	O
(	B-I	PUNCT	O
days	I-I	NOUN	B
13-24	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Plain	B-I	ADJ	B
milk	I-I	NOUN	I
and	O	CCONJ	O
rice	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
to	O	PART	O
CG	O	NOUN	B
.	O	PUNCT	O


Then	O	ADV	O
both	O	DET	O
received	O	VERB	O
11	O	NUM	O
daily	O	ADJ	B
exposures	B-I	NOUN	B
to	I-I	PART	O
vegetable	I-I	VERB	B
puree	O	NOUN	I
.	O	PUNCT	O


Intake	O	NOUN	B
was	O	AUX	O
weighed	O	VERB	B
and	O	CCONJ	O
liking	O	VERB	B
rated	O	VERB	B
on	O	ADP	O
days	O	NOUN	B
25-26	O	NUM	O
and	O	CCONJ	O
33-35	O	NUM	O
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
CF	O	NOUN	B
in	O	ADP	O
the	O	DET	O
laboratory	O	NOUN	B
,	O	PUNCT	O
supplemented	O	VERB	O
by	O	ADP	O
the	O	DET	O
same	O	ADJ	O
data	O	NOUN	B
recorded	O	VERB	O
at	O	ADP	O
home	O	NOUN	B
.	O	PUNCT	O


Vegetables	O	NOUN	B
were	O	AUX	O
rotated	O	VERB	O
daily	O	ADV	O
(	O	PUNCT	O
carrots	O	NOUN	B
,	O	PUNCT	O
green	O	ADJ	B
beans	O	NOUN	I
,	O	PUNCT	O
spinach	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
broccoli	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Intake	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
liking	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pace	I-OUT	NOUN	B
of	O	ADP	O
eating	O	VERB	B
were	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
IG	O	NOUN	B
than	B-OUT	ADP	O
CG	I-OUT	NOUN	B
infants	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Intake	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
liking	I-OUT	NOUN	B
of	O	ADP	O
carrots	O	NOUN	B
were	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
green	O	ADJ	B
beans	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
at	O	ADP	O
6m	O	NOUN	O
then	O	ADV	O
18m	O	PROPN	O
follow	O	VERB	B
up	O	ADP	I
,	O	PUNCT	O
vegetable	O	NOUN	B
(	O	PUNCT	O
carrot	O	NOUN	B
>	O	X	O
green	O	ADJ	B
beans	O	NOUN	I
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
group	O	NOUN	B
differences	B-P	NOUN	O
were	I-P	AUX	O
observed	I-P	VERB	B
.	O	PUNCT	O


Mothers	O	NOUN	B
reported	O	VERB	O
appreciation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
structure	O	NOUN	B
and	O	CCONJ	O
guidance	O	NOUN	B
of	O	ADP	O
this	O	DET	O
systematic	O	ADJ	B
approach	O	NOUN	I
.	O	PUNCT	O


Early	B-I	ADJ	B
exposure	I-I	NOUN	B
to	O	ADP	I
vegetables	O	NOUN	B
in	O	ADP	O
a	O	DET	O
step-by-step	O	ADJ	B
method	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
included	O	VERB	O
in	O	ADP	O
CF	O	NOUN	B
guidelines	O	NOUN	B
and	O	CCONJ	O
longer	O	ADJ	O
term	O	NOUN	O
benefits	O	NOUN	B
assessed	O	VERB	B
by	O	ADP	O
extending	O	VERB	O
the	O	DET	O
exposure	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
parent-implemented	B-I	ADJ	B
imitation	I-I	NOUN	O
intervention	I-I	NOUN	B
on	O	ADP	O
spontaneous	B-OUT	ADJ	B
imitation	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
exhibit	O	VERB	O
significant	O	ADJ	O
deficits	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
spontaneously	B-OUT	ADV	B
imitate	I-OUT	VERB	B
the	O	DET	O
play	B-OUT	NOUN	O
actions	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
descriptive	I-OUT	ADJ	O
gestures	I-OUT	NOUN	B
of	O	ADP	O
others	O	NOUN	O
.	O	PUNCT	O


Reciprocal	B-I	ADJ	B
imitation	I-I	NOUN	O
training	I-I	NOUN	O
(	I-I	PUNCT	O
RIT	I-I	NOUN	B
)	I-I	PUNCT	O
is	I-I	AUX	O
a	I-I	DET	O
naturalistic	I-I	ADJ	B
imitation	I-I	NOUN	B
intervention	I-I	NOUN	B
designed	O	VERB	O
to	O	PART	O
teach	O	VERB	O
spontaneous	B-OUT	ADJ	B
imitation	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
during	O	ADP	O
play	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
parent-implemented	O	ADJ	B
RIT	B-I	NOUN	O
using	O	VERB	O
a	O	DET	O
multiple-baseline	O	ADJ	B
design	O	NOUN	B
across	O	ADP	O
three	B-P	NUM	O
young	I-P	ADJ	B
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
and	I-P	CCONJ	O
their	I-P	PRON	O
mothers	I-P	NOUN	B
.	I-P	PUNCT	O


After	O	ADP	O
an	O	DET	O
initial	O	ADJ	O
baseline	O	NOUN	B
,	O	PUNCT	O
mothers	O	NOUN	B
were	O	AUX	O
taught	O	VERB	O
to	O	PART	O
implement	O	VERB	O
RIT	B-I	NOUN	B
techniques	O	NOUN	B
with	O	ADP	O
their	O	PRON	O
child	O	NOUN	B
twice	O	ADV	O
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
10	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
a	O	DET	O
clinic	O	NOUN	B
setting	O	NOUN	O
.	O	PUNCT	O


Two	O	NUM	O
mothers	O	NOUN	B
were	O	AUX	O
taught	O	VERB	O
to	O	PART	O
use	O	VERB	O
RIT	B-I	PROPN	B
to	O	PART	O
teach	O	VERB	B
object	O	NOUN	B
imitation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
third	O	ADJ	O
mother	O	NOUN	B
was	O	AUX	O
taught	O	VERB	O
to	O	PART	O
use	O	VERB	O
RIT	B-I	PROPN	B
to	O	PART	O
target	O	VERB	B
both	O	DET	O
object	O	NOUN	B
and	O	CCONJ	O
gesture	O	NOUN	B
imitation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
multiple-baseline	O	ADJ	B
design	O	NOUN	B
across	O	ADP	O
behaviors	O	NOUN	B
.	O	PUNCT	O


Generalization	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
the	O	DET	O
families	O	NOUN	B
'	O	PART	O
homes	O	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
1-month	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Parents	O	NOUN	B
learned	B-OUT	VERB	B
to	O	PART	O
use	O	VERB	O
the	O	DET	O
intervention	O	NOUN	B
strategies	O	NOUN	O
and	O	CCONJ	O
their	O	PRON	O
children	O	NOUN	B
exhibited	O	VERB	O
increases	O	NOUN	B
in	O	ADP	O
spontaneous	B-OUT	ADJ	B
imitation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
replicate	O	VERB	B
the	O	DET	O
results	O	NOUN	B
from	O	ADP	O
previous	O	ADJ	O
studies	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
RIT	O	NOUN	B
is	O	AUX	O
effective	O	ADJ	B
for	O	ADP	O
teaching	O	VERB	B
imitation	B-OUT	NOUN	B
skills	I-OUT	NOUN	I
to	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
in	O	ADP	O
a	O	DET	O
naturalistic	O	ADJ	B
setting	O	NOUN	I
and	O	CCONJ	O
extend	O	VERB	O
the	O	DET	O
findings	O	NOUN	B
to	O	ADP	O
parents	B-P	NOUN	B
.	I-P	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
food	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
antiviral	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
of	O	ADP	O
didanosine	B-I	NOUN	B
enteric-coated	I-I	ADJ	B
capsules	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
pilot	O	NOUN	O
comparative	O	ADJ	O
study	O	NOUN	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
food	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
antiviral	O	ADJ	B
activity	O	NOUN	I
of	O	ADP	O
enteric-coated	B-I	ADJ	B
(	I-I	PUNCT	O
EC	I-I	NOUN	B
)	I-I	PUNCT	O
capsules	I-I	NOUN	B
of	I-I	ADP	O
didanosine	I-I	NOUN	B
(	I-I	PUNCT	O
ddI	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
pilot	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
28-day	O	ADJ	O
ddI-EC	B-I	NOUN	B
capsules	I-I	NOUN	B
monotherapy-administered	I-I	ADJ	B
in	O	ADP	O
a	O	DET	O
fasted	B-I	ADJ	B
state	I-I	NOUN	I
(	I-P	PUNCT	O
group	I-P	NOUN	B
1	I-P	NUM	O
,	I-P	PUNCT	O
n=11	I-P	ADJ	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
with	I-I	ADP	O
food	I-I	NOUN	B
(	I-P	PUNCT	O
group	I-P	NOUN	B
2	I-P	NUM	O
,	I-P	PUNCT	O
n=10	I-P	NOUN	O
)	I-P	PUNCT	O
to	I-P	PART	O
treatment-naïve	I-P	VERB	B
chronically	I-P	ADV	B
HIV-1-infected	I-P	ADJ	B
individuals	I-P	NOUN	B
.	O	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	B-OUT	DET	O
antiviral	I-OUT	ADJ	B
efficacy	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
HIV-1	I-OUT	NOUN	B
RNA	I-OUT	NOUN	B
was	O	AUX	O
determined	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
day	O	NOUN	B
3	O	NUM	O
,	O	PUNCT	O
day	O	NOUN	B
7	O	NUM	O
and	O	CCONJ	O
weekly	O	ADJ	B
thereafter	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
area	O	NOUN	B
under	O	ADP	O
the	O	DET	O
HIV-1	O	NOUN	B
RNA	O	NOUN	I
curve	O	NOUN	I
minus	O	CCONJ	O
baseline	O	NOUN	B
weighted	O	VERB	O
by	O	ADP	O
time	B-OUT	NOUN	O
(	I-OUT	PUNCT	O
AUCMB/day	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
calculated	O	VERB	B
.	O	PUNCT	O


RESULTS	B-OUT	NOUN	B
Mean	I-OUT	VERB	O
baseline	I-OUT	NOUN	B
HIV-1	I-OUT	NOUN	B
RNA	I-OUT	NOUN	B
was	O	AUX	O
4.2	O	NUM	O
log	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
copies/mL	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
3.8	O	NUM	O
log	O	NOUN	O
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
copies/mL	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
.	O	PUNCT	O


After	O	ADP	O
28	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
the	B-OUT	DET	O
mean	I-OUT	ADJ	O
HIV-1	I-OUT	NOUN	B
RNA	I-OUT	NOUN	B
reduction	I-OUT	NOUN	B
was	O	AUX	O
0.99	O	NUM	O
log	O	NOUN	O
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
copies/mL	O	NOUN	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
0.45-1.53	O	NUM	O
]	O	PUNCT	O
for	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
0.89	O	NUM	O
log	O	NOUN	O
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
copies/mL	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.38-1.40	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
.	B-OUT	PUNCT	O


AUCMB/day	B-OUT	NOUN	B
values	I-OUT	NOUN	B
were	O	AUX	O
0.775	O	NUM	O
log	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
copies/mL	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.33-1.22	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
0.774	O	NUM	O
log	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
copies/mL	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	PROPN	B
0.48-1.07	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
showing	O	VERB	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
decrease	O	NOUN	B
of	B-OUT	ADP	O
HIV-1	I-OUT	NOUN	B
RNA	I-OUT	NOUN	I
(	O	PUNCT	O
P=0.995	O	NOUN	O
)	O	PUNCT	O
.	B-OUT	PUNCT	O


Mean	B-OUT	VERB	O
ddI	I-OUT	NOUN	B
plasma	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
at	O	ADP	O
day	O	NOUN	B
28	O	NUM	O
were	O	AUX	O
0.0234	O	NUM	O
mg/L	O	NOUN	O
for	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
0.0227	O	NUM	O
mg/L	O	NOUN	O
for	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
(	O	PUNCT	O
P=0.96	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
administration	O	NOUN	B
of	B-I	ADP	O
food	I-I	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
any	O	DET	O
significant	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
the	B-OUT	DET	O
antiviral	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
of	I-OUT	ADP	O
ddI-EC	I-OUT	NOUN	B
capsules	I-OUT	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
docosahexaenoic	B-I	ADJ	B
acid	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
retinitis	I-P	NOUN	B
pigmentosa	I-P	NOUN	I
receiving	I-P	VERB	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
treatment	I-P	NOUN	B
:	I-P	PUNCT	O
subgroup	O	NOUN	B
analyses	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
docosahexaenoic	B-I	ADJ	B
acid	I-I	NOUN	I
will	O	AUX	O
slow	O	VERB	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
retinal	O	ADJ	B
degeneration	O	NOUN	O
in	O	ADP	O
subgroups	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
retinitis	I-P	NOUN	B
pigmentosa	I-P	NOUN	I
who	I-P	PRON	O
are	I-P	AUX	O
receiving	I-P	VERB	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
.	I-I	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
cohort	O	NOUN	B
of	O	ADP	O
208	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
retinitis	I-P	NOUN	B
pigmentosa	I-P	NOUN	I
,	I-P	PUNCT	O
aged	I-P	ADJ	B
18	I-P	NUM	O
to	I-P	PART	O
55	I-P	NUM	O
years	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
1200	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
docosahexaenoic	B-I	ADJ	B
acid	I-I	NOUN	I
plus	I-I	CCONJ	O
15	I-I	NUM	O
000	I-I	NUM	O
IU/d	I-I	NOUN	O
of	I-I	ADP	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
given	I-I	VERB	O
as	I-I	ADP	O
retinyl	I-I	NOUN	B
palmitate	I-I	NOUN	I
(	I-I	PUNCT	O
DHA	I-I	NOUN	B
+	I-I	CCONJ	O
A	I-I	NOUN	O
group	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
control	I-I	ADJ	B
fatty	I-I	ADJ	I
acid	I-I	NOUN	I
plus	I-I	CCONJ	O
15	I-I	NUM	O
000	I-I	NUM	O
IU/d	I-I	NOUN	O
of	I-I	ADP	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
(	I-I	PUNCT	O
control	I-I	NOUN	B
+	I-I	CCONJ	O
A	I-I	NOUN	O
group	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
followed	O	VERB	B
up	O	ADP	I
over	O	ADV	O
4	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Seventy	B-P	NUM	O
percent	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
patients	I-P	NOUN	B
in	I-P	ADP	O
each	I-P	DET	O
group	I-P	NOUN	B
were	I-P	AUX	O
taking	I-P	VERB	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
,	I-P	PUNCT	O
15	I-P	NUM	O
000	I-P	NUM	O
IU/d	I-P	NOUN	O
,	I-P	PUNCT	O
prior	I-P	ADJ	O
to	I-P	ADP	O
entry	I-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
compared	O	VERB	O
rates	O	NOUN	B
of	O	ADP	O
decline	O	NOUN	B
in	O	ADP	O
ocular	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
the	O	DET	O
DHA	B-I	NOUN	B
+	I-I	CCONJ	O
A	I-I	NOUN	B
vs	O	CCONJ	O
control	B-I	NOUN	B
+	I-I	CCONJ	O
A	I-I	DET	O
groups	O	NOUN	B
among	O	ADP	O
the	O	DET	O
subgroups	O	NOUN	B
defined	O	VERB	O
by	O	ADP	O
use	O	NOUN	O
or	O	CCONJ	O
nonuse	O	NOUN	B
of	O	ADP	O
vitamin	B-I	NOUN	B
A	I-I	NOUN	I
prior	O	ADJ	O
to	O	PART	O
entry	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
determined	O	VERB	O
whether	O	SCONJ	O
decline	O	NOUN	B
in	O	ADP	O
ocular	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
red	O	ADJ	B
blood	O	NOUN	I
cell	O	NOUN	I
phosphatidylethanolamine	O	NOUN	B
docosahexaenoic	O	ADJ	I
acid	O	NOUN	I
level	O	NOUN	B
,	O	PUNCT	O
dietary	O	ADJ	B
omega-3	O	ADJ	O
fatty	O	ADJ	B
acid	O	NOUN	I
intake	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
vitamin	O	NOUN	B
A	O	NOUN	I
use	O	NOUN	O
.	O	PUNCT	O


Main	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	O
were	O	AUX	O
Humphrey	B-OUT	PROPN	B
Field	I-OUT	PROPN	I
Analyzer	I-OUT	PROPN	I
visual	I-OUT	ADJ	I
field	I-OUT	NOUN	I
sensitivity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
30-Hz	I-OUT	ADJ	O
electroretinogram	I-OUT	NOUN	B
amplitude	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
visual	I-OUT	ADJ	B
acuity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
Among	O	ADP	O
patients	O	NOUN	B
not	B-I	PART	O
taking	I-I	VERB	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
prior	O	ADJ	O
to	O	PART	O
entry	O	NOUN	B
,	O	PUNCT	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
DHA	B-I	NOUN	B
+	I-I	CCONJ	O
A	I-I	NOUN	O
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
slower	O	ADJ	O
decline	O	NOUN	B
in	O	ADP	O
field	B-OUT	NOUN	B
sensitivity	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
electroretinogram	I-OUT	NOUN	B
amplitude	I-OUT	NOUN	B
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
control	B-I	NOUN	B
+	I-I	CCONJ	O
A	I-I	DET	O
group	O	NOUN	B
over	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.01	O	NUM	O
and	O	CCONJ	O
P	O	NOUN	O
=.03	O	ADJ	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
;	O	PUNCT	O
these	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
years	O	NOUN	B
3	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
of	O	ADP	O
follow-up	O	NOUN	B
or	O	CCONJ	O
among	O	ADP	O
patients	O	NOUN	B
taking	O	VERB	O
vitamin	B-I	NOUN	B
A	I-I	NOUN	I
prior	O	ADJ	O
to	O	PART	O
entry	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
cohort	O	NOUN	B
,	O	PUNCT	O
red	O	ADJ	B
blood	O	NOUN	I
cell	O	NOUN	I
phosphatidylethanolamine	O	NOUN	B
docosahexaenoic	B-I	ADJ	I
acid	I-I	NOUN	I
level	O	NOUN	B
was	O	AUX	O
inversely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
rate	O	NOUN	B
of	O	ADP	O
decline	O	NOUN	B
in	O	ADP	O
total	B-OUT	ADJ	B
field	I-OUT	NOUN	I
sensitivity	I-OUT	NOUN	I
over	O	ADP	O
4	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
test	O	NOUN	B
for	O	ADP	O
trend	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=.05	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
particularly	O	ADV	O
evident	O	ADJ	O
over	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
years	O	NOUN	B
among	O	ADP	O
those	O	DET	O
not	B-I	PART	O
on	I-I	ADP	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
prior	O	ADJ	O
to	O	PART	O
entry	O	NOUN	B
(	O	PUNCT	O
test	O	NOUN	B
for	O	ADP	O
trend	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
control	B-I	NOUN	B
+	I-I	CCONJ	O
A	I-I	DET	O
group	O	NOUN	B
,	O	PUNCT	O
dietary	B-I	ADJ	B
omega-3	I-I	ADJ	O
fatty	I-I	ADJ	B
acid	I-I	NOUN	I
intake	O	NOUN	B
was	O	AUX	O
inversely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
loss	O	NOUN	B
of	O	ADP	O
total	B-OUT	ADJ	O
field	I-OUT	NOUN	O
sensitivity	I-OUT	NOUN	O
over	O	ADP	O
4	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
intake	O	NOUN	B
,	O	PUNCT	O
<	O	X	O
0.20	O	NUM	O
vs	O	CCONJ	O
>	O	X	O
or	O	CCONJ	O
=0.20	O	NOUN	O
g/d	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=.02	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
vitamin	I-OUT	NOUN	B
A	I-OUT	NOUN	I
supplementation	I-OUT	NOUN	B
prior	O	ADV	O
to	O	ADP	O
entry	O	NOUN	B
was	O	AUX	O
inversely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
rate	O	NOUN	B
of	O	ADP	O
decline	O	NOUN	B
in	O	ADP	O
electroretinogram	O	NOUN	B
amplitude	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.008	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
For	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
retinitis	I-P	NOUN	B
pigmentosa	I-P	NOUN	I
beginning	O	VERB	O
vitamin	B-I	NOUN	B
A	I-I	NOUN	I
therapy	I-I	NOUN	I
,	O	PUNCT	O
addition	O	NOUN	O
of	O	ADP	O
docosahexaenoic	B-I	ADJ	B
acid	I-I	NOUN	I
,	O	PUNCT	O
1200	O	NUM	O
mg/d	O	NOUN	O
,	O	PUNCT	O
slowed	O	VERB	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
patients	B-P	NOUN	B
on	I-P	ADP	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
for	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADV	O
2	I-P	NUM	O
years	I-P	NOUN	B
,	O	PUNCT	O
a	O	DET	O
diet	O	NOUN	B
rich	O	ADJ	O
in	O	ADP	O
omega-3	B-I	ADJ	B
fatty	I-I	ADJ	I
acids	I-I	NOUN	I
(	O	PUNCT	O
>	O	NOUN	O
or	O	CCONJ	O
=0.20	O	NOUN	B
g/d	O	NOUN	I
)	O	PUNCT	O
slowed	O	VERB	B
the	O	DET	O
decline	O	NOUN	B
in	O	ADP	O
visual	O	ADJ	B
field	O	NOUN	I
sensitivity	O	NOUN	O
.	O	PUNCT	O


Chronology	O	NOUN	B
of	O	ADP	O
panic	O	NOUN	B
and	O	CCONJ	O
avoidance	O	NOUN	B
,	O	PUNCT	O
age	B-P	NOUN	B
of	I-P	ADP	O
onset	I-P	NOUN	O
in	I-P	ADP	O
panic	I-P	NOUN	B
disorder	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
prediction	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
response	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
report	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Cross-National	O	PROPN	B
Collaborative	O	PROPN	I
Panic	O	PROPN	I
Study	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
relevance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
chronology	O	NOUN	B
between	O	ADP	O
panic	O	NOUN	B
disorder	O	NOUN	I
and	O	CCONJ	O
avoidance	O	NOUN	B
behavior	O	NOUN	I
and	O	CCONJ	O
of	O	ADP	O
an	O	DET	O
early	O	ADJ	B
,	O	PUNCT	O
medium	O	NOUN	B
or	O	CCONJ	O
late	O	ADJ	O
onset	O	NOUN	O
of	O	ADP	O
panic	O	NOUN	B
disorder	O	NOUN	I
was	O	AUX	O
tested	O	VERB	B
.	O	PUNCT	O


Groups	B-P	NOUN	B
from	O	ADP	O
the	B-P	DET	O
sample	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
cross-national	I-I	ADJ	B
collaborative	I-I	ADJ	I
panic	I-I	NOUN	B
study	I-I	NOUN	I
(	I-P	PUNCT	O
CNCPS	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
for	O	ADP	O
differences	O	NOUN	B
in	O	ADP	O
basic	O	ADJ	O
characteristics	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
the	O	DET	O
ability	O	NOUN	O
to	O	PART	O
predict	O	VERB	O
treatment	O	NOUN	B
response	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
who	I-P	PRON	O
developed	I-P	VERB	O
avoidance	I-OUT	NOUN	B
behavior	I-OUT	NOUN	I
before	I-P	ADP	O
the	I-P	DET	O
full	I-P	ADJ	B
syndrome	I-P	NOUN	I
of	I-P	ADP	O
panic	I-OUT	NOUN	B
disorder	I-OUT	NOUN	I
had	O	AUX	O
less	O	ADV	O
often	O	ADV	O
a	O	DET	O
full	O	ADJ	O
agoraphobia	B-OUT	NOUN	B
but	O	CCONJ	O
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
in	O	ADP	O
their	O	PRON	O
response	O	NOUN	B
to	O	PART	O
treatment	B-I	NOUN	B
.	I-I	PUNCT	O


Patients	B-P	NOUN	B
with	O	ADP	O
an	O	DET	O
early	B-OUT	ADJ	B
onset	I-OUT	NOUN	O
of	I-OUT	ADP	O
panic	I-OUT	NOUN	B
disorder	I-OUT	NOUN	I
suffered	O	VERB	O
more	O	ADV	O
often	O	ADV	O
from	O	ADP	O
agoraphobia	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
treatment	B-OUT	NOUN	B
response	I-OUT	NOUN	I
was	O	AUX	O
similar	B-OUT	ADJ	O
in	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
with	O	ADP	O
early	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
medium	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
late	I-OUT	ADJ	O
onset	I-OUT	NOUN	O
of	I-OUT	ADP	O
panic	I-OUT	NOUN	B
disorder	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Neither	O	CCONJ	O
the	O	DET	O
chronology	O	NOUN	B
between	O	ADP	O
panic	B-OUT	NOUN	B
disorder	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
avoidance	I-OUT	NOUN	B
behavior	I-OUT	NOUN	I
nor	O	CCONJ	O
the	O	DET	O
age	B-OUT	NOUN	B
of	I-OUT	ADP	O
onset	I-OUT	NOUN	O
of	I-OUT	ADP	O
panic	I-OUT	NOUN	B
disorder	I-OUT	NOUN	I
predicted	O	VERB	O
outcome	O	NOUN	B
in	O	ADP	O
short-term	B-I	ADJ	B
treatment	I-I	NOUN	B
with	I-I	ADP	O
alprazolam	I-I	NOUN	B
or	I-I	CCONJ	O
imipramine	I-I	NOUN	B
.	I-I	PUNCT	O


Pathological	B-OUT	ADJ	B
response	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
two	O	NUM	O
neoadjuvant	O	ADJ	B
strategies	O	NOUN	O
with	O	ADP	O
bevacizumab	B-I	NOUN	B
in	O	ADP	O
MRI-defined	B-P	ADJ	B
locally	I-P	ADV	B
advanced	I-P	ADJ	I
T3	I-P	NOUN	B
resectable	I-P	ADJ	O
rectal	I-P	ADJ	B
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
noncomparative	O	ADJ	B
phase	O	NOUN	O
II	O	NUM	O
study	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
In	O	ADP	O
T3	O	NOUN	B
rectal	O	ADJ	B
cancer	O	NOUN	I
(	O	PUNCT	O
RC	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
preoperative	O	ADJ	B
chemoradiotherapy	B-I	NOUN	B
[	I-I	PUNCT	O
5-fluorouracil	I-I	NOUN	B
(	I-I	PUNCT	O
5-FU-RT	I-I	NOUN	B
)	I-I	PUNCT	O
]	I-I	PUNCT	O
reduces	O	VERB	B
local	B-OUT	ADJ	B
recurrences	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


New	O	ADJ	O
therapeutic	O	ADJ	B
options	O	NOUN	I
are	O	AUX	O
still	O	ADV	O
necessary	O	ADJ	O
to	O	PART	O
improve	O	VERB	O
clinical	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
This	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
noncomparative	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
arms	O	NOUN	O
,	O	PUNCT	O
phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
MRI-defined	B-P	ADJ	B
locally	I-P	ADV	B
advanced	I-P	ADJ	I
T3	I-P	NOUN	B
resectable	I-P	ADJ	O
RC	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
arm	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
patients	O	NOUN	B
received	O	VERB	O
12-week	O	ADJ	O
bevacizumab	B-I	NOUN	B
plus	I-I	CCONJ	O
5-FU	I-I	NOUN	B
,	I-I	PUNCT	O
leucovorin	I-I	NOUN	B
and	I-I	CCONJ	O
oxaliplatin	I-I	NOUN	B
(	I-I	PUNCT	O
Folfox-4	I-I	NOUN	B
)	I-I	PUNCT	O
followed	I-I	VERB	O
with	I-I	ADP	O
bevacizumab-5-FU-RT	I-I	NOUN	B
before	I-I	ADP	O
total	I-I	ADJ	O
mesorectal	I-I	ADJ	O
excision	I-I	NOUN	O
(	I-I	PUNCT	O
TME	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


In	O	ADP	O
arm	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
patients	O	NOUN	B
received	O	VERB	O
only	O	ADV	O
bevacizumab-5-FU-RT	B-I	NOUN	B
before	I-I	ADP	O
TME	I-I	PROPN	B
.	I-I	PUNCT	O


Primary	B-OUT	ADJ	B
end	I-OUT	NOUN	I
point	I-OUT	NOUN	I
was	O	AUX	O
pathological	B-OUT	ADJ	B
complete	I-OUT	ADJ	O
response	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
pCR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
rate	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Forty-six	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
in	I-P	ADP	O
arm	I-P	NOUN	B
A	I-P	NOUN	I
and	I-P	CCONJ	O
45	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
arm	I-P	NOUN	B
B	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
arm	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
pCR	I-OUT	NOUN	B
was	O	AUX	O
23.8	O	NUM	O
%	O	NOUN	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
12.1	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
39.5	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
statistically	O	ADV	B
superior	O	ADJ	I
to	O	PART	O
the	O	DET	O
defined	O	VERB	O
standard	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.015	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
arm	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
pCR	I-OUT	NOUN	B
of	O	ADP	O
11.4	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
3.8	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
24.6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
from	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.906	O	NUM	O
.	O	PUNCT	O


No	O	DET	B
death	B-OUT	NOUN	I
occurred	O	VERB	O
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
start	O	NOUN	O
until	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
following	O	VERB	O
surgery	O	NOUN	B
.	O	PUNCT	O


Postoperative	B-OUT	ADJ	B
fistulas	I-OUT	NOUN	O
were	O	AUX	O
reported	O	VERB	O
for	O	ADP	O
16	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
in	O	ADP	O
arm	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
9	O	NUM	O
in	O	ADP	O
arm	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Even	O	ADV	O
if	O	SCONJ	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
bevacizumab	O	NOUN	B
induced	O	VERB	B
manageable	O	ADJ	O
toxicities	B-OUT	NOUN	B
including	O	VERB	O
an	O	DET	O
increased	B-OUT	VERB	B
risk	I-OUT	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
fistula	O	NOUN	I
and	O	CCONJ	O
no	O	DET	O
treatment-related	B-OUT	ADJ	O
death	I-OUT	NOUN	O
,	O	PUNCT	O
arm	O	NOUN	B
B	O	NOUN	I
did	O	AUX	O
not	O	PART	O
achieve	O	VERB	O
the	O	DET	O
expected	O	VERB	O
pCR	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
population	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
included	O	VERB	O
.	O	PUNCT	O


Induction	O	NOUN	B
bevacizumab-Folfox-4	B-I	NUM	O
followed	O	VERB	O
by	O	ADP	O
bevacizumab-5-FU-RT	B-I	NOUN	B
is	O	AUX	O
promising	O	ADJ	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
however	O	ADV	O
necessary	O	ADJ	O
to	O	PART	O
continue	O	VERB	O
investigations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
locally	O	ADV	B
advanced	O	ADJ	I
RC	O	NOUN	I
.	O	PUNCT	O


CLINICAL	O	X	O
TRIALSGOV	O	NOUN	B
IDENTIFIER	O	NOUN	O
NCT	O	NOUN	B
00865189	O	NUM	O
.	O	PUNCT	O


Gefitinib	B-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
tamoxifen	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
hormone	I-OUT	NOUN	B
receptor-positive	I-OUT	ADJ	O
metastatic	I-OUT	ADJ	O
breast	I-OUT	NOUN	O
cancer	I-OUT	NOUN	O
:	I-OUT	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
study	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	VERB	B
Increased	O	VERB	B
growth	O	NOUN	O
factor	O	NOUN	O
signaling	O	NOUN	O
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
tamoxifen	O	NOUN	B
resistance	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
trial	O	NOUN	I
assessed	O	VERB	B
tamoxifen	B-I	NOUN	B
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
or	O	CCONJ	O
the	O	DET	O
epidermal	O	ADJ	B
growth	O	NOUN	I
factor	O	NOUN	I
receptor	O	NOUN	I
inhibitor	O	NOUN	I
gefitinib	O	NOUN	B
in	O	ADP	O
estrogen	O	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
ER	O	NOUN	B
)	O	PUNCT	O
-positive	O	ADJ	O
metastatic	O	ADJ	B
breast	O	NOUN	I
cancer	O	NOUN	I
.	O	PUNCT	O


EXPERIMENTAL	O	NOUN	B
DESIGN	O	VERB	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
newly	I-P	ADV	B
metastatic	I-P	ADJ	I
disease	I-P	NOUN	I
or	I-P	CCONJ	O
recurred	I-P	VERB	O
after	I-P	ADP	O
adjuvant	I-P	ADJ	B
tamoxifen	I-I	NOUN	B
(	I-P	PUNCT	O
stratum	I-P	NOUN	O
1	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
recurred	I-P	VERB	O
during/after	I-P	ADJ	O
adjuvant	I-P	ADJ	B
aromatase	I-P	NOUN	O
inhibitor	I-P	NOUN	O
(	I-P	PUNCT	O
AI	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
after	I-P	ADP	O
failed	I-P	VERB	B
first-line	I-P	ADJ	B
AI	I-P	NOUN	I
(	I-P	PUNCT	O
stratum	I-P	NOUN	O
2	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
were	I-P	AUX	O
eligible	I-P	ADJ	B
.	I-P	PUNCT	O


Primary	O	ADJ	B
variables	O	NOUN	I
were	O	AUX	O
progression-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
PFS	O	NOUN	B
;	O	PUNCT	O
stratum	O	NOUN	O
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
clinical	B-OUT	ADJ	B
benefit	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
(	O	PUNCT	O
CBR	O	NOUN	B
;	O	PUNCT	O
stratum	O	NOUN	O
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
5	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
more	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
variables	O	NOUN	I
with	O	ADP	O
gefitinib	B-I	NOUN	B
was	O	AUX	O
considered	O	VERB	O
to	O	PART	O
warrant	O	VERB	O
further	O	ADJ	O
investigation	O	NOUN	B
.	O	PUNCT	O


Outcome	O	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
biomarkers	O	NOUN	B
measured	O	VERB	B
on	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
tumor	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
stratum	O	NOUN	O
1	O	NUM	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
206	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
PFS	B-OUT	NOUN	B
HR	I-OUT	NOUN	B
(	I-I	PUNCT	O
gefitinib	I-I	NOUN	B
:	I-I	PUNCT	O
placebo	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
0.84	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.59-1.18	O	NUM	O
;	O	PUNCT	O
median	B-OUT	ADJ	B
PFS	I-OUT	NOUN	B
10.9	O	NUM	O
versus	O	CCONJ	O
8.8	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
stratum	O	NOUN	O
1	O	NUM	O
endocrine	O	ADJ	B
therapy-naïve	O	ADJ	I
subset	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
158	O	NUM	O
)	O	PUNCT	O
the	B-OUT	DET	O
HR	I-OUT	NOUN	B
was	O	AUX	O
0.78	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.52-1.15	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
prior	O	ADJ	O
endocrine-treated	O	ADJ	B
subgroup	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
48	O	NUM	O
)	O	PUNCT	O
1.47	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.63-3.45	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
stratum	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
CBRs	B-OUT	NOUN	B
were	O	AUX	O
50.5	O	NUM	O
%	O	NOUN	O
with	B-I	ADP	O
gefitinib	I-I	NOUN	B
and	O	CCONJ	O
45.5	O	NUM	O
%	O	NOUN	O
with	B-I	ADP	O
placebo	I-I	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
stratum	O	NOUN	O
2	O	NUM	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
84	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
CBRs	B-OUT	NOUN	B
were	O	AUX	O
29.2	O	NUM	O
%	O	NOUN	O
with	B-I	ADP	O
gefitinib	I-I	NOUN	B
and	O	CCONJ	O
31.4	O	NUM	O
%	O	NOUN	O
with	B-I	ADP	O
placebo	I-I	NOUN	B
.	O	PUNCT	O


Biomarker	O	NOUN	B
analysis	O	NOUN	I
suggested	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
stratum	O	NOUN	O
1	O	NUM	O
there	O	PRON	O
was	O	AUX	O
greater	O	ADJ	O
benefit	O	NOUN	B
with	O	ADP	O
gefitinib	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
ER-negative	O	ADJ	B
or	O	CCONJ	O
had	O	AUX	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
ER	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
stratum	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
improved	O	VERB	O
PFS	O	NOUN	B
with	B-I	ADP	O
gefitinib	I-I	NOUN	B
plus	I-I	CCONJ	O
tamoxifen	I-I	NOUN	B
met	O	VERB	O
the	O	DET	O
protocol	O	NOUN	B
criteria	O	NOUN	B
to	O	PART	O
warrant	O	VERB	O
further	O	ADJ	O
investigation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
strategy	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
stratum	O	NOUN	O
2	O	NUM	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
numerical	O	ADJ	B
disadvantage	O	NOUN	B
for	B-I	ADP	O
gefitinib	I-I	NOUN	B
;	I-I	PUNCT	O
additional	O	ADJ	O
investigation	O	NOUN	B
after	O	ADP	O
AI	O	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
not	O	PART	O
warranted	O	VERB	O
.	O	PUNCT	O


Studies	O	NOUN	B
of	O	ADP	O
predictive	O	ADJ	B
biomarkers	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
subset	B-P	VERB	O
appropriate	I-P	ADJ	O
patients	I-P	NOUN	B
.	O	PUNCT	O


Analysis	B-OUT	NOUN	B
of	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
in	O	ADP	O
childhood	B-P	NOUN	B
leukaemia	I-P	NOUN	I
.	I-P	PUNCT	O


I.	O	PROPN	O
Predisposition	O	PROPN	B
to	O	PART	O
methotrexate-induced	O	ADJ	B
neutropenia	O	NOUN	I
after	B-P	ADP	O
craniospinal	I-P	ADJ	B
irradiation	I-P	NOUN	I
.	I-P	PUNCT	O


Report	O	NOUN	B
to	O	ADP	O
the	O	DET	O
Medical	O	PROPN	B
Research	O	PROPN	I
Council	O	PROPN	I
of	O	ADP	I
the	O	DET	I
Working	O	PROPN	I
Party	O	PROPN	I
on	O	ADP	O
Leukaemia	B-P	PROPN	B
in	I-P	ADP	O
Childhood	I-P	PROPN	B
.	I-P	PUNCT	O


The	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
drug-induced	O	ADJ	B
neutropenia	B-OUT	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
a	O	DET	O
controlled	O	VERB	B
trial	O	NOUN	I
(	O	PUNCT	O
UKALL	O	NOUN	B
I	O	NUM	I
)	O	PUNCT	O
of	O	ADP	O
treatment	O	NOUN	B
in	O	ADP	O
acute	B-P	ADJ	B
lymphoblastic	I-P	ADJ	I
leukaemia	I-P	NOUN	I
was	O	AUX	O
analysed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
agent	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
severe	B-OUT	ADJ	B
neutropenia	I-OUT	NOUN	B
was	O	AUX	O
methotrexate	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
methotrexate-induced	B-OUT	ADJ	B
neutropenia	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
received	I-P	VERB	O
craniospinal	I-P	ADJ	B
irradiation	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
synergistic	B-OUT	ADJ	B
toxic	I-OUT	ADJ	O
effect	I-OUT	NOUN	O
of	I-OUT	ADP	O
irradiation	I-OUT	NOUN	B
followed	O	VERB	O
by	O	ADP	O
methotrexate	O	NOUN	B
treatment	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
have	O	AUX	O
contributed	O	VERB	O
to	O	ADP	O
three	O	NUM	O
of	O	ADP	O
the	O	DET	O
five	O	NUM	O
deaths	B-OUT	NOUN	B
which	O	DET	O
occurred	O	VERB	O
in	O	ADP	O
complete	O	ADJ	O
remission	B-OUT	NOUN	B
in	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
;	O	PUNCT	O
all	O	DET	O
deaths	O	NOUN	B
in	O	ADP	O
remission	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
received	O	VERB	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
prophylaxis	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
subsequently	O	ADV	O
relapsed	O	VERB	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
still	O	ADV	O
in	O	ADP	O
remission	O	NOUN	B
after	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
former	O	ADJ	O
,	O	PUNCT	O
on	O	ADP	O
average	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
slightly	O	ADV	O
lower	O	ADJ	O
neutrophil	B-OUT	NOUN	B
counts	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
children	B-P	NOUN	B
who	O	PRON	O
relapsed	O	VERB	B
did	O	AUX	O
not	O	PART	O
receive	O	VERB	O
any	O	DET	O
less	O	ADV	O
aggressive	O	ADJ	B
treatment	O	NOUN	I
than	O	ADP	O
those	O	DET	O
who	O	PRON	O
remained	O	VERB	O
in	O	ADP	O
remission	O	NOUN	B
.	O	PUNCT	O


Enalapril	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg/day	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
systemic	O	ADJ	B
sclerosis	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
study	O	NOUN	I
(	O	PUNCT	O
ESS-1	O	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
echocardiographic	O	ADJ	B
substudy	O	NOUN	B
--	O	PUNCT	O
three	O	NUM	O
months	O	NOUN	B
follow-up	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
ESS-1	O	NOUN	B
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
angiotensin	O	NOUN	B
converting	O	NOUN	O
enzyme	O	NOUN	O
inhibitor	O	NOUN	O
(	O	PUNCT	O
ACEI	O	NOUN	B
)	O	PUNCT	O
enalapril	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
cardio-pulmonary	O	ADJ	B
system	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
scleroderma	I-P	NOUN	B
(	I-P	PUNCT	O
SSc	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


We	O	PRON	O
estimated	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
heart	B-OUT	NOUN	B
diameters	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
systolic	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
left	I-OUT	ADJ	I
ventricle	I-OUT	NOUN	I
function	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
mean	I-OUT	ADJ	O
values	I-OUT	NOUN	O
of	I-OUT	ADP	O
pulmonary	I-OUT	ADJ	B
artery	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
comprise	O	VERB	O
41	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
SSc	I-P	NOUN	B
.	I-P	PUNCT	O


18	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
23	O	NUM	O
ones	O	NOUN	O
were	O	AUX	O
given	O	VERB	O
enalapril	B-I	NOUN	B
.	I-I	PUNCT	O


After	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
we	O	PRON	O
did	O	AUX	O
not	O	PART	O
observe	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
heart	B-OUT	NOUN	B
diameters	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
left	I-OUT	VERB	B
ventricle	I-OUT	NOUN	I
systolic	I-OUT	NOUN	I
function	I-OUT	NOUN	I
parameters	I-OUT	NOUN	B
between	O	ADP	O
treated	O	VERB	B
group	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Enalapril	B-I	NOUN	B
therapy	O	NOUN	I
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
left	B-OUT	VERB	B
ventricle	I-OUT	NOUN	I
diastolic	I-OUT	ADJ	I
function	I-OUT	NOUN	I
,	O	PUNCT	O
nevertheless	O	ADV	O
differences	O	NOUN	O
in	O	ADP	O
MVA	B-OUT	NOUN	B
were	O	AUX	O
almost	O	ADV	O
of	O	ADP	O
statistical	O	ADJ	B
significance	O	NOUN	I
.	O	PUNCT	O


Echocardiographic	O	ADJ	B
signs	B-OUT	NOUN	B
of	O	ADP	I
pulmonary	B-OUT	ADJ	B
hypertension	I-OUT	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
4	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Cognitive	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
physical	I-OUT	ADJ	B
rehabilitation	I-OUT	NOUN	I
of	O	ADP	O
intensive	B-P	ADJ	B
care	I-P	NOUN	I
unit	I-P	NOUN	I
survivors	I-P	NOUN	B
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
RETURN	O	ADJ	B
randomized	O	VERB	I
controlled	O	VERB	I
pilot	O	NOUN	I
investigation	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Millions	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
survive	I-P	VERB	B
medical	I-P	ADJ	B
and	I-P	CCONJ	O
surgical	I-P	ADJ	B
general	I-P	ADJ	O
intensive	I-P	ADJ	O
care	I-P	NOUN	O
unit	I-P	NOUN	O
care	I-P	NOUN	O
every	O	DET	O
year	O	NOUN	B
experience	O	NOUN	B
newly	O	ADV	O
acquired	O	VERB	O
long-term	O	ADJ	B
cognitive	O	ADJ	B
impairment	O	NOUN	I
and	O	CCONJ	O
profound	O	ADJ	O
physical	O	ADJ	B
and	O	CCONJ	O
functional	O	ADJ	B
disabilities	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
overcome	O	VERB	B
the	O	DET	O
current	O	ADJ	O
reality	O	NOUN	B
in	O	ADP	O
which	O	DET	O
patients	O	NOUN	B
receive	O	VERB	O
inadequate	O	ADJ	B
rehabilitation	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
devised	O	VERB	O
a	O	DET	O
multifaceted	O	ADJ	B
,	O	PUNCT	O
in-home	O	NOUN	B
,	O	PUNCT	O
telerehabilitation	O	NOUN	B
program	O	NOUN	I
implemented	O	VERB	O
using	O	VERB	O
social	O	ADJ	B
workers	O	NOUN	I
and	O	CCONJ	O
psychology	O	NOUN	B
technicians	O	NOUN	O
with	O	ADP	O
the	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
improving	O	VERB	B
cognitive	O	ADJ	B
and	O	CCONJ	O
functional	O	ADJ	B
outcomes	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
single-site	O	ADJ	B
,	O	PUNCT	O
feasibility	O	NOUN	B
,	O	PUNCT	O
pilot	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
21	B-P	NUM	O
general	I-P	ADJ	B
medical/surgical	I-P	ADJ	I
intensive	I-P	ADJ	I
care	I-P	NOUN	I
unit	I-P	NOUN	I
survivors	I-P	NOUN	B
(	I-P	PUNCT	O
8	I-P	NUM	O
controls	I-P	NOUN	B
and	I-P	CCONJ	O
13	I-P	NUM	O
intervention	I-P	NOUN	B
patients	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
either	I-P	CCONJ	O
cognitive	I-P	ADJ	B
or	I-P	CCONJ	O
functional	I-P	ADJ	B
impairment	I-P	NOUN	I
at	I-P	ADP	O
hospital	I-P	NOUN	B
discharge	I-P	NOUN	I
.	I-P	PUNCT	O


After	O	ADP	O
discharge	O	NOUN	B
,	O	PUNCT	O
study	O	NOUN	B
controls	O	NOUN	I
received	O	VERB	O
usual	B-I	ADJ	B
care	I-I	NOUN	I
(	I-I	PUNCT	O
sporadic	I-I	ADJ	B
rehabilitation	I-I	NOUN	I
)	I-I	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
intervention	O	NOUN	B
patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
in-home	B-I	ADJ	B
cognitive	I-I	ADJ	I
,	I-I	PUNCT	O
physical	I-I	ADJ	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
functional	I-I	ADJ	B
rehabilitation	I-I	NOUN	I
over	O	ADP	O
a	O	DET	O
3-month	O	ADJ	O
period	O	NOUN	B
via	O	ADP	O
a	O	DET	O
social	O	ADJ	B
worker	O	NOUN	I
or	O	CCONJ	O
master	O	NOUN	B
's	O	PART	I
level	O	NOUN	B
psychology	O	NOUN	B
technician	O	NOUN	B
utilizing	O	VERB	O
telemedicine	O	NOUN	B
to	O	PART	O
allow	O	VERB	O
specialized	O	ADJ	O
multidisciplinary	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


Interventions	O	NOUN	B
over	O	ADP	O
12	O	NUM	O
wks	O	NOUN	O
included	O	VERB	O
six	O	NUM	O
in-person	O	NOUN	B
visits	O	NOUN	I
for	O	ADP	O
cognitive	B-I	ADJ	B
rehabilitation	I-I	NOUN	I
and	O	CCONJ	O
six	O	NUM	O
televisits	O	NOUN	B
for	O	ADP	O
physical/functional	B-I	ADJ	B
rehabilitation	I-I	NOUN	I
.	I-I	PUNCT	O


Outcomes	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rehabilitation	O	NOUN	B
program	O	NOUN	I
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
at	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
cognitive	B-OUT	ADJ	B
functioning	I-OUT	NOUN	I
as	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
.	O	PUNCT	O


Analyses	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
using	O	VERB	O
linear	O	ADJ	B
regression	O	NOUN	I
to	O	PART	O
examine	O	VERB	O
differences	O	NOUN	O
in	O	ADP	O
3-month	O	ADJ	O
outcomes	O	NOUN	B
between	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
while	O	SCONJ	O
adjusting	O	VERB	O
for	O	ADP	O
baseline	O	NOUN	B
scores	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Patients	B-P	NOUN	B
tolerated	I-OUT	VERB	B
the	I-P	DET	O
program	I-P	NOUN	B
with	I-P	ADP	O
only	I-P	ADV	O
one	I-P	NUM	O
adverse	I-P	ADJ	B
event	I-P	NOUN	I
reported	I-P	VERB	O
.	I-P	PUNCT	O


At	O	ADP	O
baseline	O	NOUN	B
both	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
well-matched	O	ADJ	B
.	O	PUNCT	O


At	O	ADP	O
3-month	O	ADJ	O
follow-up	O	NOUN	B
,	O	PUNCT	O
intervention	O	NOUN	B
group	O	NOUN	I
patients	O	NOUN	B
demonstrated	O	VERB	O
significantly	O	ADV	O
improved	B-OUT	VERB	B
cognitive	I-OUT	ADJ	B
executive	I-OUT	NOUN	I
functioning	I-OUT	NOUN	I
on	O	ADP	O
the	O	DET	O
widely	O	ADV	O
used	O	VERB	O
and	O	CCONJ	O
well-normed	O	ADJ	B
Tower	O	PROPN	I
test	O	NOUN	I
(	O	PUNCT	O
for	O	ADP	O
planning	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
strategic	I-OUT	ADJ	B
thinking	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
vs.	O	CCONJ	O
controls	O	NOUN	B
(	O	PUNCT	O
median	O	NOUN	B
[	O	PUNCT	O
interquartile	O	VERB	B
range	O	NOUN	I
]	O	PUNCT	O
,	O	PUNCT	O
13.0	O	NUM	O
[	O	PUNCT	O
11.5-14.0	O	NUM	O
]	O	PUNCT	O
vs.	O	CCONJ	O
7.5	O	NUM	O
[	O	PUNCT	O
4.0-8.5	O	PROPN	O
]	O	PUNCT	O
;	O	PUNCT	O
adjusted	O	VERB	O
p	O	NOUN	O
<	O	X	O
.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Intervention	O	NOUN	B
group	O	NOUN	I
patients	O	NOUN	B
also	O	ADV	O
reported	O	VERB	O
better	O	ADJ	O
performance	B-OUT	NOUN	B
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
lower	O	ADJ	B
score	O	NOUN	I
)	O	PUNCT	O
on	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
used	O	VERB	O
measures	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
status	O	NOUN	I
(	B-OUT	PUNCT	O
Functional	I-OUT	ADJ	B
Activities	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
at	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
vs.	O	CCONJ	O
controls	O	NOUN	B
,	O	PUNCT	O
1.0	O	NUM	O
[	O	PUNCT	O
0.0	O	NUM	O
-3.0	O	NUM	O
]	O	PUNCT	O
vs.	O	CCONJ	O
8.0	O	NUM	O
[	O	PUNCT	O
6.0-11.8	O	NUM	B
]	O	PUNCT	O
,	O	PUNCT	O
adjusted	O	VERB	O
p	O	NOUN	O
=	O	ADJ	O
.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
A	O	DET	O
multicomponent	O	ADJ	B
rehabilitation	B-I	NOUN	I
program	O	NOUN	I
for	O	ADP	O
intensive	B-P	ADJ	B
care	I-P	NOUN	I
unit	I-P	NOUN	I
survivors	I-P	NOUN	B
combining	O	VERB	O
cognitive	O	ADJ	B
,	O	PUNCT	O
physical	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
functional	O	ADJ	B
training	O	NOUN	O
appears	O	VERB	O
feasible	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
possibly	I-OUT	ADV	O
effective	I-OUT	ADJ	B
in	I-OUT	ADP	O
improving	I-OUT	VERB	B
cognitive	I-OUT	ADJ	B
performance	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
functional	I-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
in	O	ADP	O
just	O	ADV	O
3	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Future	O	ADJ	O
investigations	O	NOUN	B
with	O	ADP	O
a	O	DET	O
larger	O	ADJ	O
sample	O	NOUN	B
size	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
build	O	VERB	O
on	O	ADP	O
this	O	DET	O
pilot	O	NOUN	O
feasibility	O	NOUN	B
program	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
confirm	O	VERB	O
these	O	DET	O
results	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
to	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
elements	O	NOUN	B
of	O	ADP	O
rehabilitation	O	NOUN	B
contributing	O	VERB	O
most	O	ADV	O
to	O	PART	O
improved	O	VERB	O
outcomes	O	NOUN	B
.	O	PUNCT	O


Hepatic	O	ADJ	B
cytoprotective	O	ADJ	O
effect	O	NOUN	O
of	O	ADP	O
ischemic	B-I	ADJ	B
and	I-I	CCONJ	O
anesthetic	I-I	ADJ	B
preconditioning	I-I	NOUN	I
before	O	ADP	O
liver	O	NOUN	B
resection	O	NOUN	I
when	O	SCONJ	O
using	O	VERB	O
intermittent	O	ADJ	B
vascular	O	ADJ	B
inflow	O	NOUN	I
occlusion	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Ischemic	B-I	ADJ	B
preconditioning	I-I	NOUN	I
(	I-I	PUNCT	O
IPC	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
anesthetic	B-I	ADJ	B
preconditioning	I-I	NOUN	I
(	I-I	PUNCT	O
APC	I-I	NOUN	B
)	I-I	PUNCT	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
attenuate	O	VERB	B
ischemia-reperfusion	O	NOUN	B
(	O	PUNCT	O
IR	O	NOUN	B
)	O	PUNCT	O
injury	O	NOUN	B
after	O	ADP	O
liver	O	NOUN	B
resection	O	NOUN	I
under	O	ADP	O
continuous	O	ADJ	B
inflow	O	NOUN	O
occlusion	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
evaluates	O	VERB	O
whether	O	SCONJ	O
these	O	DET	O
strategies	O	NOUN	O
enhance	O	VERB	O
hepatic	O	ADJ	B
protection	O	NOUN	B
of	O	ADP	O
remnant	O	ADJ	B
liver	O	NOUN	B
against	O	ADP	O
IR	O	NOUN	B
after	O	ADP	O
liver	B-P	NOUN	B
resection	I-P	NOUN	I
with	I-P	ADP	O
intermittent	I-I	ADJ	B
clamping	I-I	NOUN	I
(	I-I	PUNCT	O
INT	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


METHODS	O	VERB	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
106	I-P	NUM	O
patients	I-P	NOUN	B
without	I-P	ADP	O
underlying	I-P	VERB	O
liver	I-P	NOUN	B
disease	I-P	NOUN	I
and	I-P	CCONJ	O
submitted	I-P	VERB	O
to	I-P	PART	O
liver	I-P	NOUN	B
resection	I-P	NOUN	I
using	I-P	VERB	O
INT	I-P	PROPN	B
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
3	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
IPC	B-I	PROPN	B
(	I-I	PUNCT	O
10	I-I	NUM	O
minutes	I-I	NOUN	O
of	I-I	ADP	O
inflow	I-I	NOUN	B
occlusion	I-I	NOUN	I
followed	I-I	VERB	O
by	I-I	ADP	O
10	I-I	NUM	O
minutes	I-I	NOUN	O
of	I-I	ADP	O
reperfusion	I-I	NOUN	B
before	I-I	ADP	O
liver	I-I	NOUN	B
transection	I-I	NOUN	I
)	I-I	PUNCT	O
,	I-I	PUNCT	O
APC	I-I	NOUN	B
(	I-I	PUNCT	O
sevoflurane	I-I	NOUN	B
administration	I-I	NOUN	I
for	I-I	ADP	O
20	I-I	NUM	O
minutes	I-I	NOUN	B
before	I-I	ADP	O
liver	I-I	NOUN	B
transection	I-I	NOUN	I
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
INT	I-I	PROPN	B
(	I-I	PUNCT	O
no	I-I	DET	O
preconditioning	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
stratified	O	VERB	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hepatectomy	O	NOUN	B
.	O	PUNCT	O


Cytoprotection	B-OUT	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
comparing	B-OUT	VERB	B
hepatocyte	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
endothelial	I-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
markers	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
apoptosis	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
histologic	I-OUT	ADJ	B
lesions	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
outcome	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
No	O	DET	B
differences	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
preoperative	B-OUT	ADJ	B
chemotherapy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
steatosis	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
total	I-OUT	ADJ	B
warm	I-OUT	ADJ	I
ischemia	I-OUT	NOUN	I
time	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
operative	I-OUT	ADJ	B
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
loss	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Kinetics	B-OUT	NOUN	B
of	I-OUT	ADP	O
transaminases	I-OUT	NOUN	B
(	O	PUNCT	O
aspartate	O	NOUN	B
aminotransferase	O	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.137	O	NUM	O
;	O	PUNCT	O
alanine	O	NOUN	B
aminotransferase	O	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.616	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
bilirubin	B-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.980	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
hyaluronic	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
increase	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.514	O	NUM	O
)	O	PUNCT	O
revealed	O	VERB	O
no	O	DET	O
differences	O	NOUN	O
.	O	PUNCT	O


Significant	B-OUT	ADJ	B
apoptosis	I-OUT	NOUN	B
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
mild-to-moderate	B-OUT	ADJ	B
leukocyte	I-OUT	NOUN	I
infiltration	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
steatosis	I-OUT	NOUN	B
in	O	ADP	O
45	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
55	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
mild	B-OUT	ADJ	B
sinusoidal	I-OUT	ADJ	O
congestion	I-OUT	NOUN	O
in	O	ADP	O
65	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
distribution	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
patients	O	NOUN	B
were	O	AUX	O
stratified	O	VERB	B
by	O	ADP	O
major	O	ADJ	O
versus	O	CCONJ	O
minor	O	ADJ	B
resections	O	NOUN	I
,	O	PUNCT	O
no	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
variables	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


Postoperative	O	ADJ	B
clinical	O	ADJ	B
outcomes	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
similar	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
protocols	B-I	NOUN	B
of	I-I	ADP	O
IPC	I-I	PROPN	B
and	I-I	CCONJ	O
APC	I-I	NOUN	B
used	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
do	O	AUX	O
not	O	PART	O
provide	O	VERB	O
better	O	ADJ	O
cytoprotection	O	NOUN	B
from	O	ADP	O
IR	O	NOUN	B
when	O	SCONJ	O
INT	B-I	PROPN	B
is	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Exploring	O	VERB	O
the	O	DET	O
social	B-OUT	ADJ	B
impact	I-OUT	NOUN	I
of	O	ADP	O
being	O	AUX	O
a	O	DET	O
typical	B-I	ADJ	O
peer	I-I	NOUN	B
model	I-I	NOUN	B
for	O	ADP	O
included	O	VERB	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
social	B-OUT	ADJ	B
impact	I-OUT	NOUN	I
of	O	ADP	O
being	O	AUX	O
a	O	DET	O
typical	O	ADJ	O
peer	O	NOUN	B
model	O	NOUN	B
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
social	B-I	ADJ	B
skills	I-I	NOUN	I
intervention	I-I	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
drawn	O	VERB	O
from	O	ADP	O
a	O	DET	O
randomized-controlled-treatment	O	ADJ	B
trial	O	NOUN	I
that	O	PRON	O
examined	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
targeted	O	VERB	B
interventions	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
social	B-OUT	ADJ	B
networks	I-OUT	NOUN	I
of	O	ADP	O
60	B-P	NUM	O
elementary-aged	I-P	ADJ	B
children	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Results	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
typical	O	ADJ	O
peer	O	NOUN	B
models	O	NOUN	B
had	O	AUX	O
higher	B-OUT	ADJ	B
social	I-OUT	ADJ	B
network	I-OUT	NOUN	I
centrality	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
received	I-OUT	VERB	O
friendships	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
friendship	I-OUT	NOUN	B
quality	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
less	I-OUT	ADJ	O
loneliness	I-OUT	NOUN	B
than	O	ADP	O
non-peer	O	ADJ	B
models	O	NOUN	B
.	O	PUNCT	O


Peer	B-I	NOUN	B
models	I-I	NOUN	B
were	O	AUX	O
also	O	ADV	O
more	B-OUT	ADV	O
likely	I-OUT	ADJ	O
to	O	PART	O
be	O	AUX	O
connected	O	VERB	O
with	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
ASD	O	VERB	B
than	O	ADP	O
non-peer	O	ADJ	B
models	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
exit	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
typical	O	ADJ	O
peers	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
socially	O	ADV	B
connected	O	VERB	O
to	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
ASD	O	PROPN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
other	O	ADJ	O
classmates	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
maintain	O	VERB	O
a	O	DET	O
strong	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
positive	I-OUT	ADJ	B
role	I-OUT	NOUN	O
within	O	ADP	O
the	O	DET	O
classroom	O	NOUN	B
.	O	PUNCT	O


Interactive	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
indomethacin	B-I	NOUN	B
,	I-I	PUNCT	O
angiotensin	I-I	NOUN	B
II	I-I	NUM	I
and	I-I	CCONJ	O
frusemide	I-I	NOUN	B
on	O	ADP	O
renal	B-P	ADJ	B
haemodynamics	I-P	NOUN	I
and	I-P	CCONJ	O
natriuresis	I-P	NOUN	B
in	I-P	ADP	O
man	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
responses	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
haemodynamic	O	ADJ	I
and	O	CCONJ	O
natriuretic	O	ADJ	B
indices	O	NOUN	I
to	O	PART	O
the	O	DET	O
oral	O	ADJ	B
prostaglandin	O	NOUN	B
synthetase	O	NOUN	I
inhibitor	O	NOUN	I
indomethacin	B-I	NOUN	B
(	I-I	PUNCT	O
200	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
to	I-I	PART	O
infused	I-I	VERB	B
angiotensin	I-I	NOUN	B
II	I-I	NUM	I
(	O	PUNCT	O
1	O	NUM	O
ng	O	NOUN	O
min-1	O	NOUN	O
kg-1	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
were	O	AUX	O
studies	O	NOUN	B
in	O	ADP	O
placebo-controlled	B-I	ADJ	B
fashion	O	NOUN	I
in	O	ADP	O
eight	B-P	NUM	O
normal	I-P	ADJ	O
male	I-P	NOUN	B
subjects	I-P	NOUN	B
both	I-P	CCONJ	O
prior	I-P	ADJ	O
to	I-P	ADP	O
and	I-P	CCONJ	O
following	I-P	VERB	O
administration	I-P	NOUN	B
of	I-P	ADP	O
intravenous	I-I	ADJ	B
frusemide	I-I	NOUN	O
(	I-P	PUNCT	O
20	I-P	NUM	O
mg	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


As	O	ADP	O
compared	O	VERB	O
with	O	ADP	O
placebo	B-I	NOUN	B
,	I-I	PUNCT	O
angiotensin	I-I	NOUN	B
II	I-I	NUM	I
infusion	I-I	NOUN	B
alone	O	ADV	O
caused	O	VERB	O
significant	O	ADJ	O
reductions	O	NOUN	B
in	O	ADP	O
absolute	B-OUT	ADJ	B
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
sodium	I-OUT	NOUN	B
excretion	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
fractional	I-OUT	ADJ	B
sodium	I-OUT	NOUN	I
excretion	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
urine	I-OUT	NOUN	B
flow	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
renal	I-OUT	ADJ	B
plasma	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
(	O	PUNCT	O
all	O	DET	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
vs	O	CCONJ	O
placebo	O	NOUN	B
)	O	PUNCT	O
but	O	CCONJ	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
glomerular	B-OUT	ADJ	B
filtration	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
only	O	ADJ	O
change	O	NOUN	O
observed	O	VERB	B
in	O	ADP	O
these	O	DET	O
parameters	O	NOUN	B
with	O	ADP	O
indomethacin	B-I	NOUN	B
alone	O	ADV	O
was	O	AUX	O
a	O	DET	O
small	O	ADJ	B
but	O	CCONJ	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
urine	B-OUT	NOUN	B
flow	I-OUT	NOUN	I
rate	I-OUT	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
vs	O	CCONJ	O
placebo	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


As	O	ADP	O
compared	O	VERB	O
with	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
angiotensin	O	NOUN	B
II	O	NUM	I
alone	O	ADV	O
,	O	PUNCT	O
indomethacin	B-I	NOUN	B
pre-treatment	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
angiotensin	B-I	NOUN	B
II	I-I	NUM	I
infusion	I-I	NOUN	B
led	O	VERB	O
to	O	PART	O
much	O	ADV	O
greater	O	ADJ	O
falls	B-OUT	NOUN	B
in	O	ADP	O
absolute	B-OUT	ADJ	B
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
sodium	I-OUT	NOUN	B
excretion	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
fractional	I-OUT	ADJ	B
sodium	I-OUT	NOUN	I
excretion	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
urine	I-OUT	NOUN	B
flow	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
renal	I-OUT	ADJ	B
plasma	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
(	O	PUNCT	O
all	O	DET	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
vs	O	CCONJ	O
placebo	B-I	NOUN	B
)	I-I	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
glomerular	B-OUT	ADJ	B
filtration	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
not	O	PART	O
observed	O	VERB	O
with	O	ADP	O
angiotensin	O	NOUN	B
II	O	NUM	I
alone	O	ADV	O
.	O	PUNCT	O


Frusemide	B-I	NOUN	B
administration	O	NOUN	B
at	O	ADP	O
the	O	DET	O
midpoint	O	NOUN	B
of	O	ADP	O
each	O	DET	O
study	O	NOUN	B
limb	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
each	O	DET	O
case	O	NOUN	B
in	O	ADP	O
a	O	DET	O
prompt	O	NOUN	O
15	O	NUM	O
to	O	PART	O
20	O	NUM	O
fold	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
natriuresis	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
renal	B-OUT	ADJ	B
haemodynamic	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
natriuretic	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
of	O	ADP	O
angiotensin	O	NOUN	B
II	O	NUM	I
,	O	PUNCT	O
indomethacin	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
combination	O	NOUN	B
were	O	AUX	O
not	O	PART	O
qualitatively	O	ADV	B
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
observed	O	VERB	B
in	O	ADP	O
the	O	DET	O
pre-frusemide	B-I	ADJ	B
phase	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
provide	O	VERB	O
a	O	DET	O
clear	O	ADJ	O
demonstration	O	NOUN	B
in	O	ADP	O
man	B-P	NOUN	B
of	O	ADP	O
the	O	DET	O
important	O	ADJ	O
homeostatic	B-OUT	ADJ	B
role	I-OUT	NOUN	O
of	O	ADP	O
renal	O	ADJ	B
prostaglandins	O	NOUN	I
in	O	ADP	O
preserving	O	VERB	O
renal	B-OUT	ADJ	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
particularly	I-OUT	ADV	O
glomerular	I-OUT	ADJ	B
filtration	I-OUT	NOUN	I
,	O	PUNCT	O
under	O	ADP	O
conditions	O	NOUN	B
of	O	ADP	O
elevated	O	ADJ	B
circulating	O	VERB	O
angiotensin	O	NOUN	B
II	O	NUM	I
.	O	PUNCT	O


Levels	O	NOUN	B
of	O	ADP	O
opioid	B-P	ADJ	B
physical	I-P	ADJ	B
dependence	I-P	NOUN	I
in	I-P	ADP	O
heroin	I-P	NOUN	B
addicts	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
opioid	O	ADJ	B
physical	O	ADJ	B
dependence	O	NOUN	I
in	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
long-term	B-P	ADJ	B
heroin	I-P	NOUN	B
addicts	I-P	NOUN	I
were	O	AUX	O
ascertained	O	VERB	O
by	O	ADP	O
measuring	O	VERB	B
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
opioid	B-OUT	NOUN	B
withdrawal	I-OUT	NOUN	O
syndrome	I-OUT	NOUN	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
pharmacological	O	ADJ	B
challenge	O	NOUN	O
with	O	ADP	O
either	O	CCONJ	O
0.4	O	NUM	O
mg	O	NOUN	O
naloxone	B-I	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Prior	O	ADV	O
to	O	ADP	O
challenge	O	NOUN	O
,	O	PUNCT	O
patients	O	NOUN	B
manifested	O	VERB	O
some	O	DET	O
subjective	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
but	O	CCONJ	O
few	O	ADJ	O
objective	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
opioid	O	NOUN	B
withdrawal	O	NOUN	B
.	O	PUNCT	O


Patients	B-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
18	I-P	NUM	O
)	I-P	PUNCT	O
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mean	O	ADJ	B
score	O	NOUN	I
on	O	ADP	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
rating	O	NOUN	B
scales	O	NOUN	I
used	O	VERB	O
to	O	PART	O
assess	O	VERB	O
opioid	O	NOUN	B
withdrawal	O	NOUN	B
.	O	PUNCT	O


Patients	B-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
naloxone	I-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
58	I-P	NUM	O
)	I-P	PUNCT	O
showed	O	VERB	O
significant	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
mean	O	NOUN	B
scores	O	NOUN	I
on	O	ADP	O
all	O	DET	O
three	O	NUM	O
rating	O	NOUN	B
scales	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
was	O	AUX	O
due	O	ADJ	O
primarily	O	ADV	O
to	O	PART	O
increases	O	NOUN	B
observed	O	VERB	B
in	O	ADP	O
a	O	DET	O
minority	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Sixty-one	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
manifest	O	VERB	O
clinically	O	ADV	B
significant	O	ADJ	I
changes	O	NOUN	B
in	O	ADP	O
subjective	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
74	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
manifest	O	VERB	O
clinically	O	ADV	B
significant	O	ADJ	I
changes	O	NOUN	B
in	O	ADP	O
objective	B-OUT	ADJ	O
signs	I-OUT	NOUN	O
of	I-OUT	ADP	O
opioid	I-OUT	NOUN	B
withdrawal	I-OUT	NOUN	B
following	O	VERB	O
naloxone	B-I	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
substantial	O	ADJ	O
subgroup	O	NOUN	B
of	O	ADP	O
heroin	O	NOUN	B
addicts	O	NOUN	B
are	O	AUX	O
able	O	ADJ	O
to	O	PART	O
use	O	VERB	O
opioids	O	NOUN	B
regularly	O	ADV	B
while	O	SCONJ	O
maintaining	O	VERB	O
relatively	O	ADV	O
low	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
physical	O	ADJ	B
dependence	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
comparative	O	ADJ	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
study	O	NOUN	I
of	O	ADP	O
clarithromycin	B-I	NOUN	B
,	I-I	PUNCT	O
roxithromycin	I-I	NOUN	B
and	I-I	CCONJ	O
erythromycin	I-I	NOUN	B
stearate	I-I	NOUN	B
in	O	ADP	O
mild	B-P	ADJ	B
pneumonia	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
clarithromycin	B-I	NOUN	B
,	I-I	PUNCT	O
roxithromycin	I-I	NOUN	B
and	I-I	CCONJ	O
erythromycin	I-I	NOUN	B
stearate	I-I	NOUN	B
in	O	ADP	O
mild	O	ADJ	B
pneumonia	O	NOUN	I
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Eighty-six	B-P	NUM	O
male	I-P	NOUN	B
patients	I-P	NOUN	B
,	I-P	PUNCT	O
doing	I-P	VERB	O
their	I-P	PRON	O
obligatory	I-P	ADJ	O
military	I-P	ADJ	B
service	I-P	NOUN	I
,	I-P	PUNCT	O
ranging	I-P	VERB	O
between	I-P	ADP	O
19	I-P	NUM	O
and	I-P	CCONJ	O
24	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	NOUN	O
20	I-P	NUM	O
)	I-P	PUNCT	O
,	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
treated	O	VERB	B
:	O	PUNCT	O
29	O	NUM	O
with	O	ADP	O
clarithromycin	B-I	NOUN	B
500	I-I	NUM	O
mg	I-I	NOUN	O
12-hourly	I-I	ADV	O
,	I-I	PUNCT	O
30	I-I	NUM	O
with	I-I	ADP	O
roxithromycin	I-I	NOUN	B
150	I-I	NUM	O
mg	I-I	NOUN	O
12-hourly	I-I	ADJ	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
27	I-I	NUM	O
with	I-I	ADP	O
erythromycin	I-I	NOUN	B
stearate	I-I	NOUN	B
500	O	NUM	O
mg	O	NOUN	O
6-hourly	O	ADV	B
,	O	PUNCT	O
each	O	DET	O
course	O	NOUN	B
being	O	AUX	O
administered	O	VERB	B
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Seventy-eight	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
able	I-P	ADJ	O
to	I-P	PART	O
be	I-P	AUX	O
evaluated	I-P	VERB	B
for	I-P	ADP	O
efficacy	I-OUT	NOUN	B
,	O	PUNCT	O
28	O	NUM	O
receiving	O	VERB	O
clarithromycin	B-I	NOUN	B
,	O	PUNCT	O
28	O	NUM	O
roxithromycin	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
22	O	NUM	O
erythromycin	B-I	NOUN	B
stearate	I-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
among	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
terms	B-OUT	NOUN	O
of	I-OUT	ADP	O
clinical	I-OUT	ADJ	B
success	I-OUT	NOUN	I
rates	I-OUT	NOUN	I
(	O	PUNCT	O
clinical	O	ADJ	B
cure	O	NOUN	I
or	O	CCONJ	O
improvement	O	NOUN	B
:	O	PUNCT	O
89	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
clarithromycin	B-I	NOUN	B
,	O	PUNCT	O
82	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
roxithromycin	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
73	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
erythromycin	B-I	NOUN	B
stearate	I-I	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.32	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
significant	O	ADJ	O
differences	O	NOUN	O
among	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
clinical	B-OUT	ADJ	B
cure	I-OUT	NOUN	I
rates	I-OUT	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
clarithromycin	B-I	NOUN	B
,	O	PUNCT	O
64	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
roxithromycin	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
41	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
erythromycin	B-I	NOUN	B
stearate	I-I	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
mostly	I-OUT	ADV	O
gastrointestinal	I-OUT	ADJ	B
,	O	PUNCT	O
caused	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
in	O	ADP	O
3.4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
clarithromycin	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
6.6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
roxithromycin	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
18.5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
erythromycin	B-I	NOUN	B
stearate	I-I	NOUN	B
group	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
among	O	ADP	O
the	O	DET	O
three	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
clinical	O	ADJ	B
success	O	NOUN	I
rates	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
that	O	SCONJ	O
clarithromycin	B-I	NOUN	B
and	O	CCONJ	O
roxithromycin	B-I	NOUN	B
were	O	AUX	O
better	O	ADV	O
tolerated	B-OUT	VERB	B
.	I-OUT	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
triiodothyronine	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
survival	B-OUT	NOUN	B
of	I-OUT	ADP	O
high-risk	I-OUT	ADJ	B
patients	I-OUT	NOUN	B
undergoing	I-P	VERB	O
open	I-I	ADJ	B
heart	I-I	NOUN	I
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


Experimental	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
shown	O	VERB	O
the	O	DET	O
beneficial	B-OUT	ADJ	O
effects	I-OUT	NOUN	B
of	O	ADP	I
triiodothyronine	B-I	NOUN	B
(	I-I	PUNCT	O
T3	I-I	NOUN	B
)	I-I	PUNCT	O
following	O	VERB	O
myocardial	O	ADJ	B
revascularization	O	NOUN	I
on	O	ADP	O
cardiopulmonary	B-I	NOUN	B
bypass	I-I	NOUN	I
(	I-I	PUNCT	O
CPB	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
open-label	B-P	ADJ	B
T3	I-I	NOUN	B
was	I-P	AUX	O
administered	I-P	VERB	B
to	I-P	PART	O
68	I-P	NUM	O
high-risk	I-P	ADJ	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
open	I-P	ADJ	B
heart	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
New	B-OUT	PROPN	B
Jersey	I-OUT	PROPN	I
Risk	I-OUT	NOUN	I
Assessment	I-OUT	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
calculate	O	VERB	B
the	O	DET	O
preoperative	B-OUT	ADJ	B
estimated	I-OUT	VERB	O
surgical	I-OUT	ADJ	B
mortality	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	O	DET	O
loading	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
T3	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
:	O	PUNCT	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
at	O	ADP	O
release	O	NOUN	B
of	O	ADP	O
the	O	DET	O
aortic	O	ADJ	B
cross-clamp	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
whenever	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
became	O	VERB	O
CPB	O	NOUN	B
dependent	O	ADJ	B
,	O	PUNCT	O
(	O	PUNCT	O
c	O	X	O
)	O	PUNCT	O
if	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
exhibited	O	VERB	O
low	O	ADJ	B
cardiac	O	ADJ	B
output	O	NOUN	I
after	O	ADP	O
discontinuing	O	VERB	B
CPB	O	NOUN	B
and	O	CCONJ	O
(	O	PUNCT	O
d	O	X	O
)	O	PUNCT	O
as	O	ADP	O
pretreatment	O	NOUN	B
before	O	ADP	O
initiating	O	VERB	O
CPB	O	PROPN	B
.	O	PUNCT	O


All	O	DET	O
therapeutic	O	ADJ	B
modalities	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
continuous	O	ADJ	B
T3	B-I	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
T3	B-I	NOUN	B
therapy	I-I	NOUN	I
,	I-I	PUNCT	O
CPB	I-I	PROPN	B
was	O	AUX	O
discontinued	O	VERB	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
upon	O	SCONJ	O
discriminant	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
26	O	NUM	O
deaths	B-OUT	NOUN	B
were	O	AUX	O
expected	O	VERB	O
from	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
7	O	NUM	O
patients	O	NOUN	B
died	B-OUT	VERB	B
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
observed	B-OUT	VERB	O
mortality	I-OUT	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
72	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.007	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
T3	B-I	NOUN	B
had	O	AUX	O
a	O	DET	O
major	O	ADJ	O
impact	O	NOUN	B
on	O	ADP	O
reducing	B-OUT	VERB	B
surgical	I-OUT	ADJ	B
mortality	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
advocated	O	VERB	O
as	O	ADP	O
a	O	DET	O
new	O	ADJ	O
therapeutic	O	ADJ	B
modality	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
high	I-P	ADJ	O
estimated	I-OUT	VERB	B
mortality	I-OUT	NOUN	B
undergoing	I-P	VERB	O
open	I-P	ADJ	B
heart	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


Active	B-OUT	ADJ	B
warming	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
not	I-OUT	PART	O
passive	I-OUT	ADJ	O
heat	I-OUT	NOUN	O
retention	I-OUT	NOUN	O
,	O	PUNCT	O
maintains	O	VERB	O
normothermia	B-OUT	NOUN	B
during	O	ADP	O
combined	O	ADJ	O
epidural-general	O	ADJ	B
anesthesia	O	NOUN	I
for	O	ADP	O
hip	B-P	NOUN	B
and	I-P	CCONJ	O
knee	I-P	NOUN	B
arthroplasty	I-P	NOUN	I
.	I-P	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
to	O	PART	O
compare	O	VERB	B
passive	O	ADJ	B
heat	O	NOUN	O
retention	O	NOUN	O
by	O	ADP	O
low-flow	O	ADJ	B
anesthesia	O	NOUN	I
,	O	PUNCT	O
alone	O	ADV	O
and	O	CCONJ	O
with	O	ADP	O
additional	O	ADJ	O
thermal	O	ADJ	B
insulation	O	NOUN	B
by	O	ADP	O
reflective	O	ADJ	B
blankets	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
forced-air	O	ADJ	B
warming	O	NOUN	I
preventing	O	VERB	O
intraoperative	O	ADJ	B
hypothermia	O	NOUN	B
during	O	ADP	O
combined	O	ADJ	O
epidural-general	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
study	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Inpatient	B-P	ADJ	B
anesthesia	I-P	NOUN	I
at	I-P	ADP	O
a	I-P	DET	O
university	I-P	NOUN	B
department	I-P	NOUN	I
of	I-P	ADP	O
orthopedic	I-P	ADJ	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	B-P	VERB	O
30	I-P	NUM	O
ASA	I-P	NOUN	B
physical	I-P	ADJ	B
status	I-P	NOUN	I
I	I-P	NUM	I
and	I-P	CCONJ	O
II	I-P	NUM	B
patients	I-P	NOUN	B
,	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
scheduled	I-P	VERB	B
for	I-P	ADP	O
elective	I-P	ADJ	B
hip	I-P	NOUN	B
or	I-P	CCONJ	O
knee	I-P	NOUN	B
arthroplasty	I-P	NOUN	I
and	I-P	CCONJ	O
were	I-P	AUX	O
free	I-P	ADJ	B
from	I-P	ADP	O
systemic	I-P	ADJ	B
disease	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
Patients	O	NOUN	B
received	O	VERB	O
epidural	O	ADJ	B
block	O	NOUN	I
up	O	ADV	O
to	O	PART	O
T10	O	NOUN	O
by	O	ADP	O
alkalinized	B-I	ADJ	B
lidocaine	I-I	NOUN	O
2	I-I	NUM	O
%	I-I	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
were	O	AUX	O
administered	O	VERB	B
standard	B-I	ADJ	O
general	I-I	ADJ	B
anesthesia	I-I	NOUN	I
by	I-I	ADP	O
means	I-I	NOUN	O
of	I-I	ADP	O
low-flow	I-I	ADJ	B
rebreathing	I-I	NOUN	I
system	I-I	NOUN	I
(	O	PUNCT	O
fresh	O	ADJ	B
gas	O	NOUN	O
flow	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
L/min	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
procedures	O	NOUN	B
started	O	VERB	O
between	O	ADP	O
8	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
AM	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
operating	O	VERB	B
room	O	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
)	O	PUNCT	O
temperature	O	NOUN	B
was	O	AUX	O
maintained	O	VERB	B
between	O	ADP	O
21	O	NUM	O
degrees	O	NOUN	B
and	O	CCONJ	O
23	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
relative	O	ADJ	B
humidity	O	NOUN	I
ranging	O	VERB	O
between	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
45	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


For	O	ADP	O
heat	O	NOUN	B
retention	O	NOUN	I
or	O	CCONJ	O
warming	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
patients	O	NOUN	B
received	O	VERB	O
either	O	CCONJ	O
low-flow	B-I	ADJ	B
anesthesia	I-I	NOUN	I
only	I-I	ADV	O
(	O	PUNCT	O
control	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
low-flow	B-I	ADJ	B
anesthesia	I-I	NOUN	I
with	I-I	ADP	O
additional	I-I	ADJ	O
reflective	I-I	ADJ	B
blankets	I-I	NOUN	B
(	O	PUNCT	O
blanket	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
low-flow	B-I	ADJ	B
anesthesia	I-I	NOUN	I
with	I-I	ADP	O
active	I-I	ADJ	O
forced-air	I-I	ADJ	B
warming	I-I	NOUN	I
(	O	PUNCT	O
forced-air	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Tympanic	B-OUT	ADJ	B
temperature	I-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
OR	O	ADJ	B
arrival	O	NOUN	B
(	O	PUNCT	O
baseline	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
immediately	O	ADV	O
following	O	VERB	O
general	O	ADJ	B
anesthesia	O	NOUN	I
induction	O	NOUN	B
;	O	PUNCT	O
30	O	NUM	O
,	O	PUNCT	O
60	O	NUM	O
,	O	PUNCT	O
90	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
120	O	NUM	O
minutes	O	NOUN	O
from	O	ADP	O
general	O	ADJ	B
anesthesia	O	NOUN	I
induction	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
MAIN	O	NOUN	O
RESULTS	O	NOUN	O
Duration	B-OUT	NOUN	B
of	I-OUT	ADP	I
anesthesia	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
invasiveness	I-OUT	NOUN	B
of	I-OUT	ADP	O
surgery	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
baseline	I-OUT	NOUN	B
core	I-OUT	NOUN	B
temperature	I-OUT	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Core	B-OUT	NOUN	B
temperature	I-OUT	NOUN	I
decreased	O	VERB	B
in	O	ADP	O
all	O	DET	O
the	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
30	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
general	O	ADJ	B
anesthesia	O	NOUN	I
induction	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
afterwards	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
progressively	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
and	O	CCONJ	O
blankets	O	NOUN	B
groups	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
reduction	B-OUT	NOUN	B
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
values	I-OUT	NOUN	B
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
surgery	O	NOUN	B
of	O	ADP	O
2.0	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
and	O	CCONJ	O
1.6	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
forced-air	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
after	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
significant	O	ADJ	O
decrease	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
vs.	O	CCONJ	O
baseline	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
core	B-OUT	NOUN	B
temperature	I-OUT	NOUN	I
progressively	O	ADV	O
increased	O	VERB	B
to	O	ADP	O
35.8	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
preoperative	O	ADJ	B
values	O	NOUN	B
and	O	CCONJ	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
either	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
or	O	CCONJ	O
blankets	O	NOUN	B
groups	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
During	O	ADP	O
combined	O	ADJ	O
epidural-general	O	ADJ	B
anesthesia	O	NOUN	I
for	O	ADP	O
elective	B-P	ADJ	B
hip	I-P	NOUN	B
and	I-P	CCONJ	O
knee	I-P	NOUN	B
arthroplasty	I-P	NOUN	I
,	O	PUNCT	O
passive	O	ADJ	B
heat	O	NOUN	I
retention	O	NOUN	I
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
low-flow	B-I	ADJ	B
anesthesia	I-I	NOUN	I
alone	I-I	ADV	O
and	I-I	CCONJ	O
in	I-I	ADP	O
combination	I-I	NOUN	B
with	I-I	ADP	O
reflective	I-I	ADJ	B
blankets	I-I	NOUN	B
is	O	AUX	O
ineffective	O	ADJ	B
in	O	ADP	O
maintaining	B-OUT	VERB	O
intraoperative	I-OUT	ADJ	B
normothermia	I-OUT	NOUN	B
and	O	CCONJ	O
definitely	O	ADV	O
inferior	O	ADJ	O
to	O	PART	O
active	O	ADJ	O
forced-air	O	ADJ	B
warning	O	NOUN	B
.	O	PUNCT	O


Joint	O	ADJ	B
attention	O	NOUN	B
and	O	CCONJ	O
symbolic	O	ADJ	B
play	O	NOUN	O
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
intervention	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Delays	O	NOUN	B
and	O	CCONJ	O
deficits	O	NOUN	B
in	O	ADP	O
joint	O	ADJ	B
attention	O	NOUN	B
and	O	CCONJ	O
symbolic	O	ADJ	B
play	O	NOUN	O
constitute	O	VERB	O
two	O	NUM	O
important	O	ADJ	O
developmental	O	ADJ	B
problems	O	NOUN	O
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


These	O	DET	O
areas	O	NOUN	O
of	O	ADP	O
deficit	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
well	O	ADV	O
studied	O	VERB	O
in	O	ADP	O
autism	O	NOUN	B
but	O	CCONJ	O
have	O	AUX	O
rarely	O	ADV	O
been	O	AUX	O
the	O	DET	O
focus	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
efforts	O	NOUN	O
(	O	PUNCT	O
see	O	VERB	O
Kasari	O	PROPN	B
,	O	PUNCT	O
Freeman	O	PROPN	B
,	O	PUNCT	O
&	O	CCONJ	O
Paparella	O	PROPN	B
,	O	PUNCT	O
2001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
examine	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
targeted	O	VERB	B
interventions	O	NOUN	B
of	O	ADP	O
joint	B-I	ADJ	B
attention	I-I	NOUN	B
and	I-I	CCONJ	O
symbolic	I-I	ADJ	B
play	I-I	NOUN	O
.	I-I	PUNCT	O


METHODS	O	NOUN	O
Participants	B-P	NOUN	B
were	I-P	AUX	O
58	I-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
aged	I-P	ADJ	B
3	I-P	NUM	O
and	I-P	CCONJ	O
4	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
46	I-P	NUM	O
boys	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Children	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
a	O	DET	O
joint	B-I	ADJ	B
attention	I-I	NOUN	O
intervention	I-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
symbolic	I-I	ADJ	B
play	I-I	NOUN	O
intervention	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
control	I-I	NOUN	B
group	I-I	NOUN	I
.	I-I	PUNCT	O


Interventions	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
30	O	NUM	O
minutes	O	NOUN	B
daily	O	ADV	O
for	O	ADP	O
5-6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
structured	O	ADJ	O
assessments	O	NOUN	B
of	O	ADP	O
joint	O	ADJ	B
attention	O	NOUN	B
and	O	CCONJ	O
play	O	VERB	O
skills	O	NOUN	B
and	O	CCONJ	O
mother-child	O	ADJ	B
interactions	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
pre	O	ADJ	B
and	O	CCONJ	O
post	O	NOUN	B
intervention	O	NOUN	B
by	O	ADP	O
independent	O	ADJ	O
assessors	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Results	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
intervention	O	NOUN	B
groups	O	NOUN	I
improved	O	VERB	O
significantly	O	ADV	O
over	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
on	O	ADP	O
certain	O	ADJ	O
behaviors	O	NOUN	B
.	O	PUNCT	O


Children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
joint	O	ADJ	B
attention	O	NOUN	O
intervention	O	NOUN	B
initiated	O	VERB	O
significantly	O	ADV	O
more	O	ADV	O
showing	B-OUT	NOUN	O
and	O	CCONJ	O
responsiveness	B-OUT	NOUN	B
to	I-OUT	ADP	O
joint	I-OUT	ADJ	B
attention	I-OUT	NOUN	B
on	O	ADP	O
the	O	DET	O
structured	B-OUT	ADJ	B
joint	I-OUT	ADJ	I
attention	I-OUT	NOUN	O
assessment	I-OUT	NOUN	O
and	O	CCONJ	O
more	O	ADV	O
child-initiated	B-OUT	ADJ	B
joint	I-OUT	ADJ	I
attention	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
mother-child	B-OUT	ADJ	B
interaction	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
play	O	NOUN	O
group	O	NOUN	B
showed	O	VERB	O
more	O	ADV	O
diverse	O	ADJ	B
types	B-OUT	NOUN	O
of	I-OUT	ADP	O
symbolic	I-OUT	ADJ	B
play	I-OUT	NOUN	O
in	O	ADP	O
interaction	O	NOUN	B
with	O	ADP	O
their	O	PRON	O
mothers	O	NOUN	B
and	O	CCONJ	O
higher	O	ADJ	B
play	B-OUT	NOUN	O
levels	I-OUT	NOUN	B
on	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
play	B-OUT	NOUN	O
assessment	I-OUT	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
interaction	B-OUT	NOUN	B
with	I-OUT	ADP	O
their	I-OUT	PRON	O
mothers	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
provides	O	VERB	O
promising	O	ADJ	O
data	O	NOUN	B
on	O	ADP	O
the	O	DET	O
specificity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
generalizability	I-OUT	NOUN	B
of	I-OUT	ADP	O
joint	I-OUT	ADJ	B
attention	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
play	I-OUT	VERB	O
interventions	I-OUT	NOUN	B
for	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Future	O	ADJ	O
studies	O	NOUN	B
need	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
these	O	DET	O
early	O	ADJ	B
interventions	O	NOUN	B
on	O	ADP	O
children	O	NOUN	B
's	O	PART	I
development	O	NOUN	B
.	O	PUNCT	O


Butorphanol	B-I	NOUN	B
and	I-I	CCONJ	O
meperidine	I-I	NOUN	B
compared	O	VERB	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
ureteral	I-P	ADJ	I
colic	I-P	NOUN	I
.	I-P	PUNCT	O


Pain	O	PROPN	B
relief	O	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
81	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
ureteral	I-P	ADJ	I
colic	I-P	NOUN	I
and	I-P	CCONJ	O
the	I-P	DET	O
confirmed	I-P	VERB	O
presence	I-P	NOUN	B
of	I-P	ADP	O
a	I-P	DET	O
calculus	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
randomized	B-P	ADJ	B
double-blind	I-P	ADJ	B
comparison	I-P	NOUN	B
of	I-P	ADP	O
intramuscular	I-P	NOUN	B
2	I-P	NUM	O
and	I-P	CCONJ	O
4	I-P	NUM	O
mg.	I-P	NOUN	O
butorphanol	I-I	NOUN	B
and	I-I	CCONJ	O
80	I-P	NUM	O
mg.	I-P	NOUN	O
meperidine	I-I	NOUN	B
was	I-P	AUX	O
used	I-P	VERB	O
.	I-P	PUNCT	O


Pain	B-OUT	NOUN	B
intensity	I-OUT	NOUN	I
and	O	CCONJ	O
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
at	O	ADP	O
half	O	NUM	O
hour	O	NOUN	B
and	O	CCONJ	O
hourly	O	ADJ	B
intervals	O	NOUN	B
for	O	ADP	O
4	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
2	O	NUM	O
mg.	O	NOUN	O
dose	O	NOUN	B
of	O	ADP	O
butorphanol	B-I	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
analgesically	O	ADV	B
equivalent	O	ADJ	B
to	O	PART	O
80	O	NUM	O
mg.	O	NOUN	O
meperidine	B-I	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
a	O	DET	O
4	O	NUM	O
mg.	O	NOUN	O
dose	O	NOUN	B
of	O	ADP	O
butorphanol	B-I	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
80	O	NUM	O
mg.	O	NOUN	O
meperidine	B-I	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
mg.	O	NOUN	O
butorphanol	B-I	NOUN	B
.	I-I	PUNCT	O


Each	O	DET	O
patient	O	NOUN	B
received	O	VERB	O
up	O	ADP	O
to	O	PART	O
2	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
analgesic	O	NOUN	B
medication	O	NOUN	I
when	O	SCONJ	O
necessary	O	ADJ	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
among	O	ADP	O
treatments	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
had	O	AUX	O
visual	B-OUT	ADJ	B
hallucinations	I-OUT	NOUN	I
after	O	ADP	O
a	O	DET	O
2	O	NUM	O
mg.	O	NOUN	O
dose	O	NOUN	B
of	O	ADP	O
butorphanol	B-I	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
owing	O	VERB	O
to	O	ADP	O
its	O	PRON	O
antagonistic	O	ADJ	B
activity	O	NOUN	I
to	O	PART	O
significant	O	ADJ	B
narcotic	O	ADJ	B
experience	O	NOUN	B
given	O	VERB	O
previously	O	ADV	O
at	O	ADP	O
another	O	DET	O
hospital	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
other	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
toxicity	B-OUT	NOUN	B
with	O	ADP	O
butorphanol	B-I	NOUN	B
.	I-I	PUNCT	O


It	O	PRON	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
safe	B-OUT	ADJ	O
,	I-OUT	PUNCT	O
effective	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
wall	I-OUT	NOUN	B
tolerated	I-OUT	ADJ	I
drug	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
ureteral	O	ADJ	B
colic	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
recommended	O	VERB	B
in	O	ADP	O
place	O	NOUN	O
of	O	ADP	O
narcotics	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
inhaled	O	VERB	B
heparin	B-I	NOUN	I
on	O	ADP	O
adenosine-induced	B-P	ADJ	B
bronchial	I-P	ADJ	I
hyperreactivity	I-P	NOUN	I
.	I-P	PUNCT	O


Glycosaminoglycan	B-I	NOUN	B
heparin	I-I	NOUN	I
possesses	O	VERB	O
multiple	O	ADJ	O
noncoagulant	O	ADJ	B
properties	O	NOUN	B
including	O	VERB	O
antiinflammatory	O	ADJ	B
actions	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
heparin	B-I	NOUN	B
attenuates	O	VERB	B
the	O	DET	O
methacholine-induced	O	ADJ	B
bronchoconstriction	O	NOUN	I
in	O	ADP	O
humans	B-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
methacholine	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
stimulus	O	NOUN	B
that	O	PRON	O
induces	O	VERB	B
airway	O	NOUN	B
constriction	O	NOUN	O
mainly	O	ADV	O
by	O	ADP	O
"	O	PUNCT	O
direct	O	ADJ	O
"	O	PUNCT	O
stimulation	O	NOUN	B
of	O	ADP	O
airway	O	NOUN	B
smooth	O	ADJ	B
muscle	O	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
adenosine	O	NOUN	B
airway	O	NOUN	I
responsiveness	O	NOUN	B
reflects	O	VERB	O
"	O	PUNCT	O
indirectly	O	ADV	B
"	O	PUNCT	O
induced	O	VERB	B
airway	O	NOUN	B
narrowing	O	VERB	O
via	O	ADP	O
inflammatory	O	ADJ	B
mediators	O	NOUN	I
or	O	CCONJ	O
neural	O	ADJ	B
reflex	O	ADJ	I
mechanisms	O	NOUN	B
.	O	PUNCT	O


Whether	O	SCONJ	O
heparin	B-I	NOUN	B
modulates	O	VERB	B
bronchial	O	ADJ	B
hyperreactivity	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
adenosine	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
not	O	PART	O
well	O	ADV	O
known	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
inhaled	B-I	VERB	B
heparin	I-I	NOUN	I
on	O	ADP	O
adenosine-induced	O	ADJ	B
bronchoconstriction	O	NOUN	I
and	O	CCONJ	O
compared	O	VERB	B
the	O	DET	O
inhibitory	O	ADJ	B
role	O	NOUN	O
of	O	ADP	O
heparin	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
adenosine	O	NOUN	B
challenge	O	NOUN	O
test	O	NOUN	O
with	O	ADP	O
that	O	DET	O
on	O	ADP	O
the	O	DET	O
methacholine	O	NOUN	B
challenge	O	NOUN	O
test	O	NOUN	O
.	O	PUNCT	O


Fifteen	B-P	NUM	O
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
7	I-P	NUM	O
males	I-P	NOUN	B
,	I-P	PUNCT	O
8	I-P	NUM	O
females	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
mild	I-P	ADJ	B
asthma	I-P	NOUN	I
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Bronchial	O	ADJ	B
provocation	O	NOUN	I
tests	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
a	O	DET	O
single-blind	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
order	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
repeated	O	VERB	O
45	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
placebo	B-I	NOUN	B
or	O	CCONJ	O
aerosolized	B-I	ADJ	B
heparin	I-I	NOUN	B
inhalation	I-I	NOUN	B
(	O	PUNCT	O
1,000	O	NUM	O
U/kg	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
heparin	B-I	NOUN	B
increased	O	VERB	B
the	O	DET	O
geometric	B-OUT	ADJ	B
mean	I-OUT	NOUN	I
log	I-OUT	NOUN	I
methacholine	I-OUT	NOUN	I
PD20	I-OUT	NOUN	B
value	I-OUT	NOUN	O
from	O	ADP	O
0.47	O	NUM	O
+/-	O	CCONJ	O
0.16	O	NUM	O
(	O	PUNCT	O
2.95	O	NUM	O
mg/ml	O	NOUN	O
)	O	PUNCT	O
to	O	PART	O
0.96	O	NUM	O
+/-	O	CCONJ	O
0.10	O	NUM	O
(	O	PUNCT	O
8.91	O	NUM	O
mg/ml	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0009	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
15	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
geometric	B-OUT	ADJ	B
mean	I-OUT	NOUN	I
log	I-OUT	NOUN	I
adenosine	I-OUT	NOUN	I
PD20	I-OUT	NOUN	I
values	I-OUT	NOUN	B
from	O	ADP	O
1.59	O	NUM	O
+/-	O	CCONJ	O
0.23	O	NUM	O
(	O	PUNCT	O
38.9	O	NUM	O
mg/ml	O	NOUN	O
)	O	PUNCT	O
to	O	PART	O
1.98	O	NUM	O
+/-	O	CCONJ	O
0.14	O	NUM	O
(	O	PUNCT	O
97.7	O	NUM	O
mg/ml	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
NS	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
7	O	NUM	O
patients	O	NOUN	B
whose	O	DET	O
baseline	O	NOUN	B
adenosine	O	NOUN	B
PD20	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
200	O	NUM	O
mg/ml	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
protection	I-OUT	NOUN	B
by	O	ADP	O
heparin	B-I	NOUN	B
against	O	ADP	O
adenosine-induced	O	ADJ	B
bronchoconstriction	O	NOUN	I
was	O	AUX	O
not	O	PART	O
correlated	O	VERB	B
with	O	ADP	O
that	O	DET	O
against	O	ADP	O
methacholine-induced	O	ADJ	B
bronchoconstriction	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.60	O	NUM	O
,	O	PUNCT	O
NS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
inhaled	O	VERB	B
heparin	B-I	NOUN	I
may	O	AUX	O
have	O	AUX	O
an	O	DET	O
inhibitory	O	ADJ	B
effect	O	NOUN	O
on	O	ADP	O
the	O	DET	O
methacholine	O	NOUN	B
bronchial	O	ADJ	O
challenge	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
thus	O	ADV	O
,	O	PUNCT	O
most	O	ADV	O
likely	O	ADV	O
directs	O	VERB	O
its	O	PRON	O
effect	O	NOUN	B
against	O	ADP	O
smooth	O	ADJ	B
muscle	O	NOUN	I
.	O	PUNCT	O


Heparin	B-I	NOUN	B
caused	O	VERB	O
less	O	ADJ	O
attenuation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
challenge	O	NOUN	O
with	O	ADP	O
adenosine	O	NOUN	B
and	O	CCONJ	O
probably	O	ADV	O
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
mast	O	NOUN	B
cell	O	NOUN	I
degranulation	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
verbal	B-I	ADJ	B
and	I-I	CCONJ	O
pictorial	I-I	ADJ	O
naturalistic	I-I	ADJ	O
communication	I-I	NOUN	O
strategies	I-I	NOUN	O
on	O	ADP	O
spoken	O	VERB	B
language	O	NOUN	B
for	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Presently	O	ADV	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
consensus	O	NOUN	B
on	O	ADP	O
the	O	DET	O
specific	O	ADJ	O
behavioral	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
choice	O	NOUN	O
for	O	ADP	O
targeting	O	VERB	B
language	O	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
nonverbal	I-P	ADJ	B
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
compared	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
a	B-I	DET	O
verbally-based	I-I	ADJ	B
intervention	I-I	NOUN	I
,	I-I	PUNCT	O
Pivotal	I-I	PROPN	B
Response	I-I	PROPN	I
Training	I-I	PROPN	I
(	I-I	PUNCT	O
PRT	I-I	PROPN	B
)	I-I	PUNCT	O
to	I-I	PART	O
a	I-I	DET	O
pictorially-based	I-I	ADJ	B
behavioral	I-I	ADJ	B
intervention	I-I	NOUN	B
,	I-I	PUNCT	O
the	I-I	DET	O
Picture	I-I	PROPN	B
Exchange	I-I	PROPN	I
Communication	I-I	PROPN	I
System	I-I	PROPN	I
(	I-I	PUNCT	O
PECS	I-I	NOUN	B
)	I-I	PUNCT	O
on	I-I	ADP	O
the	I-I	DET	O
acquisition	I-I	NOUN	B
of	I-I	ADP	O
spoken	I-I	VERB	B
language	I-I	NOUN	B
by	O	ADP	O
young	B-P	ADJ	B
(	I-P	PUNCT	O
2-4	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
nonverbal	I-P	ADJ	B
or	I-P	CCONJ	O
minimally	I-P	ADV	B
verbal	I-P	ADJ	I
(	I-P	PUNCT	O
≤9	I-P	ADJ	O
words	I-P	NOUN	B
)	I-P	PUNCT	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


Thirty-nine	B-P	NUM	O
children	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
the	B-I	DET	O
PRT	I-I	PROPN	B
or	I-I	CCONJ	O
PECS	I-I	NOUN	B
condition	O	NOUN	B
.	O	PUNCT	O


Participants	O	NOUN	B
received	O	VERB	O
on	O	ADP	O
average	O	ADJ	B
247	O	NUM	O
h	O	NOUN	O
of	O	ADP	O
intervention	O	NOUN	B
across	O	ADP	O
23	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Dependent	O	ADJ	B
measures	O	NOUN	B
included	B-OUT	VERB	O
overall	I-OUT	ADJ	O
communication	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
expressive	I-OUT	ADJ	B
vocabulary	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pictorial	I-OUT	ADJ	B
communication	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
parent	I-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
.	O	PUNCT	O


Children	O	NOUN	B
in	O	ADP	O
both	O	DET	O
intervention	O	NOUN	B
groups	O	NOUN	I
demonstrated	O	VERB	O
increases	B-OUT	NOUN	B
in	I-OUT	ADP	O
spoken	I-OUT	VERB	B
language	I-OUT	NOUN	B
skills	I-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
conditions	O	NOUN	B
.	O	PUNCT	O


Seventy-eight	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
all	O	DET	O
children	O	NOUN	B
exited	O	VERB	B
the	O	DET	O
program	O	NOUN	B
with	O	ADP	O
more	O	ADJ	O
than	B-OUT	ADP	O
10	I-OUT	NUM	O
functional	I-OUT	ADJ	B
words	I-OUT	NOUN	O
.	O	PUNCT	O


Parents	O	NOUN	B
were	O	AUX	O
very	O	ADV	O
satisfied	O	ADJ	O
with	O	ADP	O
both	O	DET	O
programs	O	NOUN	B
but	O	CCONJ	O
indicated	B-I	VERB	O
PECS	O	PROPN	B
was	O	AUX	O
more	O	ADV	O
difficult	O	ADJ	O
to	O	PART	O
implement	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
deep	B-I	ADJ	B
brain	I-I	NOUN	I
stimulation	I-I	NOUN	I
randomized	O	VERB	B
by	O	ADP	O
site	O	NOUN	B
on	O	ADP	O
balance	O	NOUN	B
in	O	ADP	O
Parkinson	B-P	PROPN	B
's	I-P	PART	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
surgical	O	ADJ	B
site	O	NOUN	I
of	O	ADP	O
DBS	O	PROPN	B
on	O	ADP	O
balance	O	NOUN	B
and	O	CCONJ	O
gait	O	NOUN	B
in	O	ADP	O
Parkinson	B-P	PROPN	B
's	I-P	PART	I
Disease	I-P	PROPN	I
(	I-P	PUNCT	O
PD	I-P	NOUN	B
)	I-P	PUNCT	O
is	O	AUX	O
uncertain	O	ADJ	O
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
double-blind	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
subjects	B-P	NOUN	B
randomized	I-P	VERB	B
to	I-P	PART	O
either	I-P	CCONJ	O
the	I-P	DET	O
STN	I-I	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
14	I-P	NUM	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
GPi	I-I	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
14	I-P	NUM	O
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
assessed	I-P	VERB	B
on	I-P	ADP	O
a	I-P	DET	O
range	I-P	NOUN	O
of	I-P	ADP	O
clinical	I-P	ADJ	B
balance	I-P	NOUN	O
measures	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	PROPN	O
Balance	O	NOUN	B
testing	O	NOUN	I
occurred	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
postsurgery	O	NOUN	B
.	O	PUNCT	O


A	B-P	DET	O
control	I-I	NOUN	B
PD	I-P	NOUN	B
group	I-P	NOUN	B
was	I-P	AUX	O
tested	I-P	VERB	B
over	I-P	ADP	O
the	I-P	DET	O
same	I-P	ADJ	O
period	I-P	NOUN	B
without	I-P	ADP	O
surgery	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
9	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


All	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
on	B-I	ADP	O
and	I-I	CCONJ	O
off	I-I	ADP	O
medication	I-I	NOUN	B
and	O	CCONJ	O
DBS	O	NOUN	B
subjects	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
tested	O	VERB	B
on	B-I	ADP	O
and	I-I	CCONJ	O
off	I-I	ADP	O
DBS	I-I	PROPN	B
.	I-I	PUNCT	O


The	B-OUT	DET	O
Postural	I-OUT	ADJ	B
Instability	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
Gait	I-OUT	PROPN	B
Disability	I-OUT	PROPN	I
items	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
UPDRS	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
additional	I-OUT	ADJ	O
functional	I-OUT	ADJ	B
tests	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
which	I-OUT	DET	O
we	I-OUT	PRON	O
call	I-OUT	VERB	O
the	I-OUT	DET	O
Balance	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
Gait	I-OUT	NOUN	O
scale	I-OUT	NOUN	O
,	O	PUNCT	O
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


Activities	B-OUT	NOUN	B
of	I-OUT	ADP	O
Balance	I-OUT	PROPN	O
Confidence	I-OUT	PROPN	O
and	I-OUT	CCONJ	O
Activities	I-OUT	NOUN	B
of	I-OUT	ADP	O
Daily	I-OUT	PROPN	O
Living	I-OUT	NOUN	O
questionnaires	I-OUT	NOUN	O
were	O	AUX	O
also	O	ADV	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Balance	O	NOUN	I
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
best-treated	O	ADJ	B
states	O	NOUN	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
DBS	O	PROPN	B
surgery	O	NOUN	B
for	O	ADP	O
both	O	DET	O
sites	O	NOUN	B
.	O	PUNCT	O


Switching	O	VERB	B
DBS	O	PROPN	B
on	O	ADP	O
improved	O	VERB	B
balance	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
scores	O	NOUN	B
further	O	ADV	O
improved	O	VERB	B
with	O	ADP	O
medication	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
off	O	ADJ	B
state	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
GPi	O	NOUN	B
group	O	NOUN	B
showed	O	VERB	O
improved	O	VERB	O
performance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
postsurgery	O	NOUN	B
off	O	ADP	O
state	O	NOUN	O
and	O	CCONJ	O
better	O	ADJ	O
ratings	O	NOUN	B
of	O	ADP	O
balance	B-OUT	NOUN	B
confidence	I-OUT	NOUN	I
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
STN	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Clinical	O	ADJ	B
measures	O	NOUN	I
of	O	ADP	O
balance	O	NOUN	B
function	O	NOUN	I
for	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
STN	O	NOUN	B
and	O	CCONJ	O
GPi	O	NOUN	B
sites	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
balance	O	NOUN	B
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
beyond	O	ADP	O
the	O	DET	O
best	O	ADJ	O
medically	O	ADV	O
treated	O	VERB	B
state	O	NOUN	O
before	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
clinical	O	ADJ	B
balance	O	NOUN	O
testing	O	NOUN	O
in	O	ADP	O
the	O	DET	O
off/off	O	NUM	B
state	O	NOUN	I
and	O	CCONJ	O
self-reported	O	ADJ	B
balance	O	NOUN	B
confidence	O	NOUN	I
after	O	ADP	O
surgery	O	NOUN	B
showed	O	VERB	O
better	O	ADJ	O
performance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
GPi	O	NOUN	B
than	O	ADP	O
the	O	DET	O
STN	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Dissociation	O	NOUN	B
between	O	ADP	O
cortical	O	ADJ	B
activation	O	NOUN	I
and	O	CCONJ	O
cognitive	O	ADJ	B
performance	O	NOUN	I
under	O	ADP	O
pharmacological	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
elevation	O	NOUN	I
in	O	ADP	O
chronic	O	ADJ	B
hypotension	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
explored	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
pharmacological	B-I	ADJ	B
blood	I-I	NOUN	I
pressure	I-I	NOUN	I
elevation	I-I	NOUN	I
on	O	ADP	O
cortical	O	ADJ	B
activation	O	NOUN	I
and	O	CCONJ	O
reaction	O	NOUN	B
time	O	NOUN	I
in	O	ADP	O
chronic	B-P	ADJ	B
hypotension	I-P	NOUN	I
.	I-P	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
sympathomimetic	B-I	ADJ	B
etilefrine	I-I	NOUN	I
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
50	B-P	NUM	O
hypotensive	I-P	ADJ	B
persons	I-P	NOUN	I
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
double	O	ADJ	O
blind	O	ADJ	O
design	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
an	O	DET	O
indicator	O	NOUN	B
of	O	ADP	O
cortical	O	ADJ	B
excitability	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
contingent	O	ADJ	B
negative	O	ADJ	O
variation	O	NOUN	O
(	O	PUNCT	O
CNV	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
constant	O	ADJ	B
foreperiod	O	NOUN	B
reaction	O	NOUN	O
time	O	NOUN	O
task	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
frontal	O	ADJ	B
(	O	PUNCT	O
F3	O	NOUN	O
,	O	PUNCT	O
Fz	O	NOUN	B
,	O	PUNCT	O
F4	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
central	O	ADJ	B
(	O	PUNCT	O
C3	O	NOUN	B
,	O	PUNCT	O
Cz	O	NOUN	B
,	O	PUNCT	O
C4	O	NOUN	B
)	O	PUNCT	O
scalp	O	NOUN	B
sites	O	NOUN	I
.	O	PUNCT	O


Etilefrine	B-I	NOUN	B
provoked	O	VERB	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
frontal	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
central	I-OUT	ADJ	B
CNV	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
shorter	O	ADJ	B
reaction	B-OUT	NOUN	O
times	I-OUT	NOUN	O
were	O	AUX	O
observed	O	VERB	O
following	O	VERB	O
drug	O	NOUN	B
administration	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
degree	B-OUT	NOUN	B
of	O	ADP	O
pharmacologically	O	ADV	B
induced	B-OUT	VERB	B
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
elevation	I-OUT	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
to	O	PART	O
CNV	O	NOUN	B
attrition	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
to	O	PART	O
performance	O	NOUN	B
enhancement	O	NOUN	B
.	O	PUNCT	O


Inhibitory	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
baroreceptor	O	NOUN	B
activation	O	NOUN	I
on	O	ADP	O
cortical	O	ADJ	B
excitability	O	NOUN	I
and	O	CCONJ	O
enhanced	O	VERB	B
cerebral	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
are	O	AUX	O
considered	O	VERB	O
to	O	PART	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
mediating	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
elevation	I-OUT	NOUN	I
on	O	ADP	O
cerebral	O	ADJ	B
functioning	O	NOUN	I
.	O	PUNCT	O


Implications	O	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
chronic	B-OUT	ADJ	B
hypotension	I-OUT	NOUN	I
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
trial	O	NOUN	B
of	O	ADP	O
D-cycloserine	B-I	NOUN	B
to	O	PART	O
treat	O	VERB	B
stereotypies	O	NOUN	B
in	O	ADP	O
older	B-P	ADJ	B
adolescents	I-P	NOUN	I
and	I-P	CCONJ	O
young	I-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVES	O	VERB	O
Autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
(	O	PUNCT	O
ASDs	O	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
core	O	NOUN	B
impairments	O	NOUN	I
in	O	ADP	O
social	O	ADJ	B
communication	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
repetitive	O	ADJ	B
,	O	PUNCT	O
stereotypic	O	ADJ	B
behaviors	O	NOUN	I
and	O	CCONJ	O
restricted	O	ADJ	B
interests	O	NOUN	B
.	O	PUNCT	O


Older	O	ADJ	B
adolescents	O	NOUN	I
and	O	CCONJ	O
young	O	ADJ	B
adults	O	NOUN	I
are	O	AUX	O
particularly	O	ADV	O
impacted	O	VERB	B
by	O	ADP	O
these	O	DET	O
deficits	O	NOUN	B
.	O	PUNCT	O


Preclinical	O	ADJ	B
data	O	NOUN	B
implicate	O	VERB	O
glutamatergic	O	ADJ	B
dysfunction	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
ASDs	O	PROPN	B
.	O	PUNCT	O


D-Cycloserine	B-I	NOUN	B
(	I-I	PUNCT	O
DCS	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
partial	O	ADJ	B
glycineB	O	NOUN	B
agonist	O	NOUN	B
at	O	ADP	O
the	O	DET	O
N-methyl-D-aspartic	O	ADJ	B
acid	O	NOUN	I
receptor	O	NOUN	I
site	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
improve	O	VERB	B
sociability	O	NOUN	B
in	O	ADP	O
mouse	O	NOUN	B
models	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
small	O	ADJ	O
human	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
obligatory	O	ADJ	B
glycineB	O	NOUN	B
co-agonist	O	NOUN	B
binding	O	NOUN	B
site	O	NOUN	I
may	O	AUX	O
change	O	VERB	O
with	O	ADP	O
daily	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
DCS	O	NOUN	B
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
agonist-induced	O	ADJ	B
desensitization	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
"	O	PUNCT	O
pulsed	O	ADJ	B
"	O	PUNCT	O
once-weekly	O	ADJ	B
administration	O	NOUN	B
versus	O	CCONJ	O
"	O	PUNCT	O
daily	O	ADJ	B
"	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
DCS	O	NOUN	B
was	O	AUX	O
compared	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Males	B-P	PROPN	B
and	I-P	CCONJ	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
ages	I-P	VERB	B
14	I-P	NUM	O
to	I-P	PART	O
25	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
Diagnostic	I-P	PROPN	B
and	I-P	CCONJ	O
Statistical	I-P	PROPN	O
Manual	I-P	PROPN	O
of	I-P	ADP	O
Mental	I-P	PROPN	O
Disorders	I-P	PROPN	O
,	I-P	PUNCT	O
Fourth	I-P	PROPN	O
Edition	I-P	PROPN	O
Text	I-P	PROPN	O
Revision	I-P	NOUN	B
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
an	I-P	DET	O
ASD	I-P	PROPN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
10-week	O	NOUN	I
trial	O	NOUN	I
consisting	O	VERB	O
of	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
active	O	ADJ	B
drug	O	NOUN	I
with	O	ADP	O
either	O	CCONJ	O
weekly	O	ADJ	B
or	O	CCONJ	O
daily	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
DCS	B-I	NOUN	B
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
2-week	O	ADJ	O
follow-up	O	ADJ	B
visit	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
For	O	ADP	O
the	O	DET	O
purposes	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
statistical	O	ADJ	B
or	O	CCONJ	O
clinical	O	ADJ	B
differences	B-OUT	NOUN	I
existed	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
dosage	O	NOUN	B
groups	O	NOUN	B
on	O	ADP	O
the	O	DET	O
Aberrant	B-OUT	PROPN	B
Behavior	I-OUT	PROPN	I
Checklist	I-OUT	PROPN	I
subscale	I-OUT	NOUN	I
3	I-OUT	NUM	I
,	I-OUT	PUNCT	O
which	I-OUT	DET	O
measures	I-OUT	VERB	B
stereotypies/repetitive	I-OUT	ADJ	B
movements	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


When	O	SCONJ	O
combining	O	VERB	O
groups	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
decrease	O	NOUN	B
of	O	ADP	O
37	O	NUM	O
%	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
week	O	NOUN	B
8	O	NUM	O
when	O	SCONJ	O
study	O	NOUN	B
drug	O	NOUN	B
was	O	AUX	O
completed	O	VERB	O
using	O	VERB	O
a	O	DET	O
linear	O	ADJ	B
mixed	O	ADJ	I
effects	O	NOUN	I
model	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
D-Cycloserine	B-I	NOUN	B
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
improving	O	VERB	B
stereotypic	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
in	O	ADP	O
older	O	ADJ	B
adolescents	O	NOUN	I
and	O	CCONJ	O
young	O	ADJ	B
adults	O	NOUN	I
with	O	ADP	O
ASDs	O	NOUN	B
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
Aberrant	B-OUT	PROPN	B
Behavior	I-OUT	PROPN	I
Checklist	I-OUT	PROPN	I
subscale	I-OUT	NOUN	I
3	I-OUT	NUM	I
.	I-OUT	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
DCS	B-I	NOUN	B
was	O	AUX	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
well	I-OUT	ADV	O
tolerated	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


Reduced	O	VERB	B
mortality	O	NOUN	B
among	O	ADP	O
children	B-P	NOUN	B
in	I-P	ADP	O
southern	I-P	ADJ	B
India	I-P	PROPN	I
receiving	I-P	VERB	O
a	I-P	DET	O
small	I-P	ADJ	O
weekly	I-P	ADJ	B
dose	I-P	NOUN	B
of	I-P	ADP	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
Clinical	O	ADJ	B
vitamin	O	NOUN	O
A	O	NOUN	O
deficiency	O	NOUN	B
affects	O	VERB	O
millions	O	NOUN	O
of	O	ADP	O
children	O	NOUN	B
worldwide	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
subclinical	O	ADJ	B
deficiency	O	NOUN	I
is	O	AUX	O
even	O	ADV	O
more	O	ADV	O
common	O	ADJ	O
.	O	PUNCT	O


Supplemental	O	NOUN	B
vitamin	O	NOUN	B
A	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
mortality	O	NOUN	B
among	O	ADP	O
these	O	DET	O
children	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
results	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
questioned	O	VERB	O
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
masked	O	VERB	O
clinical	O	ADJ	B
trial	O	NOUN	I
for	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
in	B-P	ADP	O
southern	I-P	ADJ	B
India	I-P	PROPN	I
involving	I-P	VERB	O
15,419	I-P	NUM	O
preschool-age	I-P	ADJ	B
children	I-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
either	I-P	CCONJ	O
8.7	I-I	NUM	O
mumol	I-I	NOUN	O
(	I-I	PUNCT	O
8333	I-I	NUM	O
IU	I-I	NOUN	B
)	I-I	PUNCT	O
of	I-I	ADP	O
vitamin	I-I	NOUN	B
A	I-I	NOUN	I
and	I-I	CCONJ	O
46	I-I	NUM	O
mumol	I-I	NOUN	O
(	I-I	PUNCT	O
20	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
of	I-I	ADP	O
vitamin	I-I	NOUN	B
E	I-I	NOUN	I
(	I-I	PUNCT	O
the	I-I	DET	O
treated	I-I	VERB	B
group	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
vitamin	I-I	NOUN	B
E	I-I	NOUN	I
alone	I-I	ADV	O
(	I-I	PUNCT	O
the	I-I	DET	O
control	I-I	NOUN	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


Vitamin	B-I	NOUN	B
supplements	I-I	NOUN	I
were	O	AUX	O
delivered	O	VERB	O
weekly	O	ADV	O
by	O	ADP	O
community	O	NOUN	B
health	O	NOUN	B
volunteers	O	NOUN	I
who	O	PRON	O
also	O	ADV	O
recorded	O	VERB	O
mortality	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
morbidity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Weekly	O	ADJ	B
contact	O	NOUN	B
was	O	AUX	O
made	O	VERB	O
with	O	ADP	O
at	O	ADP	O
least	O	ADV	O
88	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
children	O	NOUN	B
in	O	ADP	O
both	O	DET	O
study	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
base-line	O	ADJ	O
characteristics	O	NOUN	B
of	O	ADP	O
the	O	DET	O
children	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
and	O	CCONJ	O
documented	O	VERB	B
a	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
vitamin	O	NOUN	B
A	O	NOUN	I
deficiency	O	NOUN	I
and	O	CCONJ	O
undernutrition	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
One	O	NUM	O
hundred	O	NUM	O
twenty-five	O	NUM	B
deaths	O	NOUN	B
occurred	O	VERB	O
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
117	O	NUM	O
were	O	AUX	O
not	O	PART	O
accidental	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
death	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
vitamin	O	NOUN	B
A	O	NOUN	I
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
half	O	DET	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
,	O	PUNCT	O
0.46	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.30	O	NUM	O
to	O	PART	O
0.71	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
was	O	AUX	O
most	O	ADV	O
reduced	O	VERB	B
among	O	ADP	O
children	O	NOUN	B
under	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
to	O	PART	O
11	O	NUM	O
months	O	NOUN	B
--	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
,	O	PUNCT	O
0.28	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.09	O	NUM	O
to	O	PART	O
0.85	O	NUM	O
;	O	PUNCT	O
12	O	NUM	O
to	O	PART	O
35	O	NUM	O
months	O	NOUN	B
--	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
,	O	PUNCT	O
0.46	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.26	O	NUM	O
to	O	PART	O
0.81	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
among	O	ADP	O
those	O	DET	O
who	O	PRON	O
were	O	AUX	O
chronically	O	ADV	B
undernourished	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
manifested	O	VERB	O
by	O	ADP	O
stunting	O	VERB	B
(	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
,	O	PUNCT	O
0.11	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.03	O	NUM	O
to	O	PART	O
0.36	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
symptom-specific	B-OUT	ADJ	B
risk	I-OUT	NOUN	I
of	I-OUT	ADP	O
mortality	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
diarrhea	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
convulsions	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
other	I-OUT	ADJ	O
infection-related	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
regular	O	ADJ	O
provision	O	NOUN	B
of	O	ADP	O
a	O	DET	O
supplement	O	NOUN	B
of	O	ADP	O
vitamin	B-I	NOUN	B
A	I-I	NOUN	I
to	O	ADP	O
children	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
level	O	NOUN	B
potentially	O	ADV	O
obtainable	O	ADJ	O
from	O	ADP	O
foods	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
an	O	DET	O
area	O	NOUN	B
where	O	SCONJ	O
vitamin	O	NOUN	B
A	O	NOUN	I
deficiency	O	NOUN	I
and	O	CCONJ	O
under-nutrition	O	NOUN	B
are	O	AUX	O
documented	O	VERB	B
public	O	ADJ	B
health	O	NOUN	B
problems	O	NOUN	I
contributed	O	VERB	O
substantially	O	ADV	O
to	O	ADP	O
children	O	NOUN	B
's	O	PART	I
survival	O	NOUN	B
;	O	PUNCT	O
mortality	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
on	O	ADP	O
average	O	NOUN	B
by	O	ADP	O
54	O	NUM	O
percent	O	NOUN	O
.	O	PUNCT	O


Chlorhexidine	B-I	NOUN	B
swabbing	O	NOUN	B
applications	O	NOUN	B
under	O	ADP	O
various	O	ADJ	O
conditions	O	NOUN	B
of	O	ADP	O
use	O	NOUN	O
in	O	ADP	O
preventive	O	ADJ	B
oral	O	ADJ	I
care	O	NOUN	I
for	O	ADP	O
persons	B-P	NOUN	B
with	I-P	ADP	O
disabilities	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
44	B-P	NUM	O
adults	I-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
disabilities	I-P	NOUN	B
completed	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
single-blind	O	ADJ	I
cross-over	O	ADJ	I
study	O	NOUN	I
testing	O	VERB	I
chlorhexidine	B-I	NOUN	B
swabbing	O	NOUN	B
under	O	ADP	O
various	O	ADJ	O
conditions	O	NOUN	B
:	O	PUNCT	O
with/without	O	ADP	O
prior	O	ADJ	B
dental	O	ADJ	B
prophylaxis	O	NOUN	I
,	O	PUNCT	O
reduced	O	VERB	B
frequency	O	NOUN	I
of	O	ADP	O
application	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
vs.	O	CCONJ	O
5	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
week	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
prolonged	O	ADJ	B
use	O	NOUN	O
(	O	PUNCT	O
42	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
subjects	O	NOUN	B
received	O	VERB	O
therapeutic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
10	B-I	NUM	O
mL	I-I	NOUN	O
0.12	I-I	NUM	O
%	I-I	NOUN	O
chlorhexidine	I-I	NOUN	B
gluconate	I-I	NOUN	I
(	O	PUNCT	O
Peridex	O	PROPN	B
,	O	PUNCT	O
Procter	O	PROPN	B
&	O	CCONJ	I
Gamble	O	PROPN	I
)	O	PUNCT	O
and	O	CCONJ	O
10	B-I	NUM	O
mL	I-I	NOUN	O
0.05	I-I	NUM	O
%	I-I	NOUN	O
NaF	I-I	NOUN	B
applied	I-I	VERB	O
with	I-I	ADP	O
a	I-I	DET	O
Toothette	I-I	PROPN	B
(	O	PUNCT	O
Sage	O	PROPN	B
Products	O	PROPN	I
)	O	PUNCT	O
.	O	PUNCT	O


Clinical	B-OUT	ADJ	B
effectiveness	I-OUT	NOUN	I
of	O	ADP	O
chlorhexidine	B-I	NOUN	B
swabbing	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
was	O	AUX	O
previously	O	ADV	O
reported	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
initial	O	ADJ	B
benefits	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
to	O	PART	O
be	O	AUX	O
independent	O	ADJ	B
of	O	ADP	O
dental	O	ADJ	B
prophylaxis	O	NOUN	I
,	O	PUNCT	O
significant	O	ADJ	O
reductions	O	NOUN	B
in	O	ADP	O
periodontal	B-OUT	ADJ	B
scores	I-OUT	NOUN	I
were	O	AUX	O
sustained	O	VERB	B
by	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
dental	O	ADJ	B
prophylaxis	O	NOUN	I
and	O	CCONJ	O
swabbing	O	NOUN	B
protocol	O	NOUN	I
,	O	PUNCT	O
at	O	ADP	O
reduced	O	VERB	B
frequency	O	NOUN	B
of	O	ADP	O
application	O	NOUN	B
and	O	CCONJ	O
over	O	ADP	O
prolonged	O	ADJ	B
time	O	NOUN	O
.	O	PUNCT	O


High	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
acceptance	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
compliance	I-OUT	NOUN	B
by	O	ADP	O
subjects/caregivers	O	NOUN	B
were	O	AUX	O
maintained	O	VERB	B
.	O	PUNCT	O


Subjects/caregivers	O	NOUN	B
reported	O	VERB	O
improvements	B-OUT	NOUN	B
in	I-OUT	ADP	O
dental	I-OUT	NOUN	B
health	I-OUT	NOUN	I
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
in	I-OUT	ADP	O
attitude	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
smile	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Chlorhexidine	B-I	NOUN	B
swabbing	O	NOUN	B
at	O	ADP	O
maintenance	O	NOUN	B
frequency	O	NOUN	I
,	O	PUNCT	O
combined	O	VERB	O
with	O	ADP	O
periodic	O	ADJ	B
dental	O	NOUN	I
prophylaxis	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
offer	O	VERB	O
an	O	DET	O
effective	O	ADJ	B
and	O	CCONJ	O
pragmatic	O	ADJ	B
long-term	B-OUT	ADJ	B
preventive	I-OUT	ADJ	B
regimen	I-OUT	NOUN	I
for	O	ADP	O
persons	O	NOUN	B
with	O	ADP	O
disabilities	O	NOUN	B
.	O	PUNCT	O


Rituximab	B-I	NOUN	B
plus	I-I	CCONJ	O
concurrent	I-I	ADJ	B
infusional	I-I	ADJ	B
EPOCH	I-I	NOUN	O
chemotherapy	I-I	NOUN	O
is	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
in	B-P	ADP	O
HIV-associated	I-P	ADJ	B
B-cell	I-P	NOUN	I
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


Rituximab	O	NOUN	B
plus	O	CCONJ	O
intravenous	O	ADJ	B
bolus	O	NOUN	I
chemotherapy	O	NOUN	I
is	O	AUX	O
a	O	DET	O
standard	O	ADJ	B
treatment	O	NOUN	I
for	O	ADP	O
immunocompetent	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
B-cell	I-P	NOUN	B
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
(	I-P	PUNCT	O
NHL	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Some	O	DET	O
studies	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
rituximab	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
excessive	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
in	O	ADP	O
HIV-associated	O	ADJ	B
NHL	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
infusional	O	ADJ	B
chemotherapy	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
2	O	NUM	I
trial	O	NOUN	I
of	O	ADP	O
rituximab	B-I	NOUN	B
(	I-I	PUNCT	O
375	I-I	NUM	O
mg/m	I-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
given	I-I	VERB	O
either	I-I	CCONJ	O
concurrently	I-I	ADV	O
before	I-I	ADP	O
each	I-I	DET	O
infusional	I-I	ADJ	B
etoposide	I-I	NOUN	B
,	I-I	PUNCT	O
vincristine	I-I	NOUN	B
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
cyclophosphamide	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
prednisone	I-I	NOUN	B
(	I-I	PUNCT	O
EPOCH	I-I	NOUN	B
)	I-I	PUNCT	O
chemotherapy	I-I	NOUN	B
cycle	I-I	NOUN	I
or	I-I	CCONJ	O
sequentially	I-I	ADV	O
(	I-I	PUNCT	O
weekly	I-I	ADJ	B
for	I-I	ADP	O
6	I-I	NUM	O
weeks	I-I	NOUN	B
)	I-I	PUNCT	O
after	I-I	ADP	O
completion	I-I	NOUN	B
of	I-I	ADP	O
all	I-I	DET	O
chemotherapy	I-I	NOUN	B
in	I-I	ADP	O
HIV-associated	I-I	ADJ	B
NHL	I-I	NOUN	B
.	I-I	PUNCT	O


EPOCH	B-I	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
a	O	DET	O
96-hour	O	ADJ	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
etoposide	B-I	NOUN	B
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
vincristine	I-I	NOUN	B
plus	I-I	CCONJ	O
oral	I-I	ADJ	B
prednisone	I-I	NOUN	O
followed	O	VERB	O
by	O	ADP	O
intravenous	O	ADJ	B
bolus	O	NOUN	I
cyclophosphamide	B-I	NOUN	I
given	O	VERB	O
every	O	DET	O
21	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
4	O	NUM	O
to	O	PART	O
6	O	NUM	O
cycles	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
concurrent	O	ADJ	B
arm	O	NOUN	B
,	O	PUNCT	O
35	O	NUM	O
of	O	ADP	O
48	B-P	NUM	O
evaluable	I-P	ADJ	O
patients	I-P	NOUN	B
(	O	PUNCT	O
73	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
58	O	NUM	O
%	O	NOUN	O
-85	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
complete	B-OUT	ADJ	O
response	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
sequential	O	ADJ	O
arm	O	NOUN	B
,	O	PUNCT	O
29	O	NUM	O
of	O	ADP	O
53	B-P	NUM	O
evaluable	I-P	ADJ	O
patients	I-P	NOUN	B
(	O	PUNCT	O
55	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
41	O	NUM	O
%	O	NOUN	O
-68	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
complete	O	ADJ	O
response	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
endpoint	O	NOUN	B
was	O	AUX	O
met	O	VERB	O
for	O	ADP	O
the	O	DET	O
concurrent	O	ADJ	B
arm	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


Toxicity	B-OUT	NOUN	B
was	O	AUX	O
comparable	O	ADJ	O
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
arms	O	NOUN	O
,	O	PUNCT	O
although	O	SCONJ	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
baseline	O	NOUN	B
CD4	B-OUT	NOUN	B
count	O	NOUN	I
less	O	ADJ	I
than	O	ADP	O
50/microL	O	NOUN	O
had	O	AUX	O
a	O	DET	O
high	O	ADJ	O
infectious	B-OUT	ADJ	B
death	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
concurrent	O	ADJ	B
arm	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
concurrent	B-I	ADJ	B
rituximab	I-I	NOUN	B
plus	I-I	CCONJ	O
infusional	I-I	ADJ	B
EPOCH	I-I	NOUN	O
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
regimen	O	NOUN	B
for	O	ADP	O
HIV-associated	B-P	ADJ	B
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


[	O	PUNCT	O
A	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
prophylactic	O	ADJ	B
intravesical	O	ADJ	O
instillation	O	NOUN	O
of	O	ADP	O
pirarubicin	B-I	NOUN	B
(	I-I	PUNCT	O
THP	I-I	NOUN	B
)	I-I	PUNCT	O
prior	O	ADJ	O
to	O	PART	O
transurethral	B-P	ADJ	B
resection	I-P	NOUN	I
of	I-P	ADP	O
superficial	I-OUT	ADJ	B
bladder	I-OUT	NOUN	I
cancer	I-OUT	NOUN	I
]	I-OUT	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
prophylactic	B-P	ADJ	B
intravesical	I-I	ADJ	O
instillation	I-I	NOUN	O
of	I-I	ADP	O
pirarubicin	I-I	NOUN	B
(	I-I	PUNCT	O
THP	I-I	NOUN	B
)	I-I	PUNCT	O
prior	I-P	ADJ	O
to	I-P	PART	O
transurethral	I-OUT	ADJ	B
resection	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
TUR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
of	I-OUT	ADP	O
superficial	I-OUT	ADJ	B
bladder	I-OUT	NOUN	I
cancer	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
63	B-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
THP	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
THP	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
THP	O	NOUN	B
dissolved	O	VERB	B
in	O	ADP	O
50	B-I	NUM	O
ml	I-I	NOUN	O
saline	I-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
4	O	NUM	O
times	O	NOUN	O
intravesically	O	ADV	B
for	O	ADP	O
4	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
before	O	ADP	O
TUR	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
no	B-I	DET	O
instillation	I-I	NOUN	B
was	I-I	AUX	O
performed	I-I	VERB	O
before	I-I	ADP	O
TUR	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
cystoscopy	O	NOUN	B
and	O	CCONJ	O
urinary	O	ADJ	B
cytology	O	NOUN	I
every	O	DET	O
3	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
non-recurrence	B-OUT	ADJ	B
rates	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
THP	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
group	O	NOUN	I
were	O	AUX	O
54.1	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
37.6	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
and	O	CCONJ	O
40.4	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
26.8	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.086	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Time	B-OUT	NOUN	B
to	I-OUT	PART	O
recurrence	I-OUT	VERB	B
for	I-OUT	ADP	O
tumors	I-OUT	NOUN	B
larger	I-OUT	ADJ	O
than	I-OUT	ADP	O
1	I-OUT	NUM	O
cm	I-OUT	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
longer	O	ADV	O
in	O	ADP	O
the	O	DET	O
THP	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0137	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Time	B-OUT	NOUN	B
to	I-OUT	PART	O
recurrence	I-OUT	VERB	B
for	I-OUT	ADP	O
single	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
grade	I-OUT	NOUN	B
1+2	I-OUT	NUM	I
tumors	I-OUT	NOUN	I
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
longer	O	ADV	O
in	O	ADP	O
the	O	DET	O
THP	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.09	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.079	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
any	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
intravesical	O	ADJ	B
THP	O	NOUN	B
instillation	O	NOUN	B
prior	O	ADV	O
to	O	PART	O
TUR	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
effective	B-OUT	ADJ	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
single	B-OUT	ADJ	O
,	I-OUT	PUNCT	O
low	I-OUT	ADJ	B
grade	I-OUT	NOUN	O
lesions	I-OUT	NOUN	B
larger	I-OUT	ADJ	O
than	I-OUT	ADP	O
1	I-OUT	NUM	O
cm	I-OUT	NOUN	O
of	O	ADP	O
superficial	B-OUT	ADJ	B
bladder	I-OUT	NOUN	I
cancer	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Do	O	AUX	O
readers	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
make	O	VERB	O
bridging	O	VERB	O
inferences	O	NOUN	B
from	O	ADP	O
world	O	NOUN	B
knowledge	O	NOUN	I
?	O	PUNCT	O
Individuals	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
frequently	O	ADV	O
show	O	VERB	O
impairments	O	NOUN	B
in	O	ADP	O
text	O	NOUN	B
reading	O	NOUN	I
comprehension	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
often	O	ADV	O
is	O	AUX	O
attributed	O	VERB	O
to	O	ADP	O
poor	O	ADJ	O
ability	O	NOUN	O
to	O	PART	O
draw	O	VERB	O
inferences	O	NOUN	B
during	O	ADP	O
reading	O	NOUN	B
and	O	CCONJ	O
to	O	ADP	O
inadequate	O	ADJ	O
access	O	NOUN	O
to	O	ADP	O
relevant	O	ADJ	B
knowledge	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
tested	O	VERB	B
this	O	DET	O
hypothesis	O	NOUN	B
by	O	ADP	O
measuring	O	VERB	B
the	O	DET	O
time	O	NOUN	B
taken	O	VERB	O
to	O	PART	O
read	B-I	VERB	O
the	I-I	DET	O
same	I-I	ADJ	O
question	I-I	NOUN	B
,	I-I	PUNCT	O
relating	I-I	VERB	O
to	I-I	ADP	O
either	I-I	CCONJ	O
physical	I-I	ADJ	B
or	I-I	CCONJ	O
social	I-I	ADJ	B
world	I-I	NOUN	I
knowledge	I-I	NOUN	B
,	I-I	PUNCT	O
when	I-I	SCONJ	O
it	I-I	PRON	O
was	I-I	AUX	O
either	I-I	CCONJ	O
relevant	I-I	ADJ	B
or	I-I	CCONJ	O
irrelevant	I-I	ADJ	B
to	I-I	ADP	O
the	I-I	DET	O
bridging	I-I	NOUN	B
inference	I-I	NOUN	B
evoked	I-I	VERB	B
by	I-I	ADP	O
a	I-I	DET	O
preceding	I-I	VERB	O
two-sentence	I-I	ADJ	B
vignette	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
16	B-P	NUM	O
normally	I-P	ADV	O
developing	I-P	VERB	O
adolescents	I-P	NOUN	B
and	I-P	CCONJ	O
16	I-P	NUM	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
were	O	AUX	O
matched	O	VERB	O
on	O	ADP	O
word	O	NOUN	B
reading	O	NOUN	I
accuracy	O	NOUN	I
,	O	PUNCT	O
chronological	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
vocabulary	O	NOUN	B
but	O	CCONJ	O
differed	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
text	O	NOUN	B
comprehension	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
strong	O	ADJ	O
priming	O	NOUN	B
effect	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
robust	O	ADJ	B
over	O	ADP	O
participants	O	NOUN	B
and	O	CCONJ	O
over	O	ADP	O
items	O	NOUN	B
;	O	PUNCT	O
participants	O	NOUN	B
read	O	VERB	B
those	O	DET	O
questions	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
relevant	O	ADJ	B
to	O	ADP	O
the	O	DET	O
inference	O	NOUN	B
evoked	O	VERB	B
by	O	ADP	O
the	O	DET	O
vignette	O	NOUN	B
faster	O	ADV	I
than	O	ADP	O
they	O	PRON	O
read	O	VERB	B
those	O	DET	O
questions	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
irrelevant	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
interaction	O	NOUN	B
with	O	ADP	O
group	O	NOUN	B
membership	O	NOUN	I
or	O	CCONJ	O
type	O	NOUN	O
of	O	ADP	O
knowledge	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
indicates	O	VERB	O
that	O	SCONJ	O
readers	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
,	O	PUNCT	O
just	O	ADV	O
like	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
activating	O	VERB	B
appropriate	O	ADJ	O
world	O	NOUN	O
knowledge	O	NOUN	B
primed	O	VERB	B
by	O	ADP	O
implicit	O	NOUN	B
inferences	O	NOUN	B
while	O	SCONJ	O
reading	O	VERB	B
the	O	DET	O
vignettes	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
comprehension	O	NOUN	B
problems	O	NOUN	O
in	O	ADP	O
these	O	DET	O
readers	O	NOUN	B
can	O	AUX	O
not	O	PART	O
be	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
an	O	DET	O
inability	O	NOUN	B
to	O	PART	O
make	O	VERB	O
implicit	O	NOUN	B
inferences	O	NOUN	B
or	O	CCONJ	O
to	O	PART	O
draw	O	VERB	O
on	O	ADP	O
relevant	O	ADJ	B
world	O	NOUN	B
knowledge	O	NOUN	B
.	O	PUNCT	O


Instead	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
problems	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
sought	O	VERB	O
at	O	ADP	O
a	O	DET	O
higher	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
text	O	NOUN	B
processing	O	NOUN	I
.	O	PUNCT	O


Most	O	ADV	O
effective	B-OUT	ADJ	B
regimen	I-OUT	NOUN	B
of	I-OUT	ADP	O
tranexamic	I-OUT	ADJ	B
acid	I-OUT	NOUN	I
in	O	ADP	O
knee	B-P	NOUN	B
arthroplasty	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
study	O	NOUN	I
in	O	ADP	O
240	B-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
antifibrinolytic	B-I	ADJ	B
tranexamic	I-I	ADJ	I
acid	I-I	NOUN	I
reduces	O	VERB	B
surgical	O	ADJ	B
blood	O	NOUN	I
loss	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
studies	O	NOUN	B
have	O	AUX	O
not	O	PART	O
identified	O	VERB	O
an	O	DET	O
optimal	O	ADJ	B
regimen	O	NOUN	B
.	O	PUNCT	O


QUESTIONS/PURPOSES	O	PROPN	B
We	O	PRON	O
studied	O	VERB	O
different	O	ADJ	O
dosages	O	NOUN	B
,	O	PUNCT	O
timings	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
modes	O	NOUN	B
of	O	ADP	O
administration	O	NOUN	B
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
most	O	ADV	O
effective	O	ADJ	B
regimen	O	NOUN	B
of	O	ADP	O
tranexamic	B-I	ADJ	B
acid	I-I	NOUN	I
in	O	ADP	O
achieving	O	VERB	O
maximum	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
loss	O	NOUN	I
in	O	ADP	O
TKA	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
prospectively	O	ADV	O
studied	O	VERB	O
five	B-P	NUM	O
regimens	I-P	NOUN	B
(	I-P	PUNCT	O
four	I-P	NUM	O
intravenous	I-I	ADJ	B
,	I-P	PUNCT	O
one	I-P	NUM	O
local	I-I	ADJ	B
;	I-I	PUNCT	O
40	I-P	NUM	O
patients	I-P	NOUN	B
each	I-P	DET	O
)	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
control	I-P	ADJ	B
group	I-P	NOUN	I
(	O	PUNCT	O
no	O	DET	O
tranexamic	B-I	ADJ	B
acid	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
four	O	NUM	O
intravenous	B-I	ADJ	B
(	O	PUNCT	O
10-mg/kg	O	NOUN	B
dose	O	NOUN	I
)	O	PUNCT	O
regimens	O	NOUN	B
included	O	VERB	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
intraoperative	B-I	ADJ	B
dose	I-I	NOUN	I
(	I-I	PUNCT	O
IO	I-I	ADJ	B
)	I-I	PUNCT	O
given	I-I	VERB	O
before	I-I	ADP	O
tourniquet	I-I	NOUN	B
deflation	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
additional	I-I	ADJ	O
preoperative	I-I	ADJ	B
dose	I-I	NOUN	B
(	I-I	PUNCT	O
POIO	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
(	I-I	PUNCT	O
3	I-I	X	O
)	I-I	PUNCT	O
additional	I-I	ADJ	O
postoperative	I-I	ADJ	B
dose	I-I	NOUN	I
(	I-I	PUNCT	O
IOPO	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
(	I-I	PUNCT	O
4	I-I	X	O
)	I-I	PUNCT	O
all	I-I	DET	O
three	I-I	NUM	O
doses	I-I	NOUN	B
(	I-I	PUNCT	O
POIOPO	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
fifth	O	ADJ	O
regimen	O	NOUN	B
was	O	AUX	O
a	O	DET	O
single	O	ADJ	O
local	B-I	ADJ	O
application	I-I	NOUN	O
(	O	PUNCT	O
LA	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
independent	O	ADJ	B
parameters	O	NOUN	B
of	O	ADP	O
drain	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
total	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
calculated	I-OUT	VERB	B
by	I-OUT	ADP	O
the	I-OUT	DET	O
hemoglobin	I-OUT	NOUN	B
balance	I-OUT	NOUN	I
method	I-OUT	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
statistically	O	ADV	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Both	O	DET	O
parameters	O	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
all	O	DET	O
five	O	NUM	O
regimens	O	NOUN	B
as	O	ADP	O
against	O	ADP	O
the	O	DET	O
control	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
drain	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
POIO	O	NOUN	B
,	O	PUNCT	O
IOPO	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
POIOPO	O	NOUN	B
groups	O	NOUN	B
whereas	O	SCONJ	O
total	O	ADJ	B
blood	B-OUT	NOUN	I
loss	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
POIO	O	NOUN	B
,	O	PUNCT	O
POIOPO	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
LA	O	NOUN	B
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
POIOPO	O	ADJ	B
group	O	NOUN	B
had	O	AUX	O
the	O	DET	O
least	O	ADJ	O
drain	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
(	O	PUNCT	O
303	O	NUM	O
mL	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
least	O	ADJ	O
total	O	ADJ	B
blood	B-OUT	NOUN	I
loss	I-OUT	NOUN	I
(	O	PUNCT	O
688	O	NUM	O
mL	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
IO	O	ADJ	B
group	O	NOUN	B
had	O	AUX	O
the	O	DET	O
greatest	O	ADJ	O
drain	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
and	O	CCONJ	O
the	O	DET	O
IOPO	O	PROPN	B
group	O	NOUN	B
the	O	DET	O
greatest	O	ADJ	O
total	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	VERB	O
Single-dose	O	ADJ	B
tranexamic	B-I	ADJ	B
acid	I-I	NOUN	I
did	O	AUX	O
not	O	PART	O
give	O	VERB	O
effective	O	ADJ	B
results	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
two-dose	O	ADJ	B
regimen	O	NOUN	B
of	O	ADP	O
POIO	O	NOUN	B
was	O	AUX	O
the	O	DET	O
least	O	ADJ	O
amount	O	NOUN	B
necessary	O	ADJ	O
for	O	ADP	O
effective	O	ADJ	B
results	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
compared	O	VERB	O
against	O	ADP	O
the	O	DET	O
control	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
regimen	O	NOUN	B
produced	O	VERB	O
reduction	B-OUT	NOUN	B
of	I-OUT	ADP	O
drain	I-OUT	NOUN	B
loss	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
total	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
IOPO	O	NOUN	B
regimen	O	NOUN	B
did	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


The	O	DET	O
three-dose	O	ADJ	B
regimen	O	NOUN	I
of	O	ADP	O
POIOPO	O	NOUN	B
produced	O	VERB	O
maximum	O	ADJ	B
effective	O	ADJ	B
reduction	O	NOUN	B
of	O	ADP	O
drain	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
total	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


[	O	PUNCT	O
Effects	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intensive	B-I	ADJ	B
therapy	I-I	NOUN	I
program	I-I	NOUN	I
for	O	ADP	O
behaviorally	B-P	ADV	B
disordered	I-P	VERB	I
mentally	I-P	ADV	O
handicapped	I-P	ADJ	O
patients	I-P	NOUN	B
on	I-P	ADP	O
staff	I-P	NOUN	B
personnel	I-P	NOUN	I
in	I-P	ADP	O
residential	I-P	ADJ	B
care	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
evaluates	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intensive	B-I	ADJ	B
therapy	I-I	NOUN	I
program	I-I	NOUN	I
designed	O	VERB	O
for	O	ADP	O
mentally	B-P	ADV	B
handicapped	I-P	VERB	I
persons	I-P	NOUN	B
with	I-P	ADP	O
severely	I-P	ADV	O
disturbed	I-P	ADJ	O
or	I-P	CCONJ	O
autistic	I-P	ADJ	B
behavior	I-P	NOUN	I
on	I-P	ADP	O
their	I-P	PRON	O
staff	I-P	NOUN	B
personal	I-P	ADJ	B
which	I-P	DET	O
had	I-P	AUX	O
an	I-P	DET	O
active	I-P	ADJ	O
role	I-P	NOUN	O
in	I-P	ADP	O
the	I-P	DET	O
program	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
staff	O	NOUN	B
members	O	NOUN	I
rated	O	VERB	B
their	O	PRON	O
professional	O	ADJ	B
competence	O	NOUN	I
,	O	PUNCT	O
quality	O	NOUN	B
of	O	ADP	O
interaction	O	NOUN	B
with	O	ADP	O
the	O	DET	O
client	O	NOUN	B
,	O	PUNCT	O
team	O	NOUN	B
culture	O	NOUN	I
and	O	CCONJ	O
work	O	NOUN	B
satisfaction	O	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
being	O	AUX	O
engaged	O	VERB	O
in	O	ADP	O
the	O	DET	O
program	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
additional	O	ADJ	O
ratings	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
personal	O	ADJ	B
aims	O	NOUN	O
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
the	O	DET	O
program	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
sets	O	NOUN	O
of	O	ADP	O
data	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
with	O	ADP	O
the	O	DET	O
program	O	NOUN	B
being	O	AUX	O
conducted	O	VERB	O
three	O	NUM	O
times	O	NOUN	O
in	O	ADP	O
a	O	DET	O
row	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
testings	O	NOUN	B
of	O	ADP	O
the	O	DET	O
related	O	ADJ	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
independent	O	ADJ	O
samples	O	NOUN	B
show	O	VERB	O
differentiated	O	VERB	B
program	O	NOUN	B
effects	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
effect	O	NOUN	B
is	O	AUX	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
professional	B-OUT	ADJ	B
competence	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	O
interaction	I-OUT	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
by	O	ADP	O
the	O	DET	O
qualified	O	ADJ	B
staff	O	NOUN	B
members	O	NOUN	I
.	O	PUNCT	O


Trainees	O	NOUN	B
put	O	VERB	O
emphasis	O	NOUN	O
on	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
personal	O	ADJ	B
relationship	O	NOUN	I
with	O	ADP	O
the	O	DET	O
client	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
learning	O	NOUN	B
processes	O	NOUN	I
specific	O	ADJ	B
to	O	PART	O
the	O	DET	O
roles	O	NOUN	O
of	O	ADP	O
the	O	DET	O
staff	O	NOUN	B
members	O	NOUN	I
and	O	CCONJ	O
motivational	O	ADJ	B
factors	O	NOUN	I
on	O	ADP	O
learning	O	NOUN	B
and	O	CCONJ	O
therapy	O	NOUN	B
outcome	O	NOUN	B
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
institutional	O	ADJ	B
conditions	O	NOUN	I
influencing	O	VERB	O
successful	O	ADJ	O
learning	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
the	O	DET	O
program	O	NOUN	B
facilitates	O	VERB	O
the	O	DET	O
professional	O	ADJ	B
and	O	CCONJ	O
interpersonal	O	ADJ	B
learning	O	NOUN	O
process	O	NOUN	O
of	O	ADP	O
staff	O	NOUN	B
members	O	NOUN	I
in	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
way	O	NOUN	O
with	O	ADP	O
success	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
with	O	ADP	O
limitations	O	NOUN	B
.	O	PUNCT	O


Human	O	ADJ	B
motor	O	NOUN	B
responses	O	NOUN	I
to	O	PART	O
simultaneous	O	ADJ	B
aversive	B-I	ADJ	B
stimulation	I-I	NOUN	I
and	I-I	CCONJ	O
failure	I-I	NOUN	B
on	O	ADP	O
a	O	DET	O
valued	O	VERB	O
task	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
presentation	O	NOUN	B
of	O	ADP	O
an	O	DET	O
aversive	B-I	ADJ	B
stimulus	I-I	NOUN	O
and	I-I	CCONJ	O
simultaneous	I-I	ADJ	B
failure	I-I	NOUN	B
on	I-I	ADP	O
a	I-I	DET	O
bogus	I-I	ADJ	B
intelligence	I-I	NOUN	I
test	I-I	NOUN	I
upon	O	SCONJ	O
a	O	DET	O
subject	O	NOUN	B
's	O	PART	O
aggressive	B-OUT	ADJ	B
reactions	I-OUT	NOUN	I
were	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
subject	B-P	NOUN	B
's	I-P	PART	I
fist	I-OUT	NOUN	B
clenching	I-OUT	NOUN	I
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
an	O	DET	O
indicator	B-OUT	NOUN	B
of	I-OUT	ADP	O
aggression	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Four	O	NUM	O
conditions	O	NOUN	B
,	O	PUNCT	O
generated	O	VERB	O
by	O	ADP	O
the	O	DET	O
combinations	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
kinds	O	NOUN	O
of	O	ADP	O
stimulus	O	NOUN	B
delivered	O	VERB	O
to	O	PART	O
the	O	DET	O
subjects	O	NOUN	B
(	B-I	PUNCT	O
aversive	I-I	ADJ	B
or	I-I	CCONJ	O
nonaversive	I-I	ADJ	B
)	I-I	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
outcomes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
task	O	NOUN	B
(	O	PUNCT	O
failure	O	NOUN	B
or	O	CCONJ	O
success	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


20	B-P	NUM	O
female	I-P	NOUN	B
and	I-P	CCONJ	O
20	I-P	NUM	O
male	I-P	NOUN	B
students	I-P	NOUN	O
(	I-P	PUNCT	O
ages	I-P	NOUN	B
:	I-P	PUNCT	O
17-34	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
instructed	O	VERB	B
,	O	PUNCT	O
upon	O	SCONJ	O
the	O	DET	O
reception	O	NOUN	B
of	O	ADP	O
an	O	DET	O
aversive	B-I	ADJ	B
or	I-I	CCONJ	O
nonaversive	I-I	ADJ	B
acoustic	I-I	ADJ	O
signal	I-I	NOUN	O
,	O	PUNCT	O
to	O	PART	O
press	O	VERB	B
with	O	ADP	O
the	O	DET	O
right	O	ADJ	B
hand	O	NOUN	I
a	O	DET	I
device	O	NOUN	B
that	O	PRON	O
displayed	O	VERB	O
a	O	DET	O
slide	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
slide	O	NOUN	B
presented	O	VERB	O
an	O	DET	O
item	O	NOUN	B
from	O	ADP	O
an	O	DET	O
intelligence	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
to	O	PART	O
which	O	DET	O
the	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
either	O	ADV	O
allowed	O	VERB	O
to	O	PART	O
answer	O	VERB	O
successfully	O	ADV	O
(	O	PUNCT	O
success	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
not	O	PART	O
(	O	PUNCT	O
failure	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Failure	O	NOUN	B
increased	O	VERB	B
the	O	DET	O
subject	O	NOUN	B
's	O	PART	I
autonomic	B-OUT	ADJ	B
arousal	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
as	I-OUT	ADP	O
measured	I-OUT	VERB	B
by	I-OUT	ADP	O
photoplethysmographic	I-OUT	ADJ	B
sensors	I-OUT	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
all	O	DET	O
stimulation	O	NOUN	B
conditions	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
the	O	DET	O
condition	O	NOUN	B
with	O	ADP	O
aversive	O	ADJ	B
stimulation	O	NOUN	I
increased	O	VERB	B
the	O	DET	O
speed	B-OUT	NOUN	B
of	I-OUT	ADP	O
clenching	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


This	O	DET	O
was	O	AUX	O
interpreted	O	VERB	O
as	O	ADP	O
indicating	O	VERB	O
subject	O	NOUN	B
's	O	PART	I
tendencies	B-OUT	NOUN	B
to	I-OUT	PART	O
aggression	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
frustration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
herbal-based	B-I	ADJ	B
toothpaste	I-I	NOUN	I
on	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
plaque	B-P	NOUN	B
and	I-P	CCONJ	O
gingivitis	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
controlled	O	VERB	B
clinical	O	ADJ	I
trial	O	NOUN	I
with	O	ADP	O
parallel	O	ADJ	O
groups	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
a	O	DET	O
herbal-based	B-I	ADJ	B
toothpaste	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
plaque	O	NOUN	B
and	O	CCONJ	O
gingivitis	O	NOUN	B
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
a	O	DET	O
conventional	B-I	ADJ	B
dentifrice	I-I	NOUN	B
.	I-I	PUNCT	O


70	B-P	NUM	O
subjects	I-P	NOUN	B
with	I-P	ADP	O
gingivitis	I-P	NOUN	B
completed	O	VERB	O
the	O	DET	O
6-week	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


All	B-P	DET	O
participants	I-P	NOUN	B
had	I-P	AUX	O
at	I-P	ADP	O
least	I-P	ADV	O
20	I-P	NUM	O
natural	I-P	ADJ	B
teeth	I-P	NOUN	I
with	I-P	ADP	O
no	I-P	DET	O
probing	I-P	NOUN	O
depths	I-P	NOUN	O
greater	I-P	ADJ	O
than	I-P	ADP	O
3	I-P	NUM	O
mm	I-P	NOUN	O
and	I-P	CCONJ	O
a	I-P	DET	O
plaque	I-P	NOUN	B
index	I-P	NOUN	O
of	I-P	ADP	O
2	I-P	NUM	O
or	I-P	CCONJ	O
more	I-P	ADJ	O
at	I-P	ADP	O
baseline	I-P	NOUN	B
.	I-P	PUNCT	O


At	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
balanced	O	ADJ	B
for	O	ADP	O
the	O	DET	O
parameters	O	NOUN	B
measured	O	VERB	B
:	O	PUNCT	O
plaque	B-OUT	NOUN	B
index	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
plaque	I-OUT	NOUN	B
vitality	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
gingival	I-OUT	ADJ	B
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
bleeding	I-OUT	VERB	B
on	I-OUT	ADP	O
probing	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
gingival	I-OUT	ADJ	B
crevicular	I-OUT	ADJ	O
fluid	I-OUT	ADJ	O
flow	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
reductions	O	NOUN	B
within	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
herbal	B-I	ADJ	B
based	I-I	VERB	O
toothpaste	I-I	NOUN	B
was	O	AUX	O
as	O	ADV	O
effective	O	ADJ	B
as	O	ADP	O
the	O	DET	O
conventionally	B-I	ADV	B
formulated	I-I	VERB	O
dentifrice	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
plaque	O	NOUN	B
and	O	CCONJ	O
gingivitis	O	NOUN	B
.	O	PUNCT	O


Laparoscopic	B-P	ADJ	B
hysterectomy	I-P	NOUN	I
:	I-P	PUNCT	O
is	O	AUX	O
dissecting	B-I	VERB	B
the	I-I	DET	O
ureter	I-I	NOUN	B
necessary	O	ADJ	O
?	O	PUNCT	O
Laparoscopic	B-I	ADJ	B
hysterectomy	I-I	NOUN	I
has	O	AUX	O
been	O	AUX	O
first	O	ADV	O
reported	O	VERB	O
by	O	ADP	O
Reich	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O


in	O	ADP	O
1989	O	NUM	O
,	O	PUNCT	O
which	O	DET	O
confirmed	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
laparoscopic	O	ADJ	B
hysterectomy	O	NOUN	I
being	O	AUX	O
employed	O	VERB	O
as	O	ADP	O
a	O	DET	O
replacement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vast	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
traditional	O	ADJ	O
abdominal	O	ADJ	B
hysterectomies	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
three	O	NUM	O
critical	O	ADJ	O
points	O	NOUN	O
in	O	ADP	O
laparoscopic	O	ADJ	B
hysterectomy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
important	O	ADJ	O
critical	O	ADJ	B
point	O	NOUN	I
is	O	AUX	O
to	O	PART	O
identify	O	VERB	O
uterine	O	ADJ	B
arteries	O	NOUN	I
from	O	ADP	O
the	O	DET	O
ureter	O	NOUN	B
in	O	ADP	O
the	O	DET	O
paracervical	O	ADJ	B
area	O	NOUN	I
.	O	PUNCT	O


Several	O	ADJ	O
ureteral	B-OUT	ADJ	B
injuries	I-OUT	NOUN	I
at	O	ADP	O
operative	O	ADJ	B
laparoscopy	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
two	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
thirty	I-P	NUM	O
laparoscopic	I-I	ADJ	B
hysterectomies	I-I	NOUN	I
during	I-P	ADP	O
the	I-P	DET	O
period	I-P	NOUN	B
from	I-P	ADP	O
March	I-P	PROPN	O
1991	I-P	NUM	O
to	I-P	ADP	O
October	I-P	PROPN	O
1993	I-P	NUM	O
.	I-P	PUNCT	O


Sixty	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
later	I-P	ADV	O
included	I-P	VERB	O
in	I-P	ADP	O
this	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Thirty	O	NUM	O
of	O	ADP	O
these	O	DET	O
applied	O	VERB	O
the	O	DET	O
technique	O	NOUN	B
of	O	ADP	O
dissecting	B-I	VERB	B
the	I-I	DET	O
ureter	I-I	NOUN	B
at	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
laparoscopic	O	ADJ	B
hysterectomy	O	NOUN	I
.	O	PUNCT	O


Most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
discharged	O	VERB	B
on	O	ADP	O
the	O	DET	O
second	O	ADJ	O
postoperative	O	ADJ	B
day	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
dissecting	B-I	VERB	B
the	I-I	DET	O
ureter	I-I	NOUN	B
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
discrepancy	B-OUT	NOUN	B
in	O	ADP	O
operation	B-OUT	NOUN	B
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
loss	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
hospitalization	I-OUT	NOUN	B
day	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
ureter	I-OUT	NOUN	B
injury	I-OUT	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
uterine	O	NOUN	B
arteries	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
confidently	O	ADV	O
desiccated	O	VERB	B
once	O	SCONJ	O
the	O	DET	O
path	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ureter	O	NOUN	B
near	O	ADP	O
the	O	DET	O
uterosacral	O	ADJ	B
ligament	O	NOUN	I
is	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
multicenter	O	NOUN	I
trial	O	NOUN	I
comparing	O	VERB	B
resection	B-I	NOUN	B
and	I-I	CCONJ	O
radiochemotherapy	I-I	NOUN	B
for	O	ADP	O
resectable	B-P	ADJ	B
locally	I-P	ADV	B
invasive	I-P	ADJ	I
pancreatic	I-P	ADJ	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
Though	O	SCONJ	O
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
resection	O	NOUN	B
for	O	ADP	O
locally	O	ADV	B
invasive	O	ADJ	I
pancreatic	O	ADJ	B
cancer	O	NOUN	I
is	O	AUX	O
still	O	ADV	O
poor	O	ADJ	B
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
gradually	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
Japan	B-P	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
5-year	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
is	O	AUX	O
now	O	ADV	O
about	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
advantage	O	NOUN	O
of	O	ADP	O
resection	B-I	NOUN	B
over	O	ADP	O
radiochemotherapy	B-I	NOUN	B
has	O	AUX	O
not	O	PART	O
yet	O	ADV	O
been	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
this	O	DET	O
study	O	NOUN	B
to	O	PART	O
compare	O	VERB	B
surgical	B-I	ADJ	B
resection	I-I	NOUN	I
alone	O	ADV	O
versus	O	CCONJ	O
radiochemotherapy	B-I	NOUN	B
without	O	ADP	O
resection	O	NOUN	B
for	O	ADP	O
locally	O	ADV	B
invasive	O	ADJ	I
pancreatic	O	ADJ	B
cancer	O	NOUN	I
using	O	VERB	O
a	O	DET	O
multicenter	O	NOUN	B
randomized	O	ADJ	I
design	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
pancreatic	I-P	ADJ	B
cancer	I-P	NOUN	I
who	I-P	PRON	O
met	I-P	VERB	O
our	I-P	PRON	O
preoperative	I-P	ADJ	B
criteria	I-P	NOUN	B
for	I-P	ADP	O
inclusion	I-P	NOUN	B
(	I-P	PUNCT	O
pancreatic	I-P	ADJ	B
cancer	I-P	NOUN	I
invading	I-P	VERB	B
the	I-P	DET	O
pancreatic	I-P	ADJ	B
capsule	I-P	NOUN	I
without	I-P	ADP	O
involvement	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
superior	I-P	ADJ	B
mesenteric	I-P	ADJ	B
artery	I-P	NOUN	I
or	I-P	CCONJ	O
the	I-P	DET	O
common	I-P	ADJ	O
hepatic	I-P	ADJ	B
artery	I-P	NOUN	I
,	I-P	PUNCT	O
or	I-P	CCONJ	O
without	I-P	ADP	O
distant	I-P	ADJ	O
metastasis	I-P	NOUN	B
)	I-P	PUNCT	O
underwent	I-P	VERB	O
laparotomy	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
operative	O	ADJ	B
findings	O	NOUN	I
consistent	O	ADJ	B
with	O	ADP	I
our	O	PRON	O
criteria	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
a	O	DET	O
radical	B-I	ADJ	B
resection	I-I	NOUN	I
group	I-I	NOUN	I
and	I-I	CCONJ	O
a	I-I	DET	O
radiochemotherapy	I-I	NOUN	B
group	I-I	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
/day	O	NOUN	O
of	O	ADP	O
intravenous	B-I	ADJ	B
5-fluorouracil	I-I	NOUN	I
and	I-I	CCONJ	O
5040	I-I	NUM	O
cGy	I-I	NOUN	O
of	I-I	ADP	O
radiotherapy	I-I	NOUN	B
)	I-I	PUNCT	O
without	O	ADP	O
resection	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
for	O	ADP	O
mean	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
hazard	I-OUT	NOUN	B
ratio	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
1-year	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
hematologic	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
chemical	I-OUT	NOUN	I
data	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Twenty	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
assigned	I-P	VERB	O
to	I-P	PART	O
the	I-P	DET	O
resection	I-P	NOUN	B
group	I-P	NOUN	I
and	I-P	CCONJ	O
22	I-P	NUM	O
to	I-P	PART	O
the	I-P	DET	O
radiochemotherapy	I-I	NOUN	B
group	I-P	NOUN	B
.	I-P	PUNCT	O


There	O	PRON	O
was	O	AUX	O
1	O	NUM	O
operative	B-OUT	ADJ	B
death	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
surgical	O	ADJ	B
resection	O	NOUN	I
group	O	NOUN	I
had	O	AUX	O
better	O	ADJ	O
results	O	NOUN	B
than	O	ADP	O
the	O	DET	O
radiochemotherapy	O	NOUN	B
group	O	NOUN	B
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
1-year	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
32	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P=.05	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
mean	B-OUT	VERB	B
survival	I-OUT	NOUN	I
time	I-OUT	NOUN	I
(	O	PUNCT	O
>	O	NOUN	O
17	O	NUM	O
vs	O	CCONJ	O
11	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.03	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
hazard	B-OUT	NOUN	B
ratio	I-OUT	NOUN	I
(	O	PUNCT	O
0.46	O	NUM	O
,	O	PUNCT	O
P=.04	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
score	I-OUT	NOUN	I
or	O	CCONJ	O
laboratory	B-OUT	ADJ	B
data	I-OUT	NOUN	I
apart	O	ADV	O
from	O	ADP	O
increased	O	VERB	B
diarrhea	B-OUT	NOUN	B
after	O	ADP	O
surgical	O	ADJ	B
resection	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Locally	B-P	ADV	B
invasive	I-P	ADJ	I
pancreatic	I-P	ADJ	B
cancer	I-P	NOUN	I
without	I-P	ADP	O
distant	I-P	ADJ	B
metastases	I-P	NOUN	I
and	O	CCONJ	O
major	O	ADJ	O
arterial	O	ADJ	B
invasion	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
best	O	ADV	O
treated	O	VERB	B
by	O	ADP	O
surgical	O	ADJ	B
resection	O	NOUN	I
.	O	PUNCT	O


Arm-cranking	B-I	ADJ	B
exercise	I-I	NOUN	I
reduced	O	VERB	O
oxidative	B-OUT	ADJ	B
damage	I-OUT	NOUN	I
in	O	ADP	O
adults	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
spinal	I-P	ADJ	I
cord	I-P	NOUN	I
injury	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
12-week	O	NOUN	B
arm-cranking	B-I	ADJ	O
exercise	I-I	NOUN	B
program	I-I	NOUN	I
on	O	ADP	O
reducing	O	VERB	B
oxidative	B-OUT	ADJ	B
damage	I-OUT	NOUN	I
in	O	ADP	O
untrained	B-P	VERB	B
adults	I-P	NOUN	I
with	I-P	ADP	O
chronic	I-P	ADJ	B
spinal	I-P	ADJ	I
cord	I-P	NOUN	I
injury	I-P	NOUN	I
(	I-P	PUNCT	O
SCI	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Community-based	O	ADJ	B
supervised	O	ADJ	I
intervention	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	VERB	O
Male	B-P	ADJ	B
adults	I-P	NOUN	B
with	I-P	ADP	O
complete	I-P	ADJ	O
SCI	I-P	PROPN	B
at	I-P	ADP	O
or	I-P	CCONJ	O
below	I-P	ADP	O
the	I-P	DET	O
fifth	I-P	ADJ	O
thoracic	I-P	ADJ	O
level	I-P	NOUN	O
(	I-P	PUNCT	O
T5	I-P	NOUN	B
)	I-P	PUNCT	O
(	I-P	PUNCT	O
N=17	I-P	NOUN	O
)	I-P	PUNCT	O
volunteered	I-P	VERB	B
for	I-P	ADP	O
this	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
the	O	DET	O
intervention	B-P	NOUN	B
(	I-P	PUNCT	O
n=9	I-P	NOUN	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
control	I-I	NOUN	B
(	I-P	PUNCT	O
n=8	I-P	NOUN	O
)	I-P	PUNCT	O
group	I-P	NOUN	B
using	O	VERB	O
a	O	DET	O
concealed	O	VERB	B
method	O	NOUN	O
.	O	PUNCT	O


INTERVENTION	O	PROPN	B
A	O	DET	O
12-week	B-I	NOUN	B
arm-cranking	I-I	ADJ	O
exercise	I-I	NOUN	B
program	I-I	NOUN	I
,	O	PUNCT	O
3	O	NUM	O
sessions/wk	O	NOUN	O
,	O	PUNCT	O
consisting	B-I	VERB	O
of	I-I	ADP	O
warming-up	I-I	NOUN	B
(	I-I	PUNCT	O
10-15min	I-I	NOUN	O
)	I-I	PUNCT	O
followed	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
main	I-I	ADJ	O
part	I-I	NOUN	O
in	I-I	ADP	O
arm-crank	I-I	NOUN	B
(	O	PUNCT	O
20-30min	O	NOUN	O
[	O	PUNCT	O
increasing	O	VERB	B
2min	O	NOUN	O
and	O	CCONJ	O
30s	O	PROPN	O
every	O	DET	O
3wk	O	NOUN	O
]	O	PUNCT	O
)	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
moderate	O	ADJ	B
work	O	NOUN	O
intensity	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
to	O	PART	O
65	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
rate	O	NOUN	I
reserve	O	NOUN	I
(	O	PUNCT	O
starting	O	VERB	O
at	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
increasing	O	VERB	B
5	O	NUM	O
%	O	NOUN	O
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
a	O	DET	O
cooling-down	B-I	ADJ	B
period	O	NOUN	B
(	O	PUNCT	O
5-10min	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	X	B
MEASURES	O	X	O
Plasmatic	B-OUT	ADJ	B
levels	I-OUT	NOUN	O
of	I-OUT	ADP	O
total	I-OUT	ADJ	O
antioxidant	I-OUT	ADJ	O
status	I-OUT	NOUN	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
erythrocyte	B-OUT	NOUN	B
glutathione	I-OUT	NOUN	I
peroxidase	I-OUT	NOUN	I
activity	I-OUT	NOUN	O
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


Lipid	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
protein	I-OUT	NOUN	B
oxidation	I-OUT	NOUN	I
were	O	AUX	O
determined	O	VERB	O
as	O	ADP	O
malondialdehyde	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
carbonyl	I-OUT	NOUN	B
group	I-OUT	NOUN	I
levels	I-OUT	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
physical	B-OUT	ADJ	B
fitness	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
body	I-OUT	NOUN	B
composition	I-OUT	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
When	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
results	O	NOUN	B
,	O	PUNCT	O
maximum	B-OUT	ADJ	B
oxygen	I-OUT	NOUN	B
consumption	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
(	O	PUNCT	O
P=.031	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
suggesting	O	VERB	O
an	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
physical	B-OUT	ADJ	B
fitness	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Regarding	O	VERB	O
the	O	DET	O
antioxidant	O	ADJ	B
defense	O	NOUN	I
system	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
total	B-OUT	ADJ	O
antioxidant	I-OUT	ADJ	O
status	I-OUT	NOUN	O
(	O	PUNCT	O
P=.014	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
erythrocyte	B-OUT	NOUN	B
glutathione	I-OUT	NOUN	I
peroxidase	I-OUT	NOUN	I
activity	I-OUT	NOUN	I
(	O	PUNCT	O
P=.027	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
training	O	NOUN	B
program	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
consequence	O	NOUN	B
,	O	PUNCT	O
plasmatic	B-OUT	ADJ	B
levels	I-OUT	NOUN	O
of	I-OUT	ADP	O
malondialdehyde	I-OUT	NOUN	B
(	O	PUNCT	O
P=.008	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
carbonyl	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
P=.022	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
A	O	NOUN	O
12-week	O	NOUN	B
arm-cranking	B-I	ADJ	O
exercise	I-I	NOUN	B
program	I-I	NOUN	I
improved	O	VERB	B
the	O	DET	O
antioxidant	B-OUT	ADJ	B
defense	I-OUT	NOUN	I
system	I-OUT	NOUN	I
in	I-P	ADP	O
adults	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
SCI	I-P	PROPN	O
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
finally	O	ADV	O
attenuate	O	VERB	B
both	O	CCONJ	O
lipid	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
protein	I-OUT	NOUN	B
oxidation	I-OUT	NOUN	I
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


Cobedding	B-I	NOUN	B
of	I-I	ADP	O
twin	I-I	NOUN	B
premature	I-I	ADJ	I
infants	I-I	NOUN	O
:	I-I	PUNCT	O
calming	O	VERB	B
effects	B-OUT	NOUN	I
on	O	ADP	O
pain	B-OUT	NOUN	B
responses	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
cobedding	B-I	NOUN	B
of	I-I	ADP	O
preterm	I-I	NOUN	B
twins	I-I	NOUN	I
has	O	AUX	O
analgesic	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
during	O	ADP	O
heel	O	NOUN	B
lancing	O	NOUN	I
or	O	CCONJ	O
not	O	PART	O
.	O	PUNCT	O


METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
premature	I-P	ADJ	B
twins	I-P	NOUN	I
(	I-P	PUNCT	O
50	I-P	NUM	O
sets	I-P	NOUN	B
)	I-P	PUNCT	O
born	I-P	VERB	B
between	I-P	ADP	O
26	I-P	NUM	O
weeks	I-P	NOUN	B
'	I-P	PUNCT	O
and	I-P	CCONJ	O
34	I-P	NUM	O
weeks	I-P	NOUN	B
'	I-P	PART	O
gestation	I-P	NOUN	B
undergoing	I-P	VERB	O
heel	I-P	NOUN	B
blood	I-P	NOUN	I
sampling	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
the	O	DET	O
cobedding	B-I	VERB	B
group	I-I	NOUN	I
(	I-I	PUNCT	O
receiving	I-I	VERB	O
care	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
same	I-I	ADJ	O
incubator	I-I	NOUN	O
)	I-I	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
standard	B-I	ADJ	B
care	I-I	NOUN	I
group	I-I	NOUN	I
(	I-I	PUNCT	O
receiving	I-I	VERB	O
care	I-I	NOUN	B
in	I-I	ADP	O
separate	I-I	ADJ	B
incubators	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Pain	B-OUT	NOUN	B
was	I-OUT	AUX	O
assessed	I-OUT	VERB	B
using	I-OUT	VERB	O
the	I-OUT	DET	O
premature	I-OUT	ADJ	B
infant	I-OUT	ADJ	I
pain	I-OUT	NOUN	I
profile	I-OUT	NOUN	I
score	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
crying	I-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	B
after	O	ADP	O
heel	O	ADJ	B
blood	O	NOUN	I
sampling	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
salivary	B-OUT	ADJ	B
cortisol	I-OUT	NOUN	I
was	O	AUX	O
measured	O	VERB	O
prior	O	ADJ	O
to	O	PART	O
and	O	CCONJ	O
after	O	ADP	O
heel	O	NOUN	B
blood	O	NOUN	I
sampling	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
Infants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
standard	B-I	ADJ	B
care	I-I	NOUN	I
group	O	NOUN	I
cried	B-OUT	VERB	B
for	I-OUT	ADP	O
a	I-OUT	DET	O
longer	I-OUT	ADJ	O
time	I-OUT	NOUN	O
during	O	ADP	O
heel	O	NOUN	B
lancing	O	NOUN	I
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
cobedding	B-I	VERB	B
group	O	NOUN	I
(	O	PUNCT	O
42.6	O	NUM	O
±	O	NOUN	O
19.8	O	NUM	O
seconds	O	NOUN	O
vs.	O	CCONJ	O
36.4	O	NUM	O
±	O	NOUN	O
21.7	O	NUM	O
seconds	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
mean	I-OUT	ADJ	O
premature	I-OUT	ADJ	B
infant	I-OUT	ADJ	I
pain	I-OUT	NOUN	I
profile	I-OUT	NOUN	I
score	I-OUT	NOUN	I
after	O	ADP	O
heel	O	NOUN	B
lancing	O	NOUN	I
was	B-OUT	AUX	O
significantly	I-OUT	ADV	O
higher	I-OUT	ADJ	O
in	O	ADP	O
the	B-I	DET	O
standard	I-I	ADJ	B
care	I-I	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
9.8	O	NUM	O
±	O	NOUN	O
2.6	O	NUM	O
vs.	O	CCONJ	O
8.06	O	NUM	O
±	O	NOUN	O
2.8	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
mean	I-OUT	ADJ	O
salivary	I-OUT	ADJ	B
cortisol	I-OUT	NOUN	I
after	O	ADP	O
heel	O	NOUN	B
lancing	O	NOUN	I
was	O	AUX	O
also	B-OUT	ADV	O
significantly	I-OUT	ADV	O
higher	I-OUT	ADJ	O
in	O	ADP	O
the	B-I	DET	O
standard	I-I	ADJ	B
care	I-I	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
24.3	O	NUM	O
±	O	NOUN	O
7.4	O	NUM	O
nmol/L	O	NOUN	O
vs.	O	CCONJ	O
20.8	O	NUM	O
±	O	NOUN	O
7.4	O	NUM	O
nmol/L	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


No	B-OUT	DET	B
significant	I-OUT	ADJ	I
adverse	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
seen	B-I	VERB	O
with	I-I	ADP	O
cobedding	I-I	NOUN	B
.	O	PUNCT	O


CONCLUSION	B-I	NOUN	O
Cobedding	I-I	NOUN	B
is	O	AUX	O
a	O	DET	O
comforting	O	ADJ	B
measure	B-P	NOUN	I
for	I-P	ADP	O
twin	I-P	NOUN	B
premature	I-P	ADJ	I
infants	I-P	NOUN	O
during	O	ADP	O
heel	O	NOUN	B
lancing	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
can	O	AUX	O
be	O	AUX	O
performed	O	VERB	O
without	O	ADP	O
any	O	DET	O
significant	B-OUT	ADJ	B
adverse	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
flurbiprofen	B-I	ADJ	B
sodium	I-I	NOUN	I
on	O	ADP	O
pupillary	B-OUT	ADJ	B
dilatation	I-OUT	NOUN	I
during	O	ADP	O
scleral	B-P	ADJ	B
buckling	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


Maintenance	O	NOUN	B
of	O	ADP	O
pupillary	B-OUT	ADJ	B
dilatation	I-OUT	NOUN	I
is	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
success	O	NOUN	B
of	O	ADP	O
scleral	B-P	ADJ	B
buckling	I-P	NOUN	I
procedures	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
0.03	B-I	NUM	O
%	I-I	NOUN	O
flurbiprofen	I-I	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
intraoperative	O	ADJ	B
miosis	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-masked	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
of	O	ADP	O
60	B-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Thirty	B-P	NUM	O
patients	I-P	NOUN	B
received	O	VERB	O
0.03	O	NUM	O
%	O	NOUN	O
flurbiprofen	B-I	NOUN	B
6	O	NUM	O
times	O	NOUN	O
at	O	ADP	O
15	O	NUM	O
minute	O	NOUN	O
intervals	O	NOUN	B
90	O	NUM	O
minutes	O	NOUN	B
preoperatively	O	ADV	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
routine	O	ADJ	B
dilation	O	NOUN	B
regimen	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
treated	O	VERB	B
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
mean	B-OUT	ADJ	O
pupillary	I-OUT	ADJ	B
decrease	I-OUT	NOUN	B
of	O	ADP	O
1.88	O	NUM	O
mm	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
had	O	AUX	O
a	O	DET	O
decrease	O	NOUN	B
of	O	ADP	O
1.57	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Flurbiprofen	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
pupillary	B-OUT	ADJ	B
size	I-OUT	NOUN	I
at	O	ADP	O
any	O	DET	O
step	O	NOUN	O
of	O	ADP	O
the	O	DET	O
surgery	O	NOUN	B
.	O	PUNCT	O


Factors	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
age	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
patient	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
lens	I-OUT	NOUN	B
status	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
cryo	I-OUT	ADJ	B
applications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	I
surgery	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
size	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
extent	I-OUT	NOUN	B
of	I-OUT	ADP	O
buckle	I-OUT	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
flurbiprofen	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
mean	B-OUT	ADJ	O
pupillary	I-OUT	ADJ	B
change	I-OUT	NOUN	I
for	O	ADP	O
any	O	DET	O
of	O	ADP	O
these	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Preoperative	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
flurbiprofen	B-I	NOUN	B
does	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
decrease	O	VERB	B
intraoperative	B-OUT	ADJ	B
miosis	I-OUT	NOUN	B
during	I-OUT	ADP	O
scleral	I-OUT	ADJ	B
buckling	I-OUT	NOUN	I
procedures	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Growth	B-OUT	NOUN	B
hormone	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
responses	I-OUT	NOUN	B
to	O	PART	O
GH-releasing	B-I	ADJ	B
hormone	I-I	NOUN	I
alone	I-I	ADV	O
or	O	CCONJ	O
combined	B-I	VERB	B
with	I-I	ADP	O
arginine	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
adrenal	I-P	ADJ	B
incidentaloma	I-P	NOUN	I
:	I-P	PUNCT	O
evidence	O	NOUN	B
for	O	ADP	O
enhanced	O	VERB	B
somatostatinergic	O	ADJ	B
tone	O	NOUN	O
.	O	PUNCT	O


Spontaneous	O	ADJ	B
and	O	CCONJ	O
stimulated	O	VERB	B
GH	O	NOUN	B
secretion	O	NOUN	I
is	O	AUX	O
blunted	O	VERB	B
in	O	ADP	O
hypercortisolemic	O	ADJ	B
states	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
increased	O	VERB	B
hypothalamic	O	ADJ	B
somatostatinergic	O	ADJ	I
tone	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
data	O	NOUN	B
are	O	AUX	O
available	O	ADJ	O
on	O	ADP	O
the	O	DET	O
characteristics	O	NOUN	B
of	O	ADP	O
GH	O	NOUN	B
secretion	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
incidentally	I-P	ADV	B
discovered	I-P	VERB	O
adrenal	I-P	ADJ	B
adenomas	I-P	NOUN	I
.	I-P	PUNCT	O


They	O	PRON	O
represent	O	VERB	O
an	O	DET	O
interesting	O	ADJ	O
model	O	NOUN	B
for	O	ADP	O
studying	O	VERB	O
GH	O	NOUN	B
secretion	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
slight	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
cortisol	O	NOUN	B
excess	O	NOUN	B
may	O	AUX	O
frequently	O	ADV	O
be	O	AUX	O
observed	O	VERB	B
in	O	ADP	O
such	O	ADJ	O
patients	B-P	NOUN	B
who	I-P	PRON	O
do	I-P	AUX	O
not	I-P	PART	O
present	I-P	VERB	O
with	I-P	ADP	O
any	I-P	DET	O
clear	I-P	ADJ	O
Cushingoid	I-P	ADJ	B
sign	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
10	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
3	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
7	I-P	NUM	O
women	I-P	NOUN	B
,	I-P	PUNCT	O
aged	I-P	ADJ	B
48-63	I-P	NUM	O
yr	I-P	NOUN	O
)	I-P	PUNCT	O
with	I-P	ADP	O
an	I-P	DET	O
adrenal	I-P	ADJ	B
mass	I-P	NOUN	I
discovered	I-P	VERB	O
serendipitously	I-P	ADV	O
underwent	O	VERB	O
,	O	PUNCT	O
on	O	ADP	O
separate	O	ADJ	O
occasions	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
GHRH	B-I	NOUN	B
injection	I-I	NOUN	B
alone	I-I	ADV	O
or	O	CCONJ	O
combined	B-I	VERB	O
with	I-I	ADP	O
an	I-I	DET	O
infusion	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
functional	I-I	ADJ	B
somatostatin	I-I	NOUN	B
antagonist	I-I	NOUN	B
,	I-I	PUNCT	O
arginine	I-I	NOUN	B
.	I-I	PUNCT	O


Thirteen	B-P	NUM	O
age-matched	I-P	ADJ	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
served	I-P	VERB	O
as	I-P	ADP	O
controls	I-I	NOUN	B
.	I-I	PUNCT	O


Briefly	O	ADV	B
,	O	PUNCT	O
arginine	B-I	NOUN	B
(	I-I	PUNCT	O
30	I-I	NUM	O
g	I-I	NOUN	O
)	I-I	PUNCT	O
was	I-I	AUX	O
infused	I-I	VERB	B
from	I-I	ADP	O
-30	I-I	NUM	O
to	I-I	PART	O
0	I-I	NUM	O
min	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
GHRH	I-I	NOUN	B
(	I-I	PUNCT	O
100	I-I	NUM	O
microg	I-I	NOUN	B
)	I-I	PUNCT	O
was	I-I	AUX	O
injected	I-I	VERB	B
as	I-I	ADP	O
a	I-I	DET	O
bolus	I-I	NOUN	B
at	I-I	ADP	O
0	I-I	NUM	O
min	I-I	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
measurement	O	NOUN	B
of	O	ADP	O
serum	B-I	NOUN	B
GH	I-I	NOUN	I
[	I-I	PUNCT	I
immunoradiometric	I-I	ADJ	O
assay	I-I	NOUN	O
(	I-I	PUNCT	O
IRMA	I-I	NOUN	B
)	I-I	PUNCT	O
]	I-I	PUNCT	O
every	O	DET	O
15	O	NUM	O
min	O	NOUN	O
for	O	ADP	O
150	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


Plasma	B-I	NOUN	B
IGF-I	I-I	NOUN	B
(	I-I	PUNCT	O
RIA	I-I	NOUN	B
after	I-I	ADP	O
acid-ethanol	I-I	ADJ	B
extraction	I-I	NOUN	I
)	I-I	PUNCT	O
was	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
a	O	DET	O
morning	O	NOUN	B
sample	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
cortical	O	ADJ	B
adenoma	O	NOUN	I
was	O	AUX	O
based	O	VERB	O
on	O	ADP	O
computed	O	VERB	B
tomography	O	NOUN	I
features	O	NOUN	B
and	O	CCONJ	O
pattern	O	NOUN	B
of	O	ADP	O
uptake	O	NOUN	B
on	O	ADP	O
adrenal	O	ADJ	B
scintigraphy	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
obesity	I-P	NOUN	B
and/or	I-P	CCONJ	O
diabetes	I-P	NOUN	B
were	I-P	AUX	O
excluded	I-P	VERB	O
.	I-P	PUNCT	O


The	O	DET	O
study	O	NOUN	B
design	O	NOUN	B
included	O	VERB	O
also	O	ADV	O
an	O	DET	O
endocrine	O	ADJ	B
work-up	O	NOUN	I
aimed	O	VERB	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
hypothalamic-pituitary-adrenal	B-OUT	ADJ	B
axis	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
urinary	I-OUT	ADJ	B
free	I-OUT	ADJ	I
cortisol	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
UFC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
excretion	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
serum	I-OUT	NOUN	B
cortisol	I-OUT	NOUN	I
at	I-OUT	ADP	O
0800	I-OUT	NUM	O
h	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
ACTH	I-OUT	NOUN	B
at	I-OUT	ADP	O
0800	I-OUT	NUM	O
h	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
morning	I-OUT	NOUN	B
cortisol	I-OUT	NOUN	B
after	I-OUT	ADP	O
overnight	I-OUT	ADV	B
1	I-OUT	NUM	O
mg	I-OUT	NOUN	O
dexamethasone	I-OUT	NOUN	B
]	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
abnormalities	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
hypothalamic-pituitary-adrenal	I-OUT	ADJ	B
axis	I-OUT	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
borderline	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
increased	I-OUT	VERB	B
UFC	I-OUT	NOUN	B
excretion	I-OUT	NOUN	B
in	O	ADP	O
4	O	NUM	O
of	O	ADP	O
them	O	PRON	O
accompanied	O	VERB	O
by	O	ADP	O
blunted	O	VERB	B
ACTH	O	NOUN	B
in	O	ADP	O
2	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
failure	O	NOUN	B
of	O	ADP	O
cortisol	O	NOUN	B
to	O	PART	O
suppress	O	VERB	B
after	O	ADP	O
dexamethasone	O	NOUN	B
in	O	ADP	O
1	O	NUM	O
;	O	PUNCT	O
the	O	DET	O
fifth	O	ADJ	O
patient	O	NOUN	B
displayed	O	VERB	O
low	O	ADJ	B
ACTH	O	NOUN	B
and	O	CCONJ	O
resistance	O	NOUN	B
to	O	PART	O
dexamethasone	O	NOUN	B
suppression	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
unilateral	O	ADJ	B
uptake	O	NOUN	B
of	O	ADP	O
the	O	DET	O
tracer	O	NOUN	B
on	O	ADP	O
the	O	DET	O
side	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mass	O	NOUN	B
with	O	ADP	O
suppression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
contralateral	O	ADJ	B
normal	O	ADJ	O
adrenal	O	ADJ	B
gland	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
group	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
displayed	O	VERB	O
greater	O	ADJ	O
UFC	B-OUT	NOUN	B
excretion	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
lower	I-OUT	ADJ	O
ACTH	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
than	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
.	O	PUNCT	O


GH	B-OUT	NOUN	B
release	I-OUT	NOUN	I
after	I-OUT	ADP	O
GHRH	I-OUT	NOUN	B
treatment	I-OUT	NOUN	B
was	O	AUX	O
blunted	O	VERB	B
in	O	ADP	O
patients	B-P	NOUN	B
bearing	I-P	VERB	O
adrenal	I-P	ADJ	B
incidentaloma	I-P	NOUN	I
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
GH	O	NOUN	B
peak	O	NOUN	I
,	O	PUNCT	O
5.7	O	NUM	O
+/-	O	CCONJ	O
5.2	O	NUM	O
vs.	O	CCONJ	O
18.0	O	NUM	O
+/-	O	CCONJ	O
7.0	O	NUM	O
microg/L	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
GHRH	B-I	NOUN	B
plus	I-I	CCONJ	O
arginine	I-I	NOUN	B
was	O	AUX	O
able	O	ADJ	O
to	O	PART	O
elicit	O	VERB	O
a	O	DET	O
comparable	O	ADJ	O
response	O	NOUN	B
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
GH	O	NOUN	B
peak	O	NOUN	O
,	O	PUNCT	O
33.5	O	NUM	O
+/-	O	CCONJ	O
20.3	O	NUM	O
vs.	O	CCONJ	O
33.7	O	NUM	O
+/-	O	CCONJ	O
17.5	O	NUM	O
microg/L	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
NS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
ratio	O	NOUN	B
between	O	ADP	O
GH	B-OUT	NOUN	B
peaks	I-OUT	VERB	I
after	I-OUT	ADP	O
GHRH	I-OUT	NOUN	B
plus	I-OUT	CCONJ	O
arginine	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
after	I-OUT	ADP	O
GHRH	I-OUT	NOUN	B
plus	I-OUT	CCONJ	O
saline	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
751	O	NUM	O
+/-	O	CCONJ	O
531	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
81	O	NUM	O
+/-	O	CCONJ	O
45	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Similar	O	ADJ	O
data	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
when	O	SCONJ	O
comparing	O	VERB	B
GH	O	NOUN	B
area	O	NOUN	I
under	O	ADP	O
the	O	DET	O
curve	O	NOUN	O
after	O	ADP	O
GHRH	O	NOUN	B
plus	O	CCONJ	O
saline	O	NOUN	B
or	O	CCONJ	O
GHRH	O	NOUN	B
plus	O	CCONJ	O
arginine	O	NOUN	B
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
incidental	I-P	ADJ	B
adrenal	I-P	ADJ	B
adenomas	I-P	NOUN	I
the	O	DET	O
GH	B-OUT	NOUN	B
response	I-OUT	NOUN	I
to	O	PART	O
GHRH	O	NOUN	B
is	O	AUX	O
blunted	O	VERB	B
due	O	ADJ	O
to	O	PART	O
increased	O	VERB	B
somatostatinergic	B-OUT	ADJ	B
tone	I-OUT	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
restored	O	VERB	B
to	O	PART	O
normal	O	ADJ	O
by	O	ADP	O
pretreatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
functional	O	ADJ	B
somatostatin	O	NOUN	O
antagonist	O	NOUN	B
arginine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
blunted	O	ADJ	B
GH	O	NOUN	B
release	O	NOUN	I
to	O	PART	O
GHRH	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
long	O	ADJ	B
lasting	O	ADJ	I
sign	O	NOUN	I
of	O	ADP	O
autonomous	O	ADJ	B
cortisol	O	NOUN	I
secretion	O	NOUN	I
by	O	ADP	O
the	O	DET	O
adrenal	O	ADJ	B
adenoma	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
home	B-I	NOUN	B
visiting	I-I	VERB	I
asthma	I-I	NOUN	B
education	I-I	NOUN	I
program	I-I	NOUN	I
:	I-I	PUNCT	O
challenges	O	NOUN	O
to	O	ADP	O
program	O	NOUN	B
implementation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
describes	O	VERB	O
the	O	DET	O
implementation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
nurse	B-I	ADJ	B
home	I-I	NOUN	I
visiting	I-I	VERB	I
asthma	I-I	NOUN	B
education	I-I	NOUN	I
program	I-I	NOUN	I
for	O	ADP	O
low-income	B-P	ADJ	B
African	I-P	ADJ	B
American	I-P	ADJ	I
families	I-P	NOUN	B
of	I-P	ADP	O
young	I-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
asthma	I-P	NOUN	B
.	I-P	PUNCT	O


Of	B-P	ADP	O
55	I-P	NUM	O
families	I-P	NOUN	B
,	I-P	PUNCT	O
71	I-P	NUM	O
%	I-P	NOUN	O
completed	I-P	VERB	B
the	I-P	DET	O
program	I-P	NOUN	B
consisting	O	VERB	O
of	O	ADP	O
eight	O	NUM	O
lessons	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
achievement	B-OUT	NOUN	B
of	I-OUT	ADP	O
learning	I-OUT	NOUN	B
objectives	I-OUT	NOUN	I
was	O	AUX	O
predicted	O	VERB	O
by	O	ADP	O
caregiver	B-OUT	NOUN	B
factors	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
such	I-OUT	ADJ	O
as	I-OUT	ADP	O
education	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
presence	I-OUT	NOUN	B
of	I-OUT	ADP	O
father	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
surrogate	I-OUT	ADJ	B
father	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
household	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
neighborhood	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
by	O	ADP	O
child	B-OUT	NOUN	B
factors	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
such	I-OUT	ADJ	O
as	I-OUT	ADP	O
age	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
asthma	I-OUT	NOUN	B
as	O	ADP	O
implied	O	VERB	O
by	O	ADP	O
the	O	DET	O
prescribed	O	VERB	B
asthma	O	NOUN	B
medication	O	NOUN	B
regimen	O	NOUN	I
.	O	PUNCT	O


Incompatibility	O	NOUN	B
between	O	ADP	O
the	O	DET	O
scheduling	O	NOUN	B
needs	O	NOUN	O
of	O	ADP	O
the	O	DET	O
families	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
nurse	O	ADJ	B
home	O	NOUN	O
visitors	O	NOUN	O
was	O	AUX	O
a	O	DET	O
major	O	ADJ	O
obstacle	O	NOUN	O
in	O	ADP	O
delivering	O	VERB	B
the	O	DET	O
program	O	NOUN	B
on	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
despite	O	SCONJ	O
the	O	DET	O
flexibility	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nurse	O	ADJ	B
home	O	NOUN	O
visitors	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
future	O	ADJ	O
home-based	B-I	ADJ	B
asthma	I-I	NOUN	B
education	I-I	NOUN	O
programs	I-I	NOUN	O
contain	O	VERB	O
a	O	DET	O
more	O	ADV	O
limited	O	ADJ	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
home	I-OUT	NOUN	B
visits	I-OUT	NOUN	I
but	O	CCONJ	O
add	O	VERB	O
telephone	O	NOUN	B
follow-ups	O	NOUN	I
and	O	CCONJ	O
address	O	VERB	O
the	O	DET	O
broader	O	ADJ	O
needs	O	NOUN	O
of	O	ADP	O
low-income	B-P	ADJ	B
families	I-P	NOUN	B
that	O	PRON	O
most	O	ADV	O
likely	O	ADJ	O
function	O	NOUN	B
as	O	ADP	O
barriers	O	NOUN	B
to	O	ADP	O
program	O	NOUN	B
success	O	NOUN	I
.	O	PUNCT	O


Correlations	O	NOUN	B
between	O	ADP	O
the	O	DET	O
clinical	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
histological	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
neurophysiological	I-OUT	ADJ	B
examinations	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
before	I-P	ADP	O
and	I-P	CCONJ	O
after	I-P	ADP	O
parotid	I-I	NOUN	B
gland	I-I	NOUN	I
tumor	I-I	NOUN	B
surgery	I-I	NOUN	I
:	I-I	PUNCT	O
verification	O	NOUN	B
of	O	ADP	O
facial	O	ADJ	B
nerve	O	NOUN	I
transmission	O	NOUN	B
.	O	PUNCT	O


Parotid	O	ADJ	B
gland	O	NOUN	I
tumor	O	NOUN	B
surgery	O	NOUN	I
sometimes	O	ADV	O
leads	O	VERB	O
to	O	PART	O
facial	O	ADJ	B
nerve	O	NOUN	I
paralysis	O	NOUN	B
.	O	PUNCT	O


Malignant	O	ADJ	B
more	O	ADJ	O
than	O	ADP	O
benign	O	ADJ	B
tumors	O	NOUN	I
determine	O	VERB	O
nerve	O	NOUN	B
function	O	NOUN	I
preoperatively	O	ADV	B
,	O	PUNCT	O
while	O	SCONJ	O
postoperative	O	ADJ	B
observations	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
,	O	PUNCT	O
histological	O	ADJ	B
and	O	CCONJ	O
neurophysiological	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
detail	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
aims	O	NOUN	O
of	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
were	O	AUX	O
evaluation	O	NOUN	B
and	O	CCONJ	O
correlations	O	NOUN	B
of	O	ADP	O
histological	B-OUT	ADJ	B
properties	I-OUT	NOUN	B
of	I-OUT	ADP	O
tumor	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
its	I-OUT	PRON	O
size	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
location	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
clinical	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
neurophysiological	I-OUT	ADJ	B
assessment	I-OUT	NOUN	I
of	I-OUT	ADP	O
facial	I-OUT	ADJ	B
nerve	I-OUT	NOUN	I
function	I-OUT	NOUN	I
pre-	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
post-operatively	I-OUT	ADV	B
(	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Comparative	O	ADJ	B
studies	O	NOUN	I
included	O	VERB	O
17	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
benign	I-P	ADJ	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
13	I-P	NUM	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
malignant	I-P	ADJ	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
4	I-P	NUM	O
)	I-P	PUNCT	O
tumors	I-P	NOUN	B
.	I-P	PUNCT	O


Clinical	B-OUT	ADJ	B
assessment	I-OUT	NOUN	I
was	O	AUX	O
based	O	VERB	O
on	O	ADP	O
House-Brackmann	B-OUT	ADJ	B
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
H-B	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
neurophysiological	I-OUT	ADJ	B
diagnostics	I-OUT	NOUN	I
included	I-OUT	VERB	O
facial	I-OUT	ADJ	B
electroneurography	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
ENG	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
compound	I-OUT	NOUN	B
muscle	I-OUT	NOUN	I
action	I-OUT	NOUN	I
potential	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CMAP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
]	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
mimetic	I-OUT	ADJ	B
muscle	I-OUT	NOUN	I
electromyography	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
EMG	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
blink-reflex	I-OUT	ADJ	B
examinations	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Mainly	O	ADV	O
grade	O	VERB	B
I	O	NOUN	I
of	O	ADP	I
H-B	B-OUT	NOUN	I
was	O	AUX	O
recorded	O	VERB	O
both	O	CCONJ	O
pre-	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
13	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
post-operatively	O	ADV	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
small	I-P	ADJ	B
(	I-P	PUNCT	O
1.5-2.4	I-P	NUM	O
cm	I-P	NOUN	O
)	I-P	PUNCT	O
benign	I-P	ADJ	B
tumors	I-P	NOUN	I
located	I-P	ADJ	O
in	I-P	ADP	O
superficial	I-P	ADJ	B
lobes	I-P	NOUN	I
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
medium	I-P	ADJ	B
size	I-P	NOUN	I
(	I-P	PUNCT	O
2.5-3.4	I-P	NUM	O
cm	I-P	NOUN	O
)	I-P	PUNCT	O
malignant	I-P	ADJ	B
tumors	I-P	NOUN	I
in	I-P	ADP	O
both	I-P	DET	O
lobes	I-P	NOUN	B
were	O	AUX	O
scored	O	VERB	B
at	O	ADP	O
grade	O	NOUN	B
I	O	NUM	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
III	O	NUM	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
)	O	PUNCT	O
pre-	O	ADJ	B
and	O	CCONJ	O
mainly	O	ADV	O
VI	O	PROPN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
)	O	PUNCT	O
post-operatively	O	ADV	B
.	O	PUNCT	O


CMAP	B-OUT	NOUN	B
amplitudes	I-OUT	VERB	B
after	O	ADP	O
stimulation	O	NOUN	B
of	O	ADP	O
mandibular	O	ADJ	B
marginal	O	ADJ	O
branch	O	NOUN	O
were	O	AUX	O
reduced	O	VERB	B
at	O	ADP	O
about	O	ADV	O
25	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
benign	I-P	ADJ	B
tumors	I-P	NOUN	I
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
of	O	ADP	O
malignant	O	ADJ	B
tumors	O	NOUN	I
CMAPs	B-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
recorded	O	VERB	O
following	O	VERB	O
stimulation	O	NOUN	B
of	O	ADP	O
any	O	DET	O
branch	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
similar	O	ADJ	O
trend	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
BR	B-OUT	NOUN	B
results	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


H-B	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
ENG	I-OUT	NOUN	B
results	O	NOUN	B
revealed	O	VERB	O
positive	O	ADJ	B
correlations	O	NOUN	B
between	O	ADP	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
tumor	O	NOUN	B
and	O	CCONJ	O
surgery	O	NOUN	B
with	O	ADP	O
facial	O	ADJ	B
nerve	O	NOUN	I
function	O	NOUN	I
.	O	PUNCT	O


Neurophysiological	O	ADJ	B
studies	O	NOUN	I
detected	O	VERB	O
clinically	B-OUT	ADV	B
silent	I-OUT	ADJ	I
facial	I-OUT	ADJ	B
nerve	I-OUT	NOUN	I
neuropathy	I-OUT	NOUN	I
of	I-OUT	ADP	O
mandibular	I-OUT	ADJ	B
marginal	I-OUT	ADJ	O
branch	I-OUT	NOUN	O
in	O	ADP	O
postoperative	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


Needle	B-OUT	NOUN	B
EMG	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
ENG	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
BR	I-OUT	NOUN	B
examinations	I-OUT	NOUN	B
allow	O	VERB	O
for	O	ADP	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
face	B-OUT	NOUN	B
muscles	I-OUT	NOUN	I
reinnervation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
facial	I-OUT	ADJ	B
nerve	I-OUT	NOUN	I
regeneration	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
arbutamine	B-I	NOUN	B
and	O	CCONJ	O
exercise	B-I	VERB	B
echocardiography	I-I	NOUN	I
in	O	ADP	O
diagnosing	B-P	VERB	B
myocardial	I-P	ADJ	B
ischemia	I-P	NOUN	I
.	I-P	PUNCT	O


Arbutamine	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
new	O	ADJ	O
catecholamine	O	NOUN	B
designed	O	VERB	O
for	O	ADP	O
use	O	NOUN	O
as	O	ADP	O
a	O	DET	O
pharmacologic	O	ADJ	B
stress	O	NOUN	I
agent	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
compared	O	VERB	B
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
arbutamine	B-I	NOUN	B
with	O	ADP	O
symptom-limited	B-I	ADJ	B
exercise	I-I	NOUN	I
to	O	PART	O
induce	O	VERB	B
echocardiographic	B-OUT	ADJ	B
signs	I-OUT	NOUN	B
of	I-OUT	ADP	I
ischemia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Arbutamine	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
by	O	ADP	O
a	O	DET	O
computerized	O	VERB	B
closed-loop	O	ADJ	I
delivery	O	NOUN	I
system	O	NOUN	I
that	O	PRON	O
controls	O	VERB	B
the	O	DET	O
infusion	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
arbutamine	B-I	NOUN	B
toward	O	ADP	O
a	O	DET	O
predefined	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
increase	O	NOUN	B
and	O	CCONJ	O
maximum	O	ADJ	B
heart	O	NOUN	B
rate	O	NOUN	I
limit	O	NOUN	I
.	O	PUNCT	O


Beta	O	NOUN	B
blockers	O	NOUN	I
were	O	AUX	O
stopped	O	VERB	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
48	O	NUM	O
hours	O	NOUN	B
before	O	ADP	O
both	O	DET	O
tests	O	NOUN	B
.	O	PUNCT	O


Stress	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	O
for	O	ADP	O
intolerable	O	ADJ	B
symptoms	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
clinical	O	ADJ	B
,	O	PUNCT	O
electrocardiographic	O	ADJ	B
or	O	CCONJ	O
echocardiographic	O	ADJ	B
signs	O	NOUN	B
of	O	ADP	I
ischemia	O	NOUN	B
(	O	PUNCT	O
new	O	ADJ	O
or	O	CCONJ	O
worsening	O	VERB	B
wall	O	NOUN	B
motion	O	NOUN	I
abnormality	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
target	O	NOUN	B
heart	O	NOUN	O
rate	O	NOUN	O
(	O	PUNCT	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
85	O	NUM	O
%	O	NOUN	O
age	O	NOUN	B
predicted	O	VERB	O
maximum	O	ADJ	O
heart	O	NOUN	O
rate	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
plateau	O	NOUN	B
of	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
response	O	NOUN	I
.	O	PUNCT	O


Thirty-seven	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
entered	I-P	VERB	O
into	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
(	I-P	PUNCT	O
35	I-P	NUM	O
arbutamine	I-I	NOUN	B
and	I-P	CCONJ	O
exercise	I-I	NOUN	B
,	I-P	PUNCT	O
1	I-P	NUM	O
arbutamine	I-I	NOUN	B
only	I-P	ADV	O
,	I-P	PUNCT	O
1	I-P	NUM	O
exercise	I-I	NOUN	B
only	I-P	ADV	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
of	I-P	ADP	O
which	I-P	DET	O
30	I-P	NUM	O
had	I-P	AUX	O
angiographic	I-P	ADJ	B
evidence	I-P	NOUN	B
of	I-P	ADP	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
>	I-P	NOUN	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
50	I-P	NUM	O
%	I-P	NOUN	O
lumen	I-P	NOUN	B
diameter	I-P	NOUN	O
narrowing	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Rate-pressure	B-OUT	ADJ	B
product	I-OUT	NOUN	I
increased	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
both	O	CCONJ	O
stress	O	NOUN	B
modalities	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
with	O	ADP	O
exercise	O	NOUN	B
(	O	PUNCT	O
11,308	O	NUM	O
+/-	O	CCONJ	O
2,443	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
with	O	ADP	O
arbutamine	O	NOUN	B
(	O	PUNCT	O
9,486	O	NUM	O
+/-	O	CCONJ	O
2,479	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
time	B-OUT	NOUN	O
to	I-OUT	PART	O
maximum	I-OUT	VERB	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
longer	O	ADJ	O
during	O	ADP	O
arbutamine	B-I	NOUN	B
stress	O	NOUN	I
echocardiography	O	NOUN	I
than	O	ADP	O
during	O	ADP	O
exercise	B-I	NOUN	B
testing	O	NOUN	I
(	O	PUNCT	O
17.3	O	NUM	O
+/-	O	CCONJ	O
9.4	O	NUM	O
versus	O	CCONJ	O
9.3	O	NUM	O
+/-	O	CCONJ	O
4.2	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
more	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
interpretable	O	ADJ	O
echo	O	ADJ	B
data	O	NOUN	I
for	O	ADP	O
arbutamine	B-I	NOUN	B
(	O	PUNCT	O
82	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
for	O	ADP	O
exercise	B-I	NOUN	B
(	O	PUNCT	O
67	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Sensitivity	B-OUT	NOUN	B
for	I-OUT	ADP	O
recognition	I-OUT	NOUN	B
of	I-OUT	ADP	O
myocardial	I-OUT	ADJ	B
ischemia	I-OUT	NOUN	I
was	O	AUX	O
94	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
70	O	NUM	O
%	O	NOUN	O
to	O	PART	O
100	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
88	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
62	O	NUM	O
%	O	NOUN	O
to	O	PART	O
98	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
during	O	ADP	O
arbutamine	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
36	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
dyspnea	B-OUT	NOUN	B
(	O	PUNCT	O
5.6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
tremor	B-OUT	NOUN	B
(	O	PUNCT	O
5.6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
arbutamine	B-I	NOUN	B
stress	O	NOUN	I
tests	O	NOUN	I
were	O	AUX	O
discontinued	O	VERB	B
due	O	ADJ	O
to	O	ADP	O
arrhythmias	B-OUT	NOUN	B
:	I-OUT	PUNCT	O
1	O	NUM	O
patient	O	NOUN	B
had	O	AUX	O
premature	B-OUT	ADJ	B
atrial	I-OUT	ADJ	I
and	I-OUT	CCONJ	O
ventricular	I-OUT	ADJ	B
beats	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
had	O	AUX	O
premature	B-OUT	ADJ	B
atrial	I-OUT	ADJ	B
contractions	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
atrial	I-OUT	ADJ	B
fibrillation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Arrhythmias	B-OUT	NOUN	B
were	I-OUT	AUX	O
well	I-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	I-OUT	CCONJ	O
resolved	I-OUT	VERB	B
without	O	ADP	O
sequelae	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
arbutamine	B-I	NOUN	B
to	O	PART	O
induce	O	VERB	B
echocardiographic	B-OUT	ADJ	B
signs	I-OUT	NOUN	B
of	I-OUT	ADP	I
ischemia	I-OUT	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
exercise	B-I	NOUN	B
despite	O	SCONJ	O
a	O	DET	O
lower	O	ADJ	O
rate-pressure	B-OUT	ADJ	O
product	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Arbutamine	B-I	NOUN	B
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	I-OUT	CCONJ	O
provides	I-OUT	VERB	O
a	I-OUT	DET	O
reliable	I-OUT	ADJ	O
alternative	I-OUT	NOUN	B
to	I-OUT	PART	O
exercise	I-OUT	VERB	B
echocardiography	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
the	O	DET	O
dual-switch	B-I	ADJ	B
valve	I-I	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
adult	B-P	ADJ	B
normotensive	I-P	ADJ	B
or	I-P	CCONJ	O
hypertensive	I-P	ADJ	B
hydrocephalus	I-P	NOUN	I
.	I-P	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
1995	O	NUM	O
the	O	DET	O
new	B-P	ADJ	O
hydrostatic	I-I	ADJ	B
dual-switch	I-I	ADJ	I
valve	I-I	NOUN	I
(	I-I	PUNCT	O
DSV	I-I	PROPN	B
)	I-I	PUNCT	O
was	I-P	AUX	O
implanted	I-P	VERB	B
in	I-P	ADP	O
35	I-P	NUM	O
adult	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
hydrocephalus	I-P	NOUN	B
of	I-P	ADP	O
different	I-P	ADJ	O
etiology	I-P	NOUN	B
.	I-P	PUNCT	O


26	B-P	NUM	O
patients	I-P	NOUN	B
suffered	I-P	VERB	O
from	I-P	ADP	O
normotensive	I-P	ADJ	B
hydrocephalus	I-P	NOUN	I
(	I-P	PUNCT	O
10	I-P	NUM	O
idiopathic	I-P	ADJ	B
and	I-P	CCONJ	O
16	I-P	NUM	O
symptomatic	I-P	ADJ	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
9	I-P	NUM	O
patients	I-P	NOUN	B
from	I-P	ADP	O
hypertensive	I-P	ADJ	B
hydrocephalus	I-P	NOUN	I
of	I-P	ADP	O
various	I-P	ADJ	O
origin	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
first	O	ADJ	O
21	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
this	O	DET	O
cohort	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
with	O	ADP	O
a	O	DET	O
comparable	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
21	O	NUM	O
hydrocephalic	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
a	O	DET	O
conventional	B-I	ADJ	B
differential-pressure	I-I	ADJ	B
(	I-I	PUNCT	O
DP-	I-I	NOUN	B
)	I-I	PUNCT	O
valve	I-I	NOUN	O
.	I-I	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
status	O	NOUN	I
and	O	CCONJ	O
CT	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
prior	O	ADJ	O
to	O	ADP	O
shunting	O	NOUN	B
,	O	PUNCT	O
14	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
ventricular	B-OUT	ADJ	B
size	I-OUT	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
the	O	DET	O
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Evans	O	PROPN	B
Index	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
CT	O	NOUN	B
follow-up	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DSV	B-I	PROPN	B
group	O	NOUN	B
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
an	O	DET	O
only	O	ADV	O
minimal	O	ADJ	B
(	O	PUNCT	O
14	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
only	O	ADV	O
slight	O	ADJ	O
(	O	PUNCT	O
16	O	NUM	O
)	O	PUNCT	O
reduction	O	NOUN	B
of	O	ADP	O
ventricular	O	ADJ	B
size	O	NOUN	I
in	O	ADP	O
the	O	DET	O
vast	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
21	B-P	NUM	O
patients	I-P	NOUN	B
with	O	ADP	O
a	O	DET	O
DSV	B-I	PROPN	B
and	O	CCONJ	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
DP	B-I	NOUN	B
valves	I-I	NOUN	I
,	O	PUNCT	O
evaluated	O	VERB	B
by	O	ADP	O
measuring	O	VERB	B
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Evans	B-OUT	PROPN	B
Index	I-OUT	PROPN	I
,	O	PUNCT	O
revealed	O	VERB	O
a	O	DET	O
distinctly	O	ADV	O
higher	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
significant	O	ADJ	B
regressions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DP	B-I	NOUN	B
valve	I-I	NOUN	O
collective	O	ADJ	O
,	O	PUNCT	O
without	O	ADP	O
doubt	O	NOUN	O
due	O	ADJ	O
to	O	PART	O
chronic	O	ADJ	B
overdrainage	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
clinical	O	ADJ	B
result	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
35	B-P	NUM	O
patients	I-P	NOUN	B
with	O	ADP	O
a	O	DET	O
DSV	B-I	PROPN	B
was	O	AUX	O
excellent	O	ADJ	B
and	O	CCONJ	O
good	O	ADJ	O
in	O	ADP	O
31	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
outcome	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
preshunt	B-OUT	NOUN	B
damage	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
brain	I-OUT	NOUN	B
than	O	ADP	O
on	O	ADP	O
hydrocephalic	B-OUT	ADJ	B
aspects	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


A	O	DET	O
neglegible	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
subdural	B-OUT	ADJ	B
effusions	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
DSV	B-I	PROPN	B
group	O	NOUN	B
compared	O	VERB	B
to	O	ADP	O
11	O	NUM	O
cases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DP	B-I	NOUN	B
valve	I-I	NOUN	O
collective	O	ADJ	O
reflects	O	VERB	O
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
the	O	DET	O
DSV	B-I	PROPN	B
to	O	PART	O
prevent	O	VERB	B
overdrainage	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
capability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DSV	B-I	PROPN	B
to	O	PART	O
maintain	O	VERB	O
the	O	DET	O
IVP	B-OUT	NOUN	B
within	O	ADP	O
physiological	O	ADJ	B
limits	O	NOUN	O
after	O	ADP	O
shunting	O	VERB	B
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
the	O	DET	O
upright	O	ADJ	B
position	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
documented	O	VERB	B
by	O	ADP	O
a	O	DET	O
comparison	O	NOUN	B
with	O	ADP	O
possible	B-OUT	ADJ	O
unphysiological	I-OUT	ADJ	B
IVP	I-OUT	NOUN	B
variations	I-OUT	NOUN	B
in	O	ADP	O
other	O	ADJ	O
valve	O	NOUN	B
constructions	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
depend	O	VERB	O
on	O	ADP	O
the	O	DET	O
level	B-OUT	NOUN	B
of	I-OUT	ADP	O
implantation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
subcutaneous	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
CSF	I-OUT	NOUN	B
flow	I-OUT	NOUN	B
through	I-OUT	ADP	O
the	I-OUT	DET	O
valve	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Aspirin-associated	B-P	ADJ	B
iron	I-P	NOUN	I
loss	I-P	NOUN	I
as	I-P	ADP	O
an	I-P	DET	O
anticancer	I-P	NOUN	B
mechanism	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
consensus	O	NOUN	B
view	O	NOUN	I
has	O	AUX	O
emerged	O	VERB	O
favoring	O	VERB	O
an	O	DET	O
anticancer	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
long-term	O	ADJ	B
aspirin	O	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


Aspirin-induced	B-I	ADJ	B
loss	O	NOUN	B
of	O	ADP	O
stored	O	VERB	B
iron	O	NOUN	B
from	O	ADP	O
chronic	O	ADJ	B
gastrointestinal	O	ADJ	I
bleeding	O	NOUN	I
is	O	AUX	O
proposed	O	VERB	O
as	O	ADP	O
a	O	DET	O
mechanism	O	NOUN	B
underlying	O	VERB	O
this	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
iron	O	NOUN	B
depletion	O	NOUN	I
,	O	PUNCT	O
less	O	ADJ	O
iron	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
available	O	ADJ	O
for	O	ADP	O
carcinogenesis	O	NOUN	B
through	O	ADP	O
free-radical	O	ADJ	B
mediated	O	ADJ	I
mechanisms	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
promotion	O	NOUN	B
of	O	ADP	O
tumor	O	NOUN	B
growth	O	NOUN	I
.	O	PUNCT	O


Low-dose	B-I	ADJ	B
aspirin	I-I	NOUN	B
increases	O	VERB	B
gastrointestinal	B-OUT	ADJ	B
losses	I-OUT	NOUN	I
of	O	ADP	O
transfused	B-OUT	VERB	B
radiolabeled	I-OUT	VERB	O
autologous	I-OUT	ADJ	B
red	I-OUT	ADJ	I
cells	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Observational	O	ADJ	B
studies	O	NOUN	I
report	O	VERB	O
lower	O	ADJ	O
serum	O	NOUN	O
ferritin	O	NOUN	O
values	O	NOUN	O
with	O	ADP	O
regular	O	ADJ	O
aspirin	O	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
induced	O	VERB	B
iron	O	NOUN	B
reduction	O	NOUN	I
against	O	ADP	O
cancer	O	NOUN	B
mortality	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
confirmed	O	VERB	O
in	O	ADP	O
a	O	DET	O
recent	O	ADJ	O
trial	O	NOUN	O
(	O	PUNCT	O
FeAST	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
subjects	B-P	NOUN	B
randomized	I-P	VERB	B
to	I-P	PART	O
iron	I-P	NOUN	B
reduction	I-P	NOUN	I
or	I-P	CCONJ	O
observation	I-P	NOUN	B
.	I-P	PUNCT	O


Serum	B-OUT	NOUN	B
ferritin	I-OUT	NOUN	I
reductions	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
FeAST	O	NOUN	B
trial	O	NOUN	B
were	O	AUX	O
within	O	ADP	O
conventionally	O	ADV	B
normal	O	ADJ	I
reference	O	NOUN	O
ranges	O	NOUN	O
and	O	CCONJ	O
were	O	AUX	O
quantitatively	O	ADV	B
similar	O	ADJ	O
to	O	PART	O
ferritin	O	NOUN	B
reductions	O	NOUN	B
in	O	ADP	O
observational	O	ADJ	B
studies	O	NOUN	I
in	O	ADP	O
regular	B-P	ADJ	O
aspirin	I-P	NOUN	B
users	I-P	NOUN	B
.	I-P	PUNCT	O


Delayed	O	VERB	B
anticancer	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
aspirin	O	NOUN	B
are	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
the	O	DET	O
proposed	O	VERB	O
mechanism	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
continual	O	ADJ	O
microbleeding	B-OUT	NOUN	B
has	O	AUX	O
a	O	DET	O
gradual	O	ADJ	O
cumulative	O	ADJ	B
effect	O	NOUN	O
on	O	ADP	O
stored	O	VERB	B
iron	O	NOUN	B
.	O	PUNCT	O


RCT	O	NOUN	B
of	O	ADP	O
a	O	DET	O
manualized	O	VERB	B
social	B-I	ADJ	B
treatment	I-I	NOUN	I
for	O	ADP	O
high-functioning	B-P	ADJ	B
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
RCT	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
manualized	B-I	VERB	B
social	I-I	ADJ	B
intervention	I-I	NOUN	I
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
HFASDs	I-P	NOUN	B
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
treatment	B-I	NOUN	B
or	O	CCONJ	O
wait-list	B-I	ADJ	B
conditions	I-I	NOUN	I
.	I-I	PUNCT	O


Treatment	B-I	NOUN	B
included	O	VERB	O
instruction	B-I	NOUN	B
and	I-I	CCONJ	O
therapeutic	I-I	ADJ	B
activities	I-I	NOUN	I
targeting	I-I	VERB	B
social	I-I	ADJ	B
skills	I-I	NOUN	I
,	I-I	PUNCT	O
face-emotion	I-I	ADJ	B
recognition	I-I	NOUN	B
,	I-I	PUNCT	O
interest	I-I	NOUN	O
expansion	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
interpretation	I-I	NOUN	B
of	I-I	ADP	O
non-literal	I-I	ADJ	B
language	I-I	NOUN	I
.	I-I	PUNCT	O


A	O	DET	O
response-cost	O	ADJ	B
program	O	NOUN	I
was	O	AUX	O
applied	O	VERB	O
to	O	PART	O
reduce	O	VERB	O
problem	O	NOUN	B
behaviors	O	NOUN	I
and	O	CCONJ	O
foster	O	ADJ	B
skills	O	NOUN	B
acquisition	O	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
treatment	O	NOUN	B
effects	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
for	O	ADP	O
five	B-OUT	NUM	O
of	I-OUT	ADP	O
seven	I-OUT	NUM	O
primary	I-OUT	ADJ	B
outcome	I-OUT	NOUN	I
measures	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
parent	I-OUT	NOUN	B
ratings	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
direct	I-OUT	ADJ	O
child	I-OUT	NOUN	B
measures	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


Secondary	O	ADJ	B
measures	O	NOUN	I
based	O	VERB	O
on	O	ADP	O
staff	B-OUT	NOUN	B
ratings	I-OUT	NOUN	I
(	O	PUNCT	O
treatment	O	NOUN	B
group	O	NOUN	I
only	O	ADV	O
)	O	PUNCT	O
corroborated	O	VERB	O
gains	O	NOUN	B
reported	O	VERB	O
by	O	ADP	O
parents	O	NOUN	B
.	O	PUNCT	O


High	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
parent	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
child	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
staff	I-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
were	O	AUX	O
reported	O	VERB	O
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
high	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
treatment	B-OUT	NOUN	B
fidelity	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Standardized	O	ADJ	B
effect	O	NOUN	I
size	O	NOUN	I
estimates	O	NOUN	B
were	O	AUX	O
primarily	O	ADV	O
in	O	ADP	O
the	O	DET	O
medium	O	NOUN	B
and	O	CCONJ	O
large	O	ADJ	O
ranges	O	NOUN	B
and	O	CCONJ	O
favored	O	VERB	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Synthetic	B-I	ADJ	B
serum	I-I	NOUN	O
substitute	I-I	NOUN	O
(	I-I	PUNCT	O
SSS	I-I	PROPN	B
)	I-I	PUNCT	O
:	I-I	PUNCT	O
a	O	DET	O
globulin-enriched	O	ADJ	B
protein	O	NOUN	I
supplement	O	NOUN	I
for	O	ADP	O
human	B-P	ADJ	B
embryo	I-P	NOUN	B
culture	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
whether	O	SCONJ	O
an	O	DET	O
IVF	O	NOUN	B
protein	O	NOUN	B
supplement	O	NOUN	I
prepared	O	VERB	O
from	O	ADP	O
human	O	ADJ	B
serum	O	NOUN	O
albumin	O	NOUN	O
(	O	PUNCT	O
HSA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
human	O	ADJ	B
globulins	O	NOUN	B
would	O	AUX	O
retain	O	VERB	O
performance	B-OUT	NOUN	B
characteristics	I-OUT	NOUN	B
equivalent	O	ADJ	O
to	O	PART	O
those	O	DET	O
reported	O	VERB	O
for	O	ADP	O
the	O	DET	O
commercial	O	ADJ	B
plasma	O	NOUN	B
expanders	O	NOUN	I
,	O	PUNCT	O
Plasmatein	B-I	PROPN	B
(	O	PUNCT	O
Alpha	O	PROPN	B
Therapeutics	O	PROPN	I
,	O	PUNCT	O
Los	O	PROPN	B
Angeles	O	PROPN	I
,	O	PUNCT	O
California	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
Plasmanate	B-I	PROPN	B
(	O	PUNCT	O
Cutter	O	PROPN	B
Biological	O	PROPN	I
,	O	PUNCT	O
Miles	O	PROPN	B
Inc.	O	PROPN	I
,	O	PUNCT	O
Elkhart	O	PROPN	B
,	O	PUNCT	O
Indiana	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	VERB	O
Pronuclear-stage	B-P	ADJ	B
human	I-P	ADJ	B
embryos	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	B-I	VERB	B
and	I-I	CCONJ	O
cultured	I-I	VERB	B
in	I-I	ADP	O
human	I-I	ADJ	B
tubal	I-I	ADJ	B
fluid	I-I	NOUN	I
medium	I-I	NOUN	I
(	I-I	PUNCT	O
HTF	I-I	NOUN	B
)	I-I	PUNCT	O
supplemented	I-I	VERB	O
with	I-I	ADP	O
either	I-I	CCONJ	O
HSA	I-I	NOUN	B
(	I-I	PUNCT	O
5	I-I	NUM	O
mg/mL	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
Plasmatein	I-I	NOUN	B
(	I-I	PUNCT	O
10	I-I	NUM	O
%	I-I	NOUN	O
,	I-I	PUNCT	O
v/v	I-I	NOUN	B
;	I-I	PUNCT	O
5	I-I	NUM	O
mg/ml	I-I	NOUN	O
)	I-I	PUNCT	O
as	I-I	ADP	O
a	I-I	DET	O
means	I-I	NOUN	O
of	I-I	ADP	O
indirectly	I-I	ADV	O
assessing	I-I	VERB	O
the	I-I	DET	O
effect	I-I	NOUN	B
alpha-	I-I	NOUN	B
and	I-I	CCONJ	O
beta-globulins	I-I	NOUN	B
have	I-I	AUX	O
on	I-I	ADP	O
embryonic	I-I	ADJ	B
development	I-I	NOUN	I
.	I-I	PUNCT	O


Those	O	DET	O
results	O	NOUN	B
coupled	O	VERB	B
with	O	ADP	O
the	O	DET	O
known	O	ADJ	O
composition	O	NOUN	B
characteristics	O	NOUN	B
of	O	ADP	O
Plasmatein	B-I	PROPN	B
were	O	AUX	O
used	O	VERB	O
as	O	ADP	O
the	O	DET	O
starting	O	NOUN	O
basis	O	NOUN	O
to	O	PART	O
formulate	O	VERB	O
test	O	NOUN	B
lots	O	NOUN	B
of	O	ADP	O
synthetic	O	ADJ	B
serum	O	NOUN	O
substitute	O	NOUN	O
(	O	PUNCT	O
SSS	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
more	O	ADJ	O
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
embryos	O	NOUN	B
cultured	O	VERB	O
in	O	ADP	O
Plasmatein	B-I	NOUN	B
supplemented	O	VERB	I
medium	O	NOUN	I
reached	O	VERB	O
the	O	DET	O
four-cell	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
greater	I-OUT	ADJ	O
stage	I-OUT	NOUN	B
by	O	ADP	O
40	O	NUM	O
hr	O	NOUN	O
postinsemination	O	NOUN	B
than	O	ADP	O
a	O	DET	O
comparable	O	ADJ	O
group	O	NOUN	B
cultured	O	VERB	O
in	O	ADP	O
HSA	B-I	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Lot	O	NOUN	B
1	O	NUM	I
of	O	ADP	O
SSS	O	PROPN	B
,	O	PUNCT	O
formulated	O	VERB	O
with	O	ADP	O
HSA	O	NOUN	B
(	O	PUNCT	O
84	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
total	O	ADJ	B
protein	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
human	O	ADJ	B
globulins	O	NOUN	B
(	O	PUNCT	O
16	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
total	O	ADJ	B
protein	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
aqueous	O	ADJ	B
lipoprotein	O	NOUN	B
fraction	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
human	O	ADJ	B
plasma	O	NOUN	B
(	O	PUNCT	O
Excyte	O	NOUN	B
IV	O	NUM	I
;	O	PUNCT	O
Miles	O	PROPN	B
Diagnostics	O	PROPN	I
,	O	PUNCT	O
Kankakee	O	PROPN	B
,	O	PUNCT	O
Illinois	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
produced	O	VERB	O
accelerated	O	VERB	B
early	B-OUT	ADJ	O
embryonic	I-OUT	ADJ	B
growth	I-OUT	NOUN	I
relative	O	ADJ	O
to	O	PART	O
control	O	VERB	O
murine	O	ADJ	B
embryos	O	NOUN	B
grown	O	VERB	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
Plasmatein	O	PROPN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
embryos	O	NOUN	B
reaching	O	VERB	O
the	O	DET	O
hatched	O	VERB	B
blastocyst	O	NOUN	I
stage	O	NOUN	I
was	O	AUX	O
decreased	O	VERB	B
(	O	PUNCT	O
45	O	NUM	O
vs	O	CCONJ	O
100	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Human	B-P	ADJ	B
embryos	I-P	NOUN	B
from	I-P	ADP	O
seven	I-P	NUM	O
patients	I-P	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
to	O	PART	O
HTF	O	NOUN	B
medium	O	NOUN	I
supplemented	O	VERB	B
with	O	ADP	O
Plasmatein	B-I	NOUN	B
or	O	CCONJ	O
lot	O	NOUN	O
1	O	NUM	O
of	O	ADP	O
SSS	B-I	PROPN	B
,	O	PUNCT	O
showed	O	VERB	O
equivalent	O	ADJ	O
growth	B-OUT	NOUN	B
at	O	ADP	O
36-40	O	NUM	O
hr	O	NOUN	O
postinsemination	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
microprecipitate	O	NOUN	B
developed	O	VERB	O
in	O	ADP	O
media	O	NOUN	B
supplemented	O	VERB	B
with	O	ADP	O
lot	O	NOUN	O
1	O	NUM	O
after	O	ADP	O
several	O	ADJ	O
days	O	NOUN	B
of	O	ADP	O
culture	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Excyte	B-OUT	NOUN	B
IV	I-OUT	NUM	I
concentration	I-OUT	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
and	O	CCONJ	O
,	O	PUNCT	O
ultimately	O	ADV	O
,	O	PUNCT	O
eliminated	O	VERB	O
from	O	ADP	O
the	O	DET	O
subsequent	O	ADJ	B
and	O	CCONJ	O
final	O	ADJ	O
prototype	O	NOUN	B
lots	O	NOUN	B
of	O	ADP	O
SSS	O	PROPN	B
.	O	PUNCT	O


Murine	B-P	ADJ	B
embryos	I-P	NOUN	B
grown	O	VERB	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
lipoprotein	O	NOUN	B
free	O	ADJ	I
SSS	B-I	PROPN	I
showed	O	VERB	O
significantly	O	ADV	O
accelerated	B-OUT	VERB	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	PART	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
growth	I-OUT	NOUN	B
at	O	ADP	O
17	O	NUM	O
hr	O	NOUN	O
postthaw	O	NOUN	B
compared	O	VERB	O
to	O	ADP	O
Plasmatein	B-I	PROPN	B
and	O	CCONJ	O
all	O	DET	O
embryos	O	NOUN	B
progressed	O	VERB	O
to	O	ADP	O
hatching	B-OUT	NOUN	B
by	O	ADP	O
41	O	NUM	O
hr	O	NOUN	O
.	O	PUNCT	O


Human	B-P	ADJ	B
embryos	I-P	NOUN	B
,	O	PUNCT	O
randomized	O	VERB	B
to	O	PART	O
either	O	CCONJ	O
Plasmatein	B-I	PROPN	B
or	O	CCONJ	O
lot	O	NOUN	O
3	O	NUM	O
of	O	ADP	O
SSS	B-I	PROPN	B
,	O	PUNCT	O
showed	O	VERB	O
significantly	O	ADV	O
accelerated	B-OUT	VERB	B
growth	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
when	O	SCONJ	O
scored	O	VERB	B
at	O	ADP	O
38	O	NUM	O
hr	O	NOUN	O
following	O	VERB	O
insemination	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Synthetic	B-I	ADJ	B
serum	I-I	NOUN	O
substitute	I-I	NOUN	O
provides	O	VERB	O
a	O	DET	O
convient	O	NOUN	B
,	O	PUNCT	O
standardized	O	ADJ	O
means	O	NOUN	O
of	O	ADP	O
adding	O	VERB	O
protein	O	NOUN	B
to	O	PART	O
media	O	NOUN	O
used	O	VERB	O
in	O	ADP	O
assisted	O	ADJ	B
reproductive	O	ADJ	I
technology	O	NOUN	I
(	O	PUNCT	O
ART	O	NOUN	B
)	O	PUNCT	O
procedures	O	NOUN	B
.	O	PUNCT	O


Do	O	AUX	O
colonic	O	ADJ	B
short-chain	O	ADJ	B
fatty	O	ADJ	I
acids	O	NOUN	I
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
long-term	B-OUT	ADJ	B
adaptation	I-OUT	NOUN	B
of	I-OUT	ADP	O
blood	I-OUT	NOUN	B
lipids	I-OUT	NOUN	I
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
consuming	I-P	VERB	O
a	I-P	DET	O
high-fiber	I-I	ADJ	B
diet	I-I	NOUN	I
?	O	PUNCT	O
BACKGROUND	O	NOUN	O
We	O	PRON	O
recently	O	ADV	O
obtained	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
long-term	B-OUT	ADJ	B
adaptation	I-OUT	NOUN	B
of	I-OUT	ADP	O
blood	I-OUT	NOUN	B
lipids	I-OUT	NOUN	I
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
intakes	O	NOUN	B
of	O	ADP	O
carbohydrate	B-I	NOUN	B
and	I-I	CCONJ	O
fiber	I-I	NOUN	B
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
determined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
increased	B-I	VERB	B
carbohydrate	I-I	NOUN	B
and	I-I	CCONJ	O
fiber	I-I	NOUN	B
intakes	I-I	NOUN	B
on	O	ADP	O
serum	B-OUT	NOUN	B
short-chain	I-OUT	ADJ	B
fatty	I-OUT	ADJ	I
acids	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SCFAs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
relation	B-OUT	NOUN	O
between	I-OUT	ADP	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
acetate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
blood	I-OUT	NOUN	B
lipids	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


DESIGN	O	ADJ	O
Subjects	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
62	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
approximately	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
energy	B-I	NOUN	B
from	I-I	ADP	O
low-fiber	I-I	NOUN	B
breakfast	I-I	NOUN	I
cereal	I-I	NOUN	I
(	I-I	PUNCT	O
LF	I-I	NOUN	B
diet	I-I	NOUN	I
)	I-I	PUNCT	O
,	I-I	PUNCT	O
high-fiber	I-I	ADJ	B
breakfast	I-I	NOUN	I
cereal	I-I	NOUN	I
(	I-I	PUNCT	O
HF	I-I	NOUN	B
diet	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
monounsaturated	I-I	ADJ	B
fatty	I-I	ADJ	I
acids	I-I	NOUN	I
(	I-I	PUNCT	O
MUFA	I-I	NOUN	B
diet	I-I	NOUN	I
)	I-I	PUNCT	O
for	O	ADP	O
6	O	NUM	O
mo	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Carbohydrate	B-OUT	NOUN	B
intakes	I-OUT	NOUN	I
were	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
LF	O	PROPN	B
and	O	CCONJ	O
HF	O	NOUN	B
groups	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
MUFA	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
54	O	NUM	O
%	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
43	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
more	O	ADJ	O
fiber	O	NOUN	B
was	O	AUX	O
consumed	O	VERB	O
by	O	ADP	O
the	O	DET	O
HF	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
50	O	NUM	O
g/d	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
by	O	ADP	O
the	O	DET	O
LF	O	PROPN	B
or	O	CCONJ	O
MUFA	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
23	O	NUM	O
g/d	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Fasting	B-OUT	VERB	B
serum	I-OUT	NOUN	B
SCFAs	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	O
over	O	ADP	O
the	O	DET	O
first	O	ADJ	O
3	O	NUM	O
mo	O	NOUN	O
.	O	PUNCT	O


Between	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
mo	O	NOUN	O
,	O	PUNCT	O
serum	B-OUT	NOUN	B
acetate	I-OUT	NOUN	I
tended	O	VERB	O
(	O	PUNCT	O
NS	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
decrease	O	VERB	B
in	O	ADP	O
the	O	DET	O
LF	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
69	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
to	O	PART	O
59	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
micromol/L	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HF	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
100	O	NUM	O
+/-	O	CCONJ	O
18	O	NUM	O
to	O	PART	O
107	O	NUM	O
+/-	O	CCONJ	O
17	O	NUM	O
micromol/L	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
change	O	NOUN	I
in	O	ADP	O
the	O	DET	O
MUFA	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
butyrate	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
LF	O	NOUN	B
or	O	CCONJ	O
MUFA	O	NOUN	B
group	O	NOUN	B
but	O	CCONJ	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
HF	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
2.5	O	NUM	O
+/-	O	CCONJ	O
0.5	O	NUM	O
to	O	PART	O
3.1	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
micromol/L	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
acetate	I-OUT	NOUN	I
from	O	ADP	O
0	O	NUM	O
to	O	PART	O
3	O	NUM	O
mo	O	NOUN	O
were	O	AUX	O
not	O	PART	O
related	O	ADJ	O
to	O	PART	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
lipids	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
acetate	I-OUT	NOUN	I
from	O	ADP	O
3	O	NUM	O
to	O	PART	O
6	O	NUM	O
mo	O	NOUN	O
were	O	AUX	O
positively	O	ADV	O
related	O	ADJ	O
to	O	PART	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
ratio	I-OUT	NOUN	B
of	I-OUT	ADP	O
total	I-OUT	NOUN	O
to	I-OUT	PART	O
HDL	I-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.041	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
fasting	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.013	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
postprandial	B-OUT	ADJ	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.016	I-OUT	NUM	O
)	I-OUT	PUNCT	O
triacylglycerols	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
,	O	PUNCT	O
changes	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
SCFAs	I-OUT	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
carbohydrate	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
fiber	I-OUT	NOUN	B
intakes	I-OUT	NOUN	B
took	O	VERB	O
many	O	ADJ	O
months	O	NOUN	B
to	O	PART	O
occur	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
acetate	I-OUT	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
long-term	B-OUT	ADJ	B
adaptive	I-OUT	ADJ	B
changes	I-OUT	NOUN	I
in	I-OUT	ADP	O
blood	I-OUT	NOUN	B
lipids	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
immunogenicity	I-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
cluster	B-I	NOUN	B
specific	I-I	ADJ	O
immunotherapy	I-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
bronchial	I-P	ADJ	B
asthma	I-P	NOUN	I
and	I-P	CCONJ	O
mite	I-P	ADJ	B
allergy	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
Cluster	B-I	NOUN	B
specific	I-I	ADJ	O
immunotherapy	I-I	NOUN	O
(	I-I	PUNCT	O
SIT	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
a	O	DET	O
modern	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
allergen	O	NOUN	B
immunotherapy	O	NOUN	I
allowing	O	VERB	O
safe	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
allergen	O	NOUN	B
doses	O	NOUN	B
in	O	ADP	O
a	O	DET	O
short	O	ADJ	B
time	O	NOUN	I
interval	O	NOUN	I
compared	O	VERB	O
to	O	PART	O
classic	O	ADJ	O
SIT	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
profile	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
immunological	I-OUT	ADJ	B
effect	I-OUT	NOUN	O
of	O	ADP	O
cluster	O	NOUN	B
SIT	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
allergic	I-P	ADJ	B
asthma	I-P	NOUN	I
due	I-P	ADP	O
to	I-P	PART	O
house	I-P	NOUN	B
dust	I-P	NOUN	I
mite	I-P	NOUN	I
allergy	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
34	B-P	NUM	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
6-18	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
allergic	I-P	ADJ	B
asthma	I-P	NOUN	I
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
cluster	B-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
22	I-P	NUM	O
)	I-P	PUNCT	O
or	O	CCONJ	O
classic	B-P	ADJ	B
SIT	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
12	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


To	O	PART	O
achieve	O	VERB	O
a	O	DET	O
maintenance	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
allergen	O	NOUN	B
extract	O	NOUN	I
,	O	PUNCT	O
cluster	O	NOUN	B
patients	O	NOUN	B
received	O	VERB	O
14	B-I	NUM	O
injections	I-I	NOUN	B
of	I-I	ADP	O
house	I-I	NOUN	B
dust	I-I	NOUN	I
mite	I-I	NOUN	I
allergen	I-I	NOUN	B
within	I-I	ADP	O
6	I-I	NUM	O
weeks	I-I	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
classic	B-I	ADJ	B
SIT	I-I	NOUN	B
group	I-I	NOUN	B
received	I-I	VERB	O
14	I-I	NUM	O
injections	I-I	NOUN	B
within	O	ADP	O
14	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Safety	B-OUT	NOUN	B
was	O	AUX	O
monitored	O	VERB	O
by	O	ADP	O
recording	O	VERB	B
adverse	O	ADJ	I
events	O	NOUN	I
.	O	PUNCT	O


Immunogenicity	B-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	O
by	O	ADP	O
specific	O	ADJ	O
IgG	O	NOUN	B
(	O	PUNCT	O
Mite	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
IgG4	O	NOUN	B
(	O	PUNCT	O
Mite	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
by	O	ADP	O
antibody-blocking	O	ADJ	B
properties	O	NOUN	I
on	O	ADP	O
basophil	O	NOUN	B
activation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
the	O	DET	O
T	O	NOUN	B
cell	O	NOUN	I
subset	O	NOUN	O
transcription	O	NOUN	B
factors	O	NOUN	I
Foxp3	O	NOUN	B
,	O	PUNCT	O
T-bet	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
GATA-3	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
local	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
systemic	I-OUT	ADJ	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
cluster	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
serum	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
of	I-OUT	ADP	O
specific	I-OUT	ADJ	O
IgG	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
Mite	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
specific	B-OUT	ADJ	B
IgG4	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
Mite	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
significantly	O	ADV	O
increased	O	VERB	B
after	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
it	O	PRON	O
took	O	VERB	O
12	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
classic	O	ADJ	B
SIT	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
were	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
blocking	O	VERB	B
CD63	B-OUT	NOUN	B
expression	I-OUT	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
release	O	NOUN	O
of	O	ADP	O
cysteinyl	O	NOUN	B
leukotrienes	O	NOUN	I
after	O	ADP	O
in	O	X	B
vitro	O	X	I
basophil	O	NOUN	B
stimulation	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
transcription	B-OUT	NOUN	B
factor	I-OUT	NOUN	I
expression	I-OUT	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Cluster	O	NOUN	B
SIT	O	NOUN	B
is	O	AUX	O
safe	O	ADJ	O
in	O	ADP	O
children	B-P	NOUN	B
.	I-P	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
data	O	NOUN	B
demonstrated	O	VERB	O
an	O	DET	O
even	O	ADV	O
more	O	ADV	O
rapid	O	ADJ	O
induction	B-OUT	NOUN	B
of	I-OUT	ADP	O
specific	I-OUT	ADJ	O
immune	I-OUT	ADJ	B
tolerance	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Cluster	O	NOUN	B
SIT	O	NOUN	B
is	O	AUX	O
an	O	DET	O
attractive	O	ADJ	O
alternative	O	NOUN	B
to	O	ADP	O
conventional	O	ADJ	B
up-dosing	O	ADJ	B
schedules	O	NOUN	B
with	O	ADP	O
fewer	O	ADJ	O
consultations	O	NOUN	B
for	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
body	B-I	NOUN	B
mass	I-I	NOUN	I
index	I-I	NOUN	I
on	O	ADP	O
hemiparetic	O	ADJ	B
gait	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
body	B-I	NOUN	B
mass	I-I	NOUN	I
index	I-I	NOUN	I
(	I-I	PUNCT	O
BMI	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
spatiotemporal	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
kinematic	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
kinetic	I-OUT	ADJ	B
gait	I-OUT	NOUN	I
parameters	I-OUT	NOUN	B
in	O	ADP	O
chronic	B-P	ADJ	B
hemiparetic	I-P	ADJ	I
stroke	I-P	NOUN	I
survivors	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	ADJ	O
Secondary	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
data	O	NOUN	B
collected	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
comparing	O	VERB	B
two	O	NUM	O
12-week	O	ADJ	O
ambulation	B-I	NOUN	B
training	I-I	NOUN	O
treatments	I-I	NOUN	B
.	I-I	PUNCT	O


SETTING	O	VERB	O
Academic	O	ADJ	B
medical	O	ADJ	I
center	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	VERB	B
Chronic	B-P	ADJ	B
hemiparetic	I-P	ADJ	I
stroke	I-P	NOUN	I
survivors	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
108	I-P	NUM	O
,	I-P	PUNCT	O
>	I-P	X	O
3	I-P	NUM	O
months	I-P	NOUN	B
poststroke	I-P	NOUN	B
)	I-P	PUNCT	O
METHODS	O	VERB	O
Linear	B-I	ADJ	B
regression	I-I	NOUN	I
analyses	I-I	NOUN	I
were	I-I	AUX	O
performed	I-I	VERB	O
of	I-I	ADP	O
BMI	I-I	PROPN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
selected	I-I	VERB	O
pretreatment	I-I	ADJ	B
gait	I-I	NOUN	B
parameters	I-I	NOUN	B
were	I-I	AUX	O
recorded	I-I	VERB	O
using	I-I	VERB	O
quantitative	I-I	ADJ	B
gait	I-I	NOUN	I
analysis	I-I	NOUN	I
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	B
MEASURES	O	ADJ	O
Spatiotemporal	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
kinematic	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
kinetic	I-OUT	ADJ	B
gait	I-OUT	NOUN	I
parameters	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
series	O	NOUN	O
of	O	ADP	O
linear	O	ADJ	B
regression	O	NOUN	I
models	O	NOUN	I
that	O	PRON	O
controlled	O	VERB	B
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
gender	O	NOUN	B
,	O	PUNCT	O
stroke	O	NOUN	B
type	O	NOUN	O
(	O	PUNCT	O
ischemic	O	ADJ	B
versus	O	CCONJ	O
hemorrhagic	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
interval	O	NOUN	B
poststroke	O	NOUN	I
,	O	PUNCT	O
level	O	NOUN	B
of	O	ADP	O
motor	O	NOUN	B
impairment	O	NOUN	I
(	O	PUNCT	O
Fugl-Meyer	O	ADJ	B
score	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
walking	O	VERB	B
speed	O	NOUN	B
found	O	VERB	O
BMI	O	NOUN	B
to	O	PART	O
be	O	AUX	O
positively	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
step	O	NOUN	B
width	O	NOUN	I
(	O	PUNCT	O
m	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
β	O	NOUN	O
=	O	ADJ	O
0.364	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
positively	O	ADV	O
associated	O	VERB	B
with	B-OUT	ADP	I
peak	I-OUT	ADJ	B
hip	I-OUT	NOUN	I
abduction	I-OUT	NOUN	I
angle	I-OUT	NOUN	I
of	I-OUT	ADP	I
the	I-OUT	DET	I
nonparetic	I-OUT	ADJ	B
limb	I-OUT	NOUN	I
during	O	ADP	O
stance	O	NOUN	B
(	O	PUNCT	O
deg	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
β	O	NOUN	O
=	O	ADJ	O
0.177	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.040	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
negatively	O	ADV	B
associated	O	VERB	B
with	B-OUT	ADP	I
ankle	I-OUT	NOUN	B
dorsiflexion	I-OUT	NOUN	I
angle	I-OUT	NOUN	I
at	O	ADP	O
initial	O	ADJ	O
contact	O	NOUN	B
of	O	ADP	O
the	O	DET	O
paretic	O	ADJ	B
limb	O	NOUN	I
(	O	PUNCT	O
deg	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
β	O	X	O
=	O	ADJ	O
-0.222	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.023	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
negatively	O	ADV	O
associated	O	VERB	B
with	B-OUT	ADP	I
peak	I-OUT	ADJ	B
ankle	I-OUT	NOUN	I
power	I-OUT	NOUN	I
at	I-OUT	ADP	O
push-off	I-OUT	NOUN	B
(	O	PUNCT	O
W/kg	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
paretic	O	ADJ	B
limb	O	NOUN	I
(	O	PUNCT	O
W/kg	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
β	O	NOUN	O
=	O	ADJ	O
-0.142	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.026	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
When	O	SCONJ	O
walking	O	VERB	B
at	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
speed	B-P	NOUN	B
,	I-P	PUNCT	O
chronic	I-P	ADJ	B
hemiparetic	I-P	ADJ	I
stroke	I-P	NOUN	I
subjects	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
higher	I-OUT	ADJ	B
BMI	O	NOUN	B
demonstrated	O	VERB	O
greater	B-OUT	ADJ	O
step	I-OUT	NOUN	B
width	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
greater	I-OUT	ADJ	O
hip	I-OUT	NOUN	B
hiking	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
paretic	I-OUT	ADJ	B
lower	I-OUT	ADJ	O
limb	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
less	I-OUT	ADV	O
paretic	I-OUT	ADJ	B
limb	I-OUT	NOUN	I
dorsiflexion	I-OUT	NOUN	O
at	I-OUT	ADP	O
initial	I-OUT	ADJ	O
contact	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
less	B-OUT	ADV	O
paretic	I-OUT	ADJ	B
ankle	I-OUT	NOUN	I
power	I-OUT	NOUN	B
at	I-OUT	ADP	O
push-off	I-OUT	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
stroke	O	NOUN	B
subjects	O	NOUN	B
with	O	ADP	O
a	O	DET	O
lower	O	ADJ	B
BMI	O	NOUN	B
and	O	CCONJ	O
similar	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
motor	O	NOUN	B
impairment	O	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
relevance	O	NOUN	B
of	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
rehabilitation	O	NOUN	B
strategies	O	NOUN	O
for	O	ADP	O
gait	O	ADJ	B
dysfunction	B-P	NOUN	I
in	I-P	ADP	O
hemiparetic	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
higher	I-P	ADJ	O
BMIs	I-P	NOUN	B
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
trial	O	NOUN	O
of	O	ADP	O
Duraflo	B-I	NOUN	B
II	I-I	NUM	I
heparin-coated	I-I	ADJ	O
circuits	I-I	NOUN	O
in	O	ADP	O
cardiac	B-P	ADJ	B
reoperations	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	ADJ	O
Heparin-coated	B-I	ADJ	B
circuits	I-I	NOUN	I
in	O	ADP	O
cardiopulmonary	O	NOUN	B
bypass	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
decrease	O	VERB	B
the	O	DET	O
systemic	O	ADJ	B
inflammatory	O	ADJ	B
responses	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
cardiopulmonary	O	NOUN	B
bypass	O	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
on	O	ADP	O
low-risk	B-P	ADJ	B
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
coronary	I-I	ADJ	B
artery	I-I	NOUN	I
bypass	I-I	NOUN	I
grafting	I-I	NOUN	I
(	I-P	PUNCT	O
CABG	I-P	NOUN	B
)	I-P	PUNCT	O
and	O	CCONJ	O
received	O	VERB	O
full-dose	O	ADJ	B
systemic	O	ADJ	B
heparin	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
clearly	O	ADV	O
improved	O	VERB	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
beneficial	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
heparin-coated	B-I	ADJ	B
circuits	I-I	NOUN	I
might	O	AUX	O
be	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
cardiac	I-P	ADJ	B
reoperations	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Three	B-P	NUM	O
hundred	I-P	NUM	O
fifty	I-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
reoperation	I-P	NOUN	B
with	I-P	ADP	O
CABG	I-P	PROPN	B
only	I-P	ADV	O
(	I-P	PUNCT	O
58	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
with	I-P	ADP	O
valve	I-P	NOUN	B
operations	I-P	NOUN	I
(	I-P	PUNCT	O
42	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
a	O	DET	O
heparin-coated	B-I	ADJ	B
(	I-I	PUNCT	O
Duraflo	I-I	NOUN	B
II	I-I	NUM	I
;	I-I	PUNCT	O
study	I-I	NOUN	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
or	I-I	CCONJ	O
uncoated	I-I	ADJ	B
(	I-I	PUNCT	O
control	I-I	NOUN	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
circuit	I-I	NOUN	O
.	I-I	PUNCT	O


Clinical	O	ADJ	B
outcomes	O	NOUN	I
were	O	AUX	O
compared	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
variables	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
using	O	VERB	O
the	O	DET	O
following	O	VERB	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
entire	O	ADJ	O
populations	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
subgroup	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
CABG	O	PROPN	B
reoperation	O	NOUN	I
only	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
subgroup	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
valve	I-P	NOUN	B
reoperation	I-P	NOUN	I
or	I-P	CCONJ	O
combined	I-P	ADJ	O
valve	I-P	NOUN	O
and	I-P	CCONJ	O
CABG	I-P	NOUN	B
reoperation	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	VERB	O
Preoperative	O	ADJ	B
variables	O	NOUN	B
were	O	AUX	O
the	O	DET	O
same	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
difference	O	NOUN	I
in	O	ADP	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
demonstrated	O	VERB	O
except	O	SCONJ	O
that	O	SCONJ	O
the	O	DET	O
percentage	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
major	I-OUT	ADJ	O
bleeding	I-OUT	NOUN	B
episodes	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
study	B-P	NOUN	B
group	I-P	NOUN	I
(	I-P	PUNCT	O
1.2	I-P	NUM	O
%	I-P	NOUN	O
versus	I-P	CCONJ	O
5.4	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
p	I-P	NOUN	O
=	I-P	ADJ	O
0.035	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


In	O	ADP	O
the	O	DET	O
subgroup	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
valve	B-OUT	NOUN	B
reoperations	I-OUT	NOUN	I
,	O	PUNCT	O
lower	O	ADJ	B
blood	B-OUT	NOUN	I
transfusion	I-OUT	NOUN	I
requirements	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
intensive	O	ADJ	B
care	O	NOUN	I
unit	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.013	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
CABG	O	PROPN	B
reoperations	O	NOUN	B
was	O	AUX	O
analyzed	O	VERB	B
separately	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
less	O	ADJ	O
reoperation	B-OUT	NOUN	B
for	I-OUT	ADP	O
bleeding	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
4.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.058	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
heparin-coated	O	ADJ	B
circuits	O	NOUN	I
was	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
imparted	O	VERB	B
protection	O	NOUN	B
from	O	ADP	O
reoperations	O	NOUN	B
for	O	ADP	O
bleeding	O	NOUN	B
and	O	CCONJ	O
major	O	ADJ	O
bleeding	O	NOUN	B
episodes	O	NOUN	B
.	O	PUNCT	O


Material-independent	O	ADJ	B
blood	O	NOUN	I
activation	O	NOUN	I
(	O	PUNCT	O
eg	O	ADP	O
,	O	PUNCT	O
blood-air	O	ADJ	B
interface	O	NOUN	O
and	O	CCONJ	O
cardiotomy	O	NOUN	B
suction	O	NOUN	B
)	O	PUNCT	O
blunted	O	VERB	B
the	O	DET	O
total	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
heparin-coated	O	ADJ	B
surface	O	NOUN	I
.	O	PUNCT	O


Emotional	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
motivational	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
interpersonal	I-OUT	ADJ	B
responsiveness	I-OUT	NOUN	I
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
in	O	ADP	O
improvisational	B-I	ADJ	B
music	I-I	NOUN	I
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


Through	O	ADP	O
behavioural	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
investigated	O	VERB	B
the	O	DET	O
social-motivational	O	ADJ	B
aspects	O	NOUN	I
of	O	ADP	O
musical	B-I	ADJ	B
interaction	I-I	NOUN	B
between	O	ADP	O
the	O	DET	O
child	B-P	NOUN	B
and	O	CCONJ	O
the	O	DET	O
therapist	O	NOUN	B
in	O	ADP	O
improvisational	B-I	ADJ	B
music	I-I	NOUN	I
therapy	I-I	NOUN	I
by	O	ADP	O
measuring	O	VERB	B
emotional	O	ADJ	B
,	O	PUNCT	O
motivational	O	ADJ	B
and	O	CCONJ	O
interpersonal	O	ADJ	B
responsiveness	B-P	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
during	I-P	ADP	O
joint	I-P	ADJ	B
engagement	I-P	NOUN	I
episodes	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
randomized	O	ADJ	B
controlled	O	ADJ	I
study	O	NOUN	I
(	B-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
10	I-P	NUM	O
)	I-P	PUNCT	O
employed	O	VERB	O
a	O	DET	O
single	O	ADJ	O
subject	O	ADJ	O
comparison	O	NOUN	B
design	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
conditions	O	NOUN	B
,	O	PUNCT	O
improvisational	B-I	ADJ	B
music	I-I	NOUN	I
therapy	I-I	NOUN	I
and	I-I	CCONJ	O
toy	I-I	NOUN	B
play	I-I	NOUN	O
sessions	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
DVD	I-I	NOUN	B
analysis	I-I	NOUN	B
of	I-I	ADP	O
sessions	I-I	NOUN	B
.	I-I	PUNCT	O


Improvisational	B-I	ADJ	B
music	I-I	NOUN	I
therapy	I-I	NOUN	I
produced	O	VERB	O
markedly	O	ADV	O
more	O	ADV	O
and	O	CCONJ	O
longer	O	ADJ	B
events	B-OUT	NOUN	B
of	I-OUT	ADP	O
'joy	I-OUT	NOUN	B
'	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
'emotional	I-OUT	ADJ	B
synchronicity	I-OUT	NOUN	I
'	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
'initiation	I-OUT	NOUN	B
of	I-OUT	ADP	O
engagement	I-OUT	NOUN	B
'	I-OUT	PART	O
behaviours	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
children	O	NOUN	B
than	O	ADP	O
toy	B-I	NOUN	B
play	I-I	NOUN	O
sessions	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
response	O	NOUN	B
to	O	ADP	O
the	O	DET	O
therapist	O	NOUN	B
's	O	PART	O
interpersonal	O	ADJ	B
demands	O	NOUN	O
,	O	PUNCT	O
'compliant	B-OUT	ADJ	B
(	I-OUT	PUNCT	O
positive	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
responses	I-OUT	NOUN	B
'	I-OUT	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
more	O	ADV	O
in	O	ADP	O
music	O	NOUN	B
therapy	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
toy	O	NOUN	O
play	O	NOUN	O
sessions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
'no	B-OUT	PRON	B
responses	I-OUT	NOUN	B
'	I-OUT	PUNCT	O
were	O	AUX	O
twice	O	ADV	O
as	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
toy	O	NOUN	O
play	O	NOUN	O
sessions	O	NOUN	B
as	O	ADP	O
in	O	ADP	O
music	B-I	NOUN	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
exploratory	O	ADJ	B
study	O	NOUN	I
found	O	VERB	O
significant	O	ADJ	O
evidence	O	NOUN	B
supporting	O	VERB	O
the	O	DET	O
value	O	NOUN	O
of	O	ADP	O
music	B-I	NOUN	B
therapy	I-I	NOUN	B
in	O	ADP	O
promoting	O	VERB	B
social	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
emotional	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
motivational	I-OUT	ADJ	B
development	I-OUT	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
costs	B-OUT	NOUN	B
and	O	CCONJ	O
effects	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
nutritional	B-I	ADJ	B
education	I-I	NOUN	I
program	I-I	NOUN	I
following	O	VERB	O
work-site	O	ADJ	B
cholesterol	O	NOUN	I
screening	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
costs	B-OUT	NOUN	B
and	O	CCONJ	O
impact	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
nutrition	B-I	NOUN	B
education	I-I	NOUN	I
program	I-I	NOUN	I
following	O	VERB	O
a	O	DET	O
cholesterol	O	NOUN	B
screening	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Forty	B-P	NUM	O
work-sites	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
educational	B-I	ADJ	B
interventions	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
"	B-I	PUNCT	O
usual	I-I	ADJ	B
"	I-I	PUNCT	O
intervention	I-I	NOUN	B
of	I-I	ADP	O
5	I-I	NUM	O
minutes	I-I	NOUN	B
of	I-I	ADP	O
counseling	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
"	I-I	PUNCT	O
special	I-I	ADJ	B
"	I-I	PUNCT	O
intervention	I-I	NOUN	B
of	I-I	ADP	O
2	I-I	NUM	O
hours	I-I	NOUN	O
of	I-I	ADP	O
behaviorally	I-I	ADV	B
based	I-I	VERB	I
education	I-I	NOUN	I
on	I-I	ADP	O
dietary	I-I	ADJ	B
changes	I-I	NOUN	I
to	I-I	PART	O
lower	I-I	ADJ	O
serum	I-I	NOUN	B
cholesterol	I-I	NOUN	I
.	I-I	PUNCT	O


Costs	B-OUT	NOUN	B
were	O	AUX	O
monitored	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
cholesterol	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
were	O	AUX	O
retested	O	VERB	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
total	B-OUT	ADJ	O
per-person	I-OUT	ADJ	B
cost	I-OUT	NOUN	B
for	O	ADP	O
screening	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
educational	O	ADJ	B
intervention	O	NOUN	I
was	O	AUX	O
about	O	ADV	O
$	O	SYM	O
50	O	NUM	O
.	O	PUNCT	O


Cholesterol	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
differed	O	VERB	O
little	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
intervention	O	NOUN	B
groups	O	NOUN	I
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
screening	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
after	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
those	O	DET	O
in	O	ADP	O
the	O	DET	O
special	O	ADJ	O
intervention	O	NOUN	B
worksites	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
6.5	O	NUM	O
%	O	NOUN	O
drop	O	NOUN	B
in	O	ADP	O
cholesterol	B-OUT	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
those	O	DET	O
at	O	ADP	O
the	O	DET	O
usual	O	ADJ	O
intervention	O	NOUN	B
worksites	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
drop	O	NOUN	B
of	O	ADP	O
only	O	ADV	O
3.0	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Hence	O	ADV	O
a	O	DET	O
3.5	O	NUM	O
%	O	NOUN	O
cholesterol	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
was	O	AUX	O
attributable	O	ADJ	O
to	O	PART	O
the	O	DET	O
special	O	ADJ	O
intervention	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
A	O	DET	O
behaviorally	B-I	ADV	B
based	I-I	VERB	O
nutrition	I-I	NOUN	B
education	I-I	NOUN	I
program	I-I	NOUN	I
following	O	VERB	O
cholesterol	O	NOUN	B
screening	O	NOUN	I
can	O	AUX	O
have	O	AUX	O
a	O	DET	O
meaningful	O	ADJ	O
impact	O	NOUN	B
on	O	ADP	O
long-term	O	ADJ	B
cholesterol	O	NOUN	B
levels	O	NOUN	I
at	O	ADP	O
a	O	DET	O
low	O	ADJ	B
cost	O	NOUN	B
.	O	PUNCT	O


Nutrition	B-I	NOUN	B
education	I-I	NOUN	I
in	O	ADP	O
work-sites	O	NOUN	B
may	O	AUX	O
therefore	O	ADV	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
way	O	NOUN	O
to	O	PART	O
lower	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
heart	O	NOUN	B
disease	O	NOUN	I
in	O	ADP	O
communities	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
recent	B-P	ADJ	O
bereavement	I-P	NOUN	B
on	O	ADP	O
outcomes	O	NOUN	B
in	O	ADP	O
a	O	DET	O
primary	B-OUT	ADJ	B
care	I-OUT	NOUN	I
depression	I-OUT	NOUN	O
intervention	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
Although	O	SCONJ	O
bereavement	O	NOUN	B
and	O	CCONJ	O
depression	O	NOUN	B
are	O	AUX	O
both	O	CCONJ	O
common	O	ADJ	O
in	O	ADP	O
older	O	ADJ	B
primary	O	ADJ	I
care	O	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
bereavement	O	NOUN	B
on	O	ADP	O
depression	B-OUT	NOUN	B
intervention	O	NOUN	B
outcomes	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
whether	O	SCONJ	O
standard	B-I	ADJ	B
interventions	I-I	NOUN	B
for	O	ADP	O
depression	O	NOUN	B
in	O	ADP	O
primary	O	ADJ	B
care	O	NOUN	I
were	O	AUX	O
as	O	ADP	O
effective	O	ADJ	B
for	O	ADP	O
bereaved	B-P	ADJ	B
as	I-P	ADP	O
for	I-P	ADP	O
non-bereaved	I-P	ADJ	B
depressed	I-P	ADJ	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Twenty	B-P	NUM	O
community-based	I-P	ADJ	B
primary	I-P	ADJ	I
care	I-P	NOUN	I
practices	I-P	NOUN	I
in	I-P	ADP	O
New	I-P	PROPN	B
York	I-P	PROPN	I
City	I-P	PROPN	I
,	I-P	PUNCT	O
greater	I-P	ADJ	O
Philadelphia	I-P	PROPN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
Pittsburgh	I-P	PROPN	B
.	I-P	PUNCT	O


Randomization	O	VERB	B
to	O	PART	O
either	O	CCONJ	O
intervention	B-I	NOUN	B
or	O	CCONJ	O
usual	B-I	ADJ	B
care	I-I	NOUN	I
occurred	I-I	VERB	O
by	I-I	ADP	O
practice	I-I	NOUN	B
.	I-I	PUNCT	O


PARTICIPANTS	B-P	NOUN	B
Patients	I-P	NOUN	B
aged	I-P	ADJ	B
60	I-P	NUM	O
years	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
who	I-P	PRON	O
met	I-P	VERB	O
criteria	I-P	NOUN	B
for	I-P	ADP	O
major	I-P	ADJ	O
depression	I-P	NOUN	B
or	I-P	CCONJ	O
clinically	I-P	ADV	B
significant	I-P	ADJ	I
minor	I-P	ADJ	B
depression	I-P	NOUN	I
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
599	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
who	I-P	PRON	O
did	I-P	AUX	O
not	I-P	PART	O
complete	I-P	VERB	O
the	I-P	DET	O
bereavement	I-P	ADJ	B
measure	I-P	NOUN	O
or	I-P	CCONJ	O
who	I-P	PRON	O
were	I-P	AUX	O
missing	I-P	VERB	O
4-month	I-P	ADJ	B
data	I-P	NOUN	B
were	I-P	AUX	O
excluded	I-P	VERB	O
(	I-P	PUNCT	O
final	I-P	ADJ	O
N	I-P	NOUN	O
=	I-P	ADJ	O
417	I-P	NUM	O
)	I-P	PUNCT	O
.	O	PUNCT	O


INTERVENTION	B-I	NOUN	B
Study-trained	I-I	ADJ	B
depression	I-I	NOUN	B
care	I-I	NOUN	I
managers	I-I	NOUN	B
offered	I-I	VERB	O
guideline-concordant	I-I	ADJ	B
recommendations	I-I	NOUN	B
to	I-I	ADP	O
primary	I-I	ADJ	B
care	I-I	NOUN	I
physicians	I-I	NOUN	B
at	I-I	ADP	O
intervention	I-I	NOUN	B
sites	I-I	NOUN	I
and	I-I	CCONJ	O
assisted	I-I	ADJ	B
patients	I-I	NOUN	B
with	I-I	ADP	O
treatment	I-I	NOUN	B
adherence	I-I	NOUN	B
.	I-I	PUNCT	O


Patients	B-I	NOUN	B
who	I-I	PRON	O
did	I-I	AUX	O
not	I-I	PART	O
wish	I-I	VERB	O
to	I-I	PART	O
take	I-I	VERB	O
antidepressants	I-I	NOUN	B
could	I-I	AUX	O
receive	I-I	VERB	O
interpersonal	I-I	ADJ	B
psychotherapy	I-I	NOUN	O
.	O	PUNCT	O


MEASUREMENTS	B-OUT	NOUN	B
Bereavement	I-OUT	PROPN	I
was	O	AUX	O
captured	O	VERB	O
using	O	VERB	O
the	B-OUT	DET	O
Louisville	I-OUT	PROPN	B
Older	I-OUT	PROPN	I
Persons	I-OUT	PROPN	I
Events	I-OUT	PROPN	I
Schedule	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


Depression	B-OUT	NOUN	B
severity	I-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
the	B-OUT	DET	O
24-item	I-OUT	NOUN	B
Hamilton	I-OUT	PROPN	I
Depression	I-OUT	PROPN	I
Rating	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HDRS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


Outcomes	O	NOUN	B
at	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
were	B-OUT	AUX	O
remission	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
HDRS	I-OUT	NOUN	B
≤7	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
response	I-OUT	NOUN	B
(	O	PUNCT	O
HDRS	O	NOUN	B
reduction	O	NOUN	B
≥50	O	NUM	O
%	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Logistic	O	ADJ	B
regressions	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
for	O	ADP	O
non-bereaved	O	ADJ	B
participants	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
response	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
remission	I-OUT	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
intervention	O	NOUN	B
than	O	ADP	O
usual	O	ADJ	B
care	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
recently	O	ADV	O
bereaved	O	VERB	B
older	O	ADJ	B
adults	O	NOUN	I
were	O	AUX	O
less	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
achieve	B-OUT	VERB	O
response	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
remission	I-OUT	NOUN	B
at	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
if	O	SCONJ	O
treated	O	VERB	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
condition	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Standard	O	ADJ	B
depression	O	NOUN	B
care	O	NOUN	I
management	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
ineffective	O	ADJ	B
among	O	ADP	O
recently	O	ADV	O
bereaved	O	VERB	B
older	O	ADJ	O
primary	O	ADJ	B
care	O	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


Greater	O	ADJ	B
attention	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
paid	O	VERB	O
in	O	ADP	O
primary	O	ADJ	B
care	B-P	NOUN	I
to	I-P	ADP	O
emotional	I-P	ADJ	B
distress	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
context	I-P	NOUN	B
of	I-P	ADP	O
bereavement	I-P	NOUN	B
.	O	PUNCT	O


Central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
serotonin	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
cardiovascular	B-OUT	ADJ	B
responses	I-OUT	NOUN	I
to	O	PART	O
stress	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
indices	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
(	O	PUNCT	O
CNS	O	NOUN	B
)	O	PUNCT	O
serotonin	O	NOUN	B
function	O	NOUN	I
on	O	ADP	O
cardiovascular	B-OUT	ADJ	B
reactivity	I-OUT	NOUN	I
to	O	PART	O
mental	O	ADJ	B
stress	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Lumbar	B-I	ADJ	B
puncture	I-I	NOUN	I
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
54	B-P	NUM	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
to	I-P	PART	O
obtain	O	VERB	O
cerebrospinal	O	ADJ	B
fluid	O	NOUN	I
(	O	PUNCT	O
CSF	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
determination	O	NOUN	B
of	O	ADP	O
5-hydroxyindoleacetic	O	ADJ	B
acid	O	NOUN	I
(	O	PUNCT	O
5HIAA	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
.	O	PUNCT	O


Genotypes	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
a	O	DET	O
functional	O	ADJ	B
polymorphism	O	NOUN	B
of	O	ADP	O
the	O	DET	O
serotonin	O	NOUN	B
transporter	O	NOUN	I
gene	O	NOUN	I
promoter	O	NOUN	B
region	O	NOUN	I
(	O	PUNCT	O
5HTTLPR	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Subjects	O	NOUN	B
then	O	ADV	O
underwent	O	VERB	O
mental	O	ADJ	B
stress	O	NOUN	I
testing	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
Persons	B-P	NOUN	B
with	I-P	ADP	O
one	I-P	NUM	O
or	I-P	CCONJ	O
two	I-P	NUM	O
long	I-P	ADJ	O
(	I-P	PUNCT	O
l	I-P	NOUN	O
)	I-P	PUNCT	O
5HTTLPR	I-P	NOUN	B
alleles	I-P	NOUN	B
had	O	AUX	O
CSF	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
serotonin	O	NOUN	B
metabolite	O	NOUN	B
,	O	PUNCT	O
5HIAA	O	NOUN	B
,	O	PUNCT	O
that	O	PRON	O
were	O	AUX	O
50	O	NUM	O
%	O	NOUN	O
higher	O	ADJ	B
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
persons	O	NOUN	B
with	O	ADP	O
the	O	DET	O
s/s	O	NOUN	B
5HTTLPR	B-P	NOUN	B
genotype	I-P	NOUN	B
.	I-P	PUNCT	O


Persons	O	NOUN	B
with	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
two	O	NUM	O
l	O	NOUN	O
alleles	O	NOUN	B
or	O	CCONJ	O
higher	O	ADJ	B
CSF	B-OUT	NOUN	B
5HIAA	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
also	O	ADV	O
exhibited	O	VERB	O
greater	O	ADJ	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
responses	I-OUT	NOUN	I
to	O	PART	O
a	O	DET	O
mental	O	ADJ	B
stress	O	NOUN	I
protocol	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
5HTTLPR	O	NOUN	B
polymorphism	O	NOUN	B
affects	O	VERB	O
CNS	O	NOUN	B
serotonin	O	NOUN	B
function	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
they	O	PRON	O
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
general	O	ADJ	B
hypothesis	O	NOUN	I
that	O	SCONJ	O
CNS	O	NOUN	B
serotonin	O	NOUN	B
function	O	NOUN	I
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
potentially	O	ADV	O
health-damaging	O	ADJ	B
biobehavioral	O	ADJ	B
characteristics	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
l	O	NOUN	O
allele	O	NOUN	B
could	O	AUX	O
contribute	O	VERB	O
,	O	PUNCT	O
through	O	ADP	O
its	O	PRON	O
association	O	NOUN	B
with	O	ADP	O
increased	O	VERB	B
cardiovascular	B-OUT	ADJ	B
reactivity	I-OUT	NOUN	O
to	O	PART	O
stress	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
two	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
social	B-I	ADJ	B
support	I-I	NOUN	I
and	I-I	CCONJ	O
education	I-I	NOUN	B
on	O	ADP	O
adaptation	O	NOUN	B
to	O	ADP	O
early-stage	B-P	ADJ	B
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


A	B-I	DET	O
Roy	I-I	PROPN	O
adaptation	I-I	NOUN	B
model-based	I-I	ADJ	O
support	I-I	NOUN	O
and	I-I	CCONJ	O
education	I-I	NOUN	B
intervention	I-I	NOUN	I
for	O	ADP	O
women	B-P	NOUN	B
with	I-P	ADP	O
early-stage	I-P	ADJ	B
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
was	I-P	AUX	O
tested	I-P	VERB	B
in	O	ADP	O
a	B-P	DET	O
three-group	I-P	ADJ	B
,	I-P	PUNCT	O
three-phase	I-P	ADJ	O
randomized	I-P	ADJ	O
clinical	I-P	ADJ	O
trial	I-P	NOUN	O
of	I-P	ADP	O
a	I-P	DET	O
sample	I-P	NOUN	B
of	I-P	ADP	O
125	I-P	NUM	O
women	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
received	O	VERB	O
13	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
combined	B-I	ADJ	O
individual	I-I	ADJ	O
telephone	I-I	NOUN	B
and	I-I	CCONJ	O
in-person	I-I	NOUN	B
group	I-I	NOUN	I
support	I-I	NOUN	I
and	I-I	CCONJ	O
education	I-I	NOUN	B
,	O	PUNCT	O
Control	O	PROPN	B
Group	O	PROPN	I
1	O	NUM	I
received	O	VERB	O
13	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
telephone-only	B-I	ADJ	O
individual	I-I	ADJ	B
support	I-I	NOUN	O
and	I-I	CCONJ	O
education	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Control	O	PROPN	B
Group	O	PROPN	I
2	O	NUM	I
received	O	VERB	O
one-time	B-I	ADJ	O
mailed	I-I	VERB	B
educational	I-I	ADJ	B
information	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
and	O	CCONJ	O
Control	O	PROPN	B
Group	O	PROPN	I
1	O	NUM	I
reported	O	VERB	O
less	O	ADJ	O
mood	B-OUT	NOUN	B
disturbance	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
all	O	DET	O
three	O	NUM	O
phases	O	NOUN	B
,	O	PUNCT	O
less	B-OUT	ADV	O
loneliness	I-OUT	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
Phases	O	NOUN	B
II	O	NUM	I
and	O	CCONJ	O
III	O	NUM	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
higher-quality	B-OUT	ADJ	O
relationship	I-OUT	NOUN	B
with	I-OUT	ADP	O
a	I-OUT	DET	O
significant	I-OUT	ADJ	O
other	I-OUT	ADJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
Phase	O	NOUN	B
II	O	NUM	I
than	O	ADP	O
did	O	AUX	O
Control	O	PROPN	B
Group	O	PROPN	I
2	O	NUM	I
.	O	PUNCT	O


No	O	DET	B
group	O	NOUN	I
differences	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
for	O	ADP	O
cancer-related	B-OUT	ADJ	B
worry	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
well-being	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
individual	O	ADJ	O
telephone	O	NOUN	B
support	O	NOUN	O
may	O	AUX	O
provide	O	VERB	O
an	O	DET	O
effective	O	ADJ	B
alternative	O	NOUN	B
to	O	PART	O
in-person	O	NOUN	B
support	O	NOUN	O
groups	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
study	O	NOUN	B
of	O	ADP	O
telephone	O	NOUN	B
interventions	O	NOUN	I
is	O	AUX	O
recommended	O	VERB	O
using	O	VERB	O
ethnically	O	ADV	B
and	O	CCONJ	O
economically	O	ADV	O
heterogeneous	O	ADJ	B
samples	O	NOUN	B
.	O	PUNCT	O


Antimigraine	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	B
of	O	ADP	O
telcagepant	B-I	NOUN	B
based	O	VERB	O
on	O	ADP	O
patient	B-P	NOUN	B
's	I-P	PART	I
historical	I-P	ADJ	B
triptan	I-I	ADJ	B
response	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
same	O	ADJ	O
or	O	CCONJ	O
different	O	ADJ	O
patients	B-P	NOUN	B
respond	I-OUT	VERB	O
to	I-OUT	PART	O
triptans	I-OUT	NOUN	B
and	I-I	CCONJ	O
telcagepant	I-I	NOUN	B
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
Telcagepant	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
oral	B-I	ADJ	B
calcitonin	I-I	NOUN	I
gene-related	I-I	ADJ	I
peptide	I-I	NOUN	I
receptor	I-I	NOUN	I
antagonist	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
antimigraine	B-OUT	NOUN	O
efficacy	I-OUT	NOUN	B
comparable	O	ADJ	O
to	O	PART	O
oral	B-I	ADJ	B
triptans	I-I	NOUN	B
.	I-I	PUNCT	O


It	O	PRON	O
is	O	AUX	O
currently	O	ADV	O
unknown	O	ADJ	O
whether	O	SCONJ	O
migraine	B-P	NOUN	B
patients	I-P	NOUN	B
who	I-P	PRON	O
can	I-P	AUX	O
not	I-P	PART	O
be	I-P	AUX	O
adequately	I-P	ADV	O
helped	I-P	VERB	O
with	I-P	ADP	O
triptans	I-I	NOUN	B
might	O	AUX	O
benefit	O	VERB	B
from	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
telcagepant	B-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	VERB	O
Post-hoc	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
data	O	NOUN	B
from	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
telcagepant	B-I	NOUN	B
(	I-I	PUNCT	O
150	I-I	NUM	O
mg	I-I	NOUN	O
,	I-I	PUNCT	O
300	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
zolmitriptan	I-I	NOUN	B
5	I-I	NUM	O
mg	I-I	NOUN	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
for	O	ADP	O
a	O	DET	O
moderate/severe	O	ADJ	B
migraine	O	NOUN	I
.	O	PUNCT	O


Responder	O	NOUN	B
rates	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
according	O	VERB	O
to	O	PART	O
patients	B-P	NOUN	B
'	I-P	PART	O
self-reported	I-OUT	ADJ	B
historical	I-OUT	ADJ	B
triptan	I-OUT	ADJ	B
response	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HTR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
:	I-OUT	PUNCT	O
(	I-P	PUNCT	O
1	I-P	X	O
)	I-P	PUNCT	O
good	I-P	ADJ	O
HTR	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
660	I-P	NUM	O
)	I-P	PUNCT	O
:	I-P	PUNCT	O
response	I-P	NOUN	B
in	I-P	ADP	O
75-100	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
attacks	I-P	NOUN	B
;	I-P	PUNCT	O
(	I-P	PUNCT	O
2	I-P	X	O
)	I-P	PUNCT	O
intermediate	I-P	NOUN	B
HTR	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
248	I-P	NUM	O
)	I-P	PUNCT	O
:	I-P	PUNCT	O
response	I-P	NOUN	B
in	I-P	ADP	O
25-74	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
attacks	I-P	NOUN	B
;	I-P	PUNCT	O
(	I-P	PUNCT	O
3	I-P	X	O
)	I-P	PUNCT	O
poor	I-P	ADJ	O
HTR/no	I-P	NOUN	B
use	I-P	NOUN	I
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
407	I-P	NUM	O
)	I-P	PUNCT	O
:	I-P	PUNCT	O
response	I-P	NOUN	B
in	I-P	ADP	O
<	I-P	NOUN	O
25	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
attacks	I-P	NOUN	B
,	I-P	PUNCT	O
or	I-P	CCONJ	O
patient	I-P	NOUN	B
did	I-P	AUX	O
not	I-P	PART	O
take	I-P	VERB	O
triptans	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
limitation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
is	O	AUX	O
that	O	SCONJ	O
the	B-P	DET	O
last	I-P	ADJ	O
subgroup	I-P	NOUN	B
comprised	I-P	VERB	O
mainly	I-P	ADV	O
(	I-P	PUNCT	O
91	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
who	I-P	PRON	O
reported	I-P	VERB	O
that	I-P	SCONJ	O
they	I-P	PRON	O
did	I-P	AUX	O
not	I-P	PART	O
take	I-P	VERB	O
triptans	I-P	NOUN	B
,	I-P	PUNCT	O
but	I-P	CCONJ	O
it	I-P	PRON	O
was	I-P	AUX	O
not	I-P	PART	O
known	I-P	VERB	O
whether	I-P	SCONJ	O
these	I-P	DET	O
patients	I-P	NOUN	B
were	I-P	AUX	O
triptan-naïve	I-P	ADJ	B
or	I-P	CCONJ	O
had	I-P	AUX	O
previously	I-P	ADV	O
used	I-I	VERB	O
triptans	I-I	NOUN	B
and	I-P	CCONJ	O
stopped	I-P	VERB	B
taking	I-P	VERB	I
them	I-P	PRON	O
.	I-P	PUNCT	O


RESULTS	O	NOUN	O
For	B-I	ADP	O
zolmitriptan	I-I	NOUN	B
,	O	PUNCT	O
2-hour	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
relief	I-OUT	NOUN	I
rates	I-OUT	NOUN	I
were	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
good	O	ADJ	O
HTR	O	NOUN	B
subgroup	O	NOUN	B
(	O	PUNCT	O
116/162	O	NUM	O
,	O	PUNCT	O
72	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
intermediate	O	NOUN	B
(	O	PUNCT	O
29/62	O	NUM	O
,	O	PUNCT	O
47	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
poor/no	O	X	O
use	O	NOUN	O
(	O	PUNCT	O
44/111	O	PROPN	O
,	O	PUNCT	O
40	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
HTR	O	NOUN	B
subgroups	O	NOUN	B
.	O	PUNCT	O


The	B-OUT	DET	O
2-hour	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
relief	I-OUT	NOUN	O
rates	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
across	O	ADP	O
HTR	O	NOUN	B
subgroups	O	NOUN	B
for	B-I	ADP	O
telcagepant	I-I	NOUN	B
150	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
48-58	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
300	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
52-58	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
26-31	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
poor/no	O	X	O
use	O	NOUN	O
HTR	O	NOUN	B
subgroup	O	NOUN	B
,	O	PUNCT	O
more	O	ADJ	O
patients	O	NOUN	B
receiving	B-I	VERB	O
telcagepant	I-I	NOUN	B
300	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
56/98	O	NUM	O
,	O	PUNCT	O
57.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	B-OUT	AUX	O
2-hour	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
relief	I-OUT	NOUN	I
than	O	ADP	O
those	O	DET	O
receiving	B-I	VERB	O
zolmitriptan	I-I	NOUN	B
(	O	PUNCT	O
44/111	O	PROPN	O
,	O	PUNCT	O
39.6	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
=	O	ADJ	O
2.11	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
1.20,3.71	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.009	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
the	O	DET	O
percentage	O	NOUN	B
for	B-I	ADP	O
telcagepant	I-I	NOUN	B
150	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
57/119	O	NOUN	O
,	O	PUNCT	O
47.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
from	B-I	ADP	O
zolmitriptan	I-I	NOUN	B
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
=	O	ADJ	O
1.41	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
0.82	O	NUM	O
,	O	PUNCT	O
2.40	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.211	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
different	O	ADJ	O
patients	O	NOUN	B
may	O	AUX	O
respond	O	VERB	O
to	B-I	PART	O
triptans	I-I	NOUN	B
or	I-I	CCONJ	O
telcagepant	I-I	NOUN	B
300	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


Caution	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
exercised	O	VERB	O
in	O	ADP	O
interpreting	O	VERB	B
the	O	DET	O
results	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
post-hoc	O	ADJ	B
nature	O	NOUN	I
of	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
(	O	PUNCT	O
clinical	O	ADJ	B
trial	O	NOUN	I
registry	O	NOUN	I
:	O	PUNCT	O
NCT00442936	O	PROPN	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
first-in-man	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
feasibility	I-OUT	NOUN	B
of	O	ADP	O
autologous	B-I	ADJ	B
delipidated	I-I	ADJ	O
high-density	I-I	ADJ	O
lipoprotein	I-I	NOUN	O
plasma	I-I	NOUN	O
infusions	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
coronary	I-P	ADJ	I
syndrome	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVES	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
serial	B-I	ADJ	O
autologous	I-I	ADJ	B
infusions	I-I	NOUN	B
of	I-I	ADP	O
selective	I-I	ADJ	B
high-density	I-I	ADJ	I
lipoprotein	I-I	NOUN	I
(	I-I	PUNCT	I
HDL	I-I	NOUN	I
)	I-I	PUNCT	I
delipidated	I-I	ADJ	B
plasma	I-I	NOUN	B
are	O	AUX	O
feasible	B-OUT	ADJ	O
and	O	CCONJ	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
coronary	I-P	ADJ	I
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
ACS	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


BACKGROUND	O	ADJ	O
Low	O	ADJ	B
HDL	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


Plasma	O	NOUN	B
selective	O	ADJ	O
delipidation	O	NOUN	B
converts	O	VERB	O
alphaHDL	O	ADJ	B
to	O	PART	O
prebeta-like	O	ADJ	B
HDL	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
effective	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
HDL	O	NOUN	B
for	O	ADP	O
lipid	O	NOUN	B
removal	O	NOUN	I
from	O	ADP	O
arterial	O	ADJ	B
plaques	O	NOUN	I
.	O	PUNCT	O


METHODS	O	ADJ	O
ACS	B-P	NOUN	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
cardiac	I-P	ADJ	B
catheterization	I-P	NOUN	I
with	I-P	ADP	O
>	I-P	X	O
or=1	I-P	NOUN	O
nonobstructive	I-P	ADJ	B
native	I-P	ADJ	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
atheroma	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
either	O	CCONJ	O
7	O	NUM	O
weekly	O	ADJ	B
HDL	B-I	NOUN	B
selective	I-I	ADJ	O
delipidated	I-I	ADJ	B
or	I-I	CCONJ	O
control	I-I	ADJ	B
plasma	I-I	NOUN	B
apheresis/reinfusions	I-I	NOUN	O
.	I-I	PUNCT	O


Patients	O	NOUN	B
underwent	O	VERB	O
intravascular	B-OUT	ADJ	B
ultrasound	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
IVUS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
evaluation	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
target	O	NOUN	B
vessel	O	NOUN	O
during	O	ADP	O
the	O	DET	O
catheterization	O	NOUN	B
for	O	ADP	O
ACS	O	PROPN	B
and	O	CCONJ	O
up	O	ADV	O
to	O	PART	O
14	O	NUM	O
days	O	NOUN	B
following	O	VERB	O
the	O	DET	O
final	O	ADJ	O
apheresis/reinfusion	B-I	NOUN	B
session	O	NOUN	B
.	O	PUNCT	O


2-D	O	DET	B
gel	O	NOUN	I
electrophoresis	O	NOUN	I
of	O	ADP	O
delipidated	O	ADJ	B
plasmas	O	NOUN	B
established	O	VERB	O
successful	O	ADJ	O
conversion	O	NOUN	B
of	O	ADP	O
alphaHDL	O	NOUN	B
to	O	PART	O
prebeta-like	O	ADJ	B
HDL	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
complete	O	ADJ	O
with	O	ADP	O
28	B-P	NUM	O
patients	I-P	NOUN	B
randomized	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
All	O	DET	O
reinfusion	O	NOUN	B
sessions	O	NOUN	B
were	O	AUX	O
tolerated	B-OUT	VERB	B
well	O	ADV	O
by	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
prebeta-like	I-OUT	ADJ	B
HDL	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
alphaHDL	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
delipidated	O	ADJ	B
plasma	O	NOUN	B
converted	O	VERB	O
from	O	ADP	O
5.6	O	NUM	O
%	O	NOUN	O
to	O	PART	O
79.1	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
92.8	O	NUM	O
%	O	NOUN	O
to	O	PART	O
20.9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
IVUS	O	ADJ	B
data	O	NOUN	B
demonstrated	O	VERB	O
a	O	DET	O
numeric	O	ADJ	O
trend	O	NOUN	O
toward	O	ADP	O
regression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
total	O	ADJ	O
atheroma	B-OUT	NOUN	B
volume	I-OUT	NOUN	B
of	O	ADP	O
-12.18	O	NOUN	O
+/-	O	CCONJ	O
36.75	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
delipidated	O	ADJ	B
group	O	NOUN	I
versus	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
total	B-OUT	ADJ	O
atheroma	I-OUT	NOUN	B
volume	I-OUT	NOUN	B
of	O	ADP	O
2.80	O	NUM	O
+/-	O	CCONJ	O
21.25	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.268	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	B-P	ADP	O
ACS	I-P	NOUN	B
patients	I-P	NOUN	B
,	O	PUNCT	O
serial	O	ADJ	O
autologous	O	ADJ	B
infusions	O	NOUN	B
of	O	ADP	O
selective	B-I	ADJ	B
HDL	I-I	NOUN	I
delipidated	I-I	ADJ	I
plasma	I-I	NOUN	I
are	O	AUX	O
clinically	B-OUT	ADV	B
feasible	I-OUT	ADJ	O
and	O	CCONJ	O
well	O	ADV	O
tolerated	B-OUT	ADJ	B
.	I-OUT	PUNCT	O


This	O	DET	O
therapy	O	NOUN	B
may	O	AUX	O
offer	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
adjunct	O	NOUN	B
treatment	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
presenting	I-P	VERB	O
with	I-P	ADP	O
ACS	I-P	NOUN	B
.	I-P	PUNCT	O


Further	O	ADJ	O
study	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
needed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
its	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
reduce	O	VERB	O
clinical	B-OUT	ADJ	B
cardiovascular	I-OUT	ADJ	O
events	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Ascorbic	B-I	NOUN	B
acid	I-I	NOUN	I
and	O	CCONJ	O
performance	B-OUT	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
on	O	ADP	O
performance	B-OUT	NOUN	B
of	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
g	O	NOUN	O
ascorbic	B-I	ADJ	B
acid	I-I	NOUN	I
were	O	AUX	O
studied	O	VERB	O
from	O	ADP	O
0.5-5.5	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
ingestion	O	NOUN	B
in	O	ADP	O
six	B-P	NUM	O
healthy	I-P	ADJ	B
females	I-P	NOUN	B
.	I-P	PUNCT	O


Diazepam	B-I	NOUN	B
(	I-I	PUNCT	O
5	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
was	I-I	AUX	O
included	I-I	VERB	O
as	I-I	ADP	O
an	I-I	DET	O
active	I-I	ADJ	B
control	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
impaired	O	VERB	B
digit	B-OUT	NOUN	B
symbol	I-OUT	NOUN	I
substitution	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
visuomotor	I-OUT	NOUN	B
coordination	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
complex	I-OUT	ADJ	B
reaction	I-OUT	NOUN	O
time	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
effects	O	NOUN	O
of	O	ADP	O
any	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
ascorbic	B-I	ADJ	B
acid	I-I	NOUN	I
on	O	ADP	O
performance	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Social	B-OUT	ADJ	B
support	I-OUT	NOUN	I
and	O	CCONJ	O
abstinence	B-OUT	NOUN	B
from	O	ADP	O
opiates	O	NOUN	B
and	O	CCONJ	O
cocaine	O	NOUN	B
during	B-P	ADP	O
opioid	I-I	NOUN	B
maintenance	I-I	NOUN	B
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


Social	B-I	ADJ	B
support	I-I	NOUN	I
may	O	AUX	O
play	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
helping	O	VERB	O
drug	B-P	NOUN	B
users	I-P	NOUN	I
achieve	O	VERB	O
abstinence	B-OUT	NOUN	B
;	I-OUT	PUNCT	O
however	O	ADV	O
these	O	DET	O
benefits	O	NOUN	B
may	O	AUX	O
depend	O	VERB	O
on	O	ADP	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
support	O	NOUN	O
experienced	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
prospective	O	ADJ	O
observational	O	ADJ	O
study	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
extent	O	NOUN	O
to	O	PART	O
which	O	DET	O
general	B-I	ADJ	O
and	I-I	CCONJ	O
abstinence-specific	I-I	ADJ	B
support	I-I	NOUN	I
,	I-I	PUNCT	O
both	I-I	CCONJ	O
structural	I-I	ADJ	B
and	I-I	CCONJ	O
functional	I-I	ADJ	B
,	O	PUNCT	O
predicted	O	VERB	B
opiate	O	ADJ	B
and	O	CCONJ	O
cocaine	O	NOUN	B
abstinence	O	NOUN	B
in	O	ADP	O
128	B-P	NUM	O
opioid	I-P	X	B
maintenance	I-P	NOUN	B
patients	I-P	NOUN	B
receiving	I-P	VERB	O
either	I-P	CCONJ	O
methadone	I-I	NOUN	B
or	I-I	CCONJ	O
LAAM	I-I	NOUN	B
.	I-I	PUNCT	O


A	O	DET	O
new	O	ADJ	O
multidimensional	O	ADJ	B
self-report	O	ADJ	I
instrument	O	NOUN	I
assessing	O	VERB	O
abstinence-specific	B-I	ADJ	B
functional	O	ADJ	I
support	O	NOUN	I
was	O	AUX	O
developed	O	VERB	O
for	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Previously	O	ADV	O
validated	O	VERB	O
measures	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
remaining	O	VERB	O
types	O	NOUN	O
of	O	ADP	O
support	O	NOUN	O
.	O	PUNCT	O


With	O	ADP	O
baseline	O	NOUN	B
abstinence	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
statistically	O	ADV	O
important	O	ADJ	O
covariates	O	NOUN	B
adjusted	O	VERB	O
,	O	PUNCT	O
hierarchical	O	ADJ	B
logistic	O	ADJ	I
regression	O	NOUN	I
analyses	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
associations	O	NOUN	B
between	O	ADP	O
social	B-OUT	ADJ	B
support	I-OUT	NOUN	I
at	O	ADP	O
study	O	NOUN	B
baseline	O	NOUN	B
and	O	CCONJ	O
biochemically	O	ADV	B
confirmed	O	VERB	O
abstinence	O	NOUN	B
3	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
varied	O	VERB	O
by	O	ADP	O
type	O	NOUN	O
of	O	ADP	O
support	O	NOUN	O
and	O	CCONJ	O
by	O	ADP	O
drug	O	NOUN	B
.	O	PUNCT	O


Greater	O	ADJ	B
abstinence-specific	B-OUT	ADJ	B
structural	I-OUT	ADJ	I
support	I-OUT	NOUN	I
(	O	PUNCT	O
operationalized	O	VERB	O
as	O	ADP	O
fewer	O	ADJ	O
drug	O	NOUN	B
users	O	NOUN	I
in	O	ADP	O
the	O	DET	O
social	O	ADJ	B
network	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
decreases	O	VERB	B
in	O	ADP	O
three	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
negative	B-OUT	ADJ	B
abstinence-specific	I-OUT	ADJ	B
functional	I-OUT	ADJ	I
support	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
Complaints	I-OUT	NOUN	B
about	I-OUT	ADP	O
Drug	I-OUT	PROPN	B
Use	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
Drug	I-OUT	PROPN	B
Exposure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Demoralization	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
predicted	I-OUT	VERB	B
cocaine	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
opiate	B-OUT	ADJ	B
abstinence	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
effects	O	NOUN	O
for	O	ADP	O
general	B-OUT	ADJ	O
support	I-OUT	NOUN	O
,	O	PUNCT	O
whether	O	SCONJ	O
structural	O	ADJ	B
or	O	CCONJ	O
functional	O	ADJ	B
,	O	PUNCT	O
on	O	ADP	O
abstinence	B-OUT	NOUN	B
from	O	ADP	O
either	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Interventions	O	NOUN	B
that	O	PRON	O
focus	O	VERB	O
on	O	ADP	O
modifying	O	VERB	O
patients	O	NOUN	B
'	O	PART	O
abstinence-specific	B-I	ADJ	B
support	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
helpful	O	ADJ	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
high	B-P	ADJ	O
rates	I-OUT	NOUN	B
of	I-OUT	ADP	O
cocaine	I-OUT	NOUN	B
use	I-OUT	NOUN	I
disorders	I-OUT	NOUN	I
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


Increasing	B-P	VERB	B
the	I-P	DET	O
reach	I-P	NOUN	O
of	I-P	ADP	O
health	I-OUT	NOUN	B
sponsorship	I-P	NOUN	I
:	I-P	PUNCT	O
using	I-P	VERB	O
a	I-P	DET	O
"	I-I	PUNCT	O
sponsorship	I-I	NOUN	B
kit	I-I	NOUN	I
"	I-I	PUNCT	O
to	I-P	PART	O
promote	I-P	VERB	B
health	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
Australia	B-P	PROPN	B
,	O	PUNCT	O
a	O	DET	O
tobacco	O	NOUN	B
tax	O	NOUN	I
provides	O	VERB	O
funding	O	NOUN	B
for	O	ADP	O
Healthway	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
Western	O	ADJ	B
Australian	O	PROPN	I
Health	O	PROPN	I
Promotion	O	PROPN	I
Foundation	O	PROPN	I
.	O	PUNCT	O


Healthway	O	NOUN	B
provides	O	VERB	O
sponsorships	O	NOUN	B
for	O	ADP	O
the	O	DET	O
arts	O	NOUN	B
and	O	CCONJ	O
racing	O	NOUN	B
and	O	CCONJ	O
sporting	O	NOUN	B
events	O	NOUN	O
to	O	PART	O
replace	O	VERB	O
funds	O	NOUN	B
previously	O	ADV	O
provided	O	VERB	O
by	O	ADP	O
tobacco	O	NOUN	B
companies	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
sponsorships	O	NOUN	B
provide	O	VERB	O
visibility	O	NOUN	B
for	O	ADP	O
Healthway	O	PROPN	B
and	O	CCONJ	O
positive	O	ADJ	B
health	O	NOUN	B
messages	O	NOUN	I
.	O	PUNCT	O


Normally	O	ADV	O
,	O	PUNCT	O
Healthway	O	PROPN	B
staff	O	NOUN	I
attends	O	VERB	O
these	O	DET	O
events	O	NOUN	B
to	O	PART	O
help	O	VERB	O
promote	O	VERB	B
health	O	NOUN	B
messages	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
reduce	O	VERB	O
Healthway	B-P	PROPN	B
staff	I-P	NOUN	B
time	O	NOUN	I
spent	O	VERB	O
helping	O	VERB	O
event	O	NOUN	B
organizers	O	NOUN	B
promote	O	VERB	B
health	O	NOUN	B
messages	O	NOUN	I
,	O	PUNCT	O
Healthway	O	PROPN	B
developed	O	VERB	O
a	O	DET	O
sponsor	B-I	NOUN	B
kit	I-I	NOUN	I
of	I-I	ADP	O
promotional	I-I	ADJ	B
materials	I-I	NOUN	I
which	O	DET	O
communicate	O	VERB	O
health	O	NOUN	B
messages	O	NOUN	I
without	O	ADP	O
requiring	O	VERB	O
Healthway	B-P	PROPN	B
staff	I-P	NOUN	I
to	O	PART	O
attend	O	VERB	B
events	O	NOUN	O
.	O	PUNCT	O


Recognition	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
awareness	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
comprehension	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
acceptance	I-OUT	NOUN	B
of	I-OUT	ADP	O
health	I-OUT	NOUN	B
messages	I-OUT	NOUN	I
was	O	AUX	O
comparable	O	ADJ	O
at	O	ADP	O
events	O	NOUN	O
that	O	PRON	O
featured	O	VERB	O
Healthway	O	PROPN	B
staff	O	NOUN	I
versus	O	ADP	O
the	O	DET	O
sponsor	O	NOUN	B
kits	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
average	O	ADJ	B
cost	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sponsorship	B-I	NOUN	B
kits	I-I	NOUN	I
was	O	AUX	O
only	O	ADV	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cost	O	NOUN	B
when	O	SCONJ	O
Healthway	O	PROPN	B
staff	O	NOUN	B
was	O	AUX	O
featured	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
clomiphene	O	NOUN	B
citrate-resistant	O	ADJ	O
anovulation	O	NOUN	B
with	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
oral	O	ADJ	B
contraceptive	O	ADJ	O
pill	O	NOUN	O
suppression	O	NOUN	B
and	O	CCONJ	O
repeat	O	NOUN	O
clomiphene	O	NOUN	B
citrate	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
and	O	CCONJ	O
endocrine	B-OUT	ADJ	B
response	I-OUT	NOUN	I
of	O	ADP	O
oral	B-I	ADJ	B
contraceptive	I-I	ADJ	B
ovarian	O	ADJ	I
suppression	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
clomiphene	B-I	NOUN	B
citrate	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
previously	I-P	ADV	O
were	I-P	AUX	O
clomiphene	I-P	NOUN	B
citrate	I-P	NOUN	B
resistant	I-P	ADJ	B
.	I-P	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	VERB	O
Forty-eight	B-P	NUM	O
patients	I-P	NOUN	B
from	I-P	ADP	O
a	I-P	DET	O
private	I-P	ADJ	B
tertiary	I-P	ADJ	I
infertility	I-P	NOUN	I
clinic	I-P	NOUN	I
were	O	AUX	O
assigned	O	VERB	O
randomly	O	ADV	O
prospectively	B-I	ADV	O
to	I-I	PART	O
either	I-I	CCONJ	O
group	I-I	NOUN	B
1	I-I	NUM	O
(	I-I	PUNCT	O
oral	I-I	ADJ	B
contraceptive/clomiphene	I-I	NOUN	I
citrate	I-I	NOUN	I
)	I-I	PUNCT	O
,	I-I	PUNCT	O
which	I-I	DET	O
received	I-I	VERB	O
continuous	I-I	ADJ	B
oral	I-I	ADJ	B
contraceptives	I-I	NOUN	O
followed	I-I	VERB	O
by	I-I	ADP	O
clomiphene	I-I	NOUN	B
citrate	I-I	NOUN	I
,	I-I	PUNCT	O
or	I-I	CCONJ	O
to	I-I	PART	O
group	I-I	NOUN	B
2	I-I	NUM	I
(	I-I	PUNCT	O
control	I-I	NOUN	B
)	I-I	PUNCT	O
received	I-I	VERB	O
no	I-I	DET	B
treatment	I-I	NOUN	I
in	I-I	ADP	O
the	I-I	DET	O
cycle	I-I	NOUN	B
before	I-I	ADP	O
clomiphene	I-I	NOUN	B
citrate	I-I	NOUN	B
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


On	B-I	ADP	O
day	I-I	NOUN	B
3	I-I	NUM	O
,	I-I	PUNCT	O
17	I-OUT	NUM	O
beta-estradiol	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
follicle-stimulating	I-OUT	ADJ	B
hormone	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
luteinizing	I-OUT	NOUN	B
hormone	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
androgens	I-OUT	NOUN	B
were	I-I	AUX	O
assayed	I-I	VERB	B
before	I-I	ADP	O
and	I-I	CCONJ	O
after	I-I	ADP	O
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


Follicle	B-OUT	NOUN	B
growth	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
ovulation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
pregnancy	I-OUT	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
Student	B-OUT	NOUN	B
t	I-OUT	NOUN	I
test	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
analysis	I-OUT	NOUN	B
of	I-OUT	ADP	O
variance	I-OUT	NOUN	O
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
statistical	O	ADJ	B
significance	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
oral	O	ADJ	B
contraceptive/clomiphene	O	NOUN	B
citrate	O	NOUN	O
group	O	NOUN	O
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
percentage	B-OUT	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
ovulated	B-OUT	VERB	B
and	O	CCONJ	O
of	O	ADP	O
ovulatory	B-OUT	ADJ	B
cycles	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
pregnancies	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Significantly	O	ADV	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
17	B-OUT	NUM	O
beta-estradiol	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
luteinizing	I-OUT	NOUN	B
hormone	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
androgen	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
oral	O	ADJ	B
contraceptive/clomiphene	O	NOUN	O
citrate	O	NOUN	O
group	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
significant	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Suppression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ovary	O	NOUN	B
with	O	ADP	O
oral	O	ADJ	B
contraceptives	O	NOUN	I
results	O	VERB	B
in	O	ADP	O
excellent	O	ADJ	O
rates	O	NOUN	B
of	O	ADP	O
ovulation	O	NOUN	B
and	O	CCONJ	O
pregnancy	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
previously	I-P	ADV	O
were	I-P	AUX	O
resistant	I-P	ADJ	B
to	I-P	PART	O
clomiphene	I-I	NOUN	B
citrate	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
decreases	O	NOUN	B
in	O	ADP	O
ovarian	O	ADJ	B
androgens	O	NOUN	B
,	O	PUNCT	O
luteinizing	O	NOUN	B
hormone	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
17	O	NUM	O
beta-estradiol	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
improved	O	VERB	B
response	O	NOUN	B
.	O	PUNCT	O


Long-term	O	ADJ	B
heparin	B-I	NOUN	B
treatment	I-I	NOUN	B
in	O	ADP	O
ischaemic	B-P	ADJ	B
heart	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Effects	O	NOUN	B
on	O	ADP	O
clinical	O	ADJ	B
condition	O	NOUN	I
and	O	CCONJ	O
plasma	O	NOUN	B
lipids	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
oxytocin	B-I	NOUN	B
on	O	ADP	O
blood	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
during	I-OUT	ADP	O
different	I-OUT	ADJ	O
postpartum	I-OUT	NOUN	B
periods	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


OBJECTIVE	O	ADJ	O
Postpartum	B-P	ADJ	B
hemorrhage	I-P	NOUN	I
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
important	O	ADJ	O
reason	O	NOUN	O
for	O	ADP	O
maternal	O	ADJ	B
mortality	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
developed	O	VERB	O
countries	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
reason	O	NOUN	O
of	O	ADP	O
13	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
maternal	O	ADJ	B
deaths	O	NOUN	I
is	O	AUX	O
postpartum	O	NOUN	B
hemorrhage	O	NOUN	I
while	O	SCONJ	O
this	O	DET	O
percentage	O	NOUN	B
reaches	O	VERB	O
more	O	ADJ	O
than	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
other	O	ADJ	O
countries	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
oxytocin	B-I	NOUN	B
use	O	NOUN	O
in	O	ADP	O
different	O	ADJ	O
times	O	NOUN	O
at	O	ADP	O
the	O	DET	O
3rd	O	ADJ	B
stage	O	NOUN	I
of	O	ADP	O
delivery	O	NOUN	B
on	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
postpartum	B-OUT	NOUN	B
hemoglobin	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
was	O	AUX	O
compared	O	VERB	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
AND	O	CCONJ	O
SETTING	O	NOUN	O
In	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
89	B-P	NUM	O
pregnant	I-P	ADJ	B
women	I-P	NOUN	I
to	I-P	ADP	O
whom	I-P	PRON	O
oxytocin	I-I	NOUN	B
was	I-I	AUX	O
administered	I-I	VERB	B
after	I-I	ADP	O
placenta	I-I	NOUN	B
separation	I-I	NOUN	B
were	I-P	AUX	O
studied	I-P	VERB	O
in	I-P	ADP	O
Group	I-P	PROPN	B
1	I-P	NUM	O
,	I-P	PUNCT	O
89	I-P	NUM	O
pregnant	I-P	ADJ	B
women	I-P	NOUN	I
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
Group	I-P	PROPN	B
2	I-P	NUM	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
oxytocin	I-I	NOUN	B
was	I-I	AUX	O
administered	I-I	VERB	B
after	I-I	ADP	O
delivery	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
shoulder	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
hemoglobin	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
hematocrit	I-OUT	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
delivery	O	NOUN	B
were	O	AUX	O
quantified	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
biochemical	O	ADJ	B
parameters	O	NOUN	B
were	O	AUX	O
examined	O	VERB	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
statistical	O	ADJ	B
differences	O	NOUN	I
in	O	ADP	O
the	O	DET	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
hemoglobin	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
hemotocrit	I-OUT	NOUN	B
before	O	ADP	O
delivery	O	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
compared	O	VERB	O
to	O	ADP	O
Group	O	PROPN	B
1	O	NUM	O
,	O	PUNCT	O
Δ-hemoglobin	O	NOUN	B
(	O	PUNCT	O
P=	O	X	O
>	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Δ-hematocrit	O	NOUN	B
(	O	PUNCT	O
P=	O	NOUN	O
>	O	PUNCT	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
change	O	NOUN	O
between	O	ADP	O
the	B-OUT	DET	O
prepartum	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
postpartum	I-OUT	NOUN	B
hemoglobin	I-OUT	NOUN	I
percentage	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
=0.001	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
change	O	NOUN	O
between	O	ADP	O
the	B-OUT	DET	O
prepartum	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
postpartum	I-OUT	NOUN	B
hemotocrit	I-OUT	NOUN	I
percentage	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
=0.001	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
statistically	O	ADV	B
lower	O	ADJ	I
in	O	ADP	O
Group	O	PROPN	B
2	O	NUM	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
It	O	PRON	O
was	O	AUX	O
determined	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	B-I	ADP	O
oxytocin	I-I	NOUN	B
after	O	ADP	O
shoulder	O	NOUN	B
delivery	O	NOUN	B
has	O	AUX	O
more	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
decreasing	O	VERB	B
the	O	DET	O
amount	O	NOUN	B
of	B-OUT	ADP	O
postpartum	I-OUT	NOUN	B
hemorrhage	I-OUT	NOUN	I
.	O	PUNCT	O


Predictors	O	NOUN	B
of	O	ADP	O
survival	O	NOUN	B
and	O	CCONJ	O
eradication	O	NOUN	B
of	O	ADP	O
Mycobacterium	O	X	B
avium	O	NOUN	I
complex	O	NOUN	I
bacteremia	O	NOUN	B
(	O	PUNCT	O
MAC	O	NOUN	B
)	O	PUNCT	O
in	B-P	ADP	O
AIDS	I-P	NOUN	B
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
Canadian	I-P	ADJ	B
randomized	I-P	ADJ	O
MAC	I-P	NOUN	B
treatment	I-P	NOUN	B
trial	I-P	NOUN	I
.	I-P	PUNCT	O


Canadian	O	ADJ	B
HIV	O	PROPN	B
Trials	O	PROPN	I
Network	O	PROPN	B
Protocol	O	PROPN	I
010	O	NUM	I
Study	O	PROPN	O
Group	O	PROPN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
baseline	O	NOUN	B
characteristics	O	NOUN	B
including	O	VERB	O
medical	B-OUT	ADJ	B
history	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
indicators	I-OUT	NOUN	B
of	I-OUT	ADP	O
current	I-OUT	ADJ	O
disease	I-OUT	NOUN	B
status	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
therapeutic	I-OUT	ADJ	B
drug	I-OUT	NOUN	I
use	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
in	I-OUT	X	B
vitro	I-OUT	X	I
drug	I-OUT	NOUN	B
susceptibility	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
immune	I-OUT	ADJ	B
status	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
mycobacterial	I-OUT	ADJ	B
load	I-OUT	NOUN	B
on	I-OUT	ADP	O
bacteriologic	I-OUT	ADJ	B
response	I-OUT	NOUN	I
and	O	CCONJ	O
survival	B-OUT	NOUN	B
in	O	ADP	O
HIV-positive	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
Mycobacterium	I-P	X	B
avium	I-P	NOUN	I
complex	I-P	NOUN	I
(	I-P	PUNCT	O
MAC	I-P	NOUN	B
)	I-P	PUNCT	O
bacteremia	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
An	O	DET	O
observational	O	ADJ	B
substudy	O	NOUN	I
of	O	ADP	O
an	O	DET	O
open-label	O	ADJ	B
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
of	O	ADP	O
two	B-I	NUM	O
alternative	I-I	ADJ	B
therapeutic	I-I	ADJ	B
regimens	I-I	NOUN	I
for	I-I	ADP	O
MAC	I-I	NOUN	B
.	I-I	PUNCT	O


SETTING	O	VERB	O
Twenty-four	B-P	NUM	O
hospital-based	I-P	ADJ	B
HIV	I-P	NOUN	O
clinics	I-P	NOUN	O
in	I-P	ADP	O
16	I-P	NUM	O
Canadian	I-P	ADJ	B
cities	I-P	NOUN	B
.	I-P	PUNCT	O


MAIN	O	PROPN	O
OUTCOME	O	NOUN	B
MEASURES	O	NOUN	O
The	O	DET	O
main	O	ADJ	O
outcome	O	NOUN	B
measures	O	NOUN	O
were	O	AUX	O
survival	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
bacteriologic	I-OUT	ADJ	B
response	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
defined	I-OUT	VERB	O
by	I-OUT	ADP	O
consecutive	I-OUT	ADJ	B
negative	I-OUT	ADJ	B
blood	I-OUT	NOUN	B
cultures	I-OUT	NOUN	I
for	I-OUT	ADP	O
MAC	I-OUT	NOUN	B
at	O	ADP	O
least	O	ADV	O
2	O	NUM	O
weeks	O	NOUN	B
apart	O	ADV	O
within	O	ADP	O
16	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
entry	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Prior	O	ADJ	O
AIDS	O	NOUN	B
diagnosis	O	NOUN	B
,	O	PUNCT	O
low	O	ADJ	B
Karnofsky	O	ADJ	I
score	O	NOUN	I
,	O	PUNCT	O
active	O	ADJ	O
unstable	O	ADJ	O
AIDS-related	O	ADJ	B
conditions	O	NOUN	I
,	O	PUNCT	O
absence	O	NOUN	B
of	O	ADP	O
antiretroviral	O	ADJ	B
therapy	O	NOUN	I
and	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
Pneumocystis	O	NOUN	B
carinii	O	NOUN	I
pneumonia	O	NOUN	I
prophylaxis	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
shorter	O	ADJ	B
survival	B-OUT	NOUN	I
by	O	ADP	O
univariate	O	NOUN	B
regression	O	NOUN	I
using	O	VERB	O
the	O	DET	O
proportional	O	ADJ	B
hazards	O	NOUN	I
model	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
antiretroviral	O	ADJ	B
therapy	O	NOUN	I
was	O	AUX	O
not	O	PART	O
an	O	DET	O
independent	O	ADJ	B
predictor	O	NOUN	B
of	O	ADP	O
mortality	B-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
previous	O	ADJ	O
rifabutin	O	NOUN	B
prophylaxis	O	NOUN	B
was	O	AUX	O
independently	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
poor	O	ADJ	B
survival	O	NOUN	I
outcomes	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
result	O	NOUN	O
consistent	O	ADJ	O
across	O	ADP	O
study	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
logistic	O	ADJ	B
regression	O	NOUN	I
model	O	NOUN	I
,	O	PUNCT	O
baseline	B-OUT	NOUN	B
quantitative	I-OUT	ADJ	B
mycobacterial	I-OUT	ADJ	B
load	I-OUT	NOUN	I
[	O	PUNCT	O
relative	O	ADJ	O
odds	O	NOUN	B
of	O	ADP	O
clearing	O	NOUN	B
,	O	PUNCT	O
1.97	O	NUM	O
for	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
log10	O	NOUN	O
colony	O	NOUN	B
forming	O	NOUN	I
count	O	NOUN	I
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
1.36-2.87	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
]	O	PUNCT	O
and	O	CCONJ	O
Karnofsky	B-OUT	NOUN	B
score	I-OUT	NOUN	I
were	O	AUX	O
the	O	DET	O
only	O	ADV	O
statistically	O	ADV	B
significant	O	ADJ	I
univariate	O	NOUN	B
predictors	O	NOUN	I
of	O	ADP	O
clearance	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
previous	O	ADJ	O
prophylaxis	O	NOUN	B
with	O	ADP	O
rifabutin	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
a	O	DET	O
significant	O	ADJ	O
predictor	O	NOUN	B
in	O	ADP	O
a	O	DET	O
multivariate	B-OUT	ADJ	B
model	I-OUT	NOUN	I
(	O	PUNCT	O
relative	O	ADJ	O
odds	O	NOUN	B
of	O	ADP	O
clearing	O	VERB	B
,	O	PUNCT	O
0.39	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.17-0.88	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
although	O	SCONJ	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
MAC	O	NOUN	B
bacteremia	O	NOUN	B
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
clearance	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
survival	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
albuterol	B-I	NOUN	B
solution	I-I	NOUN	O
nebulized	I-I	ADJ	B
versus	I-I	CCONJ	O
albuterol	I-I	NOUN	B
powder	I-I	NOUN	I
given	O	VERB	O
by	O	ADP	O
breath	O	NOUN	B
activated	O	VERB	I
metered	O	ADJ	O
dose	O	NOUN	O
inhaler	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
nebulized	B-I	ADJ	B
vs	I-I	CCONJ	O
powdered	I-I	ADJ	B
albuterol	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
exacerbated	I-P	ADJ	B
bronchial	I-P	ADJ	B
asthma	I-P	NOUN	I
who	I-P	PRON	O
required	I-P	VERB	O
hospitalization	I-P	NOUN	B
.	I-P	PUNCT	O


From	B-P	ADP	O
January	I-P	PROPN	O
to	I-P	ADP	O
May	I-P	PROPN	O
1990	I-P	NUM	O
known	I-P	ADJ	O
asthmatics	I-P	NOUN	B
admitted	I-P	VERB	B
with	I-P	ADP	I
acute	I-P	ADJ	B
exacerbation	I-P	NOUN	I
were	I-P	AUX	O
included	I-P	VERB	O
by	I-P	ADP	O
established	I-P	VERB	O
criteria	I-P	NOUN	B
.	I-P	PUNCT	O


Two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
.	O	PUNCT	O


Group	O	INTJ	B
I	O	PRON	I
for	O	ADP	O
Albuterol	B-I	NOUN	B
powder	I-I	NOUN	I
200	O	NUM	O
micrograms	O	NOUN	O
inhaled	O	ADJ	B
q	O	NOUN	O
4	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


Group	O	PROPN	B
II	O	NUM	I
with	O	ADP	O
Albuterol	B-I	NOUN	B
nebulized	I-I	VERB	I
solution	I-I	NOUN	I
2.5	O	NUM	O
mg	O	NOUN	O
inhaled	O	ADJ	B
q	O	NOUN	O
4	O	NUM	O
hrs	O	NOUN	O
.	O	PUNCT	O


Force	B-OUT	PROPN	B
Vital	I-OUT	PROPN	O
Capacity	I-OUT	PROPN	O
and	I-OUT	CCONJ	O
Force	I-OUT	PROPN	B
Expiratory	I-OUT	PROPN	B
Volume	I-OUT	PROPN	I
in	O	ADP	O
one	O	NUM	O
second	O	NOUN	O
were	O	AUX	O
measured	O	VERB	B
with	O	ADP	O
a	O	DET	O
pressure	O	NOUN	B
differential	O	ADJ	I
transducer	O	NOUN	I
upon	O	SCONJ	O
admission	O	NOUN	B
,	O	PUNCT	O
30	O	NUM	O
minutes	O	NOUN	B
and	O	CCONJ	O
24-hours	O	ADV	B
following	O	VERB	O
therapies	O	NOUN	B
.	O	PUNCT	O


Absolute	B-OUT	ADJ	B
FEV1	I-OUT	NOUN	B
improvement	I-OUT	NOUN	B
was	O	AUX	O
calculated	O	VERB	B
.	O	PUNCT	O


Statistical	O	ADJ	B
analysis	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
student	O	NOUN	B
's	O	PART	I
T-Test	O	NOUN	I
and	O	CCONJ	O
Fisher	O	PROPN	B
's	O	PART	I
exact	O	ADJ	I
Test	O	NOUN	I
with	O	ADP	O
significance	O	NOUN	B
established	O	VERB	O
at	O	ADP	O
p	O	NOUN	O
>	O	X	O
0.01	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Fifteen	B-P	NUM	O
patients	I-P	NOUN	B
enrolled	I-P	VERB	O
in	I-P	ADP	O
both	I-P	DET	O
groups	I-P	NOUN	B
,	I-P	PUNCT	O
two	I-P	NUM	O
patients	I-P	NOUN	B
of	I-P	ADP	O
group	I-P	NOUN	B
I	I-P	PRON	I
were	I-P	AUX	O
excluded	I-P	VERB	O
from	O	ADP	O
the	O	DET	O
statistic	O	ADJ	B
analysis	O	NOUN	I
due	O	ADP	O
to	O	PART	O
refusal	O	NOUN	B
to	O	PART	O
continue	O	VERB	O
with	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
sex	O	NOUN	B
,	O	PUNCT	O
asthma	O	NOUN	B
exacerbations/year	O	NOUN	I
,	O	PUNCT	O
smoking	O	VERB	B
history	O	NOUN	I
and	O	CCONJ	O
hospital	O	NOUN	B
length	O	NOUN	I
of	O	ADP	I
stay	O	NOUN	I
.	O	PUNCT	O


FVC	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
FEV1	I-OUT	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
also	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
significant	O	ADJ	O
difference	O	NOUN	O
when	O	SCONJ	O
the	O	DET	O
absolute	O	ADJ	B
improvement	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	NOUN	O
+/-	I-OUT	CCONJ	O
SE	I-OUT	NOUN	B
for	I-OUT	ADP	O
FEV1	I-OUT	NOUN	B
absolute	O	ADJ	B
improvement	O	NOUN	B
at	O	ADP	O
the	O	DET	O
first	O	ADJ	O
30	O	NUM	O
min	O	NOUN	O
was	O	AUX	O
0.42	O	NUM	O
+/-	O	CCONJ	O
0.08	O	NUM	O
lts	O	NOUN	O
for	O	ADP	O
the	O	DET	O
Group	O	PROPN	B
I	O	NUM	I
versus	O	CCONJ	O
0.65	O	NUM	O
+/-	O	CCONJ	O
0.6	O	NUM	O
lts	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Group	O	PROPN	B
II	O	PROPN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
next	O	ADJ	O
24	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
Group	O	PROPN	B
I	O	PRON	I
was	O	AUX	O
0.16	O	NUM	O
+/-	O	CCONJ	O
0.2	O	NUM	O
lts	O	NOUN	O
versus	O	CCONJ	O
0.30	O	NUM	O
+/-	O	CCONJ	O
0.7	O	NUM	O
lts	O	NOUN	O
in	O	ADP	O
Group	O	PROPN	B
II	O	NUM	I
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
although	O	SCONJ	O
the	O	DET	O
dose	O	NOUN	B
equivalence	O	NOUN	B
of	O	ADP	O
both	O	DET	O
delivery	O	NOUN	B
systems	O	NOUN	I
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
established	O	VERB	O
in	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
nebulized	B-I	ADJ	B
solution	I-I	NOUN	B
was	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
24	O	NUM	O
hours	O	NOUN	O
of	O	ADP	O
hospitalization	O	NOUN	B
than	O	ADP	O
the	O	DET	O
dry	B-I	ADJ	B
powder	I-I	NOUN	I
.	I-I	PUNCT	O


Cemented	B-I	VERB	B
CeraOne	I-I	PROPN	I
and	I-I	CCONJ	I
porcelain	I-I	NOUN	O
fused	I-I	VERB	O
to	I-I	ADP	O
TiAdapt	I-I	ADJ	B
abutment	I-I	NOUN	B
single-implant	I-I	ADJ	B
crown	I-I	NOUN	B
restorations	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
10-year	O	ADJ	O
comparative	O	ADJ	B
follow-up	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	ADJ	O
Long-term	O	ADJ	B
data	O	NOUN	B
comparing	O	VERB	O
cemented	B-I	VERB	B
and	O	CCONJ	O
noncemented	B-I	ADJ	B
single-implant	I-I	ADJ	I
restorations	I-I	NOUN	I
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
compare	O	VERB	O
clinical	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
radiographic	I-OUT	ADJ	B
performance	I-OUT	NOUN	B
of	O	ADP	O
single-implant	B-I	ADJ	B
crown	I-I	NOUN	I
restorations	I-I	NOUN	I
made	O	VERB	O
by	O	ADP	O
either	O	CCONJ	O
directly	O	ADV	O
baked	B-I	VERB	B
porcelain	I-I	NOUN	I
to	I-I	ADP	O
custom-made	I-I	VERB	O
TiAdapt	I-I	PROPN	B
titanium	I-I	NOUN	B
abutments	I-I	NOUN	B
(	O	PUNCT	O
Nobel	O	PROPN	B
Biocare	O	PROPN	I
AB	O	PROPN	I
,	O	PUNCT	O
Göteborg	O	PROPN	B
,	O	PUNCT	O
Sweden	O	PROPN	B
)	O	PUNCT	O
(	O	PUNCT	O
test	O	NOUN	B
)	O	PUNCT	O
or	B-I	CCONJ	O
cement	I-I	NOUN	B
crowns	I-I	NOUN	B
onto	I-I	ADP	O
CeraOne	I-I	PROPN	O
(	I-I	PUNCT	O
Nobel	I-I	PROPN	O
Biocare	I-I	PROPN	O
AB	I-I	NOUN	O
)	I-I	PUNCT	O
abutments	I-I	NOUN	O
(	I-I	PUNCT	O
control	I-I	NOUN	B
)	I-I	PUNCT	O
after	O	ADP	O
10	O	NUM	O
years	O	NOUN	B
in	O	ADP	O
function	O	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	B-P	NOUN	O
Altogether	I-P	ADV	O
,	I-P	PUNCT	O
35	I-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
were	I-P	AUX	O
provided	I-P	VERB	O
with	I-P	ADP	O
41	I-P	NUM	O
turned	I-I	VERB	O
single	I-I	ADJ	O
Brånemark	I-I	PROPN	O
System	I-I	PROPN	O
implants	I-I	NOUN	O
(	I-I	PUNCT	O
Nobel	I-I	PROPN	B
Biocare	I-I	PROPN	I
AB	I-I	NOUN	I
)	I-I	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
partially	I-P	ADV	B
edentulous	I-P	ADJ	B
upper	I-P	ADJ	B
jaw	I-P	NOUN	I
.	I-P	PUNCT	O


By	B-P	ADP	O
random	I-P	ADJ	B
,	I-P	PUNCT	O
15	I-P	NUM	O
and	I-P	CCONJ	O
20	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
provided	I-P	VERB	O
with	I-P	ADP	O
18	I-I	NUM	O
test	I-I	NOUN	B
and	I-P	CCONJ	O
23	I-I	NUM	O
control	I-I	ADJ	B
implant	I-I	NOUN	I
crowns	I-I	NOUN	I
,	I-P	PUNCT	O
respectively	I-P	ADV	O
.	O	PUNCT	O


Thereafter	B-OUT	ADV	O
,	I-OUT	PUNCT	O
clinical	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
radiographic	I-OUT	ADJ	B
data	I-OUT	NOUN	B
were	O	AUX	O
collected	O	VERB	B
and	O	CCONJ	O
compared	O	VERB	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	B-OUT	VERB	O
None	I-OUT	NOUN	O
of	O	ADP	O
the	B-I	DET	O
implants	I-I	NOUN	B
were	I-OUT	AUX	O
found	I-OUT	VERB	O
loose	I-OUT	ADJ	B
during	O	ADP	O
the	O	DET	O
follow-up	O	ADJ	B
period	O	NOUN	B
(	B-OUT	PUNCT	O
100	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Few	B-OUT	ADJ	O
clinical	I-OUT	ADJ	B
problems	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	B-OUT	DET	O
overall	I-OUT	ADJ	O
average	I-OUT	ADJ	B
marginal	I-OUT	ADJ	O
bone	I-OUT	NOUN	O
loss	I-OUT	NOUN	O
was	O	AUX	O
0.26	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
SD	O	NOUN	B
0.64	O	NUM	O
)	O	PUNCT	O
during	O	ADP	O
10	O	NUM	O
years	O	NOUN	B
in	O	ADP	O
function	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
final	O	ADJ	O
tightening	O	NOUN	B
of	O	ADP	O
the	O	DET	O
crowns	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
no	I-OUT	DET	B
significant	I-OUT	ADJ	I
differences	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	B-I	DET	O
test	I-I	NOUN	B
and	I-I	CCONJ	O
control	I-I	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
head	O	NOUN	B
of	O	ADP	O
the	B-I	DET	O
implants	I-I	NOUN	B
was	O	AUX	O
placed	O	VERB	O
on	O	ADP	O
an	O	DET	O
average	O	ADJ	B
6.3	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
SD	O	NOUN	B
2.24	O	NUM	O
)	O	PUNCT	O
below	O	ADP	O
the	O	DET	O
cement/enamel	O	NOUN	B
junction	O	NOUN	I
of	O	ADP	O
the	O	DET	O
adjacent	O	ADJ	B
teeth	O	NOUN	I
(	O	PUNCT	O
range	O	NOUN	O
2.5-10.0	O	NUM	O
mm	B-I	NOUN	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Implants	B-I	NOUN	B
with	O	ADP	O
reported	O	VERB	O
mechanical	O	ADJ	B
and/or	O	CCONJ	O
mucosal	O	ADJ	B
problems	O	NOUN	I
or	O	CCONJ	O
placed	O	VERB	O
more	O	ADV	O
apically	O	ADV	B
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
the	O	DET	O
adjacent	O	ADJ	B
teeth	O	NOUN	O
did	O	AUX	O
not	O	PART	O
present	O	VERB	O
more	B-OUT	ADJ	O
bone	I-OUT	NOUN	B
loss	I-OUT	NOUN	O
as	O	ADP	O
compared	O	VERB	B
with	B-I	ADP	O
implants	I-I	NOUN	B
with	O	ADP	O
no	O	DET	O
problems	O	NOUN	O
or	O	CCONJ	O
placed	O	VERB	O
more	O	ADV	O
coronally	O	ADV	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
There	O	ADV	O
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
no	O	DET	O
obvious	B-OUT	ADJ	O
clinical	I-OUT	ADJ	B
or	I-OUT	CCONJ	O
radiographic	I-OUT	ADJ	B
differences	I-OUT	NOUN	B
between	O	ADP	O
the	B-I	DET	O
test	I-I	NOUN	B
and	I-I	CCONJ	O
control	I-I	ADJ	B
single-implant	I-I	ADJ	I
restorations	I-I	NOUN	I
during	O	ADP	O
10	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Occasionally	O	ADV	O
,	O	PUNCT	O
some	B-I	DET	O
restorations	I-I	NOUN	B
presented	O	VERB	O
loose	B-OUT	ADJ	B
abutment	I-OUT	NOUN	O
screws	I-OUT	NOUN	B
and/or	I-OUT	CCONJ	O
fistulas	I-OUT	NOUN	B
during	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
implies	O	VERB	O
a	O	DET	O
certain	O	ADJ	O
need	O	NOUN	O
for	O	ADP	O
maintenance	O	NOUN	B
where	O	SCONJ	O
a	B-I	DET	O
one-piece	I-I	ADJ	B
single-implant	I-I	ADJ	I
protocol	I-I	NOUN	I
(	I-I	PUNCT	O
test	I-I	NOUN	B
)	I-I	PUNCT	O
allows	O	VERB	O
both	O	DET	O
for	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
clinical	O	ADJ	B
procedure	O	NOUN	I
at	O	ADP	O
placement	O	NOUN	B
without	O	ADP	O
cementation	O	NOUN	B
problems	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
for	O	ADP	O
an	O	DET	O
easy	O	ADJ	O
and	O	CCONJ	O
simple	O	ADJ	O
maintenance	O	NOUN	B
of	B-I	ADP	O
installed	I-I	VERB	O
single	I-I	ADJ	O
implant	I-I	ADJ	B
crowns	I-I	NOUN	O
in	O	ADP	O
long-term	O	ADJ	B
function	O	NOUN	B
.	O	PUNCT	O


Intranasal	B-I	ADJ	B
recombinant	I-I	ADJ	O
alfa-2b	I-I	NOUN	O
interferon	I-I	NOUN	B
treatment	I-OUT	NOUN	B
of	O	ADP	O
naturally	B-OUT	ADV	O
occurring	I-OUT	VERB	O
common	I-OUT	ADJ	O
colds	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
patients	B-P	NOUN	B
with	I-P	ADP	O
naturally	I-P	ADV	O
occurring	I-P	VERB	O
common	I-P	ADJ	O
colds	I-P	NOUN	B
of	I-P	ADP	O
less	I-P	ADJ	O
than	I-P	ADP	O
or	I-P	CCONJ	O
equal	I-P	ADJ	O
to	I-P	PART	O
48	I-P	NUM	O
h	I-P	NOUN	O
duration	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
nasal	O	ADJ	B
sprays	O	NOUN	I
of	O	ADP	O
recombinant	B-I	ADJ	B
alfa-2b	I-I	NOUN	O
interferon	I-I	NOUN	B
at	O	ADP	O
10	O	NUM	O
or	O	CCONJ	O
20	O	NUM	O
MU/day	O	NOUN	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
four	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
10-MU	B-P	NUM	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
74	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
20-MU	I-P	NUM	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
74	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
72	I-P	NUM	O
)	I-P	PUNCT	O
groups	I-P	NOUN	B
had	O	AUX	O
comparable	O	ADJ	O
frequencies	O	NOUN	B
of	O	ADP	O
documented	O	VERB	B
rhinovirus	O	NOUN	B
colds	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
to	O	PART	O
65	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
mean	B-OUT	VERB	O
durations	I-OUT	NOUN	B
of	I-OUT	ADP	O
pretreatment	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
(	O	PUNCT	O
26	O	NUM	O
to	O	PART	O
27	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
colds	I-OUT	NOUN	B
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
longer	O	ADV	O
in	O	ADP	O
the	O	DET	O
20-MU	O	NUM	O
group	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
the	O	DET	O
10-MU	O	NUM	O
group	O	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
8	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.06	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
those	O	DET	O
with	O	ADP	O
proven	O	VERB	O
rhinovirus	O	NOUN	B
colds	O	NOUN	B
treated	O	VERB	B
within	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
median	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
longer	O	ADV	O
in	O	ADP	O
the	O	DET	O
20-MU	O	NUM	O
group	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
6	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
differences	O	NOUN	I
favoring	O	VERB	O
interferon	O	NOUN	B
treatment	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
respiratory	B-OUT	ADJ	B
symptom	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
specific	I-OUT	ADJ	O
symptoms	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


On	O	ADP	O
days	O	NOUN	B
5	O	NUM	O
and	O	CCONJ	O
7	O	NUM	O
,	O	PUNCT	O
nasal	B-I	ADJ	B
washings	I-I	NOUN	I
from	O	ADP	O
compliant	O	ADJ	O
subjects	O	NOUN	B
with	O	ADP	O
proven	O	VERB	O
rhinovirus	O	NOUN	B
colds	O	NOUN	B
yielded	O	VERB	O
rhinoviruses	O	NOUN	B
more	O	ADV	O
often	O	ADV	O
in	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
47	O	NUM	O
and	O	CCONJ	O
48	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
interferon	B-I	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
recipients	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.02	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
new	O	ADJ	O
respiratory	B-OUT	ADJ	B
illness	I-OUT	NOUN	I
occurrence	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
household	O	NOUN	B
contacts	O	NOUN	I
.	O	PUNCT	O


Interferon	B-I	NOUN	B
recipients	O	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
frequencies	O	NOUN	B
of	O	ADP	O
blood	B-OUT	NOUN	B
in	I-OUT	ADP	O
nasal	I-OUT	ADJ	B
mucus	I-OUT	NOUN	I
(	O	PUNCT	O
16	O	NUM	O
to	O	PART	O
18	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
did	O	AUX	O
placebo	B-I	NOUN	B
recipients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
during	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Antibiotics	B-OUT	NOUN	B
for	O	ADP	O
presumed	O	ADJ	O
secondary	O	ADJ	B
infections	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
more	O	ADV	O
often	O	ADV	O
in	O	ADP	O
the	O	DET	O
20-MU	O	NUM	O
group	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Nasal	O	ADJ	B
sprays	O	NOUN	I
of	O	ADP	O
recombinant	B-I	ADJ	B
alfa-2b	I-I	NOUN	O
interferon	I-I	NOUN	B
were	O	AUX	O
not	O	PART	O
an	O	DET	O
effective	B-OUT	ADJ	B
treatment	I-OUT	NOUN	B
for	I-OUT	ADP	O
natural	I-OUT	ADJ	B
colds	I-OUT	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
toxicity	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Testing	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
an	O	DET	O
HIV	B-OUT	NOUN	B
stigma	I-OUT	NOUN	B
reduction	I-OUT	NOUN	B
intervention	I-I	NOUN	B
with	O	ADP	O
medical	B-P	ADJ	B
students	I-P	NOUN	I
in	I-P	ADP	O
Puerto	I-P	PROPN	B
Rico	I-P	PROPN	I
:	I-P	PUNCT	O
the	O	DET	O
SPACES	O	NOUN	B
project	O	NOUN	I
.	O	PUNCT	O


INTRODUCTION	O	PROPN	O
Stigma	B-OUT	NOUN	B
associated	O	VERB	B
with	O	ADP	I
HIV	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
documented	O	VERB	B
as	O	ADP	O
a	O	DET	O
barrier	O	NOUN	B
for	O	ADP	O
accessing	O	VERB	O
quality	O	ADJ	B
health-related	O	ADJ	B
services	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
stigma	O	NOUN	B
manifests	O	VERB	O
in	O	ADP	O
the	O	DET	O
health	O	NOUN	B
care	O	NOUN	I
setting	O	NOUN	I
,	O	PUNCT	O
people	O	NOUN	B
living	O	VERB	B
with	O	ADP	O
HIV	O	NOUN	B
receive	O	VERB	O
substandard	O	ADJ	B
services	O	NOUN	I
or	O	CCONJ	O
even	O	ADV	O
be	O	AUX	O
denied	O	VERB	B
care	O	NOUN	I
altogether	O	ADV	O
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
consequences	O	NOUN	B
of	O	ADP	O
HIV	B-OUT	NOUN	B
stigma	I-OUT	NOUN	O
have	O	AUX	O
been	O	AUX	O
documented	O	VERB	B
extensively	O	ADV	B
,	O	PUNCT	O
efforts	O	NOUN	O
to	O	PART	O
reduce	O	VERB	B
these	O	DET	O
negative	O	ADJ	B
attitudes	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
scarce	O	ADJ	O
.	O	PUNCT	O


Interventions	B-I	NOUN	B
to	I-I	PART	O
reduce	I-I	VERB	B
HIV	I-OUT	NOUN	B
stigma	I-OUT	NOUN	I
should	O	AUX	O
be	O	AUX	O
implemented	O	VERB	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
formal	O	ADJ	O
training	O	NOUN	B
of	O	ADP	O
future	O	ADJ	B
health	O	NOUN	B
care	O	NOUN	I
professionals	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
interventions	O	NOUN	B
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
tested	O	VERB	B
with	O	ADP	O
health	B-P	NOUN	B
care	I-P	NOUN	I
professionals	I-P	NOUN	I
and	O	CCONJ	O
published	O	VERB	B
have	O	AUX	O
several	O	ADJ	O
limitations	O	NOUN	B
that	O	PRON	O
must	O	AUX	O
be	O	AUX	O
surpassed	O	VERB	O
(	O	PUNCT	O
i.e	O	ADV	O
.	O	PUNCT	O


lack	O	NOUN	B
of	O	ADP	O
comparison	O	NOUN	B
groups	O	NOUN	B
in	O	ADP	O
research	O	NOUN	B
designs	O	NOUN	I
and	O	CCONJ	O
longitudinal	O	ADJ	B
follow-up	O	ADJ	I
data	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
Latino	B-P	ADJ	B
health	I-P	NOUN	B
care	I-P	NOUN	I
professionals	I-P	NOUN	I
have	O	AUX	O
been	O	AUX	O
absent	O	ADJ	B
from	O	ADP	O
these	O	DET	O
intervention	O	NOUN	B
efforts	O	NOUN	O
even	O	ADV	O
though	O	SCONJ	O
the	O	DET	O
epidemic	O	NOUN	B
has	O	AUX	O
affected	O	VERB	B
this	O	DET	O
population	O	NOUN	B
disproportionately	O	ADV	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
article	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
describe	O	VERB	O
an	O	DET	O
intervention	B-I	NOUN	B
developed	I-I	VERB	O
to	I-I	PART	O
reduce	I-I	VERB	B
HIV	I-OUT	NOUN	B
stigma	I-OUT	NOUN	I
among	I-I	ADP	O
medical	I-I	ADJ	B
students	I-I	NOUN	I
in	I-I	ADP	O
Puerto	I-I	PROPN	B
Rico	I-I	PROPN	I
.	I-I	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
507	B-P	NUM	O
medical	I-P	ADJ	B
students	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
introduced	O	VERB	O
into	O	ADP	O
our	O	PRON	O
intervention	B-I	NOUN	B
and	I-I	CCONJ	O
control	I-I	NOUN	B
conditions	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
results	O	NOUN	B
show	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
intervention	B-I	NOUN	B
and	O	CCONJ	O
control	B-I	NOUN	B
groups	O	NOUN	I
;	O	PUNCT	O
intervention	O	NOUN	B
group	O	NOUN	I
participants	O	NOUN	B
had	O	AUX	O
lower	B-OUT	ADJ	O
HIV	I-OUT	NOUN	B
stigma	I-OUT	NOUN	O
levels	I-OUT	NOUN	B
than	O	ADP	O
control	O	NOUN	B
participants	O	NOUN	I
after	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
differences	O	NOUN	O
in	O	ADP	O
HIV	B-OUT	NOUN	B
stigma	I-OUT	NOUN	I
levels	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
sustained	O	ADJ	B
for	O	ADP	O
a	O	DET	O
12-month	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
demonstrate	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
modes	O	NOUN	B
of	O	ADP	O
intervention	O	NOUN	B
developed	O	VERB	O
by	O	ADP	O
us	O	PRON	O
and	O	CCONJ	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
new	O	ADJ	O
training	O	NOUN	B
tool	O	NOUN	I
for	O	ADP	O
future	B-P	ADJ	O
health	I-P	NOUN	B
care	I-P	NOUN	I
professionals	I-P	NOUN	I
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
stigma	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Abstinence	B-I	NOUN	B
or	I-I	CCONJ	O
controlled	I-I	VERB	B
drinking	I-I	NOUN	I
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
:	O	PUNCT	O
indications	O	NOUN	B
at	O	ADP	O
initial	O	ADJ	O
assessment	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
research	O	NOUN	B
has	O	AUX	O
suggested	O	VERB	O
two	O	NUM	O
leading	O	NOUN	O
hypotheses	O	NOUN	B
concerning	O	VERB	O
which	O	DET	O
excessive	B-P	ADJ	B
drinkers	I-P	NOUN	B
can	O	AUX	O
re-establish	O	VERB	O
control	O	NOUN	B
:	O	PUNCT	O
one	O	NUM	O
based	O	VERB	O
upon	O	SCONJ	O
level	O	NOUN	B
of	O	ADP	O
dependence	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
other	O	ADJ	O
upon	O	SCONJ	O
the	O	DET	O
client	O	NOUN	B
's	O	PART	O
personal	O	ADJ	B
persuasion	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
initial	O	ADJ	O
assessment	O	NOUN	B
data	O	NOUN	B
from	O	ADP	O
46	B-P	NUM	O
clients	I-P	NOUN	B
of	I-P	ADP	O
a	I-P	DET	O
clinical	I-P	ADJ	B
psychology	I-P	NOUN	O
alcohol	I-P	NOUN	B
problems	I-P	NOUN	I
service	I-P	NOUN	I
(	I-P	PUNCT	O
30	I-P	NUM	O
men	I-P	NOUN	B
,	I-P	PUNCT	O
16	I-P	NUM	O
women	I-P	NOUN	B
)	I-P	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
attempt	O	NOUN	B
was	O	AUX	O
made	O	VERB	O
to	O	PART	O
operationalize	O	VERB	B
the	O	DET	O
concepts	O	NOUN	B
of	O	ADP	O
dependence	B-I	NOUN	B
and	O	CCONJ	O
personal	B-I	ADJ	B
persuasion	I-I	NOUN	I
using	O	VERB	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
indicators	O	NOUN	B
of	O	ADP	O
each	O	DET	O
.	O	PUNCT	O


Although	O	SCONJ	O
SADQ	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
Rand	I-OUT	PROPN	B
definite	I-OUT	ADJ	I
alcoholism	I-OUT	NOUN	I
were	O	AUX	O
in	O	ADP	O
general	O	ADJ	O
agreement	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
borderline	O	NOUN	B
instances	O	NOUN	O
and	O	CCONJ	O
cases	O	NOUN	B
of	O	ADP	O
disagreement	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
neither	O	DET	O
was	O	AUX	O
in	O	ADP	O
good	O	ADJ	O
agreement	O	NOUN	O
with	O	ADP	O
estimates	O	NOUN	B
of	O	ADP	O
problem	O	NOUN	B
duration	O	NOUN	I
,	O	PUNCT	O
nor	O	CCONJ	O
with	O	ADP	O
reports	O	NOUN	B
of	O	ADP	O
recent	O	ADJ	O
or	O	CCONJ	O
earlier	O	ADJ	O
attainment	O	NOUN	B
of	O	ADP	O
abstinence	B-I	NOUN	B
or	O	CCONJ	O
control	B-I	NOUN	B
.	I-I	PUNCT	O


Indicators	O	NOUN	B
of	O	ADP	O
personal	B-OUT	ADJ	B
persuasion	I-OUT	NOUN	I
were	O	AUX	O
more	O	ADV	O
consistent	O	ADJ	O
.	O	PUNCT	O


Those	B-P	DET	O
with	I-P	ADP	O
dependence	I-I	NOUN	O
indicators	I-OUT	NOUN	B
for	I-OUT	ADP	O
abstinence	I-OUT	NOUN	B
tended	O	VERB	O
to	O	PART	O
prefer	O	VERB	O
abstinence	B-I	NOUN	B
as	O	ADP	O
a	O	DET	O
goal	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
were	O	AUX	O
many	O	ADJ	O
departures	O	NOUN	B
from	O	ADP	O
this	O	DET	O
pattern	O	NOUN	B
particularly	O	ADV	O
for	O	ADP	O
women	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
it	O	PRON	O
will	O	AUX	O
be	O	AUX	O
very	O	ADV	O
difficult	O	ADJ	O
to	O	PART	O
make	O	VERB	O
a	O	DET	O
clear	O	ADJ	O
cut	O	NOUN	O
recommendation	O	NOUN	B
about	O	ADP	O
treatment	O	NOUN	B
goal	O	NOUN	O
at	O	ADP	O
initial	O	ADJ	O
assessment	O	NOUN	B
except	O	SCONJ	O
in	O	ADP	O
a	O	DET	O
few	O	ADJ	O
cases	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Tiotropium	B-I	PROPN	B
Safety	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
Performance	I-OUT	PROPN	B
in	O	ADP	O
Respimat	O	PROPN	B
Trial	O	PROPN	I
(	O	PUNCT	O
TIOSPIR	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
large	O	ADJ	O
scale	O	NOUN	O
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
parallel-group	O	ADJ	B
trial-design	O	ADJ	B
and	O	CCONJ	O
rationale	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Tiotropium	B-I	NOUN	B
bromide	I-I	NOUN	I
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
therapy	O	NOUN	B
for	O	ADP	O
COPD	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Comparing	O	VERB	B
across	O	ADP	O
programs	O	NOUN	B
tiotropium	B-I	PROPN	B
Respimat	I-I	PROPN	B
Soft	I-I	PROPN	B
Mist	I-I	ADJ	I
inhaler	I-I	NOUN	I
was	O	AUX	O
at	O	ADV	O
least	O	ADV	O
as	O	ADV	O
efficacious	O	ADJ	B
as	O	ADP	O
tiotropium	B-I	NOUN	B
HandiHaler	I-I	PROPN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
concerns	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
raised	O	VERB	O
about	O	ADP	O
tiotropium	B-I	NOUN	B
's	I-I	PART	I
safety	O	NOUN	B
when	O	SCONJ	O
given	O	VERB	O
via	O	ADP	O
Respimat	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
TIOSPIR	O	PROPN	B
trial	O	NOUN	I
(	O	PUNCT	O
NCT01126437	O	NOUN	O
)	O	PUNCT	O
compares	O	VERB	O
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	O	ADP	O
tiotropium	B-I	PROPN	B
Respimat	I-I	PROPN	I
5	I-I	NUM	O
μg	I-I	ADP	O
once	O	ADV	O
daily	O	ADV	O
(	O	PUNCT	O
marketed	O	VERB	B
)	O	PUNCT	O
and	O	CCONJ	O
2.5	O	NUM	O
μg	O	NOUN	O
once	O	ADV	O
daily	O	ADV	O
(	O	PUNCT	O
investigational	O	ADJ	B
)	O	PUNCT	O
with	B-I	ADP	O
tiotropium	I-I	NOUN	B
HandiHaler	I-I	PROPN	B
18	I-I	NUM	O
μ	I-I	NOUN	O
once	I-I	ADV	B
daily	I-I	ADV	I
(	O	PUNCT	O
marketed	O	VERB	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
hypotheses	O	NOUN	B
to	O	PART	O
be	O	AUX	O
tested	O	VERB	B
are	O	AUX	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


that	B-I	DET	O
tiotropium	I-I	PROPN	B
Respimat	I-I	PROPN	I
5	O	NUM	O
μg	O	ADP	O
once	O	ADV	O
daily	O	ADV	B
and	B-I	CCONJ	O
Respimat	I-I	PROPN	B
2.5	O	NUM	O
μg	O	NOUN	O
once	O	ADV	O
daily	O	ADV	B
are	O	AUX	O
non-inferior	B-I	ADJ	B
to	I-I	PART	O
HandiHaler	I-I	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
all-cause	O	ADJ	B
mortality	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
2	O	X	O
)	O	PUNCT	O
.	O	PUNCT	O


that	B-I	DET	O
tiotropium	I-I	PROPN	B
Respimat	I-I	PROPN	I
5	O	NUM	O
μg	O	ADP	O
once	O	ADV	O
daily	O	ADV	O
is	O	AUX	O
superior	B-I	ADJ	O
to	I-I	ADP	O
HandiHaler	I-I	PROPN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
time	O	NOUN	O
to	O	PART	O
first	O	ADJ	O
exacerbation	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
spirometry	O	NOUN	B
substudy	O	NOUN	I
evaluates	B-OUT	VERB	O
the	I-OUT	DET	O
bronchodilator	I-OUT	NOUN	B
efficacy	I-OUT	NOUN	B
.	O	PUNCT	O


The	O	DET	O
trial	O	NOUN	B
is	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
dummy	O	NOUN	I
,	O	PUNCT	O
event-driven	O	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	B
group	O	NOUN	I
study	B-P	NOUN	I
.	I-P	PUNCT	O


Participants	B-P	NOUN	B
can	I-P	AUX	O
use	I-P	VERB	O
any	I-P	DET	O
background	I-P	NOUN	B
treatment	I-P	NOUN	B
for	I-P	ADP	O
COPD	I-P	NOUN	B
except	I-P	SCONJ	O
inhaled	I-P	VERB	B
anticholinergic	I-P	ADJ	I
agents	I-P	NOUN	I
.	I-P	PUNCT	O


The	B-P	DET	O
study	I-P	NOUN	B
encompasses	I-P	VERB	O
a	I-P	DET	O
wide	I-P	ADJ	O
range	I-P	NOUN	O
of	I-P	ADP	O
COPD	I-P	NOUN	B
patients	I-P	NOUN	B
,	I-P	PUNCT	O
e.g	I-P	X	O
.	I-P	PUNCT	O


patients	B-P	NOUN	B
with	I-P	ADP	O
stable	I-P	ADJ	B
cardiac	I-P	ADJ	I
diseases	I-P	NOUN	I
including	I-P	VERB	O
arrhythmia	I-P	NOUN	B
can	I-P	AUX	O
be	I-P	AUX	O
included	I-P	VERB	O
.	I-P	PUNCT	O


Clinical	B-P	ADJ	B
sites	I-P	NOUN	I
are	I-P	AUX	O
international	I-P	ADJ	B
and	I-P	CCONJ	O
include	I-P	VERB	O
both	I-P	CCONJ	O
primary	I-P	ADJ	B
care	I-P	NOUN	I
as	I-P	ADV	O
well	I-P	ADV	O
as	I-P	ADP	O
specialists	I-P	NOUN	B
.	O	PUNCT	O


RESULTS	B-P	NOUN	O
To	I-P	ADP	O
date	I-P	NOUN	O
,	I-P	PUNCT	O
over	I-P	ADP	O
17,000	I-P	NUM	O
participants	I-P	NOUN	B
have	I-P	AUX	O
been	I-P	AUX	O
randomized	I-P	VERB	B
from	I-P	ADP	O
over	I-P	ADP	O
1200	I-P	NUM	O
sites	I-P	NOUN	B
in	I-P	ADP	O
50	I-P	NUM	O
countries	I-P	NOUN	B
with	O	ADP	O
an	O	DET	O
anticipated	O	VERB	B
treatment	O	NOUN	B
duration	O	NOUN	O
of	O	ADP	O
2-3	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
TIOSPIR	O	NOUN	B
will	O	AUX	O
provide	O	VERB	O
precise	O	ADJ	O
estimates	O	NOUN	B
of	B-OUT	ADP	O
the	I-OUT	DET	O
relative	I-OUT	ADJ	O
safety	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
Respimat	I-I	PROPN	B
and	I-I	CCONJ	O
HandiHaler	I-I	PROPN	B
formulations	I-I	NOUN	I
of	I-I	ADP	O
tiotropium	I-I	NOUN	B
,	O	PUNCT	O
assess	O	VERB	O
potential	B-OUT	ADJ	B
dose-dependence	I-OUT	NOUN	B
of	I-OUT	ADP	O
important	I-OUT	ADJ	O
outcomes	I-OUT	NOUN	B
and	O	CCONJ	O
provide	B-OUT	VERB	O
information	I-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
clinical	I-OUT	ADJ	B
epidemiology	I-OUT	NOUN	I
of	O	ADP	O
COPD	B-OUT	NOUN	B
in	I-OUT	ADP	O
a	I-OUT	DET	O
large	I-OUT	ADJ	O
international	I-OUT	ADJ	B
patient	I-OUT	NOUN	B
cohort	I-OUT	NOUN	O
.	O	PUNCT	O


A	O	DET	O
role	O	NOUN	O
for	O	ADP	O
error	B-I	NOUN	B
training	I-I	NOUN	B
in	O	ADP	O
surgical	B-I	ADJ	B
technical	I-I	ADJ	O
skill	I-I	NOUN	O
instruction	I-I	NOUN	B
and	I-I	CCONJ	O
evaluation	I-I	NOUN	B
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	B
During	O	ADP	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
many	O	ADJ	O
instances	O	NOUN	O
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
basic	O	ADJ	O
surgical	O	ADJ	B
skill	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
several	O	ADJ	O
errors	O	NOUN	B
that	O	PRON	O
occurred	O	VERB	O
frequently	O	ADV	O
.	O	PUNCT	O


Two	O	NUM	O
studies	O	NOUN	B
were	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
these	O	DET	O
errors	O	NOUN	B
for	O	ADP	O
improving	O	VERB	B
the	O	DET	O
instruction	O	NOUN	B
and	O	CCONJ	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
skill	O	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
For	O	ADP	O
both	O	DET	O
studies	O	NOUN	B
,	O	PUNCT	O
two	B-I	NUM	O
types	I-I	NOUN	O
of	I-I	ADP	O
rater	I-I	NOUN	B
training	I-I	NOUN	O
videotapes	I-I	NOUN	B
were	O	AUX	O
developed	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
involved	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
examples	B-I	NOUN	B
of	I-I	ADP	O
common	I-I	ADJ	O
errors	I-I	NOUN	B
(	I-I	PUNCT	O
error	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
demonstrated	O	VERB	O
the	O	DET	O
skill	B-I	NOUN	B
being	I-I	AUX	O
performed	I-I	VERB	O
correctly	I-I	ADV	O
(	I-I	PUNCT	O
correct	I-I	ADJ	B
)	I-I	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
testing	O	NOUN	B
videotape	O	NOUN	B
was	O	AUX	O
created	O	VERB	O
consisting	O	VERB	O
of	O	ADP	O
24	O	NUM	O
performances	O	NOUN	B
of	O	ADP	O
the	O	DET	O
skill	O	NOUN	B
that	O	PRON	O
ranged	O	VERB	O
in	O	ADP	O
quality	O	NOUN	B
of	O	ADP	O
the	O	DET	O
performance	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
error	B-I	NOUN	B
instruction	I-I	NOUN	B
on	O	ADP	O
skill	B-OUT	NOUN	B
acquisition	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
a	B-P	DET	O
group	I-P	NOUN	B
of	I-P	ADP	O
30	I-P	NUM	O
senior	I-P	ADJ	B
medical	I-P	ADJ	I
students	I-P	NOUN	I
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
different	O	ADJ	O
training	O	NOUN	B
groups	O	NOUN	I
:	O	PUNCT	O
none	B-I	NOUN	O
,	I-I	PUNCT	O
error	I-I	NOUN	B
only	I-I	ADV	O
,	I-I	PUNCT	O
correct	I-I	ADJ	O
only	I-I	ADV	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
error+correct	I-I	NOUN	B
.	I-I	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
videotaped	O	VERB	B
performing	O	VERB	O
the	O	DET	O
skill	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
training	O	NOUN	B
and	O	CCONJ	O
three	O	NUM	O
experts	O	NOUN	B
evaluated	O	VERB	B
these	O	DET	O
performances	B-OUT	NOUN	B
independently	O	ADV	O
using	O	VERB	O
a	O	DET	O
7-point	O	ADJ	O
rating	O	NOUN	O
scale	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
error	B-I	NOUN	B
training	I-I	NOUN	B
on	O	ADP	O
skill	O	NOUN	B
evaluation	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
done	O	VERB	O
using	O	VERB	O
both	O	DET	O
novice	O	NOUN	B
and	O	CCONJ	O
expert	O	ADJ	B
raters	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
30	B-P	NUM	O
senior	I-P	ADJ	B
medical	I-P	ADJ	B
students	I-P	NOUN	I
used	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
study	I-P	NOUN	B
was	I-P	AUX	O
used	I-P	VERB	O
as	I-P	ADP	O
novice	I-P	NOUN	B
raters	I-P	NOUN	B
.	I-P	PUNCT	O


Following	O	VERB	O
training	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
four	O	NUM	O
training	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
each	O	DET	O
subject	O	NOUN	B
rated	O	VERB	B
the	O	DET	O
24	O	NUM	O
performances	O	NOUN	B
on	O	ADP	O
the	O	DET	O
testing	B-I	NOUN	B
videotape	I-I	NOUN	B
and	I-I	CCONJ	O
interrater	I-I	ADJ	B
reliability	I-I	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
each	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


Surgical	O	ADJ	B
faculty	O	NOUN	I
served	O	VERB	O
as	O	ADP	O
expert	O	ADJ	B
raters	O	NOUN	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
either	O	DET	O
error	B-I	NOUN	B
training	I-I	NOUN	B
or	O	CCONJ	O
no	B-I	DET	O
training	I-I	NOUN	O
.	I-I	PUNCT	O


Each	O	DET	O
subject	O	NOUN	B
viewed	O	VERB	O
the	O	DET	O
testing	O	NOUN	B
videotape	O	NOUN	B
,	O	PUNCT	O
rating	O	VERB	B
the	O	DET	O
performances	O	NOUN	B
and	O	CCONJ	O
giving	O	VERB	O
"	O	PUNCT	O
feedback	O	NOUN	B
"	O	PUNCT	O
commentary	O	NOUN	B
.	O	PUNCT	O


Interrater	B-OUT	ADJ	B
reliability	I-OUT	NOUN	I
was	O	AUX	O
calculated	O	VERB	B
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
precision	O	NOUN	B
of	O	ADP	O
the	O	DET	O
feedback	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
posttest	B-OUT	NOUN	B
performance	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
was	O	AUX	O
seen	O	VERB	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
"	B-I	PUNCT	O
error+correct	I-I	NOUN	B
"	I-I	PUNCT	O
training	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Interrater	B-OUT	ADJ	B
reliability	I-OUT	NOUN	I
was	O	AUX	O
somewhat	O	ADV	O
lower	O	ADJ	O
for	O	ADP	O
the	O	DET	O
"	B-I	PUNCT	O
correct	I-I	ADJ	B
only	I-I	ADV	O
"	I-I	PUNCT	O
and	O	CCONJ	O
"	B-I	PUNCT	O
error	I-I	NOUN	B
only	I-I	ADV	O
"	I-I	PUNCT	O
training	O	NOUN	B
groups	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
student	O	NOUN	B
and	O	CCONJ	O
faculty	O	NOUN	B
studies	O	NOUN	I
.	O	PUNCT	O


Faculty	O	PROPN	B
raters	O	NOUN	I
receiving	O	VERB	O
error	O	NOUN	B
training	O	NOUN	B
had	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
comments	O	NOUN	B
than	O	ADP	O
the	O	DET	O
group	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
no	O	DET	O
training	O	NOUN	B
although	O	SCONJ	O
this	O	DET	O
difference	O	NOUN	O
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
Instruction	O	NOUN	B
about	O	ADP	O
common	B-I	ADJ	O
errors	I-I	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
combined	O	VERB	O
with	O	ADP	O
instruction	O	NOUN	B
about	O	ADP	O
the	O	DET	O
correct	O	ADJ	B
performance	O	NOUN	B
enhanced	O	VERB	B
the	O	DET	O
acquisition	O	NOUN	B
of	O	ADP	O
this	O	DET	O
surgical	O	ADJ	B
skill	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
errors	O	NOUN	B
in	O	ADP	O
surgical	B-I	ADJ	B
technical	I-I	ADJ	O
skill	I-I	NOUN	O
instruction	I-I	NOUN	B
.	I-I	PUNCT	O


Our	O	PRON	O
study	O	NOUN	B
provides	O	VERB	O
no	O	DET	O
support	O	NOUN	O
for	O	ADP	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
error	B-I	NOUN	B
training	I-I	NOUN	B
in	O	ADP	O
improving	O	VERB	B
skill	O	NOUN	B
evaluation	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
thermal	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
restricted	B-I	ADJ	B
feeding	I-I	NOUN	B
and	O	CCONJ	O
combined	B-I	ADJ	B
stresses	I-I	NOUN	I
(	I-I	PUNCT	O
thermal	I-I	ADJ	B
stress	I-I	NOUN	I
and	I-I	CCONJ	O
restricted	I-I	ADJ	B
feeding	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
growth	O	NOUN	B
and	O	CCONJ	O
plasma	O	NOUN	B
reproductive	O	ADJ	I
hormone	O	NOUN	I
levels	O	NOUN	B
of	O	ADP	O
Malpura	B-P	NOUN	B
ewes	I-P	NOUN	B
under	I-P	ADP	O
semi-arid	I-P	ADJ	B
tropical	I-P	ADJ	B
environment	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
thermal	O	ADJ	B
,	O	PUNCT	O
nutritional	O	ADJ	B
and	O	CCONJ	O
combined	O	ADJ	B
stresses	O	NOUN	I
(	O	PUNCT	O
thermal	O	ADJ	B
and	O	CCONJ	O
nutritional	O	ADJ	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
growth	O	NOUN	B
,	O	PUNCT	O
oestradiol	O	NOUN	B
and	O	CCONJ	O
progesterone	O	NOUN	B
levels	O	NOUN	B
during	O	ADP	O
oestrus	O	NOUN	B
cycles	O	NOUN	B
in	O	ADP	O
Malpura	B-P	NOUN	B
ewes	I-P	NOUN	B
.	I-P	PUNCT	O


Twenty-eight	B-P	NUM	O
adult	I-P	ADJ	B
Malpura	I-P	NOUN	B
ewes	I-P	NOUN	I
were	I-P	AUX	O
used	I-P	VERB	O
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ewes	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
into	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
viz.	O	X	O
,	O	PUNCT	O
GI	O	NOUN	B
(	O	PUNCT	O
n=7	O	NOUN	O
;	O	PUNCT	O
control	B-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
GII	O	NOUN	B
(	O	PUNCT	O
n=7	O	NOUN	O
;	O	PUNCT	O
thermal	B-I	ADJ	B
stress	I-I	NOUN	I
)	I-I	PUNCT	O
,	O	PUNCT	O
GIII	O	NOUN	B
(	O	PUNCT	O
n=7	O	NOUN	O
;	O	PUNCT	O
restricted	B-I	ADJ	O
feeding	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
GIV	O	PROPN	B
(	O	PUNCT	O
n=7	O	NOUN	O
;	O	PUNCT	O
combined	B-I	ADJ	B
stress	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
animals	B-P	NOUN	B
were	I-P	AUX	O
stall	I-I	NOUN	O
fed	I-I	VERB	O
with	I-I	ADP	O
a	I-I	DET	O
diet	I-I	NOUN	B
consisting	I-I	VERB	O
of	I-I	ADP	O
60	I-I	NUM	O
%	I-I	NOUN	O
roughage	I-I	NOUN	B
and	I-I	CCONJ	O
40	I-I	NUM	O
%	I-I	NOUN	O
concentrate	I-I	NOUN	B
.	I-I	PUNCT	O


GI	O	NOUN	B
and	O	CCONJ	O
GII	O	NOUN	B
ewes	O	NOUN	B
were	O	AUX	O
provided	O	VERB	O
with	O	ADP	O
ad	O	NOUN	B
libitum	O	NOUN	I
feeding	O	NOUN	B
while	O	SCONJ	O
GIII	O	NOUN	B
and	O	CCONJ	O
GIV	O	NOUN	B
ewes	O	NOUN	B
were	O	AUX	O
provided	O	VERB	O
with	O	ADP	O
restricted	O	ADJ	B
feed	O	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
intake	O	NOUN	B
of	O	ADP	O
GI	O	NOUN	B
and	O	CCONJ	O
GII	O	NOUN	B
ewes	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
induce	O	VERB	B
nutritional	O	ADJ	B
insufficiency	O	NOUN	I
.	O	PUNCT	O


GII	O	NOUN	B
and	O	CCONJ	O
GIV	O	NOUN	B
ewes	O	NOUN	B
were	O	AUX	O
kept	O	VERB	O
in	O	ADP	O
climatic	O	ADJ	B
chamber	O	NOUN	I
at	O	ADP	O
40°C	O	NOUN	O
and	O	CCONJ	O
55	O	NUM	O
%	O	NOUN	O
RH	O	NOUN	B
for	O	ADP	O
6	O	NUM	O
h	O	NOUN	O
a	O	DET	O
day	O	NOUN	B
between	O	ADP	O
10:00	O	NUM	O
and	O	CCONJ	O
16:00	O	NUM	O
hours	O	NOUN	O
to	O	PART	O
induce	O	VERB	B
thermal	O	ADJ	B
stress	O	NOUN	I
for	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
oestrous	O	ADJ	B
cycles	O	NOUN	B
.	O	PUNCT	O


Parameters	O	NOUN	B
studied	O	VERB	O
were	B-OUT	AUX	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
oestrus	I-OUT	NOUN	B
incidences	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
oestradiol	I-OUT	NOUN	B
17-β	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
progesterone	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
conception	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
gestation	I-OUT	NOUN	B
period	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
lambing	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
birth	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
of	I-OUT	ADP	O
lambs	I-OUT	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
combined	O	ADJ	B
stress	O	NOUN	I
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
reduced	B-OUT	VERB	B
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
oestrus	I-OUT	NOUN	B
duration	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
birth	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
of	I-OUT	ADP	O
lambs	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
oestradiol	I-OUT	NOUN	B
17-β	I-OUT	ADV	O
whereas	I-OUT	SCONJ	O
significantly	I-OUT	ADV	O
(	I-OUT	PUNCT	O
p	I-OUT	NOUN	O
<	I-OUT	X	O
0.05	I-OUT	NUM	O
)	I-OUT	PUNCT	O
increased	I-OUT	VERB	B
oestrus	I-OUT	NOUN	B
cycle	I-OUT	NOUN	O
length	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
progesterone	I-OUT	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
reveal	O	VERB	O
that	O	SCONJ	O
on	O	ADP	O
comparative	O	ADJ	O
basis	O	NOUN	O
,	O	PUNCT	O
ewes	O	NOUN	B
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
better	O	ADV	O
adapt	O	VERB	B
in	B-OUT	ADP	O
terms	I-OUT	NOUN	O
of	I-OUT	ADP	O
growth	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
reproduction	I-OUT	NOUN	B
to	O	PART	O
restricted	O	ADJ	B
feeding	O	NOUN	B
than	O	ADP	O
thermal	O	ADJ	B
stress	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
restricted	O	ADJ	B
feeding	O	NOUN	B
was	O	AUX	O
coupled	O	VERB	B
with	O	ADP	O
thermal	O	ADJ	B
stress	O	NOUN	I
it	O	PRON	O
had	O	AUX	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
influence	O	NOUN	B
on	B-OUT	ADP	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
average	I-OUT	ADJ	B
daily	I-OUT	ADJ	O
gain	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
oestradiol	I-OUT	NOUN	B
17-β	I-OUT	ADV	O
and	I-OUT	CCONJ	O
progesterone	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
.	O	PUNCT	O


This	O	DET	O
showed	O	VERB	O
that	O	SCONJ	O
combined	O	ADJ	B
stress	O	NOUN	I
were	O	AUX	O
more	O	ADV	O
detrimental	O	ADJ	B
for	O	ADP	O
these	O	DET	O
reproductive	O	ADJ	B
hormones	O	NOUN	I
in	O	ADP	O
Malpura	O	NOUN	B
ewes	O	NOUN	B
under	O	ADP	O
a	O	DET	O
hot	O	ADJ	B
semi-arid	O	ADJ	I
environment	O	NOUN	O
.	O	PUNCT	O


Caphosol	B-I	PROPN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
mouthwash	I-I	NOUN	B
gives	O	VERB	O
no	O	DET	O
additional	O	ADJ	O
protection	O	NOUN	B
against	O	ADP	O
oral	O	ADJ	B
mucositis	O	NOUN	I
compared	O	VERB	O
to	B-I	ADP	O
cryotherapy	I-I	NOUN	B
alone	O	ADV	O
in	B-P	ADP	O
stem	I-P	NOUN	B
cell	I-P	NOUN	I
transplantation	I-P	NOUN	I
.	O	PUNCT	O


A	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
if	O	SCONJ	O
adding	B-I	VERB	O
Caphosol	I-I	PROPN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
mouthwash	O	NOUN	B
solution	O	NOUN	I
,	O	PUNCT	O
to	O	ADP	O
oral	B-I	ADJ	B
cryotherapy	I-I	NOUN	I
(	O	PUNCT	O
OC	O	NOUN	B
)	O	PUNCT	O
further	O	ADV	O
protects	O	VERB	O
against	O	ADP	O
oral	O	ADJ	B
mucositis	O	NOUN	I
(	O	PUNCT	O
OM	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
toxic	O	ADJ	B
painful	O	ADJ	O
complication	O	NOUN	B
to	O	PART	O
high	O	ADJ	B
dose	O	NOUN	I
chemotherapy	O	NOUN	O
.	O	PUNCT	O


METHOD	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
study	O	NOUN	B
design	B-P	NOUN	I
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
≥16	I-P	ADJ	O
years	I-P	NOUN	B
scheduled	I-P	VERB	O
for	I-P	ADP	O
allogeneic	I-P	ADJ	B
stem	I-P	NOUN	I
cell	I-P	NOUN	I
transplantation	I-P	NOUN	I
were	I-P	AUX	O
included	I-P	VERB	O
consecutively	O	ADV	B
and	O	CCONJ	O
randomised	O	VERB	B
to	O	ADP	O
experimental	O	ADJ	B
group	O	NOUN	I
receiving	B-I	VERB	O
OC	I-I	PROPN	B
combined	I-I	VERB	O
with	I-I	ADP	O
Caphosol	I-I	PROPN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	B-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
control	I-I	NOUN	B
group	I-I	NOUN	I
receiving	I-I	VERB	O
OC	I-I	PROPN	B
only	O	ADV	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	B-I	NUM	O
)	I-I	PUNCT	O
.	O	PUNCT	O


OC	O	PROPN	B
was	O	AUX	O
given	O	VERB	O
from	O	ADP	O
start	O	NOUN	O
to	O	PART	O
end	O	VERB	O
of	O	ADP	O
HDCT	B-I	NOUN	B
.	I-I	PUNCT	O


Caphosol	B-I	PROPN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
,	O	PUNCT	O
from	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
to	O	ADP	O
day	O	NOUN	B
21	O	NUM	O
.	O	PUNCT	O


RESULT	O	NOUN	B
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
regarding	O	VERB	O
age	O	NOUN	B
or	O	CCONJ	O
gender	O	NOUN	B
between	O	ADP	O
the	O	DET	O
groups	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Mucositis	B-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
with	B-OUT	ADP	O
the	I-OUT	DET	O
World	I-OUT	PROPN	B
Health	I-OUT	PROPN	I
Organisation	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
WHO	I-OUT	PRON	B
)	I-OUT	PUNCT	O
grading	I-OUT	NOUN	B
scale	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Pain	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
with	B-OUT	ADP	O
a	I-OUT	DET	O
10	I-OUT	NUM	O
cm	I-OUT	NOUN	O
visual	I-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	O	PUNCT	O
VAS	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
0	O	NUM	O
=	O	ADJ	O
no	O	DET	B
pain	O	NOUN	I
to	O	PART	O
10	O	NUM	O
=	O	ADJ	O
worst	O	ADV	O
imaginable	O	ADJ	B
pain	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Start	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
therapy	I-OUT	NOUN	B
with	I-OUT	ADP	O
pain	I-OUT	NOUN	B
relieving	I-OUT	VERB	I
drugs	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
serum	I-OUT	NOUN	B
C-reactive	I-OUT	ADJ	I
protein	I-OUT	NOUN	I
values	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
days	I-OUT	NOUN	B
of	I-OUT	ADP	O
hospitalisation	I-OUT	NOUN	B
were	O	AUX	O
collected	O	VERB	O
from	O	ADP	O
the	O	DET	O
medical	O	ADJ	B
records	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Data	B-OUT	NOUN	B
on	I-OUT	ADP	O
OM	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
oral	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
i.v	I-OUT	PROPN	O
.	I-OUT	PUNCT	O


opioids	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
total	I-OUT	ADJ	O
parenteral	I-OUT	ADJ	B
nutrition	I-OUT	NOUN	I
were	O	AUX	O
collected	O	VERB	O
during	O	ADP	O
22	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	B-OUT	NOUN	B
on	I-OUT	ADP	O
OM	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
oral	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
i.v	I-OUT	PROPN	O
.	I-OUT	PUNCT	O


opioids	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
TPN	O	NOUN	B
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
additional	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
combining	B-I	VERB	O
Caphosol	I-I	PROPN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
with	I-I	ADP	O
OC	O	PROPN	B
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
calcanean	O	NOUN	B
bone	O	NOUN	B
mineral	O	NOUN	I
occurring	O	VERB	O
spontaneously	O	ADV	B
and	O	CCONJ	O
during	O	ADP	O
hormone	B-I	NOUN	B
replacement	I-I	NOUN	I
therapy	I-I	NOUN	I
in	O	ADP	O
early	B-P	ADJ	O
post-menopausal	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
spontaneous	B-P	ADJ	B
calcanean	I-P	NOUN	B
bone	I-P	NOUN	I
loss	I-P	NOUN	O
occurring	I-P	VERB	O
in	I-P	ADP	O
healthy	I-P	ADJ	B
early	I-P	ADJ	O
post-menopausal	I-P	ADJ	B
women	I-P	NOUN	B
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
two	B-I	NUM	O
hormone	I-I	NOUN	B
replacement	I-I	NOUN	I
therapies	I-I	NOUN	I
(	I-I	PUNCT	O
HRT	I-I	NOUN	B
's	I-I	PART	I
)	I-I	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
a	O	DET	O
longitudinal	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
right	O	ADJ	B
and	O	CCONJ	O
left	O	VERB	B
calcanean	O	NOUN	I
BMC	O	PROPN	B
or	O	CCONJ	O
BMD	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.15	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
spontaneous	O	ADJ	B
bone	O	NOUN	B
loss	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
at	O	ADP	O
all	O	DET	O
the	O	DET	O
skeletal	O	ADJ	B
sites	O	NOUN	I
measured	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
spontaneous	O	ADJ	B
loss	O	NOUN	O
in	O	ADP	O
calcanean	O	NOUN	B
BMD	O	NOUN	B
of	O	ADP	O
1.6	O	NUM	O
%	O	NOUN	O
over	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
HRT	O	PROPN	B
's	O	PART	O
significantly	O	ADV	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
prevented	O	VERB	B
the	O	DET	O
bone	B-OUT	NOUN	B
loss	I-OUT	NOUN	O
from	O	ADP	O
all	O	DET	O
skeletal	O	ADJ	B
sites	O	NOUN	I
irrespective	O	ADV	O
of	O	ADP	O
the	O	DET	O
weight-bearing	O	ADJ	B
or	O	CCONJ	O
content	O	NOUN	B
of	O	ADP	O
trabecular	O	NOUN	B
bone	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
weight-bearing	O	ADJ	B
bones	O	NOUN	O
)	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
even	O	ADV	O
a	O	DET	O
gain	O	NOUN	O
in	O	ADP	O
calcanean	B-OUT	NOUN	B
BMC	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
BMD	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
spinal	I-OUT	ADJ	B
BMD	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Bone	O	NOUN	B
mineral	O	NOUN	I
of	O	ADP	O
the	O	DET	O
calcaneus	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
spine	O	NOUN	B
correlated	O	VERB	B
equally	O	ADV	O
to	O	PART	O
body	O	NOUN	B
weight	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
approximately	O	ADV	O
0.4	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
bone	O	NOUN	B
mineral	O	NOUN	I
in	O	ADP	O
the	O	DET	O
forearm	O	NOUN	B
was	O	AUX	O
not	O	PART	O
correlated	O	VERB	B
to	O	PART	O
body	O	NOUN	B
weight	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
correlations	O	NOUN	B
between	O	ADP	O
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
bone	O	NOUN	B
mineral	O	NOUN	I
at	O	ADP	O
the	O	DET	O
sites	O	NOUN	B
measured	O	VERB	B
were	O	AUX	O
all	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
r	O	NOUN	O
approximately	O	ADV	O
0.2-0.4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Heparan	B-I	NOUN	B
sulfate	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
intermittent	B-P	ADJ	B
claudication	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
multicenter	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


Peripheral	O	ADJ	B
arterial	O	ADJ	I
disease	O	NOUN	I
(	O	PUNCT	O
PAD	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
by	O	ADP	O
far	O	ADV	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
intermittent	B-P	ADJ	B
claudication	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
disease	O	NOUN	B
can	O	AUX	O
greatly	O	ADV	O
reduce	O	VERB	B
the	O	DET	O
affected	O	VERB	B
individual	O	NOUN	B
's	O	PART	O
walking	O	NOUN	B
capacity	O	NOUN	I
and	O	CCONJ	O
can	O	AUX	O
seriously	O	ADV	O
affect	O	VERB	O
daily	O	ADJ	B
life	O	NOUN	B
activities	O	NOUN	I
.	O	PUNCT	O


Few	O	ADJ	O
therapeutic	O	ADJ	B
options	O	NOUN	I
are	O	AUX	O
aimed	O	VERB	O
at	O	ADP	O
improving	O	VERB	B
walking	B-OUT	NOUN	B
capacity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
doubleblind	O	NOUN	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
multicenter	B-P	ADJ	B
trial	I-P	NOUN	I
,	I-P	PUNCT	O
performed	I-P	VERB	O
in	I-P	ADP	O
24	I-P	NUM	O
Italian	I-P	ADJ	B
centers	I-P	NOUN	I
.	I-P	PUNCT	O


Two	B-P	NUM	O
hundred	I-P	NUM	O
seventeen	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
intermittent	I-P	ADJ	B
claudication	I-P	NOUN	I
(	I-P	PUNCT	O
stages	I-P	NOUN	B
IIa	I-P	NOUN	I
and	I-P	CCONJ	O
IIb	I-P	NOUN	B
of	I-P	ADP	O
Fontaine	I-P	PROPN	O
's	I-P	PART	O
PAD	I-P	PROPN	B
classification	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	B-I	ADV	O
assigned	I-I	VERB	O
to	I-I	PART	O
heparan	I-I	NOUN	B
sulfate	I-I	NOUN	I
(	I-I	PUNCT	O
40	I-I	NUM	O
mg	I-I	NOUN	O
orally	I-I	ADV	B
twice	I-I	DET	O
a	I-I	DET	O
day	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
for	I-I	ADP	O
6	I-I	NUM	O
months	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end-point	O	NOUN	B
was	O	AUX	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
pain-free	B-OUT	ADJ	B
walking	I-OUT	NOUN	O
distance	I-OUT	NOUN	O
[	O	PUNCT	O
initial	O	ADJ	O
claudication	B-OUT	NOUN	B
distance	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
ICD	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
]	I-OUT	PUNCT	O
during	O	ADP	O
the	O	DET	O
24	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pain-free	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
absolute	I-OUT	ADJ	B
walking	I-OUT	NOUN	I
distance	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ACD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
monitored	O	VERB	O
by	O	ADP	O
standardized	O	ADJ	B
treadmill	O	NOUN	I
test	O	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
4	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
change	O	NOUN	O
in	O	ADP	O
initial	O	ADJ	O
claudication	B-OUT	NOUN	B
distance	I-OUT	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
expressed	O	VERB	B
as	O	ADP	O
integrated	O	ADJ	B
change	O	NOUN	I
over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
with	O	ADP	O
heparan	B-I	NOUN	B
sulfate	I-I	NOUN	I
than	O	ADP	O
with	O	ADP	O
placebo	O	NOUN	B
(	O	PUNCT	O
306	O	NUM	O
+/-	O	CCONJ	O
494	O	NUM	O
vs.	O	CCONJ	O
250	O	NUM	O
+/-	O	CCONJ	O
510	O	NUM	O
meters	O	NOUN	B
x	O	NOUN	O
months	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.019	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Significantly	O	ADV	O
fewer	O	ADJ	O
treated	O	VERB	B
patients	O	NOUN	B
worsened	O	VERB	B
during	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
decreased	O	VERB	B
initial	B-OUT	ADJ	O
claudication	I-OUT	NOUN	B
distance	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
9.1	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
19.6	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.027	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Functional	B-OUT	ADJ	B
recovery	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
most	O	ADV	O
severely	O	ADV	B
affected	O	VERB	B
subgroup	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
(	O	PUNCT	O
stage	O	NOUN	B
IIb	O	NOUN	O
of	O	ADP	O
Fontaine	O	PROPN	B
's	O	PART	I
classification	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
more	O	ADV	O
clearly	O	ADV	O
detected	O	VERB	B
and	O	CCONJ	O
significantly	O	ADV	O
greater	O	ADJ	O
among	O	ADP	O
treated	O	VERB	B
than	O	ADP	O
among	O	ADP	O
control	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
absolute	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
ICD	O	PROPN	B
:	O	PUNCT	O
70	O	NUM	O
+/-	O	CCONJ	O
113	O	NUM	O
vs.	O	CCONJ	O
58	O	NUM	O
+/-	O	CCONJ	O
172	O	NUM	O
meters	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.028	O	NUM	O
;	O	PUNCT	O
integrated	O	ADJ	O
increase	O	NOUN	B
:	O	PUNCT	O
304	O	NUM	O
+/-	O	CCONJ	O
422	O	NUM	O
vs.	O	CCONJ	O
208	O	NUM	O
+/-	O	CCONJ	O
503	O	NUM	O
meters	O	NOUN	B
x	O	NOUN	O
months	O	NOUN	B
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Heparan	O	NOUN	B
sulfate	O	NOUN	I
appeared	O	VERB	O
to	O	PART	O
increase	O	VERB	B
the	O	DET	O
walking	B-OUT	NOUN	B
capacity	I-OUT	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
intermittent	I-P	ADJ	B
claudication	I-P	NOUN	I
to	O	ADP	O
a	O	DET	O
significantly	O	ADV	O
greater	O	ADJ	O
extent	O	NOUN	O
than	O	ADP	O
did	O	VERB	O
placebo	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


Does	O	AUX	O
short-term	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
proton	B-I	NOUN	B
pump	I-I	NOUN	I
inhibitors	I-I	NOUN	I
cause	O	VERB	O
rebound	O	ADJ	O
aggravation	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
?	O	PUNCT	O
BACKGROUND	O	ADJ	O
Rebound	O	ADJ	B
acid	O	NOUN	I
hypersecretion	O	NOUN	I
might	O	AUX	O
occur	O	VERB	O
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
proton	B-I	NOUN	B
pump	I-I	NOUN	I
inhibitors	I-I	NOUN	I
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
looks	O	VERB	O
for	O	ADP	O
a	O	DET	O
rebound	O	ADJ	O
aggravation	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
after	O	ADP	O
short-term	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
lansoprazole	B-I	NOUN	B
.	I-I	PUNCT	O


STUDY	O	NOUN	O
Sixty-two	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
19	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
43	I-P	NUM	O
women	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
54	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
range	I-P	NOUN	B
,	I-P	PUNCT	O
32-77	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
heartburn	I-P	NOUN	B
and	I-P	CCONJ	O
regurgitation	I-P	NOUN	B
and	I-P	CCONJ	O
normal	I-P	ADJ	B
upper	I-P	ADJ	O
endoscopy	I-P	NOUN	O
findings	I-P	NOUN	B
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
with	O	ADP	O
a	O	DET	O
crossover	O	NOUN	B
design	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
two	O	NUM	O
5-day	O	ADJ	O
treatment	O	NOUN	B
periods	O	NOUN	B
with	O	ADP	O
lansoprazole	B-I	NOUN	B
60	I-I	NUM	O
mg	I-I	NOUN	O
once	I-I	ADV	B
daily	I-I	ADV	I
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
random	O	ADJ	B
order	O	NOUN	O
,	O	PUNCT	O
separated	O	VERB	O
by	O	ADP	O
a	O	DET	O
9-day	O	ADJ	O
washout	O	NOUN	O
period	O	NOUN	B
.	O	PUNCT	O


Reflux	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
total	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
antacid	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
were	O	AUX	O
calculated	O	VERB	B
for	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
periods	O	NOUN	B
.	O	PUNCT	O


Higher	O	ADJ	B
scores	O	NOUN	B
during	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
period	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
lansoprazole	B-I	NOUN	B
first	O	ADV	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
placebo	O	NOUN	B
first	O	ADV	O
indicated	O	VERB	O
a	O	DET	O
rebound	O	ADJ	O
aggravation	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
mean	O	ADJ	O
symptom	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
period	O	NOUN	B
in	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
given	O	VERB	O
lansoprazole	O	NOUN	B
first	O	ADV	O
and	O	CCONJ	O
placebo	O	NOUN	B
first	O	ADV	O
were	O	AUX	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
reflux	B-OUT	NOUN	B
score	I-OUT	NOUN	B
,	O	PUNCT	O
21.5	O	NUM	O
and	O	CCONJ	O
17.6	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
;	O	PUNCT	O
total	B-OUT	ADJ	B
score	I-OUT	NOUN	I
,	O	PUNCT	O
11.2	O	NUM	O
and	O	CCONJ	O
10.3	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
;	O	PUNCT	O
and	O	CCONJ	O
antacid	B-OUT	NOUN	B
score	I-OUT	NOUN	I
,	O	PUNCT	O
8.2	O	NUM	O
and	O	CCONJ	O
7.2	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
There	O	PRON	O
is	O	AUX	O
no	O	DET	O
indication	O	NOUN	B
of	O	ADP	O
a	O	DET	O
rebound	O	ADJ	O
aggravation	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
12	O	NUM	O
to	O	PART	O
14	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
a	O	DET	O
5-day	O	ADJ	O
treatment	O	NOUN	B
with	O	ADP	O
lansoprazole	B-I	NOUN	B
60	O	NUM	O
mg	O	NOUN	O
once	O	ADV	O
daily	O	ADV	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
reflux	I-P	NOUN	B
symptoms	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
radiotherapy	B-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
cisplatin	B-I	NOUN	B
chemo-radiotherapy	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
unresectable	I-P	ADJ	B
squamous	I-P	ADJ	I
cell	I-P	NOUN	I
cancer	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
esophagus	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
PURPOSE	O	NOUN	O
Following	O	VERB	O
our	O	PRON	O
phase	O	NOUN	B
II	O	NUM	I
experience	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
trial	O	NOUN	I
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
adding	B-I	VERB	O
chemotherapy	I-I	NOUN	B
to	I-I	PART	O
radiotherapy	I-I	NOUN	B
in	I-I	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
unresectable	I-P	ADJ	B
squamous	I-P	ADJ	I
cell	I-P	NOUN	I
cancer	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
esophagus	I-P	NOUN	B
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	O	NOUN	B
randomised	O	VERB	B
to	O	PART	O
the	O	DET	O
RT	B-I	NOUN	B
group	I-I	NOUN	B
received	I-I	VERB	O
50	I-I	NUM	O
Gy/25	I-I	NOUN	O
fx/5	I-I	ADJ	B
weeks	I-I	NOUN	B
of	I-I	ADP	O
teletherapy	I-I	NOUN	B
followed	I-I	VERB	O
1-2	I-I	NUM	O
weeks	I-I	NOUN	B
later	I-I	ADV	O
with	I-I	ADP	O
12	I-I	NUM	O
Gy/2	I-I	NOUN	O
fx	I-I	NOUN	O
of	I-I	ADP	O
high-dose-rate	I-I	ADJ	O
intra-lumenal	I-I	ADJ	O
brachytherapy	I-I	NOUN	O
spaced	I-I	VERB	O
a	I-I	DET	O
week	I-I	NOUN	B
apart	I-I	ADV	O
.	I-I	PUNCT	O


Following	O	VERB	O
the	O	DET	O
first	O	ADJ	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
recruitment	O	NOUN	B
,	O	PUNCT	O
due	O	ADP	O
to	O	PART	O
unexpected	O	ADJ	O
late	O	ADJ	O
morbidity	O	NOUN	B
,	O	PUNCT	O
brachytherapy	B-I	NOUN	B
was	O	AUX	O
excluded	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
protocol	O	NOUN	B
modified	O	VERB	B
to	O	PART	O
66	O	NUM	O
Gy/33	O	ADJ	O
fx/6.5	O	NUM	B
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
CRT	O	PROPN	B
group	O	NOUN	B
received	B-I	VERB	O
identical	I-I	ADJ	B
radiotherapy	I-I	NOUN	B
with	I-I	ADP	O
concurrent	I-I	ADJ	B
weekly	I-I	ADJ	B
cisplatin	I-I	NOUN	B
at	I-I	ADP	O
35	I-I	NUM	O
mg/m	I-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
for	I-I	ADP	O
6-7	I-I	NUM	O
cycles	I-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	NOUN	B
Between	B-P	ADP	O
April	I-P	PROPN	O
1999	I-P	NUM	O
and	I-P	CCONJ	O
December	I-P	PROPN	O
2005	I-P	NUM	O
,	I-P	PUNCT	O
125	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomised	I-P	VERB	B
to	O	PART	O
a	O	DET	O
RT	O	NOUN	B
(	O	PUNCT	O
n=60	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
CRT	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
n=65	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Radiotherapy	O	NOUN	B
treatment	O	NOUN	B
was	O	AUX	O
completed	O	VERB	O
in	O	ADP	O
78	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
47/60	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
RT	O	NOUN	B
group	O	NOUN	O
and	O	CCONJ	O
89	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
58/65	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
CRT	O	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
P=0.10	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Six	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
cycles	O	NOUN	B
of	O	ADP	O
cisplatin	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
delivered	O	VERB	O
in	O	ADP	O
63	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
41/65	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
RTOG	B-OUT	NOUN	B
grade	I-OUT	NOUN	B
3	I-OUT	NUM	I
neutropenia	I-OUT	NOUN	I
of	O	ADP	O
3	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Late	B-OUT	ADJ	B
morbidity	I-OUT	NOUN	I
in	I-OUT	ADP	O
the	I-OUT	DET	O
form	I-OUT	NOUN	O
of	I-OUT	ADP	O
ulcers	I-OUT	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
odds	O	NOUN	B
ratio	O	NOUN	I
0.29	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.08-1.11	O	NUM	O
,	O	PUNCT	O
P=0.08	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
strictures	B-OUT	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
28	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
0.40	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NUM	B
0.16-1.01	O	NUM	O
,	O	PUNCT	O
P=0.05	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
RT	O	NOUN	B
and	O	CCONJ	O
CRT	O	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


At	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow	O	NOUN	B
up	O	ADP	I
of	O	ADP	O
23	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
alive	O	ADJ	B
(	O	PUNCT	O
range	O	NOUN	O
6-82	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
with	O	ADP	O
95/125	O	NOUN	O
events	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
median	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
year	O	NOUN	B
projected	O	ADJ	B
survival	B-OUT	NOUN	I
was	O	AUX	O
7.1	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
32.3	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
22.8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
13.7	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
13.4	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
57.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
38.9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
24.8	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
RT	O	NOUN	B
and	O	CCONJ	O
CRT	O	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
0.65	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.44-0.98	O	NUM	O
,	O	PUNCT	O
P=0.038	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
concurrent	O	ADJ	B
cisplatin	B-I	NOUN	B
to	O	PART	O
radiotherapy	B-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
modest	B-OUT	ADJ	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
survival	I-OUT	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
manageable	B-OUT	ADJ	O
additional	I-OUT	ADJ	O
acute	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
late	I-OUT	ADJ	O
morbidity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Use	O	NOUN	B
of	O	ADP	I
granulocyte-macrophage	B-I	ADJ	I
colony-stimulating	I-I	ADJ	I
factor	I-I	NOUN	I
and	O	CCONJ	O
erythropoietin	B-I	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
after	B-P	ADP	O
autologous	I-I	ADJ	B
marrow	I-I	NOUN	I
transplantation	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
toxicities	O	NOUN	B
and	O	CCONJ	O
possible	O	ADJ	O
utility	O	NOUN	O
of	O	ADP	O
the	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
recombinant	I-I	ADJ	B
human	I-I	ADJ	O
granulocyte-macrophage	I-I	ADJ	O
colony-stimulating	I-I	ADJ	O
factor	I-I	NOUN	O
(	I-I	PUNCT	O
rhGM-CSF	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
recombinant	I-I	ADJ	B
human	I-I	ADJ	I
erythropoietin	I-I	NOUN	I
(	I-I	PUNCT	O
rHuEPO	I-I	NOUN	B
)	I-I	PUNCT	O
given	O	VERB	O
after	O	ADP	O
autologous	B-I	ADJ	B
BMT	I-I	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


Eighteen	B-P	NUM	O
patients	I-P	NOUN	B
received	O	VERB	O
the	O	DET	O
combination	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
six	B-I	NUM	O
concurrent	I-I	ADJ	B
control	I-I	NOUN	B
and	I-I	CCONJ	O
65	I-I	NUM	O
historical	I-I	ADJ	B
control	I-I	NOUN	O
patients	I-I	NOUN	B
treated	I-I	VERB	B
with	I-I	ADP	I
rhGM-CSF	I-I	NOUN	B
alone	I-I	ADV	O
.	I-I	PUNCT	O


Patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
combination	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
have	O	AUX	O
more	O	ADV	O
rapid	O	ADJ	O
recovery	B-OUT	NOUN	B
to	O	ADP	O
an	O	DET	O
absolute	B-OUT	ADJ	B
neutrophil	I-OUT	NOUN	B
count	I-OUT	NOUN	O
of	O	ADP	O
500	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
/l	O	PUNCT	O
(	O	PUNCT	O
median	O	NOUN	B
=	O	ADJ	O
12.5	O	NUM	O
vs	O	CCONJ	O
18	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
concurrent	O	ADJ	B
and	O	CCONJ	O
19	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
historical	O	ADJ	B
control	O	NOUN	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
apparent	O	ADJ	O
impact	O	NOUN	B
on	O	ADP	O
red	B-OUT	ADJ	B
cell	I-OUT	NOUN	I
transfusion	I-OUT	NOUN	O
requirements	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
platelet	I-OUT	NOUN	B
recovery	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
hospitalization	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Patients	O	NOUN	B
treated	O	VERB	B
in	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
with	O	ADP	O
rhGM-CSF	O	NOUN	B
plus	O	CCONJ	O
either	O	CCONJ	O
rHuEPO	O	NOUN	B
or	O	CCONJ	O
with	O	ADP	O
placebo	O	NOUN	B
had	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
rash	I-OUT	NOUN	B
than	O	ADP	O
seen	O	VERB	O
in	O	ADP	O
our	O	PRON	O
historical	O	ADJ	B
experience	O	NOUN	B
using	O	VERB	O
rhGM-CSF	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
difference	O	NOUN	O
may	O	AUX	O
reflect	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
source	O	NOUN	B
of	O	ADP	O
rhGM-CSF	O	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
schedule	O	NOUN	B
.	O	PUNCT	O


Erythropoietin	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
combined	O	VERB	B
safely	O	ADV	O
with	O	ADP	O
rhGM-CSF	O	NOUN	B
after	O	ADP	O
autologous	O	ADJ	B
transplantation	O	NOUN	I
.	O	PUNCT	O


Larger	O	ADJ	B
controlled	O	VERB	I
trials	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
detect	O	VERB	B
possible	O	ADJ	O
therapeutic	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


Standardized	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
Chinese	B-I	ADJ	B
medicine	I-I	NOUN	I
decoction	I-I	NOUN	B
for	O	ADP	O
cancer	B-P	NOUN	B
pain	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
opioid-induced	I-OUT	ADJ	B
constipation	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
a	O	DET	O
multi-center	O	ADJ	B
prospective	O	ADJ	I
randomized	O	ADJ	I
controlled	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
observe	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
the	O	DET	O
influence	O	NOUN	B
on	O	ADP	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
QOL	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
of	O	ADP	O
syndrome	O	NOUN	B
differentiation	O	NOUN	I
treatment	O	NOUN	B
with	O	ADP	O
Chinese	B-I	ADJ	B
medicine	I-I	NOUN	I
(	I-I	PUNCT	O
CM	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
opioid-induced	B-OUT	ADJ	B
constipation	I-OUT	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
influence	I-OUT	NOUN	B
on	I-OUT	ADP	O
analgesic	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
of	I-OUT	ADP	O
opioids	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	VERB	O
Totally	B-P	ADV	O
406	I-P	NUM	O
cases	I-P	NOUN	B
enrolled	I-P	VERB	O
from	I-P	ADP	O
53	I-P	NUM	O
collaborating	I-P	VERB	B
medical	I-P	ADJ	I
centers	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
CM	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
CM	O	NOUN	B
group	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
CM	B-I	NOUN	B
decoction	I-I	NOUN	B
based	O	VERB	O
on	O	ADP	O
syndrome	O	NOUN	B
differentiation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
Phenolphthalein	B-I	NOUN	B
Tablet	I-I	PROPN	I
.	I-I	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Cleveland	B-OUT	PROPN	B
constipation	I-OUT	NOUN	I
score	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CCS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
numerical	I-OUT	ADJ	B
rating	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
NRS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
Chinese	I-OUT	ADJ	B
version	I-OUT	NOUN	B
of	I-OUT	ADP	O
European	I-OUT	PROPN	B
Organisation	I-OUT	PROPN	I
for	I-OUT	ADP	I
Research	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
Treatment	I-OUT	NOUN	B
of	I-OUT	ADP	O
Cancer	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
Quality	I-OUT	PROPN	B
of	I-OUT	ADP	I
Life	I-OUT	PROPN	I
Questionnaire-C30	I-OUT	PROPN	I
V3.0	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
EORTC	I-OUT	PROPN	B
QLQ-C30	I-OUT	PROPN	I
V3.0	I-OUT	PROPN	I
)	I-OUT	PUNCT	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
controlled	I-OUT	VERB	I
and	O	CCONJ	O
QOL	B-OUT	PROPN	B
status	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
comparisons	O	NOUN	B
of	O	ADP	O
CCS	B-OUT	NOUN	B
score	I-OUT	NOUN	B
reduction	I-OUT	NOUN	B
and	O	CCONJ	O
QOL	B-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
improvements	B-OUT	NOUN	B
of	I-OUT	ADP	O
constipation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
QOL	I-OUT	PROPN	B
in	O	ADP	O
the	O	DET	O
CM	O	NOUN	B
group	O	NOUN	B
were	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
total	O	ADJ	O
efficiency	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
CM	O	NOUN	B
group	O	NOUN	B
was	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
93.5	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
86.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
NRS	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
between	O	ADP	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
serious	O	ADJ	O
drug-related	B-OUT	ADJ	B
adverse	I-OUT	ADJ	I
event	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
CM	B-I	NOUN	B
decoction	I-I	NOUN	B
could	O	AUX	O
effectively	O	ADV	O
treat	O	VERB	B
opioid-induced	B-OUT	ADJ	B
constipation	I-OUT	NOUN	I
and	O	CCONJ	O
improve	O	VERB	B
patients	B-OUT	NOUN	B
'	I-OUT	PART	O
QOL	I-OUT	PROPN	B
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
does	O	AUX	O
n't	O	PART	O
affect	O	VERB	O
the	O	DET	O
analgesic	B-OUT	ADJ	B
effect	I-OUT	NOUN	I
of	I-OUT	ADP	O
opioids	I-OUT	NOUN	B
when	O	SCONJ	O
treating	O	VERB	B
constipation	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Durability	B-OUT	NOUN	B
of	O	ADP	O
central	B-I	ADJ	B
venous	I-I	ADJ	I
catheters	I-I	NOUN	I
.	I-I	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
malignant	I-P	ADJ	B
diseases	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
the	O	DET	O
durability	B-OUT	NOUN	B
of	O	ADP	O
tunnelled	B-I	NOUN	B
and	I-I	CCONJ	O
non-tunnelled	I-I	ADJ	O
central	I-I	ADJ	O
venous	I-I	ADJ	O
catheters	I-I	NOUN	O
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
malignant	I-P	ADJ	B
diseases	I-P	NOUN	I
.	I-P	PUNCT	O


Twenty	B-P	NUM	B
children	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
but	I-P	CCONJ	O
four	I-P	NUM	O
(	I-P	PUNCT	O
two	I-P	NUM	O
in	I-P	ADP	O
each	I-P	DET	O
group	I-P	NOUN	B
)	I-P	PUNCT	O
had	I-P	AUX	O
to	I-P	PART	O
be	I-P	AUX	O
excluded	I-P	VERB	B
;	I-P	PUNCT	O
three	I-P	NUM	O
because	I-P	SCONJ	O
the	I-P	DET	O
entry	I-P	NOUN	B
criteria	I-P	NOUN	I
turned	I-P	VERB	O
out	I-P	ADP	O
not	I-P	PART	O
to	I-P	PART	O
be	I-P	AUX	O
fulfilled	I-P	VERB	O
and	I-P	CCONJ	O
one	I-P	NUM	O
because	I-P	SCONJ	O
of	I-P	ADP	O
lack	I-P	NOUN	B
of	I-P	ADP	O
data	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
tunnelled	B-I	VERB	B
catheters	I-I	NOUN	I
was	O	AUX	O
224	O	NUM	O
days	O	NOUN	B
with	O	ADP	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
25-846	O	NUM	O
days	O	NOUN	B
which	O	DET	O
was	O	AUX	O
significantly	B-OUT	ADV	O
longer	I-OUT	ADV	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
conventional	B-I	ADJ	B
catheters	I-I	NOUN	I
(	O	PUNCT	O
39.5	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
range	O	NOUN	O
9-228	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
six	O	NUM	O
of	O	ADP	O
eight	O	NUM	O
conventional	O	ADJ	B
catheters	O	NOUN	B
were	O	AUX	O
accidentally	O	ADV	O
removed	O	VERB	O
whereas	O	SCONJ	O
all	O	DET	O
catheters	O	NOUN	B
in	O	ADP	O
the	O	DET	O
tunnelled	O	VERB	B
group	O	NOUN	I
had	O	AUX	O
to	O	PART	O
be	O	AUX	O
removed	O	VERB	B
via	O	ADP	O
a	O	DET	O
small	O	ADJ	O
incision	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
catheter	B-OUT	NOUN	B
related	I-OUT	ADJ	I
sepsis	I-OUT	NOUN	I
,	O	PUNCT	O
two	O	NUM	O
in	O	ADP	O
the	O	DET	O
tunnelled	O	VERB	B
group	O	NOUN	I
and	O	CCONJ	O
one	O	NUM	O
in	O	ADP	O
the	O	DET	O
conventional	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
registered	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
corresponding	O	ADJ	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
infections	I-OUT	NOUN	B
per	I-OUT	ADP	O
catheter	I-OUT	NOUN	B
days	I-OUT	NOUN	I
were	O	AUX	O
1	O	NUM	O
in	O	ADP	O
1189	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
in	O	ADP	O
522	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
cuffed	B-I	NOUN	B
,	I-I	PUNCT	O
tunnelled	I-I	VERB	B
central	I-I	ADJ	I
venous	I-I	ADJ	I
catheters	I-I	NOUN	I
are	O	AUX	O
less	O	ADV	O
prone	O	ADJ	O
to	O	PART	O
displacement	B-OUT	NOUN	B
than	O	ADP	O
traditional	B-I	ADJ	B
percutaneous	I-I	ADJ	B
central	I-I	ADJ	I
venous	I-I	ADJ	I
catheters	I-I	NOUN	I
when	O	SCONJ	O
used	O	VERB	O
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
malignant	I-P	ADJ	B
diseases	I-P	NOUN	I
.	I-P	PUNCT	O


Cardiac	O	ADJ	B
failure	O	NOUN	I
:	O	PUNCT	O
symptoms	O	NOUN	B
and	O	CCONJ	O
functional	O	ADJ	B
status	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
associations	O	NOUN	B
between	O	ADP	O
exercise	O	NOUN	B
capacity	O	NOUN	B
,	O	PUNCT	O
symptoms	O	NOUN	B
and	O	CCONJ	O
specific	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
subjects	B-P	NOUN	B
participating	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
trial	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
treatment	I-I	NOUN	B
of	I-I	ADP	O
heart	I-I	NOUN	B
failure	I-I	NOUN	I
.	I-I	PUNCT	O


Patients	B-I	NOUN	B
were	I-I	AUX	O
assessed	I-I	VERB	B
on	I-P	ADP	O
entry	I-P	NOUN	B
and	I-P	CCONJ	O
after	I-P	ADP	O
three	I-P	NUM	O
months	I-P	NOUN	B
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
principle	O	NOUN	O
symptoms	O	NOUN	B
were	O	AUX	O
fatigue	B-P	NOUN	B
,	I-P	PUNCT	O
breathlessness	I-P	NOUN	B
and	I-P	CCONJ	O
chest	I-P	ADJ	B
pain	I-P	NOUN	I
.	I-P	PUNCT	O


These	O	DET	O
limited	O	VERB	O
the	O	DET	O
extent	O	NOUN	B
and	O	CCONJ	O
speed	O	NOUN	B
of	O	ADP	O
physical	O	ADJ	B
activities	O	NOUN	I
,	O	PUNCT	O
restricted	O	ADJ	B
social	O	ADJ	B
,	O	PUNCT	O
leisure	O	NOUN	B
and	O	CCONJ	O
family	O	NOUN	B
life	O	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
emotional	O	ADJ	B
distress	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
associations	O	NOUN	B
between	O	ADP	O
baseline	B-OUT	NOUN	B
exercise	I-OUT	NOUN	B
capacity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
measures	I-OUT	NOUN	B
of	I-OUT	ADP	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Change	O	NOUN	B
in	O	ADP	O
exercise	O	NOUN	B
capacity	O	NOUN	B
during	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
treatment	B-I	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
measures	B-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
limitation	I-OUT	NOUN	B
of	I-OUT	ADP	O
activity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
confirm	O	VERB	B
the	O	DET	O
value	O	NOUN	O
of	O	ADP	O
change	O	NOUN	O
in	O	ADP	O
exercise	B-OUT	NOUN	B
capacity	I-OUT	NOUN	B
as	O	ADP	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
status	O	NOUN	I
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
should	O	AUX	O
be	O	AUX	O
supported	O	VERB	O
by	O	ADP	O
a	O	DET	O
limited	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
specific	O	ADJ	O
measures	O	NOUN	B
of	O	ADP	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
alexithymia	O	NOUN	B
to	O	ADP	O
emotional	O	ADJ	B
dysregulation	O	NOUN	I
within	O	ADP	O
an	O	DET	O
alcohol	B-P	NOUN	B
dependent	I-P	ADJ	I
treatment	I-P	NOUN	B
sample	I-P	NOUN	O
.	I-P	PUNCT	O


Difficulties	O	NOUN	B
regulating	O	VERB	O
emotions	O	NOUN	O
have	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
,	O	PUNCT	O
maintenance	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
recovery	O	NOUN	B
from	O	ADP	O
alcohol	B-P	NOUN	B
problems	I-P	NOUN	I
.	I-P	PUNCT	O


One	O	NUM	O
construct	O	NOUN	O
thought	O	VERB	O
to	O	PART	O
impede	O	VERB	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
emotion	O	NOUN	B
is	O	AUX	O
alexithymia	O	NOUN	B
.	O	PUNCT	O


Alexithymia	O	NOUN	B
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
difficulties	O	NOUN	B
identifying	O	VERB	O
,	O	PUNCT	O
differentiating	O	VERB	B
and	O	CCONJ	O
expressing	O	VERB	B
feelings	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
limited	O	ADJ	O
imagination	O	NOUN	B
and	O	CCONJ	O
fantasy	O	NOUN	B
life	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
externally-oriented	O	ADJ	B
thinking	O	NOUN	I
style	O	NOUN	I
(	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
prefer	O	VERB	O
talking	O	VERB	B
about	O	ADP	O
daily	O	ADJ	B
activities	O	NOUN	B
rather	O	ADV	O
than	O	ADP	O
feelings	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Given	O	VERB	O
that	O	DET	O
poor	O	ADJ	B
emotion	O	NOUN	B
regulation	O	NOUN	O
skills	O	NOUN	O
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
predict	O	VERB	O
posttreatment	B-P	NOUN	B
levels	I-P	NOUN	B
of	I-P	ADP	O
alcohol	I-P	NOUN	B
use	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
several	O	ADJ	O
defining	O	VERB	O
characteristics	O	NOUN	B
of	O	ADP	O
alexithymia	O	NOUN	B
bear	O	NOUN	O
similarity	O	NOUN	B
to	O	PART	O
deficits	O	NOUN	B
in	O	ADP	O
emotion	O	NOUN	B
regulation	O	NOUN	I
skills	O	NOUN	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
possible	O	ADJ	O
that	O	SCONJ	O
alexithymia	O	NOUN	B
may	O	AUX	O
predict	O	VERB	O
poorer	O	ADJ	B
alcohol	O	NOUN	B
treatment	O	NOUN	I
outcomes	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
first	O	ADV	O
examined	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
alexithymia	B-I	NOUN	B
to	O	ADP	O
several	O	ADJ	O
other	O	ADJ	O
emotion	B-OUT	NOUN	B
regulation	I-OUT	NOUN	I
measures	I-OUT	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
investigated	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
alexithymia	B-I	NOUN	B
on	O	ADP	O
attrition	O	NOUN	B
and	O	CCONJ	O
alcohol	O	NOUN	B
treatment	O	NOUN	I
outcomes	O	NOUN	B
in	O	ADP	O
men	B-P	NOUN	B
and	I-P	CCONJ	O
women	I-P	NOUN	B
(	I-P	PUNCT	O
N=77	I-P	NOUN	O
)	I-P	PUNCT	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
12-week	I-I	ADJ	O
cognitive-behavioral	I-I	ADJ	B
intervention	I-I	NOUN	I
for	I-I	ADP	O
alcohol	I-I	NOUN	B
dependence	I-I	NOUN	I
.	I-I	PUNCT	O


At	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
higher	O	ADJ	B
scores	O	NOUN	B
on	O	ADP	O
alexithymia	O	NOUN	B
were	O	AUX	O
associated	O	VERB	O
poorer	B-OUT	ADJ	B
emotion	I-OUT	NOUN	B
regulation	I-OUT	NOUN	O
skills	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
fewer	I-OUT	ADJ	O
percent	I-OUT	NOUN	O
days	I-OUT	NOUN	B
abstinent	I-OUT	VERB	B
,	I-OUT	PUNCT	O
greater	I-OUT	ADJ	O
alcohol	I-OUT	NOUN	B
dependence	I-OUT	NOUN	I
severity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
several	I-OUT	ADJ	O
high-risk	I-OUT	ADJ	B
drinking	I-OUT	NOUN	B
situations	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Alexithymia	O	NOUN	B
was	O	AUX	O
unrelated	O	ADJ	O
to	O	PART	O
attrition	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
level	O	NOUN	B
of	O	ADP	O
alcohol	O	NOUN	B
consumption	O	NOUN	I
at	O	ADP	O
posttreatment	O	NOUN	B
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
construct	O	NOUN	O
of	O	ADP	O
alexithymia	O	NOUN	B
is	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
several	O	ADJ	O
theoretically-related	O	ADJ	B
constructs	O	NOUN	B
(	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
emotion	O	NOUN	B
regulation	O	NOUN	I
,	O	PUNCT	O
mindfulness	O	NOUN	B
)	O	PUNCT	O
but	O	CCONJ	O
demonstrated	O	VERB	O
a	O	DET	O
limited	O	ADJ	O
relationship	O	NOUN	B
to	O	ADP	O
drinking	O	VERB	B
outcomes	O	NOUN	I
in	O	ADP	O
those	B-P	DET	O
seeking	I-P	VERB	O
treatment	I-P	NOUN	B
for	I-P	ADP	O
alcohol	I-P	NOUN	B
dependence	I-P	NOUN	I
.	I-P	PUNCT	O


Contact	O	NOUN	B
lens	O	NOUN	I
lipid	O	NOUN	O
spoliation	O	NOUN	O
of	O	ADP	O
hydrogel	O	NOUN	B
and	O	CCONJ	O
silicone	O	NOUN	B
hydrogel	O	NOUN	B
lenses	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
measure	O	VERB	B
contact	B-I	NOUN	B
lens	I-I	NOUN	I
lipid	I-I	NOUN	O
spoliation	I-I	NOUN	O
of	I-I	ADP	O
silicone	I-I	NOUN	B
hydrogel	I-I	NOUN	O
PureVision	I-I	PROPN	B
(	I-I	PUNCT	O
balafilcon	I-I	NOUN	B
A	I-I	NOUN	I
)	I-I	PUNCT	O
and	I-I	CCONJ	O
hydrogel	I-I	PROPN	B
Acuvue	I-I	PROPN	I
2	I-I	NUM	I
(	I-I	PUNCT	O
etafilcon	I-I	PROPN	B
A	I-I	NOUN	O
)	I-I	PUNCT	O
contact	I-I	NOUN	B
lenses	I-I	NOUN	I
worn	I-P	VERB	B
for	I-P	ADP	O
10	I-P	NUM	O
hours	I-P	NOUN	O
single	I-P	ADJ	O
use	I-P	NOUN	O
(	I-P	PUNCT	O
DD	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
7	I-P	NUM	O
days	I-P	NOUN	B
of	I-P	ADP	O
extended	I-P	VERB	B
wear	I-P	NOUN	O
(	I-P	PUNCT	O
EW	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
Two	B-P	NUM	O
similar	I-P	ADJ	O
study	I-P	NOUN	B
populations	I-P	NOUN	I
(	I-P	PUNCT	O
DD	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
55	I-P	NUM	O
;	I-P	PUNCT	O
EW	I-P	PROPN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
53	I-P	NUM	O
)	I-P	PUNCT	O
,	O	PUNCT	O
were	O	AUX	O
enrolled	O	VERB	O
at	O	ADP	O
four	B-P	NUM	O
study	I-P	NOUN	B
sites	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
each	O	DET	O
population	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
bilateral	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
(	O	PUNCT	O
lens	O	NOUN	B
material	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
subject-masked	O	ADJ	B
experimental	O	ADJ	O
design	O	NOUN	O
was	O	AUX	O
followed	O	VERB	O
.	O	PUNCT	O


Worn	O	NOUN	B
contact	O	NOUN	I
lenses	O	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
lipid	O	NOUN	B
uptake	O	NOUN	I
using	O	VERB	O
high-performance	O	ADJ	B
liquid	B-I	ADJ	I
chromatography	I-I	NOUN	I
by	O	ADP	O
two	O	NUM	O
laboratories	O	NOUN	B
:	O	PUNCT	O
Alcon	O	PROPN	B
Laboratories	O	PROPN	I
(	O	PUNCT	O
right	O	ADJ	B
lens	O	NOUN	I
total	O	ADJ	I
uptake	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
OTG	O	PROPN	B
Research	O	PROPN	I
&	O	CCONJ	I
Consultancy	O	PROPN	I
(	O	PUNCT	O
left	O	VERB	B
lens	O	NOUN	I
total	O	ADJ	O
uptake	O	NOUN	B
and	O	CCONJ	O
individual	O	ADJ	B
lipid	O	NOUN	B
classes	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Lipid	B-OUT	NOUN	B
uptake	I-OUT	NOUN	B
was	O	AUX	O
different	O	ADJ	O
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
materials	O	NOUN	B
:	O	PUNCT	O
total	B-OUT	ADJ	B
lipid	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.007	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
cholesterol	B-OUT	NOUN	B
esters	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
cholesterol	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
EW	O	PROPN	B
only	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
triglycerides/phospholipids	B-OUT	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
higher	O	ADJ	O
for	O	ADP	O
balafilcon	O	NOUN	B
A	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
fatty	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.0025	O	NUM	O
EW	O	NOUN	B
only	O	ADV	O
)	O	PUNCT	O
was	O	AUX	O
higher	O	ADJ	O
for	O	ADP	O
etafilcon	O	ADJ	B
A	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
ratio	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
extracted	I-OUT	VERB	O
lipids	I-OUT	NOUN	B
was	O	AUX	O
also	O	ADV	O
different	O	ADJ	O
:	O	PUNCT	O
higher	O	ADJ	O
percentages	O	NOUN	B
of	O	ADP	O
triglycerides/phospholipids	B-OUT	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
cholesterol	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
EW	O	PROPN	B
only	O	ADV	O
)	O	PUNCT	O
for	O	ADP	O
balafilcon	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
higher	O	ADJ	O
percentages	O	NOUN	B
of	O	ADP	O
fatty	B-OUT	ADJ	B
acids/di-	I-OUT	ADJ	I
and	I-OUT	CCONJ	O
monoglycerides	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.014	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
etafilcon	O	ADJ	B
A	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Total	B-OUT	ADJ	B
lipid	I-OUT	NOUN	B
uptake	I-OUT	NOUN	O
was	O	AUX	O
highly	O	ADV	O
material	O	ADJ	B
dependent	O	ADJ	O
.	O	PUNCT	O


Both	O	DET	O
laboratories	O	NOUN	B
measured	O	VERB	B
a	O	DET	O
greater	O	ADJ	O
uptake	B-OUT	NOUN	B
of	I-OUT	ADP	O
lipids	I-OUT	NOUN	B
by	O	ADP	O
the	O	DET	O
silicone	O	NOUN	B
hydrogel	O	NOUN	B
than	O	ADP	O
the	O	DET	O
hydrogel	O	NOUN	B
material	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
difference	O	NOUN	O
that	O	PRON	O
was	O	AUX	O
evident	O	ADJ	O
after	O	ADP	O
only	O	ADV	O
10	O	NUM	O
hours	O	NOUN	O
of	O	ADP	O
DD	O	NOUN	B
.	O	PUNCT	O


Total	B-OUT	ADJ	O
lipid	I-OUT	NOUN	B
uptake	I-OUT	NOUN	O
was	O	AUX	O
greater	O	ADJ	O
after	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
EW	O	PROPN	B
compared	O	VERB	B
with	O	ADP	O
10	O	NUM	O
hours	O	NOUN	O
of	O	ADP	O
DD	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
interest	O	NOUN	O
for	O	ADP	O
contact	O	NOUN	B
lens	O	NOUN	I
spoliation	O	NOUN	O
and	O	CCONJ	O
its	O	PRON	O
avoidance	O	NOUN	B
was	O	AUX	O
the	O	DET	O
differential	O	ADJ	B
lipid	O	NOUN	B
uptake	O	NOUN	I
profile	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
material	O	ADJ	B
selectivity	O	NOUN	B
.	O	PUNCT	O


Whereas	O	SCONJ	O
greater	O	ADJ	O
differentiation	O	NOUN	B
between	O	ADP	O
materials	O	NOUN	B
was	O	AUX	O
possible	O	ADJ	O
after	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
EW	O	PROPN	B
for	O	ADP	O
each	O	DET	O
material	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
lipid	O	NOUN	B
uptake	O	NOUN	I
profile	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
for	O	ADP	O
DD	O	NOUN	B
and	O	CCONJ	O
EW	O	PROPN	B
,	O	PUNCT	O
indicating	O	VERB	O
a	O	DET	O
greater	O	ADJ	O
material	O	NOUN	B
effect	O	NOUN	O
than	O	ADP	O
a	O	DET	O
wear	O	NOUN	O
modality	O	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


Iron	B-I	NOUN	B
supplementation	I-I	NOUN	I
improves	O	VERB	O
energetic	O	ADJ	B
efficiency	O	NOUN	I
in	O	ADP	O
iron-depleted	B-P	ADJ	B
female	I-P	ADJ	B
rowers	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	NOUN	B
Studies	O	NOUN	I
in	O	ADP	O
both	O	DET	O
animals	O	NOUN	B
and	O	CCONJ	O
humans	O	NOUN	B
show	O	VERB	O
a	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
iron	O	NOUN	B
depletion	O	NOUN	I
without	O	ADP	O
anemia	O	NOUN	B
(	O	PUNCT	O
IDNA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
physical	O	ADJ	B
performance	O	NOUN	I
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
their	O	PRON	O
sedentary	O	ADJ	B
counterparts	O	NOUN	I
,	O	PUNCT	O
female	B-P	ADJ	B
endurance	I-P	NOUN	B
athletes	I-P	NOUN	B
are	O	AUX	O
at	O	ADP	O
greater	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
IDNA	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
consequences	O	NOUN	B
relevant	O	ADJ	I
to	O	PART	O
endurance	O	NOUN	B
athletes	O	NOUN	B
include	O	VERB	O
reduced	O	VERB	B
work	O	NOUN	O
capacity	O	NOUN	B
and	O	CCONJ	O
energetic	O	ADJ	B
efficiency	O	NOUN	I
(	O	PUNCT	O
EF	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
placebo-controlled	B-I	ADJ	I
trial	O	NOUN	I
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
iron	B-I	NOUN	B
(	I-I	PUNCT	O
Fe	I-I	NOUN	B
)	I-I	PUNCT	O
supplementation	I-I	NOUN	B
on	O	ADP	O
Fe	O	PROPN	B
status	O	NOUN	B
and	O	CCONJ	O
performance	O	NOUN	B
in	O	ADP	O
nonanemic	B-P	ADJ	B
female	I-P	ADJ	B
rowers	I-P	NOUN	B
during	I-P	ADP	O
training	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
At	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
a	O	DET	O
training	O	NOUN	B
season	O	NOUN	I
,	O	PUNCT	O
40	B-P	NUM	O
rowers	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
100	B-I	NUM	O
mg·d	I-I	NOUN	B
FeSO4	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
21	O	NUM	O
)	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
19	O	NUM	O
)	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
double-blind	O	ADJ	B
design	O	NOUN	B
.	O	PUNCT	O


Thirty-one	O	NUM	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
15	B-I	NUM	O
Fe	I-I	PROPN	B
,	I-I	PUNCT	O
16	I-I	NUM	O
placebo	I-I	NOUN	B
)	I-I	PUNCT	O
completed	O	VERB	O
the	O	DET	O
6-wk	O	ADJ	O
trial	O	NOUN	B
.	B-OUT	PUNCT	O


Fe	B-OUT	ADJ	B
status	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
hemoglobin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
serum	I-OUT	NOUN	B
ferritin	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
soluble	I-OUT	ADJ	B
transferrin	I-OUT	NOUN	B
receptor	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
composition	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
laboratory	I-OUT	NOUN	B
tests	I-OUT	NOUN	I
of	I-OUT	ADP	O
physical	I-OUT	ADJ	B
performance	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
4-km	I-OUT	ADJ	O
time	I-OUT	NOUN	B
trial	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
V˙O2peak	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
energetic	I-OUT	ADJ	B
EF	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
lactate	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
training	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Rowers	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
increased	O	VERB	B
their	B-OUT	PRON	O
fat-free	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
V˙O2peak	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
training	O	NOUN	B
.	O	PUNCT	O


Multiple	O	ADJ	B
regression	O	NOUN	I
analyses	O	NOUN	I
revealed	O	VERB	O
improvements	O	NOUN	B
in	B-OUT	ADP	O
Fe	I-OUT	PROPN	B
stores	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
serum	I-OUT	NOUN	B
ferritin	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
in	O	ADP	O
the	O	DET	O
Fe	O	NOUN	B
treatment	O	NOUN	B
group	O	NOUN	I
after	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
baseline	O	NOUN	B
Fe	O	PROPN	B
stores	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.07	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Rowers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Fe	O	PROPN	B
group	O	NOUN	B
had	O	AUX	O
slower	O	ADJ	O
lactate	O	NOUN	B
response	O	NOUN	I
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
time	O	NOUN	B
trial	O	NOUN	I
and	O	CCONJ	O
after	O	ADP	O
5	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
recovery	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
showed	O	VERB	O
greater	O	ADJ	O
improvements	O	NOUN	B
in	B-OUT	ADP	O
energy	I-OUT	NOUN	B
expenditure	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
for	O	ADP	O
group-by	O	NOUN	O
time	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
energetic	I-OUT	ADJ	B
EF	O	NOUN	I
compared	O	VERB	O
with	O	ADP	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
for	O	ADP	O
group-by	O	NOUN	O
time	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	B-P	NOUN	O
Female	I-P	ADJ	B
rowers	I-P	NOUN	B
with	I-P	ADP	O
depleted	I-P	VERB	B
Fe	O	PROPN	B
stores	O	NOUN	B
who	O	PRON	O
consumed	O	VERB	O
supplemental	O	NOUN	O
Fe	O	PROPN	B
during	O	ADP	O
training	O	NOUN	B
improved	O	VERB	B
their	B-OUT	PRON	O
Fe	I-OUT	ADJ	B
status	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
energetic	I-OUT	ADJ	B
EF	O	NOUN	I
during	O	ADP	O
endurance	O	NOUN	B
exercise	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
important	O	ADJ	O
for	B-P	ADP	O
endurance	I-P	NOUN	B
athletes	I-P	NOUN	B
whose	O	DET	O
dietary	O	ADJ	B
patterns	O	NOUN	I
and	O	CCONJ	O
physical	O	ADJ	B
training	O	NOUN	I
increase	O	VERB	B
their	O	PRON	O
risk	O	NOUN	B
of	B-OUT	ADP	O
IDNA	I-OUT	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
Fe	O	ADJ	B
supplementation	O	NOUN	B
may	O	AUX	O
maximize	O	VERB	O
the	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
endurance	O	NOUN	B
training	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Tension-free	O	ADJ	B
laparoscopic	O	NOUN	I
versus	O	CCONJ	I
open	B-I	ADJ	I
inguinal	I-I	ADJ	I
hernia	I-I	NOUN	I
repair	I-I	NOUN	I
]	I-I	PUNCT	O
.	O	PUNCT	O


AIM	O	NOUN	B
During	O	ADP	O
the	O	DET	O
last	O	ADJ	O
decade	O	NOUN	O
laparoscopic	O	ADJ	B
techniques	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
applied	O	VERB	O
to	O	PART	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
inguinal	B-OUT	ADJ	B
hernia	I-OUT	NOUN	I
to	O	PART	O
combine	O	VERB	O
tension-free	O	ADJ	B
technique	O	NOUN	I
,	O	PUNCT	O
esthetic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
functional	O	ADJ	B
benefits	O	NOUN	B
of	O	ADP	O
mini-invasive	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


Anyway	O	INTJ	O
controversy	O	NOUN	O
persists	O	VERB	O
regarding	O	VERB	O
the	O	DET	O
most	O	ADV	O
effective	B-OUT	ADJ	B
inguinal	O	ADJ	B
hernia	O	NOUN	I
repair	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
open	O	ADJ	B
technique	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
laparoscopic	O	ADJ	B
approach	O	NOUN	I
concerning	O	VERB	O
:	O	PUNCT	O
complications	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
recurrences	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
recovery	I-OUT	NOUN	B
time	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
return	I-OUT	VERB	B
to	I-OUT	ADP	I
usual	I-OUT	ADJ	I
activity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
randomized	B-P	ADJ	B
prospective	I-P	ADJ	I
analysis	I-P	NOUN	I
of	I-P	ADP	O
121	I-P	NUM	O
consecutive	I-P	ADJ	B
inguinal	I-I	ADJ	B
hernia	I-I	NOUN	I
repairs	I-I	NOUN	I
was	I-P	AUX	O
performed	I-P	VERB	O
over	I-P	ADP	O
a	I-P	DET	O
12-month	I-P	ADJ	O
period	I-P	NOUN	B
.	I-P	PUNCT	O


Male	B-P	NOUN	B
well-informed	I-P	ADJ	O
patients	I-P	NOUN	B
with	I-P	ADP	O
primary	I-P	ADJ	B
monolateral	I-P	ADJ	I
inguinal	I-P	ADJ	I
hernia	I-P	NOUN	I
(	I-P	PUNCT	O
ASA	I-P	NOUN	B
I-II	I-P	NUM	I
)	I-P	PUNCT	O
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
2	B-P	NUM	O
groups	I-P	NOUN	B
and	O	CCONJ	O
consecutively	O	ADV	O
treated	O	VERB	B
;	O	PUNCT	O
group	B-P	NOUN	B
A	I-P	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
laparoscopic	B-I	ADJ	B
transabdominal	I-I	ADJ	I
preperitoneal	I-I	ADJ	I
approach	I-I	NOUN	I
(	I-P	PUNCT	O
TAPP	I-P	NOUN	B
)	I-P	PUNCT	O
(	I-P	PUNCT	O
median	I-P	ADJ	B
age	I-P	NOUN	B
47+/-7	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
57	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
group	I-P	NOUN	B
B	I-P	NOUN	I
with	O	ADP	O
open	B-I	ADJ	O
mesh	I-I	NOUN	O
herniorrhaphy	I-I	NOUN	B
(	I-P	PUNCT	O
45+/-6	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
64	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


RESULTS	O	VERB	O
Complication	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
5.26	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
none	O	NOUN	O
needed	O	VERB	O
conversion	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
4.68	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
complications	B-OUT	NOUN	B
were	O	AUX	O
considered	O	VERB	O
minor	O	ADJ	B
.	O	PUNCT	O


No	O	DET	O
recurrences	B-OUT	NOUN	O
were	O	AUX	O
observed	O	VERB	O
over	O	ADP	O
a	O	DET	O
12-month	O	ADJ	O
follow-up	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Post-operative	B-OUT	ADJ	B
hospital	I-OUT	NOUN	B
stay	I-OUT	VERB	I
and	I-OUT	CCONJ	O
return	I-OUT	VERB	B
to	I-OUT	ADP	I
activity	I-OUT	NOUN	I
show	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	B
.	O	PUNCT	O


Median	B-OUT	ADJ	B
post-hospital	I-OUT	ADJ	B
stay	I-OUT	NOUN	I
was	O	AUX	O
1.7	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
group	O	NOUN	B
A	O	NOUN	O
while	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
longer	O	ADJ	O
(	O	PUNCT	O
2.9	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
.	O	PUNCT	O


Significant	O	ADJ	O
difference	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
convalescence	I-OUT	NOUN	B
too	O	ADV	O
(	O	PUNCT	O
group	O	NOUN	B
A	O	DET	O
9.3+/-7.2	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
12.1+/-7	O	NOUN	I
.	O	PUNCT	O


1	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
experience	O	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
if	O	SCONJ	O
a	O	DET	O
longer	O	X	O
follow-up	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
validity	O	NOUN	B
of	O	ADP	O
laparoscopic	B-I	ADJ	B
approach	I-I	NOUN	I
to	I-I	ADP	O
inguinal	I-I	ADJ	B
hernia	I-I	NOUN	I
is	O	AUX	O
confirmed	O	VERB	O
.	O	PUNCT	O


General	O	ADJ	B
anesthesia	O	NOUN	I
and	O	CCONJ	O
higher	O	ADJ	B
costs	O	NOUN	B
are	O	AUX	O
reasonable	O	ADJ	O
compromises	O	NOUN	O
for	O	ADP	O
a	O	DET	O
shorter	O	ADJ	B
period	B-OUT	NOUN	B
of	I-OUT	ADP	O
discomfort	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
low	I-P	ADJ	B
ASA	I-P	NOUN	O
index	I-P	NOUN	O
and	I-P	CCONJ	O
busy	I-P	ADJ	B
job/sport	I-P	NOUN	I
activity	I-P	NOUN	I
.	I-P	PUNCT	O


Manuka	B-I	NOUN	B
honey-impregnated	I-I	ADJ	O
dressings	I-I	NOUN	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
neuropathic	B-P	ADJ	B
diabetic	I-P	ADJ	I
foot	I-P	NOUN	B
ulcers	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
manuka	B-I	ADJ	B
honey-impregnated	I-I	ADJ	I
dressings	I-I	NOUN	I
(	I-I	PUNCT	O
MHID	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
the	O	DET	O
healing	B-P	NOUN	B
of	I-P	ADP	O
neuropathic	I-P	ADJ	B
diabetic	I-P	ADJ	I
foot	I-P	NOUN	I
ulcers	I-P	NOUN	I
(	I-P	PUNCT	O
NDFU	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
63	B-P	NUM	O
Caucasians	I-P	PROPN	B
,	I-P	PUNCT	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetic	I-P	ADJ	I
patients	I-P	NOUN	B
followed	I-P	VERB	B
up	I-P	ADP	I
in	I-P	ADP	O
the	I-P	DET	O
diabetic	I-P	ADJ	B
foot	I-P	NOUN	O
outpatient	I-P	ADJ	O
clinic	I-P	NOUN	O
comprised	O	VERB	O
the	O	DET	O
study	O	NOUN	B
population	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
in	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
group	O	NOUN	B
I	O	NOUN	I
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
MHID	B-I	NOUN	B
and	O	CCONJ	O
group	O	NOUN	B
II	O	NUM	I
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
conventional	B-I	ADJ	B
dressings	I-I	NOUN	I
(	I-I	PUNCT	O
CD	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
up	O	ADP	O
on	O	ADP	O
a	O	DET	O
weekly	O	ADJ	B
basis	O	NOUN	O
for	O	ADP	O
16	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Mean	B-OUT	VERB	B
healing	I-OUT	NOUN	I
time	I-OUT	NOUN	O
was	O	AUX	O
31	O	NUM	O
±	O	NOUN	O
4	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
I	O	NUM	I
versus	O	CCONJ	O
43	O	NUM	O
±	O	NOUN	O
3	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0·05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
group	O	NOUN	B
I	O	NOUN	I
patients	O	NOUN	B
78·13	O	ADJ	O
%	O	NOUN	O
of	O	ADP	O
ulcers	O	NOUN	B
became	O	VERB	O
sterile	O	ADJ	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
week	O	NOUN	B
versus	O	CCONJ	O
35·5	O	ADJ	O
%	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
patients	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
corresponding	O	ADJ	O
percentages	O	NOUN	B
for	O	ADP	O
weeks	O	NOUN	B
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
were	O	AUX	O
15·62	O	ADJ	O
%	O	NOUN	O
versus	O	CCONJ	O
38·7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
6·25	O	ADJ	O
%	O	NOUN	O
versus	O	CCONJ	O
12·9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
0	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
12·9	O	NUM	O
%	O	NOUN	O
respectively	B-OUT	ADV	O
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
percent	I-OUT	NOUN	O
of	I-OUT	ADP	O
ulcers	I-OUT	NOUN	B
healed	I-OUT	VERB	B
did	I-OUT	AUX	O
not	I-OUT	PART	O
differ	I-OUT	VERB	O
significantly	I-OUT	ADV	O
between	O	ADP	O
groups	O	NOUN	B
(	O	PUNCT	O
97	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
MHID	O	NOUN	B
and	B-I	CCONJ	O
90	I-I	NUM	O
%	I-I	NOUN	O
for	I-I	ADP	O
CD	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


MHID	O	NOUN	B
represent	O	VERB	O
an	O	DET	O
effective	O	ADJ	B
treatment	B-P	NOUN	B
for	O	ADP	O
NDFU	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
significant	B-OUT	ADJ	O
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
time	I-OUT	NOUN	B
of	I-OUT	ADP	O
healing	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
rapid	I-OUT	ADJ	O
disinfection	I-OUT	NOUN	B
of	O	ADP	O
ulcers	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
supplemental	O	ADJ	B
arginine	B-I	NOUN	B
to	O	PART	O
enhance	O	VERB	O
immune	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
persons	B-P	NOUN	B
with	I-P	ADP	O
HIV/AIDS	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
collected	O	VERB	O
preliminary	O	ADJ	B
data	O	NOUN	B
on	O	ADP	O
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
supplemental	O	ADJ	B
arginine	B-I	NOUN	B
to	O	PART	O
improve	O	VERB	B
natural	O	ADJ	B
killer	O	NOUN	I
cell	O	NOUN	I
cytotoxicity	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
persons	B-P	NOUN	B
with	I-P	ADP	O
human	I-P	ADJ	B
immunodeficiency	I-P	NOUN	I
virus	I-P	NOUN	I
(	I-P	PUNCT	O
HIV	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
acquired	I-P	VERB	B
immunodeficiency	I-P	NOUN	I
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
AIDS	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
pilot	O	NOUN	O
study	O	NOUN	O
in	O	ADP	O
an	O	DET	O
academic	O	ADJ	B
medical	O	ADJ	I
center-based	O	ADJ	O
infectious	O	ADJ	O
disease	O	NOUN	O
clinic	O	NOUN	O
,	O	PUNCT	O
11	B-P	NUM	O
clinically	I-P	ADV	B
stable	I-P	ADJ	I
,	I-P	PUNCT	O
HIV-infected	I-P	ADJ	B
adults	I-P	NOUN	B
had	I-P	AUX	O
been	I-P	AUX	O
treated	I-P	VERB	B
with	I-P	ADP	I
highly	I-P	ADV	O
active	I-P	ADJ	B
,	I-P	PUNCT	O
antiretroviral	I-I	ADJ	B
therapy	I-I	NOUN	I
and	I-P	CCONJ	O
had	I-P	AUX	O
HIV	I-P	NOUN	B
plasma	I-P	NOUN	O
RNA	I-P	NOUN	B
levels	I-P	NOUN	B
of	I-P	ADP	O
less	I-P	ADJ	O
than	I-P	ADP	O
10	I-P	NUM	O
000	I-P	NUM	O
copies/mL	I-P	NOUN	O
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
19.6	B-I	NUM	O
g	I-I	NOUN	O
of	I-I	ADP	O
arginine/d	I-I	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
14	O	NUM	O
d.	O	NOUN	O
Plasma	B-OUT	NOUN	B
HIV	I-OUT	NOUN	B
RNA	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
neuropsychologic	I-OUT	ADJ	B
functioning	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
self-reported	I-OUT	ADJ	B
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
safety	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	O
by	O	ADP	O
natural	O	ADJ	B
killer	O	NOUN	I
cell	O	NOUN	I
cytotoxicity	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
None	O	NOUN	O
of	O	ADP	O
the	O	DET	O
participants	O	NOUN	B
experienced	O	VERB	O
any	O	DET	O
adverse	B-OUT	ADJ	B
clinical	I-OUT	ADJ	I
,	I-OUT	PUNCT	O
virologic	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
neuropsychologic	I-OUT	ADJ	B
events	I-OUT	NOUN	I
that	O	PRON	O
necessitated	O	VERB	O
withdrawal	O	NOUN	B
from	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
arginine-supplemented	B-I	ADJ	B
group	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
mean	B-OUT	ADJ	O
natural	I-OUT	ADJ	O
killer	I-OUT	NOUN	O
cell	I-OUT	NOUN	O
cytotoxicity	I-OUT	NOUN	B
increase	O	NOUN	B
of	O	ADP	O
18.9	O	NUM	O
lytic	O	ADJ	B
units	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
showed	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
0.3	O	NUM	O
lytic	O	ADJ	B
units	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
difference	O	NOUN	O
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.79	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Short-term	O	ADJ	B
arginine	B-I	NOUN	B
supplementation	O	NOUN	B
is	O	AUX	O
safe	O	ADJ	O
for	O	ADP	O
persons	B-P	NOUN	B
with	I-P	ADP	O
HIV/AIDS	I-P	NOUN	B
.	I-P	PUNCT	O


Additional	O	ADJ	O
studies	O	NOUN	B
with	O	ADP	O
larger	O	ADJ	O
samples	O	NOUN	B
and	O	CCONJ	O
longer	O	ADJ	B
periods	O	NOUN	B
are	O	AUX	O
warranted	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
arginine	O	NOUN	B
supplementation	O	NOUN	B
on	O	ADP	O
other	O	ADJ	O
indices	O	NOUN	B
of	O	ADP	O
immune	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
on	O	ADP	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
intercurrent	O	ADJ	B
illnesses	O	NOUN	I
.	O	PUNCT	O


Transitions	O	NOUN	B
during	O	ADP	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
cocaine-abusing	B-P	ADJ	B
homeless	I-P	ADJ	B
persons	I-P	NOUN	B
:	I-P	PUNCT	O
establishing	O	VERB	O
abstinence	O	NOUN	B
,	O	PUNCT	O
lapse	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
relapse	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
reestablishing	O	VERB	B
abstinence	O	NOUN	B
.	O	PUNCT	O


Data	O	NOUN	B
are	O	AUX	O
reported	O	VERB	O
on	O	ADP	O
drug	O	NOUN	B
use	O	NOUN	I
among	O	ADP	O
cocaine-dependent	B-P	ADJ	B
homeless	I-P	ADJ	B
persons	I-P	NOUN	O
who	I-P	PRON	O
participated	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
clinical	I-P	ADJ	B
trial	I-P	NOUN	I
that	I-P	PRON	O
compared	I-P	VERB	B
day	I-I	NOUN	B
treatment	I-I	NOUN	B
only	I-I	ADV	O
(	I-P	PUNCT	O
DT	I-P	PROPN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
69	I-P	NUM	O
)	I-P	PUNCT	O
with	I-P	ADP	O
day	I-I	NOUN	B
treatment	I-I	NOUN	B
plus	I-I	CCONJ	O
abstinent-contingent	I-I	ADJ	B
housing	I-I	NOUN	B
and	I-I	CCONJ	O
work	I-I	NOUN	B
(	I-P	PUNCT	O
DT+	I-P	NOUN	B
,	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
72	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Drug	B-OUT	NOUN	B
use	I-OUT	NOUN	I
was	I-OUT	AUX	O
measured	I-OUT	VERB	B
with	I-OUT	ADP	O
multiple	I-OUT	ADJ	B
weekly	I-OUT	ADJ	B
urine	I-OUT	NOUN	B
toxicologies	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
DT	O	PROPN	B
participants	O	NOUN	B
,	O	PUNCT	O
more	O	ADV	O
DT+	O	ADJ	B
participants	O	NOUN	B
established	O	VERB	O
abstinence	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
maintained	I-OUT	ADJ	B
abstinence	I-OUT	NOUN	B
for	I-OUT	ADP	O
longer	I-OUT	ADJ	O
durations	I-OUT	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
marginally	O	ADV	O
significantly	O	ADV	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
lapse	B-OUT	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
significantly	O	ADV	O
less	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
relapse	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Of	O	ADP	O
all	O	DET	O
participants	O	NOUN	B
who	O	PRON	O
established	O	VERB	O
abstinence	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
relapsed	O	VERB	B
,	O	PUNCT	O
DT+	O	DET	B
participants	O	NOUN	B
relapsed	O	VERB	B
later	O	ADV	O
and	O	CCONJ	O
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
reestablish	B-OUT	VERB	B
abstinence	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
analyses	O	NOUN	B
yield	O	VERB	O
information	O	NOUN	B
on	O	ADP	O
the	O	DET	O
processes	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
manner	O	NOUN	O
in	O	ADP	O
which	O	DET	O
drug	O	NOUN	B
use	O	VERB	I
changes	O	NOUN	I
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
abstinent-contingent	B-I	ADJ	B
housing	I-I	NOUN	B
and	I-I	CCONJ	O
work	I-I	NOUN	B
.	I-I	PUNCT	O


Asthma	O	NOUN	B
:	O	PUNCT	O
communication	O	NOUN	B
between	O	ADP	O
hospital	O	NOUN	B
and	O	CCONJ	O
general	B-P	ADJ	B
practitioners	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
whether	O	SCONJ	O
efforts	O	NOUN	O
to	O	PART	O
actively	O	ADV	O
involve	O	VERB	O
General	B-P	PROPN	B
Practitioners	I-P	PROPN	I
(	I-P	PUNCT	O
GPs	I-P	NOUN	B
)	I-P	PUNCT	O
in	O	ADP	O
the	O	DET	O
postdischarge	O	ADJ	B
care	O	NOUN	I
of	O	ADP	O
their	O	PRON	O
paediatric	B-P	ADJ	B
asthma	I-P	NOUN	I
patients	I-P	NOUN	B
improved	O	VERB	O
their	O	PRON	O
satisfaction	B-OUT	NOUN	B
with	I-OUT	ADP	O
communication	I-OUT	NOUN	B
with	I-OUT	ADP	O
hospital	I-OUT	NOUN	B
staff	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


METHODOLOGY	O	ADJ	O
Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
involving	O	VERB	O
60	B-P	NUM	O
patients	I-P	NOUN	B
admitted	I-P	VERB	B
to	I-P	ADP	O
the	I-P	DET	O
Royal	I-P	PROPN	B
Children	I-P	PROPN	I
's	I-P	PART	I
Hospital	I-P	PROPN	I
,	I-P	PUNCT	O
Melbourne	I-P	PROPN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
acute	I-P	ADJ	B
asthma	I-P	NOUN	I
and	I-P	CCONJ	O
an	I-P	DET	O
identifiable	I-P	ADJ	O
GP	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
GPs	B-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
intervention	I-P	NOUN	B
patients	I-P	NOUN	B
were	O	AUX	O
telephoned	O	VERB	B
during	O	ADP	O
the	O	DET	O
admission	O	NOUN	B
.	O	PUNCT	O


Intervention	O	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
GPs	O	NOUN	B
received	O	VERB	O
printed	B-I	ADJ	B
information	I-I	NOUN	I
detailing	I-I	VERB	O
the	I-I	DET	O
care	I-I	NOUN	B
the	I-I	DET	O
patient	I-I	NOUN	B
received	I-I	VERB	O
in	I-I	ADP	O
hospital	I-I	NOUN	B
and	I-I	CCONJ	O
the	I-I	DET	O
recommended	I-I	VERB	B
postdischarge	I-I	ADJ	B
care	I-I	NOUN	I
,	I-I	PUNCT	O
as	I-I	ADV	O
well	I-I	ADV	O
as	I-I	ADP	O
standardized	I-I	ADJ	B
educational	I-I	ADJ	B
booklets	I-I	NOUN	I
about	I-I	ADP	O
asthma	I-I	NOUN	B
.	I-I	PUNCT	O


Follow-up	B-I	NOUN	B
appointments	I-I	NOUN	B
were	O	AUX	O
made	O	VERB	O
for	O	ADP	O
intervention	B-I	NOUN	B
patients	O	NOUN	B
to	O	PART	O
attend	O	VERB	B
their	O	PRON	O
GPs	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
GPs	B-P	NOUN	B
of	I-P	ADP	O
intervention	I-P	NOUN	B
patients	I-P	NOUN	B
were	O	AUX	O
more	O	ADV	O
satisfied	B-OUT	ADJ	O
when	O	SCONJ	O
compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
GPs	O	NOUN	B
receiving	O	VERB	O
a	O	DET	O
standard	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
communication	O	NOUN	B
(	O	PUNCT	O
96.4	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
48.3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
GPs	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
described	O	VERB	O
the	O	DET	O
communication	O	NOUN	B
as	O	ADP	O
good	O	ADJ	O
or	O	CCONJ	O
extremely	O	ADV	O
good	O	ADJ	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
GPs	O	NOUN	B
believed	B-OUT	VERB	O
they	I-OUT	PRON	O
were	I-OUT	AUX	O
more	I-OUT	ADV	O
involved	I-OUT	VERB	O
after	I-OUT	ADP	O
discharge	I-OUT	NOUN	B
(	O	PUNCT	O
75.0	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
44.8	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
greater	O	ADJ	O
understanding	B-OUT	NOUN	O
of	I-OUT	ADP	O
their	I-OUT	PRON	O
patient	I-OUT	NOUN	B
's	I-OUT	PART	I
hospitalisation	I-OUT	NOUN	B
(	O	PUNCT	O
96.4	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
62.1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
noted	O	VERB	O
despite	O	SCONJ	O
there	O	PRON	O
being	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
follow-up	I-OUT	ADJ	B
attendance	I-OUT	NOUN	B
with	O	ADP	O
GPs	O	NOUN	B
for	O	ADP	O
intervention	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
85.7	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
72.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Qualitative	O	ADJ	B
data	O	NOUN	O
supported	O	VERB	O
these	O	DET	O
findings	O	NOUN	B
with	O	ADP	O
GPs	O	NOUN	B
expressing	O	VERB	B
approval	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
intervention	I-OUT	NOUN	B
used	I-OUT	VERB	O
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
Efforts	O	NOUN	O
to	O	PART	O
actively	O	ADV	O
involve	O	VERB	O
GPs	B-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
postdischarge	I-P	ADJ	B
care	I-P	NOUN	I
of	I-P	ADP	O
their	I-P	PRON	O
paediatric	I-P	ADJ	B
patients	I-P	NOUN	I
with	I-P	ADP	O
asthma	I-P	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
marked	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
satisfaction	B-OUT	NOUN	B
with	I-OUT	ADP	O
the	I-OUT	DET	O
communication	I-OUT	NOUN	B
with	I-OUT	ADP	O
medical	I-OUT	ADJ	B
staff	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
Royal	O	PROPN	B
Children	O	PROPN	I
's	O	PART	I
Hospital	O	PROPN	I
,	O	PUNCT	O
Melbourne	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
had	O	AUX	O
insufficient	O	ADJ	B
power	O	NOUN	O
to	O	PART	O
demonstrate	O	VERB	O
a	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
morbidity	O	NOUN	B
.	O	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
relapsed	I-P	ADJ	B
follicular	I-P	ADJ	B
lymphoma	I-P	NOUN	I
treated	O	VERB	B
with	O	ADP	I
rituximab	B-I	NOUN	B
versus	I-I	CCONJ	O
tositumomab	I-I	NOUN	B
and	I-I	CCONJ	O
iodine	I-I	NOUN	B
I-131	I-I	NOUN	I
tositumomab	I-I	NOUN	B
.	I-I	PUNCT	O


Persistent	B-P	ADJ	B
phenothiazine	I-P	NOUN	B
dyskinesia	I-P	NOUN	I
treated	O	VERB	B
with	O	ADP	I
tetrabenazine	B-I	NOUN	B
.	I-I	PUNCT	O


Six	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
persistent	I-P	ADJ	B
phenothiazine	I-P	NOUN	B
dyskinesia	I-P	NOUN	I
were	O	AUX	O
treated	O	VERB	B
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
with	O	ADP	O
tetrabenazine	B-I	NOUN	B
100	I-I	NUM	O
mg	I-I	NOUN	O
in	I-I	ADP	O
divided	I-I	ADJ	O
dosage	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
three	O	NUM	O
patients	O	NOUN	B
the	O	DET	O
abnormal	O	ADJ	B
movements	O	NOUN	B
were	O	AUX	O
abolished	O	VERB	B
and	O	CCONJ	O
in	O	ADP	O
two	O	NUM	O
others	O	NOUN	O
there	O	PRON	O
was	O	AUX	O
some	O	DET	O
improvement	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
was	O	AUX	O
no	O	DET	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
achieved	O	VERB	O
with	O	ADP	O
the	O	DET	O
diazepam	B-I	NOUN	B
control	O	NOUN	B
.	O	PUNCT	O


Tetrabenazine	B-I	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
persistent	O	ADJ	B
phenothiazine	O	NOUN	B
dyskinesia	O	NOUN	I
.	O	PUNCT	O


A	B-P	DET	O
randomized	I-P	ADJ	B
trial	I-P	NOUN	I
in	I-P	ADP	O
simultaneous	I-P	ADJ	B
pancreas-kidney	I-I	NOUN	B
transplantation	I-I	NOUN	I
:	I-I	PUNCT	O
portal	I-I	ADJ	B
versus	I-I	CCONJ	O
systemic	I-OUT	ADJ	B
venous	I-OUT	ADJ	B
drainage	I-OUT	NOUN	I
of	I-I	ADP	O
the	I-I	DET	O
pancreas	I-I	NOUN	B
allograft	I-I	NOUN	I
.	I-I	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
acetazolamide	B-I	NOUN	B
on	O	ADP	O
cystoid	B-P	NOUN	B
macular	I-P	NOUN	I
oedema	I-P	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
Behcet	I-P	NOUN	B
's	I-P	PART	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
study	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
acetazolamide	B-I	NOUN	B
on	O	ADP	O
cystoid	O	NOUN	B
macular	O	NOUN	I
oedema	O	NOUN	I
(	O	PUNCT	O
CMO	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
Behcet	I-P	NOUN	B
's	I-P	PART	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
67	I-P	NUM	O
eyes	I-P	NOUN	B
of	I-P	ADP	O
35	I-P	NUM	O
Behcet	I-P	NOUN	B
's	I-P	PART	I
patients	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
,	I-P	PUNCT	O
but	I-P	CCONJ	O
well-controlled	I-P	ADJ	O
uveitis	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
CMO	I-P	PROPN	B
were	O	AUX	O
randomised	O	VERB	B
into	O	ADP	O
a	O	DET	O
double-masked	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
trial	O	NOUN	I
comparing	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
acetazolamide	B-I	NOUN	B
vs	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
an	O	DET	O
initial	O	ADJ	O
4-week	O	ADJ	B
course	O	NOUN	I
of	O	ADP	O
either	O	CCONJ	O
250	O	NUM	O
mg	O	NOUN	O
acetazolamide	B-I	NOUN	B
twice	O	ADV	O
daily	O	ADV	O
(	O	PUNCT	O
b.i.d	O	NOUN	B
.	O	PUNCT	O


)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
4-week	O	ADJ	O
washout	O	NOUN	O
period	O	NOUN	O
.	O	PUNCT	O


They	O	PRON	O
then	O	ADV	O
received	O	VERB	O
a	O	DET	O
4-week	O	ADJ	O
course	O	NOUN	O
of	O	ADP	O
the	O	DET	O
reverse	O	ADJ	B
study	O	NOUN	I
medication	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
fundus	I-OUT	NOUN	B
fluorescein	I-OUT	NOUN	I
angiographic	I-OUT	ADJ	B
findings	I-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
total	O	NOUN	O
,	O	PUNCT	O
29	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
55	I-P	NUM	O
eyes	I-P	NOUN	B
)	I-P	PUNCT	O
completed	I-P	VERB	B
the	I-P	DET	O
trial	I-P	NOUN	B
and	I-P	CCONJ	O
were	I-P	AUX	O
available	I-P	ADJ	O
for	I-P	ADP	O
analysis	I-P	NOUN	B
.	I-P	PUNCT	O


Of	B-P	ADP	O
the	I-P	DET	O
29	I-P	NUM	O
,	I-P	PUNCT	O
16	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
13	I-P	NUM	O
were	I-P	AUX	O
women	I-P	NOUN	B
.	I-P	PUNCT	O


The	B-P	DET	O
age	I-P	NOUN	B
range	I-P	NOUN	O
was	I-P	AUX	O
13-50	I-P	NUM	O
years	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	VERB	O
33.6	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Patients	O	NOUN	B
on	O	ADP	O
acetazolamide	B-I	NOUN	B
showed	O	VERB	O
a	O	DET	O
slightly	O	ADV	O
better	O	ADJ	O
improvement	O	NOUN	B
of	O	ADP	O
angiographic	B-OUT	ADJ	B
signs	I-OUT	NOUN	B
(	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
by	O	ADP	O
one	O	NUM	O
grade	O	NOUN	O
improvement	O	NOUN	B
)	O	PUNCT	O
over	O	ADP	O
that	O	DET	O
of	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
vs	O	CCONJ	O
five	O	NUM	O
eyes	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


They	O	PRON	O
also	O	ADV	O
had	O	AUX	O
less	O	ADJ	O
deterioration	B-OUT	NOUN	B
of	I-OUT	ADP	O
angiographic	I-OUT	ADJ	B
signs	I-OUT	NOUN	B
over	O	ADP	O
that	O	DET	O
of	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
three	O	NUM	O
vs	O	CCONJ	O
seven	O	NUM	O
eyes	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
findings	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P=0.99	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Acetazolamide	B-I	NOUN	B
had	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
effect	O	NOUN	O
(	O	PUNCT	O
P=0.53	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
over	O	ADP	O
that	O	DET	O
of	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
vs	O	CCONJ	O
eight	O	NUM	O
eyes	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
nor	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
deterioration	O	NOUN	B
of	O	ADP	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
(	O	PUNCT	O
three	O	NUM	O
vs	O	CCONJ	O
11	O	NUM	O
eyes	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Despite	O	SCONJ	O
seemingly	O	ADV	O
favourable	O	ADJ	O
results	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
4-week	O	ADJ	O
course	O	NOUN	O
of	O	ADP	O
acetazolamide	B-I	NOUN	B
(	O	PUNCT	O
250	O	NUM	O
mg	O	NOUN	O
b.i.d	O	NOUN	B
.	O	PUNCT	O


)	O	PUNCT	O
has	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
visual	B-OUT	ADJ	B
acuity	I-OUT	NOUN	I
and	O	CCONJ	O
the	O	DET	O
fluorescein	B-OUT	NOUN	B
angiographic	I-OUT	ADJ	I
findings	I-OUT	NOUN	B
in	O	ADP	O
Behcet	B-P	NOUN	B
's	I-P	PART	I
patients	I-P	NOUN	B
with	I-P	ADP	O
CMO	I-P	NOUN	B
.	I-P	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
warfarin	B-I	NOUN	B
and	O	CCONJ	O
aspirin	B-I	NOUN	B
for	O	ADP	O
symptomatic	O	ADJ	B
intracranial	O	ADJ	B
arterial	O	ADJ	I
stenosis	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Atherosclerotic	O	ADJ	B
intracranial	O	ADJ	O
arterial	O	ADJ	B
stenosis	O	NOUN	I
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
stroke	O	NOUN	B
.	O	PUNCT	O


Warfarin	O	NOUN	B
is	O	AUX	O
commonly	O	ADV	O
used	O	VERB	O
in	O	ADP	O
preference	O	NOUN	B
to	O	PART	O
aspirin	O	NOUN	B
for	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
these	O	DET	O
therapies	O	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
randomly	O	ADV	O
assigned	O	VERB	O
patients	B-P	NOUN	B
with	I-P	ADP	O
transient	I-P	ADJ	B
ischemic	I-P	ADJ	I
attack	I-P	NOUN	I
or	I-P	CCONJ	O
stroke	I-P	NOUN	B
caused	I-P	VERB	O
by	I-P	ADP	O
angiographically	I-P	ADV	B
verified	I-P	VERB	O
50	I-P	NUM	O
to	I-P	PART	O
99	I-P	NUM	O
percent	I-P	NOUN	O
stenosis	I-P	NOUN	B
of	I-P	ADP	O
a	I-P	DET	O
major	I-P	ADJ	O
intracranial	I-P	ADJ	B
artery	I-P	NOUN	I
to	O	PART	O
receive	B-I	VERB	O
warfarin	I-I	NOUN	B
(	I-I	PUNCT	O
target	I-I	NOUN	B
international	I-I	ADJ	B
normalized	I-I	VERB	O
ratio	I-I	NOUN	O
,	I-I	PUNCT	O
2.0	I-I	NUM	O
to	I-I	PART	O
3.0	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
aspirin	I-I	NOUN	B
(	I-I	PUNCT	O
1300	I-I	NUM	O
mg	I-I	NOUN	O
per	I-I	ADP	O
day	I-I	NOUN	B
)	I-I	PUNCT	O
in	I-I	ADP	O
a	I-I	DET	O
double-blind	I-I	ADJ	B
,	I-I	PUNCT	O
multicenter	I-I	ADJ	B
clinical	I-I	ADJ	I
trial	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
ischemic	B-OUT	ADJ	B
stroke	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
brain	I-OUT	NOUN	B
hemorrhage	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
death	I-OUT	NOUN	B
from	O	ADP	O
vascular	O	ADJ	B
causes	O	VERB	O
other	O	ADJ	O
than	O	ADP	O
stroke	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
After	B-P	ADP	O
569	I-P	NUM	O
patients	I-P	NOUN	B
had	I-P	AUX	O
undergone	I-P	VERB	O
randomization	I-P	NOUN	B
,	I-P	PUNCT	O
enrollment	I-P	NOUN	B
was	I-P	AUX	O
stopped	I-P	VERB	O
because	I-P	SCONJ	O
of	I-P	ADP	O
concerns	I-P	NOUN	B
about	I-P	ADP	O
the	I-P	DET	O
safety	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
been	I-P	AUX	O
assigned	I-P	VERB	O
to	I-P	PART	O
receive	I-P	VERB	O
warfarin	I-I	NOUN	B
.	I-I	PUNCT	O


During	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
follow-up	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
1.8	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
included	O	VERB	O
death	B-OUT	NOUN	B
(	O	PUNCT	O
4.3	O	NUM	O
percent	O	NOUN	O
in	O	ADP	O
the	O	DET	O
aspirin	B-I	NOUN	B
group	O	NOUN	B
vs.	O	CCONJ	O
9.7	O	NUM	O
percent	O	NOUN	O
in	O	ADP	O
the	O	DET	O
warfarin	O	NOUN	B
group	O	NOUN	I
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
for	O	ADP	O
aspirin	B-I	NOUN	B
relative	O	ADJ	O
to	O	ADP	O
warfarin	B-I	NOUN	B
,	O	PUNCT	O
0.46	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.23	O	NUM	O
to	O	PART	O
0.90	O	NUM	O
;	O	PUNCT	O
P=0.02	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
major	B-OUT	ADJ	O
hemorrhage	I-OUT	NOUN	B
(	O	PUNCT	O
3.2	O	NUM	O
percent	O	NOUN	O
vs.	O	CCONJ	O
8.3	O	NUM	O
percent	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.39	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.18	O	NUM	O
to	O	PART	O
0.84	O	NUM	O
;	O	PUNCT	O
P=0.01	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
myocardial	B-OUT	ADJ	B
infarction	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
sudden	I-OUT	ADJ	B
death	I-OUT	NOUN	I
(	O	PUNCT	O
2.9	O	NUM	O
percent	O	NOUN	O
vs.	O	CCONJ	O
7.3	O	NUM	O
percent	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.40	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.18	O	NUM	O
to	O	PART	O
0.91	O	NUM	O
;	O	PUNCT	O
P=0.02	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
death	I-OUT	NOUN	B
from	O	ADP	O
vascular	O	ADJ	B
causes	O	NOUN	O
was	O	AUX	O
3.2	O	NUM	O
percent	O	NOUN	O
in	O	ADP	O
the	O	DET	O
aspirin	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
5.9	O	NUM	O
percent	O	NOUN	O
in	O	ADP	O
the	O	DET	O
warfarin	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P=0.16	O	NOUN	O
)	O	PUNCT	O
;	O	PUNCT	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
death	I-OUT	NOUN	B
from	O	ADP	O
nonvascular	O	ADJ	B
causes	O	NOUN	O
was	O	AUX	O
1.1	O	NUM	O
percent	O	NOUN	O
and	O	CCONJ	O
3.8	O	NUM	O
percent	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P=0.05	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
occurred	O	VERB	O
in	O	ADP	O
22.1	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
aspirin	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
21.8	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
warfarin	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
1.04	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0.73	O	NUM	O
to	O	PART	O
1.48	O	NUM	O
;	O	PUNCT	O
P=0.83	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Warfarin	B-I	PROPN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
significantly	O	ADV	O
higher	O	ADJ	O
rates	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
and	O	CCONJ	O
provided	O	VERB	O
no	O	DET	O
benefit	O	NOUN	O
over	O	ADP	O
aspirin	O	NOUN	B
in	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


Aspirin	B-I	NOUN	B
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
in	O	ADP	O
preference	O	NOUN	B
to	O	PART	O
warfarin	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
intracranial	I-P	ADJ	B
arterial	I-P	ADJ	I
stenosis	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
the	O	DET	O
canalith	B-I	ADJ	B
repositioning	I-I	NOUN	I
procedure	I-I	NOUN	I
.	I-I	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
complications	I-OUT	NOUN	B
of	I-OUT	ADP	O
our	I-OUT	PRON	O
adaptation	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
canalith	I-OUT	ADJ	B
repositioning	I-OUT	NOUN	I
procedure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CRP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
with	O	ADP	O
the	O	DET	O
expectation	O	NOUN	B
treatment	O	NOUN	I
for	O	ADP	O
benign	O	ADJ	B
paroxysmal	O	ADJ	I
positional	O	ADJ	I
vertigo	O	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
a	O	DET	O
neurotological	O	ADJ	B
clinic	O	NOUN	I
in	O	ADP	O
Thailand	O	PROPN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Fifty-eight	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
posterior	I-P	ADJ	B
benign	I-P	ADJ	I
paroxysmal	I-P	ADJ	I
positional	I-P	ADJ	I
vertigo	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
treatment	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
using	O	VERB	O
a	O	DET	O
block	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
modified	B-I	ADJ	B
CRP	I-I	NOUN	B
technique	I-I	NOUN	I
until	O	ADP	O
the	O	DET	O
nystagmus	O	NOUN	B
disappeared	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
mastoid	O	ADJ	B
oscillator	O	NOUN	I
was	O	AUX	O
not	O	PART	O
used	O	VERB	O
,	O	PUNCT	O
nor	O	CCONJ	O
were	O	AUX	O
any	O	DET	O
instructions	O	NOUN	B
given	O	VERB	O
for	O	ADP	O
patients	O	NOUN	B
after	O	ADP	O
the	O	DET	O
maneuver	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
recorded	O	VERB	O
the	O	DET	O
daily	B-OUT	ADJ	B
grading	I-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
amount	I-OUT	NOUN	B
of	I-OUT	ADP	O
anti-vertiginous	I-OUT	ADJ	B
drugs	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
cinnarizine	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
taken	I-OUT	VERB	O
.	I-OUT	PUNCT	O


Objective	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
subjective	I-OUT	ADJ	O
assessments	I-OUT	NOUN	B
were	O	AUX	O
made	O	VERB	O
weekly	O	ADJ	B
until	O	ADP	O
the	O	DET	O
nystagmus	B-OUT	NOUN	B
disappeared	O	VERB	O
or	O	CCONJ	O
until	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
had	O	AUX	O
passed	O	VERB	O
since	O	SCONJ	O
treatment	O	NOUN	B
began	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
effectiveness	I-OUT	NOUN	B
of	I-OUT	ADP	O
CRP	I-OUT	NOUN	B
treatment	I-OUT	NOUN	I
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
treatment	O	NOUN	I
for	O	ADP	O
benign	O	ADJ	B
paroxysmal	O	ADJ	I
positional	O	ADJ	I
vertigo	O	NOUN	I
were	O	AUX	O
75.9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
48.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
outcomes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CRP	B-I	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=.03	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
CRP	B-I	NOUN	B
group	O	NOUN	I
used	B-OUT	VERB	O
significantly	I-OUT	ADV	O
fewer	I-OUT	ADJ	O
drugs	I-OUT	NOUN	B
than	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=.001	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Complications	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
CRP	B-I	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
lateral	B-OUT	ADJ	B
canalithiasis	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
fainting	I-OUT	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
13.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
CRP	B-I	NOUN	B
was	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
the	O	DET	O
expectation	O	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
benign	O	ADJ	B
paroxysmal	O	ADJ	I
positional	O	ADJ	I
vertigo	O	NOUN	I
insofar	O	ADV	O
as	O	ADP	O
it	O	PRON	O
provided	O	VERB	O
faster	O	ADJ	O
recovery	B-OUT	NOUN	B
and	O	CCONJ	O
required	O	VERB	O
less	O	ADJ	O
dependence	B-OUT	NOUN	O
on	I-OUT	ADP	O
medication	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Complications	B-OUT	NOUN	B
of	O	ADP	O
CRP	B-I	NOUN	B
were	O	AUX	O
limited	O	VERB	O
to	O	ADP	O
13.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Pathology	O	NOUN	B
parameters	O	NOUN	B
and	O	CCONJ	O
adjuvant	B-OUT	ADJ	B
tamoxifen	I-OUT	NOUN	B
response	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
premenopausal	B-P	ADJ	O
breast	I-P	NOUN	O
cancer	I-P	NOUN	O
trial	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Subgroups	O	NOUN	B
of	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
that	O	PRON	O
have	O	AUX	O
an	O	DET	O
impaired	O	ADJ	B
response	O	NOUN	O
to	O	PART	O
endocrine	O	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
despite	O	SCONJ	O
hormone	O	NOUN	B
receptor	O	NOUN	I
positivity	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
still	O	ADV	O
poorly	O	ADV	O
defined	O	VERB	O
.	O	PUNCT	O


Breast	O	NOUN	B
cancer	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
subdivided	O	VERB	O
according	O	VERB	O
to	O	PART	O
standard	O	ADJ	O
pathological	O	ADJ	B
parameters	O	NOUN	B
including	O	VERB	O
histological	O	ADJ	B
type	O	NOUN	I
,	O	PUNCT	O
grade	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
assessment	O	NOUN	B
of	O	ADP	O
proliferation	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
parameters	O	NOUN	B
are	O	AUX	O
the	O	DET	O
net	O	ADJ	O
result	O	NOUN	O
of	O	ADP	O
combinations	O	NOUN	B
of	O	ADP	O
genetic	O	ADJ	B
alterations	O	NOUN	I
effecting	O	VERB	O
tumour	O	NOUN	B
behaviour	O	NOUN	I
and	O	CCONJ	O
could	O	AUX	O
potentially	O	ADV	O
reflect	O	VERB	O
subtypes	O	NOUN	B
that	O	PRON	O
respond	O	VERB	O
differently	O	ADV	O
to	O	PART	O
endocrine	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


AIMS	O	NOUN	B
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
usefulness	O	NOUN	B
of	O	ADP	O
these	O	DET	O
parameters	O	NOUN	B
as	O	ADP	O
predictors	O	NOUN	B
of	O	ADP	O
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
tamoxifen	B-I	NOUN	B
in	O	ADP	O
premenopausal	B-P	ADJ	B
women	I-P	NOUN	B
with	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


MATERIALS/METHODS	O	NOUN	B
Clinically	O	ADV	O
established	O	VERB	O
pathological	O	ADJ	B
parameters	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
and	O	CCONJ	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
tamoxifen	B-I	NOUN	B
response	O	NOUN	B
in	O	ADP	O
500	B-P	NUM	O
available	I-P	ADJ	O
tumour	I-P	NOUN	B
specimens	I-P	NOUN	I
from	I-P	ADP	O
564	I-P	NUM	O
premenopausal	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
randomised	O	VERB	B
to	O	ADP	O
either	O	CCONJ	O
two	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
tamoxifen	B-I	NOUN	B
or	O	CCONJ	O
no	B-I	DET	B
treatment	I-I	NOUN	I
with	O	ADP	O
14	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
follow	O	VERB	B
up	O	ADP	I
.	O	PUNCT	O


Proliferation	O	NOUN	B
was	O	AUX	O
further	O	ADV	O
evaluated	O	VERB	B
by	O	ADP	O
immunohistochemical	O	ADJ	B
Ki-67	O	NOUN	O
expression	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Oestrogen	B-OUT	NOUN	B
receptor	I-OUT	NOUN	I
positive	I-OUT	ADJ	B
ductal	I-OUT	ADJ	B
carcinomas	I-OUT	NOUN	I
responded	O	VERB	O
as	O	ADP	O
expected	O	VERB	O
to	O	PART	O
tamoxifen	B-I	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
recurrence	B-OUT	NOUN	B
free	I-OUT	ADJ	O
survival	I-OUT	NOUN	O
between	O	ADP	O
control	B-I	NOUN	B
and	O	CCONJ	O
tamoxifen	B-I	NOUN	B
treated	O	ADJ	B
patients	O	NOUN	B
was	O	AUX	O
less	O	ADV	O
apparent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
relatively	O	ADV	O
few	O	ADJ	O
lobular	O	ADJ	B
carcinomas	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
histological	O	ADJ	B
grade	O	NOUN	I
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
obvious	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
treatment	O	NOUN	B
response	O	NOUN	I
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
relation	O	NOUN	O
between	O	ADP	O
proliferation	O	NOUN	B
and	O	CCONJ	O
tamoxifen	B-I	NOUN	B
response	O	NOUN	B
seemed	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	B-OUT	ADV	O
complex	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
with	I-OUT	ADP	O
a	I-OUT	DET	O
clear	I-OUT	ADJ	O
response	I-OUT	NOUN	B
in	I-OUT	ADP	O
tumours	I-OUT	NOUN	B
with	I-OUT	ADP	O
high	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
low	I-OUT	ADJ	B
proliferation	I-OUT	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
tumours	O	NOUN	B
with	O	ADP	O
intermediate	O	ADJ	B
proliferation	O	NOUN	I
defined	O	VERB	O
by	O	ADP	O
Ki-67	O	NOUN	B
responded	O	VERB	O
more	O	ADV	O
poorly	B-OUT	ADV	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Clinically	O	ADV	O
established	O	ADJ	O
pathology	O	NOUN	B
parameters	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
mirror	O	VERB	B
the	O	DET	O
endocrine	O	ADJ	B
treatment	O	NOUN	O
response	O	NOUN	O
and	O	CCONJ	O
could	O	AUX	O
potentially	O	ADV	O
be	O	AUX	O
valuable	O	ADJ	O
in	O	ADP	O
future	O	ADJ	O
treatment	O	NOUN	B
decisions	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Immediately	O	ADV	O
restored	O	VERB	B
,	O	PUNCT	O
single-tapered	O	ADJ	B
implants	B-I	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
anterior	I-P	ADJ	B
maxilla	I-P	NOUN	B
:	I-P	PUNCT	O
prosthodontic	O	ADJ	B
and	O	CCONJ	O
aesthetic	O	ADJ	B
outcomes	O	NOUN	B
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Conventional	O	ADJ	B
implant	O	NOUN	O
protocols	O	NOUN	O
advocate	O	VERB	O
a	O	DET	O
two-stage	O	ADJ	B
technique	O	NOUN	I
with	O	ADP	O
a	O	DET	O
load-free	O	ADJ	B
,	O	PUNCT	O
submerged	O	ADJ	B
healing	O	NOUN	I
period	O	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
immediate	O	ADJ	O
restoration	O	NOUN	B
of	O	ADP	O
single	O	ADJ	O
implants	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
viable	O	ADJ	O
treatment	O	NOUN	B
option	O	NOUN	O
.	O	PUNCT	O


PURPOSE	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
prosthodontic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
aesthetic	I-OUT	ADJ	B
peri-implant	I-OUT	ADJ	B
mucosal	I-OUT	ADJ	O
outcomes	O	NOUN	B
of	O	ADP	O
immediately	B-P	ADV	O
restored	I-P	VERB	B
,	I-P	PUNCT	O
Southern	I-P	ADJ	B
single-tapered	I-P	ADJ	O
implants	I-I	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
anterior	I-P	ADJ	B
maxilla	I-P	NOUN	B
after	I-P	ADP	O
1	I-P	NUM	O
year	I-P	NOUN	B
.	I-P	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
Participants	B-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
:	I-P	PUNCT	O
43.25	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
range	I-P	NOUN	O
:	I-P	PUNCT	O
23-71	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
satisfying	I-P	VERB	O
specified	I-P	VERB	O
inclusion	I-P	NOUN	B
criteria	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
conventional	O	ADJ	O
two-stage	B-I	ADJ	B
restoration	I-I	NOUN	I
(	O	PUNCT	O
control	O	NOUN	B
group	O	NOUN	I
;	O	PUNCT	O
n=14	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
immediate	B-I	ADJ	B
restoration	I-I	NOUN	B
groups	I-I	NOUN	O
(	O	PUNCT	O
test	O	NOUN	B
group	O	NOUN	I
;	O	PUNCT	O
n	O	NOUN	O
=14	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Tapered	O	VERB	B
,	O	PUNCT	O
roughened-surface	O	ADJ	B
Southern	O	ADJ	B
implants	O	NOUN	B
were	O	AUX	O
placed	O	VERB	O
using	O	VERB	O
a	O	DET	O
standardized	O	ADJ	B
technique	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
implant	O	ADJ	B
level	O	NOUN	O
bone	O	NOUN	B
impressions	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
.	O	PUNCT	O


Provisional	O	ADJ	B
screw-retained	O	ADJ	O
crowns	O	NOUN	O
,	O	PUNCT	O
out	O	ADP	O
of	O	ADP	O
occlusion	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
placed	O	VERB	O
at	O	ADP	O
second-stage	O	ADJ	B
surgery	O	NOUN	I
after	O	ADP	O
26	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
the	O	DET	O
conventional	O	ADJ	B
restoration	O	NOUN	O
group	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
within	O	ADP	O
4	O	NUM	O
hours	O	NOUN	B
of	O	ADP	O
implant	O	ADJ	B
placement	O	NOUN	O
for	O	ADP	O
the	O	DET	O
immediate	O	ADJ	B
restoration	O	NOUN	B
group	O	NOUN	O
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
had	O	AUX	O
definitive	O	ADJ	B
screw-retained	O	ADJ	B
metal-ceramic	O	ADJ	I
crowns	O	NOUN	I
placed	O	VERB	O
in	O	ADP	O
occlusion	O	NOUN	B
8	O	NUM	O
weeks	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


Peri-implant	B-OUT	ADJ	B
mucosal	I-OUT	ADJ	O
response	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
papilla	I-OUT	NOUN	B
index	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
4	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
definitive	O	ADJ	B
crown	O	NOUN	B
placement	O	NOUN	B
to	O	PART	O
allow	O	VERB	O
for	O	ADP	O
mucosal	O	ADJ	B
maturation	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Prosthodontic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
aesthetic	I-OUT	ADJ	B
outcomes	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
established	O	VERB	O
criteria	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
within	O	ADP	O
,	O	PUNCT	O
or	O	CCONJ	O
between	O	ADP	O
,	O	PUNCT	O
the	O	DET	O
control	O	NOUN	B
and	O	CCONJ	O
test	O	VERB	O
groups	O	NOUN	B
for	O	ADP	O
age	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
gender	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
bone	I-OUT	NOUN	B
quality	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
quantity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
implant	I-OUT	ADJ	B
stability	I-OUT	NOUN	I
measurements	I-OUT	NOUN	B
at	I-OUT	ADP	O
surgery	I-OUT	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
implant	B-OUT	ADJ	B
length	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
implant	B-OUT	ADJ	B
success	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
radiographic	O	ADJ	B
bone	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
and	O	CCONJ	O
stability	O	NOUN	B
tests	O	NOUN	I
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
prosthodontic	B-OUT	ADJ	B
maintenance	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
peri-implant	I-OUT	ADJ	B
mucosal	I-OUT	ADJ	O
response	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
papilla	I-OUT	NOUN	B
index	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
over	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Tapered	O	PROPN	B
,	O	PUNCT	O
roughened-surface	O	ADJ	B
implants	O	NOUN	B
immediately	O	ADV	O
restored	O	VERB	B
with	O	ADP	O
single	O	ADJ	O
provisional	O	ADJ	B
crowns	O	NOUN	O
at	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
definitive	O	ADJ	B
crowns	O	NOUN	B
8	O	NUM	O
weeks	O	NOUN	B
later	O	ADV	O
were	O	AUX	O
as	O	ADV	O
prosthodontically	O	ADV	B
and	O	CCONJ	O
aesthetically	O	ADV	O
successful	O	ADJ	O
as	O	ADP	O
conventionally	O	ADV	B
restored	O	VERB	O
two-stage	O	ADJ	B
implants	O	NOUN	I
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
of	O	ADP	O
service	O	NOUN	B
.	O	PUNCT	O


Restoring	B-I	VERB	B
single	O	ADJ	O
implants	O	NOUN	B
immediately	O	ADV	O
with	O	ADP	O
screw-retained	O	ADJ	O
crowns	O	NOUN	B
is	O	AUX	O
an	O	DET	O
efficient	O	ADJ	B
procedure	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
short-term	O	ADJ	B
outcome	O	NOUN	B
is	O	AUX	O
by	O	ADP	O
no	O	DET	O
means	O	NOUN	O
superior	O	ADJ	O
to	O	PART	O
a	O	DET	O
conventional	O	ADJ	O
two-stage	O	ADJ	B
approach	O	NOUN	I
.	O	PUNCT	O


Epicutaneous	O	ADJ	B
allergen-specific	B-I	ADJ	I
immunotherapy	I-I	NOUN	I
ameliorates	O	VERB	B
grass	O	NOUN	B
pollen-induced	O	ADJ	I
rhinoconjunctivitis	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
dose	O	NOUN	O
escalation	O	NOUN	B
study	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Epicutaneous	B-I	ADJ	B
allergen	I-I	NOUN	I
administration	O	NOUN	B
using	O	VERB	O
a	O	DET	O
patch	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
alternative	O	NOUN	B
to	O	PART	O
subcutaneous	O	ADJ	B
or	O	CCONJ	O
sublingual	O	ADJ	B
immunotherapy	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
optimize	O	VERB	O
treatment	O	NOUN	B
dose	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
demonstrate	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
epicutaneous	O	ADJ	B
immunotherapy	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
This	O	DET	O
monocentric	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
trial	O	NOUN	I
included	B-P	VERB	O
132	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
grass	I-P	NOUN	B
pollen-induced	I-P	ADJ	I
rhinoconjunctivitis	I-P	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
February	O	PROPN	O
2008	O	NUM	O
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	B-I	VERB	O
placebo	I-I	NOUN	B
or	I-I	CCONJ	O
3	I-I	NUM	O
different	I-I	ADJ	O
doses	I-I	NOUN	B
of	I-I	ADP	O
allergen	I-I	NOUN	B
.	O	PUNCT	O


Before	O	ADP	O
and	O	CCONJ	O
during	O	ADP	O
the	O	DET	O
pollen	O	NOUN	B
season	O	NOUN	B
2008	O	NUM	O
,	O	PUNCT	O
patients	B-P	NOUN	B
received	I-P	VERB	O
6	I-P	NUM	O
weekly	I-P	ADJ	B
patches	I-P	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
4	O	NUM	O
to	O	PART	O
5	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
110	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
during	O	ADP	O
the	O	DET	O
pollen	O	NOUN	B
season	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment-free	O	ADJ	B
follow-up	O	ADJ	I
year	O	NOUN	B
in	O	ADP	O
2009	O	NUM	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
93	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	B-OUT	AUX	O
patient-reported	I-OUT	ADJ	B
changes	I-OUT	NOUN	I
in	I-OUT	ADP	O
hay	I-OUT	NOUN	B
fever	I-OUT	NOUN	I
symptoms	I-OUT	NOUN	B
assessed	I-OUT	VERB	B
by	I-OUT	ADP	O
a	I-OUT	DET	O
visual	I-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
.	O	PUNCT	O


Secondary	O	ADJ	B
outcome	O	NOUN	I
measures	O	NOUN	I
were	B-OUT	AUX	O
weekly	I-OUT	ADJ	B
visual	I-OUT	ADJ	B
analog	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
symptom	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
during	I-OUT	ADP	O
pollen	I-OUT	NOUN	B
season	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
rescue	I-OUT	NOUN	B
medication	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
conjunctival	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
skin	I-OUT	NOUN	B
reactivity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
safety	I-OUT	NOUN	B
.	O	PUNCT	O


RESULTS	B-OUT	VERB	O
Hay	I-OUT	ADJ	B
fever	I-OUT	NOUN	I
symptoms	I-OUT	NOUN	B
during	I-OUT	ADP	O
the	I-OUT	DET	O
pollen	I-OUT	NOUN	B
season	I-OUT	NOUN	I
were	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
2008	O	NUM	O
and	O	CCONJ	O
by	O	ADP	O
24	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
2009	O	NUM	O
in	O	ADP	O
the	O	DET	O
high-dose	O	ADJ	B
group	O	NOUN	I
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
alleviation	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
follow-up	O	ADJ	B
year	O	NOUN	B
was	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
dose	O	NOUN	I
.	O	PUNCT	O


Higher	O	ADJ	B
allergen	O	NOUN	B
doses	O	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	B-OUT	ADP	I
drug-related	I-OUT	ADJ	B
adverse	I-OUT	ADJ	I
events	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AEs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
predominantly	O	ADV	O
manifested	O	VERB	O
by	B-OUT	ADP	O
pruritus	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
erythema	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
wheal	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
eczema	I-OUT	NOUN	B
.	O	PUNCT	O


Eleven	O	NUM	O
systemic	B-OUT	ADJ	B
AEs	I-OUT	NOUN	B
of	O	ADP	O
grades	O	NOUN	B
1	O	NUM	O
to	O	PART	O
2	O	NUM	O
required	O	VERB	O
treatment	O	NOUN	B
and	O	CCONJ	O
led	O	VERB	O
to	O	PART	O
study	O	VERB	B
exclusion	O	NOUN	B
.	O	PUNCT	O


The	B-OUT	DET	O
dropout	I-OUT	ADJ	B
rate	I-OUT	NOUN	I
due	O	ADP	O
to	B-OUT	ADP	O
AEs	I-OUT	NOUN	B
was	O	AUX	O
8.3	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


No	O	DET	O
drug-related	O	ADJ	O
serious	B-OUT	ADJ	O
AE	I-OUT	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Epicutaneous	B-I	ADJ	B
immunotherapy	I-I	NOUN	I
is	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
efficacious	O	ADJ	B
in	O	ADP	O
a	O	DET	O
dose-dependent	O	ADJ	B
manner	O	NOUN	O
after	O	ADP	O
6	O	NUM	O
patches	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
psoriasis	B-P	NOUN	B
vulgaris	I-P	X	I
by	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
yin	B-I	PROPN	B
xie	I-I	X	I
ping	I-I	X	I
granules	I-I	NOUN	I
--	I-I	PUNCT	O
a	I-I	DET	O
clinical	I-P	ADJ	B
report	I-P	NOUN	I
of	I-P	ADP	O
60	I-P	NUM	O
cases	I-P	NOUN	B
.	I-P	PUNCT	O


Initial	B-OUT	ADJ	O
abstinence	I-OUT	NOUN	B
status	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
contingency	I-OUT	NOUN	B
management	I-OUT	NOUN	B
treatment	I-OUT	NOUN	B
outcomes	O	NOUN	B
:	O	PUNCT	O
does	O	AUX	O
race	O	NOUN	B
matter	O	NOUN	I
?	O	PUNCT	O
OBJECTIVE	O	ADJ	O
Limited	O	ADJ	B
research	O	NOUN	B
has	O	AUX	O
evaluated	O	VERB	B
African	B-P	ADJ	B
American	I-P	ADJ	I
substance	I-P	NOUN	O
users	I-P	NOUN	O
'	I-P	PART	O
response	O	NOUN	B
to	O	ADP	O
evidence-based	O	ADJ	B
treatments	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
contingency	B-OUT	NOUN	B
management	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CM	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
African	B-P	ADJ	B
American	I-P	ADJ	I
and	I-P	CCONJ	O
White	I-P	ADJ	B
cocaine	I-P	NOUN	I
users	I-P	NOUN	I
.	I-P	PUNCT	O


METHOD	O	NOUN	B
A	O	DET	O
secondary	O	ADJ	B
analysis	O	NOUN	I
evaluated	O	VERB	O
effects	O	NOUN	B
of	O	ADP	I
race	O	NOUN	B
,	O	PUNCT	O
treatment	O	NOUN	B
condition	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
baseline	O	NOUN	B
cocaine	O	NOUN	B
urine	O	NOUN	B
sample	O	NOUN	I
results	O	VERB	O
on	O	ADP	O
treatment	O	NOUN	B
outcomes	O	NOUN	B
of	O	ADP	O
African	B-P	ADJ	B
American	I-P	ADJ	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
444	I-P	NUM	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
White	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
403	I-P	NUM	O
)	I-P	PUNCT	O
cocaine	I-P	NOUN	B
abusers	I-P	NOUN	I
participating	I-P	VERB	B
in	I-P	ADP	O
one	I-P	NUM	O
of	I-P	ADP	O
six	I-P	NUM	O
randomized	I-P	ADJ	B
clinical	I-P	ADJ	I
trials	I-P	NOUN	I
comparing	I-P	VERB	O
CM	I-I	NOUN	B
to	I-P	PART	O
standard	I-I	ADJ	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	VERB	B
African	B-P	ADJ	B
American	I-P	ADJ	I
and	I-P	CCONJ	O
White	I-P	ADJ	B
patients	I-P	NOUN	B
who	I-P	PRON	O
initiated	I-P	VERB	B
treatment	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
cocaine-negative	I-P	ADJ	B
urine	I-P	NOUN	B
sample	I-P	NOUN	I
remained	O	VERB	O
in	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
similar	O	ADJ	O
durations	O	NOUN	B
and	O	CCONJ	O
submitted	O	VERB	O
a	O	DET	O
comparable	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
negative	O	ADJ	B
samples	O	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
regardless	O	ADV	O
of	O	ADP	O
treatment	O	NOUN	B
type	O	NOUN	I
;	O	PUNCT	O
CM	B-I	NOUN	B
was	O	AUX	O
efficacious	O	ADJ	B
in	O	ADP	O
both	O	DET	O
races	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
engendering	O	VERB	O
longer	O	ADJ	O
durations	O	NOUN	B
of	O	ADP	O
abstinence	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
began	O	VERB	O
treatment	O	NOUN	B
abstinent	O	VERB	B
.	O	PUNCT	O


Whites	B-P	PROPN	B
who	I-P	PRON	O
began	I-P	VERB	O
treatment	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
cocaine	I-P	NOUN	B
positive	I-P	ADJ	I
sample	I-P	NOUN	B
remained	O	VERB	O
in	O	ADP	O
treatment	O	NOUN	B
longer	O	ADV	O
and	O	CCONJ	O
submitted	O	VERB	O
a	O	DET	O
higher	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
negative	O	ADJ	B
samples	O	NOUN	B
when	O	SCONJ	O
assigned	O	VERB	O
to	O	PART	O
CM	B-I	NOUN	B
than	O	ADP	O
standard	B-I	ADJ	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


African	B-P	ADJ	B
Americans	I-P	PROPN	I
who	I-P	PRON	O
initiated	I-P	VERB	B
treatment	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
cocaine	I-P	NOUN	B
positive	I-P	ADJ	I
sample	I-P	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
remain	O	VERB	O
in	O	ADP	O
treatment	O	NOUN	B
longer	O	ADV	O
with	O	ADP	O
CM	B-I	NOUN	B
compared	O	VERB	O
with	O	ADP	O
standard	B-I	ADJ	B
care	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
gains	B-OUT	NOUN	B
in	I-OUT	ADP	O
terms	I-OUT	NOUN	O
of	I-OUT	ADP	O
drug	I-OUT	NOUN	B
use	I-OUT	NOUN	I
outcomes	I-OUT	NOUN	I
were	O	AUX	O
muted	O	ADJ	O
in	O	ADP	O
nature	O	NOUN	O
relative	O	ADJ	O
to	O	ADP	O
Whites	O	PROPN	B
.	O	PUNCT	O


This	O	DET	O
interaction	O	NOUN	B
effect	O	NOUN	B
persisted	O	VERB	O
through	O	ADP	O
the	O	DET	O
9-month	O	ADJ	O
follow-up	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
CM	B-I	NOUN	B
is	O	AUX	O
not	O	PART	O
equally	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
reducing	O	VERB	B
drug	O	NOUN	B
use	O	NOUN	I
among	O	ADP	O
all	O	DET	O
subgroups	O	NOUN	B
,	O	PUNCT	O
specifically	O	ADV	O
African	B-P	ADJ	B
American	I-P	ADJ	I
patients	I-P	NOUN	B
who	I-P	PRON	O
are	I-P	AUX	O
using	I-P	VERB	O
cocaine	I-P	NOUN	B
upon	I-P	SCONJ	O
treatment	I-P	NOUN	B
entry	I-P	NOUN	I
.	I-P	PUNCT	O


Future	O	ADJ	O
research	O	NOUN	B
on	O	ADP	O
improving	O	VERB	B
treatment	O	NOUN	B
outcomes	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
.	O	PUNCT	O


Randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
radiofrequency	B-I	NOUN	B
ablation	I-I	NOUN	I
or	O	CCONJ	O
conventional	B-I	ADJ	O
high	I-I	ADJ	B
ligation	I-I	NOUN	I
and	O	CCONJ	O
stripping	O	NOUN	B
for	O	ADP	O
great	B-P	ADJ	B
saphenous	I-P	ADJ	I
varicose	I-P	NOUN	B
veins	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
This	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
compared	O	VERB	O
early	O	ADJ	O
outcomes	O	NOUN	O
after	O	ADP	O
radiofrequency	B-I	NOUN	B
ablation	I-I	NOUN	I
(	I-I	PUNCT	O
RFA	I-I	PROPN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
conventional	O	ADJ	B
surgery	O	NOUN	I
for	O	ADP	O
varicose	O	NOUN	B
veins	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Consecutive	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
symptomatic	I-P	ADJ	B
varicose	I-P	NOUN	B
veins	I-P	NOUN	I
due	I-P	ADJ	O
to	I-P	PART	O
isolated	I-P	VERB	B
great	I-P	ADJ	B
saphenous	I-P	ADJ	I
vein	I-P	NOUN	I
(	I-P	PUNCT	O
GSV	I-P	NOUN	B
)	I-P	PUNCT	O
incompetence	I-P	NOUN	B
and	I-P	CCONJ	O
suitable	I-P	ADJ	O
for	I-P	ADP	O
RFA	I-P	PROPN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
either	O	CCONJ	O
RFA	B-I	PROPN	B
or	O	CCONJ	O
conventional	O	ADJ	B
surgery	O	NOUN	I
(	O	PUNCT	O
saphenofemoral	O	ADJ	B
disconnection	O	NOUN	I
and	O	CCONJ	O
stripping	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Clinical	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
radiological	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
patient-based	I-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
at	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
intervention	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
RFA	B-I	PROPN	B
resulted	O	VERB	O
in	O	ADP	O
successful	O	ADJ	O
obliteration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GSV	B-P	PROPN	B
in	I-P	ADP	O
all	I-P	DET	O
47	I-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Complete	B-OUT	ADJ	B
above-knee	I-OUT	ADJ	B
stripping	I-OUT	NOUN	B
was	O	AUX	O
unsuccessful	O	ADJ	O
in	O	ADP	O
seven	O	NUM	O
of	O	ADP	O
41	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


RFA	O	PROPN	B
took	O	VERB	O
longer	O	ADJ	O
than	O	ADP	O
conventional	O	ADJ	B
surgery	O	NOUN	I
:	O	PUNCT	O
median	O	ADJ	B
interquartile	O	NOUN	B
range	O	NOUN	I
76	O	NUM	O
(	O	PUNCT	O
67-84	O	NUM	O
)	O	PUNCT	O
versus	O	CCONJ	O
48	O	NUM	O
(	O	PUNCT	O
39-54	O	NUM	O
)	O	PUNCT	O
min	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
.	O	PUNCT	O


Patients	O	NOUN	B
returned	B-OUT	VERB	O
to	I-OUT	ADP	O
their	I-OUT	PRON	O
normal	I-OUT	ADJ	O
activities	I-OUT	NOUN	B
significantly	O	ADV	O
earlier	O	ADV	O
after	O	ADP	O
RFA	B-I	PROPN	B
(	O	PUNCT	O
median	O	NOUN	B
3	O	NUM	O
(	O	PUNCT	O
2-5	O	NUM	O
)	O	PUNCT	O
versus	O	CCONJ	O
12.5	O	NUM	O
(	O	PUNCT	O
4-21	O	NUM	O
)	O	PUNCT	O
days	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
after	O	ADP	O
RFA	B-I	PROPN	B
(	O	PUNCT	O
median	O	ADJ	B
score	O	NOUN	I
on	O	ADP	O
visual	O	ADJ	B
analogue	O	NOUN	I
scale	O	NOUN	I
1.70	O	NUM	O
(	O	PUNCT	O
0.50-4.30	O	NOUN	O
)	O	PUNCT	O
versus	O	CCONJ	O
4.0	O	NUM	O
(	O	PUNCT	O
2.35-6.05	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Patient	B-OUT	ADJ	B
satisfaction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
improvement	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
analgesic	I-OUT	NOUN	B
requirements	I-OUT	NOUN	I
significantly	O	ADV	O
favoured	O	VERB	O
RFA	B-I	PROPN	B
.	I-I	PUNCT	O


CONCLUSION	O	NOUN	O
RFA	O	PROPN	B
took	O	VERB	O
longer	O	ADV	O
to	O	PART	O
perform	O	VERB	O
but	O	CCONJ	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
significantly	B-OUT	ADV	O
better	I-OUT	ADJ	O
early	I-OUT	ADJ	B
outcome	I-OUT	NOUN	B
than	O	ADP	O
conventional	O	ADJ	B
surgery	O	NOUN	I
in	O	ADP	O
suitable	O	ADJ	O
patients	B-P	NOUN	B
with	I-P	ADP	O
great	I-P	ADJ	B
saphenous	I-P	ADJ	I
varicose	I-P	NOUN	I
veins	I-P	NOUN	I
.	I-P	PUNCT	O


Use	O	PROPN	B
of	O	ADP	I
recombinant	B-I	ADJ	B
human	I-I	ADJ	O
granulocyte	I-I	NOUN	O
colony-stimulating	I-I	ADJ	O
factor	I-I	NOUN	O
to	O	PART	O
increase	O	VERB	B
chemotherapy	B-I	NOUN	B
dose-intensity	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
in	O	ADP	O
very	B-P	ADV	O
high-risk	I-P	ADJ	B
childhood	I-P	NOUN	I
acute	I-P	ADJ	B
lymphoblastic	I-P	ADJ	I
leukemia	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
recombinant	B-I	ADJ	B
human	I-I	ADJ	O
granulocyte	I-I	NOUN	O
colony-stimulating	I-I	ADJ	O
factor	I-I	NOUN	O
(	I-I	PUNCT	O
[	I-I	PUNCT	O
G-CSF	I-I	NOUN	B
]	I-I	PUNCT	O
lenogastrim	I-I	NOUN	B
)	I-I	PUNCT	O
can	O	AUX	O
increase	O	VERB	B
the	O	DET	O
chemotherapy	O	NOUN	B
dose-intensity	O	NOUN	B
(	O	PUNCT	O
CDI	O	PROPN	B
)	O	PUNCT	O
delivered	O	VERB	O
during	O	ADP	O
consolidation	B-I	NOUN	B
chemotherapy	I-I	NOUN	I
of	O	ADP	O
childhood	B-P	NOUN	B
acute	I-P	ADJ	I
lymphoblastic	I-P	ADJ	I
leukemia	I-P	NOUN	I
(	I-P	PUNCT	O
ALL	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Sixty-seven	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
very	I-P	ADV	O
high-risk	I-P	ADJ	B
ALL	I-P	NOUN	B
were	O	AUX	O
randomized	O	ADJ	B
(	O	PUNCT	O
slow	O	ADJ	O
early	O	ADJ	O
response	O	NOUN	O
to	O	PART	O
therapy	O	NOUN	B
,	O	PUNCT	O
55	O	NUM	O
patients	O	NOUN	B
;	O	PUNCT	O
translocation	O	NOUN	B
t	O	NOUN	O
(	O	PUNCT	O
9	O	NUM	O
;	O	PUNCT	O
22	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
t	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
;	O	PUNCT	O
11	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
12	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Consolidation	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
six	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
chemotherapy	B-I	NOUN	B
;	I-I	PUNCT	O
the	O	DET	O
first	O	ADJ	O
,	O	PUNCT	O
third	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
fifth	O	ADJ	O
courses	O	NOUN	B
were	O	AUX	O
a	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
high-dose	I-I	ADJ	B
cytarabine	I-I	NOUN	I
,	I-I	PUNCT	O
etoposide	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
dexamethasone	I-I	NOUN	B
(	I-I	PUNCT	O
R3	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
second	O	ADJ	O
,	O	PUNCT	O
fourth	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
sixth	O	ADJ	O
courses	O	NOUN	B
included	O	VERB	O
vincristine	B-I	NOUN	B
,	I-I	PUNCT	O
prednisone	I-I	NOUN	B
,	I-I	PUNCT	O
cyclophosphamide	I-I	NOUN	B
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
methotrexate	I-I	NOUN	B
(	I-I	PUNCT	O
COPADM	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


G-CSF	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
after	O	ADP	O
each	O	DET	O
course	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
next	O	ADJ	B
scheduled	O	VERB	I
course	O	NOUN	I
was	O	AUX	O
started	O	VERB	O
as	O	ADV	O
soon	O	ADV	O
as	O	ADP	O
neutrophil	O	NOUN	B
count	O	NOUN	B
was	O	AUX	O
>	O	X	O
1	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/L	O	NUM	O
and	O	CCONJ	O
platelet	O	NOUN	B
count	O	NOUN	I
was	O	AUX	O
>	O	X	O
100	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/L	O	NUM	O
.	O	PUNCT	O


CDI	B-OUT	PROPN	B
was	O	AUX	O
calculated	O	VERB	B
using	O	VERB	O
the	O	DET	O
interval	O	NOUN	B
from	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
course	O	NOUN	O
to	O	PART	O
hematologic	O	ADJ	B
recovery	O	NOUN	B
after	O	ADP	O
the	O	DET	O
fifth	O	ADJ	O
course	O	NOUN	O
(	O	PUNCT	O
100	O	NUM	O
%	O	NOUN	O
CDI	O	PROPN	B
=	O	ADJ	O
105-day	O	NOUN	B
interval	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	B
CDI	B-OUT	PROPN	B
was	O	AUX	O
significantly	O	ADV	O
increased	B-OUT	VERB	B
in	O	ADP	O
the	O	DET	O
G-CSF	B-I	NOUN	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
non-G-CSF	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
105	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
91	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
higher	B-OUT	ADJ	B
intensity	I-OUT	NOUN	B
was	O	AUX	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
shorter	O	ADJ	B
post-R3	B-OUT	ADJ	O
intervals	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
G-CSF	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
post-COPADM	B-I	ADJ	B
intervals	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
reduced	O	VERB	I
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
R3	O	NOUN	B
courses	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
days	I-OUT	NOUN	B
with	I-OUT	ADP	O
fever	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
intravenous	I-OUT	ADJ	B
antibiotics	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
hospitalization	I-OUT	NOUN	B
were	I-OUT	AUX	O
significantly	I-OUT	ADV	O
decreased	I-OUT	VERB	B
by	O	ADP	O
G-CSF	B-I	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
reductions	B-OUT	NOUN	B
observed	I-OUT	VERB	O
after	I-OUT	ADP	O
COPADM	I-OUT	NOUN	B
were	I-OUT	AUX	O
not	I-OUT	PART	O
statistically	I-OUT	ADV	B
significant	I-OUT	ADJ	I
.	I-OUT	PUNCT	O


Duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
granulocytopenia	I-OUT	NOUN	B
was	I-OUT	AUX	O
reduced	I-OUT	VERB	B
in	O	ADP	O
the	O	DET	O
G-CSF	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
thrombocytopenia	B-OUT	NOUN	B
was	I-OUT	AUX	O
prolonged	I-OUT	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
platelet	I-OUT	NOUN	B
transfusions	I-OUT	NOUN	I
was	I-OUT	AUX	O
increased	I-OUT	VERB	B
.	I-OUT	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
3-year	O	ADJ	O
probability	O	NOUN	B
of	O	ADP	O
event-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
G-CSF	B-I	NOUN	B
can	O	AUX	O
increase	O	VERB	B
CDI	O	PROPN	B
in	O	ADP	O
high-risk	B-P	ADJ	B
childhood	I-P	NOUN	I
ALL	I-P	NOUN	B
.	O	PUNCT	O


Its	O	PRON	O
effects	O	NOUN	B
depend	O	VERB	O
on	O	ADP	O
the	O	DET	O
chemotherapy	O	NOUN	B
regimen	O	NOUN	B
given	O	VERB	O
before	O	ADP	O
G-CSF	B-I	NOUN	B
administration	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
higher	O	ADJ	B
CDI	O	PROPN	B
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
disease	O	NOUN	B
control	O	NOUN	I
.	O	PUNCT	O


Randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
partial	B-I	ADJ	B
vs.	O	CCONJ	O
stepwise	B-I	ADJ	O
caries	I-P	NOUN	B
removal	O	NOUN	B
:	O	PUNCT	O
3-year	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
multicenter	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
evaluated	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
treatments	O	NOUN	B
for	O	ADP	O
deep	B-P	ADJ	B
caries	I-P	NOUN	I
lesions	I-P	NOUN	B
-	O	PUNCT	O
partial	B-I	ADJ	B
caries	I-I	NOUN	B
removal	I-I	NOUN	B
(	I-I	PUNCT	O
PCR	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
stepwise	I-I	ADJ	B
excavation	I-I	NOUN	I
(	I-I	PUNCT	O
SW	I-I	NOUN	B
)	I-I	PUNCT	O
-	O	PUNCT	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
of	O	ADP	O
pulp	O	NOUN	B
vitality	O	NOUN	B
for	O	ADP	O
a	O	DET	O
3-year	O	ADJ	O
follow-up	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


Inclusion	B-P	NOUN	B
criteria	I-P	NOUN	I
were	I-P	AUX	O
as	I-P	ADP	O
follows	I-P	VERB	O
:	I-P	PUNCT	O
patients	I-P	NOUN	B
with	I-P	ADP	O
permanent	I-P	ADJ	B
molars	I-P	NOUN	I
presenting	I-P	VERB	O
deep	I-P	ADJ	B
caries	I-P	NOUN	I
lesions	I-P	NOUN	B
(	I-P	PUNCT	O
lesion	I-P	NOUN	B
affecting	I-P	VERB	B
≥	I-P	DET	O
1/2	I-P	NUM	O
of	I-P	ADP	O
the	I-P	DET	O
dentin	I-P	NOUN	B
on	I-P	ADP	O
radiographic	I-P	ADJ	B
examination	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
positive	I-P	ADJ	B
response	I-P	NOUN	I
to	I-P	ADP	O
a	I-P	DET	O
cold	I-P	ADJ	B
test	I-P	NOUN	I
,	I-P	PUNCT	O
absence	I-P	NOUN	B
of	I-P	ADP	O
spontaneous	I-P	ADJ	B
pain	I-P	NOUN	I
,	I-P	PUNCT	O
negative	I-P	ADJ	B
sensitivity	I-P	NOUN	B
to	I-P	ADP	O
percussion	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
absence	I-P	NOUN	B
of	I-P	ADP	O
periapical	I-P	ADJ	B
lesions	I-P	NOUN	I
(	I-P	PUNCT	O
radiographic	I-P	ADJ	B
examination	I-P	NOUN	I
)	I-P	PUNCT	O
.	O	PUNCT	O


Teeth	O	NOUN	B
randomly	O	ADV	B
assigned	O	VERB	I
to	O	PART	O
PCR	O	NOUN	B
(	O	PUNCT	O
test	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
incomplete	O	ADJ	B
caries	O	NOUN	B
removal	O	NOUN	B
and	O	CCONJ	O
filling	O	VERB	B
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
session	O	NOUN	B
.	O	PUNCT	O


Outcome	O	NOUN	B
success	O	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
assessment	O	NOUN	B
of	B-OUT	ADP	O
pulp	I-OUT	NOUN	B
vitality	I-OUT	NOUN	B
,	O	PUNCT	O
determined	O	VERB	O
by	O	ADP	O
pulp	O	NOUN	B
sensitivity	O	NOUN	B
to	O	ADP	O
a	O	DET	O
cold	O	ADJ	B
test	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
periapical	O	ADJ	B
lesions	O	NOUN	O
.	O	PUNCT	O


Data	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
a	O	DET	O
Weibull	O	NOUN	B
regression	O	NOUN	I
model	O	NOUN	I
with	O	ADP	O
shared	O	VERB	O
frailty	O	NOUN	O
term	O	NOUN	O
(	O	PUNCT	O
survival	O	NOUN	B
analysis	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
baseline	B-P	NOUN	B
,	I-P	PUNCT	O
299	I-P	NUM	O
treatments	I-P	NOUN	B
were	I-P	AUX	O
executed	I-P	VERB	O
:	I-P	PUNCT	O
PCR	O	NOUN	B
,	O	PUNCT	O
152	O	NUM	O
and	O	CCONJ	O
SW	O	NOUN	B
,	O	PUNCT	O
147	B-P	NUM	O
.	O	PUNCT	O


By	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
3-year	O	ADJ	O
follow-up	O	ADJ	B
period	B-P	NOUN	B
,	I-P	PUNCT	O
213	I-P	NUM	O
teeth	I-P	NOUN	B
had	I-P	AUX	O
been	I-P	AUX	O
evaluated	I-OUT	VERB	B
.	I-OUT	PUNCT	O


Adjusted	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
91	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
PCR	O	NOUN	B
and	O	CCONJ	O
69	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
SW	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
need	O	NOUN	O
to	O	PART	O
re-open	O	VERB	O
a	O	DET	O
cavity	O	NOUN	B
and	O	CCONJ	O
perform	O	VERB	O
a	O	DET	O
second	O	ADJ	O
excavation	O	NOUN	B
for	B-OUT	ADP	O
pulp	I-OUT	NOUN	B
vitality	I-OUT	NOUN	B
to	O	PART	O
be	O	AUX	O
preserved	O	VERB	O
(	O	PUNCT	O
Clinical	O	ADJ	B
trials	O	NOUN	I
registration	O	NOUN	B
NCT00887952	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Korean	B-I	ADJ	B
version	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
PEERS	I-I	NOUN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
parent-assisted	I-I	ADJ	B
social	I-I	ADJ	B
skills	I-I	NOUN	I
training	I-I	NOUN	B
program	I-I	NOUN	I
for	I-P	ADP	O
teens	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	O	PUNCT	O


Impaired	O	ADJ	B
social	O	ADJ	B
functioning	O	NOUN	I
is	O	AUX	O
a	O	DET	O
hallmark	O	ADJ	O
feature	O	NOUN	O
of	O	ADP	O
autism	O	NOUN	B
spectrum	O	NOUN	I
disorder	O	NOUN	I
(	O	PUNCT	O
ASD	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
often	O	ADV	O
requiring	O	VERB	O
treatment	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
life	O	NOUN	B
span	O	NOUN	I
.	B-I	PUNCT	O


PEERS	B-I	NOUN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
(	I-I	PUNCT	O
Program	I-I	NOUN	B
for	I-I	ADP	O
the	I-I	DET	O
Education	I-I	PROPN	B
and	I-I	CCONJ	O
Enrichment	I-I	NOUN	O
of	I-I	ADP	O
Relational	I-I	PROPN	B
Skills	I-I	PROPN	I
)	I-I	PUNCT	O
is	O	AUX	O
a	B-P	DET	O
parent-assisted	I-P	ADJ	B
social	I-P	ADJ	B
skills	I-P	NOUN	I
training	I-P	NOUN	B
for	I-P	ADP	O
teens	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	O	PUNCT	O


Although	O	SCONJ	O
PEERS	O	NOUN	B
(	O	PUNCT	O
®	O	NOUN	O
)	O	PUNCT	O
has	O	AUX	O
an	O	DET	O
established	O	ADJ	O
evidence	O	NOUN	B
base	O	NOUN	B
in	O	ADP	O
improving	O	VERB	B
the	O	DET	O
social	O	ADJ	B
skills	O	NOUN	I
of	O	ADP	O
adolescents	O	NOUN	B
and	O	CCONJ	O
young	O	ADJ	B
adults	O	NOUN	I
with	O	ADP	O
ASD	O	VERB	B
in	O	ADP	O
North	O	PROPN	B
America	O	PROPN	I
,	O	PUNCT	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
this	O	DET	O
treatment	O	NOUN	B
has	O	AUX	O
yet	O	ADV	O
to	O	PART	O
be	O	AUX	O
established	O	VERB	O
in	O	ADP	O
cross-cultural	O	ADJ	B
validation	O	NOUN	O
trials	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
feasibility	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
efficacy	O	NOUN	B
of	B-I	ADP	O
a	I-I	DET	O
Korean	I-I	ADJ	B
version	I-I	NOUN	B
of	I-I	ADP	O
PEERS	I-I	NOUN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
for	O	ADP	O
enhancing	O	VERB	B
social	O	ADJ	B
skills	O	NOUN	I
through	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
(	O	PUNCT	O
RCT	O	NOUN	B
)	O	PUNCT	O
.The	O	PUNCT	O
English	O	ADJ	B
version	O	NOUN	B
of	O	ADP	O
the	B-I	DET	O
PEERS	I-I	NOUN	B
(	I-I	PUNCT	O
®	I-I	NOUN	O
)	I-I	PUNCT	O
Treatment	O	NOUN	O
Manual	O	PROPN	O
(	O	PUNCT	O
Laugeson	O	PROPN	B
&	O	CCONJ	I
Frankel	O	PROPN	I
,	O	PUNCT	O
2010	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
translated	O	VERB	B
into	O	ADP	O
Korean	B-P	ADJ	B
and	O	CCONJ	O
reviewed	B-P	VERB	B
by	I-P	ADP	O
21	I-P	NUM	O
child	I-P	NOUN	B
mental	I-P	ADJ	B
health	I-P	NOUN	I
professionals	I-P	NOUN	I
.	O	PUNCT	O


Items	O	NOUN	B
identified	O	VERB	B
as	O	ADP	O
culturally	O	ADV	B
sensitive	O	ADJ	I
were	B-P	AUX	O
surveyed	I-P	VERB	B
by	I-P	ADP	O
447	I-P	NUM	O
middle	I-P	ADJ	B
school	I-P	NOUN	I
students	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
material	O	NOUN	B
was	O	AUX	O
modified	O	VERB	B
accordingly	B-P	ADV	O
.	I-P	PUNCT	O


Participants	B-P	NOUN	B
included	I-P	VERB	O
47	I-P	NUM	O
teens	I-P	NOUN	B
between	I-P	ADP	O
12	I-P	NUM	O
and	I-P	CCONJ	O
18	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
ASD	I-P	VERB	B
and	I-P	CCONJ	O
a	I-P	DET	O
verbal	I-P	ADJ	B
intelligence	I-P	NOUN	I
quotient	I-P	NOUN	I
(	I-P	PUNCT	O
IQ	I-P	NOUN	B
)	I-P	PUNCT	O
≥	O	NOUN	O
65	O	NUM	O
.	O	PUNCT	O


Eligible	O	ADJ	B
teens	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
(	B-I	PUNCT	O
TG	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
delayed	I-I	VERB	B
treatment	I-I	NOUN	I
control	I-I	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
CG	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Primary	O	ADJ	B
outcome	O	NOUN	I
measures	O	NOUN	I
included	O	VERB	O
questionnaires	O	NOUN	B
and	O	CCONJ	O
direct	O	ADJ	O
observations	O	NOUN	B
quantifying	O	VERB	B
social	O	ADJ	B
ability	O	NOUN	I
and	O	CCONJ	O
problems	O	NOUN	B
directly	O	ADV	O
related	O	VERB	O
to	O	ADP	O
ASD	O	PROPN	B
.	O	PUNCT	O


Secondary	O	ADJ	B
outcome	O	NOUN	I
measures	O	NOUN	I
included	O	VERB	O
scales	O	NOUN	B
for	O	ADP	O
depressive	O	ADJ	B
symptoms	O	NOUN	I
,	O	PUNCT	O
anxiety	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
behavioral	O	ADJ	B
problems	O	NOUN	O
.	O	PUNCT	O


Rating	O	NOUN	B
scales	O	NOUN	I
for	O	ADP	O
parental	O	ADJ	B
depressive	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
anxiety	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
to	O	PART	O
detect	O	VERB	B
changes	O	NOUN	B
in	O	ADP	O
parental	O	ADJ	B
psychosocial	O	ADJ	B
functioning	O	NOUN	I
throughout	O	ADP	O
the	O	DET	O
PEERS	O	NOUN	B
(	O	PUNCT	O
®	O	NOUN	O
)	O	PUNCT	O
treatment	O	NOUN	B
.	O	PUNCT	O


Independent	O	ADJ	B
samples	O	NOUN	O
t-tests	O	NOUN	O
revealed	B-OUT	VERB	O
no	I-OUT	DET	O
significant	I-OUT	ADJ	O
differences	I-OUT	NOUN	O
at	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
across	I-OUT	ADP	O
the	I-OUT	DET	O
TG	I-OUT	NOUN	B
and	O	CCONJ	O
CG	O	NOUN	B
conditions	O	NOUN	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
age	O	NOUN	B
(	O	PUNCT	O
14.04	O	NUM	O
±	O	NOUN	O
1.64	O	NUM	O
and	O	CCONJ	O
13.54	O	NUM	O
±	O	NOUN	O
1.50	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
IQ	O	NOUN	B
(	O	PUNCT	O
99.39	O	NUM	O
±	O	NOUN	O
18.09	O	NUM	O
&	O	CCONJ	O
100.67	O	NUM	O
±	O	PROPN	O
16.97	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
parental	O	ADJ	B
education	O	NOUN	I
,	O	PUNCT	O
socioeconomic	O	ADJ	B
status	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
ASD	O	VERB	B
symptoms	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Results	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
outcome	O	NOUN	I
suggest	B-OUT	VERB	O
that	I-OUT	SCONJ	O
the	I-OUT	DET	O
TG	I-OUT	NOUN	B
showed	I-OUT	VERB	O
significant	I-OUT	ADJ	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
communication	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
social	I-OUT	ADJ	B
interaction	I-OUT	NOUN	I
domain	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
on	I-OUT	ADP	O
the	I-OUT	DET	O
Autism	I-OUT	PROPN	B
Diagnostic	I-OUT	PROPN	I
Observation	I-OUT	PROPN	I
Schedule	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
interpersonal	I-OUT	ADJ	B
relationship	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
play/leisure	I-OUT	ADJ	B
time	I-OUT	NOUN	I
on	I-OUT	ADP	O
the	I-OUT	DET	O
subdomain	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
Korean	I-OUT	ADJ	B
version	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
Vineland	I-OUT	PROPN	B
Adaptive	I-OUT	PROPN	I
Behavior	I-OUT	NOUN	I
Scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
p	I-OUT	NOUN	O
's	I-OUT	AUX	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
social	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
knowledge	I-OUT	NOUN	B
total	I-OUT	NOUN	O
scores	I-OUT	NOUN	O
on	I-OUT	ADP	O
the	I-OUT	DET	O
Test	I-OUT	PROPN	B
of	I-OUT	ADP	O
Adolescent	I-OUT	PROPN	B
Social	I-OUT	PROPN	B
Skills	I-OUT	PROPN	I
Knowledge-Revised	I-OUT	PROPN	O
(	I-OUT	PUNCT	O
p	I-OUT	NOUN	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
decreased	I-OUT	VERB	B
depressive	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
on	I-OUT	ADP	O
the	I-OUT	DET	O
Child	I-OUT	PROPN	B
Depression	I-OUT	PROPN	I
Inventory	I-OUT	PROPN	I
following	I-OUT	VERB	O
treatment	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Analyses	O	NOUN	B
of	O	ADP	O
parental	O	ADJ	B
outcome	B-OUT	NOUN	B
reveal	I-OUT	VERB	O
a	I-OUT	DET	O
significant	I-OUT	ADJ	O
decrease	I-OUT	NOUN	B
in	I-OUT	ADP	O
maternal	I-OUT	ADJ	B
state	I-OUT	NOUN	O
anxiety	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
TG	O	NOUN	B
after	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
potential	O	ADJ	B
confounding	O	NOUN	B
variables	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Despite	O	SCONJ	O
cultural	O	ADJ	B
and	O	CCONJ	O
linguistic	O	ADJ	B
differences	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
PEERS	O	NOUN	B
(	O	PUNCT	O
®	O	NOUN	O
)	O	PUNCT	O
social	O	ADJ	B
skills	O	NOUN	I
intervention	O	NOUN	B
appears	B-OUT	VERB	O
to	I-OUT	PART	O
be	I-OUT	AUX	O
efficacious	I-OUT	ADJ	B
for	I-OUT	ADP	O
teens	I-OUT	NOUN	B
with	I-P	ADP	O
ASD	O	VERB	B
in	O	ADP	O
Korea	O	PROPN	B
with	O	ADP	O
modest	O	ADJ	O
cultural	O	ADJ	B
adjustment	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
RCT	O	NOUN	B
,	O	PUNCT	O
participants	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
PEERS	O	NOUN	B
(	O	PUNCT	O
®	O	NOUN	O
)	O	PUNCT	O
treatment	B-OUT	NOUN	B
showed	I-OUT	VERB	O
significant	I-OUT	ADJ	O
improvement	I-OUT	NOUN	B
in	I-OUT	ADP	O
social	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
knowledge	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
interpersonal	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
play/leisure	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
a	I-OUT	DET	O
decrease	I-OUT	NOUN	B
in	I-OUT	ADP	O
depressive	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
ASD	O	VERB	B
symptoms	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
represents	O	VERB	O
one	O	NUM	O
of	O	ADP	O
only	O	ADV	O
a	O	DET	O
few	O	ADJ	O
cross-cultural	O	ADJ	B
validation	O	NOUN	B
trials	O	NOUN	O
of	O	ADP	O
an	O	DET	O
established	O	ADJ	O
evidence-based	O	ADJ	B
treatment	B-P	NOUN	I
for	I-P	ADP	O
adolescents	I-P	NOUN	B
with	O	ADP	O
ASD	O	PROPN	B
.	O	PUNCT	O


Dose-related	O	ADJ	B
difference	O	NOUN	I
in	O	ADP	O
progression	O	NOUN	B
rates	O	NOUN	B
of	O	ADP	O
cytomegalovirus	B-P	NOUN	B
retinopathy	I-P	NOUN	I
during	O	ADP	O
foscarnet	B-I	NOUN	B
maintenance	I-I	NOUN	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


AIDS	O	PROPN	B
Clinical	O	PROPN	B
Trials	O	PROPN	I
Group	O	PROPN	O
Protocol	O	PROPN	O
915	O	NUM	O
Team	O	PROPN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
A	O	DET	O
previous	O	ADJ	O
dose-ranging	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
foscarnet	B-I	NOUN	B
maintenance	I-I	NOUN	O
therapy	I-I	NOUN	B
for	O	ADP	O
cytomegalovirus	O	NOUN	B
retinopathy	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
positive	O	ADJ	B
relationship	O	NOUN	B
between	O	ADP	O
dose	O	NOUN	B
and	O	CCONJ	O
survival	O	NOUN	B
but	O	CCONJ	O
could	O	AUX	O
not	O	PART	O
confirm	O	VERB	O
a	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
dose	O	NOUN	B
and	O	CCONJ	O
time	O	NOUN	B
to	O	PART	O
first	O	ADJ	O
progression	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
retrospective	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
data	O	NOUN	B
from	O	ADP	O
that	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
dose	O	NOUN	B
and	O	CCONJ	O
progression	O	NOUN	B
rates	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
reflects	O	VERB	O
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
retina	O	NOUN	B
destroyed	O	VERB	B
when	O	SCONJ	O
progression	O	NOUN	B
occurs	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
given	O	VERB	O
one	O	NUM	O
of	O	ADP	O
two	B-I	NUM	O
foscarnet	I-I	NOUN	B
maintenance	I-I	NOUN	O
therapy	I-I	NOUN	O
doses	I-I	NOUN	B
(	O	PUNCT	O
90	O	NUM	O
mg/kg	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
weight/day	O	NOUN	I
[	B-I	PUNCT	O
FOS-90	I-I	NOUN	B
group	O	NOUN	B
]	O	PUNCT	O
or	O	CCONJ	O
120	B-I	NUM	O
mg/kg	I-I	NOUN	O
of	I-I	ADP	O
body	I-I	NOUN	B
weight/day	I-I	NOUN	I
[	I-I	PUNCT	O
FOS-120	I-I	NOUN	B
group	O	NOUN	B
]	O	PUNCT	O
after	O	ADP	O
induction	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
baseline	O	NOUN	B
and	O	CCONJ	O
follow-up	O	ADJ	B
photographs	O	NOUN	B
and	O	CCONJ	O
pre-established	O	ADJ	B
definitions	O	NOUN	B
and	O	CCONJ	O
methodology	O	NOUN	B
in	O	ADP	O
a	O	DET	O
masked	O	VERB	O
analysis	O	NOUN	B
,	O	PUNCT	O
posterior	O	ADJ	B
progression	O	NOUN	B
rates	O	NOUN	B
and	O	CCONJ	O
foveal	O	ADJ	B
proximity	O	NOUN	O
rates	O	NOUN	B
for	O	ADP	O
individual	O	ADJ	B
lesions	O	NOUN	B
,	O	PUNCT	O
selected	O	VERB	O
by	O	ADP	O
prospectively	O	ADV	O
defined	O	VERB	O
criteria	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
calculated	O	VERB	B
in	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Rates	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
following	O	VERB	O
median	B-OUT	ADJ	B
rates	I-OUT	NOUN	I
were	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
the	O	DET	O
FOS-90	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
for	O	ADP	O
the	O	DET	O
FOS-120	O	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
:	O	PUNCT	O
greatest	B-OUT	ADJ	O
maximum	I-OUT	ADJ	B
rate	I-OUT	NOUN	B
at	I-OUT	ADP	O
which	I-OUT	DET	O
lesions	I-OUT	NOUN	B
enlarged	O	VERB	B
in	O	ADP	O
a	O	DET	O
posterior	O	ADJ	B
direction	O	NOUN	B
(	O	PUNCT	O
43.5	O	NUM	O
vs	O	CCONJ	O
12.5	O	NUM	O
microns/day	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.002	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
posterior	B-OUT	ADJ	B
progression	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
for	I-OUT	ADP	O
lesions	I-OUT	NOUN	B
closest	I-OUT	ADJ	O
to	I-OUT	ADP	O
the	I-OUT	DET	O
fovea	I-OUT	NOUN	B
(	O	PUNCT	O
42.8	O	NUM	O
vs	O	CCONJ	O
5.5	O	NUM	O
microns/day	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.010	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
and	O	CCONJ	O
maximum	B-OUT	ADJ	B
foveal	I-OUT	NOUN	B
proximity	I-OUT	NOUN	O
rate	I-OUT	NOUN	B
for	I-OUT	ADP	O
either	I-OUT	DET	O
eye	I-OUT	NOUN	B
(	O	PUNCT	O
32.3	O	NUM	O
vs	O	CCONJ	O
3.4	O	NUM	O
microns/day	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.031	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Patients	B-P	NOUN	B
receiving	I-P	VERB	O
higher	I-P	ADJ	B
doses	I-P	NOUN	B
of	I-P	ADP	O
foscarnet	I-I	NOUN	B
have	O	AUX	O
slower	O	ADJ	O
rates	O	NOUN	B
of	O	ADP	O
progression	O	NOUN	B
and	O	CCONJ	O
therefore	O	ADV	O
less	O	ADV	O
retinal	O	ADJ	B
tissue	O	NOUN	B
damage	O	NOUN	I
during	O	ADP	O
maintenance	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
foscarnet	B-I	NOUN	B
maintenance	O	NOUN	O
therapy	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
120	O	NUM	O
mg/kg	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
weight/day	O	NOUN	I
instead	O	ADV	O
of	O	ADP	O
90	O	NUM	O
mg/kg	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
weight/day	O	NOUN	I
may	O	AUX	O
help	O	VERB	O
to	O	PART	O
preserve	O	VERB	O
vision	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cytomegalovirus	I-P	NOUN	B
retinopathy	I-P	NOUN	I
.	I-P	PUNCT	O


Neridronate	B-I	NOUN	B
prevents	O	VERB	B
bone	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
receiving	I-P	VERB	O
androgen	I-I	NOUN	B
deprivation	I-I	NOUN	I
therapy	I-I	NOUN	I
for	I-P	ADP	O
prostate	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


UNLABELLED	O	NOUN	B
Today	O	NOUN	O
,	O	PUNCT	O
androgen	B-I	NOUN	B
deprivation	I-I	NOUN	I
therapy	I-I	NOUN	I
is	O	AUX	O
a	O	DET	O
cornerstone	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
advanced	B-P	ADJ	B
prostate	I-P	NOUN	I
cancer	I-P	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
it	O	PRON	O
presents	O	VERB	O
important	O	ADJ	O
complications	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
osteoporosis	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Neridronate	B-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
relatively	I-I	ADV	O
new	I-I	ADJ	O
bisphosphonate	I-I	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
able	O	ADJ	O
to	O	PART	O
prevent	O	VERB	B
bone	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
prostate	I-P	NOUN	B
cancer	I-P	NOUN	I
during	I-P	ADP	O
androgen	I-P	NOUN	B
ablation	I-P	NOUN	I
.	I-P	PUNCT	O


INTRODUCTION	O	PUNCT	O
Androgen-deprivation	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
ADT	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
cornerstone	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
advanced	B-P	ADJ	B
prostate	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
therapy	O	NOUN	B
has	O	AUX	O
iatrogenic	O	ADJ	B
complications	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
osteoporosis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
neridronate	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
relatively	O	ADV	O
new	O	ADJ	O
bisphosphonate	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
prevent	O	VERB	B
bone	O	NOUN	B
loss	O	NOUN	I
during	O	ADP	O
androgen	O	NOUN	B
ablation	O	NOUN	I
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
Forty-eight	B-P	NUM	O
osteoporotic	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
prostate	I-P	NOUN	B
cancer	I-P	NOUN	I
,	I-P	PUNCT	O
treated	I-P	VERB	B
with	I-P	ADP	I
3-month	I-P	ADJ	O
depot	I-P	NOUN	B
triptorelina	I-I	NOUN	O
,	O	PUNCT	O
were	O	AUX	O
enrolled	O	VERB	O
and	O	CCONJ	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
two	O	NUM	O
different	O	ADJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
:	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	I
(	B-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
24	I-P	NUM	O
)	I-P	PUNCT	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
daily	B-I	ADJ	B
calcium	I-I	NOUN	B
and	I-I	CCONJ	O
cholecalciferol	I-I	NOUN	B
supplement	I-I	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
elemental	O	ADJ	B
calcium	O	NOUN	O
and	O	CCONJ	O
400	O	NUM	O
IU	O	NOUN	B
cholecalciferol	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
group	O	NOUN	B
B	O	NOUN	I
(	B-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
24	I-P	NUM	O
)	I-P	PUNCT	O
received	O	VERB	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
same	O	ADJ	O
daily	B-I	ADJ	B
calcium	I-I	NOUN	B
and	I-I	CCONJ	O
cholecalciferol	I-I	NOUN	B
supplement	I-I	NOUN	B
,	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
neridronate	B-I	NOUN	B
given	O	VERB	O
intramuscularly	O	ADV	B
every	O	DET	O
month	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
bicalutamide	B-I	NOUN	B
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Lumbar	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
femoral	I-OUT	ADJ	B
BMD	I-OUT	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
DXA	O	PROPN	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
;	O	PUNCT	O
moreover	O	ADV	O
,	O	PUNCT	O
deoxypyridinoline	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
DPD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
bone	I-OUT	NOUN	B
alkaline	I-OUT	NOUN	I
phosphatase	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BALP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
determined	O	VERB	O
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	B
,	O	PUNCT	O
midway	O	ADV	B
through	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
After	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
patients	O	NOUN	B
treated	O	VERB	B
only	O	ADV	O
with	O	ADP	O
calcium	O	NOUN	B
and	O	CCONJ	O
cholecalciferol	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
showed	O	VERB	O
a	O	DET	O
marked	B-OUT	ADJ	O
bone	I-OUT	NOUN	B
loss	I-OUT	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
increased	B-OUT	VERB	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
DPD	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
BALP	I-OUT	NOUN	B
compared	O	VERB	O
with	O	ADP	O
baseline	O	NOUN	B
values	O	NOUN	O
,	O	PUNCT	O
patients	O	NOUN	B
treated	O	VERB	B
also	O	ADV	O
with	O	ADP	O
neridronate	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
had	O	AUX	O
substantially	O	ADV	O
unchanged	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
these	O	DET	O
markers	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
lumbar	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
total	I-OUT	ADJ	B
hip	I-OUT	NOUN	I
BMD	I-OUT	NOUN	I
decreased	I-OUT	VERB	B
significantly	I-OUT	ADV	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
only	O	ADV	O
with	O	ADP	O
calcium	O	NOUN	B
and	O	CCONJ	O
cholecalciferol	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
change	B-OUT	VERB	O
significantly	I-OUT	ADV	O
at	O	ADP	O
any	O	DET	O
skeletal	O	ADJ	B
site	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
also	O	ADV	O
with	O	ADP	O
neridronate	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
relevant	B-OUT	ADJ	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
during	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Neridronate	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
bone	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
hip	O	NOUN	B
and	O	CCONJ	O
lumbar	O	ADJ	B
spine	O	NOUN	I
in	O	ADP	O
men	B-P	NOUN	B
receiving	I-P	VERB	O
ADT	I-P	NOUN	B
for	I-P	ADP	O
prostate	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
paradoxical	O	ADJ	B
outcome	O	NOUN	I
events	O	NOUN	I
in	O	ADP	O
overweight	B-P	ADJ	B
and	I-P	CCONJ	O
obese	I-P	ADJ	B
subjects	I-P	NOUN	B
with	I-P	ADP	O
cardiovascular	I-P	ADJ	B
disease	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND/OBJECTIVES	O	NOUN	B
The	O	DET	O
Sibutramine	O	NOUN	B
Cardiovascular	O	ADJ	I
OUTcomes	O	PROPN	I
(	O	PUNCT	O
SCOUT	O	NOUN	B
)	O	PUNCT	O
trial	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significantly	O	ADV	O
increased	O	VERB	B
relative	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
nonfatal	B-OUT	ADJ	B
cardiovascular	I-OUT	ADJ	O
events	I-OUT	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
mortality	B-OUT	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
overweight	B-P	ADJ	B
and	I-P	CCONJ	O
obese	I-P	ADJ	B
subjects	I-P	NOUN	B
receiving	I-P	VERB	O
long-term	I-I	ADJ	B
sibutramine	I-I	NOUN	B
treatment	I-I	NOUN	I
with	I-I	ADP	O
diet	I-I	NOUN	B
and	I-I	CCONJ	O
exercise	I-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
early	O	ADJ	O
changes	O	NOUN	B
(	O	PUNCT	O
both	O	DET	O
increases	O	VERB	B
and	O	CCONJ	O
decreases	O	VERB	B
)	O	PUNCT	O
in	O	ADP	O
body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
and	O	CCONJ	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
these	O	DET	O
changes	O	NOUN	B
on	O	ADP	O
subsequent	O	ADJ	O
cardiovascular	B-OUT	ADJ	B
outcome	I-OUT	NOUN	I
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


SUBJECTS/METHODS	O	NOUN	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
9804	I-P	NUM	O
male	I-P	NOUN	B
and	I-P	CCONJ	O
female	I-P	ADJ	B
subjects	I-P	NOUN	I
,	I-P	PUNCT	O
aged	I-P	ADJ	B
55	I-P	NUM	O
years	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
,	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
body	I-P	NOUN	B
mass	I-P	NOUN	I
index	I-P	NOUN	I
of	I-P	ADP	O
27-45	I-P	NUM	O
kg	I-P	NOUN	O
m	I-P	NOUN	O
(	I-P	PUNCT	O
-2	I-P	NUM	O
)	I-P	PUNCT	O
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
this	I-P	DET	O
current	I-P	ADJ	O
subanalysis	I-P	NOUN	B
of	O	ADP	O
the	O	DET	O
SCOUT	O	NOUN	B
trial	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
were	B-P	AUX	O
required	I-P	VERB	O
to	I-P	PART	O
have	I-P	AUX	O
a	I-P	DET	O
history	I-P	NOUN	B
of	I-P	ADP	O
cardiovascular	I-P	ADJ	B
disease	I-P	NOUN	I
and/or	I-P	CCONJ	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
mellitus	I-P	NOUN	I
with	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADJ	O
one	I-P	NUM	O
cardiovascular	I-P	ADJ	B
risk	I-P	NOUN	I
factor	I-P	NOUN	I
(	I-P	PUNCT	O
hypertension	I-P	NOUN	B
,	I-P	PUNCT	O
dyslipidemia	I-P	NOUN	B
,	I-P	PUNCT	O
current	I-P	ADJ	O
smoking	I-P	NOUN	B
or	I-P	CCONJ	O
diabetic	I-P	ADJ	B
nephropathy	I-P	NOUN	I
)	I-P	PUNCT	O
to	O	PART	O
assess	O	VERB	O
cardiovascular	O	ADJ	B
outcomes	O	NOUN	B
.	O	PUNCT	O


Post	O	NOUN	B
hoc	O	NOUN	I
subgroup	O	NOUN	I
analyses	B-OUT	NOUN	I
of	I-OUT	ADP	O
weight	I-OUT	NOUN	B
change	I-OUT	NOUN	I
(	O	PUNCT	O
categories	O	NOUN	B
)	O	PUNCT	O
and	B-OUT	CCONJ	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
were	O	AUX	O
performed	O	VERB	O
overall	O	ADV	B
and	O	CCONJ	O
by	O	ADP	O
treatment	O	NOUN	B
group	O	NOUN	I
(	B-I	PUNCT	O
6-week	I-I	ADJ	O
sibutramine	I-I	NOUN	B
followed	O	VERB	O
by	O	ADP	O
randomized	B-I	ADJ	B
placebo	I-I	NOUN	B
or	I-I	CCONJ	O
continued	I-I	VERB	O
sibutramine	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
primary	I-OUT	ADJ	B
outcome	I-OUT	NOUN	I
event	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
POE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	I-OUT	AUX	O
a	I-OUT	DET	O
composite	I-OUT	NOUN	B
of	I-OUT	ADP	O
nonfatal	I-OUT	ADJ	O
myocardial	I-OUT	ADJ	O
infarction	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
nonfatal	I-OUT	ADJ	B
stroke	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
resuscitated	I-OUT	ADJ	B
cardiac	I-OUT	ADJ	O
arrest	I-OUT	NOUN	O
or	I-OUT	CCONJ	O
cardiovascular	I-OUT	ADJ	B
death	I-OUT	NOUN	I
.	O	PUNCT	O


Time-to-event	O	ADJ	B
analyses	O	NOUN	I
of	O	ADP	O
the	O	DET	O
POE	O	PROPN	B
were	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
Cox	O	NOUN	B
regression	O	NOUN	I
models	O	NOUN	I
with	O	ADP	O
factors	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
subgroups	O	NOUN	B
and	O	CCONJ	O
interactions	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
During	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
6-week	B-I	ADJ	O
sibutramine	I-I	NOUN	B
treatment	O	NOUN	I
period	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
systolic	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
decreased	O	VERB	B
progressively	O	ADV	O
with	O	ADP	O
increasing	B-OUT	VERB	B
weight	I-OUT	NOUN	B
loss	I-OUT	NOUN	I
in	O	ADP	O
hypertensive	O	ADJ	B
subjects	O	NOUN	I
(	O	PUNCT	O
-8.1±10.5	O	PUNCT	O
mm	O	NOUN	B
Hg	O	NOUN	I
with	O	ADP	I
<	O	NOUN	O
5	O	NUM	O
kg	O	NOUN	O
weight	O	NOUN	B
loss	O	NOUN	I
to	O	PART	O
-10.8±11.0	O	NOUN	O
mm	O	X	B
Hg	O	NOUN	I
with	O	ADP	I
⩾5	O	NOUN	O
kg	O	NOUN	O
weight	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
highest	I-OUT	ADJ	O
POE	O	PROPN	B
incidence	O	NOUN	B
occurred	O	VERB	O
mainly	O	ADV	O
in	O	ADP	O
groups	O	NOUN	B
with	B-OUT	ADP	O
increases	I-OUT	NOUN	B
in	I-OUT	ADP	O
both	I-OUT	CCONJ	O
weight	I-OUT	NOUN	B
and	O	CCONJ	O
blood	O	NOUN	B
pressure	O	NOUN	I
.	O	PUNCT	O


However	B-I	ADV	O
,	I-I	PUNCT	O
with	I-I	ADP	O
long-term	I-I	ADJ	B
sibutramine	O	NOUN	B
treatment	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
a	I-OUT	DET	O
markedly	I-OUT	ADV	O
lower	I-OUT	ADJ	B
blood	O	NOUN	I
pressure	B-OUT	NOUN	I
tended	I-OUT	VERB	O
to	O	PART	O
increase	O	VERB	B
POEs	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	B-OUT	NOUN	O
Modest	O	ADJ	B
weight	O	NOUN	B
loss	B-OUT	NOUN	I
and	I-OUT	CCONJ	O
modest	I-OUT	ADJ	O
lower	I-OUT	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
each	O	DET	O
reduced	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
events	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
expected	O	VERB	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
combination	B-OUT	NOUN	B
of	I-OUT	ADP	O
early	I-OUT	ADJ	O
marked	O	ADJ	O
weight	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
rapid	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	O	NOUN	I
reduction	O	NOUN	B
seems	O	VERB	O
to	B-P	PART	O
be	I-P	AUX	O
harmful	I-P	ADJ	O
in	I-P	ADP	O
this	I-P	DET	O
obese	I-P	ADJ	B
elderly	I-P	ADJ	B
cardiovascular	I-P	ADJ	B
diseased	O	ADJ	O
population	O	NOUN	O
.	O	PUNCT	O


Efficacy	O	NOUN	B
of	O	ADP	O
bepotastine	B-I	NOUN	B
besilate	I-I	NOUN	O
ophthalmic	I-I	ADJ	O
solution	I-I	NOUN	O
1.5	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
seasonal	B-OUT	ADJ	B
allergic	I-OUT	ADJ	I
conjunctivitis	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
natural	O	ADJ	B
exposure	O	NOUN	I
,	O	PUNCT	O
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Allergic	O	ADJ	B
conjunctivitis	O	NOUN	I
(	O	PUNCT	O
AC	O	NOUN	B
)	O	PUNCT	O
affects	O	VERB	O
an	O	DET	O
estimated	O	VERB	B
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
population	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Western	O	ADJ	B
world	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
large	O	ADJ	O
fraction	O	NOUN	B
suffering	O	NOUN	B
due	O	ADP	O
to	O	PART	O
seasonal	O	ADJ	B
or	O	CCONJ	O
perennial	O	ADJ	B
allergen	O	NOUN	B
exposures	O	NOUN	B
.	O	PUNCT	O


Bepotastine	B-I	NOUN	B
besilate	I-I	NOUN	O
ophthalmic	I-I	ADJ	O
solution	I-I	NOUN	O
(	I-I	PUNCT	O
BBOS	I-I	NOUN	B
)	I-I	PUNCT	O
1.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
dual-acting	B-I	ADJ	B
histamine	I-I	NOUN	I
(	O	PUNCT	O
H	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
receptor	O	NOUN	O
antagonist	O	NOUN	B
and	O	CCONJ	O
mast	O	NOUN	B
cell	O	NOUN	I
stabilizer	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
indicated	O	VERB	O
for	O	ADP	O
itching	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
AC	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
BBOS	O	PROPN	B
1.5	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
reducing	O	VERB	B
ocular	B-P	ADJ	B
itching	I-P	NOUN	I
associated	I-P	VERB	B
with	I-P	ADP	I
AC	I-P	NOUN	B
in	I-P	ADP	O
subjects	I-P	NOUN	B
enrolled	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
natural	I-P	ADJ	B
exposure	I-P	NOUN	I
trial	I-P	NOUN	I
.	I-P	PUNCT	O


Eligible	B-P	ADJ	O
subjects	I-P	NOUN	B
in	O	ADP	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
double-masked	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
parallel-group	O	NOUN	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
natural	O	ADJ	B
exposure	O	NOUN	I
clinical	O	ADJ	I
trial	O	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
BBOS	B-I	NOUN	B
1.5	O	NUM	O
%	O	NOUN	O
or	B-I	CCONJ	O
placebo	I-I	ADJ	B
eyedrops	I-I	NOUN	B
on	O	ADP	O
a	O	DET	O
1:1	O	NUM	O
basis	O	NOUN	B
and	O	CCONJ	O
instilled	O	VERB	B
1	O	NUM	O
drop	O	NOUN	B
of	O	ADP	O
the	O	DET	O
test	O	NOUN	B
agent	O	NOUN	I
into	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
twice	O	ADV	O
daily	O	ADV	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
change	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
instantaneous	O	ADJ	B
and	O	CCONJ	O
reflective	B-OUT	ADJ	O
ocular	I-OUT	ADJ	B
itching	I-OUT	NOUN	O
scores	I-OUT	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
based	O	VERB	O
on	O	ADP	O
subject-assessed	O	ADJ	B
severity	O	NOUN	B
of	O	ADP	O
instantaneous	O	ADJ	B
and	O	CCONJ	O
reflective	O	ADJ	B
itching	O	NOUN	B
.	O	PUNCT	O


Subject-reported	B-OUT	ADJ	B
adverse	I-OUT	ADJ	I
events	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AEs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
also	O	ADV	O
recorded	O	VERB	O
for	O	ADP	O
safety	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
BBOS	O	NOUN	B
1.5	O	NUM	O
%	O	NOUN	O
significantly	O	ADV	O
reduced	O	VERB	B
instantaneous	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
reflective	I-OUT	ADJ	O
ocular	I-OUT	ADJ	B
itching	I-OUT	NOUN	O
scores	I-OUT	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
over	O	ADP	O
the	O	DET	O
2-week	O	ADJ	O
study	O	NOUN	B
period	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.007	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


BBOS	O	NOUN	B
1.5	O	NUM	O
%	O	NOUN	O
was	O	AUX	O
well	O	ADV	O
tolerated	B-OUT	VERB	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
AEs	I-OUT	NOUN	B
were	O	AUX	O
generally	O	ADV	O
transient	O	ADJ	B
and	O	CCONJ	O
mild	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
clinical	O	ADJ	B
study	O	NOUN	I
indicates	O	VERB	O
BBOS	O	NOUN	B
1.5	O	NUM	O
%	O	NOUN	O
effectively	B-OUT	ADV	B
and	I-OUT	CCONJ	O
safely	I-OUT	ADV	O
treated	I-OUT	VERB	B
ocular	I-OUT	ADJ	B
itching	I-OUT	NOUN	I
in	O	ADP	O
a	O	DET	O
natural	O	ADJ	B
exposure	O	NOUN	O
allergy	O	NOUN	O
study	O	NOUN	O
and	O	CCONJ	O
is	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
treatment	O	NOUN	B
option	O	NOUN	O
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
ocular	O	ADJ	B
itching	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
AC	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
ClinicalTrials.gov	O	NOUN	O
identifier	O	NOUN	O
number	O	NOUN	O
:	O	PUNCT	O
NCT01174823	O	PROPN	O
.	O	PUNCT	O


)	O	PUNCT	O


[	O	PUNCT	O
Safety	O	NOUN	B
of	O	ADP	O
adjuvant	B-I	ADJ	B
dose-dense	I-I	ADJ	B
chemotherapy	I-I	NOUN	I
with	I-I	ADP	O
paclitaxel	I-I	NOUN	B
and	I-I	CCONJ	O
epirubicin	I-I	NOUN	B
for	O	ADP	O
high-risk	B-P	ADJ	B
breast	I-P	NOUN	O
cancer	I-P	NOUN	O
]	I-P	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerance	I-OUT	NOUN	B
of	O	ADP	O
adjuvant	B-I	ADJ	B
dose-dense	I-I	ADJ	B
chemotherapy	I-I	NOUN	I
with	I-I	ADP	O
paclitaxel	I-I	NOUN	B
and	I-I	CCONJ	O
epirubicin	I-I	NOUN	B
for	O	ADP	O
high-risk	B-P	ADJ	B
breast	I-P	NOUN	O
cancer	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
From	O	ADP	O
January	O	PROPN	O
2004	O	NUM	O
to	O	ADP	O
December	O	PROPN	O
2006	O	NUM	O
,	O	PUNCT	O
101	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
high-risk	I-P	ADJ	B
breast	I-P	NOUN	O
cancer	I-P	NOUN	O
after	I-P	ADP	O
surgical	I-P	ADJ	B
resection	I-P	NOUN	I
were	O	AUX	O
enrolled	O	VERB	O
into	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
dose-dense	O	ADJ	B
and	O	CCONJ	O
regular	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
patient	O	NOUN	B
received	O	VERB	O
6	B-I	NUM	O
cycles	I-I	NOUN	B
of	I-I	ADP	O
chemotherapy	I-I	NOUN	B
with	I-I	ADP	O
intravenous	I-I	ADJ	B
administration	I-I	NOUN	I
of	I-I	ADP	O
paclitaxel	I-I	NOUN	B
(	I-I	PUNCT	O
175	I-I	NUM	O
mg/m2	I-I	NOUN	O
,	I-I	PUNCT	O
on	I-I	ADP	O
D3	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
epirubicin	I-I	NOUN	B
(	I-I	PUNCT	O
60	I-I	NUM	O
mg/m2	I-I	NOUN	O
,	I-I	PUNCT	O
on	I-I	ADP	O
Dl	I-I	NOUN	B
and	I-I	CCONJ	O
D2	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


The	O	DET	O
dose-dense	B-I	ADJ	B
group	I-I	NOUN	I
had	I-I	AUX	O
repeated	I-I	VERB	O
treatment	I-I	NOUN	B
every	I-I	DET	O
two	I-I	NUM	O
weeks	I-I	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
regular	B-I	ADJ	B
group	I-I	NOUN	I
repeated	I-I	VERB	O
it	I-I	PRON	O
every	I-I	DET	O
three	I-I	NUM	O
weeks	I-I	NOUN	B
.	I-I	PUNCT	O


G-CSF	B-I	NOUN	B
was	I-I	AUX	O
used	I-I	VERB	O
in	I-I	ADP	O
a	I-I	DET	O
dose	I-I	NOUN	B
of	I-I	ADP	O
3	I-I	NUM	O
microg/kg	I-I	NOUN	O
on	I-I	ADP	O
D5-D9	I-I	NOUN	B
during	O	ADP	O
each	O	DET	O
cycle	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dose-dense	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


While	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
regular	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
used	O	VERB	O
only	O	ADV	O
under	O	ADP	O
the	O	DET	O
condition	O	NOUN	B
that	O	SCONJ	O
grade	O	NOUN	B
II	O	NUM	I
neutropenia	O	NOUN	I
occurred	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
toxicity	B-OUT	NOUN	B
could	O	AUX	O
be	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
101	B-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Major	B-OUT	ADJ	O
grade	I-OUT	NOUN	O
II-IV	I-OUT	NOUN	O
toxicities	I-OUT	NOUN	B
included	I-OUT	VERB	O
:	I-OUT	PUNCT	O
neutropenia	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
vomiting	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
alopecia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
grade	B-OUT	NOUN	B
III-IV	I-OUT	NOUN	I
neutropenia	I-OUT	NOUN	B
was	O	AUX	O
16.0	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
dose-dense	O	ADJ	B
group	O	NOUN	I
versus	O	CCONJ	O
54.9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
regular	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.000	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
postponing	O	VERB	O
of	O	ADP	O
chemotherapy	O	NOUN	B
was	O	AUX	O
2.4	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
6.0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.027	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Ninety-eight	B-P	NUM	O
patients	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
chemotherapy	I-P	NOUN	B
as	I-P	ADP	O
planed	I-P	VERB	B
.	I-P	PUNCT	O


After	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow-up	O	NOUN	B
of	O	ADP	O
24	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
median	B-OUT	ADJ	B
DFS	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
OS	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
reached	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
relapse-free	B-OUT	ADJ	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
were	O	AUX	O
89.8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
100	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
dose-dense	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
87.8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
93.9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
regular	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
relapse-free	B-OUT	ADJ	B
rate	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
high-risk	I-OUT	ADJ	B
patients	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
dose-dense	O	ADJ	B
group	O	NOUN	I
was	O	AUX	O
86.8	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
81.3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
regular	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
corresponding	O	ADJ	O
survival	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
100	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
90.6	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	ADJ	O
Adjuvant	B-I	ADJ	B
dose-dense	I-I	ADJ	B
chemotherapy	I-I	NOUN	I
with	I-I	ADP	O
paclitaxel	I-I	NOUN	B
and	I-I	CCONJ	O
epirubicin	I-I	NOUN	B
is	O	AUX	O
safe	O	ADJ	O
,	O	PUNCT	O
tolerable	O	ADJ	B
and	O	CCONJ	O
promising	O	ADJ	O
for	O	ADP	O
high-risk	B-P	ADJ	B
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Analgesic	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	B
of	O	ADP	O
piroxicam	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Two	O	NUM	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
single-dose	O	ADJ	B
studies	O	NOUN	I
were	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
analgesic	B-OUT	NOUN	B
efficacy	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
piroxicam	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
moderate	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
severe	I-OUT	ADJ	B
postoperative	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Study	O	NOUN	B
1	O	NUM	O
evaluated	O	VERB	B
the	O	DET	O
analgesic	O	NOUN	B
efficacy	O	NOUN	I
of	O	ADP	O
piroxicam	B-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
codeine	B-I	NOUN	B
sulfate	I-I	NOUN	I
60	O	NUM	O
mg	O	NOUN	O
and	B-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


A	B-P	DET	O
final	I-P	ADJ	O
patient	I-P	NOUN	B
population	I-P	NOUN	I
of	I-P	ADP	O
149	I-P	NUM	O
subjects	I-P	NOUN	B
rated	O	VERB	O
pain	B-OUT	NOUN	B
intensity	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
relief	I-OUT	NOUN	I
at	O	ADP	O
one	O	NUM	O
half	O	NOUN	O
hour	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
hour	O	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
hourly	O	ADV	B
for	O	ADP	O
six	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
global	O	ADJ	B
assessment	O	NOUN	I
made	O	VERB	O
at	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


Piroxicam	B-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
efficacious	B-OUT	ADJ	B
than	O	ADP	O
placebo	B-I	NOUN	B
for	O	ADP	O
all	O	DET	O
analgesic	O	NOUN	B
variables	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
sum	B-OUT	NOUN	O
of	I-OUT	ADP	O
the	I-OUT	DET	O
pain	I-OUT	NOUN	B
intensity	I-OUT	NOUN	I
differences	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SPID	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
total	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
relief	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
TOTAL	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
percent	I-OUT	NOUN	O
SPID	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	I
effect	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
to	I-OUT	PART	O
remedication	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Codeine	B-I	NOUN	B
60	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
superior	O	ADJ	O
to	O	PART	O
placebo	B-I	NOUN	B
for	O	ADP	O
percent	B-OUT	NOUN	O
SPID	I-OUT	NOUN	B
and	O	CCONJ	O
some	O	DET	O
hourly	O	ADJ	B
measures	O	NOUN	B
.	O	PUNCT	O


Piroxicam	B-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
codeine	B-I	NOUN	B
60	O	NUM	O
mg	O	NOUN	O
for	O	ADP	O
percent	B-OUT	NOUN	O
SPID	I-OUT	NOUN	B
and	O	CCONJ	O
a	O	DET	O
few	O	ADJ	O
hourly	O	ADJ	B
measures	O	NOUN	B
including	O	VERB	O
time	O	NOUN	O
to	O	ADP	O
remedication	O	NOUN	B
.	O	PUNCT	O


Study	O	NOUN	B
2	O	NUM	O
assessed	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
piroxicam	B-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
or	O	CCONJ	O
40	O	NUM	O
mg	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
aspirin	B-I	NOUN	B
648	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Sixty	B-P	NUM	O
patients	I-P	NOUN	B
rated	O	VERB	O
their	O	PRON	O
pain	B-OUT	NOUN	B
intensity	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
relief	I-OUT	NOUN	B
hourly	O	ADV	B
for	O	ADP	O
12	O	NUM	O
hours	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
24	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
medication	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
doses	O	NOUN	B
of	O	ADP	O
piroxicam	B-I	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
effective	B-OUT	ADJ	B
than	O	ADP	O
placebo	O	NOUN	B
from	O	ADP	O
Hours	O	NOUN	O
2	O	NUM	O
to	O	PART	O
12	O	NUM	O
for	O	ADP	O
pain	B-OUT	NOUN	B
intensity	I-OUT	NOUN	I
difference	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PID	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
relief	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
for	I-OUT	ADP	O
SPID	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
TOTAL	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Aspirin	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
effective	B-OUT	ADJ	B
than	O	ADP	O
placebo	B-I	NOUN	B
from	O	ADP	O
Hours	O	NOUN	O
2	O	NUM	O
to	O	PART	O
8	O	NUM	O
for	O	ADP	O
relief	B-OUT	NOUN	B
and	O	CCONJ	O
Hours	O	NOUN	B
2	O	NUM	I
to	O	PART	O
10	O	NUM	O
for	O	ADP	O
PID	B-OUT	NOUN	B
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
SPID	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
TOTAL	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Piroxicam	B-I	NOUN	B
40	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
effective	B-OUT	ADJ	B
than	O	ADP	O
aspirin	B-I	NOUN	B
648	O	NUM	O
mg	O	NOUN	O
for	O	ADP	O
SPID	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
TOTAL	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
hourly	I-OUT	ADJ	B
measures	I-OUT	NOUN	B
beginning	O	VERB	O
with	O	ADP	O
Hour	O	NOUN	O
6	O	NUM	O
through	O	ADP	O
Hour	O	NOUN	B
12	O	NUM	O
.	O	PUNCT	O


Piroxicam	B-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
better	O	ADJ	O
than	O	ADP	O
aspirin	B-I	NOUN	B
for	O	ADP	O
a	O	DET	O
few	O	ADJ	O
hourly	O	ADJ	B
measures	O	NOUN	B
:	O	PUNCT	O
Hours	O	NOUN	O
7	O	NUM	O
to	O	PART	O
9	O	NUM	O
for	O	ADP	O
relief	O	NOUN	B
and	O	CCONJ	O
Hour	O	NOUN	O
7	O	NUM	O
for	O	ADP	O
PID	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	O
piroxicam	O	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
longer	B-OUT	ADJ	O
duration	I-OUT	NOUN	B
than	O	ADP	O
aspirin	O	NOUN	B
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
piroxicam	B-I	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
longer	B-OUT	ADJ	O
time	I-OUT	NOUN	O
to	I-OUT	PART	O
remedication	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
aspirin	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
in	O	ADP	O
support	O	NOUN	O
of	O	ADP	O
the	O	DET	O
longer	O	ADJ	B
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
analgesic	I-OUT	ADJ	B
efficacy	I-OUT	NOUN	I
of	O	ADP	O
piroxicam	B-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
codeine	B-I	NOUN	B
or	I-I	CCONJ	O
aspirin	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
postoperative	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Comparative	B-OUT	ADJ	O
efficacy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
lofexidine	B-I	NOUN	B
and	I-I	CCONJ	O
clonidine	I-I	NOUN	B
given	O	VERB	O
alone	O	ADV	O
or	O	CCONJ	O
concomitantly	O	ADV	O
with	O	ADP	O
hydrochlorothiazide	B-I	NOUN	B
in	O	ADP	O
hypertensive	B-P	ADJ	B
outpatients	I-P	NOUN	B
.	I-P	PUNCT	O


Boosting	O	VERB	B
uptake	B-OUT	NOUN	B
of	O	ADP	O
influenza	O	NOUN	B
immunisation	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
telephone	B-I	NOUN	B
appointing	I-I	VERB	B
in	O	ADP	O
general	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Immunisation	O	NOUN	B
against	O	ADP	O
influenza	O	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
intervention	O	NOUN	B
that	O	PRON	O
reduces	O	VERB	B
serologically	O	ADV	B
confirmed	O	VERB	O
cases	O	NOUN	B
by	O	ADP	O
between	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
70	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Almost	O	ADV	O
all	O	DET	O
influenza	O	NOUN	B
immunisation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
UK	B-P	PROPN	B
is	O	AUX	O
done	O	VERB	O
within	O	ADP	O
general	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


Current	O	ADJ	O
evidence	O	NOUN	B
on	O	ADP	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
patient	O	NOUN	B
reminders	O	NOUN	O
for	O	ADP	O
all	O	DET	O
types	O	NOUN	O
of	O	ADP	O
immunisation	O	NOUN	B
programmes	O	NOUN	O
is	O	AUX	O
largely	O	ADV	O
based	O	VERB	O
on	O	ADP	O
North	O	ADJ	B
American	O	ADJ	I
studies	O	NOUN	I
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
telephone	B-I	NOUN	B
appointments	I-I	NOUN	I
offered	O	VERB	O
bygeneral	O	ADJ	B
practice	O	NOUN	O
receptionists	O	NOUN	O
increase	O	VERB	B
the	O	DET	O
uptake	B-OUT	NOUN	B
of	I-OUT	ADP	O
irfluenza	I-OUT	DET	B
immunisation	I-OUT	NOUN	B
among	O	ADP	O
the	O	DET	O
registered	B-P	VERB	B
population	I-P	NOUN	B
aged	I-P	ADJ	B
over	I-P	ADP	O
65	I-P	NUM	O
years	I-P	NOUN	B
in	I-P	ADP	O
east	I-P	PROPN	B
London	I-P	PROPN	I
practices	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
OF	O	ADP	O
STUDY	O	ADJ	O
Randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Three	O	NUM	O
research	O	NOUN	B
general	O	ADJ	B
practices	O	NOUN	I
within	O	ADP	O
the	O	DET	O
East	B-P	PROPN	B
London	I-P	PROPN	I
and	I-P	CCONJ	O
Essex	I-P	PROPN	B
network	I-P	NOUN	I
of	I-P	ADP	O
researchers	I-P	NOUN	B
(	I-P	PUNCT	O
ELENoR	I-P	ADV	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHOD	O	NOUN	B
Participants	B-P	NOUN	I
were	I-P	AUX	O
1,820	I-P	NUM	O
low-risk	I-P	ADJ	B
patients	I-P	NOUN	B
aged	I-P	ADJ	B
65	I-P	NUM	O
to	I-P	PART	O
74	I-P	NUM	O
years	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
not	I-P	PART	O
previously	I-P	ADV	O
been	I-P	AUX	O
in	I-P	ADP	O
a	I-P	DET	O
recall	I-P	NOUN	B
system	I-P	NOUN	I
for	I-P	ADP	O
influenza	I-P	NOUN	B
immunisation	I-P	NOUN	I
at	I-P	ADP	O
their	I-P	PRON	O
general	I-P	ADJ	B
practice	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
intervention	O	NOUN	B
,	O	PUNCT	O
during	O	ADP	O
October	O	PROPN	O
2000	O	NUM	O
,	O	PUNCT	O
was	O	AUX	O
a	O	DET	O
telephone	B-I	NOUN	B
call	I-I	NOUN	O
from	I-I	ADP	O
the	I-I	DET	O
practice	I-I	NOUN	B
receptionist	I-I	NOUN	I
to	O	ADP	O
intervention	B-I	NOUN	B
group	O	NOUN	I
households	O	NOUN	B
,	O	PUNCT	O
offering	O	VERB	O
an	O	DET	O
appointment	O	NOUN	B
for	O	ADP	O
influenza	O	NOUN	B
immunisation	O	NOUN	I
at	O	ADP	O
a	O	DET	O
nurse-run	O	NOUN	B
.	O	PUNCT	O


clinic	O	ADJ	B
Main	O	ADJ	O
outcome	O	NOUN	O
measures	O	NOUN	O
were	O	AUX	O
the	O	DET	O
numbers	B-OUT	NOUN	O
of	I-OUT	ADP	O
individuals	I-OUT	NOUN	B
in	I-OUT	ADP	O
each	I-OUT	DET	O
group	I-OUT	NOUN	B
receiving	I-OUT	VERB	O
immunisation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
practice	I-OUT	NOUN	B
costs	I-OUT	NOUN	I
of	I-OUT	ADP	O
a	I-OUT	DET	O
telephone-appointing	I-OUT	ADJ	B
programme	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
intention	O	NOUN	B
to	O	PART	O
treat	O	VERB	B
analysis	O	NOUN	B
showed	O	VERB	O
an	O	DET	O
immunisation	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
control	B-I	ADJ	B
group	O	NOUN	I
of	O	ADP	O
44	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
compared	O	VERB	O
with	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
intervention	B-I	NOUN	B
group	I-I	NOUN	I
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
=	O	ADJ	O
1.29	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
=	O	ADJ	O
1.03	O	NUM	O
to	O	PART	O
1.63	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
patients	B-P	NOUN	B
making	I-P	VERB	O
a	I-P	DET	O
telephone	I-I	NOUN	B
appointment	I-I	NOUN	I
,	O	PUNCT	O
88	O	NUM	O
%	O	NOUN	O
recieved	O	VERB	B
immunisation	B-OUT	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
22	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
those	O	DET	O
not	O	PART	O
wanting	O	VERB	O
an	O	DET	O
appointment	O	NOUN	B
went	O	VERB	O
on	O	ADP	O
to	O	PART	O
be	O	AUX	O
immunised	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
controlgroup	B-I	NOUN	B
,	O	PUNCT	O
income	B-OUT	NOUN	B
generated	I-OUT	VERB	O
was	O	AUX	O
11.35	O	NUM	O
pounds	O	NOUN	O
per	O	ADP	O
immunisation	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
each	O	DET	O
additional	O	ADJ	O
immunisation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
the	O	DET	O
income	O	NOUN	B
was	O	AUX	O
5.20	O	NUM	O
pounds	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
'number	B-OUT	NOUN	O
needed	I-OUT	VERB	O
to	I-OUT	ADP	O
telephone	I-OUT	NOUN	B
'	I-OUT	PUNCT	O
was	O	AUX	O
17	O	NUM	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Uptake	O	NOUN	B
of	O	ADP	O
influenza	O	NOUN	B
immunisation	B-OUT	NOUN	I
among	O	ADP	O
the	O	DET	O
low-risk	B-P	ADJ	B
older	I-P	ADJ	B
population	I-P	NOUN	I
in	I-P	ADP	O
inner-city	I-P	ADJ	B
areas	I-P	NOUN	I
can	O	AUX	O
be	O	AUX	O
boosted	O	VERB	O
by	O	ADP	O
around	O	ADV	O
6	O	NUM	O
%	O	NOUN	O
using	O	VERB	O
a	O	DET	O
simple	O	ADJ	O
intervention	B-I	NOUN	B
by	O	ADP	O
receptionists	O	NOUN	B
.	O	PUNCT	O


Immunisation	B-OUT	NOUN	B
rates	I-OUT	NOUN	B
in	O	ADP	O
this	O	DET	O
low-risk	O	ADJ	B
group	O	NOUN	B
fell	O	VERB	O
well	O	ADV	O
short	O	ADJ	O
of	O	ADP	O
the	O	DET	O
60	O	NUM	O
%	O	NOUN	O
government	O	NOUN	B
target	O	NOUN	B
.	O	PUNCT	O


Improving	O	VERB	B
immunisation	B-OUT	NOUN	B
rates	I-OUT	NOUN	B
will	O	AUX	O
require	O	VERB	O
a	O	DET	O
sustained	O	ADJ	B
public	O	ADJ	B
health	O	NOUN	O
campaign	O	NOUN	O
.	O	PUNCT	O


Retaining	O	VERB	B
the	O	DET	O
item-of-service	O	ADJ	B
payments	O	NOUN	I
to	O	ADP	O
practices	O	NOUN	B
should	O	AUX	O
support	O	VERB	O
costs	O	NOUN	B
of	O	ADP	O
practice-based	O	ADJ	B
interventions	O	NOUN	I
.	O	PUNCT	O


Local	O	ADJ	B
delivery	O	NOUN	I
of	O	ADP	O
a	O	DET	O
recombinant	B-I	ADJ	B
adenoassociated	I-I	ADJ	O
vector	I-I	NOUN	O
containing	I-I	VERB	O
a	I-I	DET	O
tumour	I-I	NOUN	B
necrosis	I-I	NOUN	I
factor	I-I	NOUN	I
alpha	I-I	NOUN	I
antagonist	I-I	NOUN	I
gene	I-I	NOUN	O
in	O	ADP	O
inflammatory	O	ADJ	B
arthritis	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
1	O	NUM	I
dose-escalation	O	NOUN	B
safety	B-OUT	NOUN	I
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
examine	O	VERB	O
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
intra-articular	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
rAAV2-TNFR	B-I	NOUN	B
:	I-I	PUNCT	O
Fc	I-I	NOUN	B
,	I-I	PUNCT	O
an	I-I	DET	O
adenoassociated	I-I	ADJ	B
virus	I-I	NOUN	I
serotype	I-I	NOUN	O
2	I-I	NUM	O
vector	I-I	NOUN	O
containing	I-I	VERB	O
the	I-I	DET	O
cDNA	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
human	O	ADJ	B
tumour	O	NOUN	O
necrosis	O	NOUN	O
factor-immunoglobulin	O	ADJ	O
Fc	O	NOUN	B
fusion	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
tgAAC94	O	NUM	B
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
inflammatory	I-P	ADJ	B
arthritis	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
dose-escalation	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
15	B-P	NUM	O
subjects	I-P	NOUN	B
with	I-P	ADP	O
inflammatory	I-P	ADJ	B
arthritis	I-P	NOUN	I
(	I-P	PUNCT	O
14	I-P	NUM	O
with	I-P	ADP	O
rheumatoid	I-P	ADJ	B
arthritis	I-P	NOUN	I
and	I-P	CCONJ	O
1	I-P	NUM	O
with	I-P	ADP	O
ankylosing	I-P	ADJ	B
spondylitis	I-P	NOUN	I
)	I-P	PUNCT	O
not	I-P	PART	O
receiving	I-P	VERB	O
tumour	I-P	NOUN	B
necrosis	I-P	NOUN	I
factor	I-P	NOUN	I
alpha	I-P	NOUN	I
(	I-P	PUNCT	O
TNFalpha	I-P	NOUN	B
)	I-P	PUNCT	O
inhibitors	I-P	NOUN	B
with	I-P	ADP	O
persistent	I-P	ADJ	B
moderate	I-P	ADJ	I
(	I-P	PUNCT	O
grade	I-P	NOUN	B
2	I-P	NUM	I
)	I-P	PUNCT	O
or	I-P	CCONJ	O
severe	I-P	ADJ	B
(	I-P	PUNCT	O
grade	I-P	NOUN	O
3	I-P	NUM	O
)	I-P	PUNCT	O
swelling	I-P	NOUN	B
in	I-P	ADP	O
a	I-P	DET	O
target	I-P	NOUN	B
joint	I-P	NOUN	I
due	I-P	ADJ	O
to	I-P	PART	O
inflammatory	I-P	ADJ	B
arthritis	I-P	NOUN	I
received	O	VERB	O
a	O	DET	O
single	O	ADJ	O
intra-articular	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
rAAV2-TNFR	B-I	NOUN	B
:	I-I	PUNCT	O
Fc	I-I	NOUN	B
at	O	ADP	O
1	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
1	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
11	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
)	O	PUNCT	O
DNase	O	NOUN	B
resistant	O	ADJ	I
particles	O	NOUN	I
per	O	ADP	O
ml	O	NOUN	O
joint	O	ADJ	B
volume	O	NOUN	I
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
)	O	PUNCT	O
into	O	ADP	O
a	O	DET	O
knee	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
14	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
ankle	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Safety	B-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
through	O	ADP	O
adverse	O	ADJ	B
event	O	NOUN	I
monitoring	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
secondary	O	ADJ	O
objective	O	NOUN	B
,	O	PUNCT	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
injected	I-OUT	VERB	B
joint	I-OUT	ADJ	I
tenderness	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
swelling	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
,	O	PUNCT	O
each	O	DET	O
measured	O	VERB	B
on	O	ADP	O
a	O	DET	O
four-point	O	ADJ	O
scale	O	NOUN	O
,	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Intra-articular	O	ADJ	B
injections	O	NOUN	I
of	O	ADP	O
rAAV2-TNFR	O	NOUN	B
:	O	PUNCT	O
Fc	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
with	O	ADP	O
no	O	DET	O
major	O	ADJ	O
safety	O	NOUN	B
issues	O	NOUN	O
.	O	PUNCT	O


One	O	NUM	O
event	O	NOUN	B
,	O	PUNCT	O
mild	O	ADJ	B
knee	O	NOUN	B
pruritus	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
considered	O	VERB	O
probably	O	ADV	O
related	O	ADJ	O
.	O	PUNCT	O


Synovial	B-OUT	ADJ	B
fluid	I-OUT	ADJ	I
TNFR	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
Fc	I-OUT	NOUN	B
protein	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
detected	O	VERB	B
(	O	PUNCT	O
nor	O	CCONJ	O
expected	O	VERB	O
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
doses	O	NOUN	B
used	O	VERB	O
.	O	PUNCT	O


At	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
injection	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
two-point	O	ADJ	B
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
swelling	I-OUT	NOUN	B
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
2/11	O	NUM	O
and	O	CCONJ	O
2/4	O	NUM	O
subjects	O	NOUN	B
injected	O	VERB	B
with	O	ADP	O
rAAV2-TNFR	O	NOUN	B
:	O	PUNCT	O
Fc	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
A	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
intra-articular	O	ADJ	B
rAAV2-TNFR	O	NOUN	I
:	O	PUNCT	O
Fc	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
in	O	ADP	O
subjects	O	NOUN	B
without	O	ADP	O
concurrent	O	ADJ	B
systemic	O	ADJ	B
TNFalpha	O	NOUN	B
antagonist	O	NOUN	B
use	O	NOUN	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
thus	O	ADV	O
feasible	O	ADJ	O
to	O	PART	O
proceed	O	VERB	O
with	O	ADP	O
larger	O	ADJ	O
trials	O	NOUN	B
to	O	PART	O
further	O	ADV	O
test	O	VERB	O
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	O	ADP	O
local	O	ADJ	B
TNFR	O	NOUN	B
:	O	PUNCT	O
Fc	O	NOUN	B
gene	O	NOUN	I
transfer	O	NOUN	I
as	O	ADP	O
a	O	DET	O
therapeutic	O	ADJ	B
modality	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
inflammatory	I-P	ADJ	B
arthritis	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
heparin	B-I	NOUN	B
and	I-I	CCONJ	O
vancomycin	I-I	NOUN	B
solution	I-I	NOUN	O
in	O	ADP	O
preventing	O	VERB	B
central	B-OUT	ADJ	B
venous	I-OUT	ADJ	I
catheter	I-OUT	NOUN	I
infections	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
adding	O	VERB	O
vancomycin	B-I	NOUN	B
to	I-I	PART	O
central	I-I	ADJ	B
venous	I-I	ADJ	I
catheter	I-I	NOUN	I
(	I-I	PUNCT	O
CVC	I-I	NOUN	B
)	I-I	PUNCT	O
flush	I-I	NOUN	B
solution	O	NOUN	B
would	O	AUX	O
significantly	O	ADV	O
reduce	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
bacteremia	O	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
luminal	O	ADJ	B
colonization	O	NOUN	O
with	O	ADP	O
vancomycin-susceptible	O	ADJ	B
organisms	O	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	VERB	O
Fifty-five	B-P	NUM	B
children	I-P	NOUN	B
with	I-P	ADP	O
cancer	I-P	NOUN	B
and	I-P	CCONJ	O
eight	I-P	NUM	O
children	I-P	NOUN	B
given	I-P	VERB	O
total	I-P	ADJ	O
parenteral	I-P	ADJ	B
nutrition	I-P	NOUN	I
by	I-P	ADP	O
the	I-P	DET	O
surgery	I-P	NOUN	B
or	I-P	CCONJ	O
nutrition	I-P	NOUN	B
support	I-P	NOUN	I
services	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
a	O	DET	O
heparin	B-I	NOUN	B
CVC	I-I	NOUN	B
flush	I-I	NOUN	B
solution	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
31	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
heparin-vancomycin	B-I	ADJ	B
CVC	I-I	NOUN	I
flush	I-I	NOUN	I
solution	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
32	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
During	O	ADP	O
9158	O	NUM	O
catheter	O	NOUN	B
days	O	NOUN	B
,	O	PUNCT	O
6.5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
heparin	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
15.6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
heparin-vancomycin	O	ADJ	B
group	O	NOUN	I
had	O	AUX	O
bacteremia	O	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
luminal	O	ADJ	B
colonization	O	NOUN	O
with	O	ADP	O
vancomycin-susceptible	O	ADJ	B
organisms	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.43	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
rates	I-OUT	NOUN	B
of	I-OUT	ADP	O
bacteremia	I-OUT	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
luminal	O	ADJ	B
colonization	O	NOUN	O
with	O	ADP	O
vancomycin-susceptible	O	ADJ	B
organisms	O	NOUN	I
were	O	AUX	O
0.6/1000	O	NUM	O
catheter	O	NOUN	B
days	O	NOUN	B
in	O	ADP	O
the	O	DET	O
heparin	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
1.4/1000	O	NUM	O
catheter	O	NOUN	B
days	O	NOUN	B
in	O	ADP	O
the	O	DET	O
heparin-vancomycin	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.25	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
when	O	SCONJ	O
the	O	DET	O
time	B-OUT	NOUN	O
to	I-OUT	ADP	O
the	I-OUT	DET	O
first	I-OUT	ADJ	O
episode	I-OUT	NOUN	B
of	I-OUT	ADP	O
bacteremia	I-OUT	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
luminal	O	ADJ	B
colonization	O	NOUN	O
with	O	ADP	O
a	O	DET	O
vancomycin-susceptible	O	ADJ	B
organism	O	NOUN	I
was	O	AUX	O
compared	O	VERB	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
Kaplan-Meier	O	ADJ	B
survival	O	NOUN	I
estimates	O	NOUN	I
.	O	PUNCT	O


Streptococcus	B-OUT	X	B
viridans	I-OUT	NOUN	I
infection	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
attributable	O	ADJ	O
to	O	PART	O
luminal	O	ADJ	B
colonization	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
vancomycin	O	NOUN	B
to	O	PART	O
heparin	O	NOUN	B
CVC	O	NOUN	B
flush	O	NOUN	B
solution	O	NOUN	B
did	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
bacteremia	B-OUT	NOUN	B
with	O	ADP	O
vancomycin-susceptible	O	ADJ	B
organisms	O	NOUN	I
.	O	PUNCT	O


Bacteremia	B-OUT	NOUN	B
with	O	ADP	O
Streptococcus	O	X	B
viridans	O	NOUN	I
was	O	AUX	O
not	O	PART	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
CVC	O	PROPN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
ranitidine	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
disposition	B-OUT	NOUN	B
of	O	ADP	O
orally	O	ADV	B
and	O	CCONJ	O
intravenously	O	ADV	B
administered	O	VERB	B
triazolam	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
orally	O	ADV	B
administered	O	VERB	B
ranitidine	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
pharmacokinetic	B-OUT	ADJ	B
properties	I-OUT	NOUN	O
of	O	ADP	O
orally	O	ADV	B
and	O	CCONJ	O
intravenously	O	ADV	B
administered	O	VERB	B
triazolam	B-I	NOUN	B
was	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


Twelve	B-P	NUM	O
healthy	I-P	ADJ	B
males	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
35	I-P	NUM	O
years	I-P	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
this	O	DET	O
four-way	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Each	O	DET	O
subject	O	NOUN	B
received	O	VERB	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
four	O	NUM	O
treatments	O	NOUN	B
,	O	PUNCT	O
each	O	DET	O
separated	O	VERB	O
by	O	ADP	O
one	O	NUM	O
week	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
treatments	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
one	O	NUM	O
orally	O	ADV	B
administered	O	VERB	B
0.25-mg	B-I	ADJ	O
triazolam	I-I	NOUN	B
tablet	I-I	NOUN	B
after	I-I	ADP	O
treatment	I-I	NOUN	B
with	I-I	ADP	O
ranitidine	I-I	NOUN	B
;	I-I	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
one	O	NUM	O
orally	O	ADV	B
administered	O	VERB	B
0.25-mg	B-I	ADJ	O
triazolam	I-I	NOUN	B
tablet	I-I	NOUN	B
,	I-I	PUNCT	O
with	I-I	ADP	O
no	I-I	DET	O
ranitidine	I-I	NOUN	B
pretreatment	I-I	NOUN	B
;	I-I	PUNCT	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
a	O	DET	O
0.25-mg	B-I	ADJ	O
intravenous	I-I	ADJ	B
dose	I-I	NOUN	I
of	I-I	ADP	O
triazolam	I-I	NOUN	B
after	I-I	ADP	O
treatment	I-I	NOUN	B
with	I-I	ADP	O
ranitidine	I-I	NOUN	B
;	I-I	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
a	O	DET	O
0.25-mg	B-I	ADJ	O
intravenous	I-I	ADJ	B
dose	I-I	NOUN	I
of	I-I	ADP	O
triazolam	I-I	NOUN	B
,	I-I	PUNCT	O
with	I-I	ADP	O
no	I-I	DET	O
ranitidine	I-I	NOUN	B
pretreatment	I-I	NOUN	B
.	I-I	PUNCT	O


Ranitidine	B-I	NOUN	B
pretreatment	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
five	O	NUM	O
150-mg	O	ADJ	O
oral	O	ADJ	B
doses	O	NOUN	I
(	O	PUNCT	O
as	O	ADP	O
the	O	DET	O
hydrochloride	O	NOUN	B
salt	O	NOUN	I
)	O	PUNCT	O
given	O	VERB	O
every	O	DET	O
12	O	NUM	O
hours	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
last	O	ADJ	O
dose	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
two	O	NUM	O
hours	O	NOUN	O
before	O	ADP	O
triazolam	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


Blood	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
taken	O	VERB	O
at	O	ADP	O
intervals	O	NOUN	B
up	O	ADV	O
to	O	PART	O
12	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
triazolam	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
triazolam	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
modified	O	VERB	B
high-performance	O	ADJ	I
liquid	O	ADJ	I
chromatography	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
pharmacokinetic	B-OUT	ADJ	B
values	I-OUT	NOUN	I
were	O	AUX	O
calculated	O	VERB	B
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
ranitidine	B-I	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
disposition	B-OUT	NOUN	B
of	I-OUT	ADP	O
intravenously	I-OUT	ADV	B
administered	I-OUT	VERB	B
triazolam	I-OUT	NOUN	B
but	O	CCONJ	O
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
area	B-OUT	NOUN	B
under	I-OUT	ADP	O
the	I-OUT	DET	O
serum	I-OUT	NOUN	B
drug	I-OUT	NOUN	I
concentration-time	I-OUT	ADJ	I
curve	I-OUT	NOUN	I
of	I-OUT	ADP	O
oral	I-OUT	ADJ	B
triazolam	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Ranitidine	B-I	NOUN	B
pretreatment	O	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
triazolam	B-OUT	NOUN	B
's	I-OUT	PART	O
terminal	I-OUT	ADJ	B
elimination	I-OUT	NOUN	O
rate	I-OUT	NOUN	O
constant	I-OUT	NOUN	O
or	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
time	B-OUT	NOUN	B
to	I-OUT	PART	O
reach	I-OUT	VERB	O
maximum	I-OUT	ADJ	B
serum	I-OUT	NOUN	B
triazolam	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Ranitidine	B-I	NOUN	B
pretreatment	O	NOUN	B
increased	O	VERB	B
the	O	DET	O
systemic	B-OUT	ADJ	B
availability	I-OUT	NOUN	B
of	I-OUT	ADP	O
triazolam	I-OUT	NOUN	B
by	O	ADP	O
increasing	O	VERB	B
its	O	PRON	O
absorption	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Hip	B-I	NOUN	B
protectors	I-I	NOUN	I
improve	O	VERB	B
falls	O	NOUN	B
self-efficacy	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
external	B-I	ADJ	B
hip	I-I	NOUN	B
protectors	I-I	NOUN	I
on	O	ADP	O
subjects	O	NOUN	B
'	O	PART	O
fear	O	NOUN	B
of	O	ADP	I
falling	O	VERB	I
and	O	CCONJ	O
falls	O	VERB	B
self-efficacy	O	NOUN	B
(	O	PUNCT	O
belief	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
own	O	ADJ	O
ability	O	NOUN	O
to	O	PART	O
avoid	O	VERB	O
falling	O	VERB	B
)	O	PUNCT	O
.	O	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Aged-care	B-P	ADJ	B
health	I-P	NOUN	B
services	I-P	NOUN	I
in	I-P	ADP	O
Sydney	I-P	PROPN	B
,	I-P	PUNCT	O
Australia	I-P	PROPN	B
.	I-P	PUNCT	O


PARTICIPANTS	O	NOUN	O
131	B-P	NUM	O
women	I-P	NOUN	B
aged	I-P	ADJ	B
75	I-P	NUM	O
years	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
,	I-P	PUNCT	O
who	I-P	PRON	O
had	I-P	AUX	O
two	I-P	NUM	O
or	I-P	CCONJ	O
more	I-P	ADV	O
falls	I-P	NOUN	B
or	I-P	CCONJ	O
one	I-P	NUM	O
fall	I-P	NOUN	B
requiring	I-P	VERB	O
hospital	I-P	NOUN	B
admission	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
previous	I-P	ADJ	O
year	I-P	NOUN	B
and	I-P	CCONJ	O
who	I-P	PRON	O
live	I-P	VERB	B
at	I-P	ADP	O
home	I-P	NOUN	B
.	I-P	PUNCT	O


Sixty-one	B-P	NUM	O
subjects	I-P	NOUN	B
were	I-P	AUX	O
in	I-P	ADP	O
the	I-P	DET	O
intervention	I-P	NOUN	B
group	I-P	NOUN	I
and	O	CCONJ	O
70	B-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
control	I-I	NOUN	B
group	I-P	NOUN	I
.	I-P	PUNCT	O


INTERVENTION	O	PROPN	B
Use	O	PROPN	O
of	O	ADP	O
external	B-I	ADJ	B
hip	I-I	NOUN	B
protectors	I-I	NOUN	I
and	I-I	CCONJ	O
encouragement	I-I	NOUN	B
to	I-I	PART	O
use	I-I	VERB	O
the	I-I	DET	O
protectors	I-I	NOUN	B
by	I-I	ADP	O
an	I-I	DET	O
adherence	I-I	NOUN	B
nurse	I-I	NOUN	B
.	I-I	PUNCT	O


MEASUREMENTS	O	NOUN	O
At	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
enrolment	O	NOUN	B
into	O	ADP	O
a	O	DET	O
wider	O	ADJ	O
study	O	NOUN	B
examining	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
hip	B-I	NOUN	B
protectors	I-I	NOUN	I
on	O	ADP	O
hip	O	NOUN	B
fractures	O	NOUN	I
,	O	PUNCT	O
participants	B-P	NOUN	B
recruited	I-P	VERB	O
at	I-P	ADP	O
home	I-P	NOUN	B
completed	O	VERB	O
an	O	DET	O
assessment	O	NOUN	B
of	O	ADP	O
fear	B-OUT	NOUN	B
of	I-OUT	ADP	I
falling	I-OUT	VERB	I
and	I-OUT	CCONJ	O
falls	I-OUT	VERB	B
efficacy	I-OUT	NOUN	I
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
Falls	B-OUT	PROPN	B
Efficacy	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Modified	I-OUT	PROPN	B
Falls	I-OUT	PROPN	I
Efficacy	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


At	O	ADP	O
4-month	O	ADJ	B
follow-up	O	NOUN	I
,	O	PUNCT	O
these	O	DET	O
scales	O	NOUN	B
were	O	AUX	O
readministered	O	VERB	B
by	O	ADP	O
an	O	DET	O
observer	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
not	O	PART	O
aware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
allocation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
participant	O	NOUN	B
to	O	ADP	O
intervention	O	NOUN	B
or	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Fear	B-OUT	NOUN	B
of	I-OUT	ADP	I
falling	I-OUT	VERB	I
and	I-OUT	CCONJ	O
falls	I-OUT	VERB	B
self-efficacy	I-OUT	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
Falls	B-OUT	PROPN	B
Efficacy	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
Modified	I-OUT	PROPN	B
Falls	I-OUT	PROPN	I
Efficacy	I-OUT	PROPN	I
Scales	I-OUT	PROPN	I
,	O	PUNCT	O
were	O	AUX	O
similar	O	ADJ	O
at	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Fear	B-OUT	NOUN	B
of	I-OUT	ADP	I
falling	I-OUT	VERB	I
was	O	AUX	O
present	O	ADJ	O
at	O	ADP	O
follow-up	O	NOUN	B
in	O	ADP	O
43	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
subjects	O	NOUN	B
using	O	VERB	O
hip	O	NOUN	B
protectors	O	NOUN	I
and	O	CCONJ	O
57	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
chi2	O	NOUN	O
=	O	ADJ	O
2.58	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.11	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Hip	B-I	NOUN	B
protector	I-I	NOUN	I
users	O	NOUN	B
had	O	AUX	O
greater	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
falls	O	NOUN	B
self-efficacy	B-OUT	NOUN	B
at	O	ADP	O
follow-up	O	NOUN	B
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
Falls	B-OUT	PROPN	B
Efficacy	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
(	O	PUNCT	O
t	O	NOUN	O
=	O	ADJ	O
2.44	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.016	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Modified	B-OUT	PROPN	B
Falls	I-OUT	PROPN	I
Efficacy	I-OUT	PROPN	I
Scale	I-OUT	PROPN	I
(	O	PUNCT	O
t	O	NOUN	O
=	O	ADJ	O
2.08	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.039	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Hip	B-I	NOUN	B
protectors	I-I	NOUN	I
improve	O	VERB	B
falls	O	NOUN	B
self-efficacy	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
users	O	NOUN	B
of	O	ADP	O
hip	B-I	NOUN	B
protectors	I-I	NOUN	I
feel	O	VERB	O
more	O	ADV	O
confident	O	ADJ	O
that	O	SCONJ	O
they	O	PRON	O
can	O	AUX	O
complete	O	VERB	B
tasks	O	NOUN	B
safely	O	ADV	O
,	O	PUNCT	O
they	O	PRON	O
may	O	AUX	O
become	O	VERB	O
more	O	ADV	O
physically	O	ADV	B
active	O	ADJ	I
and	O	CCONJ	O
require	O	VERB	O
less	O	ADJ	O
assistance	O	NOUN	B
with	O	ADP	O
activities	O	NOUN	B
of	O	ADP	O
daily	O	ADJ	B
living	O	NOUN	O
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
ranolazine	B-I	NOUN	B
on	O	ADP	O
A1C	O	NOUN	B
and	O	CCONJ	O
glucose	O	NOUN	B
levels	O	NOUN	I
in	O	ADP	O
hyperglycemic	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
non-ST	I-P	ADJ	B
elevation	I-P	NOUN	I
acute	I-P	ADJ	I
coronary	I-P	ADJ	I
syndrome	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
determined	O	VERB	O
the	O	DET	O
relationships	O	NOUN	B
between	O	ADP	O
glycemia	O	NOUN	B
at	O	ADP	O
randomization	O	NOUN	B
,	O	PUNCT	O
concurrent	B-I	ADJ	B
antidiabetic	I-I	ADJ	B
therapy	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
change	O	NOUN	B
in	O	ADP	O
A1C	O	NOUN	B
and	O	CCONJ	O
fasting	O	ADJ	B
plasma	O	NOUN	O
glucose	O	NOUN	O
(	O	PUNCT	O
FPG	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
diabetes	I-P	NOUN	B
receiving	I-P	VERB	O
standard	I-P	ADJ	B
treatment	I-P	NOUN	I
for	I-P	ADP	O
diabetes	I-P	NOUN	B
and	I-P	CCONJ	O
randomized	I-P	ADJ	B
to	I-P	PART	O
ranolazine	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
within	I-P	ADP	O
the	I-P	DET	O
MERLIN-TIMI-36	I-P	PROPN	B
(	I-P	PUNCT	O
MERLIN	I-P	PROPN	B
)	I-P	PUNCT	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Ranolazine	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
first-in-class	O	ADJ	B
drug	O	NOUN	I
approved	O	VERB	I
for	O	ADP	O
treating	O	VERB	B
angina	O	ADJ	B
pectoris	O	NOUN	I
.	O	PUNCT	O


RESEARCH	O	NOUN	O
DESIGN	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	PROPN	O
Randomization	O	PROPN	B
and	O	CCONJ	O
4-month	O	ADJ	B
glycemic	B-I	ADJ	B
and	I-I	CCONJ	O
antidiabetes	I-I	VERB	B
drug	I-I	NOUN	I
usage	I-I	NOUN	O
data	I-I	NOUN	B
from	O	ADP	O
MERLIN	O	PROPN	B
were	O	AUX	O
analyzed	O	VERB	B
using	O	VERB	O
Spotfire	O	PROPN	B
and	O	CCONJ	O
SAS	O	PROPN	B
version	O	NOUN	I
9.1	O	NUM	O
software	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
diabetes	I-P	NOUN	B
and	I-P	CCONJ	O
A1C	I-P	NOUN	B
of	I-P	ADP	O
>	I-P	X	O
or=8-10	I-P	NUM	B
%	I-P	NOUN	O
at	I-P	ADP	O
randomization	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
171	I-P	NUM	O
)	I-P	PUNCT	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
an	O	DET	O
absolute	O	ADJ	B
A1C	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
ranolazine	B-I	NOUN	B
group	O	NOUN	B
of	O	ADP	O
1.2	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-1.4	O	NUM	O
to	O	PART	O
-1.0	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
placebo-adjusted	B-I	ADJ	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
182	I-P	NUM	O
)	I-P	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
A1C	B-OUT	NOUN	B
by	O	ADP	O
ranolazine	O	NOUN	B
was	O	AUX	O
0.59	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-0.99	O	NUM	O
to	O	PART	O
-0.20	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
FPG	I-P	NOUN	B
of	I-P	ADP	O
150-400	I-P	NUM	O
mg/dl	I-P	NOUN	O
at	I-P	ADP	O
randomization	I-P	NOUN	B
,	I-P	PUNCT	O
ranolazine	I-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
131	I-P	NUM	O
)	I-P	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
147	I-P	NUM	O
)	I-P	PUNCT	O
reduced	O	VERB	B
FPG	O	NOUN	B
by	O	ADP	O
25.7	O	NUM	O
mg/dl	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
-43.3	O	NUM	O
to	O	PART	O
-8.1	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


When	O	SCONJ	O
changes	O	NOUN	B
in	O	ADP	O
either	O	CCONJ	O
A1C	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
FPG	I-OUT	NOUN	B
were	O	AUX	O
correlated	O	VERB	B
to	O	PART	O
A1C	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
FPG	I-OUT	NOUN	B
at	O	ADP	O
randomization	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
slopes	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
steeper	O	ADJ	O
for	O	ADP	O
ranolazine	B-I	NOUN	B
than	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
A1C	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.046	O	NUM	O
;	O	PUNCT	O
FPG	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
lowering	O	NOUN	B
of	O	ADP	O
A1C	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
FPG	I-OUT	NOUN	B
by	O	ADP	O
ranolazine	B-I	NOUN	B
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
hyperglycemia	O	NOUN	B
at	O	ADP	O
randomization	O	NOUN	B
.	O	PUNCT	O


Ranolazine	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
serious	B-OUT	ADJ	O
hypoglycemic	I-OUT	ADJ	B
events	I-OUT	NOUN	O
,	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
significant	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
concurrent	B-OUT	ADJ	B
antidiabetic	I-OUT	ADJ	B
therapy	I-OUT	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
dependent	O	ADJ	B
on	O	ADP	O
a	O	DET	O
history	B-OUT	NOUN	B
of	I-OUT	ADP	I
angina	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Ranolazine	B-I	PROPN	B
,	O	PUNCT	O
when	O	SCONJ	O
added	O	VERB	O
to	O	PART	O
concurrent	O	ADJ	B
antidiabetes	O	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
lowers	O	VERB	O
FPG	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
A1C	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cardiovascular	I-P	ADJ	B
disease	I-P	NOUN	I
and	I-P	CCONJ	O
poorly	I-P	ADV	B
controlled	I-P	VERB	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


Differences	O	NOUN	B
in	O	ADP	O
vision	O	NOUN	B
between	O	ADP	O
clinic	O	NOUN	B
and	O	CCONJ	O
home	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
lighting	O	NOUN	B
in	O	ADP	O
older	B-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
and	I-P	CCONJ	O
without	I-P	ADP	O
glaucoma	I-P	NOUN	B
.	I-P	PUNCT	O


IMPORTANCE	O	NOUN	B
Patients	O	NOUN	B
often	O	ADV	O
report	O	VERB	O
greater	O	ADJ	O
visual	O	ADJ	B
difficulties	O	NOUN	I
at	O	ADP	O
home	O	NOUN	B
than	O	ADP	O
expected	O	VERB	O
from	O	ADP	O
vision	O	NOUN	B
testing	O	NOUN	I
in	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
discordance	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
owing	O	VERB	O
to	O	ADP	O
worse	O	ADJ	O
vision	O	NOUN	B
in	O	ADP	O
the	O	DET	O
home	O	NOUN	B
than	O	ADP	O
measured	O	VERB	B
in	O	ADP	O
clinic	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
vision	B-OUT	NOUN	B
measured	O	VERB	B
between	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
and	O	CCONJ	O
home	O	NOUN	B
and	O	CCONJ	O
evaluate	O	VERB	B
factors	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
lighting	O	NOUN	B
,	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
these	O	DET	O
differences	O	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
AND	O	CCONJ	O
PARTICIPANTS	O	NOUN	O
This	O	DET	O
cross-sectional	O	ADJ	B
study	O	NOUN	I
conducted	B-P	VERB	O
from	I-P	ADP	O
2005-2009	I-P	NUM	O
involved	I-P	VERB	O
126	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
glaucoma	I-P	NOUN	B
and	I-P	CCONJ	O
49	I-P	NUM	O
without	I-P	ADP	O
glaucoma	I-P	NOUN	B
recruited	I-P	VERB	O
from	I-P	ADP	O
the	I-P	DET	O
Glaucoma	I-P	PROPN	B
and	I-P	CCONJ	O
Comprehensive	I-P	PROPN	B
Eye	I-P	PROPN	I
Clinics	I-P	PROPN	I
at	I-P	ADP	O
Washington	I-P	PROPN	O
University	I-P	PROPN	O
,	I-P	PUNCT	O
St	I-P	PROPN	B
Louis	I-P	PROPN	I
,	I-P	PUNCT	O
Missouri	I-P	PROPN	B
.	I-P	PUNCT	O


Patients	O	NOUN	B
underwent	O	VERB	O
clinic	O	NOUN	B
and	O	CCONJ	O
home	O	NOUN	B
visits	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
aged	B-P	ADJ	B
55	I-P	NUM	O
to	I-P	PART	O
90	I-P	NUM	O
years	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
consecutively	O	ADV	O
recruited	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
met	O	VERB	O
inclusion	O	NOUN	B
criteria	O	NOUN	I
for	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
166	I-P	NUM	O
eligible	I-P	ADJ	B
patients	I-P	NOUN	B
refused	I-P	VERB	O
participation	I-P	NOUN	B
.	I-P	PUNCT	O


EXPOSURE	O	NOUN	B
Participants	B-I	NOUN	B
underwent	I-I	VERB	O
clinic	I-I	NOUN	B
and	I-I	CCONJ	O
home	I-I	NOUN	B
visits	I-I	NOUN	I
randomized	O	VERB	B
to	O	PART	O
order	O	NOUN	O
of	O	ADP	O
completion	O	NOUN	B
.	O	PUNCT	O


At	B-I	ADP	O
each	I-I	DET	O
visit	I-I	NOUN	B
,	I-I	PUNCT	O
masked	I-I	VERB	B
and	I-I	CCONJ	O
certified	I-I	VERB	O
examiners	I-I	NOUN	B
measured	I-I	VERB	B
binocular	I-OUT	ADJ	B
distance	I-OUT	NOUN	I
visual	I-OUT	ADJ	I
acuity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
DVA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
with	I-OUT	ADP	O
a	I-OUT	DET	O
nonbacklit	I-OUT	NOUN	B
chart	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
near	I-OUT	ADP	B
visual	I-OUT	ADJ	I
acuity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
NVA	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
contrast	I-OUT	NOUN	B
sensitivity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
CS	I-OUT	NOUN	B
with	I-OUT	ADP	O
glare	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
lighting	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


MAIN	O	ADJ	O
OUTCOMES	O	NOUN	O
AND	O	CCONJ	O
MEASURES	O	NOUN	O
Differences	B-OUT	NOUN	B
in	I-OUT	ADP	O
vision	I-OUT	NOUN	B
between	I-OUT	ADP	O
the	I-OUT	DET	O
clinic	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
home	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
mean	O	ADJ	O
scores	O	NOUN	B
for	O	ADP	O
all	B-OUT	DET	O
vision	I-OUT	NOUN	B
tests	I-OUT	NOUN	I
were	I-OUT	AUX	O
significantly	I-OUT	ADV	O
better	I-OUT	ADJ	O
in	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
than	O	ADP	O
home	O	NOUN	B
for	O	ADP	O
participants	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
glaucoma	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
,	O	PUNCT	O
matched-pair	O	ADJ	B
t	O	NOUN	I
tests	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
DVA	O	NOUN	B
,	O	PUNCT	O
29	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
participants	O	NOUN	B
with	O	ADP	O
glaucoma	O	NOUN	B
read	B-OUT	VERB	I
2	I-OUT	NUM	I
or	I-OUT	CCONJ	O
more	I-OUT	ADJ	O
lines	I-OUT	NOUN	B
better	I-OUT	ADV	O
in	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
than	O	ADP	O
home	O	NOUN	B
and	O	CCONJ	O
39	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
advanced	O	ADJ	B
glaucoma	O	NOUN	I
read	O	VERB	I
3	O	NUM	I
or	O	CCONJ	O
more	O	ADJ	O
lines	O	NOUN	B
better	O	ADV	O
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
sample	O	NOUN	B
,	O	PUNCT	O
21	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
participants	O	NOUN	B
read	B-OUT	VERB	B
2	I-OUT	NUM	I
or	I-OUT	CCONJ	O
more	I-OUT	ADJ	O
lines	I-OUT	NOUN	B
better	O	ADV	O
in	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
than	O	ADP	O
home	O	NOUN	B
for	O	ADP	O
NVA	O	PROPN	B
and	O	CCONJ	O
49	O	NUM	O
%	O	NOUN	O
read	O	VERB	O
2	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
triplets	O	NOUN	B
better	O	ADV	O
in	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
for	O	ADP	O
CS	O	NOUN	B
with	O	ADP	O
glare	O	NOUN	B
.	O	PUNCT	O


Lighting	O	NOUN	B
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
significant	O	ADJ	B
factor	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
differences	O	NOUN	B
in	O	ADP	O
vision	O	NOUN	B
between	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
and	O	CCONJ	O
home	O	NOUN	B
for	O	ADP	O
DVA	B-OUT	PROPN	B
,	I-OUT	PUNCT	O
NVA	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
CS	I-OUT	NOUN	B
with	O	ADP	O
glare	O	ADJ	B
testing	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
,	O	PUNCT	O
multiple	O	ADJ	B
regression	O	NOUN	I
model	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Median	B-OUT	ADJ	B
home	I-OUT	NOUN	O
lighting	I-OUT	NOUN	O
was	O	AUX	O
4.3	O	NUM	O
times	O	NOUN	O
and	O	CCONJ	O
2.8	O	NUM	O
times	O	NOUN	O
lower	O	ADJ	O
than	O	ADP	O
clinic	O	ADJ	B
lighting	O	NOUN	B
in	O	ADP	O
areas	O	NOUN	O
tested	O	VERB	B
for	O	ADP	O
DVA	O	NOUN	B
and	O	CCONJ	O
NVA	O	PROPN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Home	B-OUT	NOUN	B
lighting	I-OUT	NOUN	I
was	O	AUX	O
below	O	ADP	O
that	O	DET	O
recommended	O	VERB	B
in	O	ADP	O
85	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
greater	O	ADJ	O
of	O	ADP	O
participants	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
AND	O	CCONJ	O
RELEVANCE	O	NOUN	B
Vision	B-OUT	PROPN	I
measured	O	VERB	B
in	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
is	O	AUX	O
generally	O	ADV	O
better	O	ADJ	O
than	O	ADP	O
vision	O	NOUN	B
measured	O	VERB	B
at	O	ADP	O
home	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
differences	O	NOUN	O
mainly	O	ADV	O
owing	O	VERB	O
to	O	ADP	O
poor	O	ADJ	B
home	O	NOUN	I
lighting	O	NOUN	I
.	O	PUNCT	O


Knowledge	O	NOUN	B
that	O	SCONJ	O
vision	O	NOUN	B
discrepancies	O	NOUN	B
between	O	ADP	O
patient	O	NOUN	B
report	O	NOUN	I
and	O	CCONJ	O
clinical	O	ADJ	B
testing	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
owing	O	VERB	O
to	O	ADP	O
home	O	NOUN	B
lighting	O	NOUN	I
may	O	AUX	O
initiate	O	VERB	O
clinician-patient	O	ADJ	B
discussions	O	NOUN	B
to	O	PART	O
optimize	O	VERB	O
home	O	NOUN	B
lighting	O	NOUN	I
and	O	CCONJ	O
improve	O	VERB	B
the	O	DET	O
vision	O	NOUN	B
of	O	ADP	O
older	B-P	ADJ	B
adults	I-P	NOUN	I
in	O	ADP	O
their	O	PRON	O
homes	O	NOUN	B
.	O	PUNCT	O


Prospective	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
macrolide	B-I	NOUN	B
antibiotic	I-I	ADJ	O
dirithromycin	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
Helicobacter	B-P	NOUN	B
pylori	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Macrolide	B-I	NOUN	B
antibiotics	I-I	NOUN	B
are	O	AUX	O
active	O	ADJ	B
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
against	O	ADP	O
Helicobacter	B-P	NOUN	B
pylori	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
assessed	O	VERB	B
a	O	DET	O
newer	O	ADJ	O
macrolide	B-I	NOUN	B
,	I-I	PUNCT	O
dirithromycin	I-I	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
H.	O	X	B
pylori	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
separate	O	ADJ	O
studies	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Volunteers	B-P	NOUN	B
with	I-P	ADP	O
H.	I-P	NOUN	B
pylori	I-P	NOUN	I
infection	I-P	NOUN	I
(	I-P	PUNCT	O
by	I-P	ADP	O
13C-urea	I-P	NOUN	B
breath	I-P	NOUN	I
test	I-P	NOUN	I
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
2-week	O	ADJ	B
treatment	O	NOUN	B
regimens	O	NOUN	I
.	O	PUNCT	O


Study	O	NOUN	B
1	O	NUM	O
:	O	PUNCT	O
dirithromycin	B-I	NOUN	B
500	I-I	NUM	O
mg	I-I	NOUN	O
q.d.s.	I-I	NOUN	B
,	O	PUNCT	O
dirithromycin	B-I	NOUN	B
500	I-I	NUM	O
mg	I-I	NOUN	O
q.d.s	I-I	ADJ	B
.	I-I	PUNCT	O


plus	B-I	CCONJ	O
omeprazole	I-I	NOUN	B
40	I-I	NUM	O
mg	I-I	NOUN	O
q.d.s.	I-I	NOUN	B
,	O	PUNCT	O
or	B-I	CCONJ	O
dirithromycin	I-I	NOUN	B
500	I-I	NUM	O
mg	I-I	NOUN	O
q.d.s	I-I	ADJ	B
.	I-I	PUNCT	O


plus	B-I	CCONJ	O
metronidazole	I-I	NOUN	B
500	I-I	NUM	O
mg	I-I	NOUN	O
t.d.s	I-I	NOUN	B
.	I-I	PUNCT	O


Study	O	NOUN	B
2	O	NUM	I
:	O	PUNCT	O
dirithromycin	B-I	NOUN	B
500	I-I	NUM	O
mg	I-I	NOUN	O
q.d.s	I-I	ADJ	B
.	I-I	PUNCT	O


plus	B-I	CCONJ	O
omeprazole	I-I	NOUN	B
20	I-I	NUM	O
mg	I-I	NOUN	O
b.d.	I-I	NOUN	O
,	O	PUNCT	O
dirithromycin	B-I	NOUN	B
1000	I-I	NUM	O
mg	I-I	NOUN	O
q.d.s	I-I	ADJ	B
.	I-I	PUNCT	O


plus	B-I	CCONJ	O
omeprazole	I-I	NOUN	B
20	I-I	NUM	O
mg	I-I	NOUN	O
b.d.	I-I	NOUN	O
,	O	PUNCT	O
or	B-I	CCONJ	O
amoxycillin	I-I	NOUN	B
500	I-I	NUM	O
mg	I-I	NOUN	O
q.d.s	I-I	ADJ	B
.	I-I	PUNCT	O


plus	B-I	CCONJ	O
omepirazole	I-I	ADJ	B
20	I-I	NUM	O
mg	I-I	NOUN	O
b.d	I-I	NOUN	O
.	I-I	PUNCT	O


Four	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
a	O	DET	O
repeat	O	NOUN	O
13C-urea	O	NOUN	B
breath	O	NOUN	I
test	O	NOUN	I
was	O	AUX	O
done	O	VERB	O
to	O	PART	O
assess	O	VERB	B
for	O	ADP	O
cure	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
No	O	DET	O
patient	O	NOUN	B
taking	O	VERB	O
dirithromycin	B-I	NOUN	B
alone	I-P	ADV	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
6	I-P	NUM	O
)	I-P	PUNCT	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
omeprazole	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
26	O	NUM	O
)	O	PUNCT	O
achieved	O	VERB	O
cure	B-OUT	NOUN	B
of	I-OUT	ADP	O
their	I-OUT	PRON	O
infection	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Eradication	B-OUT	NOUN	B
of	I-OUT	ADP	O
H.	I-OUT	PROPN	B
pylori	I-OUT	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
seven	O	NUM	O
patients	O	NOUN	B
taking	O	VERB	O
dirithromycin	B-I	NOUN	B
plus	O	CCONJ	O
metronidazole	B-I	NOUN	B
.	I-I	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
taking	O	VERB	O
omeprazole-amoxycillin	B-I	ADJ	B
dual	O	ADJ	O
therapy	O	NOUN	O
had	O	AUX	O
their	O	PRON	O
H.	B-OUT	NOUN	B
pylori	I-OUT	NOUN	I
infection	I-OUT	NOUN	I
cured	I-OUT	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0007	O	NUM	O
vs.	O	CCONJ	O
patients	O	NOUN	B
taking	O	VERB	O
dirithromycin	B-I	NOUN	B
plus	O	CCONJ	O
omeprazole	B-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Eleven	O	NUM	O
(	O	PUNCT	O
47	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
32	O	NUM	O
patients	O	NOUN	B
taking	O	VERB	O
dirithromycin	B-I	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
combined	O	VERB	O
with	O	ADP	O
omeprazole	B-I	NOUN	B
reported	I-OUT	VERB	O
side-effects	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
two	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
stopped	O	VERB	O
therapy	O	NOUN	B
prematurely	O	ADV	B
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
side-effects	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	O	VERB	O
No	O	DET	B
subject	O	NOUN	I
taking	O	VERB	O
dirithromycin	B-I	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
omeprazole	B-I	NOUN	B
had	O	AUX	O
their	O	PRON	O
H.	O	NOUN	B
pylori	O	NOUN	I
infection	O	NOUN	I
cured	B-OUT	VERB	B
.	I-OUT	PUNCT	O


Dirithromycin	B-I	PROPN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
regimen	O	NOUN	B
used	O	VERB	O
,	O	PUNCT	O
shows	O	VERB	O
little	O	ADJ	O
promise	O	NOUN	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
H.	I-P	NOUN	B
pylori	I-P	NOUN	I
infection	I-P	NOUN	I
.	I-P	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
H	O	NOUN	B
reflex	O	NOUN	I
and	O	CCONJ	O
V	O	NOUN	B
wave	O	NOUN	I
following	O	VERB	O
short-term	B-I	ADJ	B
endurance	I-I	NOUN	B
and	I-I	CCONJ	O
strength	I-I	NOUN	B
training	I-I	NOUN	I
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
3	O	NUM	O
wk	O	NOUN	O
of	O	ADP	O
either	O	CCONJ	O
endurance	B-I	NOUN	B
or	I-I	CCONJ	O
strength	I-I	NOUN	B
training	I-I	NOUN	I
on	O	ADP	O
plasticity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neural	O	ADJ	B
mechanisms	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
soleus	O	NOUN	B
H	O	NOUN	I
reflex	O	NOUN	I
and	O	CCONJ	O
V	O	NOUN	B
wave	O	NOUN	I
.	O	PUNCT	O


Twenty-five	B-P	ADJ	B
sedentary	I-P	ADJ	B
healthy	I-P	ADJ	I
subjects	I-P	NOUN	O
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
an	O	DET	O
endurance	B-I	NOUN	B
group	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
13	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
strength	B-I	NOUN	B
group	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Evoked	O	ADJ	B
V-wave	O	ADJ	B
,	O	PUNCT	O
H-reflex	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
M-wave	O	ADJ	B
recruitment	O	NOUN	I
curves	O	NOUN	I
,	O	PUNCT	O
maximal	O	ADJ	B
voluntary	O	ADJ	O
contraction	O	NOUN	O
(	O	PUNCT	O
MVC	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
time-to-task-failure	O	NOUN	B
(	O	PUNCT	O
isometric	O	ADJ	B
contraction	O	NOUN	I
at	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
MVC	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
plantar	O	NOUN	B
flexors	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
training	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
strength	B-I	NOUN	B
training	I-I	NOUN	I
,	O	PUNCT	O
MVC	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
plantar	I-OUT	NOUN	B
flexors	I-OUT	NOUN	I
increased	O	VERB	B
by	O	ADP	O
14.4	O	NUM	O
±	O	NOUN	O
5.2	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
strength	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
time-to-task-failure	O	NOUN	B
was	O	AUX	O
prolonged	O	ADJ	B
in	O	ADP	O
the	O	DET	O
endurance	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
22.7	O	NUM	O
±	O	NOUN	O
17.1	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
V	I-OUT	NOUN	O
wave-to-maximal	I-OUT	ADJ	O
M	I-OUT	NOUN	O
wave	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
V/M	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
max	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
ratio	I-OUT	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
55.1	O	NUM	O
±	O	NOUN	O
28.3	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
following	O	VERB	O
strength	O	NOUN	B
training	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	B-OUT	DET	O
maximal	I-OUT	ADJ	B
H	I-OUT	NOUN	O
wave-to-maximal	I-OUT	ADJ	O
M	I-OUT	NOUN	O
wave	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
H	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
max	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
/M	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
max	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
ratio	I-OUT	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
endurance	O	NOUN	B
group	O	NOUN	I
the	B-OUT	DET	O
V/M	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
max	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
ratio	I-OUT	NOUN	B
was	O	AUX	O
not	O	PART	O
altered	O	VERB	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	B-OUT	DET	O
H	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
max	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
/M	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
max	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
ratio	I-OUT	NOUN	B
increased	O	VERB	B
by	O	ADP	O
30.8	O	NUM	O
±	O	NOUN	O
21.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-I	DET	O
endurance	I-I	NOUN	B
training	I-I	NOUN	O
group	O	NOUN	O
also	O	ADV	O
displayed	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	B-OUT	DET	O
H-reflex	I-OUT	ADJ	B
excitability	I-OUT	NOUN	B
threshold	I-OUT	NOUN	B
while	O	SCONJ	O
the	O	DET	O
H-reflex	O	ADJ	B
amplitude	O	NOUN	I
on	O	ADP	O
the	O	DET	O
ascending	O	VERB	B
limb	O	NOUN	B
of	O	ADP	O
the	O	DET	O
recruitment	O	NOUN	B
curve	O	NOUN	O
increased	O	VERB	B
.	O	PUNCT	O


Strength	O	ADJ	B
training	O	NOUN	I
only	O	ADV	O
elicited	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
H-reflex	I-OUT	ADJ	B
excitability	I-OUT	NOUN	B
threshold	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
while	I-OUT	SCONJ	O
H-reflex	I-OUT	NOUN	B
amplitudes	I-OUT	NOUN	B
over	O	ADP	O
the	B-OUT	DET	O
ascending	I-OUT	VERB	B
limb	I-OUT	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
H-reflex	O	ADJ	B
pathway	O	NOUN	I
is	O	AUX	O
strongly	O	ADV	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
enhanced	B-OUT	VERB	B
endurance	I-OUT	NOUN	B
resistance	I-OUT	NOUN	O
that	O	PRON	O
occurs	O	VERB	O
following	B-I	VERB	O
endurance	I-I	NOUN	B
training	I-I	NOUN	O
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
contrary	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
improvements	B-OUT	NOUN	B
in	I-OUT	ADP	O
MVC	O	NOUN	B
following	O	VERB	O
strength	O	NOUN	B
training	O	NOUN	I
are	O	AUX	O
likely	O	ADV	O
attributed	O	VERB	O
to	O	PART	O
increased	O	VERB	B
descending	O	ADJ	B
drive	O	NOUN	O
and/or	O	CCONJ	O
modulation	O	NOUN	B
in	O	ADP	O
afferents	O	NOUN	B
other	O	ADJ	O
than	O	ADP	O
Ia	O	NOUN	B
afferents	O	NOUN	I
.	O	PUNCT	O


Does	O	AUX	O
a	O	DET	O
first	O	ADJ	O
trimester	O	NOUN	B
dating	O	NOUN	O
scan	O	NOUN	B
using	O	VERB	O
crown	O	NOUN	B
rump	O	NOUN	I
length	O	NOUN	I
measurement	O	NOUN	I
reduce	O	VERB	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
induction	I-OUT	NOUN	B
of	I-OUT	ADP	O
labour	I-OUT	NOUN	O
for	O	ADP	O
prolonged	B-OUT	ADJ	B
pregnancy	I-OUT	NOUN	B
?	O	PUNCT	O
An	O	DET	O
uncompleted	O	ADJ	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
463	B-P	NUM	O
women	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
first	O	ADJ	O
trimester	O	NOUN	B
ultrasound	B-I	NOUN	B
dating	I-I	NOUN	I
scan	I-I	NOUN	I
on	O	ADP	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
induction	I-OUT	NOUN	B
of	I-OUT	ADP	O
labour	I-OUT	NOUN	O
for	O	ADP	O
prolonged	B-OUT	ADJ	B
pregnancy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
Randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
to	O	PART	O
include	O	VERB	O
400	B-P	NUM	O
women	I-P	NOUN	B
in	I-P	ADP	O
each	I-P	DET	O
arm	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
trial	I-P	NOUN	B
.	I-P	PUNCT	O


SETTING	O	VERB	O
Participating	B-P	VERB	B
general	I-P	ADJ	B
practices	I-P	NOUN	I
and	I-P	CCONJ	O
a	I-P	DET	O
district	I-P	NOUN	B
general	I-P	ADJ	B
teaching	I-P	NOUN	I
hospital	I-P	NOUN	I
.	I-P	PUNCT	O


POPULATION	O	NOUN	B
Women	B-P	NOUN	B
attending	I-P	VERB	B
their	I-P	PRON	O
general	I-P	ADJ	B
practitioner	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
trimester	I-P	NOUN	B
to	I-P	PART	O
confirm	I-P	VERB	B
pregnancy	I-P	NOUN	B
,	I-P	PUNCT	O
in	I-P	ADP	O
whom	I-P	PRON	O
a	I-P	DET	O
first	I-P	ADJ	O
trimester	I-P	NOUN	B
ultrasound	I-I	NOUN	B
scan	I-I	NOUN	I
was	I-P	AUX	O
not	I-P	PART	O
indicated	I-P	VERB	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Women	O	NOUN	B
randomised	O	VERB	B
to	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
scan	O	ADJ	B
group	O	NOUN	I
)	O	PUNCT	O
underwent	O	VERB	O
an	O	DET	O
ultrasound	B-I	NOUN	B
dating	I-I	NOUN	I
scan	I-I	NOUN	I
between	I-I	ADP	O
8	I-I	NUM	O
and	I-I	CCONJ	O
12	I-I	NUM	O
weeks	I-I	NOUN	B
,	I-I	PUNCT	O
measuring	I-I	VERB	B
crown-rump	I-I	ADJ	B
length	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
estimated	O	ADJ	B
date	O	NOUN	O
of	O	ADP	O
delivery	O	NOUN	B
(	O	PUNCT	O
EDD	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
changed	O	VERB	O
if	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
discrepancy	O	NOUN	B
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
from	O	ADP	O
the	O	DET	O
gestation	O	NOUN	B
,	O	PUNCT	O
calculated	O	VERB	B
from	O	ADP	O
the	O	DET	O
last	O	ADJ	O
menstrual	O	ADJ	B
period	O	NOUN	O
(	O	PUNCT	O
LMP	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
women	O	NOUN	B
(	O	PUNCT	O
no-scan	O	ADJ	B
group	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
gestation	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
using	O	VERB	O
the	O	DET	O
LMP	O	NOUN	B
.	O	PUNCT	O


MAIN	O	PROPN	O
OUTCOME	O	NOUN	B
MEASURES	O	NOUN	O
The	B-OUT	DET	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
induction	I-OUT	NOUN	B
of	I-OUT	ADP	O
labour	I-OUT	NOUN	O
for	I-OUT	ADP	O
prolonged	I-OUT	ADJ	B
pregnancy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
Due	O	ADP	O
to	O	ADP	O
circumstances	O	NOUN	B
beyond	O	ADP	O
the	O	DET	O
researchers	O	NOUN	B
'	O	PART	O
control	O	NOUN	B
,	O	PUNCT	O
recruitment	O	NOUN	B
was	O	AUX	O
abandoned	O	VERB	O
when	O	SCONJ	O
463	B-P	NUM	O
women	I-P	NOUN	B
had	I-P	AUX	O
been	I-P	AUX	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


The	O	DET	O
EDD	O	NOUN	B
was	O	AUX	O
adjusted	O	VERB	O
in	O	ADP	O
13	O	NUM	O
(	O	PUNCT	O
5.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
scan	O	ADJ	B
group	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
2	O	NUM	O
(	O	PUNCT	O
0.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
no-scan	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
induction	I-OUT	NOUN	B
for	O	ADP	O
prolonged	B-OUT	ADJ	B
pregnancy	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
scan	O	NOUN	B
(	O	PUNCT	O
19	O	NUM	O
[	O	PUNCT	O
8.2	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
no-scan	O	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
[	O	PUNCT	O
7.4	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
)	O	PUNCT	O
groups	O	NOUN	B
(	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
1.10	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.59-2.07	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Acknowledging	O	VERB	O
the	O	DET	O
reduced	O	VERB	B
numbers	O	NOUN	I
recruited	O	VERB	O
for	O	ADP	O
study	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
that	O	SCONJ	O
a	O	DET	O
first	O	ADJ	O
trimester	O	NOUN	B
ultrasound	B-I	NOUN	B
dating	I-I	NOUN	I
scan	I-I	NOUN	I
reduces	O	VERB	B
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
induction	I-OUT	NOUN	B
of	I-OUT	ADP	O
labour	I-OUT	NOUN	O
for	O	ADP	O
prolonged	B-OUT	ADJ	B
pregnancy	I-OUT	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
more	O	ADV	O
expensive	O	ADJ	B
healthcare	O	NOUN	B
strategy	O	NOUN	I
.	O	PUNCT	O


Injection	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
with	O	ADP	O
propofol	B-I	NOUN	B
.	I-I	PUNCT	O


Reduction	O	NOUN	B
with	O	ADP	O
aspiration	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
single-blind	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
100	B-P	NUM	O
patients	I-P	NOUN	B
to	O	PART	O
investigate	O	VERB	B
a	O	DET	O
new	O	ADJ	O
method	O	NOUN	B
of	O	ADP	O
reducing	O	VERB	B
pain	B-OUT	NOUN	I
on	O	ADP	O
propofol	B-I	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


Aspiration	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
's	O	PART	I
blood	O	NOUN	B
into	O	ADP	O
a	O	DET	O
syringe	O	NOUN	B
of	O	ADP	O
propofol	B-I	NOUN	B
immediately	O	ADV	O
before	O	ADP	O
injection	O	NOUN	B
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
lignocaine	B-I	NOUN	B
20	I-I	NUM	O
mg	I-I	NOUN	O
or	I-I	CCONJ	O
normal	I-I	ADJ	O
saline	I-I	NOUN	O
2	I-I	NUM	O
ml	I-I	NOUN	O
to	I-I	PART	O
the	I-I	DET	O
propofol	I-I	NOUN	B
before	I-I	ADP	O
injection	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
blood	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
reducing	B-OUT	VERB	B
pain	I-OUT	NOUN	I
on	I-OUT	ADP	O
injection	I-OUT	NOUN	B
than	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
saline	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
more	O	ADV	O
effective	B-OUT	ADJ	B
than	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
lignocaine	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
pindolol	B-I	NOUN	B
and	I-I	CCONJ	O
clopamide	I-I	NOUN	B
on	O	ADP	O
blood	B-OUT	NOUN	B
lipids	I-OUT	NOUN	I
in	O	ADP	O
arterial	B-P	ADJ	B
hypertensive	I-P	ADJ	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
clopamide	B-I	NOUN	B
,	I-I	PUNCT	O
pindolol	I-I	NOUN	B
and	I-I	CCONJ	O
its	I-I	PRON	O
combination	I-I	NOUN	B
on	I-I	ADP	O
plasma	I-I	NOUN	B
lipids	I-I	NOUN	B
in	O	ADP	O
49	B-P	NUM	O
hypertensive	I-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
WHO	I-P	PRON	B
I-II	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
divided	I-P	VERB	O
into	I-P	ADP	O
three	I-P	NUM	O
parallel	I-P	ADJ	O
randomized	I-P	ADJ	B
groups	I-P	NOUN	I
,	I-P	PUNCT	O
were	I-P	AUX	O
studied	I-P	VERB	O
over	I-P	ADP	O
a	I-P	DET	O
6	I-P	NUM	O
months	I-P	NOUN	B
period	I-P	NOUN	B
.	I-P	PUNCT	O


Total	B-OUT	ADJ	B
cholesterol	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
triglycerides	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
HDL	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
LDL	I-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
fractions	I-OUT	NOUN	I
were	O	AUX	O
determined	O	VERB	O
twice	O	ADV	O
during	O	ADP	O
an	O	DET	O
initial	O	ADJ	O
4-week	O	NOUN	B
washout	O	NOUN	B
phase	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
a	O	DET	O
1-	O	NUM	O
,	O	PUNCT	O
3-	O	NUM	O
and	O	CCONJ	O
6-month	O	ADJ	O
active	O	ADJ	O
hypotensive	O	ADJ	O
drug	O	NOUN	O
phase	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
instructed	O	VERB	O
to	O	PART	O
maintain	O	VERB	O
their	O	PRON	O
usual	O	ADJ	O
dietary	O	ADJ	B
habits	O	NOUN	I
.	O	PUNCT	O


Daily	O	ADJ	B
drug	O	NOUN	B
doses	O	NOUN	I
were	O	AUX	O
adjusted	O	VERB	O
progressively	O	ADV	O
to	O	PART	O
attain	O	VERB	O
optimal	O	ADJ	B
hypotensive	O	ADJ	B
effects	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
clopamide	O	NOUN	B
monotherapy	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
total	B-OUT	ADJ	B
cholesterol	I-OUT	NOUN	I
increased	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
triglycerides	B-OUT	NOUN	B
and	O	CCONJ	O
LDL	B-OUT	NOUN	B
showed	O	VERB	O
a	O	DET	O
tendency	O	NOUN	O
to	O	PART	O
increase	O	VERB	B
while	O	SCONJ	O
for	O	ADP	O
HDL	B-OUT	NOUN	B
a	O	DET	O
tendency	O	NOUN	O
to	O	PART	O
decrease	O	VERB	B
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
pindolol	O	NOUN	B
monotherapy	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
triglycerides	B-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
HDL	B-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
changes	O	NOUN	B
in	O	ADP	O
total	B-OUT	ADJ	B
cholesterol	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
LDL	I-OUT	NOUN	B
fraction	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


Combined	O	ADJ	B
pindolol-clopamide	O	ADJ	B
therapy	O	NOUN	I
decreased	O	VERB	B
total	B-OUT	ADJ	O
triglycerides	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
NS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
increased	O	VERB	B
HDL	B-OUT	NOUN	B
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
influence	O	VERB	B
total	B-OUT	ADJ	B
cholesterol	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
LDL	I-OUT	NOUN	B
fraction	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
pindolol	O	NOUN	B
does	O	AUX	O
not	O	PART	O
negatively	O	ADV	O
influence	O	VERB	B
blood	B-OUT	NOUN	B
lipids	I-OUT	NOUN	I
as	O	ADP	O
the	O	DET	O
thiazide-type	O	ADJ	B
diuretic	O	ADJ	I
clopamide	O	NOUN	I
does	O	AUX	O
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
when	O	SCONJ	O
both	O	DET	O
drugs	O	NOUN	B
are	O	AUX	O
used	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
beta-blocker	O	NOUN	B
can	O	AUX	O
probably	O	ADV	O
counterbalance	O	VERB	O
the	O	DET	O
diuretic-induced	O	ADJ	B
negative	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
blood	B-OUT	NOUN	B
lipids	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
pindolol	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
a	O	DET	O
more	O	ADV	O
favorable	O	ADJ	B
beta-blocker	O	NOUN	B
drug	O	NOUN	O
to	O	PART	O
be	O	AUX	O
used	O	VERB	O
on	O	ADP	O
hypertensive	B-P	ADJ	B
subjects	I-P	NOUN	B
with	I-P	ADP	O
metabolic	I-P	ADJ	B
coronary	I-P	ADJ	I
risk	I-P	NOUN	I
factors	I-P	NOUN	I
.	I-P	PUNCT	O


Hodgkin	B-P	NOUN	B
's	I-P	PART	I
disease	I-P	NOUN	I
in	I-P	ADP	O
childhood	I-P	NOUN	B
and	I-P	CCONJ	O
adolescence	I-P	NOUN	B
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
chemotherapy-radiotherapy	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
stages	O	NOUN	I
IA-IIB	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
April	O	PROPN	O
1972	O	NUM	O
to	O	ADP	O
May	O	PROPN	O
1980	O	NUM	O
,	O	PUNCT	O
72	B-P	NUM	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
5	I-P	NUM	O
to	I-P	PART	O
19	I-P	NUM	O
years	I-P	NOUN	B
old	I-P	ADJ	O
,	I-P	PUNCT	O
median	I-P	ADJ	B
16	I-P	NUM	O
)	I-P	PUNCT	O
with	I-P	ADP	O
Hodgkin	I-P	NOUN	B
's	I-P	PART	I
disease	I-P	NOUN	I
,	I-P	PUNCT	O
clinical	I-P	ADJ	B
stages	I-P	NOUN	I
IA-IIB	I-P	NOUN	B
(	I-P	PUNCT	O
IA	I-P	PROPN	B
,	I-P	PUNCT	O
18	I-P	NUM	O
;	I-P	PUNCT	O
II2A	I-P	NOUN	B
,	I-P	PUNCT	O
two	I-P	NUM	O
areas	I-P	NOUN	O
involved	I-P	VERB	O
on	I-P	ADP	O
the	I-P	DET	O
same	I-P	ADJ	O
side	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
diaphragm	I-P	NOUN	B
,	I-P	PUNCT	O
23	I-P	NUM	O
;	I-P	PUNCT	O
II3+A	I-P	INTJ	B
,	I-P	PUNCT	O
three	I-P	NUM	O
areas	I-P	NOUN	B
or	I-P	CCONJ	O
more	I-P	ADJ	O
,	I-P	PUNCT	O
16	I-P	NUM	O
;	I-P	PUNCT	O
IIB	I-P	NOUN	B
,	I-P	PUNCT	O
15	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
prospectively	O	ADV	O
treated	O	VERB	B
in	O	ADP	O
two	O	NUM	O
successive	O	ADJ	O
clinical	O	ADJ	B
trials	O	NOUN	I
(	O	PUNCT	O
H	O	NOUN	O
72	O	NUM	O
and	O	CCONJ	O
H	O	NOUN	O
77	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Clinical	O	ADJ	B
stages	O	NOUN	I
IA	O	NOUN	B
and	O	CCONJ	O
II2A	O	NOUN	B
received	O	VERB	O
three	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
mechlorethamine	B-I	NOUN	B
,	I-I	PUNCT	O
Oncovin	I-I	NOUN	B
,	I-I	PUNCT	O
procarbazine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
prednisone	I-I	NOUN	B
(	I-I	PUNCT	O
MOPP	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
supradiaphragmatic	I-I	ADJ	B
radiotherapy	I-I	NOUN	I
(	I-I	PUNCT	O
40	I-I	NUM	O
Gy	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
no	I-I	DET	O
laparotomy	I-I	NOUN	O
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Clinical	O	ADJ	B
stages	O	NOUN	I
II3+A	O	VERB	B
and	O	CCONJ	O
IIB	O	PROPN	B
received	O	VERB	O
either	O	CCONJ	O
six	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
MOPP	B-I	NOUN	B
(	O	PUNCT	O
H	O	NOUN	O
72	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
three	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
MOPP	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
three	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
CCNU	B-I	NOUN	B
,	I-I	PUNCT	O
vinblastine	I-I	NOUN	B
,	I-I	PUNCT	O
procarbazine	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
prednisone	B-I	NOUN	B
(	O	PUNCT	O
CVPP	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
H	O	NOUN	O
77	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
subsequently	O	ADV	O
had	O	AUX	O
a	O	DET	O
laparotomy	B-I	NOUN	B
followed	O	VERB	O
by	O	ADP	O
supradiaphragmatic	B-I	ADJ	B
radiotherapy	I-I	NOUN	I
and	O	CCONJ	O
a	O	DET	O
lumboaortic	O	ADJ	B
field	O	NOUN	I
if	O	SCONJ	O
results	O	NOUN	B
of	O	ADP	O
laparotomy	O	NOUN	B
were	O	AUX	O
positive	O	ADJ	B
.	O	PUNCT	O


Patients	B-P	NOUN	B
without	I-P	ADP	O
evidence	I-P	NOUN	B
of	I-P	ADP	O
mediastinal	I-P	ADJ	B
involvement	I-P	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
mediastinal	O	ADJ	B
radiotherapy	O	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
disease	O	NOUN	B
in	O	ADP	O
70	O	NUM	O
of	O	ADP	O
72	O	NUM	O
patients	O	NOUN	B
was	O	AUX	O
in	O	ADP	O
complete	O	ADJ	O
remission	O	NOUN	B
(	O	PUNCT	O
one	O	NUM	O
failure	B-OUT	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
death	B-OUT	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Eight	O	NUM	O
patients	O	NOUN	B
relapsed	B-OUT	VERB	B
(	O	PUNCT	O
in	O	X	B
situ	O	X	I
,	O	PUNCT	O
1	O	NUM	O
;	O	PUNCT	O
marginal	O	ADJ	B
,	O	PUNCT	O
1	O	NUM	O
;	O	PUNCT	O
nonirradiated	O	VERB	B
subdiaphragmatic	O	ADJ	B
area	O	NOUN	I
,	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
three	O	NUM	O
to	O	PART	O
57	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
complete	O	ADJ	B
remission	O	NOUN	I
(	O	PUNCT	O
median	O	ADJ	B
20	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
one	O	NUM	O
patient	O	NOUN	B
died	O	VERB	B
after	O	ADP	O
relapse	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
three	O	NUM	O
deaths	B-OUT	NOUN	B
after	O	ADP	O
complete	O	ADJ	O
remission	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
(	O	PUNCT	O
infection	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
;	O	PUNCT	O
acute	O	ADJ	B
nonlymphocytic	B-OUT	ADJ	I
leukemia	I-OUT	NOUN	I
[	O	PUNCT	O
ANLL	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
one	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


As	O	ADP	O
of	O	ADP	O
June	O	PROPN	O
1984	O	NUM	O
the	O	DET	O
median	O	NOUN	B
follow-up	O	NOUN	B
was	O	AUX	O
82	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
49	O	NUM	O
to	O	PART	O
145	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	B-OUT	DET	O
actuarial	I-OUT	ADJ	B
probabilities	I-OUT	NOUN	B
for	I-OUT	ADP	O
survival	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
freedom	I-OUT	NOUN	B
from	I-OUT	ADP	O
relapse	I-OUT	NOUN	B
for	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
being	O	AUX	O
91.6	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
87.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistical	O	ADJ	B
difference	O	NOUN	I
according	O	VERB	O
to	O	PART	O
clinical	O	ADJ	B
stage	O	NOUN	I
,	O	PUNCT	O
age	O	NOUN	B
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
15	O	NUM	O
or	O	CCONJ	O
less	O	ADJ	O
than	O	ADP	O
15	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
cycles	I-OUT	NOUN	B
of	I-OUT	ADP	O
chemotherapy	I-OUT	NOUN	B
(	O	PUNCT	O
six	O	NUM	O
or	O	CCONJ	O
three	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Bone	B-OUT	NOUN	B
growth	I-OUT	NOUN	I
defects	I-OUT	NOUN	O
related	I-OUT	VERB	O
to	I-OUT	PART	O
radiotherapy	I-OUT	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
particularly	O	ADV	O
in	O	ADP	O
the	O	DET	O
29	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
receive	O	VERB	O
mediastinal	O	ADJ	B
radiotherapy	O	NOUN	I
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
mediastinal	B-OUT	ADJ	B
relapse	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Azoospermia	B-OUT	NOUN	B
was	O	AUX	O
the	O	DET	O
rule	O	NOUN	O
for	O	ADP	O
the	O	DET	O
male	O	NOUN	B
patients	O	NOUN	B
studied	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
young	O	ADJ	B
girls	O	NOUN	B
and	O	CCONJ	O
young	O	ADJ	B
women	O	NOUN	B
retained	O	VERB	O
reproductive	O	ADJ	B
integrity	O	NOUN	B
.	O	PUNCT	O


Sialyl	B-I	NOUN	B
Lewisa	I-I	NOUN	I
expression	I-I	NOUN	B
as	O	ADP	O
a	O	DET	O
predictor	O	NOUN	B
of	O	ADP	O
the	O	DET	O
prognosis	O	NOUN	B
of	O	ADP	O
colon	B-P	NOUN	B
carcinoma	I-P	NOUN	I
patients	I-P	NOUN	B
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
metastatic	O	ADJ	B
potential	O	NOUN	B
of	O	ADP	O
tumors	O	NOUN	B
is	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
to	O	PART	O
cell	O	NOUN	B
adhesion	O	NOUN	I
by	O	ADP	O
cell	O	NOUN	B
surface	O	NOUN	I
carbohydrate	O	NOUN	B
antigens	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
sialyl	O	NOUN	B
Lewis	O	PROPN	I
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
important	O	ADJ	O
molecules	O	NOUN	B
of	O	ADP	O
cell	O	NOUN	B
surface	O	NOUN	I
carbohydrates	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
prognostic	O	ADJ	B
marker	O	NOUN	I
of	O	ADP	O
aggressive	O	ADJ	B
and	O	CCONJ	O
metastasizing	O	VERB	B
tumor	O	NOUN	B
growth	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
prognostic	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
sialyl	O	NOUN	B
Lewis	O	PROPN	I
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
expression	O	NOUN	B
in	O	ADP	O
colon	O	NOUN	B
cancer	O	NOUN	I
is	O	AUX	O
still	O	ADV	O
controversial	O	ADJ	O
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
expression	B-I	NOUN	B
of	I-I	ADP	O
sialyl	I-I	NOUN	B
Lewis	I-I	PROPN	I
(	I-I	PUNCT	O
a	I-I	DET	O
)	I-I	PUNCT	O
antigen	I-I	NOUN	O
in	O	ADP	O
233	B-P	NUM	O
colon	I-I	NOUN	B
cancer	I-I	NOUN	I
specimens	I-I	VERB	B
from	I-P	ADP	O
patients	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
registered	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
prospective	I-P	ADJ	B
adjuvant	I-I	ADJ	I
immunochemotherapy	I-I	NOUN	I
clinical	I-P	ADJ	B
trial	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
course	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
prognosis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
after	O	ADP	O
all	O	DET	O
the	O	DET	O
immunohistochemical	O	ADJ	B
analyses	O	NOUN	I
had	O	AUX	O
been	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Sialyl	O	NOUN	O
Lewis	O	PROPN	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
expression	O	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
both	O	CCONJ	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0006	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
disease-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
log-rank	O	ADJ	B
test	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
result	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
assumed	O	VERB	O
to	O	PART	O
have	O	AUX	O
been	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
the	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
metastatic	O	ADJ	B
preponderance	O	NOUN	B
in	O	ADP	O
a	O	DET	O
high	O	ADJ	B
versus	O	CCONJ	O
low	O	ADJ	O
sialyl	O	NOUN	O
Lewis	O	NOUN	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
expression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
tumor	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	VERB	O
This	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
sialyl	O	NOUN	B
Lewis	O	PROPN	I
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
expression	O	NOUN	B
levels	O	NOUN	O
may	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
an	O	DET	O
indicator	O	NOUN	B
of	O	ADP	O
the	O	DET	O
metastatic	O	ADJ	B
potential	O	NOUN	B
of	O	ADP	O
colon	O	NOUN	B
cancer	O	NOUN	I
cells	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
would	O	AUX	O
strongly	O	ADV	O
predict	O	VERB	O
the	O	DET	O
prognosis	O	NOUN	B
.	O	PUNCT	O


1H	O	NOUN	B
nuclear	O	ADJ	I
magnetic	O	ADJ	I
resonance-based	O	ADJ	I
metabolomic	O	ADJ	I
study	O	NOUN	I
on	O	ADP	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
Qingrehuatan	B-I	PROPN	B
decoction	I-I	NOUN	I
against	O	ADP	O
abundant	O	ADJ	B
phlegm-heat	O	ADJ	B
syndrome	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
essential	I-P	ADJ	B
hypertension	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
observe	O	VERB	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
Qingrehuatan	B-I	PROPN	B
decoction	I-I	NOUN	I
(	I-I	PUNCT	O
QRHT	I-I	PROPN	B
)	I-I	PUNCT	O
on	O	ADP	O
serum	B-OUT	NOUN	B
metabolic	I-OUT	ADJ	B
profile	I-OUT	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
essential	I-P	ADJ	I
hypertension	I-P	NOUN	I
(	I-P	PUNCT	O
YEH	I-P	NOUN	B
)	I-P	PUNCT	O
patients	I-P	NOUN	B
with	I-P	ADP	O
abundant	I-P	ADJ	B
phlegm-heat	I-P	ADJ	B
syndrome	I-P	NOUN	I
and	O	CCONJ	O
provide	O	VERB	O
a	O	DET	O
basis	O	NOUN	O
for	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
decoction	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Twelve	B-P	NUM	O
male	I-P	NOUN	B
YEH	I-P	NOUN	B
patients	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
selected	I-P	VERB	O
and	I-P	CCONJ	O
serum	I-P	NOUN	B
samples	I-P	NOUN	I
were	I-P	AUX	O
collected	I-P	VERB	O
for	I-P	ADP	O
examination	I-P	NOUN	B
before	I-P	ADP	O
and	I-P	CCONJ	O
after	I-P	ADP	O
4	I-P	NUM	O
weeks	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
treatment	I-P	NOUN	B
with	I-P	ADP	O
QRHT	I-I	PROPN	B
.	I-I	PUNCT	O


Twelve	B-P	NUM	O
healthy	I-P	ADJ	B
males	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
selected	I-P	VERB	O
and	I-P	CCONJ	O
their	I-P	PRON	O
serum	I-P	NOUN	B
samples	I-P	NOUN	I
were	I-P	AUX	O
collected	I-P	VERB	O
as	I-P	ADP	O
a	I-P	DET	O
control	I-P	NOUN	B
.	I-P	PUNCT	O


All	O	DET	O
serum	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
using	O	VERB	O
metabolomic	O	ADJ	B
technology	O	NOUN	I
with	O	ADP	I
1H	O	NOUN	B
nuclear	O	ADJ	I
magnetic	O	ADJ	I
resonance	O	NOUN	I
.	O	PUNCT	O


Differences	O	NOUN	B
in	O	ADP	O
metabolites	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
by	O	ADP	O
principal	O	ADJ	B
component	O	NOUN	I
analysis	O	NOUN	I
and	O	CCONJ	O
partial	O	ADJ	B
least	O	ADJ	O
squares-discriminate	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
produced	O	VERB	O
scores	O	NOUN	B
and	O	CCONJ	O
loadings	O	NOUN	B
plots	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
After	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
substances	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
distinguished	O	VERB	O
between	O	ADP	O
the	O	DET	O
YEH	O	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
abundant	O	ADJ	B
phlegm-heat	O	ADJ	B
syndrome	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
specific	O	ADJ	O
serum	B-OUT	NOUN	B
endog-	I-OUT	ADJ	O
enous	I-OUT	ADJ	B
metabolites	I-OUT	NOUN	I
tended	O	VERB	O
to	O	PART	O
improve	O	VERB	B
after	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


QRHT	B-I	PROPN	B
can	O	AUX	O
appropriately	O	ADV	O
increase	O	VERB	B
the	O	DET	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	I
glucose	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
lactic	I-OUT	ADJ	B
acid	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
citric	I-OUT	ADJ	B
acid	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
high-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
phosphatidylcholine	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
glycerophosphate	I-OUT	ADJ	B
choline	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
hydroxybutyrate	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
alanine	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
glutamate	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


QRHT	B-I	PROPN	B
could	O	AUX	O
also	O	ADV	O
decrease	O	VERB	B
the	O	DET	O
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
low-density	I-OUT	ADJ	B
lipoprotein/very	I-OUT	NOUN	I
low-density	I-OUT	ADJ	I
lipoprotein	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
lipids	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
N-acetyl	I-OUT	ADJ	B
glycoprotein	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
O-acetyl	I-OUT	NOUN	B
glycoprotein	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSION	O	PROPN	O
QRHT	O	PROPN	B
can	O	AUX	O
effectively	O	ADV	O
ameliorate	O	VERB	B
metabolic	B-OUT	ADJ	B
disorders	I-OUT	NOUN	I
in	O	ADP	O
YEH	O	PROPN	B
Patients	O	NOUN	B
with	O	ADP	O
abundant	O	ADJ	B
phlegm-heat	O	ADJ	B
syndrome	O	NOUN	I
.	O	PUNCT	O


1H	O	NOUN	O
NMR-based	O	ADJ	B
metabolomic	O	ADJ	B
technology	O	NOUN	I
can	O	AUX	O
provide	O	VERB	O
an	O	DET	O
objective	O	ADJ	O
basis	O	NOUN	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
YEH	B-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
abundant	I-P	ADJ	B
phlegm-heat	I-P	ADJ	B
syndrome	I-P	NOUN	I
using	O	VERB	O
QRHT	B-I	PROPN	B
.	I-I	PUNCT	O


The	O	DET	O
effects	B-OUT	NOUN	B
of	O	ADP	I
different	O	ADJ	O
intensities	O	NOUN	B
and	O	CCONJ	O
durations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
general	B-I	ADJ	B
warm-up	I-I	NOUN	I
on	I-OUT	ADP	O
leg	I-OUT	NOUN	B
press	I-OUT	NOUN	I
1RM	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
precision	O	NOUN	B
of	O	ADP	O
maximum	O	ADJ	B
strength	O	NOUN	I
assessments	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
repetition	O	NOUN	B
maximum	O	NOUN	B
;	O	PUNCT	O
1RM	O	NOUN	O
)	O	PUNCT	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
functional	O	ADJ	B
capacity	O	NOUN	O
and	O	CCONJ	O
to	O	PART	O
prescribe	O	VERB	O
and	O	CCONJ	O
monitor	O	VERB	B
the	O	DET	O
training	O	NOUN	B
load	O	NOUN	O
.	O	PUNCT	O


Several	O	ADJ	O
factors	O	NOUN	B
can	O	AUX	O
affect	O	VERB	O
the	O	DET	O
precision	O	NOUN	B
of	O	ADP	O
1RM	O	NOUN	O
tests	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
warm-up	O	NOUN	B
procedure	O	NOUN	I
.	O	PUNCT	O


General	O	ADJ	B
and	O	CCONJ	O
specific	O	ADJ	O
warm-up	O	NOUN	B
routines	O	NOUN	O
are	O	AUX	O
recommended	O	VERB	O
to	O	PART	O
enhance	O	VERB	B
performance	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
warm-up	O	NOUN	B
have	O	AUX	O
already	O	ADV	O
been	O	AUX	O
acknowledged	O	VERB	O
in	O	ADP	O
improving	O	VERB	B
performance	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
general	B-I	ADJ	B
warm-up	I-I	NOUN	I
(	I-I	PUNCT	O
GWU	I-I	NOUN	B
)	I-I	PUNCT	O
are	O	AUX	O
unclear	O	ADJ	B
but	O	CCONJ	O
seem	O	VERB	O
to	O	PART	O
depend	O	VERB	O
on	O	ADP	O
its	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
increase	O	VERB	B
muscle	O	NOUN	B
temperature	O	NOUN	B
while	O	SCONJ	O
avoiding	O	VERB	O
fatigue	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
temperature	O	NOUN	B
elevation	O	NOUN	B
is	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
duration	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
intensity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
eventually	O	ADV	O
affect	O	VERB	O
1RM	O	NOUN	O
performance	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	B-OUT	NOUN	B
of	O	ADP	O
different	O	ADJ	O
intensities	O	NOUN	B
and	O	CCONJ	O
durations	O	NOUN	B
of	O	ADP	O
GWU	O	PROPN	B
on	O	ADP	O
1RM	O	NOUN	O
performance	O	NOUN	B
.	O	PUNCT	O


Sixteen	B-P	NUM	O
strength-trained	I-P	ADJ	B
men	I-P	NOUN	B
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
1RM	B-OUT	NOUN	B
leg	I-OUT	NOUN	I
press	I-OUT	NOUN	I
after	O	ADP	O
4	O	NUM	O
GWU	O	NOUN	B
conditions	O	NOUN	B
after	O	ADP	O
specific	O	ADJ	O
warm-up	O	NOUN	B
:	O	PUNCT	O
short	O	ADJ	B
duration	O	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
intensity	O	NOUN	I
(	O	PUNCT	O
SDLI	O	NOUN	B
;	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
5	O	NUM	O
minutes	O	NOUN	B
at	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
V	O	NOUN	O
[	O	PUNCT	O
Combining	O	VERB	O
Dot	O	NOUN	B
Above	O	ADJ	I
]	O	PUNCT	O
O2max	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
long	O	ADJ	B
duration	O	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
intensity	O	NOUN	I
(	O	PUNCT	O
LDLI	O	NOUN	B
;	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
15	O	NUM	O
minutes	O	NOUN	B
at	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
V	O	NOUN	O
[	O	PUNCT	O
Combining	O	VERB	O
Dot	O	NOUN	B
Above	O	ADJ	I
]	O	PUNCT	O
O2max	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
short	O	ADJ	B
duration	O	NOUN	I
and	O	CCONJ	O
moderate	O	ADJ	B
intensity	O	NOUN	O
(	O	PUNCT	O
SDMI	O	NOUN	B
;	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
5	O	NUM	O
minutes	O	NOUN	B
at	O	ADP	O
70	O	NUM	O
%	O	NOUN	O
V	O	NOUN	O
[	O	PUNCT	O
Combining	O	VERB	O
Dot	O	NOUN	B
Above	O	ADJ	I
]	O	PUNCT	O
O2max	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
long	O	ADJ	B
duration	O	NOUN	I
and	O	CCONJ	O
moderate	O	ADJ	B
intensity	O	NOUN	O
(	O	PUNCT	O
LDMI	O	PROPN	B
;	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
15	O	NUM	O
minutes	O	NOUN	B
at	O	ADP	O
70	O	NUM	O
%	O	NOUN	O
V	O	NOUN	O
[	O	PUNCT	O
Combining	O	VERB	O
Dot	O	NOUN	B
Above	O	ADJ	I
]	O	PUNCT	O
O2max	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
(	O	PUNCT	O
CTRL	O	NOUN	B
)	O	PUNCT	O
no-GWU	O	NOUN	B
condition	O	NOUN	B
.	O	PUNCT	O


Leg	B-OUT	NOUN	B
press	I-OUT	NOUN	I
1RM	I-OUT	NOUN	O
values	I-OUT	NOUN	O
were	I-OUT	AUX	O
higher	I-OUT	ADJ	B
(	O	PUNCT	O
on	O	ADP	O
average	O	ADJ	B
3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
when	O	SCONJ	O
subjects	O	NOUN	B
performed	O	VERB	O
LDLI	O	NOUN	B
(	O	PUNCT	O
367.8	O	NUM	O
±	O	NOUN	O
70.1	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
other	O	ADJ	O
4	O	NUM	O
conditions	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
LDMI	O	PROPN	B
condition	O	NOUN	I
,	O	PUNCT	O
1RM	B-OUT	NOUN	B
values	I-OUT	NOUN	I
were	I-OUT	AUX	O
lower	I-OUT	ADJ	O
(	O	PUNCT	O
on	O	ADP	O
average	O	ADJ	B
-4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
4	O	NUM	O
conditions	O	NOUN	B
(	O	PUNCT	O
345.6	O	NUM	O
±	O	NOUN	O
70.5	O	NUM	O
kg	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	B-OUT	AUX	O
no	I-OUT	DET	O
differences	I-OUT	NOUN	O
between	I-OUT	ADP	O
SDMI	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
SDLI	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
CTRL	I-OUT	NOUN	B
(	O	PUNCT	O
359.4	O	NUM	O
±	O	PROPN	O
69.2	O	NUM	O
kg	O	NOUN	O
,	O	PUNCT	O
359.1	O	NUM	O
±	O	NOUN	O
69.3	O	NUM	O
kg	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
359.4	O	NUM	O
±	O	PROPN	O
70.4	O	NUM	O
kg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.99	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


According	O	VERB	O
to	O	ADP	O
our	O	PRON	O
results	O	NOUN	B
,	O	PUNCT	O
long-duration	O	ADJ	B
low-intensity	O	ADJ	B
general	O	ADJ	B
warm-up	O	NOUN	I
seems	O	VERB	O
be	O	AUX	O
appropriately	O	ADV	O
to	O	PART	O
improve	O	VERB	B
1RM	O	NOUN	O
performance	B-P	NOUN	B
in	I-P	ADP	O
strength-trained	I-P	ADJ	B
individuals	I-P	NOUN	B
.	O	PUNCT	O


Cardiovascular	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
non-depolarizing	B-I	ADJ	B
neuromuscular	I-I	ADJ	I
blockers	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
aortic	I-P	ADJ	B
valve	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


To	O	PART	O
compare	O	VERB	B
haemodynamic	O	ADJ	B
responses	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
equipotent	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
neuromuscular	B-I	ADJ	B
blockers	I-I	NOUN	I
and	O	CCONJ	O
high-dose	O	ADJ	B
fentanyl	B-I	NOUN	O
(	O	PUNCT	O
50	O	NUM	O
micrograms.kg-1	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
40	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
aortic	I-P	ADJ	B
valve	I-P	NOUN	I
stenosis	I-P	NOUN	I
(	I-P	PUNCT	O
AS	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
20	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
aortic	I-P	ADJ	B
insufficiency	I-P	NOUN	I
(	I-P	PUNCT	O
AI	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
four	O	NUM	O
study	O	NOUN	B
groups	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
the	O	DET	O
following	O	NOUN	O
:	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
pancuronium	B-I	NOUN	B
0.12	I-I	NUM	O
mg.kg-1	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
vecuronium	I-I	NOUN	B
0.12	I-I	NUM	O
mg.kg-1	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
3	I-I	X	O
)	I-I	PUNCT	O
atracurium	I-I	NOUN	B
0.4	I-I	NUM	O
mg.kg-1	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
(	I-I	PUNCT	O
4	I-I	X	O
)	I-I	PUNCT	O
pancuronium-metocurine	I-I	NOUN	B
mixture	I-I	NOUN	I
(	O	PUNCT	O
0.4	O	NUM	O
mg	O	NOUN	O
+	O	CCONJ	O
1.6	O	NUM	O
mg/ml	O	NOUN	O
)	O	PUNCT	O
:	O	PUNCT	O
1	O	NUM	O
ml/10	O	NOUN	O
kg	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Neuromuscular	B-I	ADJ	B
blockers	I-I	NOUN	I
were	O	AUX	O
injected	O	VERB	B
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
with	O	ADP	O
the	O	DET	O
fentanyl	B-I	NOUN	B
;	I-I	PUNCT	O
haemodynamics	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
with	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
awake	O	ADJ	B
(	O	PUNCT	O
baseline	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
at	O	ADP	O
two	O	NUM	O
minutes	O	NOUN	B
post-induction	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
two	O	NUM	O
and	O	CCONJ	O
five	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
intubation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
AS	O	NOUN	B
,	O	PUNCT	O
pancuronium	B-I	NOUN	B
increased	O	VERB	B
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
more	O	ADJ	O
than	O	ADP	O
vecuronium	B-I	NOUN	B
or	O	CCONJ	O
atracurium	B-I	NOUN	B
;	I-I	PUNCT	O
heart	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
also	O	ADV	O
higher	B-OUT	ADJ	O
with	O	ADP	O
the	O	DET	O
pancuronium-metocurine	B-I	NOUN	B
mixture	I-I	NOUN	O
than	O	ADP	O
with	O	ADP	O
vecuronium	B-I	NOUN	B
.	I-I	PUNCT	O


Although	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
ECG	B-OUT	PROPN	B
signs	I-OUT	NOUN	O
of	I-OUT	ADP	O
ischaemia	I-OUT	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
patient	O	NOUN	B
given	O	VERB	O
pancuronium	O	NOUN	B
developed	O	VERB	O
severe	B-OUT	ADJ	B
hypotension	I-OUT	NOUN	B
associated	I-OUT	VERB	B
with	I-OUT	ADP	I
tachycardia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Reductions	O	NOUN	B
in	O	ADP	O
SVR	B-OUT	NOUN	B
after	O	ADP	O
atracurium	O	NOUN	B
allowed	O	VERB	O
small	O	ADJ	B
but	O	CCONJ	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
decreases	O	VERB	B
in	O	ADP	O
MAP	B-OUT	NOUN	B
which	O	DET	O
were	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
;	I-OUT	PUNCT	O
one	O	NUM	O
patient	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
did	O	AUX	O
develop	O	VERB	O
severe	B-OUT	ADJ	B
hypotension	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Intubation	O	PROPN	B
resulted	O	VERB	O
in	O	ADP	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
increases	O	NOUN	B
in	O	ADP	O
MAP	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
pancuronium-metocurine	B-I	NOUN	B
mixture	O	NOUN	O
group	O	NOUN	O
.	O	PUNCT	O


Vecuronium	B-I	NOUN	B
permitted	O	VERB	O
the	O	DET	O
most	O	ADV	O
stable	O	ADJ	B
overall	B-OUT	ADJ	O
haemodynamic	I-OUT	ADJ	B
course	I-OUT	NOUN	O
at	O	ADP	O
all	O	DET	O
measurement	O	NOUN	B
times	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
AI	O	NOUN	B
showed	O	VERB	O
stable	B-OUT	ADJ	B
haemodynamics	I-OUT	NOUN	B
after	O	ADP	O
vecuronium	B-I	NOUN	B
,	I-I	PUNCT	O
pancuronium	I-I	NOUN	B
and	O	CCONJ	O
the	O	DET	O
pancuronium-metocurine	B-I	NOUN	B
mixture	I-I	NOUN	O
;	I-I	PUNCT	O
one	O	NUM	O
patient	O	NOUN	B
became	O	VERB	O
tachycardic	B-OUT	ADJ	B
following	O	VERB	O
vecuronium	B-I	NOUN	B
.	I-I	PUNCT	O


Atracurium	B-I	NOUN	B
caused	O	VERB	O
unexplained	O	ADJ	O
elevations	B-OUT	NOUN	B
in	I-OUT	ADP	O
diastolic	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mean	I-OUT	VERB	O
arterial	I-OUT	ADJ	B
pressures	I-OUT	NOUN	I
which	O	DET	O
were	O	AUX	O
significant	O	ADJ	B
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
vecuronium	B-I	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
in	O	ADP	O
increases	O	NOUN	B
in	O	ADP	O
PCWP	B-OUT	NOUN	B
;	I-OUT	PUNCT	O
mean	I-OUT	ADJ	B
PA	I-OUT	PROPN	I
pressures	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
CVP	I-OUT	NOUN	B
were	O	AUX	O
also	O	ADV	O
increased	B-OUT	VERB	B
.	I-OUT	PUNCT	O


These	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
atracurium	B-I	NOUN	B
inpatients	O	NOUN	B
with	O	ADP	O
Al	O	PROPN	B
need	O	AUX	O
further	O	ADJ	O
evaluation	O	NOUN	B
.	O	PUNCT	O


[	B-I	PUNCT	O
Aortofemoral	I-I	ADJ	B
bifurcation	I-I	NOUN	I
bypass	I-I	NOUN	I
.	I-I	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
anesthesia	O	NOUN	B
procedure	O	NOUN	I
(	B-I	PUNCT	O
NLA	I-I	NOUN	B
,	I-I	PUNCT	O
thoracic	I-I	ADJ	B
continuous	I-I	ADJ	I
catheter	I-I	NOUN	I
peridural	I-I	ADJ	O
anesthesia	I-I	NOUN	O
)	I-I	PUNCT	O
on	O	ADP	O
circulation	O	NOUN	B
,	O	PUNCT	O
respiration	O	NOUN	B
and	O	CCONJ	O
metabolism	O	NOUN	B
.	O	PUNCT	O


Homeostasis	O	NOUN	B
and	O	CCONJ	O
oxygen	O	NOUN	B
transport	O	NOUN	I
]	O	PUNCT	O
.	O	PUNCT	O


50	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
investigated	I-P	VERB	B
during	I-P	ADP	O
induction	I-P	NOUN	B
of	I-P	ADP	O
anaesthesia	I-P	NOUN	B
and	I-P	CCONJ	O
infrarenal	I-I	ADJ	B
aortic	I-I	ADJ	I
bypass	I-I	NOUN	I
surgery	I-I	NOUN	I
.	I-I	PUNCT	O


26	B-P	NUM	O
were	I-P	AUX	O
operated	I-P	VERB	O
on	I-P	ADP	O
under	I-P	ADP	O
neuroleptanaesthesia	I-I	NOUN	B
(	I-I	PUNCT	O
NA	I-I	PROPN	B
group	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-P	CCONJ	O
24	I-P	NUM	O
under	I-P	ADP	O
continuous	I-I	ADJ	B
epidural	I-I	ADJ	B
combined	I-I	VERB	B
with	I-I	ADP	O
a	I-I	DET	O
light	I-I	ADJ	O
general	I-I	ADJ	B
anaesthesia	I-I	NOUN	I
(	I-I	PUNCT	O
epidural	I-I	ADJ	B
group	I-I	NOUN	I
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Blood	O	NOUN	B
losses	O	NOUN	I
were	O	AUX	O
replaced	O	VERB	O
with	O	ADP	O
5	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
human	O	ADJ	B
albumin	O	NOUN	B
,	O	PUNCT	O
red	O	ADJ	B
cell	O	NOUN	I
concentrates	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
fresh	O	ADJ	B
frozen	O	ADJ	B
plasma	O	NOUN	I
.	O	PUNCT	O


Ringer	B-I	NOUN	B
lactate	I-I	NOUN	I
solution	I-I	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
replace	O	VERB	O
the	O	DET	O
functional	O	ADJ	B
extracellular	O	ADJ	O
fluid	O	ADJ	O
volume	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
induction	O	NOUN	B
and	O	CCONJ	O
maintenance	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	B
body	O	NOUN	B
temperature	O	NOUN	I
fell	O	VERB	O
(	O	PUNCT	O
NA	O	NOUN	B
group	O	NOUN	B
from	O	ADP	O
36.7	O	NUM	O
to	O	PART	O
35.3	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
;	O	PUNCT	O
epidural	O	ADJ	B
group	O	NOUN	I
from	O	ADP	O
36.7	O	NUM	O
to	O	PART	O
34.9	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
)	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
spite	O	NOUN	O
of	O	ADP	O
better	O	ADJ	O
surface	B-OUT	NOUN	B
perfusion	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
lower	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
body	O	NOUN	B
in	O	ADP	O
the	O	DET	O
epidural	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
increase	B-OUT	NOUN	B
of	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
glucose	I-OUT	NOUN	O
concentration	I-OUT	NOUN	O
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
epidural	O	ADJ	B
group	O	NOUN	I
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
NA	O	PROPN	B
group	O	NOUN	B
.	O	PUNCT	O


Stress	B-OUT	NOUN	B
mediated	I-OUT	VERB	O
hypokalaemia	I-OUT	NOUN	B
was	O	AUX	O
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
degree	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
median	B-OUT	ADJ	B
values	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
potassium	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
being	O	AUX	O
in	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
reference	O	NOUN	I
range	O	NOUN	I
(	O	PUNCT	O
3.5-3.7	O	NOUN	O
mmol	O	NOUN	O
X	O	NOUN	O
1	O	NUM	O
(	O	PUNCT	O
-1	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
although	O	SCONJ	O
large	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
red	O	ADJ	B
cell	O	NOUN	I
concentrates	O	NOUN	O
were	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


During	O	ADP	O
clamping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
aorta	O	NOUN	B
a	O	DET	O
moderate	B-OUT	ADJ	B
compensated	I-OUT	VERB	O
acidosis	I-OUT	NOUN	B
developed	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Declamping	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
more	O	ADV	O
marked	B-OUT	ADJ	O
increase	I-OUT	NOUN	B
of	I-OUT	ADP	O
paCO2	I-OUT	NOUN	B
and	O	CCONJ	O
a	O	DET	O
greater	B-OUT	ADJ	O
fall	I-OUT	NOUN	B
of	I-OUT	ADP	O
pH	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
NA	O	PROPN	B
group	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
epidural	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


Induction	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
fall	B-OUT	NOUN	B
in	I-OUT	ADP	O
oxygen	I-OUT	NOUN	B
uptake	I-OUT	NOUN	I
(	O	PUNCT	O
NA	O	NOUN	B
group	O	NOUN	B
from	O	ADP	O
221	O	NUM	O
to	O	PART	O
163	O	NUM	O
ml	O	NOUN	O
X	O	NOUN	B
min-1	O	NOUN	I
;	O	PUNCT	O
epidural	O	ADJ	B
group	O	NOUN	I
from	O	ADP	O
230	O	NUM	O
to	O	PART	O
189	O	NUM	O
ml	O	NOUN	O
X	O	NOUN	B
min-1	O	NOUN	I
)	O	PUNCT	O
which	O	DET	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
delayed	O	VERB	B
in	O	ADP	O
the	O	DET	O
epidural	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
short	O	ADJ	O
lasting	O	NOUN	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
after	O	ADP	O
eventration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gut	O	NOUN	B
(	O	PUNCT	O
NA	O	NOUN	B
group	O	NOUN	B
:	O	PUNCT	O
162	O	NUM	O
ml	O	NOUN	O
X	O	NOUN	B
min-1	O	NOUN	I
less	O	ADJ	O
than	O	ADP	O
epidural	O	ADJ	B
group	O	NOUN	I
184	O	NUM	O
ml	O	NOUN	O
X	O	NOUN	B
min-1	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Later	O	ADV	O
on	O	ADV	O
,	O	PUNCT	O
oxygen	B-OUT	NOUN	B
uptake	I-OUT	NOUN	I
was	O	AUX	O
equal	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
further	O	ADJ	O
changes	O	NOUN	B
due	O	ADP	O
to	O	ADP	O
clamping	O	NOUN	B
or	O	CCONJ	O
declamping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
aorta	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
nitrous	O	ADJ	B
oxide	O	NOUN	I
had	O	AUX	O
been	O	AUX	O
turned	O	VERB	O
of	O	ADP	O
,	O	PUNCT	O
the	O	DET	O
oxygen	B-OUT	NOUN	B
uptake	I-OUT	NOUN	I
increased	O	VERB	B
considerably	O	ADV	O
in	O	ADP	O
several	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
despite	O	SCONJ	O
continuing	O	VERB	O
artificial	O	ADJ	B
ventilation	O	NOUN	I
and	O	CCONJ	O
intravenous	O	ADJ	B
hypnotics	O	NOUN	B
and	O	CCONJ	O
analgesics	O	NOUN	B
having	O	VERB	O
been	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


Eventration	O	NOUN	B
and	O	CCONJ	O
exterioration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gut	O	NOUN	B
caused	O	VERB	O
the	O	DET	O
most	O	ADV	O
marked	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
haemodynamics	O	NOUN	B
and	O	CCONJ	O
oxygen	O	NOUN	B
transport	O	NOUN	I
with	O	ADP	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Immediately	O	ADV	O
after	O	ADP	O
eventration	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
sudden	O	ADJ	B
fall	O	NOUN	B
in	O	ADP	O
paO2	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
NA	O	NOUN	B
group	O	NOUN	B
from	O	ADP	O
99	O	NUM	O
to	O	PART	O
83	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
;	O	PUNCT	O
epidural	O	ADJ	B
group	O	NOUN	I
from	O	ADP	O
96	O	NUM	O
to	O	PART	O
84	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
calculated	O	VERB	B
intrapulmonary	O	ADJ	B
right-to-left-shunt	O	NOUN	O
(	O	PUNCT	O
NA	O	NOUN	B
group	O	NOUN	B
from	O	ADP	O
7	O	NUM	O
to	O	PART	O
21	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
epidural	O	ADJ	B
group	O	NOUN	I
from	O	ADP	O
10	O	NUM	O
to	O	PART	O
19	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
400	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O


Clinical	O	ADJ	B
usefulness	O	NOUN	I
of	O	ADP	O
serum	B-I	NOUN	B
prostate	I-I	NOUN	I
specific	I-I	ADJ	I
antigen	I-I	NOUN	I
for	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
prostate	B-P	NOUN	B
cancer	I-P	NOUN	I
is	O	AUX	O
preserved	O	VERB	O
in	O	ADP	O
men	B-P	NOUN	B
receiving	I-P	VERB	O
the	I-P	DET	O
dual	I-I	ADJ	B
5alpha-reductase	I-I	ADJ	B
inhibitor	I-I	NOUN	I
dutasteride	I-I	NOUN	B
.	I-I	PUNCT	O


PURPOSE	O	VERB	B
We	O	PRON	O
determined	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
PSA	O	NOUN	I
seen	O	VERB	O
with	O	ADP	O
5alpha-reductase	B-I	ADJ	B
inhibitors	I-I	NOUN	I
affects	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
usefulness	O	NOUN	I
of	O	ADP	O
PSA	O	NOUN	B
for	O	ADP	O
prostate	O	NOUN	B
cancer	O	NOUN	I
screening	O	NOUN	B
using	O	VERB	O
data	O	NOUN	B
from	O	ADP	O
2	O	NUM	O
dutasteride	O	NOUN	B
benign	O	ADJ	B
prostatic	O	ADJ	B
hyperplasia	O	NOUN	I
studies	O	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
2,802	I-P	NUM	O
men	I-P	NOUN	B
50	I-P	NUM	O
years	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
with	I-P	ADP	O
a	I-P	DET	O
clinical	I-P	ADJ	B
diagnosis	I-P	NOUN	I
of	I-P	ADP	O
benign	I-P	ADJ	B
prostatic	I-P	ADJ	B
hyperplasia	I-P	NOUN	I
,	I-P	PUNCT	O
no	I-P	DET	B
history	I-P	NOUN	I
of	I-P	ADP	O
prostate	I-P	NOUN	B
cancer	I-P	NOUN	I
,	I-P	PUNCT	O
PSA	I-P	NOUN	B
1.5	I-P	NUM	O
to	I-P	PART	O
10	I-P	NUM	O
ng/ml	I-P	NOUN	O
,	I-P	PUNCT	O
prostate	I-P	NOUN	B
volume	I-P	NOUN	I
30	I-P	NUM	O
cc	I-P	NOUN	O
or	I-P	CCONJ	O
greater	I-P	ADJ	B
,	I-P	PUNCT	O
an	I-P	DET	O
American	I-P	ADJ	B
Urological	I-P	PROPN	I
Association	I-P	PROPN	I
symptom	I-P	NOUN	I
score	I-P	NOUN	I
of	I-P	ADP	O
12	I-P	NUM	O
or	I-P	CCONJ	O
greater	I-P	ADJ	B
and	I-P	CCONJ	O
peak	I-P	VERB	B
urinary	I-P	ADJ	I
flow	I-P	NOUN	I
rate	I-P	NOUN	B
15	I-P	NUM	O
ml	I-P	NOUN	O
per	I-P	ADP	O
second	I-P	ADJ	O
or	I-P	CCONJ	O
less	I-P	ADJ	O
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	PART	O
0.5	I-I	NUM	O
mg	I-I	NOUN	O
dutasteride	I-I	NOUN	B
daily	I-I	ADV	B
or	I-I	CCONJ	O
matching	I-I	VERB	O
placebo	I-I	NOUN	B
for	O	ADP	O
24	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Increases	O	NOUN	B
in	O	ADP	O
PSA	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
maximum	O	ADJ	B
increase	O	NOUN	B
from	O	ADP	O
nadir	O	NOUN	B
to	O	PART	O
month	O	NOUN	B
24	O	NUM	O
were	O	AUX	O
compared	O	VERB	B
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
and	O	CCONJ	O
analyzed	O	VERB	B
by	O	ADP	O
prostate	O	NOUN	B
cancer	O	NOUN	I
status	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
PSA	O	NOUN	B
driven	O	VERB	O
biopsy	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
advised	O	ADJ	O
cutoff	O	NOUN	B
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
4	O	NUM	O
ng/ml	O	NOUN	O
after	O	ADP	O
doubling	O	VERB	B
to	O	PART	O
correct	O	VERB	O
for	O	ADP	O
dutasteride	B-I	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
sensitivity	O	NOUN	B
and	O	CCONJ	O
specificity	O	NOUN	B
calculated	O	VERB	B
for	O	ADP	O
each	O	DET	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
placebo	B-I	ADJ	B
treated	O	ADJ	B
men	O	NOUN	B
without	O	ADP	O
prostate	O	NOUN	B
cancer	O	NOUN	I
there	O	PRON	O
was	O	AUX	O
an	O	DET	O
8.3	O	NUM	O
%	O	NOUN	O
median	B-OUT	ADJ	B
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
PSA	I-OUT	NOUN	B
at	I-OUT	ADP	O
month	I-OUT	NOUN	B
24	I-OUT	NUM	O
compared	O	VERB	B
with	O	ADP	O
-59.5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
those	O	DET	O
who	O	PRON	O
received	O	VERB	O
dutasteride	B-I	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
doubled	O	VERB	O
values	O	NOUN	B
to	O	PART	O
correct	O	VERB	O
for	O	ADP	O
dutasteride	B-I	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
those	O	DET	O
with	O	ADP	O
prostate	O	NOUN	B
cancer	O	NOUN	I
these	O	DET	O
changes	O	NOUN	B
were	O	AUX	O
23.8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
-37.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Using	B-OUT	VERB	O
the	I-OUT	DET	O
upper	I-OUT	ADJ	B
PSA	I-OUT	NOUN	I
limit	I-OUT	NOUN	O
of	I-OUT	ADP	O
4	I-OUT	NUM	O
ng/ml	I-OUT	NOUN	O
sensitivity	I-OUT	NOUN	B
for	O	ADP	O
prostate	O	NOUN	B
cancer	O	NOUN	I
in	O	ADP	O
men	O	NOUN	B
receiving	O	VERB	O
dutasteride	B-I	NOUN	B
vs	I-I	CCONJ	O
placebo	I-I	NOUN	B
was	O	AUX	O
0.737	O	NUM	O
vs	O	CCONJ	O
0.804	O	NUM	O
,	O	PUNCT	O
while	O	SCONJ	O
specificity	B-OUT	NOUN	B
was	O	AUX	O
0.671	O	NUM	O
vs	O	CCONJ	O
0.578	O	NUM	O
.	O	PUNCT	O


Using	B-OUT	VERB	O
a	I-OUT	DET	O
PSA	I-OUT	NOUN	B
increase	I-OUT	NOUN	B
from	I-OUT	ADP	O
nadir	I-OUT	NOUN	B
of	I-OUT	ADP	O
0.8	I-OUT	NUM	O
ng/ml	I-OUT	NOUN	O
the	O	DET	O
sensitivity	B-OUT	NOUN	B
of	O	ADP	O
dutasteride	B-I	NOUN	B
was	O	AUX	O
0.548	O	NUM	O
and	O	CCONJ	O
its	O	PRON	O
specificity	B-OUT	NOUN	B
was	O	AUX	O
0.795	O	NUM	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
A	O	DET	O
doubling	O	NOUN	B
factor	O	NOUN	I
is	O	AUX	O
effective	O	ADJ	B
for	O	ADP	O
maintaining	O	VERB	O
the	O	DET	O
sensitivity	O	NOUN	B
and	O	CCONJ	O
specificity	O	NOUN	B
of	O	ADP	O
PSA	B-OUT	NOUN	B
for	O	ADP	O
prostate	O	NOUN	B
cancer	O	NOUN	I
detection	O	NOUN	B
in	O	ADP	O
men	O	NOUN	B
on	O	ADP	O
dutasteride	B-I	NOUN	B
.	I-I	PUNCT	O


Increases	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
PSA	I-OUT	NOUN	I
in	O	ADP	O
men	O	NOUN	B
receiving	O	VERB	O
dutasteride	B-I	NOUN	B
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
suspicious	O	ADJ	B
and	O	CCONJ	O
serial	O	ADJ	O
PSA	B-OUT	NOUN	B
measurements	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
changes	O	NOUN	B
from	O	ADP	O
nadir	O	NOUN	B
.	O	PUNCT	O


Face	B-I	NOUN	B
composite	I-I	ADJ	I
effects	O	NOUN	B
reveal	O	VERB	O
abnormal	O	ADJ	B
face	O	NOUN	O
processing	O	NOUN	O
in	O	ADP	O
Autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


Although	O	SCONJ	O
it	O	PRON	O
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
Autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	VERB	B
)	I-P	PUNCT	O
process	O	NOUN	B
faces	O	VERB	B
less	O	ADV	O
holistically	O	ADV	O
than	O	ADP	O
typically	O	ADV	O
developing	O	VERB	O
controls	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
few	O	ADJ	O
direct	O	ADJ	O
investigations	O	NOUN	B
of	O	ADP	O
this	O	DET	O
hypothesis	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
question	O	NOUN	O
was	O	AUX	O
addressed	O	VERB	O
before	O	ADP	O
using	O	VERB	O
the	O	DET	O
composite	O	ADJ	B
paradigm	O	NOUN	B
(	O	PUNCT	O
Teunisse	O	PROPN	B
,	O	PUNCT	O
J.	O	PROPN	O
P.	O	PROPN	O
,	O	PUNCT	O
&	O	CCONJ	O
de	O	PROPN	O
Gelder	O	PROPN	O
,	O	PUNCT	O
B	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
2003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Face	O	NOUN	B
processing	O	NOUN	I
in	O	ADP	O
adolescents	O	NOUN	B
with	O	ADP	O
autistic	O	ADJ	B
disorder	O	NOUN	I
:	O	PUNCT	O
The	O	DET	O
inversion	O	NOUN	B
and	O	CCONJ	O
composite	O	ADJ	B
effects	O	NOUN	B
.	O	PUNCT	O


Brain	O	PROPN	B
Cognition	O	PROPN	I
,	O	PUNCT	O
52	O	NUM	O
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
285-294.	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
had	O	AUX	O
revealed	O	VERB	O
that	O	SCONJ	O
adolescents	B-P	NOUN	B
with	I-P	ADP	O
ASDs	I-P	PROPN	B
were	O	AUX	O
less	O	ADV	O
sensitive	O	ADJ	B
than	O	ADP	O
controls	O	NOUN	B
to	O	ADP	O
the	O	DET	O
misalignment	O	NOUN	B
of	O	ADP	O
face	O	NOUN	B
parts	O	NOUN	I
and	O	CCONJ	O
it	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
their	O	PRON	O
face	O	NOUN	B
processing	O	NOUN	I
was	O	AUX	O
less	O	ADV	O
holistic	O	ADJ	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
shortcomings	O	NOUN	O
of	O	ADP	O
the	O	DET	O
design	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
not	O	PART	O
possible	O	ADJ	O
to	O	PART	O
distinguish	O	VERB	O
whether	O	SCONJ	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
Autism	I-P	NOUN	B
processed	O	VERB	O
both	O	CCONJ	O
aligned	O	VERB	B
and	O	CCONJ	O
misaligned	O	ADJ	B
composites	O	NOUN	B
in	O	ADP	O
a	O	DET	O
part-based	O	ADJ	B
fashion	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
in	O	ADP	O
a	O	DET	O
holistic	O	ADJ	B
fashion	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	O
adolescents	B-I	NOUN	B
with	I-I	ADP	O
ASDs	I-I	PROPN	B
to	I-P	PART	O
controls	I-I	NOUN	B
matched	I-P	VERB	B
on	I-P	ADP	O
sex	I-P	NOUN	B
,	I-P	PUNCT	O
age	I-P	NOUN	B
and	I-P	CCONJ	O
IQ	I-P	NOUN	B
on	O	ADP	O
a	O	DET	O
more	O	ADV	O
complete	O	ADJ	B
version	O	NOUN	B
of	O	ADP	O
the	O	DET	O
composite	B-I	ADJ	B
paradigm	I-I	NOUN	B
.	I-I	PUNCT	O


The	B-OUT	DET	O
results	I-OUT	NOUN	B
indicate	I-OUT	VERB	O
that	I-OUT	SCONJ	O
individuals	I-OUT	NOUN	B
with	I-OUT	ADP	O
ASDs	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
like	I-OUT	ADP	O
controls	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
experience	I-OUT	NOUN	O
interference	I-OUT	NOUN	B
from	I-OUT	ADP	O
facial	I-OUT	ADJ	B
features	I-OUT	NOUN	I
that	I-OUT	PRON	O
they	I-OUT	PRON	O
are	I-OUT	AUX	O
told	I-OUT	VERB	O
to	I-OUT	PART	O
ignore	I-OUT	VERB	O
.	I-OUT	PUNCT	O


However	B-OUT	ADV	O
,	I-OUT	PUNCT	O
while	I-OUT	SCONJ	O
such	I-OUT	ADJ	O
interference	I-OUT	NOUN	B
is	I-OUT	AUX	O
released	I-OUT	VERB	B
for	I-OUT	ADP	O
controls	I-OUT	NOUN	B
if	I-OUT	SCONJ	O
parts	I-OUT	NOUN	B
of	I-OUT	ADP	O
face	I-OUT	NOUN	O
composites	I-OUT	NOUN	B
are	I-OUT	AUX	O
misaligned	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
individuals	I-OUT	NOUN	B
with	I-OUT	ADP	O
ASDs	I-OUT	PROPN	B
show	I-OUT	VERB	O
comparable	I-OUT	ADJ	O
interference	I-OUT	NOUN	B
from	I-OUT	ADP	O
irrelevant	I-OUT	ADJ	B
parts	I-OUT	NOUN	B
regardless	I-OUT	ADV	O
of	I-OUT	ADP	O
alignment	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Two	B-OUT	NUM	O
different	I-OUT	ADJ	O
interpretations	I-OUT	NOUN	B
are	I-OUT	AUX	O
discussed	I-OUT	VERB	O
,	I-OUT	PUNCT	O
both	I-OUT	DET	O
compatible	I-OUT	ADJ	O
with	I-OUT	ADP	O
the	I-OUT	DET	O
idea	I-OUT	NOUN	O
that	I-OUT	SCONJ	O
perceptual	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
or	I-OUT	CCONJ	O
attentional	I-OUT	ADJ	B
abnormalities	I-OUT	NOUN	I
in	I-OUT	ADP	O
ASDs	I-OUT	PROPN	B
result	I-OUT	VERB	B
in	I-OUT	ADP	O
a	I-OUT	DET	O
diminished	I-OUT	VERB	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
expertise	I-OUT	NOUN	B
for	I-OUT	ADP	O
faces	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
long-term	O	ADJ	B
vitamin	B-I	NOUN	B
D	I-I	NOUN	I
and	O	CCONJ	O
calcium	B-I	NOUN	B
supplementation	I-I	NOUN	I
on	O	ADP	O
falls	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
parameters	I-OUT	NOUN	B
of	I-OUT	ADP	O
muscle	I-OUT	NOUN	B
function	I-OUT	NOUN	I
in	O	ADP	O
community-dwelling	B-P	ADJ	B
older	I-P	ADJ	O
individuals	I-P	NOUN	B
.	I-P	PUNCT	O


UNLABELLED	O	NOUN	B
In	O	ADP	O
242	B-P	NUM	O
community-dwelling	I-P	ADJ	B
seniors	I-P	NOUN	B
,	O	PUNCT	O
supplementation	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
1000	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
calcium	B-I	NOUN	B
or	O	CCONJ	O
1000	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
calcium	B-I	NOUN	B
plus	I-I	CCONJ	O
vitamin	I-I	NOUN	B
D	I-I	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
first	O	ADJ	O
falls	O	NOUN	B
of	O	ADP	O
27	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
month	O	NOUN	B
12	O	NUM	O
and	O	CCONJ	O
39	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
month	O	NOUN	B
20	O	NUM	O
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
parameters	O	NOUN	B
of	O	ADP	O
muscle	B-OUT	NOUN	B
function	I-OUT	NOUN	I
improved	O	VERB	O
significantly	O	ADV	O
.	O	PUNCT	O


INTRODUCTION	O	VERB	O
The	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
vitamin	B-I	NOUN	B
D	I-I	NOUN	I
and	O	CCONJ	O
calcium	B-I	NOUN	B
supplementation	O	NOUN	I
on	O	ADP	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	I
falling	I-OUT	VERB	I
in	O	ADP	O
the	O	DET	O
elderly	O	ADJ	B
is	O	AUX	O
discussed	O	VERB	O
controversially	O	ADV	O
.	O	PUNCT	O


Randomized	O	ADJ	B
controlled	O	ADJ	I
trials	O	NOUN	I
using	O	VERB	O
falls	O	NOUN	B
as	O	ADP	O
primary	O	ADJ	B
outcome	O	NOUN	I
are	O	AUX	O
needed	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
calcium	B-I	NOUN	B
and	O	CCONJ	O
vitamin	B-I	NOUN	B
D	I-I	NOUN	I
on	O	ADP	O
falls	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
parameters	I-OUT	NOUN	B
of	I-OUT	ADP	O
muscle	I-OUT	NOUN	B
function	I-OUT	NOUN	I
in	O	ADP	O
community-dwelling	B-P	ADJ	B
elderly	I-P	ADJ	B
women	I-P	NOUN	I
and	I-P	CCONJ	O
men	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
Our	O	PRON	O
study	O	NOUN	B
population	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
242	B-P	NUM	O
individuals	I-P	NOUN	B
recruited	I-P	VERB	O
by	I-P	ADP	O
advertisements	I-P	NOUN	B
and	I-P	CCONJ	O
mailing	I-P	NOUN	B
lists	I-P	NOUN	I
(	I-P	PUNCT	O
mean	I-P	NOUN	O
[	I-P	PUNCT	O
+/-	I-P	CCONJ	O
SD	I-P	NOUN	B
]	I-P	PUNCT	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
77	I-P	NUM	O
+/-	I-P	CCONJ	O
4	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


All	B-P	DET	O
serum	I-P	NOUN	B
25-hydroxyvitamin	I-P	NOUN	B
D	I-P	NOUN	I
(	I-P	PUNCT	O
25	I-P	NUM	O
[	I-P	PUNCT	O
OH	I-P	NOUN	O
]	I-P	PUNCT	O
D	I-P	NOUN	O
)	I-P	PUNCT	O
levels	I-P	NOUN	B
were	I-P	AUX	O
below	I-P	ADP	O
78	I-P	NUM	O
nmol/l	I-P	NOUN	O
.	I-P	PUNCT	O


Individuals	O	NOUN	B
received	O	VERB	O
in	O	ADP	O
a	O	DET	O
double	O	ADJ	O
blinded	O	VERB	O
fashion	O	NOUN	O
either	O	CCONJ	O
1000	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
calcium	B-I	NOUN	B
or	O	CCONJ	O
1000	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
calcium	B-I	NOUN	B
plus	O	CCONJ	O
800	O	NUM	O
IU	O	NOUN	B
of	O	ADP	O
vitamin	B-I	NOUN	B
D	I-I	NOUN	I
per	O	ADP	O
day	O	NOUN	B
over	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
treatment-free	O	ADJ	B
but	O	CCONJ	O
still	O	ADV	O
blinded	O	VERB	O
observation	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
8	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Falls	B-OUT	PROPN	B
were	O	AUX	O
documented	O	VERB	B
using	O	VERB	O
diaries	O	NOUN	B
.	O	PUNCT	O


The	B-P	DET	O
study	I-P	NOUN	B
took	I-P	VERB	O
place	I-P	NOUN	O
in	I-P	ADP	O
Bad	I-P	PROPN	B
Pyrmont	I-P	PROPN	I
,	I-P	PUNCT	O
Germany	I-P	PROPN	B
(	I-P	PUNCT	O
latitude	I-P	NOUN	B
52	I-P	NUM	O
degrees	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
Graz	I-P	PROPN	B
,	I-P	PUNCT	O
Austria	I-P	PROPN	B
(	I-P	PUNCT	O
latitude	I-P	NOUN	B
46	I-P	NUM	O
degrees	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
Compared	O	VERB	O
to	O	PART	O
calcium	O	NOUN	B
mono	O	NOUN	I
,	O	PUNCT	O
supplementation	O	NOUN	B
with	O	ADP	O
calcium	O	NOUN	B
plus	O	CCONJ	O
vitamin	B-I	NOUN	B
D	I-I	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
subjects	B-OUT	NOUN	B
with	I-OUT	ADP	O
first	I-OUT	ADJ	O
falls	I-OUT	NOUN	B
of	O	ADP	O
27	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
month	O	NOUN	B
12	O	NUM	O
(	O	PUNCT	O
RR	O	NOUN	B
=	O	ADJ	O
0.73	O	NUM	O
;	O	PUNCT	O
CI	O	NOUN	B
=	O	ADJ	O
0.54-0.96	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
39	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
month	O	NOUN	B
20	O	NUM	O
(	O	PUNCT	O
RR	O	NOUN	B
=	O	ADJ	O
0.61	O	NUM	O
;	O	PUNCT	O
CI	O	NOUN	B
=	O	ADJ	O
0.34-0.76	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Concerning	O	VERB	O
secondary	O	ADJ	O
endpoints	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
significant	O	ADJ	O
improvements	B-OUT	NOUN	B
in	I-OUT	ADP	O
quadriceps	I-OUT	ADJ	B
strength	I-OUT	NOUN	I
of	O	ADP	O
8	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
body	B-OUT	NOUN	B
sway	I-OUT	NOUN	I
of	O	ADP	O
28	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
time	B-OUT	NOUN	O
needed	I-OUT	VERB	O
to	I-OUT	PART	O
perform	I-OUT	VERB	O
the	I-OUT	DET	O
TUG	I-OUT	PROPN	B
test	I-OUT	NOUN	O
of	O	ADP	O
11	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
Combined	O	ADJ	B
calcium	B-I	NOUN	B
and	O	CCONJ	O
vitamin	B-I	NOUN	B
D	I-I	NOUN	I
supplementation	O	NOUN	B
proved	O	VERB	O
superior	O	ADJ	O
to	O	PART	O
calcium	O	NOUN	B
alone	O	ADV	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
falls	I-OUT	NOUN	B
and	O	CCONJ	O
improving	O	VERB	B
muscle	B-OUT	NOUN	B
function	I-OUT	NOUN	I
in	O	ADP	O
community-dwelling	B-P	ADJ	B
older	I-P	ADJ	O
individuals	I-P	NOUN	B
.	I-P	PUNCT	O


Long-term	O	ADJ	B
follow-up	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
randomized	O	ADJ	B
trials	O	NOUN	I
comparing	O	VERB	O
idarubicin	B-I	NOUN	B
and	I-I	CCONJ	O
daunorubicin	I-I	NOUN	B
as	O	ADP	O
induction	O	NOUN	B
therapies	O	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
untreated	I-P	ADJ	B
acute	I-P	ADJ	I
myeloid	I-P	ADJ	I
leukemia	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Most	O	ADV	O
clinical	O	ADJ	B
trials	O	NOUN	I
for	O	ADP	O
acute	O	ADJ	B
leukemia	O	NOUN	I
have	O	AUX	O
reported	O	VERB	O
results	O	NOUN	B
after	O	ADP	O
2-3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Comparisons	O	NOUN	B
between	O	ADP	O
the	O	DET	O
original	O	ADJ	B
data	O	NOUN	B
and	O	CCONJ	O
longer-term	O	ADJ	B
follow-up	O	ADJ	B
data	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
of	O	ADP	O
interest	O	NOUN	O
,	O	PUNCT	O
particularly	O	ADV	O
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
promising	O	VERB	O
new	O	ADJ	O
therapies	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	B-P	ADP	O
1996	I-P	NUM	O
,	I-P	PUNCT	O
survival	I-P	NOUN	B
data	I-P	NOUN	I
were	I-P	AUX	O
updated	I-P	VERB	O
from	I-P	ADP	O
three	I-P	NUM	O
prospective	I-P	ADJ	B
,	I-P	PUNCT	O
randomized	I-P	ADJ	B
comparisons	I-P	NOUN	I
of	I-P	ADP	O
idarubicin	I-I	NOUN	B
and	I-I	CCONJ	O
daunorubicin	I-I	NOUN	B
that	I-P	PRON	O
began	I-P	VERB	O
in	I-P	ADP	O
1984	I-P	NUM	O
and	I-P	CCONJ	O
1985	I-P	NUM	O
.	I-P	PUNCT	O


These	B-P	DET	O
were	I-P	AUX	O
trials	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
Memorial	I-P	PROPN	B
Sloan-Kettering	I-P	PROPN	I
Cancer	I-P	PROPN	I
Center	I-P	PROPN	I
(	I-P	PUNCT	O
MSKCC	I-P	PROPN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
the	I-P	DET	O
U.S.	I-P	PROPN	B
Multicenter	I-P	PROPN	I
Study	I-P	PROPN	I
Group	I-P	PROPN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
the	I-P	DET	O
Southeastern	I-P	PROPN	B
Cancer	I-P	PROPN	I
Study	I-P	PROPN	I
Group	I-P	PROPN	I
(	I-P	PUNCT	O
SEG	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
original	O	ADJ	O
results	O	NOUN	B
of	O	ADP	O
these	O	DET	O
trials	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
1991	O	NUM	O
and	O	CCONJ	O
1992	O	NUM	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
original	O	ADJ	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
SEG	O	PROPN	B
trial	O	NOUN	I
demonstrated	O	VERB	O
no	O	DET	B
significant	B-OUT	ADJ	I
difference	I-OUT	NOUN	O
between	I-OUT	ADP	O
idarubicin	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
daunorubicin	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
updated	O	ADJ	O
survival	B-OUT	NOUN	B
analysis	I-OUT	NOUN	I
showed	O	VERB	O
similar	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
MSKCC	O	PROPN	B
trial	O	NOUN	O
revealed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
advantage	B-OUT	NOUN	O
of	I-OUT	ADP	O
idarubicin	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
daunorubicin	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
original	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
updated	O	VERB	O
analyses	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
U.S.	O	PROPN	B
Multicenter	O	PROPN	B
trial	O	NOUN	I
found	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
favoring	O	VERB	O
idarubicin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
original	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
difference	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
in	O	ADP	O
the	O	DET	O
updated	O	ADJ	O
analysis	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
It	O	PRON	O
is	O	AUX	O
essential	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
median	O	ADJ	B
length	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
be	O	AUX	O
clearly	O	ADV	O
stated	O	VERB	O
in	O	ADP	O
any	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
results	O	NOUN	B
obtained	O	VERB	O
with	O	ADP	O
a	O	DET	O
particularly	O	ADV	O
promising	O	ADJ	O
new	O	ADJ	O
drug	O	NOUN	B
or	O	CCONJ	O
procedure	O	NOUN	B
are	O	AUX	O
presented	O	VERB	O
early	O	ADV	B
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
(	O	PUNCT	O
within	O	ADP	O
1-2	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
investigators	O	NOUN	B
should	O	AUX	O
strongly	O	ADV	O
consider	O	VERB	O
a	O	DET	O
repeat	O	NOUN	O
evaluation	O	NOUN	B
after	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
3-5	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Minocycline	B-I	NOUN	B
safety	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
in	O	ADP	O
Huntington	B-P	NOUN	B
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Minocycline	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
antibiotic	O	NOUN	B
with	O	ADP	O
anti-inflammatory	O	ADJ	B
and	O	CCONJ	O
antiapoptotic	O	ADJ	B
properties	O	NOUN	B
that	O	PRON	O
prolongs	O	VERB	B
survival	O	NOUN	I
in	O	ADP	O
a	O	DET	O
transgenic	O	ADJ	B
Huntington	B-P	PROPN	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
HD	I-P	NOUN	B
)	I-P	PUNCT	O
mouse	O	NOUN	B
model	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
of	O	ADP	O
minocycline	B-I	NOUN	B
in	O	ADP	O
60	B-P	NUM	O
HD	I-P	NOUN	B
patients	I-P	NOUN	B
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
determined	O	VERB	O
that	O	SCONJ	O
over	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
minocycline	B-I	NOUN	B
at	I-I	ADP	O
100	I-I	NUM	O
and	I-I	CCONJ	O
200	I-I	NUM	O
mg/day	I-I	NOUN	B
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	I-OUT	CCONJ	O
safe	I-OUT	ADJ	O
in	O	ADP	O
HD	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Tolerability	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
adverse	I-OUT	ADJ	B
event	I-OUT	NOUN	I
frequency	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
groups	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
transdermal	B-I	ADJ	B
clonidine	I-I	NOUN	B
in	O	ADP	O
autism	B-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Autistic	B-P	ADJ	B
individuals	I-P	NOUN	B
often	I-P	ADV	O
exhibit	I-P	VERB	O
hyperarousal	I-P	ADJ	B
behaviors	I-P	NOUN	I
(	I-P	PUNCT	O
e.g.	I-P	X	O
,	O	PUNCT	O
stereotyped	B-P	ADJ	B
body	I-P	NOUN	I
movements	I-P	NOUN	I
,	I-P	PUNCT	O
self-stimulation	I-P	NOUN	B
,	I-P	PUNCT	O
hypervigilance	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
hyperactivity	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


Clonidine	B-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
alpha	O	NOUN	B
2-adrenergic	O	ADJ	I
receptor	O	NOUN	I
agonist	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
reducing	O	VERB	B
impulsivity	O	NOUN	B
,	O	PUNCT	O
inattention	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hyperactivity	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
attention	O	NOUN	B
deficit	O	NOUN	I
disorder	O	NOUN	I
with	O	ADP	O
hyperactivity	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
investigated	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
transdermal	O	ADJ	B
clonidine	B-I	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
hyperarousal	B-P	ADJ	B
behaviors	I-P	NOUN	I
associated	I-P	VERB	B
with	I-P	ADP	I
autism	I-P	NOUN	B
.	I-P	PUNCT	O


METHOD	O	NOUN	B
A	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-crossover	B-I	ADJ	B
study	O	NOUN	I
with	O	ADP	O
transdermal	O	ADJ	B
clonidine	B-I	NOUN	B
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
nine	B-P	NUM	O
autistic	I-P	ADJ	B
males	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
5	I-P	NUM	O
to	I-P	PART	O
33	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Subjects	O	NOUN	B
received	O	VERB	O
either	O	DET	O
clonidine	B-I	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	B
0.005	O	NUM	O
mg/kg/day	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
by	O	ADP	O
a	O	DET	O
weekly	O	ADJ	B
transdermal	O	ADJ	B
patch	O	NOUN	I
.	O	PUNCT	O


Each	O	DET	O
trial	O	NOUN	B
lasted	O	VERB	O
4	O	NUM	O
weeks	O	NOUN	B
with	O	ADP	O
a	O	DET	O
2-week	O	ADJ	B
washout	O	NOUN	B
period	O	NOUN	I
between	O	ADP	O
treatment	O	NOUN	B
phases	O	NOUN	I
.	O	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
every	O	DET	O
2	O	NUM	O
weeks	O	NOUN	B
by	O	ADP	O
clinician	O	ADJ	B
raters	O	NOUN	B
and	O	CCONJ	O
weekly	O	ADV	B
by	O	ADP	O
parents	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
clonidine	B-I	NOUN	B
treatment	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
from	O	ADP	O
placebo	B-I	ADJ	B
treatment	O	NOUN	B
on	O	ADP	O
three	O	NUM	O
subscales	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Ritvo-Freeman	B-OUT	PROPN	B
Real	I-OUT	PROPN	I
Life	I-OUT	PROPN	I
Rating	I-OUT	NOUN	I
Scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
i.e.	I-OUT	X	O
,	O	PUNCT	O
social	B-OUT	ADJ	B
relationship	I-OUT	NOUN	I
to	I-OUT	ADP	O
people	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
affectual	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
sensory	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	O	DET	O
Clinical	B-OUT	PROPN	B
Global	I-OUT	PROPN	I
Impressions	I-OUT	PROPN	I
scale	I-OUT	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
clonidine	B-I	NOUN	B
produced	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
on	O	ADP	O
severity	B-OUT	NOUN	B
of	I-OUT	ADP	O
illness	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
global	I-OUT	ADJ	B
improvement	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
index	I-OUT	NOUN	O
for	O	ADP	O
therapeutic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
patient	B-OUT	NOUN	B
global	I-OUT	ADJ	O
rating	I-OUT	NOUN	O
scale	I-OUT	NOUN	O
showed	O	VERB	O
clonidine	B-I	NOUN	B
treatment	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
included	I-OUT	VERB	O
sedation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fatigue	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
clonidine	B-I	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Results	O	NOUN	O
from	O	ADP	O
this	O	DET	O
preliminary	O	ADJ	B
study	O	NOUN	I
show	O	VERB	O
that	O	SCONJ	O
clonidine	B-I	NOUN	B
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
reducing	O	VERB	B
several	B-OUT	ADJ	O
hyperarousal	I-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
and	O	CCONJ	O
improved	O	VERB	B
social	B-OUT	ADJ	B
relationships	I-OUT	NOUN	I
in	O	ADP	O
some	B-P	DET	O
autistic	I-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
in	O	ADP	O
a	O	DET	O
larger	B-P	ADJ	O
autistic	I-P	ADJ	B
population	I-P	NOUN	I
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
dose-response	O	ADJ	B
relationship	O	NOUN	B
of	O	ADP	O
clonidine	B-I	NOUN	B
.	I-I	PUNCT	O


Vitamin	B-I	NOUN	B
D	I-I	NOUN	I
supplementation	I-I	NOUN	B
ameliorates	O	VERB	O
hypoinsulinemia	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
hyperglycemia	I-OUT	NOUN	B
in	O	ADP	O
static	B-P	ADJ	B
magnetic	I-P	ADJ	O
field-exposed	I-P	ADJ	O
rat	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
vitamin	B-I	NOUN	B
D	I-I	NOUN	I
supplementation	I-I	NOUN	B
on	O	ADP	O
glucose	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
lipid	I-OUT	NOUN	B
metabolism	I-OUT	NOUN	I
in	O	ADP	O
static	B-P	ADJ	B
magnetic	I-P	ADJ	I
field	I-P	NOUN	I
(	I-P	PUNCT	O
SMF	I-P	NOUN	B
)	I-P	PUNCT	O
-exposed	I-P	ADJ	O
rats	I-P	NOUN	B
.	I-P	PUNCT	O


Rats	B-P	NOUN	B
exposed	O	VERB	B
to	O	PART	I
SMF	O	NOUN	B
(	O	PUNCT	O
128	O	NUM	O
mT	O	NOUN	O
;	O	PUNCT	O
1	O	NUM	O
h/day	O	NOUN	O
)	O	PUNCT	O
during	O	ADP	O
5	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
showed	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
plasma	B-OUT	NOUN	B
glucose	I-OUT	NOUN	O
level	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
decrease	I-OUT	NOUN	B
in	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
insulin	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


By	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
same	O	ADJ	O
treatment	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
alter	O	VERB	B
body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
plasmatic	I-OUT	ADJ	B
total	I-OUT	ADJ	O
cholesterol	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
high-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
HDL	I-OUT	NOUN	I
)	I-OUT	PUNCT	I
-cholesterol	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
low-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
LDL	I-OUT	NOUN	I
)	I-OUT	PUNCT	I
-cholesterol	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
triglyceride	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
supplementation	O	NOUN	B
with	O	ADP	O
vitamin	B-I	NOUN	B
D	I-I	NOUN	I
(	O	PUNCT	O
1,600	O	NUM	O
IU/100	O	NOUN	O
g	O	NOUN	O
,	O	PUNCT	O
per	O	ADP	O
os	O	X	O
)	O	PUNCT	O
corrected	O	VERB	O
and	O	CCONJ	O
restored	O	VERB	B
glycemia	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
insulinemia	I-OUT	NOUN	B
in	O	ADP	O
SMF-exposed	B-P	ADJ	B
rats	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
same	O	ADJ	O
treatment	O	NOUN	B
had	O	AUX	O
no	O	DET	B
effects	O	NOUN	I
on	O	ADP	O
lipid	B-OUT	NOUN	B
metabolism	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


[	O	PUNCT	O
Comparison	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
analgesic	O	NOUN	B
methods	O	NOUN	I
for	O	ADP	O
postoperative	B-P	ADJ	B
pain	I-P	NOUN	I
relief	O	NOUN	O
and	O	CCONJ	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
plasma	B-OUT	NOUN	B
interleukin-6	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
following	O	VERB	O
radical	B-P	ADJ	B
surgery	I-P	NOUN	I
for	I-P	ADP	O
gastric	I-P	ADJ	B
carcinoma	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
preemptive	B-I	ADJ	B
epidural	I-I	ADJ	O
analgesia	I-I	NOUN	O
combined	I-I	VERB	O
with	I-I	ADP	O
postoperative	I-I	ADJ	B
epidural	I-I	ADJ	B
analgesia	I-I	NOUN	I
,	I-I	PUNCT	O
postoperative	I-I	ADJ	B
epidural	I-I	ADJ	B
analgesia	I-I	NOUN	I
alone	I-I	ADV	O
and	O	CCONJ	O
intravenous	B-I	ADJ	B
analgesia	I-I	NOUN	I
for	O	ADP	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
relief	I-OUT	NOUN	O
and	O	CCONJ	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
plasma	B-OUT	NOUN	B
interleukin-6	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
IL-6	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
concentration	I-OUT	NOUN	B
following	O	VERB	O
radical	B-P	ADJ	B
surgery	I-P	NOUN	I
for	I-P	ADP	O
gastric	I-P	ADJ	B
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Sixty-six	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
gastric	I-P	ADJ	B
carcinoma	I-P	NOUN	I
scheduled	I-P	VERB	O
for	I-P	ADP	O
gastrectomy	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
3	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
namely	O	ADV	O
group	O	NOUN	B
P	O	NOUN	I
(	O	PUNCT	O
n=22	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
group	O	NOUN	B
E	O	NOUN	I
(	O	PUNCT	O
n=22	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
group	O	NOUN	B
V	O	NOUN	I
(	O	PUNCT	O
n=22	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
to	O	PART	O
receive	O	VERB	O
preemptive	B-I	ADJ	B
epidural	I-I	ADJ	O
analgesia	I-I	NOUN	O
combined	I-I	VERB	O
with	I-I	ADP	O
postoperative	I-I	ADJ	B
epidural	I-I	ADJ	B
analgesia	I-I	NOUN	I
,	I-I	PUNCT	O
exclusive	I-I	ADJ	O
postoperative	I-I	ADJ	B
epidural	I-I	ADJ	B
analgesia	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
exclusive	I-I	ADJ	O
postoperative	I-I	ADJ	B
intravenous	I-I	ADJ	B
analgesia	I-I	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Hemodynamic	B-OUT	ADJ	B
data	I-OUT	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
all	O	DET	O
the	O	DET	O
patients	O	NOUN	B
during	O	ADP	O
the	O	DET	O
operation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
visual	B-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
pain	B-OUT	NOUN	B
intensity	I-OUT	NOUN	I
at	O	ADP	O
4	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
16	O	NUM	O
,	O	PUNCT	O
24	O	NUM	O
,	O	PUNCT	O
48	O	NUM	O
and	O	CCONJ	O
72	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
IL-6	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
was	O	AUX	O
determined	O	VERB	O
before	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
24	O	NUM	O
,	O	PUNCT	O
48	O	NUM	O
,	O	PUNCT	O
72	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
No	O	DET	B
significant	O	ADJ	I
changes	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
hemodynamics	O	NOUN	B
during	O	ADP	O
the	O	DET	O
preoperative	O	ADJ	B
periods	O	NOUN	B
.	O	PUNCT	O


VAS	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
IL-6	I-OUT	NOUN	B
were	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
group	O	NOUN	B
P	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
group	O	NOUN	B
E	O	NOUN	I
and	O	CCONJ	O
V	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
group	O	NOUN	B
E	O	NOUN	I
had	O	AUX	O
lower	O	ADJ	O
measurement	O	NOUN	B
than	O	ADP	O
group	O	NOUN	B
V	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	ADJ	O
Preemptive	O	ADJ	B
epidural	O	ADJ	I
analgesia	O	NOUN	I
combined	O	VERB	O
with	O	ADP	O
postoperative	O	ADJ	B
epidural	O	ADJ	B
analgesia	O	NOUN	I
provides	O	VERB	O
more	O	ADV	O
satisfactory	O	ADJ	B
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
and	O	CCONJ	O
more	O	ADV	O
effectively	O	ADV	O
prevents	O	VERB	B
IL-6	B-OUT	NOUN	B
increment	I-OUT	NOUN	B
than	O	ADP	O
exclusive	O	ADJ	O
epidural	O	ADJ	B
analgesia	O	NOUN	I
or	O	CCONJ	O
intravenous	O	ADJ	B
analgesia	O	NOUN	I
after	B-P	ADP	O
gastrectomy	I-P	NOUN	B
for	I-P	ADP	O
gastric	I-P	ADJ	B
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


Actions	O	NOUN	B
of	O	ADP	O
platelet	B-I	NOUN	B
activating	I-I	NOUN	I
factor	I-I	NOUN	I
(	I-I	PUNCT	O
PAF	I-I	NOUN	B
)	I-I	PUNCT	O
homologues	I-I	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
combinations	O	NOUN	B
on	O	ADP	O
neutrophil	B-P	NOUN	B
chemokinesis	I-P	NOUN	I
and	I-P	CCONJ	O
cutaneous	I-P	ADJ	B
inflammatory	I-P	ADJ	I
responses	I-P	NOUN	I
in	I-P	ADP	O
man	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
inflammatory	O	ADJ	B
actions	O	NOUN	B
of	O	ADP	O
synthetic	B-I	ADJ	B
C16:0	I-I	NOUN	I
and	I-I	CCONJ	O
C18:0	I-I	NOUN	B
platelet	I-I	NOUN	I
activating	I-I	NOUN	I
factor	I-I	NOUN	I
(	I-I	PUNCT	O
PAF	I-I	NOUN	B
)	I-I	PUNCT	O
homologues	I-I	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
alone	O	ADV	O
and	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
an	O	DET	O
in	B-P	X	B
vitro	I-P	X	I
human	I-P	ADJ	B
neutrophil	I-P	NOUN	B
chemokinesis	I-P	NOUN	O
assay	I-P	NOUN	O
and	I-P	CCONJ	O
by	I-P	ADP	O
intradermal	I-P	ADJ	B
injection	I-P	NOUN	I
in	I-P	ADP	O
human	I-P	ADJ	B
skin	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
the	O	DET	O
chemokinesis	O	NOUN	B
assay	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
maximum	B-OUT	ADJ	B
distance	I-OUT	NOUN	B
moved	I-OUT	VERB	O
by	I-OUT	ADP	O
neutrophils	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
C18:0	B-I	NOUN	B
PAF	I-I	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
seen	O	VERB	O
with	O	ADP	O
the	O	DET	O
C16:0	B-I	NOUN	B
compound	I-I	NOUN	I
.	I-I	PUNCT	O


A	O	DET	O
mixture	O	NOUN	O
of	O	ADP	O
C16:0	B-I	NOUN	B
and	O	CCONJ	O
C18:0	B-I	NOUN	B
PAFs	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
1:9	O	NOUN	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
active	O	ADJ	B
than	O	ADP	O
in	O	ADP	O
a	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
3:1	O	NUM	O
.	O	PUNCT	O


Intradermal	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
the	O	DET	O
C16:0	B-I	NOUN	B
and	I-I	CCONJ	O
C18:0	I-I	NOUN	B
PAF	I-I	NOUN	B
homologues	I-I	NOUN	B
induced	O	VERB	B
dose-dependent	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
weal	B-OUT	NOUN	B
volume	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
flare	I-OUT	ADJ	B
area	I-OUT	NOUN	O
responses	I-OUT	NOUN	O
which	O	DET	O
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


Combination	O	NOUN	B
of	O	ADP	O
these	O	DET	O
phospholipids	O	NOUN	B
in	O	ADP	O
a	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
3:1	O	NOUN	O
or	O	CCONJ	O
1:9	O	NOUN	O
of	O	ADP	O
C16:0	O	NOUN	B
:	O	PUNCT	O
C18:0	O	NOUN	B
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
alter	O	VERB	O
the	O	DET	O
dose	O	NOUN	B
response	O	NOUN	I
curves	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
chain	O	NOUN	B
length	O	NOUN	I
of	O	ADP	O
the	O	DET	O
alkyl	O	ADJ	B
substituent	O	NOUN	I
of	O	ADP	O
synthetic	O	ADJ	B
PAF	B-I	NOUN	B
homologues	I-I	NOUN	O
and	O	CCONJ	O
combination	O	NOUN	B
of	O	ADP	O
these	O	DET	O
homologues	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
ratios	O	NOUN	B
found	O	VERB	O
in	O	X	B
vivo	O	X	I
or	O	CCONJ	O
formed	O	VERB	O
by	O	ADP	O
leukocytes	B-P	NOUN	B
in	I-P	X	B
vitro	I-P	X	I
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
alter	O	VERB	O
the	O	DET	O
cutaneous	B-P	ADJ	B
inflammatory	I-OUT	ADJ	O
responses	I-OUT	NOUN	O
to	I-OUT	PART	O
PAF	I-OUT	NOUN	B
in	I-P	ADP	O
man	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
C18:0	B-I	NOUN	B
homologue	I-I	NOUN	I
was	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
more	O	ADV	O
active	O	ADJ	B
as	O	ADP	O
a	O	DET	O
human	O	ADJ	B
neutrophil	O	NOUN	B
chemoattractant	O	NOUN	O
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


A	O	DET	O
randomised	O	ADJ	B
trial	O	NOUN	I
comparing	O	VERB	O
preoperative	B-I	ADJ	B
to	I-I	PART	O
perioperative	I-I	ADJ	B
chemotherapy	I-I	NOUN	B
in	O	ADP	O
early-stage	B-P	ADJ	B
non-small-cell	I-P	ADJ	B
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
IFCT	I-P	NOUN	B
0002	I-P	NUM	I
trial	I-P	NOUN	I
)	I-P	PUNCT	O
.	I-P	PUNCT	O


HYPOTHESIS	O	NOUN	B
There	O	PRON	O
will	O	AUX	O
be	O	AUX	O
a	O	DET	O
detectable	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
using	O	VERB	O
preoperative	B-I	ADJ	B
(	I-I	PUNCT	O
PRE	I-I	NOUN	B
)	I-I	PUNCT	O
as	I-I	ADP	O
opposed	I-I	VERB	O
to	I-I	PART	O
perioperative	I-I	ADJ	B
(	I-I	PUNCT	O
PERI	I-I	VERB	B
)	I-I	PUNCT	O
chemotherapy	I-I	NOUN	B
in	O	ADP	O
resectable	B-P	ADJ	B
StageI-II	I-P	ADJ	O
non-small-cell	I-P	ADJ	B
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
NSCLC	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
This	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
trial	O	NOUN	I
with	O	ADP	O
a	O	DET	O
2×2	O	NUM	O
factorial	O	ADJ	B
design	O	NOUN	B
first	O	ADV	O
compared	O	VERB	B
two	O	NUM	O
chemotherapy	O	NOUN	B
strategies	O	NOUN	O
(	O	PUNCT	O
PRE	O	NOUN	B
versus	O	CCONJ	O
PERI	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
then	O	ADV	O
two	B-I	NUM	O
chemotherapy	I-I	NOUN	B
regimens	I-I	NOUN	I
(	I-I	PUNCT	O
gemcitabine-cisplatin	I-I	NOUN	B
[	I-I	PUNCT	O
GP	I-I	NOUN	B
]	I-I	PUNCT	O
versus	I-I	CCONJ	O
paclitaxel-carboplatin	I-I	NOUN	B
[	I-I	PUNCT	O
TC	I-I	NOUN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
.	O	PUNCT	O


The	B-I	DET	O
PRE	I-I	NOUN	B
group	O	NOUN	B
received	O	VERB	O
two	O	NUM	O
preoperative	O	ADJ	B
cycles	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
two	O	NUM	O
additional	O	ADJ	O
preoperative	O	ADJ	B
cycles	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	B-I	DET	O
PERI	I-I	PROPN	B
group	O	NOUN	B
underwent	O	VERB	O
two	O	NUM	O
preoperative	O	ADJ	B
cycles	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
two	O	NUM	O
postoperative	O	ADJ	B
cycles	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
3rd	O	ADJ	O
and	O	CCONJ	O
4th	O	ADJ	O
cycles	O	NOUN	O
being	O	AUX	O
given	O	VERB	O
only	O	ADV	O
to	O	PART	O
responders	O	NOUN	B
in	O	ADP	O
both	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O


RESULTS	B-P	VERB	B
A	I-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
528	I-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
,	O	PUNCT	O
267	O	NUM	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
the	O	DET	O
PRE	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
261	O	NUM	O
to	O	PART	O
the	O	DET	O
PERI	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


Three-year	B-OUT	ADJ	B
OS	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
67.4	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
67.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
(	O	PUNCT	O
HR	O	NOUN	B
)	O	PUNCT	O
=1.01	O	NUM	O
[	O	PUNCT	O
0.79-1.30	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
p=0.92	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
nor	O	CCONJ	O
did	B-OUT	AUX	O
3-year	I-OUT	ADJ	O
disease-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
response	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
toxicity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
mortality	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Pathological	B-OUT	ADJ	B
complete	I-OUT	ADJ	O
response	I-OUT	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
22	O	NUM	O
(	O	PUNCT	O
8.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
16	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
6.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Although	B-OUT	SCONJ	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	B
,	O	PUNCT	O
chemotherapy	B-OUT	NOUN	B
compliance	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
PRE	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
responders	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
Cycles	O	PROPN	B
3	O	NUM	I
and	O	CCONJ	O
4	O	NUM	O
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
PRE	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
90.4	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
75.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p=0.001	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
responders	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
dose	O	NOUN	B
intensity	O	NOUN	B
of	O	ADP	O
Cycles	O	NOUN	B
3	O	NUM	I
and	O	CCONJ	O
4	O	NUM	O
was	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
PRE	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
PERI	O	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	O
relative	O	ADJ	O
dose	O	NOUN	O
intensity	O	NOUN	B
of	O	ADP	O
90.4	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
82.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
p=0.0007	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
between	B-OUT	ADP	O
GP	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
TC	I-OUT	NOUN	B
in	O	ADP	O
3-year	B-OUT	ADJ	O
OS	I-OUT	NOUN	B
(	O	PUNCT	O
HR=0.97	O	NOUN	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
0.76-1.25	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
p=0.80	O	NOUN	O
)	O	PUNCT	O
or	B-OUT	CCONJ	O
response	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
regimens	B-OUT	NOUN	B
'	I-OUT	PART	O
toxicity	I-OUT	NOUN	B
profiles	O	NOUN	B
differed	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
failed	O	VERB	O
to	O	PART	O
demonstrate	O	VERB	O
any	O	DET	O
difference	O	NOUN	O
in	B-OUT	ADP	O
survival	I-OUT	NOUN	B
between	O	ADP	O
patients	O	NOUN	B
receiving	B-I	VERB	O
preoperative	I-I	ADJ	B
and	I-I	CCONJ	O
perioperative	I-I	ADJ	B
chemotherapy	I-I	NOUN	B
in	I-P	ADP	O
early-stage	I-P	ADJ	B
NSCLC	I-P	NOUN	B
.	O	PUNCT	O


The	O	DET	O
increase	O	NOUN	B
from	O	ADP	O
two	O	NUM	O
to	O	PART	O
four	O	NUM	O
preoperative	O	ADJ	B
chemotherapy	O	NOUN	B
cycles	O	NOUN	I
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
the	B-OUT	DET	O
pathological	I-OUT	ADJ	B
response	I-OUT	NOUN	O
rate	O	NOUN	O
.	O	PUNCT	O


[	O	PUNCT	O
Clinical	O	ADJ	B
observation	O	NOUN	I
on	O	ADP	O
acupuncture	B-I	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
male	B-P	NOUN	B
osteoporosis	I-P	NOUN	B
]	I-P	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
therapeutic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
acupuncture	B-I	NOUN	B
combined	O	VERB	B
with	O	ADP	O
drug	O	NOUN	B
and	O	CCONJ	O
simple	O	ADJ	O
drug	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
male	B-P	NOUN	B
osteoporosis	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fifty-five	B-P	NUM	O
cases	I-P	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
an	O	DET	O
observation	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
25	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
30	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
randomly	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
observation	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
acupuncture	B-I	NOUN	B
and	I-I	CCONJ	O
moxibustion	I-I	NOUN	B
at	I-I	ADP	O
Pishu	I-I	NOUN	B
(	O	PUNCT	O
BL	O	NOUN	B
20	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Shenshu	B-I	NOUN	B
(	O	PUNCT	O
BL	O	NOUN	B
23	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Mingmen	B-I	PROPN	B
(	O	PUNCT	O
GV	O	NOUN	O
4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Shenque	B-I	NOUN	B
(	O	PUNCT	O
CV	O	NOUN	B
8	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
so	O	ADV	O
on	O	ADP	O
combined	O	VERB	B
with	O	ADP	O
taking	O	VERB	O
Alendronate	B-I	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
taking	O	VERB	O
Alendronate	B-I	NOUN	B
simply	I-I	ADV	O
.	I-I	PUNCT	O


The	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
Integral	B-OUT	PROPN	B
of	I-OUT	ADP	O
Clinical	I-OUT	ADJ	B
Symptoms	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ICS	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
Bone	B-OUT	PROPN	B
Mineral	I-OUT	PROPN	I
Density	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BMD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
of	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
ICS	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
both	O	CCONJ	O
decreased	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
both	O	DET	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
decreasing	O	VERB	B
degree	O	NOUN	B
in	O	ADP	O
observation	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
more	O	ADV	O
significant	O	ADJ	B
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
BMD	B-OUT	NOUN	B
of	I-OUT	ADP	O
lumbar	I-OUT	ADJ	B
vertebrae	I-OUT	NOUN	I
and	O	CCONJ	O
femur	B-OUT	NOUN	B
in	O	ADP	O
observation	O	NOUN	B
group	O	NOUN	I
increased	O	VERB	B
obviously	O	ADV	O
than	O	ADP	O
that	O	DET	O
before	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
increasing	O	VERB	B
degree	O	NOUN	B
of	O	ADP	O
BMD	B-OUT	NOUN	B
of	I-OUT	ADP	O
lumbar	I-OUT	ADJ	B
vertebrae	I-OUT	NOUN	I
in	O	ADP	O
observation	O	NOUN	B
group	O	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
was	O	AUX	O
more	O	ADV	O
obvious	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
abdominal	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
diarrhea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
vomiting	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
dyspepsia	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
other	I-OUT	ADJ	O
adverse	I-OUT	ADJ	B
reaction	I-OUT	NOUN	I
in	O	ADP	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
degree	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
occurrence	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
of	O	ADP	O
those	O	DET	O
in	O	ADP	O
observation	O	NOUN	B
group	O	NOUN	I
alleviated	O	VERB	B
and	O	CCONJ	O
decreased	O	VERB	B
obviously	O	ADV	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
acupuncture	B-I	NOUN	B
combined	O	VERB	O
with	O	ADP	O
drug	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
male	B-P	NOUN	B
osteoporosis	I-P	NOUN	O
is	O	AUX	O
good	O	ADJ	O
with	O	ADP	O
little	O	ADJ	O
adverse	O	ADJ	B
reaction	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
method	O	NOUN	B
is	O	AUX	O
better	O	ADJ	O
than	O	ADP	O
taking	O	VERB	O
Alendronate	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
fenoterol	B-I	NOUN	B
on	O	ADP	O
inspiratory	O	ADJ	B
effort	O	NOUN	O
sensation	O	NOUN	B
and	O	CCONJ	O
fatigue	O	NOUN	B
during	O	ADP	O
inspiratory	O	ADJ	B
threshold	O	NOUN	I
loading	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
fenoterol	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
inspiratory	O	ADJ	B
effort	O	NOUN	O
sensation	O	NOUN	O
(	O	PUNCT	O
IES	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
inspiratory	O	ADJ	B
muscle	O	NOUN	I
fatigue	O	NOUN	O
induced	O	VERB	B
by	O	ADP	O
inspiratory	O	ADJ	B
threshold	O	NOUN	I
loading	O	NOUN	B
in	O	ADP	O
healthy	B-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
the	O	DET	O
threshold	O	NOUN	B
was	O	AUX	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
maximal	O	ADJ	B
static	O	ADJ	O
inspiratory	O	ADJ	O
mouth	O	NOUN	O
pressure	O	NOUN	O
(	O	PUNCT	O
PI	O	NOUN	B
,	O	PUNCT	O
mmax	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
functional	O	ADJ	B
residual	O	ADJ	I
capacity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
duty	O	NOUN	B
cycle	O	NOUN	I
was	O	AUX	O
0.5	O	NUM	O
.	O	PUNCT	O


Subjects	B-P	NOUN	B
continued	O	VERB	O
the	O	DET	O
threshold	O	NOUN	B
loaded	O	VERB	B
breathing	O	NOUN	B
until	O	ADP	O
the	O	DET	O
target	O	NOUN	B
mouth	O	NOUN	O
pressure	O	NOUN	O
could	O	AUX	O
no	O	ADV	O
longer	O	ADV	O
be	O	AUX	O
maintained	O	VERB	B
(	O	PUNCT	O
endurance	O	NOUN	B
time	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
intensity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
IES	O	NOUN	B
was	O	AUX	O
scored	O	VERB	B
with	O	ADP	O
a	O	DET	O
modified	O	ADJ	B
Borg	O	NOUN	I
scale	O	NOUN	I
.	O	PUNCT	O


Either	O	CCONJ	O
fenoterol	B-I	NOUN	B
(	I-I	PUNCT	O
5	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
placebo	I-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
orally	O	ADV	B
2	O	NUM	I
h	O	NOUN	O
before	O	ADP	O
loading	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
crossover	O	NOUN	I
protocol	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
endurance	B-OUT	NOUN	B
time	I-OUT	NOUN	O
with	O	ADP	O
fenoterol	O	NOUN	B
(	O	PUNCT	O
34.4	O	NUM	O
+/-	O	CCONJ	O
8.6	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
longer	O	ADJ	O
than	O	ADP	O
that	O	DET	O
with	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
(	O	PUNCT	O
22.2	O	NUM	O
+/-	O	CCONJ	O
7.1	O	NUM	O
min	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
ratio	B-OUT	NOUN	B
of	I-OUT	ADP	O
high-	I-OUT	NOUN	O
to	I-OUT	ADP	O
low-frequency	I-OUT	ADJ	B
power	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
diaphragmatic	I-OUT	ADJ	B
electromyogram	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
EMGdi	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
decreased	O	VERB	B
during	O	ADP	O
loading	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
decrease	O	NOUN	B
was	O	AUX	O
less	O	ADJ	O
with	O	ADP	O
fenoterol	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
EMGdi	B-OUT	NOUN	B
also	O	ADV	O
decreased	O	VERB	B
with	O	ADP	O
loading	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
decrease	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
on	O	ADP	O
fenoterol	O	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
PI	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
mmax	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
maximal	I-OUT	ADJ	B
transdiaphragmatic	I-OUT	ADJ	O
pressure	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
Pdi	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
similarly	O	ADV	O
decreased	O	VERB	B
after	O	ADP	O
loading	O	VERB	B
on	O	ADP	O
either	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
intensity	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
IES	I-OUT	NOUN	B
rose	I-OUT	VERB	O
with	I-OUT	ADP	O
time	I-OUT	NOUN	O
during	O	ADP	O
loading	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
but	O	CCONJ	O
was	O	AUX	O
lower	O	ADJ	O
with	O	ADP	O
fenoterol	B-I	NOUN	B
than	O	ADP	O
with	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
ratio	B-OUT	NOUN	B
of	I-OUT	ADP	O
Pdi	I-OUT	NOUN	B
to	O	PART	O
integrated	O	ADJ	O
activity	O	NOUN	O
of	O	ADP	O
the	O	DET	O
EMGdi	O	NOUN	B
increased	O	VERB	B
with	O	ADP	O
fenoterol	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Fenoterol	O	NOUN	B
treatment	O	NOUN	B
increased	O	VERB	B
both	O	CCONJ	O
superimposed	B-OUT	VERB	B
Pdi	I-OUT	NOUN	B
twitch	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
Pdi	I-OUT	NOUN	B
twitch	I-OUT	NOUN	I
of	I-OUT	ADP	O
relaxed	I-OUT	ADJ	B
diaphragm	I-OUT	NOUN	I
and	O	CCONJ	O
decreased	O	VERB	B
the	O	DET	O
value	B-OUT	NOUN	O
of	I-OUT	ADP	O
(	I-OUT	PUNCT	O
1-superimposed	I-OUT	ADJ	B
Pdi	I-OUT	NOUN	I
twitch/Pdi	I-OUT	NOUN	O
twitch	I-OUT	NOUN	B
of	I-OUT	ADP	O
relaxed	I-OUT	ADJ	B
diaphragm	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Thus	O	ADV	O
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
normal	B-P	ADJ	B
subjects	I-P	NOUN	I
fenoterol	O	NOUN	B
reduces	O	VERB	O
diaphragmatic	O	ADJ	B
fatigue	O	NOUN	I
and	O	CCONJ	O
decreases	O	VERB	B
the	O	DET	O
motor	O	NOUN	B
command	O	NOUN	I
to	O	ADP	O
the	O	DET	O
diaphragm	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
IES	O	NOUN	B
during	O	ADP	O
inspiratory	O	ADJ	B
threshold	O	NOUN	O
loading	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
prolongation	O	NOUN	B
of	O	ADP	O
endurance	O	NOUN	B
.	O	PUNCT	O


Relation	O	NOUN	B
of	O	ADP	O
improvement	O	NOUN	B
in	O	ADP	O
estimated	O	VERB	O
glomerular	O	ADJ	O
filtration	O	NOUN	O
rate	O	NOUN	O
with	O	ADP	O
atorvastatin	B-I	NOUN	B
to	O	PART	O
reductions	O	NOUN	B
in	O	ADP	O
hospitalizations	O	NOUN	B
for	O	ADP	O
heart	O	NOUN	B
failure	O	NOUN	I
(	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
Treating	B-P	NOUN	B
to	I-P	ADP	O
New	I-P	PROPN	O
Targets	I-P	PROPN	B
[	I-P	PUNCT	O
TNT	I-P	PROPN	B
]	I-P	PUNCT	O
study	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


Impaired	O	ADJ	B
kidney	O	NOUN	I
function	O	NOUN	I
often	O	ADV	O
accompanies	O	VERB	O
heart	O	NOUN	B
failure	O	NOUN	I
(	O	PUNCT	O
HF	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
worse	O	ADJ	O
prognosis	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
post	O	NOUN	B
hoc	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Treating	B-P	NOUN	B
to	I-P	ADP	O
New	I-P	PROPN	O
Targets	I-P	PROPN	B
(	I-P	PUNCT	O
TNT	I-P	PROPN	B
)	I-P	PUNCT	O
trial	I-P	NOUN	B
examined	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
observed	O	VERB	O
decrease	O	NOUN	B
in	O	ADP	O
HF	O	NOUN	B
hospitalizations	O	NOUN	B
with	O	ADP	O
high-	O	NOUN	O
compared	O	VERB	B
to	O	PART	O
low-dose	O	ADJ	B
atorvastatin	B-I	NOUN	B
could	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	ADP	O
improvements	O	NOUN	B
in	O	ADP	O
kidney	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
10,001	B-P	NUM	O
TNT	I-P	PROPN	B
participants	I-P	NOUN	B
,	I-P	PUNCT	O
9,376	I-P	NUM	O
had	I-P	AUX	O
estimated	I-P	VERB	O
glomerular	I-OUT	ADJ	O
filtration	I-OUT	NOUN	O
rate	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
eGFR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
measurements	I-P	NOUN	B
at	I-P	ADP	O
baseline	I-P	NOUN	B
and	I-P	CCONJ	O
1	I-P	NUM	O
year	I-P	NOUN	B
and	I-P	CCONJ	O
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
this	I-P	DET	O
analysis	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
association	O	NOUN	B
of	O	ADP	O
change	O	NOUN	O
in	O	ADP	O
year-1	O	NOUN	O
eGFR	O	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
HF	O	NOUN	B
hospitalization	O	NOUN	B
was	O	AUX	O
examined	O	VERB	O
using	O	VERB	O
Cox	O	NOUN	B
regression	O	NOUN	I
models	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
total	O	ADJ	O
218	O	NUM	O
participants	O	NOUN	B
developed	O	VERB	O
subsequent	O	ADJ	O
HF	O	PROPN	B
hospitalization	O	NOUN	B
.	O	PUNCT	O


Little	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
eGFR	B-OUT	NOUN	B
occurred	O	VERB	O
over	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
in	O	ADP	O
the	O	DET	O
atorvastatin	O	NOUN	B
10-mg	O	ADJ	O
group	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
eGFR	B-OUT	NOUN	B
improved	O	VERB	B
in	O	ADP	O
the	O	DET	O
80-mg	O	ADJ	O
group	O	NOUN	B
by	O	ADP	O
1.48	O	NUM	O
ml/min/1.73	O	NOUN	O
m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.29	O	NUM	O
to	O	PART	O
1.67	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Subsequent	O	ADJ	O
HF	O	PROPN	B
was	O	AUX	O
preceded	O	VERB	O
by	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
eGFR	B-OUT	NOUN	B
over	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
modest	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
those	O	DET	O
without	O	ADP	O
subsequent	O	ADJ	O
HF	O	NOUN	B
(	O	PUNCT	O
-0.09	O	NUM	O
±	O	NOUN	O
7.89	O	NUM	O
vs	O	CCONJ	O
0.81	O	NUM	O
±	O	NOUN	O
6.90	O	NUM	O
ml/min/1.73	O	NOUN	O
m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0015	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
adjusting	O	VERB	O
for	B-OUT	ADP	O
baseline	I-OUT	NOUN	B
eGFR	I-OUT	NOUN	B
,	O	PUNCT	O
each	O	DET	O
5-ml/min/1.73	O	NUM	O
m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
increase	O	NOUN	B
in	B-OUT	ADP	O
eGFR	I-OUT	NOUN	B
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
lower	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
subsequent	O	ADJ	O
HF	O	NOUN	B
hospitalization	O	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
0.85	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
0.77	O	NUM	O
to	O	PART	O
0.94	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
relation	O	NOUN	O
was	O	AUX	O
independent	O	ADJ	B
of	O	ADP	O
treatment	O	NOUN	B
effect	O	NOUN	I
or	O	CCONJ	O
change	O	NOUN	O
in	B-OUT	ADP	O
low-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
level	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
treatment	O	NOUN	B
with	O	ADP	O
high-	O	NOUN	O
compared	O	VERB	B
to	O	PART	O
low-dose	O	ADJ	B
atorvastatin	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
improvement	O	NOUN	B
in	B-OUT	ADP	O
eGFR	I-OUT	NOUN	B
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
decrease	O	NOUN	B
in	B-OUT	ADP	O
subsequent	I-OUT	ADJ	O
HF	I-OUT	NOUN	B
hospitalization	I-OUT	NOUN	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
improvement	O	NOUN	B
in	B-OUT	ADP	O
kidney	I-OUT	NOUN	B
function	I-OUT	NOUN	I
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
high-dose	O	ADJ	B
atorvastatin	O	NOUN	B
on	O	ADP	O
HF	O	NOUN	B
hospitalization	O	NOUN	B
.	O	PUNCT	O


Accuracy	O	NOUN	B
of	O	ADP	O
noninvasive	B-OUT	ADJ	B
haemoglobin	I-OUT	NOUN	I
measurement	I-OUT	NOUN	I
by	O	ADP	O
pulse	B-I	NOUN	B
oximetry	I-I	NOUN	I
depends	O	VERB	O
on	O	ADP	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
infusion	O	NOUN	B
fluid	O	NOUN	B
.	O	PUNCT	O


CONTEXT	O	NOUN	B
Measurement	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
haemoglobin	B-OUT	NOUN	I
concentration	O	NOUN	B
by	O	ADP	O
pulse	B-I	NOUN	B
oximetry	I-I	NOUN	I
could	O	AUX	O
be	O	AUX	O
of	O	ADP	O
value	O	NOUN	O
in	O	ADP	O
determining	O	VERB	O
when	O	SCONJ	O
erythrocytes	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
transfused	O	VERB	B
during	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
infusion	O	NOUN	B
fluids	O	NOUN	B
on	O	ADP	O
the	O	DET	O
results	O	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
study	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
crystalloid	O	NOUN	B
and	O	CCONJ	O
colloid	O	NOUN	B
fluid	O	NOUN	I
on	O	ADP	O
the	O	DET	O
accuracy	O	NOUN	B
(	O	PUNCT	O
bias	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
precision	O	NOUN	B
of	O	ADP	O
pulse	O	NOUN	B
oximetry	O	NOUN	I
haemoglobin	B-OUT	NOUN	I
estimation	O	NOUN	B
to	O	PART	O
indicate	O	VERB	O
the	O	DET	O
venous	O	ADJ	B
haemoglobin	O	NOUN	I
concentration	O	NOUN	B
in	O	ADP	O
volunteers	B-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Open	O	ADJ	B
interventional	O	ADJ	I
crossover	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
Single	B-P	ADJ	B
university	I-P	NOUN	I
hospital	I-P	NOUN	I
.	I-P	PUNCT	O


PARTICIPANTS	O	VERB	B
Ten	B-P	NUM	O
male	I-P	ADJ	B
volunteers	I-P	NOUN	O
aged	I-P	ADJ	O
18-28	I-P	NUM	O
(	I-P	PUNCT	O
mean	I-P	NOUN	O
22	I-P	NUM	O
)	I-P	PUNCT	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTIONS	O	VERB	B
Each	O	DET	O
volunteer	O	NOUN	B
underwent	O	VERB	O
three	O	NUM	O
infusion	B-I	NOUN	B
experiments	I-I	NOUN	B
on	O	ADP	O
separate	O	ADJ	B
days	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
random	O	ADJ	B
order	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
infusions	O	NOUN	B
were	O	AUX	O
Ringer	B-I	NOUN	B
's	I-I	PART	I
acetate	I-I	NOUN	I
(	I-I	PUNCT	O
20	I-I	NUM	O
ml	I-I	NOUN	O
kg	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
hydroxyethyl	I-I	NOUN	B
starch	I-I	NOUN	I
130/0.4	I-I	NUM	I
(	I-I	PUNCT	O
10	I-I	NUM	O
ml	I-I	NOUN	O
kg	I-I	NOUN	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
a	I-I	DET	O
combination	I-I	NOUN	B
of	O	ADP	O
both	O	DET	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
infusions	B-I	NOUN	B
of	I-I	ADP	O
Ringer	I-I	NOUN	B
's	I-I	PART	I
acetate	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
pulse	I-OUT	NOUN	B
oximetry	I-OUT	NOUN	I
haemoglobin	I-OUT	NOUN	I
concentration	O	NOUN	B
had	O	AUX	O
decreased	O	VERB	B
more	O	ADJ	O
than	O	ADP	O
the	O	DET	O
true	O	ADJ	B
haemoglobin	O	NOUN	I
concentration	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
vs.	O	CCONJ	O
8	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
whereas	O	SCONJ	O
starch	O	NOUN	B
solution	B-OUT	NOUN	I
decreased	I-OUT	VERB	B
pulse	I-OUT	NOUN	B
oximetry	I-OUT	NOUN	I
haemoglobin	I-OUT	NOUN	I
concentration	O	NOUN	B
less	O	ADJ	O
than	O	ADP	O
true	O	ADJ	B
haemoglobin	O	NOUN	I
concentration	O	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
vs.	O	CCONJ	O
11	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.02	O	NUM	O
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
seen	O	VERB	O
when	O	SCONJ	O
the	O	DET	O
fluids	O	NOUN	B
were	O	AUX	O
infused	O	VERB	B
separately	O	ADV	B
and	O	CCONJ	O
when	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
combined	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
difference	O	NOUN	O
between	B-OUT	ADP	O
all	I-OUT	DET	O
956	I-OUT	NUM	O
pairs	I-OUT	NOUN	B
of	I-OUT	ADP	O
pulse	I-OUT	NOUN	B
oximetry	I-OUT	NOUN	I
haemoglobin	I-OUT	NOUN	I
concentration	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
true	I-OUT	ADJ	B
haemoglobin	I-OUT	NOUN	I
concentrations	O	NOUN	I
(	O	PUNCT	O
the	O	DET	O
bias	O	NOUN	B
)	O	PUNCT	O
averaged	O	VERB	O
only	O	ADV	O
-0.7	O	NUM	O
g	O	NOUN	O
l	O	NOUN	O
whereas	O	SCONJ	O
the	O	DET	O
95	O	NUM	O
%	O	NOUN	O
prediction	O	NOUN	B
interval	O	NOUN	I
was	O	AUX	O
wide	O	ADJ	O
,	O	PUNCT	O
ranging	O	VERB	O
from	O	ADP	O
-24.9	O	NUM	O
to	O	PART	O
23.7	O	NUM	O
g	O	NOUN	O
l.	O	X	O
In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
choice	O	NOUN	O
of	O	ADP	O
infusion	O	NOUN	B
fluid	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
bias	O	NOUN	B
was	O	AUX	O
strongly	O	ADV	O
dependent	O	ADJ	O
on	O	ADP	O
the	O	DET	O
volunteer	O	NOUN	B
(	O	PUNCT	O
each	O	DET	O
factor	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
bias	O	NOUN	B
of	O	ADP	O
measuring	B-I	VERB	B
haemoglobin	I-I	NOUN	B
concentration	O	NOUN	B
by	O	ADP	O
pulse	O	NOUN	B
oximetry	O	NOUN	I
is	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
whether	O	SCONJ	O
a	O	DET	O
crystalloid	O	NOUN	B
or	O	CCONJ	O
a	O	DET	O
colloid	O	NOUN	B
fluid	O	NOUN	I
is	O	AUX	O
infused	O	VERB	B
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
ClinicalTrials	O	NOUN	B
identifier	O	NOUN	I
:	O	PUNCT	O
NCT01195025	O	NOUN	O
.	O	PUNCT	O


Improved	O	ADJ	O
acidosis	O	NOUN	B
correction	O	NOUN	B
and	O	CCONJ	O
recovery	O	NOUN	B
of	O	ADP	O
mesothelial	O	ADJ	B
cell	O	NOUN	I
mass	O	NOUN	O
with	O	ADP	O
neutral-pH	B-I	ADJ	B
bicarbonate	I-I	NOUN	I
dialysis	I-I	NOUN	O
solution	I-I	NOUN	O
among	O	ADP	O
children	B-P	NOUN	B
undergoing	I-P	VERB	O
automated	I-I	VERB	B
peritoneal	I-I	ADJ	I
dialysis	I-I	NOUN	I
.	I-I	PUNCT	O


Acid-base	O	ADJ	B
balance	O	NOUN	B
and	O	CCONJ	O
peritoneal	O	ADJ	B
membrane	O	NOUN	O
longevity	O	NOUN	O
are	O	AUX	O
of	O	ADP	O
utmost	O	ADJ	O
relevance	O	NOUN	B
for	O	ADP	O
pediatric	B-P	ADJ	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
peritoneal	I-I	ADJ	B
dialysis	I-I	NOUN	I
(	I-I	PUNCT	O
PD	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


PD	O	NOUN	B
fluids	O	NOUN	B
with	O	ADP	O
neutral	O	ADJ	B
pH	O	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
glucose	O	NOUN	O
degradation	O	NOUN	O
product	O	NOUN	O
contents	O	NOUN	B
are	O	AUX	O
considered	O	VERB	O
more	O	ADV	O
biocompatible	O	ADJ	B
,	O	PUNCT	O
because	O	SCONJ	O
they	O	PRON	O
preserve	O	VERB	O
peritoneal	O	ADJ	B
cell	O	NOUN	O
functions	O	NOUN	O
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
effects	B-OUT	NOUN	I
of	O	ADP	O
a	O	DET	O
novel	B-I	ADJ	B
PD	I-I	NOUN	B
fluid	I-I	ADJ	O
buffered	I-I	NOUN	O
with	I-I	ADP	O
34	I-I	NUM	O
mM	I-I	NOUN	O
pure	I-I	ADJ	O
bicarbonate	I-I	NOUN	B
at	I-I	ADP	O
neutral	I-I	ADJ	B
pH	I-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
comparison	O	NOUN	B
with	O	ADP	O
conventional	B-I	ADJ	B
,	I-I	PUNCT	O
acidic	I-I	ADJ	B
,	I-I	PUNCT	O
35	I-I	NUM	O
mM	I-I	NOUN	O
lactate	I-I	NOUN	B
PD	I-I	NOUN	I
fluid	I-I	NOUN	B
was	O	AUX	O
performed	O	VERB	O
for	O	ADP	O
two	O	NUM	O
consecutive	O	ADJ	B
12-wk	O	ADJ	O
periods	O	NOUN	B
with	O	ADP	O
28	B-P	NUM	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
6	I-P	NUM	O
mo	I-P	NOUN	O
to	I-P	PART	O
15	I-P	NUM	O
yr	I-P	NOUN	O
)	I-P	PUNCT	O
undergoing	I-P	VERB	O
automated	I-I	VERB	B
PD	I-I	NOUN	I
(	I-I	PUNCT	O
APD	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Blood	B-OUT	NOUN	B
bicarbonate	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
arterial	I-OUT	ADJ	B
pH	I-OUT	NOUN	B
were	O	AUX	O
significantly	O	ADV	B
higher	B-OUT	ADJ	I
after	O	ADP	O
3	O	NUM	O
mo	O	NOUN	O
of	O	ADP	O
bicarbonate	B-OUT	NOUN	B
PD	I-OUT	NOUN	I
(	O	PUNCT	O
24.6	O	NUM	O
+/-	O	CCONJ	O
2.3	O	NUM	O
mM	O	NOUN	O
and	O	CCONJ	O
7.43	O	NUM	O
+/-	O	CCONJ	O
0.06	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
lactate	B-OUT	NOUN	B
PD	I-OUT	NOUN	I
(	O	PUNCT	O
22.8	O	NUM	O
+/-	O	CCONJ	O
3.9	O	NUM	O
mM	O	NOUN	O
and	O	CCONJ	O
7.38	O	NUM	O
+/-	O	CCONJ	O
0.05	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
reversible	O	ADJ	O
among	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
returned	O	VERB	O
from	O	ADP	O
bicarbonate	O	NOUN	B
to	O	PART	O
lactate	O	NOUN	B
fluid	O	NOUN	I
.	O	PUNCT	O


Low	O	ADJ	B
initial	B-OUT	ADJ	B
pH	I-OUT	NOUN	B
and	O	CCONJ	O
young	O	ADJ	B
patient	O	NOUN	B
age	O	NOUN	B
independently	O	ADV	O
predicted	O	VERB	O
increased	O	VERB	B
blood	B-OUT	NOUN	B
pH	I-OUT	NOUN	B
during	O	ADP	O
bicarbonate	B-OUT	NOUN	B
APD	I-OUT	PROPN	B
.	I-OUT	PUNCT	O


Peritoneal	O	NOUN	B
equilibration	O	NOUN	O
tests	O	NOUN	O
revealed	O	VERB	O
subtle	B-OUT	ADJ	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
solute	I-OUT	NOUN	B
transport	I-OUT	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
less	B-OUT	ADV	O
steep	I-OUT	ADJ	O
creatinine	I-OUT	NOUN	O
equilibration	I-OUT	NOUN	O
curve	I-OUT	NOUN	O
during	O	ADP	O
bicarbonate	O	NOUN	B
dialysis	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
reduced	O	VERB	B
peritoneal	O	ADJ	B
vasodilation	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
peritoneal	B-OUT	ADJ	B
release	I-OUT	NOUN	B
of	I-OUT	ADP	O
carcinogen	I-OUT	NOUN	B
antigen-125	I-OUT	NOUN	B
increased	I-OUT	VERB	B
twofold	O	ADV	O
during	O	ADP	O
bicarbonate	O	NOUN	B
APD	O	PROPN	B
(	O	PUNCT	O
29	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
versus	O	CCONJ	O
15	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
U/ml	O	NOUN	O
per	O	ADP	O
4	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
recovery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mesothelial	O	ADJ	B
cell	O	NOUN	I
layer	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
fully	O	ADV	O
reversed	O	VERB	O
when	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
returned	O	VERB	O
to	O	PART	O
lactate	O	NOUN	B
fluid	O	NOUN	I
.	O	PUNCT	O


Effluent	B-OUT	NOUN	B
carcinogen	I-OUT	NOUN	B
antigen-125	I-OUT	NOUN	O
levels	I-OUT	NOUN	B
were	O	AUX	O
inversely	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
peritoneal	O	ADJ	B
glucose	O	NOUN	B
exposure	O	NOUN	I
during	O	ADP	O
lactate	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
bicarbonate	O	NOUN	B
APD	O	PROPN	B
,	O	PUNCT	O
indicating	O	VERB	O
improved	O	VERB	B
in	O	X	B
vivo	O	X	I
mesothelial	O	ADJ	B
cell	O	NOUN	I
tolerance	O	NOUN	O
of	O	ADP	O
high-dose	O	ADJ	B
glucose	O	NOUN	I
with	O	ADP	O
the	O	DET	O
neutral-pH	B-I	ADJ	B
PD	I-I	NOUN	I
fluid	I-I	NOUN	B
with	I-I	ADP	O
reduced	I-I	VERB	B
glucose	I-I	NOUN	B
degradation	I-I	NOUN	I
product	I-I	NOUN	I
content	I-I	NOUN	B
.	I-I	PUNCT	O


Among	O	ADP	O
children	B-P	NOUN	B
undergoing	I-P	VERB	O
APD	I-I	PROPN	B
,	I-I	PUNCT	O
neutral-pH	I-I	ADJ	B
,	I-I	PUNCT	O
bicarbonate-buffered	I-I	ADJ	B
PD	I-I	NOUN	I
fluid	I-I	NOUN	I
provides	O	VERB	O
more	O	ADV	O
effective	O	ADJ	B
correction	O	NOUN	B
of	O	ADP	O
metabolic	O	ADJ	B
acidosis	O	NOUN	I
and	O	CCONJ	O
better	O	ADJ	O
preservation	O	NOUN	B
of	O	ADP	O
peritoneal	O	ADJ	B
cell	O	NOUN	O
mass	O	NOUN	O
than	O	ADP	O
do	O	AUX	O
conventional	B-I	ADJ	B
,	I-I	PUNCT	O
acidic	I-I	ADJ	B
,	I-I	PUNCT	O
lactate-based	I-I	ADJ	B
fluids	I-I	NOUN	I
.	I-I	PUNCT	O


Low-dose	B-I	ADJ	B
oral	I-I	ADJ	O
etoposide-based	I-I	ADJ	O
induction	O	NOUN	O
regimen	O	NOUN	O
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
lymphoblastic	I-P	ADJ	I
leukemia	I-P	NOUN	I
in	I-P	ADP	O
first	I-P	ADJ	O
bone	I-P	NOUN	B
marrow	I-P	NOUN	I
relapse	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
clinical	B-OUT	ADJ	B
response	I-OUT	NOUN	I
to	O	PART	O
low-dose	B-I	ADJ	B
etoposide	I-I	NOUN	B
in	O	ADP	O
relapsed	B-P	ADJ	B
acute	I-P	ADJ	B
lymphoblastic	I-P	ADJ	I
leukemia	I-P	NOUN	I
(	I-P	PUNCT	O
ALL	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Of	O	ADP	O
the	O	DET	O
45	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
ALL	I-P	NOUN	B
in	I-P	ADP	O
first	I-P	ADJ	O
bone	I-P	NOUN	B
marrow	I-P	NOUN	I
relapse	I-P	NOUN	I
enrolled	I-P	VERB	O
on	O	ADP	O
the	O	DET	O
ALL	O	NOUN	B
R15	O	NOUN	B
protocol	O	NOUN	B
,	O	PUNCT	O
44	O	NUM	O
had	O	AUX	O
received	O	VERB	O
epipodophyllotoxins	B-I	NOUN	B
during	I-I	ADP	O
frontline	I-I	NOUN	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
first	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
remission	O	NOUN	B
induction	O	NOUN	I
therapy	O	NOUN	I
,	O	PUNCT	O
patients	B-I	NOUN	B
received	I-I	VERB	O
etoposide	I-I	NOUN	B
(	I-I	PUNCT	O
50	I-I	NUM	O
mg/m	I-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
per	I-I	ADP	O
day	I-I	NOUN	B
)	I-I	PUNCT	O
administered	I-I	VERB	B
orally	I-I	ADV	B
as	I-I	ADP	O
a	I-I	DET	O
single	I-I	ADJ	O
agent	I-I	NOUN	O
once	I-I	SCONJ	O
or	I-I	CCONJ	O
twice	I-I	ADV	O
daily	I-I	ADV	B
.	I-I	PUNCT	O


On	O	ADP	O
Day	O	PROPN	O
8	O	NUM	O
,	O	PUNCT	O
patients	O	NOUN	B
started	O	VERB	O
to	O	PART	O
receive	O	VERB	O
dexamethasone	B-I	NOUN	B
,	I-I	PUNCT	O
vincristine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
L-asparaginase	I-I	NOUN	B
.	I-I	PUNCT	O


Etoposide	B-I	NOUN	B
was	I-I	AUX	O
administered	I-I	VERB	B
until	I-I	ADP	O
Day	I-I	PROPN	B
22	I-I	NUM	O
.	I-I	PUNCT	O


Two	B-I	NUM	O
courses	I-I	NOUN	B
of	I-I	ADP	O
consolidation	I-I	NOUN	B
therapy	I-I	NOUN	I
were	I-I	AUX	O
followed	I-I	VERB	O
by	I-I	ADP	O
continuation	I-I	NOUN	B
therapy	I-I	NOUN	I
or	I-I	CCONJ	O
hematopoietic	I-I	ADJ	B
stem	I-I	NOUN	I
cell	I-I	NOUN	I
transplantation	I-I	NOUN	I
.	I-I	PUNCT	O


After	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
single-agent	O	ADJ	B
etoposide	O	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
peripheral	B-OUT	ADJ	B
blast	I-OUT	NOUN	B
cell	I-OUT	NOUN	I
counts	I-OUT	NOUN	I
(	O	PUNCT	O
P=0.013	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
percentages	B-OUT	NOUN	B
of	I-OUT	ADP	O
bone	I-OUT	NOUN	B
marrow	I-OUT	NOUN	I
blasts	I-OUT	NOUN	I
(	O	PUNCT	O
P=0.016	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
,	O	PUNCT	O
38	O	NUM	O
(	O	PUNCT	O
84.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
attained	O	VERB	O
second	B-OUT	ADJ	O
remission	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Only	O	ADV	O
time	B-OUT	NOUN	O
to	I-OUT	ADP	O
relapse	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
outcome	O	NOUN	B
(	O	PUNCT	O
P=0.025	O	NOUN	O
)	O	PUNCT	O
:	O	PUNCT	O
the	O	DET	O
5-year	B-OUT	ADJ	O
event-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
estimates	O	NOUN	I
(	O	PUNCT	O
+/-se	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
52.0+/-9.6	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
those	O	DET	O
with	O	ADP	O
late	O	ADJ	O
relapse	O	NOUN	B
and	O	CCONJ	O
20.0+/-8.0	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
those	O	DET	O
with	O	ADP	O
early	O	ADJ	O
relapse	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
low-dose	B-I	ADJ	B
etoposide	I-I	NOUN	B
administered	O	VERB	B
orally	O	ADV	B
has	O	AUX	O
a	O	DET	O
cytoreductive	O	ADJ	B
effect	O	NOUN	I
in	O	ADP	O
relapsed	O	ADJ	B
ALL	O	NOUN	B
.	O	PUNCT	O


Nasal	B-I	ADJ	B
versus	I-I	CCONJ	O
oronasal	I-I	ADJ	B
continuous	I-I	ADJ	I
positive	I-I	ADJ	I
airway	I-I	NOUN	O
pressure	I-I	NOUN	O
masks	I-I	NOUN	O
for	O	ADP	O
obstructive	B-P	ADJ	B
sleep	I-P	NOUN	I
apnea	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
pilot	O	NOUN	O
investigation	O	NOUN	B
of	O	ADP	O
pressure	O	NOUN	B
requirement	O	NOUN	B
,	O	PUNCT	O
residual	O	ADJ	B
disease	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
leak	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
single-blinded	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
pilot	O	NOUN	I
study	O	NOUN	I
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
nasal	B-I	ADJ	B
and	I-I	CCONJ	O
oronasal	I-I	ADJ	B
masks	I-I	NOUN	I
in	O	ADP	O
therapeutic	O	ADJ	B
continuous	O	ADJ	O
positive	O	ADJ	O
airway	O	NOUN	O
pressure	O	NOUN	O
(	O	PUNCT	O
CPAP	O	NOUN	B
)	O	PUNCT	O
requirement	O	NOUN	B
,	O	PUNCT	O
residual	O	ADJ	B
disease	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
leak	O	VERB	B
when	O	SCONJ	O
treating	O	VERB	B
obstructive	B-P	ADJ	B
sleep	I-P	NOUN	I
apnea	I-P	NOUN	I
(	I-P	PUNCT	O
OSA	I-P	NOUN	B
)	I-P	PUNCT	O
and	O	CCONJ	O
if	O	SCONJ	O
differences	O	NOUN	B
were	O	AUX	O
related	O	ADJ	O
to	O	ADP	O
measures	O	NOUN	B
of	O	ADP	O
upper	O	ADJ	B
airway	O	NOUN	I
size	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
OSA	I-P	PROPN	B
currently	I-P	ADV	O
using	I-P	VERB	O
CPAP	I-P	NOUN	B
at	I-P	ADP	O
≥4	I-P	NOUN	O
h/night	I-P	VERB	O
with	I-P	ADP	O
a	I-I	DET	O
nasal	I-I	ADJ	B
mask	I-I	NOUN	I
were	I-P	AUX	O
examined	I-P	VERB	O
(	I-P	PUNCT	O
including	I-P	VERB	O
Mallampati	I-P	PROPN	B
scale	I-P	NOUN	I
,	I-P	PUNCT	O
incisal	I-P	NOUN	B
relationship	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
mandibular	I-P	ADJ	B
protrusion	I-P	NOUN	I
)	I-P	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
receive	B-I	VERB	O
auto-positive	I-I	ADJ	B
airway	I-I	NOUN	I
pressure	I-I	NOUN	I
(	I-I	PUNCT	O
PAP	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
fixed	I-I	VERB	B
CPAP	I-I	NOUN	B
at	I-I	ADP	O
a	I-I	DET	O
manually	I-I	ADV	B
titrated	I-I	VERB	I
pressure	I-I	NOUN	I
for	O	ADP	O
1	O	NUM	O
week	O	NOUN	B
each	O	DET	O
at	O	ADP	O
home	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
immediate	O	ADJ	B
crossover	O	NOUN	B
.	O	PUNCT	O


Within	O	ADP	O
each	O	DET	O
week	O	NOUN	B
,	O	PUNCT	O
a	B-I	DET	O
nasal	I-I	ADJ	B
mask	I-I	NOUN	I
and	O	CCONJ	O
two	B-I	NUM	O
oronasal	I-I	ADJ	B
masks	I-I	NOUN	I
were	O	AUX	O
to	O	PART	O
be	O	AUX	O
used	O	VERB	O
for	O	ADP	O
two	O	NUM	O
or	O	CCONJ	O
three	O	NUM	O
nights	O	NOUN	B
each	O	DET	O
in	O	ADP	O
random	O	ADJ	B
order	O	NOUN	O
.	O	PUNCT	O


Data	O	NOUN	B
were	O	AUX	O
downloaded	O	VERB	O
from	O	ADP	O
the	O	DET	O
device	O	NOUN	B
.	O	PUNCT	O


RESULTS	B-P	VERB	O
Twelve	I-P	NUM	O
patients	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
trial	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	NOUN	O
±	I-P	X	O
SD	I-P	NOUN	B
AHI	I-P	NOUN	B
59.8	I-P	NUM	O
±	I-P	NOUN	O
28.6	I-P	NUM	O
events/h	I-P	NOUN	B
;	I-P	PUNCT	O
CPAP	I-P	NOUN	B
11.1	I-P	NUM	O
±	I-P	NOUN	O
3.2	I-P	NUM	O
cmH	I-P	NOUN	O
(	I-P	PUNCT	O
2	I-P	NUM	O
)	I-P	PUNCT	O
O	I-P	NOUN	O
;	I-P	PUNCT	O
BMI	I-P	NOUN	B
37.7	I-P	NUM	O
±	I-P	NOUN	O
5.0	I-P	NUM	O
kg/m	I-P	NOUN	O
(	I-P	PUNCT	O
2	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
.	O	PUNCT	O


During	O	ADP	O
auto-PAP	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
median	I-OUT	ADJ	B
95th	I-OUT	NOUN	O
percentile	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
delivered	O	VERB	O
with	O	ADP	O
all	O	DET	O
masks	O	NOUN	B
was	O	AUX	O
within	O	ADP	O
0.5	O	NUM	O
cmH	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
O	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


During	O	ADP	O
CPAP	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
median	I-OUT	ADJ	B
residual	I-OUT	ADJ	I
AHI	O	NOUN	B
was	O	AUX	O
0.61	O	NUM	O
(	O	PUNCT	O
IQR	O	NOUN	B
=	O	ADJ	O
1.18	O	NUM	O
)	O	PUNCT	O
for	B-I	ADP	O
the	I-I	DET	O
nasal	I-I	ADJ	B
mask	O	NOUN	I
,	O	PUNCT	O
1.70	O	NUM	O
(	O	PUNCT	O
IQR	O	NOUN	B
=	O	ADJ	O
4.04	B-I	NUM	O
)	I-I	PUNCT	O
for	I-I	ADP	O
oronasal	I-I	ADJ	B
mask	O	NOUN	I
1	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
2.48	O	NUM	O
(	O	PUNCT	O
IQR	O	NOUN	B
=	O	ADJ	O
3.74	B-I	NUM	O
)	I-I	PUNCT	O
for	I-I	ADP	O
oronasal	I-I	ADJ	B
mask	O	NOUN	I
2	O	NUM	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
95th	I-OUT	ADJ	O
percentile	I-OUT	NOUN	B
leak	O	NOUN	I
was	O	AUX	O
lowest	O	ADJ	O
with	O	ADP	O
the	O	DET	O
nasal	O	ADJ	B
mask	O	NOUN	I
during	O	ADP	O
both	O	CCONJ	O
CPAP	O	NOUN	B
and	O	CCONJ	O
auto-PAP	O	NOUN	B
(	O	PUNCT	O
both	O	CCONJ	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Differences	O	NOUN	B
in	O	ADP	O
pressure	O	NOUN	B
or	O	CCONJ	O
residual	O	ADJ	B
disease	O	NOUN	I
were	O	AUX	O
not	O	PART	O
related	O	ADJ	O
to	O	ADP	O
measures	O	NOUN	B
of	O	ADP	O
upper	O	ADJ	B
airway	O	NOUN	I
shape	O	NOUN	B
or	O	CCONJ	O
body	O	NOUN	B
habitus	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
obese	O	ADJ	B
OSA	O	NOUN	B
patients	O	NOUN	B
changing	O	VERB	B
from	O	ADP	O
a	O	DET	O
nasal	B-I	NOUN	B
to	I-I	PART	O
oronasal	I-I	ADJ	B
mask	O	NOUN	I
increased	B-OUT	VERB	B
leak	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
residual	I-OUT	ADJ	B
AHI	O	NOUN	B
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
therapeutic	O	ADJ	B
pressure	O	NOUN	I
requirement	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
of	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
highlight	O	VERB	O
mask	O	NOUN	B
leak	O	NOUN	I
as	O	ADP	O
the	O	DET	O
major	O	ADJ	O
difficulty	O	NOUN	B
in	O	ADP	O
the	O	DET	O
use	B-I	NOUN	O
of	I-I	ADP	O
oronasal	I-I	ADJ	B
masks	O	NOUN	I
.	O	PUNCT	O


Effectiveness	B-OUT	NOUN	B
of	O	ADP	O
once-daily	B-I	ADJ	B
monotherapy	I-I	NOUN	B
with	O	ADP	O
a	O	DET	O
new	O	ADJ	O
nifedipine	O	NOUN	B
sustained	O	ADJ	B
release	O	NOUN	B
calcium	O	NOUN	B
antagonist	O	NOUN	I
.	O	PUNCT	O


Data	O	NOUN	B
from	O	ADP	O
2	B-P	NUM	O
separate	I-P	ADJ	O
multicenter	I-P	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
clinical	O	ADJ	B
studies	O	NOUN	I
following	O	VERB	O
the	O	DET	O
same	O	ADJ	O
protocol	O	NOUN	B
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
the	O	DET	O
selection	O	NOUN	B
of	O	ADP	O
doses	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
pooled	O	VERB	B
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
fixed	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
a	O	DET	O
new	B-I	ADJ	O
sustained-release	I-I	NOUN	B
(	I-I	PUNCT	O
SR	I-I	ADJ	B
)	I-I	PUNCT	O
formulation	I-I	NOUN	B
of	I-I	ADP	O
nifedipine	I-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
in	O	ADP	O
388	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
mild	I-P	ADJ	B
to	I-P	PART	O
moderate	I-P	ADJ	B
uncomplicated	I-P	ADJ	O
essential	I-P	ADJ	O
hypertension	I-P	NOUN	B
.	I-P	PUNCT	O


After	O	ADP	O
a	O	DET	O
3-6	O	NUM	O
week	O	NOUN	B
placebo	O	ADJ	B
washout	O	NOUN	B
period	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
placebo	B-I	NOUN	B
or	I-I	CCONJ	O
nifedipine	I-I	NOUN	B
SR-20	O	NOUN	B
mg	O	NOUN	O
(	O	PUNCT	O
study	O	NOUN	B
I	O	NOUN	I
only	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
150	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
study	O	NOUN	B
II	O	NUM	I
only	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
278	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
completed	O	VERB	O
6	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
active	O	ADJ	B
therapy	O	NOUN	I
,	O	PUNCT	O
mean	B-OUT	VERB	O
supine	I-OUT	NOUN	O
diastolic	I-OUT	ADJ	O
blood	I-OUT	NOUN	O
pressure	I-OUT	NOUN	O
reductions	I-OUT	NOUN	B
from	O	ADP	O
pretreatment	O	NOUN	B
baseline	O	NOUN	B
were	O	AUX	O
5.9	O	NUM	O
,	O	PUNCT	O
9.3	O	NUM	O
,	O	PUNCT	O
9.2	O	NUM	O
,	O	PUNCT	O
11.1	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
13.2	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
,	O	PUNCT	O
20-	O	NUM	O
,	O	PUNCT	O
50-	O	NUM	O
,	O	PUNCT	O
100-	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
150-mg	O	ADJ	O
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
reductions	O	NOUN	B
achieved	O	VERB	O
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
nifedipine	B-I	NOUN	B
SR	O	ADJ	B
groups	O	NOUN	B
were	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
versus	O	CCONJ	O
baseline	O	NOUN	B
values	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
nifedipine-SR	O	ADJ	B
doses	O	NOUN	B
reduced	B-OUT	VERB	B
supine	I-OUT	ADJ	B
systolic	I-OUT	NOUN	O
blood	I-OUT	NOUN	O
pressure	I-OUT	NOUN	O
significantly	O	ADV	O
more	O	ADV	O
than	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	B
linear	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
log	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
dose	I-OUT	NOUN	B
and	O	CCONJ	O
the	O	DET	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
reduction	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Automated	B-OUT	VERB	B
ambulatory	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
recordings	I-OUT	NOUN	I
performed	O	VERB	O
in	O	ADP	O
221	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
was	I-OUT	AUX	O
lowered	I-OUT	VERB	B
evenly	O	ADV	O
through	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
24-hour	O	ADJ	B
dosing	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
doses	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
effective	O	ADJ	B
and	O	CCONJ	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
fewest	O	ADJ	O
adverse	O	ADJ	B
reactions	O	NOUN	I
were	O	AUX	O
20	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
50	O	NUM	O
mg	O	NOUN	O
once	O	ADV	O
daily	O	ADV	O
.	O	PUNCT	O


Cross-over	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
intensive	O	ADJ	B
monotherapy	O	NOUN	I
with	O	ADP	O
atorvastatin	B-I	NOUN	B
and	O	CCONJ	O
combined	O	ADJ	B
therapy	O	NOUN	I
with	O	ADP	O
atorvastatin	B-I	NOUN	B
and	O	CCONJ	O
colestimide	B-I	NOUN	B
for	O	ADP	O
Japanese	B-P	ADJ	B
familial	I-P	ADJ	B
hypercholesterolemia	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
In	O	ADP	O
familial	B-P	ADJ	B
hypercholesterolemia	I-P	NOUN	I
(	I-P	PUNCT	O
FH	I-P	NOUN	B
)	I-P	PUNCT	O
,	O	PUNCT	O
low-density	B-OUT	ADJ	B
lipoprotein-cholesterol	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
LDL-C	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
-lowering	I-OUT	ADJ	O
therapy	O	NOUN	B
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
avoid	O	VERB	O
predisposition	O	NOUN	B
to	O	PART	O
coronary	O	ADJ	B
artery	O	NOUN	I
disease	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
investigated	O	VERB	B
the	O	DET	O
advantages	O	NOUN	O
of	O	ADP	O
combined	O	ADJ	B
therapy	O	NOUN	I
with	O	ADP	O
atorvastatin	B-I	NOUN	B
and	O	CCONJ	O
colestimide	B-I	NOUN	B
vs	O	CCONJ	O
intensive	O	ADJ	B
monotherapy	O	NOUN	I
with	O	ADP	O
atorvastatin	B-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
The	O	DET	O
trial	O	NOUN	B
used	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
cross-over	O	ADJ	I
design	O	NOUN	I
consisting	O	VERB	O
of	O	ADP	O
2	O	NUM	O
16-week	O	NOUN	O
periods	O	NOUN	B
of	O	ADP	O
open-label	O	ADJ	B
drug	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
24	B-P	NUM	O
initial	I-P	ADJ	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
17	I-P	NUM	O
heterozygous	I-P	ADJ	B
FH	I-P	NOUN	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
age	I-P	NOUN	B
:	I-P	PUNCT	O
54.1	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
5	I-P	NUM	O
males	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
enrolled	O	VERB	O
after	B-I	ADP	O
20	I-I	NUM	O
mg/day	I-I	ADJ	O
atorvastatin	I-I	NOUN	B
failed	I-I	VERB	B
to	I-I	PART	O
achieve	I-I	VERB	O
their	I-I	PRON	O
target	I-I	NOUN	B
level	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
20	O	NUM	O
mg/day	O	ADJ	O
atorvastatin	B-I	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
g/day	O	NOUN	O
colestimide	B-I	NOUN	B
or	O	CCONJ	O
40	O	NUM	O
mg/day	O	ADJ	O
atorvastatin	B-I	NOUN	B
.	I-I	PUNCT	O


Fifteen	B-P	NUM	O
patients	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
trial	I-P	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
LDL-C	B-OUT	NOUN	B
reduced	O	VERB	B
from	O	ADP	O
5.07	O	NUM	O
+/-	O	CCONJ	O
1.10	O	NUM	O
mmol/L	O	NOUN	O
to	O	PART	O
3.76	O	NUM	O
+/-	O	CCONJ	O
0.90	O	NUM	O
mmol/L	O	NOUN	O
with	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
therapy	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
3.81	O	NUM	O
+/-	O	CCONJ	O
0.50	O	NUM	O
mmol/L	O	NOUN	O
with	O	ADP	O
the	O	DET	O
intensive	O	ADJ	B
monotherapy	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
2	O	NUM	O
therapies	O	NOUN	B
showed	O	VERB	O
comparable	O	ADJ	O
mean	O	ADJ	O
effects	O	NOUN	B
for	O	ADP	O
decreasing	O	VERB	B
LDL-C	B-OUT	NOUN	B
,	O	PUNCT	O
similar	O	ADJ	O
adverse	O	ADJ	B
reaction	O	NOUN	I
and	O	CCONJ	O
cost	O	NOUN	B
,	O	PUNCT	O
each	O	DET	O
therapy	O	NOUN	B
was	O	AUX	O
predominantly	O	ADV	O
more	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
others	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
triglyceride	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
high-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
therapies	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
To	O	PART	O
achieve	O	VERB	O
the	O	DET	O
therapeutic	O	ADJ	B
target	O	NOUN	B
of	O	ADP	O
LDL-C	B-OUT	NOUN	B
level	O	NOUN	B
for	O	ADP	O
refractory	O	ADJ	B
FH	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
LDL-C-lowering	O	NOUN	B
therapy	O	NOUN	I
selected	O	VERB	O
can	O	AUX	O
be	O	AUX	O
either	O	CCONJ	O
intensive	O	ADJ	B
monotherapy	O	NOUN	I
or	O	CCONJ	O
combined	O	ADJ	B
therapy	O	NOUN	I
as	O	ADP	O
the	O	DET	O
next	O	NOUN	O
to	O	PART	O
standard	O	ADJ	O
statin	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
mizolastine	B-I	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
a	O	DET	O
placebo-controlled	B-I	ADJ	B
comparison	O	NOUN	B
with	O	ADP	O
loratadine	B-I	NOUN	B
in	O	ADP	O
chronic	B-P	ADJ	B
idiopathic	I-P	ADJ	I
urticaria	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
MILOR	O	PROPN	B
Study	O	PROPN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Mizolastine	B-I	PROPN	B
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
histamine	O	NOUN	B
H1-antagonist	O	ADJ	B
registered	O	VERB	O
in	O	ADP	O
Europe	O	PROPN	B
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
allergic	O	ADJ	B
rhinitis	O	NOUN	I
and	O	CCONJ	O
urticaria	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
efficacy	B-OUT	NOUN	I
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
mizolastine	B-I	NOUN	B
with	I-I	ADP	O
loratadine	I-I	NOUN	B
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
idiopathic	I-P	ADJ	I
urticaria	I-P	NOUN	I
(	I-P	PUNCT	O
CIU	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
multicentre	O	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	B
group	O	NOUN	I
study	O	NOUN	I
was	O	AUX	O
designed	O	VERB	O
in	O	ADP	O
which	O	DET	O
247	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
CIU	I-P	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
after	O	ADP	O
a	O	DET	O
1-week	O	ADJ	O
placebo	B-I	NOUN	B
run-in	O	ADJ	B
period	O	NOUN	B
to	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
daily	O	ADJ	B
mizolastine	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
88	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
daily	O	ADJ	B
loratadine	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
79	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
80	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
a	O	DET	O
4-week	O	NOUN	B
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Mizolastine	B-I	NOUN	B
and	O	CCONJ	O
loratadine	B-I	NOUN	B
both	O	CCONJ	O
relieved	B-OUT	VERB	O
symptoms	I-OUT	NOUN	B
of	I-OUT	ADP	O
CIU	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


After	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
'	O	PART	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
severity	B-OUT	NOUN	B
of	I-OUT	ADP	O
pruritus	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
visual	I-OUT	ADJ	B
analogue	I-OUT	NOUN	I
score	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
assessed	I-OUT	VERB	B
by	I-OUT	ADP	O
patients	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
decreased	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
mizolastine	B-I	NOUN	B
and	I-I	CCONJ	O
loratadine	I-I	NOUN	B
groups	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
(	I-I	PUNCT	O
mizolastine	I-I	NOUN	B
:	I-I	PUNCT	O
-36.7	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0001	O	NUM	O
;	O	PUNCT	O
loratadine	B-I	NOUN	B
:	I-I	PUNCT	O
-29.8	O	X	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0071	O	NUM	O
;	O	PUNCT	O
placebo	B-I	NOUN	B
:	I-I	PUNCT	O
-16.3	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
this	O	DET	O
improvement	O	NOUN	B
with	O	ADP	O
both	O	CCONJ	O
active	O	ADJ	B
treatments	O	NOUN	I
was	O	AUX	O
maintained	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
difference	O	NOUN	O
being	O	AUX	O
significant	O	ADJ	B
only	O	ADV	O
for	O	ADP	O
the	O	DET	O
mizolastine	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0090	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	CCONJ	O
active	O	ADJ	B
treatments	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
reduced	O	VERB	B
weekly	O	ADJ	B
episodes	B-OUT	NOUN	B
of	I-OUT	ADP	O
urticaria	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
significant	O	ADJ	O
after	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
'	O	PART	O
treatment	O	NOUN	B
(	B-I	PUNCT	O
mizolastine	I-I	NOUN	B
:	I-I	PUNCT	O
7.9	O	NUM	O
episodes	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0061	O	NUM	O
;	O	PUNCT	O
loratadine	B-I	NOUN	B
:	I-I	PUNCT	O
8.3	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0221	O	NUM	O
;	O	PUNCT	O
placebo	B-I	NOUN	B
:	I-I	PUNCT	O
13.3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Angioedema	B-OUT	NOUN	B
was	O	AUX	O
improved	O	VERB	B
to	O	PART	O
a	O	DET	O
clinically	O	ADV	B
significant	O	ADJ	I
extent	O	NOUN	O
with	O	ADP	O
mizolastine	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
loratadine	B-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
in	O	ADP	O
those	O	DET	O
patients	B-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
this	I-P	DET	O
symptom	I-P	NOUN	B
before	I-P	ADP	O
treatment	I-P	NOUN	B
.	I-P	PUNCT	O


Overall	B-OUT	ADJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
both	O	DET	O
treatments	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
clinically	O	ADV	O
relevant	O	ADJ	B
effects	B-OUT	NOUN	B
on	I-OUT	ADP	O
cardiac	I-OUT	ADJ	B
repolarisation	I-OUT	NOUN	I
with	O	ADP	O
either	O	CCONJ	O
mizolastine	B-I	NOUN	B
or	I-I	CCONJ	O
loratadine	I-I	NOUN	B
.	I-I	PUNCT	O


CONCLUSION	O	NOUN	O
Mizolastine	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
is	O	AUX	O
confirmed	O	VERB	O
as	O	ADP	O
an	O	DET	O
effective	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
well	I-OUT	ADV	O
tolerated	I-OUT	VERB	B
agent	O	NOUN	I
,	O	PUNCT	O
comparable	O	ADJ	O
to	O	PART	O
loratadine	O	NOUN	B
and	O	CCONJ	O
superior	O	ADJ	B
to	O	PART	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
CIU	O	NOUN	B
.	O	PUNCT	O


Mizolastine	B-I	NOUN	B
acted	O	VERB	O
as	O	ADV	O
rapidly	O	ADV	O
as	O	ADP	O
loratadine	B-I	NOUN	B
in	O	ADP	O
improving	O	VERB	B
urticarial	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
from	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Baseline	O	NOUN	B
characteristics	O	NOUN	B
of	O	ADP	O
participants	B-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
Appropriate	I-P	PROPN	B
Blood	I-P	PROPN	B
Pressure	I-P	PROPN	I
Control	I-P	PROPN	B
in	I-P	ADP	O
Diabetes	I-P	PROPN	B
trial	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
ABCD	O	PROPN	B
(	O	PUNCT	O
Appropriate	O	PROPN	O
Blood	O	PROPN	B
Pressure	O	PROPN	I
Control	O	PROPN	I
in	O	ADP	I
Diabetes	O	NOUN	I
)	O	PUNCT	O
trial	O	NOUN	O
is	O	AUX	O
a	O	DET	O
large	O	ADJ	O
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
designed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
intensive	B-I	ADJ	B
with	O	ADP	O
moderate	B-I	ADJ	B
blood	I-I	NOUN	I
pressure	I-I	NOUN	I
control	I-I	NOUN	I
on	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
and	O	CCONJ	O
progression	O	NOUN	B
of	O	ADP	O
diabetic	O	ADJ	B
nephropathy	O	NOUN	I
,	O	PUNCT	O
retinopathy	O	NOUN	B
,	O	PUNCT	O
cardiovascular	O	ADJ	B
disease	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
neuropathy	O	NOUN	B
in	O	ADP	O
non-insulin-dependent	O	ADJ	B
diabetes	O	NOUN	I
(	O	PUNCT	O
NIDDM	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
secondary	O	ADJ	O
objective	O	NOUN	B
is	O	AUX	O
to	O	PART	O
determine	O	VERB	O
equivalency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
calcium	B-I	NOUN	B
channel	I-I	NOUN	I
blocker	I-I	NOUN	I
(	I-I	PUNCT	O
nisoldipine	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
of	O	ADP	O
an	O	DET	O
angiotensin-converting	B-I	ADJ	B
enzyme	I-I	NOUN	I
inhibitor	I-I	NOUN	I
(	I-I	PUNCT	O
enalapril	I-I	NOUN	B
)	I-I	PUNCT	O
as	O	ADP	O
a	O	DET	O
first-line	O	ADJ	O
antihypertensive	O	ADJ	B
agent	O	NOUN	I
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
and/or	O	CCONJ	O
progression	O	NOUN	B
of	O	ADP	O
these	O	DET	O
diabetic	O	ADJ	B
vascular	O	ADJ	B
complications	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
consists	O	VERB	O
of	O	ADP	O
two	B-P	NUM	O
study	I-P	NOUN	B
populations	I-P	NOUN	B
:	I-P	PUNCT	O
a	I-P	DET	O
hypertensive	I-P	ADJ	B
one	I-P	NUM	O
(	I-OUT	PUNCT	O
diastolic	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
of	I-P	ADP	O
>	I-P	NOUN	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
90.0	I-P	NUM	O
mm	I-P	NOUN	O
Hg	I-P	NOUN	O
at	I-P	ADP	O
the	I-P	DET	O
time	I-P	NOUN	B
of	I-P	ADP	O
randomization	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
a	I-P	DET	O
normotensive	I-P	ADJ	B
one	I-P	NUM	O
(	I-OUT	PUNCT	O
diastolic	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
of	I-P	ADP	O
80.0-89.0	I-P	NUM	O
mm	I-P	X	B
Hg	I-P	NOUN	I
at	I-P	ADP	O
the	I-P	DET	O
time	I-P	NOUN	B
of	I-P	ADP	O
randomization	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
950	B-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
women	I-P	NOUN	B
aged	I-P	ADJ	O
40-74	I-P	NUM	B
years	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
and	O	CCONJ	O
are	O	AUX	O
being	O	AUX	O
followed	O	VERB	O
for	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
at	O	ADP	O
a	O	DET	O
single	O	ADJ	O
center	O	NOUN	O
.	O	PUNCT	O


There	B-P	PRON	O
were	I-P	AUX	O
470	I-P	NUM	O
randomized	I-P	ADJ	B
participants	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
hypertensive	I-P	ADJ	B
population	I-P	NOUN	I
and	I-P	CCONJ	O
480	I-P	NUM	O
randomized	I-P	ADJ	B
participants	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
normotensive	I-P	ADJ	B
population	I-P	NOUN	O
.	I-P	PUNCT	O


This	O	DET	O
report	O	NOUN	B
summarizes	O	VERB	O
the	O	DET	O
demographic	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
biochemical	I-OUT	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
clinical	B-OUT	ADJ	B
characteristics	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
randomized	B-P	ADJ	B
patients	I-P	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
entry	O	NOUN	B
into	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
and	O	CCONJ	O
evaluates	O	VERB	B
the	O	DET	O
balance	O	NOUN	B
between	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
groups	O	NOUN	I
within	O	ADP	O
each	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


Vinegar	B-I	NOUN	B
intake	O	NOUN	I
enhances	O	VERB	O
flow-mediated	B-P	ADJ	B
vasodilatation	I-P	NOUN	I
via	O	ADP	O
upregulation	O	NOUN	B
of	O	ADP	O
endothelial	O	ADJ	B
nitric	O	ADJ	I
oxide	O	NOUN	I
synthase	O	NOUN	I
activity	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
acetate	B-I	NOUN	B
on	O	ADP	O
endothelial	O	ADJ	B
nitric	O	ADJ	I
oxide	O	NOUN	I
synthase	O	NOUN	I
(	O	PUNCT	O
eNOS	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
human	O	ADJ	B
umbilical	O	ADJ	I
vein	O	NOUN	I
endothelial	O	ADJ	I
cells	O	NOUN	I
(	O	PUNCT	O
HUVECs	O	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
immunoblotting	O	NOUN	B
assay	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
ability	O	NOUN	B
of	O	ADP	O
acetic	O	ADJ	B
acid	O	NOUN	I
to	O	PART	O
upregulate	O	VERB	B
flow-mediated	B-P	ADJ	B
vasodilatation	I-P	NOUN	I
in	I-P	ADP	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
HUVECs	O	NOUN	B
,	O	PUNCT	O
acetate	O	NOUN	B
induced	O	VERB	B
a	O	DET	O
biphasic	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
phosphorylated	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
eNOS	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
phosphorylated	O	VERB	B
eNOS	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
by	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
200	B-I	NUM	O
mumol/l	I-I	NOUN	O
acetate	I-I	NOUN	B
for	I-I	ADP	O
20	I-I	NUM	O
min	I-I	NOUN	O
(	I-I	PUNCT	O
early	I-I	ADJ	B
phase	I-I	NOUN	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
for	I-I	ADP	O
4	I-I	NUM	O
h	I-I	NOUN	O
(	I-I	PUNCT	O
late	I-I	ADJ	B
phase	I-I	NOUN	I
)	I-I	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
inhibitors	O	NOUN	B
of	O	ADP	O
cAMP-dependent	O	ADJ	B
protein	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
PKA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
AMP-activated	O	ADJ	B
protein	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
AMPK	O	NOUN	B
)	O	PUNCT	O
blocked	O	VERB	B
acetate-induced	O	ADJ	O
eNOS	O	NOUN	B
phosphorylation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
late	O	ADJ	B
phase	O	NOUN	I
respectively	O	ADV	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
postmenopausal	B-P	ADJ	B
women	I-P	NOUN	B
,	O	PUNCT	O
maximum	B-OUT	ADJ	B
forearm	I-OUT	NOUN	B
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
FBF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
shear	O	NOUN	B
stress	O	NOUN	I
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
vinegar	B-P	NOUN	B
(	I-I	PUNCT	O
acetic	I-I	ADJ	B
acid	I-I	NOUN	I
)	I-I	PUNCT	O
administered	I-P	VERB	B
group	I-P	NOUN	B
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
acetic	O	ADJ	B
acid-induced	O	ADJ	O
eNOS	O	NOUN	B
phosphorylation	O	NOUN	B
contributes	O	VERB	O
to	O	PART	O
upregulation	O	NOUN	B
of	O	ADP	O
flow-mediated	O	ADJ	B
vasodilatation	O	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


Long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
ezetimibe-plus-statin	B-I	ADJ	B
therapy	I-I	NOUN	I
on	O	ADP	O
low-density	B-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
levels	I-OUT	NOUN	I
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
double-dose	B-I	ADJ	B
statin	I-I	NOUN	I
therapy	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
long-term	O	ADJ	B
LDL-C-lowering	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
ezetimibe-plus-statin	B-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	VERB	O
Coronary	B-P	ADJ	B
artery	I-P	NOUN	I
disease	I-P	NOUN	I
patients	I-P	NOUN	B
whose	I-P	DET	O
LDL-C	I-P	NOUN	B
≥	I-P	NOUN	O
70	I-P	NUM	O
mg/dL	I-P	NOUN	O
after	I-P	ADP	O
treatment	I-P	NOUN	B
with	I-I	ADP	O
atorvastatin	I-I	NOUN	B
10	I-I	NUM	O
mg/day	I-I	NOUN	B
or	I-I	CCONJ	O
rosuvastatin	I-I	NOUN	B
2.5	I-I	NUM	O
mg/day	I-I	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	B-I	VERB	O
ezetimibe	I-I	NOUN	B
10	I-I	NUM	O
mg/day	I-I	NOUN	B
+	I-I	CCONJ	O
statin	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
78	O	NUM	O
)	O	PUNCT	O
or	B-I	CCONJ	O
double-dose	I-I	ADJ	B
statin	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
72	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
52	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Greater	B-OUT	X	B
LDL-C	I-OUT	NOUN	B
reduction	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	B
and	O	CCONJ	O
maintained	O	VERB	B
until	O	ADP	O
52	O	NUM	O
weeks	O	NOUN	B
in	B-I	ADP	O
ezetimibe-plus-statin	I-I	NOUN	B
,	O	PUNCT	O
while	B-OUT	SCONJ	O
LDL-C	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
re-increased	O	VERB	B
after	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
double-dose	O	ADJ	B
statin	O	NOUN	I
.	O	PUNCT	O


Although	B-OUT	SCONJ	O
lathosterol/TC	I-OUT	ADJ	B
increased	I-OUT	VERB	B
,	I-OUT	PUNCT	O
campesterol/TC	I-OUT	ADJ	B
decreased	O	VERB	B
more	O	ADV	O
in	B-I	ADP	O
ezetimibe-plus-statin	I-I	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	B-OUT	NOUN	O
,	I-OUT	PUNCT	O
lathosterol/TC	I-OUT	ADJ	B
unchanged	O	ADJ	B
and	B-OUT	CCONJ	O
campesterol/TC	I-OUT	ADJ	B
increased	O	VERB	B
,	O	PUNCT	O
increasing	B-OUT	VERB	O
campesterol/lathosterol	I-OUT	NOUN	B
ratio	I-OUT	NOUN	I
for	O	ADP	O
52	O	NUM	O
weeks	O	NOUN	B
in	B-I	ADP	O
double-dose	I-I	ADJ	B
statin	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Plasma	B-OUT	NOUN	B
PCSK9	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
in	B-I	ADP	O
double-dose	I-I	ADJ	B
statin	I-I	NOUN	I
than	O	ADP	O
in	B-I	ADP	O
ezetimibe-plus-statin	I-I	ADJ	O
at	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
similar	O	ADJ	O
at	O	ADP	O
52	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Although	O	SCONJ	O
the	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
PCSK9	O	NOUN	B
between	O	ADP	O
2	O	NUM	O
groups	O	NOUN	B
was	O	AUX	O
transient	O	ADJ	B
,	O	PUNCT	O
that	O	SCONJ	O
in	O	ADP	O
both	O	CCONJ	O
campesterol	O	NOUN	B
and	O	CCONJ	O
lathosterol	O	NOUN	B
persisted	O	VERB	O
until	O	ADP	O
52	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
demonstrated	O	VERB	O
simultaneous	O	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
cholesterol	O	NOUN	B
absorption	O	NOUN	I
and	O	CCONJ	O
synthesis	O	NOUN	B
provides	O	VERB	O
stable	O	ADJ	B
and	O	CCONJ	O
greater	O	ADJ	O
decrease	O	NOUN	B
in	B-OUT	ADP	O
LDL-C	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
.	O	PUNCT	O


Comparative	O	ADJ	O
efficacy	O	NOUN	B
of	O	ADP	O
LEAP	B-I	NOUN	B
,	I-I	PUNCT	O
TEACCH	I-I	NOUN	B
and	O	CCONJ	O
non-model-specific	B-I	ADJ	B
special	I-I	ADJ	B
education	I-I	NOUN	I
programs	I-I	NOUN	I
for	O	ADP	O
preschoolers	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


LEAP	B-I	NOUN	B
and	I-I	CCONJ	O
TEACCH	I-I	PROPN	B
represent	O	VERB	O
two	O	NUM	O
comprehensive	O	ADJ	B
treatment	O	NOUN	B
models	O	NOUN	I
(	O	PUNCT	O
CTMs	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
widely	O	ADV	O
used	O	VERB	O
across	O	ADP	O
several	O	ADJ	O
decades	O	NOUN	B
to	O	PART	O
educate	O	VERB	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
quasi-experimental	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
high	B-I	ADJ	O
fidelity	I-I	NOUN	B
LEAP	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
22	O	NUM	O
)	O	PUNCT	O
and	B-I	CCONJ	O
TEACCH	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
)	O	PUNCT	O
classrooms	O	NOUN	B
to	O	ADP	O
each	O	DET	O
other	O	ADJ	O
and	O	CCONJ	O
a	O	DET	O
control	O	ADJ	B
condition	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
28	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
teachers	B-P	NOUN	B
in	I-P	ADP	O
high	I-P	ADJ	O
quality	I-P	NOUN	B
special	I-P	ADJ	O
education	I-P	NOUN	O
programs	I-P	NOUN	O
used	O	VERB	O
non-model-specific	O	ADJ	B
practices	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	B-P	NOUN	O
of	I-P	ADP	O
198	I-P	NUM	O
children	I-P	NOUN	B
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
data	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


Across	O	ADP	O
conditions	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
children	I-OUT	NOUN	B
's	I-OUT	PART	I
performances	I-OUT	NOUN	B
improved	O	VERB	B
over	O	ADP	O
time	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
raises	O	VERB	O
issues	O	NOUN	B
of	O	ADP	O
the	O	DET	O
replication	O	NOUN	B
of	O	ADP	O
effects	O	NOUN	B
for	O	ADP	O
CTMs	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
whether	O	SCONJ	O
having	O	VERB	O
access	O	NOUN	O
to	O	ADP	O
a	O	DET	O
high	O	ADJ	O
quality	B-I	NOUN	B
special	I-I	ADJ	O
education	I-I	NOUN	O
program	I-I	NOUN	O
is	O	AUX	O
as	O	ADV	O
beneficial	O	ADJ	O
as	O	ADP	O
access	O	NOUN	O
to	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
CTM	O	NOUN	B
.	O	PUNCT	O


Pelvic	B-I	ADJ	B
lymphadenectomy	I-I	NOUN	I
for	O	ADP	O
cervical	B-P	ADJ	B
carcinoma	I-P	NOUN	I
:	I-P	PUNCT	O
laparotomy	I-I	NOUN	B
extraperitoneal	I-I	NOUN	B
,	I-I	PUNCT	O
transperitoneal	I-I	NOUN	B
or	I-I	CCONJ	O
laparoscopic	I-I	ADJ	B
approach	O	NOUN	I
?	O	PUNCT	O
A	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
transperitoneal	B-I	NOUN	B
,	I-I	PUNCT	O
extraperitoneal	I-I	ADJ	B
and	I-I	CCONJ	O
laparoscopic	I-I	ADJ	B
pelvic	I-I	ADJ	I
lymphadenectomy	I-I	NOUN	I
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
feasibility	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
morbidity	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
affected	I-P	VERB	B
by	I-P	ADP	O
cervical	I-P	ADJ	B
cancer	I-P	NOUN	I
undergoing	I-P	VERB	O
radical	I-I	ADJ	B
hysterectomy	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	VERB	O
Consecutive	B-P	ADJ	B
patients	I-P	NOUN	B
affected	I-P	VERB	B
by	I-P	ADP	O
stage	I-P	NOUN	B
IB-IIB	I-P	NOUN	I
cervical	I-P	ADJ	I
carcinoma	I-P	NOUN	I
scheduled	I-P	VERB	B
for	I-P	ADP	O
radical	I-I	ADJ	B
surgery	I-I	NOUN	I
entered	O	VERB	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
transperitoneal	B-I	NOUN	B
(	I-I	PUNCT	O
TPL	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
extraperitoneal	I-I	ADJ	B
(	I-I	PUNCT	O
EPL	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
laparoscopic	I-I	ADJ	B
pelvic	I-I	ADJ	I
lymphadenectomy	I-I	NOUN	I
(	I-I	PUNCT	O
LPL	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


All	B-P	DET	O
patients	I-P	NOUN	B
underwent	I-P	VERB	O
classical	I-I	ADJ	B
radical	I-I	ADJ	I
hysterectomy	I-I	NOUN	I
.	I-I	PUNCT	O


Perioperative	O	ADJ	B
data	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


Follow	O	VERB	B
up	O	ADP	I
examinations	B-OUT	NOUN	I
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
the	O	DET	O
15th	O	NOUN	O
,	O	PUNCT	O
30th	O	ADJ	O
and	O	CCONJ	O
60th	O	ADJ	O
day	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
168	B-P	NUM	O
patients	I-P	NOUN	B
entered	I-P	VERB	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
operative	I-OUT	ADJ	B
times	I-OUT	NOUN	I
were	O	AUX	O
:	O	PUNCT	O
63+/-7.6	O	NUM	B
,	O	PUNCT	O
54+/-6.7	O	NUM	O
and	O	CCONJ	O
75+/-8.4	O	NUM	O
min	O	NOUN	O
(	B-I	PUNCT	O
TPL	I-I	NOUN	B
vs	O	CCONJ	O
EPL	B-I	NOUN	B
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
;	O	PUNCT	O
EPL	O	NOUN	B
vs	O	CCONJ	O
LPL	O	NOUN	B
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
;	O	PUNCT	O
TPL	B-I	NOUN	B
vs	O	CCONJ	O
LPL	B-I	NOUN	B
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
TPL	B-I	NOUN	B
,	I-I	PUNCT	O
EPL	I-I	NOUN	B
and	O	CCONJ	O
LPL	B-I	NOUN	B
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
feasibility	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
procedures	I-OUT	NOUN	B
,	O	PUNCT	O
analyzed	O	VERB	B
on	O	ADP	O
an	O	DET	O
intention-to-treat	O	ADJ	B
basis	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
96	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
93	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
95	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
TPL	B-I	NOUN	B
,	I-I	PUNCT	O
EPL	I-I	NOUN	B
and	I-I	CCONJ	O
LPL	I-I	NOUN	B
group	I-I	NOUN	B
respectively	O	ADV	O
(	O	PUNCT	O
P=ns	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
average	B-OUT	ADJ	B
hospitalizations	I-OUT	NOUN	B
were	O	AUX	O
:	O	PUNCT	O
5.6+/-0.9	O	NUM	O
,	O	PUNCT	O
3.2+/-0.4	O	NUM	O
and	O	CCONJ	O
3.1+/-0.3	O	NUM	O
days	O	NOUN	B
(	B-I	PUNCT	O
TPL	I-I	NOUN	B
vs	O	CCONJ	O
EPL	B-I	NOUN	B
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
;	O	PUNCT	O
TPL	B-I	NOUN	B
vs	O	CCONJ	O
LPL	B-I	NOUN	B
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
TPL	B-I	NOUN	B
,	I-I	PUNCT	O
EPL	I-I	NOUN	B
and	O	CCONJ	O
LPL	B-I	NOUN	B
respectively	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
EPL	B-I	NOUN	B
and	O	CCONJ	O
LPL	B-I	NOUN	B
are	O	AUX	O
as	O	ADV	O
feasible	B-OUT	ADJ	O
and	O	CCONJ	O
effective	B-OUT	ADJ	B
as	O	ADP	O
TPL	B-I	NOUN	B
and	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
adequately	O	ADV	O
performed	O	VERB	O
with	O	ADP	O
a	O	DET	O
reasonable	O	ADJ	O
complication	O	NOUN	B
rate	O	NOUN	B
.	O	PUNCT	O


LPL	B-I	NOUN	B
showed	O	VERB	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
longer	O	ADV	O
operative	B-OUT	ADJ	B
time	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
both	O	CCONJ	O
EPL	B-I	NOUN	B
and	O	CCONJ	O
LPL	B-I	NOUN	B
can	O	AUX	O
minimize	O	VERB	O
some	O	DET	O
postoperative	O	ADJ	B
complications	O	NOUN	B
reducing	O	VERB	B
length	B-OUT	NOUN	B
of	I-OUT	ADP	I
stay	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Albendazole	B-I	NOUN	B
trial	O	NOUN	B
at	O	ADP	O
15	O	NUM	O
or	O	CCONJ	O
30	O	NUM	O
mg/kg/day	O	NOUN	O
for	O	ADP	O
subarachnoid	B-P	ADJ	B
and	I-P	CCONJ	O
intraventricular	I-P	ADJ	B
cysticercosis	I-P	NOUN	I
.	I-P	PUNCT	O


Thirty-six	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
subarachnoid	I-P	ADJ	B
and	I-P	CCONJ	O
intraventricular	I-P	ADJ	B
cysticercosis	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
albendazole	B-I	NOUN	B
at	O	ADP	O
15	O	NUM	O
or	O	CCONJ	O
30	O	NUM	O
mg/kg/day	O	NOUN	O
plus	O	CCONJ	O
dexamethasone	B-I	NOUN	B
for	O	ADP	O
8	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
favored	O	VERB	O
a	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
larger	B-OUT	ADJ	O
cyst	I-OUT	NOUN	B
reduction	I-OUT	NOUN	B
on	O	ADP	O
MRI	O	NOUN	B
at	O	ADP	O
90	O	NUM	O
and	O	CCONJ	O
180	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
higher	O	ADJ	B
albendazole	B-OUT	ADJ	B
sulfoxide	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
in	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


An	O	DET	O
albendazole	B-I	NOUN	B
course	O	NOUN	B
at	O	ADP	O
30	O	NUM	O
mg/kg/day	O	NOUN	O
combined	O	VERB	B
with	O	ADP	O
corticosteroids	B-I	NOUN	B
is	O	AUX	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
more	I-OUT	ADV	O
effective	I-OUT	ADJ	B
than	O	ADP	O
the	O	DET	O
usual	O	ADJ	B
dose	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
treatment	O	NOUN	B
was	O	AUX	O
insufficient	B-OUT	ADJ	B
in	O	ADP	O
intraventricular	O	ADJ	B
and	O	CCONJ	O
giant	O	ADJ	B
cysts	O	NOUN	I
.	O	PUNCT	O


Abstinence	B-OUT	NOUN	B
incentive	I-OUT	ADJ	B
effects	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
short-term	O	ADJ	B
outpatient	O	ADJ	B
detoxification	O	NOUN	B
program	O	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
being	O	AUX	O
widely	O	ADV	O
available	O	ADJ	O
,	O	PUNCT	O
outpatient	O	ADJ	B
detoxification	O	NOUN	B
has	O	AUX	O
limited	O	VERB	O
efficacy	O	NOUN	B
as	O	ADP	O
a	O	DET	O
stand-alone	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
whether	O	SCONJ	O
abstinence-contingent	B-I	ADJ	B
incentives	I-I	NOUN	I
would	O	AUX	O
improve	O	VERB	B
outcomes	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
entering	I-P	VERB	O
outpatient	I-P	ADJ	B
opiate	I-OUT	ADJ	O
detoxification	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Participants	B-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
211	I-P	NUM	O
)	I-P	PUNCT	O
received	O	VERB	O
a	O	DET	O
100	O	NUM	O
US	O	PROPN	B
dollars	O	NOUN	B
voucher	O	NOUN	I
on	O	ADP	O
the	O	DET	O
last	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
detoxification	B-I	NOUN	B
either	O	CCONJ	O
contingent	O	NOUN	B
on	O	ADP	O
opiate	O	ADJ	B
and	O	CCONJ	O
cocaine	O	NOUN	B
abstinence	O	NOUN	B
or	O	CCONJ	O
noncontingently	O	ADV	B
.	O	PUNCT	O


Urine	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
collected	O	VERB	B
at	O	ADP	O
intake	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
Wednesday	O	PROPN	B
,	O	PUNCT	O
Friday	O	PROPN	B
(	O	PUNCT	O
the	O	DET	O
last	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
detoxification	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
following	O	VERB	O
Monday	O	PROPN	B
.	O	PUNCT	O


Among	O	ADP	O
contingent-voucher	B-I	ADJ	O
participants	O	NOUN	B
,	O	PUNCT	O
31	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
drug-free	B-OUT	ADJ	O
on	O	ADP	O
Friday	O	PROPN	B
compared	O	VERB	B
with	O	ADP	O
18	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
noncontingent	O	ADJ	B
controls	O	NOUN	I
(	O	PUNCT	O
Z	O	NOUN	B
=	O	ADJ	O
2.4	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Few	O	ADJ	O
(	O	PUNCT	O
12-13	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
participants	O	NOUN	B
tested	O	VERB	O
negative	B-OUT	ADJ	B
on	O	ADP	O
Monday	O	PROPN	B
.	O	PUNCT	O


Results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
vouchers	O	NOUN	B
to	O	PART	O
produce	O	VERB	O
modest	B-OUT	ADJ	O
improvements	I-OUT	NOUN	B
in	I-OUT	ADP	O
abstinence	I-OUT	NOUN	B
initiation	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
during	O	ADP	O
brief	O	ADJ	O
detoxification	O	NOUN	B
but	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
additional	O	ADJ	O
interventions	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
sustain	O	VERB	O
improvements	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
gonadotropin-releasing	B-I	ADJ	B
hormone	I-I	NOUN	I
agonists	I-I	NOUN	B
and	O	CCONJ	O
antagonists	B-I	NOUN	B
in	O	ADP	O
assisted	O	ADJ	B
reproduction	O	NOUN	I
cycles	O	NOUN	I
of	O	ADP	O
polycystic	B-P	ADJ	B
ovarian	I-P	ADJ	I
syndrome	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


AIM	O	NOUN	B
Gonadotropin-releasing	O	ADJ	I
hormone	O	NOUN	I
(	O	PUNCT	O
GnRH	O	NOUN	B
)	O	PUNCT	O
antagonists	O	NOUN	B
have	O	AUX	O
reduced	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
ovarian	O	ADJ	B
hyper	O	NOUN	I
stimulation	O	NOUN	I
syndrome	O	NOUN	I
(	O	PUNCT	O
OHSS	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
rate	O	NOUN	B
of	O	ADP	O
hospitalization	O	NOUN	B
due	O	ADP	O
to	O	PART	O
severe	O	ADJ	B
OHSS	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
polycystic	B-P	ADJ	B
ovarian	I-P	ADJ	I
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
PCOS	I-P	NOUN	B
)	I-P	PUNCT	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
outcomes	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
PCOS	I-P	NOUN	B
undergoing	I-P	VERB	O
controlled	I-P	VERB	B
ovarian	I-P	ADJ	I
hyperstimulation	I-P	NOUN	I
(	I-P	PUNCT	O
COH	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
GnRH	I-I	NOUN	B
agonist	I-I	NOUN	B
versus	I-I	CCONJ	O
GnRH	I-I	NOUN	B
antagonist	I-I	NOUN	B
protocols	I-I	NOUN	B
for	O	ADP	O
assisted	O	ADJ	B
reproduction	O	NOUN	I
cycles	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
present	O	ADJ	O
clinical	O	ADJ	B
trial	O	NOUN	I
compared	O	VERB	O
GnRH	B-I	NOUN	B
antagonist	I-I	NOUN	B
(	I-I	PUNCT	O
cetrorelix	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
GnRH	B-I	NOUN	B
agonist	I-I	NOUN	B
(	I-I	PUNCT	O
buserelin	I-I	NOUN	B
)	I-I	PUNCT	O
protocols	O	NOUN	B
during	O	ADP	O
COH	O	NOUN	B
of	O	ADP	O
112	B-P	NUM	O
infertile	I-P	ADJ	B
PCOS	I-P	NOUN	B
patients	I-P	NOUN	B
entering	I-P	VERB	O
assisted	I-P	ADJ	B
reproduction	I-P	NOUN	I
cycles	I-P	NOUN	O
.	I-P	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
was	O	AUX	O
pregnancy	B-OUT	NOUN	B
occurrence	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Basal	O	ADJ	B
characteristics	O	NOUN	I
of	O	ADP	O
the	O	DET	O
participants	O	NOUN	B
,	O	PUNCT	O
stimulation	B-OUT	NOUN	B
cycle	I-OUT	NOUN	I
responses	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pregnancy	I-OUT	NOUN	B
outcomes	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
OHSS	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
types	I-OUT	NOUN	O
of	I-OUT	ADP	O
OHSS	I-OUT	NOUN	B
were	O	AUX	O
considered	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Regarding	O	VERB	O
chemical	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
clinical	I-OUT	ADJ	B
pregnancy	I-OUT	NOUN	I
rates	I-OUT	NOUN	I
,	O	PUNCT	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
retrieved	I-OUT	VERB	O
oocytes	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
and	O	CCONJ	O
OHSS	O	PROPN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
antagonist	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Follicle	B-OUT	NOUN	B
stimulating	I-OUT	NOUN	O
hormone	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
FSH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
luteinizing	I-OUT	NOUN	B
hormone	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
LH	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
follicles	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
follicles	I-OUT	NOUN	B
>	I-OUT	X	O
18	I-OUT	NUM	O
mm	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
relative	I-OUT	ADJ	B
frequency	I-OUT	NOUN	I
of	I-OUT	ADP	O
mature	I-OUT	ADJ	B
oocytes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
days	I-OUT	NOUN	B
of	I-OUT	ADP	O
gonadotropin	I-OUT	NOUN	B
injections	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
day	I-OUT	NOUN	B
of	I-OUT	ADP	O
human	I-OUT	ADJ	B
chorionic	I-OUT	ADJ	O
gonadotropin	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
HCG	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
administration	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
estradiol	I-OUT	NOUN	B
level	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
abortion	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
GnRH	O	NOUN	B
antagonists	O	NOUN	B
are	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
,	O	PUNCT	O
safe	O	ADJ	O
and	O	CCONJ	O
a	O	DET	O
well	O	ADV	O
tolerated	O	VERB	B
alternative	O	NOUN	B
to	O	PART	O
agonists	O	NOUN	B
for	O	ADP	O
assisted	O	ADJ	B
reproduction	O	NOUN	I
cycles	O	NOUN	I
in	O	ADP	O
PCOS	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


GnRH	O	NOUN	B
antagonists	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
OHSS	O	NOUN	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Prediction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
infarct-related	O	ADJ	B
artery	O	NOUN	I
in	O	ADP	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
by	O	ADP	O
a	O	DET	O
scoring	O	NOUN	B
system	O	NOUN	I
using	O	VERB	O
summary	B-I	ADJ	O
ST-segment	I-I	ADJ	B
and	I-I	CCONJ	O
T-wave	I-I	ADJ	B
changes	I-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
developed	O	VERB	O
a	O	DET	O
scoring	O	NOUN	B
system	O	NOUN	I
to	O	PART	O
predict	O	VERB	O
the	O	DET	O
artery	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
an	O	DET	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
(	O	PUNCT	O
AMI	O	NOUN	B
)	O	PUNCT	O
using	O	VERB	O
ST-segment	B-I	ADJ	B
and	I-I	CCONJ	O
T-wave	I-I	ADJ	B
changes	I-I	NOUN	B
on	I-I	ADP	O
the	I-I	DET	O
initial	I-I	ADJ	O
electrocardiogram	I-I	NOUN	B
(	I-I	PUNCT	O
ECG	I-I	PROPN	B
)	I-I	PUNCT	O
using	O	VERB	O
data	O	NOUN	B
from	O	ADP	O
228	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
development	I-P	NOUN	B
set	I-P	VERB	O
)	I-P	PUNCT	O
with	I-P	ADP	O
symptoms	I-P	NOUN	B
compatible	I-P	ADJ	O
with	I-P	ADP	O
AMI	I-P	NOUN	B
and	I-P	CCONJ	O
tested	I-P	VERB	B
in	I-P	ADP	O
a	I-P	DET	O
similar	I-P	ADJ	O
group	I-P	NOUN	B
of	I-P	ADP	O
223	I-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
test	I-P	NOUN	B
set	I-P	NOUN	I
)	I-P	PUNCT	O
from	I-P	ADP	O
the	I-P	DET	O
Thrombolysis	I-P	NOUN	B
and	I-P	CCONJ	O
Angioplasty	I-P	PROPN	B
in	I-P	ADP	O
Myocardial	I-P	PROPN	B
Infarction	I-P	NOUN	I
(	I-P	PUNCT	O
TAMI-5	I-P	NOUN	B
)	I-P	PUNCT	O
Trial	I-P	PROPN	B
.	I-P	PUNCT	O


Using	O	VERB	O
stepwise	O	ADJ	O
logistic	O	ADJ	B
regression	O	NOUN	I
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
accurately	O	ADV	O
predict	O	VERB	O
the	O	DET	O
left	O	ADJ	B
anterior	O	ADJ	I
descending	O	NOUN	I
(	O	PUNCT	O
LAD	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
right	O	ADJ	B
,	O	PUNCT	O
or	O	CCONJ	O
left	O	VERB	B
circumflex	O	NOUN	I
(	O	PUNCT	O
LC	O	NOUN	B
)	O	PUNCT	O
coronary	O	ADJ	B
artery	O	NOUN	I
as	O	ADP	O
the	O	DET	O
infarct-related	O	ADJ	B
artery	O	NOUN	I
using	O	VERB	O
2	O	NUM	O
variables	O	NOUN	B
:	O	PUNCT	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
the	O	DET	O
summation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ST-segment	O	ADJ	B
elevation	O	NOUN	B
in	O	ADP	O
leads	O	VERB	O
V1	O	NOUN	O
to	O	ADP	O
V4	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
the	O	DET	O
summation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
T-wave	O	ADJ	B
negativity	O	NOUN	B
in	O	ADP	O
leads	O	VERB	O
I	O	NOUN	B
,	O	PUNCT	O
aVL	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
V5	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
development	O	NOUN	B
set	O	NOUN	O
,	O	PUNCT	O
these	O	DET	O
2	O	NUM	O
variables	O	NOUN	B
demonstrated	O	VERB	O
respective	O	ADJ	O
sensitivity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
specificity	I-OUT	NOUN	B
of	O	ADP	O
98	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
90	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
LAD	O	NOUN	B
lesions	O	NOUN	B
,	O	PUNCT	O
82	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
85	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
right	O	ADJ	B
narrowings	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
82	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
84	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
LC	O	NOUN	B
narrowings	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
test	O	NOUN	B
set	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
sensitivity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
specificity	I-OUT	NOUN	B
were	O	AUX	O
97	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
95	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
LAD	O	NOUN	B
lesions	O	NOUN	B
,	O	PUNCT	O
85	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
86	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
right	O	ADJ	B
lesions	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
73	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
60	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
LC	B-OUT	NOUN	B
coronary	I-OUT	ADJ	I
artery	I-OUT	NOUN	I
lesions	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Information	O	NOUN	B
easily	O	ADV	O
obtained	O	VERB	O
on	O	ADP	O
the	O	DET	O
ECG	O	PROPN	B
can	O	AUX	O
accurately	O	ADV	O
predict	O	VERB	O
the	O	DET	O
likelihood	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LAD	O	NOUN	B
,	O	PUNCT	O
right	O	ADJ	B
,	O	PUNCT	O
or	O	CCONJ	O
LC	O	NOUN	B
artery	O	NOUN	I
as	O	ADP	O
the	O	DET	O
infarct-related	O	ADJ	B
artery	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
the	O	DET	O
decision	O	NOUN	O
to	O	PART	O
administer	O	VERB	O
thrombolytic	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


Resource	B-OUT	NOUN	B
utilization	I-OUT	NOUN	B
and	O	CCONJ	O
economic	B-OUT	ADJ	B
costs	I-OUT	NOUN	I
of	O	ADP	O
care	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
vacuum-assisted	B-I	ADJ	B
closure	I-I	NOUN	I
therapy	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
diabetic	B-P	ADJ	B
foot	I-P	NOUN	B
wounds	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
resource	B-OUT	NOUN	B
utilization	I-OUT	NOUN	B
and	O	CCONJ	O
direct	B-OUT	ADJ	O
economic	I-OUT	ADJ	B
costs	I-OUT	NOUN	I
of	O	ADP	O
care	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
negative-pressure	I-I	ADJ	B
wound	I-I	NOUN	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
NPWT	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
using	O	VERB	O
the	B-I	DET	O
Vacuum-Assisted	I-I	PROPN	B
Closure	I-I	PROPN	I
(	I-I	PUNCT	O
V.A.C	I-I	PROPN	B
.	I-I	PUNCT	O


)	B-I	PUNCT	O
system	I-I	NOUN	O
,	O	PUNCT	O
compared	O	VERB	O
to	O	ADP	O
standard	B-I	ADJ	B
moist	I-I	ADJ	B
wound	I-I	NOUN	B
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
MWT	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
162	B-P	NUM	O
diabetic	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
post-amputation	I-P	ADJ	B
wounds	I-P	NOUN	I
(	I-P	PUNCT	O
up	I-P	ADV	O
to	I-P	ADP	O
the	I-P	DET	O
trans-metatarsal	I-P	ADJ	B
level	I-P	NOUN	B
)	I-P	PUNCT	O
entered	O	VERB	O
a	O	DET	O
16-week	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
randomized	I-P	VERB	B
to	I-P	ADP	O
V.A.C	I-I	PROPN	B
.	I-I	PUNCT	O


(	B-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
77	I-P	NUM	O
)	I-P	PUNCT	O
received	I-P	VERB	O
therapy	I-I	NOUN	B
with	I-I	ADP	O
dressing	I-I	NOUN	B
changes	I-I	NOUN	I
every	O	DET	O
48	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


Control	B-P	ADJ	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
85	I-P	NUM	O
)	I-P	PUNCT	O
received	I-P	VERB	O
standard	I-P	ADJ	B
MWT	I-I	PROPN	B
.	I-I	PUNCT	O


Resource	B-OUT	NOUN	B
utilization	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
procedures	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
direct	I-OUT	ADJ	O
costs	I-OUT	NOUN	B
were	O	AUX	O
calculated	O	VERB	B
and	O	CCONJ	O
analyzed	O	VERB	B
in	O	ADP	O
this	O	DET	O
post	O	NOUN	B
hoc	O	NOUN	I
retrospective	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
groups	B-P	NOUN	B
for	O	ADP	O
in-patient	B-OUT	ADJ	B
hospital	I-OUT	NOUN	O
stay	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
admissions	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
length	I-OUT	NOUN	B
of	I-OUT	ADP	I
stay	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	O	PUNCT	O


More	O	ADV	O
surgical	O	ADJ	B
procedures	O	NOUN	I
(	O	PUNCT	O
including	O	VERB	O
debridement	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
required	O	VERB	O
in	O	ADP	O
the	O	DET	O
MWT	B-I	PROPN	B
group	O	NOUN	O
(	O	PUNCT	O
120	O	NUM	O
vs	O	CCONJ	O
43	O	NUM	O
NPWT	B-I	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
average	B-OUT	ADJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
dressing	I-OUT	NOUN	B
changes	I-OUT	NOUN	B
performed	I-OUT	VERB	O
per	I-OUT	ADP	O
patient	I-OUT	NOUN	B
was	O	AUX	O
118.0	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	O
12-226	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
MWT	B-I	PROPN	B
versus	O	CCONJ	O
41	O	NUM	O
(	O	PUNCT	O
6-140	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
NPWT	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
MWT	B-I	PROPN	B
group	O	NOUN	B
had	O	AUX	O
11	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	O
0-106	O	NUM	O
)	O	PUNCT	O
outpatient	B-OUT	ADJ	B
treatment	I-OUT	NOUN	B
visits	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
versus	O	CCONJ	O
4	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	O
0-47	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
NPWT	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
average	B-OUT	ADJ	O
direct	I-OUT	ADJ	O
cost	I-OUT	NOUN	B
per	I-OUT	ADP	O
patient	I-OUT	NOUN	B
treated	O	VERB	B
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
or	O	CCONJ	O
longer	O	ADJ	B
(	O	PUNCT	O
independent	O	ADJ	O
of	O	ADP	O
clinical	O	ADJ	B
outcome	O	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
$	O	SYM	O
27,270	O	NUM	O
and	O	CCONJ	O
$	O	SYM	O
36,096	O	NUM	O
in	O	ADP	O
the	O	DET	O
NPWT	O	NOUN	B
and	O	CCONJ	O
MWT	O	PROPN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
average	B-OUT	ADJ	B
total	I-OUT	NOUN	O
cost	I-OUT	NOUN	B
to	I-OUT	PART	O
achieve	I-OUT	VERB	O
healing	I-OUT	NOUN	B
was	O	AUX	O
$	O	SYM	O
25,954	O	NUM	O
for	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
NPWT	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
43	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
$	O	SYM	O
38,806	O	NUM	O
for	O	ADP	O
the	O	DET	O
MWT	B-I	PROPN	B
group	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
33	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Treatment	O	NOUN	B
of	O	ADP	O
diabetic	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
post	I-P	NOUN	B
amputation	I-P	NOUN	B
wounds	I-P	NOUN	I
using	O	VERB	O
NPWT	B-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
lower	O	ADJ	O
resource	B-OUT	NOUN	B
utilization	I-OUT	NOUN	B
and	O	CCONJ	O
a	O	DET	O
greater	O	ADJ	O
proportion	B-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
obtaining	O	VERB	O
wound	O	NOUN	B
healing	O	NOUN	I
at	O	ADP	O
a	O	DET	O
lower	B-OUT	ADJ	O
overall	I-OUT	ADJ	B
cost	I-OUT	NOUN	B
of	I-OUT	ADP	O
care	I-OUT	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
to	O	ADP	O
MWT	B-I	PROPN	B
.	I-I	PUNCT	O


Chemoradiotherapy	O	NOUN	B
with	O	ADP	O
concurrent	B-I	ADJ	B
gemcitabine	I-I	NOUN	B
and	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
sequential	I-I	ADJ	B
chemotherapy	I-I	NOUN	B
with	I-I	ADP	O
gemcitabine/cisplatin	I-I	NOUN	B
vs	O	CCONJ	O
chemoradiotherapy	B-I	NOUN	B
with	I-I	ADP	O
concurrent	I-I	ADJ	B
5-fluorouracil	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
locally	I-P	ADV	B
advanced	I-P	ADJ	I
pancreatic	I-P	ADJ	O
cancer	I-P	NOUN	O
--	I-P	PUNCT	O
a	I-P	DET	O
multi-centre	I-P	ADJ	B
randomised	O	ADJ	I
phase	O	NOUN	I
II	O	NUM	I
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
No	O	DET	B
standard	O	ADJ	I
treatment	O	NOUN	B
for	O	ADP	O
locally	B-P	ADV	B
advanced	I-P	ADJ	I
pancreatic	I-P	ADJ	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
LAPC	I-P	NOUN	B
)	I-P	PUNCT	O
is	O	AUX	O
defined	O	VERB	O
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Within	O	ADP	O
a	O	DET	O
multi-centre	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
trial	O	NOUN	I
,	O	PUNCT	O
95	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
LAPC	I-P	NOUN	B
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
three	O	NUM	O
different	O	ADJ	O
chemoradiotherapy	O	NOUN	B
(	O	PUNCT	O
CRT	O	NOUN	B
)	O	PUNCT	O
regimens	O	NOUN	B
:	O	PUNCT	O
patients	O	NOUN	B
received	O	VERB	O
conventionally	O	ADV	B
fractionated	O	VERB	I
radiotherapy	B-I	NOUN	O
of	O	ADP	O
50	O	NUM	O
Gy	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
concurrent	O	ADJ	B
5-fluorouracil	B-I	NOUN	B
(	O	PUNCT	O
350	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
per	O	ADP	O
day	O	NOUN	B
on	O	ADP	O
each	O	DET	O
day	O	NOUN	B
of	O	ADP	O
radiotherapy	B-I	NOUN	B
,	O	PUNCT	O
RT-5-FU	O	NOUN	B
arm	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
concurrent	B-I	ADJ	B
gemcitabine	I-I	NOUN	B
(	O	PUNCT	O
300	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
cisplatin	B-I	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
22	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
29	O	NUM	O
(	O	PUNCT	O
RT-GC	O	NUM	B
arm	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
same	B-I	ADJ	O
concurrent	I-I	ADJ	B
treatment	I-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
sequential	I-I	ADJ	B
full-dose	I-I	ADJ	B
gemcitabine	I-I	NOUN	B
(	O	PUNCT	O
1000	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
cisplatin	B-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
every	O	DET	O
2	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
RT-GC+GC	O	NUM	O
arm	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Primary	O	ADJ	B
end	O	NOUN	I
point	O	NOUN	I
was	O	AUX	O
the	O	DET	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
rate	I-OUT	NOUN	B
after	I-OUT	ADP	O
9	I-OUT	NUM	O
months	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
9-month	B-OUT	ADJ	O
OS	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
was	O	AUX	O
58	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
RT-5-FU	O	NOUN	B
arm	O	NOUN	B
,	O	PUNCT	O
52	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
RT-GC	O	NUM	B
arm	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
45	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
RT-GC+GC	O	NUM	B
arm	O	NOUN	I
.	O	PUNCT	O


Corresponding	O	ADJ	O
median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
times	I-OUT	NOUN	I
were	O	AUX	O
9.6	O	NUM	O
,	O	PUNCT	O
9.3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
7.3	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
P=0.61	O	NOUN	O
)	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
intent-to-treat	B-OUT	ADJ	B
response	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
was	O	AUX	O
19	O	NUM	O
,	O	PUNCT	O
22	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
13	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


Median	B-OUT	ADJ	B
progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
estimated	O	VERB	O
with	O	ADP	O
4.0	O	NUM	O
,	O	PUNCT	O
5.6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
6.0	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
P=0.21	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Grade	B-OUT	NOUN	B
3/4	I-OUT	NUM	O
haematological	I-OUT	ADJ	B
toxicities	I-OUT	NOUN	B
were	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
GC-containing	O	ADJ	B
arms	O	NOUN	O
,	O	PUNCT	O
no	O	DET	O
grade	B-OUT	NOUN	O
3/4	I-OUT	NUM	O
febrile	I-OUT	ADJ	B
neutropaenia	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
None	O	NOUN	O
of	O	ADP	O
the	O	DET	O
three	O	NUM	O
CRT	O	NOUN	B
regimens	O	NOUN	B
tested	O	VERB	B
met	O	VERB	O
the	O	DET	O
investigators	O	NOUN	B
'	O	PART	O
definition	O	NOUN	B
for	O	ADP	O
efficacy	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
median	O	ADJ	B
OS	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
with	O	ADP	O
gemcitabine	O	NOUN	B
alone	O	ADV	O
in	O	ADP	O
LAPC	O	NOUN	B
.	O	PUNCT	O


Language	O	NOUN	B
,	O	PUNCT	O
speech	O	NOUN	B
sound	O	NOUN	I
production	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cognition	O	NOUN	B
in	O	ADP	O
three-year-old	B-P	ADJ	O
children	I-P	NOUN	B
in	I-P	ADP	O
relation	I-P	NOUN	O
to	I-P	PART	O
otitis	I-P	NOUN	B
media	I-P	NOUN	I
in	I-P	ADP	O
their	I-P	PRON	O
first	I-P	ADJ	O
three	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
life	I-P	NOUN	O
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
As	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
possible	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
early-life	O	ADJ	B
otitis	O	NOUN	O
media	O	NOUN	O
on	O	ADP	O
speech	O	NOUN	B
,	O	PUNCT	O
language	O	NOUN	B
,	O	PUNCT	O
cognitive	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
psychosocial	O	ADJ	B
development	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
tested	O	VERB	B
relationships	O	NOUN	B
between	O	ADP	O
children	O	NOUN	B
's	O	PART	I
cumulative	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	O
middle	O	ADJ	B
ear	O	NOUN	I
effusion	O	NOUN	I
(	O	PUNCT	O
MEE	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
their	O	PRON	O
first	O	ADJ	O
3	O	NUM	O
years	O	NOUN	O
of	O	ADP	O
life	O	NOUN	O
and	O	CCONJ	O
their	O	PRON	O
scores	O	NOUN	B
on	O	ADP	O
measures	B-OUT	NOUN	B
of	I-OUT	ADP	O
language	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
speech	I-OUT	NOUN	B
sound	I-OUT	NOUN	I
production	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cognition	I-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	B-P	PRON	O
enrolled	I-P	VERB	O
6350	I-P	NUM	O
healthy	I-P	ADJ	B
infants	I-P	NOUN	B
by	I-P	ADP	O
2	I-P	NUM	O
months	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
who	I-P	PRON	O
presented	I-P	VERB	O
for	I-P	ADP	O
primary	I-P	ADJ	B
care	I-P	NOUN	I
at	I-P	ADP	O
1	I-P	NUM	O
of	I-P	ADP	O
2	I-P	NUM	O
urban	I-P	ADJ	B
hospitals	I-P	NOUN	B
or	I-P	CCONJ	O
1	I-P	NUM	O
of	I-P	ADP	O
2	I-P	NUM	O
small	I-P	ADJ	B
town/rural	I-P	ADJ	B
and	I-P	CCONJ	O
4	I-P	NUM	O
suburban	I-P	ADJ	B
private	I-P	ADJ	O
pediatric	I-P	ADJ	B
practices	I-P	NOUN	O
.	I-P	PUNCT	O


We	O	PRON	O
intensively	O	ADV	O
monitored	O	VERB	O
the	O	DET	O
children	O	NOUN	B
's	O	PART	I
middle	O	ADJ	B
ear	O	NOUN	I
status	O	NOUN	I
by	O	ADP	O
pneumatic	B-I	ADJ	B
otoscopy	I-I	NOUN	I
,	I-I	PUNCT	O
supplemented	I-I	VERB	B
by	I-I	ADP	O
tympanometry	I-I	NOUN	B
,	O	PUNCT	O
throughout	O	ADP	O
their	O	PRON	O
first	O	ADJ	O
3	O	NUM	O
years	O	NOUN	O
of	O	ADP	O
life	O	NOUN	O
;	O	PUNCT	O
we	O	PRON	O
monitored	O	VERB	B
the	O	DET	O
validity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
otoscopic	O	ADJ	B
observations	O	NOUN	I
on	O	ADP	O
an	O	DET	O
ongoing	O	ADJ	O
basis	O	NOUN	O
;	O	PUNCT	O
and	O	CCONJ	O
we	B-I	PRON	O
treated	I-I	VERB	B
children	I-I	NOUN	B
for	I-I	ADP	O
otitis	I-I	NOUN	B
media	I-I	NOUN	I
according	I-I	VERB	O
to	I-I	ADP	O
specified	I-I	VERB	O
guidelines	I-I	NOUN	B
.	I-I	PUNCT	O


Children	B-P	NOUN	B
who	I-P	PRON	O
met	I-P	VERB	O
specified	I-P	VERB	O
minimum	I-P	NOUN	O
criteria	I-P	NOUN	B
regarding	I-P	VERB	O
the	I-P	DET	O
persistence	I-P	NOUN	B
of	I-P	ADP	O
MEE	I-P	PROPN	B
became	I-P	VERB	O
eligible	I-P	ADJ	B
for	I-P	ADP	O
a	I-P	DET	O
clinical	I-P	ADJ	B
trial	I-P	NOUN	I
in	O	ADP	O
which	O	DET	O
they	O	PRON	O
were	O	AUX	O
assigned	O	VERB	O
randomly	O	ADV	O
to	O	PART	O
undergo	O	VERB	O
tympanostomy	B-I	NOUN	B
tube	I-I	NOUN	B
placement	I-I	NOUN	B
either	O	CCONJ	O
promptly	O	ADV	O
or	O	CCONJ	O
after	O	ADP	O
a	O	DET	O
defined	O	VERB	O
extended	O	VERB	O
period	O	NOUN	B
if	O	SCONJ	O
MEE	O	PROPN	B
remained	O	VERB	O
present	O	ADJ	O
.	O	PUNCT	O


From	B-P	ADP	O
among	I-P	ADP	O
those	I-P	DET	O
remaining	I-P	NOUN	O
,	I-P	PUNCT	O
we	I-P	PRON	O
selected	I-P	VERB	O
randomly	I-P	ADV	O
,	I-P	PUNCT	O
within	I-P	ADP	O
sociodemographic	I-P	ADJ	B
strata	I-P	NOUN	I
,	I-P	PUNCT	O
a	I-P	DET	O
sample	I-P	NOUN	B
of	I-P	ADP	O
241	I-P	NUM	O
children	I-P	NOUN	B
who	I-P	PRON	O
represented	I-P	VERB	O
a	I-P	DET	O
spectrum	I-P	NOUN	B
of	I-P	ADP	O
MEE	I-P	NOUN	B
experience	I-P	NOUN	B
from	I-P	ADP	O
having	I-P	VERB	O
no	I-P	DET	O
MEE	I-P	PROPN	B
to	I-P	PART	O
having	I-P	VERB	O
MEE	I-P	PROPN	B
whose	I-P	DET	O
cumulative	I-P	ADJ	B
duration	I-P	NOUN	B
fell	I-P	VERB	O
just	I-P	ADV	O
short	I-P	ADJ	O
of	I-P	ADP	O
meeting	I-P	NOUN	O
randomization	I-P	NOUN	B
criteria	I-P	NOUN	I
.	I-P	PUNCT	O


In	B-P	ADP	O
subjects	I-P	NOUN	B
so	I-P	ADV	O
selected	I-P	VERB	O
,	I-P	PUNCT	O
the	I-P	DET	O
estimated	I-P	VERB	O
duration	I-P	NOUN	B
of	I-P	ADP	O
MEE	I-P	NOUN	B
ranged	I-P	VERB	O
from	I-P	ADP	O
none	I-P	NOUN	O
to	I-P	ADP	O
65.6	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
year	I-P	NOUN	B
of	I-P	ADP	O
life	I-P	NOUN	O
and	I-P	CCONJ	O
44.8	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
first	I-P	ADJ	O
3	I-P	NUM	O
years	I-P	NOUN	O
of	I-P	ADP	O
life	I-P	NOUN	O
.	I-P	PUNCT	O


In	O	ADP	O
these	O	DET	O
241	B-P	NUM	O
children	I-P	NOUN	B
we	O	PRON	O
assessed	O	VERB	B
language	B-OUT	NOUN	B
development	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
speech	I-OUT	NOUN	B
sound	I-OUT	NOUN	I
production	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cognition	I-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
both	O	DET	O
formal	O	ADJ	O
tests	O	NOUN	O
and	O	CCONJ	O
conversational	O	ADJ	B
samples	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
We	O	PRON	O
found	O	VERB	O
weak	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
,	O	PUNCT	O
statistically	O	ADV	B
significant	O	ADJ	I
negative	O	ADJ	B
correlations	O	NOUN	B
between	O	ADP	O
children	O	NOUN	B
's	O	PART	I
cumulative	O	ADJ	B
durations	O	NOUN	B
of	O	ADP	O
MEE	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
first	O	ADJ	O
year	O	NOUN	B
of	O	ADP	O
life	O	NOUN	O
or	O	CCONJ	O
in	O	ADP	O
age	O	NOUN	B
periods	O	NOUN	O
that	O	PRON	O
included	O	VERB	O
their	O	PRON	O
first	O	ADJ	O
year	O	NOUN	B
of	O	ADP	O
life	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
scores	B-OUT	NOUN	B
on	I-OUT	ADP	O
formal	I-OUT	ADJ	O
tests	I-OUT	NOUN	B
of	I-OUT	ADP	O
receptive	I-OUT	ADJ	B
vocabulary	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
verbal	I-OUT	ADJ	B
aspects	I-OUT	NOUN	I
of	I-OUT	ADP	O
cognition	I-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
percent	O	NOUN	O
of	O	ADP	O
variance	O	NOUN	B
in	O	ADP	O
these	O	DET	O
scores	O	NOUN	B
explained	O	VERB	O
by	O	ADP	O
time	O	NOUN	B
with	O	ADP	O
MEE	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
of	O	ADP	O
life	O	NOUN	O
beyond	O	ADP	O
that	O	DET	O
explained	O	VERB	O
by	O	ADP	O
sociodemographic	O	ADJ	B
variables	O	NOUN	I
ranged	O	VERB	O
only	O	ADV	O
from	O	ADP	O
1.2	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
2.9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
negative	O	ADJ	B
correlations	O	NOUN	B
were	O	AUX	O
concentrated	O	VERB	O
in	O	ADP	O
the	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
whose	O	DET	O
families	O	NOUN	B
had	O	AUX	O
private	O	ADJ	B
health	O	NOUN	I
insurance	O	NOUN	I
(	O	PUNCT	O
rather	O	ADV	O
than	O	ADP	O
Medicaid	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
correlations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
population	O	NOUN	I
as	O	ADP	O
a	O	DET	O
whole	O	NOUN	O
or	O	CCONJ	O
in	O	ADP	O
any	O	DET	O
subgroup	O	NOUN	B
between	O	ADP	O
time	O	NOUN	B
with	O	ADP	O
MEE	O	NOUN	B
during	O	ADP	O
antecedent	O	ADJ	B
periods	O	NOUN	B
and	O	CCONJ	O
children	O	NOUN	B
's	O	PART	I
scores	O	NOUN	B
on	O	ADP	O
measures	O	NOUN	B
of	O	ADP	O
spontaneous	B-OUT	ADJ	B
expressive	I-OUT	ADJ	O
language	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
speech	I-OUT	NOUN	B
sound	I-OUT	NOUN	I
production	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
other	I-OUT	ADJ	O
measured	I-OUT	VERB	B
aspects	I-OUT	NOUN	O
of	I-OUT	ADP	O
cognition	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
by	O	ADP	O
wide	O	ADJ	O
margins	O	NOUN	O
,	O	PUNCT	O
scores	B-OUT	NOUN	B
on	I-OUT	ADP	O
all	I-OUT	DET	O
measures	I-OUT	NOUN	B
were	O	AUX	O
consistently	O	ADV	O
highest	O	ADJ	O
among	O	ADP	O
the	O	DET	O
most	O	ADV	O
socioeconomically	O	ADV	B
advantaged	O	ADJ	B
children	O	NOUN	B
and	O	CCONJ	O
lowest	O	ADJ	B
among	O	ADP	O
the	O	DET	O
most	O	ADV	O
socioeconomically	O	ADV	B
disadvantaged	O	ADJ	B
children	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Our	O	PRON	O
findings	O	NOUN	B
suggest	O	VERB	O
either	O	CCONJ	O
that	O	SCONJ	O
persistent	B-P	ADJ	B
early-life	I-P	ADJ	B
MEE	I-P	NOUN	B
actually	O	ADV	O
causes	O	VERB	O
later	O	ADV	O
small	O	ADJ	B
,	O	PUNCT	O
circumscribed	O	ADJ	B
impairments	O	NOUN	I
of	O	ADP	O
receptive	O	ADJ	B
language	O	NOUN	I
and	O	CCONJ	O
verbal	O	ADJ	B
aspects	O	NOUN	I
of	O	ADP	O
cognition	O	NOUN	B
in	O	ADP	O
certain	O	ADJ	O
groups	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
or	O	CCONJ	O
that	O	SCONJ	O
unidentified	O	ADJ	O
,	O	PUNCT	O
confounding	O	NOUN	B
factors	O	NOUN	I
predispose	O	VERB	O
children	O	NOUN	B
both	O	CCONJ	O
to	O	PART	O
early-life	O	ADJ	B
otitis	O	NOUN	B
media	O	NOUN	I
and	O	CCONJ	O
to	O	ADP	O
certain	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
developmental	B-OUT	ADJ	B
impairment	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Findings	O	NOUN	B
in	O	ADP	O
the	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
component	O	NOUN	O
of	O	ADP	O
the	O	DET	O
larger	O	ADJ	O
study	O	NOUN	B
should	O	AUX	O
help	O	VERB	O
distinguish	O	VERB	O
between	O	ADP	O
causality	O	NOUN	B
and	O	CCONJ	O
confounding	O	NOUN	B
as	O	ADP	O
explanations	O	NOUN	B
for	O	ADP	O
our	O	PRON	O
findings.language	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
speech	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
cognition	I-OUT	NOUN	B
,	O	PUNCT	O
development	O	NOUN	B
,	O	PUNCT	O
otitis	O	NOUN	B
media	O	NOUN	I
,	O	PUNCT	O
middle	O	ADJ	B
ear	O	NOUN	I
effusion	O	NOUN	I
.	O	PUNCT	O


Laparoscopic	B-I	ADJ	B
vs	O	CCONJ	O
open	B-I	ADJ	O
appendectomy	I-I	NOUN	B
in	O	ADP	O
overweight	B-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	ADJ	O
Laparoscopic	B-I	ADJ	B
appendectomy	I-I	NOUN	I
(	I-I	PUNCT	O
LA	I-I	NOUN	B
)	I-I	PUNCT	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
faster	O	ADJ	O
recovery	O	NOUN	B
and	O	CCONJ	O
less	O	ADV	O
postoperative	O	ADJ	B
pain	O	NOUN	I
than	O	ADP	O
the	O	DET	O
open	O	ADJ	B
technique	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
few	O	ADJ	O
data	O	NOUN	B
are	O	AUX	O
available	O	ADJ	O
on	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
outcome	O	NOUN	I
of	O	ADP	O
LA	B-I	NOUN	B
in	O	ADP	O
overweight	B-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
A	B-P	DET	O
group	I-P	NOUN	B
of	I-P	ADP	O
106	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
body	I-P	NOUN	B
mass	I-P	NOUN	I
index	I-P	NOUN	I
(	I-P	PUNCT	O
BMI	I-P	NOUN	B
)	I-P	PUNCT	O
>	I-P	PROPN	O
26.4	I-P	NUM	O
,	I-P	PUNCT	O
representing	I-P	VERB	O
the	I-P	DET	O
upper	I-P	ADJ	B
quintile	I-P	NOUN	I
of	I-P	ADP	O
500	I-P	NUM	O
prospectively	I-P	ADV	O
randomized	I-P	ADJ	B
patients	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
undergo	O	VERB	O
either	O	CCONJ	O
laparoscopic	B-I	ADJ	B
or	I-I	CCONJ	O
open	I-I	ADJ	B
appendectomy	I-I	NOUN	I
(	I-I	PUNCT	O
OA	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Operating	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
anesthesia	I-OUT	NOUN	B
times	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
postoperative	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
complications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
hospital	I-OUT	NOUN	B
stay	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
functional	I-OUT	ADJ	B
index	I-OUT	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
week	O	NOUN	B
postoperatively	O	ADV	B
)	O	PUNCT	O
,	O	PUNCT	O
sick	B-OUT	ADJ	B
leave	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
to	I-OUT	ADP	O
full	I-OUT	ADJ	O
recovery	I-OUT	NOUN	B
were	O	AUX	O
documented	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
OA	B-I	NOUN	B
,	O	PUNCT	O
the	O	DET	O
operating	B-OUT	VERB	B
time	I-OUT	NOUN	I
for	O	ADP	O
overweight	B-OUT	ADJ	B
patients	I-P	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
longer	O	ADV	O
than	O	ADP	O
that	O	DET	O
for	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
weight	O	NOUN	I
range	O	NOUN	I
(	O	PUNCT	O
40	O	NUM	O
vs	O	CCONJ	O
35	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
LA	B-I	PROPN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
operating	B-OUT	VERB	B
time	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
overweight	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Overweight	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
LA	B-I	PROPN	B
had	O	AUX	O
longer	O	ADV	O
operating	B-OUT	VERB	B
and	I-OUT	CCONJ	O
anesthesia	I-OUT	NOUN	B
times	I-OUT	NOUN	O
than	O	ADP	O
their	O	PRON	O
OA	B-I	NOUN	B
counterparts	O	NOUN	B
(	O	PUNCT	O
55	O	NUM	O
vs	O	CCONJ	O
40	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
125	O	NUM	O
vs	O	CCONJ	O
100	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
overweight	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
OA	B-I	NOUN	B
than	O	ADP	O
in	O	ADP	O
those	O	DET	O
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
laparoscopic	B-I	ADJ	B
technique	I-I	NOUN	I
.	I-I	PUNCT	O


Postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
was	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
overweight	O	ADJ	B
patients	O	NOUN	B
subjected	O	VERB	O
to	O	PART	O
OA	B-I	NOUN	B
than	O	ADP	O
in	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
weight	O	NOUN	I
after	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
clinical	O	ADJ	B
significance	O	NOUN	I
may	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
be	O	AUX	O
of	O	ADP	O
less	O	ADJ	O
importance	O	NOUN	O
since	O	SCONJ	O
the	O	DET	O
values	O	NOUN	B
are	O	AUX	O
low	O	ADJ	B
(	O	PUNCT	O
0.26	O	NUM	O
vs	O	CCONJ	O
0.09	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
operating	O	NOUN	B
techniques	O	NOUN	I
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
complications	O	NOUN	B
.	O	PUNCT	O


Hospital	B-OUT	PROPN	B
stay	I-OUT	NOUN	I
was	O	AUX	O
longer	O	ADJ	O
for	O	ADP	O
overweight	O	ADJ	B
patients	O	NOUN	B
than	O	ADP	O
for	O	ADP	O
normal-weight	O	ADJ	B
patients	O	NOUN	B
undergoing	O	VERB	O
OA	B-I	NOUN	B
(	O	PUNCT	O
3.0	O	NUM	O
vs	O	CCONJ	O
2.0	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
functional	O	ADJ	B
index	O	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
any	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Sick	B-OUT	PROPN	B
leave	I-OUT	NOUN	O
was	O	AUX	O
longer	O	ADJ	O
for	O	ADP	O
overweight	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
OA	B-I	NOUN	B
than	O	ADP	O
for	O	ADP	O
normal-weight	O	ADJ	B
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
same	O	ADJ	O
technique	O	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
vs	O	CCONJ	O
13	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
laparoscopic	B-I	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
overweight	B-P	ADJ	B
and	I-P	CCONJ	O
normal-weight	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Time	B-OUT	NOUN	O
to	I-OUT	ADP	O
full	I-OUT	ADJ	O
recovery	I-OUT	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
overweight	O	ADJ	B
patients	O	NOUN	B
subjected	O	VERB	O
to	O	PART	O
OA	B-I	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
overweight	O	ADJ	B
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
LA	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
vs	O	CCONJ	O
15	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
overweight	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
submitted	O	VERB	O
to	O	ADP	O
LA	B-I	PROPN	B
had	O	AUX	O
less	O	ADV	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
and	O	CCONJ	O
a	O	DET	O
faster	O	ADV	O
postoperative	B-OUT	ADJ	B
recovery	I-OUT	NOUN	B
than	O	ADP	O
overweight	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
OA	B-I	NOUN	B
.	I-I	PUNCT	O


LA	B-I	PROPN	B
also	O	ADV	O
abolished	O	VERB	O
some	O	DET	O
of	O	ADP	O
the	O	DET	O
negative	O	ADJ	B
effects	O	NOUN	B
that	O	PRON	O
overweight	O	NOUN	B
had	O	AUX	O
on	O	ADP	O
operating	B-OUT	VERB	B
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
hospital	I-OUT	NOUN	B
stay	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
sick	I-OUT	ADJ	B
leave	I-OUT	NOUN	O
with	O	ADP	O
the	O	DET	O
open	O	ADJ	B
technique	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
anesthesia	O	NOUN	B
and	O	CCONJ	O
operating	O	VERB	B
times	O	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
longer	O	ADV	O
in	O	ADP	O
LA	B-I	NOUN	B
for	O	ADP	O
both	O	CCONJ	O
overweight	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
a	O	DET	O
normal	O	ADJ	B
BMI	O	NOUN	I
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
fatigue	I-OUT	NOUN	B
management	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
nursing	O	NOUN	B
randomized	O	ADJ	O
clinical	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


PURPOSE/OBJECTIVES	O	ADV	B
Through	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
,	O	PUNCT	O
to	O	PART	O
compare	O	VERB	B
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
an	I-P	DET	O
initial	I-P	ADJ	O
course	I-P	NOUN	B
of	I-P	ADP	O
chemotherapy	I-I	NOUN	B
who	I-P	PRON	O
report	I-P	VERB	B
pain	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
fatigue	I-OUT	NOUN	B
at	I-P	ADP	O
baseline	I-P	NOUN	B
and	I-P	CCONJ	O
who	I-P	PRON	O
are	I-P	AUX	O
receiving	I-P	VERB	O
conventional	I-I	ADJ	B
care	I-I	NOUN	I
alone	I-I	ADV	O
with	I-P	ADP	O
those	I-P	DET	O
receiving	I-P	VERB	O
conventional	I-I	ADJ	B
care	I-I	NOUN	I
plus	I-I	CCONJ	O
a	I-I	DET	O
nursing	I-I	NOUN	B
intervention	I-I	NOUN	I
on	O	ADP	O
outcomes	O	NOUN	B
reported	O	VERB	O
at	O	ADP	O
20	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


SETTING	O	VERB	B
Chemotherapy	B-P	NOUN	B
clinics	I-P	NOUN	I
of	I-P	ADP	O
two	I-P	NUM	O
comprehensive	I-P	ADJ	B
and	I-P	CCONJ	O
two	I-P	NUM	O
community	I-P	NOUN	B
cancer	I-P	NOUN	I
centers	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Interviews	O	PROPN	B
were	O	AUX	O
conducted	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
18-week	O	NOUN	B
,	O	PUNCT	O
10-contact	O	ADJ	B
nursing	B-I	NOUN	I
intervention	I-I	NOUN	I
utilizing	I-I	VERB	O
problem-solving	I-I	ADJ	B
approaches	I-I	NOUN	I
to	I-I	PART	O
symptom	I-I	VERB	B
management	I-I	NOUN	I
and	I-I	CCONJ	O
improving	I-I	VERB	B
physical	I-OUT	ADJ	B
functioning	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
emotional	I-OUT	ADJ	B
health	I-OUT	NOUN	I
was	O	AUX	O
implemented	O	VERB	O
.	O	PUNCT	O


SAMPLE	O	NOUN	O
The	O	DET	O
sample	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
53	B-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
experimental	I-P	ADJ	B
arm	I-P	NOUN	I
and	I-P	CCONJ	O
60	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
control	I-P	ADJ	B
arm	I-P	NOUN	I
who	I-P	PRON	O
reported	I-P	VERB	O
pain	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fatigue	I-OUT	NOUN	B
at	I-P	ADP	O
baseline	I-P	NOUN	B
.	I-P	PUNCT	O


VARIABLES	O	NOUN	B
Pain	B-OUT	PROPN	I
and	I-OUT	CCONJ	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
numbers	I-OUT	NOUN	O
of	I-OUT	ADP	O
other	I-OUT	ADJ	O
symptoms	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
physical	I-OUT	ADJ	B
role	I-OUT	NOUN	I
impact	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
social-functioning	I-OUT	ADJ	B
subscales	I-OUT	NOUN	I
from	O	ADP	O
the	O	DET	O
Medical	O	PROPN	B
Outcomes	O	PROPN	I
Study	O	PROPN	I
36	O	NUM	I
Short	O	PROPN	I
Form	O	NOUN	I
.	O	PUNCT	O


FINDINGS	O	NOUN	B
Patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
intervention	B-I	NOUN	B
reported	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
experienced	I-OUT	VERB	B
and	O	CCONJ	O
improved	O	VERB	B
physical	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
social	I-OUT	ADJ	B
functioning	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Fewer	O	ADJ	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
arm	O	NOUN	I
reported	O	VERB	O
both	O	CCONJ	O
pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
fatigue	I-OUT	NOUN	B
at	O	ADP	O
20	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Behavioral	B-I	ADJ	B
interventions	I-I	NOUN	B
targeted	O	VERB	O
to	O	PART	O
patients	O	NOUN	B
with	O	ADP	O
pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
fatigue	I-OUT	NOUN	B
can	O	AUX	O
reduce	O	VERB	B
symptom	B-OUT	NOUN	B
burden	I-OUT	NOUN	O
,	O	PUNCT	O
improve	O	VERB	B
the	O	DET	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
daily	I-OUT	ADJ	B
life	I-OUT	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
demonstrate	O	VERB	O
the	O	DET	O
"	O	PUNCT	O
value-added	O	ADJ	B
"	O	PUNCT	O
role	O	NOUN	O
of	O	ADP	O
nursing	B-I	NOUN	B
care	I-I	NOUN	I
for	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


IMPLICATIONS	O	NOUN	O
FOR	O	ADP	O
NURSING	O	NOUN	O
These	O	DET	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
"	O	PUNCT	O
value-added	O	ADJ	B
"	O	PUNCT	O
role	O	NOUN	O
of	O	ADP	O
nursing	B-I	NOUN	B
interventions	I-I	NOUN	I
for	O	ADP	O
symptom	O	NOUN	B
management	O	NOUN	I
and	O	CCONJ	O
improved	B-OUT	VERB	B
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
cancer	O	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
low-level	B-I	ADJ	B
laser	I-I	NOUN	B
and	I-I	CCONJ	O
plyometric	I-I	VERB	B
exercises	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
lateral	B-P	ADJ	B
epicondylitis	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
a	O	DET	O
protocol	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
of	O	ADP	O
laser	B-I	NOUN	B
with	I-I	ADP	O
plyometric	I-I	NOUN	B
exercises	I-I	NOUN	I
and	O	CCONJ	O
a	O	DET	O
protocol	O	NOUN	B
of	O	ADP	O
placebo	B-I	ADJ	B
laser	I-I	NOUN	I
with	I-I	ADP	O
the	I-I	DET	O
same	I-I	ADJ	O
program	I-I	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
tennis	B-P	NOUN	B
elbow	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
DATA	O	PROPN	B
The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
low-level	B-I	ADJ	B
laser	I-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
recommended	O	VERB	B
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
tennis	B-P	NOUN	B
elbow	I-P	NOUN	I
with	O	ADP	O
contradictory	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
plyometric	B-I	NOUN	B
exercises	I-I	NOUN	I
was	O	AUX	O
recommended	O	VERB	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
tendinopathy	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Fifty	B-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
had	I-P	AUX	O
tennis	I-P	NOUN	B
elbow	I-P	NOUN	I
participated	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
randomised	O	VERB	B
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Group	O	PROPN	B
A	O	PROPN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
904	B-I	NUM	O
Ga-As	I-I	NOUN	B
laser	I-I	NOUN	B
CW	I-I	NOUN	I
,	O	PUNCT	O
frequency	O	NOUN	B
50	O	NUM	O
Hz	O	NOUN	O
,	O	PUNCT	O
intensity	O	NOUN	B
40	O	NUM	O
mW	O	NOUN	O
and	O	CCONJ	O
energy	O	NOUN	B
density	O	NOUN	I
2.4	O	NUM	O
J/cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
plus	B-I	CCONJ	O
plyometric	I-I	NOUN	B
exercises	I-I	NOUN	I
and	O	CCONJ	O
group	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
)	O	PUNCT	O
that	O	PRON	O
received	O	VERB	O
placebo	B-I	ADJ	B
laser	I-I	NOUN	O
plus	I-I	CCONJ	O
the	I-I	DET	O
same	I-I	ADJ	O
plyometric	I-I	NOUN	B
exercises	I-I	NOUN	I
.	I-I	PUNCT	O


During	O	ADP	O
eight	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
received	O	VERB	O
12	O	NUM	O
sessions	O	NOUN	B
of	O	ADP	O
laser	B-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
sessions	O	NOUN	B
per	O	ADP	O
week	O	NOUN	B
(	O	PUNCT	O
weeks	O	NOUN	B
1-4	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
session	O	NOUN	B
per	O	ADP	O
week	O	NOUN	B
(	O	PUNCT	O
weeks	O	NOUN	B
5-8	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Pain	B-OUT	NOUN	B
at	I-OUT	ADP	O
rest	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
at	I-OUT	ADP	O
palpation	I-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
lateral	I-OUT	ADJ	B
epicondyle	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
during	I-OUT	ADP	O
resisted	I-OUT	VERB	O
wrist	I-OUT	NOUN	B
extension	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
middle	I-OUT	ADJ	B
finger	I-OUT	NOUN	I
test	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
strength	B-OUT	NOUN	B
testing	I-OUT	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
Visual	B-OUT	ADJ	B
Analogue	I-OUT	PROPN	I
Scales	I-OUT	PROPN	I
.	I-OUT	PUNCT	O


Also	O	ADV	O
it	O	PRON	O
was	O	AUX	O
evaluated	O	VERB	B
the	O	DET	O
grip	B-OUT	NOUN	B
strength	I-OUT	NOUN	I
,	O	PUNCT	O
the	O	DET	O
range	B-OUT	NOUN	O
of	I-OUT	ADP	O
motion	I-OUT	NOUN	O
and	O	CCONJ	O
weight	B-OUT	NOUN	B
test	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Parameters	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
before	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
eighth	O	ADJ	O
week	O	NOUN	B
course	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
week	O	NOUN	B
8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
eighth	O	ADJ	O
(	O	PUNCT	O
week	O	NOUN	B
8	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Relative	O	ADJ	O
to	O	PART	O
the	O	DET	O
group	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
group	O	NOUN	B
A	O	NOUN	I
had	O	AUX	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
decrease	B-OUT	NOUN	B
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
at	I-OUT	ADP	O
rest	I-OUT	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
following	O	VERB	O
up	O	ADP	O
period	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
pain	I-OUT	NOUN	B
at	I-OUT	ADP	O
palpation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
on	I-OUT	ADP	O
isometric	I-OUT	ADJ	B
testing	I-OUT	NOUN	I
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
follow-up	O	X	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
during	I-OUT	ADP	O
middle	I-OUT	ADJ	B
finger	I-OUT	NOUN	I
test	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
follow-up	O	ADJ	B
period	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
(	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
decrease	B-OUT	NOUN	B
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
during	I-OUT	ADP	O
grip	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
testing	I-OUT	NOUN	O
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
follow-up	O	X	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
wrist	I-OUT	NOUN	B
range	I-OUT	NOUN	I
of	I-OUT	ADP	I
motion	I-OUT	NOUN	I
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
follow-up	O	X	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
an	O	DET	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
grip	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
follow-up	O	X	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
7	O	X	O
)	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
weight-test	I-OUT	NOUN	O
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
follow-up	O	X	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
The	O	DET	O
results	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
laser	I-I	NOUN	B
with	I-I	ADP	O
plyometric	I-I	NOUN	B
exercises	I-I	NOUN	I
was	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
treatment	O	NOUN	B
than	O	ADP	O
placebo	B-I	ADJ	B
laser	I-I	NOUN	I
with	I-I	ADP	O
the	I-I	DET	O
same	I-I	ADJ	O
plyometric	I-I	NOUN	B
exercises	I-I	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
at	O	ADP	O
the	O	DET	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Future	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
establish	O	VERB	O
the	O	DET	O
relative	O	ADJ	B
and	O	CCONJ	O
absolute	O	ADJ	B
effectiveness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
above	O	ADJ	O
protocol	O	NOUN	B
.	O	PUNCT	O


Perioperative	B-I	ADJ	B
enteral	I-I	ADJ	B
nutrition	I-I	NOUN	I
and	O	CCONJ	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
of	O	ADP	O
severely	B-P	ADV	B
malnourished	I-P	ADJ	I
head	I-P	NOUN	O
and	I-P	CCONJ	O
neck	I-P	NOUN	O
cancer	I-P	NOUN	O
patients	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
AIMS	O	ADJ	B
This	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
perioperative	B-I	ADJ	B
nutritional	I-I	ADJ	B
support	I-I	NOUN	O
on	O	ADP	O
Quality	B-OUT	PROPN	B
of	I-OUT	ADP	I
Life	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
QOL	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
malnourished	B-P	ADJ	B
head	I-P	NOUN	I
and	I-P	CCONJ	O
neck	I-P	NOUN	O
cancer	I-P	NOUN	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
surgery	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
49	B-P	NUM	O
Malnourished	I-P	PROPN	B
(	I-P	PUNCT	O
weight	I-P	NOUN	B
loss	I-P	NOUN	I
>	I-P	NOUN	O
10	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
head	I-P	NOUN	B
and	I-P	CCONJ	I
neck	I-P	NOUN	O
cancer	I-P	NOUN	O
patients	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
nutrition	I-P	NOUN	B
intervention	I-P	NOUN	I
trial	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
no	B-I	DET	O
preoperative	I-I	ADJ	B
and	I-I	CCONJ	O
standard	I-I	ADJ	B
postoperative	I-I	ADJ	B
tube-feeding	I-I	ADJ	O
(	I-I	PUNCT	O
group	I-I	NOUN	B
I	I-I	NUM	I
)	I-I	PUNCT	O
,	I-I	PUNCT	O
standard	I-I	ADJ	B
preoperative	I-I	ADJ	B
and	I-I	CCONJ	O
postoperative	I-I	ADJ	B
tube-feeding	I-I	ADJ	B
(	I-I	PUNCT	O
group	I-I	NOUN	B
II	I-I	NUM	I
)	I-I	PUNCT	O
or	O	CCONJ	O
arginine-supplemented	B-I	ADJ	B
preoperative	I-I	ADJ	I
and	I-I	CCONJ	O
postoperative	I-I	ADJ	B
tube-feeding	I-I	ADJ	B
(	O	PUNCT	O
group	O	NOUN	B
III	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
patients	B-P	NOUN	B
,	O	PUNCT	O
31	O	NUM	O
completed	O	VERB	O
a	O	DET	O
full	O	ADJ	O
QOL	B-OUT	PROPN	B
assessment	I-OUT	NOUN	B
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
preoperative	O	ADJ	B
nutritional	O	ADJ	B
support	O	NOUN	O
,	O	PUNCT	O
one	O	NUM	O
day	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
a	O	DET	O
disease-specific	O	ADJ	B
(	O	PUNCT	O
EORTC	O	NOUN	B
QLQ-C30	O	PROPN	I
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
generic	O	ADJ	B
questionnaire	O	NOUN	I
(	O	PUNCT	O
COOP-WONCA	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
way	O	NOUN	O
analysis	O	NOUN	B
of	O	ADP	O
variance	O	NOUN	O
(	O	PUNCT	O
ANOVA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Kruskal-Wallis	O	PROPN	B
test	O	NOUN	I
were	O	AUX	O
applied	O	VERB	O
for	O	ADP	O
testing	O	NOUN	B
differences	O	NOUN	O
in	O	ADP	O
scores	O	NOUN	B
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Between	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
day	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
preoperatively	B-I	ADV	B
fed	I-I	VERB	O
groups	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
positive	O	ADJ	B
change	O	NOUN	O
for	O	ADP	O
the	O	DET	O
dimensions	O	NOUN	B
physical	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
emotional	I-OUT	ADJ	B
functioning	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
dyspnea	I-OUT	NOUN	B
(	O	PUNCT	O
with	O	ADP	O
significance	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
,	O	PUNCT	O
P=0.050,0.031,0.045	O	NOUN	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Group	O	PROPN	B
III	O	PROPN	O
showed	O	VERB	O
a	O	DET	O
negative	O	ADJ	B
change	O	NOUN	O
in	O	ADP	O
appetite	B-OUT	NOUN	O
(	O	PUNCT	O
P=0.049	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Between	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
group	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
both	B-I	CCONJ	O
pre-fed	I-I	ADJ	B
groups	I-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
favour	O	NOUN	O
of	O	ADP	O
group	O	NOUN	B
III	O	NUM	I
compared	O	VERB	B
to	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Enteral	B-I	ADJ	B
nutrition	I-I	NOUN	I
improves	O	VERB	O
QOL	B-OUT	PROPN	B
of	O	ADP	O
severely	O	ADV	B
malnourished	O	ADJ	I
head	O	NOUN	O
and	O	CCONJ	O
neck	O	NOUN	O
cancer	O	NOUN	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
period	O	NOUN	B
preceding	O	VERB	O
surgery	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
benefit	O	NOUN	O
of	O	ADP	O
preoperative	B-I	ADJ	B
enteral	I-I	ADJ	B
feeding	I-I	NOUN	B
on	O	ADP	O
QOL	B-OUT	PROPN	B
could	O	AUX	O
be	O	AUX	O
demonstrated	O	VERB	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
a	O	DET	O
high	B-I	ADJ	B
protein	I-I	NOUN	I
,	I-I	PUNCT	O
low	I-I	ADJ	B
carbohydrate	I-I	NOUN	I
diet	I-I	NOUN	I
for	O	ADP	O
weight	O	NOUN	B
loss	O	NOUN	I
in	O	ADP	O
severely	B-P	ADV	B
obese	I-P	ADJ	B
adolescents	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
a	O	DET	O
carbohydrate	B-I	NOUN	B
restricted	I-I	ADJ	O
versus	I-I	CCONJ	O
a	I-I	DET	O
low	I-I	ADJ	B
fat	I-I	ADJ	B
diet	I-I	NOUN	I
on	O	ADP	O
weight	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
metabolic	I-OUT	ADJ	B
markers	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
composition	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cardiac	B-OUT	ADJ	B
function	I-OUT	NOUN	I
tests	I-OUT	NOUN	I
in	O	ADP	O
severely	B-P	ADV	B
obese	I-P	ADJ	B
adolescents	I-P	NOUN	B
.	I-P	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
Subjects	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
1	O	NUM	O
of	O	ADP	O
2	O	NUM	O
diets	B-I	NOUN	B
:	I-I	PUNCT	O
a	I-I	DET	O
high	I-I	ADJ	B
protein	I-I	NOUN	I
,	I-I	PUNCT	O
low	I-I	ADJ	B
carbohydrate	I-I	NOUN	I
(	I-I	PUNCT	O
20	I-I	NUM	O
g/d	I-I	NOUN	O
)	I-I	PUNCT	O
diet	I-I	NOUN	B
(	I-I	PUNCT	O
high	I-I	ADJ	B
protein	I-I	NOUN	I
,	I-I	PUNCT	O
low	I-I	ADJ	B
carbohydrate	I-I	NOUN	I
,	I-I	PUNCT	O
HPLC	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
low	I-I	ADJ	B
fat	I-I	NOUN	I
(	I-I	PUNCT	O
30	I-I	NUM	O
%	I-I	NOUN	O
of	I-I	ADP	O
calories	I-I	NOUN	B
)	I-I	PUNCT	O
regimen	I-I	NOUN	B
for	I-I	ADP	O
13	I-I	NUM	O
weeks	I-I	NOUN	B
;	I-I	PUNCT	O
close	O	ADJ	O
monitoring	O	NOUN	B
was	O	AUX	O
maintained	O	ADJ	B
to	O	PART	O
evaluate	O	VERB	B
safety	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
clinical	O	ADJ	B
contact	O	NOUN	O
was	O	AUX	O
made	O	VERB	O
until	O	ADP	O
follow-up	O	ADJ	B
measurements	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
at	O	ADP	O
24	O	NUM	O
and	O	CCONJ	O
36	O	NUM	O
weeks	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
change	B-OUT	NOUN	O
in	I-OUT	ADP	O
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
Z-score	I-OUT	NOUN	B
for	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
sex	O	NOUN	B
(	B-OUT	PUNCT	O
BMI-Z	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
at	O	ADP	O
13	O	NUM	O
,	O	PUNCT	O
24	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
36	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Forty-six	B-P	NUM	O
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
24	I-P	NUM	O
HPLC	I-P	NOUN	B
,	I-P	PUNCT	O
22	I-P	NUM	O
in	I-P	ADP	O
low	I-P	ADJ	B
fat	I-P	NOUN	I
)	I-P	PUNCT	O
initiated	I-P	VERB	B
and	I-P	CCONJ	O
33	I-P	NUM	O
subjects	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
intervention	I-P	NOUN	B
;	I-P	PUNCT	O
follow-up	O	ADJ	B
data	O	NOUN	B
were	O	AUX	O
available	O	ADJ	O
on	O	ADP	O
approximately	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
reduction	O	NOUN	B
in	O	ADP	O
(	B-OUT	PUNCT	O
BMI-Z	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
during	O	ADP	O
intervention	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
for	O	ADP	O
the	O	DET	O
HPLC	O	NOUN	B
group	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	DET	O
groups	O	NOUN	B
maintained	O	VERB	O
significant	O	ADJ	B
BMI-Z	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
at	O	ADP	O
follow-up	O	NOUN	B
;	O	PUNCT	O
changes	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
lean	B-OUT	ADJ	O
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
was	O	AUX	O
not	O	PART	O
spared	O	VERB	O
in	O	ADP	O
the	O	DET	O
HPLC	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
serious	B-OUT	ADJ	O
adverse	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	O
related	O	ADJ	O
to	O	PART	O
metabolic	B-OUT	ADJ	B
profiles	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
cardiac	I-OUT	ADJ	B
function	I-OUT	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
subjective	B-OUT	ADJ	B
complaints	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
HPLC	B-I	NOUN	B
diet	O	NOUN	I
is	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
option	O	NOUN	O
for	O	ADP	O
medically	O	ADV	B
supervised	O	VERB	I
weight	O	NOUN	B
loss	O	NOUN	I
in	O	ADP	O
severely	B-P	ADV	B
obese	I-P	ADJ	B
adolescents	I-P	NOUN	B
.	I-P	PUNCT	O


Computer-Assisted	B-I	ADJ	B
Face	I-I	PROPN	I
Processing	I-I	PROPN	I
Instruction	I-I	PROPN	O
Improves	O	PROPN	B
Emotion	B-OUT	PROPN	B
Recognition	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
Mentalizing	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Social	I-OUT	PROPN	B
Skills	I-OUT	PROPN	I
in	O	ADP	O
Students	B-P	PROPN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
extent	O	NOUN	O
to	O	PART	O
which	O	DET	O
a	O	DET	O
computer-based	B-I	ADJ	B
social	I-I	ADJ	B
skills	I-I	NOUN	I
intervention	I-I	NOUN	B
called	I-I	VERB	O
FaceSay	I-I	PROPN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
improvements	O	NOUN	B
in	O	ADP	O
affect	B-OUT	VERB	O
recognition	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
mentalizing	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
social	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
of	O	ADP	O
school-aged	B-P	ADJ	B
children	I-P	NOUN	I
with	I-P	ADP	O
Autism	I-P	PROPN	B
Spectrum	I-P	PROPN	I
Disorder	I-P	PROPN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


FaceSay	B-I	PROPN	B
offers	O	VERB	O
students	B-P	NOUN	B
simulated	O	VERB	O
practice	O	NOUN	O
with	O	ADP	O
eye	B-OUT	NOUN	B
gaze	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
joint	I-OUT	ADJ	B
attention	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
facial	I-OUT	ADJ	B
recognition	I-OUT	NOUN	I
skills	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
control	O	NOUN	I
trial	O	NOUN	I
included	O	VERB	O
school-aged	B-P	ADJ	B
children	I-P	NOUN	O
meeting	I-P	NOUN	O
educational	I-P	ADJ	B
criteria	I-P	NOUN	I
for	I-P	ADP	O
autism	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
31	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Results	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
participants	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
intervention	O	NOUN	B
improved	O	VERB	O
their	O	PRON	O
affect	B-OUT	NOUN	O
recognition	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mentalizing	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
as	I-OUT	ADV	O
well	I-OUT	ADV	O
as	I-OUT	ADP	O
their	I-OUT	PRON	O
social	I-OUT	ADJ	B
skills	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
by	O	ADP	O
targeting	O	VERB	B
face-processing	O	ADJ	B
skills	O	NOUN	I
,	O	PUNCT	O
computer-based	O	ADJ	B
interventions	O	NOUN	I
may	O	AUX	O
produce	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
broader	B-OUT	ADJ	O
cognitive	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
social-skills	I-OUT	ADJ	B
domains	I-OUT	NOUN	I
in	O	ADP	O
a	O	DET	O
cost-	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
time-efficient	I-OUT	ADJ	B
manner	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Association	O	NOUN	B
of	O	ADP	O
efavirenz	B-I	NOUN	B
hypersusceptibility	O	NOUN	B
with	O	ADP	O
virologic	O	ADJ	B
response	O	NOUN	I
in	O	ADP	O
ACTG	B-I	NOUN	B
368	I-I	NUM	O
,	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
abacavir	B-I	NOUN	B
(	I-I	PUNCT	O
ABC	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
efavirenz	B-I	NOUN	B
(	I-I	PUNCT	O
EFV	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
indinavir	B-I	NOUN	B
(	I-I	PUNCT	O
IDV	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
HIV-infected	B-P	ADJ	B
subjects	I-P	NOUN	B
with	I-P	ADP	O
prior	I-P	ADJ	O
nucleoside	I-P	NOUN	B
analog	I-P	NOUN	I
experience	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
efavirenz	O	NOUN	B
hypersusceptibility	O	NOUN	B
(	O	PUNCT	O
EFV-HS	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
clinical	O	ADJ	B
outcome	O	NOUN	I
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
EFV	B-I	NOUN	B
plus	I-I	CCONJ	O
indinavir	I-I	NOUN	B
(	I-I	PUNCT	O
EFV+IDV	I-I	NOUN	B
)	I-I	PUNCT	O
vs.	I-I	CCONJ	O
EFV+IDV	I-I	NOUN	B
plus	I-I	CCONJ	O
abacavir	I-I	NOUN	B
(	I-I	PUNCT	O
ABC	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
283	B-P	NUM	O
nucleoside-experienced	I-P	ADJ	B
HIV-infected	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


METHOD	O	NOUN	B
AND	O	CCONJ	O
RESULTS	O	NOUN	O
Rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
virologic	I-OUT	ADJ	B
failure	I-OUT	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
arms	O	NOUN	O
at	O	ADP	O
week	O	NOUN	B
16	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.509	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Treatment	B-OUT	NOUN	B
discontinuations	I-OUT	NOUN	B
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
the	O	DET	O
ABC	O	PROPN	B
arm	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Using	O	VERB	O
logistic	O	ADJ	B
regression	O	NOUN	I
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
association	O	NOUN	B
between	O	ADP	O
virologic	B-OUT	ADJ	B
failure	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
either	I-OUT	CCONJ	O
baseline	I-OUT	NOUN	B
ABC	I-OUT	NOUN	B
resistance	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
regimen	I-OUT	NOUN	B
sensitivity	I-OUT	NOUN	O
score	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Using	O	VERB	O
3	O	NUM	O
different	O	ADJ	O
genotypic	O	ADJ	B
scoring	O	NOUN	I
systems	O	NOUN	I
,	O	PUNCT	O
EFV-HS	B-I	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
reduced	B-OUT	VERB	B
virologic	I-OUT	ADJ	B
failure	I-OUT	NOUN	I
at	O	ADP	O
week	O	NOUN	B
16	O	NUM	O
,	O	PUNCT	O
independent	O	ADJ	B
of	O	ADP	O
treatment	O	NOUN	B
assignment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
on	O	ADP	O
the	O	DET	O
nucleoside-sparing	O	ADJ	B
arm	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
nucleoside-resistance	O	NOUN	B
mutation	O	NOUN	I
L74V	O	NOUN	B
was	O	AUX	O
selected	O	VERB	O
for	O	ADP	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
the	O	DET	O
uncommonly	O	ADV	O
occurring	O	VERB	O
EFV-resistance	O	ADJ	B
mutations	O	NOUN	B
K103N+L100I	O	NOUN	B
;	O	PUNCT	O
L74V	O	NOUN	B
was	O	AUX	O
not	O	PART	O
detected	O	VERB	O
as	O	ADP	O
a	O	DET	O
minority	O	NOUN	B
variant	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
clonal	O	ADJ	B
sequence	O	NOUN	I
analysis	O	NOUN	I
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
nucleoside-sparing	O	ADJ	B
regimen	O	NOUN	I
was	O	AUX	O
initiated	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
Premature	O	ADJ	B
treatment	B-OUT	NOUN	I
discontinuations	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
ABC	O	PROPN	B
arm	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
EFV-HS	B-I	NOUN	B
HIV	I-I	NOUN	B
variants	O	NOUN	B
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
population	O	NOUN	I
likely	O	ADV	O
made	O	VERB	O
it	O	PRON	O
difficult	O	ADJ	O
to	O	PART	O
detect	O	VERB	B
a	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
adding	B-OUT	VERB	O
ABC	I-OUT	PROPN	B
to	I-OUT	PART	O
EFV+IDV	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
L74V	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
combined	O	VERB	O
with	O	ADP	O
K103N+L100I	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
confer	O	VERB	O
a	O	DET	O
selective	O	ADJ	O
advantage	O	NOUN	O
to	O	PART	O
the	O	DET	O
virus	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
independent	O	ADJ	B
of	O	ADP	O
its	O	PRON	O
effects	B-OUT	NOUN	B
on	I-OUT	ADP	O
nucleoside	I-OUT	NOUN	B
resistance	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Is	O	AUX	O
psychotherapy	B-I	NOUN	B
more	O	ADV	O
effective	O	ADJ	B
when	O	SCONJ	O
therapists	B-P	NOUN	B
disclose	O	VERB	O
information	O	NOUN	B
about	O	ADP	O
themselves	O	PRON	O
?	O	PUNCT	O
Theorists	O	NOUN	B
have	O	AUX	O
long	O	ADV	O
debated	O	VERB	O
the	O	DET	O
wisdom	O	NOUN	B
of	O	ADP	O
therapists	B-P	NOUN	B
disclosing	I-OUT	VERB	O
personal	I-OUT	ADJ	B
information	I-OUT	NOUN	I
during	I-P	ADP	O
psychotherapy	I-I	NOUN	B
.	I-I	PUNCT	O


Some	O	DET	O
observers	O	NOUN	B
have	O	AUX	O
argued	O	VERB	O
that	O	SCONJ	O
such	O	ADJ	O
therapist	O	NOUN	B
self-disclosure	O	NOUN	B
impedes	O	VERB	B
treatment	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
others	O	NOUN	O
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
enhances	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
of	I-OUT	ADP	O
therapy	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


To	O	PART	O
test	O	VERB	O
these	O	DET	O
competing	O	VERB	O
positions	O	NOUN	B
,	O	PUNCT	O
therapists	B-P	NOUN	B
at	I-P	ADP	O
a	I-P	DET	O
university	I-P	NOUN	B
counseling	I-P	NOUN	I
center	I-P	NOUN	I
were	O	AUX	O
instructed	O	VERB	O
to	O	PART	O
increase	B-I	VERB	B
the	I-I	DET	O
number	I-I	NOUN	O
of	I-I	ADP	O
self-disclosures	I-I	NOUN	B
they	O	PRON	O
made	O	VERB	O
during	O	ADP	O
treatment	B-I	NOUN	B
of	O	ADP	O
one	B-P	NUM	O
client	I-P	NOUN	B
and	O	CCONJ	O
refrain	B-I	VERB	O
from	I-I	ADP	O
making	I-I	VERB	O
self-disclosures	I-I	NOUN	B
during	I-I	ADP	O
treatment	I-I	NOUN	B
of	O	ADP	O
another	B-P	DET	O
client	I-P	NOUN	B
.	I-P	PUNCT	O


Analyses	O	NOUN	B
revealed	O	VERB	O
that	O	SCONJ	O
clients	O	NOUN	B
receiving	O	VERB	O
psychotherapy	B-I	NOUN	B
under	O	ADP	O
conditions	O	NOUN	B
of	O	ADP	O
heightened	O	ADJ	B
therapist	B-I	NOUN	B
disclosure	I-I	NOUN	B
not	O	PART	O
only	O	ADV	O
reported	O	VERB	O
lower	B-OUT	ADJ	O
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
symptom	I-OUT	NOUN	B
distress	I-OUT	NOUN	I
but	O	CCONJ	O
also	O	ADV	O
liked	B-OUT	VERB	O
their	I-OUT	PRON	O
therapist	I-OUT	NOUN	B
more	I-OUT	ADV	O
.	I-OUT	PUNCT	O


Such	O	ADJ	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
self-disclosure	O	NOUN	B
by	O	ADP	O
the	O	DET	O
therapist	O	NOUN	B
may	O	AUX	O
improve	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
therapeutic	I-OUT	ADJ	B
relationship	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
outcome	I-OUT	NOUN	B
of	I-OUT	ADP	O
treatment	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Efficacy	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
tobacco	B-I	NOUN	B
quitline	I-I	NOUN	I
among	O	ADP	O
adult	B-P	ADJ	B
cancer	I-P	NOUN	B
survivors	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
(	B-P	PUNCT	O
conducted	I-P	VERB	O
2010-2013	I-P	NUM	O
)	I-P	PUNCT	O
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
common	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
tobacco	B-I	NOUN	B
quitlines	I-I	NOUN	I
in	O	ADP	O
adult	B-P	ADJ	B
cancer	I-P	NOUN	O
survivors	I-P	NOUN	B
who	I-P	PRON	O
regularly	I-P	ADV	O
smoked	I-P	VERB	B
cigarettes	I-P	NOUN	I
.	I-P	PUNCT	O


METHOD	O	PROPN	O
Adult	B-P	ADJ	B
onset	I-P	NOUN	O
cancer	I-P	NOUN	O
survivors	I-P	NOUN	B
in	I-P	ADP	O
Memphis	I-P	PROPN	B
,	I-P	PUNCT	O
Tennessee	I-P	PROPN	B
(	I-P	PUNCT	O
n=427	I-P	PROPN	O
,	I-P	PUNCT	O
67	I-P	NUM	O
%	I-P	NOUN	O
female	I-P	NOUN	B
,	I-P	PUNCT	O
60	I-P	NUM	O
%	I-P	NOUN	O
Caucasian	I-P	ADJ	B
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
either	O	CCONJ	O
to	O	ADP	O
a	O	DET	O
Proactive	B-I	ADJ	B
(	I-I	PUNCT	O
i.e.	I-I	X	O
,	O	PUNCT	O
counselor-initiated	B-I	ADJ	B
calls	I-I	NOUN	I
)	I-I	PUNCT	O
or	O	CCONJ	O
Reactive	B-I	ADJ	B
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
participant-initiated	B-I	ADJ	O
calls	I-I	NOUN	O
)	I-I	PUNCT	O
quitline	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
conditions	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
nicotine	B-I	NOUN	B
replacement	I-I	NOUN	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
biochemically-verified	O	ADJ	B
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
salivary	O	ADJ	B
cotinine	O	NOUN	I
)	O	PUNCT	O
smoking	B-OUT	NOUN	B
cessation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
While	O	SCONJ	O
12-month	O	ADJ	O
self-reported	O	ADJ	B
abstinence	O	NOUN	B
was	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
other	O	ADJ	O
published	O	VERB	B
studies	O	NOUN	I
of	O	ADP	O
smoking	B-OUT	NOUN	B
cessation	I-OUT	NOUN	I
(	O	PUNCT	O
22	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
26	O	NUM	O
%	O	NOUN	O
point	O	NOUN	B
prevalence	O	NOUN	I
abstinence	O	NOUN	B
for	O	ADP	O
Proactive	O	ADJ	B
and	O	CCONJ	O
Reactive	O	ADJ	B
conditions	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
participants	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
cotinine	O	NOUN	B
failed	O	VERB	O
biochemical	O	ADJ	B
verification	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
a	O	DET	O
considerable	O	ADJ	O
falsification	O	NOUN	B
of	O	ADP	O
self-reported	B-OUT	ADJ	B
cessation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Adjusted	B-OUT	ADJ	B
cessation	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
both	O	DET	O
intervention	O	NOUN	B
conditions	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	VERB	O
Our	O	PRON	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
other	O	ADJ	O
studies	O	NOUN	B
indicating	O	VERB	O
that	O	SCONJ	O
traditional	B-OUT	ADJ	B
smoking	I-OUT	NOUN	B
cessation	I-OUT	NOUN	B
interventions	I-OUT	NOUN	B
are	O	AUX	O
ineffective	O	ADJ	B
among	O	ADP	O
cancer	O	NOUN	B
survivors	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
self-reports	B-OUT	NOUN	B
of	I-OUT	ADP	O
cessation	I-OUT	NOUN	B
were	O	AUX	O
unreliable	O	ADJ	O
in	O	ADP	O
cancer	O	NOUN	B
survivors	O	NOUN	I
participating	O	VERB	O
in	O	ADP	O
a	O	DET	O
quitline	B-I	NOUN	B
intervention	I-I	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
future	O	ADJ	O
studies	O	NOUN	B
should	O	AUX	O
include	O	VERB	O
biochemical	O	ADJ	B
verification	O	NOUN	B
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
smoking	O	NOUN	B
cessation	O	NOUN	B
among	O	ADP	O
cancer	B-P	NOUN	B
survivors	I-P	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
cessation	B-OUT	NOUN	B
rates	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
design	O	VERB	B
alternative	O	ADJ	B
interventions	O	NOUN	B
for	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


ClinicalTrials.gov	O	NOUN	B
identifier	O	NOUN	I
:	O	PUNCT	O
NCT00827866	O	PROPN	O
.	O	PUNCT	O


Evidence	O	NOUN	B
for	O	ADP	O
diminished	O	VERB	B
multisensory	B-OUT	ADJ	B
integration	I-OUT	NOUN	B
in	O	ADP	O
autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
.	I-P	PUNCT	O


Individuals	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
exhibit	O	VERB	O
alterations	O	NOUN	B
in	O	ADP	O
sensory	O	ADJ	B
processing	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
integration	O	NOUN	B
of	O	ADP	O
information	O	NOUN	B
across	O	ADP	O
the	O	DET	O
different	O	ADJ	O
sensory	O	ADJ	B
modalities	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
used	O	VERB	O
the	O	DET	O
sound-induced	B-I	ADJ	B
flash	I-I	NOUN	I
illusion	I-I	NOUN	I
to	O	PART	O
assess	O	VERB	O
multisensory	B-OUT	ADJ	B
integration	I-OUT	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	VERB	B
and	I-P	CCONJ	O
typically-developing	I-P	ADJ	B
(	I-P	PUNCT	O
TD	I-P	NOUN	B
)	I-P	PUNCT	O
controls	I-P	NOUN	B
.	I-P	PUNCT	O


Thirty-one	B-P	NUM	B
children	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	VERB	B
and	I-P	CCONJ	O
31	I-P	NUM	O
age	I-P	NOUN	B
and	I-P	CCONJ	O
IQ	I-P	NOUN	B
matched	I-P	VERB	O
TD	I-P	ADJ	B
children	I-P	NOUN	B
(	I-P	PUNCT	O
average	I-P	ADJ	O
age	I-P	NOUN	B
=	I-P	ADJ	O
12	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
presented	O	VERB	O
with	B-I	ADP	O
simple	I-I	ADJ	O
visual	I-I	NOUN	B
(	I-I	PUNCT	O
i.e.	I-I	X	O
,	O	PUNCT	O
flash	B-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
auditory	I-I	ADJ	B
(	I-I	PUNCT	O
i.e.	I-I	X	O
,	O	PUNCT	O
beep	B-I	NOUN	B
)	I-I	PUNCT	O
stimuli	I-I	NOUN	B
of	I-I	ADP	O
varying	I-I	VERB	O
number	I-I	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
illusory	O	ADJ	B
conditions	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
single	O	ADJ	O
flash	O	NOUN	O
was	O	AUX	O
presented	O	VERB	O
with	O	ADP	O
2-4	O	NUM	O
beeps	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
TD	O	ADJ	B
children	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
conditions	O	NOUN	B
generally	O	ADV	O
result	O	VERB	O
in	O	ADP	O
the	B-OUT	DET	O
perception	I-OUT	NOUN	B
of	I-OUT	ADP	O
multiple	I-OUT	ADJ	B
flashes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
implying	I-OUT	VERB	O
a	I-OUT	DET	O
perceptual	I-OUT	ADJ	B
fusion	I-OUT	NOUN	B
across	I-OUT	ADP	O
vision	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
audition	I-OUT	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
children	O	NOUN	B
with	O	ADP	O
ASD	O	VERB	B
were	O	AUX	O
significantly	O	ADV	O
less	O	ADV	O
likely	O	ADJ	O
to	B-OUT	PART	O
perceive	I-OUT	VERB	O
the	I-OUT	DET	O
illusion	I-OUT	NOUN	B
relative	O	ADJ	O
to	O	PART	O
TD	O	ADJ	B
controls	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	B-OUT	SCONJ	O
multisensory	I-OUT	ADJ	B
integration	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
cross-modal	I-OUT	ADJ	B
binding	I-OUT	NOUN	I
may	O	AUX	O
be	O	AUX	O
weaker	O	ADJ	O
in	O	ADP	O
some	O	DET	O
children	O	NOUN	B
with	O	ADP	O
ASD	B-P	PROPN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
previous	O	ADJ	O
findings	O	NOUN	B
for	B-OUT	ADP	O
multisensory	I-OUT	ADJ	B
integration	I-OUT	NOUN	B
in	O	ADP	O
ASD	O	VERB	B
and	O	CCONJ	O
future	O	ADJ	O
directions	O	NOUN	B
for	O	ADP	O
research	O	NOUN	B
.	O	PUNCT	O


Alleviating	O	VERB	B
social	O	ADJ	B
avoidance	O	NOUN	I
:	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	I
single	B-I	ADJ	B
dose	I-I	NOUN	I
testosterone	I-I	NOUN	B
administration	I-I	NOUN	B
on	O	ADP	O
approach-avoidance	B-OUT	ADJ	B
action	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Testosterone	B-I	NOUN	B
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
regulator	O	NOUN	B
of	O	ADP	O
social-motivational	B-OUT	ADJ	B
behavior	I-OUT	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
known	O	VERB	O
for	O	ADP	O
its	O	PRON	O
dominance-enhancing	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
social-anxiolytic	I-OUT	ADJ	B
properties	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
date	O	VERB	O
no	O	DET	O
studies	O	NOUN	O
have	O	AUX	O
systematically	O	ADV	B
investigated	O	VERB	B
the	O	DET	O
causal	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
testosterone	O	NOUN	B
on	O	ADP	O
actual	B-OUT	ADJ	B
social	I-OUT	ADJ	B
approach-avoidance	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
sets	O	VERB	I
out	O	ADP	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
testosterone	B-I	NOUN	B
administration	I-I	NOUN	B
in	O	ADP	O
healthy	B-P	ADJ	B
female	I-P	ADJ	O
volunteers	I-P	NOUN	O
using	I-P	VERB	O
an	I-P	DET	O
objective	I-P	ADJ	O
implicit	I-P	NOUN	B
measure	I-P	NOUN	B
of	I-P	ADP	O
social	I-OUT	ADJ	B
motivational	I-OUT	ADJ	O
behavior	I-OUT	NOUN	O
:	I-OUT	PUNCT	O
the	O	DET	O
social	B-OUT	ADJ	B
Approach-Avoidance	I-OUT	PROPN	I
Task	I-OUT	PROPN	I
,	O	PUNCT	O
a	O	DET	O
reaction	O	NOUN	B
time	O	NOUN	I
task	O	NOUN	I
requiring	O	VERB	O
participants	O	NOUN	B
to	O	PART	O
approach	B-OUT	VERB	O
or	I-OUT	CCONJ	O
avoid	I-OUT	VERB	O
visually	I-OUT	ADV	B
presented	I-OUT	VERB	O
emotional	I-OUT	ADJ	B
(	I-OUT	PUNCT	O
happy	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
angry	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
neutral	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
faces	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Participants	O	NOUN	B
showed	O	VERB	O
significantly	O	ADV	O
diminished	O	VERB	B
avoidance	B-OUT	NOUN	B
tendencies	I-OUT	NOUN	B
to	O	PART	O
angry	B-OUT	ADJ	B
faces	I-OUT	NOUN	I
after	O	ADP	O
testosterone	B-I	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Testosterone	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
approach-avoidance	B-OUT	ADJ	B
tendencies	I-OUT	NOUN	B
to	I-OUT	PART	O
social	I-OUT	ADJ	B
affiliation	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
happy	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
faces	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
testosterone	B-I	NOUN	B
administration	O	NOUN	B
reduces	O	VERB	B
automatic	B-OUT	ADJ	B
avoidance	I-OUT	NOUN	I
of	I-OUT	ADP	O
social	I-OUT	ADJ	B
threat	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
promotes	I-OUT	VERB	B
relative	I-OUT	ADJ	O
increase	I-OUT	NOUN	B
of	I-OUT	ADP	O
threat	I-OUT	NOUN	B
approach	I-OUT	NOUN	O
tendencies	I-OUT	NOUN	B
in	O	ADP	O
healthy	B-P	ADJ	B
females	I-P	NOUN	B
.	I-P	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
further	O	ADV	O
the	O	DET	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
neuroendocrine	O	ADJ	B
regulation	O	NOUN	I
of	O	ADP	O
social	B-OUT	ADJ	B
motivational	I-OUT	ADJ	I
behavior	I-OUT	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
have	O	AUX	O
direct	O	ADJ	O
treatment	O	NOUN	B
implications	O	NOUN	O
for	O	ADP	O
social	B-OUT	ADJ	B
anxiety	I-OUT	NOUN	I
,	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
persistent	O	ADJ	B
social	B-OUT	ADJ	B
avoidance	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Electrothermal	B-I	ADJ	B
arthroscopic	I-I	ADJ	I
capsulorrhaphy	I-I	NOUN	I
:	I-I	PUNCT	O
old	O	ADJ	B
technology	O	NOUN	I
,	O	PUNCT	O
new	O	ADJ	O
evidence	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
multicenter	O	NOUN	B
randomized	O	ADJ	O
clinical	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Radiofrequency	O	NOUN	B
technology	O	NOUN	I
for	O	ADP	O
shoulder	B-P	NOUN	B
instability	I-P	NOUN	B
was	O	AUX	O
rapidly	O	ADV	O
adopted	O	VERB	O
despite	O	SCONJ	O
limited	O	ADJ	O
clinical	O	ADJ	B
evidence	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
poor	O	ADJ	O
understanding	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
indications	O	NOUN	B
.	O	PUNCT	O


Reports	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
followed	O	VERB	O
,	O	PUNCT	O
leading	O	VERB	O
to	O	ADP	O
its	O	PRON	O
abandonment	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
paper	O	NOUN	O
presents	O	VERB	O
findings	O	NOUN	B
from	O	ADP	O
a	O	DET	O
multicenter	O	NOUN	B
randomized	O	ADJ	O
clinical	O	ADJ	O
trial	O	NOUN	O
evaluating	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
electrothermal	B-I	ADJ	B
arthroscopic	I-I	ADJ	I
capsulorrhaphy	I-I	NOUN	I
(	I-I	PUNCT	O
ETAC	I-I	NOUN	B
)	I-I	PUNCT	O
compared	I-I	VERB	B
with	I-I	ADP	O
open	I-I	ADJ	B
inferior	I-I	ADJ	I
capsular	I-I	ADJ	I
shift	I-I	NOUN	I
(	I-I	PUNCT	O
ICS	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
reviews	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
randomized	O	ADJ	B
trials	O	NOUN	I
in	O	ADP	O
adopting	O	VERB	O
new	O	ADJ	O
technology	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
(	I-P	PUNCT	O
>	I-P	NOUN	O
14	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
diagnosed	I-P	VERB	B
with	I-P	ADP	O
multidirectional	I-P	ADJ	B
instability	I-P	NOUN	I
or	I-P	CCONJ	O
multidirectional	I-P	ADJ	B
laxity	I-P	NOUN	I
with	I-P	ADP	O
anteroinferior	I-P	ADJ	B
instability	I-P	NOUN	I
and	I-P	CCONJ	O
failed	I-P	VERB	B
nonoperative	I-P	ADJ	B
treatment	I-P	NOUN	I
were	I-P	AUX	O
enrolled	I-P	VERB	O
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
bone	I-P	NOUN	B
lesions	I-P	NOUN	I
or	I-P	CCONJ	O
labral	I-P	ADJ	B
,	I-P	PUNCT	O
biceps	I-P	NOUN	B
anchor	I-P	NOUN	I
,	I-P	PUNCT	O
or	I-P	CCONJ	O
full-thickness	I-P	ADJ	B
rotator	I-P	NOUN	O
cuff	I-P	NOUN	O
tears	I-P	NOUN	O
were	I-P	AUX	O
excluded	I-P	VERB	O
intraoperatively	I-P	ADV	B
.	I-P	PUNCT	O


Outcomes	O	NOUN	B
included	B-OUT	VERB	O
Western	I-OUT	PROPN	B
Ontario	I-OUT	PROPN	I
Shoulder	I-OUT	PROPN	I
Instability	I-OUT	PROPN	I
Index	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
function	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
recurrent	I-OUT	ADJ	B
instability	I-OUT	NOUN	I
at	I-OUT	ADP	O
2	I-OUT	NUM	O
years	I-OUT	NOUN	B
postoperatively	I-OUT	ADV	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
surgical	I-OUT	ADJ	B
times	I-OUT	NOUN	I
.	O	PUNCT	O


RESULTS	B-P	VERB	O
Fifty-four	I-P	NUM	O
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	NOUN	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
23	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
37	I-P	NUM	O
women	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
ETAC	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
28	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
open	O	ADJ	B
ICS	O	NOUN	I
(	B-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
26	I-P	NUM	O
)	I-P	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
except	B-OUT	SCONJ	O
for	I-OUT	ADP	O
external	I-OUT	ADJ	B
rotation	I-OUT	NOUN	B
at	I-OUT	ADP	O
the	I-OUT	DET	O
side	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
postoperatively	O	ADV	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
statistically	O	ADV	O
or	O	CCONJ	O
clinically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
for	B-OUT	ADP	O
the	I-OUT	DET	O
Western	I-OUT	PROPN	B
Ontario	I-OUT	PROPN	I
Shoulder	I-OUT	PROPN	I
Instability	I-OUT	PROPN	I
Index	O	PROPN	I
(	B-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
.71	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
American	I-OUT	ADJ	B
Shoulder	I-OUT	PROPN	I
and	I-OUT	CCONJ	I
Elbow	I-OUT	PROPN	I
Surgeons	I-OUT	PROPN	I
score	O	NOUN	I
(	B-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
.43	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Constant	I-OUT	ADJ	B
score	O	NOUN	I
(	B-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
.43	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
active	I-OUT	ADJ	B
range	I-OUT	NOUN	I
of	I-OUT	ADP	I
motion	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Recurrent	B-OUT	ADJ	B
instability	O	NOUN	I
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	O
different	O	ADJ	O
(	O	PUNCT	O
ETAC	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
;	O	PUNCT	O
open	O	ADJ	O
,	O	PUNCT	O
4	B-OUT	NUM	O
;	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
.41	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


ETAC	O	NOUN	B
(	O	PUNCT	O
23	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	O
than	O	ADP	O
open	O	ADJ	B
ICS	O	NOUN	I
(	O	PUNCT	O
59	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.01	O	NUM	O
)	O	PUNCT	O
surgery	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
subjects	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
ETAC	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
open	O	ADJ	O
)	O	PUNCT	O
had	O	AUX	O
stiff	O	ADJ	B
shoulders	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
At	O	ADP	O
2	O	NUM	O
years	B-OUT	NOUN	B
postoperatively	I-OUT	ADV	B
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
functional	O	ADJ	B
outcomes	O	NOUN	I
between	O	ADP	O
groups	O	NOUN	B
were	O	AUX	O
not	O	PART	O
clinically	O	ADV	B
different	B-OUT	ADJ	O
.	I-OUT	PUNCT	O


ETAC	B-OUT	NOUN	B
had	I-OUT	AUX	O
fewer	I-OUT	ADJ	O
complications	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
episodes	I-OUT	NOUN	B
of	O	ADP	O
recurrence	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
open	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
evidence	O	NOUN	B
reinforces	O	VERB	O
the	O	DET	O
need	O	NOUN	O
to	O	PART	O
critically	O	ADV	O
evaluate	O	VERB	B
new	O	ADJ	O
technology	O	NOUN	B
before	O	ADP	O
widespread	O	ADJ	O
clinical	O	ADJ	B
use	O	NOUN	O
.	O	PUNCT	O


Toxicity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	O	ADP	O
6-thioguanine	B-I	NOUN	B
versus	I-I	CCONJ	O
6-mercaptopurine	I-I	NOUN	B
in	O	ADP	O
childhood	B-P	NOUN	B
lymphoblastic	I-P	ADJ	I
leukaemia	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
6-mercaptopurine	B-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
a	O	DET	O
standard	O	ADJ	O
component	O	NOUN	B
of	O	ADP	O
long-term	O	ADJ	B
continuing	O	VERB	B
treatment	O	NOUN	I
for	O	ADP	O
childhood	B-P	NOUN	B
lymphoblastic	I-P	ADJ	I
leukaemia	I-P	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
6-thioguanine	B-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
mainly	O	ADV	O
used	O	VERB	O
for	O	ADP	O
intensification	O	NOUN	B
courses	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
preliminary	O	ADJ	B
data	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
6-thioguanine	B-I	NOUN	B
is	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
6-mercaptopurine	B-I	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
compared	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
drugs	O	NOUN	B
for	O	ADP	O
childhood	B-P	NOUN	B
lymphoblastic	I-P	ADJ	I
leukaemia	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Consecutive	B-P	ADJ	B
children	I-P	NOUN	B
with	I-P	ADP	O
lymphoblastic	I-P	ADJ	B
leukaemia	I-P	NOUN	I
diagnosed	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
UK	I-P	PROPN	B
and	I-P	CCONJ	O
Ireland	I-P	PROPN	B
between	I-P	ADP	O
April	I-P	PROPN	O
,	I-P	PUNCT	O
1997	I-P	NUM	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
June	I-P	PROPN	O
,	I-P	PUNCT	O
2002	I-P	NUM	O
,	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
either	O	CCONJ	O
6-thioguanine	B-I	NOUN	B
(	I-I	PUNCT	O
750	I-I	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
6-mercaptopurine	B-I	NOUN	B
(	O	PUNCT	O
748	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
interim	O	ADJ	B
maintenance	O	NOUN	B
and	O	CCONJ	O
continuing	O	VERB	B
therapy	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
6-thioguanine	B-I	NOUN	B
during	O	ADP	O
intensification	O	NOUN	B
courses	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
analysed	O	VERB	O
event-free	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
on	O	ADP	O
an	O	DET	O
intention-to-treat	O	ADJ	B
basis	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
obtained	O	VERB	O
toxicity	B-OUT	NOUN	B
data	O	NOUN	B
using	O	VERB	O
an	O	DET	O
adverse-event	O	ADJ	B
reporting	O	NOUN	O
system	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
follow-up	O	ADJ	B
questionnaires	O	NOUN	B
to	O	PART	O
seek	O	VERB	O
detailed	O	ADJ	O
information	O	NOUN	B
for	O	ADP	O
specific	O	ADJ	O
toxicities	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
trial	O	NOUN	B
is	O	AUX	O
registered	O	VERB	O
with	O	ADP	O
the	O	DET	O
International	O	PROPN	B
Standard	O	PROPN	I
Randomised	O	PROPN	I
Controlled	O	PROPN	I
Number	O	PROPN	I
26727615	O	NUM	I
with	O	ADP	O
the	O	DET	O
name	O	NOUN	O
ALL97	O	NOUN	B
.	O	PUNCT	O


FINDINGS	O	NOUN	B
After	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow	O	NOUN	B
up	O	ADP	I
of	O	ADP	O
6	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
event-free	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
6-thioguanine	B-I	NOUN	B
conferred	O	VERB	O
a	O	DET	O
significantly	O	ADV	O
lower	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
isolated	O	VERB	B
CNS	B-OUT	NOUN	B
relapse	I-OUT	NOUN	B
than	O	ADP	O
did	O	AUX	O
6-mercaptopurine	B-I	NOUN	B
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
[	O	PUNCT	O
OR	O	CCONJ	B
]	O	PUNCT	O
0.53	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.30-0.92	O	NUM	O
,	O	PUNCT	O
p=0.02	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
benefit	O	NOUN	B
was	O	AUX	O
offset	O	VERB	O
by	O	ADP	O
an	O	DET	O
increased	O	VERB	B
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
death	I-OUT	NOUN	B
in	O	ADP	O
remission	O	NOUN	B
(	O	PUNCT	O
2.22	O	NUM	O
,	O	PUNCT	O
1.20-4.14	O	NUM	O
,	O	PUNCT	O
p=0.01	O	INTJ	O
)	O	PUNCT	O
,	O	PUNCT	O
mainly	O	ADV	O
due	O	ADJ	O
to	O	ADP	O
infections	O	NOUN	B
during	O	ADP	O
continuing	O	VERB	B
therapy	O	NOUN	I
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
95	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
veno-occlusive	B-OUT	ADJ	B
disease	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
liver	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
82	O	NUM	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
6-thioguanine	B-I	NOUN	B
,	O	PUNCT	O
representing	O	VERB	O
11	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
6-thioguanine	B-I	ADJ	B
recipients	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
long-term	O	ADJ	B
follow-up	O	NOUN	B
,	O	PUNCT	O
about	O	ADV	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
6-thioguanine	B-I	NOUN	B
recipients	O	NOUN	B
have	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
non-cirrhotic	B-OUT	ADJ	B
portal	I-OUT	ADJ	B
hypertension	I-OUT	NOUN	I
due	O	ADP	O
to	O	PART	O
periportal	O	ADJ	B
liver	O	NOUN	B
fibrosis	O	NOUN	I
or	O	CCONJ	O
nodular	O	ADJ	B
regenerative	O	ADJ	O
hyperplasia	O	NOUN	O
.	O	PUNCT	O


INTERPRETATION	O	NOUN	B
Compared	O	VERB	B
with	O	ADP	O
6-mercaptopurine	B-I	NOUN	B
,	I-I	PUNCT	O
6-thioguanine	I-I	NOUN	B
causes	O	VERB	O
excess	O	ADJ	B
toxicity	B-OUT	NOUN	B
without	O	ADP	O
an	O	DET	O
overall	B-OUT	ADJ	O
benefit	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


6-mercaptopurine	B-I	NOUN	B
should	O	AUX	O
remain	O	VERB	O
the	O	DET	O
thiopurine	O	NOUN	B
of	O	ADP	O
choice	O	NOUN	O
for	O	ADP	O
continuing	O	VERB	B
therapy	O	NOUN	I
of	O	ADP	O
childhood	O	NOUN	B
lymphoblastic	O	ADJ	I
leukaemia	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Effects	O	NOUN	B
of	O	ADP	O
simvastatin	B-I	NOUN	B
on	O	ADP	O
plasma	B-OUT	NOUN	B
lipids	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
lipoproteins	I-OUT	NOUN	B
and	O	CCONJ	O
apoproteins	B-OUT	NOUN	B
(	O	PUNCT	O
A1	O	NOUN	B
and	O	CCONJ	O
B	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


24	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
major	O	ADJ	O
primary	O	ADJ	B
hypercholesterolemia	B-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
simvastatin	B-I	NOUN	B
(	I-I	PUNCT	O
MK	I-I	PROPN	B
733	I-I	NUM	O
)	I-I	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
competitive	O	ADJ	B
inhibitor	O	NOUN	B
of	O	ADP	O
HMG	B-I	NOUN	B
CoA	I-I	NOUN	I
reductase	I-I	NOUN	I
,	I-I	PUNCT	O
alone	I-I	ADV	O
and	I-I	CCONJ	O
in	I-I	ADP	O
combination	I-I	NOUN	B
with	I-I	ADP	O
a	I-I	DET	O
bile	I-I	NOUN	B
acid	I-I	NOUN	I
sequestrant	I-I	NOUN	B
,	I-I	PUNCT	O
cholestyramine	I-I	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
serum	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
lipoproteins	O	NOUN	B
and	O	CCONJ	O
apoproteins	O	NOUN	B
A1	O	NOUN	I
and	O	CCONJ	O
B	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
24	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
familial	I-P	ADJ	B
hypercholesterolemia	I-P	NOUN	I
.	I-P	PUNCT	O


After	O	ADP	O
simvastatin	B-I	NOUN	B
treatment	I-I	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
mg/day	O	NOUN	B
)	O	PUNCT	O
alone	O	ADV	O
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
total	O	NOUN	O
and	O	CCONJ	O
low	B-OUT	ADJ	B
density	I-OUT	NOUN	I
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
decreased	O	VERB	B
by	O	ADP	O
31	O	NUM	O
and	O	CCONJ	O
36	O	NUM	O
percent	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


With	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
cholestyramine	B-I	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
41	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
total	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
from	O	ADP	O
the	O	DET	O
control	O	NOUN	B
value	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
50	O	NUM	O
percent	O	NOUN	O
decrease	O	NOUN	B
in	O	ADP	O
low	B-OUT	ADJ	B
density	I-OUT	NOUN	I
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


After	O	ADP	O
cholestyramine	B-I	NOUN	B
treatment	I-I	NOUN	B
alone	O	ADV	O
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
serum	B-OUT	NOUN	B
total	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
low	I-OUT	ADJ	B
density	I-OUT	NOUN	I
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
decreased	O	VERB	B
by	O	ADP	O
20	O	NUM	O
percent	O	NOUN	O
and	O	CCONJ	O
29	O	NUM	O
percent	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


With	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
simvastatin	B-I	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
32	O	NUM	O
percent	O	NOUN	O
total	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
from	O	ADP	O
the	O	DET	O
control	O	NOUN	B
value	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
43	O	NUM	O
percent	O	NOUN	O
decrease	O	NOUN	B
in	O	ADP	O
low	O	ADJ	B
density	B-OUT	NOUN	I
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


High	B-OUT	ADJ	B
density	I-OUT	NOUN	I
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
remained	O	VERB	O
unchanged	O	ADJ	B
.	O	PUNCT	O


No	O	DET	O
major	B-OUT	ADJ	O
adverse	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


If	O	SCONJ	O
long	O	ADJ	B
term	O	NOUN	I
safety	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
confirmed	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
simvastatin-cholestyramine	B-I	ADJ	B
regimen	I-I	NOUN	I
may	O	AUX	O
prove	O	VERB	O
useful	O	ADJ	O
in	O	ADP	O
heterozygous	B-P	ADJ	B
familial	I-P	ADJ	B
hypercholesterolemia	I-P	NOUN	I
.	I-P	PUNCT	O


Concentration	O	NOUN	B
of	O	ADP	O
inhaled	B-I	ADJ	B
amiloride	I-I	NOUN	B
in	O	ADP	O
cystic	B-P	ADJ	B
fibrosis	I-P	NOUN	I
.	I-P	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
TENS	O	PROPN	B
on	O	ADP	O
pain	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
medications	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
pulmonary	I-OUT	ADJ	B
function	I-OUT	NOUN	I
following	I-P	VERB	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
bypass	I-P	NOUN	I
graft	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
transcutaneous	B-I	ADJ	B
electrical	I-I	ADJ	I
nerve	I-I	NOUN	I
stimulation	I-I	NOUN	I
(	I-I	PUNCT	O
TENS	I-I	NOUN	B
)	I-I	PUNCT	O
as	O	ADP	O
an	O	DET	O
adjunct	O	NOUN	B
to	O	PART	O
narcotic	O	ADJ	B
medications	O	NOUN	I
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
a	O	DET	O
prospective	B-P	ADJ	B
,	I-P	PUNCT	O
randomized	I-P	ADJ	B
,	I-P	PUNCT	O
controlled	I-P	VERB	B
study	I-P	NOUN	I
of	I-P	ADP	O
patients	I-P	NOUN	B
following	I-P	VERB	O
coronary	I-P	ADJ	B
artery	I-P	NOUN	I
bypass	I-P	NOUN	I
graft	I-P	NOUN	I
(	I-P	PUNCT	O
CABG	I-P	NOUN	B
)	I-P	PUNCT	O
surgery	I-P	NOUN	O
with	I-P	ADP	O
the	I-P	DET	O
right	I-P	ADJ	B
or	I-P	CCONJ	O
left	I-P	VERB	B
internal	I-P	ADJ	I
thoracic	I-P	ADJ	I
artery	I-P	NOUN	I
(	I-P	PUNCT	O
ITA	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Forty-five	B-P	ADJ	O
male	I-P	NOUN	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
57	I-P	NUM	O
+/-	I-P	CCONJ	O
6	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	O	ADP	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
TENS	B-I	PROPN	B
,	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
placebo	B-I	NOUN	B
TENS	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
(	I-I	PUNCT	O
3	I-I	X	O
)	I-I	PUNCT	O
control	I-I	NOUN	B
treatments	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
each	O	DET	O
)	O	PUNCT	O
,	O	PUNCT	O
following	O	VERB	O
extubation	O	NOUN	B
and	O	CCONJ	O
during	O	ADP	O
the	O	DET	O
24-	O	NUM	O
to	O	PART	O
72-h	O	ADJ	O
postoperative	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


Two-way	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	I
variance	O	NOUN	I
tests	O	NOUN	I
indicated	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
among	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
for	O	ADP	O
(	B-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
with	I-OUT	ADP	O
cough	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
2	I-OUT	X	O
)	I-OUT	PUNCT	O
narcotic	I-OUT	ADJ	B
medication	I-OUT	NOUN	I
intake	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
3	I-OUT	X	O
)	I-OUT	PUNCT	O
FVC	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
4	I-OUT	X	O
)	I-OUT	PUNCT	O
FEV1	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
(	I-OUT	PUNCT	O
5	I-OUT	X	O
)	I-OUT	PUNCT	O
PEFR	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
pain	B-OUT	NOUN	B
at	I-OUT	ADP	O
rest	I-OUT	NOUN	O
reported	O	VERB	O
by	O	ADP	O
the	O	DET	O
TENS	B-P	PROPN	B
group	I-P	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
that	O	DET	O
reported	O	VERB	O
by	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
treatment	O	NOUN	B
main	O	ADJ	O
effect	O	NOUN	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.04	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
although	O	SCONJ	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
TENS	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
or	O	CCONJ	O
between	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
six	O	NUM	O
criterion	O	NOUN	B
measures	O	NOUN	B
were	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
significant	O	ADJ	O
changes	O	NOUN	B
over	O	ADP	O
time	O	NOUN	O
for	O	ADP	O
the	O	DET	O
entire	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
45	O	NUM	O
;	O	PUNCT	O
time	O	NOUN	O
main	O	ADJ	O
effect	O	NOUN	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
pain	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
medication	I-OUT	NOUN	B
intake	I-OUT	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
were	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
on	O	ADP	O
day	O	NOUN	B
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
pulmonary	B-OUT	ADJ	B
functions	I-OUT	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
preoperatively	O	ADV	B
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
decreased	O	VERB	B
further	O	ADV	O
on	O	ADP	O
day	O	NOUN	B
2	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
despite	O	SCONJ	O
an	O	DET	O
improvement	O	NOUN	B
on	O	ADP	O
day	O	NOUN	B
3	O	NUM	O
,	O	PUNCT	O
remained	O	VERB	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
preoperative	O	ADJ	B
values	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
TENS	B-I	PROPN	B
,	O	PUNCT	O
applied	O	VERB	O
continuously	O	ADV	O
during	O	ADP	O
the	O	DET	O
immediate	O	ADJ	B
postoperative	O	ADJ	B
period	O	NOUN	B
following	O	VERB	O
CABG	O	PROPN	B
with	O	ADP	O
ITA	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
advantageous	O	ADJ	O
in	O	ADP	O
pain	B-OUT	NOUN	B
management	I-OUT	NOUN	I
or	O	CCONJ	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
pulmonary	B-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Patient	B-OUT	ADJ	B
satisfaction	I-OUT	NOUN	I
with	O	ADP	O
nutrition	O	NOUN	B
services	O	NOUN	I
amongst	O	ADP	O
cancer	B-P	NOUN	B
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
autologous	I-P	ADJ	B
stem	I-P	NOUN	I
cell	I-P	NOUN	I
transplantation	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
usual	B-I	ADJ	B
and	O	CCONJ	O
extended	B-I	VERB	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
patient	O	NOUN	B
satisfaction	O	NOUN	I
with	O	ADP	O
clinical	O	ADJ	B
nutrition	B-I	NOUN	O
services	I-I	NOUN	O
delivered	O	VERB	O
by	O	ADP	O
an	O	DET	O
accredited	O	VERB	B
practicing	O	VERB	B
dietitian	O	NOUN	B
amongst	O	ADP	O
cancer	B-P	NOUN	B
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
autologous	I-P	ADJ	B
stem	I-P	NOUN	I
cell	I-P	NOUN	I
transplantation	I-P	NOUN	I
that	O	PRON	O
was	O	AUX	O
provided	O	VERB	O
with	O	ADP	O
usual	B-I	ADJ	O
and	O	CCONJ	O
extended	B-I	VERB	B
care	I-I	NOUN	I
at	O	ADP	O
100	O	NUM	O
days	O	NOUN	B
post-transplantation	O	ADJ	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	O	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	B-I	VERB	O
usual	I-I	ADJ	O
nutrition	I-I	NOUN	B
care	I-I	NOUN	I
or	I-I	CCONJ	O
extended	I-I	VERB	B
nutrition	I-I	NOUN	B
care	I-I	NOUN	I
during	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
stem	O	NOUN	B
cell	O	NOUN	I
transplantation	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
hospital	O	NOUN	B
discharge	O	NOUN	I
,	O	PUNCT	O
usual	B-I	ADJ	B
care	I-I	NOUN	I
patients	I-I	NOUN	B
received	I-I	VERB	O
no	I-I	DET	O
further	I-I	ADJ	O
nutrition	I-I	NOUN	B
support	I-I	NOUN	I
,	I-I	PUNCT	O
whereas	I-I	SCONJ	O
extended	I-I	VERB	O
care	I-I	NOUN	B
patients	I-I	NOUN	B
received	I-I	VERB	O
telephone	I-I	NOUN	B
dietary	I-I	ADJ	I
counselling	I-I	NOUN	I
from	I-I	ADP	O
the	I-I	DET	O
same	I-I	ADJ	O
dietitian	I-I	NOUN	B
for	I-I	ADP	O
up	I-I	ADV	O
to	I-I	PART	O
100	I-I	NUM	O
days	I-I	NOUN	B
post-transplantation	I-I	ADJ	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
satisfaction	O	NOUN	I
with	O	ADP	O
clinical	O	ADJ	B
nutrition	O	NOUN	O
service	O	NOUN	O
questionnaire	O	NOUN	O
was	O	AUX	O
completed	O	VERB	O
anonymously	O	ADV	B
at	O	ADP	O
100	O	NUM	O
days	O	NOUN	B
post-transplantation	O	ADJ	B
.	O	PUNCT	O


Group	O	NOUN	B
comparisons	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
using	O	VERB	O
independent	O	ADJ	B
t-tests	O	NOUN	B
.	O	PUNCT	O


RESULTS	B-P	VERB	O
Thirty-seven	I-P	NUM	O
patients	I-P	NOUN	B
consented	I-P	VERB	B
to	I-P	PART	O
participate	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
(	I-P	PUNCT	O
54	I-P	NUM	O
%	I-P	NOUN	O
male	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
58.7	I-P	NUM	O
±	I-P	NOUN	O
9.5	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
median	I-P	ADJ	B
body	I-P	NOUN	B
mass	I-P	NOUN	I
index	I-P	NOUN	I
26.8	I-P	NUM	O
kg	I-P	NOUN	O
m	I-P	NOUN	O
(	I-P	PUNCT	O
-2	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
range	I-P	VERB	O
16.4-47.6	I-P	NUM	O
kg	I-P	NOUN	O
m	I-P	NOUN	O
(	I-P	PUNCT	O
-2	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
;	I-P	PUNCT	O
33	I-P	NUM	O
patients	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
study	I-P	NOUN	B
and	I-P	CCONJ	O
28	I-P	NUM	O
patients	I-P	NOUN	B
returned	I-P	VERB	O
the	I-P	DET	O
questionnaire	I-P	NOUN	B
(	I-P	PUNCT	O
response	I-P	NOUN	B
rate	I-OUT	NOUN	I
=	I-OUT	ADJ	O
85	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


All	B-OUT	DET	O
components	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
questionnaire	I-OUT	NOUN	B
were	O	AUX	O
rated	O	VERB	O
highly	O	ADV	O
by	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
;	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Although	O	SCONJ	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
,	O	PUNCT	O
extended	O	VERB	B
care	O	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
three	O	NUM	O
telephone	B-OUT	NOUN	B
calls	O	NOUN	O
rated	O	VERB	O
a	O	DET	O
higher	B-OUT	ADJ	B
overall	I-OUT	ADJ	O
satisfaction	O	NOUN	B
compared	O	VERB	B
to	O	ADP	O
those	O	DET	O
who	O	PRON	O
received	O	VERB	O
less	O	ADJ	O
calls	O	NOUN	O
;	O	PUNCT	O
this	O	DET	O
difference	O	NOUN	O
was	O	AUX	O
clinically	O	ADV	B
important	O	ADJ	O
(	O	PUNCT	O
score	O	NOUN	B
difference	B-P	NOUN	O
=	I-P	ADJ	O
0.56	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


CONCLUSIONS	B-P	NOUN	O
Cancer	I-P	NOUN	B
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
autologous	I-P	ADJ	B
stem	I-P	NOUN	I
cell	I-P	NOUN	I
transplantation	O	NOUN	I
were	B-I	AUX	O
satisfied	I-I	ADJ	O
with	I-I	ADP	O
usual	I-I	ADJ	O
and	I-I	CCONJ	O
extended	I-I	VERB	B
nutrition	I-I	NOUN	B
care	I-I	NOUN	I
.	I-P	PUNCT	O


Extended	B-P	ADJ	B
care	O	NOUN	I
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
three	O	NUM	O
telephone	O	NOUN	B
calls	O	NOUN	O
after	O	ADP	O
hospital	O	NOUN	B
discharge	O	NOUN	I
were	O	AUX	O
more	O	ADV	O
satisfied	O	ADJ	O
than	O	ADP	O
those	O	DET	O
with	O	ADP	O
less	O	ADV	O
frequent	O	ADJ	B
intervention	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
exploration	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
intensity	O	NOUN	B
of	O	ADP	O
nutrition	O	NOUN	B
service	O	NOUN	I
is	O	AUX	O
required	O	VERB	O
.	O	PUNCT	O


Developmental	O	NOUN	B
disabilities	O	NOUN	B
modification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
's	O	PART	I
Global	O	PROPN	B
Assessment	O	PROPN	I
Scale	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Interventions	B-I	NOUN	B
for	O	ADP	O
pervasive	B-P	ADJ	B
developmental	I-P	ADJ	O
disorders	I-P	NOUN	O
(	I-P	PUNCT	O
PDD	I-P	NOUN	B
)	I-P	PUNCT	O
aim	O	VERB	O
to	O	PART	O
alleviate	O	VERB	B
symptoms	O	NOUN	B
and	O	CCONJ	O
improve	O	VERB	B
functioning	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
measure	O	VERB	B
global	O	ADJ	B
functioning	O	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
studies	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
Children	O	PROPN	B
's	O	PART	I
Global	O	PROPN	B
Assessment	O	PROPN	I
Scale	O	NOUN	I
was	O	AUX	O
modified	O	VERB	B
and	O	CCONJ	O
psychometric	B-I	ADJ	B
properties	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
revised	I-I	VERB	B
version	I-I	NOUN	O
(	I-I	PUNCT	O
DD-CGAS	I-I	NOUN	B
)	I-I	PUNCT	O
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
PDD	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	PROPN	O
Developmental	O	ADJ	B
disabilities-relevant	O	ADJ	O
descriptors	O	NOUN	O
were	O	AUX	O
developed	O	VERB	O
for	O	ADP	O
the	O	DET	O
DD-CGAS	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
administration	O	NOUN	B
procedures	O	NOUN	I
were	O	AUX	O
established	O	VERB	O
to	O	PART	O
enhance	O	VERB	O
rater	O	NOUN	B
consistency	O	NOUN	B
.	O	PUNCT	O


Ratings	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
case	O	NOUN	I
vignettes	O	NOUN	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	O
inter-rater	O	ADJ	B
reliability	O	NOUN	I
and	O	CCONJ	O
temporal	O	ADJ	B
stability	O	NOUN	I
.	O	PUNCT	O


Validity	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
correlating	O	VERB	B
the	O	DET	O
DD-CGAS	O	NOUN	B
with	O	ADP	O
measures	O	NOUN	B
of	O	ADP	O
functioning	O	VERB	B
and	O	CCONJ	O
symptoms	O	NOUN	B
in	O	ADP	O
83	B-P	NUM	O
youngsters	I-P	NOUN	B
with	I-P	ADP	O
PDD	I-P	NOUN	B
.	I-P	PUNCT	O


Sensitivity	O	NOUN	B
to	O	PART	O
change	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
comparing	O	VERB	B
change	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
post-treatment	O	ADJ	B
with	O	ADP	O
change	O	NOUN	O
on	O	ADP	O
the	O	DET	O
Aberrant	O	PROPN	B
Behavior	O	PROPN	B
Checklist-Irritability	O	PROPN	I
and	O	CCONJ	O
Clinical	O	PROPN	O
Global	O	PROPN	O
Impressions-Improvement	O	ADJ	O
subscale	O	NOUN	O
scores	O	NOUN	O
in	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
14	O	NUM	O
children	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Inter-rater	B-OUT	NOUN	B
reliability	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
intraclass	I-OUT	NOUN	B
correlation	I-OUT	NOUN	I
coefficient	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
ICC	I-OUT	PROPN	B
]	I-OUT	PUNCT	O
=	I-OUT	ADJ	O
.79	I-OUT	NUM	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
temporal	I-OUT	ADJ	B
stability	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
average	I-OUT	ADJ	O
ICC	I-OUT	NOUN	B
=	I-OUT	ADJ	O
.86	I-OUT	NUM	O
)	I-OUT	PUNCT	O
were	I-OUT	AUX	O
excellent	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
DD-CGAS	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
correlated	I-OUT	VERB	B
with	I-OUT	ADP	O
measures	I-OUT	NOUN	B
of	I-OUT	ADP	O
functioning	I-OUT	VERB	B
and	I-OUT	CCONJ	O
symptoms	I-OUT	NOUN	B
with	O	ADP	O
moderate	O	ADJ	B
to	O	PART	O
large	O	ADJ	O
effect	O	NOUN	B
sizes	O	NOUN	I
.	O	PUNCT	O


Changes	B-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
DD-CGAS	I-OUT	NOUN	B
correlated	I-OUT	VERB	B
with	I-OUT	ADP	O
changes	I-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
Aberrant	I-OUT	ADJ	B
Behavior	I-OUT	NOUN	I
Checklist-I	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-.71	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
Global	B-OUT	PROPN	B
Impressions	I-OUT	PROPN	I
Scale-I	I-OUT	VERB	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-.52	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	B-OUT	DET	O
pre-post	I-OUT	ADJ	B
DD-CGAS	I-OUT	NOUN	B
change	I-OUT	NOUN	O
had	O	AUX	O
an	O	DET	O
effect	O	NOUN	B
size	O	NOUN	I
of	O	ADP	O
.72	O	NUM	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
DD-CGAS	O	NOUN	B
is	O	AUX	O
a	O	DET	O
reliable	O	ADJ	O
instrument	O	NOUN	B
with	O	ADP	O
apparent	O	ADJ	B
convergent	O	ADJ	O
validity	O	NOUN	O
for	O	ADP	O
measuring	O	VERB	B
global	O	ADJ	B
functioning	O	NOUN	O
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
PDD	I-P	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
studies	O	NOUN	I
.	O	PUNCT	O


Atypical	O	ADJ	B
recruitment	O	NOUN	B
of	O	ADP	O
medial	O	ADJ	B
prefrontal	O	ADJ	B
cortex	O	NOUN	I
in	O	ADP	O
autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
:	I-P	PUNCT	O
an	O	DET	O
fMRI	B-I	NOUN	B
study	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
executive	B-I	ADJ	B
function	I-I	NOUN	I
tasks	I-I	NOUN	I
.	I-I	PUNCT	O


Recent	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
an	O	DET	O
uneven	O	ADJ	O
profile	O	NOUN	O
of	O	ADP	O
executive	O	ADJ	B
dysfunction	O	NOUN	I
in	O	ADP	O
autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


For	O	ADP	O
example	O	NOUN	O
,	O	PUNCT	O
some	O	DET	O
authors	O	NOUN	B
have	O	AUX	O
reported	O	VERB	O
deficits	O	NOUN	B
on	O	ADP	O
newly	O	ADV	O
developed	O	VERB	O
tests	O	NOUN	B
of	O	ADP	O
executive	O	ADJ	B
function	O	NOUN	I
sensitive	O	ADJ	B
to	O	PART	O
rostral	O	ADJ	B
prefrontal	O	ADJ	I
function	O	NOUN	I
,	O	PUNCT	O
despite	O	SCONJ	O
spared	O	ADJ	O
,	O	PUNCT	O
or	O	CCONJ	O
even	O	ADV	O
superior	O	ADJ	B
,	O	PUNCT	O
performance	O	NOUN	B
on	O	ADP	O
other	O	ADJ	O
tests	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
performance	O	NOUN	B
of	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
high-functioning	B-P	ADJ	B
participants	I-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
(	I-P	PUNCT	O
N=15	I-P	NOUN	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
an	I-P	DET	O
age-	I-P	ADJ	B
and	I-P	CCONJ	I
IQ-matched	I-P	ADJ	B
control	I-P	NOUN	I
group	I-P	NOUN	I
(	I-P	PUNCT	O
N=18	I-P	NOUN	O
)	I-P	PUNCT	O
on	O	ADP	O
two	B-I	NUM	O
executive	I-I	ADJ	B
function	I-I	NOUN	I
tests	I-I	NOUN	I
,	O	PUNCT	O
whilst	O	SCONJ	O
undergoing	B-I	VERB	O
functional	I-I	ADJ	B
magnetic	I-I	ADJ	B
resonance	I-I	NOUN	I
imaging	I-I	NOUN	I
(	I-I	PUNCT	O
fMRI	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Behaviourally	O	ADV	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
classical	B-I	ADJ	O
test	I-I	NOUN	O
of	I-I	ADP	O
executive	I-I	ADJ	B
function	I-I	NOUN	I
(	O	PUNCT	O
random	O	ADJ	B
response	O	NOUN	I
generation	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
BOLD	B-OUT	NOUN	B
signal	I-OUT	NOUN	B
differed	O	VERB	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cerebellum	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
frontal	O	ADJ	B
lobes	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
on	O	ADP	O
a	O	DET	O
new	B-I	ADJ	O
test	I-I	NOUN	O
of	I-I	ADP	O
executive	I-I	ADJ	B
function	I-I	NOUN	I
(	O	PUNCT	O
selection	O	NOUN	B
between	O	ADP	O
stimulus-oriented	O	ADJ	B
and	O	CCONJ	O
stimulus-independent	O	ADJ	B
thought	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
ASD	O	PROPN	B
group	O	NOUN	B
exhibited	O	VERB	O
significantly	O	ADV	O
greater	O	ADJ	O
signal-change	B-OUT	NOUN	B
in	I-OUT	ADP	O
medial	I-OUT	ADJ	B
rostral	I-OUT	ADJ	O
prefrontal	I-OUT	ADJ	O
cortex	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
especially	I-OUT	ADV	O
Brodmann	I-OUT	PROPN	B
Area	I-OUT	PROPN	I
10	I-OUT	NUM	I
)	I-OUT	PUNCT	O
in	O	ADP	O
the	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
stimulus-oriented	O	ADJ	B
versus	O	CCONJ	O
stimulus-independent	O	ADJ	B
attention	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
new	O	ADJ	O
test	O	NOUN	B
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
classical	O	ADJ	O
test	O	NOUN	O
)	O	PUNCT	O
provided	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
abnormal	B-OUT	ADJ	B
functional	I-OUT	ADJ	O
organisation	I-OUT	NOUN	O
of	I-OUT	ADP	O
medial	I-OUT	ADJ	B
prefrontal	I-OUT	ADJ	B
cortex	I-OUT	NOUN	I
in	I-OUT	ADP	O
ASD	I-OUT	PROPN	B
.	I-OUT	PUNCT	O


These	O	DET	O
results	O	NOUN	B
underline	O	VERB	O
the	O	DET	O
heterogeneity	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
tests	O	NOUN	B
of	O	ADP	O
executive	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
executive	O	ADJ	B
functioning	O	NOUN	I
in	O	ADP	O
ASD	B-P	PROPN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
task-specific	O	ADJ	B
functional	O	ADJ	I
change	O	NOUN	I
.	O	PUNCT	O


Should	O	AUX	O
insertion	O	NOUN	B
of	O	ADP	O
intramedullary	O	ADJ	B
nails	O	NOUN	I
for	O	ADP	O
tibial	B-P	ADJ	B
fractures	I-P	NOUN	I
be	O	AUX	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
reaming	O	NOUN	B
?	O	PUNCT	O
A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
with	O	ADP	O
3.8	O	NUM	O
years	O	NOUN	B
'	O	PART	O
follow-up	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
any	O	DET	O
differences	O	NOUN	O
exist	O	VERB	O
in	O	ADP	O
healing	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
complications	I-OUT	NOUN	B
between	O	ADP	O
reamed	B-I	VERB	B
and	I-I	CCONJ	O
unreamed	I-I	ADJ	B
nailing	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
tibial	I-P	ADJ	B
shaft	I-P	NOUN	I
fractures	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
.	O	PUNCT	O


SETTING	O	VERB	O
Level	B-P	NOUN	O
1	I-P	NUM	O
trauma	I-P	NOUN	O
center	I-P	NOUN	O
.	I-P	PUNCT	O


PATIENTS	O	VERB	O
Forty-five	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
displaced	I-P	ADJ	O
closed	I-P	ADJ	O
and	I-P	CCONJ	O
open	I-P	ADJ	O
Gustilo	I-P	ADJ	O
type	I-P	NOUN	O
I-IIIA	I-P	ADJ	O
fractures	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
central	I-P	ADJ	B
two	I-P	NUM	O
thirds	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
tibia	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTION	O	PROPN	B
Stabilization	B-I	PROPN	B
of	I-I	ADP	O
tibial	I-I	ADJ	B
fractures	I-I	NOUN	I
either	I-I	CCONJ	O
with	I-I	ADP	O
a	I-I	DET	O
slotted	I-I	ADJ	B
,	I-I	PUNCT	O
stainless	I-I	ADJ	B
steel	I-I	NOUN	I
reamed	I-I	VERB	I
nail	I-I	NOUN	I
or	I-I	CCONJ	O
a	I-I	DET	O
solid	I-I	ADJ	B
,	I-I	PUNCT	O
titanium	I-I	NOUN	B
unreamed	I-I	ADJ	O
nail	I-I	NOUN	B
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	O
MEASUREMENTS	O	NOUN	O
Nonunions	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
time	I-OUT	NOUN	O
to	I-OUT	ADP	O
fracture	I-OUT	NOUN	B
healing	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
malunions	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
average	B-OUT	ADJ	B
time	I-OUT	NOUN	O
to	I-OUT	ADP	O
fracture	I-OUT	NOUN	B
healing	I-OUT	NOUN	I
was	O	AUX	O
16.7	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
reamed	B-I	VERB	B
group	O	NOUN	B
and	O	CCONJ	O
25.7	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
unreamed	B-I	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	B
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
three	O	NUM	O
nonunions	B-OUT	NOUN	B
,	O	PUNCT	O
all	O	DET	O
in	O	ADP	O
the	O	DET	O
unreamed	B-I	ADJ	B
nail	I-I	NOUN	I
group	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
these	O	DET	O
fractures	O	NOUN	B
healed	B-OUT	VERB	B
after	I-OUT	ADP	O
dynamization	I-OUT	NOUN	B
by	I-OUT	ADP	O
removing	I-OUT	VERB	O
static	I-OUT	ADJ	B
interlocking	I-OUT	NOUN	I
screws	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
third	O	ADJ	O
nonunion	O	NOUN	B
did	O	AUX	O
not	O	PART	O
heal	B-OUT	VERB	B
despite	O	SCONJ	O
exchange	O	NOUN	B
reamed	B-I	ADJ	I
nailing	O	NOUN	I
2	O	NUM	I
years	O	NOUN	B
after	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
surgery	O	NOUN	I
and	O	CCONJ	O
dynamization	O	NOUN	B
with	O	ADP	O
a	O	DET	O
fibular	O	NOUN	B
osteotomy	O	NOUN	I
after	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
two	O	NUM	O
malunions	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
reamed	B-I	VERB	B
group	O	NOUN	B
and	O	CCONJ	O
four	O	NUM	O
malunions	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
unreamed	B-I	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
for	O	ADP	O
all	O	DET	O
other	O	ADJ	O
outcome	O	NOUN	B
measurements	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Unreamed	B-I	PROPN	B
nailing	I-I	NOUN	I
in	I-I	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
tibial	I-P	ADJ	B
shaft	I-P	NOUN	I
fractures	I-P	NOUN	I
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
higher	O	ADJ	O
rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
secondary	I-OUT	ADJ	B
operations	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
malunions	I-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
reamed	B-I	ADJ	B
nailing	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
time	B-OUT	NOUN	O
to	I-OUT	ADP	O
fracture	I-OUT	NOUN	B
healing	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
longer	O	ADJ	O
with	O	ADP	O
unreamed	B-I	ADJ	B
nails	I-I	NOUN	I
.	I-I	PUNCT	O


Modafinil	B-I	NOUN	B
effects	O	NOUN	B
during	O	ADP	O
acute	B-P	ADJ	B
continuous	I-P	ADJ	I
positive	I-P	ADJ	I
airway	I-P	NOUN	O
pressure	I-P	NOUN	O
withdrawal	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
crossover	O	NOUN	I
double-blind	O	ADJ	I
placebo-controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


RATIONALE	O	VERB	B
Continuous	B-I	ADJ	B
positive	I-I	ADJ	I
airway	I-I	NOUN	O
pressure	I-I	NOUN	O
(	I-I	PUNCT	O
CPAP	I-I	NOUN	B
)	I-I	PUNCT	O
use	O	NOUN	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
reduced	O	VERB	B
motor	O	NOUN	B
vehicle	O	NOUN	I
accidents	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
obstructive	I-P	ADJ	B
sleep	I-P	NOUN	I
apnea	I-P	NOUN	I
(	I-P	PUNCT	O
OSA	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
interruption	O	NOUN	B
of	O	ADP	O
CPAP	O	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
common	O	ADJ	O
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
decline	O	NOUN	B
in	O	ADP	O
daytime	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
wakefulness	O	NOUN	B
promoter	O	NOUN	B
,	O	PUNCT	O
modafinil	O	NOUN	B
,	O	PUNCT	O
would	O	AUX	O
ameliorate	O	VERB	B
this	O	DET	O
decline	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
were	I-P	AUX	O
admitted	I-P	VERB	B
to	I-P	ADP	O
the	I-P	DET	O
laboratory	I-P	NOUN	B
for	I-P	ADP	O
three	I-P	NUM	O
consecutive	I-P	ADJ	B
nights	I-P	NOUN	B
.	I-P	PUNCT	O


CPAP	B-I	NOUN	B
was	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
night	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
baseline	O	NOUN	B
day	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
then	O	ADV	O
withdrawn	O	VERB	O
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
subsequent	O	ADJ	O
nights	O	NOUN	B
(	O	PUNCT	O
nasal	O	ADJ	B
airflow	O	NOUN	I
monitored	O	VERB	O
)	O	PUNCT	O
.	O	PUNCT	O


On	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
mornings	O	NOUN	B
after	O	ADP	O
the	O	DET	O
two	O	NUM	O
CPAP	O	NOUN	B
withdrawal	O	NOUN	O
nights	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
received	O	VERB	O
200	B-I	NUM	O
mg	I-I	NOUN	O
modafinil	I-I	NOUN	B
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
21	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
design	O	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
periods	O	NOUN	B
were	O	AUX	O
separated	O	VERB	O
by	O	ADP	O
a	O	DET	O
5-week	O	ADJ	B
washout	O	NOUN	B
.	O	PUNCT	O


Driving	B-OUT	VERB	B
simulator	I-OUT	NOUN	B
performance	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
neurocognitive	I-OUT	ADJ	B
performance	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
subjective	I-OUT	ADJ	B
alertness	I-OUT	NOUN	I
were	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
AusEd	O	ADJ	B
driving	O	NOUN	I
simulator	O	NOUN	I
,	O	PUNCT	O
psychomotor	O	NOUN	B
vigilance	O	NOUN	I
task	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
Karolinska	O	PROPN	B
Sleepiness	O	PROPN	I
Scale	O	PROPN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
MAIN	O	NOUN	O
RESULTS	O	NOUN	O
During	O	ADP	O
CPAP	O	NOUN	B
withdrawal	O	NOUN	B
,	O	PUNCT	O
severe	B-OUT	ADJ	B
sleep-disordered	I-OUT	ADJ	B
breathing	I-OUT	NOUN	I
was	O	AUX	O
evident	O	ADJ	O
and	O	CCONJ	O
administration	O	NOUN	B
of	O	ADP	O
modafinil	O	NOUN	B
improved	O	VERB	B
simulated	B-OUT	ADJ	O
driving	I-OUT	NOUN	O
performance	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
steering	I-OUT	NOUN	O
variability	I-OUT	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
;	O	PUNCT	O
mean	B-OUT	ADJ	O
reaction	I-OUT	NOUN	B
time	I-OUT	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or=	O	ADJ	O
0.0002	O	NUM	O
;	O	PUNCT	O
lapses	B-OUT	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or=	O	ADJ	O
0.01	O	NUM	O
on	O	ADP	O
a	O	DET	O
concurrent	O	ADJ	B
task	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
psychomotor	B-OUT	NOUN	B
vigilance	I-OUT	NOUN	I
task	I-OUT	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
1/reaction	O	NOUN	B
time	O	NOUN	O
and	O	CCONJ	O
lapses	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
P	O	NOUN	O
<	O	X	O
or=	O	ADJ	O
0.0002	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
subjective	B-OUT	ADJ	B
sleepiness	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Modafinil	O	PROPN	B
prevented	O	VERB	B
the	O	DET	O
decline	O	NOUN	B
in	O	ADP	O
simulated	O	ADJ	B
driving	B-OUT	NOUN	O
performance	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
neurocognitive	I-OUT	ADJ	B
performance	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
subjective	B-OUT	ADJ	B
sleepiness	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
OSA	I-P	NOUN	B
with	O	ADP	O
acutely	O	ADV	O
interrupted	O	ADJ	B
CPAP	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Clinical	O	ADJ	B
trial	O	NOUN	I
registered	O	VERB	O
with	O	ADP	O
the	O	DET	O
Australian	O	ADJ	B
New	O	PROPN	B
Zealand	O	PROPN	I
Clinical	O	PROPN	O
Trials	O	PROPN	O
Registry	O	PROPN	O
at	O	ADP	O
www.anzctr.org.au	O	NOUN	O
(	O	PUNCT	O
ACTRN12606000027516	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
local	O	ADJ	B
estrogen	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
local	O	ADJ	B
testosterone	B-I	NOUN	B
on	O	ADP	O
vulvovaginal	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
sexual	I-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
in	I-P	ADP	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


INTRODUCTION	O	NOUN	O
A	O	DET	O
significant	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
postmenopausal	B-P	ADJ	B
women	I-P	NOUN	B
suffer	O	VERB	O
from	O	ADP	O
distressing	O	VERB	B
problems	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
urogenital	O	ADJ	B
atrophy	O	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
the	O	DET	O
decline	O	NOUN	B
in	O	ADP	O
circulating	O	VERB	B
estrogen	O	NOUN	B
levels	O	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
topical	B-I	ADJ	B
hormones	I-I	NOUN	I
may	O	AUX	O
provide	O	VERB	O
relief	O	NOUN	B
in	O	ADP	O
such	O	ADJ	O
women	O	NOUN	B
when	O	SCONJ	O
used	O	VERB	O
judiciously	O	ADV	B
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
study	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
local	O	ADJ	B
estrogen	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
local	B-I	ADJ	B
testosterone	I-I	NOUN	B
on	O	ADP	O
urogenital	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
sexual	I-OUT	ADJ	B
health	I-OUT	NOUN	I
in	O	ADP	O
postmenopausal	B-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
Seventy-five	B-P	NUM	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
symptomatic	I-P	ADJ	B
for	I-P	ADP	O
urogenital	I-P	ADJ	B
atrophy	I-P	NOUN	I
and	I-P	CCONJ	O
sexual	I-P	ADJ	B
dysfunction	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
study	O	NOUN	B
groups	O	NOUN	I
and	O	CCONJ	O
one	O	NUM	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
women	O	NOUN	B
in	O	ADP	O
study	O	NOUN	B
group	O	NOUN	I
1	O	NUM	O
received	B-I	VERB	O
local	I-I	ADJ	B
estrogen	I-I	NOUN	B
cream	I-I	NOUN	I
;	I-I	PUNCT	O
study	I-I	NOUN	B
group	I-I	NOUN	I
2	I-I	NUM	O
received	I-I	VERB	O
local	I-I	ADJ	B
estrogen	I-I	NOUN	B
and	I-I	CCONJ	O
testosterone	I-I	NOUN	B
cream	I-I	NOUN	I
;	I-I	PUNCT	O
the	I-I	DET	O
control	I-I	NOUN	B
group	I-I	NOUN	I
received	I-I	VERB	O
nonhormonal	I-I	ADJ	B
lubricant	I-I	NOUN	I
KY	I-I	NOUN	I
gel	I-I	NOUN	I
for	I-I	ADP	O
12	I-I	NUM	O
weeks	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
urogenital	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
sexuality	I-OUT	NOUN	B
score	I-OUT	NOUN	O
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
the	O	DET	O
vaginal	B-OUT	ADJ	B
health	I-OUT	NOUN	I
index	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
vaginal	I-OUT	ADJ	B
maturation	I-OUT	NOUN	I
index	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VMI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
calculated	O	VERB	B
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
and	O	CCONJ	O
12	O	NUM	O
weeks	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	B
MEASURES	O	X	O
Changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
urogenital	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
sexuality	I-OUT	NOUN	B
score	I-OUT	NOUN	I
along	I-OUT	ADP	O
with	I-OUT	ADP	O
vaginal	I-OUT	ADJ	B
health	I-OUT	NOUN	I
index	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
VMI	I-OUT	PROPN	B
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
After	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
all	O	DET	O
the	O	DET	O
four	O	NUM	O
study	O	NOUN	B
parameters	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
correlated	O	VERB	B
well	O	ADV	O
with	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
symptoms	O	NOUN	B
of	O	ADP	O
urogenital	O	ADJ	B
atrophy	O	NOUN	I
and	O	CCONJ	O
sexual	O	ADJ	B
dysfunction	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
study	B-P	NOUN	B
groups	I-P	NOUN	I
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
control	B-P	NOUN	B
group	I-P	NOUN	I
.	I-P	PUNCT	O


Improvement	O	NOUN	B
in	O	ADP	O
sexuality	B-OUT	NOUN	B
score	I-OUT	NOUN	I
was	O	AUX	O
greatest	O	ADJ	O
with	O	ADP	O
combined	O	ADJ	O
estrogen-androgen	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
and	O	CCONJ	O
the	O	DET	O
therapies	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
accepted	O	VERB	B
without	O	ADP	O
any	O	DET	O
compliance	O	NOUN	B
issue	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	ADJ	O
Local	B-I	ADJ	B
estrogen	I-I	NOUN	O
either	O	CCONJ	O
alone	O	ADV	O
or	O	CCONJ	O
with	O	ADP	O
androgen	O	NOUN	B
is	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
relieving	O	VERB	B
symptoms	O	NOUN	B
of	O	ADP	O
urogenital	B-OUT	ADJ	B
atrophy	I-OUT	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
improving	B-OUT	VERB	B
sexual	I-OUT	ADJ	B
function	I-OUT	NOUN	I
in	O	ADP	O
symptomatic	B-P	ADJ	B
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


Potential	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
ovarian	B-I	ADJ	B
cancer	I-I	NOUN	I
algorithm	I-I	NOUN	B
(	I-I	PUNCT	O
ROCA	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
the	O	DET	O
mortality	B-OUT	NOUN	B
outcome	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
Prostate	O	NOUN	B
,	O	PUNCT	O
Lung	O	PROPN	B
,	O	PUNCT	O
Colorectal	O	PROPN	B
and	O	CCONJ	O
Ovarian	O	ADJ	B
(	O	PUNCT	O
PLCO	O	NOUN	B
)	O	PUNCT	O
trial	O	NOUN	O
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
Prostate	B-P	PROPN	B
,	I-P	PUNCT	O
Lung	I-P	PROPN	B
,	I-P	PUNCT	O
Colorectal	I-P	PROPN	B
and	I-P	CCONJ	O
Ovarian	I-P	ADJ	B
(	I-P	PUNCT	O
PLCO	I-P	NOUN	B
)	I-P	PUNCT	O
Trial	I-P	PROPN	B
reported	O	VERB	O
no	O	DET	O
mortality	O	NOUN	B
benefit	O	NOUN	B
for	O	ADP	O
annual	O	ADJ	B
screening	B-I	NOUN	B
with	I-I	ADP	O
CA-125	I-I	NOUN	B
and	I-I	CCONJ	O
transvaginal	I-I	ADJ	B
ultrasound	I-I	NOUN	I
(	I-I	PUNCT	O
TVU	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Currently	O	ADV	O
ongoing	O	ADJ	B
is	O	AUX	O
the	O	DET	O
UK	O	PROPN	B
Collaborative	O	PROPN	O
Trial	O	PROPN	O
of	O	ADP	O
Ovarian	O	ADJ	B
Cancer	O	PROPN	I
Screening	O	PROPN	B
(	O	PUNCT	O
UKCTOCS	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
utilizes	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
ovarian	B-I	ADJ	B
cancer	I-I	NOUN	I
algorithm	I-I	NOUN	B
(	I-I	PUNCT	O
ROCA	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
statistical	O	ADJ	B
tool	O	NOUN	I
that	O	PRON	O
considers	O	VERB	O
current	O	ADJ	B
and	O	CCONJ	O
past	O	ADJ	O
CA125	O	NOUN	B
values	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
ovarian	O	ADJ	B
cancer	O	NOUN	I
risk	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
PLCO	O	PROPN	B
used	O	VERB	O
a	O	DET	O
single	O	ADJ	O
cutoff	O	NOUN	B
for	O	ADP	O
CA125	O	NOUN	B
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
current	O	ADJ	O
levels	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
having	O	VERB	O
had	O	AUX	O
used	O	VERB	O
ROCA	B-I	PROPN	B
in	I-I	ADP	O
PLCO	I-I	PROPN	B
could	O	AUX	O
have	O	AUX	O
,	O	PUNCT	O
under	O	ADP	O
optimal	O	ADJ	B
assumptions	O	NOUN	B
,	O	PUNCT	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	B-OUT	ADJ	B
mortality	I-OUT	NOUN	B
benefit	I-OUT	NOUN	B
by	O	ADP	O
applying	O	VERB	O
ROCA	O	PROPN	B
to	O	ADP	O
PLCO	O	NOUN	B
CA125	O	NOUN	B
screening	O	NOUN	B
values	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
best-case	O	ADJ	O
scenario	O	NOUN	O
assumed	O	VERB	O
that	O	SCONJ	O
all	B-P	DET	O
cancers	I-P	NOUN	B
showing	I-P	VERB	O
a	I-P	DET	O
positive	I-P	ADJ	B
screen	I-P	NOUN	B
result	I-P	VERB	O
earlier	I-P	ADV	O
with	I-P	ADP	O
ROCA	I-P	NOUN	B
than	I-P	ADP	O
under	I-P	ADP	O
the	I-P	DET	O
PLCO	I-P	PROPN	B
protocol	O	NOUN	I
would	O	AUX	O
have	O	AUX	O
avoided	O	VERB	O
mortality	B-OUT	NOUN	B
;	I-OUT	PUNCT	O
under	O	ADP	O
a	O	DET	O
stage-shift	O	ADJ	B
scenario	O	NOUN	I
,	O	PUNCT	O
such	B-P	ADJ	O
women	I-P	NOUN	B
were	O	AUX	O
assigned	O	VERB	B
survival	O	NOUN	B
equivalent	O	ADJ	O
to	O	PART	O
Stage	O	NOUN	B
I/II	O	NOUN	I
screen-detected	O	ADJ	B
cases	O	NOUN	B
.	O	PUNCT	O


Updated	O	ADJ	O
PLCO	O	NOUN	B
data	O	NOUN	B
show	O	VERB	O
132	B-P	NUM	O
intervention	I-P	NOUN	B
arm	I-P	NOUN	O
ovarian	I-P	ADJ	O
cancer	I-P	NOUN	O
deaths	I-P	NOUN	B
versus	I-P	CCONJ	O
119	I-P	NUM	O
in	I-P	ADP	O
usual	I-P	ADJ	B
care	I-P	NOUN	I
(	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
,	O	PUNCT	O
RR	O	NOUN	B
=	O	ADJ	O
1.11	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Forty-three	O	NUM	B
ovarian	O	ADJ	I
cancer	O	NOUN	I
cases	O	NOUN	B
,	O	PUNCT	O
25	O	NUM	O
fatal	O	ADJ	B
,	O	PUNCT	O
would	O	AUX	O
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
earlier	O	ADV	O
with	O	ADP	O
ROCA	B-I	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
median	O	ADJ	B
(	O	PUNCT	O
minimum	O	ADJ	B
)	O	PUNCT	O
advance	O	NOUN	O
time	O	NOUN	O
for	O	ADP	O
fatal	B-OUT	ADJ	B
cases	I-OUT	NOUN	B
of	O	ADP	O
344	O	NUM	O
(	O	PUNCT	O
147	O	NUM	O
)	O	PUNCT	O
days	O	NOUN	B
.	O	PUNCT	O


Best-case	O	ADJ	B
and	O	CCONJ	O
stage-shift	O	ADJ	B
scenarios	O	NOUN	B
gave	O	VERB	O
25	O	NUM	O
and	O	CCONJ	O
19	O	NUM	O
deaths	B-OUT	NOUN	B
prevented	O	VERB	B
with	O	ADP	O
ROCA	B-I	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
RRs	O	NOUN	B
of	O	ADP	O
0.90	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
0.69-1.17	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
0.95	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
0.74-1.23	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Having	O	VERB	O
utilized	O	VERB	O
ROCA	B-I	PROPN	B
in	O	ADP	O
PLCO	O	PROPN	B
would	O	AUX	O
not	O	PART	O
have	O	AUX	O
led	O	VERB	O
to	O	PART	O
a	O	DET	O
significant	O	ADJ	B
mortality	B-OUT	NOUN	B
benefit	I-OUT	NOUN	B
of	O	ADP	O
screening	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
ROCA	B-I	PROPN	B
could	O	AUX	O
still	O	ADV	O
show	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
effect	O	NOUN	B
in	O	ADP	O
other	O	ADJ	O
screening	O	NOUN	B
trials	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
UKCTOCS	O	PROPN	B
.	O	PUNCT	O


Dose-dependent	O	ADJ	B
effects	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
CRF	B-I	NOUN	B
(	I-I	PUNCT	O
1	I-I	NUM	O
)	I-I	PUNCT	O
receptor	I-I	NOUN	O
antagonist	I-I	NOUN	B
R317573	I-I	NOUN	B
on	O	ADP	O
regional	O	ADJ	B
brain	O	NOUN	O
activity	O	NOUN	O
in	O	ADP	O
healthy	B-P	ADJ	B
male	I-P	ADJ	B
subjects	I-P	NOUN	O
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Corticotropin-releasing	B-I	ADJ	B
factor	I-I	NOUN	I
receptor	I-I	NOUN	I
type	I-I	NOUN	I
1	I-I	NUM	I
(	I-I	PUNCT	O
CRF	I-I	NOUN	B
(	I-I	PUNCT	O
1	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
antagonists	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
as	O	ADP	O
therapeutic	O	ADJ	B
agents	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
mood	O	NOUN	B
and	O	CCONJ	O
anxiety	O	NOUN	B
disorders	O	NOUN	I
although	O	SCONJ	O
clinical	O	ADJ	B
evidence	O	NOUN	I
supporting	O	VERB	O
their	O	PRON	O
development	O	NOUN	B
and	O	CCONJ	O
understanding	O	NOUN	O
of	O	ADP	O
a	O	DET	O
dose-response	O	ADJ	B
relationship	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
lacking	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
tested	O	VERB	B
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CRF	B-I	NOUN	B
(	I-I	PUNCT	O
1	I-I	NUM	O
)	I-I	PUNCT	O
antagonist	I-I	NOUN	B
R317573	I-I	NOUN	B
for	O	ADP	O
effects	O	NOUN	B
on	O	ADP	O
regional	B-OUT	ADJ	B
cerebral	I-OUT	ADJ	I
glucose	I-OUT	NOUN	I
metabolism	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
rCMglu	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
using	O	VERB	O
[	B-I	PUNCT	O
(	I-I	PUNCT	O
18	I-I	NUM	O
)	I-I	PUNCT	O
F	I-I	PROPN	O
]	I-I	PUNCT	O
fluoro-2-deoxy-D	I-I	NOUN	B
:	I-I	PUNCT	O
-glucose	I-I	NOUN	O
(	I-I	PUNCT	O
FDG	I-I	NOUN	B
)	I-I	PUNCT	O
positron	I-I	NOUN	B
emission	I-I	NOUN	I
tomography	I-I	NOUN	I
(	I-I	PUNCT	O
PET	I-I	NOUN	B
)	I-I	PUNCT	O
following	O	VERB	O
single-dose	O	ADJ	B
challenges	O	NOUN	B
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
cross-over	O	ADJ	B
design	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
12	B-P	NUM	O
healthy	I-P	ADJ	B
male	I-P	NOUN	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	VERB	O
Single	O	ADJ	O
30-	O	NUM	O
and	O	CCONJ	O
200-mg	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
R317573	B-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
dose-related	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
rCMglu	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Relative	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
rCMglu	B-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
frontal	O	ADJ	B
cortical	O	ADJ	I
regions	O	NOUN	I
while	O	SCONJ	O
relative	O	ADJ	O
decreases	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
putamen	O	NOUN	B
and	O	CCONJ	O
right	O	ADJ	B
amygdala	O	NOUN	I
after	O	ADP	O
both	O	DET	O
doses	O	NOUN	B
.	O	PUNCT	O


Relative	O	ADJ	O
decreases	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
cerebellum	O	NOUN	B
and	O	CCONJ	O
right	O	ADJ	B
parahippocampal	O	ADJ	I
gyrus	O	NOUN	I
following	O	VERB	O
the	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
R317573	B-I	NOUN	B
appears	O	VERB	O
to	O	PART	O
produce	O	VERB	O
acute	O	ADJ	B
dose-dependent	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
rCMglu	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
regions	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
behaviorally	O	ADV	B
relevant	O	ADJ	I
to	O	ADP	O
mood	O	NOUN	B
and	O	CCONJ	O
anxiety	O	NOUN	B
disorders	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
some	O	DET	O
regions	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
effects	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
receptor	O	NOUN	B
(	O	PUNCT	O
target	O	NOUN	B
)	O	PUNCT	O
density	O	NOUN	B
.	O	PUNCT	O


Measuring	O	VERB	B
acute	O	ADJ	B
effects	O	NOUN	O
on	O	ADP	O
rCMglu	B-I	NOUN	B
with	O	ADP	O
FDG-PET	B-I	NOUN	B
may	O	AUX	O
offer	O	VERB	O
a	O	DET	O
method	O	NOUN	B
for	O	ADP	O
defining	O	VERB	O
pharmacologically	O	ADV	B
active	O	ADJ	O
doses	O	NOUN	O
for	O	ADP	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
targets	O	VERB	B
for	O	ADP	O
which	O	DET	O
selective	O	ADJ	O
radiotracers	O	NOUN	B
are	O	AUX	O
lacking	O	VERB	B
.	O	PUNCT	O


Problem-solving	B-I	ADJ	B
counseling	I-I	NOUN	I
for	O	ADP	O
caregivers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cognitively	O	ADV	B
impaired	O	ADJ	I
:	O	PUNCT	O
effective	O	ADJ	B
for	O	ADP	O
whom	O	PRON	O
?	O	PUNCT	O
BACKGROUND	O	ADJ	O
Individualized	O	ADJ	B
problem-solving	B-I	ADJ	B
counseling	I-I	NOUN	I
for	O	ADP	O
caregivers	O	NOUN	B
of	O	ADP	O
cognitively	O	ADV	B
impaired	O	ADJ	I
relatives	O	NOUN	I
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
help	O	VERB	O
caregivers	O	NOUN	B
cope	O	VERB	B
with	O	ADP	O
the	O	DET	O
stress	O	NOUN	B
and	O	CCONJ	O
burden	O	NOUN	B
of	O	ADP	O
caregiving	O	NOUN	B
.	O	PUNCT	O


Few	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
counseling	O	NOUN	B
for	O	ADP	O
these	O	DET	O
caregivers	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
individualized	B-I	ADJ	B
problem-solving	I-I	ADJ	B
counseling	I-I	NOUN	I
by	I-I	ADP	O
nurses	I-I	NOUN	B
for	O	ADP	O
caregivers	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
expenditures	O	NOUN	B
of	O	ADP	O
health	O	NOUN	B
care	O	NOUN	I
utilization	O	NOUN	B
.	O	PUNCT	O


METHOD	O	PROPN	B
Caregivers	B-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
77	I-P	NUM	O
)	I-P	PUNCT	O
of	I-P	ADP	O
the	I-P	DET	O
cognitively	I-P	ADV	B
impaired	I-P	ADJ	I
living	I-P	NOUN	O
at	I-P	ADP	O
home	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
nurse	B-I	ADJ	B
counseling	I-I	NOUN	I
or	I-I	CCONJ	O
not	I-I	PART	O
.	I-I	PUNCT	O


Psychosocial	O	ADJ	B
adjustment	O	NOUN	B
to	O	ADP	O
their	O	PRON	O
relative	B-OUT	ADJ	B
's	I-OUT	PART	I
illness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
psychological	I-OUT	ADJ	B
distress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
burden	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
coping	I-OUT	NOUN	B
skills	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
expenditures	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Although	O	SCONJ	O
on	O	ADP	O
average	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
caregivers	O	NOUN	B
receiving	O	VERB	O
nurse	B-I	ADJ	B
counseling	I-I	NOUN	I
indicated	O	VERB	O
no	O	DET	O
improvement	B-OUT	NOUN	B
in	O	ADP	O
psychosocial	O	ADJ	B
adjustment	O	NOUN	O
to	O	ADP	O
their	O	PRON	O
relative	B-OUT	ADJ	B
's	I-OUT	PART	I
illness	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
psychological	I-OUT	ADJ	B
distress	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
caregiver	I-OUT	NOUN	B
burden	I-OUT	NOUN	B
,	O	PUNCT	O
they	O	PRON	O
found	O	VERB	O
counseling	O	VERB	B
very	O	ADV	O
helpful	O	ADJ	O
and	O	CCONJ	O
it	O	PRON	O
was	O	AUX	O
effective	O	ADJ	B
for	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
caregivers	O	NOUN	B
.	O	PUNCT	O


Those	O	DET	O
with	O	ADP	O
poor	O	ADJ	O
logical	O	ADJ	B
analysis	O	NOUN	I
coping	O	NOUN	B
skills	O	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
had	O	AUX	O
decreased	B-OUT	VERB	B
psychological	I-OUT	ADJ	B
distress	I-OUT	NOUN	I
(	O	PUNCT	O
F	O	NOUN	B
(	O	PUNCT	O
1,53	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
9.7	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.003	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
improved	B-OUT	VERB	B
psychosocial	I-OUT	ADJ	B
adjustment	I-OUT	NOUN	O
(	O	PUNCT	O
F	O	NOUN	B
(	O	PUNCT	O
1,53	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
4.7	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.035	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Caregivers	O	NOUN	B
in	O	ADP	O
control	B-I	NOUN	B
and	O	CCONJ	O
counseling	B-I	NOUN	B
groups	O	NOUN	I
whose	O	DET	O
relatives	O	NOUN	B
entered	O	VERB	O
a	O	DET	O
nursing	O	NOUN	B
home	O	NOUN	I
improved	O	VERB	B
their	O	PRON	O
psychosocial	B-OUT	ADJ	B
adjustment	I-OUT	NOUN	B
23	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
average	O	NOUN	B
whereas	O	SCONJ	O
those	O	DET	O
continuing	O	VERB	O
to	O	PART	O
live	O	VERB	B
in	O	ADP	O
the	O	DET	O
community	O	NOUN	B
decreased	O	VERB	B
by	O	ADP	O
8	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Almost	O	ADV	O
half	O	ADV	O
as	O	ADV	O
many	O	ADJ	O
relatives	O	NOUN	B
entered	O	VERB	O
nursing	O	NOUN	B
homes	O	NOUN	I
in	O	ADP	O
the	O	DET	O
counseling	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
vs.	O	CCONJ	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
these	O	DET	O
compared	O	VERB	B
to	O	PART	O
control	B-I	ADJ	B
group	O	NOUN	I
relatives	O	NOUN	I
had	O	AUX	O
greater	O	ADJ	O
annualized	O	VERB	B
per	O	ADP	O
person	O	NOUN	B
expenditures	O	NOUN	B
for	O	ADP	O
health	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
social	I-OUT	ADJ	B
services	I-OUT	NOUN	I
(	O	PUNCT	O
Cdn	O	PROPN	B
$	O	SYM	O
23,437	O	NUM	O
vs.	O	CCONJ	O
Cdn	O	PROPN	O
$	O	SYM	O
15,151	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Caregivers	O	NOUN	B
found	O	VERB	O
nurse	B-I	ADJ	B
counseling	I-I	NOUN	I
most	O	ADV	O
helpful	O	ADJ	O
.	O	PUNCT	O


Those	O	DET	O
indicating	O	VERB	O
infrequent	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
logical	O	ADJ	B
analysis	O	NOUN	I
coping	O	NOUN	B
skills	O	NOUN	I
showed	O	VERB	O
benefits	O	NOUN	B
.	O	PUNCT	O


Safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
PNU-142633	B-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
selective	I-I	ADJ	O
5-HT1D	I-I	NOUN	B
agonist	I-I	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
migraine	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
parallel-group	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
patients	B-P	NOUN	B
received	O	VERB	O
a	O	DET	O
single	O	ADJ	O
50-mg	B-I	ADJ	O
oral	I-I	ADJ	B
dose	I-I	NOUN	I
of	I-I	ADP	O
a	I-I	DET	O
5-HT	I-I	NOUN	B
(	I-I	PUNCT	O
1D	I-I	NOUN	B
)	I-I	PUNCT	O
agonist	I-I	NOUN	B
,	I-I	PUNCT	O
PNU-142633	I-I	NOUN	B
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
34	I-I	NUM	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
matching	I-I	VERB	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
35	O	NUM	O
)	O	PUNCT	O
during	O	ADP	O
an	O	DET	O
acute	B-P	ADJ	B
migraine	I-P	NOUN	I
attack	I-P	NOUN	B
.	I-P	PUNCT	O


No	O	DET	O
statistically	O	ADV	O
significant	O	ADJ	O
treatment	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
observed	O	VERB	B
at	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
dosing	O	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
after	O	ADP	O
stratifying	O	VERB	B
by	O	ADP	O
baseline	O	NOUN	B
headache	O	NOUN	B
intensity	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
h	O	NOUN	O
post-dose	O	NOUN	B
,	O	PUNCT	O
8.8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
29.4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PNU-142633	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
8.6	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
40.0	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
experienced	O	VERB	O
headache	B-OUT	NOUN	B
relief	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
2.9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
8.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PNU-142633	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
0	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
5.7	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	O
were	O	AUX	O
free	B-OUT	ADJ	B
of	I-OUT	ADP	O
headache	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
associated	O	VERB	B
with	O	ADP	I
PNU-142633	B-I	NOUN	B
treatment	O	NOUN	B
included	O	VERB	O
chest	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
(	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
QTc	B-OUT	NOUN	B
prolongation	I-OUT	NOUN	I
(	O	PUNCT	O
three	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Results	O	NOUN	B
from	O	ADP	O
this	O	DET	O
study	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
anti-migraine	O	ADJ	B
efficacy	O	NOUN	B
is	O	AUX	O
not	O	PART	O
mediated	O	VERB	O
solely	O	ADV	O
through	O	ADP	O
the	O	DET	O
5-HT	B-I	NOUN	B
(	I-I	PUNCT	O
1D	I-I	NOUN	B
)	I-I	PUNCT	O
receptor	O	NOUN	O
subtype	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
this	O	DET	O
receptor	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
the	O	DET	O
adverse	O	ADJ	B
cardiovascular	O	ADJ	B
effects	O	NOUN	O
observed	O	VERB	O
with	O	ADP	O
5-HT	B-I	NOUN	B
agonist	I-I	NOUN	B
medications	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
phase	O	NOUN	B
I	O	NOUN	I
study	O	NOUN	B
of	O	ADP	O
recombinant	B-I	ADJ	B
human	I-I	ADJ	B
ciliary	I-I	ADJ	O
neurotrophic	I-I	ADJ	O
factor	I-I	NOUN	O
(	I-I	PUNCT	O
rHCNTF	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
amyotrophic	I-P	ADJ	B
lateral	I-P	ADJ	I
sclerosis	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
ALS	O	NOUN	B
CNTF	O	NOUN	B
Treatment	O	NOUN	B
Study	O	PROPN	I
(	O	PUNCT	O
ACTS	O	NOUN	B
)	O	PUNCT	O
Phase	O	NOUN	B
I-II	O	NUM	I
Study	O	PROPN	I
Group	O	PROPN	B
.	O	PUNCT	O


Fifty-seven	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
amyotrophic	I-P	ADJ	B
lateral	I-P	ADJ	I
sclerosis	I-P	NOUN	I
(	I-P	PUNCT	O
ALS	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
0.5	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
30	O	NUM	O
micrograms/kg	O	NOUN	O
recombinant	B-I	ADJ	B
human	I-I	ADJ	B
ciliary	I-I	ADJ	O
neurotrophic	I-I	ADJ	O
factor	I-I	NOUN	O
(	I-I	PUNCT	O
rHCNTF	I-I	NOUN	B
)	I-I	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
subcutaneously	O	ADV	B
3	O	NUM	I
times	O	NOUN	O
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Dose-limiting	B-OUT	ADJ	B
toxicity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
consisting	I-OUT	VERB	O
of	I-OUT	ADP	O
febrile	I-OUT	ADJ	B
reactions	I-OUT	NOUN	I
in	I-OUT	ADP	O
some	I-OUT	DET	O
patients	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
nonproductive	I-OUT	ADJ	B
cough	I-OUT	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
micrograms/kg	O	NOUN	O
.	O	PUNCT	O


Dose-related	B-OUT	ADJ	B
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
parameters	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
acute-phase	I-OUT	ADJ	B
response	I-OUT	NOUN	I
were	O	AUX	O
noted	O	VERB	O
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
CNTF	B-I	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
receptor	O	NOUN	B
system	O	NOUN	I
to	O	PART	O
the	O	DET	O
cytokine	O	NOUN	B
interleukin-6	O	NOUN	B
(	O	PUNCT	O
IL-6	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
receptor	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
adverse	B-OUT	ADJ	I
neurologic	I-OUT	ADJ	B
consequences	I-OUT	NOUN	B
of	I-OUT	ADP	O
rHCNTF	I-OUT	ADJ	B
administration	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Antibodies	B-OUT	NOUN	B
to	I-OUT	PART	O
rHCNTF	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
sera	O	NOUN	B
of	O	ADP	O
most	O	ADJ	O
patients	O	NOUN	B
tested	O	VERB	B
after	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
continuous	O	ADJ	B
treatment	O	NOUN	I
and	O	CCONJ	O
4	O	NUM	O
weeks	O	NOUN	B
'	O	PART	O
withdrawal	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


rHCNTF	B-I	NOUN	B
was	O	AUX	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
tolerated	I-OUT	VERB	B
within	O	ADP	O
acceptable	O	ADJ	O
limits	O	NOUN	B
when	O	SCONJ	O
administered	O	VERB	B
to	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
ALS	I-P	NOUN	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
up	O	ADV	O
to	O	PART	O
30	O	NUM	O
micrograms/kg	O	NOUN	O
3	O	NUM	O
times	O	NOUN	O
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
rHCNTF	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
motor	O	NOUN	B
neuron	O	NOUN	I
diseases	O	NOUN	B
are	O	AUX	O
justified	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
an	O	DET	O
aqueous	B-I	ADJ	B
and	O	CCONJ	O
a	O	DET	O
pressurized	B-I	ADJ	B
nasal	I-I	ADJ	B
spray	I-I	NOUN	I
of	O	ADP	O
beclomethasone	B-I	NOUN	B
dipropionate	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
management	B-OUT	NOUN	B
of	I-OUT	ADP	O
seasonal	I-OUT	ADJ	B
rhinitis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	O	DET	O
multi-centre	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	B
group	O	NOUN	I
study	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
38	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
seasonal	I-P	ADJ	B
rhinitis	I-P	NOUN	I
to	O	PART	O
compare	O	VERB	B
a	O	DET	O
new	O	ADJ	O
aqueous	B-I	ADJ	B
nasal	I-I	ADJ	B
spray	I-I	NOUN	I
of	I-I	ADP	O
beclomethasone	I-I	NOUN	B
dipropionate	I-I	NOUN	I
with	I-I	ADP	O
the	I-I	DET	O
conventional	I-I	ADJ	B
pressurized	I-I	ADJ	B
nasal	I-I	ADJ	B
spray	I-I	NOUN	I
.	I-I	PUNCT	O


Beclomethasone	B-I	NOUN	B
dipropionate	I-I	NOUN	I
(	O	PUNCT	O
200	O	NUM	O
micrograms	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
twice	O	ADV	O
daily	O	ADV	B
for	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
treatments	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
equally	O	ADV	O
effective	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
well	I-OUT	ADV	O
tolerated	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
that	O	SCONJ	O
the	O	DET	O
new	O	ADJ	O
aqueous	B-I	ADJ	B
nasal	I-I	ADJ	B
spray	I-I	NOUN	I
provides	O	VERB	O
an	O	DET	O
alternative	O	ADJ	B
method	O	NOUN	O
of	O	ADP	O
intranasal	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
the	O	DET	O
steroid	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
may	O	AUX	O
prefer	O	VERB	O
an	O	DET	O
aqueous	O	ADJ	B
product	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
individual	O	ADJ	B
responsiveness	O	NOUN	B
to	O	PART	O
growth	B-I	NOUN	B
hormone	I-I	NOUN	I
(	I-I	PUNCT	O
GH	I-I	NOUN	O
)	I-I	PUNCT	O
treatment	I-I	NOUN	B
in	O	ADP	O
GH-deficient	B-P	ADJ	B
adults	I-P	NOUN	B
is	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
GH-binding	O	ADJ	B
protein	O	NOUN	I
,	O	PUNCT	O
body	B-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
gender	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
trial	O	NOUN	B
was	O	AUX	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
individual	O	ADJ	B
responsiveness	O	NOUN	B
to	O	PART	O
GH	B-I	NOUN	B
treatment	I-I	NOUN	I
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
composition	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
search	O	VERB	B
for	O	ADP	O
possible	O	ADJ	O
predictors	O	NOUN	B
of	O	ADP	O
the	O	DET	O
response	O	NOUN	B
in	O	ADP	O
GH-deficient	O	ADJ	B
adults	O	NOUN	B
.	O	PUNCT	O


Sixty-eight	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
44	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
24	I-P	NUM	O
women	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
44.3	I-P	NUM	O
(	I-P	PUNCT	O
1.2	I-P	NUM	O
)	I-P	PUNCT	O
yr	I-P	NOUN	O
and	I-P	CCONJ	O
verified	I-P	VERB	O
GH	I-P	NOUN	B
deficiency	I-P	NOUN	I
participated	I-P	VERB	O
in	I-P	ADP	O
a	I-P	DET	O
2-phase	I-P	ADJ	B
treatment	I-P	NOUN	I
trial	I-P	NOUN	I
with	O	ADP	O
an	O	DET	O
initial	O	ADJ	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
6-month	O	ADJ	O
period	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
an	O	DET	O
open	O	ADJ	B
treatment	O	NOUN	I
period	O	NOUN	B
,	O	PUNCT	O
thereby	O	ADV	O
ensuring	O	VERB	O
all	O	DET	O
patients	B-P	NOUN	B
12	I-P	NUM	O
months	I-P	NOUN	B
of	I-P	ADP	O
GH	I-P	NOUN	B
treatment	I-P	NOUN	I
.	I-P	PUNCT	O


Recombinant	B-I	ADJ	B
human	I-I	ADJ	B
GH	I-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
sc	O	ADV	B
daily	O	ADV	O
at	O	ADP	O
bedtime	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
target	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
micrograms/kg	O	NOUN	O
x	O	NOUN	O
day	O	NOUN	B
.	O	PUNCT	O


GHBP	O	NOUN	B
was	O	AUX	O
measured	O	VERB	O
by	O	ADP	O
ligand-mediated	O	ADJ	B
immunofunctional	O	ADJ	I
assay	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
serum	O	NOUN	B
insulin-like	O	ADJ	B
growth	O	NOUN	I
factor	O	NOUN	I
I	O	NOUN	I
(	O	PUNCT	O
IGF-I	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
RIA	O	NOUN	B
after	O	ADP	O
acid-ethanol	O	ADJ	B
extraction	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
truncated	O	VERB	B
IGF-I	O	NOUN	O
analog	O	NOUN	O
as	O	ADP	O
the	O	DET	O
radioligand	O	NOUN	B
.	O	PUNCT	O


Lean	B-OUT	ADJ	B
body	I-OUT	NOUN	I
mass	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
LBM	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
body	I-OUT	NOUN	B
fat	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
dual	O	ADJ	B
energy	O	NOUN	I
x-ray	O	NOUN	I
absorptiometry	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
total	O	ADJ	B
body	O	NOUN	I
water	O	NOUN	I
(	O	PUNCT	O
TBW	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
bioelectrical	O	ADJ	B
impedance	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
control	O	NOUN	O
period	O	NOUN	O
,	O	PUNCT	O
serum	B-OUT	NOUN	B
IGF-I	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
LBM	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
TBW	I-OUT	NOUN	B
increased	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
BF	B-OUT	NOUN	B
decreased	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
serum	B-OUT	NOUN	B
GHBP	I-OUT	NOUN	B
was	O	AUX	O
unchanged	O	ADJ	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
GH	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
placebo	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
GH	O	NOUN	B
treatment	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
individual	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
BF	B-OUT	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
-12.5	O	NUM	O
to	O	PART	O
4.3	O	NUM	O
kg	O	NOUN	O
and	O	CCONJ	O
from	O	ADP	O
-4.5	O	NUM	O
to	O	PART	O
10.1	O	NUM	O
kg	O	NOUN	O
in	O	ADP	O
LBM	O	PROPN	B
.	O	PUNCT	O


Age	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
baseline	B-OUT	NOUN	B
GHBP	I-OUT	NOUN	B
level	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
inversely	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
LBM	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
GH-induced	B-OUT	ADJ	B
increment	I-OUT	NOUN	B
in	I-OUT	ADP	O
IGF-I	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
TBW	I-OUT	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
men	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
women	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
decreases	O	NOUN	B
in	O	ADP	O
BF	B-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
men	O	NOUN	B
and	O	CCONJ	O
women	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
trial	O	NOUN	B
demonstrates	O	VERB	O
the	O	DET	O
variability	O	NOUN	B
in	O	ADP	O
responsiveness	O	NOUN	B
to	O	PART	O
GH	B-I	NOUN	B
administration	O	NOUN	I
in	O	ADP	O
GH-deficient	O	ADJ	B
adults	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
best	O	ADJ	O
response	O	NOUN	B
to	O	PART	O
GH	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
younger	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
GHBP	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
men	O	NOUN	B
responded	O	VERB	O
better	O	ADJ	O
than	O	ADP	O
women	O	NOUN	B
.	O	PUNCT	O


Mediation	O	NOUN	B
analysis	O	NOUN	I
demonstrates	O	VERB	O
that	O	SCONJ	O
trans-eQTLs	B-OUT	NOUN	B
are	O	AUX	O
often	O	ADV	O
explained	O	VERB	O
by	O	ADP	O
cis-mediation	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
genome-wide	O	ADJ	B
analysis	O	NOUN	I
among	O	ADP	O
1,800	B-P	NUM	O
South	I-P	PROPN	B
Asians	I-P	PROPN	I
.	I-P	PUNCT	O


A	O	DET	O
large	O	ADJ	O
fraction	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
genes	O	NOUN	I
are	O	AUX	O
regulated	O	VERB	O
by	O	ADP	O
genetic	O	ADJ	B
variation	O	NOUN	I
near	O	ADP	I
the	O	DET	O
transcribed	O	VERB	B
sequence	O	NOUN	I
(	O	PUNCT	O
cis-eQTL	O	NOUN	B
,	O	PUNCT	O
expression	O	NOUN	B
quantitative	O	ADJ	O
trait	O	NOUN	O
locus	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
many	O	ADJ	O
cis-eQTLs	O	NOUN	B
have	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
human	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


Less	O	ADV	O
is	O	AUX	O
known	O	VERB	O
regarding	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
genetic	O	ADJ	B
variation	O	NOUN	I
on	O	ADP	O
expression	B-OUT	NOUN	B
of	I-OUT	ADP	O
distant	I-OUT	ADJ	B
genes	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
trans-eQTLs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
biological	O	ADJ	B
mechanisms	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
work	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
use	O	VERB	O
genome-wide	B-I	ADJ	B
data	I-I	NOUN	B
on	I-I	ADP	O
SNPs	I-I	NOUN	B
and	O	CCONJ	O
array-based	B-I	ADJ	B
expression	I-I	NOUN	I
measures	I-I	NOUN	I
from	O	ADP	O
mononuclear	O	ADJ	B
cells	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
a	O	DET	O
population-based	O	ADJ	B
cohort	O	NOUN	I
of	O	ADP	O
1,799	B-P	NUM	O
Bangladeshi	I-P	ADJ	B
individuals	I-P	NOUN	B
to	O	PART	O
characterize	O	VERB	B
cis-	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
trans-eQTLs	I-OUT	NOUN	B
and	O	CCONJ	O
determine	O	VERB	O
if	O	SCONJ	O
observed	O	VERB	O
trans-eQTL	B-OUT	ADJ	B
associations	I-OUT	NOUN	B
are	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
transcripts	O	NOUN	B
in	O	ADP	O
cis	O	NOUN	O
with	O	ADP	O
the	O	DET	O
SNPs	O	NOUN	B
showing	O	VERB	O
trans-association	O	ADV	B
,	O	PUNCT	O
using	O	VERB	O
Sobel	B-OUT	NOUN	B
tests	I-OUT	NOUN	I
of	I-OUT	ADP	I
mediation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


We	O	PRON	O
observed	O	VERB	B
434	B-P	NUM	O
independent	I-P	ADJ	O
trans-eQTL	I-OUT	ADJ	B
associations	I-OUT	NOUN	B
at	O	ADP	O
a	O	DET	O
false-discovery	O	ADJ	B
rate	O	NOUN	I
of	O	ADP	O
0.05	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
189	O	NUM	O
of	O	ADP	O
these	O	DET	O
trans-eQTLs	B-OUT	NOUN	B
were	O	AUX	O
also	O	ADV	O
cis-eQTLs	O	NOUN	B
(	O	PUNCT	O
enrichment	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Among	O	ADP	O
these	O	DET	O
189	B-P	NUM	O
trans-eQTL	I-OUT	ADJ	B
associations	I-OUT	NOUN	B
,	I-P	PUNCT	O
39	I-P	NUM	O
were	I-P	AUX	O
significantly	I-P	ADV	O
attenuated	I-P	VERB	B
after	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
a	O	DET	O
cis-mediator	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
Sobel	O	NOUN	B
P	O	NOUN	I
<	O	X	O
10-5	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
attempted	O	VERB	O
to	O	PART	O
replicate	O	VERB	B
21	O	NUM	O
of	O	ADP	O
these	O	DET	O
mediation	O	NOUN	B
signals	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
European	O	ADJ	B
cohorts	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
while	O	SCONJ	O
only	O	ADV	O
7	O	NUM	O
trans-eQTL	B-OUT	ADJ	B
associations	I-OUT	NOUN	B
were	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
both	O	DET	O
cohorts	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
showed	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
cis-mediation	O	NOUN	B
.	O	PUNCT	O


Analyses	O	NOUN	B
of	O	ADP	O
simulated	O	ADJ	B
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
complete	O	ADJ	B
mediation	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
observed	O	VERB	O
as	O	ADP	O
partial	O	ADJ	B
mediation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
mediator	O	NOUN	O
measurement	O	NOUN	B
error	O	NOUN	O
or	O	CCONJ	O
imperfect	O	ADJ	B
LD	O	NOUN	B
between	O	ADP	O
measured	O	VERB	B
and	O	CCONJ	O
causal	O	ADJ	O
variants	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
trans-associations	O	NOUN	B
can	O	AUX	O
become	O	VERB	O
significantly	O	ADV	O
stronger	O	ADJ	O
or	O	CCONJ	O
switch	O	NOUN	B
directions	O	NOUN	B
after	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
a	O	DET	O
potential	O	ADJ	O
mediator	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
simulated	O	ADJ	B
data	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
demonstrate	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
phenomenon	O	NOUN	B
is	O	AUX	O
expected	O	VERB	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
strong	O	ADJ	B
cis-trans	O	ADJ	B
confounding	O	NOUN	B
and	O	CCONJ	O
when	O	SCONJ	O
the	O	DET	O
measured	O	VERB	B
cis-transcript	O	NOUN	B
is	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
true	O	ADJ	O
(	O	PUNCT	O
unmeasured	O	ADJ	O
)	O	PUNCT	O
mediator	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
by	O	ADP	O
applying	O	VERB	O
mediation	O	NOUN	B
analysis	O	NOUN	I
to	O	PART	O
eQTL	O	NOUN	B
data	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
substantial	O	ADJ	O
fraction	O	NOUN	B
of	O	ADP	O
observed	O	VERB	O
trans-eQTL	B-OUT	ADJ	B
associations	I-OUT	NOUN	B
can	O	AUX	O
be	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
cis-mediation	O	NOUN	B
.	O	PUNCT	O


Future	O	ADJ	O
studies	O	NOUN	B
should	O	AUX	O
focus	O	VERB	O
on	O	ADP	O
understanding	O	VERB	O
the	O	DET	O
mechanisms	O	NOUN	B
underlying	O	VERB	O
widespread	O	ADJ	B
cis-mediation	O	ADJ	B
and	O	CCONJ	O
their	O	PRON	O
relevance	O	NOUN	B
to	O	PART	O
disease	O	NOUN	B
biology	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
using	O	VERB	O
mediation	O	NOUN	B
analysis	O	NOUN	I
to	O	PART	O
improve	O	VERB	O
eQTL	O	NOUN	B
discovery	O	NOUN	B
.	O	PUNCT	O


Fondaparinux	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
intermittent	I-I	ADJ	B
pneumatic	I-I	ADJ	I
compression	I-I	NOUN	I
vs.	O	CCONJ	O
intermittent	B-I	ADJ	B
pneumatic	I-I	ADJ	O
compression	I-I	NOUN	O
alone	I-I	ADV	O
for	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
venous	B-OUT	ADJ	B
thromboembolism	I-OUT	NOUN	I
after	I-P	ADP	O
abdominal	I-P	ADJ	B
surgery	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
comparison	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
combined	O	ADJ	B
mechanical	O	ADJ	B
and	O	CCONJ	O
pharmacologic	O	ADJ	B
methods	O	NOUN	I
for	O	ADP	O
venous	B-OUT	ADJ	B
thromboembolism	I-OUT	NOUN	I
prevention	O	NOUN	I
after	B-P	ADP	O
abdominal	I-P	ADJ	B
surgery	I-P	NOUN	I
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
clearly	O	ADV	O
established	O	VERB	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
safety	B-OUT	NOUN	B
of	O	ADP	O
fondaparinux	B-I	NOUN	B
in	I-I	ADP	O
conjunction	I-I	NOUN	B
with	I-I	ADP	O
intermittent	I-I	ADJ	B
pneumatic	I-I	ADJ	I
compression	I-I	NOUN	I
vs.	O	CCONJ	O
intermittent	B-I	ADJ	B
pneumatic	I-I	ADJ	O
compression	I-I	NOUN	O
alone	I-I	ADV	O
in	O	ADP	O
this	O	DET	O
context	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
superiority	O	NOUN	O
trial	O	NOUN	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
aged	I-P	ADJ	B
at	I-P	ADP	O
least	I-P	ADJ	O
40	I-P	NUM	O
years	I-P	NOUN	B
undergoing	I-P	VERB	O
abdominal	I-P	ADJ	B
surgery	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
fondaparinux	B-I	NOUN	B
2.5	O	NUM	O
mg	O	NOUN	O
or	O	CCONJ	O
placebo	B-I	ADJ	B
s.c.	O	ADV	O
for	O	ADP	O
5-9	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
starting	O	VERB	O
6-8	O	NUM	O
h	O	NOUN	O
postoperatively	O	ADV	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
intermittent	B-I	ADJ	B
pneumatic	I-I	ADJ	B
compression	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
outcome	O	NOUN	B
was	O	AUX	O
venous	B-OUT	ADJ	B
thromboembolism	I-OUT	NOUN	I
up	I-OUT	ADV	O
to	I-OUT	ADP	O
day	I-OUT	NOUN	B
10	I-OUT	NUM	O
.	I-OUT	PUNCT	O


The	O	DET	O
main	O	ADJ	O
safety	O	NOUN	B
outcomes	O	NOUN	B
were	O	AUX	O
major	B-OUT	ADJ	O
bleeding	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
all-cause	I-OUT	ADJ	O
mortality	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Follow-up	O	X	B
lasted	O	VERB	O
32	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Of	O	ADP	O
the	O	DET	O
1309	B-P	NUM	O
patients	I-P	NOUN	B
randomized	O	ADJ	B
,	O	PUNCT	O
842	O	NUM	O
(	O	PUNCT	O
64.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
evaluable	O	ADJ	O
for	O	ADP	O
efficacy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
venous	B-OUT	ADJ	B
thromboembolism	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
was	O	AUX	O
1.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
7/424	O	ADJ	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
fondaparinux-treated	B-I	ADJ	B
patients	I-P	NOUN	B
and	O	CCONJ	O
5.3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
22/418	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
placebo-treated	B-I	ADJ	B
patients	I-P	NOUN	B
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
reduction	O	NOUN	B
69.8	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
27.9-87.3	O	X	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Fondaparinux	B-I	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	O
the	O	DET	O
proximal	B-OUT	ADJ	B
deep	I-OUT	ADJ	O
vein	I-OUT	NOUN	O
thrombosis	I-OUT	NOUN	O
rate	I-OUT	NOUN	B
from	O	ADP	O
1.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
7/417	O	ADV	O
)	O	PUNCT	O
to	O	PART	O
0.2	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
1/424	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.037	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Major	B-OUT	ADJ	O
bleeds	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
1.6	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
10/635	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
0.2	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
1/650	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
fondaparinux-treated	B-I	ADJ	B
and	O	CCONJ	O
placebo-treated	B-I	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.006	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
none	O	NOUN	O
being	O	AUX	O
fatal	O	ADJ	B
or	O	CCONJ	O
involving	O	VERB	O
a	O	DET	O
critical	O	ADJ	B
organ	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
day	O	NOUN	B
32	O	NUM	O
,	O	PUNCT	O
eight	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
1.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
receiving	O	VERB	O
fondaparinux	B-I	NOUN	B
and	O	CCONJ	O
five	O	NUM	O
(	O	PUNCT	O
0.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
receiving	O	VERB	O
placebo	B-I	NOUN	B
had	O	AUX	O
died	B-OUT	VERB	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
abdominal	I-P	ADJ	B
surgery	I-P	NOUN	I
and	I-P	CCONJ	O
receiving	I-P	VERB	O
intermittent	I-I	ADJ	B
pneumatic	I-I	ADJ	I
compression	I-I	NOUN	I
,	I-I	PUNCT	O
fondaparinux	I-I	NOUN	B
2.5	O	NUM	O
mg	O	NOUN	O
reduced	O	VERB	B
the	O	DET	O
venous	B-OUT	ADJ	B
thromboembolism	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
by	O	ADP	O
69.8	O	NUM	O
%	O	NOUN	O
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
pneumatic	B-I	ADJ	B
compression	I-I	NOUN	I
alone	I-I	ADV	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
low	B-OUT	ADJ	O
bleeding	I-OUT	ADJ	B
risk	I-OUT	NOUN	O
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Unopposed	B-I	ADJ	B
estrogen	I-I	NOUN	I
increases	O	VERB	O
total	O	ADJ	B
plasma	O	NOUN	I
factor	O	NOUN	I
VII	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
active	O	ADJ	O
factor	O	NOUN	O
VII	O	NOUN	O
--	O	PUNCT	O
a	O	DET	O
short-term	O	ADJ	B
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
in	O	ADP	O
healthy	B-P	ADJ	B
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


Estrogen	B-I	NOUN	B
therapy	I-I	NOUN	I
may	O	AUX	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
arterial	O	ADJ	B
thromboembolism	O	NOUN	I
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
in	O	ADP	O
the	O	DET	O
short	O	ADJ	B
term	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
and	O	CCONJ	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
25	B-P	NUM	O
healthy	I-P	ADJ	B
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
(	I-P	PUNCT	O
52.5	I-P	NUM	O
+/-	I-P	CCONJ	O
2.8	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
,	O	PUNCT	O
we	O	PRON	O
therefore	O	ADV	O
examined	O	VERB	B
the	O	DET	O
short-term	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
unopposed	B-I	ADJ	B
estrogen	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
fasting	O	NOUN	B
and	O	CCONJ	O
fat-load-stimulated	O	ADJ	O
plasma	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
total	O	ADJ	B
factor	O	NOUN	I
VII	O	NOUN	I
versus	O	CCONJ	O
active	O	ADJ	B
factor	O	NOUN	I
VII	O	NOUN	I
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
total	I-OUT	ADJ	B
factor	I-OUT	NOUN	I
VII	I-OUT	NOUN	I
was	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
chromogenic	O	ADJ	B
assay	O	NOUN	I
;	O	PUNCT	O
plasma	O	NOUN	B
active	O	ADJ	O
FVII	O	NOUN	B
by	O	ADP	O
a	O	DET	O
recently	O	ADV	O
developed	O	VERB	O
method	O	NOUN	B
using	O	VERB	O
truncated	O	VERB	B
tissue	O	NOUN	I
factor	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
compared	O	VERB	O
to	O	ADP	O
placebo	B-I	NOUN	B
,	O	PUNCT	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
oral	B-I	ADJ	B
17beta-estradiol	I-I	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
increased	O	VERB	B
the	O	DET	O
mean	B-OUT	ADJ	O
fasting	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
postprandial	I-OUT	ADJ	B
plasma	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
total	I-OUT	ADJ	B
factor	I-OUT	NOUN	I
VII	I-OUT	NOUN	I
by	O	ADP	O
17	O	NUM	O
and	O	CCONJ	O
21	O	NUM	O
%	O	NOUN	O
points	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
both	O	DET	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
fasting	B-OUT	NOUN	B
and/or	I-OUT	CCONJ	O
postprandial	I-OUT	ADJ	B
plasma	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
active	I-OUT	ADJ	B
factor	I-OUT	NOUN	I
VII	I-OUT	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
change	O	NOUN	O
both	O	CCONJ	O
0.05	O	NUM	O
ng/mL	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.35	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
change	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
fasting	I-OUT	ADJ	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
total	I-OUT	ADJ	B
factor	I-OUT	NOUN	I
VII	I-OUT	NOUN	I
after	O	ADP	O
therapy	O	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
change	B-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
fasting	I-OUT	ADJ	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
active	I-OUT	ADJ	B
factor	I-OUT	NOUN	I
VII	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.27	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.21	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
argue	O	VERB	O
against	O	ADP	O
the	O	DET	O
idea	O	NOUN	O
that	O	SCONJ	O
elevated	O	ADJ	B
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
total	I-OUT	ADJ	B
factor	I-OUT	NOUN	I
VII	I-OUT	NOUN	I
underlie	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
arterial	I-OUT	ADJ	B
thromboembolism	I-OUT	NOUN	I
in	O	ADP	O
postmenopausal	B-P	ADJ	B
women	I-P	NOUN	B
using	O	VERB	O
unopposed	B-I	ADJ	B
estrogen	I-I	NOUN	B
replacement	I-I	NOUN	I
.	I-I	PUNCT	O


Evaluating	O	VERB	B
intervention	B-I	NOUN	B
using	O	VERB	O
time	B-I	NOUN	B
aids	I-I	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
disabilities	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
complex	B-I	ADJ	B
intervention	I-I	NOUN	B
using	I-I	VERB	O
time	I-I	NOUN	B
aids	I-I	NOUN	I
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
intellectual	I-P	ADJ	B
and	I-P	CCONJ	O
developmental	I-P	ADJ	B
disabilities	I-P	NOUN	B
who	I-P	PRON	O
exhibit	I-P	VERB	O
limitations	I-P	NOUN	B
in	I-P	ADP	O
daily	I-P	ADJ	B
time	I-P	NOUN	O
management	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Participating	B-P	VERB	B
children	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
47	I-P	NUM	O
)	I-P	PUNCT	O
(	I-P	PUNCT	O
F17/M30	I-P	PROPN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
aged	I-P	ADJ	B
6-11	I-P	NUM	O
with	I-P	ADP	O
ADHD	I-P	NOUN	B
,	I-P	PUNCT	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
,	I-P	PUNCT	O
mild	I-P	ADJ	B
or	I-P	CCONJ	O
moderate	I-P	ADJ	B
intellectual	I-P	ADJ	B
disability	I-P	NOUN	I
,	I-P	PUNCT	O
spina	I-P	ADJ	B
bifida	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
cerebral	I-P	ADJ	B
palsy	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
used	O	VERB	O
a	O	DET	O
Randomized	O	PROPN	B
Block	O	PROPN	I
and	O	CCONJ	I
Waiting	O	PROPN	O
List	O	NOUN	O
control	O	NOUN	B
group	O	NOUN	I
design	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
25	O	NUM	O
children	O	NOUN	B
allocated	O	VERB	O
to	O	PART	O
control	B-I	NOUN	B
and	O	CCONJ	O
22	O	NUM	O
to	O	ADP	O
intervention	B-I	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


In	B-P	ADP	O
total	I-P	NOUN	O
10	I-P	NUM	O
children	I-P	NOUN	B
(	I-P	PUNCT	O
21.3	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
five	I-P	NUM	O
from	I-P	ADP	O
each	I-P	DET	O
group	I-P	NOUN	B
,	I-P	PUNCT	O
dropped	I-P	VERB	O
out	I-P	ADP	O
,	I-P	PUNCT	O
leaving	I-P	VERB	O
37	I-P	NUM	O
children	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
data	I-P	NOUN	B
analysis	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	VERB	B
Children	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
gained	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
time-processing	B-OUT	ADJ	B
ability	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
first	O	ADJ	O
and	O	CCONJ	O
second	O	ADJ	O
data	O	NOUN	B
collection	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
improved	O	VERB	B
time-processing	B-OUT	ADJ	B
ability	I-OUT	NOUN	I
significantly	O	ADV	O
more	O	ADJ	O
than	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
also	O	ADV	O
displayed	O	VERB	O
significant	O	ADJ	O
changes	O	NOUN	B
after	O	ADP	O
receiving	O	VERB	O
intervention	O	NOUN	B
between	O	ADP	O
the	O	DET	O
second	O	ADJ	O
and	O	CCONJ	O
third	O	ADJ	O
data	O	NOUN	B
collection	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
intervention	O	NOUN	B
had	O	AUX	O
a	O	DET	O
large	O	ADJ	O
effect	O	NOUN	O
(	O	PUNCT	O
ES	O	PROPN	B
Cohen	O	PROPN	O
's	O	PART	O
d	O	NOUN	O
=	O	ADJ	O
0.81	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
time-processing	B-OUT	ADJ	B
ability	I-OUT	NOUN	I
and	O	CCONJ	O
a	O	DET	O
medium	O	NOUN	B
effect	O	NOUN	O
(	O	PUNCT	O
ES	O	PROPN	B
Cohen	O	PROPN	O
's	O	PART	O
d	O	NOUN	O
=	O	ADJ	O
0.68	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
managing	B-OUT	VERB	O
one	I-OUT	NUM	O
's	I-OUT	PART	O
time	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
preliminary	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
time-processing	B-OUT	ADJ	B
ability	I-OUT	NOUN	I
and	O	CCONJ	O
managing	B-OUT	VERB	B
one	I-OUT	NUM	O
's	I-OUT	PART	O
time	I-OUT	NOUN	B
can	O	AUX	O
be	O	AUX	O
improved	O	VERB	B
by	O	ADP	O
intervention	O	NOUN	B
using	O	VERB	O
time	O	NOUN	B
aids	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
intellectual	I-P	ADJ	B
and	I-P	CCONJ	O
developmental	I-P	ADJ	B
disabilities	I-P	NOUN	B
,	O	PUNCT	O
supporting	O	VERB	O
the	O	DET	O
need	O	NOUN	O
to	O	PART	O
consider	O	VERB	O
time	O	NOUN	B
aids	O	NOUN	I
in	O	ADP	O
intervention	O	NOUN	B
in	O	ADP	O
these	O	DET	O
children	O	NOUN	B
.	O	PUNCT	O


Line-item	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Aberrant	O	PROPN	B
Behavior	O	PROPN	I
Checklist	O	PROPN	I
:	O	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
two	B-P	NUM	O
studies	I-P	NOUN	B
of	I-P	ADP	O
aripiprazole	I-I	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
treatment	I-P	NOUN	B
of	I-P	ADP	O
irritability	I-P	NOUN	B
associated	I-P	VERB	B
with	I-P	ADP	I
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVES	O	VERB	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
aripiprazole	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
discrete	O	ADJ	B
symptoms	O	NOUN	B
of	O	ADP	O
irritability	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
autistic	O	ADJ	B
disorder	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
other	O	ADJ	O
symptoms	O	NOUN	B
captured	O	VERB	O
on	O	ADP	O
the	O	DET	O
Aberrant	O	PROPN	B
Behavior	O	PROPN	I
Checklist	O	PROPN	I
(	O	PUNCT	O
ABC	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
post	O	NOUN	B
hoc	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
data	O	NOUN	B
from	O	ADP	O
two	B-P	NUM	O
8-week	I-P	NOUN	B
,	I-P	PUNCT	O
randomized	I-P	ADJ	B
,	I-P	PUNCT	O
double-blind	I-P	ADJ	B
,	I-P	PUNCT	O
multicenter	I-P	NOUN	B
trials	I-P	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
aripiprazole	B-I	NOUN	B
dosed	I-I	VERB	B
flexibly	I-I	ADV	O
(	O	PUNCT	O
2-15	O	NUM	O
mg/day	O	NOUN	B
,	O	PUNCT	O
n=47	O	ADJ	O
)	O	PUNCT	O
or	O	CCONJ	O
fixed	O	VERB	B
(	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
15	O	NUM	O
mg/day	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
166	O	NUM	O
)	O	PUNCT	O
versus	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
flexibly	O	ADV	O
dosed	O	VERB	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
51	O	NUM	O
;	O	PUNCT	O
fixed	O	VERB	B
dose	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
52	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	B
on	O	ADP	O
the	O	DET	O
58	O	NUM	O
ABC	O	PROPN	B
items	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Statistically	O	ADV	B
significantly	O	ADV	I
greater	O	ADJ	O
improvement	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
with	O	ADP	O
aripiprazole	B-I	NOUN	B
versus	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
all	O	DET	O
arms	O	NOUN	O
in	O	ADP	O
both	O	DET	O
trials	O	NOUN	B
on	O	ADP	O
the	O	DET	O
ABC-Irritability	B-OUT	NOUN	B
total	I-OUT	NOUN	B
subscale	I-OUT	NOUN	I
score	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
on	I-OUT	ADP	O
the	I-OUT	DET	O
following	I-OUT	VERB	O
individual	I-OUT	ADJ	O
ABC-Irritability	I-OUT	NOUN	B
items	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
Mood	I-OUT	NOUN	B
changes	I-OUT	NOUN	I
quickly	I-OUT	ADV	O
,	I-OUT	PUNCT	O
cries/screams	I-OUT	PROPN	B
inappropriately	I-OUT	ADV	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
stamps	I-OUT	VERB	B
feet/bangs	I-OUT	NOUN	I
objects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Several	O	ADJ	O
additional	O	ADJ	O
items	O	NOUN	B
measuring	O	VERB	B
tantrum-like	B-OUT	ADJ	B
behaviors	I-OUT	NOUN	I
improved	O	VERB	B
in	O	ADP	O
the	O	DET	O
flexibly	O	ADV	O
dosed	O	VERB	B
trial	O	NOUN	O
and	O	CCONJ	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
arm	O	NOUN	O
of	O	ADP	O
the	O	DET	O
fixed-dose	O	ADJ	B
trial	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Measures	B-OUT	NOUN	B
of	I-OUT	ADP	O
self-injurious	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
,	O	PUNCT	O
which	O	DET	O
had	O	AUX	O
low	O	ADJ	O
baseline	O	NOUN	B
values	O	NOUN	O
,	O	PUNCT	O
demonstrated	O	VERB	O
numerical	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
,	O	PUNCT	O
improvement	O	NOUN	B
in	O	ADP	O
both	O	DET	O
trials	O	NOUN	B
.	O	PUNCT	O


Statistically	O	ADV	B
significantly	O	ADV	I
greater	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
ABC	B-OUT	PROPN	B
Stereotypic	I-OUT	ADJ	B
Behavior	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
Hyperactivity	I-OUT	NOUN	B
total	I-OUT	NOUN	O
subscale	I-OUT	NOUN	O
scores	I-OUT	NOUN	O
was	O	AUX	O
also	O	ADV	O
consistent	O	ADJ	O
across	O	ADP	O
all	O	DET	O
arms	O	NOUN	O
in	O	ADP	O
both	O	DET	O
trials	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
cluster	O	NOUN	B
of	O	ADP	O
items	O	NOUN	B
related	O	VERB	O
to	O	PART	O
hyperkinesis	B-OUT	NOUN	B
that	O	PRON	O
were	O	AUX	O
consistently	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Aripiprazole	B-I	NOUN	B
is	O	AUX	O
efficacious	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
irritability	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
disorder	I-P	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
symptoms	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
tantrum	O	ADJ	B
behavior	O	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
videotape	B-I	NOUN	B
information	I-I	NOUN	O
intervention	I-I	NOUN	O
at	O	ADP	O
discharge	O	NOUN	B
on	O	ADP	O
diet	O	NOUN	B
and	O	CCONJ	O
exercise	O	NOUN	B
compliance	O	NOUN	B
after	O	ADP	O
coronary	O	ADJ	B
bypass	O	NOUN	I
surgery	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
relative	O	ADJ	O
effects	O	NOUN	O
on	O	ADP	O
compliance	O	NOUN	B
with	O	ADP	O
recommended	O	VERB	B
lifestyle	O	NOUN	B
changes	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
experimental	B-I	ADJ	B
videotapes	I-I	NOUN	B
that	O	PRON	O
involved	O	VERB	O
different	O	ADJ	O
approaches	O	NOUN	B
for	O	ADP	O
preparing	O	VERB	O
coronary	B-P	ADJ	B
artery	I-P	NOUN	I
bypass	I-P	NOUN	I
graft	I-P	NOUN	I
(	I-P	PUNCT	O
CABG	I-P	NOUN	B
)	I-P	PUNCT	O
patients	I-P	NOUN	B
for	O	ADP	O
the	O	DET	O
posthospital	O	ADJ	B
recovery	O	NOUN	I
period	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
tapes	O	NOUN	B
differed	O	VERB	O
in	O	ADP	O
the	O	DET	O
extent	O	NOUN	O
to	O	PART	O
which	O	DET	O
they	O	PRON	O
portrayed	O	VERB	O
the	O	DET	O
recovery	O	NOUN	B
period	O	NOUN	B
as	O	ADP	O
a	O	DET	O
steady	O	ADJ	B
,	O	PUNCT	O
forward	O	ADJ	O
progression	O	NOUN	B
versus	O	CCONJ	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
"	O	PUNCT	O
ups	O	NOUN	B
and	O	CCONJ	O
downs	O	NOUN	B
.	O	PUNCT	O


"	O	PUNCT	O
METHODS	O	NOUN	O
Two	B-P	NUM	O
hundred	I-P	NUM	O
sixteen	I-P	NUM	O
male	I-P	NOUN	B
and	I-P	CCONJ	O
female	I-P	ADJ	B
CABG	I-P	NOUN	B
patients	I-P	NOUN	B
were	O	AUX	O
assigned	O	VERB	O
randomly	O	ADV	O
either	O	CCONJ	O
to	O	PART	O
view	O	VERB	O
one	B-I	NUM	O
of	I-I	ADP	O
the	I-I	DET	O
two	I-I	NUM	O
videotapes	I-I	NOUN	B
before	I-I	ADP	O
discharge	I-I	NOUN	B
from	I-I	ADP	O
the	I-I	DET	O
hospital	I-I	NOUN	B
or	I-I	CCONJ	O
to	I-I	PART	O
receive	I-I	VERB	O
only	I-I	ADV	O
the	I-I	DET	O
standard	I-I	ADJ	B
discharge	I-I	NOUN	I
preparation	I-I	NOUN	I
provided	O	VERB	O
by	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
completed	O	VERB	O
measures	B-OUT	NOUN	B
of	I-OUT	ADP	O
anxiety	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
self-efficacy	I-OUT	NOUN	B
at	O	ADP	O
discharge	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
month	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
discharge	O	NOUN	B
from	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
also	O	ADV	O
completed	O	VERB	O
measures	O	NOUN	B
of	O	ADP	O
dietary	B-OUT	ADJ	B
fat	I-OUT	ADJ	O
consumption	I-OUT	NOUN	B
and	O	CCONJ	O
activity	B-OUT	NOUN	B
level	I-OUT	NOUN	O
1	I-OUT	NUM	O
and	I-OUT	CCONJ	O
3	I-OUT	NUM	O
months	O	NOUN	B
after	O	ADP	O
discharge	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Relative	O	ADJ	O
to	O	PART	O
controls	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
who	O	PRON	O
viewed	O	VERB	O
either	O	DET	O
of	O	ADP	O
the	O	DET	O
videotapes	B-I	NOUN	B
before	O	ADP	O
hospital	O	NOUN	B
release	O	NOUN	I
reported	O	VERB	O
higher	O	ADJ	B
self-efficacy	B-OUT	NOUN	B
for	I-OUT	ADP	O
adhering	I-OUT	VERB	O
to	I-OUT	ADP	O
the	I-OUT	DET	O
recommended	I-OUT	VERB	B
low-fat	I-OUT	NOUN	B
diet	I-OUT	NOUN	I
both	O	CCONJ	O
at	O	ADP	O
discharge	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
month	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Viewing	O	VERB	O
either	O	DET	O
of	O	ADP	O
the	O	DET	O
videotapes	O	NOUN	B
also	O	ADV	O
resulted	O	VERB	O
in	O	ADP	O
significantly	B-OUT	ADV	O
less	I-OUT	ADV	O
dietary	I-OUT	ADJ	B
fat	I-OUT	ADJ	O
intake	I-OUT	NOUN	O
1	I-OUT	NUM	O
month	I-OUT	NOUN	B
after	I-OUT	ADP	O
hospital	I-OUT	NOUN	B
release	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
viewed	O	VERB	O
the	O	DET	O
tape	O	NOUN	B
that	O	PRON	O
portrayed	O	VERB	O
the	O	DET	O
recovery	O	NOUN	B
period	O	NOUN	B
as	O	ADP	O
consisting	O	VERB	O
of	O	ADP	O
ups	O	NOUN	B
and	O	CCONJ	O
downs	O	NOUN	B
also	O	ADV	O
reported	O	VERB	O
significantly	O	ADV	O
more	O	ADV	O
frequent	O	ADJ	B
moderate	B-OUT	ADJ	B
exercise	I-OUT	NOUN	B
at	I-OUT	ADP	O
1	I-OUT	NUM	O
month	I-OUT	NOUN	B
and	O	CCONJ	O
more	O	ADV	O
frequent	O	ADJ	B
strenuous	B-OUT	ADJ	B
exercise	I-OUT	NOUN	I
3	O	NUM	I
months	O	NOUN	B
after	O	ADP	O
discharge	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
experimental	O	ADJ	B
videotapes	B-I	NOUN	B
proved	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
method	O	NOUN	B
for	O	ADP	O
increasing	O	VERB	B
dietary	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
exercise	I-OUT	VERB	B
compliance	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
3	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
CABG	O	PROPN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
40	O	NUM	O
milliliters	O	NOUN	B
of	O	ADP	O
0.25	O	NUM	O
%	O	NOUN	O
intrapleural	O	ADJ	B
bupivacaine	B-I	NOUN	I
with	O	ADP	O
epinephrine	B-I	NOUN	B
with	O	ADP	O
20	O	NUM	O
milliliters	O	NOUN	B
of	O	ADP	O
0.5	O	NUM	O
%	O	NOUN	O
intrapleural	O	ADJ	B
bupivacaine	O	NOUN	I
with	O	ADP	O
epinephrine	O	NOUN	B
after	O	ADP	O
cholecystectomy	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
volume	O	NOUN	B
of	O	ADP	O
local	O	ADJ	B
anesthetic	O	NOUN	I
injected	O	VERB	O
for	O	ADP	O
intrapleural	O	ADJ	B
analgesia	O	NOUN	I
,	O	PUNCT	O
40	B-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
cholecystectomy	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
allocated	I-P	VERB	O
to	I-P	ADP	O
two	I-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
20	I-P	NUM	O
patients	I-P	NOUN	B
each	I-P	DET	O
.	I-P	PUNCT	O


One	B-I	NUM	O
group	I-I	NOUN	B
received	I-I	VERB	O
40	I-I	NUM	O
mL	I-I	NOUN	O
of	I-I	ADP	O
0.25	I-I	NUM	O
%	I-I	NOUN	O
bupivacaine	I-I	NOUN	B
with	I-I	ADP	O
epinephrine	I-I	NOUN	B
injected	I-I	VERB	B
intrapleurally	I-I	ADV	B
postoperatively	I-I	ADV	B
.	I-I	PUNCT	O


The	B-I	DET	O
other	I-I	ADJ	O
group	I-I	NOUN	B
received	I-I	VERB	O
20	I-I	NUM	O
mL	I-I	NOUN	O
of	I-I	ADP	O
0.5	I-I	NUM	O
%	I-I	NOUN	O
bupivacaine	I-I	NOUN	B
with	I-I	ADP	O
epinephrine	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
onset	B-OUT	NOUN	O
time	I-OUT	NOUN	O
of	I-OUT	ADP	O
analgesia	I-OUT	NOUN	B
was	O	AUX	O
nearly	O	ADV	O
the	O	DET	O
same	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
and	O	CCONJ	O
within	O	ADP	O
25	O	NUM	O
min	O	NOUN	O
all	O	DET	O
patients	B-P	NOUN	B
were	O	AUX	O
nearly	O	ADV	O
pain	O	NOUN	B
free	O	ADV	I
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
100	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
bupivacaine	O	NOUN	B
with	O	ADP	O
epinephrine	O	NOUN	B
elicits	O	VERB	O
effective	O	ADJ	B
analgesia	O	NOUN	B
after	O	ADP	O
cholecystectomy	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
only	O	ADV	O
minor	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
20	O	NUM	O
and	O	CCONJ	O
40	O	NUM	O
mL	O	NOUN	O
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
pain	B-OUT	VERB	B
relief	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
volume	O	NOUN	B
of	O	ADP	O
local	O	ADJ	B
anesthetic	O	NOUN	I
within	O	ADP	O
the	O	DET	O
range	O	NOUN	B
of	O	ADP	O
20-40	O	NUM	O
mL	O	NOUN	O
in	O	ADP	O
an	O	DET	O
adult	O	NOUN	B
has	O	AUX	O
little	O	ADJ	O
influence	O	NOUN	B
on	O	ADP	O
the	O	DET	O
extent	O	NOUN	B
or	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
intrapleural	O	ADJ	B
analgesia	O	NOUN	I
.	O	PUNCT	O


Use	O	PROPN	O
of	O	ADP	O
the	O	DET	O
learning	B-I	NOUN	B
conversation	I-I	NOUN	I
improves	O	VERB	B
instructor	B-P	NOUN	B
confidence	I-P	NOUN	I
in	I-P	ADP	O
life	I-P	NOUN	B
support	I-P	NOUN	I
training	I-P	NOUN	B
:	I-P	PUNCT	O
An	O	DET	O
open	O	ADJ	O
randomised	O	VERB	B
controlled	O	VERB	I
cross-over	O	ADJ	I
trial	O	NOUN	I
comparing	O	VERB	B
teaching	O	NOUN	B
feedback	O	NOUN	O
mechanisms	O	NOUN	B
.	O	PUNCT	O


AIMS	O	PROPN	B
Feedback	O	NOUN	B
is	O	AUX	O
vital	O	ADJ	O
for	O	ADP	O
the	O	DET	O
effective	O	ADJ	B
delivery	O	NOUN	B
of	O	ADP	O
skills-based	O	ADJ	B
education	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
sought	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
sandwich	B-I	ADJ	B
technique	I-I	NOUN	I
and	O	CCONJ	O
learning	B-I	NOUN	B
conversation	I-I	NOUN	I
structured	O	ADJ	O
methods	O	NOUN	O
of	O	ADP	O
feedback	O	NOUN	B
delivery	O	NOUN	I
in	O	ADP	O
competency-based	O	ADJ	B
basic	O	ADJ	I
life	O	NOUN	I
support	O	NOUN	I
(	O	PUNCT	O
BLS	O	NOUN	B
)	O	PUNCT	O
training	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Open	O	ADJ	B
randomised	O	ADJ	I
crossover	O	NOUN	I
study	O	NOUN	I
undertaken	O	VERB	O
between	B-P	ADP	O
October	I-P	PROPN	O
2014	I-P	NUM	O
and	I-P	CCONJ	O
March	I-P	PROPN	O
2015	I-P	NUM	O
at	I-P	ADP	O
the	I-P	DET	O
University	I-P	PROPN	B
of	I-P	ADP	I
Birmingham	I-P	PROPN	I
,	I-P	PUNCT	O
United	I-P	PROPN	B
Kingdom	I-P	PROPN	I
.	I-P	PUNCT	O


Six-hundred	B-P	ADJ	B
and	I-P	CCONJ	O
forty	I-P	NUM	O
healthcare	I-P	NOUN	B
students	I-P	NOUN	I
undertaking	I-P	VERB	O
a	I-P	DET	O
European	I-P	PROPN	B
Resuscitation	I-P	PROPN	I
Council	I-P	PROPN	I
(	I-P	PUNCT	O
ERC	I-P	PROPN	B
)	I-P	PUNCT	O
BLS	I-P	PROPN	B
course	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
,	I-P	PUNCT	O
each	I-P	DET	O
of	I-P	ADP	O
whom	I-P	PRON	O
was	I-P	AUX	O
randomised	I-P	VERB	B
to	I-P	PART	O
receive	I-P	VERB	O
teaching	I-I	NOUN	B
using	I-I	VERB	O
either	I-I	CCONJ	O
the	I-I	DET	O
sandwich	I-I	ADJ	B
technique	I-I	NOUN	I
or	I-I	CCONJ	O
the	I-I	DET	O
learning	I-I	NOUN	B
conversation	I-I	NOUN	I
.	I-I	PUNCT	O


Fifty-eight	B-P	NUM	O
instructors	I-P	NOUN	B
were	I-P	AUX	O
randomised	I-P	VERB	B
to	I-P	PART	O
initially	I-P	ADV	O
teach	I-P	VERB	B
using	I-P	VERB	O
either	I-P	CCONJ	O
the	I-P	DET	O
learning	I-I	NOUN	B
conversation	I-I	NOUN	I
or	I-I	CCONJ	O
sandwich	I-I	ADJ	B
technique	I-I	NOUN	I
,	O	PUNCT	O
prior	O	ADJ	O
to	O	PART	O
crossing-over	O	ADJ	B
and	O	CCONJ	O
teaching	O	VERB	B
with	O	ADP	O
the	O	DET	O
alternative	O	ADJ	B
technique	O	NOUN	I
after	O	ADP	O
a	O	DET	O
pre-defined	O	ADJ	O
time	O	NOUN	O
period	O	NOUN	O
.	O	PUNCT	O


Outcome	O	NOUN	B
measures	O	NOUN	I
included	O	VERB	O
skill	B-OUT	NOUN	B
acquisition	I-OUT	NOUN	B
as	I-OUT	ADP	O
measured	I-OUT	VERB	B
by	I-OUT	ADP	O
an	I-OUT	DET	O
end-of-course	I-OUT	ADJ	B
competency	I-OUT	NOUN	I
assessment	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
instructors	I-OUT	NOUN	B
'	I-OUT	PART	O
perception	I-OUT	NOUN	B
of	I-OUT	ADP	O
teaching	I-OUT	NOUN	B
with	I-OUT	ADP	O
each	I-OUT	DET	O
feedback	I-OUT	NOUN	B
technique	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
candidates	I-OUT	NOUN	B
'	I-OUT	PART	O
perception	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
feedback	I-OUT	NOUN	B
they	I-OUT	PRON	O
were	I-OUT	AUX	O
provided	I-OUT	VERB	O
with	I-OUT	ADP	O
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
Scores	O	NOUN	B
assigned	O	VERB	B
to	O	PART	O
use	O	VERB	O
of	O	ADP	O
the	O	DET	O
learning	O	NOUN	B
conversation	O	NOUN	I
by	O	ADP	O
instructors	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
favourable	O	ADJ	O
than	O	ADP	O
for	O	ADP	O
the	O	DET	O
sandwich	O	ADJ	B
technique	O	NOUN	I
across	O	ADP	O
all	O	DET	O
but	O	CCONJ	O
two	O	NUM	O
assessed	O	VERB	B
domains	O	NOUN	B
relating	O	VERB	O
to	O	ADP	O
instructor	B-OUT	NOUN	B
perception	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
feedback	I-OUT	NOUN	B
technique	I-OUT	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
all	O	DET	O
skills-based	O	ADJ	B
domains	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
difference	O	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
either	O	CCONJ	O
assessment	B-OUT	NOUN	B
pass	I-OUT	NOUN	O
rates	I-OUT	NOUN	B
(	O	PUNCT	O
80.9	O	NUM	O
%	O	NOUN	O
sandwich	O	NOUN	B
technique	O	NOUN	I
vs.	O	CCONJ	O
77.2	O	NUM	O
%	O	NOUN	O
learning	O	NOUN	B
conversation	O	NOUN	I
;	O	PUNCT	O
OR	O	CCONJ	B
1.2	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.85-1.84	O	NUM	O
;	O	PUNCT	O
p=0.29	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
any	O	DET	O
domain	O	NOUN	B
relating	O	VERB	O
to	O	ADP	O
candidates	O	NOUN	O
'	O	PART	O
perception	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
teaching	O	NOUN	B
technique	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
&	O	CCONJ	O
RELEVANCE	O	NOUN	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
direct	O	ADJ	O
comparison	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
feedback	O	NOUN	O
techniques	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
medical	O	ADJ	I
education	O	NOUN	I
using	O	VERB	O
both	O	CCONJ	O
quantitative	O	ADJ	B
and	O	CCONJ	O
qualitative	O	ADJ	B
methodology	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
learning	B-I	NOUN	B
conversation	I-I	NOUN	I
is	O	AUX	O
preferred	O	VERB	O
by	O	ADP	O
instructors	B-P	NOUN	B
providing	I-P	VERB	O
competency-based	I-P	ADJ	B
life	I-P	NOUN	I
support	I-P	NOUN	I
training	I-P	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
perceived	O	VERB	B
to	O	PART	O
favour	O	VERB	O
skills	O	NOUN	B
acquisition	O	NOUN	I
.	O	PUNCT	O


B-vitamins	B-I	NOUN	B
reduce	O	VERB	O
plasma	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	O	ADP	O
beta	O	NOUN	B
amyloid	O	NOUN	I
.	O	PUNCT	O


Elevated	O	ADJ	B
plasma	O	NOUN	O
homocysteine	O	NOUN	O
(	O	PUNCT	O
tHcy	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
Alzheimer	O	NOUN	B
's	O	PART	I
disease	O	NOUN	I
(	O	PUNCT	O
AD	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
thus	O	ADV	O
B	B-I	NOUN	B
vitamins	I-I	NOUN	B
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
AD	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
tHcy	O	NOUN	B
lowering	O	VERB	O
vitamins	O	NOUN	B
decrease	O	VERB	B
the	O	DET	O
circulating	B-OUT	VERB	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
A-beta	I-OUT	NOUN	B
protein	I-OUT	NOUN	I
1-40	I-OUT	NUM	I
(	I-OUT	PUNCT	O
A	I-OUT	NOUN	O
beta	I-OUT	NOUN	O
40	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


We	O	PRON	O
randomized	O	VERB	B
299	B-P	NUM	O
older	I-P	ADJ	B
men	I-P	NOUN	B
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
2mg	B-I	NOUN	O
of	I-I	ADP	O
folate	I-I	NOUN	B
,	I-I	PUNCT	O
plus	I-I	CCONJ	O
25mg	I-I	NOUN	O
of	I-I	ADP	O
B6	I-I	NOUN	B
and	I-I	CCONJ	O
400	I-I	NUM	O
microg	I-I	NOUN	B
of	I-I	ADP	O
B12	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


After	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
the	O	DET	O
mean	B-OUT	NOUN	O
(	I-OUT	PUNCT	O
S.E	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


)	B-OUT	PUNCT	O
increase	I-OUT	NOUN	B
of	I-OUT	ADP	O
A	I-OUT	NOUN	O
beta	I-OUT	NOUN	B
40	I-OUT	NUM	O
was	O	AUX	O
7.0	O	NUM	O
pg/ml	O	NOUN	O
(	O	PUNCT	O
8.4	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
vitamin	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
4.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
26.8	O	NUM	O
pg/ml	O	NOUN	O
(	O	PUNCT	O
7.7	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
18.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
B	O	NOUN	B
vitamins	O	NOUN	B
may	O	AUX	O
decrease	O	VERB	B
the	B-OUT	DET	O
plasma	I-OUT	NOUN	B
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
A	I-OUT	NOUN	O
beta	I-OUT	NOUN	O
40	I-OUT	NUM	O
and	O	CCONJ	O
have	O	AUX	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
AD	O	NOUN	B
.	O	PUNCT	O


Double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
risperidone	B-I	NOUN	B
plus	I-I	CCONJ	O
amantadine	I-I	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
10-week	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
adding	O	VERB	O
amantadine	B-I	NOUN	B
to	I-I	PART	O
risperidone	I-I	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
autism	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Forty	B-P	NUM	O
outpatients	I-P	NOUN	B
aged	I-P	ADJ	B
4	I-P	NUM	O
to12	I-P	NOUN	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
diagnosed	I-P	VERB	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
based	I-P	VERB	O
on	I-P	ADP	O
the	I-P	DET	O
Diagnostic	I-P	PROPN	B
and	I-P	CCONJ	O
Statistical	I-P	PROPN	O
Manual	I-P	PROPN	O
of	I-P	ADP	O
Mental	I-P	PROPN	O
Disorders	I-P	PROPN	O
,	I-P	PUNCT	O
Fourth	I-P	PROPN	O
Edition	I-P	PROPN	O
,	I-P	PUNCT	O
Text	I-P	PROPN	O
Revision	I-P	NOUN	B
criteria	I-P	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
this	O	DET	O
double-blind	O	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
randomly	O	ADV	O
into	O	ADP	O
2	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
group	O	NOUN	B
received	O	VERB	O
risperidone	B-I	NOUN	B
plus	I-I	CCONJ	O
amantadine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
the	I-I	DET	O
other	I-I	ADJ	O
group	I-I	NOUN	B
received	I-I	VERB	O
risperidone	I-I	NOUN	B
plus	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
risperidone	O	NOUN	B
was	O	AUX	O
titrated	O	VERB	B
between	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
2.0	O	NUM	O
mg/d	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
amantadine	B-I	NOUN	B
was	O	AUX	O
100	O	NUM	O
or	O	CCONJ	O
150	O	NUM	O
mg/d	O	NOUN	O
for	O	ADP	O
patients	O	NOUN	B
less	O	ADJ	O
than	O	ADP	O
30	O	NUM	O
kg	O	NOUN	O
or	O	CCONJ	O
more	O	ADJ	O
than	O	ADP	O
30	O	NUM	O
kg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
the	O	DET	O
Aberrant	B-OUT	PROPN	B
Behavioral	I-OUT	PROPN	B
Checklist-Community	I-OUT	PROPN	I
(	I-OUT	PUNCT	I
ABC-C	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
adverse	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
checklist	I-OUT	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
clinical	B-OUT	ADJ	B
global	I-OUT	ADJ	I
impression-improvement	I-OUT	ADJ	I
(	I-OUT	PUNCT	O
CGI-I	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
at2	O	NOUN	B
checkpoints	O	NOUN	I
of	O	ADP	O
5-week	O	ADJ	B
intervals	O	NOUN	I
after	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
.	O	PUNCT	O


Informed	O	ADJ	O
consentwas	O	VERB	O
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
parents	O	NOUN	B
of	O	ADP	O
each	O	DET	O
participant	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Among	O	ADP	O
ABC-C	B-OUT	NOUN	B
subscales	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
Hyperactivity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
Irritability	I-OUT	PROPN	B
showed	O	VERB	O
significantly	O	ADV	O
greater	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
amantadine	O	NOUN	B
group	O	NOUN	O
than	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
adverse	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
CGI-I	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
show	O	VERB	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
amantadine	B-I	NOUN	B
group	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
amantadine	B-I	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
potential	O	ADJ	O
adjunctive	O	ADJ	B
treatment	O	NOUN	I
strategy	O	NOUN	O
for	O	ADP	O
autism	O	NOUN	B
and	O	CCONJ	O
it	O	PRON	O
was	O	AUX	O
generally	O	ADV	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


[	O	PUNCT	O
Effect	O	NOUN	B
on	O	ADP	O
pressure	O	NOUN	B
after	O	ADP	O
instillation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
drop	O	NOUN	B
of	O	ADP	O
depot-pilocarpine	B-I	NOUN	B
.	I-I	PUNCT	O


Clinical	O	ADJ	B
results	O	NOUN	I
of	O	ADP	O
its	O	PRON	O
medium-term	O	ADJ	B
action	O	NOUN	I
]	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
clinical	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
an	O	DET	O
emulsion	O	NOUN	B
containing	O	VERB	O
a	O	DET	O
new	B-I	ADJ	O
pilocarpine	I-I	NOUN	B
polymer	I-I	NOUN	O
(	I-I	PUNCT	O
Polym	I-I	NOUN	B
)	I-I	PUNCT	O
compound	O	NOUN	O
to	O	ADP	O
that	O	DET	O
of	O	ADP	O
a	O	DET	O
traditional	B-I	ADJ	B
pilocarpine	I-I	NOUN	B
salt	I-I	NOUN	I
solution	I-I	NOUN	I
(	I-I	PUNCT	O
Plc	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
the	O	DET	O
intraocular	B-OUT	ADJ	B
pressure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
IOP	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
has	O	AUX	O
been	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
40	B-P	NUM	O
open-angle	I-P	ADJ	B
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
the	I-P	DET	O
long	I-P	ADJ	B
acting	I-P	VERB	I
pilocarpine-complex	I-P	ADJ	I
for	I-P	ADP	O
120	I-P	NUM	O
days	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
protocol	O	NOUN	I
was	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
3	O	NUM	O
stages	O	NOUN	B
:	O	PUNCT	O
Stage	O	NOUN	B
1	O	NUM	I
is	O	AUX	O
a	O	DET	O
single	O	ADJ	O
dose	O	NOUN	O
treatment	O	NOUN	B
where	O	SCONJ	O
12	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
randomly	O	ADV	O
into	O	ADP	O
2	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
each	O	DET	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
of	O	ADP	O
each	O	DET	O
group	O	NOUN	B
were	O	AUX	O
given	B-I	VERB	O
1	I-I	NUM	O
drop	I-I	NOUN	B
into	I-I	ADP	O
each	I-I	DET	O
eye	I-I	NOUN	B
:	I-I	PUNCT	O
1	I-I	NUM	O
drop	I-I	NOUN	B
every	I-I	DET	O
12	I-I	NUM	O
hours	I-I	NOUN	B
for	I-I	ADP	O
Polym	I-I	PROPN	B
,	I-I	PUNCT	O
1	I-I	NUM	O
drop	I-I	VERB	B
every	I-I	DET	O
6	I-I	NUM	O
hours	I-I	NOUN	B
for	I-I	ADP	O
Plc	I-I	PROPN	B
.	I-I	PUNCT	O


The	B-I	DET	O
patients	I-I	NOUN	B
were	I-I	AUX	O
observed	I-I	VERB	O
for	I-I	ADP	O
a	I-I	DET	O
period	I-I	NOUN	B
of	I-I	ADP	O
24	I-I	NUM	O
hours	I-I	NOUN	B
.	I-I	PUNCT	O


After	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
without	O	ADP	O
medication	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
treatments	O	NOUN	B
were	O	AUX	O
crossed	O	VERB	O
over	O	ADP	O
and	O	CCONJ	O
nycthemeral	O	ADJ	B
graph	O	NOUN	O
curves	O	NOUN	O
were	O	AUX	O
registered	O	VERB	O
for	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Stage	O	NOUN	B
2	O	NUM	I
is	O	AUX	O
a	O	DET	O
medium	O	ADJ	O
term	O	NOUN	O
study	O	NOUN	O
were	O	AUX	O
the	O	DET	O
12	O	NUM	O
patients	O	NOUN	B
used	O	VERB	O
in	O	ADP	O
Stage	O	NOUN	B
1	O	NUM	I
were	O	AUX	O
added	O	VERB	O
to	O	PART	O
another	O	DET	O
28	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
40	O	NUM	O
were	O	AUX	O
then	O	ADV	O
assigned	O	VERB	B
to	O	PART	O
1	O	NUM	O
of	O	ADP	O
2	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
20	O	NUM	O
patients	O	NOUN	B
each	O	DET	O
)	O	PUNCT	O
according	O	VERB	O
to	O	ADP	O
a	O	DET	O
table	O	NOUN	O
of	O	ADP	O
random	O	ADJ	B
numbers	O	NOUN	B
.	O	PUNCT	O


Treatments	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
during	O	ADP	O
one	O	NUM	O
month	O	NOUN	B
,	O	PUNCT	O
then	O	ADV	O
cross-overed	O	VERB	B
again	O	ADV	O
during	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Stage	O	NOUN	B
3	O	NUM	O
:	O	PUNCT	O
finally	O	ADV	O
,	O	PUNCT	O
every	O	DET	O
patient	O	NOUN	B
could	O	AUX	O
choose	O	VERB	O
his	O	PRON	O
treatment	O	NOUN	B
(	O	PUNCT	O
either	O	CCONJ	O
Polym	B-I	PROPN	B
or	O	CCONJ	O
Plc	B-I	PROPN	B
)	I-I	PUNCT	O
for	O	ADP	O
the	O	DET	O
rest	O	NOUN	B
of	O	ADP	O
the	O	DET	O
period	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
study	O	NOUN	I
shows	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
polymer	O	NOUN	B
complex	O	NOUN	I
(	O	PUNCT	O
Polym	O	NOUN	B
)	O	PUNCT	O
produced	O	VERB	O
a	O	DET	O
prolonged	B-OUT	ADJ	B
therapeutic	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
,	O	PUNCT	O
this	O	DET	O
being	O	AUX	O
consistant	O	ADJ	B
with	O	ADP	O
a	O	DET	O
slow	O	ADJ	B
release	O	NOUN	I
pattern	O	NOUN	B
and	O	CCONJ	O
maintained	O	VERB	B
a	O	DET	O
more	O	ADV	O
effective	O	ADJ	B
around-the-clock	O	ADJ	B
control	O	NOUN	I
than	O	ADP	O
pilocarpine	B-I	NOUN	B
solution	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
were	O	AUX	O
accomplished	O	VERB	O
by	O	ADP	O
two	O	NUM	O
applications	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
as	O	ADP	O
compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
four	O	NUM	O
necessary	O	ADJ	O
applications	O	NOUN	B
of	O	ADP	O
Plc	B-I	PROPN	B
,	O	PUNCT	O
on	O	ADP	O
a	O	DET	O
half	O	NOUN	O
daily	O	ADJ	B
pilocarpine	B-I	NOUN	B
dose	O	NOUN	B
with	O	ADP	O
Polym	B-I	PROPN	B
.	I-I	PUNCT	O


The	O	DET	O
medium	O	ADJ	B
term	O	NOUN	O
results	O	NOUN	O
confirmed	O	VERB	O
the	O	DET	O
efficacity	B-OUT	NOUN	B
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
short	O	ADJ	B
term	O	NOUN	I
survey	O	NOUN	I
.	O	PUNCT	O


Most	O	ADJ	O
patients	O	NOUN	B
preferred	O	VERB	O
Polym	B-I	PROPN	B
to	O	ADP	O
Plc	B-I	PROPN	B
when	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
asked	O	VERB	O
.	O	PUNCT	O


Throughout	O	ADP	O
the	O	DET	O
4	O	NUM	O
months	O	NOUN	B
study	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
adverse	B-OUT	ADJ	O
side	I-OUT	NOUN	O
effects	I-OUT	NOUN	O
were	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Visual	B-OUT	ADJ	B
disturbances	I-OUT	NOUN	I
characteristic	O	ADJ	O
of	O	ADP	O
pilocarpine	B-I	NOUN	B
eye-drops	O	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
from	O	ADP	O
3	O	NUM	O
times	O	NOUN	O
a	O	DET	O
day	O	NOUN	B
on	O	ADP	O
pilocarpine	B-I	NOUN	B
salt	I-I	NOUN	O
solution	O	NOUN	O
to	O	ADP	O
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
on	O	ADP	O
pilocarpine	B-I	NOUN	B
polymer	I-I	NOUN	B
complex	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
pulsed-dye	B-I	ADJ	B
laser	I-I	NOUN	I
as	O	ADP	O
an	O	DET	O
adjuvant	O	ADJ	B
treatment	O	NOUN	B
modality	O	NOUN	B
in	O	ADP	O
acne	B-P	NOUN	B
vulgaris	I-P	X	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
single-blinded	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Acne	O	NOUN	B
vulgaris	O	NOUN	I
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
skin	O	NOUN	B
disease	O	NOUN	I
and	O	CCONJ	O
can	O	AUX	O
pose	O	VERB	O
a	O	DET	O
substantial	O	ADJ	O
therapeutic	O	ADJ	B
challenge	O	NOUN	O
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
several	O	ADJ	O
phototherapeutic	O	ADJ	B
modalities	O	NOUN	B
,	O	PUNCT	O
most	O	ADV	O
notably	O	ADV	O
pulsed-dye	B-I	ADJ	B
laser	I-I	NOUN	I
(	I-I	PUNCT	O
PDL	I-I	NOUN	B
)	I-I	PUNCT	O
treatment	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
introduced	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
published	O	VERB	B
results	O	NOUN	I
-	O	PUNCT	O
albeit	O	SCONJ	O
promising	O	VERB	B
-	O	PUNCT	O
are	O	AUX	O
controversial	O	ADJ	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
an	O	DET	O
adjuvant	O	ADJ	B
PDL	B-I	NOUN	B
treatment	O	NOUN	B
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
a	O	DET	O
proven	O	VERB	O
topical	O	ADJ	B
treatment	O	NOUN	I
[	O	PUNCT	O
fixed-combination	O	ADJ	B
clindamycin	O	NOUN	I
1	O	NUM	O
%	O	NOUN	O
-benzoyl	O	ADJ	O
peroxide	O	NOUN	B
5	O	NUM	O
%	O	NOUN	O
hydrating	O	ADJ	B
gel	O	NOUN	I
(	O	PUNCT	O
C/BPO	O	NOUN	B
)	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	VERB	O
Eighty	B-P	NUM	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
38	I-P	NUM	O
males	I-P	NOUN	B
and	I-P	CCONJ	O
42	I-P	NUM	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
mean	I-P	NOUN	O
+/-	I-P	CCONJ	O
SD	I-P	NOUN	B
age	I-P	NOUN	B
19.7	I-P	NUM	O
+/-	I-P	CCONJ	O
5.9	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
in	O	ADP	O
a	O	DET	O
1	O	NUM	O
:	O	PUNCT	O
2	O	NUM	O
ratio	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
C/BPO	B-I	NOUN	B
alone	I-I	ADV	O
or	I-I	CCONJ	O
in	I-I	ADP	O
combination	I-I	NOUN	B
with	I-I	ADP	O
PDL	I-I	NOUN	B
treatment	I-I	NOUN	B
(	O	PUNCT	O
wavelength	O	NOUN	B
585	O	NUM	I
nm	O	NOUN	I
,	O	PUNCT	O
energy	O	NOUN	B
fluence	O	NOUN	I
3	O	NUM	I
J	O	NOUN	I
cm	O	NOUN	I
(	O	PUNCT	O
-2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
pulse	O	NOUN	B
duration	O	NOUN	I
0.35	O	NUM	O
ms	O	NOUN	O
,	O	PUNCT	O
spot	O	VERB	B
size	O	NOUN	I
7	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
2	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
initial	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
points	O	NOUN	O
were	O	AUX	O
the	O	DET	O
Investigator	B-OUT	PROPN	B
's	I-OUT	PART	I
Static	I-OUT	PROPN	B
Global	I-OUT	PROPN	I
Assessment	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
ISGA	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
score	I-OUT	NOUN	O
and	O	CCONJ	O
lesion	B-OUT	NOUN	B
count	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
the	O	DET	O
secondary	O	ADJ	B
end	O	NOUN	I
point	O	NOUN	I
was	O	AUX	O
the	O	DET	O
Dermatology	B-OUT	PROPN	B
Life	I-OUT	PROPN	I
Quality	I-OUT	PROPN	I
Index	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
DLQI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
Both	O	DET	O
groups	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
during	O	ADP	O
observation	B-OUT	NOUN	B
[	O	PUNCT	O
ISGA	O	NOUN	B
27.1	O	NUM	O
%	O	NOUN	O
(	B-I	PUNCT	O
C/BPO	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
24.6	O	NUM	O
%	O	NOUN	O
(	B-I	PUNCT	O
C/BPO	I-I	NOUN	B
+	I-I	CCONJ	O
laser	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
total	B-OUT	ADJ	O
lesion	I-OUT	NOUN	B
count	I-OUT	NOUN	O
9.2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
9.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
inflammatory	B-OUT	ADJ	B
lesion	I-OUT	NOUN	O
count	I-OUT	NOUN	O
36.3	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
36.9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
DLQI	O	NOUN	B
54.5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
42.5	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
or	O	CCONJ	O
otherwise	O	ADV	O
appreciable	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
treatment	O	NOUN	B
modalities	O	NOUN	B
as	O	ADV	O
far	O	ADV	O
as	O	ADP	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
improvement	O	NOUN	B
was	O	AUX	O
concerned	O	ADJ	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
more	O	ADV	O
severe	O	ADJ	B
findings	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
had	O	AUX	O
a	O	DET	O
greater	O	ADJ	O
benefit	O	NOUN	B
from	O	ADP	O
either	O	CCONJ	O
therapy	O	NOUN	B
regimen	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Our	O	PRON	O
findings	O	NOUN	B
do	O	AUX	O
not	O	PART	O
support	O	VERB	O
the	O	DET	O
concept	O	NOUN	B
of	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
benefit	O	NOUN	O
of	O	ADP	O
PDL	B-I	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
acne	O	NOUN	B
vulgaris	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Efficacy	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
granisetron	B-I	NOUN	B
and	I-I	CCONJ	O
methylprednisolone	I-I	NOUN	B
for	O	ADP	O
nausea	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
vomiting	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
appetite	I-OUT	ADJ	B
loss	I-OUT	NOUN	I
in	I-P	ADP	O
remission	I-P	NOUN	B
induction	I-P	NOUN	O
chemotherapy	I-P	NOUN	O
of	I-P	ADP	O
acute	I-P	ADJ	B
myeloid	I-P	ADJ	I
leukemia	I-P	NOUN	I
--	I-P	PUNCT	O
a	I-P	DET	O
randomized	O	ADJ	B
comparative	O	ADJ	I
trial	O	NOUN	I
between	O	ADP	O
granisetron	B-I	NOUN	B
alone	I-I	ADV	O
and	I-I	CCONJ	O
granisetron	I-I	NOUN	B
plus	I-I	CCONJ	I
methylprednisolone	I-I	NOUN	B
]	I-I	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
nausea	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
vomiting	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
appetite	I-OUT	ADJ	B
loss	I-OUT	NOUN	I
induced	O	VERB	B
by	O	ADP	O
remission	O	NOUN	B
induction	O	NOUN	O
chemotherapy	O	NOUN	O
for	O	ADP	O
acute	B-P	ADJ	B
myeloid	I-P	ADJ	I
leukemia	I-P	NOUN	I
was	O	AUX	O
compared	O	VERB	O
by	O	ADP	O
randomization	O	NOUN	B
between	O	ADP	O
granisetron	B-I	NOUN	B
alone	I-I	ADV	O
and	I-P	CCONJ	O
combination	I-P	NOUN	B
with	I-P	ADP	O
granisetron	I-I	NOUN	B
plus	I-I	CCONJ	O
methylprednisolone	I-I	NOUN	B
.	I-I	PUNCT	O


Granisetron	B-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
at	O	ADP	O
40	B-I	NUM	O
micrograms/kg	I-I	NOUN	O
during	I-I	ADP	O
chemotherapy	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
methylprednisolone	I-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
concomitantly	O	ADV	O
at	O	ADP	O
125	O	NUM	O
mg/body	O	NOUN	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
or	O	CCONJ	O
more	O	ADJ	O
in	O	ADP	O
the	O	DET	O
combination	B-P	NOUN	B
group	I-P	NOUN	I
.	I-P	PUNCT	O


The	B-P	DET	O
single	I-P	ADJ	O
and	I-P	CCONJ	O
combination	I-P	NOUN	B
groups	I-P	NOUN	I
comprised	I-P	VERB	O
14	I-P	NUM	O
and	I-P	CCONJ	O
13	I-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
respectively	I-P	ADV	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
there	I-P	PRON	O
was	I-P	AUX	O
no	I-P	DET	B
significant	I-P	ADJ	I
difference	I-P	NOUN	O
between	I-P	ADP	O
the	I-P	DET	O
background	I-P	NOUN	B
of	I-P	ADP	O
both	I-P	DET	O
groups	I-P	NOUN	B
.	I-P	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
they	O	PRON	O
were	O	AUX	O
scored	O	VERB	B
according	O	VERB	O
to	O	PART	O
4	O	NUM	O
grades	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
evaluated	O	VERB	B
every	O	DET	O
24	O	NUM	O
hours	O	NOUN	B
from	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
chemotherapy	O	NOUN	B
to	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
its	O	PRON	O
completion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
complete	B-OUT	ADJ	B
inhibition	I-OUT	NOUN	B
rate	I-OUT	NOUN	O
of	I-OUT	ADP	O
vomiting	I-OUT	NOUN	B
was	O	AUX	O
as	O	ADV	O
high	O	ADJ	O
as	O	ADP	O
71.4	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
92.3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
single	O	ADJ	O
and	O	CCONJ	O
combination	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
showing	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
grade	B-OUT	NOUN	B
of	I-OUT	ADP	I
vomiting	I-OUT	NOUN	I
was	O	AUX	O
mild	O	ADJ	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Nausea	B-OUT	NOUN	B
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
71.4	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
46.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
inhibitory	O	ADJ	B
effect	O	NOUN	O
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Appetite	B-OUT	ADJ	B
loss	I-OUT	NOUN	O
developed	O	VERB	O
in	O	ADP	O
92.9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
41.7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
prevention	O	NOUN	B
effect	O	NOUN	I
was	O	AUX	O
clearly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
prevention	O	NOUN	B
effects	O	NOUN	I
on	O	ADP	O
nausea	B-OUT	NOUN	B
7	O	NUM	I
,	O	PUNCT	O
8	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
chemotherapy	O	NOUN	B
,	O	PUNCT	O
on	B-OUT	ADP	O
appetite	I-OUT	ADJ	B
loss	I-OUT	NOUN	I
2-10	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
it	O	PRON	O
,	O	PUNCT	O
and	O	CCONJ	O
2-5	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
its	O	PRON	O
completion	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Granisetron	B-I	NOUN	B
revealed	O	VERB	O
an	O	DET	O
excellent	O	ADJ	B
inhibitory	B-OUT	ADJ	B
effect	I-OUT	NOUN	O
on	I-OUT	ADP	O
vomiting	I-OUT	NOUN	B
induced	O	VERB	B
by	O	ADP	O
remission	O	NOUN	B
induction	O	NOUN	I
chemotherapy	O	NOUN	I
for	O	ADP	O
acute	O	ADJ	B
myeloid	O	ADJ	I
leukemia	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
combination	O	NOUN	B
with	O	ADP	O
granisetron	B-I	NOUN	B
and	I-I	CCONJ	O
methylprednisolone	I-I	NOUN	B
was	O	AUX	O
considered	O	VERB	O
useful	O	ADJ	O
for	O	ADP	O
nausea	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
appetite	B-OUT	ADJ	B
loss	I-OUT	NOUN	O
during	O	ADP	O
the	O	DET	O
whole	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


Fusidic	O	ADJ	B
acid	O	NOUN	I
prophylaxis	O	NOUN	O
before	B-P	ADP	O
cataract	I-P	NOUN	B
surgery	I-P	NOUN	I
:	I-P	PUNCT	O
patient	I-P	NOUN	B
self-administration	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
patient-administered	O	ADJ	B
1	O	NUM	I
%	O	NOUN	O
fusidic	B-I	ADJ	B
acid	I-I	NOUN	I
viscous	I-I	ADJ	B
eye	I-I	NOUN	I
drops	I-I	NOUN	I
in	O	ADP	O
clearing	O	VERB	B
the	O	DET	O
commonest	O	ADJ	O
organisms	O	NOUN	B
causing	O	VERB	O
pseudophakic	O	NOUN	B
endophthalmitis	O	NOUN	I
(	O	PUNCT	O
Staphylococcus	O	X	B
epidermidis	O	NOUN	I
and	O	CCONJ	O
aureus	O	X	B
)	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
lids	O	NOUN	B
and	O	CCONJ	O
conjunctivae	O	NOUN	B
of	O	ADP	O
79	B-P	NUM	O
patients	I-P	NOUN	B
before	I-P	ADP	O
cataract	I-P	NOUN	B
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
self-administered	O	ADJ	O
fusidic	B-I	ADJ	B
acid	I-I	NOUN	I
viscous	O	ADJ	B
eye	O	NOUN	I
drops	O	VERB	I
four	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
for	O	ADP	O
seven	O	NUM	O
days	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
received	O	VERB	O
inert	B-I	ADJ	B
ophthalmic	I-I	ADJ	I
drops	I-I	NOUN	I
.	I-I	PUNCT	O


Fellow	O	ADJ	B
eyes	O	NOUN	B
of	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
remained	O	VERB	O
untreated	O	ADJ	B
as	O	ADP	O
a	O	DET	O
natural	O	ADJ	B
control	O	NOUN	I
.	O	PUNCT	O


Lower	O	ADJ	B
fornix	O	NOUN	B
and	O	CCONJ	O
lid	O	ADJ	B
margin	O	NOUN	I
cultures	O	NOUN	I
were	O	AUX	O
taken	O	VERB	O
from	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Before	O	ADP	B
treatment	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistical	O	ADJ	B
difference	O	NOUN	I
in	O	ADP	O
organism	B-OUT	NOUN	B
counts	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
eyes	O	NOUN	B
receiving	O	VERB	O
fusidic	B-I	ADJ	B
acid	I-I	NOUN	I
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
free	O	ADJ	B
of	O	ADP	O
clinically	O	ADV	B
relevant	O	ADJ	O
Staphylococcus	O	X	B
spp	O	NOUN	I
.	O	PUNCT	O


than	O	ADP	O
all	O	DET	O
pre-treatment	O	ADJ	B
eyes	O	NOUN	B
(	O	PUNCT	O
for	O	ADP	O
lids	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
;	O	PUNCT	O
conjunctivae	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
highly	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
lid	I-OUT	ADJ	B
margins	I-OUT	NOUN	I
were	O	AUX	O
rendered	O	VERB	O
'clinically	O	ADV	O
clean	O	ADJ	B
'	O	PUNCT	O
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
0-49	O	NUM	O
organisms/swab	O	NOUN	O
)	O	PUNCT	O
by	O	ADP	O
fusidic	O	ADJ	B
acid	O	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
untreated	O	ADJ	B
eyes	O	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
also	O	ADV	O
effectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
reduced	O	VERB	B
the	O	DET	O
numbers	B-OUT	NOUN	B
of	I-OUT	ADP	O
bacteria	I-OUT	NOUN	B
isolated	I-OUT	VERB	B
from	I-OUT	ADP	O
conjunctivae	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
highly	O	ADV	O
significant	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
Staphylococcus	O	X	B
spp	O	NOUN	I
.	O	PUNCT	O


(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
non-Staphylococcus	O	ADJ	B
spp	O	NOUN	I
.	O	PUNCT	O


(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
attainment	O	NOUN	B
of	O	ADP	O
sterile	O	ADJ	B
eyes	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
operation	O	NOUN	B
gained	O	VERB	O
by	O	ADP	O
patient	O	NOUN	B
self-administration	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
%	O	NOUN	O
fusidic	O	ADJ	B
acid	O	NOUN	I
four	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
for	O	ADP	O
seven	O	NUM	O
days	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Pre-exposure	O	ADJ	B
studies	O	NOUN	I
with	O	ADP	O
purified	B-I	VERB	B
chick	I-I	NOUN	B
embryo	I-I	NOUN	B
cell	I-I	NOUN	B
culture	I-I	NOUN	I
rabies	I-I	NOUN	B
vaccine	I-I	NOUN	B
and	O	CCONJ	O
human	B-I	ADJ	B
diploid	I-I	ADJ	O
cell	I-I	NOUN	O
vaccine	I-I	NOUN	O
:	I-I	PUNCT	O
serological	O	ADJ	B
and	O	CCONJ	O
clinical	B-P	ADJ	B
responses	I-P	NOUN	I
in	I-P	ADP	O
man	I-P	NOUN	B
.	I-P	PUNCT	O


Clinical	O	ADJ	B
reactions	O	NOUN	I
and	O	CCONJ	O
neutralizing	O	VERB	B
antibody	O	NOUN	I
responses	O	NOUN	I
to	O	PART	O
six	O	NUM	O
pre-exposure	O	ADJ	B
regimens	O	NOUN	B
of	O	ADP	O
purified	B-I	VERB	B
chick	I-I	NOUN	B
embryo	I-I	NOUN	B
cell	I-I	NOUN	B
culture	I-I	NOUN	I
rabies	I-I	NOUN	O
vaccine	I-I	NOUN	O
(	I-I	PUNCT	O
PCECV	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
human	B-I	ADJ	B
diploid	I-I	ADJ	I
cell	I-I	NOUN	I
strain	I-I	NOUN	O
rabies	I-I	NOUN	O
vaccine	I-I	NOUN	O
(	I-I	PUNCT	O
HDCSV	I-I	NOUN	B
)	I-I	PUNCT	O
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
177	B-P	NUM	O
volunteers	I-P	NOUN	B
.	I-P	PUNCT	O


Antibody	B-OUT	NOUN	B
kinetics	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
height	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
response	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
persistence	I-OUT	NOUN	B
of	I-OUT	ADP	O
antibody	I-OUT	NOUN	B
over	I-OUT	ADP	O
two	I-OUT	NUM	O
years	I-OUT	NOUN	B
were	O	AUX	O
virtually	O	ADV	O
identical	O	ADJ	O
after	O	ADP	O
PCECV	B-I	NOUN	B
and	O	CCONJ	O
HDCSV	B-I	NOUN	B
.	I-I	PUNCT	O


An	O	DET	O
antibody	B-OUT	NOUN	B
response	I-OUT	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
all	O	DET	O
subjects	O	NOUN	B
on	O	ADP	O
day	O	NOUN	B
14	O	NUM	O
when	O	SCONJ	O
the	O	DET	O
highest	O	ADJ	B
titres	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
after	O	ADP	O
two	O	NUM	O
intramuscular	O	ADJ	B
(	O	PUNCT	O
i.m	O	NOUN	O
.	O	PUNCT	O


)	O	PUNCT	O
1.0	O	NUM	O
ml	O	NOUN	O
doses	O	NOUN	B
of	O	ADP	O
a	O	DET	O
schedule	O	NOUN	B
of	O	ADP	O
immunization	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
and	O	CCONJ	O
21	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
comparison	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
schedule	O	NOUN	B
of	O	ADP	O
immunization	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
28	O	NUM	O
and	O	CCONJ	O
56	O	NUM	O
ultimately	O	ADV	O
evoked	O	VERB	O
the	O	DET	O
highest	O	ADJ	B
titres	B-OUT	NOUN	B
21	I-OUT	NUM	O
days	I-OUT	NOUN	B
after	I-OUT	ADP	O
the	I-OUT	DET	O
final	I-OUT	ADJ	O
injection	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
antibody	O	NOUN	B
persisted	O	VERB	O
equally	O	ADV	O
well	O	ADV	O
over	O	ADP	O
two	O	NUM	O
years	O	NOUN	B
with	O	ADP	O
either	O	DET	O
schedule	O	NOUN	B
.	O	PUNCT	O


Neutralizing	B-OUT	VERB	B
antibody	I-OUT	NOUN	I
titres	I-OUT	NOUN	B
were	O	AUX	O
lower	O	ADJ	O
after	O	ADP	O
intradermal	O	ADJ	B
(	O	PUNCT	O
i.d	O	PROPN	O
.	O	PUNCT	O


)	O	PUNCT	O
vaccination	O	NOUN	B
with	O	ADP	O
0.1	O	NUM	O
ml	O	NOUN	O
compared	O	VERB	B
to	O	PART	O
1.0	O	NUM	O
ml	O	NOUN	O
i.m	O	NOUN	O
.	O	PUNCT	O


on	O	ADP	O
days	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
and	O	CCONJ	O
21	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
when	O	SCONJ	O
given	O	VERB	O
on	O	ADP	O
days	O	NOUN	B
0	O	NUM	O
,	O	PUNCT	O
28	O	NUM	O
and	O	CCONJ	O
56	O	NUM	O
the	O	DET	O
responses	O	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
.	O	PUNCT	O


Three	O	NUM	O
subjects	O	NOUN	B
with	O	ADP	O
a	O	DET	O
personal	O	ADJ	B
or	O	CCONJ	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	O
atopy	O	NOUN	B
developed	O	VERB	O
urticarial	B-OUT	ADJ	B
lesions	I-OUT	NOUN	I
after	O	ADP	O
PCECV	B-I	NOUN	B
.	I-I	PUNCT	O


Both	O	DET	O
vaccines	O	NOUN	B
were	O	AUX	O
otherwise	O	ADV	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
desonide	B-I	NOUN	B
ointment	I-I	NOUN	B
,	I-I	PUNCT	O
0.05	I-I	NUM	O
%	I-I	NOUN	O
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
hypothalamic-pituitary-adrenal	O	ADJ	B
axis	O	NOUN	I
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
atopic	I-P	ADJ	B
dermatitis	I-P	NOUN	I
.	I-P	PUNCT	O


Desonide	B-I	NOUN	B
ointment	I-I	NOUN	B
has	O	AUX	O
demonstrated	O	VERB	O
a	O	DET	O
good	O	ADJ	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
profile	O	NOUN	B
during	O	ADP	O
the	O	DET	O
many	O	ADJ	O
years	O	NOUN	B
it	O	PRON	O
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
in	O	ADP	O
treating	O	VERB	B
dermatoses	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
have	O	AUX	O
been	O	AUX	O
no	O	DET	B
controlled	O	VERB	I
clinical	O	ADJ	O
trials	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
its	O	PRON	O
systemic	O	ADJ	B
safety	O	NOUN	I
when	O	SCONJ	O
used	O	VERB	O
in	O	ADP	O
treating	O	VERB	B
children	B-P	NOUN	B
.	I-P	PUNCT	O


Suppression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hypothalamic-pituitary-adrenal	O	ADJ	B
(	O	PUNCT	I
HPA	O	ADJ	I
)	O	PUNCT	I
axis	O	NOUN	I
can	O	AUX	O
occur	O	VERB	O
after	O	ADP	O
repeated	O	VERB	O
application	O	NOUN	B
of	O	ADP	O
topical	O	ADJ	B
corticosteroids	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
general	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
suppression	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
HPA	I-OUT	ADJ	B
axis	I-OUT	NOUN	I
function	I-OUT	NOUN	I
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
daily	O	ADJ	B
dosage	O	NOUN	B
of	O	ADP	O
steroid	O	NOUN	B
given	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
its	O	PRON	O
administration	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
surface	O	NOUN	I
covered	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
potency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
corticosteroid	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
comparative	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
0.05	B-I	NUM	O
percent	I-I	NOUN	O
desonide	I-I	NOUN	B
and	I-I	CCONJ	O
2.5	I-I	NUM	O
percent	I-I	NOUN	O
hydrocortisone	I-I	NOUN	B
ointments	I-I	NOUN	O
on	O	ADP	O
the	O	DET	O
HPA	O	ADJ	B
axis	O	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
atopic	I-P	ADJ	B
dermatitis	I-P	NOUN	I
.	I-P	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
suppression	B-OUT	NOUN	B
of	I-OUT	ADP	O
early	I-OUT	ADJ	B
morning	I-OUT	NOUN	I
cortisol	I-OUT	NOUN	B
in	O	ADP	O
either	O	CCONJ	O
treatment	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ACTH-stimulated	B-OUT	ADJ	B
mean	I-OUT	ADJ	O
cortisol	I-OUT	NOUN	B
values	I-OUT	NOUN	I
after	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
values	O	NOUN	B
for	O	ADP	O
either	O	CCONJ	O
treatment	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
neither	O	CCONJ	O
0.05	B-I	NUM	O
percent	I-I	NOUN	O
desonide	I-I	NOUN	B
ointment	I-I	NOUN	B
nor	O	CCONJ	O
2.5	B-I	NUM	O
percent	I-I	NOUN	O
hydrocortisone	I-I	NOUN	B
ointment	I-I	NOUN	B
compromised	O	VERB	B
the	O	DET	O
HPA	O	ADJ	B
axis	O	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
atopic	I-P	ADJ	B
dermatitis	I-P	NOUN	I
treated	O	VERB	B
topically	O	ADV	B
for	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
memory	O	NOUN	B
support	O	NOUN	O
system	O	NOUN	O
for	O	ADP	O
mild	B-P	ADJ	B
cognitive	I-P	ADJ	I
impairment	I-P	NOUN	I
:	I-P	PUNCT	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
cognitive	B-I	ADJ	B
rehabilitation	I-I	NOUN	I
intervention	I-I	NOUN	B
.	I-I	PUNCT	O


OBJECTIVE	O	VERB	O
Individuals	B-P	NOUN	B
with	I-P	ADP	O
amnestic	I-P	ADJ	B
mild	I-P	ADJ	O
cognitive	I-P	ADJ	O
impairment	I-P	NOUN	O
(	I-P	PUNCT	O
MCI	I-P	NOUN	B
)	I-P	PUNCT	O
have	O	AUX	O
few	O	ADJ	O
empirically	O	ADV	O
based	O	VERB	O
treatment	O	NOUN	B
options	O	NOUN	O
for	O	ADP	O
combating	O	VERB	O
their	O	PRON	O
memory	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
calendar/notebook	B-I	NOUN	B
rehabilitation	I-I	NOUN	B
intervention	I-I	NOUN	B
,	O	PUNCT	O
the	O	DET	O
memory	B-OUT	NOUN	B
support	I-OUT	NOUN	I
system	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
MSS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
for	O	ADP	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
amnestic	I-P	ADJ	B
MCI	I-P	PROPN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Forty	B-P	NUM	O
individuals	I-P	NOUN	B
with	I-P	ADP	O
single	I-P	ADJ	B
domain	I-P	NOUN	I
amnestic	I-I	ADJ	O
MCI	I-I	PROPN	B
and	I-P	CCONJ	O
their	I-P	PRON	O
program	I-P	NOUN	B
partners	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
receive	O	VERB	O
the	O	DET	O
MSS	O	NOUN	B
,	O	PUNCT	O
either	O	CCONJ	O
with	O	ADP	O
training	O	NOUN	B
or	O	CCONJ	O
without	O	ADP	O
(	O	PUNCT	O
controls	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Measures	B-OUT	NOUN	B
of	I-OUT	ADP	O
adherence	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
activities	I-OUT	NOUN	B
of	I-OUT	ADP	O
daily	I-OUT	ADJ	B
living	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
emotional	I-OUT	ADJ	B
impact	I-OUT	NOUN	O
were	O	AUX	O
completed	O	VERB	B
at	O	ADP	O
the	O	DET	O
first	O	ADJ	O
and	O	CCONJ	O
last	O	ADJ	O
intervention	O	NOUN	B
sessions	O	NOUN	O
and	O	CCONJ	O
again	O	ADV	O
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
post	O	NOUN	B
intervention	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Training	O	NOUN	B
in	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
notebook/calendar	O	NOUN	B
system	O	NOUN	I
significantly	O	ADV	O
improved	O	VERB	B
adherence	B-OUT	NOUN	B
over	O	ADP	O
those	O	DET	O
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
calendars	O	NOUN	B
but	O	CCONJ	O
no	O	DET	O
training	O	NOUN	B
.	O	PUNCT	O


Functional	B-OUT	ADJ	B
ability	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
memory	I-OUT	NOUN	B
self-efficacy	I-OUT	NOUN	B
significantly	O	ADV	O
improved	O	VERB	B
for	O	ADP	O
those	O	DET	O
who	O	PRON	O
received	O	VERB	O
MSS	O	NOUN	B
training	O	NOUN	B
.	O	PUNCT	O


Change	B-OUT	NOUN	B
in	I-OUT	ADP	O
functional	I-OUT	ADJ	B
ability	I-OUT	NOUN	I
remained	O	VERB	O
significantly	O	ADV	O
better	O	ADJ	O
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
out	O	ADP	O
to	O	PART	O
8-week	O	VERB	B
follow-up	O	NOUN	B
.	O	PUNCT	O


Care	O	NOUN	O
partners	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
demonstrated	O	VERB	O
improved	O	VERB	B
mood	B-OUT	NOUN	B
by	O	ADP	O
8-week	O	NOUN	B
and	O	CCONJ	O
6-month	O	ADJ	O
follow-ups	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
control	O	NOUN	B
care	O	NOUN	I
partners	O	NOUN	I
reported	O	VERB	O
worse	O	ADJ	O
caregiver	B-OUT	NOUN	B
burden	I-OUT	NOUN	B
by	O	ADP	O
6-month	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
Memory	B-I	NOUN	B
support	I-I	NOUN	I
system	I-I	NOUN	I
training	I-I	NOUN	O
resulted	O	VERB	O
in	O	ADP	O
improvement	O	NOUN	B
in	O	ADP	O
activities	B-OUT	NOUN	B
of	I-OUT	ADP	O
daily	I-OUT	ADJ	B
living	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
sense	I-OUT	NOUN	O
of	I-OUT	ADP	O
memory	I-OUT	NOUN	B
self-efficacy	I-OUT	NOUN	B
for	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
MCI	O	PROPN	B
.	O	PUNCT	O


Although	O	SCONJ	O
activities	O	NOUN	B
of	O	ADP	O
daily	O	ADJ	B
living	O	NOUN	O
benefits	O	NOUN	O
were	O	AUX	O
maintained	O	VERB	B
out	O	ADP	O
to	O	PART	O
8	O	NUM	O
weeks	O	NOUN	B
post	O	NOUN	B
intervention	O	NOUN	B
,	O	PUNCT	O
future	O	ADJ	O
inclusion	O	NOUN	B
of	O	ADP	O
booster	O	NOUN	B
sessions	O	NOUN	B
may	O	AUX	O
help	O	VERB	O
extend	O	VERB	O
the	O	DET	O
therapeutic	O	ADJ	B
effect	O	NOUN	I
out	O	ADP	O
even	O	ADV	O
further	O	ADV	O
.	O	PUNCT	O


Improved	B-OUT	ADJ	B
mood	I-OUT	NOUN	B
of	O	ADP	O
care	O	NOUN	O
partners	O	NOUN	B
of	O	ADP	O
trained	O	VERB	B
individuals	O	NOUN	B
and	O	CCONJ	O
worsening	B-OUT	VERB	B
sense	I-OUT	NOUN	B
of	I-OUT	ADP	I
caregiver	I-OUT	NOUN	B
burden	I-OUT	NOUN	B
over	O	ADP	O
time	O	NOUN	O
for	O	ADP	O
partners	O	NOUN	B
of	O	ADP	O
untrained	O	ADJ	B
individuals	O	NOUN	B
further	O	ADV	O
support	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
MSS	O	PROPN	B
for	O	ADP	O
MCI	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
values	O	NOUN	B
affirmation	O	NOUN	B
on	O	ADP	O
race-discordant	B-P	ADJ	B
patient-provider	I-P	ADJ	B
communication	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Communication	O	NOUN	B
between	O	ADP	O
African	B-P	ADJ	B
American	I-P	ADJ	I
patients	I-P	NOUN	B
and	I-P	CCONJ	O
white	I-P	ADJ	B
health	I-P	NOUN	I
care	I-P	NOUN	I
providers	I-P	NOUN	I
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
poorer	O	ADJ	B
quality	O	NOUN	O
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
race-concordant	O	ADJ	B
patient-provider	O	ADJ	O
communication	O	NOUN	O
.	O	PUNCT	O


Fear	O	NOUN	B
on	O	ADP	O
the	O	DET	O
part	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
that	O	PRON	O
providers	O	NOUN	B
stereotype	O	VERB	B
them	O	PRON	O
negatively	O	ADV	B
might	O	AUX	O
be	O	AUX	O
one	O	NUM	O
cause	O	NOUN	O
of	O	ADP	O
this	O	DET	O
poorer	O	ADJ	B
communication	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
stereotype	O	NOUN	B
threat	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
lessened	O	VERB	O
by	O	ADP	O
a	O	DET	O
values-affirmation	O	ADJ	B
intervention	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
blinded	O	ADJ	B
experiment	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
randomized	O	VERB	B
99	B-P	NUM	O
African	I-P	ADJ	B
American	I-P	ADJ	I
patients	I-P	NOUN	B
with	I-P	ADP	O
hypertension	I-P	NOUN	B
to	O	PART	O
perform	O	VERB	O
a	O	DET	O
values-affirmation	B-I	ADJ	B
exercise	I-I	NOUN	I
or	I-I	CCONJ	O
a	I-I	DET	O
control	I-I	NOUN	B
exercise	I-I	NOUN	I
before	O	ADP	O
a	O	DET	O
visit	O	NOUN	B
with	O	ADP	O
their	O	PRON	O
primary	O	ADJ	B
care	O	NOUN	I
provider	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	B
patient-provider	O	ADJ	B
communication	O	NOUN	B
for	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
using	O	VERB	O
audio	O	ADJ	B
recordings	O	NOUN	I
of	O	ADP	O
the	O	DET	O
visit	O	NOUN	B
analyzed	O	VERB	B
with	O	ADP	O
the	O	DET	O
Roter	O	NOUN	B
Interaction	O	PROPN	I
Analysis	O	PROPN	I
System	O	PROPN	I
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
evaluated	O	VERB	B
visit	O	NOUN	B
satisfaction	O	NOUN	I
,	O	PUNCT	O
trust	O	NOUN	B
,	O	PUNCT	O
stress	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mood	O	NOUN	B
after	O	ADP	O
the	O	DET	O
visit	O	NOUN	B
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
a	O	DET	O
questionnaire	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
requested	O	VERB	O
and	O	CCONJ	O
provided	O	VERB	O
more	O	ADJ	O
information	B-OUT	NOUN	B
about	O	ADP	O
their	O	PRON	O
medical	B-OUT	ADJ	B
condition	I-OUT	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
[	O	PUNCT	O
SE	O	NOUN	B
]	O	PUNCT	O
number	O	NOUN	O
of	O	ADP	O
utterances	O	NOUN	B
,	O	PUNCT	O
66.3	O	NUM	O
[	O	PUNCT	O
6.8	O	NUM	O
]	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
values-affirmation	O	ADJ	B
group	O	NOUN	I
vs	O	CCONJ	O
48.1	O	NUM	O
[	O	PUNCT	O
5.9	O	NUM	O
]	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
[	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Patient-provider	O	ADJ	B
communication	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
characterized	O	VERB	B
as	O	ADP	O
being	O	AUX	O
more	O	ADV	O
interested	B-OUT	ADJ	O
,	I-OUT	PUNCT	O
friendly	I-OUT	ADJ	O
,	I-OUT	PUNCT	O
responsive	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
interactive	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
respectful	I-OUT	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.02	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
less	O	ADV	O
depressed	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
distressed	I-OUT	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Patient	O	NOUN	B
questionnaires	O	NOUN	I
did	O	AUX	O
not	O	PART	O
detect	O	VERB	B
differences	O	NOUN	B
in	O	ADP	O
visit	B-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
trust	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
stress	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
mood	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Mean	B-OUT	VERB	B
visit	I-OUT	NOUN	I
duration	I-OUT	NOUN	O
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
(	O	PUNCT	O
19.2	O	NUM	O
minutes	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
vs	O	CCONJ	O
20.5	O	NUM	O
minutes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
[	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.29	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
A	O	DET	O
values-affirmation	B-I	ADJ	B
exercise	I-I	NOUN	I
improves	O	VERB	O
aspects	O	NOUN	O
of	O	ADP	O
patient-provider	O	ADJ	B
communication	O	NOUN	O
in	O	ADP	O
race-discordant	O	ADJ	B
primary	O	ADJ	I
care	O	NOUN	I
visits	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
impact	O	NOUN	I
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
defined	O	VERB	O
before	O	ADP	O
widespread	O	ADJ	B
implementation	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
recommended	O	VERB	B
.	O	PUNCT	O


Magnocellular	B-I	ADJ	B
visual	I-I	ADJ	B
evoked	O	VERB	O
potential	O	ADJ	O
delay	O	NOUN	B
with	O	ADP	O
high	B-P	ADJ	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
quotient	I-P	NOUN	I
yields	O	VERB	O
a	O	DET	O
neural	O	ADJ	B
mechanism	O	NOUN	B
for	O	ADP	O
altered	B-OUT	ADJ	O
perception	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Everyone	O	PRON	B
has	O	AUX	O
autistic	O	ADJ	B
characteristics	O	NOUN	B
to	O	PART	O
a	O	DET	O
greater	O	ADJ	B
or	O	CCONJ	O
lesser	O	ADJ	B
degree	O	NOUN	B
,	O	PUNCT	O
encapsulated	O	VERB	B
in	O	ADP	O
the	O	DET	O
Autism	B-OUT	PROPN	B
Spectrum	I-OUT	PROPN	I
Quotient	I-OUT	PROPN	I
,	O	PUNCT	O
a	O	DET	O
scale	O	NOUN	O
that	O	PRON	O
measures	O	VERB	B
the	O	DET	O
degree	O	NOUN	B
to	O	PART	O
which	O	DET	O
an	O	DET	O
adult	B-P	NOUN	B
of	I-P	ADP	O
normal	I-P	ADJ	B
intelligence	I-P	NOUN	I
displays	O	VERB	O
traits	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
.	O	PUNCT	O


Recent	O	ADJ	O
psychophysical	O	ADJ	B
analyses	O	NOUN	I
of	O	ADP	O
autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
point	O	VERB	O
to	O	ADP	O
superior	O	ADJ	B
local	O	ADJ	B
processing	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
impaired	O	ADJ	B
or	O	CCONJ	O
ignored	O	VERB	O
global	O	ADJ	B
and	O	CCONJ	O
contextual	O	ADJ	B
processing	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
test	O	VERB	B
whether	O	SCONJ	O
low-	B-I	ADJ	O
and	I-P	CCONJ	O
high-scoring	I-I	ADJ	B
individuals	I-I	NOUN	B
on	I-I	ADP	O
the	I-I	DET	O
Autism	I-I	PROPN	B
Spectrum	I-I	PROPN	I
Quotient	I-I	PROPN	I
differ	O	VERB	O
on	O	ADP	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
local	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
global	I-OUT	ADJ	B
processing	I-OUT	NOUN	I
,	I-I	PUNCT	O
motion	I-I	NOUN	B
processing	I-I	NOUN	I
and	I-I	CCONJ	O
visual	I-I	ADJ	B
pathway	I-I	NOUN	I
integrity	I-I	NOUN	B
.	I-I	PUNCT	O


Fifteen	B-P	NUM	O
low-scoring	I-P	ADJ	B
individuals	I-P	NOUN	B
and	I-P	CCONJ	O
14	I-P	NUM	O
high-scoring	I-P	ADJ	B
individuals	I-P	NOUN	B
derived	I-P	VERB	O
from	I-P	ADP	O
a	I-P	DET	O
normal	I-P	ADJ	B
population	I-P	NOUN	I
participated	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
initial	O	ADJ	B
cortical	B-OUT	ADJ	B
response	I-OUT	NOUN	I
to	O	PART	O
the	O	DET	O
magnocellular	O	ADJ	B
afferents	O	NOUN	B
is	O	AUX	O
weaker	O	ADJ	O
at	O	ADP	O
low	O	ADJ	O
contrast	O	NOUN	O
in	O	ADP	O
the	O	DET	O
high	O	ADJ	O
autistic	O	ADJ	B
tendency	O	NOUN	O
group	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
a	O	DET	O
second-order	O	ADJ	B
response	O	NOUN	I
,	O	PUNCT	O
reflecting	O	VERB	O
magnocellular	O	ADJ	B
activity	O	NOUN	O
,	O	PUNCT	O
demonstrated	O	VERB	O
a	B-OUT	DET	O
delay	I-OUT	NOUN	B
for	O	ADP	O
high	O	ADJ	B
versus	O	CCONJ	O
low	O	ADJ	B
scorers	O	NOUN	B
when	O	SCONJ	O
the	O	DET	O
parvocellular	O	ADJ	B
pathway	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
active	O	ADJ	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
a	O	DET	O
high	O	ADJ	O
contrast	O	NOUN	O
stimulus	O	NOUN	B
.	O	PUNCT	O


High-scoring	O	ADJ	B
individuals	O	NOUN	B
also	O	ADV	O
demonstrated	O	VERB	O
difficulty	O	NOUN	B
in	O	ADP	O
identifying	B-OUT	VERB	O
the	I-OUT	DET	O
global	I-OUT	ADJ	B
components	I-OUT	NOUN	I
of	O	ADP	O
locally	O	ADV	B
salient	O	ADJ	I
hierarchical	O	ADJ	O
Navon	O	PROPN	B
figures	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
cross-validated	O	ADJ	B
discriminant	O	ADJ	I
analysis	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
four	O	NUM	O
physiologically	O	ADV	B
and	O	CCONJ	O
three	O	NUM	O
psychophysically	O	ADV	B
derived	O	VERB	O
parameters	O	NOUN	B
,	O	PUNCT	O
correctly	O	ADV	O
classified	O	VERB	O
83	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
individuals	O	NOUN	B
who	O	PRON	O
scored	O	VERB	B
either	O	CCONJ	O
high	O	ADJ	B
or	O	CCONJ	O
low	O	ADJ	B
on	O	ADP	O
the	O	DET	O
Autism	O	PROPN	B
Spectrum	O	PROPN	I
Quotient	O	PROPN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
scoring	O	NOUN	I
high	O	ADV	O
on	O	ADP	O
the	O	DET	O
Autism	B-P	PROPN	B
Spectrum	I-P	PROPN	I
Quotient	I-P	PROPN	I
indicate	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
delay	O	NOUN	B
in	O	ADP	O
primary	O	ADJ	B
visual/prestriate	O	NOUN	O
cortical	O	ADJ	O
processing	O	NOUN	O
of	O	ADP	O
magnocellular	O	ADJ	B
input	O	NOUN	B
diminishes	O	VERB	B
the	O	DET	O
advantage	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
early	O	ADJ	B
arrival	O	NOUN	I
to	O	ADP	O
primary	O	ADJ	B
visual	O	ADJ	B
cortex	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
impaired	B-OUT	ADJ	B
global	I-OUT	ADJ	B
visual	I-OUT	ADJ	O
perception	I-OUT	NOUN	B
,	O	PUNCT	O
predicting	O	VERB	B
with	O	ADP	O
high	O	ADJ	O
accuracy	O	NOUN	B
behavioural	B-OUT	ADJ	B
tendencies	I-OUT	NOUN	I
associated	O	VERB	B
with	O	ADP	I
autism	O	NOUN	B
spectrum	O	NOUN	I
disorders	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
that	O	SCONJ	O
perceptual	O	ADJ	B
impairment	O	NOUN	B
in	O	ADP	O
autism	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
a	O	DET	O
dysfunction	O	NOUN	B
of	O	ADP	O
horizontal	O	ADJ	B
connections	O	NOUN	B
within	O	ADP	O
early	O	ADJ	B
visual	O	ADJ	B
areas	O	NOUN	I
,	O	PUNCT	O
presumably	O	ADV	O
parvocellular	O	ADJ	B
in	O	ADP	O
nature	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
timing	O	NOUN	B
of	O	ADP	O
such	O	ADJ	O
form	O	NOUN	O
processing	O	NOUN	B
aberrations	O	NOUN	B
is	O	AUX	O
much	O	ADV	O
later	O	ADV	O
than	O	ADP	O
the	O	DET	O
timing	O	NOUN	B
of	O	ADP	O
abnormal	O	ADJ	B
magnocellular	O	ADJ	B
visual	O	ADJ	B
processing	O	NOUN	I
measured	O	VERB	O
directly	O	ADV	O
here	O	ADV	O
.	O	PUNCT	O


Thus	O	ADV	O
it	O	PRON	O
is	O	AUX	O
proposed	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
magnocellular	O	ADJ	B
processing	O	NOUN	I
delay	O	NOUN	I
decreases	O	VERB	B
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
autistic	B-P	ADJ	B
individuals	I-P	NOUN	B
to	O	PART	O
benefit	O	VERB	B
perceptually	O	ADV	B
from	O	ADP	O
feedback	O	NOUN	B
normally	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
magnocellular	O	ADJ	B
advantage	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
netilmicin-cefoxitin	B-I	ADJ	B
and	O	CCONJ	O
gentamicin-cefoxitin	B-I	NOUN	B
in	O	ADP	O
surgical	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
serious	I-P	ADJ	O
systemic	I-P	ADJ	B
infection	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
gentamicin	B-I	NOUN	B
and	O	CCONJ	O
netilmicin	B-I	NOUN	B
,	O	PUNCT	O
each	O	DET	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
cefoxitin	B-I	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
done	O	VERB	O
to	O	PART	O
compare	O	VERB	B
their	O	PRON	O
respective	O	ADJ	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
serious	I-P	ADJ	O
systemic	I-P	ADJ	B
infection	I-P	NOUN	I
.	I-P	PUNCT	O


Thirty-seven	B-P	NUM	O
surgical	I-P	ADJ	B
patients	I-P	NOUN	I
were	I-P	AUX	O
evaluated	I-P	VERB	B
for	I-P	ADP	O
efficacy	I-OUT	NOUN	B
and	I-P	CCONJ	O
46	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
evaluated	I-P	VERB	B
for	I-P	ADP	O
toxicity	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
cultured	O	VERB	B
organisms	O	NOUN	I
were	O	AUX	O
Escherichia	O	X	B
coli	O	X	I
(	O	PUNCT	O
15	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Klebsiella	O	X	B
sp	O	X	I
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Proteus	O	X	B
sp	O	X	I
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Bacteroides	O	X	B
sp	O	X	I
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
23	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
gentamicin-cefoxitin	B-I	NOUN	B
(	O	PUNCT	I
G-C	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
clinical	B-OUT	ADJ	B
response	I-OUT	NOUN	I
was	O	AUX	O
favorable	O	ADJ	B
in	O	ADP	O
20/21	O	NUM	O
(	O	PUNCT	O
95.2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
evaluable	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
elimination	O	NOUN	B
or	O	CCONJ	O
marked	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
33/34	O	NUM	O
(	O	PUNCT	O
97.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
organisms	O	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
.	O	PUNCT	O


For	O	ADP	O
14	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
netilmicin-cefoxitin	B-I	ADJ	B
(	O	PUNCT	I
N-C	O	NOUN	I
)	O	PUNCT	I
,	O	PUNCT	O
the	O	DET	O
clinical	B-OUT	ADJ	B
response	I-OUT	NOUN	I
was	O	AUX	O
favorable	O	ADJ	B
in	O	ADP	O
13/13	O	NUM	O
(	O	PUNCT	O
100	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
evaluable	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
19/20	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
organisms	O	NOUN	B
were	O	AUX	O
eliminated	O	VERB	O
or	O	CCONJ	O
markedly	O	ADV	O
reduced	O	VERB	B
.	O	PUNCT	O


Nephrotoxicity	B-OUT	NOUN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
creatinine	I-OUT	NOUN	I
to	O	PART	O
greater	O	ADJ	O
than	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
over	O	ADP	O
baseline	O	NOUN	B
with	O	ADP	O
an	O	DET	O
absolute	O	ADJ	B
rise	O	NOUN	O
of	O	ADP	O
at	O	ADV	O
least	O	ADV	O
0.5	O	NUM	O
mg/100	O	NOUN	O
ml	O	NOUN	O
to	O	PART	O
a	O	DET	O
value	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
1.3	O	NUM	O
mg/100	O	NOUN	O
ml	O	NOUN	O
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
these	O	DET	O
criteria	O	NOUN	B
,	O	PUNCT	O
nephrotoxicity	B-OUT	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
2/27	O	NUM	O
(	O	PUNCT	O
7.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
G-C	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
3/19	O	NUM	O
(	O	PUNCT	O
15.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
N-C.	O	NOUN	B
Ototoxicity	B-OUT	NOUN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
greater	O	ADJ	O
than	O	ADP	O
20	O	NUM	O
dB	O	NOUN	O
loss	O	NOUN	B
at	O	ADP	O
any	O	DET	O
frequency	O	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
these	O	DET	O
criteria	O	NOUN	B
,	O	PUNCT	O
ototoxicity	B-OUT	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
5/27	O	NUM	O
(	O	PUNCT	O
18.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
G-C	O	NOUN	B
and	O	CCONJ	O
2/19	O	NUM	O
(	O	PUNCT	O
10.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
N-C	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
show	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
toxicity	B-OUT	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
netilmicin	O	NOUN	B
and	O	CCONJ	O
gentamicin	O	NOUN	B
are	O	AUX	O
both	O	CCONJ	O
highly	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
cefoxitin	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
have	I-P	AUX	O
serious	I-P	ADJ	O
infections	I-P	NOUN	B
after	I-P	ADP	O
surgery	I-P	NOUN	B
.	I-P	PUNCT	O


Cimetidine	B-I	NOUN	B
as	O	ADP	O
an	O	DET	O
immunomodulator	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
herpes	B-P	NOUN	B
zoster	I-P	NOUN	I
.	I-P	PUNCT	O


As	O	ADP	O
there	O	PRON	O
is	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
immunoregulatory	O	ADJ	B
role	O	NOUN	O
for	O	ADP	O
H2-histamine	B-I	ADJ	B
receptor	I-I	NOUN	I
antagonists	I-I	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
carried	O	VERB	O
out	O	ADP	O
a	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	O
trial	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
in	O	X	B
vivo	O	X	I
and	O	CCONJ	O
in	O	X	B
vitro	O	X	I
effect	O	NOUN	B
of	O	ADP	O
cimetidine	B-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
H2-blocker	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
herpes	B-P	NOUN	B
zoster	I-P	NOUN	I
infection	I-P	NOUN	O
.	I-P	PUNCT	O


Cimetidine	B-I	NOUN	B
treatment	O	NOUN	B
shortened	O	VERB	B
the	O	DET	O
median	B-OUT	ADJ	B
interval	I-OUT	NOUN	I
until	I-OUT	ADP	O
the	I-OUT	DET	O
first	I-OUT	ADJ	O
decrease	I-OUT	NOUN	B
in	I-OUT	ADP	O
pain	I-OUT	NOUN	B
,	O	PUNCT	O
the	O	DET	O
median	B-OUT	ADJ	B
interval	I-OUT	NOUN	I
until	I-OUT	ADP	O
the	I-OUT	DET	O
complete	I-OUT	ADJ	B
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
pain	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
promoted	I-OUT	VERB	B
faster	I-OUT	ADV	O
complete	I-OUT	ADJ	B
healing	I-OUT	NOUN	B
of	I-OUT	ADP	O
skin	I-OUT	NOUN	B
lesions	I-OUT	NOUN	I
than	O	ADP	O
symptomatic	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
immunological	O	ADJ	B
trends	O	NOUN	B
observed	O	VERB	O
in	O	X	B
vitro	O	X	I
support	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
for	O	ADP	O
histamine	O	NOUN	B
in	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
immunosuppression	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
the	O	DET	O
mitogen	O	NOUN	B
phytohemagglutinin	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
histamine	O	NOUN	B
was	O	AUX	O
antagonized	O	VERB	B
by	O	ADP	O
cimetidine	B-I	NOUN	B
.	I-I	PUNCT	O


ACE	B-I	NOUN	B
inhibitors	I-I	NOUN	O
or	I-I	CCONJ	O
AT-1	I-I	NOUN	B
antagonists	I-I	NOUN	I
-	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
OPTIMAAL	O	NOUN	B
after	O	ADP	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
?	O	PUNCT	O
OPTIMAAL	O	NOUN	B
(	O	PUNCT	O
Optimal	O	ADJ	B
Trial	O	PROPN	I
in	O	ADP	O
Myocardial	O	PROPN	B
Infarction	O	NOUN	I
with	O	ADP	O
the	O	DET	O
Angiotensin	O	NOUN	B
II	O	NUM	I
Antagonist	O	PROPN	O
Losartan	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
major	O	ADJ	O
study	O	NOUN	B
to	O	PART	O
compare	O	VERB	B
an	O	DET	O
angiotensin	B-I	NOUN	B
II	I-I	NUM	I
Type	I-I	NOUN	I
1	I-I	NUM	I
antagonist	I-I	NOUN	I
losartan	I-I	NOUN	B
(	O	PUNCT	O
Cozaar	O	NOUN	B
trade	O	NOUN	I
mark	O	NOUN	I
,	O	PUNCT	O
Merck	O	PROPN	B
)	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
ACE	O	NOUN	B
inhibitor	O	NOUN	I
captonpril	B-I	NOUN	O
(	O	PUNCT	O
Capoten	O	PROPN	B
trade	O	NOUN	I
mark	O	NOUN	I
,	O	PUNCT	O
Elan	O	PROPN	B
)	O	PUNCT	O
after	B-P	ADP	O
myocardial	I-P	ADJ	B
infarction	I-P	NOUN	I
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
left	I-P	ADJ	B
ventricular	I-P	ADJ	I
dysfunction	I-P	NOUN	I
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
target	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
losartan	B-I	NOUN	B
50	O	NUM	O
mg/day	O	NOUN	B
and	O	CCONJ	O
captopril	B-I	NOUN	B
50	O	NUM	O
mg	O	NOUN	O
t.i.d.	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
tolerated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
all-cause	B-OUT	ADJ	O
mortality	I-OUT	NOUN	B
and	O	CCONJ	O
there	O	PRON	O
were	O	AUX	O
499	O	NUM	O
(	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
447	O	NUM	O
(	O	PUNCT	O
16	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
deaths	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
losartan	B-I	NOUN	B
and	I-I	CCONJ	O
captopril	I-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.07	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
significantly	O	ADV	O
more	O	ADJ	O
cardiovascular	B-OUT	ADJ	B
deaths	I-OUT	NOUN	B
with	O	ADP	O
losartan	O	NOUN	B
(	O	PUNCT	O
420	O	NUM	O
,	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
with	O	ADP	O
captopril	B-I	NOUN	B
(	O	PUNCT	O
363	O	NUM	O
,	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Losartan	B-I	NOUN	B
was	O	AUX	O
better	O	ADV	O
tolerated	B-OUT	VERB	B
than	O	ADP	O
captopril	B-I	NOUN	B
with	O	ADP	O
fewer	O	ADJ	O
patients	B-OUT	NOUN	B
discontinuing	I-OUT	VERB	O
medication	I-OUT	NOUN	O
(	O	PUNCT	O
17	O	NUM	O
versus	O	CCONJ	O
23	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
losartan	B-I	NOUN	B
and	O	CCONJ	O
captopril	B-I	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
if	O	SCONJ	O
tolerated	O	VERB	B
,	O	PUNCT	O
captopril	B-I	NOUN	B
should	O	AUX	O
remain	O	VERB	O
the	O	DET	O
preferred	O	ADJ	O
treatment	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
after	O	ADP	O
complicated	O	ADJ	O
acute	B-OUT	ADJ	O
myocardial	I-OUT	ADJ	O
infarction	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	O
walnut	B-I	ADJ	B
consumption	I-I	NOUN	B
on	O	ADP	O
endothelial	B-OUT	ADJ	B
function	I-OUT	NOUN	I
in	O	ADP	O
type	B-P	NOUN	B
2	I-P	NUM	I
diabetic	I-P	ADJ	I
subjects	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
crossover	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
daily	O	ADJ	B
walnut	B-I	ADJ	B
consumption	I-I	NOUN	O
on	O	ADP	O
endothelial	B-OUT	ADJ	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
cardiovascular	I-OUT	ADJ	B
biomarkers	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anthropometric	I-OUT	ADJ	B
measures	I-OUT	NOUN	B
in	O	ADP	O
type	B-P	NOUN	B
2	I-P	NUM	I
diabetic	I-P	ADJ	I
individuals	I-P	NOUN	B
.	I-P	PUNCT	O


RESEARCH	O	NOUN	O
DESIGN	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
single-blind	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


Twenty-four	B-P	NUM	O
participants	I-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
(	I-P	PUNCT	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
58	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
14	I-P	NUM	O
women	I-P	NOUN	B
and	I-P	CCONJ	O
10	I-P	NUM	O
men	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
possible	O	ADJ	O
sequence	O	NOUN	B
permutations	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
an	O	DET	O
ad	B-I	NOUN	B
libitum	I-I	NOUN	I
diet	I-I	NOUN	I
enriched	I-I	VERB	O
with	I-I	ADP	O
56	I-I	NUM	O
g	I-I	NOUN	O
(	I-I	PUNCT	O
366	I-I	NUM	O
kcal	I-I	ADJ	O
)	I-I	PUNCT	O
walnuts/day	I-I	NOUN	O
and	I-I	CCONJ	O
an	I-I	DET	O
ad	I-I	NOUN	B
libitum	I-I	NOUN	I
diet	I-I	NOUN	I
without	I-I	ADP	O
walnuts	I-I	NOUN	B
for	I-I	ADP	O
8	I-I	NUM	O
weeks	I-I	NOUN	B
.	I-I	PUNCT	O


Subjects	O	NOUN	B
underwent	O	VERB	O
endothelial	B-I	ADJ	B
function	I-I	NOUN	I
testing	I-I	NOUN	I
(	O	PUNCT	O
measured	O	VERB	B
as	O	ADP	O
flow-mediated	O	ADJ	B
dilatation	O	NOUN	I
[	O	PUNCT	O
FMD	O	NOUN	B
]	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
assessment	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
biomarkers	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
each	O	DET	O
8-week	O	ADJ	B
treatment	O	NOUN	B
phase	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
was	O	AUX	O
the	O	DET	O
change	B-OUT	NOUN	O
in	I-OUT	ADP	O
FMD	I-OUT	NOUN	B
after	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Secondary	O	ADJ	B
outcome	O	NOUN	I
measures	O	NOUN	I
included	O	VERB	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
lipids	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
A1C	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
fasting	I-OUT	ADJ	B
glucose	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
insulin	I-OUT	NOUN	B
sensitivity	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anthropometric	I-OUT	ADJ	B
measures	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Endothelial	B-OUT	ADJ	B
function	I-OUT	NOUN	I
significantly	O	ADV	O
improved	O	VERB	O
after	O	ADP	O
consumption	O	NOUN	B
of	O	ADP	O
a	O	DET	O
walnut-enriched	O	ADJ	B
ad	O	NOUN	B
libitum	O	NOUN	I
diet	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
after	O	ADP	O
consumption	O	NOUN	B
of	O	ADP	O
an	O	DET	O
ad	O	NOUN	B
libitum	O	NOUN	I
diet	O	NOUN	I
without	O	ADP	O
walnuts	O	NOUN	B
(	O	PUNCT	O
2.2	O	NUM	O
+/-	O	CCONJ	O
1.7	O	NUM	O
vs.	O	CCONJ	O
1.2	O	NUM	O
+/-	O	CCONJ	O
1.6	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
walnut-enriched	O	ADJ	B
diet	O	NOUN	I
increased	O	VERB	B
fasting	B-OUT	NOUN	B
serum	I-OUT	NOUN	O
glucose	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
lowered	I-OUT	VERB	B
serum	I-OUT	NOUN	O
total	I-OUT	NOUN	O
cholesterol	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
LDL	I-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
from	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
10.0	O	NUM	O
+/-	O	CCONJ	O
20.5	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
;	O	PUNCT	O
-9.7	O	NUM	O
+/-	O	CCONJ	O
14.5	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
-7.7	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
mg/dl	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
although	O	SCONJ	O
these	O	DET	O
changes	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
for	O	ADP	O
an	O	DET	O
ad	O	NOUN	B
libitum	O	NOUN	I
diet	O	NOUN	I
without	O	ADP	O
walnuts	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
anthropometric	B-OUT	ADJ	B
measures	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
plasma	I-OUT	NOUN	B
A1C	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
insulin	I-OUT	NOUN	B
sensitivity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
A	O	DET	O
walnut-enriched	O	ADJ	B
ad	O	NOUN	B
libitum	O	NOUN	I
diet	O	NOUN	I
improves	O	VERB	O
endothelium-dependent	O	ADJ	B
vasodilatation	O	NOUN	I
in	O	ADP	O
type	O	NOUN	B
2	O	NUM	I
diabetic	O	ADJ	I
individuals	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
potential	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
overall	O	ADJ	B
cardiac	B-OUT	ADJ	B
risk	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Rationale	O	NOUN	B
and	O	CCONJ	O
study	O	NOUN	B
design	O	NOUN	B
of	O	ADP	O
the	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
vagal	O	ADJ	B
tone	O	NOUN	I
in	O	ADP	O
heart	B-P	NOUN	B
failure	I-P	NOUN	I
study	O	NOUN	B
:	O	PUNCT	O
INOVATE-HF	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Imbalance	O	NOUN	B
between	O	ADP	O
the	O	DET	O
parasympathetic	O	ADJ	B
and	O	CCONJ	O
sympathetic	O	ADJ	B
nervous	O	ADJ	I
systems	O	NOUN	I
is	O	AUX	O
a	O	DET	O
recognized	O	VERB	O
contributor	O	NOUN	O
to	O	PART	O
progression	O	NOUN	B
of	O	ADP	O
chronic	B-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
.	I-P	PUNCT	O


Current	O	ADJ	O
therapy	O	NOUN	B
with	O	ADP	O
beta	O	NOUN	B
adrenergic	O	ADJ	I
antagonists	O	NOUN	I
is	O	AUX	O
designed	O	VERB	O
to	O	PART	O
moderate	O	VERB	B
the	O	DET	O
up-regulation	O	NOUN	B
of	O	ADP	O
norepinephrine	O	NOUN	B
and	O	CCONJ	O
sympathetic	O	ADJ	B
effects	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
to	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
no	O	DET	O
therapies	O	NOUN	B
that	O	PRON	O
specifically	O	ADV	O
address	O	VERB	O
the	O	DET	O
withdrawal	O	NOUN	B
of	O	ADP	I
parasympathetic	O	ADJ	B
influences	O	NOUN	B
on	O	ADP	O
cardiac	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
structure	O	NOUN	B
.	O	PUNCT	O


METHODS/RESULTS	O	NOUN	B
In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
vagus	O	ADJ	B
nerve	O	NOUN	I
stimulation	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
international	O	ADJ	B
multi-center	O	ADJ	O
randomized	O	ADJ	O
clinical	O	ADJ	O
trial	O	NOUN	O
(	O	PUNCT	O
INOVATE-HF	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
designed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
efficacy	I-OUT	NOUN	B
of	O	ADP	O
vagus	O	ADJ	B
nerve	O	NOUN	I
stimulation	O	NOUN	B
in	O	ADP	O
symptomatic	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
heart	I-P	NOUN	B
failure	I-P	NOUN	I
on	I-P	ADP	O
optimal	I-P	ADJ	B
medical	I-P	ADJ	B
therapy	I-P	NOUN	I
using	O	VERB	O
the	O	DET	O
CardioFit	B-I	PROPN	B
System	I-I	PROPN	I
(	O	PUNCT	O
BioControl	O	PROPN	B
Medical	O	PROPN	I
,	O	PUNCT	O
Yehud	O	PROPN	B
,	O	PUNCT	O
Israel	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


Up	B-P	ADP	O
to	I-P	PART	O
650	I-P	NUM	O
patients	I-P	NOUN	B
from	I-P	ADP	O
80	I-P	NUM	O
sites	I-P	NOUN	B
will	I-P	AUX	O
be	I-P	AUX	O
recruited	I-P	VERB	B
and	O	CCONJ	O
randomized	O	ADJ	B
in	O	ADP	O
a	O	DET	O
3:2	O	NUM	O
ratio	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
active	O	ADJ	B
treatment	O	NOUN	I
or	O	CCONJ	O
standard	B-I	ADJ	B
optimal	I-I	ADJ	I
medical	I-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


Inclusion	B-P	NOUN	B
criteria	I-P	NOUN	I
include	I-P	VERB	O
left	I-P	VERB	B
ventricular	I-P	ADJ	I
systolic	I-P	NOUN	I
dysfunction	I-P	NOUN	I
,	I-P	PUNCT	O
the	I-P	DET	O
presence	I-P	NOUN	B
of	I-P	ADP	O
New	I-P	PROPN	B
York	I-P	PROPN	I
Heart	I-P	PROPN	I
Association	I-P	PROPN	I
Class	I-P	PROPN	I
III	I-P	NUM	I
symptoms	I-P	NOUN	B
,	I-P	PUNCT	O
sinus	I-P	NOUN	B
rhythm	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
QRS	I-P	PROPN	B
width	I-P	VERB	I
less	I-P	ADJ	O
than	I-P	ADP	O
120	I-P	NUM	O
milliseconds	I-P	NOUN	O
.	I-P	PUNCT	O


The	O	DET	O
study	O	NOUN	B
is	O	AUX	O
powered	O	ADJ	O
to	O	PART	O
detect	O	VERB	B
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
end	O	NOUN	O
point	O	NOUN	O
of	O	ADP	O
all-cause	B-OUT	ADJ	B
mortality	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
heart	I-OUT	NOUN	B
failure	I-OUT	NOUN	I
hospitalization	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
2	I-OUT	NUM	O
safety	I-OUT	NOUN	B
end	I-OUT	NOUN	O
points	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
Vagal	O	ADJ	B
nerve	O	NOUN	I
stimulation	O	NOUN	B
with	O	ADP	O
CardioFit	B-I	PROPN	B
as	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
for	O	ADP	O
symptomatic	O	ADJ	B
heart	O	NOUN	B
failure	O	NOUN	I
is	O	AUX	O
under	O	ADP	O
active	O	ADJ	B
investigation	O	NOUN	B
as	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
approach	O	NOUN	O
to	O	PART	O
restore	O	VERB	B
balance	O	NOUN	B
between	O	ADP	O
the	O	DET	O
sympathetic	O	ADJ	B
and	O	CCONJ	O
parasympathetic	O	ADJ	B
nervous	O	ADJ	I
systems	O	NOUN	I
.	O	PUNCT	O


If	O	SCONJ	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
in	O	ADP	O
decreasing	O	VERB	B
heart	B-OUT	NOUN	B
failure	I-OUT	NOUN	I
events	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
mortality	I-OUT	NOUN	B
,	O	PUNCT	O
this	O	DET	O
novel	O	ADJ	O
approach	O	NOUN	O
will	O	AUX	O
impact	O	VERB	B
the	O	DET	O
treatment	O	NOUN	B
paradigm	O	NOUN	B
for	O	ADP	O
heart	O	NOUN	B
failure	O	NOUN	I
.	O	PUNCT	O


Intervention	B-I	NOUN	B
for	I-I	ADP	O
ineffective	I-OUT	ADJ	B
airway	I-OUT	NOUN	B
clearance	I-OUT	NOUN	B
in	I-I	ADP	O
asthmatic	I-I	ADJ	B
children	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
controlled	O	VERB	B
and	O	CCONJ	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
analyse	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intervention	O	NOUN	B
for	O	ADP	O
the	O	DET	O
nursing	O	NOUN	B
diagnosis	O	NOUN	I
of	O	ADP	O
ineffective	B-OUT	ADJ	B
airway	I-OUT	NOUN	B
clearance	I-OUT	NOUN	B
in	O	ADP	O
asthmatic	B-P	ADJ	B
children	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
blinded	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
and	O	CCONJ	O
controlled	O	VERB	B
clinical	O	ADJ	I
trial	O	NOUN	I
was	O	AUX	O
developed	O	VERB	O
in	O	ADP	O
a	O	DET	O
paediatric	B-P	ADJ	B
hospital	I-P	NOUN	I
located	I-P	ADJ	O
on	I-P	ADP	O
northeast	I-P	ADV	B
of	I-P	ADP	O
Brazil	I-P	PROPN	B
with	I-P	ADP	O
42	I-P	NUM	O
asthmatic	I-P	ADJ	B
children	I-P	NOUN	B
aged	I-P	ADJ	B
≤	I-P	ADJ	O
36	I-P	NUM	O
months	I-P	NOUN	B
.	O	PUNCT	O


The	B-P	DET	O
children	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
intervention	O	NOUN	B
and	B-I	CCONJ	O
control	I-I	NOUN	B
)	I-I	PUNCT	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
drawing	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
applied	O	ADJ	O
intervention	O	NOUN	B
included	O	VERB	O
actions	O	NOUN	B
related	O	VERB	O
to	B-I	PART	O
change	I-I	NOUN	O
of	I-I	ADP	O
positioning	I-I	NOUN	B
and	I-I	CCONJ	O
stimulation	I-I	NOUN	B
of	I-I	ADP	O
cough	I-I	NOUN	B
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
findings	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
before	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
,	O	PUNCT	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	B-OUT	DET	O
health	I-OUT	NOUN	B
status	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
children	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
indicators	O	NOUN	B
of	B-OUT	ADP	O
choking	I-OUT	VERB	B
(	O	PUNCT	O
16.83	O	NUM	O
vs.	O	CCONJ	O
26.17	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.007	O	NUM	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
adventitious	I-OUT	ADJ	B
breath	I-OUT	NOUN	I
sounds	I-OUT	NOUN	I
(	O	PUNCT	O
16.4	O	NUM	O
vs.	O	CCONJ	O
26.6	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
higher	O	ADJ	B
,	O	PUNCT	O
on	O	ADP	O
average	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
observed	O	VERB	O
an	O	DET	O
improvement	O	NOUN	B
in	B-OUT	ADP	O
obstructive	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
the	I-P	DET	O
intervention	I-P	NOUN	B
proposed	O	VERB	O
.	O	PUNCT	O


Decreased	O	VERB	B
expression	B-OUT	NOUN	B
of	I-OUT	ADP	O
Yes-associated	I-OUT	ADJ	B
protein	I-OUT	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
outcome	O	NOUN	B
in	O	ADP	O
the	O	DET	O
luminal	B-P	ADJ	B
A	I-P	NOUN	I
breast	I-P	NOUN	O
cancer	I-P	NOUN	O
subgroup	I-P	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
an	O	DET	O
impaired	O	ADJ	B
tamoxifen	B-I	NOUN	B
response	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Yes-associated	B-OUT	ADJ	B
protein	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
YAP1	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
is	O	AUX	O
frequently	O	ADV	O
reported	O	VERB	O
to	O	PART	O
function	O	VERB	B
as	O	ADP	O
an	O	DET	O
oncogene	O	NOUN	B
in	O	ADP	O
many	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
cancer	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
results	O	VERB	B
remain	O	VERB	O
controversial	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
set	O	VERB	O
out	O	ADP	O
to	O	PART	O
clarify	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
YAP1	B-OUT	NOUN	B
in	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
by	O	ADP	O
examining	O	VERB	O
gene	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
subgroups	O	NOUN	B
of	O	ADP	O
patient	O	NOUN	B
material	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
downregulating	O	VERB	B
YAP1	O	NOUN	B
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
studying	O	VERB	O
its	O	PRON	O
role	O	NOUN	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
the	O	DET	O
widely	O	ADV	O
used	O	VERB	O
anti-estrogen	O	ADJ	B
tamoxifen	B-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	NOUN	O
YAP1	B-OUT	NOUN	B
protein	I-OUT	NOUN	I
intensity	I-OUT	NOUN	B
was	O	AUX	O
scored	O	VERB	B
as	O	ADP	O
absent	O	ADJ	B
,	O	PUNCT	O
weak	O	ADJ	B
,	O	PUNCT	O
intermediate	O	ADJ	B
or	O	CCONJ	O
strong	O	ADJ	B
in	O	ADP	O
two	B-P	NUM	O
primary	I-P	ADJ	B
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
cohorts	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
144	I-P	NUM	O
and	I-P	CCONJ	O
n	I-P	NOUN	O
=	I-P	ADJ	O
564	I-P	NUM	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
mRNA	I-OUT	NOUN	B
expression	I-OUT	NOUN	O
of	I-OUT	ADP	O
YAP1	I-OUT	NOUN	B
was	I-P	AUX	O
evaluated	I-P	VERB	B
in	I-P	ADP	O
a	I-P	DET	O
gene	I-P	NOUN	B
expression	I-P	NOUN	I
dataset	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
1107	I-P	NUM	O
)	I-P	PUNCT	O
.	O	PUNCT	O


Recurrence-free	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
analysed	O	VERB	B
using	O	VERB	O
the	O	DET	O
log-rank	O	ADJ	B
test	O	NOUN	I
and	O	CCONJ	O
Cox	O	NOUN	B
multivariate	O	ADJ	I
analysis	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
test	O	VERB	B
for	O	ADP	O
independence	O	NOUN	B
.	O	PUNCT	O


WST-1	B-I	NOUN	B
assay	I-I	NOUN	I
was	O	AUX	O
employed	O	VERB	O
to	O	PART	O
measure	O	VERB	B
cell	B-OUT	NOUN	B
viability	I-OUT	NOUN	I
and	O	CCONJ	O
a	O	DET	O
luciferase	B-OUT	NOUN	B
ERE	I-OUT	NOUN	I
(	O	PUNCT	O
estrogen	O	NOUN	B
responsive	O	ADJ	I
element	O	NOUN	I
)	O	PUNCT	O
construct	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
tamoxifen	B-I	NOUN	B
,	O	PUNCT	O
following	O	VERB	O
downregulation	O	NOUN	B
of	O	ADP	O
YAP1	O	NOUN	B
using	O	VERB	O
siRNAs	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
the	O	DET	O
ER+	B-P	ADJ	B
(	I-P	PUNCT	O
Estrogen	I-P	NOUN	B
Receptor	I-P	NOUN	I
α	I-P	DET	I
positive	I-P	ADJ	B
)	I-P	PUNCT	O
subgroup	I-P	NOUN	B
of	O	ADP	O
the	O	DET	O
randomised	O	ADJ	B
cohort	O	NOUN	I
,	O	PUNCT	O
YAP1	B-OUT	NOUN	B
expression	I-OUT	NOUN	B
was	O	AUX	O
inversely	O	ADV	O
correlated	O	VERB	B
to	O	PART	O
histological	O	ADJ	B
grade	O	NOUN	I
and	O	CCONJ	O
proliferation	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0.016	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
the	B-P	DET	O
ER-	I-P	NOUN	B
(	I-P	PUNCT	O
Estrogen	I-P	NOUN	B
Receptor	I-P	NOUN	I
α	I-P	DET	O
negative	I-P	ADJ	B
)	I-P	PUNCT	O
subgroup	I-OUT	NOUN	B
YAP1	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
correlated	O	VERB	B
positively	O	ADV	O
to	O	PART	O
proliferation	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Notably	O	ADV	O
,	O	PUNCT	O
low	B-OUT	ADJ	O
YAP1	I-OUT	NOUN	B
mRNA	I-OUT	NOUN	B
was	O	AUX	O
independently	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
decreased	B-OUT	VERB	B
recurrence-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
expression	O	NOUN	I
dataset	O	NOUN	I
,	O	PUNCT	O
specifically	O	ADV	O
for	O	ADP	O
the	O	DET	O
luminal	O	ADJ	B
A	O	NOUN	I
subgroup	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
which	O	DET	O
includes	O	VERB	O
low	O	ADJ	O
proliferating	O	VERB	B
tumours	O	NOUN	I
of	O	ADP	O
lower	O	ADJ	O
grade	O	NOUN	O
,	O	PUNCT	O
usually	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
good	O	ADJ	O
prognosis	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
subgroup	O	NOUN	B
specificity	O	NOUN	B
led	O	VERB	O
us	O	PRON	O
to	O	PART	O
hypothesize	O	VERB	O
that	B-OUT	SCONJ	O
YAP1	I-OUT	NOUN	B
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
for	O	ADP	O
response	O	NOUN	B
to	O	PART	O
endocrine	O	ADJ	B
therapies	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	B-I	ADP	O
tamoxifen	I-I	NOUN	B
,	O	PUNCT	O
extensively	O	ADV	O
used	O	VERB	O
for	O	ADP	O
luminal	O	ADJ	B
A	O	NOUN	I
breast	O	NOUN	B
cancers	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	B-I	DET	O
tamoxifen	I-I	NOUN	B
randomised	O	ADJ	B
patient	O	NOUN	B
material	O	NOUN	I
,	O	PUNCT	O
absent	B-OUT	ADJ	O
YAP1	I-OUT	NOUN	B
protein	I-OUT	NOUN	O
expression	I-OUT	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
impaired	B-OUT	ADJ	B
tamoxifen	I-OUT	NOUN	B
response	I-OUT	NOUN	B
which	O	DET	O
was	O	AUX	O
significant	O	ADJ	O
upon	O	SCONJ	O
interaction	O	NOUN	B
analysis	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.042	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


YAP1	O	NOUN	B
downregulation	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
increased	B-OUT	VERB	B
progesterone	I-OUT	NOUN	B
receptor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PgR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
expression	I-OUT	NOUN	B
and	O	CCONJ	O
a	O	DET	O
delayed	O	VERB	B
and	O	CCONJ	O
weaker	B-I	ADJ	O
tamoxifen	I-I	NOUN	B
in	O	ADP	O
support	O	NOUN	O
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
data	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Decreased	B-OUT	VERB	B
YAP1	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
is	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
prognostic	O	ADJ	B
factor	O	NOUN	I
for	O	ADP	O
recurrence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
less	O	ADV	O
aggressive	B-P	ADJ	B
luminal	I-P	ADJ	O
A	I-P	NOUN	O
breast	I-P	NOUN	O
cancer	I-P	NOUN	O
subgroup	I-P	NOUN	B
,	O	PUNCT	O
likely	O	ADV	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
decreased	B-I	VERB	B
tamoxifen	I-I	NOUN	B
sensitivity	O	NOUN	B
conferred	O	VERB	O
by	O	ADP	O
YAP1	O	NOUN	B
downregulation	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
stable	B-P	ADJ	B
angina	I-P	NOUN	I
of	I-P	ADP	O
effort	I-P	NOUN	O
with	O	ADP	O
verapamil	B-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
randomized	O	ADJ	B
crossover	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
verapamil	B-I	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
26	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
stable	I-P	ADJ	B
exertional	I-P	ADJ	B
angina	I-P	ADJ	I
pectoris	I-P	NOUN	I
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
crossover	O	NOUN	I
protocol	O	NOUN	I
using	O	VERB	O
serial	O	ADJ	B
treadmill	O	NOUN	I
tests	O	NOUN	I
.	O	PUNCT	O


Verapamil	B-I	NOUN	B
,	O	PUNCT	O
480	O	NUM	O
mg/day	O	NOUN	B
,	O	PUNCT	O
reduced	O	VERB	B
anginal	B-OUT	ADJ	B
frequency	I-OUT	NOUN	I
from	O	ADP	O
5.6	O	NUM	O
+/-	O	CCONJ	O
7.3	O	NUM	O
to	O	PART	O
2.2	O	NUM	O
+/-	O	CCONJ	O
3.9	O	NUM	O
attacks	O	NOUN	B
per	O	ADP	B
week	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
nitroglycerin	B-OUT	NOUN	B
consumption	I-OUT	NOUN	B
from	O	ADP	O
3.4	O	NUM	O
+/-	O	CCONJ	O
4.9	O	NUM	O
to	O	PART	O
1.2	O	NUM	O
+/-	O	CCONJ	O
2.5	O	NUM	O
tablets	O	NOUN	B
per	O	ADP	O
week	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Treadmill	B-OUT	NOUN	B
time	I-OUT	NOUN	O
increased	O	VERB	B
from	O	ADP	O
6.4	O	NUM	O
+/-	O	CCONJ	O
2.1	O	NUM	O
minutes	O	NOUN	B
during	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
phase	O	NOUN	B
to	O	PART	O
7.5	O	NUM	O
+/-	O	CCONJ	O
1.8	O	NUM	O
minutes	O	NOUN	B
during	O	ADP	O
the	O	DET	O
verapamil	B-I	NOUN	B
phase	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Verapamil	B-I	NOUN	B
's	I-I	PART	I
beneficial	O	ADJ	B
effect	O	NOUN	I
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
related	O	ADJ	O
,	O	PUNCT	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
a	O	DET	O
10	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rate-pressure	B-OUT	ADJ	B
product	I-OUT	NOUN	O
at	O	ADP	O
rest	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
12	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
during	O	ADP	O
submaximal	O	ADJ	B
exercise	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Verapamil	B-I	NOUN	B
also	O	ADV	O
caused	O	VERB	O
less	O	ADV	O
marked	O	ADJ	O
ST-segment	B-OUT	ADJ	B
depressions	I-OUT	NOUN	B
at	I-OUT	ADP	O
peak	I-OUT	NOUN	B
exercise	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
rate-pressure	O	ADJ	B
product	O	NOUN	O
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
favorable	O	ADJ	O
redistribution	O	NOUN	B
of	O	ADP	O
coronary	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
to	O	PART	O
the	O	DET	O
ischemic	O	ADJ	B
zone	O	NOUN	I
.	O	PUNCT	O


Side	O	ADJ	B
effects	O	NOUN	I
from	O	ADP	O
verapamil	B-I	NOUN	B
were	O	AUX	O
minimal	O	ADJ	B
,	O	PUNCT	O
consisting	O	VERB	O
mainly	O	ADV	O
of	O	ADP	O
constipation	B-OUT	NOUN	B
(	O	PUNCT	O
six	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Verapamil	B-I	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
drug	O	NOUN	B
for	O	ADP	O
treating	O	VERB	B
angina	B-P	ADJ	B
of	O	ADP	O
effort	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
effectiveness	B-OUT	NOUN	I
trial	O	NOUN	I
of	O	ADP	O
collaborative	B-I	ADJ	B
care	I-I	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
panic	I-P	NOUN	B
disorder	I-P	NOUN	I
in	I-P	ADP	O
primary	I-P	ADJ	B
care	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Effectiveness	B-OUT	NOUN	B
studies	O	NOUN	I
have	O	AUX	O
tested	O	VERB	B
interventions	O	NOUN	B
to	O	PART	O
improve	O	VERB	B
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
care	I-OUT	NOUN	I
for	O	ADP	O
depression	O	NOUN	B
in	O	ADP	O
primary	O	ADJ	B
care	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
none	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
completed	O	VERB	O
for	O	ADP	O
panic	O	NOUN	B
disorder	O	NOUN	I
(	O	PUNCT	O
PD	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
this	O	DET	O
setting	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
clinical	B-OUT	ADJ	B
effectiveness	I-OUT	NOUN	I
of	O	ADP	O
PD	B-I	NOUN	B
pharmacotherapy	I-I	NOUN	I
embedded	I-I	ADJ	O
in	I-I	ADP	O
a	I-I	DET	O
disease	I-I	NOUN	B
management	I-I	NOUN	I
framework	I-I	NOUN	O
of	I-I	ADP	O
"	I-I	PUNCT	O
collaborative	I-I	ADJ	B
care	I-I	NOUN	I
"	I-I	PUNCT	O
(	I-I	PUNCT	O
CC	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
fifteen	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
PD	I-P	NOUN	B
from	I-P	ADP	O
3	I-P	NUM	O
primary	I-P	ADJ	B
care	I-P	NOUN	I
clinics	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
CC	B-I	NOUN	B
or	O	CCONJ	O
"	B-I	PUNCT	O
usual	I-I	ADJ	B
care	I-I	NOUN	I
"	I-I	PUNCT	O
(	I-I	PUNCT	O
UC	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
CC	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
57	O	NUM	O
)	O	PUNCT	O
received	O	VERB	O
educational	B-I	ADJ	B
videotapes	I-I	NOUN	I
and	I-I	CCONJ	O
pamphlets	I-I	NOUN	B
;	I-I	PUNCT	O
pharmacotherapy	I-I	NOUN	B
with	I-I	ADP	O
the	I-I	DET	O
selective	I-I	ADJ	O
serotonin	I-I	NOUN	B
reuptake	I-I	NOUN	I
inhibitor	I-I	NOUN	I
paroxetine	I-I	NOUN	B
;	I-I	PUNCT	O
2	I-I	NUM	O
psychiatrist	I-I	NOUN	B
visits	I-I	NOUN	I
and	I-I	CCONJ	O
2	I-I	NUM	O
telephone	I-I	NOUN	B
calls	I-I	NOUN	O
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
8	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
up	O	ADP	O
to	O	PART	O
5	O	NUM	O
telephone	B-I	NOUN	B
calls	I-I	NOUN	O
between	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
'	O	PART	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Usual	O	ADJ	B
care	O	NOUN	I
patients	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
58	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
their	O	PRON	O
primary	O	ADJ	B
care	O	NOUN	I
physician	O	NOUN	I
.	O	PUNCT	O


Telephone	O	NOUN	B
assessments	O	NOUN	I
of	O	ADP	O
panic	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
anxiety	I-OUT	NOUN	B
sensitivity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
depression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
variables	I-OUT	NOUN	B
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
'	O	PART	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Adequacy	B-OUT	NOUN	B
of	I-OUT	ADP	O
pharmacotherapy	I-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
with	O	ADP	O
an	O	DET	O
algorithm	B-OUT	NOUN	B
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
review	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
studies	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Patients	O	NOUN	B
in	O	ADP	O
CC	O	NOUN	B
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
receive	O	VERB	O
adequate	B-OUT	ADJ	B
(	I-OUT	PUNCT	O
type	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
dose	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
medication	I-OUT	NOUN	B
and	O	CCONJ	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
adhere	B-OUT	VERB	O
to	I-OUT	ADP	O
this	I-OUT	DET	O
medication	I-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Random	O	ADJ	B
regression	O	NOUN	I
analyses	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
CC	O	NOUN	B
patients	O	NOUN	B
improved	B-OUT	VERB	B
significantly	O	ADV	O
more	O	ADV	O
over	O	ADP	O
time	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
UC	O	NOUN	B
patients	O	NOUN	B
on	O	ADP	O
anxiety	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
depression	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
disability	I-OUT	NOUN	B
measures	I-OUT	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
greatest	O	ADJ	O
effects	B-OUT	NOUN	B
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Compared	O	VERB	O
with	O	ADP	O
UC	O	NOUN	B
,	O	PUNCT	O
CC	O	NOUN	B
interventions	O	NOUN	B
significantly	O	ADV	O
improved	O	VERB	O
both	O	CCONJ	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
care	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
clinical	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
functional	I-OUT	ADJ	B
outcomes	I-OUT	NOUN	B
in	O	ADP	O
primary	B-P	ADJ	B
care	I-P	NOUN	I
PD	I-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Clinical	O	ADJ	B
differences	O	NOUN	I
were	O	AUX	O
greatest	O	ADJ	O
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
greater	O	ADJ	O
quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
care	I-OUT	NOUN	I
and	O	CCONJ	O
the	O	DET	O
greater	O	ADJ	O
intensity	B-OUT	NOUN	B
of	O	ADP	O
intervention	O	NOUN	B
.	O	PUNCT	O


Twenty-four	O	NUM	O
vs.	O	CCONJ	O
forty-eight	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
re-therapy	O	NOUN	B
with	O	ADP	O
interferon	B-I	NOUN	B
alpha	I-I	NOUN	I
2b	I-I	NOUN	I
and	I-I	CCONJ	O
ribavirin	I-I	NOUN	B
in	O	ADP	O
interferon	B-P	NOUN	B
alpha	I-P	NOUN	I
monotherapy	I-P	NOUN	B
relapsers	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
C.	I-P	X	O
BACKGROUND/AIM	O	NOUN	O
Roughly	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
hepatitis	O	NOUN	I
C	O	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
relapsed	O	VERB	B
after	O	ADP	O
a	O	DET	O
previous	O	ADJ	O
monotherapy	O	NOUN	B
with	O	ADP	O
interferon	O	NOUN	B
alpha	O	NOUN	I
,	O	PUNCT	O
will	O	AUX	O
respond	O	VERB	O
in	O	ADP	O
a	O	DET	O
sustained	O	ADJ	B
fashion	O	NOUN	O
to	O	PART	O
24	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
re-therapy	O	NOUN	B
with	O	ADP	O
the	O	DET	O
combination	B-I	NOUN	B
of	I-I	ADP	O
interferon	I-I	NOUN	B
alpha	I-I	NOUN	I
plus	I-I	CCONJ	O
ribavirin	I-I	NOUN	B
.	I-I	PUNCT	O


Whether	O	SCONJ	O
prolonging	O	VERB	B
treatment	O	NOUN	B
duration	O	NOUN	O
to	O	PART	O
48	O	NUM	O
weeks	O	NOUN	B
will	O	AUX	O
further	O	ADV	O
increase	O	VERB	B
sustained	O	ADJ	O
response	O	NOUN	B
rates	O	NOUN	I
remains	O	VERB	O
ill	O	ADV	B
defined	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
pilot	O	NOUN	I
trial	O	NOUN	I
we	O	PRON	O
compared	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
24	O	NUM	O
week	O	NOUN	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
a	O	DET	O
48	O	NUM	O
week	O	NOUN	B
course	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
therapy	O	NOUN	I
with	O	ADP	O
interferon	O	NOUN	B
alpha	O	NOUN	I
and	O	CCONJ	O
ribavirin	O	NOUN	B
in	O	ADP	O
interferon	B-P	NOUN	B
monotherapy	I-P	NOUN	I
relapsers	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
C.	I-P	NOUN	O
METHODS	O	NOUN	O
Interferon	B-P	NOUN	B
alpha	I-P	NOUN	I
monotherapy	I-P	NOUN	B
relapsers	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
C	I-P	NOUN	I
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
interferon	B-I	NOUN	B
alpha	I-I	NOUN	I
2b	I-I	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
x	O	CCONJ	O
3	O	NUM	O
MIU	O	NOUN	B
sc	O	NOUN	B
weekly	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
oral	B-I	ADJ	B
ribavirin	I-I	NOUN	I
(	O	PUNCT	O
1000/1200	O	NOUN	O
mg	O	NOUN	O
po	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
for	O	ADP	O
either	O	CCONJ	O
24	O	NUM	O
weeks	O	NOUN	B
or	O	CCONJ	O
48	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Virological	O	ADJ	B
response	O	NOUN	O
was	O	AUX	O
evaluated	O	VERB	O
by	O	ADP	O
HCV	O	NOUN	B
RNA	O	NOUN	I
PCR	O	NOUN	I
at	O	ADP	O
week	O	NOUN	B
10	O	NUM	O
(	O	PUNCT	O
initial	O	ADJ	O
response	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
end	O	NOUN	O
of-	O	ADP	O
treatment	O	NOUN	O
response	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
24	O	NUM	O
weeks	O	NOUN	B
follow-up	O	X	B
(	O	PUNCT	O
sustained	O	ADJ	B
response	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Only	B-P	ADV	O
patients	I-P	NOUN	B
with	I-P	ADP	O
negative	I-P	ADJ	B
HCV	I-P	NOUN	B
RNA	I-P	NOUN	O
at	I-P	ADP	O
week	I-P	NOUN	B
10	I-P	NUM	O
continued	I-P	ADJ	O
treatment	I-P	NOUN	B
.	I-P	PUNCT	O


Adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
at	O	ADP	O
regular	O	ADJ	O
intervals	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Thirty-seven	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
,	I-P	PUNCT	O
19	I-P	NUM	O
(	I-P	PUNCT	O
6	I-P	NUM	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
median	I-P	ADJ	O
age	I-P	NOUN	B
43	I-P	NUM	O
)	I-P	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
24	I-P	NUM	O
week	I-P	NOUN	B
and	I-P	CCONJ	O
18	I-P	NUM	O
(	I-P	PUNCT	O
5	I-P	NUM	O
females	I-P	NOUN	B
,	I-P	PUNCT	O
median	I-P	ADJ	B
age	I-P	NOUN	B
40	I-P	NUM	O
)	I-P	PUNCT	O
in	I-P	ADP	O
the	I-P	DET	O
48	I-P	NUM	O
week	I-P	NOUN	B
treatment	I-P	NOUN	B
arm	I-P	NOUN	I
.	I-P	PUNCT	O


Baseline	B-P	NOUN	B
characteristics	I-P	NOUN	B
were	I-P	AUX	O
similar	I-P	ADJ	O
in	I-P	ADP	O
both	I-P	DET	O
groups	I-P	NOUN	B
.	I-P	PUNCT	O


At	O	ADP	O
treatment	O	NOUN	B
week	O	NOUN	B
10	O	NUM	O
,	O	PUNCT	O
12/19	O	NUM	O
(	O	PUNCT	O
63	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
24	O	NUM	O
week	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
14/18	O	NUM	O
(	O	PUNCT	O
78	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
48	O	NUM	O
week	O	NOUN	B
group	O	NOUN	B
had	O	AUX	O
lost	B-OUT	VERB	O
HCV	I-OUT	NOUN	B
RNA	I-OUT	NOUN	I
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.33	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
initial	O	ADJ	O
responders	O	NOUN	B
remained	O	VERB	O
HCV	B-OUT	NOUN	B
RNA	I-OUT	NOUN	B
negative	I-OUT	ADJ	B
throughout	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Sustained	B-OUT	ADJ	B
response	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
10/19	O	NUM	O
(	O	PUNCT	O
53	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
24	O	NUM	O
week	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
13/18	O	NUM	O
(	O	PUNCT	O
72	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
48	O	NUM	O
week	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.31	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Three	B-P	NUM	O
patients	I-P	NOUN	B
discontinued	I-P	VERB	B
treatment	I-P	NOUN	B
early	I-P	ADV	O
(	I-P	PUNCT	O
two	I-P	NUM	O
due	I-P	ADP	O
to	I-P	PART	O
moderate	I-OUT	ADJ	B
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
,	I-P	PUNCT	O
one	I-P	NUM	O
due	I-P	ADP	O
to	I-P	ADP	O
non-compliance	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Dose	O	NOUN	B
modifications	O	NOUN	B
were	O	AUX	O
necessary	O	ADJ	O
in	O	ADP	O
9	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
in	O	ADP	O
the	O	DET	O
24	O	NUM	O
week	O	NOUN	B
and	O	CCONJ	O
5	O	NUM	O
in	O	ADP	O
the	O	DET	O
48	O	NUM	O
week	O	NOUN	B
group	O	NOUN	B
for	O	ADP	O
anaemia	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
neutropenia	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
depression	I-OUT	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Prolonging	O	VERB	B
interferon	O	NOUN	B
/	O	SYM	O
ribavirin	O	NOUN	B
combination	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
interferon	O	NOUN	B
alpha	O	NOUN	I
monotherapy	O	NOUN	B
relapsers	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
hepatitis	O	NOUN	I
C	O	NOUN	I
from	O	ADP	O
24	O	NUM	O
to	O	PART	O
48	O	NUM	O
weeks	O	NOUN	B
may	O	AUX	O
increase	O	VERB	B
sustained	B-OUT	ADJ	B
response	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Larger	O	ADJ	B
controlled	O	VERB	I
trials	O	NOUN	I
using	O	VERB	O
pegylated	O	ADJ	B
interferon	O	NOUN	I
alpha	O	NOUN	I
and	O	CCONJ	O
ribavirin	O	NOUN	B
in	O	ADP	O
relapsers	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
C	I-P	NOUN	I
seem	O	VERB	O
warranted	O	VERB	O
.	O	PUNCT	O


Final	O	ADJ	O
report	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
study	O	NOUN	I
with	O	ADP	O
streptococcal	O	ADJ	B
preparation	O	NOUN	I
OK-432	B-I	NOUN	B
as	O	ADP	O
a	O	DET	O
supplementary	O	ADJ	O
immunopotentiator	O	NOUN	B
for	O	ADP	O
laryngeal	B-P	ADJ	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
study	O	NOUN	I
of	O	ADP	O
streptococcal	O	ADJ	B
preparation	O	NOUN	I
OK-432	B-I	NOUN	B
on	O	ADP	O
120	B-P	NUM	O
newly	I-P	ADV	O
identified	I-P	VERB	O
cases	I-P	NOUN	B
of	I-P	ADP	O
laryngeal	I-P	ADJ	B
squamous	I-P	ADJ	I
cell	I-P	NOUN	I
carcinoma	I-P	NOUN	I
who	I-P	PRON	O
were	I-P	AUX	O
registered	I-P	VERB	O
at	I-P	ADP	O
10	I-P	NUM	O
participating	I-P	VERB	B
institutions	I-P	NOUN	B
between	I-P	ADP	O
November	I-P	PROPN	O
1984	I-P	NUM	O
and	I-P	CCONJ	O
October	I-P	PROPN	O
1989	I-P	NUM	O
.	I-P	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
those	O	DET	O
in	O	ADP	O
early	O	ADJ	B
stages	O	NOUN	I
(	O	PUNCT	O
stage	O	NOUN	B
I	O	NUM	I
or	O	CCONJ	O
II	O	NUM	B
)	O	PUNCT	O
and	O	CCONJ	O
those	O	DET	O
in	O	ADP	O
advanced	O	ADJ	B
stages	O	NOUN	I
(	O	PUNCT	O
stage	O	NOUN	B
III	O	NUM	I
or	O	CCONJ	I
IV	O	NUM	B
)	O	PUNCT	O
;	O	PUNCT	O
these	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
further	O	ADV	O
subdivided	O	VERB	O
into	O	ADP	O
an	O	DET	O
immunotherapy	O	NOUN	B
group	O	NOUN	I
(	B-I	PUNCT	O
receiving	I-I	VERB	O
OK-432	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
control	B-I	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
receive	O	VERB	O
OK-432	B-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
usefulness	O	NOUN	B
of	O	ADP	O
OK-432	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
using	O	VERB	O
the	O	DET	O
sealed	O	VERB	B
envelope	O	NOUN	I
method	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
basic	O	ADJ	O
therapy	O	NOUN	B
for	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
was	O	AUX	O
radiotherapy	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
when	O	SCONJ	O
required	O	VERB	O
,	O	PUNCT	O
surgery	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
adjuvant	O	ADJ	B
therapy	O	NOUN	I
,	O	PUNCT	O
5Fu	O	NOUN	B
or	O	CCONJ	O
derivatives	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
from	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
to	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
the	O	DET	O
basic	O	ADJ	O
therapy	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
exception	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
side	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
serious	O	ADJ	O
enough	O	ADJ	O
to	O	PART	O
contraindicate	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
target	O	NOUN	B
administration	O	NOUN	B
period	O	NOUN	B
was	O	AUX	O
5	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Of	B-P	ADP	O
the	I-P	DET	O
initial	I-P	ADJ	O
120	I-P	NUM	O
cases	I-P	NOUN	B
,	I-P	PUNCT	O
11	I-P	NUM	O
cases	I-P	NOUN	B
were	I-P	AUX	O
disqualified	I-P	VERB	O
(	I-P	PUNCT	O
3	I-P	NUM	O
cases	I-P	NOUN	B
of	I-P	ADP	O
double	I-P	ADJ	B
cancer	I-P	NOUN	I
and	I-P	CCONJ	O
8	I-P	NUM	O
of	I-P	ADP	O
incomplete	I-P	ADJ	B
primary	I-P	ADJ	B
therapy	I-P	NOUN	I
)	I-P	PUNCT	O
and	I-P	CCONJ	O
the	I-P	DET	O
remaining	I-P	VERB	O
109	I-P	NUM	O
were	I-P	AUX	O
used	I-P	VERB	O
for	I-P	ADP	O
evaluation	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
5-year	B-OUT	ADJ	O
survival	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
5-year	I-OUT	ADJ	O
recurrence-free	I-OUT	ADJ	B
rate	I-OUT	NOUN	I
were	O	AUX	O
76	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
84	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
immunized	O	VERB	B
groups	O	NOUN	I
(	O	PUNCT	O
both	O	CCONJ	O
the	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
advanced	O	ADJ	B
groups	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
same	O	ADJ	O
rates	O	NOUN	B
for	O	ADP	O
the	O	DET	O
control	O	NOUN	B
groups	O	NOUN	I
were	O	AUX	O
78	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
75	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
tendency	O	NOUN	O
for	O	ADP	O
the	O	DET	O
immunized	O	VERB	B
groups	O	NOUN	I
to	O	PART	O
enjoy	O	VERB	O
a	O	DET	O
slightly	B-OUT	ADV	O
longer	I-OUT	ADJ	O
recurrence-free	I-OUT	ADJ	B
period	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Over	O	ADP	O
a	O	DET	O
24-month	O	ADJ	O
observation	O	NOUN	B
period	O	NOUN	O
the	O	DET	O
immunized	O	VERB	B
group	O	NOUN	I
always	O	ADV	O
had	O	AUX	O
higher	O	ADJ	B
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
peripheral	I-OUT	ADJ	B
leukocytes	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
peripheral	I-OUT	ADJ	B
lymphocytes	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
this	O	DET	O
difference	O	NOUN	O
was	O	AUX	O
significant	O	ADJ	B
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
21	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Inhibition	B-OUT	NOUN	B
of	I-OUT	ADP	O
bone	I-OUT	NOUN	B
marrow	I-OUT	NOUN	I
function	I-OUT	NOUN	I
is	O	AUX	O
sometimes	O	ADV	O
observed	O	VERB	O
with	O	ADP	O
radiotherapy	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
hoped	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
if	O	SCONJ	O
this	O	DET	O
inhibition	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
mitigated	O	VERB	B
,	O	PUNCT	O
it	O	PRON	O
will	O	AUX	O
be	O	AUX	O
possible	O	ADJ	O
to	O	PART	O
assist	O	VERB	O
the	O	DET	O
compromised	O	VERB	O
immune	O	ADJ	B
system	O	NOUN	I
and	O	CCONJ	O
maintain	O	VERB	O
a	O	DET	O
certain	B-OUT	ADJ	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
immune	I-OUT	ADJ	B
performance	I-OUT	NOUN	I
which	O	DET	O
will	O	AUX	O
prevent	O	VERB	B
recurrence	O	NOUN	B
and	O	CCONJ	O
improve	B-OUT	VERB	B
survival	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
observed	O	VERB	O
a	O	DET	O
tendency	O	NOUN	O
of	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
recurrence	O	NOUN	B
rate	O	NOUN	B
in	O	ADP	O
the	O	DET	O
immunized	O	VERB	B
group	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
we	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
OK-432	B-I	NOUN	B
is	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
extending	O	VERB	O
the	O	DET	O
recurrence-free	O	ADJ	B
period	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
controlled	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
'Senokot	B-I	VERB	B
'	I-I	PUNCT	O
in	O	ADP	O
faecal	O	ADJ	B
soiling	O	NOUN	I
treated	O	VERB	B
by	O	ADP	O
behavioural	O	ADJ	B
methods	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
randomly	O	ADV	B
controlled	O	VERB	I
trial	O	NOUN	I
of	O	ADP	O
one	O	NUM	O
particular	O	ADJ	O
laxative	O	NOUN	B
,	O	PUNCT	O
Senokot	B-I	NOUN	B
,	O	PUNCT	O
used	O	VERB	O
in	O	ADP	O
moderate	O	ADJ	B
dosage	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
on	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
40	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
and	I-P	CCONJ	O
persistent	I-P	ADJ	B
soiling	I-P	NOUN	O
and	I-P	CCONJ	O
often	I-P	ADV	O
with	I-P	ADP	O
a	I-P	DET	O
history	I-P	NOUN	B
of	I-P	ADP	O
faecal	I-P	ADJ	B
retention	I-P	NOUN	I
.	I-P	PUNCT	O


Significant	B-OUT	ADJ	B
improvement	I-OUT	NOUN	B
occurred	O	VERB	O
following	O	VERB	O
three	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
outpatient	O	ADJ	B
treatment	O	NOUN	O
using	O	VERB	O
a	O	DET	O
behavioural	B-I	ADJ	B
approach	I-I	NOUN	I
and	I-I	CCONJ	O
either	I-I	CCONJ	O
Senokot	I-I	NOUN	B
,	I-I	PUNCT	O
placebo	I-I	NOUN	B
or	I-I	CCONJ	O
no	I-I	DET	O
medication	I-I	NOUN	O
.	I-I	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
either	O	CCONJ	O
during	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
or	O	CCONJ	O
subsequently	O	ADV	O
when	O	SCONJ	O
Senokot	O	NOUN	B
was	O	AUX	O
employed	O	VERB	O
to	O	PART	O
supplement	O	VERB	B
behavioural	O	ADJ	B
treatment	O	NOUN	I
in	O	ADP	O
every	O	DET	O
child	O	NOUN	B
who	O	PRON	O
continued	O	VERB	O
with	O	ADP	O
therapy	O	NOUN	B
that	O	SCONJ	O
this	O	DET	O
laxative	O	NOUN	B
contributed	O	VERB	O
in	O	ADP	O
any	O	DET	O
way	O	NOUN	O
to	O	ADP	O
relieving	B-OUT	VERB	O
the	I-OUT	DET	O
problem	I-OUT	NOUN	B
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
cases	O	NOUN	B
.	O	PUNCT	O


Safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
sitaxsentan	B-I	NOUN	B
50	O	NUM	O
and	O	CCONJ	O
100	O	NUM	O
mg	O	NOUN	O
in	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
pulmonary	I-P	ADJ	B
arterial	I-P	ADJ	I
hypertension	I-P	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	B-I	ADP	O
sitaxsentan	I-I	NOUN	B
50	O	NUM	O
and	O	CCONJ	O
100	O	NUM	O
mg	O	NOUN	O
in	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
pulmonary	I-P	ADJ	B
arterial	I-P	ADJ	I
hypertension	I-P	NOUN	I
(	I-P	PUNCT	O
PAH	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


BACKGROUND	B-I	NOUN	O
Sitaxsentan	I-I	NOUN	B
is	O	AUX	O
a	O	DET	O
highly	O	ADV	O
selective	O	ADJ	O
endothelin-A	O	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
recently	O	ADV	O
withdrawn	O	VERB	O
by	O	ADP	O
the	O	DET	O
manufacturer	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
a	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
idiosyncratic	O	ADJ	B
liver	O	NOUN	I
injury	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Before	B-I	ADP	O
sitaxsentan	I-I	NOUN	B
withdrawal	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
18-week	O	ADJ	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
study	O	NOUN	I
randomized	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
PAH	I-P	NOUN	B
to	I-P	PART	O
receive	I-I	VERB	O
placebo	I-I	NOUN	B
or	I-I	CCONJ	O
sitaxsentan	I-I	NOUN	B
50	I-P	NUM	O
or	I-P	CCONJ	O
100	I-P	NUM	O
mg	I-P	NOUN	O
once	I-P	ADV	B
daily	I-P	ADV	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
endpoint	O	NOUN	B
was	O	AUX	O
change	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
6-min	O	ADJ	B
walk	O	NOUN	I
distance	O	NOUN	I
(	O	PUNCT	O
6MWD	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
week	O	NOUN	B
18	O	NUM	O
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
(	O	PUNCT	O
WHO	O	PRON	B
)	O	PUNCT	O
functional	O	ADJ	B
class	O	NOUN	I
and	O	CCONJ	O
time	O	NOUN	O
to	O	PART	O
clinical	O	ADJ	B
worsening	O	NOUN	I
(	O	PUNCT	O
TTCW	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
secondary	O	ADJ	O
endpoints	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
analysis	O	NOUN	B
was	O	AUX	O
powered	O	VERB	O
for	B-I	ADP	O
sitaxsentan	I-I	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
versus	B-I	CCONJ	O
placebo	I-I	NOUN	B
.	O	PUNCT	O


RESULTS	B-P	NOUN	O
Of	I-P	ADP	O
98	I-P	NUM	O
randomized	I-P	ADJ	B
patients	I-P	NOUN	B
,	I-P	PUNCT	O
61	I-P	NUM	O
%	I-P	NOUN	O
were	I-P	AUX	O
WHO	I-P	ADP	B
functional	I-P	ADJ	O
class	I-P	NOUN	O
II	I-P	NUM	O
at	I-P	ADP	O
baseline	I-P	NOUN	B
.	O	PUNCT	O


Improvement	O	NOUN	B
from	B-OUT	ADP	O
baseline	I-OUT	NOUN	B
to	I-OUT	PART	O
week	I-OUT	NOUN	B
18	I-OUT	NUM	O
in	I-OUT	ADP	O
6MWD	I-OUT	NOUN	B
occurred	O	VERB	O
with	B-I	ADP	O
sitaxsentan	I-I	NOUN	B
100	O	NUM	O
but	O	CCONJ	O
not	O	PART	O
50	O	NUM	O
mg	O	NOUN	O
;	O	PUNCT	O
a	O	DET	O
strong	B-I	ADJ	O
placebo	I-I	NOUN	B
effect	O	NOUN	O
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


At	O	ADP	O
week	B-OUT	NOUN	B
18	I-OUT	NUM	O
,	I-OUT	PUNCT	O
WHO	I-OUT	PRON	B
functional	I-OUT	ADJ	B
class	I-OUT	NOUN	I
was	O	AUX	O
improved	O	VERB	B
or	O	CCONJ	O
maintained	O	VERB	B
in	O	ADP	O
more	O	ADJ	O
patients	O	NOUN	B
receiving	B-I	VERB	O
sitaxsentan	I-I	NOUN	B
100	I-I	NUM	O
mg	I-I	NOUN	O
than	I-I	ADP	O
placebo	I-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.038	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
12	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
deteriorated	O	VERB	B
,	O	PUNCT	O
respectively	B-OUT	ADV	O
.	O	PUNCT	O


TTCW	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
for	B-I	ADP	O
100-mg	I-I	ADJ	B
sitaxsentan	I-I	NOUN	B
patients	I-I	NOUN	B
than	I-I	ADP	O
placebo	O	NOUN	B
(	B-OUT	PUNCT	O
P	I-OUT	NOUN	O
=	I-OUT	ADJ	O
0.090	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
(	O	PUNCT	O
AEs	O	NOUN	B
)	O	PUNCT	O
occurring	O	VERB	O
more	O	ADV	O
frequently	B-I	ADV	O
with	I-I	ADP	O
sitaxsentan	I-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
or	O	CCONJ	O
100	B-OUT	NUM	O
mg	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
included	I-OUT	VERB	O
headache	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
peripheral	I-OUT	ADJ	B
edema	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
dizziness	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
extremity	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
fatigue	O	NOUN	B
;	O	PUNCT	O
most	O	ADJ	O
AEs	O	NOUN	B
were	O	AUX	O
of	O	ADP	O
mild	O	ADJ	B
or	O	CCONJ	O
moderate	O	ADJ	B
severity	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	B-I	NOUN	O
Sitaxsentan	I-I	NOUN	B
100	I-OUT	NUM	O
mg	I-OUT	NOUN	O
improved	I-OUT	VERB	B
functional	I-OUT	ADJ	B
class	I-OUT	NOUN	I
but	I-OUT	CCONJ	O
not	I-P	PART	O
6MWD	I-P	NOUN	B
in	I-P	ADP	O
PAH	I-P	NOUN	B
patients	I-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
mostly	I-P	ADV	O
WHO	I-P	PRON	B
functional	I-P	ADJ	B
class	I-P	NOUN	I
II	I-P	NUM	I
at	I-P	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
patient	B-I	NOUN	B
receiving	I-I	VERB	O
sitaxsentan	O	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
experienced	O	VERB	O
clinical	B-I	ADJ	B
worsening	I-I	NOUN	I
;	I-I	PUNCT	O
sitaxsentan	O	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


Dental	O	NOUN	B
bacteremia	O	NOUN	I
in	B-P	ADP	O
children	I-P	NOUN	B
.	I-P	PUNCT	O


Bacteremia	O	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
dental	B-I	NOUN	B
extraction	I-I	NOUN	I
is	I-I	AUX	O
regarded	O	VERB	O
as	O	ADP	O
an	O	DET	O
important	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
bacterial	O	ADJ	B
endocarditis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
therefore	O	ADV	O
recommended	O	VERB	O
that	O	SCONJ	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
tooth	I-P	NOUN	B
extraction	I-P	NOUN	I
be	O	AUX	O
given	O	VERB	O
prophylactic	B-I	ADJ	B
antibiotics	I-I	NOUN	I
.	I-I	PUNCT	O


As	O	ADP	O
dental	O	NOUN	B
procedures	O	NOUN	I
other	O	ADJ	O
than	O	ADP	O
extractions	O	NOUN	B
may	O	AUX	O
also	O	ADV	O
cause	O	VERB	O
bacteremias	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
dental	O	NOUN	B
procedures	O	NOUN	I
routinely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
pediatric	O	ADJ	B
dentistry	O	NOUN	I
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
samples	I-OUT	NOUN	I
for	O	ADP	O
cultures	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
30	O	NUM	O
s	O	NOUN	O
after	O	ADP	O
each	O	DET	O
of	O	ADP	O
13	O	NUM	O
dental	O	NOUN	B
operative	O	ADJ	I
procedures	O	NOUN	I
in	O	ADP	O
735	B-P	NUM	O
anesthetized	I-P	VERB	B
children	I-P	NOUN	B
aged	I-P	ADJ	O
2-16	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


Four	O	NUM	O
procedures	O	NOUN	B
used	O	VERB	O
for	O	ADP	O
conservative	O	ADJ	B
dentistry	O	NOUN	I
caused	O	VERB	O
bacteremias	B-OUT	NOUN	B
significantly	O	ADV	O
more	O	ADV	O
often	O	ADV	O
than	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
value	O	NOUN	O
of	O	ADP	O
9.4	O	NUM	O
%	O	NOUN	O
:	O	PUNCT	O
polishing	B-I	NOUN	B
teeth	I-I	NOUN	I
24.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
intraligamental	B-I	ADJ	B
injection	I-I	NOUN	I
96.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
rubber	B-I	NOUN	B
dam	I-I	NOUN	I
placement	I-I	NOUN	B
29.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
matrix	B-I	NOUN	B
band	I-I	NOUN	I
with	I-I	ADP	O
wedge	I-I	ADJ	B
placement	I-I	NOUN	I
32.1	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
comparison	O	NOUN	B
,	O	PUNCT	O
toothbrushing	O	NOUN	B
alone	O	ADV	O
caused	O	VERB	O
a	O	DET	O
bacteremia	B-OUT	NOUN	B
on	O	ADP	O
38.5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
occasions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
organisms	O	NOUN	B
isolated	O	VERB	B
were	O	AUX	O
typical	O	ADJ	O
of	O	ADP	O
odontogenic	B-OUT	ADJ	B
bacteremias	I-OUT	NOUN	I
in	O	ADP	O
that	O	DET	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
isolates	O	NOUN	B
were	O	AUX	O
identified	O	VERB	O
as	O	ADP	O
varieties	O	NOUN	B
of	O	ADP	O
viridans	O	X	B
streptococci	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
wider	O	ADJ	O
variety	O	NOUN	O
of	O	ADP	O
dental	O	NOUN	B
procedures	O	NOUN	I
than	O	ADP	O
was	O	AUX	O
previously	O	ADV	O
documented	O	VERB	B
cause	O	NOUN	O
bacteremia	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
I	O	NUM	I
study	O	NOUN	I
of	O	ADP	O
MEDI-545	B-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
anti-interferon-alfa	O	ADJ	O
monoclonal	O	ADJ	B
antibody	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
subjects	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
psoriasis	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
Interferon-alfa	O	NOUN	B
(	O	PUNCT	O
IFN-alpha	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
psoriasis	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
profile	O	NOUN	I
of	O	ADP	O
MEDI-545	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
fully	O	ADV	O
human	O	ADJ	B
anti-IFN-alpha	O	NOUN	B
monoclonal	O	ADJ	B
antibody	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
explore	O	VERB	O
its	O	PRON	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
type	O	NOUN	B
I	O	NUM	I
IFN-alpha	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
established	O	ADJ	O
plaque	O	NOUN	B
psoriasis	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
conducted	O	VERB	O
an	O	DET	O
18-week	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
dose-escalating	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
36	B-P	NUM	O
subjects	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
plaque	I-P	NOUN	I
psoriasis	I-P	NOUN	B
.	I-P	PUNCT	O


Subjects	O	NOUN	B
received	O	VERB	O
one	O	NUM	O
intravenous	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
MEDI-545	B-I	NOUN	B
(	I-I	PUNCT	O
0.3-30.0	I-I	NUM	O
mg/kg	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Study	O	NOUN	B
outcomes	O	NOUN	B
were	O	AUX	O
safety	B-OUT	NOUN	B
profile	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pharmacokinetics	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
immunogenicity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
clinical	I-OUT	ADJ	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
between	O	ADP	O
MEDI-545	B-I	NOUN	B
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Two	O	NUM	O
serious	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
reported	O	VERB	O
;	O	PUNCT	O
one	O	NUM	O
drug-related	B-OUT	ADJ	B
hypotensive	I-OUT	ADJ	I
infusion	I-OUT	NOUN	B
reaction	I-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
one	O	NUM	O
subject	O	NOUN	B
in	O	ADP	O
the	O	DET	O
30.0	O	NUM	O
mg/kg	O	NOUN	O
MEDI-545	B-I	NOUN	B
dose	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
causing	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
drug	O	NOUN	B
in	O	ADP	O
that	O	DET	O
subject	O	NOUN	B
and	O	CCONJ	O
study	O	NOUN	B
dismissal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
subjects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
cohort	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
myocardial	B-OUT	ADJ	B
infarction	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
one	O	NUM	O
subject	O	NOUN	B
in	O	ADP	O
the	O	DET	O
10	O	NUM	O
mg/kg	O	NOUN	O
MEDI-545	B-I	NOUN	B
dose	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
considered	O	VERB	O
to	O	PART	O
be	O	AUX	O
unrelated	O	ADJ	O
to	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


MEDI-545	B-I	NOUN	B
was	O	AUX	O
nonimmunogenic	O	ADJ	B
,	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
half-life	B-OUT	NOUN	B
of	O	ADP	O
21	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
inhibition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
type	O	NOUN	B
I	O	NUM	I
IFN	O	NOUN	I
gene	O	NOUN	I
signature	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
no	O	DET	O
clinical	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


LIMITATIONS	O	VERB	B
The	O	DET	O
study	O	NOUN	B
addressed	O	VERB	O
only	O	ADV	O
IFN-alpha	O	NOUN	B
and	O	CCONJ	O
chronic	O	ADJ	B
psoriatic	O	ADJ	I
lesions	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
safety	O	NOUN	B
profile	O	NOUN	I
of	O	ADP	O
MEDI-545	B-I	NOUN	B
supports	O	VERB	O
further	O	ADJ	O
clinical	O	ADJ	B
development	O	NOUN	I
.	O	PUNCT	O


IFN-alpha	O	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
significantly	O	ADV	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
established	O	ADJ	O
plaque	O	NOUN	B
psoriasis	O	NOUN	B
.	O	PUNCT	O


Endurance	B-I	NOUN	B
physical	I-I	ADJ	B
activity	I-I	NOUN	I
,	I-I	PUNCT	O
diet	I-I	NOUN	B
and	O	CCONJ	O
fibrinolysis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
long-term	B-I	ADJ	B
,	I-I	PUNCT	O
heavy	I-I	ADJ	B
exercise	I-I	NOUN	I
on	O	ADP	O
recently	O	ADV	O
established	O	VERB	O
cardiovascular/thromboembolic	O	ADJ	B
risk	O	NOUN	I
factors	O	NOUN	I
of	O	ADP	O
the	O	DET	O
fibrinolytic	O	ADJ	B
system	O	NOUN	I
,	O	PUNCT	O
tissue	O	NOUN	B
plasminogen	O	NOUN	I
activator	O	NOUN	I
(	O	PUNCT	O
tPA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
plasminogen	O	NOUN	B
activator	O	NOUN	I
inhibitor	O	NOUN	I
(	O	PUNCT	O
PAI-1	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
food	O	NOUN	B
composition	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


Twenty	B-P	NUM	O
healthy	I-P	ADJ	B
men	I-P	NOUN	B
,	I-P	PUNCT	O
aged	I-P	ADJ	O
18-55	I-P	NUM	O
years	I-P	NOUN	B
participated	O	VERB	O
in	O	ADP	O
a	O	DET	O
14-day	B-I	ADJ	O
skiing	I-I	NOUN	B
tour	I-I	NOUN	O
through	I-I	ADP	O
the	I-I	DET	O
Swedish	I-I	ADJ	B
mountains	I-I	NOUN	B
,	I-I	PUNCT	O
carrying	I-I	VERB	O
a	I-I	DET	O
pack	I-I	NOUN	O
load	I-I	NOUN	B
of	I-I	ADP	O
30	I-I	NUM	O
kg	I-I	NOUN	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
spending	I-I	VERB	B
each	I-I	DET	O
night	I-I	NOUN	B
in	I-I	ADP	O
self-dug	I-I	ADJ	B
igloos	I-I	NOUN	I
(	I-I	PUNCT	O
ambient	I-I	ADJ	B
temp	I-I	NOUN	I
-10	I-I	NUM	O
degrees	I-I	NOUN	O
to	I-I	ADP	O
-25	I-I	NUM	O
degrees	I-I	NOUN	O
C	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
were	I-I	AUX	O
randomized	I-I	VERB	B
to	I-I	PART	O
2	I-I	NUM	O
food	I-I	NOUN	B
regimens	I-I	NOUN	I
having	I-I	VERB	O
30	I-I	NUM	O
or	I-I	CCONJ	O
40	I-I	NUM	O
energy	I-I	NOUN	B
percent	I-I	NOUN	O
of	I-I	ADP	O
fat	I-I	NOUN	B
.	I-I	PUNCT	O


Individual	B-I	ADJ	B
records	I-I	NOUN	I
were	I-I	AUX	O
kept	I-I	VERB	O
of	I-I	ADP	O
all	I-I	DET	O
consumed	I-I	VERB	O
food	I-I	NOUN	B
.	I-I	PUNCT	O


Citrated	B-OUT	ADJ	B
plasma	I-OUT	NOUN	B
was	I-I	AUX	O
obtained	I-I	VERB	O
before	I-I	ADP	O
and	I-I	CCONJ	O
after	I-I	ADP	O
1	I-I	NUM	O
and	I-I	CCONJ	O
2	I-I	NUM	O
weeks	I-I	NOUN	B
of	I-I	ADP	O
exercise	I-I	NOUN	B
:	I-I	PUNCT	O
tPA	I-OUT	NOUN	B
release	I-OUT	NOUN	B
was	I-I	AUX	O
assessed	I-I	VERB	B
by	I-I	ADP	O
a	I-I	DET	O
10	I-I	NUM	O
min	I-I	NOUN	O
venous	I-I	ADJ	B
occlusion	I-I	NOUN	I
(	I-I	PUNCT	O
VO	I-I	NOUN	B
)	I-I	PUNCT	O
test	I-I	NOUN	O
.	I-I	PUNCT	O


At	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
daily	B-OUT	ADJ	B
dietary	I-OUT	ADJ	B
fiber	I-OUT	NOUN	I
intake	I-OUT	NOUN	B
correlated	O	VERB	B
negatively	O	ADV	O
with	O	ADP	O
PAI-1	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


Already	O	ADV	O
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
the	O	DET	O
skiing	O	NOUN	B
tour	O	NOUN	O
there	O	PRON	O
were	O	AUX	O
significant	O	ADJ	O
drops	O	NOUN	B
in	O	ADP	O
PAI-1	B-OUT	NOUN	B
activities	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
cholesterol	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
triglycerides	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
tPA	B-OUT	NOUN	B
mass	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	I
also	O	ADV	O
dropped	O	VERB	O
,	O	PUNCT	O
both	O	CCONJ	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
VO	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
tPA	B-OUT	NOUN	B
activities	I-OUT	NOUN	B
were	O	AUX	O
unchanged	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
were	O	AUX	O
von	B-OUT	NOUN	B
Willebrand	I-OUT	NOUN	I
factor	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
vWF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
were	O	AUX	O
related	O	VERB	O
mainly	O	ADV	O
to	O	ADP	O
the	O	DET	O
expenditure	O	NOUN	B
of	O	ADP	O
energy	O	NOUN	B
,	O	PUNCT	O
calculated	O	VERB	B
from	O	ADP	O
the	O	DET	O
food	O	NOUN	B
consumption	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
mediated	O	VERB	O
through	O	ADP	O
changed	O	VERB	O
insulin	O	NOUN	B
sensitivity	O	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
body	O	NOUN	B
fat	O	NOUN	I
mass	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
energy	O	NOUN	B
percent	O	NOUN	O
of	O	ADP	O
fat	O	NOUN	B
in	O	ADP	O
the	O	DET	O
food	O	NOUN	B
had	O	AUX	O
no	O	DET	O
differential	O	ADJ	O
impact	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
receded	O	VERB	O
a	O	DET	O
few	O	ADJ	O
weeks	O	NOUN	B
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
endurance	O	NOUN	B
exercise	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
endurance	B-I	NOUN	B
physical	I-I	ADJ	B
activity	I-I	NOUN	I
improves	O	VERB	B
the	O	DET	O
fibrinolytic	O	ADJ	B
risk	O	NOUN	I
factor	O	NOUN	I
profile	O	NOUN	I
by	O	ADP	O
reducing	O	VERB	B
PAI-1	O	NOUN	B
while	O	SCONJ	O
leaving	O	VERB	B
tPA	B-OUT	NOUN	B
activity	O	NOUN	B
unaffected	O	ADJ	O
,	O	PUNCT	O
independently	O	ADV	O
of	O	ADP	O
food	O	NOUN	B
composition	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
low	O	ADJ	B
dietary	O	ADJ	B
fiber	O	NOUN	I
intake	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
higher	O	ADJ	O
PAI-1	B-OUT	NOUN	B
activities	I-OUT	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Tofacitinib	B-I	NOUN	B
with	I-I	ADP	O
methotrexate	I-I	NOUN	B
in	O	ADP	O
third-line	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
active	I-P	ADJ	B
rheumatoid	I-P	ADJ	I
arthritis	I-P	NOUN	I
:	I-P	PUNCT	O
patient-reported	O	ADJ	B
outcomes	O	NOUN	I
from	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
patient-reported	O	ADJ	B
outcomes	O	NOUN	I
(	O	PUNCT	O
PROs	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
tofacitinib	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
oral	O	ADJ	B
JAK	O	NOUN	B
inhibitor	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
rheumatoid	O	ADJ	B
arthritis	O	NOUN	I
(	O	PUNCT	O
RA	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
6-month	O	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
III	O	NUM	I
,	O	PUNCT	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
ages	I-P	VERB	B
≥18	I-P	NUM	O
years	I-P	NOUN	B
with	I-P	ADP	O
active	I-P	ADJ	O
RA	I-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
inadequate	I-P	ADJ	B
response	I-P	NOUN	I
to	I-P	PART	O
≥1	I-P	ADJ	O
tumor	I-P	NOUN	B
necrosis	I-P	NOUN	I
factor	I-P	NOUN	I
inhibitor	I-P	NOUN	I
(	I-P	PUNCT	O
TNFi	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
receiving	I-P	VERB	O
stable	I-P	ADJ	B
background	I-P	NOUN	O
methotrexate	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
2:2:1:1	I-I	NOUN	O
to	I-I	PART	O
tofacitinib	I-I	NOUN	B
5	I-I	NUM	O
mg	I-I	NOUN	O
or	I-I	CCONJ	O
10	I-I	NUM	O
mg	I-I	NOUN	O
twice	I-I	ADV	O
daily	I-I	ADV	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
advanced	I-I	ADJ	O
to	I-I	PART	O
tofacitinib	I-I	NOUN	B
5	I-I	NUM	O
mg	I-I	NOUN	O
or	I-I	CCONJ	O
10	I-I	NUM	O
mg	I-I	NOUN	O
twice	I-I	ADV	O
daily	I-I	ADV	B
at	I-I	ADP	O
month	I-I	NOUN	B
3	O	NUM	O
.	O	PUNCT	O


PROs	O	NOUN	B
measured	O	VERB	B
at	O	ADP	O
month	O	NOUN	B
3	O	NUM	O
included	B-OUT	VERB	O
patient	I-OUT	NOUN	B
global	I-OUT	ADJ	O
assessment	I-OUT	NOUN	O
of	I-OUT	ADP	O
disease	I-OUT	NOUN	B
activity	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PtGA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
Health	I-OUT	PROPN	B
Assessment	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
HAQ	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
disability	I-OUT	NOUN	O
index	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
DI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Medical	I-OUT	PROPN	B
Outcomes	I-OUT	PROPN	I
Study	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
MOS	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
Short	I-OUT	PROPN	B
Form	I-OUT	NOUN	I
36	I-OUT	NUM	I
Health	I-OUT	PROPN	I
Survey	I-OUT	PROPN	I
version	I-OUT	NOUN	I
2	I-OUT	NUM	I
(	I-OUT	PUNCT	O
SF-36v2	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
acute	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Functional	I-OUT	ADJ	B
Assessment	I-OUT	NOUN	I
of	I-OUT	ADP	I
Chronic	I-OUT	PROPN	B
Illness	I-OUT	PROPN	I
Therapy-Fatigue	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
FACIT-F	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
MOS	I-OUT	PROPN	B
Sleep	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
Patients	O	NOUN	B
received	O	VERB	O
tofacitinib	O	NOUN	B
5	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
133	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
134	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
advanced	O	ADJ	O
to	O	PART	O
tofacitinib	O	NOUN	B
5	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
66	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
66	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


HAQ	B-OUT	NOUN	B
DI	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
reported	I-OUT	VERB	O
previously	I-OUT	ADV	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
PtGA	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
0.0001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
SF-36v2	I-OUT	NOUN	B
physical	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
mental	I-OUT	ADJ	B
component	I-OUT	NOUN	I
summary	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	X	O
0.05	I-OUT	NUM	O
)	I-OUT	PUNCT	O
scores	I-OUT	NOUN	B
were	I-OUT	AUX	O
improved	I-OUT	VERB	B
for	O	ADP	O
both	O	CCONJ	O
tofacitinib	O	NOUN	B
doses	O	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
improvements	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	ADP	O
the	O	DET	O
minimum	O	ADJ	B
clinically	O	ADV	I
important	O	ADJ	O
difference	O	NOUN	O
were	O	AUX	O
more	O	ADV	O
frequently	O	ADV	O
reported	O	VERB	O
by	O	ADP	O
tofacitinib-treated	O	ADJ	B
patients	O	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
for	B-OUT	ADP	O
PtGA	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
HAQ	I-OUT	NOUN	B
DI	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
SF-36v2	I-OUT	NOUN	B
physical	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
mental	I-OUT	ADJ	B
component	I-OUT	NOUN	I
summary	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-OUT	CCONJ	O
FACIT-F	I-OUT	PROPN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
for	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	B-OUT	ADV	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


No	B-OUT	DET	O
statistical	I-OUT	ADJ	O
differences	I-OUT	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	B-OUT	DET	O
MOS	I-OUT	PROPN	B
Sleep	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Tofacitinib	O	NOUN	B
treatment	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
significant	O	ADJ	B
,	O	PUNCT	O
clinically	O	ADV	B
meaningful	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
multiple	O	ADJ	B
PROs	O	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
over	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	B-P	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
active	I-P	ADJ	O
RA	I-P	NOUN	B
and	I-P	CCONJ	O
a	I-P	DET	O
previous	I-P	ADJ	O
inadequate	I-P	ADJ	O
response	I-P	NOUN	O
to	I-P	PART	O
TNFi	I-P	NOUN	B
.	O	PUNCT	O


Pregabalin	B-I	NOUN	B
versus	O	CCONJ	O
naltrexone	B-I	NOUN	B
in	I-P	ADP	O
alcohol	I-P	NOUN	B
dependence	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
comparison	O	NOUN	B
trial	O	NOUN	B
.	O	PUNCT	O


Pregabalin	B-I	NOUN	B
(	I-I	PUNCT	O
PRE	I-I	NOUN	B
)	I-I	PUNCT	O
acts	O	VERB	O
as	O	ADP	O
a	O	DET	O
presynaptic	O	ADJ	B
inhibitor	O	NOUN	B
of	O	ADP	O
the	O	DET	O
release	O	NOUN	B
of	O	ADP	O
excessive	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
excitatory	O	ADJ	B
neurotransmitters	O	NOUN	B
by	O	ADP	O
selectively	O	ADV	O
binding	O	VERB	B
to	O	PART	O
the	O	DET	O
alpha	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
-delta	O	NOUN	O
subunit	O	NOUN	B
of	O	ADP	O
voltage-gated	O	ADJ	B
calcium	O	NOUN	I
channels	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
comparison	O	NOUN	O
trial	O	NOUN	O
with	O	ADP	O
naltrexone	B-I	NOUN	B
(	I-I	PUNCT	O
NAL	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
we	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
PRE	O	NOUN	B
on	B-P	ADP	O
alcohol	I-OUT	NOUN	B
drinking	I-OUT	NOUN	I
indices	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Craving	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
and	O	CCONJ	O
improvement	B-OUT	NOUN	B
of	I-OUT	ADP	O
psychiatric	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
were	O	AUX	O
the	O	DET	O
secondary	O	ADJ	B
endpoints	O	NOUN	B
.	O	PUNCT	O


Seventy-one	B-P	NUM	B
alcohol-dependent	I-P	ADJ	B
subjects	I-P	NOUN	I
were	O	AUX	O
detoxified	O	VERB	B
and	O	CCONJ	O
subsequently	O	ADV	O
randomised	O	VERB	B
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
receiving	B-I	VERB	O
50	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
NAL	I-I	NOUN	B
or	I-I	CCONJ	O
150-450	I-I	NUM	O
mg	I-I	NOUN	O
of	I-I	ADP	O
PRE	I-I	NOUN	B
.	I-I	PUNCT	O


Craving	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
OCDS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
withdrawal	I-OUT	NOUN	B
(	I-OUT	PUNCT	I
CIWA-Ar	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
psychiatric	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SCL-90-R	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
rating	I-OUT	NOUN	O
scales	I-OUT	NOUN	O
were	O	AUX	O
applied	O	VERB	O
.	O	PUNCT	O


Alcohol	B-OUT	NOUN	B
drinking	I-OUT	NOUN	I
indices	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
craving	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
NAL	B-I	NOUN	B
,	I-I	PUNCT	O
PRE	I-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
greater	O	ADJ	O
improvement	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
symptoms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
areas	O	NOUN	B
of	O	ADP	O
anxiety	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
hostility	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
psychoticism	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
function	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
abstinence	I-OUT	NOUN	B
from	I-OUT	ADP	O
alcohol	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


PRE	O	NOUN	B
also	O	ADV	O
resulted	O	VERB	O
in	O	ADP	O
better	O	ADJ	O
outcome	O	NOUN	B
in	B-P	ADP	O
patients	I-P	NOUN	B
reporting	I-P	VERB	O
a	I-P	DET	O
comorbid	I-P	ADJ	B
psychiatric	I-P	ADJ	B
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Results	O	NOUN	B
from	O	ADP	O
this	O	DET	O
study	O	NOUN	B
globally	O	ADV	O
place	O	VERB	O
PRE	B-I	NOUN	B
within	O	ADP	O
the	O	DET	O
same	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
efficacy	O	NOUN	B
as	O	ADP	O
that	O	DET	O
of	O	ADP	O
NAL	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
PRE	B-I	NOUN	B
in	O	ADP	O
relapse	O	NOUN	B
prevention	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
less	O	ADV	O
related	O	ADJ	O
to	O	PART	O
alcohol	B-OUT	NOUN	B
craving	I-OUT	NOUN	I
and	O	CCONJ	O
more	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
comorbid	O	ADJ	B
psychiatric	O	ADJ	B
symptomatology	O	NOUN	I
.	O	PUNCT	O


Including	O	VERB	O
a	O	DET	O
'no	O	NOUN	B
active	O	ADJ	O
intervention	O	NOUN	B
'	O	PART	O
arm	O	NOUN	B
in	O	ADP	O
surgical	O	ADJ	B
trials	O	NOUN	I
is	O	AUX	O
possible	O	ADJ	O
:	O	PUNCT	O
evidence	O	NOUN	B
from	O	ADP	O
the	O	DET	O
CLasP	O	ADJ	B
randomised	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
examine	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
including	O	VERB	O
a	B-I	DET	O
'no	I-I	NOUN	B
active	I-I	ADJ	O
intervention	I-I	NOUN	B
'	I-I	PART	O
arm	I-I	NOUN	B
(	I-I	PUNCT	O
called	I-I	VERB	O
'conservative	I-I	ADJ	B
management	I-I	NOUN	B
'	I-I	PUNCT	O
)	I-I	PUNCT	O
in	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
comparing	O	NOUN	O
treatments	O	NOUN	B
(	O	PUNCT	O
including	O	VERB	O
surgery	B-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
men	B-P	NOUN	B
with	I-P	ADP	O
lower	I-P	ADJ	O
urinary	I-P	ADJ	B
tract	I-P	NOUN	I
symptoms	I-P	NOUN	B
related	I-P	VERB	O
to	I-P	PART	O
benign	I-P	ADJ	B
prostatic	I-P	ADJ	B
enlargement	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Outcomes	O	NOUN	B
7.5	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
randomisation	O	NOUN	B
were	O	AUX	O
acceptability	B-OUT	NOUN	B
of	I-OUT	ADP	O
randomisation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
overall	I-OUT	ADJ	O
acceptability	I-OUT	NOUN	B
of	I-OUT	ADP	O
and	I-OUT	CCONJ	O
satisfaction	I-OUT	NOUN	B
with	I-OUT	ADP	O
conservative	I-OUT	ADJ	B
management	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
impact	I-OUT	NOUN	B
on	I-OUT	ADP	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
perceived	I-OUT	VERB	B
need	I-OUT	NOUN	O
for	I-OUT	ADP	O
further	I-OUT	ADJ	O
treatment	I-OUT	NOUN	B
and	O	CCONJ	O
treatment	B-OUT	NOUN	B
failure	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
defined	I-OUT	VERB	O
a	I-OUT	DET	O
priori	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
total	O	NOUN	O
,	O	PUNCT	O
177	B-P	NUM	O
(	I-P	PUNCT	O
out	I-P	ADP	O
of	I-P	ADP	O
755	I-P	NUM	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
refused	I-P	VERB	O
randomisation	I-P	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
31	O	NUM	O
%	O	NOUN	O
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
want	O	VERB	O
surgery	O	NOUN	B
and	O	CCONJ	O
22	O	NUM	O
%	O	NOUN	O
who	O	PRON	O
wanted	O	VERB	O
surgery	O	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
men	O	NOUN	B
randomised	O	VERB	B
to	O	ADP	O
conservative	O	ADJ	B
management	O	NOUN	I
were	O	AUX	O
willing	O	ADJ	O
to	O	PART	O
undertake	O	VERB	O
it	O	PRON	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
trial	O	NOUN	B
but	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
they	O	PRON	O
were	O	AUX	O
divided	O	VERB	O
between	O	ADP	O
those	O	DET	O
who	O	PRON	O
wanted	O	VERB	O
to	O	PART	O
continue	O	VERB	O
with	O	ADP	O
it	O	PRON	O
and	O	CCONJ	O
those	O	DET	O
who	O	PRON	O
expected	O	VERB	O
surgery	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
follow-up	O	NOUN	B
,	O	PUNCT	O
39	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
conservative	O	ADJ	O
management	O	NOUN	O
patients	O	NOUN	B
requested	O	VERB	O
surgery	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
interference	B-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
with	I-OUT	ADP	I
life	I-OUT	NOUN	B
and	O	CCONJ	O
an	O	DET	O
unsuccessful	B-OUT	ADJ	O
outcome	I-OUT	NOUN	B
were	O	AUX	O
more	O	ADV	O
commonly	O	ADV	O
reported	O	VERB	O
in	O	ADP	O
this	O	DET	O
arm	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
appreciable	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
treatment	B-OUT	NOUN	B
failures	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Including	O	VERB	O
a	O	DET	O
'no	B-I	NOUN	B
active	I-I	ADJ	O
intervention	I-I	NOUN	B
'	I-I	PART	O
arm	I-I	NOUN	B
did	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
detrimental	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
patient	B-OUT	NOUN	B
recruitment	I-OUT	NOUN	B
or	O	CCONJ	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
in	O	ADP	O
the	O	DET	O
short-term	O	ADJ	B
;	O	PUNCT	O
overall	O	ADV	B
,	O	PUNCT	O
conservative	O	ADJ	B
management	O	NOUN	I
was	O	AUX	O
successfully	O	ADV	O
completed	O	VERB	O
by	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
during	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
researchers	O	NOUN	B
need	O	VERB	O
not	O	PART	O
avoid	O	VERB	O
including	O	VERB	O
a	O	DET	O
no-intervention	O	ADJ	B
arm	O	NOUN	I
in	O	ADP	O
surgical	O	ADJ	B
trials	O	NOUN	I
as	O	ADV	O
long	O	ADV	O
as	O	ADP	O
they	O	PRON	O
take	O	VERB	O
care	O	NOUN	B
with	O	ADP	O
its	O	PRON	O
presentation	O	NOUN	B
.	O	PUNCT	O


Does	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
completion	B-I	NOUN	B
axillary	I-I	ADJ	B
lymph	I-I	NOUN	I
node	I-I	NOUN	I
dissection	I-I	NOUN	I
influence	O	VERB	B
the	O	DET	O
recommendation	O	NOUN	B
for	O	ADP	O
adjuvant	B-I	ADJ	B
treatment	I-I	NOUN	B
in	O	ADP	O
sentinel	B-P	NOUN	B
lymph	I-P	NOUN	I
node-positive	I-P	ADJ	I
patients	I-P	NOUN	B
?	O	PUNCT	O
OBJECTIVE	O	NOUN	O
The	O	DET	O
Hungarian	O	PROPN	B
National	O	PROPN	I
Institute	O	PROPN	I
of	O	ADP	I
Oncology	O	PROPN	I
has	O	AUX	O
just	O	ADV	O
closed	O	VERB	B
a	O	DET	O
single-center	O	ADJ	B
randomized	O	ADJ	B
clinical	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Optimal	O	ADJ	B
Treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Axilla-Surgery	O	PROPN	B
or	O	CCONJ	O
Radiotherapy	O	NOUN	B
(	O	PUNCT	O
OTOASOR	O	PROPN	B
)	O	PUNCT	O
trial	O	NOUN	B
compares	O	VERB	O
completion	B-I	NOUN	B
axillary	I-I	ADJ	B
lymph	I-I	NOUN	I
node	I-I	NOUN	I
dissection	I-I	NOUN	I
(	I-I	PUNCT	O
cALND	I-I	NOUN	B
)	I-I	PUNCT	O
with	O	ADP	O
regional	B-I	ADJ	B
nodal	I-I	ADJ	I
irradiation	I-I	NOUN	I
(	I-I	PUNCT	O
RNI	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
sentinel	I-P	NOUN	B
lymph	I-P	NOUN	I
node-positive	I-P	ADJ	I
(	I-P	PUNCT	O
SLN+	I-P	ADJ	B
)	I-P	PUNCT	O
primary	I-P	ADJ	B
invasive	I-P	ADJ	I
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
the	O	DET	O
investigational	O	ADJ	B
treatment	O	NOUN	I
arm	O	NOUN	I
,	O	PUNCT	O
patients	O	NOUN	B
received	O	VERB	O
50	O	NUM	O
Gy	O	NOUN	O
RNI	B-I	NOUN	B
instead	O	ADV	O
of	O	ADP	O
cALND	B-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
we	O	PRON	O
had	O	AUX	O
information	O	NOUN	B
only	O	ADV	O
about	O	ADP	O
the	O	DET	O
sentinel	O	NOUN	B
lymph	O	NOUN	I
node	O	NOUN	I
(	O	PUNCT	O
SLN	O	PROPN	B
)	O	PUNCT	O
status	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
further	O	ADJ	O
axillary	O	ADJ	B
nodal	O	ADJ	I
involvement	O	NOUN	B
remained	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
cALND	B-I	NOUN	B
influenced	O	VERB	O
the	O	DET	O
recommendation	O	NOUN	B
for	O	ADP	O
adjuvant	O	ADJ	B
treatment	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
SLN+	I-P	ADJ	B
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
SLN+	I-P	ADJ	B
primary	I-P	ADJ	B
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
for	O	ADP	O
cALND	B-I	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
standard	O	ADJ	B
treatment	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
RNI	O	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
investigational	O	ADJ	B
treatment	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Adjuvant	O	ADJ	B
systemic	O	ADJ	B
treatments	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
standard	O	ADJ	B
institutional	O	ADJ	B
protocol	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
patients	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
actual	O	ADJ	B
institutional	O	ADJ	B
guidelines	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
Between	O	ADP	O
August	O	PROPN	O
2002	O	NUM	O
and	O	CCONJ	O
June	O	PROPN	O
2009	O	NUM	O
,	O	PUNCT	O
474	B-P	NUM	O
SLN+	I-P	ADJ	B
patients	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
cALND	B-I	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
standard	O	ADJ	B
treatment	O	NOUN	I
=	O	ADJ	O
244	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
RNI	B-I	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
investigational	O	ADJ	B
treatment	O	NOUN	I
=	O	ADJ	O
230	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
2	O	NUM	O
arms	O	NOUN	O
were	O	AUX	O
well	O	ADV	O
balanced	O	ADJ	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
main	O	ADJ	O
prognostic	O	ADJ	B
factors	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
more	O	ADJ	O
patients	B-P	NOUN	B
were	I-P	AUX	O
premenopausal	I-P	ADJ	B
(	I-P	PUNCT	O
34	I-P	NUM	O
%	I-P	NOUN	O
vs.	I-P	CCONJ	O
27	I-P	NUM	O
%	I-P	NOUN	O
;	I-P	PUNCT	O
P	I-P	NOUN	O
=	I-P	ADJ	O
.095	I-P	NUM	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
had	I-P	AUX	O
pT2-3	I-P	NOUN	B
tumors	I-P	NOUN	I
(	O	PUNCT	O
57	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
40	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.003	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
axillary	O	ADJ	B
lymph	O	NOUN	I
node	O	NOUN	I
dissection	O	NOUN	I
(	O	PUNCT	O
ALND	O	NOUN	B
)	O	PUNCT	O
arm	O	NOUN	O
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
more	O	ADJ	O
patients	B-P	NOUN	B
with	I-P	ADP	O
known	I-P	VERB	O
human	I-P	ADJ	B
epidermal	I-P	ADJ	O
growth	I-P	NOUN	O
factor	I-P	NOUN	O
receptor	I-P	NOUN	O
type	I-P	NOUN	O
2	I-P	NUM	O
positive	I-P	ADJ	O
tumor	I-P	NOUN	O
(	I-P	PUNCT	O
12	I-P	NUM	O
%	I-P	NOUN	O
vs.	I-P	CCONJ	O
17	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
P	I-P	NOUN	O
=	I-P	ADJ	O
.066	I-P	NUM	O
)	I-P	PUNCT	O
in	O	ADP	O
the	O	DET	O
RNI	O	NOUN	B
arm	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
ALND	B-I	NOUN	B
and	O	CCONJ	O
RNI	B-I	NOUN	B
arms	O	NOUN	O
,	O	PUNCT	O
78	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
190/244	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
69	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
159/230	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
received	O	VERB	O
chemotherapy	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.020	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Endocrine	B-I	NOUN	B
therapy	I-I	NOUN	I
was	O	AUX	O
administered	O	VERB	B
in	O	ADP	O
87	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
213/244	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ALND	O	NOUN	B
arm	O	NOUN	B
and	O	CCONJ	O
89	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
204/230	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
RNI	O	NOUN	B
arm	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.372	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Six	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
2.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
arm	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
13	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
5.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
arm	O	NOUN	B
B	O	NOUN	I
received	O	VERB	O
adjuvant	O	ADJ	B
trastuzumab	O	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Subgroup	O	NOUN	B
analyses	O	NOUN	B
explored	O	VERB	O
that	O	SCONJ	O
more	O	ADV	O
frequent	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
adjuvant	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
in	O	ADP	O
arm	O	NOUN	B
A	O	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
higher	O	ADJ	B
percentage	O	NOUN	B
of	O	ADP	O
premenopausal	B-P	ADJ	B
patients	I-P	NOUN	B
and	I-P	CCONJ	O
patients	I-P	NOUN	B
with	I-P	ADP	O
larger	I-P	ADJ	O
(	I-P	PUNCT	O
pT2-3	I-P	NOUN	B
)	I-P	PUNCT	O
tumors	I-P	NOUN	B
.	I-P	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
result	O	NOUN	O
of	O	ADP	O
cALND	B-I	NOUN	B
after	O	ADP	O
positive	O	ADJ	B
SLN	O	PROPN	B
biopsy	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
have	O	AUX	O
no	O	DET	O
major	O	ADJ	O
impact	O	NOUN	B
on	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
adjuvant	B-I	ADJ	B
systemic	I-I	ADJ	I
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


p16	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
INK4a	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
Expression	I-OUT	NOUN	B
does	O	AUX	O
not	O	PART	O
predict	O	VERB	O
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
cervical	O	ADJ	B
intraepithelial	O	ADJ	I
neoplasia	O	NOUN	I
grade	O	NOUN	I
2	O	NUM	I
.	O	PUNCT	O


Spontaneous	O	ADJ	B
regression	O	NOUN	I
of	O	ADP	O
cervical	O	ADJ	B
intraepithelial	O	ADJ	I
neoplasia	O	NOUN	I
grade	O	NOUN	I
2	O	NUM	I
(	O	PUNCT	O
CIN2	O	NOUN	B
)	O	PUNCT	O
lesions	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
recognized	O	VERB	O
since	O	SCONJ	O
1955	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
predictors	O	NOUN	B
of	O	ADP	O
this	O	DET	O
are	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
predictive	O	ADJ	B
markers	O	NOUN	B
studied	O	VERB	O
,	O	PUNCT	O
p16	B-I	NOUN	B
(	I-I	PUNCT	O
INK4a	I-I	NOUN	B
)	I-I	PUNCT	O
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
some	O	DET	O
value	O	NOUN	O
in	O	ADP	O
monitoring	O	VERB	B
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
CIN2	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
90	B-P	NUM	O
Brazilian	I-P	ADJ	B
women	I-P	NOUN	B
,	I-P	PUNCT	O
diagnosed	I-P	VERB	B
to	I-P	PART	O
CIN2	I-P	NOUN	B
and	I-P	CCONJ	O
high-risk	I-P	ADJ	B
human	I-P	ADJ	O
papillomavirus	I-P	NOUN	O
infection	I-P	NOUN	O
,	I-P	PUNCT	O
were	I-P	AUX	O
randomized	I-P	VERB	B
into	I-P	ADP	O
two	I-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
equal	I-P	ADJ	O
size	I-P	NOUN	B
:	I-P	PUNCT	O
45	I-P	NUM	O
women	I-P	NOUN	B
whose	I-P	DET	O
lesions	I-I	NOUN	B
were	I-I	AUX	O
excised	I-I	VERB	B
and	I-P	CCONJ	O
45	I-P	NUM	O
women	I-P	NOUN	B
subjected	I-P	VERB	O
to	I-P	PART	O
prospective	I-I	ADJ	B
follow-up	I-I	NOUN	I
at	I-P	ADP	O
3-month	I-P	ADJ	O
intervals	I-P	NOUN	B
at	I-P	ADP	O
least	I-P	ADJ	O
for	I-P	ADP	O
1	I-P	NUM	O
year	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	NOUN	O
6.8	I-P	NUM	O
months	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


p16	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
INK4a	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
expression	I-OUT	NOUN	B
was	O	AUX	O
analyzed	O	VERB	B
in	O	ADP	O
paraffin-embedded	O	ADJ	B
sections	O	NOUN	I
using	O	VERB	O
immunohistochemical	B-I	ADJ	B
staining	I-I	NOUN	I
.	I-I	PUNCT	O


Among	O	ADP	O
the	O	DET	O
45	B-P	NUM	O
women	I-P	NOUN	B
in	O	ADP	O
the	O	DET	O
follow-up	O	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
42	O	NUM	O
%	O	NOUN	O
experienced	O	VERB	O
spontaneous	O	ADJ	B
regression	O	NOUN	I
,	O	PUNCT	O
11	O	NUM	O
%	O	NOUN	O
showed	O	VERB	O
persistence	O	NOUN	B
,	O	PUNCT	O
22	O	NUM	O
%	O	NOUN	O
progressed	O	VERB	O
to	O	PART	O
CIN3	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
20	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
partial	O	ADJ	B
regression	O	NOUN	O
to	O	PART	O
CIN1	O	NOUN	B
or	O	CCONJ	O
ASCUS	O	NOUN	B
(	O	PUNCT	O
atypical	O	ADJ	B
squamous	O	ADJ	B
cell	O	NOUN	I
undetermined	O	ADJ	O
signifiance	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


p16	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
INK4a	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
expression	I-OUT	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
68.9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
univariate	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
Cox	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
analysis	I-OUT	NOUN	O
,	O	PUNCT	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
regression	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
between	O	ADP	O
p16	B-I	NOUN	B
(	I-I	PUNCT	O
INK4a	I-I	NOUN	B
)	I-I	PUNCT	O
-negative	I-I	ADJ	O
and	I-I	CCONJ	O
-positive	I-I	ADJ	O
CIN2	O	NOUN	B
lesions	O	NOUN	B
(	O	PUNCT	O
adjusted	O	VERB	O
HR	O	NOUN	B
=	O	ADJ	O
1.1	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.6-2.0	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
p16	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
INK4a	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
expression	I-OUT	NOUN	B
could	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
the	O	DET	O
diagnosis	B-OUT	NOUN	B
of	I-OUT	ADP	O
CIN2	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
failed	O	VERB	O
to	O	PART	O
predict	O	VERB	O
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
CIN2	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
its	O	PRON	O
high	O	ADJ	O
spontaneous	O	ADJ	B
regression	O	NOUN	O
rate	O	NOUN	O
,	O	PUNCT	O
follow-up	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
a	O	DET	O
management	O	NOUN	B
option	O	NOUN	O
of	O	ADP	O
CIN2	O	NOUN	B
in	O	ADP	O
young	O	ADJ	B
and	O	CCONJ	O
compliant	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


Dacarbazine	B-I	NOUN	B
versus	I-I	CCONJ	O
dacarbazine-vindesine	I-I	NOUN	B
in	O	ADP	O
disseminated	O	ADJ	B
malignant	O	ADJ	B
melanoma	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
study	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	I
119	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
disseminated	I-P	ADJ	B
malignant	I-P	ADJ	B
melanoma	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
dacarbazine	B-I	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
vindesine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
reveal	O	VERB	O
an	O	DET	O
additive	O	ADJ	B
response	O	NOUN	I
rate	O	NOUN	O
when	O	SCONJ	O
the	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
combined	O	VERB	O
.	O	PUNCT	O


Dacarbazine	B-I	NOUN	B
was	I-I	AUX	O
given	I-I	VERB	O
i.v	I-I	PROPN	O
.	I-I	PUNCT	O


at	B-I	ADP	O
250	I-I	NUM	O
mg	I-I	NOUN	O
m-2	I-I	NOUN	O
per	I-I	ADP	O
day	I-I	NOUN	B
X	I-I	NOUN	O
V	I-I	NOUN	O
every	I-I	DET	O
4	I-I	NUM	O
weeks	I-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
combination	O	NOUN	O
regimen	O	NOUN	B
vindesine	B-I	NOUN	B
given	O	VERB	O
at	O	ADP	O
3	O	NUM	O
mg	O	NOUN	O
m-2	O	NOUN	O
per	O	ADP	O
week	O	NOUN	B
was	O	AUX	O
included	O	VERB	O
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
ten	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
available	I-P	ADJ	O
for	I-P	ADP	O
evaluation	I-P	NOUN	B
of	I-P	ADP	O
response	I-P	NOUN	B
.	I-P	PUNCT	O


With	O	ADP	O
dacarbazine	B-I	NOUN	B
4/51	O	NUM	O
patients	O	NOUN	B
obtained	O	VERB	O
a	O	DET	O
complete	B-OUT	ADJ	O
remission	I-OUT	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
5/51	O	NUM	O
patients	O	NOUN	B
a	O	DET	O
partial	B-OUT	ADJ	B
remission	I-OUT	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Overall	B-OUT	ADJ	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
18	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


With	O	ADP	O
dacarbazine-vindesine	B-I	ADJ	B
8/59	O	NUM	O
patients	O	NOUN	B
obtained	O	VERB	O
a	O	DET	O
complete	B-OUT	ADJ	O
remission	I-OUT	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
7/59	O	NUM	O
patients	O	NOUN	B
a	O	DET	O
partial	B-OUT	ADJ	B
remission	I-OUT	NOUN	I
(	O	PUNCT	O
12	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Overall	B-OUT	ADJ	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
25	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
response	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
arms	O	NOUN	I
is	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


Median	O	ADJ	B
response	O	NOUN	I
duration	O	NOUN	O
was	O	AUX	O
123	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
dacarbazine	O	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
171	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
dacarbazine-vindesine	O	ADJ	B
(	O	PUNCT	O
difference	O	NOUN	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
)	O	PUNCT	O
.	O	PUNCT	O


Disopyramide-pyridostigmine	B-I	ADJ	B
interaction	O	NOUN	I
:	O	PUNCT	O
selective	O	ADJ	O
reversal	O	NOUN	B
of	O	ADP	O
anticholinergic	O	ADJ	B
symptoms	O	NOUN	B
with	O	ADP	O
preservation	O	NOUN	B
of	O	ADP	O
antiarrhythmic	O	ADJ	B
effect	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo	B-I	ADJ	B
crossover	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
cholinesterase	B-I	NOUN	B
inhibitor	I-I	NOUN	I
--	I-I	PUNCT	O
slow-release	I-I	ADJ	B
pyridostigmine	I-I	NOUN	B
(	O	PUNCT	O
180	O	NUM	O
mg	O	NOUN	O
orally	O	ADV	B
every	O	DET	O
12	O	NUM	O
hours	O	NOUN	B
)	O	PUNCT	O
--	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
anticholinergic	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
antiarrhythmic	I-OUT	ADJ	B
properties	I-OUT	NOUN	I
of	O	ADP	O
disopyramide	B-I	NOUN	B
.	I-I	PUNCT	O


Quantitative	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
questionnaire	O	NOUN	B
scores	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
guide	O	VERB	O
disopyramide	B-I	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
20	B-P	NUM	O
men	I-P	NOUN	B
with	I-P	ADP	O
ventricular	I-P	ADJ	B
tachycardia	I-P	NOUN	I
.	I-P	PUNCT	O


Disopyramide	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
to	O	ADP	O
each	O	DET	O
patient	B-P	NOUN	B
both	I-P	CCONJ	O
with	I-P	ADP	O
placebo	I-I	NOUN	B
and	I-P	CCONJ	O
with	I-P	ADP	O
active	I-P	ADJ	B
pyridostigmine	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
maximal	O	ADJ	B
administered	O	VERB	B
dose	O	NOUN	B
for	O	ADP	O
each	O	DET	O
regimen	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
corresponding	O	ADJ	O
questionnaire	O	NOUN	B
scores	O	NOUN	B
to	O	PART	O
calculate	O	VERB	B
an	O	DET	O
index	O	NOUN	B
or	O	CCONJ	O
estimate	O	NOUN	B
of	O	ADP	O
the	O	DET	O
maximal	B-OUT	ADJ	B
tolerable	I-OUT	ADJ	O
dose	I-OUT	NOUN	B
of	O	ADP	O
disopyramide	B-I	NOUN	B
.	I-I	PUNCT	O


Additional	O	ADJ	O
evaluations	O	NOUN	B
performed	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
each	O	DET	O
maximal	O	ADJ	B
administered	O	VERB	B
dose	O	NOUN	B
regimen	O	NOUN	B
included	O	VERB	O
tear	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
saliva	I-OUT	NOUN	B
quantitation	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
24	I-OUT	NUM	O
hour	I-OUT	NOUN	O
electrocardiogram	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
ECG	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
exercise	I-OUT	NOUN	B
testing	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
programmed	I-OUT	VERB	B
ventricular	I-OUT	ADJ	I
stimulation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
maximal	O	ADJ	B
administered	O	VERB	B
dose	O	NOUN	B
of	O	ADP	O
disopyramide	B-I	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
with	O	ADP	O
active	O	ADJ	B
pyridostigmine	B-I	NOUN	B
than	O	ADP	O
with	O	ADP	O
placebo	O	NOUN	B
:	O	PUNCT	O
295	O	NUM	O
+/-	O	CCONJ	O
75	O	NUM	O
versus	O	CCONJ	O
245	O	NUM	O
+/-	O	CCONJ	O
100	O	NUM	O
mg	O	NOUN	O
every	O	DET	O
6	O	NUM	O
hours	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
calculated	O	VERB	B
maximal	B-OUT	ADJ	B
tolerable	I-OUT	ADJ	O
dose	I-OUT	NOUN	B
was	O	AUX	O
substantially	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
pyridostigmine	B-I	NOUN	B
:	I-I	PUNCT	O
355	O	NUM	O
+/-	O	CCONJ	O
90	O	NUM	O
versus	O	CCONJ	O
260	O	NUM	O
+/-	O	CCONJ	O
115	O	NUM	O
mg	O	NOUN	O
every	O	DET	O
6	O	NUM	O
hours	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Maximal	B-OUT	ADJ	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
questionnaire	I-OUT	NOUN	B
scores	I-OUT	NOUN	B
also	O	ADV	O
reflected	O	VERB	O
decreased	O	VERB	B
anticholinergic	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
pyridostigmine	B-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
:	I-I	PUNCT	O
101.9	O	NUM	O
+/-	O	CCONJ	O
2.2	O	NUM	O
versus	O	CCONJ	O
104.6	O	NUM	O
+/-	O	CCONJ	O
2.8	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Baseline	O	NOUN	B
tear	O	NOUN	B
and	O	CCONJ	O
saliva	O	NOUN	B
production	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
during	O	ADP	O
disopyramide	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
restored	O	VERB	B
toward	O	ADP	O
normal	O	ADJ	B
by	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
pyridostigmine	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O


A	O	DET	O
web-based	B-I	ADJ	B
approach	I-I	NOUN	I
to	O	PART	O
address	O	VERB	O
cardiovascular	B-OUT	ADJ	B
risks	I-OUT	NOUN	B
in	I-P	ADP	O
managers	I-P	NOUN	B
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
examine	O	VERB	O
whether	O	SCONJ	O
a	O	DET	O
Web-based	B-I	ADJ	B
health	I-I	NOUN	I
and	I-I	CCONJ	O
leadership	I-I	NOUN	B
development	I-I	NOUN	B
program	I-I	NOUN	B
--	I-I	PUNCT	O
designed	I-I	VERB	B
specifically	O	ADV	O
for	O	ADP	O
managers	B-P	NOUN	B
--	I-P	PUNCT	O
was	I-P	AUX	O
associated	O	VERB	B
with	O	ADP	I
changes	O	NOUN	B
in	O	ADP	O
self-reported	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
biometric	I-OUT	ADJ	B
indicators	I-OUT	NOUN	I
of	I-OUT	ADP	O
cardiovascular	I-OUT	ADJ	B
disease	I-OUT	NOUN	I
within	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
control	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
145	B-P	NUM	O
managers	I-P	NOUN	B
from	I-P	ADP	O
8	I-P	NUM	O
organizations	I-P	NOUN	B
participated	O	VERB	O
in	O	ADP	O
a	O	DET	O
6-month	B-I	ADJ	O
Internet-based	I-I	ADJ	B
program	I-I	NOUN	I
or	I-I	CCONJ	O
a	I-I	DET	O
control	I-I	ADJ	B
condition	I-I	NOUN	I
.	I-I	PUNCT	O


They	O	PRON	O
completed	O	VERB	O
pre-	O	ADJ	B
and	O	CCONJ	O
posttest	O	NOUN	B
assessments	O	NOUN	I
that	O	PRON	O
included	O	VERB	O
both	O	DET	O
self-reported	B-OUT	ADJ	B
attitudes	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
on	I-OUT	ADP	O
diet	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
exercise	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
mental	I-OUT	ADJ	B
health	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	O	CCONJ	O
biometric	B-OUT	ADJ	B
measures	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
eg	I-OUT	ADP	O
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
weight	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
waist	I-OUT	NOUN	B
circumference	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
intervention	B-I	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
improvements	O	NOUN	B
in	O	ADP	O
dietary	B-OUT	ADJ	B
attitudes	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
dietary	I-OUT	ADJ	B
self-efficacy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
exercise	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
reductions	I-OUT	NOUN	B
in	I-OUT	ADP	O
distress	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
program	O	NOUN	B
reduced	O	VERB	B
their	O	PRON	O
waist	B-OUT	NOUN	B
circumference	I-OUT	NOUN	I
significantly	O	ADV	O
more	O	ADJ	O
than	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
program	O	NOUN	B
showed	O	VERB	O
promise	O	NOUN	O
for	O	ADP	O
reducing	O	VERB	B
cardiovascular	B-OUT	ADJ	B
disease	I-OUT	NOUN	O
risk	I-OUT	NOUN	B
factors	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Similar	O	ADJ	O
results	O	NOUN	B
across	O	ADP	O
diverse	O	ADJ	B
organizations	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
program	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
across	O	ADP	O
industry	O	NOUN	B
types	O	NOUN	O
.	O	PUNCT	O


Can	O	AUX	O
a	O	DET	O
home-visit	B-I	ADJ	B
invitation	I-I	NOUN	B
increase	I-P	VERB	B
Pap	I-P	NOUN	B
smear	I-P	NOUN	I
screening	I-P	NOUN	B
in	I-P	ADP	O
Samliem	I-P	PROPN	B
,	I-P	PUNCT	O
Khon	I-P	PROPN	B
Kaen	I-P	PROPN	I
,	I-P	PUNCT	O
Thailand	I-P	PROPN	B
?	O	PUNCT	O
Our	O	PRON	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficiency	O	NOUN	B
of	O	ADP	O
a	O	DET	O
home-visit	B-I	ADJ	B
invitation	I-I	NOUN	B
aimed	O	VERB	O
to	O	PART	O
increase	O	VERB	B
uptake	O	NOUN	B
of	O	ADP	O
cervical	B-P	ADJ	B
cancer	I-P	NOUN	I
screening	I-P	NOUN	B
in	I-P	ADP	O
women	I-P	NOUN	B
between	I-P	ADP	O
35	I-P	NUM	O
and	I-P	CCONJ	O
60	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
.	I-P	PUNCT	O


From	O	ADP	O
May	O	PROPN	O
,	O	PUNCT	O
2006	O	NUM	O
,	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
quasi-randomized	O	ADJ	B
trial	O	NOUN	I
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
an	O	DET	O
in-home	B-I	ADJ	B
education	I-I	NOUN	I
and	I-I	CCONJ	O
invitation	I-I	NOUN	B
intervention	I-I	NOUN	B
would	O	AUX	O
increase	O	VERB	B
uptake	O	NOUN	B
of	O	ADP	O
cervical	O	ADJ	B
cancer	O	NOUN	I
screening	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
randomly	B-P	ADV	O
recruited	I-P	VERB	O
304	I-P	NUM	O
women	I-P	NOUN	B
from	I-P	ADP	O
the	I-P	DET	O
Samliem	I-P	ADJ	B
inner-city	I-P	ADJ	B
community	I-P	NOUN	O
,	I-P	PUNCT	O
Khon	I-P	PROPN	B
Kaen	I-P	PROPN	I
,	I-P	PUNCT	O
Northeast	I-P	PROPN	B
Thailand	I-P	PROPN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
assigned	I-P	VERB	O
participants	I-P	NOUN	B
to	O	PART	O
either	O	CCONJ	O
the	O	DET	O
intervention	B-I	NOUN	B
or	O	CCONJ	O
control	B-I	NOUN	B
zone	I-I	NOUN	I
.	I-I	PUNCT	O


Baseline	O	NOUN	B
screening	O	NOUN	B
coverage	O	NOUN	O
interviews	O	NOUN	B
were	O	AUX	O
then	O	ADV	O
performed	O	VERB	O
:	O	PUNCT	O
58	B-P	NUM	O
of	I-P	ADP	O
158	I-P	NUM	O
women	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
intervention	I-P	NOUN	B
zone	I-P	NOUN	I
and	I-P	CCONJ	O
46	I-P	NUM	O
of	I-P	ADP	O
146	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
control	I-P	NOUN	B
zone	I-P	NOUN	I
were	I-P	AUX	O
excluded	I-P	VERB	O
from	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
because	I-P	SCONJ	O
of	I-P	ADP	O
having	I-P	VERB	O
had	I-P	AUX	O
a	I-P	DET	O
Pap	I-P	NOUN	B
smear	I-P	NOUN	I
within	I-P	ADP	O
5	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
but	I-P	CCONJ	O
these	I-P	DET	O
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
final	I-P	ADJ	O
analysis	I-P	NOUN	B
.	I-P	PUNCT	O


First	O	ADV	O
,	O	PUNCT	O
100	B-P	NUM	O
women	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
intervention	I-P	NOUN	B
group	I-P	NOUN	I
were	O	AUX	O
visited	B-I	VERB	O
in	I-I	ADP	O
their	I-I	PRON	O
homes	I-I	NOUN	B
by	I-I	ADP	O
one	I-I	NUM	O
of	I-I	ADP	O
the	I-I	DET	O
researchers	I-I	NOUN	B
,	I-I	PUNCT	O
who	I-I	PRON	O
provided	I-I	VERB	O
culturally-sensitive	I-I	ADJ	B
health	I-I	NOUN	I
education	I-I	NOUN	I
that	I-I	PRON	O
emphasized	I-I	VERB	O
the	I-I	DET	O
need	I-I	NOUN	O
for	I-I	ADP	O
screening	I-I	NOUN	B
.	I-I	PUNCT	O


Four	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
post-intervention	O	ADJ	B
,	O	PUNCT	O
screening-coverage	B-I	ADJ	B
interviews	I-I	NOUN	I
were	O	AUX	O
again	O	ADV	O
performed	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
health	O	NOUN	B
education	O	NOUN	I
for	O	ADP	O
100	B-P	NUM	O
women	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
control	I-I	ADJ	B
group	I-P	NOUN	I
for	O	ADP	O
a	O	DET	O
comparison	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
baseline	B-OUT	NOUN	B
Pap	I-OUT	NOUN	B
smear	I-OUT	NOUN	I
screening-coverage	I-OUT	ADJ	B
rate	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
vs.	O	CCONJ	O
control	O	NOUN	B
zones	O	NOUN	I
(	O	PUNCT	O
36.7	O	NUM	O
vs.	O	CCONJ	O
31.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p=0.339	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
completed	O	VERB	O
the	O	DET	O
intervention	O	NOUN	B
interviews	O	NOUN	I
and	O	CCONJ	O
after	O	ADP	O
four	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
100	O	NUM	O
women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
100	O	NUM	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
also	O	ADV	O
completed	O	VERB	O
the	O	DET	O
post-intervention	O	ADJ	B
interviews	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
increased	O	VERB	B
screening-coverage	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
zone	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
zone	O	NOUN	I
(	O	PUNCT	O
43.6	O	NUM	O
vs.	O	CCONJ	O
34.9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p=0.119	O	ADJ	O
)	O	PUNCT	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
borderline	O	NOUN	B
significant	O	ADJ	I
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
zone	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
36.7	O	NUM	O
to	O	PART	O
43.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p=0.070	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
home	B-I	NOUN	B
visit	I-I	NOUN	I
education	I-I	NOUN	I
and	I-I	CCONJ	O
invitation	I-I	NOUN	B
intervention	I-I	NOUN	B
produced	O	VERB	O
only	O	ADV	O
a	O	DET	O
nominal	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
increasing	O	VERB	B
Pap	O	NOUN	B
smear	O	NOUN	I
coverage	O	NOUN	B
within	O	ADP	O
a	O	DET	O
4-month	O	ADJ	O
study	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
study	O	NOUN	I
comparing	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
THUNDERBEAT	O	PROPN	B
technology	O	NOUN	B
vs	O	CCONJ	O
standard	O	ADJ	B
electrosurgery	O	NOUN	I
during	O	ADP	O
laparoscopic	B-P	ADJ	B
radical	I-P	ADJ	I
hysterectomy	I-P	NOUN	I
and	I-P	CCONJ	O
pelvic	I-P	ADJ	B
lymphadenectomy	I-P	NOUN	I
for	I-P	ADP	O
gynecologic	I-P	ADJ	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	O
operative	O	ADJ	B
time	O	NOUN	I
with	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
THUNDERBEAT	B-I	NOUN	B
(	O	PUNCT	O
TB	O	NOUN	B
)	O	PUNCT	O
vs	O	CCONJ	O
standard	B-I	ADJ	B
electrosurgery	I-I	NOUN	I
(	O	PUNCT	O
SES	O	PROPN	B
)	O	PUNCT	O
during	O	ADP	O
laparoscopic	O	ADJ	B
radical	O	ADJ	I
hysterectomy	O	NOUN	I
and	O	CCONJ	O
pelvic	O	ADJ	B
lymphadenectomy	O	NOUN	I
to	O	PART	O
treat	O	VERB	B
gynecologic	B-P	ADJ	B
tumors	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
Evidence	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
a	O	DET	O
properly	O	ADV	O
designed	O	VERB	O
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
(	O	PUNCT	O
Canadian	O	PROPN	B
Task	O	PROPN	I
Force	O	PROPN	I
classification	O	NOUN	I
I	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


SETTING	O	VERB	B
Gynecologic	B-P	PROPN	I
Oncology	I-P	PROPN	I
Unit	I-P	PROPN	I
of	I-P	ADP	I
the	I-P	DET	I
Catholic	I-P	PROPN	I
University	I-P	PROPN	I
of	I-P	ADP	I
the	I-P	DET	I
Sacred	I-P	PROPN	I
Heart	I-P	PROPN	I
in	I-P	ADP	I
Rome	I-P	PROPN	I
,	I-P	PUNCT	O
Italy	I-P	PROPN	B
.	I-P	PUNCT	O


PATIENTS	O	VERB	O
Fifty	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
early	I-P	ADJ	B
cervical	I-P	ADJ	B
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
FIGO	I-P	NOUN	B
stages	I-P	NOUN	I
IA2	I-P	NOUN	O
,	I-P	PUNCT	O
IB1	I-P	NOUN	B
,	I-P	PUNCT	O
IIA	I-P	NOUN	B
<	I-P	NOUN	O
2	I-P	NUM	O
cm	I-P	NOUN	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
locally	I-P	ADV	B
advanced	I-P	ADJ	I
cervical	I-P	ADJ	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
FIGO	I-P	NOUN	B
stages	I-P	NOUN	I
IB2	I-P	NOUN	I
,	I-P	PUNCT	O
IIA	I-P	NOUN	B
>	I-P	X	O
2cm	I-P	NOUN	B
,	I-P	PUNCT	O
IIB	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
received	I-P	VERB	O
neoadjuvant	I-I	ADJ	B
treatment	I-I	NOUN	I
(	I-I	PUNCT	O
chemotherapy	I-I	NOUN	B
or	I-I	CCONJ	O
radiochemotherapy	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-P	CCONJ	O
demonstrated	I-P	VERB	O
a	I-P	DET	O
complete	I-P	ADJ	B
or	I-P	CCONJ	O
partial	I-P	ADJ	B
clinical	I-P	ADJ	B
response	I-P	NOUN	I
and	I-P	CCONJ	O
early	I-P	ADJ	B
stage	I-P	NOUN	I
endometrioid	I-P	ADJ	O
endometrial	I-P	ADJ	O
cancer	I-P	NOUN	O
(	I-P	PUNCT	O
FIGO	I-P	NOUN	B
stages	I-P	NOUN	I
IB	I-P	NOUN	B
,	I-P	PUNCT	O
II	I-P	NUM	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
undergo	O	VERB	O
TB	O	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
SES	O	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	B
B	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


INTERVENTION	O	PROPN	B
Laparoscopic	B-I	ADJ	B
radical	I-I	ADJ	I
hysterectomy	I-I	NOUN	I
with	I-I	ADP	O
bilateral	I-I	ADJ	B
pelvic	I-I	ADJ	I
lymphadenectomy	I-I	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
an	O	DET	O
easily	O	ADV	O
reproducible	O	ADJ	O
technique	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
MAIN	O	NOUN	O
RESULTS	O	NOUN	O
Fifty	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
available	I-P	ADJ	O
for	I-P	ADP	O
analysis	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
25	I-P	NUM	O
women	I-P	NOUN	B
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
TB	I-P	NOUN	B
(	I-P	PUNCT	O
arm	I-P	NOUN	B
A	I-P	NOUN	I
)	I-P	PUNCT	O
and	I-P	CCONJ	O
25	I-P	NUM	O
to	I-P	PART	O
SES	I-P	PROPN	B
(	I-P	PUNCT	O
arm	I-P	NOUN	B
B	I-P	NOUN	I
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
operative	I-OUT	ADJ	B
time	I-OUT	NOUN	I
was	O	AUX	O
85	O	NUM	O
minutes	O	NOUN	B
for	O	ADP	O
TB	O	NOUN	B
vs	O	CCONJ	O
115	O	NUM	O
minutes	O	NOUN	O
for	O	ADP	O
SES	O	PROPN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
endometrial	O	ADJ	B
cancer	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
TB	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.001	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
independently	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
shorter	B-OUT	ADJ	B
operating	I-OUT	NOUN	O
time	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


No	O	DET	O
differences	B-OUT	NOUN	O
in	O	ADP	O
perioperative	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
arms	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
TB	O	NOUN	B
reported	O	VERB	O
less	O	ADV	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
,	O	PUNCT	O
both	O	CCONJ	O
at	O	ADP	O
rest	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.005	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
Valsalva	O	PROPN	B
maneuver	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.008	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
less	O	ADV	O
additional	O	ADJ	O
analgesic	O	NOUN	B
therapy	O	NOUN	I
other	O	ADJ	O
than	O	ADP	O
standard	O	ADJ	B
therapy	O	NOUN	I
required	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
SES	O	PROPN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
TB	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
shorter	B-OUT	ADJ	B
operative	I-OUT	ADJ	B
time	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
less	I-OUT	ADV	O
postoperative	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
than	O	ADP	O
is	O	AUX	O
the	O	DET	O
standard	O	ADJ	B
technique	O	NOUN	I
(	O	PUNCT	O
SES	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
uterine	I-P	ADJ	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


[	O	PUNCT	O
A	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
radiotherapy	B-I	NOUN	B
volume	I-I	NOUN	B
for	O	ADP	O
limited-stage	O	ADJ	B
small	O	ADJ	I
cell	O	NOUN	I
lung	O	NOUN	I
cancer	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
preliminary	O	ADJ	B
report	O	NOUN	B
]	O	PUNCT	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
AND	O	CCONJ	O
OBJECTIVE	O	NOUN	O
Controversies	O	NOUN	B
exists	O	VERB	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
target	O	VERB	B
volumes	O	NOUN	B
as	O	ADV	O
far	O	ADV	O
as	O	ADP	O
thoracic	B-I	ADJ	B
radiotherapy	I-I	NOUN	I
(	I-I	PUNCT	O
TRT	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
concerned	O	ADJ	O
in	O	ADP	O
the	O	DET	O
multimodality	O	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
limited-stage	B-P	ADJ	B
small	I-P	ADJ	I
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
LSCLC	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
prospectively	O	ADV	O
compare	O	VERB	B
the	O	DET	O
local	O	ADJ	B
control	O	NOUN	I
rate	O	NOUN	I
,	O	PUNCT	O
toxicity	O	NOUN	B
profiles	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
overall	O	ADJ	B
survival	O	NOUN	I
(	O	PUNCT	O
OS	O	NOUN	B
)	O	PUNCT	O
between	O	ADP	O
patients	O	NOUN	B
received	O	VERB	O
different	B-I	ADJ	O
target	I-I	NOUN	B
volumes	I-I	NOUN	B
irradiation	I-I	NOUN	I
after	I-I	ADP	O
induction	I-I	NOUN	B
chemotherapy	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	NOUN	O
LSCLC	B-P	NOUN	B
patients	I-P	NOUN	B
received	O	VERB	O
2	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
etoposide	B-I	NOUN	B
and	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
(	I-I	PUNCT	O
EP	I-I	NOUN	B
)	I-I	PUNCT	O
induction	I-I	NOUN	B
chemotherapy	I-I	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
TRT	B-I	NOUN	B
to	O	PART	O
either	O	CCONJ	O
the	O	DET	O
post-	O	ADJ	O
or	O	CCONJ	O
pre-chemotherapy	O	ADJ	B
tumor	O	NOUN	O
extent	O	NOUN	O
(	O	PUNCT	O
GTV-T	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
study	O	VERB	B
arm	O	NOUN	I
and	O	CCONJ	O
control	O	NOUN	B
arm	O	NOUN	I
,	O	PUNCT	O
CTV-N	O	NOUN	B
included	O	VERB	O
the	O	DET	O
positive	O	ADJ	B
nodal	O	ADJ	B
drainage	O	NOUN	I
area	O	NOUN	O
for	O	ADP	O
both	O	DET	O
arms	O	NOUN	O
.	O	PUNCT	O


One	O	NUM	O
to	O	PART	O
2	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
induction	B-I	NOUN	B
chemotherapy	I-I	NOUN	I
,	I-I	PUNCT	O
45	I-I	NUM	O
Gy/30	I-I	NOUN	B
Fx/19	I-I	NOUN	B
d	I-I	NOUN	O
TRT	I-I	NOUN	B
was	O	AUX	O
administered	O	VERB	B
concurrently	O	ADV	O
with	O	ADP	O
the	O	DET	O
third	O	ADJ	B
cycle	O	NOUN	I
of	O	ADP	O
EP	B-I	NOUN	B
regimen	I-I	NOUN	B
.	I-I	PUNCT	O


After	O	ADP	O
that	O	DET	O
,	O	PUNCT	O
additional	O	ADJ	O
3	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
EP	B-I	NOUN	B
consolidation	O	NOUN	I
were	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


Prophylactic	B-I	ADJ	B
cranial	I-I	ADJ	I
irradiation	I-I	NOUN	I
(	I-I	PUNCT	O
PCI	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
response	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Thirty-seven	B-P	NUM	O
and	I-P	CCONJ	O
40	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
study	I-P	VERB	B
arm	I-P	NOUN	I
and	I-P	CCONJ	O
control	I-P	NOUN	B
arm	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
local	B-OUT	ADJ	B
recurrence	I-OUT	NOUN	O
rates	I-OUT	NOUN	O
were	O	AUX	O
32.4	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
28.2	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.80	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
the	O	DET	O
isolated	O	VERB	B
nodal	B-OUT	ADJ	O
failure	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
INF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
rates	O	NOUN	B
were	O	AUX	O
3.0	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
2.6	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.91	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
all	O	DET	O
INF	O	NOUN	B
sites	O	NOUN	B
were	O	AUX	O
in	O	ADP	O
the	O	DET	O
ipsilateral	O	ADJ	B
supraclavicular	O	ADJ	B
fossa	O	NOUN	I
.	O	PUNCT	O


Medastinal	B-OUT	PROPN	B
N3	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
was	O	AUX	O
the	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
INF	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
,	O	PUNCT	O
OR	O	CCONJ	B
=	O	ADJ	O
14.13	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
1.47-136.13	O	X	O
)	O	PUNCT	O
.	O	PUNCT	O


During	O	ADP	O
radiotherapy	O	NOUN	B
,	O	PUNCT	O
grade	B-OUT	NOUN	B
I	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
II	I-OUT	NUM	B
weight	I-OUT	NOUN	I
loss	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
29.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
5.9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
56.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
7.7	O	NUM	O
%	O	NOUN	O
patients	O	NOUN	B
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Grade	B-OUT	NOUN	B
0-I	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
II-III	I-OUT	ADJ	B
late	I-OUT	ADJ	I
pulmonary	I-OUT	ADJ	I
injury	I-OUT	NOUN	I
was	O	AUX	O
developed	O	VERB	O
in	O	ADP	O
97.1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
2.9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
86.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
15.4	O	NUM	O
%	O	NOUN	O
patients	O	NOUN	B
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.07	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
time	I-OUT	NOUN	I
was	O	AUX	O
22.1	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
26.9	O	NUM	O
months	O	NOUN	B
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
1	B-OUT	NUM	O
to	I-OUT	PART	O
3-year	I-OUT	ADJ	O
OS	I-OUT	NOUN	B
were	O	AUX	O
77.9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
44.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
37.3	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
75.8	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
56.3	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
41.7	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.79	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
preliminary	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
irradiant	O	ADJ	B
the	O	DET	O
post-chemotherapy	O	ADJ	B
tumor	O	NOUN	I
extent	O	NOUN	O
(	O	PUNCT	O
GTV-T	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
positive	O	ADJ	B
nodal	O	ADJ	O
drainage	O	NOUN	O
area	O	NOUN	O
did	O	AUX	O
not	O	PART	O
decrease	O	VERB	B
local	O	ADJ	B
control	O	NOUN	I
and	O	CCONJ	O
overall	O	ADJ	B
survival	O	NOUN	B
while	O	SCONJ	O
radiation	O	NOUN	B
toxicity	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
.	O	PUNCT	O


But	O	CCONJ	O
the	O	DET	O
current	O	ADJ	O
sample	O	NOUN	B
size	O	NOUN	I
has	O	AUX	O
not	O	PART	O
met	O	VERB	O
designed	O	VERB	O
requirements	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
further	O	ADJ	O
investigation	O	NOUN	B
is	O	AUX	O
warranted	O	VERB	O
before	O	ADP	O
final	O	ADJ	O
conclusions	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
drawn	O	VERB	O
.	O	PUNCT	O


Long	O	ADJ	B
term	O	NOUN	I
response	O	NOUN	I
to	O	PART	O
therapy	O	NOUN	B
of	O	ADP	O
chronic	B-P	ADJ	B
anti-HBe-positive	I-P	ADJ	O
hepatitis	I-P	NOUN	B
B	I-P	NOUN	I
is	O	AUX	O
poor	O	ADJ	O
independent	O	ADJ	O
of	O	ADP	O
type	O	NOUN	B
and	O	CCONJ	O
schedule	O	NOUN	B
of	O	ADP	O
interferon	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
to	I-OUT	PART	O
alpha	I-OUT	NOUN	B
interferon	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
IFN	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
of	O	ADP	O
chronic	O	ADJ	B
anti-HBe-positive	O	ADJ	O
hepatitis	O	NOUN	B
B	O	NOUN	I
is	O	AUX	O
variable	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
whether	O	SCONJ	O
type	O	NOUN	B
,	O	PUNCT	O
dose	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
schedule	O	NOUN	B
of	O	ADP	O
IFN	B-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
type	O	NOUN	B
and	O	CCONJ	O
frequency	O	NOUN	B
of	O	ADP	O
posttreatment	O	NOUN	B
monitoring	O	NOUN	B
,	O	PUNCT	O
influence	O	VERB	B
the	O	DET	O
response	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Seventy-two	B-P	NUM	O
consecutive	I-P	ADJ	B
anti-HBe-positive	I-P	ADJ	B
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
B	I-P	NOUN	I
patients	I-P	NOUN	B
(	I-P	PUNCT	O
59	I-P	NUM	O
male	I-P	NOUN	B
and	I-P	CCONJ	O
13	I-P	NUM	O
female	I-P	ADJ	B
,	I-P	PUNCT	O
median	I-P	ADJ	B
age	I-P	NOUN	B
41	I-P	NUM	O
yr	I-P	NOUN	O
)	I-P	PUNCT	O
stratified	I-P	VERB	B
by	I-P	ADP	O
sex	I-P	NOUN	B
and	I-P	CCONJ	O
histology	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
three	O	NUM	O
treatment	O	NOUN	B
arms	O	NOUN	I
.	O	PUNCT	O


Twenty-seven	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
received	O	VERB	O
10	O	NUM	O
million	O	NUM	O
units	O	NOUN	O
alpha-N1	B-I	NOUN	O
IFN	I-I	NOUN	B
i.m	I-I	NOUN	O
.	I-I	PUNCT	O


t.w	O	ADV	O
.	O	PUNCT	O


for	O	ADP	O
24	O	NUM	O
wk	O	NOUN	O
(	O	PUNCT	O
total	O	ADJ	B
dose	O	NOUN	I
:	O	PUNCT	O
720	O	NUM	O
million	O	NUM	O
units	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
21	O	NUM	O
(	O	PUNCT	O
B	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
9	O	NUM	O
million	O	NUM	O
units	O	NOUN	B
alpha-2a	B-I	NOUN	O
IFN	I-I	NOUN	B
i.m	I-I	NOUN	O
.	I-I	PUNCT	O


t.w	O	ADV	O
.	O	PUNCT	O


for	O	ADP	O
4	O	NUM	O
wk	O	NOUN	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
18	O	NUM	O
million	O	NUM	O
units	O	NOUN	B
for	O	ADP	O
12	O	NUM	O
wk	O	NOUN	O
and	O	CCONJ	O
9	O	NUM	O
million	O	NUM	O
units	O	NOUN	B
for	O	ADP	O
8	O	NUM	O
wk	O	NOUN	O
(	O	PUNCT	O
972	O	NUM	O
million	O	NUM	O
units	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
24	O	NUM	O
(	O	PUNCT	O
C	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
2	B-I	NUM	O
alpha-2a	I-I	NOUN	O
IFN	I-I	NOUN	B
courses	I-I	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
million	O	NUM	O
units	O	NOUN	B
i.m	O	NOUN	O
.	O	PUNCT	O


t.w	O	ADV	O
.	O	PUNCT	O


for	O	ADP	O
16	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
wk	O	NOUN	O
separated	O	VERB	O
by	O	ADP	O
a	O	DET	O
6-month	O	ADJ	B
interval	O	NOUN	I
[	O	PUNCT	O
756	O	NUM	O
million	O	NUM	O
units	O	NOUN	B
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Primary	O	ADJ	B
response	O	NOUN	I
was	O	AUX	O
defined	O	VERB	O
by	O	ADP	O
normal	B-OUT	ADJ	O
ALT	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
HBV-DNA	I-OUT	NOUN	B
levels	I-OUT	NOUN	O
below	O	ADP	O
10	O	NUM	O
pg/ml	O	NOUN	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
and	O	CCONJ	O
sustained	O	ADJ	B
response	O	NOUN	B
by	O	ADP	O
normal	B-OUT	ADJ	O
ALT	I-OUT	NOUN	B
(	O	PUNCT	O
tested	O	VERB	B
monthly	O	ADV	B
)	O	PUNCT	O
,	O	PUNCT	O
undetectable	B-OUT	ADJ	B
HBV-DNA	I-OUT	NOUN	B
and	O	CCONJ	O
IgM	O	NOUN	B
anti-HBc	O	NOUN	I
(	O	PUNCT	O
<	O	X	O
7	O	NUM	O
I.U	O	NOUN	B
.	O	PUNCT	O


Paul	O	PROPN	B
Ehrlich	O	PROPN	I
Institute	O	PROPN	I
)	O	PUNCT	O
(	O	PUNCT	O
tested	O	VERB	B
every	O	DET	O
3	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
posttreatment	O	NOUN	B
follow-up	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
13	O	NUM	O
patients	O	NOUN	B
from	O	ADP	O
groups	O	NOUN	B
A	O	NOUN	O
,	O	PUNCT	O
B	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
C	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
responders	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
18-month	O	ADJ	O
follow-up	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
only	O	ADV	O
one	O	NUM	O
in	O	ADP	O
groups	O	NOUN	B
B	O	NOUN	O
and	O	CCONJ	O
C	O	NOUN	O
maintained	O	VERB	B
the	O	DET	O
response	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
after	O	ADP	O
34	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
posttreatment	O	NOUN	B
follow-up	O	X	B
)	O	PUNCT	O
,	O	PUNCT	O
three	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
long	O	ADJ	B
term	O	NOUN	I
responders	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
three	O	NUM	O
showed	O	VERB	O
a	O	DET	O
sustained	O	ADJ	B
remission	B-OUT	NOUN	B
after	O	ADP	O
relapse	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
long	I-OUT	ADJ	B
term	I-OUT	NOUN	I
response	I-OUT	NOUN	O
to	O	PART	O
interferon	O	NOUN	B
of	O	ADP	O
anti-HBe-positive	O	ADJ	B
chronic	O	ADJ	B
hepatitis	O	NOUN	I
B	O	NOUN	I
is	O	AUX	O
poor	O	ADJ	B
,	O	PUNCT	O
independent	O	ADJ	B
of	O	ADP	O
IFN	O	NOUN	B
type	O	NOUN	I
,	O	PUNCT	O
dose	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
schedule	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
more	O	ADV	O
stringent	O	ADJ	O
the	O	DET	O
monitoring	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
higher	O	ADJ	B
the	O	DET	O
relapse	O	NOUN	B
rate	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
dental	O	ADJ	B
cream	O	NOUN	I
containing	O	VERB	O
amorphous	B-I	ADJ	B
cream	I-I	NOUN	I
phosphate	I-I	NOUN	I
complexes	I-I	NOUN	O
on	O	ADP	O
white	O	ADJ	B
spot	O	NOUN	I
lesion	O	NOUN	O
regression	O	NOUN	O
assessed	O	VERB	B
by	O	ADP	O
laser	O	NOUN	B
fluorescence	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
and	O	CCONJ	O
compare	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
dental	O	ADJ	B
cream	O	NOUN	I
containing	O	VERB	O
complexes	O	NOUN	B
of	O	ADP	O
casein	B-I	NOUN	B
phosphoprotein-amorphous	I-I	ADJ	B
calcium	I-I	NOUN	I
phosphate	I-I	NOUN	I
(	O	PUNCT	O
CPP-ACP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
fluoride	B-I	NOUN	B
mouthwashes	O	NOUN	I
on	O	ADP	O
the	O	DET	O
regression	O	NOUN	B
of	O	ADP	O
white	B-P	ADJ	B
spot	I-P	NOUN	I
lesions	I-P	NOUN	I
(	I-P	PUNCT	O
WSL	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
26	B-P	NUM	O
healthy	I-P	ADJ	B
adolescents	I-P	NOUN	B
(	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
14.6	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
exhibiting	I-P	VERB	O
60	I-P	NUM	O
teeth	I-P	NOUN	B
with	I-P	ADP	O
152	I-P	NUM	O
visible	I-P	ADJ	B
WSL	I-P	NOUN	B
sites	I-P	NOUN	B
on	I-P	ADP	O
incisors	I-P	NOUN	B
and	I-P	CCONJ	O
canines	I-P	NOUN	B
immediately	I-P	ADV	O
after	I-P	ADP	O
debonding	I-P	NOUN	B
of	I-P	ADP	O
fixed	I-P	ADJ	B
orthodontic	I-P	ADJ	I
appliances	I-P	NOUN	I
.	I-P	PUNCT	O


After	O	ADP	O
bracket	B-I	NOUN	B
removal	I-I	NOUN	I
,	I-I	PUNCT	O
professional	I-I	ADJ	B
tooth	I-I	NOUN	I
cleaning	I-I	NOUN	B
and	I-I	CCONJ	O
drying	I-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
visual	I-I	ADJ	B
scoring	I-I	NOUN	I
(	I-I	PUNCT	O
0-4	I-I	NUM	O
)	I-I	PUNCT	O
and	I-I	CCONJ	O
laser	I-I	NOUN	B
fluorescence	I-I	NOUN	I
(	I-I	PUNCT	I
LF	I-I	NOUN	I
)	I-I	PUNCT	O
readings	I-I	NOUN	B
were	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
two	O	NUM	O
different	O	ADJ	O
treatment	O	NOUN	B
protocols	O	NOUN	I
with	O	ADP	O
the	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
remineralising	O	VERB	B
the	O	DET	O
lesions	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
)	O	PUNCT	O
daily	B-I	ADJ	O
topical	I-I	ADJ	B
applications	I-I	NOUN	O
of	I-I	ADP	O
a	I-I	DET	O
dental	I-I	ADJ	B
cream	I-I	NOUN	I
containing	I-I	VERB	O
CPP-ACP	I-I	NOUN	B
(	I-I	PUNCT	O
Topacal	I-I	NOUN	B
)	I-I	PUNCT	O
for	I-I	ADP	O
3	I-I	NUM	O
months	I-I	NOUN	B
followed	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
3-month	I-I	ADJ	O
period	I-I	NOUN	B
of	I-I	ADP	O
daily	I-I	ADJ	B
toothbrushing	I-I	NOUN	O
with	I-I	ADP	O
fluoridated	I-I	ADJ	B
dentifrice	I-I	NOUN	I
,	I-I	PUNCT	O
or	I-I	CCONJ	O
B	I-I	NOUN	B
)	I-I	PUNCT	O
daily	I-I	ADV	O
0.05	I-I	NUM	O
%	I-I	NOUN	O
sodium	I-I	NOUN	B
fluoride	I-I	NOUN	I
mouthwash	I-I	NOUN	I
combined	I-I	VERB	O
with	I-I	ADP	O
fluoridated	I-I	ADJ	B
dentifrice	I-I	NOUN	I
for	I-I	ADP	O
6	I-I	NUM	O
months	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
registrations	O	NOUN	B
were	O	AUX	O
repeated	O	VERB	O
after	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
follow-up	O	ADJ	B
data	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
with	O	ADP	O
aid	O	NOUN	O
of	O	ADP	O
chi-square	O	ADJ	B
and	O	CCONJ	O
paired	O	ADJ	B
t-tests	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	B-OUT	ADJ	B
WSL-scores	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
over	O	ADP	O
time	O	NOUN	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
concerning	O	VERB	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
sites	I-OUT	NOUN	B
that	I-OUT	PRON	O
totally	I-OUT	ADV	O
disappeared	I-OUT	VERB	O
after	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
favour	O	NOUN	O
of	O	ADP	O
the	O	DET	O
CPP-ACP	O	NOUN	B
regime	O	NOUN	B
,	O	PUNCT	O
63	O	NUM	O
%	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
registrations	O	NOUN	I
were	O	AUX	O
mirrored	O	VERB	O
by	O	ADP	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
decrease	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
LF	B-OUT	PROPN	B
readings	I-OUT	NOUN	B
at	O	ADP	O
the	O	DET	O
6-	O	NUM	O
and	O	CCONJ	O
12-month	O	ADJ	O
follow-ups	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
displayed	O	VERB	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Clinical	O	ADJ	B
scoring	O	NOUN	I
and	O	CCONJ	O
LF	O	NOUN	B
assessment	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
regimens	O	NOUN	B
could	O	AUX	O
promote	O	VERB	B
regression	O	NOUN	B
of	O	ADP	O
WSL	O	PROPN	B
after	O	ADP	O
debonding	O	NOUN	B
of	O	ADP	O
fixed	O	ADJ	B
orthodontic	O	ADJ	I
appliances	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
visual	O	ADJ	B
evaluation	O	NOUN	B
suggested	O	VERB	O
an	O	DET	O
aesthetically	O	ADV	O
more	O	ADV	O
favourable	O	ADJ	O
outcome	O	NOUN	B
of	O	ADP	O
the	O	DET	O
amorphous	B-I	ADJ	B
calcium	I-I	NOUN	B
phosphate	I-I	NOUN	I
treatments	I-I	NOUN	B
.	O	PUNCT	O


Xuezhikang	B-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
extract	O	NOUN	B
of	O	ADP	O
cholestin	O	NOUN	B
,	O	PUNCT	O
decreases	O	VERB	B
plasma	O	NOUN	B
inflammatory	O	ADJ	B
markers	O	NOUN	B
and	O	CCONJ	O
endothelin-1	O	NOUN	B
,	O	PUNCT	O
improve	O	VERB	O
exercise-induced	O	ADJ	B
ischemia	O	NOUN	I
and	O	CCONJ	O
subjective	O	ADJ	O
feelings	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cardiac	I-P	ADJ	B
syndrome	I-P	NOUN	I
X	I-P	NOUN	I
.	I-P	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
Xuezhikang	B-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
extract	O	NOUN	B
of	O	ADP	O
cholestin	O	NOUN	B
,	O	PUNCT	O
available	O	ADJ	O
from	O	ADP	O
Chinese	O	ADJ	B
red	O	ADJ	I
yeast	O	NOUN	I
rice	O	NOUN	I
,	O	PUNCT	O
could	O	AUX	O
effectively	O	ADV	O
modify	O	VERB	B
lipid	O	NOUN	B
profile	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
Xuezhikang	B-I	PROPN	B
could	O	AUX	O
modify	O	VERB	O
endothelin-1	O	NOUN	B
(	O	PUNCT	O
ET-1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
interleukin-6	O	NOUN	B
(	O	PUNCT	O
IL-6	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
high-sensitivity	O	ADJ	B
C-reactive	O	ADJ	I
protein	O	NOUN	I
(	O	PUNCT	O
CRP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
exercise-induced	O	ADJ	B
ischemia	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cardiac	I-P	ADJ	B
syndrome	I-P	NOUN	I
X	I-P	NOUN	I
(	I-P	PUNCT	O
CSX	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Thirty-six	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
CSX	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
1200	O	NUM	O
mg/d	O	NOUN	O
of	O	ADP	O
Xuezhikang	B-I	NOUN	B
or	O	CCONJ	O
placebo	B-I	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
n=18	O	NOUN	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Blood	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
drawn	O	VERB	O
at	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
and	O	CCONJ	O
day	O	NOUN	B
90	O	NUM	O
for	O	ADP	O
measuring	O	VERB	B
above	O	ADP	O
parameters	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
treadmill	O	NOUN	B
exercise	O	NOUN	B
tests	O	NOUN	I
and	O	CCONJ	O
subjective	O	ADJ	B
feelings	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
assessed	O	VERB	B
at	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
and	O	CCONJ	O
day	O	NOUN	B
90	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
Xuezhikang	B-I	NOUN	B
therapy	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
significant	O	ADJ	O
reductions	O	NOUN	B
in	O	ADP	O
total	B-OUT	ADJ	B
cholesterol	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
TC	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
19	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
low-density	I-OUT	ADJ	B
lipoprotein	I-OUT	NOUN	I
cholesterol	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
LDL-C	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
26	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
triglycerides	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
TG	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
16	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.01	O	NUM	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
also	O	ADV	O
showed	O	VERB	O
that	O	SCONJ	O
Xuezhikang	B-I	NOUN	B
led	O	VERB	O
significantly	O	ADV	O
to	O	PART	O
reductions	B-OUT	NOUN	B
in	I-OUT	ADP	O
median	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
log-CRP	I-OUT	NOUN	B
levels	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
38	I-OUT	NUM	O
%	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
44	I-OUT	NUM	O
%	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
p	I-OUT	X	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
respectively	I-OUT	ADV	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
IL-6	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
20	I-OUT	NUM	O
%	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
p	I-OUT	X	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
ET-1	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
47	I-OUT	NUM	O
%	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
p	I-OUT	X	O
<	I-OUT	X	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
exercise	O	NOUN	B
duration	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
time	B-OUT	NOUN	O
to	I-OUT	ADP	O
1	I-OUT	NUM	O
mm	I-OUT	NOUN	O
ST-segment	I-OUT	ADJ	B
depression	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
prolonged	O	ADJ	B
after	O	ADP	O
Xuezhikang	B-I	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0.05	O	NUM	O
respectively	O	ADV	O
)	O	PUNCT	O
accompanied	O	VERB	O
by	O	ADP	O
improvement	B-OUT	NOUN	B
of	I-OUT	ADP	O
subjective	I-OUT	ADJ	B
feelings	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Data	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
Xuezhikang	B-I	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
significant	O	ADJ	O
modification	O	NOUN	B
vascular	B-OUT	ADJ	B
function	I-OUT	NOUN	I
by	O	ADP	O
reduction	O	NOUN	B
of	O	ADP	O
ET-1	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
inflammatory	I-OUT	ADJ	B
markers	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
LDL	I-OUT	NOUN	B
cholesterol	I-OUT	NOUN	I
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
clinically	O	ADV	B
important	O	ADJ	O
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
CSX	I-P	NOUN	B
.	I-P	PUNCT	O


Evaluating	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
peer	B-I	NOUN	B
,	I-I	PUNCT	O
nurse	I-I	ADJ	B
case-managed	I-I	ADJ	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
standard	I-I	ADJ	B
HIV	I-I	NOUN	B
risk-reduction	I-I	ADJ	B
programs	I-I	NOUN	I
on	O	ADP	O
psychosocial	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
health-promoting	I-OUT	ADJ	B
behavioral	I-OUT	ADJ	B
outcomes	I-OUT	NOUN	B
among	O	ADP	O
homeless	B-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


Investigators	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
6-month	O	ADJ	O
impact	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
cognitive-behavioral	B-I	ADJ	B
HIV	I-I	NOUN	I
risk-reduction	I-I	ADJ	B
programs	I-I	NOUN	I
on	O	ADP	O
behavioral	B-OUT	ADJ	B
factors	I-OUT	NOUN	I
(	O	PUNCT	O
substance	O	NOUN	B
use	O	NOUN	I
and	O	CCONJ	O
sexual	O	ADJ	B
risk	O	NOUN	I
behaviors	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
cognitive	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
psychological	I-OUT	ADJ	B
resources	I-OUT	NOUN	B
of	O	ADP	O
325	B-P	NUM	O
women	I-P	NOUN	B
who	I-P	PRON	O
resided	I-P	VERB	O
in	I-P	ADP	O
emergency	I-P	NOUN	B
or	I-P	CCONJ	O
sober-living	I-P	ADJ	B
shelters	I-P	NOUN	I
and	I-P	CCONJ	O
their	I-P	PRON	O
308	I-P	NUM	O
intimate	I-P	ADJ	B
sexual	I-P	ADJ	I
partners	I-P	NOUN	I
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
by	O	ADP	O
shelter	O	NOUN	B
to	O	ADP	O
a	O	DET	O
peer-mentored	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
a	I-OUT	DET	O
nurse	I-OUT	NOUN	B
case-managed	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
a	I-OUT	DET	O
standard	I-OUT	ADJ	B
care	I-OUT	NOUN	I
HIV	I-OUT	NOUN	B
risk-reduction	I-OUT	ADJ	B
program	I-I	NOUN	I
.	I-I	PUNCT	O


Significant	O	ADJ	O
improvements	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
all	O	DET	O
behavioral	B-OUT	ADJ	B
factors	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
cognitive	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
psychological	I-OUT	ADJ	B
resources	I-OUT	NOUN	O
except	O	SCONJ	O
for	O	ADP	O
self-esteem	B-OUT	ADJ	B
.	I-OUT	PUNCT	O


Participants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
peer-mentored	B-I	ADJ	B
and	I-I	CCONJ	O
nurse	I-I	ADJ	B
case-managed	I-I	ADJ	B
groups	O	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
from	O	ADP	O
the	O	DET	O
standard	B-I	ADJ	B
group	I-I	NOUN	I
in	O	ADP	O
self-esteem	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
life	I-OUT	NOUN	B
satisfaction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
psychological	I-OUT	ADJ	B
well-being	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
use	I-OUT	NOUN	O
of	I-OUT	ADP	O
noninjection	I-OUT	NOUN	B
drugs	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
sex	I-OUT	NOUN	B
with	I-OUT	ADP	O
multiple	I-OUT	ADJ	O
partners	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
unprotected	I-OUT	ADJ	B
sex	I-OUT	NOUN	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
633	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
standard	O	ADJ	B
approach	O	NOUN	I
by	O	ADP	O
health	O	NOUN	B
care	O	NOUN	I
professionals	O	NOUN	I
appears	O	VERB	O
to	O	PART	O
effectively	O	ADV	O
modify	B-OUT	VERB	B
HIV	I-OUT	NOUN	B
risk	I-OUT	NOUN	B
behaviors	I-OUT	NOUN	I
for	O	ADP	O
a	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
homeless	B-P	ADJ	B
participants	I-P	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
have	O	AUX	O
important	O	ADJ	O
economic	O	ADJ	B
and	O	CCONJ	O
policy	O	NOUN	B
implications	O	NOUN	B
.	O	PUNCT	O


Further	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
short-term	O	ADJ	B
programs	O	NOUN	B
that	O	PRON	O
address	O	VERB	O
psychological	O	ADJ	B
vulnerabilities	O	NOUN	B
of	O	ADP	O
impoverished	B-P	ADJ	B
populations	I-P	NOUN	I
needs	O	VERB	O
to	O	PART	O
be	O	AUX	O
studied	O	VERB	O
further	O	ADV	O
.	O	PUNCT	O


Evaluation	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
pharmacodynamics	O	NOUN	B
of	O	ADP	O
acetylsalicylic	O	ADJ	B
acid	O	NOUN	I
81	O	NUM	O
mg	O	NOUN	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
esomeprazole	O	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
healthy	B-P	ADJ	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
pharmacokinetic	B-OUT	ADJ	B
interaction	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
proton	O	NOUN	B
pump	O	NOUN	I
inhibitor	O	NOUN	I
esomeprazole	O	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
acetylsalicylic	O	ADJ	B
acid	O	NOUN	I
(	O	PUNCT	O
aspirin	O	NOUN	B
,	O	PUNCT	O
ASA	O	NOUN	B
;	O	PUNCT	O
325	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
has	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
established	O	VERB	O
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
set	O	VERB	O
out	O	ADP	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
pharmacodynamic	B-OUT	ADJ	B
interaction	I-OUT	NOUN	B
between	O	ADP	O
low-dose	O	ADJ	B
ASA	O	NOUN	B
and	O	CCONJ	O
esomeprazole	O	NOUN	B
in	O	ADP	O
healthy	B-P	ADJ	B
volunteers	I-P	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
measuring	O	VERB	B
ASA	O	NOUN	B
antiplatelet	B-OUT	NOUN	B
activity	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
single-center	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
two-period	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
crossover	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	VERB	O
Healthy	B-P	ADJ	B
male	I-P	NOUN	B
and	I-P	CCONJ	O
female	I-P	ADJ	B
volunteers	I-P	NOUN	I
aged	I-P	ADJ	O
18-75	I-P	NUM	O
years	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
.	I-P	PUNCT	O


All	B-I	DET	O
volunteers	I-I	NOUN	B
received	I-I	VERB	O
ASA	I-I	NOUN	B
81	I-I	NUM	O
mg	I-I	NOUN	O
once	I-I	ADV	B
daily	I-I	ADV	I
for	I-I	ADP	O
5	I-I	NUM	O
days	I-I	NOUN	B
prior	I-I	ADV	O
to	I-I	PART	O
the	I-I	DET	O
study	I-I	NOUN	B
(	I-I	PUNCT	O
pre-screen	I-I	ADJ	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Subjects	B-P	NOUN	B
were	I-P	AUX	O
eligible	I-P	ADJ	O
for	I-P	ADP	O
inclusion	I-P	NOUN	B
if	I-P	SCONJ	O
they	I-P	PRON	O
had	I-P	AUX	O
aspirin	I-OUT	NOUN	B
reactivity	I-OUT	NOUN	O
units	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
ARU	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
as	I-OUT	ADP	O
measured	I-OUT	VERB	B
by	I-OUT	ADP	O
the	I-OUT	DET	O
VerifyNow	I-OUT	PROPN	B
ASA	I-OUT	NOUN	I
assay	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
of	I-P	ADP	O
<	I-P	X	O
550	I-P	NUM	O
on	I-P	ADP	O
Day	I-P	PROPN	B
6	I-P	NUM	O
.	I-P	PUNCT	O


INTERVENTION	O	NOUN	B
After	B-I	ADP	O
pre-screening	I-I	ADJ	B
and	I-I	CCONJ	O
a	I-I	DET	O
washout	I-I	NOUN	O
period	I-I	NOUN	B
of	I-I	ADP	O
at	I-I	ADP	O
least	I-I	ADV	O
14	I-I	NUM	O
days	I-I	NOUN	B
,	I-I	PUNCT	O
eligible	I-I	ADJ	B
volunteers	I-I	NOUN	B
received	I-I	VERB	O
ASA	I-I	NOUN	B
81	I-I	NUM	O
mg	I-I	NOUN	O
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
esomeprazole	I-I	NOUN	B
20	I-I	NUM	O
mg	I-I	NOUN	O
once	I-I	ADV	B
daily	I-I	ADV	I
for	I-I	ADP	O
5	I-I	NUM	O
days	I-I	NOUN	B
in	I-I	ADP	O
randomized	I-I	ADJ	B
order	I-I	NOUN	O
,	I-I	PUNCT	O
with	I-I	ADP	O
a	I-I	DET	O
14-day	I-I	ADJ	O
washout	I-I	NOUN	O
between	I-I	ADP	O
treatments	I-I	NOUN	B
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	X	O
MEASURE	O	NOUN	O
The	O	DET	O
main	O	ADJ	O
outcome	O	NOUN	B
measure	O	NOUN	I
was	O	AUX	O
the	O	DET	O
antiplatelet	B-OUT	NOUN	B
activity	I-OUT	NOUN	O
of	I-OUT	ADP	O
ASA	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
as	I-OUT	ADP	O
assessed	I-OUT	VERB	B
by	I-OUT	ADP	O
ARU	I-OUT	NOUN	B
ratio	I-OUT	NOUN	B
relative	I-OUT	ADJ	O
to	I-OUT	PART	O
baseline	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
VerifyNow	I-OUT	PROPN	B
ASA	I-OUT	NOUN	I
assay	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
suppression	I-OUT	NOUN	B
of	I-OUT	ADP	O
serum	I-OUT	NOUN	B
thromboxane	I-OUT	NOUN	I
B	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
TXB	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
was	O	AUX	O
a	O	DET	O
secondary	O	ADJ	B
endpoint	O	NOUN	I
.	O	PUNCT	O


Statistical	O	ADJ	B
comparisons	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
using	O	VERB	O
linear	O	ADJ	B
mixed	O	ADJ	I
models	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
29	I-P	NUM	O
volunteers	I-P	NOUN	B
(	I-P	PUNCT	O
19	I-P	NUM	O
aged	I-P	ADJ	B
≥50	I-P	ADJ	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
8	I-P	NUM	O
women	I-P	NOUN	B
;	I-P	PUNCT	O
21	I-P	NUM	O
men	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
evaluable	I-P	ADJ	O
for	O	ADP	O
pharmacodynamic	O	ADJ	B
analysis	O	NOUN	I
(	O	PUNCT	O
per	O	ADP	O
protocol	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
volunteers	O	NOUN	B
on	O	ADP	O
both	O	DET	O
treatments	O	NOUN	B
achieved	B-OUT	VERB	O
ARU	I-OUT	PROPN	B
<	O	X	O
550	O	NUM	O
at	O	ADP	O
Day	O	PROPN	B
6	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
geometric	O	ADJ	B
mean	O	NOUN	I
ratio	O	NOUN	I
of	O	ADP	O
Day	O	NOUN	O
6	O	NUM	O
to	O	PART	O
Day	O	PROPN	O
1	O	NUM	O
(	B-OUT	PUNCT	O
baseline	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
platelet	I-OUT	NOUN	B
aggregation	I-OUT	NOUN	I
was	O	AUX	O
0.70	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
0.68	O	NUM	O
,	O	PUNCT	O
0.72	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
ASA	O	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
0.71	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.69	O	NUM	O
,	O	PUNCT	O
0.74	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
ASA	O	NOUN	B
+	O	CCONJ	O
esomeprazole	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ratio	O	NOUN	B
of	B-OUT	ADP	O
platelet	I-OUT	NOUN	O
aggregation	I-OUT	NOUN	O
(	O	PUNCT	O
ASA	O	NOUN	B
+	O	CCONJ	O
esomeprazole/ASA	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
1.02	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.99	O	NUM	O
,	O	PUNCT	O
1.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


ASA	O	NOUN	B
administered	O	VERB	B
alone	O	ADV	O
or	O	CCONJ	O
with	O	ADP	O
esomeprazole	O	NOUN	B
reduced	B-OUT	VERB	B
serum	I-OUT	NOUN	B
TXB	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
by	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
99.5	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
suppression	O	NOUN	B
of	B-OUT	ADP	O
serum	I-OUT	NOUN	B
TXB	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
(	O	PUNCT	O
ASA	O	NOUN	B
+	O	CCONJ	O
esomeprazole/ASA	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
1.06	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	PROPN	B
0.88	O	NUM	O
,	O	PUNCT	O
1.29	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
ASA	O	NOUN	B
and	O	CCONJ	O
esomeprazole	O	NOUN	B
was	O	AUX	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
No	B-OUT	DET	O
pharmacodynamic	I-OUT	ADJ	B
interaction	I-OUT	NOUN	B
between	O	ADP	O
low-dose	O	ADJ	B
ASA	O	NOUN	B
and	O	CCONJ	O
esomeprazole	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
with	O	ADP	O
regard	O	NOUN	O
to	B-OUT	PART	O
platelet	I-OUT	NOUN	B
function	I-OUT	NOUN	I
.	O	PUNCT	O


TRIAL	O	NOUN	B
REGISTRATION	O	NOUN	I
Registered	O	VERB	O
at	O	ADP	O
ClinicalTrials	O	PROPN	B
.	O	PUNCT	O


gov	O	NOUN	O
as	O	ADP	O
NCT01199328	O	PROPN	O
.	O	PUNCT	O


Immunotherapy	B-I	NOUN	B
using	O	VERB	O
BCG	B-I	NOUN	B
during	O	ADP	O
remission	O	NOUN	B
induction	O	NOUN	B
and	O	CCONJ	O
as	O	ADP	O
the	O	DET	O
sole	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
maintenance	O	NOUN	B
in	O	ADP	O
acute	B-P	ADJ	B
myeloid	I-P	ADJ	I
leukaemia	I-P	NOUN	I
.	I-P	PUNCT	O


Thirty-two	B-P	NUM	O
adults	I-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
myeloid	I-P	ADJ	I
leukaemia	I-P	NOUN	I
(	I-P	PUNCT	O
AML	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
,	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
either	O	CCONJ	O
chemotherapy	B-I	NOUN	B
alone	I-I	ADV	O
(	O	PUNCT	O
C	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
chemotherapy	B-I	NOUN	B
plus	I-I	CCONJ	O
Bacille	I-I	PROPN	B
Calmette-Guérin	I-I	PROPN	I
vaccine	I-I	NOUN	I
(	I-I	PUNCT	O
BCG	I-I	NOUN	B
)	I-I	PUNCT	O
(	O	PUNCT	O
C+I	O	NOUN	B
group	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
remission	O	NOUN	B
induction	O	NOUN	B
and	O	CCONJ	O
consolidation	O	NOUN	B
,	O	PUNCT	O
chemotherapy	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
but	O	CCONJ	O
BCG	O	NOUN	B
was	O	AUX	O
continued	O	VERB	O
in	O	ADP	O
the	O	DET	O
C+I	O	NOUN	B
group	O	NOUN	B
.	B-OUT	PUNCT	O


The	B-OUT	DET	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
C+I	O	NOUN	B
group	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
significant	B-OUT	ADJ	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
first	I-OUT	ADJ	O
remission	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
C+I	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
0.05	O	NUM	O
less	O	ADJ	O
than	O	ADP	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.1	O	NUM	O
)	O	PUNCT	O
nor	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
time	O	NOUN	B
from	O	ADP	O
first	B-OUT	ADJ	O
relapse	I-OUT	NOUN	B
to	I-OUT	PART	O
death	I-OUT	NOUN	B
(	O	PUNCT	O
0.05	O	NUM	O
less	O	ADJ	O
than	O	ADP	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	B-OUT	DET	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
first	I-OUT	ADJ	O
or	I-OUT	CCONJ	O
second	I-OUT	ADJ	O
remissions	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	B-OUT	DET	O
time	I-OUT	NOUN	B
taken	I-OUT	VERB	O
to	I-OUT	PART	O
enter	I-OUT	VERB	O
remission	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
trials	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
maintenance	O	NOUN	B
chemotherapy	O	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
immunotherapy	O	NOUN	B
produces	O	VERB	O
longer	B-OUT	ADJ	O
remissions	I-OUT	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
C	O	NOUN	B
group	O	NOUN	I
developed	B-OUT	VERB	O
leukaemic	I-OUT	ADJ	B
central-nervous-system	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
CSN	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
involvement	I-OUT	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
none	O	NOUN	O
in	O	ADP	O
the	O	DET	O
C+I	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


CNS	O	NOUN	B
relapse	O	NOUN	B
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	B-OUT	ADP	O
remission	I-OUT	NOUN	B
length	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
0.1	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
reduction	O	NOUN	B
in	B-OUT	ADP	O
survival	I-OUT	NOUN	B
after	I-OUT	ADP	O
CNS	I-OUT	NOUN	B
relapse	I-OUT	NOUN	B
was	O	AUX	O
highly	O	ADV	O
significant	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
administration	O	NOUN	B
of	B-I	ADP	O
BCG	I-I	NOUN	B
from	O	ADP	O
an	O	DET	O
early	O	ADJ	B
stage	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
AML	O	NOUN	B
may	B-OUT	AUX	O
protect	I-OUT	VERB	O
the	I-OUT	DET	O
CNS	I-OUT	NOUN	B
against	I-OUT	ADP	O
leukaemic	I-OUT	ADJ	B
infiltration	I-OUT	NOUN	I
and	O	CCONJ	O
therefore	O	ADV	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
,	O	PUNCT	O
innocuous	O	ADJ	B
form	O	NOUN	O
of	B-OUT	ADP	O
CNS	I-OUT	NOUN	B
prophylaxis	I-OUT	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
intranasal	O	ADJ	B
beclomethasone	B-I	NOUN	B
dipropionate	I-I	NOUN	I
after	O	ADP	O
polypectomy	O	NOUN	B
.	O	PUNCT	O


Beneficial	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
intranasal	B-I	ADJ	B
beclomethasone	I-I	NOUN	O
dipropionate	I-I	NOUN	O
(	I-I	PUNCT	O
Bdp	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
nasal	I-P	ADJ	B
polyposis	I-P	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
earlier	O	ADV	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
long-term	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
Bdp	B-I	NOUN	B
after	O	ADP	O
polypectomy	O	NOUN	B
could	O	AUX	O
prevent	O	VERB	B
formation	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
polyps	O	NOUN	B
and	O	CCONJ	O
reduce	O	VERB	B
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
surgical	O	ADJ	B
removals	O	NOUN	B
.	O	PUNCT	O


Forty	B-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
without	I-P	ADP	O
laboratory	I-P	NOUN	B
or	I-P	CCONJ	O
other	I-P	ADJ	O
clinical	I-P	ADJ	B
signs	I-P	NOUN	O
of	I-P	ADP	O
allergy	I-P	NOUN	B
but	I-P	CCONJ	O
with	I-P	ADP	O
severe	I-P	ADJ	B
nasal	I-P	ADJ	B
polyposis	I-P	NOUN	I
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Twenty	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
treated	I-P	VERB	B
with	I-P	ADP	I
intranasal	I-I	ADJ	B
Bdp	I-I	NOUN	B
and	I-P	CCONJ	O
twenty	I-P	NUM	O
patients	I-P	NOUN	B
received	I-P	VERB	O
no	I-P	DET	B
treatment	I-P	NOUN	I
after	I-P	ADP	O
polypectomy	I-I	NOUN	B
.	I-I	PUNCT	O


All	O	DET	O
patients	B-P	NOUN	B
were	I-P	AUX	O
followed	I-P	VERB	O
for	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADJ	O
2.5	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
size	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
polyps	I-OUT	NOUN	B
that	I-OUT	PRON	O
recurred	I-OUT	VERB	B
was	O	AUX	O
estimated	O	VERB	B
at	O	ADP	O
different	O	ADJ	O
time-intervals	O	NOUN	B
by	O	ADP	O
the	O	DET	O
examining	O	VERB	B
doctor	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
already	O	ADV	O
a	O	DET	O
significant	B-OUT	ADJ	O
difference	I-OUT	NOUN	O
in	O	ADP	O
favour	O	NOUN	O
of	O	ADP	O
the	O	DET	O
group	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
intranasal	O	ADJ	B
Bdp	B-I	NOUN	B
.	I-I	PUNCT	O


Further	O	ADJ	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
clinical	O	ADJ	B
implications	O	NOUN	O
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
telephone	B-I	NOUN	B
call	I-I	NOUN	O
interventions	I-I	NOUN	B
on	O	ADP	O
patients	B-P	NOUN	B
'	I-P	PART	O
well-being	I-P	NOUN	B
in	I-P	ADP	O
a	I-P	DET	O
radiation	I-P	NOUN	B
therapy	I-P	NOUN	I
department	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
telephone	B-I	NOUN	B
call	I-I	NOUN	O
interventions	I-I	NOUN	B
by	O	ADP	O
a	O	DET	O
collaborative	O	ADJ	B
team	O	NOUN	B
on	O	ADP	O
patients	B-P	NOUN	B
'	I-P	PART	O
well-being	I-P	NOUN	B
.	I-P	PUNCT	O


Fifty-five	B-P	ADJ	B
subjects	I-P	NOUN	I
undergoing	I-P	VERB	O
radiation	I-P	NOUN	B
therapy	I-P	NOUN	I
for	I-P	ADP	O
cure	I-P	NOUN	B
and	I-P	CCONJ	O
who	I-P	PRON	O
were	I-P	AUX	O
able	I-P	ADJ	O
to	I-P	PART	O
communicate	I-P	VERB	O
by	I-P	ADP	O
telephone	I-P	NOUN	B
comprised	I-P	VERB	O
the	I-P	DET	O
sample	I-P	NOUN	B
.	I-P	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
control	B-I	ADJ	B
group	I-I	NOUN	I
,	I-I	PUNCT	O
who	I-I	PRON	O
received	I-I	VERB	O
the	I-I	DET	O
usual	I-I	ADJ	B
care	I-I	NOUN	I
or	I-I	CCONJ	O
to	I-I	ADP	O
an	I-I	DET	O
experimental	I-I	ADJ	B
group	I-I	NOUN	I
,	I-I	PUNCT	O
who	I-I	PRON	O
received	I-I	VERB	O
a	I-I	DET	O
weekly	I-I	ADJ	B
telephone	I-I	NOUN	B
call	I-I	NOUN	O
intervention	I-I	NOUN	B
in	I-I	ADP	O
addition	I-I	NOUN	O
to	I-I	PART	O
the	I-I	DET	O
usual	I-I	ADJ	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


Speilberger	B-OUT	PROPN	B
's	I-OUT	PART	I
State	I-OUT	PROPN	B
Trait	I-OUT	PROPN	I
Inventory	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
Side	I-OUT	ADJ	B
Effects	I-OUT	PROPN	I
Profile	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
Coping	I-OUT	NOUN	B
Strategies	I-OUT	PROPN	I
Profile	I-OUT	PROPN	I
were	O	AUX	O
used	O	VERB	O
along	O	ADP	O
with	O	ADP	O
a	O	DET	O
telephone	O	NOUN	B
survey	O	NOUN	I
to	O	PART	O
collect	O	VERB	O
data	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
data	O	NOUN	B
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
in	O	ADP	O
anxiety	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
helpfulness	I-OUT	NOUN	B
of	I-OUT	ADP	O
self-care	I-OUT	ADJ	B
strategies	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
coping	I-OUT	VERB	B
strategies	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
survey	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
telephone	O	NOUN	B
calls	O	NOUN	O
were	O	AUX	O
clinically	B-OUT	ADV	B
significant	I-OUT	ADJ	I
and	O	CCONJ	O
provided	O	VERB	O
a	O	DET	O
mechanism	O	NOUN	B
for	O	ADP	O
demonstrating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
health	O	NOUN	B
care	O	NOUN	I
professionals	O	NOUN	I
cared	O	VERB	B
about	O	ADP	O
their	O	PRON	O
patients	O	NOUN	B
and	O	CCONJ	O
provided	O	VERB	O
an	O	DET	O
opportunity	O	NOUN	O
for	O	ADP	O
patients	O	NOUN	B
to	O	PART	O
talk	O	VERB	O
about	O	ADP	O
their	O	PRON	O
concerns	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
investigators	O	NOUN	B
believe	O	VERB	O
that	O	SCONJ	O
collaboration	O	NOUN	B
,	O	PUNCT	O
caring	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
communication	O	NOUN	B
are	O	AUX	O
the	O	DET	O
essence	O	NOUN	O
of	O	ADP	O
exemplary	O	ADJ	B
health	O	NOUN	B
care	O	NOUN	I
.	O	PUNCT	O


Comparing	O	VERB	O
two	O	NUM	O
web-based	B-P	ADJ	B
smoking	I-OUT	NOUN	I
cessation	I-OUT	NOUN	I
programs	I-P	NOUN	I
:	I-P	PUNCT	O
randomized	O	VERB	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Smoking	B-OUT	NOUN	B
cessation	I-OUT	NOUN	B
remains	O	VERB	O
a	O	DET	O
significant	O	ADJ	B
public	O	ADJ	B
health	O	NOUN	I
problem	O	NOUN	O
.	O	PUNCT	O


Innovative	O	ADJ	B
interventions	O	NOUN	I
that	O	PRON	O
use	O	VERB	O
the	O	DET	O
Internet	O	NOUN	B
have	O	AUX	O
begun	O	VERB	O
to	O	PART	O
emerge	O	VERB	O
that	O	SCONJ	O
offer	O	VERB	O
great	O	ADJ	O
promise	O	NOUN	O
in	O	ADP	O
reaching	O	VERB	O
large	O	ADJ	O
numbers	O	NOUN	O
of	O	ADP	O
participants	O	NOUN	B
and	O	CCONJ	O
encouraging	O	VERB	O
widespread	O	ADJ	B
behavior	O	NOUN	B
change	O	NOUN	I
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
relatively	O	ADV	O
few	O	ADJ	O
controlled	O	VERB	B
trials	O	NOUN	I
of	O	ADP	O
Web-based	O	ADJ	B
smoking	B-OUT	NOUN	I
cessation	I-OUT	NOUN	I
programs	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
limited	O	VERB	O
by	O	ADP	O
short	O	ADJ	B
follow-up	O	ADJ	I
intervals	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
6-month	O	ADJ	O
follow-up	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
in	O	ADP	O
which	O	DET	O
participants	B-P	NOUN	B
recruited	I-P	VERB	O
online	I-P	ADV	O
were	O	AUX	O
randomly	B-I	ADV	O
assigned	I-I	VERB	O
to	I-I	PART	O
either	I-I	CCONJ	O
a	I-I	DET	O
Web-based	I-I	ADJ	B
smoking	I-OUT	NOUN	I
cessation	I-OUT	NOUN	I
program	I-I	NOUN	I
(	I-I	PUNCT	O
Quit	I-I	PROPN	B
Smoking	I-I	PROPN	I
Network	I-I	PROPN	I
;	I-I	PUNCT	O
QSN	I-I	PROPN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
Web-based	I-I	ADJ	B
exercise	I-I	NOUN	I
enhancement	I-I	NOUN	I
program	I-I	NOUN	I
(	I-I	PUNCT	O
Active	I-I	ADJ	B
Lives	I-I	NOUN	I
)	I-I	PUNCT	O
adapted	I-I	VERB	O
somewhat	I-I	ADV	O
to	I-I	PART	O
encourage	I-I	VERB	O
smoking	I-I	NOUN	B
cessation	I-I	NOUN	I
.	I-I	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
two-arm	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
that	O	PRON	O
compared	O	VERB	B
two	B-I	NUM	O
Web-based	I-I	ADJ	B
smoking	I-OUT	NOUN	I
cessation	I-OUT	NOUN	I
programs	I-I	NOUN	I
:	I-I	PUNCT	O
(	I-I	PUNCT	O
1	I-I	X	O
)	I-I	PUNCT	O
the	I-I	DET	O
QSN	I-I	NOUN	B
intervention	I-I	NOUN	B
condition	I-I	NOUN	I
presented	I-I	VERB	O
cognitive-behavioral	I-I	ADJ	B
strategies	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
(	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
the	I-I	DET	O
Active	I-I	ADJ	B
Lives	I-I	NOUN	I
control	I-I	NOUN	O
condition	I-I	NOUN	O
provided	I-I	VERB	O
participants	I-I	NOUN	B
with	I-I	ADP	O
guidance	I-I	NOUN	B
in	I-I	ADP	O
developing	I-I	VERB	O
a	I-I	DET	O
physical	I-I	ADJ	B
activity	I-I	NOUN	I
program	I-I	NOUN	I
to	I-I	PART	O
assist	I-I	VERB	O
them	I-I	PRON	O
with	I-I	ADP	O
quitting	I-I	NOUN	B
.	I-I	PUNCT	O


The	B-I	DET	O
QSN	I-I	PROPN	B
condition	I-I	NOUN	B
provided	I-I	VERB	O
smoking	I-I	NOUN	B
cessation	I-I	NOUN	B
information	I-I	NOUN	B
and	I-I	CCONJ	O
behavior	I-I	NOUN	B
change	I-I	NOUN	I
strategies	I-I	NOUN	B
while	I-I	SCONJ	O
the	I-I	DET	O
Active	I-I	PROPN	B
Lives	I-I	NOUN	I
condition	I-I	NOUN	O
provided	I-I	VERB	O
participants	I-I	NOUN	B
with	I-I	ADP	O
physical	I-I	ADJ	B
activity	I-I	NOUN	I
recommendations	I-I	NOUN	B
and	I-I	CCONJ	O
goal	I-I	NOUN	B
setting	I-I	NOUN	O
.	I-I	PUNCT	O


The	B-I	DET	O
QSN	I-I	PROPN	B
condition	I-I	NOUN	B
was	I-I	AUX	O
designed	I-I	VERB	O
to	I-I	PART	O
be	I-I	AUX	O
more	I-I	ADV	O
engaging	I-I	ADJ	B
(	I-I	PUNCT	O
eg	I-I	ADP	O
,	I-I	PUNCT	O
it	I-I	PRON	O
included	I-I	VERB	O
multimedia	I-I	NOUN	B
components	I-I	NOUN	I
)	I-I	PUNCT	O
and	I-I	CCONJ	O
to	I-I	PART	O
present	I-I	VERB	O
much	I-I	ADV	O
greater	I-I	ADJ	O
content	I-I	NOUN	B
than	I-I	ADP	O
is	I-I	AUX	O
typically	I-I	ADV	O
found	I-I	VERB	O
in	I-I	ADP	O
smoking	I-I	NOUN	B
cessation	I-I	NOUN	I
programs	I-I	NOUN	I
.	I-I	PUNCT	O


RESULTS	O	NOUN	B
Contrary	O	ADV	O
to	O	ADP	O
our	O	PRON	O
hypotheses	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
between-condition	O	ADJ	B
differences	O	NOUN	O
in	O	ADP	O
smoking	B-OUT	NOUN	B
abstinence	I-OUT	NOUN	B
were	O	AUX	O
found	O	VERB	O
at	O	ADP	O
3-	O	NUM	O
and	O	CCONJ	O
6-month	O	ADJ	O
follow-up	O	ADJ	B
assessments	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
participants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
QSN	O	PROPN	B
intervention	O	NOUN	B
condition	O	NOUN	I
spent	O	VERB	O
more	O	ADJ	O
time	O	NOUN	O
than	O	ADP	O
controls	O	NOUN	B
visiting	O	VERB	B
the	O	DET	O
online	O	ADJ	B
program	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
median	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
1.0	O	NUM	O
visit	O	NOUN	B
in	O	ADP	O
each	O	DET	O
condition	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
substantial	O	ADJ	B
attrition	O	NOUN	I
(	O	PUNCT	O
60.8	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
the	O	DET	O
6-month	O	ADJ	O
follow-up	O	NOUN	B
)	O	PUNCT	O
indicate	O	VERB	O
that	O	SCONJ	O
participants	O	NOUN	B
were	O	AUX	O
not	O	PART	O
as	O	ADV	O
engaged	O	VERB	O
as	O	ADP	O
we	O	PRON	O
had	O	AUX	O
expected	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Contrary	O	VERB	O
to	O	ADP	O
our	O	PRON	O
hypothesis	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
test	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
Web-based	O	ADJ	B
smoking	B-OUT	NOUN	I
cessation	I-OUT	NOUN	B
conditions	O	NOUN	O
,	O	PUNCT	O
an	O	DET	O
intervention	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
attention	O	NOUN	O
placebo	O	NOUN	B
control	O	NOUN	O
,	O	PUNCT	O
failed	O	VERB	B
to	O	PART	O
show	O	VERB	O
differences	O	NOUN	B
at	O	ADP	O
3-	O	NUM	O
and	O	CCONJ	O
6-month	O	ADJ	O
assessments	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
explored	O	VERB	O
possible	O	ADJ	O
reasons	O	NOUN	O
for	O	ADP	O
this	O	DET	O
finding	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
limited	O	ADJ	O
engagement	O	NOUN	B
of	O	ADP	O
participants	O	NOUN	B
and	O	CCONJ	O
simplifying	O	VERB	O
program	O	NOUN	B
content	O	NOUN	B
and	O	CCONJ	O
architecture	O	NOUN	B
.	O	PUNCT	O


Future	O	ADJ	O
research	O	NOUN	B
needs	O	VERB	O
to	O	PART	O
address	O	VERB	O
methods	O	NOUN	B
to	O	PART	O
improve	O	VERB	B
participant	O	NOUN	B
engagement	O	NOUN	B
in	O	ADP	O
online	O	ADJ	B
smoking	O	NOUN	I
cessation	O	NOUN	B
programs	O	NOUN	O
.	O	PUNCT	O


Possible	O	ADJ	O
approaches	O	NOUN	B
in	O	ADP	O
this	O	DET	O
regard	O	NOUN	O
can	O	AUX	O
include	O	VERB	O
new	O	ADJ	O
informed	O	ADJ	O
consent	O	NOUN	O
procedures	O	NOUN	O
that	O	PRON	O
better	O	ADV	O
explain	O	VERB	O
the	O	DET	O
roles	O	NOUN	B
and	O	CCONJ	O
responsibilities	O	NOUN	B
of	O	ADP	O
being	O	AUX	O
a	O	DET	O
research	O	NOUN	B
participant	O	NOUN	I
,	O	PUNCT	O
new	O	ADJ	O
program	O	NOUN	B
designs	O	NOUN	O
that	O	PRON	O
add	O	VERB	O
more	O	ADJ	O
vitality	O	NOUN	B
(	O	PUNCT	O
changing	O	VERB	B
content	O	NOUN	B
from	O	ADP	O
visit	O	NOUN	B
to	O	PART	O
visit	O	VERB	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
new	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
reminders	O	NOUN	B
pushed	O	VERB	O
out	O	ADP	O
to	O	ADP	O
participants	O	NOUN	B
to	O	PART	O
encourage	O	VERB	O
return	O	NOUN	B
visits	O	NOUN	I
.	O	PUNCT	O


Simplifying	O	VERB	B
program	O	NOUN	B
content	O	NOUN	B
through	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
enhanced	O	VERB	B
tailoring	O	NOUN	O
and	O	CCONJ	O
information	O	NOUN	B
architecture	O	NOUN	O
also	O	ADV	O
merits	O	VERB	O
further	O	ADJ	O
research	O	NOUN	B
attention	O	NOUN	O
.	O	PUNCT	O


Stroke	O	ADJ	B
team	O	NOUN	B
remote	O	ADJ	I
evaluation	O	NOUN	B
using	O	VERB	O
a	O	DET	O
digital	O	ADJ	B
observation	O	NOUN	I
camera	O	NOUN	I
in	O	ADP	O
Arizona	B-P	PROPN	B
:	I-P	PUNCT	O
the	O	DET	O
initial	O	ADJ	B
mayo	O	NOUN	B
clinic	O	NOUN	I
experience	O	NOUN	O
trial	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
PURPOSE	O	PROPN	O
Telemedicine	O	NOUN	B
techniques	O	NOUN	O
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
address	O	VERB	O
the	O	DET	O
rural-metropolitan	B-P	ADJ	B
disparity	O	NOUN	I
in	O	ADP	O
acute	O	ADJ	B
stroke	O	NOUN	I
care	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Stroke	O	PROPN	B
Team	O	PROPN	I
Remote	O	PROPN	I
Evaluation	O	PROPN	B
Using	O	VERB	O
a	O	DET	O
Digital	O	PROPN	B
Observation	O	PROPN	I
Camera	O	PROPN	I
(	O	PUNCT	O
STRokE	O	PROPN	O
DOC	O	NOUN	B
)	O	PUNCT	O
trial	O	NOUN	B
reported	O	VERB	O
more	O	ADV	O
accurate	O	ADJ	B
decision	O	NOUN	B
making	O	VERB	I
for	O	ADP	O
telemedicine	B-I	NOUN	B
consultations	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
telephone-only	B-I	ADJ	O
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
California-based	O	ADJ	B
research	O	NOUN	I
network	O	NOUN	I
facilitated	O	VERB	O
a	O	DET	O
high	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
thrombolysis	O	NOUN	B
use	O	NOUN	O
,	O	PUNCT	O
improved	O	VERB	B
data	O	NOUN	B
collection	O	NOUN	I
,	O	PUNCT	O
low	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
complications	O	NOUN	B
,	O	PUNCT	O
low	O	ADJ	B
technical	O	ADJ	B
complications	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
favorable	O	ADJ	O
assessment	O	NOUN	B
times	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
objective	O	NOUN	B
of	O	ADP	O
the	O	DET	O
STRokE	O	PROPN	B
DOC	O	PROPN	I
Arizona	O	PROPN	I
TIME	O	PROPN	I
(	O	PUNCT	O
The	O	DET	O
Initial	O	PROPN	O
Mayo	O	PROPN	B
Clinic	O	PROPN	I
Experience	O	PROPN	O
)	O	PUNCT	O
trial	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
feasibility	O	NOUN	B
of	O	ADP	O
establishing	O	VERB	O
,	O	PUNCT	O
de	O	X	O
novo	O	X	O
,	O	PUNCT	O
a	O	DET	O
single-hub	O	NOUN	B
,	O	PUNCT	O
multirural	O	ADJ	B
spoke	O	VERB	I
hospital	O	NOUN	I
telestroke	O	NOUN	B
research	O	NOUN	B
network	O	NOUN	B
across	O	ADP	O
a	O	DET	O
large	O	ADJ	O
geographical	O	ADJ	B
area	O	NOUN	I
in	O	ADP	O
Arizona	O	PROPN	B
by	O	ADP	O
replicating	O	VERB	B
the	O	DET	O
STRokE	O	ADJ	B
DOC	O	NOUN	B
protocol	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Methods	O	NOUN	O
included	O	VERB	O
prospective	O	ADJ	B
,	O	PUNCT	O
single-hub	O	NOUN	B
,	O	PUNCT	O
2-spoke	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
blinded	O	VERB	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
2-way	O	ADJ	B
,	O	PUNCT	O
site-independent	O	ADJ	B
,	O	PUNCT	O
audiovisual	B-I	ADJ	B
telemedicine	I-I	NOUN	O
system	I-I	NOUN	O
designed	I-I	VERB	O
for	I-I	ADP	O
remote	I-I	ADJ	B
examination	I-I	NOUN	B
of	O	ADP	O
adult	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
acute	I-P	ADJ	B
stroke	I-P	NOUN	I
versus	I-P	CCONJ	O
telephone	I-I	NOUN	B
consultation	I-I	NOUN	I
to	I-I	PART	O
assess	I-I	VERB	O
eligibility	I-I	NOUN	B
for	I-I	ADP	O
treatment	I-I	NOUN	B
with	I-P	ADP	O
intravenous	I-I	ADJ	B
thrombolysis	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
was	O	AUX	O
whether	O	SCONJ	O
the	O	DET	O
decision	B-OUT	NOUN	O
to	I-OUT	PART	O
give	I-OUT	VERB	O
thrombolysis	I-OUT	NOUN	B
was	I-OUT	AUX	O
correct	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


Secondary	O	ADJ	B
outcomes	O	NOUN	I
were	O	AUX	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
thrombolytic	I-OUT	ADJ	B
use	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
90-day	I-OUT	ADJ	O
functional	I-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
intracerebral	I-OUT	ADJ	B
hemorrhages	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
technical	I-OUT	ADJ	B
observations	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
From	B-P	ADP	O
December	I-P	PROPN	O
2007	I-P	NUM	O
to	I-P	ADP	O
October	I-P	PROPN	O
2008	I-P	NUM	O
,	I-P	PUNCT	O
54	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
assessed	I-P	VERB	B
,	O	PUNCT	O
27	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
randomized	O	ADJ	B
to	O	ADP	O
each	O	DET	O
arm	O	NOUN	B
.	O	PUNCT	O


Mean	O	VERB	B
National	O	PROPN	I
Institutes	O	PROPN	I
of	O	ADP	I
Health	O	PROPN	I
Stroke	O	PROPN	I
Scale	O	NOUN	I
score	O	NOUN	I
at	O	ADP	O
presentation	O	NOUN	B
was	O	AUX	O
7.3	O	NUM	O
(	O	PUNCT	O
SD	O	NOUN	B
6.2	O	NUM	O
)	O	PUNCT	O
points	O	NOUN	O
.	O	PUNCT	O


No	O	DET	O
consultations	O	NOUN	O
were	O	AUX	O
aborted	O	VERB	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
technical	B-OUT	ADJ	B
problems	I-OUT	NOUN	I
(	O	PUNCT	O
74	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
prevalent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
telemedicine	O	NOUN	B
arm	O	NOUN	I
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
correct	O	ADJ	B
treatment	B-OUT	NOUN	B
decision	I-OUT	NOUN	B
was	O	AUX	O
established	O	VERB	O
in	O	ADP	O
87	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
consultations	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
modalities	O	NOUN	B
,	O	PUNCT	O
telephone	O	NOUN	B
(	O	PUNCT	O
89	O	NUM	O
%	O	NOUN	O
correct	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
telemedicine	O	NOUN	B
(	O	PUNCT	O
85	O	NUM	O
%	O	NOUN	O
correct	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
performed	O	VERB	O
well	O	ADV	O
.	O	PUNCT	O


Intravenous	O	ADJ	B
thrombolytic	B-I	ADJ	B
treatment	I-I	NOUN	I
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
telemedicine	O	NOUN	B
and	O	CCONJ	O
telephone	O	NOUN	B
consultations	O	NOUN	I
.	O	PUNCT	O


Good	O	ADJ	O
functional	B-OUT	ADJ	O
outcomes	I-OUT	NOUN	B
at	O	ADP	O
90	O	NUM	O
days	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
mortality	B-OUT	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
telemedicine	O	NOUN	B
and	O	CCONJ	O
11	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
telephone	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
intracerebral	I-OUT	ADJ	B
hemorrhage	I-OUT	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
telemedicine	O	NOUN	B
and	O	CCONJ	O
0	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
telephone	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
It	O	PRON	O
is	O	AUX	O
feasible	O	ADJ	O
to	O	PART	O
extend	O	VERB	O
the	O	DET	O
original	O	ADJ	O
STRokE	O	ADJ	B
DOC	O	NOUN	B
trial	O	NOUN	O
protocol	O	NOUN	O
to	O	ADP	O
a	O	DET	O
new	O	ADJ	O
state	O	NOUN	B
and	O	CCONJ	O
establish	O	VERB	O
an	O	DET	O
operational	O	ADJ	B
single-hub	O	NOUN	I
,	O	PUNCT	O
multispoke	O	ADJ	B
rural	O	ADJ	I
hospital	O	NOUN	I
telestroke	O	NOUN	B
research	O	NOUN	B
network	O	NOUN	B
in	O	ADP	O
Arizona	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
not	O	PART	O
designed	O	VERB	O
to	O	PART	O
have	O	AUX	O
sufficient	O	ADJ	O
power	O	NOUN	O
to	O	PART	O
detect	O	VERB	B
a	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
consultative	O	ADJ	B
modes	O	NOUN	I
:	O	PUNCT	O
telemedicine	O	NOUN	B
and	O	CCONJ	O
telephone-only	O	ADV	B
.	O	PUNCT	O


Whether	O	SCONJ	O
by	O	ADP	O
telemedicine	O	NOUN	B
or	O	CCONJ	O
telephone	O	NOUN	B
consultative	O	ADJ	O
modalities	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
appropriate	O	ADJ	O
treatment	B-OUT	NOUN	B
decisions	I-OUT	NOUN	B
,	O	PUNCT	O
high	O	ADJ	O
rates	O	NOUN	B
of	O	ADP	O
thrombolysis	B-OUT	NOUN	B
use	I-OUT	NOUN	O
,	O	PUNCT	O
improved	O	VERB	B
data	B-OUT	NOUN	B
collection	I-OUT	NOUN	I
,	O	PUNCT	O
low	O	ADJ	O
rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
intracerebral	I-OUT	ADJ	B
hemorrhage	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
equally	O	ADV	O
favorable	O	ADJ	B
time	B-OUT	NOUN	O
requirements	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
learning	O	NOUN	B
curve	O	NOUN	I
was	O	AUX	O
steep	O	ADJ	O
for	O	ADP	O
the	O	DET	O
hub	O	NOUN	B
and	O	CCONJ	O
spoke	O	VERB	B
personnel	O	NOUN	B
of	O	ADP	O
the	O	DET	O
new	O	ADJ	O
telestroke	O	NOUN	B
network	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
reflected	O	VERB	O
by	O	ADP	O
frequent	O	ADJ	B
technical	O	ADJ	B
problems	O	NOUN	I
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
highly	O	ADV	O
organized	O	VERB	B
and	O	CCONJ	O
structured	O	ADJ	B
stroke	O	NOUN	B
telemedicine	O	NOUN	B
networks	O	NOUN	O
for	O	ADP	O
extending	O	VERB	O
expert	O	ADJ	B
stroke	O	NOUN	B
care	O	NOUN	I
into	O	ADP	O
rural	B-P	ADJ	B
remote	I-P	ADJ	I
communities	I-P	NOUN	B
lacking	I-P	VERB	B
sufficient	I-P	ADJ	O
neurological	I-P	ADJ	B
expertise	I-P	NOUN	I
.	I-P	PUNCT	O


Atrial	B-I	ADJ	B
fibrillation	I-I	NOUN	I
catheter	I-I	NOUN	B
ablation	I-I	NOUN	I
versus	I-I	CCONJ	O
surgical	I-I	ADJ	B
ablation	I-I	NOUN	I
treatment	I-I	NOUN	I
(	I-I	PUNCT	O
FAST	I-I	NOUN	B
)	I-I	PUNCT	O
:	I-I	PUNCT	O
a	O	DET	O
2-center	O	ADJ	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Catheter	B-I	PROPN	B
ablation	I-I	NOUN	I
(	I-I	PUNCT	O
CA	I-I	PROPN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
minimally	B-I	ADV	B
invasive	I-I	ADJ	I
surgical	I-I	ADJ	I
ablation	I-I	NOUN	I
(	I-I	PUNCT	O
SA	I-I	PROPN	B
)	I-I	PUNCT	O
have	O	AUX	O
become	O	VERB	O
accepted	O	VERB	O
therapy	O	NOUN	B
for	O	ADP	O
antiarrhythmic	O	ADJ	B
drug-refractory	O	ADJ	I
atrial	O	ADJ	I
fibrillation	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
describes	O	VERB	O
the	O	DET	O
first	O	ADJ	O
randomized	O	ADJ	B
clinical	O	ADJ	O
trial	O	NOUN	O
comparing	O	VERB	B
their	O	PRON	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
during	O	ADP	O
a	O	DET	O
12-month	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	VERB	O
One	B-P	NUM	O
hundred	I-P	NUM	O
twenty-four	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
antiarrhythmic	I-P	ADJ	B
drug-refractory	I-P	ADJ	I
atrial	I-P	ADJ	I
fibrillation	I-P	NOUN	I
with	I-P	ADP	O
left	I-P	ADJ	B
atrial	I-P	ADJ	I
dilatation	I-P	NOUN	I
and	I-P	CCONJ	O
hypertension	I-P	NOUN	B
(	I-P	PUNCT	O
42	I-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
33	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
failed	I-P	VERB	B
prior	I-P	ADJ	O
CA	I-I	PROPN	B
(	I-P	PUNCT	O
82	I-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
67	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
CA	B-I	PROPN	B
(	O	PUNCT	O
63	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
SA	B-I	PROPN	B
(	O	PUNCT	O
61	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CA	B-I	PROPN	B
consisted	O	VERB	O
of	O	ADP	O
linear	O	ADJ	B
antral	O	ADJ	I
pulmonary	O	ADJ	I
vein	O	NOUN	I
isolation	O	NOUN	B
and	O	CCONJ	O
optional	O	ADJ	O
additional	O	ADJ	O
lines	O	NOUN	O
.	O	PUNCT	O


SA	B-I	PROPN	B
consisted	O	VERB	O
of	O	ADP	O
bipolar	O	ADJ	B
radiofrequency	O	NOUN	I
isolation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
bilateral	O	ADJ	B
pulmonary	O	ADJ	I
vein	O	NOUN	I
,	O	PUNCT	O
ganglionated	O	VERB	B
plexi	O	NOUN	I
ablation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
left	O	VERB	B
atrial	O	ADJ	I
appendage	O	NOUN	I
excision	O	NOUN	I
with	O	ADP	O
optional	O	ADJ	O
additional	O	ADJ	O
lines	O	NOUN	O
.	O	PUNCT	O


Follow-up	O	X	B
at	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
by	O	ADP	O
ECG	O	PROPN	B
and	O	CCONJ	O
7-day	O	ADJ	O
Holter	O	PROPN	B
recording	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
,	O	PUNCT	O
freedom	O	NOUN	B
from	O	ADP	O
left	O	VERB	B
atrial	O	ADJ	I
arrhythmia	O	NOUN	I
>	O	NOUN	O
30	O	NUM	O
seconds	O	NOUN	O
without	O	ADP	O
antiarrhythmic	B-I	ADJ	B
drugs	I-I	NOUN	I
after	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
36.5	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
CA	B-I	PROPN	B
and	O	CCONJ	O
65.6	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
SA	B-I	PROPN	B
(	O	PUNCT	O
P=0.0022	O	PROPN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
effect	O	NOUN	B
for	O	ADP	O
subgroups	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
consistent	O	ADJ	O
at	O	ADP	O
both	O	DET	O
sites	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
safety	O	NOUN	B
end	O	NOUN	O
point	O	NOUN	O
of	O	ADP	O
significant	O	ADJ	B
adverse	O	ADJ	B
events	O	NOUN	I
during	O	ADP	O
the	O	DET	O
12-month	O	ADJ	B
follow-up	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
for	O	ADP	O
SA	B-I	PROPN	B
than	O	ADP	O
for	O	ADP	O
CA	B-I	PROPN	B
(	O	PUNCT	O
n=21	O	PROPN	O
[	O	PUNCT	O
34.4	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
versus	O	CCONJ	O
n=10	O	NOUN	O
[	O	PUNCT	O
15.9	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
;	O	PUNCT	O
P=0.027	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
driven	O	VERB	O
mainly	O	ADV	O
by	O	ADP	O
procedural	O	ADJ	B
complications	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
pneumothorax	O	NOUN	B
,	O	PUNCT	O
major	O	ADJ	O
bleeding	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
pacemaker	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
CA	B-I	PROPN	B
group	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
patient	O	NOUN	B
died	O	VERB	B
at	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
of	O	ADP	O
subarachnoid	O	ADJ	B
hemorrhage	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
atrial	B-P	ADJ	B
fibrillation	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
dilated	I-P	ADJ	B
left	I-P	ADJ	I
atrium	I-P	NOUN	I
and	I-P	CCONJ	O
hypertension	I-P	NOUN	B
or	I-P	CCONJ	O
failed	I-P	VERB	O
prior	I-P	ADJ	O
atrial	I-P	ADJ	B
fibrillation	I-P	NOUN	I
CA	I-I	PROPN	I
,	I-I	PUNCT	O
SA	I-I	PROPN	B
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
CA	B-I	PROPN	B
in	O	ADP	O
achieving	O	VERB	O
freedom	O	NOUN	B
from	O	ADP	O
left	O	VERB	B
atrial	O	ADJ	I
arrhythmias	O	NOUN	I
after	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
procedural	O	ADJ	B
adverse	O	ADJ	B
event	O	NOUN	I
rate	O	NOUN	B
is	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
for	O	ADP	O
SA	B-I	PROPN	B
than	O	ADP	O
for	O	ADP	O
CA	B-I	PROPN	B
.	I-I	PUNCT	O


CLINICAL	O	X	B
TRIAL	O	NOUN	I
REGISTRATION	O	NOUN	I
URL	O	NOUN	O
:	O	PUNCT	O
http	O	NOUN	B
:	O	PUNCT	O
//clinicaltrials.gov	O	ADJ	B
.	O	PUNCT	O


Unique	O	ADJ	O
identifier	O	NOUN	O
:	O	PUNCT	O
NCT00662701	O	NOUN	O
.	O	PUNCT	O


Psychiatric	B-I	ADJ	B
treatment	I-I	NOUN	I
of	O	ADP	O
eczema	B-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


Seventy-two	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
eczema	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allotted	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
,	O	PUNCT	O
those	O	DET	O
receiving	O	VERB	O
dermatological	B-I	ADJ	B
treatment	I-I	NOUN	I
only	I-I	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
B	O	NOUN	B
,	O	PUNCT	O
those	O	DET	O
receiving	O	VERB	O
the	O	DET	O
same	B-I	ADJ	O
dermatological	I-I	ADJ	B
treatment	I-I	NOUN	I
plus	I-I	CCONJ	O
psychiatric	I-I	ADJ	B
treatment	I-I	NOUN	I
,	O	PUNCT	O
limited	O	VERB	O
where	O	SCONJ	O
possible	O	ADJ	O
to	O	ADP	O
four	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Cases	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
up	O	ADP	O
at	O	ADP	O
six-monthly	O	ADJ	O
dermatological	O	ADJ	B
assessments	O	NOUN	I
,	O	PUNCT	O
57	O	NUM	O
(	O	PUNCT	O
79	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
presence	B-OUT	NOUN	B
of	I-OUT	ADP	O
overt	I-OUT	ADJ	B
emotional	I-OUT	ADJ	B
disturbance	I-OUT	NOUN	I
,	O	PUNCT	O
of	O	ADP	O
new	B-OUT	ADJ	O
psychological	I-OUT	ADJ	B
or	I-OUT	CCONJ	O
psychophysiological	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
preceding	I-OUT	VERB	O
the	I-OUT	DET	O
rash	I-OUT	NOUN	B
by	O	ADP	O
up	O	ADV	O
to	O	ADP	O
a	O	DET	O
year	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
of	O	ADP	O
high	B-OUT	ADJ	B
motivation	I-OUT	NOUN	B
for	O	ADP	O
it	O	PRON	O
,	O	PUNCT	O
brief	O	ADJ	O
psychiatric	B-I	ADJ	B
treatment	I-I	NOUN	I
improves	I-OUT	VERB	B
the	O	DET	O
outcome	O	NOUN	B
in	O	ADP	O
eczema	B-OUT	NOUN	B
(	O	PUNCT	O
the	O	DET	O
proportion	O	NOUN	B
clear	O	ADJ	O
at	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
was	O	AUX	O
about	O	ADV	O
doubled	O	VERB	B
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
their	O	PRON	O
absence	O	NOUN	B
such	O	ADJ	O
treatment	O	NOUN	B
may	O	AUX	O
worsen	B-OUT	VERB	B
it	I-OUT	PRON	O
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
the	O	DET	O
short	O	ADJ	B
term	O	NOUN	I
.	O	PUNCT	O


Are	O	AUX	O
PRO	B-I	NOUN	B
discharge	I-I	NOUN	I
screens	I-I	NOUN	O
associated	O	VERB	B
with	O	ADP	I
postdischarge	O	ADJ	B
adverse	O	ADJ	O
outcomes	O	NOUN	O
?	O	PUNCT	O
OBJECTIVE	O	NOUN	O
We	O	PRON	O
evaluate	O	VERB	B
whether	O	SCONJ	O
patient	O	NOUN	B
outcomes	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
possible	O	ADJ	O
errors	O	NOUN	B
in	O	ADP	O
care	O	NOUN	B
at	O	ADP	O
discharge	O	NOUN	B
as	O	ADP	O
assessed	O	VERB	B
by	O	ADP	O
Peer	O	PROPN	B
Review	O	PROPN	I
Organizations	O	PROPN	I
(	O	PUNCT	O
PROs	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


DATA	O	NOUN	B
SOURCES/STUDY	O	NOUN	O
SETTING	O	VERB	O
The	B-P	DET	O
three	I-P	NUM	O
data	I-P	NOUN	B
sources	I-P	NOUN	B
for	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
were	I-P	AUX	O
(	I-P	PUNCT	O
1	I-P	X	O
)	I-P	PUNCT	O
the	I-P	DET	O
generic	I-I	ADJ	B
screen	I-I	NOUN	I
results	I-I	NOUN	B
of	I-P	ADP	O
a	I-P	DET	O
3	I-P	NUM	O
percent	I-P	NOUN	O
random	I-P	ADJ	O
sample	I-P	NOUN	B
of	I-P	ADP	O
Medicare	I-P	PROPN	B
beneficiaries	I-P	NOUN	B
age	I-P	NOUN	B
65	I-P	NUM	O
years	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
who	I-P	PRON	O
were	I-P	AUX	O
admitted	I-P	VERB	B
to	I-P	ADP	O
California	I-P	PROPN	B
hospitals	I-P	NOUN	B
between	I-P	ADP	O
1	I-P	NUM	O
July	I-P	PROPN	O
1987	I-P	NUM	O
and	I-P	CCONJ	O
30	I-P	NUM	O
June	I-P	PROPN	O
1988	I-P	NUM	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
20,136	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
;	I-P	PUNCT	O
(	I-P	PUNCT	O
2	I-P	X	O
)	I-P	PUNCT	O
the	I-P	DET	O
1987	I-P	NUM	O
and	I-P	CCONJ	O
1988	I-P	NUM	O
California	I-P	PROPN	B
Medicare	I-P	PROPN	B
Provided	I-P	VERB	O
Analysis	I-I	PROPN	B
and	I-I	CCONJ	O
Review	I-I	NOUN	B
(	I-I	PUNCT	O
MEDPAR	I-I	NOUN	B
)	I-I	PUNCT	O
data	I-I	NOUN	B
files	I-I	NOUN	I
;	I-I	PUNCT	O
and	I-P	CCONJ	O
(	I-P	PUNCT	O
3	I-P	X	O
)	I-P	PUNCT	O
the	I-P	DET	O
American	I-I	PROPN	B
Hospital	I-I	PROPN	I
Association	I-I	PROPN	I
(	I-I	PUNCT	O
AHA	I-I	PROPN	B
)	I-I	PUNCT	O
1988	I-I	NUM	O
Annual	I-I	PROPN	B
Survey	I-I	PROPN	B
of	I-I	ADP	I
Hospitals	I-I	PROPN	I
.	I-I	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	VERB	O
Multivariate	B-I	ADJ	B
logistic	I-I	ADJ	I
regression	I-I	NOUN	I
analysis	I-I	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
generic	O	ADJ	B
discharge	O	NOUN	I
administered	O	VERB	B
by	O	ADP	O
the	O	DET	O
PROs	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
patient	O	NOUN	B
outcomes	O	NOUN	B
:	O	PUNCT	O
mortality	O	NOUN	B
and	O	CCONJ	O
readmission	O	NOUN	B
within	O	ADP	O
30	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
analysis	O	NOUN	B
was	O	AUX	O
adjusted	O	VERB	O
for	O	ADP	O
other	O	ADJ	O
patient	O	NOUN	B
characteristics	O	NOUN	B
recorded	O	VERB	O
on	O	ADP	O
the	O	DET	O
uniform	O	ADJ	B
discharge	O	NOUN	I
abstract	O	ADJ	O
.	O	PUNCT	O


PRINCIPAL	O	ADJ	B
FINDINGS	O	NOUN	B
Four	O	NUM	O
discharge	O	NOUN	B
screens	O	NOUN	I
indicated	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
an	I-OUT	DET	O
adverse	I-OUT	ADJ	B
outcome-absence	I-OUT	NOUN	I
of	I-OUT	ADP	O
documentation	I-OUT	NOUN	B
of	I-OUT	ADP	O
discharge	I-OUT	NOUN	B
planning	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
elevated	I-OUT	ADJ	B
temperature	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
abnormal	I-OUT	ADJ	B
pulse	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
unaddressed	I-OUT	ADJ	O
abnormal	I-OUT	ADJ	O
test	I-OUT	NOUN	O
results	I-OUT	NOUN	O
at	O	ADP	O
discharge	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
three	O	NUM	O
discharge	O	NOUN	B
screens	O	NOUN	I
examined-abnormal	B-OUT	ADJ	B
blood	I-OUT	NOUN	O
pressure	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
IV	I-OUT	NUM	B
fluids	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
drugs	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
wound	I-OUT	NOUN	B
drainage	I-OUT	NOUN	I
before	O	ADP	O
discharge-were	O	ADJ	B
unrelated	O	ADJ	O
to	O	PART	O
postdischarge	O	VERB	B
adverse	O	ADJ	O
outcomes	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Generic	B-I	ADJ	B
discharge	I-I	NOUN	I
screens	I-I	NOUN	I
based	O	VERB	O
on	O	ADP	O
inadequate	O	ADJ	B
discharge	O	NOUN	B
planning	O	NOUN	I
,	O	PUNCT	O
abnormal	B-OUT	ADJ	B
pulse	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
increased	I-OUT	VERB	B
temperature	I-OUT	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
unaddressed	B-OUT	ADJ	O
abnormal	I-OUT	ADJ	B
tests	I-OUT	NOUN	I
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
indicators	O	NOUN	B
of	O	ADP	O
substandard	O	ADJ	B
care	O	NOUN	I
.	O	PUNCT	O


Other	O	ADJ	O
discharge	O	NOUN	B
screens	O	NOUN	I
apparently	O	ADV	O
do	O	AUX	O
not	O	PART	O
detect	O	VERB	B
errors	O	NOUN	B
in	O	ADP	O
care	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
major	O	ADJ	O
consequences	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nightly	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
sodium	B-I	NOUN	B
oxybate	I-I	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
nocturnal	B-OUT	ADJ	B
sleep	I-OUT	NOUN	O
disruption	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
narcolepsy	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
further	O	ADV	O
explore	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
sodium	B-I	NOUN	B
oxybate	I-I	NOUN	I
(	I-I	PUNCT	O
SXB	I-I	NOUN	B
)	I-I	PUNCT	O
administration	O	NOUN	B
on	O	ADP	O
nocturnal	B-OUT	ADJ	B
sleep	I-OUT	NOUN	I
in	O	ADP	O
narcolepsy	B-P	ADJ	B
patients	I-P	NOUN	B
during	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
parallel	O	ADJ	B
group	O	NOUN	I
study	O	NOUN	I
conducted	O	VERB	O
with	O	ADP	O
228	B-P	NUM	O
adult	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
narcolepsy/cataplexy	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
United	I-P	PROPN	B
States	I-P	PROPN	I
,	I-P	PUNCT	O
Canada	I-P	PROPN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
Europe	I-P	PROPN	B
.	I-P	PUNCT	O


METHOD	O	NOUN	B
Patients	O	NOUN	B
were	O	AUX	O
withdrawn	B-I	VERB	O
from	I-I	ADP	O
antidepressants	I-I	NOUN	B
and	I-I	CCONJ	O
sedative/hypnotics	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
4.5	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
9	O	NUM	O
g	O	NOUN	O
SXB	O	NOUN	B
or	O	CCONJ	O
placebo	B-I	ADJ	B
nightly	O	ADV	B
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
receiving	B-P	VERB	O
6	I-P	NUM	O
and	I-P	CCONJ	O
9	I-P	NUM	O
g/night	I-P	NOUN	O
doses	I-P	NOUN	B
were	O	AUX	O
titrated	O	VERB	B
to	O	ADP	O
their	O	PRON	O
final	O	ADJ	O
dose	O	NOUN	B
in	O	ADP	O
weekly	O	ADJ	B
1.5	O	NUM	O
g	O	NOUN	O
increments	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
patients	O	NOUN	B
receiving	O	VERB	O
placebo	B-I	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
undergo	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
mock	O	ADJ	B
dose	O	NOUN	I
titration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
stimulant	O	ADJ	B
therapy	O	NOUN	I
continued	O	VERB	O
unchanged	O	ADJ	B
.	O	PUNCT	O


Changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
sleep	I-OUT	NOUN	B
architecture	I-OUT	NOUN	I
were	I-OUT	AUX	O
measured	I-OUT	VERB	B
using	I-OUT	VERB	O
centrally	I-OUT	ADV	B
scored	I-OUT	VERB	I
nocturnal	I-OUT	ADJ	B
polysomnograms	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Daily	O	NOUN	B
diaries	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
record	O	VERB	B
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
narcolepsy	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
Following	O	VERB	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
SXB	O	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
study	O	NOUN	B
patients	O	NOUN	B
demonstrated	O	VERB	O
significant	O	ADJ	O
dose-related	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	I
stage	I-OUT	NOUN	O
3	I-OUT	NUM	O
and	I-OUT	CCONJ	O
4	I-OUT	NUM	O
sleep	I-OUT	NOUN	B
,	O	PUNCT	O
reaching	O	VERB	O
a	O	DET	O
median	O	ADJ	B
increase	O	NOUN	B
of	O	ADP	O
52.5	O	NUM	O
minutes	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
9	O	NUM	O
g	O	NOUN	O
nightly	O	ADV	B
.	O	PUNCT	O


Compared	O	VERB	O
to	O	PART	O
placebo-treated	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
delta	B-OUT	NOUN	B
power	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
all	O	DET	O
dose	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Stage	B-OUT	NOUN	B
1	I-OUT	NUM	I
sleep	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
nocturnal	I-OUT	ADJ	B
awakenings	I-OUT	NOUN	B
were	O	AUX	O
each	O	DET	O
significantly	O	ADV	O
decreased	O	VERB	B
at	O	ADP	O
the	O	DET	O
6	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
g/night	O	NOUN	O
doses	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
nocturnal	I-OUT	ADJ	B
sleep	I-OUT	NOUN	I
coincided	O	VERB	O
with	O	ADP	O
significant	O	ADJ	O
decreases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
severity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
narcolepsy	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
nightly	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
SXB	O	NOUN	B
to	O	PART	O
narcolepsy	O	NOUN	B
patients	O	NOUN	B
significantly	O	ADV	O
impacts	O	VERB	B
measures	O	NOUN	B
of	O	ADP	O
slow	B-OUT	ADJ	B
wave	I-OUT	NOUN	I
sleep	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
wake	I-OUT	VERB	O
after	I-OUT	ADP	O
sleep	I-OUT	NOUN	B
onset	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
awakenings	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
total	I-OUT	ADJ	B
sleep	I-OUT	NOUN	I
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
stage	I-OUT	NOUN	B
1	I-OUT	NUM	I
sleep	I-OUT	NOUN	I
in	O	ADP	O
a	O	DET	O
dose-related	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
frequency	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
narcolepsy	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
decreased	O	VERB	B
with	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
diuretics	B-I	NOUN	I
on	O	ADP	O
pulmonary	O	ADJ	B
mechanics	O	NOUN	B
in	O	ADP	O
infants	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
bronchopulmonary	I-P	ADJ	I
dysplasia	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
double-blind	B-P	ADJ	B
crossover	I-P	NOUN	B
sequential	I-P	ADJ	I
trial	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
crossover	O	NOUN	I
trial	O	NOUN	I
with	O	ADP	O
sequential	O	ADJ	B
analysis	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
oral	O	ADJ	B
diuretics	B-I	NOUN	I
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
placebo	B-I	NOUN	B
on	O	ADP	O
pulmonary	O	ADJ	B
mechanics	O	NOUN	B
in	O	ADP	O
ten	B-P	NUM	O
infants	I-P	NOUN	B
with	I-P	ADP	O
bronchopulmonary	I-P	ADJ	B
dysplasia	I-P	NOUN	I
(	I-P	PUNCT	O
BPD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Pulmonary	O	ADJ	B
mechanics	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
a	O	DET	O
week	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
oral	B-I	ADJ	B
diuretics	I-I	NOUN	I
(	I-I	PUNCT	O
chlorothiazide	I-I	NOUN	B
,	I-I	PUNCT	O
20	I-I	NUM	O
mg/kg/dose	I-I	NOUN	B
and	I-I	CCONJ	O
spironolactone	I-I	NOUN	B
,	I-I	PUNCT	O
1.5	I-I	NUM	O
mg/kg/dose	I-I	NOUN	O
)	I-I	PUNCT	O
given	I-I	VERB	O
twice	I-I	ADV	O
daily	I-I	ADV	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Mean	B-OUT	VERB	B
airway	I-OUT	NOUN	B
resistance	I-OUT	NOUN	I
decreased	O	VERB	B
35.3	O	NUM	O
cm	O	NOUN	O
H2O/L/s	O	NOUN	O
,	O	PUNCT	O
mean	O	VERB	O
specific	B-OUT	ADJ	O
airway	I-OUT	NOUN	B
conductance	I-OUT	NOUN	B
increased	O	VERB	B
0.095	O	NUM	O
1/L/s/cm	O	NUM	O
H2O	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mean	B-OUT	VERB	B
dynamic	I-OUT	ADJ	I
pulmonary	I-OUT	ADJ	I
compliance	I-OUT	NOUN	I
increased	O	VERB	B
1.74	O	NUM	O
mL/cm	O	NOUN	B
H2O	O	NOUN	I
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
diuretics	O	NOUN	B
(	O	PUNCT	O
all	O	DET	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
placebo	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
infants	B-P	NOUN	B
'	I-P	PART	O
rate	I-P	NOUN	B
of	I-P	ADP	O
weight	I-OUT	NOUN	B
gain	I-OUT	NOUN	I
decreased	O	VERB	B
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
three	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
diuretic	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
thereafter	O	ADV	O
comparable	O	ADJ	B
with	O	ADP	I
weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Fluid	B-OUT	ADJ	B
intake	I-OUT	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
infants	B-P	NOUN	B
receiving	O	VERB	O
diuretics	O	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


But	O	CCONJ	O
,	O	PUNCT	O
infants	B-P	NOUN	B
receiving	O	VERB	O
diuretics	O	NOUN	B
not	O	PART	O
only	O	ADV	O
had	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
urine	B-OUT	NOUN	B
output	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
osmolal	I-OUT	ADJ	B
clearance	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
potassium	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
phosphorus	I-OUT	NOUN	B
excretion	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
these	O	DET	O
infants	O	NOUN	B
also	O	ADV	O
retained	B-OUT	VERB	O
less	I-OUT	ADV	O
fluid	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
excreted	B-OUT	VERB	B
less	I-OUT	ADJ	O
calcium	I-OUT	NOUN	B
than	O	ADP	O
infants	O	NOUN	B
receiving	O	VERB	O
placebo	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
oral	O	ADJ	B
diuretics	B-I	NOUN	B
improve	O	VERB	O
lung	B-OUT	NOUN	B
function	I-OUT	NOUN	I
in	O	ADP	O
infants	B-P	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
bronchopulmonary	O	ADJ	I
dysplasia	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
potassium	O	NOUN	B
and	O	CCONJ	O
phosphorus	O	NOUN	B
depletion	O	NOUN	B
are	O	AUX	O
potential	O	ADJ	O
complications	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Oxytocin	B-I	NOUN	B
improves	O	VERB	B
behavioural	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
neural	I-OUT	ADJ	B
deficits	I-OUT	NOUN	I
in	O	ADP	O
inferring	O	VERB	O
others	O	NOUN	O
'	O	PART	O
social	O	ADJ	B
emotions	O	NOUN	I
in	O	ADP	O
autism	B-P	NOUN	B
.	I-P	PUNCT	O


Recent	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
oxytocin	B-I	NOUN	B
's	I-I	PART	O
therapeutic	O	ADJ	B
effects	O	NOUN	I
on	O	ADP	O
deficits	O	NOUN	B
in	O	ADP	O
social	O	ADJ	B
communication	O	NOUN	I
and	O	CCONJ	O
interaction	O	NOUN	B
in	O	ADP	O
autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
through	O	ADP	O
improvement	O	NOUN	B
of	O	ADP	O
emotion	B-OUT	NOUN	B
recognition	I-OUT	NOUN	I
with	O	ADP	O
direct	O	ADJ	O
emotional	O	ADJ	B
cues	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
facial	O	ADJ	B
expression	O	NOUN	I
and	O	CCONJ	O
voice	O	NOUN	B
prosody	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
difficulty	O	NOUN	B
in	O	ADP	O
understanding	O	NOUN	O
of	O	ADP	O
others	O	NOUN	O
'	O	PART	O
social	O	ADJ	B
emotions	O	NOUN	I
and	O	CCONJ	O
beliefs	O	NOUN	B
under	O	ADP	O
conditions	O	NOUN	B
without	O	ADP	O
direct	O	ADJ	O
emotional	O	ADJ	B
cues	O	NOUN	B
also	O	ADV	O
plays	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
,	O	PUNCT	O
no	O	DET	O
study	O	NOUN	O
has	O	AUX	O
examined	O	VERB	O
the	O	DET	O
potential	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
oxytocin	B-I	NOUN	B
on	O	ADP	O
this	O	DET	O
difficulty	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
sequentially	O	ADV	O
conducted	O	VERB	O
both	O	CCONJ	O
a	O	DET	O
case-control	O	ADJ	B
study	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
potential	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
oxytocin	B-I	NOUN	B
on	O	ADP	O
this	O	DET	O
difficulty	O	NOUN	B
at	O	ADP	O
behavioural	O	ADJ	B
and	O	CCONJ	O
neural	O	ADJ	B
levels	O	NOUN	I
measured	O	VERB	B
using	O	VERB	O
functional	O	ADJ	B
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
during	O	ADP	O
a	O	DET	O
psychological	O	ADJ	B
task	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
task	O	NOUN	B
was	O	AUX	O
modified	O	VERB	O
from	O	ADP	O
the	O	DET	O
Sally-Anne	O	ADJ	B
Task	O	PROPN	I
,	O	PUNCT	O
a	O	DET	O
well-known	O	ADJ	O
first-order	O	ADJ	O
false	O	ADJ	O
belief	O	NOUN	O
task	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
task	O	NOUN	B
was	O	AUX	O
optimized	O	VERB	O
for	O	ADP	O
investigation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
abilities	O	NOUN	B
to	O	PART	O
infer	O	VERB	O
another	O	DET	O
person	O	NOUN	B
's	O	PART	O
social	O	ADJ	B
emotions	O	NOUN	I
and	O	CCONJ	O
beliefs	O	NOUN	B
distinctively	O	ADV	O
so	O	SCONJ	O
as	O	ADP	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
oxytocin	B-I	NOUN	B
improves	O	VERB	B
deficit	O	NOUN	B
in	O	ADP	O
inferring	O	VERB	O
others	O	NOUN	O
'	O	PART	O
social	O	ADJ	B
emotions	O	NOUN	I
rather	O	ADV	O
than	O	ADP	O
beliefs	O	NOUN	B
,	O	PUNCT	O
under	O	ADP	O
conditions	O	NOUN	B
without	O	ADP	O
direct	O	ADJ	O
emotional	O	ADJ	B
cues	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
case-control	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
17	B-P	NUM	O
males	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
showed	O	VERB	O
significant	O	ADJ	O
behavioural	B-OUT	ADJ	B
deficits	I-OUT	NOUN	I
in	I-OUT	ADP	O
inferring	I-OUT	VERB	O
others	I-OUT	NOUN	O
'	I-OUT	PART	O
social	I-OUT	ADJ	B
emotions	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.018	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
inferring	B-OUT	VERB	O
others	I-OUT	NOUN	O
'	I-OUT	PART	O
beliefs	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.064	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
17	B-P	NUM	O
typically	I-P	ADV	O
developing	I-P	VERB	O
demographically-matched	I-P	ADJ	O
male	I-P	NOUN	B
participants	I-P	NOUN	B
.	I-P	PUNCT	O


They	O	PRON	O
also	O	ADV	O
showed	O	VERB	O
significantly	O	ADV	O
less	O	ADJ	O
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
right	B-OUT	ADJ	B
anterior	I-OUT	ADJ	I
insula	I-OUT	NOUN	I
and	O	CCONJ	O
posterior	B-OUT	ADJ	B
superior	I-OUT	ADJ	O
temporal	I-OUT	ADJ	O
sulcus	I-OUT	NOUN	O
during	O	ADP	O
inferring	O	VERB	O
others	O	NOUN	O
'	O	PART	O
social	O	ADJ	B
emotions	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
dorsomedial	O	ADJ	B
prefrontal	O	ADJ	B
cortex	O	NOUN	I
during	O	ADP	O
inferring	O	VERB	O
others	O	NOUN	O
'	O	PART	O
beliefs	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
typically	O	ADV	O
developing	O	VERB	O
participants	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
and	O	CCONJ	O
cluster	O	NOUN	B
size	O	NOUN	I
>	O	NOUN	O
10	O	NUM	O
voxels	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Then	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
investigate	O	VERB	B
potential	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
oxytocin	B-I	NOUN	B
on	O	ADP	O
these	O	DET	O
behavioural	O	ADJ	B
and	O	CCONJ	O
neural	O	ADJ	B
deficits	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
double-blind	O	ADJ	B
placebo-controlled	B-I	ADJ	B
crossover	O	NOUN	B
within-subject	O	ADJ	I
trial	O	NOUN	I
for	O	ADP	O
single-dose	O	ADJ	B
intranasal	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
24	O	NUM	O
IU	O	NOUN	B
oxytocin	B-I	NOUN	B
in	O	ADP	O
an	O	DET	O
independent	O	ADJ	B
group	O	NOUN	B
of	O	ADP	O
20	B-P	NUM	O
males	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Behaviourally	B-OUT	ADV	B
,	I-OUT	PUNCT	O
oxytocin	I-OUT	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
correct	B-OUT	ADJ	O
rate	I-OUT	NOUN	B
in	I-OUT	ADP	O
inferring	I-OUT	VERB	O
others	I-OUT	NOUN	O
'	I-OUT	PART	O
social	I-OUT	ADJ	B
emotions	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.043	O	NUM	O
,	O	PUNCT	O
one-tail	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
neural	O	ADJ	B
level	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
peptide	O	NOUN	B
significantly	O	ADV	O
enhanced	O	VERB	B
the	O	DET	O
originally-diminished	B-OUT	ADJ	B
brain	I-OUT	NOUN	B
activity	I-OUT	NOUN	I
in	I-OUT	ADP	O
the	I-OUT	DET	O
right	I-OUT	ADJ	B
anterior	I-OUT	ADJ	I
insula	I-OUT	NOUN	B
during	O	ADP	O
inferring	O	VERB	O
others	O	NOUN	O
'	O	PART	O
social	O	ADJ	B
emotions	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
dorsomedial	O	ADJ	B
prefrontal	O	ADJ	B
cortex	O	NOUN	I
during	O	ADP	O
inferring	O	VERB	O
others	O	NOUN	O
'	O	PART	O
beliefs	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.858	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
oxytocin	B-I	NOUN	B
enhances	O	VERB	B
the	O	DET	O
ability	B-OUT	NOUN	O
to	I-OUT	PART	O
understand	I-OUT	VERB	O
others	I-OUT	NOUN	O
'	I-OUT	PART	O
social	I-OUT	ADJ	B
emotions	I-OUT	NOUN	I
that	O	PRON	O
have	O	AUX	O
also	O	ADV	O
required	O	VERB	O
second-order	O	ADJ	B
false	O	ADJ	I
belief	O	NOUN	B
rather	O	ADV	O
than	O	ADP	O
first-order	O	ADJ	O
false	O	ADJ	B
beliefs	O	NOUN	I
under	O	ADP	O
conditions	O	NOUN	B
without	O	ADP	O
direct	O	ADJ	O
emotional	O	ADJ	B
cues	O	NOUN	O
in	O	ADP	O
autism	B-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
at	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
behaviour	O	NOUN	B
and	O	CCONJ	O
neural	O	ADJ	B
levels	O	NOUN	I
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
therapeutic	O	ADJ	B
efficacy	O	NOUN	I
of	O	ADP	O
phonophoresis	B-I	NOUN	B
and	O	CCONJ	O
iontophoresis	B-I	NOUN	B
using	O	VERB	O
dexamethasone	B-I	NOUN	B
sodium	I-I	NOUN	B
phosphate	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
knee	I-P	NOUN	B
osteoarthritis	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
AND	O	CCONJ	O
OBJECTIVE	O	ADJ	O
Many	O	ADJ	O
treatment	O	NOUN	B
options	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
non-pharmacological	O	ADJ	B
and	O	CCONJ	O
pharmacological	O	ADJ	B
measures	O	NOUN	O
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
recommended	O	VERB	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
osteoarthritis	O	NOUN	B
(	O	PUNCT	O
OA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
non-pharmacological	O	ADJ	B
approach	O	NOUN	I
is	O	AUX	O
physiotherapy	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
involves	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
physical	O	ADJ	B
modalities	O	NOUN	I
like	O	ADP	O
,	O	PUNCT	O
heat	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
exercise	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
electrical	O	ADJ	B
stimulation	O	NOUN	I
,	O	PUNCT	O
therapeutic	O	ADJ	B
ultrasound	O	NOUN	I
,	O	PUNCT	O
iontophoresis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
phonophoresis	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
therefore	O	ADV	O
designed	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
0.4	O	NUM	O
%	O	NOUN	O
Dexamethasone	B-I	NOUN	B
sodium	I-I	NOUN	I
phosphate	I-I	NOUN	I
(	I-I	PUNCT	O
DEX-P	I-I	NOUN	B
)	I-I	PUNCT	O
phonophoresis	I-I	NOUN	B
(	I-I	PUNCT	O
PH	I-I	NOUN	B
)	I-I	PUNCT	O
with	O	ADP	O
0.4	B-I	NUM	O
%	I-I	NOUN	O
DEX-P	I-I	NOUN	B
iontophoresis	I-I	NOUN	I
(	I-I	PUNCT	O
ION	I-I	NOUN	B
)	I-I	PUNCT	O
therapy	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
knee	I-P	NOUN	B
joint	I-P	ADJ	I
OA	I-P	NOUN	O
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fifty	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
19	I-P	NUM	O
males	I-P	NOUN	B
and	I-P	CCONJ	O
31	I-P	NUM	O
females	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
53.6	I-P	NUM	O
+/-	I-P	CCONJ	O
8.9	I-P	NUM	O
years	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
PH	B-I	NOUN	B
or	O	CCONJ	O
ION	B-I	NOUN	B
groups	O	NOUN	B
with	O	ADP	O
25	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


Ultrasound	O	NOUN	B
waves	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
MHz	O	NOUN	O
frequency	O	NOUN	B
was	O	AUX	O
applied	O	VERB	O
for	O	ADP	O
5	O	NUM	O
minutes	O	NOUN	B
to	O	ADP	O
the	O	DET	O
target	O	NOUN	B
knee	O	NOUN	B
,	O	PUNCT	O
so	O	CCONJ	O
also	O	ADV	O
was	O	AUX	O
the	O	DET	O
direct	O	ADJ	O
current	O	NOUN	O
for	O	ADP	O
10	O	NUM	O
minutes	O	NOUN	B
for	O	ADP	O
10	O	NUM	O
sessions	O	NOUN	B
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Western	B-OUT	PROPN	B
Ontario	I-OUT	PROPN	I
and	I-OUT	CCONJ	I
McMaster	I-OUT	PROPN	I
University	I-OUT	PROPN	I
Osteoarthritis	I-OUT	PROPN	I
Index	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
WOMAC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
scores	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
20	I-OUT	NUM	O
meters	I-OUT	NOUN	B
ambulatory	I-OUT	ADJ	B
time	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
knee	B-OUT	NOUN	B
range	I-OUT	NOUN	I
of	I-OUT	ADP	I
motion	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ROM	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
therapy	O	NOUN	B
as	O	ADP	O
the	O	DET	O
outcome	O	NOUN	B
measures	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
significant	O	ADJ	B
improvement	O	NOUN	B
in	O	ADP	O
total	O	ADJ	O
WOMAC	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
15	O	NUM	O
(	O	PUNCT	O
60	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
16	O	NUM	O
(	O	PUNCT	O
64	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PH	O	NOUN	B
and	O	CCONJ	O
ION	O	PROPN	B
groups	O	NOUN	B
respectively	O	ADV	O
,	O	PUNCT	O
indicating	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
rate	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	O
(	O	PUNCT	O
20	O	NUM	O
)	O	PUNCT	O
metres	O	VERB	B
ambulatory	B-OUT	ADJ	B
time	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
knee	I-OUT	NOUN	B
range	I-OUT	NOUN	I
of	I-OUT	ADP	I
motion	I-OUT	NOUN	B
also	O	ADV	O
improved	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
yet	O	CCONJ	O
these	O	DET	O
variables	O	NOUN	B
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Both	O	CCONJ	O
therapeutic	O	ADJ	B
modalities	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
and	O	CCONJ	O
generally	O	ADV	O
well	O	ADV	O
tolerated	O	VERB	B
after	O	ADP	O
10	O	NUM	O
treatment	O	NOUN	B
sessions	O	NOUN	O
.	O	PUNCT	O


DEX-P	B-I	NOUN	B
phonophoresis	I-I	NOUN	B
was	O	AUX	O
not	O	PART	O
superior	O	ADJ	O
to	O	PART	O
DEX-P	B-I	NOUN	B
iontophoresis	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
OA	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
knee	I-P	NOUN	B
.	I-P	PUNCT	O


Women	B-P	PROPN	B
's	I-P	PART	O
responses	I-P	NOUN	B
to	I-P	PART	O
information	I-P	NOUN	B
on	I-P	ADP	O
mammographic	I-P	ADJ	B
breast	I-P	NOUN	B
density	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
negative	O	ADJ	B
and	O	CCONJ	O
positive	O	ADJ	B
outcomes	O	NOUN	B
of	O	ADP	O
providing	O	VERB	O
mammographic	O	ADJ	B
breast	O	NOUN	O
density	O	NOUN	O
(	O	PUNCT	O
MBD	O	NOUN	B
)	O	PUNCT	O
information	O	NOUN	B
to	O	ADP	O
participants	B-P	NOUN	B
of	I-P	ADP	O
a	I-P	DET	O
screening	I-I	VERB	B
program	I-I	NOUN	I
.	I-I	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
experiment	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
with	O	ADP	O
a	O	DET	O
sample	B-P	NOUN	B
of	I-P	ADP	O
618	I-P	NUM	O
women	I-P	NOUN	B
50	I-P	NUM	O
years	I-P	NOUN	B
or	I-P	CCONJ	O
older	I-P	ADJ	B
with	I-P	ADP	O
MBD	I-P	NOUN	B
greater	I-P	ADJ	O
than	I-P	ADP	O
50	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
breast	I-P	NOUN	B
volume	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
intervention	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
reporting	B-I	VERB	B
the	I-I	DET	O
presence	I-I	NOUN	B
of	I-I	ADP	O
MBD	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
screening	I-I	VERB	B
mammography	I-I	NOUN	I
results	I-I	VERB	B
letter	I-I	NOUN	B
that	I-I	PRON	O
was	I-I	AUX	O
sent	I-I	VERB	O
along	I-I	ADP	O
with	I-I	ADP	O
an	I-I	DET	O
information	I-I	NOUN	B
pamphlet	I-I	NOUN	I
.	I-I	PUNCT	O


Compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
controls	B-I	NOUN	B
,	O	PUNCT	O
more	O	ADJ	O
women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
described	O	VERB	O
the	O	DET	O
term	O	NOUN	O
breast	B-OUT	NOUN	B
density	I-OUT	NOUN	I
correctly	O	ADV	O
and	O	CCONJ	O
recognized	O	VERB	O
it	O	PRON	O
as	O	ADP	O
a	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
at	O	ADP	O
the	O	DET	O
4-week	O	NOUN	O
follow-up	O	NOUN	B
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
"	O	PUNCT	O
very	O	ADV	O
likely	O	ADV	O
"	O	PUNCT	O
to	O	PART	O
have	O	AUX	O
an	O	DET	O
annual	B-I	ADJ	B
clinical	I-I	ADJ	B
breast	I-I	NOUN	O
examination	I-I	NOUN	O
more	O	ADV	O
frequently	O	ADV	O
than	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
detected	O	VERB	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
on	O	ADP	O
other	O	ADJ	O
behavioural	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
psychological	I-OUT	ADJ	B
measures	I-OUT	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
at	O	ADP	O
the	O	DET	O
4-week	O	NOUN	O
follow-up	O	X	B
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
perceived	O	VERB	B
their	O	PRON	O
risk	O	NOUN	B
for	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
,	O	PUNCT	O
relative	O	ADJ	O
to	O	PART	O
other	O	ADJ	O
women	O	NOUN	B
their	O	PRON	O
age	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
"	O	PUNCT	O
a	O	DET	O
lot	O	NOUN	O
lower	O	ADJ	O
"	O	PUNCT	O
than	O	ADP	O
did	O	AUX	O
women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
a	O	DET	O
feasible	O	ADJ	O
and	O	CCONJ	O
non-threatening	O	ADJ	B
way	O	NOUN	O
to	O	PART	O
provide	O	VERB	O
women	O	NOUN	B
with	O	ADP	O
important	O	ADJ	O
personalized	O	ADJ	B
information	O	NOUN	B
about	O	ADP	O
breast	B-OUT	NOUN	B
cancer	I-OUT	NOUN	I
risk	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Project	B-P	NOUN	B
Towards	I-P	PROPN	O
No	I-P	PROPN	O
Drug	I-P	PROPN	B
Abuse	I-P	PROPN	I
:	I-P	PUNCT	O
long-term	O	ADJ	B
substance	O	NOUN	B
use	O	VERB	I
outcomes	O	NOUN	I
evaluation	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
This	O	DET	O
paper	O	NOUN	O
presents	O	VERB	O
up	O	ADV	O
to	O	PART	O
5	O	NUM	O
years	O	NOUN	B
post-program	O	ADJ	B
outcomes	O	NOUN	B
of	O	ADP	O
Project	B-P	PROPN	B
Towards	I-P	PROPN	O
No	I-P	PROPN	O
Drug	I-P	PROPN	B
Abuse	I-P	PROPN	I
(	I-P	PUNCT	O
Project	I-P	NOUN	B
TND	I-P	PROPN	I
)	I-P	PUNCT	O
,	I-P	PUNCT	O
a	I-P	DET	O
drug	I-P	NOUN	B
abuse	I-P	NOUN	I
prevention	I-P	NOUN	I
program	I-P	NOUN	I
conducted	I-P	VERB	O
in	I-P	ADP	O
South	I-P	PROPN	B
California	I-P	PROPN	I
alternative	I-P	VERB	O
high	I-P	ADJ	B
school	I-P	NOUN	I
system	I-P	NOUN	I
during	I-P	ADP	O
years	I-P	NOUN	B
1994-1999	I-P	NUM	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
9-session	O	ADJ	B
health	B-I	NOUN	B
motivation	I-I	NOUN	B
--	I-I	PUNCT	O
social	I-I	ADJ	B
skills	I-I	NOUN	I
--	I-I	PUNCT	O
decision-making	I-I	ADJ	B
curriculum	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


Twenty-one	B-P	NUM	B
schools	I-P	NOUN	B
recruited	O	VERB	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
standard	B-I	ADJ	B
care	I-I	NOUN	I
(	I-I	PUNCT	O
control	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
classroom	I-I	NOUN	B
only	I-I	ADV	O
,	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
classroom	B-I	NOUN	B
plus	I-I	CCONJ	O
semester-long	I-I	ADJ	B
school-as-community	I-I	NOUN	I
component	I-I	NOUN	I
.	I-I	PUNCT	O


Last	O	ADJ	O
30-day	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
cigarettes	O	NOUN	B
,	O	PUNCT	O
alcohol	O	NOUN	B
,	O	PUNCT	O
marijuana	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hard	O	ADJ	B
drugs	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
three	O	NUM	O
time	O	NOUN	B
intervals	O	NOUN	I
:	O	PUNCT	O
short-term	O	ADJ	B
(	O	PUNCT	O
year	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
middle-term	O	ADJ	B
(	O	PUNCT	O
years	O	NOUN	B
2	O	NUM	O
or	O	CCONJ	O
3	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
long-term	O	ADJ	B
(	O	PUNCT	O
years	O	NOUN	B
4	O	NUM	O
or	O	CCONJ	O
5	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Multilevel	O	ADJ	B
random	O	ADJ	I
coefficients	O	NOUN	I
modeling	O	NOUN	I
were	O	AUX	O
employed	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
adjusted	O	VERB	O
levels	O	NOUN	B
of	O	ADP	O
substance	O	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
Among	B-P	ADP	O
1578	I-P	NUM	O
baseline	I-P	NOUN	B
subjects	I-P	NOUN	B
,	I-P	PUNCT	O
follow-up	I-P	ADJ	B
data	I-P	NOUN	B
were	I-P	AUX	O
available	I-P	ADJ	O
for	I-P	ADP	O
68	I-P	NUM	O
%	I-P	NOUN	O
(	I-P	PUNCT	O
year	I-P	NOUN	B
1	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
66	I-P	NUM	O
%	I-P	NOUN	O
(	I-P	PUNCT	O
years	I-P	NOUN	B
2	I-P	NUM	O
or	I-P	CCONJ	O
3	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
46	I-P	NUM	O
%	I-P	NOUN	O
(	I-P	PUNCT	O
years	I-P	NOUN	B
4	I-P	NUM	O
or	I-P	CCONJ	O
5	I-P	NUM	O
)	I-P	PUNCT	O
of	I-P	ADP	O
subjects	I-P	NOUN	B
,	I-P	PUNCT	O
respectively	I-P	ADV	O
.	I-P	PUNCT	O


Results	O	NOUN	B
revealed	O	VERB	O
significant	O	ADJ	O
positive	O	ADJ	B
long-term	O	ADJ	B
program	O	NOUN	O
effects	O	NOUN	B
for	O	ADP	O
hard	O	ADJ	B
drug	O	NOUN	I
use	O	NOUN	O
at	O	ADP	O
year	O	NOUN	B
4	O	NUM	O
or	O	CCONJ	O
5	O	NUM	O
for	O	ADP	O
the	O	DET	O
two	O	NUM	O
program	O	NOUN	B
interventions	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Project	O	PROPN	B
TND	O	PROPN	B
reduced	O	VERB	B
hard	O	ADJ	O
drug	O	NOUN	O
use	O	NOUN	O
in	O	ADP	O
the	O	DET	O
46	O	NUM	O
%	O	NOUN	O
who	O	PRON	O
were	O	AUX	O
successfully	O	ADV	O
followed	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
program	O	NOUN	B
to	O	PART	O
demonstrate	O	VERB	O
long-term	O	ADJ	B
self-reported	O	ADJ	B
behavioral	O	ADJ	B
effects	O	NOUN	O
on	O	ADP	O
hard	O	ADJ	B
drug	O	NOUN	I
use	O	NOUN	O
among	O	ADP	O
high-risk	B-P	ADJ	B
youth	I-P	NOUN	B
by	O	ADP	O
using	O	VERB	O
a	O	DET	O
school-based	O	ADJ	B
,	O	PUNCT	O
limited-session	O	ADJ	B
model	O	NOUN	I
.	O	PUNCT	O


Efficacy	B-OUT	NOUN	B
and	O	CCONJ	O
safety	B-OUT	NOUN	B
of	O	ADP	O
intraseptal	O	NOUN	B
and	O	CCONJ	O
periodontal	O	ADJ	B
ligament	O	NOUN	I
anesthesia	O	NOUN	I
achieved	O	VERB	O
by	O	ADP	O
computer-controlled	B-I	ADJ	B
articaine	I-I	NOUN	I
+	I-I	CCONJ	O
epinephrine	I-I	NOUN	B
delivery	I-I	NOUN	B
:	I-I	PUNCT	O
a	O	DET	O
dose-finding	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
The	O	DET	O
main	O	ADJ	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
dose-dependent	O	ADJ	B
anesthetic	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
intraseptal	B-I	NOUN	B
anesthesia	I-I	NOUN	I
(	I-I	PUNCT	O
ISA	I-I	PROPN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
periodontal	B-I	ADJ	B
ligament	I-I	NOUN	I
anesthesia	I-I	NOUN	I
(	I-I	PUNCT	O
PLA	I-I	PROPN	B
)	I-I	PUNCT	O
obtained	O	VERB	O
with	O	ADP	O
different	O	ADJ	O
volumes	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
%	O	NOUN	O
articaine	B-I	NOUN	B
and	O	CCONJ	O
1:100,000	O	NUM	B
epinephrine	B-I	NOUN	I
(	I-I	PUNCT	O
Ar	I-I	NOUN	B
+	I-I	CCONJ	O
Ep	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
human	O	ADJ	B
mandibular	O	ADJ	B
premolars	O	NOUN	O
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
computer-controlled	B-I	ADJ	B
local	I-I	ADJ	I
anesthetic	I-I	ADJ	I
delivery	I-I	NOUN	I
system	I-I	NOUN	I
(	I-I	PUNCT	O
CCLADS	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


The	O	DET	O
safety	B-OUT	NOUN	B
profile	I-OUT	NOUN	I
of	O	ADP	O
Ar	O	NOUN	B
+	O	CCONJ	O
Ep	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
studied	O	VERB	O
by	O	ADP	O
investigating	O	VERB	B
the	O	DET	O
stability	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
parameters	O	NOUN	B
.	O	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
eighty	I-P	NUM	O
randomly	I-P	ADV	O
selected	I-P	VERB	O
healthy	I-P	ADJ	B
volunteers	I-P	NOUN	I
(	I-P	PUNCT	O
ASA	I-P	NOUN	B
I	I-P	NUM	I
)	I-P	PUNCT	O
entered	O	VERB	O
the	O	DET	O
single-blinded	O	ADJ	B
study	O	NOUN	I
to	O	PART	O
receive	B-I	VERB	O
16	I-I	NUM	O
mg	I-I	NOUN	O
+	I-I	CCONJ	O
4	I-I	NUM	O
μg	I-I	NOUN	O
,	I-I	PUNCT	O
24	I-I	NUM	O
mg	I-I	NOUN	O
+	I-I	CCONJ	O
6	I-I	NUM	O
μg	I-I	NOUN	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
32	I-I	NUM	O
mg	I-I	NOUN	O
+	I-I	CCONJ	O
8	I-I	NUM	O
μg	I-I	NOUN	O
of	I-I	ADP	O
Ar	I-I	PROPN	B
+	I-I	CCONJ	O
Ep	I-I	NOUN	B
,	I-I	PUNCT	O
obtained	I-I	VERB	O
with	I-I	ADP	O
different	I-I	ADJ	O
volumes	I-I	NOUN	B
(	I-I	PUNCT	O
0.4	I-I	NUM	O
,	I-I	PUNCT	O
0.6	I-I	NUM	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
0.8	I-I	NUM	O
ml	I-I	NOUN	O
,	I-I	PUNCT	O
respectively	I-I	ADV	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
for	I-I	ADP	O
the	I-I	DET	O
ISA	I-I	PROPN	B
and	I-I	CCONJ	O
PLA	I-OUT	PROPN	B
.	I-OUT	PUNCT	O


Success	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
onset	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
profound	I-OUT	ADJ	O
pulpal	I-OUT	ADJ	B
anesthesia	I-OUT	NOUN	I
were	I-I	AUX	O
evaluated	I-I	VERB	B
by	I-I	ADP	O
the	I-OUT	DET	O
electrical	I-OUT	ADJ	B
pulp	I-OUT	NOUN	I
tester	I-OUT	NOUN	I
,	I-I	PUNCT	O
while	I-I	SCONJ	O
the	I-OUT	DET	O
width	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
anesthetic	I-OUT	ADJ	B
field	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
soft	I-OUT	ADJ	B
tissue	I-OUT	NOUN	I
anesthesia	I-OUT	NOUN	I
were	I-I	AUX	O
recorded	I-I	VERB	O
using	I-I	VERB	O
the	I-OUT	DET	O
pinprick	I-OUT	NOUN	B
testing	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


A	B-OUT	DET	O
monitor	I-OUT	NOUN	B
was	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
measurement	O	NOUN	B
of	B-OUT	ADP	O
cardiovascular	I-OUT	ADJ	B
parameters	I-OUT	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
dose-dependent	B-OUT	ADJ	B
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
pulpal	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
soft	I-OUT	ADJ	B
tissue	I-OUT	NOUN	I
anesthesia	I-OUT	NOUN	I
was	O	AUX	O
obtained	O	VERB	O
only	O	ADV	O
by	O	ADP	O
the	B-I	DET	O
ISA	I-OUT	PROPN	B
.	I-OUT	PUNCT	O


Success	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
of	I-OUT	ADP	O
both	I-OUT	CCONJ	O
pulpal	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
soft	I-OUT	ADJ	B
tissue	I-OUT	NOUN	I
anesthesia	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
its	I-OUT	PRON	O
width	I-OUT	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
better	O	ADJ	O
in	O	ADP	O
the	O	DET	O
ISA	O	PROPN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
PLA	O	PROPN	B
.	O	PUNCT	O


No	O	DET	B
significant	B-OUT	ADJ	I
cardiovascular	I-OUT	ADJ	B
changes	I-OUT	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
It	O	PRON	O
can	O	AUX	O
be	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
0.6	O	NUM	O
and	O	CCONJ	O
0.8	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
4	B-I	NUM	O
%	I-I	NOUN	O
Ar	O	PROPN	O
+	O	CCONJ	O
1:100,000	B-I	NUM	O
Ep	O	NOUN	B
,	O	PUNCT	O
delivered	O	VERB	O
by	O	ADP	O
CCLADS	O	PROPN	B
,	O	PUNCT	O
offer	O	VERB	O
high	B-OUT	ADJ	O
success	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
clinical	I-OUT	ADJ	B
parameters	I-OUT	NOUN	B
of	O	ADP	O
ISA	O	PROPN	B
as	O	ADP	O
a	O	DET	O
primary	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


CLINICAL	O	X	O
RELEVANCE	O	NOUN	O
It	O	PRON	O
seems	O	VERB	O
that	O	SCONJ	O
dental	O	NOUN	B
procedures	O	NOUN	I
requiring	O	VERB	O
profound	O	ADJ	O
pulpal	O	NOUN	B
,	O	PUNCT	O
bone	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
soft	O	ADJ	B
tissue	O	NOUN	I
anesthesia	O	NOUN	I
could	O	AUX	O
be	B-OUT	AUX	O
effectively	I-OUT	ADV	B
and	I-OUT	CCONJ	O
safely	I-OUT	ADV	O
obtained	O	VERB	O
by	O	ADP	O
mentioned	O	VERB	O
anesthetic	O	ADJ	B
protocol	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
KRAS-variant	O	ADJ	B
and	O	CCONJ	O
miRNA	O	NOUN	B
expression	O	NOUN	B
in	O	ADP	O
RTOG	O	NOUN	B
endometrial	B-P	ADJ	B
cancer	I-P	NOUN	I
clinical	O	ADJ	B
trials	O	NOUN	I
9708	O	NUM	O
and	O	CCONJ	O
9905	O	NUM	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
explore	O	VERB	O
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
a	O	DET	O
functional	O	ADJ	B
germline	O	NOUN	B
variant	O	NOUN	I
in	O	ADP	O
the	O	DET	O
3'-UTR	O	NOUN	B
of	O	ADP	O
KRAS	O	NOUN	B
with	O	ADP	O
endometrial	O	ADJ	B
cancer	O	NOUN	I
risk	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
microRNA	O	NOUN	B
(	O	PUNCT	O
miRNA	O	NOUN	B
)	O	PUNCT	O
signatures	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
KRAS-variant	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
characteristics	O	NOUN	I
and	O	CCONJ	O
survival	O	NOUN	B
outcomes	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
prospective	O	ADJ	O
RTOG	O	PROPN	B
endometrial	O	ADJ	O
cancer	O	NOUN	O
trials	O	NOUN	B
.	O	PUNCT	O


METHODS/MATERIALS	O	NOUN	B
The	O	DET	O
association	O	NOUN	B
of	O	ADP	O
the	O	DET	O
KRAS-variant	O	NOUN	B
with	O	ADP	O
endometrial	O	ADJ	B
cancer	O	NOUN	I
risk	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
case-control	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
467	B-P	NUM	O
women	I-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
1	I-P	NUM	I
or	I-P	CCONJ	O
2	I-P	NUM	O
endometrial	I-P	ADJ	B
cancer	I-P	NOUN	I
and	I-P	CCONJ	O
582	I-P	NUM	O
age-matched	I-P	ADJ	O
controls	I-P	NOUN	B
.	I-P	PUNCT	O


miRNA	O	NOUN	B
and	O	CCONJ	O
DNA	O	NOUN	B
were	O	AUX	O
isolated	O	VERB	B
for	O	ADP	O
expression	O	NOUN	B
profiling	O	NOUN	I
and	O	CCONJ	O
genotyping	O	NOUN	B
from	O	ADP	O
tumor	B-P	NOUN	B
specimens	I-P	NOUN	I
of	I-P	ADP	O
46	I-P	NUM	O
women	I-P	NOUN	B
with	I-P	ADP	O
type	I-P	NOUN	B
1	I-P	NUM	I
endometrial	I-P	ADJ	I
cancer	I-P	NOUN	I
enrolled	I-P	VERB	O
in	I-P	ADP	O
RTOG	I-P	PROPN	B
trials	I-P	NOUN	B
9708	I-P	NUM	O
and	I-P	CCONJ	O
9905.	I-P	NOUN	O
miRNA	O	NOUN	B
expression	O	NOUN	B
levels	O	NOUN	O
and	O	CCONJ	O
KRAS-variant	O	ADJ	B
genotype	O	NOUN	I
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
patient	O	NOUN	B
and	O	CCONJ	O
tumor	O	NOUN	B
characteristics	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
survival	O	NOUN	B
outcomes	O	NOUN	O
were	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
variant	O	ADJ	B
allele	O	NOUN	B
type	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
KRAS-variant	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
overall	B-OUT	ADJ	O
endometrial	I-OUT	ADJ	B
cancer	I-OUT	NOUN	I
risk	I-OUT	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
controls	O	NOUN	B
and	O	CCONJ	O
17	O	NUM	O
%	O	NOUN	O
type	O	NOUN	B
1	O	NUM	I
cancers	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
although	O	SCONJ	O
was	O	AUX	O
enriched	O	ADJ	O
in	O	ADP	O
type	O	NOUN	B
2	O	NUM	I
endometrial	O	ADJ	I
cancers	O	NOUN	I
(	O	PUNCT	O
24	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
RTOG	O	PROPN	B
9708/9905	B-OUT	NUM	O
,	I-OUT	PUNCT	O
miRNA	I-OUT	NOUN	B
expression	I-OUT	NOUN	B
differed	O	VERB	O
by	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
presence	O	NOUN	B
of	O	ADP	O
lymphovascular	O	ADJ	B
invasion	O	NOUN	I
and	O	CCONJ	O
KRAS-variant	O	ADJ	B
status	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
at	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
for	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
the	I-P	DET	O
variant	I-P	NOUN	B
and	I-P	CCONJ	O
wild-type	I-P	ADJ	B
alleles	I-P	NOUN	O
were	O	AUX	O
100	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
77	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
HR	O	NOUN	B
0.3	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.24	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
favoring	O	VERB	O
the	O	DET	O
variant	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
KRAS-variant	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
genetic	O	ADJ	B
marker	O	NOUN	I
of	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
type	O	NOUN	B
2	O	NUM	I
endometrial	O	ADJ	I
cancers	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
tumor	O	NOUN	B
miRNA	O	NOUN	B
expression	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
patient	O	NOUN	B
age	O	NOUN	I
,	O	PUNCT	O
lymphovascular	O	ADJ	B
invasion	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
KRAS-variant	O	ADJ	B
,	O	PUNCT	O
supporting	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
altered	O	VERB	O
tumor	O	NOUN	B
biology	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
miRNA	O	NOUN	B
expression	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
KRAS-variant	O	ADJ	B
likely	O	ADV	O
impacts	O	VERB	B
endometrial	O	ADJ	B
tumor	O	NOUN	O
biology	O	NOUN	O
.	O	PUNCT	O


Opioid-immune	O	ADJ	B
interactions	O	NOUN	B
in	O	ADP	O
autism	B-P	NOUN	B
:	I-P	PUNCT	O
behavioural	O	ADJ	B
and	O	CCONJ	O
immunological	O	ADJ	B
assessment	O	NOUN	O
during	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
naltrexone	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
emerging	O	VERB	O
concept	O	NOUN	B
of	O	ADP	O
opioid	O	NOUN	B
peptides	O	NOUN	I
as	O	ADP	O
a	O	DET	O
new	O	ADJ	O
class	O	NOUN	O
of	O	ADP	O
chemical	O	ADJ	B
messengers	O	NOUN	I
of	O	ADP	O
the	O	DET	O
neuroimmune	O	ADJ	B
axis	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
immunological	O	ADJ	B
abnormalities	O	NOUN	I
in	O	ADP	O
infantile	O	ADJ	B
autism	O	NOUN	I
prompted	O	VERB	O
us	O	PRON	O
to	O	PART	O
correlate	O	VERB	O
biological	O	ADJ	B
(	O	PUNCT	O
hormonal	O	ADJ	B
and	O	CCONJ	O
immunological	O	ADJ	B
)	O	PUNCT	O
determinations	O	NOUN	B
and	O	CCONJ	O
behavioural	O	ADJ	B
performances	O	NOUN	I
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
potent	O	ADJ	O
opiate	O	ADJ	B
antagonist	O	NOUN	I
,	O	PUNCT	O
naltrexone	B-I	NOUN	B
(	I-I	PUNCT	O
NAL	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Twelve	B-P	NUM	O
autistic	I-P	ADJ	B
patients	I-P	NOUN	B
ranging	I-P	VERB	O
from	I-P	ADP	O
7	I-P	NUM	O
to	I-P	PART	O
15	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
diagnosed	I-P	VERB	B
according	I-P	VERB	O
to	I-P	ADP	O
DSM-III-R	I-P	NOUN	B
,	O	PUNCT	O
entered	O	VERB	O
a	O	DET	O
double-blind	B-I	ADJ	B
crossover	I-I	NOUN	B
study	I-I	NOUN	I
with	I-I	ADP	O
NAL	I-I	NOUN	B
at	I-I	ADP	O
the	I-I	DET	O
doses	I-I	NOUN	B
of	I-I	ADP	O
0.5	I-I	NUM	O
,	I-I	PUNCT	O
1.0	I-I	NUM	O
and	I-I	CCONJ	O
1.5	I-I	NUM	O
mg/kg	I-I	NOUN	O
every	I-I	DET	O
48	I-I	NUM	O
hours	I-I	NOUN	B
.	I-I	PUNCT	O


The	B-I	DET	O
behavioural	I-I	ADJ	B
evaluation	I-I	NOUN	I
was	I-I	AUX	O
conducted	I-I	VERB	O
using	I-I	VERB	O
the	I-I	DET	O
specific	I-I	ADJ	O
BSE	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
CARS	I-OUT	PROPN	B
rating	I-OUT	NOUN	I
scales	I-OUT	NOUN	O
NAL	I-I	NOUN	B
treatment	I-I	NOUN	B
produced	I-I	VERB	O
a	I-I	DET	O
significant	I-I	ADJ	O
reduction	I-I	NOUN	B
of	I-I	ADP	O
the	I-I	DET	O
autistic	I-OUT	ADJ	B
symptomatology	I-OUT	NOUN	B
in	I-I	ADP	O
seven	I-I	NUM	O
(	I-I	PUNCT	O
"	I-I	PUNCT	O
responders	I-I	NOUN	B
"	I-I	PUNCT	O
)	I-I	PUNCT	O
out	I-I	ADP	O
of	I-I	ADP	O
12	I-I	NUM	O
children	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
behavioural	O	ADJ	B
improvement	O	NOUN	I
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
distribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
lymphocyte	O	NOUN	B
subsets	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
T-helper-inducers	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
CD4+CD8-	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
T-cytotoxic-suppressor	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
CD4-CD8+	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
normalization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CD4/CD8	B-OUT	NOUN	B
ratio	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
natural	B-OUT	ADJ	B
killer	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
activity	I-OUT	NOUN	B
were	O	AUX	O
inversely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
plasma	O	NOUN	B
beta-endorphin	O	ADJ	B
levels	O	NOUN	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mechanisms	O	NOUN	B
underlying	O	VERB	O
opioid-immune	O	ADJ	B
interactions	O	NOUN	B
are	O	AUX	O
altered	O	VERB	O
in	O	ADP	O
this	O	DET	O
population	B-P	NOUN	B
of	I-P	ADP	O
autistic	I-P	ADJ	B
children	I-P	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
an	O	DET	O
immunological	O	ADJ	B
screening	O	NOUN	O
may	O	AUX	O
have	O	AUX	O
prognostic	O	ADJ	B
value	O	NOUN	I
for	O	ADP	O
the	O	DET	O
pharmacological	B-I	ADJ	B
therapy	I-I	NOUN	I
with	I-I	ADP	O
opiate	I-I	ADJ	B
antagonists	I-I	NOUN	I
.	I-I	PUNCT	O


Norfloxacin	B-I	NOUN	B
modulates	I-P	VERB	B
the	I-P	DET	O
inflammatory	I-P	ADJ	B
response	I-P	NOUN	I
and	I-P	CCONJ	O
directly	I-P	ADV	O
affects	I-P	VERB	O
neutrophils	I-P	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
decompensated	I-P	ADJ	B
cirrhosis	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
&	O	CCONJ	O
AIMS	O	ADJ	B
Patients	B-P	NOUN	B
with	I-P	ADP	O
cirrhosis	I-P	NOUN	B
undergoing	I-P	VERB	O
selective	I-P	ADJ	B
intestinal	I-P	ADJ	I
decontamination	I-P	NOUN	I
with	I-P	ADP	O
norfloxacin	I-I	NOUN	B
show	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
cytokine	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
probably	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
a	O	DET	O
combined	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
norfloxacin	B-I	NOUN	B
on	O	ADP	O
bowel	O	NOUN	B
flora	O	NOUN	I
and	O	CCONJ	O
neutrophils	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Thirty-one	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
cirrhosis	I-P	NOUN	B
receiving	I-P	VERB	O
norfloxacin	I-I	NOUN	B
(	I-P	PUNCT	O
400	I-P	NUM	O
mg/day	I-P	NOUN	O
)	I-P	PUNCT	O
were	I-P	AUX	O
included	I-P	VERB	O
.	I-P	PUNCT	O


Blood	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
at	O	ADP	O
0.5-4	O	NUM	O
hours	O	NOUN	B
(	O	PUNCT	O
peak	O	NOUN	B
samples	O	NOUN	I
group	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
47	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
22-24	O	NUM	O
hours	O	NOUN	B
(	O	PUNCT	O
trough	O	NOUN	O
samples	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
84	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
dose	O	NOUN	B
.	O	PUNCT	O


Fifty-nine	B-P	NUM	O
ascitic	I-P	ADJ	B
fluid	I-P	ADJ	I
samples	I-P	NOUN	O
were	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O


Single	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
norfloxacin	B-I	NOUN	B
and	I-I	CCONJ	O
trimethoprim/sulfamethoxazole	I-I	NOUN	B
were	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
13	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
(	O	PUNCT	O
temporal	O	ADJ	B
profile	O	NOUN	I
group	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
samples	O	NOUN	B
were	O	AUX	O
collected	O	VERB	B
at	O	ADP	O
0	O	NUM	O
,	O	PUNCT	O
0.5	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
1.5	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


Norfloxacin	B-I	NOUN	B
,	I-I	PUNCT	O
trimethoprim/sulfamethoxazole	I-I	NOUN	B
,	I-I	PUNCT	O
cytokines	I-I	NOUN	B
,	I-I	PUNCT	O
nitric	I-I	ADJ	B
oxide	I-I	NOUN	I
,	O	PUNCT	O
expression	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
nuclear	O	ADJ	B
factor	O	NOUN	I
(	O	PUNCT	O
NF	O	NOUN	B
)	O	PUNCT	O
-kappaB	O	NOUN	O
and	O	CCONJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
NF-kappaB	O	NOUN	B
(	O	PUNCT	O
IkB-alpha	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
neutrophil	O	NOUN	B
oxidative	O	ADJ	B
burst	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
rate	O	NOUN	B
of	O	ADP	O
apoptotic	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
All	O	DET	O
samples	O	NOUN	B
were	O	AUX	O
bacterial	O	ADJ	B
DNA	O	NOUN	O
negative	O	ADJ	O
and	O	CCONJ	O
had	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
levels	O	NOUN	B
of	O	ADP	O
lipopolysaccharide	O	NOUN	B
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
ascitic	I-OUT	ADJ	B
levels	I-OUT	NOUN	O
of	I-OUT	ADP	O
tumor	I-OUT	NOUN	B
necrosis	I-OUT	NOUN	I
factor-alpha	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
interferon-gamma	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
interleukin-12	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
nitric	I-OUT	ADJ	B
oxide	I-OUT	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
peak	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
trough	O	NOUN	O
samples	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
correlation	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
between	O	ADP	O
serum	B-OUT	NOUN	B
norfloxacins	I-OUT	VERB	B
concentrations	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
tumor	I-OUT	NOUN	B
necrosis	I-OUT	NOUN	I
factor-alpha	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-0.68	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
interferon-gamma	B-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-0.66	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
interleukin-12	B-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-0.66	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
nitric	B-OUT	ADJ	B
oxide	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-0.68	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
norfloxacin	I-OUT	NOUN	O
's	I-OUT	PART	O
highest	I-OUT	ADJ	B
concentrations	I-OUT	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
+/-	O	CCONJ	O
0.5	O	NUM	O
microg/mL	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
achieved	O	VERB	O
at	O	ADP	O
1-2	O	NUM	O
hours	O	NOUN	B
and	O	CCONJ	O
concurred	O	VERB	B
in	O	ADP	O
time	O	NOUN	O
with	O	ADP	O
the	O	DET	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
cytokines	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
nitric	I-OUT	ADJ	B
oxide	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Intracellular	B-OUT	ADJ	B
norfloxacin	I-OUT	NOUN	B
's	I-OUT	PART	O
highest	I-OUT	ADJ	O
levels	I-OUT	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
microg/mL/10	O	NOUN	O
(	O	PUNCT	O
7	O	NUM	O
)	O	PUNCT	O
cells	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	B
at	O	ADP	O
2	O	NUM	O
hours	O	NOUN	B
and	O	CCONJ	O
concurred	O	VERB	O
with	O	ADP	O
a	O	DET	O
lower	O	ADJ	O
NF-kappaB	O	NOUN	B
expression	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
reduced	O	VERB	B
anion	O	NOUN	B
superoxide	O	NOUN	I
generation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
apoptotic	O	ADJ	B
rate	O	NOUN	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
phorbol	O	NOUN	B
myristate	O	NOUN	B
acetate	O	NOUN	I
.	O	PUNCT	O


Trimethoprim/sulfamethoxazole	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
modulate	O	VERB	B
cytokine	B-OUT	NOUN	B
expression	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Norfloxacin	B-I	NOUN	B
but	O	CCONJ	O
not	O	PART	O
trimethoprim/sulfamethoxazole	B-I	NOUN	B
modulates	O	VERB	B
inflammatory	O	ADJ	B
response	O	NOUN	I
and	O	CCONJ	O
directly	O	ADV	O
affects	O	VERB	O
neutrophils	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cirrhosis	I-P	NOUN	B
.	I-P	PUNCT	O


Relationship	O	NOUN	B
between	O	ADP	O
baseline	O	NOUN	B
blood	O	NOUN	B
pressure	O	NOUN	I
parameters	O	NOUN	B
(	O	PUNCT	O
including	O	VERB	O
mean	O	ADJ	B
pressure	O	NOUN	I
,	O	PUNCT	O
pulse	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
variability	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
early	O	ADJ	B
outcome	O	NOUN	I
after	O	ADP	O
stroke	B-P	NOUN	B
:	I-P	PUNCT	O
data	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Tinzaparin	B-I	PROPN	B
in	I-I	ADP	O
Acute	I-I	PROPN	B
Ischaemic	I-I	PROPN	I
Stroke	I-I	PROPN	I
Trial	I-I	PROPN	I
(	I-P	PUNCT	O
TAIST	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
PURPOSE	O	ADJ	O
High	B-P	ADJ	B
blood	I-P	NOUN	I
pressure	I-P	NOUN	I
(	I-P	PUNCT	O
BP	I-P	NOUN	B
)	I-P	PUNCT	O
in	I-P	ADP	O
acute	I-P	ADJ	B
stroke	I-P	NOUN	I
is	O	AUX	O
associated	O	VERB	O
independently	O	ADV	O
with	O	ADP	O
a	O	DET	O
poor	O	ADJ	B
outcome	O	NOUN	I
.	O	PUNCT	O


Recent	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
other	O	ADJ	O
hemodynamic	O	ADJ	B
parameters	O	NOUN	B
may	O	AUX	O
also	O	ADV	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
outcomes	O	NOUN	B
following	O	VERB	O
stroke	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
baseline	O	NOUN	B
BP	O	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
rate	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
hemodynamic	O	ADJ	B
parameters	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
early	O	ADJ	B
outcomes	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
using	B-P	VERB	O
data	I-P	NOUN	B
from	I-P	ADP	O
TAIST	I-P	ADJ	B
trial	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	VERB	B
Death	B-OUT	NOUN	I
or	I-OUT	CCONJ	O
neurological	I-OUT	ADJ	B
deterioration	I-OUT	NOUN	I
at	I-OUT	ADP	O
day	I-OUT	NOUN	B
10	I-OUT	NUM	O
was	O	AUX	O
associated	O	VERB	O
,	O	PUNCT	O
both	O	CCONJ	O
in	O	ADP	O
unadjusted	O	ADJ	B
and	O	CCONJ	O
adjusted	O	VERB	O
analyses	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
systolic	B-OUT	NOUN	B
BP	I-OUT	NOUN	I
(	O	PUNCT	O
adjusted	O	VERB	O
OR	O	CCONJ	B
,	O	PUNCT	O
1.02	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.01-1.03	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
mean	B-OUT	VERB	B
arterial	I-OUT	ADJ	I
pressure	I-OUT	NOUN	I
(	O	PUNCT	O
OR	O	CCONJ	B
,	O	PUNCT	O
1.02	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.01-1.04	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
pulse	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
(	O	PUNCT	O
OR	O	CCONJ	B
,	O	PUNCT	O
1.02	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.01-1.03	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
BP	B-OUT	NOUN	B
variability	I-OUT	NOUN	B
(	O	PUNCT	O
OR	O	CCONJ	B
,	O	PUNCT	O
1.03	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1.01-1.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Similar	O	ADJ	O
relationships	O	NOUN	B
were	O	AUX	O
noted	O	VERB	O
for	O	ADP	O
deterioration	B-OUT	NOUN	B
alone	I-OUT	ADV	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
recurrent	I-OUT	ADJ	B
stroke	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Early	O	ADJ	B
death	B-OUT	NOUN	I
or	O	CCONJ	O
neurologic	B-OUT	ADJ	B
deterioration	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
deterioration	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
recurrent	B-OUT	ADJ	B
stroke	I-OUT	NOUN	I
are	O	AUX	O
associated	O	VERB	O
independently	O	ADV	O
with	O	ADP	O
high	B-OUT	ADJ	O
systolic	I-OUT	NOUN	O
BP	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
mean	I-OUT	VERB	O
arterial	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
pulse	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
BP	I-OUT	NOUN	B
variability	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
measures	O	NOUN	B
offer	O	VERB	O
potential	O	ADJ	B
therapeutic	B-I	ADJ	B
targets	I-I	NOUN	O
for	O	ADP	O
improving	O	VERB	B
early	O	ADJ	B
outcome	O	NOUN	I
after	O	ADP	O
acute	B-P	ADJ	B
ischemic	I-P	ADJ	I
stroke	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
acupuncture	B-I	NOUN	B
with	O	ADP	O
advice	B-I	NOUN	B
and	I-I	CCONJ	O
exercises	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
symptomatic	B-OUT	ADJ	B
treatment	I-OUT	NOUN	B
of	O	ADP	O
osteoarthritis	B-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
hip	I-P	NOUN	B
--	I-P	PUNCT	O
a	I-P	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Acupuncture	B-I	NOUN	B
is	O	AUX	O
becoming	O	VERB	O
a	O	DET	O
common	O	ADJ	O
technique	O	NOUN	B
within	O	ADP	O
the	O	DET	O
physiotherapy	O	NOUN	B
profession	O	NOUN	I
as	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
modality	O	NOUN	O
for	O	ADP	O
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
few	O	ADJ	O
randomised	O	VERB	B
controlled	O	ADJ	I
trials	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
acupuncture	B-I	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
osteoarthritis	B-P	NOUN	B
(	I-P	PUNCT	O
OA	I-P	NOUN	B
)	I-P	PUNCT	O
of	I-P	ADP	O
the	I-P	DET	O
hip	I-P	NOUN	B
.	I-P	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
trial	O	NOUN	I
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
acupuncture	B-I	NOUN	B
with	O	ADP	O
advice	O	NOUN	B
and	O	CCONJ	O
exercises	B-I	NOUN	B
on	O	ADP	O
the	O	DET	O
symptomatic	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
OA	B-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
hip	I-P	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


Thirty-two	B-P	NUM	O
patients	I-P	NOUN	B
awaiting	I-P	VERB	O
a	I-P	DET	O
total	I-P	ADJ	B
hip	I-P	NOUN	I
arthroplasty	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
the	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
to	O	PART	O
have	O	AUX	O
six	B-I	NUM	O
sessions	I-I	NOUN	B
of	I-I	ADP	O
acupuncture	I-I	NOUN	B
each	O	DET	O
lasting	O	NOUN	O
up	O	ADV	O
to	O	PART	O
25	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
(	O	PUNCT	O
B	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
to	O	PART	O
be	O	AUX	O
given	O	VERB	O
advice	B-I	NOUN	B
and	I-I	CCONJ	O
exercises	I-I	NOUN	B
for	O	ADP	O
their	O	PRON	O
hip	O	NOUN	B
over	O	ADP	O
a	O	DET	O
six	O	NUM	O
week	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Group	B-P	PROPN	B
A	I-P	PROPN	O
consisted	I-P	VERB	O
of	I-P	ADP	O
three	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
13	I-P	NUM	O
women	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
group	I-P	NOUN	B
B	I-P	NOUN	I
consisted	I-P	VERB	O
of	I-P	ADP	O
four	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
eight	I-P	NUM	O
women	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
average	B-P	ADJ	O
age	I-P	NOUN	B
in	I-P	ADP	O
group	I-P	NOUN	B
A	I-P	NOUN	I
was	I-P	AUX	O
66	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
in	I-P	ADP	O
group	I-P	NOUN	B
B	I-P	NOUN	I
it	I-P	PRON	O
was	I-P	AUX	O
68	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
pain	O	NOUN	B
and	O	CCONJ	O
functional	O	ADJ	B
ability	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
modified	O	VERB	B
version	O	NOUN	O
of	O	ADP	O
the	O	DET	O
WOMAC	B-OUT	NOUN	B
questionnaire	I-OUT	NOUN	I
,	O	PUNCT	O
pre-treatment	O	NOUN	B
,	O	PUNCT	O
immediately	O	ADV	O
post-treatment	O	ADJ	B
and	O	CCONJ	O
at	O	ADP	O
eight	O	NUM	O
weeks	O	NOUN	B
post-treatment	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
pre-treatment	O	ADJ	B
WOMAC	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
(	O	PUNCT	O
p=0.85	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
WOMAC	B-OUT	NOUN	B
score	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
immediately	O	ADV	O
post-treatment	O	ADJ	B
(	O	PUNCT	O
p=0.002	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
was	O	AUX	O
maintained	O	VERB	B
at	O	ADP	O
the	O	DET	O
eight-week	O	ADJ	B
follow-up	O	NOUN	I
(	O	PUNCT	O
p=0.03	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
WOMAC	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
significantly	O	ADV	O
greater	O	ADJ	O
improvement	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
pre-treatment	O	ADJ	B
and	O	CCONJ	O
immediately	O	ADV	O
post-treatment	O	ADJ	B
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
p=0.02	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
changes	O	NOUN	B
between	O	ADP	O
pre-treatment	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
eight-week	O	NOUN	B
follow-up	O	NOUN	I
also	O	ADV	O
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
p=0.03	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
trial	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
acupuncture	B-I	NOUN	B
is	O	AUX	O
more	O	ADV	O
effective	B-OUT	ADJ	B
than	O	ADP	O
advice	O	NOUN	B
and	O	CCONJ	O
exercises	O	NOUN	B
in	O	ADP	O
the	O	DET	O
symptomatic	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
OA	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hip	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Clinical	O	ADJ	B
application	O	NOUN	I
of	O	ADP	O
irradiated	O	ADJ	B
drug-containing	B-I	ADJ	B
porcine-cornea	I-I	NOUN	B
to	O	PART	O
patients	B-P	NOUN	B
with	I-P	ADP	O
ocular	I-P	ADJ	B
burns	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
explore	O	VERB	O
a	O	DET	O
new	O	ADJ	O
method	O	NOUN	B
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
ocular	I-P	ADJ	B
burns	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fifty-five	B-P	NUM	O
cases	I-P	NOUN	B
of	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
ocular	I-P	ADJ	B
burns	I-P	NOUN	I
(	I-P	PUNCT	O
in	I-P	ADP	O
88	I-P	NUM	O
eyes	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Thirty	O	NUM	O
cases	O	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
group	O	NOUN	I
with	O	ADP	O
49	B-P	NUM	O
eyes	I-P	NOUN	B
were	I-P	AUX	O
transplanted	I-P	VERB	B
with	O	ADP	O
irradiated	B-I	ADJ	B
drug-containing	I-I	NOUN	B
(	I-I	PUNCT	O
ofloxacin	I-I	NOUN	B
,	I-I	PUNCT	O
acetyl	I-I	ADJ	B
cysteine	I-I	NOUN	I
and	I-I	CCONJ	O
reduced	I-I	VERB	B
glutathione	I-I	NOUN	B
)	I-I	PUNCT	O
porcine-cornea	I-I	NOUN	B
.	I-I	PUNCT	O


25	O	NUM	O
cases	O	NOUN	B
in	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
with	O	ADP	O
39	O	NUM	O
eyes	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
routine	O	ADJ	B
program	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
Thirty-two	O	NUM	O
eyes	B-OUT	NOUN	B
were	I-OUT	AUX	O
rescued	I-OUT	VERB	B
in	O	ADP	O
treatment	O	NOUN	B
group	O	NOUN	I
with	O	ADP	O
the	O	DET	O
cure	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
65.3	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


But	O	CCONJ	O
only	O	ADV	O
17	O	NUM	O
eyes	B-OUT	NOUN	B
were	I-OUT	AUX	O
saved	I-OUT	VERB	O
in	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
with	O	ADP	O
the	O	DET	O
cure	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
43.59	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
indicating	O	VERB	O
significant	O	ADJ	O
difference	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cure	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	ADJ	O
Irradiated	O	ADJ	B
drug-containing	O	ADJ	B
porcine-cornea	B-I	NOUN	B
might	O	AUX	O
well	O	ADV	O
be	O	AUX	O
an	O	DET	O
ideal	O	ADJ	O
therapeutic	O	ADJ	B
material	O	NOUN	I
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
ocular	I-P	ADJ	B
burns	I-P	NOUN	I
.	I-P	PUNCT	O


Randomized	O	ADJ	B
comparative	O	ADJ	I
study	O	NOUN	I
of	O	ADP	O
group	B-I	NOUN	B
versus	I-I	CCONJ	O
individual	I-I	ADJ	B
cognitive	I-I	ADJ	B
behavioural	I-I	ADJ	I
therapy	I-I	NOUN	I
for	O	ADP	O
obsessive	B-P	ADJ	B
compulsive	I-P	ADJ	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
primary	O	ADJ	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
group	B-I	NOUN	B
and	I-I	CCONJ	O
individual	I-I	ADJ	B
cognitive	I-I	ADJ	B
behaviour	I-I	NOUN	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
CBT	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
obsessive	B-P	ADJ	B
compulsive	I-P	ADJ	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
OCD	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHOD	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
ten	I-P	NUM	O
out-patients	I-P	NOUN	B
with	I-P	ADP	O
OCD	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
15	O	NUM	O
sessions	O	NOUN	B
of	O	ADP	O
either	O	DET	O
group	B-I	NOUN	B
CBT	I-I	NOUN	B
or	I-I	CCONJ	O
individual	I-I	ADJ	O
CBT	I-I	NOUN	B
.	I-I	PUNCT	O


Outcome	O	NOUN	B
measures	O	NOUN	I
were	O	AUX	O
administered	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
at	O	ADP	O
6-	O	NUM	O
and	O	CCONJ	O
12-month	O	ADJ	O
follow-ups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
supplemented	O	VERB	O
by	O	ADP	O
a	O	DET	O
meta-analysis	O	NOUN	B
of	O	ADP	O
accomplished	O	VERB	O
comparative	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
group	B-I	NOUN	B
vs.	I-I	CCONJ	O
individual	I-I	ADJ	B
CBT	I-I	NOUN	B
for	O	ADP	O
OCD	O	PROPN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Large	O	ADJ	O
and	O	CCONJ	O
stable	O	ADJ	B
pre-post	O	ADJ	B
effect	B-OUT	NOUN	O
sizes	I-OUT	NOUN	O
were	O	AUX	O
found	O	VERB	O
for	O	ADP	O
both	O	DET	O
treatment	O	NOUN	B
conditions	O	NOUN	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
(	O	PUNCT	O
d	O	NOUN	O
=	O	ADJ	O
1.06-1.24	O	NOUN	O
on	O	ADP	O
the	O	DET	O
Yale-Brown	B-OUT	PROPN	B
Obsessive	I-OUT	PROPN	I
Compulsive	I-OUT	PROPN	I
Scale	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
between-group	O	NOUN	B
differences	O	NOUN	I
in	O	ADP	O
outcome	O	NOUN	B
at	O	ADP	O
any	O	DET	O
data	O	NOUN	B
point	O	NOUN	I
(	O	PUNCT	O
ds=	O	NOUN	O
-0.13	O	NUM	O
to	O	PART	O
0.15	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
meta-analysis	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
accomplished	O	VERB	O
comparative	O	ADJ	B
studies	O	NOUN	I
(	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
present	O	ADJ	O
one	O	NUM	O
)	O	PUNCT	O
found	O	VERB	O
a	O	DET	O
between-group	O	ADJ	B
mean	O	ADJ	O
effect	O	NOUN	O
size	O	NOUN	O
of	O	ADP	O
(	O	PUNCT	O
d=	O	NOUN	O
0.15	O	NUM	O
favouring	O	VERB	O
individual	O	NOUN	B
over	O	ADP	O
group	O	NOUN	B
CBT	B-I	NOUN	B
at	O	ADP	O
posttreatment	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
-0.12	O	NOUN	O
,	O	PUNCT	O
0.42	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
OCD	O	PROPN	B
can	O	AUX	O
be	O	AUX	O
treated	O	VERB	B
effectively	B-OUT	ADV	O
with	O	ADP	O
a	O	DET	O
group	B-I	NOUN	B
format	I-I	NOUN	I
of	I-I	ADP	O
CBT	I-I	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
sparing	O	VERB	B
some	O	DET	O
therapist	O	NOUN	B
resources	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
four	O	NUM	O
accomplished	O	ADJ	O
comparative	O	ADJ	B
studies	O	NOUN	I
do	O	AUX	O
not	O	PART	O
rule	O	VERB	O
out	O	ADP	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
small	O	ADJ	O
superiority	O	NOUN	B
of	O	ADP	O
individually	O	ADV	O
conducted	O	VERB	O
CBT	B-I	NOUN	B
.	I-I	PUNCT	O


Late	O	ADJ	O
patient-reported	O	ADJ	B
toxicity	O	NOUN	O
after	O	ADP	O
preoperative	O	ADJ	B
radiotherapy	B-I	NOUN	B
or	O	CCONJ	O
chemoradiotherapy	B-I	NOUN	B
in	O	ADP	O
nonresectable	B-P	ADJ	B
rectal	I-P	ADJ	I
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
Phase	O	NOUN	I
III	O	NUM	I
study	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	VERB	O
Preoperative	B-I	ADJ	B
chemoradiotherapy	I-I	NOUN	O
(	O	PUNCT	O
CRT	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
radiotherapy	B-I	NOUN	B
(	O	PUNCT	O
RT	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
locally	B-P	ADV	B
advanced	I-P	ADJ	I
rectal	I-P	ADJ	I
cancer	I-P	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
survival	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
is	O	AUX	O
limited	O	VERB	O
.	O	PUNCT	O


Late	O	ADJ	B
toxicity	B-OUT	NOUN	B
is	O	AUX	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
important	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
late	B-OUT	ADJ	B
bowel	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
urinary	I-OUT	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
sexual	B-OUT	ADJ	B
functions	I-OUT	NOUN	I
after	O	ADP	O
CRT	O	NOUN	B
or	O	CCONJ	O
RT	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
MATERIALS	O	X	O
Patients	B-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
207	I-P	NUM	O
)	I-P	PUNCT	O
with	I-P	ADP	O
nonresectable	I-P	ADJ	B
rectal	I-P	ADJ	I
cancer	I-P	NOUN	I
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	PART	O
preoperative	I-I	ADJ	B
CRT	I-I	NOUN	B
or	I-I	CCONJ	O
RT	I-I	NOUN	B
(	I-P	PUNCT	O
2	I-P	NUM	O
Gy	I-P	NOUN	O
×	I-P	NOUN	O
25	I-P	NUM	O
±	I-P	NOUN	O
5-fluorouracil/leucovorin	I-I	NOUN	B
)	I-I	PUNCT	O
.	O	PUNCT	O


Extended	O	ADJ	B
surgery	O	NOUN	I
was	O	AUX	O
often	O	ADV	O
required	B-OUT	VERB	O
.	I-OUT	PUNCT	O


Self-reported	B-OUT	ADJ	B
late	I-OUT	ADJ	O
toxicity	I-OUT	NOUN	B
was	O	AUX	O
scored	O	VERB	B
according	O	VERB	O
to	O	ADP	O
the	B-OUT	DET	O
LENT	I-OUT	PROPN	B
SOMA	I-OUT	PROPN	O
criteria	I-OUT	NOUN	O
in	O	ADP	O
a	B-OUT	DET	O
structured	I-OUT	ADJ	B
telephone	I-OUT	NOUN	I
interview	I-OUT	NOUN	I
and	O	CCONJ	O
with	B-OUT	ADP	O
questionnaires	I-OUT	NOUN	B
European	I-OUT	PROPN	B
Organisation	I-OUT	PROPN	I
for	I-OUT	ADP	I
Research	I-OUT	PROPN	B
and	I-OUT	CCONJ	O
Treatment	I-OUT	NOUN	B
of	I-OUT	ADP	O
Cancer	I-OUT	PROPN	O
(	I-OUT	PUNCT	O
EORTC	I-OUT	PROPN	O
)	I-OUT	PUNCT	O
Quality	I-OUT	PROPN	O
of	I-OUT	ADP	O
Life	I-OUT	PROPN	O
Questionnaire	I-OUT	PROPN	O
(	I-OUT	PUNCT	O
QLQ-C30	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
International	I-OUT	PROPN	B
Index	I-OUT	PROPN	I
of	I-OUT	ADP	I
Erectile	I-OUT	PROPN	I
Function	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
IIEF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
sexual	I-OUT	ADJ	B
function-vaginal	I-OUT	ADJ	I
changes	I-OUT	NOUN	I
questionnaire	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
SVQ	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
Of	O	ADP	O
the	B-P	DET	O
105	I-P	NUM	O
patients	I-P	NOUN	B
alive	I-P	ADJ	B
in	I-P	ADP	O
Norway	I-P	PROPN	B
and	I-P	CCONJ	O
Sweden	I-P	PROPN	B
after	I-P	ADP	O
4	I-P	NUM	O
to	I-P	PART	O
12	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
follow-up	I-P	NOUN	B
,	I-P	PUNCT	O
78	I-P	NUM	O
(	I-P	PUNCT	O
74	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
responded	O	VERB	O
.	O	PUNCT	O


More	O	ADJ	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CRT	O	NOUN	B
group	O	NOUN	B
had	O	AUX	O
received	O	VERB	O
a	B-OUT	DET	O
stoma	I-OUT	NOUN	B
(	O	PUNCT	O
73	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
52	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.09	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Most	O	ADJ	O
patients	O	NOUN	B
without	O	ADP	O
a	B-OUT	DET	O
stoma	I-OUT	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
of	O	ADP	O
12	O	NUM	O
in	O	ADP	O
CRT	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
9	O	NUM	O
of	O	ADP	O
16	O	NUM	O
in	O	ADP	O
RT	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
had	O	AUX	O
incontinence	O	NOUN	B
for	B-OUT	ADP	O
liquid	I-OUT	ADJ	B
stools	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
gas	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


No	B-OUT	DET	B
stoma	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
good	I-OUT	ADJ	O
anal	I-OUT	ADJ	B
function	I-OUT	NOUN	I
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
5	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
CRT	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
11	O	NUM	O
(	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
RT	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.046	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	B-P	ADP	O
44	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
CRT	I-P	NOUN	B
group	I-P	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
(	O	PUNCT	O
28	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
had	B-OUT	AUX	O
bowel	I-OUT	NOUN	B
obstruction	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
5	O	NUM	O
of	O	ADP	O
33	O	NUM	O
(	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
RT	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.27	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


One-quarter	O	ADJ	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
reported	B-OUT	VERB	O
urinary	I-OUT	ADJ	B
incontinence	I-OUT	NOUN	I
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
men	O	NOUN	B
had	B-OUT	AUX	O
severe	I-OUT	ADJ	B
erectile	I-OUT	NOUN	B
dysfunction	I-OUT	NOUN	I
.	O	PUNCT	O


Few	O	ADJ	O
women	O	NOUN	B
reported	B-OUT	VERB	O
sexual	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
during	O	ADP	O
the	O	DET	O
previous	O	ADJ	O
month	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
majority	O	NOUN	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
concerns	O	NOUN	B
about	O	ADP	O
their	O	PRON	O
sex	O	NOUN	B
life	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	B-OUT	NOUN	O
Fecal	I-OUT	ADJ	B
incontinence	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
erectile	I-OUT	NOUN	B
dysfunction	I-OUT	NOUN	I
are	O	AUX	O
frequent	O	ADJ	B
after	O	ADP	O
combined	O	ADJ	B
treatment	O	NOUN	B
for	B-P	ADP	O
locally	I-P	ADV	B
advanced	I-P	ADJ	I
rectal	I-P	ADJ	O
cancer	I-P	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
clear	O	ADJ	O
tendency	O	NOUN	O
for	O	ADP	O
the	O	DET	O
problems	O	NOUN	B
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
after	O	ADP	O
CRT	O	NOUN	B
than	O	ADP	O
after	O	ADP	O
RT	O	NOUN	B
.	O	PUNCT	O


New	B-I	ADJ	O
mini-extracorporeal	I-I	ADJ	O
circulation	I-I	NOUN	O
system	I-I	NOUN	O
(	I-I	PUNCT	O
ECC.O	I-I	NOUN	O
)	I-I	PUNCT	O
is	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
technique	O	NOUN	B
in	O	ADP	O
coronary	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
Cardiopulmonary	B-I	PROPN	B
bypass	I-I	NOUN	I
(	I-I	PUNCT	O
CPB	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
the	O	DET	O
systemic	O	ADJ	B
inflammatory	O	ADJ	I
reaction	O	NOUN	I
after	O	ADP	O
cardiac	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


New	O	ADJ	B
coated	O	VERB	B
and	O	CCONJ	O
closed	O	ADJ	B
loop	O	NOUN	I
circuit	O	NOUN	I
systems	O	NOUN	I
may	O	AUX	O
reduce	O	VERB	O
this	O	DET	O
inflammation	B-OUT	NOUN	B
response	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
improve	I-OUT	VERB	B
the	I-OUT	DET	O
surgical	I-OUT	ADJ	B
outcome	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mini-extracorporeal	B-I	ADJ	B
circulation	I-I	NOUN	I
system	I-I	NOUN	I
(	I-I	PUNCT	O
ECC.O	I-I	NOUN	O
)	I-I	PUNCT	O
in	O	ADP	O
CABG	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
Forty	B-P	NUM	O
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
coronary	I-P	ADJ	I
surgery	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
ECC.O	B-I	NOUN	O
group	I-I	NOUN	B
and	I-I	CCONJ	O
the	I-I	DET	O
standard	I-I	ADJ	B
CPB	I-I	NOUN	B
group	I-I	NOUN	O
.	I-I	PUNCT	O


Routine	O	ADJ	B
hemodynamic	O	ADJ	B
monitoring	O	NOUN	B
and	O	CCONJ	O
biochemical	O	ADJ	B
measurements	O	NOUN	I
were	O	AUX	O
registered	O	VERB	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
practice	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
clinical	O	ADJ	B
outcome	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
the	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
intubation	I-OUT	NOUN	B
following	I-OUT	VERB	O
surgery	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
length	I-OUT	NOUN	B
of	I-OUT	ADP	O
intensive	I-OUT	ADJ	B
care	I-OUT	NOUN	I
unit-stay	I-OUT	ADV	O
or	I-OUT	CCONJ	O
the	I-OUT	DET	O
total	I-OUT	ADJ	B
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
haemoglobin	B-OUT	NOUN	B
level	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	B
higher	O	ADJ	I
(	O	PUNCT	O
p=0.0069	O	NOUN	O
)	O	PUNCT	O
during	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
perfusion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ECC.O	B-I	NOUN	O
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
ECC.O	B-I	NOUN	O
system	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
safely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
CABG	B-P	NOUN	B
patients	I-P	NOUN	B
and	O	CCONJ	O
it	O	PRON	O
maintains	O	VERB	O
haemoglobin	O	NOUN	B
level	O	NOUN	B
better	O	ADJ	O
than	O	ADP	O
conventional	O	ADJ	B
CPB	B-I	PROPN	B
.	I-I	PUNCT	O


Disparities	O	NOUN	B
in	O	ADP	O
transition	B-I	NOUN	B
planning	I-I	NOUN	B
for	O	ADP	O
youth	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
Little	O	ADV	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
accessibility	O	NOUN	B
to	O	ADP	O
health	B-I	NOUN	B
care	I-I	NOUN	I
transition	I-I	NOUN	I
(	I-I	PUNCT	O
HCT	I-I	NOUN	B
)	I-I	PUNCT	O
services	O	NOUN	O
for	O	ADP	O
youth	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
expands	O	VERB	O
our	O	PRON	O
understanding	O	NOUN	O
by	O	ADP	O
examining	O	VERB	B
the	O	DET	O
receipt	O	NOUN	B
of	O	ADP	O
HCT	O	NOUN	B
services	O	NOUN	I
in	O	ADP	O
youth	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	VERB	B
compared	I-P	VERB	O
with	I-P	ADP	O
youth	I-P	NOUN	B
with	I-P	ADP	O
other	I-P	ADJ	O
special	I-P	ADJ	O
health	I-P	NOUN	B
care	I-P	NOUN	I
needs	I-P	NOUN	O
(	I-P	PUNCT	O
OSHCN	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
We	B-P	PRON	O
used	I-P	VERB	O
the	I-P	DET	O
2005-2006	I-P	NUM	O
National	I-P	PROPN	B
Survey	I-P	PROPN	I
of	I-P	ADP	I
Children	I-P	PROPN	I
with	I-P	ADP	O
Special	I-P	PROPN	B
Health	I-P	PROPN	I
Care	I-P	PROPN	I
Needs	I-P	PROPN	O
to	I-P	PART	O
examine	I-P	VERB	O
receipt	I-P	NOUN	B
of	I-P	ADP	O
HCT	I-I	NOUN	B
services	I-I	NOUN	I
for	I-P	ADP	O
youth	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
12-17	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
ASD	I-P	VERB	B
and	I-P	CCONJ	O
youth	I-P	NOUN	B
with	I-P	ADP	O
OSHCN	I-P	PROPN	B
.	I-P	PUNCT	O


Logistic	O	ADJ	B
regression	O	NOUN	I
analyses	O	NOUN	I
explored	O	VERB	O
whether	O	SCONJ	O
individual	O	NOUN	B
,	O	PUNCT	O
family	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
health	O	NOUN	B
system	O	NOUN	I
factors	O	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
receipt	O	NOUN	B
of	O	ADP	O
HCT	O	NOUN	B
services	O	NOUN	I
for	O	ADP	O
youth	O	NOUN	B
with	O	ADP	O
ASD	O	PROPN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Whereas	O	SCONJ	O
half	O	DET	O
of	O	ADP	O
youth	O	NOUN	B
with	O	ADP	O
OSHCN	O	NOUN	B
received	O	VERB	O
HCT	B-OUT	NOUN	B
services	I-OUT	NOUN	I
,	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
a	O	DET	O
quarter	O	NOUN	B
of	O	ADP	O
youth	O	NOUN	B
with	O	ADP	O
ASD	O	PROPN	B
did	O	AUX	O
.	O	PUNCT	O


Only	O	ADV	O
14	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
youth	O	NOUN	B
with	O	ADP	O
ASD	O	PROPN	B
had	O	AUX	O
a	O	DET	O
discussion	O	NOUN	B
with	O	ADP	O
their	O	PRON	O
pediatrician	O	NOUN	B
about	O	ADP	O
transitioning	O	VERB	O
to	O	ADP	O
an	O	DET	O
adult	O	ADJ	B
provider	O	NOUN	B
,	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
a	O	DET	O
quarter	O	NOUN	B
had	O	AUX	O
a	O	DET	O
discussion	O	NOUN	B
about	O	ADP	O
health	B-OUT	NOUN	B
insurance	I-OUT	NOUN	I
retention	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
just	O	ADV	O
under	O	ADP	O
half	O	NOUN	B
discussed	O	VERB	O
adult	B-OUT	ADJ	B
health	I-OUT	NOUN	B
care	I-OUT	NOUN	I
needs	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
were	I-OUT	AUX	O
encouraged	I-OUT	VERB	O
to	I-OUT	PART	O
take	I-OUT	VERB	O
on	I-OUT	ADP	O
appropriate	I-OUT	ADJ	O
responsibility	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Logistic	O	ADJ	B
regression	O	NOUN	I
analyses	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
having	O	VERB	O
a	O	DET	O
developmental	O	ADJ	B
disability	O	NOUN	I
or	O	CCONJ	O
multiple	O	ADJ	B
health	O	NOUN	B
conditions	O	NOUN	I
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
ASD	O	VERB	B
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	O
health	O	NOUN	B
care	O	NOUN	I
were	O	AUX	O
strong	O	ADJ	O
predictors	O	NOUN	B
of	O	ADP	O
HCT	B-OUT	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
demographic	O	ADJ	B
and	O	CCONJ	O
family	O	NOUN	B
variables	O	NOUN	I
accounted	O	VERB	O
for	O	ADP	O
little	O	ADJ	O
variance	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Youth	B-P	PROPN	B
with	I-P	ADP	O
ASD	I-P	VERB	B
experience	O	NOUN	O
disparities	O	NOUN	B
in	O	ADP	O
access	O	NOUN	O
to	O	ADP	O
HCT	B-I	NOUN	B
services	O	NOUN	I
.	O	PUNCT	O


Youth	B-P	NOUN	B
with	I-P	ADP	O
comorbid	I-P	ADJ	B
conditions	I-P	NOUN	I
are	O	AUX	O
at	O	ADP	O
greatest	O	ADJ	O
risk	O	NOUN	B
for	O	ADP	O
poor	O	ADJ	B
access	O	NOUN	I
to	O	ADP	O
HCT	B-I	NOUN	B
services	O	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
quality	O	NOUN	B
of	O	ADP	I
care	O	NOUN	I
has	O	AUX	O
a	O	DET	O
positive	O	ADJ	B
effect	O	NOUN	O
.	O	PUNCT	O


Research	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
to	O	PART	O
understand	O	VERB	O
barriers	O	NOUN	B
to	O	PART	O
care	O	VERB	B
and	O	CCONJ	O
develop	O	VERB	O
policy	O	NOUN	B
and	O	CCONJ	O
practice	O	NOUN	B
guidelines	O	NOUN	I
tailored	O	VERB	O
for	O	ADP	O
youth	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


Hyperinsulinemia	O	NOUN	B
fails	O	VERB	O
to	O	PART	O
augment	O	VERB	O
ET-1	O	NOUN	B
action	O	NOUN	B
in	O	ADP	O
the	O	DET	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
vascular	O	ADJ	B
bed	O	NOUN	I
in	O	X	B
vivo	B-P	X	I
in	I-P	ADP	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


Endogenous	O	ADJ	B
endothelin	O	NOUN	B
action	O	NOUN	O
is	O	AUX	O
augmented	O	VERB	B
in	O	ADP	O
human	O	ADJ	B
obesity	O	NOUN	B
and	O	CCONJ	O
type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
and	O	CCONJ	O
contributes	O	VERB	O
to	O	PART	O
endothelial	O	ADJ	B
dysfunction	O	NOUN	I
and	O	CCONJ	O
impairs	O	VERB	B
insulin-mediated	O	ADJ	B
vasodilation	O	NOUN	I
in	O	ADP	O
humans	B-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
insulin	O	NOUN	B
resistance-associated	O	ADJ	B
hyperinsulinemia	O	NOUN	B
could	O	AUX	O
preferentially	O	ADV	O
drive	O	VERB	O
endothelin-mediated	B-OUT	ADJ	B
vasoconstriction	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


We	O	PRON	O
applied	O	VERB	O
hyperinsulinemic-euglycemic	B-I	ADJ	B
clamps	I-I	NOUN	I
with	O	ADP	O
higher	B-P	ADJ	B
insulin	I-I	NOUN	B
dosing	I-P	NOUN	B
in	I-P	ADP	O
obese	I-P	ADJ	B
subjects	I-P	NOUN	B
than	I-P	ADP	O
lean	I-P	ADJ	B
subjects	I-P	NOUN	I
(	I-P	PUNCT	O
30	I-P	NUM	O
vs.	I-P	CCONJ	O
10	I-P	NUM	O
mU.m	I-P	NOUN	O
(	I-P	PUNCT	O
-2	I-P	NUM	O
)	I-P	PUNCT	O
.min	I-P	NOUN	O
(	I-P	PUNCT	O
-1	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
respectively	I-P	ADV	O
)	I-P	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
matching	O	VERB	B
insulin	O	NOUN	B
's	O	PART	I
nitric	O	ADJ	B
oxide	O	NOUN	I
(	O	PUNCT	O
NO	O	NOUN	B
)	O	PUNCT	O
-mediated	O	ADJ	O
vascular	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
predicted	O	VERB	B
that	O	SCONJ	O
,	O	PUNCT	O
under	O	ADP	O
these	O	DET	O
circumstances	O	NOUN	B
,	O	PUNCT	O
insulin-stimulated	O	ADJ	B
endothelin-1	O	NOUN	B
(	O	PUNCT	O
ET-1	O	NOUN	B
)	O	PUNCT	O
action	O	NOUN	O
(	O	PUNCT	O
assessed	O	VERB	B
with	O	ADP	O
the	O	DET	O
type	O	NOUN	B
A	O	NOUN	I
endothelin	O	NOUN	I
receptor	O	NOUN	I
antagonist	O	NOUN	B
BQ-123	O	NOUN	B
)	O	PUNCT	O
would	O	AUX	O
be	O	AUX	O
augmented	O	VERB	B
in	O	ADP	O
proportion	O	NOUN	B
to	O	PART	O
hyperinsulinemia	O	NOUN	B
.	O	PUNCT	O


NO	B-OUT	NOUN	B
bioactivity	I-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
the	O	DET	O
nitric	O	ADJ	B
oxide	O	NOUN	I
synthase	O	NOUN	I
inhibitor	O	NOUN	I
N	O	NOUN	I
(	O	PUNCT	O
G	O	NOUN	B
)	O	PUNCT	O
-monomethyl-l-arginine	O	NOUN	O
.	O	PUNCT	O


Insulin-mediated	B-OUT	ADJ	B
vasodilation	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
insulin-stimulated	I-OUT	ADJ	B
NO	I-OUT	NOUN	B
bioavailability	I-OUT	NOUN	B
were	O	AUX	O
well	O	ADV	O
matched	O	VERB	O
across	O	ADP	O
groups	O	NOUN	B
by	O	ADP	O
this	O	DET	O
approach	O	NOUN	O
.	O	PUNCT	O


As	O	ADP	O
expected	O	VERB	O
,	O	PUNCT	O
steady-state	B-OUT	ADJ	B
insulin	I-OUT	NOUN	O
levels	I-OUT	NOUN	O
were	O	AUX	O
approximately	O	ADV	O
threefold	O	ADV	O
higher	O	ADJ	B
in	O	ADP	O
obese	O	ADJ	B
than	O	ADP	O
lean	O	ADJ	B
subjects	O	NOUN	I
(	O	PUNCT	O
109.2	O	NUM	O
+/-	O	CCONJ	O
10.2	O	NUM	O
pmol/l	O	NOUN	O
vs.	O	CCONJ	O
518.4	O	NUM	O
+/-	O	CCONJ	O
84.0	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Despite	O	SCONJ	O
this	O	DET	O
,	O	PUNCT	O
the	O	DET	O
augmentation	O	NOUN	B
of	O	ADP	O
insulin-mediated	B-OUT	ADJ	B
vasodilation	I-OUT	NOUN	I
by	O	ADP	O
BQ-123	O	NOUN	B
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


ET-1	B-OUT	NOUN	B
flux	I-OUT	NOUN	B
across	O	ADP	O
the	O	DET	O
leg	O	NOUN	B
was	O	AUX	O
not	O	PART	O
augmented	O	VERB	B
by	O	ADP	O
insulin	O	NOUN	B
alone	O	ADV	O
but	O	CCONJ	O
was	O	AUX	O
increased	O	VERB	B
with	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
BQ-123	O	NOUN	B
to	O	PART	O
insulin	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
BQ-123	O	NOUN	B
effect	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
not	O	PART	O
significant	O	ADJ	O
comparing	O	VERB	B
groups	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Endothelin	O	NOUN	B
antagonism	O	NOUN	B
augmented	O	VERB	B
insulin-stimulated	B-OUT	ADJ	B
NO	I-OUT	NOUN	B
bioavailability	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
NOx	I-OUT	NOUN	B
flux	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
differently	O	ADV	O
between	O	ADP	O
groups	O	NOUN	B
and	O	CCONJ	O
not	O	PART	O
proportional	O	ADJ	O
to	O	PART	O
hyperinsulinemia	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
do	O	AUX	O
not	O	PART	O
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
insulin	O	NOUN	B
resistance-associated	O	ADJ	B
hyperinsulinemia	O	NOUN	B
preferentially	O	ADV	O
drives	O	VERB	O
endothelin-mediated	B-OUT	ADJ	B
vasoconstriction	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Aerobic	B-I	ADJ	B
and	I-I	CCONJ	O
strength	I-I	NOUN	B
training	I-I	NOUN	I
reduces	O	VERB	O
adiposity	B-OUT	NOUN	B
in	O	ADP	O
overweight	B-P	ADJ	B
Latina	I-P	ADJ	B
adolescents	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	NOUN	O
To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
no	O	DET	O
study	O	NOUN	O
has	O	AUX	O
examined	O	VERB	O
the	O	DET	O
synergistic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
nutrition	B-I	NOUN	B
and	O	CCONJ	O
combination	B-I	NOUN	B
of	I-I	ADP	O
aerobic	I-I	ADJ	B
and	I-I	CCONJ	O
strength	I-I	NOUN	B
training	I-I	NOUN	I
(	I-I	PUNCT	O
CAST	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
both	O	CCONJ	O
adiposity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
metabolic	I-OUT	ADJ	B
parameters	I-OUT	NOUN	B
in	O	ADP	O
overweight	B-P	ADJ	B
Latina	I-P	ADJ	B
adolescent	I-P	ADJ	B
females	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
goal	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
if	O	SCONJ	O
a	O	DET	O
16-wk	O	ADJ	O
nutrition	B-I	NOUN	B
plus	O	CCONJ	I
CAST	B-I	NOUN	B
pilot	O	NOUN	O
study	O	NOUN	O
had	O	AUX	O
stronger	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
reducing	O	VERB	B
adiposity	B-OUT	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
improving	O	VERB	B
glucose/insulin	B-OUT	NOUN	B
indices	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
control	O	NOUN	B
(	O	PUNCT	I
C	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
nutrition	B-I	NOUN	B
only	I-I	ADV	O
(	O	PUNCT	O
N	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
nutrition	B-I	NOUN	B
plus	O	CCONJ	I
strength	B-I	NOUN	I
training	I-I	NOUN	I
(	O	PUNCT	O
N	O	NOUN	B
+	O	CCONJ	O
ST	O	ADJ	B
)	O	PUNCT	O
groups	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
16-wk	O	ADJ	O
randomized	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
41	B-P	NUM	O
overweight	I-P	ADJ	B
Latina	I-P	ADJ	B
girls	I-P	NOUN	B
(	I-P	PUNCT	O
15.2	I-P	NUM	O
+/-	I-P	CCONJ	O
1.1	I-P	NUM	O
yr	I-P	NOUN	O
)	I-P	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
C	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
N	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
N	B-I	NOUN	B
+	I-I	CCONJ	O
ST	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
N	B-I	NOUN	B
+	I-I	CCONJ	O
CAST	I-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
intervention	O	NOUN	B
groups	O	NOUN	I
received	O	VERB	O
modified	B-I	VERB	B
carbohydrate	I-I	NOUN	O
nutrition	I-I	NOUN	O
classes	I-I	NOUN	O
(	O	PUNCT	O
once	O	ADV	O
a	O	DET	O
week	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
N	B-I	NOUN	B
+	I-I	CCONJ	O
ST	I-I	PROPN	B
also	O	ADV	O
received	B-I	VERB	O
strength	I-I	NOUN	B
training	I-I	NOUN	I
(	O	PUNCT	O
twice	O	ADV	O
a	O	DET	O
week	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
N	B-I	NOUN	B
+	I-I	CCONJ	O
CAST	I-I	NOUN	B
received	O	VERB	O
a	B-I	DET	O
combination	I-I	NOUN	B
of	I-I	ADP	O
strength	I-I	NOUN	B
and	I-I	CCONJ	O
aerobic	I-I	ADJ	B
training	I-I	NOUN	I
(	O	PUNCT	O
twice	O	ADV	O
a	O	DET	O
week	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
following	O	NOUN	O
were	O	AUX	O
measured	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
intervention	O	NOUN	B
:	O	PUNCT	O
strength	B-OUT	NOUN	B
by	O	ADP	O
one	O	NUM	O
repetition	O	NOUN	B
maximum	O	NOUN	B
,	O	PUNCT	O
physical	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
by	I-OUT	ADP	O
the	I-OUT	DET	O
7-d	I-OUT	ADJ	O
accelerometry	I-OUT	NOUN	B
and	O	CCONJ	O
the	O	DET	O
3-d	B-OUT	ADJ	O
physical	I-OUT	ADJ	B
activity	I-OUT	NOUN	I
recall	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
dietary	I-OUT	ADJ	B
intake	I-OUT	NOUN	I
by	I-OUT	ADP	O
3-d	I-OUT	ADJ	O
records	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
composition	I-OUT	NOUN	I
by	O	ADP	O
dual-energy	O	ADJ	B
x-ray	O	NOUN	I
absorptiometry	O	NOUN	I
(	O	PUNCT	O
DEXA	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
glucose/insulin	B-OUT	NOUN	B
indices	I-OUT	NOUN	I
by	O	ADP	O
oral	O	ADJ	B
glucose	O	NOUN	I
tolerance	O	NOUN	I
test	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
intravenous	B-OUT	ADJ	B
glucose	I-OUT	NOUN	I
tolerance	I-OUT	NOUN	I
test	I-OUT	NOUN	I
with	O	ADP	O
minimal	O	ADJ	O
modeling	O	NOUN	B
.	O	PUNCT	O


Across	O	ADP	O
intervention	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
effects	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
using	O	VERB	O
ANCOVA	O	NOUN	B
with	O	ADP	O
post	O	NOUN	B
hoc	O	NOUN	I
pairwise	O	NOUN	I
comparisons	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
were	O	AUX	O
significant	O	ADJ	B
overall	O	ADJ	O
intervention	O	NOUN	B
effects	O	NOUN	O
for	O	ADP	O
all	O	DET	O
adiposity	B-OUT	NOUN	B
measures	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
weight	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
[	I-OUT	PUNCT	O
BMI	I-OUT	PROPN	B
]	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
BMI	I-OUT	NOUN	B
z-scores	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
DEXA	I-OUT	NOUN	B
total	I-OUT	ADJ	I
body	I-OUT	NOUN	I
fat	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
N	B-I	NOUN	B
+	I-I	CCONJ	O
CAST	I-I	NOUN	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
a	O	DET	O
3	O	NUM	O
%	O	NOUN	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
N	B-I	NOUN	B
+	I-I	CCONJ	O
ST	I-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
also	O	ADV	O
an	O	DET	O
intervention	O	NOUN	B
effect	O	NOUN	I
for	O	ADP	O
fasting	B-OUT	VERB	B
glucose	I-OUT	NOUN	B
with	O	ADP	O
the	O	DET	O
N	B-I	NOUN	B
group	O	NOUN	I
increasing	O	VERB	B
by	O	ADP	O
3	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
N	B-I	NOUN	B
+	I-I	CCONJ	O
CAST	I-I	NOUN	B
group	O	NOUN	B
decreasing	O	VERB	B
by	O	ADP	O
4	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
The	O	DET	O
CAST	B-I	NOUN	B
was	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
nutrition	B-I	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
nutrition	B-I	NOUN	B
plus	O	CCONJ	I
strength	B-I	NOUN	I
training	I-I	NOUN	B
for	O	ADP	O
reducing	O	VERB	B
multiple	B-OUT	ADJ	B
adiposity	I-OUT	NOUN	B
outcomes	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
fasting	I-OUT	ADJ	B
glucose	I-OUT	NOUN	B
in	O	ADP	O
overweight	B-P	ADJ	B
Latina	I-P	ADJ	B
girls	I-P	NOUN	B
.	I-P	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
further	O	ADJ	O
research	O	NOUN	B
investigating	O	VERB	B
and	O	CCONJ	O
identifying	O	VERB	O
intervention	O	NOUN	B
approaches	O	NOUN	I
that	O	PRON	O
improve	O	VERB	O
both	O	CCONJ	O
adiposity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
insulin	I-OUT	NOUN	B
indices	I-OUT	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
high-risk	O	ADJ	B
populations	O	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
warranted	O	VERB	O
.	O	PUNCT	O


Mecamylamine	B-I	NOUN	B
reduces	O	VERB	B
some	O	DET	O
EEG	B-OUT	ADJ	B
effects	I-OUT	NOUN	B
of	O	ADP	O
nicotine	B-P	NOUN	B
chewing	I-P	NOUN	B
gum	I-P	NOUN	I
in	I-P	ADP	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


Spontaneous	B-OUT	ADJ	B
EEG	I-OUT	PROPN	B
was	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
nine	B-P	NUM	O
cigarette	I-P	NOUN	B
smokers	I-P	NOUN	I
who	I-P	PRON	O
had	I-P	AUX	O
been	I-P	AUX	O
abstinent	I-P	VERB	B
from	I-P	ADP	O
tobacco	I-P	NOUN	B
for	I-P	ADP	O
12	I-P	NUM	O
hr	I-P	NOUN	O
.	I-P	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
capsule	O	NOUN	B
containing	O	VERB	O
either	O	CCONJ	O
centrally	B-I	ADV	O
acting	I-I	VERB	O
nicotine	I-I	NOUN	B
blocker	I-I	NOUN	B
,	I-I	PUNCT	O
mecamylamine	I-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
or	B-I	CCONJ	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


At	O	ADP	O
each	O	DET	O
of	O	ADP	O
three	O	NUM	O
60-min	O	ADJ	O
intervals	O	NOUN	B
after	O	ADP	O
the	O	DET	O
capsule	O	NOUN	B
was	O	AUX	O
ingested	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
subjects	O	NOUN	B
chewed	O	VERB	B
two	O	NUM	O
pieces	O	NOUN	O
of	O	ADP	O
gum	O	NOUN	B
containing	O	VERB	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
0	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
or	O	CCONJ	O
8	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
nicotine	O	NOUN	B
.	O	PUNCT	O


Nicotine	B-I	NOUN	B
and	I-I	CCONJ	O
mecamylamine	I-I	NOUN	B
dose	O	NOUN	O
combinations	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
across	O	ADP	O
subjects	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
three-minute	O	ADJ	B
periods	O	NOUN	B
of	O	ADP	O
spontaneous	B-OUT	ADJ	B
EEG	I-OUT	PROPN	B
were	O	AUX	O
recorded	O	VERB	O
before	O	ADP	O
the	O	DET	O
capsule	O	NOUN	B
and	O	CCONJ	O
before	O	ADP	B
and	O	CCONJ	O
after	O	ADP	O
gum	O	NOUN	B
chewing	O	NOUN	I
from	O	ADP	O
bipolar	O	ADJ	B
electrode	O	NOUN	I
montages	O	NOUN	B
at	O	ADP	O
the	O	DET	O
following	O	VERB	O
positions	O	NOUN	B
:	O	PUNCT	O
Cz-T5	O	PROPN	B
,	O	PUNCT	O
Cz-T6	O	NOUN	B
,	O	PUNCT	O
Cz-F7	O	PROPN	B
and	O	CCONJ	O
Cz-F8	O	PROPN	B
.	O	PUNCT	O


During	O	ADP	O
one	O	NUM	O
period	O	NOUN	B
the	O	DET	O
subjects	O	NOUN	B
relaxed	O	VERB	O
with	O	ADP	O
eyes	O	NOUN	B
closed	O	VERB	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
period	O	NOUN	B
they	O	PRON	O
performed	O	VERB	O
a	O	DET	O
math	O	NOUN	B
task	O	NOUN	B
with	O	ADP	O
eyes	O	NOUN	B
open	O	ADJ	O
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
individually	O	ADV	O
,	O	PUNCT	O
mecamylamine	B-I	NOUN	B
decreased	O	VERB	B
beta	B-OUT	NOUN	B
power	I-OUT	NOUN	I
and	O	CCONJ	O
nicotine	O	NOUN	B
gum	O	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
increased	O	VERB	B
alpha	B-OUT	NOUN	B
frequency	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Mecamylamine	B-I	NOUN	B
pretreatment	O	NOUN	B
prevented	O	VERB	B
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
alpha	B-OUT	NOUN	B
frequency	I-OUT	NOUN	I
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
4	O	NUM	O
mg	O	NOUN	O
gum	O	NOUN	B
dose	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
8	O	NUM	O
mg	O	NOUN	O
dose	O	NOUN	B
.	O	PUNCT	O


Alpha	B-OUT	NOUN	B
power	I-OUT	NOUN	I
was	O	AUX	O
increased	O	VERB	B
by	O	ADP	O
the	O	DET	O
8	O	NUM	O
mg	O	NOUN	O
gum	O	NOUN	B
dose	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
increase	O	NOUN	B
was	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
mecamylamine	B-I	NOUN	B
.	I-I	PUNCT	O


Self-reported	B-OUT	ADJ	B
ratings	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
"	B-OUT	PUNCT	O
strength	I-OUT	NOUN	B
"	I-OUT	PUNCT	O
of	O	ADP	O
the	O	DET	O
gum	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
diminished	O	VERB	O
by	O	ADP	O
mecamylamine	O	NOUN	B
pretreatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
earlier	O	ADJ	O
studies	O	NOUN	B
which	O	DET	O
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
tobacco	O	NOUN	B
administration	O	NOUN	I
and	O	CCONJ	O
withdrawal	O	NOUN	B
are	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
central	O	ADJ	B
actions	O	NOUN	I
of	O	ADP	O
nicotine	O	NOUN	B
.	O	PUNCT	O


Naltrexone	B-I	NOUN	B
and	O	CCONJ	O
communication	O	NOUN	B
skills	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
naltrexone	B-I	NOUN	B
on	O	ADP	O
communication	O	NOUN	B
skills	O	NOUN	I
of	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


METHOD	O	NOUN	B
Twenty-four	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
,	I-P	PUNCT	O
3.0	I-P	NUM	O
to	I-P	PART	O
8.3	I-P	NUM	O
years	I-P	NOUN	B
old	I-P	ADJ	I
(	I-P	PUNCT	O
mean	I-P	NOUN	O
5.1	I-P	NUM	O
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
living	I-P	VERB	B
at	I-P	ADP	O
home	I-P	NOUN	B
and	I-P	CCONJ	O
attending	I-P	VERB	B
appropriate	I-P	ADJ	O
school	I-P	NOUN	B
programs	I-P	NOUN	I
,	O	PUNCT	O
participated	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


Naltrexone	B-I	NOUN	B
,	I-I	PUNCT	O
1.0	I-I	NUM	O
mg/kg	I-I	NOUN	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
was	I-I	AUX	O
administered	I-I	VERB	B
daily	I-I	ADV	B
for	I-I	ADP	O
2	I-I	NUM	O
weeks	I-I	NOUN	B
.	I-I	PUNCT	O


Communication	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
from	O	ADP	O
videotaped	B-I	VERB	B
samples	I-I	NOUN	B
of	I-I	ADP	O
seminaturalistic	I-I	ADJ	B
parent-child	I-I	ADJ	B
interaction	I-I	NOUN	B
.	I-I	PUNCT	O


Child	O	ADJ	B
and	O	CCONJ	O
parent	O	NOUN	B
language	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
similar	O	ADJ	O
measures	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
this	O	DET	O
heterogeneous	O	ADJ	B
sample	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
median	B-OUT	ADJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
words	I-OUT	NOUN	O
the	I-OUT	DET	O
child	I-OUT	NOUN	B
produced	I-OUT	VERB	O
on	O	ADP	O
placebo	O	NOUN	B
was	O	AUX	O
9.5	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	O
0-124	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
proportion	I-OUT	NOUN	B
of	I-OUT	ADP	O
utterances	I-OUT	NOUN	B
with	I-OUT	ADP	I
echolalia	I-OUT	NOUN	B
was	O	AUX	O
0.16	O	NUM	O
.	O	PUNCT	O


No	O	DET	B
differences	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
naltrexone	B-I	NOUN	B
and	O	CCONJ	O
placebo	B-I	NOUN	B
conditions	O	NOUN	B
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
measures	O	NOUN	B
of	O	ADP	O
children	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
parents	I-OUT	NOUN	B
'	I-OUT	PART	O
communication	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Significant	O	ADJ	O
correlations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
child	B-OUT	NOUN	B
's	I-OUT	PART	I
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
words	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
developmental	I-OUT	ADJ	B
quotient	I-OUT	NOUN	I
(	O	PUNCT	O
Spearman	O	NOUN	B
rho	O	ADJ	I
=	O	ADJ	O
0.58	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.003	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
between	O	ADP	O
the	O	DET	O
child	O	NOUN	B
's	O	PART	I
and	O	CCONJ	O
parent	O	NOUN	B
's	O	PART	I
number	O	NOUN	O
of	O	ADP	O
words	O	NOUN	O
(	O	PUNCT	O
rho	O	NOUN	O
=	O	ADJ	O
0.55	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Previous	O	ADJ	O
studies	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
naltrexone	B-I	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
modest	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
hyperactivity	O	NOUN	B
and	O	CCONJ	O
restlessness	O	NOUN	B
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
autism	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
short-term	O	ADJ	B
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
medication	O	NOUN	B
did	O	AUX	O
not	O	PART	O
lead	O	VERB	O
to	O	PART	O
improvement	O	NOUN	B
in	O	ADP	O
communication	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
core	O	NOUN	B
deficit	O	NOUN	I
of	O	ADP	O
autism	O	NOUN	B
.	O	PUNCT	O


Modest	O	ADJ	B
antihypertensive	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
epanolol	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
beta	O	NOUN	B
1-selective	O	ADJ	I
receptor	O	NOUN	I
blocker	O	NOUN	I
with	O	ADP	O
beta	O	NOUN	B
1	O	NUM	I
agonist	O	NOUN	B
activity	O	NOUN	B
:	O	PUNCT	O
an	O	DET	O
acute	O	ADJ	B
and	O	CCONJ	O
long-term	O	ADJ	B
hemodynamic	O	ADJ	B
study	O	NOUN	I
at	O	ADP	O
rest	O	NOUN	B
and	O	CCONJ	O
during	O	ADP	O
exercise	O	NOUN	B
and	O	CCONJ	O
double	O	ADJ	B
crossover	O	NOUN	I
comparison	O	NOUN	I
with	O	ADP	O
atenolol	O	NOUN	B
on	O	ADP	O
ambulatory	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
.	O	PUNCT	O


Beta-blockers	O	NOUN	B
with	O	ADP	O
less	O	ADV	O
cardiodepressive	O	ADJ	B
effect	O	NOUN	I
than	O	ADP	O
traditional	O	ADJ	B
nonselective	O	ADJ	B
beta	O	NOUN	I
(	O	PUNCT	I
1+2	O	NUM	O
)	O	PUNCT	O
-blocking	O	ADJ	O
agents	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
hypertension	O	NOUN	B
,	O	PUNCT	O
provided	O	VERB	O
the	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
was	O	AUX	O
satisfactory	O	ADJ	B
.	O	PUNCT	O


Epanolol	B-I	PROPN	B
,	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
beta	O	NOUN	B
1-receptor	O	NOUN	I
blocker	O	NOUN	I
with	O	ADP	O
intrinsic	O	ADJ	B
sympathomimetic	O	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
induced	O	VERB	B
a	O	DET	O
fall	O	NOUN	B
in	O	ADP	O
intraarterial	B-OUT	ADJ	B
pressure	I-OUT	NOUN	B
of	O	ADP	O
8	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
rest	O	NOUN	B
sitting	O	NOUN	I
and	O	CCONJ	O
11	O	NUM	O
%	O	NOUN	O
during	O	ADP	O
100	O	NUM	O
W	O	NOUN	O
bicycle	O	NOUN	B
exercise	O	NOUN	B
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
12	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
essential	I-P	ADJ	B
hypertension	I-P	NOUN	I
.	I-P	PUNCT	O


Heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
stroke	I-OUT	NOUN	B
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cardiac	I-OUT	ADJ	B
index	I-OUT	NOUN	I
initially	O	ADV	O
fell	O	VERB	O
by	O	ADP	O
14	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
11	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
23	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
total	B-OUT	ADJ	O
peripheral	I-OUT	ADJ	O
resistance	I-OUT	NOUN	O
index	I-OUT	NOUN	O
increased	O	VERB	B
by	O	ADP	O
21	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
2	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
reverted	O	VERB	O
towards	O	ADP	O
the	O	DET	O
pretreatment	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
10	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
epanolol	B-I	ADJ	B
treatment	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
300	O	NUM	O
mg/day	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
reduction	B-OUT	NOUN	B
in	O	ADP	O
arterial	B-OUT	ADJ	B
pressure	I-OUT	NOUN	I
was	O	AUX	O
5	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
rest	O	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
%	O	NOUN	O
during	O	ADP	O
exercise	O	NOUN	B
.	O	PUNCT	O


Cardiac	B-OUT	ADJ	B
index	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
were	O	AUX	O
still	O	ADV	O
reduced	O	VERB	B
14-21	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
total	B-OUT	ADJ	O
peripheral	I-OUT	ADJ	O
resistance	I-OUT	NOUN	O
was	O	AUX	O
unchanged	O	ADJ	B
or	O	CCONJ	O
slightly	O	ADV	O
increased	O	VERB	B
(	O	PUNCT	O
2-10	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Twenty-four	B-OUT	NUM	O
hour	I-OUT	NOUN	B
ambulatory	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
was	O	AUX	O
higher	O	ADJ	O
on	O	ADP	O
epanolol	B-I	NOUN	B
(	O	PUNCT	O
300	O	NUM	O
mg/day	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
on	O	ADP	O
atenolol	B-I	PROPN	B
(	O	PUNCT	O
150	O	NUM	O
mg/day	O	NOUN	O
)	O	PUNCT	O
treatment	O	NOUN	B
(	O	PUNCT	O
137/97	O	NUM	O
vs.	O	CCONJ	O
128/91	O	NUM	O
mmHg	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
achieved	B-OUT	VERB	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
reduction	I-OUT	NOUN	B
induced	O	VERB	B
by	O	ADP	O
epanolol	B-I	NOUN	B
was	O	AUX	O
moderate	O	ADJ	B
,	O	PUNCT	O
while	O	SCONJ	O
other	O	ADJ	O
characteristics	O	NOUN	B
of	O	ADP	O
beta-receptor	O	ADJ	B
blockade	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
reduction	B-OUT	NOUN	B
of	I-OUT	ADP	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
cardiac	I-OUT	ADJ	B
output	I-OUT	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
maintained	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
compound	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
other	O	ADJ	O
cardiovascular	B-P	ADJ	B
disorders	I-P	NOUN	I
,	O	PUNCT	O
e.g.	O	X	O
,	O	PUNCT	O
angina	B-P	ADJ	B
pectoris	I-P	NOUN	I
in	I-P	ADP	O
patients	I-P	NOUN	B
without	I-P	ADP	O
hypertension	I-P	NOUN	B
or	I-P	CCONJ	O
cardiac	I-P	ADJ	B
arrhythmia	I-P	NOUN	I
.	I-P	PUNCT	O


Controlled	O	ADJ	B
prospective	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
prednisolone	B-I	NOUN	B
and	I-I	CCONJ	O
cytotoxics	I-I	NOUN	B
in	O	ADP	O
progressive	B-P	ADJ	B
IgA	I-P	NOUN	B
nephropathy	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
single-center	O	ADJ	B
,	O	PUNCT	O
multiple-referral	O	ADJ	B
source	O	NOUN	I
study	O	NOUN	I
,	O	PUNCT	O
38	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
progressive	I-P	ADJ	B
IgA	I-P	NOUN	B
nephropathy	I-P	NOUN	I
and	I-P	CCONJ	O
controlled	I-P	VERB	B
hypertension	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
prednisolone	B-I	NOUN	B
and	I-I	CCONJ	O
cytotoxic	I-I	ADJ	B
agents	I-I	NOUN	I
,	O	PUNCT	O
to	O	PART	O
therapy	O	NOUN	B
with	O	ADP	O
low-dose	B-I	ADJ	B
cyclophosphamide	I-I	NOUN	I
then	I-I	ADV	O
azathioprine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
to	I-I	PART	O
control	I-I	VERB	B
groups	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
follow-up	O	ADJ	B
period	O	NOUN	B
lasted	O	VERB	O
2	O	NUM	O
to	O	PART	O
6	O	NUM	O
yr.	O	NOUN	B
Renal	O	ADJ	B
survival	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
assessed	O	VERB	B
by	O	ADP	O
Kaplan-Meier	O	ADJ	B
analysis	O	NOUN	I
annually	O	ADV	O
to	O	PART	O
5	O	NUM	O
yr	O	NOUN	O
,	O	PUNCT	O
showed	O	VERB	O
significant	O	ADJ	O
preservation	O	NOUN	B
of	O	ADP	O
function	O	NOUN	B
from	O	ADP	O
3	O	NUM	O
yr	O	NOUN	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
82	O	NUM	O
,	O	PUNCT	O
82	O	NUM	O
,	O	PUNCT	O
72	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
72	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
yr	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
68	O	NUM	O
,	O	PUNCT	O
47	O	NUM	O
,	O	PUNCT	O
26	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
6	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Rate	O	NOUN	B
of	O	ADP	O
loss	B-OUT	NOUN	B
of	I-OUT	ADP	O
renal	I-OUT	ADJ	B
function	I-OUT	NOUN	I
,	O	PUNCT	O
evaluated	O	VERB	B
objectively	O	ADV	B
by	O	ADP	O
least-squares	B-OUT	NOUN	B
analyses	I-OUT	NOUN	I
of	I-OUT	ADP	O
reciprocal	I-OUT	ADJ	B
serum	I-OUT	NOUN	O
creatinine	I-OUT	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
reduced-and	O	ADJ	O
in	O	ADP	O
one-third	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
arrested-during	O	ADJ	B
immunosuppressive	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


Proteinuria	B-OUT	NOUN	B
,	I-P	PUNCT	O
present	I-P	ADJ	O
in	I-P	ADP	O
all	I-P	DET	O
patients	I-P	NOUN	B
at	I-P	ADP	O
the	I-P	DET	O
time	I-P	NOUN	O
of	I-P	ADP	O
entry	I-P	NOUN	B
into	I-P	ADP	O
the	I-P	DET	O
trial	I-P	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
treatment	O	NOUN	B
from	O	ADP	O
12	O	NUM	O
mo	O	NOUN	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
pretreatment	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
controls	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
erythrocyturia	I-OUT	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
from	O	ADP	O
6	O	NUM	O
mo	O	NOUN	O
.	O	PUNCT	O


Histologic	B-OUT	ADJ	B
activity	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
chronicity	I-OUT	NOUN	B
indexes	I-OUT	NOUN	B
were	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
renal	O	ADJ	B
biopsies	O	NOUN	I
performed	O	VERB	O
at	O	ADP	O
trial	O	NOUN	B
entry	O	NOUN	I
.	O	PUNCT	O


Multivariate	B-OUT	ADJ	B
analysis	I-OUT	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
mesangial	B-OUT	ADJ	B
cell	I-OUT	NOUN	I
proliferation	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
matrix	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
were	O	AUX	O
highest	O	ADJ	O
in	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
more	O	ADV	O
rapidly	O	ADV	O
progressive	O	ADJ	B
disease	O	NOUN	O
.	O	PUNCT	O


No	O	DET	O
morphologic	B-OUT	ADJ	B
variable	I-OUT	ADJ	I
or	I-OUT	CCONJ	O
residual	I-OUT	ADJ	B
renal	I-OUT	ADJ	O
function	I-OUT	NOUN	O
predicted	O	VERB	O
response	O	NOUN	O
to	O	PART	O
immunosuppressive	O	ADJ	B
therapy	O	NOUN	I
at	O	ADP	O
entry	O	NOUN	B
.	O	PUNCT	O


Mean	B-OUT	VERB	O
arterial	I-OUT	ADJ	B
pressures	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
thus	O	ADV	O
no	O	DET	O
explanation	O	NOUN	O
other	O	ADJ	O
than	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
improved	O	ADJ	B
outcome	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
immunosuppressive	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Morbidity	B-OUT	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
treatment	O	NOUN	B
or	O	CCONJ	O
to	O	PART	O
renal	B-OUT	ADJ	B
failure	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
;	O	PUNCT	O
an	O	DET	O
audit	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
benefits	B-OUT	NOUN	B
of	I-OUT	ADP	O
therapy	I-OUT	NOUN	B
outweighed	O	VERB	O
expected	O	VERB	O
or	O	CCONJ	O
minor	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
drugs	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
of	O	ADP	O
end-stage	O	ADJ	B
renal	O	ADJ	I
failure	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
selected	I-P	VERB	O
for	I-P	ADP	O
moderately	I-P	ADV	O
progressive	I-OUT	ADJ	B
IgA	I-OUT	NOUN	B
nephropathy	I-OUT	NOUN	I
benefit	O	NOUN	B
from	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
prednisolone	B-I	NOUN	B
and	O	CCONJ	O
cytotoxic	B-I	ADJ	B
agents	I-I	NOUN	I
;	I-I	PUNCT	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
modulation	B-OUT	NOUN	B
of	I-OUT	ADP	O
systemic	I-OUT	ADJ	B
immune	I-OUT	ADJ	B
response	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
nephritic	I-OUT	ADJ	B
injury	I-OUT	NOUN	I
,	O	PUNCT	O
thus	O	ADV	O
explaining	O	VERB	O
improved	O	ADJ	O
outcome	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
indicate	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
therapy	O	NOUN	B
has	O	AUX	O
an	O	DET	O
acceptably	O	ADV	O
low	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
side	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
sperm	O	NOUN	B
with	O	ADP	O
platelet-activating	B-I	ADJ	B
factor	I-I	NOUN	I
does	O	AUX	O
not	O	PART	O
improve	O	VERB	O
intrauterine	B-I	ADJ	B
insemination	I-I	NOUN	I
outcome	O	NOUN	B
in	O	ADP	O
unselected	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
mild	B-P	ADJ	B
male	I-P	ADJ	O
factor	I-P	NOUN	O
infertility	I-P	NOUN	O
:	I-P	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
double-blind	O	ADJ	I
randomized	O	ADJ	B
crossover	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	B-OUT	NOUN	B
of	O	ADP	O
sperm	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
exogenous	B-I	ADJ	B
platelet-activating	I-I	ADJ	B
factor	I-I	NOUN	I
(	I-I	PUNCT	O
PAF	I-I	NOUN	B
)	I-I	PUNCT	O
on	O	ADP	O
intrauterine	B-I	ADJ	B
insemination	I-I	NOUN	I
(	I-I	PUNCT	O
IUI	I-I	NOUN	B
)	I-I	PUNCT	O
clinical	O	ADJ	B
pregnancy	O	NOUN	I
rate	O	NOUN	O
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
mild	B-P	ADJ	B
male	I-P	ADJ	O
factor	I-P	NOUN	O
infertility	I-P	NOUN	O
.	I-P	PUNCT	O


PAF	O	NOUN	B
is	O	AUX	O
a	O	DET	O
phospholipid	O	ADJ	B
mediator	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
human	O	ADJ	B
sperm	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
The	B-P	DET	O
study	I-P	NOUN	B
was	I-P	AUX	O
performed	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
Assisted	I-P	PROPN	B
Reproduction	I-P	PROPN	I
Unit	I-P	PROPN	I
of	I-P	ADP	O
the	I-P	DET	O
2nd	I-P	PROPN	O
Department	I-P	PROPN	O
of	I-P	ADP	O
Obstetrics	I-P	PROPN	O
and	I-P	CCONJ	O
Gynecology	I-P	PROPN	B
,	I-P	PUNCT	O
University	I-P	PROPN	B
of	I-P	ADP	I
Athens	I-P	PROPN	I
,	I-P	PUNCT	O
Aretaieion	I-P	PROPN	B
Hospital	I-P	PROPN	I
,	I-P	PUNCT	O
Athens	I-P	PROPN	B
,	I-P	PUNCT	O
Greece	I-P	PROPN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
included	I-P	VERB	O
92	I-P	NUM	O
couples	I-P	NOUN	B
who	I-P	PRON	O
presented	I-P	VERB	O
with	I-P	ADP	O
mild	I-P	ADJ	B
male	I-P	ADJ	B
factor	I-P	NOUN	I
infertility-all	I-P	NOUN	O
candidates	I-P	NOUN	O
for	I-P	ADP	O
IUI	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
IUI	B-I	NOUN	B
cycles	O	NOUN	B
per	O	ADP	O
couple	O	NOUN	O
with	B-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
exogenous	I-I	ADJ	B
PAF	I-I	NOUN	B
treatment	I-I	NOUN	B
were	O	AUX	O
performed	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
main	O	ADJ	O
outcome	O	NOUN	B
measure	O	NOUN	I
was	O	AUX	O
the	O	DET	O
clinical	B-OUT	ADJ	B
pregnancy	I-OUT	NOUN	I
rate	I-OUT	NOUN	I
(	O	PUNCT	O
pregnancies	O	NOUN	B
confirmed	O	VERB	O
by	O	ADP	O
ultrasonography	O	NOUN	B
per	O	ADP	O
100	O	NUM	O
cycles	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
overall	B-OUT	ADJ	O
clinical	I-OUT	ADJ	B
pregnancy	I-OUT	NOUN	I
rate	I-OUT	NOUN	O
after	O	ADP	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
IUI	B-I	NOUN	B
cycles	O	NOUN	B
was	O	AUX	O
comparable	O	ADJ	O
in	O	ADP	O
cases	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
sperm	B-I	NOUN	B
treatment	I-I	NOUN	B
with	I-I	ADP	O
PAF	I-I	NOUN	B
(	O	PUNCT	O
12.24	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
11.11	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Addition	O	NOUN	B
or	O	CCONJ	O
exclusion	O	NOUN	B
of	O	ADP	O
PAF	B-I	NOUN	B
sperm	I-I	NOUN	B
treatment	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
patients	O	NOUN	B
did	B-OUT	AUX	O
not	I-OUT	PART	O
significantly	I-OUT	ADV	O
alter	I-OUT	VERB	O
the	I-OUT	DET	O
outcome	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
generalized	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
exogenous	B-I	ADJ	B
PAF	I-I	NOUN	B
for	O	ADP	O
the	O	DET	O
preparation	O	NOUN	B
of	O	ADP	O
sperm	O	NOUN	B
in	O	ADP	O
unselected	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
mild	B-P	ADJ	B
male	I-P	NOUN	B
infertility	I-P	NOUN	O
does	O	AUX	O
not	O	PART	O
improve	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
outcome	O	NOUN	I
of	O	ADP	O
IUI	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
body	B-I	NOUN	B
orientation	I-I	NOUN	I
on	O	ADP	O
maximum	O	ADJ	B
voluntary	O	ADJ	O
arm	O	NOUN	O
torques	O	NOUN	B
.	O	PUNCT	O


INTRODUCTION	O	NOUN	O
Increased	O	VERB	B
reliance	O	NOUN	O
on	O	ADP	O
bulbospinal	B-I	ADJ	B
motor	I-I	NOUN	B
systems	I-I	NOUN	I
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
stroke	I-P	NOUN	I
during	O	ADP	O
maximum	O	ADJ	B
voluntary	O	ADJ	O
arm	O	NOUN	O
joint	O	ADJ	O
torque	O	NOUN	O
generation	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Maximum	O	ADJ	B
isometric	B-OUT	ADJ	B
single-joint	I-OUT	ADJ	O
and	I-OUT	CCONJ	O
multi-joint	I-OUT	ADJ	O
arm	I-OUT	NOUN	O
strength	I-OUT	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
two	B-I	NUM	O
body	I-I	NOUN	B
orientations	I-I	NOUN	I
(	I-I	PUNCT	O
sitting	I-I	NOUN	B
and	I-I	CCONJ	O
supine	I-I	NOUN	B
)	I-I	PUNCT	O
while	O	SCONJ	O
maintaining	O	VERB	O
identical	O	ADJ	O
head/neck/trunk/extremity	B-I	NOUN	B
joint	I-I	ADJ	I
configurations	I-I	NOUN	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
identify	O	VERB	O
bulbospinal	B-P	ADJ	B
contributions	I-P	NOUN	B
to	I-P	PART	O
maximum	I-P	VERB	O
joint	I-P	ADJ	B
torque	I-P	NOUN	I
generation	I-P	NOUN	B
in	I-P	ADP	O
11	I-P	NUM	O
individuals	I-P	NOUN	B
with	I-P	ADP	O
stroke	I-P	NOUN	B
and	I-P	CCONJ	O
10	I-P	NUM	O
individuals	I-P	NOUN	B
without	I-P	ADP	O
stroke	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
During	O	ADP	O
sitting	B-I	NOUN	B
,	O	PUNCT	O
shoulder	B-OUT	NOUN	B
flexion	I-OUT	NOUN	I
was	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
shoulder	B-OUT	NOUN	B
extension	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
elbow	I-OUT	NOUN	B
flexion	I-OUT	NOUN	I
,	O	PUNCT	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
flexion	O	NOUN	B
synergy	O	NOUN	B
,	O	PUNCT	O
"	O	PUNCT	O
were	O	AUX	O
greater	O	ADJ	O
only	O	ADV	O
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
stroke	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Body	B-I	NOUN	B
orientation	I-I	NOUN	I
influenced	O	VERB	O
isometric	B-OUT	ADJ	B
arm	I-OUT	NOUN	I
strength	I-OUT	NOUN	I
,	O	PUNCT	O
notably	O	ADV	O
the	O	DET	O
constituents	O	NOUN	B
of	O	ADP	O
flexion	B-OUT	NOUN	B
synergy	I-OUT	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
stroke	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
bulbospinal	O	ADJ	B
motor	O	NOUN	B
pathway	O	NOUN	I
involvement	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
a	O	DET	O
practical	O	ADJ	B
perspective	O	NOUN	I
,	O	PUNCT	O
clinical	O	ADJ	B
evaluation	O	NOUN	I
of	O	ADP	O
single	B-OUT	ADJ	B
joint	I-OUT	ADJ	I
strength	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
supine	B-I	ADJ	B
position	I-I	NOUN	I
may	O	AUX	O
underestimate	O	VERB	O
strength	O	NOUN	B
available	O	ADJ	O
during	O	ADP	O
activities	O	NOUN	B
of	O	ADP	O
daily	O	ADJ	B
living	O	NOUN	O
that	O	PRON	O
are	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
an	O	DET	O
upright	B-I	ADJ	B
orientation	I-I	NOUN	B
.	I-I	PUNCT	O


QT/QTc	O	NOUN	B
study	O	NOUN	I
conducted	O	VERB	O
in	O	ADP	O
Japanese	B-P	ADJ	B
adult	I-P	ADJ	B
healthy	I-P	ADJ	B
subjects	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
novel	O	ADJ	B
xanthine	O	NOUN	B
oxidase	O	NOUN	I
inhibitor	O	NOUN	B
topiroxostat	B-I	NOUN	O
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
QT	O	NOUN	B
prolongation	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
QT/QTc	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
compliance	O	NOUN	B
with	O	ADP	O
ICH	O	NOUN	B
E14	O	NOUN	B
guideline	O	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	B-I	ADJ	O
xanthine	I-I	NOUN	B
oxidase	I-I	NOUN	I
inhibitor	I-I	NOUN	I
topiroxostat	I-I	NOUN	O
in	O	ADP	O
Japanese	B-P	ADJ	B
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
.	I-P	PUNCT	O


Forty-eight	B-P	NUM	O
Japanese	I-P	ADJ	B
healthy	I-P	ADJ	B
subjects	I-P	NOUN	I
(	I-P	PUNCT	O
males	I-P	NOUN	B
24	I-P	NUM	O
;	I-P	PUNCT	O
females	I-P	NOUN	B
24	I-P	NUM	O
)	I-P	PUNCT	O
received	O	VERB	O
a	O	DET	O
single	O	ADJ	O
oral	B-I	ADJ	B
dose	I-I	NOUN	I
of	I-I	ADP	O
topiroxostat	I-I	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
or	O	CCONJ	O
180	B-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
moxifloxacin	I-I	NOUN	B
(	I-I	PUNCT	O
400	I-I	NUM	O
mg	I-I	NOUN	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	I-P	ADP	O
a	I-P	DET	O
single-center	I-P	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
four-period	O	ADJ	B
crossover	O	NOUN	O
design	B-OUT	NOUN	O
.	I-OUT	PUNCT	O


Fridericia	B-OUT	PROPN	B
's	I-OUT	PART	I
formula	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
QTcF	I-OUT	NOUN	B
=	I-OUT	ADJ	O
QT/RR	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
0.33	I-OUT	NUM	O
)	I-OUT	PUNCT	O
)	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
primary	O	ADJ	B
method	B-OUT	NOUN	I
for	I-OUT	ADP	O
QT-interval	I-OUT	ADJ	B
correction	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
mean	I-OUT	ADJ	O
QTcF	O	NOUN	B
was	O	AUX	O
prolonged	B-I	ADJ	B
by	I-I	ADP	O
moxifloxacin	I-I	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
largest	O	ADJ	O
time-matched	O	ADJ	B
difference	O	NOUN	I
from	O	ADP	O
placebo	O	NOUN	B
administration	O	NOUN	B
was	O	AUX	O
13.6	O	NUM	O
milliseconds	O	NOUN	O
with	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
11.2	O	NUM	O
and	O	CCONJ	O
15.9	O	NUM	O
milliseconds	O	NOUN	O
at	O	ADP	O
4	O	NUM	O
hours	O	NOUN	B
post-dose	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
QTcF	O	NOUN	B
was	O	AUX	O
hardly	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
either	O	CCONJ	O
dose	O	NOUN	B
of	O	ADP	O
topiroxostat	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
largest	O	ADJ	O
time-matched	O	ADJ	B
difference	O	NOUN	I
from	O	ADP	O
placebo	O	NOUN	B
administration	O	NOUN	B
was	O	AUX	O
2.9	O	NUM	O
milliseconds	O	NOUN	O
with	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
of	O	ADP	O
0.6	O	NUM	O
and	O	CCONJ	O
5.3	O	NUM	O
milliseconds	O	NOUN	O
at	O	ADP	O
4	O	NUM	O
hours	O	NOUN	B
post-dose	O	NOUN	B
for	O	ADP	O
60	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
2.3	O	NUM	O
milliseconds	O	NOUN	O
with	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
and	O	CCONJ	O
4.7	O	NUM	O
milliseconds	O	NOUN	O
at	O	ADP	O
1	O	NUM	O
hour	O	NOUN	B
post-dose	O	NOUN	B
for	O	ADP	O
180	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
were	O	AUX	O
essentially	O	ADV	O
the	O	DET	O
same	O	ADJ	O
in	B-I	ADP	O
the	I-I	DET	O
sex	I-I	NOUN	B
subgroup	I-I	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


Moxifloxacin	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
positive	O	ADJ	B
control	B-P	NOUN	B
for	I-P	ADP	O
QT/QTc	I-P	NOUN	B
studies	O	NOUN	I
in	O	ADP	O
Japanese	O	ADJ	B
subjects	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
topiroxostat	O	NOUN	B
may	O	AUX	O
not	O	PART	O
cause	O	VERB	O
QT-interval	O	ADJ	B
prolongation	O	NOUN	B
in	O	ADP	O
males	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


Liposome-encapsulated	B-I	ADJ	B
doxorubicin	I-I	NOUN	I
compared	O	VERB	O
with	O	ADP	O
conventional	B-I	ADJ	B
doxorubicin	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
multicenter	O	NOUN	I
trial	O	NOUN	I
as	O	ADP	O
first-line	O	ADJ	B
therapy	O	NOUN	I
of	O	ADP	O
metastatic	B-P	ADJ	B
breast	I-P	NOUN	I
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
toxicity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
liposome-encapsulated	B-I	ADJ	B
doxorubicin	I-I	NOUN	I
,	I-I	PUNCT	O
TLC	I-I	NOUN	B
D-99	I-I	NOUN	O
(	I-I	PUNCT	O
Myocet	I-I	PROPN	B
,	I-I	PUNCT	O
Elan	I-I	PROPN	B
Pharmaceuticals	I-I	PROPN	I
,	I-I	PUNCT	O
Princeton	I-I	PROPN	B
,	I-I	PUNCT	O
NJ	I-I	PROPN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
conventional	B-I	ADJ	B
doxorubicin	I-I	NOUN	B
in	O	ADP	O
first-line	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
metastatic	O	ADJ	B
breast	O	NOUN	I
carcinoma	O	NOUN	I
(	O	PUNCT	O
MBC	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Two	B-P	NUM	O
hundred	I-P	NUM	O
twenty-four	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
MBC	I-P	NOUN	B
and	I-P	CCONJ	O
no	I-P	DET	O
prior	I-P	ADJ	O
therapy	I-P	NOUN	B
for	I-P	ADP	O
metastatic	I-P	ADJ	B
disease	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
TLC	B-I	NOUN	B
D-99	I-I	NOUN	O
(	I-I	PUNCT	O
75	I-I	NUM	O
mg/m	I-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
doxorubicin	I-I	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
or	O	CCONJ	O
unacceptable	O	ADJ	O
toxicity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
endpoint	O	NOUN	B
was	O	AUX	O
response	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


Responses	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
criteria	O	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
required	O	VERB	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
at	O	ADV	O
least	O	ADJ	O
6	O	NUM	O
weeks	O	NOUN	B
'	O	PART	O
duration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
safety	O	NOUN	O
endpoint	O	NOUN	O
was	O	AUX	O
cardiotoxicity	O	NOUN	B
.	O	PUNCT	O


Cardiac	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
monitored	O	VERB	O
by	O	ADP	O
multiple-gated	B-I	ADJ	B
radionuclide	I-I	NOUN	I
cardioangiography	I-I	NOUN	I
scan	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
left	O	ADJ	B
ventricular	O	ADJ	I
ejection	O	NOUN	I
fraction	O	NOUN	I
(	O	PUNCT	O
LVEF	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
scored	O	VERB	B
at	O	ADP	O
a	O	DET	O
central	O	ADJ	B
laboratory	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
were	I-P	AUX	O
removed	I-P	VERB	O
from	I-P	ADP	O
study	I-P	NOUN	B
if	I-P	SCONJ	O
LVEF	I-P	NOUN	B
declined	I-P	VERB	B
20	I-P	NUM	O
or	I-P	CCONJ	O
more	I-P	ADJ	O
EF	I-P	NOUN	B
units	I-P	NOUN	O
from	I-P	ADP	O
baseline	I-P	NOUN	B
to	I-P	PART	O
a	I-P	DET	O
final	I-P	ADJ	O
value	I-P	NOUN	O
of	I-P	ADP	O
greater	I-P	ADJ	O
than	I-P	ADP	O
or	I-P	CCONJ	O
equal	I-P	ADJ	O
to	I-P	PART	O
50	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
by	I-P	ADP	O
10	I-P	NUM	O
or	I-P	CCONJ	O
more	I-P	ADJ	O
units	I-P	NOUN	B
to	I-P	ADP	O
a	I-P	DET	O
final	I-P	ADJ	O
value	I-P	NOUN	O
of	I-P	ADP	O
less	I-P	ADJ	O
than	I-P	ADP	O
50	I-P	NUM	O
%	I-P	NOUN	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
onset	I-P	NOUN	O
of	I-P	ADP	O
clinical	I-P	ADJ	B
congestive	I-P	ADJ	O
heart	I-P	NOUN	O
failure	I-P	NOUN	O
(	I-P	PUNCT	O
CHF	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Median	B-P	ADJ	B
age	I-P	NOUN	I
was	I-P	AUX	O
54	I-P	NUM	O
years	I-P	NOUN	B
in	I-P	ADP	O
both	I-P	CCONJ	O
treatment	I-P	NOUN	B
groups	I-P	NOUN	I
.	I-P	PUNCT	O


All	O	DET	O
relevant	O	ADJ	O
prognostic	O	ADJ	B
factors	O	NOUN	I
were	O	AUX	O
balanced	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
exception	O	NOUN	O
that	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
significantly	O	ADV	O
more	O	ADJ	O
progesterone	O	NOUN	B
receptor	O	NOUN	I
positive	O	ADJ	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
doxorubicin-treated	B-I	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


Protocol-defined	B-OUT	ADJ	B
cardiotoxicity	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
13	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
TLC	O	NOUN	B
D-99	O	NOUN	O
patients	O	NOUN	B
(	O	PUNCT	O
including	O	VERB	O
2	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
CHF	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
29	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
doxorubicin	B-I	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
including	O	VERB	O
9	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
CHF	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Median	B-OUT	ADJ	B
cumulative	I-OUT	ADJ	B
doxorubicin	I-OUT	NOUN	B
dose	I-OUT	NOUN	I
at	I-OUT	ADP	O
onset	I-OUT	NOUN	O
of	I-OUT	ADP	O
cardiotoxicity	I-OUT	NOUN	B
was	O	AUX	O
785	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
TLC	B-I	NOUN	B
D-99	I-I	NOUN	O
versus	O	CCONJ	O
570	O	NUM	O
mg/m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
doxorubicin	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.0001	O	NUM	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
,	O	PUNCT	O
3.56	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
overall	B-OUT	ADJ	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
was	O	AUX	O
26	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
TTP	I-OUT	NOUN	B
was	O	AUX	O
2.9	O	NUM	O
months	O	NOUN	B
on	O	ADP	O
TLC	O	NOUN	B
D-99	O	NOUN	O
versus	O	CCONJ	O
3.1	O	NUM	O
months	O	NOUN	B
on	O	ADP	O
doxorubicin	B-I	NOUN	B
.	I-I	PUNCT	O


Median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
was	O	AUX	O
16	O	NUM	O
versus	O	CCONJ	O
20	O	NUM	O
months	O	NOUN	B
with	O	ADP	O
a	O	DET	O
nonsignificant	O	ADJ	O
trend	O	NOUN	O
in	O	ADP	O
favor	O	NOUN	O
of	O	ADP	O
doxorubicin	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.09	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Clinical	B-OUT	ADJ	B
toxicities	I-OUT	NOUN	B
,	O	PUNCT	O
commonly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
doxorubicin	O	NOUN	B
,	O	PUNCT	O
appeared	O	VERB	O
less	O	ADV	O
common	O	ADJ	O
with	O	ADP	O
TLC	O	NOUN	B
D-99	O	NOUN	O
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
difference	O	NOUN	B
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
only	O	ADV	O
one	O	NUM	O
report	O	NOUN	B
of	O	ADP	O
palmar-plantar	B-OUT	ADJ	B
erythrodysesthesia	I-OUT	NOUN	I
(	O	PUNCT	O
Grade	O	NOUN	B
2	O	NUM	I
)	O	PUNCT	O
with	O	ADP	O
this	O	DET	O
liposomal	O	ADJ	B
formulation	O	NOUN	I
of	O	ADP	O
doxorubicin	B-I	NOUN	B
.	I-I	PUNCT	O


CONCLUSIONS	O	NOUN	O
Single-agent	O	ADJ	B
TLC	B-I	NOUN	B
D-99	I-I	NOUN	O
produces	O	VERB	O
less	O	ADJ	O
cardiotoxicity	O	NOUN	B
than	O	ADP	O
doxorubicin	B-I	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
providing	O	VERB	O
comparable	O	ADJ	O
antitumor	O	NOUN	B
activity	O	NOUN	O
.	O	PUNCT	O


Effectiveness	O	NOUN	B
of	O	ADP	O
active	B-I	ADJ	B
physical	I-I	ADJ	B
training	I-I	NOUN	I
as	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
long-standing	B-P	ADJ	O
adductor-related	I-P	ADJ	B
groin	I-P	NOUN	I
pain	I-P	NOUN	I
in	I-P	ADP	O
athletes	I-P	NOUN	B
:	I-P	PUNCT	O
randomised	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Groin	O	PROPN	B
pain	O	NOUN	I
is	O	AUX	O
common	O	ADJ	O
among	O	ADP	O
athletes	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
major	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
long-standing	O	ADJ	B
problems	O	NOUN	B
is	O	AUX	O
adductor-related	B-P	ADJ	B
groin	I-P	NOUN	I
pain	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
randomised	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
an	O	DET	O
active	B-I	ADJ	B
training	I-I	NOUN	I
programme	I-I	NOUN	I
(	I-I	PUNCT	O
AT	I-I	NOUN	B
)	I-I	PUNCT	O
with	I-I	ADP	O
a	I-I	DET	O
physiotherapy	I-I	NOUN	B
treatment	I-I	NOUN	I
without	I-I	ADP	O
active	I-I	ADJ	B
training	I-I	NOUN	I
(	I-I	PUNCT	O
PT	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
adductor-related	B-P	ADJ	B
groin	I-P	NOUN	I
pain	I-P	NOUN	I
in	I-P	ADP	O
athletes	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
68	B-P	NUM	O
athletes	I-P	NOUN	B
with	I-P	ADP	O
long-standing	I-P	ADJ	O
(	I-P	PUNCT	O
median	I-P	ADJ	B
40	I-P	NUM	O
weeks	I-P	NOUN	B
)	I-P	PUNCT	O
adductor-related	I-P	ADJ	B
groin	I-P	NOUN	O
pain	I-P	NOUN	O
--	I-P	PUNCT	O
after	I-P	ADP	O
examination	I-P	NOUN	B
according	I-P	VERB	O
to	I-P	ADP	O
a	I-P	DET	O
standardised	I-P	VERB	B
protocol	I-P	NOUN	I
--	I-P	PUNCT	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
AT	I-I	ADP	B
or	I-P	CCONJ	O
PT	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
was	O	AUX	O
8-12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


4	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
a	O	DET	O
standardised	O	ADJ	B
examination	O	NOUN	I
was	O	AUX	O
done	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
examining	O	VERB	B
physician	O	NOUN	B
was	O	AUX	O
unaware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
allocation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ultimate	O	ADJ	O
outcome	O	NOUN	B
measure	O	NOUN	I
was	O	AUX	O
full	B-OUT	ADJ	O
return	I-OUT	NOUN	B
to	I-OUT	ADP	I
sports	I-OUT	NOUN	B
at	I-OUT	ADP	O
the	I-OUT	DET	O
same	I-OUT	ADJ	O
level	I-OUT	NOUN	B
without	I-OUT	ADP	O
groin	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Analyses	O	NOUN	B
were	O	AUX	O
by	O	ADP	O
intention	O	NOUN	B
to	O	PART	O
treat	O	VERB	B
.	O	PUNCT	O


FINDINGS	O	NOUN	B
23	B-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
AT	I-P	NOUN	B
group	I-P	NOUN	I
and	I-P	CCONJ	O
four	I-P	NUM	O
in	I-P	ADP	O
the	I-P	DET	O
PT	I-P	PROPN	B
group	I-P	NOUN	B
returned	I-P	VERB	O
to	I-P	ADP	O
sports	I-P	NOUN	B
without	I-P	ADP	O
groin	I-OUT	NOUN	B
pain	I-OUT	NOUN	I
(	I-P	PUNCT	O
odds	I-P	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
multiple-logistic-regression	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
12.7	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
3.4-47.2	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
subjective	O	ADJ	O
global	O	ADJ	O
assessments	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatments	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
p=0.006	O	ADJ	O
)	O	PUNCT	O
linear	O	ADJ	O
trend	O	NOUN	O
towards	O	ADP	O
a	O	DET	O
better	O	ADJ	O
effect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
AT	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
per-protocol	O	ADJ	B
analysis	O	NOUN	I
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
appreciably	O	ADV	O
different	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


INTERPRETATION	O	NOUN	B
AT	O	ADP	B
with	O	ADP	O
a	O	DET	O
programme	O	NOUN	B
aimed	O	VERB	O
at	O	ADP	O
improving	O	VERB	B
strength	O	NOUN	B
and	O	CCONJ	O
coordination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
muscles	O	NOUN	B
acting	O	VERB	O
on	O	ADP	O
the	O	DET	O
pelvis	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
particular	O	ADJ	O
the	O	DET	O
adductor	O	NOUN	B
muscles	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
very	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
athletes	O	NOUN	B
with	O	ADP	O
long-standing	O	ADJ	O
adductor-related	O	ADJ	B
groin	O	NOUN	I
pain	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
potential	O	ADJ	B
preventive	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
a	O	DET	O
short	O	ADJ	B
programme	O	NOUN	I
based	O	VERB	O
upon	O	SCONJ	O
the	O	DET	O
principles	O	NOUN	O
of	O	ADP	O
AT	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
future	O	NOUN	B
,	O	PUNCT	O
randomised	O	VERB	B
,	O	PUNCT	O
clinical	O	ADJ	B
trials	O	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
exposure	O	NOUN	B
to	O	PART	I
thin-ideal	O	ADJ	B
media	O	NOUN	I
images	O	NOUN	B
on	O	ADP	O
body	B-OUT	NOUN	B
dissatisfaction	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
testing	O	VERB	B
the	O	DET	O
inclusion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
disclaimer	B-I	NOUN	B
versus	I-I	ADP	O
warning	I-I	NOUN	B
label	I-I	NOUN	O
.	I-I	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
inclusion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
disclaimer	O	NOUN	B
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
"	O	PUNCT	O
Retouched	O	ADJ	B
photograph	O	NOUN	I
aimed	O	VERB	O
at	O	ADP	O
changing	O	VERB	B
a	O	DET	O
person	O	NOUN	B
's	O	PART	O
physical	O	ADJ	B
appearance	O	NOUN	I
.	O	PUNCT	O


"	O	PUNCT	O
)	O	PUNCT	O
or	O	CCONJ	O
warning	O	VERB	B
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
"	O	PUNCT	O
Warning	O	VERB	B
:	O	PUNCT	O
Trying	O	VERB	O
to	O	PART	O
look	O	VERB	O
as	O	ADV	O
thin	O	ADJ	O
as	O	ADP	O
this	O	DET	O
model	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
dangerous	O	ADJ	O
to	O	ADP	O
your	O	PRON	O
health	O	NOUN	B
.	O	PUNCT	O


"	O	PUNCT	O
)	O	PUNCT	O
added	O	VERB	O
to	O	PART	O
images	O	NOUN	B
of	O	ADP	O
thin/attractive	O	ADJ	B
models	O	NOUN	I
would	O	AUX	O
affect	O	VERB	O
body	B-OUT	NOUN	B
dissatisfaction	I-OUT	NOUN	I
and	O	CCONJ	O
intent	O	NOUN	B
to	O	PART	O
diet	O	NOUN	B
in	O	ADP	O
female	B-P	ADJ	B
undergraduate	I-P	NOUN	O
students	I-P	NOUN	O
(	I-P	PUNCT	O
n=342	I-P	PROPN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
groups	B-I	NOUN	B
:	I-I	PUNCT	O
(	I-I	PUNCT	O
a	I-I	X	O
)	I-I	PUNCT	O
disclaimer	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
b	I-I	X	O
)	I-I	PUNCT	O
warning	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
c	I-I	X	O
)	I-I	PUNCT	O
model	I-I	NOUN	O
control	I-I	NOUN	O
,	I-I	PUNCT	O
or	I-I	CCONJ	O
(	I-I	PUNCT	O
d	I-I	X	O
)	I-I	PUNCT	O
car	I-I	NOUN	B
control	I-I	NOUN	I
.	I-I	PUNCT	O


Results	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
interaction	O	NOUN	B
between	O	ADP	O
group	O	NOUN	B
and	O	CCONJ	O
time	O	NOUN	B
,	O	PUNCT	O
whereby	O	SCONJ	O
only	O	ADV	O
the	O	DET	O
car	O	NOUN	B
control	O	NOUN	B
group	O	NOUN	I
reported	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
change	O	NOUN	O
(	O	PUNCT	O
i.e.	O	X	O
,	O	PUNCT	O
decrease	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
body	B-OUT	NOUN	B
dissatisfaction	I-OUT	NOUN	I
over	O	ADP	O
time	O	NOUN	O
.	O	PUNCT	O


Groups	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
on	O	ADP	O
intent	O	NOUN	B
to	O	PART	O
diet	B-OUT	NOUN	B
measured	O	VERB	B
at	O	ADP	O
post-exposure	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
largely	O	ADV	O
replicate	O	VERB	B
other	O	ADJ	O
findings	O	NOUN	B
in	O	ADP	O
this	O	DET	O
area	O	NOUN	B
and	O	CCONJ	O
call	O	VERB	O
into	O	ADP	O
question	O	NOUN	O
advocacy	O	NOUN	B
efforts	O	NOUN	O
to	O	PART	O
label	O	VERB	B
media	O	NOUN	I
images	O	NOUN	B
as	O	ADP	O
a	O	DET	O
strategy	O	NOUN	O
to	O	PART	O
decrease	O	VERB	B
women	B-P	NOUN	B
's	I-P	PART	O
identification	O	NOUN	B
with	O	ADP	O
the	O	DET	O
stimuli	O	NOUN	B
.	O	PUNCT	O


Randomized	O	ADJ	B
Phase	O	NOUN	I
II	O	NUM	I
trial	O	NOUN	I
assessing	O	VERB	O
estramustine	B-I	NOUN	B
and	I-I	CCONJ	O
vinblastine	I-I	NOUN	B
combination	I-I	NOUN	O
chemotherapy	I-I	NOUN	B
vs	I-I	CCONJ	O
estramustine	I-I	NOUN	B
alone	I-I	ADV	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
progressive	I-P	ADJ	B
hormone-escaped	I-P	ADJ	B
metastatic	I-P	ADJ	B
prostate	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
combined	O	ADJ	B
data	O	NOUN	B
from	O	ADP	O
three	O	NUM	O
North	O	ADJ	B
American	O	ADJ	I
Phase	O	NOUN	I
II	O	NUM	I
studies	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
Phase	O	NOUN	I
II	O	NUM	I
study	O	NOUN	I
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
patient	O	NOUN	B
population	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
,	O	PUNCT	O
using	O	VERB	O
combination	O	NOUN	B
chemotherapy	B-I	NOUN	I
with	I-I	ADP	O
estramustine	I-I	NOUN	B
phosphate	I-I	NOUN	I
(	I-I	PUNCT	O
EMP	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
vinblastine	I-I	NOUN	B
(	I-I	PUNCT	O
VBL	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
hormone	O	NOUN	B
refractory	O	ADJ	I
prostate	O	NOUN	B
cancer	O	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
,	O	PUNCT	O
92	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomised	I-P	VERB	B
into	I-P	ADP	O
a	I-P	DET	O
Phase	I-P	NOUN	B
II	I-P	NUM	I
study	I-P	NOUN	I
of	O	ADP	O
oral	B-I	ADJ	B
EMP	I-I	NOUN	B
(	I-I	PUNCT	O
10	I-I	NUM	O
mg	I-I	NOUN	O
kg	I-I	NOUN	O
day	I-I	NOUN	B
continuously	I-I	ADV	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
oral	I-I	ADJ	B
EMP	I-I	NOUN	B
in	I-I	ADP	O
combination	I-I	NOUN	B
with	I-I	ADP	O
intravenous	I-I	ADJ	B
VBL	I-I	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
week	O	NOUN	B
for	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
rest	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
end	O	NOUN	O
points	O	NOUN	O
were	O	AUX	O
toxicity	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
PSA	I-OUT	NOUN	B
response	I-OUT	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
option	O	NOUN	O
to	O	PART	O
continue	O	VERB	O
the	O	DET	O
trial	O	NOUN	B
as	O	ADP	O
a	O	DET	O
Phase	O	NOUN	B
III	O	NUM	I
study	O	NOUN	I
with	O	ADP	O
time	B-OUT	NOUN	O
to	I-OUT	PART	O
progression	I-OUT	NOUN	B
and	O	CCONJ	O
survival	B-OUT	NOUN	B
as	O	ADP	O
end	O	NOUN	O
points	O	NOUN	O
,	O	PUNCT	O
if	O	SCONJ	O
sufficient	O	ADJ	O
responses	O	NOUN	B
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Toxicity	B-OUT	NOUN	B
was	O	AUX	O
unexpectedly	O	ADV	O
high	O	ADJ	O
in	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
arms	O	NOUN	I
and	O	CCONJ	O
led	O	VERB	O
to	O	PART	O
treatment	O	NOUN	B
withdrawal	O	NOUN	B
or	O	CCONJ	O
refusal	O	NOUN	B
in	O	ADP	O
49	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
predominantly	O	ADV	O
already	O	ADV	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
treatment	O	NOUN	B
cycle	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	B
treatment	I-OUT	NOUN	B
duration	I-OUT	NOUN	O
was	O	AUX	O
10	O	NUM	O
and	O	CCONJ	O
14	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
median	B-OUT	ADJ	B
time	I-OUT	NOUN	O
to	I-OUT	PART	O
PSA	I-OUT	NOUN	B
progression	I-OUT	NOUN	B
was	O	AUX	O
27.2	O	NUM	O
and	O	CCONJ	O
30.8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
median	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
time	I-OUT	NOUN	I
was	O	AUX	O
44	O	NUM	O
and	O	CCONJ	O
50.9	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
PSA	B-OUT	NOUN	B
response	I-OUT	NOUN	O
rate	I-OUT	NOUN	O
was	O	AUX	O
only	O	ADV	O
24.6	O	NUM	O
and	O	CCONJ	O
28.9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
EMP/VBL	B-I	NOUN	B
and	O	CCONJ	O
EMP	B-I	NOUN	B
arms	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
PSA	B-OUT	NOUN	B
response	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
survival	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
PSA	B-OUT	NOUN	B
response	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
tested	O	VERB	B
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
half	O	DET	O
that	O	PRON	O
recorded	O	VERB	O
in	O	ADP	O
the	O	DET	O
North	O	ADJ	B
American	O	ADJ	I
studies	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
toxicity	B-OUT	NOUN	B
of	I-OUT	ADP	O
EMP	I-OUT	NOUN	B
monotherapy	I-OUT	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
VBL	B-I	NOUN	B
was	O	AUX	O
much	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
expected	O	VERB	O
.	O	PUNCT	O


Further	O	ADJ	O
research	O	NOUN	B
on	O	ADP	O
more	O	ADV	O
effective	B-OUT	ADJ	B
and	O	CCONJ	O
less	O	ADV	O
toxic	B-OUT	ADJ	B
treatment	O	NOUN	B
strategies	O	NOUN	O
for	O	ADP	O
hormone	O	NOUN	B
refractory	O	ADJ	I
prostate	O	NOUN	B
cancer	O	NOUN	I
is	O	AUX	O
mandatory	O	ADJ	O
.	O	PUNCT	O


Post-laparoscopic	B-P	ADJ	B
cholecystectomy	I-P	NOUN	I
pain	I-P	NOUN	I
:	I-P	PUNCT	O
effects	I-OUT	NOUN	B
of	O	ADP	I
intraperitoneal	O	ADJ	B
local	O	ADJ	O
anesthetics	B-I	NOUN	O
on	O	ADP	O
pain	O	NOUN	B
control	O	NOUN	I
--	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
prospective	O	ADJ	I
double-blinded	O	ADJ	I
placebo-controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


Postoperative	B-P	ADJ	B
pain	I-P	NOUN	I
after	I-P	ADP	O
laparoscopic	I-P	ADJ	B
cholecystectomy	I-P	NOUN	I
(	I-P	PUNCT	O
LC	I-P	NOUN	B
)	I-P	PUNCT	O
is	O	AUX	O
generally	O	ADV	O
less	O	ADJ	O
than	O	ADP	O
open	O	ADJ	B
cholecystectomy	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
postoperative	O	ADJ	B
shoulder	O	NOUN	I
and	O	CCONJ	O
abdominal	O	ADJ	B
pain	O	NOUN	I
experienced	O	VERB	O
by	O	ADP	O
patients	O	NOUN	B
still	O	ADV	O
causes	O	VERB	O
preventable	O	ADJ	B
distress	O	NOUN	I
.	O	PUNCT	O


Intraperitoneal	O	ADJ	B
irrigation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
diaphragmatic	O	ADJ	B
surface	O	NOUN	I
and	O	CCONJ	O
gallbladder	O	NOUN	B
fossa	O	ADJ	I
using	O	VERB	O
normal	O	ADJ	B
saline	B-I	NOUN	I
,	I-I	PUNCT	O
bupivacaine	I-I	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
lignocaine	B-I	NOUN	B
may	O	AUX	O
effectively	O	ADV	O
control	O	VERB	B
visceral	B-OUT	ADJ	B
abdominal	I-OUT	ADJ	I
pain	I-OUT	NOUN	I
after	O	ADP	O
an	O	DET	O
LC	O	NOUN	B
.	O	PUNCT	O


Two	B-P	NUM	O
hundred	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
similar	I-P	ADJ	O
demographics	I-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
LC	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
four	B-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
50	I-P	NUM	O
patients	I-P	NOUN	B
each	I-P	DET	O
,	O	PUNCT	O
including	O	VERB	O
Group	O	PROPN	B
A	O	NOUN	O
placebo	B-I	NOUN	B
control	O	NOUN	O
,	O	PUNCT	O
Group	O	PROPN	B
B	O	NOUN	O
with	O	ADP	O
isotonic	B-I	ADJ	B
saline	I-I	NOUN	I
irrigation	I-I	NOUN	I
,	O	PUNCT	O
Group	O	PROPN	B
C	O	NOUN	O
with	O	ADP	O
bupivacaine	B-I	NOUN	B
irrigation	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Group	O	PROPN	B
D	O	NOUN	I
with	O	ADP	O
lignocaine	B-I	NOUN	B
irrigation	I-I	NOUN	B
.	I-I	PUNCT	O


All	O	DET	O
patients	B-P	NOUN	B
received	O	VERB	O
preperitoneal	O	ADJ	B
abdominal	O	ADJ	I
wall	O	NOUN	I
infiltration	O	NOUN	B
with	O	ADP	O
0.25	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
bupivacaine	B-I	NOUN	B
to	O	PART	O
control	O	VERB	B
parietal	B-P	ADJ	I
(	I-P	PUNCT	O
somatic	I-P	ADJ	B
)	I-P	PUNCT	O
abdominal	I-P	ADJ	B
pain	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
visual	B-OUT	ADJ	B
analogue	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
verbal	I-OUT	ADJ	B
rating	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
at	O	ADP	O
0	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
hours	O	NOUN	O
for	O	ADP	O
both	O	DET	O
shoulder	O	NOUN	B
and	O	CCONJ	O
abdominal	O	ADJ	B
pain	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
double-blind	O	ADJ	I
fashion	O	NOUN	I
at	O	ADP	O
four	O	NUM	O
points	O	NOUN	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
24	O	NUM	O
postoperative	O	ADJ	B
hours	O	NOUN	O
.	O	PUNCT	O


Analgesia	B-OUT	NOUN	B
requirements	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
vital	I-OUT	ADJ	B
signs	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
blood	I-OUT	NOUN	B
glucose	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
nausea	I-OUT	NOUN	B
and	I-OUT	CCONJ	I
vomiting	I-OUT	NOUN	B
were	O	AUX	O
also	O	ADV	O
recorded	O	VERB	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
in	I-P	ADP	O
each	I-P	DET	O
group	I-P	NOUN	B
demonstrated	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
visual	B-OUT	ADJ	B
analogue	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
verbal	I-OUT	ADJ	B
rating	I-OUT	NOUN	I
pain	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
analgesic	I-OUT	NOUN	B
consumption	I-OUT	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Lignocaine	B-I	NOUN	B
controlled	I-OUT	VERB	O
pain	I-OUT	NOUN	O
significantly	O	ADV	B
better	O	ADJ	I
than	O	ADP	O
saline	B-I	NOUN	B
or	O	CCONJ	O
bupivacaine	B-I	NOUN	B
.	I-I	PUNCT	O


Bowel	B-OUT	ADJ	B
function	I-OUT	NOUN	I
recovery	I-OUT	NOUN	B
was	O	AUX	O
similar	B-OUT	ADJ	O
in	O	ADP	O
all	B-P	DET	O
patients	I-P	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
complications	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
intraperitoneal	O	ADJ	B
irrigation	O	NOUN	B
with	O	ADP	O
either	O	DET	O
saline	B-I	NOUN	B
,	I-I	PUNCT	O
bupivacaine	I-I	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
lignocaine	B-I	NOUN	B
can	O	AUX	O
significantly	O	ADV	O
reduce	O	VERB	B
visceral	B-OUT	ADJ	B
abdominal	I-OUT	ADJ	I
pain	I-OUT	NOUN	I
after	O	ADP	O
LC	O	NOUN	B
.	O	PUNCT	O


Lignocaine	B-I	NOUN	B
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
efficacious	O	ADJ	B
local	O	ADJ	B
anesthetic	O	NOUN	I
in	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
a	O	DET	O
high	O	ADJ	O
safety	O	NOUN	B
profile	O	NOUN	O
when	O	SCONJ	O
used	O	VERB	O
at	O	ADP	O
recommended	O	VERB	B
doses	O	NOUN	I
.	O	PUNCT	O


BCG	B-I	NOUN	B
(	I-I	PUNCT	O
RIVM	I-I	PROPN	B
)	I-I	PUNCT	O
versus	O	CCONJ	O
mitomycin	B-I	NOUN	B
intravesical	I-I	ADJ	B
therapy	I-I	NOUN	I
in	O	ADP	O
superficial	B-P	ADJ	B
bladder	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


First	O	ADJ	O
results	O	NOUN	B
of	O	ADP	O
randomized	O	ADJ	B
prospective	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
presents	O	VERB	O
the	O	DET	O
preliminary	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
prospective	O	ADJ	I
two-arm	O	ADJ	I
study	O	NOUN	I
in	O	ADP	O
which	O	DET	O
bacillus	B-I	X	B
Calmette-Guérin	I-I	X	I
(	I-I	PUNCT	O
BCG	I-I	PROPN	B
)	I-I	PUNCT	O
RIVM	I-I	PROPN	B
,	I-I	PUNCT	O
a	I-I	DET	O
Dutch	I-I	ADJ	B
BCG	I-I	NOUN	I
preparation	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
compared	O	VERB	O
with	B-I	ADP	O
mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
(	O	PUNCT	O
MMC	O	NOUN	B
)	O	PUNCT	O
in	B-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
primary	I-P	ADJ	B
or	I-P	CCONJ	O
recurrent	I-P	ADJ	B
superficial	I-P	ADJ	O
bladder	I-P	NOUN	O
tumors	I-P	NOUN	O
,	I-P	PUNCT	O
including	I-P	VERB	O
carcinoma	I-P	NOUN	B
in	I-P	X	B
situ	I-P	X	I
(	I-P	PUNCT	O
CIS	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


Therapeutic	O	ADJ	B
regimens	O	NOUN	I
were	O	AUX	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
after	O	ADP	O
complete	O	ADJ	O
transurethral	O	ADJ	B
resection	O	NOUN	I
of	O	ADP	O
all	O	DET	O
visible	O	ADJ	B
tumors	O	NOUN	I
,	O	PUNCT	O
BCG	B-I	PROPN	B
RIVM	I-I	PROPN	I
(	O	PUNCT	O
1	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
bacilli	O	NOUN	O
in	O	ADP	O
50	O	NUM	O
mL	O	NOUN	O
saline	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
instilled	O	VERB	B
once	O	ADV	O
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
six	O	NUM	O
consecutive	O	ADJ	B
weeks	O	NOUN	B
,	O	PUNCT	O
and	B-I	CCONJ	O
mitomycin	I-I	NOUN	B
C	I-I	NOUN	I
(	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
50	O	NUM	O
mL	O	NOUN	O
saline	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
once	O	ADV	O
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
one	O	NUM	O
month	O	NOUN	B
(	O	PUNCT	O
weeks	O	NOUN	B
1	O	NUM	O
to	O	PART	O
4	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
thereafter	O	ADV	O
once	O	ADV	O
a	O	DET	O
month	O	NOUN	B
for	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
.	B-OUT	PUNCT	O


Reported	B-OUT	VERB	B
are	I-OUT	AUX	O
the	I-OUT	DET	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
in	I-P	ADP	O
165	I-P	NUM	O
patients	I-P	NOUN	B
and	I-P	CCONJ	O
the	I-OUT	DET	O
recurrence	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
tumors	I-OUT	NOUN	B
in	I-P	ADP	O
308	I-P	NUM	O
patients	I-P	NOUN	B
after	I-P	ADP	O
a	I-P	DET	O
follow-up	I-P	ADJ	B
period	I-P	NOUN	B
of	I-P	ADP	O
twelve	I-P	NUM	O
months	I-P	NOUN	B
.	I-OUT	PUNCT	O


Drug-induced	B-OUT	ADJ	B
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
chemical	I-OUT	NOUN	B
cystitis	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
13	O	NUM	O
(	O	PUNCT	O
16.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
78	O	NUM	O
BCG-treated	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
12	O	NUM	O
(	O	PUNCT	O
13.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
87	O	NUM	O
MMC-treated	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
same	O	ADJ	O
groups	B-OUT	NOUN	B
bacterial	I-OUT	ADJ	B
cystitis	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
17	O	NUM	O
(	O	PUNCT	O
21.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
16	O	NUM	O
(	O	PUNCT	O
18.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
BCG-treated	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
148	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
44	O	NUM	O
(	O	PUNCT	O
29.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	B-OUT	AUX	O
recurrent	I-OUT	ADJ	B
tumors	I-OUT	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
MMC-treated	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
160	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
40	O	NUM	O
(	O	PUNCT	O
25.0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
a	B-OUT	DET	O
recurrence	I-OUT	NOUN	B
.	O	PUNCT	O


The	B-OUT	DET	O
recurrence	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
for	I-I	ADP	O
BCG-treated	I-I	ADJ	B
patients	O	NOUN	B
was	O	AUX	O
0.33	O	NUM	O
;	O	PUNCT	O
the	O	DET	O
recurrence	O	NOUN	B
rate	O	NOUN	B
for	B-I	ADP	O
MMC-treated	I-I	ADJ	B
patients	O	NOUN	B
was	O	AUX	O
0.29	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.560	O	NUM	O
,	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
preliminary	O	ADJ	B
data	O	NOUN	B
demonstrated	O	VERB	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
arms	O	NOUN	O
with	O	ADP	O
regard	O	NOUN	O
to	B-OUT	PART	O
toxicity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
recurrence	I-OUT	NOUN	B
of	I-OUT	ADP	O
tumors	I-OUT	NOUN	B
.	O	PUNCT	O


Intravenous	O	ADJ	B
aflibercept	B-I	NOUN	B
administered	O	VERB	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
irinotecan	B-I	NOUN	B
,	I-I	PUNCT	O
5-fluorouracil	I-I	NOUN	B
and	I-I	CCONJ	O
leucovorin	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
solid	I-P	ADJ	B
tumours	I-P	NOUN	I
:	I-P	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
the	O	DET	O
expansion	O	NOUN	B
cohort	O	NOUN	B
of	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
I	O	NUM	I
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Following	O	VERB	O
the	O	DET	O
dose-escalation	O	ADJ	B
stage	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
double-blind	O	ADJ	B
expansion	O	NOUN	B
stage	O	NOUN	O
of	O	ADP	O
the	O	DET	O
phase	O	NOUN	B
I	O	NUM	I
study	O	NOUN	I
evaluated	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
,	O	PUNCT	O
pharmacodynamics	O	NOUN	B
,	O	PUNCT	O
pharmacokinetics	O	NOUN	B
,	O	PUNCT	O
anti-vascular	O	ADJ	B
effects	O	NOUN	I
and	O	CCONJ	O
antitumour	O	ADJ	B
activity	O	NOUN	I
of	O	ADP	O
aflibercept	B-I	NOUN	B
4	O	NUM	O
mg/kg	O	NOUN	O
with	O	ADP	O
irinotecan	B-I	NOUN	B
,	I-I	PUNCT	O
5-fluorouracil	I-I	NOUN	B
and	I-I	CCONJ	O
leucovorin	I-I	NOUN	B
(	I-I	PUNCT	O
LV5FU2	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	O
solid	I-P	ADJ	B
tumours	I-P	NOUN	I
were	O	AUX	O
randomised	O	VERB	B
at	O	ADP	O
cycle-1	O	NOUN	O
to	O	PART	O
placebo	B-I	NOUN	B
or	I-I	CCONJ	O
aflibercept	I-I	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
then	O	ADV	O
irinotecan-LV5FU2	B-I	ADJ	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


Subsequently	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
aflibercept	B-I	NOUN	B
with	O	ADP	O
irinotecan-LV5FU2	B-I	NOUN	B
every	O	DET	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Anti-vascular	O	ADJ	B
effects	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
dynamic	O	ADJ	B
contrast-enhanced	O	ADJ	I
magnetic	O	ADJ	I
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
DCE-MRI	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
Twenty-seven	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
treated	I-P	VERB	B
;	I-P	PUNCT	O
14	O	NUM	O
received	O	VERB	O
placebo	B-I	NOUN	B
in	O	ADP	O
cycle-1	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
aflibercept	B-I	NOUN	B
in	O	ADP	O
later	O	ADJ	O
cycles	O	NOUN	B
and	O	CCONJ	O
13	O	NUM	O
received	O	VERB	O
aflibercept	B-I	NOUN	B
4	O	NUM	O
mg/kg	O	NOUN	O
upfront	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
aflibercept	I-OUT	NOUN	B
cycles	I-OUT	NOUN	B
was	O	AUX	O
16	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	O
1-44	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
12	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
≥20	O	VERB	O
cycles	O	NOUN	B
.	O	PUNCT	O


Most	O	ADV	O
frequent	O	ADJ	B
grade	O	NOUN	B
3/4	O	NUM	O
adverse	O	ADJ	B
events	O	NOUN	I
were	B-OUT	AUX	O
neutropenia	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
37	I-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
fatigue	I-OUT	NOUN	B
(	O	PUNCT	O
33	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
hypertension	I-OUT	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
anti-aflibercept	O	ADJ	O
antibodies	O	NOUN	O
were	O	AUX	O
detected	B-P	VERB	B
.	I-P	PUNCT	O


Four	B-P	NUM	O
patients	I-P	NOUN	B
achieved	I-P	VERB	O
partial	I-P	ADJ	B
responses	I-P	NOUN	O
and	O	CCONJ	O
17	O	NUM	O
had	O	AUX	O
stable	O	ADJ	B
disease	O	NOUN	I
,	O	PUNCT	O
lasting	O	VERB	O
>	O	NOUN	O
3	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
14	O	NUM	O
patients	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Plasma	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
free	I-OUT	ADV	B
over	I-OUT	ADP	O
vascular	I-OUT	ADJ	B
endothelial	I-OUT	ADJ	I
growth	I-OUT	NOUN	I
factor-bound	I-OUT	ADJ	O
aflibercept	I-OUT	NOUN	B
were	O	AUX	O
adequate	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
steady-state	O	NOUN	B
achieved	O	VERB	O
from	O	ADP	O
cycle-3	O	NOUN	B
.	O	PUNCT	O


Exploratory	O	ADJ	B
DCE-MRI	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
perfusion	O	NOUN	B
changes	O	NOUN	B
with	O	ADP	O
aflibercept	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	B-I	NOUN	O
Aflibercept	I-I	NOUN	B
4	O	NUM	O
mg/kg	O	NOUN	O
plus	B-I	CCONJ	O
irinotecan-LV5FU2	I-I	NOUN	B
every	O	DET	O
2	O	NUM	O
weeks	O	NOUN	B
had	O	AUX	O
acceptable	O	ADJ	O
toxicity	O	NOUN	B
and	O	CCONJ	O
pharmacokinetics	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
showed	O	VERB	O
promising	O	ADJ	O
antitumour	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


Venlafaxine	B-I	NOUN	B
versus	O	CCONJ	O
clonidine	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	B-P	NOUN	B
of	I-P	ADP	O
hot	I-OUT	ADJ	B
flashes	I-OUT	NOUN	I
in	I-P	ADP	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
cross-over	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	PROPN	B
Breast	B-P	NOUN	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
treatment-induced	I-P	ADJ	B
menopause	I-P	NOUN	B
experience	I-P	NOUN	B
frequent	I-P	ADJ	B
and	I-P	CCONJ	O
severe	I-OUT	ADJ	B
hot	I-OUT	ADJ	B
flashes	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


We	O	PRON	O
compared	O	VERB	O
venlafaxine	B-I	NOUN	B
and	O	CCONJ	O
clonidine	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
HF	O	NOUN	B
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
side	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
efficacy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
sexual	I-OUT	ADJ	B
functioning	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
cross-over	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
60	B-P	NUM	O
breast	I-P	NOUN	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
experiencing	I-P	VERB	O
HF	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	O	PART	O
8	O	NUM	O
weeks	O	NOUN	B
venlafaxine	B-I	NOUN	B
followed	O	VERB	O
by	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
wash-out	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
weeks	O	NOUN	B
clonidine	B-I	NOUN	B
or	O	CCONJ	O
vice	O	ADV	O
versa	O	ADV	O
.	O	PUNCT	O


HF	B-OUT	NOUN	B
frequency	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
severity	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
sexuality	I-OUT	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Thirty	B-P	NUM	O
patients	I-P	NOUN	B
started	O	VERB	B
with	O	ADP	I
venlafaxine	B-I	NOUN	B
and	O	CCONJ	O
30	O	NUM	O
with	O	ADP	O
clonidine	B-I	NOUN	B
.	I-I	PUNCT	O


Premature	O	ADJ	B
discontinuation	O	NOUN	I
for	O	ADP	O
toxicity	B-OUT	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
14/59	O	NUM	O
during	O	ADP	O
venlafaxine	B-I	NOUN	B
and	O	CCONJ	O
5/53	O	NUM	O
during	O	ADP	O
clonidine	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.038	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Venlafaxine	B-I	NOUN	B
induced	O	VERB	B
more	O	ADJ	O
side	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
HF	I-OUT	NOUN	B
score	I-OUT	NOUN	B
was	O	AUX	O
49	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
venlafaxine	B-I	NOUN	B
and	O	CCONJ	O
55	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
clonidine	B-I	NOUN	B
(	O	PUNCT	O
ns	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Venlafaxine	B-I	NOUN	B
and	O	CCONJ	O
clonidine	B-I	NOUN	B
are	O	AUX	O
equally	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
moderately	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
HF	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Side	B-OUT	ADJ	B
effects	I-OUT	NOUN	I
are	O	AUX	O
the	O	DET	O
main	O	ADJ	O
reason	O	NOUN	O
for	O	ADP	O
drug	O	NOUN	B
discontinuation	O	NOUN	I
,	O	PUNCT	O
occurring	O	VERB	O
more	O	ADV	O
often	O	ADV	O
with	O	ADP	O
venlafaxine	B-I	NOUN	B
.	I-I	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
interferon	O	NOUN	B
gamma	O	NOUN	I
on	O	ADP	O
infection-related	O	ADJ	B
death	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
injuries	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
interferon	B-I	NOUN	B
gamma	I-I	NOUN	I
in	O	ADP	O
reducing	O	VERB	B
infection	B-OUT	NOUN	B
and	O	CCONJ	O
death	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
sustaining	I-P	VERB	O
severe	I-P	ADJ	B
injury	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
Multicenter	O	PROPN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
with	O	ADP	O
observation	O	NOUN	B
for	O	ADP	O
60	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
until	O	ADP	O
discharge	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
major	I-P	ADJ	O
infection	I-P	NOUN	B
on	I-P	ADP	O
day	I-P	NOUN	B
60	I-P	NUM	O
.	I-P	PUNCT	O


SETTING	O	VERB	O
Nine	B-P	NUM	O
university-affiliated	I-P	ADJ	O
level	I-P	NOUN	O
1	I-P	NUM	O
trauma	I-P	NOUN	B
centers	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	O	VERB	O
Four	B-P	NUM	O
hundred	I-P	NUM	O
sixteen	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
injuries	I-P	NOUN	B
,	I-P	PUNCT	O
assessed	I-P	VERB	B
by	I-P	ADP	O
Injury	I-OUT	PROPN	B
Severity	I-OUT	PROPN	I
Score	I-OUT	PROPN	I
and	I-OUT	CCONJ	O
degree	I-OUT	NOUN	B
of	I-OUT	ADP	O
contamination	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


INTERVENTION	O	ADJ	B
Recombinant	B-I	ADJ	B
human	I-I	ADJ	B
interferon	I-I	NOUN	B
gamma	I-I	NOUN	I
,	I-I	PUNCT	O
100	I-I	NUM	O
micrograms	I-I	NOUN	B
,	I-I	PUNCT	O
was	I-I	AUX	O
administered	I-I	VERB	B
subcutaneously	I-I	ADV	B
once	I-I	ADV	O
daily	I-I	ADV	O
for	I-I	ADP	O
21	I-I	NUM	O
days	I-I	NOUN	B
(	I-I	PUNCT	O
or	I-I	CCONJ	O
until	I-I	ADP	O
patient	I-I	NOUN	B
discharge	I-I	NOUN	I
if	I-I	SCONJ	O
prior	I-I	ADJ	O
to	I-I	PART	O
21	I-I	NUM	O
days	I-I	NOUN	B
)	I-I	PUNCT	O
as	I-I	ADP	O
an	I-I	DET	O
adjunct	I-I	NOUN	B
to	I-I	PART	O
standard	I-I	ADJ	B
antibiotic	I-I	ADJ	B
and	I-I	CCONJ	O
supportive	I-I	ADJ	B
therapy	I-I	NOUN	I
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	X	B
MEASURES	O	NOUN	O
Incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
major	I-OUT	ADJ	B
infection	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
death	I-OUT	NOUN	B
related	I-OUT	ADJ	O
to	I-OUT	PART	O
infection	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
death	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Infection	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
interferon	O	NOUN	B
gamma	O	NOUN	I
experienced	O	VERB	O
fewer	O	ADJ	O
deaths	B-OUT	NOUN	B
related	O	ADJ	O
to	O	PART	O
infection	B-OUT	NOUN	B
(	O	PUNCT	O
seven	O	NUM	O
[	O	PUNCT	O
3	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
vs	O	CCONJ	O
18	O	NUM	O
[	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.008	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
fewer	O	ADJ	O
overall	O	ADJ	B
deaths	B-OUT	NOUN	I
(	O	PUNCT	O
21	O	NUM	O
[	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
vs	O	CCONJ	O
30	O	NUM	O
[	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.17	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


While	O	SCONJ	O
12	O	NUM	O
early	B-OUT	ADJ	B
deaths	I-OUT	NOUN	I
(	O	PUNCT	O
days	O	NOUN	B
1	O	NUM	O
through	O	ADP	O
7	O	NUM	O
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
late	O	ADJ	B
death	B-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
18	O	NUM	O
placebo-treated	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
nine	O	NUM	O
in	O	ADP	O
interferon	B-I	NOUN	B
gamma-treated	I-I	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
were	O	AUX	O
dominated	O	VERB	O
by	O	ADP	O
findings	O	NOUN	B
at	O	ADP	O
one	O	NUM	O
center	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
had	O	AUX	O
the	O	DET	O
highest	O	ADJ	B
enrollment	O	NOUN	B
and	O	CCONJ	O
higher	O	ADJ	B
infection	O	NOUN	B
and	O	CCONJ	O
death	O	NOUN	B
rates	O	NOUN	I
.	O	PUNCT	O


Statistical	O	ADJ	B
analysis	O	NOUN	I
did	O	AUX	O
not	O	PART	O
eliminate	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
an	O	DET	O
unidentified	O	ADJ	O
imbalance	O	NOUN	B
between	O	ADP	O
arms	O	NOUN	O
as	O	ADP	O
an	O	DET	O
explanation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
results	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Further	O	ADJ	O
evaluation	O	NOUN	B
is	O	AUX	O
required	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
validity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
observed	O	VERB	O
reduction	O	NOUN	B
in	O	ADP	O
infection-related	B-OUT	ADJ	B
deaths	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
interferon	I-I	NOUN	B
gamma	I-I	NOUN	I
.	I-I	PUNCT	O


Treatment	B-P	NOUN	B
of	I-P	ADP	O
hepatitis	I-P	NOUN	B
B	I-P	NOUN	I
virus	I-P	NOUN	I
infection	I-P	NOUN	I
with	I-P	ADP	O
interferon	I-I	NOUN	B
.	I-I	PUNCT	O


Factors	O	NOUN	B
predicting	O	VERB	B
response	O	NOUN	O
to	O	PART	O
interferon	B-I	NOUN	B
.	I-I	PUNCT	O


Several	O	ADJ	O
randomised	O	VERB	B
controlled	O	ADJ	I
trials	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
alpha-interferon	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
hepatitis	O	NOUN	I
B	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
HBe	I-P	NOUN	B
antigen-positive	I-P	ADJ	I
disease	I-P	NOUN	I
acquired	I-P	VERB	O
in	I-P	ADP	O
adult	I-P	ADJ	B
life	I-P	NOUN	O
the	O	DET	O
response	O	NOUN	B
rates	O	NOUN	I
vary	O	VERB	O
from	O	ADP	O
25-50	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
those	O	DET	O
infected	O	VERB	B
at	O	ADP	O
birth	O	NOUN	B
,	O	PUNCT	O
response	O	NOUN	B
rates	O	NOUN	I
are	O	AUX	O
lower	O	ADJ	O
.	O	PUNCT	O


Twenty-one	B-P	NUM	O
pretreatment	I-P	NOUN	B
variables	I-P	NOUN	B
were	I-P	AUX	O
assessed	I-P	VERB	B
for	I-P	ADP	O
their	I-P	PRON	O
significance	I-P	NOUN	B
in	I-P	ADP	O
response	I-OUT	NOUN	B
prediction	I-P	NOUN	I
using	I-P	VERB	O
data	I-P	NOUN	B
from	I-P	ADP	O
114	I-P	NUM	O
patients	I-P	NOUN	B
given	I-P	VERB	O
alpha-interferon	I-I	NOUN	B
for	I-P	ADP	O
chronic	I-P	ADJ	B
hepatitis	I-P	NOUN	I
B	I-P	NOUN	I
virus	I-P	NOUN	I
infection	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
received	O	VERB	O
a	O	DET	O
minimum	O	NOUN	B
of	O	ADP	O
90	O	NUM	O
million	O	NUM	O
units	O	NOUN	B
per	O	ADP	O
m2	O	NOUN	O
total	O	ADJ	O
dose	O	NOUN	O
over	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
negative	O	ADJ	B
anti-human	B-OUT	ADJ	B
immunodeficiency	I-OUT	NOUN	I
virus	I-OUT	NOUN	I
antibody	I-OUT	NOUN	I
status	I-OUT	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
chronic	B-OUT	ADJ	B
active	I-OUT	ADJ	I
hepatitis	I-OUT	NOUN	I
on	I-OUT	ADP	O
liver	I-OUT	NOUN	B
biopsy	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.005	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
high	O	ADJ	O
AST	B-OUT	NOUN	B
level	I-OUT	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
low	O	ADJ	B
hepatitis	B-OUT	NOUN	B
B	I-OUT	NOUN	I
virus	I-OUT	NOUN	I
DNA	I-OUT	NOUN	I
level	I-OUT	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
acute	B-OUT	ADJ	B
hepatitis	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.005	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
all	O	DET	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
likelihood	O	NOUN	B
of	O	ADP	O
response	O	NOUN	B
on	O	ADP	O
univariate	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
stepwise	O	ADJ	O
logistic	O	ADJ	B
regression	O	NOUN	I
analysis	O	NOUN	I
,	O	PUNCT	O
hepatitis	O	NOUN	B
B	O	NOUN	I
virus	O	NOUN	I
DNA	O	NOUN	I
,	O	PUNCT	O
AST	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
hepatitis	O	NOUN	I
predicted	O	VERB	O
response	O	NOUN	O
independently	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
reliable	O	ADJ	O
combination	O	NOUN	B
of	O	ADP	O
predictive	O	ADJ	B
factors	O	NOUN	I
was	O	AUX	O
a	O	DET	O
negative	O	ADJ	B
anti-human	B-OUT	ADJ	B
immunodeficiency	I-OUT	NOUN	I
virus	I-OUT	NOUN	I
antibody	I-OUT	NOUN	B
status	I-OUT	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
positive	O	ADJ	B
history	O	NOUN	I
of	O	ADP	O
acute	B-OUT	ADJ	B
icteric	I-OUT	ADJ	I
hepatitis	I-OUT	NOUN	I
and	O	CCONJ	O
AST	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
45	O	NUM	O
IU	O	NOUN	B
per	O	ADP	O
liter	O	NOUN	O
or	O	CCONJ	O
no	O	DET	O
history	O	NOUN	O
of	O	ADP	O
acute	O	ADJ	B
icteric	O	ADJ	I
hepatitis	O	NOUN	I
and	O	CCONJ	O
AST	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
85	O	NUM	O
IU	O	NOUN	B
per	O	ADP	O
liter	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
predicted	O	VERB	O
response	O	NOUN	B
in	O	ADP	O
77	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
a	O	DET	O
specificity	O	NOUN	B
of	O	ADP	O
79	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
HBsAg	B-OUT	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
HBeAg	B-OUT	NOUN	B
and	O	CCONJ	O
hepatitis	B-OUT	NOUN	B
B	I-OUT	NOUN	I
virus	I-OUT	NOUN	I
DNA	I-OUT	NOUN	O
was	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
occur	O	VERB	O
in	O	ADP	O
patients	B-P	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
infection	O	NOUN	I
of	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
duration	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Randomised	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	B-I	NOUN	B
controlled	O	ADJ	O
study	O	NOUN	O
of	O	ADP	O
fluticasone	B-I	NOUN	B
propionate	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
chronic	I-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
:	I-P	PUNCT	O
the	O	DET	O
ISOLDE	O	PROPN	B
trial	O	NOUN	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
long	O	ADJ	B
term	O	NOUN	I
inhaled	O	ADJ	B
corticosteroids	B-I	NOUN	I
on	O	ADP	O
lung	B-OUT	NOUN	B
function	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
exacerbations	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
health	I-OUT	NOUN	B
status	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
chronic	I-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	VERB	O
Double	O	ADJ	B
blind	O	ADJ	I
,	O	PUNCT	O
placebo	B-I	NOUN	B
controlled	O	ADJ	O
study	O	NOUN	O
.	O	PUNCT	O


SETTING	O	VERB	O
Eighteen	B-P	NUM	O
UK	I-P	PROPN	B
hospitals	I-P	NOUN	B
.	I-P	PUNCT	O


PARTICIPANTS	O	NOUN	O
751	B-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
women	I-P	NOUN	B
aged	I-P	ADJ	B
between	I-P	ADP	O
40	I-P	NUM	O
and	I-P	CCONJ	O
75	I-P	NUM	O
years	I-P	NOUN	B
with	I-P	ADP	O
mean	I-P	ADJ	O
forced	I-P	ADJ	O
expiratory	I-P	ADJ	O
volume	I-P	NOUN	O
in	I-P	ADP	O
one	I-P	NUM	O
second	I-P	NOUN	O
(	I-P	PUNCT	O
FEV	I-P	NOUN	B
(	I-P	PUNCT	O
1	I-P	NUM	O
)	I-P	PUNCT	O
)	I-P	PUNCT	O
50	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
predicted	I-P	VERB	B
normal	I-P	ADJ	B
.	I-P	PUNCT	O


INTERVENTIONS	O	VERB	B
Inhaled	O	ADJ	B
fluticasone	B-I	NOUN	I
propionate	I-I	NOUN	B
500	I-I	NUM	O
microgram	I-I	NOUN	O
twice	I-I	ADV	O
daily	I-I	ADV	O
from	I-I	ADP	O
a	I-I	DET	O
metered	I-I	ADJ	B
dose	I-I	NOUN	O
inhaler	I-I	NOUN	B
or	I-I	CCONJ	O
identical	I-I	ADJ	B
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	B
MEASURES	O	ADJ	O
Efficacy	B-OUT	PROPN	B
measures	O	NOUN	B
:	O	PUNCT	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
decline	I-OUT	NOUN	B
in	I-OUT	ADP	O
FEV	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
after	I-OUT	ADP	O
the	I-OUT	DET	O
bronchodilator	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
in	I-OUT	ADP	O
health	I-OUT	NOUN	B
status	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
exacerbations	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
respiratory	I-OUT	ADJ	B
withdrawals	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Safety	O	NOUN	B
measures	O	NOUN	B
:	O	PUNCT	O
morning	B-OUT	NOUN	B
serum	I-OUT	NOUN	B
cortisol	I-OUT	NOUN	O
concentration	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
There	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	B
significant	I-OUT	ADJ	I
difference	I-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
annual	B-OUT	ADJ	B
rate	I-OUT	NOUN	B
of	I-OUT	ADP	O
decline	I-OUT	NOUN	B
in	I-OUT	ADP	O
FEV	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
P=0.16	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
.	O	PUNCT	O


Mean	B-OUT	VERB	B
FEV	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
after	O	ADP	O
bronchodilator	O	NOUN	B
remained	O	VERB	O
significantly	B-OUT	ADV	O
higher	I-OUT	ADJ	O
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
with	O	ADP	O
fluticasone	B-I	NOUN	B
propionate	I-I	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Median	B-OUT	ADJ	B
exacerbation	I-OUT	NOUN	B
rate	I-OUT	NOUN	B
was	O	AUX	O
reduced	B-OUT	VERB	B
by	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
from	O	ADP	O
1.32	O	NUM	O
a	O	DET	O
year	O	NOUN	B
on	O	ADP	O
placebo	B-I	NOUN	B
to	O	PART	O
0.99	O	NUM	O
a	O	DET	O
year	O	NOUN	B
on	O	ADP	O
with	O	ADP	O
fluticasone	B-I	NOUN	B
propionate	I-I	NOUN	O
(	O	PUNCT	O
P=0.026	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Health	B-OUT	PROPN	B
status	I-OUT	NOUN	I
deteriorated	I-OUT	VERB	B
by	O	ADP	O
3.2	O	NUM	O
units	O	NOUN	O
a	O	DET	O
year	O	NOUN	B
on	O	ADP	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
2.0	O	NUM	O
units	O	NOUN	O
a	O	DET	O
year	O	NOUN	B
on	O	ADP	O
fluticasone	B-I	NOUN	B
propionate	I-I	NOUN	B
(	O	PUNCT	O
P=0.0043	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Withdrawals	B-OUT	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
respiratory	O	ADJ	B
disease	O	NOUN	I
not	O	PART	O
related	O	ADJ	O
to	O	PART	O
malignancy	O	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
25	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
19	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P=0.034	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Fluticasone	B-I	NOUN	B
propionate	I-I	NOUN	B
500	O	NUM	O
microgram	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
decline	I-OUT	NOUN	B
in	I-OUT	ADP	O
FEV	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
produce	B-OUT	VERB	O
a	I-OUT	DET	O
small	I-OUT	ADJ	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
FEV	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
1	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Patients	O	NOUN	B
on	O	ADP	O
fluticasone	B-I	NOUN	B
propionate	I-I	NOUN	B
had	O	AUX	O
fewer	O	ADJ	O
exacerbations	B-OUT	NOUN	B
and	O	CCONJ	O
a	O	DET	O
slower	B-OUT	ADJ	O
decline	I-OUT	NOUN	B
in	I-OUT	ADP	O
health	I-OUT	NOUN	B
status	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


These	O	DET	O
improvements	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
support	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
this	O	DET	O
treatment	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
chronic	I-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Different	B-I	ADJ	O
aprotinin	I-I	NOUN	B
applications	I-I	NOUN	B
influencing	O	VERB	O
hemostatic	O	ADJ	B
changes	O	NOUN	I
in	O	ADP	O
orthotopic	B-P	ADJ	B
liver	I-P	NOUN	I
transplantation	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
aprotinin	B-I	NOUN	B
applications	I-I	NOUN	B
on	O	ADP	O
hemostatic	O	ADJ	B
changes	O	NOUN	I
and	O	CCONJ	O
blood	O	NOUN	B
product	O	NOUN	I
requirements	O	NOUN	B
in	O	ADP	O
orthotopic	B-P	ADJ	B
liver	I-P	NOUN	I
transplantation	I-P	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
open	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


From	B-P	ADP	O
November	I-P	PROPN	O
1989	I-P	NUM	O
to	I-P	ADP	O
June	I-P	PROPN	O
1990	I-P	NUM	O
,	I-P	PUNCT	O
13	I-P	NUM	O
patients	I-P	NOUN	B
received	O	VERB	O
aprotinin	B-I	NOUN	B
as	O	ADP	O
a	O	DET	O
bolus	B-I	NOUN	B
of	I-I	ADP	O
0.5	I-I	NUM	O
Mill	I-I	NOUN	B
.	I-I	PUNCT	O


Kallikrein	O	NOUN	B
inactivator	O	NOUN	I
units	O	NOUN	I
(	O	PUNCT	O
KIU	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
three	O	NUM	O
occasions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
an	O	DET	O
OLT	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
10	O	NUM	O
other	O	ADJ	O
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
continuous	B-I	ADJ	O
aprotinin	I-I	NOUN	B
infusion	I-I	NOUN	B
of	I-I	ADP	O
0.1-0.4	I-I	NUM	O
Mill	I-I	NOUN	B
.	I-I	PUNCT	O


KIU/hr	O	NOUN	B
.	O	PUNCT	O


Before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
reperfusion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
graft	B-OUT	NOUN	B
liver	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
signs	I-OUT	NOUN	B
of	I-OUT	ADP	O
hyperfibrinolysis	I-OUT	NOUN	B
,	O	PUNCT	O
measured	O	VERB	B
by	O	ADP	O
thrombelastography	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Tissue-type	B-OUT	ADJ	B
plasminogen	I-OUT	NOUN	I
activator	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
t-PA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
activity	I-OUT	NOUN	B
increased	O	VERB	B
during	O	ADP	O
the	O	DET	O
anhepatic	O	ADJ	B
phase	O	NOUN	I
but	O	CCONJ	O
to	O	ADP	O
a	O	DET	O
significantly	O	ADV	O
lesser	O	ADJ	B
extent	O	NOUN	B
in	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
product	I-OUT	NOUN	I
requirements	I-OUT	NOUN	B
during	O	ADP	O
OLT	O	NOUN	B
were	O	AUX	O
tendentiously	O	ADV	B
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
bolus	O	NOUN	B
group	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
significantly	O	ADV	O
so	O	ADV	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
packed	B-OUT	ADJ	B
red	I-OUT	ADJ	I
blood	I-OUT	NOUN	I
cells	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
postoperative	O	ADJ	B
period	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
fresh	O	ADJ	B
frozen	O	ADJ	B
plasma	B-OUT	NOUN	B
requirements	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
23	B-P	NUM	O
patients	I-P	NOUN	B
have	O	AUX	O
survived	B-OUT	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
one	O	NUM	O
woman	O	NOUN	B
of	O	ADP	O
each	O	DET	O
group	O	NOUN	B
required	O	VERB	O
retransplantation	B-OUT	NOUN	B
due	O	ADP	O
to	O	PART	O
severe	O	ADJ	B
host-versus-graft	B-OUT	ADJ	B
reactions	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
perfusate	O	NOUN	B
of	O	ADP	O
the	O	DET	O
graft	O	NOUN	B
liver	O	NOUN	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
and	O	CCONJ	O
detected	O	VERB	B
signs	O	NOUN	B
of	O	ADP	O
a	O	DET	O
decreased	O	VERB	B
t-PA	B-OUT	NOUN	B
release	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
demonstrate	O	VERB	O
an	O	DET	O
advantage	O	NOUN	O
of	O	ADP	O
aprotinin	B-I	NOUN	B
given	O	VERB	O
as	O	ADP	O
continuous	O	ADJ	B
infusion	O	NOUN	B
over	O	ADP	O
bolus	O	NOUN	B
application	O	NOUN	B
in	O	ADP	O
OLT	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
New	O	ADJ	O
approaches	O	NOUN	O
to	O	PART	O
evaluation	O	NOUN	B
of	O	ADP	O
nonspecific	B-I	ADJ	B
inhalation	I-I	NOUN	B
provocation	I-I	NOUN	O
(	O	PUNCT	O
dose-response	O	ADJ	B
relationship	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
comparative	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
bronchial	B-P	ADJ	B
hyperreactivity	I-P	NOUN	I
within	O	ADP	O
the	O	DET	O
scope	O	NOUN	O
of	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
]	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
performance	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
drug	O	NOUN	I
trials	O	NOUN	I
in	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
for	O	ADP	O
bronchial	B-P	ADJ	B
hyperresponsiveness	I-P	NOUN	I
,	O	PUNCT	O
unspecific	O	ADJ	O
inhalatory	O	ADJ	B
provocation	O	NOUN	I
tests	O	NOUN	I
are	O	AUX	O
generally	O	ADV	O
employed	O	VERB	O
to	O	PART	O
judge	O	VERB	O
therapeutic	O	ADJ	B
success	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
parameter-specific	O	ADJ	B
provocation	O	NOUN	I
doses	O	NOUN	B
are	O	AUX	O
considered	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
main	O	ADJ	O
target	O	NOUN	B
values	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
must	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
provocation	O	NOUN	B
doses	O	NOUN	I
are	O	AUX	O
not	O	PART	O
equally	O	ADV	O
calculable	O	ADJ	B
for	O	ADP	O
every	O	DET	O
patient	O	NOUN	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
way	O	NOUN	O
and	O	CCONJ	O
at	O	ADP	O
any	O	DET	O
examination	O	NOUN	B
time	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
leads	O	VERB	O
to	O	PART	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
evaluable	O	ADJ	O
case	O	NOUN	B
studies	O	NOUN	I
is	O	AUX	O
often	O	ADV	O
appreciably	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
test	O	NOUN	B
participants	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
a	O	DET	O
meaningful	O	ADJ	O
therapy	O	NOUN	B
group	O	NOUN	B
comparison	O	NOUN	B
may	O	AUX	O
even	O	ADV	O
not	O	PART	O
be	O	AUX	O
possible	O	ADJ	O
under	O	ADP	O
certain	O	ADJ	O
circumstances	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
evaluation	B-P	NOUN	B
model	I-P	NOUN	I
is	O	AUX	O
presented	O	VERB	O
here	O	ADV	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
fully	O	ADV	O
exploit	O	VERB	O
the	O	DET	O
obtained	O	VERB	O
data	O	NOUN	B
;	O	PUNCT	O
in	O	ADP	O
this	O	DET	O
the	O	DET	O
percentile	O	NOUN	B
changes	O	NOUN	I
of	O	ADP	O
the	O	DET	O
function	O	NOUN	B
parameters	O	NOUN	B
(	O	PUNCT	O
estimated	O	VERB	O
by	O	ADP	O
linear	O	ADJ	B
regression	O	NOUN	I
)	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
defined	O	VERB	O
dose	O	NOUN	B
of	O	ADP	O
the	O	DET	O
provocation	O	NOUN	B
substance	O	NOUN	I
are	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
analogy	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
survival	B-OUT	NOUN	B
time	I-OUT	NOUN	I
model	I-OUT	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
supplement	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
best	O	ADJ	O
case/worst	O	ADJ	B
case	O	NOUN	I
analysis	O	NOUN	I
are	O	AUX	O
performed	O	VERB	O
for	O	ADP	O
further	O	ADJ	O
statistical	O	ADJ	B
evaluation	O	NOUN	I
.	O	PUNCT	O


With	O	ADP	O
the	O	DET	O
present	O	ADJ	O
procedure	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
evaluation	O	NOUN	B
with	O	ADP	O
inclusion	O	NOUN	B
of	O	ADP	O
all	O	DET	O
test	O	NOUN	O
participants	O	NOUN	B
is	O	AUX	O
possible	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
the	O	DET	O
previously	O	ADV	O
used	O	VERB	O
evaluation	O	NOUN	B
procedures	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
allows	O	VERB	O
a	O	DET	O
reliable	O	ADJ	O
statistical	O	ADJ	B
confirmation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
tests	O	NOUN	I
in	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
for	O	ADP	O
bronchial	B-P	ADJ	B
hyperresponsiveness	I-P	NOUN	I
.	I-P	PUNCT	O


Blood	O	NOUN	B
pressure	O	NOUN	I
control	O	NOUN	I
during	O	ADP	O
weight	O	NOUN	B
reduction	O	NOUN	I
in	O	ADP	O
obese	B-P	ADJ	B
hypertensive	I-P	ADJ	B
men	I-P	NOUN	B
:	I-P	PUNCT	O
separate	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	I
sodium	O	NOUN	B
and	O	CCONJ	O
energy	O	NOUN	B
restriction	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
separate	O	ADJ	B
and	O	CCONJ	O
combined	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
dietary	O	ADJ	B
energy	O	NOUN	I
and	O	CCONJ	O
sodium	B-I	NOUN	B
restriction	I-I	NOUN	I
on	O	ADP	O
regulation	O	NOUN	B
of	O	ADP	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
30	B-P	NUM	O
middle	I-P	ADJ	B
aged	I-P	ADJ	I
obese	I-P	ADJ	B
men	I-P	NOUN	B
with	I-P	ADP	O
essential	I-P	ADJ	O
hypertension	I-P	NOUN	B
attending	I-P	VERB	B
the	I-P	DET	O
outpatient	I-P	ADJ	B
department	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
group	B-P	NOUN	B
1	I-P	NUM	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
)	O	PUNCT	O
a	O	DET	O
basal	O	ADJ	B
period	O	NOUN	B
with	O	ADP	O
no	B-I	DET	O
dietary	I-I	ADJ	B
restriction	I-I	NOUN	I
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
period	O	NOUN	B
taking	O	VERB	O
an	B-I	DET	O
energy	I-I	NOUN	B
reduced	I-I	VERB	I
diet	I-I	NOUN	I
(	O	PUNCT	O
5.1	O	NUM	O
MJ	O	NOUN	B
;	O	PUNCT	O
1230	O	NUM	O
kcal	O	ADJ	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
sodium	B-I	NOUN	B
intake	I-I	NOUN	I
being	I-I	AUX	O
supplemented	I-I	VERB	B
and	I-I	CCONJ	O
hence	I-I	ADV	O
unchanged	I-I	ADJ	B
(	O	PUNCT	O
1	O	NUM	O
:	O	PUNCT	O
ErSn	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
group	B-P	NOUN	B
2	I-P	NUM	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
)	O	PUNCT	O
the	O	DET	O
basal	O	ADJ	B
period	O	NOUN	O
preceded	O	VERB	O
a	O	DET	O
control	O	ADJ	O
period	O	NOUN	B
with	O	ADP	O
no	B-I	DET	O
intervention	I-I	NOUN	B
,	I-I	PUNCT	O
which	I-I	DET	O
was	I-I	AUX	O
followed	I-I	VERB	O
by	I-I	ADP	O
taking	I-I	VERB	O
a	I-I	DET	O
diet	I-I	NOUN	B
restricted	I-I	ADJ	B
in	I-I	ADP	O
energy	I-I	NOUN	B
(	O	PUNCT	O
5.1	O	NUM	O
MJ	O	NOUN	B
;	O	PUNCT	O
1220	O	NUM	O
kcal	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
sodium	B-I	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
:	O	PUNCT	O
ErSr	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


During	O	ADP	O
period	O	NOUN	B
1	O	NUM	O
:	O	PUNCT	O
ErSn	O	PROPN	B
there	O	PRON	O
were	O	AUX	O
reductions	O	NOUN	B
in	O	ADP	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
urinary	I-OUT	ADJ	B
noradrenaline	I-OUT	NOUN	O
output	I-OUT	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
systolic	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressure	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Body	B-OUT	NOUN	B
weight	I-OUT	NOUN	I
decreased	O	VERB	B
by	O	ADP	O
4.9-11.7	O	NUM	O
kg	O	NOUN	O
and	O	CCONJ	O
urinary	B-OUT	ADJ	B
sodium	I-OUT	NOUN	I
excretion	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
period	O	NOUN	O
2	O	NUM	O
:	O	PUNCT	O
ErSr	O	NOUN	B
urinary	B-OUT	ADJ	B
sodium	I-OUT	NOUN	I
output	I-OUT	NOUN	O
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
81.4	O	NUM	O
(	O	PUNCT	O
SEM	O	NOUN	B
17.8	O	NUM	O
)	O	PUNCT	O
mmol	O	NOUN	O
(	O	PUNCT	O
mEq	O	NOUN	B
)	O	PUNCT	O
/24	O	PUNCT	O
h	O	NOUN	O
and	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
weight	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
of	O	ADP	O
8.2	O	NUM	O
(	O	PUNCT	O
SEM	O	NOUN	B
0.7	O	NUM	O
)	O	PUNCT	O
kg	O	NOUN	O
.	O	PUNCT	O


Systolic	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
pressures	I-OUT	NOUN	I
fell	O	VERB	O
significantly	O	ADV	O
,	O	PUNCT	O
as	O	ADP	O
did	O	AUX	O
the	O	DET	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	O	CCONJ	O
urinary	B-OUT	ADJ	B
noradrenaline	I-OUT	NOUN	B
excretion	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
hypertensive	B-P	ADJ	B
obese	I-P	ADJ	B
men	I-P	NOUN	B
a	O	DET	O
moderate	O	ADJ	B
weight	O	NOUN	B
reducing	O	VERB	I
diet	O	NOUN	B
decreases	O	VERB	O
indices	O	NOUN	B
of	O	ADP	O
sympathetic	B-OUT	ADJ	B
nervous	I-OUT	ADJ	I
system	I-OUT	NOUN	I
activity	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Reduction	O	NOUN	B
of	O	ADP	O
blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
to	O	PART	O
the	O	DET	O
normotensive	O	ADJ	B
range	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
only	O	ADV	O
when	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
concomitant	O	ADJ	B
restriction	O	NOUN	B
of	O	ADP	O
sodium	O	NOUN	B
intake	O	NOUN	I
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
medical	B-I	ADJ	B
ozone	I-I	NOUN	I
therapy	I-I	NOUN	I
on	O	ADP	O
renal	B-OUT	ADJ	B
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
renal	I-OUT	ADJ	B
function	I-OUT	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
severe	I-P	ADJ	I
hepatitis	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Medical	B-I	ADJ	B
ozone	I-I	NOUN	I
therapy	I-I	NOUN	I
system	I-I	NOUN	I
was	O	AUX	O
reported	O	VERB	O
to	O	PART	O
have	O	AUX	O
certain	O	ADJ	O
effects	B-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
treatment	I-OUT	NOUN	B
of	I-OUT	ADP	O
severe	I-OUT	ADJ	B
hepatitis	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
its	O	PRON	O
mechanism	O	NOUN	B
is	O	AUX	O
not	O	PART	O
very	O	ADV	O
clear	O	ADJ	O
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
causes	O	NOUN	O
of	O	ADP	O
death	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
hepatitis	O	NOUN	B
is	O	AUX	O
complication	B-OUT	NOUN	B
of	I-OUT	ADP	O
renal	I-OUT	ADJ	B
damage	I-OUT	NOUN	I
or	O	CCONJ	O
hepatorenal	B-OUT	ADJ	B
syndrome	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
observe	O	VERB	O
effects	O	NOUN	B
of	O	ADP	I
medical	B-I	ADJ	B
ozone	I-I	NOUN	I
therapy	I-I	NOUN	I
system	I-I	NOUN	O
on	O	ADP	O
plasma	B-OUT	NOUN	B
renin	I-OUT	NOUN	O
activity	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
PRA	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
angiotensin	I-OUT	NOUN	B
II	I-OUT	NUM	I
(	I-OUT	PUNCT	O
AII	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
aldosterone	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
ALD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
renal	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
renal	I-OUT	ADJ	B
function	I-OUT	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
severe	I-P	ADJ	I
hepatitis	I-P	NOUN	I
and	O	CCONJ	O
explore	O	VERB	O
mechanisms	O	NOUN	B
of	O	ADP	O
medical	B-I	ADJ	B
ozone	I-I	NOUN	I
therapy	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
hepatitis	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Eighty-five	B-P	NUM	O
cases	I-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
severe	I-P	ADJ	I
hepatitis	I-P	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
ozone	B-I	NOUN	B
therapy	I-I	NOUN	I
group	I-I	NOUN	B
(	O	PUNCT	O
43	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
control	B-I	NOUN	B
group	I-I	NOUN	I
(	O	PUNCT	O
42	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ozone	B-I	NOUN	B
therapy	I-I	NOUN	I
group	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
basic	B-I	ADJ	O
treatments	I-I	NOUN	B
plus	I-I	CCONJ	O
ozone	I-I	NOUN	B
therapy	I-I	NOUN	I
system	I-I	NOUN	I
.	I-I	PUNCT	O


Basic	B-OUT	ADJ	B
autohemotherapy	I-OUT	NOUN	I
was	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
milliliter	O	NOUN	O
venous	O	ADJ	B
blood	O	NOUN	I
was	O	AUX	O
drawn	O	VERB	O
from	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
mixed	O	ADJ	O
with	O	ADP	O
100	O	NUM	O
ml	O	NOUN	O
(	O	PUNCT	O
35	O	NUM	O
µg/ml	B-I	NOUN	O
)	I-I	PUNCT	O
medical	I-I	ADJ	B
ozone	I-I	NOUN	I
and	O	CCONJ	O
then	O	ADV	O
was	O	AUX	O
returned	O	VERB	O
the	O	DET	O
blood	O	NOUN	B
to	O	PART	O
the	O	DET	O
patient	O	NOUN	B
intravenously	O	ADV	B
,	O	PUNCT	O
once	O	ADV	O
every	O	DET	O
other	O	ADJ	O
day	O	NOUN	B
for	O	ADP	O
20	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Only	O	ADV	O
the	B-I	DET	O
basic	I-I	ADJ	O
treatments	I-I	NOUN	B
were	O	AUX	O
given	O	VERB	O
to	O	PART	O
the	B-I	DET	O
control	I-I	ADJ	B
group	I-I	NOUN	I
.	I-OUT	PUNCT	O


PRA	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
AII	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
ALD	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
renal	I-OUT	ADJ	B
blood	I-OUT	NOUN	I
flow	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
damage	I-OUT	NOUN	B
to	I-OUT	PART	O
renal	I-OUT	ADJ	B
function	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
before	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
20	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
.	B-OUT	PUNCT	O


Survival	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
were	O	AUX	O
also	O	ADV	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Twenty	O	NUM	B
days	O	NOUN	I
after	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
,	O	PUNCT	O
in	B-I	ADP	O
ozone	I-I	NOUN	B
therapy	I-I	NOUN	I
group	O	NOUN	B
,	O	PUNCT	O
PRA	B-OUT	NOUN	B
was	O	AUX	O
(	O	PUNCT	O
1.31	O	NUM	O
±	O	NOUN	O
0.12	O	NUM	O
)	O	PUNCT	O
ng·ml⁻¹·h⁻¹	B-OUT	NOUN	O
,	O	PUNCT	O
AII	O	NOUN	B
(	O	PUNCT	O
111.25	O	NUM	O
±	O	NOUN	O
17.35	B-OUT	NUM	O
)	I-OUT	PUNCT	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
ALD	O	NOUN	B
(	O	PUNCT	O
251.31	O	NUM	O
±	O	PROPN	O
22.60	O	NUM	O
)	O	PUNCT	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
decreased	O	VERB	B
significantly	O	ADV	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
before	B-OUT	ADP	O
treatment	I-OUT	NOUN	B
(	O	PUNCT	O
PRA	O	NOUN	B
(	O	PUNCT	O
2.23	O	NUM	O
±	O	NOUN	O
0.13	O	NUM	O
)	O	PUNCT	O
ng·ml⁻¹·h⁻¹	B-OUT	NOUN	O
,	O	PUNCT	O
AII	O	NOUN	B
(	B-OUT	PUNCT	O
155.18	I-OUT	NUM	O
±	O	NOUN	O
19.13	O	NUM	O
)	O	PUNCT	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
ALD	O	NOUN	B
(	O	PUNCT	O
405.31	O	NUM	O
±	O	NOUN	O
29.88	O	NUM	O
)	O	PUNCT	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
t	O	NOUN	O
=	O	ADJ	O
4.67	O	NUM	O
-	O	SYM	O
14.23	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
also	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
20	O	NUM	O
days	B-OUT	NOUN	B
after	I-OUT	ADP	O
the	O	DET	O
treatment	O	NOUN	B
(	O	PUNCT	O
PRA	O	NOUN	B
(	B-OUT	PUNCT	O
2.02	I-OUT	NUM	O
±	I-OUT	NOUN	O
0.11	O	NUM	O
)	O	PUNCT	O
ng·ml⁻¹·h⁻¹	B-OUT	NOUN	O
,	O	PUNCT	O
AII	O	NOUN	B
(	O	PUNCT	O
162.21	O	NUM	O
±	O	PROPN	O
15.32	O	NUM	O
)	O	PUNCT	O
pg/ml	O	NOUN	O
,	O	PUNCT	O
ALD	O	NOUN	B
(	O	PUNCT	O
401.20	O	NUM	O
±	O	PROPN	O
35.02	O	NUM	O
)	O	PUNCT	O
pg/ml	B-OUT	NOUN	O
,	I-OUT	PUNCT	O
t	I-OUT	NOUN	O
=	I-OUT	ADJ	O
4.97	I-OUT	NUM	O
-	I-OUT	SYM	O
15.61	I-OUT	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
was	O	AUX	O
(	O	PUNCT	O
175.15	O	NUM	O
±	O	NOUN	O
28.20	O	NUM	O
)	O	PUNCT	O
ml/min	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
increased	O	VERB	B
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
before	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
(	O	PUNCT	O
(	O	PUNCT	O
125.68	O	NUM	O
±	O	NOUN	O
21.25	O	NUM	O
)	O	PUNCT	O
ml/min	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
20	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
(	O	PUNCT	O
(	O	PUNCT	O
128.59	O	NUM	O
±	O	NOUN	O
23.15	B-OUT	NUM	O
)	I-OUT	PUNCT	O
ml/min	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
t	I-OUT	NOUN	O
=	I-OUT	ADJ	O
4.78	O	NUM	O
,	O	PUNCT	O
4.61	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Renal	O	ADJ	B
damage	O	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
2	O	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
ozone	O	NOUN	B
therapy	O	NOUN	I
group	O	NOUN	B
,	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
9	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
21	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
χ²	O	NOUN	O
=	O	ADJ	O
5.295	O	NUM	O
,	O	PUNCT	O
P	B-I	NOUN	O
<	I-I	X	O
0.05	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Thirty-three	B-I	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
77	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
ozone	B-I	NOUN	B
therapy	I-I	NOUN	I
group	I-OUT	NOUN	B
vs.	I-OUT	CCONJ	O
16	I-OUT	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
38	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
control	O	NOUN	B
group	O	NOUN	I
survived	B-I	VERB	O
(	I-I	PUNCT	O
χ²	I-I	NOUN	O
=	I-I	ADJ	O
12.993	I-I	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	B-I	X	O
0.01	I-I	NUM	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


CONCLUSIONS	B-I	VERB	O
Basic	I-I	ADJ	B
treatment	I-P	NOUN	I
plus	I-P	CCONJ	O
medical	I-P	ADJ	B
ozone	I-P	NOUN	I
therapy	I-P	NOUN	I
for	I-P	ADP	O
patients	O	NOUN	B
with	B-OUT	ADP	O
chronic	I-OUT	ADJ	B
severe	I-OUT	ADJ	I
hepatitis	I-OUT	NOUN	I
could	O	AUX	O
decrease	B-OUT	VERB	B
PRA	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
AII	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
ALD	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
significantly	I-OUT	ADV	O
increase	I-OUT	VERB	B
renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
,	O	PUNCT	O
prevent	O	VERB	B
renal	B-OUT	ADJ	B
damage	I-OUT	NOUN	I
to	I-OUT	ADP	O
certain	O	ADJ	O
extent	O	NOUN	B
and	O	CCONJ	O
improve	O	VERB	B
survival	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Educational	B-I	ADJ	B
intervention	I-I	NOUN	I
for	O	ADP	O
altering	O	VERB	O
water-sanitation	O	ADJ	B
behavior	O	NOUN	I
to	O	PART	O
reduce	O	VERB	B
childhood	B-P	NOUN	B
diarrhea	I-OUT	NOUN	I
in	I-P	ADP	O
urban	I-P	ADJ	B
Bangladesh	I-P	PROPN	B
:	I-P	PUNCT	O
impact	O	VERB	B
on	O	ADP	O
nutritional	O	ADJ	B
status	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
whether	O	SCONJ	O
an	O	DET	O
educational	B-I	ADJ	B
intervention	I-I	NOUN	I
that	O	PRON	O
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
reducing	O	VERB	B
childhood	B-P	NOUN	B
diarrhea	I-OUT	NOUN	I
also	O	ADV	O
improved	O	VERB	O
childhood	B-OUT	ADJ	B
nutritional	I-OUT	ADJ	B
status	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Fifty-one	B-P	NUM	O
communities	I-P	NOUN	B
of	I-P	ADP	O
38	I-P	NUM	O
families	I-P	NOUN	B
each	I-P	DET	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
the	O	DET	O
intervention	B-I	NOUN	B
or	I-I	CCONJ	O
no	I-I	DET	O
intervention	I-I	NOUN	B
.	I-I	PUNCT	O


During	O	ADP	O
1	O	NUM	O
y	O	NOUN	O
of	O	ADP	O
follow-up	O	X	B
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
diarrhea	I-OUT	NOUN	B
(	O	PUNCT	O
per	O	ADP	O
100	O	NUM	O
wk	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
children	B-P	NOUN	B
less	I-P	ADJ	O
than	I-P	ADP	O
6	I-P	NUM	O
y	I-P	NOUN	O
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
5.89	O	NUM	O
episodes	O	NOUN	B
whereas	O	SCONJ	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
nonintervention	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
7.55	O	NUM	O
episodes	O	NOUN	B
(	O	PUNCT	O
protective	O	ADJ	O
efficacy	O	NOUN	B
22	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
same	O	ADJ	O
follow-up	O	ADJ	B
period	O	NOUN	B
children	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
exhibited	O	VERB	O
comparable	O	ADJ	O
patterns	O	NOUN	B
of	O	ADP	O
weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
1	O	NUM	O
y	O	NOUN	O
after	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
the	O	DET	O
mean	B-OUT	ADJ	O
weight	I-OUT	NOUN	O
for	I-OUT	ADP	O
age	I-OUT	NOUN	B
of	O	ADP	O
children	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
was	O	AUX	O
76	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
NCHS	O	PROPN	B
standard	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
each	O	DET	O
group	O	NOUN	B
that	O	PRON	O
experienced	O	VERB	O
a	O	DET	O
major	B-OUT	ADJ	O
deterioration	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
improvement	I-OUT	NOUN	B
of	I-OUT	ADP	O
nutritional	I-OUT	ADJ	B
status	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
an	O	DET	O
intervention	O	NOUN	B
that	O	PRON	O
reduces	O	VERB	O
rates	O	NOUN	B
of	O	ADP	O
childhood	B-OUT	NOUN	B
diarrhea	I-OUT	NOUN	I
may	O	AUX	O
not	O	PART	O
necessarily	O	ADV	O
also	O	ADV	O
improve	O	VERB	O
nutritional	B-OUT	ADJ	B
status	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
melatonin	B-I	NOUN	B
for	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
and	I-P	CCONJ	O
sleep	I-P	NOUN	B
problems	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Melatonin	O	NOUN	B
is	O	AUX	O
often	O	ADV	O
used	O	VERB	O
for	O	ADP	O
autistic	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
sleep	I-P	NOUN	B
disorders	I-P	NOUN	I
,	O	PUNCT	O
despite	O	SCONJ	O
a	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
published	O	VERB	B
evidence	O	NOUN	I
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
double-blind	O	ADJ	B
crossover	O	NOUN	B
trial	O	NOUN	I
of	O	ADP	O
melatonin	B-I	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
in	O	ADP	O
11	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autistic	I-P	ADJ	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


RESULTS	O	VERB	O
Seven	B-P	NUM	O
children	I-P	NOUN	B
completed	I-P	VERB	O
the	I-P	DET	O
trial	I-P	NOUN	B
.	I-P	PUNCT	O


Sleep	B-OUT	ADJ	B
latency	I-OUT	NOUN	I
was	O	AUX	O
2.6	O	NUM	O
h	O	NOUN	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
intervals	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
2.28-2.93	O	NUM	O
]	O	PUNCT	O
baseline	O	NOUN	B
,	O	PUNCT	O
1.91	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1.78-2.03	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
placebo	O	NOUN	B
and	O	CCONJ	O
1.06	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.98-1.13	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
melatonin	O	NOUN	B
.	O	PUNCT	O


Wakings	B-OUT	NOUN	B
per	I-OUT	ADP	O
night	I-OUT	NOUN	B
were	O	AUX	O
0.35	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.18-0.53	O	NUM	O
)	O	PUNCT	O
baseline	O	NOUN	B
,	O	PUNCT	O
0.26	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.20-0.34	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
0.08	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.04-0.12	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
melatonin	O	NOUN	B
.	O	PUNCT	O


Total	B-OUT	ADJ	B
sleep	I-OUT	NOUN	I
duration	I-OUT	NOUN	I
was	O	AUX	O
8.05	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
7.65-8.44	O	ADJ	O
)	O	PUNCT	O
baseline	O	NOUN	B
,	O	PUNCT	O
8.75	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
8.56-8.98	O	ADV	O
)	O	PUNCT	O
with	O	ADP	O
placebo	O	NOUN	B
and	O	CCONJ	O
9.84	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
9.68-9.99	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
melatonin	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Although	O	SCONJ	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
small	O	ADJ	O
owing	O	VERB	O
to	O	ADP	O
recruitment	O	NOUN	B
difficulties	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
still	O	ADV	O
provides	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
melatonin	O	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
sleep	I-P	NOUN	B
difficulties	I-P	NOUN	I
and	I-P	CCONJ	O
ASD	I-P	PROPN	B
,	O	PUNCT	O
which	O	DET	O
we	O	PRON	O
predict	O	VERB	O
a	O	DET	O
larger	O	ADJ	O
study	O	NOUN	B
would	O	AUX	O
confirm	O	VERB	B
.	O	PUNCT	O


Probiotics	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
atopic	B-P	ADJ	B
eczema	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Over	O	ADP	O
the	O	DET	O
last	O	ADJ	O
two	O	NUM	O
decades	O	NOUN	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
allergic	O	ADJ	B
diseases	O	NOUN	I
has	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
industrialized	O	ADJ	B
countries	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
consequently	O	ADV	O
new	O	ADJ	O
approaches	O	NOUN	B
have	O	AUX	O
to	O	PART	O
be	O	AUX	O
explored	O	VERB	O
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
probiotics	O	NOUN	B
to	O	PART	O
control	O	VERB	B
allergic	B-OUT	ADJ	B
inflammation	I-OUT	NOUN	I
at	I-P	ADP	O
an	I-P	DET	O
early	I-P	ADJ	B
age	I-P	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
placebo-controlled	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
A	B-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
27	I-P	NUM	O
infants	I-P	NOUN	B
,	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
4.6	I-P	NUM	O
months	I-P	NOUN	B
,	I-P	PUNCT	O
who	I-P	PRON	O
manifested	I-P	VERB	O
atopic	I-P	ADJ	B
eczema	I-P	NOUN	I
during	I-P	ADP	O
exclusive	I-P	ADJ	O
breast-feeding	I-P	NOUN	B
and	I-P	CCONJ	O
who	I-P	PRON	O
have	I-P	AUX	O
had	I-P	AUX	O
no	I-P	DET	O
exposure	I-P	NOUN	B
to	I-P	PART	I
any	I-P	DET	O
infant	I-P	NOUN	B
or	I-P	CCONJ	O
substitute	I-P	VERB	B
formula	I-P	NOUN	I
were	O	AUX	O
weaned	O	VERB	B
to	O	PART	O
probiotic-supplemented	B-I	ADJ	B
,	I-I	PUNCT	O
Bifidobacterium	I-I	X	B
lactis	I-I	X	I
Bb-12	I-I	NOUN	I
or	I-I	CCONJ	O
Lactobacillus	I-I	X	B
strain	I-I	NOUN	I
GG	I-I	NOUN	I
(	I-I	PUNCT	O
ATCC	I-I	NOUN	O
53103	I-I	NUM	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
extensively	I-I	ADV	O
hydrolysed	I-I	VERB	B
whey	I-I	NOUN	B
formulas	I-I	NOUN	B
or	I-I	CCONJ	O
to	I-I	ADP	O
the	I-I	DET	O
same	I-I	ADJ	O
formula	I-I	NOUN	B
without	I-I	ADP	O
probiotics	I-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
extent	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
atopic	O	ADJ	B
eczema	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
growth	O	NOUN	B
and	O	CCONJ	O
nutrition	O	NOUN	B
of	O	ADP	O
infants	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
concentrations	O	NOUN	B
of	O	ADP	O
circulating	O	VERB	B
cytokines/chemokines	O	NOUN	B
and	O	CCONJ	O
soluble	O	ADJ	B
cell	O	NOUN	O
surface	O	NOUN	O
adhesion	O	NOUN	O
molecules	O	NOUN	O
in	O	ADP	O
serum	O	NOUN	B
and	O	CCONJ	O
methyl-histamine	O	NOUN	B
and	O	CCONJ	O
eosinophilic	O	ADJ	B
protein	O	NOUN	I
X	O	NOUN	I
in	O	ADP	O
urine	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
SCORAD	B-OUT	NOUN	B
score	I-OUT	NOUN	B
reflecting	O	VERB	O
the	O	DET	O
extent	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
severity	I-OUT	NOUN	B
of	I-OUT	ADP	O
atopic	I-OUT	ADJ	B
eczema	I-OUT	NOUN	I
was	O	AUX	O
16	O	NUM	O
(	O	PUNCT	O
7-25	O	NUM	O
)	O	PUNCT	O
during	O	ADP	O
breast-feeding	O	NOUN	B
,	O	PUNCT	O
median	O	ADJ	B
(	O	PUNCT	O
interquartile	O	NOUN	B
range	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
skin	B-OUT	NOUN	B
condition	I-OUT	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
given	O	VERB	O
probiotic-supplemented	O	ADJ	B
formulas	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
unsupplemented	O	ADJ	B
group	O	NOUN	I
;	O	PUNCT	O
chi	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
12.27	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
.	O	PUNCT	O


SCORAD	B-OUT	NOUN	B
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
Bifidobacterium	O	NOUN	B
lactis	O	X	I
Bb-12	O	X	I
group	O	NOUN	B
to	O	PART	O
0	O	NUM	O
(	O	PUNCT	O
0-3.8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
Lactobacillus	O	NOUN	B
GG	O	NOUN	I
group	O	NOUN	I
to	O	ADP	O
1	O	NUM	O
(	O	PUNCT	O
0.1-8.7	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
vs	O	CCONJ	O
unsupplemented	O	ADJ	O
13.4	O	NUM	O
(	O	PUNCT	O
4.5-18.2	O	NUM	B
)	O	PUNCT	O
,	O	PUNCT	O
median	O	ADJ	B
(	O	PUNCT	O
interquartile	O	NOUN	B
range	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
parallel	O	NOUN	O
with	O	ADP	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
concentration	O	NOUN	B
of	O	ADP	O
soluble	O	ADJ	B
CD4	B-OUT	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
and	O	CCONJ	O
eosinophilic	O	ADJ	B
protein	O	NOUN	I
X	O	NOUN	I
in	O	ADP	O
urine	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
The	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
the	O	DET	O
first	O	ADJ	O
clinical	O	ADJ	B
demonstration	O	NOUN	O
of	O	ADP	O
specific	O	ADJ	O
probiotic	O	ADJ	B
strains	O	NOUN	B
modifying	O	VERB	O
the	O	DET	O
changes	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
allergic	B-OUT	ADJ	B
inflammation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
data	O	NOUN	B
further	O	ADV	O
indicate	O	VERB	O
that	O	SCONJ	O
probiotics	O	NOUN	B
may	O	AUX	O
counteract	O	VERB	O
inflammatory	B-OUT	ADJ	B
responses	I-OUT	NOUN	I
beyond	O	ADP	O
the	O	DET	O
intestinal	O	ADJ	B
milieu	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
combined	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
these	O	DET	O
probiotic	O	ADJ	B
strains	O	NOUN	B
will	O	AUX	O
guide	O	VERB	O
infants	B-P	NOUN	B
through	O	ADP	O
the	O	DET	O
weaning	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
sensitization	O	NOUN	B
to	O	PART	O
newly	O	ADV	O
encountered	O	VERB	O
antigens	O	NOUN	B
is	O	AUX	O
initiated	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
probiotic	O	ADJ	B
approach	O	NOUN	B
may	O	AUX	O
thus	O	ADV	O
offer	O	VERB	O
a	O	DET	O
new	O	ADJ	O
direction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
search	O	NOUN	B
for	O	ADP	O
future	O	ADJ	O
foods	O	NOUN	B
for	O	ADP	O
allergy	O	NOUN	B
treatment	O	NOUN	I
and	O	CCONJ	O
prevention	O	NOUN	B
strategies	O	NOUN	I
.	O	PUNCT	O


Pretreatment	O	NOUN	B
and	O	CCONJ	O
co-administration	O	NOUN	B
of	O	ADP	O
oral	B-I	ADJ	B
anti-diabetic	I-I	ADJ	O
agent	I-I	NOUN	O
with	O	ADP	O
clomiphene	B-I	NOUN	B
citrate	I-I	NOUN	I
or	O	CCONJ	O
rFSH	B-I	NOUN	B
for	O	ADP	O
ovulation	O	NOUN	B
induction	O	NOUN	B
in	O	ADP	O
clomiphene-citrate-resistant	B-P	ADJ	B
polycystic	I-P	ADJ	I
ovary	I-P	ADJ	I
syndrome	I-P	NOUN	I
.	I-P	PUNCT	O


AIM	O	VERB	B
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
pretreatment	O	NOUN	B
and	O	CCONJ	O
concomitant	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
metformin	B-I	NOUN	B
with	O	ADP	O
clomiphene	B-I	NOUN	B
citrate	I-I	NOUN	I
(	I-I	PUNCT	O
CC	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
rFSH	B-I	NOUN	B
for	O	ADP	O
ovulation	O	NOUN	B
induction	O	NOUN	B
in	O	ADP	O
clomiphene-citrate-resistant	B-P	ADJ	B
polycystic	I-P	ADJ	I
ovary	I-P	ADJ	I
syndrome	I-P	NOUN	I
(	I-P	PUNCT	O
PCOS	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
This	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
was	O	AUX	O
done	O	VERB	O
in	O	ADP	O
the	O	DET	O
Dhaka	B-P	PROPN	B
Medical	I-P	PROPN	I
College	I-P	PROPN	I
and	I-P	CCONJ	I
Hospital	I-P	PROPN	I
and	I-P	CCONJ	O
the	I-P	DET	O
Infertility	I-P	PROPN	B
Care	I-P	PROPN	I
and	I-P	CCONJ	O
Research	I-P	PROPN	O
Centre	I-P	PROPN	O
,	I-P	PUNCT	O
Dhaka	I-P	PROPN	B
,	I-P	PUNCT	O
Bangladesh	I-P	PROPN	B
.	I-P	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
165	B-P	NUM	O
infertile	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
CC-resistant	I-P	ADJ	B
PCOS	I-P	NOUN	B
who	I-P	PRON	O
attended	I-P	VERB	B
for	I-P	ADP	O
treatment	I-P	NOUN	B
were	I-P	AUX	O
the	I-P	DET	O
target	I-P	NOUN	B
population	I-P	NOUN	B
for	I-P	ADP	O
this	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
groups	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
B	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
metformin	B-I	NOUN	B
and	O	CCONJ	O
group	O	NOUN	B
C	O	NOUN	I
was	O	AUX	O
the	O	DET	O
control	B-I	NOUN	B
.	I-I	PUNCT	O


Along	O	ADP	O
with	O	ADP	O
metformin	B-I	NOUN	B
,	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	O
received	O	VERB	O
CC	B-I	NOUN	B
and	O	CCONJ	O
group	O	NOUN	B
B	O	NOUN	I
received	O	VERB	O
rFSH	B-I	NOUN	B
.	I-I	PUNCT	O


Group	O	PROPN	B
C	O	NOUN	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
only	O	ADJ	O
rFSH	B-I	NOUN	B
.	I-I	PUNCT	O


Metformin	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
1500	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Afterwards	B-I	ADV	O
CC	I-I	NOUN	B
or	I-I	CCONJ	O
rFSH	I-I	NOUN	B
were	O	AUX	O
added	O	VERB	O
for	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
ovulation	O	NOUN	B
along	O	ADP	O
with	B-I	ADP	O
metformin	I-I	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
ovulatory	O	ADJ	B
cycles	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


Treatment	O	NOUN	B
was	O	AUX	O
terminated	O	VERB	O
when	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
response	O	NOUN	O
with	O	ADP	O
maximum	O	ADJ	B
dose	O	NOUN	B
of	B-I	ADP	O
CC	I-I	NOUN	B
and	I-I	CCONJ	O
rFSH	I-I	NOUN	B
or	O	CCONJ	O
after	O	ADP	O
six	O	NUM	O
ovulatory	O	ADJ	B
cycles	O	NOUN	O
without	O	ADP	O
pregnancy	O	NOUN	B
or	O	CCONJ	O
after	O	ADP	O
achieving	O	VERB	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
P-value	O	NOUN	B
of	O	ADP	O
<	O	X	O
0.5	O	NUM	O
was	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
significant	O	ADJ	B
.	O	PUNCT	O


RESULTS	B-OUT	VERB	B
Ovulation	I-OUT	NOUN	B
(	O	PUNCT	O
89.09	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
pregnancy	I-OUT	NOUN	B
(	O	PUNCT	O
54.55	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
rates	O	NOUN	B
were	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
group	O	NOUN	B
B.	B-OUT	PROPN	B
Ovulation	I-OUT	PROPN	I
(	O	PUNCT	O
74.55	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
pregnancy	I-OUT	NOUN	B
(	O	PUNCT	O
29.09	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
rates	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
satisfactory	O	ADJ	B
in	O	ADP	O
group	O	NOUN	B
C	O	NOUN	I
but	O	CCONJ	O
a	O	DET	O
dose	O	NOUN	B
of	B-I	ADP	O
rFSH	I-I	NOUN	B
requirement	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	B
higher	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.000	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
both	B-OUT	CCONJ	O
ovulation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pregnancy	I-OUT	NOUN	B
rate	O	NOUN	I
were	O	AUX	O
much	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
the	O	DET	O
other	O	ADJ	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
27.27	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
12.73	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Use	B-I	PROPN	O
of	I-I	ADP	O
metformin	I-I	NOUN	B
increases	O	VERB	B
the	O	DET	O
response	O	NOUN	B
of	O	ADP	O
ovulation-inducing	O	ADJ	B
agents	O	NOUN	I
and	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
safely	B-P	ADV	O
in	I-P	ADP	O
PCOS	O	NOUN	B
.	O	PUNCT	O


Antibiotic	O	ADJ	B
elimination	O	NOUN	B
of	O	ADP	O
group-B	O	ADJ	B
streptococci	O	NOUN	I
in	O	ADP	O
urine	O	NOUN	B
in	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
preterm	B-OUT	NOUN	B
labour	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
group-B	O	ADJ	B
streptococci	O	NOUN	I
in	O	ADP	O
the	O	DET	O
urine	O	NOUN	B
of	O	ADP	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
preterm	O	NOUN	B
labour	O	NOUN	I
.	O	PUNCT	O


Urine	O	NOUN	B
samples	O	NOUN	I
from	O	ADP	O
4122	B-P	NUM	O
women	I-P	NOUN	B
at	I-P	ADP	O
27-31	I-P	NUM	O
weeks	I-P	NOUN	B
'	I-P	PART	O
gestation	I-P	NOUN	B
were	O	AUX	O
examined	O	VERB	O
for	O	ADP	O
bacteria	O	NOUN	B
.	O	PUNCT	O


Group-B	O	NOUN	B
streptococci	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
urine	O	NOUN	B
of	O	ADP	O
69	B-P	NUM	O
women	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
study	O	NOUN	I
these	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
either	O	CCONJ	O
penicillin	B-I	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
IU	O	NOUN	B
three	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
for	O	ADP	O
6	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
37	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
32	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
rates	O	NOUN	B
of	O	ADP	O
primary	B-OUT	ADJ	B
rupture	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
membranes	I-OUT	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
53	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
preterm	B-OUT	NOUN	B
labour	I-OUT	NOUN	I
(	O	PUNCT	O
5.4	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
38	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.002	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
penicillin	B-I	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
treatment	O	NOUN	B
and	O	CCONJ	O
follow-up	O	VERB	B
to	O	PART	O
prevent	O	VERB	B
recolonisation	O	NOUN	B
in	O	ADP	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
with	I-P	ADP	O
group-B	I-P	ADJ	B
streptococci	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
urine	I-P	NOUN	B
may	O	AUX	O
reduce	O	VERB	O
the	O	DET	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
preterm	I-OUT	NOUN	B
labour	I-OUT	NOUN	I
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Pharmacokinetics	O	NOUN	B
of	O	ADP	O
theophylline	O	NOUN	B
in	O	ADP	O
sustained-release	O	ADJ	B
formulation	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
asthmatics	I-P	NOUN	B
]	I-P	PUNCT	O
.	O	PUNCT	O


Pharmacokinetics	O	NOUN	B
of	O	ADP	O
two	B-I	NUM	O
theophylline	I-I	NOUN	B
(	I-I	PUNCT	O
CAS	I-I	NOUN	B
58-55-9	I-I	NOUN	O
)	I-I	PUNCT	O
sustained	I-I	ADJ	O
release	I-I	NOUN	O
preparations	I-I	NOUN	O
(	I-I	PUNCT	O
T	I-I	NOUN	B
:	I-I	PUNCT	O
Bronchoretard	I-I	PROPN	B
Capsules/R	I-I	X	B
:	I-I	PUNCT	O
Capsule	I-I	NOUN	B
formulation	I-I	NOUN	I
from	I-I	ADP	O
the	I-I	DET	O
US	I-I	PROPN	B
market	I-I	NOUN	B
)	I-I	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
randomised	O	VERB	B
two-way	O	NOUN	O
crossover	O	NOUN	B
design	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
capsules	O	NOUN	B
of	O	ADP	O
the	O	DET	O
test	O	NOUN	B
formulation	O	NOUN	B
were	O	AUX	O
opened	O	VERB	B
and	O	CCONJ	O
administered	O	VERB	B
on	O	ADP	O
a	O	DET	O
tablespoonful	O	NOUN	O
of	O	ADP	O
apple	O	NOUN	B
sauce	O	NOUN	I
.	O	PUNCT	O


Nineteen	B-P	NUM	B
asthmatics	I-P	NOUN	B
aged	I-P	ADJ	B
6	I-P	NUM	O
to	I-P	PART	O
12	I-P	NUM	O
years	I-P	NOUN	B
participated	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Following	B-I	VERB	O
individual	I-I	ADJ	B
dosing	I-I	NOUN	B
of	I-I	ADP	O
100-300	I-I	NUM	O
mg	I-I	NOUN	O
theophylline	I-I	NOUN	B
twice	I-I	ADV	O
a	I-I	DET	O
day	I-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
pharmacokinetic	I-I	ADJ	B
profile	I-I	NOUN	I
for	I-I	ADP	O
24	I-I	NUM	O
h	I-I	NOUN	O
was	I-I	AUX	O
derived	I-I	VERB	O
after	I-I	ADP	O
seven	I-I	NUM	O
days	I-I	NOUN	B
of	I-I	ADP	O
multiple	I-I	ADJ	B
dosing	I-I	NOUN	B
.	I-I	PUNCT	O


All	B-I	DET	O
relevant	I-OUT	ADJ	B
parameters	I-OUT	NOUN	B
for	I-OUT	ADP	O
rate	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
Cmax	I-OUT	NOUN	B
ss	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
Cmin	I-OUT	NOUN	B
ss	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
Cav	I-OUT	NOUN	B
ss	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
plateau	I-OUT	ADJ	B
time	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
peak-trough	I-OUT	ADJ	B
fluctuation	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
nocturnal	I-OUT	ADJ	B
excess	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
tmax	I-OUT	NOUN	B
ss	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
and	I-I	CCONJ	O
extent	I-OUT	NOUN	B
of	I-OUT	ADP	O
absorption	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
AUCss	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	I-I	AUX	O
calculated	I-I	VERB	B
for	I-I	ADP	O
both	I-I	DET	O
formulations	I-I	NOUN	B
.	I-I	PUNCT	O


With	O	ADP	O
long	O	ADJ	B
plateau	B-OUT	NOUN	I
times	I-OUT	NOUN	I
(	O	PUNCT	O
T	O	NOUN	B
:	O	PUNCT	O
17.3	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
small	B-OUT	ADJ	B
peak-trough	I-OUT	ADJ	I
fluctuations	I-OUT	NOUN	I
(	O	PUNCT	O
T	O	NOUN	B
:	O	PUNCT	O
49.0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
established	O	VERB	O
quality	O	NOUN	B
criteria	O	NOUN	B
for	O	ADP	O
high	O	ADJ	O
quality	O	NOUN	B
theophylline	O	NOUN	B
preparations	O	NOUN	B
were	O	AUX	O
fulfilled	O	VERB	O
by	O	ADP	O
the	O	DET	O
test	O	NOUN	B
formulation	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
symmetrical	B-OUT	ADJ	B
peaks	I-OUT	NOUN	I
resulted	O	VERB	O
after	O	ADP	O
morning	O	NOUN	B
and	O	CCONJ	O
evening	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
test	O	NOUN	B
formulation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
smooth	O	ADJ	B
and	O	CCONJ	O
predictable	O	ADJ	B
concentration/time	B-OUT	NOUN	B
profiles	I-OUT	NOUN	I
were	O	AUX	O
achieved	O	VERB	O
,	O	PUNCT	O
enabling	O	VERB	O
an	O	DET	O
efficacious	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
therapy	O	NOUN	B
of	O	ADP	O
asthma	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
individual	O	ADJ	B
mode	O	NOUN	B
of	O	ADP	O
administration	O	NOUN	B
allows	O	VERB	O
not	O	PART	O
only	O	ADV	O
a	O	DET	O
perfect	O	ADJ	O
dose	O	NOUN	B
titration	O	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
asthmatics	I-P	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
also	O	ADV	O
helpful	O	ADJ	O
to	O	ADP	O
patients	B-P	NOUN	B
who	I-P	PRON	O
have	I-P	AUX	O
difficulty	I-P	NOUN	B
in	I-P	ADP	O
swallowing	I-P	VERB	B
large	I-P	ADJ	I
dosage	I-P	NOUN	B
forms	I-P	NOUN	O
.	I-P	PUNCT	O


Weight	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
leptin	I-OUT	NOUN	B
changes	I-OUT	VERB	B
among	O	ADP	O
risperidone-treated	B-I	ADJ	B
youths	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
:	I-P	PUNCT	O
6-month	O	ADJ	O
prospective	O	ADJ	B
data	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
authors	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
developmental	O	ADJ	B
impact	O	NOUN	B
and	O	CCONJ	O
temporal	O	ADJ	B
characteristics	O	NOUN	B
of	O	ADP	O
risperidone-associated	B-I	ADJ	B
weight	I-OUT	NOUN	O
change	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


METHOD	O	NOUN	O
Weight	B-OUT	NOUN	B
change	I-OUT	NOUN	I
was	O	AUX	O
measured	O	VERB	B
for	O	ADP	O
63	B-P	NUM	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
risperidone	I-I	NOUN	B
for	I-P	ADP	O
6	I-P	NUM	O
months	I-P	NOUN	B
.	I-P	PUNCT	O


Change	B-OUT	NOUN	B
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
leptin	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
after	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
was	O	AUX	O
examined	O	VERB	O
as	O	ADP	O
a	O	DET	O
predictor	O	NOUN	B
of	O	ADP	O
final	B-OUT	ADJ	O
weight	I-OUT	NOUN	O
gain	I-OUT	NOUN	O
in	O	ADP	O
mixed	O	ADJ	O
regression	O	NOUN	B
models	O	NOUN	I
that	O	PRON	O
controlled	O	VERB	B
for	O	ADP	O
site	O	NOUN	B
,	O	PUNCT	O
gender	O	NOUN	B
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
risperidone	B-I	NOUN	B
dose	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Age-	O	NOUN	B
and	O	CCONJ	I
gender-standardized	O	ADJ	B
weight	B-OUT	NOUN	I
increased	I-OUT	VERB	B
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
gross	O	NOUN	B
:	O	PUNCT	O
mean=5.6	O	ADJ	O
kg	O	NOUN	O
[	O	PUNCT	O
SD=3.9	O	NUM	O
]	O	PUNCT	O
;	O	PUNCT	O
standardized	O	VERB	B
:	O	PUNCT	O
mean=0.6	O	NOUN	O
z	O	NOUN	O
[	O	PUNCT	O
SD=0.5	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
positively	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
weight	B-OUT	NOUN	B
gained	I-OUT	VERB	I
after	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
.	O	PUNCT	O


Change	B-OUT	NOUN	B
in	I-OUT	ADP	O
leptin	I-OUT	NOUN	B
levels	I-OUT	NOUN	B
after	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
mean=-0.3	O	NOUN	O
ng/ml	O	NOUN	O
,	O	PUNCT	O
SD=6.2	O	ADJ	B
)	O	PUNCT	O
(	O	PUNCT	O
N=48	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
predict	O	VERB	O
final	B-OUT	ADJ	O
weight	I-OUT	NOUN	B
gain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
Chronic	O	ADJ	B
risperidone	B-I	NOUN	I
exposure	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
autism	O	NOUN	B
causes	O	VERB	O
weight	B-OUT	NOUN	B
gain	I-OUT	NOUN	I
in	O	ADP	O
excess	O	NOUN	B
of	O	ADP	O
developmentally	O	ADV	O
expected	O	VERB	O
norms	O	NOUN	B
that	O	PRON	O
follows	O	VERB	O
a	O	DET	O
curvilinear	O	ADJ	B
trajectory	O	NOUN	I
and	O	CCONJ	O
decelerates	O	VERB	B
over	O	ADP	O
time	O	NOUN	B
.	O	PUNCT	O


Serum	B-OUT	NOUN	B
leptin	I-OUT	NOUN	O
change	I-OUT	NOUN	O
does	O	AUX	O
not	O	PART	O
reliably	O	ADV	O
predict	O	VERB	O
risperidone-associated	O	ADJ	B
weight	B-OUT	NOUN	O
gain	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Intravenous	B-I	ADJ	B
regional	I-I	ADJ	O
anaesthesia	I-I	NOUN	O
below	O	ADP	O
the	O	DET	O
knee	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
cross-over	O	ADJ	B
study	O	NOUN	I
with	O	ADP	O
prilocaine	B-I	NOUN	B
in	I-P	ADP	O
volunteers	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
quality	O	NOUN	B
of	O	ADP	I
anaesthesia	O	NOUN	I
provided	O	VERB	O
by	O	ADP	O
three	O	NUM	O
dosages	O	NOUN	B
of	O	ADP	O
prilocaine	B-I	NOUN	B
,	O	PUNCT	O
40	O	NUM	O
ml	O	NOUN	O
0.5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
20	O	NUM	O
ml	O	NOUN	O
1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
40	O	NUM	O
ml	O	NOUN	O
1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
administered	O	VERB	B
in	O	ADP	O
random	O	ADJ	B
order	O	NOUN	O
,	O	PUNCT	O
for	O	ADP	O
intravenous	O	ADJ	B
regional	O	ADJ	O
anaesthesia	O	NOUN	O
of	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
extremity	O	NOUN	B
below	O	ADP	O
the	O	DET	O
knee	O	NOUN	B
was	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
six	B-P	NUM	O
volunteers	I-P	NOUN	B
.	I-P	PUNCT	O


Limited	O	ADJ	B
sensory	O	ADJ	O
blockade	O	NOUN	O
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
with	O	ADP	O
40	O	NUM	O
ml	O	NOUN	O
0.5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
20	O	NUM	O
ml	O	NOUN	O
1	O	NUM	O
%	O	NOUN	O
during	O	ADP	O
the	O	DET	O
30-minute	O	ADJ	O
test	O	NOUN	O
period	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
subject	O	NOUN	B
was	O	AUX	O
not	O	PART	O
fully	O	ADV	O
anaesthetised	O	VERB	B
with	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
dosages	O	NOUN	B
used	O	VERB	O
.	O	PUNCT	O


Recovery	B-OUT	NOUN	B
was	I-OUT	AUX	O
rapid	I-OUT	ADJ	O
(	O	PUNCT	O
mean	O	NOUN	O
12-13	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
these	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
subjects	O	NOUN	B
given	O	VERB	O
40	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
complete	B-OUT	ADJ	B
recovery	I-OUT	NOUN	B
took	O	VERB	O
90	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
flexion	I-OUT	NOUN	B
remaining	I-OUT	VERB	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
great	I-OUT	ADJ	B
toe	I-OUT	NOUN	I
(	O	PUNCT	O
control	O	NOUN	B
100	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
4	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
40	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
0.5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
34	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
those	O	DET	O
who	O	PRON	O
received	O	VERB	O
20	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


Full	B-OUT	ADJ	B
motor	I-OUT	NOUN	I
recovery	I-OUT	NOUN	I
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
8-9	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
six	O	NUM	O
volunteers	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
400-mg	O	ADJ	B
dose	O	NOUN	B
experienced	O	VERB	O
subjective	B-OUT	ADJ	O
signs	I-OUT	NOUN	O
of	I-OUT	ADP	O
central	I-OUT	ADJ	B
nervous	I-OUT	ADJ	I
system	I-OUT	NOUN	I
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
when	O	SCONJ	O
the	O	DET	O
cuff	O	NOUN	B
was	O	AUX	O
released	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
group	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mean	B-OUT	ADJ	O
plasma	I-OUT	NOUN	B
level	I-OUT	NOUN	B
of	O	ADP	O
prilocaine	B-I	NOUN	B
at	O	ADP	O
2	O	NUM	O
minutes	O	NOUN	B
was	O	AUX	O
1.22	O	NUM	O
micrograms/ml	O	NOUN	O
,	O	PUNCT	O
maximum	O	NOUN	O
2.12	O	NUM	O
micrograms/ml	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
radiological	O	ADJ	B
examination	O	NOUN	I
,	O	PUNCT	O
no	B-OUT	DET	O
leak	I-OUT	NOUN	B
of	I-OUT	ADP	O
contrast	I-OUT	NOUN	B
medium	I-OUT	NOUN	I
under	I-OUT	ADP	O
the	I-OUT	DET	O
tourniquet	I-OUT	NOUN	B
cuff	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
300	I-OUT	NUM	O
mmHg	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	B
was	O	AUX	O
fastest	B-OUT	ADJ	O
following	O	VERB	O
the	O	DET	O
largest	O	ADJ	B
dose	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
large	B-OUT	ADJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
central	I-OUT	ADJ	B
side	I-OUT	NOUN	I
effects	I-OUT	NOUN	I
makes	O	VERB	O
that	O	SCONJ	O
dosage	O	NOUN	B
less	B-OUT	ADV	O
suitable	I-OUT	ADJ	O
for	I-OUT	ADP	O
clinical	I-OUT	ADJ	B
work	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Complement	O	NOUN	B
activation	O	NOUN	I
on	O	ADP	O
the	O	DET	O
surface	O	NOUN	B
of	O	ADP	O
cell-derived	O	ADJ	B
microparticles	O	NOUN	B
during	O	ADP	O
cardiac	B-P	ADJ	B
surgery	I-P	NOUN	I
with	I-P	ADP	O
cardiopulmonary	I-I	ADJ	B
bypass	I-I	NOUN	I
-	O	PUNCT	O
is	O	AUX	O
retransfusion	O	NOUN	B
of	O	ADP	O
pericardial	O	ADJ	B
blood	O	NOUN	I
harmful	O	ADJ	I
?	O	PUNCT	O
OBJECTIVES	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
cell-derived	O	ADJ	B
microparticles	O	NOUN	B
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
complement	B-OUT	NOUN	B
activation	I-OUT	NOUN	I
in	O	ADP	O
pericardial	O	ADJ	B
blood	O	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
cardiac	I-I	ADJ	B
surgery	I-I	NOUN	I
with	I-I	ADP	O
cardiopulmonary	I-I	NOUN	B
bypass	I-I	NOUN	I
(	I-I	PUNCT	O
CPB	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
whether	O	SCONJ	O
microparticles	O	NOUN	B
in	O	ADP	O
pericardial	O	ADJ	B
blood	O	NOUN	I
contribute	O	VERB	O
to	O	PART	O
systemic	B-OUT	ADJ	B
complement	I-OUT	NOUN	O
activation	I-OUT	NOUN	O
upon	O	SCONJ	O
retransfusion	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Pericardial	B-P	ADJ	B
blood	I-P	NOUN	I
of	I-P	ADP	O
13	I-P	NUM	O
patients	I-P	NOUN	B
was	O	AUX	O
retransfused	O	VERB	B
in	O	ADP	O
9	O	NUM	O
and	O	CCONJ	O
discarded	O	VERB	O
in	O	ADP	O
4	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Microparticles	O	NOUN	B
were	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
systemic	O	ADJ	B
blood	B-I	NOUN	I
collected	I-I	VERB	O
before	I-I	ADP	O
anesthesia	I-I	NOUN	B
(	O	PUNCT	O
T1	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
CPB	B-I	NOUN	B
(	O	PUNCT	O
T2	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
from	O	ADP	O
pericardial	O	ADJ	B
blood	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
microparticles	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
flow	O	NOUN	B
cytometry	O	NOUN	I
for	O	ADP	O
bound	O	VERB	B
complement	O	NOUN	O
components	O	NOUN	O
C1q	O	NOUN	B
,	O	PUNCT	O
C4	O	NOUN	B
and	O	CCONJ	O
C3	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bound	O	VERB	B
complement	O	NOUN	I
activator	O	NOUN	I
molecules	O	NOUN	I
C-reactive	O	ADJ	I
protein	O	NOUN	I
(	O	PUNCT	O
CRP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
serum	O	NOUN	B
amyloid	O	NOUN	I
P-component	O	NOUN	I
(	O	PUNCT	O
SAP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
immunoglobulin	O	NOUN	B
(	O	PUNCT	I
Ig	O	NOUN	I
)	O	PUNCT	I
M	O	NOUN	I
and	O	CCONJ	O
IgG	O	NOUN	B
.	O	PUNCT	O


Fluid-phase	O	ADJ	B
complement	O	NOUN	I
activation	O	NOUN	I
products	O	NOUN	I
(	O	PUNCT	O
C4b/c	O	NOUN	B
,	O	PUNCT	O
C3b/c	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
activator	O	NOUN	B
molecules	O	NOUN	I
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
ELISA	B-I	NOUN	B
.	I-I	PUNCT	O


RESULTS	O	NOUN	B
Compared	O	VERB	O
with	O	ADP	O
systemic	O	ADJ	B
T1	O	NOUN	I
blood	O	NOUN	I
,	O	PUNCT	O
pericardial	O	ADJ	B
blood	O	NOUN	I
contained	O	VERB	O
increased	O	VERB	B
C4b/c	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
C3b/c	I-OUT	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
levels	B-OUT	NOUN	B
of	I-OUT	ADP	O
microparticles	I-OUT	NOUN	B
with	O	ADP	O
bound	O	VERB	B
complement	O	NOUN	I
components	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
systemic	O	ADJ	B
T1	O	NOUN	I
samples	O	NOUN	B
,	O	PUNCT	O
microparticle-bound	O	ADJ	B
CRP	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
pericardial	O	ADJ	B
blood	O	NOUN	I
,	O	PUNCT	O
microparticle-bound	O	ADJ	B
SAP	O	NOUN	B
and	O	CCONJ	O
IgM	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
complement	O	NOUN	B
activation	O	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
CPB	B-I	PROPN	B
,	O	PUNCT	O
increased	O	VERB	B
C3b/c	B-OUT	ADJ	B
(	I-OUT	PUNCT	O
but	I-OUT	CCONJ	O
not	I-OUT	PART	O
C4b/c	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
systemic	O	ADJ	B
T2	O	NOUN	B
blood	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
T1	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
concentrations	O	NOUN	B
of	O	ADP	O
microparticles	O	NOUN	B
binding	O	NOUN	O
complement	O	NOUN	O
components	O	NOUN	O
and	O	CCONJ	O
of	O	ADP	O
those	O	DET	O
binding	O	NOUN	B
complement	O	NOUN	I
activator	O	NOUN	I
molecules	O	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
.	O	PUNCT	O


Concentrations	B-OUT	NOUN	B
of	I-OUT	ADP	O
fluid-phase	I-OUT	ADJ	B
complement	I-OUT	NOUN	O
activation	I-OUT	NOUN	O
products	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
microparticles	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
retransfused	O	VERB	B
with	O	ADP	O
pericardial	O	ADJ	B
blood	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
pericardial	O	ADJ	B
blood	O	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
cardiac	I-P	ADJ	B
surgery	I-P	NOUN	I
with	I-P	ADP	O
CPB	I-I	NOUN	B
,	O	PUNCT	O
microparticles	O	NOUN	B
contribute	O	VERB	O
to	O	PART	O
activation	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
complement	I-OUT	NOUN	B
system	I-OUT	NOUN	I
via	O	ADP	O
bound	O	VERB	B
SAP	O	NOUN	B
and	O	CCONJ	O
IgM	O	NOUN	B
.	O	PUNCT	O


Retransfusion	O	NOUN	B
of	O	ADP	O
pericardial	O	ADJ	B
blood	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
does	O	AUX	O
not	O	PART	O
contribute	O	VERB	O
to	O	PART	O
systemic	B-OUT	ADJ	B
complement	I-OUT	NOUN	O
activation	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
simvastatin	B-I	NOUN	B
and	I-I	CCONJ	O
fenofibrate	I-I	NOUN	B
on	O	ADP	O
endothelium	O	NOUN	B
in	O	ADP	O
Type	B-P	NOUN	B
2	I-P	NUM	I
diabetes	I-P	NOUN	I
.	I-P	PUNCT	O


Statins	O	NOUN	B
and	O	CCONJ	O
fibrates	O	NOUN	B
influence	O	VERB	B
endothelial	O	ADJ	B
activity	O	NOUN	I
and	O	CCONJ	O
consequently	O	ADV	O
atherogenesis	O	NOUN	B
but	O	CCONJ	O
the	O	DET	O
mechanisms	O	NOUN	B
are	O	AUX	O
not	O	PART	O
well	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


Twenty	B-P	NUM	O
Type	I-P	NOUN	B
2	I-P	NUM	I
diabetic	I-P	ADJ	I
patients	I-P	NOUN	B
with	I-P	ADP	O
dyslipidemia	I-P	NOUN	B
were	I-P	AUX	O
treated	I-P	VERB	B
3	O	NUM	O
months	O	NOUN	B
with	O	ADP	O
simvastatin	B-I	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
3	O	NUM	O
months	O	NOUN	B
with	O	ADP	O
fenofibrate	B-I	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
with	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
wash-out	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatments	O	NOUN	B
.	O	PUNCT	O


Laboratory	O	ADJ	B
parameters	O	NOUN	B
of	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
fibrinolysis	O	NOUN	B
and	O	CCONJ	O
endothelial	O	ADJ	B
function	O	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
total	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
LDL-cholesterol	I-OUT	ADJ	B
concentrations	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
caused	O	VERB	O
by	O	ADP	O
simvastatin	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
N-acetyl-beta-glucosaminidase	I-OUT	NOUN	O
activity	I-OUT	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
ascorbic	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
plasminogen	B-OUT	NOUN	B
activator	I-OUT	NOUN	I
inhibitor	I-OUT	NOUN	I
(	O	PUNCT	O
PAI-1	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
vonWillebrand	B-OUT	ADJ	B
factor	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
E-selectin	B-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
vascular	B-OUT	ADJ	B
endothelial	I-OUT	ADJ	I
growth	I-OUT	NOUN	I
factor	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	NOUN	O
0.05	O	NUM	O
)	O	PUNCT	O
concentrations	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
a	O	DET	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
glutathione	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	PART	O
0.01	I-OUT	NUM	O
)	I-OUT	PUNCT	O
levels	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Fenofibrate	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
triglyceride	I-OUT	NOUN	I
concentration	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.0001	O	NUM	O
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
plasma	B-OUT	NOUN	B
malondialdehyde	I-OUT	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
increase	B-OUT	NOUN	B
in	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
PAI-1	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
P-selectin	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
P	I-OUT	NOUN	O
<	I-OUT	NOUN	O
0.05	I-OUT	NUM	O
)	I-OUT	PUNCT	O
concentrations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
simvastatin	O	NOUN	B
and	O	CCONJ	O
fenofibrate	O	NOUN	B
interact	O	VERB	B
,	O	PUNCT	O
by	O	ADP	O
different	O	ADJ	O
mechanisms	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
key	O	ADJ	O
factor	O	NOUN	B
in	O	ADP	O
the	O	DET	O
modification	O	NOUN	B
of	O	ADP	O
fibrinolysis	O	NOUN	B
and	O	CCONJ	O
endothelial	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
Type	O	NOUN	B
2	O	NUM	I
diabetes	O	NOUN	I
.	O	PUNCT	O


Comparative	B-OUT	ADJ	B
bioavailability	I-OUT	NOUN	B
of	O	ADP	O
two	O	NUM	O
formulations	O	NOUN	B
of	O	ADP	O
terbinafine	B-I	NOUN	B
.	I-I	PUNCT	O


Data	O	NOUN	B
from	O	ADP	O
a	O	DET	O
cross-over	O	ADJ	B
,	O	PUNCT	O
randomised	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
bioequivalence	O	NOUN	B
study	O	NOUN	O
in	O	ADP	O
healthy	B-P	ADJ	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


An	O	DET	O
open-label	O	ADJ	B
,	O	PUNCT	O
randomised	O	VERB	B
,	O	PUNCT	O
cross-over	O	ADJ	B
single	O	ADJ	I
dose	O	NOUN	I
study	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
2	O	NUM	O
periods	O	NOUN	B
x	O	NOUN	O
2	O	NUM	O
sequences	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
minimum	O	ADJ	O
washout	O	NOUN	O
period	O	NOUN	O
of	O	ADP	O
21	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
comparative	B-OUT	ADJ	B
bioavailability	I-OUT	NOUN	B
of	O	ADP	O
two	O	NUM	O
formulations	O	NOUN	B
of	O	ADP	O
terbinafine	B-I	NOUN	B
(	I-I	PUNCT	O
CAS	I-I	NOUN	B
78628-80-5	I-I	X	O
)	I-I	PUNCT	O
250	O	NUM	O
mg	O	NOUN	O
tablets	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
samples	I-OUT	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
+0.333	O	NOUN	B
;	O	PUNCT	O
0.667	O	NUM	O
;	O	PUNCT	O
1.00	O	NUM	O
;	O	PUNCT	O
1.33	O	NUM	O
;	O	PUNCT	O
1.67	O	NUM	O
;	O	PUNCT	O
2.00	O	NUM	O
;	O	PUNCT	O
2.33	O	NUM	O
;	O	PUNCT	O
2.67	O	NUM	O
;	O	PUNCT	O
3.00	O	NUM	O
;	O	PUNCT	O
3.50	O	NUM	O
;	O	PUNCT	O
4.00	O	NUM	O
;	O	PUNCT	O
6.00	O	NUM	O
;	O	PUNCT	O
8.00	O	NUM	O
;	O	PUNCT	O
12.0	O	NUM	O
;	O	PUNCT	O
24.0	O	NUM	O
;	O	PUNCT	O
36.0	O	NUM	O
;	O	PUNCT	O
48.0	O	NUM	O
and	O	CCONJ	O
72.0	O	NUM	O
h	O	NOUN	O
post-administration	O	NOUN	B
.	O	PUNCT	O


Terbinafine	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
were	I-OUT	AUX	O
determined	I-OUT	VERB	O
by	I-OUT	ADP	O
high	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
liquid	I-OUT	ADJ	I
chromatography	I-OUT	NOUN	I
with	I-OUT	ADP	O
tandem	I-OUT	ADJ	B
mass	I-OUT	NOUN	I
detection	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HPLC-MS/MS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
lower	O	ADJ	O
limit	O	NOUN	O
of	O	ADP	O
quantification	O	NOUN	B
was	O	AUX	O
set	O	VERB	O
at	O	ADP	O
9.99	O	NUM	O
ng/mL	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
pharmacokinetic	B-OUT	ADJ	B
parameters	I-OUT	NOUN	B
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
bioequivalence	B-OUT	NOUN	B
assessment	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
AUClast	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
AUCinf	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
Cmax	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
determined	O	VERB	O
from	O	ADP	O
the	O	DET	O
terbinafine	O	NOUN	B
concentration	O	NOUN	B
data	O	NOUN	B
using	O	VERB	O
non-compartmental	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


Classical	B-OUT	ADJ	O
90	I-OUT	NUM	O
%	I-OUT	NOUN	O
confidence	I-OUT	NOUN	B
intervals	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
90CI	I-OUT	NUM	O
)	I-OUT	PUNCT	O
were	O	AUX	O
calculated	O	VERB	B
for	O	ADP	O
the	O	DET	O
overall	O	ADJ	O
sample	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
males	B-P	NOUN	B
and	I-P	CCONJ	O
females	I-P	NOUN	B
separately	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
gender	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
investigated	O	VERB	B
using	O	VERB	O
an	O	DET	O
appropriate	O	ADJ	O
model	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
overall	O	ADJ	O
classical	B-OUT	ADJ	O
90CI	I-OUT	NUM	O
were	O	AUX	O
96.08-105.40	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
AUCinf	O	NOUN	B
,	O	PUNCT	O
95.68-105.33	O	NOUN	O
for	O	ADP	O
AUClast	B-OUT	NOUN	B
and	O	CCONJ	O
88.24-112.83	O	NOUN	O
for	O	ADP	O
Cmax	B-OUT	NOUN	B
,	O	PUNCT	O
that	O	ADV	O
is	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
within	O	ADP	O
the	O	DET	O
predefined	O	ADJ	O
ranges	O	NOUN	B
for	O	ADP	O
bioequivalence	O	NOUN	B
acceptance	O	NOUN	B
.	O	PUNCT	O


Separate	O	ADJ	B
gender	O	NOUN	B
analysis	O	NOUN	I
showed	O	VERB	O
very	O	ADV	O
similar	O	ADJ	O
results	B-OUT	NOUN	B
for	O	ADP	O
males	B-P	NOUN	B
and	I-P	CCONJ	O
females	I-P	NOUN	B
when	O	SCONJ	O
analysed	O	VERB	B
independently	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
gender	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
detected	O	VERB	B
(	O	PUNCT	O
p	O	NOUN	O
>	O	X	O
0.05	O	NUM	O
for	O	ADP	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
tested	O	VERB	B
model	O	NOUN	O
effects	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


It	O	PRON	O
may	O	AUX	O
be	O	AUX	O
therefore	O	ADV	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
evaluated	O	VERB	B
formulations	O	NOUN	B
are	O	AUX	O
bioequivalent	O	ADJ	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
rate	O	NOUN	B
and	O	CCONJ	O
extent	O	NOUN	B
of	O	ADP	O
absorption	O	NOUN	B
.	O	PUNCT	O


[	O	PUNCT	O
Effect	O	NOUN	B
of	O	ADP	O
alpha	B-I	NOUN	B
dihydroergocryptine	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
fibrocystic	I-P	ADJ	B
breast	I-P	NOUN	I
disease	I-P	NOUN	I
]	I-P	PUNCT	O
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
alpha	B-I	NOUN	B
dihidroergocriptine	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
fibrocystic	I-P	ADJ	B
mastopathy	I-P	NOUN	I
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
diagnosis	I-P	NOUN	B
of	I-P	ADP	O
fibrocystic	I-P	ADJ	B
breast	I-P	NOUN	I
disease	I-P	NOUN	I
were	I-P	AUX	O
included	I-P	VERB	O
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
longitudinal	O	ADJ	I
blind	O	NOUN	I
double	O	ADV	O
,	O	PUNCT	O
controlled	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
:	O	PUNCT	O
of	O	ADP	O
treatment	O	NOUN	B
group	O	NOUN	I
A	O	NOUN	O
:	O	PUNCT	O
Alpha	B-I	NOUN	B
dihidroergocriptine	I-I	NOUN	I
tablets	I-I	NOUN	I
of	I-I	ADP	O
10	I-I	NUM	O
mg	I-I	NOUN	O
,	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
:	O	PUNCT	O
Placebo	B-I	NOUN	B
,	O	PUNCT	O
during	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
to	O	PART	O
basal	O	ADJ	B
evaluation	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
revised	O	VERB	B
in	O	ADP	O
a	O	DET	O
monthly	O	ADJ	B
way	O	NOUN	O
evaluating	O	VERB	B
the	O	DET	O
following	O	VERB	O
symptoms	O	NOUN	B
and	O	CCONJ	O
signs	O	NOUN	B
:	O	PUNCT	O
mastalgia	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
mammary	I-OUT	ADJ	B
tension	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
presence	I-OUT	NOUN	B
of	I-OUT	ADP	O
nodules	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
nipple	I-OUT	ADJ	B
secretion	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
presence	I-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
39	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
alpha	I-I	NOUN	B
dihidroergocriptine	I-I	NOUN	I
and	I-P	CCONJ	O
38	I-P	NUM	O
with	I-P	ADP	O
placebo	I-I	NOUN	B
.	I-I	PUNCT	O


Mastodinia	B-OUT	PROPN	B
,	O	PUNCT	O
a	O	DET	O
satisfactory	O	ADJ	O
response	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
100	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
alpha	B-I	NOUN	B
dihidroergocriptine	I-I	NOUN	I
group	O	NOUN	B
vs	O	CCONJ	O
61.11	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
placebo	B-I	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Mastalgia	B-OUT	PROPN	B
responded	O	VERB	O
in	O	ADP	O
100	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
alpha	O	NOUN	B
dihidroergocriptine	O	NOUN	I
group	O	NOUN	B
vs	O	CCONJ	O
64.86	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
placebo	O	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Galactorrea	B-OUT	PROPN	B
responded	O	VERB	O
100	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
alpha	B-I	NOUN	B
dihidroergocriptine	I-I	NOUN	I
group	O	NOUN	B
vs	O	CCONJ	O
93.33	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nodules	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
alpha	O	NOUN	I
dihidroergocriptine	O	NOUN	O
disappeared	O	VERB	O
in	O	ADP	O
23.1	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
21.1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Ultrasound	B-OUT	ADJ	B
evaluation	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
nodules	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Prolactin	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
showed	O	VERB	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
alpha	B-I	NOUN	B
dihidroergocriptine	I-I	NOUN	I
with	O	ADP	O
an	O	DET	O
important	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
6	O	NUM	O
months	O	NOUN	B
study	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
not	O	PART	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
presence	B-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Alpha	B-I	NOUN	B
dihidroergocriptine	I-I	NOUN	I
is	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
fribrocystic	B-OUT	ADJ	B
breast	I-OUT	NOUN	I
disease	I-OUT	NOUN	I
with	O	ADP	O
minimum	O	ADJ	B
adverse	O	ADJ	I
events	O	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
similar	O	ADJ	O
drugs	O	NOUN	B
.	O	PUNCT	O


Pre-treatment	O	ADJ	B
proliferation	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
conventional	B-I	ADJ	B
and	I-I	CCONJ	O
accelerated	I-I	VERB	B
radiotherapy	I-I	NOUN	B
.	I-I	PUNCT	O


This	O	DET	O
study	O	NOUN	B
investigated	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
pre-treatment	O	ADJ	B
proliferation	O	NOUN	B
characteristics	O	NOUN	B
,	O	PUNCT	O
assessed	B-I	VERB	B
by	I-I	ADP	O
Ki-67	I-I	NOUN	B
staining	I-I	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
patients	B-P	NOUN	B
treated	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
CHART	I-P	NOUN	B
trial	I-P	NOUN	I
of	I-P	ADP	O
accelerated	I-I	VERB	B
radiotherapy	I-I	NOUN	B
in	I-P	ADP	O
head	I-P	NOUN	B
and	I-P	CCONJ	I
neck	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Histological	O	ADJ	B
material	O	NOUN	I
from	O	ADP	O
402	B-P	NUM	O
patients	I-P	NOUN	B
was	O	AUX	O
collected	O	VERB	B
and	O	CCONJ	O
stained	O	VERB	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
and	O	CCONJ	O
pattern	O	NOUN	B
of	O	ADP	O
Ki-67	O	NOUN	B
staining	O	NOUN	I
.	O	PUNCT	O


Locoregional	B-OUT	ADJ	B
control	I-OUT	NOUN	I
and	O	CCONJ	O
overall	O	ADJ	B
survival	O	NOUN	B
were	O	AUX	O
the	O	DET	O
main	O	ADJ	O
clinical	O	ADJ	B
endpoints	O	NOUN	B
.	O	PUNCT	O


Increasing	O	VERB	B
Ki-67	O	NOUN	B
positivity	O	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
decreasing	O	VERB	B
differentiation	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
increasing	O	VERB	B
N-stage	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Increasing	O	VERB	B
N-stage	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
proliferation	O	NOUN	B
pattern	O	NOUN	B
from	O	ADP	O
marginal	O	ADJ	B
to	O	PART	O
random	O	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
multivariate	O	ADJ	B
model	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
trend	O	NOUN	O
was	O	AUX	O
seen	O	VERB	O
towards	O	ADP	O
a	O	DET	O
greater	O	ADJ	O
benefit	O	NOUN	B
from	O	ADP	O
CHART	O	NOUN	B
in	O	ADP	O
the	O	DET	O
lower	O	ADJ	O
Ki-67	O	NOUN	B
tumours	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.08	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
this	O	DET	O
became	O	VERB	O
significant	O	ADJ	O
by	O	ADP	O
pooling	O	VERB	B
the	O	DET	O
low	O	ADJ	B
and	O	CCONJ	O
intermediate	O	ADJ	B
Ki-67	O	NOUN	B
groups	O	NOUN	O
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
high	O	ADJ	O
Ki-67	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.032	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Tumours	O	NOUN	B
with	O	ADP	O
marginal	O	ADJ	B
proliferation	O	NOUN	I
pattern	O	NOUN	O
showed	O	VERB	O
a	O	DET	O
lower	O	ADJ	B
hazard	O	NOUN	B
ratio	O	NOUN	I
with	O	ADP	O
CHART	O	NOUN	B
versus	O	CCONJ	O
conventional	O	ADJ	B
for	O	ADP	O
locoregional	O	ADJ	B
control	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
presented	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
do	O	AUX	O
not	O	PART	O
support	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
high	O	ADJ	O
pre-treatment	O	ADJ	B
Ki-67	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
therapeutic	B-OUT	ADJ	B
benefit	I-OUT	NOUN	B
from	O	ADP	O
accelerated	B-I	VERB	B
radiotherapy	I-I	NOUN	B
.	I-I	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
apical	O	ADJ	B
sealing	O	NOUN	I
ability	O	NOUN	B
and	O	CCONJ	O
adaptation	O	NOUN	B
to	O	PART	O
dentine	O	NOUN	B
of	O	ADP	O
two	B-I	NUM	O
resin-based	I-I	ADJ	B
sealers	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
apical	O	ADJ	B
sealing	O	NOUN	I
ability	O	NOUN	B
and	O	CCONJ	O
adaptation	O	NOUN	B
to	O	PART	O
dentine	O	NOUN	B
of	O	ADP	O
two	B-I	NUM	O
resin-based	I-I	ADJ	B
root	I-I	NOUN	I
canal	I-I	NOUN	I
sealers	I-I	NOUN	I
.	I-I	PUNCT	O


The	B-P	DET	O
root	I-P	NOUN	B
canals	I-P	NOUN	B
of	I-P	ADP	O
55	I-P	NUM	O
human	I-P	ADJ	B
maxillary	I-P	NOUN	B
anterior	I-P	ADJ	I
teeth	I-P	NOUN	O
were	O	AUX	O
prepared	O	VERB	O
using	O	VERB	O
a	O	DET	O
step-back	O	ADJ	B
technique	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
smear	O	ADJ	B
layer	O	NOUN	I
removed	O	VERB	O
with	O	ADP	O
17	O	NUM	O
%	O	NOUN	O
ethylenediaminetetraacetic	O	ADJ	B
acid	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
teeth	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
25	O	NUM	O
teeth	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
remaining	O	VERB	O
five	O	NUM	O
teeth	O	NOUN	B
served	O	VERB	O
as	O	ADP	O
control	O	NOUN	B
.	O	PUNCT	O


Then	O	ADV	O
the	O	DET	O
teeth	O	NOUN	B
were	O	AUX	O
prepared	B-I	VERB	B
and	I-I	CCONJ	O
obturated	I-I	VERB	B
with	I-I	ADP	O
gutta-percha	I-I	NOUN	B
by	I-I	ADP	O
a	I-I	DET	O
lateral	I-I	ADJ	B
condensation	I-I	NOUN	I
and	I-I	CCONJ	O
either	I-I	CCONJ	O
AH	I-I	PROPN	B
plus	I-I	CCONJ	B
and	I-I	CCONJ	O
EndoRez	I-I	PROPN	B
used	I-I	VERB	O
as	I-I	ADP	O
a	I-I	DET	O
sealer	I-I	NOUN	B
.	I-I	PUNCT	O


Twenty	O	NUM	B
teeth	O	NOUN	B
from	O	ADP	O
each	O	DET	O
group	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
apical	O	ADJ	B
leakage	O	NOUN	O
test	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
remaining	O	VERB	O
five	O	NUM	O
teeth	O	NOUN	B
from	O	ADP	O
each	O	DET	O
group	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
examination	O	NOUN	B
under	O	ADP	O
the	O	DET	O
scanning	O	NOUN	B
electron	O	NOUN	I
microscope	O	NOUN	I
(	O	PUNCT	O
SEM	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
apical	O	ADJ	B
leakage	O	NOUN	I
test	O	NOUN	I
,	O	PUNCT	O
teeth	B-I	NOUN	B
were	I-I	AUX	O
covered	I-I	VERB	O
with	I-I	ADP	O
nail	I-I	NOUN	B
varnish	I-I	NOUN	I
and	I-I	CCONJ	O
sticky	I-I	ADJ	B
wax	I-I	NOUN	I
to	I-I	ADP	O
within	I-I	ADP	O
1	I-I	NUM	O
mm	I-I	NOUN	O
of	I-I	ADP	O
the	I-I	DET	O
apical	I-I	ADJ	B
foramen	I-I	NOUN	B
and	I-I	CCONJ	O
placed	I-I	VERB	O
in	I-I	ADP	O
2	I-I	NUM	O
%	I-I	NOUN	O
methylene	I-I	NOUN	B
blue	I-I	NOUN	I
for	I-I	ADP	O
7	I-I	NUM	O
days	I-I	NOUN	B
.	I-I	PUNCT	O


After	O	ADP	O
this	O	DET	O
period	O	NOUN	B
,	O	PUNCT	O
the	B-I	DET	O
teeth	I-I	NOUN	B
were	I-I	AUX	O
sectioned	I-I	VERB	O
longitudinally	I-I	ADV	B
and	O	CCONJ	O
apical	O	ADJ	B
leakage	O	NOUN	O
measurements	O	NOUN	B
made	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	B
value	I-OUT	NOUN	I
of	I-OUT	ADP	O
dye	I-OUT	NOUN	B
penetration	I-OUT	NOUN	I
for	I-OUT	ADP	O
AH	I-OUT	PROPN	B
plus	I-OUT	CCONJ	O
was	O	AUX	O
2.87	O	NUM	O
+/-	O	CCONJ	O
0.43	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
that	O	DET	O
of	O	ADP	O
EndoRez	B-I	PROPN	B
was	O	AUX	O
4.54	O	NUM	O
+/-	O	CCONJ	O
0.36	O	NUM	O
mm	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
mean	O	NOUN	O
of	O	ADP	O
dye	B-OUT	NOUN	B
penetration	I-OUT	NOUN	I
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
SEM	O	PROPN	B
examination	O	NOUN	B
showed	O	VERB	O
both	O	DET	O
sealers	O	NOUN	B
had	O	AUX	O
better	B-OUT	ADJ	O
adaptation	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
penetration	I-OUT	NOUN	B
in	I-OUT	ADP	O
coronal	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
middle	I-OUT	ADJ	O
thirds	I-OUT	NOUN	O
than	O	ADP	O
apical	O	ADJ	B
third	O	NOUN	O
of	O	ADP	O
root	O	NOUN	B
canal	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
apical	O	ADJ	B
third	O	NOUN	O
,	O	PUNCT	O
AH	B-I	PROPN	B
plus	I-I	CCONJ	O
was	O	AUX	O
adapted	B-OUT	VERB	O
better	I-OUT	ADV	O
adpated	O	VERB	B
to	O	PART	O
dentine	O	NOUN	B
than	O	ADP	O
EndoRez	B-I	PROPN	B
.	I-I	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
AH	B-I	PROPN	B
plus	I-I	CCONJ	O
sealer	I-I	NOUN	B
has	O	AUX	O
better	B-OUT	ADJ	O
apical	I-OUT	ADJ	B
sealing	I-OUT	NOUN	I
ability	I-OUT	NOUN	B
and	O	CCONJ	O
adaptation	O	NOUN	B
to	O	PART	O
dentine	O	NOUN	B
than	O	ADP	O
EndoRez	B-I	PROPN	B
sealer	I-I	NOUN	I
.	I-I	PUNCT	O


Internet-based	B-I	ADJ	B
program	I-I	NOUN	I
for	O	ADP	O
coping	O	VERB	B
with	O	ADP	O
cancer	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
with	O	ADP	O
hematologic	B-P	ADJ	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
Psychosocial	O	ADJ	B
patient	O	NOUN	B
care	O	NOUN	I
in	O	ADP	O
oncology	O	NOUN	B
is	O	AUX	O
no	O	ADV	O
longer	O	ADV	O
limited	O	ADJ	O
to	O	ADP	O
the	O	DET	O
inpatient	O	ADJ	B
setting	O	NOUN	O
.	O	PUNCT	O


Outpatient	O	ADJ	B
services	O	NOUN	I
are	O	AUX	O
in	O	ADP	O
demand	O	NOUN	B
.	O	PUNCT	O


Internet-based	B-I	ADJ	B
interventions	I-I	NOUN	I
could	O	AUX	O
aid	O	VERB	O
in	O	ADP	O
optimizing	O	VERB	B
service	O	NOUN	B
delivery	O	NOUN	B
across	O	ADP	O
disciplines	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
an	O	DET	O
Internet-based	O	ADJ	B
program	O	NOUN	I
for	O	ADP	O
hematologic	B-P	ADJ	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
was	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
under	O	ADP	O
field	O	NOUN	O
experimental	O	ADJ	O
conditions	O	NOUN	O
.	O	PUNCT	O


METHODS	O	VERB	O
A	O	DET	O
4-week	B-I	ADJ	O
cognitive-behavioral	I-I	ADJ	B
program	I-I	NOUN	I
for	I-I	ADP	O
coping	I-I	VERB	B
with	O	ADP	O
cancer	O	NOUN	B
was	O	AUX	O
offered	O	VERB	O
to	O	PART	O
hematologic	B-P	ADJ	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
online	I-P	ADV	O
.	I-P	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
eighty-six	I-P	NUM	O
registrants	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
an	O	DET	O
intervention	B-I	NOUN	B
group	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
105	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
waiting	B-I	NOUN	B
list	I-I	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
81	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
outcome	O	NOUN	B
measures	O	NOUN	I
,	O	PUNCT	O
'mental	B-OUT	ADJ	B
adjustment	I-OUT	NOUN	B
'	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
MAC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
'psychological	I-OUT	ADJ	B
distress	I-OUT	NOUN	I
'	I-OUT	PUNCT	I
(	I-OUT	PUNCT	O
BSI	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
registration	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Patient	B-OUT	ADJ	B
satisfaction	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
(	O	PUNCT	O
ZUF-8	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
complete-cases	O	NOUN	B
and	O	CCONJ	O
intention-to-treat	O	ADJ	B
analyses	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
registration	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
participants	O	NOUN	B
displayed	O	VERB	O
clinically	O	ADV	B
significant	O	ADJ	I
distress	O	NOUN	I
(	B-OUT	PUNCT	O
BSI	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
lacked	O	VERB	O
alternative	O	ADJ	O
access	O	NOUN	O
concerning	O	VERB	O
psychosocial	O	ADJ	B
care	O	NOUN	I
.	O	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
eleven	I-P	NUM	O
patients	I-P	NOUN	B
filled	O	VERB	B
out	O	ADP	O
the	O	DET	O
post	O	NOUN	B
questionnaire	O	NOUN	I
at	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
the	O	DET	O
waiting	O	NOUN	B
list	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
displayed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
fighting	B-OUT	VERB	B
spirit	I-OUT	NOUN	I
(	O	PUNCT	O
d	O	NOUN	O
=	O	ADJ	O
0.42	O	NUM	O
;	O	PUNCT	O
CI	O	NOUN	B
95	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
0.04	O	NUM	O
to	O	PART	O
0.80	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
intention-to-treat	O	ADJ	B
analysis	O	NOUN	I
(	O	PUNCT	O
d	O	NOUN	O
=	O	ADJ	O
0.33	O	NUM	O
;	O	PUNCT	O
CI	O	NOUN	B
95	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
0.04	O	NUM	O
to	O	PART	O
0.62	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Otherwise	O	ADV	O
,	O	PUNCT	O
no	O	DET	B
effects	O	NOUN	I
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Patient	B-OUT	ADJ	B
satisfaction	I-OUT	NOUN	I
with	O	ADP	O
the	O	DET	O
program	O	NOUN	B
was	O	AUX	O
high	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
The	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
the	O	DET	O
potential	O	ADJ	O
efficacy	O	NOUN	B
of	O	ADP	O
Internet-based	O	ADJ	B
programs	O	NOUN	I
while	O	SCONJ	O
highlighting	O	VERB	O
their	O	PRON	O
limitations	O	NOUN	B
.	O	PUNCT	O


Future	O	ADJ	O
research	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
to	O	PART	O
clarify	O	VERB	O
and	O	CCONJ	O
optimize	O	VERB	O
efficacy	O	NOUN	B
,	O	PUNCT	O
taking	O	VERB	O
different	O	ADJ	O
program	O	NOUN	B
components	O	NOUN	I
and	O	CCONJ	O
patient	O	NOUN	B
characteristics	O	NOUN	B
into	O	ADP	O
particular	O	ADJ	O
consideration	O	NOUN	O
.	O	PUNCT	O


Evolution	O	NOUN	B
of	O	ADP	O
coronary	O	ADJ	B
stenoses	O	NOUN	I
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
baseline	O	NOUN	B
severity	O	NOUN	B
--	O	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
quantitative	O	ADJ	I
angiographic	O	ADJ	I
analysis	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
coronary	I-P	ADJ	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


INTACT	O	NOUN	B
Investigators	O	NOUN	I
.	O	PUNCT	O


International	O	ADJ	B
Nifedipine	O	PROPN	B
Trial	O	PROPN	O
on	O	ADP	O
Antiatherosclerotic	O	PROPN	B
Therapy	O	PROPN	I
.	O	PUNCT	O


A	O	DET	O
correlation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
angiographic	O	ADJ	B
evolution	O	NOUN	B
of	O	ADP	O
coronary	O	ADJ	B
stenoses	O	NOUN	I
(	O	PUNCT	O
stenosis	O	NOUN	B
diameter	O	NOUN	B
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
20	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
with	O	ADP	O
morphological	O	ADJ	B
stenosis	O	NOUN	B
parameters	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
could	O	AUX	O
help	O	VERB	O
to	O	PART	O
identify	B-OUT	VERB	O
the	I-OUT	DET	O
risk	I-OUT	NOUN	B
of	I-OUT	ADP	O
progressive	I-OUT	ADJ	B
stenoses	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
data	O	NOUN	B
of	O	ADP	O
the	O	DET	O
prospective	O	ADJ	B
INTACT	O	NOUN	O
study	O	NOUN	O
(	O	PUNCT	O
International	O	PROPN	B
Nifedipine	O	PROPN	I
Trial	O	PROPN	I
on	O	ADP	O
Antiatherosclerotic	O	PROPN	B
Therapy	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
reviewed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
348	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
moderate	I-P	ADJ	B
coronary	I-P	ADJ	I
artery	I-P	NOUN	I
disease	I-P	NOUN	I
,	I-P	PUNCT	O
standardized	I-I	ADJ	B
coronary	I-I	ADJ	I
angiograms	I-I	NOUN	I
were	I-P	AUX	O
taken	I-P	VERB	O
3	I-P	NUM	O
years	I-P	NOUN	B
apart	I-P	ADV	O
and	O	CCONJ	O
were	O	AUX	O
quantitatively	O	ADV	B
analysed	O	VERB	B
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
minimal	B-OUT	ADJ	B
diameter	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
1063	O	NUM	O
preexisting	O	VERB	O
coronary	O	ADJ	B
stenoses	O	NOUN	I
compared	O	VERB	O
between	O	ADP	O
both	O	DET	O
angiograms	O	NOUN	B
were	O	AUX	O
set	O	VERB	O
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
a	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
conventional	I-OUT	ADJ	B
stenosis	I-OUT	NOUN	B
parameters	I-OUT	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Regression	O	NOUN	B
analysis	O	NOUN	I
demonstrated	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
correlation	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
changes	B-OUT	NOUN	B
in	I-OUT	ADP	O
minimal	I-OUT	ADJ	B
diameter	I-OUT	NOUN	B
with	O	ADP	O
baseline	B-OUT	NOUN	B
%	I-OUT	NOUN	O
diameter	I-OUT	NOUN	B
stenosis	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.30	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
minimal	B-OUT	ADJ	B
diameter	I-OUT	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-0.28	O	PUNCT	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
reference	B-OUT	NOUN	B
diameter	I-OUT	NOUN	I
of	I-OUT	ADP	O
stenoses	I-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-0.14	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
changes	B-OUT	NOUN	B
were	I-OUT	AUX	O
not	I-OUT	PART	O
correlated	I-OUT	VERB	B
with	O	ADP	O
stenosis	B-OUT	NOUN	B
length	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
plaque	I-OUT	NOUN	B
area	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
baseline	O	NOUN	B
parameters	O	NOUN	B
of	O	ADP	O
22	O	NUM	O
preexisting	O	VERB	O
stenoses	O	NOUN	B
progressing	B-OUT	VERB	O
to	I-OUT	ADP	O
occlusions	I-OUT	NOUN	B
differed	O	VERB	O
from	O	ADP	O
those	O	DET	O
remaining	B-OUT	VERB	O
patent	I-OUT	NOUN	B
only	O	ADV	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
the	O	DET	O
%	B-OUT	NOUN	O
diameter	I-OUT	NOUN	B
stenosis	I-OUT	NOUN	I
(	O	PUNCT	O
43	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
39	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Additional	O	ADJ	O
progression	B-OUT	NOUN	B
of	I-OUT	ADP	O
coronary	I-OUT	ADJ	B
disease	I-OUT	NOUN	I
became	O	VERB	O
manifest	O	ADJ	B
through	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
228	O	NUM	O
stenoses	B-OUT	NOUN	B
and	O	CCONJ	O
19	O	NUM	O
occlusions	B-OUT	NOUN	B
at	O	ADP	O
arterial	O	ADJ	B
sites	O	NOUN	I
free	O	ADJ	B
from	O	ADP	O
definitive	O	ADJ	O
stenoses	O	NOUN	B
in	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
angiograms	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
progression	B-OUT	NOUN	B
of	I-OUT	ADP	O
atherosclerosis	I-OUT	NOUN	B
predominantly	I-OUT	ADV	O
occurred	I-OUT	VERB	O
in	O	ADP	O
mild	O	ADJ	B
preexisting	O	ADJ	O
coronary	O	ADJ	B
stenoses	O	NOUN	I
and	O	CCONJ	O
developed	O	VERB	O
at	O	ADP	O
previously	O	ADV	O
angiographically	O	ADV	B
normal	O	ADJ	O
sites	O	NOUN	O
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
conventional	O	ADJ	O
angiographic	O	ADJ	B
parameters	O	NOUN	B
analysed	O	VERB	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
identify	O	VERB	O
individual	O	ADJ	O
arterial	O	ADJ	B
sites	O	NOUN	I
with	O	ADP	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
progression	O	NOUN	B
,	O	PUNCT	O
definition	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
angiographic	O	ADJ	B
parameters	O	NOUN	B
or	O	CCONJ	O
application	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
techniques	O	NOUN	B
seem	O	VERB	O
mandatory	O	ADJ	O
to	O	ADP	O
this	O	DET	O
end	O	NOUN	O
.	O	PUNCT	O


Heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
variability	I-OUT	NOUN	B
and	O	CCONJ	O
QT	B-OUT	NOUN	B
dispersion	I-OUT	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
subclinical	I-P	ADJ	B
hypothyroidism	I-P	NOUN	I
.	I-P	PUNCT	O


UNLABELLED	O	VERB	B
The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
subclinical	B-P	ADJ	B
hypothyroidism	I-P	NOUN	I
(	I-P	PUNCT	O
SH	I-P	NOUN	B
)	I-P	PUNCT	O
on	O	ADP	O
cardiovascular	O	ADJ	B
autonomic	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
ventricular	O	ADJ	B
repolarization	O	NOUN	I
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
yet	O	ADV	O
elucidated	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
dispersion	O	NOUN	B
of	O	ADP	O
QT	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
i.e	O	ADV	O
.	O	PUNCT	O


an	O	DET	O
index	O	NOUN	O
of	O	ADP	O
inhomogeneity	O	NOUN	B
of	O	ADP	O
repolarization	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
variability	O	NOUN	I
(	O	PUNCT	O
HRV	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
i.e	O	ADV	O
.	O	PUNCT	O


a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
autonomic	O	ADJ	B
modulation	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
SH	B-P	NOUN	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
study	O	NOUN	B
included	O	VERB	O
42	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
29	I-P	NUM	O
women	I-P	NOUN	B
and	I-P	CCONJ	O
13	I-P	NUM	O
men	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
53.2+/-14.2	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
body	I-P	NOUN	B
surface	I-P	NOUN	I
area	I-P	NOUN	I
1.76+/-0.14	I-P	NUM	O
m2	I-P	NOUN	O
)	I-P	PUNCT	O
with	I-P	ADP	O
SH	I-P	NOUN	B
,	I-P	PUNCT	O
as	I-P	ADP	O
judged	I-P	VERB	O
by	I-P	ADP	O
elevated	I-P	ADJ	B
serum	I-P	NOUN	O
TSH	I-P	NOUN	O
levels	I-P	NOUN	B
(	I-P	PUNCT	O
>	I-P	NOUN	O
3.6	I-P	NUM	O
mIU/l	I-P	NOUN	O
;	I-P	PUNCT	O
range	I-P	NOUN	O
,	I-P	PUNCT	O
3.8-12.0	I-P	NUM	O
)	I-P	PUNCT	O
and	I-P	CCONJ	O
normal	I-P	ADJ	B
free	I-P	ADJ	I
thyroid	I-P	NOUN	I
hormones	I-P	NOUN	I
(	I-P	PUNCT	O
FT4	I-P	NOUN	B
and	I-P	CCONJ	O
FT3	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
30	I-P	NUM	O
euthyroid	I-P	ADJ	B
volunteer	I-P	NOUN	B
.	I-P	PUNCT	O


Subjects	B-P	NOUN	B
with	I-P	ADP	O
cardiac	I-P	ADJ	B
,	I-P	PUNCT	O
metabolic	I-P	ADJ	B
,	I-P	PUNCT	O
neurological	I-P	ADJ	B
disease	I-P	NOUN	I
or	I-P	CCONJ	O
any	I-P	DET	O
other	I-P	ADJ	O
systemic	I-P	ADJ	B
disease	I-P	NOUN	I
that	I-P	PRON	O
could	I-P	AUX	O
affect	I-P	VERB	O
autonomic	I-P	ADJ	B
activity	I-P	NOUN	I
were	I-P	AUX	O
excluded	I-P	VERB	O
from	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
SH	I-P	NOUN	B
and	O	CCONJ	O
control	O	ADJ	B
subjects	O	NOUN	I
underwent	O	VERB	O
a	O	DET	O
full	O	ADJ	O
history	O	NOUN	B
,	O	PUNCT	O
physical	O	ADJ	B
examination	O	NOUN	I
,	O	PUNCT	O
standard	O	ADJ	B
12-lead	B-I	NOUN	I
ECG	I-I	PROPN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
24-h	I-I	ADV	O
ambulatory	I-I	ADJ	B
ECG	I-I	PROPN	B
monitoring	I-I	NOUN	B
.	I-I	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
L-thyroxine	B-I	NOUN	B
on	O	ADP	O
QT	O	NOUN	B
dispersion	O	NOUN	I
and	O	CCONJ	O
HRV	O	NOUN	B
,	O	PUNCT	O
15	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
SH	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
therapy	O	NOUN	B
with	O	ADP	O
L-thyroxine	B-I	NOUN	B
.	I-I	PUNCT	O


All	O	DET	O
the	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
at	O	ADP	O
enrolment	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Patients	B-P	NOUN	B
with	I-P	ADP	O
SH	I-P	NOUN	B
showed	O	VERB	O
higher	O	ADJ	B
QT	B-OUT	PROPN	B
dispersion	I-OUT	NOUN	O
and	O	CCONJ	O
lower	B-OUT	ADJ	O
HRV	I-OUT	NOUN	B
measures	I-OUT	NOUN	B
than	O	ADP	O
healthy	O	ADJ	B
controls	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
for	O	ADP	O
all	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
SH	O	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
standard	B-OUT	ADJ	B
deviation	I-OUT	NOUN	I
of	I-OUT	ADP	O
N-Ns	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
SDNN	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
was	O	AUX	O
negatively	O	ADV	O
related	O	ADJ	O
to	O	PART	O
TSH	O	NOUN	B
(	O	PUNCT	O
r=-0.42	O	NOUN	O
,	O	PUNCT	O
P=0.006	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
while	O	SCONJ	O
low	B-OUT	ADJ	B
frequency	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
LF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
/high	I-OUT	ADJ	B
frequency	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
HF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
ratio	I-OUT	NOUN	B
was	O	AUX	O
positively	O	ADV	O
related	O	ADJ	O
to	O	PART	O
TSH	O	NOUN	B
(	O	PUNCT	O
r=0.42	O	NOUN	O
,	O	PUNCT	O
P=0.006	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
SH	B-P	NOUN	B
patients	I-P	NOUN	B
both	O	CCONJ	O
QT	B-OUT	NOUN	B
dispersion	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
QTc	I-OUT	NOUN	B
dispersion	I-OUT	NOUN	I
were	O	AUX	O
positively	O	ADV	O
related	O	ADJ	O
to	O	PART	O
TSH	O	NOUN	B
(	O	PUNCT	O
r=0.64	O	NOUN	O
and	O	CCONJ	O
r=0.63	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
for	O	ADP	O
both	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
L-tiroxine	B-I	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
QT	B-OUT	NOUN	B
dispersion	I-OUT	NOUN	O
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
HRV	B-OUT	NOUN	B
parameters	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
SH	O	NOUN	B
can	O	AUX	O
alter	O	VERB	O
autonomic	O	ADJ	B
modulation	O	NOUN	I
of	O	ADP	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
and	O	CCONJ	O
cause	O	VERB	O
increased	O	VERB	B
inhomogeneity	O	NOUN	B
of	O	ADP	O
ventricular	O	ADJ	B
recovery	O	NOUN	I
times	O	NOUN	I
.	O	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
early	O	ADJ	O
L-thyroxine	B-I	NOUN	B
treatment	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
advised	O	VERB	O
not	O	PART	O
only	O	ADV	O
to	O	PART	O
prevent	O	VERB	B
progression	O	NOUN	B
to	O	PART	O
overt	O	ADJ	B
hypothyroidism	O	NOUN	B
but	O	CCONJ	O
also	O	ADV	O
to	O	PART	O
improve	O	VERB	O
abnormal	O	ADJ	B
cardiac	O	ADJ	B
autonomic	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
ventricular	O	ADJ	B
repolarization	O	NOUN	I
inhomogeneity	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Prevention	O	PROPN	B
of	O	ADP	O
vascular	B-OUT	ADJ	B
complications	I-OUT	NOUN	O
following	O	VERB	O
cerebral	O	ADJ	B
ischemia	O	NOUN	I
of	O	ADP	O
arterial	O	ADJ	B
origin	O	NOUN	I
;	O	PUNCT	O
the	O	DET	O
ESPRIT	O	NOUN	B
trial	O	NOUN	B
:	O	PUNCT	O
mild	B-I	ADJ	B
anticoagulant	I-I	ADJ	B
therapy	I-I	NOUN	I
,	O	PUNCT	O
combination	O	NOUN	B
treatment	O	NOUN	I
with	O	ADP	O
acetylsalicylic	B-I	ADJ	B
acid	I-I	NOUN	I
plus	I-I	CCONJ	I
dipyridamole	I-I	NOUN	B
or	I-I	CCONJ	O
treatment	I-I	NOUN	B
with	I-I	ADP	O
acetylsalicylic	I-I	ADJ	B
acid	I-I	NOUN	I
alone	I-I	ADV	O
?	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
European	O	ADJ	B
and	O	CCONJ	O
Australian	O	ADJ	B
Stroke	O	PROPN	O
Prevention	O	PROPN	O
in	O	ADP	O
Reversible	O	ADJ	B
Ischaemia	O	PROPN	I
Trial	O	PROPN	I
(	O	PUNCT	O
ESPRIT	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
randomised	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
in	O	ADP	O
which	O	DET	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cerebral	I-P	ADJ	B
ischaemia	I-P	NOUN	I
of	I-P	ADP	O
arterial	I-P	ADJ	B
origin	I-P	NOUN	I
will	O	AUX	O
be	O	AUX	O
randomised	O	VERB	B
between	O	ADP	O
oral	B-I	ADJ	B
anticoagulation	I-I	NOUN	I
(	O	PUNCT	O
international	O	ADJ	B
normalized	O	VERB	I
ratio	O	NOUN	I
(	O	PUNCT	O
INR	O	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
2.0-3.0	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
acetylsalicylic	B-I	ADJ	B
acid	I-I	NOUN	I
(	O	PUNCT	O
in	O	ADP	O
any	O	DET	O
dose	O	NOUN	B
between	O	ADP	O
30	O	NUM	O
and	O	CCONJ	O
325	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
)	O	PUNCT	O
plus	O	CCONJ	O
dipyridamole	B-I	NOUN	B
(	O	PUNCT	O
400	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
and	O	CCONJ	O
acetylsalicylic	B-I	ADJ	B
acid	I-I	NOUN	I
only	O	ADV	O
(	O	PUNCT	O
in	O	ADP	O
any	O	DET	O
dose	O	NOUN	B
between	O	ADP	O
30	O	NUM	O
and	O	CCONJ	O
325	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
planned	B-P	VERB	B
to	I-P	PART	O
enroll	I-P	VERB	O
4500	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
mean	I-P	NOUN	O
follow-up	I-P	NOUN	B
of	I-P	ADP	O
three	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


Primary	O	ADJ	B
outcome	O	NOUN	I
is	O	AUX	O
the	O	DET	O
composite	B-OUT	ADJ	B
event	I-OUT	NOUN	B
of	I-OUT	ADP	O
vascular	I-OUT	ADJ	B
death	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
stroke	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
myocardial	I-OUT	ADJ	B
infarction	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
major	I-OUT	ADJ	O
bleeding	I-OUT	ADJ	B
complication	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
outcome	O	NOUN	B
assessment	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
blinded	O	VERB	B
.	O	PUNCT	O


ESPRIT	O	NOUN	B
is	O	AUX	O
an	O	DET	O
international	B-P	ADJ	B
,	I-P	PUNCT	O
multicentre	I-P	NOUN	B
study	I-P	NOUN	I
in	I-P	ADP	O
which	I-P	DET	O
60-80	I-P	NUM	O
hospitals	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
Netherlands	I-P	PROPN	B
and	I-P	CCONJ	O
other	I-P	ADJ	O
countries	I-P	NOUN	B
in	I-P	ADP	O
Europe	I-P	PROPN	B
and	I-P	CCONJ	O
Australia	I-P	PROPN	B
will	I-P	AUX	O
participate	I-P	VERB	B
.	I-P	PUNCT	O


Efficacy	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
barrier	B-I	NOUN	B
cream	I-I	NOUN	I
and	I-I	CCONJ	O
its	I-I	PRON	O
vehicle	I-I	NOUN	B
as	O	ADP	O
protective	O	ADJ	B
measures	O	NOUN	I
against	O	ADP	O
occupational	B-OUT	ADJ	B
irritant	I-OUT	ADJ	I
contact	I-OUT	NOUN	B
dermatitis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
actual	O	ADJ	O
advantage	O	NOUN	O
of	O	ADP	O
barrier	B-I	NOUN	B
creams	I-I	NOUN	B
over	O	ADP	O
bland	O	ADJ	B
emollients	O	NOUN	I
for	O	ADP	O
skin	O	NOUN	B
protection	O	NOUN	I
is	O	AUX	O
still	O	ADV	O
hotly	O	ADV	O
debated	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blinded	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
newly-introduced	O	ADJ	B
barrier	B-I	NOUN	I
cream	I-I	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
moisturizing	B-I	NOUN	B
vehicle	I-I	NOUN	I
were	O	AUX	O
compared	O	VERB	B
regarding	O	VERB	O
their	O	PRON	O
skin	B-OUT	NOUN	B
compatibility	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
efficacy	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
resulting	I-OUT	VERB	O
acceptance	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
2	B-P	NUM	O
panels	I-P	NOUN	O
of	I-P	ADP	O
25	I-P	NUM	O
hospital	I-P	NOUN	B
nurses	I-P	NOUN	I
with	I-P	ADP	O
mild	I-P	ADJ	O
signs	I-P	NOUN	O
of	I-P	ADP	O
skin	I-P	NOUN	B
irritation	I-P	NOUN	I
were	O	AUX	O
asked	O	VERB	O
to	O	PART	O
use	O	VERB	O
1	O	NUM	O
of	O	ADP	O
the	O	DET	O
test	O	NOUN	B
products	O	NOUN	I
provided	O	VERB	O
(	B-I	PUNCT	O
verum	I-I	NOUN	B
or	I-I	CCONJ	O
vehicle	I-I	NOUN	B
)	I-I	PUNCT	O
over	I-I	ADP	O
a	I-I	DET	O
period	I-I	NOUN	B
of	I-I	ADP	O
4	I-I	NUM	O
weeks	I-I	NOUN	B
.	I-I	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
both	O	DET	O
types	O	NOUN	O
of	O	ADP	O
preparations	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
weekly	O	ADV	O
by	O	ADP	O
clinical	O	ADJ	B
examination	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
instrumental	O	ADJ	B
assessment	O	NOUN	I
of	O	ADP	O
bioengineering	O	VERB	B
parameters	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
barrier	B-I	NOUN	B
cream	I-I	NOUN	B
and	O	CCONJ	O
vehicle	B-I	NOUN	B
.	I-I	PUNCT	O


In	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
clinical	B-OUT	ADJ	B
skin	I-OUT	NOUN	I
status	I-OUT	NOUN	I
improved	O	VERB	B
and	O	CCONJ	O
stratum	B-OUT	NOUN	B
corneum	I-OUT	NOUN	I
hydration	I-OUT	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
preparations	O	NOUN	B
were	O	AUX	O
tolerated	B-OUT	VERB	B
and	I-OUT	CCONJ	O
accepted	I-OUT	VERB	B
well	I-OUT	ADV	O
,	O	PUNCT	O
thus	O	ADV	O
showing	O	VERB	O
both	O	CCONJ	O
skin	B-OUT	NOUN	B
protection	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
skin	I-OUT	NOUN	B
care	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


These	O	DET	O
results	O	NOUN	B
contribute	O	VERB	O
to	O	ADP	O
the	O	DET	O
debate	O	NOUN	O
as	O	ADP	O
to	O	ADP	O
whether	O	SCONJ	O
a	O	DET	O
strict	O	ADJ	O
distinction	O	NOUN	O
between	O	ADP	O
"	O	PUNCT	O
skin	O	NOUN	B
care	O	NOUN	I
"	O	PUNCT	O
and	O	CCONJ	O
"	O	PUNCT	O
skin	O	NOUN	B
protection	O	NOUN	I
"	O	PUNCT	O
products	O	NOUN	B
is	O	AUX	O
justified	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
vehicle	B-I	NOUN	B
alone	O	ADV	O
is	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
positively	O	ADV	B
influencing	O	VERB	O
skin	O	NOUN	B
status	O	NOUN	I
.	O	PUNCT	O


Emphasis	O	NOUN	O
must	O	AUX	O
be	O	AUX	O
laid	O	VERB	O
on	O	ADP	O
regular	O	ADJ	B
,	O	PUNCT	O
frequent	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
correct	O	ADJ	O
application	O	NOUN	B
of	O	ADP	O
a	O	DET	O
product	O	NOUN	B
for	O	ADP	O
it	O	PRON	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
assessing	O	VERB	O
the	O	DET	O
health	B-OUT	NOUN	B
economics	I-OUT	NOUN	I
of	I-OUT	ADP	O
realtime	I-OUT	NOUN	B
teledermatology	I-OUT	NOUN	B
compared	I-I	VERB	O
with	I-I	ADP	O
conventional	I-I	ADJ	B
care	I-I	NOUN	I
:	I-I	PUNCT	O
an	O	DET	O
urban	B-P	ADJ	B
versus	I-P	CCONJ	O
rural	I-P	ADJ	B
perspective	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
measure	O	VERB	B
the	O	DET	O
cost-effectiveness	B-OUT	NOUN	B
of	I-OUT	ADP	O
realtime	I-OUT	NOUN	B
teledermatology	I-OUT	NOUN	B
compared	O	VERB	O
with	O	ADP	O
conventional	B-I	ADJ	O
outpatient	I-I	ADJ	B
dermatology	I-I	NOUN	I
care	I-I	NOUN	I
for	O	ADP	O
patients	B-P	NOUN	B
from	I-P	ADP	O
urban	I-P	ADJ	B
and	I-P	CCONJ	O
rural	I-P	ADJ	B
areas	I-P	NOUN	I
.	I-P	PUNCT	O


One	O	NUM	O
urban	O	ADJ	B
and	O	CCONJ	O
one	O	NUM	O
rural	O	ADJ	B
health	O	NOUN	O
centre	O	NOUN	O
were	O	AUX	O
linked	O	VERB	O
to	O	PART	O
a	O	DET	O
regional	O	ADJ	B
hospital	O	NOUN	I
in	O	ADP	O
Northern	O	PROPN	B
Ireland	O	PROPN	I
by	O	ADP	O
ISDN	O	NOUN	B
at	O	ADP	O
128	O	NUM	O
kbit/s	O	NOUN	O
.	O	PUNCT	O


Over	B-P	ADP	O
two	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
274	I-P	NUM	O
patients	I-P	NOUN	B
required	I-P	VERB	O
a	I-P	DET	O
hospital	I-P	NOUN	B
outpatient	I-P	ADJ	I
dermatology	I-P	NOUN	I
referral	I-P	NOUN	I
--	I-P	PUNCT	O
126	I-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
46	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
a	O	DET	O
telemedicine	B-I	NOUN	B
consultation	I-I	NOUN	I
and	O	CCONJ	O
148	O	NUM	O
(	O	PUNCT	O
54	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
to	O	PART	O
a	O	DET	O
conventional	B-I	ADJ	B
hospital	I-I	NOUN	B
outpatient	I-I	ADJ	I
consultation	I-I	NOUN	I
.	I-I	PUNCT	O


Of	O	ADP	O
those	O	DET	O
seen	O	VERB	O
by	O	ADP	O
telemedicine	B-I	NOUN	B
,	O	PUNCT	O
61	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
registered	O	VERB	O
with	O	ADP	O
an	O	DET	O
urban	O	ADJ	B
practice	O	NOUN	I
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
71	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
those	O	DET	O
seen	O	VERB	O
conventionally	B-I	ADV	B
.	I-I	PUNCT	O


The	O	DET	O
clinical	B-OUT	ADJ	B
outcomes	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
consultation	B-OUT	NOUN	B
were	O	AUX	O
similar	B-OUT	ADJ	O
--	I-OUT	PUNCT	O
almost	I-OUT	ADV	O
half	O	DET	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
managed	O	VERB	O
after	O	ADP	O
a	O	DET	O
single	O	ADJ	O
consultation	O	NOUN	B
with	O	ADP	O
the	O	DET	O
dermatologist	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
observed	B-OUT	VERB	O
marginal	I-OUT	ADJ	B
cost	I-OUT	NOUN	B
per	I-OUT	ADP	O
patient	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
realtime	B-I	NOUN	B
teledermatology	I-I	NOUN	O
consultation	I-I	NOUN	O
was	O	AUX	O
52.85	O	NUM	O
Pounds	O	NOUN	O
for	O	ADP	O
those	O	DET	O
in	O	ADP	O
urban	O	ADJ	B
areas	O	NOUN	I
and	O	CCONJ	O
59.93	O	NUM	O
Pounds	O	NOUN	O
per	O	ADP	O
patient	O	NOUN	B
for	O	ADP	O
those	O	DET	O
from	O	ADP	O
rural	O	ADJ	B
areas	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
observed	B-OUT	VERB	O
marginal	I-OUT	ADJ	B
cost	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
conventional	B-I	ADJ	B
consultation	I-I	NOUN	B
was	O	AUX	O
47.13	O	NUM	O
Pounds	O	PROPN	O
for	O	ADP	O
urban	B-P	ADJ	B
patients	I-P	NOUN	B
and	O	CCONJ	O
48.77	O	NUM	B
Pounds	O	PROPN	I
for	O	ADP	O
rural	B-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
total	B-OUT	NOUN	O
observed	I-OUT	VERB	O
costs	I-OUT	NOUN	B
of	O	ADP	O
teledermatology	B-OUT	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
the	O	DET	O
costs	O	NOUN	B
of	O	ADP	O
conventional	B-I	ADJ	B
care	I-I	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
urban	O	ADJ	B
and	O	CCONJ	O
rural	O	ADJ	B
areas	O	NOUN	I
,	O	PUNCT	O
mainly	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
fixed	O	ADJ	O
equipment	O	NOUN	B
costs	O	NOUN	O
.	O	PUNCT	O


Sensitivity	O	NOUN	B
analysis	O	NOUN	I
using	O	VERB	O
a	O	DET	O
real-world	O	ADJ	O
scenario	O	NOUN	O
showed	O	VERB	O
that	O	SCONJ	O
in	B-P	ADP	O
urban	I-P	ADJ	B
areas	I-P	NOUN	I
the	O	DET	O
average	B-OUT	ADJ	B
costs	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
telemedicine	B-I	NOUN	B
and	O	CCONJ	O
conventional	B-I	ADJ	B
consultations	I-I	NOUN	B
were	O	AUX	O
about	O	ADP	O
equal	O	ADJ	O
,	O	PUNCT	O
while	O	SCONJ	O
in	B-P	ADP	O
rural	I-P	ADJ	B
areas	I-P	NOUN	I
the	O	DET	O
average	O	ADJ	B
cost	O	NOUN	B
of	O	ADP	O
the	O	DET	O
telemedicine	B-I	NOUN	B
consultation	I-I	NOUN	O
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
conventional	B-I	ADJ	B
consultation	I-I	NOUN	B
.	I-I	PUNCT	O


Nutrient	O	ADJ	B
retention	O	NOUN	B
in	O	ADP	O
preterm	B-P	NOUN	B
infants	I-P	NOUN	I
fed	I-P	VERB	O
standard	I-P	ADJ	O
infant	I-P	NOUN	B
formulas	I-P	NOUN	B
.	I-P	PUNCT	O


Our	O	PRON	O
purpose	O	NOUN	O
was	O	AUX	O
to	O	PART	O
compare	B-OUT	VERB	B
nitrogen	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
mineral	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
zinc	I-OUT	NOUN	B
balance	I-OUT	NOUN	B
in	O	ADP	O
preterm	B-P	NOUN	B
infants	I-P	NOUN	I
fed	I-P	VERB	O
standard	I-I	ADJ	O
infant	I-I	NOUN	B
formulas	I-I	NOUN	B
,	I-I	PUNCT	O
Similac	I-I	PROPN	B
With	I-I	ADP	O
Iron	I-I	PROPN	B
and	I-I	CCONJ	O
Similac	I-I	PROPN	B
With	I-I	ADP	O
Whey	I-I	PROPN	B
+	I-I	CCONJ	O
Iron	I-I	NOUN	B
.	I-I	PUNCT	O


Nitrogen	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
magnesium	I-OUT	NOUN	B
balances	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
during	O	ADP	O
both	O	DET	O
feeds	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
met	O	VERB	O
estimated	O	VERB	O
fetal	O	ADJ	B
requirements	O	NOUN	O
.	O	PUNCT	O


Infants	O	NOUN	B
absorbed	O	VERB	B
and	O	CCONJ	O
retained	O	VERB	B
(	O	PUNCT	O
milligrams	O	NOUN	O
per	O	ADP	O
kilogram	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
)	O	PUNCT	O
more	O	ADJ	O
calcium	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
phosphorus	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
zinc	I-OUT	NOUN	B
when	O	SCONJ	O
fed	O	VERB	B
Similac	B-I	PROPN	O
With	I-I	ADP	O
Iron	I-I	PROPN	B
.	I-I	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
retention	B-OUT	NOUN	B
of	I-OUT	ADP	O
calcium	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
phosphorus	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
both	I-OUT	DET	O
formulas	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
zinc	I-OUT	NOUN	B
(	O	PUNCT	O
Similac	O	PROPN	B
With	O	ADP	O
Whey	O	PROPN	B
+	O	CCONJ	O
Iron	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
inadequate	O	ADJ	B
to	O	PART	O
meet	O	VERB	O
estimated	O	VERB	O
fetal	O	ADJ	B
requirements	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
the	O	DET	O
rapidly	B-P	ADV	O
growing	I-P	VERB	O
preterm	I-P	NOUN	B
infant	I-P	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
is	O	AUX	O
already	O	ADV	O
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
rickets	O	NOUN	B
and	O	CCONJ	O
zinc	O	NOUN	B
deficiency	O	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
fed	O	VERB	B
either	O	DET	O
formula	O	NOUN	B
on	O	ADP	O
discharge	O	NOUN	B
from	O	ADP	O
the	O	DET	O
newborn	O	ADJ	B
nursery	O	NOUN	B
.	O	PUNCT	O


CT	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
MRI	I-OUT	NOUN	B
measurements	I-OUT	NOUN	B
of	I-OUT	ADP	O
tibial	I-OUT	ADJ	B
tubercle-trochlear	I-OUT	ADJ	O
groove	I-OUT	NOUN	O
distances	I-OUT	NOUN	B
are	O	AUX	O
not	O	PART	O
equivalent	O	ADJ	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
patellar	I-P	ADJ	B
instability	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	ADJ	O
Tibial	B-OUT	ADJ	B
tubercle-trochlear	I-OUT	ADJ	O
groove	I-OUT	NOUN	O
distance	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
TT-TG	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
is	O	AUX	O
a	O	DET	O
commonly	O	ADV	O
used	O	VERB	O
measurement	O	NOUN	B
for	O	ADP	O
surgical	O	ADJ	B
decision	O	NOUN	I
making	O	VERB	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
patellofemoral	I-P	ADJ	B
malalignment	I-P	NOUN	I
and	I-P	CCONJ	O
instability	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
measurement	O	NOUN	B
has	O	AUX	O
historically	O	ADV	O
been	O	AUX	O
performed	O	VERB	O
utilizing	O	VERB	O
axial	O	ADJ	B
computed	O	VERB	I
tomography	O	NOUN	I
(	O	PUNCT	O
CT	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


More	O	ADV	O
recently	O	ADV	O
,	O	PUNCT	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
MRI	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
as	O	ADP	O
an	O	DET	O
equivalent	O	ADJ	B
method	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
has	O	AUX	O
not	O	PART	O
yet	O	ADV	O
been	O	AUX	O
fully	O	ADV	O
validated	O	VERB	O
.	O	PUNCT	O


PURPOSE	O	VERB	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
reliability	O	NOUN	B
of	O	ADP	O
TT-TG	B-OUT	NOUN	B
distance	I-OUT	NOUN	O
measurements	I-OUT	NOUN	B
on	O	ADP	O
both	O	CCONJ	O
MRI	O	NOUN	B
and	O	CCONJ	O
CT	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
measurements	O	NOUN	B
are	O	AUX	O
interchangeable	O	ADJ	O
with	O	ADP	O
one	O	NUM	O
another	O	DET	O
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
Cohort	O	NOUN	B
study	O	NOUN	I
(	O	PUNCT	O
diagnosis	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
Level	O	NOUN	B
of	O	ADP	I
evidence	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


METHODS	O	VERB	O
All	B-P	DET	O
patients	I-P	NOUN	B
with	I-P	ADP	O
patellar	I-P	ADJ	B
instability	I-P	NOUN	I
who	I-P	PRON	O
underwent	I-P	VERB	O
both	I-P	CCONJ	O
CT	I-I	NOUN	B
and	I-I	CCONJ	O
MRI	I-I	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
knee	I-P	NOUN	B
from	I-P	ADP	O
2003	I-P	NUM	O
to	I-P	PART	O
2011	I-P	NUM	O
were	I-P	AUX	O
included	I-P	VERB	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
59	I-P	NUM	O
knees	I-P	NOUN	B
in	I-P	ADP	O
54	I-P	NUM	O
patients	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Two	O	NUM	O
fellowship-trained	O	ADJ	B
musculoskeletal	O	ADJ	B
radiologists	O	NOUN	I
measured	O	VERB	B
the	O	DET	O
TT-TG	B-OUT	NOUN	B
distances	I-OUT	NOUN	B
for	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
by	O	ADP	O
CT	B-I	NOUN	B
and	I-I	CCONJ	O
MRI	I-I	NOUN	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
blinded	O	VERB	B
fashion	O	NOUN	I
.	O	PUNCT	O


Interobserver	B-OUT	ADJ	B
reliability	I-OUT	NOUN	I
was	O	AUX	O
calculated	O	VERB	O
between	O	ADP	O
radiologists	O	NOUN	B
for	O	ADP	O
both	O	CCONJ	O
imaging	O	NOUN	B
modalities	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
intermethod	B-OUT	NOUN	B
reliability	I-OUT	NOUN	I
was	O	AUX	O
calculated	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
imaging	O	NOUN	B
modalities	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
reported	O	VERB	O
using	O	VERB	O
intraclass	O	ADJ	B
correlation	O	NOUN	I
coefficients	O	NOUN	I
(	O	PUNCT	O
ICCs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Bland-Altman	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
59	O	NUM	O
knees	O	NOUN	B
had	O	AUX	O
a	O	DET	O
mean	O	ADJ	O
TT-TG	B-OUT	NOUN	B
distance	I-OUT	NOUN	B
of	O	ADP	O
16.9	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
8.3-25.8	O	NUM	O
mm	O	PROPN	O
)	O	PUNCT	O
by	O	ADP	O
CT	O	NOUN	B
and	O	CCONJ	O
14.7	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
1.5-25.1	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
by	O	ADP	O
MRI	O	NOUN	B
.	O	PUNCT	O


Interobserver	B-OUT	ADJ	B
reliability	I-OUT	NOUN	I
between	O	ADP	O
the	O	DET	O
radiologists	O	NOUN	B
was	O	AUX	O
considered	O	VERB	O
excellent	O	ADJ	B
for	O	ADP	O
both	O	CCONJ	O
CT	B-I	NOUN	B
and	O	CCONJ	O
MRI	B-I	NOUN	B
(	O	PUNCT	O
ICC	O	NOUN	B
=	O	ADJ	O
0.777	O	NUM	O
and	O	CCONJ	O
0.843	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


When	O	SCONJ	O
comparing	O	VERB	B
CT	O	NOUN	B
to	O	ADP	O
MRI	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
ICC	B-OUT	PROPN	B
was	O	AUX	O
considered	O	VERB	O
only	O	ADV	O
fair	O	ADJ	O
for	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
raters	O	NOUN	B
(	O	PUNCT	O
0.532	O	NUM	O
and	O	CCONJ	O
0.539	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Eleven	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
19	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
TT-TG	B-OUT	NOUN	B
distance	I-OUT	NOUN	B
of	O	ADP	O
≥20	O	VERB	O
mm	O	NOUN	O
on	O	ADP	O
CT	O	NOUN	B
preoperatively	O	ADV	B
and	O	CCONJ	O
underwent	B-OUT	VERB	O
distal	I-OUT	ADJ	B
realignment	I-OUT	NOUN	I
by	O	ADP	O
tibial	O	ADJ	B
tubercle	O	NOUN	I
osteotomy	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
surgical	O	ADJ	B
subgroup	O	NOUN	I
,	O	PUNCT	O
the	B-OUT	DET	O
mean	I-OUT	ADJ	O
TT-TG	I-OUT	NOUN	B
distance	I-OUT	NOUN	B
was	O	AUX	O
22.5	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
19.8-25.8	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
by	O	ADP	O
CT	O	NOUN	B
and	O	CCONJ	O
only	O	ADV	O
18.7	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
14.4-22.8	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
by	O	ADP	O
MRI	O	NOUN	B
for	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
difference	O	NOUN	O
of	O	ADP	O
3.80	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
The	B-OUT	DET	O
TT-TG	I-OUT	NOUN	B
distance	I-OUT	NOUN	B
can	O	AUX	O
be	O	AUX	O
measured	O	VERB	B
with	O	ADP	O
excellent	B-OUT	ADJ	B
interrater	I-OUT	NOUN	B
reliability	I-OUT	NOUN	I
on	O	ADP	O
both	O	CCONJ	O
MRI	O	NOUN	B
and	O	CCONJ	O
CT	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
values	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
these	O	DET	O
2	O	NUM	O
tests	O	NOUN	B
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
interchangeable	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
taken	O	VERB	O
into	O	ADP	O
consideration	O	NOUN	O
when	O	SCONJ	O
MRI	O	NOUN	B
is	O	AUX	O
used	O	VERB	O
for	O	ADP	O
surgical	O	ADJ	B
planning	O	NOUN	I
because	O	SCONJ	O
MRI	O	NOUN	B
may	O	AUX	O
underestimate	O	VERB	O
the	B-OUT	DET	O
TT-TG	I-OUT	NOUN	B
distance	I-OUT	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
CT	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
platelet	B-I	NOUN	B
suppressant	I-I	NOUN	I
,	I-I	PUNCT	O
anticoagulant	I-I	ADJ	B
and	I-I	CCONJ	O
fibrinolytic	I-I	ADJ	B
therapy	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
recurrent	I-P	ADJ	B
venous	I-P	ADJ	B
thrombosis	I-P	NOUN	I
.	I-P	PUNCT	O


Phase-dependent	B-OUT	ADJ	B
modulation	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
soleus	B-OUT	NOUN	B
H-reflex	I-OUT	NOUN	B
during	O	ADP	O
rhythmical	B-I	ADJ	B
arm	I-OUT	NOUN	I
swing	I-OUT	NOUN	I
in	I-P	ADP	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
modulation	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
soleus	I-OUT	NOUN	B
H-reflex	I-OUT	NOUN	B
during	O	ADP	O
rhythmic	B-I	ADJ	B
arm	I-I	NOUN	I
swing	I-I	NOUN	I
in	I-P	ADP	O
humans	I-P	NOUN	B
.	I-P	PUNCT	O


Significant	O	ADJ	B
depression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
soleus	O	NOUN	B
H-reflex	B-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
when	O	SCONJ	O
subjects	B-P	NOUN	B
swung	I-P	VERB	O
their	I-P	PRON	O
ipsilateral	I-P	ADJ	B
arms	I-P	NOUN	O
or	I-P	CCONJ	O
both	I-P	DET	O
arms	I-P	NOUN	O
reciprocally	I-P	ADV	O
during	I-P	ADP	O
testing	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
soleus	B-OUT	NOUN	B
H-reflex	I-OUT	ADJ	B
depression	I-OUT	NOUN	I
appeared	O	VERB	O
directly	O	ADV	O
proportional	O	ADJ	B
to	O	ADP	O
the	O	DET	O
speed	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arm	O	NOUN	B
swing	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
depression	B-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
conditioning-testing	O	ADJ	B
intervals	O	NOUN	I
of	O	ADP	O
400	O	NUM	O
,	O	PUNCT	O
500	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
600	O	NUM	O
msec	O	NOUN	O
during	O	ADP	O
the	O	DET	O
ipsilateral	B-I	ADJ	B
backward	I-I	ADJ	O
arm	I-I	NOUN	O
swing	I-I	NOUN	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ipsilateral	B-I	ADJ	B
arm	I-I	NOUN	O
forward	I-I	ADJ	O
swing	I-I	NOUN	O
.	I-I	PUNCT	O


This	O	DET	O
phase	O	NOUN	B
of	O	ADP	O
depression	B-OUT	NOUN	B
partially	O	ADV	O
overlapped	O	VERB	O
the	O	DET	O
phase	O	NOUN	B
of	O	ADP	O
depression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
soleus	O	NOUN	B
H-reflex	O	NOUN	B
during	O	ADP	O
walking	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
modulation	O	NOUN	B
during	O	ADP	O
arm	O	NOUN	B
swing	O	NOUN	I
was	O	AUX	O
not	O	PART	O
exactly	O	ADV	O
the	O	DET	O
same	O	ADJ	O
as	O	ADP	O
that	O	DET	O
during	O	ADP	O
walking	O	VERB	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
ipsilateral	B-OUT	ADJ	B
arm	I-OUT	NOUN	O
swing	I-OUT	NOUN	O
may	O	AUX	O
partially	O	ADV	O
affect	O	VERB	O
the	O	DET	O
depression	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
soleus	I-OUT	NOUN	B
H-reflex	I-OUT	NOUN	B
during	O	ADP	O
the	O	DET	O
arm	O	NOUN	B
swing	O	NOUN	I
phase	O	NOUN	I
of	O	ADP	I
walking	O	NOUN	I
but	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
responsible	O	ADJ	O
for	O	ADP	O
depression	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
soleus	I-OUT	NOUN	B
H-reflex	I-OUT	NOUN	B
throughout	O	ADP	O
the	O	DET	O
entire	O	ADJ	B
walking	O	NOUN	I
cycle	O	NOUN	I
.	O	PUNCT	O


Prevalence	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
outcome	O	NOUN	I
of	O	ADP	O
cervicitis	B-OUT	NOUN	B
of	I-P	ADP	O
unknown	I-P	ADJ	O
etiology	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Mucopurulent	O	ADJ	B
cervicitis	O	NOUN	I
(	O	PUNCT	O
MPC	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
clinical	O	ADJ	B
syndrome	O	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
mucopurulent	O	ADJ	B
discharge	O	NOUN	I
from	O	ADP	O
the	O	DET	O
cervix	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
inflammation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
a	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
,	O	PUNCT	O
multicenter	O	ADJ	B
study	O	NOUN	I
designed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
placebo	B-I	NOUN	B
versus	O	CCONJ	O
empiric	B-I	ADJ	B
antibiotic	I-I	ADJ	O
treatment	I-I	NOUN	B
for	O	ADP	O
clinical	O	ADJ	B
cure	O	NOUN	I
of	O	ADP	O
MPC	B-OUT	NOUN	B
of	O	ADP	O
unknown	O	ADJ	O
etiology	O	NOUN	B
at	O	ADP	O
2-month	O	ADJ	O
follow-up	O	NOUN	B
.	O	PUNCT	O


Unfortunately	O	ADV	O
,	O	PUNCT	O
enrollment	O	NOUN	B
was	O	AUX	O
terminated	O	VERB	B
because	O	SCONJ	O
of	O	ADP	O
low	O	ADJ	B
accrual	O	NOUN	B
of	O	ADP	O
women	B-P	NOUN	B
with	I-P	ADP	O
cervicitis	I-P	NOUN	B
of	I-P	ADP	O
unknown	I-P	ADJ	O
etiology	I-P	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
important	O	ADJ	O
prevalence	O	NOUN	B
and	O	CCONJ	O
outcome	O	NOUN	B
data	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Five	B-P	NUM	O
hundred	I-P	NUM	O
seventy-seven	I-P	NUM	O
women	I-P	NOUN	B
were	I-P	AUX	O
screened	I-P	VERB	B
for	I-P	ADP	O
MPC	I-P	NOUN	B
.	I-P	PUNCT	O


Women	B-P	NOUN	B
with	I-P	ADP	O
MPC	I-P	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
the	O	DET	O
treatment	O	NOUN	B
or	O	CCONJ	O
placebo	B-I	ADJ	B
arm	O	NOUN	I
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
2	O	NUM	O
arms	O	NOUN	O
were	O	AUX	O
evaluated	O	VERB	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
etiology	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
clinical	I-OUT	ADJ	B
cure	I-OUT	NOUN	I
rates	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AEs	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
rates	I-OUT	NOUN	B
of	I-OUT	ADP	O
pelvic	I-OUT	ADJ	B
inflammatory	I-OUT	ADJ	I
disease	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
thirty-one	I-P	NUM	O
(	I-P	PUNCT	O
23	I-P	NUM	O
%	I-P	NOUN	O
[	I-P	PUNCT	O
131/577	I-P	PROPN	O
]	I-P	PUNCT	O
)	I-P	PUNCT	O
screened	I-P	VERB	B
women	I-P	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
MPC	O	PROPN	B
.	O	PUNCT	O


Eighty-seven	B-P	NUM	O
were	I-P	AUX	O
enrolled	I-P	VERB	O
and	O	CCONJ	O
randomized	O	ADJ	B
.	O	PUNCT	O


After	O	ADP	O
excluding	O	VERB	O
women	O	NOUN	B
with	O	ADP	O
sexually	O	ADV	B
transmitted	O	VERB	I
infections	O	NOUN	I
and	O	CCONJ	O
other	O	ADJ	O
exclusions	O	NOUN	B
,	O	PUNCT	O
61	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
53/87	O	NUM	O
)	O	PUNCT	O
had	O	AUX	O
cervicitis	B-OUT	NOUN	B
of	O	ADP	O
unknown	O	ADJ	O
etiology	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
overall	B-OUT	ADJ	O
clinical	I-OUT	ADJ	B
failure	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
was	O	AUX	O
30	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
10/33	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
clinical	B-OUT	ADJ	B
cure	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
was	O	AUX	O
only	O	ADV	O
24	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
8/33	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Rates	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
arms	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
24	O	NUM	O
gastrointestinal	B-OUT	ADJ	B
AEs	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
arm	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
1	O	NUM	O
AE	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
arm	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
More	O	ADJ	O
than	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
of	O	ADP	O
MPC	O	NOUN	B
were	O	AUX	O
of	O	ADP	O
unknown	O	ADJ	O
etiology	O	NOUN	B
.	O	PUNCT	O


Clinical	B-OUT	ADJ	B
cure	I-OUT	NOUN	I
rates	I-OUT	NOUN	B
for	O	ADP	O
the	O	DET	O
placebo	B-I	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
arms	O	NOUN	I
were	O	AUX	O
extremely	O	ADV	O
low	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
most	O	ADJ	O
women	O	NOUN	B
concluding	O	VERB	O
the	O	DET	O
study	O	NOUN	B
with	O	ADP	O
a	O	DET	O
partial	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


Gastrointestinal	B-OUT	ADJ	B
AEs	I-OUT	NOUN	I
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
arm	O	NOUN	I
.	O	PUNCT	O


Gender	B-P	NOUN	B
differences	I-P	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
nicotine	B-I	NOUN	B
replacement	I-I	NOUN	B
therapy	I-I	NOUN	I
:	I-I	PUNCT	O
objective	O	ADJ	B
and	O	CCONJ	O
subjective	O	ADJ	O
indexes	O	NOUN	B
of	O	ADP	O
tobacco	B-P	NOUN	B
withdrawal	I-P	NOUN	I
.	I-P	PUNCT	O


K.	O	PROPN	B
A.	O	NOUN	I
Perkins	O	PROPN	I
(	O	PUNCT	O
1996	O	NUM	O
)	O	PUNCT	O
recently	O	ADV	O
proposed	O	VERB	O
that	O	SCONJ	O
nicotine	B-I	NOUN	B
reinforcement	I-I	NOUN	B
controls	I-P	VERB	I
smoking	I-P	VERB	B
to	I-P	PART	O
a	I-P	DET	O
greater	I-P	ADJ	O
degree	I-P	NOUN	B
among	I-P	ADP	O
men	I-P	NOUN	B
than	I-P	ADP	O
women	I-P	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
consequently	O	ADV	O
,	O	PUNCT	O
nicotine	B-I	NOUN	B
replacement	I-I	NOUN	O
therapy	I-I	NOUN	O
(	I-I	PUNCT	O
NRT	I-I	NOUN	B
)	I-I	PUNCT	O
during	O	ADP	O
smoking	O	NOUN	B
cessation	O	NOUN	I
should	O	AUX	O
benefit	O	VERB	O
men	O	NOUN	B
more	O	ADJ	O
than	O	ADP	O
women	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
tested	O	VERB	B
this	O	DET	O
hypothesis	O	NOUN	B
.	O	PUNCT	O


Polysomnographic	O	ADJ	B
measures	O	NOUN	B
of	O	ADP	O
sleep	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
self-report	I-OUT	ADJ	B
indexes	I-OUT	NOUN	B
of	O	ADP	O
tobacco	O	NOUN	B
withdrawal	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
pre-	O	ADJ	B
and	O	CCONJ	O
postcessation	O	NOUN	B
from	O	ADP	O
an	O	DET	O
active	B-P	ADJ	B
nicotine	I-I	NOUN	B
patch	I-I	NOUN	B
group	I-P	NOUN	I
and	I-P	CCONJ	O
a	I-P	DET	O
placebo	I-I	ADJ	B
patch	I-I	NOUN	O
group	I-P	NOUN	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
clinical	O	ADJ	O
trial	O	NOUN	O
(	B-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
34	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Objective	O	ADJ	B
sleep	O	NOUN	B
parameters	O	NOUN	B
supported	O	VERB	O
Perkins	O	PROPN	B
's	O	PART	I
hypothesis	O	NOUN	B
and	O	CCONJ	O
indicated	O	VERB	O
that	O	SCONJ	O
among	O	ADP	O
women	O	NOUN	B
,	O	PUNCT	O
NRT	B-I	PROPN	B
may	O	AUX	O
be	O	AUX	O
less	O	ADV	O
effective	O	ADJ	B
at	O	ADP	O
suppressing	B-OUT	VERB	B
certain	I-OUT	ADJ	O
withdrawal	I-OUT	NOUN	B
responses	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
men	O	NOUN	B
and	O	CCONJ	O
may	B-OUT	AUX	O
produce	I-OUT	VERB	O
some	I-OUT	DET	O
iatrogenic	I-OUT	ADJ	B
effects	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Valid	O	ADJ	B
and	O	CCONJ	O
reliable	O	ADJ	O
self-report	O	ADJ	B
measures	O	NOUN	B
of	O	ADP	O
withdrawal	B-OUT	NOUN	B
did	I-OUT	AUX	O
not	I-OUT	PART	O
reveal	I-OUT	VERB	O
gender	I-OUT	NOUN	B
differences	I-OUT	NOUN	B
in	I-OUT	ADP	O
response	I-OUT	NOUN	B
to	I-OUT	PART	O
NRT	I-OUT	PROPN	B
.	I-OUT	PUNCT	O


Predicting	O	VERB	B
Overall	B-OUT	PROPN	B
Survival	I-OUT	PROPN	I
After	I-OUT	ADP	O
Stereotactic	I-OUT	PROPN	B
Ablative	I-OUT	PROPN	I
Radiation	I-OUT	PROPN	I
Therapy	I-OUT	PROPN	I
in	O	ADP	O
Early-Stage	O	PROPN	B
Lung	O	PROPN	B
Cancer	O	PROPN	I
:	O	PUNCT	O
Development	O	PROPN	B
and	O	CCONJ	O
External	O	PROPN	B
Validation	O	PROPN	B
of	O	ADP	O
the	O	DET	O
Amsterdam	O	PROPN	B
Prognostic	O	PROPN	I
Model	O	PROPN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
A	O	DET	O
prognostic	O	ADJ	B
model	O	NOUN	I
for	O	ADP	O
5-year	O	ADJ	O
overall	O	ADJ	B
survival	O	NOUN	I
(	O	PUNCT	O
OS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
consisting	O	VERB	O
of	O	ADP	O
recursive	O	ADJ	B
partitioning	O	NOUN	I
analysis	O	NOUN	I
(	O	PUNCT	O
RPA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
nomogram	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
developed	O	VERB	O
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
early-stage	I-P	ADJ	B
non-small	I-P	NOUN	B
cell	I-P	NOUN	I
lung	I-P	NOUN	I
cancer	I-P	NOUN	I
(	I-P	PUNCT	O
ES-NSCLC	I-P	NOUN	B
)	I-P	PUNCT	O
treated	I-P	VERB	B
with	I-P	ADP	I
stereotactic	I-I	ADJ	B
ablative	I-I	ADJ	I
radiation	I-I	NOUN	I
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
SABR	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
MATERIALS	O	VERB	O
A	B-P	DET	O
primary	I-P	ADJ	O
dataset	I-P	NOUN	B
of	I-P	ADP	O
703	I-P	NUM	O
ES-NSCLC	I-P	NOUN	B
SABR	I-I	NOUN	B
patients	I-P	NOUN	B
was	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
a	O	DET	O
training	O	NOUN	B
(	O	PUNCT	O
67	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
internal	O	ADJ	B
validation	O	NOUN	B
(	O	PUNCT	O
33	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
dataset	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
former	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
21	O	NUM	O
unique	O	ADJ	B
parameters	O	NOUN	B
consisting	O	VERB	O
of	O	ADP	O
patient	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
treatment	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
tumor	I-OUT	NOUN	B
factors	I-OUT	NOUN	I
were	O	AUX	O
entered	O	VERB	O
into	O	ADP	O
an	O	DET	O
RPA	O	NOUN	B
model	O	NOUN	B
to	O	PART	O
predict	O	VERB	O
OS	O	NOUN	B
.	O	PUNCT	O


Univariate	O	NOUN	B
and	O	CCONJ	O
multivariate	O	ADJ	B
models	O	NOUN	I
were	O	AUX	O
constructed	O	VERB	O
for	O	ADP	O
RPA-selected	O	ADJ	B
factors	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
their	O	PRON	O
relationship	O	NOUN	B
with	O	ADP	O
OS	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
nomogram	O	NOUN	B
for	O	ADP	O
OS	O	NOUN	B
was	O	AUX	O
constructed	O	VERB	O
based	O	VERB	O
on	O	ADP	O
factors	O	NOUN	B
significant	O	ADJ	B
in	O	ADP	O
multivariate	O	ADJ	B
modeling	O	NOUN	I
and	O	CCONJ	O
validated	O	VERB	O
with	O	ADP	O
calibration	O	NOUN	B
plots	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
RPA	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
nomogram	O	NOUN	B
were	O	AUX	O
externally	O	ADV	B
validated	O	VERB	O
in	O	ADP	O
independent	O	ADJ	B
surgical	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
193	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
SABR	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
543	O	NUM	O
)	O	PUNCT	O
datasets	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
RPA	B-OUT	NOUN	B
identified	I-OUT	VERB	B
2	I-OUT	NUM	O
distinct	I-OUT	ADJ	O
risk	I-OUT	NOUN	B
classes	I-OUT	NOUN	I
based	I-OUT	VERB	O
on	I-OUT	ADP	O
tumor	I-OUT	NOUN	B
diameter	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
age	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
World	I-OUT	PROPN	B
Health	I-OUT	PROPN	I
Organization	I-OUT	PROPN	I
performance	I-OUT	NOUN	I
status	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Charlson	I-OUT	PROPN	B
comorbidity	I-OUT	NOUN	I
index	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
RPA	O	NOUN	B
had	O	AUX	O
moderate	O	ADJ	B
discrimination	O	NOUN	B
in	O	ADP	O
SABR	O	NOUN	B
datasets	O	NOUN	B
(	O	PUNCT	O
c-index	O	NOUN	B
range	O	NOUN	I
:	O	PUNCT	O
0.52-0.60	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
of	O	ADP	O
limited	O	ADJ	O
value	O	NOUN	O
in	O	ADP	O
the	O	DET	O
surgical	O	ADJ	B
validation	O	NOUN	O
cohort	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
nomogram	O	NOUN	B
predicting	O	VERB	O
OS	O	NOUN	B
included	O	VERB	O
smoking	O	NOUN	B
history	O	NOUN	I
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
RPA-identified	O	ADJ	B
factors	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
RPA	O	NOUN	B
,	O	PUNCT	O
validation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nomogram	O	NOUN	B
performed	O	VERB	O
well	O	ADV	O
in	O	ADP	O
internal	O	ADJ	B
validation	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
0.97	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
external	O	ADJ	B
SABR	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
0.79	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
surgical	O	ADJ	B
cohorts	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
=	O	ADJ	O
0.91	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
Amsterdam	B-OUT	PROPN	B
prognostic	I-OUT	ADJ	B
model	I-OUT	NOUN	I
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
externally	O	ADV	B
validated	O	VERB	O
prognostication	O	NOUN	B
tool	O	NOUN	I
for	O	ADP	O
OS	O	NOUN	B
in	O	ADP	O
ES-NSCLC	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
SABR	O	NOUN	B
available	O	ADJ	O
to	O	PART	O
individualize	O	VERB	B
patient	O	NOUN	B
decision	O	NOUN	B
making	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
nomogram	O	NOUN	B
retained	O	VERB	O
strong	O	ADJ	O
performance	O	NOUN	B
across	O	ADP	O
surgical	O	ADJ	B
and	O	CCONJ	O
SABR	O	PROPN	B
external	O	ADJ	O
validation	O	NOUN	B
datasets	O	NOUN	B
.	O	PUNCT	O


RPA	B-OUT	NOUN	B
performance	I-OUT	NOUN	B
was	O	AUX	O
poor	O	ADJ	B
in	O	ADP	O
surgical	O	ADJ	B
patients	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
2	O	NUM	O
different	O	ADJ	O
distinct	O	ADJ	O
patient	O	NOUN	B
populations	O	NOUN	O
are	O	AUX	O
being	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
these	O	DET	O
2	O	NUM	O
effective	O	ADJ	B
modalities	O	NOUN	B
.	O	PUNCT	O


Partial-area	B-P	ADJ	B
method	I-P	NOUN	I
in	I-P	ADP	O
bioequivalence	I-P	NOUN	B
assessment	O	NOUN	B
:	O	PUNCT	O
naproxen	B-I	NOUN	B
.	I-I	PUNCT	O


Regulatory	O	ADJ	B
authorities	O	NOUN	I
require	O	VERB	O
demonstration	O	NOUN	O
of	O	ADP	O
bioequivalence	B-P	NOUN	B
through	O	ADP	O
comparisons	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
pharmacokinetic	O	ADJ	B
parameters	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
area	B-OUT	NOUN	B
under	I-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
concentration-time	I-OUT	NOUN	O
curve	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
AUC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
maximum	I-OUT	ADJ	B
plasma	I-OUT	NOUN	B
concentration	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
Cmax	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	B-OUT	DET	O
time	I-OUT	NOUN	O
to	I-OUT	PART	O
reach	I-OUT	VERB	O
peak	I-OUT	NOUN	B
concentration	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
Tmax	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	O	DET	O
applicability	O	NOUN	B
and	O	CCONJ	O
validity	O	NOUN	B
of	O	ADP	O
regulatory	O	ADJ	B
requirements	O	NOUN	O
have	O	AUX	O
been	O	AUX	O
widely	O	ADV	O
criticized	O	VERB	O
on	O	ADP	O
statistical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
relevance	O	NOUN	O
grounds	O	NOUN	O
.	O	PUNCT	O


For	O	ADP	O
most	O	ADV	O
noncomplicated	O	ADJ	B
absorption	O	NOUN	B
models	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
AUC	B-OUT	PROPN	B
correlates	O	VERB	O
well	O	ADV	O
with	O	ADP	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
absorption	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
nonlinear	O	ADJ	B
models	O	NOUN	I
of	O	ADP	O
absorption	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
mechanisms	O	NOUN	B
involving	O	VERB	O
recycling	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
drugs	O	NOUN	B
with	O	ADP	O
long	O	ADJ	B
half-life	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
total	O	ADJ	O
AUC	B-OUT	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
zero	O	NUM	O
to	O	PART	O
infinity	O	NOUN	B
)	O	PUNCT	O
can	O	AUX	O
give	O	VERB	O
erroneous	O	ADJ	B
and	O	CCONJ	O
clinically	O	ADV	B
irrelevant	O	ADJ	I
results	O	NOUN	B
since	O	SCONJ	O
the	O	DET	O
area	O	NOUN	B
is	O	AUX	O
mostly	O	ADV	O
determined	O	VERB	O
by	O	ADP	O
elimination	O	NOUN	B
phase	O	NOUN	B
or	O	CCONJ	O
by	O	ADP	O
recycling	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
calculation	O	NOUN	B
of	O	ADP	O
total	O	ADJ	O
AUC	B-OUT	NOUN	B
also	O	ADV	O
involves	O	VERB	O
prolonged	O	ADJ	B
sampling	O	NOUN	B
,	O	PUNCT	O
adding	O	VERB	O
to	O	ADP	O
the	O	DET	O
cost	O	NOUN	B
and	O	CCONJ	O
risks	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
bioequivalence	O	NOUN	B
studies	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
Cmax	B-OUT	NOUN	B
or	I-OUT	CCONJ	O
Tmax	I-OUT	NOUN	B
as	O	ADP	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
rate	O	NOUN	B
of	O	ADP	O
absorption	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
correlate	O	VERB	B
with	O	ADP	O
clinical	O	ADJ	B
relevance	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
widely	O	ADV	O
criticized	O	VERB	O
on	O	ADP	O
logical	O	ADJ	B
,	O	PUNCT	O
technical	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
statistical	O	ADJ	B
grounds	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
drugs	O	NOUN	B
used	O	VERB	O
on	O	ADP	O
a	O	DET	O
multiple-dose	O	ADJ	B
basis	O	NOUN	O
,	O	PUNCT	O
Cmax	B-OUT	NOUN	B
and	O	CCONJ	O
Tmax	B-OUT	PROPN	B
evaluations	O	NOUN	B
become	O	VERB	O
redundant	O	ADJ	O
since	O	SCONJ	O
the	O	DET	O
average	O	ADJ	B
plateau	B-OUT	NOUN	B
concentration	I-OUT	NOUN	B
is	O	AUX	O
not	O	PART	O
affected	O	VERB	O
by	O	ADP	O
these	O	DET	O
parameters	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
resolve	O	VERB	O
the	O	DET	O
drawbacks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
traditional	O	ADJ	O
methodology	O	NOUN	B
of	O	ADP	O
bioequivalence	O	NOUN	B
evaluation	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
partial	O	ADJ	B
areas	O	NOUN	O
in	O	ADP	O
lieu	O	NOUN	O
of	O	ADP	O
total	O	ADJ	O
AUC	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
Tmax	I-OUT	PROPN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Cmax	I-OUT	NOUN	B
is	O	AUX	O
suggested	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
investigates	O	VERB	B
the	O	DET	O
logic	O	NOUN	B
and	O	CCONJ	O
robustness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
partial-area	B-P	ADJ	B
method	I-P	NOUN	I
in	I-P	ADP	O
establishing	I-P	VERB	O
bioequivalence	I-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
5h	B-OUT	NOUN	B
AUC	I-OUT	NOUN	B
is	O	AUX	O
a	O	DET	O
more	O	ADV	O
relevant	O	ADJ	B
parameter	O	NOUN	B
to	O	PART	O
establish	O	VERB	O
naproxen	B-I	NOUN	B
bioequivalence	O	NOUN	B
than	O	ADP	O
AUCinf	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


We	O	PRON	O
recommend	O	VERB	O
against	O	ADP	O
using	O	VERB	O
symmetrical	O	ADJ	B
confidence	O	NOUN	I
intervals	O	NOUN	I
and	O	CCONJ	O
report	O	VERB	B
excellent	O	ADJ	B
agreement	O	NOUN	O
among	O	ADP	O
several	O	ADJ	O
methods	O	NOUN	B
of	O	ADP	O
calculating	O	VERB	O
confidence	B-OUT	NOUN	B
intervals	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
probability	I-OUT	NOUN	B
values	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
nonparametric	I-OUT	ADJ	B
tests	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
single-point	B-OUT	ADJ	B
short-term	I-OUT	ADJ	B
AUC	I-OUT	NOUN	B
is	O	AUX	O
a	O	DET	O
better	O	ADJ	O
indicator	O	NOUN	B
of	O	ADP	O
the	O	DET	O
bioequivalence	O	NOUN	B
of	O	ADP	O
generic	O	ADJ	B
products	O	NOUN	I
than	O	ADP	O
the	O	DET	O
total	O	ADJ	O
AUC	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
Cmax	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Tmax	I-OUT	PROPN	B
as	O	ADP	O
required	O	VERB	O
currently	O	ADV	O
by	O	ADP	O
the	O	DET	O
regulatory	O	ADJ	B
authorities	O	NOUN	I
.	O	PUNCT	O


Propofol	B-I	NOUN	B
and	I-I	CCONJ	O
midazolam	I-I	NOUN	B
act	O	VERB	O
synergistically	O	ADV	B
in	O	ADP	O
combination	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
interactions	O	NOUN	B
between	O	ADP	O
i.v	B-I	NOUN	O
.	I-I	PUNCT	O


propofol	B-I	NOUN	B
and	I-I	CCONJ	O
midazolam	I-I	NOUN	B
for	O	ADP	O
induction	B-P	NOUN	B
of	I-P	ADP	O
anaesthesia	I-P	NOUN	O
in	I-P	ADP	O
200	I-P	NUM	O
unpremedicated	I-P	ADJ	O
female	I-P	ADJ	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
gynaecological	I-P	ADJ	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


Using	O	VERB	O
end-points	O	NOUN	B
of	O	ADP	O
"	B-OUT	PUNCT	O
hypnosis	I-OUT	NOUN	B
"	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
loss	I-OUT	NOUN	B
of	I-OUT	ADP	I
response	I-OUT	NOUN	I
to	I-OUT	ADP	O
verbal	I-OUT	ADJ	B
command	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	O	CCONJ	O
"	B-OUT	PUNCT	O
anaesthesia	I-OUT	NOUN	B
"	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
loss	I-OUT	NOUN	B
of	I-OUT	ADP	I
response	I-OUT	NOUN	I
to	I-OUT	PART	O
a	I-OUT	DET	O
5-s	I-OUT	ADJ	O
transcutaneous	I-OUT	ADJ	B
tetanic	I-OUT	ADJ	B
stimulus	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
we	O	PRON	O
determined	O	VERB	O
dose-response	O	ADJ	B
curves	O	NOUN	I
for	O	ADP	O
propofol	B-I	NOUN	B
and	I-I	CCONJ	O
midazolam	I-I	NOUN	B
alone	I-I	ADV	O
and	I-I	CCONJ	O
in	I-I	ADP	O
combination	I-I	NOUN	B
.	I-I	PUNCT	O


For	O	ADP	O
hypnosis	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
synergistic	I-OUT	ADJ	B
interaction	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
combination	O	NOUN	B
having	O	VERB	O
1.44	O	NUM	O
times	O	NOUN	O
the	O	DET	O
potency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
individual	O	ADJ	B
agents	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
midazolam	B-I	NOUN	B
failed	O	VERB	B
to	O	PART	O
produce	O	VERB	O
anaesthesia	B-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
range	O	NOUN	O
used	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
propofol	B-I	NOUN	B
required	I-OUT	VERB	O
to	I-OUT	PART	O
produce	I-OUT	VERB	O
anaesthesia	I-OUT	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
52	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
midazolam	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
arterial	B-OUT	ADJ	B
pressure	I-OUT	NOUN	I
at	I-OUT	ADP	O
induction	I-OUT	NOUN	B
was	O	AUX	O
the	O	DET	O
same	O	ADJ	O
for	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
as	O	ADP	O
for	O	ADP	O
the	O	DET	O
individual	O	ADJ	B
agents	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
synergism	O	NOUN	B
was	O	AUX	O
not	O	PART	O
clear	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
interaction	O	NOUN	B
at	O	ADP	O
CNS	O	NOUN	B
GABAA	O	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


Single-dose	O	ADJ	B
tranexamic	B-I	ADJ	B
acid	I-I	NOUN	I
reduces	O	VERB	B
postoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
after	O	ADP	O
coronary	B-I	ADJ	B
surgery	I-I	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
aspirin	I-I	NOUN	B
until	I-P	ADP	O
surgery	I-P	NOUN	B
.	I-P	PUNCT	O


UNLABELLED	O	NOUN	B
Tranexamic	B-I	ADJ	B
acid	I-I	NOUN	I
reduces	O	VERB	B
postoperative	O	ADJ	B
bleeding	O	NOUN	I
after	O	ADP	O
coronary	B-I	ADJ	B
artery	I-I	NOUN	I
bypass	I-I	NOUN	I
grafting	I-I	NOUN	I
.	I-I	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
effects	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
tranexamic	B-I	ADJ	B
acid	I-I	NOUN	I
given	O	VERB	O
immediately	O	ADV	O
before	O	ADP	O
cardiopulmonary	B-I	ADJ	B
bypass	I-I	NOUN	I
(	I-I	PUNCT	O
CPB	I-I	NOUN	B
)	I-I	PUNCT	O
in	I-P	ADP	O
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
aspirin	I-I	NOUN	B
until	I-P	ADP	O
the	I-P	DET	O
day	I-P	NOUN	B
before	I-P	ADP	O
surgery	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blinded	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
parallel-group	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Eighty	B-P	NUM	B
patients	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
and	I-P	CCONJ	O
divided	I-P	VERB	B
into	I-P	ADP	O
two	I-P	NUM	O
groups	I-P	NOUN	B
:	I-P	PUNCT	O
one	I-P	NUM	O
group	I-P	NOUN	B
received	I-P	VERB	O
tranexamic	I-I	ADJ	B
acid	I-I	NOUN	I
30	I-I	NUM	O
mg/kg	I-I	NOUN	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
one	I-I	NUM	O
group	I-I	NOUN	B
received	I-I	VERB	O
placebo	I-I	NOUN	B
(	I-I	PUNCT	O
0.9	I-I	NUM	O
%	I-I	NOUN	O
NaCl	I-I	NOUN	B
)	I-I	PUNCT	O
as	I-I	ADP	O
a	I-I	DET	O
bolus	I-I	NOUN	B
injection	I-I	NOUN	I
before	I-I	ADP	O
CPB	I-I	NOUN	B
.	I-I	PUNCT	O


Postoperative	B-OUT	ADJ	B
blood	I-OUT	NOUN	O
loss	I-OUT	NOUN	O
was	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
16	O	NUM	O
h.	O	NOUN	O
Transfusions	B-OUT	NOUN	B
of	I-OUT	ADP	O
blood	I-OUT	NOUN	B
products	I-OUT	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
the	O	DET	O
whole	O	ADJ	B
hospital	O	NOUN	I
stay	O	NOUN	I
.	O	PUNCT	O


Transfusions	O	NOUN	B
of	O	ADP	O
packed	O	ADJ	B
red	O	ADJ	I
cells	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
when	O	SCONJ	O
the	O	DET	O
hematocrit	B-OUT	NOUN	B
value	I-OUT	NOUN	I
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
during	O	ADP	O
CPB	O	NOUN	B
and	O	CCONJ	O
less	O	ADJ	O
than	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


The	B-P	DET	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
tranexamic	I-I	ADJ	B
acid	I-I	NOUN	I
group	I-P	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
less	O	ADV	O
postoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	O
compared	O	VERB	B
with	O	ADP	O
the	B-P	DET	O
patients	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
placebo	I-I	ADJ	B
group	I-P	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
[	O	PUNCT	O
SD	O	NOUN	B
]	O	PUNCT	O
)	O	PUNCT	O
(	O	PUNCT	O
475	O	NUM	O
[	O	PUNCT	O
274	O	NUM	O
]	O	PUNCT	O
mL	O	NOUN	O
versus	O	CCONJ	O
713	O	NUM	O
[	O	PUNCT	O
243	O	NUM	O
]	O	PUNCT	O
mL	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
effective	O	ADJ	B
inhibition	B-OUT	NOUN	B
of	I-OUT	ADP	O
fibrinolysis	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
patients	B-P	NOUN	B
receiving	I-P	VERB	O
tranexamic	I-I	ADJ	B
acid	I-I	NOUN	I
.	I-I	PUNCT	O


Tranexamic	B-I	ADJ	B
acid	I-I	NOUN	I
reduces	O	VERB	B
postoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
in	O	ADP	O
coronary	B-I	ADJ	B
artery	I-I	NOUN	I
bypass	I-I	NOUN	I
grafting	I-I	NOUN	I
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
aspirin	O	NOUN	B
until	O	ADP	O
the	O	DET	O
day	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


IMPLICATIONS	O	NOUN	B
Continuation	O	NOUN	B
of	O	ADP	O
aspirin	B-I	NOUN	B
medication	O	NOUN	B
until	O	ADP	O
the	O	DET	O
day	O	NOUN	B
before	O	ADP	O
coronary	B-I	ADJ	B
artery	I-I	NOUN	I
bypass	I-I	NOUN	I
grafting	I-I	NOUN	I
may	O	AUX	O
increase	O	VERB	B
postoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
tranexamic	B-I	ADJ	B
acid	I-I	NOUN	I
(	O	PUNCT	O
30	O	NUM	O
mg/kg	O	NOUN	O
)	O	PUNCT	O
immediately	O	ADV	O
before	O	ADP	O
cardiopulmonary	O	NOUN	B
bypass	O	NOUN	I
significantly	O	ADV	O
reduced	O	VERB	O
postoperative	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
and	O	CCONJ	O
inhibited	O	VERB	B
fibrinolysis	B-OUT	NOUN	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Pseudoephedrine	B-I	NOUN	B
and	O	CCONJ	O
preexercise	B-I	NOUN	B
feeding	I-I	NOUN	B
:	I-I	PUNCT	O
influence	O	NOUN	B
on	O	ADP	O
performance	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
preexercise	O	NOUN	B
food	O	NOUN	B
intake	O	NOUN	I
on	O	ADP	O
plasma	B-OUT	NOUN	B
pseudoephedrine	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
PSE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
concentrations	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
subsequent	I-OUT	ADJ	O
high-intensity	I-OUT	ADJ	B
exercise	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
urinary	O	ADJ	B
PSE	O	NOUN	B
concentrations	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
under	O	ADP	O
the	O	DET	O
same	O	ADJ	O
conditions	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
present	O	ADJ	O
threshold	O	NOUN	B
of	O	ADP	O
the	O	DET	O
World	O	PROPN	B
Anti-Doping	O	PROPN	I
Agency	O	PROPN	I
(	O	PUNCT	O
WADA	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	VERB	O
Ten	B-P	NUM	O
highly	I-P	ADV	O
trained	I-P	VERB	O
male	I-P	NOUN	B
cyclists	I-P	NOUN	B
and	I-P	CCONJ	O
triathletes	I-P	NOUN	B
(	I-P	PUNCT	O
age	I-P	NOUN	B
=	I-P	ADJ	O
30.6	I-P	NUM	O
±	I-P	NOUN	O
6.6	I-P	NUM	O
yr	I-P	NOUN	O
,	I-P	PUNCT	O
body	I-P	NOUN	B
mass	I-P	NOUN	I
[	I-P	PUNCT	O
BM	I-P	NOUN	B
]	I-P	PUNCT	O
=	I-P	ADJ	O
72.9	I-P	NUM	O
±	I-P	SYM	O
5.1	I-P	NUM	O
kg	I-P	NOUN	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
V˙O2max	I-P	NOUN	B
=	I-P	VERB	O
64.8	I-P	NUM	O
±	I-P	NOUN	O
4.5	I-P	NUM	O
mL·kg·min	I-P	NOUN	B
;	I-P	PUNCT	O
mean	I-P	VERB	O
±	O	NOUN	O
SD	O	NOUN	B
)	O	PUNCT	O
undertook	O	VERB	O
four	O	NUM	O
cycling	O	NOUN	B
time	O	NOUN	I
trials	O	NOUN	I
(	O	PUNCT	O
TT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
each	O	DET	O
requiring	O	VERB	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
set	O	VERB	O
amount	O	NOUN	B
of	O	ADP	O
work	O	NOUN	O
(	O	PUNCT	O
7	O	NUM	O
kJ·kg	O	NOUN	O
BM	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
shortest	O	ADV	B
possible	O	ADJ	O
time	O	NOUN	O
.	O	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
randomized	B-I	VERB	B
into	I-I	ADP	O
a	I-I	DET	O
fed	I-I	VERB	B
or	I-I	CCONJ	O
nonfed	I-I	ADJ	B
condition	I-I	NOUN	B
and	I-I	CCONJ	O
orally	I-I	ADV	B
ingested	I-I	VERB	B
2.8	I-I	NUM	O
mg·kg	I-I	NOUN	O
BM	I-I	NOUN	B
of	I-I	ADP	O
PSE	I-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
placebo	I-I	NOUN	B
(	I-I	PUNCT	O
PLA	I-I	NOUN	B
)	I-I	PUNCT	O
90	I-I	NUM	O
min	I-I	NOUN	O
before	I-I	ADP	O
exercise	I-I	NOUN	B
;	I-I	PUNCT	O
in	I-I	ADP	O
the	I-I	DET	O
fed	I-I	VERB	B
trials	I-I	NOUN	B
,	I-I	PUNCT	O
they	I-I	PRON	O
consumed	I-I	VERB	O
a	I-I	DET	O
meal	I-I	NOUN	B
providing	I-I	VERB	O
1.5	I-I	NUM	O
g·kg	I-I	NOUN	B
BM	O	NOUN	B
of	O	ADP	O
CHO	O	NOUN	B
.	O	PUNCT	O


Venous	O	ADJ	B
blood	O	NOUN	I
was	O	AUX	O
sampled	O	VERB	B
at	O	ADP	O
30	O	NUM	O
,	O	PUNCT	O
50	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
70	O	NUM	O
min	O	NOUN	B
and	O	CCONJ	O
pre-warm-up	O	ADV	B
and	O	CCONJ	O
postexercise	O	NOUN	B
for	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
PSE	O	NOUN	B
and	O	CCONJ	O
catecholamine	O	NOUN	B
concentrations	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
urine	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
collected	O	VERB	O
for	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
PSE	O	NOUN	B
concentration	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Independent	O	PROPN	B
of	O	ADP	O
the	O	DET	O
preexercise	O	NOUN	B
meal	O	NOUN	B
,	O	PUNCT	O
2.8	O	NUM	O
mg·kg	O	NOUN	O
BM	O	NOUN	B
of	O	ADP	O
PSE	O	NOUN	B
did	O	AUX	O
not	O	PART	O
significantly	B-OUT	ADV	O
improve	I-OUT	VERB	B
cycling	I-OUT	NOUN	B
TT	I-OUT	NOUN	B
performance	I-OUT	NOUN	B
.	O	PUNCT	O


The	O	DET	O
fed	O	VERB	O
trials	O	NOUN	B
resulted	B-OUT	VERB	O
in	I-OUT	ADP	O
lower	I-OUT	ADJ	O
plasma	I-OUT	NOUN	B
PSE	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
at	O	ADP	O
all	O	DET	O
time	O	NOUN	B
points	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
nonfed	O	ADJ	B
trials	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Both	B-OUT	CCONJ	O
plasma	I-OUT	NOUN	B
epinephrine	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
lactate	I-OUT	NOUN	I
concentrations	I-OUT	NOUN	I
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
PSE	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
PLA	O	PROPN	B
trials	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
preexercise	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
postexercise	I-OUT	VERB	B
urinary	I-OUT	ADJ	B
PSE	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
the	O	DET	O
threshold	O	NOUN	B
(	O	PUNCT	O
150	O	NUM	O
μg·mL	O	NOUN	O
)	O	PUNCT	O
used	O	VERB	O
by	O	ADP	O
WADA	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
illicit	O	NOUN	B
PSE	O	NOUN	I
use	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Irrespective	O	ADV	O
of	O	ADP	O
the	O	DET	O
preexercise	B-OUT	NOUN	B
meal	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
cycling	I-OUT	NOUN	B
TT	I-OUT	NOUN	B
performance	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	O
30	O	NUM	O
min	O	NOUN	O
was	O	AUX	O
not	O	PART	O
improved	O	VERB	O
after	O	ADP	O
PSE	O	NOUN	B
supplementation	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
2.8	O	NUM	O
mg·kg	O	NOUN	O
BM	O	NOUN	B
of	O	ADP	O
PSE	O	NOUN	B
taken	O	VERB	O
90	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
exercise	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
food	O	NOUN	B
,	O	PUNCT	O
resulted	O	VERB	O
in	O	ADP	O
urinary	O	ADJ	B
PSE	O	NOUN	B
concentrations	O	NOUN	B
exceeding	O	VERB	O
the	O	DET	O
present	O	ADJ	O
WADA	O	PROPN	B
threshold	O	NOUN	B
.	O	PUNCT	O


Cranberry	B-I	NOUN	B
concentrate	I-I	VERB	B
:	I-I	PUNCT	O
UTI	I-P	NOUN	B
prophylaxis	O	NOUN	B
.	O	PUNCT	O


Endoscopic	B-I	ADJ	B
ligation	I-I	NOUN	I
compared	O	VERB	B
with	O	ADP	O
sclerotherapy	B-I	NOUN	B
for	O	ADP	O
bleeding	B-OUT	VERB	B
esophageal	I-OUT	NOUN	I
varices	I-OUT	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
extrahepatic	I-P	ADJ	B
portal	I-P	ADJ	I
venous	I-P	ADJ	B
obstruction	I-P	NOUN	I
.	I-P	PUNCT	O


Endoscopic	B-I	ADJ	B
sclerotherapy	I-I	NOUN	I
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
bleeding	B-OUT	VERB	B
esophageal	I-OUT	NOUN	I
varices	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
significant	B-OUT	ADJ	O
complications	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Endoscopic	B-I	ADJ	B
ligation	I-I	NOUN	I
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
endoscopic	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
bleeding	B-OUT	VERB	B
varices	I-OUT	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
sclerotherapy	O	NOUN	B
in	O	ADP	O
adult	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
cirrhosis	I-P	NOUN	B
.	I-P	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
endoscopic	O	ADJ	B
sclerotherapy	O	NOUN	I
and	O	CCONJ	O
ligation	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
2	O	NUM	O
methods	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
control	O	NOUN	I
trial	O	NOUN	I
in	O	ADP	O
49	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
extrahepatic	I-P	ADJ	B
portal	I-P	ADJ	I
venous	I-P	ADJ	B
obstruction	I-P	NOUN	I
who	I-P	PRON	O
had	I-P	AUX	O
proven	I-P	VERB	O
bleeding	I-P	VERB	B
from	I-P	ADP	O
esophageal	I-P	NOUN	B
varices	I-P	NOUN	I
.	I-P	PUNCT	O


Twenty-four	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
treated	I-P	VERB	B
with	I-P	ADP	I
sclerotherapy	I-I	NOUN	B
and	I-P	CCONJ	O
25	I-P	NUM	O
with	I-P	ADP	O
band	I-I	NOUN	B
ligation	I-I	NOUN	I
.	I-I	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
sclerotherapy	O	NOUN	B
and	O	CCONJ	O
ligation	O	NOUN	B
groups	O	NOUN	I
in	O	ADP	O
arresting	B-OUT	VERB	B
active	I-OUT	ADJ	O
index	I-OUT	NOUN	O
bleeding	I-OUT	NOUN	O
(	O	PUNCT	O
100	O	NUM	O
%	O	NOUN	O
each	O	DET	O
)	O	PUNCT	O
and	O	CCONJ	O
achieving	B-OUT	VERB	O
variceal	I-OUT	NOUN	B
eradication	I-OUT	NOUN	B
(	O	PUNCT	O
91.7	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
96	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=.61	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Band	O	NOUN	B
ligation	O	NOUN	I
eradicated	O	VERB	O
varices	B-OUT	NOUN	B
in	O	ADP	O
fewer	O	ADJ	O
endoscopic	B-OUT	ADJ	B
sessions	I-OUT	NOUN	B
than	O	ADP	O
did	O	AUX	O
sclerotherapy	O	NOUN	B
(	O	PUNCT	O
3.9	O	NUM	O
+/-	O	CCONJ	O
1.1	O	NUM	O
vs.	O	CCONJ	O
6.1	O	NUM	O
+/-	O	CCONJ	O
1.7	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
rebleeding	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
sclerotherapy	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=.049	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADP	O
was	O	AUX	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
major	I-OUT	ADJ	O
complications	I-OUT	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=.049	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


After	O	ADP	O
eradication	O	NOUN	B
,	O	PUNCT	O
esophageal	B-OUT	ADJ	B
variceal	I-OUT	NOUN	B
recurrence	I-OUT	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
by	O	ADP	O
ligation	O	NOUN	B
than	O	ADP	O
by	O	ADP	O
sclerotherapy	O	NOUN	B
(	O	PUNCT	O
17.4	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
10	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=.67	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
variceal	B-I	NOUN	B
band	I-I	NOUN	I
ligation	I-I	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
is	O	AUX	O
a	O	DET	O
safe	B-OUT	ADJ	O
and	I-OUT	CCONJ	O
effective	I-OUT	ADJ	B
technique	O	NOUN	B
that	O	PRON	O
achieves	O	VERB	O
variceal	B-OUT	NOUN	B
eradication	I-OUT	NOUN	B
more	O	ADV	O
quickly	O	ADV	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
lower	O	ADJ	O
rebleeding	B-OUT	NOUN	B
rate	I-OUT	NOUN	B
and	O	CCONJ	O
fewer	O	ADJ	O
complications	B-OUT	NOUN	B
compared	O	VERB	B
with	O	ADP	O
sclerotherapy	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
perioperative	O	ADJ	B
parecoxib	B-I	NOUN	B
on	O	ADP	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
local	I-OUT	ADJ	B
inflammation	I-OUT	NOUN	B
factors	O	NOUN	O
PGE2	O	NOUN	B
and	O	CCONJ	O
IL-6	O	NOUN	B
for	O	ADP	O
total	O	ADJ	B
knee	O	NOUN	I
arthroplasty	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
pain	O	NOUN	B
management	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
concentration	O	NOUN	B
change	O	NOUN	O
of	O	ADP	O
PGE-2	O	NOUN	B
and	O	CCONJ	O
IL-6	O	NOUN	B
of	O	ADP	O
joint	O	ADJ	B
fluid	O	NOUN	I
with	O	ADP	O
parecoxib	B-I	NOUN	B
after	O	ADP	O
postoperative	O	ADJ	B
total	O	ADJ	B
knee	O	NOUN	I
arthroplasty	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
100	B-P	NUM	O
patients	I-P	NOUN	B
experiencing	I-P	VERB	O
primary	I-P	ADJ	B
TKA	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
study	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
receiving	O	VERB	O
parecoxib	B-I	NOUN	B
sodium	I-I	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
intravenously	O	ADV	B
(	O	PUNCT	O
IV	O	NUM	B
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
once	O	ADV	O
every	O	DET	O
12	O	NUM	O
h	O	NOUN	O
for	O	ADP	O
totally	O	ADV	O
6	O	NUM	O
times	O	NOUN	O
postoperatively	O	ADV	B
,	O	PUNCT	O
and	B-I	CCONJ	O
placebo	I-I	ADJ	B
group	O	NOUN	O
,	O	PUNCT	O
receiving	B-I	VERB	O
normal	I-I	ADJ	O
saline	I-I	NOUN	O
2	O	NUM	O
mL	O	NOUN	O
IV	O	NUM	B
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
points	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Efficacy	B-OUT	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	B-OUT	ADP	O
total	I-OUT	ADJ	O
amount	I-OUT	NOUN	O
of	I-OUT	ADP	O
morphine	I-OUT	NOUN	B
consumed	I-OUT	VERB	B
,	I-OUT	PUNCT	O
pain	I-OUT	NOUN	B
intensity	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
range	I-OUT	NOUN	B
of	I-OUT	ADP	I
motion	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
ROM	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
concentration	I-OUT	NOUN	B
change	I-OUT	NOUN	O
of	I-OUT	ADP	O
PGE-2	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
IL-6	I-OUT	NOUN	B
of	I-OUT	ADP	O
joint	I-OUT	ADJ	B
fluid	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
nausea	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
vomiting	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
PONV	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
postoperatively	O	ADV	B
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
study	O	NOUN	B
group	O	NOUN	I
consumed	O	VERB	O
significantly	O	ADV	O
less	B-OUT	ADJ	O
morphine	I-OUT	NOUN	B
,	O	PUNCT	O
experienced	O	VERB	O
significant	O	ADJ	O
less	B-OUT	ADJ	O
pain	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
obtained	O	VERB	O
significantly	O	ADV	O
more	B-OUT	ADJ	O
ROM	I-OUT	PROPN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
in	O	ADP	O
placebo	O	ADJ	B
group	O	NOUN	O
during	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
postoperatively	B-OUT	ADV	B
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
concentration	I-OUT	NOUN	B
of	I-OUT	ADP	O
PGE-2	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
IL-6	I-OUT	NOUN	B
of	I-OUT	ADP	O
joint	I-OUT	ADJ	B
fluid	O	NOUN	I
in	O	ADP	O
study	O	NOUN	B
group	O	NOUN	I
are	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
that	B-I	DET	O
in	I-I	ADP	O
placebo	I-I	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
during	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
postoperatively	B-OUT	ADV	B
.	I-OUT	PUNCT	O


The	B-OUT	DET	O
overall	I-OUT	ADJ	O
incidence	I-OUT	NOUN	B
of	O	ADP	O
PONV	O	NOUN	B
was	O	AUX	O
low	O	ADJ	B
and	O	CCONJ	O
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
perioperative	O	ADJ	B
administration	B-I	NOUN	B
of	I-I	ADP	O
parecoxib	I-I	NOUN	B
after	O	ADP	O
primary	O	ADJ	B
TKA	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
significantly	O	ADV	O
improved	B-OUT	VERB	O
postoperative	I-OUT	ADJ	B
analgesic	I-OUT	NOUN	B
management	I-OUT	NOUN	I
as	O	ADP	O
defined	O	VERB	O
by	O	ADP	O
reduction	O	NOUN	B
in	O	ADP	O
opioid	O	NOUN	B
requirement	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
lower	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
and	O	CCONJ	O
ROM	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
significantly	B-OUT	ADV	O
lowered	I-OUT	VERB	B
local	I-OUT	ADJ	O
inflammation	I-OUT	NOUN	B
factors	I-OUT	NOUN	O
PGE2	I-OUT	NOUN	B
and	O	CCONJ	O
IL-6	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
enamel	B-I	NOUN	B
pretreatment	I-I	NOUN	B
on	O	ADP	O
shear	B-OUT	NOUN	B
bond	I-OUT	NOUN	I
strength	I-OUT	NOUN	I
of	O	ADP	O
brackets	B-P	NOUN	B
bonded	I-P	VERB	O
with	I-P	ADP	O
resin-modified	I-P	ADJ	B
glass-ionomer	I-P	ADJ	I
cement	I-P	NOUN	I
.	I-P	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
shear	B-OUT	NOUN	B
bond	I-OUT	NOUN	I
strength	I-OUT	NOUN	I
of	O	ADP	O
brackets	O	NOUN	B
bonded	O	VERB	O
with	O	ADP	O
resin-modified	B-I	ADJ	B
glass-ionomer	I-I	ADJ	I
cement	I-I	NOUN	I
(	I-I	PUNCT	O
RMGIC	I-I	NOUN	B
)	I-I	PUNCT	O
using	O	VERB	O
various	O	ADJ	O
methods	O	NOUN	B
of	O	ADP	O
enamel	B-I	NOUN	B
conditioning	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Forty-five	B-P	NUM	O
human	I-P	ADJ	B
premolars	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
divided	I-P	VERB	O
into	I-P	ADP	O
five	I-P	NUM	O
groups	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
roots	O	NOUN	B
of	O	ADP	O
these	O	DET	O
teeth	O	NOUN	B
were	O	AUX	O
fixed	O	VERB	O
in	O	ADP	O
acrylic	O	ADJ	B
resin	O	NOUN	I
cylinders	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
brackets	O	NOUN	B
were	O	AUX	O
bonded	O	VERB	B
to	O	ADP	O
the	O	DET	O
teeth	O	NOUN	B
's	O	PART	O
crowns	O	NOUN	B
using	O	VERB	O
the	O	DET	O
following	O	VERB	O
material	O	NOUN	B
combinations	O	NOUN	I
:	O	PUNCT	O
RMGIC	B-I	NOUN	B
only	O	ADV	O
;	O	PUNCT	O
RMGIC	O	NOUN	B
and	O	CCONJ	O
corresponding	O	ADJ	O
primer	B-I	NOUN	B
;	I-I	PUNCT	O
RMGIC	O	NOUN	B
,	O	PUNCT	O
acid	B-I	NOUN	B
etching	I-I	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
Scotchbond	B-I	PROPN	B
Multipurpose	O	PROPN	I
;	O	PUNCT	O
RMGIC	O	NOUN	B
and	O	CCONJ	O
two-step	O	ADJ	O
self-etching	O	ADJ	B
primer	O	NOUN	I
;	O	PUNCT	O
and	O	CCONJ	O
RMGIC	B-I	NOUN	B
and	O	CCONJ	O
one-step	O	ADJ	B
primer	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
specimens	O	NOUN	B
were	O	AUX	O
submitted	O	VERB	O
to	O	PART	O
pH	O	NOUN	B
cycling	O	NOUN	I
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
before	O	ADP	O
shear	O	NOUN	B
bond	B-OUT	NOUN	I
strength	I-OUT	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
a	O	DET	O
universal	O	ADJ	B
test	O	NOUN	I
machine	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
medians	O	NOUN	B
and	O	CCONJ	O
standard	O	ADJ	B
deviations	O	NOUN	I
(	O	PUNCT	O
in	O	ADP	O
MPa	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
RMGIC	B-I	NOUN	B
only	O	ADV	O
=	O	ADJ	O
8.34	O	NUM	O
±	O	NOUN	O
1.11	O	NUM	O
;	O	PUNCT	O
RMGIC	O	NOUN	B
and	O	CCONJ	O
corresponding	O	ADJ	O
primer	O	NOUN	B
=	O	ADJ	O
7.05	O	NUM	O
±	O	NOUN	O
2.24	O	NUM	O
;	O	PUNCT	O
RMGIC	O	NOUN	B
,	O	PUNCT	O
acid	O	NOUN	B
etching	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
Scotchbond	O	PROPN	B
Multipurpose	O	PROPN	I
=	O	ADJ	O
7.00	O	NUM	O
±	O	NOUN	O
4.79	O	NUM	O
;	O	PUNCT	O
RMGIC	O	NOUN	B
and	O	CCONJ	O
two-step	O	ADJ	O
self-etching	O	ADJ	B
primer	O	NOUN	I
=	O	ADJ	O
0.54	O	NUM	O
±	O	NOUN	O
0.30	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
RMGIC	O	NOUN	B
and	O	CCONJ	O
one-step	O	ADJ	B
primer	O	NOUN	I
=	O	ADJ	O
10.61	O	NUM	O
±	O	PROPN	O
4.58	O	NUM	O
.	B-OUT	PUNCT	O


The	B-OUT	DET	O
value	I-OUT	NOUN	O
for	I-I	ADP	O
RMGIC	I-I	NOUN	B
and	O	CCONJ	O
two-step	O	ADJ	O
self-etching	O	ADJ	B
primer	B-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
all	O	DET	O
other	O	ADJ	O
values	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
It	O	PRON	O
can	O	AUX	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
tested	O	VERB	B
RMGIC	O	NOUN	B
is	O	AUX	O
suitable	O	ADJ	O
for	O	ADP	O
bonding	O	VERB	B
orthodontic	O	ADJ	B
brackets	O	NOUN	I
,	O	PUNCT	O
even	O	ADV	O
when	O	SCONJ	O
used	O	VERB	O
by	O	ADP	O
itself	O	PRON	O
.	O	PUNCT	O


Different	O	ADJ	O
enamel	O	NOUN	B
preparations	O	NOUN	O
do	O	AUX	O
not	O	PART	O
improve	O	VERB	O
its	O	PRON	O
performance	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
they	O	PRON	O
can	O	AUX	O
worsen	O	VERB	B
its	O	PRON	O
bonding	O	NOUN	B
capacity	O	NOUN	B
as	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
with	O	ADP	O
the	O	DET	O
two-step	O	ADJ	O
primer	O	NOUN	B
system	O	NOUN	I
clearly	O	ADV	O
shows	O	VERB	O
.	O	PUNCT	O


Visual	B-I	ADJ	B
feedback	I-I	NOUN	I
and	I-I	CCONJ	O
target	I-I	VERB	B
size	I-I	NOUN	B
effects	I-I	NOUN	B
on	I-I	ADP	O
reach-to-grasp	I-I	ADJ	B
tasks	I-I	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


This	O	DET	O
study	O	NOUN	B
explores	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
visual	O	ADJ	B
condition	O	NOUN	I
and	O	CCONJ	O
target	O	VERB	B
size	O	NOUN	O
during	O	ADP	O
four	O	NUM	O
reach-to-grasp	B-OUT	ADJ	B
tasks	I-OUT	NOUN	I
between	O	ADP	O
autistic	B-P	ADJ	B
children	I-P	NOUN	B
and	I-P	CCONJ	O
healthy	I-P	ADJ	B
controls	I-P	NOUN	I
.	I-P	PUNCT	O


Twenty	B-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
and	I-P	CCONJ	O
20	I-P	NUM	O
healthy	I-P	ADJ	B
controls	I-P	NOUN	I
participated	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Qualisys	B-OUT	PROPN	B
motion	I-OUT	NOUN	I
capture	I-OUT	NOUN	I
system	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
kinematic	I-OUT	ADJ	B
measures	I-OUT	NOUN	I
were	I-I	AUX	O
used	I-I	VERB	O
to	I-I	PART	O
record	I-I	VERB	B
movement	I-I	NOUN	B
.	I-I	PUNCT	O


Autistic	B-P	ADJ	B
group	O	NOUN	I
showed	O	VERB	O
significantly	O	ADV	O
longer	B-OUT	ADJ	O
movement	I-OUT	NOUN	B
time	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
larger	I-OUT	ADJ	O
normalized	I-OUT	VERB	O
jerk	I-OUT	NOUN	B
score	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
more	I-OUT	ADJ	O
movement	I-OUT	NOUN	B
unit	O	NOUN	O
than	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
non-visual	O	ADJ	B
feedback	O	NOUN	I
and	O	CCONJ	O
small	O	ADJ	B
target	O	NOUN	O
blocks	O	NOUN	O
.	O	PUNCT	O


Autistic	B-P	ADJ	B
group	O	NOUN	I
also	O	ADV	O
showed	O	VERB	O
significantly	O	ADV	O
larger	B-OUT	ADJ	O
maximal	I-OUT	ADJ	B
grip	I-OUT	NOUN	O
aperture	I-OUT	NOUN	O
and	O	CCONJ	O
normalized	B-OUT	VERB	O
maximal	I-OUT	ADJ	B
grip	I-OUT	NOUN	I
aperture	I-OUT	NOUN	I
in	O	ADP	O
visual	O	ADJ	B
feedback	O	NOUN	I
condition	O	NOUN	I
than	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Autistic	B-P	ADJ	B
children	I-P	NOUN	B
demonstrate	O	VERB	O
motor	B-OUT	NOUN	B
coordination	I-OUT	NOUN	I
problems	I-OUT	NOUN	O
and	O	CCONJ	O
also	O	ADV	O
depend	O	VERB	O
on	O	ADP	O
more	O	ADV	O
visual	B-OUT	ADJ	B
cuing	I-OUT	NOUN	O
in	O	ADP	O
high	O	ADJ	O
accuracy	O	NOUN	B
tasks	O	NOUN	B
.	O	PUNCT	O


Autistic	B-P	ADJ	B
children	I-P	NOUN	O
develop	O	VERB	O
other	O	ADJ	O
compensatory	B-OUT	ADJ	B
skills	I-OUT	NOUN	I
while	O	SCONJ	O
performing	O	VERB	O
tasks	O	NOUN	B
.	O	PUNCT	O


Cisplatin	B-I	NOUN	B
,	I-I	PUNCT	O
epirubicin	I-I	NOUN	B
,	I-I	PUNCT	O
leucovorin	I-I	NOUN	B
and	I-I	CCONJ	O
5-fluorouracil	I-I	NOUN	B
(	I-I	PUNCT	O
PELF	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
more	O	ADV	O
active	O	ADJ	B
than	O	ADP	O
5-fluorouracil	B-I	NOUN	B
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
and	I-I	CCONJ	O
methotrexate	I-I	NOUN	B
(	I-I	PUNCT	O
FAMTX	I-I	NOUN	B
)	I-I	PUNCT	O
in	O	ADP	O
advanced	B-P	ADJ	B
gastric	I-P	ADJ	I
carcinoma	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
5-Fluorouracil	B-I	NOUN	B
(	I-I	PUNCT	O
5-FU	I-I	NOUN	B
)	I-I	PUNCT	O
,	I-I	PUNCT	O
doxorubicin	I-I	NOUN	B
and	I-I	CCONJ	O
methotrexate	I-I	NOUN	B
(	I-I	PUNCT	O
FAMTX	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
cisplatin	I-I	NOUN	B
,	I-I	PUNCT	O
epirubicin	I-I	NOUN	B
,	I-I	PUNCT	O
leucovorin	I-I	NOUN	B
and	I-I	CCONJ	O
5-FU	I-I	NOUN	B
(	I-I	PUNCT	O
PELF	I-I	NOUN	B
)	I-I	PUNCT	O
have	O	AUX	O
both	O	DET	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
the	O	DET	O
combination	O	NOUN	B
5-FU	O	NOUN	B
,	O	PUNCT	O
doxorubicin	O	NOUN	B
and	O	CCONJ	O
mitomycin	O	NOUN	B
C	O	NOUN	I
(	O	PUNCT	O
FAM	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
advanced	B-P	ADJ	B
gastric	I-P	ADJ	I
carcinoma	I-P	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
and	O	CCONJ	O
dose	O	NOUN	B
intensity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
included	O	VERB	O
agents	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
hypothesised	O	VERB	O
that	O	SCONJ	O
PELF	O	PROPN	B
would	O	AUX	O
be	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
FAMTX	B-I	PROPN	B
.	I-I	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Two	B-P	NUM	O
hundred	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
untreated	I-P	ADJ	B
advanced	I-P	ADJ	O
gastric	I-P	ADJ	O
carcinoma	I-P	NOUN	O
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
PELF	B-I	NOUN	B
or	I-I	CCONJ	O
FAMTX	I-I	PROPN	B
for	O	ADP	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
six	O	NUM	O
cycles	O	NOUN	B
or	O	CCONJ	O
until	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
complete	B-OUT	ADJ	B
response	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CR	I-OUT	ADJ	B
)	I-OUT	PUNCT	O
rates	I-OUT	NOUN	B
to	O	ADP	O
PELF	O	PROPN	B
and	O	CCONJ	O
FAMTX	B-I	PROPN	B
were	O	AUX	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
intervals	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
to	O	PART	O
20	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
%	O	NOUN	O
to	O	PART	O
5	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
objective	B-OUT	ADJ	O
response	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
[	O	PUNCT	O
CR	O	ADJ	B
plus	O	CCONJ	O
partial	B-OUT	ADJ	B
response	I-OUT	NOUN	I
(	O	PUNCT	O
PR	O	NOUN	B
)	O	PUNCT	O
rates	O	NOUN	B
]	O	PUNCT	O
39	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
29	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
49	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
22	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
13	O	NUM	O
%	O	NOUN	O
to	O	PART	O
30	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.009	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
thus	O	ADV	O
significantly	O	ADV	O
favouring	O	VERB	O
the	O	DET	O
PELF	O	NOUN	B
combination	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
survival	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
after	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
30.8	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
22.4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
24	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
15.7	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
9.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
higher	O	ADJ	O
among	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
PELF	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
these	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


The	O	DET	O
toxicities	B-OUT	NOUN	B
were	O	AUX	O
qualitatively	O	ADV	B
different	O	ADJ	O
but	O	CCONJ	O
quantitatively	O	ADV	B
similar	O	ADJ	O
.	O	PUNCT	O


Both	O	DET	O
regimens	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
feasible	O	ADJ	O
provided	O	VERB	O
that	O	DET	O
careful	O	ADJ	O
patient	O	NOUN	B
monitoring	O	NOUN	B
is	O	AUX	O
assured	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
PELF	B-I	PROPN	B
is	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
active	O	ADJ	B
than	O	ADP	O
FAMTX	B-I	PROPN	B
and	O	CCONJ	O
deserves	O	VERB	O
further	O	ADJ	O
research	O	NOUN	B
in	O	ADP	O
the	O	DET	O
adjuvant	O	ADJ	B
setting	O	NOUN	I
.	O	PUNCT	O


Visit-to-visit	O	NOUN	B
blood	B-OUT	NOUN	O
pressure	I-OUT	NOUN	O
variability	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
European	O	PROPN	B
Lacidipine	O	PROPN	I
Study	O	PROPN	I
on	O	ADP	O
Atherosclerosis	O	NOUN	B
:	O	PUNCT	O
methodological	O	ADJ	B
aspects	O	NOUN	I
and	O	CCONJ	O
effects	O	NOUN	B
of	O	ADP	O
antihypertensive	B-I	ADJ	B
treatment	I-I	NOUN	B
.	I-I	PUNCT	O


BACKGROUND	O	ADJ	O
Recent	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
reported	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
patients	B-P	NOUN	B
under	I-P	ADP	O
antihypertensive	I-P	ADJ	B
treatment	I-P	NOUN	I
visit-to-visit	I-P	NOUN	B
(	I-P	PUNCT	O
or	I-P	CCONJ	O
long-term	I-P	ADJ	B
)	I-P	PUNCT	O
variability	I-OUT	NOUN	B
of	I-OUT	ADP	O
clinic	I-OUT	ADJ	B
BP	I-OUT	NOUN	B
within	O	ADP	O
a	O	DET	O
given	O	VERB	O
patient	O	NOUN	B
has	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
prognostic	O	ADJ	B
significance	O	NOUN	O
.	O	PUNCT	O


Partly	O	ADV	B
based	O	VERB	O
on	O	ADP	O
between-patient	O	ADJ	B
dispersion	O	NOUN	B
of	O	ADP	O
BP	O	NOUN	B
values	O	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
interindividual	O	ADJ	B
variability	O	NOUN	B
)	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
that	O	SCONJ	O
long-term	B-OUT	ADJ	B
clinic	I-OUT	NOUN	B
BP	I-OUT	NOUN	B
variability	I-OUT	NOUN	B
is	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
β-blocker	B-I	NOUN	B
than	O	ADP	O
for	B-I	ADP	O
calcium	I-I	NOUN	B
antagonist	I-I	NOUN	I
and	O	CCONJ	O
other	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


GOALS	O	NOUN	B
To	O	PART	O
measure	B-OUT	VERB	B
visit-to-visit	I-OUT	ADJ	B
intraindividual	I-OUT	ADJ	B
variations	I-OUT	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
clinic	O	NOUN	B
and	O	CCONJ	O
24-h	O	ADV	O
mean	O	VERB	O
BP	O	NOUN	B
in	O	ADP	O
the	B-P	DET	O
hypertensive	I-P	ADJ	B
patients	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
European	I-P	PROPN	B
Lacidipine	I-P	PROPN	I
Study	I-P	PROPN	I
on	I-P	ADP	O
Atherosclerosis	I-P	NOUN	B
(	I-P	PUNCT	O
ELSA	I-P	NOUN	B
)	I-P	PUNCT	O
trial	I-P	NOUN	O
treated	I-P	VERB	B
for	I-P	ADP	O
4	I-P	NUM	O
years	I-P	NOUN	B
with	I-P	ADP	O
either	I-I	CCONJ	O
atenolol	I-I	ADJ	B
or	I-I	CCONJ	O
lacidipine	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
check	O	VERB	O
whether	O	SCONJ	O
interindividual	O	ADJ	B
clinic	O	NOUN	B
and	O	CCONJ	O
24-h	B-OUT	ADJ	O
BP	I-OUT	NOUN	B
variabilities	I-OUT	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
can	O	AUX	O
really	O	ADV	O
be	O	AUX	O
considered	O	VERB	O
a	O	DET	O
surrogate	O	NOUN	B
of	O	ADP	O
intraindividual	O	ADJ	B
variabilities	O	NOUN	B
in	O	ADP	O
exploring	O	VERB	O
differences	O	NOUN	O
between	B-I	ADP	O
β-blocker	I-I	NOUN	B
and	I-I	CCONJ	O
calcium	I-I	NOUN	B
antagonist	I-I	NOUN	I
treatments	I-I	NOUN	B
.	O	PUNCT	O


METHODS	B-OUT	VERB	O
Long-term	I-OUT	ADJ	B
intraindividual	I-OUT	ADJ	B
BP	I-OUT	NOUN	B
variability	I-OUT	NOUN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
the	B-OUT	DET	O
coefficient	I-OUT	NOUN	B
of	I-OUT	ADP	O
variation	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
average	I-OUT	ADJ	B
systolic	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
values	I-OUT	NOUN	I
of	I-OUT	ADP	O
clinic	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
24-h	I-OUT	ADJ	O
BP	I-OUT	NOUN	B
measured	O	VERB	B
at	O	ADP	O
each	O	DET	O
visit	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	B-P	NOUN	B
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
in	I-P	ADP	O
whom	I-P	PRON	O
at	I-P	ADP	O
least	I-P	ADJ	O
seven	I-P	NUM	O
clinic	I-P	NOUN	B
(	I-P	PUNCT	O
6-month	I-P	ADJ	O
intervals	I-P	NOUN	B
)	I-P	PUNCT	O
or	I-P	CCONJ	O
at	I-P	ADP	O
least	I-P	ADJ	O
three	I-P	NUM	O
(	I-P	PUNCT	O
yearly	I-P	ADJ	B
intervals	I-P	NOUN	I
)	I-P	PUNCT	O
24-h	I-P	ADJ	O
values	I-P	NOUN	B
were	I-P	AUX	O
available	I-P	ADJ	O
from	I-P	ADP	O
the	I-P	DET	O
end	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
drug	I-P	NOUN	B
titration	I-P	NOUN	I
phase	I-P	NOUN	I
to	I-P	PART	O
the	I-P	DET	O
end	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
were	I-P	AUX	O
considered	I-P	VERB	O
.	O	PUNCT	O


RESULTS	B-OUT	VERB	B
Visit-to-visit	I-OUT	NOUN	B
24-h	I-OUT	ADJ	O
SBP/DBP	I-OUT	NOUN	B
variabilities	I-OUT	NOUN	I
were	O	AUX	O
20-25	O	NUM	O
%	O	NOUN	O
smaller	O	ADJ	O
than	O	ADP	O
,	O	PUNCT	O
and	O	CCONJ	O
loosely	O	ADV	O
correlated	O	VERB	B
with	B-OUT	ADP	O
clinic	I-OUT	ADJ	B
BP	I-OUT	NOUN	B
variability	I-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
<	O	X	O
0.022	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
also	O	ADV	O
a	O	DET	O
very	O	ADV	O
limited	O	ADJ	O
relationship	O	NOUN	B
(	B-OUT	PUNCT	O
r	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
2	I-OUT	NUM	O
)	I-OUT	PUNCT	O
<	I-OUT	X	O
0.026	I-OUT	NUM	O
)	I-OUT	PUNCT	O
between	I-OUT	ADP	O
visit-to-visit	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
within	I-OUT	ADP	O
24-h	I-OUT	ADJ	O
ambulatory	I-OUT	ADJ	B
BP	I-OUT	NOUN	I
variabilities	I-OUT	NOUN	B
,	O	PUNCT	O
the	O	DET	O
latter	O	ADJ	O
being	O	AUX	O
two	O	NUM	O
to	O	PART	O
three	O	NUM	O
times	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
the	B-OUT	DET	O
former	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Visit-to-visit	B-OUT	NOUN	B
intraindividual	I-OUT	ADJ	O
clinic	I-OUT	NOUN	B
SBP	I-OUT	NOUN	B
variability	I-OUT	NOUN	B
was	O	AUX	O
only	O	ADV	O
slightly	O	ADV	O
lower	O	ADJ	O
on	O	ADP	O
calcium	O	NOUN	B
antagonist	O	NOUN	I
than	O	ADP	O
on	O	ADP	O
β-blocker	O	NOUN	B
treatment	O	NOUN	B
but	O	CCONJ	O
little	O	ADJ	O
or	O	CCONJ	O
no	O	DET	O
between-treatment	O	ADJ	O
difference	O	NOUN	O
was	B-OUT	AUX	O
found	I-OUT	VERB	O
for	I-OUT	ADP	O
visit-to-visit	I-OUT	ADJ	B
clinic	I-OUT	NOUN	I
DBP	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
ambulatory	I-OUT	ADJ	B
SBP/DBP	O	NOUN	I
particularly	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
under	O	ADP	O
monotherapy	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Interindividual	B-OUT	ADJ	B
BP	I-OUT	NOUN	B
variability	I-OUT	NOUN	B
was	O	AUX	O
markedly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
the	O	DET	O
intra-individiual	O	ADJ	B
one	O	NUM	O
of	O	ADP	O
which	O	DET	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
precisely	O	ADV	O
reflect	O	VERB	O
the	O	DET	O
treatment-induced	O	ADJ	B
changes	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	B-P	NOUN	O
In	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
hypertensive	I-OUT	ADJ	I
patients	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
visit-to-visit	I-OUT	ADJ	B
BP	I-OUT	NOUN	I
variability	I-OUT	NOUN	B
does	O	AUX	O
not	O	PART	O
differ	O	VERB	O
substantially	B-I	ADV	O
between	I-I	ADP	O
β-blocker	I-I	NOUN	B
and	I-I	CCONJ	O
calcium	I-I	NOUN	B
antagonist	I-I	NOUN	I
treatment	O	NOUN	B
.	O	PUNCT	O


Major	O	ADJ	O
discrepancies	O	NOUN	B
exist	O	VERB	O
between	O	ADP	O
visit-to-visit	O	ADJ	B
BP	O	NOUN	I
variability	O	NOUN	B
as	O	ADP	O
quantified	O	VERB	B
by	O	ADP	O
24-h	O	ADJ	O
vs.	O	CCONJ	O
clinic	O	NOUN	B
BP	O	NOUN	B
,	O	PUNCT	O
making	O	VERB	O
investigation	O	NOUN	B
of	O	ADP	O
which	O	DET	O
of	O	ADP	O
these	O	DET	O
indices	O	NOUN	B
is	O	AUX	O
clinically	O	ADV	B
more	O	ADV	O
relevant	O	ADJ	B
important	O	ADJ	O
.	O	PUNCT	O


Interindividual	B-OUT	ADJ	B
BP	I-OUT	NOUN	B
variability	O	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
shows	O	VERB	O
marked	O	ADJ	O
quantitative	O	ADJ	B
differences	O	NOUN	B
with	O	ADP	O
intraindividual	O	ADJ	B
BP	O	NOUN	B
variability	O	NOUN	B
questioning	O	VERB	B
whether	O	SCONJ	O
its	O	PRON	O
use	O	NOUN	O
can	O	AUX	O
accurately	O	ADV	O
reflect	O	VERB	O
individual	O	ADJ	O
BP	O	NOUN	B
variations	O	NOUN	B
from	O	ADP	O
one	O	NUM	O
visit	O	NOUN	B
to	O	ADP	O
another	O	DET	O
.	O	PUNCT	O


[	B-I	PUNCT	O
Local	I-I	ADJ	B
therapy	I-I	NOUN	I
of	I-I	ADP	O
grade	I-I	NOUN	B
1	I-I	NUM	I
and	I-I	CCONJ	O
2	I-I	NUM	O
hemorrhoids	I-I	NOUN	B
.	I-I	PUNCT	O


Effectiveness	O	NOUN	B
of	O	ADP	O
a	O	DET	O
combination	B-I	NOUN	O
preparation	I-I	NOUN	B
with	I-I	ADP	O
standardized	I-I	ADJ	B
blood	I-I	NOUN	I
leech	I-I	ADJ	I
extract	I-I	NOUN	I
]	I-I	PUNCT	O
.	O	PUNCT	O


AIMS	O	PROPN	B
Testing	O	VERB	I
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
a	O	DET	O
topical	B-I	ADJ	B
combination	I-I	NOUN	O
preparation	I-I	NOUN	O
containing	I-I	VERB	O
standardized	I-I	ADJ	O
leech	I-I	ADJ	B
extract	I-I	NOUN	I
,	I-I	PUNCT	O
polidocanol	I-I	NOUN	B
and	I-I	CCONJ	O
allantoin	I-I	NOUN	B
.	I-I	PUNCT	O


STUDY	O	NOUN	B
DESIGN	O	NOUN	O
Placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
80	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
first	I-P	ADJ	O
and	I-P	CCONJ	O
second	I-P	ADJ	O
degree	I-P	NOUN	B
hemorrhoids	I-P	NOUN	O
;	I-P	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
one	O	NUM	O
week	O	NOUN	B
;	O	PUNCT	O
examinations	O	NOUN	B
performed	O	VERB	O
on	O	ADP	O
admission	O	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
days	O	NOUN	B
3	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	O
Both	O	CCONJ	O
the	O	DET	O
subjective	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
objective	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
signs	I-OUT	NOUN	O
improved	I-OUT	VERB	B
during	O	ADP	O
the	O	DET	O
one	O	NUM	O
week	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
statistically	O	ADV	O
significantly	O	ADV	O
more	O	ADV	O
rapidly	O	ADV	O
under	O	ADP	O
the	O	DET	O
test	B-I	NOUN	B
preparation	I-I	NOUN	B
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


Histologically	B-OUT	ADV	B
demonstrable	I-OUT	ADJ	O
signs	I-OUT	NOUN	O
of	I-OUT	ADP	O
inflammation	I-OUT	NOUN	B
were	O	AUX	O
more	O	ADV	O
clearly	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
the	O	DET	O
preparation	B-I	NOUN	B
group	O	NOUN	I
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


No	B-OUT	DET	B
side	I-OUT	NOUN	B
effects	I-OUT	NOUN	I
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
good	O	ADJ	O
efficacy	O	NOUN	B
and	O	CCONJ	O
tolerability	O	NOUN	B
of	O	ADP	O
a	O	DET	O
topical	B-I	ADJ	B
therapeutic	I-I	ADJ	B
preparation	I-I	NOUN	I
in	O	ADP	O
first	B-P	ADJ	O
and	I-P	CCONJ	O
second	I-P	ADJ	O
degree	I-P	NOUN	B
hemorrhoids	I-P	NOUN	O
have	O	AUX	O
been	O	AUX	O
convincingly	O	ADV	B
demonstrated	O	VERB	O
.	O	PUNCT	O


Noradrenergic	B-OUT	ADJ	B
response	I-OUT	NOUN	O
to	O	PART	O
intravenous	B-I	ADJ	B
yohimbine	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
depression	I-P	NOUN	B
and	I-P	CCONJ	O
comorbidity	I-P	NOUN	B
of	I-P	ADP	O
depression	I-P	NOUN	B
and	I-P	CCONJ	O
panic	I-P	NOUN	B
.	I-P	PUNCT	O


Adrenergic	B-OUT	ADJ	B
response	I-OUT	NOUN	I
following	O	VERB	O
infusions	O	NOUN	B
of	O	ADP	O
yohimbine	B-I	NOUN	B
or	I-I	CCONJ	O
normal	I-I	ADJ	B
saline	I-I	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
9	B-P	NUM	O
control	I-P	NOUN	B
subjects	I-P	NOUN	I
,	I-P	PUNCT	O
8	I-P	NUM	O
patients	I-P	NOUN	B
suffering	I-P	VERB	B
from	I-P	ADP	O
a	I-P	DET	O
major	I-P	ADJ	O
depressive	I-P	ADJ	B
episode	I-P	NOUN	I
(	I-P	PUNCT	O
MDE	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
12	I-P	NUM	O
patients	I-P	NOUN	B
suffering	I-P	VERB	B
from	I-P	ADP	O
concurrent	I-P	ADJ	B
MDE	I-P	NOUN	B
and	I-P	CCONJ	O
panic	I-P	NOUN	B
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
MDE	I-P	NOUN	B
+	I-P	CCONJ	O
P	I-P	NOUN	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Blood	O	NOUN	B
was	O	AUX	O
drawn	O	VERB	O
at	O	ADP	O
-20	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
20	O	NUM	O
,	O	PUNCT	O
45	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
90	O	NUM	O
min	O	NOUN	O
following	O	VERB	O
the	O	DET	O
infusions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
assayed	O	VERB	B
for	O	ADP	O
norepinephrine	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
NE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
3-methoxy-4-hydroxy-phenyl	I-OUT	ADJ	B
glycol	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
MHPG	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
groups	O	NOUN	I
exhibited	O	VERB	O
higher	O	ADJ	O
baseline	B-OUT	NOUN	B
NE	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
greater	O	ADJ	O
NE	B-OUT	NOUN	B
area	I-OUT	NOUN	B
under	I-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
concentration	I-OUT	NOUN	B
versus	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
curve	I-OUT	NOUN	I
(	O	PUNCT	O
AUC0-90	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
yohimbine	B-I	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


Baseline	B-OUT	NOUN	B
NE	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
NE	B-OUT	NOUN	B
AUC0-90	I-OUT	NOUN	B
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
NE	O	NOUN	B
system	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
dysregulated	O	VERB	B
in	O	ADP	O
the	O	DET	O
MDE	O	NOUN	B
and	O	CCONJ	O
MDE	O	NOUN	B
+	O	CCONJ	O
P	O	NOUN	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
NE	O	NOUN	B
system	O	NOUN	B
still	O	ADV	O
appears	O	VERB	O
to	O	PART	O
respond	O	VERB	O
somewhat	O	ADV	O
predictably	O	ADV	O
following	O	VERB	O
a	O	DET	O
challenge	O	NOUN	O
,	O	PUNCT	O
even	O	ADV	O
though	O	SCONJ	O
the	O	DET	O
actual	O	ADJ	B
magnitude	O	NOUN	B
of	O	ADP	O
response	O	NOUN	B
may	O	AUX	O
vary	O	VERB	O
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
selumetinib	B-I	NOUN	B
vs	O	CCONJ	O
chemotherapy	B-I	NOUN	B
on	O	ADP	O
progression-free	O	ADJ	B
survival	O	NOUN	I
in	O	ADP	O
uveal	B-P	ADJ	B
melanoma	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


IMPORTANCE	O	ADJ	O
Uveal	O	ADJ	B
melanoma	O	NOUN	I
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
GNAQ	O	NOUN	B
and	O	CCONJ	O
GNA11	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
mitogen-activated	O	ADJ	B
protein	O	NOUN	I
kinase	O	NOUN	I
pathway	O	NOUN	I
activation	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
selumetinib	B-I	NOUN	B
,	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
,	O	PUNCT	O
non-adenosine	O	ADJ	B
triphosphate	O	NOUN	I
competitive	O	ADJ	B
inhibitor	O	NOUN	B
of	O	ADP	O
MEK1	O	NOUN	B
and	O	CCONJ	O
MEK2	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
uveal	B-P	ADJ	B
melanoma	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
AND	O	CCONJ	O
PARTICIPANTS	O	NOUN	O
Randomized	O	ADJ	B
,	O	PUNCT	O
open-label	O	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
2	O	NUM	I
clinical	O	ADJ	B
trial	O	NOUN	I
comparing	O	VERB	O
selumetinib	B-I	NOUN	B
vs	O	CCONJ	O
chemotherapy	B-I	NOUN	B
conducted	O	VERB	O
from	B-P	ADP	O
August	I-P	PROPN	O
2010	I-P	NUM	O
through	I-P	ADP	O
December	I-P	PROPN	O
2013	I-P	NUM	O
among	I-P	ADP	O
120	I-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
metastatic	I-P	ADJ	B
uveal	I-P	ADJ	I
melanoma	I-P	NOUN	I
at	I-P	ADP	O
15	I-P	NUM	O
academic	I-P	ADJ	B
oncology	I-P	NOUN	I
centers	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
United	I-P	PROPN	B
States	I-P	PROPN	I
and	I-P	CCONJ	O
Canada	I-P	PROPN	B
.	I-P	PUNCT	O


INTERVENTIONS	O	NOUN	B
One	B-P	NUM	O
hundred	I-P	NUM	O
one	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
in	I-P	ADP	O
a	I-P	DET	O
1:1	I-P	NUM	O
ratio	I-P	NOUN	B
to	O	PART	O
receive	O	VERB	O
selumetinib	B-I	NOUN	B
,	O	PUNCT	O
75	O	NUM	O
mg	O	NOUN	O
orally	O	ADV	B
twice	O	ADV	O
daily	O	ADV	B
on	O	ADP	O
a	O	DET	O
continual	O	ADJ	O
basis	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
50	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
or	B-I	CCONJ	O
chemotherapy	I-I	NOUN	B
(	I-I	PUNCT	O
temozolomide	I-I	NOUN	B
,	O	PUNCT	O
150	O	NUM	O
mg/m2	O	NOUN	O
orally	O	ADV	B
daily	O	ADV	O
for	O	ADP	O
5	O	NUM	O
of	O	ADP	O
every	O	DET	O
28	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
or	B-I	CCONJ	O
dacarbazine	I-I	NOUN	B
,	O	PUNCT	O
1000	O	NUM	O
mg/m2	O	NOUN	O
intravenously	O	ADV	B
every	O	DET	O
21	O	NUM	O
days	O	NOUN	B
[	O	PUNCT	O
investigator	O	NOUN	B
choice	O	NOUN	B
]	O	PUNCT	O
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
51	O	NUM	O
)	O	PUNCT	O
until	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
,	O	PUNCT	O
death	O	NOUN	B
,	O	PUNCT	O
intolerable	O	ADJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
withdrawal	O	NOUN	B
of	O	ADP	I
consent	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
primary	O	ADJ	B
outcome	O	NOUN	I
analysis	B-P	NOUN	I
,	I-P	PUNCT	O
19	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
registered	I-P	VERB	B
and	I-P	CCONJ	O
18	I-P	NUM	O
treated	I-P	VERB	B
with	I-P	ADP	I
selumetinib	I-P	NOUN	B
without	I-P	ADP	O
randomization	I-P	NOUN	B
to	I-P	PART	O
complete	I-P	VERB	O
the	I-P	DET	O
planned	I-P	VERB	B
120-patient	I-P	ADJ	B
enrollment	I-P	NOUN	B
.	O	PUNCT	O


Patients	B-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
chemotherapy	I-I	NOUN	B
group	O	NOUN	O
could	O	AUX	O
receive	B-I	VERB	O
selumetinib	I-I	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
radiographic	O	ADJ	B
progression	O	NOUN	B
.	O	PUNCT	O


MAIN	O	ADJ	O
OUTCOMES	O	NOUN	O
AND	O	CCONJ	O
MEASURES	B-OUT	ADJ	O
Progression-free	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	O	PUNCT	O
the	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
assessed	O	VERB	B
as	O	ADP	O
of	O	ADP	O
April	O	PROPN	O
22	O	NUM	O
,	O	PUNCT	O
2013	O	NUM	O
.	O	PUNCT	O


Additional	O	ADJ	O
end	O	NOUN	O
points	O	NOUN	O
,	O	PUNCT	O
including	B-OUT	VERB	O
overall	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
response	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
safety/toxicity	I-OUT	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
assessed	O	VERB	B
as	O	ADP	O
of	O	ADP	O
December	O	PROPN	O
31	O	NUM	O
,	O	PUNCT	O
2013	O	NUM	O
.	O	PUNCT	O


RESULTS	O	VERB	O
Median	O	ADJ	O
progression-free	O	ADJ	B
survival	O	NOUN	I
among	O	ADP	O
patients	O	NOUN	B
randomized	B-I	ADJ	B
to	I-I	PART	O
chemotherapy	I-I	NOUN	B
was	O	AUX	O
7	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
4.3-8.4	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
median	O	ADJ	B
treatment	O	NOUN	B
duration	O	NOUN	O
,	O	PUNCT	O
8	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
interquartile	O	ADJ	B
range	O	NOUN	I
[	O	PUNCT	O
IQR	O	PROPN	B
]	O	PUNCT	O
,	O	PUNCT	O
4.3-16	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
among	O	ADP	O
those	O	DET	O
randomized	B-I	ADJ	B
to	I-I	PART	O
selumetinib	I-I	NOUN	B
was	O	AUX	O
15.9	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
8.4-21.1	O	NOUN	O
weeks	O	NOUN	B
;	O	PUNCT	O
median	O	ADJ	B
treatment	O	NOUN	B
duration	O	NOUN	O
,	O	PUNCT	O
16.1	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
IQR	O	NOUN	B
,	O	PUNCT	O
8.1-25.3	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.46	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.30-0.71	O	NUM	O
;	O	PUNCT	O
P	B-OUT	NOUN	O
<	I-OUT	X	O
.001	I-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
overall	I-OUT	ADJ	O
survival	I-OUT	NOUN	B
time	O	NOUN	I
was	O	AUX	O
9.1	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
6.1-11.1	O	NOUN	O
months	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
chemotherapy	O	NOUN	B
and	O	CCONJ	O
11.8	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
9.8-15.7	O	NUM	O
months	B-I	NOUN	B
)	I-I	PUNCT	O
with	I-I	ADP	O
selumetinib	O	NOUN	B
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
0.66	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0.41-1.06	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.09	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
objective	O	ADJ	O
responses	O	NOUN	B
were	B-I	AUX	O
observed	I-I	VERB	O
with	I-I	ADP	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


Forty-nine	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	B-I	NOUN	B
treated	I-I	VERB	B
with	I-I	ADP	I
selumetinib	I-OUT	NOUN	B
achieved	I-OUT	VERB	O
tumor	I-OUT	NOUN	B
regression	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
14	O	NUM	O
%	O	NOUN	O
achieving	O	VERB	O
an	O	DET	O
objective	O	ADJ	O
radiographic	O	ADJ	B
response	O	NOUN	O
to	O	PART	O
therapy	O	NOUN	B
.	O	PUNCT	O


Treatment-related	O	ADJ	B
adverse	O	ADJ	I
events	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
97	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
selumetinib	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
37	O	NUM	O
%	O	NOUN	O
requiring	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
1	O	NUM	O
dose	O	NOUN	B
reduction	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
AND	O	CCONJ	O
RELEVANCE	O	NOUN	B
In	O	ADP	O
this	O	DET	O
hypothesis-generating	B-P	ADJ	B
study	I-P	NOUN	I
of	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
uveal	O	ADJ	I
melanoma	O	NOUN	I
,	O	PUNCT	O
selumetinib	B-I	NOUN	B
compared	I-I	VERB	O
with	I-I	ADP	O
chemotherapy	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
modestly	O	ADV	O
improved	O	VERB	O
progression-free	O	ADJ	B
survival	O	NOUN	I
and	O	CCONJ	O
response	O	NOUN	B
rate	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
overall	O	ADJ	B
survival	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


Improvement	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
outcomes	O	NOUN	I
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
a	O	DET	O
high	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


TRIAL	O	NOUN	O
REGISTRATION	O	NOUN	O
clinicaltrials.gov	O	NOUN	O
Identifier	O	NOUN	O
:	O	PUNCT	O
NCT01143402	O	NOUN	O
.	O	PUNCT	O


Continued	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
pressure-flow	B-OUT	ADJ	B
parameters	I-OUT	NOUN	B
in	O	ADP	O
men	B-P	NOUN	B
receiving	I-P	VERB	O
finasteride	I-P	NOUN	B
for	I-P	ADP	O
2	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


Finasteride	O	NOUN	B
Urodynamics	O	PROPN	B
Study	O	PROPN	O
Group	O	PROPN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
long-term	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
finasteride	O	NOUN	B
on	O	ADP	O
pressure-flow	B-OUT	ADJ	B
parameters	I-OUT	NOUN	B
in	O	ADP	O
men	B-P	NOUN	B
with	I-P	ADP	O
urodynamically	I-P	ADV	B
documented	I-P	VERB	B
bladder	I-P	NOUN	B
outflow	I-P	NOUN	I
obstruction	I-P	NOUN	I
(	I-P	PUNCT	O
BOO	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
One	B-P	NUM	O
hundred	I-P	NUM	O
twenty-one	I-P	NUM	O
men	I-P	NOUN	B
with	I-P	ADP	O
benign	I-P	ADJ	B
prostatic	I-P	ADJ	I
enlargement	I-P	NOUN	I
(	I-P	PUNCT	O
BPE	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
lower	I-P	ADJ	B
urinary	I-P	ADJ	B
tract	I-P	NOUN	I
symptoms	I-P	NOUN	O
(	I-P	PUNCT	O
LUTS	I-P	NOUN	B
)	I-P	PUNCT	O
underwent	O	VERB	O
a	O	DET	O
pressure-flow	O	ADJ	B
study	O	NOUN	I
(	O	PUNCT	O
PFS	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
1	O	NUM	O
of	O	ADP	O
11	O	NUM	O
clinical	O	ADJ	B
centers	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
PFS	O	NOUN	B
technique	O	NOUN	B
was	O	AUX	O
standardized	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
tracings	O	NOUN	B
were	O	AUX	O
read	O	VERB	O
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
reader	O	NOUN	O
unaware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Patients	B-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
obstructed	I-P	VERB	B
according	I-P	VERB	O
to	I-P	ADP	O
a	I-P	DET	O
modified	I-OUT	ADJ	B
Abrams-Griffiths	I-OUT	ADJ	B
nomogram	I-OUT	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
5	B-I	NUM	O
mg	I-I	NOUN	O
finasteride	I-I	NOUN	B
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
81	I-I	NUM	O
)	I-I	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	I-I	PUNCT	O
n	I-I	NOUN	O
=	I-I	ADJ	O
40	I-I	NUM	O
)	I-I	PUNCT	O
for	I-I	ADP	O
12	I-I	NUM	O
months	I-I	NOUN	B
;	I-I	PUNCT	O
all	I-I	DET	O
patients	I-I	NOUN	B
continuing	I-I	VERB	B
into	I-I	ADP	O
an	I-I	DET	O
open	I-I	ADJ	O
extension	I-I	NOUN	B
received	I-I	VERB	O
finasteride	I-I	NOUN	B
during	I-I	ADP	O
the	I-I	DET	O
second	I-I	ADJ	O
12	I-I	NUM	O
months	I-I	NOUN	B
of	I-I	ADP	O
therapy	I-I	NOUN	B
.	I-I	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
12-month	O	ADJ	O
study	O	NOUN	B
demonstrated	O	VERB	O
the	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
finasteride	O	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
PFS	B-OUT	NOUN	B
parameters	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


To	O	PART	O
examine	O	VERB	O
the	O	DET	O
continuing	O	VERB	B
effects	O	NOUN	I
over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
data	O	NOUN	B
from	O	ADP	O
54	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
completed	O	VERB	O
24	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
finasteride	O	NOUN	B
is	O	AUX	O
provided	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	B
Detrusor	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
at	O	ADP	O
maximum	O	ADJ	O
flow	O	NOUN	O
(	B-OUT	PUNCT	O
PdetQmax	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
continued	O	VERB	O
to	O	PART	O
decrease	O	VERB	B
during	O	ADP	O
the	O	DET	O
second	O	ADJ	O
12	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
(	O	PUNCT	O
decreases	O	NOUN	B
of	O	ADP	O
5.3	O	NUM	O
and	O	CCONJ	O
11.7	O	NUM	O
cm	O	NOUN	O
H2O	O	NOUN	B
at	O	ADP	O
months	O	NOUN	B
12	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
obstructed	O	VERB	B
by	O	ADP	O
Abrams-Griffiths	B-OUT	ADJ	B
classification	I-OUT	NOUN	I
decreased	O	VERB	B
from	O	ADP	O
76.2	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
66.7	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
month	O	NOUN	B
12	O	NUM	O
and	O	CCONJ	O
59.6	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
month	O	NOUN	B
24	O	NUM	O
.	O	PUNCT	O


An	O	DET	O
intention-to-treat	O	ADJ	B
analysis	O	NOUN	I
yielded	O	VERB	O
similar	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Finasteride	O	NOUN	B
improves	O	VERB	O
urodynamic	O	ADJ	B
measures	O	NOUN	B
of	O	ADP	O
obstruction	O	NOUN	B
in	O	ADP	O
men	B-P	NOUN	B
with	I-P	ADP	O
BPE	I-P	NOUN	B
and	I-P	CCONJ	O
LUTS	I-P	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
continued	O	ADJ	O
improvement	O	NOUN	B
during	O	ADP	O
the	O	DET	O
second	O	ADJ	O
12	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O
